Morphological	O
characterization	O
of	O
the	O
AlphaA	B-GGP
-	I-GGP
and	I-GGP
AlphaB	I-GGP
-	I-GGP
crystallin	I-GGP
double	O
knockout	O
mouse	B-Taxon
lens	O

Abstract	O

Background	O

One	O
approach	O
to	O
resolving	O
some	O
of	O
the	O
in	O
vivo	O
functions	O
of	O
alpha	O
-	O
crystallin	O
is	O
to	O
generate	O
animal	B-Taxon
models	O
where	O
one	O
or	O
both	O
of	O
the	O
alpha	O
-	O
crystallin	O
gene	B-SO
products	O
have	O
been	O
eliminated	O
.	O

In	O
the	O
single	O
alpha	B-GGP
-	I-GGP
crystallin	I-GGP
knockout	O
mice	B-Taxon
,	O
the	O
remaining	O
alpha	B-GGP
-	I-GGP
crystallin	I-GGP
may	O
fully	O
or	O
partially	O
compensate	O
for	O
some	O
of	O
the	O
functions	O
of	O
the	O
missing	O
protein	B-CHEBI
,	O
especially	O
in	O
the	O
lens	O
,	O
where	O
both	O
alphaA	B-GGP
and	O
alphaB	B-GGP
are	O
normally	O
expressed	O
at	O
high	O
levels	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
characterize	O
gross	O
lenticular	O
morphology	O
in	O
normal	O
mice	B-Taxon
and	O
mice	B-Taxon
with	O
the	O
targeted	O
disruption	O
of	O
alphaA	B-GGP
-	I-GGP
and	I-GGP
alphaB	I-GGP
-	I-GGP
crystallin	I-GGP
genes	B-SO
(	O
alphaA	B-GGP
/	O
BKO	O
)	O
.	O

Methods	O

Lenses	O
from	O
129SvEvTac	O
mice	B-Taxon
and	O
alphaA	B-GGP
/	O
BKO	O
mice	B-Taxon
were	O
examined	O
by	O
standard	O
scanning	O
electron	B-CHEBI
microscopy	O
and	O
confocal	O
microscopy	O
methodologies	O
.	O

Results	O

Equatorial	O
and	O
axial	O
(	O
sagittal	O
)	O
dimensions	O
of	O
lenses	O
for	O
alphaA	B-GGP
/	O
BKO	O
mice	B-Taxon
were	O
significantly	O
smaller	O
than	O
age	O
-	O
matched	O
wild	B-SO
type	I-SO
lenses	O
.	O

No	O
posterior	O
sutures	O
or	O
fiber	O
cells	B-CL
extending	O
to	O
the	O
posterior	O
capsule	O
of	O
the	O
lens	O
were	O
found	O
in	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
.	O

Ectopical	O
nucleic	B-CHEBI
acid	I-CHEBI
staining	O
was	O
observed	O
in	O
the	O
posterior	O
subcapsular	O
region	O
of	O
5	O
wk	O
and	O
anterior	O
subcapsular	O
cortex	O
of	O
54	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
.	O

Gross	O
morphological	O
differences	O
were	O
also	O
observed	O
in	O
the	O
equatorial	O
/	O
bow	O
,	O
posterior	O
and	O
anterior	O
regions	O
of	O
lenses	O
from	O
alphaA	B-GGP
/	O
BKO	O
mice	B-Taxon
as	O
compared	O
to	O
wild	B-SO
mice	B-Taxon
.	O

Conclusion	O

These	O
results	O
indicated	O
that	O
both	O
alphaA	B-GGP
-	I-GGP
and	I-GGP
alphaB	I-GGP
-	I-GGP
crystallin	I-GGP
are	O
necessary	O
for	O
proper	O
fiber	O
cell	B-CL
formation	O
,	O
and	O
that	O
the	O
absence	O
of	O
alpha	B-GGP
-	I-GGP
crystallin	I-GGP
can	O
lead	O
to	O
cataract	O
formation	O
.	O

Background	O

Alpha	O
-	O
Crystallin	O
is	O
comprised	O
of	O
two	O
polypeptides	B-SO
,	O
alphaA	B-GGP
-	I-GGP
crystallin	I-GGP
(	O
alphaA	B-GGP
)	O
and	O
alphaB	B-GGP
-	I-GGP
crystallin	I-GGP
(	O
alphaB	B-GGP
)	O
,	O
which	O
share	O
55	O
%	O
amino	B-SO
acid	I-SO
sequence	I-SO
homology	B-SO
[	O
1	O
]	O
.	O

They	O
are	O
the	O
most	O
abundant	O
proteins	B-CHEBI
in	O
lens	O
fiber	O
cells	B-CL
[	O
2	O
,	O
3	O
]	O
and	O
exist	O
as	O
heteroaggregates	O
of	O
approximately	O
800	O
kDa	O
that	O
can	O
undergo	O
inter	O
-	O
aggregate	O
subunit	O
exchange	O
[	O
4	O
]	O
.	O

The	O
expression	O
of	O
these	O
two	O
proteins	B-CHEBI
in	O
the	O
lens	O
epithelium	O
,	O
however	O
,	O
is	O
not	O
uniform	O
throughout	O
different	O
regions	O
of	O
the	O
anterior	O
epithelium	O
.	O

AlphaB	B-GGP
expression	O
is	O
detected	O
in	O
central	O
epithelium	O
and	O
increases	O
from	O
the	O
central	O
to	O
elongation	O
zones	O
,	O
where	O
epithelial	B-CL
cells	I-CL
differentiate	O
into	O
fiber	O
cells	B-CL
.	O

AlphaA	B-GGP
,	O
however	O
,	O
is	O
not	O
detected	O
in	O
the	O
central	O
epithelium	O
.	O

The	O
relative	O
proportion	O
of	O
alphaA	B-GGP
and	O
alphaB	B-GGP
changes	O
from	O
a	O
molar	O
ratio	O
of	O
1	O
:	O
3	O
in	O
the	O
pericentral	O
and	O
germative	O
zones	O
to	O
a	O
molar	O
ratio	O
of	O
3	O
:	O
1	O
in	O
the	O
elongation	O
zone	O
and	O
fiber	O
cells	B-CL
[	O
2	O
,	O
3	O
]	O
.	O

These	O
differences	O
in	O
the	O
relative	O
proportions	O
of	O
alphaA	B-GGP
and	O
alphaB	B-GGP
within	O
the	O
lens	O
suggest	O
different	O
functions	O
for	O
the	O
two	O
subunits	O
in	O
the	O
developing	O
lens	O
.	O

Prior	O
to	O
the	O
1990	O
'	O
s	O
,	O
alpha	O
-	O
crystallin	O
was	O
thought	O
to	O
be	O
a	O
structural	O
protein	B-CHEBI
whose	O
major	O
cellular	B-CL
function	O
was	O
to	O
produce	O
a	O
dense	O
solution	O
necessary	O
for	O
the	O
refraction	O
of	O
light	O
in	O
the	O
lens	O
.	O

During	O
the	O
early	O
1990	O
'	O
s	O
,	O
alpha	O
-	O
crystallin	O
was	O
shown	O
to	O
act	O
as	O
a	O
molecular	B-CHEBI
chaperone	O
,	O
binding	O
to	O
partially	O
denatured	O
proteins	B-CHEBI
,	O
both	O
in	O
vitro	O
[	O
5	O
]	O
and	O
probably	O
in	O
vivo	O
[	O
6	O
]	O
,	O
to	O
inhibit	O
further	O
denaturation	O
and	O
aggregation	O
of	O
lens	O
proteins	B-CHEBI
.	O

AlphaA	B-GGP
and	O
alphaB	B-GGP
were	O
also	O
shown	O
to	O
have	O
sequence	B-SO
homology	B-SO
with	O
several	O
other	O
proteins	B-CHEBI
that	O
are	O
members	O
of	O
the	O
small	B-GGP
heat	I-GGP
shock	I-GGP
protein	I-GGP
(	O
hsp	O
)	O
family	O
[	O
7	O
]	O
.	O

Moreover	O
,	O
expression	O
of	O
alpha	O
-	O
crystallin	O
,	O
particularly	O
alphaB	B-GGP
,	O
was	O
shown	O
to	O
not	O
be	O
restricted	O
to	O
the	O
lens	O
.	O

AlphaB	B-GGP
was	O
found	O
to	O
be	O
expressed	O
at	O
significant	O
levels	O
in	O
a	O
variety	O
of	O
nonlenticular	O
tissues	O
,	O
while	O
alphaA	B-GGP
has	O
only	O
been	O
detected	O
in	O
small	O
amounts	O
in	O
a	O
few	O
other	O
tissues	O
such	O
as	O
retina	O
,	O
spleen	O
and	O
thymus	O
[	O
8	O
-	O
12	O
]	O
.	O

Collectively	O
,	O
these	O
findings	O
have	O
challenged	O
the	O
dogma	O
that	O
alpha	O
-	O
crystallin	O
is	O
purely	O
a	O
structural	O
protein	B-CHEBI
necessary	O
for	O
light	O
refraction	O
,	O
and	O
have	O
led	O
to	O
the	O
realization	O
that	O
alpha	O
-	O
crystallin	O
may	O
have	O
a	O
variety	O
of	O
biological	O
functions	O
in	O
the	O
lens	O
.	O

A	O
much	O
broader	O
scope	O
of	O
cellular	B-CL
functions	O
of	O
alpha	O
-	O
crystallin	O
in	O
lens	O
is	O
inferred	O
from	O
in	O
vitro	O
observations	O
.	O

Both	O
alphaA	B-GGP
and	O
alphaB	B-GGP
can	O
bind	O
specifically	O
to	O
actin	O
,	O
in	O
vitro	O
[	O
13	O
]	O
and	O
in	O
vivo	O
[	O
14	O
]	O
.	O

Although	O
actin	B-GO
filament	I-GO
formation	O
has	O
been	O
shown	O
to	O
be	O
necessary	O
for	O
differentiation	O
of	O
lens	O
epithelial	B-CL
cells	I-CL
[	O
15	O
]	O
,	O
the	O
significance	O
of	O
alpha	O
-	O
crystallin	O
'	O
s	O
interaction	O
with	O
actin	O
in	O
differentiation	O
is	O
not	O
known	O
.	O

In	O
the	O
lens	O
,	O
alpha	O
-	O
crystallin	O
also	O
associates	O
with	O
type	B-GO
III	I-GO
intermediate	I-GO
filament	I-GO
proteins	B-CHEBI
and	O
the	O
beaded	O
filament	O
proteins	B-CHEBI
CP49	B-GGP
and	O
CP115	B-GGP
,	O
and	O
correct	O
beaded	O
filament	O
assembly	O
has	O
been	O
shown	O
depend	O
on	O
the	O
presence	O
of	O
alpha	O
-	O
crystallin	O
[	O
16	O
]	O
.	O

Beaded	O
filament	O
mRNA	B-CHEBI
levels	O
are	O
greatly	O
increased	O
in	O
differentiating	O
lens	O
epithelium	O
and	O
have	O
been	O
suggested	O
as	O
a	O
pan	O
-	O
specific	O
marker	O
for	O
lens	O
fiber	O
development	O
[	O
17	O
]	O
.	O

Alpha	O
-	O
crystallin	O
has	O
also	O
been	O
shown	O
to	O
interact	O
directly	O
with	O
DNA	B-SO
[	O
18	O
]	O
.	O

In	O
transfected	O
CHO	O
cells	B-CL
,	O
alphaB	B-GGP
has	O
also	O
been	O
shown	O
to	O
ectopically	O
localize	O
to	O
interphase	O
nuclei	B-GO
,	O
suggesting	O
a	O
role	O
for	O
this	O
protein	B-CHEBI
in	O
the	O
nucleus	B-GO
[	O
19	O
]	O
.	O

A	O
nuclear	B-GO
role	O
for	O
alphaB	B-GGP
in	O
the	O
lens	O
was	O
supported	O
by	O
the	O
findings	O
that	O
a	O
subset	O
of	O
lens	O
epithelial	B-CL
cells	I-CL
derived	O
from	O
alphaB	B-GGP
knockout	O
mice	B-Taxon
demonstrated	O
hyperproliferation	O
and	O
genomic	B-SO
instability	O
[	O
20	O
]	O
.	O

In	O
addition	O
,	O
the	O
administration	O
of	O
exogenous	O
alpha	O
-	O
crystallin	O
to	O
primary	O
bovine	B-Taxon
lens	O
epithelial	B-CL
cell	I-CL
cultures	O
resulted	O
in	O
the	O
formation	O
of	O
lentoid	O
bodies	O
,	O
consistent	O
with	O
a	O
role	O
for	O
these	O
proteins	B-CHEBI
in	O
lens	O
differentiation	O
[	O
21	O
]	O
.	O

These	O
findings	O
indicate	O
that	O
alpha	O
-	O
crystallin	O
may	O
have	O
a	O
multitude	O
of	O
in	O
vivo	O
functions	O
.	O

One	O
approach	O
to	O
resolving	O
some	O
of	O
the	O
in	O
vivo	O
functions	O
of	O
alpha	O
-	O
crystallin	O
is	O
to	O
generate	O
animal	B-Taxon
models	O
where	O
one	O
or	O
both	O
of	O
the	O
alpha	O
-	O
crystallin	O
gene	B-SO
products	O
have	O
been	O
eliminated	O
.	O

Brady	O
et	O
al	O
.	O

[	O
22	O
]	O
demonstrated	O
,	O
by	O
targeted	O
disruption	O
of	O
the	O
mouse	B-GGP
alphaA	I-GGP
gene	B-SO
,	O
that	O
this	O
protein	B-CHEBI
was	O
essential	O
for	O
the	O
maintenance	O
of	O
lens	O
transparency	O
,	O
possibly	O
by	O
maintaining	O
the	O
solubility	O
of	O
alphaB	B-GGP
,	O
or	O
associated	O
proteins	B-CHEBI
,	O
in	O
the	O
lens	O
.	O

These	O
lenses	O
were	O
also	O
reported	O
to	O
be	O
smaller	O
in	O
equatorial	O
and	O
light	O
axial	O
dimensions	O
than	O
age	O
matched	O
wild	B-SO
type	I-SO
lens	O
.	O

It	O
was	O
not	O
possible	O
using	O
the	O
techniques	O
employed	O
in	O
the	O
study	O
to	O
determine	O
if	O
the	O
smaller	O
lenses	O
were	O
due	O
to	O
reduced	O
volume	O
or	O
number	O
of	O
fiber	O
cells	B-CL
.	O

Targeted	O
disruption	O
of	O
the	O
mouse	B-GGP
alphaB	I-GGP
gene	B-SO
resulted	O
in	O
lenses	O
similar	O
in	O
size	O
to	O
aged	O
-	O
matched	O
wild	B-SO
type	I-SO
lens	O
.	O

Moreover	O
,	O
no	O
cataract	O
formation	O
was	O
observed	O
in	O
the	O
alphaB	B-GGP
knockout	O
lenses	O
.	O

These	O
animals	B-Taxon
have	O
muscle	B-CL
cell	I-CL
abnormalities	O
,	O
severe	O
postural	O
anomalies	O
,	O
selective	O
muscle	O
degeneration	O
,	O
and	O
shorter	O
life	O
spans	O
compared	O
to	O
normal	O
controls	O
[	O
23	O
]	O
.	O

In	O
the	O
single	O
alpha	B-GGP
-	I-GGP
crystallin	I-GGP
knockout	O
mice	B-Taxon
,	O
the	O
remaining	O
alpha	B-GGP
-	I-GGP
crystallin	I-GGP
may	O
fully	O
or	O
partially	O
compensate	O
for	O
some	O
of	O
the	O
functions	O
of	O
the	O
missing	O
protein	B-CHEBI
,	O
especially	O
in	O
the	O
lens	O
,	O
where	O
both	O
alphaA	B-GGP
and	O
alphaB	B-GGP
are	O
normally	O
expressed	O
at	O
high	O
levels	O
.	O

The	O
objectives	O
of	O
the	O
current	O
report	O
were	O
to	O
characterize	O
gross	O
morphology	O
of	O
young	O
(	O
5	O
wk	O
)	O
and	O
old	O
(	O
54	O
wk	O
)	O
mouse	B-Taxon
lenses	O
with	O
targeted	O
disruption	O
of	O
both	O
the	O
alphaA	B-GGP
and	O
alphaB	B-GGP
genes	B-SO
,	O
in	O
comparison	O
to	O
age	O
matched	O
wild	B-SO
type	I-SO
lenses	O
,	O
using	O
scanning	O
electron	B-CHEBI
microscopy	O
(	O
SEM	O
)	O
and	O
confocal	O
microscopy	O
,	O
to	O
elucidate	O
the	O
possible	O
functions	O
of	O
alpha	B-GGP
-	I-GGP
crystallin	I-GGP
in	O
the	O
lens	O
.	O

The	O
results	O
indicate	O
that	O
alpha	B-GGP
-	I-GGP
crystallin	I-GGP
is	O
necessary	O
for	O
proper	O
fiber	O
cell	B-CL
formation	O
and	O
resulting	O
lens	O
transparency	O
.	O

Methods	O

Lenses	O

The	O
wild	B-SO
type	I-SO
mouse	B-Taxon
strain	O
used	O
in	O
this	O
study	O
was	O
the	O
129SvEvTac	O
mouse	B-Taxon
.	O

Lenses	O
examined	O
were	O
from	O
5	O
(	O
8	O
lenses	O
)	O
,	O
46	O
(	O
8	O
lenses	O
)	O
and	O
72	O
(	O
6	O
lenses	O
)	O
wk	O
old	O
mice	B-Taxon
.	O

AlphaA	B-GGP
/	O
BKO	O
was	O
generated	O
by	O
cross	O
breeding	O
alphaAKO	O
-	O
127	O
[	O
22	O
]	O
and	O
alphaBKO	O
-	O
168	O
mice	B-Taxon
[	O
23	O
]	O
,	O
also	O
in	O
a	O
129Sv	O
background	O
.	O

These	O
mice	B-Taxon
also	O
lack	O
the	O
HSPB2	B-GGP
gene	B-SO
product	O
[	O
23	O
]	O
.	O

Lenses	O
examined	O
were	O
from	O
5	O
wk	O
(	O
6	O
lenses	O
)	O
and	O
54	O
wk	O
(	O
16	O
lenses	O
)	O
old	O
mice	B-Taxon
.	O

All	O
animals	B-Taxon
were	O
treated	O
in	O
accordance	O
with	O
the	O
Association	O
for	O
Research	O
in	O
Vision	O
and	O
Ophthalmology	O
Statement	O
for	O
the	O
Use	O
of	O
Animals	B-Taxon
in	O
Ophthalmic	O
and	O
Vision	O
Research	O
.	O

Immediately	O
after	O
euthanizing	O
animals	B-Taxon
,	O
eyes	O
were	O
enucleated	O
.	O

A	O
scalpel	O
blade	O
was	O
then	O
used	O
to	O
make	O
a	O
small	O
incision	O
into	O
the	O
anterior	O
chamber	O
near	O
the	O
equator	O
and	O
then	O
both	O
eyes	O
from	O
individual	O
animals	B-Taxon
were	O
immersed	O
in	O
5	O
ml	O
fixative	O
(	O
2	O
%	O
(	O
w	O
/	O
v	O
)	O
paraformaldehyde	O
and	O
2	O
%	O
glutaraldehyde	O
(	O
v	O
/	O
v	O
)	O
in	O
0	O
.	O
1	O
M	O
sodium	B-CHEBI
cacodylate	B-CHEBI
buffer	O
,	O
pH	O
7	O
.	O
2	O
)	O
.	O

Eyes	O
were	O
fixed	O
for	O
at	O
least	O
24	O
hr	O
at	O
room	O
temperature	O
(	O
RT	O
)	O
prior	O
to	O
dissection	O
of	O
the	O
lenses	O
.	O

At	O
this	O
time	O
,	O
equatorial	O
and	O
axial	O
dimensions	O
of	O
lenses	O
and	O
gross	O
lenticular	O
appearance	O
were	O
recorded	O
.	O

Statistical	O
analyses	O
on	O
data	O
consisted	O
of	O
Student	O
'	O
s	O
t	O
-	O
test	O
,	O
means	O
and	O
standard	O
deviation	O
,	O
using	O
the	O
statistical	O
software	O
package	O
StatMost	O
(	O
Dataxiom	O
Software	O
Inc	O
.	O
,	O
Los	O
Angeles	O
,	O
CA	O
)	O
.	O

Confocal	O
microscopy	O

Lenses	O
were	O
vibratome	O
sectioned	O
into	O
100	O
-	O
200	O
mu	O
m	O
thick	O
sections	O
along	O
the	O
optical	O
(	O
anterior	O
to	O
posterior	O
)	O
or	O
equatorial	O
axes	O
.	O

Thick	O
sections	O
were	O
fixed	O
in	O
2	O
%	O
(	O
w	O
/	O
v	O
)	O
paraformaldehyde	O
and	O
2	O
%	O
glutaraldehyde	O
(	O
v	O
/	O
v	O
)	O
in	O
0	O
.	O
1	O
M	O
sodium	B-CHEBI
cacodylate	B-CHEBI
buffer	O
pH	O
7	O
.	O
2	O
at	O
RT	O
for	O
24	O
hrs	O
then	O
washed	O
several	O
times	O
in	O
Tris	B-CHEBI
buffered	B-CHEBI
saline	O
(	O
0	O
.	O
5	O
M	O
Tris	B-CHEBI
,	O
150	O
mM	O
NaCl	B-CHEBI
,	O
pH	O
7	O
.	O
4	O
)	O
.	O

To	O
visualize	O
lipid	B-CHEBI
membranes	B-GO
,	O
sections	O
were	O
stained	O
with	O
1	O
,	O
1	O
'	O
-	O
dioctadecyl	O
-	O
3	O
,	O
3	O
,	O
3	O
'	O
,	O
3	O
'	O
-	O
tetramethylindocarbocyanine	O
perchlorate	B-CHEBI
(	O
'	O
DiI	O
'	O
;	O
DiIC18	O
;	O
Molecular	B-CHEBI
Probes	O
)	O
as	O
previously	O
described	O
[	O
24	O
]	O
.	O

Sections	O
were	O
then	O
washed	O
several	O
times	O
with	O
Tris	B-CHEBI
buffered	B-CHEBI
saline	O
,	O
and	O
nucleic	B-CHEBI
acids	I-CHEBI
were	O
stained	O
by	O
incubating	O
sections	O
in	O
TBS	O
containing	O
1	O
mu	O
M	O
SYTOX	O
Green	O
(	O
Molecular	B-CHEBI
Probes	O
)	O
for	O
10	O
min	O
at	O
RT	O
followed	O
by	O
several	O
washes	O
with	O
TBS	O
prior	O
to	O
confocal	O
imaging	O
.	O

Lens	O
sections	O
were	O
viewed	O
on	O
a	O
Zeiss	O
laser	O
scanning	O
confocal	O
microscope	O
model	O
LSM	O
410	O
equipped	O
with	O
an	O
Axiovert	O
100	O
inverted	O
microscope	O
,	O
an	O
Argon	B-CHEBI
-	O
Krypton	B-CHEBI
488	O
/	O
568	O
/	O
647	O
laser	O
,	O
a	O
KP	O
line	O
selection	O
filter	O
,	O
a	O
FT	O
488	O
/	O
568	O
Dichroic	O
beam	O
splitter	O
,	O
a	O
FT	O
560	O
Dichroic	O
beam	O
splitter	O
,	O
a	O
LP	O
590	O
emission	O
filter	O
for	O
viewing	O
DiI	O
,	O
a	O
BP	O
515	O
-	O
540	O
emission	O
filter	O
for	O
viewing	O
SYTOX	O
green	O
,	O
and	O
the	O
software	O
package	O
LSM	O
3	O
.	O
993	O
.	O

Scanning	O
electron	B-CHEBI
microscopy	O

Lenses	O
bisected	O
along	O
the	O
optical	O
axes	O
were	O
immersion	O
fixed	O
in	O
2	O
%	O
(	O
w	O
/	O
v	O
)	O
paraformaldehyde	O
and	O
2	O
%	O
glutaraldehyde	O
(	O
v	O
/	O
v	O
)	O
in	O
0	O
.	O
1	O
M	O
sodium	B-CHEBI
cacodylate	B-CHEBI
buffer	O
pH	O
7	O
.	O
2	O
at	O
RT	O
for	O
24	O
hrs	O
.	O

Samples	O
were	O
then	O
washed	O
several	O
times	O
with	O
distilled	O
water	B-CHEBI
and	O
postfixed	O
in	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
aqueous	B-CHEBI
osmium	B-CHEBI
tetroxide	O
at	O
RT	O
for	O
1	O
hr	O
.	O

Lens	O
halves	O
were	O
dehydrated	O
in	O
an	O
ascending	O
ethanol	B-CHEBI
series	O
from	O
50	O
-	O
100	O
%	O
.	O

Once	O
lens	O
halves	O
were	O
in	O
100	O
%	O
ethanol	B-CHEBI
,	O
they	O
were	O
critical	O
point	O
dried	O
in	O
carbon	B-CHEBI
dioxide	I-CHEBI
in	O
a	O
Samdri	O
-	O
790B	O
(	O
Tousimis	O
Research	O
Corp	O
.	O
,	O
Rockville	O
,	O
MD	O
)	O
.	O

Critical	O
point	O
dried	O
lens	O
halves	O
were	O
secured	O
on	O
aluminum	B-CHEBI
stubs	O
with	O
double	O
sided	O
tape	O
.	O

Mounted	O
specimens	O
were	O
then	O
sputter	O
coated	O
with	O
gold	B-CHEBI
and	O
viewed	O
on	O
a	O
Hitachi	O
S	O
-	O
3500N	O
scanning	O
electron	B-CHEBI
microscope	O
(	O
Tokyo	O
,	O
Japan	O
)	O
at	O
1	O
-	O
5	O
kV	O
.	O

This	O
microscope	O
is	O
equipped	O
with	O
Hitachi	O
'	O
s	O
patented	O
"	O
Dual	O
-	O
Bias	O
"	O
which	O
allows	O
extremely	O
high	O
emission	O
currents	O
at	O
acceleration	O
voltages	O
of	O
5	O
kV	O
and	O
lower	O
.	O

Results	O

Equatorial	O
and	O
axial	O
(	O
sagittal	O
)	O
dimensions	O
of	O
lenses	O
,	O
and	O
gross	O
lenticular	O
appearance	O
,	O
were	O
recorded	O
(	O
Table	O
1	O
)	O
.	O

AlphaA	B-GGP
/	O
BKO	O
lenses	O
at	O
5	O
wks	O
of	O
age	O
were	O
significantly	O
smaller	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
both	O
equatorially	O
and	O
axially	O
,	O
than	O
5	O
wk	O
old	O
wild	B-SO
type	I-SO
lenses	O
and	O
remain	O
smaller	O
throughout	O
life	O
.	O

Fifty	O
-	O
four	O
wk	O
old	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
were	O
much	O
smaller	O
than	O
similarly	O
aged	O
normal	O
lenses	O
,	O
and	O
were	O
similar	O
in	O
size	O
to	O
5	O
wk	O
old	O
wild	B-SO
type	I-SO
lenses	O
.	O

Both	O
the	O
5	O
wk	O
old	O
wild	B-SO
type	I-SO
lenses	O
and	O
the	O
54	O
wk	O
old	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
were	O
significantly	O
smaller	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
than	O
the	O
46	O
or	O
72	O
wk	O
old	O
wild	B-SO
type	I-SO
lenses	O
.	O

AlphaA	B-GGP
/	O
BKO	O
lenses	O
at	O
5	O
wks	O
of	O
age	O
exhibited	O
vacuoles	B-GO
at	O
the	O
equatorial	O
region	O
(	O
Figure	O
1A	O
see	O
arrows	O
)	O
and	O
an	O
area	O
of	O
slight	O
light	O
scatter	O
at	O
the	O
posterior	O
subcapsular	O
regions	O
(	O
Figure	O
1B	O
see	O
arrowheads	O
)	O
.	O

By	O
54	O
wks	O
of	O
age	O
,	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
exhibited	O
dense	O
cortical	O
and	O
nuclear	O
cataracts	O
(	O
Figure	O
1C	O
)	O
.	O

No	O
posterior	O
sutures	O
were	O
observed	O
in	O
any	O
of	O
the	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
examined	O
.	O

All	O
wild	B-SO
type	I-SO
lenses	O
were	O
transparent	O
upon	O
removal	O
from	O
the	O
eye	O
(	O
Figure	O
1D	O
,	O
1E	O
and	O
1F	O
)	O
and	O
had	O
well	O
defined	O
posterior	O
sutures	O
.	O

Figure	O
1	O

Light	O
micrographs	O
of	O
lenses	O
dissected	O
from	O
fixed	O
eyes	O
of	O
alphaA	B-GGP
/	O
BKO	O
(	O
A	O
-	O
C	O
)	O
and	O
wild	B-SO
type	I-SO
(	O
D	O
-	O
F	O
)	O
mice	B-Taxon
.	O

All	O
micrographs	O
were	O
generated	O
using	O
a	O
4	O
x	O
/	O
0	O
.	O
10	O
objective	O
on	O
a	O
Zeiss	O
LSM	O
410	O
using	O
transmitted	O
light	O
mode	O
.	O

Images	O
in	O
(	O
A	O
&	O
B	O
)	O
were	O
enlarged	O
compared	O
to	O
images	O
(	O
C	O
-	O
F	O
)	O
(	O
see	O
scale	O
bars	O
)	O
.	O

For	O
all	O
micrographs	O
except	O
(	O
B	O
)	O
the	O
objective	O
focal	O
point	O
was	O
set	O
at	O
the	O
equatorial	O
plane	O
of	O
the	O
lens	O
,	O
while	O
(	O
B	O
)	O
was	O
set	O
at	O
the	O
posterior	O
pole	O
of	O
the	O
lens	O
.	O

(	O
A	O
&	O
B	O
)	O
Representative	O
micrographs	O
of	O
lenses	O
from	O
5	O
wk	O
alphaA	B-GGP
/	O
BKO	O
mice	B-Taxon
,	O
showing	O
changes	O
in	O
the	O
equatorial	O
(	O
A	O
)	O
and	O
posterior	O
sub	O
capsular	O
(	O
B	O
)	O
regions	O
.	O

(	O
C	O
)	O
Representative	O
micrograph	O
of	O
54	O
wk	O
alphaA	B-GGP
/	O
BKO	O
mouse	B-Taxon
lens	O
showing	O
dense	O
whole	O
lens	O
cataract	O
.	O

(	O
D	O
-	O
F	O
)	O
Representative	O
clear	O
lenses	O
from	O
5	O
wk	O
(	O
D	O
)	O
,	O
46	O
wk	O
(	O
E	O
)	O
,	O
and	O
wk	O
72	O
(	O
F	O
)	O
wild	B-SO
type	I-SO
mice	B-Taxon
.	O

Arrows	O
(	O
A	O
)	O
indicate	O
vacuoles	B-GO
in	O
the	O
equatorial	O
region	O
of	O
a	O
representative	O
5	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lens	O
.	O

The	O
arrowheads	O
(	O
B	O
)	O
indicate	O
an	O
area	O
of	O
minor	O
light	O
scattering	O
deep	O
to	O
the	O
posterior	O
capsule	O
in	O
a	O
representative	O
5	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lens	O
.	O

Table	O
1	O

Dimensions	O
and	O
gross	O
lenticular	O
appearance	O
of	O
lenses	O
.	O

Examination	O
of	O
mid	O
-	O
axial	O
sections	O
stained	O
with	O
DiI	O
and	O
SYTOX	O
green	O
revealed	O
unique	O
differences	O
in	O
gross	O
morphology	O
and	O
nucleic	B-CHEBI
acid	I-CHEBI
staining	O
between	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
and	O
wild	B-SO
type	I-SO
lenses	O
(	O
Figure	O
2	O
)	O
.	O

In	O
five	O
week	O
old	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
,	O
Sytox	O
green	O
stained	O
nuclei	B-GO
(	O
green	O
)	O
in	O
the	O
anterior	O
epithelium	O
,	O
equatorial	O
/	O
bow	O
,	O
and	O
posterior	O
subcapsular	O
regions	O
(	O
Figure	O
2A	O
)	O
.	O

Cell	B-CL
nuclei	B-GO
localized	O
to	O
the	O
equatorial	O
/	O
bow	O
region	O
were	O
disorganized	O
as	O
compared	O
to	O
wild	B-SO
type	I-SO
.	O

There	O
were	O
enlarged	O
extracellular	B-GO
spaces	I-GO
between	O
cells	B-CL
in	O
the	O
equatorial	O
/	O
bow	O
region	O
in	O
5	O
wk	O
old	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
.	O

Fifty	O
-	O
four	O
wk	O
old	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
(	O
Figure	O
2B	O
)	O
did	O
not	O
stain	O
for	O
nucleic	B-CHEBI
acid	I-CHEBI
in	O
the	O
posterior	O
subcapsular	O
region	O
,	O
however	O
,	O
the	O
entire	O
anterior	O
subcapsular	O
lens	O
region	O
stained	O
for	O
nucleic	B-CHEBI
acid	I-CHEBI
(	O
refer	O
to	O
Figure	O
3I	O
for	O
high	O
magnification	O
/	O
resolution	O
image	O
of	O
this	O
area	O
)	O
.	O

A	O
defined	O
equatorial	O
/	O
bow	O
region	O
was	O
not	O
observed	O
in	O
these	O
older	O
lenses	O
,	O
and	O
fiber	O
cells	B-CL
extending	O
to	O
the	O
posterior	O
capsule	O
of	O
the	O
lens	O
were	O
not	O
found	O
.	O

Disorganized	O
cellular	B-CL
material	O
capped	O
the	O
anterior	O
region	O
of	O
the	O
embryonic	O
/	O
fetal	O
nucleus	O
,	O
and	O
a	O
distinctive	O
indentation	O
of	O
the	O
lens	O
mass	O
at	O
the	O
equatorial	O
region	O
was	O
apparent	O
in	O
mid	O
-	O
axial	O
sections	O
as	O
well	O
as	O
whole	O
lenses	O
.	O

In	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
the	O
embryonic	O
/	O
fetal	O
nucleus	O
(	O
primary	O
lens	O
fibers	O
)	O
had	O
migrated	O
posteriorly	O
and	O
appeared	O
to	O
be	O
in	O
contact	O
with	O
the	O
posterior	O
capsule	O
.	O

In	O
5	O
wk	O
,	O
46	O
wk	O
or	O
72	O
wk	O
old	O
wild	B-SO
type	I-SO
lenses	O
(	O
Figure	O
2C	O
,	O
2D	O
and	O
2E	O
)	O
,	O
however	O
,	O
there	O
was	O
no	O
posterior	O
or	O
anterior	O
subcapsular	O
nucleic	B-CHEBI
acid	I-CHEBI
staining	O
and	O
the	O
embryonic	O
-	O
fetal	O
nucleus	O
was	O
centrally	O
located	O
,	O
not	O
in	O
contact	O
with	O
the	O
posterior	O
capsule	O
.	O

Figure	O
2	O

Representative	O
confocal	O
optical	O
sections	O
taken	O
from	O
mid	O
-	O
axial	O
vibratome	O
sections	O
of	O
alphaA	B-GGP
/	O
BKO	O
(	O
A	O
&	O
B	O
)	O
and	O
wild	B-SO
type	I-SO
(	O
C	O
-	O
E	O
)	O
lenses	O
.	O

All	O
optical	O
sections	O
were	O
generated	O
using	O
a	O
4	O
x	O
/	O
0	O
.	O
10	O
objective	O
on	O
a	O
Zeiss	O
LSM	O
410	O
.	O

The	O
red	O
color	O
represents	O
DiI	O
staining	O
(	O
membrane	B-GO
)	O
,	O
while	O
the	O
green	O
color	O
represents	O
SYTOX	O
green	O
staining	O
(	O
DNA	B-SO
)	O
.	O

(	O
A	O
&	O
B	O
)	O
were	O
taken	O
from	O
5	O
wk	O
and	O
54	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
,	O
respectively	O
.	O

(	O
C	O
-	O
E	O
)	O
were	O
taken	O
from	O
5	O
wk	O
,	O
46	O
wk	O
,	O
and	O
72	O
wk	O
wild	B-SO
type	I-SO
lenses	O
,	O
respectively	O
.	O

The	O
arrowheads	O
indicate	O
representative	O
anterior	O
epithelial	O
nuclei	B-GO
stained	O
with	O
SYTOX	O
green	O
.	O

Figure	O
3	O

Representative	O
confocal	O
optical	O
sections	O
from	O
alphaA	B-GGP
/	O
BKO	O
(	O
A	O
-	O
J	O
)	O
and	O
wild	B-SO
type	I-SO
(	O
K	O
-	O
T	O
)	O
lenses	O
.	O

All	O
optical	O
sections	O
were	O
generated	O
using	O
a	O
63	O
x	O
/	O
1	O
.	O
4	O
objective	O
on	O
a	O
Zeiss	O
LSM	O
410	O
.	O

The	O
red	O
color	O
represents	O
DiI	O
staining	O
(	O
membrane	B-GO
)	O
,	O
while	O
the	O
green	O
color	O
represents	O
SYTOX	O
green	O
staining	O
(	O
DNA	B-SO
)	O
.	O

(	O
A	O
-	O
E	O
)	O
are	O
from	O
5	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
.	O

(	O
F	O
-	O
J	O
)	O
are	O
from	O
54	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
.	O

(	O
K	O
-	O
O	O
)	O
are	O
from	O
5	O
wk	O
wild	B-SO
type	I-SO
lenses	O
.	O

(	O
P	O
-	O
T	O
)	O
are	O
from	O
46	O
wk	O
wild	B-SO
type	I-SO
lenses	O
.	O

(	O
A	O
,	O
F	O
,	O
K	O
,	O
and	O
P	O
)	O
are	O
anterior	O
central	O
cortex	O
and	O
epithelium	O
.	O

(	O
B	O
,	O
G	O
,	O
L	O
,	O
and	O
Q	O
)	O
are	O
equatorial	O
bow	O
region	O
.	O

(	O
C	O
,	O
H	O
,	O
M	O
,	O
and	O
R	O
)	O
are	O
embryonic	O
/	O
fetal	O
nucleus	O
.	O

(	O
D	O
,	O
I	O
,	O
N	O
,	O
and	O
S	O
)	O
are	O
deep	O
anterior	O
cortex	O
.	O

(	O
E	O
,	O
J	O
,	O
O	O
,	O
and	O
T	O
)	O
are	O
posterior	O
subcapsular	O
region	O
.	O

(	O
*	O
)	O
indicates	O
areas	O
devoid	O
of	O
cellular	B-CL
material	O
(	O
B	O
and	O
G	O
)	O
.	O

Arrow	O
indicates	O
posterior	O
suture	O
(	O
O	O
)	O
.	O

Arrowheads	O
indicate	O
representative	O
nuclei	B-GO
stained	O
with	O
SYTOX	O
green	O
(	O
A	O
,	O
B	O
,	O
E	O
,	O
F	O
,	O
G	O
,	O
I	O
,	O
K	O
,	O
L	O
,	O
P	O
,	O
and	O
Q	O
)	O
.	O

At	O
higher	O
magnification	O
,	O
examination	O
of	O
sections	O
stained	O
with	O
DiI	O
and	O
SYTOX	O
green	O
revealed	O
ultrastructural	O
differences	O
between	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
and	O
wild	B-SO
type	I-SO
lenses	O
(	O
Figure	O
3	O
)	O
.	O

Anterior	O
epithelial	O
staining	O
in	O
5	O
wk	O
old	O
alphaA	B-GGP
/	O
BKO	O
(	O
Figure	O
3A	O
)	O
and	O
5	O
wk	O
old	O
wild	B-SO
type	I-SO
lenses	O
were	O
similar	O
(	O
Figure	O
3K	O
)	O
with	O
respect	O
to	O
nuclear	B-GO
staining	O
with	O
SYTOX	O
green	O
.	O

However	O
,	O
some	O
differences	O
in	O
54	O
wk	O
old	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
(	O
Figure	O
3F	O
)	O
were	O
observed	O
in	O
the	O
central	O
anterior	O
epithelium	O
compared	O
to	O
5	O
wk	O
(	O
Figure	O
3K	O
)	O
,	O
46	O
wk	O
(	O
Figure	O
3P	O
)	O
,	O
and	O
72	O
wk	O
(	O
data	O
not	O
shown	O
)	O
wild	B-SO
type	I-SO
lenses	O
.	O

These	O
differences	O
included	O
changes	O
in	O
central	O
epithelial	O
nuclear	B-GO
staining	O
,	O
nuclear	B-GO
shape	O
and	O
epithelial	O
thickness	O
and	O
continuity	O
.	O

Superficial	O
and	O
deep	O
anterior	O
cortical	O
staining	O
was	O
grossly	O
different	O
between	O
alphaA	B-GGP
/	O
BKO	O
(	O
Figure	O
3A	O
,	O
3D	O
,	O
3F	O
and	O
3I	O
)	O
and	O
wild	B-SO
type	I-SO
lenses	O
(	O
Figure	O
3K	O
,	O
3N	O
,	O
3P	O
and	O
3S	O
)	O
.	O

In	O
5	O
and	O
54	O
wk	O
old	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
,	O
superficial	O
and	O
deep	O
anterior	O
cortical	O
regions	O
,	O
stained	O
for	O
lipid	B-CHEBI
membranes	B-GO
,	O
did	O
not	O
reveal	O
any	O
patterns	O
typical	O
of	O
fiber	O
cells	B-CL
cut	O
in	O
cross	O
-	O
section	O
or	O
longitudinal	O
section	O
.	O

In	O
5	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
there	O
was	O
a	O
high	O
density	O
of	O
stained	O
membranes	B-GO
per	O
unit	O
area	O
throughout	O
the	O
cortex	O
,	O
with	O
no	O
nucleic	B-CHEBI
acid	I-CHEBI
staining	O
in	O
these	O
regions	O
.	O

In	O
54	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
,	O
large	O
,	O
irregularly	O
shaped	O
cells	B-CL
were	O
observed	O
,	O
interspersed	O
among	O
regions	O
of	O
high	O
membrane	B-GO
staining	O
density	O
per	O
unit	O
area	O
.	O

These	O
large	O
objects	O
were	O
not	O
vacuoles	B-GO
,	O
because	O
examination	O
of	O
the	O
interior	O
of	O
these	O
structures	O
by	O
transmitted	O
and	O
reflected	O
light	O
microscopy	O
showed	O
that	O
the	O
membranes	B-GO
encompassed	O
cellular	B-CL
material	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
addition	O
,	O
nucleic	B-CHEBI
acid	I-CHEBI
staining	O
was	O
observed	O
(	O
Figure	O
3F	O
and	O
3I	O
)	O
within	O
many	O
of	O
these	O
cells	B-CL
exhibiting	O
large	O
cross	O
-	O
sectional	O
profiles	O
.	O

In	O
the	O
wild	B-SO
type	I-SO
lenses	O
,	O
typical	O
cross	O
-	O
sectional	O
patterns	O
of	O
fiber	O
cells	B-CL
organized	O
in	O
radial	O
columns	O
were	O
observed	O
(	O
Figure	O
3K	O
,	O
3N	O
,	O
3P	O
and	O
3S	O
)	O
.	O

Ultrastructural	O
differences	O
at	O
the	O
equatorial	O
/	O
bow	O
region	O
were	O
also	O
observed	O
between	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
(	O
Figure	O
3B	O
and	O
3G	O
)	O
and	O
wild	B-SO
type	I-SO
lenses	O
(	O
Figure	O
3L	O
and	O
3Q	O
)	O
.	O

In	O
contrast	O
to	O
wild	B-SO
type	I-SO
lenses	O
(	O
Figure	O
3L	O
and	O
3Q	O
)	O
,	O
the	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
(	O
Figure	O
3B	O
and	O
3G	O
)	O
contained	O
large	O
areas	O
devoid	O
of	O
cellular	B-CL
material	O
,	O
their	O
nuclei	B-GO
were	O
not	O
limited	O
to	O
a	O
well	O
defined	O
equatorial	O
/	O
bow	O
region	O
,	O
and	O
ordered	O
radial	O
columns	O
of	O
elongating	O
fiber	O
cells	B-CL
extending	O
from	O
the	O
posterior	O
capsule	O
to	O
the	O
anterior	O
epithelium	O
were	O
not	O
observed	O
.	O

In	O
addition	O
to	O
the	O
equatorial	O
region	O
,	O
ultrastructural	O
differences	O
between	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
(	O
Figure	O
3C	O
and	O
3H	O
)	O
and	O
wild	B-SO
type	I-SO
lenses	O
(	O
Figure	O
3M	O
and	O
3R	O
)	O
were	O
observed	O
in	O
fiber	O
cells	B-CL
of	O
the	O
embryonic	O
and	O
fetal	O
nucleus	O
.	O

In	O
5	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
(	O
Figure	O
3C	O
)	O
,	O
a	O
greater	O
variation	O
in	O
cross	O
sectional	O
diameter	O
was	O
observed	O
,	O
with	O
cell	B-CL
diameters	O
ranging	O
from	O
less	O
than	O
2	O
microns	O
up	O
to	O
approximately	O
25	O
microns	O
,	O
compared	O
to	O
the	O
5	O
wk	O
and	O
46	O
wk	O
wild	B-SO
type	I-SO
lenses	O
,	O
whose	O
diameters	O
ranged	O
from	O
less	O
than	O
2	O
microns	O
up	O
to	O
approximately	O
10	O
microns	O
(	O
Figure	O
3M	O
and	O
3R	O
)	O
.	O

At	O
54	O
wk	O
,	O
these	O
cells	B-CL
in	O
the	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
were	O
larger	O
in	O
cross	O
sectional	O
diameter	O
than	O
wild	B-SO
type	I-SO
,	O
and	O
exhibited	O
a	O
much	O
greater	O
variation	O
in	O
the	O
cross	O
sectional	O
size	O
and	O
cell	B-CL
shape	O
.	O

Cells	B-CL
adjacent	O
to	O
the	O
posterior	O
capsule	O
of	O
5	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
(	O
Figure	O
3E	O
)	O
exhibited	O
nucleic	B-CHEBI
acid	I-CHEBI
staining	O
,	O
were	O
small	O
and	O
non	O
-	O
elongated	O
,	O
with	O
numerous	O
membrane	B-GO
projections	I-GO
.	O
,	O
These	O
were	O
,	O
however	O
,	O
not	O
observed	O
in	O
54	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
.	O

In	O
5	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
,	O
deep	O
to	O
the	O
posterior	O
capsule	O
,	O
larger	O
diameter	O
cells	B-CL
,	O
similar	O
to	O
those	O
observed	O
in	O
the	O
embryonic	O
/	O
fetal	O
nucleus	O
were	O
observed	O
(	O
data	O
not	O
shown	O
)	O
.	O

Fiber	O
cells	B-CL
of	O
similar	O
dimension	O
and	O
appearance	O
to	O
embryonic	O
/	O
fetal	O
nuclear	O
fibers	O
were	O
seen	O
at	O
the	O
posterior	O
capsule	O
in	O
54	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
(	O
Figure	O
3J	O
)	O
.	O

In	O
both	O
5	O
and	O
54	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
,	O
no	O
posterior	O
sutures	O
could	O
be	O
found	O
in	O
any	O
axial	O
or	O
equatorial	O
vibratome	O
sections	O
examined	O
.	O

Posterior	O
sutures	O
were	O
readily	O
found	O
in	O
vibratome	O
sections	O
of	O
wild	B-SO
type	I-SO
lenses	O
(	O
Figure	O
3O	O
,	O
arrow	O
)	O
.	O

Fiber	O
cells	B-CL
attached	O
to	O
the	O
posterior	O
capsule	O
and	O
extending	O
anteriorly	O
were	O
observed	O
in	O
5	O
wk	O
(	O
Figure	O
3O	O
)	O
,	O
46	O
wk	O
(	O
Figure	O
3T	O
)	O
and	O
72	O
wk	O
(	O
data	O
not	O
shown	O
)	O
wild	B-SO
type	I-SO
lenses	O
.	O

SEM	O
confirmed	O
many	O
of	O
the	O
observations	O
made	O
by	O
confocal	O
microscopy	O
.	O

In	O
the	O
equatorial	O
/	O
bow	O
region	O
,	O
a	O
disorganized	O
array	O
of	O
relatively	O
small	O
irregular	O
shaped	O
cells	B-CL
were	O
observed	O
in	O
5	O
wk	O
(	O
Figure	O
4A	O
)	O
and	O
54	O
wk	O
(	O
Figure	O
4D	O
)	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
,	O
while	O
elongated	O
fiber	O
cells	B-CL
organized	O
into	O
radial	O
columns	O
,	O
with	O
ball	O
and	O
socket	O
interdigitations	O
,	O
were	O
observed	O
in	O
5	O
wk	O
(	O
Figure	O
4G	O
)	O
,	O
46	O
wk	O
(	O
Figure	O
4J	O
)	O
and	O
72	O
wk	O
(	O
data	O
not	O
shown	O
)	O
wild	B-SO
type	I-SO
lenses	O
.	O

In	O
the	O
anterior	O
cortical	O
region	O
of	O
5	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
,	O
radial	O
columns	O
of	O
cells	B-CL
with	O
numerous	O
cell	B-GO
surface	I-GO
projections	I-GO
were	O
observed	O
(	O
Figure	O
4B	O
)	O
,	O
but	O
these	O
radial	O
columns	O
were	O
no	O
longer	O
present	O
at	O
54	O
weeks	O
of	O
age	O
(	O
Figure	O
4E	O
)	O
.	O

In	O
these	O
older	O
lenses	O
,	O
irregularly	O
shaped	O
,	O
convoluted	O
cells	B-CL
,	O
with	O
no	O
recognizable	O
pattern	O
of	O
organization	O
,	O
were	O
present	O
.	O

In	O
contrast	O
,	O
radial	O
columns	O
of	O
elongated	O
fiber	O
cells	B-CL
of	O
uniform	O
size	O
and	O
shape	O
,	O
with	O
ball	O
and	O
socket	O
interdigitations	O
,	O
were	O
present	O
in	O
the	O
anterior	O
cortical	O
region	O
of	O
5	O
wk	O
(	O
Figure	O
4H	O
)	O
,	O
46	O
wk	O
(	O
Figure	O
4K	O
)	O
and	O
72	O
week	O
(	O
data	O
not	O
shown	O
)	O
wild	B-SO
type	I-SO
lenses	O
.	O

The	O
posterior	O
subcapsular	O
regions	O
of	O
5	O
wk	O
(	O
Figure	O
4C	O
)	O
and	O
54	O
wk	O
(	O
Figure	O
4F	O
)	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
were	O
filled	O
with	O
irregularly	O
shaped	O
cells	B-CL
with	O
numerous	O
cell	B-GO
surface	I-GO
projections	I-GO
.	O

In	O
the	O
fetal	O
/	O
embryonic	O
nucleus	O
,	O
elongated	O
fiber	O
cells	B-CL
with	O
numerous	O
long	O
,	O
finger	O
-	O
like	O
projections	O
and	O
furrowed	O
membranes	B-GO
were	O
evident	O
(	O
not	O
shown	O
)	O
.	O

No	O
elongated	O
cells	B-CL
extending	O
from	O
the	O
bow	O
region	O
to	O
the	O
posterior	O
capsule	O
of	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
were	O
observed	O
.	O

In	O
contrast	O
,	O
radial	O
columns	O
of	O
elongated	O
fiber	O
cells	B-CL
of	O
uniform	O
size	O
and	O
shape	O
containing	O
ball	O
and	O
socket	O
interdigitations	O
were	O
observed	O
in	O
the	O
posterior	O
subcapsular	O
region	O
in	O
5	O
wk	O
(	O
Figure	O
4I	O
)	O
,	O
46	O
wk	O
(	O
Figure	O
4L	O
)	O
and	O
72	O
wk	O
(	O
data	O
not	O
shown	O
)	O
wild	B-SO
type	I-SO
lenses	O
,	O
and	O
fiber	O
cells	B-CL
in	O
contact	O
with	O
the	O
posterior	O
capsule	O
could	O
be	O
traced	O
back	O
to	O
the	O
equatorial	O
bow	O
region	O
and	O
anterior	O
epithelium	O
.	O

Figure	O
4	O

Representative	O
scanning	O
electron	B-CHEBI
micrographs	O
of	O
alphaA	B-GGP
/	O
BKO	O
(	O
A	O
-	O
F	O
)	O
and	O
wild	B-SO
type	I-SO
(	O
G	O
-	O
L	O
)	O
lenses	O
.	O

(	O
A	O
-	O
C	O
)	O
Representative	O
images	O
from	O
5	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
.	O

(	O
D	O
-	O
F	O
)	O
Representative	O
images	O
from	O
54	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
.	O

(	O
G	O
-	O
I	O
)	O
Representative	O
images	O
from	O
5	O
wk	O
wild	B-SO
type	I-SO
lenses	O
.	O

(	O
J	O
-	O
L	O
)	O
Representative	O
images	O
from	O
46	O
wk	O
wild	B-SO
type	I-SO
lenses	O
.	O

(	O
A	O
,	O
D	O
,	O
G	O
,	O
and	O
J	O
)	O
Equatorial	O
/	O
bow	O
region	O
.	O

(	O
B	O
,	O
E	O
,	O
H	O
,	O
and	O
K	O
)	O
Anterior	O
cortex	O
.	O

C	O
,	O
(	O
F	O
,	O
I	O
,	O
and	O
L	O
)	O
Posterior	O
subcapsular	O
region	O
.	O

Discussion	O

One	O
approach	O
to	O
resolving	O
some	O
of	O
the	O
in	O
vivo	O
functions	O
of	O
alpha	O
-	O
crystallin	O
is	O
to	O
generate	O
animal	B-Taxon
models	O
where	O
one	O
or	O
both	O
of	O
the	O
alpha	O
-	O
crystallin	O
gene	B-SO
products	O
have	O
been	O
eliminated	O
.	O

Brady	O
et	O
al	O
.	O

[	O
22	O
]	O
demonstrated	O
,	O
by	O
targeted	O
disruption	O
of	O
the	O
mouse	B-GGP
alphaA	I-GGP
gene	B-SO
,	O
that	O
this	O
protein	B-CHEBI
was	O
essential	O
for	O
the	O
maintenance	O
of	O
lens	O
transparency	O
,	O
possibly	O
by	O
maintaining	O
the	O
solubility	O
of	O
alphaB	B-GGP
,	O
or	O
associated	O
proteins	B-CHEBI
,	O
in	O
the	O
lens	O
.	O

These	O
lenses	O
were	O
also	O
reported	O
to	O
be	O
smaller	O
in	O
equatorial	O
and	O
axial	O
dimensions	O
than	O
age	O
matched	O
wild	B-SO
type	I-SO
lens	O
,	O
which	O
was	O
very	O
similar	O
to	O
that	O
which	O
was	O
observed	O
with	O
the	O
double	O
knockout	O
lens	O
.	O

Targeted	O
disruption	O
of	O
the	O
mouse	B-GGP
alphaB	I-GGP
gene	B-SO
,	O
however	O
,	O
resulted	O
in	O
lenses	O
similar	O
in	O
size	O
to	O
aged	O
-	O
matched	O
wild	B-SO
type	I-SO
lens	O
with	O
no	O
cataracts	O
reported	O
[	O
23	O
]	O
.	O

This	O
indicates	O
that	O
alphaA	B-GGP
may	O
play	O
a	O
greater	O
role	O
in	O
maintaining	O
the	O
transparency	O
of	O
the	O
lens	O
then	O
alphaB	B-GGP
.	O

In	O
the	O
single	O
alpha	B-GGP
-	I-GGP
crystallin	I-GGP
knockout	O
mice	B-Taxon
,	O
the	O
remaining	O
alpha	B-GGP
-	I-GGP
crystallin	I-GGP
may	O
fully	O
or	O
partially	O
compensate	O
for	O
some	O
of	O
the	O
functions	O
of	O
the	O
missing	O
protein	B-CHEBI
,	O
especially	O
in	O
the	O
lens	O
,	O
where	O
both	O
alphaA	B-GGP
and	O
alphaB	B-GGP
are	O
normally	O
expressed	O
at	O
high	O
levels	O
.	O

This	O
was	O
supported	O
by	O
the	O
morphological	O
observation	O
made	O
in	O
this	O
study	O
of	O
no	O
posterior	O
sutures	O
or	O
fiber	O
cells	B-CL
extending	O
to	O
the	O
posterior	O
capsule	O
of	O
the	O
lens	O
,	O
ectopically	O
staining	O
nucleic	B-CHEBI
acids	I-CHEBI
in	O
the	O
posterior	O
subcapsular	O
region	O
of	O
5	O
wk	O
and	O
anterior	O
subcapsular	O
cortex	O
of	O
54	O
wk	O
,	O
gross	O
morphological	O
differences	O
in	O
the	O
equatorial	O
/	O
bow	O
,	O
posterior	O
and	O
anterior	O
regions	O
of	O
lenses	O
from	O
alphaA	B-GGP
/	O
BKO	O
mice	B-Taxon
as	O
compared	O
to	O
wild	B-SO
mice	B-Taxon
.	O

None	O
of	O
these	O
morphological	O
differences	O
have	O
been	O
reported	O
in	O
the	O
single	O
alphaA	B-GGP
or	O
alphaB	B-GGP
knockout	O
mice	B-Taxon
.	O

It	O
must	O
be	O
noted	O
,	O
however	O
,	O
that	O
the	O
alphaA	B-GGP
/	O
BKO	O
mice	B-Taxon
also	O
lack	O
the	O
HSPB2	B-GGP
gene	B-SO
product	O
[	O
23	O
]	O
and	O
the	O
contribution	O
of	O
this	O
protein	B-CHEBI
to	O
normal	O
lens	O
morphology	O
and	O
functions	O
should	O
not	O
be	O
overlooked	O
.	O

Future	O
studies	O
should	O
address	O
the	O
possible	O
functions	O
of	O
HSPB2	B-GGP
in	O
normal	O
lens	O
.	O

The	O
results	O
of	O
the	O
current	O
study	O
support	O
the	O
hypothesis	O
that	O
alpha	B-GGP
-	I-GGP
crystallin	I-GGP
plays	O
an	O
active	O
role	O
in	O
the	O
differentiation	O
and	O
growth	O
of	O
lens	O
fiber	O
cells	B-CL
.	O

Normal	O
differentiation	O
of	O
lens	O
fiber	O
cells	B-CL
consists	O
of	O
a	O
progression	O
from	O
a	O
simple	O
cuboidal	O
epithelial	B-CL
cell	I-CL
,	O
containing	O
a	O
nucleus	B-GO
and	O
a	O
minimal	O
numbers	O
of	O
organelles	B-GO
,	O
to	O
a	O
stratified	O
layer	O
of	O
elongated	O
fiber	O
-	O
like	O
cells	B-CL
,	O
devoid	O
of	O
nuclei	B-GO
and	O
organelles	B-GO
.	O

Differentiation	O
of	O
epithelial	B-CL
cells	I-CL
occurs	O
in	O
the	O
equatorial	O
/	O
bow	O
region	O
of	O
the	O
lens	O
,	O
where	O
epithelial	B-CL
cells	I-CL
begin	O
to	O
elongate	O
and	O
differentiate	O
into	O
fiber	O
cells	B-CL
of	O
uniform	O
cellular	B-CL
shape	O
,	O
arranged	O
in	O
radial	O
columns	O
of	O
cells	B-CL
extending	O
from	O
the	O
anterior	O
epithelium	O
to	O
the	O
posterior	O
capsule	O
.	O

This	O
process	O
did	O
not	O
appear	O
to	O
have	O
proceeded	O
normally	O
in	O
lenses	O
lacking	O
alphaA	B-GGP
and	O
alphaB	B-GGP
.	O

The	O
morphological	O
observations	O
presented	O
in	O
this	O
study	O
demonstrate	O
that	O
fiber	O
cells	B-CL
in	O
lenses	O
lacking	O
alphaA	B-GGP
and	O
alphaB	B-GGP
fail	O
to	O
elongate	O
symmetrically	O
from	O
the	O
bow	O
region	O
and	O
therefore	O
do	O
not	O
establish	O
the	O
typical	O
"	O
onion	O
skin	O
"	O
conformation	O
in	O
which	O
cells	B-CL
extend	O
from	O
the	O
anterior	O
epithelium	O
to	O
the	O
posterior	O
capsule	O
.	O

Additionally	O
,	O
in	O
lenses	O
from	O
54	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
,	O
there	O
was	O
a	O
persistence	O
of	O
cell	B-CL
nuclei	B-GO
in	O
deeper	O
cortical	O
regions	O
,	O
and	O
ectopic	O
cell	B-CL
nuclei	B-GO
were	O
present	O
in	O
large	O
numbers	O
in	O
the	O
anterior	O
central	O
cortex	O
.	O

At	O
5	O
wks	O
of	O
age	O
cell	B-CL
nuclei	B-GO
were	O
present	O
,	O
adjacent	O
to	O
the	O
posterior	O
capsule	O
.	O

These	O
morphological	O
observations	O
are	O
consistent	O
with	O
a	O
defect	O
in	O
the	O
normal	O
differentiation	O
pathway	O
of	O
lens	O
epithelial	B-CL
cells	I-CL
into	O
fiber	O
cells	B-CL
.	O

It	O
is	O
unlikely	O
that	O
these	O
alterations	O
in	O
alphaA	B-GGP
/	O
BKO	O
mouse	B-Taxon
lenses	O
result	O
from	O
increased	O
susceptibility	O
of	O
these	O
lenses	O
to	O
light	O
-	O
induced	O
damage	O
in	O
the	O
absence	O
of	O
the	O
molecular	B-CHEBI
chaperone	O
protection	O
afforded	O
by	O
alphaA	B-GGP
and	O
alphaB	B-GGP
in	O
normal	O
lenses	O
.	O

With	O
the	O
normal	O
time	O
of	O
eye	O
opening	O
at	O
approximately	O
14	O
days	O
after	O
birth	O
,	O
the	O
5	O
wk	O
old	O
mice	B-Taxon
had	O
their	O
eyes	O
open	O
and	O
lenses	O
exposed	O
to	O
light	O
for	O
only	O
about	O
3	O
weeks	O
prior	O
to	O
morphological	O
analysis	O
.	O

Moreover	O
,	O
these	O
animals	B-Taxon
had	O
been	O
exposed	O
to	O
only	O
animal	B-Taxon
facility	O
fluorescent	O
lighting	O
and	O
were	O
protected	O
from	O
UV	O
light	O
by	O
plastic	O
cages	O
.	O

If	O
lack	O
of	O
protection	O
from	O
light	O
-	O
induced	O
damage	O
was	O
the	O
major	O
factor	O
affecting	O
the	O
changes	O
in	O
these	O
lenses	O
,	O
then	O
the	O
bulk	O
of	O
the	O
damage	O
should	O
have	O
resided	O
along	O
the	O
visual	O
axis	O
,	O
particularly	O
in	O
the	O
central	O
anterior	O
epithelium	O
and	O
subcapsular	O
cortex	O
in	O
the	O
5	O
wk	O
lenses	O
,	O
but	O
this	O
was	O
not	O
the	O
case	O
.	O

In	O
these	O
lenses	O
,	O
gross	O
morphological	O
changes	O
were	O
apparent	O
in	O
the	O
equatorial	O
and	O
posterior	O
subcapsular	O
regions	O
.	O

These	O
changes	O
included	O
posterior	O
subcapsular	O
nucleic	B-CHEBI
acid	I-CHEBI
staining	O
,	O
absence	O
of	O
posterior	O
sutures	O
,	O
and	O
small	O
irregularly	O
shaped	O
cells	B-CL
,	O
not	O
arranged	O
in	O
any	O
discernable	O
pattern	O
,	O
in	O
the	O
equatorial	O
/	O
bow	O
region	O
.	O

Systemic	O
stress	O
factors	O
crossing	O
the	O
blood	O
/	O
aqueous	B-CHEBI
barrier	O
might	O
explain	O
some	O
morphological	O
changes	O
at	O
the	O
equatorial	O
region	O
,	O
but	O
this	O
would	O
not	O
explain	O
nucleic	B-CHEBI
acid	I-CHEBI
staining	O
in	O
the	O
posterior	O
subcapsular	O
region	O
.	O

In	O
the	O
5	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
,	O
nucleic	B-CHEBI
acid	I-CHEBI
staining	O
in	O
the	O
posterior	O
subcapsular	O
region	O
is	O
consistent	O
with	O
either	O
anterior	O
epithelial	B-CL
cells	I-CL
migrating	O
aberrantly	O
to	O
the	O
posterior	O
pole	O
,	O
or	O
primary	O
fiber	O
cells	B-CL
failing	O
to	O
fully	O
differentiate	O
by	O
5	O
wks	O
of	O
age	O
.	O

These	O
two	O
possibilities	O
could	O
not	O
be	O
differentiated	O
in	O
the	O
methods	O
employed	O
,	O
and	O
were	O
beyond	O
the	O
objectives	O
of	O
the	O
current	O
study	O
.	O

Future	O
studies	O
are	O
being	O
designed	O
to	O
address	O
which	O
of	O
these	O
two	O
processes	O
might	O
explain	O
nucleic	B-CHEBI
acid	I-CHEBI
staining	O
in	O
the	O
posterior	O
subcapsular	O
region	O
.	O

Staining	O
in	O
this	O
region	O
was	O
not	O
observed	O
in	O
older	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
,	O
suggesting	O
that	O
this	O
pattern	O
was	O
transient	O
.	O

The	O
fate	O
of	O
the	O
nucleic	B-CHEBI
acid	I-CHEBI
-	O
containing	O
cells	B-CL
in	O
the	O
posterior	O
capsular	O
region	O
of	O
younger	O
lenses	O
is	O
not	O
known	O
at	O
this	O
time	O
,	O
nor	O
is	O
the	O
morphology	O
of	O
earlier	O
stage	O
lenses	O
.	O

Future	O
studies	O
with	O
defined	O
objectives	O
to	O
address	O
the	O
development	O
and	O
progression	O
of	O
morphological	O
changes	O
seen	O
in	O
this	O
study	O
are	O
being	O
designed	O
.	O

The	O
morphological	O
differences	O
in	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
,	O
compared	O
to	O
age	O
matched	O
wild	B-SO
type	I-SO
lenses	O
,	O
were	O
consistent	O
with	O
the	O
hypothesis	O
that	O
alpha	B-GGP
-	I-GGP
crystallin	I-GGP
plays	O
an	O
active	O
role	O
in	O
the	O
differentiation	O
and	O
growth	O
of	O
lens	O
fiber	O
cells	B-CL
.	O

In	O
addition	O
,	O
it	O
was	O
clearly	O
evident	O
that	O
alpha	B-GGP
-	I-GGP
crystallin	I-GGP
is	O
necessary	O
for	O
lens	O
transparency	O
.	O

The	O
final	O
biological	O
event	O
in	O
a	O
lens	O
epithelial	B-CL
cell	I-CL
'	O
s	O
life	O
is	O
the	O
transformation	O
from	O
an	O
epithelial	B-CL
cell	I-CL
into	O
a	O
fiber	O
cell	B-CL
,	O
which	O
occurs	O
at	O
the	O
equatorial	O
/	O
bow	O
region	O
of	O
the	O
lens	O
.	O

The	O
newly	O
forming	O
fiber	O
cell	B-CL
continues	O
to	O
differentiate	O
in	O
the	O
cortex	O
until	O
a	O
mature	O
fiber	O
cell	B-CL
devoid	O
of	O
organelles	B-GO
with	O
suture	O
formation	O
at	O
the	O
ends	O
of	O
the	O
cell	B-CL
is	O
formed	O
.	O

This	O
entire	O
process	O
from	O
epithelial	B-CL
cell	I-CL
to	O
mature	O
fiber	O
cell	B-CL
is	O
defined	O
as	O
lens	O
differentiation	O
.	O

The	O
precise	O
spatial	O
and	O
temporal	O
expression	O
of	O
the	O
crystallin	O
proteins	B-CHEBI
in	O
the	O
developing	O
lens	O
may	O
not	O
be	O
simply	O
a	O
consequence	O
of	O
the	O
differentiation	O
process	O
,	O
but	O
instead	O
may	O
play	O
an	O
important	O
,	O
if	O
not	O
essential	O
,	O
role	O
in	O
the	O
differentiation	O
process	O
itself	O
.	O

The	O
results	O
of	O
the	O
current	O
study	O
support	O
this	O
hypothesis	O
.	O

The	O
exact	O
in	O
vivo	O
molecular	B-CHEBI
mechanisms	O
,	O
by	O
which	O
alpha	O
-	O
crystallin	O
might	O
influence	O
lens	O
epithelial	B-CL
cell	I-CL
differentiation	O
,	O
and	O
maintenance	O
of	O
lens	O
transparency	O
,	O
remain	O
to	O
be	O
determined	O
.	O

AlphaA	B-GGP
and	O
alphaB	B-GGP
are	O
members	O
of	O
the	O
shsp	B-GGP
family	O
[	O
7	O
]	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
the	O
alpha	O
-	O
crystallin	O
possesses	O
molecular	B-CHEBI
chaperone	O
activity	O
,	O
binding	O
to	O
partially	O
denatured	O
proteins	B-CHEBI
,	O
both	O
in	O
vitro	O
[	O
5	O
]	O
and	O
probably	O
in	O
vivo	O
[	O
6	O
]	O
,	O
to	O
inhibit	O
further	O
denaturation	O
.	O

Although	O
this	O
property	O
may	O
be	O
a	O
major	O
contributor	O
to	O
the	O
maintenance	O
of	O
lens	O
clarity	O
,	O
the	O
early	O
changes	O
in	O
the	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
indicate	O
a	O
much	O
broader	O
cellular	B-CL
function	O
for	O
alpha	B-GGP
-	I-GGP
crystallin	I-GGP
.	O

Stress	O
proteins	B-CHEBI
have	O
been	O
shown	O
to	O
be	O
expressed	O
in	O
non	O
-	O
stressed	O
cells	B-CL
during	O
development	O
and	O
differentiation	O
[	O
25	O
]	O
.	O

Hsps	O
were	O
shown	O
to	O
be	O
expressed	O
during	O
the	O
differentiation	O
of	O
mammalian	B-Taxon
osteoblasts	B-CL
and	O
promelocytic	O
leukemia	O
cells	B-CL
[	O
26	O
]	O
.	O

In	O
addition	O
,	O
hsp	O
expression	O
has	O
been	O
shown	O
to	O
accompany	O
growth	O
arrest	O
in	O
human	B-Taxon
B	B-CL
lymphocytes	I-CL
[	O
27	O
]	O
and	O
macrophage	B-CL
differentiation	O
of	O
HL	O
60	O
cells	B-CL
[	O
28	O
]	O
.	O

During	O
myogenic	O
differentiation	O
,	O
mRNA	B-CHEBI
for	O
alphaB	B-GGP
increases	O
in	O
conjunction	O
with	O
the	O
induction	O
of	O
mRNA	B-CHEBI
for	O
myogenin	B-GGP
,	O
the	O
earliest	O
known	O
event	O
in	O
myogenesis	O
[	O
29	O
]	O
.	O

The	O
addition	O
of	O
exogenous	O
alpha	O
-	O
crystallin	O
to	O
primary	O
bovine	B-Taxon
lens	O
epithelium	O
was	O
shown	O
to	O
induce	O
rapid	O
changes	O
in	O
cell	B-CL
shape	O
,	O
leading	O
to	O
the	O
formation	O
of	O
lentoid	O
bodies	O
[	O
21	O
]	O
.	O

These	O
studies	O
strongly	O
suggest	O
that	O
the	O
hsp	O
family	O
of	O
proteins	B-CHEBI
has	O
other	O
functions	O
in	O
addition	O
to	O
protecting	O
proteins	B-CHEBI
and	O
cells	B-CL
during	O
stress	O
.	O

Alpha	O
-	O
crystallin	O
may	O
play	O
a	O
functional	O
role	O
in	O
the	O
cell	B-CL
nucleus	B-GO
and	O
may	O
have	O
a	O
role	O
in	O
regulating	O
the	O
cell	B-CL
cycle	O
.	O

Several	O
heat	O
shock	O
proteins	B-CHEBI
have	O
been	O
found	O
in	O
cell	B-CL
nuclei	B-GO
in	O
the	O
absence	O
of	O
stress	O
[	O
30	O
]	O
,	O
and	O
alpha	O
-	O
crystallin	O
has	O
been	O
shown	O
to	O
interact	O
directly	O
with	O
DNA	B-SO
[	O
18	O
]	O
.	O

AlphaB	B-GGP
,	O
expressed	O
in	O
transfected	O
CHO	O
cells	B-CL
,	O
has	O
been	O
shown	O
to	O
ectopically	O
localize	O
to	O
interphase	O
nuclei	B-GO
,	O
suggesting	O
a	O
regulatory	O
role	O
for	O
this	O
protein	B-CHEBI
in	O
the	O
nucleus	B-GO
[	O
19	O
]	O
.	O

A	O
subset	O
of	O
immortalized	O
lens	O
epithelial	B-CL
cells	I-CL
from	O
alphaBKO	O
mice	B-Taxon
have	O
been	O
shown	O
to	O
hyperproliferate	O
[	O
20	O
]	O
suggesting	O
that	O
alphaB	B-GGP
may	O
be	O
important	O
in	O
maintaining	O
genomic	B-SO
stability	O
.	O

In	O
lens	O
epithelium	O
derived	O
from	O
alphaAKO	O
lenses	O
,	O
cell	B-CL
growth	O
rates	O
were	O
reported	O
to	O
be	O
50	O
%	O
lower	O
compared	O
to	O
wild	B-SO
type	I-SO
[	O
31	O
]	O
,	O
suggesting	O
a	O
role	O
for	O
alphaA	B-GGP
in	O
regulating	O
the	O
cell	B-CL
cycle	O
.	O

All	O
of	O
these	O
findings	O
raise	O
many	O
questions	O
as	O
to	O
the	O
possible	O
role	O
(	O
s	O
)	O
of	O
alpha	O
-	O
crystallin	O
in	O
the	O
nucleus	B-GO
and	O
in	O
cell	B-CL
cycle	O
regulation	O
during	O
differentiation	O
.	O

In	O
the	O
current	O
study	O
,	O
the	O
observation	O
of	O
a	O
disorganized	O
pattern	O
of	O
nuclei	B-GO
localized	O
to	O
the	O
equatorial	O
bow	O
region	O
of	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
,	O
and	O
nucleic	B-CHEBI
acid	I-CHEBI
staining	O
of	O
structures	O
throughout	O
the	O
anterior	O
cortex	O
of	O
54	O
wk	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
,	O
is	O
consistent	O
with	O
a	O
role	O
for	O
alpha	B-GGP
-	I-GGP
crystallin	I-GGP
in	O
the	O
nucleus	B-GO
.	O

There	O
is	O
extensive	O
evidence	O
from	O
previous	O
studies	O
demonstrating	O
that	O
alpha	O
-	O
crystallin	O
plays	O
a	O
role	O
in	O
the	O
cytoskeletal	B-GO
organization	O
.	O

Both	O
alphaA	B-GGP
and	O
alphaB	B-GGP
can	O
bind	O
specifically	O
to	O
actin	O
,	O
both	O
in	O
vitro	O
[	O
13	O
]	O
and	O
in	O
vivo	O
[	O
14	O
]	O
.	O

Actin	B-GO
filament	I-GO
formation	O
has	O
been	O
shown	O
to	O
be	O
necessary	O
for	O
the	O
differentiation	O
of	O
lens	O
epithelial	B-CL
cells	I-CL
[	O
15	O
]	O
,	O
however	O
,	O
the	O
significance	O
of	O
alpha	O
-	O
crystallin	O
interaction	O
with	O
actin	O
in	O
differentiation	O
is	O
not	O
known	O
.	O

In	O
the	O
lens	O
,	O
alpha	O
-	O
crystallin	O
also	O
forms	O
a	O
complex	O
with	O
type	B-GO
III	I-GO
intermediate	I-GO
filament	I-GO
proteins	B-CHEBI
and	O
the	O
lens	O
-	O
specific	O
beaded	O
filament	O
proteins	B-CHEBI
CP49	B-GGP
and	O
CP115	B-GGP
,	O
which	O
may	O
be	O
critical	O
for	O
proper	O
filament	O
assembly	O
[	O
16	O
]	O
.	O

Beaded	O
filament	O
mRNA	B-CHEBI
levels	O
increase	O
greatly	O
in	O
differentiating	O
lens	O
epithelial	B-CL
cells	I-CL
,	O
and	O
have	O
been	O
suggested	O
as	O
a	O
pan	O
-	O
specific	O
marker	O
for	O
lens	O
fiber	O
cells	B-CL
[	O
17	O
]	O
.	O

It	O
is	O
therefore	O
possible	O
that	O
increased	O
synthesis	O
of	O
alpha	O
-	O
crystallin	O
in	O
epithelial	B-CL
cells	I-CL
early	O
in	O
the	O
differentiation	O
process	O
may	O
have	O
profound	O
effects	O
upon	O
the	O
cytoskeleton	B-GO
,	O
which	O
in	O
turn	O
may	O
profoundly	O
affect	O
cell	B-CL
shape	O
and	O
migration	O
.	O

The	O
lack	O
of	O
cellar	O
organization	O
and	O
uniform	O
cell	B-CL
shape	O
at	O
the	O
equatorial	O
region	O
observed	O
in	O
alphaA	B-GGP
/	O
BKO	O
lenses	O
supports	O
this	O
hypothesis	O
.	O

Studies	O
are	O
currently	O
underway	O
to	O
characterize	O
cytoskeletal	B-GO
organization	O
in	O
the	O
alphaA	B-GGP
/	O
BKO	O
lens	O
.	O

Competing	O
interests	O

None	O
declared	O

Authors	O
'	O
contributions	O

DLB	O
conceived	O
and	O
designed	O
the	O
study	O
,	O
carried	O
out	O
sample	O
preparation	O
,	O
confocal	O
microscopy	O
,	O
scanning	O
electron	B-CHEBI
microscopy	O
,	O
statistical	O
analysis	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O

JPB	O
assisted	O
in	O
the	O
production	O
of	O
the	O
Alpha	B-GGP
/	O
BKO	O
mice	B-Taxon
.	O

EFW	O
assisted	O
in	O
the	O
production	O
of	O
the	O
AlphaA	B-GGP
/	O
BKO	O
mice	B-Taxon
,	O
experimental	O
design	O
,	O
and	O
initial	O
fixation	O
of	O
samples	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

Acknowledgements	O

This	O
research	O
was	O
supported	O
in	O
part	O
by	O
a	O
NIH	O
Grant	O
for	O
Vision	O
Research	O
EY02932	O
awarded	O
to	O
LT	O
.	O

A	O
model	O
of	O
tripeptidyl	B-GGP
-	I-GGP
peptidase	I-GGP
I	I-GGP
(	O
CLN2	B-GGP
)	O
,	O
a	O
ubiquitous	O
and	O
highly	O
conserved	B-SO
member	O
of	O
the	O
sedolisin	O
family	O
of	O
serine	B-CHEBI
-	O
carboxyl	B-CHEBI
peptidases	O

Abstract	O

Background	O

Tripeptidyl	B-GGP
-	I-GGP
peptidase	I-GGP
I	I-GGP
,	O
also	O
known	O
as	O
CLN2	B-GGP
,	O
is	O
a	O
member	O
of	O
the	O
family	O
of	O
sedolisins	O
(	O
serine	B-CHEBI
-	O
carboxyl	B-CHEBI
peptidases	O
)	O
.	O

In	O
humans	B-Taxon
,	O
defects	O
in	O
expression	O
of	O
this	O
enzyme	B-SO
lead	O
to	O
a	O
fatal	O
neurodegenerative	O
disease	O
,	O
classical	O
late	O
-	O
infantile	O
neuronal	B-CL
ceroid	O
lipofuscinosis	O
.	O

Similar	O
enzymes	B-SO
have	O
been	O
found	O
in	O
the	O
genomic	B-SO
sequences	I-SO
of	O
several	O
species	O
,	O
but	O
neither	O
systematic	O
analyses	O
of	O
their	O
distribution	O
nor	O
modeling	O
of	O
their	O
structures	O
have	O
been	O
previously	O
attempted	O
.	O

Results	O

We	O
have	O
analyzed	O
the	O
presence	O
of	O
orthologs	B-SO
of	O
human	B-GGP
CLN2	I-GGP
in	O
the	O
genomic	B-SO
sequences	I-SO
of	O
a	O
number	O
of	O
eukaryotic	B-Taxon
species	O
.	O

Enzymes	B-SO
with	O
sequences	B-SO
sharing	O
over	O
80	O
%	O
identity	O
have	O
been	O
found	O
in	O
the	O
genomes	B-SO
of	O
macaque	B-Taxon
,	O
mouse	B-Taxon
,	O
rat	B-Taxon
,	O
dog	B-Taxon
,	O
and	O
cow	B-Taxon
.	O

Closely	O
related	O
,	O
although	O
clearly	O
distinct	O
,	O
enzymes	B-SO
are	O
present	O
in	O
fish	B-Taxon
(	O
fugu	B-Taxon
and	O
zebra	B-Taxon
)	O
,	O
as	O
well	O
as	O
in	O
frogs	B-Taxon
(	O
Xenopus	B-Taxon
tropicalis	I-Taxon
)	O
.	O

A	O
three	O
-	O
dimensional	O
model	O
of	O
human	B-GGP
CLN2	I-GGP
was	O
built	O
based	O
mainly	O
on	O
the	O
homology	B-SO
with	O
Pseudomonas	B-Taxon
sp	O
.	O

101	O
sedolisin	O
.	O

Conclusion	O

CLN2	B-GGP
is	O
very	O
highly	O
conserved	B-SO
and	O
widely	O
distributed	O
among	O
higher	O
organisms	B-Taxon
and	O
may	O
play	O
an	O
important	O
role	O
in	O
their	O
life	O
cycles	O
.	O

The	O
model	O
presented	O
here	O
indicates	O
a	O
very	O
open	O
and	O
accessible	O
active	B-SO
site	I-SO
that	O
is	O
almost	O
completely	O
conserved	B-SO
among	O
all	O
known	B-SO
CLN2	B-GGP
enzymes	B-SO
.	O

This	O
result	O
is	O
somehow	O
surprising	O
for	O
a	O
tripeptidase	O
where	O
the	O
presence	O
of	O
a	O
more	O
constrained	O
binding	O
pocket	O
was	O
anticipated	O
.	O

This	O
structural	O
model	O
should	O
be	O
useful	O
in	O
the	O
search	O
for	O
the	O
physiological	O
substrates	O
of	O
these	O
enzymes	B-SO
and	O
in	O
the	O
design	O
of	O
more	O
specific	O
inhibitors	B-CHEBI
of	O
CLN2	B-GGP
.	O

Background	O

Although	O
the	O
existence	O
of	O
tripeptidyl	B-GGP
-	I-GGP
peptidase	I-GGP
I	I-GGP
(	O
TPP	B-GGP
-	I-GGP
I	I-GGP
)	O
was	O
first	O
noted	O
over	O
40	O
years	O
ago	O
[	O
1	O
]	O
,	O
the	O
structural	O
and	O
mechanistic	O
basis	O
of	O
its	O
activity	O
has	O
been	O
largely	O
misunderstood	O
until	O
quite	O
recently	O
.	O

The	O
situation	O
changed	O
after	O
it	O
was	O
shown	O
that	O
TPP	B-GGP
-	I-GGP
I	I-GGP
is	O
identical	O
to	O
an	O
independently	O
characterized	O
enzyme	B-SO
named	O
CLN2	B-GGP
.	O

It	O
was	O
also	O
demonstrated	O
that	O
mutations	B-SO
leading	O
to	O
abolishment	O
of	O
the	O
enzymatic	B-SO
activity	O
of	O
CLN2	B-GGP
were	O
the	O
direct	O
cause	O
of	O
a	O
fatal	O
inherited	O
neurodegenerative	O
disease	O
,	O
classical	O
late	O
-	O
infantile	O
neuronal	B-CL
ceroid	O
lipofuscinosis	O
[	O
2	O
]	O
.	O

This	O
important	O
observation	O
was	O
followed	O
by	O
the	O
identification	O
of	O
CLN2	B-GGP
as	O
a	O
serine	B-CHEBI
peptidase	O
[	O
3	O
,	O
4	O
]	O
,	O
without	O
,	O
however	O
,	O
specifying	O
its	O
structural	O
fold	O
and	O
the	O
details	O
of	O
the	O
catalytic	B-SO
site	I-SO
.	O

More	O
accurate	O
placement	O
of	O
CLN2	B-GGP
within	O
the	O
context	O
of	O
a	O
family	O
of	O
related	O
enzymes	B-SO
became	O
possible	O
only	O
after	O
high	O
-	O
resolution	O
crystal	O
structures	O
of	O
two	O
bacterial	B-Taxon
enzymes	B-SO
with	O
a	O
limited	O
sequence	B-SO
similarity	O
to	O
CLN2	B-GGP
,	O
sedolisin	O
and	O
kumamolisin	O
,	O
became	O
available	O
[	O
5	O
-	O
7	O
]	O
.	O

These	O
structures	O
defined	O
a	O
novel	O
family	O
of	O
enzymes	B-SO
,	O
now	O
called	O
sedolisins	O
or	O
serine	B-CHEBI
-	O
carboxyl	B-CHEBI
peptidases	O
,	O
that	O
is	O
characterized	O
by	O
the	O
utilization	O
of	O
a	O
fully	O
conserved	B-SO
catalytic	O
triad	O
(	O
Ser	B-CHEBI
,	O
Glu	B-CHEBI
,	O
Asp	B-CHEBI
)	O
and	O
by	O
the	O
presence	O
of	O
an	O
Asp	B-CHEBI
in	O
the	O
oxyanion	B-CHEBI
hole	O
[	O
8	O
]	O
.	O

Sedolisin	O
and	O
its	O
several	O
variants	B-SO
(	O
e	O
.	O
g	O
.	O
,	O
kumamolisin	O
,	O
aorsin	O
[	O
9	O
]	O
,	O
and	O
physarolisin	O
[	O
10	O
]	O
)	O
have	O
now	O
been	O
found	O
in	O
archaea	B-Taxon
,	O
bacteria	B-Taxon
,	O
fungi	B-Taxon
and	O
amoebae	B-Taxon
,	O
whereas	O
the	O
higher	O
organisms	B-Taxon
seem	O
to	O
contain	O
only	O
variants	B-SO
of	O
CLN2	B-GGP
[	O
8	O
]	O
.	O

The	O
physiological	O
role	O
of	O
sedolisins	O
in	O
the	O
lower	O
organisms	B-Taxon
has	O
not	O
yet	O
been	O
elucidated	O
.	O

Despite	O
the	O
potential	O
medical	O
importance	O
of	O
CLN2	B-GGP
and	O
related	O
enzymes	B-SO
,	O
no	O
systematic	O
studies	O
of	O
their	O
genomic	B-SO
distribution	O
have	O
been	O
published	O
to	O
date	O
.	O

There	O
are	O
also	O
no	O
published	O
reports	O
of	O
the	O
crystallization	O
of	O
this	O
enzyme	B-SO
.	O

In	O
the	O
absence	O
of	O
an	O
experimental	O
structure	O
obtained	O
by	O
crystallography	O
or	O
NMR	O
it	O
is	O
sometimes	O
necessary	O
to	O
resort	O
to	O
molecular	B-CHEBI
modeling	O
in	O
order	O
to	O
provide	O
a	O
structural	O
basis	O
for	O
the	O
explanation	O
of	O
the	O
biological	O
properties	O
of	O
an	O
enzyme	B-SO
,	O
and	O
,	O
in	O
particular	O
,	O
to	O
initiate	O
design	O
of	O
its	O
inhibitors	B-CHEBI
.	O

Examples	O
of	O
such	O
very	O
successful	O
and	O
useful	O
modeling	O
efforts	O
are	O
provided	O
by	O
HIV	B-Taxon
protease	O
[	O
11	O
]	O
,	O
or	O
very	O
recently	O
by	O
the	O
peptidase	O
from	O
a	O
coronavirus	B-Taxon
involved	O
in	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
[	O
12	O
]	O
,	O
among	O
others	O
.	O

We	O
have	O
now	O
applied	O
the	O
tools	O
of	O
molecular	B-CHEBI
homology	B-SO
modeling	O
to	O
predicting	O
a	O
structure	O
of	O
CLN2	B-GGP
that	O
could	O
be	O
used	O
as	O
a	O
basis	O
for	O
a	O
search	O
for	O
the	O
biological	O
substrates	O
of	O
this	O
family	O
of	O
enzymes	B-SO
and	O
for	O
the	O
design	O
of	O
specific	O
inhibitors	B-CHEBI
.	O

Results	O
and	O
discussion	O

Sequence	B-SO
comparisons	O
of	O
the	O
CLN2	B-GGP
-	O
like	O
enzymes	B-SO

Mammalian	B-Taxon
enzymes	B-SO
homologous	B-SO
to	O
human	B-GGP
CLN2	I-GGP
[	O
2	O
,	O
4	O
]	O
form	O
a	O
subfamily	O
of	O
sedolisins	O
with	O
highly	O
conserved	B-SO
sequences	I-SO
(	O
Figure	O
1	O
)	O
.	O

These	O
enzymes	B-SO
are	O
expressed	O
with	O
a	O
prosegment	B-SO
consisting	O
of	O
195	O
residues	B-CHEBI
that	O
is	O
cleaved	O
off	O
during	O
maturation	O
,	O
yielding	O
the	O
active	O
catalytic	O
domain	B-SO
.	O

Complete	O
sequences	B-SO
are	O
available	O
for	O
CLN2	B-GGP
from	O
six	O
species	O
in	O
which	O
it	O
has	O
been	O
found	O
so	O
far	O
(	O
human	B-Taxon
,	O
macaque	B-Taxon
,	O
dog	B-Taxon
,	O
mouse	B-Taxon
,	O
rat	B-Taxon
,	O
and	O
cow	B-Taxon
)	O
.	O

The	O
full	O
-	O
length	O
enzymes	B-SO
consist	O
of	O
563	O
amino	B-CHEBI
acids	I-CHEBI
arranged	O
in	O
a	O
single	O
polypeptide	B-SO
chain	I-SO
containing	O
both	O
the	O
prosegment	B-SO
and	O
the	O
catalytic	O
domain	B-SO
,	O
with	O
the	O
exception	O
of	O
mouse	B-GGP
CLN2	I-GGP
that	O
has	O
a	O
single	O
deletion	B-SO
in	O
the	O
prosegment	B-SO
.	O

The	O
overall	O
sequence	B-SO
identity	O
for	O
these	O
enzymes	B-SO
is	O
81	O
%	O
,	O
whereas	O
the	O
similarity	O
is	O
92	O
%	O
.	O

A	O
pairwise	O
comparison	O
of	O
the	O
human	B-Taxon
and	O
mouse	B-Taxon
enzymes	B-SO
yields	O
88	O
%	O
identity	O
and	O
94	O
%	O
similarity	O
,	O
considerably	O
higher	O
than	O
the	O
median	O
78	O
.	O
5	O
%	O
identity	O
reported	O
for	O
all	O
identified	O
mouse	B-Taxon
-	O
human	B-Taxon
orthologs	B-SO
[	O
13	O
]	O
.	O

Thus	O
,	O
mammalian	B-Taxon
CLN2	B-GGP
appears	O
to	O
be	O
a	O
highly	O
conserved	B-SO
enzyme	B-SO
.	O

Figure	O
1	O

Sequence	B-SO
comparisons	O
of	O
mammalian	B-Taxon
CLN2	B-GGP
-	O
like	O
enzymes	B-SO
.	O
These	O
sequences	B-SO
correspond	O
to	O
the	O
complete	O
enzymes	B-SO
,	O
including	O
the	O
prosegment	B-SO
.	O

Residues	B-CHEBI
forming	O
the	O
active	B-SO
site	I-SO
are	O
shown	O
in	O
yellow	O
on	O
red	O
background	O
,	O
other	O
conserved	B-SO
residues	B-CHEBI
identified	O
as	O
important	O
for	O
the	O
stability	O
of	O
the	O
enzyme	B-SO
are	O
marked	O
with	O
yellow	O
background	O
,	O
residues	B-CHEBI
identical	O
in	O
at	O
least	O
5	O
of	O
the	O
structures	O
are	O
green	O
,	O
and	O
residues	B-CHEBI
similar	O
in	O
their	O
character	O
are	O
shown	O
in	O
magenta	O
.	O

The	O
maturation	O
cleavage	O
point	O
generating	O
the	O
N	B-SO
terminus	I-SO
of	O
the	O
active	O
enzyme	B-SO
is	O
marked	O
with	O
black	O
triangles	O
.	O

In	O
addition	O
to	O
the	O
mammals	B-Taxon
,	O
CLN2	B-GGP
-	O
like	O
enzymes	B-SO
are	O
also	O
found	O
in	O
fugu	B-Taxon
(	O
puffer	B-Taxon
fish	I-Taxon
-	O
unannotated	O
record	O
SINFRUP00000077297	O
in	O
the	O
NCBI	O
fugu	B-Taxon
sequence	B-SO
database	O
,	O
)	O
and	O
zebrafish	B-Taxon
(	O
contig	B-SO
wz4596	O
.	O
2	O
in	O
the	O
zebrafish	B-Taxon
EST	B-SO
database	O
,	O
)	O
.	O

Only	O
a	O
fragment	B-SO
of	O
the	O
sequence	B-SO
of	O
the	O
latter	O
enzyme	B-SO
agreed	O
with	O
the	O
former	O
.	O

However	O
,	O
a	O
few	O
comparatively	O
minor	O
modifications	B-SO
can	O
bring	O
the	O
zebrafish	B-Taxon
sequence	B-SO
into	O
good	O
agreement	O
with	O
that	O
of	O
the	O
fugu	B-Taxon
CLN2	B-GGP
.	O

These	O
modifications	B-SO
include	O
a	O
deletion	B-SO
of	O
a	O
single	O
nucleotide	B-CHEBI
from	O
a	O
run	O
of	O
three	O
,	O
as	O
well	O
as	O
three	O
insertions	B-SO
of	O
repeated	B-SO
nucleotide	B-SO
pairs	I-SO
(	O
Figure	O
2	O
)	O
.	O

It	O
must	O
be	O
stressed	O
that	O
these	O
modifications	B-SO
are	O
speculative	O
and	O
may	O
lead	O
to	O
prediction	O
of	O
several	O
incorrect	O
amino	B-CHEBI
acids	I-CHEBI
;	O
however	O
,	O
they	O
bring	O
the	O
two	O
sequences	B-SO
into	O
good	O
global	O
agreement	O
(	O
69	O
%	O
identities	O
and	O
83	O
%	O
similarities	O
)	O
.	O

Figure	O
2	O

Corrected	O
gene	B-SO
sequence	I-SO
of	O
the	O
zebrafish	B-GGP
CLN2	I-GGP
.	O
This	O
putative	O
sequence	B-SO
shows	O
the	O
manual	O
corrections	O
that	O
bring	O
it	O
into	O
alignment	O
with	O
the	O
sequence	B-SO
of	O
the	O
fugu	B-Taxon
enzyme	B-SO
.	O

Inserted	B-SO
nucleotides	B-CHEBI
are	O
marked	O
in	O
green	O
and	O
a	O
deleted	B-SO
one	O
in	O
red	O
.	O

The	O
available	O
amino	B-SO
acid	I-SO
sequence	I-SO
of	O
the	O
fugu	B-Taxon
CLN2	B-GGP
analog	O
,	O
named	O
by	O
us	O
sedolisin	O
-	O
TPP	O
[	O
8	O
]	O
,	O
is	O
also	O
in	O
good	O
agreement	O
with	O
the	O
sequences	B-SO
of	O
the	O
mammalian	B-Taxon
orthologs	B-SO
(	O
Figure	O
3	O
)	O
.	O

The	O
only	O
major	O
difference	O
in	O
the	O
translated	O
amino	B-SO
acid	I-SO
sequence	I-SO
compared	O
to	O
the	O
mammalian	B-Taxon
and	O
zebrafish	B-Taxon
enzymes	B-SO
is	O
in	O
the	O
amino	B-SO
terminus	I-SO
of	O
the	O
propeptide	B-SO
region	I-SO
that	O
is	O
shorter	O
by	O
30	O
amino	B-CHEBI
acids	I-CHEBI
(	O
not	O
shown	O
)	O
.	O

It	O
is	O
very	O
likely	O
that	O
this	O
represents	O
a	O
fault	O
in	O
the	O
assembled	B-SO
sequence	I-SO
rather	O
than	O
a	O
real	O
variation	B-SO
,	O
since	O
the	O
current	O
coding	B-SO
frame	I-SO
is	O
not	O
initiated	O
with	O
a	O
methionine	B-CHEBI
,	O
and	O
a	O
few	O
extra	O
residues	B-CHEBI
are	O
present	O
in	O
the	O
full	O
genomic	B-SO
sequence	I-SO
available	O
from	O
the	O
fugu	B-Taxon
sequencing	O
consortium	O
.	O

Figure	O
3	O

Sequences	B-SO
of	O
the	O
catalytic	O
domains	B-SO
of	O
CLN2	B-GGP
.	O

Complete	O
sequences	B-SO
are	O
shown	O
for	O
CLN2	B-GGP
from	I-GGP
human	I-GGP
,	I-GGP
fugu	I-GGP
,	I-GGP
and	I-GGP
zebrafish	I-GGP
,	O
together	O
with	O
the	O
partial	B-SO
sequence	B-SO
of	O
putative	O
CLN2	B-GGP
in	I-GGP
Xenopus	I-GGP
tropicalis	I-GGP
.	O

Residues	B-CHEBI
identical	O
in	O
all	O
four	O
enzymes	B-SO
are	O
colored	O
green	O
and	O
those	O
similar	O
are	O
colored	O
magenta	O
.	O

Active	B-SO
site	I-SO
residues	I-SO
are	O
marked	O
as	O
in	O
Figure	O
1	O
.	O

CLN2	B-GGP
is	O
present	O
not	O
only	O
in	O
fish	B-Taxon
,	O
but	O
also	O
in	O
amphibians	B-Taxon
,	O
in	O
particular	O
in	O
Xenopus	B-Taxon
tropicalis	I-Taxon
(	O
a	O
species	O
of	O
frog	B-Taxon
)	O
.	O

A	O
partial	B-SO
sequence	B-SO
of	O
its	O
sedolisin	O
-	O
TPP	O
(	O
AL594774	O
)	O
found	O
in	O
the	O
EST	B-SO
database	O
spans	O
the	O
middle	O
part	O
of	O
the	O
catalytic	O
domain	B-SO
,	O
without	O
reaching	O
the	O
part	O
of	O
the	O
active	B-SO
site	I-SO
closer	O
to	O
the	O
N	B-SO
terminus	I-SO
that	O
contains	O
the	O
aspartic	B-CHEBI
and	I-CHEBI
glutamic	I-CHEBI
acids	I-CHEBI
that	O
belong	O
to	O
the	O
catalytic	O
triad	O
.	O

However	O
,	O
the	O
sequenced	O
part	B-SO
of	O
the	O
enzyme	B-SO
shows	O
75	O
%	O
identity	O
with	O
the	O
fugu	B-Taxon
sedolisin	O
-	O
TPP	O
,	O
and	O
69	O
%	O
identity	O
with	O
human	B-GGP
CLN2	I-GGP
(	O
Figure	O
3	O
)	O
.	O

Sequence	B-SO
similarity	O
to	O
bacterial	B-Taxon
or	O
fungal	B-Taxon
sedolisins	O
is	O
much	O
lower	O
,	O
indicating	O
that	O
the	O
enzyme	B-SO
found	O
in	O
frogs	B-Taxon
might	O
also	O
share	O
the	O
functional	O
properties	O
of	O
the	O
CLN2	B-GGP
subfamily	O
.	O

The	O
discovery	O
of	O
highly	O
conserved	B-SO
CLN2	B-GGP
-	O
like	O
enzymes	B-SO
not	O
only	O
in	O
mammals	B-Taxon
but	O
also	O
in	O
two	O
fish	B-Taxon
species	O
and	O
one	O
of	O
frogs	B-Taxon
may	O
indicate	O
that	O
these	O
peptidases	O
are	O
universally	O
present	O
in	O
the	O
vertebrates	B-Taxon
,	O
and	O
that	O
their	O
important	O
role	O
identified	O
in	O
humans	B-Taxon
[	O
2	O
]	O
and	O
mice	B-Taxon
[	O
14	O
]	O
might	O
be	O
a	O
more	O
general	O
feature	O
.	O

Modeling	O
of	O
the	O
structure	O
of	O
human	B-GGP
CLN2	I-GGP

The	O
medical	O
importance	O
of	O
CLN2	B-GGP
and	O
the	O
lack	O
of	O
a	O
crystal	O
structure	O
inspired	O
attempts	O
at	O
protein	B-CHEBI
modeling	O
.	O

The	O
first	O
such	O
model	O
assumed	O
that	O
this	O
enzyme	B-SO
is	O
membrane	B-GO
-	O
bound	O
,	O
with	O
the	O
sequence	B-SO
271	O
-	O
294	O
(	O
numbering	O
corresponding	O
to	O
the	O
mature	O
enzyme	B-SO
,	O
Figure	O
1	O
)	O
forming	O
the	O
putative	O
transmembrane	B-GO
anchor	O
[	O
15	O
]	O
.	O

However	O
,	O
in	O
view	O
of	O
the	O
subsequently	O
obtained	O
structures	O
of	O
the	O
fully	O
water	B-CHEBI
-	O
soluble	O
sedolisins	O
,	O
this	O
model	O
was	O
clearly	O
incorrect	O
.	O

Exploiting	O
the	O
sequence	B-SO
similarity	O
between	O
CLN2	B-GGP
,	O
sedolisin	O
,	O
and	O
kumamolisin	O
(	O
Figure	O
4	O
)	O
,	O
we	O
have	O
now	O
used	O
the	O
experimentally	B-SO
obtained	I-SO
structures	O
of	O
the	O
latter	O
two	O
enzymes	B-SO
to	O
form	O
a	O
new	O
,	O
homology	B-SO
-	O
derived	O
model	O
of	O
human	B-GGP
CLN2	I-GGP
.	O

The	O
primary	O
basis	O
of	O
the	O
homology	B-SO
model	O
was	O
the	O
structure	O
of	O
a	O
complex	O
of	O
sedolisin	O
with	O
a	O
covalently	O
-	O
bound	O
inhibitor	B-CHEBI
,	O
pseudo	O
-	O
iodotyrostatin	O
.	O

Although	O
it	O
has	O
not	O
been	O
directly	O
shown	O
that	O
this	O
compound	B-CHEBI
can	O
inhibit	O
human	B-GGP
CLN2	I-GGP
,	O
other	O
similar	O
peptides	B-SO
with	O
an	O
aldehyde	B-CHEBI
functionality	O
on	O
their	O
"	O
C	B-SO
-	I-SO
termini	I-SO
"	O
are	O
weak	O
,	O
but	O
detectable	O
,	O
inhibitors	B-CHEBI
of	I-CHEBI
this	I-CHEBI
enzyme	I-CHEBI
(	O
Oda	O
,	O
unpublished	O
)	O
.	O

It	O
is	O
thus	O
likely	O
that	O
pseudo	O
-	O
iodotyrostatin	O
or	O
a	O
similar	O
inhibitor	B-CHEBI
might	O
work	O
for	O
CLN2	B-GGP
as	O
well	O
,	O
although	O
the	O
actual	O
contacts	O
between	O
the	O
inhibitor	B-CHEBI
and	O
the	O
enzyme	B-SO
that	O
are	O
seen	O
in	O
the	O
model	O
have	O
to	O
be	O
treated	O
with	O
caution	O
.	O

Another	O
reason	O
for	O
the	O
modeling	O
of	O
a	O
pseudo	O
-	O
iodotyrostatin	O
complex	O
is	O
that	O
CLN2	B-GGP
is	O
a	O
tripeptidase	O
,	O
and	O
that	O
this	O
inhibitor	B-CHEBI
it	O
represents	O
the	O
only	O
experimental	O
structure	O
of	O
a	O
tripeptide	O
analog	O
bound	O
to	O
sedolisin	O
.	O

Figure	O
4	O

Sequence	B-SO
alignment	O
of	O
bacterial	B-Taxon
and	O
mammalian	B-Taxon
enzymes	B-SO
.	O

Alignment	O
of	O
the	O
sequences	B-SO
of	O
sedolisin	O
,	O
kumamolisin	O
,	O
and	O
human	B-GGP
CLN2	I-GGP
used	O
in	O
the	O
construction	O
of	O
the	O
model	O
of	O
the	O
latter	O
enzyme	B-SO
.	O

The	O
colors	O
scheme	O
is	O
the	O
same	O
as	O
in	O
Figure	O
2	O
.	O

The	O
r	O
.	O
m	O
.	O
s	O
.	O
deviation	O
between	O
the	O
corresponding	O
C	O
alpha	O
coordinates	O
of	O
the	O
model	O
of	O
CLN2	B-GGP
(	O
Figure	O
5	O
)	O
and	O
the	O
experimental	O
structure	O
of	O
sedolisin	O
is	O
about	O
1	O
.	O
75	O
A	O
,	O
not	O
much	O
larger	O
than	O
the	O
experimental	O
difference	O
between	O
sedolisin	O
and	O
kumamolisin	O
.	O

Interestingly	O
,	O
the	O
Cys327	O
and	O
Cys342	O
residues	B-CHEBI
in	O
the	O
model	O
were	O
found	O
to	O
be	O
ideally	O
positioned	O
to	O
form	O
a	O
disulfide	O
bond	O
even	O
though	O
this	O
was	O
not	O
part	O
of	O
the	O
design	O
strategy	O
.	O

That	O
this	O
bond	O
likely	O
occurs	O
in	O
the	O
real	O
protein	B-CHEBI
is	O
suggested	O
by	O
the	O
fact	O
that	O
these	O
two	O
cysteines	B-CHEBI
are	O
strictly	O
conserved	B-SO
in	O
all	O
known	O
animal	B-Taxon
species	O
of	O
CLN2	B-GGP
(	O
Figures	O
1	O
and	O
3	O
)	O
,	O
although	O
they	O
are	O
absent	O
in	O
all	O
known	B-SO
sequences	B-SO
of	O
bacterial	B-Taxon
sedolisins	O
.	O

Thus	O
,	O
if	O
this	O
disulfide	O
were	O
experimentally	O
found	O
to	O
exist	O
in	O
CLN2	B-GGP
it	O
would	O
provide	O
support	O
for	O
the	O
correctness	O
of	O
the	O
model	O
.	O

Figure	O
5	O

A	O
homology	B-SO
-	O
derived	O
model	O
of	O
human	B-GGP
CLN2	I-GGP
.	O

Ribbon	O
diagram	O
of	O
the	O
C	O
alpha	O
trace	O
of	O
CLN2	B-GGP
,	O
with	O
the	O
segments	B-SO
that	O
were	O
modeled	O
based	O
on	O
the	O
highly	O
conserved	B-SO
core	O
of	O
sedolisin	O
and	O
kumamolisin	O
(	O
r	O
.	O
m	O
.	O
s	O
.	O
deviation	O
of	O
1	O
A	O
)	O
colored	O
in	O
red	O
.	O

Side	O
chains	O
of	O
the	O
residues	B-CHEBI
that	O
were	O
found	O
to	O
be	O
mutated	B-SO
in	O
the	O
genes	B-SO
of	O
families	O
of	O
patients	O
with	O
late	O
-	O
infantile	O
neuronal	B-CL
ceroid	O
lipofuscinosis	O
[	O
17	O
]	O
are	O
marked	O
in	O
ball	O
-	O
and	O
-	O
stick	O
.	O

Comparisons	O
of	O
the	O
substrate	O
binding	O
pockets	O
of	O
CLN2	B-GGP
and	O
sedolisin	O

Since	O
the	O
principal	O
known	O
activity	O
of	O
CLN2	B-GGP
is	O
that	O
of	O
a	O
tripeptidase	O
,	O
it	O
is	O
expected	O
that	O
three	O
substrate	O
-	O
binding	O
pockets	O
,	O
S1	O
through	O
S3	O
(	O
using	O
the	O
nomenclature	O
of	O
Schechter	O
and	O
Berger	O
[	O
16	O
]	O
)	O
,	O
should	O
be	O
discernible	O
.	O

Residues	B-CHEBI
P1	O
-	O
P3	O
of	O
the	O
inhibitor	B-CHEBI
that	O
should	O
occupy	O
these	O
pockets	O
are	O
shown	O
in	O
Figure	O
6	O
.	O

All	O
the	O
available	O
structures	O
of	O
the	O
complexes	O
of	O
either	O
sedolisin	O
or	O
kumamolisin	O
with	O
inhibitors	B-CHEBI
contain	O
either	O
a	O
tyrosine	B-CHEBI
or	O
a	O
phenylalanine	B-CHEBI
occupying	O
the	O
S1	O
pocket	O
.	O

Parts	O
of	O
this	O
pocket	O
are	O
fully	O
conserved	B-SO
among	O
different	O
sedolisins	O
,	O
whereas	O
other	O
parts	O
of	O
it	O
differ	O
.	O

The	O
right	O
-	O
hand	O
side	O
of	O
the	O
pocket	O
(	O
in	O
the	O
view	O
used	O
in	O
Figure	O
6	O
)	O
is	O
made	O
of	O
the	O
main	O
chain	B-SO
including	O
residues	B-CHEBI
164	O
-	O
165	O
(	O
unless	O
otherwise	O
indicated	O
,	O
the	O
numbering	O
refers	O
to	O
the	O
sequence	B-SO
of	O
the	O
mature	O
human	B-GGP
CLN2	I-GGP
)	O
.	O

This	O
part	O
of	O
the	O
main	O
chain	B-SO
is	O
held	O
in	O
place	O
through	O
a	O
hydrogen	B-CHEBI
-	O
bonded	O
interaction	O
with	O
the	O
side	O
chain	O
of	O
Thr279	O
,	O
part	O
of	O
the	O
signature	O
sequence	B-SO
SGTSAS	O
surrounding	O
the	O
catalytic	O
Ser280	O
and	O
its	O
equivalents	O
in	O
the	O
other	O
enzymes	B-SO
.	O

Asp165	O
itself	O
is	O
also	O
conserved	B-SO
since	O
that	O
residue	B-CHEBI
provides	O
the	O
lining	O
of	O
the	O
oxyanion	B-CHEBI
hole	O
,	O
so	O
it	O
can	O
be	O
safely	O
assumed	O
that	O
this	O
part	O
of	O
the	O
S1	O
pocket	O
is	O
virtually	O
identical	O
.	O

No	O
side	O
chains	O
point	O
into	O
the	O
pocket	O
from	O
there	O
,	O
though	O
,	O
so	O
its	O
importance	O
is	O
limited	O
to	O
providing	O
a	O
steric	O
barrier	O
and	O
excluding	O
solvent	B-CHEBI
.	O

Another	O
wall	O
of	O
the	O
pocket	O
is	O
made	O
up	O
of	O
the	O
main	O
chain	B-SO
of	I-SO
residues	I-SO
130	O
-	O
132	O
that	O
flank	O
the	O
conserved	B-SO
Gly131	O
.	O

Again	O
,	O
this	O
part	O
of	O
the	O
chain	B-SO
does	O
not	O
provide	O
any	O
specific	O
interactions	O
with	O
the	O
P1	O
residue	B-CHEBI
of	O
the	O
substrate	O
.	O

Figure	O
6	O

A	O
model	O
of	O
the	O
active	B-SO
site	I-SO
of	O
human	B-GGP
CLN2	I-GGP
.	O

The	O
enzyme	B-SO
is	O
shown	O
in	O
complex	O
with	O
pseudo	O
-	O
iodotyrostatin	O
,	O
a	O
good	O
inhibitor	B-CHEBI
of	O
the	O
sedolisin	O
family	O
of	O
peptidases	O
.	O

Only	O
selected	O
residues	B-CHEBI
of	O
the	O
enzyme	B-SO
are	O
explicitly	O
shown	O
on	O
the	O
background	O
consisting	O
of	O
the	O
molecular	B-CHEBI
surface	O
.	O

The	O
stick	O
model	O
of	O
the	O
inhibitor	B-CHEBI
is	O
colored	O
gold	O
and	O
the	O
P1	O
-	O
P3	O
residues	B-CHEBI
are	O
labeled	O
in	O
black	O
.	O

Similar	O
views	O
have	O
been	O
previously	O
published	O
for	O
the	O
experimentally	B-SO
-	I-SO
determined	I-SO
structures	O
of	O
sedolisin	O
and	O
kumamolisin	O
[	O
8	O
]	O
.	O

The	O
figure	O
was	O
prepared	O
using	O
the	O
program	O
DINO	O
.	O

Considerable	O
differences	O
are	O
seen	O
,	O
however	O
,	O
at	O
the	O
bottom	O
of	O
the	O
pocket	O
,	O
where	O
the	O
side	O
chains	O
of	O
Asp179	O
in	O
kumamolisin	O
and	O
the	O
equivalent	O
Ser190	O
in	O
sedolisin	O
make	O
hydrogen	B-CHEBI
bonds	O
to	O
the	O
P1	O
tyrosine	B-CHEBI
of	O
the	O
inhibitor	B-CHEBI
(	O
if	O
present	O
)	O
.	O

The	O
equivalent	O
residue	B-CHEBI
in	O
CLN2	B-GGP
is	O
Thr182	O
,	O
but	O
it	O
is	O
very	O
unlikely	O
that	O
it	O
can	O
assume	O
an	O
orientation	O
that	O
would	O
allow	O
it	O
to	O
make	O
a	O
hydrogen	B-CHEBI
bond	O
to	O
a	O
P1	O
tyrosine	B-CHEBI
.	O

Other	O
polar	O
residues	B-CHEBI
in	O
the	O
vicinity	O
are	O
Glu175	O
in	O
sedolisin	O
and	O
the	O
corresponding	O
Asp169	O
in	O
kumamolisin	O
.	O

However	O
,	O
the	O
residue	B-CHEBI
found	O
here	O
in	O
CLN2	B-GGP
is	O
Cys170	O
,	O
much	O
less	O
polar	O
than	O
its	O
counterparts	B-SO
.	O

There	O
is	O
also	O
no	O
equivalent	O
to	O
the	O
polar	O
interaction	O
between	O
Glu175	O
and	O
Glu171	O
in	O
sedolisin	O
,	O
since	O
the	O
equivalent	O
of	O
the	O
latter	O
residue	B-CHEBI
in	O
CLN2	B-GGP
is	O
Ser166	O
,	O
much	O
smaller	O
and	O
pointing	O
away	O
.	O

The	O
side	O
of	O
the	O
S1	O
pocket	O
that	O
is	O
created	O
by	O
the	O
very	O
flexible	O
side	O
chain	O
of	O
Arg179	O
in	O
sedolisin	O
contains	O
only	O
a	O
much	O
smaller	O
Ser174	O
in	O
CLN2	B-GGP
,	O
and	O
thus	O
is	O
much	O
more	O
open	O
in	O
the	O
latter	O
protein	B-CHEBI
.	O

This	O
part	O
of	O
the	O
pocket	O
,	O
with	O
the	O
main	O
chain	B-CHEBI
of	I-CHEBI
the	I-CHEBI
protein	I-CHEBI
quite	O
distant	O
from	O
the	O
substrate	O
,	O
is	O
indeed	O
not	O
well	O
conserved	B-SO
in	O
these	O
proteins	B-CHEBI
,	O
with	O
kumamolisin	O
missing	O
it	O
entirely	O
due	O
to	O
a	O
deletion	B-SO
in	O
the	O
corresponding	O
sequence	B-SO
position	O
.	O

In	O
summary	O
,	O
the	O
S1	O
pocket	O
in	O
CLN2	B-GGP
has	O
less	O
polar	O
character	O
than	O
the	O
equivalent	O
pocket	O
in	O
the	O
related	O
proteins	B-CHEBI
,	O
and	O
is	O
lacking	O
direct	O
polar	O
anchors	O
for	O
any	O
side	O
chains	O
that	O
might	O
be	O
present	O
in	O
the	O
substrate	O
.	O

The	O
S2	O
pocket	O
in	O
CLN2	B-GGP
is	O
also	O
quite	O
open	O
and	O
accessible	O
to	O
solvent	B-CHEBI
.	O

It	O
is	O
most	O
likely	O
larger	O
than	O
the	O
equivalent	O
pockets	O
in	O
either	O
sedolisin	O
or	O
kumamolisin	O
,	O
since	O
these	O
are	O
limited	O
by	O
Trp81	O
in	O
the	O
former	O
and	O
Trp129	O
in	O
the	O
latter	O
(	O
these	O
residues	B-CHEBI
originate	O
from	O
different	O
parts	O
of	O
the	O
backbone	O
in	O
the	O
two	O
enzymes	B-SO
and	O
are	O
not	O
topologically	O
related	O
)	O
.	O

Tyr130	O
,	O
an	O
equivalent	O
of	O
the	O
latter	O
residue	B-CHEBI
in	O
CLN2	B-GGP
,	O
is	O
unlikely	O
to	O
come	O
into	O
direct	O
contact	O
with	O
the	O
P2	O
residue	B-CHEBI
of	O
the	O
substrate	O
due	O
to	O
its	O
greater	O
distance	O
(	O
almost	O
4	O
A	O
for	O
the	O
closest	O
atoms	B-CHEBI
)	O
.	O

An	O
important	O
remaining	O
puzzle	O
is	O
that	O
the	O
predicted	B-SO
structure	O
of	O
CLN2	B-GGP
does	O
not	O
show	O
any	O
clear	O
limitations	O
of	O
the	O
S3	O
pocket	O
that	O
could	O
explain	O
the	O
tripeptidase	O
activity	O
of	O
this	O
enzyme	B-SO
.	O

The	O
location	O
of	O
the	O
P3	O
side	O
chain	O
of	O
the	O
substrate	O
is	O
ambiguous	O
,	O
since	O
it	O
could	O
point	O
in	O
either	O
one	O
of	O
two	O
directions	O
by	O
exchange	O
with	O
the	O
N	B-SO
-	I-SO
terminal	I-SO
amine	B-CHEBI
.	O

The	O
only	O
negatively	O
charged	O
residue	B-CHEBI
of	O
CLN2	B-GGP
that	O
is	O
found	O
in	O
this	O
vicinity	O
is	O
Asp132	O
.	O

Although	O
in	O
the	O
current	O
model	O
the	O
distance	O
between	O
its	O
carboxylate	B-CHEBI
and	O
the	O
nitrogen	B-CHEBI
of	O
the	O
N	B-SO
-	I-SO
terminus	I-SO
of	O
the	O
modeled	O
substrate	O
is	O
about	O
6	O
A	O
,	O
these	O
two	O
groups	B-CHEBI
could	O
be	O
brought	O
into	O
hydrogen	B-CHEBI
-	O
bonding	O
range	O
by	O
some	O
allowed	O
changes	O
in	O
the	O
torsion	O
angles	O
of	O
the	O
protein	B-CHEBI
.	O

Such	O
a	O
conformational	O
change	O
would	O
involve	O
breaking	O
of	O
the	O
hydrogen	B-CHEBI
bond	O
between	O
Asp132	O
and	O
Ser139	O
.	O

However	O
,	O
this	O
latter	O
interaction	O
is	O
not	O
likely	O
to	O
be	O
structurally	O
crucial	O
since	O
the	O
serine	B-CHEBI
is	O
not	O
absolutely	O
conserved	B-SO
in	O
all	O
CLN2	B-GGP
-	O
like	O
enzymes	B-SO
.	O

Location	O
of	O
mutations	B-SO
implicated	O
in	O
disease	O

Location	O
of	O
mutations	B-SO
found	O
through	O
a	O
genetic	B-SO
survey	O
of	O
families	O
of	O
classic	O
late	O
-	O
infantile	O
neuronal	B-CL
ceroid	O
lipofuscinosis	O
patients	O
has	O
been	O
described	O
previously	O
[	O
17	O
]	O
.	O

Most	O
such	O
mutations	B-SO
result	O
in	O
expression	O
of	O
either	O
truncated	O
enzyme	B-SO
or	O
in	O
incorrect	O
intron	B-SO
-	O
exon	B-SO
splices	O
.	O

However	O
,	O
some	O
of	O
the	O
mutations	B-SO
lead	O
to	O
single	O
amino	B-CHEBI
acid	I-CHEBI
substitutions	B-SO
in	O
the	O
mature	O
enzyme	B-SO
.	O

Such	O
mutations	B-SO
include	O
I92N	O
,	O
E148K	O
,	O
C170R	O
and	O
C170Y	O
,	O
V190D	O
,	O
G194E	O
,	O
Q227H	O
,	O
R252H	O
,	O
A259E	O
,	O
and	O
S280L	O
(	O
Figure	O
5	O
)	O
.	O

Only	O
the	O
role	O
of	O
the	O
latter	O
mutation	B-SO
is	O
completely	O
clear	O
,	O
since	O
it	O
replaces	B-SO
the	O
catalytic	O
serine	B-CHEBI
of	O
CLN2	B-GGP
with	O
a	O
side	O
chain	O
that	O
cannot	O
support	O
its	O
enzymatic	B-SO
activity	O
.	O

No	O
other	O
residues	B-CHEBI
appear	O
to	O
be	O
located	O
in	O
the	O
immediate	O
vicinity	O
of	O
the	O
substrate	O
.	O

Residues	B-CHEBI
Val190	O
,	O
Gly194	O
,	O
and	O
Arg252	O
are	O
very	O
highly	O
conserved	B-SO
not	O
only	O
in	O
CLN2	B-GGP
but	O
also	O
in	O
other	O
sedolisins	O
and	O
must	O
play	O
an	O
important	O
structural	O
role	O
.	O

The	O
reasons	O
why	O
the	O
remaining	O
mutations	B-SO
would	O
lead	O
to	O
the	O
loss	O
of	O
enzymatic	B-SO
activity	O
are	O
much	O
less	O
clear	O
,	O
but	O
the	O
wide	O
distribution	O
of	O
these	O
mutations	B-SO
in	O
the	O
structure	O
supports	O
the	O
conclusion	O
that	O
any	O
modifications	B-SO
to	O
CLN2	B-GGP
that	O
would	O
abolish	O
or	O
impair	O
its	O
function	O
could	O
lead	O
to	O
the	O
development	O
of	O
the	O
disease	O
.	O

Substrates	O
and	O
inhibitors	B-CHEBI
of	O
CLN2	B-GGP

Little	O
is	O
known	O
at	O
this	O
time	O
about	O
biologically	O
-	O
relevant	O
substrates	O
of	O
CLN2	B-GGP
.	O

Various	O
defects	O
that	O
include	O
truncations	O
and	O
single	B-SO
-	I-SO
site	I-SO
mutations	I-SO
in	O
CLN2	B-GGP
have	O
been	O
found	O
in	O
the	O
genes	B-SO
of	O
patients	O
that	O
display	O
symptoms	O
of	O
late	O
-	O
infantile	O
neuronal	B-CL
ceroid	O
lipofuscinosis	O
[	O
17	O
]	O
.	O

One	O
of	O
the	O
symptoms	O
of	O
the	O
disease	O
is	O
the	O
accumulation	O
of	O
an	O
autofluorescent	O
material	O
,	O
ceroid	O
-	O
lipofuscin	O
,	O
in	O
lysosomal	B-GO
storage	B-GO
bodies	I-GO
in	O
various	O
cell	B-CL
types	O
,	O
primarily	O
in	O
the	O
nervous	O
system	O
.	O

Since	O
a	O
major	O
component	O
of	O
such	O
bodies	O
appears	O
to	O
be	O
intact	O
subunit	B-GGP
c	I-GGP
of	I-GGP
mitochondrial	I-GGP
ATP	I-GGP
synthase	I-GGP
,	O
this	O
protein	B-CHEBI
has	O
been	O
implicated	O
as	O
a	O
potential	O
biological	O
target	O
of	O
the	O
protease	O
.	O

It	O
has	O
been	O
shown	O
recently	O
that	O
CLN2	B-GGP
can	O
indeed	O
degrade	O
this	O
subunit	O
on	O
its	O
N	B-SO
terminus	I-SO
[	O
18	O
]	O
,	O
but	O
the	O
unambiguous	O
proof	O
that	O
this	O
is	O
indeed	O
the	O
most	O
important	O
target	O
is	O
still	O
lacking	O
.	O

CLN2	B-GGP
is	O
capable	O
of	O
processing	O
a	O
number	O
of	O
different	O
angiotensin	B-CHEBI
-	O
derived	O
peptides	B-SO
[	O
19	O
]	O
,	O
with	O
the	O
efficiency	O
of	O
cleavage	O
dependent	O
on	O
the	O
length	O
of	O
such	O
peptides	B-SO
.	O

The	O
most	O
efficiently	O
processed	O
peptide	B-SO
consisted	O
of	O
14	O
amino	B-CHEBI
acids	I-CHEBI
,	O
with	O
the	O
tripeptide	O
Asp	B-CHEBI
-	O
Arg	B-CHEBI
-	O
Val	B-CHEBI
removed	B-SO
from	O
its	O
N	B-SO
terminus	I-SO
.	O

The	O
model	O
of	O
CLN2	B-GGP
presented	O
here	O
can	O
easily	O
accommodate	O
this	O
peptide	B-SO
on	O
the	O
P	O
side	O
of	O
the	O
substrate	O
-	O
binding	B-SO
site	I-SO
,	O
although	O
the	O
exact	O
mode	O
of	O
binding	O
of	O
the	O
long	O
P	O
'	O
portion	O
of	O
the	O
substrate	O
remains	O
obscure	O
.	O

The	O
observation	O
that	O
an	O
analogous	O
peptide	B-SO
acetylated	O
on	O
its	O
N	B-SO
terminus	I-SO
cannot	O
be	O
processed	O
supports	O
the	O
postulate	O
that	O
the	O
interactions	O
of	O
the	O
N	B-SO
-	I-SO
terminal	I-SO
amino	B-CHEBI
group	I-CHEBI
with	O
the	O
side	O
chain	O
of	O
Asp132	O
may	O
be	O
the	O
most	O
important	O
feature	O
defining	O
the	O
tripeptidase	O
specificity	O
of	O
CLN2	B-GGP
.	O

A	O
number	O
of	O
different	O
tripeptides	O
can	O
be	O
serially	O
processed	O
from	O
glucagon	B-GGP
,	O
with	O
their	O
sequences	B-SO
varying	O
widely	O
[	O
20	O
]	O
.	O

Again	O
,	O
however	O
,	O
all	O
of	O
these	O
tripeptides	O
can	O
be	O
easily	O
accommodated	O
in	O
the	O
substrate	O
-	O
binding	B-SO
site	I-SO
of	O
the	O
CLN2	B-GGP
model	O
.	O

Other	O
potentially	O
biologically	O
relevant	O
substrates	O
include	O
cholecystokinin	B-GGP
and	O
possibly	O
other	O
neuropeptides	O
[	O
21	O
]	O
.	O

An	O
intriguing	O
property	O
of	O
CLN2	B-GGP
is	O
its	O
reported	O
ability	O
to	O
cleave	O
collagen	B-GGP
-	O
related	O
peptides	B-SO
[	O
22	O
]	O
.	O

The	O
tripeptides	O
resulting	O
from	O
such	O
processing	O
include	O
Gly	B-CHEBI
-	O
Pro	B-CHEBI
-	O
Met	B-CHEBI
,	O
Gly	B-CHEBI
-	O
Pro	B-CHEBI
-	O
Arg	B-CHEBI
,	O
and	O
Gly	B-CHEBI
-	O
Pro	B-CHEBI
-	O
Ala	B-CHEBI
.	O

It	O
has	O
been	O
recently	O
reported	O
that	O
kumamolisin	O
,	O
and	O
particularly	O
a	O
closely	O
related	O
protein	B-CHEBI
from	O
Alicyclobacillus	B-Taxon
sendaiensis	I-Taxon
(	O
kumamolisin	O
-	O
As	B-Taxon
)	O
can	O
efficiently	O
cleave	O
not	O
only	O
collagen	B-GGP
-	O
related	O
peptides	B-SO
,	O
but	O
also	O
native	B-SO
type	B-GGP
I	I-GGP
collagen	I-GGP
[	O
23	O
]	O
.	O

With	O
the	O
substrate	O
-	O
binding	B-SO
site	I-SO
of	O
CLN2	B-GGP
resembling	O
that	O
of	O
kumamolisin	O
more	O
than	O
sedolisin	O
(	O
the	O
latter	O
enzyme	B-SO
has	O
low	O
,	O
if	O
any	O
,	O
collagenase	O
activity	O
)	O
,	O
the	O
potential	O
collagen	B-GGP
-	O
processing	O
role	O
of	O
CLN2	B-GGP
might	O
warrant	O
further	O
investigation	O
.	O

Conclusions	O

Since	O
the	O
catalytic	O
machinery	O
of	O
CLN2	B-GGP
matches	O
closely	O
that	O
of	O
sedolisin	O
,	O
kumamolisin	O
,	O
and	O
other	O
members	O
of	O
the	O
family	O
of	O
serine	B-CHEBI
-	O
carboxyl	B-CHEBI
peptidases	O
,	O
the	O
enzymatic	B-SO
mechanism	O
of	O
all	O
these	O
enzymes	B-SO
is	O
most	O
likely	O
the	O
same	O
.	O

Design	O
of	O
inhibitors	B-CHEBI
specific	O
for	O
CLN2	B-GGP
should	O
incorporate	O
the	O
features	B-SO
that	O
have	O
been	O
proven	O
to	O
be	O
important	O
for	O
the	O
related	O
enzymes	B-SO
,	O
such	O
as	O
the	O
placement	O
of	O
an	O
aldehyde	B-CHEBI
functionality	O
capable	O
of	O
making	O
covalent	O
interactions	O
with	O
the	O
catalytic	O
serine	B-CHEBI
,	O
or	O
the	O
utilization	O
of	O
chloromethyl	O
ketone	B-CHEBI
for	O
the	O
same	O
purpose	O
.	O

Since	O
the	O
few	O
inhibitors	B-CHEBI
that	O
have	O
been	O
successfully	O
used	O
in	O
the	O
studies	O
of	O
sedolisins	O
are	O
either	O
longer	O
than	O
tripeptides	O
or	O
contain	O
blocking	O
groups	B-CHEBI
on	O
their	O
N	B-SO
termini	I-SO
,	O
new	O
tripeptide	O
-	O
based	O
inhibitors	B-CHEBI
with	O
free	O
N	B-SO
termini	I-SO
are	O
now	O
being	O
synthesized	O
(	O
Oda	O
,	O
unpublished	O
)	O
.	O

It	O
will	O
be	O
necessary	O
to	O
test	O
the	O
binding	O
properties	O
of	O
different	O
substrates	O
in	O
order	O
to	O
determine	O
the	O
most	O
promising	O
peptide	B-SO
sequences	I-SO
.	O

Analysis	O
of	O
the	O
model	O
of	O
CLN2	B-GGP
suggests	O
that	O
the	O
size	O
of	O
the	O
S1	O
subsite	O
is	O
much	O
larger	O
than	O
in	O
either	O
sedolisin	O
or	O
kumamolisin	O
,	O
and	O
thus	O
the	O
use	O
of	O
a	O
large	O
P1	O
group	B-CHEBI
might	O
be	O
indicated	O
.	O

Of	O
course	O
,	O
the	O
availability	O
of	O
an	O
experimental	O
crystal	O
structure	O
will	O
make	O
the	O
design	O
of	O
inhibitors	B-CHEBI
easier	O
and	O
we	O
are	O
continuing	O
our	O
efforts	O
to	O
crystallize	O
CLN2	B-GGP
from	O
different	O
sources	O
.	O

Methods	O

Homology	B-SO
modeling	O

Three	O
-	O
dimensional	O
,	O
atomic	B-CHEBI
-	O
scale	O
models	O
of	O
CLN2	B-GGP
were	O
developed	O
by	O
exploiting	O
the	O
sequence	B-SO
similarity	O
to	O
the	O
sedolisin	O
and	O
kumamolisin	O
proteins	B-CHEBI
(	O
r	O
.	O
m	O
.	O
s	O
.	O
deviation	O
of	O
1	O
.	O
0	O
A	O
for	O
273	O
pairs	O
of	O
C	O
alpha	O
atoms	B-CHEBI
in	O
the	O
core	O
of	O
the	O
enzymes	B-SO
)	O
.	O

Presently	O
,	O
these	O
two	O
enzymes	B-SO
are	O
the	O
only	O
members	O
of	O
the	O
newly	O
-	O
defined	O
sedolisin	O
/	O
serine	B-CHEBI
-	O
carboxyl	B-CHEBI
peptidase	O
family	O
[	O
8	O
]	O
for	O
which	O
the	O
crystal	O
structures	O
have	O
been	O
published	O
[	O
5	O
-	O
7	O
]	O
.	O

The	O
actual	O
Protein	B-CHEBI
Data	O
Bank	O
[	O
24	O
]	O
:	O
)	O
entries	O
used	O
in	O
the	O
modeling	O
were	O
1GA4	O
.	O
pdb	O
and	O
1GT9	O
.	O
pdb	O
for	O
sedolisin	O
and	O
kumamolisin	O
,	O
respectively	O
.	O

The	O
first	O
step	O
was	O
to	O
form	O
a	O
global	O
,	O
multiple	O
sequence	B-SO
alignment	O
between	O
all	O
known	B-SO
members	O
of	O
the	O
sedolisin	O
family	O
.	O

Studies	O
have	O
shown	O
that	O
incorporating	O
the	O
specific	O
patterns	O
of	O
amino	B-CHEBI
acid	I-CHEBI
residue	I-CHEBI
-	O
type	O
variation	O
and	O
conservation	B-SO
among	O
a	O
family	O
of	O
homologous	B-SO
proteins	B-CHEBI
provides	O
superior	O
results	O
over	O
simple	O
,	O
pair	O
-	O
wise	O
sequence	B-SO
alignment	O
[	O
25	O
]	O
.	O

Sequence	B-SO
files	O
representing	O
the	O
different	O
subfamilies	O
were	O
extracted	O
from	O
the	O
non	O
-	O
redundant	O
GenBank	O
database	O
[	O
26	O
]	O
using	O
sedolisin	O
,	O
kumamolisin	O
,	O
and	O
the	O
human	B-GGP
CLN2	I-GGP
sequences	B-SO
as	O
queries	O
to	O
the	O
web	O
-	O
based	O
version	O
of	O
the	O
BLAST	O
program	O
[	O
27	O
]	O
:	O
.	O

Initial	O
multiple	O
sequence	B-SO
alignments	O
were	O
formed	O
with	O
the	O
ClustalX	O
computer	O
program	O
[	O
28	O
]	O
.	O

As	O
is	O
expected	O
for	O
a	O
family	O
of	O
proteins	B-CHEBI
,	O
highly	O
-	O
conserved	B-SO
segments	I-SO
were	O
found	O
aligned	O
to	O
the	O
crystal	O
structure	O
-	O
identified	O
core	O
regions	B-SO
of	O
the	O
sedolisin	O
and	O
kumamolisin	O
sequences	B-SO
.	O

Subsequently	O
,	O
the	O
sequences	B-SO
were	O
divided	O
into	O
two	O
groups	O
:	O
those	O
closer	O
to	O
sedolisin	O
than	O
kumamolisin	O
and	O
vise	O
-	O
a	O
-	O
versa	O
.	O

The	O
alignment	O
of	O
these	O
two	O
groups	O
was	O
then	O
manually	O
set	O
by	O
the	O
observed	O
structural	O
alignment	O
of	O
the	O
sedolisin	O
and	O
kumamolisin	O
proteins	B-CHEBI
.	O

Finally	O
,	O
some	O
additional	O
adjustment	O
was	O
required	O
to	O
correct	O
the	O
few	O
places	O
where	O
highly	O
conserved	B-SO
residues	B-CHEBI
of	O
the	O
core	O
regions	B-SO
were	O
slightly	O
out	O
of	O
alignment	O
among	O
different	O
subfamilies	O
of	O
sequences	B-SO
.	O

The	O
model	O
of	O
human	B-GGP
CLN2	I-GGP
was	O
built	O
using	O
the	O
structure	O
of	O
sedolisin	O
complexed	O
with	O
the	O
inhibitor	B-CHEBI
pseudo	O
-	O
tyrostatin	O
[	O
5	O
,	O
6	O
]	O
as	O
a	O
template	O
.	O

The	O
reason	O
for	O
this	O
choice	O
is	O
that	O
while	O
different	O
protein	B-CHEBI
models	O
were	O
generally	O
comparable	O
,	O
the	O
chosen	O
inhibitor	B-CHEBI
was	O
most	O
compatible	O
with	O
the	O
tripeptidase	O
character	O
of	O
CLN2	B-GGP
.	O

With	O
the	O
correspondence	O
of	O
residues	B-CHEBI
specified	O
in	O
the	O
alignments	O
,	O
atomic	B-CHEBI
coordinates	O
were	O
transferred	O
to	O
the	O
target	O
sequence	B-SO
by	O
a	O
variety	O
of	O
methods	O
,	O
including	O
the	O
homology	B-SO
modeling	O
modules	O
of	O
the	O
Look	O
/	O
GeneMine	O
[	O
29	O
]	O
and	O
DeepView	O
[	O
30	O
]	O
computer	O
program	O
packages	O
.	O

For	O
the	O
core	O
and	O
active	B-SO
site	I-SO
of	I-SO
the	I-SO
protein	I-SO
,	O
coordinates	O
for	O
identical	O
residues	B-CHEBI
were	O
simply	O
transferred	O
unchanged	O
;	O
whereas	O
,	O
special	O
care	O
was	O
required	O
to	O
position	O
the	O
side	O
chains	O
of	O
residues	B-CHEBI
differing	O
from	O
the	O
template	O
.	O

This	O
was	O
first	O
accomplished	O
automatically	O
by	O
the	O
two	O
computer	O
packages	O
,	O
then	O
manually	O
adjusted	O
in	O
the	O
Quanta	O
molecular	B-CHEBI
modeling	O
package	O
(	O
Accelrys	O
,	O
Inc	O
.	O
)	O
to	O
better	O
mimic	O
the	O
templates	O
and	O
optimize	O
the	O
interactions	O
with	O
surrounding	O
residues	B-CHEBI
.	O

A	O
similar	O
two	O
-	O
step	O
approach	O
was	O
used	O
to	O
manifest	O
the	O
insertions	B-SO
and	O
deletions	B-SO
in	O
the	O
variable	O
,	O
loop	O
regions	B-SO
of	O
the	O
protein	B-CHEBI
,	O
where	O
it	O
was	O
necessary	O
to	O
create	O
new	O
backbone	O
as	O
well	O
as	O
side	O
chain	O
coordinates	O
for	O
the	O
models	O
.	O

It	O
should	O
be	O
noted	O
that	O
,	O
for	O
obvious	O
reasons	O
,	O
the	O
conformation	O
of	O
poorly	O
conserved	B-SO
loop	I-SO
regions	I-SO
is	O
generally	O
the	O
least	O
accurate	O
aspect	O
of	O
a	O
homology	B-SO
model	O
.	O

Fortunately	O
,	O
these	O
problematic	O
loops	O
will	O
not	O
significantly	O
affect	O
the	O
active	B-SO
site	I-SO
of	O
the	O
model	O
,	O
since	O
only	O
two	O
of	O
them	O
impinge	O
on	O
the	O
boundary	B-SO
of	O
this	O
highly	O
conserved	B-SO
,	I-SO
functional	I-SO
region	I-SO
.	O

Refinement	O
and	O
analysis	O
of	O
the	O
model	O

The	O
model	O
was	O
finished	O
by	O
performing	O
energy	O
minimization	O
in	O
vacuo	O
with	O
the	O
computer	O
program	O
CHARMM	O
[	O
31	O
]	O
.	O

This	O
refined	O
the	O
structure	O
by	O
bringing	O
the	O
covalent	O
geometry	O
and	O
non	O
-	O
bonded	O
interactions	O
into	O
agreement	O
with	O
experimentally	O
observed	O
and	O
calculated	O
values	O
.	O

Such	O
optimizations	O
included	O
adjusting	O
bond	O
lengths	O
,	O
3	O
-	O
point	O
angles	O
and	O
4	O
-	O
point	O
dihedral	O
angles	O
,	O
as	O
well	O
as	O
eliminating	O
atomic	B-CHEBI
overlap	O
and	O
forming	O
salt	B-CHEBI
-	O
bridges	O
and	O
hydrogen	B-CHEBI
bonds	O
.	O

Since	O
presently	O
the	O
potential	O
energy	O
functions	O
used	O
to	O
describe	O
the	O
atomic	B-CHEBI
-	O
scale	O
models	O
are	O
not	O
sufficiently	O
comprehensive	O
and	O
accurate	O
,	O
the	O
final	O
energy	O
of	O
the	O
model	O
was	O
not	O
used	O
as	O
an	O
indicator	O
of	O
the	O
realistic	O
quality	O
of	O
the	O
structure	O
.	O

The	O
final	O
quality	O
of	O
the	O
structure	O
was	O
analyzed	O
with	O
the	O
computer	O
program	O
PROCHECK	O
[	O
32	O
]	O
.	O

The	O
structure	O
was	O
deposited	O
at	O
the	O
PDB	O
under	O
accession	O
code	O
1R60	O
.	O

Authors	O
'	O
contributions	O

AW	O
initiated	O
this	O
project	O
and	O
analyzed	O
the	O
genomic	B-SO
distribution	O
of	O
this	O
family	O
of	O
enzymes	B-SO
.	O

SRD	O
contributed	O
the	O
modeling	O
of	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
CLN2	B-GGP
.	O

ML	O
analyzed	O
the	O
model	O
and	O
compared	O
it	O
to	O
the	O
crystal	O
structures	O
of	O
sedolisins	O
.	O

HO	O
,	O
KO	O
and	O
BMD	O
contributed	O
their	O
experience	O
gained	O
from	O
studies	O
of	O
serine	B-CHEBI
-	O
carboxyl	B-CHEBI
peptidases	O
and	O
the	O
design	O
of	O
their	O
inhibitors	B-CHEBI
,	O
aimed	O
at	O
analysis	O
of	O
substrate	O
-	O
enzyme	B-SO
interactions	O
and	O
enzyme	B-SO
specificity	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Acknowledgements	O

Extensive	O
discussions	O
with	O
Dr	O
.	O
A	O
.	O

Barrett	O
(	O
Wellcome	O
Trust	O
Sanger	O
Institute	O
,	O
Hinxton	O
,	O
UK	O
)	O
are	O
gratefully	O
acknowledged	O
.	O

Modeling	O
efforts	O
were	O
facilitated	O
by	O
Dr	O
.	O
Robert	O
Jernigan	O
(	O
Iowa	O
State	O
University	O
)	O
.	O

This	O
work	O
was	O
supported	O
in	O
part	O
by	O
a	O
Grant	O
-	O
in	O
-	O
Aid	O
for	O
Scientific	O
Research	O
(	O
B	O
)	O
,	O
15380072	O
,	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Culture	O
,	O
Sports	O
,	O
Science	O
and	O
Technology	O
of	O
Japan	O
(	O
to	O
K	O
.	O
O	O
.	O
)	O
;	O
by	O
NIH	O
grants	O
DK18865	O
and	O
AI39211	O
(	O
to	O
B	O
.	O
M	O
.	O
D	O
.	O
)	O
;	O
and	O
in	O
part	O
with	O
Federal	O
funds	O
from	O
the	O
National	O
Cancer	O
Institute	O
,	O
National	O
Institutes	O
of	O
Health	O
,	O
under	O
contract	O
No	O
.	O

NO1	O
-	O
CO	O
-	O
12400	O
.	O

The	O
content	O
of	O
this	O
publication	O
does	O
not	O
necessarily	O
reflect	O
the	O
views	O
or	O
policies	O
of	O
the	O
Department	O
of	O
Health	O
and	O
Human	B-Taxon
Services	O
,	O
nor	O
does	O
the	O
mention	O
of	O
trade	O
names	O
,	O
commercial	O
products	O
or	O
organizations	O
imply	O
endorsement	O
by	O
the	O
U	O
.	O

S	O
.	O

Government	O
.	O

The	O
Zebrafish	B-GGP
moonshine	I-GGP
Gene	B-SO
Encodes	O
Transcriptional	B-GGP
Intermediary	I-GGP
Factor	I-GGP
1	I-GGP
gamma	I-GGP
,	O
an	O
Essential	O
Regulator	O
of	O
Hematopoiesis	O

Abstract	O

Hematopoiesis	O
is	O
precisely	O
orchestrated	O
by	O
lineage	O
-	O
specific	O
DNA	B-SO
-	O
binding	O
proteins	B-CHEBI
that	O
regulate	O
transcription	O
in	O
concert	O
with	O
coactivators	O
and	O
corepressors	O
.	O

Mutations	B-SO
in	O
the	O
zebrafish	B-GGP
moonshine	I-GGP
(	O
mon	B-GGP
)	O
gene	B-SO
specifically	O
disrupt	O
both	O
embryonic	O
and	O
adult	O
hematopoiesis	O
,	O
resulting	O
in	O
severe	O
red	B-CL
blood	I-CL
cell	I-CL
aplasia	O
.	O

We	O
report	O
that	O
mon	B-GGP
encodes	O
the	O
zebrafish	B-Taxon
ortholog	B-SO
of	O
mammalian	B-Taxon
transcriptional	B-GGP
intermediary	I-GGP
factor	I-GGP
1	I-GGP
gamma	I-GGP
(	O
TIF1	B-GGP
gamma	I-GGP
)	O
(	O
or	O
TRIM33	B-GGP
)	O
,	O
a	O
member	O
of	O
the	O
TIF1	O
family	O
of	O
coactivators	O
and	O
corepressors	O
.	O

During	O
development	O
,	O
hematopoietic	B-CL
progenitor	I-CL
cells	I-CL
in	O
mon	B-GGP
mutants	B-SO
fail	O
to	O
express	O
normal	O
levels	O
of	O
hematopoietic	O
transcription	O
factors	O
,	O
including	O
gata1	B-GGP
,	O
and	O
undergo	O
apoptosis	O
.	O

Three	O
different	O
mon	B-GGP
mutant	B-SO
alleles	B-SO
each	O
encode	O
premature	O
stop	B-SO
codons	I-SO
,	O
and	O
enforced	O
expression	O
of	O
wild	B-SO
-	I-SO
type	I-SO
tif1	B-GGP
gamma	I-GGP
mRNA	B-CHEBI
rescues	O
embryonic	O
hematopoiesis	O
in	O
homozygous	O
mon	B-GGP
mutants	B-SO
.	O

Surprisingly	O
,	O
a	O
high	O
level	O
of	O
zygotic	O
tif1	B-GGP
gamma	I-GGP
mRNA	B-CHEBI
expression	O
delineates	O
ventral	O
mesoderm	O
during	O
hematopoietic	B-CL
stem	I-CL
cell	I-CL
and	O
progenitor	O
formation	O
prior	O
to	O
gata1	B-GGP
expression	O
.	O

Transplantation	O
studies	O
reveal	O
that	O
tif1	B-GGP
gamma	I-GGP
functions	O
in	O
a	O
cell	B-CL
-	O
autonomous	O
manner	O
during	O
the	O
differentiation	O
of	O
erythroid	B-CL
precursors	O
.	O

Studies	O
in	O
murine	B-Taxon
erythroid	B-CL
cell	I-CL
lines	O
demonstrate	O
that	O
Tif1	B-GGP
gamma	I-GGP
protein	B-CHEBI
is	O
localized	O
within	O
novel	O
nuclear	B-GO
foci	O
,	O
and	O
expression	O
decreases	O
during	O
erythroid	B-CL
cell	I-CL
maturation	O
.	O

Our	O
results	O
establish	O
a	O
major	O
role	O
for	O
this	O
transcriptional	O
intermediary	O
factor	O
in	O
the	O
differentiation	O
of	O
hematopoietic	B-CL
cells	I-CL
in	O
vertebrates	B-Taxon
.	O

Introduction	O

Hematopoiesis	O
involves	O
the	O
coordinated	O
processes	O
of	O
cell	B-CL
proliferation	O
and	O
differentiation	O
of	O
a	O
relatively	O
small	O
number	O
of	O
progenitor	O
cells	B-CL
into	O
billions	O
of	O
circulating	O
red	B-CL
and	I-CL
white	I-CL
blood	I-CL
cells	I-CL
(	O
Thisse	O
and	O
Zon	O
2002	O
)	O
.	O

Hematopoiesis	O
in	O
vertebrates	B-Taxon
,	O
from	O
zebrafish	B-Taxon
to	O
humans	B-Taxon
,	O
is	O
an	O
evolutionarily	O
conserved	O
program	O
that	O
produces	O
two	O
waves	O
of	O
stem	B-CL
or	I-CL
progenitor	I-CL
cells	I-CL
that	O
differ	O
both	O
in	O
their	O
embryonic	O
origins	O
and	O
in	O
the	O
lineages	O
of	O
differentiated	O
blood	B-CL
cells	I-CL
produced	O
(	O
Palis	O
and	O
Yoder	O
2001	O
;	O
Orkin	O
and	O
Zon	O
2002	O
;	O
Galloway	O
and	O
Zon	O
2003	O
)	O
.	O

The	O
first	O
,	O
or	O
primitive	O
,	O
wave	O
of	O
hematopoiesis	O
originates	O
from	O
ventral	O
mesoderm	O
and	O
gives	O
rise	O
to	O
progenitor	O
cells	B-CL
that	O
differentiate	O
in	O
embryonic	O
blood	O
islands	O
.	O

The	O
primitive	O
wave	O
of	O
hematopoiesis	O
produces	O
a	O
burst	O
of	O
embryonic	O
erythrocytes	B-CL
and	O
macrophages	B-CL
.	O

The	O
second	O
,	O
or	O
definitive	O
,	O
wave	O
of	O
hematopoiesis	O
arises	O
from	O
self	O
-	O
renewing	O
stem	B-CL
cells	I-CL
that	O
develop	O
primarily	O
in	O
the	O
intraembryonic	O
aorta	O
-	O
gonad	O
-	O
mesonephros	O
region	O
.	O

These	O
definitive	O
hematopoietic	B-CL
stem	I-CL
cells	I-CL
seed	O
the	O
later	O
developing	O
marrow	O
spaces	O
,	O
to	O
produce	O
all	O
lineages	O
of	O
adult	O
blood	B-CL
cells	I-CL
,	O
including	O
definitive	O
erythrocytes	B-CL
,	O
myeloid	B-CL
cells	I-CL
,	O
and	O
lymphocytes	B-CL
.	O

We	O
have	O
undertaken	O
a	O
genetic	B-SO
approach	O
to	O
characterize	O
genes	B-SO
that	O
control	O
hematopoiesis	O
using	O
the	O
zebrafish	B-Taxon
as	O
a	O
model	O
system	O
(	O
Thisse	O
and	O
Zon	O
2002	O
)	O
.	O

As	O
part	O
of	O
a	O
large	O
-	O
scale	O
forward	O
genetic	B-SO
screen	O
,	O
we	O
previously	O
identified	O
bloodless	O
zebrafish	B-Taxon
mutants	B-SO
that	O
failed	O
to	O
express	O
the	O
erythroid	B-CL
transcription	O
factor	O
gata1	B-GGP
normally	O
in	O
embryonic	O
hematopoietic	O
precursors	O
(	O
Ransom	O
et	O
al	O
.	O
1996	O
)	O
.	O

We	O
named	O
one	O
of	O
these	O
zebrafish	B-Taxon
genes	B-SO
moonshine	B-GGP
(	O
mon	B-GGP
)	O
,	O
and	O
another	O
group	O
named	O
a	O
noncomplementing	O
allele	B-SO
vampire	B-GGP
(	O
Weinstein	O
et	O
al	O
.	O
1996	O
)	O
.	O

Here	O
,	O
we	O
have	O
determined	O
that	O
mutations	B-SO
in	O
the	O
mon	B-GGP
gene	B-SO
cause	O
a	O
disruption	O
in	O
both	O
primitive	O
embryonic	O
and	O
definitive	O
adult	O
hematopoiesis	O
,	O
resulting	O
in	O
a	O
severe	O
loss	O
of	O
erythroid	B-CL
cells	I-CL
.	O

Erythroid	B-CL
progenitor	I-CL
cells	I-CL
in	O
mon	B-GGP
mutants	B-SO
are	O
initially	O
present	O
,	O
but	O
fail	O
to	O
express	O
normal	O
levels	O
of	O
hematopoietic	O
transcription	O
factors	O
and	O
undergo	O
apoptosis	O
.	O

Positional	B-SO
cloning	O
identifies	O
the	O
mon	B-GGP
gene	B-SO
as	O
the	O
zebrafish	B-Taxon
ortholog	B-SO
of	O
mammalian	B-Taxon
transcriptional	B-GGP
intermediary	I-GGP
factor	I-GGP
1	I-GGP
gamma	I-GGP
(	O
TIF1	B-GGP
gamma	I-GGP
)	O
,	O
a	O
member	O
of	O
the	O
TIF1	O
family	O
of	O
transcriptional	O
coactivators	O
and	O
corepressors	O
(	O
Le	O
Douarin	O
et	O
al	O
.	O
1995	O
;	O
Friedman	O
et	O
al	O
.	O
1996	O
;	O
Kim	O
et	O
al	O
.	O
1996	O
;	O
Venturini	O
et	O
al	O
.	O
1999	O
;	O
Peng	O
et	O
al	O
.	O
2002	O
)	O
.	O

The	O
three	O
members	O
of	O
the	O
vertebrate	B-Taxon
TIF1	O
family	O
(	O
alpha	O
,	O
beta	O
,	O
and	O
gamma	O
)	O
are	O
large	O
nuclear	B-GO
proteins	B-CHEBI
that	O
each	O
contain	O
an	O
N	B-SO
-	I-SO
terminal	I-SO
RBCC	I-SO
or	I-SO
TRIM	I-SO
domain	I-SO
(	O
Reymond	O
et	O
al	O
.	O
2001	O
)	O
composed	O
of	O
a	O
RING	O
finger	O
,	O
two	O
B	B-SO
-	I-SO
boxes	I-SO
,	O
and	O
a	O
coiled	B-SO
-	I-SO
coil	I-SO
domain	B-SO
.	O

TIF1	O
family	O
members	O
also	O
contain	O
a	O
C	B-SO
-	I-SO
terminal	I-SO
plant	B-Taxon
homeodomain	O
finger	O
and	O
bromodomain	O
that	O
are	O
characteristic	O
of	O
chromatin	B-GO
remodeling	O
factors	O
.	O

TIF1	B-GGP
alpha	I-GGP
has	O
been	O
shown	O
to	O
associate	O
with	O
a	O
variety	O
of	O
ligand	O
-	O
bound	O
nuclear	B-GO
hormone	B-CHEBI
receptors	O
(	O
Le	O
Douarin	O
et	O
al	O
.	O
1995	O
)	O
and	O
function	O
as	O
a	O
coactivator	O
for	O
retinoic	B-CHEBI
acid	I-CHEBI
receptors	O
(	O
Zhong	O
et	O
al	O
.	O
1999	O
)	O
.	O

TIF1	B-GGP
beta	I-GGP
has	O
been	O
shown	O
to	O
act	O
as	O
a	O
corepressor	O
for	O
the	O
large	O
family	O
of	O
Kr	O
u	O
ppel	O
-	O
associated	O
box	O
(	O
KRAB	O
)	O
domain	B-SO
zinc	B-CHEBI
-	O
finger	O
transcription	O
factors	O
(	O
Friedman	O
et	O
al	O
.	O
1996	O
;	O
Abrink	O
et	O
al	O
.	O
2001	O
)	O
.	O

In	O
contrast	O
,	O
TIF1	B-GGP
gamma	I-GGP
does	O
not	O
associate	O
directly	O
with	O
either	O
nuclear	B-GO
receptors	O
or	O
KRAB	O
domains	B-SO
that	O
bind	O
to	O
the	O
other	O
TIF1	O
family	O
members	O
(	O
Venturini	O
et	O
al	O
.	O
1999	O
;	O
Abrink	O
et	O
al	O
.	O
2001	O
)	O
.	O

Biochemical	O
studies	O
also	O
demonstrate	O
that	O
TIF1	B-GGP
gamma	I-GGP
forms	O
both	O
homo	O
-	O
oligomers	O
and	O
hetero	O
-	O
oligomers	O
with	O
TIF1	B-GGP
alpha	I-GGP
but	O
not	O
with	O
TIF1	B-GGP
beta	I-GGP
(	O
Peng	O
et	O
al	O
.	O
2002	O
)	O
.	O

The	O
murine	B-Taxon
Tif1	B-GGP
alpha	I-GGP
and	O
Tif1	B-GGP
gamma	I-GGP
genes	B-SO
have	O
not	O
yet	O
been	O
subjected	O
to	O
gene	B-SO
targeting	O
experiments	O
,	O
whereas	O
analysis	O
of	O
mouse	B-Taxon
mutants	B-SO
demonstrates	O
that	O
Tif1	B-GGP
beta	I-GGP
is	O
required	O
for	O
postimplantation	O
embryogenesis	O
and	O
mesoderm	O
induction	O
in	O
particular	O
(	O
Cammas	O
et	O
al	O
.	O
2000	O
)	O
.	O

Taken	O
together	O
,	O
these	O
studies	O
suggest	O
that	O
a	O
major	O
function	O
of	O
TIF1	O
family	O
members	O
is	O
to	O
link	O
DNA	B-SO
-	O
binding	O
proteins	B-CHEBI
with	O
other	O
coactivators	O
or	O
corepressors	O
during	O
development	O
.	O

Our	O
studies	O
establish	O
that	O
tif1	B-GGP
gamma	I-GGP
functions	O
as	O
an	O
essential	O
regulator	O
of	O
embryonic	O
and	O
adult	O
hematopoiesis	O
in	O
vertebrates	B-Taxon
.	O

Cell	B-CL
transplantation	O
studies	O
demonstrate	O
that	O
tif1	B-GGP
gamma	I-GGP
acts	O
in	O
a	O
cell	B-CL
-	O
autonomous	O
manner	O
during	O
embryonic	O
hematopoiesis	O
.	O

The	O
tif1	B-GGP
gamma	I-GGP
gene	B-SO
is	O
expressed	O
specifically	O
in	O
ventral	O
mesoderm	O
and	O
hematopoietic	B-CL
progenitors	I-CL
,	O
then	O
downregulated	O
as	O
erythroid	B-CL
maturation	O
occurs	O
.	O

Tif1	B-GGP
gamma	I-GGP
protein	B-CHEBI
localizes	O
to	O
a	O
novel	O
class	O
of	O
nuclear	B-GO
bodies	I-GO
in	O
both	O
primary	O
mouse	B-Taxon
embryo	O
fibroblasts	B-CL
and	O
erythroleukemia	O
cell	B-CL
lines	O
.	O

Taken	O
together	O
,	O
our	O
studies	O
demonstrate	O
that	O
Tif1	B-GGP
gamma	I-GGP
is	O
required	O
for	O
normal	O
erythroid	B-CL
cell	I-CL
development	O
and	O
survival	O
.	O

Results	O

The	O
Zebrafish	B-GGP
mon	I-GGP
Gene	B-SO
Is	O
Essential	O
for	O
Both	O
Primitive	O
and	O
Definitive	O
Erythropoiesis	O

In	O
order	O
to	O
determine	O
when	O
the	O
mon	B-GGP
gene	B-SO
is	O
required	O
in	O
development	O
,	O
we	O
first	O
examined	O
hematopoietic	O
gene	B-SO
expression	O
and	O
apoptosis	O
in	O
zebrafish	B-Taxon
homozygous	O
mon	B-GGP
mutant	B-SO
embryos	O
.	O

During	O
embryogenesis	O
,	O
homozygous	O
zebrafish	B-GGP
mon	I-GGP
mutants	B-SO
have	O
no	O
red	B-CL
blood	I-CL
cells	I-CL
(	O
RBCs	B-CL
)	O
visible	O
in	O
circulation	O
(	O
Ransom	O
et	O
al	O
.	O
1996	O
;	O
Weinstein	O
et	O
al	O
.	O
1996	O
)	O
.	O

The	O
mon	B-GGP
mutants	B-SO
initiate	O
expression	O
of	O
gata1	B-GGP
in	O
hematopoietic	B-CL
cells	I-CL
around	O
the	O
five	O
-	O
somite	O
stage	O
,	O
similar	O
to	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
(	O
data	O
not	O
shown	O
)	O
;	O
however	O
,	O
based	O
on	O
TUNEL	O
staining	O
,	O
the	O
differentiating	O
erythroid	B-CL
cells	I-CL
undergo	O
programmed	O
cell	B-CL
death	O
from	O
the	O
12	O
-	O
somite	O
stage	O
to	O
22	O
h	O
postfertilization	O
(	O
hpf	O
)	O
(	O
Figure	O
1A	O
and	O
1B	O
,	O
arrows	O
)	O
.	O

At	O
12	O
somites	O
,	O
gata1	B-GGP
expression	O
is	O
only	O
slightly	O
reduced	O
.	O

By	O
18	O
-	O
22	O
hpf	O
,	O
hematopoietic	O
-	O
specific	O
markers	O
such	O
as	O
gata1	B-GGP
,	O
scl	B-GGP
,	O
gata2	B-GGP
,	O
and	O
ikaros	B-GGP
are	O
not	O
detected	O
in	O
the	O
embryonic	O
blood	O
island	O
(	O
Figure	O
1A	O
and	O
1B	O
;	O
unpublished	O
data	O
)	O
.	O

The	O
hematopoietic	B-CL
cells	I-CL
are	O
thus	O
correctly	O
specified	O
early	O
during	O
the	O
development	O
of	O
mon	B-GGP
mutant	B-SO
embryos	O
,	O
but	O
these	O
precursors	O
undergo	O
cell	B-CL
death	O
.	O

Based	O
on	O
expression	O
of	O
c	B-GGP
-	I-GGP
myb	I-GGP
and	O
rag1	B-GGP
(	O
Figure	O
1B	O
,	O
arrows	O
)	O
,	O
mon	B-GGP
mutants	B-SO
have	O
normal	O
myeloid	B-CL
and	O
lymphoid	O
development	O
,	O
respectively	O
.	O

In	O
addition	O
to	O
the	O
deficit	O
of	O
RBCs	B-CL
in	O
mon	B-GGP
mutants	B-SO
,	O
there	O
is	O
a	O
prominent	O
loss	O
of	O
fin	O
-	O
fold	O
and	O
tail	O
mesenchyme	O
(	O
Ransom	O
et	O
al	O
.	O
1996	O
)	O
.	O

TUNEL	O
staining	O
of	O
mon	B-GGP
mutants	B-SO
demonstrates	O
extensive	O
apoptosis	O
of	O
mesenchymal	B-CL
cells	I-CL
in	O
the	O
trunk	O
and	O
tail	O
bud	O
regions	O
(	O
Figure	O
1A	O
and	O
1B	O
,	O
arrows	O
)	O
.	O

The	O
mon	B-GGP
gene	B-SO
is	O
thus	O
required	O
for	O
normal	O
development	O
and	O
survival	O
of	O
both	O
committed	O
erythroid	B-CL
progenitor	I-CL
cells	I-CL
and	O
posterior	O
mesenchymal	B-CL
cells	I-CL
.	O

We	O
next	O
examined	O
definitive	O
hematopoiesis	O
in	O
rare	O
surviving	O
homozygous	O
adult	O
zebrafish	B-GGP
mon	I-GGP
mutants	B-SO
.	O

Mutations	B-SO
in	O
mon	B-GGP
are	O
generally	O
lethal	O
by	O
10	O
to	O
14	O
d	O
of	O
development	O
(	O
Ransom	O
et	O
al	O
.	O
1996	O
)	O
,	O
although	O
rare	O
mon	B-GGP
homozygous	O
mutants	B-SO
(	O
approximately	O
1	O
in	O
500	O
bloodless	O
embryos	O
)	O
of	O
all	O
tested	O
alleles	B-SO
survive	O
to	O
adulthood	O
.	O

Adult	O
mon	B-GGP
mutants	B-SO
show	O
cardiac	O
hypertrophy	O
,	O
presumably	O
due	O
to	O
the	O
severe	O
anemia	O
leading	O
to	O
a	O
high	O
output	O
state	O
(	O
Figure	O
2	O
)	O
.	O

In	O
wild	B-SO
-	I-SO
type	I-SO
zebrafish	B-Taxon
,	O
the	O
adult	O
site	O
of	O
hematopoiesis	O
is	O
the	O
kidney	O
(	O
Al	O
Adhami	O
and	O
Kunz	O
1977	O
)	O
,	O
which	O
contains	O
erythroid	B-CL
,	O
lymphoid	O
,	O
and	O
myeloid	B-CL
populations	O
at	O
various	O
stages	O
of	O
differentiation	O
(	O
Bennett	O
et	O
al	O
.	O
2001	O
)	O
.	O

In	O
mon	B-GGP
homozygous	O
mutants	B-SO
,	O
there	O
is	O
a	O
severe	O
block	O
in	O
maturation	O
at	O
the	O
proerythroblast	B-CL
stage	O
(	O
Figure	O
2	O
)	O
,	O
whereas	O
the	O
differentiation	O
of	O
myeloid	B-CL
cells	I-CL
is	O
normal	O
(	O
unpublished	O
data	O
)	O
.	O

This	O
demonstrates	O
that	O
the	O
mon	B-GGP
gene	B-SO
product	O
acts	O
during	O
both	O
primitive	O
and	O
definitive	O
erythropoiesis	O
.	O

Positional	B-SO
Cloning	O
Identifies	O
mon	B-GGP
as	O
the	O
Zebrafish	B-Taxon
Ortholog	B-SO
of	O
Mammalian	B-Taxon
TIF1	B-GGP
gamma	I-GGP

We	O
identified	O
the	O
mon	B-GGP
gene	B-SO
by	O
positional	B-SO
cloning	O
using	O
a	O
panel	O
of	O
2	O
,	O
200	O
diploid	O
mutants	B-SO
collected	O
from	O
T	O
u	O
bingen	O
background	O
(	O
TU	O
)	O
/	O
WIK	O
strain	O
hybrid	O
parents	O
carrying	O
the	O
montg234	O
allele	B-SO
.	O

The	O
mon	B-GGP
mutant	B-SO
gene	B-SO
was	O
positioned	O
on	O
Chromosome	B-GO
8	O
between	O
microsatellite	B-SO
markers	I-SO
z987	O
and	O
z11001	O
(	O
Figure	O
3A	O
)	O
(	O
Knapik	O
et	O
al	O
.	O
1998	O
)	O
.	O

For	O
positional	B-SO
cloning	O
purposes	O
,	O
over	O
12	O
,	O
000	O
polymorphic	B-SO
markers	O
were	O
screened	O
using	O
amplified	O
fragment	B-SO
length	O
polymorphism	B-SO
(	O
AFLP	O
)	O
(	O
Ransom	O
and	O
Zon	O
1999	O
)	O
,	O
and	O
36	O
markers	O
within	O
the	O
interval	B-SO
were	O
isolated	O
.	O

One	O
of	O
these	O
,	O
MA3	O
,	O
was	O
found	O
to	O
be	O
0	O
.	O
3	O
cM	O
from	O
the	O
gene	B-SO
(	O
Figure	O
3A	O
)	O
and	O
was	O
utilized	O
as	O
the	O
starting	O
point	B-SO
of	O
a	O
chromosomal	B-GO
walk	O
.	O

A	O
critical	O
P1	B-SO
bacterial	I-SO
artificial	I-SO
chromosome	I-SO
clone	B-SO
(	O
PAC	B-SO
)	O
,	O
107N19	O
,	O
was	O
obtained	O
that	O
spanned	O
the	O
genetic	B-SO
interval	B-SO
.	O

Two	O
simple	O
sequence	B-SO
conformation	O
polymorphism	B-SO
(	O
SSCP	O
)	O
markers	O
found	O
on	O
this	O
PAC	B-SO
clone	B-SO
flank	O
the	O
critical	O
genetic	B-SO
interval	B-SO
.	O

The	O
marker	O
80M12	O
-	O
T7	O
maps	O
two	O
recombinants	O
out	O
of	O
4	O
,	O
400	O
meioses	O
telomeric	B-SO
of	O
the	O
mutation	B-SO
,	O
and	O
the	O
marker	O
157J23	O
-	O
T7	O
maps	O
one	O
recombinant	O
centromic	B-SO
of	O
the	O
mutation	B-SO
(	O
Figure	O
3A	O
)	O
.	O

The	O
end	O
sequences	B-SO
and	O
SSCP	O
markers	O
of	O
PAC	B-SO
107N19	O
are	O
found	O
in	O
the	O
zebrafish	B-Taxon
genomic	B-SO
sequence	I-SO
contig	B-SO
ctg23107	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ensembl	O
.	O
org	O
/	O
Danio	O
_	O
rerio	O
/	O
)	O
containing	O
a	O
predicted	B-SO
zebrafish	I-SO
TIF1	I-SO
family	I-SO
gene	I-SO
.	O

This	O
PAC	B-SO
was	O
hybridized	O
to	O
a	O
kidney	O
cDNA	B-SO
library	O
,	O
resulting	O
in	O
the	O
isolation	O
of	O
four	O
clones	B-SO
that	O
represented	O
the	O
same	O
gene	B-SO
.	O

The	O
mon	B-GGP
gene	B-SO
encodes	O
a	O
member	O
of	O
the	O
TIF1	O
family	O
of	O
transcriptional	O
cofactors	B-CHEBI
(	O
Figure	O
3B	O
and	O
3C	O
)	O
.	O

The	O
coding	B-SO
sequence	I-SO
of	O
mon	B-GGP
is	O
most	O
similar	O
to	O
human	B-GGP
TIF	I-GGP
gamma	I-GGP
(	O
Le	O
Douarin	O
et	O
al	O
.	O
1995	O
;	O
Friedman	O
et	O
al	O
.	O
1996	O
;	O
Venturini	O
et	O
al	O
.	O
1999	O
)	O
,	O
and	O
the	O
locations	B-SO
of	O
exon	B-SO
boundaries	I-SO
are	O
conserved	B-SO
between	O
the	O
zebrafish	B-Taxon
and	O
human	B-Taxon
genes	B-SO
(	O
unpublished	O
data	O
)	O
.	O

The	O
mon	B-GGP
locus	B-SO
on	I-SO
zebrafish	I-SO
Chromosome	I-SO
8	O
is	O
also	O
predicted	O
to	O
be	O
syntenic	B-SO
to	O
the	O
region	B-SO
of	I-SO
human	I-SO
Chromosome	I-SO
1p	O
that	O
contains	O
the	O
TIF1	B-GGP
gamma	I-GGP
gene	B-SO
based	O
on	O
the	O
conserved	B-SO
locations	I-SO
of	O
12	O
other	O
orthologous	B-SO
gene	B-SO
pairs	O
,	O
including	O
NRAS	B-GGP
,	O
mapped	O
to	O
these	O
regions	B-SO
in	O
human	B-Taxon
and	O
zebrafish	B-Taxon
(	O
Barbazuk	O
et	O
al	O
.	O
2000	O
)	O
.	O

Therefore	O
,	O
based	O
on	O
sequence	B-SO
similarity	O
and	O
chromosomal	B-SO
location	I-SO
,	O
the	O
zebrafish	B-GGP
mon	I-GGP
gene	B-SO
is	O
the	O
likely	O
ortholog	B-SO
of	O
the	O
human	B-GGP
TIF1	I-GGP
gamma	I-GGP
gene	B-SO
.	O

We	O
have	O
identified	O
ethyl	B-CHEBI
-	I-CHEBI
nitrosourea	I-CHEBI
(	O
ENU	B-CHEBI
)	O
-	O
induced	O
point	B-SO
mutations	I-SO
in	O
three	O
alleles	B-SO
of	O
mon	B-GGP
(	O
Figure	O
3C	O
and	O
3D	O
)	O
,	O
each	O
of	O
which	O
generates	O
a	O
premature	O
stop	B-SO
codon	I-SO
.	O

The	O
montb222b	O
and	O
montg234	O
alleles	B-SO
have	O
a	O
severe	O
phenotype	O
with	O
no	O
circulating	O
blood	B-CL
cells	I-CL
.	O

In	O
contrast	O
,	O
the	O
monm262	O
allele	B-SO
has	O
10	O
-	O
100	O
circulating	O
blood	B-CL
cells	I-CL
by	O
48	O
hpf	O
,	O
in	O
comparison	O
to	O
the	O
approximately	O
3	O
,	O
000	O
RBCs	B-CL
in	O
the	O
circulation	O
of	O
wild	B-SO
-	I-SO
type	I-SO
or	O
heterozygous	O
embryos	O
at	O
the	O
same	O
time	O
point	O
.	O

The	O
monm262	O
allele	B-SO
was	O
found	O
to	O
encode	O
a	O
premature	O
stop	B-SO
codon	I-SO
at	O
position	B-SO
E40	O
,	O
which	O
would	O
encode	O
a	O
putative	O
protein	B-CHEBI
of	O
only	O
40	O
amino	B-CHEBI
acids	I-CHEBI
.	O

Although	O
this	O
mutation	B-SO
would	O
be	O
expected	O
to	O
lead	O
to	O
a	O
complete	O
loss	O
of	O
mon	B-GGP
gene	B-SO
product	O
,	O
another	O
methionine	B-CHEBI
is	O
found	O
downstream	O
at	O
amino	B-SO
acid	I-SO
position	I-SO
104	O
.	O

In	O
vitro	O
translation	O
experiments	O
in	O
reticulocyte	B-CL
lysates	O
demonstrate	O
reinitiation	O
of	O
translation	O
from	O
this	O
methionine	B-CHEBI
(	O
unpublished	O
data	O
)	O
.	O

Therefore	O
,	O
the	O
hypomorphic	O
larval	O
phenotype	O
of	O
the	O
monm262	O
allele	B-SO
is	O
likely	O
due	O
to	O
partial	O
loss	O
of	O
mon	B-GGP
function	O
or	O
expression	O
.	O

The	O
presence	O
of	O
mutations	B-SO
in	O
each	O
of	O
the	O
mon	B-GGP
alleles	B-SO
indicates	O
that	O
defective	O
Tif1	B-GGP
gamma	I-GGP
function	O
is	O
the	O
cause	O
of	O
the	O
mon	B-GGP
phenotype	O
.	O

In	O
order	O
to	O
determine	O
whether	O
tif1	B-GGP
gamma	I-GGP
is	O
expressed	O
in	O
hematopoietic	O
mesoderm	O
,	O
we	O
next	O
examined	O
zebrafish	B-Taxon
embryos	O
by	O
whole	O
-	O
mount	O
in	O
situ	O
hybridization	O
(	O
Figure	O
4A	O
)	O
.	O

tif1	B-GGP
gamma	I-GGP
mRNA	B-CHEBI
is	O
expressed	O
maternally	O
and	O
is	O
found	O
throughout	O
the	O
embryo	O
during	O
blastula	O
stages	O
.	O

During	O
gastrulation	O
and	O
epiboly	O
stages	O
,	O
zygotic	O
expression	O
of	O
mon	B-GGP
is	O
highest	O
in	O
the	O
mesendoderm	O
of	O
the	O
germ	O
ring	O
.	O

At	O
tail	O
bud	O
and	O
early	O
somite	O
stages	O
a	O
high	O
level	O
of	O
tif1	B-GGP
gamma	I-GGP
expression	O
delineates	O
a	O
horseshoe	O
-	O
shaped	O
population	O
of	O
ventral	O
/	O
lateral	O
mesoderm	O
that	O
will	O
give	O
rise	O
to	O
blood	O
and	O
also	O
expresses	O
stem	B-GGP
cell	I-GGP
leukemiahematopoietic	I-GGP
transcription	I-GGP
factor	I-GGP
(	O
scl	B-GGP
)	O
(	O
Liao	O
et	O
al	O
.	O
1997	O
)	O
.	O

This	O
group	O
of	O
cells	B-CL
continues	O
to	O
express	O
tif1	B-GGP
gamma	I-GGP
and	O
scl	B-GGP
while	O
it	O
converges	O
and	O
forms	O
the	O
embryonic	O
blood	O
island	O
(	O
Detrich	O
et	O
al	O
.	O
1995	O
)	O
.	O

The	O
tif1	B-GGP
gamma	I-GGP
gene	B-SO
is	O
also	O
highly	O
expressed	O
in	O
the	O
central	O
nervous	O
system	O
as	O
well	O
as	O
the	O
mesenchyme	O
of	O
the	O
trunk	O
and	O
tail	O
.	O

Homozygous	O
montg234	O
mutants	B-SO
have	O
a	O
greatly	O
reduced	O
amount	O
of	O
tif1	B-GGP
gamma	I-GGP
mRNA	B-CHEBI
in	O
all	O
tissues	O
consistent	O
with	O
nonsense	O
-	O
mediated	O
message	B-SO
decay	O
.	O

Thus	O
,	O
zebrafish	B-GGP
tif1	I-GGP
gamma	I-GGP
is	O
specifically	O
expressed	O
in	O
ventral	O
mesoderm	O
and	O
putative	O
hemangioblasts	O
prior	O
to	O
and	O
during	O
the	O
embryonic	O
stages	O
when	O
hematopoietic	B-CL
progenitors	I-CL
are	O
undergoing	O
apoptosis	O
in	O
mon	B-GGP
mutants	B-SO
.	O

We	O
also	O
compared	O
the	O
expression	O
of	O
zebrafish	B-GGP
mon	I-GGP
to	O
mouse	B-GGP
Tif1	I-GGP
gamma	I-GGP
(	O
Figure	O
4A	O
and	O
4B	O
)	O
.	O

Mouse	B-GGP
Tif1	I-GGP
gamma	I-GGP
is	O
highly	O
expressed	O
in	O
erythroid	B-CL
blood	O
islands	O
of	O
the	O
yolk	O
sac	O
,	O
and	O
it	O
is	O
subsequently	O
expressed	O
in	O
the	O
fetal	O
liver	O
at	O
a	O
high	O
level	O
,	O
and	O
in	O
other	O
tissues	O
,	O
including	O
the	O
central	O
nervous	O
system	O
.	O

Taken	O
together	O
these	O
results	O
strongly	O
suggest	O
that	O
zebrafish	B-GGP
mon	I-GGP
and	O
mouse	B-GGP
Tif1	I-GGP
gamma	I-GGP
are	O
orthologs	B-SO
that	O
function	O
during	O
hematopoiesis	O
.	O

Given	O
that	O
mammalian	B-Taxon
TIF1	B-GGP
gamma	I-GGP
has	O
been	O
shown	O
to	O
form	O
hetero	O
-	O
oligomers	O
with	O
Tif1	B-GGP
alpha	I-GGP
(	O
Peng	O
et	O
al	O
.	O
2002	O
)	O
,	O
we	O
searched	O
for	O
additional	O
TIF1	O
family	O
members	O
in	O
zebrafish	B-Taxon
to	O
compare	O
with	O
tif1	B-GGP
gamma	I-GGP
.	O

Using	O
zebrafish	B-Taxon
expressed	B-SO
sequence	I-SO
tag	I-SO
(	I-SO
EST	I-SO
)	I-SO
sequences	I-SO
,	O
we	O
designed	O
primers	B-SO
to	O
RT	O
-	O
PCR	O
amplify	O
a	O
TIF1	O
-	O
related	O
cDNA	B-SO
from	O
embryonic	O
10	O
-	O
hpf	O
and	O
24	O
-	O
hpf	O
RNA	B-SO
.	O

This	O
cDNA	B-SO
encodes	O
a	O
predicted	B-SO
zebrafish	B-Taxon
ortholog	B-SO
of	O
human	B-GGP
TIF1	I-GGP
alpha	I-GGP
based	O
on	O
predicted	B-SO
amino	B-SO
acid	I-SO
sequences	I-SO
(	O
see	O
Figure	O
3B	O
)	O
.	O

In	O
addition	O
,	O
zebrafish	B-GGP
tif1	I-GGP
alpha	I-GGP
ESTs	B-SO
map	O
to	O
LG4	O
in	O
a	O
region	B-SO
predicted	B-SO
to	O
be	O
syntenic	B-SO
to	O
the	O
region	B-SO
of	I-SO
human	I-SO
Chromosome	I-SO
7	O
that	O
contains	O
the	O
TIF1	B-GGP
alpha	I-GGP
gene	B-SO
based	O
on	O
the	O
conserved	B-SO
locations	I-SO
of	O
eight	O
other	O
orthologous	B-SO
gene	B-SO
pairs	O
,	O
including	O
SEMA3A	B-GGP
,	O
mapped	O
to	O
these	O
regions	B-SO
in	O
human	B-Taxon
and	O
zebrafish	B-Taxon
(	O
Barbazuk	O
et	O
al	O
.	O
2000	O
)	O
.	O

We	O
next	O
compared	O
the	O
embryonic	O
expression	O
pattern	O
of	O
tif1	B-GGP
alpha	I-GGP
mRNA	B-CHEBI
to	O
tif1	B-GGP
gamma	I-GGP
by	O
in	O
situ	O
hybridization	O
.	O

Like	O
mammalian	B-Taxon
TIF1	B-GGP
alpha	I-GGP
(	O
Le	O
Douarin	O
et	O
al	O
.	O
1995	O
;	O
Niederreither	O
et	O
al	O
.	O
1999	O
)	O
,	O
the	O
predicted	B-SO
zebrafish	I-SO
tif1	I-SO
gamma	I-SO
gene	I-SO
is	O
broadly	O
expressed	O
(	O
see	O
Figure	O
4A	O
)	O
.	O

At	O
five	O
somites	O
,	O
zebrafish	B-GGP
tif1	I-GGP
alpha	I-GGP
does	O
not	O
display	O
the	O
relatively	O
high	O
expression	O
in	O
the	O
horseshoe	O
-	O
shaped	O
region	O
of	O
hematopoietic	O
mesoderm	O
seen	O
with	O
tif1	B-GGP
gamma	I-GGP
.	O

At	O
later	O
stages	O
,	O
tif1	B-GGP
alpha	I-GGP
is	O
evenly	O
expressed	O
throughout	O
most	O
of	O
the	O
embryo	O
,	O
including	O
the	O
developing	O
blood	O
islands	O
.	O

Therefore	O
,	O
tif1	B-GGP
alpha	I-GGP
is	O
coexpressed	O
in	O
the	O
same	O
cells	B-CL
with	O
tif1	B-GGP
gamma	I-GGP
and	O
may	O
therefore	O
be	O
available	O
to	O
form	O
hetero	O
-	O
oligomers	O
in	O
vivo	O
.	O

Forced	O
Expression	O
of	O
tif1	B-GGP
gamma	I-GGP
Rescues	O
Hematopoiesis	O
in	O
mon	B-GGP
Mutants	B-SO

To	O
further	O
confirm	O
that	O
a	O
mutation	B-SO
in	O
the	O
zebrafish	B-GGP
tif1	I-GGP
gamma	I-GGP
gene	B-SO
is	O
responsible	O
for	O
the	O
mon	B-GGP
mutant	B-SO
phenotype	O
we	O
performed	O
embryo	O
rescue	O
experiments	O
(	O
Figure	O
5A	O
;	O
Table	O
1	O
)	O
.	O

Microinjection	O
of	O
synthetic	B-SO
wild	B-SO
-	I-SO
type	I-SO
mon	B-GGP
mRNA	B-CHEBI
at	O
the	O
one	O
-	O
cell	B-CL
stage	O
rescues	O
the	O
formation	O
of	O
embryonic	O
erythrocytes	B-CL
in	O
genotyped	O
mutant	B-SO
embryos	O
without	O
causing	O
obvious	O
defects	O
in	O
embryonic	O
patterning	O
or	O
organogenesis	O
.	O

At	O
4	O
d	O
of	O
development	O
,	O
70	O
%	O
(	O
n	O
=	O
10	O
)	O
of	O
montg234	O
mutants	B-SO
show	O
significant	O
(	O
greater	O
than	O
200	O
cells	B-CL
in	O
comparison	O
to	O
a	O
wild	B-SO
-	I-SO
type	I-SO
estimate	O
of	O
3	O
,	O
000	O
cells	B-CL
)	O
rescue	O
of	O
circulating	O
hemoglobinized	O
RBCs	B-CL
in	O
comparison	O
to	O
control	O
sibling	O
mutants	B-SO
(	O
n	O
=	O
75	O
)	O
.	O

Based	O
on	O
the	O
correction	O
of	O
the	O
jagged	O
fin	O
-	O
fold	O
phenotype	O
(	O
Ransom	O
et	O
al	O
.	O
1996	O
)	O
,	O
the	O
mesenchymal	B-CL
cells	I-CL
are	O
rescued	O
to	O
a	O
similar	O
extent	O
as	O
the	O
anemia	O
(	O
unpublished	O
data	O
)	O
.	O

Overexpression	O
of	O
mon	B-GGP
did	O
not	O
result	O
in	O
expanded	O
blood	B-CL
cell	I-CL
numbers	O
in	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
and	O
was	O
not	O
toxic	B-CHEBI
at	O
doses	O
that	O
rescue	O
the	O
phenotype	O
of	O
mon	B-GGP
mutants	B-SO
(	O
unpublished	O
data	O
)	O
.	O

Since	O
there	O
were	O
no	O
expanded	O
or	O
ectopic	O
blood	O
populations	O
in	O
the	O
embryos	O
,	O
these	O
rescue	O
experiments	O
suggest	O
that	O
mon	B-GGP
functions	O
as	O
a	O
permissive	O
factor	O
required	O
for	O
hematopoiesis	O
.	O

Marrow	O
Transplantation	O
Rescues	O
Erythropoiesis	O
in	O
mon	B-GGP
Mutants	B-SO

The	O
high	O
levels	O
of	O
tif1	B-GGP
gamma	I-GGP
expression	O
in	O
erythroid	B-CL
cells	I-CL
suggest	O
that	O
it	O
functions	O
as	O
a	O
cell	B-CL
-	O
autonomous	O
regulator	O
of	O
gene	B-SO
expression	O
in	O
hematopoietic	B-CL
cells	I-CL
.	O

In	O
order	O
to	O
test	O
this	O
hypothesis	O
,	O
we	O
transplanted	O
wild	B-SO
-	I-SO
type	I-SO
adult	O
zebrafish	B-Taxon
kidney	O
marrow	O
cells	B-CL
carrying	O
a	O
gata1	B-GGP
:	O
green	O
fluorescent	O
protein	B-CHEBI
(	O
GFP	O
)	O
transgene	B-SO
into	O
48	O
-	O
hpf	O
mon	B-GGP
mutant	B-SO
embryos	O
(	O
Figure	O
5B	O
;	O
Table	O
2	O
)	O
.	O

The	O
gata1	B-GGP
:	O
GFP	O
transgene	B-SO
makes	O
use	O
of	O
the	O
gata1	B-GGP
promoter	B-SO
to	O
drive	O
GFP	O
expression	O
and	O
can	O
thus	O
be	O
used	O
to	O
mark	O
donor	O
-	O
derived	O
erythroid	B-CL
cells	I-CL
(	O
Long	O
et	O
al	O
.	O
1997	O
)	O
.	O

Untransplanted	O
mutant	B-SO
embryos	O
have	O
no	O
embryonic	O
blood	B-CL
cells	I-CL
in	O
circulation	O
.	O

Following	O
transplantation	O
,	O
mutant	B-SO
host	O
embryos	O
were	O
observed	O
daily	O
for	O
2	O
wk	O
.	O

Of	O
191	O
mutant	B-SO
embryos	O
injected	O
,	O
129	O
(	O
68	O
%	O
)	O
showed	O
GFP	O
+	O
cells	B-CL
in	O
circulation	O
2	O
d	O
later	O
.	O

Many	O
recipients	O
showed	O
robust	O
increases	O
in	O
donor	O
-	O
derived	O
cells	B-CL
over	O
the	O
observation	O
period	O
.	O

Of	O
81	O
recipients	O
initially	O
scored	O
as	O
having	O
less	O
than	O
ten	O
GFP	O
+	O
cells	B-CL
at	O
day	O
2	O
posttransplant	O
,	O
13	O
(	O
16	O
%	O
)	O
of	O
these	O
demonstrated	O
a	O
marked	O
increase	O
in	O
erythroid	B-CL
cells	I-CL
with	O
100	O
-	O
1	O
,	O
000	O
GFP	O
+	O
cells	B-CL
in	O
circulation	O
6	O
d	O
later	O
.	O

By	O
day	O
10	O
,	O
these	O
transplanted	O
embryos	O
showed	O
approximately	O
3	O
,	O
000	O
cells	B-CL
in	O
circulation	O
,	O
similar	O
to	O
the	O
number	O
of	O
blood	B-CL
cells	I-CL
in	O
normal	O
embryos	O
.	O

Despite	O
robust	O
reconstitution	O
of	O
blood	B-CL
cells	I-CL
,	O
mutant	B-SO
recipients	O
did	O
not	O
inflate	O
their	O
swim	O
bladders	O
and	O
thus	O
failed	O
to	O
survive	O
longer	O
than	O
nontransplanted	O
sibling	O
controls	O
,	O
all	O
dying	O
by	O
3	O
wk	O
of	O
age	O
.	O

In	O
contrast	O
,	O
13	O
/	O
35	O
(	O
37	O
%	O
)	O
heterozygous	O
montg234	O
transplants	O
survived	O
to	O
early	O
adulthood	O
.	O

Similar	O
transplants	O
of	O
wild	B-SO
-	I-SO
type	I-SO
cells	B-CL
can	O
fully	O
rescue	O
vlad	B-GGP
tepes	I-GGP
(	O
gata1	B-GGP
)	O
mutants	B-SO
(	O
Traver	O
et	O
al	O
.	O
2003	O
)	O
.	O

Therefore	O
,	O
the	O
results	O
of	O
cell	B-CL
transplantations	O
suggests	O
that	O
tif1	B-GGP
gamma	I-GGP
plays	O
a	O
cell	B-CL
-	O
autonomous	O
role	O
in	O
erythroid	B-CL
cells	I-CL
,	O
and	O
its	O
role	O
in	O
nonhematopoietic	O
tissues	O
,	O
such	O
as	O
trunk	O
mesenchyme	O
or	O
the	O
nervous	O
system	O
,	O
is	O
also	O
required	O
for	O
embryo	O
survival	O
.	O

Tif1	B-GGP
gamma	I-GGP
in	O
Punctate	O
Nuclear	B-GO
Foci	O
Is	O
Developmentally	O
Regulated	O

In	O
order	O
to	O
examine	O
the	O
subcellular	O
distribution	O
of	O
Tif1	B-GGP
gamma	I-GGP
protein	B-CHEBI
,	O
we	O
generated	O
an	O
affinity	O
-	O
purified	O
rabbit	B-Taxon
polyclonal	O
antiserum	O
directed	O
against	O
the	O
C	B-SO
-	I-SO
terminal	I-SO
15	O
amino	B-CHEBI
acids	I-CHEBI
conserved	B-SO
in	O
human	B-GGP
TIF1	I-GGP
gamma	I-GGP
and	O
mouse	B-GGP
Tif1	I-GGP
gamma	I-GGP
.	O

Immunofluorescence	O
of	O
mouse	B-Taxon
embryo	O
fibroblast	B-CL
nuclei	B-GO
with	O
the	O
anti	O
-	O
Tif1	B-GGP
gamma	I-GGP
antiserum	O
demonstrates	O
that	O
Tif1	B-GGP
gamma	I-GGP
is	O
localized	O
in	O
small	O
nuclear	B-GO
foci	O
(	O
Figure	O
6A	O
)	O
.	O

The	O
localization	O
of	O
Tif1	B-GGP
gamma	I-GGP
protein	B-CHEBI
appears	O
different	O
from	O
the	O
more	O
diffuse	O
nuclear	B-GO
patterns	O
typically	O
seen	O
in	O
studies	O
of	O
Tif1	B-GGP
alpha	I-GGP
(	O
Remboutsika	O
et	O
al	O
.	O
2002	O
)	O
or	O
TIF1	B-GGP
beta	I-GGP
(	O
Cammas	O
et	O
al	O
.	O
2002	O
)	O
.	O

A	O
recent	O
report	O
demonstrates	O
that	O
TIF1	B-GGP
beta	I-GGP
associates	O
with	O
heterochromatin	B-GO
-	O
containing	O
foci	O
after	O
retinoic	B-CHEBI
acid	I-CHEBI
treatment	O
or	O
serum	O
starvation	O
(	O
Cammas	O
et	O
al	O
.	O
2002	O
)	O
.	O

Thus	O
,	O
localization	O
or	O
expression	O
of	O
the	O
TIF1	O
proteins	B-CHEBI
may	O
be	O
regulated	O
during	O
distinct	O
developmental	O
processes	O
or	O
by	O
environmental	O
cues	O
.	O

The	O
nuclear	B-GO
foci	O
that	O
contain	O
Tif1	B-GGP
gamma	I-GGP
do	O
not	O
colocalize	O
with	O
two	O
markers	O
of	O
heterochromatin	B-GO
,	O
HP1	B-GGP
alpha	I-GGP
protein	B-CHEBI
and	O
DAPI	O
staining	O
of	O
DNA	B-SO
(	O
Figure	O
6A	O
)	O
.	O

Furthermore	O
,	O
Tif1	B-GGP
gamma	I-GGP
does	O
not	O
colocalize	O
with	O
promyelocytic	B-GO
leukemia	I-GO
gene	I-GO
product	I-GO
(	I-GO
PML	I-GO
)	I-GO
nuclear	I-GO
bodies	I-GO
,	O
DNA	B-SO
repair	O
complexes	B-GO
that	O
contain	O
Mre11	B-GGP
,	O
or	O
transcriptional	B-GO
complexes	I-GO
containing	O
TFII	B-GGP
-	I-GGP
B	I-GGP
(	O
unpublished	O
data	O
)	O
.	O

We	O
next	O
examined	O
the	O
expression	O
of	O
Tif1	B-GGP
gamma	I-GGP
protein	B-CHEBI
during	O
the	O
differentiation	O
of	O
G1E	O
cells	B-CL
,	O
a	O
murine	B-Taxon
erythroleukemia	O
cell	B-CL
line	O
that	O
can	O
terminally	O
differentiate	O
into	O
erythrocytes	B-CL
when	O
a	O
Gata1	B-GGP
:	O
estrogen	B-GGP
receptor	I-GGP
fusion	B-SO
protein	B-CHEBI
is	O
stabilized	O
in	O
response	O
to	O
estrogen	O
exposure	O
(	O
Weiss	O
et	O
al	O
.	O
1997	O
)	O
.	O

Western	O
blot	O
analysis	O
demonstrated	O
that	O
Tif1	B-GGP
gamma	I-GGP
protein	B-CHEBI
expression	O
decreases	O
with	O
terminal	O
erythroid	B-CL
differentiation	O
(	O
Figure	O
6B	O
)	O
.	O

Consistent	O
with	O
this	O
finding	O
,	O
after	O
24	O
hpf	O
,	O
zebrafish	B-GGP
mon	I-GGP
mRNA	B-CHEBI
expression	O
falls	O
during	O
the	O
terminal	O
maturation	O
of	O
the	O
primitive	O
erythroid	B-CL
cells	I-CL
(	O
unpublished	O
data	O
)	O
.	O

In	O
two	O
different	O
murine	B-Taxon
erythroleukemia	O
cell	B-CL
lines	O
(	O
MEL	O
and	O
G1E	O
)	O
,	O
Tif1	B-GGP
gamma	I-GGP
is	O
also	O
expressed	O
in	O
nuclear	B-GO
foci	O
,	O
and	O
even	O
though	O
the	O
overall	O
Tif1	B-GGP
gamma	I-GGP
protein	B-CHEBI
level	O
is	O
reduced	O
,	O
this	O
nuclear	B-GO
foci	O
localization	O
does	O
not	O
change	O
with	O
differentiation	O
(	O
unpublished	O
data	O
)	O
.	O

This	O
provides	O
further	O
support	O
for	O
the	O
hypothesis	O
that	O
Tif1	B-GGP
gamma	I-GGP
acts	O
within	O
novel	O
nuclear	B-GO
foci	O
,	O
during	O
erythroid	B-CL
differentiation	O
.	O

Discussion	O

The	O
zebrafish	B-Taxon
is	O
an	O
excellent	O
model	O
system	O
to	O
elucidate	O
the	O
molecular	B-CHEBI
machinery	O
controlling	O
gene	B-SO
expression	O
during	O
hematopoiesis	O
(	O
Thisse	O
and	O
Zon	O
2002	O
;	O
Galloway	O
and	O
Zon	O
2003	O
)	O
.	O

As	O
part	O
of	O
a	O
large	O
-	O
scale	O
forward	O
genetic	B-SO
screen	O
,	O
we	O
originally	O
identified	O
a	O
complementation	O
group	O
of	O
independent	O
mutant	B-SO
alleles	B-SO
in	O
the	O
zebrafish	B-Taxon
gene	B-SO
that	O
we	O
named	O
moonshine	B-GGP
(	O
Ransom	O
et	O
al	O
.	O
1996	O
)	O
.	O

Positional	B-SO
cloning	O
was	O
used	O
to	O
identify	O
the	O
mon	B-GGP
gene	B-SO
,	O
establishing	O
a	O
critical	O
role	O
for	O
a	O
transcriptional	O
intermediary	O
factor	O
,	O
Tif1	B-GGP
gamma	I-GGP
,	O
during	O
hematopoietic	O
development	O
.	O

The	O
mon	B-GGP
Gene	B-SO
Encodes	O
the	O
Zebrafish	B-Taxon
Ortholog	B-SO
of	O
Mammalian	B-Taxon
TIF1	B-GGP
gamma	I-GGP

Our	O
results	O
strongly	O
support	O
the	O
conclusion	O
that	O
we	O
have	O
positionally	B-SO
cloned	O
the	O
zebrafish	B-GGP
mon	I-GGP
gene	B-SO
correctly	O
,	O
and	O
it	O
is	O
the	O
ortholog	B-SO
of	O
mammalian	B-Taxon
Tif1	B-GGP
gamma	I-GGP
.	O

Tif1	B-GGP
gamma	I-GGP
is	O
present	O
in	O
the	O
critical	O
genetic	B-SO
interval	B-SO
encompassing	O
a	O
single	O
approximately	O
50	O
-	O
kb	O
PAC	B-SO
clone	B-SO
defined	O
by	O
linkage	O
analysis	O
(	O
see	O
Figure	O
3	O
)	O
.	O

Sequence	B-SO
analysis	O
indicates	O
that	O
zebrafish	B-GGP
tif1	I-GGP
gamma	I-GGP
is	O
most	O
similar	O
in	O
predicted	B-SO
amino	B-SO
acid	I-SO
sequence	I-SO
and	O
intron	B-SO
/	O
exon	B-SO
structure	O
compared	O
to	O
the	O
predicted	B-SO
orthologous	I-SO
human	I-SO
and	I-SO
mouse	I-SO
genes	I-SO
.	O

Zebrafish	B-GGP
tif1	I-GGP
gamma	I-GGP
is	O
located	O
in	O
a	O
region	B-SO
of	I-SO
zebrafish	I-SO
Chromosome	I-SO
8	O
syntenic	B-SO
to	O
the	O
region	B-SO
of	I-SO
human	I-SO
Chromosome	I-SO
1	O
containing	O
TIF1	B-GGP
gamma	I-GGP
.	O

We	O
identified	O
point	B-SO
mutations	I-SO
in	O
tif1	B-GGP
gamma	I-GGP
from	O
three	O
different	O
alleles	B-SO
of	O
mon	B-GGP
that	O
each	O
result	O
in	O
premature	O
stop	B-SO
codons	I-SO
and	O
mRNA	B-CHEBI
decay	O
.	O

In	O
addition	O
,	O
tif1	B-GGP
gamma	I-GGP
/	O
Tif1	B-GGP
gamma	I-GGP
is	O
highly	O
expressed	O
in	O
hematopoietic	B-CL
cells	I-CL
throughout	O
embryogenesis	O
in	O
both	O
zebrafish	B-Taxon
and	O
mouse	B-Taxon
(	O
see	O
Figure	O
4	O
)	O
.	O

And	O
as	O
predicted	O
,	O
forced	O
expression	O
of	O
wild	B-SO
-	I-SO
type	I-SO
tif1	B-GGP
gamma	I-GGP
mRNA	B-CHEBI
efficiently	O
rescues	O
hematopoiesis	O
in	O
mon	B-GGP
mutants	B-SO
and	O
does	O
not	O
perturb	O
hematopoiesis	O
in	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
(	O
see	O
Figure	O
5	O
)	O
.	O

We	O
have	O
also	O
cloned	O
the	O
predicted	B-SO
zebrafish	B-Taxon
ortholog	B-SO
of	O
tif1	B-GGP
alpha	I-GGP
,	O
which	O
is	O
more	O
uniformly	O
expressed	O
in	O
zebrafish	B-Taxon
embryos	O
like	O
mammalian	B-Taxon
TIF1	B-GGP
alpha	I-GGP
(	O
Le	O
Douarin	O
et	O
al	O
.	O
1995	O
;	O
Niederreither	O
et	O
al	O
.	O
1999	O
)	O
(	O
see	O
Figures	O
3A	O
and	O
4A	O
)	O
and	O
may	O
therefore	O
be	O
available	O
to	O
form	O
hetero	O
-	O
oligomers	O
with	O
Tif1	B-GGP
gamma	I-GGP
protein	B-CHEBI
in	O
developing	O
hematopoietic	B-CL
cells	I-CL
.	O

Comparing	O
available	O
zebrafish	B-Taxon
and	O
mammalian	B-Taxon
TIF1	O
-	O
predicted	B-SO
amino	B-SO
acid	I-SO
sequences	I-SO
,	O
it	O
appears	O
that	O
the	O
Tif1	B-GGP
gamma	I-GGP
orthologs	B-SO
are	O
the	O
most	O
highly	O
conserved	B-SO
family	O
members	O
while	O
the	O
Tif1	B-GGP
alpha	I-GGP
sequences	B-SO
are	O
relatively	O
more	O
divergent	O
.	O

We	O
have	O
not	O
found	O
a	O
Tif1	B-GGP
beta	I-GGP
ortholog	B-SO
,	O
thus	O
far	O
,	O
in	O
the	O
zebrafish	B-Taxon
or	O
fugu	B-Taxon
genome	B-SO
or	O
EST	B-SO
sequences	I-SO
.	O

It	O
is	O
possible	O
that	O
Tif1	B-GGP
beta	I-GGP
,	O
like	O
the	O
KRAB	O
domain	B-SO
transcription	O
factors	O
it	O
binds	O
to	O
,	O
may	O
be	O
present	O
only	O
in	O
tetrapods	B-Taxon
(	O
Urrutia	O
2003	O
)	O
.	O

However	O
,	O
more	O
complete	O
genome	B-SO
sequences	I-SO
will	O
be	O
needed	O
to	O
confirm	O
this	O
hypothesis	O
.	O

Based	O
on	O
our	O
analysis	O
of	O
zebrafish	B-GGP
mon	I-GGP
mutants	B-SO
,	O
it	O
is	O
reasonable	O
to	O
predict	O
that	O
Tif1	B-GGP
gamma	I-GGP
,	O
the	O
most	O
evolutionarily	B-SO
conserved	I-SO
TIF1	O
family	O
member	O
,	O
plays	O
a	O
similarly	O
essential	O
role	O
in	O
human	B-Taxon
and	O
mouse	B-Taxon
hematopoiesis	O
.	O

Mutations	B-SO
in	O
tif1	B-GGP
gamma	I-GGP
Cause	O
Apoptosis	O
of	O
Erythroid	B-CL
Progenitors	I-CL

Our	O
examination	O
of	O
hematopoietic	O
gene	B-SO
expression	O
,	O
apoptosis	O
,	O
and	O
marrow	O
histology	O
in	O
mon	B-GGP
mutants	B-SO
demonstrates	O
that	O
early	O
erythroid	B-CL
progenitors	I-CL
are	O
formed	O
in	O
homozygous	O
mutants	B-SO
,	O
but	O
they	O
fail	O
to	O
properly	O
differentiate	O
and	O
instead	O
undergo	O
programmed	O
cell	B-CL
death	O
(	O
see	O
Figure	O
1	O
)	O
.	O

The	O
expression	O
of	O
gata1	B-GGP
appears	O
to	O
initiate	O
normally	O
in	O
the	O
committed	O
erythroid	B-CL
cells	I-CL
of	O
mon	B-GGP
mutants	B-SO
.	O

However	O
,	O
the	O
cells	B-CL
are	O
abnormal	O
prior	O
to	O
the	O
complete	O
loss	O
of	O
gata1	B-GGP
expression	O
.	O

TUNEL	O
-	O
positive	O
apoptotic	B-CL
cells	I-CL
are	O
abundant	O
by	O
the	O
12	O
-	O
somite	O
stage	O
of	O
development	O
,	O
and	O
by	O
22	O
hpf	O
all	O
hematopoietic	O
gene	B-SO
expression	O
is	O
extinguished	O
.	O

The	O
expression	O
of	O
marker	O
genes	B-SO
,	O
including	O
scl	B-GGP
and	O
gata2	B-GGP
,	O
characteristic	O
of	O
hematopoietic	B-CL
stem	I-CL
cells	I-CL
and	O
primitive	O
hematopoietic	B-CL
progenitors	I-CL
,	O
are	O
also	O
not	O
detected	O
in	O
the	O
embryonic	O
blood	O
islands	O
of	O
mutants	B-SO
at	O
22	O
hpf	O
.	O

This	O
indicates	O
that	O
the	O
mutant	B-SO
hematopoietic	B-CL
cells	I-CL
are	O
not	O
blocked	O
prior	O
to	O
commitment	O
to	O
the	O
erythroid	B-CL
lineage	O
,	O
but	O
instead	O
develop	O
as	O
abnormal	O
erythroid	B-CL
cells	I-CL
and	O
undergo	O
apoptosis	O
,	O
similar	O
to	O
gata1	B-GGP
-	O
deficient	O
erythroid	B-CL
cells	I-CL
(	O
Fujiwara	O
et	O
al	O
.	O
1996	O
;	O
Lyons	O
et	O
al	O
.	O
2002	O
)	O
.	O

Defective	O
erythropoiesis	O
and	O
severe	O
anemia	O
were	O
also	O
observed	O
in	O
rare	O
surviving	O
homozygous	O
mutant	B-SO
mon	B-GGP
adults	O
,	O
demonstrating	O
that	O
tif1	B-GGP
gamma	I-GGP
is	O
also	O
required	O
in	O
definitive	O
hematopoiesis	O
(	O
see	O
Figure	O
2	O
)	O
.	O

The	O
zygotic	O
phenotypes	O
of	O
mon	B-GGP
mutants	B-SO
may	O
not	O
reveal	O
the	O
function	O
of	O
maternally	O
inherited	O
Tif1	B-GGP
gamma	I-GGP
.	O

Maternally	O
expressed	O
zebrafish	B-GGP
Tif1	I-GGP
gamma	I-GGP
may	O
play	O
roles	O
in	O
hematopoiesis	O
or	O
other	O
aspects	O
of	O
organogenesis	O
that	O
are	O
not	O
detectable	O
due	O
to	O
the	O
presence	O
of	O
wild	B-SO
-	I-SO
type	I-SO
mRNA	B-CHEBI
in	O
eggs	B-CL
laid	O
by	O
heterozygous	O
mothers	O
.	O

Analysis	O
of	O
the	O
offspring	O
of	O
homozygous	O
mon	B-GGP
mutant	B-SO
female	O
zebrafish	B-Taxon
will	O
aid	O
in	O
defining	O
the	O
function	O
of	O
this	O
maternal	O
mRNA	B-CHEBI
.	O

The	O
present	O
analysis	O
of	O
zygotic	O
mon	B-GGP
mutants	B-SO
provides	O
data	O
that	O
are	O
consistent	O
with	O
the	O
conclusion	O
that	O
tif1	B-GGP
gamma	I-GGP
is	O
essential	O
for	O
erythropoiesis	O
but	O
do	O
not	O
rule	O
out	O
essential	O
functions	O
in	O
other	O
hematopoietic	O
lineages	O
.	O

The	O
hematopoietic	O
phenotype	O
of	O
mon	B-GGP
mutants	B-SO
resembles	O
the	O
loss	O
of	O
erythroid	B-CL
cells	I-CL
seen	O
in	O
both	O
mouse	B-GGP
Gata1	I-GGP
knockout	O
embryos	O
and	O
zebrafish	B-GGP
vlad	I-GGP
tepes	I-GGP
(	I-GGP
gata1	I-GGP
)	O
mutant	B-SO
embryos	O
(	O
Fujiwara	O
et	O
al	O
.	O
1996	O
;	O
Lyons	O
et	O
al	O
.	O
2002	O
)	O
.	O

In	O
an	O
effort	O
to	O
determine	O
if	O
there	O
is	O
a	O
genetic	B-SO
relationship	O
between	O
mon	B-GGP
and	O
gata1	B-GGP
,	O
we	O
tested	O
their	O
ability	O
to	O
rescue	O
erythropoiesis	O
.	O

Both	O
injection	O
of	O
gata1	B-GGP
mRNA	B-CHEBI
into	O
mon	B-GGP
homozygous	O
mutant	B-SO
embryos	O
and	O
injection	O
of	O
tif1	B-GGP
gamma	I-GGP
mRNA	B-CHEBI
into	O
gata1	B-GGP
knock	O
-	O
down	O
embryos	O
failed	O
to	O
rescue	O
hematopoiesis	O
(	O
unpublished	O
data	O
)	O
.	O

We	O
also	O
tested	O
for	O
a	O
direct	O
interaction	O
between	O
Tif1	B-GGP
gamma	I-GGP
and	O
Gata1	B-GGP
proteins	B-CHEBI
by	O
coimmunoprecipitation	O
and	O
yeast	B-Taxon
two	O
-	O
hybrid	O
assays	O
and	O
found	O
no	O
association	O
(	O
unpublished	O
data	O
)	O
.	O

Although	O
the	O
mutations	B-SO
in	O
each	O
of	O
these	O
genes	B-SO
arrest	O
cells	B-CL
at	O
a	O
similar	O
stage	O
of	O
development	O
,	O
our	O
results	O
suggest	O
that	O
gata1	B-GGP
and	O
tif1	B-GGP
gamma	I-GGP
act	O
independently	O
.	O

This	O
does	O
not	O
rule	O
out	O
the	O
possibility	O
that	O
parallel	O
genetic	B-SO
pathways	O
involving	O
gata1	B-GGP
and	O
tif1	B-GGP
gamma	I-GGP
,	O
operating	O
together	O
,	O
regulate	O
gene	B-SO
transcription	O
within	O
blood	B-CL
cells	I-CL
.	O

The	O
Role	O
of	O
Tif1	B-GGP
gamma	I-GGP
in	O
Primitive	O
and	O
Definitive	O
Erythropoiesis	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
tif1	B-GGP
gamma	I-GGP
is	O
required	O
as	O
a	O
permissive	O
cofactor	B-CHEBI
for	O
the	O
erythroid	B-CL
lineage	O
-	O
specific	O
control	O
of	O
hematopoietic	O
gene	B-SO
expression	O
.	O

We	O
reasonably	O
predict	O
that	O
Tif1	B-GGP
gamma	I-GGP
protein	B-CHEBI
functions	O
as	O
a	O
transcriptional	O
intermediary	O
factor	O
in	O
hematopoietic	B-CL
progenitor	I-CL
cells	I-CL
given	O
that	O
both	O
TIF1	B-GGP
alpha	I-GGP
(	O
Zhong	O
et	O
al	O
.	O
1999	O
)	O
and	O
TIF1	B-GGP
beta	I-GGP
(	O
Friedman	O
et	O
al	O
.	O
1996	O
;	O
Abrink	O
et	O
al	O
.	O
2001	O
)	O
have	O
been	O
shown	O
to	O
act	O
as	O
intermediary	O
factors	O
that	O
positively	O
or	O
negatively	O
regulate	O
gene	B-SO
transcription	O
.	O

These	O
studies	O
indicate	O
that	O
TIF1	B-GGP
alpha	I-GGP
and	O
TIF1	B-GGP
beta	I-GGP
act	O
as	O
scaffolds	O
that	O
link	O
different	O
classes	O
of	O
DNA	B-SO
-	O
binding	O
proteins	B-CHEBI
and	O
chromatin	B-GO
-	O
associated	O
proteins	B-CHEBI
into	O
larger	O
regulatory	O
complexes	B-GO
.	O

Tif1	B-GGP
gamma	I-GGP
is	O
detected	O
within	O
nuclear	B-GO
foci	O
(	O
see	O
Figure	O
6	O
)	O
,	O
which	O
,	O
based	O
on	O
our	O
analysis	O
,	O
do	O
not	O
appear	O
to	O
correspond	O
to	O
several	O
types	O
of	O
previously	O
described	O
nuclear	B-GO
bodies	I-GO
,	O
including	O
PML	B-GO
bodies	I-GO
.	O

Localization	O
of	O
Tif1	B-GGP
gamma	I-GGP
to	O
these	O
nuclear	B-GO
bodies	I-GO
may	O
be	O
regulated	O
by	O
posttranslational	O
modification	O
such	O
as	O
SUMO	O
modification	O
that	O
is	O
required	O
for	O
PML	B-GGP
to	O
form	O
PML	B-GO
nuclear	I-GO
domains	I-GO
(	O
Zhong	O
et	O
al	O
.	O
2000a	O
,	O
2000b	O
;	O
Best	O
et	O
al	O
.	O
2002	O
)	O
.	O

These	O
foci	O
may	O
serve	O
as	O
assembly	O
points	O
where	O
Tif1	B-GGP
gamma	I-GGP
forms	O
multisubunit	O
complexes	B-GO
with	O
DNA	B-SO
-	O
binding	O
transcription	O
factors	O
and	O
their	O
other	O
essential	O
coactivators	O
or	O
corepressors	O
,	O
during	O
the	O
early	O
stages	O
of	O
erythroid	B-CL
differentiation	O
.	O

It	O
will	O
be	O
important	O
to	O
determine	O
the	O
identity	O
of	O
Tif1	B-GGP
gamma	I-GGP
-	O
interacting	O
proteins	B-CHEBI
in	O
nuclear	B-GO
foci	O
and	O
establish	O
how	O
they	O
function	O
with	O
Tif1	B-GGP
gamma	I-GGP
to	O
regulate	O
blood	B-CL
cell	I-CL
development	O
.	O

Materials	O
and	O
Methods	O

Zebrafish	B-Taxon
and	O
mouse	B-Taxon
strains	O
and	O
studies	O

Zebrafish	B-Taxon
were	O
maintained	O
and	O
staged	O
as	O
described	O
(	O
Westerfield	O
1998	O
)	O
.	O

The	O
alleles	B-SO
montb222b	O
and	O
montg234	O
were	O
generated	O
in	O
a	O
large	O
-	O
scale	O
screen	O
for	O
ENU	B-CHEBI
-	O
induced	O
mutations	B-SO
(	O
Ransom	O
et	O
al	O
.	O
1996	O
)	O
on	O
the	O
TU	O
,	O
whereas	O
the	O
monm262	O
allele	B-SO
was	O
derived	O
on	O
the	O
AB	O
strain	O
and	O
was	O
originally	O
called	O
vampire	O
(	O
Weinstein	O
et	O
al	O
.	O
1996	O
)	O
.	O

Mapping	O
strains	O
were	O
constructed	O
by	O
mating	O
to	O
WIK	O
or	O
SJD	O
polymorphic	B-SO
strains	O
.	O

Linkage	O
analysis	O
was	O
performed	O
on	O
haploid	O
or	O
diploid	O
embryos	O
obtained	O
from	O
TU	O
/	O
SJD	O
or	O
TU	O
/	O
WIK	O
hybrids	O
.	O

In	O
situ	O
hybridization	O
and	O
stainings	O
of	O
embryos	O
were	O
done	O
as	O
described	O
(	O
Thompson	O
et	O
al	O
.	O
1998	O
;	O
Liao	O
et	O
al	O
.	O
2002	O
)	O
.	O

In	O
situ	O
hybridization	O
of	O
mouse	B-Taxon
embryos	O
was	O
performed	O
as	O
described	O
(	O
Kingsley	O
et	O
al	O
.	O
2001	O
)	O
.	O

Genomic	B-SO
DNA	I-SO
isolation	O
,	O
genotyping	O
,	O
AFLP	O
analysis	O
,	O
and	O
chromosomal	B-GO
walking	O
were	O
each	O
performed	O
as	O
previously	O
described	O
(	O
Brownlie	O
et	O
al	O
.	O
1998	O
;	O
Ransom	O
and	O
Zon	O
1999	O
)	O
.	O

A	O
complete	O
list	O
of	O
primers	B-SO
for	O
genetic	B-SO
mapping	O
,	O
RT	O
-	O
PCR	O
,	O
and	O
sequencing	O
of	O
mon	B-GGP
are	O
available	O
on	O
request	O
.	O

mRNA	B-CHEBI
expression	O
constructs	B-SO
,	O
morpholinos	B-SO
,	O
and	O
microinjection	O

The	O
full	O
-	O
length	O
mon	B-GGP
cDNA	B-SO
was	O
subcloned	O
into	O
EcoRI	O
and	O
XhoI	O
sites	B-SO
in	O
the	O
pCS2	O
+	O
vector	B-SO
.	O

Synthetic	B-SO
mRNA	B-CHEBI
was	O
transcribed	O
in	O
vitro	O
,	O
and	O
microinjection	O
was	O
performed	O
essentially	O
as	O
described	O
(	O
Liao	O
et	O
al	O
.	O
2002	O
)	O
.	O

Cell	B-CL
transplantation	O

Whole	O
kidney	O
marrow	O
cells	B-CL
were	O
isolated	O
from	O
adult	O
gata1	B-GGP
:	O
EGFP	O
transgenic	B-SO
donors	O
,	O
resuspended	O
in	O
0	O
.	O
9X	O
phosphate	B-CHEBI
-	O
buffered	B-CHEBI
saline	O
+	O
5	O
%	O
fetal	O
bovine	B-Taxon
serum	O
,	O
and	O
injected	O
into	O
the	O
sinus	O
venosus	O
of	O
2	O
-	O
d	O
-	O
old	O
montg234	O
-	O
/	O
-	O
and	O
control	O
embryos	O
.	O

Between	O
102	O
and	O
103	O
kidney	O
marrow	O
cells	B-CL
were	O
injected	O
per	O
embryo	O
.	O

Individual	O
transplanted	O
embryos	O
were	O
anesthetized	O
and	O
visualized	O
daily	O
under	O
an	O
inverted	O
fluorescent	O
microscope	O
(	O
DM	O
-	O
IRE2	O
;	O
Leica	O
,	O
Wetzlar	O
,	O
Germany	O
)	O
for	O
GFP	O
+	O
cells	B-CL
over	O
a	O
span	O
of	O
12	O
d	O
.	O

On	O
day	O
13	O
posttransplant	O
,	O
all	O
surviving	O
larvae	O
(	O
12	O
/	O
129	O
;	O
9	O
%	O
)	O
were	O
placed	O
in	O
tanks	O
and	O
monitored	O
for	O
survival	O
.	O

Antibodies	B-GO
,	O
immunostaining	O
,	O
and	O
immunoblots	O

Antisera	O
against	O
the	O
human	B-Taxon
C	B-SO
-	I-SO
terminal	I-SO
TIF1	I-SO
gamma	I-SO
sequence	I-SO
RRKRLKSDERPVHIK	O
was	O
generated	O
in	O
rabbits	B-Taxon
(	O
Genemed	O
Synthesis	O
,	O
South	O
San	O
Francisco	O
,	O
California	O
,	O
United	O
States	O
)	O
and	O
affinity	O
purified	O
.	O

Mouse	B-Taxon
embryonic	O
fibroblasts	B-CL
grown	O
on	O
coverslips	O
were	O
immunostained	O
with	O
HP1	B-GGP
alpha	I-GGP
(	O
Chemicon	O
,	O
Temecula	O
,	O
California	O
,	O
United	O
States	O
)	O
and	O
Tif1	B-GGP
gamma	I-GGP
antisera	O
simultaneously	O
.	O

In	O
brief	O
,	O
cells	B-CL
were	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
for	O
5	O
min	O
,	O
washed	O
with	O
phosphate	B-CHEBI
-	O
buffered	B-CHEBI
saline	O
,	O
and	O
blocked	O
with	O
5	O
%	O
serum	O
(	O
PBST	O
)	O
for	O
30	O
min	O
.	O

After	O
incubation	O
with	O
the	O
primary	O
antibodies	B-GO
(	O
PBST	O
,	O
60	O
min	O
)	O
cells	B-CL
were	O
washed	O
three	O
times	O
with	O
PBST	O
and	O
incubated	O
with	O
secondary	O
antibodies	B-GO
(	O
Jackson	O
Laboratory	O
,	O
Bar	O
Harbor	O
,	O
Maine	O
,	O
United	O
States	O
)	O
followed	O
by	O
three	O
washes	O
in	O
PBST	O
.	O

Cells	B-CL
were	O
embedded	O
with	O
Vectashield	O
/	O
DAPI	O
and	O
analyzed	O
using	O
an	O
Axioplan	O
2	O
microscope	O
(	O
Zeiss	O
,	O
Jena	O
,	O
Germany	O
)	O
.	O

Digital	O
images	O
were	O
processed	O
using	O
the	O
Volocity	O
1	O
.	O
0	O
software	O
(	O
Improvision	O
,	O
Lexington	O
,	O
Massachusetts	O
,	O
United	O
States	O
)	O
.	O

G1E	O
cell	B-CL
differentiation	O
experiments	O
were	O
performed	O
essentially	O
as	O
described	O
(	O
Weiss	O
et	O
al	O
.	O
1997	O
)	O
.	O

Supporting	O
Information	O

Transplantation	O
of	O
wild	B-SO
-	I-SO
type	I-SO
zebrafish	B-Taxon
marrow	O
cells	B-CL
carrying	O
a	O
gata1	B-GGP
:	O
GFP	O
transgene	B-SO
into	O
2	O
-	O
d	O
-	O
old	O
embryos	O
reconstitutes	O
erythropoiesis	O
,	O
but	O
not	O
viability	O
,	O
in	O
montg234	O
homozygous	O
mutants	B-SO
.	O

Movies	O
of	O
live	O
embryos	O
at	O
day	O
3	O
posttransplant	O
highlight	O
less	O
than	O
100	O
GFP	O
+	O
RBCs	B-CL
in	O
circulation	O
.	O

Transplanted	O
cells	B-CL
were	O
observed	O
to	O
proliferate	O
,	O
resulting	O
in	O
thousands	O
of	O
donor	O
-	O
derived	O
erythrocytes	B-CL
7	O
d	O
later	O
.	O

Movies	O
present	O
GFP	O
-	O
fluorescent	O
images	O
of	O
live	O
zebrafish	B-Taxon
larvae	O
.	O

Video	O
S1	O

Untransplanted	O
Control	O
montg234	O
Homozygous	O
Mutants	B-SO
Had	O
No	O
Fluorescent	O
Cells	B-CL
in	O
Circulation	O
at	O
3	O
Days	O
of	O
Development	O

(	O
13	O
.	O
7	O
MB	O
MOV	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Video	O
S2	O

One	O
Day	O
after	O
Transplantation	O
,	O
Less	O
Than	O
100	O
GFP	O
+	O
Erythrocytes	B-CL
Were	O
Visible	O
in	O
the	O
Circulation	O
of	O
Three	O
montg234	O
Homozygous	O
Mutants	B-SO

(	O
11	O
.	O
3	O
MB	O
MOV	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Video	O
S3	O

Untransplanted	O
Control	O
montg234	O
Homozygous	O
Mutants	B-SO
Had	O
No	O
Fluorescent	O
Cells	B-CL
in	O
Circulation	O
at	O
9	O
Days	O
of	O
Development	O

(	O
7	O
.	O
9	O
MB	O
MOV	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Video	O
S4	O

Seven	O
Days	O
after	O
Transplantation	O
,	O
Thousands	O
of	O
Donor	O
-	O
Derived	O
Erythrocytes	B-CL
Were	O
Visible	O
in	O
the	O
Circulation	O
of	O
a	O
Representative	O
montg234	O
Homozygous	O
Mutant	B-SO

(	O
11	O
.	O
2	O
MB	O
MOV	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Accession	O
Numbers	O

The	O
GenBank	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
Genbank	O
)	O
accession	O
numbers	O
for	O
the	O
genes	B-SO
and	O
gene	B-SO
products	O
discussed	O
in	O
this	O
paper	O
are	O
fly	B-GGP
bonus	I-GGP
(	O
AAF19646	O
)	O
,	O
human	B-GGP
TIF1	I-GGP
alpha	I-GGP
(	O
015164	O
)	O
,	O
human	B-GGP
TIF1	I-GGP
beta	I-GGP
(	O
Q13263	O
)	O
,	O
human	B-GGP
TIF	I-GGP
gamma	I-GGP
(	O
Q9UPN9	O
)	O
,	O
human	B-GGP
TIF1	I-GGP
gamma	I-GGP
(	O
Q9UPN9	O
)	O
,	O
mon	B-GGP
(	O
AY59853	O
)	O
,	O
mouse	B-GGP
Tif1	I-GGP
alpha	I-GGP
(	O
Q64127	O
)	O
,	O
mouse	B-GGP
Tif1	I-GGP
beta	I-GGP
(	O
AAH58391	O
)	O
,	O
and	O
mouse	B-GGP
Tif1	I-GGP
gamma	I-GGP
(	O
NP444400	O
)	O
.	O

The	O
cDNA	B-GGP
sequences	I-GGP
of	I-GGP
zebrafish	I-GGP
mon	I-GGP
/	I-GGP
tif1	I-GGP
gamma	I-GGP
and	I-GGP
tif1	I-GGP
alpha	I-GGP
have	O
been	O
deposited	O
in	O
GenBank	O
under	O
the	O
accession	O
numbers	O
AY598453	O
and	O
AY598454	O
,	O
respectively	O
.	O

Acknowledgements	O

We	O
thank	O
A	O
.	O

Davidson	O
,	O
J	O
.	O

Amatruda	O
,	O
and	O
J	O
.	O

Christian	O
for	O
critical	O
review	O
of	O
this	O
manuscript	O
;	O
J	O
.	O

Postlethwait	O
and	O
W	O
.	O

Talbot	O
for	O
helpful	O
discussions	O
and	O
experimental	O
advice	O
;	O
B	O
.	O

Weinstein	O
for	O
the	O
gift	O
of	O
the	O
m262	O
allele	B-SO
of	O
mon	B-GGP
;	O
and	O
D	O
.	O

Giarla	O
for	O
administrative	O
assistance	O
.	O

DGR	O
was	O
funded	O
by	O
the	O
American	O
Cancer	O
Society	O
and	O
an	O
award	O
to	O
Oregon	O
Health	O
and	O
Science	O
University	O
by	O
the	O
Howard	O
Hughes	O
Medical	O
Institute	O
(	O
HHMI	O
)	O
Biomedical	O
Research	O
Support	O
Program	O
for	O
Medical	O
Schools	O
.	O

LIZ	O
and	O
SHO	O
are	O
investigators	O
of	O
the	O
HHMI	O
.	O

This	O
work	O
was	O
supported	O
by	O
grants	O
from	O
the	O
National	O
Institutes	O
of	O
Health	O
.	O

Abbreviations	O

AFLP	O
-	O
amplified	O
fragment	B-SO
length	O
polymorphism	B-SO

ENU	B-CHEBI
-	O
ethyl	B-CHEBI
-	I-CHEBI
nitrosourea	I-CHEBI

EST	B-SO
-	O
expressed	B-SO
sequence	I-SO
tag	I-SO

GFP	O
-	O
green	O
fluorescent	O
protein	B-CHEBI

hpf	O
-	O
hours	O
postfertilization	O

KRAB	O
-	O
Kr	O
u	O
ppel	O
-	O
associated	O
box	O

mon	B-GGP
-	O
moonshine	B-GGP
;	O
PAC	B-SO

PML	B-GGP
-	O
promyelocytic	B-GGP
leukemia	I-GGP
gene	B-SO
product	O

RBCs	B-CL
-	O
red	B-CL
blood	I-CL
cells	I-CL

scl	B-GGP
-	O
stem	B-GGP
cell	I-GGP
leukemia	I-GGP
;	O
SSCP	O

TIF	O
-	O
transcriptional	O
intermediary	O
factor	O

TU	O
-	O
T	O
u	O
bingen	O
background	O

Figures	O
and	O
Tables	O

Figure	O
1	O

Zebrafish	B-GGP
mon	I-GGP
Mutants	B-SO
Have	O
Severe	O
Defects	O
in	O
Primitive	O
Hematopoiesis	O

(	O
A	O
)	O
Whole	O
-	O
mount	O
TUNEL	O
assays	O
reveal	O
that	O
ventral	O
-	O
posterior	O
mesodermal	B-CL
cells	I-CL
undergo	O
apoptosis	O
in	O
homozygous	O
montg234	O
mutant	B-SO
embryos	O
.	O

Whole	O
-	O
mount	O
in	O
situ	O
hybridization	O
of	O
gata1	B-GGP
detected	O
at	O
the	O
12	O
-	O
and	O
18	O
-	O
somite	O
stage	O
in	O
genotyped	O
embryos	O
.	O

Posterior	O
views	O
,	O
anterior	O
to	O
the	O
left	O
.	O

(	O
B	O
)	O
Extensive	O
apoptosis	O
is	O
visible	O
in	O
the	O
trunk	O
and	O
tail	O
(	O
arrowhead	O
)	O
and	O
also	O
in	O
hematopoietic	B-CL
cells	I-CL
of	O
the	O
embryonic	O
blood	O
island	O
at	O
22	O
h	O
of	O
development	O
(	O
arrow	O
)	O
.	O

Whole	O
-	O
mount	O
in	O
situ	O
hybridization	O
at	O
22	O
hpf	O
including	O
scl	B-GGP
,	O
gata2	B-GGP
,	O
gata1	B-GGP
,	O
ikaros	B-GGP
,	O
and	O
myb	B-GGP
in	O
montg234	O
mutants	B-SO
.	O

Expression	O
of	O
myb	B-GGP
is	O
greatly	O
reduced	O
in	O
the	O
blood	O
islands	O
because	O
of	O
a	O
loss	O
of	O
erythroid	B-CL
cells	I-CL
,	O
but	O
embryonic	O
macrophages	B-CL
are	O
still	O
present	O
(	O
arrows	O
)	O
.	O

The	O
expression	O
of	O
rag1	B-GGP
in	O
thymic	O
T	B-CL
-	I-CL
cells	I-CL
appears	O
normal	O
in	O
mon	B-GGP
mutants	B-SO
at	O
5	O
d	O
postfertilization	O
(	O
arrow	O
heads	O
)	O
.	O

Lateral	O
views	O
of	O
22	O
hpf	O
and	O
5	O
-	O
d	O
-	O
old	O
embryos	O
.	O

Figure	O
2	O

Zebrafish	B-GGP
mon	I-GGP
Mutants	B-SO
Also	O
Have	O
Severe	O
Defects	O
in	O
Definitive	O
Hematopoiesis	O

Adult	O
phenotype	O
of	O
wild	B-SO
-	I-SO
type	I-SO
and	O
mon	B-GGP
mutants	B-SO
.	O

A	O
rare	O
surviving	O
montb222	O
homozygous	O
adult	O
shows	O
significant	O
cardiomegaly	O
in	O
comparison	O
to	O
a	O
wild	B-SO
-	I-SO
type	I-SO
age	O
-	O
matched	O
control	O
.	O

Wright	O
-	O
Giemsa	O
stained	O
marrow	O
of	O
wild	B-SO
-	I-SO
type	I-SO
adult	O
in	O
comparison	O
to	O
a	O
homozygous	O
mutant	B-SO
.	O

Note	O
the	O
dramatic	O
reduction	O
of	O
terminally	O
differentiated	O
erythroid	B-CL
cells	I-CL
and	O
the	O
presence	O
of	O
abnormally	O
large	O
megaloblastic	O
proerythroblasts	B-CL
in	O
the	O
montb222	O
mutant	B-SO
marrow	O
.	O

Figure	O
3	O

Positional	B-SO
Cloning	O
Identifies	O
the	O
mon	B-GGP
Gene	B-SO
as	O
Zebrafish	B-GGP
tif1	I-GGP
gamma	I-GGP

(	O
A	O
)	O
Physical	B-SO
map	I-SO
of	O
the	O
mon	B-GGP
locus	B-SO
on	I-SO
zebrafish	I-SO
Chromosome	I-SO
8	O
.	O

Microsatellite	B-SO
markers	I-SO
z987	O
and	O
z11001	O
were	O
used	O
to	O
initially	O
identify	O
recombinants	O
in	O
a	O
panel	O
of	O
2	O
,	O
200	O
diploid	O
montg234	O
homozygous	O
mutants	B-SO
.	O

The	O
AFLP	O
marker	O
MA3	O
was	O
used	O
to	O
initiate	O
a	O
chromosomal	B-GO
walk	O
in	O
PAC	B-SO
libraries	O
.	O

The	O
critical	O
PACS	B-SO
that	O
were	O
isolated	O
to	O
encompass	O
the	O
mon	B-GGP
locus	B-SO
are	O
indicated	O
by	O
numbers	O
above	O
bar	O
.	O

The	O
PAC	B-SO
107N19	O
defines	O
the	O
critical	O
interval	B-SO
for	O
the	O
mon	B-GGP
gene	B-SO
.	O

This	O
PAC	B-SO
was	O
used	O
as	O
a	O
probe	B-SO
to	O
screen	O
cDNA	B-SO
libraries	O
and	O
to	O
identify	O
zebrafish	B-GGP
tif1	I-GGP
gamma	I-GGP
cDNAs	B-SO
.	O

Numbers	O
below	O
the	O
bar	O
indicate	O
the	O
number	O
of	O
recombinants	O
identified	O
by	O
SSCP	O
analysis	O
.	O

(	O
B	O
)	O
Clustal	O
-	O
W	O
-	O
generated	O
phylogentic	O
tree	O
of	O
zebrafish	B-GGP
(	I-GGP
Danio	I-GGP
rerio	I-GGP
[	I-GGP
Dr	I-GGP
]	I-GGP
)	I-GGP
Tif1	I-GGP
gamma	I-GGP
and	I-GGP
Tif1	I-GGP
alpha	I-GGP
peptide	B-SO
sequences	I-SO
in	O
comparison	O
to	O
TIF1	O
family	O
members	O
:	O
human	B-GGP
(	I-GGP
Hs	I-GGP
)	I-GGP
TIF1	I-GGP
alpha	I-GGP
,	I-GGP
TIF1	I-GGP
beta	I-GGP
,	I-GGP
and	I-GGP
TIF1	I-GGP
gamma	I-GGP
;	O
mouse	B-GGP
(	I-GGP
Mm	I-GGP
)	I-GGP
Tif1	I-GGP
alpha	I-GGP
,	I-GGP
Tif1	I-GGP
beta	I-GGP
,	I-GGP
and	I-GGP
Tif1	I-GGP
gamma	I-GGP
;	O
;	O
and	O
fly	B-GGP
(	I-GGP
Dm	I-GGP
)	I-GGP
bonus	I-GGP
.	O

(	O
C	O
)	O
Diagrams	O
illustrating	O
the	O
structure	O
of	O
the	O
Tif1	B-GGP
gamma	I-GGP
-	O
predicted	B-SO
peptide	B-SO
and	O
the	O
three	O
identified	O
point	O
mutants	B-SO
.	O

RING	O
finger	O
(	O
RING	O
)	O
,	O
B	B-SO
-	I-SO
boxes	I-SO
(	O
B1	O
and	O
B2	O
)	O
,	O
plant	B-Taxon
homeodomain	O
finger	O
(	O
PHD	O
)	O
and	O
bromodomain	O
(	O
BROMO	O
)	O
.	O

Numbers	O
below	O
the	O
first	O
diagram	O
indicate	O
the	O
percent	O
identity	O
shared	O
between	O
each	O
of	O
these	O
domains	B-SO
in	O
zebrafish	B-GGP
and	I-GGP
human	I-GGP
TIF1	I-GGP
gamma	I-GGP
.	O

The	O
predicted	B-SO
truncated	O
proteins	B-CHEBI
are	O
indicated	O
.	O

(	O
D	O
)	O
DNA	B-SO
sequence	I-SO
chromatograms	O
showing	O
the	O
three	O
ENU	B-CHEBI
-	O
induced	O
point	O
mutants	B-SO
in	O
comparison	O
to	O
wild	B-SO
-	I-SO
type	I-SO
control	O
sequences	B-SO

Figure	O
4	O

The	O
mon	B-GGP
/	O
tif1	B-GGP
gamma	I-GGP
Gene	B-SO
Is	O
Highly	O
Expressed	O
in	O
Hematopoietic	O
Mesoderm	O

(	O
A	O
)	O
In	O
situ	O
hybridization	O
of	O
zebrafish	B-Taxon
embryos	O
demonstrating	O
the	O
embryonic	O
expression	O
of	O
tif1	B-GGP
gamma	I-GGP
.	O

tif1	B-GGP
gamma	I-GGP
is	O
initially	O
expressed	O
as	O
a	O
maternal	O
mRNA	B-CHEBI
.	O

Increased	O
expression	O
of	O
tif1	B-GGP
gamma	I-GGP
in	O
ventral	O
-	O
lateral	O
mesoderm	O
begins	O
between	O
the	O
one	O
-	O
to	O
three	O
-	O
somite	O
stages	O
and	O
increases	O
through	O
early	O
development	O
.	O

By	O
five	O
somites	O
,	O
tif1	B-GGP
gamma	I-GGP
is	O
strongly	O
expressed	O
in	O
lateral	O
stripes	O
of	O
mesoderm	O
that	O
also	O
express	O
scl	B-GGP
.	O

At	O
22	O
hpf	O
tif1	B-GGP
gamma	I-GGP
is	O
expressed	O
broadly	O
in	O
the	O
brain	O
,	O
spinal	O
cord	O
,	O
trunk	O
,	O
and	O
tail	O
mesenchyme	O
,	O
but	O
is	O
at	O
much	O
higher	O
levels	O
in	O
hematopoietic	B-CL
cells	I-CL
of	O
the	O
blood	O
island	O
.	O

Zebrafish	B-GGP
tif1	I-GGP
alpha	I-GGP
is	O
also	O
broadly	O
expressed	O
but	O
relatively	O
more	O
uniform	O
in	O
most	O
tissues	O
,	O
in	O
comparison	O
to	O
tif1	B-GGP
gamma	I-GGP
.	O

Tif1	B-GGP
alpha	I-GGP
is	O
weakly	O
expressed	O
at	O
early	O
somite	O
stages	O
in	O
hematopoietic	O
mesoderm	O
and	O
uniformly	O
expressed	O
at	O
22	O
hpf	O
,	O
including	O
expression	O
in	O
the	O
blood	O
islands	O
.	O

Expression	O
of	O
scl	B-GGP
at	O
five	O
somites	O
and	O
22	O
hpf	O
highlights	O
the	O
embryonic	O
blood	O
island	O
in	O
comparison	O
to	O
tif1	B-GGP
gamma	I-GGP
expression	O
.	O

(	O
B	O
)	O
In	O
situ	O
hybridization	O
of	O
mouse	B-Taxon
embryos	O
detects	O
broad	O
expression	O
of	O
Tif1	B-GGP
gamma	I-GGP
at	O
embryonic	O
day	O
8	O
.	O
5	O
including	O
the	O
yolk	O
sac	O
blood	O
islands	O
(	O
arrow	O
)	O
.	O

AT	O
embryonic	O
day	O
12	O
.	O
5	O
,	O
there	O
is	O
high	O
level	O
expression	O
in	O
the	O
fetal	O
liver	O
(	O
arrow	O
)	O
and	O
broad	O
expression	O
in	O
the	O
embryonic	O
brain	O
,	O
spinal	O
chord	O
,	O
gut	O
,	O
and	O
muscle	O
.	O

Figure	O
5	O

Overexpression	O
of	O
Wild	B-SO
-	I-SO
Type	I-SO
tif1	B-GGP
gamma	I-GGP
mRNA	B-CHEBI
or	O
Marrow	O
Transplantation	O
Rescues	O
Embryonic	O
Hematopoiesis	O
in	O
mon	B-GGP
Mutants	B-SO

(	O
A	O
)	O
montg234	O
mutants	B-SO
are	O
rescued	O
by	O
injection	O
of	O
mRNA	B-CHEBI
-	O
encoding	O
wild	B-SO
-	I-SO
type	I-SO
Tif1	B-GGP
gamma	I-GGP
protein	B-CHEBI
.	O

At	O
4	O
d	O
of	O
development	O
,	O
large	O
numbers	O
of	O
RBCs	B-CL
are	O
visible	O
in	O
the	O
circulation	O
of	O
wild	B-SO
-	I-SO
type	I-SO
zebrafish	B-Taxon
,	O
shown	O
here	O
by	O
o	O
-	O
dianisidine	O
staining	O
of	O
hemoglobin	B-GO
.	O

Uninjected	O
monttg234	O
homozygous	O
mutants	B-SO
are	O
completely	O
bloodless	O
.	O

Injection	O
of	O
100	O
pg	O
of	O
wild	B-SO
-	I-SO
type	I-SO
tif1	B-GGP
gamma	I-GGP
mRNA	B-CHEBI
rescues	O
erythropoiesis	O
in	O
mutant	B-SO
embryos	O
.	O

o	O
-	O
dianisidine	O
-	O
stained	O
larvae	O
are	O
shown	O
in	O
ventral	O
views	O
to	O
highlight	O
blood	O
in	O
vessels	O
.	O

(	O
B	O
)	O
Transplantation	O
of	O
wild	B-SO
-	I-SO
type	I-SO
zebrafish	B-Taxon
marrow	O
cells	B-CL
carrying	O
a	O
gata1	B-GGP
:	O
GFP	O
transgene	B-SO
into	O
2	O
-	O
d	O
-	O
old	O
embryos	O
reconstitutes	O
erythropoiesis	O
,	O
but	O
not	O
viability	O
,	O
in	O
montg234	O
homozygous	O
mutants	B-SO
.	O

Still	O
frames	O
from	O
movies	O
of	O
live	O
embryos	O
at	O
day	O
3	O
posttransplant	O
highlight	O
less	O
than	O
100	O
GFP	O
+	O
RBCs	B-CL
in	O
circulation	O
(	O
top	O
)	O
.	O

Transplanted	O
cells	B-CL
were	O
observed	O
to	O
proliferate	O
resulting	O
in	O
thousands	O
of	O
donor	O
-	O
derived	O
erythrocytes	B-CL
7	O
d	O
later	O
(	O
bottom	O
)	O
.	O

Arrows	O
indicate	O
the	O
hearts	O
of	O
control	O
and	O
transplanted	O
zebrafish	B-Taxon
.	O

See	O
Videos	O
S1	O
-	O
S4	O
.	O

Figure	O
6	O

Mammalian	B-Taxon
Tif1	B-GGP
gamma	I-GGP
Protein	B-CHEBI
Localizes	O
to	O
Nuclear	B-GO
Bodies	I-GO
Distinct	O
from	O
Heterochromatin	B-GO

(	O
A	O
)	O
Deconvolved	O
immunofluorescence	O
images	O
of	O
a	O
mouse	B-Taxon
embryonic	O
fibroblast	B-CL
cell	I-CL
nucleus	B-GO
stained	O
with	O
an	O
anti	O
-	O
Tif1	B-GGP
gamma	I-GGP
antibody	B-GO
and	O
stained	O
with	O
a	O
monoclonal	O
antibody	B-GO
directed	O
against	O
HP1	B-GGP
alpha	I-GGP
.	O

This	O
is	O
also	O
compared	O
to	O
DAPI	O
staining	O
.	O

The	O
merged	O
images	O
of	O
the	O
nucleus	B-GO
show	O
that	O
Tif1	B-GGP
gamma	I-GGP
does	O
not	O
colocalize	O
with	O
the	O
HP1	B-GGP
alpha	I-GGP
or	O
DAPI	O
staining	O
of	O
heterochromatin	B-GO
while	O
HP1	B-GGP
alpha	I-GGP
and	O
DAPI	O
staining	O
overlap	O
.	O

(	O
B	O
)	O
G1ER	O
mouse	B-Taxon
erythroleukemia	O
cells	B-CL
express	O
high	O
levels	O
of	O
Tif1	B-GGP
gamma	I-GGP
protein	B-CHEBI
as	O
detected	O
by	O
Western	O
blot	O
analysis	O
.	O

Expression	O
of	O
Tif1	B-GGP
gamma	I-GGP
decreases	O
during	O
Gata1	B-GGP
-	O
dependent	O
erythroid	B-CL
maturation	O
induced	O
by	O
beta	B-CHEBI
-	I-CHEBI
estradiol	I-CHEBI
treatment	O
to	O
induce	O
a	O
Gata1	B-GGP
-	O
ER	B-GGP
fusion	B-SO
protein	B-CHEBI
.	O

Table	O
1	O

Overexpression	O
of	O
tif1	B-GGP
gamma	I-GGP
mRNA	B-CHEBI
Rescues	O
mon	B-GGP
Mutants	B-SO
:	O
Hematopoietic	O
Phenotypes	O

Synthetic	B-SO
tif1	B-GGP
gamma	I-GGP
mRNA	B-CHEBI
(	O
100	O
pg	O
)	O
was	O
injected	O
at	O
the	O
one	O
-	O
cell	B-CL
stage	O
into	O
embryos	O
of	O
the	O
indicated	O
genotypes	B-SO
.	O

For	O
the	O
mon	B-GGP
embryos	O
,	O
circulating	B-CL
cells	I-CL
where	O
counted	O
each	O
day	O
through	O
4	O
d	O
,	O
when	O
the	O
embryos	O
were	O
fixed	O
and	O
stained	O
with	O
o	O
-	O
dianisidine	O
to	O
detect	O
hemoglobin	B-CHEBI
in	O
mature	O
RBCs	B-CL
.	O

Normal	O
embryos	O
contain	O
approximately	O
3	O
,	O
000	O
circulating	B-CL
cells	I-CL
at	O
these	O
time	O
points	O
.	O

Results	O
are	O
given	O
as	O
number	O
of	O
embryos	O
with	O
the	O
indicated	O
phenotype	O
.	O

Numbers	O
in	O
parentheses	O
represent	O
percentage	O
of	O
total	O
embryos	O
analyzed	O

Table	O
2	O

Marrow	O
Transplantation	O
Rescues	O
Hematopoiesis	O
But	O
Not	O
Survival	O
in	O
mon	B-GGP
Mutants	B-SO
:	O
Embryos	O
with	O
Transplanted	O
Erythroid	B-CL
Cells	I-CL

Between	O
100	O
and	O
1	O
,	O
000	O
kidney	O
marrow	O
cells	B-CL
from	O
adult	O
gata1	B-GGP
:	O
EGFP	O
transgenic	B-SO
donors	O
were	O
injected	O
per	O
zebrafish	B-Taxon
embryo	O
at	O
48	O
hpf	O
.	O

Individual	O
transplanted	O
embryos	O
were	O
anesthetized	O
and	O
visualized	O
for	O
GFP	O
+	O
erythroid	B-CL
cells	I-CL
.	O

By	O
10	O
d	O
posttransplantation	O
the	O
indicated	O
number	O
of	O
embryos	O
had	O
an	O
estimated	O
100	O
to	O
3	O
,	O
000	O
GFP	O
+	O
cells	B-CL
in	O
circulation	O
.	O

At	O
3	O
mo	O
the	O
indicated	O
number	O
of	O
fish	B-Taxon
were	O
alive	O
.	O

The	O
relative	O
percentage	O
of	O
embryos	O
is	O
shown	O
in	O
parentheses	O

Footnotes	O

Conflicts	O
of	O
interest	O
.	O

The	O
authors	O
have	O
declared	O
that	O
no	O
conflicts	O
of	O
interest	O
exist	O
.	O

Author	O
contributions	O
.	O

DGR	O
,	O
NB	O
,	O
KN	O
,	O
DT	O
,	O
CB	O
,	O
NST	O
,	O
YZ	O
,	O
JP	O
,	O
SHO	O
,	O
and	O
LIZ	O
conceived	O
and	O
designed	O
the	O
experiments	O
.	O

DGR	O
,	O
NB	O
,	O
KN	O
,	O
DT	O
,	O
CB	O
,	O
NST	O
,	O
NPL	O
,	O
WJS	O
,	O
CAL	O
,	O
CH	O
,	O
BAB	O
,	O
and	O
PDK	O
performed	O
the	O
experiments	O
.	O

DGR	O
,	O
NB	O
,	O
KN	O
,	O
DT	O
,	O
CB	O
,	O
NST	O
,	O
NPL	O
,	O
YZ	O
,	O
JP	O
,	O
SHO	O
,	O
and	O
LIZ	O
analyzed	O
the	O
data	O
.	O

DGR	O
,	O
NB	O
,	O
KN	O
,	O
DT	O
,	O
NST	O
,	O
YZ	O
,	O
BAB	O
,	O
SL	O
,	O
and	O
JP	O
contributed	O
reagents	B-CHEBI
/	O
materials	O
/	O
analysis	O
tools	O
.	O

DGR	O
,	O
NB	O
,	O
KN	O
,	O
DT	O
,	O
and	O
LIZ	O
wrote	O
the	O
paper	O
.	O

Academic	O
Editor	O
:	O
William	O
Talbot	O
,	O
Stanford	O
University	O

currency	O
Current	O
address	O
:	O
Department	O
of	O
Cell	B-CL
and	O
Developmental	O
Biology	O
,	O
Oregon	O
Health	O
and	O
Science	O
University	O
,	O
Portland	O
,	O
Oregon	O
,	O
United	O
States	O
of	O
America	O

Citation	O
:	O
Ransom	O
DG	O
,	O
Bahary	O
N	O
,	O
Niss	O
K	O
,	O
Traver	O
D	O
,	O
Burns	O
C	O
,	O
et	O
al	O
.	O

(	O
2004	O
)	O
The	O
zebrafish	B-GGP
moonshine	I-GGP
gene	B-SO
encodes	O
transcriptional	B-GGP
intermediary	I-GGP
factor	I-GGP
1	I-GGP
gamma	I-GGP
,	O
an	O
essential	O
regulator	O
of	O
hematopoiesis	O
.	O

PLoS	O
Biol	O
2	O
(	O
8	O
)	O
:	O
e237	O
.	O

Spontaneous	O
Autoimmunity	O
in	O
129	O
and	O
C57BL	O
/	O
6	O
Mice	B-Taxon
--	O
Implications	O
for	O
Autoimmunity	O
Described	O
in	O
Gene	B-SO
-	O
Targeted	O
Mice	B-Taxon

Abstract	O

Systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
is	O
a	O
multisystem	O
autoimmune	O
disorder	O
in	O
which	O
complex	O
genetic	B-SO
factors	O
play	O
an	O
important	O
role	O
.	O

Several	O
strains	O
of	O
gene	B-SO
-	O
targeted	O
mice	B-Taxon
have	O
been	O
reported	O
to	O
develop	O
SLE	O
,	O
implicating	O
the	O
null	O
genes	B-SO
in	O
the	O
causation	O
of	O
disease	O
.	O

However	O
,	O
hybrid	O
strains	O
between	O
129	O
and	O
C57BL	O
/	O
6	O
mice	B-Taxon
,	O
widely	O
used	O
in	O
the	O
generation	O
of	O
gene	B-SO
-	O
targeted	O
mice	B-Taxon
,	O
develop	O
spontaneous	O
autoimmunity	O
.	O

Furthermore	O
,	O
the	O
genetic	B-SO
background	O
markedly	O
influences	O
the	O
autoimmune	O
phenotype	O
of	O
SLE	O
in	O
gene	B-SO
-	O
targeted	O
mice	B-Taxon
.	O

This	O
suggests	O
an	O
important	O
role	O
in	O
the	O
expression	O
of	O
autoimmunity	O
of	O
as	O
-	O
yet	O
-	O
uncharacterised	O
background	O
genes	B-SO
originating	O
from	O
these	O
parental	O
mouse	B-Taxon
strains	O
.	O

Using	O
genome	B-SO
-	O
wide	O
linkage	O
analysis	O
,	O
we	O
identified	O
several	O
susceptibility	O
loci	B-SO
,	O
derived	O
from	O
129	O
and	O
C57BL	O
/	O
6	O
mice	B-Taxon
,	O
mapped	O
in	O
the	O
lupus	O
-	O
prone	O
hybrid	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
model	O
.	O

By	O
creating	O
a	O
C57BL	O
/	O
6	O
congenic	O
strain	O
carrying	O
a	O
129	O
-	O
derived	O
Chromosome	B-SO
1	I-SO
segment	I-SO
,	O
we	O
found	O
that	O
this	O
129	O
interval	B-SO
was	O
sufficient	O
to	O
mediate	O
the	O
loss	O
of	O
tolerance	O
to	O
nuclear	B-GO
antigens	O
,	O
which	O
had	O
previously	O
been	O
attributed	O
to	O
a	O
disrupted	O
gene	B-SO
.	O

These	O
results	O
demonstrate	O
important	O
epistatic	O
modifiers	O
of	O
autoimmunity	O
in	O
129	O
and	O
C57BL	O
/	O
6	O
mouse	B-Taxon
strains	O
,	O
widely	O
used	O
in	O
gene	B-SO
targeting	O
.	O

These	O
background	O
gene	B-SO
influences	O
may	O
account	O
for	O
some	O
,	O
or	O
even	O
all	O
,	O
of	O
the	O
autoimmune	O
traits	O
described	O
in	O
some	O
gene	B-SO
-	O
targeted	O
models	O
of	O
SLE	O
.	O

Introduction	O

Systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
is	O
a	O
chronic	O
autoimmune	O
disease	O
characterised	O
by	O
the	O
production	O
of	O
autoantibodies	O
(	O
auto	O
-	O
Abs	B-GO
)	O
against	O
a	O
wide	O
spectrum	O
of	O
self	O
-	O
antigens	O
,	O
mainly	O
from	O
subcellular	O
compartments	O
,	O
especially	O
the	O
cell	B-CL
nucleus	B-GO
.	O

Genetic	B-SO
predisposition	O
is	O
an	O
important	O
contributor	O
to	O
susceptibility	O
to	O
SLE	O
in	O
both	O
humans	B-Taxon
and	O
animals	B-Taxon
(	O
Vyse	O
and	O
Todd	O
1996	O
;	O
Harley	O
et	O
al	O
.	O
1998	O
;	O
Theofilopoulos	O
and	O
Kono	O
1999	O
;	O
Wakeland	O
et	O
al	O
.	O
2001	O
)	O
.	O

Genes	B-SO
in	O
multiple	O
pathways	O
participate	O
in	O
mediating	O
disease	O
pathogenesis	O
,	O
and	O
epistatic	O
interactions	O
amongst	O
these	O
genes	B-SO
influence	O
the	O
expression	O
of	O
disease	O
.	O

In	O
this	O
context	O
,	O
both	O
genetic	B-SO
linkage	O
studies	O
in	O
spontaneous	O
lupus	O
-	O
prone	O
models	O
and	O
synthetic	O
murine	B-Taxon
models	O
of	O
autoimmunity	O
generated	O
by	O
targeted	O
disruption	O
of	O
specific	O
genes	B-SO
modulating	O
the	O
immune	O
system	O
have	O
widely	O
been	O
used	O
to	O
investigate	O
the	O
complexity	O
of	O
SLE	O
.	O

The	O
best	O
-	O
studied	O
strains	O
of	O
mice	B-Taxon
that	O
spontaneously	O
develop	O
a	O
lupus	O
-	O
like	O
pathology	O
are	O
the	O
New	O
Zealand	O
Black	O
/	O
New	O
Zealand	O
White	O
hybrid	O
strain	O
(	O
NZB	O
/	O
WF1	O
)	O
;	O
the	O
MRL	O
/	O
Mp	O
lpr	O
/	O
lpr	O
strain	O
,	O
which	O
carries	O
the	O
lpr	O
mutation	B-SO
of	O
the	O
FAS	B-GGP
receptor	I-GGP
gene	B-SO
;	O
and	O
the	O
BXSB	O
strain	O
,	O
which	O
carries	O
the	O
Y	B-GGP
chromosome	I-GGP
autoimmune	I-GGP
accelerator	I-GGP
(	O
Yaa	B-GGP
)	O
gene	B-SO
(	O
Theofilopoulos	O
and	O
Dixon	O
1985	O
)	O
.	O

Extensive	O
genetic	B-SO
mapping	O
studies	O
in	O
all	O
three	O
strains	O
have	O
identified	O
multiple	O
intervals	B-SO
associated	O
with	O
disease	O
susceptibility	O
.	O

Interestingly	O
,	O
the	O
majority	O
of	O
the	O
intervals	B-SO
detected	O
are	O
strain	O
-	O
specific	O
,	O
confirming	O
the	O
genetic	B-SO
complexity	O
of	O
the	O
disease	O
and	O
indicating	O
the	O
presence	O
of	O
extensive	O
heterogeneity	O
in	O
the	O
genes	B-SO
contributing	O
to	O
the	O
pathogenesis	O
of	O
the	O
disease	O
.	O

However	O
,	O
some	O
susceptibility	O
loci	B-SO
have	O
been	O
mapped	O
to	O
similar	O
chromosome	B-SO
locations	I-SO
in	O
different	O
strains	O
,	O
suggesting	O
that	O
at	O
least	O
some	O
susceptibility	O
may	O
be	O
shared	O
amongst	O
lupus	O
-	O
prone	O
strains	O
.	O

Amongst	O
these	O
shared	O
susceptibility	O
loci	B-SO
,	O
the	O
most	O
striking	O
are	O
loci	B-SO
on	I-SO
distal	I-SO
Chromosome	I-SO
1	O
,	O
for	O
which	O
important	O
contributing	O
genes	B-SO
have	O
been	O
found	O
in	O
New	O
Zealand	O
and	O
BXSB	O
models	O
(	O
Theofilopoulos	O
and	O
Kono	O
1999	O
;	O
Wakeland	O
et	O
al	O
.	O
2001	O
)	O
.	O

Although	O
considerable	O
efforts	O
have	O
been	O
made	O
to	O
identify	O
the	O
genes	B-SO
responsible	O
for	O
the	O
development	O
of	O
the	O
disease	O
,	O
with	O
the	O
exception	O
of	O
the	O
lpr	O
mutation	B-SO
,	O
none	O
of	O
the	O
genetic	B-SO
contributions	O
to	O
disease	O
in	O
the	O
three	O
well	O
-	O
documented	O
murine	B-Taxon
SLE	O
strains	O
have	O
yet	O
been	O
fully	O
resolved	O
at	O
the	O
molecular	B-CHEBI
or	O
protein	B-CHEBI
level	O
.	O

Thus	O
,	O
targeted	O
genetic	B-SO
disruption	O
of	O
candidate	O
genes	B-SO
encoding	O
proteins	B-CHEBI
of	O
the	O
immune	O
system	O
has	O
been	O
extensively	O
used	O
to	O
examine	O
their	O
role	O
in	O
immune	O
regulation	O
.	O

However	O
,	O
the	O
most	O
surprising	O
result	O
of	O
this	O
powerful	O
approach	O
has	O
been	O
the	O
high	O
frequency	O
with	O
which	O
such	O
mutations	B-SO
have	O
been	O
associated	O
with	O
an	O
autoimmune	O
phenotype	O
.	O

In	O
this	O
regard	O
,	O
it	O
is	O
of	O
note	O
that	O
hybrid	O
strains	O
between	O
129	O
and	O
C57BL	O
/	O
6	O
mice	B-Taxon
,	O
widely	O
used	O
in	O
the	O
generation	O
of	O
gene	B-SO
-	O
targeted	O
mice	B-Taxon
,	O
are	O
spontaneously	O
predisposed	O
to	O
development	O
of	O
humoral	O
autoimmunity	O
with	O
low	O
levels	O
of	O
glomerulonephritis	O
(	O
Obata	O
et	O
al	O
.	O
1979	O
;	O
Botto	O
et	O
al	O
.	O
1998	O
;	O
Bickerstaff	O
et	O
al	O
.	O
1999	O
;	O
Santiago	O
-	O
Raber	O
et	O
al	O
.	O
2001	O
)	O
.	O

Furthermore	O
,	O
the	O
genetic	B-SO
background	O
markedly	O
influences	O
the	O
autoimmune	O
phenotype	O
in	O
gene	B-SO
-	O
targeted	O
mice	B-Taxon
(	O
Bolland	O
and	O
Ravetch	O
2000	O
;	O
Santiago	O
-	O
Raber	O
et	O
al	O
.	O
2001	O
;	O
Mitchell	O
et	O
al	O
.	O
2002	O
)	O
.	O

These	O
observations	O
led	O
to	O
the	O
hypothesis	O
that	O
the	O
autoimmune	O
phenotype	O
described	O
in	O
some	O
gene	B-SO
-	O
targeted	O
mice	B-Taxon
might	O
be	O
due	O
primarily	O
to	O
combinations	O
of	O
as	O
-	O
yet	O
-	O
uncharacterised	O
background	O
genes	B-SO
,	O
originating	O
from	O
129	O
and	O
C57BL	O
/	O
6	O
mice	B-Taxon
strains	O
,	O
interacting	O
or	O
not	O
with	O
the	O
mutated	B-SO
allele	B-SO
.	O

To	O
test	O
this	O
,	O
we	O
conducted	O
a	O
genome	B-SO
-	O
wide	O
scan	O
analysis	O
of	O
two	O
large	O
cohorts	O
of	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
mice	B-Taxon
,	O
one	O
of	O
which	O
carried	O
a	O
mutation	B-SO
in	O
the	O
serum	B-GGP
amyloid	I-GGP
P	I-GGP
component	I-GGP
gene	B-SO
(	O
Apcs	B-GGP
)	O
.	O

The	O
Apcs	B-GGP
-	O
deficient	O
mice	B-Taxon
(	O
Apcs	B-GGP
-	O
/	O
-	O
)	O
were	O
chosen	O
as	O
an	O
example	O
of	O
a	O
gene	B-SO
-	O
targeted	O
strain	O
previously	O
reported	O
to	O
develop	O
a	O
lupus	O
-	O
like	O
disease	O
on	O
the	O
hybrid	O
genetic	B-SO
background	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
;	O
autoimmunity	O
in	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
persists	O
even	O
after	O
backcrossing	O
the	O
mutated	B-SO
gene	B-SO
onto	O
C57BL	O
/	O
6	O
(	O
Bickerstaff	O
et	O
al	O
.	O
1999	O
)	O
.	O

We	O
chose	O
this	O
targeted	O
gene	B-SO
in	O
particular	O
to	O
study	O
since	O
the	O
Apcs	B-GGP
gene	B-SO
is	O
located	O
on	O
Chromosome	B-GO
1	O
,	O
approximately	O
94	O
cM	O
from	O
the	O
centromere	B-SO
,	O
within	O
a	O
region	B-SO
where	O
several	O
lupus	O
-	O
susceptibility	O
loci	B-SO
,	O
designated	O
Sle1	B-GGP
(	O
Morel	O
et	O
al	O
.	O
2001	O
)	O
,	O
Nba2	B-GGP
(	O
Drake	O
et	O
al	O
.	O
1995	O
;	O
Vyse	O
et	O
al	O
.	O
1997	O
)	O
,	O
and	O
Bxs3	B-GGP
(	O
Hogarth	O
et	O
al	O
.	O
1998	O
;	O
Haywood	O
et	O
al	O
.	O
2000	O
)	O
,	O
have	O
been	O
mapped	O
in	O
NZW	O
,	O
NZB	O
,	O
and	O
BXSB	O
lupus	O
-	O
prone	O
strains	O
,	O
respectively	O
.	O

This	O
region	B-SO
contains	O
several	O
genes	B-SO
,	O
including	O
those	O
encoding	O
Fc	B-GGP
gamma	I-GGP
RII	I-GGP
,	O
the	O
complement	O
receptor	O
CR1	B-GGP
/	O
2	O
(	O
CD35	B-GGP
/	O
CD21	B-GGP
)	O
,	O
and	O
the	O
decay	O
-	O
accelerating	O
factor	O
CD55	B-GGP
(	O
Prodeus	O
et	O
al	O
.	O
1998	O
;	O
Bolland	O
and	O
Ravetch	O
2000	O
;	O
Miwa	O
et	O
al	O
.	O
2002	O
;	O
Wu	O
et	O
al	O
.	O
2002	O
)	O
,	O
which	O
have	O
each	O
been	O
implicated	O
in	O
the	O
causation	O
of	O
SLE	O
when	O
inactivated	O
by	O
gene	B-SO
-	O
targeting	O
in	O
129	O
embryonic	O
stem	B-CL
cells	I-CL
.	O

Here	O
we	O
show	O
that	O
there	O
are	O
multiple	O
genetic	B-SO
loci	B-SO
,	O
derived	O
from	O
both	O
129	O
and	O
C57BL	O
/	O
6	O
mice	B-Taxon
,	O
contributing	O
to	O
autoimmunity	O
.	O

Furthermore	O
,	O
a	O
129	O
-	O
derived	O
interval	B-SO
on	I-SO
distal	I-SO
Chromosome	I-SO
1	O
,	O
when	O
transferred	B-SO
onto	O
the	O
C57BL	O
/	O
6	O
genome	B-SO
,	O
a	O
combination	O
commonly	O
created	O
by	O
backcrossing	O
onto	O
C57BL	O
/	O
6	O
a	O
gene	B-SO
that	O
has	O
been	O
inactivated	O
in	O
129	O
embryonic	O
stem	B-CL
cells	I-CL
,	O
was	O
sufficient	O
to	O
cause	O
humoral	O
autoimmunity	O
in	O
its	O
own	O
right	O
,	O
irrespective	O
of	O
the	O
presence	O
of	O
the	O
mutated	B-SO
Apcs	B-GGP
gene	B-SO
.	O

These	O
results	O
demonstrate	O
important	O
epistatic	O
interactions	O
between	O
genes	B-SO
from	O
129	O
and	O
C57BL	O
/	O
6	O
genomes	B-SO
on	O
the	O
development	O
of	O
autoimmunity	O
and	O
illustrate	O
the	O
important	O
effects	O
of	O
background	O
genes	B-SO
in	O
the	O
analysis	O
and	O
interpretation	O
of	O
autoimmune	O
phenotypes	O
associated	O
with	O
targeted	O
genetic	B-SO
disruptions	O
.	O

Results	O

Disease	O
Traits	O
in	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
and	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
Mice	B-Taxon

To	O
investigate	O
the	O
genetic	B-SO
basis	O
of	O
the	O
lupus	O
-	O
like	O
disease	O
observed	O
in	O
the	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
hybrid	O
mice	B-Taxon
,	O
we	O
generated	O
two	O
large	O
cohorts	O
of	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
animals	B-Taxon
,	O
one	O
carrying	O
a	O
mutation	B-SO
in	O
the	O
Apcs	B-GGP
gene	B-SO
,	O
and	O
monitored	O
them	O
for	O
1	O
y	O
under	O
identical	O
environmental	O
conditions	O
.	O

Since	O
female	O
mice	B-Taxon
in	O
the	O
original	O
reports	O
showed	O
a	O
higher	O
penetrance	O
of	O
disease	O
,	O
the	O
present	O
study	O
was	O
conducted	O
only	O
on	O
female	O
mice	B-Taxon
.	O

The	O
results	O
of	O
the	O
phenotypic	O
analysis	O
at	O
1	O
y	O
of	O
age	O
are	O
summarised	O
in	O
Tables	O
1	O
and	O
2	O
.	O

As	O
previously	O
reported	O
(	O
Botto	O
et	O
al	O
.	O
1998	O
)	O
,	O
the	O
wild	B-SO
-	I-SO
type	I-SO
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
mice	B-Taxon
developed	O
lupus	O
traits	O
with	O
elevated	O
levels	O
of	O
auto	O
-	O
Abs	B-GO
,	O
starting	O
from	O
6	O
mo	O
of	O
age	O
(	O
data	O
not	O
shown	O
)	O
,	O
and	O
histological	O
evidence	O
of	O
proliferative	O
glomerulonephritis	O
.	O

In	O
agreement	O
with	O
our	O
previous	O
observations	O
(	O
Bickerstaff	O
et	O
al	O
.	O
1999	O
)	O
,	O
the	O
titres	O
of	O
anti	O
-	O
nuclear	B-GO
Abs	B-GO
(	O
ANAs	O
)	O
and	O
anti	O
-	O
chromatin	B-GO
Ab	B-GO
were	O
considerably	O
greater	O
in	O
the	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
compared	O
with	O
the	O
strain	O
-	O
matched	O
controls	O
.	O

However	O
,	O
in	O
contrast	O
to	O
our	O
original	O
findings	O
,	O
the	O
levels	O
of	O
the	O
other	O
two	O
disease	O
serological	O
markers	O
analysed	O
(	O
anti	O
-	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
[	O
ssDNA	O
]	O
and	O
anti	O
-	O
double	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
[	O
dsDNA	O
]	O
Abs	B-GO
)	O
and	O
the	O
severity	O
of	O
the	O
renal	O
pathology	O
were	O
not	O
different	O
between	O
the	O
two	O
experimental	O
groups	O
.	O

In	O
view	O
of	O
the	O
possibility	O
of	O
an	O
association	O
between	O
the	O
fixed	O
129	O
-	O
derived	O
segment	B-SO
flanking	O
the	O
mutated	B-SO
Apcs	B-GGP
gene	B-SO
and	O
the	O
autoimmune	O
traits	O
observed	O
,	O
the	O
genome	B-SO
-	O
wide	O
linkage	O
analysis	O
of	O
the	O
two	O
experimental	O
cohorts	O
was	O
carried	O
out	O
separately	O
.	O

Mapping	O
of	O
Loci	B-SO
Predisposing	O
to	O
Lupus	O
in	O
the	O
Hybrid	O
Strain	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O

Mice	B-Taxon
were	O
genotyped	O
with	O
143	O
microsatellite	B-SO
markers	I-SO
distributed	O
throughout	O
the	O
autosomes	B-GO
such	O
that	O
98	O
%	O
of	O
the	O
genes	B-SO
were	O
within	O
20	O
cM	O
of	O
an	O
informative	O
marker	O
.	O

A	O
summary	O
of	O
the	O
genome	B-SO
-	O
wide	O
linkage	O
analysis	O
for	O
each	O
of	O
the	O
disease	O
traits	O
measured	O
is	O
shown	O
in	O
Table	O
3	O
.	O

The	O
areas	B-SO
of	I-SO
linkage	I-SO
were	O
defined	O
according	O
to	O
the	O
parental	O
origin	O
,	O
129	O
or	O
C57BL	O
/	O
6	O
.	O

Only	O
linkages	O
identified	O
in	O
both	O
experimental	O
groups	O
are	O
reported	O
in	O
Table	O
3	O
,	O
with	O
the	O
exception	O
of	O
the	O
Chromosome	B-SO
1	I-SO
distal	I-SO
segment	I-SO
,	O
where	O
the	O
linkage	O
analysis	O
could	O
not	O
be	O
applied	O
to	O
the	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
as	O
this	O
region	B-SO
was	O
of	O
fixed	O
129	O
origin	O
.	O

Chromosomes	B-GO
where	O
linkages	O
were	O
present	O
only	O
in	O
one	O
of	O
the	O
two	O
cohorts	O
are	O
shown	O
in	O
Figures	O
1	O
-	O
3	O
.	O

The	O
quantitative	B-SO
trait	I-SO
linkage	I-SO
(	O
QTL	B-SO
)	O
analysis	O
identified	O
several	O
intervals	B-SO
on	I-SO
Chromosome	I-SO
1	O
with	O
linkage	O
to	O
disease	O
serological	O
markers	O
,	O
and	O
these	O
regions	B-SO
were	O
all	O
derived	O
from	O
the	O
129	O
mouse	B-Taxon
strain	O
(	O
see	O
Table	O
3	O
;	O
Figures	O
4	O
and	O
5	O
)	O
.	O

Interestingly	O
,	O
whilst	O
ANA	O
and	O
anti	O
-	O
chromatin	B-GO
Ab	B-GO
levels	O
showed	O
suggestive	O
or	O
significant	O
linkages	O
only	O
to	O
the	O
telomeric	B-GO
region	I-GO
of	I-GO
Chromosome	I-GO
1	O
,	O
with	O
an	O
estimated	O
peak	O
occurring	O
at	O
a	O
position	B-SO
approximately	O
90	O
cM	O
near	O
the	O
Apcs	B-GGP
gene	B-SO
,	O
anti	O
-	O
dsDNA	O
or	O
anti	O
-	O
ssDNA	O
Ab	B-GO
production	O
was	O
also	O
linked	O
to	O
other	O
segments	B-SO
on	I-SO
Chromosome	I-SO
1	O
,	O
indicating	O
a	O
more	O
complex	O
genetic	B-SO
contribution	O
from	O
the	O
129	O
mouse	B-Taxon
strain	O
.	O

Guided	O
by	O
these	O
observations	O
,	O
we	O
investigated	O
whether	O
the	O
increased	O
levels	O
of	O
ANA	O
and	O
anti	O
-	O
chromatin	B-GO
Ab	B-GO
observed	O
in	O
the	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
were	O
caused	O
by	O
a	O
gene	B-SO
(	I-SO
s	I-SO
)	I-SO
within	O
the	O
fixed	O
129	O
region	B-SO
surrounding	O
the	O
mutated	B-SO
Apcs	B-GGP
gene	B-SO
,	O
rather	O
than	O
caused	O
by	O
the	O
mutated	B-SO
Apcs	B-GGP
gene	B-SO
itself	O
.	O

We	O
compared	O
the	O
levels	O
of	O
these	O
auto	O
-	O
Abs	B-GO
between	O
all	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
and	O
a	O
group	O
of	O
33	O
wild	B-SO
-	I-SO
type	I-SO
mice	B-Taxon
that	O
were	O
selected	O
for	O
being	O
homozygous	O
129	O
in	O
the	O
region	B-SO
of	I-SO
Chromosome	I-SO
1	O
between	O
microsatellites	B-SO
D1Mit105	O
and	O
D1Mit	O
223	O
(	O
80	O
-	O
106	O
cM	O
)	O
(	O
Figure	O
6A	O
-	O
6D	O
)	O
.	O

In	O
contrast	O
to	O
the	O
results	O
reported	O
in	O
Table	O
1	O
,	O
this	O
comparison	O
showed	O
no	O
significant	O
differences	O
between	O
the	O
two	O
experimental	O
groups	O
.	O

This	O
result	O
demonstrates	O
that	O
,	O
most	O
likely	O
,	O
the	O
129	O
-	O
derived	O
region	B-SO
and	O
not	O
the	O
lack	O
of	O
Apcs	B-GGP
was	O
mediating	O
the	O
production	O
of	O
ANA	O
and	O
anti	O
-	O
chromatin	B-GO
Ab	B-GO
.	O

Consistent	O
with	O
this	O
explanation	O
,	O
we	O
found	O
that	O
the	O
129	O
mice	B-Taxon
have	O
significantly	O
higher	O
levels	O
of	O
Apcs	B-GGP
in	O
circulation	O
compared	O
with	O
the	O
C57BL	O
/	O
6	O
mice	B-Taxon
(	O
median	O
,	O
83	O
mg	O
/	O
l	O
;	O
range	O
,	O
25	O
-	O
208	O
;	O
n	O
=	O
16	O
versus	O
median	O
,	O
5	O
mg	O
/	O
l	O
;	O
range	O
,	O
4	O
-	O
9	O
;	O
n	O
=	O
10	O
,	O
respectively	O
;	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

The	O
C57BL	O
/	O
6	O
strain	O
has	O
previously	O
been	O
reported	O
to	O
be	O
one	O
of	O
the	O
murine	B-Taxon
strains	O
defined	O
as	O
low	O
Apcs	B-GGP
producers	O
(	O
Pepys	O
et	O
al	O
.	O
1979	O
;	O
Baltz	O
et	O
al	O
.	O
1980	O
)	O
.	O

In	O
addition	O
,	O
sequence	B-SO
analysis	O
of	O
the	O
entire	O
Apcs	B-GGP
coding	B-SO
region	I-SO
in	O
both	O
strains	O
failed	O
to	O
identify	O
any	O
coding	B-SO
sequence	I-SO
polymorphisms	B-SO
in	O
the	O
Apcs	B-GGP
gene	B-SO
(	O
data	O
not	O
shown	O
)	O
,	O
indicating	O
that	O
a	O
structural	O
variant	B-SO
of	O
the	O
protein	B-CHEBI
is	O
unlikely	O
to	O
be	O
the	O
explanation	O
for	O
our	O
findings	O
.	O

This	O
is	O
consistent	O
with	O
a	O
previous	O
report	O
by	O
Drake	O
et	O
al	O
.	O

(	O
1996	O
)	O
that	O
showed	O
no	O
Apcs	B-GGP
coding	B-SO
sequence	I-SO
differences	O
amongst	O
several	O
autoimmune	O
and	O
nonautoimmune	O
murine	B-Taxon
strains	O
.	O

In	O
addition	O
to	O
the	O
129	O
-	O
derived	O
segments	B-SO
,	O
in	O
both	O
cohorts	O
the	O
C57BL	O
/	O
6	O
strain	O
contributed	O
to	O
the	O
autoimmune	O
traits	O
with	O
one	O
major	O
susceptibility	O
locus	B-SO
on	I-SO
Chromosome	I-SO
3	O
.	O

A	O
genomic	B-SO
region	I-SO
between	O
D3Mit40	O
and	O
D3Mit13	O
,	O
with	O
an	O
estimated	O
peak	O
at	O
position	B-SO
approximately	O
51	O
cM	O
,	O
showed	O
a	O
significant	O
linkage	O
to	O
ANA	O
production	O
and	O
weaker	O
linkages	O
to	O
anti	O
-	O
ssDNA	O
and	O
anti	O
-	O
chromatin	B-GO
production	O
(	O
see	O
Table	O
3	O
;	O
Figure	O
7	O
)	O
.	O

The	O
high	O
frequency	O
of	O
autoimmune	O
phenotype	O
in	O
the	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
hybrid	O
genetic	B-SO
background	O
and	O
its	O
absence	O
in	O
either	O
of	O
the	O
inbred	O
parental	O
strains	O
imply	O
that	O
there	O
are	O
essential	O
interactions	O
between	O
129	O
-	O
and	O
C57BL	O
/	O
6	O
-	O
derived	O
alleles	B-SO
for	O
the	O
expression	O
of	O
autoimmunity	O
.	O

We	O
investigated	O
further	O
the	O
effects	O
of	O
genes	B-SO
from	O
the	O
C57BL	O
/	O
6	O
background	O
by	O
repeating	O
the	O
linkage	O
analysis	O
in	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
mice	B-Taxon
,	O
whilst	O
controlling	O
for	O
the	O
very	O
strong	O
129	O
effect	O
on	O
distal	O
Chromosome	B-GO
1	O
,	O
as	O
previously	O
described	O
(	O
Zeng	O
1994	O
)	O
.	O

The	O
results	O
of	O
this	O
analysis	O
showed	O
that	O
the	O
statistical	O
support	O
for	O
the	O
linkage	O
of	O
the	O
C57BL	O
/	O
6	O
locus	B-SO
on	I-SO
Chromosome	I-SO
3	O
for	O
ANA	O
increased	O
from	O
logarithm	O
of	O
odds	O
(	O
LOD	O
)	O
5	O
.	O
4	O
to	O
LOD	O
6	O
.	O
4	O
.	O

In	O
contrast	O
to	O
these	O
strong	O
associations	O
with	O
disease	O
serological	O
markers	O
,	O
the	O
QTL	B-SO
analysis	O
identified	O
only	O
two	O
potential	O
linkages	O
to	O
glomerulonephritis	O
:	O
one	O
in	O
the	O
wild	B-SO
-	I-SO
type	I-SO
mice	B-Taxon
on	O
Chromosome	B-GO
7	O
across	O
a	O
10	O
cM	O
region	B-SO
between	O
D7Mit246	O
(	O
15	O
cM	O
)	O
and	O
D7Mit145	O
(	O
26	O
.	O
5	O
cM	O
)	O
of	O
129	O
origin	O
(	O
LOD	O
2	O
.	O
86	O
,	O
p	O
=	O
0	O
.	O
0013	O
)	O
,	O
and	O
one	O
on	O
Chromosome	B-GO
17	O
between	O
D17Mit100	O
(	O
11	O
.	O
7	O
cM	O
)	O
and	O
D17Mit216	O
(	O
29	O
.	O
4	O
cM	O
)	O
from	O
the	O
C57BL	O
/	O
6	O
strain	O
(	O
LOD	O
1	O
.	O
3	O
,	O
p	O
=	O
0	O
.	O
049	O
and	O
LOD	O
1	O
.	O
67	O
,	O
p	O
=	O
0	O
.	O
021	O
in	O
the	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
,	O
respectively	O
)	O
.	O

Histological	O
evidence	O
of	O
glomerulonephritis	O
was	O
only	O
found	O
in	O
approximately	O
20	O
%	O
of	O
the	O
mice	B-Taxon
in	O
each	O
cohort	O
,	O
which	O
reduces	O
the	O
power	O
of	O
the	O
QTL	B-SO
analysis	O
for	O
this	O
disease	O
trait	O
.	O

Production	O
of	O
a	O
C57BL	O
/	O
6	O
.	O
129	O
Chromosome	B-GO
1	O
Congenic	O
Line	O
and	O
Its	O
Phenotypic	O
Analysis	O

We	O
generated	O
a	O
C57BL	O
/	O
6	O
congenic	O
line	O
carrying	O
the	O
telomeric	B-GO
region	I-GO
of	I-GO
Chromosome	I-GO
1	O
from	O
the	O
129	O
mouse	B-Taxon
strain	O
,	O
in	O
order	O
to	O
dissect	O
the	O
complex	O
polygenic	O
disease	O
phenotype	O
of	O
the	O
(	O
C57BL	O
/	O
6	O
x	O
129	O
/	O
Sv	O
)	O
F2	O
hybrid	O
strain	O
into	O
its	O
individual	O
genetic	B-SO
components	O
.	O

The	O
129	O
interval	O
was	O
backcrossed	O
seven	O
times	O
onto	O
C57BL	O
/	O
6	O
,	O
and	O
at	O
each	O
generation	O
the	O
presence	O
or	O
absence	O
of	O
the	O
Chromosome	B-SO
1	I-SO
interval	I-SO
was	O
determined	O
with	O
several	O
microsatellite	B-SO
markers	I-SO
.	O

Each	O
backcrossed	O
generation	O
was	O
screened	O
with	O
more	O
than	O
three	O
markers	O
per	O
chromosome	B-GO
to	O
facilitate	O
the	O
removal	B-SO
of	O
unselected	O
129	O
genomic	B-SO
regions	I-SO
.	O

At	O
the	O
end	O
of	O
the	O
backcrossing	O
,	O
the	O
129	O
-	O
derived	O
Chromosome	B-SO
1	I-SO
interval	I-SO
in	O
the	O
congenic	O
mice	B-Taxon
extended	O
from	O
microsatellite	B-SO
marker	I-SO
D1Mit105	O
to	O
D1Mit223	O
(	O
80	O
-	O
106	O
cM	O
)	O
,	O
which	O
encompasses	O
the	O
most	O
important	O
129	O
interval	B-SO
identified	O
by	O
the	O
linkage	O
studies	O
in	O
the	O
(	O
C57BL	O
/	O
6	O
x	O
129	O
/	O
Sv	O
)	O
F2	O
mice	B-Taxon
.	O

Female	O
Chromosome	B-GO
1	O
congenic	O
mice	B-Taxon
(	O
C57BL	O
/	O
6	O
.	O
129	O
[	O
D1Mit105	O
-	O
223	O
]	O
)	O
,	O
together	O
with	O
sex	O
-	O
matched	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
backcrossed	O
onto	O
C57BL	O
/	O
6	O
for	O
ten	O
generations	O
(	O
C57BL	O
/	O
6	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
)	O
and	O
C57BL	O
/	O
6	O
controls	O
,	O
were	O
monitored	O
for	O
the	O
presence	O
of	O
lupus	O
.	O

In	O
the	O
C57BL	O
/	O
6	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
,	O
the	O
129	O
genome	B-SO
around	O
the	O
Apcs	B-GGP
locus	B-SO
was	O
mapped	O
as	O
a	O
stretch	B-SO
of	O
approximately	O
17	O
cM	O
,	O
positioned	O
from	O
87	O
.	O
9	O
cM	O
(	O
D1Mit15	O
)	O
to	O
105	O
cM	O
(	O
D1Mit17	O
)	O
.	O

Thus	O
,	O
the	O
congenic	O
line	O
carried	O
a	O
similar	O
129	O
region	B-SO
(	O
80	O
-	O
106	O
cM	O
)	O
to	O
the	O
one	O
present	O
in	O
the	O
C57BL	O
/	O
6	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
(	O
87	O
.	O
9	O
-	O
105	O
cM	O
)	O
.	O

At	O
1	O
y	O
of	O
age	O
,	O
all	O
animals	B-Taxon
were	O
sacrificed	O
,	O
the	O
auto	O
-	O
Abs	B-GO
assessed	O
,	O
and	O
the	O
renal	O
histology	O
examined	O
.	O

The	O
results	O
of	O
this	O
analysis	O
are	O
shown	O
in	O
Figure	O
8	O
.	O

As	O
previously	O
reported	O
(	O
Bickerstaff	O
et	O
al	O
.	O
1999	O
)	O
,	O
the	O
levels	O
of	O
auto	O
-	O
Abs	B-GO
were	O
markedly	O
increased	O
in	O
the	O
C57BL	O
/	O
6	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
compared	O
to	O
the	O
wild	B-SO
-	I-SO
type	I-SO
C57BL	O
/	O
6	O
controls	O
.	O

However	O
,	O
the	O
C57BL	O
/	O
6	O
.	O
129	O
(	O
D1Mit105	O
-	O
223	O
)	O
animals	B-Taxon
also	O
expressed	O
high	O
levels	O
of	O
auto	O
-	O
Abs	B-GO
,	O
and	O
these	O
titres	O
were	O
not	O
different	O
from	O
those	O
detected	O
in	O
the	O
matched	O
congenic	O
mice	B-Taxon
containing	O
a	O
null	O
mutation	B-SO
of	O
the	O
Apcs	B-GGP
gene	B-SO
.	O

These	O
results	O
clearly	O
demonstrated	O
that	O
epistatic	O
interactions	O
between	O
129	O
loci	B-SO
on	I-SO
Chromosome	I-SO
1	O
and	O
C57BL	O
/	O
6	O
genes	B-SO
were	O
sufficient	O
to	O
mediate	O
the	O
loss	O
of	O
tolerance	O
to	O
nuclear	B-GO
autoantigens	O
.	O

However	O
,	O
in	O
contrast	O
to	O
the	O
serological	O
data	O
,	O
the	O
histological	O
assessment	O
of	O
the	O
kidneys	O
showed	O
evidence	O
of	O
markedly	O
increased	O
glomerulonephritis	O
in	O
the	O
C57BL	O
/	O
6	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
compared	O
to	O
both	O
control	O
groups	O
(	O
Figure	O
9	O
)	O
,	O
suggesting	O
that	O
the	O
lack	O
of	O
Apcs	B-GGP
,	O
when	O
combined	O
with	O
other	O
C57BL	O
/	O
6	O
susceptibility	O
alleles	B-SO
,	O
can	O
induce	O
the	O
development	O
of	O
severe	O
renal	O
damage	O
.	O

Discussion	O

There	O
is	O
accumulating	O
evidence	O
that	O
background	O
genes	B-SO
may	O
influence	O
the	O
expression	O
of	O
autoimmunity	O
in	O
gene	B-SO
-	O
targeted	O
mice	B-Taxon
.	O

Here	O
we	O
report	O
what	O
is	O
to	O
our	O
knowledge	O
the	O
first	O
systematic	O
study	O
that	O
has	O
examined	O
this	O
in	O
the	O
129	O
and	O
C57BL	O
/	O
6	O
mouse	B-Taxon
strains	O
,	O
widely	O
used	O
for	O
gene	B-SO
targeting	O
.	O

Our	O
results	O
demonstrate	O
interacting	O
loci	B-SO
between	O
129	O
and	O
C57BL	O
/	O
6	O
mice	B-Taxon
that	O
can	O
cause	O
the	O
expression	O
of	O
a	O
powerful	O
autoimmune	O
phenotype	O
in	O
these	O
animals	B-Taxon
,	O
in	O
the	O
absence	O
of	O
any	O
gene	B-SO
-	O
targeted	O
mutations	B-SO
.	O

We	O
also	O
developed	O
a	O
congenic	O
mouse	B-Taxon
strain	O
bearing	O
a	O
portion	B-SO
of	I-SO
129	I-SO
Chromosome	I-SO
1	O
on	O
a	O
C57BL	O
/	O
6	O
background	O
and	O
showed	O
that	O
this	O
wild	B-SO
-	I-SO
type	I-SO
congenic	O
line	O
expressed	O
striking	O
anti	O
-	O
nuclear	B-GO
autoimmunity	O
.	O

By	O
comparing	O
this	O
Chromosome	B-GO
1	O
congenic	O
strain	O
with	O
matched	O
congenic	O
mice	B-Taxon
lacking	O
the	O
Apcs	B-GGP
gene	B-SO
,	O
we	O
demonstrated	O
that	O
serum	B-GGP
amyloid	I-GGP
P	I-GGP
component	I-GGP
deficiency	O
influences	O
the	O
severity	O
of	O
glomerulonephritis	O
,	O
but	O
is	O
not	O
the	O
prime	O
mover	O
in	O
the	O
induction	O
of	O
anti	O
-	O
nuclear	B-GO
autoimmunity	O
,	O
contrary	O
to	O
our	O
own	O
original	O
interpretation	O
of	O
our	O
data	O
(	O
Bickerstaff	O
et	O
al	O
.	O
1999	O
)	O
.	O

The	O
same	O
consideration	O
applies	O
to	O
other	O
genes	B-SO
located	O
in	O
the	O
same	O
Chromosome	B-SO
1	I-SO
region	I-SO
that	O
have	O
been	O
implicated	O
in	O
the	O
development	O
of	O
SLE	O
when	O
inactivated	O
by	O
gene	B-SO
-	O
targeting	O
in	O
129	O
embryonic	O
stem	B-CL
cells	I-CL
and	O
then	O
backcrossed	O
onto	O
a	O
pure	O
genetic	B-SO
background	O
(	O
Bolland	O
and	O
Ravetch	O
2000	O
;	O
Miwa	O
et	O
al	O
.	O
2002	O
;	O
Wu	O
et	O
al	O
.	O
2002	O
)	O
.	O

For	O
each	O
,	O
there	O
has	O
to	O
be	O
a	O
question	O
as	O
to	O
whether	O
the	O
anti	O
-	O
nuclear	B-GO
autoimmunity	O
is	O
due	O
to	O
the	O
gene	B-SO
-	O
targeted	O
mutant	B-SO
gene	B-SO
or	O
to	O
the	O
normal	O
129	O
genes	B-SO
expressed	O
in	O
the	O
same	O
region	B-SO
as	O
the	O
targeted	O
gene	B-SO
.	O

The	O
influence	O
of	O
background	O
genes	B-SO
on	O
the	O
development	O
of	O
spontaneous	O
autoimmune	O
disease	O
is	O
well	O
known	O
,	O
especially	O
with	O
respect	O
to	O
the	O
lpr	O
and	O
Yaa	B-GGP
disease	O
-	O
susceptibility	O
genes	B-SO
.	O

In	O
MRL	O
/	O
Mp	O
mice	B-Taxon
,	O
the	O
presence	O
of	O
the	O
lpr	O
gene	B-SO
accelerates	O
the	O
development	O
of	O
high	O
level	O
and	O
broad	O
-	O
spectrum	O
auto	O
-	O
Ab	B-GO
production	O
and	O
lethal	O
glomerulonephritis	O
,	O
in	O
addition	O
to	O
marked	O
lymphoproliferative	O
disease	O
.	O

In	O
contrast	O
,	O
homozygosity	O
of	O
the	O
lpr	O
gene	B-SO
in	O
other	O
strains	O
such	O
as	O
C57BL	O
/	O
6	O
,	O
AKR	O
,	O
LG	O
/	O
J	O
,	O
and	O
C3H	O
leads	O
only	O
to	O
auto	O
-	O
Ab	B-GO
production	O
(	O
Izui	O
et	O
al	O
.	O
1984	O
)	O
.	O

Similarly	O
,	O
the	O
Y	B-GO
-	I-GO
chromosome	I-GO
-	O
linked	O
Yaa	B-GGP
gene	B-SO
in	O
BXSB	O
and	O
MRL	O
/	O
Mp	O
males	O
enhances	O
the	O
rapid	O
development	O
of	O
auto	O
-	O
Abs	B-GO
and	O
glomerulonephritis	O
(	O
Izui	O
et	O
al	O
.	O
1988	O
;	O
Merino	O
et	O
al	O
.	O
1989	O
)	O
.	O

However	O
,	O
in	O
the	O
C57BL	O
/	O
6	O
background	O
,	O
the	O
Yaa	B-GGP
gene	B-SO
does	O
not	O
lead	O
to	O
an	O
autoimmune	O
phenotype	O
(	O
Izui	O
et	O
al	O
.	O
1988	O
)	O
.	O

Not	O
surprisingly	O
,	O
important	O
effects	O
of	O
the	O
genetic	B-SO
background	O
on	O
the	O
expression	O
of	O
autoimmunity	O
have	O
also	O
been	O
reported	O
in	O
gene	B-SO
-	O
targeted	O
mice	B-Taxon
(	O
Bolland	O
and	O
Ravetch	O
2000	O
;	O
Santiago	O
-	O
Raber	O
et	O
al	O
.	O
2001	O
;	O
Mitchell	O
et	O
al	O
.	O
2002	O
)	O
.	O

Thus	O
,	O
SLE	O
exists	O
as	O
a	O
complex	O
-	O
trait	O
disorder	O
in	O
which	O
specific	O
combinations	O
of	O
susceptibility	O
alleles	B-SO
are	O
required	O
for	O
the	O
expression	O
of	O
the	O
full	O
phenotype	O
.	O

Through	O
the	O
use	O
of	O
microsatellite	B-SO
marker	I-SO
maps	O
,	O
the	O
identification	O
of	O
murine	B-Taxon
SLE	O
susceptibility	O
intervals	B-SO
in	O
experimental	O
crosses	O
has	O
been	O
made	O
possible	O
.	O

These	O
mapping	O
studies	O
have	O
shown	O
that	O
the	O
disease	O
expression	O
in	O
relation	O
to	O
the	O
inheritance	O
of	O
the	O
different	O
alleles	B-SO
followed	O
a	O
threshold	O
liability	O
pattern	O
in	O
which	O
a	O
positive	O
phenotype	O
depended	O
upon	O
the	O
presence	O
of	O
multiple	O
discrete	O
susceptibility	O
loci	B-SO
with	O
no	O
single	O
locus	B-SO
being	O
a	O
prerequisite	O
factor	O
.	O

We	O
have	O
employed	O
the	O
same	O
approach	O
to	O
analyse	O
the	O
genetic	B-SO
basis	O
of	O
disease	O
inheritance	O
in	O
the	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
hybrid	O
strain	O
,	O
the	O
most	O
common	O
genetic	B-SO
background	O
in	O
gene	B-SO
-	O
targeted	O
mice	B-Taxon
.	O

Although	O
spontaneous	O
autoimmunity	O
has	O
not	O
been	O
documented	O
in	O
either	O
of	O
the	O
pure	O
129	O
or	O
C57BL	O
/	O
6	O
strains	O
,	O
a	O
spontaneous	O
lupus	O
-	O
like	O
phenotype	O
has	O
been	O
described	O
in	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
hybrid	O
strains	O
(	O
Obata	O
et	O
al	O
.	O
1979	O
;	O
Botto	O
et	O
al	O
.	O
1998	O
;	O
Bickerstaff	O
et	O
al	O
.	O
1999	O
;	O
Santiago	O
-	O
Raber	O
et	O
al	O
.	O
2001	O
)	O
,	O
suggesting	O
that	O
the	O
predisposition	O
in	O
these	O
hybrid	O
mice	B-Taxon
may	O
arise	O
as	O
a	O
result	O
of	O
the	O
interaction	O
between	O
specific	O
combinations	O
of	O
alleles	B-SO
inherited	O
from	O
both	O
the	O
129	O
and	O
C57BL	O
/	O
6	O
parental	O
strains	O
.	O

This	O
was	O
confirmed	O
by	O
the	O
mapping	O
study	O
reported	O
here	O
.	O

We	O
showed	O
that	O
there	O
are	O
multiple	O
genetic	B-SO
loci	B-SO
contributing	O
to	O
the	O
disease	O
and	O
these	O
are	O
derived	O
from	O
both	O
129	O
and	O
C57BL	O
/	O
6	O
mice	B-Taxon
.	O

We	O
demonstrated	O
that	O
a	O
129	O
-	O
derived	O
segment	B-SO
of	I-SO
Chromosome	I-SO
1	O
was	O
strongly	O
linked	O
to	O
the	O
expression	O
of	O
auto	O
-	O
Abs	B-GO
.	O

This	O
region	B-SO
is	O
probably	O
capable	O
of	O
causing	O
the	O
initiation	O
of	O
a	O
humoral	O
autoimmune	O
response	O
to	O
nuclear	B-GO
antigens	O
;	O
however	O
,	O
this	O
response	O
does	O
not	O
occur	O
in	O
the	O
absence	O
of	O
C57BL	O
/	O
6	O
genes	B-SO
.	O

In	O
support	O
of	O
this	O
,	O
we	O
identified	O
a	O
C57BL	O
/	O
6	O
segment	B-SO
on	I-SO
Chromosome	I-SO
3	O
,	O
which	O
may	O
interact	O
with	O
the	O
129	O
genes	B-SO
on	O
Chromosome	B-GO
1	O
to	O
mediate	O
the	O
loss	O
of	O
tolerance	O
.	O

Interestingly	O
,	O
although	O
the	O
C57BL	O
/	O
6	O
SLE	O
-	O
susceptibility	O
region	B-SO
on	I-SO
Chromosome	I-SO
3	O
is	O
novel	O
,	O
disease	O
-	O
modifying	O
alleles	B-SO
derived	O
from	O
C57BL	O
/	O
10	O
and	O
C57BL	O
/	O
6	O
strains	O
have	O
been	O
mapped	O
to	O
a	O
portion	B-SO
of	I-SO
Chromosome	I-SO
3	O
close	O
to	O
the	O
region	B-SO
identified	O
in	O
this	O
study	O
(	O
Morel	O
et	O
al	O
.	O
1999	O
;	O
Haywood	O
et	O
al	O
.	O
2000	O
)	O
.	O

Furthermore	O
,	O
the	O
region	B-SO
on	I-SO
Chromosome	I-SO
7	O
associated	O
with	O
the	O
development	O
of	O
lupus	O
nephritis	O
has	O
been	O
linked	O
to	O
the	O
same	O
trait	O
in	O
other	O
murine	B-Taxon
models	O
of	O
SLE	O
(	O
Santiago	O
et	O
al	O
.	O
1998	O
;	O
Morel	O
et	O
al	O
.	O
1999	O
;	O
Xie	O
et	O
al	O
.	O
2002	O
)	O
,	O
suggesting	O
the	O
possibility	O
of	O
shared	O
susceptibility	O
loci	B-SO
.	O

Taken	O
together	O
our	O
results	O
suggest	O
a	O
complex	O
genetic	B-SO
contribution	O
from	O
the	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
hybrid	O
background	O
genome	B-SO
,	O
with	O
both	O
enhancing	O
as	O
well	O
as	O
inhibitory	O
loci	B-SO
from	O
the	O
129	O
mouse	B-Taxon
,	O
in	O
addition	O
to	O
genes	B-SO
promoting	O
autoimmunity	O
from	O
the	O
C57BL	O
/	O
6	O
mice	B-Taxon
.	O

The	O
impact	O
that	O
these	O
interacting	O
loci	B-SO
may	O
have	O
on	O
the	O
lupus	O
-	O
like	O
disease	O
present	O
in	O
several	O
gene	B-SO
-	O
targeted	O
animals	B-Taxon
was	O
further	O
assessed	O
by	O
comparing	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
with	O
Chromosome	B-GO
1	O
genetically	B-SO
matched	O
controls	O
.	O

In	O
the	O
context	O
of	O
SLE	O
susceptibility	O
,	O
one	O
of	O
the	O
most	O
consistently	O
mapped	O
non	O
-	O
MHC	B-GO
regions	B-SO
of	O
the	O
mouse	B-Taxon
genome	B-SO
is	O
the	O
telomeric	B-GO
Chromosome	I-GO
1	I-GO
segment	I-GO
,	O
where	O
several	O
disease	O
loci	B-SO
,	O
designated	O
Sle1	B-GGP
(	O
Morel	O
et	O
al	O
.	O
2001	O
)	O
,	O
Nba2	B-GGP
(	O
Drake	O
et	O
al	O
.	O
1995	O
;	O
Rozzo	O
et	O
al	O
.	O
1996	O
;	O
Vyse	O
et	O
al	O
.	O
1997	O
)	O
,	O
and	O
Bxs3	B-GGP
(	O
Hogarth	O
et	O
al	O
.	O
1998	O
)	O
,	O
have	O
been	O
mapped	O
in	O
lupus	O
-	O
prone	O
strains	O
.	O

Moreover	O
,	O
this	O
region	B-SO
of	I-SO
mouse	I-SO
Chromosome	I-SO
1	O
is	O
orthologous	B-SO
to	O
a	O
region	B-SO
on	I-SO
human	I-SO
Chromosome	I-SO
1q22	O
-	O
1q25	O
,	O
which	O
has	O
also	O
been	O
linked	O
with	O
human	B-Taxon
SLE	O
(	O
Moser	O
et	O
al	O
.	O
1998	O
)	O
.	O

The	O
Apcs	B-GGP
gene	B-SO
is	O
one	O
of	O
the	O
candidate	O
genes	B-SO
known	O
to	O
lie	O
within	O
this	O
region	B-SO
.	O

The	O
human	B-GGP
serum	I-GGP
amyloid	I-GGP
P	I-GGP
component	I-GGP
binds	O
avidly	O
to	O
DNA	B-SO
,	O
chromatin	B-GO
,	O
and	O
apoptotic	B-CL
cells	I-CL
in	O
physiological	O
conditions	O
in	O
vitro	O
(	O
Pepys	O
1974	O
;	O
Pepys	O
and	O
Butler	O
1987	O
;	O
Butler	O
et	O
al	O
.	O
1990	O
)	O
and	O
also	O
to	O
exposed	O
chromatin	B-GO
and	O
apoptotic	B-CL
cells	I-CL
in	O
vivo	O
(	O
Hintner	O
et	O
al	O
.	O
1988	O
;	O
Breathnach	O
et	O
al	O
.	O
1989	O
;	O
Familian	O
et	O
al	O
.	O
2001	O
)	O
.	O

We	O
have	O
previously	O
reported	O
that	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
spontaneously	O
produce	O
a	O
wide	O
range	O
of	O
ANAs	O
and	O
develop	O
significant	O
immune	B-GO
complex	I-GO
glomerulonephritis	O
(	O
Bickerstaff	O
et	O
al	O
.	O
1999	O
)	O
.	O

On	O
the	O
basis	O
of	O
these	O
observations	O
,	O
it	O
was	O
postulated	O
that	O
Apcs	B-GGP
,	O
by	O
altering	O
the	O
clearance	O
of	O
chromatin	B-GO
,	O
contributes	O
to	O
the	O
pathogenesis	O
of	O
SLE	O
.	O

However	O
,	O
in	O
this	O
study	O
we	O
found	O
that	O
only	O
ANA	O
and	O
anti	O
-	O
chromatin	B-GO
Ab	B-GO
levels	O
were	O
significantly	O
increased	O
in	O
the	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
.	O

A	O
possible	O
explanation	O
for	O
this	O
discrepancy	O
may	O
lie	O
in	O
the	O
fact	O
that	O
the	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
analysed	O
in	O
the	O
original	O
study	O
were	O
generated	O
from	O
a	O
limited	O
number	O
of	O
founders	O
and	O
that	O
this	O
may	O
have	O
caused	O
a	O
nonrandom	O
inheritance	O
of	O
the	O
loci	B-SO
from	O
the	O
parental	O
strains	O
.	O

Furthermore	O
,	O
the	O
whole	O
-	O
genome	B-SO
analysis	O
identified	O
the	O
129	O
region	B-SO
surrounding	O
the	O
Apcs	B-GGP
gene	B-SO
as	O
the	O
main	O
locus	B-SO
contributing	O
to	O
the	O
development	O
of	O
ANA	O
and	O
anti	O
-	O
chromatin	B-GO
Ab	B-GO
.	O

In	O
agreement	O
with	O
this	O
,	O
when	O
we	O
carried	O
out	O
a	O
selective	O
comparison	O
between	O
the	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
and	O
Chromosome	B-GO
1	O
genetically	B-SO
matched	O
controls	O
,	O
we	O
failed	O
to	O
detect	O
any	O
significant	O
difference	O
in	O
the	O
levels	O
of	O
these	O
two	O
auto	O
-	O
Abs	B-GO
.	O

These	O
findings	O
,	O
taken	O
together	O
,	O
indicated	O
that	O
the	O
phenotype	O
associated	O
with	O
Apcs	B-GGP
deficiency	O
was	O
caused	O
by	O
the	O
presence	O
of	O
unaltered	O
129	O
genes	B-SO
from	O
the	O
telomeric	B-GO
region	I-GO
of	I-GO
Chromosome	I-GO
1	O
operating	O
in	O
the	O
C57BL	O
/	O
6	O
genomic	B-SO
background	O
.	O

Strong	O
supportive	O
evidence	O
for	O
this	O
was	O
provided	O
by	O
the	O
analysis	O
of	O
the	O
C57BL	O
/	O
6	O
mice	B-Taxon
congenic	O
for	O
this	O
129	O
region	B-SO
.	O

The	O
generation	O
and	O
analysis	O
of	O
congenic	O
strains	O
have	O
successfully	O
been	O
used	O
to	O
dissect	O
the	O
contribution	O
of	O
individual	O
susceptibility	O
alleles	B-SO
to	O
a	O
multigenic	O
trait	O
such	O
as	O
SLE	O
.	O

We	O
adopted	O
the	O
same	O
strategy	O
to	O
investigate	O
the	O
relative	O
contribution	O
of	O
the	O
129	O
Chromosome	B-SO
1	I-SO
segment	I-SO
and	O
the	O
Apcs	B-GGP
gene	B-SO
to	O
each	O
disease	O
trait	O
.	O

Using	O
this	O
approach	O
,	O
we	O
demonstrated	O
that	O
the	O
129	O
interval	B-SO
on	I-SO
distal	I-SO
Chromosome	I-SO
1	O
,	O
when	O
transferred	B-SO
onto	O
the	O
C57BL	O
/	O
6	O
genome	B-SO
,	O
a	O
combination	O
commonly	O
created	O
by	O
backcrossing	O
onto	O
C57BL	O
/	O
6	O
a	O
mutated	B-SO
gene	B-SO
located	O
in	O
that	O
chromosomal	B-SO
region	I-SO
,	O
was	O
sufficient	O
to	O
mediate	O
the	O
production	O
of	O
auto	O
-	O
Abs	B-GO
.	O

In	O
this	O
context	O
,	O
it	O
is	O
of	O
note	O
that	O
several	O
strains	O
of	O
mice	B-Taxon
with	O
targeted	O
mutations	B-SO
of	O
genes	B-SO
encoded	O
in	O
this	O
region	B-SO
have	O
been	O
reported	O
to	O
express	O
a	O
lupus	O
-	O
like	O
illness	O
,	O
including	O
mice	B-Taxon
lacking	O
Fc	B-GGP
gamma	I-GGP
RIIB	I-GGP
(	O
Bolland	O
and	O
Ravetch	O
2000	O
)	O
,	O
complement	O
receptors	O
(	O
CR1	B-GGP
/	O
2	O
)	O
(	O
Prodeus	O
et	O
al	O
.	O
1998	O
;	O
Wu	O
et	O
al	O
.	O
2002	O
)	O
,	O
and	O
decay	B-GGP
-	I-GGP
accelerating	I-GGP
factor	I-GGP
(	O
CD55	B-GGP
)	O
(	O
Miwa	O
et	O
al	O
.	O
2002	O
)	O
.	O

In	O
each	O
case	O
,	O
the	O
autoimmune	O
phenotype	O
was	O
described	O
in	O
mice	B-Taxon
in	O
which	O
the	O
null	O
mutation	B-SO
was	O
generated	O
in	O
129	O
embryonic	O
stem	B-CL
cells	I-CL
and	O
then	O
backcrossed	O
to	O
the	O
C57BL	O
/	O
6	O
or	O
another	O
genetic	B-SO
background	O
.	O

Thus	O
,	O
in	O
view	O
of	O
our	O
findings	O
,	O
one	O
may	O
postulate	O
that	O
in	O
each	O
of	O
these	O
murine	B-Taxon
models	O
of	O
SLE	O
,	O
the	O
effects	O
of	O
the	O
targeted	O
null	O
gene	B-SO
were	O
irrelevant	O
.	O

Similar	O
conclusions	O
may	O
apply	O
to	O
other	O
gene	B-SO
-	O
targeted	O
animals	B-Taxon
carrying	O
mutations	B-SO
of	O
genes	B-SO
mapped	O
in	O
the	O
129	O
-	O
derived	O
susceptibility	O
allele	B-SO
on	O
Chromosome	B-GO
7	O
(	O
O	O
'	O
Keefe	O
et	O
al	O
.	O
1996	O
,	O
1999	O
)	O
.	O

The	O
expression	O
of	O
anti	O
-	O
nuclear	B-GO
autoimmunity	O
was	O
identical	O
comparing	O
the	O
congenic	O
with	O
the	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
.	O

The	O
only	O
difference	O
in	O
phenotype	O
between	O
these	O
mice	B-Taxon
was	O
in	O
the	O
expression	O
of	O
glomerulonephritis	O
,	O
which	O
was	O
more	O
pronounced	O
in	O
the	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
compared	O
with	O
the	O
congenic	O
mice	B-Taxon
.	O

Although	O
these	O
findings	O
demonstrate	O
that	O
Apcs	B-GGP
is	O
not	O
implicated	O
in	O
the	O
processing	O
of	O
autoantigens	O
,	O
as	O
it	O
had	O
previously	O
been	O
suggested	O
,	O
they	O
indicate	O
that	O
Apcs	B-GGP
might	O
still	O
play	O
an	O
important	O
protective	O
role	O
in	O
lupus	O
nephritis	O
.	O

In	O
support	O
of	O
this	O
,	O
the	O
expression	O
of	O
the	O
human	B-GGP
C	I-GGP
-	I-GGP
reactive	I-GGP
protein	I-GGP
,	O
an	O
acute	O
-	O
phase	O
protein	B-CHEBI
closely	O
related	O
to	O
Apcs	B-GGP
,	O
has	O
been	O
shown	O
to	O
delay	O
the	O
onset	O
and	O
severity	O
of	O
lupus	O
nephritis	O
in	O
the	O
NZB	O
/	O
W	O
strain	O
by	O
preventing	O
the	O
deposition	O
of	O
immune	B-GO
complexes	I-GO
in	O
the	O
renal	O
cortex	O
(	O
Szalai	O
et	O
al	O
.	O
2003	O
)	O
.	O

Consistent	O
with	O
this	O
,	O
a	O
polymorphism	B-SO
associated	O
with	O
reduced	O
basal	O
level	O
of	O
C	B-GGP
-	I-GGP
reactive	I-GGP
protein	I-GGP
has	O
been	O
reported	O
to	O
be	O
linked	O
to	O
SLE	O
in	O
humans	B-Taxon
(	O
Russell	O
et	O
al	O
.	O
2004	O
)	O
.	O

However	O
,	O
as	O
the	O
congenic	O
mice	B-Taxon
and	O
the	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
carried	O
similar	O
but	O
not	O
identical	O
129	O
regions	B-SO
on	I-SO
Chromosome	I-SO
1	O
,	O
an	O
alternative	O
explanation	O
for	O
our	O
findings	O
may	O
still	O
lay	O
in	O
the	O
numerous	O
and	O
complex	O
synergistic	O
and	O
counteractive	O
interactions	O
between	O
129	O
and	O
C57BL	O
/	O
6	O
genes	B-SO
involved	O
in	O
self	O
-	O
tolerance	O
and	O
end	O
organ	O
damage	O
.	O

Thus	O
,	O
whilst	O
the	O
lack	O
of	O
lupus	O
nephritis	O
in	O
the	O
congenic	O
mice	B-Taxon
is	O
consistent	O
with	O
the	O
need	O
for	O
multiple	O
susceptibility	O
genes	B-SO
for	O
the	O
full	O
expression	O
of	O
lupus	O
,	O
further	O
studies	O
will	O
be	O
required	O
to	O
fully	O
elucidate	O
the	O
role	O
of	O
Apcs	B-GGP
in	O
the	O
pathogenesis	O
of	O
renal	O
damage	O
.	O

In	O
summary	O
,	O
our	O
findings	O
demonstrate	O
the	O
impact	O
of	O
epistatic	O
interactions	O
between	O
129	O
and	O
C57BL	O
/	O
6	O
genomes	B-SO
on	O
the	O
development	O
of	O
SLE	O
and	O
illustrate	O
how	O
these	O
background	O
gene	B-SO
effects	O
may	O
lead	O
to	O
incorrect	O
interpretations	O
when	O
analysing	O
the	O
autoimmune	O
phenotype	O
of	O
specific	O
genetic	B-SO
disruptions	O
.	O

Materials	O
and	O
Methods	O

Mice	B-Taxon
.	O

All	O
the	O
mice	B-Taxon
were	O
females	O
.	O

Wild	B-SO
-	I-SO
type	I-SO
C57BL	O
/	O
6	O
and	O
129	O
/	O
Sv	O
(	O
129S6	O
,	O
according	O
to	O
the	O
revised	O
nomenclature	O
)	O
were	O
bred	O
and	O
maintained	O
in	O
the	O
animal	B-Taxon
care	O
facility	O
at	O
Imperial	O
College	O
,	O
London	O
,	O
United	O
Kingdom	O
.	O

(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F1	O
mice	B-Taxon
were	O
generated	O
by	O
intercrossing	O
the	O
two	O
wild	B-SO
-	I-SO
type	I-SO
strains	O
and	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
mice	B-Taxon
by	O
interbreeding	O
the	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F1	O
mice	B-Taxon
.	O

The	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
were	O
generated	O
as	O
previously	O
reported	O
(	O
Botto	O
et	O
al	O
.	O
1997	O
)	O
,	O
and	O
the	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
were	O
generated	O
by	O
intercrossing	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
on	O
the	O
129	O
genetic	B-SO
background	O
with	O
Apcs	B-GGP
-	O
/	O
-	O
animals	B-Taxon
backcrossed	O
onto	O
C57BL	O
/	O
6	O
for	O
ten	O
generations	O
.	O

A	O
total	O
of	O
141	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
and	O
158	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
female	O
mice	B-Taxon
were	O
produced	O
and	O
monitored	O
for	O
1	O
y	O
.	O

Wild	B-SO
-	I-SO
type	I-SO
congenic	O
C57BL	O
/	O
6	O
.	O
129	O
(	O
D1Mit105	O
-	O
223	O
)	O
mice	B-Taxon
were	O
generated	O
by	O
backcrossing	O
the	O
129	O
interval	B-SO
between	O
microsatellites	B-SO
D1Mit105	O
and	O
D1Mit223	O
(	O
80	O
cM	O
to	O
106	O
cM	O
)	O
onto	O
the	O
C57BL	O
/	O
6	O
strain	O
.	O

Inherited	O
129	O
regions	B-SO
were	O
mapped	O
with	O
microsatellite	B-SO
markers	I-SO
polymorphic	B-SO
between	O
129	O
and	O
C57BL	O
/	O
6	O
mice	B-Taxon
(	O
see	O
below	O
)	O
.	O

After	O
seven	O
generations	O
of	O
backcrossing	O
,	O
siblings	O
were	O
intercrossed	O
to	O
generate	O
C57BL	O
/	O
6	O
.	O
129	O
(	O
D1Mit105	O
-	O
223	O
)	O
congenic	O
mice	B-Taxon
homozygous	O
for	O
the	O
129	O
Chromosome	B-SO
1	I-SO
interval	I-SO
.	O

Inside	O
129	O
markers	O
at	O
positions	B-SO
81	O
.	O
6	O
cM	O
(	O
D1Mit159	O
)	O
and	O
105	O
cM	O
(	O
D1Mit17	O
)	O
,	O
respectively	O
,	O
and	O
an	O
outside	O
C57BL	O
/	O
6	O
marker	O
at	O
position	B-SO
74	O
.	O
3cM	O
(	O
D1Mit159	O
)	O
were	O
used	O
to	O
further	O
define	O
the	O
interval	B-SO
.	O

In	O
the	O
C57BL	O
/	O
6	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
(	O
backcrossed	O
onto	O
C57BL	O
/	O
6	O
for	O
ten	O
generations	O
)	O
,	O
the	O
129	O
genome	B-SO
around	O
the	O
Apcs	B-GGP
locus	B-SO
was	O
mapped	O
as	O
a	O
segment	B-SO
from	O
87	O
.	O
9	O
cM	O
(	O
D1Mit15	O
)	O
to	O
105	O
cM	O
(	O
D1Mit17	O
)	O
.	O

In	O
this	O
analysis	O
,	O
the	O
inside	O
129	O
markers	O
were	O
at	O
positions	B-SO
93	O
cM	O
(	O
D1Mit36	O
)	O
and	O
99	O
.	O
7	O
cM	O
(	O
D1Mit115	O
)	O
and	O
the	O
outside	O
C57BL	O
/	O
6	O
markers	O
at	O
positions	B-SO
81	O
.	O
6	O
cM	O
(	O
D1Mit159	O
)	O
and	O
106	O
cM	O
(	O
D1Mit223	O
)	O
.	O

Along	O
with	O
28	O
C57BL	O
/	O
6	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
and	O
30	O
C57BL	O
/	O
6	O
wild	B-SO
-	I-SO
type	I-SO
animals	B-Taxon
,	O
26	O
C57BL	O
/	O
6	O
.	O
129	O
(	O
D1Mit105	O
-	O
223	O
)	O
female	O
mice	B-Taxon
-	O
/	O
-	O
were	O
followed	O
up	O
to	O
1	O
y	O
of	O
age	O
.	O

Animals	B-Taxon
were	O
maintained	O
in	O
specific	O
pathogen	O
-	O
free	O
conditions	O
.	O

All	O
animal	B-Taxon
procedures	O
were	O
in	O
accordance	O
with	O
institutional	O
guidelines	O
.	O

Serological	O
analyses	O
.	O

Sera	O
,	O
collected	O
at	O
6	O
and	O
12	O
mo	O
of	O
age	O
,	O
were	O
assayed	O
for	O
the	O
presence	O
of	O
auto	O
-	O
Abs	B-GO
.	O

Levels	O
of	O
IgG	O
ANA	O
were	O
sought	O
by	O
indirect	O
immunofluorescence	O
using	O
Hep	O
-	O
2	O
cells	B-CL
,	O
and	O
anti	O
-	O
dsDNA	O
Abs	B-GO
were	O
detected	O
by	O
indirect	O
immunofluorescence	O
on	O
Crithidia	B-Taxon
luciliae	I-Taxon
as	O
previously	O
described	O
(	O
Mitchell	O
et	O
al	O
.	O
2002	O
)	O
.	O

Serum	O
samples	O
were	O
screened	O
at	O
a	O
1	O
:	O
80	O
(	O
ANA	O
)	O
or	O
1	O
:	O
20	O
(	O
anti	O
-	O
dsDNA	O
)	O
dilution	O
and	O
the	O
positive	O
samples	O
titrated	O
to	O
endpoint	O
.	O

Abs	B-GO
to	O
ssDNA	O
and	O
anti	O
-	O
chromatin	B-GO
were	O
measured	O
by	O
ELISA	O
,	O
as	O
previously	O
described	O
(	O
Mitchell	O
et	O
al	O
.	O
2002	O
)	O
.	O

Samples	O
were	O
screened	O
at	O
a	O
1	O
:	O
100	O
dilution	O
,	O
and	O
the	O
results	O
were	O
expressed	O
in	O
arbitrary	O
ELISA	O
units	O
(	O
AEUs	O
)	O
relative	O
to	O
a	O
standard	O
positive	O
sample	O
(	O
derived	O
from	O
an	O
MRL	O
/	O
Mp	O
.	O
lpr	B-GGP
/	O
lpr	B-GGP
mouse	B-Taxon
)	O
,	O
which	O
was	O
assigned	O
a	O
value	O
of	O
100	O
.	O

For	O
interplate	O
comparison	O
,	O
serial	O
dilutions	O
of	O
a	O
positive	O
control	O
serum	O
sample	O
were	O
included	O
on	O
each	O
plate	O
.	O

Apcs	B-GGP
levels	O
were	O
assessed	O
by	O
ELISA	O
using	O
sheep	B-Taxon
anti	O
-	O
mouse	B-GGP
Apcs	I-GGP
and	O
rabbit	B-Taxon
anti	O
-	O
mouse	B-GGP
Apcs	I-GGP
Abs	B-GO
(	O
Calbiochem	O
,	O
Nottigham	O
,	O
United	O
Kingdom	O
)	O
.	O

Samples	O
were	O
screened	O
at	O
a	O
1	O
:	O
3	O
,	O
000	O
dilution	O
,	O
and	O
the	O
results	O
were	O
expressed	O
in	O
milligrams	O
per	O
liters	O
,	O
referring	O
to	O
a	O
standard	O
curve	O
derived	O
from	O
an	O
acute	O
-	O
phase	O
serum	O
with	O
a	O
known	O
concentration	O
of	O
Apcs	B-GGP
(	O
Calbiochem	O
)	O
.	O

Apcs	B-GGP
-	O
/	O
-	O
mouse	B-Taxon
serum	O
was	O
included	O
as	O
a	O
negative	O
control	O
.	O

Histological	O
analysis	O
.	O

All	O
the	O
mice	B-Taxon
,	O
except	O
the	O
few	O
that	O
died	O
before	O
the	O
end	O
of	O
the	O
experiment	O
,	O
were	O
sacrificed	O
at	O
1	O
y	O
of	O
age	O
,	O
and	O
kidney	O
portions	O
were	O
fixed	O
in	O
Bouin	O
'	O
s	O
solution	O
and	O
paraffin	O
embedded	O
,	O
and	O
sections	O
were	O
stained	O
with	O
periodic	B-CHEBI
acid	I-CHEBI
-	O
Schiff	O
reagent	B-CHEBI
.	O

Glomerular	O
histology	O
was	O
graded	O
in	O
a	O
blinded	O
fashion	O
as	O
follows	O
:	O
grade	O
0	O
,	O
normal	O
;	O
grade	O
1	O
,	O
hypercellularity	O
involving	O
greater	O
than	O
50	O
%	O
of	O
the	O
glomerular	O
tuft	O
in	O
25	O
%	O
-	O
50	O
%	O
of	O
glomeruli	O
;	O
grade	O
2	O
,	O
hypercellularity	O
involving	O
greater	O
than	O
50	O
%	O
of	O
the	O
glomerular	O
tuft	O
in	O
50	O
%	O
-	O
75	O
%	O
of	O
glomeruli	O
;	O
grade	O
3	O
,	O
glomerular	O
hypercellularity	O
in	O
greater	O
than	O
75	O
%	O
of	O
glomeruli	O
or	O
crescents	O
in	O
greater	O
than	O
25	O
%	O
of	O
glomeruli	O
.	O

Statistical	O
analysis	O

Non	O
-	O
parametric	O
data	O
are	O
expressed	O
as	O
median	O
with	O
range	O
of	O
values	O
in	O
parentheses	O
.	O

All	O
statistics	O
were	O
calculated	O
using	O
GraphPad	O
PrismTM	O
version	O
3	O
.	O
0	O
for	O
Windows	O
(	O
GraphPad	O
Software	O
,	O
San	O
Diego	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

Non	O
-	O
parametric	O
tests	O
were	O
applied	O
throughout	O
,	O
with	O
differences	O
being	O
considered	O
significant	O
for	O
p	O
values	O
<	O
0	O
.	O
05	O
.	O

The	O
Mann	O
-	O
Whitney	O
test	O
was	O
used	O
for	O
comparison	O
of	O
two	O
groups	O
,	O
whilst	O
for	O
analysis	O
of	O
three	O
groups	O
the	O
Kruskal	O
-	O
Wallis	O
test	O
with	O
Dunn	O
'	O
s	O
multiple	O
comparison	O
test	O
was	O
used	O
.	O

Genotypic	O
analysis	O

Genotyping	O
was	O
carried	O
out	O
by	O
PCR	O
of	O
genomic	B-SO
DNA	I-SO
using	O
143	O
polymorphic	B-SO
markers	O
(	O
list	O
available	O
on	O
request	O
)	O
distributed	O
throughout	O
all	O
19	O
autosomes	B-GO
.	O

PCRs	O
were	O
performed	O
using	O
standard	O
reagents	B-CHEBI
containing	O
1	O
.	O
5	O
mM	O
MgCl2	B-CHEBI
and	O
0	O
.	O
4	O
mu	O
M	O
primers	B-SO
.	O

Microsatellite	B-SO
markers	I-SO
were	O
screened	O
for	O
size	O
polymorphisms	B-SO
between	O
129	O
and	O
C57BL	O
/	O
6	O
mice	B-Taxon
.	O

Only	O
primers	B-SO
with	O
differences	O
detectable	O
on	O
ethidium	B-CHEBI
bromide	I-CHEBI
-	O
stained	O
agarose	B-CHEBI
gels	O
or	O
on	O
SDS	B-CHEBI
-	O
polyacrylamide	O
gels	O
were	O
used	O
.	O

Linkage	O
analysis	O

The	O
QTL	B-SO
program	O
MAPMANAGER	O
.	O
QTL	B-SO
(	O
ftp	O
:	O
/	O
/	O
mcbio	O
.	O
med	O
.	O
buffalo	O
.	O
edu	O
/	O
pub	O
/	O
MapMgr	O
/	O
)	O
was	O
used	O
,	O
and	O
the	O
two	O
experimental	O
groups	O
were	O
examined	O
independently	O
.	O

Only	O
data	O
from	O
mice	B-Taxon
at	O
12	O
mo	O
of	O
age	O
were	O
analysed	O
.	O

Log	O
transformations	O
of	O
auto	O
-	O
Abs	B-GO
levels	O
resulted	O
in	O
more	O
normalised	O
distribution	O
and	O
were	O
used	O
in	O
QTL	B-SO
mapping	O
.	O

LOD	O
thresholds	O
for	O
suggestive	O
and	O
significant	O
linkages	O
were	O
determined	O
by	O
using	O
a	O
cohort	O
-	O
and	O
trait	O
-	O
specific	O
permutation	O
test	O
(	O
1	O
,	O
000	O
permutations	O
)	O
.	O

The	O
average	O
threshold	O
for	O
suggestive	O
,	O
significant	O
,	O
and	O
highly	O
significant	O
linkages	O
were	O
LOD	O
>=	O
2	O
.	O
1	O
(	O
p	O
<=	O
7	O
.	O
8	O
x	O
10	O
-	O
3	O
)	O
,	O
LOD	O
>=	O
3	O
.	O
6	O
(	O
p	O
<=	O
2	O
.	O
4	O
x	O
10	O
-	O
4	O
)	O
,	O
and	O
LOD	O
>=	O
5	O
(	O
p	O
<=	O
1	O
x	O
10	O
-	O
5	O
)	O
,	O
respectively	O
(	O
Manly	O
and	O
Olson	O
1999	O
)	O
.	O

Supporting	O
Information	O

Accession	O
Numbers	O

The	O
LocusLink	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
LocusLink	O
/	O
)	O
ID	O
numbers	O
for	O
the	O
genes	B-SO
and	O
gene	B-SO
products	O
discussed	O
in	O
this	O
paper	O
are	O
Apcs	B-GGP
(	O
LocusLink	O
ID	O
20219	O
)	O
,	O
CD35	B-GGP
/	O
CD21	B-GGP
(	O
LocusLink	O
ID	O
12902	O
)	O
,	O
CD55	B-GGP
(	O
LocusLink	O
ID	O
13136	O
)	O
,	O
the	O
FAS	B-GGP
receptor	I-GGP
gene	B-SO
(	O
LocusLink	O
ID	O
14102	O
)	O
,	O
and	O
Fc	B-GGP
gamma	I-GGP
RII	I-GGP
(	O
LocusLink	O
ID	O
14130	O
)	O
.	O

Acknowledgements	O

We	O
are	O
grateful	O
to	O
M	O
.	O

Lewis	O
for	O
the	O
processing	O
of	O
the	O
samples	O
for	O
histology	O
and	O
to	O
F	O
.	O

Reid	O
and	O
D	O
.	O

Mitchell	O
for	O
their	O
help	O
.	O

We	O
thank	O
all	O
of	O
the	O
staff	O
in	O
the	O
animal	B-Taxon
facility	O
for	O
their	O
technical	O
assistance	O
.	O

This	O
work	O
was	O
supported	O
by	O
the	O
Wellcome	O
Trust	O
(	O
grant	O
number	O
061438	O
)	O
.	O

JCH	O
was	O
a	O
recipient	O
of	O
a	O
fellowship	O
from	O
the	O
National	O
Institute	O
of	O
Health	O
,	O
Spain	O
(	O
BEFI	O
99	O
/	O
9212	O
)	O
.	O

Abbreviations	O

Ab	B-GO
-	O
antibody	B-GO

ANA	O
-	O
anti	O
-	O
nuclear	O
antibody	B-GO

AEU	O
-	O
arbitrary	O
ELISA	O
unit	O

Apcs	B-GGP
-	O
/	O
-	O
-	O
Apcs	B-GGP
-	O
deficient	O
mice	B-Taxon

Apcs	B-GGP
-	O
serum	B-GGP
amyloid	I-GGP
P	I-GGP
component	I-GGP
gene	B-SO

dsDNA	O
-	O
double	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO

LOD	O
-	O
logarithm	O
of	O
odds	O

QTL	B-SO
-	O
quantitative	B-SO
trait	I-SO
linkage	I-SO

SLE	O
-	O
systemic	O
lupus	O
erythematosus	O

ssDNA	O
-	O
anti	O
-	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO

Figures	O
and	O
Tables	O

Figure	O
1	O

Linkage	O
of	O
Chromosome	B-GO
2	O
with	O
ANA	O
and	O
Anti	O
-	O
Chromatin	B-GO
Abs	B-GO
in	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
Mice	B-Taxon

These	O
associations	O
were	O
not	O
detected	O
in	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
animals	B-Taxon
.	O

Centimorgan	O
positions	B-SO
were	O
deduced	O
by	O
interval	B-SO
mapping	O
,	O
anchoring	O
marker	O
locations	B-SO
to	O
data	O
from	O
http	O
:	O
/	O
/	O
www	O
.	O
informatics	O
.	O
jax	O
.	O
org	O
.	O

Dotted	O
lines	O
and	O
the	O
dashed	O
line	O
indicate	O
the	O
threshold	O
over	O
which	O
linkages	O
were	O
considered	O
suggestive	O
or	O
significant	O
,	O
respectively	O
,	O
as	O
defined	O
in	O
Materials	O
and	O
Methods	O
.	O

Figure	O
3	O

Linkage	O
of	O
Chromosome	B-GO
4	O
with	O
Anti	O
-	O
dsDNA	O
Abs	B-GO

The	O
estimated	O
peak	O
in	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
mice	B-Taxon
was	O
at	O
position	B-SO
51	O
.	O
3	O
cM	O
,	O
whilst	O
in	O
the	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
animals	B-Taxon
it	O
was	O
was	O
at	O
position	B-SO
71	O
cM	O
,	O
indicating	O
that	O
most	O
likely	O
these	O
were	O
two	O
independent	O
loci	B-SO
.	O

Centimorgan	O
positions	B-SO
were	O
deduced	O
by	O
interval	B-SO
mapping	O
,	O
anchoring	O
marker	O
locations	B-SO
to	O
data	O
from	O
http	O
:	O
/	O
/	O
www	O
.	O
informatics	O
.	O
jax	O
.	O
org	O
.	O

Dotted	O
lines	O
the	O
indicate	O
threshold	O
over	O
which	O
linkage	O
was	O
considered	O
suggestive	O
,	O
as	O
defined	O
in	O
Materials	O
and	O
Methods	O
.	O

Figure	O
4	O

Interval	B-SO
Mapping	O
Scans	O
Showing	O
QTL	B-SO
on	O
Chromosome	B-GO
1	O
with	O
Anti	O
-	O
dsDNA	O
and	O
Anti	O
-	O
ssDNA	O
Abs	B-GO

Centimorgan	O
positions	B-SO
were	O
deduced	O
by	O
interval	B-SO
mapping	O
,	O
anchoring	O
marker	O
locations	B-SO
to	O
data	O
from	O
http	O
:	O
/	O
/	O
www	O
.	O
informatics	O
.	O
jax	O
.	O
org	O
.	O

Dotted	O
lines	O
indicate	O
the	O
threshold	O
over	O
which	O
linkage	O
was	O
considered	O
suggestive	O
,	O
dashed	O
lines	O
indicate	O
the	O
threshold	O
over	O
which	O
linkage	O
was	O
considered	O
significant	O
,	O
and	O
dotted	O
/	O
dashed	O
lines	O
indicate	O
highly	O
significant	O
linkage	O
,	O
as	O
defined	O
in	O
Materials	O
and	O
Methods	O
.	O

See	O
Table	O
3	O
for	O
additional	O
details	O
.	O

Figure	O
5	O

Interval	B-SO
Mapping	O
Scans	O
Showing	O
QTL	B-SO
on	O
Chromosome	B-GO
1	O
with	O
ANA	O
and	O
Anti	O
-	O
Chromatin	B-GO
Abs	B-GO

Centimorgan	O
positions	B-SO
were	O
deduced	O
by	O
interval	B-SO
mapping	O
,	O
anchoring	O
marker	O
locations	B-SO
to	O
data	O
from	O
http	O
:	O
/	O
/	O
www	O
.	O
informatics	O
.	O
jax	O
.	O
org	O
.	O

Dotted	O
lines	O
indicate	O
the	O
threshold	O
over	O
which	O
linkage	O
was	O
considered	O
suggestive	O
,	O
and	O
dashed	O
lines	O
indicate	O
the	O
threshold	O
over	O
which	O
linkage	O
was	O
considered	O
significant	O
,	O
as	O
defined	O
in	O
Materials	O
and	O
Methods	O
.	O

See	O
Table	O
3	O
for	O
additional	O
details	O
.	O

Figure	O
6	O

Auto	O
-	O
Ab	B-GO
Profiles	O

(	O
A	O
)	O
ANA	O
titres	O
in	O
the	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
and	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
at	O
1	O
y	O
of	O
age	O
.	O

A	O
small	O
circle	O
represents	O
one	O
mouse	B-Taxon
;	O
a	O
large	O
circle	O
,	O
a	O
variable	O
number	O
of	O
animals	B-Taxon
,	O
as	O
indicated	O
in	O
parentheses	O
.	O

Serum	O
samples	O
were	O
titrated	O
to	O
endpoint	O
.	O

(	O
B	O
)	O
ANA	O
titres	O
in	O
the	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
and	O
a	O
selected	O
number	O
of	O
wild	B-SO
-	I-SO
type	I-SO
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
animals	B-Taxon
carrying	O
the	O
Chromosome	B-SO
1	I-SO
region	I-SO
between	O
D1Mit105	O
and	O
D1Mit223	O
(	O
80	O
-	O
106	O
cM	O
)	O
of	O
129	O
origin	O
.	O

The	O
symbols	O
are	O
as	O
in	O
(	O
A	O
)	O
.	O

(	O
C	O
and	O
D	O
)	O
Anti	O
-	O
chromatin	B-GO
Ab	B-GO
levels	O
expressed	O
in	O
AEUs	O
related	O
to	O
a	O
standard	O
positive	O
sample	O
,	O
which	O
was	O
assigned	O
a	O
value	O
of	O
100	O
AEU	O
.	O

The	O
comparison	O
is	O
between	O
the	O
same	O
groups	O
of	O
mice	B-Taxon
as	O
in	O
(	O
A	O
)	O
and	O
(	O
B	O
)	O
,	O
respectively	O
.	O

The	O
symbols	O
are	O
as	O
in	O
(	O
A	O
)	O
.	O

Figure	O
7	O

Interval	B-SO
Mapping	O
Scans	O
Showing	O
QTL	B-SO
on	O
Chromosome	B-GO
3	O
with	O
ANA	O
,	O
Anti	O
-	O
Chromatin	B-GO
,	O
and	O
Anti	O
-	O
ssDNA	O
Abs	B-GO

See	O
Table	O
3	O
for	O
additional	O
details	O
.	O

Centimorgan	O
positions	B-SO
were	O
deduced	O
by	O
interval	B-SO
mapping	O
,	O
anchoring	O
marker	O
locations	B-SO
to	O
data	O
from	O
http	O
:	O
/	O
/	O
www	O
.	O
informatics	O
.	O
jax	O
.	O
org	O
.	O

Dotted	O
lines	O
indicate	O
the	O
threshold	O
over	O
which	O
linkage	O
was	O
considered	O
suggestive	O
,	O
the	O
dashed	O
line	O
indicate	O
the	O
threshold	O
over	O
which	O
linkage	O
was	O
considered	O
significant	O
,	O
and	O
dotted	O
/	O
dashed	O
lines	O
indicate	O
highly	O
significant	O
linkage	O
,	O
as	O
defined	O
in	O
Materials	O
and	O
Methods	O
.	O

Figure	O
8	O

Auto	O
-	O
Ab	B-GO
Profiles	O

(	O
A	O
)	O
ANA	O
titres	O
in	O
C57BL	O
/	O
6	O
mice	B-Taxon
,	O
C57BL	O
/	O
6	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
,	O
and	O
C57BL	O
/	O
6	O
.	O
129	O
(	O
D1Mit105	O
-	O
223	O
)	O
congenic	O
mice	B-Taxon
at	O
1	O
y	O
of	O
age	O
.	O

Small	O
symbols	O
represent	O
one	O
mouse	B-Taxon
;	O
large	O
symbols	O
,	O
a	O
variable	O
number	O
of	O
animals	B-Taxon
as	O
indicated	O
in	O
parentheses	O
.	O

Serum	O
sample	O
were	O
titrated	O
to	O
endpoint	O
.	O

(	O
B	O
and	O
C	O
)	O
Anti	O
-	O
ssDNA	O
(	O
B	O
)	O
and	O
anti	O
-	O
chromatin	B-GO
(	O
C	O
)	O
Ab	B-GO
levels	O
in	O
the	O
same	O
cohorts	O
of	O
mice	B-Taxon
as	O
in	O
(	O
A	O
)	O
.	O

The	O
Ab	B-GO
levels	O
are	O
expressed	O
in	O
AEUs	O
related	O
to	O
a	O
standard	O
positive	O
sample	O
,	O
which	O
was	O
assigned	O
a	O
value	O
of	O
100	O
AEU	O
.	O

(	O
D	O
)	O
Anti	O
-	O
dsDNA	O
Ab	B-GO
levels	O
.	O

Serum	O
samples	O
were	O
screened	O
at	O
1	O
:	O
20	O
.	O

Samples	O
that	O
were	O
positive	O
were	O
titrated	O
to	O
endpoint	O
.	O

The	O
symbols	O
are	O
as	O
in	O
(	O
A	O
)	O
.	O

Figure	O
9	O

Renal	O
Histological	O
Assessment	O

C57BL	O
/	O
6	O
mice	B-Taxon
,	O
C57BL	O
/	O
6	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
mice	B-Taxon
,	O
and	O
C57BL	O
/	O
6	O
.	O
129	O
(	O
D1Mit105	O
-	O
223	O
)	O
congenic	O
mice	B-Taxon
were	O
sacrificed	O
at	O
1	O
y	O
of	O
age	O
to	O
obtain	O
age	O
-	O
matched	O
autopsy	O
specimens	O
.	O

Bouin	O
'	O
s	O
fixed	O
kidney	O
sections	O
were	O
scored	O
blinded	O
for	O
glomerulonephritis	O
.	O

Glomerulonephritis	O
was	O
graded	O
on	O
a	O
0	O
-	O
3	O
scale	O
(	O
see	O
Materials	O
and	O
Methods	O
for	O
details	O
)	O
.	O

Figure	O
2	O

Linkage	O
of	O
Chromosome	B-GO
8	O
with	O
Anti	O
-	O
Chromatin	B-GO
and	O
Anti	O
-	O
dsDNA	O
Abs	B-GO
in	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
Mice	B-Taxon

These	O
linkages	O
were	O
not	O
detected	O
in	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
.	O
Apcs	B-GGP
-	O
/	O
-	O
animals	B-Taxon
.	O

Centimorgan	O
positions	B-SO
were	O
deduced	O
by	O
interval	B-SO
mapping	O
,	O
anchoring	O
marker	O
locations	B-SO
to	O
data	O
from	O
http	O
:	O
/	O
/	O
www	O
.	O
informatics	O
.	O
jax	O
.	O
org	O
.	O

Dotted	O
lines	O
indicate	O
the	O
threshold	O
over	O
which	O
linkage	O
was	O
considered	O
suggestive	O
,	O
as	O
defined	O
in	O
Materials	O
and	O
Methods	O
.	O

Table	O
1	O

Spontaneous	O
Auto	O
-	O
Abs	B-GO
in	O
Apcs	B-GGP
-	O
/	O
-	O
and	O
Wild	B-SO
-	I-SO
Type	I-SO
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
Female	O
Mice	B-Taxon

Significant	O
differences	O
between	O
Apcs	B-GGP
-	O
/	O
-	O
and	O
wild	B-SO
-	I-SO
type	I-SO
controls	O
by	O
Mann	O
-	O
Whitney	O
U	O
test	O
.	O

The	O
numbers	O
tested	O
for	O
different	O
phenotypes	O
are	O
not	O
equal	O
due	O
to	O
the	O
limited	O
amount	O
of	O
serum	O
or	O
death	O
of	O
the	O
mice	B-Taxon
before	O
the	O
end	O
of	O
the	O
experiment	O
.	O

NS	O
,	O
not	O
significant	O

Table	O
2	O

Histological	O
Assessment	O
of	O
Kidney	O
Sections	O
in	O
Apcs	B-GGP
-	O
/	O
-	O
and	O
Wild	B-SO
-	I-SO
Type	I-SO
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
Female	O
Mice	B-Taxon

The	O
renal	O
sections	O
were	O
scored	O
on	O
a	O
0	O
-	O
3	O
scale	O
on	O
the	O
intensity	O
and	O
extent	O
of	O
the	O
histopathological	O
changes	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

The	O
difference	O
between	O
the	O
two	O
experimental	O
groups	O
was	O
not	O
significant	O

Table	O
3	O

Summary	O
of	O
Genome	B-SO
-	O
Wide	O
Linkage	O
Analysis	O
in	O
Apcs	B-GGP
-	O
/	O
-	O
and	O
Wild	B-SO
-	I-SO
Type	I-SO
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
Female	O
Mice	B-Taxon

a	O
Suggestive	O
linkage	O

b	O
Significant	O
linkage	O

c	O
Highly	O
significant	O
linkage	O
as	O
defined	O
in	O
the	O
material	O
and	O
method	O
section	O

Chr	B-GO
,	O
Chromosome	B-GO
;	O
Est	O
.	O

Peak	O
,	O
Estimated	O
Peak	O
;	O
LOD	O
,	O
logarithm	O
of	O
odds	O
;	O
N	O
/	O
A	O
,	O
not	O
applicable	O

Chromosomes	B-GO
where	O
linkages	O
were	O
not	O
present	O
in	O
both	O
experimental	O
groups	O
are	O
not	O
illustrated	O
.	O

See	O
Materials	O
and	O
Methods	O
for	O
details	O
.	O

The	O
oligonucleotide	B-SO
sequences	I-SO
and	O
approximate	O
positions	B-SO
of	O
the	O
microsatellite	B-SO
markers	I-SO
used	O
were	O
taken	O
from	O
the	O
Mouse	B-Taxon
Genome	B-SO
Database	O
,	O
Mouse	B-Taxon
Genome	B-SO
Informatics	O
,	O
Jackson	O
Laboratory	O
,	O
Bar	O
Harbor	O
,	O
Maine	O
,	O
United	O
States	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
informatics	O
.	O
jax	O
.	O
org	O
)	O

Footnotes	O

Conflicts	O
of	O
interest	O
.	O

The	O
authors	O
have	O
declared	O
that	O
no	O
conflicts	O
of	O
interest	O
exist	O
.	O

Author	O
contributions	O
.	O

MJW	O
,	O
TJV	O
,	O
and	O
MB	O
conceived	O
and	O
designed	O
the	O
experiments	O
.	O

AEB	O
,	O
KLR	O
,	O
JW	O
,	O
JC	O
-	O
H	O
,	O
and	O
RJR	O
performed	O
the	O
experiments	O
.	O

AEB	O
,	O
KLR	O
,	O
RJR	O
,	O
and	O
HTC	O
analyzed	O
the	O
data	O
.	O

MB	O
wrote	O
the	O
paper	O
.	O

Academic	O
Editor	O
:	O
David	O
Nemazee	O
,	O
Scripps	O
Research	O
Institute	O

currency	O
Current	O
address	O
:	O
The	O
Wellcome	O
Trust	O
,	O
London	O
,	O
United	O
Kingdom	O

Citation	O
:	O
Bygrave	O
AE	O
,	O
Rose	O
KL	O
,	O
Cortes	O
-	O
Hernandez	O
J	O
,	O
Warren	O
J	O
,	O
Rigby	O
RJ	O
,	O
et	O
al	O
.	O

(	O
2004	O
)	O
Spontaneous	O
autoimmunity	O
in	O
129	O
and	O
C57BL	O
/	O
6	O
mice	B-Taxon
--	O
Implications	O
for	O
autoimmunity	O
described	O
in	O
gene	B-SO
-	O
targeted	O
mice	B-Taxon
.	O

PLoS	O
Biol	O
2	O
(	O
8	O
)	O
:	O
e243	O
.	O

The	O
phosphatidylserine	B-GGP
receptor	I-GGP
has	O
essential	O
functions	O
during	O
embryogenesis	O
but	O
not	O
in	O
apoptotic	B-CL
cell	I-CL
removal	O

Abstract	O

Background	O

Phagocytosis	O
of	O
apoptotic	B-CL
cells	I-CL
is	O
fundamental	O
to	O
animal	B-Taxon
development	O
,	O
immune	O
function	O
and	O
cellular	B-CL
homeostasis	O
.	O

The	O
phosphatidylserine	B-GGP
receptor	I-GGP
(	O
Ptdsr	B-GGP
)	O
on	O
phagocytes	B-CL
has	O
been	O
implicated	O
in	O
the	O
recognition	O
and	O
engulfment	O
of	O
apoptotic	B-CL
cells	I-CL
and	O
in	O
anti	O
-	O
inflammatory	O
signaling	O
.	O

To	O
determine	O
the	O
biological	O
function	O
of	O
the	O
phosphatidylserine	B-GGP
receptor	I-GGP
in	O
vivo	O
,	O
we	O
inactivated	O
the	O
Ptdsr	B-GGP
gene	B-SO
in	O
the	O
mouse	B-Taxon
.	O

Results	O

Ablation	O
of	O
Ptdsr	B-GGP
function	O
in	O
mice	B-Taxon
causes	O
perinatal	O
lethality	O
,	O
growth	O
retardation	O
and	O
a	O
delay	O
in	O
terminal	O
differentiation	O
of	O
the	O
kidney	O
,	O
intestine	O
,	O
liver	O
and	O
lungs	O
during	O
embryogenesis	O
.	O

Moreover	O
,	O
eye	O
development	O
can	O
be	O
severely	O
disturbed	O
,	O
ranging	O
from	O
defects	O
in	O
retinal	O
differentiation	O
to	O
complete	O
unilateral	O
or	O
bilateral	O
absence	O
of	O
eyes	O
.	O

Ptdsr	B-GGP
-	O
/	O
-	O
mice	B-Taxon
with	O
anophthalmia	O
develop	O
novel	O
lesions	O
,	O
with	O
induction	O
of	O
ectopic	O
retinal	O
-	O
pigmented	O
epithelium	O
in	O
nasal	O
cavities	O
.	O

A	O
comprehensive	O
investigation	O
of	O
apoptotic	B-CL
cell	I-CL
clearance	O
in	O
vivo	O
and	O
in	O
vitro	O
demonstrated	O
that	O
engulfment	O
of	O
apoptotic	B-CL
cells	I-CL
was	O
normal	O
in	O
Ptdsr	B-GGP
knockout	O
mice	B-Taxon
,	O
but	O
Ptdsr	B-GGP
-	O
deficient	O
macrophages	B-CL
were	O
impaired	O
in	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
cytokine	O
signaling	O
after	O
stimulation	O
with	O
apoptotic	B-CL
cells	I-CL
or	O
with	O
lipopolysaccharide	B-CHEBI
.	O

Conclusion	O

Ptdsr	B-GGP
is	O
essential	O
for	O
the	O
development	O
and	O
differentiation	O
of	O
multiple	O
organs	O
during	O
embryogenesis	O
but	O
not	O
for	O
apoptotic	B-CL
cell	I-CL
removal	O
.	O

Ptdsr	B-GGP
may	O
thus	O
have	O
a	O
novel	O
,	O
unexpected	O
developmental	O
function	O
as	O
an	O
important	O
differentiation	O
-	O
promoting	O
gene	B-SO
.	O

Moreover	O
,	O
Ptdsr	B-GGP
is	O
not	O
required	O
for	O
apoptotic	B-CL
cell	I-CL
clearance	O
by	O
macrophages	B-CL
but	O
seems	O
to	O
be	O
necessary	O
for	O
the	O
regulation	O
of	O
macrophage	B-CL
cytokine	O
responses	O
.	O

These	O
results	O
clearly	O
contradict	O
the	O
current	O
view	O
that	O
the	O
phosphatidylserine	B-GGP
receptor	I-GGP
primarily	O
functions	O
in	O
apoptotic	B-CL
cell	I-CL
clearance	O
.	O

Background	O

Programmed	O
cell	B-CL
death	O
,	O
or	O
apoptosis	O
,	O
is	O
required	O
for	O
the	O
normal	O
development	O
of	O
almost	O
all	O
multicellular	O
organisms	B-Taxon
and	O
is	O
a	O
physiological	O
mechanism	O
for	O
controlling	O
cell	B-CL
number	O
;	O
as	O
a	O
result	O
,	O
structures	O
that	O
are	O
no	O
longer	O
needed	O
are	O
deleted	O
during	O
development	O
and	O
abnormal	O
cells	B-CL
are	O
eliminated	O
[	O
1	O
,	O
2	O
]	O
.	O

Most	O
of	O
the	O
cells	B-CL
produced	O
during	O
mammalian	B-Taxon
embryonic	O
development	O
undergo	O
physiological	O
cell	B-CL
death	O
before	O
the	O
end	O
of	O
the	O
perinatal	O
period	O
[	O
3	O
]	O
.	O

Apoptotic	B-CL
cells	I-CL
are	O
removed	O
rapidly	O
and	O
efficiently	O
as	O
intact	O
cells	B-CL
or	O
apoptotic	O
bodies	O
by	O
professional	O
phagocytes	B-CL
or	O
by	O
neighboring	O
cells	B-CL
.	O

This	O
highly	O
regulated	O
process	O
prevents	O
the	O
release	O
of	O
potentially	O
noxious	O
or	O
immunogenic	O
intracellular	B-GO
materials	O
and	O
constitutes	O
the	O
fate	O
of	O
most	O
dying	O
cells	B-CL
throughout	O
the	O
lifespan	O
of	O
an	O
organism	B-Taxon
[	O
4	O
,	O
5	O
]	O
.	O

Phagocytosis	O
of	O
apoptotic	B-CL
cells	I-CL
is	O
very	O
distinct	O
from	O
other	O
engulfment	O
processes	O
that	O
result	O
,	O
for	O
example	O
,	O
in	O
the	O
clearance	O
of	O
microorganisms	O
,	O
because	O
engulfment	O
of	O
apoptotic	B-CL
cells	I-CL
triggers	O
the	O
secretion	O
of	O
potent	O
anti	B-CHEBI
-	I-CHEBI
inflammatory	I-CHEBI
and	I-CHEBI
immunosuppressive	I-CHEBI
mediators	I-CHEBI
,	O
whereas	O
pathogen	O
recognition	O
causes	O
the	O
release	O
of	O
pro	O
-	O
inflammatory	O
signals	O
[	O
6	O
]	O
.	O

Almost	O
all	O
cell	B-CL
types	O
can	O
recognize	O
,	O
respond	O
to	O
,	O
and	O
ingest	O
apoptotic	B-CL
cells	I-CL
by	O
using	O
specific	O
sets	O
of	O
phagocytic	O
receptors	O
that	O
bind	O
to	O
specific	O
ligands	O
on	O
apoptotic	B-CL
cells	I-CL
.	O

Detailed	O
genetic	B-SO
studies	O
in	O
Drosophila	B-Taxon
and	O
Caenorhabditis	B-Taxon
elegans	I-Taxon
have	O
recently	O
yielded	O
evidence	O
that	O
basic	O
phagocytic	O
mechanisms	O
and	O
pathways	O
for	O
the	O
recognition	O
and	O
engulfment	O
of	O
apoptotic	B-CL
cells	I-CL
are	O
highly	O
conserved	O
throughout	O
phylogeny	O
[	O
7	O
,	O
8	O
]	O
.	O

In	O
vertebrates	B-Taxon
,	O
a	O
number	O
of	O
receptors	O
have	O
been	O
identified	O
that	O
can	O
mediate	O
phagocytosis	O
of	O
apoptotic	B-CL
cells	I-CL
.	O

These	O
include	O
,	O
for	O
example	O
,	O
scavenger	O
receptors	O
and	O
pattern	O
recognition	O
receptors	O
such	O
as	O
CD36	B-GGP
,	O
SR	B-GGP
-	I-GGP
A	I-GGP
and	O
CD14	B-GGP
,	O
integrins	B-GO
such	O
as	O
the	O
vitronectin	O
receptor	O
alpha	O
v	O
beta	O
3	O
,	O
and	O
members	O
of	O
the	O
collectin	O
family	O
and	O
their	O
receptors	O
CD91	B-GGP
and	O
calreticulin	B-GGP
[	O
9	O
-	O
13	O
]	O
.	O

The	O
individual	O
roles	O
of	O
these	O
molecules	B-CHEBI
in	O
binding	O
,	O
phagocytosis	O
or	O
transduction	O
of	O
anti	O
-	O
inflammatory	O
signals	O
upon	O
apoptotic	B-CL
cell	I-CL
recognition	O
have	O
not	O
been	O
well	O
defined	O
,	O
however	O
[	O
5	O
,	O
6	O
,	O
14	O
]	O
.	O

The	O
importance	O
of	O
efficient	O
mechanisms	O
for	O
apoptotic	B-CL
cell	I-CL
clearance	O
in	O
vivo	O
is	O
supported	O
by	O
the	O
observation	O
that	O
autoimmune	O
responses	O
can	O
be	O
provoked	O
in	O
mice	B-Taxon
when	O
key	O
molecules	B-CHEBI
for	O
apoptotic	B-CL
cell	I-CL
recognition	O
and	O
uptake	O
are	O
missing	O
.	O

This	O
has	O
been	O
reported	O
for	O
knockout	O
mice	B-Taxon
lacking	O
the	O
complement	O
protein	B-CHEBI
C1q	B-GGP
[	O
15	O
]	O
,	O
for	O
mice	B-Taxon
with	O
a	O
mutation	B-SO
in	O
the	O
tyrosine	B-GGP
kinase	I-GGP
receptor	I-GGP
gene	B-SO
Mer	B-GGP
[	O
16	O
]	O
and	O
,	O
more	O
recently	O
,	O
in	O
mice	B-Taxon
lacking	O
transglutaminase	B-GGP
2	I-GGP
or	O
milk	B-GGP
fat	I-GGP
globule	I-GGP
epidermal	I-GGP
growth	I-GGP
factor	I-GGP
8	I-GGP
(	O
MFG	B-GGP
-	I-GGP
E8	I-GGP
)	O
[	O
17	O
,	O
18	O
]	O
.	O

The	O
exposure	O
of	O
the	O
phospholipid	B-CHEBI
phosphatidylserine	B-CHEBI
(	O
PS	B-CHEBI
)	O
in	O
the	O
outer	O
leaflet	O
of	O
the	O
plasma	B-GO
membrane	I-GO
of	O
apoptotic	B-CL
cells	I-CL
has	O
been	O
described	O
as	O
one	O
of	O
the	O
hallmarks	O
of	O
the	O
induction	O
of	O
apoptosis	O
and	O
is	O
considered	O
to	O
be	O
one	O
of	O
the	O
most	O
important	O
signals	O
required	O
for	O
apoptotic	B-CL
cell	I-CL
recognition	O
and	O
removal	O
[	O
19	O
]	O
.	O

A	O
number	O
of	O
cell	B-GO
-	I-GO
surface	I-GO
and	O
bridging	O
molecules	B-CHEBI
can	O
interact	O
with	O
exposed	O
PS	B-CHEBI
on	O
apoptotic	B-CL
cells	I-CL
.	O

These	O
include	O
the	O
serum	O
proteins	B-CHEBI
beta	B-GGP
2	I-GGP
-	I-GGP
glycoprotein	I-GGP
1	I-GGP
and	O
protein	B-GGP
S	I-GGP
[	O
20	O
,	O
21	O
]	O
,	O
the	O
growth	O
-	O
arrest	O
-	O
specific	O
gene	B-SO
product	O
GAS	B-GGP
-	I-GGP
6	I-GGP
[	O
22	O
]	O
,	O
complement	O
activation	O
products	O
[	O
23	O
]	O
,	O
the	O
milk	O
fat	O
globule	O
protein	B-CHEBI
MFG	B-GGP
-	I-GGP
E8	I-GGP
[	O
24	O
]	O
,	O
and	O
annexin	B-GGP
I	I-GGP
[	O
25	O
]	O
.	O

In	O
most	O
cases	O
the	O
receptors	O
on	O
phagocytes	B-CL
that	O
recognize	O
these	O
PS	B-CHEBI
-	O
bridging	O
molecules	B-CHEBI
have	O
not	O
been	O
defined	O
,	O
but	O
it	O
has	O
been	O
reported	O
that	O
GAS	B-GGP
-	I-GGP
6	I-GGP
is	O
a	O
ligand	O
for	O
the	O
tyrosine	B-GGP
kinase	I-GGP
receptor	I-GGP
Mer	B-GGP
and	O
that	O
MFG	B-GGP
-	I-GGP
E8	I-GGP
can	O
bind	O
to	O
the	O
vitronectin	O
receptor	O
alpha	O
v	O
beta	O
3	O
[	O
16	O
,	O
24	O
]	O
.	O

Other	O
molecules	B-CHEBI
that	O
bind	O
PS	B-CHEBI
with	O
varying	O
specificity	O
are	O
the	O
lectin	B-GGP
-	I-GGP
like	I-GGP
oxidized	I-GGP
low	I-GGP
-	I-GGP
density	I-GGP
lipoprotein	I-GGP
receptor	I-GGP
-	I-GGP
1	I-GGP
(	O
LOX	B-GGP
-	I-GGP
1	I-GGP
)	O
and	O
the	O
scavenger	O
receptors	O
CD36	B-GGP
and	O
CD68	B-GGP
(	O
for	O
review	O
see	O
[	O
5	O
]	O
and	O
references	O
therein	O
)	O
.	O

The	O
best	O
-	O
characterized	O
molecule	B-CHEBI
so	O
far	O
that	O
binds	O
PS	B-CHEBI
in	O
a	O
stereo	O
-	O
specific	O
manner	O
is	O
the	O
phosphatidylserine	B-GGP
receptor	I-GGP
(	O
Ptdsr	B-GGP
)	O
[	O
26	O
]	O
.	O

In	O
vitro	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
Ptdsr	B-GGP
can	O
mediate	O
the	O
uptake	O
of	O
apoptotic	B-CL
cells	I-CL
and	O
that	O
such	O
Ptdsr	B-GGP
-	O
mediated	O
phagocytosis	O
can	O
be	O
inhibited	O
through	O
addition	O
of	O
PS	B-CHEBI
liposomes	O
,	O
the	O
PS	B-CHEBI
-	O
binding	O
molecule	B-CHEBI
annexin	B-GGP
V	I-GGP
or	O
an	O
anti	O
-	O
Ptdsr	B-GGP
antibody	B-GO
[	O
26	O
]	O
.	O

Moreover	O
,	O
the	O
binding	O
of	O
Ptdsr	B-GGP
to	O
PS	B-CHEBI
on	O
apoptotic	B-CL
cells	I-CL
has	O
been	O
reported	O
to	O
be	O
important	O
for	O
the	O
release	O
of	O
anti	B-CHEBI
-	I-CHEBI
inflammatory	I-CHEBI
mediators	I-CHEBI
,	O
including	O
transforming	B-GGP
growth	I-GGP
factor	I-GGP
-	I-GGP
beta	I-GGP
1	I-GGP
(	O
TGF	B-GGP
-	I-GGP
beta	I-GGP
1	I-GGP
)	O
,	O
platelet	B-CL
-	O
activating	O
factor	O
(	O
PAF	O
)	O
,	O
and	O
prostaglandin	B-CHEBI
E2	I-CHEBI
[	O
26	O
,	O
27	O
]	O
.	O

These	O
data	O
supported	O
the	O
hypothesis	O
that	O
Ptdsr	B-GGP
fulfils	O
a	O
role	O
as	O
a	O
crucial	O
signaling	O
switch	O
after	O
the	O
engagement	O
of	O
macrophages	B-CL
with	O
apoptotic	B-CL
cells	I-CL
and	O
is	O
thereby	O
fundamental	O
for	O
preventing	O
local	O
immune	O
responses	O
to	O
apoptotic	B-CL
cells	I-CL
before	O
their	O
clearance	O
[	O
28	O
]	O
.	O

Very	O
recently	O
,	O
Ptdsr	B-GGP
has	O
been	O
found	O
in	O
the	O
cell	B-CL
nucleus	B-GO
.	O

Its	O
nuclear	B-GO
localization	O
is	O
mediated	O
by	O
five	O
independent	O
nuclear	B-GO
localization	O
signals	B-SO
,	O
each	O
of	O
which	O
alone	O
is	O
capable	O
of	O
targeting	O
Ptdsr	B-GGP
to	O
the	O
cell	B-CL
nucleus	B-GO
[	O
29	O
]	O
.	O

Moreover	O
,	O
an	O
additional	O
study	O
performed	O
recently	O
in	O
Hydra	B-Taxon
showed	O
an	O
exclusively	O
nuclear	B-GO
localization	O
for	O
the	O
Ptdsr	B-GGP
protein	B-CHEBI
[	O
30	O
]	O
.	O

Most	O
interestingly	O
,	O
the	O
nuclear	B-GO
localization	O
of	O
Ptdsr	B-GGP
in	O
Hydra	B-Taxon
epithelial	B-CL
cells	I-CL
did	O
not	O
change	O
upon	O
phagocytosis	O
of	O
apoptotic	B-CL
cells	I-CL
.	O

These	O
reports	O
challenge	O
the	O
original	O
hypothesis	O
,	O
according	O
to	O
which	O
Ptdsr	B-GGP
is	O
an	O
exclusively	O
transmembrane	B-GO
receptor	O
for	O
apoptotic	B-CL
cell	I-CL
recognition	O
and	O
anti	O
-	O
inflammatory	O
signaling	O
.	O

To	O
examine	O
further	O
the	O
role	O
of	O
Ptdsr	B-GGP
in	O
vivo	O
,	O
we	O
performed	O
gene	B-SO
-	O
expression	O
and	O
gene	B-SO
-	O
targeting	O
studies	O
in	O
mice	B-Taxon
.	O

A	O
perinatally	O
lethal	O
phenotype	O
was	O
observed	O
in	O
Ptdsr	B-GGP
-	O
knockout	O
mice	B-Taxon
,	O
and	O
Ptdsr	B-GGP
-	O
deficient	O
embryos	O
displayed	O
multiple	O
defects	O
in	O
tissue	O
and	O
organ	O
differentiation	O
.	O

While	O
this	O
work	O
was	O
in	O
progress	O
,	O
both	O
Li	O
et	O
al	O
.	O

[	O
31	O
]	O
and	O
Kunisaki	O
et	O
al	O
.	O

[	O
32	O
]	O
also	O
reported	O
the	O
generation	O
and	O
phenotypic	O
characterization	O
of	O
Ptdsr	B-GGP
-	O
knockout	O
mice	B-Taxon
.	O

Of	O
note	O
,	O
although	O
some	O
of	O
their	O
results	O
were	O
confirmed	O
in	O
our	O
study	O
,	O
we	O
found	O
a	O
fundamentally	O
different	O
phenotype	O
with	O
regard	O
to	O
clearance	O
of	O
apoptotic	B-CL
cells	I-CL
.	O

Moreover	O
,	O
our	O
study	O
revealed	O
marked	O
and	O
unexpected	O
findings	O
in	O
Ptdsr	B-GGP
-	O
deficient	O
mice	B-Taxon
that	O
are	O
not	O
related	O
to	O
apoptosis	O
.	O

Results	O

Generation	O
of	O
Ptdsr	B-GGP
-	O
deficient	O
mice	B-Taxon

To	O
investigate	O
in	O
vivo	O
the	O
functions	O
of	O
the	O
phosphatidylserine	B-GGP
receptor	I-GGP
Ptdsr	B-GGP
,	O
we	O
generated	O
a	O
null	O
allele	B-SO
in	O
the	O
mouse	B-Taxon
by	O
gene	B-SO
targeting	O
(	O
Figure	O
1a	O
,	O
1b	O
,	O
1c	O
)	O
.	O

In	O
contrast	O
to	O
previously	O
described	O
Ptdsr	B-GGP
-	O
knockout	O
mice	B-Taxon
[	O
31	O
,	O
32	O
]	O
,	O
we	O
used	O
Bruce4	O
embryonic	O
stem	B-CL
(	I-CL
ES	I-CL
)	I-CL
cells	I-CL
for	O
gene	B-SO
targeting	O
[	O
33	O
]	O
,	O
thus	O
generating	O
a	O
Ptdsr	B-GGP
-	O
null	O
allele	B-SO
in	O
a	O
pure	O
,	O
isogenic	O
C57BL	O
/	O
6J	O
genetic	B-SO
background	O
.	O

The	O
newly	O
established	O
knockout	O
mouse	B-Taxon
line	O
was	O
named	O
Ptdsrtm1Gbf	O
(	O
hereafter	O
referred	O
to	O
as	O
Ptdsr	B-GGP
-	O
/	O
-	O
)	O
.	O

Heterozygous	O
Ptdsr	B-GGP
+	B-SO
/	O
-	O
mice	B-Taxon
were	O
viable	O
and	O
fertile	O
and	O
showed	O
no	O
obvious	O
abnormalities	O
.	O

Ptdsr	B-GGP
+	B-SO
/	O
-	O
mice	B-Taxon
were	O
intercrossed	O
to	O
generate	O
homozygous	O
Ptdsr	B-GGP
-	O
deficient	O
mice	B-Taxon
.	O

The	O
absence	O
of	O
Ptdsr	B-GGP
expression	O
in	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
was	O
confirmed	O
by	O
RT	O
-	O
PCR	O
(	O
data	O
not	O
shown	O
)	O
,	O
and	O
by	O
northern	O
and	O
western	O
blotting	O
analyses	O
(	O
Figure	O
1d	O
,	O
e	O
)	O
.	O

Interbreeding	O
of	O
heterozygous	O
mice	B-Taxon
showed	O
that	O
the	O
mutation	B-SO
was	O
lethal	O
,	O
since	O
homozygous	O
mutants	O
were	O
not	O
detected	O
in	O
over	O
100	O
analyzed	O
litters	O
at	O
weaning	O
.	O

To	O
determine	O
the	O
stages	O
of	O
embryonic	O
development	O
affected	O
by	O
the	O
Ptdsrtm1Gbf	O
mutation	B-SO
,	O
timed	O
breedings	O
were	O
followed	O
by	O
PCR	O
genotyping	O
(	O
Figure	O
1c	O
)	O
of	O
embryos	O
.	O

We	O
recovered	O
fewer	O
than	O
the	O
expected	O
number	O
of	O
homozygous	O
embryos	O
from	O
intercrosses	O
of	O
Ptdsr	B-GGP
+	B-SO
/	O
-	O
mice	B-Taxon
.	O

From	O
a	O
total	O
of	O
1	O
,	O
031	O
embryos	O
analyzed	O
between	O
gestational	O
day	O
(	O
E	O
)	O
9	O
.	O
5	O
and	O
E18	O
.	O
5	O
,	O
198	O
(	O
19	O
.	O
2	O
%	O
)	O
Ptdsr	B-GGP
-	O
deficient	O
homozygous	O
embryos	O
were	O
harvested	O
,	O
indicating	O
that	O
the	O
introduced	O
mutation	B-SO
is	O
associated	O
with	O
a	O
low	O
rate	O
of	O
embryonic	O
lethality	O
in	O
utero	O
.	O

From	O
E9	O
.	O
5	O
to	O
E12	O
.	O
5	O
,	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
were	O
viable	O
and	O
of	O
normal	O
size	O
.	O

At	O
E13	O
.	O
5	O
and	O
thereafter	O
,	O
however	O
,	O
most	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
showed	O
morphological	O
abnormalities	O
(	O
Table	O
1	O
)	O
.	O

All	O
homozygous	O
embryos	O
harvested	O
were	O
growth	O
-	O
retarded	O
from	O
E13	O
.	O
5	O
onwards	O
,	O
had	O
a	O
pale	O
appearance	O
,	O
and	O
displayed	O
multiple	O
developmental	O
dysmorphologies	O
.	O

These	O
included	O
various	O
head	O
and	O
craniofacial	O
malformations	O
,	O
such	O
as	O
exencephaly	O
,	O
cleft	O
palate	O
and	O
abnormal	O
head	O
shape	O
(	O
Figure	O
1f	O
,	O
g	O
)	O
.	O

Gross	O
inspection	O
revealed	O
that	O
eye	O
development	O
was	O
severely	O
affected	O
in	O
14	O
.	O
1	O
%	O
of	O
homozygous	O
embryos	O
.	O

The	O
affected	O
animals	B-Taxon
displayed	O
a	O
complete	O
unilateral	O
or	O
bilateral	O
absence	O
of	O
the	O
eyes	O
(	O
Table	O
1	O
)	O
that	O
was	O
never	O
detected	O
in	O
Ptdsr	B-GGP
+	B-SO
/	O
+	B-SO
or	O
Ptdsr	B-GGP
+	B-SO
/	O
-	O
littermates	O
.	O

Furthermore	O
,	O
homozygous	O
embryos	O
harvested	O
between	O
E12	O
.	O
5	O
and	O
E15	O
.	O
5	O
had	O
subcutaneous	O
edema	O
(	O
Figure	O
1f	O
,	O
g	O
)	O
.	O

Because	O
we	O
were	O
able	O
to	O
recover	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
until	O
E18	O
.	O
5	O
,	O
we	O
investigated	O
whether	O
Ptdsr	B-GGP
-	O
knockout	O
mice	B-Taxon
could	O
be	O
born	O
alive	O
.	O

Careful	O
observation	O
of	O
timed	O
matings	O
allowed	O
us	O
to	O
recover	O
Ptdsr	B-GGP
-	O
/	O
-	O
neonates	O
,	O
but	O
homozygous	O
pups	O
died	O
during	O
delivery	O
or	O
within	O
minutes	O
after	O
birth	O
.	O

Ptdsr	B-GGP
-	O
deficient	O
neonates	O
were	O
also	O
growth	O
-	O
retarded	O
,	O
had	O
a	O
pale	O
appearance	O
and	O
displayed	O
various	O
malformations	O
.	O

These	O
included	O
cleft	O
palate	O
,	O
abnormal	O
head	O
shape	O
,	O
absence	O
of	O
eyes	O
and	O
edematous	O
skin	O
(	O
Figure	O
1h	O
)	O
.	O

Thus	O
,	O
deletion	B-SO
of	O
the	O
Ptdsr	B-GGP
gene	B-SO
resulted	O
in	O
perinatal	O
lethality	O
with	O
variable	O
severity	O
and	O
penetrance	O
of	O
phenotypes	O
.	O

Expression	O
of	O
Ptdsr	B-GGP
during	O
embryogenesis	O
and	O
in	O
adult	O
tissues	O

The	O
observed	O
perinatal	O
lethality	O
indicates	O
that	O
Ptdsr	B-GGP
plays	O
an	O
important	O
role	O
during	O
development	O
.	O

Analysis	O
by	O
RT	O
-	O
PCR	O
(	O
data	O
not	O
shown	O
)	O
showed	O
that	O
Ptdsr	B-GGP
is	O
expressed	O
early	O
in	O
development	O
,	O
because	O
we	O
were	O
able	O
to	O
detect	O
Ptdsr	B-GGP
transcripts	B-SO
in	O
ES	O
cells	B-CL
and	O
embryos	O
at	O
all	O
developmental	O
stages	O
.	O

To	O
analyze	O
in	O
more	O
detail	O
the	O
temporal	O
and	O
spatial	O
expression	O
patterns	O
of	O
Ptdsr	B-GGP
,	O
and	O
to	O
correlate	O
expression	O
patterns	O
with	O
observed	O
pathological	O
malformations	O
,	O
we	O
made	O
use	O
of	O
a	O
Ptdsr	B-GGP
-	O
beta	O
-	O
geo	O
gene	B-SO
-	O
trap	O
reporter	O
mouse	B-Taxon
line	O
generated	O
from	O
a	O
Ptdsr	B-GGP
gene	B-SO
-	O
trap	O
ES	O
cell	B-CL
clone	O
.	O

This	O
line	O
has	O
an	O
insertion	B-SO
of	O
beta	O
-	O
galactosidase	O
in	O
the	O
3	O
'	O
region	B-SO
of	I-SO
the	I-SO
gene	I-SO
(	O
Figure	O
2a	O
)	O
.	O

We	O
first	O
examined	O
Ptdsr	B-GGP
expression	O
by	O
X	O
-	O
Gal	O
staining	O
in	O
heterozygous	O
embryos	O
staged	O
from	O
E9	O
.	O
5	O
to	O
E12	O
.	O
5	O
.	O

These	O
developmental	O
stages	O
were	O
chosen	O
so	O
as	O
to	O
investigate	O
Ptdsr	B-GGP
expression	O
in	O
affected	O
organs	O
prior	O
to	O
the	O
onset	O
of	O
pathological	O
malformations	O
in	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
.	O

At	O
E9	O
.	O
5	O
we	O
found	O
Ptdsr	B-GGP
expression	O
in	O
the	O
developing	O
neural	O
tube	O
,	O
somites	O
,	O
heart	O
,	O
gut	O
and	O
branchial	O
arches	O
(	O
Figure	O
2b	O
)	O
.	O

At	O
E10	O
.	O
5	O
,	O
Ptdsr	B-GGP
expression	O
remained	O
high	O
in	O
the	O
developing	O
nervous	O
system	O
,	O
with	O
most	O
intense	O
staining	O
in	O
the	O
forebrain	O
,	O
hindbrain	O
and	O
neural	O
tube	O
.	O

At	O
this	O
stage	O
of	O
embryogenesis	O
,	O
high	O
levels	O
of	O
Ptdsr	B-GGP
expression	O
could	O
also	O
be	O
detected	O
in	O
the	O
developing	O
limb	O
buds	O
and	O
eyes	O
(	O
Figure	O
2b	O
)	O
.	O

Ptdsr	B-GGP
expression	O
was	O
altered	O
at	O
E12	O
.	O
5	O
,	O
with	O
most	O
intensive	O
beta	O
-	O
galactosidase	O
staining	O
in	O
the	O
eyes	O
,	O
developing	O
condensations	O
of	O
the	O
limb	O
buds	O
,	O
neural	O
tube	O
and	O
brain	O
(	O
Figure	O
2b	O
)	O
.	O

Transverse	O
sections	O
of	O
X	O
-	O
Gal	O
-	O
stained	O
embryos	O
at	O
E12	O
.	O
5	O
showed	O
an	O
asymmetric	O
expression	O
pattern	O
in	O
the	O
neural	O
tube	O
with	O
intense	O
staining	O
of	O
the	O
central	O
mantle	O
layer	O
but	O
no	O
expression	O
in	O
the	O
dorsal	O
part	O
of	O
the	O
neural	O
tube	O
(	O
for	O
example	O
,	O
the	O
roof	O
plate	O
;	O
Figure	O
2c	O
)	O
.	O

Expression	O
in	O
dorsal	O
root	O
ganglia	O
lateral	O
to	O
the	O
neural	O
tube	O
and	O
in	O
the	O
somites	O
was	O
observed	O
;	O
Ptdsr	B-GGP
was	O
expressed	O
throughout	O
the	O
somite	O
structure	O
(	O
myotome	O
,	O
dermatome	O
and	O
sclerotome	O
;	O
Figure	O
2d	O
)	O
.	O

Expression	O
boundaries	O
between	O
somites	O
were	O
evident	O
,	O
with	O
no	O
expression	O
in	O
the	O
segmental	O
interzones	O
,	O
which	O
correspond	O
to	O
the	O
prospective	O
intervertebral	O
discs	O
(	O
Figure	O
2d	O
)	O
.	O

Transverse	O
sections	O
of	O
the	O
developing	O
eye	O
at	O
E12	O
.	O
5	O
revealed	O
strong	O
Ptdsr	B-GGP
expression	O
in	O
the	O
inner	O
layer	O
of	O
the	O
neural	O
cup	O
,	O
which	O
will	O
later	O
develop	O
into	O
the	O
neural	O
retina	O
.	O

Furthermore	O
,	O
Ptdsr	B-GGP
expression	O
was	O
detected	O
in	O
the	O
primary	O
lens	O
fiber	O
cells	B-CL
of	O
the	O
developing	O
lens	O
(	O
Figure	O
2e	O
)	O
.	O

We	O
carefully	O
investigated	O
whether	O
Ptdsr	B-GGP
is	O
expressed	O
from	O
E10	O
.	O
5	O
to	O
E12	O
.	O
5	O
in	O
the	O
developing	O
kidney	O
and	O
lungs	O
,	O
but	O
no	O
expression	O
could	O
be	O
detected	O
indicating	O
that	O
Ptdsr	B-GGP
expression	O
is	O
required	O
only	O
at	O
later	O
stages	O
in	O
the	O
development	O
of	O
these	O
organs	O
(	O
see	O
below	O
)	O
.	O

Hybridization	O
of	O
a	O
multiple	O
-	O
tissue	O
northern	O
blot	O
revealed	O
a	O
single	O
transcript	B-SO
of	O
about	O
1	O
.	O
8	O
kb	O
in	O
almost	O
every	O
tissue	O
analyzed	O
in	O
adult	O
mice	B-Taxon
(	O
Figure	O
2f	O
)	O
.	O

The	O
most	O
prominent	O
expression	O
was	O
observed	O
in	O
testis	O
,	O
thymus	O
,	O
kidney	O
,	O
liver	O
and	O
skin	O
,	O
with	O
moderate	O
to	O
low	O
expression	O
in	O
lung	O
,	O
small	O
intestine	O
,	O
spleen	O
,	O
stomach	O
and	O
skeletal	O
muscle	O
.	O

Thus	O
,	O
Ptdsr	B-GGP
is	O
ubiquitously	O
expressed	O
throughout	O
embryogenesis	O
and	O
in	O
adult	O
tissues	O
,	O
although	O
at	O
different	O
levels	O
.	O

Ptdsr	B-GGP
is	O
required	O
for	O
normal	O
tissue	O
and	O
organ	O
differentiation	O

We	O
next	O
examined	O
the	O
role	O
of	O
Ptdsr	B-GGP
in	O
organ	O
development	O
.	O

Serial	O
histological	O
sections	O
of	O
Ptdsr	B-GGP
-	O
/	O
-	O
and	O
control	O
embryos	O
were	O
taken	O
to	O
perform	O
a	O
detailed	O
morphological	O
analysis	O
of	O
all	O
organ	O
systems	O
during	O
development	O
.	O

A	O
significant	O
delay	O
in	O
organ	O
and	O
tissue	O
differentiation	O
was	O
observed	O
at	O
E16	O
.	O
5	O
in	O
lungs	O
,	O
kidneys	O
and	O
intestine	O
.	O

Lungs	O
of	O
control	O
littermates	O
were	O
properly	O
developed	O
with	O
expanding	O
alveoli	O
(	O
Figure	O
3a	O
)	O
.	O

Terminal	O
bronchi	O
and	O
bronchioles	O
were	O
already	O
well	O
developed	O
,	O
and	O
terminally	O
differentiated	O
epithelial	B-CL
cells	I-CL
with	O
cilia	B-GO
on	O
the	O
luminal	O
cell	B-GO
surface	I-GO
were	O
present	O
.	O

In	O
contrast	O
,	O
almost	O
no	O
alveoli	O
or	O
bronchioles	O
were	O
present	O
in	O
Ptdsr	B-GGP
-	O
/	O
-	O
lungs	O
,	O
indicating	O
a	O
delay	O
or	O
arrest	O
in	O
lung	O
sacculation	O
and	O
expansion	O
.	O

Instead	O
,	O
we	O
observed	O
an	O
abundance	O
of	O
mesenchyme	O
that	O
appeared	O
highly	O
immature	O
(	O
Figure	O
3g	O
)	O
.	O

A	O
similar	O
delay	O
in	O
tissue	O
differentiation	O
of	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
was	O
found	O
in	O
the	O
kidneys	O
(	O
Figure	O
3h	O
)	O
.	O

Kidneys	O
from	O
Ptdsr	B-GGP
+	B-SO
/	O
+	B-SO
embryos	O
were	O
well	O
developed	O
at	O
E16	O
.	O
5	O
,	O
showing	O
terminally	O
differentiated	O
glomeruli	O
with	O
Bowman	O
'	O
s	O
capsule	O
and	O
collecting	O
tubules	O
lined	O
with	O
cuboidal	O
epithelial	B-CL
cells	I-CL
(	O
Figure	O
3b	O
)	O
.	O

In	O
contrast	O
,	O
Ptdsr	B-GGP
-	O
deficient	O
kidneys	O
had	O
only	O
primitive	O
glomeruli	O
at	O
E16	O
.	O
5	O
,	O
and	O
collecting	O
tubules	O
were	O
less	O
well	O
-	O
developed	O
.	O

Instead	O
,	O
a	O
large	O
amount	O
of	O
undifferentiated	O
mesenchyme	O
was	O
present	O
in	O
Ptdsr	B-GGP
-	O
/	O
-	O
kidneys	O
(	O
Figure	O
3h	O
)	O
.	O

A	O
delay	O
in	O
tissue	O
differentiation	O
was	O
also	O
found	O
in	O
the	O
intestine	O
at	O
this	O
stage	O
of	O
development	O
.	O

Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
displayed	O
improperly	O
developed	O
villi	O
and	O
an	O
underdeveloped	O
or	O
absent	O
submucosa	O
(	O
Figure	O
3i	O
)	O
.	O

In	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
(	O
Figure	O
3c	O
)	O
,	O
intestinal	O
cellular	B-CL
differentiation	O
was	O
already	O
highly	O
organized	O
,	O
with	O
intramural	O
ganglion	O
cells	B-CL
between	O
the	O
external	O
and	O
internal	O
muscular	O
layers	O
.	O

Such	O
neuronal	B-CL
cells	I-CL
were	O
absent	O
from	O
the	O
intestine	O
of	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
(	O
Figure	O
3i	O
)	O
,	O
however	O
.	O

Some	O
Ptdsr	B-GGP
-	O
/	O
-	O
mice	B-Taxon
(	O
4	O
.	O
5	O
%	O
)	O
also	O
displayed	O
extensive	O
brain	O
malformations	O
that	O
resulted	O
in	O
externally	O
visible	O
head	O
abnormalities	O
,	O
with	O
occasional	O
ectopic	O
tissue	O
outside	O
the	O
skull	O
or	O
exencephaly	O
(	O
Figure	O
1f	O
,	O
h	O
)	O
.	O

Histological	O
analysis	O
revealed	O
an	O
extensive	O
hyperplasia	O
of	O
brain	O
tissue	O
with	O
herniation	O
of	O
brain	O
tissue	O
either	O
through	O
the	O
skull	O
-	O
cap	O
or	O
through	O
the	O
ventral	O
skull	O
(	O
Figure	O
3d	O
,	O
j	O
)	O
.	O

In	O
the	O
most	O
severe	O
cases	O
,	O
expansion	O
of	O
brain	O
tissue	O
in	O
mutant	B-SO
mice	B-Taxon
resulted	O
in	O
further	O
perturbations	O
of	O
cortical	O
structures	O
(	O
Figure	O
3d	O
,	O
j	O
)	O
.	O

Of	O
note	O
,	O
a	O
similar	O
brain	O
phenotype	O
was	O
observed	O
in	O
the	O
Ptdsr	B-GGP
-	O
deficient	O
mouse	B-Taxon
line	O
generated	O
by	O
Li	O
and	O
colleagues	O
[	O
31	O
]	O
.	O

In	O
contrast	O
to	O
the	O
study	O
of	O
Li	O
et	O
al	O
.	O

[	O
31	O
]	O
,	O
however	O
,	O
we	O
found	O
almost	O
normally	O
developed	O
lungs	O
at	O
birth	O
.	O

Ptdsr	B-GGP
-	O
/	O
-	O
lungs	O
showed	O
,	O
in	O
comparison	O
to	O
wild	B-SO
-	I-SO
type	I-SO
,	O
only	O
a	O
slight	O
delay	O
in	O
maturation	O
and	O
were	O
fully	O
ventilated	O
in	O
neonates	O
in	O
most	O
cases	O
(	O
Figure	O
3e	O
,	O
k	O
)	O
.	O

This	O
demonstrates	O
that	O
Ptdsr	B-GGP
-	O
deficient	O
mice	B-Taxon
can	O
overcome	O
the	O
delay	O
in	O
embryonic	O
lung	O
differentiation	O
and	O
display	O
normal	O
lung	O
morphology	O
at	O
birth	O
.	O

Thus	O
,	O
it	O
would	O
appear	O
highly	O
unlikely	O
that	O
Ptdsr	B-GGP
-	O
/	O
-	O
mice	B-Taxon
die	O
from	O
respiratory	O
failure	O
.	O

Consistent	O
with	O
the	O
observations	O
of	O
Kunisaki	O
and	O
colleagues	O
[	O
32	O
]	O
,	O
we	O
found	O
severely	O
blocked	O
erythropoietic	O
differentiation	O
at	O
an	O
early	B-CL
erythroblast	I-CL
stage	O
in	O
the	O
liver	O
(	O
Figure	O
3f	O
,	O
3l	O
)	O
,	O
suggesting	O
an	O
explanation	O
for	O
the	O
grossly	O
anemic	O
appearance	O
that	O
we	O
observed	O
in	O
our	O
Ptdsr	B-GGP
-	O
/	O
-	O
mice	B-Taxon
.	O

Loss	O
of	O
Ptdsr	B-GGP
activity	O
is	O
associated	O
with	O
defects	O
in	O
ocular	O
development	O
and	O
can	O
lead	O
to	O
formation	O
of	O
ectopic	O
eye	O
structures	O

By	O
gross	O
morphology	O
we	O
could	O
differentiate	O
two	O
classes	O
of	O
Ptdsr	B-GGP
mutants	B-SO
:	O
those	O
that	O
appeared	O
normal	O
with	O
both	O
eyes	O
present	O
(	O
Figure	O
4	O
)	O
and	O
those	O
that	O
were	O
severely	O
affected	O
and	O
displayed	O
uni	O
-	O
or	O
bilateral	O
anophthalmia	O
(	O
Figure	O
5	O
)	O
.	O

Analysis	O
of	O
normal	O
or	O
mildly	O
affected	O
embryos	O
revealed	O
no	O
differences	O
between	O
mutant	B-SO
and	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
in	O
the	O
differentiation	O
of	O
the	O
developing	O
eye	O
until	O
E16	O
.	O
5	O
.	O

In	O
both	O
genotypes	B-SO
,	O
inner	O
and	O
outer	O
layers	O
of	O
the	O
retina	O
displayed	O
a	O
comparable	O
differentiation	O
status	O
,	O
as	O
shown	O
,	O
for	O
example	O
,	O
at	O
E12	O
.	O
5	O
(	O
Figure	O
4a	O
,	O
e	O
)	O
.	O

At	O
day	O
E16	O
.	O
5	O
,	O
however	O
,	O
retinal	O
layers	O
in	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
were	O
much	O
thinner	O
than	O
in	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
,	O
contained	O
fewer	O
cells	B-CL
and	O
were	O
greatly	O
reduced	O
in	O
size	O
(	O
Figure	O
4b	O
,	O
f	O
)	O
.	O

Comparison	O
of	O
the	O
retinal	O
structures	O
of	O
Ptdsr	B-GGP
+	B-SO
/	O
+	B-SO
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
revealed	O
that	O
all	O
four	O
retinal	O
layers	O
were	O
present	O
in	O
Ptdsr	B-GGP
-	O
knockout	O
mice	B-Taxon
at	O
E16	O
.	O
5	O
(	O
Figure	O
4b	O
,	O
f	O
)	O
.	O

At	O
E18	O
.	O
5	O
(	O
Figure	O
4c	O
,	O
g	O
)	O
and	O
in	O
neonatal	O
animals	B-Taxon
(	O
postnatal	O
day	O
P0	O
;	O
Figure	O
4d	O
,	O
h	O
)	O
,	O
the	O
differences	O
in	O
retinal	O
differentiation	O
between	O
Ptdsr	B-GGP
+	B-SO
/	O
+	B-SO
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
mice	B-Taxon
were	O
still	O
evident	O
,	O
but	O
the	O
size	O
reduction	O
of	O
the	O
retinal	O
layers	O
was	O
less	O
pronounced	O
in	O
the	O
knockout	O
mice	B-Taxon
.	O

Ptdsr	B-GGP
-	O
deficient	O
animals	B-Taxon
seem	O
to	O
have	O
compensated	O
for	O
the	O
marked	O
delay	O
in	O
cellular	B-CL
differentiation	O
and	O
expansion	O
of	O
retinal	O
layers	O
.	O

Close	O
examination	O
of	O
retinal	O
structures	O
revealed	O
that	O
the	O
inner	O
granular	O
layer	O
was	O
still	O
less	O
expanded	O
in	O
Ptdsr	B-GGP
-	O
deficient	O
animals	B-Taxon
,	O
however	O
,	O
and	O
that	O
it	O
contained	O
fewer	O
cells	B-CL
and	O
was	O
still	O
severely	O
underdeveloped	O
in	O
comparison	O
with	O
the	O
corresponding	O
retinal	O
layer	O
in	O
control	O
animals	B-Taxon
(	O
Figure	O
4c	O
,	O
4g	O
and	O
4d	O
,	O
4h	O
)	O
.	O

Thus	O
,	O
even	O
mildly	O
affected	O
Ptdsr	B-GGP
-	O
/	O
-	O
mutants	B-SO
had	O
ocular	O
malformations	O
with	O
defects	O
in	O
differentiation	O
of	O
retinal	O
structures	O
.	O

We	O
next	O
examined	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
that	O
displayed	O
unilateral	O
or	O
bilateral	O
absence	O
of	O
eyes	O
(	O
Figure	O
5a	O
)	O
by	O
serial	O
sectioning	O
of	O
whole	O
embryos	O
.	O

These	O
embryos	O
showed	O
complex	O
malformations	O
of	O
the	O
optical	O
cup	O
,	O
including	O
absence	O
of	O
the	O
lens	O
(	O
Figure	O
5b	O
)	O
.	O

Most	O
surprisingly	O
,	O
we	O
found	O
pigmented	B-CL
epithelial	I-CL
cells	I-CL
in	O
the	O
nasal	O
cavity	O
of	O
all	O
Ptdsr	B-GGP
-	O
knockout	O
mice	B-Taxon
with	O
anophthalmia	O
that	O
were	O
analyzed	O
histopathologically	O
.	O

We	O
could	O
identify	O
black	O
-	O
colored	O
pigmented	B-CL
cells	I-CL
embedded	O
in	O
the	O
epithelium	O
of	O
the	O
maxillary	O
sinus	O
that	O
resembled	O
presumptive	O
retinal	O
-	O
pigmented	O
epithelium	O
(	O
Figure	O
5b	O
,	O
c	O
)	O
.	O

Examination	O
of	O
consecutive	O
serial	O
sections	O
revealed	O
the	O
formation	O
of	O
a	O
primitive	O
eye	O
structure	O
,	O
with	O
induction	O
and	O
subsequent	O
proliferation	O
of	O
ectopic	O
mesenchymal	O
tissue	O
immediately	O
adjacent	O
to	O
the	O
displaced	O
pigmented	O
epithelium	O
(	O
Figure	O
5d	O
)	O
.	O

This	O
structure	O
was	O
clearly	O
induced	O
ectopically	O
,	O
and	O
we	O
failed	O
to	O
identify	O
similar	O
changes	O
in	O
any	O
of	O
the	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
.	O

In	O
summary	O
,	O
we	O
observed	O
a	O
wide	O
range	O
of	O
ocular	O
malformations	O
in	O
Ptdsr	B-GGP
-	O
deficient	O
mice	B-Taxon
that	O
ranged	O
from	O
differentiation	O
defects	O
in	O
retinal	O
cell	B-CL
layers	O
(	O
for	O
example	O
,	O
the	O
inner	O
granular	O
layer	O
)	O
in	O
mildly	O
affected	O
homozygotes	O
to	O
anophthalmia	O
in	O
severely	O
affected	O
Ptdsr	B-GGP
-	O
/	O
-	O
mice	B-Taxon
that	O
was	O
associated	O
with	O
induction	O
of	O
ectopic	O
eye	O
structures	O
in	O
nasal	O
cavities	O
.	O

Phagocytosis	O
and	O
clearance	O
of	O
apoptotic	B-CL
cells	I-CL
is	O
normal	O
in	O
Ptdsr	B-GGP
-	O
deficient	O
mice	B-Taxon

We	O
next	O
tested	O
whether	O
Ptdsr	B-GGP
is	O
functionally	O
required	O
for	O
the	O
clearance	O
of	O
apoptotic	B-CL
cells	I-CL
.	O

We	O
started	O
with	O
an	O
investigation	O
of	O
cell	B-CL
death	O
in	O
vivo	O
in	O
the	O
interdigital	O
areas	O
of	O
the	O
developing	O
limbs	O
.	O

Apoptosis	O
of	O
interdigital	O
cells	B-CL
in	I-CL
the	I-CL
distal	I-CL
mesenchyme	I-CL
of	O
limb	O
buds	O
occurs	O
most	O
prominently	O
from	O
developmental	O
stages	O
E12	O
.	O
0	O
to	O
E13	O
.	O
5	O
and	O
can	O
be	O
easily	O
examined	O
in	O
situ	O
by	O
whole	O
-	O
mount	O
terminal	B-GGP
deoxynucleotide	I-GGP
transferase	I-GGP
-	O
mediated	O
UTP	B-CHEBI
end	O
-	O
labeling	O
(	O
TUNEL	O
)	O
.	O

We	O
compared	O
the	O
pattern	O
of	O
interdigital	O
cell	B-CL
death	O
in	O
fore	O
and	O
hind	O
limb	O
buds	O
from	O
Ptdsr	B-GGP
-	O
/	O
-	O
(	O
n	O
=	O
3	O
)	O
and	O
Ptdsr	B-GGP
+	B-SO
/	O
+	B-SO
(	O
n	O
=	O
3	O
)	O
mice	B-Taxon
at	O
E12	O
.	O
5	O
and	O
E13	O
.	O
5	O
.	O

No	O
differences	O
in	O
accumulation	O
of	O
TUNEL	O
-	O
positive	O
cell	B-CL
corpses	O
were	O
observed	O
between	O
the	O
two	O
genotypes	B-SO
(	O
Figure	O
6a	O
)	O
.	O

The	O
kinetics	O
of	O
cell	B-CL
death	O
occurrence	O
and	O
regression	O
of	O
the	O
interdigital	O
web	O
was	O
similar	O
in	O
wild	B-SO
-	I-SO
type	I-SO
and	O
mutant	B-SO
littermates	O
,	O
providing	O
no	O
evidence	O
that	O
Ptdsr	B-GGP
-	O
deficiency	O
is	O
associated	O
with	O
impaired	O
clearance	O
of	O
apoptotic	B-CL
interdigital	I-CL
cells	I-CL
during	O
limb	O
development	O
.	O

To	O
investigate	O
further	O
whether	O
removal	O
of	O
apoptotic	B-CL
cells	I-CL
is	O
impaired	O
in	O
Ptdsr	B-GGP
-	O
/	O
-	O
mice	B-Taxon
,	O
we	O
stained	O
immunohistochemically	O
for	O
activated	B-GGP
caspase	I-GGP
3	I-GGP
(	O
aCasp3	B-GGP
)	O
and	O
analyzed	O
additional	O
organs	O
and	O
tissues	O
where	O
apoptosis	O
plays	O
a	O
crucial	O
role	O
in	O
tissue	O
remodeling	O
during	O
development	O
.	O

Starting	O
at	O
E12	O
.	O
5	O
,	O
we	O
analyzed	O
and	O
compared	O
the	O
number	O
and	O
distribution	O
of	O
aCasp3	B-GGP
-	O
positive	O
cells	B-CL
in	O
over	O
140	O
serial	O
sections	O
of	O
three	O
wild	B-SO
-	I-SO
type	I-SO
and	O
six	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
in	O
consecutive	O
and	O
corresponding	O
sections	O
.	O

The	O
sagittal	O
sections	O
were	O
separated	O
by	O
5	O
mu	O
m	O
,	O
allowing	O
a	O
detailed	O
analysis	O
of	O
apoptosis	O
in	O
several	O
organs	O
and	O
tissues	O
.	O

Tissue	O
restructuring	O
by	O
programmed	O
cell	B-CL
death	O
occurred	O
most	O
notably	O
within	O
the	O
ventral	O
part	O
of	O
the	O
neural	O
tube	O
(	O
Figure	O
6b	O
,	O
f	O
)	O
and	O
in	O
the	O
developing	O
paravertebral	O
ganglia	O
(	O
Figure	O
6d	O
,	O
h	O
)	O
with	O
many	O
apoptotic	B-CL
cells	I-CL
being	O
present	O
.	O

In	O
these	O
tissues	O
Ptdsr	B-GGP
is	O
highly	O
expressed	O
at	O
E12	O
.	O
5	O
(	O
Figure	O
2c	O
)	O
but	O
we	O
observed	O
no	O
difference	O
in	O
the	O
number	O
or	O
distribution	O
of	O
apoptotic	B-CL
cells	I-CL
in	O
Ptdsr	B-GGP
+	B-SO
/	O
+	B-SO
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
.	O

The	O
same	O
was	O
true	O
for	O
the	O
developing	O
kidney	O
:	O
apoptotic	B-CL
cells	I-CL
were	O
present	O
in	O
Ptdsr	B-GGP
+	B-SO
/	O
+	B-SO
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
,	O
in	O
limited	O
numbers	O
,	O
but	O
we	O
failed	O
to	O
detect	O
any	O
differences	O
in	O
the	O
number	O
of	O
apoptotic	B-CL
cells	I-CL
between	O
the	O
genotypes	B-SO
(	O
Figure	O
6c	O
,	O
6g	O
)	O
.	O

Furthermore	O
,	O
when	O
we	O
continued	O
our	O
analysis	O
of	O
apoptotic	B-CL
cell	I-CL
clearance	O
in	O
vivo	O
at	O
E16	O
.	O
5	O
,	O
E17	O
.	O
5	O
and	O
E18	O
.	O
5	O
of	O
embryonic	O
development	O
as	O
well	O
as	O
in	O
neonatal	O
mice	B-Taxon
,	O
the	O
number	O
and	O
distribution	O
of	O
apoptotic	B-CL
cells	I-CL
was	O
similar	O
in	O
both	O
genotypes	B-SO
.	O

As	O
already	O
observed	O
at	O
E12	O
.	O
5	O
,	O
analysis	O
of	O
aCasp3	B-GGP
-	O
stained	O
sections	O
of	O
the	O
developing	O
thymus	O
,	O
heart	O
,	O
diaphragm	O
,	O
genital	O
ridge	O
,	O
eyes	O
and	O
retina	O
convincingly	O
showed	O
that	O
there	O
was	O
no	O
impairment	O
in	O
apoptotic	B-CL
cell	I-CL
removal	O
in	O
Ptdsr	B-GGP
-	O
/	O
-	O
mice	B-Taxon
.	O

Moreover	O
,	O
because	O
Li	O
and	O
colleagues	O
[	O
31	O
]	O
reported	O
impaired	O
clearance	O
of	O
dead	O
cells	B-CL
during	O
lung	O
development	O
in	O
Ptdsr	B-GGP
-	O
deficient	O
mice	B-Taxon
,	O
we	O
examined	O
the	O
rate	O
of	O
apoptosis	O
induction	O
and	O
cell	B-CL
clearance	O
in	O
our	O
Ptdsr	B-GGP
-	O
knockout	O
mice	B-Taxon
in	O
the	O
lung	O
.	O

Analysis	O
of	O
aCasp3	B-GGP
-	O
stained	O
lung	O
tissue	O
from	O
Ptdsr	B-GGP
+	B-SO
/	O
+	B-SO
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
mice	B-Taxon
at	O
E17	O
.	O
5	O
and	O
P0	O
demonstrated	O
that	O
apoptosis	O
was	O
an	O
extremely	O
rare	O
event	O
during	O
lung	O
morphogenesis	O
at	O
this	O
stage	O
.	O

In	O
addition	O
,	O
there	O
were	O
no	O
differences	O
in	O
the	O
number	O
or	O
distribution	O
of	O
apoptotic	B-CL
cells	I-CL
in	O
Ptdsr	B-GGP
-	O
/	O
-	O
and	O
Ptdsr	B-GGP
+	B-SO
/	O
+	B-SO
mice	B-Taxon
.	O

Furthermore	O
,	O
we	O
were	O
unable	O
to	O
detect	O
any	O
evidence	O
of	O
tissue	O
necrosis	O
in	O
lungs	O
from	O
Ptdsr	B-GGP
-	O
deficient	O
mice	B-Taxon
.	O

In	O
contrast	O
to	O
the	O
report	O
of	O
Li	O
et	O
al	O
.	O

[	O
31	O
]	O
,	O
we	O
never	O
observed	O
recruitment	O
of	O
neutrophils	B-CL
or	O
other	O
signs	O
of	O
pulmonary	O
inflammation	O
at	O
any	O
stage	O
of	O
development	O
in	O
our	O
Ptdsr	B-GGP
-	O
deficient	O
mice	B-Taxon
.	O

To	O
analyze	O
whether	O
macrophages	B-CL
are	O
recruited	O
into	O
areas	O
where	O
apoptosis	O
is	O
prominent	O
during	O
embryogenesis	O
,	O
we	O
stained	O
consecutive	O
serial	O
sections	O
either	O
with	O
the	O
macrophage	B-CL
surface	B-GO
marker	O
F4	B-GGP
/	I-GGP
80	I-GGP
or	O
with	O
aCasp3	B-GGP
.	O

Surprisingly	O
,	O
there	O
was	O
no	O
co	O
-	O
localization	O
of	O
macrophages	B-CL
with	O
apoptotic	B-CL
cells	I-CL
.	O

In	O
virtually	O
all	O
embryonic	O
tissues	O
,	O
apoptotic	B-CL
cells	I-CL
and	O
macrophages	B-CL
were	O
localized	O
in	O
different	O
compartments	O
(	O
Figure	O
6e	O
,	O
6i	O
;	O
and	O
see	O
also	O
Additional	O
data	O
file	O
1	O
,	O
Figure	O
S1	O
)	O
.	O

This	O
suggests	O
that	O
at	O
this	O
stage	O
of	O
development	O
it	O
is	O
mainly	O
neighboring	O
cells	B-CL
that	O
are	O
involved	O
in	O
removal	O
of	O
apoptotic	B-CL
cells	I-CL
,	O
rather	O
than	O
professional	O
macrophages	B-CL
.	O

In	O
summary	O
,	O
our	O
analysis	O
in	O
vivo	O
did	O
not	O
reveal	O
any	O
impairment	O
in	O
apoptotic	B-CL
cell	I-CL
clearance	O
in	O
Ptdsr	B-GGP
-	O
deficient	O
embryos	O
during	O
development	O
and	O
further	O
suggests	O
that	O
phagocytosis	O
of	O
apoptotic	B-CL
cells	I-CL
is	O
mainly	O
mediated	O
by	O
non	O
-	O
professional	O
'	O
bystander	O
'	O
cells	B-CL
.	O

To	O
determine	O
whether	O
macrophages	B-CL
from	O
Ptdsr	B-GGP
-	O
knockout	O
mice	B-Taxon
were	O
impaired	O
in	O
the	O
efficacy	O
of	O
apoptotic	B-CL
cell	I-CL
uptake	O
in	O
vitro	O
,	O
we	O
performed	O
phagocytosis	O
assays	O
with	O
fetal	O
-	O
liver	O
-	O
derived	O
macrophages	B-CL
(	O
FLDMs	O
)	O
and	O
quantified	O
their	O
phagocytosis	O
rates	O
.	O

Phagocytosis	O
of	O
apoptotic	O
thymocytes	O
was	O
investigated	O
at	O
60	O
,	O
90	O
and	O
120	O
minutes	O
after	O
addition	O
of	O
target	O
cells	B-CL
in	O
the	O
absence	O
of	O
serum	O
.	O

Analysis	O
of	O
phagocytosis	O
rates	O
by	O
flow	O
cytometric	O
analysis	O
(	O
FACS	O
)	O
revealed	O
no	O
differences	O
in	O
the	O
efficacy	O
of	O
apoptotic	B-CL
cell	I-CL
uptake	O
between	O
Ptdsr	B-GGP
-	O
/	O
-	O
and	O
Ptdsr	B-GGP
+	B-SO
/	O
+	B-SO
macrophages	B-CL
and	O
demonstrated	O
no	O
differences	O
in	O
apoptotic	B-CL
cell	I-CL
engulfment	O
between	O
selected	O
time	O
points	O
(	O
data	O
not	O
shown	O
)	O
.	O

To	O
re	O
-	O
examine	O
and	O
further	O
independently	O
validate	O
the	O
result	O
of	O
normal	O
apoptotic	B-CL
cell	I-CL
uptake	O
by	O
Ptdsr	B-GGP
-	O
/	O
-	O
macrophages	B-CL
,	O
we	O
performed	O
phagocytosis	O
assays	O
for	O
60	O
min	O
and	O
determined	O
the	O
percentage	O
of	O
macrophages	B-CL
that	O
had	O
engulfed	O
apoptotic	B-CL
cells	I-CL
,	O
in	O
a	O
total	O
of	O
at	O
least	O
300	O
macrophages	B-CL
counted	O
by	O
fluorescence	O
microscopy	O
.	O

Phagocytosed	O
,	O
5	O
-	O
carboxytetramethylrhodamine	O
-	O
(	O
TAMRA	O
-	O
)	O
labeled	O
apoptotic	B-CL
cells	I-CL
were	O
identified	O
as	O
being	O
engulfed	O
by	O
inclusion	O
in	O
F4	B-GGP
/	I-GGP
80	I-GGP
-	O
labeled	O
macrophages	B-CL
.	O

Analysis	O
was	O
done	O
independently	O
by	O
three	O
investigators	O
who	O
were	O
not	O
aware	O
of	O
macrophage	B-CL
genotypes	B-SO
(	O
Ptdsr	B-GGP
-	O
/	O
-	O
or	O
Ptdsr	B-GGP
+	B-SO
/	O
+	B-SO
)	O
.	O

Again	O
,	O
no	O
differences	O
were	O
found	O
in	O
the	O
percentage	O
of	O
macrophages	B-CL
that	O
had	O
engulfed	O
apoptotic	B-CL
cells	I-CL
(	O
Figure	O
7a	O
,	O
c	O
,	O
e	O
)	O
or	O
in	O
the	O
relative	O
number	O
of	O
phagocytosed	O
apoptotic	B-CL
cells	I-CL
per	O
macrophage	B-CL
(	O
phagocytotic	O
index	O
;	O
Figure	O
7f	O
)	O
.	O

Moreover	O
,	O
single	O
Ptdsr	B-GGP
-	O
/	O
-	O
macrophages	B-CL
could	O
be	O
identified	O
that	O
had	O
engulfed	O
even	O
more	O
apoptotic	B-CL
target	I-CL
cells	I-CL
than	O
had	O
wild	B-SO
-	I-SO
type	I-SO
macrophages	B-CL
(	O
Figure	O
7b	O
,	O
d	O
)	O
.	O

Thus	O
,	O
Ptdsr	B-GGP
-	O
deficient	O
macrophages	B-CL
had	O
a	O
normal	O
ability	O
to	O
ingest	O
apoptotic	B-CL
cells	I-CL
and	O
were	O
not	O
impaired	O
in	O
recognition	O
or	O
phagocytosis	O
of	O
cells	B-CL
that	O
had	O
undergone	O
programmed	O
cell	B-CL
death	O
.	O

Ptdsr	B-GGP
-	O
deficiency	O
results	O
in	O
reduced	O
production	O
of	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
cytokines	O
after	O
macrophage	B-CL
stimulation	O

In	O
addition	O
to	O
its	O
suggested	O
importance	O
for	O
phagocytosis	O
of	O
apoptotic	B-CL
cells	I-CL
,	O
it	O
has	O
been	O
proposed	O
that	O
Ptdsr	B-GGP
fulfils	O
a	O
second	O
crucial	O
role	O
in	O
regulating	O
and	O
maintaining	O
a	O
non	O
-	O
inflammatory	O
environment	O
upon	O
the	O
recognition	O
of	O
apoptotic	B-CL
cells	I-CL
by	O
macrophages	B-CL
[	O
26	O
]	O
.	O

We	O
therefore	O
tested	O
whether	O
Ptdsr	B-GGP
-	O
/	O
-	O
macrophages	B-CL
were	O
able	O
to	O
release	O
anti	O
-	O
inflammatory	O
cytokines	O
after	O
ingestion	O
of	O
apoptotic	B-CL
cells	I-CL
.	O

We	O
examined	O
levels	O
of	O
TGF	B-GGP
-	I-GGP
beta	I-GGP
1	I-GGP
and	O
interleukin	B-GGP
-	I-GGP
10	I-GGP
(	O
IL	B-GGP
-	I-GGP
10	I-GGP
)	O
after	O
stimulation	O
of	O
FLDMs	O
with	O
lipopolysaccharide	B-CHEBI
(	O
LPS	B-CHEBI
)	O
,	O
with	O
and	O
without	O
co	O
-	O
culture	O
of	O
apoptotic	B-CL
cells	I-CL
.	O

Quantification	O
of	O
TGF	B-GGP
-	I-GGP
beta	I-GGP
1	I-GGP
and	O
IL	B-GGP
-	I-GGP
10	I-GGP
levels	O
after	O
22	O
hours	O
of	O
culture	O
demonstrated	O
that	O
Ptdsr	B-GGP
-	O
/	O
-	O
macrophages	B-CL
were	O
able	O
to	O
secrete	O
these	O
anti	O
-	O
inflammatory	O
cytokines	O
upon	O
ingestion	O
of	O
apoptotic	B-CL
cells	I-CL
,	O
although	O
at	O
a	O
slightly	O
lower	O
level	O
than	O
wild	B-SO
-	I-SO
type	I-SO
(	O
Figure	O
8a	O
,	O
b	O
)	O
.	O

This	O
indicates	O
that	O
ablation	O
of	O
Ptdsr	B-GGP
function	O
does	O
not	O
compromise	O
in	O
general	O
the	O
ability	O
of	O
macrophages	B-CL
to	O
release	O
immune	O
-	O
suppressive	O
cytokines	O
after	O
recognition	O
and	O
engulfment	O
of	O
apoptotic	B-CL
cells	I-CL
.	O

To	O
analyze	O
whether	O
pro	O
-	O
inflammatory	O
signaling	O
is	O
affected	O
in	O
Ptdsr	B-GGP
-	O
/	O
-	O
macrophages	B-CL
,	O
we	O
stimulated	O
FLDMs	O
from	O
Ptdsr	B-GGP
+	B-SO
/	O
+	B-SO
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
mice	B-Taxon
with	O
LPS	B-CHEBI
and	O
measured	O
levels	O
of	O
tumor	B-GGP
necrosis	I-GGP
factor	I-GGP
-	I-GGP
alpha	I-GGP
(	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
)	O
at	O
different	O
time	O
points	O
after	O
stimulation	O
(	O
Figure	O
8c	O
)	O
.	O

Ptdsr	B-GGP
-	O
/	O
-	O
macrophages	B-CL
produced	O
significantly	O
less	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
than	O
did	O
wild	B-SO
-	I-SO
type	I-SO
macrophages	B-CL
.	O

The	O
difference	O
in	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
secretion	O
was	O
first	O
visible	O
after	O
3	O
h	O
of	O
LPS	B-CHEBI
stimulation	O
and	O
became	O
more	O
prominent	O
during	O
the	O
course	O
of	O
the	O
experiment	O
(	O
for	O
example	O
,	O
after	O
9	O
h	O
and	O
12	O
h	O
of	O
LPS	B-CHEBI
stimulation	O
;	O
Figure	O
8c	O
)	O
.	O

To	O
analyze	O
whether	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
release	O
by	O
Ptdsr	B-GGP
-	O
/	O
-	O
macrophages	B-CL
can	O
be	O
affected	O
by	O
engulfment	O
of	O
apoptotic	B-CL
cells	I-CL
,	O
we	O
stimulated	O
FLDMs	O
with	O
LPS	B-CHEBI
,	O
apoptotic	B-CL
cells	I-CL
or	O
both	O
.	O

Quantification	O
of	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
levels	O
by	O
ELISA	O
after	O
22	O
h	O
showed	O
that	O
Ptdsr	B-GGP
-	O
deficient	O
macrophages	B-CL
release	O
less	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
after	O
stimulation	O
with	O
LPS	B-CHEBI
alone	O
,	O
and	O
also	O
after	O
double	O
stimulation	O
of	O
macrophages	B-CL
with	O
LPS	B-CHEBI
and	O
apoptotic	B-CL
cells	I-CL
(	O
Figure	O
8d	O
)	O
.	O

Moreover	O
,	O
the	O
double	O
stimulation	O
demonstrated	O
that	O
the	O
LPS	B-CHEBI
-	O
induced	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
release	O
by	O
Ptdsr	B-GGP
-	O
/	O
-	O
macrophages	B-CL
could	O
be	O
inhibited	O
by	O
co	O
-	O
administration	O
of	O
apoptotic	B-CL
cells	I-CL
to	O
an	O
extent	O
comparable	O
to	O
that	O
seen	O
in	O
wild	B-SO
-	I-SO
type	I-SO
macrophages	B-CL
.	O

Similar	O
results	O
were	O
obtained	O
when	O
other	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
such	O
as	O
interleukin	B-GGP
-	I-GGP
6	I-GGP
and	O
monocyte	B-GGP
chemoattractant	I-GGP
protein	I-GGP
-	I-GGP
1	I-GGP
,	O
were	O
analyzed	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
results	O
indicate	O
that	O
Ptdsr	B-GGP
is	O
not	O
required	O
in	O
macrophages	B-CL
for	O
the	O
inhibition	O
of	O
pro	O
-	O
inflammatory	O
signaling	O
after	O
recognition	O
and	O
engulfment	O
of	O
apoptotic	B-CL
cells	I-CL
.	O

Ptdsr	B-GGP
-	O
deficiency	O
does	O
,	O
however	O
,	O
affect	O
the	O
overall	O
release	O
of	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
cytokines	O
after	O
stimulation	O
with	O
LPS	B-CHEBI
and	O
after	O
double	O
treatment	O
with	O
LPS	B-CHEBI
and	O
apoptotic	B-CL
cells	I-CL
,	O
indicating	O
that	O
Ptdsr	B-GGP
-	O
deficient	O
macrophages	B-CL
have	O
a	O
reduced	O
capacity	O
to	O
produce	O
or	O
secrete	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
cytokines	O
.	O

Discussion	O

Ptdsr	B-GGP
is	O
required	O
for	O
the	O
differentiation	O
of	O
multiple	O
organ	O
systems	O
during	O
development	O

In	O
this	O
study	O
,	O
we	O
have	O
generated	O
a	O
null	O
mutation	B-SO
in	O
the	O
phosphatidylserine	B-GGP
receptor	I-GGP
(	O
Ptdsr	B-GGP
)	O
gene	B-SO
in	O
C57BL	O
/	O
6J	O
mice	B-Taxon
.	O

We	O
show	O
that	O
ablation	O
of	O
Ptdsr	B-GGP
results	O
in	O
profound	O
differentiation	O
defects	O
in	O
multiple	O
organs	O
and	O
tissues	O
during	O
embryogenesis	O
,	O
although	O
with	O
variable	O
penetrance	O
.	O

While	O
this	O
work	O
was	O
in	O
progress	O
,	O
two	O
other	O
groups	O
reported	O
the	O
generation	O
of	O
Ptdsr	B-GGP
-	O
deficient	O
mice	B-Taxon
[	O
31	O
,	O
32	O
]	O
.	O

In	O
all	O
three	O
knockout	O
mouse	B-Taxon
lines	O
,	O
the	O
first	O
two	O
exons	B-SO
(	O
[	O
31	O
]	O
and	O
this	O
study	O
)	O
or	O
exons	B-SO
one	O
to	O
three	O
[	O
32	O
]	O
were	O
deleted	B-SO
by	O
replacement	B-SO
with	O
a	O
neomycin	B-CHEBI
-	O
selection	O
cassette	B-SO
.	O

The	O
Ptdsr	B-GGP
-	O
knockout	O
mouse	B-Taxon
lines	O
differ	O
in	O
the	O
genetic	B-SO
background	O
in	O
which	O
the	O
mutation	B-SO
was	O
generated	O
and	O
maintained	O
,	O
however	O
.	O

In	O
our	O
case	O
,	O
the	O
Ptdsr	B-GGP
-	O
null	O
allele	B-SO
was	O
generated	O
in	O
an	O
isogenic	O
C57BL	O
/	O
6J	O
background	O
,	O
whereas	O
Li	O
et	O
al	O
.	O

[	O
31	O
]	O
and	O
Kunisaki	O
et	O
al	O
.	O

[	O
32	O
]	O
investigated	O
the	O
phenotype	O
of	O
their	O
Ptdsr	B-GGP
-	O
knockout	O
mice	B-Taxon
in	O
a	O
mixed	O
129	O
x	O
C57BL	O
/	O
6	O
background	O
.	O

The	O
ablation	O
of	O
Ptdsr	B-GGP
function	O
results	O
in	O
perinatal	O
lethality	O
in	O
all	O
cases	O
,	O
but	O
there	O
are	O
interesting	O
differences	O
in	O
severity	O
or	O
expressivities	O
of	O
phenotypes	O
among	O
the	O
different	O
Ptdsr	B-GGP
-	O
deficient	O
mouse	B-Taxon
lines	O
.	O

This	O
might	O
be	O
due	O
either	O
to	O
differences	O
in	O
genetic	B-SO
background	O
or	O
because	O
the	O
phenotypes	O
that	O
have	O
been	O
investigated	O
in	O
this	O
study	O
have	O
not	O
been	O
analyzed	O
in	O
such	O
detail	O
before	O
.	O

In	O
the	O
Ptdsr	B-GGP
-	O
knockout	O
mouse	B-Taxon
line	O
reported	O
here	O
,	O
growth	O
retardation	O
started	O
from	O
E12	O
.	O
5	O
onwards	O
and	O
was	O
associated	O
with	O
delayed	O
differentiation	O
in	O
several	O
organs	O
in	O
which	O
Ptdsr	B-GGP
is	O
expressed	O
either	O
during	O
embryogenesis	O
or	O
later	O
in	O
adulthood	O
.	O

At	O
E16	O
.	O
5	O
almost	O
no	O
branching	O
morphogenesis	O
of	O
the	O
lung	O
epithelium	O
was	O
observed	O
in	O
Ptdsr	B-GGP
-	O
/	O
-	O
lungs	O
.	O

Similarly	O
,	O
epithelial	O
structures	O
were	O
only	O
partially	O
developed	O
in	O
mutant	B-SO
kidneys	O
,	O
without	O
terminal	O
differentiation	O
of	O
Bowman	O
'	O
s	O
capsule	O
and	O
with	O
a	O
severe	O
reduction	O
in	O
the	O
number	O
of	O
differentiated	O
collecting	O
tubules	O
.	O

Likewise	O
,	O
the	O
differentiation	O
of	O
the	O
intestine	O
was	O
also	O
severely	O
delayed	O
at	O
this	O
developmental	O
stage	O
.	O

When	O
compared	O
with	O
wild	B-SO
-	I-SO
type	I-SO
controls	O
,	O
intestinal	O
tissues	O
of	O
Ptdsr	B-GGP
knockout	O
mice	B-Taxon
appeared	O
unstructured	O
,	O
with	O
an	O
absence	O
of	O
enteric	O
ganglia	O
and	O
of	O
differentiated	O
smooth	O
muscle	O
tissue	O
.	O

Interestingly	O
,	O
defects	O
in	O
kidney	O
and	O
intestine	O
differentiation	O
were	O
not	O
described	O
in	O
the	O
Ptdsr	B-GGP
-	O
knockouts	O
generated	O
by	O
Li	O
et	O
al	O
.	O

[	O
31	O
]	O
and	O
Kunisaki	O
et	O
al	O
.	O

[	O
32	O
]	O
.	O

Surprisingly	O
,	O
when	O
we	O
examined	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
shortly	O
before	O
birth	O
(	O
E18	O
.	O
5	O
)	O
or	O
neonatally	O
,	O
we	O
found	O
only	O
mild	O
differentiation	O
delays	O
in	O
organs	O
that	O
appeared	O
severely	O
affected	O
at	O
mid	O
-	O
gestation	O
.	O

This	O
'	O
recovery	O
'	O
was	O
most	O
visible	O
in	O
Ptdsr	B-GGP
-	O
/	O
-	O
lungs	O
:	O
at	O
P0	O
we	O
found	O
expanded	O
lungs	O
in	O
the	O
knockout	O
mice	B-Taxon
that	O
showed	O
normal	O
branching	O
patterns	O
,	O
with	O
differentiated	O
alveoli	O
and	O
bronchioles	O
.	O

We	O
investigated	O
the	O
occurrence	O
of	O
programmed	O
cell	B-CL
death	O
during	O
lung	O
development	O
in	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Ptdsr	B-GGP
-	O
knockout	O
mice	B-Taxon
throughout	O
embryogenesis	O
(	O
E16	O
.	O
5	O
to	O
P0	O
)	O
.	O

Comparative	O
immunohistochemistry	O
for	O
aCasp3	B-GGP
revealed	O
that	O
apoptosis	O
is	O
a	O
rare	O
event	O
during	O
lung	O
morphogenesis	O
.	O

Furthermore	O
,	O
we	O
failed	O
to	O
detect	O
any	O
differences	O
in	O
the	O
number	O
of	O
apoptotic	B-CL
cells	I-CL
in	O
Ptdsr	B-GGP
-	O
knockout	O
and	O
wild	B-SO
-	I-SO
type	I-SO
animals	B-Taxon
in	O
the	O
rare	O
cases	O
where	O
we	O
could	O
detect	O
apoptotic	B-CL
cells	I-CL
within	O
lung	O
tissues	O
.	O

These	O
findings	O
are	O
contrary	O
to	O
the	O
results	O
reported	O
by	O
Li	O
et	O
al	O
.	O

[	O
31	O
]	O
,	O
who	O
suggested	O
that	O
impaired	O
clearance	O
of	O
apoptotic	B-CL
mesenchymal	I-CL
and	I-CL
epithelial	I-CL
cells	I-CL
causes	O
a	O
failure	O
in	O
lung	O
morphogenesis	O
in	O
Ptdsr	B-GGP
-	O
deficient	O
mice	B-Taxon
.	O

In	O
contrast	O
,	O
our	O
findings	O
are	O
in	O
line	O
with	O
the	O
current	O
view	O
on	O
lung	O
development	O
during	O
embryogenesis	O
.	O

Accordingly	O
,	O
formation	O
of	O
the	O
epithelial	O
lung	O
via	O
branching	O
morphogenesis	O
can	O
be	O
subdivided	O
into	O
a	O
series	O
of	O
sequential	O
steps	O
that	O
involve	O
:	O
first	O
,	O
formation	O
of	O
the	O
organ	O
anlage	O
in	O
the	O
form	O
of	O
a	O
placode	O
;	O
second	O
,	O
primary	O
bud	O
formation	O
by	O
placode	O
invagination	O
;	O
third	O
,	O
branch	O
initiation	O
and	O
branch	O
outgrowth	O
;	O
fourth	O
,	O
further	O
reiteration	O
of	O
the	O
branching	O
process	O
;	O
and	O
fifth	O
,	O
terminal	O
differentiation	O
of	O
organ	O
-	O
specific	O
proximal	O
and	O
distal	O
structures	O
[	O
34	O
,	O
35	O
]	O
.	O

In	O
contrast	O
to	O
other	O
invagination	O
processes	O
during	O
embryogenesis	O
,	O
such	O
as	O
mammary	O
gland	O
formation	O
,	O
the	O
lumen	O
of	O
the	O
lungs	O
is	O
expanded	O
by	O
successive	O
branching	O
events	O
,	O
branch	O
outgrowth	O
and	O
elongation	O
,	O
rather	O
than	O
by	O
apoptosis	O
[	O
34	O
,	O
36	O
]	O
.	O

Finally	O
,	O
because	O
the	O
lungs	O
of	O
Ptdsr	B-GGP
-	O
/	O
-	O
neonates	O
were	O
almost	O
fully	O
expanded	O
and	O
appeared	O
normal	O
in	O
structure	O
in	O
comparison	O
to	O
wild	B-SO
-	I-SO
type	I-SO
littermates	O
,	O
it	O
is	O
highly	O
unlikely	O
that	O
Ptdsr	B-GGP
mutants	B-SO
die	O
of	O
respiratory	O
lung	O
failure	O
.	O

In	O
addition	O
,	O
Li	O
and	O
colleagues	O
[	O
31	O
]	O
demonstrated	O
that	O
surfactant	B-CHEBI
expression	O
is	O
normal	O
in	O
Ptdsr	B-GGP
-	O
deficient	O
animals	B-Taxon
,	O
supporting	O
the	O
idea	O
of	O
normal	O
maturation	O
of	O
surfactant	B-CHEBI
-	O
producing	O
type	O
II	O
alveolar	O
epithelial	B-CL
cells	I-CL
and	O
lung	O
function	O
.	O

Other	O
defects	O
must	O
therefore	O
be	O
responsible	O
for	O
the	O
death	O
of	O
Ptdsr	B-GGP
-	O
mutant	B-SO
mice	B-Taxon
.	O

The	O
frequently	O
observed	O
subcutaneous	O
edema	O
of	O
various	O
extents	O
in	O
Ptdsr	B-GGP
-	O
deficient	O
homozygotes	O
gave	O
us	O
a	O
hint	O
that	O
Ptdsr	B-GGP
-	O
deficiency	O
and	O
lethality	O
might	O
be	O
associated	O
with	O
cardiovascular	O
problems	O
.	O

Indeed	O
,	O
very	O
recently	O
we	O
have	O
obtained	O
strong	O
evidence	O
that	O
Ptdsr	B-GGP
-	O
knockout	O
mice	B-Taxon
die	O
as	O
a	O
result	O
of	O
defects	O
in	O
heart	O
development	O
that	O
are	O
associated	O
with	O
specific	O
cardiopulmonary	O
malformations	O
;	O
(	O
J	O
.	O
E	O
.	O
Schneider	O
,	O
J	O
.	O
B	O
.	O
,	O
S	O
.	O
D	O
.	O
Bamfort	O
,	O
A	O
.	O
D	O
.	O
G	O
.	O
,	O
C	O
.	O
Broadbent	O
,	O
K	O
.	O
Clarke	O
,	O
S	O
.	O
Neubauer	O
,	O
A	O
.	O
L	O
.	O
and	O
S	O
.	O
Battacharya	O
,	O
unpublished	O
observations	O
)	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
eye	O
development	O
requires	O
a	O
functional	O
Ptdsr	B-GGP
gene	B-SO
.	O

Ptdsr	B-GGP
-	O
deficient	O
embryos	O
can	O
be	O
roughly	O
divided	O
into	O
two	O
categories	O
.	O

The	O
first	O
,	O
severely	O
affected	O
group	O
develops	O
anophthalmia	O
that	O
correlates	O
with	O
formation	O
of	O
ectopic	O
retinal	O
-	O
pigmented	O
epithelium	O
and	O
induction	O
of	O
proliferation	O
of	O
underlying	O
mesenchyme	O
in	O
the	O
nasal	O
cavity	O
.	O

This	O
phenotype	O
represents	O
a	O
completely	O
novel	O
lesion	O
that	O
to	O
our	O
knowledge	O
has	O
not	O
been	O
described	O
before	O
in	O
any	O
other	O
mouse	B-Taxon
mutant	B-SO
.	O

The	O
second	O
group	O
shows	O
normal	O
external	O
eye	O
structures	O
,	O
although	O
in	O
this	O
case	O
retinal	O
development	O
is	O
temporally	O
delayed	O
during	O
mid	O
-	O
gestation	O
,	O
with	O
persistent	O
,	O
abnormal	O
morphogenesis	O
of	O
the	O
inner	O
granular	O
retinal	O
layer	O
at	O
later	O
stages	O
of	O
embryogenesis	O
.	O

A	O
possible	O
explanation	O
for	O
these	O
two	O
phenotypes	O
can	O
be	O
found	O
in	O
the	O
expression	O
pattern	O
of	O
the	O
Ptdsr	B-GGP
gene	B-SO
.	O

Initially	O
,	O
Ptdsr	B-GGP
is	O
expressed	O
throughout	O
the	O
whole	O
developing	O
nervous	O
system	O
,	O
with	O
exceptionally	O
high	O
levels	O
in	O
the	O
anterior	O
part	O
of	O
the	O
forebrain	O
.	O

Later	O
expression	O
becomes	O
more	O
restricted	O
to	O
the	O
developing	O
retina	O
and	O
lens	O
.	O

Thus	O
,	O
Ptdsr	B-GGP
might	O
play	O
an	O
important	O
role	O
in	O
early	O
events	O
of	O
ocular	O
morphogenesis	O
,	O
such	O
as	O
establishment	O
and	O
bisection	O
of	O
eye	O
fields	O
and	O
formation	O
of	O
optic	O
cups	O
.	O

These	O
early	O
eye	O
-	O
formation	O
steps	O
are	O
closely	O
interconnected	O
with	O
development	O
of	O
the	O
forebrain	O
[	O
37	O
,	O
38	O
]	O
and	O
the	O
nose	O
[	O
39	O
-	O
41	O
]	O
.	O

Interestingly	O
,	O
we	O
occasionally	O
observed	O
serious	O
malformations	O
of	O
forebrain	O
and	O
nasal	O
structures	O
in	O
Ptdsr	B-GGP
-	O
knockout	O
embryos	O
that	O
were	O
associated	O
with	O
bilateral	O
anophthalmia	O
(	O
see	O
for	O
example	O
the	O
mutant	B-SO
embryo	O
in	O
Figure	O
1g	O
)	O
.	O

This	O
suggests	O
that	O
Ptdsr	B-GGP
is	O
involved	O
in	O
the	O
regulation	O
of	O
differentiation	O
processes	O
within	O
forebrain	O
regions	O
,	O
and	O
that	O
ablation	O
of	O
Ptdsr	B-GGP
function	O
might	O
secondarily	O
affect	O
early	O
eye	O
formation	O
.	O

Li	O
et	O
al	O
.	O

[	O
31	O
]	O
found	O
smaller	O
lenses	O
in	O
Ptdsr	B-GGP
-	O
knockout	O
mice	B-Taxon
and	O
described	O
the	O
formation	O
of	O
retinal	O
protrusions	O
,	O
although	O
anophthalmia	O
and	O
specific	O
differentiation	O
defects	O
of	O
retinal	O
cell	B-CL
layers	O
were	O
not	O
reported	O
in	O
their	O
study	O
.	O

Li	O
et	O
al	O
.	O
proposed	O
[	O
31	O
]	O
that	O
the	O
eye	O
phenotype	O
they	O
observed	O
could	O
be	O
explained	O
by	O
failed	O
removal	O
of	O
apoptotic	B-CL
cells	I-CL
during	O
eye	O
development	O
,	O
but	O
we	O
think	O
that	O
the	O
observed	O
defects	O
are	O
unrelated	O
to	O
a	O
failure	O
of	O
apoptotic	B-CL
cell	I-CL
clearance	O
.	O

A	O
recent	O
comprehensive	O
kinetic	O
analysis	O
of	O
apoptosis	O
induction	O
during	O
mouse	B-Taxon
retinal	O
development	O
described	O
four	O
major	O
peaks	O
of	O
apoptotic	B-CL
cell	I-CL
death	O
[	O
42	O
]	O
.	O

This	O
study	O
demonstrated	O
that	O
there	O
is	O
an	O
initial	O
phase	O
of	O
cell	B-CL
death	O
during	O
the	O
invagination	O
of	O
the	O
optic	O
cup	O
(	O
E10	O
.	O
5	O
)	O
,	O
followed	O
by	O
subsequent	O
waves	O
of	O
apoptosis	O
induction	O
immediately	O
before	O
and	O
after	O
birth	O
(	O
E18	O
.	O
5	O
to	O
postnatal	O
day	O
P2	O
)	O
,	O
and	O
from	O
postnatal	O
days	O
P9	O
to	O
P10	O
and	O
P14	O
to	O
P16	O
[	O
42	O
]	O
.	O

Thus	O
,	O
besides	O
the	O
formation	O
of	O
the	O
inner	O
and	O
outer	O
layers	O
of	O
the	O
optic	O
cup	O
in	O
early	O
eye	O
development	O
,	O
other	O
major	O
phases	O
of	O
retinal	O
cell	B-CL
apoptosis	O
take	O
place	O
only	O
postnatally	O
and	O
correspond	O
to	O
important	O
periods	O
in	O
the	O
establishment	O
of	O
neuronal	B-CL
connections	O
.	O

Furthermore	O
,	O
cell	B-CL
death	O
during	O
normal	O
retinal	O
development	O
occurs	O
in	O
retinal	O
layers	O
distinct	O
from	O
the	O
inner	O
granular	O
layer	O
where	O
we	O
observed	O
the	O
most	O
pronounced	O
differentiation	O
defects	O
in	O
the	O
Ptdsr	B-GGP
-	O
/	O
-	O
mutants	B-SO
described	O
here	O
.	O

Other	O
studies	O
that	O
connect	O
the	O
postnatal	O
elimination	O
of	O
apoptotic	B-CL
photoreceptor	I-CL
cells	I-CL
to	O
Ptdsr	B-GGP
-	O
mediated	O
macrophage	B-CL
engulfment	O
[	O
43	O
]	O
should	O
be	O
interpreted	O
with	O
extreme	O
caution	O
as	O
these	O
studies	O
were	O
based	O
on	O
the	O
monoclonal	O
anti	O
-	O
Ptdsr	B-GGP
antibody	B-GO
mAb	O
217G8E9	O
[	O
26	O
,	O
43	O
]	O
(	O
see	O
below	O
)	O
.	O

Consistent	O
with	O
the	O
results	O
of	O
Li	O
et	O
al	O
.	O

[	O
31	O
]	O
,	O
we	O
found	O
particular	O
brain	O
malformations	O
in	O
our	O
Ptdsr	B-GGP
-	O
/	O
-	O
mice	B-Taxon
.	O

Exencephaly	O
and	O
hyperplastic	O
brain	O
phenotypes	O
were	O
observed	O
at	O
a	O
low	O
penetrance	O
in	O
Ptdsr	B-GGP
-	O
mutant	B-SO
mice	B-Taxon
(	O
less	O
then	O
4	O
.	O
5	O
%	O
of	O
homozygotes	O
)	O
,	O
but	O
these	O
do	O
not	O
resemble	O
to	O
any	O
extent	O
the	O
brain	O
-	O
overgrowth	O
phenotypes	O
of	O
caspase	O
-	O
or	O
Apaf1	B-GGP
-	O
knockout	O
mice	B-Taxon
(	O
[	O
44	O
]	O
,	O
and	O
references	O
therein	O
)	O
in	O
that	O
we	O
failed	O
to	O
identify	O
any	O
differences	O
in	O
the	O
number	O
or	O
distribution	O
of	O
apoptotic	B-CL
cells	I-CL
or	O
pyknotic	O
cell	B-CL
clusters	O
in	O
the	O
neuroepithelium	O
of	O
Ptdsr	B-GGP
-	O
/	O
-	O
and	O
Ptdsr	B-GGP
+	B-SO
/	O
+	B-SO
mice	B-Taxon
.	O

Thus	O
,	O
reduced	O
cell	B-CL
death	O
or	O
diminished	O
clearance	O
of	O
apoptotic	B-CL
neural	I-CL
progenitor	I-CL
cells	I-CL
is	O
unlikely	O
to	O
be	O
the	O
cause	O
of	O
the	O
brain	O
hyperplasia	O
.	O

In	O
summary	O
,	O
our	O
studies	O
demonstrate	O
that	O
Ptdsr	B-GGP
is	O
required	O
for	O
normal	O
tissue	O
differentiation	O
,	O
especially	O
during	O
the	O
mid	O
-	O
gestation	O
period	O
when	O
we	O
observed	O
the	O
most	O
severe	O
differentiation	O
delays	O
in	O
several	O
organs	O
of	O
Ptdsr	B-GGP
-	O
knockout	O
mice	B-Taxon
.	O

The	O
multiple	O
defects	O
in	O
tissue	O
differentiation	O
cannot	O
be	O
explained	O
by	O
failure	O
of	O
apoptotic	B-CL
cell	I-CL
clearance	O
,	O
as	O
this	O
process	O
is	O
normal	O
in	O
our	O
Ptdsr	B-GGP
-	O
knockout	O
line	O
.	O

This	O
result	O
therefore	O
indicates	O
that	O
Ptdsr	B-GGP
has	O
a	O
novel	O
,	O
hitherto	O
unexpected	O
,	O
role	O
in	O
promoting	O
tissue	O
maturation	O
and	O
terminal	O
differentiation	O
.	O

Additional	O
studies	O
with	O
conditionally	O
targeted	O
Ptdsr	B-GGP
-	O
deficient	O
mice	B-Taxon
are	O
required	O
to	O
investigate	O
the	O
role	O
of	O
spatial	O
and	O
temporal	O
Ptdsr	B-GGP
expression	O
and	O
function	O
during	O
tissue	O
differentiation	O
.	O

Ptdsr	B-GGP
is	O
not	O
essential	O
for	O
the	O
clearance	O
of	O
apoptotic	B-CL
cells	I-CL

Our	O
studies	O
demonstrate	O
that	O
Ptdsr	B-GGP
is	O
not	O
a	O
primary	O
receptor	O
for	O
the	O
uptake	O
of	O
apoptotic	B-CL
cells	I-CL
.	O

Investigation	O
of	O
apoptotic	B-CL
cell	I-CL
clearance	O
in	O
vivo	O
in	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
conclusively	O
showed	O
that	O
removal	O
of	O
apoptotic	B-CL
cells	I-CL
is	O
not	O
compromised	O
by	O
ablation	O
of	O
Ptdsr	B-GGP
function	O
.	O

Comparative	O
analysis	O
of	O
ten	O
different	O
tissues	O
and	O
organs	O
in	O
Ptdsr	B-GGP
+	B-SO
/	O
+	B-SO
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
animals	B-Taxon
at	O
several	O
stages	O
of	O
embryonic	O
development	O
and	O
in	O
neonates	O
failed	O
to	O
identify	O
impaired	O
uptake	O
of	O
apoptotic	B-CL
cells	I-CL
at	O
any	O
time	O
during	O
development	O
.	O

Furthermore	O
,	O
phagocytosis	O
assays	O
in	O
vitro	O
demonstrated	O
a	O
completely	O
normal	O
uptake	O
of	O
apoptotic	B-CL
cells	I-CL
by	O
Ptdsr	B-GGP
-	O
/	O
-	O
macrophages	B-CL
,	O
with	O
some	O
knockout	O
macrophages	B-CL
showing	O
loads	O
even	O
higher	O
than	O
wild	B-SO
-	I-SO
type	I-SO
of	O
engulfed	O
dead	O
cells	B-CL
.	O

These	O
results	O
are	O
contrary	O
to	O
the	O
expected	O
role	O
of	O
Ptdsr	B-GGP
in	O
apoptotic	B-CL
cell	I-CL
clearance	O
and	O
to	O
the	O
reported	O
findings	O
of	O
Li	O
et	O
al	O
.	O

[	O
31	O
]	O
and	O
Kunisaki	O
et	O
al	O
.	O

[	O
32	O
]	O
,	O
as	O
well	O
as	O
to	O
a	O
study	O
done	O
with	O
a	O
phosphatidylserine	B-GGP
receptor	I-GGP
null	O
allele	B-SO
in	O
C	B-Taxon
.	I-Taxon
elegans	I-Taxon
[	O
45	O
]	O
.	O

In	O
previous	O
studies	O
in	O
the	O
mouse	B-Taxon
,	O
the	O
distribution	O
and	O
amount	O
of	O
apoptotic	B-CL
cells	I-CL
in	O
Ptdsr	B-GGP
-	O
knockout	O
and	O
control	O
animals	B-Taxon
were	O
investigated	O
in	O
only	O
a	O
few	O
tissues	O
and	O
at	O
one	O
[	O
31	O
]	O
or	O
two	O
[	O
32	O
]	O
developmental	O
stages	O
.	O

Li	O
et	O
al	O
.	O

[	O
31	O
]	O
examined	O
lung	O
,	O
midbrain	O
and	O
retina	O
at	O
day	O
E17	O
.	O
5	O
of	O
gestation	O
and	O
identified	O
apoptotic	B-CL
cells	I-CL
by	O
TUNEL	O
staining	O
.	O

Their	O
findings	O
must	O
be	O
interpreted	O
with	O
caution	O
because	O
remodeling	O
of	O
cellular	B-CL
structures	O
by	O
apoptosis	O
in	O
specific	O
retina	O
layers	O
is	O
known	O
to	O
occur	O
mainly	O
postnatally	O
[	O
42	O
]	O
,	O
and	O
apoptosis	O
plays	O
an	O
important	O
physiological	O
role	O
in	O
the	O
maintenance	O
and	O
homeostasis	O
of	O
lung	O
epithelium	O
after	O
birth	O
or	O
in	O
pathological	O
conditions	O
involving	O
pulmonary	O
inflammation	O
and	O
not	O
during	O
lung	O
development	O
[	O
46	O
]	O
.	O

This	O
postnatal	O
role	O
for	O
apoptosis	O
is	O
in	O
accordance	O
with	O
our	O
data	O
,	O
as	O
we	O
rarely	O
observed	O
apoptotic	B-CL
cells	I-CL
in	O
retina	O
or	O
lung	O
tissue	O
throughout	O
embryogenesis	O
in	O
Ptdsr	B-GGP
+	B-SO
/	O
+	B-SO
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
mice	B-Taxon
.	O

Kunisaki	O
et	O
al	O
.	O

[	O
32	O
]	O
analyzed	O
TUNEL	O
-	O
stained	O
sections	O
of	O
liver	O
and	O
thymus	O
at	O
days	O
E13	O
.	O
5	O
and	O
E16	O
.	O
5	O
of	O
development	O
in	O
Ptdsr	B-GGP
+	B-SO
/	O
-	O
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
and	O
found	O
reduced	O
rather	O
than	O
increased	O
numbers	O
of	O
TUNEL	O
-	O
positive	O
cells	B-CL
in	O
Ptdsr	B-GGP
-	O
deficient	O
embryos	O
.	O

Using	O
co	O
-	O
localization	O
of	O
TUNEL	O
-	O
positive	O
cells	B-CL
with	O
F4	B-GGP
/	I-GGP
80	I-GGP
-	O
positive	O
macrophages	B-CL
they	O
suggested	O
that	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
exhibited	O
a	O
three	O
-	O
fold	O
increase	O
in	O
the	O
frequency	O
of	O
unphagocytosed	O
TUNEL	O
-	O
positive	O
cells	B-CL
together	O
with	O
a	O
severely	O
reduced	O
number	O
of	O
F4	B-GGP
/	I-GGP
80	I-GGP
-	O
positive	O
cells	B-CL
.	O

These	O
results	O
must	O
be	O
interpreted	O
very	O
carefully	O
,	O
however	O
,	O
as	O
it	O
is	O
technically	O
difficult	O
to	O
unambiguously	O
identify	O
engulfed	O
target	O
cells	B-CL
in	O
individual	O
macrophages	B-CL
in	O
solid	O
tissues	O
by	O
fluorescence	O
microscopy	O
.	O

In	O
addition	O
,	O
our	O
data	O
suggest	O
that	O
during	O
embryogenesis	O
,	O
macrophage	B-CL
-	O
mediated	O
clearance	O
of	O
apoptotic	B-CL
cells	I-CL
is	O
not	O
the	O
only	O
-	O
or	O
even	O
the	O
primary	O
-	O
mechanism	O
for	O
the	O
removal	O
of	O
apoptotic	B-CL
cells	I-CL
.	O

In	O
many	O
tissues	O
where	O
programmed	O
cell	B-CL
death	O
occurs	O
as	O
a	O
prominent	O
event	O
during	O
embryogenesis	O
,	O
such	O
as	O
remodeling	O
of	O
the	O
genital	O
ridge	O
during	O
gonad	O
morphogenesis	O
and	O
differentiation	O
of	O
the	O
neural	O
tube	O
,	O
we	O
found	O
almost	O
no	O
co	O
-	O
localization	O
of	O
apoptotic	B-CL
cells	I-CL
and	O
macrophages	B-CL
.	O

This	O
indicates	O
that	O
in	O
these	O
cases	O
clearance	O
of	O
apoptotic	B-CL
cells	I-CL
is	O
directly	O
mediated	O
by	O
neighboring	O
'	O
bystander	O
'	O
cells	B-CL
rather	O
than	O
by	O
macrophages	B-CL
that	O
have	O
been	O
recruited	O
into	O
areas	O
where	O
apoptosis	O
occurs	O
.	O

Obviously	O
these	O
in	O
vivo	O
clearance	O
mechanisms	O
are	O
not	O
compromised	O
by	O
Ptdsr	B-GGP
-	O
deficiency	O
in	O
our	O
knockout	O
mutant	B-SO
.	O

This	O
finding	O
is	O
in	O
line	O
with	O
studies	O
in	O
macrophageless	O
Sfpi1	B-GGP
-	O
knockout	O
embryos	O
that	O
are	O
deficient	O
for	O
the	O
hematopoietic	O
-	O
lineage	O
-	O
specific	O
transcription	O
factor	O
PU	B-GGP
.	I-GGP
1	I-GGP
.	O

Here	O
,	O
the	O
phagocytosis	O
of	O
apoptotic	B-CL
cells	I-CL
during	O
embryogenesis	O
is	O
taken	O
over	O
by	O
'	O
stand	O
-	O
in	O
'	O
mesenchymal	O
neighbors	O
[	O
47	O
]	O
.	O

As	O
recognition	O
of	O
phosphatidylserine	B-CHEBI
is	O
thought	O
to	O
be	O
a	O
universal	O
engulfment	O
mechanism	O
for	O
all	O
cells	B-CL
that	O
are	O
able	O
to	O
phagocytose	O
apoptotic	B-CL
cells	I-CL
,	O
it	O
is	O
very	O
striking	O
that	O
apoptotic	B-CL
cell	I-CL
clearance	O
mediated	O
by	O
non	O
-	O
professional	O
bystander	O
cells	B-CL
is	O
also	O
not	O
compromised	O
by	O
Ptdsr	B-GGP
-	O
deficiency	O
.	O

In	O
contrast	O
to	O
Li	O
et	O
al	O
.	O

[	O
31	O
]	O
,	O
we	O
did	O
not	O
observe	O
any	O
impairment	O
in	O
the	O
uptake	O
of	O
apoptotic	B-CL
cells	I-CL
by	O
Ptdsr	B-GGP
-	O
/	O
-	O
macrophages	B-CL
in	O
vitro	O
.	O

We	O
performed	O
phagocytosis	O
assays	O
in	O
vitro	O
with	O
fetal	O
-	O
liver	O
-	O
derived	O
macrophages	B-CL
,	O
while	O
in	O
their	O
assays	O
,	O
Li	O
and	O
colleagues	O
used	O
thioglycollate	B-CHEBI
-	O
elicited	O
peritoneal	B-CL
macrophages	I-CL
after	O
adoptive	O
transfer	O
of	O
Ptdsr	B-GGP
-	O
/	O
-	O
hematopoietic	B-CL
stem	I-CL
cells	I-CL
.	O

The	O
different	O
results	O
obtained	O
in	O
the	O
two	O
studies	O
are	O
puzzling	O
;	O
they	O
might	O
be	O
due	O
to	O
the	O
use	O
of	O
different	O
macrophage	B-CL
or	O
cell	B-CL
populations	O
.	O

We	O
and	O
Kunisaki	O
et	O
al	O
.	O

[	O
32	O
]	O
found	O
that	O
Ptdsr	B-GGP
-	O
deficiency	O
is	O
to	O
some	O
extent	O
associated	O
with	O
defects	O
in	O
hematopoiesis	O
.	O

Thus	O
,	O
it	O
seems	O
possible	O
that	O
recruitment	O
and	O
activation	O
/	O
differentiation	O
of	O
macrophages	B-CL
after	O
adoptive	O
transfer	O
and	O
thioglycollate	B-CHEBI
elicitation	O
are	O
affected	O
by	O
Ptdsr	B-GGP
-	O
deficiency	O
.	O

We	O
do	O
not	O
think	O
that	O
the	O
different	O
results	O
observed	O
in	O
Ptdsr	B-GGP
-	O
knockout	O
mice	B-Taxon
in	O
a	O
mixed	O
C57BL	O
/	O
6	O
x	O
129	O
background	O
and	O
in	O
a	O
pure	O
C57BL	O
/	O
6J	O
background	O
can	O
be	O
attributed	O
to	O
genetic	B-SO
background	O
effects	O
:	O
comparison	O
of	O
apoptotic	B-CL
cell	I-CL
engulfment	O
efficacies	O
of	O
thioglycollate	B-CHEBI
-	O
elicited	O
macrophages	B-CL
from	O
129P2	O
/	O
OlaHsd	O
and	O
C57BL	O
/	O
6J	O
mice	B-Taxon
did	O
not	O
show	O
any	O
differences	O
in	O
apoptotic	B-CL
cell	I-CL
uptake	O
(	O
J	O
.	O
B	O
.	O
and	O
A	O
.	O
L	O
.	O
,	O
unpublished	O
observations	O
)	O
.	O

Moreover	O
,	O
in	O
contrast	O
to	O
our	O
studies	O
,	O
neither	O
Li	O
et	O
al	O
.	O

[	O
31	O
]	O
nor	O
Kunisaki	O
et	O
al	O
.	O

[	O
32	O
]	O
determined	O
phagocytotic	O
engulfment	O
indexes	O
for	O
Ptdsr	B-GGP
-	O
deficient	O
macrophages	B-CL
.	O

Interestingly	O
,	O
we	O
observed	O
differences	O
between	O
Ptdsr	B-GGP
+	B-SO
/	O
+	B-SO
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
macrophages	B-CL
in	O
the	O
secretion	O
of	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
cytokines	O
after	O
stimulation	O
with	O
LPS	B-CHEBI
and	O
apoptotic	B-CL
cells	I-CL
.	O

This	O
provides	O
evidence	O
that	O
cellular	B-CL
activation	O
and	O
effector	B-CHEBI
mechanisms	O
are	O
impaired	O
in	O
Ptdsr	B-GGP
-	O
deleted	B-SO
macrophages	B-CL
.	O

It	O
remains	O
to	O
be	O
determined	O
which	O
classical	O
pathways	O
of	O
macrophage	B-CL
activation	O
and	O
function	O
involve	O
Ptdsr	B-GGP
.	O

This	O
is	O
especially	O
important	O
in	O
light	O
of	O
recent	O
findings	O
that	O
demonstrated	O
nuclear	B-GO
localization	O
of	O
the	O
Ptdsr	B-GGP
protein	B-CHEBI
[	O
29	O
]	O
.	O

Most	O
strikingly	O
,	O
the	O
recently	O
published	O
data	O
regarding	O
the	O
genetic	B-SO
ablation	O
or	O
perturbation	O
of	O
phosphatidylserine	B-GGP
receptor	I-GGP
function	O
in	O
C	B-Taxon
.	I-Taxon
elegans	I-Taxon
are	O
also	O
contradictory	O
.	O

Wang	O
et	O
al	O
.	O

[	O
45	O
]	O
reported	O
that	O
psr	B-GGP
-	I-GGP
1	I-GGP
,	O
the	O
C	B-Taxon
.	I-Taxon
elegans	I-Taxon
homolog	B-SO
of	O
Ptdsr	B-GGP
,	O
is	O
important	O
for	O
cell	B-CL
-	O
corpse	O
engulfment	O
,	O
whereas	O
psr	B-GGP
-	I-GGP
1	I-GGP
RNAi	O
studies	O
performed	O
by	O
Arur	O
et	O
al	O
.	O

[	O
25	O
]	O
yielded	O
,	O
in	O
this	O
respect	O
,	O
no	O
phenotype	O
.	O

Moreover	O
,	O
Wang	O
and	O
colleagues	O
hypothesized	O
on	O
the	O
basis	O
of	O
their	O
data	O
that	O
psr	B-GGP
-	I-GGP
1	I-GGP
might	O
act	O
to	O
transduce	O
an	O
engulfment	O
signal	O
upstream	O
of	O
Ced	B-GGP
-	I-GGP
2	I-GGP
(	O
Crk	B-GGP
II	I-GGP
)	O
,	O
Ced	B-GGP
-	I-GGP
5	I-GGP
(	O
Dock	B-GGP
180	I-GGP
)	O
,	O
Ced	B-GGP
-	I-GGP
10	I-GGP
(	O
Rac	B-GGP
1	I-GGP
)	O
and	O
Ced	B-GGP
-	I-GGP
12	I-GGP
(	O
Elmo	O
)	O
in	O
one	O
of	O
the	O
two	O
cell	B-CL
-	O
corpse	O
engulfment	O
pathways	O
in	O
the	O
worm	B-Taxon
[	O
45	O
]	O
.	O

But	O
the	O
loss	O
-	O
of	O
-	O
function	O
phenotype	O
of	O
psr	B-GGP
-	I-GGP
1	I-GGP
mutants	B-SO
and	O
the	O
complementation	O
phenotypes	O
in	O
overexpressing	O
transgenic	B-SO
worms	B-Taxon
shown	O
by	O
Wang	O
et	O
al	O
.	O

[	O
45	O
]	O
are	O
rather	O
weak	O
as	O
compared	O
to	O
the	O
classical	O
C	B-Taxon
.	I-Taxon
elegans	I-Taxon
engulfment	O
mutants	B-SO
[	O
8	O
]	O
.	O

Many	O
previous	O
functional	O
studies	O
that	O
reported	O
a	O
requirement	O
for	O
Ptdsr	B-GGP
for	O
the	O
phagocytosis	O
of	O
apoptotic	B-CL
cells	I-CL
used	O
the	O
monoclonal	O
anti	O
-	O
Ptdsr	B-GGP
antibody	B-GO
mAb	O
217G8E9	O
[	O
26	O
]	O
.	O

This	O
antibody	B-GO
was	O
used	O
in	O
Ptdsr	B-GGP
binding	O
and	O
blocking	O
experiments	O
,	O
as	O
well	O
as	O
in	O
subcellular	O
localization	O
studies	O
,	O
which	O
led	O
to	O
the	O
conclusion	O
that	O
Ptdsr	B-GGP
is	O
a	O
transmembrane	B-GO
receptor	O
critical	O
for	O
signal	O
transduction	O
at	O
the	O
engulfment	O
interface	O
.	O

More	O
recently	O
it	O
was	O
used	O
in	O
binding	O
assays	O
to	O
show	O
that	O
the	O
human	B-GGP
and	I-GGP
worm	I-GGP
Ptdsr	I-GGP
molecules	B-CHEBI
can	O
recognize	O
phosphatidylserine	B-CHEBI
[	O
45	O
]	O
.	O

In	O
the	O
course	O
of	O
the	O
study	O
presented	O
here	O
,	O
we	O
stained	O
immunohistochemically	O
for	O
Ptdsr	B-GGP
with	O
mAb	O
217G8E9	O
on	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Ptdsr	B-GGP
-	O
deficient	O
macrophages	B-CL
and	O
fibroblasts	B-CL
(	O
see	O
Additional	O
data	O
file	O
1	O
,	O
Figure	O
S2	O
and	O
data	O
not	O
shown	O
)	O
.	O

To	O
our	O
surprise	O
,	O
we	O
observed	O
similar	O
staining	O
patterns	O
with	O
cells	B-CL
of	O
both	O
genotypes	B-SO
.	O

Furthermore	O
,	O
using	O
a	O
Ptdsr	B-GGP
-	O
peptide	B-SO
array	O
we	O
found	O
that	O
mAb	O
217G8E9	O
can	O
bind	O
weakly	O
to	O
a	O
Ptdsr	B-GGP
peptide	B-SO
,	O
explaining	O
the	O
original	O
isolation	O
of	O
Ptdsr	B-GGP
cDNA	B-SO
clones	I-SO
by	O
phage	O
display	O
[	O
26	O
]	O
;	O
but	O
the	O
antibody	B-GO
mainly	O
recognizes	O
additional	O
,	O
as	O
-	O
yet	O
unknown	O
,	O
membrane	B-GO
-	O
associated	O
protein	B-CHEBI
(	I-CHEBI
s	I-CHEBI
)	I-CHEBI
(	O
see	O
Additional	O
data	O
file	O
1	O
,	O
Figure	O
S2	O
)	O
.	O

Experiments	O
that	O
have	O
used	O
this	O
antibody	B-GO
should	O
therefore	O
be	O
interpreted	O
with	O
great	O
caution	O
as	O
they	O
might	O
come	O
to	O
be	O
viewed	O
in	O
a	O
different	O
light	O
.	O

Conclusion	O

Our	O
results	O
demonstrate	O
that	O
Ptdsr	B-GGP
is	O
essential	O
for	O
the	O
differentiation	O
and	O
maturation	O
of	O
multiple	O
tissues	O
during	O
embryogenesis	O
.	O

Ablation	O
of	O
Ptdsr	B-GGP
function	O
results	O
in	O
neonatal	O
lethality	O
and	O
severe	O
defects	O
in	O
the	O
morphogenesis	O
of	O
several	O
organs	O
.	O

The	O
developmental	O
malformations	O
cannot	O
be	O
explained	O
by	O
impaired	O
clearance	O
of	O
apoptotic	B-CL
cells	I-CL
,	O
a	O
process	O
that	O
proved	O
to	O
be	O
normal	O
in	O
Ptdsr	B-GGP
-	O
deficient	O
mice	B-Taxon
.	O

This	O
opens	O
up	O
the	O
possibility	O
either	O
that	O
there	O
is	O
an	O
as	O
-	O
yet	O
unknown	O
Ptdsr	B-GGP
receptor	O
,	O
which	O
might	O
act	O
as	O
a	O
primary	O
phosphatidylserine	B-CHEBI
recognition	O
receptor	O
,	O
or	O
that	O
recognition	O
of	O
phosphatidylserine	B-CHEBI
and	O
subsequent	O
apoptotic	B-CL
cell	I-CL
engulfment	O
and	O
anti	O
-	O
inflammatory	O
signaling	O
are	O
mainly	O
mediated	O
through	O
phosphatidylserine	B-CHEBI
bridging	O
proteins	B-CHEBI
and	O
their	O
cognate	O
receptors	O
.	O

Although	O
Ptdsr	B-GGP
-	O
/	O
-	O
macrophages	B-CL
were	O
not	O
impaired	O
in	O
their	O
ability	O
to	O
phagocytose	O
apoptotic	B-CL
cells	I-CL
,	O
they	O
showed	O
reduced	O
cytokine	O
responses	O
after	O
stimulation	O
.	O

Further	O
work	O
will	O
be	O
required	O
to	O
determine	O
the	O
molecular	B-CHEBI
mechanisms	O
of	O
these	O
newly	O
recognized	O
Ptdsr	B-GGP
functions	O
during	O
development	O
.	O

Materials	O
and	O
methods	O

Construction	O
of	O
the	O
targeting	O
vector	B-SO
and	O
generation	O
of	O
Ptdsr	B-GGP
-	O
knockout	O
and	O
gene	B-SO
-	O
trap	O
mice	B-Taxon

Targeting	O
vector	B-SO

A	O
Ptdsr	B-GGP
-	O
containing	O
bacterial	B-SO
artificial	I-SO
chromosome	I-SO
(	O
BAC	B-SO
)	O
clone	B-SO
(	O
GenBank	O
accession	O
number	O
AC091694	O
;	O
RP	O
-	O
23	O
-	O
316F3	O
)	O
was	O
isolated	O
by	O
sequence	B-SO
homology	O
from	O
a	O
C57BL	O
/	O
6J	O
genomic	B-SO
BAC	B-SO
library	O
(	O
RP	O
-	O
23	O
;	O
BACPAC	O
Resources	O
,	O
Oakland	O
,	O
USA	O
)	O
.	O

A	O
14	O
.	O
5	O
kb	O
KpnI	O
/	O
BamHI	O
fragment	B-SO
containing	O
the	O
entire	O
Ptdsr	B-GGP
locus	B-SO
and	O
5	B-SO
'	I-SO
and	I-SO
3	I-SO
'	I-SO
flanking	I-SO
regions	I-SO
was	O
subcloned	O
from	O
this	O
BAC	B-SO
clone	B-SO
and	O
a	O
1	O
.	O
9	O
kb	O
RsrII	O
/	O
AatII	O
fragment	B-SO
containing	O
exons	B-SO
I	O
and	O
II	O
of	O
the	O
Ptdsr	B-GGP
gene	B-SO
was	O
replaced	B-SO
by	O
a	O
1	O
.	O
2	O
kb	O
loxP	B-SO
-	I-SO
flanked	I-SO
neomycin	B-CHEBI
-	O
resistance	O
gene	B-SO
cassette	I-SO
(	O
neo	O
)	O
.	O

Homologous	O
recombination	O
in	O
ES	O
cells	B-CL
and	O
generation	O
of	O
germ	O
-	O
line	O
chimeras	O

Bruce4	O
ES	O
cells	B-CL
were	O
transfected	O
with	O
KpnI	O
-	O
linearized	O
targeting	O
vector	B-SO
and	O
selected	O
with	O
G418	O
.	O

ES	O
-	O
cell	B-CL
clones	B-SO
resistant	O
to	O
G418	O
were	O
isolated	O
and	O
analyzed	O
by	O
Southern	O
blot	O
analysis	O
for	O
homologous	O
recombination	O
events	O
within	O
the	O
Ptdsr	B-GGP
locus	B-SO
.	O

Chimeric	O
mice	B-Taxon
were	O
produced	O
by	O
microinjection	O
of	O
two	O
independent	O
homologous	O
recombinant	O
(	O
Ptdsr	B-GGP
+	B-SO
/	O
-	O
)	O
ES	O
cells	B-CL
into	O
BALB	O
/	O
c	O
blastocysts	O
and	O
transfer	O
to	O
pseudopregnant	O
foster	O
mothers	O
followed	O
by	O
development	O
to	O
term	O
.	O

Chimeric	O
males	O
were	O
mated	O
with	O
C57BL	O
/	O
6J	O
females	O
.	O

From	O
the	O
two	O
selected	O
ES	O
-	O
cell	B-CL
clones	B-SO
,	O
one	O
successfully	O
contributed	O
to	O
the	O
germ	O
-	O
line	O
.	O

Germ	O
-	O
line	O
transmission	O
of	O
the	O
mutant	B-SO
allele	B-SO
was	O
verified	O
by	O
PCR	O
and	O
Southern	O
blot	O
of	O
genomic	B-SO
DNA	I-SO
from	O
black	O
coat	O
-	O
color	O
F1	O
offspring	O
.	O

Ptdsr	B-GGP
gene	B-SO
-	O
trap	O
and	O
generation	O
of	O
germ	O
-	O
line	O
chimeras	O

An	O
ES	O
-	O
cell	B-CL
line	O
carrying	O
a	O
beta	O
-	O
geo	O
gene	B-SO
-	O
trap	O
vector	B-SO
in	O
the	O
Ptdsr	B-GGP
locus	B-SO
was	O
identified	O
by	O
searching	O
the	O
BayGenomics	O
database	O
(	O
BayGenomics	O
,	O
San	O
Francisco	O
,	O
USA	O
;	O
[	O
48	O
]	O
)	O
with	O
the	O
full	O
-	O
length	O
Ptdsr	B-GGP
cDNA	B-SO
.	O

A	O
single	O
ES	O
-	O
cell	B-CL
line	O
was	O
identified	O
carrying	O
the	O
gene	B-SO
-	O
trap	O
in	O
intron	B-SO
V	O
,	O
between	O
exons	B-SO
V	O
and	O
VI	O
of	O
the	O
Ptdsr	B-GGP
gene	B-SO
.	O

Chimeric	O
mice	B-Taxon
were	O
generated	O
by	O
microinjection	O
into	O
CB20	O
blastocysts	O
and	O
transfer	O
to	O
pseudopregnant	O
foster	O
mothers	O
.	O

Chimeric	O
males	O
were	O
mated	O
with	O
129P2	O
/	O
OlaHsd	O
females	O
.	O

Germ	O
-	O
line	O
transmission	O
of	O
the	O
mutant	B-SO
gene	B-SO
-	O
trap	O
allele	B-SO
was	O
verified	O
by	O
expression	O
analysis	O
using	O
beta	O
-	O
galactosidase	O
staining	O
and	O
RT	O
-	O
PCR	O
.	O

Genotype	B-SO
analysis	O

The	O
genotypes	B-SO
of	O
embryos	O
or	O
animals	B-Taxon
were	O
determined	O
by	O
PCR	O
analysis	O
and	O
confirmed	O
by	O
Southern	O
blot	O
.	O

Genomic	B-SO
DNA	I-SO
for	O
PCR	O
was	O
prepared	O
from	O
extraembryonic	O
membranes	O
or	O
tail	O
clips	O
using	O
a	O
non	O
-	O
organic	B-CHEBI
tail	O
-	O
DNA	B-SO
extraction	O
protocol	O
[	O
49	O
]	O
.	O

High	O
molecular	B-CHEBI
weight	O
genomic	B-SO
DNA	I-SO
for	O
Southern	O
blotting	O
was	O
prepared	O
according	O
to	O
standard	O
protocols	O
.	O

For	O
PCR	O
analysis	O
the	O
wild	B-SO
-	I-SO
type	I-SO
Ptdsr	B-GGP
allele	B-SO
was	O
detected	O
using	O
forward	B-SO
primer	I-SO
1	O
(	O
5	O
'	O
-	O
GACACTGTCCATGGCAAACAC	O
-	O
3	O
'	O
)	O
and	O
reverse	B-SO
primer	I-SO
2	O
(	O
5	O
'	O
-	O
TAAAGTCGCCTTCCAGAAGATT	O
-	O
3	O
'	O
)	O
.	O

The	O
primer	B-SO
1	I-SO
site	I-SO
is	O
located	O
5	O
'	O
to	O
the	O
deletion	B-SO
and	O
the	O
primer	B-SO
2	I-SO
site	I-SO
within	O
the	O
deletion	B-SO
.	O

This	O
primer	B-SO
pair	O
amplified	O
a	O
fragment	B-SO
of	O
approximately	O
300	O
bp	B-SO
from	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Ptdsr	B-GGP
+	B-SO
/	O
-	O
mice	B-Taxon
but	O
not	O
from	O
Ptdsr	B-GGP
-	O
/	O
-	O
mutants	B-SO
.	O

To	O
detect	O
the	O
mutant	B-SO
Ptdsr	B-GGP
allele	B-SO
,	O
genomic	B-SO
DNA	I-SO
was	O
also	O
amplified	O
using	O
primer	B-SO
1	O
and	O
reverse	B-SO
primer	I-SO
3	O
(	O
5	O
'	O
-	O
CCACACGCGTCACCTTAATA	O
-	O
3	O
'	O
)	O
,	O
which	O
corresponds	O
to	O
a	O
sequence	B-SO
in	O
the	O
neo	O
cassette	B-SO
.	O

In	O
this	O
case	O
,	O
a	O
500	O
bp	B-SO
fragment	B-SO
was	O
detected	O
in	O
mice	B-Taxon
heterozygous	O
or	O
homozygous	O
for	O
the	O
mutant	B-SO
allele	B-SO
,	O
while	O
no	O
signal	O
was	O
detected	O
in	O
wild	B-SO
-	I-SO
type	I-SO
mice	B-Taxon
.	O

For	O
Southern	O
blot	O
analysis	O
,	O
genomic	B-SO
DNA	I-SO
(	O
30	O
mu	O
g	O
)	O
was	O
digested	O
overnight	O
with	O
BamHI	O
(	O
30	O
U	O
;	O
Roche	O
Diagnostics	O
GmbH	O
,	O
Mannheim	O
,	O
Germany	O
)	O
and	O
ScaI	O
(	O
30	O
U	O
;	O
Roche	O
)	O
,	O
fractionated	O
on	O
a	O
0	O
.	O
8	O
%	O
agarose	B-CHEBI
gel	O
,	O
transferred	O
to	O
a	O
nylon	B-CHEBI
membrane	O
(	O
Hybond	O
N	O
;	O
Amersham	O
Biosciences	O
Europe	O
GmbH	O
,	O
Freiburg	O
,	O
Germany	O
)	O
and	O
hybridized	O
with	O
5	O
'	O
and	O
3	O
'	O
flanking	O
probes	B-SO
.	O

The	O
BamHI	O
digest	O
was	O
hybridized	O
with	O
a	O
Ptdsr	B-GGP
-	O
specific	O
5	O
'	O
flanking	O
probe	B-SO
,	O
and	O
Southern	O
blot	O
gave	O
a	O
single	O
17	O
.	O
2	O
kb	O
band	O
for	O
wild	B-SO
-	I-SO
type	I-SO
(	O
+	B-SO
/	O
+	B-SO
)	O
,	O
an	O
11	O
.	O
6	O
kb	O
band	O
for	O
homozygous	O
(	O
-	O
/	O
-	O
)	O
and	O
both	O
bands	O
for	O
heterozygous	O
(	O
+	B-SO
/	O
-	O
)	O
mice	B-Taxon
.	O

The	O
ScaI	O
digest	O
was	O
hybridized	O
using	O
a	O
3	O
'	O
flanking	O
probe	B-SO
,	O
and	O
Southern	O
blot	O
gave	O
a	O
single	O
12	O
.	O
4	O
kb	O
band	O
for	O
wild	B-SO
-	I-SO
type	I-SO
,	O
a	O
17	O
.	O
2	O
kb	O
band	O
for	O
homozygous	O
and	O
both	O
bands	O
for	O
heterozygous	O
mice	B-Taxon
.	O

Northern	O
blot	O
analysis	O

Total	O
RNA	B-SO
was	O
isolated	O
from	O
homogenized	O
embryos	O
using	O
TRIZOL	O
reagent	B-CHEBI
(	O
Invitrogen	O
GmbH	O
,	O
Karlsruhe	O
,	O
Germany	O
)	O
.	O

For	O
northern	O
blots	O
,	O
either	O
total	O
RNA	B-SO
(	O
30	O
mu	O
g	O
)	O
was	O
extracted	O
from	O
embryos	O
,	O
electrophoresed	O
and	O
transferred	O
to	O
a	O
nylon	B-CHEBI
membrane	O
(	O
Hybond	O
N	O
;	O
Amersham	O
)	O
or	O
a	O
polyA	B-SO
+	I-SO
RNA	I-SO
northern	O
blot	O
(	O
OriGene	O
Technologies	O
Inc	O
.	O
,	O
Rockville	O
,	O
USA	O
)	O
was	O
hybridized	O
using	O
as	O
the	O
probe	B-SO
a	O
Ptdsr	B-GGP
fragment	B-SO
amplified	O
from	O
wild	B-SO
-	I-SO
type	I-SO
cDNA	B-SO
using	O
forward	B-SO
primer	I-SO
5	O
'	O
-	O
GTTCCAGCTCGTCAGACTCG	O
-	O
3	O
'	O
and	O
reverse	B-SO
primer	I-SO
5	O
'	O
-	O
TGCCCCTAAGACATGACCAC	O
-	O
3	O
'	O
.	O

In	O
all	O
experiments	O
the	O
same	O
membrane	O
was	O
re	O
-	O
hybridized	O
with	O
a	O
beta	B-GGP
-	I-GGP
actin	I-GGP
probe	B-SO
(	O
OriGene	O
)	O
to	O
confirm	O
that	O
equivalent	O
RNA	B-SO
levels	O
were	O
present	O
in	O
each	O
lane	O
.	O

Northern	O
blotting	O
indicated	O
that	O
homozygous	O
mutant	B-SO
embryos	O
did	O
not	O
express	O
Ptdsr	B-GGP
mRNA	B-CHEBI
and	O
heterozygous	O
mutant	B-SO
embryos	O
expressed	O
only	O
reduced	O
amounts	O
of	O
Ptdsr	B-GGP
mRNA	B-CHEBI
.	O

Western	O
blot	O
analysis	O

Embryos	O
(	O
E13	O
.	O
5	O
)	O
for	O
protein	B-CHEBI
isolation	O
were	O
homogenized	O
in	O
lysis	O
buffer	O
containing	O
1	O
x	O
PBS	O
,	O
1	O
%	O
Nonidet	O
P	O
-	O
40	O
,	O
0	O
.	O
5	O
%	O
sodium	B-CHEBI
deoxycholate	I-CHEBI
,	O
0	O
.	O
1	O
%	O
SDS	B-CHEBI
and	O
protease	B-CHEBI
inhibitor	I-CHEBI
cocktail	O
(	O
CompleteMini	O
;	O
Roche	O
)	O
.	O

Equal	O
amounts	O
(	O
25	O
mu	O
g	O
)	O
of	O
protein	B-CHEBI
lysate	O
were	O
separated	O
by	O
SDS	B-CHEBI
-	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
transferred	O
onto	O
a	O
PVDF	O
membrane	O
(	O
Millipore	O
,	O
Billerica	O
,	O
USA	O
)	O
according	O
to	O
standard	O
protocols	O
.	O

Western	O
blots	O
were	O
done	O
using	O
a	O
specific	O
antibody	B-GO
to	O
Ptdsr	B-GGP
(	O
PSR	B-GGP
N	O
-	O
20	O
,	O
sc	O
-	O
11632	O
;	O
Santa	O
Cruz	O
Biotechnology	O
Inc	O
.	O
,	O
Santa	O
Cruz	O
,	O
USA	O
)	O
and	O
beta	B-GGP
-	I-GGP
actin	I-GGP
(	O
ab	O
-	O
6276	O
;	O
Abcam	O
,	O
Cambridge	O
,	O
UK	O
)	O
as	O
described	O
by	O
the	O
supplier	O
.	O

Secondary	O
antibodies	B-GO
conjugated	O
to	O
horseradish	B-Taxon
peroxidase	O
were	O
from	O
Santa	O
Cruz	O
and	O
Abcam	O
,	O
used	O
as	O
described	O
by	O
the	O
supplier	O
,	O
and	O
detection	O
was	O
performed	O
with	O
an	O
enhanced	O
chemiluminescence	O
system	O
(	O
ECLPlus	O
;	O
Amersham	O
)	O
.	O

Animal	B-Taxon
experiments	O

Wild	B-SO
-	I-SO
type	I-SO
C57BL	O
/	O
6J	O
and	O
129P2	O
/	O
OlaHsd	O
mice	B-Taxon
were	O
obtained	O
from	O
Jackson	O
Laboratories	O
(	O
Bar	O
Harbor	O
,	O
USA	O
)	O
and	O
Harlan	O
UK	O
(	O
Bicester	O
,	O
UK	O
)	O
,	O
respectively	O
.	O

All	O
mice	B-Taxon
were	O
housed	O
in	O
individually	O
ventilated	O
cages	O
in	O
a	O
specific	O
pathogen	O
-	O
free	O
environment	O
with	O
a	O
12	O
h	O
light	O
-	O
dark	O
cycle	O
and	O
were	O
fed	O
a	O
regular	O
unrestricted	O
diet	O
.	O

The	O
GBF	O
'	O
s	O
routine	O
surveillance	O
program	O
screened	O
for	O
selected	O
pathogens	O
.	O

The	O
Ptdsrtm1Gbf	O
mutant	B-SO
was	O
crossed	O
to	O
C57BL	O
/	O
6J	O
mice	B-Taxon
to	O
establish	O
the	O
co	O
-	O
isogenic	O
C57BL	O
/	O
6J	O
-	O
Ptdsrtm1Gbf	O
mouse	B-Taxon
line	O
.	O

All	O
studies	O
were	O
approved	O
by	O
the	O
appropriate	O
authorities	O
.	O

Isolation	O
of	O
embryos	O

Heterozygous	O
male	O
and	O
female	O
mice	B-Taxon
were	O
intercrossed	O
in	O
order	O
to	O
obtain	O
Ptdsr	B-GGP
-	O
deficient	O
progeny	O
.	O

Females	O
were	O
daily	O
monitored	O
for	O
vaginal	O
plugs	O
,	O
and	O
noon	O
of	O
the	O
day	O
of	O
plug	O
detection	O
was	O
defined	O
as	O
E0	O
.	O
5	O
.	O

Embryos	O
at	O
indicated	O
time	O
points	O
were	O
dissected	O
in	O
sterile	O
PBS	O
,	O
washed	O
in	O
ice	O
-	O
cold	O
PBS	O
and	O
transferred	O
to	O
cold	O
fixative	O
.	O

Extra	O
-	O
embryonic	O
membranes	O
were	O
kept	O
and	O
used	O
for	O
genotyping	O
.	O

Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
and	O
their	O
wild	B-SO
-	I-SO
type	I-SO
littermates	O
were	O
used	O
for	O
experiments	O
.	O

Histology	O
,	O
TUNEL	O
staining	O
and	O
immunohistochemistry	O

Embryos	O
for	O
histology	O
and	O
immunohistochemistry	O
were	O
harvested	O
and	O
fixed	O
in	O
10	O
%	O
neutral	O
-	O
buffered	B-CHEBI
formalin	O
,	O
dehydrated	O
through	O
a	O
graded	O
series	O
of	O
alcohol	B-CHEBI
,	O
embedded	O
in	O
paraffin	O
,	O
sagittally	O
sectioned	O
at	O
5	O
mu	O
m	O
intervals	O
,	O
and	O
every	O
fifth	O
section	O
was	O
processed	O
for	O
hematoxylin	O
and	O
eosin	O
(	O
H	O
&	O
E	O
)	O
staining	O
according	O
to	O
standard	O
protocols	O
.	O

Remaining	O
sections	O
of	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
specimens	O
were	O
used	O
for	O
immunohistochemistry	O
.	O

For	O
detection	O
of	O
apoptotic	B-CL
cells	I-CL
and	O
macrophages	B-CL
,	O
anti	O
-	O
aCasp3	B-GGP
(	O
an	O
antibody	B-GO
specific	O
for	O
activated	B-GGP
caspase	I-GGP
3	I-GGP
;	O
R	O
&	O
D	O
Systems	O
,	O
Minneapolis	O
,	O
USA	O
)	O
and	O
anti	O
-	O
F4	B-GGP
/	I-GGP
80	I-GGP
(	O
Serotec	O
GmBH	O
,	O
D	O
u	O
sseldorf	O
,	O
Germany	O
;	O
#	O
MCA	O
1957	O
)	O
antibodies	B-GO
were	O
used	O
as	O
described	O
by	O
the	O
supplier	O
.	O

Detection	O
was	O
performed	O
using	O
indirect	O
streptavidin	O
with	O
biotinylated	O
secondary	O
antibodies	B-GO
and	O
cobalt	B-CHEBI
-	O
enhanced	O
diaminobenzidine	O
(	O
brown	O
)	O
or	O
fast	O
-	O
red	O
(	O
red	O
)	O
as	O
chromogens	O
.	O

Sections	O
were	O
counterstained	O
with	O
hematoxylin	O
.	O

For	O
whole	O
-	O
mount	O
terminal	B-GGP
deoxynucleotidyl	I-GGP
transferase	I-GGP
-	O
mediated	O
UTP	B-CHEBI
end	O
labeling	O
(	O
TUNEL	O
)	O
,	O
limb	O
buds	O
were	O
dissected	O
from	O
E12	O
.	O
5	O
and	O
E13	O
.	O
5	O
embryos	O
,	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
and	O
processed	O
for	O
analysis	O
as	O
previously	O
described	O
[	O
50	O
]	O
.	O

Preparation	O
of	O
fetal	O
liver	O
-	O
derived	O
macrophages	B-CL
(	O
FLDMs	O
)	O

Fetal	O
livers	O
were	O
excised	O
from	O
embryos	O
at	O
E12	O
.	O
5	O
and	O
E13	O
.	O
5	O
,	O
respectively	O
,	O
washed	O
in	O
PBS	O
and	O
dissociated	O
enzymatically	B-SO
for	O
60	O
min	O
at	O
37	O
degrees	O
C	O
.	O

The	O
digestion	O
buffer	O
(	O
150	O
mu	O
l	O
per	O
liver	O
)	O
comprised	O
0	O
.	O
6	O
U	O
/	O
ml	O
dispase	O
I	O
(	O
Roche	O
)	O
,	O
0	O
.	O
1	O
%	O
collagenase	O
D	O
(	O
Roche	O
)	O
,	O
10	O
U	O
DNase	O
(	O
Roche	O
)	O
,	O
and	O
20	O
%	O
FCS	O
in	O
PBS	O
.	O

X	O
-	O
Vivo	O
15	O
medium	O
(	O
Cambrex	O
,	O
East	O
Rutherford	O
,	O
USA	O
)	O
was	O
added	O
to	O
the	O
resulting	O
cell	B-CL
suspension	O
,	O
and	O
after	O
centrifugation	O
(	O
200	O
x	O
g	O
;	O
3	O
min	O
)	O
cells	B-CL
were	O
resuspended	O
in	O
X	O
-	O
Vivo	O
15	O
medium	O
supplemented	O
with	O
50	O
ng	O
/	O
ml	O
macrophage	B-GGP
colony	I-GGP
-	I-GGP
stimulating	I-GGP
factor	I-GGP
(	O
M	B-GGP
-	I-GGP
CSF	I-GGP
;	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
.	O
Louis	O
,	O
USA	O
)	O
and	O
cultured	O
on	O
non	O
-	O
treated	O
tissue	O
-	O
culture	O
dishes	O
at	O
37	O
degrees	O
C	O
with	O
5	O
%	O
CO2	B-CHEBI
.	O

Every	O
second	O
or	O
third	O
day	O
the	O
medium	O
was	O
changed	O
by	O
centrifugation	O
.	O

Following	O
withdrawal	O
of	O
M	B-GGP
-	I-GGP
CSF	I-GGP
on	O
day	O
6	O
after	O
excision	O
,	O
adherent	O
cells	B-CL
were	O
cultured	O
for	O
an	O
additional	O
24	O
-	O
48	O
h	O
in	O
X	O
-	O
Vivo	O
15	O
medium	O
.	O

Macrophage	B-CL
phagocytosis	O
assays	O

For	O
preparation	O
of	O
monolayer	O
cultures	O
of	O
macrophages	B-CL
,	O
FLDMs	O
were	O
plated	O
on	O
glass	O
coverslips	O
in	O
24	O
well	O
plates	O
(	O
2	O
x	O
105	O
cells	B-CL
per	O
well	O
)	O
in	O
X	O
-	O
Vivo	O
15	O
medium	O
.	O

For	O
preparation	O
of	O
apoptotic	B-CL
target	I-CL
cells	I-CL
,	O
primary	O
thymocytes	O
were	O
harvested	O
from	O
the	O
thymus	O
of	O
4	O
-	O
to	O
8	O
-	O
week	O
-	O
old	O
C57BL	O
/	O
6J	O
mice	B-Taxon
,	O
stained	O
with	O
TAMRA	O
for	O
15	O
min	O
,	O
and	O
apoptosis	O
was	O
induced	O
either	O
by	O
treating	O
cells	B-CL
with	O
5	O
mu	O
M	O
staurosporine	B-CHEBI
in	O
medium	O
for	O
4	O
h	O
at	O
37	O
degrees	O
C	O
or	O
by	O
culturing	O
cells	B-CL
in	O
medium	O
overnight	O
.	O

The	O
efficacy	O
of	O
apoptosis	O
induction	O
was	O
compared	O
in	O
thymic	O
target	O
cells	B-CL
and	O
controls	O
by	O
FACS	O
analysis	O
.	O

On	O
average	O
,	O
60	O
%	O
of	O
the	O
cells	B-CL
of	O
the	O
resulting	O
population	O
were	O
apoptotic	O
,	O
with	O
exposed	O
PS	B-CHEBI
on	O
their	O
surface	B-GO
,	O
and	O
less	O
than	O
5	O
%	O
of	O
the	O
cells	B-CL
were	O
necrotic	O
,	O
as	O
confirmed	O
by	O
FITC	B-CHEBI
-	O
annexin	B-GGP
V	I-GGP
and	O
propidium	O
iodide	B-CHEBI
staining	O
.	O

The	O
apoptotic	O
thymocytes	O
obtained	O
were	O
washed	O
with	O
PBS	O
and	O
added	O
to	O
the	O
prepared	O
FLDM	O
cultures	O
(	O
ratio	O
10	O
:	O
1	O
)	O
.	O

Phagocytosis	O
was	O
then	O
allowed	O
to	O
proceed	O
at	O
37	O
degrees	O
C	O
and	O
5	O
%	O
CO2	B-CHEBI
.	O

After	O
the	O
indicated	O
time	O
periods	O
,	O
the	O
uptake	O
of	O
apoptotic	B-CL
cells	I-CL
by	O
FLDMs	O
was	O
stopped	O
by	O
intensive	O
washing	O
of	O
co	O
-	O
cultures	O
with	O
cold	O
PBS	O
to	O
remove	O
unphagocytosed	O
cells	B-CL
.	O

To	O
measure	O
phagocytosis	O
of	O
apoptotic	O
thymocytes	O
,	O
macrophages	B-CL
were	O
further	O
processed	O
for	O
immunofluorescence	O
analysis	O
.	O

Cells	B-CL
were	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
,	O
blocked	O
in	O
0	O
.	O
5	O
%	O
BSA	O
/	O
PBS	O
and	O
stained	O
with	O
an	O
anti	O
-	O
F4	B-GGP
/	I-GGP
80	I-GGP
antibody	B-GO
(	O
Serotec	O
)	O
followed	O
by	O
a	O
secondary	O
antibody	B-GO
coupled	O
to	O
Alexa	O
488	O
(	O
Molecular	B-CHEBI
Probes	O
Inc	O
.	O
,	O
Eugene	O
,	O
USA	O
)	O
.	O

Coverslips	O
were	O
mounted	O
on	O
slides	O
and	O
engulfed	O
thymocytes	O
were	O
enumerated	O
by	O
fluorescence	O
microscopy	O
.	O

The	O
percentage	O
of	O
phagocytosis	O
was	O
calculated	O
by	O
counting	O
at	O
least	O
300	O
macrophages	B-CL
and	O
determining	O
the	O
number	O
of	O
macrophages	B-CL
that	O
had	O
engulfed	O
apoptotic	O
thymocytes	O
.	O

The	O
phagocytotic	O
index	O
was	O
calculated	O
according	O
to	O
the	O
following	O
formula	O
:	O
phagocytotic	O
index	O
=	O
(	O
total	O
number	O
of	O
engulfed	O
cells	B-CL
/	O
total	O
number	O
of	O
counted	O
macrophages	B-CL
)	O
x	O
(	O
number	O
of	O
macrophages	B-CL
containing	O
engulfed	O
cells	B-CL
/	O
total	O
number	O
of	O
counted	O
macrophages	B-CL
)	O
x	O
100	O
.	O

The	O
experiments	O
were	O
performed	O
at	O
least	O
three	O
times	O
,	O
each	O
time	O
in	O
triplicate	O
,	O
and	O
the	O
counting	O
was	O
done	O
by	O
three	O
different	O
investigators	O
.	O

Measurement	O
of	O
macrophage	B-CL
cytokine	O
production	O

Monolayer	O
cultures	O
of	O
FLDMs	O
and	O
apoptotic	O
thymocytes	O
were	O
prepared	O
as	O
described	O
above	O
.	O

FLDMs	O
were	O
incubated	O
with	O
medium	O
,	O
LPS	B-CHEBI
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
apoptotic	B-CL
cells	I-CL
(	O
ratio	O
1	O
:	O
10	O
)	O
or	O
both	O
for	O
the	O
determination	O
of	O
IL	B-GGP
-	I-GGP
10	I-GGP
,	O
TGF	B-GGP
-	I-GGP
beta	I-GGP
1	I-GGP
or	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
levels	O
after	O
co	O
-	O
culture	O
for	O
22	O
h	O
.	O

For	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
quantification	O
at	O
various	O
time	O
points	O
,	O
FLDMs	O
were	O
cultured	O
with	O
a	O
high	O
concentration	O
of	O
LPS	B-CHEBI
(	O
100	O
ng	O
/	O
ml	O
)	O
.	O

Culture	O
supernatants	O
were	O
harvested	O
and	O
TNF	B-GGP
-	I-GGP
alpha	I-GGP
(	O
Mouse	B-GGP
TNF	I-GGP
-	I-GGP
alpha	I-GGP
OptEIA	O
set	O
;	O
BD	O
Biosciences	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
and	O
TGF	B-GGP
-	I-GGP
beta	I-GGP
1	I-GGP
(	O
Quantikine	O
,	O
TGF	B-GGP
-	I-GGP
beta	I-GGP
1	I-GGP
immunoassay	O
;	O
R	O
&	O
D	O
Systems	O
)	O
were	O
measured	O
by	O
ELISA	O
as	O
described	O
by	O
the	O
supplier	O
.	O

IL	B-GGP
-	I-GGP
10	I-GGP
in	O
culture	O
supernatants	O
was	O
determined	O
by	O
a	O
cytometric	O
bead	O
assay	O
(	O
Mouse	B-Taxon
inflammation	O
CBA	O
;	O
BD	O
Biosciences	O
)	O
as	O
indicated	O
in	O
the	O
manual	O
.	O

Data	O
are	O
presented	O
as	O
mean	O
+/-	O
SEM	O
from	O
at	O
least	O
three	O
independent	O
experiments	O
,	O
each	O
carried	O
out	O
in	O
triplicate	O
.	O

Analysis	O
of	O
the	O
results	O
used	O
the	O
Wilcoxon	O
-	O
signed	O
rank	O
test	O
;	O
p	O
values	O
below	O
0	O
.	O
05	O
were	O
considered	O
significant	O
.	O

Additional	O
data	O
files	O

Additional	O
data	O
file	O
1	O
contains	O
:	O
Figure	O
S1	O
showing	O
the	O
localization	O
of	O
apoptotic	B-CL
cells	I-CL
and	O
macrophages	B-CL
in	O
the	O
subcutis	O
of	O
developing	O
embryos	O
;	O
and	O
Figure	O
S2	O
showing	O
immunohistochemical	O
staining	O
of	O
the	O
Ptdsr	B-GGP
protein	B-CHEBI
in	O
macrophages	B-CL
derived	O
from	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Ptdsr	B-GGP
-	O
knockout	O
mice	B-Taxon
.	O

Supplementary	O
Material	O

Additional	O
data	O
file	O
1	O

Figure	O
S1	O
showing	O
the	O
localization	O
of	O
apoptotic	B-CL
cells	I-CL
and	O
macrophages	B-CL
in	O
the	O
subcutis	O
of	O
developing	O
embryos	O
;	O
and	O
Figure	O
S2	O
showing	O
immunohistochemical	O
staining	O
of	O
the	O
Ptdsr	B-GGP
protein	B-CHEBI
in	O
macrophages	B-CL
derived	O
from	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Ptdsr	B-GGP
-	O
knockout	O
mice	B-Taxon

Click	O
here	O
for	O
additional	O
data	O
file	O

Acknowledgements	O

We	O
thank	O
Rudi	O
Balling	O
(	O
GBF	O
Research	O
Center	O
)	O
and	O
Shoumo	O
Bhattacharya	O
(	O
University	O
of	O
Oxford	O
)	O
for	O
many	O
helpful	O
and	O
stimulating	O
discussions	O
.	O

We	O
thank	O
Evi	O
Wollscheid	O
-	O
Lengeling	O
(	O
GBF	O
)	O
for	O
help	O
with	O
harvest	O
of	O
neonatal	O
mice	B-Taxon
,	O
Ronald	O
Frank	O
(	O
GBF	O
)	O
for	O
providing	O
Ptdsr	B-GGP
peptide	B-SO
arrays	O
,	O
Maria	O
Ebel	O
(	O
GBF	O
)	O
for	O
ES	O
cell	B-CL
blastocyst	O
injections	O
,	O
Manfred	O
Rohde	O
(	O
GBF	O
)	O
for	O
electron	B-CHEBI
microscopy	O
,	O
Kurt	O
Dittmar	O
(	O
GBF	O
)	O
for	O
help	O
with	O
confocal	O
microscopy	O
and	O
Bastian	O
Pasche	O
(	O
GBF	O
)	O
for	O
critical	O
reading	O
of	O
the	O
manuscript	O
.	O

We	O
thank	O
BayGenomics	O
,	O
a	O
genomic	B-SO
consortium	O
funded	O
by	O
the	O
US	O
National	O
Heart	O
,	O
Lung	O
,	O
and	O
Blood	O
Institute	O
,	O
for	O
providing	O
the	O
ES	O
cell	B-CL
gene	B-SO
-	O
trap	O
line	O
RRJ099	O
.	O

This	O
work	O
was	O
supported	O
in	O
part	O
by	O
the	O
EU	O
project	O
EUMORPHIA	O
,	O
"	O
Understanding	O
human	B-Taxon
molecular	B-CHEBI
physiology	O
and	O
pathology	O
through	O
integrated	O
functional	O
genomics	O
in	O
the	O
mouse	B-Taxon
model	O
"	O
(	O
QLG2	O
-	O
CT	O
-	O
2002	O
-	O
00930	O
)	O
.	O

Figures	O
and	O
Tables	O

Figure	O
1	O

Targeted	O
inactivation	O
of	O
the	O
phosphatidylserine	B-GGP
receptor	I-GGP
gene	B-SO
.	O

(	O
a	O
)	O
Ptdsr	B-GGP
gene	B-SO
-	O
targeting	O
strategy	O
.	O

Homologous	O
recombination	O
in	O
ES	O
cells	B-CL
results	O
in	O
the	O
deletion	B-SO
of	O
exons	B-SO
I	O
and	O
II	O
of	O
the	O
murine	B-GGP
Ptdsr	I-GGP
gene	B-SO
through	O
replacement	B-SO
of	O
a	O
loxP	B-SO
-	I-SO
flanked	I-SO
neomycin	B-CHEBI
phosphotransferase	O
gene	B-SO
(	O
neo	O
)	O
,	O
thereby	O
ablating	O
the	O
reading	B-SO
frame	I-SO
of	O
the	O
encoded	O
protein	B-CHEBI
.	O

Coding	B-SO
exons	I-SO
I	I-SO
-	O
VI	O
are	O
shown	O
as	O
filled	O
boxes	O
,	O
and	O
deleted	B-SO
exons	B-SO
are	O
colored	O
green	O
.	O

Restriction	B-SO
sites	I-SO
are	O
:	O
A	O
,	O
AatII	O
;	O
B	O
,	O
BamHI	O
;	O
EI	O
,	O
EcoRI	O
;	O
EV	O
,	O
EcoRV	O
;	O
K	O
,	O
KpnI	O
;	O
R	O
,	O
RsrII	O
;	O
S	O
,	O
SacII	O
;	O
Sc	O
,	O
ScaI	O
,	O
X	O
,	O
XhoI	O
.	O

The	O
probe	B-SO
sites	B-SO
are	O
red	O
boxes	O
labeled	O
:	O
C	O
,	O
5	O
'	O
outside	O
probe	B-SO
;	O
D	O
,	O
3	O
'	O
outside	O
probe	B-SO
.	O

(	O
b	O
)	O
Southern	O
blot	O
analysis	O
of	O
genomic	B-SO
DNA	I-SO
extracted	O
from	O
wild	B-SO
-	I-SO
type	I-SO
(	O
+	B-SO
/	O
+	B-SO
)	O
and	O
Ptdsr	B-GGP
+	B-SO
/	O
-	O
(	O
+	B-SO
/	O
-	O
)	O
animals	B-Taxon
,	O
digested	O
with	O
BamHI	O
and	O
hybridized	O
with	O
the	O
5	O
'	O
outside	O
probe	B-SO
to	O
confirm	O
germ	O
-	O
line	O
transmission	O
of	O
the	O
mutant	B-SO
Ptdsr	B-GGP
allele	B-SO
.	O

'	O
Wild	B-SO
-	I-SO
type	I-SO
'	O
indicates	O
the	O
BamHI	O
fragment	B-SO
of	O
17	O
.	O
2	O
kb	O
from	O
the	O
wild	B-SO
-	I-SO
type	I-SO
Ptdsr	B-GGP
allele	B-SO
;	O
'	O
mutant	B-SO
'	O
indicates	O
the	O
BamHI	O
fragment	B-SO
of	O
11	O
.	O
6	O
kb	O
from	O
the	O
targeted	O
Ptdsr	B-GGP
allele	B-SO
.	O

(	O
c	O
)	O
PCR	O
genotyping	O
of	O
embryos	O
and	O
animals	B-Taxon
from	O
intercrosses	O
of	O
heterozygous	O
Ptdsr	B-GGP
+	B-SO
/	O
-	O
using	O
a	O
wild	B-SO
-	I-SO
type	I-SO
and	O
a	O
mutant	B-SO
allele	B-SO
-	O
specific	O
primer	B-SO
combination	O
,	O
respectively	O
.	O

(	O
d	O
)	O
Northern	O
blot	O
analysis	O
of	O
total	O
RNA	B-SO
isolated	O
from	O
E13	O
.	O
5	O
wild	B-SO
-	I-SO
type	I-SO
,	O
Ptdsr	B-GGP
+	B-SO
/	O
-	O
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
.	O

(	O
e	O
)	O
Western	O
blot	O
analysis	O
of	O
protein	B-CHEBI
from	O
homogenates	O
of	O
E13	O
.	O
5	O
wild	B-SO
-	I-SO
type	I-SO
,	O
Ptdsr	B-GGP
+	B-SO
/	O
-	O
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
using	O
a	O
Ptdsr	B-GGP
-	O
specific	O
antibody	B-GO
.	O

Developmental	O
abnormalities	O
at	O
(	O
f	O
,	O
g	O
)	O
E15	O
.	O
5	O
and	O
(	O
h	O
)	O
birth	O
;	O
in	O
this	O
and	O
all	O
subsequent	O
figures	O
wild	B-SO
-	I-SO
type	I-SO
littermates	O
are	O
located	O
on	O
the	O
left	O
and	O
homozygous	O
mutant	B-SO
mice	B-Taxon
on	O
the	O
right	O
.	O

The	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
show	O
exencephaly	O
(	O
f	O
)	O
or	O
prosencephalic	O
hernia	O
in	O
the	O
forebrain	O
region	O
(	O
arrowhead	O
,	O
neonate	O
2	O
;	O
h	O
)	O
,	O
uni	O
-	O
or	O
bilateral	O
absence	O
of	O
the	O
eyes	O
(	O
f	O
,	O
g	O
and	O
neonate	O
2	O
in	O
h	O
,	O
and	O
arrow	O
,	O
neonate	O
3	O
in	O
h	O
)	O
,	O
an	O
abnormal	O
head	O
shape	O
with	O
proboscis	O
(	O
g	O
)	O
,	O
edema	O
(	O
arrowheads	O
in	O
f	O
and	O
g	O
)	O
,	O
and	O
general	O
anemia	O
(	O
asterisk	O
,	O
neonate	O
3	O
in	O
h	O
)	O
.	O

Figure	O
2	O

Expression	O
analysis	O
of	O
Ptdsr	B-GGP
during	O
embryonic	O
development	O
.	O

(	O
a	O
)	O
Schematic	O
representation	O
of	O
the	O
construction	O
of	O
the	O
Ptdsr	B-GGP
gene	B-SO
-	O
trap	O
mouse	B-Taxon
line	O
used	O
for	O
expression	O
analysis	O
at	O
different	O
embryonic	O
stages	O
.	O

Gray	O
and	O
bright	O
blue	O
boxes	O
represent	O
regulatory	B-SO
elements	I-SO
of	O
the	O
gene	B-SO
-	O
trap	O
,	O
and	O
beta	O
-	O
geo	O
,	O
the	O
beta	O
-	O
galactosidase	O
/	O
neomycin	B-CHEBI
phosphotransferase	O
fusion	B-SO
protein	B-CHEBI
-	O
expression	O
cassette	B-SO
[	O
48	O
,	O
51	O
]	O
.	O

Restriction	O
enzyme	B-SO
nomenclature	O
is	O
as	O
in	O
Figure	O
1	O
(	O
b	O
)	O
Whole	O
-	O
mount	O
beta	O
-	O
galactosidase	O
staining	O
of	O
heterozygous	O
Ptdsr	B-GGP
gene	B-SO
-	O
trap	O
embryos	O
at	O
mid	O
-	O
gestation	O
.	O

Expression	O
of	O
Ptdsr	B-GGP
is	O
highest	O
in	O
neural	O
tissues	O
and	O
somites	O
,	O
in	O
the	O
branchial	O
arches	O
,	O
the	O
developing	O
limbs	O
,	O
the	O
heart	O
,	O
the	O
primitive	O
gut	O
and	O
the	O
developing	O
eye	O
.	O

(	O
c	O
-	O
e	O
)	O
Sectioning	O
of	O
E12	O
.	O
5	O
beta	O
-	O
galactosidase	O
-	O
stained	O
embryos	O
confirms	O
expression	O
of	O
Ptdsr	B-GGP
in	O
(	O
c	O
)	O
the	O
neural	O
tube	O
;	O
(	O
inset	O
in	O
c	O
)	O
neural	O
epithelium	O
;	O
(	O
d	O
)	O
somites	O
;	O
and	O
(	O
e	O
)	O
eyes	O
.	O

Expression	O
in	O
the	O
eye	O
is	O
restricted	O
to	O
developing	O
neural	O
retinal	O
and	O
lens	O
cells	B-CL
.	O

(	O
f	O
)	O
Expression	O
analysis	O
of	O
adult	O
tissues	O
by	O
northern	O
blot	O
.	O

Expression	O
of	O
Ptdsr	B-GGP
in	O
the	O
muscle	O
(	O
asterisk	O
)	O
was	O
detected	O
only	O
on	O
long	O
-	O
term	O
exposures	O
of	O
the	O
filter	O
(	O
>	O
48	O
h	O
)	O
.	O

A	O
beta	B-GGP
-	I-GGP
actin	I-GGP
hybridization	O
was	O
used	O
to	O
confirm	O
equal	O
loading	O
of	O
RNA	B-SO
samples	O
.	O

Scale	O
bar	O
,	O
100	O
mu	O
m	O
.	O

Figure	O
3	O

Histological	O
analysis	O
of	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
organs	O
during	O
embryogenesis	O
.	O

(	O
a	O
-	O
f	O
)	O
Wild	B-SO
-	I-SO
type	I-SO
embryos	O
and	O
(	O
g	O
-	O
l	O
)	O
Ptdsr	B-GGP
-	O
/	O
-	O
littermates	O
were	O
isolated	O
at	O
various	O
embryonic	O
stages	O
,	O
serially	O
sectioned	O
sagittally	O
and	O
analyzed	O
for	O
developmental	O
abnormalities	O
in	O
detail	O
after	O
H	O
&	O
E	O
staining	O
.	O

At	O
E16	O
.	O
5	O
,	O
the	O
lungs	O
of	O
(	O
g	O
)	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
had	O
sacculation	O
just	O
starting	O
,	O
and	O
well	O
-	O
formed	O
alveoli	O
(	O
asterisks	O
)	O
or	O
epithelium	O
-	O
lined	O
bronchioles	O
(	O
arrows	O
)	O
were	O
scarce	O
compared	O
to	O
(	O
a	O
)	O
wild	B-SO
-	I-SO
type	I-SO
lungs	O
.	O

At	O
E16	O
.	O
5	O
,	O
the	O
glomeruli	O
(	O
arrows	O
)	O
in	O
the	O
kidney	O
of	O
(	O
h	O
)	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
were	O
underdeveloped	O
compared	O
to	O
(	O
b	O
)	O
wild	B-SO
-	I-SO
type	I-SO
,	O
collecting	O
tubules	O
(	O
arrowheads	O
)	O
were	O
missing	O
and	O
undifferentiated	O
blastemas	O
(	O
asterisks	O
)	O
were	O
more	O
abundant	O
.	O

The	O
jejunum	O
had	O
no	O
intramural	O
ganglia	O
in	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
(	O
i	O
;	O
and	O
arrows	O
in	O
c	O
)	O
;	O
and	O
a	O
well	O
-	O
developed	O
submucosa	O
(	O
asterisk	O
in	O
c	O
)	O
was	O
missing	O
.	O

Brain	O
sections	O
at	O
E18	O
.	O
5	O
show	O
that	O
(	O
j	O
)	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
may	O
have	O
herniation	O
(	O
arrow	O
)	O
of	O
the	O
hypothalamus	O
through	O
the	O
ventral	O
skull	O
(	O
secondary	O
palate	O
)	O
,	O
most	O
likely	O
through	O
Rathke	O
'	O
s	O
pouch	O
,	O
and	O
a	O
severe	O
malformation	O
of	O
the	O
cortex	O
(	O
asterisks	O
)	O
compared	O
to	O
(	O
d	O
)	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
.	O

At	O
E18	O
.	O
5	O
,	O
(	O
e	O
)	O
wild	B-SO
-	I-SO
type	I-SO
and	O
(	O
k	O
)	O
Ptdsr	B-GGP
-	O
/	O
-	O
lungs	O
showed	O
normal	O
sacculation	O
and	O
formation	O
of	O
alveoli	O
(	O
asterisks	O
)	O
and	O
bronchioles	O
(	O
arrow	O
)	O
.	O

(	O
f	O
)	O
Wild	B-SO
-	I-SO
type	I-SO
neonatal	O
liver	O
had	O
significant	O
numbers	O
of	O
megakaryocytes	B-CL
(	O
arrows	O
)	O
,	O
compared	O
to	O
(	O
l	O
)	O
homozygous	O
mutant	B-SO
littermates	O
,	O
and	O
higher	O
numbers	O
of	O
erythropoietic	O
islands	O
and	O
of	O
mature	O
erythrocytes	B-CL
.	O

Hepatocellular	O
vacuoles	O
are	O
due	O
to	O
glycogen	B-CHEBI
stores	O
(	O
asterisks	O
)	O
that	O
were	O
not	O
metabolized	O
in	O
perinatally	O
dying	O
Ptdsr	B-GGP
-	O
/	O
-	O
animals	B-Taxon
,	O
in	O
contrast	O
to	O
wild	B-SO
-	I-SO
type	I-SO
newborns	O
.	O

Scale	O
bar	O
,	O
100	O
mu	O
m	O
,	O
except	O
for	O
(	O
d	O
)	O
and	O
(	O
j	O
)	O
,	O
1	O
mm	O
.	O

Figure	O
4	O

Morphology	O
of	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
retinas	O
.	O

Serial	O
sagittal	O
sections	O
of	O
(	O
a	O
-	O
d	O
)	O
wild	B-SO
-	I-SO
type	I-SO
and	O
(	O
e	O
-	O
h	O
)	O
Ptdsr	B-GGP
-	O
/	O
-	O
retina	O
were	O
analyzed	O
for	O
developmental	O
abnormalities	O
at	O
(	O
a	O
,	O
e	O
)	O
E12	O
.	O
5	O
,	O
(	O
b	O
,	O
f	O
)	O
E16	O
.	O
5	O
,	O
(	O
c	O
,	O
g	O
)	O
E18	O
.	O
5	O
,	O
and	O
(	O
d	O
,	O
h	O
)	O
P0	O
.	O

Normal	O
patterning	O
of	O
the	O
retina	O
was	O
observed	O
in	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
,	O
with	O
an	O
outer	O
granular	O
layer	O
(	O
OGL	O
)	O
,	O
outer	O
plexiform	O
layer	O
(	O
OPL	O
)	O
,	O
inner	O
granular	O
layer	O
(	O
IGL	O
)	O
and	O
inner	O
plexiform	O
layer	O
(	O
IPL	O
)	O
.	O

Note	O
that	O
the	O
IGL	O
in	O
Ptdsr	B-GGP
-	O
/	O
-	O
retinas	O
is	O
less	O
thick	O
than	O
that	O
in	O
wild	B-SO
-	I-SO
type	I-SO
littermates	O
in	O
comparing	O
(	O
c	O
,	O
g	O
)	O
and	O
(	O
d	O
,	O
h	O
)	O
.	O

Morphometric	O
analysis	O
(	O
numbered	O
lines	O
)	O
of	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
retinas	O
confirmed	O
the	O
initial	O
finding	O
of	O
a	O
thinner	O
retina	O
in	O
Ptdsr	B-GGP
-	O
/	O
-	O
animals	B-Taxon
than	O
in	O
wild	B-SO
-	I-SO
type	I-SO
(	O
all	O
values	O
in	O
mu	O
m	O
)	O
.	O

Scale	O
bar	O
,	O
50	O
mu	O
m	O
.	O

Figure	O
5	O

Histological	O
analysis	O
of	O
eye	O
development	O
in	O
severely	O
affected	O
eyeless	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
.	O

(	O
a	O
)	O
In	O
anophthalmic	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
,	O
unilateral	O
or	O
bilateral	O
absence	O
of	O
the	O
eyes	O
could	O
be	O
detected	O
.	O

(	O
b	O
-	O
d	O
)	O
Serial	O
H	O
&	O
E	O
-	O
stained	O
sagittal	O
sections	O
of	O
homozygous	O
mutant	B-SO
embryos	O
at	O
(	O
b	O
)	O
E17	O
.	O
5	O
and	O
(	O
c	O
,	O
d	O
)	O
E18	O
.	O
5	O
show	O
complex	O
malformation	O
of	O
the	O
optic	O
cup	O
and	O
lack	O
of	O
any	O
lens	O
structure	O
.	O

Careful	O
examination	O
of	O
adjacent	O
sections	O
(	O
b	O
-	O
d	O
)	O
reveals	O
an	O
ectopic	O
misplacement	O
of	O
retinal	O
-	O
pigmented	O
epithelium	O
in	O
the	O
maxillary	O
sinus	O
.	O

Not	O
only	O
is	O
the	O
deposition	O
of	O
pigment	O
clearly	O
visible	O
(	O
higher	O
magnification	O
insets	O
)	O
but	O
also	O
the	O
induction	O
of	O
proliferation	O
of	O
underlying	O
tissues	O
and	O
the	O
change	O
in	O
morphology	O
of	O
the	O
maxillary	O
sinus	O
(	O
d	O
)	O
.	O

Scale	O
bar	O
,	O
100	O
mu	O
m	O
in	O
(	O
b	O
-	O
d	O
)	O
.	O

Figure	O
6	O

Analysis	O
of	O
programmed	O
cell	B-CL
death	O
and	O
involvement	O
of	O
macrophages	B-CL
in	O
the	O
removal	O
of	O
apoptotic	B-CL
cells	I-CL
in	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
.	O

(	O
a	O
)	O
Whole	O
-	O
mount	O
TUNEL	O
staining	O
(	O
blue	O
)	O
of	O
limb	O
buds	O
from	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
at	O
E13	O
.	O
5	O
show	O
no	O
differences	O
in	O
the	O
amount	O
or	O
localization	O
of	O
apoptotic	B-CL
cells	I-CL
during	O
the	O
beginning	O
regression	O
of	O
the	O
interdigital	O
web	O
.	O

Serial	O
sagittal	O
sections	O
stained	O
for	O
activated	B-GGP
caspase	I-GGP
3	I-GGP
(	O
aCasp3	B-GGP
;	O
red	O
)	O
in	O
(	O
b	O
-	O
d	O
)	O
wild	B-SO
-	I-SO
type	I-SO
and	O
(	O
f	O
-	O
h	O
)	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
at	O
E12	O
.	O
5	O
show	O
apoptotic	B-CL
cells	I-CL
in	O
the	O
neural	O
tube	O
(	O
b	O
,	O
f	O
)	O
,	O
the	O
mesonephros	O
(	O
c	O
,	O
g	O
)	O
and	O
the	O
developing	O
paravertebral	O
ganglia	O
(	O
d	O
,	O
h	O
)	O
.	O

Tissue	O
distribution	O
and	O
total	O
number	O
of	O
apoptotic	B-CL
cells	I-CL
was	O
indistinguishable	O
between	O
genotypes	B-SO
and	O
was	O
confirmed	O
by	O
the	O
comparison	O
of	O
consecutive	O
sections	O
of	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
from	O
different	O
developmental	O
stages	O
.	O

Analysis	O
of	O
macrophage	B-CL
numbers	O
and	O
location	O
by	O
F4	B-GGP
/	I-GGP
80	I-GGP
staining	O
(	O
brown	O
)	O
of	O
consecutive	O
sections	O
in	O
paravertebral	O
ganglia	O
of	O
(	O
e	O
)	O
wild	B-SO
-	I-SO
type	I-SO
and	O
(	O
i	O
)	O
homozygous	O
mutant	B-SO
embryos	O
revealed	O
that	O
macrophages	B-CL
(	O
arrows	O
)	O
are	O
not	O
located	O
close	O
to	O
apoptotic	B-CL
cells	I-CL
during	O
embryonic	O
development	O
.	O

(	O
For	O
comparison	O
,	O
see	O
also	O
Additional	O
data	O
file	O
1	O
,	O
Figure	O
S1	O
,	O
with	O
the	O
online	O
version	O
of	O
this	O
article	O
)	O
.	O

Scale	O
bar	O
,	O
100	O
mu	O
m	O
.	O

Figure	O
7	O

Phagocytosis	O
of	O
apoptotic	B-CL
cells	I-CL
by	O
fetal	O
liver	O
-	O
derived	O
macrophages	B-CL
(	O
FLDMs	O
)	O
.	O

FLDMs	O
from	O
(	O
a	O
,	O
b	O
)	O
wild	B-SO
-	I-SO
type	I-SO
and	O
(	O
c	O
,	O
d	O
)	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
were	O
cultured	O
for	O
60	O
min	O
with	O
TAMRA	O
-	O
stained	O
(	O
red	O
)	O
apoptotic	O
thymocytes	O
(	O
treated	O
with	O
staurosporine	B-CHEBI
)	O
from	O
C57BL	O
/	O
6J	O
mice	B-Taxon
and	O
then	O
stained	O
with	O
F4	B-GGP
/	I-GGP
80	I-GGP
(	O
green	O
)	O
.	O

Macrophages	B-CL
of	O
both	O
genotypes	B-SO
have	O
phagocytosed	O
apoptotic	B-CL
cells	I-CL
(	O
arrowheads	O
)	O
.	O

(	O
e	O
)	O
Quantification	O
of	O
phagocytosis	O
of	O
apoptotic	B-CL
cells	I-CL
by	O
wild	B-SO
-	I-SO
type	I-SO
or	O
Ptdsr	B-GGP
-	O
/	O
-	O
macrophages	B-CL
revealed	O
no	O
differences	O
in	O
the	O
percentage	O
of	O
macrophages	B-CL
that	O
had	O
engulfed	O
apoptotic	B-CL
cells	I-CL
,	O
whether	O
or	O
not	O
apoptosis	O
had	O
been	O
induced	O
by	O
staurosporine	B-CHEBI
.	O

Microscopic	O
analysis	O
(	O
b	O
,	O
d	O
)	O
and	O
quantification	O
of	O
the	O
number	O
of	O
apoptotic	B-CL
cells	I-CL
phagocytosed	O
by	O
single	O
macrophages	B-CL
and	O
(	O
f	O
)	O
calculation	O
of	O
the	O
average	O
number	O
of	O
cells	B-CL
phagocytosed	O
per	O
macrophage	B-CL
failed	O
to	O
reveal	O
differences	O
in	O
the	O
efficacy	O
of	O
removal	O
of	O
apoptotic	B-CL
cells	I-CL
between	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
FLDMs	O
.	O

Figure	O
8	O

Cytokine	O
production	O
by	O
FLDMs	O
upon	O
stimulation	O
with	O
lipopolysaccharide	B-CHEBI
(	O
LPS	B-CHEBI
)	O
and	O
apoptotic	B-CL
cells	I-CL
.	O

FLDMs	O
from	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Ptdsr	B-GGP
-	O
/	O
-	O
embryos	O
were	O
incubated	O
(	O
a	O
,	O
b	O
,	O
d	O
)	O
with	O
medium	O
(	O
0	O
)	O
,	O
LPS	B-CHEBI
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
apoptotic	B-CL
cells	I-CL
(	O
ratio	O
1	O
:	O
10	O
)	O
or	O
in	O
combination	O
with	O
LPS	B-CHEBI
and	O
apoptotic	B-CL
cells	I-CL
or	O
(	O
c	O
)	O
with	O
LPS	B-CHEBI
(	O
100	O
ng	O
/	O
ml	O
)	O
alone	O
.	O

Culture	O
supernatants	O
were	O
harvested	O
after	O
22	O
h	O
(	O
a	O
,	O
b	O
,	O
d	O
)	O
or	O
at	O
the	O
indicated	O
time	O
points	O
(	O
c	O
)	O
.	O

TNF	B-GGP
-	I-GGP
alpha	I-GGP
and	O
TGF	B-GGP
-	I-GGP
beta	I-GGP
1	I-GGP
were	O
quantified	O
by	O
ELISA	O
and	O
IL	B-GGP
-	I-GGP
10	I-GGP
by	O
cytometric	O
bead	O
array	O
(	O
CBA	O
)	O
assay	O
.	O

Data	O
are	O
presented	O
as	O
mean	O
+/-	O
SEM	O
from	O
at	O
least	O
three	O
independent	O
experiments	O
,	O
each	O
carried	O
out	O
in	O
triplicate	O
.	O

*	O
,	O
significant	O
difference	O
between	O
genotypes	B-SO
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
significant	O
difference	O
between	O
genotypes	B-SO
,	O
p	O
<	O
0	O
.	O
01	O
;	O
Wilcoxon	O
-	O
signed	O
rank	O
test	O
.	O

Table	O
1	O

Penetrance	O
of	O
phenotypes	O
in	O
Ptdsr	B-GGP
-	O
/	O
-	O
mice	B-Taxon
from	O
E9	O
.	O
5	O
to	O
E18	O
.	O
5	O
,	O
as	O
detected	O
by	O
gross	O
morphology	O

Subsets	O
of	O
the	O
major	O
categories	O
of	O
malformation	O
are	O
indicated	O
by	O
indentation	O
.	O

BMP	B-GGP
Receptor	O
Signaling	O
Is	O
Required	O
for	O
Postnatal	O
Maintenance	O
of	O
Articular	O
Cartilage	O

Abstract	O

Articular	O
cartilage	O
plays	O
an	O
essential	O
role	O
in	O
health	O
and	O
mobility	O
,	O
but	O
is	O
frequently	O
damaged	O
or	O
lost	O
in	O
millions	O
of	O
people	B-Taxon
that	O
develop	O
arthritis	O
.	O

The	O
molecular	B-CHEBI
mechanisms	O
that	O
create	O
and	O
maintain	O
this	O
thin	O
layer	O
of	O
cartilage	O
that	O
covers	O
the	O
surface	O
of	O
bones	O
in	O
joint	O
regions	O
are	O
poorly	O
understood	O
,	O
in	O
part	O
because	O
tools	O
to	O
manipulate	O
gene	B-SO
expression	O
specifically	O
in	O
this	O
tissue	O
have	O
not	O
been	O
available	O
.	O

Here	O
we	O
use	O
regulatory	O
information	O
from	O
the	O
mouse	B-GGP
Gdf5	I-GGP
gene	B-SO
(	O
a	O
bone	B-GGP
morphogenetic	I-GGP
protein	I-GGP
[	O
BMP	B-GGP
]	O
family	O
member	O
)	O
to	O
develop	O
new	O
mouse	B-Taxon
lines	O
that	O
can	O
be	O
used	O
to	O
either	O
activate	O
or	O
inactivate	O
genes	B-SO
specifically	O
in	O
developing	O
joints	O
.	O

Expression	O
of	O
Cre	O
recombinase	O
from	O
Gdf5	B-GGP
bacterial	B-SO
artificial	I-SO
chromosome	I-SO
clones	B-SO
leads	O
to	O
specific	O
activation	O
or	O
inactivation	O
of	O
floxed	B-SO
target	I-SO
genes	I-SO
in	O
developing	O
joints	O
,	O
including	O
early	O
joint	O
interzones	O
,	O
adult	O
articular	O
cartilage	O
,	O
and	O
the	O
joint	O
capsule	O
.	O

We	O
have	O
used	O
this	O
system	O
to	O
test	O
the	O
role	O
of	O
BMP	B-GGP
receptor	O
signaling	O
in	O
joint	O
development	O
.	O

Mice	B-Taxon
with	O
null	O
mutations	B-SO
in	O
Bmpr1a	B-GGP
are	O
known	O
to	O
die	O
early	O
in	O
embryogenesis	O
with	O
multiple	O
defects	O
.	O

However	O
,	O
combining	O
a	O
floxed	B-SO
Bmpr1a	B-GGP
allele	B-SO
with	O
the	O
Gdf5	B-GGP
-	O
Cre	O
driver	O
bypasses	O
this	O
embryonic	O
lethality	O
,	O
and	O
leads	O
to	O
birth	O
and	O
postnatal	O
development	O
of	O
mice	B-Taxon
missing	O
the	O
Bmpr1a	B-GGP
gene	B-SO
in	O
articular	O
regions	O
.	O

Most	O
joints	O
in	O
the	O
body	O
form	O
normally	O
in	O
the	O
absence	O
of	O
Bmpr1a	B-GGP
receptor	I-GGP
function	O
.	O

However	O
,	O
articular	O
cartilage	O
within	O
the	O
joints	O
gradually	O
wears	O
away	O
in	O
receptor	O
-	O
deficient	O
mice	B-Taxon
after	O
birth	O
in	O
a	O
process	O
resembling	O
human	B-Taxon
osteoarthritis	O
.	O

Gdf5	B-GGP
-	O
Cre	O
mice	B-Taxon
provide	O
a	O
general	O
system	O
that	O
can	O
be	O
used	O
to	O
test	O
the	O
role	O
of	O
genes	B-SO
in	O
articular	O
regions	O
.	O

BMP	B-GGP
receptor	O
signaling	O
is	O
required	O
not	O
only	O
for	O
early	O
development	O
and	O
creation	O
of	O
multiple	O
tissues	O
,	O
but	O
also	O
for	O
ongoing	O
maintenance	O
of	O
articular	O
cartilage	O
after	O
birth	O
.	O

Genetic	B-SO
variation	O
in	O
the	O
strength	O
of	O
BMP	B-GGP
receptor	O
signaling	O
may	O
be	O
an	O
important	O
risk	O
factor	O
in	O
human	B-Taxon
osteoarthritis	O
,	O
and	O
treatments	O
that	O
mimic	O
or	O
augment	O
BMP	B-GGP
receptor	O
signaling	O
should	O
be	O
investigated	O
as	O
a	O
possible	O
therapeutic	O
strategy	O
for	O
maintaining	O
the	O
health	O
of	O
joint	O
linings	O
.	O

Introduction	O

Thin	O
layers	O
of	O
articular	O
cartilage	O
line	O
the	O
bones	O
of	O
synovial	O
joints	O
and	O
provide	O
a	O
smooth	O
,	O
wear	O
-	O
resistant	O
structure	O
that	O
reduces	O
friction	O
and	O
absorbs	O
impact	O
forces	O
(	O
Brandt	O
et	O
al	O
.	O
1998	O
)	O
.	O

Loss	O
or	O
damage	O
to	O
articular	O
cartilage	O
is	O
a	O
hallmark	O
of	O
arthritic	O
diseases	O
and	O
is	O
one	O
of	O
the	O
most	O
common	O
reasons	O
that	O
both	O
young	O
and	O
old	O
adults	O
seek	O
medical	O
care	O
.	O

Millions	O
of	O
people	B-Taxon
are	O
afflicted	O
with	O
arthritis	O
,	O
and	O
it	O
ultimately	O
affects	O
more	O
than	O
half	O
of	O
people	B-Taxon
over	O
the	O
age	O
of	O
65	O
(	O
Badley	O
1995	O
;	O
Yelin	O
and	O
Callahan	O
1995	O
)	O
.	O

A	O
better	O
understanding	O
of	O
the	O
molecular	B-CHEBI
mechanisms	O
that	O
create	O
and	O
maintain	O
articular	O
cartilage	O
is	O
crucial	O
for	O
discovering	O
the	O
causes	O
of	O
joint	O
disorders	O
and	O
providing	O
useful	O
medical	O
treatments	O
.	O

Joint	O
formation	O
begins	O
during	O
embryogenesis	O
,	O
when	O
stripes	O
of	O
high	O
cell	B-CL
density	O
called	O
interzones	O
form	O
across	O
developing	O
skeletal	O
precursors	O
(	O
Haines	O
1947	O
)	O
.	O

Programmed	O
cell	B-CL
death	O
occurs	O
within	O
the	O
interzone	O
,	O
and	O
a	O
three	O
-	O
layered	O
interzone	O
forms	O
that	O
has	O
two	O
layers	O
of	O
higher	O
cell	B-CL
density	O
flanking	O
a	O
region	O
of	O
lower	O
cell	B-CL
density	O
.	O

Non	O
-	O
joint	O
precursors	O
of	O
the	O
skeleton	O
typically	O
develop	O
into	O
cartilage	O
,	O
which	O
hypertrophies	O
and	O
is	O
replaced	O
by	O
bone	O
.	O

However	O
,	O
cells	B-CL
within	O
the	O
high	O
-	O
density	O
layers	O
of	O
the	O
interzone	O
are	O
excluded	O
from	O
this	O
process	O
and	O
develop	O
into	O
the	O
permanent	O
layers	O
of	O
articular	O
cartilage	O
found	O
in	O
the	O
mature	O
joint	O
(	O
Mitrovic	O
1978	O
)	O
.	O

Studies	O
over	O
the	O
last	O
10	O
y	O
have	O
begun	O
to	O
elucidate	O
some	O
of	O
the	O
signaling	O
pathways	O
that	O
contribute	O
to	O
the	O
early	O
stages	O
of	O
joint	O
formation	O
.	O

Wnt14	B-GGP
is	O
expressed	O
in	O
stripes	O
at	O
the	O
sites	O
where	O
joints	O
will	O
form	O
,	O
and	O
it	O
is	O
capable	O
of	O
inducing	O
expression	O
of	O
other	O
joint	O
markers	O
when	O
misexpressed	O
at	O
new	O
locations	O
in	O
the	O
limb	O
(	O
Hartmann	O
and	O
Tabin	O
2001	O
)	O
.	O

Several	O
members	O
of	O
the	O
bone	B-GGP
morphogenetic	I-GGP
protein	I-GGP
(	O
BMP	B-GGP
)	O
family	O
of	O
secreted	O
signaling	O
molecules	B-CHEBI
are	O
also	O
expressed	O
in	O
stripes	O
at	O
sites	O
where	O
joints	O
will	O
form	O
,	O
including	O
those	O
encoded	O
by	O
the	O
genes	B-SO
Gdf5	B-GGP
,	O
Gdf6	B-GGP
,	O
Gdf7	B-GGP
,	O
Bmp2	B-GGP
,	O
and	O
Bmp4	B-GGP
(	O
Storm	O
and	O
Kingsley	O
1996	O
;	O
Wolfman	O
et	O
al	O
.	O
1997	O
;	O
Francis	O
-	O
West	O
et	O
al	O
.	O
1999	O
;	O
Settle	O
et	O
al	O
.	O
2003	O
)	O
.	O

Of	O
these	O
,	O
Gdf5	B-GGP
expression	O
is	O
most	O
strikingly	O
limited	O
to	O
regions	O
where	O
joints	O
will	O
develop	O
and	O
is	O
one	O
of	O
the	O
earliest	O
known	B-SO
markers	O
of	O
joint	O
formation	O
.	O

Mutations	B-SO
in	O
either	O
Gdf5	B-GGP
or	O
the	O
closely	O
related	O
Gdf6	B-GGP
gene	B-SO
also	O
block	O
formation	O
of	O
joints	O
at	O
specific	O
locations	O
,	O
providing	O
strong	O
evidence	O
that	O
these	O
molecules	O
are	O
essential	O
for	O
the	O
joint	O
formation	O
process	O
(	O
Storm	O
et	O
al	O
.	O
1994	O
;	O
Settle	O
et	O
al	O
.	O
2003	O
)	O
.	O

However	O
,	O
mutations	B-SO
in	O
Bmp2	B-GGP
or	O
Bmp4	B-GGP
cause	O
early	O
embryonic	O
lethality	O
,	O
making	O
it	O
difficult	O
to	O
test	O
their	O
role	O
in	O
joint	O
formation	O
(	O
Winnier	O
et	O
al	O
.	O
1995	O
;	O
Zhang	O
and	O
Bradley	O
1996	O
)	O
.	O

Much	O
less	O
is	O
known	O
about	O
how	O
signaling	O
pathways	O
function	O
during	O
the	O
subsequent	O
maturation	O
and	O
maintenance	O
of	O
adult	O
joint	O
structures	O
.	O

Importantly	O
,	O
BMP	B-GGP
signaling	O
components	O
are	O
present	O
in	O
adult	O
articular	O
cartilage	O
,	O
suggesting	O
that	O
they	O
may	O
function	O
during	O
the	O
late	O
development	O
or	O
maintenance	O
of	O
this	O
critical	O
structure	O
(	O
Erlacher	O
et	O
al	O
.	O
1998	O
;	O
Chubinskaya	O
et	O
al	O
.	O
2000	O
;	O
Muehleman	O
et	O
al	O
.	O
2002	O
;	O
Bau	O
et	O
al	O
.	O
2002	O
;	O
Bobacz	O
et	O
al	O
.	O
2003	O
)	O
.	O

BMPs	B-GGP
bind	O
tetrameric	O
complexes	B-GO
of	O
two	O
type	O
I	O
and	O
two	O
type	O
II	O
transmembrane	B-GO
serine	B-CHEBI
-	O
threonine	B-CHEBI
kinase	O
receptors	O
.	O

Upon	O
BMP	B-GGP
binding	O
,	O
these	O
complexes	B-GO
transduce	O
a	O
signal	O
by	O
phosphorylating	O
members	O
of	O
the	O
Smad	B-GGP
family	O
of	O
transcription	O
factors	O
(	O
Massague	O
1996	O
)	O
.	O

Recent	O
experiments	O
have	O
implicated	O
two	O
different	O
BMP	B-GGP
type	O
I	O
receptors	O
in	O
skeletal	O
patterning	O
,	O
BMPR1A	B-GGP
and	O
BMPR1B	B-GGP
.	O

Both	O
receptors	O
can	O
bind	O
BMP2	B-GGP
,	O
BMP4	B-GGP
,	O
and	O
GDF5	B-GGP
,	O
although	O
GDF5	B-GGP
shows	O
higher	O
affinity	O
for	O
BMPR1B	B-GGP
(	O
Koenig	O
et	O
al	O
.	O
1994	O
;	O
ten	O
Dijke	O
et	O
al	O
.	O
1994	O
;	O
Yamaji	O
et	O
al	O
.	O
1994	O
;	O
Nishitoh	O
et	O
al	O
.	O
1996	O
;	O
Chalaux	O
et	O
al	O
.	O
1998	O
)	O
.	O

Both	O
receptors	O
are	O
also	O
expressed	O
in	O
dynamic	O
patterns	O
during	O
normal	O
development	O
.	O

In	O
limbs	O
,	O
Bmpr1a	B-GGP
expression	O
becomes	O
restricted	O
to	O
joint	O
interzones	O
,	O
perichondrium	O
,	O
periarticular	O
cartilage	O
,	O
hypertrophic	B-CL
chondrocytes	I-CL
,	O
and	O
interdigital	O
limb	O
mesenchyme	O
.	O

In	O
comparison	O
,	O
Bmpr1b	B-GGP
expression	O
is	O
seen	O
primarily	O
in	O
condensing	O
precartilaginous	O
mesenchymal	B-CL
cells	I-CL
,	O
regions	O
flanking	O
joint	O
interzones	O
,	O
perichondrium	O
,	O
and	O
periarticular	O
cartilage	O
(	O
Dewulf	O
et	O
al	O
.	O
1995	O
;	O
Mishina	O
et	O
al	O
.	O
1995	O
;	O
Zou	O
et	O
al	O
.	O
1997	O
;	O
Baur	O
et	O
al	O
.	O
2000	O
)	O
.	O

Null	O
mutations	B-SO
in	O
the	O
Bmpr1b	B-GGP
gene	B-SO
produce	O
viable	O
mice	B-Taxon
with	O
defects	O
in	O
bone	O
and	O
joint	O
formation	O
that	O
closely	O
resemble	O
those	O
seen	O
in	O
mice	B-Taxon
missing	O
Gdf5	B-GGP
(	O
Storm	O
and	O
Kingsley	O
1996	O
;	O
Baur	O
et	O
al	O
.	O
2000	O
;	O
Yi	O
et	O
al	O
.	O
2000	O
)	O
.	O

Null	O
mutations	B-SO
in	O
Bmpr1a	B-GGP
cause	O
early	O
embryonic	O
lethality	O
,	O
with	O
defects	O
in	O
gastrulation	O
similar	O
to	O
those	O
seen	O
in	O
mice	B-Taxon
with	O
mutations	B-SO
in	O
Bmp4	B-GGP
(	O
Mishina	O
et	O
al	O
.	O
1995	O
;	O
Winnier	O
et	O
al	O
.	O
1995	O
)	O
.	O

Recent	O
studies	O
with	O
floxed	B-SO
alleles	B-SO
suggest	O
that	O
Bmpr1a	B-GGP
is	O
also	O
required	O
for	O
many	O
later	O
developmental	O
events	O
,	O
but	O
its	O
roles	O
in	O
bone	O
and	O
joint	O
formation	O
have	O
not	O
yet	O
been	O
tested	O
(	O
Mishina	O
2003	O
)	O
.	O

A	O
genetic	B-SO
system	O
for	O
activating	O
or	O
inactivating	O
genes	B-SO
specifically	O
in	O
joint	O
tissues	O
would	O
be	O
particularly	O
useful	O
for	O
further	O
studies	O
of	O
joint	O
formation	O
and	O
maintenance	O
.	O

Here	O
we	O
take	O
advantage	O
of	O
the	O
tissue	O
-	O
specific	O
expression	O
pattern	O
of	O
the	O
Gdf5	B-GGP
gene	B-SO
to	O
engineer	O
a	O
Cre	O
/	O
loxP	O
system	O
(	O
Nagy	O
2000	O
)	O
,	O
Gdf5	B-GGP
-	O
Cre	O
,	O
that	O
can	O
be	O
used	O
to	O
remove	O
or	O
ectopically	O
express	O
genes	B-SO
in	O
joints	O
.	O

Tests	O
with	O
reporter	O
mice	B-Taxon
show	O
that	O
this	O
system	O
is	O
capable	O
of	O
modifying	B-SO
genes	B-SO
in	O
all	O
of	O
the	O
structures	O
of	O
the	O
mature	O
synovial	O
joint	O
,	O
including	O
the	O
ligaments	O
of	O
the	O
joint	O
capsule	O
,	O
the	O
synovial	O
membrane	O
,	O
and	O
the	O
articular	O
cartilage	O
.	O

Gdf5	B-GGP
-	O
Cre	O
recombination	O
bypasses	O
the	O
early	O
embryonic	O
lethality	O
of	O
null	O
mutations	B-SO
in	O
Bmpr1a	B-GGP
,	O
and	O
shows	O
that	O
this	O
receptor	O
is	O
required	O
for	O
early	O
joint	O
formation	O
at	O
some	O
locations	O
and	O
for	O
initiation	O
of	O
programmed	O
cell	B-CL
death	O
in	O
webbing	O
between	O
digits	O
.	O

Interestingly	O
,	O
Bmpr1a	B-GGP
is	O
also	O
required	O
for	O
postnatal	O
maintenance	O
of	O
articular	O
cartilage	O
throughout	O
most	O
of	O
the	O
skeleton	O
.	O

In	O
Gdf5	B-GGP
-	O
Cre	O
/	O
Bmpr1afloxP	O
mice	B-Taxon
,	O
articular	O
cartilage	O
initially	O
forms	O
normally	O
,	O
but	O
subsequently	O
loses	O
expression	O
of	O
several	O
key	O
cartilage	O
markers	O
after	O
birth	O
.	O

It	O
ultimately	O
fibrillates	O
and	O
degenerates	O
,	O
resulting	O
in	O
severe	O
osteoarthritis	O
and	O
loss	O
of	O
mobility	O
.	O

These	O
experiments	O
suggest	O
that	O
BMP	B-GGP
signaling	O
is	O
required	O
for	O
normal	O
maintenance	O
of	O
postnatal	O
articular	O
cartilage	O
,	O
and	O
that	O
modulation	O
of	O
the	O
BMP	B-GGP
signaling	O
pathway	O
may	O
play	O
an	O
important	O
role	O
in	O
joint	O
disease	O
.	O

Results	O

Genetic	B-SO
System	O
for	O
Testing	O
the	O
Function	O
of	O
Genes	B-SO
in	O
Joint	O
Development	O

To	O
generate	O
a	O
general	O
system	O
capable	O
of	O
specifically	O
testing	O
genes	B-SO
for	O
functions	O
in	O
skeletal	O
joint	O
development	O
,	O
we	O
engineered	O
transgenic	B-SO
mice	B-Taxon
to	O
express	O
Cre	O
recombinase	O
in	O
developing	O
joints	O
(	O
Figure	O
1	O
)	O
.	O

Gdf5	B-GGP
is	O
a	O
gene	B-SO
strongly	O
expressed	O
in	O
stripes	O
across	O
developing	O
skeletal	O
elements	O
during	O
embryonic	O
joint	O
formation	O
.	O

A	O
bacterial	B-SO
artificial	I-SO
chromosome	I-SO
(	O
BAC	B-SO
)	O
containing	O
the	O
Gdf5	B-GGP
locus	B-SO
was	O
modified	B-SO
by	O
homologous	O
recombination	O
in	O
bacteria	B-Taxon
to	O
insert	B-SO
a	O
cassette	B-SO
encoding	O
Cre	O
-	O
internal	B-SO
ribosome	I-SO
entry	I-SO
site	I-SO
(	O
IRES	B-SO
)	O
-	O
human	B-GGP
placental	I-GGP
alkaline	I-GGP
phosphatase	I-GGP
(	O
hPLAP	B-GGP
)	O
into	O
the	O
translation	B-SO
start	I-SO
site	I-SO
of	O
Gdf5	B-GGP
(	O
Figure	O
1A	O
)	O
.	O

This	O
modified	B-SO
BAC	B-SO
was	O
then	O
used	O
to	O
make	O
lines	O
of	O
transgenic	B-SO
mice	B-Taxon
.	O

The	O
resulting	O
Gdf5	B-GGP
-	O
Cre	O
transgenic	B-SO
mice	B-Taxon
were	O
tested	O
for	O
transgene	B-SO
expression	O
and	O
Cre	O
recombinase	O
activity	O
by	O
crossing	O
them	O
to	O
R26R	O
reporter	O
mice	B-Taxon
that	O
activate	O
the	O
expression	O
of	O
lacZ	O
after	O
Cre	O
-	O
mediated	O
removal	B-SO
of	O
transcriptional	B-SO
stop	I-SO
sequences	I-SO
(	O
Soriano	O
1999	O
)	O
.	O

The	O
resulting	O
progeny	O
were	O
analyzed	O
both	O
for	O
expression	O
of	O
the	O
transgene	B-SO
by	O
assaying	O
HPLAP	B-GGP
activity	O
and	O
for	O
recombination	O
of	O
DNA	B-SO
by	O
assaying	O
LACZ	O
activity	O
.	O

The	O
progeny	O
from	O
all	O
three	O
lines	O
showed	O
strong	O
LACZ	O
expression	O
primarily	O
in	O
joints	O
,	O
and	O
in	O
two	O
of	O
three	O
lines	O
HPLAP	B-GGP
expression	O
could	O
also	O
be	O
seen	O
in	O
joint	O
regions	O
.	O

Interestingly	O
,	O
HPLAP	B-GGP
expression	O
in	O
the	O
Gdf5	B-GGP
-	O
Cre	O
transgenic	B-SO
GAC	O
(	O
A	O
)	O
line	O
used	O
for	O
all	O
subsequent	O
breeding	O
experiments	O
was	O
seen	O
to	O
precede	O
LACZ	O
expression	O
during	O
successive	O
development	O
of	O
joints	O
in	O
the	O
digits	O
(	O
Figure	O
1C	O
)	O
(	O
unpublished	O
data	O
)	O
.	O

These	O
experiments	O
clearly	O
demonstrate	O
that	O
the	O
Gdf5	B-GGP
-	O
Cre	O
transgene	B-SO
expresses	O
Cre	O
recombinase	O
and	O
causes	O
DNA	B-SO
recombination	O
in	O
developing	O
joint	O
regions	O
.	O

GAC	O
(	O
A	O
)	O
mice	B-Taxon
were	O
crossed	O
with	O
lacZ	O
ROSA26	O
Cre	O
reporter	O
strain	O
(	O
R26R	O
)	O
mice	B-Taxon
to	O
analyze	O
the	O
pattern	O
of	O
Cre	O
-	O
mediated	O
lacZ	O
recombination	O
throughout	O
development	O
.	O

Joints	O
in	O
developing	O
limbs	O
begin	O
forming	O
in	O
a	O
proximal	O
-	O
distal	O
pattern	O
such	O
that	O
the	O
shoulder	O
joint	O
forms	O
prior	O
to	O
the	O
elbow	O
joint	O
.	O

In	O
addition	O
,	O
three	O
major	O
stages	O
of	O
early	O
joint	O
development	O
have	O
been	O
defined	O
by	O
histology	O
as	O
(	O
1	O
)	O
interzone	O
formation	O
,	O
(	O
2	O
)	O
three	O
-	O
layer	O
interzone	O
formation	O
,	O
and	O
(	O
3	O
)	O
cavitation	O
(	O
Mitrovic	O
1978	O
)	O
.	O

Consistent	O
with	O
the	O
proximal	O
-	O
distal	O
pattern	O
of	O
joint	O
development	O
in	O
the	O
limbs	O
,	O
LACZ	O
activity	O
is	O
seen	O
at	O
embryonic	O
day	O
12	O
.	O
5	O
(	O
E12	O
.	O
5	O
)	O
in	O
the	O
more	O
proximal	O
joints	O
,	O
including	O
the	O
shoulder	O
and	O
knee	O
(	O
unpublished	O
data	O
)	O
.	O

By	O
E14	O
.	O
5	O
,	O
LACZ	O
expression	O
is	O
typically	O
seen	O
in	O
all	O
but	O
the	O
most	O
distal	O
joints	O
of	O
the	O
limbs	O
(	O
Figure	O
1B	O
and	O
1C	O
)	O
,	O
but	O
with	O
some	O
variability	O
in	O
both	O
strength	O
and	O
extent	O
of	O
expression	O
from	O
embryo	O
to	O
embryo	O
.	O

The	O
strongest	O
-	O
staining	O
embryos	O
often	O
have	O
additional	O
staining	O
in	O
fingertips	O
(	O
not	O
seen	O
in	O
the	O
E14	O
.	O
5	O
embryo	O
in	O
Figure	O
1C	O
,	O
but	O
clearly	O
detectable	O
in	O
the	O
E13	O
.	O
5	O
embryo	O
shown	O
in	O
Figure	O
2	O
)	O
.	O

Sections	O
through	O
developing	O
joints	O
show	O
that	O
LACZ	O
is	O
present	O
in	O
many	O
cells	B-CL
at	O
the	O
interzone	O
stage	O
(	O
unpublished	O
data	O
)	O
.	O

However	O
,	O
expression	O
of	O
LACZ	O
in	O
nearly	O
100	O
%	O
of	O
joint	O
cells	B-CL
is	O
not	O
achieved	O
until	O
the	O
three	O
-	O
layer	O
interzone	O
stage	O
(	O
for	O
example	O
,	O
in	O
the	O
knee	O
joint	O
at	O
E14	O
.	O
5	O
or	O
in	O
any	O
of	O
the	O
phalangeal	O
joints	O
at	O
E16	O
.	O
5	O
(	O
unpublished	O
data	O
)	O
.	O

Within	O
the	O
developing	O
skeleton	O
,	O
Cre	O
-	O
mediated	O
expression	O
of	O
LACZ	O
remains	O
strikingly	O
specific	O
to	O
joints	O
throughout	O
development	O
.	O

Furthermore	O
,	O
it	O
is	O
seen	O
in	O
all	O
the	O
structures	O
of	O
postnatal	O
synovial	O
joints	O
including	O
the	O
articular	O
cartilage	O
,	O
joint	O
capsule	O
,	O
and	O
synovial	O
membrane	O
(	O
Figure	O
1D	O
and	O
1E	O
)	O
(	O
unpublished	O
data	O
)	O
.	O

These	O
patterns	O
are	O
consistent	O
with	O
the	O
well	O
-	O
established	O
expression	O
of	O
Gdf5	B-GGP
in	O
interzone	O
regions	O
during	O
embryonic	O
development	O
(	O
Storm	O
and	O
Kingsley	O
1996	O
)	O
.	O

Adult	O
expression	O
patterns	O
of	O
the	O
Gdf5	B-GGP
gene	B-SO
are	O
not	O
as	O
well	O
characterized	O
,	O
but	O
Gdf5	B-GGP
expression	O
has	O
previously	O
been	O
detected	O
in	O
adult	O
articular	O
cartilage	O
using	O
both	O
RT	O
-	O
PCR	O
and	O
immunocytochemistry	O
(	O
Chang	O
et	O
al	O
.	O
1994	O
;	O
Erlacher	O
et	O
al	O
.	O
1998	O
;	O
Bobacz	O
et	O
al	O
.	O
2002	O
)	O
.	O

Other	O
sites	O
besides	O
limb	O
joints	O
also	O
have	O
Cre	O
-	O
mediated	O
lacZ	O
expression	O
.	O

Starting	O
at	O
E13	O
.	O
5	O
,	O
LACZ	O
activity	O
is	O
detected	O
in	O
an	O
anterior	O
and	O
posterior	O
domain	O
of	O
the	O
limb	O
bud	O
(	O
Figure	O
2C	O
)	O
.	O

At	O
E14	O
.	O
5	O
,	O
LACZ	O
activity	O
is	O
detectable	O
in	O
the	O
developing	O
ear	O
pinnae	O
,	O
ribs	O
,	O
sternum	O
,	O
tissues	O
in	O
the	O
face	O
,	O
and	O
some	O
regions	O
of	O
the	O
brain	O
and	O
spinal	O
cord	O
(	O
Figure	O
1B	O
)	O
(	O
unpublished	O
data	O
)	O
.	O

At	O
birth	O
,	O
LACZ	O
is	O
also	O
expressed	O
in	O
tendons	O
running	O
along	O
the	O
vertebral	O
column	O
,	O
regions	O
of	O
tendons	O
in	O
the	O
wrist	O
and	O
ankle	O
,	O
and	O
some	O
tendon	O
insertions	O
(	O
Figure	O
1D	O
)	O
(	O
unpublished	O
data	O
)	O
.	O

By	O
5	O
wk	O
of	O
age	O
,	O
LACZ	O
is	O
also	O
expressed	O
in	O
the	O
hair	O
follicles	O
,	O
ear	O
cartilage	O
,	O
some	O
cells	B-CL
in	O
the	O
growth	O
plate	O
of	O
the	O
long	O
bones	O
,	O
and	O
portions	O
of	O
the	O
brain	O
and	O
spinal	O
cord	O
(	O
unpublished	O
data	O
)	O
.	O

Surprisingly	O
,	O
23	O
of	O
63	O
,	O
or	O
37	O
%	O
of	O
transgenic	B-SO
mice	B-Taxon
analyzed	O
also	O
show	O
some	O
degree	O
of	O
wider	O
"	O
ectopic	O
"	O
LACZ	O
expression	O
,	O
which	O
can	O
extend	O
throughout	O
many	O
different	O
tissues	O
in	O
the	O
animal	B-Taxon
.	O

However	O
,	O
sustained	O
expression	O
of	O
the	O
transgene	B-SO
itself	O
,	O
as	O
assayed	O
by	O
HPLAP	B-GGP
activity	O
,	O
is	O
still	O
restricted	O
primarily	O
to	O
joints	O
in	O
animals	B-Taxon
that	O
show	O
evidence	O
of	O
more	O
generalized	O
recombination	O
based	O
on	O
LACZ	O
expression	O
(	O
unpublished	O
data	O
)	O
.	O

This	O
suggests	O
that	O
in	O
a	O
fraction	O
of	O
animals	B-Taxon
,	O
sporadic	O
expression	O
of	O
Cre	O
at	O
some	O
time	O
early	O
in	O
development	O
is	O
sufficient	O
to	O
lead	O
to	O
both	O
ectopic	O
recombination	O
and	O
LACZ	O
expression	O
.	O

While	O
the	O
fraction	O
of	O
animals	B-Taxon
with	O
broader	O
recombination	O
patterns	O
must	O
be	O
tracked	O
and	O
accounted	O
for	O
during	O
experiments	O
,	O
these	O
animals	B-Taxon
offer	O
the	O
potential	O
benefit	O
of	O
revealing	O
additional	O
new	O
functions	O
of	O
target	O
genes	B-SO
that	O
could	O
be	O
subsequently	O
studied	O
with	O
additional	O
site	B-SO
-	O
specific	O
Cre	O
drivers	O
.	O

Gdf5	B-GGP
-	O
Cre	O
/	O
Bmpr1afloxP	O
Animals	B-Taxon
Survive	O
to	O
Adulthood	O
with	O
Ear	O
,	O
Webbing	O
,	O
and	O
Joint	O
Defects	O

We	O
next	O
used	O
the	O
Gdf5	B-GGP
-	O
Cre	O
system	O
to	O
test	O
the	O
role	O
of	O
BMP	B-GGP
signaling	O
during	O
normal	O
joint	O
development	O
.	O

Gdf5	B-GGP
-	O
Cre	O
transgenic	B-SO
mice	B-Taxon
were	O
bred	O
to	O
animals	B-Taxon
carrying	O
a	O
conditional	O
floxed	B-SO
allele	B-SO
of	O
the	O
Bmpr1a	B-GGP
locus	B-SO
(	O
Mishina	O
et	O
al	O
.	O
2002	O
)	O
,	O
usually	O
in	O
the	O
presence	O
of	O
the	O
R26R	O
reporter	O
allele	B-SO
to	O
facilitate	O
simultaneous	O
visualization	O
of	O
Cre	O
-	O
mediated	O
recombination	O
patterns	O
(	O
see	O
typical	O
cross	O
in	O
Figure	O
3	O
)	O
.	O

PCR	O
amplification	O
confirmed	O
that	O
a	O
key	O
exon	B-SO
of	O
the	O
Bmpr1a	B-GGP
gene	B-SO
was	O
deleted	B-SO
in	O
mice	B-Taxon
that	O
also	O
carried	O
the	O
Gdf5	B-GGP
-	O
Cre	O
transgene	B-SO
(	O
unpublished	O
data	O
)	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
the	O
recombined	O
Bmpr1afloxP	O
allele	B-SO
mimics	O
a	O
null	O
allele	B-SO
of	O
the	O
Bmpr1a	B-GGP
locus	B-SO
when	O
transmitted	O
through	O
the	O
germline	O
(	O
Mishina	O
et	O
al	O
.	O
2002	O
)	O
.	O

The	O
Gdf5	B-GGP
-	O
Cre	O
/	O
Bmpr1afloxP	O
conditional	O
knockout	O
mice	B-Taxon
were	O
viable	O
and	O
survived	O
to	O
adulthood	O
,	O
showing	O
that	O
the	O
Gdf5	B-GGP
-	O
Cre	O
driver	O
can	O
bypass	O
the	O
early	O
embryonic	O
lethality	O
previously	O
reported	O
in	O
animals	B-Taxon
with	O
a	O
null	O
mutation	B-SO
in	O
the	O
Bmpr1a	B-GGP
locus	B-SO
(	O
Mishina	O
et	O
al	O
.	O
1995	O
)	O
.	O

The	O
viable	O
Gdf5	B-GGP
-	O
Cre	O
/	O
Bmpr1afloxP	O
mice	B-Taxon
showed	O
several	O
phenotypes	O
.	O

First	O
,	O
the	O
conditional	O
knockout	O
mice	B-Taxon
had	O
shorter	O
ears	O
that	O
often	O
lay	O
flatter	O
against	O
their	O
heads	O
than	O
controls	O
(	O
controls	O
13	O
.	O
1	O
+/-	O
0	O
.	O
1	O
mm	O
long	O
,	O
n	O
=	O
38	O
;	O
mutants	B-SO
11	O
.	O
8	O
+/-	O
0	O
.	O
2	O
mm	O
,	O
n	O
=	O
11	O
;	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

BMP	B-GGP
signaling	O
is	O
known	O
to	O
be	O
required	O
for	O
growth	O
of	O
the	O
external	O
ear	O
of	O
mice	B-Taxon
(	O
Kingsley	O
et	O
al	O
.	O
1992	O
)	O
,	O
and	O
this	O
phenotype	O
likely	O
reflects	O
loss	O
of	O
Bmpr1a	B-GGP
function	O
in	O
the	O
fraction	O
of	O
ear	O
cells	B-CL
that	O
express	O
the	O
Gdf5	B-GGP
-	O
Cre	O
transgene	B-SO
.	O

Most	O
mutant	B-SO
mice	B-Taxon
also	O
showed	O
soft	O
tissue	O
syndactyly	O
or	O
retention	O
of	O
webbing	O
between	O
the	O
first	O
and	O
second	O
digits	O
of	O
their	O
feet	O
,	O
a	O
phenotype	O
that	O
was	O
more	O
frequent	O
and	O
more	O
severe	O
in	O
the	O
forelimbs	O
(	O
201	O
of	O
220	O
,	O
or	O
91	O
%	O
,	O
of	O
forefeet	O
and	O
109	O
of	O
220	O
,	O
or	O
50	O
%	O
,	O
of	O
hindfeet	O
)	O
.	O

Finally	O
,	O
mutant	B-SO
animals	B-Taxon
showed	O
obvious	O
skeletal	O
changes	O
in	O
whole	O
-	O
mount	O
skeletal	O
preparations	O
.	O

At	O
some	O
sites	O
in	O
the	O
ankles	O
,	O
joints	O
seemed	O
to	O
be	O
missing	O
entirely	O
,	O
with	O
fusion	O
of	O
bones	O
that	O
would	O
normally	O
be	O
separate	O
.	O

For	O
example	O
,	O
the	O
second	O
distal	O
tarsal	O
was	O
fused	O
to	O
the	O
central	O
tarsal	O
bone	O
in	O
every	O
conditional	O
knockout	O
animal	B-Taxon
examined	O
(	O
18	O
of	O
18	O
)	O
,	O
a	O
phenotype	O
not	O
observed	O
in	O
controls	O
(	O
zero	O
of	O
18	O
)	O
(	O
Figure	O
3B	O
and	O
3C	O
)	O
.	O

At	O
other	O
locations	O
,	O
joints	O
had	O
clearly	O
formed	O
but	O
showed	O
dramatic	O
loss	O
of	O
staining	O
with	O
the	O
cartilage	O
matrix	B-GO
marker	O
Alcian	O
blue	O
(	O
Figure	O
3B	O
-	O
3E	O
)	O
(	O
unpublished	O
data	O
)	O
.	O

Normal	O
Alcian	O
blue	O
staining	O
was	O
seen	O
in	O
non	O
-	O
articular	O
regions	O
,	O
such	O
as	O
the	O
cartilaginous	O
growth	O
plate	O
(	O
Figure	O
3D	O
and	O
3E	O
,	O
asterisk	O
)	O
.	O

These	O
data	O
suggest	O
that	O
Bmpr1a	B-GGP
function	O
is	O
required	O
for	O
the	O
formation	O
of	O
specific	O
joints	O
in	O
the	O
ankle	O
region	O
and	O
for	O
either	O
generation	O
or	O
maintenance	O
of	O
articular	O
cartilage	O
in	O
most	O
other	O
joints	O
of	O
the	O
limb	O
.	O

Developmental	O
Origin	O
of	O
Webbing	O
Phenotype	O

Interdigital	O
mesenchyme	O
is	O
normally	O
eliminated	O
by	O
apoptosis	O
during	O
embryonic	O
development	O
,	O
a	O
process	O
that	O
can	O
be	O
stimulated	O
by	O
BMP	B-GGP
beads	O
,	O
inhibited	O
by	O
Noggin	O
,	O
or	O
blocked	O
by	O
overexpression	O
of	O
dominant	O
-	O
negative	O
BMP	B-GGP
receptors	O
(	O
Garcia	O
-	O
Martinez	O
et	O
al	O
.	O
1993	O
;	O
Yokouchi	O
et	O
al	O
.	O
1996	O
;	O
Zou	O
and	O
Niswander	O
1996	O
;	O
Guha	O
et	O
al	O
.	O
2002	O
)	O
.	O

Limbs	O
of	O
Gdf5	B-GGP
-	O
Cre	O
/	O
Bmpr1afloxP	O
mutant	B-SO
embryos	O
showed	O
obvious	O
retention	O
of	O
interdigital	O
webbing	O
between	O
the	O
first	O
and	O
second	O
,	O
but	O
not	O
other	O
,	O
digits	O
of	O
E14	O
.	O
5	O
forelimbs	O
(	O
Figure	O
2A	O
and	O
2B	O
)	O
,	O
a	O
pattern	O
that	O
corresponds	O
to	O
the	O
presence	O
or	O
absence	O
of	O
webbing	O
seen	O
in	O
the	O
adult	O
limb	O
.	O

They	O
also	O
showed	O
excess	O
tissue	O
on	O
the	O
posterior	O
margin	O
of	O
the	O
fifth	O
digit	O
(	O
Figure	O
2B	O
,	O
arrow	O
)	O
.	O

Analysis	O
of	O
LACZ	O
expression	O
in	O
Gdf5	B-GGP
-	O
Cre	O
/	O
R26R	O
reporter	O
embryos	O
showed	O
that	O
Cre	O
-	O
mediated	O
recombination	O
has	O
occurred	O
by	O
E13	O
.	O
5	O
in	O
the	O
metacarpal	O
-	O
phalangeal	O
joints	O
,	O
and	O
in	O
the	O
interdigital	O
region	O
between	O
the	O
first	O
and	O
second	O
,	O
but	O
not	O
other	O
,	O
digits	O
.	O

In	O
addition	O
,	O
a	O
domain	O
of	O
recombination	O
and	O
expression	O
of	O
LACZ	O
is	O
also	O
reproducibly	O
seen	O
in	O
the	O
posterior	O
half	O
of	O
the	O
fifth	O
digit	O
(	O
Figure	O
2C	O
)	O
.	O

Terminal	B-GGP
deoxynucleotidyl	I-GGP
transferase	I-GGP
-	O
mediated	O
deoxyuridine	B-CHEBI
triphosphate	I-CHEBI
nick	O
end	O
labeling	O
(	O
TUNEL	O
)	O
staining	O
of	O
interdigital	O
mesenchyme	O
between	O
the	O
first	O
and	O
second	O
digits	O
(	O
Figure	O
2D	O
and	O
2E	O
)	O
and	O
the	O
fifth	O
digit	O
flanking	O
mesenchyme	O
showed	O
a	O
decreased	O
number	O
of	O
dying	O
cells	B-CL
in	O
the	O
regions	O
where	O
excess	O
tissue	O
is	O
retained	O
in	O
the	O
mutant	B-SO
limbs	O
.	O

Numbers	O
of	O
phosphorylated	O
histone	B-CHEBI
H3	O
-	O
labeled	O
proliferating	O
cells	B-CL
were	O
also	O
elevated	O
in	O
these	O
regions	O
(	O
Figure	O
2F	O
)	O
.	O

Most	O
cells	B-CL
found	O
in	O
the	O
webbed	O
region	O
between	O
the	O
first	O
and	O
second	O
digits	O
at	O
E15	O
.	O
5	O
strongly	O
expressed	O
LACZ	O
in	O
Gdf5	B-GGP
-	O
Cre	O
/	O
Bmpr1afloxP	O
mutant	B-SO
embryos	O
(	O
Figure	O
2H	O
)	O
.	O

These	O
data	O
suggest	O
that	O
regional	O
loss	O
of	O
BMPR1A	B-GGP
receptor	I-GGP
signaling	O
blocks	O
programmed	O
cell	B-CL
death	O
in	O
interdigital	O
mesenchyme	O
,	O
and	O
that	O
the	O
recombined	O
cells	B-CL
survive	O
and	O
proliferate	O
in	O
the	O
absence	O
of	O
BMPR1A	B-GGP
signaling	O
.	O

Failure	O
of	O
Early	O
Joint	O
Formation	O
in	O
Ankle	O
Regions	O

The	O
Bmpr1a	B-GGP
gene	B-SO
is	O
expressed	O
in	O
the	O
interzone	O
region	O
of	O
developing	O
joints	O
at	O
E13	O
.	O
5	O
(	O
Baur	O
et	O
al	O
.	O
2000	O
)	O
.	O

In	O
situ	O
hybridization	O
showed	O
that	O
the	O
gene	B-SO
is	O
also	O
expressed	O
in	O
the	O
interzones	O
of	O
ankle	O
joints	O
and	O
prospective	O
articular	O
cartilage	O
regions	O
of	O
digit	O
joints	O
at	O
E15	O
.	O
5	O
(	O
Figure	O
4	O
)	O
.	O

LACZ	O
staining	O
indicated	O
that	O
Cre	O
-	O
mediated	O
recombination	O
begins	O
to	O
occur	O
in	O
ankle	O
joints	O
around	O
E14	O
.	O
5	O
,	O
and	O
is	O
extensive	O
by	O
E15	O
.	O
5	O
(	O
Figure	O
4G	O
and	O
4J	O
)	O
(	O
unpublished	O
data	O
)	O
.	O

In	O
the	O
ankle	O
joint	O
regions	O
that	O
were	O
obviously	O
fused	O
in	O
postnatal	O
mutant	B-SO
animals	B-Taxon
,	O
alterations	O
in	O
early	O
joint	O
marker	O
expression	O
could	O
also	O
be	O
seen	O
by	O
E15	O
.	O
5	O
.	O

At	O
this	O
stage	O
,	O
the	O
Gdf5	B-GGP
gene	B-SO
is	O
normally	O
expressed	O
in	O
stripes	O
that	O
mark	O
the	O
sites	O
of	O
joint	O
formation	O
(	O
Figure	O
4F	O
)	O
,	O
and	O
the	O
gene	B-SO
for	O
the	O
major	O
collagen	B-GGP
protein	B-CHEBI
of	O
cartilage	O
matrix	B-GO
(	O
Col2a1	B-GGP
)	O
is	O
down	O
-	O
regulated	O
in	O
the	O
interzone	O
region	O
(	O
Figure	O
4E	O
)	O
.	O

In	O
contrast	O
,	O
Col2a1	B-GGP
staining	O
extended	O
completely	O
through	O
the	O
joint	O
region	O
between	O
the	O
second	O
and	O
central	O
tarsal	O
of	O
Gdf5	B-GGP
-	O
Cre	O
/	O
Bmpr1afloxP	O
mutants	B-SO
(	O
Figure	O
4H	O
,	O
black	O
arrow	O
)	O
,	O
and	O
Gdf5	B-GGP
expression	O
was	O
seen	O
only	O
as	O
a	O
small	O
notch	O
extending	O
into	O
where	O
the	O
joint	O
should	O
be	O
forming	O
(	O
Figure	O
4I	O
,	O
bracket	O
)	O
.	O

These	O
data	O
suggest	O
that	O
the	O
fusions	O
seen	O
between	O
ankle	O
bones	O
in	O
postnatal	O
mutant	B-SO
skeletons	O
are	O
the	O
result	O
of	O
incomplete	O
segmentation	O
of	O
skeletal	O
precursors	O
during	O
embryonic	O
development	O
,	O
a	O
defect	O
confined	O
to	O
some	O
locations	O
in	O
the	O
ankle	O
.	O

Failure	O
to	O
Maintain	O
Articular	O
Cartilage	O
in	O
Other	O
Joints	O

In	O
most	O
joints	O
of	O
Bmpr1a	B-GGP
conditional	O
knockout	O
mice	B-Taxon
,	O
embryonic	O
segmentation	O
of	O
skeletal	O
precursors	O
occurred	O
normally	O
.	O

Although	O
Gdf5	B-GGP
-	O
Cre	O
-	O
mediated	O
recombination	O
was	O
seen	O
as	O
early	O
as	O
E13	O
.	O
5	O
in	O
digit	O
interzone	O
regions	O
(	O
see	O
Figure	O
2C	O
)	O
,	O
no	O
changes	O
in	O
cell	B-CL
death	O
or	O
cell	B-CL
proliferation	O
could	O
be	O
seen	O
in	O
the	O
metacarpal	O
-	O
phalangeal	O
or	O
metatarsal	O
-	O
phalangeal	O
joints	O
at	O
E13	O
.	O
5	O
or	O
E14	O
.	O
5	O
(	O
unpublished	O
data	O
)	O
.	O

Similarly	O
,	O
although	O
clear	O
LACZ	O
expression	O
was	O
seen	O
by	O
E15	O
.	O
5	O
in	O
interphalangeal	O
joints	O
and	O
periarticular	O
regions	O
(	O
Figure	O
4D	O
)	O
,	O
no	O
difference	O
in	O
morphology	O
or	O
expression	O
of	O
Col2a1	B-GGP
,	O
Gdf5	B-GGP
,	O
or	O
Bmpr1b	B-GGP
was	O
seen	O
in	O
the	O
articular	O
regions	O
of	O
the	O
phalanges	O
at	O
these	O
stages	O
(	O
unpublished	O
data	O
)	O
.	O

At	O
birth	O
,	O
digit	O
joints	O
were	O
generally	O
indistinguishable	O
from	O
those	O
in	O
control	O
animals	B-Taxon
;	O
chondrocytes	B-CL
were	O
abundant	O
in	O
articular	O
regions	O
and	O
were	O
surrounded	O
by	O
typical	O
cartilage	O
matrix	B-GO
with	O
normal	O
staining	O
by	O
Safranin	O
O	O
,	O
a	O
histological	O
stain	O
for	O
proteoglycans	B-CHEBI
(	O
Figure	O
5	O
)	O
.	O

At	O
this	O
stage	O
,	O
both	O
wild	B-SO
-	I-SO
type	I-SO
and	O
mutant	B-SO
cells	B-CL
in	O
articular	O
regions	O
also	O
expressed	O
high	O
levels	O
of	O
Col2a1	B-GGP
and	O
Aggrecan	B-GGP
(	O
Agg	B-GGP
)	O
,	O
the	O
genes	B-SO
encoding	O
the	O
major	O
structural	O
proteins	B-CHEBI
of	O
cartilage	O
matrix	B-GO
(	O
Figure	O
5B	O
and	O
5G	O
)	O
(	O
unpublished	O
data	O
)	O
.	O

No	O
alterations	O
in	O
cellular	B-CL
apoptosis	O
or	O
proliferation	O
were	O
observed	O
(	O
unpublished	O
data	O
)	O
.	O

To	O
determine	O
whether	O
articular	O
cells	B-CL
were	O
properly	O
specified	O
in	O
mutants	B-SO
,	O
we	O
also	O
analyzed	O
expression	O
of	O
Matrilin	B-GGP
-	I-GGP
4	I-GGP
(	O
Mat4	B-GGP
)	O
,	O
a	O
gene	B-SO
expressed	O
specifically	O
in	O
the	O
periarticular	O
and	O
perichondral	O
regions	O
of	O
developing	O
joints	O
(	O
Klatt	O
et	O
al	O
.	O
2001	O
)	O
.	O

In	O
both	O
control	O
and	O
mutant	B-SO
animals	B-Taxon
,	O
transcription	O
of	O
Mat4	B-GGP
was	O
clearly	O
detectable	O
in	O
the	O
articular	O
cartilage	O
layers	O
of	O
newborn	O
joints	O
(	O
Figure	O
5D	O
and	O
5I	O
)	O
.	O

In	O
all	O
experiments	O
,	O
expression	O
of	O
LACZ	O
throughout	O
articular	O
regions	O
indicated	O
that	O
Cre	O
-	O
mediated	O
recombination	O
had	O
occurred	O
throughout	O
the	O
articular	O
regions	O
(	O
Figure	O
5C	O
,	O
5H	O
,	O
5E	O
,	O
and	O
5J	O
)	O
.	O

The	O
normal	O
histological	O
appearance	O
,	O
staining	O
properties	O
,	O
and	O
marker	O
gene	B-SO
expression	O
patterns	O
suggest	O
that	O
Bmpr1a	B-GGP
is	O
not	O
required	O
for	O
the	O
initial	O
formation	O
or	O
specification	O
of	O
articular	O
cartilage	O
.	O

By	O
1	O
wk	O
after	O
birth	O
,	O
obvious	O
differences	O
began	O
to	O
be	O
detected	O
in	O
the	O
articular	O
regions	O
of	O
mutant	B-SO
animals	B-Taxon
.	O

The	O
expression	O
of	O
Col2a1	B-GGP
was	O
reduced	O
throughout	O
the	O
articular	O
surfaces	O
of	O
the	O
carpals	O
,	O
metacarpals	O
,	O
and	O
phalanges	O
of	O
the	O
forefeet	O
(	O
unpublished	O
data	O
)	O
.	O

Less	O
severe	O
reductions	O
were	O
also	O
seen	O
in	O
articular	O
cells	B-CL
of	O
tarsals	O
and	O
metatarsals	O
in	O
the	O
hindfeet	O
(	O
unpublished	O
data	O
)	O
.	O

By	O
2	O
wk	O
of	O
age	O
,	O
Col2a1	B-GGP
expression	O
was	O
reduced	O
in	O
most	O
cells	B-CL
of	O
the	O
articular	O
region	O
(	O
Figure	O
5L	O
and	O
5Q	O
)	O
,	O
accompanied	O
by	O
markedly	O
reduced	O
Safranin	O
O	O
staining	O
(	O
Figure	O
5K	O
and	O
5P	O
)	O
,	O
and	O
decreased	O
expression	O
of	O
Agg	B-GGP
and	O
two	O
genes	B-SO
normally	O
expressed	O
in	O
more	O
mature	O
articular	O
cartilage	B-CL
cells	I-CL
,	O
Collagen	B-GGP
3	I-GGP
(	O
Col3a1	B-GGP
)	O
and	O
Collagen	B-GGP
10	I-GGP
(	O
Col10a1	B-GGP
)	O
(	O
Figure	O
5M	O
and	O
5R	O
)	O
(	O
unpublished	O
data	O
)	O
(	O
Eyre	O
2002	O
)	O
.	O

Inhibition	O
of	O
BMP	B-GGP
signaling	O
in	O
cultured	O
chondrocytes	B-CL
has	O
previously	O
been	O
reported	O
to	O
induce	O
Collagen	B-GGP
1	I-GGP
(	O
Col1a1	B-GGP
)	O
expression	O
,	O
increase	O
proliferation	O
,	O
and	O
result	O
in	O
cells	B-CL
with	O
flattened	O
,	O
fibroblast	B-CL
-	O
like	O
morphology	O
(	O
Enomoto	O
-	O
Iwamoto	O
et	O
al	O
.	O
1998	O
)	O
.	O

However	O
,	O
we	O
saw	O
no	O
increase	O
in	O
the	O
expression	O
of	O
Col1a1	B-GGP
in	O
mutant	B-SO
articular	O
cartilage	O
,	O
and	O
no	O
proliferation	O
was	O
detected	O
in	O
articular	O
cells	B-CL
of	O
either	O
mutant	B-SO
or	O
control	O
animals	B-Taxon
(	O
unpublished	O
data	O
)	O
.	O

While	O
recombined	O
LACZ	O
marker	O
expression	O
was	O
detected	O
in	O
most	O
articular	O
cartilage	B-CL
cells	I-CL
,	O
it	O
was	O
also	O
observed	O
in	O
scattered	O
subarticular	O
chondrocytes	B-CL
,	O
growth	O
plate	O
chondrocytes	B-CL
,	O
and	O
osteoblasts	B-CL
(	O
Figure	O
5O	O
and	O
5T	O
)	O
(	O
unpublished	O
data	O
)	O
.	O

Although	O
this	O
implies	O
that	O
BMP	B-GGP
signaling	O
was	O
defective	O
in	O
multiple	O
cell	B-CL
types	O
,	O
the	O
observed	O
defects	O
were	O
confined	O
to	O
the	O
articular	O
cartilage	O
.	O

For	O
example	O
,	O
Osteocalcin	B-GGP
and	O
Col1a1	B-GGP
expression	O
appeared	O
normal	O
in	O
osteoblasts	B-CL
(	O
unpublished	O
data	O
)	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
BMPR1A	B-GGP
activity	O
is	O
required	O
in	O
postnatal	O
joint	O
articular	O
cartilage	O
to	O
maintain	O
expression	O
of	O
many	O
genes	B-SO
encoding	O
structural	O
components	B-GO
of	I-GO
cartilage	I-GO
matrix	I-GO
.	O

Previous	O
studies	O
have	O
shown	O
that	O
Sox9	B-GGP
is	O
required	O
for	O
normal	O
cartilage	O
differentiation	O
,	O
for	O
expression	O
of	O
cartilage	O
extracellular	B-GO
matrix	I-GO
(	O
ECM	B-GO
)	O
genes	B-SO
including	O
Agg	B-GGP
,	O
and	O
is	O
a	O
direct	O
transcriptional	O
regulator	O
of	O
the	O
key	O
cartilage	O
matrix	B-GO
gene	B-SO
Col2a1	B-GGP
(	O
Bell	O
et	O
al	O
.	O
1997	O
;	O
Lefebvre	O
et	O
al	O
.	O
1997	O
;	O
Bi	O
et	O
al	O
.	O
1999	O
;	O
Sekiya	O
et	O
al	O
.	O
2000	O
)	O
.	O

Notably	O
,	O
despite	O
reduced	O
expression	O
of	O
many	O
cartilage	O
matrix	B-GO
marker	O
genes	B-SO
in	O
Bmpr1a	B-GGP
mutant	B-SO
mice	B-Taxon
,	O
the	O
SOX9	B-GGP
protein	B-CHEBI
was	O
present	O
at	O
normal	O
levels	O
in	O
articular	O
regions	O
at	O
all	O
stages	O
examined	O
,	O
including	O
newborn	O
,	O
2	O
-	O
wk	O
-	O
old	O
,	O
7	O
-	O
wk	O
-	O
old	O
,	O
and	O
9	O
-	O
mo	O
-	O
old	O
mice	B-Taxon
(	O
Figure	O
5N	O
and	O
5S	O
)	O
(	O
unpublished	O
data	O
)	O
.	O

Synovial	O
Hypertrophy	O
,	O
Cartilage	O
Erosion	O
,	O
and	O
Accelerated	O
Cartilage	O
Maturation	O

Conditional	O
loss	O
of	O
Bmpr1a	B-GGP
led	O
to	O
marked	O
hypertrophy	O
of	O
the	O
synovial	O
membrane	O
in	O
the	O
joint	O
capsule	O
of	O
some	O
joints	O
,	O
particularly	O
in	O
the	O
ankle	O
region	O
.	O

In	O
the	O
most	O
severely	O
affected	O
joints	O
,	O
the	O
expanded	O
synovial	O
membrane	O
grew	O
into	O
the	O
joint	O
space	O
and	O
was	O
associated	O
with	O
obvious	O
loss	O
or	O
erosion	O
of	O
the	O
articular	O
cartilage	O
(	O
Figure	O
6A	O
and	O
6B	O
,	O
asterisks	O
,	O
arrows	O
)	O
.	O

Accelerated	O
cartilage	O
maturation	O
and	O
increased	O
expression	O
of	O
Col10a1	B-GGP
was	O
frequently	O
seen	O
in	O
the	O
chondrocytes	B-CL
underlying	O
the	O
articular	O
erosions	O
(	O
Figure	O
6C	O
and	O
6D	O
,	O
brackets	O
)	O
(	O
unpublished	O
data	O
)	O
.	O

Interestingly	O
,	O
the	O
regions	O
of	O
increased	O
Col10a1	B-GGP
expression	O
did	O
not	O
correspond	O
to	O
the	O
regions	O
that	O
had	O
undergone	O
Cre	O
-	O
mediated	O
recombination	O
.	O

Instead	O
,	O
increased	O
expression	O
of	O
Col10a1	B-GGP
was	O
seen	O
in	O
a	O
zone	O
of	O
largely	O
LACZ	O
-	O
negative	O
cells	B-CL
stretching	O
from	O
the	O
cartilage	O
adjacent	O
to	O
the	O
ossification	O
front	O
(	O
where	O
Col10a1	B-GGP
is	O
normally	O
expressed	O
in	O
maturing	O
cartilage	B-CL
cells	I-CL
)	O
,	O
toward	O
the	O
regions	O
where	O
surface	O
articular	O
cartilage	O
was	O
severely	O
eroded	O
or	O
missing	O
(	O
Figure	O
6A	O
and	O
6B	O
,	O
arrowheads	O
)	O
.	O

Previous	O
studies	O
suggest	O
that	O
parathyroid	B-GGP
hormone	I-GGP
-	I-GGP
related	I-GGP
protein	I-GGP
,	O
a	O
diffusible	O
signal	O
made	O
in	O
the	O
articular	O
surface	O
,	O
may	O
normally	O
inhibit	O
maturation	O
of	O
underlying	O
cartilage	O
(	O
Vortkamp	O
et	O
al	O
.	O
1996	O
;	O
Weir	O
et	O
al	O
.	O
1996	O
)	O
.	O

Local	O
loss	O
of	O
the	O
articular	O
surface	O
could	O
remove	O
this	O
inhibition	O
and	O
lead	O
to	O
a	O
cell	B-CL
-	O
nonautonomous	O
acceleration	O
of	O
maturation	O
in	O
chondrocytes	B-CL
underlying	O
points	O
of	O
articular	O
erosion	O
.	O

This	O
synovial	O
hypertrophy	O
is	O
associated	O
with	O
increased	O
numbers	O
of	O
mononuclear	B-CL
cells	I-CL
resembling	O
synoviocytes	B-CL
or	O
macrophages	B-CL
,	O
cell	B-CL
types	O
that	O
are	O
difficult	O
to	O
distinguish	O
even	O
with	O
surface	B-GO
markers	O
at	O
early	O
postnatal	O
stages	O
.	O

However	O
,	O
no	O
neutrophils	B-CL
were	O
observed	O
,	O
suggesting	O
that	O
there	O
is	O
little	O
inflammation	O
.	O

At	O
later	O
stages	O
synovial	O
hypertrophy	O
is	O
reduced	O
.	O

Further	O
work	O
will	O
be	O
needed	O
to	O
determine	O
whether	O
synovial	O
development	O
is	O
regulated	O
by	O
BMP	B-GGP
signaling	O
,	O
or	O
whether	O
the	O
synovium	O
becomes	O
enlarged	O
as	O
a	O
response	O
to	O
nearby	O
skeletal	O
malformations	O
(	O
such	O
as	O
fusion	O
of	O
the	O
second	O
and	O
central	O
tarsals	O
or	O
defects	O
in	O
the	O
articular	O
cartilage	O
)	O
.	O

Noninflammatory	O
Degeneration	O
of	O
Articular	O
Cartilage	O
in	O
Digit	O
and	O
Knee	O
Joints	O

Outside	O
of	O
the	O
ankle	O
region	O
,	O
little	O
or	O
no	O
evidence	O
was	O
seen	O
for	O
expansion	O
of	O
the	O
synovial	O
membrane	O
.	O

Instead	O
,	O
mutant	B-SO
mice	B-Taxon
showed	O
histological	O
signs	O
of	O
osteoarthritis	O
,	O
such	O
as	O
fibrillation	O
of	O
the	O
articular	O
surface	O
(	O
Figure	O
7	O
)	O
.	O

As	O
previously	O
seen	O
in	O
1	O
-	O
and	O
2	O
-	O
wk	O
-	O
old	O
animals	B-Taxon
,	O
Safranin	O
O	O
staining	O
and	O
Agg	B-GGP
and	O
Col10	B-GGP
expression	O
were	O
all	O
reduced	O
in	O
mutant	B-SO
articular	O
regions	O
of	O
the	O
forefeet	O
and	O
hindfeet	O
by	O
7	O
wk	O
of	O
age	O
,	O
and	O
the	O
beginning	O
signs	O
of	O
cartilage	O
loss	O
were	O
observed	O
(	O
unpublished	O
data	O
)	O
.	O

By	O
9	O
mo	O
of	O
age	O
,	O
many	O
regions	O
of	O
articular	O
cartilage	O
were	O
completely	O
missing	O
or	O
extremely	O
fibrillated	O
,	O
leaving	O
regions	O
of	O
exposed	O
bone	O
on	O
the	O
surface	O
(	O
Figure	O
7A	O
-	O
7D	O
)	O
.	O

No	O
alterations	O
were	O
seen	O
in	O
the	O
expression	O
of	O
Osteocalcin	B-GGP
,	O
Col1a1	B-GGP
,	O
or	O
matrix	B-GGP
metalloprotease	I-GGP
-	I-GGP
13	I-GGP
at	O
either	O
7	O
wk	O
or	O
9	O
mo	O
.	O

The	O
major	O
weight	O
-	O
bearing	O
joint	O
of	O
the	O
hindlimb	O
,	O
the	O
knee	O
,	O
showed	O
changes	O
that	O
closely	O
paralleled	O
that	O
seen	O
in	O
the	O
foot	O
joints	O
.	O

All	O
markers	O
of	O
cartilage	O
matrix	B-GO
looked	O
similar	O
to	O
controls	O
at	O
E16	O
.	O
5	O
,	O
suggesting	O
that	O
early	O
stages	O
of	O
joint	O
formation	O
were	O
not	O
disrupted	O
(	O
unpublished	O
data	O
)	O
.	O

By	O
postnatal	O
day	O
7	O
,	O
Safranin	O
O	O
staining	O
and	O
Col2a1	B-GGP
and	O
Agg	B-GGP
expression	O
were	O
clearly	O
reduced	O
in	O
the	O
mutant	B-SO
,	O
despite	O
continued	O
expression	O
of	O
Sox9	B-GGP
(	O
unpublished	O
data	O
)	O
.	O

The	O
overall	O
shape	O
of	O
mutant	B-SO
knee	O
skeletal	O
elements	O
appeared	O
similar	O
to	O
controls	O
,	O
although	O
the	O
fibrocartilaginous	O
meniscus	O
that	O
resides	O
between	O
the	O
femur	O
and	O
tibia	O
appeared	O
much	O
less	O
dense	O
in	O
mutants	B-SO
at	O
E16	O
.	O
5	O
.	O

Some	O
cartilage	O
formed	O
in	O
the	O
meniscus	O
region	O
,	O
but	O
the	O
size	O
of	O
these	O
elements	O
was	O
greatly	O
reduced	O
and	O
contained	O
abundant	O
cells	B-CL
with	O
fibrous	O
,	O
noncartilaginous	O
appearance	O
(	O
unpublished	O
data	O
)	O
.	O

This	O
reduction	O
of	O
the	O
meniscus	O
can	O
also	O
be	O
seen	O
in	O
sections	O
from	O
7	O
-	O
wk	O
-	O
and	O
9	O
-	O
mo	O
-	O
old	O
animals	B-Taxon
(	O
Figure	O
7E	O
,	O
7H	O
,	O
7K	O
,	O
and	O
7N	O
,	O
arrows	O
)	O
.	O

At	O
7	O
wk	O
of	O
age	O
the	O
normally	O
domed	O
tibial	O
epiphysis	O
was	O
flattened	O
and	O
depressed	O
in	O
the	O
knees	O
of	O
mutant	B-SO
animals	B-Taxon
,	O
markedly	O
reducing	O
the	O
distance	O
between	O
the	O
growth	O
plate	O
and	O
articular	O
surface	O
(	O
Figure	O
7E	O
and	O
7H	O
,	O
vertical	O
bar	O
)	O
.	O

Articular	O
cartilage	O
was	O
also	O
thinner	O
than	O
in	O
control	O
animals	B-Taxon
,	O
showed	O
nearly	O
complete	O
absence	O
of	O
Safranin	O
O	O
staining	O
,	O
and	O
was	O
either	O
acellular	O
or	O
beginning	O
to	O
fibrillate	O
in	O
many	O
regions	O
(	O
Figure	O
7F	O
and	O
7I	O
)	O
.	O

The	O
few	O
large	O
Safranin	O
O	O
-	O
stained	O
cells	B-CL
still	O
apparent	O
in	O
mutant	B-SO
articular	O
regions	O
appeared	O
to	O
correspond	O
in	O
position	O
to	O
rare	O
LACZ	O
-	O
negative	O
cells	B-CL
in	O
adjacent	O
sections	O
,	O
suggesting	O
that	O
Bmpr1a	B-GGP
is	O
required	O
cell	B-CL
-	O
autonomously	O
in	O
articular	O
cartilage	O
(	O
Figure	O
7I	O
and	O
7J	O
,	O
white	O
arrowheads	O
)	O
.	O

By	O
9	O
mo	O
,	O
large	O
areas	O
of	O
mutant	B-SO
knees	O
were	O
devoid	O
of	O
articular	O
cells	B-CL
,	O
and	O
the	O
bones	O
of	O
the	O
femur	O
and	O
tibia	O
appeared	O
to	O
rub	O
directly	O
against	O
each	O
other	O
.	O

Furthermore	O
,	O
the	O
epiphysis	O
of	O
the	O
tibia	O
was	O
extremely	O
depressed	O
,	O
to	O
the	O
point	O
that	O
growth	O
plate	O
cartilage	O
was	O
almost	O
exposed	O
through	O
the	O
surface	O
of	O
the	O
bone	O
(	O
Figure	O
7K	O
,	O
7L	O
,	O
7N	O
,	O
and	O
7O	O
)	O
.	O

In	O
addition	O
,	O
mutants	B-SO
at	O
7	O
wk	O
and	O
9	O
mo	O
showed	O
subchondral	O
sclerosis	O
,	O
especially	O
in	O
the	O
epiphysis	O
of	O
the	O
femur	O
(	O
Figure	O
7E	O
,	O
7H	O
,	O
7K	O
,	O
and	O
7N	O
,	O
asterisks	O
)	O
.	O

While	O
subchondral	O
sclerosis	O
is	O
commonly	O
seen	O
in	O
cases	O
of	O
osteoarthritis	O
,	O
it	O
is	O
unclear	O
in	O
this	O
case	O
whether	O
the	O
sclerosis	O
is	O
mainly	O
a	O
response	O
of	O
bone	O
formation	O
to	O
compensate	O
for	O
decreased	O
articular	O
cartilage	O
,	O
or	O
whether	O
it	O
is	O
the	O
effect	O
of	O
loss	O
of	O
Bmpr1a	B-GGP
signaling	O
in	O
some	O
LACZ	O
-	O
positive	O
cells	B-CL
that	O
are	O
also	O
observed	O
in	O
these	O
regions	O
(	O
unpublished	O
data	O
)	O
.	O

The	O
histological	O
signs	O
of	O
joint	O
arthritis	O
were	O
accompanied	O
by	O
functional	O
impairments	O
in	O
both	O
grasping	O
ability	O
and	O
range	O
of	O
motion	O
in	O
mutant	B-SO
animals	B-Taxon
.	O

Gdf5	B-GGP
-	O
Cre	O
/	O
Bmpr1afloxP	O
mutant	B-SO
animals	B-Taxon
showed	O
a	O
highly	O
significantly	O
reduced	O
ability	O
to	O
grasp	O
and	O
remain	O
suspended	O
on	O
a	O
slender	O
rod	O
(	O
mean	O
suspension	O
time	O
:	O
controls	O
38	O
+/-	O
6	O
s	O
,	O
n	O
=	O
39	O
;	O
mutants	B-SO
6	O
+/-	O
3	O
s	O
,	O
n	O
=	O
11	O
;	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Mutant	B-SO
mice	B-Taxon
also	O
showed	O
a	O
clear	O
decrease	O
in	O
the	O
maximum	O
range	O
of	O
mobility	O
of	O
two	O
different	O
joints	O
in	O
the	O
digits	O
,	O
as	O
assayed	O
by	O
passive	O
manipulation	O
(	O
MT	O
/	O
P1	O
joint	O
:	O
controls	O
100	O
+/-	O
0	O
degrees	O
,	O
n	O
=	O
26	O
;	O
mutants	B-SO
82	O
+/-	O
3	O
degrees	O
,	O
n	O
=	O
8	O
;	O
p	O
<	O
0	O
.	O
0003	O
;	O
P1	O
/	O
P2	O
joint	O
:	O
controls	O
152	O
+/-	O
1	O
degrees	O
,	O
n	O
=	O
23	O
;	O
mutants	B-SO
140	O
+/-	O
5	O
degrees	O
,	O
n	O
=	O
6	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
structural	O
,	O
histological	O
,	O
marker	O
gene	B-SO
expression	O
,	O
and	O
functional	O
changes	O
in	O
mutant	B-SO
mice	B-Taxon
demonstrate	O
that	O
BMPR1A	B-GGP
is	O
required	O
for	O
normal	O
postnatal	O
maintenance	O
of	O
articular	O
cartilage	O
.	O

Discussion	O

Previous	O
studies	O
suggest	O
that	O
BMP	B-GGP
signaling	O
is	O
involved	O
in	O
a	O
large	O
number	O
of	O
developmental	O
events	O
.	O

Many	O
of	O
these	O
events	O
occur	O
early	O
in	O
embryogenesis	O
,	O
and	O
complete	O
inactivation	O
of	O
BMP	B-GGP
receptors	O
causes	O
death	O
by	O
E9	O
.	O
5	O
(	O
Mishina	O
et	O
al	O
.	O
1995	O
)	O
.	O

The	O
Gdf5	B-GGP
-	O
Cre	O
recombination	O
system	O
bypasses	O
the	O
early	O
embryonic	O
lethality	O
of	O
Bmpr1a	B-GGP
mutations	B-SO
,	O
and	O
provides	O
important	O
new	O
information	O
about	O
the	O
role	O
of	O
this	O
receptor	O
in	O
limb	O
and	O
skeletal	O
development	O
.	O

The	O
three	O
major	O
limb	O
phenotypes	O
revealed	O
by	O
eliminating	B-SO
Bmpr1a	B-GGP
with	O
Gdf5	B-GGP
-	O
driven	O
Cre	O
include	O
webbing	O
between	O
digits	O
,	O
lack	O
of	O
joint	O
formation	O
at	O
specific	O
locations	O
in	O
the	O
ankle	O
,	O
and	O
failure	O
to	O
maintain	O
articular	O
cartilage	O
after	O
birth	O
,	O
resulting	O
in	O
severe	O
arthritis	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
manipulation	O
of	O
BMP	B-GGP
signaling	O
alters	O
interdigital	O
apoptosis	O
during	O
development	O
of	O
the	O
limb	O
,	O
but	O
no	O
experiment	O
has	O
identified	O
a	O
specific	O
member	O
of	O
the	O
BMP	B-GGP
signaling	O
pathway	O
that	O
is	O
required	O
for	O
this	O
process	O
(	O
Yokouchi	O
et	O
al	O
.	O
1996	O
;	O
Zou	O
and	O
Niswander	O
1996	O
;	O
Zou	O
et	O
al	O
.	O
1997	O
;	O
Guha	O
et	O
al	O
.	O
2002	O
)	O
.	O

Our	O
new	O
loss	O
-	O
of	O
-	O
function	O
data	O
confirm	O
that	O
BMP	B-GGP
signaling	O
is	O
required	O
for	O
interdigital	O
apoptosis	O
and	O
suggests	O
that	O
Bmpr1a	B-GGP
is	O
a	O
critical	O
component	O
for	O
mediating	O
this	O
signal	O
.	O

At	O
some	O
sites	O
,	O
loss	O
of	O
Bmpr1a	B-GGP
function	O
leads	O
to	O
a	O
defect	O
in	O
the	O
early	O
stages	O
of	O
joint	O
formation	O
,	O
resulting	O
in	O
a	O
complete	O
failure	O
to	O
form	O
a	O
joint	O
and	O
fusion	O
of	O
bones	O
in	O
the	O
ankle	O
.	O

Mutations	B-SO
in	O
two	O
different	O
ligands	O
in	O
the	O
BMP	B-GGP
family	O
,	O
Gdf5	B-GGP
and	O
Gdf6	B-GGP
,	O
the	O
Bmpr1b	B-GGP
receptor	O
,	O
and	O
in	O
the	O
human	B-GGP
Noggin	I-GGP
locus	B-SO
(	O
Storm	O
and	O
Kingsley	O
1996	O
;	O
Gong	O
et	O
al	O
.	O
1999	O
;	O
Baur	O
et	O
al	O
.	O
2000	O
;	O
Yi	O
et	O
al	O
.	O
2000	O
;	O
Settle	O
et	O
al	O
.	O
2003	O
)	O
also	O
produce	O
defects	O
in	O
joint	O
formation	O
at	O
specific	O
locations	O
in	O
the	O
limbs	O
.	O

The	O
joint	O
defects	O
associated	O
with	O
multiple	O
components	O
of	O
the	O
BMP	B-GGP
pathway	O
provide	O
strong	O
evidence	O
that	O
BMP	B-GGP
signaling	O
is	O
required	O
for	O
early	O
stages	O
of	O
joint	O
formation	O
at	O
some	O
anatomical	O
locations	O
.	O

Most	O
joints	O
still	O
form	O
normally	O
when	O
Bmpr1a	B-GGP
is	O
knocked	O
out	O
in	O
Gdf5	B-GGP
expression	O
domains	O
.	O

The	O
lack	O
of	O
joint	O
fusions	O
outside	O
the	O
ankle	O
region	O
could	O
be	O
due	O
to	O
differences	O
in	O
requirement	O
for	O
BMP	B-GGP
signaling	O
in	O
different	O
joints	O
,	O
to	O
compensating	O
expression	O
of	O
other	O
BMP	B-GGP
receptors	O
outside	O
the	O
ankles	O
,	O
or	O
to	O
differences	O
in	O
the	O
detailed	O
timing	O
of	O
Gdf5	B-GGP
-	O
Cre	O
stimulated	O
gene	B-SO
inactivation	O
in	O
ankles	O
and	O
other	O
joint	O
regions	O
.	O

Comparison	O
of	O
the	O
expression	O
of	O
the	O
HPLAP	B-GGP
marker	O
(	O
driven	O
directly	O
by	O
Gdf5	B-GGP
control	O
elements	O
)	O
and	O
the	O
R26R	O
LACZ	O
marker	O
(	O
expressed	O
following	O
Gdf5	B-GGP
-	O
Cre	O
recombination	O
)	O
suggests	O
that	O
recombination	O
-	O
stimulated	O
changes	O
in	O
gene	B-SO
expression	O
may	O
be	O
delayed	O
for	O
a	O
0	O
.	O
5	O
-	O
1	O
d	O
in	O
the	O
digit	O
region	O
(	O
see	O
Figure	O
1C	O
)	O
.	O

In	O
addition	O
,	O
levels	O
of	O
Bmpr1a	B-GGP
mRNA	B-CHEBI
and	O
protein	B-CHEBI
may	O
persist	O
for	O
some	O
time	O
following	O
Gdf5	B-GGP
-	O
Cre	O
stimulated	O
recombination	O
,	O
making	O
it	O
possible	O
to	O
bypass	O
an	O
early	O
requirement	O
for	O
Bmpr1a	B-GGP
in	O
joint	O
formation	O
at	O
some	O
locations	O
.	O

Following	O
the	O
decay	O
of	O
Bmpr1a	B-GGP
mRNA	B-CHEBI
and	O
protein	B-CHEBI
,	O
the	O
Gdf5	B-GGP
-	O
Cre	O
strategy	O
should	O
result	O
in	O
permanent	O
inactivation	O
of	O
Bmpr1a	B-GGP
function	O
in	O
recombined	O
cells	B-CL
.	O

This	O
system	O
thus	O
provides	O
one	O
of	O
the	O
first	O
strong	O
genetic	B-SO
tests	O
of	O
Bmpr1a	B-GGP
function	O
at	O
later	O
stages	O
of	O
joint	O
development	O
.	O

Despite	O
the	O
normal	O
appearance	O
of	O
articular	O
regions	O
and	O
gene	B-SO
expression	O
immediately	O
after	O
birth	O
,	O
Bmpr1a	B-GGP
-	O
deficient	O
animals	B-Taxon
are	O
unable	O
to	O
maintain	O
the	O
normal	O
differentiated	O
state	O
of	O
articular	O
cartilage	O
as	O
they	O
continue	O
to	O
develop	O
and	O
age	O
.	O

These	O
results	O
suggest	O
that	O
BMP	B-GGP
receptor	O
signaling	O
is	O
essential	O
for	O
continued	O
health	O
and	O
integrity	O
of	O
articular	O
cartilage	O
in	O
the	O
postnatal	O
period	O
.	O

Articular	O
cartilage	O
is	O
a	O
key	O
component	O
of	O
synovial	O
joints	O
and	O
is	O
one	O
of	O
the	O
few	O
regions	O
in	O
the	O
skeleton	O
where	O
cartilage	O
is	O
maintained	O
into	O
adulthood	O
.	O

Despite	O
the	O
importance	O
of	O
articular	O
cartilage	O
in	O
joint	O
health	O
and	O
mobility	O
,	O
little	O
is	O
known	O
about	O
the	O
factors	O
that	O
create	O
and	O
maintain	O
it	O
in	O
thin	O
layers	O
at	O
the	O
ends	O
of	O
long	O
bones	O
.	O

In	O
our	O
experiments	O
,	O
articular	O
cartilage	O
lacking	O
Bmpr1a	B-GGP
retains	O
some	O
normal	O
characteristics	O
,	O
in	O
that	O
it	O
maintains	O
a	O
very	O
low	O
proliferation	O
rate	O
,	O
does	O
not	O
express	O
Col1a1	B-GGP
,	O
and	O
continues	O
to	O
express	O
SOX9	B-GGP
,	O
a	O
major	O
transcription	O
factor	O
regulating	O
expression	O
of	O
structural	O
components	B-GO
of	I-GO
cartilage	I-GO
matrix	I-GO
.	O

However	O
,	O
several	O
of	O
the	O
most	O
prominent	O
structural	O
components	B-GO
of	I-GO
cartilage	I-GO
matrix	I-GO
fail	O
to	O
be	O
maintained	O
in	O
mutant	B-SO
animals	B-Taxon
,	O
resulting	O
in	O
decreased	O
synthesis	O
of	O
Col2a1	B-GGP
,	O
Agg	B-GGP
,	O
and	O
proteoglycans	B-CHEBI
.	O

Therefore	O
,	O
BMPR1A	B-GGP
appears	O
to	O
maintain	O
articular	O
cartilage	O
primarily	O
through	O
inducing	O
expression	O
of	O
key	O
ECM	B-GO
components	I-GO
.	O

It	O
is	O
interesting	O
that	O
the	O
SOX9	B-GGP
transcription	I-GGP
factor	I-GGP
continues	O
to	O
be	O
expressed	O
in	O
mutant	B-SO
cartilage	O
despite	O
loss	O
of	O
Col2a1	B-GGP
,	O
a	O
direct	O
target	O
of	O
this	O
transcription	O
factor	O
(	O
Bell	O
et	O
al	O
.	O
1997	O
;	O
Lefebvre	O
et	O
al	O
.	O
1997	O
)	O
.	O

Previous	O
studies	O
suggest	O
that	O
SOX9	B-GGP
activity	O
can	O
be	O
modified	O
by	O
protein	B-CHEBI
kinase	O
A	O
(	O
PKA	O
)	O
-	O
dependent	O
protein	B-CHEBI
phosphorylation	O
,	O
or	O
by	O
coexpression	O
of	O
two	O
related	O
proteins	B-CHEBI
,	O
L	B-GGP
-	I-GGP
SOX5	I-GGP
and	O
SOX6	B-GGP
(	O
Lefebvre	O
et	O
al	O
.	O
1998	O
;	O
Huang	O
et	O
al	O
.	O
2000	O
)	O
.	O

In	O
addition	O
,	O
close	O
examination	O
of	O
the	O
order	O
of	O
genes	B-SO
induced	O
during	O
chicken	B-Taxon
digit	O
formation	O
reveals	O
that	O
Sox9	B-GGP
turns	O
on	O
first	O
,	O
followed	O
by	O
Bmpr1b	B-GGP
with	O
L	B-GGP
-	I-GGP
Sox5	I-GGP
,	O
and	O
then	O
Sox6	B-GGP
and	O
the	O
cartilage	O
matrix	B-GO
structural	I-GO
components	I-GO
Col2a1	B-GGP
and	O
Agg	B-GGP
(	O
Chimal	O
-	O
Monroy	O
et	O
al	O
.	O
2003	O
)	O
.	O

These	O
results	O
,	O
together	O
with	O
the	O
altered	O
pattern	O
of	O
gene	B-SO
expression	O
seen	O
in	O
our	O
Bmpr1a	B-GGP
-	O
deficient	O
mice	B-Taxon
,	O
suggest	O
that	O
BMPR1A	B-GGP
signaling	O
may	O
normally	O
act	O
to	O
stimulate	O
SOX9	B-GGP
by	O
post	O
-	O
translational	O
protein	B-CHEBI
modification	O
,	O
or	O
to	O
induce	O
L	B-GGP
-	I-GGP
Sox5	I-GGP
or	O
Sox6	B-GGP
in	O
cartilage	O
to	O
maintain	O
expression	O
of	O
ECM	B-GO
components	I-GO
.	O

These	O
models	O
are	O
consistent	O
with	O
the	O
ability	O
of	O
BMP2	B-GGP
to	O
both	O
increase	O
PKA	O
activity	O
and	O
induce	O
expression	O
of	O
Sox6	B-GGP
in	O
tissue	O
culture	O
cells	B-CL
(	O
Lee	O
and	O
Chuong	O
1997	O
;	O
Fernandez	O
-	O
Lloris	O
et	O
al	O
.	O
2003	O
)	O
.	O

Although	O
we	O
have	O
tried	O
to	O
monitor	O
the	O
expression	O
of	O
L	B-GGP
-	I-GGP
Sox5	I-GGP
or	O
Sox6	B-GGP
in	O
postnatal	O
articular	O
cartilage	O
,	O
and	O
test	O
the	O
phosphorylation	O
state	O
of	O
SOX9	B-GGP
using	O
previously	O
described	O
reagents	B-CHEBI
(	O
Lefebvre	O
et	O
al	O
.	O
1998	O
;	O
Huang	O
et	O
al	O
.	O
2000	O
)	O
,	O
we	O
have	O
been	O
unable	O
to	O
obtain	O
specific	O
signal	O
at	O
the	O
late	O
postnatal	O
stages	O
required	O
(	O
unpublished	O
data	O
)	O
.	O

Furthermore	O
,	O
null	O
mutations	B-SO
in	O
L	B-GGP
-	I-GGP
Sox5	I-GGP
or	O
Sox	B-GGP
-	I-GGP
6	I-GGP
cause	O
lethality	O
at	O
or	O
soon	O
after	O
birth	O
,	O
and	O
no	O
effect	O
on	O
cartilage	O
maintenance	O
has	O
been	O
reported	O
(	O
Smits	O
et	O
al	O
.	O
2001	O
)	O
.	O

However	O
,	O
it	O
seems	O
likely	O
that	O
these	O
or	O
other	O
processes	O
regulated	O
by	O
BMP	B-GGP
signaling	O
cooperate	O
with	O
SOX9	B-GGP
to	O
induce	O
target	O
genes	B-SO
in	O
articular	O
cartilage	O
.	O

Mutation	B-SO
of	O
Smad3	B-GGP
or	O
expression	O
of	O
dominant	O
negative	O
transforming	B-GGP
growth	I-GGP
factor	I-GGP
beta	I-GGP
(	I-GGP
TGF	I-GGP
-	I-GGP
beta	I-GGP
)	I-GGP
type	I-GGP
II	I-GGP
receptor	I-GGP
also	O
disrupts	O
normal	O
articular	O
cartilage	O
maintenance	O
(	O
Serra	O
et	O
al	O
.	O
1997	O
;	O
Yang	O
et	O
al	O
.	O
2001	O
)	O
.	O

Both	O
manipulations	O
should	O
disrupt	O
TGF	B-GGP
beta	I-GGP
rather	O
than	O
BMP	B-GGP
signaling	O
,	O
and	O
both	O
manipulations	O
cause	O
articular	O
cartilage	O
to	O
hypertrophy	O
and	O
be	O
replaced	O
by	O
bone	O
.	O

In	O
contrast	O
,	O
our	O
analysis	O
of	O
Bmpr1a	B-GGP
mutant	B-SO
articular	O
cartilage	O
showed	O
a	O
loss	O
of	O
ECM	B-GO
components	I-GO
,	O
but	O
no	O
signs	O
of	O
hypertrophy	O
or	O
bone	O
replacement	O
.	O

Therefore	O
,	O
TGF	B-GGP
beta	I-GGP
and	O
BMP	B-GGP
signaling	O
are	O
playing	O
distinct	O
but	O
necessary	O
roles	O
to	O
maintain	O
articular	O
cartilage	O
.	O

Although	O
BMPs	B-GGP
were	O
originally	O
isolated	O
on	O
the	O
basis	O
of	O
their	O
ability	O
to	O
induce	O
ectopic	O
bone	O
formation	O
,	O
their	O
presence	O
in	O
articular	O
cartilage	O
and	O
strong	O
effect	O
on	O
cartilage	O
formation	O
has	O
stimulated	O
interest	O
in	O
using	O
them	O
to	O
repair	O
or	O
regenerate	O
cartilage	O
defects	O
in	O
adult	O
animals	B-Taxon
(	O
Chang	O
et	O
al	O
.	O
1994	O
;	O
Erlacher	O
et	O
al	O
.	O
1998	O
;	O
Edwards	O
and	O
Francis	O
-	O
West	O
2001	O
;	O
Chubinskaya	O
and	O
Kuettner	O
2003	O
)	O
.	O

The	O
failure	O
to	O
maintain	O
articular	O
cartilage	O
in	O
the	O
absence	O
of	O
normal	O
BMPR1A	B-GGP
function	O
suggests	O
that	O
ligands	O
or	O
small	O
molecule	B-CHEBI
agonists	B-CHEBI
that	O
interact	O
specifically	O
with	O
this	O
receptor	O
subtype	O
may	O
be	O
particularly	O
good	O
candidates	O
for	O
designing	O
new	O
approaches	O
to	O
maintain	O
or	O
heal	O
articular	O
cartilage	O
at	O
postnatal	O
stages	O
.	O

Lack	O
of	O
Bmpr1a	B-GGP
function	O
in	O
articular	O
cartilage	O
results	O
in	O
severe	O
fibrillation	O
of	O
the	O
articular	O
surface	O
and	O
loss	O
of	O
joint	O
mobility	O
.	O

The	O
development	O
of	O
severe	O
arthritis	O
symptoms	O
in	O
Bmpr1a	B-GGP
-	O
deficient	O
mice	B-Taxon
raises	O
the	O
possibility	O
that	O
defects	O
in	O
BMP	B-GGP
signaling	O
also	O
contribute	O
to	O
human	B-Taxon
joint	O
disease	O
.	O

Osteoarthritis	O
is	O
known	O
to	O
have	O
a	O
significant	O
genetic	B-SO
component	O
,	O
but	O
it	O
likely	O
involves	O
multiple	O
genetic	B-SO
factors	O
that	O
have	O
been	O
difficult	O
to	O
identify	O
(	O
Spector	O
et	O
al	O
.	O
1996	O
;	O
Felson	O
et	O
al	O
.	O
1998	O
;	O
Hirsch	O
et	O
al	O
.	O
1998	O
)	O
.	O

Humans	B-Taxon
that	O
are	O
heterozygous	O
for	O
loss	O
-	O
of	O
-	O
function	O
mutations	B-SO
in	O
BMPR1A	B-GGP
are	O
known	O
to	O
be	O
at	O
risk	O
for	O
juvenile	O
polyposis	O
(	O
Howe	O
et	O
al	O
.	O
2001	O
;	O
Zhou	O
et	O
al	O
.	O
2001	O
)	O
,	O
but	O
the	O
risk	O
of	O
osteoarthritis	O
for	O
these	O
people	B-Taxon
has	O
not	O
been	O
reported	O
.	O

However	O
,	O
the	O
control	O
mice	B-Taxon
used	O
in	O
this	O
study	O
were	O
heterozygous	O
for	O
a	O
null	O
allele	B-SO
of	O
Bmpr1a	B-GGP
,	O
and	O
they	O
showed	O
little	O
sign	O
of	O
osteoarthritis	O
even	O
late	O
in	O
life	O
.	O

Several	O
chromosome	B-SO
regions	I-SO
have	O
been	O
previously	O
linked	O
to	O
arthritis	O
phenotypes	O
in	O
humans	B-Taxon
using	O
either	O
association	O
studies	O
in	O
populations	O
or	O
linkage	O
studies	O
in	O
families	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
several	O
of	O
these	O
chromosome	B-SO
regions	I-SO
contain	O
genes	B-SO
encoding	O
different	O
members	O
of	O
the	O
BMP	B-GGP
signaling	O
pathway	O
,	O
including	O
the	O
BMP5	B-GGP
gene	B-SO
on	O
human	B-Taxon
chromosome	B-GO
6p12	O
(	O
Loughlin	O
et	O
al	O
.	O
2002	O
)	O
,	O
the	O
MADH1	B-GGP
gene	B-SO
on	O
human	B-Taxon
chromosome	B-GO
4q26	O
-	O
4q31	O
(	O
Leppavuori	O
et	O
al	O
.	O
1999	O
;	O
Kent	O
et	O
al	O
.	O
2002	O
)	O
,	O
and	O
the	O
BMPR2	B-GGP
receptor	I-GGP
on	O
human	B-Taxon
chromosome	B-GO
2q33	O
(	O
Wright	O
et	O
al	O
.	O
1996	O
)	O
.	O

The	O
complex	O
nature	O
of	O
human	B-Taxon
osteoarthritis	O
suggests	O
that	O
interactions	O
between	O
multiple	O
genes	B-SO
may	O
be	O
involved	O
in	O
modifying	O
susceptibility	O
to	O
the	O
disease	O
.	O

The	O
inclusion	B-SO
of	O
genetic	B-SO
markers	O
near	O
BMP	B-GGP
signaling	O
components	O
may	O
help	O
identify	O
additional	O
osteoarthritis	O
susceptibility	O
loci	B-SO
and	O
facilitate	O
the	O
search	O
for	O
causative	O
mutations	B-SO
.	O

Development	O
and	O
disease	O
processes	O
in	O
synovial	O
joints	O
have	O
been	O
difficult	O
to	O
study	O
genetically	B-SO
,	O
because	O
synovial	O
joints	O
are	O
generated	O
and	O
function	O
at	O
relatively	O
late	O
stages	O
of	O
vertebrate	B-Taxon
development	O
.	O

The	O
Gdf5	B-GGP
-	O
Cre	O
system	O
provides	O
a	O
new	O
method	O
for	O
restricting	O
gene	B-SO
expression	O
or	O
inactivation	O
primarily	O
to	O
articular	O
regions	O
,	O
thus	O
avoiding	O
the	O
pleiotropic	O
functions	O
of	O
many	O
genes	B-SO
in	O
other	O
tissues	O
.	O

Depending	O
on	O
the	O
configuration	O
of	O
the	O
floxed	B-SO
target	I-SO
gene	I-SO
,	O
this	O
system	O
can	O
be	O
used	O
to	O
either	O
activate	O
the	O
expression	O
of	O
a	O
gene	B-SO
primarily	O
in	O
developing	O
joints	O
(	O
ssee	O
Figure	O
1B	O
-	O
1D	O
)	O
,	O
or	O
to	O
inactivate	O
gene	B-SO
function	O
in	O
articular	O
regions	O
(	O
see	O
Figure	O
3	O
)	O
.	O

Additional	O
studies	O
with	O
this	O
system	O
should	O
greatly	O
enhance	O
our	O
knowledge	O
of	O
the	O
development	O
,	O
function	O
,	O
and	O
disease	O
mechanisms	O
of	O
joints	O
,	O
and	O
may	O
bring	O
us	O
closer	O
to	O
better	O
prevention	O
and	O
treatment	O
of	O
joint	O
diseases	O
.	O

Materials	O
and	O
Methods	O

Generation	O
of	O
Gdf5	B-GGP
-	O
Cre	O
transgenic	B-SO
mice	B-Taxon

A	O
mouse	B-Taxon
129x1	O
/	O
SvJ	O
BAC	B-SO
library	O
(	O
Invitrogen	O
)	O
was	O
screened	O
to	O
identify	O
a	O
140	O
-	O
kb	O
BAC	B-SO
from	O
the	O
Gdf5	B-GGP
locus	B-SO
.	O

This	O
BAC	B-SO
was	O
modified	B-SO
using	O
a	O
homologous	O
recombination	O
system	O
in	O
E	B-Taxon
.	I-Taxon
coli	I-Taxon
(	O
Yang	O
et	O
al	O
.	O
1997	O
)	O
to	O
place	O
nuclear	B-GO
-	O
localized	O
Cre	O
recombinase	O
(	O
from	O
plasmid	B-SO
pML78	O
,	O
gift	O
of	O
Gail	O
Martin	O
)	O
followed	O
by	O
IRES	B-SO
-	O
hPLAP	B-GGP
(	O
from	O
plasmid	B-SO
1726	O
,	O
gift	O
of	O
Oliver	O
Bogler	O
)	O
directly	O
behind	O
the	O
ATG	B-SO
start	I-SO
site	I-SO
of	O
Gdf5	B-GGP
.	O

In	O
the	O
process	O
,	O
583	O
bp	B-SO
of	O
the	O
first	O
exon	B-SO
of	O
Gdf5	B-GGP
was	O
removed	B-SO
and	O
no	O
functional	O
GDF5	B-GGP
protein	B-CHEBI
is	O
predicted	O
to	O
be	O
produced	O
.	O

The	O
5	O
'	O
homology	O
arm	O
was	O
subcloned	O
from	O
a	O
PCR	B-SO
product	I-SO
tailed	O
with	O
XhoI	O
and	O
Bsp120I	O
restriction	B-SO
sites	I-SO
that	O
contains	O
781	O
bp	B-SO
of	O
5	O
'	O
genomic	B-SO
Gdf5	I-SO
sequence	I-SO
ending	O
at	O
the	O
ATG	B-SO
translation	I-SO
start	I-SO
site	I-SO
(	O
forward	B-SO
primer	I-SO
5	O
'	O
-	O
CTGTCTCGAGATGAGGTGGAGGTGAAGACCCC	O
-	O
3	O
'	O
;	O
reverse	B-SO
5	O
'	O
-	O
GTTTGGGCCCATCCTCTGGCCAGCCGCTG	O
-	O
3	O
'	O
)	O
.	O

Cre	O
was	O
subcloned	O
from	O
a	O
1	O
.	O
1	O
-	O
kb	O
Bsp120I	O
/	O
EcoRI	O
fragment	B-SO
of	O
pML78	O
.	O

IRES	B-SO
hPLAP	B-GGP
was	O
subcloned	O
from	O
a	O
2	O
.	O
1	O
-	O
kb	O
PCR	B-SO
product	I-SO
tailed	O
with	O
EcoRI	O
and	O
SpeI	O
sites	B-SO
that	O
contains	O
the	O
hPLAP	B-GGP
translation	B-SO
stop	I-SO
site	I-SO
(	O
forward	B-SO
primer	I-SO
5	O
'	O
-	O
ATCTCTCGAGGAATTCTCCACCATATTGCCGTCTTTTG	O
-	O
3	O
'	O
;	O
reverse	B-SO
5	O
'	O
-	O
AGAACTCGAGACTAGTCGGGACACTCAGGGAGTAGTGG	O
-	O
3	O
'	O
)	O
.	O

The	O
3	O
'	O
homology	O
arm	O
was	O
subcloned	O
from	O
a	O
0	O
.	O
8	O
-	O
kb	O
PCR	B-SO
product	I-SO
amplified	O
from	O
a	O
0	O
.	O
9	O
-	O
kb	O
XhoI	O
Gdf5	B-GGP
genomic	B-SO
subclone	O
containing	O
part	B-SO
of	I-SO
the	I-SO
first	I-SO
exon	I-SO
and	I-SO
downstream	I-SO
intron	I-SO
.	O

The	O
forward	B-SO
primer	I-SO
contains	O
the	O
3	O
'	O
end	O
of	O
the	O
first	O
exon	B-SO
and	O
is	O
tailed	O
with	O
a	O
SpeI	O
site	B-SO
;	O
the	O
reverse	B-SO
primer	I-SO
is	O
from	O
the	O
T7	B-Taxon
promoter	B-SO
of	O
the	O
vector	B-SO
containing	O
the	O
0	O
.	O
9	O
-	O
kb	O
subclone	O
and	O
flanks	O
the	O
intronic	B-SO
XhoI	I-SO
site	I-SO
(	O
forward	B-SO
primer	I-SO
5	O
'	O
-	O
CTAAACTAGTCACCAGCTTTATTGACAAAGG	O
-	O
3	O
'	O
;	O
reverse	B-SO
5	O
'	O
-	O
GATTTCTAGAGTAATACGACTCACTATAGGGC	O
-	O
3	O
'	O
)	O
.	O

The	O
targeting	O
construct	B-SO
was	O
built	O
and	O
verified	O
in	O
pBSSK	O
(	O
Stratagene	O
,	O
La	O
Jolla	O
,	O
California	O
,	O
United	O
States	O
)	O
,	O
then	O
digested	O
with	O
XhoI	O
and	O
subcloned	O
into	O
pSV1	O
,	O
the	O
vector	B-SO
used	O
for	O
homologous	O
recombination	O
(	O
Yang	O
et	O
al	O
.	O
1997	O
)	O
.	O

Southern	O
blotting	O
,	O
PCR	O
,	O
and	O
DNA	B-SO
sequence	I-SO
analysis	O
confirmed	O
the	O
appropriate	O
targeting	O
construct	B-SO
and	O
BAC	B-SO
modifications	B-SO
were	O
made	O
(	O
unpublished	O
data	O
)	O
.	O

Before	O
the	O
modified	B-SO
BAC	B-SO
was	O
injected	O
to	O
produce	O
transgenic	B-SO
animals	B-Taxon
,	O
a	O
loxP	B-SO
site	I-SO
present	O
in	O
the	O
BAC	B-SO
vector	I-SO
,	O
pBeloBAC11	O
,	O
was	O
removed	B-SO
to	O
prevent	O
the	O
addition	O
of	O
undesired	O
Cre	O
target	O
sites	B-SO
into	O
the	O
genome	B-SO
.	O

To	O
do	O
this	O
,	O
BAC	B-SO
DNA	B-SO
was	O
prepared	O
by	O
CsCl	O
separation	O
,	O
digested	O
with	O
NotI	O
to	O
free	O
the	O
insert	B-SO
from	O
the	O
vector	B-SO
,	O
and	O
size	O
-	O
fractionated	O
over	O
a	O
sucrose	B-CHEBI
gradient	O
.	O

Aliquots	O
of	O
fractions	O
were	O
run	O
on	O
a	O
pulse	O
-	O
field	O
gel	O
and	O
Southern	O
blotted	O
using	O
vector	B-SO
-	O
specific	O
DNA	B-SO
as	O
a	O
probe	B-SO
.	O

Fractions	O
containing	O
unsheared	O
insert	B-SO
and	O
almost	O
no	O
detectable	O
vector	B-SO
DNA	B-SO
were	O
dialyzed	O
in	O
microinjection	O
buffer	O
(	O
10	O
mM	O
Tris	B-CHEBI
[	O
pH	O
7	O
.	O
4	O
]	O
with	O
0	O
.	O
15	O
mM	O
EDTA	B-CHEBI
[	O
pH	O
8	O
.	O
0	O
]	O
)	O
using	O
Centriprep	O
-	O
30	O
concentrators	O
(	O
Millipore	O
,	O
Billerica	O
,	O
Massachusetts	O
,	O
United	O
States	O
)	O
.	O

This	O
purified	O
insert	B-SO
DNA	B-SO
was	O
adjusted	O
to	O
1	O
ng	O
/	O
mu	O
l	O
and	O
injected	O
into	O
the	O
pronucleus	B-GO
of	O
fertilized	O
eggs	B-CL
from	O
FVB	O
/	O
N	O
mice	B-Taxon
by	O
the	O
Stanford	O
Transgenic	B-SO
Facility	O
.	O

Transgenic	B-SO
founder	O
mice	B-Taxon
were	O
identified	O
by	O
PCR	O
using	O
Cre	O
-	O
specific	O
primers	B-SO
5	O
'	O
-	O
GCCTGCATTACCGGTCGATGCAACGA	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
GTGGCAGATGGCGCGGCAACACCATT	O
-	O
3	O
'	O
,	O
which	O
amplify	O
a	O
725	O
-	O
bp	B-SO
product	B-SO
,	O
and	O
were	O
assessed	O
for	O
absence	O
of	O
BAC	B-SO
vector	I-SO
using	O
vector	B-SO
-	O
specific	O
primers	B-SO
5	O
'	O
-	O
CGGAGTCTGATGCGGTTGCGATG	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
AGTGCTGTTCCCTGGTGCTTCCTC	O
-	O
3	O
'	O
,	O
which	O
amplify	O
a	O
465	O
-	O
bp	B-SO
product	B-SO
.	O

Three	O
lines	O
of	O
Gdf5	B-GGP
-	O
Cre	O
mice	B-Taxon
were	O
established	O
and	O
maintained	O
on	O
the	O
FVB	O
background	O
.	O

Matings	O
with	O
R26R	O
Cre	O
-	O
inducible	O
LACZ	O
reporter	O
mice	B-Taxon
(	O
Soriano	O
1999	O
)	O
were	O
used	O
to	O
test	O
for	O
Cre	O
activity	O
.	O

Staining	O
for	O
LACZ	O
and	O
HPLAP	B-GGP
on	O
whole	O
embryos	O
or	O
sections	O
of	O
embryos	O
was	O
accomplished	O
following	O
established	O
protocols	O
(	O
Lobe	O
et	O
al	O
.	O
1999	O
)	O
.	O

The	O
red	O
LACZ	O
substrate	O
(	O
see	O
Figure	O
1E	O
)	O
is	O
6	O
-	O
chloro	B-CHEBI
-	O
3	O
-	O
indoxyl	O
-	O
beta	O
-	O
D	O
-	O
galactopyranoside	O
(	O
Biosynth	O
International	O
,	O
Naperville	O
,	O
Illinois	O
,	O
United	O
States	O
)	O
.	O

General	O
characterization	O
of	O
Bmpr1a	B-GGP
mutant	B-SO
mice	B-Taxon

Bmpr1a	B-GGP
null	O
and	O
floxed	B-SO
alleles	B-SO
(	O
Ahn	O
et	O
al	O
.	O
2001	O
;	O
Mishina	O
et	O
al	O
.	O
2002	O
)	O
were	O
obtained	O
on	O
a	O
mixed	O
129	O
and	O
C57BL	O
/	O
6	O
background	O
and	O
maintained	O
by	O
random	O
breeding	O
.	O

Mice	B-Taxon
carrying	O
the	O
null	O
and	O
floxed	B-SO
alleles	B-SO
were	O
typically	O
mated	O
to	O
Gdf5	B-GGP
-	O
Cre	O
mice	B-Taxon
as	O
shown	O
in	O
Figure	O
3	O
.	O

The	O
resulting	O
mice	B-Taxon
are	O
on	O
a	O
mixed	O
129	O
;	O
C57Bl	O
/	O
6	O
;	O
FVB	O
/	O
N	O
background	O
,	O
with	O
both	O
controls	O
and	O
mutant	B-SO
animals	B-Taxon
generated	O
as	O
littermates	O
from	O
the	O
same	O
matings	O
.	O

Whole	O
-	O
mount	O
skeletal	O
preparations	O
were	O
made	O
from	O
34	O
-	O
to	O
36	O
-	O
d	O
-	O
old	O
mice	B-Taxon
(	O
Lufkin	O
et	O
al	O
.	O
1992	O
)	O
.	O

Pairs	O
of	O
ears	O
from	O
euthanized	O
6	O
-	O
mo	O
-	O
old	O
animals	B-Taxon
were	O
removed	O
,	O
pinned	O
,	O
photographed	O
,	O
projected	O
,	O
and	O
measured	O
from	O
the	O
base	O
of	O
the	O
curve	O
formed	O
between	O
the	O
tragus	O
and	O
antitragus	O
to	O
the	O
farthest	O
point	O
at	O
the	O
edge	O
of	O
the	O
pinnae	O
.	O

Grasping	O
ability	O
in	O
6	O
-	O
mo	O
-	O
old	O
mice	B-Taxon
was	O
measured	O
by	O
placing	O
animals	B-Taxon
on	O
a	O
slender	O
rod	O
and	O
timing	O
how	O
long	O
they	O
could	O
remain	O
suspended	O
on	O
the	O
rod	O
,	O
to	O
a	O
maximum	O
time	O
allowed	O
of	O
2	O
min	O
.	O

Data	O
from	O
five	O
consecutive	O
trials	O
for	O
each	O
mouse	B-Taxon
were	O
averaged	O
.	O

Range	O
of	O
motion	O
assays	O
were	O
conducted	O
on	O
the	O
MT	O
/	O
P1	O
and	O
P1	O
/	O
P2	O
joints	O
of	O
the	O
second	O
hindlimb	O
digit	O
from	O
euthanized	O
18	O
-	O
wk	O
-	O
old	O
animals	B-Taxon
.	O

Forceps	O
were	O
used	O
to	O
bend	O
the	O
joint	O
to	O
its	O
natural	O
stopping	O
position	O
,	O
and	O
the	O
resulting	O
angle	O
was	O
measured	O
to	O
the	O
nearest	O
10	O
degrees	O
under	O
12	O
.	O
5	O
x	O
magnification	O
using	O
a	O
360	O
degrees	O
reticule	O
.	O

Analysis	O
described	O
in	O
this	O
section	O
occurred	O
on	O
animals	B-Taxon
lacking	O
R26R	O
.	O

Control	O
mice	B-Taxon
included	O
all	O
nonmutant	O
genotypes	B-SO
generated	O
by	O
Parent	O
1	O
being	O
heterozygous	O
for	O
Gdf5	B-GGP
-	O
Cre	O
and	O
Bmpr1anull	O
and	O
Parent	O
2	O
being	O
heterozygous	O
for	O
Bmpr1afloxP	O
(	O
see	O
Figure	O
3	O
)	O
.	O

All	O
statistical	O
analysis	O
used	O
the	O
Student	O
'	O
s	O
t	O
-	O
test	O
or	O
Welch	O
'	O
s	O
t	O
-	O
test	O
,	O
and	O
values	O
listed	O
are	O
mean	O
+/-	O
standard	O
error	O
of	O
the	O
mean	O
.	O

Cell	B-CL
death	O
and	O
proliferation	O
assays	O

Limbs	O
from	O
mutant	B-SO
and	O
control	O
animals	B-Taxon
at	O
E13	O
.	O
5	O
and	O
E14	O
.	O
5	O
were	O
dissected	O
and	O
frozen	O
in	O
OCT	O
(	O
Sakura	O
Finetek	O
,	O
Torrence	O
,	O
CA	O
,	O
United	O
States	O
)	O
.	O

Cryosections	O
of	O
tissue	O
were	O
assayed	O
by	O
TUNEL	O
using	O
the	O
In	O
Situ	O
Cell	B-CL
Death	O
Detection	O
Kit	O
,	O
Fluorescein	O
(	O
Roche	O
,	O
Basel	O
,	O
Switzerland	O
)	O
.	O

Following	O
TUNEL	O
,	O
slides	O
were	O
washed	O
in	O
PBS	O
,	O
blocked	O
with	O
PBS	O
+	O
0	O
.	O
05	O
%	O
Tween	O
-	O
20	O
+	O
5	O
%	O
goat	B-Taxon
serum	O
,	O
washed	O
again	O
,	O
and	O
incubated	O
with	O
a	O
1	O
:	O
200	O
dilution	O
of	O
a	O
rabbit	B-Taxon
anti	O
-	O
phospho	B-CHEBI
-	O
histone	B-CHEBI
-	O
H3	O
antibody	B-GO
called	O
Mitosis	O
Marker	O
(	O
Upstate	O
Biotechnology	O
,	O
Lake	O
Placid	O
,	O
New	O
York	O
,	O
United	O
States	O
)	O
to	O
identify	O
cells	B-CL
in	O
mitosis	O
.	O

Cy3	O
-	O
labeled	O
anti	O
-	O
rabbit	B-Taxon
secondary	O
antibody	B-GO
was	O
used	O
to	O
detect	O
the	O
antibody	B-GO
.	O

Cell	B-CL
nuclei	B-GO
were	O
labeled	O
with	O
DAPI	O
,	O
and	O
slides	O
were	O
mounted	O
in	O
Vectamount	O
(	O
Vector	O
Laboratories	O
,	O
Burlingame	O
,	O
California	O
,	O
United	O
States	O
)	O
and	O
visualized	O
at	O
100	O
x	O
magnification	O
.	O

The	O
area	O
of	O
selected	O
anatomical	O
sites	O
were	O
measured	O
,	O
and	O
the	O
number	O
of	O
TUNEL	O
-	O
labeled	O
nuclear	B-GO
fragments	I-GO
and	O
the	O
number	O
of	O
Cy3	O
-	O
labeled	O
nuclei	B-GO
were	O
counted	O
from	O
three	O
10	O
-	O
mu	O
m	O
sections	O
spanning	O
50	O
mu	O
m	O
,	O
from	O
three	O
control	O
and	O
three	O
mutant	B-SO
animals	B-Taxon
.	O

The	O
number	O
of	O
labeled	O
cells	B-CL
in	O
the	O
metacarpal	O
-	O
phalangeal	O
and	O
metatarsal	O
-	O
phalangeal	O
joints	O
was	O
counted	O
in	O
a	O
290	O
mu	O
m	O
x	O
365	O
mu	O
m	O
rectangle	O
placed	O
around	O
the	O
center	O
of	O
the	O
joint	O
.	O

The	O
posterior	O
region	O
of	O
the	O
fifth	O
digit	O
was	O
defined	O
by	O
drawing	O
a	O
line	O
from	O
the	O
tip	O
of	O
the	O
digit	O
down	O
2	O
.	O
15	O
mm	O
and	O
across	O
to	O
the	O
lateral	O
edge	O
of	O
the	O
tissue	O
.	O

For	O
this	O
analysis	O
,	O
the	O
R26R	O
Cre	O
reporter	O
was	O
not	O
present	O
.	O

Histology	O
and	O
histochemistry	O

Tissue	O
from	O
animals	B-Taxon
ranging	O
from	O
stages	O
E14	O
.	O
5	O
to	O
P14	O
was	O
prepared	O
for	O
analysis	O
by	O
fixing	O
in	O
4	O
%	O
paraformaldehyde	O
(	O
PFA	O
)	O
in	O
PBS	O
for	O
45	O
min	O
to	O
4	O
h	O
depending	O
on	O
the	O
stage	O
;	O
washing	O
three	O
times	O
in	O
PBS	O
,	O
once	O
in	O
PBS	O
+	O
15	O
%	O
sucrose	B-CHEBI
for	O
1	O
h	O
,	O
and	O
once	O
in	O
PBS	O
+	O
30	O
%	O
sucrose	B-CHEBI
for	O
2	O
h	O
to	O
overnight	O
depending	O
on	O
the	O
stage	O
;	O
and	O
then	O
freezing	O
in	O
OCT	O
.	O

Tissue	O
from	O
animals	B-Taxon
aged	O
7	O
wk	O
to	O
9	O
mo	O
was	O
processed	O
similarly	O
to	O
earlier	O
stages	O
except	O
that	O
it	O
was	O
decalcified	O
in	O
0	O
.	O
5	O
M	O
EDTA	B-CHEBI
(	O
pH	O
7	O
.	O
4	O
)	O
for	O
4	O
d	O
prior	O
to	O
incubating	O
in	O
sucrose	B-CHEBI
.	O

All	O
solutions	O
were	O
prechilled	O
and	O
used	O
at	O
4	O
degrees	O
C	O
with	O
agitation	O
,	O
and	O
skin	O
from	O
tissues	O
of	O
P0	O
or	O
older	O
mice	B-Taxon
was	O
lacerated	O
or	O
removed	O
prior	O
to	O
processing	O
.	O

Tissue	O
was	O
then	O
cryosectioned	O
at	O
12	O
mu	O
m	O
and	O
processed	O
.	O

Staining	O
of	O
sections	O
with	O
Safranin	O
O	O
,	O
Fast	O
Green	O
,	O
and	O
Harris	O
'	O
hematoxylin	O
was	O
carried	O
out	O
using	O
standard	O
histological	O
procedures	O
.	O

Detection	O
of	O
LACZ	O
activity	O
with	O
X	O
-	O
Gal	O
was	O
performed	O
as	O
described	O
(	O
Lobe	O
et	O
al	O
.	O
1999	O
)	O
and	O
was	O
followed	O
by	O
refixing	O
in	O
4	O
%	O
PFA	O
,	O
rinsing	O
with	O
deionized	O
water	B-CHEBI
,	O
counterstaining	O
with	O
Nuclear	B-GO
Fast	O
Red	O
(	O
Vector	O
Labs	O
)	O
,	O
rinsing	O
with	O
water	B-CHEBI
again	O
,	O
and	O
then	O
mounting	O
in	O
Aquamount	O
(	O
Lerner	O
Labs	O
,	O
Pittsburgh	O
,	O
Pennsylvania	O
,	O
United	O
States	O
)	O
.	O

RNA	B-SO
in	O
situ	O
hybridization	O
was	O
performed	O
as	O
described	O
(	O
Storm	O
and	O
Kingsley	O
1996	O
)	O
,	O
with	O
the	O
following	O
modifications	O
:	O
(	O
1	O
)	O
Prior	O
to	O
the	O
acetylation	O
step	O
,	O
sections	O
were	O
incubated	O
with	O
10	O
-	O
20	O
mu	O
g	O
/	O
ml	O
proteinase	O
K	O
for	O
30	O
s	O
to	O
7	O
min	O
at	O
room	O
temperature	O
(	O
depending	O
on	O
the	O
developmental	O
stage	O
)	O
,	O
followed	O
by	O
refixing	O
in	O
4	O
%	O
PFA	O
and	O
washing	O
three	O
times	O
in	O
PBS	O
;	O
(	O
2	O
)	O
prehybridization	O
step	O
was	O
skipped	O
,	O
and	O
(	O
3	O
)	O
embryonic	O
tissue	O
sections	O
used	O
a	O
different	O
color	O
development	O
mix	O
(	O
Thut	O
et	O
al	O
.	O
2001	O
)	O
.	O

Probes	B-SO
for	O
the	O
following	O
genes	B-SO
have	O
been	O
published	O
previously	O
:	O
Bmpr1a	B-GGP
(	O
Mishina	O
et	O
al	O
.	O
1995	O
)	O
,	O
Col2a1	B-GGP
(	O
Metsaranta	O
et	O
al	O
.	O
1991	O
)	O
,	O
Col10a1	B-GGP
(	O
Apte	O
et	O
al	O
.	O
1992	O
)	O
,	O
Gdf5	B-GGP
(	O
Storm	O
and	O
Kingsley	O
1996	O
)	O
,	O
Osteocalcin	O
(	O
Celeste	O
et	O
al	O
.	O
1986	O
)	O
,	O
and	O
Sox5	B-GGP
and	O
Sox6	B-GGP
(	O
Lefebvre	O
et	O
al	O
.	O
1998	O
)	O
.	O

The	O
following	O
probe	B-SO
templates	O
were	O
gifts	O
:	O
Agg	B-GGP
,	O
Dr	O
.	O
Vicki	O
Rosen	O
,	O
Genetics	O
Institute	O
;	O
Bmp2	B-GGP
and	O
Bmp4	B-GGP
,	O
Arend	O
Sidow	O
,	O
Stanford	O
University	O
;	O
Col1a1	B-GGP
,	O
Bjorn	O
Olsen	O
,	O
Harvard	O
Medical	O
School	O
;	O
Bmpr1b	B-GGP
,	O
Col3a1	B-GGP
,	O
and	O
Mat4	B-GGP
probes	B-SO
were	O
made	O
from	O
ESTs	B-SO
with	O
IMAGE	O
clone	B-SO
numbers	O
5056341	O
,	O
478480	O
,	O
and	O
406027	O
,	O
respectively	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

Sections	O
for	O
immunohistochemistry	O
were	O
fixed	O
in	O
4	O
%	O
PFA	O
,	O
then	O
digested	O
with	O
942	O
-	O
2	O
,	O
000	O
U	O
/	O
ml	O
type	O
IV	O
-	O
S	O
bovine	B-Taxon
hyaluronindase	O
(	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
Missouri	O
,	O
United	O
States	O
)	O
in	O
PBS	O
(	O
pH	O
5	O
)	O
at	O
37	O
degrees	O
C	O
for	O
30	O
min	O
to	O
2	O
h	O
depending	O
on	O
the	O
stage	O
.	O

Slides	O
were	O
then	O
washed	O
in	O
PBS	O
,	O
treated	O
with	O
0	O
.	O
3	O
%	O
hydrogen	B-CHEBI
peroxide	I-CHEBI
in	O
100	O
%	O
methanol	B-CHEBI
for	O
30	O
min	O
,	O
washed	O
,	O
blocked	O
with	O
PBS	O
+	O
0	O
.	O
05	O
%	O
Tween20	O
+	O
5	O
%	O
goat	B-Taxon
or	O
fetal	O
bovine	B-Taxon
serum	O
,	O
washed	O
again	O
,	O
and	O
incubated	O
with	O
primary	O
antibodies	B-GO
in	O
PBS	O
+	O
0	O
.	O
05	O
%	O
Tween	O
20	O
+	O
1	O
%	O
goat	B-Taxon
or	O
fetal	O
bovine	B-Taxon
serum	O
overnight	O
at	O
4	O
degrees	O
C	O
.	O

Biotin	B-CHEBI
-	O
labeled	O
secondary	O
antibodies	B-GO
(	O
Vector	O
Labs	O
)	O
were	O
tagged	O
with	O
HRP	O
using	O
the	O
Vectastain	O
Elite	O
ABC	O
kit	O
(	O
Vector	O
Labs	O
)	O
followed	O
by	O
detection	O
with	O
DAB	O
(	O
Vector	O
Labs	O
)	O
.	O

Primary	O
antibodies	B-GO
and	O
dilutions	O
used	O
were	O
:	O
goat	B-Taxon
anti	O
-	O
mouse	B-GGP
MMP13	I-GGP
,	O
1	O
:	O
100	O
(	O
Chemicon	O
International	O
,	O
Temecula	O
,	O
California	O
,	O
United	O
States	O
)	O
;	O
rabbit	B-Taxon
anti	O
-	O
human	B-GGP
SOX9	I-GGP
,	O
1	O
:	O
500	O
(	O
Morais	O
da	O
Silva	O
et	O
al	O
.	O
1996	O
)	O
;	O
rabbit	B-Taxon
anti	O
-	O
phosphorylated	O
-	O
SOX9	B-GGP
(	O
SOX9	B-GGP
.	O
P	O
)	O
,	O
1	O
:	O
10	O
-	O
1	O
:	O
250	O
(	O
Huang	O
et	O
al	O
.	O
2000	O
)	O
.	O

Supporting	O
Information	O

Accession	O
Numbers	O

GenBank	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nih	O
.	O
gov	O
/	O
Genbank	O
/	O
)	O
accession	O
numbers	O
for	O
the	O
genes	B-SO
discussed	O
in	O
this	O
paper	O
are	O
Gdf5	B-GGP
(	O
AC084323	O
)	O
and	O
Bmpr1a	B-GGP
(	O
NM	O
_	O
009758	O
)	O
.	O

Acknowledgements	O

We	O
thank	O
Gail	O
Martin	O
for	O
the	O
Cre	O
construct	B-SO
(	O
plasmid	B-SO
pML78	O
)	O
and	O
Oliver	O
Bogler	O
for	O
the	O
IRES	B-SO
-	O
hPLAP	B-GGP
construct	B-SO
(	O
plasmid	B-SO
1726	O
)	O
;	O
Bjorn	O
Olsen	O
and	O
Benoit	O
de	O
Crombrugghe	O
for	O
antibodies	B-GO
;	O
the	O
following	O
individuals	B-Taxon
for	O
in	O
situ	O
probe	B-SO
templates	O
:	O
Sophie	O
Candille	O
,	O
Arend	O
Sidow	O
(	O
Bmp2	B-GGP
and	O
Bmp4	B-GGP
)	O
,	O
Vicki	O
Rosen	O
(	O
Agg	O
)	O
,	O
and	O
Bjorn	O
Olsen	O
(	O
Col1a1	B-GGP
)	O
;	O
V	O
e	O
ronique	O
Lefebvre	O
for	O
Sox5	B-GGP
and	O
Sox6	B-GGP
probe	B-SO
templates	O
and	O
useful	O
discussions	O
;	O
Michelle	O
Johnson	O
for	O
help	O
with	O
phenotypic	O
assays	O
on	O
mice	B-Taxon
;	O
Dr	O
.	O
Corrine	O
Davis	O
for	O
help	O
in	O
evaluating	O
synovial	O
sections	O
;	O
Rebecca	O
Rountree	O
for	O
Adobe	O
Photoshop	O
and	O
Illustrator	O
tips	O
;	O
and	O
members	O
of	O
the	O
Kingsley	O
lab	O
for	O
helpful	O
comments	O
on	O
the	O
manuscript	O
.	O

This	O
work	O
was	O
supported	O
by	O
an	O
NIH	O
predoctoral	O
training	O
grant	O
(	O
RR	O
)	O
,	O
a	O
postdoctoral	O
fellowship	O
from	O
the	O
Arthritis	O
Foundation	O
(	O
MS	O
)	O
,	O
and	O
grants	O
from	O
the	O
National	O
Institutes	O
of	O
Health	O
(	O
DK	O
)	O
.	O

Dr	O
.	O
Kingsley	O
is	O
an	O
associate	O
investigator	O
of	O
the	O
Howard	O
Hughes	O
Medical	O
Institute	O
.	O

Abbreviations	O

BAC	B-SO
-	O
bacterial	B-SO
artificial	I-SO
chromosome	I-SO

Bmpr1a	B-GGP
-	O
bone	B-GGP
morphogenetic	I-GGP
protein	I-GGP
receptor	I-GGP
1a	I-GGP

E	O
[	O
number	O
]	O
-	O
embyonic	O
day	O
[	O
number	O
]	O

ECM	B-GO
-	O
extracellular	B-GO
matrix	I-GO

GAC	O
-	O
transgenic	B-SO
line	O
carrying	O
Gdf5	B-GGP
-	O
alkaline	B-CHEBI
phosphatase	O
-	O
Cre	O
construct	B-SO

Gdf5	B-GGP
-	O
growth	B-GGP
differentiation	I-GGP
factor	I-GGP
5	I-GGP

hPLAP	B-GGP
-	O
human	B-GGP
placental	I-GGP
alkaline	I-GGP
phosphatase	I-GGP

IRES	B-SO
-	O
internal	B-SO
ribosome	I-SO
entry	I-SO
site	I-SO

PFA	O
-	O
paraformaldehyde	O

R26R	O
-	O
lacZ	O
ROSA26	B-GGP
Cre	O
reporter	O
strain	O

TGF	B-GGP
-	I-GGP
beta	I-GGP
-	O
transforming	B-GGP
growth	I-GGP
factor	I-GGP
beta	I-GGP

TUNEL	O
-	O
terminal	B-GGP
deoxynucleotidyl	I-GGP
transferase	I-GGP
-	O
mediated	O
deoxyuridine	B-CHEBI
triphosphate	I-CHEBI
nick	O
end	O
labeling	O

Figures	O
and	O
Tables	O

Figure	O
1	O

A	O
Genetic	B-SO
System	O
to	O
Drive	O
Gene	B-SO
Recombination	O
in	O
Developing	O
Joints	O

(	O
A	O
)	O
A	O
140	O
-	O
kb	O
BAC	B-SO
from	O
the	O
Gdf5	B-GGP
locus	B-SO
was	O
modified	B-SO
by	O
inserting	B-SO
Cre	O
-	O
IRES	B-SO
-	O
hPLAP	B-GGP
into	O
the	O
translation	B-SO
start	I-SO
site	I-SO
of	O
Gdf5	B-GGP
and	O
used	O
to	O
make	O
transgenic	B-SO
mice	B-Taxon
.	O

Not	O
to	O
scale	O
.	O

See	O
Materials	O
and	O
Methods	O
for	O
details	O
.	O

(	O
B	O
-	O
E	O
)	O
Visualization	O
of	O
Gdf5	B-GGP
-	O
Cre	O
driven	O
recombination	O
patterns	O
based	O
on	O
activation	O
of	O
lacZ	O
expression	O
from	O
the	O
R26R	O
Cre	O
reporter	O
allele	B-SO
.	O

(	O
B	O
)	O
LACZ	O
activity	O
is	O
visible	O
as	O
blue	O
staining	O
in	O
the	O
ear	O
(	O
ea	O
)	O
and	O
the	O
joints	O
of	O
the	O
shoulder	O
(	O
s	O
)	O
,	O
elbow	O
(	O
eb	O
)	O
,	O
wrist	O
(	O
w	O
)	O
,	O
knee	O
(	O
k	O
)	O
,	O
ankle	O
(	O
a	O
)	O
,	O
vertebra	O
(	O
vj	O
)	O
,	O
and	O
phalanges	O
(	O
black	O
arrowheads	O
)	O
of	O
an	O
E14	O
.	O
5	O
mouse	B-Taxon
embryo	O
.	O

(	O
C	O
)	O
E14	O
.	O
5	O
hindlimb	O
double	O
-	O
stained	O
to	O
show	O
both	O
HPLAP	B-GGP
expression	O
from	O
the	O
transgene	B-SO
(	O
grey	O
/	O
purple	O
staining	O
)	O
and	O
LACZ	O
expression	O
from	O
the	O
rearranged	O
R26R	O
allele	B-SO
(	O
blue	O
staining	O
)	O
.	O

Note	O
that	O
both	O
markers	O
are	O
visible	O
in	O
the	O
oldest	O
,	O
proximal	O
interphalangeal	O
joint	O
(	O
black	O
arrowhead	O
)	O
,	O
only	O
HPLAP	B-GGP
activity	O
is	O
visible	O
in	O
the	O
more	O
recently	O
formed	O
medial	O
interphalangeal	O
joint	O
(	O
black	O
arrow	O
)	O
,	O
and	O
neither	O
HPLAP	B-GGP
nor	O
LACZ	O
expression	O
is	O
visible	O
in	O
the	O
youngest	O
,	O
most	O
distal	O
joint	O
of	O
the	O
digit	O
(	O
white	O
arrowhead	O
)	O
.	O

(	O
D	O
)	O
Newborn	O
(	O
P0	O
)	O
forelimb	O
with	O
skin	O
partially	O
removed	O
showing	O
LACZ	O
activity	O
expressed	O
in	O
all	O
phalangeal	O
joints	O
(	O
red	O
Salmon	O
gal	O
staining	O
,	O
black	O
arrowheads	O
)	O
and	O
regions	O
of	O
some	O
tendons	O
(	O
asterisk	O
)	O
.	O

(	O
E	O
)	O
Section	O
through	O
the	O
most	O
distal	O
phalangeal	O
joint	O
of	O
a	O
P0	O
hindlimb	O
stained	O
with	O
Alcian	O
blue	O
to	O
mark	O
cartilage	O
showing	O
LACZ	O
expression	O
(	O
stained	O
red	O
)	O
in	O
all	O
tissues	O
of	O
developing	O
joints	O
:	O
articular	O
cartilage	O
(	O
black	O
arrowhead	O
)	O
,	O
precursors	O
of	O
ligaments	O
and	O
synovial	O
membranes	O
(	O
black	O
arrow	O
)	O
,	O
and	O
cells	B-CL
where	O
cavitation	O
is	O
occurring	O
(	O
asterisk	O
)	O
.	O

Figure	O
2	O

Bmpr1a	B-GGP
Is	O
Required	O
for	O
Webbing	O
Regression	O
and	O
Apoptosis	O
in	O
Specific	O
Regions	O
of	O
the	O
Limb	O

(	O
A	O
and	O
B	O
)	O
Control	O
E14	O
.	O
5	O
forelimb	O
(	O
A	O
)	O
compared	O
to	O
a	O
,	O
E14	O
.	O
5	O
mutant	B-SO
forelimb	O
(	O
B	O
)	O
showing	O
webbing	O
between	O
digits	O
1	O
and	O
2	O
(	O
arrowheads	O
)	O
and	O
extra	O
tissue	O
at	O
the	O
posterior	O
of	O
digit	O
5	O
(	O
arrows	O
)	O
.	O

(	O
C	O
)	O
Gdf5	B-GGP
-	O
Cre	O
induced	O
lacZ	O
expression	O
from	O
R26R	O
in	O
an	O
E13	O
.	O
5	O
forelimb	O
showing	O
LACZ	O
staining	O
(	O
blue	O
)	O
in	O
metacarpal	O
-	O
phalangeal	O
joints	O
,	O
between	O
digits	O
1	O
and	O
2	O
(	O
arrowhead	O
)	O
,	O
and	O
in	O
a	O
region	O
posterior	O
to	O
digit	O
5	O
(	O
arrow	O
)	O
.	O

(	O
D	O
and	O
E	O
)	O
Sections	O
of	O
E14	O
.	O
5	O
hindlimbs	O
showing	O
apoptosis	O
visualized	O
by	O
TUNEL	O
staining	O
(	O
green	O
)	O
and	O
proliferation	O
visualized	O
by	O
staining	O
for	O
histone	B-CHEBI
H3	O
phosphorylation	O
(	O
red	O
)	O
.	O

Controls	O
show	O
strong	O
,	O
uniform	O
TUNEL	O
staining	O
between	O
digits	O
1	O
and	O
2	O
(	O
D	O
,	O
arrowhead	O
)	O
while	O
mutants	B-SO
show	O
patchy	O
TUNEL	O
staining	O
interspersed	O
with	O
mitotic	O
cells	B-CL
in	O
similar	O
regions	O
(	O
E	O
)	O
.	O

Scale	O
bar	O
=	O
200	O
mu	O
m	O
.	O

(	O
F	O
)	O
Quantitation	O
of	O
TUNEL	O
staining	O
and	O
mitotic	O
cells	B-CL
in	O
the	O
posterior	O
region	O
of	O
the	O
fifth	O
digit	O
shows	O
apoptosis	O
is	O
reduced	O
30	O
%	O
while	O
proliferation	O
is	O
increased	O
20	O
%	O
(	O
asterisks	O
indicate	O
statistically	O
significant	O
difference	O
)	O
.	O

(	O
G	O
and	O
H	O
)	O
By	O
E15	O
.	O
5	O
,	O
interdigital	O
tissue	O
has	O
regressed	O
in	O
controls	O
(	O
G	O
,	O
arrowhead	O
)	O
.	O

In	O
contrast	O
,	O
tissue	O
remains	O
in	O
mutants	B-SO
at	O
this	O
location	O
,	O
primarily	O
derived	O
from	O
cells	B-CL
that	O
have	O
undergone	O
Gdf5	B-GGP
-	O
Cre	O
-	O
mediated	O
recombination	O
that	O
inactivates	O
Bmpr1a	B-GGP
function	O
and	O
activates	O
expression	O
of	O
LACZ	O
(	O
H	O
)	O
.	O

Scale	O
bar	O
=	O
75	O
mu	O
m	O
.	O

Figure	O
3	O

Gdf5	B-GGP
-	O
Cre	O
-	O
Mediated	O
Deletion	B-SO
of	O
Bmpr1a	B-GGP

(	O
A	O
)	O
Breeding	O
strategy	O
simultaneously	O
deletes	B-SO
Bmpr1afloxP	O
and	O
allows	O
visualization	O
of	O
Gdf5	B-GGP
-	O
Cre	O
-	O
mediated	O
recombination	O
by	O
lacZ	O
expression	O
from	O
R26R	O
.	O

(	O
B	O
-	O
E	O
)	O
5	O
-	O
week	O
-	O
old	O
mutant	B-SO
and	O
control	O
mice	B-Taxon
stained	O
with	O
Alcian	O
blue	O
to	O
mark	O
cartilage	O
and	O
alizarin	B-CHEBI
red	I-CHEBI
to	O
mark	O
bone	O
.	O

(	O
B	O
)	O
Ankle	O
of	O
control	O
with	O
strong	O
blue	O
staining	O
lining	O
each	O
joint	O
(	O
arrowheads	O
)	O
.	O

(	O
C	O
)	O
Ankle	O
of	O
mutant	B-SO
showing	O
an	O
absence	O
of	O
blue	O
staining	O
in	O
most	O
regions	O
(	O
arrowheads	O
)	O
and	O
a	O
joint	O
fusion	O
between	O
the	O
central	O
(	O
c	O
)	O
and	O
second	O
(	O
2	O
)	O
tarsals	O
(	O
arrow	O
)	O
.	O

(	O
D	O
)	O
Control	O
and	O
(	O
E	O
)	O
mutant	B-SO
metatarsal	O
/	O
phalangeal	O
joint	O
which	O
lacks	O
blue	O
staining	O
in	O
articular	O
regions	O
(	O
arrowheads	O
)	O
but	O
retains	O
staining	O
in	O
the	O
growth	O
plate	O
(	O
asterisks	O
)	O
.	O

(	O
F	O
)	O
Control	O
forelimb	O
.	O

(	O
G	O
)	O
Mutant	B-SO
forelimb	O
with	O
webbing	O
between	O
the	O
first	O
and	O
second	O
digit	O
(	O
black	O
arrowhead	O
)	O
.	O

Figure	O
4	O

Bmpr1a	B-GGP
Is	O
Expressed	O
in	O
Joints	O
and	O
Is	O
Required	O
for	O
Continued	O
Joint	O
Formation	O
in	O
the	O
Ankle	O
Region	O

(	O
A	O
)	O
Diagram	O
of	O
ankle	O
bones	O
from	O
a	O
wild	B-SO
-	I-SO
type	I-SO
mouse	B-Taxon
;	O
bones	O
fusing	O
in	O
mutant	B-SO
are	O
colored	O
red	O
.	O

Roman	O
numerals	O
II	O
-	O
IV	O
,	O
metatarsals	O
;	O
2	O
,	O
3	O
,	O
and	O
4	O
/	O
5	O
,	O
distal	O
row	O
of	O
tarsal	O
bones	O
;	O
c	O
,	O
central	O
tarsal	O
bone	O
;	O
ta	O
,	O
talus	O
;	O
ca	O
,	O
calcaneus	O
.	O

(	O
B	O
and	O
C	O
)	O
In	O
situ	O
hybridization	O
at	O
E15	O
.	O
5	O
showing	O
that	O
Bmpr1a	B-GGP
is	O
expressed	O
in	O
ankle	O
joint	O
interzones	O
(	O
B	O
,	O
arrowheads	O
)	O
and	O
in	O
the	O
forming	O
articular	O
regions	O
of	O
the	O
phalangeal	O
joints	O
(	O
C	O
,	O
arrowheads	O
)	O
.	O

(	O
D	O
)	O
Near	O
adjacent	O
section	O
to	O
(	O
C	O
)	O
showing	O
Gdf5	B-GGP
-	O
Cre	O
induced	O
LACZ	O
expression	O
from	O
R26R	O
in	O
the	O
forming	O
joints	O
of	O
the	O
digits	O
(	O
arrowheads	O
)	O
.	O

(	O
E	O
-	O
J	O
)	O
Marker	O
gene	B-SO
expression	O
and	O
R26R	O
LACZ	O
staining	O
patterns	O
on	O
near	O
adjacent	O
sections	O
of	O
control	O
and	O
mutant	B-SO
embryos	O
.	O

In	O
control	O
mice	B-Taxon
at	O
E15	O
.	O
5	O
ankle	O
joints	O
are	O
clearly	O
delineated	O
as	O
regions	O
that	O
have	O
down	O
-	O
regulated	O
Col2	B-GGP
(	O
E	O
)	O
,	O
express	O
Gdf5	B-GGP
throughout	O
(	O
F	O
)	O
,	O
and	O
express	O
LACZ	O
in	O
most	O
cells	B-CL
(	O
G	O
;	O
white	O
arrowheads	O
and	O
black	O
arrows	O
)	O
.	O

In	O
mutant	B-SO
embryos	O
at	O
the	O
same	O
stage	O
,	O
joint	O
formation	O
is	O
incomplete	O
.	O

Faint	O
Col2	B-GGP
expression	O
can	O
be	O
seen	O
connecting	O
a	O
medial	O
region	O
of	O
tarsal	O
2	O
with	O
metatarsal	O
II	O
(	O
H	O
,	O
white	O
arrowhead	O
)	O
,	O
and	O
Gdf5	B-GGP
expression	O
does	O
not	O
extend	O
all	O
the	O
way	O
across	O
the	O
joint	O
at	O
this	O
location	O
(	O
I	O
,	O
white	O
arrowhead	O
)	O
.	O

Between	O
tarsals	O
c	O
and	O
2	O
,	O
mutants	B-SO
express	O
Col2	B-GGP
across	O
the	O
normal	O
joint	O
-	O
forming	O
region	O
(	O
H	O
,	O
black	O
arrow	O
)	O
and	O
lack	O
expression	O
of	O
Gdf5	B-GGP
at	O
sites	O
where	O
skeletal	O
fusions	O
are	O
observed	O
(	O
I	O
,	O
black	O
arrow	O
and	O
bracket	O
)	O
.	O

(	O
J	O
)	O
Scale	O
bar	O
=	O
100	O
mu	O
m	O
.	O

Figure	O
5	O

Bmpr1a	B-GGP
Is	O
Required	O
to	O
Maintain	O
Expression	O
of	O
ECM	B-GO
Components	I-GO
in	O
Articular	O
Cartilage	O

In	O
situ	O
hybridization	O
or	O
LACZ	O
staining	O
on	O
near	O
adjacent	O
sections	O
of	O
metacarpal	O
-	O
phalangeal	O
joints	O
(	O
A	O
-	O
C	O
and	O
F	O
-	O
H	O
)	O
and	O
the	O
tarsal	O
2	O
-	O
metatarsal	O
II	O
joint	O
(	O
D	O
-	O
E	O
and	O
I	O
-	O
J	O
)	O
of	O
P0	O
mice	B-Taxon
.	O

At	O
birth	O
,	O
articular	O
cartilage	O
of	O
controls	O
(	O
A	O
-	O
E	O
)	O
and	O
mutants	B-SO
(	O
F	O
-	O
J	O
)	O
appears	O
similar	O
by	O
Safranin	O
O	O
staining	O
(	O
A	O
and	O
F	O
)	O
,	O
and	O
Col2	B-GGP
expression	O
(	O
B	O
,	O
G	O
)	O
.	O

Mat4	B-GGP
expression	O
confirms	O
that	O
articular	O
cartilage	O
is	O
initially	O
specified	O
in	O
mutants	B-SO
(	O
D	O
andI	O
,	O
brackets	O
)	O
.	O

LACZ	O
expression	O
confirms	O
Cre	O
-	O
mediated	O
recombination	O
has	O
occurred	O
in	O
articular	O
cartilage	O
(	O
C	O
,	O
H	O
,	O
E	O
,	O
and	O
J	O
)	O
.	O

(	O
K	O
-	O
T	O
)	O
Near	O
adjacent	O
sections	O
of	O
the	O
metacarpal	O
-	O
phalangeal	O
joints	O
of	O
P14	O
mice	B-Taxon
.	O

Two	O
weeks	O
after	O
birth	O
,	O
articular	O
cartilage	O
of	O
controls	O
stains	O
with	O
pericellular	O
Safranin	O
O	O
(	O
orange	O
staining	O
,	O
K	O
)	O
,	O
and	O
expresses	O
Col2	B-GGP
(	O
L	O
)	O
,	O
Agg	B-GGP
(	O
M	O
)	O
,	O
and	O
SOX9	B-GGP
(	O
N	O
)	O
.	O

In	O
contrast	O
,	O
mutant	B-SO
articular	O
cells	B-CL
are	O
smaller	O
and	O
more	O
densely	O
packed	O
,	O
lack	O
pericellular	O
Safranin	O
O	O
staining	O
(	O
P	O
)	O
,	O
have	O
reduced	O
expression	O
of	O
Col2	B-GGP
(	O
Q	O
)	O
and	O
Agg	B-GGP
(	O
R	O
)	O
,	O
but	O
retain	O
normal	O
levels	O
of	O
SOX9	B-GGP
protein	B-CHEBI
(	O
S	O
,	O
brackets	O
;	O
dashed	O
line	O
marks	O
faint	O
edges	O
of	O
articular	O
surfaces	O
)	O
.	O

LACZ	O
expression	O
confirms	O
Cre	O
-	O
mediated	O
recombination	O
has	O
occurred	O
in	O
articular	O
cells	B-CL
(	O
O	O
ansd	O
T	O
,	O
brackets	O
)	O
.	O

(	O
A	O
and	O
K	O
)	O
Scale	O
bar	O
=	O
75	O
mu	O
m	O
.	O

Figure	O
6	O

Synovial	O
Membrane	O
Expansion	O
,	O
Articular	O
Surface	O
Erosion	O
,	O
and	O
Accelerated	O
Maturation	O
of	O
Underlying	O
Cartilage	O
in	O
Ankles	O
of	O
Bmpr1a	B-GGP
Mutant	B-SO
Mice	B-Taxon

Near	O
adjacent	O
sections	O
from	O
the	O
tarsal	O
2	O
-	O
metatarsal	O
II	O
joint	O
of	O
7	O
-	O
d	O
-	O
old	O
mice	B-Taxon
.	O

(	O
A	O
and	O
B	O
)	O
LACZ	O
staining	O
(	O
blue	O
)	O
shows	O
Cre	O
-	O
mediated	O
recombination	O
is	O
largely	O
restricted	O
to	O
articular	O
(	O
arrowheads	O
)	O
and	O
synovial	B-CL
cells	I-CL
(	O
asterisks	O
)	O
in	O
both	O
controls	O
and	O
mutants	B-SO
.	O

(	O
C	O
and	O
D	O
)	O
In	O
situ	O
hybridization	O
shows	O
Col10	B-GGP
expression	O
expands	O
in	O
mutants	B-SO
toward	O
regions	O
of	O
synovial	O
membrane	O
expansion	O
and	O
articular	O
surface	O
erosion	O
(	O
brackets	O
and	O
arrows	O
)	O
.	O

This	O
may	O
be	O
a	O
cell	B-CL
nonautonomous	O
effect	O
of	O
joint	O
damage	O
,	O
since	O
the	O
LACZ	O
expressing	O
cells	B-CL
at	O
the	O
articular	O
surface	O
do	O
not	O
show	O
upregulation	O
of	O
Col10	B-GGP
(	O
arrowheads	O
)	O
and	O
the	O
region	O
of	O
expanded	O
Col10	B-GGP
expression	O
is	O
largely	O
made	O
up	O
of	O
cells	B-CL
that	O
have	O
not	O
undergone	O
Cre	O
-	O
mediated	O
recombination	O
.	O

Note	O
the	O
formation	O
of	O
a	O
cartilaginous	O
bridge	O
along	O
the	O
joint	O
capsule	O
of	O
the	O
mutant	B-SO
where	O
joint	O
formation	O
is	O
disrupted	O
at	O
earlier	O
stages	O
(	O
B	O
,	O
white	O
arrowhead	O
,	O
and	O
Figure	O
3	O
,	O
white	O
arrowheads	O
)	O
.	O

(	O
A	O
)	O
Scale	O
bar	O
=	O
75	O
mu	O
m	O
.	O

Figure	O
7	O

Loss	O
of	O
Bmpr1a	B-GGP
Signaling	O
Leads	O
to	O
Articular	O
Cartilage	O
Fibrillation	O
and	O
Degeneration	O
in	O
Digits	O
and	O
Knees	O
of	O
Aging	O
Mice	B-Taxon

(	O
A	O
-	O
D	O
)	O
Near	O
adjacent	O
sections	O
of	O
metatarsal	O
-	O
phalangeal	O
joints	O
from	O
9	O
month	O
old	O
mice	B-Taxon
.	O

Articular	O
cartilage	O
of	O
controls	O
is	O
complete	O
and	O
stains	O
strongly	O
with	O
Safranin	O
O	O
(	O
A	O
,	O
orange	O
stain	O
)	O
.	O

In	O
contrast	O
,	O
articular	O
cells	B-CL
of	O
mutants	B-SO
are	O
severely	O
fibrillated	O
or	O
absent	O
with	O
much	O
reduced	O
staining	O
of	O
Safranin	O
O	O
(	O
C	O
,	O
arrowheads	O
)	O
.	O

LACZ	O
expression	O
confirms	O
Cre	O
-	O
mediated	O
recombination	O
has	O
occurred	O
in	O
articular	O
cells	B-CL
(	O
B	O
and	O
D	O
)	O
.	O

(	O
E	O
-	O
P	O
)	O
Sagittal	O
sections	O
through	O
knee	O
joints	O
of	O
7	O
-	O
wk	O
-	O
(	O
E	O
-	O
J	O
)	O
or	O
9	O
-	O
mo	O
-	O
old	O
animals	B-Taxon
(	O
K	O
-	O
P	O
)	O
;	O
fe	O
,	O
femur	O
;	O
ti	O
,	O
tibia	O
;	O
gp	O
,	O
growth	O
plate	O
.	O

Seven	O
weeks	O
after	O
birth	O
,	O
the	O
height	O
of	O
the	O
tibial	O
epiphysis	O
is	O
reduced	O
in	O
mutants	B-SO
(	O
E	O
and	O
H	O
,	O
bars	O
)	O
,	O
and	O
their	O
articular	O
layer	O
stains	O
poorly	O
with	O
Safranin	O
O	O
,	O
is	O
fibrillated	O
,	O
and	O
is	O
strikingly	O
thinner	O
(	O
F	O
and	O
I	O
,	O
black	O
arrowhead	O
,	O
and	O
brackets	O
)	O
.	O

Near	O
adjacent	O
sections	O
with	O
LACZ	O
staining	O
confirm	O
Cre	O
-	O
mediated	O
recombination	O
has	O
occurred	O
in	O
articular	O
cells	B-CL
(	O
G	O
and	O
J	O
)	O
.	O

Note	O
that	O
in	O
mutants	B-SO
,	O
LACZ	O
is	O
absent	O
in	O
cells	B-CL
adjacent	O
to	O
those	O
that	O
do	O
stain	O
with	O
Safranin	O
O	O
,	O
suggesting	O
Bmpr1a	B-GGP
may	O
act	O
cell	B-CL
autonomously	O
(	O
I	O
and	O
J	O
,	O
white	O
arrowheads	O
)	O
.	O

At	O
9	O
mo	O
old	O
,	O
the	O
mutant	B-SO
tibial	O
epiphysis	O
is	O
extremely	O
thin	O
(	O
K	O
and	O
N	O
,	O
bars	O
)	O
,	O
and	O
the	O
articular	O
layer	O
is	O
completely	O
absent	O
,	O
leaving	O
bone	O
to	O
rub	O
directly	O
on	O
bone	O
(	O
L	O
and	O
O	O
,	O
bracket	O
)	O
.	O

LACZ	O
staining	O
shows	O
Cre	O
-	O
mediated	O
recombination	O
occurred	O
in	O
articular	O
cells	B-CL
of	O
controls	O
(	O
M	O
)	O
and	O
in	O
some	O
remaining	O
skeletal	O
tissue	O
of	O
mutants	B-SO
(	O
P	O
)	O
.	O

Also	O
note	O
aberrantly	O
formed	O
meniscal	O
cartilage	O
in	O
mutants	B-SO
(	O
E	O
,	O
H	O
,	O
K	O
,	O
and	O
N	O
,	O
arrows	O
)	O
,	O
and	O
increased	O
sclerosis	O
in	O
mutant	B-SO
epiphyses	O
(	O
E	O
,	O
H	O
,	O
K	O
,	O
and	O
N	O
,	O
asterisks	O
)	O
.	O

(	O
A	O
and	O
K	O
)	O
Scale	O
bar	O
=	O
50	O
mu	O
m	O
;	O
(	O
I	O
)	O
scale	O
bar	O
=	O
300	O
mu	O
m	O
.	O

Footnotes	O

Conflicts	O
of	O
interest	O
.	O

The	O
authors	O
have	O
declared	O
that	O
no	O
conflicts	O
of	O
interest	O
exist	O
.	O

Author	O
contributions	O
.	O

RBR	O
,	O
MS	O
,	O
and	O
DMK	O
conceived	O
and	O
designed	O
the	O
experiments	O
.	O

RBR	O
and	O
MEM	O
performed	O
the	O
experiments	O
.	O

RBR	O
,	O
HC	O
,	O
and	O
DMK	O
analyzed	O
the	O
data	O
.	O

MS	O
,	O
HC	O
,	O
VH	O
,	O
and	O
YM	O
contributed	O
reagents	B-CHEBI
/	O
materials	O
/	O
analysis	O
tools	O
.	O

RBR	O
and	O
DMK	O
wrote	O
the	O
paper	O
.	O

Academic	O
Editor	O
:	O
Lee	O
Niswander	O
,	O
University	O
of	O
Colorado	O
Health	O
Sciences	O
Center	O

currency	O
Current	O
address	O
:	O
ARTEMIS	O
Pharmaceuticals	B-CHEBI
,	O
an	O
Exelixis	O
Company	O
,	O
K	O
o	O
ln	O
,	O
Germany	O

Citation	O
:	O
Rountree	O
RB	O
,	O
Schoor	O
M	O
,	O
Chen	O
H	O
,	O
Marks	O
ME	O
,	O
Harley	O
V	O
,	O
et	O
al	O
.	O

(	O
2004	O
)	O
BMP	B-GGP
receptor	O
signaling	O
is	O
required	O
for	O
postnatal	O
maintenance	O
of	O
articular	O
cartilage	O
.	O

PLoS	O
Biol	O
2	O
(	O
11	O
)	O
:	O
e355	O
.	O

A	O
Chemoattractant	O
Role	O
for	O
NT	B-GGP
-	I-GGP
3	I-GGP
in	O
Proprioceptive	O
Axon	B-GO
Guidance	O

Abstract	O

Neurotrophin	B-GGP
-	I-GGP
3	I-GGP
(	O
NT	B-GGP
-	I-GGP
3	I-GGP
)	O
is	O
required	O
for	O
proprioceptive	O
neuron	B-CL
survival	O
.	O

Deletion	B-SO
of	O
the	O
proapoptotic	O
gene	B-SO
Bax	B-GGP
in	O
NT	B-GGP
-	I-GGP
3	I-GGP
knockout	O
mice	B-Taxon
rescues	O
these	O
neurons	B-CL
and	O
allows	O
for	O
examination	O
of	O
their	O
axon	B-GO
growth	O
in	O
the	O
absence	O
of	O
NT	B-GGP
-	I-GGP
3	I-GGP
signaling	O
.	O

TrkC	B-GGP
-	O
positive	O
peripheral	O
and	O
central	O
axons	B-GO
from	O
dorsal	O
root	O
ganglia	O
follow	O
proper	O
trajectories	O
and	O
arrive	O
in	O
close	O
proximity	O
to	O
their	O
targets	O
but	O
fail	O
to	O
innervate	O
them	O
.	O

Peripherally	O
,	O
muscle	O
spindles	O
are	O
absent	O
and	O
TrkC	B-GGP
-	O
positive	O
axons	B-GO
do	O
not	O
enter	O
their	O
target	O
muscles	O
.	O

Centrally	O
,	O
proprioceptive	O
axons	B-GO
branch	O
in	O
ectopic	O
regions	O
of	O
the	O
spinal	O
cord	O
,	O
even	O
crossing	O
the	O
midline	O
.	O

In	O
vitro	O
assays	O
reveal	O
chemoattractant	O
effects	O
of	O
NT	B-GGP
-	I-GGP
3	I-GGP
on	O
dorsal	O
root	O
ganglion	O
axons	B-GO
.	O

Our	O
results	O
show	O
that	O
survival	O
factor	O
NT	B-GGP
-	I-GGP
3	I-GGP
acts	O
as	O
a	O
short	O
-	O
distance	O
axon	B-GO
guidance	O
molecule	B-CHEBI
for	O
muscle	O
sensory	O
afferents	O
as	O
they	O
approach	O
their	O
proper	O
targets	O
.	O

Introduction	O

Neurotrophin	B-GGP
-	I-GGP
3	I-GGP
(	O
NT	B-GGP
-	I-GGP
3	I-GGP
)	O
is	O
a	O
key	O
requirement	O
for	O
the	O
development	O
of	O
proprioceptive	O
inputs	O
to	O
motor	B-CL
neurons	I-CL
(	O
Chen	O
and	O
Frank	O
1999	O
;	O
Chen	O
et	O
al	O
.	O
2003	O
)	O
.	O

Mice	B-Taxon
deficient	O
in	O
NT	B-GGP
-	I-GGP
3	I-GGP
,	O
its	O
tyrosine	B-GGP
kinase	I-GGP
receptor	I-GGP
,	O
TrkC	B-GGP
,	O
or	O
in	O
TrkC	B-GGP
-	O
positive	O
neuron	B-CL
-	O
specific	O
transcription	O
factor	O
Runx3	B-GGP
display	O
severe	O
ataxia	O
associated	O
with	O
the	O
absence	O
of	O
muscle	O
spindles	O
,	O
and	O
loss	O
of	O
proprioceptive	O
neurons	B-CL
in	O
dorsal	O
root	O
ganglia	O
(	O
DRGs	O
)	O
or	O
their	O
axons	B-GO
(	O
Ernfors	O
et	O
al	O
.	O
1994	O
;	O
Klein	O
et	O
al	O
.	O
1994	O
;	O
Tessarollo	O
et	O
al	O
.	O
1994	O
;	O
Fari	O
n	O
as	O
et	O
al	O
.	O
1996	O
;	O
Liebl	O
et	O
al	O
.	O
1997	O
;	O
Inoue	O
et	O
al	O
.	O
2002	O
;	O
Levanon	O
et	O
al	O
.	O
2002	O
)	O
.	O

NT	B-GGP
-	I-GGP
3	I-GGP
is	O
expressed	O
in	O
the	O
ventral	O
spinal	O
cord	O
,	O
in	O
the	O
developing	O
limb	O
buds	O
,	O
and	O
in	O
intrafusal	O
bag	O
fibers	O
of	O
muscle	O
spindles	O
later	O
in	O
development	O
(	O
Copray	O
and	O
Brouwer	O
1994	O
;	O
Fari	O
n	O
as	O
et	O
al	O
.	O
1996	O
;	O
Tojo	O
et	O
al	O
.	O
1996	O
)	O
.	O

When	O
sensory	O
axons	B-GO
contact	O
developing	O
myotubes	O
,	O
they	O
induce	O
muscle	O
spindle	O
differentiation	O
,	O
forming	O
ring	O
-	O
like	O
spiral	O
nerve	B-GO
endings	I-GO
around	O
them	O
.	O

In	O
the	O
chicken	B-Taxon
embryo	O
,	O
limb	O
ablations	O
or	O
anti	O
-	O
NT	B-GGP
-	I-GGP
3	I-GGP
antibody	B-GO
injections	O
into	O
limb	O
buds	O
lead	O
to	O
elimination	O
of	O
TrkC	B-GGP
-	O
positive	O
neurons	B-CL
and	O
decreased	O
innervation	O
of	O
motor	B-CL
neurons	I-CL
(	O
Oakley	O
et	O
al	O
.	O
1995	O
,	O
1997	O
)	O
.	O

Is	O
NT	B-GGP
-	I-GGP
3	I-GGP
only	O
a	O
chemotrophic	O
survival	O
factor	O
for	O
muscle	O
sensory	O
afferents	O
,	O
or	O
does	O
it	O
have	O
additional	O
roles	O
in	O
the	O
development	O
of	O
the	O
proprioceptors	O
and	O
the	O
establishment	O
of	O
the	O
monosynaptic	O
reflex	O
arc	O
?	O

Here	O
we	O
provide	O
evidence	O
that	O
NT	B-GGP
-	I-GGP
3	I-GGP
acts	O
as	O
a	O
chemoattractant	O
for	O
sensory	O
axons	B-GO
during	O
the	O
final	O
phase	O
of	O
their	O
target	O
-	O
directed	O
pathfinding	O
.	O

Results	O

TrkC	B-GGP
-	O
Positive	O
DRG	O
Neurons	B-CL
Are	O
Rescued	O
in	O
Bax	B-GGP
/	O
NT	B-GGP
-	I-GGP
3	I-GGP
Double	O
Knockout	O
Mice	B-Taxon

Mice	B-Taxon
lacking	O
proapoptotic	O
protein	B-CHEBI
Bax	B-GGP
allow	O
for	O
distinguishing	O
survival	O
effects	O
of	O
neurotrophins	B-GGP
from	O
other	O
effects	O
.	O

Bax	B-GGP
-	O
deficient	O
sensory	B-CL
neurons	I-CL
no	O
longer	O
require	O
neurotrophins	B-GGP
for	O
survival	O
(	O
White	O
et	O
al	O
.	O
1998	O
;	O
Patel	O
et	O
al	O
.	O
2000	O
)	O
,	O
thus	O
they	O
can	O
be	O
used	O
to	O
examine	O
axonal	B-GO
effects	O
.	O

We	O
bred	O
NT	B-GGP
-	I-GGP
3	I-GGP
heterozygote	O
and	O
Bax	B-GGP
knockout	O
(	O
KO	O
)	O
mice	B-Taxon
to	O
obtain	O
mice	B-Taxon
with	O
double	O
KO	O
of	O
both	O
NT	B-GGP
-	I-GGP
3	I-GGP
and	O
Bax	B-GGP
genes	B-SO
,	O
and	O
examined	O
proprioceptive	O
axonal	B-GO
projections	B-GO
.	O

All	O
NT	B-GGP
-	I-GGP
3	I-GGP
and	O
double	O
KOs	O
died	O
within	O
48	O
h	O
after	O
birth	O
(	O
Tessarollo	O
et	O
al	O
.	O
1994	O
)	O
.	O

We	O
performed	O
TrkA	B-GGP
/	O
TrkC	B-GGP
double	O
immunohistochemistry	O
(	O
Huang	O
et	O
al	O
.	O
1999	O
)	O
,	O
enabling	O
detection	O
of	O
both	O
proteins	B-CHEBI
in	O
the	O
same	O
sample	O
.	O

TrkC	B-GGP
-	O
positive	O
cells	B-CL
(	O
Figure	O
1A	O
)	O
and	O
fibers	O
(	O
Figure	O
1E	O
)	O
were	O
absent	O
in	O
NT	B-GGP
-	I-GGP
3	I-GGP
KOs	O
at	O
embryonic	O
day	O
(	O
E	O
)	O
15	O
.	O

Two	O
subsets	O
of	O
DRG	O
cells	B-CL
expressing	O
either	O
TrkA	B-GGP
or	O
TrkC	B-GGP
were	O
detected	O
in	O
double	O
KOs	O
,	O
similar	O
to	O
wild	B-SO
-	I-SO
type	I-SO
(	O
WT	B-SO
)	O
or	O
Bax	B-GGP
KO	O
animals	B-Taxon
.	O

Surprisingly	O
,	O
at	O
postnatal	O
day	O
(	O
P	O
)	O
0	O
,	O
a	O
few	O
cells	B-CL
expressed	O
TrkC	B-GGP
even	O
in	O
NT	B-GGP
-	I-GGP
3	I-GGP
KO	O
animals	B-Taxon
in	O
the	O
Bax	B-GGP
+	B-SO
/	O
+	B-SO
genetic	B-SO
background	O
,	O
and	O
some	O
cells	B-CL
co	O
-	O
expressed	O
TrkA	B-GGP
and	O
TrkC	B-GGP
,	O
regardless	O
of	O
the	O
genotype	B-SO
(	O
Figure	O
1B	O
)	O
.	O

In	O
order	O
to	O
quantify	O
our	O
results	O
,	O
we	O
analyzed	O
the	O
ratio	O
of	O
TrkA	B-GGP
and	O
TrkC	B-GGP
immunopositive	O
cells	B-CL
from	O
four	O
different	O
DRGs	O
of	O
animals	B-Taxon
of	O
different	O
genotypes	B-SO
.	O

At	O
all	O
ages	O
studied	O
,	O
Bax	B-GGP
/	O
NT	B-GGP
-	I-GGP
3	I-GGP
double	O
null	O
DRGs	O
had	O
TrkA	B-GGP
/	O
TrkC	B-GGP
ratios	O
similar	O
to	O
those	O
of	O
Bax	B-GGP
null	O
DRGs	O
,	O
and	O
higher	O
than	O
those	O
of	O
NT	B-GGP
-	I-GGP
3	I-GGP
null	O
DRGs	O
(	O
Figure	O
1D	O
)	O
.	O

TrkC	B-GGP
-	O
positive	O
neurons	B-CL
rescued	O
by	O
Bax	B-GGP
deletion	B-SO
,	O
however	O
,	O
failed	O
to	O
differentiate	O
properly	O
,	O
as	O
evidenced	O
by	O
the	O
lack	O
of	O
expression	O
of	O
the	O
proprioceptive	O
molecular	B-CHEBI
marker	O
Parvalbumin	B-GGP
(	O
PV	B-GGP
)	O
(	O
Figure	O
1C	O
)	O
.	O

NT	B-GGP
-	I-GGP
3	I-GGP
Is	O
Necessary	O
for	O
Proper	O
Innervation	O
of	O
Motor	B-CL
Neurons	I-CL

TrkA	B-GGP
/	O
TrkC	B-GGP
-	O
positive	O
fibers	O
in	O
the	O
spinal	O
cord	O
could	O
be	O
detected	O
at	O
E15	O
(	O
Figure	O
1E	O
)	O
.	O

TrkA	B-GGP
-	O
positive	O
fibers	O
were	O
restricted	O
to	O
and	O
terminated	O
in	O
the	O
dorsolateral	O
spinal	O
cord	O
,	O
whereas	O
TrkC	B-GGP
-	O
positive	O
fibers	O
entered	O
the	O
cord	O
dorsomedially	O
,	O
and	O
descended	O
into	O
the	O
ventral	O
horns	O
in	O
WT	B-SO
(	O
Ozaki	O
and	O
Snider	O
1997	O
)	O
and	O
Bax	B-GGP
KO	O
embryos	O
.	O

There	O
was	O
no	O
detectable	O
TrkC	B-GGP
expression	O
in	O
NT	B-GGP
-	I-GGP
3	I-GGP
KO	O
spinal	O
cord	O
,	O
indicating	O
complete	O
absence	O
of	O
proprioceptive	O
fibers	O
.	O

In	O
double	O
KO	O
spinal	O
cord	O
,	O
TrkC	B-GGP
-	O
positive	O
fibers	O
entered	O
the	O
dorsal	O
spinal	O
cord	O
and	O
descended	O
medially	O
in	O
a	O
manner	O
similar	O
to	O
that	O
seen	O
in	O
WT	B-SO
or	O
Bax	B-GGP
KO	O
cases	O
.	O

However	O
,	O
it	O
was	O
not	O
possible	O
to	O
follow	O
TrkC	B-GGP
immunolabeled	O
fibers	O
all	O
the	O
way	O
to	O
their	O
terminal	O
zones	O
in	O
any	O
of	O
the	O
cases	O
.	O

Next	O
we	O
examined	O
the	O
central	O
projections	B-GO
of	O
DRG	O
axons	B-GO
with	O
the	O
lipophilic	O
tracer	O
DiI	O
at	O
P0	O
.	O

In	O
WT	B-SO
and	O
Bax	B-GGP
KO	O
pups	O
,	O
proprioceptive	O
afferents	O
entered	O
the	O
dorsal	O
spinal	O
cord	O
and	O
followed	O
a	O
medial	O
course	O
towards	O
the	O
ventral	O
horn	O
.	O

They	O
then	O
turned	O
laterally	O
towards	O
motor	B-CL
neurons	I-CL
in	O
the	O
lateral	O
motor	O
column	O
,	O
where	O
they	O
branched	O
and	O
terminated	O
(	O
Figure	O
2A	O
)	O
.	O

DiI	O
labeling	O
was	O
confined	O
to	O
dorsal	O
spinal	O
cord	O
in	O
NT	B-GGP
-	I-GGP
3	I-GGP
KOs	O
(	O
Figure	O
2A	O
)	O
,	O
as	O
reported	O
earlier	O
,	O
consistent	O
with	O
a	O
complete	O
absence	O
of	O
proprioceptive	O
innervation	O
(	O
Ernfors	O
et	O
al	O
.	O
1994	O
;	O
Tessarollo	O
et	O
al	O
.	O
1994	O
)	O
.	O

In	O
double	O
KOs	O
,	O
proprioceptive	O
afferents	O
initially	O
followed	O
a	O
trajectory	O
similar	O
to	O
that	O
of	O
WT	B-SO
counterparts	O
,	O
but	O
most	O
of	O
them	O
failed	O
to	O
project	O
all	O
the	O
way	O
to	O
the	O
ventral	O
cord	O
and	O
into	O
the	O
lateral	O
motor	O
column	O
.	O

Instead	O
,	O
they	O
arborized	O
near	O
the	O
ventral	O
midline	O
;	O
some	O
crossed	O
the	O
midline	O
and	O
extended	O
into	O
the	O
contralateral	O
ventral	O
cord	O
(	O
Figure	O
2A	O
and	O
2C	O
)	O
.	O

In	O
order	O
to	O
distinguish	O
between	O
a	O
role	O
for	O
NT	B-GGP
-	I-GGP
3	I-GGP
in	O
initiation	O
of	O
motor	B-CL
neuron	I-CL
innervation	O
and	O
a	O
role	O
for	O
maintenance	O
,	O
we	O
repeated	O
the	O
DiI	O
labeling	O
at	O
E17	O
.	O

Innervation	O
patterns	O
of	O
E17	O
spinal	O
cords	O
(	O
Figure	O
3	O
)	O
were	O
similar	O
to	O
those	O
at	O
P0	O
(	O
Figure	O
2	O
)	O
.	O

Dorsal	O
horns	O
of	O
all	O
genotypes	B-SO
were	O
filled	O
with	O
DiI	O
-	O
labeled	O
fibers	O
corresponding	O
to	O
nerve	B-GGP
growth	I-GGP
factor	I-GGP
-	O
dependent	O
nociceptive	O
axons	B-GO
.	O

In	O
WT	B-SO
and	O
Bax	B-GGP
KO	O
embryos	O
,	O
proprioceptive	O
fibers	O
extended	O
towards	O
ventral	O
horn	O
motor	B-CL
neurons	I-CL
(	O
Figure	O
3A	O
and	O
3B	O
)	O
,	O
whereas	O
the	O
ventral	O
horns	O
of	O
the	O
NT	B-GGP
-	I-GGP
3	I-GGP
KO	O
embryos	O
were	O
devoid	O
of	O
innervation	O
(	O
Figure	O
3C	O
)	O
.	O

In	O
the	O
Bax	B-GGP
/	O
NT	B-GGP
-	I-GGP
3	I-GGP
double	O
KOs	O
,	O
DiI	O
-	O
labeled	O
fibers	O
entered	O
the	O
ventral	O
spinal	O
cord	O
,	O
but	O
extended	O
towards	O
the	O
midline	O
instead	O
of	O
the	O
ventral	O
horn	O
(	O
Figure	O
3D	O
)	O
,	O
in	O
a	O
pattern	O
similar	O
to	O
that	O
observed	O
at	O
P0	O
.	O

Our	O
data	O
point	O
to	O
a	O
complete	O
absence	O
of	O
proprioceptive	O
innervation	O
of	O
the	O
ventral	O
horn	O
of	O
the	O
Bax	B-GGP
/	O
NT	B-GGP
-	I-GGP
3	I-GGP
null	O
spinal	O
cord	O
throughout	O
the	O
developmental	O
stages	O
investigated	O
.	O

As	O
the	O
sensory	O
axons	B-GO
never	O
reach	O
motor	B-CL
neuron	I-CL
dendrites	B-GO
in	O
the	O
ventral	O
horn	O
(	O
Figure	O
S1	O
)	O
,	O
the	O
stretch	O
reflex	O
arc	O
circuit	O
is	O
not	O
established	O
.	O

The	O
failure	O
to	O
initiate	O
contact	O
between	O
sensory	O
axons	B-GO
and	O
motor	B-CL
neurons	I-CL
in	O
the	O
absence	O
of	O
NT	B-GGP
-	I-GGP
3	I-GGP
suggests	O
a	O
requirement	O
for	O
NT	B-GGP
-	I-GGP
3	I-GGP
for	O
proper	O
axon	B-GO
targeting	O
in	O
addition	O
to	O
a	O
role	O
in	O
sensory	O
axon	B-GO
maintenance	O
.	O

NT	B-GGP
-	I-GGP
3	I-GGP
Is	O
Required	O
for	O
Proper	O
Peripheral	O
Innervation	O

In	O
order	O
to	O
study	O
peripheral	O
innervation	O
in	O
double	O
KO	O
animals	B-Taxon
,	O
we	O
investigated	O
spindle	O
development	O
in	O
the	O
gastrocnemius	O
muscle	O
.	O

Muscle	O
spindles	O
could	O
be	O
identified	O
easily	O
in	O
P0	O
WT	B-SO
and	O
Bax	B-GGP
KO	O
animals	B-Taxon
by	O
their	O
characteristic	O
morphology	O
(	O
Figure	O
4A	O
and	O
4B	O
)	O
.	O

Proprioceptive	O
fibers	O
labeled	O
with	O
neurofilament	B-GGP
-	I-GGP
M	I-GGP
(	O
NF	B-GGP
-	I-GGP
M	I-GGP
)	O
antibody	B-GO
formed	O
ring	O
-	O
like	O
spiral	O
endings	O
wrapped	O
around	O
intrafusal	O
bag	O
fibers	O
labeled	O
with	O
S46	O
antibody	B-GO
,	O
specific	O
for	O
slow	O
developmental	O
myosin	B-GO
heavy	O
chain	B-SO
protein	B-CHEBI
(	O
Miller	O
et	O
al	O
.	O
1985	O
)	O
.	O

As	O
reported	O
earlier	O
,	O
there	O
were	O
no	O
muscle	O
spindles	O
in	O
NT	B-GGP
-	I-GGP
3	I-GGP
KO	O
animals	B-Taxon
(	O
Ernfors	O
et	O
al	O
.	O
1994	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
Bax	B-GGP
KO	O
animals	B-Taxon
had	O
more	O
spindles	O
than	O
WT	B-SO
,	O
and	O
spindles	O
were	O
in	O
clusters	O
similar	O
to	O
animals	B-Taxon
over	O
-	O
expressing	O
NT	B-GGP
-	I-GGP
3	I-GGP
in	O
the	O
muscle	O
(	O
Wright	O
et	O
al	O
.	O
1997	O
)	O
.	O

Although	O
NT	B-GGP
-	I-GGP
3	I-GGP
-	O
dependent	O
cells	B-CL
were	O
rescued	O
,	O
no	O
muscle	O
spindles	O
were	O
detected	O
in	O
the	O
limbs	O
of	O
double	O
KOs	O
(	O
Figure	O
4A	O
and	O
4B	O
)	O
.	O

Muscle	O
spindles	O
could	O
be	O
observed	O
with	O
TrkC	B-GGP
antibody	B-GO
in	O
WT	B-SO
and	O
Bax	B-GGP
KO	O
animals	B-Taxon
,	O
but	O
not	O
in	O
NT	B-GGP
-	I-GGP
3	I-GGP
or	O
double	O
KOs	O
(	O
Figure	O
4E	O
)	O
.	O

In	O
both	O
NT	B-GGP
-	I-GGP
3	I-GGP
and	O
double	O
KO	O
animals	B-Taxon
,	O
NF	B-GGP
-	I-GGP
M	I-GGP
-	O
labeled	O
fibers	O
could	O
be	O
detected	O
in	O
muscles	O
,	O
thus	O
the	O
muscles	O
of	O
these	O
animals	B-Taxon
were	O
not	O
completely	O
devoid	O
of	O
nerve	O
fibers	O
.	O

Since	O
there	O
were	O
no	O
TrkC	B-GGP
-	O
positive	O
fibers	O
in	O
these	O
muscles	O
,	O
we	O
think	O
that	O
these	O
NF	B-GGP
-	I-GGP
M	I-GGP
-	O
labeled	O
fibers	O
correspond	O
to	O
motor	O
axons	B-GO
.	O

Absence	O
of	O
muscle	O
spindles	O
might	O
be	O
due	O
to	O
a	O
failure	O
in	O
initiation	O
of	O
differentiation	O
by	O
proprioceptive	O
axons	B-GO
,	O
or	O
a	O
failure	O
of	O
maturation	O
and	O
maintenance	O
in	O
the	O
absence	O
of	O
NT	B-GGP
-	I-GGP
3	I-GGP
.	O

To	O
distinguish	O
between	O
these	O
two	O
possibilities	O
,	O
we	O
investigated	O
muscle	O
spindle	O
development	O
at	O
E15	O
and	O
E17	O
with	O
S46	O
/	O
NF	B-GGP
-	I-GGP
M	I-GGP
immunostaining	O
as	O
well	O
as	O
DiI	O
labeling	O
.	O

No	O
structures	O
with	O
the	O
characteristic	O
muscle	O
spindle	O
shape	O
could	O
be	O
detected	O
in	O
any	O
of	O
the	O
genotypes	B-SO
at	O
E15	O
(	O
Figure	O
S2	O
)	O
.	O

However	O
,	O
numerous	O
developing	O
spindles	O
could	O
be	O
identified	O
at	O
E17	O
in	O
WT	B-SO
and	O
Bax	B-GGP
KOs	O
,	O
but	O
not	O
in	O
NT	B-GGP
-	I-GGP
3	I-GGP
KO	O
embryos	O
(	O
Figure	O
4C	O
)	O
.	O

Bax	B-GGP
/	O
NT	B-GGP
-	I-GGP
3	I-GGP
double	O
null	O
muscles	O
were	O
devoid	O
of	O
spindles	O
(	O
Figure	O
4C	O
)	O
,	O
except	O
for	O
one	O
spindle	O
-	O
like	O
structure	O
observed	O
in	O
one	O
leg	O
of	O
an	O
embryo	O
(	O
Figure	O
4C	O
,	O
inset	O
,	O
denoted	O
by	O
the	O
asterisk	O
)	O
.	O

DiI	O
labeling	O
through	O
the	O
DRGs	O
at	O
E17	O
yielded	O
similar	O
results	O
,	O
with	O
muscle	O
spindles	O
identified	O
in	O
parallel	O
sections	O
in	O
WT	B-SO
and	O
Bax	B-GGP
null	O
muscles	O
(	O
Figure	O
4D	O
)	O
,	O
but	O
not	O
in	O
NT	B-GGP
-	I-GGP
3	I-GGP
or	O
double	O
KO	O
animals	B-Taxon
.	O

Although	O
DiI	O
-	O
labeled	O
fibers	O
could	O
be	O
detected	O
in	O
double	O
null	O
muscles	O
,	O
they	O
never	O
formed	O
ring	O
-	O
like	O
structures	O
characteristic	O
of	O
muscle	O
spindles	O
.	O

We	O
also	O
examined	O
TrkA	B-GGP
/	O
TrkC	B-GGP
expression	O
at	O
P0	O
in	O
the	O
tibial	O
nerve	O
,	O
which	O
carries	O
sensory	O
fibers	O
to	O
the	O
gastrocnemius	O
muscle	O
as	O
well	O
as	O
the	O
skin	O
of	O
the	O
lower	O
leg	O
.	O

In	O
NT	B-GGP
-	I-GGP
3	I-GGP
KOs	O
,	O
TrkA	B-GGP
-	O
positive	O
axons	B-GO
could	O
be	O
seen	O
in	O
the	O
tibial	O
nerve	O
but	O
there	O
were	O
no	O
TrkC	B-GGP
-	O
positive	O
axons	B-GO
;	O
in	O
contrast	O
,	O
TrkA	B-GGP
-	O
and	O
TrkC	B-GGP
-	O
labeled	O
axons	B-GO
are	O
both	O
present	O
in	O
WT	B-SO
,	O
Bax	B-GGP
KO	O
,	O
and	O
double	O
KO	O
animals	B-Taxon
(	O
Figure	O
4F	O
)	O
.	O

These	O
results	O
suggest	O
that	O
although	O
proprioceptive	O
axons	B-GO
follow	O
proper	O
trajectories	O
in	O
distal	O
peripheral	O
nerves	O
,	O
they	O
fail	O
to	O
innervate	O
their	O
target	O
muscles	O
in	O
the	O
absence	O
of	O
NT	B-GGP
-	I-GGP
3	I-GGP
.	O

NT	B-GGP
-	I-GGP
3	I-GGP
Is	O
a	O
Chemoattractant	O
for	O
DRG	O
Axons	B-GO
In	O
Vitro	O

To	O
test	O
the	O
hypothesis	O
that	O
NT	B-GGP
-	I-GGP
3	I-GGP
acts	O
as	O
a	O
chemoattractant	O
for	O
sensory	O
axons	B-GO
,	O
we	O
performed	O
a	O
series	O
of	O
in	O
vitro	O
assays	O
.	O

Proprioceptive	O
axons	B-GO
in	O
mice	B-Taxon
enter	O
the	O
gray	O
matter	O
in	O
the	O
spinal	O
cord	O
and	O
advance	O
ventrally	O
parallel	O
to	O
the	O
midline	O
by	O
E13	O
and	O
reach	O
the	O
motor	B-CL
neurons	I-CL
by	O
E15	O
(	O
Ozaki	O
and	O
Snider	O
1994	O
)	O
.	O

We	O
co	O
-	O
cultured	O
collagen	B-GGP
-	O
embedded	O
E13	O
WT	B-SO
DRG	O
explants	O
with	O
NT	B-GGP
-	I-GGP
3	I-GGP
-	O
soaked	O
sepharose	O
beads	O
(	O
n	O
=	O
26	O
)	O
.	O

Control	O
cultures	O
were	O
set	O
up	O
using	O
bovine	B-GGP
serum	I-GGP
albumin	I-GGP
(	O
BSA	B-GGP
)	O
-	O
or	O
phosphate	B-CHEBI
buffer	O
saline	O
(	O
PBS	O
)	O
-	O
soaked	O
beads	O
(	O
n	O
=	O
12	O
)	O
.	O

DRG	O
axons	B-GO
began	O
extending	O
towards	O
the	O
localized	O
NT	B-GGP
-	I-GGP
3	I-GGP
source	O
by	O
the	O
end	O
of	O
the	O
first	O
day	O
and	O
consistently	O
displayed	O
a	O
strong	O
chemoattraction	O
by	O
3	O
d	O
in	O
vitro	O
,	O
whereas	O
they	O
did	O
not	O
show	O
such	O
preference	O
for	O
BSA	B-GGP
-	O
loaded	O
control	O
beads	O
(	O
Figure	O
5A	O
and	O
5B	O
)	O
.	O

This	O
attraction	O
was	O
not	O
due	O
to	O
survival	O
support	O
of	O
NT	B-GGP
-	I-GGP
3	I-GGP
because	O
Bax	B-GGP
null	O
ganglia	O
displayed	O
the	O
same	O
chemoattraction	O
(	O
Figure	O
5C	O
;	O
n	O
=	O
16	O
)	O
.	O

NT	B-GGP
-	I-GGP
3	I-GGP
may	O
act	O
through	O
either	O
TrkC	B-GGP
,	O
or	O
the	O
p75NTR	B-GGP
.	O

We	O
repeated	O
the	O
co	O
-	O
culture	O
experiments	O
with	O
DRG	O
explants	O
derived	O
from	O
p75NTR	B-GGP
KO	O
mice	B-Taxon
(	O
n	O
=	O
18	O
)	O
.	O

Axons	B-GO
of	O
these	O
ganglia	O
also	O
showed	O
strong	O
chemoattraction	O
towards	O
the	O
NT	B-GGP
-	I-GGP
3	I-GGP
beads	O
(	O
Figure	O
5D	O
)	O
.	O

Finally	O
,	O
we	O
used	O
diffusible	O
TrkC	B-GGP
receptors	I-GGP
conjugated	O
to	O
IgG	O
constant	O
regions	B-SO
(	O
TrkC	B-GGP
-	O
Fc	O
)	O
added	O
to	O
the	O
medium	O
(	O
n	O
=	O
6	O
)	O
to	O
deplete	O
soluble	O
NT	B-GGP
-	I-GGP
3	I-GGP
from	O
the	O
collagen	B-GGP
gels	O
(	O
Figure	O
5E	O
)	O
.	O

In	O
the	O
presence	O
of	O
TrkC	B-GGP
-	O
Fc	O
the	O
chemoattraction	O
was	O
completely	O
blocked	O
,	O
demonstrating	O
that	O
the	O
effect	O
we	O
see	O
is	O
specific	O
for	O
NT	B-GGP
-	I-GGP
3	I-GGP
.	O

In	O
order	O
to	O
investigate	O
the	O
active	O
range	O
of	O
our	O
beads	O
,	O
we	O
have	O
repeated	O
the	O
cultures	O
with	O
WT	B-SO
E13	O
DRGs	O
by	O
placing	O
the	O
beads	O
at	O
increasing	O
distances	O
from	O
the	O
ganglia	O
(	O
n	O
=	O
4	O
each	O
)	O
(	O
Figure	O
5F	O
)	O
.	O

There	O
was	O
still	O
preferred	O
growth	O
towards	O
the	O
bead	O
at	O
1	O
,	O
200	O
mu	O
m	O
,	O
the	O
longest	O
distance	O
studied	O
,	O
although	O
the	O
number	O
of	O
axons	B-GO
and	O
the	O
extent	O
of	O
growth	O
were	O
not	O
as	O
robust	O
.	O

Next	O
,	O
we	O
set	O
up	O
E13	O
DRG	O
spinal	O
cord	O
explant	O
cultures	O
using	O
NT	B-GGP
-	I-GGP
3	I-GGP
-	O
loaded	O
beads	O
placed	O
at	O
the	O
midline	O
at	O
mid	O
-	O
spinal	O
cord	O
level	O
as	O
an	O
ectopic	O
NT	B-GGP
-	I-GGP
3	I-GGP
source	O
(	O
n	O
=	O
15	O
)	O
.	O

Control	O
cultures	O
were	O
set	O
using	O
PBS	O
-	O
loaded	O
beads	O
(	O
n	O
=	O
6	O
)	O
.	O

DiI	O
labeling	O
through	O
the	O
DRGs	O
revealed	O
numerous	O
fibers	O
entering	O
the	O
spinal	O
cord	O
at	O
ectopic	O
regions	O
and	O
growing	O
towards	O
the	O
NT	B-GGP
-	I-GGP
3	I-GGP
beads	O
(	O
Figure	O
6A	O
)	O
,	O
surrounding	O
the	O
beads	O
and	O
forming	O
bundles	O
around	O
them	O
(	O
Figure	O
6C	O
-	O
6E	O
)	O
.	O

In	O
control	O
cultures	O
,	O
all	O
labeled	O
fibers	O
were	O
directed	O
towards	O
the	O
dorsal	O
spinal	O
cord	O
and	O
terminated	O
there	O
,	O
where	O
they	O
normally	O
enter	O
the	O
gray	O
matter	O
at	O
E13	O
(	O
Figure	O
6B	O
)	O
.	O

No	O
axons	B-GO
were	O
observed	O
around	O
the	O
PBS	O
-	O
loaded	O
control	O
beads	O
(	O
Figure	O
6F	O
)	O
.	O

Axons	B-GO
that	O
normally	O
enter	O
the	O
gray	O
matter	O
through	O
dorsal	O
spinal	O
cord	O
grow	O
towards	O
the	O
midline	O
when	O
presented	O
with	O
a	O
localized	O
NT	B-GGP
-	I-GGP
3	I-GGP
source	O
,	O
and	O
new	O
axon	B-GO
growth	O
towards	O
the	O
NT	B-GGP
-	I-GGP
3	I-GGP
bead	O
is	O
initiated	O
from	O
DRGs	O
,	O
entering	O
the	O
spinal	O
cord	O
at	O
ectopic	O
loci	O
at	O
lateral	O
mid	O
-	O
spinal	O
cord	O
(	O
Figure	O
6G	O
)	O
.	O

NT	B-GGP
-	I-GGP
3	I-GGP
is	O
therefore	O
capable	O
of	O
acting	O
as	O
a	O
chemoattractant	O
for	O
DRG	O
axons	B-GO
.	O

Discussion	O

Relatively	O
few	O
studies	O
have	O
implicated	O
NT	B-GGP
-	I-GGP
3	I-GGP
as	O
a	O
chemoattractant	O
agent	O
for	O
sensory	O
and	O
motor	O
axons	B-GO
.	O

Previously	O
noted	O
chemoattractant	O
action	O
of	O
the	O
embryonic	O
mouse	B-Taxon
maxillary	O
process	O
on	O
trigeminal	O
ganglion	O
neurons	B-CL
(	O
Lumsden	O
and	O
Davies	O
1986	O
)	O
is	O
now	O
attributed	O
to	O
NT	B-GGP
-	I-GGP
3	I-GGP
and	O
brain	B-GGP
-	I-GGP
derived	I-GGP
neurotrophic	I-GGP
factor	I-GGP
(	O
BDNF	B-GGP
)	O
(	O
O	O
'	O
Connor	O
et	O
al	O
.	O
1999	O
)	O
.	O

Recently	O
,	O
Tucker	O
et	O
al	O
.	O

(	O
2001	O
)	O
showed	O
that	O
developing	O
sensory	O
and	O
motor	O
axons	B-GO
in	O
limb	O
slice	O
cultures	O
preferentially	O
grow	O
towards	O
neurotrophin	B-GGP
-	O
soaked	O
beads	O
instead	O
of	O
following	O
their	O
normal	O
trajectories	O
.	O

Conversely	O
,	O
beads	O
soaked	O
with	O
neurotrophin	B-GGP
function	O
-	O
blocking	O
antibodies	B-GO
led	O
to	O
reduction	O
of	O
sensory	O
and	O
motor	O
axon	B-GO
growth	O
towards	O
the	O
limb	O
.	O

In	O
transgenic	B-SO
mice	B-Taxon
,	O
which	O
over	O
-	O
express	O
NT	B-GGP
-	I-GGP
3	I-GGP
under	O
the	O
nestin	B-GGP
promoter	B-SO
in	O
the	O
central	O
nervous	O
system	O
,	O
the	O
course	O
of	O
the	O
proprioceptive	O
afferents	O
are	O
altered	O
and	O
directed	O
towards	O
the	O
regions	O
with	O
high	O
levels	O
of	O
ectopic	O
NT	B-GGP
-	I-GGP
3	I-GGP
expression	O
in	O
the	O
spinal	O
cord	O
(	O
Ringstedt	O
et	O
al	O
.	O
1997	O
)	O
.	O

Ringstedt	O
et	O
al	O
.	O
considered	O
the	O
possibility	O
that	O
NT	B-GGP
-	I-GGP
3	I-GGP
may	O
play	O
a	O
chemoattractant	O
role	O
during	O
the	O
innervation	O
of	O
ventral	O
horns	O
by	O
proprioceptive	O
afferents	O
.	O

However	O
,	O
earlier	O
findings	O
of	O
normal	O
proprioceptive	O
afferent	O
trajectories	O
in	O
chicken	B-Taxon
embryos	O
despite	O
injection	O
of	O
function	O
-	O
blocking	O
NT	B-GGP
-	I-GGP
3	I-GGP
antibody	B-GO
into	O
the	O
spinal	O
cord	O
(	O
Oakley	O
et	O
al	O
.	O
1995	O
)	O
led	O
them	O
to	O
discount	O
this	O
possibility	O
.	O

In	O
that	O
study	O
,	O
though	O
,	O
assays	O
on	O
the	O
effectiveness	O
of	O
antibody	B-GO
perturbation	O
on	O
NT	B-GGP
-	I-GGP
3	I-GGP
-	O
dependent	O
cell	B-CL
survival	O
showed	O
that	O
effectiveness	O
was	O
significant	O
(	O
approximately	O
90	O
%	O
)	O
but	O
not	O
complete	O
(	O
Oakley	O
et	O
al	O
.	O
1995	O
)	O
.	O

Ringstedt	O
et	O
al	O
.	O

(	O
1997	O
)	O
argue	O
that	O
while	O
central	O
sensory	O
axons	B-GO
may	O
still	O
navigate	O
properly	O
in	O
the	O
absence	O
of	O
NT	B-GGP
-	I-GGP
3	I-GGP
,	O
ectopic	O
expression	O
of	O
NT	B-GGP
-	I-GGP
3	I-GGP
disrupts	O
their	O
targeting	O
.	O

Recently	O
,	O
another	O
member	O
of	O
the	O
neurotrophin	B-GGP
family	O
,	O
BDNF	B-GGP
,	O
has	O
been	O
suggested	O
to	O
act	O
as	O
a	O
chemoattractant	O
for	O
sensory	O
axons	B-GO
innervating	O
ear	O
(	O
Tessarollo	O
et	O
al	O
.	O
2004	O
)	O
.	O

In	O
a	O
gene	B-SO
replacement	O
strategy	O
in	O
which	O
BDNF	B-GGP
expression	O
was	O
driven	O
by	O
the	O
NT	B-GGP
-	I-GGP
3	I-GGP
promoter	B-SO
,	O
vestibular	O
axons	B-GO
rerouted	O
towards	O
ectopic	O
sources	O
of	O
BDNF	B-GGP
in	O
the	O
cochlea	O
that	O
normally	O
expressed	O
NT	B-GGP
-	I-GGP
3	I-GGP
and	O
were	O
not	O
innervated	O
by	O
these	O
axons	B-GO
.	O

Ectopic	O
NT	B-GGP
-	I-GGP
3	I-GGP
supplied	O
using	O
osmotic	O
pumps	O
and	O
adenovirus	B-Taxon
-	O
mediated	O
expression	O
induce	O
sensory	O
axon	B-GO
growth	O
during	O
regeneration	O
(	O
Zhang	O
et	O
al	O
.	O
1998	O
,	O
Bradbury	O
et	O
al	O
.	O
1999	O
,	O
Oudega	O
et	O
al	O
.	O
1999	O
,	O
Ramer	O
et	O
al	O
.	O
2002	O
)	O
,	O
and	O
induce	O
axonal	B-GO
plasticity	O
of	O
corticospinal	O
axons	B-GO
in	O
injured	O
adult	O
spinal	O
cord	O
(	O
Zhou	O
et	O
al	O
.	O
2003	O
)	O
,	O
where	O
the	O
sprouting	O
axons	B-GO
from	O
the	O
intact	O
site	O
cross	O
the	O
midline	O
towards	O
the	O
NT	B-GGP
-	I-GGP
3	I-GGP
source	O
on	O
the	O
lesion	O
side	O
of	O
the	O
spinal	O
cord	O
.	O

Our	O
present	O
results	O
are	O
in	O
agreement	O
with	O
these	O
observations	O
,	O
and	O
provide	O
further	O
evidence	O
that	O
NT	B-GGP
-	I-GGP
3	I-GGP
acts	O
as	O
a	O
chemoattractant	O
for	O
sensory	O
afferents	O
.	O

Previously	O
,	O
normal	O
motor	B-CL
neuron	I-CL
innervation	O
was	O
rescued	O
in	O
NT	B-GGP
-	I-GGP
3	I-GGP
KO	O
animals	B-Taxon
by	O
over	O
-	O
expressing	O
NT	B-GGP
-	I-GGP
3	I-GGP
selectively	O
in	O
their	O
muscles	O
(	O
Wright	O
et	O
al	O
.	O
1997	O
)	O
.	O

It	O
appears	O
that	O
peripheral	O
NT	B-GGP
-	I-GGP
3	I-GGP
alone	O
is	O
sufficient	O
for	O
rescuing	O
proprioceptive	O
neurons	B-CL
in	O
NT	B-GGP
-	I-GGP
3	I-GGP
KO	O
animals	B-Taxon
and	O
proper	O
axonal	B-GO
pathfinding	O
in	O
the	O
spinal	O
cord	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
NT	B-GGP
-	I-GGP
3	I-GGP
is	O
absent	O
from	O
the	O
ventral	O
spinal	O
cords	O
of	O
these	O
animals	B-Taxon
.	O

The	O
possibility	O
has	O
been	O
raised	O
that	O
motor	B-CL
neurons	I-CL
may	O
retrogradely	O
transport	O
NT	B-GGP
-	I-GGP
3	I-GGP
in	O
muscle	O
to	O
the	O
spinal	O
cord	O
(	O
Chen	O
and	O
Frank	O
1999	O
)	O
.	O

Assays	O
to	O
determine	O
whether	O
any	O
NT	B-GGP
-	I-GGP
3	I-GGP
is	O
present	O
in	O
the	O
ventral	O
horns	O
of	O
these	O
mice	B-Taxon
would	O
be	O
informative	O
.	O

Recently	O
,	O
Patel	O
et	O
al	O
.	O

(	O
2003	O
)	O
reported	O
their	O
observations	O
on	O
Bax	B-GGP
/	O
NT	B-GGP
-	I-GGP
3	I-GGP
double	O
KO	O
mice	B-Taxon
they	O
bred	O
.	O

Their	O
results	O
are	O
significantly	O
different	O
from	O
ours	O
.	O

They	O
see	O
no	O
proprioceptive	O
afferents	O
in	O
the	O
periphery	O
of	O
the	O
double	O
knockouts	O
and	O
note	O
that	O
central	O
proprioceptive	O
afferents	O
terminate	O
in	O
the	O
intermediate	O
spinal	O
cord	O
without	O
extending	O
ventrally	O
.	O

Their	O
observations	O
are	O
based	O
on	O
PV	B-GGP
immunostaining	O
and	O
DiI	O
labeling	O
of	O
the	O
peripheral	O
nerves	O
.	O

We	O
noted	O
that	O
PV	B-GGP
immunolabeling	O
is	O
diminished	O
in	O
our	O
Bax	B-GGP
/	O
NT	B-GGP
-	I-GGP
3	I-GGP
double	O
KOs	O
.	O

In	O
various	O
manipulations	O
of	O
the	O
neurotrophins	B-GGP
it	O
has	O
been	O
noted	O
that	O
molecular	B-CHEBI
markers	O
for	O
proprioceptive	O
axons	B-GO
such	O
as	O
PV	B-GGP
or	O
calcitonin	B-GGP
gene	I-GGP
-	I-GGP
related	I-GGP
peptide	I-GGP
for	O
nerve	B-GGP
growth	I-GGP
factor	I-GGP
-	O
responsive	O
axons	B-GO
are	O
compromised	O
(	O
Ringstedt	O
et	O
al	O
.	O
1997	O
;	O
Patel	O
et	O
al	O
.	O
2000	O
)	O
,	O
thus	O
PV	B-GGP
immunostaining	O
in	O
Bax	B-GGP
/	O
NT	B-GGP
-	I-GGP
3	I-GGP
double	O
KOs	O
cannot	O
reveal	O
the	O
extent	O
of	O
proprioceptive	O
axons	B-GO
in	O
the	O
periphery	O
.	O

Seventy	O
-	O
three	O
percent	O
of	O
retrogradely	O
labeled	O
gastrocnemius	O
muscle	O
afferents	O
were	O
reported	O
to	O
be	O
expressing	O
TrkC	B-GGP
RNA	B-SO
in	O
the	O
adult	O
rat	B-Taxon
DRG	O
,	O
although	O
some	O
of	O
these	O
(	O
about	O
10	O
%	O
)	O
may	O
represent	O
cutaneous	O
innervation	O
(	O
McMahon	O
et	O
al	O
.	O
1994	O
)	O
.	O

Presently	O
,	O
it	O
is	O
not	O
clear	O
whether	O
TrkC	B-GGP
protein	B-CHEBI
is	O
also	O
made	O
by	O
cutaneous	O
afferents	O
and	O
if	O
so	O
at	O
what	O
stage	O
in	O
development	O
this	O
receptor	O
is	O
expressed	O
by	O
cutaneous	O
axons	B-GO
.	O

Based	O
on	O
the	O
available	O
evidence	O
showing	O
that	O
all	O
proprioceptive	O
neurons	B-CL
are	O
eliminated	O
in	O
NT	B-GGP
-	I-GGP
3	I-GGP
or	O
TrkC	B-GGP
null	O
mice	B-Taxon
,	O
we	O
think	O
that	O
TrkC	B-GGP
staining	O
in	O
the	O
tibial	O
nerve	O
mostly	O
represents	O
proprioceptive	O
axons	B-GO
in	O
the	O
vicinity	O
of	O
their	O
peripheral	O
target	O
.	O

Altogether	O
,	O
our	O
findings	O
suggest	O
a	O
role	O
for	O
NT	B-GGP
-	I-GGP
3	I-GGP
in	O
initiation	O
of	O
muscle	O
innervation	O
and	O
spindle	O
differentiation	O
by	O
the	O
proprioceptive	O
axons	B-GO
.	O

Patel	O
et	O
al	O
.	O

(	O
2003	O
)	O
examined	O
DiI	O
-	O
labeled	O
central	O
DRG	O
axons	B-GO
in	O
the	O
spinal	O
cord	O
of	O
three	O
E17	O
and	O
two	O
P0	O
cases	O
,	O
and	O
report	O
that	O
central	O
proprioceptive	O
axons	B-GO
stop	O
in	O
the	O
intermediate	O
laminae	O
,	O
never	O
entering	O
the	O
ventral	O
cord	O
.	O

We	O
have	O
examined	O
nine	O
Bax	B-GGP
/	O
NT	B-GGP
-	I-GGP
3	I-GGP
double	O
KO	O
cases	O
,	O
and	O
often	O
incomplete	O
DiI	O
labeling	O
gives	O
the	O
impression	O
that	O
there	O
are	O
no	O
axons	B-GO
reaching	O
the	O
ventral	O
spinal	O
cord	O
.	O

We	O
have	O
also	O
seen	O
cases	O
similar	O
to	O
theirs	O
(	O
n	O
=	O
4	O
)	O
,	O
but	O
at	O
higher	O
magnification	O
these	O
axons	B-GO
did	O
not	O
have	O
terminal	B-GO
boutons	I-GO
and	O
were	O
not	O
completely	O
labeled	O
.	O

However	O
,	O
with	O
complete	O
fills	O
(	O
n	O
=	O
5	O
)	O
,	O
it	O
was	O
possible	O
to	O
trace	O
these	O
axons	B-GO
into	O
the	O
ventral	O
midline	O
and	O
across	O
to	O
the	O
contralateral	O
side	O
,	O
and	O
visualize	O
terminal	B-GO
boutons	I-GO
at	O
their	O
tips	O
(	O
see	O
Figure	O
3C	O
)	O
.	O

Previously	O
,	O
Arber	O
et	O
al	O
.	O

(	O
2000	O
)	O
reported	O
that	O
members	O
of	O
the	O
Ets	O
family	O
of	O
transcription	O
factors	O
,	O
Er81	B-GGP
and	O
Pea3	B-GGP
,	O
are	O
expressed	O
by	O
DRG	O
neurons	B-CL
as	O
well	O
as	O
motor	B-CL
neurons	I-CL
and	O
their	O
target	O
muscle	O
fibers	O
.	O

They	O
found	O
that	O
in	O
the	O
spinal	O
cord	O
of	O
Er81	B-GGP
KO	O
mice	B-Taxon
,	O
ventral	O
projections	B-GO
of	O
proprioceptive	O
axons	B-GO
were	O
mostly	O
absent	O
,	O
and	O
very	O
few	O
axons	B-GO
made	O
it	O
to	O
the	O
ventral	O
cord	O
.	O

Patel	O
et	O
al	O
.	O

(	O
2003	O
)	O
note	O
that	O
the	O
phenotype	O
they	O
observed	O
in	O
their	O
Bax	B-GGP
/	O
NT	B-GGP
-	I-GGP
3	I-GGP
double	O
KO	O
mice	B-Taxon
is	O
quite	O
similar	O
to	O
that	O
of	O
Er81	B-GGP
KO	O
mice	B-Taxon
.	O

They	O
provide	O
evidence	O
that	O
NT	B-GGP
-	I-GGP
3	I-GGP
induces	O
Er81	B-GGP
expression	O
in	O
DRG	O
explants	O
in	O
vitro	O
.	O

Patel	O
et	O
al	O
.	O

(	O
2003	O
)	O
report	O
that	O
Er81	B-GGP
mRNA	B-CHEBI
expression	O
is	O
diminished	O
(	O
but	O
not	O
abolished	O
)	O
in	O
both	O
NT	B-GGP
-	I-GGP
3	I-GGP
KO	O
and	O
Bax	B-GGP
/	O
NT	B-GGP
-	I-GGP
3	I-GGP
double	O
KO	O
mice	B-Taxon
,	O
while	O
their	O
immunohistochemistry	O
shows	O
much	O
less	O
protein	B-CHEBI
expression	O
in	O
the	O
double	O
KO	O
mice	B-Taxon
.	O

It	O
is	O
highly	O
possible	O
that	O
a	O
small	O
but	O
considerable	O
number	O
of	O
DRG	O
cells	B-CL
express	O
the	O
transcription	O
factor	O
Er81	B-GGP
and	O
that	O
their	O
axons	B-GO
grow	O
beyond	O
the	O
intermediate	O
levels	O
of	O
the	O
spinal	O
cord	O
in	O
Bax	B-GGP
/	O
NT	B-GGP
-	I-GGP
3	I-GGP
double	O
KO	O
mice	B-Taxon
.	O

While	O
the	O
phenotype	O
of	O
Er81	B-GGP
KO	O
mice	B-Taxon
is	O
quite	O
dramatic	O
,	O
and	O
most	O
proprioceptive	O
axons	B-GO
stop	O
within	O
the	O
intermediate	O
spinal	O
cord	O
,	O
it	O
is	O
important	O
to	O
note	O
that	O
a	O
few	O
axons	B-GO
still	O
find	O
their	O
way	O
to	O
the	O
ventral	O
spinal	O
cord	O
and	O
target	O
properly	O
to	O
the	O
motor	B-CL
neurons	I-CL
(	O
Arber	O
et	O
al	O
.	O
2000	O
)	O
.	O

Patel	O
et	O
al	O
.	O

(	O
2003	O
)	O
also	O
present	O
observations	O
from	O
islet2DTA	O
mice	B-Taxon
,	O
which	O
lack	O
a	O
significant	O
portion	O
of	O
the	O
motor	B-CL
neurons	I-CL
in	O
the	O
ventral	O
cord	O
.	O

In	O
these	O
mice	B-Taxon
PV	B-GGP
immunostaining	O
shows	O
axons	B-GO
in	O
the	O
ventral	O
horns	O
.	O

Patel	O
et	O
al	O
.	O
argue	O
that	O
since	O
motor	B-CL
neurons	I-CL
are	O
absent	O
in	O
these	O
mice	B-Taxon
,	O
NT	B-GGP
-	I-GGP
3	I-GGP
secreted	O
by	O
them	O
could	O
not	O
be	O
a	O
signal	O
for	O
proprioceptive	O
axons	B-GO
to	O
enter	O
the	O
lateral	O
motor	O
columns	O
.	O

However	O
,	O
there	O
is	O
no	O
evidence	O
showing	O
that	O
NT	B-GGP
-	I-GGP
3	I-GGP
mRNA	B-CHEBI
or	O
protein	B-CHEBI
expressed	O
in	O
the	O
ventral	O
spinal	O
cord	O
is	O
exclusively	O
from	O
motor	B-CL
neurons	I-CL
,	O
and	O
there	O
are	O
no	O
available	O
data	O
indicating	O
that	O
in	O
islet2DTA	O
mice	B-Taxon
,	O
NT	B-GGP
-	I-GGP
3	I-GGP
expression	O
in	O
the	O
ventral	O
spinal	O
cord	O
is	O
abolished	O
(	O
Yang	O
et	O
al	O
.	O
2001	O
;	O
Pun	O
et	O
al	O
.	O
2002	O
)	O
.	O

Studies	O
in	O
embryonic	O
mice	B-Taxon
reported	O
NT	B-GGP
-	I-GGP
3	I-GGP
mRNA	B-CHEBI
in	O
the	O
ventral	O
horns	O
of	O
the	O
spinal	O
cord	O
,	O
but	O
it	O
is	O
not	O
definitive	O
that	O
both	O
mRNA	B-CHEBI
and	O
protein	B-CHEBI
are	O
expressed	O
solely	O
by	O
motor	B-CL
neurons	I-CL
.	O

In	O
the	O
adult	O
spinal	O
cord	O
,	O
while	O
motor	B-CL
neurons	I-CL
express	O
high	O
levels	O
of	O
NT	B-GGP
-	I-GGP
3	I-GGP
,	O
other	O
cells	B-CL
,	O
including	O
glia	B-CL
,	O
also	O
express	O
it	O
(	O
Zhou	O
and	O
Rush	O
1994	O
;	O
Dreyfus	O
et	O
al	O
.	O
1999	O
;	O
Buck	O
et	O
al	O
.	O
2000	O
)	O
.	O

Our	O
present	O
results	O
,	O
along	O
with	O
those	O
from	O
transgenic	B-SO
mice	B-Taxon
with	O
NT	B-GGP
-	I-GGP
3	I-GGP
over	O
-	O
expression	O
in	O
ectopic	O
regions	O
of	O
the	O
spinal	O
cord	O
(	O
Ringstedt	O
et	O
al	O
.	O
1997	O
)	O
,	O
argue	O
for	O
a	O
role	O
of	O
NT	B-GGP
-	I-GGP
3	I-GGP
in	O
chemoattractant	O
axon	B-GO
guidance	O
of	O
proprioceptive	O
axons	B-GO
in	O
the	O
spinal	O
cord	O
.	O

Finally	O
,	O
in	O
culture	O
assays	O
,	O
we	O
see	O
a	O
strong	O
chemoattraction	O
of	O
DRG	O
neurons	B-CL
to	O
localized	O
sources	O
of	O
NT	B-GGP
-	I-GGP
3	I-GGP
.	O

This	O
response	O
is	O
seen	O
in	O
WT	B-SO
,	O
Bax	B-GGP
null	O
and	O
in	O
p75	B-GGP
null	O
DRG	O
explants	O
,	O
and	O
in	O
the	O
absence	O
of	O
any	O
other	O
neurotrophins	B-GGP
or	O
target	O
-	O
derived	O
axon	B-GO
guidance	O
molecules	B-CHEBI
.	O

Furthermore	O
,	O
in	O
vitro	O
,	O
sensory	O
axon	B-GO
response	O
to	O
NT	B-GGP
-	I-GGP
3	I-GGP
does	O
not	O
appear	O
to	O
be	O
dose	O
-	O
dependent	O
(	O
Ringstedt	O
et	O
al	O
.	O
1997	O
;	O
Tucker	O
et	O
al	O
.	O
2001	O
)	O
.	O

NT	B-GGP
-	I-GGP
3	I-GGP
is	O
capable	O
of	O
attracting	O
axons	B-GO
along	O
distances	O
of	O
up	O
to	O
1	O
mm	O
in	O
collagen	B-GGP
gel	O
matrix	O
,	O
covering	O
the	O
physiological	O
range	O
it	O
needs	O
to	O
attract	O
axons	B-GO
during	O
development	O
.	O

Previous	O
studies	O
with	O
exogenous	O
or	O
local	O
applications	O
of	O
NT	B-GGP
-	I-GGP
3	I-GGP
to	O
developing	O
primary	O
sensory	O
axons	B-GO
have	O
indicated	O
that	O
this	O
neurotrophin	B-GGP
can	O
attract	O
and	O
induce	O
axonal	B-GO
branching	O
(	O
Ulup	O
i	O
nar	O
et	O
al	O
.	O
2000	O
;	O
O	O
zdinler	O
and	O
Erzurumlu	O
2001	O
,	O
O	O
zdinler	O
et	O
al	O
.	O
2004	O
)	O
.	O

Along	O
the	O
monosynaptic	O
stretch	O
reflex	O
pathway	O
,	O
only	O
Wnt	B-GGP
-	I-GGP
3	I-GGP
has	O
been	O
implicated	O
as	O
an	O
axon	B-GO
arborization	O
factor	O
in	O
the	O
spinal	O
cord	O
(	O
Krylova	O
et	O
al	O
.	O
2002	O
)	O
.	O

Another	O
molecule	B-CHEBI
,	O
Slit2	B-GGP
,	O
expressed	O
in	O
the	O
midline	O
and	O
by	O
motor	B-CL
neurons	I-CL
(	O
Wang	O
et	O
al	O
.	O
1999	O
)	O
is	O
capable	O
of	O
inducing	O
axonal	B-GO
branching	O
(	O
Nguyen	O
Ba	O
-	O
Charvet	O
et	O
al	O
.	O
2001	O
;	O
O	O
zdinler	O
and	O
Erzurumlu	O
2002	O
)	O
.	O

DRG	O
neurons	B-CL
express	O
Robo	O
receptors	O
,	O
which	O
bind	O
to	O
Slits	O
,	O
and	O
proprioceptive	O
axons	B-GO
are	O
therefore	O
capable	O
of	O
responding	O
to	O
Slit	O
signals	O
(	O
Wang	O
et	O
al	O
.	O
1999	O
)	O
.	O

Slit2	B-GGP
does	O
not	O
cause	O
repulsion	O
of	O
NT	B-GGP
-	I-GGP
3	I-GGP
-	O
responsive	O
DRG	O
axons	B-GO
in	O
vitro	O
(	O
Nguyen	O
Ba	O
-	O
Charvet	O
et	O
al	O
.	O
2001	O
)	O
,	O
but	O
causes	O
ectopic	O
branching	O
and	O
arborization	O
of	O
trigeminal	O
axons	B-GO
in	O
the	O
brainstem	O
(	O
O	O
zdinler	O
and	O
Erzurumlu	O
2002	O
)	O
.	O

Thus	O
,	O
Slit2	B-GGP
might	O
also	O
be	O
involved	O
in	O
terminal	O
branching	O
of	O
propioceptive	O
axons	B-GO
in	O
the	O
ventral	O
cord	O
and	O
in	O
the	O
midline	O
branching	O
observed	O
in	O
our	O
double	O
KOs	O
.	O

Lack	O
of	O
PV	B-GGP
expression	O
in	O
Bax	B-GGP
/	O
NT	B-GGP
-	I-GGP
3	I-GGP
KO	O
mice	B-Taxon
suggests	O
that	O
PV	B-GGP
expression	O
might	O
be	O
responsible	O
for	O
proper	O
axon	B-GO
targeting	O
and	O
muscle	O
spindle	O
differentiation	O
.	O

Presently	O
we	O
cannot	O
completely	O
rule	O
out	O
this	O
possibility	O
.	O

However	O
,	O
no	O
defects	O
in	O
axon	B-GO
pathfinding	O
along	O
the	O
monosynaptic	O
reflex	O
arc	O
or	O
in	O
muscle	O
spindle	O
differentiation	O
have	O
been	O
noted	O
in	O
PV	B-GGP
KO	O
mice	B-Taxon
,	O
which	O
develop	O
normally	O
and	O
show	O
no	O
apparent	O
changes	O
in	O
their	O
behavior	O
or	O
physical	O
activity	O
(	O
Schwaller	O
et	O
al	O
.	O
1999	O
)	O
.	O

These	O
observations	O
suggest	O
that	O
axonal	B-GO
targeting	O
defects	O
in	O
Bax	B-GGP
/	O
NT	B-GGP
-	I-GGP
3	I-GGP
double	O
KO	O
mice	B-Taxon
cannot	O
be	O
simply	O
due	O
to	O
lack	O
of	O
PV	B-GGP
expression	O
in	O
proprioceptive	O
cells	B-CL
.	O

Our	O
present	O
results	O
suggest	O
that	O
NT	B-GGP
-	I-GGP
3	I-GGP
acts	O
as	O
a	O
short	O
-	O
range	O
axon	B-GO
guidance	O
cue	O
for	O
proprioceptive	O
axons	B-GO
centrally	O
and	O
peripherally	O
,	O
as	O
they	O
navigate	O
to	O
their	O
targets	O
using	O
other	O
axon	B-GO
guidance	O
cues	O
.	O

In	O
its	O
absence	O
,	O
these	O
axons	B-GO
terminate	O
in	O
inappropriate	O
loci	O
.	O

However	O
,	O
NT	B-GGP
-	I-GGP
3	I-GGP
may	O
not	O
be	O
the	O
only	O
molecule	B-CHEBI
that	O
plays	O
a	O
role	O
in	O
targeting	O
and	O
terminal	O
branching	O
of	O
sensory	O
axons	B-GO
in	O
the	O
ventral	O
spinal	O
cord	O
.	O

NT	B-GGP
-	I-GGP
3	I-GGP
most	O
likely	O
acts	O
cooperatively	O
with	O
other	O
axon	B-GO
guidance	O
molecules	B-CHEBI
or	O
by	O
regulating	O
expression	O
of	O
yet	O
to	O
be	O
identified	O
proprioceptive	O
neuron	B-CL
-	O
specific	O
receptors	O
/	O
ligands	O
for	O
numerous	O
axon	B-GO
guidance	O
cues	O
.	O

Materials	O
and	O
Methods	O

Generation	O
of	O
double	O
KOs	O
.	O

We	O
crossed	O
Bax	B-GGP
KO	O
females	O
on	O
a	O
C57BL	O
/	O
6	O
background	O
(	O
Jackson	O
Laboratory	O
,	O
Bar	O
Harbor	O
,	O
Maine	O
,	O
United	O
States	O
)	O
to	O
NT	B-GGP
-	I-GGP
3	I-GGP
heterozygote	O
males	O
on	O
a	O
129	O
Sv	O
background	O
to	O
generate	O
double	O
heterozygote	O
animals	B-Taxon
.	O

Progeny	O
was	O
genotyped	O
with	O
PCR	O
,	O
and	O
animals	B-Taxon
heterozygous	O
for	O
both	O
genes	B-SO
were	O
bred	O
to	O
obtain	O
the	O
double	O
KOs	O
.	O

Primers	B-SO
used	O
for	O
the	O
Bax	B-GGP
locus	B-SO
were	O
R661	O
,	O
GTT	O
GAC	O
CAG	O
AGT	O
GGC	O
GTA	O
GG	O
;	O
R662	O
,	O
CCG	O
CTT	O
CCA	O
TTG	O
CTC	O
AGC	O
GG	O
;	O
and	O
R663	O
,	O
GAG	O
CTG	O
ATC	O
AGA	O
ACC	O
ATC	O
ATG	O
.	O

Primers	B-SO
used	O
for	O
the	O
NT	B-GGP
-	I-GGP
3	I-GGP
locus	B-SO
were	O
NT3A	O
,	O
CGT	O
GGT	O
GAG	O
GTT	O
CTA	O
TTG	O
GCT	O
AC	O
;	O
NT3B	O
,	O
CAG	O
AGC	O
ACC	O
CTG	O
CCC	O
AAA	O
GCA	O
GAG	O
;	O
NT3R	O
,	O
CCT	O
TGA	O
CAA	O
TAC	O
TGA	O
ATG	O
CC	O
;	O
and	O
NEOF	O
,	O
GGG	O
AAC	O
TTC	O
CTG	O
ACT	O
AGG	O
.	O

WT	B-SO
,	O
Bax	B-GGP
KO	O
,	O
and	O
NT	B-GGP
-	I-GGP
3	I-GGP
KO	O
littermates	O
were	O
used	O
as	O
controls	O
.	O

A	O
total	O
of	O
11	O
Bax	B-GGP
/	O
NT	B-GGP
-	I-GGP
3	I-GGP
double	O
KO	O
mice	B-Taxon
were	O
analyzed	O
,	O
of	O
these	O
nine	O
were	O
P0	O
pups	O
.	O

The	O
p75	B-GGP
colony	O
on	O
a	O
129	O
S1	O
background	O
was	O
received	O
from	O
Jackson	O
Laboratory	O
.	O

We	O
used	O
tail	O
DNA	B-SO
to	O
genotype	O
animals	B-Taxon
using	O
the	O
primers	B-SO
IMR0013	O
,	O
CTT	O
GGG	O
TGG	O
AGA	O
GGC	O
TAT	O
TC	O
;	O
IMR0014	O
,	O
AGG	O
TGA	O
GAT	O
GAC	O
AGG	O
AGA	O
TC	O
(	O
generic	O
neo	O
primers	B-SO
)	O
;	O
IMR0710	O
,	O
TGT	O
TAC	O
GTT	O
CTC	O
TGA	O
CGT	O
GGT	O
GAG	O
;	O
and	O
IMR0711	O
,	O
TCA	O
GCC	O
CAG	O
GGT	O
GTG	O
CAC	O
TC	O
(	O
p75	B-GGP
locus	B-SO
)	O
.	O

For	O
embryonic	O
experiments	O
,	O
day	O
of	O
plug	O
positivity	O
was	O
considered	O
E0	O
.	O

All	O
of	O
the	O
protocols	O
used	O
in	O
this	O
study	O
were	O
approved	O
by	O
the	O
Louisiana	O
State	O
University	O
Health	O
Sciences	O
Center	O
Institutional	O
Animal	B-Taxon
Care	O
and	O
Use	O
Committee	O
and	O
conformed	O
to	O
the	O
National	O
Institutes	O
of	O
Health	O
guidelines	O
for	O
use	O
of	O
experimental	O
animals	B-Taxon
.	O

TrkA	B-GGP
/	O
TrkC	B-GGP
immunohistochemistry	O
.	O

Frozen	O
spinal	O
cord	O
sections	O
(	O
10	O
mu	O
m	O
thick	O
)	O
were	O
blocked	O
and	O
incubated	O
in	O
a	O
cocktail	O
of	O
rabbit	B-Taxon
anti	O
-	O
TrkA	B-GGP
and	O
goat	B-Taxon
anti	O
-	O
TrkC	B-GGP
antibodies	B-GO
(	O
gift	O
of	O
Dr	O
.	O
Reichardt	O
;	O
Huang	O
et	O
al	O
.	O
1999	O
)	O
,	O
followed	O
by	O
a	O
cocktail	O
of	O
CY3	O
conjugated	O
donkey	B-Taxon
anti	O
-	O
rabbit	B-Taxon
and	O
FITC	B-CHEBI
conjugated	O
donkey	B-Taxon
anti	O
-	O
goat	B-Taxon
antibodies	B-GO
(	O
Chemicon	O
,	O
Temecula	O
,	O
California	O
,	O
United	O
States	O
)	O
in	O
the	O
presence	O
of	O
0	O
.	O
3	O
%	O
TritonX	O
-	O
100	O
and	O
10	O
%	O
normal	O
donkey	B-Taxon
serum	O
.	O

For	O
PV	B-GGP
immunohistochemistry	O
,	O
sections	O
were	O
reacted	O
with	O
monoclonal	O
mouse	B-Taxon
anti	O
-	O
PV	B-GGP
antibody	B-GO
(	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
Missouri	O
,	O
United	O
States	O
)	O
,	O
and	O
developed	O
by	O
Vector	O
fluorescein	B-CHEBI
mouse	B-Taxon
on	O
mouse	B-Taxon
kit	O
(	O
Vector	O
Laboratories	O
,	O
Burlingame	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

For	O
quantification	O
purposes	O
,	O
TrkA	B-GGP
-	O
and	O
TrkC	B-GGP
-	O
labeled	O
cells	B-CL
from	O
four	O
different	O
DRGs	O
of	O
each	O
genotype	B-SO
and	O
age	O
studied	O
were	O
counted	O
,	O
and	O
ratios	O
plotted	O
.	O

Muscle	O
spindle	O
detection	O
.	O

Gastrocnemius	O
muscle	O
was	O
dissected	O
out	O
in	O
P0	O
pups	O
and	O
sectioned	O
longitudinally	O
,	O
or	O
,	O
in	O
some	O
cases	O
,	O
the	O
whole	O
leg	O
at	O
the	O
level	O
of	O
gastrocnemius	O
muscle	O
with	O
tibial	O
nerve	O
was	O
sectioned	O
in	O
cross	O
section	O
.	O

Sections	O
were	O
incubated	O
with	O
monoclonal	O
S46	O
antibody	B-GO
(	O
gift	O
of	O
Dr	O
.	O
Stockdale	O
)	O
reactive	O
to	O
the	O
spindle	O
-	O
specific	O
slow	O
-	O
tonic	O
myosin	B-GO
heavy	O
chain	B-SO
isoform	B-SO
and	O
developed	O
by	O
Vector	O
mouse	B-Taxon
on	O
mouse	B-Taxon
kit	O
as	O
described	O
above	O
,	O
followed	O
by	O
rabbit	B-Taxon
anti	O
-	O
NF	B-GGP
-	I-GGP
M	I-GGP
antibody	B-GO
(	O
Chemicon	O
)	O
and	O
CY3	O
conjugated	O
goat	B-Taxon
anti	O
-	O
rabbit	B-Taxon
antibody	B-GO
(	O
Chemicon	O
)	O
in	O
a	O
sequential	O
double	O
-	O
labeling	O
protocol	O
.	O

In	O
another	O
method	O
,	O
DiI	O
crystals	O
were	O
placed	O
in	O
DRGs	O
of	O
E17	O
embryos	O
from	O
different	O
genotypes	B-SO
(	O
n	O
=	O
2	O
)	O
,	O
and	O
the	O
gastrocnemius	O
muscle	O
was	O
isolated	O
and	O
sectioned	O
into	O
40	O
-	O
mu	O
m	O
-	O
thick	O
slices	O
on	O
a	O
vibratome	O
.	O

DiI	O
labeling	O
.	O

Spinal	O
cords	O
were	O
dissected	O
out	O
with	O
the	O
DRGs	O
attached	O
,	O
motor	O
root	O
was	O
cut	O
to	O
prevent	O
backfilling	O
of	O
motor	B-CL
neurons	I-CL
,	O
and	O
crystals	O
of	O
1	O
,	O
1	O
'	O
-	O
dioctadecyl	O
-	O
3	O
,	O
3	O
,	O
3	O
'	O
,	O
3	O
'	O
-	O
tetramethylindocarbocyanine	O
perchlorate	B-CHEBI
(	O
DiI	O
;	O
Molecular	B-CHEBI
Probes	O
,	O
Eugene	O
,	O
Oregon	O
,	O
United	O
States	O
)	O
were	O
inserted	O
in	O
DRGs	O
.	O

Labeled	O
spinal	O
cords	O
were	O
incubated	O
at	O
37	O
degrees	O
C	O
for	O
8	O
d	O
and	O
sectioned	O
on	O
a	O
vibrotome	O
at	O
100	O
mu	O
m	O
.	O

Sections	O
were	O
observed	O
under	O
the	O
fluorescent	O
microscope	O
and	O
photographed	O
,	O
and	O
images	O
were	O
transferred	O
to	O
Adobe	O
Photoshop	O
,	O
inverted	O
,	O
and	O
adjusted	O
for	O
brightness	O
and	O
contrast	O
.	O

Photoconverted	O
in	O
0	O
.	O
15	O
%	O
DAB	O
(	O
3	O
,	O
3	O
'	O
-	O
diaminobenzidine	O
;	O
Sigma	O
)	O
in	O
0	O
.	O
1M	O
Tris	B-CHEBI
buffer	O
(	O
pH	O
8	O
.	O
2	O
)	O
.	O

In	O
vitro	O
co	O
-	O
culture	O
assay	O
.	O

DRG	O
explants	O
were	O
derived	O
from	O
Swiss	O
Webster	O
,	O
Bax	B-GGP
null	O
,	O
and	O
p75	B-GGP
null	O
mouse	B-Taxon
embryos	O
(	O
E13	O
)	O
.	O

For	O
collagen	B-GGP
matrix	O
assays	O
,	O
DRGs	O
were	O
dissected	O
out	O
under	O
a	O
stereomicroscope	O
using	O
tungsten	B-CHEBI
needles	O
.	O

Collagen	B-GGP
matrix	O
was	O
prepared	O
with	O
430	O
mu	O
l	O
of	O
collagen	B-GGP
(	O
3	O
mg	O
/	O
ml	O
dissolved	O
in	O
0	O
.	O
1M	O
acetic	B-CHEBI
acid	I-CHEBI
,	O
Sigma	O
)	O
,	O
50	O
mu	O
l	O
of	O
10X	O
DMEM	O
medium	O
,	O
and	O
2	O
.	O
5	O
mu	O
l	O
of	O
0	O
.	O
8	O
M	O
NaCa2	O
,	O
and	O
the	O
pH	O
was	O
adjusted	O
to	O
7	O
.	O
5	O
.	O

Individual	O
ganglion	O
explants	O
were	O
placed	O
in	O
24	O
-	O
well	O
plates	O
and	O
covered	O
with	O
freshly	O
prepared	O
collagen	B-GGP
.	O

Sepharose	O
beads	O
with	O
an	O
average	O
diameter	O
of	O
150	O
mu	O
m	O
were	O
used	O
.	O

Beads	O
were	O
washed	O
twice	O
with	O
PBS	O
,	O
air	O
dried	O
,	O
and	O
loaded	O
with	O
10	O
,	O
20	O
,	O
50	O
,	O
or	O
100	O
ng	O
/	O
mu	O
l	O
NT	B-GGP
-	I-GGP
3	I-GGP
(	O
Collaborative	O
Research	O
,	O
Chemicon	O
)	O
at	O
4	O
degrees	O
C	O
overnight	O
with	O
constant	O
shaking	O
.	O

For	O
negative	O
control	O
,	O
beads	O
were	O
loaded	O
with	O
BSA	B-GGP
(	O
10	O
-	O
100	O
ng	O
/	O
mu	O
l	O
)	O
or	O
PBS	O
.	O

Either	O
a	O
single	O
neurotrophin	B-GGP
-	O
loaded	O
bead	O
or	O
a	O
single	O
BSA	B-GGP
(	O
or	O
PBS	O
)	O
-	O
loaded	O
bead	O
was	O
implanted	O
about	O
200	O
-	O
1	O
,	O
200	O
mu	O
m	O
away	O
from	O
the	O
ganglion	O
explant	O
.	O

Collagen	B-GGP
-	O
embedded	O
cultures	O
were	O
then	O
placed	O
at	O
33	O
degrees	O
C	O
for	O
15	O
min	O
for	O
the	O
matrix	O
to	O
harden	O
.	O

Serum	O
-	O
free	O
culture	O
medium	O
was	O
then	O
added	O
to	O
each	O
well	O
.	O

In	O
cultures	O
with	O
WT	B-SO
DRG	O
and	O
control	O
beads	O
,	O
10	O
%	O
serum	O
was	O
added	O
to	O
ensure	O
viability	O
of	O
the	O
explants	O
.	O

TrkC	B-GGP
-	O
Fc	O
(	O
Regeneron	O
Pharmaceuticals	B-CHEBI
,	O
Tarrytown	O
,	O
New	O
York	O
,	O
United	O
States	O
)	O
was	O
added	O
(	O
20	O
mu	O
g	O
/	O
ml	O
)	O
into	O
the	O
culture	O
medium	O
.	O

Explant	O
co	O
-	O
cultures	O

Spinal	O
cords	O
with	O
attached	O
DRGs	O
were	O
dissected	O
out	O
from	O
Swiss	O
Webster	O
mouse	B-Taxon
embryos	O
at	O
E13	O
,	O
and	O
sectioned	O
into	O
300	O
-	O
mu	O
m	O
-	O
thick	O
slices	O
.	O

Tissue	O
slices	O
were	O
placed	O
on	O
Millicell	O
Tissue	O
Culture	O
Inserts	O
(	O
Millipore	O
,	O
Billrica	O
,	O
Massachusetts	O
,	O
United	O
States	O
)	O
.	O

NT	B-GGP
-	I-GGP
3	I-GGP
-	O
loaded	O
(	O
n	O
=	O
15	O
)	O
or	O
PBS	O
-	O
loaded	O
(	O
n	O
=	O
6	O
)	O
sepharose	O
beads	O
were	O
prepared	O
as	O
described	O
above	O
,	O
and	O
placed	O
in	O
the	O
midline	O
at	O
mid	O
-	O
spinal	O
cord	O
level	O
.	O

Inserts	O
were	O
placed	O
in	O
six	O
-	O
well	O
plates	O
with	O
serum	O
-	O
free	O
medium	O
at	O
the	O
bottom	O
of	O
the	O
wells	O
,	O
and	O
kept	O
at	O
33	O
degrees	O
C	O
for	O
3	O
d	O
in	O
the	O
presence	O
of	O
5	O
%	O
CO2	B-CHEBI
.	O

Cultures	O
were	O
then	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
in	O
PBS	O
,	O
and	O
small	O
crystals	O
of	O
DiI	O
were	O
placed	O
into	O
the	O
DRGs	O
.	O

Samples	O
were	O
incubated	O
in	O
a	O
37	O
-	O
degrees	O
C	O
incubator	O
,	O
allowing	O
the	O
dye	B-CHEBI
to	O
diffuse	O
,	O
and	O
photographed	O
under	O
a	O
Nikon	O
(	O
Tokyo	O
,	O
Japan	O
)	O
inverted	O
epifluoresence	O
microscope	O
.	O

Supporting	O
Information	O

Figure	O
S1	O

Motor	B-CL
Neuron	I-CL
Innervation	O
Initiated	O
in	O
WT	B-SO
E17	O
Embryos	O
Cannot	O
Be	O
Detected	O
in	O
Bax	B-GGP
/	O
NT	B-GGP
-	I-GGP
3	I-GGP
Double	O
KOs	O

In	O
some	O
of	O
the	O
samples	O
,	O
motor	B-CL
neurons	I-CL
were	O
labeled	O
by	O
backfilling	O
through	O
the	O
ventral	O
root	O
in	O
addition	O
to	O
the	O
sensory	O
axons	B-GO
labeled	O
through	O
the	O
DRGs	O
.	O

(	O
A	O
)	O
WT	B-SO
embryo	O
showing	O
proprioceptive	O
axons	B-GO
contacting	O
motor	B-CL
neuron	I-CL
dendrites	B-GO
in	O
the	O
ventral	O
horn	O
,	O
forming	O
synapses	B-GO
.	O

(	O
B	O
)	O
Bax	B-GGP
/	O
NT	B-GGP
-	I-GGP
3	I-GGP
double	O
null	O
spinal	O
cord	O
.	O

Although	O
labeled	O
fibers	O
enter	O
the	O
ventral	O
spinal	O
cord	O
,	O
they	O
extend	O
towards	O
the	O
midline	O
instead	O
of	O
the	O
ventral	O
horn	O
and	O
never	O
contact	O
the	O
motor	B-CL
neuron	I-CL
dendrites	B-GO
.	O

(	O
C	O
)	O
High	O
-	O
power	O
image	O
of	O
the	O
inset	O
in	O
(	O
A	O
)	O
.	O

Arrows	O
point	O
to	O
the	O
proprioceptive	O
fibers	O
contacting	O
motor	B-CL
neurons	I-CL
(	O
asterisk	O
)	O
.	O

(	O
D	O
)	O
High	O
-	O
power	O
image	O
of	O
the	O
inset	O
in	O
(	O
B	O
)	O
.	O

Notice	O
that	O
there	O
are	O
no	O
sensory	O
axons	B-GO
contacting	O
labeled	O
motor	B-CL
neurons	I-CL
(	O
asterisk	O
)	O
.	O

Scale	O
bar	O
:	O
100	O
mu	O
m	O
(	O
A	O
and	O
B	O
)	O
,	O
50	O
mu	O
m	O
(	O
C	O
and	O
D	O
)	O
.	O

(	O
24	O
MB	O
TIF	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Figure	O
S2	O

S46	O
/	O
NF	B-GGP
-	I-GGP
M	I-GGP
Immunohistochemistry	O
at	O
E15	O
Gastrocnemius	O
Muscle	O

Although	O
numerous	O
muscle	O
and	O
nerve	O
fibers	O
were	O
labeled	O
,	O
no	O
muscle	O
spindles	O
could	O
be	O
identified	O
because	O
the	O
characteristic	O
morphology	O
of	O
sensory	O
nerve	O
ending	O
wrapped	O
around	O
muscle	O
bag	O
fiber	O
had	O
not	O
begun	O
to	O
develop	O
in	O
any	O
of	O
the	O
genotypes	B-SO
yet	O
.	O

Scale	O
bar	O
:	O
25	O
mu	O
m	O
.	O

(	O
13	O
MB	O
TIF	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Acknowledgements	O

We	O
thank	O
L	O
.	O

Tessarollo	O
for	O
providing	O
NT	B-GGP
-	I-GGP
3	I-GGP
KO	O
animals	B-Taxon
,	O
L	O
.	O

Reichardt	O
for	O
TrkA	B-GGP
and	O
TrkC	B-GGP
antibodies	B-GO
,	O
F	O
.	O

Stockdale	O
for	O
the	O
S46	O
antibody	B-GO
,	O
K	O
.	O

Muneoka	O
for	O
sepharose	O
beads	O
,	O
and	O
B	O
.	O

King	O
for	O
maintenance	O
of	O
animals	B-Taxon
used	O
in	O
this	O
study	O
.	O

We	O
particularly	O
thank	O
E	O
.	O

Frank	O
for	O
many	O
helpful	O
comments	O
and	O
discussions	O
about	O
this	O
study	O
and	O
for	O
sharing	O
unpublished	O
data	O
from	O
his	O
laboratory	O
.	O

Supported	O
by	O
National	O
Institutes	O
of	O
Health	O
/	O
National	O
Institute	O
of	O
Dental	O
and	O
Craniofacial	O
Research	O
grant	O
P01	O
DE07734	O
.	O

Abbreviations	O

BDNF	B-GGP
-	O
brain	B-GGP
-	I-GGP
derived	I-GGP
neurotrophic	I-GGP
factor	I-GGP

BSA	B-GGP
-	O
bovine	B-GGP
serum	I-GGP
albumin	I-GGP

DRG	O
-	O
dorsal	O
root	O
ganglion	O

E	O
-	O
embryonic	O
day	O

KO	O
-	O
knockout	O

NF	B-GGP
-	I-GGP
M	I-GGP
-	O
neurofilament	B-GGP
-	I-GGP
M	I-GGP

NT	B-GGP
-	I-GGP
3	I-GGP
-	O
neurotrophin	B-GGP
-	I-GGP
3	I-GGP

P	O
-	O
postnatal	O
day	O

PBS	O
-	O
phosphate	B-CHEBI
buffer	O
saline	O

PV	B-GGP
-	O
parvalbumin	B-GGP

TrkC	B-GGP
-	O
Fc	O
-	O
diffusible	O
TrkC	B-GGP
receptors	I-GGP
conjugated	O
to	O
IgG	O
constant	O
regions	B-SO

WT	B-SO
-	O
wild	B-SO
-	I-SO
type	I-SO

Figures	O
and	O
Tables	O

Figure	O
1	O

TrkA	B-GGP
/	O
TrkC	B-GGP
and	O
PV	B-GGP
Immunohistochemistry	O
in	O
DRG	O
and	O
Spinal	O
Cord	O

Red	O
represents	O
TrkA	B-GGP
,	O
green	O
represents	O
TrkC	B-GGP
(	O
and	O
PV	B-GGP
in	O
[	O
C	O
]	O
)	O
,	O
and	O
yellow	O
represents	O
co	O
-	O
expression	O
.	O

(	O
A	O
)	O
TrkA	B-GGP
/	O
TrkC	B-GGP
immunostaining	O
in	O
E15	O
DRG	O
.	O

TrkC	B-GGP
-	O
positive	O
neurons	B-CL
normally	O
eliminated	O
in	O
NT	B-GGP
-	I-GGP
3	I-GGP
KOs	O
are	O
rescued	O
in	O
double	O
KOs	O
.	O

(	O
B	O
)	O
TrkA	B-GGP
/	O
TrkC	B-GGP
immunostaining	O
at	O
P0	O
in	O
DRG	O
.	O

(	O
C	O
)	O
PV	B-GGP
immunostaining	O
in	O
P0	O
DRG	O
.	O

Rescued	O
TrkC	B-GGP
-	O
positive	O
cells	B-CL
fail	O
to	O
express	O
PV	B-GGP
.	O

(	O
D	O
)	O
Ratio	O
of	O
TrkA	B-GGP
-	O
immunopositive	O
cells	B-CL
to	O
TrkC	B-GGP
-	O
immunopositive	O
cells	B-CL
in	O
E15	O
and	O
P0	O
DRGs	O
.	O

Data	O
are	O
presented	O
as	O
percentage	O
of	O
cells	B-CL
with	O
standard	O
deviation	O
.	O

Double	O
KOs	O
always	O
had	O
similar	O
ratios	O
to	O
Bax	B-GGP
KOs	O
,	O
and	O
NT	B-GGP
-	I-GGP
3	I-GGP
KOs	O
had	O
the	O
least	O
amount	O
of	O
TrkC	B-GGP
-	O
positive	O
cells	B-CL
,	O
if	O
any	O
.	O

(	O
E	O
)	O
TrkA	B-GGP
/	O
TrkC	B-GGP
immunostaining	O
in	O
E15	O
spinal	O
cord	O
.	O

Arrow	O
points	O
to	O
group	O
Ia	O
fibers	O
.	O

Dorsal	O
is	O
up	O
.	O

Scale	O
bar	O
:	O
50	O
mu	O
m	O
(	O
A	O
-	O
C	O
)	O
,	O
1	O
mm	O
(	O
E	O
)	O
.	O

Figure	O
2	O

Axonal	B-GO
Projections	B-GO
in	O
the	O
Spinal	O
Cord	O
after	O
DiI	O
Labeling	O
of	O
DRG	O
at	O
P0	O

(	O
A	O
)	O
Rescued	O
DRG	O
proprioceptive	O
neurons	B-CL
fail	O
to	O
properly	O
innervate	O
motor	B-CL
neurons	I-CL
in	O
double	O
KOs	O
.	O

Instead	O
,	O
some	O
axons	B-GO
are	O
directed	O
towards	O
the	O
ventral	O
midline	O
;	O
they	O
cross	O
the	O
midline	O
and	O
branch	O
.	O

(	O
B	O
)	O
Schematic	O
drawing	O
of	O
the	O
monosynaptic	O
reflex	O
arc	O
as	O
it	O
normally	O
develops	O
.	O

Small	O
black	O
dots	O
represent	O
NT	B-GGP
-	I-GGP
3	I-GGP
released	O
centrally	O
by	O
the	O
motor	B-CL
neurons	I-CL
and	O
peripherally	O
by	O
the	O
muscle	O
spindles	O
.	O

(	O
C	O
)	O
High	O
-	O
power	O
magnification	O
of	O
the	O
inset	O
in	O
(	O
A	O
)	O
.	O

Arrow	O
points	O
to	O
the	O
midline	O
,	O
and	O
arrowheads	O
point	O
to	O
synaptic	B-GO
bouton	I-GO
-	O
like	O
structures	O
.	O

Scale	O
bar	O
:	O
1	O
mm	O
(	O
A	O
)	O
,	O
400	O
mu	O
m	O
(	O
C	O
)	O
.	O

Figure	O
3	O

Sensory	O
Axons	B-GO
Labeled	O
with	O
DiI	O
through	O
the	O
DRG	O
at	O
E17	O

(	O
A	O
)	O
DiI	O
-	O
labeled	O
fibers	O
in	O
WT	B-SO
spinal	O
cord	O
.	O

Notice	O
proprioceptive	O
axons	B-GO
extending	O
towards	O
the	O
motor	B-CL
neurons	I-CL
located	O
in	O
the	O
ventral	O
horn	O
of	O
the	O
spinal	O
cord	O
in	O
cross	O
section	O
.	O

(	O
B	O
)	O
Bax	B-GGP
null	O
spinal	O
cord	O
.	O

(	O
C	O
)	O
NT	B-GGP
-	I-GGP
3	I-GGP
null	O
spinal	O
cord	O
.	O

Stained	O
fibers	O
are	O
restricted	O
to	O
the	O
nociceptive	O
axons	B-GO
in	O
the	O
dorsal	O
horn	O
,	O
as	O
evidenced	O
by	O
the	O
complete	O
absence	O
of	O
labeling	O
in	O
the	O
ventral	O
spinal	O
cord	O
.	O

(	O
D	O
)	O
Bax	B-GGP
/	O
NT	B-GGP
-	I-GGP
3	I-GGP
double	O
null	O
spinal	O
cord	O
.	O

Although	O
fibers	O
extend	O
into	O
the	O
ventral	O
spinal	O
cord	O
,	O
they	O
never	O
grow	O
towards	O
the	O
motor	B-CL
neurons	I-CL
,	O
but	O
are	O
directed	O
towards	O
the	O
midline	O
instead	O
.	O

Scale	O
bar	O
:	O
100	O
mu	O
m	O
.	O

Figure	O
4	O

Muscle	O
Spindles	O
in	O
Gastrocnemius	O
Muscle	O
and	O
TrkA	B-GGP
/	O
TrkC	B-GGP
Staining	O
in	O
the	O
Tibial	O
Nerve	O
at	O
P0	O

(	O
A	O
)	O
NF	B-GGP
-	I-GGP
M	I-GGP
(	O
red	O
)	O
and	O
S46	O
(	O
green	O
)	O
immunostaining	O
in	O
cross	O
section	O
of	O
gastrocnemius	O
muscle	O
at	O
P0	O
.	O

There	O
are	O
no	O
muscle	O
spindles	O
detected	O
in	O
double	O
KOs	O
.	O

(	O
B	O
)	O
NF	B-GGP
-	I-GGP
M	I-GGP
(	O
red	O
)	O
and	O
S46	O
(	O
green	O
)	O
immunostaining	O
in	O
parallel	O
sections	O
of	O
gastrocnemius	O
muscle	O
at	O
P0	O
.	O

(	O
C	O
)	O
NF	B-GGP
-	I-GGP
M	I-GGP
(	O
red	O
)	O
and	O
S46	O
(	O
green	O
)	O
immunostaining	O
in	O
parallel	O
sections	O
of	O
gastrocnemius	O
muscle	O
at	O
E17	O
.	O

Double	O
null	O
muscles	O
are	O
mostly	O
devoid	O
of	O
muscle	O
spindles	O
,	O
except	O
for	O
one	O
spindle	O
-	O
like	O
structure	O
detected	O
(	O
shown	O
in	O
inset	O
,	O
denoted	O
by	O
the	O
asterisk	O
)	O
.	O

(	O
D	O
)	O
Muscle	O
spindles	O
detected	O
by	O
DiI	O
labeling	O
through	O
the	O
DRG	O
.	O

Gastrocnemius	O
muscle	O
is	O
sectioned	O
at	O
40	O
mu	O
m	O
thickness	O
in	O
parallel	O
plane	O
to	O
the	O
muscle	O
fibers	O
.	O

(	O
E	O
)	O
Muscle	O
spindles	O
detected	O
by	O
TrkC	B-GGP
staining	O
in	O
cross	O
section	O
of	O
gastrocnemius	O
muscle	O
at	O
P0	O
.	O

(	O
F	O
)	O
TrkA	B-GGP
(	O
red	O
)	O
and	O
TrkC	B-GGP
(	O
green	O
)	O
immunostaining	O
in	O
the	O
tibial	O
nerve	O
cross	O
section	O
at	O
P0	O
.	O

TrkC	B-GGP
-	O
positive	O
fibers	O
are	O
missing	O
in	O
NT	B-GGP
-	I-GGP
3	I-GGP
KOs	O
.	O

Red	O
-	O
green	O
overlap	O
(	O
yellow	O
)	O
is	O
due	O
to	O
the	O
thickness	O
of	O
the	O
section	O
and	O
overlapping	O
of	O
red	O
-	O
and	O
green	O
-	O
labeled	O
(	O
TrkA	B-GGP
and	O
TrkC	B-GGP
)	O
fibers	O
present	O
at	O
different	O
focal	O
depths	O
,	O
rather	O
than	O
co	O
-	O
localization	O
.	O

Arrows	O
indicate	O
muscle	O
spindles	O
.	O

Scale	O
bar	O
:	O
50	O
mu	O
m	O
(	O
A	O
,	O
B	O
,	O
D	O
)	O
,	O
25	O
mu	O
m	O
(	O
C	O
,	O
E	O
)	O
,	O
75	O
mu	O
m	O
(	O
F	O
)	O
.	O

Figure	O
5	O

Chemoattraction	O
of	O
E13	O
DRG	O
Axons	B-GO
to	O
Local	O
NT	B-GGP
-	I-GGP
3	I-GGP
Observed	O
by	O
In	O
Vitro	O
Co	O
-	O
Culture	O
Assays	O

(	O
A	O
)	O
WT	B-SO
DRG	O
with	O
NT	B-GGP
-	I-GGP
3	I-GGP
-	O
loaded	O
bead	O
.	O

(	O
B	O
)	O
WT	B-SO
DRG	O
with	O
BSA	O
-	O
loaded	O
bead	O
.	O

(	O
C	O
)	O
Bax	B-GGP
null	O
DRG	O
with	O
NT	B-GGP
-	I-GGP
3	I-GGP
-	O
loaded	O
bead	O
.	O

(	O
D	O
)	O
p75	B-GGP
null	O
DRG	O
with	O
NT	B-GGP
-	I-GGP
3	I-GGP
-	O
loaded	O
bead	O
.	O

(	O
E	O
)	O
WT	B-SO
DRG	O
with	O
NT	B-GGP
-	I-GGP
3	I-GGP
-	O
loaded	O
bead	O
and	O
TrkC	B-GGP
-	O
Fc	O
in	O
the	O
medium	O
.	O

(	O
F	O
)	O
WT	B-SO
DRG	O
with	O
NT	B-GGP
-	I-GGP
3	I-GGP
loaded	O
beads	O
placed	O
at	O
increasing	O
distances	O
away	O
from	O
the	O
ganglia	O
(	O
range	O
,	O
500	O
-	O
1	O
,	O
200	O
mu	O
m	O
)	O
.	O

Scale	O
bar	O
:	O
150	O
mu	O
m	O
(	O
A	O
-	O
E	O
)	O
,	O
350	O
mu	O
m	O
(	O
F	O
)	O
.	O

Figure	O
6	O

Chemoattraction	O
Towards	O
NT	B-GGP
-	I-GGP
3	I-GGP
Beads	O
Placed	O
in	O
E13	O
Spinal	O
Cord	O
DRG	O
Explant	O
Co	O
-	O
Cultures	O

(	O
A	O
)	O
NT	B-GGP
-	I-GGP
3	I-GGP
bead	O
placed	O
in	O
the	O
midline	O
of	O
E13	O
WT	B-SO
spinal	O
cord	O
.	O

Notice	O
axons	B-GO
labeled	O
through	O
the	O
DRGs	O
(	O
circled	O
with	O
black	O
dashed	O
lines	O
)	O
growing	O
towards	O
the	O
bead	O
(	O
circled	O
with	O
white	O
dashed	O
lines	O
)	O
enter	O
the	O
spinal	O
cord	O
at	O
ectopic	O
loci	O
instead	O
of	O
dorsal	O
spinal	O
cord	O
.	O

(	O
B	O
)	O
PBS	O
-	O
loaded	O
bead	O
in	O
E13	O
spinal	O
cord	O
.	O

All	O
labeled	O
axons	B-GO
extend	O
along	O
the	O
dorsal	O
spinal	O
cord	O
,	O
where	O
they	O
terminate	O
.	O

(	O
C	O
)	O
High	O
-	O
power	O
image	O
of	O
the	O
bead	O
in	O
(	O
A	O
)	O
.	O

Notice	O
labeled	O
axons	B-GO
surrounding	O
the	O
bead	O
.	O

(	O
D	O
)	O
High	O
-	O
power	O
image	O
of	O
an	O
NT	B-GGP
-	I-GGP
3	I-GGP
-	O
loaded	O
bead	O
.	O

Notice	O
axons	B-GO
bundled	O
around	O
the	O
bead	O
.	O

(	O
E	O
)	O
High	O
-	O
power	O
image	O
of	O
an	O
NT	B-GGP
-	I-GGP
3	I-GGP
-	O
loaded	O
bead	O
.	O

Notice	O
the	O
axons	B-GO
approaching	O
the	O
bead	O
via	O
the	O
dorsal	O
spinal	O
cord	O
.	O

(	O
F	O
)	O
High	O
-	O
power	O
image	O
of	O
a	O
PBS	O
-	O
loaded	O
bead	O
.	O

No	O
labeled	O
fibers	O
were	O
observed	O
around	O
control	O
beads	O
.	O

(	O
G	O
)	O
Summary	O
of	O
our	O
observations	O
from	O
E13	O
spinal	O
cord	O
DRG	O
organotypic	O
cultures	O
.	O

In	O
control	O
cultures	O
fibers	O
extend	O
along	O
the	O
dorsal	O
spinal	O
cord	O
,	O
where	O
they	O
normally	O
enter	O
the	O
gray	O
matter	O
at	O
E13	O
.	O

In	O
the	O
presence	O
of	O
an	O
ectopic	O
NT	B-GGP
-	I-GGP
3	I-GGP
source	O
localized	O
at	O
the	O
midline	O
,	O
these	O
axons	B-GO
grow	O
towards	O
the	O
NT	B-GGP
-	I-GGP
3	I-GGP
bead	O
.	O

NT	B-GGP
-	I-GGP
3	I-GGP
also	O
initiates	O
axon	O
growth	O
from	O
the	O
DRGs	O
,	O
entering	O
the	O
spinal	O
cord	O
at	O
ectopic	O
lateral	O
loci	O
,	O
growing	O
towards	O
the	O
bead	O
,	O
surrounding	O
the	O
bead	O
,	O
forming	O
nerve	O
bundles	O
,	O
and	O
branching	O
around	O
it	O
.	O

Scale	O
bar	O
,	O
175	O
mu	O
m	O
(	O
A	O
and	O
B	O
)	O
,	O
100	O
mu	O
m	O
(	O
C	O
-	O
F	O
)	O
.	O

Footnotes	O

Conflicts	O
of	O
interest	O
.	O

The	O
authors	O
have	O
declared	O
that	O
no	O
conflicts	O
of	O
interest	O
exist	O
.	O

Author	O
contributions	O
.	O

BG	O
and	O
RE	O
conceived	O
and	O
designed	O
the	O
experiments	O
.	O

BG	O
,	O
AEM	O
,	O
and	O
PHO	O
performed	O
the	O
experiments	O
.	O

BG	O
,	O
PHO	O
,	O
and	O
RE	O
analyzed	O
the	O
data	O
.	O

BG	O
and	O
RE	O
wrote	O
the	O
paper	O
.	O

Academic	O
Editor	O
:	O
Joshua	O
R	O
.	O
Sanes	O
,	O
Harvard	O
University	O

currency	O
Current	O
address	O
:	O
Massachusetts	O
General	O
Hospital	O
,	O
Harvard	O
Medical	O
School	O
Center	O
for	O
Nervous	O
System	O
Repair	O
,	O
Boston	O
,	O
Massachusetts	O
,	O
United	O
States	O
of	O
America	O

Citation	O
:	O
Gen	O
c	O
B	O
,	O
O	O
zdinler	O
PH	O
,	O
Mendoza	O
AE	O
,	O
Erzurumlu	O
RS	O
(	O
2004	O
)	O
A	O
chemoattractant	O
role	O
for	O
NT	B-GGP
-	I-GGP
3	I-GGP
in	O
proprioceptive	O
axon	B-GO
guidance	O
.	O

PLoS	O
Biol	O
2	O
(	O
12	O
)	O
:	O
e403	O
.	O

DNA	B-SO
binding	O
and	O
helicase	O
actions	O
of	O
mouse	B-GGP
MCM4	I-GGP
/	O
6	O
/	O
7	O
helicase	O

Abstract	O

Helicases	O
play	O
central	O
roles	O
in	O
initiation	O
and	O
elongation	O
of	O
DNA	B-SO
replication	O
.	O

We	O
previously	O
reported	O
that	O
helicase	O
and	O
ATPase	O
activities	O
of	O
the	O
mammalian	B-Taxon
Mcm4	B-GGP
/	O
6	O
/	O
7	O
complex	B-GO
are	O
activated	O
specifically	O
by	O
thymine	B-CHEBI
-	O
rich	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
.	O

Here	O
,	O
we	O
examined	O
its	O
substrate	O
preference	O
and	O
helicase	O
actions	O
using	O
various	O
synthetic	B-SO
DNAs	B-SO
.	O

On	O
a	O
bubble	O
substrate	O
,	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
makes	O
symmetric	O
dual	O
contacts	O
with	O
the	O
5	O
'	O
-	O
proximal	O
25	O
nt	B-CHEBI
single	B-SO
-	I-SO
stranded	I-SO
segments	B-SO
adjacent	O
to	O
the	O
branch	O
points	O
,	O
presumably	O
generating	O
double	O
hexamers	O
.	O

Loss	O
of	O
thymine	B-CHEBI
residues	B-CHEBI
from	O
one	O
single	O
-	O
strand	B-SO
results	O
in	O
significant	O
decrease	O
of	O
unwinding	O
efficacy	O
,	O
suggesting	O
that	O
concurrent	O
bidirectional	O
unwinding	O
by	O
a	O
single	O
double	O
hexameric	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
may	O
play	O
a	O
role	O
in	O
efficient	O
unwinding	O
of	O
the	O
bubble	O
.	O

Mcm4	B-GGP
/	O
6	O
/	O
7	O
binds	O
and	O
unwinds	O
various	O
fork	B-GO
and	O
extension	O
structures	O
carrying	O
a	O
single	B-SO
-	I-SO
stranded	I-SO
3	O
'	O
-	O
tail	O
DNA	B-SO
.	O

The	O
extent	O
of	O
helicase	O
activation	O
depends	O
on	O
the	O
sequence	B-SO
context	O
of	O
the	O
3	O
'	O
-	O
tail	O
,	O
and	O
the	O
maximum	O
level	O
is	O
achieved	O
by	O
DNA	B-SO
with	O
50	O
%	O
or	O
more	O
thymine	B-CHEBI
content	O
.	O

Strand	B-SO
displacement	O
by	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
is	O
inhibited	O
,	O
as	O
the	O
GC	O
content	O
of	O
the	O
duplex	B-SO
region	B-SO
increases	O
.	O

Replacement	B-SO
of	O
cytosine	B-CHEBI
-	O
guanine	B-CHEBI
pairs	O
with	O
cytosine	B-CHEBI
-	O
inosine	B-CHEBI
pairs	O
in	O
the	O
duplex	O
restored	O
unwinding	O
,	O
suggesting	O
that	O
mammalian	B-Taxon
Mcm4	B-GGP
/	O
6	O
/	O
7	O
helicase	O
has	O
difficulties	O
in	O
unwinding	O
stably	O
base	B-SO
-	I-SO
paired	I-SO
duplex	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
reveal	O
important	O
features	O
on	O
activation	O
and	O
substrate	O
preference	O
of	O
the	O
eukaryotic	B-Taxon
replicative	O
helicase	O
.	O

INTRODUCTION	O

DNA	B-SO
helicases	O
couple	O
the	O
hydrolysis	O
of	O
nucleotide	B-CHEBI
or	I-CHEBI
deoxynucleotide	I-CHEBI
triphosphate	I-CHEBI
to	O
duplex	O
unwinding	O
(	O
1	O
)	O
.	O

Coordination	O
of	O
a	O
set	O
of	O
subactivities	O
including	O
nucleotide	B-CHEBI
binding	O
,	O
DNA	B-SO
binding	O
and	O
ATP	B-CHEBI
hydrolysis	O
is	O
required	O
for	O
unwinding	O
of	O
duplex	B-SO
DNA	B-SO
(	O
1	O
,	O
2	O
)	O
.	O

The	O
hexameric	O
helicases	O
,	O
to	O
which	O
minichromosome	B-GO
maintenance	I-GO
(	I-GO
Mcm	I-GO
)	I-GO
helicase	I-GO
belongs	O
,	O
are	O
known	O
to	O
assemble	O
a	O
ring	O
-	O
like	O
structure	O
(	O
3	O
-	O
5	O
)	O
.	O

Whereas	O
most	O
of	O
DNA	B-SO
helicases	O
of	O
this	O
group	O
,	O
including	O
simian	B-GGP
virus	I-GGP
40	I-GGP
large	I-GGP
T	I-GGP
-	I-GGP
antigen	I-GGP
(	O
6	O
)	O
,	O
Escherichia	B-Taxon
coli	I-Taxon
DnaB	B-GGP
(	O
7	O
)	O
and	O
Archaeal	B-Taxon
Mcm	O
(	O
4	O
,	O
8	O
,	O
9	O
)	O
,	O
are	O
composed	O
of	O
a	O
single	O
subunit	O
,	O
the	O
active	O
eukaryotic	B-Taxon
Mcm	B-GO
helicases	I-GO
are	O
composed	O
of	O
two	O
trimeric	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
proteins	B-CHEBI
(	O
10	O
-	O
14	O
)	O
.	O

All	O
the	O
six	O
Mcm	B-GGP
2	I-GGP
-	I-GGP
7	I-GGP
proteins	B-CHEBI
contain	O
highly	O
conserved	B-SO
DNA	B-SO
-	O
dependent	O
ATPase	O
motifs	O
in	O
their	O
central	O
regions	B-SO
(	O
15	O
,	O
16	O
)	O
.	O

Among	O
the	O
several	O
stable	O
subcomplexes	O
which	O
MCM	B-GO
proteins	B-CHEBI
can	O
generate	O
,	O
only	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
complex	B-GO
has	O
been	O
shown	O
to	O
possess	O
an	O
intrinsic	O
DNA	B-SO
helicase	O
activity	O
(	O
10	O
-	O
14	O
,	O
17	O
-	O
18	O
)	O
.	O

While	O
Mcm4	B-GGP
,	O
Mcm6	B-GGP
and	O
Mcm7	B-GGP
proteins	B-CHEBI
make	O
distinct	O
contribution	O
to	O
its	O
helicase	O
activity	O
(	O
11	O
-	O
13	O
)	O
,	O
Mcm2	B-GGP
or	O
Mcm3	B-GGP
/	O
5	O
inhibit	O
the	O
helicase	O
activity	O
of	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
complex	B-GO
by	O
converting	O
its	O
double	O
trimer	O
structure	O
into	O
a	O
heterotetramer	O
or	O
heteropentamer	O
,	O
respectively	O
(	O
3	O
,	O
11	O
)	O
.	O

Chromatin	B-GO
immunoprecipitation	O
assays	O
and	O
genetic	B-SO
characterization	O
in	O
Saccharomyces	B-Taxon
cerevisiae	I-Taxon
strongly	O
suggested	O
that	O
Mcm	B-GO
is	O
involved	O
not	O
only	O
in	O
initiation	O
but	O
also	O
in	O
the	O
DNA	B-SO
chain	I-SO
elongation	O
stage	O
as	O
a	O
replicative	O
helicase	O
(	O
19	O
,	O
20	O
)	O
.	O

Consistent	O
with	O
this	O
notion	O
,	O
the	O
processivity	O
of	O
the	O
Schizosaccharomyces	B-GGP
pombe	I-GGP
and	I-GGP
mouse	I-GGP
Mcm4	I-GGP
/	O
6	O
/	O
7	O
complexes	B-GO
is	O
significantly	O
stimulated	O
on	O
forked	B-GO
DNA	B-SO
structures	O
and	O
it	O
can	O
unwind	O
duplex	B-SO
DNA	B-SO
of	O
400	O
-	O
500	O
bp	B-SO
(	O
13	O
,	O
14	O
)	O
.	O

Mcm4	B-GGP
/	O
6	O
/	O
7	O
binds	O
to	O
fork	B-GO
and	I-GO
bubble	I-GO
structures	I-GO
in	O
an	O
ATP	B-CHEBI
-	O
dependent	O
manner	O
,	O
and	O
generates	O
a	O
double	O
-	O
hexameric	O
complex	B-GO
,	O
as	O
was	O
shown	O
for	O
T	B-GGP
-	I-GGP
antigen	I-GGP
(	O
13	O
,	O
14	O
,	O
21	O
)	O
.	O

Recently	O
,	O
we	O
reported	O
that	O
the	O
helicase	O
and	O
ATP	B-CHEBI
hydrolysis	O
activities	O
of	O
mammalian	B-Taxon
Mcm4	B-GGP
/	O
6	O
/	O
7	O
are	O
specifically	O
activated	O
by	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
containing	O
stretches	O
of	O
thymine	B-CHEBI
residues	B-CHEBI
and	O
proposed	O
a	O
novel	O
model	O
that	O
Mcm	B-GO
may	O
play	O
a	O
crucial	O
role	O
in	O
selection	O
of	O
replication	B-SO
origins	I-SO
in	O
higher	O
eukaryotes	B-Taxon
(	O
13	O
)	O
.	O

In	O
this	O
report	O
,	O
in	O
order	O
to	O
clarify	O
the	O
mode	O
of	O
action	O
of	O
the	O
Mcm	B-GO
helicase	I-GO
and	O
obtain	O
insight	O
into	O
how	O
it	O
may	O
function	O
at	O
the	O
replication	B-GO
forks	I-GO
in	O
vivo	O
,	O
we	O
have	O
conducted	O
detailed	O
analyses	O
of	O
helicase	O
action	O
and	O
DNA	B-SO
binding	O
of	O
mouse	B-GGP
Mcm4	I-GGP
/	O
6	O
/	O
7	O
helicase	O
using	O
various	O
forked	B-GO
and	O
bubble	O
substrate	O
DNAs	B-SO
.	O

We	O
specifically	O
addressed	O
sequence	B-SO
requirement	O
for	O
the	O
Mcm	B-GO
helicase	I-GO
activation	O
,	O
mode	O
of	O
interaction	O
with	O
DNA	B-SO
substrates	O
and	O
whether	O
the	O
thymine	O
sequences	B-SO
are	O
required	O
for	O
continuous	O
activation	O
of	O
Mcm	B-GO
helicase	I-GO
during	O
the	O
unwinding	O
process	O
.	O

The	O
results	O
indicate	O
that	O
mammalian	B-Taxon
Mcm4	B-GGP
/	O
6	O
/	O
7	O
primarily	O
binds	O
to	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
region	I-SO
,	O
and	O
that	O
the	O
extent	O
of	O
helicase	O
activation	O
is	O
related	O
to	O
the	O
thymine	O
content	O
of	O
the	O
single	B-SO
-	I-SO
stranded	I-SO
segment	B-SO
.	O

Unexpectedly	O
,	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
helicase	O
is	O
not	O
capable	O
of	O
efficiently	O
unwinding	O
the	O
GC	O
-	O
rich	O
duplex	B-SO
segment	B-SO
,	O
suggesting	O
that	O
some	O
other	O
mechanism	O
may	O
be	O
required	O
for	O
completion	O
of	O
replication	O
of	O
the	O
entire	O
genome	B-SO
.	O

MATERIALS	O
AND	O
METHODS	O

Reagents	B-CHEBI

Labeled	O
and	O
unlabeled	O
dNTPs	B-CHEBI
/	O
rNTPs	B-CHEBI
and	O
Sequenase	O
were	O
purchased	O
from	O
Amersham	O
Pharmacia	O
.	O

M13mp18	O
and	O
M13mp19	O
single	B-SO
-	I-SO
stranded	I-SO
circular	B-SO
DNA	B-SO
,	O
T4	B-GGP
polynucleotide	I-GGP
kinase	I-GGP
,	O
DNase	B-GGP
I	I-GGP
and	O
the	O
Klenow	O
fragment	B-SO
were	O
from	O
TAKARA	O
,	O
Nuclease	O
P1	O
was	O
from	O
Roche	O
,	O
and	O
anti	O
-	O
FLAG	O
M2	O
Ab	B-GO
(	O
antibody	B-GO
)	O
-	O
agarose	B-CHEBI
and	O
FLAG	O
peptide	B-SO
were	O
from	O
Sigma	O
.	O

SV40	B-GGP
T	I-GGP
-	I-GGP
antigen	I-GGP
was	O
purified	O
from	O
baculovirus	B-Taxon
-	O
infected	O
insect	B-Taxon
cells	B-CL
as	O
reported	O
(	O
22	O
)	O
.	O

PriA	B-GGP
helicase	I-GGP
protein	B-CHEBI
was	O
provided	O
by	O
Dr	O
Taku	O
Tanaka	O
(	O
23	O
)	O
.	O

Oligonucleotides	B-SO
were	O
purchased	O
from	O
Hokkaido	O
system	O
science	O
Co	O
.	O
,	O
Ltd	O
(	O
Hokkaido	O
,	O
Japan	O
)	O
,	O
and	O
were	O
purified	O
on	O
polyacrylamide	O
gel	O
,	O
followed	O
by	O
purification	O
by	O
Sep	O
-	O
Pak	O
Plus	O
C18	O
cartridge	O
column	O
(	O
Waters	O
)	O
.	O

Expression	O
and	O
purification	O
of	O
mouse	B-GGP
Mcm4	I-GGP
/	O
6	O
/	O
7	O
complex	B-GO

The	O
recombinant	O
baculoviruses	B-Taxon
expressing	O
His6	O
-	O
Mcm4	B-GGP
/	O
Mcm6	B-GGP
or	O
Mcm7	B-GGP
-	O
FLAG	O
proteins	B-CHEBI
were	O
previously	O
described	O
(	O
11	O
)	O
.	O

Sf9	O
and	O
High	O
five	O
insect	B-Taxon
cells	B-CL
were	O
cultured	O
at	O
27	O
degrees	O
C	O
in	O
Sf	O
-	O
900	O
II	O
SFM	O
(	O
Life	O
Technologies	O
,	O
Inc	O
.	O
)	O
and	O
EX	O
-	O
CELL	B-CL
405	O
medium	O
(	O
JRH	O
Biosciences	O
)	O
,	O
respectively	O
.	O

For	O
expression	O
of	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
proteins	B-CHEBI
,	O
High	O
five	O
cells	B-CL
were	O
coinfected	O
with	O
recombinant	O
baculoviruses	B-Taxon
expressing	O
the	O
His6	O
-	O
Mcm4	B-GGP
/	O
Mcm6	B-GGP
proteins	B-CHEBI
and	O
those	O
expressing	O
the	O
Mcm7	B-GGP
-	O
FLAG	O
,	O
and	O
were	O
collected	O
at	O
48	O
h	O
post	O
-	O
infection	O
.	O

The	O
recombinant	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
complexes	B-GO
were	O
purified	O
as	O
previously	O
described	O
(	O
12	O
)	O
.	O

DNA	B-SO
substrates	O

The	O
sequences	B-SO
for	O
all	O
the	O
oligonucleotides	B-SO
used	O
for	O
constructions	O
of	O
DNA	B-SO
substrates	O
are	O
listed	O
in	O
Tables	O
1	O
and	O
2	O
.	O

The	O
partial	O
heteroduplex	O
substrates	O
were	O
constructed	O
by	O
annealing	O
labeled	O
oligonucleotides	B-SO
with	O
M13mp18	O
single	B-SO
-	I-SO
stranded	I-SO
circular	B-SO
DNA	B-SO
or	O
its	O
derivative	O
.	O

The	O
labeled	O
substrates	O
were	O
purified	O
by	O
Sepharose	O
CL4B	O
column	O
chromatography	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
)	O
.	O

The	O
DNA	B-SO
bubble	O
substrates	O
were	O
assembled	O
from	O
two	O
partially	O
complementary	O
oligonucleotides	B-SO
with	O
top	O
and	O
bottom	O
strand	B-SO
sequences	I-SO
(	O
Table	O
1	O
)	O
.	O

T	O
-	O
tailed	O
Y	O
-	O
fork	B-GO
substrates	O
were	O
prepared	O
by	O
annealing	O
two	O
oligonucleotides	B-SO
(	O
dT30	O
and	O
dT60	O
series	O
)	O
.	O

To	O
construct	O
the	O
arrested	O
fork	B-GO
and	O
3	O
'	O
-	O
or	O
5	O
'	O
-	O
extension	O
substrates	O
,	O
various	O
combinations	O
of	O
oligonucleotides	B-SO
shown	O
in	O
Table	O
1	O
were	O
annealed	O
.	O

Bub	O
-	O
82	O
/	O
lamin	B-GGP
B2	I-GGP
containing	O
the	O
T	B-CHEBI
-	O
rich	O
strand	B-SO
of	O
the	O
lamin	B-GGP
B2	I-GGP
origin	B-SO
region	B-SO
was	O
constructed	O
as	O
previously	O
described	O
(	O
13	O
)	O
.	O

The	O
bubble	O
substrate	O
,	O
c	B-GGP
-	I-GGP
myc	I-GGP
/	O
DUE	O
or	O
c	B-GGP
-	I-GGP
myc	I-GGP
/	O
DUE	O
-	O
C	O
,	O
contains	O
sequences	B-SO
(	O
GenBank	O
accession	O
number	O
K01908	O
)	O
from	O
nucleotides	B-SO
722	O
to	O
853	O
or	O
those	O
from	O
828	O
to	O
747	O
(	O
complementary	O
strand	B-SO
)	O
,	O
respectively	O
,	O
in	O
the	O
central	O
melted	O
region	B-SO
.	O

For	O
each	O
substrate	O
,	O
labeled	O
oligonucleotide	B-SO
(	O
3	O
pmol	O
)	O
was	O
annealed	O
with	O
the	O
unlabeled	O
oligonucleotide	B-SO
(	O
6	O
pmol	O
)	O
in	O
a	O
reaction	O
mixture	O
(	O
50	O
mu	O
l	O
)	O
containing	O
20	O
mM	O
Tris	B-CHEBI
-	O
HCl	B-CHEBI
(	O
pH	O
7	O
.	O
5	O
)	O
,	O
10	O
mM	O
MgCl2	B-CHEBI
and	O
25	O
mM	O
NaCl	B-CHEBI
,	O
which	O
were	O
heated	O
to	O
95	O
degrees	O
C	O
,	O
kept	O
at	O
67	O
degrees	O
C	O
for	O
1	O
h	O
,	O
and	O
then	O
allowed	O
to	O
slowly	O
cool	O
down	O
to	O
37	O
degrees	O
C	O
.	O

The	O
assembled	O
substrates	O
were	O
purified	O
from	O
polyacrylamide	O
gel	O
by	O
elution	O
into	O
TE	O
buffer	O
(	O
24	O
)	O
.	O

The	O
partial	O
heteroduplex	O
substrates	O
on	O
a	O
single	B-SO
-	I-SO
stranded	I-SO
circular	B-SO
DNA	B-SO
with	O
varied	O
lengths	O
of	O
duplex	B-SO
regions	B-SO
were	O
prepared	O
by	O
extending	O
DNA	B-SO
chains	I-SO
from	O
the	O
3	O
'	O
end	O
of	O
the	O
dT40	O
-	O
37mer	O
(	O
37mer	O
region	B-SO
hybridizing	O
at	O
positions	B-SO
6289	O
-	O
6326	O
of	O
M13mp18	O
vector	B-SO
)	O
annealed	O
to	O
the	O
single	B-SO
-	I-SO
stranded	I-SO
circular	B-SO
DNA	B-SO
.	O

DNA	B-SO
chains	I-SO
were	O
elongated	O
with	O
Sequenase	O
in	O
the	O
presence	O
of	O
[	O
alpha	O
-	O
32P	B-CHEBI
]	O
dGTP	B-CHEBI
,	O
followed	O
by	O
extension	O
after	O
addition	O
of	O
ddGTP	O
and	O
all	O
four	O
dNTPs	B-CHEBI
,	O
resulting	O
in	O
substrates	O
containing	O
labeled	O
duplex	B-SO
regions	B-SO
of	O
varied	O
lengths	O
(	O
13	O
)	O
.	O

The	O
substrate	O
(	O
5	O
fmol	O
)	O
was	O
first	O
incubated	O
with	O
indicated	O
amount	O
of	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
complex	B-GO
at	O
37	O
degrees	O
C	O
for	O
1	O
h	O
in	O
reaction	O
mixture	O
as	O
described	O
(	O
11	O
)	O
,	O
and	O
then	O
reactions	O
were	O
stopped	O
by	O
addition	O
of	O
EDTA	B-CHEBI
(	O
20	O
mM	O
)	O
,	O
SDS	B-CHEBI
(	O
0	O
.	O
1	O
%	O
)	O
and	O
2	O
mu	O
g	O
proteinase	O
K	O
,	O
followed	O
by	O
incubation	O
for	O
20	O
min	O
.	O

Aliquots	O
were	O
electrophoresed	O
on	O
a	O
6	O
.	O
5	O
%	O
polyacrylamide	O
gel	O
in	O
1	O
x	O
TBE	O
at	O
300	O
V	O
for	O
2	O
.	O
5	O
h	O
.	O

The	O
single	B-SO
-	I-SO
stranded	I-SO
circular	B-SO
DNAs	B-SO
used	O
were	O
M13mp18	O
and	O
M13mp19	O
+	O
G	O
-	O
rich	O
.	O

The	O
latter	O
was	O
constructed	O
by	O
inserting	B-SO
a	O
G	B-CHEBI
-	O
rich	O
repeat	B-SO
sequence	I-SO
(	O
GGGGCGTGGGC	O
)	O
6	O
,	O
prepared	O
by	O
annealing	O
of	O
two	O
oligonucleotides	B-SO
(	O
5	O
'	O
-	O
GATCC	O
-	O
[	O
GGGGCGTGGGC	O
]	O
6	O
-	O
3	O
'	O
/	O
5	O
'	O
-	O
GATCC	O
-	O
[	O
GCCCACGCCCC	O
]	O
6	O
-	O
3	O
'	O
)	O
at	O
the	O
BamHI	O
site	B-SO
of	O
M13mp19	O
and	O
the	O
sequences	B-SO
of	O
the	O
insert	B-SO
were	O
confirmed	O
.	O

DNA	B-SO
helicase	O
and	O
gel	O
shift	O
assays	O

In	O
gel	O
shift	O
assays	O
,	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
proteins	B-CHEBI
were	O
incubated	O
at	O
30	O
degrees	O
C	O
for	O
30	O
min	O
in	O
reaction	O
mixtures	O
(	O
15	O
mu	O
l	O
)	O
containing	O
25	O
mM	O
HEPES	B-CHEBI
-	O
NaOH	B-CHEBI
(	O
pH	O
7	O
.	O
5	O
)	O
,	O
50	O
mM	O
sodium	B-CHEBI
acetate	I-CHEBI
,	O
10	O
mM	O
Mg	B-CHEBI
(	O
CH3COO	B-CHEBI
)	O
2	O
,	O
1	O
mM	O
DTT	B-CHEBI
,	O
0	O
.	O
25	O
mu	O
g	O
/	O
ml	O
BSA	B-GGP
,	O
0	O
.	O
5	O
mM	O
ATP	B-CHEBI
-	I-CHEBI
gamma	I-CHEBI
-	I-CHEBI
S	I-CHEBI
and	O
labeled	O
substrates	O
of	O
the	O
amount	O
indicated	O
.	O

After	O
addition	O
of	O
2	O
mu	O
l	O
of	O
50	O
%	O
glycerol	B-CHEBI
,	O
the	O
reaction	O
mixtures	O
were	O
directly	O
applied	O
on	O
a	O
polyacrylamide	O
gel	O
containing	O
6	O
mM	O
magnesium	B-CHEBI
acetate	B-CHEBI
and	O
5	O
%	O
glycerol	B-CHEBI
in	O
0	O
.	O
5	O
x	O
TBE	O
,	O
and	O
electrophoresis	O
was	O
conducted	O
at	O
room	O
temperature	O
.	O

For	O
DNA	B-SO
helicase	O
assays	O
,	O
the	O
reaction	O
mixtures	O
of	O
the	O
gel	O
shift	O
assays	O
,	O
as	O
described	O
above	O
,	O
were	O
incubated	O
at	O
30	O
degrees	O
C	O
for	O
15	O
min	O
,	O
and	O
then	O
the	O
ATP	B-CHEBI
was	O
added	O
at	O
10	O
mM	O
,	O
followed	O
by	O
incubation	O
at	O
37	O
degrees	O
C	O
for	O
additional	O
30	O
min	O
.	O

The	O
reactions	O
were	O
terminated	O
by	O
addition	O
of	O
EDTA	B-CHEBI
(	O
20	O
mM	O
)	O
,	O
SDS	B-CHEBI
(	O
0	O
.	O
1	O
%	O
)	O
and	O
2	O
mu	O
g	O
proteinase	O
K	O
,	O
and	O
were	O
incubated	O
for	O
additional	O
15	O
min	O
.	O

The	O
samples	O
were	O
separated	O
by	O
electrophoresis	O
on	O
nondenaturing	O
polyacrylamide	O
gel	O
in	O
1	O
x	O
TBE	O
.	O

Nuclease	O
protection	O
assays	O

The	O
reaction	O
mixtures	O
(	O
25	O
mu	O
l	O
)	O
contained	O
25	O
mM	O
HEPES	B-CHEBI
-	O
NaOH	B-CHEBI
(	O
pH	O
7	O
.	O
5	O
)	O
,	O
50	O
mM	O
sodium	B-CHEBI
acetate	I-CHEBI
,	O
10	O
mM	O
Mg	B-CHEBI
(	O
CH3COO	B-CHEBI
)	O
2	O
,	O
1	O
mM	O
DTT	B-CHEBI
,	O
0	O
.	O
25	O
mg	O
/	O
ml	O
BSA	B-GGP
,	O
0	O
.	O
5	O
mM	O
ATP	B-CHEBI
-	I-CHEBI
gamma	I-CHEBI
-	I-CHEBI
S	I-CHEBI
,	O
0	O
.	O
5	O
mM	O
CaCl2	B-CHEBI
,	O
10	O
fmol	O
of	O
32P	B-CHEBI
-	O
labeled	O
bubble	O
substrate	O
,	O
and	O
the	O
indicated	O
amount	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
proteins	B-CHEBI
.	O

After	O
incubation	O
at	O
30	O
degrees	O
C	O
for	O
30	O
min	O
,	O
the	O
indicated	O
amount	O
of	O
DNase	B-GGP
I	I-GGP
(	O
TAKARA	O
Biomedical	O
,	O
Japan	O
)	O
was	O
added	O
,	O
and	O
the	O
mixtures	O
were	O
incubated	O
at	O
room	O
temperature	O
for	O
1	O
min	O
.	O

DNase	B-GGP
I	I-GGP
was	O
inactivated	O
by	O
the	O
addition	O
of	O
250	O
mu	O
l	O
of	O
stop	O
solution	O
(	O
20	O
mM	O
EDTA	B-CHEBI
,	O
0	O
.	O
2M	O
sodium	B-CHEBI
chloride	I-CHEBI
,	O
1	O
%	O
SDS	B-CHEBI
and	O
12	O
.	O
5	O
mu	O
g	O
/	O
ml	O
yeast	B-Taxon
RNA	B-SO
)	O
.	O

For	O
nuclease	O
P1	O
footprinting	O
assay	O
,	O
binding	O
reactions	O
were	O
carried	O
out	O
under	O
the	O
same	O
conditions	O
except	O
that	O
CaCl2	B-CHEBI
was	O
omitted	O
.	O

P1	O
nuclease	O
(	O
0	O
.	O
3	O
U	O
,	O
Roche	O
)	O
was	O
added	O
and	O
incubation	O
was	O
continued	O
at	O
37	O
degrees	O
C	O
for	O
1	O
min	O
.	O

Cleavage	O
was	O
stopped	O
by	O
addition	O
of	O
50	O
mu	O
l	O
of	O
25	O
mM	O
EDTA	B-CHEBI
and	O
0	O
.	O
4	O
M	O
NaOH	B-CHEBI
;	O
the	O
mixture	O
was	O
incubated	O
at	O
room	O
temperature	O
for	O
10	O
min	O
followed	O
by	O
the	O
addition	O
of	O
12	O
mu	O
l	O
of	O
3	O
M	O
sodium	B-CHEBI
acetate	I-CHEBI
(	O
pH	O
4	O
.	O
8	O
)	O
.	O

Proteins	B-CHEBI
were	O
removed	O
by	O
phenol	B-CHEBI
-	O
chloroform	B-CHEBI
extraction	O
,	O
and	O
DNAs	B-SO
were	O
collected	O
by	O
ethanol	B-CHEBI
precipitation	O
followed	O
by	O
wash	O
with	O
70	O
%	O
ethanol	B-CHEBI
.	O

The	O
digested	O
DNA	B-SO
was	O
subjected	O
to	O
electrophoresis	O
through	O
a	O
10	O
or	O
12	O
%	O
polyacrylamide	O
sequencing	O
gel	O
containing	O
7	O
M	O
urea	B-CHEBI
,	O
followed	O
by	O
autoradiography	O
.	O

RESULTS	O

Mcm4	B-GGP
/	O
6	O
/	O
7	O
complex	B-GO
primarily	O
interacts	O
with	O
the	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
segment	I-SO

Mcm4	B-GGP
/	O
6	O
/	O
7	O
binds	O
to	O
'	O
bubble	O
'	O
DNA	B-SO
substrates	O
and	O
unwinds	O
the	O
duplex	B-SO
segments	B-SO
when	O
the	O
central	O
single	B-SO
-	I-SO
stranded	I-SO
segment	B-SO
contains	O
thymine	B-CHEBI
stretches	B-SO
(	O
13	O
)	O
.	O

In	O
order	O
to	O
examine	O
the	O
mode	O
of	O
binding	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
on	O
bubble	O
DNAs	B-SO
,	O
we	O
conducted	O
nuclease	O
protection	O
assays	O
using	O
labeled	O
bubble	O
substrate	O
DNAs	B-SO
and	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
in	O
the	O
presence	O
of	O
ATP	B-CHEBI
-	I-CHEBI
gamma	I-CHEBI
-	I-CHEBI
S	I-CHEBI
which	O
permits	O
binding	O
to	O
substrate	O
DNA	B-SO
but	O
does	O
not	O
mobilize	O
the	O
helicase	O
.	O

At	O
an	O
optimum	O
concentration	O
of	O
DNase	B-GGP
I	I-GGP
,	O
strong	O
cleavages	O
were	O
detected	O
on	O
the	O
21	O
bp	B-SO
duplex	B-SO
regions	B-SO
at	O
both	O
ends	O
of	O
the	O
substrates	O
,	O
whereas	O
weaker	O
cleavages	O
were	O
detected	O
on	O
the	O
central	O
single	B-SO
-	I-SO
stranded	I-SO
region	B-SO
,	O
consistent	O
with	O
preference	O
of	O
DNase	B-GGP
I	I-GGP
to	O
double	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
.	O

With	O
the	O
Bub66	O
/	O
T	B-CHEBI
-	O
rich	O
substrate	O
,	O
strong	O
protection	O
was	O
detected	O
on	O
the	O
entire	O
single	B-SO
-	I-SO
stranded	I-SO
regions	B-SO
of	O
both	O
top	O
and	O
bottom	O
strands	B-SO
with	O
increasing	O
concentration	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
,	O
consistent	O
with	O
high	O
affinity	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
to	O
T	B-CHEBI
-	O
rich	O
bubble	O
sequences	B-SO
(	O
Figure	O
1A	O
)	O
.	O

Similar	O
,	O
but	O
less	O
significant	O
protection	O
was	O
detected	O
on	O
the	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
segment	I-SO
with	O
P1	O
nucleases	O
(	O
Figure	O
1A	O
)	O
,	O
which	O
is	O
specific	O
to	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
.	O

The	O
results	O
indicate	O
that	O
the	O
Mcm	B-GO
complex	I-GO
is	O
loaded	O
onto	O
bubble	O
DNA	B-SO
through	O
binding	O
to	O
both	O
strands	B-SO
of	O
the	O
single	B-SO
-	I-SO
stranded	I-SO
region	B-SO
.	O

Careful	O
examination	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
footprints	O
on	O
a	O
bubble	O
indicated	O
strong	O
protection	O
on	O
the	O
5	O
'	O
-	O
half	O
of	O
the	O
top	O
strand	B-SO
and	O
moderate	O
protection	O
on	O
the	O
remaining	O
3	O
'	O
-	O
half	O
,	O
as	O
well	O
as	O
on	O
several	O
base	B-SO
-	I-SO
pair	I-SO
duplex	B-SO
segment	B-SO
adjacent	O
to	O
the	O
branch	O
point	O
(	O
Figure	O
1A	O
and	O
data	O
not	O
shown	O
)	O
.	O

A	O
similar	O
pattern	O
of	O
protection	O
was	O
observed	O
also	O
on	O
the	O
bottom	O
strand	B-SO
.	O

This	O
suggests	O
that	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
may	O
bind	O
to	O
a	O
replication	O
bubble	O
substrate	O
with	O
a	O
2	O
-	O
fold	O
symmetry	O
as	O
a	O
double	O
hexamer	O
(	O
Figure	O
1A	O
,	O
see	O
the	O
lower	O
scheme	O
)	O
,	O
in	O
a	O
manner	O
similar	O
to	O
SV40	B-GGP
T	I-GGP
-	I-GGP
antigen	I-GGP
(	O
21	O
)	O
.	O

Nuclease	O
protection	O
assays	O
were	O
conducted	O
also	O
on	O
a	O
T	O
-	O
tailed	O
Y	O
-	O
fork	O
structure	O
(	O
Figure	O
1B	O
)	O
.	O

Not	O
only	O
the	O
single	B-SO
-	I-SO
stranded	I-SO
tail	O
region	B-SO
but	O
also	O
the	O
7	O
bp	B-SO
duplex	B-SO
DNA	B-SO
adjacent	O
to	O
the	O
duplex	B-SO
-	O
to	O
-	O
single	B-SO
-	I-SO
strand	I-SO
junction	B-SO
were	O
protected	O
by	O
Mcm	B-GO
binding	O
from	O
DNaseI	B-GGP
digestion	O
.	O

These	O
results	O
indicate	O
that	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
protein	B-CHEBI
primarily	O
interacts	O
with	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
region	I-SO
and	O
that	O
the	O
interaction	O
also	O
spans	O
the	O
duplex	B-SO
segments	B-SO
near	O
the	O
branchpoint	O
of	O
the	O
replication	B-GO
fork	I-GO
.	O

Formation	O
of	O
double	O
hexameric	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
complexes	B-GO
facilitates	O
helicase	O
actions	O
on	O
bubble	O
substrates	O

The	O
above	O
results	O
suggest	O
that	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
generates	O
a	O
double	O
hexameric	O
complex	B-GO
on	O
a	O
bubble	O
,	O
each	O
hexamer	O
of	O
which	O
makes	O
symmetric	O
contact	O
with	O
the	O
5	O
'	O
-	O
proximal	O
central	O
single	B-SO
-	I-SO
stranded	I-SO
segment	B-SO
.	O

This	O
predicts	O
that	O
the	O
single	B-SO
-	I-SO
stranded	I-SO
segment	B-SO
needs	O
to	O
be	O
of	O
a	O
sufficient	O
length	O
in	O
order	O
to	O
accommodate	O
the	O
Mcm	B-GO
complex	I-GO
.	O

In	O
fact	O
,	O
we	O
previously	O
showed	O
that	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
mainly	O
forms	O
a	O
single	O
hexameric	O
complex	B-GO
on	O
bubble	O
-	O
20	O
(	O
a	O
bubble	O
substrate	O
with	O
20	O
nt	B-SO
long	O
central	O
single	B-SO
-	I-SO
stranded	I-SO
segment	B-SO
)	O
and	O
a	O
double	O
hexameric	O
complex	B-GO
on	O
bubble	O
-	O
60	O
DNA	B-SO
(	O
13	O
)	O
.	O

In	O
order	O
to	O
determine	O
the	O
minimum	O
requirement	O
for	O
double	O
-	O
hexamer	O
formation	O
,	O
a	O
set	O
of	O
synthetic	B-SO
bubble	O
-	O
like	O
substrates	O
(	O
Bub	O
-	O
T10	O
,	O
Bub	O
-	O
T20	O
,	O
Bub	O
-	O
T30	O
,	O
Bub	O
-	O
T40	O
and	O
Bub	O
-	O
T50	O
)	O
that	O
differed	O
in	O
the	O
length	O
of	O
the	O
central	O
unpaired	B-SO
segment	B-SO
were	O
constructed	O
,	O
and	O
the	O
binding	O
and	O
helicase	O
activities	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
on	O
these	O
substrates	O
were	O
examined	O
.	O

Mcm4	B-GGP
/	O
6	O
/	O
7	O
was	O
incubated	O
with	O
a	O
radiolabeled	B-CHEBI
synthetic	B-SO
bubble	O
substrate	O
in	O
the	O
presence	O
of	O
0	O
.	O
5	O
mM	O
ATP	B-CHEBI
-	I-CHEBI
gamma	I-CHEBI
-	I-CHEBI
S	I-CHEBI
to	O
allow	O
complex	B-GO
formation	O
.	O

A	O
half	O
of	O
these	O
reaction	O
mixtures	O
were	O
analyzed	O
for	O
DNA	B-SO
binding	O
in	O
gel	O
shift	O
assays	O
(	O
Figure	O
2A	O
)	O
,	O
and	O
the	O
remainder	O
was	O
further	O
incubated	O
in	O
the	O
presence	O
of	O
10	O
mM	O
ATP	B-CHEBI
to	O
measure	O
DNA	B-SO
helicase	O
activity	O
(	O
Figure	O
2B	O
)	O
.	O

Bub	O
-	O
10	O
generated	O
only	O
a	O
low	O
level	O
of	O
complexes	B-GO
with	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
,	O
and	O
Bub	O
-	O
20	O
generated	O
primarily	O
a	O
single	O
mobility	O
-	O
shifted	O
form	O
,	O
which	O
may	O
contain	O
a	O
single	O
hexamer	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
.	O

On	O
Bub	O
-	O
30	O
,	O
significant	O
amount	O
of	O
complexes	B-GO
containing	O
a	O
double	O
hexamer	O
were	O
generated	O
in	O
addition	O
to	O
those	O
containing	O
a	O
single	O
hexamer	O
(	O
Figure	O
2A	O
)	O
(	O
13	O
,	O
21	O
)	O
.	O

The	O
amounts	O
of	O
double	O
hexamer	O
complexes	B-GO
increased	O
on	O
Bub	O
-	O
T40	O
and	O
Bub	O
-	O
T50	O
with	O
concomitant	O
decrease	O
of	O
single	O
hexamer	O
complexes	B-GO
(	O
Figure	O
2A	O
)	O
.	O

The	O
results	O
indicate	O
that	O
a	O
single	B-SO
-	I-SO
stranded	I-SO
segment	B-SO
of	O
at	O
least	O
40	O
nt	B-SO
long	O
is	O
required	O
for	O
efficient	O
loading	O
of	O
the	O
double	O
-	O
hexameric	O
Mcm	B-GO
helicase	I-GO
on	O
a	O
bubble	O
substrate	O
.	O

In	O
DNA	B-SO
helicase	O
assays	O
,	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
complex	B-GO
did	O
not	O
show	O
helicase	O
activity	O
on	O
either	O
Bub	O
-	O
10	O
or	O
Bub	O
-	O
20	O
substrate	O
.	O

The	O
efficiency	O
of	O
displacement	O
slightly	O
improved	O
as	O
the	O
length	O
of	O
the	O
single	B-SO
-	I-SO
stranded	I-SO
segment	B-SO
increased	O
up	O
to	O
30	O
nt	B-SO
.	O

On	O
Bub	O
-	O
T40	O
and	O
Bub	O
-	O
T50	O
,	O
on	O
the	O
other	O
hand	O
,	O
significant	O
displacement	O
was	O
observed	O
,	O
indicating	O
that	O
a	O
single	B-SO
-	I-SO
stranded	I-SO
segment	B-SO
of	O
at	O
least	O
40	O
nt	B-SO
long	O
is	O
required	O
for	O
efficient	O
helicase	O
actions	O
on	O
bubble	O
substrates	O
(	O
Figure	O
2B	O
)	O
.	O

Taken	O
together	O
,	O
the	O
above	O
results	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
complex	B-GO
,	O
loaded	O
onto	O
DNA	B-SO
as	O
a	O
double	O
hexameric	O
complex	B-GO
,	O
efficiently	O
unwinds	O
the	O
duplex	B-SO
region	B-SO
of	O
the	O
substrate	O
DNA	B-SO
.	O

Both	O
strands	B-SO
of	O
thymine	B-CHEBI
-	O
rich	O
single	B-SO
-	I-SO
stranded	I-SO
segments	B-SO
are	O
required	O
for	O
efficient	O
unwinding	O
of	O
bubble	O
DNA	B-SO
by	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O

Symmetric	O
binding	O
of	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
double	O
hexamer	O
to	O
bubble	O
suggests	O
that	O
each	O
hexamer	O
catalyzes	O
unwinding	O
of	O
one	O
of	O
the	O
two	O
duplex	B-SO
segments	B-SO
.	O

We	O
asked	O
whether	O
activation	O
of	O
both	O
hexamers	O
is	O
required	O
for	O
unwinding	O
of	O
the	O
bubble	O
substrate	O
.	O

The	O
preferred	O
bubble	O
substrate	O
which	O
is	O
efficiently	O
unwound	O
by	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
contains	O
thymine	B-CHEBI
stretches	B-SO
on	O
both	O
strands	B-SO
of	O
the	O
single	B-SO
-	I-SO
stranded	I-SO
segment	B-SO
.	O

We	O
constructed	O
a	O
hetero	O
-	O
bubble	O
(	O
Bub66	O
/	O
T	B-CHEBI
-	O
G	B-CHEBI
-	O
rich	O
)	O
in	O
which	O
one	O
strand	B-SO
is	O
T	B-CHEBI
-	O
rich	O
(	O
same	O
as	O
Bub66	O
/	O
T	B-CHEBI
-	O
rich	O
)	O
and	O
the	O
other	O
strand	B-SO
is	O
G	B-CHEBI
-	O
rich	O
(	O
same	O
as	O
Bub66	O
/	O
G	B-CHEBI
-	O
rich	O
)	O
(	O
13	O
)	O
,	O
and	O
helicase	O
assays	O
were	O
conducted	O
with	O
increasing	O
amount	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
.	O

Only	O
weak	O
unwinding	O
was	O
detected	O
on	O
this	O
substrate	O
compared	O
to	O
Bub66	O
/	O
T	B-CHEBI
-	O
rich	O
(	O
Figure	O
3A	O
)	O
.	O

Since	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
can	O
bind	O
to	O
Bub66	O
/	O
T	B-CHEBI
-	O
G	B-CHEBI
-	O
rich	O
and	O
forms	O
a	O
double	O
hexameric	O
complex	B-GO
(	O
data	O
not	O
shown	O
)	O
,	O
the	O
defective	O
unwinding	O
is	O
not	O
due	O
to	O
inefficient	O
loading	O
of	O
the	O
helicase	O
onto	O
the	O
substrate	O
.	O

If	O
one	O
hexamer	O
interacting	O
with	O
the	O
thymine	B-CHEBI
-	O
rich	O
strand	B-SO
dissociates	O
from	O
the	O
other	O
hexamer	O
and	O
displaces	O
only	O
one	O
of	O
the	O
duplex	B-SO
segments	B-SO
,	O
then	O
it	O
would	O
result	O
in	O
generation	O
of	O
Y	O
-	O
fork	B-GO
structures	I-GO
which	O
could	O
not	O
be	O
further	O
displaced	O
due	O
to	O
the	O
presence	O
of	O
G	B-CHEBI
-	O
rich	O
3	O
'	O
-	O
tail	O
and	O
would	O
appear	O
on	O
the	O
gel	O
.	O

However	O
,	O
we	O
did	O
not	O
detect	O
such	O
intermediates	O
during	O
the	O
course	O
of	O
the	O
experiment	O
(	O
Figure	O
3B	O
)	O
,	O
suggesting	O
that	O
bubble	O
can	O
be	O
displaced	O
efficiently	O
only	O
when	O
two	O
molecules	B-CHEBI
of	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
hexamers	O
are	O
simultaneously	O
activated	O
.	O

Binding	O
and	O
helicase	O
actions	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
on	O
forked	B-GO
and	O
3	O
'	O
-	O
or	O
5	O
'	O
-	O
extension	O
substrates	O

In	O
order	O
to	O
examine	O
more	O
precisely	O
the	O
interaction	O
and	O
helicase	O
actions	O
with	O
forked	B-GO
substrates	O
,	O
Y	O
-	O
fork	B-GO
substrates	O
containing	O
a	O
nascent	O
leading	O
strand	B-SO
(	O
A	O
-	O
fork	B-GO
[	O
3	O
'	O
]	O
)	O
,	O
nascent	O
lagging	O
strand	B-SO
(	O
A	O
-	O
fork	B-GO
[	O
5	O
'	O
]	O
)	O
,	O
or	O
both	O
of	O
them	O
(	O
A	O
-	O
fork	B-GO
[	O
3	O
'	O
,	O
5	O
'	O
]	O
)	O
,	O
as	O
well	O
as	O
5	O
'	O
-	O
extension	O
or	O
3	O
'	O
-	O
extension	O
structures	O
were	O
constructed	O
.	O

Mcm4	B-GGP
/	O
6	O
/	O
7	O
bound	O
to	O
A	O
-	O
fork	B-GO
[	O
3	O
'	O
]	O
or	O
A	O
-	O
fork	B-GO
[	O
5	O
'	O
]	O
with	O
affinity	O
similar	O
to	O
that	O
of	O
a	O
simple	O
Y	O
-	O
fork	B-GO
(	O
Figure	O
4A	O
and	O
data	O
not	O
shown	O
)	O
.	O

In	O
contrast	O
,	O
PriA	B-GGP
helicase	I-GGP
,	O
used	O
as	O
a	O
control	O
,	O
bound	O
to	O
A	O
-	O
fork	B-GO
[	O
3	O
'	O
]	O
more	O
efficiently	O
than	O
to	O
A	O
-	O
fork	B-GO
[	O
5	O
'	O
]	O
,	O
as	O
reported	O
previously	O
(	O
23	O
,	O
25	O
)	O
.	O

Mcm4	B-GGP
/	O
6	O
/	O
7	O
bound	O
also	O
to	O
5	O
'	O
-	O
extension	O
and	O
3	O
'	O
-	O
extension	O
,	O
albeit	O
with	O
slightly	O
reduced	O
affinity	O
compared	O
to	O
A	O
-	O
fork	B-GO
[	O
3	O
'	O
]	O
and	O
A	O
-	O
fork	B-GO
[	O
5	O
'	O
]	O
(	O
Figure	O
4A	O
)	O
.	O

Mcm4	B-GGP
/	O
6	O
/	O
7	O
bound	O
to	O
A	O
-	O
fork	B-GO
[	O
3	O
'	O
,	O
5	O
'	O
]	O
with	O
much	O
lower	O
affinity	O
,	O
and	O
the	O
complex	B-GO
gave	O
rise	O
to	O
a	O
single	O
band	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
complex	B-GO
is	O
loaded	O
onto	O
DNA	B-SO
preferentially	O
and	O
efficiently	O
through	O
single	B-SO
-	I-SO
stranded	I-SO
region	B-SO
,	O
regardless	O
of	O
the	O
presence	O
of	O
3	O
'	O
-	O
or	O
5	O
'	O
-	O
terminus	O
.	O

In	O
contrast	O
,	O
only	O
the	O
substrate	O
containing	O
a	O
3	O
'	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
tail	O
(	O
A	O
-	O
fork	B-GO
[	O
5	O
'	O
]	O
)	O
was	O
efficiently	O
unwound	O
and	O
A	O
-	O
fork	B-GO
[	O
3	O
'	O
]	O
or	O
A	O
-	O
fork	B-GO
[	O
3	O
'	O
,	O
5	O
'	O
]	O
,	O
was	O
not	O
unwound	O
by	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
(	O
Figure	O
4B	O
)	O
.	O

Absence	O
of	O
helicase	O
actions	O
on	O
A	O
-	O
fork	B-GO
[	O
3	O
'	O
,	O
5	O
'	O
]	O
composed	O
only	O
of	O
duplex	B-SO
regions	B-SO
is	O
expected	O
since	O
double	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
is	O
not	O
able	O
to	O
activate	O
the	O
ATPase	O
activity	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
(	O
10	O
)	O
.	O

In	O
contrast	O
,	O
the	O
PriA	B-GGP
,	O
a	O
structure	O
-	O
specific	O
helicase	O
used	O
as	O
a	O
control	O
,	O
binds	O
at	O
the	O
fork	B-GO
junction	B-SO
and	O
unwinds	O
the	O
fork	B-GO
and	O
the	O
nascent	O
lagging	O
strand	B-SO
DNA	B-SO
on	O
A	O
-	O
fork	B-GO
[	O
5	O
'	O
]	O
,	O
or	O
unwinds	O
the	O
nascent	O
lagging	O
strand	B-SO
on	O
A	O
-	O
fork	B-GO
[	O
3	O
'	O
,	O
5	O
'	O
]	O
,	O
as	O
reported	O
before	O
(	O
25	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
complex	B-GO
binds	O
to	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
and	O
that	O
its	O
helicase	O
is	O
activated	O
only	O
in	O
the	O
presence	O
of	O
a	O
single	B-SO
-	I-SO
stranded	I-SO
3	O
'	O
-	O
tail	O
.	O

3	O
'	O
-	O
extension	O
with	O
poly	O
(	O
dT	O
)	O
tail	O
is	O
displaced	O
by	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O

It	O
has	O
been	O
reported	O
that	O
the	O
3	O
'	O
-	O
extension	O
can	O
be	O
unwound	O
by	O
the	O
archaeal	B-Taxon
Mcm	B-GO
homohexamer	O
but	O
not	O
by	O
fission	B-Taxon
and	I-Taxon
budding	I-Taxon
yeast	I-Taxon
Mcm	B-GO
complexes	I-GO
(	O
14	O
,	O
26	O
,	O
27	O
)	O
.	O

We	O
have	O
constructed	O
3	O
'	O
-	O
extension	O
substrates	O
containing	O
poly	O
(	O
dT	O
)	O
,	O
poly	O
(	O
dA	O
)	O
,	O
poly	O
(	O
dC	O
)	O
and	O
poly	O
(	O
dG	O
)	O
3	O
'	O
-	O
tails	O
in	O
order	O
to	O
examine	O
whether	O
mouse	B-GGP
Mcm4	I-GGP
/	O
6	O
/	O
7	O
can	O
displace	O
these	O
substrates	O
.	O

We	O
first	O
found	O
that	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
binds	O
to	O
dT	O
-	O
,	O
dC	O
-	O
and	O
dG	O
-	O
3	O
'	O
-	O
extension	O
with	O
similar	O
affinity	O
,	O
and	O
to	O
dA	O
-	O
3	O
'	O
-	O
extension	O
with	O
much	O
lower	O
affinity	O
(	O
Figure	O
5A	O
)	O
.	O

This	O
is	O
consistent	O
with	O
the	O
previous	O
results	O
that	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
binds	O
to	O
50mer	O
oligo	B-SO
-	O
dT	O
,	O
-	O
dC	O
and	O
-	O
dG	O
,	O
but	O
not	O
to	O
a	O
50mer	O
oligo	B-SO
-	O
dA	O
(	O
13	O
)	O
.	O

We	O
found	O
that	O
dT	O
-	O
tailed	O
3	O
'	O
-	O
extension	O
was	O
displaced	O
efficiently	O
by	O
Mcm	B-GGP
4	I-GGP
/	I-GGP
6	I-GGP
/	I-GGP
7	I-GGP
while	O
almost	O
no	O
or	O
very	O
little	O
activity	O
was	O
detected	O
on	O
other	O
substrates	O
(	O
Figure	O
5B	O
and	O
C	O
)	O
.	O

This	O
is	O
in	O
sharp	O
contrast	O
to	O
yeast	B-Taxon
Mcm4	B-GGP
/	O
6	O
/	O
7	O
helicases	O
which	O
are	O
not	O
capable	O
of	O
unwinding	O
3	O
'	O
-	O
extension	O
substrates	O
.	O

Furthermore	O
,	O
dT	O
-	O
tailed	O
5	O
'	O
-	O
extension	O
,	O
to	O
which	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
could	O
bind	O
,	O
was	O
not	O
displaced	O
by	O
the	O
Mcm	B-GO
helicase	I-GO
.	O

The	O
addition	O
of	O
the	O
5	O
'	O
-	O
tail	O
to	O
dT	O
-	O
tailed	O
3	O
'	O
-	O
extension	O
further	O
stimulated	O
the	O
displacement	O
(	O
Figure	O
5D	O
)	O
,	O
confirming	O
the	O
previous	O
report	O
that	O
the	O
fork	B-GO
structures	I-GO
facilitate	O
the	O
helicase	O
action	O
.	O

Thus	O
,	O
these	O
results	O
further	O
strengthen	O
our	O
conclusion	O
that	O
the	O
mammalian	B-Taxon
Mcm	B-GO
helicase	I-GO
is	O
generally	O
activated	O
by	O
the	O
thymine	B-CHEBI
-	O
stretch	B-SO
on	O
the	O
3	O
'	O
-	O
single	B-SO
-	I-SO
stranded	I-SO
tail	O
.	O

The	O
effects	O
of	O
the	O
thymine	B-CHEBI
content	O
of	O
the	O
3	O
'	O
-	O
tail	O
on	O
Mcm	B-GO
helicase	I-GO
activity	O

We	O
next	O
examined	O
more	O
systematically	O
the	O
effect	O
of	O
the	O
compositions	O
of	O
the	O
thymine	B-CHEBI
residues	B-CHEBI
of	O
the	O
3	O
'	O
-	O
tail	O
on	O
the	O
Mcm	B-GO
helicase	I-GO
activity	O
.	O

A	O
partial	O
heteroduplex	O
M13	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
containing	O
a	O
37	O
bp	B-SO
duplex	B-SO
region	B-SO
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
50	O
nt	B-CHEBI
long	O
3	O
'	O
-	O
tail	O
of	O
various	O
nucleotide	B-CHEBI
compositions	O
were	O
constructed	O
and	O
the	O
unwinding	O
by	O
mouse	B-GGP
Mcm4	I-GGP
/	O
6	O
/	O
7	O
was	O
examined	O
(	O
Figure	O
6A	O
)	O
.	O

Due	O
to	O
its	O
low	O
processivity	O
,	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
barely	O
displaced	O
the	O
annealed	O
37mer	O
oligonucleotide	B-SO
without	O
a	O
3	O
'	O
-	O
tail	O
(	O
37mer	O
;	O
Figure	O
6A	O
)	O
.	O

Only	O
weak	O
helicase	O
activity	O
was	O
observed	O
on	O
the	O
substrate	O
carrying	O
the	O
3	O
'	O
-	O
tail	O
of	O
25	O
repeats	B-SO
of	O
TA	O
dinucleotide	O
(	O
37	O
-	O
TA25	O
;	O
Figure	O
6A	O
)	O
,	O
whereas	O
strong	O
helicase	O
activity	O
was	O
observed	O
on	O
37	O
-	O
TTA17	O
.	O

Increase	O
of	O
thymine	B-CHEBI
content	O
on	O
the	O
3	O
'	O
-	O
tail	O
did	O
not	O
further	O
increase	O
the	O
extent	O
of	O
unwinding	O
(	O
37	O
-	O
TTTA13	O
,	O
37	O
-	O
TTTTA10	O
and	O
37	O
-	O
T50	O
;	O
Figure	O
6A	O
)	O
,	O
suggesting	O
that	O
17	O
repeats	B-SO
of	O
TT	O
dinucleotides	O
(	O
67	O
%	O
thymine	B-CHEBI
)	O
may	O
be	O
sufficient	O
for	O
activation	O
of	O
Mcm	B-GO
helicase	I-GO
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
TA25	O
tail	O
would	O
self	O
-	O
anneal	O
and	O
this	O
would	O
prevent	O
the	O
loading	O
of	O
Mcm	B-GO
,	O
since	O
the	O
3	O
'	O
-	O
tail	O
containing	O
TTAA13	O
or	O
TTTAAA8	O
did	O
not	O
enhance	O
the	O
unwinding	O
either	O
(	O
data	O
not	O
shown	O
)	O
.	O

Therefore	O
,	O
we	O
next	O
examined	O
the	O
effects	O
of	O
repeating	B-SO
sequences	I-SO
of	O
thymine	B-CHEBI
and	O
cytosine	B-CHEBI
(	O
Figure	O
6B	O
)	O
.	O

Partial	O
heteroduplex	O
substrates	O
containing	O
the	O
3	O
'	O
-	O
tail	O
of	O
TC25	O
,	O
TTCC13	O
,	O
TTTCCC8	O
,	O
TTTTCCCC6	O
,	O
TTCC17	O
were	O
displaced	O
by	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
complex	B-GO
to	O
the	O
extent	O
similar	O
to	O
that	O
achieved	O
by	O
TTA17	O
,	O
suggesting	O
that	O
50	O
%	O
thymine	B-CHEBI
content	O
is	O
sufficient	O
for	O
full	O
activation	O
of	O
Mcm	B-GO
helicase	I-GO
.	O

TTCC13	O
and	O
TTCC17	O
were	O
displaced	O
to	O
a	O
similar	O
extent	O
,	O
consistent	O
with	O
the	O
earlier	O
result	O
that	O
a	O
40	O
nt	B-CHEBI
tail	O
is	O
sufficient	O
for	O
activation	O
(	O
13	O
)	O
.	O

However	O
,	O
the	O
efficiency	O
of	O
the	O
displacement	O
significantly	O
decreased	O
as	O
the	O
thymine	B-CHEBI
content	O
of	O
the	O
3	O
'	O
-	O
tail	O
dropped	O
to	O
33	O
%	O
,	O
as	O
in	O
TAA17	O
or	O
TCC17	O
(	O
Figure	O
6B	O
and	O
C	O
)	O
.	O

Thus	O
,	O
the	O
minimal	O
thymine	B-CHEBI
content	O
required	O
for	O
activation	O
of	O
the	O
Mcm	B-GO
helicase	I-GO
may	O
be	O
somewhere	O
between	O
33	O
and	O
50	O
%	O
.	O

DUE	O
sequences	B-SO
from	O
the	O
c	B-GGP
-	I-GGP
myc	I-GGP
origin	B-SO
activate	O
Mcm	B-GO
helicase	I-GO

Our	O
previous	O
studies	O
have	O
shown	O
that	O
the	O
sequences	B-SO
containing	O
periodic	O
(	O
dT	O
)	O
n	O
tracts	B-SO
derived	O
from	O
the	O
human	B-GGP
lamin	I-GGP
B2	I-GGP
origin	B-SO
(	O
48	O
%	O
thymine	B-CHEBI
content	O
)	O
can	O
serve	O
as	O
an	O
efficient	O
activator	O
for	O
the	O
Mcm	B-GO
helicase	I-GO
on	O
a	O
bubble	O
,	O
and	O
replacement	B-SO
of	O
thymines	B-CHEBI
with	O
guanines	B-CHEBI
abolished	O
the	O
helicase	O
activation	O
(	O
13	O
,	O
28	O
)	O
.	O

In	O
order	O
to	O
examine	O
other	O
natural	B-SO
replication	B-SO
origins	I-SO
with	O
different	O
thymine	B-CHEBI
contents	O
for	O
the	O
ability	O
to	O
activate	O
Mcm	B-GO
helicase	I-GO
on	O
a	O
bubble	O
substrate	O
,	O
we	O
constructed	O
new	O
bubble	O
substrates	O
,	O
Bub82	O
/	O
c	B-GGP
-	I-GGP
myc	I-GGP
,	O
containing	O
sequences	B-SO
derived	O
from	O
the	O
DUE	O
(	O
DNA	B-SO
unwinding	O
element	O
)	O
region	B-SO
of	O
the	O
human	B-GGP
c	I-GGP
-	I-GGP
myc	I-GGP
origin	B-SO
which	O
is	O
essential	O
for	O
c	B-GGP
-	I-GGP
myc	I-GGP
replicator	O
activity	O
(	O
29	O
,	O
30	O
)	O
.	O

The	O
unpaired	B-SO
segment	B-SO
in	O
Bub82	O
/	O
c	B-GGP
-	I-GGP
myc	I-GGP
/	O
DUE	O
contains	O
one	O
strand	B-SO
of	O
DUE	O
and	O
that	O
in	O
Bub82	O
/	O
c	B-GGP
-	I-GGP
myc	I-GGP
/	O
DUE	O
-	O
C	O
contains	O
another	O
strand	B-SO
.	O

This	O
DUE	O
is	O
believed	O
to	O
coincide	O
with	O
the	O
initially	O
unwound	O
region	B-SO
of	O
the	O
c	B-GGP
-	I-GGP
myc	I-GGP
origin	B-SO
(	O
29	O
)	O
,	O
and	O
its	O
deletion	B-SO
substantially	O
reduced	O
the	O
replicator	O
activity	O
(	O
30	O
)	O
.	O

Mcm4	B-GGP
/	O
6	O
/	O
7	O
unwound	O
Bub82	O
/	O
lamin	B-GGP
B2	I-GGP
(	O
thymine	B-CHEBI
48	O
%	O
)	O
,	O
Bub82	O
/	O
c	B-GGP
-	I-GGP
myc	I-GGP
/	O
DUE	O
(	O
37	O
%	O
)	O
and	O
Bub82	O
/	O
c	B-GGP
-	I-GGP
myc	I-GGP
/	O
DUE	O
-	O
C	O
(	O
39	O
%	O
)	O
with	O
similar	O
efficiency	O
(	O
Figure	O
7A	O
)	O
,	O
indicating	O
that	O
the	O
sequences	B-SO
from	O
the	O
c	B-GGP
-	I-GGP
myc	I-GGP
origin	B-SO
also	O
can	O
serve	O
as	O
efficient	O
activators	O
of	O
the	O
Mcm	B-GO
helicase	I-GO
.	O

This	O
result	O
also	O
indicates	O
that	O
sequences	B-SO
with	O
37	O
%	O
thymine	B-CHEBI
content	O
can	O
activate	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
to	O
displace	O
24	O
nt	B-CHEBI
duplex	O
on	O
both	O
sides	O
in	O
a	O
bubble	O
substrate	O
,	O
suggesting	O
that	O
the	O
not	O
only	O
thymine	B-CHEBI
content	O
but	O
also	O
the	O
sequence	B-SO
context	O
may	O
affect	O
the	O
Mcm	B-GO
helicase	I-GO
activation	O
.	O

In	O
gel	O
shift	O
assays	O
,	O
MCM4	B-GGP
/	O
6	O
/	O
7	O
bound	O
to	O
all	O
the	O
three	O
bubbles	O
,	O
although	O
the	O
affinity	O
to	O
Bub82	O
/	O
c	B-GGP
-	I-GGP
myc	I-GGP
/	O
DUE	O
and	O
to	O
Bub82	O
/	O
c	B-GGP
-	I-GGP
myc	I-GGP
/	O
DUE	O
-	O
C	O
is	O
slightly	O
lower	O
than	O
that	O
to	O
Bub	O
-	O
82	O
/	O
lamin	B-GGP
B2	I-GGP
(	O
Figure	O
7B	O
)	O
.	O

Therefore	O
,	O
helicase	O
and	O
DNA	B-SO
binding	O
activities	O
do	O
not	O
necessarily	O
correlate	O
with	O
each	O
other	O
.	O

This	O
was	O
also	O
indicated	O
by	O
our	O
previous	O
results	O
that	O
guanine	B-CHEBI
and	O
cytosine	B-CHEBI
stretches	B-SO
can	O
bind	O
to	O
Mcm	B-GO
but	O
cannot	O
activate	O
the	O
helicase	O
(	O
13	O
)	O
.	O

DNA	B-SO
unwinding	O
by	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
is	O
inhibited	O
by	O
the	O
GC	O
-	O
rich	O
sequences	B-SO
on	O
the	O
duplex	B-SO
segment	B-SO

Our	O
results	O
indicate	O
that	O
thymine	B-CHEBI
-	O
rich	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
is	O
required	O
for	O
initial	O
loading	O
and	O
activation	O
of	O
the	O
Mcm	B-GO
helicase	I-GO
.	O

However	O
,	O
it	O
is	O
not	O
known	O
whether	O
thymine	B-CHEBI
sequences	B-SO
are	O
required	O
for	O
processive	O
unwinding	O
of	O
duplex	B-SO
DNA	B-SO
.	O

Therefore	O
,	O
we	O
have	O
examined	O
whether	O
the	O
nucleotide	B-CHEBI
composition	O
of	O
the	O
duplex	B-SO
region	B-SO
affects	O
its	O
unwinding	O
activity	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
constructed	O
a	O
series	O
of	O
T	O
-	O
tailed	O
Y	O
-	O
fork	B-GO
structures	I-GO
(	O
T	O
-	O
fork	B-GO
)	O
containing	O
various	O
sequences	B-SO
in	O
the	O
duplex	B-SO
segment	B-SO
.	O

They	O
carried	O
varied	O
contents	O
of	O
cytosine	B-CHEBI
residues	B-CHEBI
on	O
the	O
3	O
'	O
-	O
tail	O
strand	B-SO
.	O

In	O
gel	O
shift	O
assays	O
,	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
bound	O
to	O
these	O
Y	O
-	O
fork	B-GO
substrates	O
with	O
identical	O
affinity	O
(	O
Figure	O
8A	O
)	O
,	O
consistent	O
with	O
the	O
notion	O
that	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
binds	O
to	O
single	B-SO
-	I-SO
stranded	I-SO
tails	O
.	O

However	O
,	O
in	O
DNA	B-SO
helicase	O
assays	O
,	O
T	O
-	O
fork	B-GO
/	O
(	O
C	O
:	O
G	O
)	O
49	O
was	O
hardly	O
displaced	O
by	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
,	O
but	O
was	O
readily	O
displaced	O
by	O
SV40	B-GGP
T	I-GGP
-	I-GGP
antigen	I-GGP
DNA	I-GGP
helicase	I-GGP
(	O
Figure	O
8B	O
)	O
.	O

When	O
thymine	B-CHEBI
or	O
adenine	B-CHEBI
is	O
inserted	B-SO
as	O
every	O
third	O
nucleotide	B-CHEBI
(	O
repeats	B-SO
of	O
CCT	O
or	O
CCA	O
)	O
,	O
the	O
extent	O
of	O
unwinding	O
increased	O
(	O
T	O
-	O
fork	B-GO
/	O
(	O
CCT	O
:	O
GGA	O
)	O
16	O
and	O
T	O
-	O
fork	B-GO
/	O
(	O
CCA	O
:	O
GGT	O
)	O
16	O
)	O
.	O

The	O
efficiency	O
of	O
unwinding	O
is	O
roughly	O
correlated	O
with	O
the	O
content	O
of	O
GC	O
pairs	O
in	O
the	O
duplex	B-SO
segment	B-SO
[	O
T	O
-	O
fork	B-GO
/	O
(	O
CCAA	O
:	O
GGTT	O
)	O
12	O
,	O
T	O
-	O
fork	B-GO
/	O
(	O
CCTT	O
:	O
GGAA	O
)	O
12	O
,	O
T	O
-	O
fork	B-GO
/	O
(	O
CAAA	O
:	O
GTTT	O
)	O
12	O
and	O
T	O
-	O
fork	B-GO
/	O
(	O
CTTT	O
:	O
GAAA	O
)	O
12	O
;	O
Figure	O
8B	O
]	O
.	O

It	O
appears	O
that	O
the	O
duplex	B-SO
segment	B-SO
containing	O
<	O
50	O
%	O
GC	O
pairs	O
is	O
efficiently	O
unwound	O
(	O
Figure	O
8C	O
)	O
.	O

We	O
next	O
examined	O
the	O
effect	O
of	O
GC	O
-	O
rich	O
segments	B-SO
on	O
a	O
partial	O
heteroduplex	O
DNA	B-SO
on	O
a	O
single	B-SO
-	I-SO
stranded	I-SO
circular	B-SO
DNA	B-SO
.	O

We	O
have	O
constructed	O
two	O
sets	O
of	O
5	O
'	O
-	O
tailed	O
partial	O
heteroduplex	O
DNA	B-SO
substrates	O
containing	O
duplex	B-SO
regions	B-SO
of	O
variable	O
lengths	O
;	O
one	O
on	O
M13mp18	O
vector	B-SO
and	O
the	O
other	O
on	O
M13mp19	O
containing	O
a	O
66	O
nt	B-SO
long	O
G	B-CHEBI
-	O
rich	O
segment	B-SO
downstream	O
of	O
the	O
hybridizing	O
oligonucleotide	B-SO
.	O

We	O
found	O
that	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
helicase	O
can	O
displace	O
duplex	B-SO
DNA	B-SO
up	O
to	O
350	O
nt	B-SO
long	O
on	O
its	O
own	O
on	O
the	O
former	O
substrate	O
(	O
Figure	O
8D	O
,	O
left	O
)	O
,	O
consistent	O
with	O
previous	O
results	O
(	O
13	O
)	O
.	O

In	O
contrast	O
,	O
displacement	O
was	O
inhibited	O
over	O
the	O
GC	O
-	O
rich	O
segments	B-SO
on	O
the	O
latter	O
substrate	O
(	O
Figure	O
8D	O
,	O
right	O
panel	O
)	O
,	O
although	O
displacement	O
up	O
to	O
250	O
nt	B-SO
in	O
length	O
,	O
albeit	O
at	O
a	O
reduced	O
level	O
,	O
was	O
observed	O
at	O
a	O
high	O
concentration	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
complex	B-GO
.	O

This	O
result	O
is	O
consistent	O
with	O
that	O
on	O
Y	O
-	O
fork	B-GO
and	O
indicates	O
that	O
GC	O
-	O
rich	O
duplex	B-SO
segment	B-SO
is	O
inhibitory	O
for	O
unwinding	O
by	O
the	O
Mcm	B-GO
helicase	I-GO
.	O

These	O
results	O
may	O
indicate	O
that	O
the	O
presence	O
of	O
thymine	B-CHEBI
-	O
adenine	B-CHEBI
pairs	B-SO
with	O
a	O
certain	O
frequency	O
in	O
the	O
duplex	B-SO
region	B-SO
may	O
facilitate	O
continuous	O
unwinding	O
by	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
.	O

Alternatively	O
,	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
is	O
not	O
efficient	O
enough	O
to	O
displace	O
thermodynamically	O
stable	O
GC	O
-	O
base	B-SO
-	I-SO
paired	I-SO
segment	B-SO
.	O

In	O
order	O
to	O
distinguish	O
these	O
two	O
possibilities	O
,	O
we	O
designed	O
a	O
new	O
T	O
-	O
fork	B-GO
substrate	O
containing	O
inosine	B-SO
(	I-SO
I	I-SO
)	I-SO
residue	I-SO
instead	O
of	O
guanosine	B-CHEBI
residue	B-CHEBI
.	O

The	O
thermal	O
stability	O
of	O
the	O
I	B-CHEBI
:	O
C	B-CHEBI
base	B-SO
pair	I-SO
is	O
lower	O
than	O
that	O
of	O
the	O
G	B-CHEBI
:	O
C	B-CHEBI
base	B-SO
pair	I-SO
in	O
duplex	B-SO
DNA	B-SO
due	O
to	O
loss	O
of	O
one	O
hydrogen	B-CHEBI
bond	O
and	O
is	O
even	O
lower	O
than	O
A	B-CHEBI
:	O
T	B-CHEBI
base	B-SO
pair	I-SO
(	O
31	O
)	O
.	O

We	O
constructed	O
the	O
T	O
-	O
tailed	O
fork	B-GO
substrates	O
containing	O
the	O
(	O
GCC	O
:	O
CGG	O
)	O
10	O
,	O
(	O
GCC	O
:	O
CIG	O
)	O
10	O
or	O
(	O
GAA	O
:	O
CTT	O
)	O
10	O
duplex	B-SO
DNA	B-SO
segment	I-SO
(	O
Figure	O
8E	O
)	O
.	O

Mcm4	B-GGP
/	O
6	O
/	O
7	O
hardly	O
displaced	O
the	O
31	O
nt	B-CHEBI
long	O
duplex	O
of	O
GCC	O
:	O
CGG	O
repeats	B-SO
,	O
whereas	O
the	O
T	O
-	O
fork	B-GO
/	O
(	O
GAA	O
:	O
CTT	O
)	O
10	O
was	O
displaced	O
efficiently	O
,	O
as	O
described	O
above	O
.	O

T	O
-	O
fork	B-GO
/	O
(	O
GCC	O
:	O
CIG	O
)	O
10	O
was	O
displaced	O
with	O
efficiency	O
much	O
greater	O
than	O
that	O
of	O
T	O
-	O
fork	B-GO
/	O
(	O
GCC	O
:	O
CGG	O
)	O
10	O
,	O
indicating	O
that	O
the	O
thermostability	O
of	O
the	O
duplex	B-SO
segment	B-SO
,	O
not	O
the	O
lack	O
of	O
AT	O
base	B-SO
pair	I-SO
,	O
is	O
responsible	O
for	O
inability	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
to	O
displace	O
the	O
duplex	O
.	O

DISCUSSION	O

DNA	B-SO
helicase	O
is	O
a	O
central	O
factor	O
for	O
operation	O
of	O
replication	B-GO
forks	I-GO
.	O

It	O
also	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
initiation	O
step	O
at	O
the	O
replication	B-SO
origins	I-SO
.	O

Therefore	O
,	O
the	O
elucidation	O
of	O
how	O
the	O
replicative	O
helicases	O
interact	O
with	O
DNA	B-SO
substrate	O
and	O
how	O
they	O
are	O
activated	O
is	O
crucial	O
for	O
understanding	O
the	O
molecular	B-CHEBI
basis	O
of	O
initiation	O
of	O
DNA	B-SO
replication	O
.	O

It	O
is	O
now	O
believed	O
that	O
Mcm	B-GO
is	O
a	O
major	O
component	O
of	O
the	O
eukaryotic	B-Taxon
replicative	O
helicase	O
.	O

In	O
this	O
report	O
,	O
we	O
have	O
conducted	O
detailed	O
analyses	O
on	O
binding	O
and	O
helicase	O
actions	O
of	O
mouse	B-GGP
Mcm4	I-GGP
/	O
6	O
/	O
7	O
using	O
various	O
substrates	O
including	O
fork	B-GO
and	I-GO
bubble	I-GO
structures	I-GO
.	O

Modes	O
of	O
binding	O
and	O
activation	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
helicase	O
on	O
a	O
bubble	O
structure	O

Initiation	O
of	O
DNA	B-SO
replication	O
is	O
associated	O
with	O
localized	O
melting	O
of	O
duplex	B-SO
DNA	B-SO
near	O
replication	B-SO
origins	I-SO
.	O

Helicases	O
are	O
loaded	O
onto	O
replication	B-GO
forks	I-GO
through	O
the	O
melted	O
region	B-SO
,	O
induced	O
by	O
initiator	O
binding	O
,	O
in	O
bacteria	B-Taxon
(	O
32	O
)	O
.	O

We	O
previously	O
reported	O
that	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
can	O
be	O
loaded	O
onto	O
a	O
bubble	O
-	O
like	O
structure	O
and	O
can	O
serve	O
as	O
a	O
DNA	B-SO
helicase	O
at	O
the	O
forks	B-GO
(	O
13	O
)	O
.	O

The	O
ability	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
to	O
unwind	O
the	O
bubble	O
substrate	O
but	O
not	O
the	O
conventional	O
duplex	B-SO
DNA	B-SO
(	O
Figures	O
2	O
and	O
13	O
)	O
indicates	O
that	O
Mcm	B-GO
can	O
be	O
loaded	O
through	O
the	O
single	B-SO
-	I-SO
stranded	I-SO
segment	B-SO
of	O
the	O
bubble	O
.	O

Furthermore	O
,	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
complex	B-GO
displays	O
marked	O
preference	O
for	O
thymine	B-CHEBI
-	O
rich	O
sequences	B-SO
within	O
the	O
single	B-SO
-	I-SO
stranded	I-SO
segment	B-SO
for	O
helicase	O
activation	O
(	O
13	O
)	O
.	O

The	O
results	O
in	O
this	O
report	O
indicate	O
that	O
helicase	O
action	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
on	O
synthetic	B-SO
bubbles	O
may	O
depend	O
on	O
the	O
presence	O
of	O
an	O
unpaired	B-SO
region	B-SO
of	O
sufficient	O
length	O
(	O
at	O
least	O
40	O
nt	B-CHEBI
)	O
,	O
which	O
may	O
permit	O
assembly	O
of	O
a	O
double	O
-	O
hexameric	O
complex	B-GO
on	O
the	O
substrate	O
DNA	B-SO
,	O
similar	O
to	O
SV40	B-GGP
T	I-GGP
-	I-GGP
antigen	I-GGP
protein	B-CHEBI
(	O
Figure	O
2A	O
)	O
(	O
21	O
)	O
.	O

When	O
one	O
strand	B-SO
of	O
the	O
single	B-SO
-	I-SO
stranded	I-SO
segment	B-SO
in	O
T	B-CHEBI
-	O
rich	O
bubble	O
was	O
replaced	B-SO
by	O
guanine	B-CHEBI
-	O
rich	O
sequences	B-SO
,	O
the	O
efficiency	O
of	O
unwinding	O
was	O
significantly	O
reduced	O
.	O

Our	O
footprinting	O
analyses	O
showed	O
that	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
strongly	O
protects	O
25	O
nt	B-SO
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
segment	I-SO
adjacent	O
to	O
each	O
branch	O
point	O
and	O
proximal	O
to	O
5	O
'	O
ends	O
of	O
both	O
strands	B-SO
of	O
the	O
bubble	O
.	O

At	O
each	O
fork	B-GO
,	O
one	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
complex	B-GO
is	O
likely	O
to	O
encircle	O
the	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
strand	I-SO
and	O
two	O
hexamers	O
may	O
bind	O
symmetrically	O
to	O
the	O
bubble	O
substrate	O
,	O
forming	O
a	O
double	O
hexameric	O
structure	O
on	O
the	O
bubble	O
(	O
see	O
schematic	O
drawing	O
of	O
Figure	O
1A	O
)	O
.	O

Efficient	O
unwinding	O
into	O
both	O
directions	O
may	O
require	O
simultaneous	O
activation	O
of	O
both	O
hexamers	O
which	O
may	O
sit	O
at	O
the	O
center	O
while	O
extruding	O
the	O
unwound	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
through	O
the	O
rings	O
.	O

This	O
may	O
closely	O
resemble	O
the	O
proposed	O
modes	O
of	O
binding	O
and	O
helicase	O
actions	O
of	O
T	B-GGP
-	I-GGP
antigen	I-GGP
(	O
21	O
)	O
.	O

Although	O
we	O
cannot	O
totally	O
exclude	O
the	O
possibility	O
that	O
one	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
hexamer	O
at	O
each	O
fork	B-GO
unwinds	O
the	O
duplex	O
independently	O
,	O
ring	O
-	O
shaped	O
structures	O
of	O
mouse	B-Taxon
and	O
archea	B-Taxon
MCM	B-GO
,	O
as	O
revealed	O
by	O
electron	B-CHEBI
microscopy	O
,	O
bear	O
much	O
similarity	O
to	O
the	O
recently	O
solved	O
structure	O
of	O
the	O
SV40	B-GGP
large	I-GGP
T	I-GGP
-	I-GGP
antigen	I-GGP
(	O
4	O
,	O
6	O
)	O
,	O
and	O
are	O
in	O
favor	O
of	O
the	O
double	O
-	O
hexameric	O
structure	O
of	O
mouse	B-Taxon
Mcm	B-GO
on	O
a	O
bubble	O
DNA	B-SO
.	O

Substrate	O
and	O
sequence	B-SO
requirement	O
for	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
helicase	O
activation	O

DNA	B-SO
binding	O
assays	O
indicate	O
that	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
binds	O
to	O
those	O
substrates	O
containing	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
regions	I-SO
regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
single	B-SO
-	I-SO
stranded	I-SO
3	O
'	O
or	O
5	O
'	O
end	O
.	O

Unwinding	O
of	O
the	O
duplex	B-SO
DNA	B-SO
depends	O
on	O
translocation	B-SO
of	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
from	O
3	O
'	O
to	O
5	O
'	O
direction	O
.	O

This	O
is	O
most	O
clearly	O
shown	O
by	O
its	O
helicase	O
action	O
on	O
A	O
-	O
fork	B-GO
[	O
5	O
'	O
]	O
and	O
3	O
'	O
-	O
extension	O
but	O
not	O
on	O
A	O
-	O
fork	B-GO
[	O
3	O
'	O
]	O
,	O
A	O
-	O
fork	B-GO
[	O
3	O
'	O
,	O
5	O
'	O
]	O
nor	O
5	O
'	O
-	O
extension	O
.	O

However	O
,	O
it	O
does	O
not	O
necessarily	O
require	O
3	O
'	O
end	O
of	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
,	O
since	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
can	O
displace	O
annealing	O
oligonucleotide	B-SO
on	O
a	O
circular	B-SO
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
.	O

The	O
ability	O
of	O
the	O
mouse	B-GGP
Mcm4	I-GGP
/	O
6	O
/	O
7	O
to	O
unwind	O
3	O
'	O
-	O
extension	O
is	O
shared	O
by	O
the	O
archaeal	B-Taxon
Mcm	B-GO
helicase	I-GO
but	O
not	O
by	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
from	O
S	B-Taxon
.	I-Taxon
pombe	I-Taxon
and	O
S	B-Taxon
.	I-Taxon
cerevisiae	I-Taxon
(	O
14	O
,	O
26	O
,	O
27	O
)	O
.	O

The	O
archaeal	B-Taxon
Mcm	B-GO
can	O
unwind	O
A	O
-	O
fork	B-GO
[	O
3	O
'	O
]	O
but	O
eukaryotic	B-Taxon
Mcm4	B-GGP
/	O
6	O
/	O
7	O
cannot	O
,	O
since	O
the	O
former	O
binds	O
to	O
double	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
but	O
the	O
latter	O
does	O
not	O
(	O
5	O
,	O
27	O
)	O
.	O

While	O
yeast	B-Taxon
Mcm	B-GO
helicases	I-GO
can	O
translocate	B-SO
on	O
duplex	B-SO
DNA	B-SO
,	O
such	O
activity	O
was	O
not	O
observed	O
with	O
mammalian	B-Taxon
Mcm4	B-GGP
/	O
6	O
/	O
7	O
(	O
data	O
not	O
shown	O
)	O
.	O

Occurrence	O
of	O
AT	O
-	O
rich	O
sequences	B-SO
,	O
with	O
asymmetric	O
distribution	O
of	O
adenine	B-CHEBI
and	O
thymine	B-CHEBI
,	O
near	O
the	O
replication	B-SO
origins	I-SO
,	O
lead	O
us	O
to	O
propose	O
that	O
Mcm	B-GO
may	O
play	O
a	O
role	O
in	O
selection	O
of	O
initiation	O
sites	B-SO
of	O
mammalian	B-Taxon
DNA	B-SO
replication	O
,	O
and	O
prompted	O
us	O
to	O
examine	O
the	O
ability	O
of	O
sequences	B-SO
from	O
human	B-Taxon
replication	B-SO
origins	I-SO
to	O
activate	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
helicase	O
.	O

Both	O
lamin	B-GGP
-	I-GGP
B2	I-GGP
and	O
c	B-GGP
-	I-GGP
myc	I-GGP
origins	B-SO
served	O
as	O
efficient	O
activator	O
for	O
Mcm	B-GO
helicase	I-GO
in	O
vitro	O
.	O

Consistent	O
with	O
it	O
,	O
site	B-SO
-	O
specific	O
loading	O
of	O
Mcm	B-GO
in	O
the	O
DNA	B-SO
replication	O
initiation	O
zone	B-SO
of	O
the	O
c	B-GGP
-	I-GGP
myc	I-GGP
was	O
recently	O
reported	O
(	O
33	O
)	O
.	O

We	O
have	O
examined	O
in	O
detail	O
the	O
effect	O
of	O
sequence	B-SO
context	O
of	O
the	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
on	O
the	O
helicase	O
activity	O
of	O
Mcm	B-GO
.	O

The	O
results	O
indicate	O
that	O
thymine	B-CHEBI
content	O
of	O
50	O
%	O
is	O
sufficient	O
for	O
the	O
maximum	O
helicase	O
activity	O
.	O

The	O
efficiency	O
of	O
displacement	O
decreased	O
as	O
the	O
thymine	B-CHEBI
content	O
of	O
the	O
3	O
'	O
-	O
tail	O
dropped	O
to	O
33	O
%	O
(	O
Figure	O
6	O
)	O
.	O

The	O
stretches	B-SO
of	O
thymine	B-CHEBI
residues	B-CHEBI
may	O
not	O
be	O
necessarily	O
required	O
,	O
since	O
repeats	B-SO
of	O
TC	O
dinucleotides	O
served	O
as	O
a	O
potent	O
activator	O
for	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
.	O

We	O
also	O
noticed	O
that	O
the	O
presence	O
of	O
a	O
secondary	B-SO
structure	I-SO
within	O
the	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
is	O
inhibitory	O
for	O
helicase	O
action	O
.	O

Nuclease	O
footprinting	O
assays	O
indicated	O
that	O
binding	O
was	O
interfered	O
by	O
the	O
secondary	B-SO
structure	I-SO
(	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
,	O
we	O
have	O
concluded	O
that	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
helicase	O
is	O
most	O
efficiently	O
activated	O
by	O
non	O
-	O
structured	O
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
with	O
thymine	B-CHEBI
content	O
of	O
50	O
%	O
or	O
more	O
,	O
although	O
significant	O
stimulation	O
is	O
observed	O
also	O
by	O
DNA	B-SO
with	O
less	O
thymine	B-CHEBI
content	O
(	O
Figure	O
7	O
)	O
,	O
suggesting	O
that	O
the	O
sequence	B-SO
specificity	O
for	O
Mcm	B-GO
helicase	I-GO
activation	O
is	O
rather	O
relaxed	O
and	O
that	O
the	O
extent	O
of	O
the	O
activation	O
may	O
depend	O
on	O
the	O
sequence	B-SO
context	O
.	O

This	O
would	O
be	O
reasonable	O
given	O
the	O
flexibility	O
and	O
differential	O
regulation	O
of	O
site	B-SO
selection	O
for	O
initiation	O
of	O
DNA	B-SO
replication	O
during	O
development	O
or	O
in	O
various	O
cell	B-CL
types	O
,	O
as	O
well	O
as	O
the	O
variability	O
in	O
initiation	O
potential	O
of	O
each	O
replication	B-SO
origin	I-SO
on	O
the	O
genome	B-SO
even	O
within	O
the	O
single	O
cell	B-CL
type	O
.	O

Mcm4	B-GGP
/	O
6	O
/	O
7	O
helicase	O
during	O
processive	O
unwinding	O
at	O
the	O
fork	B-GO

The	O
specific	O
requirement	O
of	O
single	B-SO
-	I-SO
stranded	I-SO
thymine	B-CHEBI
residues	B-CHEBI
for	O
activation	O
of	O
Mcm	B-GO
helicase	I-GO
prompted	O
us	O
to	O
examine	O
whether	O
they	O
are	O
required	O
also	O
for	O
processive	O
unwinding	O
of	O
duplex	B-SO
DNA	B-SO
.	O

Our	O
results	O
indicated	O
that	O
increase	O
of	O
GC	O
pair	B-SO
in	O
the	O
duplex	B-SO
segment	B-SO
significantly	O
inhibited	O
the	O
Mcm	B-GO
helicase	I-GO
activity	O
.	O

Duplex	B-SO
DNA	B-SO
composed	O
only	O
of	O
GC	O
pairs	B-SO
(	O
10	O
repeats	B-SO
of	O
CGG	O
)	O
on	O
a	O
Y	O
-	O
fork	B-GO
was	O
not	O
displaced	O
at	O
all	O
,	O
while	O
the	O
same	O
template	O
was	O
readily	O
displaced	O
by	O
SV40	B-GGP
T	I-GGP
-	I-GGP
antigen	I-GGP
(	O
Figure	O
8B	O
)	O
.	O

Mcm	B-GO
helicase	I-GO
was	O
inhibited	O
by	O
the	O
presence	O
of	O
GC	O
-	O
rich	O
duplex	B-SO
segment	B-SO
also	O
on	O
a	O
circular	B-SO
single	B-SO
-	I-SO
stranded	I-SO
partial	O
heteroduplex	O
substrate	O
.	O

However	O
,	O
on	O
this	O
substrate	O
,	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
was	O
able	O
to	O
displace	O
DNA	B-SO
past	O
the	O
GC	O
-	O
rich	O
region	B-SO
,	O
albeit	O
to	O
a	O
limited	O
extent	O
,	O
when	O
it	O
was	O
added	O
at	O
a	O
high	O
concentration	O
.	O

On	O
the	O
partial	O
heteroduplex	O
template	O
,	O
Mcm	B-GO
is	O
loaded	O
onto	O
the	O
circular	B-SO
single	B-SO
-	I-SO
stranded	I-SO
DNA	B-SO
of	O
6	O
.	O
4	O
kb	O
,	O
while	O
it	O
is	O
loaded	O
onto	O
the	O
50	O
nt	B-CHEBI
long	O
3	O
'	O
-	O
tail	O
DNA	B-SO
on	O
the	O
Y	O
-	O
fork	B-GO
.	O

Thus	O
,	O
the	O
difference	O
of	O
helicase	O
actions	O
may	O
reflect	O
the	O
efficiency	O
of	O
Mcm	B-GO
loading	O
.	O

Alternatively	O
,	O
the	O
presence	O
of	O
'	O
random	B-SO
'	O
sequence	B-SO
at	O
the	O
initially	O
unwound	O
duplex	B-SO
segment	B-SO
in	O
the	O
former	O
template	O
may	O
engage	O
the	O
Mcm	B-GO
helicase	I-GO
in	O
a	O
more	O
active	O
conformation	O
which	O
can	O
displace	O
the	O
GC	O
-	O
rich	O
duplex	B-SO
segment	B-SO
.	O

On	O
Y	O
-	O
fork	B-GO
substrates	O
,	O
increase	O
of	O
AT	O
base	B-SO
pairs	I-SO
in	O
the	O
duplex	O
(	O
10	O
repeats	B-SO
of	O
CTT	O
)	O
restored	O
the	O
unwinding	O
.	O

These	O
results	O
indicate	O
either	O
that	O
thymine	B-CHEBI
residues	B-CHEBI
are	O
required	O
on	O
the	O
duplex	B-SO
DNA	B-SO
for	O
continuous	O
unwinding	O
,	O
or	O
that	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
is	O
simply	O
not	O
efficient	O
enough	O
to	O
unwind	O
the	O
stable	O
GC	O
pairs	B-SO
.	O

Replacement	B-SO
of	O
the	O
central	O
guanosine	B-CHEBI
with	O
inosine	B-CHEBI
in	O
the	O
CGG	O
repeat	B-SO
duplex	B-SO
DNA	B-SO
resulted	O
in	O
displacement	O
(	O
Figure	O
8E	O
)	O
(	O
31	O
)	O
,	O
suggesting	O
that	O
the	O
continuous	O
presence	O
of	O
AT	O
base	B-SO
pair	I-SO
may	O
not	O
be	O
essential	O
for	O
the	O
Mcm	B-GO
helicase	I-GO
function	O
and	O
that	O
the	O
thermostability	O
of	O
GC	O
base	B-SO
pairs	I-SO
is	O
inhibitory	O
for	O
helicase	O
action	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
.	O

The	O
results	O
described	O
in	O
this	O
manuscript	O
reveal	O
potentially	O
important	O
features	O
of	O
mammalian	B-Taxon
Mcm4	B-GGP
/	O
6	O
/	O
7	O
helicase	O
,	O
which	O
is	O
likely	O
to	O
be	O
a	O
key	O
component	O
of	O
the	O
eukaryotic	B-Taxon
replicative	O
helicase	O
.	O

Prior	O
to	O
initiation	O
of	O
DNA	B-SO
replication	O
,	O
Mcm	B-GO
helicase	I-GO
may	O
adopt	O
a	O
double	O
hexameric	O
complex	B-GO
at	O
the	O
partially	O
melted	O
origin	B-SO
region	B-SO
,	O
and	O
may	O
catalyze	O
concurrent	O
unwinding	O
of	O
duplex	B-SO
DNA	B-SO
into	O
both	O
directions	O
,	O
while	O
stably	O
associated	O
with	O
the	O
origins	B-SO
of	I-SO
DNA	I-SO
replication	I-SO
.	O

This	O
is	O
similar	O
to	O
the	O
T	B-GGP
-	I-GGP
antigen	I-GGP
model	O
originally	O
proposed	O
by	O
Smelkova	O
and	O
Borowiec	O
(	O
21	O
)	O
.	O

We	O
propose	O
that	O
,	O
only	O
when	O
both	O
hexamers	O
are	O
activated	O
by	O
the	O
interacting	O
thymine	B-CHEBI
-	O
rich	O
sequences	B-SO
present	O
within	O
the	O
melted	O
region	B-SO
,	O
the	O
Mcm	B-GO
helicase	I-GO
is	O
mobilized	O
and	O
initiation	O
takes	O
place	O
.	O

A	O
crucial	O
question	O
is	O
how	O
these	O
double	O
hexameric	O
helicase	B-GO
complexes	I-GO
are	O
generated	O
and	O
turn	O
into	O
active	O
helicases	O
at	O
the	O
origins	B-SO
.	O

This	O
process	O
would	O
involve	O
melting	O
of	O
duplex	B-SO
DNA	B-SO
,	O
which	O
may	O
be	O
facilitated	O
by	O
binding	O
of	O
preRC	B-GO
components	O
in	O
the	O
context	O
of	O
proper	O
chromatin	B-GO
structures	I-GO
,	O
or	O
by	O
other	O
unwinding	O
factors	O
including	O
a	O
topoisomerase	O
or	O
a	O
newly	O
identified	O
Mcm8	B-GGP
helicase	I-GGP
(	O
34	O
-	O
36	O
)	O
.	O

It	O
may	O
also	O
require	O
association	O
of	O
fork	B-GO
-	O
assisting	O
proteins	B-CHEBI
such	O
as	O
Cdc45	B-GGP
(	O
37	O
,	O
38	O
)	O
as	O
well	O
as	O
phosphorylation	O
events	O
by	O
Cdk	O
and	O
Cdc7	B-GGP
kinases	I-GGP
(	O
39	O
,	O
40	O
)	O
.	O

One	O
unexpected	O
finding	O
of	O
this	O
study	O
is	O
low	O
helicase	O
activity	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
on	O
GC	O
-	O
rich	O
duplex	B-SO
DNA	B-SO
.	O

This	O
,	O
in	O
conjunction	O
with	O
the	O
low	O
processivity	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
helicase	O
,	O
strongly	O
indicates	O
that	O
the	O
replicative	O
helicase	O
at	O
the	O
replication	B-GO
forks	I-GO
would	O
require	O
more	O
than	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
complex	B-GO
.	O

During	O
the	O
processive	O
unwinding	O
of	O
duplex	B-SO
DNA	B-GO
replication	I-GO
forks	I-GO
,	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
may	O
be	O
further	O
stimulated	O
by	O
interaction	O
with	O
other	O
proteins	B-CHEBI
,	O
including	O
remaining	O
Mcm	B-GO
subunits	O
,	O
Cdc45	B-GGP
(	O
37	O
,	O
38	O
)	O
,	O
GINS	B-GO
(	O
41	O
,	O
42	O
)	O
,	O
DNA	B-GO
polymerase	I-GO
subunits	O
(	O
43	O
)	O
,	O
Mcm8	B-GGP
(	O
35	O
,	O
36	O
)	O
,	O
etc	O
.	O
to	O
become	O
a	O
truly	O
processive	O
and	O
potent	O
helicase	O
capable	O
of	O
replicating	O
the	O
entire	O
genome	B-SO
.	O

Acknowledgements	O

We	O
thank	O
Dr	O
Taku	O
Tanaka	O
for	O
preparations	O
of	O
some	O
of	O
the	O
substrate	O
DNAs	B-SO
used	O
in	O
this	O
study	O
and	O
for	O
useful	O
suggestions	O
,	O
and	O
also	O
the	O
members	O
of	O
our	O
laboratory	O
for	O
helpful	O
discussion	O
.	O

This	O
work	O
was	O
supported	O
in	O
part	O
by	O
grants	O
-	O
in	O
-	O
aid	O
for	O
scientific	O
research	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Culture	O
,	O
Sports	O
,	O
Science	O
and	O
Technology	O
of	O
Japan	O
(	O
MEXT	O
)	O
awarded	O
to	O
Z	O
.	O
Y	O
.	O
and	O
H	O
.	O
M	O
.	O

Funding	O
to	O
pay	O
the	O
Open	O
Access	O
publication	O
charges	O
for	O
this	O
article	O
was	O
provided	O
by	O
MEXT	O
.	O

Conflict	O
of	O
interest	O
statement	O
.	O

None	O
declared	O
.	O

Figures	O
and	O
Tables	O

Figure	O
1	O

Nuclease	O
protection	O
analyses	O
of	O
binding	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
protein	B-CHEBI
to	O
synthetic	B-SO
bubble	O
and	O
fork	B-GO
substrates	O
.	O

(	O
A	O
)	O
The	O
Bub66	O
/	O
T	B-CHEBI
-	O
rich	O
substrate	O
(	O
4	O
fmol	O
)	O
,	O
the	O
top	O
strand	B-SO
or	O
bottom	O
strand	B-SO
of	O
which	O
were	O
32P	B-CHEBI
-	O
labeled	O
at	O
the	O
5	O
'	O
end	O
,	O
were	O
incubated	O
with	O
0	O
(	O
lane	O
1	O
)	O
,	O
25	O
ng	O
(	O
lane	O
2	O
)	O
,	O
50	O
ng	O
(	O
lane	O
3	O
)	O
or	O
75	O
ng	O
(	O
lane	O
4	O
)	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
protein	B-CHEBI
.	O

Reaction	O
mixtures	O
were	O
then	O
treated	O
with	O
0	O
.	O
11	O
U	O
of	O
DNase	B-GGP
I	I-GGP
or	O
0	O
.	O
3	O
U	O
of	O
nuclease	O
P1	O
.	O

(	O
B	O
)	O
The	O
T	O
-	O
tailed	O
Y	O
-	O
fork	B-GO
/	O
random	B-SO
substrate	O
(	O
4	O
fmol	O
)	O
was	O
incubated	O
with	O
0	O
(	O
lane	O
1	O
)	O
,	O
15	O
ng	O
(	O
lane	O
2	O
)	O
,	O
30	O
ng	O
(	O
lane	O
3	O
)	O
,	O
60	O
ng	O
(	O
lane	O
4	O
)	O
or	O
120	O
ng	O
(	O
lane	O
5	O
)	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
protein	B-CHEBI
,	O
and	O
then	O
treated	O
with	O
0	O
.	O
037	O
U	O
of	O
DNase	B-GGP
I	I-GGP
or	O
0	O
.	O
3	O
U	O
of	O
nuclease	O
P1	O
.	O

The	O
reaction	O
products	O
were	O
separated	O
on	O
denaturing	O
PAGE	O
.	O

Single	B-SO
-	I-SO
stranded	I-SO
and	O
duplex	B-SO
regions	B-SO
of	O
the	O
substrates	O
used	O
in	O
the	O
assays	O
are	O
indicated	O
along	O
the	O
gel	O
.	O

In	O
(	O
A	O
)	O
,	O
top	O
and	O
bottom	O
strands	B-SO
are	O
indicated	O
by	O
boldface	O
and	O
normal	O
lines	O
,	O
respectively	O
.	O

Regions	B-SO
of	O
strong	O
and	O
moderate	O
protection	O
are	O
indicated	O
by	O
bold	O
and	O
normal	O
gray	O
lines	O
,	O
respectively	O
,	O
along	O
the	O
substrate	O
structure	O
.	O

The	O
drawing	O
at	O
the	O
bottom	O
of	O
(	O
A	O
)	O
shows	O
summary	O
of	O
the	O
protection	O
pattern	O
(	O
protected	O
regions	B-SO
indicated	O
by	O
gray	O
bold	O
lines	O
)	O
and	O
predicted	O
binding	O
modes	O
of	O
the	O
double	O
hexameric	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
(	O
shown	O
by	O
pale	O
gray	O
ovals	O
)	O
on	O
the	O
bubble	O
substrate	O
.	O

The	O
star	O
marks	O
represent	O
the	O
radioactive	O
5	O
'	O
ends	O
of	O
the	O
annealed	O
oligonucleotides	B-SO
.	O

M	O
,	O
radiolabeled	B-CHEBI
10	O
and	O
50	O
bp	B-SO
ladder	O
.	O

Figure	O
2	O

Binding	O
and	O
helicase	O
actions	O
of	O
mouse	B-GGP
Mcm4	I-GGP
/	O
6	O
/	O
7	O
on	O
bubble	O
substrates	O
containing	O
single	B-SO
-	I-SO
stranded	I-SO
segments	B-SO
of	O
varied	O
lengths	O
.	O

Gel	O
shift	O
(	O
A	O
)	O
and	O
DNA	B-SO
helicase	O
(	O
B	O
)	O
assays	O
were	O
performed	O
with	O
mouse	B-GGP
Mcm4	I-GGP
/	O
6	O
/	O
7	O
on	O
synthetic	B-SO
bubble	O
DNAs	B-SO
(	O
4	O
fmol	O
)	O
,	O
Bub	O
-	O
T10	O
,	O
Bub	O
-	O
T20	O
,	O
Bub	O
-	O
T30	O
,	O
Bub	O
-	O
T40	O
and	O
Bub	O
-	O
T50	O
(	O
Table	O
1	O
)	O
.	O

Lanes	O
1	O
-	O
4	O
contain	O
0	O
,	O
25	O
,	O
50	O
and	O
100	O
ng	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
protein	B-CHEBI
,	O
respectively	O
.	O

B	O
,	O
boiled	O
substrate	O
.	O

The	O
drawing	O
in	O
(	O
A	O
)	O
shows	O
a	O
schematic	O
representation	O
of	O
the	O
substrates	O
used	O
.	O

The	O
asterisk	O
indicates	O
32P	B-CHEBI
-	O
labeled	O
5	O
'	O
-	O
terminus	O
.	O

Figure	O
3	O

Effect	O
of	O
the	O
loss	O
of	O
thymine	B-CHEBI
-	O
rich	O
sequences	B-SO
from	O
one	O
single	B-SO
-	O
strand	B-SO
of	O
the	O
T	B-CHEBI
-	O
rich	O
bubble	O
on	O
unwinding	O
by	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
.	O

(	O
A	O
)	O
The	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
helicase	O
activity	O
was	O
measured	O
by	O
using	O
bubble	O
DNA	B-SO
substrate	O
(	O
4	O
fmol	O
)	O
containing	O
an	O
unpaired	B-SO
segment	B-SO
of	O
two	O
thymine	B-CHEBI
-	O
rich	O
sequences	B-SO
(	O
Bub66	O
/	O
T	B-CHEBI
-	O
rich	O
)	O
or	O
that	O
containing	O
thymine	B-CHEBI
-	O
and	O
guanine	B-CHEBI
-	O
rich	O
sequence	B-SO
on	O
each	O
strand	B-SO
(	O
Bub66	O
/	O
T	O
-	O
G	O
-	O
rich	O
)	O
.	O

The	O
drawings	O
under	O
the	O
panels	O
show	O
schematic	O
representations	O
of	O
the	O
substrates	O
used	O
in	O
this	O
assay	O
.	O

B	O
,	O
boiled	O
substrate	O
;	O
lane	O
1	O
,	O
no	O
protein	B-CHEBI
;	O
lanes	O
2	O
-	O
4	O
contain	O
25	O
,	O
50	O
and	O
100	O
ng	O
of	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
complex	B-GO
,	O
respectively	O
.	O

(	O
B	O
)	O
Helicase	O
assays	O
were	O
conducted	O
with	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
(	O
50	O
ng	O
)	O
on	O
the	O
bubble	O
substrates	O
indicated	O
for	O
various	O
time	O
.	O

Quantification	O
of	O
displaced	O
substrates	O
is	O
presented	O
in	O
the	O
graphs	O
.	O

Figure	O
4	O

DNA	B-SO
binding	O
and	O
helicase	O
actions	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
on	O
various	O
fork	B-GO
substrates	O
.	O

(	O
A	O
)	O
Gel	O
-	O
shift	O
assays	O
were	O
conducted	O
with	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
on	O
specific	O
fork	B-GO
and	O
extension	O
substrates	O
(	O
3	O
fmol	O
)	O
as	O
indicated	O
.	O

(	O
B	O
)	O
DNA	B-SO
helicase	O
assays	O
were	O
conducted	O
on	O
various	O
substrates	O
(	O
3	O
fmol	O
)	O
used	O
in	O
(	O
A	O
)	O
.	O

The	O
amounts	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
added	O
were	O
0	O
(	O
lane	O
1	O
)	O
,	O
25	O
(	O
lane	O
2	O
)	O
,	O
50	O
(	O
lane	O
3	O
)	O
and	O
100	O
ng	O
(	O
lane	O
4	O
)	O
.	O

Lane	O
5	O
,	O
PriA	B-GGP
helicase	I-GGP
at	O
10	O
nM	O
.	O

B	O
,	O
boiled	O
substrate	O
.	O

The	O
drawings	O
show	O
schematic	O
representation	O
of	O
the	O
substrates	O
used	O
in	O
the	O
assays	O
.	O

Arrows	O
a	O
-	O
d	O
indicate	O
displaced	O
products	O
,	O
and	O
their	O
structures	O
are	O
indicated	O
below	O
the	O
panel	O
.	O

The	O
positions	B-SO
of	O
the	O
complexes	B-GO
containing	O
a	O
single	O
hexamer	O
or	O
double	O
hexamer	O
are	O
indicated	O
.	O

In	O
the	O
schematic	O
drawings	O
of	O
the	O
substrates	O
,	O
the	O
labeled	O
oligonucleotides	B-SO
are	O
shown	O
as	O
bold	O
lines	O
,	O
and	O
the	O
asterisks	O
indicate	O
32P	B-CHEBI
-	O
labeled	O
5	O
'	O
-	O
termini	O
.	O

Figure	O
5	O

DNA	B-SO
binding	O
and	O
helicase	O
actions	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
on	O
5	O
'	O
-	O
and	O
3	O
'	O
-	O
extension	O
substrates	O
.	O

DNA	B-SO
-	O
binding	O
(	O
A	O
)	O
and	O
helicase	O
(	O
B	O
)	O
activities	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
were	O
examined	O
on	O
various	O
3	O
'	O
-	O
extension	O
substrates	O
(	O
4	O
fmol	O
)	O
as	O
shown	O
.	O

(	O
C	O
)	O
Quantification	O
of	O
the	O
displaced	O
substrates	O
in	O
(	O
B	O
)	O
.	O

(	O
D	O
)	O
DNA	B-SO
helicase	O
assays	O
on	O
5	O
'	O
-	O
extension	O
,	O
3	O
'	O
-	O
extension	O
and	O
Y	O
-	O
forked	B-GO
substrates	O
.	O

Lanes	O
1	O
-	O
4	O
are	O
reactions	O
with	O
0	O
,	O
25	O
,	O
50	O
and	O
100	O
ng	O
of	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
complex	B-GO
,	O
respectively	O
.	O

Schematic	O
drawings	O
of	O
the	O
substrates	O
used	O
in	O
the	O
assays	O
are	O
also	O
shown	O
.	O

The	O
star	O
marks	O
indicate	O
32P	B-CHEBI
-	O
labeled	O
5	O
'	O
-	O
termini	O
.	O

Figure	O
6	O

The	O
effects	O
of	O
the	O
nucleotide	B-CHEBI
compositions	O
of	O
the	O
3	O
'	O
-	O
tail	O
on	O
displacement	O
of	O
partial	O
heteroduplex	O
substrates	O
by	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
.	O

(	O
A	O
)	O
DNA	B-SO
helicase	O
assays	O
were	O
performed	O
with	O
3	O
'	O
-	O
tailed	O
partial	O
heteroduplex	O
helicase	O
substrates	O
(	O
on	O
a	O
single	B-SO
-	I-SO
stranded	I-SO
circular	B-SO
DNA	B-SO
;	O
4	O
fmol	O
)	O
carrying	O
various	O
nucleotide	B-SO
sequences	I-SO
in	O
the	O
3	O
'	O
-	O
tail	O
as	O
shown	O
.	O

The	O
asterisks	O
represent	O
the	O
32P	B-CHEBI
-	O
labeled	O
5	O
'	O
ends	O
of	O
the	O
annealed	O
oligonucleotides	B-SO
.	O

(	O
B	O
)	O
DNA	B-SO
helicase	O
assays	O
were	O
performed	O
with	O
similar	O
sets	O
of	O
partial	O
heteroduplex	O
helicase	O
substrates	O
carrying	O
the	O
3	O
'	O
-	O
tails	O
as	O
shown	O
.	O

(	O
C	O
)	O
Quantification	O
of	O
displaced	O
oligonucleotides	B-SO
in	O
(	O
B	O
)	O
.	O

Lanes	O
1	O
-	O
4	O
contain	O
0	O
,	O
25	O
,	O
50	O
and	O
100	O
ng	O
of	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
complex	B-GO
,	O
respectively	O
.	O

B	O
,	O
boiled	O
substrate	O
.	O

Figure	O
7	O

Activation	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
DNA	B-SO
helicase	O
by	O
sequences	B-SO
derived	O
from	O
the	O
human	B-GGP
c	I-GGP
-	I-GGP
myc	I-GGP
origin	B-SO
.	O

(	O
A	O
)	O
DNA	B-SO
helicase	O
assays	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
were	O
conducted	O
using	O
Bub	O
-	O
82	O
bubble	O
substrates	O
(	O
6	O
fmol	O
)	O
containing	O
c	B-GGP
-	I-GGP
myc	I-GGP
/	O
DUE	O
,	O
Lamin	B-GGP
B2	I-GGP
and	O
c	B-GGP
-	I-GGP
myc	I-GGP
/	O
DUE	O
-	O
C	O
sequences	B-SO
in	O
the	O
unpaired	B-SO
segment	B-SO
,	O
the	O
thymine	B-CHEBI
contents	O
of	O
which	O
are	O
48	O
,	O
37	O
and	O
39	O
%	O
,	O
respectively	O
.	O

Quantification	O
of	O
displaced	O
substrates	O
is	O
presented	O
in	O
the	O
graph	O
.	O

(	O
B	O
)	O
DNA	B-SO
binding	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
was	O
examined	O
in	O
gel	O
shift	O
assays	O
using	O
the	O
same	O
set	O
of	O
substrates	O
.	O

Lanes	O
1	O
-	O
4	O
are	O
reactions	O
with	O
0	O
,	O
25	O
,	O
50	O
and	O
100	O
ng	O
of	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
complex	B-GO
,	O
respectively	O
.	O

B	O
,	O
boiled	O
substrate	O
.	O

Figure	O
8	O

Effect	O
of	O
nucleotide	B-CHEBI
compositions	O
of	O
the	O
duplex	B-SO
segments	B-SO
on	O
helicase	O
action	O
of	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
.	O

DNA	B-SO
binding	O
(	O
A	O
)	O
and	O
helicase	O
(	O
B	O
,	O
D	O
and	O
E	O
)	O
activities	O
of	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
helicase	O
were	O
examined	O
on	O
various	O
Y	O
-	O
fork	B-GO
DNAs	B-SO
(	O
3	O
fmol	O
)	O
carrying	O
different	O
nucleotides	B-CHEBI
in	O
the	O
duplex	B-SO
region	B-SO
as	O
shown	O
(	O
A	O
,	O
B	O
and	O
E	O
)	O
or	O
on	O
single	B-SO
-	I-SO
stranded	I-SO
circular	B-SO
partial	O
heteroduplex	O
DNA	B-SO
substrates	O
(	O
5	O
fmol	O
)	O
(	O
D	O
)	O
.	O

(	O
A	O
,	O
B	O
and	O
E	O
)	O
Lane	O
1	O
,	O
no	O
protein	B-CHEBI
added	O
;	O
lanes	O
2	O
-	O
4	O
contain	O
25	O
,	O
50	O
and	O
100	O
ng	O
of	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
protein	B-CHEBI
,	O
respectively	O
;	O
lane	O
5	O
[	O
in	O
(	O
B	O
)	O
]	O
,	O
50	O
ng	O
of	O
SV40	B-GGP
T	I-GGP
-	I-GGP
antigen	I-GGP
.	O

(	O
C	O
)	O
Quantification	O
of	O
the	O
displaced	O
substrates	O
in	O
(	O
B	O
)	O
.	O

(	O
D	O
)	O
Helicase	O
assays	O
on	O
dT40	O
-	O
Nmer	O
/	O
M13mp18	O
and	O
dT40	O
-	O
Nmer	O
/	O
M13mp19	O
+	O
G	O
-	O
rich	O
carrying	O
the	O
labeled	O
duplex	B-SO
regions	B-SO
of	O
varied	O
lengths	O
.	O

Lane	O
1	O
,	O
no	O
protein	B-CHEBI
added	O
;	O
lanes	O
2	O
-	O
7	O
contain	O
25	O
,	O
50	O
,	O
75	O
,	O
125	O
,	O
200	O
and	O
300	O
ng	O
of	O
the	O
Mcm4	B-GGP
/	O
6	O
/	O
7	O
protein	B-CHEBI
,	O
respectively	O
.	O

Lanes	O
8	O
and	O
9	O
,	O
boiled	O
M13mp18	O
and	O
M13mp19	O
+	O
G	B-CHEBI
-	O
rich	O
substrates	O
,	O
respectively	O
.	O

The	O
drawings	O
show	O
schematic	O
representations	O
of	O
the	O
substrates	O
used	O
in	O
the	O
assays	O
.	O

The	O
red	O
segment	B-SO
in	O
bold	O
face	O
in	O
(	O
D	O
)	O
indicates	O
the	O
66	O
nt	B-CHEBI
long	O
G	B-CHEBI
-	O
rich	O
segment	B-SO
.	O

The	O
asterisks	O
represent	O
radiaoactive	O
[	O
alpha	O
-	O
32P	B-CHEBI
]	O
dGTP	B-CHEBI
incorporated	B-SO
into	O
the	O
duplex	B-SO
segment	B-SO
or	O
32P	B-CHEBI
-	O
labeled	O
5	O
'	O
ends	O
of	O
the	O
annealed	O
oligonucleotides	B-SO
.	O

M	O
[	O
in	O
(	O
D	O
)	O
]	O
,	O
denatured	O
50	O
bp	B-SO
ladder	O
DNA	B-SO
marker	O
;	O
and	O
I	B-CHEBI
[	O
in	O
(	O
E	O
)	O
]	O
,	O
inosine	B-CHEBI
.	O

B	O
,	O
boiled	O
substrate	O
.	O

Table	O
1	O

Constructions	O
of	O
helicase	O
substrates	O
used	O
in	O
this	O
study	O

The	O
numbers	O
with	O
'	O
#	O
'	O
refer	O
to	O
oligonucleotides	B-SO
whose	O
sequences	B-SO
are	O
given	O
in	O
Table	O
2	O
.	O

Table	O
2	O

List	O
of	O
oligonucleotides	B-SO
used	O
in	O
this	O
study	O

Inactivation	O
of	O
the	O
Huntington	B-GGP
'	I-GGP
s	I-GGP
disease	I-GGP
gene	I-GGP
(	O
Hdh	B-GGP
)	O
impairs	O
anterior	O
streak	O
formation	O
and	O
early	O
patterning	O
of	O
the	O
mouse	B-Taxon
embryo	O

Abstract	O

Background	O

Huntingtin	B-GGP
,	O
the	O
HD	B-GGP
gene	B-SO
encoded	O
protein	B-CHEBI
mutated	B-SO
by	O
polyglutamine	O
expansion	O
in	O
Huntington	O
'	O
s	O
disease	O
,	O
is	O
required	O
in	O
extraembryonic	O
tissues	O
for	O
proper	O
gastrulation	O
,	O
implicating	O
its	O
activities	O
in	O
nutrition	O
or	O
patterning	O
of	O
the	O
developing	O
embryo	O
.	O

To	O
test	O
these	O
possibilities	O
,	O
we	O
have	O
used	O
whole	O
mount	O
in	O
situ	O
hybridization	O
to	O
examine	O
embryonic	O
patterning	O
and	O
morphogenesis	O
in	O
homozygous	O
Hdhex4	O
/	O
5	O
huntingtin	B-GGP
deficient	O
embryos	O
.	O

Results	O

In	O
the	O
absence	O
of	O
huntingtin	B-GGP
,	O
expression	O
of	O
nutritive	O
genes	B-SO
appears	O
normal	O
but	O
E7	O
.	O
0	O
-	O
7	O
.	O
5	O
embryos	O
exhibit	O
a	O
unique	O
combination	O
of	O
patterning	O
defects	O
.	O

Notable	O
are	O
a	O
shortened	O
primitive	O
streak	O
,	O
absence	O
of	O
a	O
proper	O
node	O
and	O
diminished	O
production	O
of	O
anterior	O
streak	O
derivatives	O
.	O

Reduced	O
Wnt3a	B-GGP
,	O
Tbx6	B-GGP
and	O
Dll1	B-GGP
expression	O
signify	O
decreased	O
paraxial	O
mesoderm	O
and	O
reduced	O
Otx2	B-GGP
expression	O
and	O
lack	O
of	O
headfolds	O
denote	O
a	O
failure	O
of	O
head	O
development	O
.	O

In	O
addition	O
,	O
genes	B-SO
initially	O
broadly	O
expressed	O
are	O
not	O
properly	O
restricted	O
to	O
the	O
posterior	O
,	O
as	O
evidenced	O
by	O
the	O
ectopic	O
expression	O
of	O
Nodal	B-GGP
,	O
Fgf8	B-GGP
and	O
Gsc	B-GGP
in	O
the	O
epiblast	O
and	O
T	B-GGP
(	O
Brachyury	B-GGP
)	O
and	O
Evx1	B-GGP
in	O
proximal	O
mesoderm	O
derivatives	O
.	O

Despite	O
impaired	O
posterior	O
restriction	O
and	O
anterior	O
streak	O
deficits	O
,	O
overall	O
anterior	O
/	O
posterior	O
polarity	O
is	O
established	O
.	O

A	O
single	O
primitive	O
streak	O
forms	O
and	O
marker	O
expression	O
shows	O
that	O
the	O
anterior	O
epiblast	O
and	O
anterior	O
visceral	O
endoderm	O
(	O
AVE	O
)	O
are	O
specified	O
.	O

Conclusion	O

Huntingtin	B-GGP
is	O
essential	O
in	O
the	O
early	O
patterning	O
of	O
the	O
embryo	O
for	O
formation	O
of	O
the	O
anterior	O
region	O
of	O
the	O
primitive	O
streak	O
,	O
and	O
for	O
down	O
-	O
regulation	O
of	O
a	O
subset	O
of	O
dynamic	O
growth	O
and	O
transcription	O
factor	O
genes	B-SO
.	O

These	O
findings	O
provide	O
fundamental	O
starting	O
points	O
for	O
identifying	O
the	O
novel	O
cellular	B-CL
and	O
molecular	B-CHEBI
activities	O
of	O
huntingtin	B-GGP
in	O
the	O
extraembryonic	O
tissues	O
that	O
govern	O
normal	O
anterior	O
streak	O
development	O
.	O

This	O
knowledge	O
may	O
prove	O
to	O
be	O
important	O
for	O
understanding	O
the	O
mechanism	O
by	O
which	O
the	O
dominant	O
polyglutamine	O
expansion	O
in	O
huntingtin	B-GGP
determines	O
the	O
loss	O
of	O
neurons	B-CL
in	O
Huntington	O
'	O
s	O
disease	O
.	O

Background	O

Huntington	O
'	O
s	O
disease	O
(	O
HD	O
)	O
is	O
a	O
dominantly	O
inherited	O
neurodegenerative	O
disorder	O
that	O
is	O
caused	O
by	O
CAG	O
repeats	B-SO
in	O
the	O
HD	B-GGP
locus	B-SO
that	O
extend	O
a	O
polyglutamine	O
tract	B-SO
in	O
a	O
ubiquitous	O
HEAT	O
domain	B-SO
protein	B-CHEBI
called	O
huntingtin	B-GGP
[	O
1	O
]	O
.	O

The	O
molecular	B-CHEBI
mechanism	O
by	O
which	O
the	O
new	O
property	B-SO
that	O
is	O
conferred	O
on	O
huntingtin	B-GGP
by	O
the	O
polyglutamine	O
expansion	O
leads	O
to	O
the	O
hallmark	O
loss	O
of	O
striatal	O
neurons	B-CL
in	O
HD	O
is	O
not	O
known	O
.	O

However	O
,	O
polyglutamine	O
expansions	O
in	O
unrelated	O
proteins	B-CHEBI
that	O
target	O
distinct	O
neuronal	B-CL
cell	B-CL
populations	O
cause	O
distinct	O
'	O
polyglutamine	O
'	O
neurodegenerative	O
disorders	O
.	O

This	O
observation	O
strongly	O
suggests	O
that	O
the	O
striatal	O
cell	B-CL
specificity	O
of	O
the	O
polyglutamine	O
expansion	O
in	O
the	O
context	O
of	O
huntingtin	B-GGP
must	O
be	O
determined	O
by	O
some	O
aspect	O
of	O
huntingtin	B-GGP
'	O
s	O
structure	O
,	O
subcellular	O
location	O
or	O
activities	O
[	O
2	O
]	O
.	O

Huntingtin	B-GGP
is	O
postulated	O
to	O
function	O
as	O
a	O
flexible	O
~	O
350	O
kDa	O
HEAT	O
domain	B-SO
scaffold	O
that	O
may	O
facilitate	O
the	O
assembly	O
and	O
possibly	O
the	O
subcellular	O
location	O
of	O
large	O
protein	B-GO
complexes	I-GO
[	O
3	O
-	O
7	O
]	O
.	O

Huntingtin	B-GGP
'	O
s	O
large	O
number	O
of	O
diverse	O
cytoplasmic	B-GO
and	O
nuclear	B-GO
protein	B-CHEBI
binding	O
partners	O
strongly	O
suggest	O
that	O
huntingtin	B-GGP
may	O
participate	O
in	O
a	O
variety	O
of	O
cellular	B-CL
processes	O
that	O
range	O
from	O
trafficking	O
of	O
growth	O
factor	O
complexes	B-GO
to	O
gene	B-SO
transcription	O
(	O
reviewed	O
in	O
[	O
5	O
,	O
8	O
,	O
9	O
]	O
.	O

However	O
,	O
despite	O
the	O
potential	O
importance	O
of	O
huntingtin	B-GGP
'	O
s	O
normal	O
function	O
to	O
our	O
understanding	O
of	O
how	O
the	O
dominant	O
polyglutamine	O
mutation	B-SO
causes	O
HD	O
pathology	O
,	O
huntingtin	B-GGP
'	O
s	O
precise	O
molecular	B-CHEBI
and	O
cellular	B-CL
activities	O
have	O
not	O
been	O
defined	O
.	O

Therefore	O
,	O
we	O
,	O
and	O
others	O
,	O
set	O
out	O
to	O
discover	O
huntingtin	B-GGP
'	O
s	O
essential	O
activities	O
by	O
studying	O
the	O
effects	O
of	O
huntingtin	B-GGP
deficiency	O
in	O
the	O
mouse	B-Taxon
.	O

Inactivation	O
of	O
the	O
mouse	B-GGP
HD	I-GGP
gene	I-GGP
(	O
Hdh	B-GGP
)	O
has	O
shown	O
that	O
huntingtin	B-GGP
is	O
not	O
required	O
for	O
cell	B-CL
viability	O
,	O
as	O
evidenced	O
by	O
the	O
survival	O
of	O
mouse	B-Taxon
embryonic	O
stem	B-CL
cells	I-CL
and	O
neurons	B-CL
that	O
lack	O
huntingtin	B-GGP
[	O
10	O
-	O
12	O
]	O
.	O

However	O
,	O
huntingtin	B-GGP
is	O
needed	O
at	O
the	O
level	O
of	O
the	O
organism	B-Taxon
for	O
proper	O
mammalian	B-Taxon
embryonic	O
development	O
[	O
10	O
,	O
13	O
,	O
14	O
]	O
.	O

Complete	O
lack	O
of	O
huntingtin	B-GGP
results	O
in	O
developmental	O
arrest	O
during	O
gastrulation	O
,	O
while	O
severe	O
reduction	O
of	O
huntingtin	B-GGP
levels	O
results	O
in	O
abnormal	O
neurogenesis	O
and	O
perinatal	O
lethality	O
[	O
15	O
]	O
.	O

Analysis	O
of	O
huntingtin	B-GGP
deficient	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
reveals	O
that	O
homozygous	O
inactivation	O
of	O
the	O
mouse	B-GGP
HD	I-GGP
gene	I-GGP
does	O
not	O
overtly	O
affect	O
development	O
until	O
E7	O
.	O
0	O
.	O

By	O
E7	O
.	O
5	O
,	O
mutant	B-SO
embryos	O
exhibit	O
a	O
shortened	O
primitive	O
streak	O
,	O
reduced	O
size	O
and	O
,	O
by	O
morphology	O
,	O
lack	O
a	O
node	O
and	O
head	O
folds	O
.	O

Mutants	B-SO
are	O
rapidly	O
resorbed	O
by	O
E8	O
.	O
0	O
[	O
10	O
]	O
.	O

Importantly	O
,	O
the	O
expression	O
of	O
huntingtin	B-GGP
only	O
in	O
extraembryonic	O
tissues	O
in	O
chimeras	O
rescues	O
this	O
gastrulation	O
phenotype	O
,	O
suggesting	O
that	O
huntingtin	B-GGP
is	O
required	O
only	O
in	O
cells	B-CL
of	O
the	O
extraembryonic	O
lineage	O
and	O
acts	O
in	O
a	O
cell	B-CL
non	O
-	O
autonomous	O
manner	O
at	O
this	O
stage	O
[	O
16	O
]	O
.	O

Extraembryonic	O
tissues	O
are	O
essential	O
for	O
supplying	O
nutrients	B-CHEBI
and	O
signals	O
that	O
direct	O
anterior	O
/	O
posterior	O
axis	O
formation	O
and	O
patterning	O
in	O
the	O
developing	O
embryo	O
(	O
reviewed	O
in	O
[	O
17	O
]	O
)	O
,	O
implicating	O
huntingtin	B-GGP
in	O
either	O
or	O
both	O
of	O
these	O
processes	O
.	O

Of	O
these	O
possibilities	O
,	O
the	O
nutritive	O
role	O
has	O
been	O
more	O
extensively	O
investigated	O
.	O

However	O
,	O
huntingtin	B-GGP
deficient	O
embryos	O
do	O
not	O
display	O
obvious	O
visceral	O
endoderm	O
defects	O
,	O
with	O
the	O
notable	O
exception	O
of	O
compromised	O
iron	B-CHEBI
transport	O
in	O
later	O
stage	O
mutants	B-SO
,	O
although	O
iron	B-CHEBI
uptake	O
is	O
undisturbed	O
[	O
16	O
]	O
and	O
endocytosis	O
is	O
not	O
impaired	O
in	O
huntingtin	B-GGP
deficient	O
embryos	O
or	O
embryonic	O
stem	B-CL
cells	I-CL
[	O
16	O
,	O
18	O
]	O
.	O

By	O
the	O
same	O
token	O
,	O
huntingtin	B-GGP
shuttles	O
through	O
the	O
nucleus	B-GO
,	O
where	O
it	O
is	O
required	O
for	O
proper	O
nuclear	B-GO
localization	O
of	O
its	O
transcription	O
factor	O
partners	O
,	O
suggesting	O
that	O
huntingtin	B-GGP
may	O
play	O
a	O
role	O
in	O
transcription	O
cascades	O
in	O
extraembryonic	O
tissues	O
that	O
pattern	O
the	O
embryo	O
[	O
18	O
]	O
.	O

Therefore	O
,	O
we	O
have	O
examined	O
this	O
hypothesis	O
,	O
by	O
monitoring	O
the	O
expression	O
of	O
genes	B-SO
that	O
determine	O
normal	O
embryonic	O
patterning	O
and	O
morphogenesis	O
in	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
huntingtin	B-GGP
deficient	O
embryos	O
.	O

Our	O
results	O
support	O
and	O
refine	O
the	O
hypothesis	O
,	O
indicating	O
that	O
huntingtin	B-GGP
is	O
required	O
for	O
proper	O
mesoderm	O
patterning	O
and	O
for	O
normal	O
regional	O
restriction	O
of	O
the	O
expression	O
of	O
a	O
subset	O
of	O
growth	O
and	O
transcription	O
factors	O
.	O

Results	O

Huntingtin	B-GGP
-	O
deficient	O
embryos	O
exhibit	O
abnormal	O
streak	O
progression	O
and	O
paraxial	O
mesoderm	O
production	O

Since	O
extraembryonic	O
tissues	O
supply	O
nutrients	B-CHEBI
to	O
the	O
developing	O
embryo	O
,	O
we	O
tested	O
the	O
possibility	O
that	O
huntingtin	B-GGP
deficiency	O
may	O
perturb	O
this	O
function	O
by	O
performing	O
RT	O
-	O
PCR	O
analysis	O
to	O
examine	O
the	O
expression	O
of	O
a	O
panel	O
of	O
'	O
nutritive	O
'	O
genes	B-SO
in	O
E7	O
.	O
5	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
huntingtin	B-GGP
deficient	O
embryos	O
.	O

Consistent	O
with	O
a	O
previous	O
report	O
[	O
16	O
]	O
,	O
no	O
obvious	O
differences	O
were	O
found	O
in	O
the	O
expression	O
of	O
"	O
nutritive	O
"	O
genes	B-SO
(	O
Hnf4	B-GGP
,	O
Afp	B-GGP
,	O
Tfn	B-GGP
,	O
ApoAI	B-GGP
,	O
Apo	B-GGP
-	I-GGP
AIV	I-GGP
,	O
and	O
ApoB	B-GGP
)	O
or	O
genes	B-SO
involved	O
in	O
yolk	O
sac	O
hematopoiesis	O
or	O
vasculogenesis	O
(	O
Ttr	B-GGP
,	O
Rbp	B-GGP
,	O
Flt1	B-GGP
,	O
Flk1	B-GGP
,	O
Tal1	B-GGP
,	O
Rbtn2	B-GGP
,	O
GATA1	B-GGP
)	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
that	O
huntingtin	B-GGP
is	O
not	O
essential	O
for	O
the	O
proper	O
expression	O
of	O
genes	B-SO
required	O
for	O
the	O
nutritive	O
function	O
of	O
the	O
extraembryonic	O
tissues	O
.	O

To	O
investigate	O
huntingtin	B-GGP
'	O
s	O
developmental	O
activities	O
,	O
we	O
then	O
analyzed	O
the	O
expression	O
of	O
genes	B-SO
which	O
pattern	O
the	O
early	O
embryo	O
or	O
mark	O
morphogenic	O
landmarks	O
in	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
by	O
whole	O
mount	O
and	O
section	O
in	O
situ	O
hybridization	O
.	O

The	O
dissections	O
confirmed	O
previous	O
morphologic	O
data	O
at	O
E7	O
.	O
0	O
-	O
7	O
.	O
5	O
that	O
all	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
homozygotes	O
exhibit	O
abnormal	O
morphology	O
,	O
including	O
shortened	O
primitive	O
streak	O
and	O
a	O
lack	O
of	O
morphological	O
head	O
folds	O
or	O
node	O
[	O
10	O
,	O
13	O
]	O
.	O

The	O
results	O
of	O
in	O
situ	O
hybridization	O
analysis	O
also	O
confirmed	O
that	O
all	O
three	O
germ	O
layers	O
and	O
extraembryonic	O
tissue	O
are	O
formed	O
in	O
huntingtin	B-GGP
deficient	O
embryos	O
.	O

Otx2	B-GGP
,	O
normally	O
expressed	O
in	O
the	O
anterior	O
neuroectoderm	O
and	O
anterior	O
visceral	O
endoderm	O
[	O
19	O
]	O
,	O
is	O
expressed	O
in	O
mutant	B-SO
embryos	O
at	O
E7	O
.	O
5	O
(	O
Fig	O
.	O
1A	O
,	O
B	O
)	O
although	O
the	O
expression	O
domain	O
appears	O
reduced	O
.	O

Similarly	O
,	O
Hesx1	B-GGP
expression	O
is	O
grossly	O
normal	O
in	O
mutant	B-SO
embryos	O
,	O
with	O
expression	O
localized	O
to	O
the	O
AVE	O
and	O
neuroectoderm	O
(	O
Fig	O
.	O
1C	O
-	O
F	O
,	O
[	O
20	O
]	O
)	O
,	O
although	O
the	O
expression	O
domain	O
also	O
appears	O
reduced	O
.	O

These	O
results	O
indicate	O
appropriate	O
specification	O
and	O
movement	O
of	O
anterior	O
visceral	O
endoderm	B-CL
(	I-CL
AVE	I-CL
)	I-CL
cells	I-CL
from	O
the	O
distal	O
tip	O
and	O
suggest	O
that	O
neuroectoderm	O
is	O
induced	O
in	O
the	O
mutant	B-SO
embryos	O
.	O

Figure	O
1	O

AVE	O
displacement	O
and	O
anterior	O
neurectoderm	O
induction	O
occur	O
normally	O
in	O
the	O
absence	O
of	O
huntingtin	B-GGP
.	O

Whole	O
mount	O
in	O
situ	O
hybridization	O
analysis	O
of	O
Otx2	B-GGP
(	O
A	O
,	O
B	O
)	O
and	O
Hesx	B-GGP
(	O
C	O
-	O
F	O
)	O
in	O
E7	O
.	O
5	O
normal	O
(	O
A	O
,	O
C	O
,	O
E	O
)	O
and	O
mutant	B-SO
(	O
B	O
,	O
D	O
,	O
F	O
)	O
embryos	O
reveals	O
that	O
neuroectoderm	O
and	O
anterior	O
visceral	O
endoderm	O
(	O
AVE	O
)	O
develop	O
normally	O
in	O
huntingtin	B-GGP
deficient	O
embryos	O
,	O
although	O
the	O
neuroectoderm	O
expression	O
domain	O
is	O
reduced	O
.	O

Asymmetrical	O
expression	O
of	O
Hesx	B-GGP
in	O
mutant	B-SO
embryos	O
(	O
F	O
)	O
suggests	O
that	O
left	O
-	O
right	O
transcriptional	O
control	O
is	O
maintained	O
.	O

Hnf3	B-GGP
beta	I-GGP
expression	O
in	O
the	O
definitive	O
endoderm	O
extends	O
around	O
the	O
distal	O
tip	O
and	O
is	O
reduced	O
in	O
the	O
AVE	O
(	O
*	O
)	O
in	O
both	O
normal	O
(	O
G	O
,	O
I	O
)	O
and	O
mutant	B-SO
embryos	O
(	O
H	O
,	O
J	O
)	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
normal	O
ectoderm	O
and	O
endoderm	O
induction	O
and	O
localization	O
in	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
.	O

Embryos	O
are	O
shown	O
in	O
lateral	O
views	O
,	O
with	O
anterior	O
to	O
the	O
left	O
in	O
all	O
pictures	O
with	O
the	O
exception	O
of	O
E	O
and	O
F	O
.	O

Embryos	O
are	O
viewed	O
from	O
the	O
anterior	O
aspect	O
in	O
E	O
and	O
F	O
.	O

To	O
examine	O
definitive	O
endoderm	O
formation	O
,	O
the	O
expression	O
of	O
Hnf3	B-GGP
beta	I-GGP
(	O
FoxA2	B-GGP
)	O
in	O
mutant	B-SO
and	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
was	O
analyzed	O
.	O

In	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
,	O
Hnf3	B-GGP
beta	I-GGP
expression	O
is	O
confined	O
to	O
the	O
node	O
and	O
anterior	O
definitive	O
endoderm	O
(	O
Fig	O
.	O
1G	O
,	O
I	O
[	O
21	O
]	O
)	O
.	O

Mutant	B-SO
embryos	O
exhibit	O
Hnf3	B-GGP
beta	I-GGP
-	O
reactive	O
definitive	O
endoderm	O
over	O
the	O
disorganized	O
anterior	O
streak	O
region	O
and	O
proceeding	O
rostrally	O
around	O
the	O
distal	O
tip	O
(	O
Fig	O
.	O
1H	O
,	O
J	O
)	O
.	O

In	O
both	O
normal	O
and	O
mutant	B-SO
embryos	O
,	O
the	O
AVE	O
exhibits	O
little	O
Hnf3	B-GGP
beta	I-GGP
expression	O
.	O

Therefore	O
,	O
huntingtin	B-GGP
deficiency	O
does	O
not	O
greatly	O
affect	O
Hnf3	B-GGP
beta	I-GGP
regulation	O
or	O
the	O
reorganization	O
of	O
the	O
visceral	O
endoderm	O
.	O

The	O
lack	O
of	O
a	O
morphological	O
node	O
and	O
presence	O
of	O
a	O
shortened	O
streak	O
,	O
together	O
with	O
reduced	O
neuroectoderm	O
and	O
lack	O
of	O
headfolds	O
,	O
suggest	O
that	O
anterior	O
streak	O
formation	O
may	O
be	O
impaired	O
in	O
huntingtin	B-GGP
deficient	O
embryos	O
.	O

To	O
investigate	O
this	O
possibility	O
,	O
we	O
examined	O
mesoderm	O
formation	O
in	O
mutant	B-SO
embryos	O
.	O

Mesoderm	O
is	O
specified	O
in	O
the	O
mutant	B-SO
embryos	O
,	O
as	O
marked	O
by	O
the	O
expression	O
of	O
T	B-GGP
(	O
Brachyury	B-GGP
)	O
and	O
Evx1	B-GGP
(	O
Fig	O
.	O
2A	O
-	O
F	O
)	O
.	O

However	O
,	O
close	O
inspection	O
of	O
the	O
data	O
reveals	O
abnormal	O
patterning	O
within	O
this	O
tissue	O
and	O
its	O
derivatives	O
.	O
T	B-GGP
,	O
normally	O
expressed	O
in	O
the	O
primitive	O
streak	O
,	O
node	O
and	O
axial	O
head	O
process	O
/	O
notochord	O
mesoderm	O
[	O
22	O
]	O
,	O
is	O
detected	O
in	O
the	O
shortened	O
streak	O
and	O
axial	O
mesoderm	O
in	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
,	O
extending	O
rostrally	O
from	O
a	O
region	O
of	O
weakly	O
positive	O
cells	B-CL
(	O
Fig	O
.	O
2A	O
,	O
B	O
)	O
.	O

T	B-GGP
expression	O
appears	O
weaker	O
,	O
however	O
,	O
in	O
the	O
anterior	O
streak	O
,	O
corresponding	O
to	O
cells	B-CL
that	O
will	O
give	O
rise	O
to	O
axial	O
mesoderm	O
(	O
Fig	O
.	O
2D	O
)	O
.	O

T	B-GGP
is	O
also	O
ectopically	O
expressed	O
in	O
mutant	B-SO
extraembryonic	O
mesoderm	O
at	O
the	O
anterior	O
embryonic	O
junction	O
and	O
along	O
the	O
chorion	O
(	O
Fig	O
.	O
2B	O
,	O
D	O
)	O
.	O

Similarly	O
,	O
Evx1	B-GGP
,	O
normally	O
expressed	O
in	O
primitive	O
streak	O
mesoderm	O
at	O
E7	O
.	O
5	O
with	O
highest	O
levels	O
in	O
proximal	O
cells	B-CL
[	O
23	O
]	O
,	O
is	O
expressed	O
in	O
the	O
proximal	O
shortened	O
streak	O
but	O
is	O
also	O
aberrantly	O
expressed	O
throughout	O
the	O
extraembryonic	O
mesoderm	O
,	O
allantois	O
and	O
chorion	O
(	O
Fig	O
.	O
2E	O
,	O
F	O
)	O
.	O

Extraembryonic	O
mesoderm	O
,	O
derived	O
from	O
the	O
proximal	O
streak	O
,	O
does	O
not	O
normally	O
express	O
T	B-GGP
or	O
Evx1	B-GGP
in	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
[	O
22	O
]	O
.	O

Therefore	O
,	O
the	O
inappropriate	O
expression	O
of	O
T	B-GGP
and	O
Evx1	B-GGP
,	O
the	O
shortened	O
primitive	O
streak	O
,	O
and	O
the	O
absence	O
of	O
a	O
morphological	O
node	O
,	O
all	O
suggest	O
that	O
the	O
anterior	O
primitive	O
streak	O
is	O
deficient	O
in	O
the	O
mutant	B-SO
embryos	O
.	O

Figure	O
2	O

Huntingtin	B-GGP
is	O
required	O
for	O
formation	O
of	O
anterior	O
primitive	O
streak	O
and	O
paraxial	O
mesoderm	O
.	O

Whole	O
mount	O
and	O
section	O
insitu	O
hybridizations	O
of	O
E7	O
.	O
5	O
embryos	O
shows	O
T	B-GGP
(	O
Brachyury	B-GGP
)	O
(	O
A	O
-	O
D	O
)	O
is	O
expressed	O
in	O
the	O
primitive	O
streak	O
,	O
node	O
,	O
axial	O
mesoderm	O
and	O
Evx1	B-GGP
(	O
E	O
-	O
F	O
)	O
is	O
expressed	O
in	O
the	O
primitive	O
streak	O
,	O
most	O
strongly	O
in	O
the	O
proximal	O
streak	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
.	O

However	O
,	O
in	O
mutant	B-SO
embryos	O
,	O
both	O
T	B-GGP
(	O
B	O
,	O
D	O
)	O
and	O
Evx1	B-GGP
(	O
F	O
)	O
are	O
ectopically	O
expressed	O
in	O
the	O
extraembryonic	O
region	O
.	O

Wnt3A	B-GGP
expression	O
is	O
reduced	O
in	O
mutant	B-SO
embryos	O
(	O
H	O
)	O
,	O
although	O
the	O
localization	O
of	O
its	O
expression	O
to	O
the	O
proximal	O
streak	O
is	O
the	O
same	O
as	O
in	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
(	O
G	O
)	O
.	O

Analysis	O
of	O
paraxial	O
mesoderm	O
markers	O
Tbx6	B-GGP
(	O
I	O
,	O
J	O
)	O
and	O
Dll1	B-GGP
(	O
K	O
,	O
L	O
)	O
,	O
reveals	O
that	O
these	O
markers	O
are	O
reduced	O
in	O
mutant	B-SO
embryos	O
(	O
J	O
,	O
L	O
)	O
,	O
suggesting	O
impaired	O
paraxial	O
mesoderm	O
production	O
in	O
the	O
absence	O
of	O
huntingtin	B-GGP
.	O

Embryos	O
in	O
A	O
-	O
H	O
are	O
shown	O
in	O
a	O
lateral	O
view	O
with	O
anterior	O
oriented	O
to	O
the	O
left	O
.	O

Embryos	O
in	O
I	O
-	O
L	O
are	O
shown	O
in	O
a	O
posterior	O
view	O
(	O
I	O
,	O
K	O
)	O
or	O
near	O
posterior	O
(	O
J	O
,	O
L	O
)	O
view	O
with	O
proximal	O
oriented	O
toward	O
the	O
top	O
.	O

In	O
(	O
C	O
,	O
D	O
)	O
,	O
al	O
=	O
allantois	O
,	O
a	O
=	O
amnion	O
,	O
ch	O
=	O
chorion	O
,	O
ee	O
=	O
embryonic	O
node	O
(	O
N	O
)	O
,	O
em	O
=	O
extraembryonic	O
mesoderm	O
,	O
n	O
=	O
node	O
,	O
ps	O
=	O
primitive	O
streak	O
.	O

Rather	O
than	O
a	O
node	O
,	O
mutant	B-SO
embryos	O
exhibit	O
a	O
region	O
of	O
disorganized	O
cells	B-CL
(	O
*	O
)	O
at	O
the	O
distal	O
extent	O
of	O
the	O
short	O
primitive	O
streak	O
.	O

The	O
anterior	O
streak	O
generates	O
paraxial	O
mesoderm	O
.	O

Therefore	O
we	O
examined	O
paraxial	O
mesoderm	O
formation	O
in	O
wild	B-SO
-	I-SO
type	I-SO
and	O
mutant	B-SO
embryos	O
,	O
revealing	O
deficits	O
in	O
mesoderm	O
patterning	O
.	O

Starting	O
at	O
E	O
.	O
7	O
.	O
5	O
,	O
Wnt3A	B-GGP
is	O
expressed	O
in	O
the	O
primitive	O
streak	O
in	O
cells	B-CL
fated	O
to	O
become	O
paraxial	O
mesoderm	O
.	O

In	O
huntingtin	B-GGP
deficient	O
mutants	B-SO
,	O
Wnt3a	B-GGP
is	O
induced	O
in	O
the	O
proximal	O
streak	O
(	O
Fig	O
.	O
2G	O
,	O
H	O
)	O
,	O
confirming	O
stage	O
appropriate	O
posterior	O
development	O
,	O
in	O
contrast	O
to	O
the	O
absence	O
of	O
anterior	O
head	O
folds	O
.	O

However	O
,	O
expression	O
of	O
Wnt3a	B-GGP
is	O
noticeably	O
reduced	O
in	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
,	O
suggesting	O
a	O
defect	O
in	O
paraxial	O
mesoderm	O
development	O
(	O
Fig	O
.	O
2H	O
)	O
.	O

Reduced	O
expression	O
of	O
Tbx6	B-GGP
in	O
the	O
mesoderm	O
lateral	O
to	O
the	O
primitive	O
streak	O
in	O
mutant	B-SO
embryos	O
confirms	O
this	O
interpretation	O
(	O
Fig	O
.	O
2I	O
,	O
J	O
)	O
.	O

Furthermore	O
,	O
in	O
mutant	B-SO
embryos	O
at	O
E7	O
.	O
5	O
,	O
the	O
expression	O
of	O
Dll1	B-GGP
in	O
the	O
distal	O
streak	O
region	O
and	O
in	O
only	O
a	O
narrow	O
swath	O
of	O
cells	B-CL
located	O
laterally	O
confirms	O
the	O
paucity	O
of	O
paraxial	O
mesoderm	O
(	O
Fig	O
.	O
2K	O
,	O
L	O
,	O
[	O
24	O
]	O
)	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
anterior	O
primitive	O
streak	O
formation	O
is	O
impaired	O
,	O
resulting	O
in	O
reduced	O
axial	O
and	O
paraxial	O
mesoderm	O
formation	O
and	O
impaired	O
neural	O
development	O
.	O

Impaired	O
regional	O
restriction	O
of	O
growth	O
factor	O
expression	O
in	O
the	O
absence	O
of	O
huntingtin	B-GGP

To	O
elucidate	O
the	O
apparent	O
patterning	O
deficits	O
,	O
we	O
next	O
analyzed	O
signaling	O
molecules	B-CHEBI
that	O
are	O
required	O
for	O
early	O
patterning	O
.	O

Nodal	B-GGP
,	O
a	O
member	O
of	O
the	O
Tgf	B-GGP
beta	I-GGP
family	O
of	O
secreted	O
molecules	B-CHEBI
is	O
required	O
for	O
the	O
formation	O
and	O
maintenance	O
of	O
the	O
primitive	O
streak	O
and	O
induction	O
of	O
the	O
AVE	O
[	O
25	O
-	O
27	O
]	O
.	O

Nodal	B-GGP
is	O
normally	O
expressed	O
throughout	O
the	O
epiblast	O
and	O
overlying	O
visceral	O
endoderm	O
at	O
early	O
post	O
implantation	O
stages	O
[	O
28	O
]	O
,	O
but	O
later	O
becomes	O
restricted	O
to	O
the	O
posterior	O
of	O
the	O
embryo	O
to	O
the	O
site	O
of	O
primitive	O
streak	O
with	O
asymmetrical	O
visceral	O
endoderm	O
expression	O
marking	O
the	O
left	O
-	O
right	O
axis	O
.	O

By	O
E7	O
.	O
5	O
,	O
Nodal	B-GGP
expression	O
is	O
restricted	O
to	O
the	O
node	O
.	O

Nodal	B-GGP
expression	O
was	O
assessed	O
in	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
heterozygous	O
for	O
the	O
Ndl	B-GGP
lac	O
Z	O
allele	B-SO
[	O
28	O
,	O
29	O
]	O
.	O

Notably	O
,	O
heterozygous	O
loss	O
of	O
nodal	B-GGP
does	O
not	O
alter	O
the	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
phenotype	O
,	O
as	O
determined	O
by	O
morphology	O
of	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
:	O
Ndllacz	O
/	O
Ndl	B-GGP
+	O
embryos	O
compared	O
with	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
contrast	O
to	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
,	O
which	O
exhibit	O
tight	O
restriction	O
of	O
Nodal	B-GGP
.	O
LacZ	O
expression	O
to	O
the	O
node	O
,	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
:	O
Ndllacz	O
/	O
Ndl	B-GGP
+	O
embryos	O
express	O
Nodal	B-GGP
.	O
LacZ	O
throughout	O
the	O
endoderm	O
overlying	O
the	O
epiblast	O
,	O
with	O
higher	O
levels	O
in	O
the	O
posterior	O
in	O
an	O
asymmetric	O
pattern	O
(	O
Fig	O
.	O
3A	O
-	O
D	O
)	O
.	O

The	O
lack	O
of	O
tight	O
restriction	O
of	O
nodal	B-GGP
signal	O
is	O
consistent	O
with	O
a	O
failure	O
to	O
form	O
an	O
organized	O
node	O
structure	O
.	O

Figure	O
3	O

Impaired	O
regional	O
restriction	O
of	O
gene	B-SO
expression	O
in	O
huntingtin	B-GGP
deficient	O
embryos	O
.	O

X	O
-	O
gal	O
staining	O
of	O
Nodal	B-GGP
-	O
LacZ	O
embryos	O
shows	O
staining	O
in	O
endoderm	O
near	O
the	O
node	O
of	O
normal	O
embryos	O
(	O
A	O
,	O
C	O
)	O
but	O
broad	O
staining	O
in	O
mutant	B-SO
embryos	O
(	O
B	O
,	O
D	O
)	O
,	O
although	O
expression	O
is	O
higher	O
in	O
the	O
posterior	O
.	O

The	O
tight	O
node	O
expression	O
of	O
Nodal	B-GGP
in	O
normal	O
embryos	O
(	O
C	O
)	O
is	O
lost	O
in	O
mutant	B-SO
embryos	O
(	O
D	O
)	O
,	O
consistent	O
with	O
the	O
loss	O
of	O
a	O
morphological	O
node	O
in	O
the	O
absence	O
of	O
huntingtin	B-GGP
.	O

Whole	O
mount	O
and	O
in	O
situ	O
hybridization	O
of	O
E7	O
.	O
5	O
day	O
embryos	O
reveals	O
that	O
Fgf8	B-GGP
is	O
detected	O
in	O
the	O
proximal	O
streak	O
and	O
is	O
downregulated	O
in	O
cells	B-CL
migrating	O
out	O
of	O
the	O
streak	O
in	O
normal	O
embryos	O
(	O
E	O
,	O
G	O
)	O
.	O

In	O
contrast	O
,	O
Fgf8	B-GGP
remains	O
highly	O
expressed	O
in	O
mutant	B-SO
embryos	O
(	O
F	O
,	O
H	O
)	O
.	O

Transient	O
expression	O
of	O
Gsc	B-GGP
in	O
the	O
definitive	O
endoderm	O
overlying	O
the	O
prospective	O
head	O
region	O
in	O
normal	O
embryos	O
(	O
I	O
,	O
K	O
)	O
is	O
distinguished	O
in	O
other	O
cell	B-CL
layers	O
in	O
normal	O
embryos	O
but	O
remains	O
unrestricted	O
in	O
mutant	B-SO
embryos	O
(	O
J	O
,	O
L	O
)	O
.	O

Earlier	O
posterior	O
expression	O
of	O
Gsc	B-GGP
is	O
also	O
maintained	O
in	O
mutant	B-SO
embryos	O
(	O
J	O
)	O
while	O
it	O
is	O
down	O
-	O
regulated	O
in	O
normal	O
embryos	O
(	O
I	O
)	O
.	O

Embryos	O
(	O
A	O
,	O
B	O
,	O
E	O
,	O
F	O
,	O
G	O
,	O
H	O
,	O
I	O
,	O
K	O
,	O
L	O
)	O
are	O
shown	O
in	O
a	O
lateral	O
view	O
with	O
anterior	O
oriented	O
to	O
the	O
left	O
.	O

Embryos	O
(	O
C	O
,	O
D	O
)	O
are	O
in	O
a	O
posterior	O
view	O
.	O

Fgf8	B-GGP
signaling	O
is	O
also	O
essential	O
for	O
normal	O
gastrulation	O
in	O
the	O
mouse	B-Taxon
embryo	O
.	O

Fgf8	B-GGP
is	O
required	O
for	O
cell	B-CL
migration	O
away	O
from	O
the	O
primitive	O
streak	O
[	O
30	O
]	O
.	O

Expressed	O
just	O
prior	O
to	O
streak	O
formation	O
in	O
the	O
posterior	O
epiblast	O
and	O
visceral	O
endoderm	O
,	O
Fgf8	B-GGP
is	O
restricted	O
to	O
the	O
streak	O
mesoderm	O
at	O
E7	O
.	O
5	O
in	O
a	O
decreasing	O
proximal	O
-	O
distal	O
gradient	O
and	O
is	O
downregulated	O
in	O
cells	B-CL
shortly	O
after	O
they	O
exit	O
the	O
streak	O
(	O
Fig	O
.	O
3E	O
,	O
G	O
)	O
.	O

In	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
,	O
Fgf8	B-GGP
expression	O
is	O
strongly	O
expressed	O
in	O
the	O
posterior	O
region	O
in	O
the	O
primitive	O
streak	O
and	O
ectopically	O
in	O
the	O
endoderm	O
overlying	O
the	O
entire	O
epiblast	O
(	O
Fig	O
.	O
3F	O
,	O
H	O
)	O
.	O

However	O
,	O
streak	O
derivatives	O
appear	O
to	O
migrate	O
normally	O
as	O
evidenced	O
by	O
the	O
proper	O
anterior	O
expression	O
of	O
markers	O
such	O
as	O
Otx2	B-GGP
,	O
Hnf3	B-GGP
beta	I-GGP
and	O
Hesx1	B-GGP
anteriorly	O
(	O
Fig	O
.	O
1	O
)	O
.	O

Therefore	O
,	O
mutant	B-SO
embryos	O
exhibit	O
normal	O
migration	O
of	O
streak	O
derivatives	O
but	O
display	O
impaired	O
Fgf8	B-GGP
repression	O
in	O
mutant	B-SO
endoderm	O
.	O

Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
also	O
fail	O
to	O
restrict	O
the	O
expression	O
of	O
goosecoid	B-GGP
(	O
Gsc	B-GGP
)	O
.	O

Normally	O
,	O
Gsc	B-GGP
is	O
initially	O
expressed	O
in	O
the	O
visceral	O
endoderm	O
and	O
proximal	O
,	O
posterior	O
streak	O
where	O
the	O
primitive	O
streak	O
will	O
form	O
prior	O
to	O
gastrulation	O
.	O

As	O
the	O
primitive	O
streak	O
forms	O
and	O
extends	O
,	O
Gsc	B-GGP
is	O
expressed	O
in	O
the	O
distal	O
streak	O
,	O
the	O
node	O
,	O
and	O
the	O
axial	O
mesoderm	O
extending	O
anteriorly	O
from	O
the	O
node	O
(	O
Fig	O
.	O
3I	O
,	O
K	O
,	O
[	O
31	O
,	O
32	O
]	O
)	O
.	O

However	O
,	O
in	O
the	O
mutant	B-SO
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
,	O
high	O
levels	O
of	O
Gsc	B-GGP
expression	O
remain	O
unrestricted	O
in	O
the	O
endoderm	O
overlying	O
the	O
entire	O
embryo	O
and	O
ectopically	O
in	O
cells	B-CL
adjacent	O
to	O
the	O
ectoplacental	O
cone	O
(	O
Fig	O
.	O
3J	O
,	O
L	O
)	O
.	O

These	O
results	O
suggest	O
that	O
,	O
in	O
contrast	O
to	O
proper	O
Hnf3	B-GGP
beta	I-GGP
regulation	O
,	O
Gsc	B-GGP
remains	O
inappropriately	O
activated	O
in	O
mutant	B-SO
visceral	O
and	O
definitive	O
endoderm	O
,	O
implicating	O
huntingtin	B-GGP
in	O
the	O
proper	O
restriction	O
of	O
this	O
homeodomain	O
transcription	O
factor	O
.	O

Huntingtin	B-GGP
is	O
not	O
required	O
for	O
expression	O
of	O
extraembryonic	O
signaling	O
molecules	B-CHEBI

Previous	O
studies	O
of	O
chimeric	O
embryos	O
suggest	O
that	O
huntingtin	B-GGP
is	O
required	O
only	O
in	O
the	O
extraembryonic	O
tissue	O
for	O
proper	O
development	O
[	O
16	O
]	O
.	O

Signals	O
from	O
the	O
extraembryonic	O
tissue	O
are	O
critical	O
for	O
the	O
induction	O
of	O
embryonic	O
signals	O
and	O
for	O
patterning	O
the	O
epiblast	O
.	O

Consequently	O
,	O
we	O
examined	O
extraembryonic	O
development	O
in	O
huntingtin	B-GGP
deficient	O
embryos	O
.	O

Hnf4	B-GGP
is	O
a	O
transcription	O
factor	O
expressed	O
in	O
the	O
primitive	O
endoderm	O
as	O
soon	O
as	O
this	O
tissue	O
becomes	O
distinct	O
and	O
is	O
a	O
key	O
regulator	O
of	O
visceral	O
endoderm	O
secreted	O
factors	O
such	O
as	O
alphafetoprotein	B-GGP
,	O
apolipoproteins	B-CHEBI
,	O
and	O
transferrin	B-GGP
.	O

Inactivation	O
of	O
Hnf4	B-GGP
results	O
in	O
impaired	O
gastrulation	O
[	O
33	O
,	O
34	O
]	O
.	O

At	O
E7	O
.	O
5	O
,	O
Hnf4	B-GGP
is	O
expressed	O
in	O
the	O
columnar	O
visceral	O
endoderm	B-CL
cells	I-CL
at	O
the	O
extraembryonic	O
-	O
ectoderm	O
junction	O
(	O
Fig	O
.	O
4A	O
,	O
[	O
33	O
]	O
)	O
.	O

In	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
,	O
consistent	O
with	O
normal	O
primitive	O
and	O
visceral	O
endoderm	O
differentiation	O
,	O
Hnf4	B-GGP
expression	O
appears	O
normal	O
,	O
although	O
the	O
signal	O
is	O
stronger	O
in	O
mutant	B-SO
embryos	O
compared	O
to	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
(	O
Fig	O
.	O
4B	O
)	O
.	O

Similarly	O
,	O
Pem	B-GGP
,	O
a	O
transcription	O
factor	O
expressed	O
in	O
proximal	O
visceral	O
endoderm	O
and	O
ectoplacental	O
cone	O
in	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
at	O
E7	O
.	O
5	O
,	O
also	O
is	O
expressed	O
in	O
these	O
tissues	O
in	O
the	O
mutant	B-SO
embryos	O
(	O
Fig	O
.	O
4C	O
,	O
D	O
[	O
35	O
]	O
)	O
.	O

However	O
,	O
Pem	B-GGP
expressing	O
visceral	O
endoderm	O
hangs	O
over	O
the	O
anterior	O
of	O
the	O
mutant	B-SO
embryos	O
,	O
revealing	O
abnormal	O
location	O
despite	O
grossly	O
normal	O
differentiation	O
.	O

Figure	O
4	O

Normal	O
expression	O
of	O
extraembryonic	O
markers	O
in	O
huntingtin	B-GGP
deficient	O
embryos	O
.	O

Whole	O
mount	O
in	O
situ	O
hybridization	O
analysis	O
at	O
E7	O
.	O
5	O
of	O
markers	O
of	O
the	O
extraembryonic	O
tissues	O
reveals	O
grossly	O
normal	O
expression	O
in	O
the	O
absence	O
of	O
huntingtin	B-GGP
.	O

Hnf4	B-GGP
,	O
expressed	O
in	O
the	O
visceral	O
endoderm	O
at	O
the	O
junction	O
of	O
embryonic	O
-	O
ectoderm	O
junction	O
(	O
A	O
)	O
,	O
is	O
normal	O
in	O
mutant	B-SO
embryos	O
,	O
although	O
the	O
signal	O
is	O
slightly	O
higher	O
(	O
B	O
)	O
.	O

Similarly	O
,	O
the	O
expression	O
of	O
Pem	B-GGP
transcripts	B-SO
is	O
maintained	O
in	O
mutant	B-SO
embryos	O
(	O
D	O
)	O
similar	O
to	O
normal	O
embryos	O
(	O
C	O
)	O
,	O
although	O
Pem	B-GGP
is	O
expressed	O
in	O
the	O
abnormal	O
lopsided	O
overhang	O
of	O
visceral	O
endoderm	O
over	O
the	O
anterior	O
of	O
the	O
mutant	B-SO
embryos	O
.	O

Expression	O
of	O
extraembryonic	O
signaling	O
molecules	B-CHEBI
is	O
unaffected	O
by	O
the	O
loss	O
of	O
huntingtin	B-GGP
,	O
as	O
evidenced	O
by	O
the	O
expression	O
of	O
Bmp4	B-GGP
(	O
E	O
,	O
F	O
)	O
in	O
the	O
extraembryonic	O
ectoderm	O
,	O
and	O
Lefty1	B-GGP
and	O
Dkk1	B-GGP
(	O
I	O
-	O
L	O
)	O
in	O
the	O
AVE	O
in	O
mutant	B-SO
embryos	O
.	O

Bmp4	B-GGP
is	O
not	O
localized	O
,	O
however	O
,	O
to	O
a	O
ring	O
of	O
extraembryonic	O
ectoderm	O
in	O
mutant	B-SO
embryos	O
(	O
F	O
)	O
as	O
in	O
normal	O
embryos	O
(	O
E	O
)	O
.	O

Primitive	B-CL
germ	I-CL
cells	I-CL
(	I-CL
PCGs	I-CL
)	O
are	O
induced	O
normally	O
in	O
both	O
wild	B-SO
-	I-SO
type	I-SO
(	O
G	O
)	O
and	O
mutant	B-SO
embryos	O
(	O
H	O
)	O
,	O
suggesting	O
the	O
Bmp4	B-GGP
signaling	O
from	O
the	O
extraembryonic	O
ectoderm	O
to	O
the	O
epiblast	O
is	O
normal	O
.	O

Lefty1	B-GGP
expression	O
appears	O
disorganized	O
in	O
mutant	B-SO
embryos	O
(	O
I	O
)	O
compared	O
to	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
(	O
J	O
)	O
.	O

In	O
contrast	O
,	O
the	O
anterior	O
expression	O
of	O
Dkk1	B-GGP
in	O
the	O
AVE	O
in	O
mutant	B-SO
embryos	O
(	O
L	O
)	O
matches	O
the	O
wild	B-SO
-	I-SO
type	I-SO
expression	O
pattern	O
(	O
K	O
)	O
.	O

Despite	O
normal	O
AVE	O
formation	O
,	O
head	O
folds	O
fail	O
to	O
form	O
in	O
mutant	B-SO
embryos	O
,	O
even	O
when	O
cultured	O
in	O
nutrient	B-CHEBI
rich	O
media	O
for	O
24	O
hours	O
.	O

Wild	B-SO
-	I-SO
type	I-SO
E7	O
.	O
5	O
embryos	O
,	O
when	O
cultured	O
in	O
75	O
%	O
rat	B-Taxon
serum	O
,	O
develop	O
somites	O
(	O
M	O
)	O
,	O
heart	O
(	O
white	O
arrow	O
,	O
N	O
)	O
and	O
head	O
folds	O
(	O
blue	O
arrow	O
head	O
,	O
N	O
)	O
in	O
culture	O
.	O

In	O
contrast	O
,	O
huntingtin	B-GGP
deficient	O
embryos	O
continue	O
to	O
live	O
in	O
culture	O
but	O
do	O
not	O
form	O
headfolds	O
,	O
heart	O
or	O
somites	O
(	O
O	O
)	O
.	O

Embryos	O
are	O
shown	O
in	O
a	O
lateral	O
view	O
(	O
A	O
-	O
F	O
,	O
I	O
-	O
J	O
)	O
with	O
anterior	O
oriented	O
to	O
the	O
left	O
.	O

Embryos	O
in	O
(	O
G	O
,	O
H	O
,	O
K	O
,	O
L	O
)	O
are	O
shown	O
in	O
an	O
anterior	O
view	O
with	O
proximal	O
oriented	O
up	O
.	O

Signals	O
from	O
the	O
extraembryonic	O
tissues	O
,	O
including	O
the	O
anterior	O
visceral	O
endoderm	O
and	O
extraembryonic	O
ectoderm	O
are	O
required	O
for	O
proper	O
formation	O
and	O
patterning	O
of	O
the	O
epiblast	O
[	O
17	O
]	O
.	O

Bmp4	B-GGP
is	O
a	O
signaling	O
molecule	B-CHEBI
that	O
is	O
first	O
expressed	O
uniformly	O
throughout	O
the	O
extraembryonic	O
ectoderm	O
and	O
subsequently	O
is	O
localized	O
to	O
a	O
ring	O
of	O
extraembryonic	O
ectoderm	O
adjacent	O
to	O
the	O
epiblast	O
(	O
Fig	O
.	O
4E	O
,	O
[	O
36	O
]	O
)	O
.	O

A	O
key	O
factor	O
in	O
regulating	O
the	O
formation	O
of	O
the	O
node	O
and	O
primitive	O
streak	O
,	O
Bmp4	B-GGP
is	O
required	O
for	O
patterning	O
the	O
embryo	O
along	O
the	O
proximodistal	O
axis	O
[	O
37	O
-	O
40	O
]	O
.	O

In	O
the	O
absence	O
of	O
huntingtin	B-GGP
,	O
Bmp4	B-GGP
expression	O
is	O
properly	O
maintained	O
in	O
the	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
extraembryonic	O
ectoderm	O
but	O
is	O
also	O
expressed	O
throughout	O
the	O
extraembryonic	O
ectoderm	O
(	O
Fig	O
.	O
4F	O
)	O
in	O
a	O
pattern	O
that	O
is	O
similar	O
to	O
early	O
Bmp4	B-GGP
expression	O
rather	O
than	O
being	O
restricted	O
to	O
a	O
ring	O
of	O
extraembryonic	O
ectoderm	O
as	O
seen	O
in	O
the	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
To	O
assess	O
Bmp4	B-GGP
signaling	O
from	O
the	O
extraembryonic	O
ectoderm	O
,	O
we	O
evaluated	O
primordial	B-CL
germ	I-CL
cells	I-CL
(	O
PGCs	B-CL
)	O
,	O
which	O
require	O
Bmp4	B-GGP
for	O
their	O
induction	O
[	O
37	O
]	O
.	O

PGCs	B-CL
can	O
first	O
be	O
detected	O
at	O
E7	O
.	O
0	O
and	O
subsequently	O
underlie	O
the	O
posterior	O
portion	O
of	O
the	O
primitive	O
streak	O
.	O

Whole	O
mount	O
staining	O
of	O
E7	O
.	O
5	O
mutant	B-SO
and	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
for	O
alkaline	B-CHEBI
phosphatase	O
activity	O
reveals	O
that	O
PCGs	B-CL
form	O
in	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
,	O
suggesting	O
that	O
Bmp4	B-GGP
signaling	O
is	O
functional	O
in	O
the	O
absence	O
of	O
huntingtin	B-GGP
(	O
Fig	O
.	O
4G	O
,	O
H	O
)	O
.	O

The	O
anterior	O
visceral	O
endoderm	O
(	O
AVE	O
)	O
is	O
also	O
an	O
extraembryonic	O
source	O
of	O
signals	O
that	O
are	O
critical	O
for	O
early	O
patterning	O
.	O

Wnt	O
and	O
nodal	B-GGP
antagonists	O
,	O
Dkk1	B-GGP
(	O
mdkk	B-GGP
-	I-GGP
1	I-GGP
)	O
and	O
Lefty1	B-GGP
respectively	O
,	O
are	O
expressed	O
in	O
the	O
AVE	O
and	O
are	O
important	O
in	O
limiting	O
the	O
posteriorization	O
of	O
the	O
anterior	O
embryo	O
by	O
restricting	O
Nodal	B-GGP
and	O
Wnt	O
signaling	O
[	O
41	O
-	O
43	O
]	O
.	O

In	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
,	O
both	O
Dkk1	B-GGP
(	O
Fig	O
.	O
4I	O
,	O
J	O
)	O
and	O
Lefty1	B-GGP
(	O
Fig	O
.	O
4K	O
,	O
L	O
)	O
are	O
expressed	O
normally	O
in	O
the	O
AVE	O
as	O
compared	O
with	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
.	O

However	O
,	O
Dkk	B-GGP
-	I-GGP
1	I-GGP
levels	O
appear	O
to	O
be	O
slightly	O
increased	O
in	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
,	O
although	O
the	O
pattern	O
of	O
Dkk	B-GGP
-	I-GGP
1	I-GGP
expression	O
remains	O
unchanged	O
and	O
this	O
increase	O
may	O
just	O
reflect	O
the	O
same	O
amount	O
of	O
expression	O
in	O
a	O
smaller	O
area	O
.	O

Therefore	O
,	O
the	O
ectopic	O
expression	O
of	O
Nodal	B-GGP
(	O
Fig	O
.	O
3A	O
-	O
D	O
)	O
and	O
the	O
decreased	O
Wnt3a	B-GGP
expression	O
(	O
Fig	O
.	O
2H	O
)	O
in	O
mutant	B-SO
embryos	O
do	O
not	O
appear	O
to	O
be	O
result	O
of	O
changes	O
in	O
the	O
expression	O
pattern	O
of	O
Lefty1	B-GGP
or	O
Dkk1	B-GGP
.	O

Despite	O
normal	O
AVE	O
formation	O
and	O
neuroectoderm	O
induction	O
,	O
head	O
folds	O
do	O
not	O
form	O
in	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
.	O

Therefore	O
,	O
to	O
determine	O
whether	O
mutant	B-SO
embryos	O
are	O
inherently	O
capable	O
of	O
forming	O
head	O
folds	O
,	O
embryos	O
harvested	O
at	O
stage	O
E7	O
.	O
5	O
were	O
allowed	O
to	O
progress	O
in	O
rich	O
culture	O
medium	O
in	O
vitro	O
for	O
24	O
hours	O
.	O

Wild	B-SO
-	I-SO
type	I-SO
embryos	O
continued	O
to	O
develop	O
head	O
folds	O
,	O
somites	O
and	O
hearts	O
(	O
Fig	O
.	O
4M	O
,	O
N	O
)	O
.	O

In	O
contrast	O
,	O
mutant	B-SO
stage	O
7	O
.	O
5	O
embryos	O
did	O
not	O
develop	O
headfolds	O
,	O
hearts	O
or	O
somites	O
,	O
although	O
these	O
embryos	O
continued	O
to	O
live	O
(	O
Fig	O
.	O
4O	O
)	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
in	O
the	O
absence	O
of	O
huntingtin	B-GGP
,	O
embryos	O
are	O
unable	O
to	O
undergo	O
organogenesis	O
,	O
even	O
if	O
they	O
continue	O
to	O
live	O
past	O
E7	O
.	O
5	O
in	O
a	O
nutrient	B-CHEBI
rich	O
environment	O
.	O

Discussion	O

We	O
have	O
investigated	O
the	O
embryonic	O
processes	O
that	O
require	O
huntingtin	B-GGP
in	O
order	O
to	O
more	O
precisely	O
delineate	O
huntingtin	B-GGP
'	O
s	O
essential	O
molecular	B-CHEBI
and	O
cellular	B-CL
activities	O
and	O
to	O
provide	O
clues	O
to	O
the	O
mechanism	O
by	O
which	O
the	O
dominant	O
polyglutamine	O
expansion	O
mutation	B-SO
in	O
huntingtin	B-GGP
leads	O
to	O
HD	O
pathogenesis	O
.	O

In	O
pursuing	O
the	O
finding	O
that	O
huntingtin	B-GGP
is	O
needed	O
only	O
in	O
extraembryonic	O
tissues	O
for	O
normal	O
gastrulation	O
,	O
our	O
data	O
fail	O
to	O
provide	O
evidence	O
of	O
abnormal	O
nutritive	O
gene	B-SO
expression	O
in	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
.	O

Instead	O
,	O
our	O
results	O
reveal	O
that	O
huntingtin	B-GGP
is	O
required	O
for	O
normal	O
anterior	O
streak	O
formation	O
and	O
the	O
consequent	O
production	O
of	O
paraxial	O
mesoderm	O
,	O
with	O
a	O
previously	O
unrecognized	O
role	O
for	O
huntingtin	B-GGP
in	O
the	O
proper	O
extinction	O
of	O
transiently	O
and	O
/	O
or	O
dynamically	O
expressed	O
genes	B-SO
.	O

Indeed	O
,	O
the	O
hallmark	O
of	O
the	O
huntingtin	B-GGP
deficient	O
molecular	B-CHEBI
phenotype	O
is	O
the	O
impaired	O
down	O
-	O
regulation	O
of	O
a	O
subset	O
of	O
dynamically	O
expressed	O
genes	B-SO
,	O
after	O
the	O
proper	O
onset	O
of	O
expression	O
.	O

This	O
phenomenon	O
does	O
not	O
reflect	O
a	O
lack	O
of	O
anterior	O
/	O
posterior	O
axis	O
formation	O
,	O
as	O
evidenced	O
by	O
the	O
formation	O
of	O
the	O
AVE	O
anteriorly	O
and	O
the	O
primitive	O
streak	O
posteriorly	O
.	O

Nor	O
can	O
it	O
be	O
simply	O
explained	O
by	O
delayed	O
development	O
,	O
as	O
stage	O
-	O
specific	O
markers	O
,	O
such	O
as	O
Wnt3a	B-GGP
and	O
primordial	B-CL
germ	I-CL
cells	I-CL
,	O
which	O
are	O
detectable	O
at	O
E7	O
.	O
0	O
in	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
,	O
are	O
induced	O
appropriately	O
.	O

Furthermore	O
,	O
the	O
expression	O
of	O
T	B-GGP
and	O
Evx1	B-GGP
in	O
the	O
extraembryonic	O
mesoderm	O
of	O
mutant	B-SO
embryos	O
is	O
not	O
a	O
feature	O
of	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
,	O
even	O
at	O
earlier	O
stages	O
.	O

This	O
strongly	O
suggests	O
that	O
in	O
huntingtin	B-GGP
deficient	O
embryos	O
,	O
the	O
migration	O
of	O
the	O
distal	O
streak	O
derivatives	O
to	O
the	O
extraembryonic	O
mesoderm	O
occurs	O
normally	O
but	O
that	O
the	O
down	O
-	O
regulation	O
of	O
these	O
genes	B-SO
is	O
impaired	O
.	O

This	O
impairment	O
may	O
also	O
explain	O
the	O
failure	O
of	O
huntingtin	B-GGP
deficient	O
embryos	O
to	O
properly	O
restrict	O
the	O
expression	O
of	O
Fgf8	B-GGP
,	O
Nodal	B-GGP
and	O
Gsc	B-GGP
.	O

Thus	O
,	O
huntingtin	B-GGP
may	O
play	O
a	O
direct	O
role	O
in	O
the	O
transcriptional	O
regulation	O
,	O
or	O
mRNA	B-CHEBI
stability	O
of	O
these	O
genes	B-SO
or	O
it	O
may	O
act	O
indirectly	O
by	O
intersecting	O
with	O
other	O
pathways	O
that	O
regulate	O
the	O
expression	O
of	O
these	O
genes	B-SO
.	O

The	O
requirement	O
for	O
huntingtin	B-GGP
in	O
the	O
extraembryonic	O
tissues	O
had	O
prompted	O
us	O
to	O
test	O
whether	O
impaired	O
extraembryonic	O
signals	O
might	O
be	O
responsible	O
for	O
the	O
dysregulation	O
of	O
gene	B-SO
expression	O
within	O
the	O
epiblast	O
that	O
is	O
observed	O
in	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
.	O

Extraembryonic	O
development	O
in	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
is	O
associated	O
with	O
mildly	O
elevated	O
levels	O
expression	O
of	O
Hnf4	B-GGP
in	O
the	O
primitive	O
endoderm	O
and	O
Pem	B-GGP
in	O
the	O
lopsided	O
anterior	O
chorion	O
but	O
the	O
expression	O
of	O
other	O
known	B-SO
signals	O
,	O
such	O
as	O
Bmp4	B-GGP
from	O
the	O
extraembryonic	O
ectoderm	O
,	O
and	O
Dkk1	B-GGP
and	O
Lefty1	B-GGP
from	O
the	O
AVE	O
,	O
appear	O
to	O
be	O
normal	O
,	O
although	O
the	O
slight	O
increase	O
in	O
Dkk	B-GGP
-	I-GGP
1	I-GGP
expression	O
in	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
suggests	O
that	O
further	O
investigation	O
into	O
Wnt	O
signaling	O
is	O
warranted	O
.	O

Moreover	O
,	O
extraembryonic	O
Bmp4	B-GGP
signaling	O
is	O
not	O
impaired	O
in	O
the	O
absence	O
of	O
huntingtin	B-GGP
,	O
as	O
the	O
induction	O
of	O
PCGs	B-CL
in	O
mutant	B-SO
embryos	O
is	O
normal	O
,	O
implying	O
proper	O
transport	O
and	O
secretion	O
of	O
the	O
appropriate	O
extraembryonic	O
signals	O
.	O

However	O
,	O
Nodal	B-GGP
,	O
Fgf8	B-GGP
and	O
Gsc	B-GGP
are	O
expressed	O
ectopically	O
in	O
the	O
visceral	O
endoderm	O
of	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
.	O

Both	O
Nodal	B-GGP
and	O
Fgf8	B-GGP
,	O
important	O
growth	O
factors	O
required	O
for	O
normal	O
development	O
of	O
the	O
epiblast	O
,	O
are	O
tightly	O
regulated	O
during	O
gastrulation	O
.	O

Therefore	O
,	O
misexpression	O
of	O
either	O
or	O
both	O
of	O
these	O
factors	O
,	O
or	O
of	O
goosecoid	B-GGP
,	O
in	O
the	O
visceral	O
endoderm	O
could	O
contribute	O
to	O
the	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
mutant	B-SO
phenotype	O
.	O

In	O
addition	O
,	O
it	O
is	O
possible	O
that	O
other	O
extraembryonic	O
signal	O
(	O
s	O
)	O
that	O
we	O
have	O
not	O
analyzed	O
may	O
also	O
be	O
affected	O
by	O
the	O
lack	O
of	O
huntingtin	B-GGP
activity	O
in	O
extraembryonic	B-CL
cells	I-CL
in	O
mutant	B-SO
embryos	O
.	O

Huntingtin	B-GGP
deficient	O
embryos	O
also	O
fail	O
to	O
form	O
headfolds	O
,	O
and	O
to	O
undergo	O
organogenesis	O
,	O
even	O
after	O
culturing	O
in	O
nutrient	B-CHEBI
rich	O
media	O
.	O

The	O
absence	O
of	O
headfold	O
formation	O
in	O
these	O
embryos	O
does	O
not	O
appear	O
to	O
be	O
a	O
result	O
of	O
a	O
failure	O
to	O
induce	O
neurectoderm	O
or	O
a	O
failure	O
to	O
form	O
the	O
AVE	O
,	O
since	O
mutant	B-SO
embryos	O
express	O
markers	O
such	O
as	O
Otx2	B-GGP
,	O
Ddk1	B-GGP
,	O
Lefty1	B-GGP
and	O
Hesx1	B-GGP
.	O

In	O
addition	O
,	O
since	O
node	O
formation	O
is	O
not	O
required	O
for	O
neural	O
induction	O
[	O
44	O
-	O
46	O
]	O
,	O
the	O
failure	O
to	O
form	O
a	O
node	O
in	O
huntingtin	B-GGP
deficient	O
embryos	O
is	O
also	O
unlikely	O
to	O
explain	O
the	O
lack	O
of	O
headfolds	O
.	O

The	O
apparent	O
reduction	O
of	O
paraxial	O
mesoderm	O
in	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embryos	O
could	O
explain	O
the	O
lack	O
of	O
headfolds	O
since	O
paraxial	O
mesoderm	O
is	O
important	O
for	O
the	O
full	O
development	O
of	O
neuroectoderm	O
,	O
and	O
consequently	O
,	O
headfolds	O
.	O

Alternatively	O
,	O
the	O
inability	O
to	O
manifest	O
headfolds	O
could	O
suggest	O
that	O
huntingtin	B-GGP
is	O
required	O
at	O
a	O
very	O
early	O
stage	O
for	O
normal	O
CNS	O
development	O
.	O

This	O
conclusion	O
is	O
consistent	O
with	O
the	O
finding	O
that	O
severely	O
reduced	O
levels	O
of	O
huntingtin	B-GGP
,	O
from	O
a	O
hypomorphic	O
Hdh	B-GGP
allele	B-SO
,	O
lead	O
to	O
abnormal	O
brains	O
later	O
in	O
embryonic	O
development	O
[	O
15	O
]	O
.	O

The	O
cardinal	O
features	O
of	O
complete	O
Hdh	B-GGP
inactivation	O
that	O
we	O
observe	O
are	O
similar	O
to	O
the	O
phenotypes	O
that	O
stem	O
from	O
the	O
complete	O
inactivation	O
of	O
the	O
Polycomb	O
group	O
gene	B-SO
(	O
Pc	O
-	O
g	O
)	O
Eed	B-GGP
(	O
embryonic	B-GGP
ectoderm	I-GGP
development	I-GGP
)	O
.	O

Indeed	O
,	O
complete	O
deficiency	O
for	O
either	O
huntingtin	B-GGP
or	O
the	O
eed	B-GGP
protein	B-CHEBI
leads	O
to	O
abnormal	O
streak	O
development	O
,	O
lack	O
of	O
headfold	O
formation	O
,	O
ectopic	O
T	B-GGP
,	O
Evx1	B-GGP
and	O
Nodal	B-GGP
expression	O
and	O
disruption	O
of	O
anterior	O
primitive	O
streak	O
mesoderm	O
production	O
[	O
47	O
]	O
.	O

Interestingly	O
,	O
Eed	B-GGP
protein	B-CHEBI
is	O
also	O
required	O
for	O
proper	O
trophoblast	O
development	O
and	O
normal	O
maintenance	O
of	O
imprinted	O
X	B-GO
-	O
inactivation	O
and	O
genomic	B-SO
imprinting	O
[	O
47	O
-	O
49	O
]	O
,	O
suggesting	O
that	O
these	O
activities	O
warrant	O
investigation	O
in	O
huntingtin	B-GGP
deficient	O
embryos	O
.	O

Thus	O
,	O
our	O
observations	O
provide	O
unexpected	O
starting	O
-	O
points	O
in	O
the	O
search	O
for	O
huntingtin	B-GGP
'	O
s	O
precise	O
molecular	B-CHEBI
activities	O
,	O
which	O
began	O
with	O
the	O
discovery	O
that	O
this	O
HEAT	O
domain	B-SO
protein	B-CHEBI
hosts	O
the	O
dominant	O
polyglutamine	O
property	B-SO
that	O
is	O
the	O
fundamental	O
basis	O
of	O
HD	O
pathogenesis	O
.	O

In	O
HD	O
patients	O
and	O
in	O
accurate	O
genetic	B-SO
replicas	O
,	O
HD	B-GGP
CAG	O
knock	O
-	O
in	O
mice	B-Taxon
,	O
the	O
dominant	O
mutation	B-SO
specifically	O
affects	O
the	O
major	O
population	O
of	O
neurons	B-CL
in	O
the	O
striatum	O
,	O
without	O
impairing	O
huntingtin	B-GGP
'	O
s	O
essential	O
activities	O
in	O
embryonic	O
development	O
[	O
50	O
-	O
53	O
]	O
.	O

Indeed	O
,	O
homozygous	O
HD	O
patients	O
make	O
no	O
wild	B-SO
-	I-SO
type	I-SO
huntingtin	B-GGP
,	O
and	O
,	O
in	O
the	O
mouse	B-Taxon
,	O
a	O
single	O
mutant	B-SO
Hdh	B-GGP
allele	B-SO
'	O
s	O
worth	O
of	O
mutant	B-SO
huntingtin	B-GGP
can	O
fully	O
rescue	O
huntingtin	B-GGP
deficiency	O
embryonic	O
phenotypes	O
[	O
15	O
,	O
51	O
]	O
.	O

The	O
quest	O
to	O
understand	O
the	O
HD	O
mechanism	O
,	O
therefore	O
,	O
is	O
aimed	O
at	O
delineating	O
the	O
huntingtin	B-GGP
activity	O
that	O
may	O
explain	O
the	O
striatal	O
cell	B-CL
specificity	O
of	O
the	O
polyglutamine	O
mutant	B-SO
version	B-SO
of	O
huntingtin	B-GGP
.	O

One	O
hypothesis	O
is	O
that	O
huntingtin	B-GGP
is	O
normally	O
involved	O
in	O
gene	B-SO
transcription	O
,	O
as	O
proposed	O
for	O
NRSF	B-GGP
/	O
REST	B-GGP
mediated	O
BDNF	B-GGP
expression	O
[	O
54	O
]	O
.	O

Now	O
,	O
our	O
finding	O
that	O
huntingtin	B-GGP
can	O
be	O
absolutely	O
necessary	O
for	O
the	O
appropriate	O
regulation	O
of	O
genes	B-SO
with	O
dynamic	O
expression	O
patterns	O
in	O
vivo	O
,	O
provides	O
a	O
compelling	O
reason	O
to	O
elucidate	O
the	O
cellular	B-CL
machinery	O
that	O
is	O
necessary	O
for	O
huntingtin	B-GGP
mediated	O
gene	B-SO
regulation	O
.	O

Conclusion	O

Our	O
findings	O
indicate	O
that	O
huntingtin	B-GGP
is	O
required	O
for	O
proper	O
patterning	O
of	O
the	O
epiblast	O
during	O
early	O
embryogenesis	O
,	O
for	O
proper	O
anterior	O
streak	O
and	O
node	O
formation	O
,	O
primitive	O
streak	O
progression	O
,	O
paraxial	O
mesoderm	O
and	O
head	O
fold	O
formation	O
,	O
as	O
well	O
as	O
for	O
the	O
proper	O
restriction	O
of	O
transiently	O
expressed	O
growth	O
and	O
transcription	O
factor	O
genes	B-SO
.	O

Knowledge	O
of	O
the	O
molecular	B-CHEBI
basis	O
of	O
these	O
changes	O
in	O
huntingtin	B-GGP
deficient	O
embryos	O
should	O
facilitate	O
the	O
identification	O
of	O
the	O
cellular	B-CL
pathways	O
that	O
are	O
dependent	O
on	O
huntingtin	B-GGP
activities	O
.	O

These	O
will	O
be	O
important	O
for	O
implicating	O
candidates	O
to	O
be	O
assessed	O
in	O
the	O
extraembryonic	O
signals	O
that	O
determine	O
anterior	O
streak	O
progression	O
in	O
the	O
developing	O
embryo	O
and	O
in	O
delineating	O
the	O
dominant	O
activity	O
of	O
the	O
polyglutamine	O
tract	B-SO
in	O
huntingtin	B-GGP
that	O
determines	O
the	O
striatal	O
specificity	O
of	O
HD	O
.	O

Methods	O

Mice	B-Taxon
and	O
genotyping	O

The	O
Hdhex4	O
/	O
5	O
mice	B-Taxon
carrying	O
a	O
pGKneo	O
insertion	B-SO
/	O
replacement	B-SO
inactivating	O
mutation	B-SO
in	O
the	O
mouse	B-GGP
HD	I-GGP
gene	I-GGP
homologue	I-GGP
have	O
been	O
described	O
previously	O
[	O
10	O
]	O
.	O

The	O
experiments	O
were	O
conducted	O
in	O
accordance	O
with	O
an	O
IACUC	O
approved	O
protocol	O
,	O
through	O
the	O
MGH	O
Subcommittee	O
on	O
Animal	B-Taxon
Research	O
.	O

Mutant	B-SO
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
and	O
normal	O
littermates	O
were	O
obtained	O
in	O
timed	O
pregnancies	O
from	O
mating	O
of	O
Hdhex4	O
/	O
5	O
/	O
Hdh	B-GGP
+	O
heterozygotes	O
,	O
genotyped	O
by	O
PCR	O
assay	O
,	O
as	O
described	O
[	O
10	O
]	O
.	O

The	O
day	O
of	O
plug	O
was	O
taken	O
to	O
be	O
E0	O
.	O
5	O
.	O

Embryos	O
that	O
were	O
morphologically	O
normal	O
were	O
pooled	O
separately	O
from	O
morphologically	O
mutant	B-SO
embryos	O
for	O
analysis	O
.	O

Nodal	B-GGP
expression	O
was	O
determined	O
in	O
embryos	O
from	O
matings	O
of	O
Hdhex4	O
/	O
5	O
/	O
Hdh	B-GGP
+	O
;	O
NdllacZ	O
/	O
Ndl	B-GGP
+	O
compound	O
heterozygotes	O
genotyped	O
by	O
PCR	O
assay	O
as	O
described	O
in	O
[	O
29	O
]	O
.	O

Whole	O
mount	O
and	O
section	O
in	O
situ	O
hybridization	O
and	O
beta	O
-	O
gal	O
staining	O

After	O
dissection	O
in	O
PBS	O
,	O
embryos	O
were	O
fixed	O
overnight	O
in	O
4	O
%	O
paraformaldehyde	O
at	O
4	O
degrees	O
C	O
.	O

For	O
sections	O
,	O
decidua	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
,	O
were	O
embedded	O
in	O
paraffin	O
and	O
sectioned	O
at	O
7	O
microns	O
.	O

RNA	B-SO
in	O
situ	O
hybridizations	O
were	O
performed	O
as	O
described	O
previously	O
[	O
55	O
]	O
.	O

Nodal	B-GGP
.	O
lacZ	O
expression	O
was	O
assessed	O
by	O
beta	O
-	O
galactosidase	O
staining	O
as	O
reported	O
[	O
29	O
]	O
,	O
on	O
embryos	O
post	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
.	O

Embryos	O
were	O
mounted	O
in	O
80	O
%	O
glycerol	B-CHEBI
before	O
being	O
photographed	O
.	O

The	O
huntingtin	B-GGP
deficient	O
phenotype	O
is	O
fully	O
penetrant	O
at	O
each	O
of	O
the	O
stages	O
that	O
were	O
assessed	O
[	O
10	O
]	O
.	O

Three	O
to	O
six	O
embryos	O
were	O
evaluated	O
for	O
each	O
marker	O
,	O
with	O
every	O
embryo	O
exhibiting	O
the	O
same	O
mutant	B-SO
phenotype	O
in	O
each	O
case	O
.	O

Alkaline	B-CHEBI
phosphatase	O
staining	O
of	O
Primordial	B-CL
Germ	I-CL
Cells	I-CL
(	O
PCGs	B-CL
)	O

After	O
dissections	O
,	O
embryos	O
were	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
briefly	O
and	O
washed	O
and	O
stored	O
in	O
1	O
x	O
PBS	O
/	O
0	O
.	O
1	O
%	O
TX	O
-	O
100	O
at	O
4	O
degrees	O
C	O
.	O

Embryos	O
were	O
washed	O
once	O
with	O
Tris	B-CHEBI
-	O
Maleate	B-CHEBI
Buffer	O
(	O
25	O
mM	O
Tris	B-CHEBI
-	O
Maleate	B-CHEBI
,	O
pH	O
=	O
9	O
.	O
0	O
,	O
0	O
.	O
8	O
mM	O
MgCl2	B-CHEBI
)	O
and	O
were	O
subsequently	O
incubated	O
in	O
alkaline	B-CHEBI
phosphatase	O
staining	O
solution	O
(	O
25	O
mM	O
Tris	B-CHEBI
-	O
Maleate	B-CHEBI
,	O
pH	O
=	O
9	O
.	O
0	O
,	O
0	O
.	O
8	O
mM	O
MgCl2	B-CHEBI
,	O
0	O
.	O
4	O
mg	O
/	O
ml	O
alpha	O
-	O
naphthyl	B-CHEBI
phosphate	B-CHEBI
,	O
1	O
mg	O
/	O
ml	O
Fast	O
-	O
Red	O
)	O
.	O

Stained	O
embryos	O
were	O
washed	O
in	O
1	O
x	O
PBS	O
/	O
0	O
.	O
1	O
%	O
TX	O
-	O
100	O
.	O

Whole	O
embryo	O
culture	O

Embryos	O
were	O
dissected	O
at	O
E7	O
.	O
5	O
and	O
washed	O
in	O
DMEM	O
.	O

Embryos	O
were	O
then	O
cultured	O
individually	O
in	O
1	O
ml	O
of	O
culture	O
media	O
(	O
75	O
%	O
immediately	O
centrifuged	O
rat	B-Taxon
serum	O
and	O
25	O
%	O
DMEM	O
[	O
56	O
]	O
)	O
for	O
24	O
hours	O
while	O
rotating	O
in	O
a	O
37	O
degrees	O
C	O
incubator	O
in	O
5	O
%	O
CO2	B-CHEBI
.	O

Embryos	O
were	O
then	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
for	O
analysis	O
.	O

Abbreviations	O

AVE	O
,	O
anterior	O
visceral	O
endoderm	O
;	O
HD	B-GGP
,	O
Huntington	B-GGP
'	I-GGP
s	I-GGP
disease	I-GGP
gene	I-GGP
;	O
HD	O
,	O
Huntington	O
'	O
s	O
disease	O
;	O
Hdh	B-GGP
,	O
mouse	B-GGP
HD	I-GGP
gene	I-GGP
homologue	I-GGP
;	O
PCGs	B-CL
,	O
primordial	B-CL
germ	I-CL
cells	I-CL

Authors	O
'	O
contributions	O

JMW	O
,	O
TC	O
,	O
PH	O
-	O
M	O
and	O
MD	O
performed	O
whole	O
mount	O
and	O
in	O
situ	O
hybridization	O
assays	O
.	O

MEM	O
and	O
RC	O
contributed	O
to	O
the	O
conception	O
of	O
this	O
study	O
.	O

JMW	O
,	O
TC	O
,	O
PH	O
-	O
M	O
and	O
MEM	O
drafted	O
the	O
manuscript	O
and	O
RC	O
contributed	O
to	O
its	O
finalization	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Acknowledgements	O

We	O
are	O
grateful	O
to	O
Drs	O
.	O

A	O
.	O

Gossler	O
,	O
J	O
.	O

Darnell	O
,	O
Jr	O
.	O
,	O
J	O
Rossant	O
,	O
G	O
.	O

Keller	O
,	O
S	O
.	O

Orkin	O
,	O
G	O
.	O

Martin	O
,	O
T	O
.	O

Yamaguchi	O
,	O
A	O
.	O

McMahon	O
,	O
R	O
.	O

Maas	O
,	O
K	O
.	O
,	O
Muneoka	O
,	O
A	O
.	O

Simeone	O
,	O
Hamada	O
H	O
.	O
and	O
C	O
.	O

Niehrs	O
for	O
the	O
generous	O
gifts	O
of	O
clones	B-SO
and	O
antibody	B-GO
reagents	B-CHEBI
and	O
Dr	O
.	O
E	O
.	O

Robertson	O
for	O
NdllacZ	O
mice	B-Taxon
.	O

We	O
would	O
like	O
to	O
thank	O
Kathy	O
Molyneaux	O
for	O
her	O
helpful	O
suggestions	O
and	O
technical	O
assistance	O
.	O

We	O
also	O
thank	O
Vladimir	O
Vrbanac	O
,	O
Janice	O
Espinola	O
and	O
Edith	O
Toral	O
Lopez	O
for	O
assistance	O
with	O
animal	B-Taxon
husbandry	O
.	O

We	O
also	O
thank	O
the	O
members	O
of	O
the	O
MacDonald	O
lab	O
for	O
helpful	O
discussions	O
during	O
the	O
completion	O
of	O
this	O
work	O
.	O

This	O
work	O
was	O
supported	O
by	O
the	O
NINDS	O
grants	O
NS32765	O
and	O
NS16367	O
,	O
and	O
grants	O
from	O
the	O
Foundation	O
for	O
the	O
Care	O
and	O
Cure	O
of	O
Huntington	O
'	O
s	O
disease	O
and	O
with	O
the	O
support	O
of	O
the	O
Huntington	O
'	O
s	O
Disease	O
Society	O
of	O
America	O
Coalition	O
for	O
the	O
Cure	O
and	O
the	O
Hereditary	O
Disease	O
Foundation	O
.	O

Juliana	O
M	O
.	O
Woda	O
is	O
the	O
recipient	O
of	O
the	O
Milton	O
Wexler	O
Postdoctoral	O
Fellowship	O
from	O
the	O
Hereditary	O
Disease	O
Foundation	O
.	O

Diabetes	O
Insipidus	O
in	O
Mice	B-Taxon
with	O
a	O
Mutation	B-SO
in	O
Aquaporin	B-GGP
-	I-GGP
2	I-GGP

Abstract	O

Congenital	O
nephrogenic	O
diabetes	O
insipidus	O
(	O
NDI	O
)	O
is	O
a	O
disease	O
characterized	O
by	O
failure	O
of	O
the	O
kidney	O
to	O
concentrate	O
urine	O
in	O
response	O
to	O
vasopressin	B-GGP
.	O

Human	B-Taxon
kindreds	O
with	O
nephrogenic	O
diabetes	O
insipidus	O
have	O
been	O
found	O
to	O
harbor	O
mutations	B-SO
in	O
the	O
vasopressin	B-GGP
receptor	I-GGP
2	I-GGP
(	O
Avpr2	B-GGP
)	O
gene	B-SO
or	O
the	O
vasopressin	B-GGP
-	O
sensitive	O
water	B-CHEBI
channel	O
aquaporin	B-GGP
-	I-GGP
2	I-GGP
(	O
Aqp2	B-GGP
)	O
gene	B-SO
.	O

Development	O
of	O
a	O
treatment	O
is	O
rendered	O
difficult	O
due	O
to	O
the	O
lack	O
of	O
a	O
viable	O
animal	B-Taxon
model	O
.	O

Through	O
forward	O
genetic	B-SO
screening	O
of	O
ethylnitrosourea	B-CHEBI
-	O
mutagenized	O
mice	B-Taxon
,	O
we	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
a	O
mouse	B-Taxon
model	O
of	O
NDI	O
,	O
with	O
an	O
F204V	O
mutation	B-SO
in	O
the	O
Aqp2	B-GGP
gene	B-SO
.	O

Unlike	O
previously	O
attempted	O
murine	B-Taxon
models	O
of	O
NDI	O
,	O
our	O
mice	B-Taxon
survive	O
to	O
adulthood	O
and	O
more	O
exactly	O
recapitulate	O
the	O
human	B-Taxon
disorder	O
.	O

Previous	O
in	O
vitro	O
experiments	O
using	O
renal	O
cell	B-CL
lines	O
suggest	O
recessive	O
Aqp2	B-GGP
mutations	B-SO
result	O
in	O
improper	O
trafficking	O
of	O
the	O
mutant	B-SO
water	B-CHEBI
pore	O
.	O

Using	O
these	O
animals	B-Taxon
,	O
we	O
have	O
directly	O
proven	O
this	O
hypothesis	O
of	O
improper	O
AQP2	B-GGP
translocation	O
as	O
the	O
molecular	B-CHEBI
defect	O
in	O
nephrogenic	O
diabetes	O
insipidus	O
in	O
the	O
intact	O
organism	B-Taxon
.	O

Additionally	O
,	O
using	O
a	O
renal	O
cell	B-CL
line	O
we	O
show	O
that	O
the	O
mutated	B-SO
protein	B-CHEBI
,	O
AQP2	B-GGP
-	O
F204V	O
,	O
is	O
retained	O
in	O
the	O
endoplasmic	B-GO
reticulum	I-GO
and	O
that	O
this	O
abnormal	O
localization	O
can	O
be	O
rescued	O
by	O
wild	B-SO
-	I-SO
type	I-SO
protein	B-CHEBI
.	O

This	O
novel	O
mouse	B-Taxon
model	O
allows	O
for	O
further	O
mechanistic	O
studies	O
as	O
well	O
as	O
testing	O
of	O
pharmacological	O
and	O
gene	B-SO
therapies	O
for	O
NDI	O
.	O

Synopsis	O

Nephrogenic	O
diabetes	O
insipidus	O
(	O
NDI	O
)	O
is	O
a	O
disease	O
marked	O
by	O
excessive	O
urination	O
and	O
thirst	O
.	O

Normally	O
,	O
the	O
hypothalamus	O
senses	O
situations	O
where	O
water	B-CHEBI
is	O
limited	O
and	O
signals	O
to	O
the	O
kidney	O
to	O
increase	O
water	B-CHEBI
reabsorption	O
from	O
urine	O
.	O

The	O
signaling	O
molecule	B-CHEBI
secreted	O
by	O
the	O
hypothalamus	O
is	O
arginine	B-GGP
vasopressin	I-GGP
(	O
AVP	B-GGP
)	O
,	O
which	O
binds	O
to	O
a	O
specific	O
protein	B-CHEBI
on	O
the	O
surface	B-GO
of	I-GO
kidney	I-GO
cells	I-GO
,	O
AVP	B-GGP
receptor	I-GGP
(	O
AVPR2	B-GGP
)	O
.	O

AVP	B-GGP
binding	O
to	O
its	O
receptor	O
on	O
kidney	O
cells	B-CL
begins	O
a	O
series	O
of	O
biochemical	O
events	O
that	O
ultimately	O
results	O
in	O
the	O
insertion	O
of	O
a	O
protein	B-CHEBI
,	O
aquaporin	B-GGP
2	I-GGP
(	O
AQP2	B-GGP
)	O
,	O
into	O
the	O
outer	O
surface	B-GO
of	I-GO
the	I-GO
kidney	I-GO
cell	I-GO
.	O

As	O
its	O
name	O
suggests	O
,	O
AQP2	B-GGP
facilitates	O
the	O
reuptake	O
of	O
water	B-CHEBI
from	O
the	O
urinary	O
space	B-GO
into	O
the	O
cell	B-CL
,	O
thus	O
concentrating	O
the	O
urine	O
and	O
conserving	O
water	B-CHEBI
.	O

Congenital	O
NDI	O
is	O
caused	O
by	O
mutations	B-SO
in	O
either	O
the	O
water	B-CHEBI
channel	O
,	O
AQP2	B-GGP
,	O
or	O
in	O
the	O
receptor	O
,	O
AVPR2	B-GGP
.	O

While	O
these	O
mutations	B-SO
have	O
been	O
studied	O
extensively	O
in	O
the	O
lab	O
,	O
work	O
in	O
live	O
animals	B-Taxon
has	O
been	O
very	O
limited	O
.	O

This	O
report	O
describes	O
the	O
first	O
viable	O
mouse	B-Taxon
model	O
of	O
NDI	O
.	O

Previous	O
models	O
have	O
been	O
attempted	O
by	O
targeted	O
mutation	B-SO
,	O
i	O
.	O
e	O
.	O
,	O
genes	B-SO
known	O
to	O
be	O
involved	O
in	O
the	O
disease	O
have	O
been	O
altered	B-SO
in	O
the	O
mouse	B-Taxon
,	O
a	O
so	O
-	O
called	O
reverse	O
genetic	B-SO
approach	O
.	O

Reverse	O
genetic	B-SO
approaches	O
have	O
so	O
far	O
failed	O
to	O
produce	O
a	O
viable	O
mouse	B-Taxon
model	O
of	O
NDI	O
.	O

Here	O
the	O
authors	O
take	O
a	O
forward	O
genetic	B-SO
approach	O
in	O
which	O
genes	B-SO
are	O
mutated	B-SO
at	O
random	O
and	O
animals	B-Taxon
are	O
screened	O
for	O
disease	O
-	O
like	O
properties	O
.	O

As	O
well	O
as	O
proving	O
hypotheses	O
that	O
come	O
from	O
lab	O
studies	O
,	O
this	O
model	O
opens	O
the	O
door	O
to	O
the	O
testing	O
of	O
gene	B-SO
therapy	O
or	O
other	O
therapies	O
for	O
treatment	O
of	O
NDI	O
.	O

Introduction	O

Nephrogenic	O
diabetes	O
insipidus	O
(	O
NDI	O
)	O
is	O
a	O
disease	O
characterized	O
by	O
excessive	O
urination	O
and	O
thirst	O
,	O
despite	O
normal	O
production	O
of	O
the	O
antidiuretic	O
hormone	B-CHEBI
arginine	B-GGP
vasopressin	I-GGP
(	O
AVP	B-GGP
)	O
[	O
1	O
]	O
.	O

The	O
inherited	O
forms	O
are	O
either	O
X	B-GO
-	O
linked	O
as	O
a	O
consequence	O
of	O
mutation	B-SO
of	O
the	O
Avpr2	B-GGP
gene	B-SO
[	O
2	O
]	O
,	O
or	O
autosomal	B-GO
due	O
to	O
mutation	B-SO
of	O
the	O
Aqp2	B-GGP
gene	B-SO
[	O
3	O
]	O
.	O

Aquaporin	B-GGP
-	I-GGP
2	I-GGP
(	O
AQP2	B-GGP
)	O
is	O
a	O
pore	O
-	O
forming	O
protein	B-CHEBI
belonging	O
to	O
a	O
family	O
of	O
water	B-CHEBI
channels	O
[	O
4	O
]	O
,	O
and	O
it	O
is	O
expressed	O
in	O
collecting	O
-	O
duct	O
principal	O
cells	B-CL
in	O
the	O
kidney	O
[	O
5	O
]	O
.	O

Generally	O
these	O
proteins	B-CHEBI
permit	O
the	O
passage	O
of	O
water	B-CHEBI
through	O
the	O
plasma	B-GO
membrane	I-GO
(	O
PM	B-GO
)	O
of	O
cells	B-CL
,	O
several	O
of	O
which	O
carry	O
out	O
this	O
role	O
specifically	O
in	O
the	O
process	O
of	O
water	B-CHEBI
reabsorption	O
from	O
urine	O
in	O
the	O
kidney	O
.	O

It	O
has	O
been	O
established	O
that	O
aquaporins	O
,	O
although	O
functional	O
as	O
a	O
monomer	O
,	O
tetramerize	O
before	O
their	O
insertion	O
into	O
the	O
plasma	B-GO
membrane	I-GO
[	O
4	O
,	O
6	O
]	O
.	O

Furthermore	O
these	O
proteins	B-CHEBI
can	O
also	O
be	O
differentially	O
targeted	O
to	O
distinct	O
regions	B-GO
of	I-GO
the	I-GO
PM	I-GO
;	O
for	O
example	O
,	O
AQP2	B-GGP
is	O
routed	O
to	O
the	O
apical	B-GO
membrane	I-GO
of	I-GO
cells	I-GO
surrounding	O
the	O
collecting	O
duct	O
,	O
whereas	O
other	O
aquaporins	O
(	O
AQP3	B-GGP
or	O
4	O
)	O
are	O
inserted	O
into	O
the	O
basolateral	O
face	O
.	O

Unlike	O
all	O
other	O
family	O
members	O
,	O
AQP2	B-GGP
is	O
not	O
constitutively	O
inserted	O
into	O
the	O
plasma	B-GO
membrane	I-GO
.	O

Under	O
basal	O
conditions	O
,	O
the	O
protein	B-CHEBI
resides	O
in	O
subapical	O
intracellular	B-GO
vesicles	B-GO
;	O
however	O
,	O
under	O
conditions	O
requiring	O
water	B-CHEBI
retention	O
AQP2	B-GGP
translocates	O
to	O
the	O
apical	B-GO
membrane	I-GO
,	O
permitting	O
water	B-CHEBI
reabsorption	O
[	O
7	O
,	O
8	O
]	O
.	O

For	O
this	O
process	O
to	O
occur	O
,	O
AVP	O
binds	O
its	O
receptor	O
,	O
AVPR2	B-GGP
,	O
on	O
the	O
basolateral	O
face	O
of	O
the	O
collecting	O
duct	O
cells	B-CL
,	O
leading	O
to	O
a	O
rise	O
in	O
intracellular	B-GO
cAMP	B-CHEBI
,	O
ultimately	O
resulting	O
in	O
phosphorylation	O
of	O
AQP2	B-GGP
at	O
serine	B-CHEBI
256	O
by	O
cAMP	B-CHEBI
-	O
dependent	O
protein	B-CHEBI
kinase	O
[	O
9	O
]	O
and	O
its	O
redistribution	O
to	O
the	O
plasma	B-GO
membrane	I-GO
.	O

The	O
importance	O
of	O
AQP2	B-GGP
redistribution	O
has	O
been	O
highlighted	O
by	O
functional	O
characterization	O
of	O
Aqp2	B-GGP
mutations	B-SO
resulting	O
in	O
severe	O
NDI	O
in	O
humans	B-Taxon
[	O
3	O
,	O
10	O
]	O
.	O

Recessive	O
Aqp2	B-GGP
mutations	B-SO
are	O
generally	O
thought	O
to	O
produce	O
an	O
abnormally	O
localized	O
and	O
,	O
in	O
most	O
instances	O
,	O
misfolded	O
water	B-CHEBI
pore	O
that	O
responds	O
abnormally	O
to	O
an	O
increase	O
in	O
cAMP	B-CHEBI
[	O
6	O
,	O
11	O
]	O
.	O

Furthermore	O
,	O
dominant	O
mutations	B-SO
have	O
been	O
described	O
and	O
found	O
to	O
misroute	O
both	O
the	O
mutant	B-SO
and	O
the	O
wild	B-SO
-	I-SO
type	I-SO
protein	B-CHEBI
to	O
the	O
basolateral	B-GO
membrane	I-GO
[	O
6	O
,	O
12	O
]	O
.	O

Several	O
mouse	B-Taxon
models	O
of	O
diabetes	O
insipidus	O
have	O
been	O
generated	O
[	O
13	O
-	O
17	O
]	O
.	O

In	O
an	O
attempt	O
to	O
recapitulate	O
human	B-Taxon
NDI	O
,	O
mice	B-Taxon
have	O
been	O
generated	O
with	O
mutations	B-SO
in	O
Aqp2	B-GGP
and	O
Avpr2	B-GGP
[	O
15	O
,	O
18	O
]	O
.	O

Yang	O
and	O
colleagues	O
created	O
a	O
mouse	B-Taxon
with	O
a	O
T126M	O
knock	O
-	O
in	O
mutation	B-SO
in	O
the	O
Aqp2	B-GGP
gene	B-SO
.	O

Unexpectedly	O
,	O
homozygous	O
mutant	B-SO
mice	B-Taxon
died	O
within	O
6	O
d	O
after	O
birth	O
.	O

Interestingly	O
,	O
AVPR2	B-GGP
-	O
deficient	O
male	O
pups	O
also	O
die	O
within	O
the	O
first	O
week	O
after	O
birth	O
.	O

Together	O
these	O
models	O
suggest	O
that	O
the	O
mouse	B-Taxon
may	O
be	O
a	O
highly	O
sensitive	O
organism	B-Taxon
with	O
regard	O
to	O
water	B-CHEBI
homeostasis	O
,	O
and	O
is	O
unable	O
to	O
survive	O
with	O
polyuria	O
.	O

In	O
a	O
forward	O
genetic	B-SO
screen	O
,	O
a	O
mouse	B-Taxon
with	O
an	O
Aqp2	B-GGP
mutation	B-SO
was	O
identified	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
characterize	O
this	O
murine	B-Taxon
model	O
of	O
recessive	O
nephrogenic	O
DI	O
.	O

We	O
now	O
report	O
a	O
novel	O
F204V	O
mutation	B-SO
in	O
the	O
Aqp2	B-GGP
gene	B-SO
.	O

This	O
allele	B-SO
of	O
Aqp2	B-GGP
was	O
found	O
to	O
cause	O
the	O
first	O
mouse	B-Taxon
model	O
of	O
NDI	O
to	O
survive	O
past	O
the	O
first	O
week	O
of	O
life	O
.	O

Molecular	B-CHEBI
analyses	O
concluded	O
that	O
mutant	B-SO
AQP2	B-GGP
adopts	O
a	O
different	O
subcellular	O
localization	O
in	O
renal	O
collecting	O
-	O
duct	O
cells	B-CL
,	O
and	O
was	O
resistant	O
to	O
translocation	O
induced	O
by	O
desmopressin	O
,	O
an	O
agonist	B-CHEBI
of	O
AVP	O
.	O

In	O
vitro	O
studies	O
using	O
the	O
Madin	O
-	O
Darby	O
canine	B-Taxon
kidney	O
(	O
MDCK	O
)	O
cell	B-CL
line	O
demonstrated	O
an	O
endoplasmic	B-GO
reticulum	I-GO
pattern	O
for	O
the	O
mutant	B-SO
protein	B-CHEBI
,	O
and	O
apparent	O
resistance	O
to	O
translocation	O
.	O

These	O
data	O
conclusively	O
prove	O
that	O
autosomal	B-GO
recessive	O
NDI	O
is	O
a	O
consequence	O
of	O
improper	O
AQP2	B-GGP
routing	O
in	O
the	O
intact	O
mammal	B-Taxon
.	O

Results	O

In	O
a	O
forward	O
genetic	B-SO
screen	O
that	O
used	O
ethylnitrosourea	B-CHEBI
(	O
ENU	B-CHEBI
)	O
to	O
induce	O
mutations	B-SO
in	O
a	O
founder	O
animal	B-Taxon
whose	O
offspring	O
were	O
then	O
screened	O
for	O
abnormal	O
whole	O
body	O
metabolism	O
[	O
19	O
,	O
20	O
]	O
,	O
we	O
found	O
a	O
family	O
of	O
mice	B-Taxon
that	O
urinated	O
and	O
drank	O
excessively	O
.	O

Serum	O
and	O
urine	O
analysis	O
showed	O
that	O
plasma	O
glucose	B-CHEBI
levels	O
were	O
normal	O
and	O
there	O
was	O
no	O
glucose	B-CHEBI
in	O
the	O
urine	O
(	O
unpublished	O
data	O
)	O
.	O

Hence	O
,	O
this	O
was	O
an	O
example	O
of	O
diabetes	O
insipidus	O
.	O

The	O
disorder	O
in	O
these	O
mice	B-Taxon
segregated	O
in	O
a	O
monogenic	O
,	O
autosomal	B-GO
recessive	O
manner	O
,	O
making	O
Aqp2	B-GGP
a	O
candidate	O
gene	B-SO
.	O

Sequencing	O
of	O
Aqp2	B-GGP
coding	B-SO
region	I-SO
of	O
affected	O
mice	B-Taxon
identified	O
a	O
thymine	B-SO
to	I-SO
guanine	I-SO
(	I-SO
T	I-SO
to	I-SO
G	I-SO
)	I-SO
transversion	I-SO
(	O
Figure	O
1A	O
)	O
,	O
which	O
is	O
predicted	O
to	O
lead	O
to	O
a	O
valine	B-CHEBI
for	O
phenylalanine	B-CHEBI
substitution	B-SO
at	O
amino	B-CHEBI
acid	I-CHEBI
204	O
of	O
the	O
protein	B-CHEBI
(	O
F204V	O
)	O
.	O

AQP2	B-GGP
is	O
a	O
six	O
-	O
transmembrane	B-GO
water	B-CHEBI
channel	O
,	O
and	O
F204	O
lies	O
near	O
the	O
extracellular	B-GO
face	O
of	O
the	O
sixth	O
membrane	B-GO
spanning	O
domain	B-SO
,	O
a	O
region	B-SO
rich	O
in	O
hydrophobic	O
amino	B-CHEBI
acids	I-CHEBI
.	O

This	O
and	O
the	O
other	O
membrane	B-GO
-	O
spanning	O
domains	B-SO
are	O
conserved	B-SO
among	O
vertebrate	B-Taxon
species	O
.	O

The	O
phenylalanine	B-CHEBI
at	O
position	B-SO
204	O
is	O
particularly	O
well	O
conserved	B-SO
(	O
Figure	O
1B	O
)	O
,	O
not	O
only	O
among	O
vertebrate	B-Taxon
AQP2	B-GGP
proteins	B-CHEBI
,	O
but	O
also	O
among	O
others	O
members	O
of	O
this	O
family	O
.	O

Aqp2F204V	O
/	O
F204V	O
mice	B-Taxon
have	O
dramatically	O
increased	O
urine	O
production	O
,	O
in	O
some	O
cases	O
producing	O
an	O
amount	O
of	O
urine	O
in	O
24	O
h	O
that	O
exceeds	O
their	O
body	O
weight	O
,	O
compared	O
to	O
their	O
heterozygous	O
or	O
wild	B-SO
-	I-SO
type	I-SO
littermates	O
.	O

Such	O
loss	O
of	O
water	B-CHEBI
would	O
rapidly	O
lead	O
to	O
dehydration	O
were	O
it	O
not	O
compensated	O
by	O
increased	O
water	B-CHEBI
intake	O
.	O

Indeed	O
,	O
mutant	B-SO
mice	B-Taxon
also	O
dramatically	O
increase	O
their	O
water	B-CHEBI
intake	O
(	O
Figure	O
1C	O
)	O
compared	O
to	O
their	O
heterozygous	O
or	O
wild	B-SO
-	I-SO
type	I-SO
littermates	O
.	O

This	O
phenotype	O
--	O
increased	O
urinary	O
output	O
and	O
water	B-CHEBI
intake	O
--	O
showed	O
complete	O
concordance	O
with	O
homozygosity	O
of	O
the	O
F204V	O
mutation	B-SO
in	O
the	O
58	O
animals	B-Taxon
tested	O
.	O

Diabetes	O
insipidus	O
can	O
be	O
defined	O
as	O
an	O
inability	O
to	O
concentrate	O
urine	O
where	O
appropriate	O
.	O

Compared	O
to	O
wild	B-SO
-	I-SO
type	I-SO
or	O
heterozygous	O
littermates	O
,	O
Aqp2F204V	O
/	O
F204V	O
mice	B-Taxon
produce	O
very	O
dilute	O
urine	O
(	O
Figure	O
1D	O
)	O
.	O

Basal	O
urine	O
concentration	O
in	O
mutant	B-SO
mice	B-Taxon
is	O
about	O
161	O
mOsm	O
,	O
compared	O
to	O
about	O
1	O
,	O
293	O
mOsm	O
in	O
wild	B-SO
-	I-SO
type	I-SO
mice	B-Taxon
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Normally	O
,	O
urine	O
concentration	O
is	O
under	O
the	O
control	O
of	O
the	O
hypothalamus	O
,	O
which	O
,	O
in	O
response	O
to	O
hypovolemia	O
or	O
hypernatremia	O
[	O
21	O
]	O
,	O
secretes	O
AVP	O
.	O

The	O
synthetic	B-SO
AVP	O
analog	O
,	O
1	O
-	O
deamino	O
-	O
8	O
-	O
D	B-CHEBI
-	I-CHEBI
arginine	I-CHEBI
vasopressin	O
(	O
dDAVP	O
;	O
also	O
called	O
desmopressin	O
)	O
,	O
is	O
a	O
potent	O
agonist	B-CHEBI
of	O
AVPR2	B-GGP
.	O

When	O
administered	O
to	O
wild	B-SO
-	I-SO
type	I-SO
mice	B-Taxon
,	O
dDAVP	O
leads	O
to	O
a	O
dramatic	O
increase	O
in	O
urine	O
concentration	O
,	O
from	O
1	O
,	O
293	O
to	O
5	O
,	O
885	O
mOsm	O
(	O
4	O
.	O
6	O
-	O
fold	O
;	O
Figure	O
1D	O
)	O
.	O

With	O
similar	O
treatment	O
,	O
mutant	B-SO
mice	B-Taxon
concentrate	O
their	O
urine	O
to	O
a	O
lesser	O
but	O
still	O
significant	O
extent	O
,	O
from	O
161	O
to	O
470	O
mOsm	O
(	O
2	O
.	O
9	O
-	O
fold	O
)	O
,	O
indicating	O
that	O
these	O
animals	B-Taxon
are	O
not	O
only	O
unable	O
to	O
concentrate	O
their	O
urine	O
properly	O
but	O
are	O
also	O
defective	O
in	O
their	O
response	O
to	O
dDAVP	O
.	O

The	O
smaller	O
response	O
to	O
dDAVP	O
indicates	O
some	O
residual	O
activity	O
of	O
the	O
mutant	B-SO
AQP2	B-GGP
channel	I-GGP
,	O
which	O
must	O
be	O
sufficient	O
to	O
allow	O
survival	O
of	O
the	O
individual	B-Taxon
,	O
in	O
contrast	O
to	O
the	O
T126M	O
knock	O
-	O
in	O
mouse	B-Taxon
[	O
18	O
]	O
.	O

Multiple	O
heterozygous	O
matings	O
yielded	O
101	O
animals	B-Taxon
,	O
which	O
appeared	O
at	O
a	O
ratio	O
of	O
26	O
:	O
49	O
:	O
26	O
,	O
near	O
the	O
expected	O
Mendelian	O
wild	B-SO
type	I-SO
,	O
heterozygote	O
,	O
and	O
mutant	B-SO
frequencies	O
,	O
respectively	O
,	O
indicating	O
that	O
there	O
is	O
no	O
reduced	O
viability	O
associated	O
with	O
this	O
mutation	B-SO
.	O

Other	O
than	O
the	O
increased	O
urine	O
production	O
and	O
water	B-CHEBI
intake	O
,	O
there	O
was	O
no	O
overt	O
phenotype	O
in	O
mutant	B-SO
mice	B-Taxon
,	O
save	O
distended	O
kidneys	O
,	O
which	O
appeared	O
variably	O
in	O
adult	O
animals	B-Taxon
(	O
Figure	O
2A	O
)	O
.	O

Although	O
not	O
specifically	O
measured	O
,	O
mutant	B-SO
mice	B-Taxon
seem	O
to	O
have	O
a	O
normal	O
lifespan	O
.	O

The	O
one	O
animal	B-Taxon
that	O
was	O
followed	O
lived	O
to	O
18	O
mo	O
,	O
typical	O
for	O
animals	B-Taxon
in	O
our	O
colony	O
.	O

Aqp2F204V	O
/	O
F204V	O
mice	B-Taxon
suffer	O
from	O
severe	O
hydronephrosis	O
(	O
Figure	O
2A	O
and	O
2B	O
)	O
,	O
presumably	O
as	O
a	O
consequence	O
of	O
an	O
inability	O
to	O
cope	O
with	O
the	O
extreme	O
polyuria	O
.	O

We	O
found	O
distended	O
kidneys	O
in	O
all	O
Aqp2F204V	O
/	O
F204V	O
mice	B-Taxon
;	O
however	O
,	O
the	O
degree	O
of	O
inflation	O
was	O
variable	O
in	O
affected	O
mice	B-Taxon
and	O
worsened	O
with	O
age	O
.	O

Severe	O
hydronephrosis	O
has	O
previously	O
been	O
observed	O
in	O
double	O
Aqp1	B-GGP
/	O
Aqp3	B-GGP
knock	O
-	O
out	O
mice	B-Taxon
[	O
17	O
]	O
,	O
and	O
appears	O
at	O
6	O
wk	O
.	O

Even	O
at	O
4	O
wk	O
,	O
Aqp2F204V	O
/	O
F204V	O
mice	B-Taxon
had	O
hydronephrosis	O
.	O

Histologic	O
sections	O
from	O
Aqp2F204V	O
/	O
F204V	O
mice	B-Taxon
demonstrated	O
marked	O
dilatation	O
of	O
the	O
renal	O
pelvis	O
yet	O
normal	O
morphology	O
of	O
the	O
ureter	O
(	O
Figure	O
2C	O
and	O
2D	O
)	O
.	O

In	O
particular	O
,	O
the	O
muscularis	O
propria	O
was	O
neither	O
hypertrophied	O
nor	O
thinned	O
.	O

There	O
was	O
the	O
normal	O
festooned	O
appearance	O
of	O
the	O
urothelium	O
,	O
and	O
this	O
transitional	O
epithelium	O
was	O
of	O
normal	O
thickness	O
.	O

There	O
was	O
thinning	O
of	O
the	O
kidney	O
as	O
measured	O
from	O
renal	O
capsule	O
to	O
renal	O
pelvis	O
.	O

However	O
,	O
the	O
morphologic	O
features	O
of	O
the	O
glomeruli	O
and	O
proximal	O
/	O
distal	O
tubules	O
were	O
unremarkable	O
(	O
Figure	O
2D	O
)	O
.	O

As	O
shown	O
previously	O
[	O
18	O
,	O
22	O
]	O
,	O
immunoblotting	O
revealed	O
three	O
different	B-SO
forms	I-SO
of	O
AQP2	B-GGP
,	O
due	O
to	O
different	O
degrees	O
and	O
forms	O
of	O
glycosylation	O
(	O
Figure	O
3A	O
)	O
.	O

Previous	O
reports	O
have	O
demonstrated	O
that	O
nonglycosylated	O
protein	B-CHEBI
appears	O
as	O
a	O
29	O
kDa	O
band	O
,	O
while	O
complex	O
glycosylated	O
protein	B-CHEBI
runs	O
as	O
a	O
smear	O
between	O
35	O
and	O
45	O
kDa	O
.	O

A	O
short	O
-	O
lived	O
intermediate	B-SO
form	B-SO
of	O
31	O
kDa	O
representing	O
core	O
,	O
high	O
-	O
mannose	B-CHEBI
glycosylation	O
of	O
AQP2	B-GGP
is	O
apparent	O
from	O
pulse	O
-	O
chase	O
labeling	O
experiments	O
[	O
22	O
]	O
.	O

Compared	O
to	O
that	O
from	O
the	O
kidneys	O
of	O
wild	B-SO
-	I-SO
type	I-SO
animals	B-Taxon
,	O
AQP2	B-GGP
from	O
mutant	B-SO
animals	B-Taxon
was	O
reduced	O
in	O
both	O
the	O
high	O
molecular	B-CHEBI
weight	O
,	O
diffuse	O
form	B-SO
and	O
the	O
lowest	O
molecular	B-CHEBI
weight	O
form	B-SO
,	O
but	O
enriched	O
in	O
the	O
intermediate	B-SO
molecular	B-CHEBI
weight	O
form	B-SO
(	O
Figure	O
3A	O
)	O
.	O

Heterozygous	O
animals	B-Taxon
showed	O
intermediate	O
amounts	O
of	O
all	O
three	O
forms	B-SO
.	O

The	O
nature	O
of	O
these	O
glycosylated	O
forms	B-SO
was	O
revealed	O
by	O
digestion	O
with	O
endoglycosidase	B-GGP
H	I-GGP
,	O
which	O
specifically	O
cleaves	O
mannose	B-CHEBI
-	O
rich	O
carbohydrate	O
from	O
the	O
protein	B-CHEBI
backbone	O
.	O

Treatment	O
of	O
endogenous	O
AQP2	B-GGP
from	O
kidneys	O
of	O
wild	B-SO
-	I-SO
type	I-SO
,	O
heterozygous	O
,	O
and	O
mutant	B-SO
animals	B-Taxon
specifically	O
affected	O
the	O
intermediate	B-SO
molecular	B-CHEBI
weight	O
form	B-SO
(	O
Figure	O
3B	O
)	O
.	O

The	O
presence	O
of	O
some	O
mature	O
glycosylated	O
proteins	B-CHEBI
(	O
35	O
-	O
45	O
kDa	O
)	O
in	O
Aqp2F204V	O
/	O
F204V	O
mice	B-Taxon
presumably	O
permits	O
their	O
survival	O
compared	O
to	O
Aqp2T126M	O
/	O
T126M	O
mice	B-Taxon
,	O
and	O
is	O
consistent	O
with	O
a	O
diminished	O
response	O
to	O
dDAVP	O
.	O

In	O
humans	B-Taxon
,	O
recessive	O
alleles	B-SO
of	O
Aqp2	B-GGP
are	O
postulated	O
to	O
cause	O
NDI	O
because	O
they	O
do	O
not	O
properly	O
translocate	O
to	O
the	O
apical	B-GO
cell	B-GO
surface	I-GO
in	O
response	O
to	O
AVP	B-GGP
.	O

This	O
postulate	O
comes	O
solely	O
from	O
in	O
vitro	O
studies	O
in	O
which	O
mutant	B-SO
Aqp2	B-GGP
cDNAs	B-SO
corresponding	O
to	O
human	B-Taxon
disease	O
mutations	B-SO
are	O
transfected	O
into	O
kidney	O
cell	B-CL
lines	O
.	O

In	O
general	O
,	O
such	O
recessive	O
alleles	B-SO
,	O
when	O
visualized	O
immunocytochemically	O
,	O
fail	O
to	O
localize	O
to	O
AVP	B-GGP
-	O
responsive	O
vesicles	B-GO
.	O

Rather	O
,	O
they	O
get	O
trapped	O
in	O
the	O
endoplasmic	B-GO
reticulum	I-GO
(	O
ER	B-GO
)	O
.	O

Our	O
mouse	B-Taxon
model	O
of	O
NDI	O
affords	O
the	O
first	O
opportunity	O
to	O
test	O
this	O
hypothesis	O
in	O
a	O
mature	O
animal	B-Taxon
.	O

As	O
shown	O
in	O
Figure	O
4A	O
(	O
top	O
row	O
of	O
photomicrographs	O
)	O
,	O
AQP2	B-GGP
(	O
stained	O
red	O
)	O
normally	O
localized	O
to	O
the	O
subapical	O
region	B-GO
of	I-GO
collecting	I-GO
duct	I-GO
cells	I-GO
in	O
kidneys	O
of	O
wild	B-SO
-	I-SO
type	I-SO
mice	B-Taxon
.	O

Upon	O
stimulation	O
with	O
dDAVP	O
,	O
AQP2	B-GGP
translocated	O
to	O
or	O
near	O
the	O
cell	B-GO
surface	I-GO
(	O
Figure	O
4A	O
,	O
second	O
row	O
)	O
.	O

In	O
kidneys	O
taken	O
from	O
mutant	B-SO
animals	B-Taxon
,	O
however	O
,	O
AQP2	B-GGP
was	O
distributed	O
randomly	O
throughout	O
the	O
cell	B-CL
in	O
the	O
basal	O
state	O
(	O
Figure	O
4A	O
,	O
third	O
row	O
)	O
,	O
while	O
AQP3	B-GGP
(	O
green	O
)	O
appropriately	O
localized	O
to	O
the	O
basolateral	O
surface	B-GO
[	O
23	O
]	O
.	O

Furthermore	O
,	O
upon	O
dDAVP	O
stimulation	O
,	O
AQP2	B-GGP
-	O
F204V	O
failed	O
to	O
translocate	O
to	O
the	O
cell	B-GO
surface	I-GO
(	O
Figure	O
4A	O
,	O
bottom	O
row	O
)	O
.	O

To	O
confirm	O
these	O
findings	O
,	O
the	O
staining	O
was	O
repeated	O
in	O
kidneys	O
taken	O
from	O
two	O
further	O
mice	B-Taxon
for	O
each	O
class	O
,	O
wild	B-SO
-	I-SO
type	I-SO
or	O
mutant	B-SO
,	O
with	O
or	O
without	O
dDAVP	O
treatment	O
,	O
with	O
identical	O
results	O
.	O

To	O
investigate	O
the	O
mechanism	O
of	O
defective	O
translocation	O
of	O
AQP2	B-GGP
-	O
F204V	O
,	O
we	O
turned	O
to	O
transfection	O
of	O
MDCK	O
cells	B-CL
.	O

Stable	O
cell	B-CL
lines	O
expressing	O
mouse	B-GGP
wild	I-GGP
-	I-GGP
type	I-GGP
AQP2	I-GGP
and	I-GGP
AQP2	I-GGP
-	O
F204V	O
were	O
established	O
.	O

Immunoblots	O
of	O
protein	B-CHEBI
extracts	O
from	O
stable	O
cell	B-CL
lines	O
showed	O
that	O
MDCK	O
cells	B-CL
recapitulate	O
the	O
glycosylation	O
defect	O
seen	O
in	O
mutant	B-SO
mice	B-Taxon
(	O
unpublished	O
data	O
)	O
.	O

The	O
wild	B-SO
-	I-SO
type	I-SO
protein	B-CHEBI
was	O
again	O
present	O
in	O
three	O
different	B-SO
forms	I-SO
.	O

Cells	B-CL
expressing	O
AQP2	B-GGP
-	O
F204V	O
lacked	O
the	O
35	O
-	O
45	O
kDa	O
form	B-SO
and	O
were	O
enriched	O
in	O
the	O
core	O
-	O
glycosylated	O
31	O
kDa	O
form	B-SO
.	O

In	O
transfected	O
,	O
unstimulated	O
MDCK	O
cells	B-CL
,	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
(	O
stained	O
green	O
)	O
appeared	O
in	O
a	O
punctate	O
pattern	O
distributed	O
throughout	O
the	O
subapical	O
region	O
(	O
Figure	O
4B	O
,	O
left	O
column	O
photomicrographs	O
)	O
,	O
consistent	O
with	O
vesicular	B-GO
compartmentalization	O
.	O

AQP2	B-GGP
-	O
F204V	O
,	O
on	O
the	O
other	O
hand	O
,	O
appeared	O
in	O
a	O
punctate	O
but	O
perinuclear	B-GO
pattern	O
(	O
Figure	O
4B	O
,	O
third	O
column	O
)	O
.	O

Upon	O
stimulation	O
with	O
forskolin	O
,	O
a	O
cAMP	B-CHEBI
-	O
dependent	O
protein	B-CHEBI
kinase	O
activator	O
,	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
translocated	O
to	O
the	O
apical	B-GO
surface	B-GO
of	I-GO
polarized	I-GO
MDCK	I-GO
cells	I-GO
(	O
Figure	O
4B	O
,	O
second	O
column	O
)	O
.	O

Along	O
the	O
z	O
-	O
axis	O
,	O
the	O
perinuclear	B-GO
distribution	O
of	O
AQP2	B-GGP
-	O
F204V	O
was	O
clearly	O
seen	O
,	O
and	O
this	O
distribution	O
is	O
not	O
altered	O
by	O
forskolin	O
(	O
Figure	O
4B	O
,	O
bottom	O
row	O
,	O
two	O
right	O
columns	O
)	O
.	O

The	O
perinuclear	B-GO
distribution	O
of	O
AQP2	B-GGP
-	O
F204V	O
is	O
consistent	O
with	O
an	O
ER	B-GO
compartmentalization	O
.	O

To	O
test	O
the	O
idea	O
that	O
AQP2	B-GGP
-	O
F204V	O
localizes	O
to	O
the	O
ER	B-GO
,	O
we	O
co	O
-	O
stained	O
cells	B-CL
transfected	O
with	O
Aqp2F204V	O
(	O
cDNA	B-SO
)	O
for	O
AQP2	B-GGP
and	O
an	O
ER	B-GO
marker	O
,	O
calnexin	B-GGP
(	O
Figure	O
4C	O
)	O
.	O

Colocalization	O
of	O
calnexin	B-GGP
with	O
AQP2	B-GGP
was	O
investigated	O
directly	O
,	O
and	O
it	O
was	O
found	O
that	O
80	O
%	O
of	O
all	O
AQP2	B-GGP
-	O
F204V	O
protein	B-CHEBI
colocalized	O
with	O
calnexin	B-GGP
.	O

The	O
remaining	O
20	O
%	O
appeared	O
at	O
the	O
periphery	O
of	O
the	O
ER	B-GO
,	O
representing	O
AQP2	B-GGP
-	O
F204V	O
that	O
had	O
potentially	O
progressed	O
beyond	O
the	O
ER	B-GO
.	O

This	O
"	O
ER	B-GO
escape	O
"	O
was	O
consistent	O
with	O
the	O
small	O
proportion	O
of	O
mature	O
,	O
complex	O
glycosylated	O
,	O
AQP2	B-GGP
-	O
F204V	O
in	O
mutant	B-SO
kidneys	O
(	O
see	O
Figure	O
3A	O
)	O
.	O

Animals	B-Taxon
heterozygous	O
for	O
the	O
Aqp2F204V	O
mutation	B-SO
were	O
not	O
affected	O
in	O
their	O
urine	O
production	O
or	O
urine	O
osmolality	O
(	O
see	O
Figure	O
1C	O
and	O
1D	O
)	O
.	O

It	O
has	O
also	O
been	O
shown	O
that	O
a	O
recessive	O
NDI	O
allele	B-SO
,	O
AQP2	B-GGP
-	O
R187C	O
,	O
does	O
not	O
interact	O
with	O
wild	B-SO
-	I-SO
type	I-SO
protein	B-CHEBI
in	O
oocytes	B-CL
[	O
24	O
]	O
,	O
nor	O
does	O
it	O
homo	O
-	O
oligomerize	O
in	O
MDCK	O
cells	B-CL
[	O
22	O
]	O
.	O

Therefore	O
,	O
kidneys	O
from	O
heterozygous	O
animals	B-Taxon
were	O
examined	O
for	O
evidence	O
of	O
two	O
populations	O
of	O
AQP2	B-GGP
protein	B-CHEBI
.	O

Surprisingly	O
,	O
immunohistochemical	O
staining	O
of	O
kidney	O
collecting	O
ducts	O
from	O
Aqp2F204V	O
/	O
+	B-SO
mice	B-Taxon
revealed	O
a	O
pattern	O
remarkably	O
similar	O
to	O
wild	B-SO
type	I-SO
(	O
Figure	O
5A	O
)	O
.	O

AQP2	B-GGP
translocated	O
completely	O
to	O
the	O
apical	B-GO
cell	B-GO
surface	I-GO
upon	O
dDAVP	O
stimulation	O
.	O

This	O
wild	B-SO
-	I-SO
type	I-SO
staining	O
pattern	O
may	O
simply	O
reflect	O
the	O
fact	O
that	O
decreasing	O
the	O
amount	O
of	O
mutant	B-SO
protein	B-CHEBI
by	O
half	O
makes	O
it	O
undetectable	O
by	O
immunocytochemistry	O
.	O

Alternatively	O
,	O
the	O
presence	O
of	O
wild	B-SO
-	I-SO
type	I-SO
protein	B-CHEBI
may	O
alter	O
the	O
localization	O
of	O
the	O
mutant	B-SO
protein	B-CHEBI
.	O

Indeed	O
,	O
Hendriks	O
et	O
al	O
.	O
proposed	O
a	O
"	O
piggy	O
-	O
back	O
"	O
mechanism	O
to	O
explain	O
the	O
transport	O
of	O
nonglycosylated	O
subunits	O
of	O
AQP2	B-GGP
to	O
the	O
cell	B-GO
surface	I-GO
by	O
glycosylated	O
subunits	O
[	O
22	O
]	O
.	O

It	O
has	O
also	O
been	O
shown	O
that	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
protein	B-CHEBI
can	O
rescue	O
a	O
translocation	O
-	O
defective	O
mutant	B-SO
protein	B-CHEBI
,	O
AQP2	B-GGP
-	O
P262L	O
,	O
when	O
the	O
two	O
are	O
coexpressed	O
in	O
MDCK	O
cells	B-CL
[	O
25	O
]	O
.	O

In	O
the	O
collecting	O
ducts	O
from	O
Aqp2F204V	O
/	O
+	B-SO
mice	B-Taxon
,	O
the	O
wild	B-SO
type	I-SO
may	O
rescue	O
the	O
mutant	B-SO
protein	B-CHEBI
as	O
suggested	O
by	O
the	O
subcellular	O
distribution	O
of	O
AQP2	B-GGP
protein	B-CHEBI
.	O

To	O
test	O
this	O
idea	O
,	O
we	O
first	O
looked	O
for	O
an	O
interaction	O
between	O
mutant	B-SO
and	O
wild	B-SO
-	I-SO
type	I-SO
proteins	B-CHEBI
in	O
transfected	O
MDCK	O
cells	B-CL
(	O
Figure	O
5B	O
)	O
.	O

MDCK	O
cells	B-CL
stably	O
expressing	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
were	O
transiently	O
transfected	O
with	O
GFP	O
expression	O
constructs	B-SO
encoding	O
GFP	O
-	O
tagged	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
,	O
AQP2	B-GGP
-	O
F204V	O
,	O
or	O
GFP	O
alone	O
.	O

Antibodies	B-GO
against	O
GFP	O
coimmunoprecipitated	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
when	O
AQP2	B-GGP
-	O
GFP	O
or	O
AQP2	B-GGP
-	O
F204V	O
-	O
GFP	O
was	O
transiently	O
transfected	O
,	O
but	O
not	O
when	O
GFP	O
by	O
itself	O
was	O
transiently	O
transfected	O
into	O
MDCK	O
cells	B-CL
stably	O
expressing	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
(	O
Figure	O
5B	O
,	O
upper	O
blots	O
)	O
.	O

Western	O
blot	O
of	O
total	O
membranes	B-GO
showed	O
that	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
is	O
equivalently	O
expressed	O
in	O
all	O
three	O
cases	O
(	O
Figure	O
5B	O
,	O
lower	O
blots	O
)	O
.	O

If	O
wild	B-SO
-	I-SO
type	I-SO
and	O
mutant	B-SO
proteins	B-CHEBI
are	O
indeed	O
interacting	O
in	O
the	O
cell	B-CL
,	O
is	O
this	O
interaction	O
sufficient	O
to	O
rescue	O
the	O
localization	O
of	O
mutant	B-SO
protein	B-CHEBI
?	O

To	O
answer	O
this	O
question	O
,	O
we	O
used	O
MDCK	O
cells	B-CL
stably	O
transfected	O
with	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
expressing	O
vector	B-SO
or	O
with	O
empty	O
vector	B-SO
.	O

On	O
top	O
of	O
these	O
,	O
we	O
transiently	O
transfected	O
AQP2	B-GGP
-	O
GFP	O
or	O
AQP2	B-GGP
-	O
F204V	O
-	O
GFP	O
expression	O
constructs	B-SO
.	O

AQP2	B-GGP
-	O
GFP	O
localized	O
to	O
the	O
apical	B-GO
surface	B-GO
upon	O
forskolin	O
stimulation	O
whether	O
it	O
was	O
transiently	O
transfected	O
into	O
vector	B-SO
-	O
only	O
cells	B-CL
(	O
Figure	O
5C	O
,	O
upper	O
left	O
images	O
)	O
or	O
into	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
cells	B-CL
(	O
Figure	O
5C	O
,	O
upper	O
right	O
)	O
.	O

AQP2	B-GGP
-	O
F204V	O
-	O
GFP	O
,	O
when	O
expressed	O
by	O
transient	O
transfection	O
into	O
vector	B-SO
only	O
cells	B-CL
,	O
showed	O
a	O
diffuse	O
cytoplasmic	B-GO
distribution	O
pattern	O
(	O
Figure	O
5C	O
,	O
lower	O
left	O
)	O
.	O

When	O
expressed	O
in	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
cells	B-CL
,	O
however	O
,	O
AQP2	B-GGP
-	O
F204V	O
-	O
GFP	O
localized	O
to	O
the	O
apical	B-GO
surface	B-GO
to	O
varying	O
degrees	O
(	O
Figure	O
5C	O
,	O
lower	O
right	O
images	O
[	O
i	O
-	O
iii	O
]	O
)	O
.	O

The	O
lower	O
right	O
images	O
of	O
Figure	O
5C	O
shows	O
three	O
cells	B-CL
from	O
a	O
single	O
transfection	O
.	O

The	O
first	O
is	O
a	O
nontransfected	O
cell	B-CL
that	O
shows	O
the	O
localization	O
of	O
the	O
stably	O
expressing	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
,	O
which	O
is	O
apical	B-GO
upon	O
forskolin	O
stimulation	O
.	O

The	O
next	O
two	O
show	O
expression	O
of	O
both	O
the	O
stable	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
and	O
the	O
transient	O
AQP2	B-GGP
-	O
F204V	O
-	O
GFP	O
.	O

In	O
cell	B-CL
(	O
ii	O
)	O
,	O
localization	O
of	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
was	O
indistinguishable	O
from	O
AQP2	B-GGP
-	O
F204V	O
-	O
GFP	O
;	O
both	O
were	O
apical	B-GO
upon	O
forskolin	O
stimulation	O
.	O

Although	O
the	O
effect	O
was	O
subtle	O
in	O
cell	B-CL
(	O
iii	O
)	O
,	O
AQP2	B-GGP
-	O
F204V	O
-	O
GFP	O
was	O
partly	O
localized	O
to	O
the	O
apical	B-GO
surface	B-GO
.	O

Generally	O
,	O
the	O
localization	O
of	O
AQP2	B-GGP
-	O
F204V	O
-	O
GFP	O
was	O
clearly	O
more	O
apical	B-GO
when	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
was	O
also	O
expressed	O
.	O

To	O
confirm	O
these	O
results	O
biochemically	O
,	O
we	O
transfected	O
the	O
same	O
cell	B-CL
lines	O
(	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
or	O
vector	B-SO
)	O
with	O
F204V	O
-	O
GFP	O
,	O
biotinylated	O
surface	B-GO
proteins	B-CHEBI
after	O
forskolin	O
stimulation	O
,	O
and	O
precipitated	O
the	O
biotinylated	O
proteins	B-CHEBI
(	O
Figure	O
5D	O
)	O
.	O

AQP2	B-GGP
-	O
F204V	O
-	O
GFP	O
is	O
expressed	O
approximately	O
equally	O
in	O
both	O
cell	B-CL
lines	O
(	O
Figure	O
5D	O
,	O
total	O
cells	B-CL
)	O
,	O
but	O
is	O
biotinylated	O
only	O
when	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
is	O
also	O
expressed	O
(	O
Figure	O
5D	O
,	O
surface	B-GO
biotinylated	O
)	O
.	O

Since	O
only	O
cell	B-GO
surface	I-GO
proteins	B-CHEBI
are	O
accessible	O
to	O
biotin	B-CHEBI
,	O
these	O
results	O
indicate	O
that	O
AQP2	B-GGP
-	O
F204V	O
is	O
transported	O
to	O
the	O
cell	B-GO
surface	I-GO
when	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
is	O
present	O
,	O
but	O
not	O
on	O
its	O
own	O
.	O

Discussion	O

Aqp2F204	O
/	O
F204V	O
mice	B-Taxon
are	O
viable	O
and	O
grow	O
and	O
reproduce	O
normally	O
.	O

They	O
are	O
,	O
however	O
,	O
severely	O
defective	O
in	O
their	O
ability	O
to	O
concentrate	O
urine	O
,	O
leading	O
to	O
increased	O
urine	O
output	O
and	O
water	B-CHEBI
intake	O
,	O
thus	O
making	O
them	O
the	O
first	O
mouse	B-Taxon
model	O
of	O
NDI	O
to	O
survive	O
to	O
maturity	O
.	O

In	O
humans	B-Taxon
,	O
NDI	O
is	O
caused	O
by	O
mutations	B-SO
in	O
Avpr2	B-GGP
or	O
Aqp2	B-GGP
.	O

Knockout	O
of	O
the	O
X	B-GO
-	O
linked	O
Avpr2	B-GGP
gene	I-GGP
in	I-GGP
mice	I-GGP
[	O
15	O
]	O
gave	O
an	O
NDI	O
-	O
like	O
phenotype	O
in	O
male	O
,	O
hemizygous	O
neonates	O
,	O
but	O
the	O
phenotype	O
could	O
not	O
be	O
assessed	O
in	O
adults	O
as	O
the	O
mice	B-Taxon
died	O
within	O
1	O
wk	O
of	O
birth	O
.	O

The	O
adult	O
heterozygous	O
females	O
showed	O
a	O
mild	O
tendency	O
toward	O
increased	O
urinary	O
output	O
and	O
water	B-CHEBI
intake	O
and	O
decreased	O
urine	O
osmolality	O
.	O

Knockout	O
of	O
the	O
mouse	B-GGP
Aqp2	I-GGP
gene	B-SO
has	O
not	O
been	O
reported	O
.	O

A	O
knock	O
-	O
in	O
of	O
a	O
human	B-Taxon
disease	O
-	O
causing	O
mutation	B-SO
(	O
T126M	O
)	O
,	O
however	O
,	O
has	O
been	O
made	O
[	O
18	O
]	O
.	O

These	O
mice	B-Taxon
have	O
a	O
severe	O
urine	O
-	O
concentrating	O
defect	O
resulting	O
in	O
dehydration	O
and	O
death	O
within	O
1	O
wk	O
of	O
birth	O
.	O

Curiously	O
,	O
AQP2	B-GGP
-	O
T126M	O
does	O
localize	O
properly	O
in	O
at	O
least	O
a	O
subset	O
of	O
cells	B-CL
.	O

The	O
grossly	O
abnormal	O
collecting	O
duct	O
morphology	O
makes	O
it	O
impossible	O
to	O
pinpoint	O
the	O
molecular	B-CHEBI
defect	O
in	O
these	O
knock	O
-	O
in	O
mice	B-Taxon
.	O

The	O
T126M	O
knock	O
-	O
in	O
clearly	O
shows	O
that	O
Aqp2	B-GGP
is	O
an	O
essential	O
gene	B-SO
[	O
18	O
]	O
.	O

The	O
fact	O
that	O
our	O
mice	B-Taxon
survive	O
shows	O
either	O
that	O
AQP2	B-GGP
-	O
F204V	O
possesses	O
some	O
residual	O
water	B-CHEBI
transporting	O
ability	O
or	O
that	O
there	O
are	O
AVP	B-GGP
-	O
independent	O
pathways	O
for	O
water	B-CHEBI
reabsorption	O
.	O

Residual	O
activity	O
of	O
AQP2	B-GGP
-	O
F204V	O
is	O
likely	O
,	O
as	O
mutant	B-SO
animals	B-Taxon
show	O
some	O
small	O
response	O
to	O
dDAVP	O
,	O
although	O
dDAVP	O
-	O
stimulated	O
urine	O
osmolality	O
remains	O
quite	O
low	O
.	O

Immunostaining	O
of	O
kidney	O
shows	O
that	O
AQP2	B-GGP
-	O
F204V	O
does	O
not	O
efficiently	O
transport	O
water	B-CHEBI
,	O
because	O
it	O
fails	O
to	O
localize	O
to	O
the	O
apical	B-GO
cell	B-GO
surface	I-GO
after	O
dDAVP	O
treatment	O
.	O

Some	O
residual	O
activity	O
of	O
AQP2	B-GGP
would	O
imply	O
that	O
some	O
small	O
,	O
undetectable	O
portion	O
of	O
the	O
mutant	B-SO
protein	B-CHEBI
is	O
getting	O
to	O
the	O
cell	B-GO
surface	I-GO
.	O

The	O
surface	B-GO
biotinylation	O
experiment	O
(	O
Figure	O
5D	O
)	O
suggests	O
that	O
no	O
mutant	B-SO
protein	B-CHEBI
gets	O
to	O
the	O
surface	B-GO
,	O
but	O
this	O
does	O
not	O
necessarily	O
reflect	O
the	O
situation	O
in	O
vivo	O
.	O

While	O
this	O
small	O
fraction	O
of	O
protein	B-CHEBI
may	O
not	O
be	O
detectable	O
by	O
immunofluorescence	O
,	O
Western	O
blotting	O
shows	O
that	O
some	O
mutant	B-SO
protein	B-CHEBI
does	O
progress	O
beyond	O
the	O
ER	B-GO
(	O
35	O
-	O
45	O
kDa	O
species	B-SO
in	O
Figure	O
3A	O
)	O
.	O

Compared	O
to	O
wild	B-SO
-	I-SO
type	I-SO
,	O
mutant	B-SO
protein	B-CHEBI
is	O
enriched	O
in	O
the	O
high	O
-	O
mannose	B-CHEBI
,	O
core	O
-	O
glycosylated	O
form	B-SO
(	O
31	O
kDa	O
)	O
and	O
deficient	O
in	O
nonglycosylated	O
(	O
29	O
kDa	O
)	O
and	O
complex	O
glycosylated	O
(	O
35	O
-	O
45	O
kDa	O
)	O
forms	B-SO
.	O

The	O
presence	O
of	O
a	O
reduced	O
but	O
detectable	O
amount	O
of	O
protein	B-CHEBI
in	O
the	O
35	O
-	O
45	O
kDa	O
range	O
indicates	O
that	O
mutant	B-SO
protein	B-CHEBI
is	O
transported	O
out	O
of	O
the	O
ER	B-GO
,	O
but	O
with	O
greatly	O
reduced	O
efficiency	O
.	O

Colocalization	O
of	O
AQP2	B-GGP
-	O
F204V	O
with	O
the	O
ER	B-GO
protein	B-CHEBI
calnexin	B-GGP
in	O
transfected	O
MDCK	O
cells	B-CL
shows	O
that	O
,	O
while	O
most	O
of	O
the	O
mutant	B-SO
protein	B-CHEBI
is	O
trapped	O
in	O
the	O
ER	B-GO
,	O
some	O
does	O
progress	O
beyond	O
the	O
ER	B-GO
.	O

Diminished	O
response	O
to	O
dDAVP	O
,	O
diminished	O
abundance	O
of	O
mature	O
glycosylated	O
protein	B-CHEBI
in	O
mutant	B-SO
animals	B-Taxon
,	O
and	O
the	O
transport	O
of	O
a	O
fraction	O
of	O
mutant	B-SO
protein	B-CHEBI
beyond	O
the	O
ER	B-GO
in	O
MDCK	O
cells	B-CL
are	O
all	O
consistent	O
with	O
the	O
notion	O
that	O
AQP2	B-GGP
-	O
F204V	O
misfolding	O
is	O
limited	O
and	O
that	O
it	O
may	O
retain	O
some	O
residual	O
water	B-CHEBI
transporting	O
activity	O
.	O

Evidently	O
this	O
residual	O
activity	O
is	O
sufficient	O
for	O
the	O
viability	O
and	O
growth	O
of	O
mutant	B-SO
animals	B-Taxon
.	O

Reduced	O
efficiency	O
in	O
exiting	O
the	O
ER	B-GO
may	O
explain	O
why	O
AQP2	B-GGP
-	O
F204V	O
is	O
enriched	O
in	O
the	O
31	O
kDa	O
high	O
-	O
mannose	B-CHEBI
glycosylated	O
form	B-SO
.	O

The	O
high	O
-	O
mannose	B-CHEBI
core	O
oligosaccharide	B-CHEBI
is	O
added	O
in	O
the	O
ER	B-GO
and	O
is	O
later	O
modified	B-SO
and	O
elaborated	O
in	O
the	O
Golgi	B-GO
apparatus	I-GO
[	O
26	O
]	O
.	O

The	O
increase	O
in	O
the	O
high	O
-	O
mannose	B-CHEBI
glycosylated	O
form	B-SO
of	O
AQP2	B-GGP
-	O
F204V	O
may	O
simply	O
reflect	O
its	O
prolonged	O
presence	O
in	O
the	O
ER	B-GO
and	O
exposure	O
to	O
oligosaccharyl	B-CHEBI
transferase	O
.	O

While	O
improper	O
localization	O
of	O
AQP2	B-GGP
explains	O
the	O
phenotype	O
of	O
homozygous	O
mutant	B-SO
mice	B-Taxon
,	O
the	O
complete	O
lack	O
of	O
a	O
phenotype	O
in	O
heterozygous	O
mice	B-Taxon
is	O
more	O
difficult	O
to	O
explain	O
.	O

Physiologically	O
,	O
heterozygous	O
mice	B-Taxon
have	O
no	O
symptoms	O
(	O
see	O
Figure	O
1C	O
)	O
,	O
and	O
they	O
are	O
indistinguishable	O
from	O
wild	B-SO
type	I-SO
on	O
immunostaining	O
of	O
kidneys	O
(	O
Figure	O
5A	O
)	O
.	O

The	O
presence	O
of	O
50	O
%	O
of	O
the	O
normal	O
amount	O
of	O
wild	B-SO
-	I-SO
type	I-SO
protein	B-CHEBI
may	O
explain	O
the	O
lack	O
of	O
symptoms	O
,	O
but	O
it	O
cannot	O
explain	O
the	O
lack	O
of	O
any	O
ER	B-GO
-	O
retained	O
mutant	B-SO
protein	B-CHEBI
.	O

Rather	O
,	O
the	O
phenotype	O
of	O
the	O
Aqp2F204V	O
/	O
+	B-SO
animals	B-Taxon
suggests	O
that	O
the	O
mutant	B-SO
protein	B-CHEBI
is	O
being	O
rescued	O
by	O
the	O
wild	B-SO
-	I-SO
type	I-SO
protein	B-CHEBI
.	O

Indeed	O
,	O
de	O
Mattia	O
et	O
al	O
.	O

(	O
26	O
)	O
have	O
demonstrated	O
that	O
one	O
recessive	O
allele	B-SO
of	O
Aqp2	B-GGP
,	O
P262L	O
,	O
does	O
not	O
properly	O
translocate	O
when	O
expressed	O
by	O
itself	O
in	O
MDCK	O
cells	B-CL
,	O
but	O
that	O
in	O
the	O
presence	O
of	O
wild	B-SO
-	I-SO
type	I-SO
protein	B-CHEBI
,	O
it	O
localizes	O
normally	O
.	O

The	O
same	O
mechanism	O
seems	O
to	O
apply	O
in	O
vivo	O
with	O
Aqp2F204V	O
/	O
+	B-SO
mice	B-Taxon
.	O

In	O
support	O
of	O
this	O
,	O
AQP2	B-GGP
-	O
F204V	O
can	O
interact	O
with	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
(	O
Figure	O
5B	O
)	O
,	O
and	O
when	O
coexpressed	O
with	O
wild	B-SO
-	I-SO
type	I-SO
protein	B-CHEBI
,	O
AQP2	B-GGP
-	O
F204V	O
can	O
reach	O
the	O
cell	B-GO
surface	I-GO
(	O
Figure	O
5C	O
bottom	O
right	O
panel	O
and	O
5D	O
)	O
.	O

Although	O
it	O
has	O
been	O
demonstrated	O
that	O
a	O
recessive	O
allele	B-SO
(	O
encoding	O
AQP2	B-GGP
-	O
R187C	O
)	O
of	O
NDI	O
fails	O
to	O
interact	O
with	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
[	O
6	O
]	O
,	O
here	O
we	O
show	O
that	O
AQP2	B-GGP
-	O
F204V	O
does	O
interact	O
with	O
the	O
wild	B-SO
-	I-SO
type	I-SO
protein	B-CHEBI
,	O
presumably	O
as	O
part	O
of	O
heterotetramers	O
,	O
and	O
represents	O
a	O
rescuable	O
allele	B-SO
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Immunostaining	O
the	O
kidneys	O
of	O
homozygous	O
Aqp2F204V	O
/	O
F204V	O
mice	B-Taxon
shows	O
that	O
the	O
mutant	B-SO
-	O
expressing	O
collecting	O
duct	O
cells	B-CL
can	O
not	O
mediate	O
water	B-CHEBI
reabsorption	O
,	O
because	O
it	O
fails	O
to	O
insert	O
into	O
the	O
apical	B-GO
plasma	I-GO
membrane	I-GO
in	O
response	O
to	O
dDAVP	O
.	O

This	O
is	O
this	O
first	O
in	O
vivo	O
proof	O
of	O
a	O
long	O
-	O
standing	O
hypothesis	O
that	O
comes	O
from	O
in	O
vitro	O
studies	O
with	O
recessive	O
Aqp2	B-GGP
mutations	B-SO
.	O

Transfection	O
into	O
MDCK	O
cells	B-CL
of	O
any	O
of	O
several	O
Aqp2	B-GGP
mutations	B-SO
corresponding	O
to	O
recessive	O
human	B-Taxon
alleles	B-SO
shows	O
abnormal	O
subcellular	O
localization	O
[	O
25	O
]	O
,	O
[	O
27	O
]	O
and	O
failure	O
to	O
appropriately	O
translocate	O
to	O
the	O
plasma	B-GO
membrane	I-GO
.	O

Thus	O
,	O
misfolding	O
,	O
retention	O
in	O
the	O
ER	B-GO
,	O
and	O
failure	O
to	O
translocate	O
in	O
response	O
to	O
dDAVP	O
were	O
proposed	O
as	O
the	O
mechanism	O
for	O
autosomal	B-GO
recessive	O
NDI	O
.	O

Here	O
we	O
not	O
only	O
prove	O
this	O
hypothesis	O
but	O
also	O
establish	O
a	O
useful	O
model	O
for	O
human	B-Taxon
NDI	O
.	O

This	O
mouse	B-Taxon
model	O
of	O
NDI	O
based	O
on	O
an	O
Aqp2	B-GGP
allele	B-SO
that	O
can	O
be	O
rescued	O
provides	O
the	O
opportunity	O
to	O
test	O
therapies	O
,	O
including	O
gene	B-SO
therapy	O
,	O
that	O
may	O
promote	O
proper	O
subcellular	O
localization	O
.	O

Materials	O
and	O
Methods	O

Generation	O
of	O
ENU	O
mice	B-Taxon
and	O
housing	O
.	O

ENU	B-CHEBI
mutagenized	O
C57BL	O
/	O
6	O
mice	B-Taxon
were	O
generated	O
as	O
described	O
[	O
19	O
]	O
.	O

Mice	B-Taxon
were	O
maintained	O
by	O
backcrossing	O
affected	O
animals	B-Taxon
to	O
C57BL	O
/	O
6	O
and	O
housed	O
in	O
the	O
Genomics	O
Institute	O
of	O
the	O
Novartis	O
Research	O
Foundation	O
Specific	O
Pathogen	O
Free	O
animal	B-Taxon
facility	O
(	O
La	O
Jolla	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

All	O
procedures	O
were	O
approved	O
by	O
the	O
Genomics	O
Institute	O
of	O
the	O
Novartis	O
Research	O
Foundation	O
Institutional	O
Animal	B-Taxon
Care	O
and	O
Use	O
Committee	O
.	O

Constructs	B-SO
.	O

The	O
complete	O
coding	B-SO
sequence	I-SO
of	O
mouse	B-GGP
AQP2	I-GGP
from	O
an	O
IMAGE	O
clone	B-SO
was	O
digested	O
from	O
the	O
pCMV	O
.	O
SPORT6	O
plasmid	B-SO
with	O
EcoRI	O
and	O
NotI	O
and	O
ligated	O
into	O
pcDNA3	O
.	O
1	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

The	O
F204V	O
mutation	B-SO
was	O
introduced	O
by	O
site	B-SO
-	O
directed	O
mutagenesis	B-SO
(	O
Stratagene	O
,	O
La	O
Jolla	O
,	O
California	O
,	O
United	O
States	O
)	O
,	O
using	O
the	O
sense	O
oligonucleotide	B-SO
5	O
'	O
-	O
GATGATCACTGGGTCGTCTGGATCGGACCCC	O
-	O
3	O
'	O
,	O
and	O
antisense	B-SO
oligonucleotide	B-SO
5	O
'	O
-	O
GGGGTCCGATCCAGACGACCCAGTGATCATC	O
-	O
3	O
'	O
.	O

To	O
generate	O
GFP	O
fusions	O
of	O
AQP2	B-GGP
,	O
the	O
pCMV	O
.	O
SPORT6	O
AQP2	B-GGP
construct	B-SO
was	O
used	O
in	O
a	O
PCR	O
reaction	O
with	O
the	O
primers	B-SO
Sp6	O
and	O
5	O
'	O
-	O
GACTGGATCCCGGCCTTGCTGCCGCGCGGCAG	O
-	O
3	O
'	O
to	O
remove	B-SO
the	O
stop	B-SO
codon	I-SO
of	O
AQP2	B-GGP
.	O

The	O
product	B-SO
was	O
digested	O
with	O
KpnI	O
and	O
BamHI	O
and	O
ligated	O
into	O
pEGFP	O
-	O
N2	O
(	O
BD	O
Biosciences	O
,	O
San	O
Diego	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

The	O
F204V	O
mutation	B-SO
was	O
introduced	O
using	O
the	O
same	O
mutagenic	B-CHEBI
oligonucleotides	B-SO
.	O

Cell	B-CL
culture	O
and	O
generation	O
of	O
stable	O
cell	B-CL
lines	O
.	O

MDCK	O
cells	B-CL
(	O
CCL	O
-	O
34	O
;	O
ATCC	O
,	O
Manassas	O
,	O
Virginia	O
,	O
United	O
States	O
)	O
were	O
cultured	O
in	O
DMEM	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
.	O
Louis	O
,	O
Missouri	O
,	O
United	O
States	O
)	O
supplemented	O
with	O
10	O
%	O
FBS	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
,	O
100	O
U	O
/	O
ml	O
of	O
penicillin	B-CHEBI
,	O
and	O
100	O
mu	O
g	O
/	O
ml	O
of	O
streptomycin	B-CHEBI
at	O
37	O
degrees	O
C	O
in	O
5	O
%	O
CO2	O
.	O

To	O
generate	O
stable	O
MDCK	O
cell	B-CL
lines	O
,	O
cells	B-CL
were	O
transfected	O
using	O
Lipofectamine	O
2000	O
(	O
Invitrogen	O
)	O
and	O
the	O
pcDNA3	O
.	O
1	O
expression	O
constructs	B-SO
(	O
containing	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
,	O
AQP2	B-GGP
-	O
F204V	O
,	O
or	O
no	O
insert	B-SO
)	O
and	O
selected	O
with	O
900	O
mu	O
g	O
/	O
ml	O
G418	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
.	O

Individual	O
colonies	O
were	O
expanded	O
14	O
d	O
later	O
.	O

For	O
the	O
duration	O
of	O
these	O
experiments	O
,	O
the	O
antibiotic	B-CHEBI
was	O
continually	O
added	O
to	O
the	O
media	O
.	O

Transient	O
GFP	O
transfections	O
were	O
carried	O
out	O
in	O
subconfluent	O
stable	O
cells	B-CL
lines	O
also	O
using	O
Lipofectamine	O
2000	O
.	O

Sequencing	O
of	O
Aqp2	B-GGP
and	O
genotyping	O
of	O
mice	B-Taxon
.	O

All	O
exons	B-SO
of	O
Aqp2	B-GGP
were	O
amplified	O
from	O
mouse	B-Taxon
genomic	B-SO
DNA	I-SO
and	O
sequenced	O
.	O

For	O
genotyping	O
,	O
exon	B-SO
4	O
was	O
amplified	O
using	O
the	O
primers	B-SO
5	O
'	O
-	O
TCAGAACTTGCCCACTAGCC	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
TGTAGAGGAGGGAACCGATG	O
-	O
3	O
'	O
.	O

Urine	O
measurements	O
.	O

Total	O
urine	O
output	O
was	O
measured	O
by	O
separately	O
housing	O
adult	O
mice	B-Taxon
in	O
Nalgene	O
Metabolic	O
Cages	O
(	O
Minimitter	O
,	O
Bend	O
,	O
Oregon	O
,	O
United	O
States	O
)	O
for	O
2	O
-	O
3	O
d	O
and	O
collecting	O
urine	O
every	O
24	O
h	O
period	O
.	O

Urine	O
osmolalities	O
were	O
determined	O
using	O
an	O
Osmometer	O
(	O
Osmette	O
5004	O
;	O
Precision	O
Systems	O
,	O
Natick	O
,	O
Massachusetts	O
,	O
United	O
States	O
)	O
.	O

Urine	O
concentrating	O
experiments	O
were	O
carried	O
out	O
by	O
intraperitoneal	O
injection	O
of	O
dDAVP	O
(	O
0	O
.	O
4	O
mu	O
g	O
/	O
kg	O
)	O
.	O

Mice	B-Taxon
were	O
injected	O
twice	O
with	O
dDAVP	O
,	O
once	O
at	O
time	O
0	O
and	O
again	O
at	O
30	O
min	O
.	O

Urine	O
was	O
collected	O
at	O
the	O
start	O
of	O
the	O
experiment	O
and	O
30	O
min	O
after	O
the	O
second	O
injection	O
.	O

Kidney	O
membrane	B-GO
preparation	O
.	O

Whole	O
mouse	B-Taxon
kidneys	O
were	O
homogenized	O
in	O
10	O
mM	O
Tris	B-CHEBI
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
350	O
mM	O
sucrose	B-CHEBI
,	O
and	O
5	O
mM	O
EDTA	B-CHEBI
containing	O
protease	B-CHEBI
inhibitors	I-CHEBI
(	O
Sigma	O
-	O
Aldrich	O
,	O
#	O
P	O
-	O
8340	O
)	O
in	O
a	O
Potter	O
-	O
Elvehjem	O
homogenizer	O
.	O

The	O
homogenate	O
was	O
centrifuged	O
at	O
2	O
,	O
000	O
g	O
for	O
10	O
min	O
and	O
the	O
supernatant	O
was	O
subjected	O
to	O
ultracentrifugation	O
at	O
100	O
,	O
000	O
g	O
for	O
1	O
h	O
at	O
4	O
degrees	O
C	O
.	O

Pelleted	O
membranes	B-GO
were	O
resuspended	O
in	O
the	O
same	O
buffer	O
,	O
and	O
protein	B-CHEBI
concentration	O
was	O
determined	O
by	O
Bradford	O
assay	O
.	O

Immunoblotting	O
.	O

Kidney	O
membrane	B-GO
fractions	I-GO
(	O
60	O
mu	O
g	O
)	O
were	O
resolved	O
on	O
a	O
12	O
%	O
SDS	B-CHEBI
-	O
polyacrylamide	O
gel	O
and	O
transferred	O
to	O
a	O
nitrocellulose	O
membrane	O
.	O

Membranes	O
were	O
blocked	O
in	O
5	O
%	O
nonfat	O
milk	O
in	O
Tris	B-CHEBI
-	O
buffered	B-CHEBI
saline	O
with	O
0	O
.	O
05	O
%	O
Tween	O
20	O
(	O
TBST	O
)	O
,	O
followed	O
by	O
an	O
overnight	O
incubation	O
(	O
at	O
4	O
degrees	O
C	O
)	O
with	O
AQP2	B-GGP
polyclonal	O
antibody	B-GO
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
California	O
,	O
United	O
States	O
;	O
#	O
sc	O
-	O
9882	O
)	O
.	O

Membranes	O
were	O
washed	O
in	O
TBST	O
then	O
incubated	O
with	O
HRP	O
-	O
conjugated	O
donkey	B-Taxon
anti	O
-	O
goat	B-Taxon
antibody	B-GO
.	O

Membranes	O
were	O
washed	O
further	O
in	O
TBST	O
and	O
bands	O
were	O
visualized	O
using	O
ECL	O
reagent	B-CHEBI
(	O
Amersham	O
Biosciences	O
,	O
Little	O
Chalfont	O
,	O
United	O
Kingdom	O
)	O
.	O

Endoglycosidase	O
digestion	O
.	O

Kidney	O
membranes	B-GO
(	O
60	O
mu	O
g	O
)	O
were	O
incubated	O
in	O
50	O
mM	O
sodium	B-CHEBI
phosphate	I-CHEBI
(	O
pH	O
5	O
.	O
5	O
)	O
,	O
0	O
.	O
1	O
%	O
SDS	B-CHEBI
,	O
and	O
50	O
mM	O
beta	B-CHEBI
-	I-CHEBI
mercaptoethanol	I-CHEBI
,	O
heated	O
to	O
100	O
degrees	O
C	O
for	O
5	O
min	O
,	O
then	O
cooled	O
.	O

Endoglycosidase	B-GGP
H	I-GGP
(	O
0	O
.	O
01	O
units	O
;	O
Sigma	O
-	O
Aldrich	O
)	O
was	O
added	O
and	O
incubated	O
at	O
37	O
degrees	O
C	O
for	O
2	O
h	O
.	O

The	O
reaction	O
was	O
stopped	O
by	O
boiling	O
the	O
samples	O
in	O
Laemmli	O
buffer	O
.	O

Total	O
reactants	O
were	O
immunoblotted	O
as	O
described	O
above	O
.	O

Coimmunoprecipitation	O
and	O
biotinylation	O
in	O
MDCK	O
cells	B-CL
.	O

MDCK	O
cells	B-CL
stably	O
expressing	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
(	O
grown	O
on	O
10	O
-	O
cm	O
plates	O
)	O
were	O
transfected	O
with	O
pEGFP	O
-	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
,	O
pEGFP	O
-	O
AQP2	B-GGP
-	O
F204V	O
,	O
or	O
vector	B-SO
alone	O
.	O

The	O
cells	B-CL
were	O
homogenized	O
in	O
10	O
mM	O
Tris	B-CHEBI
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
1	O
mM	O
EDTA	B-CHEBI
,	O
and	O
250	O
mM	O
sucrose	B-CHEBI
40	O
h	O
later	O
.	O

The	O
clarified	O
supernatant	O
was	O
centrifuged	O
at	O
200	O
,	O
000	O
g	O
for	O
30	O
min	O
.	O

Pelleted	O
membranes	B-GO
were	O
resuspended	O
in	O
the	O
same	O
buffer	O
but	O
containing	O
4	O
%	O
sodium	B-CHEBI
deoxycholate	I-CHEBI
and	O
incubated	O
at	O
37	O
degrees	O
C	O
for	O
1	O
h	O
.	O

From	O
the	O
dissolved	O
membranes	B-GO
,	O
a	O
30	O
mu	O
l	O
sample	O
was	O
removed	O
and	O
used	O
as	O
the	O
total	O
membrane	B-GO
fraction	I-GO
.	O

The	O
remaining	O
membranes	B-GO
were	O
diluted	O
with	O
600	O
mu	O
l	O
of	O
the	O
homogenization	O
buffer	O
,	O
and	O
incubated	O
with	O
1	O
mu	O
l	O
of	O
GFP	O
antisera	O
(	O
Invitrogen	O
,	O
#	O
46	O
-	O
0092	O
)	O
and	O
protein	B-CHEBI
A	O
/	O
G	O
sepharose	O
.	O

Following	O
overnight	O
incubation	O
,	O
the	O
precipitated	O
proteins	B-CHEBI
were	O
washed	O
in	O
RIPA	O
buffer	O
and	O
finally	O
boiled	O
in	O
50	O
mu	O
l	O
of	O
Laemmli	O
buffer	O
.	O

Half	O
of	O
the	O
total	O
membrane	B-GO
and	I-GO
the	I-GO
IP	I-GO
fractions	I-GO
were	O
processed	O
for	O
immunoblotting	O
.	O

Cell	B-GO
surface	I-GO
biotinylation	O
was	O
performed	O
in	O
a	O
similar	O
manner	O
.	O

However	O
,	O
pEGFP	O
-	O
AQP2	B-GGP
-	O
F204V	O
,	O
was	O
transfected	O
into	O
MDCK	O
cells	B-CL
stably	O
expressing	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
and	O
cells	B-CL
made	O
stable	O
with	O
vector	B-SO
alone	O
.	O

Twenty	O
-	O
four	O
hours	O
post	O
-	O
transfection	O
,	O
cells	B-CL
were	O
stimulated	O
with	O
forskolin	O
,	O
trypsinized	O
,	O
resuspended	O
in	O
1	O
ml	O
of	O
PBS	O
(	O
2	O
.	O
5	O
x	O
106	O
cells	B-CL
/	O
ml	O
)	O
,	O
and	O
incubated	O
with	O
0	O
.	O
5	O
mg	O
of	O
NHS	O
-	O
PEO4	O
-	O
biotin	B-CHEBI
(	O
Pierce	O
Biotechnology	O
)	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

Cells	B-CL
were	O
washed	O
once	O
in	O
10	O
mM	O
Tris	B-CHEBI
(	O
pH	O
8	O
)	O
and	O
three	O
times	O
in	O
PBS	O
,	O
after	O
which	O
membranes	B-GO
were	O
purified	O
and	O
solubilized	O
as	O
described	O
above	O
.	O

Solubilized	O
membranes	B-GO
were	O
incubated	O
with	O
20	O
mu	O
l	O
of	O
immobilized	O
streptavidin	O
(	O
Pierce	O
Biotechnology	O
)	O
for	O
2	O
h	O
at	O
4	O
degrees	O
C	O
.	O

Finally	O
the	O
precipitated	O
proteins	B-CHEBI
were	O
washed	O
in	O
RIPA	O
buffer	O
and	O
boiled	O
in	O
50	O
mu	O
l	O
of	O
Laemmli	O
buffer	O
.	O

Total	O
cells	B-CL
and	O
the	O
biotinylated	O
precipitates	O
were	O
immunoblotting	O
using	O
an	O
antibody	B-GO
to	O
AQP2	B-GGP
.	O

Kidney	O
immunohistochemistry	O
.	O

Whole	O
mouse	B-Taxon
kidneys	O
were	O
fixed	O
in	O
10	O
%	O
phosphate	B-CHEBI
-	O
buffered	B-CHEBI
formalin	O
for	O
24	O
h	O
.	O

Kidneys	O
were	O
embedded	O
in	O
paraffin	O
,	O
and	O
5	O
-	O
mu	O
m	O
sections	O
were	O
prepared	O
.	O

Following	O
antigen	O
retrieval	O
using	O
10	O
mM	O
sodium	B-CHEBI
citrate	B-CHEBI
(	O
pH	O
8	O
)	O
for	O
10	O
min	O
at	O
98	O
degrees	O
C	O
,	O
sections	O
were	O
sequentially	O
probed	O
,	O
first	O
for	O
AQP3	B-GGP
and	O
then	O
for	O
AQP2	B-GGP
.	O

Sections	O
were	O
incubated	O
in	O
5	O
%	O
donkey	B-Taxon
serum	O
and	O
then	O
in	O
goat	B-Taxon
anti	O
-	O
AQP3	B-GGP
antibody	B-GO
(	O
1	O
:	O
100	O
;	O
Santa	O
Cruz	O
Biotechnology	O
;	O
#	O
sc	O
-	O
9885	O
)	O
.	O

Slides	O
were	O
washed	O
with	O
PBS	O
and	O
incubated	O
with	O
AlexaFluor	O
488	O
-	O
conjugated	O
donkey	B-Taxon
anti	O
-	O
goat	B-Taxon
antibody	B-GO
(	O
Molecular	B-CHEBI
Probes	O
,	O
Eugene	O
,	O
Oregon	O
,	O
United	O
States	O
)	O
.	O

The	O
slides	O
were	O
subsequently	O
blocked	O
in	O
5	O
%	O
chicken	B-Taxon
serum	O
,	O
incubated	O
with	O
a	O
rabbit	B-Taxon
anti	O
-	O
AQP2	B-GGP
antibody	B-GO
(	O
1	O
:	O
250	O
;	O
USB	O
,	O
Cleveland	O
,	O
Ohio	O
,	O
United	O
States	O
;	O
#	O
A3000	O
-	O
06	O
)	O
,	O
which	O
was	O
detected	O
with	O
a	O
AlexaFluor	O
594	O
-	O
conjugated	O
chicken	B-Taxon
anti	O
-	O
rabbit	B-Taxon
antibody	B-GO
(	O
1	O
:	O
500	O
;	O
Molecular	B-CHEBI
Probes	O
)	O
.	O

The	O
sections	O
were	O
stained	O
with	O
DAPI	O
and	O
mounted	O
in	O
Vectashield	O
(	O
Vector	O
Labs	O
,	O
Burlingame	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

Immunocytochemistry	O
on	O
MDCK	O
cells	B-CL
.	O

MDCK	O
stable	O
cell	B-CL
lines	O
expressing	O
vector	B-SO
alone	O
,	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
,	O
or	O
AQP2	B-GGP
-	O
F204V	O
(	O
and	O
in	O
some	O
cases	O
transiently	O
expressing	O
a	O
GFP	O
construct	B-SO
)	O
were	O
grown	O
on	O
fibronectin	B-GGP
-	O
coated	O
coverslips	O
until	O
tight	B-GO
junctions	I-GO
formed	O
.	O

Cells	B-CL
were	O
treated	O
with	O
or	O
without	O
150	O
mu	O
M	O
forskolin	O
for	O
90	O
min	O
,	O
and	O
fixed	O
in	O
methanol	B-CHEBI
at	O
-	O
20	O
degrees	O
C	O
.	O

Subsequently	O
,	O
cells	B-CL
were	O
washed	O
and	O
permeabilized	O
in	O
0	O
.	O
2	O
%	O
Triton	O
X	O
-	O
100	O
for	O
5	O
min	O
,	O
and	O
sequentially	O
probed	O
for	O
AQP2	B-GGP
and	O
organelle	B-GO
markers	O
for	O
either	O
the	O
PM	B-GO
or	O
the	O
ER	B-GO
.	O

AQP2	B-GGP
was	O
detected	O
using	O
goat	B-Taxon
anti	O
-	O
AQP2	B-GGP
(	O
1	O
:	O
100	O
;	O
Santa	O
Cruz	O
Biotechnology	O
;	O
#	O
sc	O
-	O
9882	O
)	O
and	O
a	O
1	O
:	O
200	O
dilution	O
of	O
AlexaFluor	O
488	O
-	O
conjugated	O
donkey	B-Taxon
anti	O
-	O
goat	B-Taxon
secondary	O
antibody	B-GO
.	O

The	O
PM	B-GO
and	O
ER	B-GO
were	O
probed	O
using	O
mouse	B-Taxon
anti	O
-	O
Na	B-CHEBI
+	I-CHEBI
/	O
K	B-CHEBI
+	I-CHEBI
-	O
ATPase	O
(	O
Upstate	O
,	O
Waltham	O
,	O
Massachusetts	O
,	O
United	O
States	O
)	O
or	O
rabbit	B-Taxon
anti	O
-	O
calnexin	B-GGP
(	O
Stressgen	O
Biotechnology	O
,	O
Victoria	O
,	O
British	O
Columbia	O
,	O
Canada	O
)	O
antibodies	B-GO
and	O
the	O
secondary	O
antibodies	B-GO
,	O
Cy3	O
-	O
conjugated	O
goat	B-Taxon
anti	O
-	O
mouse	B-Taxon
(	O
1	O
:	O
200	O
;	O
Jackson	O
ImmunoResearch	O
,	O
West	O
Grove	O
,	O
Pennsylvania	O
,	O
United	O
States	O
)	O
or	O
AlexaFluor	O
594	O
-	O
conjugated	O
chicken	B-Taxon
anti	O
-	O
rabbit	B-Taxon
(	O
1	O
:	O
200	O
)	O
respectively	O
.	O

Cells	B-CL
were	O
washed	O
in	O
PBS	O
,	O
counterstained	O
with	O
DAPI	O
,	O
and	O
mounted	O
in	O
Vectashield	O
.	O

In	O
experiments	O
in	O
which	O
GFP	O
fusions	O
were	O
used	O
,	O
AQP2	B-GGP
was	O
probed	O
using	O
the	O
antibody	B-GO
combination	O
used	O
for	O
kidney	O
immunohistochemistry	O
in	O
order	O
to	O
detect	O
the	O
AQP2	B-GGP
at	O
594	O
nm	O
,	O
to	O
distinguish	O
between	O
the	O
GFP	O
fusion	B-SO
proteins	B-CHEBI
.	O

Confocal	O
microscopy	O
.	O

Optical	O
z	O
-	O
section	O
images	O
were	O
collected	O
on	O
a	O
BioRad	O
(	O
Hercules	O
,	O
California	O
,	O
United	O
States	O
)	O
Rainbow	O
Radiance	O
2100	O
Laser	O
Scanning	O
Confocal	O
Microscope	O
.	O

Image	O
stacks	O
were	O
flattened	O
,	O
or	O
sectioned	O
along	O
the	O
z	O
-	O
axis	O
,	O
then	O
further	O
processed	O
using	O
BioRad	O
Laser	O
Sharp	O
2000	O
software	O
and	O
Image	O
J	O
software	O
(	O
v	O
.	O
1	O
.	O
32	O
;	O
National	O
Institutes	O
of	O
Health	O
)	O
.	O

Colocalization	O
was	O
performed	O
using	O
the	O
overlay	O
coefficient	O
of	O
Image	O
J	O
software	O
.	O

Supporting	O
Information	O

Accession	O
Numbers	O

The	O
GenBank	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
)	O
accession	O
number	O
of	O
Aqp2	B-GGP
is	O
NM	O
_	O
009699	O
.	O

The	O
IMAGE	O
(	O
http	O
:	O
/	O
/	O
image	O
.	O
llnl	O
.	O
gov	O
)	O
accession	O
number	O
of	O
AQP2	B-GGP
is	O
4222942	O
.	O

Acknowledgements	O

We	O
thank	O
Debby	O
Stradley	O
for	O
all	O
genotyping	O
,	O
Lacey	O
Kischassey	O
for	O
breeding	O
and	O
care	O
of	O
mice	B-Taxon
,	O
Karina	O
Ayala	O
and	O
Sandy	O
Bohan	O
for	O
phenotyping	O
the	O
study	O
mice	B-Taxon
,	O
Miah	O
Gilmore	O
for	O
performing	O
endoglycosidase	B-GGP
H	I-GGP
experiments	O
,	O
James	O
Watson	O
for	O
sectioning	O
tissue	O
,	O
and	O
Dr	O
.	O
William	O
Kiossis	O
for	O
collecting	O
confocal	O
images	O
.	O

Abbreviations	O

AQP	O
[	O
number	O
]	O
-	O
aquaporin	O
-	O
[	O
number	O
]	O

AVPR2	B-GGP
-	O
AVP	B-GGP
type	I-GGP
2	I-GGP
receptor	I-GGP

AVP	B-GGP
-	O
arginine	B-GGP
vasopressin	I-GGP

dDAVP	O
-	O
1	O
-	O
deamino	O
-	O
8	O
-	O
D	B-CHEBI
-	I-CHEBI
arginine	I-CHEBI
vasopressin	O

ER	B-GO
-	O
endoplasmic	B-GO
reticulum	I-GO

MDCK	O
-	O
Madin	O
-	O
Darby	O
canine	B-Taxon
kidney	O

NDI	O
-	O
nephrogenic	O
diabetes	O
insipidus	O

PM	B-GO
-	O
plasma	B-GO
membrane	I-GO

Figures	O

Figure	O
1	O

Analysis	O
of	O
Aqp2	B-GGP
Sequence	B-SO
and	O
Phenotype	O
in	O
Mutant	B-SO
Mice	B-Taxon

(	O
A	O
)	O
Chromatographic	O
traces	O
of	O
Aqp2	B-GGP
F204V	O
mutation	B-SO
.	O

The	O
box	O
shows	O
the	O
mutated	B-SO
codon	B-SO
,	O
TTC	O
(	O
Phe	B-CHEBI
)	O
to	O
GTC	O
(	O
Val	B-CHEBI
)	O
at	O
position	B-SO
204	O
.	O

WT	B-SO
,	O
wild	B-SO
type	I-SO
;	O
Mut	B-SO
,	O
mutant	B-SO
.	O

(	O
B	O
)	O
Amino	B-CHEBI
acid	I-CHEBI
conservation	B-SO
of	O
mouse	B-GGP
AQP2	I-GGP
(	O
residues	B-CHEBI
194	O
-	O
214	O
)	O
.	O

The	O
boxed	O
residue	B-CHEBI
indicates	O
phenylalanine	B-CHEBI
at	O
position	B-SO
204	O
.	O

hAQP2	B-GGP
,	O
human	B-GGP
AQP2	I-GGP
;	O
mAQP1	B-GGP
,	O
mouse	B-GGP
AQP1	I-GGP
;	O
mAQP2	B-GGP
,	O
mouse	B-GGP
AQP2	I-GGP
;	O
rAQP2	B-GGP
,	O
rat	B-GGP
AQP2	I-GGP
;	O
xAQP2	B-GGP
,	O
Xenopus	B-GGP
AQP2	I-GGP
.	O

(	O
C	O
)	O
Urine	O
production	O
(	O
ml	O
)	O
and	O
water	B-CHEBI
consumption	O
(	O
ml	O
)	O
of	O
58	O
F2	O
mice	B-Taxon
over	O
a	O
24	O
-	O
h	O
period	O
(	O
both	O
sexes	O
,	O
aged	O
10	O
-	O
22	O
wk	O
)	O
.	O

Mutant	B-SO
mice	B-Taxon
(	O
black	O
squares	O
)	O
exhibit	O
overt	O
polyuria	O
and	O
polydipsia	O
compared	O
to	O
littermate	O
wild	B-SO
-	I-SO
type	I-SO
(	O
white	O
triangles	O
)	O
and	O
heterozygous	O
(	O
grey	O
circles	O
)	O
mice	B-Taxon
.	O

(	O
D	O
)	O
Urine	O
osmolality	O
and	O
concentrating	O
ability	O
in	O
Aqp2	B-GGP
mutant	B-SO
and	O
their	O
littermates	O
(	O
10	O
-	O
22	O
wk	O
,	O
both	O
sexes	O
)	O
,	O
before	O
(	O
white	O
bars	O
)	O
and	O
after	O
(	O
black	O
bars	O
)	O
dDAVP	O
treatment	O
.	O

Wild	B-SO
type	I-SO
(	O
WT	B-SO
;	O
n	O
=	O
12	O
)	O
;	O
heterozygote	O
(	O
Het	O
;	O
n	O
=	O
20	O
)	O
;	O
mutant	B-SO
(	O
Mut	B-SO
;	O
n	O
=	O
9	O
)	O
.	O

Data	O
represent	O
averages	O
+/-	O
standard	O
error	O
of	O
the	O
mean	O
,	O
*	O
*	O
p	O
<	O
0	O
.	O
01	O
;	O
*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
.	O

Figure	O
2	O

Anatomy	O
and	O
Histology	O
of	O
Mouse	B-Taxon
Kidneys	O

(	O
A	O
)	O
Gross	O
anatomy	O
of	O
an	O
affected	O
mouse	B-Taxon
(	O
8	O
-	O
mo	O
-	O
old	O
male	O
)	O
.	O

This	O
shows	O
the	O
enlargement	O
and	O
cystic	O
dilatation	O
of	O
the	O
renal	O
pelvis	O
.	O

There	O
is	O
thinning	O
of	O
the	O
overlying	O
renal	O
parenchyma	O
imparting	O
a	O
translucent	O
appearance	O
to	O
portions	O
of	O
the	O
kidney	O
and	O
collecting	O
system	O
.	O

The	O
bladder	O
is	O
also	O
dilated	O
.	O

(	O
B	O
)	O
Left	O
kidney	O
from	O
mutant	B-SO
mouse	B-Taxon
(	O
right	O
)	O
shown	O
in	O
(	O
A	O
)	O
compared	O
to	O
a	O
kidney	O
from	O
an	O
age	O
-	O
sex	O
matched	O
unaffected	O
littermate	O
(	O
left	O
)	O
.	O

(	O
C	O
)	O
Hematoxylin	O
and	O
eosin	O
stained	O
section	O
of	O
ureter	O
from	O
a	O
mutant	B-SO
mouse	B-Taxon
,	O
showing	O
normal	O
histology	O
despite	O
bloating	O
of	O
the	O
kidney	O
.	O

(	O
D	O
)	O
Hematoxylin	O
and	O
eosin	O
stained	O
histologic	O
section	O
of	O
a	O
kidney	O
from	O
a	O
4	O
-	O
wk	O
-	O
old	O
female	O
mutant	B-SO
mouse	B-Taxon
.	O

The	O
mutant	B-SO
kidney	O
shows	O
marked	O
dilatation	O
of	O
the	O
renal	O
pelvis	O
with	O
blunting	O
of	O
the	O
papilla	O
.	O

There	O
is	O
preservation	O
of	O
the	O
cortex	O
and	O
medulla	O
.	O

Figure	O
3	O

Immunoblot	O
Analyses	O
of	O
AQP2	B-GGP
from	O
Mouse	B-Taxon
Kidneys	O

(	O
A	O
)	O
Western	O
blot	O
analyses	O
of	O
total	O
kidney	O
membranes	B-GO
from	O
littermate	O
mice	B-Taxon
.	O

An	O
intermediate	B-SO
form	B-SO
of	O
AQP2	B-GGP
at	O
31	O
kDa	O
was	O
identified	O
in	O
kidney	O
membranes	B-GO
from	O
a	O
mutant	B-SO
mouse	B-Taxon
(	O
Mut	B-SO
)	O
and	O
partially	O
in	O
a	O
heterozygous	O
mouse	B-Taxon
(	O
Het	O
)	O
.	O

(	O
B	O
)	O
Total	O
kidney	O
membranes	B-GO
were	O
subjected	O
to	O
endoglycosidase	B-GGP
H	I-GGP
treatment	O
(	O
Endo	B-GGP
H	I-GGP
)	O
prior	O
to	O
Western	O
blotting	O
.	O

High	O
-	O
mannose	B-CHEBI
(	O
h	O
.	O
m	B-CHEBI
.	I-CHEBI
)	O
glycosylated	O
proteins	B-CHEBI
that	O
have	O
not	O
exited	O
the	O
ER	B-GO
are	O
sensitive	O
to	O
endoglycosidase	B-GGP
H	I-GGP
digestion	O
.	O

Figure	O
4	O

AQP2	B-GGP
Subcellular	O
Localization	O
and	O
Translocation	O
in	O
Mouse	B-Taxon
Kidney	O
Collecting	O
Ducts	O
and	O
MDCK	O
Cell	B-CL
Lines	O

(	O
A	O
)	O
Immunohistochemistry	O
on	O
collecting	O
ducts	O
in	O
kidney	O
sections	O
from	O
an	O
AQP2	B-GGP
-	O
F204V	O
mutant	B-SO
(	O
Mut	B-SO
)	O
mouse	B-Taxon
and	O
an	O
age	O
-	O
sex	O
matched	O
wild	B-SO
-	I-SO
type	I-SO
(	O
WT	B-SO
)	O
littermate	O
.	O

Mice	B-Taxon
were	O
injected	O
intraperitoneally	O
with	O
PBS	O
(	O
NT	O
)	O
or	O
dDAVP	O
before	O
sacrificing	O
and	O
fixation	O
of	O
the	O
kidneys	O
.	O

Kidneys	O
sections	O
were	O
immunostained	O
for	O
AQP2	B-GGP
(	O
red	O
)	O
and	O
the	O
basolateral	O
marker	O
AQP3	B-GGP
(	O
green	O
)	O
.	O

The	O
images	O
were	O
merged	O
and	O
an	O
area	B-GO
of	I-GO
the	I-GO
cytoplasm	I-GO
was	O
magnified	O
(	O
zoom	O
)	O
.	O

Note	O
that	O
mutant	B-SO
AQP2	B-GGP
is	O
not	O
properly	O
localized	O
to	O
the	O
subapical	O
compartment	O
,	O
nor	O
does	O
it	O
respond	O
to	O
dDAVP	O
.	O

(	O
B	O
)	O
MDCK	O
cell	B-CL
lines	O
,	O
stably	O
transfected	O
with	O
constructs	B-SO
encoding	O
mouse	B-GGP
WT	I-GGP
or	I-GGP
AQP2	I-GGP
-	O
F204V	O
,	O
were	O
treated	O
with	O
and	O
without	O
150	O
mu	O
M	O
forskolin	O
for	O
90	O
min	O
,	O
after	O
which	O
cells	B-CL
were	O
fixed	O
,	O
permeabilized	O
,	O
and	O
subjected	O
to	O
immunocytochemistry	O
.	O

AQP2	B-GGP
is	O
shown	O
in	O
green	O
,	O
and	O
the	O
basolateral	O
marker	O
Na	B-CHEBI
+	I-CHEBI
/	O
K	B-CHEBI
+	I-CHEBI
-	O
ATPase	O
is	O
shown	O
in	O
red	O
,	O
alongside	O
the	O
nuclear	B-GO
stain	O
DAPI	O
.	O

The	O
z	O
-	O
profile	O
images	O
were	O
reconstructed	O
from	O
multiple	O
z	O
-	O
sections	O
,	O
along	O
the	O
dotted	O
line	O
.	O

Mutant	B-SO
AQP2	B-GGP
fails	O
to	O
localize	O
to	O
the	O
cell	B-GO
surface	I-GO
upon	O
forskolin	O
stimulation	O
.	O

Rather	O
,	O
the	O
perinuclear	B-GO
staining	O
is	O
consistent	O
with	O
an	O
ER	B-GO
localization	O
of	O
mutant	B-SO
AQP2	B-GGP
.	O

(	O
C	O
)	O
The	O
MDCK	O
cell	B-CL
line	O
expressing	O
AQP2	B-GGP
-	O
F204V	O
was	O
grown	O
on	O
fibronectin	B-GGP
-	O
coated	O
coverslips	O
until	O
tight	B-GO
junctions	I-GO
formed	O
,	O
at	O
which	O
point	O
the	O
cells	B-CL
were	O
treated	O
with	O
150	O
mu	O
M	O
forskolin	O
for	O
90	O
min	O
.	O

Cells	B-CL
were	O
fixed	O
,	O
permeabilized	O
,	O
and	O
sequentially	O
immunoblotted	O
for	O
AQP2	B-GGP
(	O
green	O
)	O
and	O
calnexin	B-GGP
(	O
red	O
)	O
,	O
an	O
ER	B-GO
marker	O
.	O

The	O
merged	O
image	O
shows	O
that	O
AQP2	B-GGP
-	O
F204V	O
colocalizes	O
with	O
the	O
endoplasmic	B-GO
reticulum	I-GO
marker	O
.	O

Scale	O
bar	O
refers	O
to	O
10	O
mu	O
m	O
.	O

Figure	O
5	O

AQP2	B-GGP
-	O
F204V	O
Rescue	O
in	O
Heterozygous	O
Mouse	B-Taxon
Collecting	O
Ducts	O
and	O
in	O
Cotransfected	O
MDCK	O
Cells	B-CL

(	O
A	O
)	O
In	O
heterozygous	O
animals	B-Taxon
,	O
AQP2	B-GGP
localizes	O
and	O
responds	O
to	O
dDAVP	O
normally	O
.	O

Immunohistochemistry	O
was	O
carried	O
out	O
on	O
kidney	O
sections	O
from	O
an	O
Aqp2F204V	O
/	O
+	B-SO
mouse	B-Taxon
,	O
after	O
injection	O
with	O
dDAVP	O
.	O

Kidney	O
sections	O
were	O
sequentially	O
immunostained	O
for	O
AQP2	B-GGP
(	O
red	O
)	O
and	O
the	O
basolateral	O
marker	O
AQP3	B-GGP
(	O
green	O
)	O
.	O

(	O
B	O
)	O
Mutant	B-SO
and	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
physically	O
interact	O
.	O

MDCK	O
cells	B-CL
stably	O
expressing	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
were	O
transiently	O
transfected	O
with	O
GFP	O
tagged	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
,	O
AQP2	B-GGP
-	O
F204V	O
,	O
or	O
GFP	O
alone	O
.	O

Solubilized	O
membranes	B-GO
were	O
immunoprecipitated	O
with	O
a	O
GFP	O
antibody	B-GO
.	O

Total	O
membranes	B-GO
and	O
immunoprecipitates	O
(	O
GFP	O
-	O
IP	O
)	O
were	O
Western	O
blotted	O
using	O
an	O
antibody	B-GO
against	O
AQP2	B-GGP
(	O
arrow	O
)	O
or	O
AQP2	B-GGP
-	O
GFP	O
fusions	O
(	O
arrowhead	O
)	O
.	O

(	O
C	O
)	O
Wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
rescues	O
the	O
localization	O
defect	O
of	O
mutant	B-SO
AQP2	B-GGP
.	O

GFP	O
fusions	O
of	O
either	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
(	O
WT	B-SO
-	O
GFP	O
,	O
top	O
photomicrographs	O
)	O
or	O
F204V	O
AQP2	B-GGP
(	O
F204V	O
-	O
GFP	O
,	O
bottom	O
photomicrographs	O
)	O
were	O
expressed	O
in	O
polarized	O
MDCK	O
stable	O
cell	B-CL
lines	O
expressing	O
vector	B-SO
alone	O
(	O
vector	B-SO
,	O
left	O
photomicrographs	O
)	O
or	O
AQP2	B-GGP
-	O
WT	B-SO
(	O
right	O
photomicrographs	O
)	O
.	O

Cells	B-CL
were	O
stimulated	O
with	O
forskolin	O
,	O
processed	O
for	O
immunocytochemistry	O
,	O
and	O
used	O
to	O
generate	O
z	O
-	O
sectional	O
images	O
.	O

(	O
D	O
)	O
Mutant	B-SO
AQP2	B-GGP
is	O
present	O
at	O
the	O
cell	B-GO
surface	I-GO
in	O
cells	B-CL
coexpressing	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
(	O
AQP2	B-GGP
-	O
WT	B-SO
)	O
.	O

GFP	O
fused	O
to	O
AQP2	B-GGP
-	O
F204V	O
was	O
expressed	O
in	O
MDCK	O
cells	B-CL
expressing	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
or	O
vector	B-SO
alone	O
.	O

Cells	B-CL
were	O
stimulated	O
with	O
forskolin	O
,	O
and	O
cell	B-GO
surface	I-GO
biotinylated	O
proteins	B-CHEBI
were	O
precipitated	O
then	O
analyzed	O
for	O
the	O
presence	O
of	O
wild	B-SO
-	I-SO
type	I-SO
AQP2	B-GGP
(	O
arrow	O
)	O
and	O
AQP2	B-GGP
-	O
F204V	O
(	O
arrowhead	O
)	O
by	O
Western	O
blot	O
.	O

Footnotes	O

Competing	O
interests	O
.	O

The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Author	O
contributions	O
.	O

DJL	O
and	O
NG	O
conceived	O
and	O
designed	O
the	O
experiments	O
.	O

DJL	O
performed	O
the	O
experiments	O
.	O

DJL	O
,	O
FWH	O
,	O
and	O
NG	O
analyzed	O
the	O
data	O
.	O

DJL	O
and	O
LMT	O
contributed	O
reagents	B-CHEBI
/	O
materials	O
/	O
analysis	O
tools	O
.	O

DJL	O
and	O
NG	O
wrote	O
the	O
paper	O
.	O

Citation	O
:	O
Lloyd	O
DJ	O
,	O
Hall	O
FW	O
,	O
Tarantino	O
LM	O
,	O
Gekakis	O
N	O
(	O
2005	O
)	O
Diabetes	O
insipidus	O
in	O
mice	B-Taxon
with	O
a	O
mutation	B-SO
in	O
aquaporin	B-GGP
-	I-GGP
2	I-GGP
.	O

PLoS	O
Genet	O
1	O
(	O
2	O
)	O
:	O
e20	O
.	O

Enhanced	O
Odor	O
Discrimination	O
and	O
Impaired	O
Olfactory	O
Memory	O
by	O
Spatially	O
Controlled	O
Switch	O
of	O
AMPA	O
Receptors	O

Abstract	O

Genetic	B-SO
perturbations	O
of	O
alpha	O
-	O
amino	B-CHEBI
-	O
3	O
-	O
hydroxy	B-CHEBI
-	O
5	O
-	O
methyl	B-CHEBI
-	O
4	O
-	O
isoxazolepropionate	O
receptors	O
(	O
AMPARs	O
)	O
are	O
widely	O
used	O
to	O
dissect	O
molecular	B-CHEBI
mechanisms	O
of	O
sensory	O
coding	O
,	O
learning	O
,	O
and	O
memory	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
Ca2	B-CHEBI
+	I-CHEBI
-	O
permeable	O
AMPARs	O
in	O
olfactory	O
behavior	O
.	O

AMPAR	O
modification	B-SO
was	O
obtained	O
by	O
depletion	O
of	O
the	O
GluR	B-GGP
-	I-GGP
B	I-GGP
subunit	I-GGP
or	O
expression	O
of	O
unedited	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
Q	B-CHEBI
)	O
,	O
both	O
leading	O
to	O
increased	O
Ca2	B-CHEBI
+	I-CHEBI
permeability	O
of	O
AMPARs	O
.	O

Mice	B-Taxon
with	O
this	O
functional	O
AMPAR	O
switch	O
,	O
specifically	O
in	O
forebrain	O
,	O
showed	O
enhanced	O
olfactory	O
discrimination	O
and	O
more	O
rapid	O
learning	O
in	O
a	O
go	O
/	O
no	O
-	O
go	O
operant	O
conditioning	O
task	O
.	O

Olfactory	O
memory	O
,	O
however	O
,	O
was	O
dramatically	O
impaired	O
.	O

GluR	B-GGP
-	I-GGP
B	I-GGP
depletion	O
in	O
forebrain	O
was	O
ectopically	O
variable	O
(	O
"	O
mosaic	O
"	O
)	O
among	O
individuals	B-Taxon
and	O
strongly	O
correlated	O
with	O
decreased	O
olfactory	O
memory	O
in	O
hippocampus	O
and	O
cortex	O
.	O

Accordingly	O
,	O
memory	O
was	O
rescued	O
by	O
transgenic	B-SO
GluR	B-GGP
-	I-GGP
B	I-GGP
expression	O
restricted	O
to	O
piriform	O
cortex	O
and	O
hippocampus	O
,	O
while	O
enhanced	O
odor	O
discrimination	O
was	O
independent	O
of	O
both	O
GluR	B-GGP
-	I-GGP
B	I-GGP
variability	O
and	O
transgenic	B-SO
GluR	B-GGP
-	I-GGP
B	I-GGP
expression	O
.	O

Thus	O
,	O
correlated	O
differences	O
in	O
behavior	O
and	O
levels	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
expression	O
allowed	O
a	O
mechanistic	O
and	O
spatial	O
dissection	O
of	O
olfactory	O
learning	O
,	O
discrimination	O
,	O
and	O
memory	O
capabilities	O
.	O

Introduction	O

The	O
sense	O
of	O
smell	O
is	O
of	O
paramount	O
importance	O
for	O
rodents	B-Taxon
[	O
1	O
]	O
,	O
for	O
which	O
rapid	O
odor	O
discrimination	O
and	O
long	O
-	O
lasting	O
olfactory	O
memory	O
permits	O
responses	O
to	O
predator	O
and	O
prey	O
critical	O
for	O
survival	O
.	O

Consequently	O
,	O
the	O
behavioral	O
analyses	O
of	O
olfactory	O
capabilities	O
in	O
rodents	B-Taxon
are	O
efficient	O
,	O
quantitative	O
,	O
and	O
reproducible	O
[	O
2	O
-	O
4	O
]	O
.	O

While	O
in	O
the	O
formation	O
and	O
storage	O
of	O
olfactory	O
memory	O
piriform	O
cortex	O
[	O
5	O
-	O
7	O
]	O
,	O
hippocampus	O
[	O
8	O
,	O
9	O
]	O
,	O
and	O
olfactory	O
bulb	O
[	O
10	O
-	O
12	O
]	O
are	O
all	O
implicated	O
,	O
the	O
cellular	B-CL
correlates	O
for	O
these	O
processes	O
have	O
not	O
been	O
clearly	O
delineated	O
.	O

The	O
contribution	O
of	O
the	O
hippocampus	O
to	O
olfactory	O
memory	O
is	O
presently	O
controversial	O
[	O
2	O
,	O
13	O
-	O
18	O
]	O
,	O
but	O
is	O
deemed	O
unlikely	O
for	O
simple	O
olfactory	O
discrimination	O
tasks	O
[	O
9	O
,	O
19	O
]	O
.	O

In	O
fact	O
,	O
the	O
most	O
likely	O
candidates	O
for	O
a	O
cellular	B-CL
correlate	O
of	O
olfactory	O
memory	O
appear	O
to	O
be	O
the	O
neuronal	B-CL
connections	O
in	O
the	O
piriform	O
cortex	O
due	O
to	O
the	O
associational	O
connectivity	O
[	O
5	O
]	O
and	O
the	O
expression	O
of	O
several	O
forms	O
of	O
cellular	B-CL
and	O
synaptic	B-GO
plasticity	O
[	O
7	O
,	O
20	O
-	O
23	O
]	O
.	O

Concerning	O
odor	O
discrimination	O
itself	O
,	O
cellular	B-CL
mechanisms	O
for	O
this	O
process	O
are	O
often	O
attributed	O
to	O
the	O
inhibitory	O
circuitry	O
of	O
the	O
olfactory	O
bulb	O
(	O
[	O
24	O
-	O
30	O
]	O
;	O
reviewed	O
in	O
[	O
31	O
-	O
33	O
]	O
)	O
.	O

Lateral	O
inhibitory	O
circuits	O
were	O
postulated	O
,	O
in	O
analogy	O
to	O
retina	O
[	O
34	O
,	O
35	O
]	O
,	O
to	O
mediate	O
contrast	O
enhancement	O
[	O
24	O
]	O
,	O
for	O
which	O
physiological	O
recordings	O
[	O
24	O
,	O
36	O
,	O
37	O
]	O
and	O
modeling	O
data	O
,	O
based	O
on	O
the	O
well	O
-	O
known	O
anatomy	O
[	O
29	O
]	O
,	O
provide	O
additional	O
support	O
.	O

Such	O
contrast	O
enhancement	O
may	O
rest	O
in	O
large	O
part	O
on	O
the	O
particular	O
properties	O
of	O
dendrodendritic	O
synapses	B-GO
between	O
the	O
principal	B-CL
output	I-CL
neurons	I-CL
(	O
mitral	O
cells	B-CL
)	O
and	O
local	O
inhibitory	O
neurons	B-CL
(	O
granule	B-CL
cells	I-CL
)	O
of	O
the	O
olfactory	O
bulb	O
.	O

In	O
these	O
distinct	O
synapses	B-GO
,	O
lateral	O
and	O
recurrent	O
inhibition	O
mediated	O
by	O
the	O
gamma	B-CHEBI
-	I-CHEBI
aminobutyric	I-CHEBI
acid	I-CHEBI
-	O
A	O
system	O
may	O
be	O
controlled	O
by	O
the	O
activity	O
of	O
the	O
closely	O
appositioned	O
glutamatergic	B-CHEBI
part	O
,	O
perhaps	O
triggering	O
increased	O
gamma	B-CHEBI
-	I-CHEBI
aminobutyric	I-CHEBI
acid	I-CHEBI
release	O
by	O
Ca2	B-CHEBI
+	I-CHEBI
influx	O
through	O
glutamate	B-CHEBI
-	O
gated	O
receptor	O
channels	O
(	O
[	O
38	O
]	O
;	O
see	O
also	O
[	O
39	O
]	O
)	O
.	O

Given	O
that	O
neuronal	B-CL
circuits	O
underlying	O
odor	O
discrimination	O
,	O
as	O
well	O
as	O
olfactory	O
memory	O
,	O
rely	O
on	O
properties	O
of	O
fast	O
excitatory	O
neurotransmission	O
mediated	O
by	O
alpha	O
-	O
amino	B-CHEBI
-	O
3	O
-	O
hydroxy	B-CHEBI
-	O
5	O
-	O
methyl	B-CHEBI
-	O
4	O
-	O
isoxazolepropionate	O
receptors	O
(	O
AMPARs	O
)	O
,	O
we	O
sought	O
to	O
alter	O
,	O
by	O
genetic	B-SO
means	O
,	O
the	O
specific	O
functional	O
contribution	O
of	O
alpha	O
-	O
amino	B-CHEBI
-	O
3	O
-	O
hydroxy	B-CHEBI
-	O
5	O
-	O
methyl	B-CHEBI
-	O
4	O
-	O
isoxazolepropionate	O
(	O
AMPA	O
)	O
channels	O
containing	O
the	O
dominant	O
subunit	O
GluR	B-GGP
-	I-GGP
B	I-GGP
.	O

Of	O
the	O
four	O
AMPAR	O
constituents	O
,	O
GluR	B-GGP
-	I-GGP
A	I-GGP
to	I-GGP
D	I-GGP
(	O
GluR1	B-GGP
to	O
4	O
)	O
,	O
which	O
form	O
tetrameric	O
channels	O
with	O
different	O
binary	O
subunit	O
combinations	O
,	O
GluR	B-GGP
-	I-GGP
B	I-GGP
is	O
contained	O
in	O
the	O
majority	O
of	O
AMPARs	O
.	O

GluR	B-GGP
-	I-GGP
B	I-GGP
is	O
critically	O
involved	O
in	O
the	O
formation	O
and	O
trafficking	O
of	O
AMPARs	O
,	O
and	O
dominates	O
their	O
ion	B-CHEBI
conductance	O
and	O
gating	O
properties	O
[	O
40	O
-	O
46	O
]	O
.	O

Notably	O
,	O
the	O
normally	O
low	O
Ca2	B-CHEBI
+	I-CHEBI
permeability	O
of	O
AMPA	O
channels	O
in	O
principal	B-CL
neurons	I-CL
is	O
solely	O
mediated	O
by	O
GluR	B-GGP
-	I-GGP
B	I-GGP
,	O
due	O
to	O
a	O
unique	O
arginine	B-CHEBI
residue	I-CHEBI
(	O
R587	O
)	O
in	O
the	O
functionally	O
critical	O
glutamine	B-CHEBI
/	O
arginine	B-CHEBI
(	O
Q	B-CHEBI
/	O
R	B-CHEBI
)	O
site	B-SO
of	O
the	O
pore	O
-	O
forming	O
segment	O
M2	O
[	O
44	O
,	O
47	O
,	O
48	O
]	O
,	O
resulting	O
from	O
RNA	B-SO
editing	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
pre	B-SO
-	I-SO
mRNA	I-SO
(	O
[	O
49	O
]	O
;	O
reviewed	O
in	O
[	O
50	O
]	O
)	O
.	O

Hence	O
,	O
either	O
GluR	B-GGP
-	I-GGP
B	I-GGP
deficiency	O
,	O
or	O
the	O
expression	O
of	O
Q	B-CHEBI
/	O
R	B-CHEBI
site	B-SO
-	O
unedited	O
GluR	B-GGP
-	I-GGP
B	I-GGP
with	O
a	O
glutamine	B-CHEBI
residue	I-CHEBI
at	O
the	O
critical	O
channel	O
site	B-SO
,	O
leads	O
to	O
increased	O
Ca2	B-CHEBI
+	I-CHEBI
permeability	O
of	O
AMPA	O
channels	O
,	O
as	O
amply	O
demonstrated	O
in	O
gene	B-SO
-	O
targeted	O
mice	B-Taxon
[	O
51	O
,	O
53	O
,	O
58	O
,	O
60	O
]	O
.	O

Thus	O
,	O
the	O
absence	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
,	O
or	O
the	O
expression	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
Q	B-CHEBI
)	O
in	O
the	O
olfactory	O
bulb	O
,	O
may	O
generate	O
increased	O
inhibition	O
in	O
mitral	O
cells	B-CL
.	O

Moreover	O
,	O
the	O
ablation	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
,	O
but	O
also	O
changes	O
in	O
the	O
extent	O
of	O
Q	B-CHEBI
/	O
R	B-CHEBI
site	B-SO
editing	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
,	O
can	O
alter	O
the	O
strength	O
of	O
excitatory	B-GO
synaptic	I-GO
transmission	O
in	O
the	O
genetically	B-SO
addressed	O
neuronal	B-CL
populations	O
[	O
51	O
,	O
58	O
,	O
60	O
]	O
,	O
thus	O
potentially	O
shifting	O
the	O
balance	O
of	O
excitatory	O
and	O
inhibitory	O
transmission	O
in	O
the	O
affected	O
circuits	O
.	O

Similarly	O
,	O
changes	O
in	O
synaptic	B-GO
plasticity	O
due	O
to	O
Ca2	B-CHEBI
+	I-CHEBI
-	O
permeable	O
AMPARs	O
[	O
51	O
,	O
52	O
,	O
60	O
]	O
,	O
e	O
.	O
g	O
.	O
,	O
in	O
piriform	O
cortex	O
,	O
might	O
alter	O
odor	O
memorization	O
processes	O
.	O

Thus	O
,	O
alterations	O
of	O
AMPAR	O
properties	O
in	O
these	O
brain	O
regions	O
will	O
allow	O
investigation	O
and	O
possibly	O
separation	O
of	O
mechanisms	O
underlying	O
these	O
behavioral	O
traits	O
.	O

Concerning	O
this	O
intended	O
switch	O
in	O
AMPAR	O
properties	O
,	O
mice	B-Taxon
lacking	O
all	O
GluR	B-GGP
-	I-GGP
B	I-GGP
,	O
however	O
,	O
show	O
a	O
widespread	O
impairment	O
in	O
behavior	O
,	O
including	O
lethargy	O
,	O
motor	O
coordination	O
problems	O
,	O
and	O
deficits	O
in	O
exploratory	O
activity	O
[	O
51	O
]	O
,	O
which	O
preclude	O
detailed	O
behavioral	O
analyses	O
.	O

Similarly	O
,	O
mice	B-Taxon
expressing	O
(	O
in	O
the	O
entire	O
brain	O
)	O
a	O
substantial	O
part	O
of	O
the	O
GluR	B-GGP
-	I-GGP
B	I-GGP
population	O
in	O
the	O
Q	B-CHEBI
/	O
R	B-CHEBI
site	B-SO
-	O
unedited	O
form	B-SO
become	O
seizure	O
-	O
prone	O
and	O
die	O
prematurely	O
[	O
53	O
]	O
.	O

Some	O
of	O
these	O
problems	O
can	O
be	O
partially	O
overcome	O
by	O
use	O
of	O
spatially	O
and	O
temporally	O
restricted	O
expression	O
systems	O
[	O
54	O
-	O
56	O
]	O
,	O
in	O
particular	O
the	O
Cre	O
-	O
lox	O
system	O
,	O
with	O
Cre	O
-	O
recombinase	O
expression	O
in	O
defined	O
brain	O
areas	O
of	O
gene	B-SO
-	O
targeted	O
mice	B-Taxon
carrying	O
GluR	B-GGP
-	I-GGP
B	I-GGP
alleles	B-SO
marked	O
by	O
loxP	B-SO
sites	I-SO
for	O
Cre	O
-	O
mediated	O
recombination	O
[	O
55	O
,	O
57	O
]	O
.	O

Indeed	O
,	O
restricting	O
the	O
expression	O
of	O
Q	B-CHEBI
/	O
R	B-CHEBI
site	B-SO
-	O
unedited	O
GluR	B-GGP
-	I-GGP
B	I-GGP
to	O
forebrain	O
resulted	O
in	O
almost	O
normal	O
lifespan	O
and	O
an	O
only	O
weakly	O
seizure	O
-	O
prone	O
phenotype	O
[	O
58	O
]	O
.	O

Mice	B-Taxon
with	O
forebrain	O
-	O
specific	O
GluR	B-GGP
-	I-GGP
B	I-GGP
depletion	O
appeared	O
almost	O
completely	O
normal	O
throughout	O
life	O
with	O
no	O
developmental	O
abnormalities	O
,	O
thus	O
permitting	O
a	O
detailed	O
,	O
quantitative	O
investigation	O
of	O
olfactory	O
behavior	O
.	O

To	O
allow	O
for	O
the	O
mechanistic	O
separation	O
of	O
olfactory	O
learning	O
,	O
discrimination	O
,	O
and	O
memory	O
,	O
we	O
exploited	O
a	O
well	O
-	O
known	O
phenomenon	O
of	O
transgenes	B-SO
,	O
which	O
concerns	O
heterogeneous	O
expression	O
among	O
different	O
founder	O
lines	O
and	O
even	O
among	O
genetically	B-SO
identical	O
individuals	B-Taxon
of	O
a	O
given	O
line	O
.	O

Although	O
such	O
"	O
mosaic	O
"	O
expression	O
is	O
usually	O
undesired	O
,	O
here	O
we	O
took	O
advantage	O
of	O
it	O
by	O
ablating	O
GluR	B-GGP
-	I-GGP
B	I-GGP
via	O
gene	B-SO
-	O
targeted	O
,	O
floxed	B-SO
GluR	B-GGP
-	I-GGP
B	I-GGP
alleles	B-SO
with	O
the	O
help	O
of	O
a	O
transgenic	B-SO
mouse	B-Taxon
line	O
with	O
variegated	O
Cre	O
expression	O
in	O
forebrain	O
.	O

By	O
correlating	O
GluR	B-GGP
-	I-GGP
B	I-GGP
levels	O
in	O
olfaction	O
-	O
related	O
brain	O
regions	O
with	O
quantitative	O
behavioral	O
data	O
,	O
we	O
investigated	O
the	O
dependence	O
on	O
GluR	B-GGP
-	I-GGP
B	I-GGP
of	O
olfactory	O
discrimination	O
and	O
memory	O
.	O

Moreover	O
,	O
to	O
delineate	O
the	O
brain	O
areas	O
involved	O
in	O
these	O
distinctive	O
olfactory	O
processes	O
we	O
used	O
transgenic	B-SO
"	O
rescue	O
"	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
ablation	O
,	O
specifically	O
in	O
piriform	O
cortex	O
and	O
hippocampus	O
.	O

These	O
efforts	O
allowed	O
us	O
to	O
dissect	O
,	O
both	O
spatially	O
and	O
mechanistically	O
,	O
the	O
role	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
-	O
mediated	O
AMPAR	O
properties	O
in	O
selected	O
brain	O
regions	O
in	O
odor	O
learning	O
,	O
discrimination	O
,	O
and	O
memory	O
.	O

Results	O

GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
Q	B-CHEBI
)	O
Expression	O
in	O
the	O
Forebrain	O
Increases	O
Olfactory	O
Learning	O
and	O
Discrimination	O

To	O
explore	O
the	O
role	O
of	O
fast	O
excitatory	O
neurotransmission	O
carried	O
by	O
GluR	B-GGP
-	I-GGP
B	I-GGP
-	O
containing	O
AMPA	O
channels	O
in	O
olfactory	O
processes	O
,	O
we	O
first	O
analyzed	O
mice	B-Taxon
that	O
express	O
part	O
of	O
the	O
GluR	B-GGP
-	I-GGP
B	I-GGP
population	O
in	O
a	O
Q	B-CHEBI
/	O
R	B-CHEBI
site	B-SO
-	O
unedited	O
form	B-SO
(	O
Figure	O
1A	O
;	O
termed	O
"	O
GluR	O
-	O
B	O
Delta	O
ECS	O
:	O
FB	O
"	O
;	O
see	O
also	O
[	O
58	O
]	O
)	O
.	O

These	O
mice	B-Taxon
carry	O
,	O
in	O
addition	O
to	O
a	O
wild	B-SO
-	I-SO
type	I-SO
GluR	B-GGP
-	I-GGP
B	I-GGP
allele	B-SO
,	O
a	O
gene	B-SO
-	O
targeted	O
GluR	O
-	O
Bneo	O
allele	B-SO
in	O
which	O
the	O
intronic	B-SO
sequence	I-SO
critical	O
for	O
GluR	B-GGP
-	I-GGP
B	I-GGP
pre	B-SO
-	I-SO
mRNA	I-SO
editing	O
at	O
the	O
Q	B-CHEBI
/	O
R	B-CHEBI
site	B-SO
is	O
replaced	B-SO
by	O
a	O
floxed	B-SO
TK	I-SO
-	I-SO
neo	I-SO
gene	I-SO
,	O
which	O
severely	O
reduces	O
splicing	O
of	O
the	O
modified	B-SO
intron	B-SO
and	O
hence	O
attenuates	O
the	O
expression	O
of	O
the	O
GluR	O
-	O
Bneo	O
allele	B-SO
[	O
60	O
]	O
.	O

To	O
unsilence	O
the	O
attenuated	O
GluR	O
-	O
Bneo	O
allele	B-SO
,	O
specifically	O
in	O
the	O
postnatal	O
forebrain	O
,	O
we	O
crossed	O
in	O
the	O
TgCre4	O
transgene	B-SO
,	O
which	O
encodes	O
Cre	O
-	O
recombinase	O
and	O
is	O
driven	O
by	O
the	O
alpha	B-GGP
CaMKII	I-GGP
promoter	B-SO
(	O
[	O
59	O
]	O
;	O
"	O
Camkcre4	O
"	O
)	O
.	O

Thus	O
,	O
Cre	O
-	O
recombinase	O
removes	B-SO
in	O
forebrain	O
neurons	B-CL
the	O
intronic	B-SO
TK	O
-	O
neo	O
gene	B-SO
,	O
leading	O
to	O
the	O
active	O
GluR	O
-	O
B	O
Delta	O
ECS	O
allele	B-SO
for	O
Q	B-CHEBI
/	O
R	B-CHEBI
site	B-SO
-	O
unedited	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	I-GGP
Q	I-GGP
)	I-GGP
subunits	I-GGP
(	O
Figures	O
1	O
and	O
S1	O
)	O
.	O

As	O
expected	O
[	O
53	O
,	O
60	O
]	O
,	O
also	O
in	O
mice	B-Taxon
expressing	O
postnatally	O
forebrain	O
-	O
specific	O
Q	B-CHEBI
/	O
R	B-CHEBI
site	B-SO
-	O
unedited	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	I-GGP
Q	I-GGP
)	I-GGP
subunits	I-GGP
,	O
Ca2	B-CHEBI
+	I-CHEBI
permeability	O
through	O
AMPAR	O
was	O
increased	O
and	O
AMPAR	O
currents	O
showed	O
rectification	O
(	O
[	O
58	O
]	O
and	O
unpublished	O
data	O
)	O
.	O

GluR	O
-	O
B	O
Delta	O
ECS	O
:	O
FB	O
mice	B-Taxon
had	O
,	O
in	O
contrast	O
to	O
mice	B-Taxon
expressing	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
Q	B-CHEBI
)	O
globally	O
,	O
a	O
prolonged	O
lifespan	O
and	O
no	O
severe	O
developmental	O
alterations	O
.	O

They	O
were	O
however	O
,	O
still	O
seizure	O
-	O
prone	O
[	O
58	O
]	O
,	O
and	O
hence	O
behavioral	O
training	O
was	O
restricted	O
to	O
short	O
periods	O
of	O
time	O
.	O

We	O
trained	O
six	O
GluR	O
-	O
B	O
Delta	O
ECS	O
:	O
FB	O
mice	B-Taxon
and	O
six	O
littermate	O
controls	O
on	O
one	O
odor	O
pair	O
in	O
an	O
automated	O
go	O
/	O
no	O
-	O
go	O
olfactory	O
conditioning	O
task	O
[	O
3	O
,	O
61	O
]	O
.	O

In	O
this	O
task	O
,	O
water	B-CHEBI
-	O
deprived	O
mice	B-Taxon
are	O
trained	O
to	O
distinguish	O
a	O
water	B-CHEBI
-	O
rewarded	O
odor	O
(	O
S	O
+	O
)	O
and	O
an	O
unrewarded	O
odor	O
(	O
S	O
-	O
)	O
by	O
their	O
licking	O
response	O
(	O
Figure	O
1B	O
)	O
.	O

Both	O
GluR	O
-	O
B	O
Delta	O
ECS	O
:	O
FB	O
and	O
control	O
mice	B-Taxon
acquired	O
the	O
"	O
simple	O
"	O
task	O
to	O
discriminate	O
between	O
the	O
monomolecular	O
odors	O
amylacetate	O
and	O
ethylbutyrate	O
(	O
percentage	O
correct	O
>	O
70	O
%	O
after	O
400	O
trials	O
)	O
.	O

Strikingly	O
,	O
GluR	O
-	O
B	O
Delta	O
ECS	O
:	O
FB	O
mice	B-Taxon
showed	O
more	O
rapid	O
learning	O
and	O
enhanced	O
discrimination	O
capabilities	O
(	O
Figure	O
1C	O
,	O
group	O
effect	O
:	O
F	O
(	O
1	O
,	O
10	O
)	O
=	O
10	O
.	O
2	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

This	O
was	O
confirmed	O
by	O
fitting	O
linear	O
trend	O
lines	O
to	O
the	O
initial	O
part	O
of	O
the	O
learning	O
curve	O
(	O
slope	O
difference	O
:	O
p	O
<	O
0	O
.	O
05	O
;	O
see	O
Materials	O
and	O
Methods	O
)	O
.	O

The	O
training	O
system	O
employed	O
allows	O
for	O
careful	O
monitoring	O
of	O
head	O
positions	O
[	O
3	O
]	O
.	O

For	O
rewarded	O
trials	O
(	O
Figure	O
1D	O
,	O
green	O
)	O
,	O
already	O
weakly	O
trained	O
animals	B-Taxon
kept	O
their	O
head	O
in	O
the	O
sampling	O
port	O
(	O
large	O
tube	O
in	O
Figure	O
1B	O
)	O
during	O
the	O
entire	O
2	O
-	O
s	O
trial	O
,	O
whereas	O
for	O
unrewarded	O
trials	O
the	O
head	O
is	O
retracted	O
quickly	O
(	O
Figure	O
1D	O
,	O
red	O
)	O
.	O

The	O
difference	O
of	O
these	O
two	O
curves	O
(	O
Figure	O
1E	O
,	O
black	O
)	O
is	O
a	O
very	O
sensitive	O
assay	O
for	O
discrimination	O
performance	O
;	O
the	O
fitted	O
maximum	O
of	O
this	O
curve	O
(	O
Figure	O
1E	O
,	O
blue	O
)	O
is	O
referred	O
to	O
as	O
the	O
"	O
discrimination	O
index	O
"	O
in	O
the	O
remainder	O
of	O
the	O
paper	O
and	O
is	O
again	O
strongly	O
improved	O
for	O
GluR	O
-	O
B	O
Delta	O
ECS	O
:	O
FB	O
mice	B-Taxon
,	O
compared	O
with	O
controls	O
(	O
Figure	O
1F	O
;	O
group	O
effect	O
:	O
F	O
(	O
1	O
,	O
10	O
)	O
=	O
11	O
.	O
7	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

This	O
was	O
not	O
due	O
to	O
general	O
motor	O
performance	O
,	O
attention	O
,	O
or	O
motivation	O
changes	O
,	O
as	O
both	O
the	O
intertrial	O
interval	O
(	O
group	O
effect	O
:	O
F	O
(	O
1	O
,	O
10	O
)	O
=	O
0	O
.	O
56	O
,	O
p	O
>	O
0	O
.	O
4	O
)	O
and	O
the	O
overall	O
licking	O
frequency	O
(	O
group	O
effect	O
:	O
F	O
(	O
1	O
,	O
10	O
)	O
=	O
0	O
.	O
72	O
,	O
p	O
>	O
0	O
.	O
4	O
)	O
were	O
unaffected	O
.	O

Thus	O
,	O
expression	O
of	O
Ca2	B-CHEBI
+	I-CHEBI
-	O
permeable	O
AMPARs	O
in	O
forebrain	O
areas	O
,	O
including	O
the	O
olfactory	O
bulb	O
,	O
resulted	O
in	O
more	O
rapid	O
odor	O
learning	O
and	O
enhanced	O
olfactory	O
discrimination	O
.	O

GluR	O
-	O
B	O
Delta	O
FB	O
Mice	B-Taxon
Exhibit	O
Increased	O
Olfactory	O
Discrimination	O
Performance	O

To	O
ascertain	O
if	O
enhanced	O
olfactory	O
learning	O
and	O
odor	O
discrimination	O
may	O
indeed	O
correlate	O
with	O
the	O
increased	O
Ca2	B-CHEBI
+	I-CHEBI
permeability	O
of	O
AMPA	O
channels	O
in	O
the	O
Q	B-CHEBI
/	O
R	B-CHEBI
site	B-SO
-	O
unedited	O
form	B-SO
,	O
we	O
next	O
analyzed	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
,	O
which	O
lack	O
GluR	B-GGP
-	I-GGP
B	I-GGP
in	O
forebrain	O
.	O

This	O
specific	O
ablation	O
was	O
generated	O
by	O
forebrain	O
-	O
selective	O
TgCre4	O
expression	O
(	O
[	O
59	O
]	O
"	O
Camkcre4	O
"	O
)	O
in	O
gene	B-SO
-	O
targeted	O
GluR	O
-	O
B2lox	O
mice	B-Taxon
carrying	O
,	O
in	O
both	O
GluR	B-GGP
-	I-GGP
B	I-GGP
alleles	B-SO
,	O
a	O
floxed	B-SO
exon	B-SO
11	O
(	O
Figure	O
2A	O
)	O
.	O

The	O
specific	O
GluR	B-GGP
-	I-GGP
B	I-GGP
depletion	O
in	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
can	O
be	O
monitored	O
by	O
immunohistochemistry	O
(	O
see	O
below	O
)	O
and	O
immunoblotting	O
.	O

In	O
quantitative	O
immunoblot	O
analyses	O
,	O
we	O
found	O
GluR	B-GGP
-	I-GGP
B	I-GGP
levels	O
reduced	O
to	O
28	O
+/-	O
7	O
%	O
,	O
29	O
+/-	O
8	O
%	O
,	O
and	O
52	O
+/-	O
9	O
%	O
(	O
+/-	O
SEM	O
;	O
n	O
=	O
10	O
)	O
in	O
the	O
hippocampus	O
,	O
cortical	O
areas	O
,	O
and	O
olfactory	O
bulb	O
,	O
respectively	O
,	O
relative	O
to	O
GluR	B-GGP
-	I-GGP
B	I-GGP
levels	O
in	O
GluR	O
-	O
B2lox	O
littermate	O
controls	O
.	O

In	O
the	O
absence	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
,	O
the	O
electrophysiological	O
properties	O
of	O
AMPA	O
channels	O
become	O
similar	O
to	O
those	O
with	O
GluR	B-GGP
-	I-GGP
B	I-GGP
/	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
Q	B-CHEBI
)	O
switch	O
[	O
51	O
]	O
showing	O
strong	O
rectification	O
and	O
increased	O
Ca2	B-CHEBI
+	I-CHEBI
permeability	O
through	O
AMPA	O
channels	O
(	O
unpublished	O
data	O
)	O
.	O

However	O
,	O
GluR	B-GGP
-	I-GGP
B	I-GGP
depletion	O
is	O
not	O
lethal	O
and	O
does	O
not	O
produce	O
seizures	O
.	O

In	O
addition	O
,	O
in	O
contrast	O
to	O
the	O
complete	O
GluR	B-GGP
-	I-GGP
B	I-GGP
knockouts	O
,	O
mice	B-Taxon
with	O
forebrain	O
-	O
specific	O
GluR	B-GGP
-	I-GGP
B	I-GGP
depletion	O
appeared	O
normal	O
throughout	O
life	O
with	O
no	O
developmental	O
abnormalities	O
,	O
or	O
difference	O
in	O
body	O
size	O
and	O
weight	O
in	O
adulthood	O
(	O
wild	B-SO
-	I-SO
type	I-SO
:	O
31	O
.	O
0	O
g	O
+/-	O
1	O
.	O
2	O
;	O
GluR	O
-	O
B	O
Delta	O
FB	O
:	O
28	O
.	O
4	O
+/-	O
0	O
.	O
9	O
;	O
each	O
n	O
=	O
10	O
)	O
.	O

Exploratory	O
activity	O
in	O
an	O
open	O
field	O
task	O
was	O
slightly	O
increased	O
in	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
(	O
3	O
,	O
480	O
cm	O
+/-	O
180	O
,	O
n	O
=	O
11	O
)	O
,	O
compared	O
with	O
wild	B-SO
-	I-SO
type	I-SO
littermates	O
(	O
2	O
,	O
512	O
cm	O
+/-	O
96	O
,	O
n	O
=	O
12	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Motor	O
coordination	O
measured	O
in	O
an	O
accelerating	O
rotarod	O
was	O
somewhat	O
impaired	O
in	O
the	O
mutant	B-SO
mice	B-Taxon
(	O
wild	B-SO
-	I-SO
type	I-SO
:	O
156	O
s	O
+/-	O
37	O
,	O
n	O
=	O
6	O
;	O
GluR	O
-	O
B	O
Delta	O
FB	O
:	O
37	O
s	O
+/-	O
10	O
,	O
n	O
=	O
6	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Tests	O
in	O
the	O
dark	O
/	O
light	O
box	O
revealed	O
increased	O
anxiety	O
of	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
(	O
latency	O
of	O
first	O
exit	O
:	O
wild	B-SO
-	I-SO
type	I-SO
[	O
17	O
s	O
+/-	O
3	O
]	O
,	O
GluR	O
-	O
B	O
Delta	O
FB	O
[	O
97	O
s	O
+/-	O
42	O
]	O
,	O
p	O
=	O
0	O
.	O
047	O
;	O
compartment	O
changes	O
:	O
wild	B-SO
-	I-SO
type	I-SO
[	O
17	O
s	O
+/-	O
3	O
]	O
,	O
GluR	O
-	O
B	O
Delta	O
FB	O
[	O
7	O
+/-	O
2	O
]	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
time	O
spent	O
in	O
lit	O
compartment	O
:	O
wild	B-SO
-	I-SO
type	I-SO
[	O
103	O
s	O
+/-	O
10	O
]	O
,	O
GluR	O
-	O
B	O
Delta	O
FB	O
[	O
59	O
s	O
+/-	O
19	O
]	O
,	O
p	O
=	O
0	O
.	O
051	O
;	O
each	O
n	O
=	O
6	O
)	O
.	O

Hence	O
,	O
unlike	O
the	O
complete	O
GluR	B-GGP
-	I-GGP
B	I-GGP
knockouts	O
,	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
show	O
only	O
very	O
minor	O
changes	O
in	O
general	O
activity	O
and	O
no	O
sign	O
of	O
any	O
major	O
developmental	O
disturbance	O
,	O
thus	O
allowing	O
detailed	O
,	O
quantitative	O
behavioral	O
investigations	O
.	O

If	O
the	O
GluR	B-GGP
-	I-GGP
B	I-GGP
/	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
Q	B-CHEBI
)	O
switch	O
-	O
induced	O
alterations	O
in	O
the	O
Ca2	B-CHEBI
+	I-CHEBI
permeability	O
of	O
the	O
AMPA	O
channels	O
are	O
linked	O
to	O
enhanced	O
odor	O
discrimination	O
and	O
learning	O
,	O
the	O
depletion	O
of	O
the	O
GluR	B-GGP
-	I-GGP
B	I-GGP
subunit	I-GGP
should	O
lead	O
to	O
a	O
similar	O
phenotypic	O
readout	O
.	O

We	O
therefore	O
trained	O
nine	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
and	O
nine	O
littermate	O
controls	O
in	O
the	O
same	O
automated	O
associative	O
go	O
/	O
no	O
-	O
go	O
olfactory	O
conditioning	O
task	O
described	O
above	O
.	O

To	O
cover	O
even	O
small	O
phenotypic	O
changes	O
in	O
olfaction	O
,	O
we	O
tested	O
different	O
odor	O
pairs	O
,	O
"	O
simple	O
"	O
monomolecular	O
odors	O
and	O
"	O
difficult	O
"	O
binary	O
mixtures	O
[	O
3	O
]	O
.	O

After	O
habituation	O
,	O
GluR	O
-	O
B	O
Delta	O
FB	O
and	O
control	O
mice	B-Taxon
were	O
trained	O
to	O
discriminate	O
between	O
the	O
"	O
simple	O
"	O
monomolecular	O
odors	O
amylacetate	O
and	O
ethylbutyrate	O
,	O
and	O
subsequently	O
additionally	O
on	O
a	O
"	O
difficult	O
"	O
discrimination	O
task	O
consisting	O
of	O
similar	O
binary	O
mixtures	O
of	O
cineol	B-CHEBI
and	O
eugenol	B-CHEBI
;	O
and	O
finally	O
again	O
on	O
a	O
"	O
simple	O
"	O
discrimination	O
task	O
with	O
the	O
monomolecular	O
odors	O
pelargonic	B-CHEBI
and	I-CHEBI
valeric	I-CHEBI
acid	I-CHEBI
.	O

Similar	O
to	O
GluR	O
-	O
B	O
Delta	O
ECS	O
:	O
FB	O
,	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
also	O
showed	O
enhanced	O
learning	O
and	O
discrimination	O
compared	O
with	O
controls	O
(	O
Figure	O
2B	O
;	O
group	O
effect	O
:	O
F	O
(	O
1	O
,	O
16	O
)	O
=	O
6	O
.	O
55	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Increased	O
discrimination	O
performance	O
is	O
expected	O
to	O
show	O
more	O
pronounced	O
effects	O
for	O
closely	O
related	O
odors	O
because	O
of	O
the	O
more	O
challenging	O
"	O
difficult	O
"	O
discrimination	O
task	O
that	O
is	O
closer	O
to	O
the	O
psychophysical	O
limits	O
of	O
the	O
system	O
[	O
3	O
,	O
4	O
]	O
.	O

Consistent	O
with	O
this	O
notion	O
,	O
differences	O
between	O
GluR	O
-	O
B	O
Delta	O
FB	O
and	O
control	O
mice	B-Taxon
were	O
not	O
only	O
larger	O
if	O
the	O
detailed	O
sampling	O
pattern	O
and	O
discrimination	O
index	O
were	O
investigated	O
(	O
Figure	O
2C	O
and	O
2D	O
,	O
group	O
effect	O
:	O
F	O
(	O
1	O
,	O
16	O
)	O
=	O
29	O
.	O
5	O
;	O
p	O
<	O
10	O
-	O
4	O
)	O
,	O
but	O
in	O
particular	O
for	O
the	O
discrimination	O
of	O
binary	O
mixtures	O
with	O
similar	O
composition	O
(	O
group	O
effect	O
:	O
F	O
(	O
1	O
,	O
16	O
)	O
=	O
27	O
.	O
8	O
;	O
p	O
<	O
10	O
-	O
4	O
for	O
the	O
mixture	O
;	O
FAA	O
EB	O
(	O
1	O
,	O
16	O
)	O
=	O
7	O
.	O
0	O
;	O
p	O
=	O
0	O
.	O
02	O
,	O
and	O
FPel	O
Val	O
(	O
1	O
,	O
16	O
)	O
=	O
5	O
.	O
8	O
;	O
p	O
=	O
0	O
.	O
03	O
for	O
the	O
"	O
simple	O
"	O
discrimination	O
tasks	O
;	O
3	O
-	O
way	O
ANOVA	O
:	O
F	O
(	O
6	O
,	O
96	O
)	O
=	O
2	O
.	O
9	O
;	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

As	O
activity	O
,	O
measured	O
by	O
the	O
intertrial	O
interval	O
,	O
was	O
not	O
significantly	O
different	O
between	O
genotypes	B-SO
(	O
F	O
(	O
1	O
,	O
16	O
)	O
=	O
3	O
.	O
1	O
;	O
p	O
=	O
0	O
.	O
1	O
)	O
,	O
and	O
analysis	O
of	O
the	O
lick	O
frequency	O
showed	O
a	O
tendency	O
to	O
reduced	O
motivation	O
of	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
in	O
this	O
particular	O
task	O
(	O
F	O
(	O
1	O
,	O
16	O
)	O
=	O
9	O
.	O
2	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
we	O
conclude	O
that	O
depletion	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
in	O
forebrain	O
areas	O
indeed	O
resulted	O
in	O
increased	O
olfactory	O
learning	O
and	O
discrimination	O
performances	O
,	O
rather	O
than	O
motivational	O
alterations	O
.	O

To	O
assess	O
olfaction	O
specificity	O
,	O
we	O
trained	O
ten	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
and	O
ten	O
controls	O
in	O
a	O
nonolfactory	O
hippocampus	O
-	O
dependent	O
spatial	O
learning	O
task	O
(	O
elevated	O
Y	O
-	O
maze	O
)	O
.	O

Performance	O
in	O
this	O
task	O
was	O
not	O
improved	O
compared	O
with	O
controls	O
(	O
Figure	O
S2	O
)	O
;	O
on	O
the	O
contrary	O
,	O
the	O
acquisition	O
of	O
this	O
task	O
was	O
slightly	O
impaired	O
,	O
allowing	O
the	O
conclusion	O
that	O
the	O
enhanced	O
olfactory	O
discrimination	O
performance	O
is	O
likely	O
to	O
be	O
specific	O
to	O
the	O
sense	O
of	O
smell	O
and	O
possibly	O
related	O
to	O
enhanced	O
discrimination	O
capability	O
,	O
rather	O
than	O
a	O
general	O
increase	O
in	O
alertness	O
.	O

Furthermore	O
,	O
enhancement	O
in	O
odor	O
discrimination	O
in	O
both	O
GluR	O
-	O
B	O
Delta	O
ECS	O
:	O
FB	O
and	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
makes	O
it	O
likely	O
that	O
improvement	O
in	O
this	O
task	O
results	O
from	O
the	O
common	O
AMPAR	O
property	O
change	O
mediated	O
by	O
the	O
depletion	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
and	O
the	O
lack	O
of	O
the	O
Q	B-CHEBI
/	O
R	B-CHEBI
site	B-SO
-	O
edited	O
GluR	B-GGP
-	I-GGP
B	I-GGP
subunit	I-GGP
,	O
both	O
resulting	O
in	O
Ca2	B-CHEBI
+	I-CHEBI
-	O
permeable	O
AMPARs	O
.	O

Thus	O
,	O
this	O
suggests	O
that	O
increased	O
Ca2	B-CHEBI
+	I-CHEBI
influx	O
via	O
AMPARs	O
leads	O
to	O
enhanced	O
olfactory	O
learning	O
and	O
discrimination	O
.	O

Olfactory	O
Memory	O
Is	O
Significantly	O
Decreased	O
but	O
Highly	O
Variable	O
in	O
GluR	O
-	O
B	O
Delta	O
FB	O
Mice	B-Taxon

To	O
capture	O
the	O
full	O
extent	O
of	O
the	O
role	O
of	O
Ca2	B-CHEBI
+	I-CHEBI
-	O
permeable	O
AMPARs	O
in	O
olfactory	O
behavior	O
,	O
we	O
next	O
assessed	O
the	O
effects	O
of	O
altered	O
AMPA	O
channels	O
on	O
olfactory	O
memory	O
.	O

To	O
probe	O
olfactory	O
memory	O
in	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
,	O
six	O
days	O
after	O
the	O
end	O
of	O
the	O
first	O
training	O
phase	O
for	O
odor	O
discrimination	O
(	O
amylacetate	O
versus	O
ethylbutyrate	O
)	O
,	O
the	O
training	O
trials	O
for	O
the	O
third	O
odor	O
pair	O
(	O
pelargonic	B-CHEBI
versus	I-CHEBI
valeric	I-CHEBI
acid	I-CHEBI
)	O
were	O
interleaved	O
with	O
unrewarded	O
trials	O
in	O
which	O
amylacetate	O
or	O
ethylbutyrate	O
were	O
again	O
presented	O
(	O
black	O
bar	O
in	O
Figure	O
2C	O
)	O
.	O

Whereas	O
control	O
mice	B-Taxon
reliably	O
responded	O
only	O
to	O
the	O
previously	O
rewarded	O
odor	O
(	O
memory	O
of	O
86	O
+/-	O
8	O
%	O
,	O
mean	O
+/-	O
SD	O
,	O
n	O
=	O
9	O
,	O
Figure	O
2E	O
)	O
,	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
showed	O
reduced	O
olfactory	O
memory	O
(	O
69	O
+/-	O
16	O
%	O
,	O
n	O
=	O
9	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
Mann	O
-	O
Whitney	O
)	O
.	O

Due	O
to	O
the	O
more	O
rapid	O
learning	O
observed	O
in	O
GluR	O
-	O
B	O
Delta	O
FB	O
,	O
one	O
could	O
speculate	O
that	O
a	O
decrease	O
in	O
olfactory	O
memory	O
might	O
simply	O
reflect	O
increased	O
extinction	O
.	O

However	O
,	O
extinction	O
levels	O
were	O
low	O
in	O
general	O
,	O
no	O
significant	O
group	O
-	O
trial	O
interaction	O
could	O
be	O
found	O
for	O
the	O
memory	O
trials	O
(	O
2	O
-	O
way	O
ANOVA	O
,	O
F	O
(	O
6	O
,	O
90	O
)	O
=	O
1	O
.	O
5	O
,	O
p	O
>	O
0	O
.	O
1	O
)	O
,	O
and	O
a	O
restriction	O
of	O
the	O
analysis	O
to	O
early	O
memory	O
trials	O
displayed	O
essentially	O
the	O
same	O
pattern	O
(	O
Figure	O
S3A	O
)	O
.	O

Thus	O
,	O
reduced	O
performance	O
in	O
the	O
probe	O
trials	O
is	O
not	O
due	O
to	O
increased	O
extinction	O
but	O
reflects	O
genuine	O
memory	O
impairment	O
.	O

Moreover	O
,	O
because	O
the	O
hippocampus	O
-	O
dependent	O
spatial	O
memory	O
after	O
-	O
task	O
acquisition	O
in	O
the	O
Y	O
-	O
maze	O
was	O
not	O
affected	O
(	O
Figure	O
S2	O
)	O
,	O
we	O
conclude	O
that	O
the	O
observed	O
olfactory	O
memory	O
deficit	O
is	O
rather	O
specific	O
for	O
olfaction	O
and	O
does	O
not	O
readily	O
generalize	O
to	O
other	O
modalities	O
.	O

While	O
the	O
improved	O
odor	O
discrimination	O
and	O
learning	O
behavior	O
showed	O
only	O
little	O
variability	O
,	O
the	O
significantly	O
impaired	O
memory	O
performance	O
observed	O
in	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
was	O
highly	O
variable	O
among	O
individual	O
animals	B-Taxon
compared	O
with	O
control	O
littermates	O
(	O
Figure	O
2E	O
)	O
.	O

This	O
variability	O
in	O
olfactory	O
memory	O
was	O
reflected	O
in	O
the	O
level	O
and	O
extent	O
of	O
Cre	O
-	O
recombinase	O
expression	O
in	O
forebrain	O
of	O
transgenic	B-SO
TgCre4	O
mice	B-Taxon
,	O
as	O
visualized	O
by	O
Cre	O
-	O
activity	O
in	O
the	O
Cre	O
-	O
indicator	O
mouse	B-Taxon
line	O
R26R	O
.	O

We	O
observed	O
that	O
onset	O
and	O
extent	O
of	O
Cre	O
-	O
recombinase	O
expression	O
in	O
different	O
forebrain	O
regions	O
varied	O
among	O
individual	O
TgCre4	O
mice	B-Taxon
(	O
Figure	O
3A	O
)	O
,	O
which	O
could	O
also	O
be	O
directly	O
visualized	O
by	O
immunohistochemistry	O
with	O
a	O
Cre	O
-	O
antibody	B-GO
(	O
unpublished	O
data	O
)	O
.	O

As	O
this	O
variability	O
persisted	O
after	O
several	O
backcrosses	O
,	O
and	O
Southern	O
blot	O
analysis	O
revealed	O
no	O
differences	O
of	O
transgene	B-SO
integration	B-SO
or	O
number	O
among	O
animals	B-Taxon
(	O
Figure	O
3B	O
)	O
,	O
it	O
could	O
not	O
be	O
attributed	O
to	O
genetic	B-SO
differences	O
but	O
rather	O
to	O
epigenetic	O
mechanisms	O
.	O

Hence	O
,	O
we	O
hypothesized	O
that	O
the	O
variability	O
in	O
olfactory	O
memory	O
reflected	O
the	O
mosaicism	O
observed	O
in	O
the	O
transgenic	B-SO
TgCre4	O
line	O
.	O

The	O
evaluation	O
of	O
regional	O
differences	O
in	O
expression	O
pattern	O
of	O
animals	B-Taxon
with	O
robust	O
and	O
poor	O
olfactory	O
memory	O
could	O
then	O
be	O
applied	O
to	O
identify	O
brain	O
areas	O
responsible	O
for	O
the	O
observed	O
phenotypes	O
.	O

Olfactory	O
Memory	O
Correlates	O
with	O
Residual	O
GluR	B-GGP
-	I-GGP
B	I-GGP
Protein	B-CHEBI
Expression	O
in	O
GluR	O
-	O
B	O
Delta	O
FB	O
Mice	B-Taxon

Thus	O
,	O
to	O
examine	O
whether	O
the	O
pronounced	O
variability	O
of	O
olfactory	O
memory	O
in	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
(	O
Figure	O
2E	O
)	O
reflects	O
variability	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
levels	O
in	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
,	O
we	O
analyzed	O
the	O
residual	O
amount	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
protein	B-CHEBI
in	O
mice	B-Taxon
with	O
disparate	O
memory	O
performances	O
(	O
Figure	O
4A	O
-	O
C	O
)	O
.	O

Notably	O
,	O
mice	B-Taxon
with	O
pronounced	O
memory	O
deficits	O
(	O
memory	O
<	O
70	O
%	O
)	O
showed	O
essentially	O
no	O
detectable	O
GluR	B-GGP
-	I-GGP
B	I-GGP
protein	B-CHEBI
in	O
hippocampus	O
,	O
amygdala	O
,	O
olfactory	O
bulb	O
,	O
and	O
piriform	O
cortex	O
(	O
n	O
=	O
2	O
,	O
Figure	O
4B	O
,	O
and	O
unpublished	O
data	O
)	O
,	O
but	O
mice	B-Taxon
with	O
almost	O
complete	O
memory	O
displayed	O
substantial	O
residual	O
GluR	B-GGP
-	I-GGP
B	I-GGP
levels	O
in	O
all	O
brain	O
areas	O
investigated	O
(	O
n	O
=	O
2	O
,	O
Figure	O
4B	O
,	O
and	O
unpublished	O
data	O
)	O
.	O

To	O
quantify	O
the	O
relation	O
between	O
residual	O
GluR	B-GGP
-	I-GGP
B	I-GGP
protein	B-CHEBI
and	O
olfactory	O
memory	O
,	O
the	O
memory	O
experiment	O
was	O
repeated	O
with	O
nine	O
additional	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
and	O
two	O
GluR	O
-	O
B2lox	O
control	O
animals	B-Taxon
(	O
indicated	O
with	O
shaded	O
symbols	O
in	O
Figure	O
4A	O
)	O
,	O
resulting	O
in	O
the	O
same	O
mean	O
,	O
variability	O
,	O
and	O
range	O
of	O
memory	O
performance	O
(	O
control	O
:	O
89	O
+/-	O
10	O
%	O
;	O
GluR	O
-	O
B	O
Delta	O
FB	O
:	O
63	O
+/-	O
14	O
%	O
)	O
.	O

Subsequently	O
,	O
protein	B-CHEBI
was	O
extracted	O
from	O
olfactory	O
bulbs	O
,	O
cortical	O
areas	O
,	O
and	O
hippocampi	O
from	O
each	O
mouse	B-Taxon
,	O
and	O
GluR	B-GGP
-	I-GGP
B	I-GGP
protein	B-CHEBI
was	O
quantified	O
(	O
Figure	O
4C	O
)	O
.	O

The	O
summarized	O
correlations	O
are	O
depicted	O
in	O
Figure	O
4D	O
(	O
two	O
animals	B-Taxon
were	O
used	O
for	O
immunofluorescent	O
analysis	O
that	O
yielded	O
the	O
same	O
results	O
as	O
in	O
the	O
first	O
experiment	O
)	O
.	O

Whereas	O
no	O
learning	O
or	O
discrimination	O
-	O
related	O
parameter	O
correlated	O
with	O
residual	O
protein	B-CHEBI
levels	O
(	O
Figure	O
4D	O
,	O
R2	O
<	O
0	O
.	O
3	O
)	O
,	O
a	O
strong	O
correlation	O
between	O
memory	O
and	O
GluR	B-GGP
-	I-GGP
B	I-GGP
protein	B-CHEBI
was	O
observed	O
in	O
hippocampus	O
(	O
Figure	O
4D	O
,	O
R2	O
=	O
0	O
.	O
72	O
,	O
p	O
<	O
0	O
.	O
003	O
,	O
n	O
=	O
10	O
)	O
and	O
cortical	O
areas	O
(	O
Figure	O
4D	O
,	O
R2	O
=	O
0	O
.	O
62	O
,	O
p	O
<	O
0	O
.	O
006	O
,	O
n	O
=	O
10	O
)	O
.	O

Only	O
a	O
weakly	O
significant	O
correlation	O
was	O
found	O
in	O
the	O
olfactory	O
bulb	O
(	O
Figure	O
4D	O
,	O
R2	O
=	O
0	O
.	O
48	O
,	O
p	O
=	O
0	O
.	O
03	O
,	O
n	O
=	O
10	O
)	O
.	O

GluR	B-GGP
-	I-GGP
A	I-GGP
levels	O
were	O
unchanged	O
from	O
wild	B-SO
-	I-SO
type	I-SO
,	O
indicating	O
that	O
compensatory	O
up	O
-	O
regulation	O
of	O
other	O
AMPAR	O
subunits	O
is	O
unlikely	O
(	O
GluR	B-GGP
-	I-GGP
A	I-GGP
levels	O
relative	O
to	O
control	O
:	O
1	O
.	O
02	O
+/-	O
0	O
.	O
05	O
,	O
mean	O
+/-	O
SEM	O
,	O
n	O
=	O
10	O
)	O
.	O

In	O
summary	O
,	O
mice	B-Taxon
with	O
reduced	O
GluR	B-GGP
-	I-GGP
B	I-GGP
levels	O
in	O
forebrain	O
areas	O
showed	O
decreased	O
olfactory	O
memory	O
,	O
which	O
correlated	O
tightly	O
with	O
a	O
reduction	O
in	O
GluR	B-GGP
-	I-GGP
B	I-GGP
levels	O
in	O
the	O
hippocampus	O
and	O
cortical	O
areas	O
.	O

Enhanced	O
odor	O
learning	O
and	O
discrimination	O
,	O
on	O
the	O
other	O
hand	O
,	O
was	O
independent	O
of	O
residual	O
GluR	B-GGP
-	I-GGP
B	I-GGP
levels	O
in	O
the	O
olfactory	O
bulb	O
and	O
other	O
forebrain	O
areas	O
,	O
indicating	O
that	O
moderate	O
GluR	B-GGP
-	I-GGP
B	I-GGP
reductions	O
are	O
sufficient	O
to	O
saturate	O
enhanced	O
odor	O
learning	O
and	O
discrimination	O
.	O

Thus	O
,	O
although	O
both	O
are	O
mediated	O
by	O
alterations	B-SO
in	O
the	O
AMPAR	O
subunit	O
GluR	B-GGP
-	I-GGP
B	I-GGP
,	O
due	O
to	O
the	O
qualitatively	O
different	O
dose	O
-	O
response	O
curves	O
,	O
the	O
phenotypes	O
regarding	O
olfactory	O
memory	O
,	O
and	O
olfactory	O
learning	O
/	O
discrimination	O
must	O
be	O
mechanistically	O
distinct	O
.	O

Partial	O
Rescue	O
of	O
Olfactory	O
Memory	O
Deficit	O
by	O
Selective	O
Transgenic	B-SO
GluR	B-GGP
-	I-GGP
B	I-GGP
Expression	O
in	O
Hippocampus	O
and	O
Piriform	O
Cortex	O
in	O
GluR	O
-	O
B	O
Delta	O
FB	O
Mice	B-Taxon

The	O
effect	O
of	O
selective	O
GluR	B-GGP
-	I-GGP
B	I-GGP
depletion	O
in	O
mice	B-Taxon
indicated	O
that	O
GluR	B-GGP
-	I-GGP
B	I-GGP
-	O
containing	O
AMPARs	O
in	O
the	O
hippocampus	O
,	O
and	O
/	O
or	O
(	O
olfactory	O
)	O
cortex	O
are	O
likely	O
to	O
be	O
important	O
for	O
olfactory	O
memory	O
.	O

The	O
olfactory	O
memory	O
phenotype	O
could	O
be	O
due	O
to	O
depletion	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
in	O
olfactory	O
cortex	O
or	O
hippocampus	O
;	O
enhanced	O
learning	O
and	O
discrimination	O
capabilities	O
might	O
rather	O
be	O
evoked	O
by	O
AMPARs	O
lacking	O
GluR	B-GGP
-	I-GGP
B	I-GGP
in	O
the	O
olfactory	O
bulb	O
.	O

To	O
obtain	O
independent	O
evidence	O
for	O
this	O
spatial	O
and	O
mechanistic	O
dissection	O
of	O
the	O
roles	O
of	O
Ca2	B-CHEBI
+	I-CHEBI
-	O
permeable	O
AMPARs	O
,	O
we	O
expressed	O
by	O
transgenic	B-SO
means	O
N	B-SO
-	I-SO
terminally	I-SO
green	O
fluorescent	O
protein	B-CHEBI
(	O
GFP	O
)	O
-	O
tagged	O
GluR	B-GGP
-	I-GGP
B	I-GGP
specifically	O
in	O
hippocampus	O
and	O
piriform	O
cortex	O
of	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
(	O
Figure	O
5A	O
and	O
5B	O
)	O
.	O

In	O
accordance	O
with	O
the	O
proposed	O
region	O
-	O
dependence	O
,	O
we	O
expected	O
that	O
additional	O
GluR	B-GGP
-	I-GGP
B	I-GGP
subunits	I-GGP
in	O
hippocampus	O
and	O
/	O
or	O
piriform	O
cortex	O
improve	O
odor	O
memory	O
but	O
do	O
not	O
alter	O
odor	O
discrimination	O
performance	O
.	O

The	O
mouse	B-Taxon
line	O
employed	O
for	O
this	O
purpose	O
,	O
termed	O
GluR	O
-	O
BRescue	O
,	O
had	O
the	O
genetic	B-SO
background	O
of	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
but	O
additionally	O
carried	O
a	O
bidirectional	O
module	O
for	O
beta	O
-	O
galactosidase	O
and	O
GFPGluR	O
-	O
B	O
expression	O
,	O
responsive	O
to	O
the	O
tetracycline	B-CHEBI
-	O
controlled	O
transcriptional	O
transactivator	O
[	O
62	O
]	O
.	O

The	O
transactivator	O
was	O
under	O
the	O
control	O
of	O
a	O
modified	B-SO
alpha	B-GGP
CaMKII	I-GGP
-	O
promoter	B-SO
fragment	B-SO
to	O
obtain	O
high	O
expression	O
selectivity	O
(	O
Figure	O
5A	O
;	O
see	O
also	O
Materials	O
and	O
Methods	O
)	O
.	O

The	O
transgenic	B-SO
expression	O
level	O
of	O
GFPGluR	O
-	O
B	O
was	O
9	O
.	O
72	O
%	O
+/-	O
1	O
.	O
25	O
(	O
n	O
=	O
3	O
)	O
in	O
the	O
hippocampus	O
,	O
compared	O
with	O
endogenous	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
Figure	O
5C	O
and	O
5D	O
)	O
.	O

Analysis	O
of	O
beta	O
-	O
galactosidase	O
activity	O
and	O
GFPGluR	O
-	O
B	O
expression	O
in	O
brain	O
sections	O
of	O
GluR	O
-	O
BRescue	O
mice	B-Taxon
revealed	O
expression	O
in	O
hippocampus	O
and	O
piriform	O
cortex	O
,	O
whereas	O
cortex	O
,	O
amygdala	O
,	O
and	O
striatum	O
only	O
rarely	O
showed	O
any	O
positive	O
cells	B-CL
(	O
Figure	O
5B	O
)	O
.	O

Importantly	O
,	O
both	O
the	O
spatial	O
pattern	O
and	O
intensity	O
of	O
GFPGluR	O
-	O
B	O
expression	O
were	O
constant	O
among	O
all	O
GluR	O
-	O
BRescue	O
mice	B-Taxon
analyzed	O
(	O
n	O
=	O
11	O
)	O
.	O

Olfactory	O
memory	O
experiments	O
with	O
GluR	O
-	O
BRescue	O
,	O
and	O
both	O
GluR	O
-	O
B	O
Delta	O
FB	O
and	O
GluR	O
-	O
B2lox	O
mice	B-Taxon
as	O
controls	O
,	O
were	O
performed	O
as	O
described	O
above	O
(	O
indicated	O
with	O
shaded	O
symbols	O
in	O
Figure	O
6A	O
)	O
.	O

Memory	O
was	O
again	O
highly	O
reproducible	O
in	O
both	O
GluR	O
-	O
B	O
Delta	O
FB	O
(	O
66	O
+/-	O
12	O
%	O
;	O
n	O
=	O
4	O
)	O
and	O
GluR	O
-	O
B2lox	O
(	O
94	O
+/-	O
2	O
%	O
;	O
n	O
=	O
3	O
)	O
mice	B-Taxon
,	O
compared	O
with	O
experiments	O
performed	O
earlier	O
(	O
Figures	O
2E	O
and	O
4A	O
)	O
.	O

Importantly	O
,	O
olfactory	O
memory	O
in	O
GluR	O
-	O
BRescue	O
mice	B-Taxon
was	O
intermediate	O
(	O
75	O
+/-	O
15	O
%	O
,	O
n	O
=	O
8	O
)	O
,	O
below	O
GluR	O
-	O
B2lox	O
control	O
levels	O
,	O
but	O
better	O
than	O
in	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
.	O

Assessing	O
memory	O
under	O
extinction	O
-	O
free	O
condition	O
,	O
where	O
each	O
trial	O
was	O
rewarded	O
,	O
confirmed	O
again	O
that	O
the	O
memory	O
deficit	O
was	O
a	O
true	O
memory	O
deficit	O
and	O
not	O
due	O
to	O
increased	O
extinction	O
(	O
Figure	O
S3B	O
)	O
.	O

Data	O
from	O
the	O
experiments	O
described	O
in	O
Figures	O
2	O
and	O
4	O
were	O
combined	O
to	O
allow	O
statistical	O
comparison	O
(	O
Figure	O
6A	O
and	O
6B	O
)	O
.	O

In	O
summary	O
,	O
GluR	O
-	O
BRescue	O
mice	B-Taxon
showed	O
both	O
enhanced	O
memory	O
performances	O
compared	O
with	O
GluR	O
-	O
B	O
Delta	O
FB	O
(	O
overall	O
ANOVA	O
:	O
F	O
(	O
2	O
,	O
41	O
)	O
=	O
13	O
.	O
6	O
,	O
p	O
<	O
10	O
-	O
4	O
;	O
memoryRescue	O
=	O
75	O
+/-	O
15	O
%	O
,	O
n	O
=	O
8	O
;	O
memory	O
Delta	O
FB	O
=	O
66	O
+/-	O
14	O
%	O
,	O
n	O
=	O
22	O
;	O
p	O
<	O
0	O
.	O
05	O
;	O
Figure	O
6A	O
)	O
,	O
but	O
were	O
still	O
impaired	O
relative	O
to	O
GluR	O
-	O
B2lox	O
controls	O
(	O
memory2lox	O
=	O
88	O
+/-	O
8	O
%	O
,	O
n	O
=	O
14	O
;	O
p	O
<	O
0	O
.	O
005	O
)	O
,	O
consistent	O
with	O
a	O
partial	O
rescue	O
of	O
the	O
memory	O
deficit	O
by	O
circumscribed	O
transgenic	B-SO
GFPGluR	O
-	O
B	O
expression	O
in	O
hippocampus	O
and	O
piriform	O
cortex	O
.	O

Notably	O
,	O
the	O
partial	O
memory	O
is	O
in	O
numerical	O
agreement	O
with	O
the	O
predictions	O
from	O
the	O
protein	B-CHEBI
correlation	O
and	O
the	O
measurement	O
of	O
transgenic	B-SO
protein	B-CHEBI
expression	O
(	O
see	O
predicted	O
memory	O
,	O
blue	O
line	O
,	O
in	O
Figure	O
6B	O
)	O
.	O

In	O
the	O
olfactory	O
memory	O
experiments	O
with	O
GluR	O
-	O
B	O
Delta	O
FB	O
animals	B-Taxon
,	O
olfactory	O
memory	O
linearly	O
depended	O
on	O
GluR	B-GGP
-	I-GGP
B	I-GGP
expression	O
in	O
cortex	O
and	O
hippocampus	O
with	O
a	O
slope	O
of	O
9	O
.	O
1	O
+/-	O
2	O
.	O
5	O
%	O
(	O
cortex	O
)	O
and	O
8	O
.	O
9	O
+/-	O
2	O
.	O
0	O
%	O
(	O
hippocampus	O
)	O
increase	O
in	O
memory	O
per	O
10	O
%	O
increase	O
in	O
protein	B-CHEBI
(	O
Figure	O
4D	O
)	O
.	O

A	O
9	O
.	O
7	O
%	O
increase	O
in	O
GluR	B-GGP
-	I-GGP
B	I-GGP
in	O
these	O
brain	O
regions	O
,	O
as	O
achieved	O
by	O
GluR	O
-	O
BRescue	O
animals	B-Taxon
(	O
Figure	O
5	O
)	O
,	O
is	O
thus	O
predicted	O
to	O
increase	O
olfactory	O
memory	O
by	O
approximately	O
9	O
%	O
throughout	O
the	O
heterogeneous	O
population	O
(	O
blue	O
line	O
in	O
Figure	O
6B	O
)	O
.	O

This	O
confirms	O
the	O
role	O
of	O
these	O
brain	O
areas	O
as	O
inferred	O
from	O
the	O
mosaic	O
expression	O
and	O
protein	B-CHEBI
correlation	O
analysis	O
described	O
above	O
(	O
Figure	O
4	O
)	O
.	O

However	O
,	O
odor	O
discrimination	O
(	O
measured	O
by	O
the	O
discrimination	O
index	O
as	O
in	O
Figures	O
1	O
,	O
2	O
,	O
and	O
4D	O
)	O
was	O
as	O
enhanced	O
as	O
in	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
(	O
0	O
.	O
79	O
+/-	O
0	O
.	O
05	O
,	O
mean	O
+/-	O
SEM	O
compared	O
with	O
0	O
.	O
76	O
+/-	O
0	O
.	O
02	O
,	O
p	O
>	O
0	O
.	O
7	O
,	O
Figure	O
6C	O
)	O
,	O
and	O
improved	O
relative	O
to	O
GluR	O
-	O
B2lox	O
controls	O
(	O
0	O
.	O
48	O
+/-	O
0	O
.	O
06	O
;	O
Figure	O
6C	O
;	O
overall	O
ANOVA	O
:	O
F	O
(	O
2	O
,	O
41	O
)	O
=	O
17	O
.	O
2	O
,	O
p	O
<	O
10	O
-	O
5	O
;	O
post	O
hoc	O
Newman	O
Keuls	O
:	O
p	O
<	O
10	O
-	O
3	O
)	O
,	O
as	O
expected	O
if	O
the	O
enhanced	O
discrimination	O
phenotype	O
is	O
due	O
to	O
Ca2	B-CHEBI
+	I-CHEBI
-	O
permeable	O
AMPARs	O
in	O
the	O
olfactory	O
bulb	O
and	O
unaffected	O
by	O
GluR	B-GGP
-	I-GGP
B	I-GGP
expression	O
in	O
piriform	O
cortex	O
or	O
hippocampus	O
.	O

Hence	O
,	O
transgenic	B-SO
GluR	B-GGP
-	I-GGP
B	I-GGP
expression	O
,	O
specifically	O
in	O
the	O
piriform	O
cortex	O
and	O
hippocampus	O
in	O
the	O
GluR	B-GGP
-	I-GGP
B	I-GGP
knockout	O
background	O
,	O
rescues	O
the	O
odor	O
memory	O
deficit	O
but	O
leaves	O
enhanced	O
olfactory	O
discrimination	O
and	O
learning	O
unaltered	O
.	O

Discussion	O

Here	O
we	O
present	O
mechanistic	O
and	O
spatial	O
dissections	O
of	O
olfactory	O
discrimination	O
,	O
learning	O
,	O
and	O
memory	O
.	O

We	O
employed	O
gene	B-SO
-	O
targeted	O
and	O
transgenic	B-SO
mice	B-Taxon
with	O
region	O
-	O
specific	O
expression	O
to	O
demonstrate	O
that	O
a	O
change	O
in	O
GluR	B-GGP
-	I-GGP
B	I-GGP
-	O
mediated	O
properties	O
of	O
AMPA	O
channels	O
in	O
alpha	B-GGP
CaMKII	I-GGP
-	O
expressing	O
neurons	B-CL
of	O
mouse	B-Taxon
forebrain	O
,	O
including	O
olfactory	O
bulb	O
mitral	O
and	O
granule	B-CL
cells	I-CL
,	O
enhances	O
olfactory	O
discrimination	O
and	O
learning	O
but	O
impairs	O
olfactory	O
memory	O
.	O

These	O
pertinent	O
olfactory	O
behaviors	O
were	O
assessed	O
in	O
a	O
go	O
/	O
no	O
-	O
go	O
operant	O
conditioning	O
task	O
,	O
which	O
provides	O
a	O
quantitative	O
,	O
robust	O
,	O
and	O
reproducible	O
behavioral	O
tool	O
[	O
3	O
]	O
.	O

We	O
observed	O
among	O
individual	O
mice	B-Taxon
a	O
striking	O
variability	O
in	O
olfactory	O
memory	O
performance	O
but	O
not	O
in	O
odor	O
discrimination	O
.	O

This	O
variability	O
could	O
be	O
traced	O
to	O
epigenetic	O
variability	O
in	O
the	O
transgenic	B-SO
expression	O
of	O
Cre	O
-	O
recombinase	O
,	O
which	O
mediated	O
recombination	O
within	O
loxP	B-SO
-	I-SO
flanked	I-SO
segments	B-SO
of	O
gene	B-SO
-	O
targeted	O
alleles	B-SO
for	O
the	O
dominant	O
AMPAR	O
subunit	O
GluR	B-GGP
-	I-GGP
B	I-GGP
,	O
and	O
hence	O
operated	O
the	O
switch	O
in	O
AMPAR	O
properties	O
toward	O
GluR	B-GGP
-	I-GGP
B	I-GGP
ablation	O
and	O
increased	O
Ca2	B-CHEBI
+	I-CHEBI
permeability	O
.	O

In	O
contrast	O
to	O
variable	O
memory	O
,	O
olfactory	O
discrimination	O
and	O
learning	O
performances	O
appeared	O
already	O
saturated	O
by	O
even	O
moderate	O
extents	O
of	O
Cre	O
expression	O
,	O
and	O
hence	O
moderate	O
changes	O
in	O
AMPAR	O
properties	O
.	O

The	O
subsequent	O
transgene	B-SO
-	O
driven	O
re	O
-	O
introduction	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
,	O
specifically	O
in	O
piriform	O
cortex	O
and	O
hippocampus	O
,	O
reversed	O
the	O
Cre	O
-	O
induced	O
loss	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
and	O
partially	O
rescued	O
the	O
odor	O
memory	O
deficit	O
,	O
but	O
left	O
unaltered	O
the	O
enhanced	O
olfactory	O
discrimination	O
.	O

In	O
a	O
nutshell	O
,	O
we	O
conclude	O
that	O
olfactory	O
discrimination	O
is	O
enhanced	O
by	O
an	O
increase	O
in	O
AMPAR	O
-	O
mediated	O
Ca2	B-CHEBI
+	I-CHEBI
permeability	O
within	O
the	O
olfactory	O
bulb	O
,	O
whereas	O
olfactory	O
memory	O
becomes	O
impaired	O
upon	O
genetically	B-SO
induced	O
GluR	B-GGP
-	I-GGP
B	I-GGP
ablation	O
in	O
higher	O
brain	O
centers	O
,	O
specifically	O
in	O
piriform	O
cortex	O
.	O

Olfactory	O
Discrimination	O
Is	O
Increased	O
in	O
Mice	B-Taxon
with	O
Forebrain	O
-	O
Specific	O
GluR	B-GGP
-	I-GGP
B	I-GGP
Ablation	O
or	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
Q	B-CHEBI
)	O
Expression	O

Both	O
forebrain	O
-	O
specific	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
Q	B-CHEBI
)	O
expression	O
and	O
GluR	B-GGP
-	I-GGP
B	I-GGP
depletion	O
led	O
to	O
increased	O
olfactory	O
learning	O
and	O
discrimination	O
capabilities	O
.	O

This	O
was	O
rather	O
pronounced	O
for	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
Q	B-CHEBI
)	O
-	O
expressing	O
mice	B-Taxon
,	O
consistent	O
with	O
the	O
overall	O
stronger	O
phenotypic	O
consequences	O
in	O
comparison	O
to	O
GluR	B-GGP
-	I-GGP
B	I-GGP
depletion	O
,	O
both	O
when	O
forebrain	O
-	O
selective	O
(	O
[	O
58	O
]	O
,	O
and	O
this	O
study	O
)	O
or	O
global	O
[	O
53	O
,	O
60	O
]	O
.	O

A	O
detailed	O
analysis	O
of	O
the	O
sampling	O
pattern	O
[	O
3	O
]	O
,	O
and	O
in	O
particular	O
the	O
analysis	O
of	O
discrimination	O
tasks	O
that	O
involved	O
"	O
simple	O
"	O
dissimilar	O
monomolecular	O
odor	O
pairs	O
and	O
"	O
difficult	O
"	O
binary	O
mixtures	O
,	O
were	O
necessary	O
to	O
fully	O
capture	O
the	O
characteristics	O
of	O
the	O
olfactory	O
discrimination	O
phenotype	O
for	O
forebrain	O
-	O
specific	O
GluR	B-GGP
-	I-GGP
B	I-GGP
-	O
depleted	O
mice	B-Taxon
.	O

For	O
closely	O
related	O
binary	O
mixtures	O
,	O
discrimination	O
improvements	O
were	O
largest	O
,	O
consistent	O
with	O
a	O
specific	O
alteration	O
in	O
odor	O
discrimination	O
,	O
rather	O
than	O
a	O
general	O
enhancement	O
of	O
learning	O
capabilities	O
.	O

This	O
is	O
further	O
supported	O
by	O
the	O
notion	O
that	O
no	O
general	O
improvement	O
was	O
observed	O
in	O
other	O
nonolfactory	O
behavioral	O
tasks	O
,	O
e	O
.	O
g	O
.	O
,	O
hippocampus	O
-	O
dependent	O
spatial	O
learning	O
tasks	O
such	O
as	O
matching	O
-	O
to	O
-	O
place	O
spatial	O
reference	O
memory	O
tasks	O
(	O
Figure	O
S2	O
)	O
.	O

As	O
no	O
Cre	O
expression	O
and	O
activity	O
was	O
observed	O
in	O
the	O
main	O
olfactory	B-CL
sensory	I-CL
neurons	I-CL
at	O
any	O
developmental	O
stage	O
(	O
Figure	O
S4	O
and	O
unpublished	O
data	O
)	O
,	O
olfactory	O
epithelial	O
function	O
was	O
unaltered	O
by	O
the	O
genetic	B-SO
modification	B-SO
.	O

The	O
vomeronasal	O
organ	O
showed	O
very	O
weak	O
Cre	O
expression	O
(	O
unpublished	O
data	O
)	O
,	O
but	O
a	O
role	O
of	O
this	O
structure	O
concerning	O
performance	O
in	O
the	O
olfactory	O
discrimination	O
task	O
is	O
unlikely	O
(	O
for	O
review	O
,	O
see	O
[	O
63	O
]	O
)	O
.	O

The	O
behavioral	O
phenotype	O
is	O
thus	O
likely	O
to	O
be	O
associated	O
with	O
the	O
processing	O
of	O
olfactory	O
information	O
rather	O
than	O
the	O
detection	O
of	O
odors	O
.	O

Furthermore	O
,	O
increased	O
performance	O
even	O
after	O
long	O
stretches	O
of	O
training	O
and	O
,	O
in	O
particular	O
,	O
increased	O
sampling	O
pattern	O
differences	O
(	O
TB	O
and	O
ATS	O
,	O
unpublished	O
data	O
)	O
supported	O
the	O
notion	O
that	O
GluR	B-GGP
-	I-GGP
B	I-GGP
depletion	O
resulted	O
in	O
enhanced	O
odor	O
discrimination	O
capability	O
.	O

The	O
learning	O
phenotype	O
might	O
thus	O
be	O
a	O
result	O
of	O
this	O
enhanced	O
discrimination	O
capability	O
or	O
reflect	O
additional	O
changes	O
in	O
circuits	O
underlying	O
task	O
acquisition	O
.	O

Putative	O
Cellular	B-CL
Basis	O
of	O
Enhanced	O
Odor	O
Discrimination	O
and	O
Learning	O

AMPAR	O
properties	O
were	O
altered	O
specifically	O
in	O
neurons	B-CL
of	O
forebrain	O
areas	O
,	O
most	O
notably	O
olfactory	O
bulb	O
,	O
olfactory	O
cortex	O
,	O
and	O
other	O
cortical	O
areas	O
and	O
hippocampus	O
,	O
leading	O
to	O
enhanced	O
odor	O
discrimination	O
and	O
learning	O
.	O

Interestingly	O
,	O
transgenic	B-SO
expression	O
of	O
GFPGluR	O
-	O
B	O
in	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
(	O
genetic	B-SO
"	O
rescue	O
"	O
)	O
,	O
specifically	O
in	O
piriform	O
cortex	O
and	O
hippocampus	O
with	O
no	O
detectable	O
expression	O
in	O
the	O
olfactory	O
bulb	O
,	O
did	O
not	O
alter	O
enhanced	O
discrimination	O
and	O
learning	O
capabilities	O
.	O

This	O
is	O
consistent	O
with	O
a	O
primary	O
role	O
of	O
the	O
olfactory	O
bulb	O
in	O
olfactory	O
discrimination	O
and	O
learning	O
.	O

Alternatively	O
,	O
transgenic	B-SO
protein	B-CHEBI
levels	O
might	O
have	O
been	O
too	O
low	O
to	O
alter	O
discrimination	O
and	O
learning	O
capabilities	O
,	O
although	O
memory	O
was	O
clearly	O
affected	O
.	O

This	O
notion	O
will	O
be	O
further	O
tested	O
in	O
mice	B-Taxon
with	O
piriform	O
cortex	O
-	O
specific	O
GluR	B-GGP
-	I-GGP
B	I-GGP
ablation	O
.	O

A	O
direct	O
contribution	O
to	O
the	O
phenotype	O
by	O
Ca2	B-CHEBI
+	I-CHEBI
influx	O
through	O
genetically	B-SO
modified	B-SO
AMPA	O
channels	O
seems	O
to	O
be	O
likely	O
,	O
since	O
mice	B-Taxon
expressing	O
Q	B-CHEBI
/	O
R	B-CHEBI
site	B-SO
-	O
unedited	O
GluR	B-GGP
-	I-GGP
B	I-GGP
showed	O
even	O
better	O
odor	O
learning	O
and	O
discrimination	O
performance	O
compared	O
with	O
mice	B-Taxon
with	O
depleted	O
GluR	B-GGP
-	I-GGP
B	I-GGP
.	O

In	O
both	O
mouse	B-Taxon
models	O
Ca2	B-CHEBI
+	I-CHEBI
influx	O
through	O
AMPA	O
channels	O
is	O
increased	O
,	O
whereas	O
the	O
effect	O
on	O
the	O
macroscopic	O
AMPA	O
conductance	O
differs	O
.	O

AMPAR	O
currents	O
are	O
reduced	O
in	O
mice	B-Taxon
not	O
expressing	O
GluR	B-GGP
-	I-GGP
B	I-GGP
[	O
51	O
]	O
,	O
possibly	O
due	O
to	O
fewer	O
synaptic	B-GO
AMPA	O
channels	O
and	O
impaired	O
AMPAR	O
trafficking	O
and	O
recycling	O
.	O

In	O
mice	B-Taxon
expressing	O
the	O
unedited	O
form	B-SO
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
Q	B-CHEBI
)	O
,	O
macroscopic	O
conductance	O
in	O
whole	O
-	O
cell	B-CL
patches	O
of	O
CA1	O
pyramidals	O
is	O
increased	O
[	O
60	O
]	O
,	O
but	O
excitatory	O
transmission	O
in	O
CA3	O
-	O
to	O
-	O
CA1	O
cell	B-CL
synapses	B-GO
is	O
somewhat	O
reduced	O
,	O
in	O
spite	O
of	O
a	O
lower	O
threshold	O
for	O
generating	O
a	O
population	O
spike	O
[	O
58	O
]	O
,	O
indicating	O
increased	O
synaptic	B-GO
excitability	O
by	O
sustained	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
Q	B-CHEBI
)	O
expression	O
,	O
in	O
line	O
with	O
the	O
seizure	O
-	O
prone	O
phenotype	O
.	O

Yet	O
,	O
both	O
mouse	B-Taxon
models	O
yield	O
enhanced	O
discrimination	O
and	O
learning	O
capability	O
.	O

The	O
milder	O
phenotype	O
upon	O
GluR	B-GGP
-	I-GGP
B	I-GGP
depletion	O
could	O
be	O
attributed	O
to	O
reduced	O
AMPAR	O
densities	O
at	O
synapses	B-GO
[	O
40	O
,	O
41	O
]	O
and	O
therefore	O
probably	O
to	O
a	O
lesser	O
extent	O
of	O
Ca2	B-CHEBI
+	I-CHEBI
influx	O
.	O

This	O
is	O
further	O
supported	O
by	O
kainate	O
-	O
induced	O
Co2	B-CHEBI
+	I-CHEBI
uptake	O
in	O
acute	O
brain	O
slices	O
,	O
revealing	O
considerably	O
higher	O
Co2	B-CHEBI
+	I-CHEBI
uptake	O
via	O
Ca2	B-CHEBI
+	I-CHEBI
-	O
permeable	O
AMPARs	O
in	O
hippocampal	O
pyramidal	B-CL
neurons	I-CL
of	O
mice	B-Taxon
expressing	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
Q	B-CHEBI
)	O
,	O
than	O
those	O
lacking	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
DRS	O
,	O
RS	O
,	O
and	O
PHS	O
,	O
unpublished	O
data	O
)	O
.	O

Normally	O
,	O
GluR	B-GGP
-	I-GGP
B	I-GGP
-	O
containing	O
AMPARs	O
are	O
prominently	O
localized	O
at	O
the	O
dendrodendritic	O
synapse	B-GO
between	O
mitral	O
and	O
granule	B-CL
cells	I-CL
in	O
the	O
olfactory	O
bulb	O
[	O
64	O
,	O
65	O
]	O
.	O

As	O
Ca2	B-CHEBI
+	I-CHEBI
influx	O
through	O
glutamate	B-CHEBI
receptors	O
is	O
thought	O
to	O
contribute	O
to	O
lateral	O
and	O
recurrent	O
inhibition	O
(	O
[	O
38	O
]	O
see	O
also	O
[	O
39	O
]	O
)	O
,	O
the	O
absence	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
,	O
or	O
the	O
presence	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
Q	B-CHEBI
)	O
in	O
the	O
olfactory	O
bulb	O
,	O
is	O
likely	O
to	O
result	O
in	O
increased	O
inhibition	O
between	O
the	O
principal	B-CL
neurons	I-CL
in	O
this	O
structure	O
.	O

Notably	O
,	O
the	O
improved	O
olfactory	O
discrimination	O
capabilities	O
were	O
apparent	O
even	O
upon	O
relatively	O
small	O
reductions	O
in	O
GluR	B-GGP
-	I-GGP
B	I-GGP
levels	O
.	O

It	O
will	O
be	O
interesting	O
to	O
see	O
if	O
GluR	B-GGP
-	I-GGP
B	I-GGP
+	O
/	O
neo	O
mice	B-Taxon
also	O
exhibit	O
enhanced	O
odor	O
discrimination	O
,	O
which	O
is	O
indeed	O
likely	O
given	O
that	O
low	O
levels	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
Q	B-CHEBI
)	O
,	O
and	O
hence	O
a	O
small	O
increase	O
in	O
Ca2	B-CHEBI
+	I-CHEBI
-	O
permeable	O
AMPARs	O
,	O
arise	O
from	O
the	O
attenuated	O
GluR	O
-	O
Bneo	O
allele	B-SO
[	O
60	O
]	O
,	O
and	O
,	O
moreover	O
,	O
that	O
GluR	B-GGP
-	I-GGP
B	I-GGP
levels	O
are	O
decreased	O
in	O
these	O
mice	B-Taxon
due	O
to	O
the	O
single	O
copy	O
of	O
the	O
GluR	B-GGP
-	I-GGP
B	I-GGP
+	O
allele	B-SO
.	O

In	O
virtually	O
all	O
models	O
of	O
the	O
olfactory	O
bulb	O
,	O
lateral	O
(	O
and	O
,	O
in	O
fewer	O
models	O
,	O
also	O
recurrent	O
)	O
inhibition	O
plays	O
a	O
dominant	O
role	O
,	O
either	O
in	O
establishing	O
spatiotemporal	O
dynamics	O
[	O
32	O
,	O
66	O
-	O
69	O
]	O
,	O
or	O
in	O
directly	O
enhancing	O
contrast	O
and	O
therefore	O
simplifying	O
discrimination	O
and	O
learning	O
of	O
similar	O
odorants	O
[	O
24	O
,	O
28	O
,	O
29	O
,	O
36	O
]	O
.	O

Increased	O
inhibition	O
will	O
thus	O
in	O
general	O
improve	O
discriminability	O
,	O
consistent	O
with	O
the	O
behavioral	O
improvements	O
observed	O
with	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
Q	B-CHEBI
)	O
expression	O
,	O
the	O
GluR	B-GGP
-	I-GGP
B	I-GGP
knockout	O
,	O
and	O
the	O
"	O
rescue	O
"	O
mice	B-Taxon
.	O

A	O
direct	O
test	O
of	O
this	O
link	O
would	O
require	O
the	O
quantitative	O
measurement	O
of	O
inhibition	O
in	O
the	O
intact	O
preparation	O
,	O
a	O
task	O
that	O
might	O
be	O
feasible	O
with	O
further	O
improved	O
in	O
vivo	O
electrophysiological	O
techniques	O
,	O
such	O
as	O
targeted	O
recordings	O
[	O
70	O
,	O
71	O
]	O
or	O
simultaneous	O
pre	O
-	O
and	O
postsynaptic	O
intracellular	B-GO
measurements	O
.	O

Olfactory	O
Memory	O
Is	O
Reduced	O
in	O
GluR	B-GGP
-	I-GGP
B	I-GGP
Knockout	O
Mice	B-Taxon
and	O
Improved	O
by	O
GluR	B-GGP
-	I-GGP
B	I-GGP
Expression	O
in	O
Piriform	O
Cortex	O
and	O
Hippocampus	O

To	O
assess	O
olfactory	O
memory	O
of	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
,	O
after	O
six	O
days	O
the	O
mice	B-Taxon
were	O
probed	O
with	O
unrewarded	O
odor	O
presentations	O
that	O
interleaved	O
a	O
simple	O
discrimination	O
task	O
.	O

Prolonged	O
behavioral	O
tasks	O
such	O
as	O
the	O
assessment	O
of	O
long	O
-	O
term	O
olfactory	O
memory	O
were	O
not	O
performed	O
with	O
the	O
seizure	O
-	O
prone	O
GluR	O
-	O
B	O
Delta	O
ECS	O
:	O
FB	O
mice	B-Taxon
.	O

Memory	O
in	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
,	O
however	O
,	O
was	O
dramatically	O
impaired	O
.	O

This	O
cannot	O
be	O
attributed	O
to	O
a	O
general	O
,	O
unspecific	O
deficit	O
because	O
,	O
simultaneous	O
to	O
the	O
memory	O
trials	O
,	O
the	O
normal	O
,	O
rewarded	O
discrimination	O
task	O
was	O
performed	O
even	O
better	O
than	O
by	O
controls	O
.	O

Reduced	O
olfactory	O
memory	O
can	O
also	O
not	O
be	O
simply	O
attributed	O
to	O
increased	O
extinction	O
,	O
as	O
no	O
significant	O
trial	O
-	O
group	O
interactions	O
were	O
observed	O
and	O
also	O
,	O
when	O
restricted	O
to	O
the	O
first	O
unrewarded	O
memory	O
trials	O
,	O
a	O
significant	O
impairment	O
was	O
observed	O
(	O
Figure	O
S3A	O
)	O
.	O

Additionally	O
,	O
investigating	O
relearning	O
of	O
the	O
first	O
discrimination	O
task	O
revealed	O
a	O
significant	O
correlation	O
with	O
the	O
memory	O
performance	O
,	O
showing	O
a	O
"	O
memory	O
"	O
deficit	O
under	O
extinction	O
-	O
free	O
conditions	O
(	O
Figure	O
S3B	O
)	O
.	O

Finally	O
,	O
in	O
other	O
memory	O
-	O
related	O
tasks	O
,	O
such	O
as	O
a	O
hippocampus	O
-	O
dependent	O
spatial	O
reference	O
memory	O
task	O
(	O
Figure	O
S2	O
)	O
,	O
mice	B-Taxon
with	O
GluR	B-GGP
-	I-GGP
B	I-GGP
depletion	O
were	O
not	O
impaired	O
after	O
task	O
acquisition	O
.	O

We	O
therefore	O
conclude	O
that	O
forebrain	O
-	O
specific	O
ablation	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
results	O
in	O
a	O
specific	O
loss	O
of	O
long	O
-	O
term	O
olfactory	O
memory	O
but	O
,	O
at	O
the	O
same	O
time	O
,	O
in	O
enhanced	O
odor	O
discrimination	O
and	O
learning	O
capabilities	O
.	O

To	O
dissect	O
the	O
discrimination	O
,	O
learning	O
,	O
and	O
memory	O
phenotypes	O
,	O
and	O
ultimately	O
identify	O
potential	O
cellular	B-CL
correlates	O
,	O
we	O
made	O
use	O
of	O
the	O
variegated	O
Cre	O
expression	O
of	O
TgCre4	O
mice	B-Taxon
.	O

Therefore	O
,	O
residual	O
GluR	B-GGP
-	I-GGP
B	I-GGP
levels	O
were	O
determined	O
from	O
each	O
mouse	B-Taxon
that	O
had	O
been	O
tested	O
in	O
the	O
behavioral	O
experiments	O
,	O
and	O
levels	O
were	O
correlated	O
with	O
odor	O
learning	O
,	O
discrimination	O
,	O
and	O
olfactory	O
memory	O
.	O

The	O
significant	O
direct	O
correlation	O
between	O
residual	O
GluR	B-GGP
-	I-GGP
B	I-GGP
levels	O
in	O
hippocampus	O
and	O
cortical	O
areas	O
with	O
olfactory	O
memory	O
suggested	O
hippocampal	O
and	O
/	O
or	O
cortical	O
neurons	B-CL
as	O
putative	O
mediators	O
for	O
odor	O
memorization	O
and	O
/	O
or	O
storage	O
.	O

No	O
measure	O
of	O
discrimination	O
and	O
learning	O
,	O
on	O
the	O
other	O
hand	O
,	O
correlated	O
with	O
residual	O
GluR	B-GGP
-	I-GGP
B	I-GGP
levels	O
;	O
even	O
the	O
smallest	O
reduction	O
in	O
GluR	B-GGP
-	I-GGP
B	I-GGP
levels	O
(	O
about	O
20	O
%	O
-	O
60	O
%	O
)	O
was	O
sufficient	O
to	O
establish	O
and	O
saturate	O
enhanced	O
odor	O
discrimination	O
capabilities	O
.	O

Together	O
,	O
this	O
allows	O
the	O
conclusion	O
that	O
distinct	O
mechanisms	O
mediate	O
discrimination	O
/	O
learning	O
and	O
memory	O
.	O

This	O
is	O
furthermore	O
consistent	O
with	O
a	O
prominent	O
role	O
of	O
cortical	O
areas	O
or	O
hippocampus	O
in	O
olfactory	O
memory	O
,	O
although	O
GluR	B-GGP
-	I-GGP
B	I-GGP
levels	O
in	O
the	O
olfactory	O
bulb	O
were	O
also	O
weakly	O
correlated	O
with	O
memory	O
performance	O
.	O

Transgenic	B-SO
expression	O
of	O
GFPGluR	O
-	O
B	O
in	O
piriform	O
cortex	O
and	O
hippocampus	O
indeed	O
rescued	O
memory	O
to	O
an	O
extent	O
strikingly	O
consistent	O
with	O
the	O
transgenic	B-SO
protein	B-CHEBI
levels	O
(	O
approximately	O
10	O
%	O
of	O
wild	B-SO
-	I-SO
type	I-SO
GluR	B-GGP
-	I-GGP
B	I-GGP
)	O
,	O
confirming	O
the	O
reliability	O
of	O
the	O
correlation	O
analysis	O
and	O
the	O
sensitivity	O
of	O
the	O
behavioral	O
assay	O
.	O

In	O
general	O
,	O
the	O
hippocampus	O
is	O
thought	O
to	O
be	O
involved	O
in	O
only	O
those	O
olfactory	O
memory	O
tasks	O
that	O
involve	O
temporal	O
sequence	O
analysis	O
or	O
require	O
other	O
higher	O
cognitive	O
features	O
[	O
2	O
,	O
13	O
,	O
72	O
-	O
74	O
]	O
.	O

In	O
particular	O
,	O
extensive	O
lesions	O
to	O
the	O
hippocampal	O
formation	O
in	O
rats	B-Taxon
do	O
not	O
interfere	O
with	O
long	O
-	O
term	O
olfactory	O
memory	O
in	O
go	O
/	O
no	O
-	O
go	O
successive	O
olfactory	O
discrimination	O
tasks	O
[	O
72	O
]	O
,	O
such	O
as	O
the	O
one	O
described	O
.	O

This	O
leaves	O
piriform	O
cortex	O
as	O
the	O
most	O
prominent	O
candidate	O
for	O
the	O
locus	O
of	O
the	O
olfactory	O
memory	O
deficit	O
described	O
,	O
consistent	O
with	O
the	O
prevalent	O
view	O
of	O
piriform	O
cortex	O
as	O
an	O
associational	O
memory	O
structure	O
[	O
75	O
]	O
and	O
learning	O
-	O
associated	O
changes	O
in	O
piriform	O
cortex	O
[	O
7	O
,	O
20	O
-	O
23	O
]	O
.	O

Potential	O
Mechanisms	O
of	O
Specific	O
Olfactory	O
Memory	O
Impairment	O

What	O
could	O
be	O
the	O
cellular	B-CL
basis	O
of	O
the	O
long	O
-	O
term	O
memory	O
deficit	O
brought	O
about	O
by	O
lack	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
-	O
containing	O
AMPARs	O
?	O

For	O
complete	O
GluR	B-GGP
-	I-GGP
B	I-GGP
knockouts	O
,	O
increased	O
long	O
-	O
term	O
plasticity	O
(	O
LTP	O
)	O
was	O
reported	O
in	O
hippocampal	O
field	O
recordings	O
[	O
51	O
]	O
.	O

In	O
addition	O
,	O
in	O
hippocampal	O
and	O
amygdala	O
pathways	O
lacking	O
GluR	B-GGP
-	I-GGP
B	I-GGP
,	O
an	O
AMPAR	O
-	O
dependent	O
,	O
N	B-CHEBI
-	O
methyl	B-CHEBI
-	O
D	B-CHEBI
-	I-CHEBI
aspartate	I-CHEBI
(	O
NMDA	O
)	O
receptor	O
-	O
independent	O
form	O
of	O
LTP	O
can	O
be	O
readily	O
induced	O
[	O
51	O
,	O
52	O
]	O
.	O

Mechanistically	O
,	O
this	O
is	O
likely	O
to	O
be	O
due	O
to	O
Ca2	B-CHEBI
+	I-CHEBI
influx	O
through	O
GluR	B-GGP
-	I-GGP
B	I-GGP
-	O
less	O
AMPA	O
channels	O
leading	O
to	O
non	O
-	O
hebbian	O
forms	O
of	O
plasticity	O
.	O

However	O
,	O
hebbian	O
dependence	O
on	O
simultaneous	O
pre	O
-	O
and	O
postsynaptic	O
activity	O
is	O
often	O
a	O
critical	O
feature	O
for	O
memory	O
storage	O
(	O
reviewed	O
in	O
e	O
.	O
g	O
.	O
[	O
76	O
]	O
)	O
;	O
hence	O
,	O
a	O
non	O
-	O
hebbian	O
form	O
of	O
plasticity	O
should	O
result	O
in	O
impaired	O
memorization	O
.	O

Surprisingly	O
,	O
in	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
no	O
LTP	O
changes	O
could	O
be	O
observed	O
in	O
field	O
measurements	O
in	O
the	O
hippocampus	O
,	O
nor	O
could	O
NMDA	O
-	O
independent	O
LTP	O
be	O
induced	O
in	O
hippocampal	O
synapses	B-GO
between	O
Schaffer	O
collaterals	O
and	O
CA1	O
pyramidal	B-CL
cells	I-CL
in	O
presence	O
of	O
the	O
NMDA	O
antagonist	B-CHEBI
APV	O
(	O
K	O
.	O
Jensen	O
,	O
O	O
.	O
Hvalby	O
,	O
personal	O
communication	O
)	O
.	O

However	O
,	O
in	O
other	O
brain	O
areas	O
that	O
are	O
potentially	O
important	O
for	O
the	O
processing	O
of	O
olfactory	O
information	O
,	O
such	O
as	O
piriform	O
cortex	O
or	O
olfactory	O
bulb	O
,	O
LTP	O
measurements	O
have	O
not	O
yet	O
been	O
performed	O
;	O
synapses	B-GO
of	O
these	O
pathways	O
may	O
be	O
regulated	O
differently	O
than	O
hippocampal	O
CA3	O
/	O
CA1	O
synapses	B-GO
.	O

Additionally	O
,	O
by	O
changing	O
the	O
Ca2	B-CHEBI
+	I-CHEBI
permeability	O
of	O
AMPARs	O
,	O
Ca2	B-CHEBI
+	I-CHEBI
signaling	O
via	O
AMPA	O
and	O
colocalized	O
NMDA	O
channels	O
might	O
be	O
disturbed	O
,	O
thereby	O
impairing	O
memory	O
formation	O
.	O

Other	O
forms	O
of	O
plasticity	O
[	O
77	O
,	O
78	O
]	O
induced	O
by	O
Ca2	B-CHEBI
+	I-CHEBI
-	O
permeable	O
AMPARs	O
might	O
play	O
a	O
prevalent	O
role	O
in	O
olfactory	O
memory	O
.	O

Alternatively	O
,	O
long	O
-	O
term	O
stabilization	O
might	O
involve	O
GluR	B-GGP
-	I-GGP
B	I-GGP
phosphorylation	O
similar	O
to	O
cerebellar	O
long	O
-	O
term	O
depression	O
[	O
79	O
]	O
and	O
thus	O
be	O
selectively	O
impaired	O
by	O
GluR	B-GGP
-	I-GGP
B	I-GGP
depletion	O
.	O

Physiological	O
experiments	O
to	O
assess	O
these	O
hypotheses	O
will	O
ideally	O
make	O
use	O
of	O
even	O
more	O
restricted	O
genetic	B-SO
modifications	B-SO
with	O
completely	O
undisturbed	O
input	O
structures	O
.	O

One	O
possibility	O
would	O
be	O
Cre	O
-	O
mediated	O
GluR	B-GGP
-	I-GGP
B	I-GGP
depletion	O
and	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
Q	B-CHEBI
)	O
expression	O
in	O
piriform	O
cortex	O
as	O
suggested	O
above	O
.	O

Correlating	O
Quantitative	O
Behavior	O
and	O
Mosaic	O
Gene	B-SO
Expression	O
for	O
Dissecting	O
Phenotypes	O

A	O
critical	O
step	O
in	O
discerning	O
the	O
discrimination	O
and	O
learning	O
phenotypes	O
from	O
the	O
memory	O
phenotype	O
was	O
the	O
observation	O
of	O
increased	O
variability	O
in	O
the	O
memory	O
of	O
the	O
GluR	B-GGP
-	I-GGP
B	I-GGP
knockout	O
animals	B-Taxon
and	O
,	O
subsequently	O
,	O
the	O
individual	O
analyses	O
of	O
protein	B-CHEBI
expression	O
levels	O
.	O

We	O
made	O
use	O
of	O
the	O
epigenetic	O
variability	O
in	O
GluR	B-GGP
-	I-GGP
B	I-GGP
excision	B-SO
that	O
could	O
be	O
correlated	O
to	O
the	O
variability	O
in	O
memory	O
but	O
showed	O
no	O
correlation	O
to	O
variability	O
in	O
discrimination	O
.	O

The	O
analysis	O
of	O
quantitative	B-SO
trait	I-SO
loci	I-SO
(	O
for	O
review	O
,	O
see	O
[	O
80	O
]	O
)	O
,	O
or	O
classically	O
correlating	O
different	O
behavioral	O
phenotypes	O
within	O
a	O
truly	O
wild	B-SO
-	I-SO
type	I-SO
population	O
[	O
81	O
-	O
84	O
]	O
,	O
also	O
attempts	O
to	O
find	O
common	O
or	O
distinct	O
genetic	B-SO
origins	O
of	O
different	O
behavioral	O
traits	O
.	O

These	O
attempts	O
undoubtedly	O
contribute	O
significantly	O
to	O
unraveling	O
the	O
molecular	B-CHEBI
basis	O
of	O
behavior	O
.	O

Due	O
to	O
subtle	O
and	O
multigenic	O
differences	O
between	O
different	O
strains	O
of	O
rodents	B-Taxon
or	O
different	O
individuals	B-Taxon
in	O
a	O
wild	B-SO
-	I-SO
type	I-SO
population	O
,	O
however	O
,	O
they	O
suffer	O
from	O
a	O
rather	O
low	O
"	O
signal	O
-	O
to	O
-	O
noise	O
"	O
ratio	O
.	O

Differences	O
in	O
individual	O
genes	B-SO
are	O
rather	O
small	O
compared	O
with	O
the	O
vast	O
number	O
of	O
genes	B-SO
involved	O
.	O

As	O
a	O
result	O
,	O
purely	O
correlating	O
behavioral	O
traits	O
within	O
a	O
wild	B-SO
-	I-SO
type	I-SO
population	O
usually	O
remains	O
rather	O
descriptive	O
,	O
whereas	O
quantitative	B-SO
trait	I-SO
loci	I-SO
analysis	O
is	O
capable	O
of	O
revealing	O
multigenic	O
basis	O
of	O
behavioral	O
traits	O
but	O
usually	O
lacks	O
the	O
power	O
to	O
identify	O
the	O
individual	O
genes	B-SO
themselves	O
.	O

Herein	O
,	O
we	O
described	O
a	O
way	O
to	O
enhance	O
the	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
by	O
making	O
use	O
of	O
the	O
mosaic	O
expression	O
often	O
associated	O
with	O
transgenic	B-SO
approaches	O
:	O
combining	O
the	O
advantages	O
of	O
"	O
classical	O
"	O
genetic	B-SO
manipulation	O
--	O
namely	O
,	O
that	O
the	O
target	O
of	O
the	O
manipulation	O
is	O
well	O
defined	O
--	O
with	O
the	O
possibility	O
to	O
analyze	O
variability	O
,	O
might	O
also	O
in	O
future	O
provide	O
novel	O
ways	O
to	O
define	O
molecular	B-CHEBI
and	O
cellular	B-CL
correlates	O
of	O
complex	O
behavioral	O
traits	O
.	O

In	O
this	O
study	O
,	O
we	O
combined	O
genetically	B-SO
induced	O
manipulation	O
of	O
the	O
AMPAR	O
composition	O
with	O
quantitative	O
behavioral	O
and	O
molecular	B-CHEBI
analyses	O
.	O

We	O
could	O
thus	O
provide	O
evidence	O
for	O
opposing	O
roles	O
of	O
specific	O
GluR	B-GGP
-	I-GGP
B	I-GGP
manipulation	O
and	O
increased	O
Ca2	B-CHEBI
+	I-CHEBI
influx	O
via	O
AMPARs	O
in	O
olfactory	O
discrimination	O
/	O
learning	O
,	O
and	O
memory	O
,	O
potentially	O
in	O
the	O
olfactory	O
bulb	O
and	O
piriform	O
cortex	O
,	O
respectively	O
.	O

To	O
achieve	O
this	O
,	O
we	O
made	O
use	O
of	O
the	O
epigenetic	O
variability	O
in	O
the	O
extent	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
ablation	O
,	O
which	O
correlated	O
with	O
the	O
variability	O
in	O
odor	O
memory	O
,	O
but	O
not	O
in	O
discrimination	O
and	O
learning	O
;	O
this	O
finding	O
was	O
subsequently	O
confirmed	O
in	O
GluR	B-GGP
-	I-GGP
B	I-GGP
rescue	O
mice	B-Taxon
with	O
piriform	O
cortex	O
-	O
specific	O
transgenic	B-SO
expression	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
.	O

Extending	O
these	O
principles	O
of	O
combining	O
quantitative	O
behavioral	O
analyses	O
with	O
minimal	O
and	O
dosed	O
genetic	B-SO
interference	O
,	O
together	O
with	O
further	O
physiological	O
analyses	O
,	O
will	O
ultimately	O
pinpoint	O
the	O
neural	O
circuitries	O
underlying	O
related	O
,	O
but	O
distinct	O
,	O
behavioral	O
traits	O
in	O
olfactory	O
and	O
other	O
systems	O
.	O

Materials	O
and	O
Methods	O

Mouse	B-Taxon
lines	O

The	O
R26R	O
line	O
[	O
85	O
]	O
was	O
employed	O
as	O
Cre	O
indicator	O
.	O

GluR	O
-	O
B	O
Delta	O
ECS	O
:	O
FB	O
mice	B-Taxon
were	O
of	O
mixed	O
C57Bl	O
/	O
6	O
and	O
NMRI	O
genetic	B-SO
background	O
and	O
generated	O
from	O
TgCre4	O
(	O
"	O
Camkcre4	O
"	O
in	O
[	O
59	O
]	O
)	O
and	O
GluR	B-GGP
-	I-GGP
B	I-GGP
+	O
/	O
neo	O
[	O
60	O
]	O
mice	B-Taxon
.	O

GluR	B-GGP
-	I-GGP
B	I-GGP
+	O
/	O
neo	O
mice	B-Taxon
carry	O
a	O
wild	B-SO
-	I-SO
type	I-SO
GluR	B-GGP
-	I-GGP
B	I-GGP
allele	B-SO
and	O
a	O
gene	B-SO
-	O
targeted	O
GluR	B-GGP
-	I-GGP
B	I-GGP
allele	B-SO
in	O
which	O
the	O
intron	B-SO
11	I-SO
sequence	I-SO
critical	O
for	O
Q	B-CHEBI
/	O
R	B-CHEBI
site	B-SO
editing	O
is	O
replaced	B-SO
by	O
a	O
TK	O
-	O
neo	O
gene	B-SO
flanked	B-SO
by	O
loxP	B-SO
sites	I-SO
(	O
"	O
floxed	B-SO
"	O
)	O
.	O

GluR	O
-	O
B2lox	O
mice	B-Taxon
[	O
86	O
]	O
carry	O
gene	B-SO
-	O
targeted	O
GluR	B-GGP
-	I-GGP
B	I-GGP
alleles	B-SO
in	O
which	O
exon	B-SO
11	O
is	O
floxed	B-SO
.	O

GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
were	O
of	O
C57Bl	O
/	O
6	O
genetic	B-SO
background	O
and	O
generated	O
from	O
TgCre4	O
and	O
GluR	O
-	O
B2lox	O
mice	B-Taxon
.	O

TgCN12	O
-	O
itTA	O
mice	B-Taxon
were	O
generated	O
as	O
described	O
for	O
TgCN10	O
-	O
itTA	O
mice	B-Taxon
(	O
see	O
Materials	O
and	O
Methods	O
in	O
[	O
58	O
]	O
)	O
,	O
and	O
represent	O
another	O
founder	O
line	O
obtained	O
from	O
the	O
same	O
pronucleus	B-GO
injection	O
,	O
with	O
more	O
widespread	O
forebrain	O
expression	O
.	O

For	O
exogeneous	O
expression	O
of	O
GFPGluR	O
-	O
B	O
,	O
the	O
mouse	B-Taxon
line	O
TgOCN1	O
was	O
generated	O
:	O
an	O
AseI	O
fragment	B-SO
of	O
plasmid	B-SO
pnlacZ	O
/	O
GFPGluR	O
-	O
B	O
was	O
injected	O
into	O
the	O
pronucleus	B-GO
of	O
oocytes	B-CL
obtained	O
from	O
DBA1	O
/	O
C57Bl	O
/	O
6	O
F1	O
hybrids	O
.	O

Positive	O
founders	O
were	O
backcrossed	O
into	O
C57Bl	O
/	O
6	O
for	O
further	O
analysis	O
.	O

Plasmid	B-SO
pnlacZ	O
/	O
GFPGluR	O
-	O
B	O
was	O
constructed	O
from	O
pnlacZ	O
/	O
GFPGluR	O
-	O
A	O
[	O
87	O
]	O
by	O
replacing	B-SO
GluR	B-GGP
-	I-GGP
A	I-GGP
cDNA	B-SO
with	O
the	O
rat	B-Taxon
cDNA	B-SO
for	O
GluR	B-GGP
-	I-GGP
B	I-GGP
.	O

Transgenic	B-SO
GFPGluR	O
-	O
B	O
protein	B-CHEBI
levels	O
were	O
measured	O
in	O
hippocampus	O
of	O
TgOCN1	O
mice	B-Taxon
also	O
carrying	O
a	O
transgene	B-SO
for	O
forebrain	O
-	O
specific	O
homogeneous	O
tTA	O
expression	O
[	O
88	O
]	O
.	O

Experimental	O
groups	O

Mice	B-Taxon
heterozygous	O
for	O
TgCre4	O
and	O
heterozygous	O
for	O
the	O
TK	O
-	O
neo	O
cassette	B-SO
in	O
the	O
GluR	B-GGP
-	I-GGP
B	I-GGP
allele	B-SO
(	O
GluR	O
-	O
B	O
Delta	O
ECS	O
:	O
FB	O
)	O
or	O
homozygous	O
for	O
the	O
floxed	B-SO
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
GluR	O
-	O
B	O
Delta	O
FB	O
)	O
were	O
used	O
in	O
the	O
experiments	O
.	O

The	O
"	O
rescue	O
"	O
mice	B-Taxon
(	O
GluR	O
-	O
BRescue	O
)	O
were	O
positive	O
for	O
TgCre4	O
,	O
homozygous	O
for	O
the	O
floxed	B-SO
GluR	I-SO
-	I-SO
B	I-SO
gene	I-SO
,	O
and	O
positive	O
for	O
the	O
tet	B-CHEBI
-	O
sensitive	O
responder	O
transgene	B-SO
TgOCN1	O
and	O
for	O
the	O
itTA	O
expressing	O
activator	O
transgene	B-SO
TgCN12	O
-	O
itTA	O
.	O

Control	O
groups	O

Littermate	O
controls	O
were	O
used	O
in	O
all	O
experiments	O
.	O

GluR	B-GGP
-	I-GGP
B	I-GGP
+	O
/	O
+	O
mice	B-Taxon
were	O
used	O
as	O
controls	O
in	O
the	O
task	O
described	O
in	O
Figure	O
1	O
.	O

GluR	B-GGP
-	I-GGP
B	I-GGP
+	O
/	O
2lox	O
and	O
GluR	O
-	O
B2lox	O
/	O
2lox	O
(	O
both	O
negative	O
for	O
TgCre4	O
)	O
mice	B-Taxon
were	O
used	O
as	O
controls	O
in	O
experiments	O
described	O
in	O
Figures	O
2	O
,	O
4	O
,	O
and	O
6	O
.	O

For	O
the	O
GluR	O
-	O
BRescue	O
experiments	O
(	O
Figure	O
6	O
)	O
,	O
controls	O
positive	O
for	O
either	O
TgCN12	O
-	O
itTA	O
or	O
TgOCN1	O
in	O
a	O
GluR	B-GGP
-	I-GGP
B	I-GGP
+	O
/	O
2lox	O
and	O
GluR	O
-	O
B2lox	O
/	O
2lox	O
(	O
both	O
negative	O
for	O
TgCre4	O
)	O
background	O
were	O
used	O
.	O

Genotyping	O

Mice	B-Taxon
were	O
selected	O
by	O
PCR	O
of	O
mouse	B-Taxon
-	O
tail	O
DNA	B-SO
with	O
specific	O
primers	B-SO
as	O
described	O
below	O
.	O

Indicated	O
are	O
the	O
sequences	B-SO
and	O
the	O
approximate	O
length	O
of	O
the	O
amplified	O
DNA	B-SO
fragments	B-SO
.	O

TgCre4	O
:	O
rspCre1	O
(	O
5	O
'	O
-	O
ACCAGGTTCGTTCACTCATGG	O
-	O
3	O
'	O
)	O
and	O
rspCre2	O
(	O
5	O
'	O
-	O
AGGCTAAGTGCCTTCTCTACAC	O
-	O
3	O
'	O
)	O
,	O
200	O
basepairs	B-SO
(	O
bp	B-SO
)	O
.	O

GluR	O
-	O
Bneo	O
:	O
MH60	O
(	O
5	O
'	O
-	O
CACTCACAGCAATGAAGCAGGAC	O
-	O
3	O
'	O
)	O
,	O
MH53a	O
(	O
5	O
'	O
-	O
GAATGTTGATCATGTGTTTCCCTG	O
-	O
3	O
'	O
)	O
,	O
and	O
MH117	O
(	O
5	O
'	O
-	O
GTTCGAATTCGCCAATGACAAGACG	O
-	O
3	O
'	O
)	O
,	O
wild	B-SO
-	I-SO
type	I-SO
:	O
500	O
bp	B-SO
and	O
mutant	B-SO
:	O
400	O
bp	B-SO
.	O

GluR	O
-	O
B2lox	O
:	O
VM12	O
(	O
5	O
'	O
-	O
GCGTAAGCCTGTGAAATACCTG	O
-	O
3	O
'	O
)	O
and	O
VM10	O
(	O
5	O
'	O
-	O
GTTGTCTAACAAGTTGTTGACC	O
-	O
3	O
'	O
)	O
,	O
wild	B-SO
-	I-SO
type	I-SO
:	O
250	O
bp	B-SO
and	O
mutant	B-SO
:	O
350	O
bp	B-SO
.	O

TgOCN1	O
:	O
VM4	O
(	O
5	O
'	O
-	O
CTCCCAGACAACCATTACCTGTCC	O
-	O
3	O
'	O
)	O
and	O
GluR	O
-	O
B882BST	O
(	O
5	O
'	O
-	O
CGAAGTATACTTAATTGTCGCTGTGTG	O
-	O
3	O
'	O
)	O
,	O
600	O
bp	B-SO
.	O

TgCN12	O
-	O
itTA	O
:	O
htTA1	O
(	O
5	O
'	O
-	O
AGAGCAAAGTCATCAACTCTG	O
-	O
3	O
'	O
)	O
and	O
htTA2	O
(	O
5	O
'	O
-	O
GTGAGAGCCAGACTCACATTTCA	O
-	O
3	O
'	O
)	O
,	O
1	O
,	O
000	O
bp	B-SO
.	O

Southern	O
blot	O
analysis	O

Genomic	B-SO
DNA	I-SO
from	O
mouse	B-Taxon
-	O
tail	O
/	O
liver	O
was	O
digested	O
with	O
restriction	O
enzyme	B-SO
BglII	O
(	O
NEB	O
)	O
,	O
and	O
the	O
Southern	O
blot	O
was	O
done	O
with	O
a	O
320	O
-	O
bp	B-SO
probe	B-SO
(	O
"	O
integ	O
"	O
)	O
obtained	O
by	O
PCR	O
detecting	O
the	O
alpha	B-GGP
CaMKII	I-GGP
promoter	B-SO
.	O

Histochemistry	O

Histochemistry	O
was	O
performed	O
as	O
described	O
previously	O
[	O
89	O
]	O
,	O
with	O
the	O
following	O
exceptions	O
:	O
Coronal	O
70	O
-	O
to	O
100	O
-	O
mu	O
m	O
vibratome	O
slices	O
were	O
used	O
for	O
immunohistochemistry	O
with	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
1	O
:	O
60	O
,	O
polyclonal	O
;	O
Chemicon	O
,	O
Temecula	O
,	O
California	O
,	O
United	O
States	O
)	O
,	O
GFP	O
(	O
1	O
:	O
8	O
,	O
000	O
,	O
polyclonal	O
;	O
MobiTech	O
,	O
G	O
o	O
ttingen	O
,	O
Germany	O
)	O
,	O
and	O
Cre	O
(	O
1	O
:	O
8	O
,	O
000	O
,	O
polyclonal	O
;	O
BAbCO	O
,	O
Berkeley	O
,	O
California	O
,	O
United	O
States	O
)	O
primary	O
antibodies	B-GO
,	O
and	O
FITC	B-CHEBI
-	O
coupled	O
(	O
1	O
:	O
200	O
;	O
Dianova	O
,	O
Hamburg	O
,	O
Germany	O
)	O
and	O
peroxidase	O
-	O
coupled	O
(	O
1	O
:	O
600	O
;	O
Vector	O
,	O
Burlingame	O
,	O
California	O
,	O
United	O
States	O
)	O
secondary	O
goat	B-Taxon
anti	O
-	O
rabbit	B-Taxon
antibodies	B-GO
.	O

The	O
main	O
olfactory	O
epithelium	O
was	O
obtained	O
via	O
cryostat	O
sectioning	O
,	O
and	O
immunohistochemistry	O
was	O
performed	O
(	O
primary	O
antibody	B-GO
Cre	O
,	O
1	O
:	O
5	O
,	O
000	O
,	O
polyclonal	O
;	O
BAbCO	O
)	O
.	O

X	O
-	O
gal	O
staining	O
was	O
performed	O
as	O
described	O
[	O
89	O
]	O
.	O

Immunoblot	O
analysis	O

Mouse	B-Taxon
brains	O
were	O
removed	O
,	O
and	O
the	O
hippocampus	O
,	O
olfactory	O
bulb	O
,	O
and	O
remaining	O
forebrain	O
areas	O
were	O
isolated	O
.	O

Total	O
protein	B-CHEBI
was	O
prepared	O
,	O
and	O
immunoblots	O
were	O
performed	O
as	O
described	O
[	O
87	O
]	O
.	O

Antibodies	B-GO
used	O
were	O
against	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
1	O
:	O
800	O
,	O
monoclonal	O
;	O
Chemicon	O
)	O
,	O
beta	B-GGP
-	I-GGP
actin	I-GGP
(	O
1	O
:	O
40	O
,	O
000	O
,	O
monoclonal	O
;	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
Missouri	O
,	O
United	O
States	O
)	O
as	O
an	O
internal	O
standard	O
,	O
and	O
secondary	O
goat	B-Taxon
anti	O
-	O
rabbit	B-Taxon
and	O
goat	B-Taxon
anti	O
-	O
mouse	B-Taxon
antibodies	B-GO
(	O
Vector	O
,	O
1	O
:	O
15	O
,	O
000	O
)	O
.	O

Immunoreactivity	O
was	O
detected	O
with	O
ECLplus	O
(	O
Amersham	O
,	O
Little	O
Chalfont	O
,	O
United	O
Kingdom	O
)	O
,	O
and	O
immunoblots	O
were	O
scanned	O
and	O
quantitatively	O
analyzed	O
with	O
ImageJ	O
.	O

Behavioral	O
analysis	O
:	O
Subjects	O

All	O
mice	B-Taxon
were	O
four	O
to	O
six	O
weeks	O
old	O
at	O
the	O
beginning	O
of	O
the	O
experiments	O
.	O

Subjects	O
were	O
maintained	O
on	O
a	O
12	O
-	O
h	O
light	O
-	O
dark	O
cycle	O
in	O
isolated	O
cages	O
in	O
a	O
temperature	O
and	O
humidity	O
-	O
controlled	O
animal	B-Taxon
facility	O
.	O

All	O
behavioral	O
training	O
was	O
conducted	O
during	O
daytime	O
.	O

During	O
the	O
training	O
period	O
,	O
animals	B-Taxon
were	O
kept	O
on	O
free	O
food	B-CHEBI
but	O
on	O
a	O
water	B-CHEBI
-	O
restriction	O
schedule	O
designed	O
to	O
keep	O
them	O
at	O
>	O
85	O
%	O
of	O
their	O
free	O
food	B-CHEBI
body	O
weight	O
.	O

Continuous	O
water	B-CHEBI
restriction	O
was	O
never	O
longer	O
than	O
12	O
h	O
.	O

All	O
animal	B-Taxon
care	O
and	O
procedures	O
were	O
in	O
accordance	O
with	O
the	O
animal	B-Taxon
ethics	O
guidelines	O
of	O
the	O
Max	O
-	O
Planck	O
Society	O
.	O

Apparatus	O

All	O
olfactory	O
discrimination	O
experiments	O
were	O
performed	O
using	O
three	O
modified	O
eight	O
-	O
channel	O
olfactometers	O
(	O
[	O
61	O
]	O
,	O
Knosys	O
,	O
Bethesda	O
,	O
Maryland	O
,	O
United	O
States	O
of	O
America	O
)	O
operated	O
by	O
custom	O
-	O
written	O
software	O
in	O
Igor	O
(	O
Wave	O
Metrics	O
,	O
Lake	O
Oswego	O
,	O
Oregon	O
,	O
United	O
States	O
of	O
America	O
)	O
on	O
Pentium	O
I	O
,	O
II	O
,	O
and	O
III	O
PCs	O
running	O
Microsoft	O
Windows	O
98	O
.	O

Great	O
care	O
was	O
taken	O
to	O
counterbalance	O
groups	O
between	O
setups	O
.	O

In	O
brief	O
,	O
animals	B-Taxon
were	O
presented	O
with	O
odor	O
from	O
one	O
out	O
of	O
eight	O
possible	O
odor	O
channels	O
and	O
rewarded	O
with	O
a	O
2	O
-	O
to	O
4	O
-	O
mu	O
l	O
drop	O
of	O
water	B-CHEBI
in	O
a	O
combined	O
odor	O
/	O
reward	O
port	O
(	O
Figure	O
1B	O
)	O
,	O
ensuring	O
tight	O
association	O
of	O
the	O
water	B-CHEBI
-	O
reward	O
with	O
a	O
presented	O
odorant	O
.	O

Head	O
insertion	O
into	O
the	O
port	O
was	O
monitored	O
by	O
an	O
IR	O
beam	O
and	O
photodiode	O
(	O
Figure	O
1B	O
)	O
.	O

Odors	O
used	O
were	O
n	O
-	O
amyl	O
acetate	B-CHEBI
,	O
ethyl	B-CHEBI
butyrate	B-CHEBI
,	O
pelargonic	B-CHEBI
acid	I-CHEBI
,	O
valeric	B-CHEBI
acid	I-CHEBI
,	O
and	O
binary	O
mixtures	O
of	O
cineol	B-CHEBI
and	O
eugenol	B-CHEBI
.	O

If	O
not	O
otherwise	O
noted	O
,	O
odors	O
were	O
diluted	O
to	O
1	O
%	O
in	O
mineral	O
oil	O
(	O
Fluka	O
Chemie	O
,	O
Steinheim	O
,	O
Germany	O
)	O
and	O
further	O
diluted	O
by	O
airflow	O
to	O
a	O
final	O
concentration	O
of	O
approximately	O
0	O
.	O
15	O
%	O
.	O

All	O
dilutions	O
in	O
the	O
text	O
refer	O
to	O
the	O
dilution	O
in	O
mineral	O
oil	O
.	O

All	O
chemicals	B-CHEBI
were	O
obtained	O
from	O
Fluka	O
Chemie	O
.	O

Task	O
habituation	O
training	O

Beginning	O
1	O
-	O
3	O
d	O
after	O
the	O
start	O
of	O
the	O
water	B-CHEBI
restriction	O
schedule	O
,	O
animals	B-Taxon
were	O
trained	O
using	O
standard	O
operant	O
-	O
conditioning	O
procedures	O
[	O
3	O
]	O
.	O

In	O
a	O
first	O
pretraining	O
step	O
,	O
each	O
lick	O
at	O
the	O
water	B-CHEBI
delivery	O
tube	O
was	O
rewarded	O
.	O

After	O
20	O
licks	O
,	O
a	O
second	O
stage	O
was	O
entered	O
in	O
which	O
head	O
insertion	O
initiated	O
a	O
2	O
-	O
s	O
"	O
odor	O
"	O
presentation	O
during	O
which	O
a	O
lick	O
was	O
rewarded	O
.	O

The	O
"	O
odorant	O
"	O
used	O
in	O
the	O
pretraining	O
was	O
the	O
carrier	O
medium	O
mineral	O
oil	O
.	O

All	O
animals	B-Taxon
learned	O
this	O
task	O
within	O
one	O
day	O
(	O
2	O
-	O
3	O
sessions	O
30	O
min	O
each	O
)	O
.	O

Structure	O
of	O
an	O
individual	O
trial	O

The	O
mouse	B-Taxon
initiates	O
each	O
trial	O
by	O
breaking	O
a	O
light	O
barrier	O
at	O
the	O
opening	O
of	O
the	O
sampling	O
port	O
(	O
see	O
also	O
[	O
3	O
]	O
)	O
.	O

This	O
opens	O
one	O
of	O
eight	O
odor	O
valves	O
,	O
and	O
a	O
diversion	O
valve	O
that	O
diverts	O
all	O
air	O
flow	O
away	O
from	O
the	O
animal	B-Taxon
for	O
typically	O
500	O
ms	O
.	O

After	O
the	O
release	O
of	O
the	O
diversion	O
valve	O
,	O
the	O
odor	O
is	O
accessible	O
to	O
the	O
animal	B-Taxon
for	O
2	O
,	O
000	O
ms	O
.	O

If	O
it	O
continuously	O
licks	O
at	O
the	O
lick	O
port	O
during	O
this	O
time	O
(	O
once	O
in	O
at	O
least	O
three	O
out	O
of	O
four	O
500	O
-	O
ms	O
bins	O
)	O
,	O
it	O
can	O
receive	O
a	O
2	O
-	O
to	O
4	O
-	O
mu	O
l	O
water	B-CHEBI
reward	O
after	O
the	O
end	O
of	O
the	O
2	O
,	O
000	O
-	O
ms	O
period	O
.	O

If	O
the	O
animal	B-Taxon
does	O
not	O
continuously	O
lick	O
,	O
or	O
if	O
the	O
presented	O
odor	O
was	O
a	O
designated	O
nonrewarded	O
odor	O
,	O
neither	O
a	O
reward	O
is	O
given	O
nor	O
any	O
sort	O
of	O
punishment	O
,	O
to	O
minimize	O
stress	O
for	O
the	O
animal	B-Taxon
.	O

Trials	O
are	O
counted	O
as	O
correct	O
if	O
the	O
animal	B-Taxon
licks	O
continuously	O
upon	O
presentation	O
of	O
a	O
rewarded	O
odor	O
or	O
does	O
not	O
lick	O
continuously	O
with	O
a	O
nonrewarded	O
odor	O
.	O

A	O
second	O
trial	O
cannot	O
be	O
initiated	O
unless	O
an	O
intertrial	O
interval	O
of	O
at	O
least	O
5	O
s	O
has	O
passed	O
.	O

This	O
interval	O
is	O
sufficiently	O
long	O
so	O
that	O
animals	B-Taxon
typically	O
retract	O
quickly	O
after	O
the	O
end	O
of	O
the	O
trial	O
.	O

Odors	O
are	O
presented	O
in	O
a	O
pseudo	O
-	O
randomized	O
scheme	O
(	O
no	O
more	O
than	O
two	O
successive	O
presentations	O
of	O
the	O
same	O
odor	O
,	O
equal	O
numbers	O
within	O
each	O
20	O
-	O
trial	O
block	O
)	O
.	O

No	O
intrinsic	O
preference	O
toward	O
any	O
of	O
the	O
odors	O
was	O
observed	O
but	O
controlled	O
for	O
by	O
counterbalancing	O
.	O

A	O
total	O
of	O
100	O
-	O
300	O
trials	O
were	O
performed	O
each	O
day	O
,	O
separated	O
into	O
30	O
-	O
to	O
40	O
-	O
min	O
stretches	O
to	O
ensure	O
maximal	O
motivation	O
despite	O
the	O
mild	O
water	B-CHEBI
restriction	O
scheme	O
.	O

Additionally	O
,	O
motivation	O
was	O
controlled	O
by	O
monitoring	O
intertrial	O
intervals	O
and	O
the	O
response	O
frequency	O
[	O
3	O
]	O
.	O

Measurement	O
of	O
performance	O

The	O
simplest	O
measure	O
of	O
performance	O
is	O
the	O
fraction	O
of	O
trials	O
in	O
which	O
the	O
animal	B-Taxon
responds	O
correctly	O
--	O
that	O
is	O
,	O
responds	O
with	O
licking	O
to	O
the	O
presentation	O
of	O
the	O
S	O
+	O
odor	O
and	O
does	O
not	O
lick	O
with	O
presentation	O
of	O
the	O
S	O
-	O
odor	O
.	O

It	O
was	O
shown	O
previously	O
,	O
however	O
,	O
that	O
the	O
detailed	O
sampling	O
pattern	O
is	O
a	O
more	O
sensitive	O
measure	O
of	O
discrimination	O
performance	O
[	O
3	O
]	O
.	O

To	O
avoid	O
long	O
(	O
>	O
3	O
-	O
week	O
)	O
training	O
periods	O
,	O
we	O
chose	O
not	O
to	O
measure	O
discrimination	O
times	O
[	O
3	O
]	O
but	O
to	O
analyze	O
the	O
average	O
sampling	O
behavior	O
in	O
total	O
.	O

Upon	O
presentation	O
of	O
a	O
rewarded	O
odor	O
,	O
the	O
animal	B-Taxon
usually	O
continuously	O
breaks	O
the	O
beam	O
,	O
whereas	O
upon	O
presentation	O
of	O
an	O
unrewarded	O
odor	O
the	O
head	O
is	O
quickly	O
retracted	O
.	O

The	O
difference	O
in	O
response	O
to	O
the	O
rewarded	O
and	O
unrewarded	O
odor	O
is	O
approximately	O
sigmoidal	O
(	O
Figures	O
1D	O
,	O
1E	O
,	O
and	O
2D	O
)	O
and	O
yields	O
a	O
sensitive	O
measure	O
of	O
the	O
discrimination	O
performance	O
.	O

From	O
this	O
difference	O
or	O
from	O
a	O
sigmoidal	O
fit	O
to	O
the	O
difference	O
(	O
Figure	O
1E	O
)	O
,	O
several	O
measures	O
of	O
discrimination	O
can	O
be	O
determined	O
:	O
the	O
average	O
difference	O
,	O
peak	O
,	O
or	O
maximum	O
,	O
time	O
of	O
half	O
maximum	O
,	O
and	O
slope	O
of	O
the	O
fitted	O
sigmoid	O
.	O

Whereas	O
for	O
small	O
trial	O
numbers	O
(	O
<	O
200	O
)	O
the	O
slope	O
often	O
is	O
not	O
well	O
constrained	O
,	O
any	O
of	O
the	O
other	O
parameters	O
yielded	O
essentially	O
the	O
same	O
results	O
.	O

The	O
discrimination	O
index	O
plotted	O
in	O
Figures	O
1F	O
,	O
2C	O
,	O
4D	O
,	O
and	O
6C	O
refers	O
to	O
the	O
fitted	O
maximum	O
,	O
generally	O
ranging	O
from	O
zero	O
to	O
one	O
,	O
one	O
indicating	O
the	O
best	O
discrimination	O
.	O

Identical	O
results	O
were	O
obtained	O
with	O
other	O
measures	O
of	O
discrimination	O
,	O
such	O
as	O
the	O
average	O
sampling	O
difference	O
.	O

Structure	O
of	O
training	O

After	O
habituation	O
,	O
mice	B-Taxon
were	O
trained	O
to	O
discriminate	O
1	O
%	O
amylacetate	O
from	O
1	O
%	O
ethylbutyrate	O
for	O
500	O
trials	O
.	O

During	O
the	O
last	O
100	O
trials	O
,	O
the	O
S	O
+	O
odor	O
was	O
rewarded	O
in	O
only	O
50	O
%	O
of	O
the	O
cases	O
to	O
increase	O
the	O
resistance	O
to	O
extinction	O
of	O
the	O
acquired	O
memory	O
.	O

These	O
trials	O
were	O
excluded	O
for	O
the	O
statistical	O
analysis	O
of	O
the	O
learning	O
curves	O
.	O

Inclusion	O
did	O
not	O
alter	O
the	O
result	O
of	O
the	O
ANOVA	O
;	O
however	O
,	O
linear	O
fitting	O
of	O
the	O
learning	O
curve	O
was	O
not	O
appropriate	O
anymore	O
as	O
partial	O
saturation	O
of	O
learning	O
performance	O
had	O
already	O
occurred	O
.	O

Subsequently	O
,	O
animals	B-Taxon
were	O
trained	O
for	O
500	O
trials	O
on	O
the	O
"	O
difficult	O
"	O
discrimination	O
task	O
[	O
3	O
]	O
between	O
the	O
binary	O
mixtures	O
0	O
.	O
6	O
%	O
eugenol	B-CHEBI
/	O
0	O
.	O
4	O
%	O
cineol	B-CHEBI
and	O
0	O
.	O
4	O
%	O
eugenol	B-CHEBI
/	O
0	O
.	O
6	O
%	O
cineol	B-CHEBI
.	O

To	O
allow	O
comparison	O
,	O
the	O
last	O
100	O
trials	O
were	O
altered	O
as	O
for	O
the	O
"	O
simple	O
"	O
discrimination	O
task	O
above	O
.	O

After	O
two	O
days	O
of	O
rest	O
,	O
animals	B-Taxon
were	O
finally	O
trained	O
on	O
the	O
"	O
simple	O
"	O
discrimination	O
task	O
between	O
1	O
%	O
pelargonic	B-CHEBI
acid	I-CHEBI
and	O
1	O
%	O
valeric	B-CHEBI
acid	I-CHEBI
for	O
another	O
600	O
trials	O
.	O

In	O
all	O
experiments	O
,	O
counterbalancing	O
between	O
both	O
odors	O
and	O
setups	O
was	O
ensured	O
within	O
and	O
between	O
genetic	B-SO
groups	O
,	O
or	O
results	O
were	O
compared	O
with	O
counterbalanced	O
subgroups	O
,	O
which	O
in	O
every	O
case	O
yielded	O
identical	O
results	O
.	O

During	O
the	O
entire	O
course	O
of	O
the	O
experiment	O
,	O
the	O
person	B-Taxon
handling	O
the	O
animals	B-Taxon
and	O
operating	O
the	O
olfactometers	O
was	O
blind	O
to	O
the	O
genotype	B-SO
of	O
the	O
mice	B-Taxon
.	O

Memory	O
measurement	O

To	O
assess	O
memory	O
,	O
after	O
280	O
trials	O
of	O
training	O
to	O
discriminate	O
between	O
pelargonic	B-CHEBI
acid	I-CHEBI
and	O
valeric	B-CHEBI
acid	I-CHEBI
,	O
memory	O
trials	O
were	O
interleaved	O
for	O
120	O
trials	O
;	O
that	O
is	O
,	O
within	O
each	O
block	O
of	O
20	O
trials	O
two	O
unrewarded	O
amylacetate	O
and	O
two	O
unrewarded	O
ethylbutyrate	O
trials	O
were	O
included	O
.	O

Memory	O
scores	O
are	O
given	O
as	O
the	O
fraction	O
of	O
those	O
unrewarded	O
trials	O
that	O
were	O
responded	O
to	O
"	O
correctly	O
"	O
(	O
licking	O
response	O
to	O
the	O
odor	O
that	O
was	O
rewarded	O
in	O
the	O
initial	O
training	O
session	O
[	O
S	O
+	O
]	O
,	O
no	O
response	O
to	O
the	O
odor	O
that	O
was	O
not	O
rewarded	O
initially	O
[	O
S	O
-	O
]	O
)	O
.	O

Due	O
to	O
the	O
epileptic	O
phenotype	O
and	O
the	O
slightly	O
increased	O
mortality	O
[	O
58	O
]	O
,	O
GluRB	O
Delta	O
ECS	O
:	O
FB	O
mice	B-Taxon
were	O
trained	O
only	O
for	O
the	O
initial	O
period	O
of	O
400	O
trials	O
.	O

Statistics	O

Learning	O
curves	O
for	O
both	O
correct	O
performance	O
(	O
"	O
percentage	O
correct	O
"	O
)	O
and	O
the	O
discrimination	O
performance	O
were	O
analyzed	O
by	O
repeated	O
measure	O
ANOVA	O
.	O

Additionally	O
,	O
learning	O
curves	O
were	O
assessed	O
by	O
linearly	O
fitting	O
of	O
trend	O
lines	O
to	O
the	O
data	O
with	O
fixed	O
offsets	O
,	O
leaving	O
the	O
slope	O
as	O
the	O
only	O
variable	O
.	O

In	O
general	O
,	O
binning	O
was	O
100	O
trials	O
per	O
block	O
.	O

To	O
allow	O
for	O
the	O
investigation	O
of	O
group	O
/	O
block	O
interactions	O
,	O
the	O
repeated	O
measure	O
ANOVA	O
binning	O
was	O
reduced	O
to	O
20	O
trials	O
per	O
block	O
.	O

To	O
compare	O
memory	O
performance	O
in	O
the	O
GluR	O
-	O
BRescue	O
(	O
n	O
=	O
8	O
)	O
and	O
GluR	O
-	O
B	O
Delta	O
FB	O
(	O
n	O
=	O
22	O
)	O
mice	B-Taxon
,	O
due	O
to	O
the	O
high	O
variability	O
,	O
a	O
bootstrap	O
approach	O
was	O
employed	O
.	O

Subpopulations	O
of	O
eight	O
animals	B-Taxon
were	O
selected	O
from	O
the	O
population	O
of	O
22	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
,	O
and	O
mean	O
memory	O
was	O
determined	O
.	O

In	O
only	O
343	O
out	O
of	O
20	O
,	O
000	O
subpopulations	O
,	O
mean	O
memory	O
exceeded	O
the	O
mean	O
GluR	O
-	O
BRescue	O
memory	O
of	O
74	O
.	O
99	O
%	O
,	O
resulting	O
in	O
a	O
p	O
value	O
of	O
p	O
=	O
343	O
/	O
20	O
,	O
000	O
=	O
0	O
.	O
017	O
.	O

Supporting	O
Information	O

Figure	O
S1	O

Forebrain	O
-	O
Specific	O
Gene	B-SO
Manipulation	O

(	O
A	O
)	O
Schematic	O
diagrams	O
depicting	O
Cre	O
under	O
the	O
alpha	B-GGP
CaMKII	I-GGP
promoter	B-SO
control	O
[	O
59	O
]	O
and	O
Cre	O
-	O
dependent	O
expression	O
of	O
beta	O
-	O
galactosidase	O
(	O
LacZ	O
)	O
by	O
the	O
R26R	O
indicator	O
mouse	B-Taxon
[	O
85	O
]	O
.	O

(	O
B	O
)	O
Coronal	O
forebrain	O
sections	O
(	O
left	O
)	O
and	O
sagittal	O
brainstem	O
/	O
cerebellum	O
sections	O
of	O
mice	B-Taxon
at	O
P42	O
positive	O
for	O
TgCre4	O
and	O
R26R	O
Cre	O
-	O
indicator	O
.	O

Cre	O
expression	O
visualized	O
by	O
enzymatic	B-SO
beta	O
-	O
galactosidase	O
activity	O
(	O
blue	O
,	O
X	O
-	O
gal	O
,	O
counterstain	O
by	O
eosin	O
)	O
of	O
R26R	O
and	O
by	O
anti	O
-	O
Cre	O
immunostainings	O
(	O
brown	O
,	O
DAB	O
[	O
diaminobenzadine	O
]	O
)	O
was	O
restricted	O
to	O
forebrain	O
regions	O
.	O

Scale	O
bars	O
:	O
1	O
mm	O
.	O

A	O
,	O
amygdala	O
;	O
Ce	O
,	O
Cerebellum	O
;	O
Cx	O
,	O
cortex	O
;	O
H	O
,	O
hippocampus	O
;	O
Me	O
,	O
medulla	O
oblongata	O
.	O

(	O
C	O
)	O
Olfactory	O
bulb	O
sections	O
of	O
the	O
same	O
mouse	B-Taxon
to	O
visualize	O
Cre	O
expression	O
by	O
Cre	O
immunoreactivity	O
(	O
left	O
,	O
DAB	O
)	O
and	O
by	O
enzymatic	B-SO
beta	O
-	O
galactosidase	O
activity	O
(	O
right	O
,	O
X	O
-	O
gal	O
,	O
counterstain	O
by	O
eosin	O
)	O
in	O
granule	B-CL
cells	I-CL
(	O
GC	B-CL
)	O
and	O
mitral	O
cells	B-CL
(	O
MC	O
)	O
as	O
indicated	O
by	O
arrows	O
.	O

Scale	O
bars	O
:	O
400	O
mu	O
m	O
(	O
upper	O
panel	O
)	O
,	O
50	O
mu	O
m	O
(	O
lower	O
panel	O
)	O
.	O

(	O
3	O
.	O
4	O
MB	O
TIF	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Figure	O
S2	O

Performance	O
of	O
GluR	O
-	O
B	O
Delta	O
FB	O
(	O
n	O
=	O
10	O
)	O
and	O
Littermate	O
Control	O
(	O
n	O
=	O
10	O
)	O
Mice	B-Taxon
in	O
a	O
Spatial	O
Reference	O
Task	O
on	O
the	O
Elevated	O
Y	O
-	O
Maze	O

Details	O
of	O
the	O
methodology	O
are	O
described	O
in	O
[	O
90	O
]	O
.	O

*	O
indicates	O
p	O
<	O
0	O
.	O
05	O
.	O

(	O
126	O
KB	O
TIF	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Figure	O
S3	O

Memory	O
Deficit	O
Is	O
Not	O
Due	O
to	O
Increased	O
Extinction	O

(	O
A	O
)	O
Memory	O
performance	O
as	O
a	O
function	O
of	O
time	O
for	O
the	O
experiment	O
described	O
in	O
Figure	O
2E	O
(	O
nine	O
GluR	O
-	O
B	O
Delta	O
FB	O
and	O
nine	O
GluR	O
-	O
B2lox	O
control	O
animals	B-Taxon
)	O
.	O

Only	O
four	O
unrewarded	O
"	O
memory	O
+	O
"	O
trials	O
are	O
binned	O
for	O
each	O
data	O
point	O
.	O

Memory	O
of	O
GluR	O
-	O
B	O
Delta	O
FB	O
animals	B-Taxon
was	O
significantly	O
reduced	O
(	O
F	O
(	O
1	O
,	O
33	O
)	O
=	O
17	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Whereas	O
a	O
weak	O
overall	O
time	O
effect	O
could	O
be	O
observed	O
(	O
F	O
(	O
2	O
,	O
66	O
)	O
=	O
3	O
.	O
6	O
;	O
p	O
=	O
0	O
.	O
03	O
)	O
,	O
there	O
was	O
no	O
genotype	B-SO
-	O
time	O
interaction	O
effect	O
(	O
F	O
(	O
2	O
,	O
66	O
)	O
=	O
0	O
.	O
67	O
;	O
p	O
=	O
0	O
.	O
5	O
)	O
,	O
indicating	O
that	O
there	O
is	O
no	O
differential	O
effect	O
of	O
putative	O
extinction	O
on	O
memory	O
performance	O
.	O

*	O
indicates	O
p	O
-	O
values	O
for	O
a	O
Mann	O
-	O
Whitney	O
U	O
test	O
(	O
*	O
<	O
0	O
.	O
05	O
,	O
*	O
*	O
<	O
0	O
.	O
01	O
)	O
.	O

(	O
B	O
)	O
After	O
the	O
memory	O
experiments	O
from	O
Figure	O
6A	O
,	O
the	O
last	O
set	O
of	O
animals	B-Taxon
(	O
eight	O
GluR	O
-	O
BRescue	O
,	O
four	O
GluR	O
-	O
B	O
Delta	O
FB	O
,	O
and	O
three	O
controls	O
)	O
was	O
further	O
trained	O
on	O
AA	O
versus	O
EB	O
for	O
900	O
trials	O
one	O
week	O
after	O
the	O
memory	O
experiment	O
.	O

Subsequently	O
,	O
training	O
continued	O
on	O
AA	O
/	O
EB	O
mixtures	O
for	O
1	O
,	O
200	O
trials	O
.	O

Finally	O
,	O
the	O
animals	B-Taxon
were	O
retrained	O
on	O
AA	O
and	O
EB	O
for	O
100	O
trials	O
.	O

Relearning	O
performance	O
during	O
the	O
last	O
retraining	O
task	O
is	O
highly	O
correlated	O
to	O
the	O
original	O
memory	O
performance	O
(	O
R2	O
=	O
0	O
.	O
46	O
,	O
p	O
=	O
0	O
.	O
006	O
,	O
n	O
=	O
15	O
)	O
.	O

(	O
264	O
KB	O
TIF	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Figure	O
S4	O

Absence	O
of	O
Cre	O
Expression	O
in	O
the	O
Main	O
Olfactory	O
Epithelium	O
of	O
TgCre4	O
Mice	B-Taxon

(	O
A	O
)	O
Overview	O
of	O
the	O
main	O
olfactory	O
epithelium	O
.	O

(	O
B	O
)	O
Higher	O
magnification	O
of	O
(	O
A	O
)	O
showing	O
all	O
cells	B-CL
with	O
propidium	O
iodide	B-CHEBI
(	O
red	O
)	O
and	O
absence	O
of	O
Cre	O
-	O
positive	O
cells	B-CL
(	O
green	O
,	O
anti	O
-	O
Cre	O
)	O
.	O

(	O
C	O
)	O
Positive	O
control	O
showing	O
granule	B-CL
cells	I-CL
of	O
the	O
dentate	O
gyrus	O
stained	O
for	O
nuclear	B-GO
Cre	O
(	O
green	O
)	O
from	O
the	O
same	O
mouse	B-Taxon
.	O

(	O
3	O
.	O
7	O
MB	O
TIF	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Acknowledgements	O

The	O
authors	O
want	O
to	O
thank	O
Troy	O
Margrie	O
and	O
Bert	O
Sakmann	O
for	O
support	O
,	O
encouragement	O
,	O
and	O
discussion	O
;	O
Onyeka	O
Nobuka	O
for	O
help	O
with	O
the	O
construct	B-SO
OCN	O
;	O
Mark	O
Mayford	O
for	O
the	O
alpha	B-GGP
CaMKII	I-GGP
promoter	B-SO
;	O
Bettina	O
Suchanek	O
for	O
the	O
NR2C	B-GGP
silencer	B-SO
;	O
Annette	O
Herold	O
,	O
Juliana	O
Kling	O
,	O
and	O
Christiane	O
Zacher	O
for	O
experimental	O
and	O
technical	O
supports	O
;	O
Nixon	O
Abraham	O
for	O
assistance	O
with	O
some	O
behavioral	O
experiments	O
;	O
and	O
David	O
Bannerman	O
,	O
Thomas	O
Kuner	O
,	O
and	O
Pavel	O
Osten	O
for	O
critically	O
reading	O
early	O
versions	O
of	O
the	O
manuscript	O
.	O

This	O
work	O
was	O
supported	O
by	O
a	O
Deutsche	O
Forschungsgemeinschaft	O
grant	O
(	O
SFB	O
636	O
)	O
to	O
RS	O
,	O
the	O
Heidelberger	O
Akademie	O
der	O
Wissenschaften	O
,	O
the	O
Boeringer	O
Ingelheim	O
Fonds	O
,	O
and	O
the	O
Leopoldina	O
Akademie	O
der	O
Wissenschaften	O
to	O
ATS	O
,	O
the	O
BMBF	O
,	O
and	O
the	O
MPG	O
.	O

Competing	O
interests	O
.	O

The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Abbreviations	O

AMPA	O
-	O
alpha	O
-	O
amino	B-CHEBI
-	O
3	O
-	O
hydroxy	B-CHEBI
-	O
5	O
-	O
methyl	B-CHEBI
-	O
4	O
-	O
isoxazolepropionate	O

AMPAR	O
-	O
alpha	O
-	O
amino	B-CHEBI
-	O
3	O
-	O
hydroxy	B-CHEBI
-	O
5	O
-	O
methyl	B-CHEBI
-	O
4	O
-	O
isoxazolepropionate	O
receptor	O

bp	B-SO
-	O
basepair	B-SO

GFP	O
-	O
green	O
fluorescent	O
protein	B-CHEBI

LTP	O
-	O
long	O
-	O
term	O
plasticity	O

NMDA	O
-	O
N	B-CHEBI
-	O
methyl	B-CHEBI
-	O
D	B-CHEBI
-	I-CHEBI
aspartate	I-CHEBI

Q	B-CHEBI
-	O
glutamine	B-CHEBI

R	B-CHEBI
-	O
arginine	B-CHEBI

Figures	O
and	O
Tables	O

Figure	O
1	O

Odor	O
Learning	O
and	O
Discrimination	O
Is	O
Enhanced	O
in	O
GluR	O
-	O
B	O
Delta	O
ECS	O
:	O
FB	O
Mice	B-Taxon

(	O
A	O
)	O
Schematic	O
diagram	O
depicting	O
Cre	O
-	O
mediated	O
activation	O
of	O
GluR	B-GGP
-	I-GGP
B	I-GGP
(	O
Q	B-CHEBI
)	O
by	O
removing	B-SO
the	O
loxP	B-SO
-	I-SO
flanked	I-SO
TK	O
-	O
neo	O
(	O
TK	O
-	O
neo	O
pA	O
,	O
GluR	O
-	O
Bneo	O
)	O
element	B-SO
in	O
intron	B-SO
11	O
,	O
which	O
is	O
acting	O
as	O
a	O
suppressor	O
in	O
expression	O
from	O
the	O
Q	B-CHEBI
/	O
R	B-CHEBI
site	B-SO
editing	O
deficient	O
GluR	O
-	O
Bneo	O
allele	B-SO
.	O

Exon	B-SO
10	O
and	O
11	O
encode	O
membrane	B-SO
-	I-SO
spanning	I-SO
segments	I-SO
1	O
,	O
2	O
,	O
and	O
3	O
(	O
M1	O
,	O
2	O
,	O
3	O
)	O
of	O
the	O
GluR	B-GGP
-	I-GGP
B	I-GGP
subunit	I-GGP
.	O

The	O
intronic	B-SO
element	I-SO
necessary	O
for	O
editing	O
the	O
Q	B-CHEBI
/	O
R	B-CHEBI
site	B-SO
is	O
shown	O
for	O
the	O
wild	B-SO
-	I-SO
type	I-SO
allele	B-SO
(	O
+	B-SO
)	O
.	O

(	O
B	O
)	O
Scheme	O
of	O
an	O
individual	O
trial	O
.	O

Breaking	O
a	O
light	O
barrier	O
,	O
the	O
mouse	B-Taxon
initiates	O
a	O
trial	O
.	O

An	O
odor	O
is	O
presented	O
,	O
and	O
(	O
depending	O
on	O
the	O
odor	O
denotation	O
and	O
the	O
mouse	B-Taxon
'	O
s	O
response	O
)	O
the	O
mouse	B-Taxon
is	O
rewarded	O
or	O
retracts	O
its	O
head	O
.	O

A	O
small	O
(	O
2	O
-	O
to	O
4	O
-	O
mu	O
l	O
)	O
water	B-CHEBI
reward	O
is	O
given	O
at	O
the	O
end	O
of	O
an	O
S	O
+	O
odor	O
if	O
the	O
mouse	B-Taxon
continuously	O
licks	O
at	O
the	O
delivery	O
tube	O
during	O
the	O
2	O
-	O
s	O
trial	O
.	O

A	O
trial	O
is	O
counted	O
as	O
correct	O
if	O
the	O
mouse	B-Taxon
licks	O
continuously	O
upon	O
presentation	O
of	O
a	O
rewarded	O
(	O
S	O
+	O
)	O
odor	O
or	O
does	O
not	O
lick	O
continuously	O
with	O
a	O
nonrewarded	O
(	O
S	O
-	O
)	O
odor	O
[	O
3	O
]	O
.	O

(	O
C	O
)	O
Twelve	O
experimentally	O
na	O
i	O
ve	O
animals	B-Taxon
(	O
six	O
GluR	O
-	O
B	O
Delta	O
ECS	O
:	O
FB	O
[	O
orange	O
]	O
and	O
six	O
GluR	B-GGP
-	I-GGP
B	I-GGP
+	B-SO
/	O
+	B-SO
littermate	O
controls	O
[	O
black	O
]	O
)	O
were	O
trained	O
on	O
1	O
%	O
AA	O
versus	O
1	O
%	O
EB	O
for	O
two	O
tasks	O
of	O
200	O
trials	O
each	O
.	O

Both	O
groups	O
acquired	O
the	O
task	O
(	O
>	O
70	O
%	O
correct	O
)	O
;	O
however	O
,	O
the	O
GluR	O
-	O
B	O
Delta	O
ECS	O
:	O
FB	O
were	O
both	O
quicker	O
,	O
and	O
performed	O
better	O
overall	O
,	O
than	O
the	O
littermate	O
controls	O
(	O
group	O
effect	O
:	O
F	O
(	O
1	O
,	O
10	O
)	O
=	O
10	O
.	O
2	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

AA	O
,	O
amylacetate	O
;	O
EB	O
,	O
ethylbutyrate	O
.	O

(	O
D	O
)	O
Average	O
head	O
position	O
for	O
one	O
mouse	B-Taxon
and	O
50	O
presentations	O
of	O
the	O
S	O
+	O
(	O
green	O
)	O
and	O
50	O
presentations	O
of	O
the	O
S	O
-	O
(	O
red	O
)	O
odor	O
.	O

"	O
1	O
"	O
indicates	O
the	O
breaking	O
of	O
the	O
light	O
beam	O
(	O
head	O
in	O
the	O
sampling	O
port	O
[	O
3	O
]	O
)	O
.	O

Note	O
the	O
rapid	O
head	O
retraction	O
for	O
the	O
S	O
-	O
odor	O
.	O

(	O
E	O
)	O
Difference	O
of	O
the	O
average	O
head	O
positions	O
from	O
(	O
D	O
)	O
for	O
S	O
+	O
and	O
S	O
-	O
odors	O
.	O

Blue	O
line	O
indicates	O
sigmoidal	O
fit	O
.	O

"	O
Discrimination	O
index	O
"	O
refers	O
to	O
the	O
maximum	O
of	O
the	O
fitted	O
sigmoid	O
.	O

(	O
F	O
)	O
As	O
(	O
C	O
)	O
but	O
depicting	O
the	O
discrimination	O
index	O
as	O
a	O
function	O
of	O
trial	O
number	O
(	O
group	O
effect	O
:	O
F	O
(	O
1	O
,	O
10	O
)	O
=	O
1	O
.	O
7	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Figure	O
2	O

Odor	O
Learning	O
and	O
Discrimination	O
Is	O
Enhanced	O
,	O
but	O
Odor	O
Memory	O
Is	O
Reduced	O
in	O
GluR	O
-	O
B	O
Delta	O
FB	O
Mice	B-Taxon

(	O
A	O
)	O
Schematic	O
diagram	O
depicting	O
Cre	O
-	O
mediated	O
ablation	O
of	O
loxP	B-SO
-	I-SO
flanked	I-SO
exon	B-SO
11	O
of	O
the	O
GluR	B-GGP
-	I-GGP
B	I-GGP
alleles	B-SO
.	O

(	O
B	O
and	O
C	O
)	O
Nine	O
GluR	O
-	O
B	O
Delta	O
FB	O
(	O
red	O
)	O
and	O
nine	O
GluRB2lox	O
littermate	O
controls	O
(	O
black	O
)	O
were	O
trained	O
for	O
successive	O
odor	O
discrimination	O
tasks	O
on	O
1	O
%	O
AA	O
versus	O
1	O
%	O
EB	O
(	O
400	O
trials	O
)	O
,	O
0	O
.	O
4	O
%	O
Cin	B-CHEBI
/	O
0	O
.	O
6	O
%	O
Eu	B-CHEBI
versus	O
0	O
.	O
6	O
%	O
Cin	B-CHEBI
/	O
0	O
.	O
4	O
%	O
Eu	B-CHEBI
(	O
400	O
trials	O
)	O
and	O
1	O
%	O
Pel	B-CHEBI
versus	O
1	O
%	O
Val	B-CHEBI
.	O

GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
showed	O
increased	O
learning	O
/	O
discrimination	O
compared	O
with	O
controls	O
,	O
both	O
using	O
the	O
performance	O
as	O
measured	O
by	O
percentage	O
of	O
correct	O
trials	O
(	O
[	O
B	O
]	O
;	O
group	O
effect	O
:	O
F1	O
,	O
16	O
=	O
6	O
.	O
55	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
or	O
the	O
discrimination	O
index	O
(	O
C	O
)	O
,	O
that	O
is	O
the	O
maximal	O
difference	O
of	O
the	O
sampling	O
pattern	O
(	O
see	O
Materials	O
and	O
Methods	O
and	O
Figure	O
1D	O
-	O
1F	O
;	O
F1	O
,	O
16	O
=	O
29	O
.	O
5	O
,	O
p	O
<	O
10	O
-	O
4	O
)	O
.	O

(	O
D	O
)	O
Sampling	O
difference	O
for	O
the	O
last	O
100	O
trials	O
of	O
the	O
mixture	O
discrimination	O
task	O
(	O
indicated	O
with	O
a	O
black	O
arrow	O
in	O
[	O
C	O
]	O
)	O
for	O
all	O
18	O
individual	O
mice	B-Taxon
.	O

Note	O
that	O
the	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
show	O
a	O
consistently	O
larger	O
sampling	O
difference	O
.	O

(	O
E	O
)	O
Olfactory	O
memory	O
performance	O
for	O
nine	O
littermate	O
controls	O
(	O
black	O
)	O
and	O
nine	O
GluR	O
-	O
B	O
Delta	O
FB	O
(	O
red	O
)	O
mice	B-Taxon
.	O

Olfactory	O
memory	O
was	O
tested	O
at	O
the	O
time	O
indicated	O
by	O
the	O
black	O
bar	O
in	O
(	O
C	O
)	O
by	O
interleaving	O
the	O
Pel	B-CHEBI
and	O
Val	B-CHEBI
trials	O
with	O
unrewarded	O
AA	O
and	O
EB	O
trials	O
.	O

AA	O
,	O
amylacetate	O
;	O
Cin	B-CHEBI
,	O
cineol	B-CHEBI
;	O
EB	O
,	O
ethylbutyrate	O
;	O
Eu	B-CHEBI
,	O
eugenol	B-CHEBI
;	O
Pel	B-CHEBI
,	O
pelargonic	B-CHEBI
acid	I-CHEBI
;	O
Val	B-CHEBI
,	O
valeric	B-CHEBI
acid	I-CHEBI
.	O

Figure	O
3	O

Variability	O
of	O
Cre	O
Expression	O
of	O
Mouse	B-Taxon
Line	O
TgCre4	O

(	O
A	O
)	O
Variable	O
Cre	O
expression	O
in	O
forebrains	O
of	O
three	O
different	O
mice	B-Taxon
positive	O
for	O
TgCre4	O
and	O
R26R	O
Cre	O
indicator	O
(	O
see	O
Figure	O
S1	O
)	O
at	O
postnatal	O
day	O
12	O
pictured	O
by	O
the	O
Cre	O
-	O
dependent	O
beta	O
-	O
galactosidase	O
activity	O
(	O
blue	O
,	O
X	O
-	O
gal	O
,	O
counterstain	O
by	O
eosin	O
)	O
in	O
coronal	O
brain	O
slices	O
.	O

Scale	O
bar	O
:	O
1	O
.	O
25	O
mm	O
.	O

(	O
B	O
)	O
Southern	O
blot	O
analysis	O
of	O
BglII	O
-	O
digested	O
genomic	B-SO
mouse	I-SO
DNA	I-SO
of	O
four	O
TgCre4	O
mice	B-Taxon
that	O
differed	O
in	O
the	O
Cre	O
expression	O
pattern	O
.	O

Southern	O
probe	B-SO
detects	O
the	O
wild	B-SO
-	I-SO
type	I-SO
(	O
4	O
.	O
5	O
kbp	O
)	O
and	O
the	O
transgenic	B-SO
(	O
7	O
,	O
5	O
,	O
3	O
,	O
and	O
2	O
kbp	O
)	O
alleles	B-SO
.	O

Figure	O
4	O

Olfactory	O
Memory	O
but	O
not	O
Odor	O
Learning	O
/	O
Discrimination	O
Is	O
Correlated	O
with	O
Residual	O
GluR	B-GGP
-	I-GGP
B	I-GGP
Levels	O
in	O
Hippocampus	O
and	O
Forebrain	O
of	O
GluR	O
-	O
B	O
Delta	O
FB	O
Mice	B-Taxon

(	O
A	O
)	O
The	O
olfactory	O
memory	O
performance	O
for	O
18	O
GluR	O
-	O
B	O
Delta	O
FB	O
(	O
red	O
)	O
and	O
11	O
littermate	O
control	O
(	O
black	O
)	O
mice	B-Taxon
is	O
given	O
as	O
mean	O
(	O
thick	O
lines	O
+/-	O
SEM	O
)	O
and	O
as	O
individual	O
performance	O
in	O
open	O
circles	O
and	O
triangles	O
.	O

Arrows	O
with	O
numbers	O
(	O
#	O
)	O
indicate	O
those	O
mice	B-Taxon
used	O
in	O
experiments	O
(	O
B	O
-	O
C	O
)	O
.	O

Data	O
were	O
combined	O
from	O
Figure	O
2	O
(	O
open	O
symbols	O
)	O
and	O
an	O
additional	O
experiment	O
with	O
nine	O
GluR	O
-	O
B	O
Delta	O
FB	O
and	O
two	O
littermate	O
controls	O
(	O
shaded	O
symbols	O
)	O
.	O

(	O
B	O
and	O
C	O
)	O
Residual	O
GluR	B-GGP
-	I-GGP
B	I-GGP
levels	O
as	O
detected	O
by	O
anti	O
-	O
GluR	B-GGP
-	I-GGP
B	I-GGP
immunofluorescence	O
in	O
hippocampus	O
,	O
amygdala	O
,	O
piriform	O
cortex	O
,	O
and	O
olfactory	O
bulb	O
of	O
one	O
control	O
(	O
#	O
1	O
)	O
and	O
two	O
GluR	O
-	O
B	O
Delta	O
FB	O
(	O
#	O
2	O
and	O
#	O
3	O
)	O
coronal	O
mouse	B-Taxon
brain	O
sections	O
(	O
B	O
)	O
and	O
by	O
immunoblot	O
analysis	O
from	O
hippocampal	O
(	O
Hip	O
)	O
,	O
cortical	O
forebrain	O
(	O
FB	O
)	O
,	O
and	O
olfactory	O
bulb	O
(	O
OB	O
)	O
protein	B-CHEBI
extracts	O
of	O
control	O
(	O
#	O
4	O
)	O
and	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
(	O
#	O
5	O
,	O
#	O
6	O
,	O
#	O
7	O
,	O
and	O
#	O
8	O
)	O
probed	O
with	O
antibodies	B-GO
detecting	O
GluR	B-GGP
-	I-GGP
B	I-GGP
and	O
beta	B-GGP
-	I-GGP
actin	I-GGP
as	O
an	O
internal	O
loading	O
control	O
(	O
C	O
)	O
.	O

Scale	O
bars	O
:	O
200	O
mu	O
m	O
(	O
first	O
panel	O
)	O
,	O
100	O
mu	O
m	O
(	O
other	O
panels	O
)	O
.	O

(	O
D	O
)	O
From	O
ten	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
,	O
the	O
individual	O
odor	O
learning	O
/	O
discrimination	O
and	O
olfactory	O
memory	O
performance	O
was	O
determined	O
together	O
with	O
the	O
relative	O
GluR	B-GGP
-	I-GGP
B	I-GGP
levels	O
in	O
immunoblots	O
of	O
hippocampal	O
,	O
forebrain	O
,	O
and	O
olfactory	O
bulb	O
protein	B-CHEBI
extracts	O
.	O

Memory	O
performance	O
(	O
top	O
panels	O
)	O
and	O
discrimination	O
capability	O
(	O
bottom	O
panels	O
;	O
discrimination	O
index	O
is	O
measured	O
for	O
the	O
last	O
100	O
trials	O
of	O
the	O
mixture	O
discrimination	O
task	O
as	O
indicated	O
by	O
the	O
arrow	O
in	O
Figure	O
2C	O
)	O
were	O
plotted	O
against	O
GluR	B-GGP
-	I-GGP
B	I-GGP
levels	O
.	O

Memory	O
was	O
tightly	O
correlated	O
to	O
GluR	B-GGP
-	I-GGP
B	I-GGP
protein	B-CHEBI
level	O
in	O
hippocampus	O
(	O
R2	O
=	O
0	O
.	O
72	O
;	O
p	O
<	O
0	O
.	O
003	O
)	O
and	O
cortical	O
forebrain	O
(	O
R2	O
=	O
0	O
.	O
62	O
;	O
p	O
<	O
0	O
.	O
006	O
)	O
and	O
only	O
weakly	O
in	O
the	O
olfactory	O
bulb	O
(	O
R2	O
=	O
0	O
.	O
48	O
;	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O

No	O
measure	O
of	O
learning	O
/	O
discrimination	O
(	O
discrimination	O
index	O
for	O
last	O
100	O
mixture	O
trials	O
[	O
D	O
]	O
,	O
slopes	O
of	O
trend	O
lines	O
,	O
average	O
discrimination	O
index	O
,	O
average	O
sampling	O
pattern	O
differences	O
,	O
correct	O
performance	O
,	O
etc	O
.	O
[	O
not	O
shown	O
]	O
)	O
displayed	O
any	O
correlation	O
(	O
R2	O
<	O
0	O
.	O
3	O
)	O
.	O

Figure	O
5	O

Specific	O
Hippocampus	O
and	O
Piriform	O
Cortex	O
Expression	O
of	O
Transgenic	B-SO
GFPGluR	O
-	O
B	O

(	O
A	O
)	O
Schematic	O
diagrams	O
depicting	O
forebrain	O
-	O
specific	O
GluR	B-GGP
-	I-GGP
B	I-GGP
deletion	B-SO
as	O
in	O
Figure	O
2A	O
and	O
itTA	O
-	O
dependent	O
expression	O
of	O
GFPGluR	O
-	O
B	O
and	O
nuclear	B-GO
-	O
localized	O
beta	O
-	O
galactosidase	O
(	O
nLacZ	O
)	O
in	O
GluR	O
-	O
B	O
Delta	O
FB	O
mice	B-Taxon
(	O
termed	O
GluR	O
-	O
BRescue	O
)	O
.	O

GFPGluR	O
-	O
B	O
and	O
nLacZ	O
are	O
both	O
encoded	O
by	O
TgOCN1	O
,	O
and	O
itTA	O
is	O
controlled	O
by	O
a	O
fusion	O
of	O
the	O
NR2C	B-GGP
silencer	B-SO
element	I-SO
[	O
91	O
]	O
and	O
the	O
alpha	B-GGP
CaMKII	I-GGP
promoter	B-SO
(	O
termed	O
TgCN12	O
-	O
itTA	O
[	O
92	O
]	O
)	O
.	O

(	O
B	O
)	O
In	O
coronal	O
brain	O
sections	O
of	O
mice	B-Taxon
positive	O
for	O
both	O
transgenes	B-SO
(	O
TgCN12	O
-	O
itTA	O
and	O
TgOCN1	O
)	O
beta	O
-	O
galactosidase	O
activity	O
(	O
blue	O
,	O
X	O
-	O
gal	O
,	O
counterstain	O
by	O
eosin	O
)	O
is	O
restricted	O
to	O
hippocampal	O
neurons	B-CL
in	O
CA1	O
,	O
DG	O
,	O
and	O
neurons	B-CL
in	O
the	O
piriform	O
cortex	O
.	O

The	O
same	O
neurons	B-CL
show	O
GFPGluR	O
-	O
B	O
expression	O
when	O
analyzed	O
in	O
immunohistochemical	O
sections	O
with	O
an	O
antibody	B-GO
against	O
GFP	O
.	O

Scale	O
bars	O
:	O
500	O
mu	O
m	O
.	O

(	O
C	O
)	O
Immunoblot	O
detecting	O
endogenous	O
GluR	B-GGP
-	I-GGP
B	I-GGP
and	O
transgenic	B-SO
GFPGluR	O
-	O
B	O
in	O
the	O
hippocampus	O
of	O
three	O
different	O
mice	B-Taxon
(	O
#	O
1	O
,	O
#	O
2	O
,	O
#	O
3	O
)	O
.	O

(	O
D	O
)	O
Relative	O
quantification	O
from	O
(	O
C	O
)	O
of	O
transgenic	B-SO
GFPGluR	O
-	O
B	O
compared	O
with	O
endogenous	O
GluR	B-GGP
-	I-GGP
B	I-GGP
in	O
the	O
hippocampus	O
.	O

Figure	O
6	O

GluR	B-GGP
-	I-GGP
B	I-GGP
Expression	O
in	O
Hippocampus	O
and	O
Forebrain	O
Partially	O
Rescues	O
the	O
Memory	O
Deficit	O
of	O
GluR	O
-	O
B	O
Delta	O
FB	O
Mice	B-Taxon

(	O
A	O
)	O
Olfactory	O
memory	O
experiments	O
as	O
in	O
Figure	O
2	O
were	O
performed	O
with	O
GluR	O
-	O
BRescue	O
.	O

Individual	O
mice	B-Taxon
are	O
indicated	O
:	O
control	O
GluR	O
-	O
B2lox	O
with	O
black	O
circles	O
,	O
GluR	O
-	O
B	O
Delta	O
FB	O
with	O
red	O
triangles	O
,	O
GluR	O
-	O
BRescue	O
with	O
green	O
squares	O
.	O

Data	O
were	O
combined	O
from	O
Figure	O
3	O
and	O
4	O
(	O
open	O
symbols	O
)	O
and	O
an	O
additional	O
experiment	O
with	O
four	O
GluR	O
-	O
B	O
Delta	O
FB	O
,	O
three	O
littermate	O
controls	O
,	O
and	O
eight	O
GluR	O
-	O
BRescue	O
(	O
shaded	O
symbols	O
)	O
.	O

(	O
B	O
)	O
Cumulative	O
histogram	O
of	O
the	O
memory	O
performance	O
.	O

Memory	O
performance	O
is	O
indicated	O
as	O
a	O
stepped	O
line	O
.	O

The	O
sigmoidal	O
fit	O
is	O
indicated	O
as	O
a	O
continuous	O
line	O
.	O

The	O
predicted	O
rescue	O
on	O
the	O
basis	O
of	O
the	O
extent	O
of	O
transgenic	B-SO
GFPGluR	O
-	O
B	O
expression	O
(	O
Figure	O
5D	O
)	O
and	O
the	O
correlation	O
between	O
memory	O
and	O
GluR	B-GGP
-	I-GGP
B	I-GGP
levels	O
in	O
piriform	O
cortex	O
(	O
9	O
.	O
1	O
+/-	O
2	O
.	O
5	O
%	O
increase	O
in	O
memory	O
for	O
10	O
%	O
increase	O
in	O
protein	B-CHEBI
,	O
Figure	O
4D	O
)	O
is	O
shown	O
in	O
blue	O
.	O

Note	O
that	O
the	O
predicted	O
rescue	O
is	O
in	O
perfect	O
numerical	O
correspondence	O
to	O
the	O
memory	O
performance	O
of	O
GluR	O
-	O
BRescue	O
mice	B-Taxon
.	O

(	O
C	O
)	O
The	O
discrimination	O
index	O
was	O
calculated	O
as	O
in	O
Figures	O
1E	O
,	O
2C	O
,	O
and	O
4D	O
(	O
last	O
100	O
trials	O
of	O
the	O
mixture	O
discrimination	O
task	O
)	O
for	O
GluRBRescue	O
(	O
n	O
=	O
8	O
)	O
,	O
GluR	O
-	O
B	O
Delta	O
FB	O
(	O
n	O
=	O
22	O
)	O
,	O
and	O
control	O
(	O
n	O
=	O
14	O
)	O
animals	B-Taxon
.	O

Footnotes	O

Author	O
contributions	O
.	O

DRS	O
and	O
ATS	O
conceived	O
and	O
designed	O
most	O
of	O
the	O
experiments	O
.	O

The	O
manuscript	O
was	O
written	O
by	O
DRS	O
,	O
PHS	O
,	O
RS	O
,	O
and	O
ATS	O
.	O

Mouse	B-Taxon
lines	O
were	O
conceived	O
and	O
designed	O
by	O
DRS	O
,	O
PHS	O
,	O
RS	O
(	O
GluR	O
-	O
B	O
Delta	O
FB	O
,	O
GluR	O
-	O
B	O
Delta	O
ECS	O
:	O
FB	O
)	O
;	O
DRS	O
,	O
PHS	O
,	O
RS	O
,	O
ATS	O
(	O
GluR	O
-	O
BRescue	O
)	O
;	O
JK	O
,	O
PHS	O
,	O
RS	O
(	O
TgCN12	O
-	O
itTA	O
)	O
;	O
and	O
VM	O
,	O
PHS	O
,	O
RS	O
(	O
GluR	O
-	O
B2lox	O
,	O
TgOCN1	O
)	O
.	O

Olfactory	O
behavioral	O
experiments	O
were	O
done	O
by	O
TB	O
and	O
ATS	O
;	O
AM	O
performed	O
the	O
GFPGluR	O
-	O
B	O
Western	O
blots	O
;	O
immunohistochemical	O
experiments	O
and	O
other	O
Western	O
blots	O
as	O
well	O
as	O
the	O
nonolfactory	O
behavioral	O
experiments	O
were	O
performed	O
by	O
DRS	O
.	O

currency	O
Current	O
address	O
:	O
Department	O
of	O
Physiology	O
,	O
University	O
College	O
London	O
,	O
London	O
,	O
United	O
Kingdom	O

Citation	O
:	O
Shimshek	O
DR	O
,	O
Bus	O
T	O
,	O
Kim	O
J	O
,	O
Mihaljevic	O
A	O
,	O
Mack	O
V	O
,	O
et	O
al	O
.	O

(	O
2005	O
)	O
Enhanced	O
odor	O
discrimination	O
and	O
impaired	O
olfactory	O
memory	O
by	O
spatially	O
controlled	O
switch	O
of	O
AMPA	O
receptors	O
.	O

PLoS	O
Biol	O
3	O
(	O
11	O
)	O
:	O
e354	O
.	O

Two	O
major	O
branches	O
of	O
anti	O
-	O
cadmium	B-CHEBI
defense	O
in	O
the	O
mouse	B-Taxon
:	O
MTF	B-GGP
-	I-GGP
1	I-GGP
/	O
metallothioneins	O
and	O
glutathione	B-CHEBI

Abstract	O

Metal	B-GGP
-	I-GGP
responsive	I-GGP
transcription	I-GGP
factor	I-GGP
1	I-GGP
(	O
MTF	B-GGP
-	I-GGP
1	I-GGP
)	O
regulates	O
expression	O
of	O
its	O
target	O
genes	B-SO
in	O
response	O
to	O
various	O
stress	O
conditions	O
,	O
notably	O
heavy	O
metal	B-CHEBI
load	O
,	O
via	O
binding	O
to	O
metal	B-CHEBI
response	O
elements	B-SO
(	O
MREs	O
)	O
in	O
the	O
respective	O
enhancer	B-SO
/	I-SO
promoter	I-SO
regions	I-SO
.	O

Furthermore	O
,	O
it	O
serves	O
a	O
vital	O
function	O
in	O
embryonic	O
liver	O
development	O
.	O

However	O
,	O
targeted	O
deletion	B-SO
of	O
Mtf1	B-GGP
in	O
the	O
liver	O
after	O
birth	O
is	O
no	O
longer	O
lethal	O
.	O

For	O
this	O
study	O
,	O
Mtf1	B-GGP
conditional	O
knockout	O
mice	B-Taxon
and	O
control	O
littermates	O
were	O
both	O
mock	O
-	O
or	O
cadmium	B-CHEBI
-	O
treated	O
and	O
liver	O
-	O
specific	O
transcription	O
was	O
analyzed	O
.	O

Besides	O
the	O
well	O
-	O
characterized	O
metallothionein	O
genes	B-SO
,	O
several	O
new	O
MTF	B-GGP
-	I-GGP
1	I-GGP
target	O
genes	B-SO
with	O
MRE	O
motifs	O
in	O
the	O
promoter	B-SO
region	I-SO
emerged	O
.	O

MTF	B-GGP
-	I-GGP
1	I-GGP
is	O
required	O
for	O
the	O
basal	O
expression	O
of	O
selenoprotein	B-GGP
W	I-GGP
,	I-GGP
muscle	I-GGP
1	I-GGP
gene	B-SO
(	O
Sepw1	B-GGP
)	O
that	O
encodes	O
a	O
glutathione	B-CHEBI
-	O
binding	O
and	O
putative	O
antioxidant	B-CHEBI
protein	B-CHEBI
,	O
supporting	O
a	O
role	O
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
in	O
the	O
oxidative	O
stress	O
response	O
.	O

Furthermore	O
,	O
MTF	B-GGP
-	I-GGP
1	I-GGP
mediates	O
the	O
cadmium	B-CHEBI
-	O
induced	O
expression	O
of	O
N	B-GGP
-	I-GGP
myc	I-GGP
downstream	I-GGP
regulated	I-GGP
gene	I-GGP
1	I-GGP
(	O
Ndrg1	B-GGP
)	O
,	O
which	O
is	O
induced	O
by	O
several	O
stress	O
conditions	O
and	O
is	O
overexpressed	O
in	O
many	O
cancers	O
.	O

MTF	B-GGP
-	I-GGP
1	I-GGP
is	O
also	O
involved	O
in	O
the	O
cadmium	B-CHEBI
response	O
of	O
cysteine	B-GGP
-	I-GGP
and	I-GGP
glycine	I-GGP
-	I-GGP
rich	I-GGP
protein	I-GGP
1	I-GGP
gene	B-SO
(	O
Csrp1	B-GGP
)	O
,	O
which	O
is	O
implicated	O
in	O
cytoskeletal	B-GO
organization	O
.	O

In	O
contrast	O
,	O
MTF	B-GGP
-	I-GGP
1	I-GGP
represses	O
the	O
basal	O
expression	O
of	O
Slc39a10	B-GGP
,	O
a	O
putative	O
zinc	B-CHEBI
transporter	O
.	O

In	O
a	O
pathway	O
independent	O
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
,	O
cadmium	B-CHEBI
also	O
induced	O
the	O
transcription	O
of	O
genes	B-SO
involved	O
in	O
the	O
synthesis	O
and	O
regeneration	O
of	O
glutathione	B-CHEBI
,	O
a	O
cadmium	B-CHEBI
-	O
binding	O
antioxidant	B-CHEBI
.	O

These	O
data	O
provide	O
strong	O
evidence	O
for	O
two	O
major	O
branches	O
of	O
cellular	B-CL
anti	O
-	O
cadmium	B-CHEBI
defense	O
,	O
one	O
via	O
MTF	B-GGP
-	I-GGP
1	I-GGP
and	O
its	O
target	O
genes	B-SO
,	O
notably	O
metallothioneins	O
,	O
the	O
other	O
via	O
glutathione	B-CHEBI
,	O
with	O
an	O
apparent	O
overlap	O
in	O
selenoprotein	B-GGP
W	I-GGP
.	O

INTRODUCTION	O

All	O
organisms	B-Taxon
have	O
evolved	O
mechanisms	O
to	O
cope	O
with	O
a	O
variety	O
of	O
stress	O
situations	O
.	O

One	O
type	O
of	O
stress	O
response	O
is	O
triggered	O
by	O
heavy	O
metals	B-CHEBI
,	O
such	O
as	O
zinc	B-CHEBI
,	O
copper	B-CHEBI
and	O
cadmium	B-CHEBI
(	O
for	O
convenience	O
,	O
the	O
terms	O
zinc	B-CHEBI
,	O
copper	B-CHEBI
and	O
cadmium	B-CHEBI
are	O
also	O
used	O
here	O
to	O
denote	O
Zn2	B-CHEBI
+	I-CHEBI
,	O
Cu2	B-CHEBI
+	I-CHEBI
and	O
Cd2	B-CHEBI
+	I-CHEBI
,	O
respectively	O
)	O
.	O

Metallothioneins	O
(	O
MTs	O
)	O
,	O
small	O
,	O
cysteine	B-CHEBI
-	O
rich	O
proteins	B-CHEBI
,	O
play	O
an	O
important	O
role	O
in	O
metal	B-CHEBI
homeostasis	O
and	O
detoxification	O
due	O
to	O
their	O
ability	O
to	O
bind	O
different	O
heavy	O
metal	B-CHEBI
ions	B-CHEBI
(	O
1	O
-	O
3	O
)	O
.	O

In	O
the	O
mouse	B-Taxon
,	O
there	O
are	O
four	O
metallothionein	O
genes	B-SO
,	O
designated	O
as	O
Mt1	B-GGP
to	O
Mt4	B-GGP
.	O

Basal	O
,	O
as	O
well	O
as	O
heavy	O
metal	B-CHEBI
-	O
induced	O
,	O
expression	O
of	O
Mt1	B-GGP
and	O
Mt2	B-GGP
is	O
mediated	O
by	O
metal	B-GGP
-	I-GGP
responsive	I-GGP
transcription	I-GGP
factor	I-GGP
1	I-GGP
(	O
MTF	B-GGP
-	I-GGP
1	I-GGP
)	O
(	O
4	O
-	O
7	O
)	O
.	O

This	O
zinc	B-CHEBI
finger	O
protein	B-CHEBI
recognizes	O
short	O
cis	B-SO
-	I-SO
acting	I-SO
DNA	I-SO
sequences	I-SO
,	O
termed	O
metal	B-CHEBI
response	O
elements	B-SO
(	O
MREs	O
;	O
core	O
consensus	B-SO
sequence	I-SO
TGCRCNC	O
)	O
,	O
which	O
are	O
present	O
in	O
the	O
promoters	B-SO
of	O
target	O
genes	B-SO
(	O
8	O
,	O
9	O
)	O
.	O

MTF	B-GGP
-	I-GGP
1	I-GGP
is	O
conserved	B-SO
in	O
evolution	O
,	O
and	O
homologs	B-SO
have	O
been	O
characterized	O
in	O
the	O
mouse	B-Taxon
(	O
10	O
)	O
,	O
humans	B-Taxon
(	O
11	O
)	O
,	O
Drosophila	B-Taxon
(	O
12	O
-	O
14	O
)	O
and	O
fish	B-Taxon
(	O
15	O
,	O
16	O
)	O
.	O

The	O
role	O
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
has	O
been	O
studied	O
most	O
extensively	O
in	O
the	O
mouse	B-Taxon
.	O

Besides	O
coping	O
with	O
heavy	O
metal	B-CHEBI
load	O
,	O
MTF	B-GGP
-	I-GGP
1	I-GGP
can	O
also	O
mediate	O
the	O
induction	O
of	O
Mt	O
genes	B-SO
in	O
response	O
to	O
other	O
stress	O
situations	O
,	O
such	O
as	O
oxidative	O
stress	O
(	O
5	O
,	O
17	O
)	O
and	O
hypoxia	O
(	O
18	O
)	O
.	O

In	O
addition	O
,	O
it	O
is	O
required	O
for	O
the	O
metalloregulation	O
of	O
Znt1	B-GGP
,	O
encoding	O
the	O
major	O
plasma	B-GO
membrane	I-GO
-	O
localized	O
zinc	B-CHEBI
efflux	O
transporter	O
(	O
19	O
)	O
,	O
the	O
hypoxic	O
/	O
anoxic	O
induction	O
of	O
the	O
gene	B-GGP
for	I-GGP
placental	I-GGP
growth	I-GGP
factor	I-GGP
(	O
Plgf	B-GGP
)	O
,	O
an	O
angiogenic	O
protein	B-CHEBI
of	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
family	O
(	O
20	O
)	O
,	O
and	O
has	O
recently	O
been	O
invoked	O
in	O
tumor	O
development	O
(	O
21	O
,	O
22	O
)	O
.	O

Furthermore	O
,	O
MTF	B-GGP
-	I-GGP
1	I-GGP
has	O
an	O
essential	O
function	O
during	O
embryogenesis	O
:	O
targeted	O
disruption	O
of	O
Mtf1	B-GGP
results	O
in	O
embryonic	O
lethality	O
around	O
14	O
days	O
post	O
coitum	O
due	O
to	O
hepatocyte	B-CL
necrosis	O
(	O
23	O
)	O
.	O

In	O
contrast	O
,	O
mice	B-Taxon
with	O
null	O
mutations	B-SO
for	O
the	O
stress	O
-	O
inducible	O
metallothionein	O
genes	B-SO
(	O
Mt1	B-GGP
and	O
Mt2	B-GGP
)	O
are	O
viable	O
,	O
though	O
sensitive	O
to	O
cadmium	B-CHEBI
(	O
24	O
,	O
25	O
)	O
,	O
indicating	O
that	O
additional	O
important	O
MTF	B-GGP
-	I-GGP
1	I-GGP
target	O
genes	B-SO
are	O
involved	O
in	O
the	O
lethal	O
phenotype	O
.	O

With	O
the	O
Cre	O
-	O
loxP	B-SO
conditional	O
knockout	O
technique	O
,	O
it	O
is	O
possible	O
to	O
circumvent	O
the	O
embryonic	O
lethal	O
phenotype	O
of	O
conventional	O
Mtf1	B-GGP
knockout	O
mice	B-Taxon
.	O

Previous	O
experiments	O
with	O
this	O
technique	O
revealed	O
that	O
deletion	B-SO
of	O
Mtf1	B-GGP
from	O
the	O
liver	O
after	O
birth	O
is	O
no	O
longer	O
lethal	O
under	O
non	O
-	O
stress	O
conditions	O
(	O
26	O
)	O
.	O

For	O
this	O
study	O
,	O
an	O
inducible	O
,	O
liver	O
-	O
specific	O
Mtf1	B-GGP
knockout	O
mouse	B-Taxon
line	O
was	O
generated	O
to	O
perform	O
a	O
search	O
for	O
MTF	B-GGP
-	I-GGP
1	I-GGP
target	O
genes	B-SO
and	O
cadmium	B-CHEBI
-	O
inducible	O
genes	B-SO
in	O
the	O
adult	O
liver	O
.	O

A	O
number	O
of	O
target	O
gene	B-SO
candidates	O
emerged	O
upon	O
a	O
transcriptome	O
analysis	O
of	O
mock	O
-	O
and	O
cadmium	B-CHEBI
-	O
treated	O
Mtf1	B-GGP
conditional	O
knockout	O
mice	B-Taxon
and	O
control	O
littermates	O
and	O
several	O
of	O
these	O
were	O
confirmed	O
by	O
semiquantitative	O
RT	O
-	O
PCR	O
.	O

Besides	O
the	O
stress	O
-	O
inducible	O
metallothionein	O
genes	B-SO
that	O
were	O
already	O
known	O
as	O
target	O
genes	B-SO
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
,	O
we	O
find	O
that	O
MTF	B-GGP
-	I-GGP
1	I-GGP
is	O
important	O
for	O
basal	O
liver	O
expression	O
of	O
the	O
gene	B-SO
for	O
selenoprotein	B-GGP
W	I-GGP
,	I-GGP
muscle	I-GGP
1	I-GGP
(	O
Sepw1	B-GGP
)	O
as	O
well	O
as	O
for	O
cadmium	B-CHEBI
-	O
induced	O
expression	O
of	O
N	B-GGP
-	I-GGP
myc	I-GGP
downstream	I-GGP
regulated	I-GGP
gene	I-GGP
1	I-GGP
(	O
Ndrg1	B-GGP
)	O
and	O
the	O
gene	B-SO
encoding	O
cysteine	B-GGP
-	I-GGP
and	I-GGP
glycine	I-GGP
-	I-GGP
rich	I-GGP
protein	I-GGP
1	I-GGP
(	O
Csrp1	B-GGP
)	O
.	O

In	O
addition	O
,	O
MTF	B-GGP
-	I-GGP
1	I-GGP
appears	O
to	O
repress	O
the	O
expression	O
of	O
solute	B-GGP
carrier	I-GGP
family	I-GGP
39	I-GGP
,	I-GGP
member	I-GGP
10	I-GGP
gene	B-SO
(	O
Slc39a10	B-GGP
)	O
,	O
which	O
encodes	O
a	O
putative	O
metal	B-CHEBI
ion	B-CHEBI
transporter	O
.	O

In	O
an	O
MTF	B-GGP
-	I-GGP
1	I-GGP
-	O
independent	O
transcriptome	O
response	O
,	O
several	O
genes	B-SO
involved	O
in	O
glutathione	B-CHEBI
metabolism	O
are	O
induced	O
.	O

Further	O
studies	O
confirmed	O
a	O
dual	O
anti	O
-	O
cadmium	B-CHEBI
defense	O
,	O
one	O
via	O
glutathione	B-CHEBI
and	O
another	O
one	O
via	O
MTF	B-GGP
-	I-GGP
1	I-GGP
and	O
its	O
target	O
genes	B-SO
,	O
including	O
metallothioneins	O
.	O

MATERIALS	O
AND	O
METHODS	O

Generation	O
of	O
Mtf1	B-GGP
conditional	O
knockout	O
mice	B-Taxon
and	O
liver	O
-	O
specific	O
deletion	B-SO

Mtf1	B-GGP
conditional	O
knockout	O
mice	B-Taxon
were	O
generated	O
in	O
collaboration	O
with	O
Dr	O
Michael	O
Leviten	O
(	O
San	O
Carlos	O
,	O
CA	O
)	O
.	O

Two	O
genomic	B-SO
clones	I-SO
containing	O
exons	B-SO
3	O
to	O
6	O
of	O
Mtf1	B-GGP
were	O
used	O
to	O
construct	O
a	O
gene	B-SO
targeting	O
vector	B-SO
for	O
homologous	O
recombination	O
(	O
Supplementary	O
Data	O
)	O
.	O

A	O
neomycin	B-CHEBI
resistance	O
cassette	B-SO
(	O
PGK	O
-	O
neo	O
)	O
flanked	B-SO
by	O
two	O
loxP	B-SO
sites	I-SO
was	O
cloned	O
into	O
the	O
SacI	O
site	B-SO
5	O
'	O
of	O
exon	B-SO
3	O
of	O
Mtf1	B-GGP
,	O
the	O
third	O
loxP	B-SO
site	I-SO
was	O
cloned	O
into	O
the	O
ScaI	O
site	B-SO
3	O
'	O
of	O
exon	B-SO
4	O
.	O

A	O
thymidine	B-CHEBI
kinase	O
(	O
TK	O
)	O
cassette	B-SO
was	O
inserted	B-SO
in	O
the	O
HpaI	O
site	B-SO
3	O
'	O
of	O
exon	B-SO
6	O
.	O

129	O
ES	O
cells	B-CL
were	O
electroporated	O
with	O
the	O
linearized	O
targeting	O
vector	B-SO
,	O
selected	O
in	O
the	O
presence	O
of	O
G418	O
and	O
FIAU	O
,	O
and	O
screened	O
for	O
correct	O
integration	B-SO
events	I-SO
by	O
PCR	O
and	O
Southern	O
blot	O
analysis	O
.	O

Transient	O
expression	O
of	O
Cre	O
recombinase	O
led	O
to	O
removal	B-SO
of	O
the	O
PGK	O
-	O
neo	O
cassette	B-SO
,	O
and	O
mice	B-Taxon
carrying	O
the	O
modified	B-SO
Mtf1loxP	O
allele	B-SO
were	O
generated	O
by	O
injection	O
of	O
positive	O
clones	B-SO
into	O
C57Bl	O
/	O
6	O
blastocysts	O
and	O
subsequent	O
crosses	O
.	O

Homozygous	O
conditional	O
knockout	O
animals	B-Taxon
(	O
Mtf1loxP	O
/	O
loxP	B-SO
)	O
were	O
crossed	O
with	O
the	O
Cre	O
recombinase	O
transgenic	B-SO
line	O
Mx	B-GGP
-	O
cre	O
(	O
a	O
gift	O
from	O
Prof	O
.	O
Michel	O
Aguet	O
)	O
to	O
obtain	O
an	O
inducible	O
,	O
liver	O
-	O
specific	O
Mtf1	B-GGP
knockout	O
line	O
.	O

The	O
mice	B-Taxon
were	O
genotyped	O
by	O
PCR	O
using	O
the	O
following	O
primers	B-SO
(	O
Microsynth	O
)	O
:	O
Cre	O
recombinase	O
:	O
5	O
'	O
-	O
CTATCCAGCAACATTTGGGCCAGC	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
CCAGGTTACGGATATAGTTCATGAC	O
-	O
3	O
'	O
,	O
Mtf1loxP	O
or	O
wild	B-SO
-	I-SO
type	I-SO
allele	B-SO
:	O
5	O
'	O
-	O
CACACCCAGTTTGTGTATGTCTTC	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
CAGTCACAAGCAAATTACCAAACACTGCC	O
-	O
3	O
'	O
.	O

Animal	B-Taxon
treatment	O

At	O
8	O
weeks	O
of	O
age	O
,	O
male	O
Mtf1loxP	O
/	O
loxP	B-SO
mice	B-Taxon
harboring	O
the	O
Mx	B-GGP
-	O
cre	O
transgene	B-SO
(	O
Mtf1loxP	O
/	O
loxP	B-SO
Mx	B-GGP
-	O
cre	O
,	O
abbr	O
.	O
:	O
Mtf1Mx	O
-	O
cre	O
)	O
and	O
control	O
littermates	O
without	O
transgene	B-SO
(	O
Mtf1loxP	O
/	O
loxP	B-SO
,	O
abbr	O
.	O
:	O
Mtf1loxP	O
)	O
received	O
four	O
intraperitoneal	O
injections	O
each	O
of	O
300	O
micro	O
g	O
synthetic	B-SO
double	B-SO
-	I-SO
stranded	I-SO
RNA	B-SO
polyinosinic	O
-	O
polycytidylic	O
acid	B-CHEBI
[	O
pI	O
-	O
pC	O
;	O
Sigma	O
;	O
in	O
a	O
volume	O
of	O
60	O
micro	O
l	O
phosphate	B-CHEBI
-	O
buffered	B-CHEBI
saline	O
(	O
PBS	O
)	O
]	O
at	O
3	O
day	O
intervals	O
.	O

Only	O
in	O
the	O
case	O
of	O
DNA	B-SO
-	O
binding	O
studies	O
with	O
MRE	O
sequences	B-SO
from	O
MTF	B-GGP
-	I-GGP
1	I-GGP
target	O
gene	B-SO
candidates	O
,	O
the	O
control	O
mice	B-Taxon
received	O
no	O
pI	O
-	O
pC	O
injections	O
.	O

For	O
experiments	O
with	O
metal	B-CHEBI
treatment	O
,	O
mice	B-Taxon
received	O
2	O
days	O
after	O
the	O
last	O
pI	O
-	O
pC	O
treatment	O
a	O
subcutaneous	O
(	O
s	O
.	O
c	O
.	O
)	O
injection	O
of	O
either	O
20	O
micro	O
mol	O
/	O
kg	O
body	O
weight	O
CdSO4	O
(	O
2	O
mM	O
CdSO4	O
in	O
H2O	B-CHEBI
;	O
cadmium	B-CHEBI
treatment	O
)	O
or	O
10	O
ml	O
/	O
kg	O
body	O
weight	O
H2O	B-CHEBI
(	O
mock	O
treatment	O
)	O
6	O
h	O
before	O
sacrificing	O
them	O
.	O

Microarray	O
analysis	O
and	O
data	O
processing	O

Total	O
RNA	B-SO
was	O
isolated	O
from	O
liver	O
tissue	O
of	O
pI	O
-	O
pC	O
-	O
induced	O
,	O
mock	O
-	O
or	O
cadmium	B-CHEBI
-	O
treated	O
Mtf1Mx	O
-	O
cre	O
and	O
Mtf1loxP	O
mice	B-Taxon
(	O
n	O
=	O
3	O
per	O
genotype	B-SO
and	O
respective	O
treatment	O
;	O
all	O
male	O
)	O
essentially	O
as	O
described	O
by	O
Chomczynski	O
and	O
Sacchi	O
(	O
27	O
)	O
.	O

Gene	B-SO
expression	O
analysis	O
was	O
performed	O
in	O
the	O
Functional	O
Genomics	O
Center	O
Zurich	O
using	O
GeneChip	O
(R)	O
Mouse	B-Taxon
Genome	B-SO
430	O
2	O
.	O
0	O
Arrays	O
(	O
Affymetrix	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
and	O
the	O
following	O
reagents	B-CHEBI
and	O
conditions	O
.	O

cDNA	B-SO
was	O
synthesized	O
with	O
SuperScript	O
(TM)	O
Double	B-SO
-	I-SO
Stranded	I-SO
cDNA	I-SO
Synthesis	O
Kit	O
(	O
Invitrogen	O
)	O
,	O
using	O
15	O
micro	O
g	O
total	O
RNA	B-SO
.	O

In	O
vitro	O
transcription	O
was	O
performed	O
with	O
BioArray	O
(TM)	O
High	O
Yield	O
(TM)	O
RNA	B-SO
Transcript	I-SO
Labeling	O
Kit	O
(	O
Enzo	O
)	O
and	O
3	O
.	O
5	O
to	O
6	O
micro	O
g	O
of	O
each	O
cDNA	B-SO
.	O

Clean	O
-	O
up	O
of	O
both	O
cDNA	B-SO
and	O
cRNA	O
samples	O
was	O
done	O
using	O
GeneChip	O
(R)	O
Sample	O
Clean	O
-	O
up	O
Module	O
(	O
Affymetrix	O
)	O
.	O

For	O
the	O
automated	O
washing	O
and	O
staining	O
in	O
the	O
Affymetrix	O
fluidics	O
station	O
450	O
,	O
the	O
protocol	O
EukGE	O
-	O
Ws2v4	O
_	O
450	O
was	O
used	O
.	O

The	O
probe	B-SO
arrays	O
were	O
scanned	O
with	O
the	O
Affymetrix	O
GS	O
3000	O
scanner	O
.	O

Raw	O
data	O
are	O
available	O
at	O
ArrayExpress	O
(	O
,	O
accession	O
number	O
E	O
-	O
MEXP	O
-	O
438	O
)	O
.	O

Data	O
analysis	O
was	O
performed	O
with	O
GeneSpring	O
6	O
.	O
1	O
software	O
(	O
Silicon	O
Genetics	O
)	O
,	O
applying	O
a	O
significance	O
level	O
P	O
<=	O
0	O
.	O
05	O
.	O

Furthermore	O
,	O
multiple	O
testing	O
correction	O
was	O
used	O
in	O
addition	O
to	O
obtain	O
cadmium	B-CHEBI
-	O
responsive	O
,	O
MTF	B-GGP
-	I-GGP
1	I-GGP
-	O
independent	O
genes	B-SO
.	O

Genes	B-SO
were	O
considered	O
to	O
be	O
differentially	O
expressed	O
if	O
there	O
was	O
at	O
least	O
a	O
2	O
-	O
fold	O
difference	O
in	O
expression	O
levels	O
of	O
the	O
compared	O
experimental	O
groups	O
(	O
genotype	B-SO
and	O
respective	O
treatment	O
)	O
.	O

The	O
result	O
was	O
considered	O
reliable	O
if	O
signal	O
values	O
for	O
the	O
respective	O
gene	B-SO
were	O
scored	O
'	O
present	O
'	O
at	O
least	O
for	O
all	O
mice	B-Taxon
in	O
one	O
experimental	O
group	O
or	O
for	O
two	O
mice	B-Taxon
in	O
each	O
of	O
two	O
groups	O
.	O

To	O
screen	O
for	O
the	O
presence	O
of	O
the	O
MRE	O
core	O
consensus	B-SO
sequence	I-SO
TGCRCNC	O
in	O
the	O
promoter	B-SO
region	I-SO
,	O
the	O
upstream	O
sequences	B-SO
of	O
the	O
respective	O
genes	B-SO
were	O
obtained	O
from	O
the	O
University	O
of	O
California	O
Santa	O
Cruz	O
(	O
UCSC	O
)	O
Genome	B-SO
Browser	O
Database	O
(	O
;	O
October	O
/	O
November	O
2004	O
)	O
(	O
28	O
)	O
.	O

RT	O
-	O
PCR	O

All	O
RT	O
-	O
PCRs	O
were	O
performed	O
with	O
QIAGEN	O
(R)	O
OneStep	O
RT	O
-	O
PCR	O
Kit	O
(	O
QIAGEN	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
,	O
using	O
150	O
-	O
200	O
ng	O
DNase	B-GGP
I	I-GGP
-	O
digested	O
total	O
RNA	B-SO
(	O
RNA	B-SO
isolation	O
see	O
microarray	O
analysis	O
)	O
.	O

The	O
reactions	O
were	O
carried	O
out	O
using	O
the	O
following	O
primers	B-SO
:	O
Csrp1	B-GGP
:	O
5	O
'	O
-	O
TTCCGATGTGCCAAGTGTGGC	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
AGTAGAGAGTGGACATTCAGC	O
-	O
3	O
'	O
,	O
hypoxanthin	B-GGP
-	I-GGP
guanin	I-GGP
-	I-GGP
phosphoribosyltransferase	I-GGP
(	O
Hprt	B-GGP
)	O
:	O
5	O
'	O
-	O
GCTGGTGAAAAGGACCTCTCG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
CCACAGGACTAGGACACCTGC	O
-	O
3	O
'	O
,	O
Mtf1	B-GGP
:	O
5	O
'	O
-	O
GTGACTTTTGAGACTGTACTGAGTG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
CATGCCAAGAAACATTGAAGGTG	O
-	O
3	O
'	O
,	O
Ndrg1	B-GGP
:	O
5	O
'	O
-	O
AGATACACAACAACGTGGAGG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
TGTGCGAGCGGCTTCGGGGGC	O
-	O
3	O
'	O
,	O
Sepw1	B-GGP
:	O
5	O
'	O
-	O
TAGAGGCAGGGTCCTGAAAGC	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
ACACCTGGAAACATGGCTGCC	O
-	O
3	O
'	O
,	O
Slc39a10	B-GGP
:	O
5	O
'	O
-	O
GCTGTGGCTGGTAGTAAAAGC	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
GTGGCATGGGATGTAAACAGC	O
-	O
3	O
'	O
.	O

S1	O
nuclease	O
mapping	O
of	O
transcripts	B-SO
(	O
S1	O
analysis	O
)	O

S1	O
analysis	O
was	O
performed	O
as	O
previously	O
described	O
(	O
29	O
)	O
,	O
using	O
100	O
micro	O
g	O
DNase	B-GGP
I	I-GGP
-	O
digested	O
total	O
RNA	B-SO
(	O
RNA	B-SO
isolation	O
see	O
microarray	O
analysis	O
)	O
.	O

The	O
gels	O
were	O
developed	O
using	O
PhosphorImager	O
(	O
Molecular	B-CHEBI
Dynamics	O
)	O
.	O

S1	O
analysis	O
was	O
done	O
with	O
the	O
following	O
32P	B-CHEBI
-	O
labeled	O
oligonucleotides	B-SO
:	O
Hprt	B-GGP
S1	O
:	O
5	O
'	O
-	O
TCTTCAGTCTGATAAAATCTACAGTCATAGGAATGGATCTATCACTATTTCTATTCAGTGATTACATTAAAG	O
-	O
3	O
'	O
,	O
Sepw1	B-GGP
S1	O
:	O
5	O
'	O
-	O
TTCAACCGGGAACACCTGGAAACATGGCTGCCTGTCTTCTTGAAGTCTTGAGGTGGAAAGGGAAAGCAAAGCAGGAGGGTTTTCCCACCC	O
-	O
3	O
'	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O

Protein	B-CHEBI
was	O
extracted	O
from	O
liver	O
tissue	O
with	O
T	O
-	O
PER	O
(TM)	O
Tissue	O
Protein	B-CHEBI
Extraction	O
Reagent	B-CHEBI
(	O
Pierce	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
,	O
using	O
a	O
1	O
:	O
10	O
ratio	O
of	O
mouse	B-Taxon
tissue	O
(	O
mg	O
)	O
to	O
T	O
-	O
PER	O
reagent	B-CHEBI
(	O
micro	O
l	O
)	O
.	O

EMSA	O
was	O
essentially	O
performed	O
as	O
previously	O
described	O
(	O
10	O
)	O
.	O

All	O
binding	O
reactions	O
were	O
carried	O
out	O
by	O
incubating	O
2	O
-	O
5	O
fmol	O
32P	B-CHEBI
-	O
end	O
-	O
labeled	O
double	B-SO
-	I-SO
stranded	I-SO
oligonucleotides	I-SO
with	O
100	O
to	O
130	O
micro	O
g	O
liver	O
protein	B-CHEBI
extract	O
.	O

For	O
competition	O
experiments	O
,	O
5	O
pmol	O
of	O
unlabeled	O
competitor	O
oligonucleotide	B-SO
was	O
added	O
to	O
the	O
binding	O
reaction	O
before	O
addition	O
of	O
the	O
extract	O
.	O

All	O
EMSA	O
gels	O
were	O
developed	O
using	O
PhosphorImager	O
(	O
Molecular	B-CHEBI
Dynamics	O
)	O
.	O

The	O
following	O
oligonucleotides	B-SO
were	O
annealed	O
and	O
used	O
for	O
the	O
reactions	O
:	O
Csrp1	B-GGP
MRE1	O
:	O
5	O
'	O
-	O
GGAAACAAAACGGCGCGCACTCCGGCGC	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
GGCTGCGC	O
CGGAGTGCGCGCCGTTTTGT	O
-	O
3	O
'	O
,	O
Csrp1	B-GGP
MRE2	O
:	O
5	O
'	O
-	O
TGTTGTGGTGCAGTGTGCAAAGCCTAC	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
ACCAGTAGGCTTTGCACACTGCACCAC	O
-	O
3	O
'	O
,	O
Csrp1	B-GGP
MRE3	O
:	O
5	O
'	O
-	O
GAGATCGCCATAGGGTGCAAAGAGAAG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
GTGACTTCTCTTTGCACCCTATGGCGA	O
-	O
3	O
'	O
,	O
Csrp1	B-GGP
MRE4	O
:	O
5	O
'	O
-	O
TGTCTTATTCTGGAGTGCAAGTTAGTC	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
AGGGGACTAACTTGCACTCCAGAATAA	O
-	O
3	O
'	O
,	O
Gal4	O
:	O
5	O
'	O
-	O
TCCGGAGGACTGTCCTCCGG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
GCCGGAGGACAGTCCTCCGG	O
-	O
3	O
'	O
,	O
MREd	O
[	O
MRE	O
derived	O
from	O
mouse	B-GGP
Mt1	I-GGP
promoter	B-SO
(	O
10	O
)	O
]	O
:	O
5	O
'	O
-	O
CGAGGGAGCTCTGCACTCCGCCCGAAAAGTG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
TCGACACTTTTCGGGCGGAGTGCAGAGCTCCCTCGAGCT	O
-	O
3	O
'	O
,	O
MRE	O
-	O
s	O
[	O
synthetic	B-SO
MRE	O
consensus	B-SO
sequence	I-SO
(	O
10	O
)	O
]	O
:	O
5	O
'	O
-	O
CGAGGGAGCTCTGCACACGGCCCGAAAAGTG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
TCGACACTTTTCGGGCCGTGTGCAGAGCTCCCTCGAGCT	O
-	O
3	O
'	O
,	O
Ndrg1	B-GGP
MRE1	O
:	O
5	O
'	O
-	O
CAGCCCAGGCAGGGTGCAGCACGAG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
CCGCCTCGTGCTGCACCCTGCCTGG	O
-	O
3	O
'	O
,	O
Ndrg1	B-GGP
MRE2	O
:	O
5	O
'	O
-	O
CACACGTTCGCTGCACACGCCGCGG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
GGGACCGCGGCGTGTGCAGCGAACG	O
-	O
3	O
'	O
,	O
Ndrg1	B-GGP
MRE3	O
,	O
4	O
:	O
5	O
'	O
-	O
GGAGTCCTTATGCACACGCGCACGAGCGCGCACGGGCAC	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
TGGTGTGCCCGTGCGCGCTCGTGCGCGTGTGCATAAGGAC	O
-	O
3	O
'	O
,	O
Sepw1	B-GGP
MRE1	O
:	O
5	O
'	O
-	O
GAGGCAGTCGGCTGTGCGCACGGCCCCACGCTC	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
CTCTGAGCGTGGGGCCGTGCGCACAGCCGACTGC	O
-	O
3	O
'	O
,	O
Sepw1	B-GGP
MRE2	O
:	O
5	O
'	O
-	O
ATGGTTTTGGGGGTGCGCAGGGGGTCTG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
CGACAGACCCCCTGCGCACCCCCAAAAC	O
-	O
3	O
'	O
,	O
Slc39a10	B-GGP
MRE1	O
:	O
5	O
'	O
-	O
GAATACACGACTGGGTGCAGCCGGGGTTTGG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
GGTACCAAACCCCGGCTGCACCCAGTCGTGTA	O
-	O
3	O
'	O
,	O
Slc39a10	B-GGP
MRE2	O
:	O
5	O
'	O
-	O
GCGGAGAGGAGATGCACACGGCACTCG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
CACTCGAGTGCCGTGTGCATCTCCTCT	O
-	O
3	O
'	O
,	O
Specificity	B-GGP
protein	I-GGP
1	I-GGP
(	O
Sp1	B-GGP
)	O
binding	B-SO
sequence	I-SO
(	O
10	O
)	O
:	O
5	O
'	O
-	O
CGAGGCCCCGCCCAG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
TCGACTGGGCGGGGCCTCGAGct	O
-	O
3	O
'	O
.	O

Cell	B-CL
culture	O

Primary	O
embryonic	O
fibroblasts	B-CL
were	O
isolated	O
from	O
a	O
12	O
.	O
5	O
day	O
old	O
Mtf1loxP	O
mouse	B-Taxon
embryo	O
and	O
grown	O
in	O
DMEM	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	B-Taxon
serum	O
(	O
ICN	O
)	O
,	O
100	O
U	O
/	O
ml	O
penicillin	B-CHEBI
-	O
streptomycin	B-CHEBI
(	O
Gibco	O
BRL	O
)	O
and	O
2	O
mM	O
l	B-CHEBI
-	I-CHEBI
glutamine	I-CHEBI
(	O
Gibco	O
BRL	O
)	O
.	O

100	O
mm	O
plates	O
with	O
primary	O
cells	B-CL
were	O
transfected	O
with	O
10	O
micro	O
g	O
of	O
an	O
expression	O
plasmid	B-SO
coding	O
for	O
simian	B-GGP
virus	I-GGP
40	I-GGP
(	I-GGP
SV40	I-GGP
)	I-GGP
large	I-GGP
T	I-GGP
antigen	I-GGP
driven	O
by	O
the	O
cytomegalovirus	B-Taxon
(	O
CMV	B-Taxon
)	O
promoter	B-SO
,	O
using	O
lipofectamine	O
(TM)	O
reagent	B-CHEBI
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Cell	B-CL
foci	O
were	O
isolated	O
and	O
the	O
immortalized	O
mouse	B-Taxon
embryonic	O
fibroblast	B-CL
cell	I-CL
line	O
ckoC	O
was	O
derived	O
from	O
one	O
of	O
them	O
.	O

The	O
Mtf1loxP	O
genotype	B-SO
of	O
this	O
line	O
as	O
well	O
as	O
the	O
genomic	B-SO
integration	B-SO
of	O
the	O
T	O
antigen	O
were	O
confirmed	O
by	O
PCR	O
.	O

100	O
mm	O
plates	O
with	O
these	O
cells	B-CL
were	O
further	O
transfected	O
by	O
the	O
calcium	B-CHEBI
phosphate	I-CHEBI
method	O
(	O
30	O
)	O
with	O
19	O
.	O
6	O
micro	O
g	O
of	O
an	O
expression	O
plasmid	B-SO
for	O
Cre	O
recombinase	O
driven	O
by	O
the	O
CMV	B-Taxon
promoter	B-SO
and	O
0	O
.	O
4	O
micro	O
g	O
of	O
an	O
expression	O
plasmid	B-SO
for	O
the	O
neomycin	B-CHEBI
resistance	O
gene	B-SO
under	O
the	O
control	O
of	O
the	O
TK	O
promoter	B-SO
.	O

Stably	O
transfected	O
cells	B-CL
were	O
selected	O
in	O
the	O
presence	O
of	O
0	O
.	O
4	O
micro	O
g	O
/	O
micro	O
l	O
G418	O
(	O
Calbiochem	O
)	O
,	O
isolated	O
clones	O
of	O
resistant	O
cells	B-CL
were	O
harvested	O
and	O
grown	O
independently	O
,	O
and	O
the	O
expression	O
of	O
Cre	O
recombinase	O
and	O
excision	B-SO
of	O
exons	B-SO
3	O
and	O
4	O
of	O
Mtf1	B-GGP
were	O
analyzed	O
by	O
RT	O
-	O
PCR	O
.	O

The	O
cell	B-CL
lines	O
delC19	O
,	O
delC21	O
and	O
delC23	O
with	O
a	O
deletion	B-SO
of	O
Mtf1	B-GGP
were	O
chosen	O
for	O
further	O
experiments	O
.	O

Cytotoxicity	O
assay	O

Samples	O
of	O
1	O
x	O
104	O
cells	B-CL
/	O
well	O
were	O
plated	O
in	O
96	O
-	O
well	O
tissue	O
culture	O
plates	O
and	O
allowed	O
to	O
adhere	O
for	O
24	O
h	O
.	O

The	O
cells	B-CL
were	O
then	O
pre	O
-	O
incubated	O
for	O
24	O
h	O
in	O
medium	O
containing	O
0	O
,	O
5	O
,	O
10	O
,	O
25	O
or	O
50	O
micro	O
M	O
l	O
-	O
buthionine	O
-	O
[	O
S	O
,	O
R	O
]	O
-	O
sulfoximine	O
(	O
BSO	O
)	O
(	O
Sigma	O
)	O
,	O
a	O
drug	B-CHEBI
that	O
inhibits	O
glutathione	B-CHEBI
synthesis	O
(	O
31	O
)	O
.	O

Later	O
,	O
cells	B-CL
were	O
exposed	O
to	O
0	O
,	O
5	O
,	O
10	O
or	O
20	O
micro	O
M	O
CdCl2	B-CHEBI
in	O
the	O
specified	O
pre	O
-	O
incubation	O
medium	O
for	O
an	O
additional	O
24	O
h	O
.	O

Cytotoxicity	O
was	O
determined	O
by	O
the	O
MTT	O
(	O
3	O
-	O
[	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
]	O
-	O
2	O
,	O
5	O
-	O
diphenyl	O
tetrazolium	O
bromid	B-CHEBI
)	O
-	O
based	O
Cell	B-CL
Proliferation	O
Kit	O
I	O
(	O
Roche	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

RESULTS	O

Generation	O
of	O
an	O
inducible	O
,	O
liver	O
-	O
specific	O
Mtf1	B-GGP
knockout	O
mouse	B-Taxon
line	O

Using	O
a	O
homologous	O
recombination	O
strategy	O
,	O
mice	B-Taxon
were	O
obtained	O
with	O
a	O
modified	B-SO
Mtf1	B-GGP
allele	B-SO
Mtf1loxP	O
where	O
exons	B-SO
3	O
and	O
4	O
,	O
encoding	O
four	O
of	O
the	O
six	O
zinc	B-CHEBI
fingers	O
of	O
the	O
DNA	B-SO
-	O
binding	O
domain	B-SO
,	O
are	O
flanked	B-SO
by	O
loxP	B-SO
sites	I-SO
(	O
Figure	O
1a	O
)	O
.	O

Mice	B-Taxon
homozygous	O
for	O
the	O
Mtf1loxP	O
allele	B-SO
were	O
further	O
crossed	O
with	O
animals	B-Taxon
of	O
the	O
Cre	O
recombinase	O
transgenic	B-SO
line	O
Mx	B-GGP
-	O
cre	O
.	O

Cre	O
recombinase	O
is	O
expressed	O
in	O
this	O
line	O
under	O
the	O
control	O
of	O
the	O
mouse	B-GGP
Mx1	I-GGP
gene	B-SO
promoter	B-SO
,	O
which	O
is	O
inducible	O
by	O
administration	O
of	O
interferon	O
alpha	O
or	O
beta	O
,	O
or	O
synthetic	B-SO
double	B-SO
-	I-SO
stranded	I-SO
RNA	B-SO
pI	O
-	O
pC	O
(	O
32	O
)	O
.	O

Cre	O
-	O
mediated	O
deletion	B-SO
was	O
reported	O
to	O
be	O
complete	O
in	O
the	O
liver	O
,	O
while	O
varying	O
in	O
other	O
tissues	O
,	O
ranging	O
from	O
94	O
%	O
in	O
spleen	O
to	O
8	O
%	O
in	O
brain	O
(	O
32	O
)	O
.	O

After	O
Cre	O
-	O
mediated	O
deletion	B-SO
of	O
exons	B-SO
3	O
and	O
4	O
,	O
which	O
results	O
in	O
a	O
frameshift	B-SO
and	O
premature	O
translation	B-SO
stop	I-SO
,	O
no	O
functional	O
MTF	B-GGP
-	I-GGP
1	I-GGP
protein	B-CHEBI
can	O
be	O
produced	O
.	O

For	O
induction	O
of	O
Cre	O
recombinase	O
,	O
Mtf1	B-GGP
conditional	O
knockout	O
mice	B-Taxon
harboring	O
the	O
Mx	B-GGP
-	O
cre	O
transgene	B-SO
(	O
Mtf1Mx	O
-	O
cre	O
)	O
received	O
four	O
intraperitoneal	O
pI	O
-	O
pC	O
injections	O
at	O
3	O
day	O
intervals	O
(	O
pI	O
-	O
pC	O
induction	O
)	O
;	O
control	O
littermates	O
without	O
transgene	B-SO
(	O
Mtf1loxP	O
)	O
received	O
similar	O
injections	O
.	O

Using	O
RT	O
-	O
PCRs	O
(	O
Figure	O
1b	O
)	O
,	O
a	O
shortened	O
product	B-SO
was	O
obtained	O
with	O
RNA	B-SO
from	O
Mtf1Mx	O
-	O
cre	O
livers	O
,	O
indicating	O
a	O
successful	O
excision	B-SO
of	O
exons	B-SO
3	O
and	O
4	O
of	O
Mtf1	B-GGP
in	O
these	O
animals	B-Taxon
.	O

On	O
close	O
examination	O
,	O
a	O
very	O
faint	O
band	O
similar	O
in	O
size	O
to	O
full	O
-	O
length	O
signal	O
was	O
also	O
observed	O
in	O
those	O
mice	B-Taxon
,	O
probably	O
due	O
to	O
a	O
low	O
amount	O
of	O
residual	O
full	O
-	O
length	O
Mtf1	B-GGP
mRNA	B-CHEBI
.	O

The	O
level	O
of	O
functional	O
MTF	B-GGP
-	I-GGP
1	I-GGP
protein	B-CHEBI
was	O
examined	O
by	O
EMSA	O
(	O
Figure	O
1c	O
)	O
:	O
MTF	B-GGP
-	I-GGP
1	I-GGP
protein	B-GO
-	I-GO
DNA	I-GO
complex	I-GO
was	O
detectable	O
with	O
liver	O
protein	B-CHEBI
extract	O
from	O
an	O
Mtf1loxP	O
control	O
mouse	B-Taxon
,	O
but	O
no	O
functional	O
MRE	O
-	O
binding	O
protein	B-CHEBI
was	O
observed	O
with	O
an	O
Mtf1Mx	O
-	O
cre	O
sample	O
.	O

Thus	O
,	O
deletion	B-SO
of	O
exons	B-SO
3	O
and	O
4	O
of	O
Mtf1	B-GGP
in	O
the	O
liver	O
of	O
Mtf1Mx	O
-	O
cre	O
mice	B-Taxon
was	O
virtually	O
complete	O
.	O

All	O
examined	O
liver	O
-	O
specific	O
knockout	O
mice	B-Taxon
were	O
viable	O
under	O
laboratory	O
conditions	O
and	O
appeared	O
normal	O
.	O

MTF	B-GGP
-	I-GGP
1	I-GGP
target	O
gene	B-SO
search	O

For	O
the	O
identification	O
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
target	O
genes	B-SO
,	O
we	O
compared	O
the	O
liver	O
transcript	B-SO
profiles	O
of	O
mice	B-Taxon
with	O
and	O
without	O
functional	O
Mtf1	B-GGP
gene	B-SO
that	O
had	O
been	O
mock	O
-	O
treated	O
or	O
exposed	O
to	O
cadmium	B-CHEBI
(	O
n	O
=	O
3	O
per	O
genotype	B-SO
and	O
respective	O
treatment	O
)	O
.	O

In	O
a	O
first	O
screen	O
,	O
the	O
transcripts	B-SO
were	O
analyzed	O
with	O
a	O
differential	O
display	O
-	O
based	O
method	O
,	O
called	O
amplification	O
of	O
double	B-SO
-	I-SO
stranded	I-SO
cDNA	I-SO
end	O
restriction	B-SO
fragments	I-SO
(	O
ADDER	O
)	O
(	O
33	O
)	O
.	O

Thereby	O
an	O
overwhelming	O
number	O
of	O
signals	O
was	O
obtained	O
for	O
the	O
two	O
stress	O
-	O
inducible	O
metallothioneins	O
(	O
Mt1	B-GGP
and	O
Mt2	B-GGP
)	O
,	O
due	O
to	O
the	O
abundance	O
of	O
their	O
transcripts	B-SO
both	O
in	O
mock	O
-	O
treated	O
and	O
especially	O
in	O
cadmium	B-CHEBI
-	O
treated	O
livers	O
that	O
harbored	O
a	O
functional	O
MTF	B-GGP
-	I-GGP
1	I-GGP
gene	B-SO
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
result	O
confirmed	O
the	O
importance	O
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
for	O
both	O
basal	O
and	O
metal	B-CHEBI
-	O
induced	O
expression	O
of	O
metallothionein	O
genes	B-SO
.	O

In	O
a	O
second	O
approach	O
,	O
the	O
gene	B-SO
expression	O
profile	O
in	O
livers	O
of	O
the	O
above	O
mentioned	O
mice	B-Taxon
was	O
compared	O
by	O
Affymetrix	O
GeneChip	O
(R)	O
Mouse	B-Taxon
Genome	B-SO
430	O
2	O
.	O
0	O
Arrays	O
(	O
Table	O
1	O
)	O
.	O

When	O
analyzing	O
the	O
probe	B-SO
array	O
data	O
of	O
livers	O
from	O
mock	O
-	O
treated	O
Mtf1Mx	O
-	O
cre	O
and	O
Mtf1loxP	O
mice	B-Taxon
,	O
an	O
at	O
least	O
2	O
-	O
fold	O
,	O
reliable	O
downregulation	O
of	O
expression	O
was	O
detected	O
in	O
Mtf1Mx	O
-	O
cre	O
livers	O
for	O
13	O
Affymetrix	O
GeneChip	O
(R)	O
probe	B-SO
sets	O
corresponding	O
to	O
11	O
characterized	O
genes	B-SO
(	O
Table	O
1	O
,	O
a	O
)	O
.	O

Seven	O
of	O
these	O
genes	B-SO
contain	O
one	O
or	O
more	O
MRE	O
core	O
consensus	B-SO
sequence	I-SO
TGCRCNC	O
within	O
a	O
segment	B-SO
of	O
1000	O
bp	B-SO
upstream	O
of	O
the	O
transcription	B-SO
start	I-SO
.	O

For	O
26	O
probe	B-SO
sets	O
corresponding	O
to	O
24	O
different	O
characterized	O
genes	B-SO
,	O
a	O
2	O
-	O
fold	O
or	O
higher	O
,	O
reliable	O
upregulation	O
was	O
detected	O
in	O
Mtf1Mx	O
-	O
cre	O
livers	O
(	O
Table	O
1	O
,	O
b	O
)	O
;	O
17	O
of	O
these	O
24	O
genes	B-SO
contain	O
MRE	O
core	O
consensus	B-SO
sequences	I-SO
in	O
the	O
upstream	O
region	B-SO
.	O

The	O
data	O
set	O
for	O
livers	O
of	O
cadmium	B-CHEBI
-	O
treated	O
Mtf1Mx	O
-	O
cre	O
and	O
Mtf1loxP	O
mice	B-Taxon
revealed	O
an	O
at	O
least	O
2	O
-	O
fold	O
,	O
reliable	O
downregulation	O
in	O
Mtf1Mx	O
-	O
cre	O
livers	O
for	O
21	O
probe	B-SO
sets	O
corresponding	O
to	O
16	O
different	O
characterized	O
genes	B-SO
(	O
Table	O
1	O
,	O
c	O
)	O
;	O
10	O
of	O
these	O
contain	O
MRE	O
core	O
consensus	B-SO
sequences	I-SO
in	O
their	O
upstream	O
region	B-SO
.	O

For	O
9	O
probe	B-SO
sets	O
corresponding	O
to	O
9	O
different	O
characterized	O
genes	B-SO
,	O
an	O
at	O
least	O
2	O
-	O
fold	O
,	O
reliable	O
upregulation	O
was	O
detected	O
(	O
Table	O
1	O
,	O
d	O
)	O
;	O
five	O
of	O
them	O
contain	O
MRE	O
motifs	O
.	O

In	O
addition	O
to	O
characterized	O
genes	B-SO
,	O
ESTs	B-SO
and	O
RIKEN	O
cDNA	B-SO
sequences	I-SO
were	O
also	O
found	O
in	O
the	O
comparison	O
of	O
Mtf1Mx	O
-	O
cre	O
and	O
Mtf1loxP	O
livers	O
to	O
be	O
differentially	O
expressed	O
(	O
Supplementary	O
Table	O
1	O
)	O
.	O

Downregulation	O
of	O
Mt1	B-GGP
and	O
Mt2	B-GGP
was	O
detected	O
in	O
Mtf1Mx	O
-	O
cre	O
livers	O
for	O
both	O
conditions	O
(	O
though	O
the	O
level	O
of	O
significance	O
for	O
the	O
downregulation	O
of	O
Mt1	B-GGP
in	O
mock	O
-	O
treated	O
animals	B-Taxon
was	O
above	O
0	O
.	O
05	O
;	O
data	O
not	O
shown	O
)	O
.	O

For	O
all	O
MTF	B-GGP
-	I-GGP
1	I-GGP
target	O
genes	B-SO
characterized	O
so	O
far	O
,	O
such	O
as	O
Mt1	B-GGP
,	O
Mt2	B-GGP
and	O
Znt1	B-GGP
,	O
MTF	B-GGP
-	I-GGP
1	I-GGP
exerts	O
its	O
transcriptional	O
activation	O
activity	O
via	O
standard	O
MRE	O
sequences	B-SO
located	O
proximal	O
to	O
the	O
transcription	B-SO
start	I-SO
(	O
4	O
,	O
5	O
,	O
8	O
,	O
18	O
,	O
19	O
)	O
.	O

Even	O
a	O
specific	O
search	O
for	O
MTF	B-GGP
-	I-GGP
1	I-GGP
binding	B-SO
sites	I-SO
by	O
selection	O
from	O
a	O
pool	O
of	O
double	B-SO
-	I-SO
stranded	I-SO
oligonucleotides	I-SO
with	O
random	B-SO
sequences	B-SO
yielded	O
no	O
new	O
binding	O
motif	O
for	O
MTF	B-GGP
-	I-GGP
1	I-GGP
in	O
addition	O
to	O
the	O
known	B-SO
MREs	O
(	O
34	O
)	O
.	O

Thus	O
,	O
an	O
MRE	O
sequence	B-SO
is	O
to	O
date	O
the	O
only	O
indication	O
for	O
a	O
direct	O
MTF	B-GGP
-	I-GGP
1	I-GGP
target	O
gene	B-SO
,	O
and	O
four	O
MRE	O
-	O
containing	O
target	O
gene	B-SO
candidates	O
were	O
further	O
analyzed	O
.	O

Basal	O
expression	O
of	O
Sepw1	B-GGP
depends	O
on	O
MTF	B-GGP
-	I-GGP
1	I-GGP

Sepw1	B-GGP
was	O
found	O
in	O
microarray	O
analysis	O
to	O
be	O
significantly	O
downregulated	O
in	O
livers	O
from	O
cadmium	B-CHEBI
-	O
and	O
mock	O
-	O
treated	O
Mtf1Mx	O
-	O
cre	O
mice	B-Taxon
(	O
Table	O
1	O
,	O
a	O
and	O
c	O
)	O
.	O

SEPW1	B-GGP
is	O
a	O
selenocysteine	B-CHEBI
-	O
containing	O
protein	B-CHEBI
that	O
binds	O
glutathione	B-CHEBI
(	O
35	O
)	O
and	O
is	O
thought	O
to	O
act	O
as	O
an	O
antioxidant	B-CHEBI
in	O
vivo	O
(	O
36	O
)	O
.	O

Sepw1	B-GGP
expression	O
in	O
livers	O
of	O
pI	O
-	O
pC	O
-	O
induced	O
,	O
mock	O
-	O
or	O
cadmium	B-CHEBI
-	O
treated	O
Mtf1Mx	O
-	O
cre	O
and	O
Mtf1loxP	O
mice	B-Taxon
was	O
further	O
analyzed	O
by	O
semiquantitative	O
RT	O
-	O
PCRs	O
and	O
S1	O
analysis	O
(	O
Figure	O
2a	O
and	O
b	O
)	O
.	O

In	O
accordance	O
with	O
microarray	O
data	O
a	O
slight	O
,	O
if	O
any	O
,	O
upregulation	O
of	O
Sepw1	B-GGP
transcription	O
was	O
observed	O
in	O
livers	O
from	O
Mtf1loxP	O
mice	B-Taxon
upon	O
cadmium	B-CHEBI
treatment	O
.	O

The	O
basal	O
level	O
was	O
reduced	O
in	O
livers	O
from	O
mock	O
-	O
and	O
cadmium	B-CHEBI
-	O
treated	O
Mtf1Mx	O
-	O
cre	O
mice	B-Taxon
,	O
indicating	O
that	O
MTF	B-GGP
-	I-GGP
1	I-GGP
is	O
important	O
for	O
the	O
basal	O
expression	O
of	O
Sepw1	B-GGP
.	O

Three	O
MRE	O
core	O
consensus	B-SO
sequences	I-SO
were	O
found	O
in	O
the	O
region	B-SO
upstream	O
of	O
the	O
mouse	B-GGP
Sepw1	I-GGP
transcription	B-SO
start	I-SO
(	O
Figure	O
2c	O
)	O
.	O

Two	O
of	O
them	O
in	O
opposite	O
orientation	O
overlap	O
almost	O
completely	O
proximal	O
to	O
the	O
transcription	B-SO
start	I-SO
(	O
MRE1	O
,	O
-	O
40	O
bp	B-SO
)	O
,	O
the	O
third	O
one	O
is	O
located	O
further	O
upstream	O
(	O
MRE2	O
,	O
-	O
527	O
bp	B-SO
)	O
.	O

Specific	O
binding	O
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
to	O
Sepw1	B-GGP
MRE1	O
but	O
not	O
MRE2	O
oligonucleotide	B-SO
was	O
observed	O
in	O
EMSA	O
with	O
liver	O
protein	B-CHEBI
extract	O
from	O
an	O
Mtf1loxP	O
control	O
mouse	B-Taxon
(	O
Figure	O
2d	O
)	O
.	O

As	O
a	O
control	O
,	O
no	O
binding	O
to	O
MRE1	O
was	O
detected	O
with	O
extract	O
from	O
a	O
pI	O
-	O
pC	O
-	O
induced	O
Mtf1Mx	O
-	O
cre	O
mouse	B-Taxon
,	O
confirming	O
that	O
the	O
bandshift	O
was	O
indeed	O
dependent	O
on	O
the	O
presence	O
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
.	O

Cadmium	B-CHEBI
response	O
of	O
Ndrg1	B-GGP
depends	O
on	O
MTF	B-GGP
-	I-GGP
1	I-GGP

Ndrg1	B-GGP
was	O
significantly	O
downregulated	O
in	O
microarrays	O
of	O
liver	O
transcripts	B-SO
from	O
cadmium	B-CHEBI
-	O
treated	O
Mtf1Mx	O
-	O
cre	O
mice	B-Taxon
compared	O
to	O
similarly	O
treated	O
Mtf1loxP	O
control	O
mice	B-Taxon
(	O
Table	O
1	O
,	O
c	O
)	O
.	O

Ndrg1	B-GGP
probably	O
has	O
some	O
role	O
in	O
stress	O
response	O
since	O
various	O
stimuli	O
,	O
including	O
hypoxia	O
and	O
nickel	B-CHEBI
compounds	B-CHEBI
,	O
activate	O
expression	O
of	O
rodent	B-Taxon
Ndrg1	B-GGP
and	O
/	O
or	O
its	O
human	B-Taxon
ortholog	B-SO
(	O
37	O
-	O
40	O
)	O
.	O

The	O
Ndrg1	B-GGP
microarray	O
results	O
were	O
confirmed	O
with	O
semiquantitative	O
RT	O
-	O
PCRs	O
(	O
Figure	O
3a	O
)	O
:	O
for	O
Mtf1loxP	O
control	O
livers	O
,	O
a	O
clear	O
increase	O
of	O
Ndrg1	B-GGP
expression	O
was	O
observed	O
after	O
cadmium	B-CHEBI
exposure	O
;	O
in	O
livers	O
from	O
Mtf1Mx	O
-	O
cre	O
mice	B-Taxon
,	O
this	O
cadmium	B-CHEBI
response	O
was	O
not	O
detectable	O
,	O
while	O
basal	O
expression	O
was	O
similar	O
to	O
controls	O
.	O

This	O
indicates	O
that	O
cadmium	B-CHEBI
-	O
induced	O
expression	O
of	O
Ndrg1	B-GGP
depends	O
on	O
MTF	B-GGP
-	I-GGP
1	I-GGP
.	O

Five	O
MRE	O
core	O
consensus	B-SO
sequences	I-SO
are	O
located	O
upstream	O
of	O
the	O
mouse	B-GGP
Ndrg1	I-GGP
transcription	B-SO
start	I-SO
(	O
Figure	O
3b	O
)	O
.	O

Four	O
of	O
them	O
are	O
clustered	B-SO
(	O
MRE1	O
to	O
MRE4	O
,	O
-	O
138	O
to	O
-	O
332	O
bp	B-SO
)	O
,	O
the	O
fifth	O
one	O
is	O
located	O
farther	O
upstream	O
(	O
MRE5	O
,	O
-	O
883	O
bp	B-SO
)	O
.	O

EMSA	O
was	O
performed	O
to	O
test	O
whether	O
MTF	B-GGP
-	I-GGP
1	I-GGP
is	O
interacting	O
with	O
some	O
or	O
all	O
of	O
the	O
four	O
proximal	O
MRE	O
sequences	B-SO
(	O
Figure	O
3c	O
)	O
.	O

Separate	O
oligonucleotides	B-SO
were	O
tested	O
for	O
MRE1	O
and	O
MRE2	O
,	O
whereas	O
one	O
oligonucleotide	B-SO
spanning	O
both	O
sequences	B-SO
was	O
used	O
for	O
MRE3	O
and	O
MRE4	O
(	O
MRE3	O
,	O
4	O
)	O
.	O

No	O
complex	B-GO
was	O
seen	O
with	O
MRE1	O
,	O
but	O
specific	O
MTF	B-GGP
-	I-GGP
1	I-GGP
complexes	B-GO
were	O
observed	O
for	O
both	O
the	O
MRE2	O
and	O
MRE3	O
,	O
4	O
oligonucleotides	B-SO
with	O
liver	O
protein	B-CHEBI
extract	O
from	O
an	O
Mtf1loxP	O
mouse	B-Taxon
.	O

As	O
expected	O
,	O
no	O
bandshift	O
was	O
observed	O
with	O
protein	B-CHEBI
extract	O
from	O
a	O
mouse	B-Taxon
lacking	O
MTF	B-GGP
-	I-GGP
1	I-GGP
(	O
Mtf1Mx	O
-	O
cre	O
)	O
.	O

Cadmium	B-CHEBI
response	O
of	O
Csrp1	B-GGP
depends	O
on	O
MTF	B-GGP
-	I-GGP
1	I-GGP

Csrp1	B-GGP
was	O
found	O
in	O
microarray	O
analyses	O
to	O
be	O
significantly	O
downregulated	O
in	O
cadmium	B-CHEBI
-	O
treated	O
Mtf1Mx	O
-	O
cre	O
mice	B-Taxon
compared	O
to	O
Mtf1loxP	O
mice	B-Taxon
(	O
Table	O
1	O
,	O
c	O
)	O
.	O

CSRP1	B-GGP
is	O
a	O
member	O
of	O
the	O
evolutionary	B-SO
conserved	I-SO
CRP	O
family	O
of	O
proteins	B-CHEBI
that	O
have	O
been	O
implicated	O
in	O
myogenesis	O
and	O
cytoskeletal	B-GO
remodeling	O
(	O
41	O
,	O
42	O
)	O
.	O

Semiquantitative	O
RT	O
-	O
PCRs	O
confirmed	O
the	O
microarray	O
results	O
,	O
namely	O
,	O
that	O
Csrp1	B-GGP
expression	O
is	O
elevated	O
in	O
Mtf1loxP	O
livers	O
upon	O
cadmium	B-CHEBI
exposure	O
(	O
Figure	O
4a	O
)	O
.	O

In	O
contrast	O
,	O
no	O
cadmium	B-CHEBI
response	O
was	O
detectable	O
in	O
livers	O
from	O
Mtf1Mx	O
-	O
cre	O
mice	B-Taxon
,	O
suggesting	O
that	O
MTF	B-GGP
-	I-GGP
1	I-GGP
is	O
required	O
for	O
cadmium	B-CHEBI
induction	O
of	O
Csrp1	B-GGP
.	O

Three	O
MRE	O
core	O
consensus	B-SO
sequences	I-SO
were	O
found	O
upstream	O
of	O
the	O
Csrp1	B-GGP
transcription	B-SO
start	I-SO
(	O
MRE2	O
to	O
MRE4	O
,	O
-	O
56	O
to	O
-	O
366	O
bp	B-SO
)	O
,	O
one	O
was	O
found	O
immediately	O
downstream	O
(	O
MRE1	O
,	O
+	O
7	O
bp	B-SO
;	O
Figure	O
4b	O
)	O
.	O

Specific	O
binding	O
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
was	O
observed	O
with	O
EMSA	O
for	O
MRE2	O
oligonucleotide	B-SO
and	O
protein	B-CHEBI
extract	O
from	O
an	O
Mtf1loxP	O
liver	O
,	O
but	O
not	O
an	O
Mtf1Mx	O
-	O
cre	O
liver	O
extract	O
lacking	O
MTF	B-GGP
-	I-GGP
1	I-GGP
,	O
confirming	O
the	O
participation	O
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
in	O
the	O
complex	B-GO
(	O
Figure	O
4c	O
)	O
.	O

MTF	B-GGP
-	I-GGP
1	I-GGP
inhibits	O
expression	O
of	O
Slc39a10	B-GGP

Slc39a10	B-GGP
was	O
detected	O
in	O
microarray	O
analysis	O
to	O
be	O
significantly	O
upregulated	O
in	O
livers	O
from	O
both	O
mock	O
-	O
and	O
cadmium	B-CHEBI
-	O
treated	O
Mtf1Mx	O
-	O
cre	O
mice	B-Taxon
compared	O
to	O
control	O
animals	B-Taxon
(	O
Table	O
1	O
,	O
b	O
and	O
d	O
)	O
.	O

SLC39	O
proteins	B-CHEBI
are	O
members	O
of	O
the	O
Zrt	O
-	O
and	O
Irt	O
-	O
like	O
protein	B-CHEBI
(	O
ZIP	O
)	O
family	O
of	O
metal	B-CHEBI
ion	B-CHEBI
transporters	O
that	O
transport	O
,	O
with	O
no	O
known	O
exception	O
,	O
metal	B-CHEBI
ion	B-CHEBI
substrates	O
across	O
cellular	B-GO
membranes	I-GO
into	O
the	O
cytoplasm	B-GO
(	O
43	O
,	O
44	O
)	O
.	O

In	O
accordance	O
with	O
microarray	O
data	O
,	O
semiquantitative	O
RT	O
-	O
PCRs	O
showed	O
a	O
downregulation	O
of	O
Slc39a10	B-GGP
expression	O
in	O
livers	O
of	O
Mtf1loxP	O
mice	B-Taxon
upon	O
cadmium	B-CHEBI
exposure	O
.	O

In	O
samples	O
from	O
Mtf1Mx	O
-	O
cre	O
mice	B-Taxon
,	O
the	O
basal	O
expression	O
was	O
significantly	O
increased	O
;	O
cadmium	B-CHEBI
treatment	O
still	O
resulted	O
in	O
a	O
decrease	O
of	O
Slc39a10	B-GGP
expression	O
(	O
Figure	O
5a	O
)	O
.	O

It	O
cannot	O
be	O
judged	O
by	O
this	O
experiment	O
whether	O
the	O
degree	O
of	O
cadmium	B-CHEBI
-	O
induced	O
reduction	O
of	O
Slc39a10	B-GGP
transcription	O
was	O
identical	O
for	O
Mtf1Mx	O
-	O
cre	O
and	O
Mtf1loxP	O
mice	B-Taxon
or	O
lower	O
in	O
the	O
absence	O
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
.	O

In	O
microarray	O
analysis	O
,	O
the	O
degree	O
of	O
the	O
downregulation	O
was	O
either	O
comparable	O
to	O
the	O
one	O
in	O
control	O
livers	O
or	O
lower	O
,	O
depending	O
on	O
the	O
considered	O
Affymetrix	O
GeneChip	O
(R)	O
probe	B-SO
set	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
results	O
indicate	O
that	O
MTF	B-GGP
-	I-GGP
1	I-GGP
is	O
involved	O
in	O
repression	O
of	O
the	O
basal	O
expression	O
of	O
Slc39a10	B-GGP
.	O

It	O
might	O
also	O
participate	O
in	O
the	O
cadmium	B-CHEBI
response	O
of	O
this	O
gene	B-SO
,	O
but	O
it	O
is	O
apparently	O
not	O
exclusively	O
responsible	O
.	O

One	O
MRE	O
core	O
consensus	B-SO
sequence	I-SO
was	O
found	O
just	O
upstream	O
of	O
the	O
mouse	B-GGP
Slc39a10	I-GGP
transcription	B-SO
start	I-SO
(	O
MRE1	O
,	O
-	O
21	O
bp	B-SO
)	O
,	O
another	O
one	O
directly	O
downstream	O
(	O
MRE2	O
,	O
+	O
17	O
bp	B-SO
;	O
Figure	O
5b	O
)	O
.	O

Specific	O
binding	O
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
was	O
observed	O
in	O
EMSA	O
analysis	O
for	O
MRE2	O
with	O
liver	O
protein	B-CHEBI
extract	O
from	O
an	O
Mtf1loxP	O
but	O
not	O
from	O
an	O
Mtf1Mx	O
-	O
cre	O
mouse	B-Taxon
,	O
while	O
no	O
binding	O
was	O
detected	O
with	O
MRE1	O
(	O
Figure	O
5c	O
)	O
.	O

Cadmium	B-CHEBI
-	O
responsive	O
,	O
MTF	B-GGP
-	I-GGP
1	I-GGP
-	O
independent	O
genes	B-SO

Finally	O
,	O
we	O
also	O
identified	O
a	O
number	O
of	O
cadmium	B-CHEBI
-	O
responsive	O
genes	B-SO
that	O
were	O
independent	O
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
presence	O
,	O
by	O
comparing	O
the	O
probe	B-SO
array	O
data	O
of	O
all	O
cadmium	B-CHEBI
-	O
treated	O
mice	B-Taxon
with	O
the	O
data	O
of	O
all	O
mock	O
-	O
treated	O
mice	B-Taxon
,	O
irrespective	O
of	O
the	O
genotype	B-SO
(	O
Table	O
2	O
)	O
.	O

An	O
at	O
least	O
2	O
-	O
fold	O
,	O
reliable	O
upregulation	O
was	O
observed	O
after	O
cadmium	B-CHEBI
exposure	O
for	O
31	O
probe	B-SO
sets	O
corresponding	O
to	O
21	O
different	O
characterized	O
genes	B-SO
(	O
Table	O
2	O
,	O
a	O
)	O
.	O

For	O
2	O
probe	B-SO
sets	O
corresponding	O
to	O
2	O
characterized	O
genes	B-SO
,	O
an	O
at	O
least	O
2	O
-	O
fold	O
downregulation	O
was	O
detected	O
(	O
Table	O
2	O
,	O
b	O
)	O
.	O

Several	O
genes	B-SO
involved	O
in	O
the	O
metabolism	O
of	O
the	O
antioxidant	B-CHEBI
glutathione	B-CHEBI
were	O
found	O
to	O
be	O
upregulated	O
by	O
cadmium	B-CHEBI
exposure	O
,	O
namely	O
the	O
genes	B-SO
encoding	O
the	O
catalytic	B-GGP
subunit	I-GGP
of	I-GGP
glutamate	I-GGP
-	I-GGP
cysteine	I-GGP
ligase	I-GGP
(	O
Gclc	B-GGP
)	O
that	O
is	O
the	O
rate	O
limiting	O
enzyme	B-SO
in	O
de	O
novo	O
synthesis	O
of	O
glutathione	B-CHEBI
(	O
45	O
)	O
;	O
glutathione	B-GGP
reductase	I-GGP
1	I-GGP
(	O
Gsr	B-GGP
)	O
,	O
the	O
reducing	O
enzyme	B-SO
for	O
oxidized	B-CHEBI
glutathione	I-CHEBI
(	O
45	O
)	O
;	O
and	O
glutathione	B-GGP
-	I-GGP
S	I-GGP
-	I-GGP
transferase	I-GGP
,	I-GGP
mu	I-GGP
4	I-GGP
(	O
Gstm4	B-GGP
)	O
,	O
which	O
is	O
a	O
member	O
of	O
the	O
glutathione	B-CHEBI
-	O
S	B-CHEBI
-	O
transferase	O
supergene	O
family	O
of	O
detoxification	O
enzymes	B-SO
(	O
45	O
)	O
.	O

In	O
all	O
of	O
these	O
cases	O
,	O
induction	O
was	O
confirmed	O
by	O
semiquantitative	O
RT	O
-	O
PCRs	O
(	O
data	O
not	O
shown	O
)	O
.	O

Gclc	B-GGP
,	O
also	O
referred	O
to	O
as	O
heavy	B-GGP
chain	I-GGP
subunit	I-GGP
of	I-GGP
gamma	I-GGP
-	I-GGP
glutamylcysteine	I-GGP
synthetase	I-GGP
(	O
Ggcs	B-GGP
-	I-GGP
hc	I-GGP
)	O
,	O
had	O
been	O
discussed	O
previously	O
as	O
a	O
target	O
gene	B-SO
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
(	O
6	O
)	O
.	O

Our	O
expression	O
data	O
indicate	O
that	O
Gclc	B-GGP
is	O
induced	O
by	O
cadmium	B-CHEBI
but	O
,	O
at	O
least	O
in	O
the	O
adult	O
mouse	B-Taxon
liver	O
,	O
not	O
dependent	O
on	O
MTF	B-GGP
-	I-GGP
1	I-GGP
.	O

To	O
analyze	O
the	O
role	O
of	O
the	O
glutathione	B-CHEBI
system	O
in	O
the	O
cellular	B-CL
cadmium	B-CHEBI
response	O
,	O
mouse	B-Taxon
embryonic	O
fibroblasts	B-CL
with	O
and	O
without	O
functional	O
Mtf1	B-GGP
were	O
treated	O
with	O
cadmium	B-CHEBI
in	O
combination	O
with	O
BSO	O
,	O
a	O
specific	O
inhibitor	B-CHEBI
of	O
glutamate	B-CHEBI
-	O
cysteine	B-CHEBI
ligase	O
(	O
31	O
)	O
,	O
and	O
cell	B-CL
viability	O
was	O
assessed	O
by	O
a	O
colorimetric	O
assay	O
based	O
on	O
the	O
tetrazolium	O
salt	B-CHEBI
MTT	O
(	O
Figure	O
6	O
)	O
.	O

Increasing	O
concentrations	O
of	O
BSO	O
or	O
cadmium	B-CHEBI
alone	O
were	O
to	O
some	O
extent	O
cytotoxic	O
for	O
the	O
examined	O
cell	B-CL
lines	O
.	O

Treatment	O
with	O
both	O
BSO	O
and	O
cadmium	B-CHEBI
resulted	O
in	O
an	O
enhanced	O
lethality	O
particularly	O
for	O
the	O
cells	B-CL
without	O
functional	O
Mtf1	B-GGP
,	O
indicating	O
that	O
a	O
depletion	O
of	O
glutathione	B-CHEBI
together	O
with	O
a	O
lack	O
of	O
Mtf1	B-GGP
impair	O
an	O
efficient	O
anti	O
-	O
cadmium	B-CHEBI
defense	O
.	O

Thus	O
,	O
adequate	O
glutathione	B-CHEBI
supply	O
as	O
well	O
as	O
MTF	B-GGP
-	I-GGP
1	I-GGP
and	O
its	O
target	O
genes	B-SO
are	O
essential	O
for	O
the	O
survival	O
of	O
the	O
cell	B-CL
under	O
cadmium	B-CHEBI
stress	O
.	O

Besides	O
genes	B-SO
related	O
to	O
the	O
glutathione	B-CHEBI
pathway	O
,	O
several	O
other	O
stress	O
-	O
related	O
genes	B-SO
were	O
upregulated	O
upon	O
cadmium	B-CHEBI
exposure	O
,	O
including	O
genes	B-GGP
for	I-GGP
thioredoxin	I-GGP
reductase	I-GGP
1	I-GGP
(	O
Txnrd1	B-GGP
)	O
,	O
one	O
of	O
the	O
reducing	O
enzymes	B-SO
of	O
the	O
antioxidant	B-CHEBI
thioredoxin	B-CHEBI
(	O
46	O
)	O
;	O
KDEL	B-GGP
endoplasmic	I-GGP
reticulum	I-GGP
protein	I-GGP
retention	I-GGP
receptor	I-GGP
2	I-GGP
(	O
Kdelr2	B-GGP
)	O
participating	O
in	O
ER	B-GO
stress	O
response	O
(	O
47	O
)	O
;	O
and	O
the	O
anti	O
-	O
apoptotic	O
Bcl2	B-GGP
-	I-GGP
associated	I-GGP
athanogene	I-GGP
3	I-GGP
(	O
Bag3	B-GGP
)	O
involved	O
in	O
stress	O
-	O
induced	O
apoptosis	O
(	O
48	O
)	O
.	O

DISCUSSION	O

In	O
this	O
study	O
,	O
a	O
virtually	O
complete	O
deletion	B-SO
of	O
Mtf1	B-GGP
in	O
the	O
liver	O
of	O
adult	O
,	O
pI	O
-	O
pC	O
-	O
induced	O
Mtf1Mx	O
-	O
cre	O
mice	B-Taxon
did	O
not	O
detectably	O
affect	O
the	O
phenotype	O
of	O
the	O
respective	O
mice	B-Taxon
under	O
non	O
-	O
stress	O
conditions	O
,	O
confirming	O
that	O
MTF	B-GGP
-	I-GGP
1	I-GGP
is	O
dispensable	O
in	O
the	O
adult	O
liver	O
(	O
26	O
)	O
,	O
in	O
contrast	O
to	O
its	O
essential	O
role	O
in	O
embryonic	O
liver	O
development	O
(	O
23	O
)	O
.	O

The	O
comparison	O
of	O
gene	B-SO
expression	O
in	O
livers	O
of	O
mock	O
-	O
or	O
cadmium	B-CHEBI
-	O
treated	O
Mtf1Mx	O
-	O
cre	O
and	O
Mtf1loxP	O
mice	B-Taxon
revealed	O
several	O
MTF	B-GGP
-	I-GGP
1	I-GGP
target	O
gene	B-SO
candidates	O
.	O

Transcripts	B-SO
of	O
the	O
two	O
stress	O
-	O
responsive	O
metallothionein	O
genes	B-SO
Mt1	B-GGP
and	O
Mt2	B-GGP
were	O
severely	O
reduced	O
,	O
in	O
support	O
of	O
a	O
crucial	O
role	O
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
for	O
both	O
basal	O
and	O
metal	B-CHEBI
-	O
induced	O
expression	O
of	O
metallothioneins	O
(	O
4	O
,	O
6	O
)	O
.	O

One	O
of	O
the	O
newly	O
found	O
target	O
genes	B-SO
is	O
Sepw1	B-GGP
.	O

The	O
exact	O
molecular	B-CHEBI
function	O
of	O
SEPW1	B-GGP
protein	B-CHEBI
is	O
unknown	O
to	O
date	O
,	O
but	O
a	O
role	O
as	O
antioxidant	B-CHEBI
has	O
been	O
proposed	O
due	O
to	O
its	O
ability	O
to	O
bind	O
glutathione	B-CHEBI
(	O
35	O
)	O
.	O

In	O
accordance	O
with	O
this	O
,	O
ectopic	O
expression	O
of	O
mouse	B-GGP
Sepw1	I-GGP
renders	O
cells	B-CL
resistant	O
to	O
hydrogen	B-CHEBI
peroxide	I-CHEBI
,	O
and	O
this	O
resistance	O
is	O
dependent	O
on	O
it	O
binding	O
glutathione	B-CHEBI
(	O
36	O
)	O
.	O

Furthermore	O
,	O
Amantana	O
et	O
al	O
.	O

(	O
49	O
)	O
showed	O
that	O
expression	O
of	O
a	O
reporter	O
gene	B-SO
fused	O
to	O
a	O
rat	B-GGP
Sepw1	I-GGP
promoter	B-SO
fragment	B-SO
can	O
be	O
induced	O
in	O
rat	B-Taxon
glial	B-CL
cells	I-CL
by	O
copper	B-CHEBI
and	O
zinc	B-CHEBI
,	O
but	O
not	O
cadmium	B-CHEBI
.	O

This	O
response	O
was	O
dependent	O
on	O
an	O
overlapping	B-SO
-	O
inverted	B-SO
MRE	I-SO
sequence	I-SO
located	O
proximal	O
to	O
the	O
rat	B-GGP
Sepw1	I-GGP
transcription	B-SO
start	I-SO
(	O
49	O
)	O
,	O
even	O
though	O
initial	O
studies	O
failed	O
to	O
demonstrate	O
MTF	B-GGP
-	I-GGP
1	I-GGP
binding	O
to	O
that	O
sequence	B-SO
(	O
50	O
)	O
.	O

Our	O
expression	O
and	O
DNA	B-SO
-	O
binding	O
studies	O
strongly	O
suggest	O
that	O
MTF	B-GGP
-	I-GGP
1	I-GGP
is	O
important	O
for	O
the	O
basal	O
expression	O
of	O
mouse	B-GGP
Sepw1	I-GGP
by	O
binding	O
to	O
the	O
corresponding	O
overlapping	B-SO
-	O
inverted	B-SO
MRE	I-SO
sequence	I-SO
.	O

Ndrg1	B-GGP
,	O
another	O
interesting	O
MTF	B-GGP
-	I-GGP
1	I-GGP
target	O
gene	B-SO
was	O
named	O
N	B-GGP
-	I-GGP
myc	I-GGP
downstream	I-GGP
regulated	I-GGP
gene	I-GGP
1	I-GGP
following	O
the	O
discovery	O
that	O
the	O
transcription	O
factor	O
N	B-GGP
-	I-GGP
myc	I-GGP
represses	O
the	O
expression	O
of	O
mouse	B-GGP
Ndrg1	I-GGP
(	O
51	O
)	O
.	O

Transcription	O
of	O
Ndrg1	B-GGP
and	O
/	O
or	O
its	O
human	B-Taxon
ortholog	B-SO
is	O
induced	O
by	O
different	O
physiological	O
and	O
cell	B-CL
stress	O
conditions	O
,	O
such	O
as	O
androgens	O
,	O
nickel	B-CHEBI
compounds	B-CHEBI
,	O
DNA	B-SO
damage	O
and	O
hypoxia	O
(	O
37	O
-	O
40	O
,	O
52	O
,	O
53	O
)	O
.	O

In	O
addition	O
,	O
the	O
protein	B-CHEBI
is	O
overexpressed	O
in	O
human	B-Taxon
cancers	O
of	O
many	O
tissues	O
,	O
such	O
as	O
lung	O
,	O
liver	O
,	O
brain	O
,	O
breast	O
,	O
kidney	O
and	O
skin	O
(	O
40	O
)	O
.	O

Although	O
Ndrg1	B-GGP
and	O
especially	O
its	O
human	B-Taxon
ortholog	B-SO
have	O
been	O
quite	O
intensely	O
studied	O
,	O
its	O
function	O
remains	O
unclear	O
;	O
however	O
,	O
the	O
induction	O
by	O
stimuli	O
like	O
nickel	B-CHEBI
and	O
hypoxia	O
suggests	O
an	O
involvement	O
in	O
the	O
cell	B-CL
stress	O
response	O
.	O

Such	O
a	O
role	O
is	O
strongly	O
endorsed	O
by	O
our	O
finding	O
that	O
Ndrg1	B-GGP
gene	B-SO
expression	O
is	O
also	O
induced	O
by	O
cadmium	B-CHEBI
,	O
and	O
that	O
MTF	B-GGP
-	I-GGP
1	I-GGP
plays	O
a	O
crucial	O
role	O
in	O
this	O
induction	O
.	O

In	O
the	O
case	O
of	O
Csrp1	B-GGP
,	O
expression	O
analyses	O
and	O
DNA	B-SO
-	O
binding	O
studies	O
indicate	O
that	O
MTF	B-GGP
-	I-GGP
1	I-GGP
is	O
required	O
for	O
cadmium	B-CHEBI
induction	O
by	O
binding	O
to	O
an	O
MRE	O
upstream	O
of	O
the	O
transcription	B-SO
start	I-SO
.	O

Studies	O
with	O
human	B-GGP
,	I-GGP
avian	I-GGP
and	I-GGP
chicken	I-GGP
CSRP1	I-GGP
have	O
shown	O
that	O
this	O
protein	B-CHEBI
is	O
localized	O
at	O
adhesion	B-GO
plaques	I-GO
and	O
in	O
association	O
with	O
filamentous	B-GO
actin	I-GO
,	O
and	O
interacts	O
with	O
the	O
adhesion	B-GO
plaque	I-GO
protein	B-CHEBI
zyxin	B-GGP
,	O
as	O
well	O
as	O
the	O
actin	O
-	O
cross	O
-	O
linking	O
protein	B-CHEBI
alpha	O
-	O
actinin	O
(	O
54	O
-	O
57	O
)	O
.	O

The	O
ability	O
to	O
bind	O
these	O
partners	O
suggests	O
a	O
role	O
in	O
cytoskeletal	B-GO
organization	O
(	O
58	O
)	O
.	O

Exposure	O
of	O
cultured	O
cells	B-CL
to	O
cadmium	B-CHEBI
causes	O
a	O
decrease	O
in	O
,	O
and	O
destruction	O
of	O
,	O
cellular	B-CL
contact	O
proteins	B-CHEBI
and	O
the	O
actin	B-GO
cytoskeleton	I-GO
(	O
59	O
)	O
.	O

In	O
the	O
proximal	O
tubule	O
cells	B-CL
of	O
the	O
rat	B-Taxon
kidney	O
,	O
a	O
partial	O
loss	O
of	O
actin	O
and	O
the	O
actin	O
-	O
bundling	O
protein	B-CHEBI
villin	B-GGP
is	O
observed	O
upon	O
cadmium	B-CHEBI
treatment	O
,	O
as	O
well	O
as	O
the	O
derangement	O
and	O
depolymerization	O
of	O
microtubules	B-GO
(	O
60	O
)	O
.	O

Assuming	O
that	O
CSRP1	B-GGP
is	O
important	O
for	O
the	O
organization	O
of	O
cytoskeletal	B-GO
elements	I-GO
in	O
the	O
mouse	B-Taxon
,	O
its	O
upregulation	O
by	O
cadmium	B-CHEBI
might	O
protect	O
the	O
organism	B-Taxon
from	O
damage	O
of	O
the	O
cytoskeleton	B-GO
.	O

Such	O
a	O
mechanism	O
would	O
expand	O
the	O
role	O
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
in	O
stress	O
response	O
.	O

Our	O
expression	O
studies	O
also	O
suggest	O
that	O
MTF	B-GGP
-	I-GGP
1	I-GGP
represses	O
basal	O
transcription	O
of	O
Slc39a10	B-GGP
,	O
in	O
contrast	O
to	O
its	O
role	O
as	O
activator	O
for	O
the	O
expression	O
of	O
other	O
target	O
genes	B-SO
like	O
Mt1	B-GGP
,	O
Mt2	B-GGP
,	O
and	O
Znt1	B-GGP
(	O
4	O
,	O
19	O
)	O
.	O

SLC39A10	B-GGP
is	O
one	O
of	O
14	O
mouse	B-Taxon
SLC39	O
members	O
,	O
which	O
belong	O
to	O
the	O
ZIP	O
family	O
of	O
metal	B-CHEBI
ion	B-CHEBI
transporters	O
(	O
43	O
,	O
44	O
)	O
.	O

All	O
members	O
of	O
the	O
ZIP	O
family	O
characterized	O
so	O
far	O
increase	O
intracellular	B-GO
cytoplasmic	B-GO
metal	B-CHEBI
ion	B-CHEBI
concentrations	O
by	O
promoting	O
extracellular	B-GO
and	O
vesicular	B-GO
ion	B-CHEBI
transport	O
into	O
the	O
cytoplasm	B-GO
.	O

ZIP	O
proteins	B-CHEBI
have	O
been	O
reported	O
to	O
be	O
transporters	O
of	O
zinc	B-CHEBI
,	O
iron	B-CHEBI
,	O
manganese	B-CHEBI
and	O
/	O
or	O
cadmium	B-CHEBI
(	O
44	O
,	O
61	O
-	O
63	O
)	O
.	O

Although	O
SLC39A10	B-GGP
is	O
largely	O
uncharacterized	O
(	O
44	O
)	O
,	O
it	O
is	O
referred	O
to	O
in	O
several	O
databases	O
as	O
putative	O
zinc	B-CHEBI
transporter	O
.	O

It	O
has	O
been	O
previously	O
shown	O
that	O
MTF	B-GGP
-	I-GGP
1	I-GGP
is	O
important	O
for	O
both	O
basal	O
expression	O
and	O
metal	B-CHEBI
induction	O
of	O
the	O
mouse	B-GGP
Znt1	I-GGP
gene	B-SO
(	O
19	O
)	O
.	O

ZnT	O
proteins	B-CHEBI
represent	O
a	O
different	O
family	O
of	O
transporters	O
that	O
reduce	O
intracellular	B-GO
cytoplasmic	B-GO
zinc	B-CHEBI
by	O
promoting	O
zinc	B-CHEBI
efflux	O
from	O
cells	B-CL
or	O
into	O
intracellular	B-GO
vesicles	B-GO
.	O

Thus	O
,	O
members	O
of	O
the	O
ZnT	O
and	O
ZIP	O
family	O
with	O
zinc	B-CHEBI
as	O
predominant	O
substrate	O
have	O
opposite	O
roles	O
in	O
cellular	B-CL
zinc	B-CHEBI
homeostasis	O
(	O
43	O
)	O
.	O

Assuming	O
that	O
SLC39A10	B-GGP
is	O
indeed	O
a	O
zinc	B-CHEBI
transporter	O
,	O
MTF	B-GGP
-	I-GGP
1	I-GGP
would	O
control	O
expression	O
of	O
two	O
zinc	B-CHEBI
transporters	O
with	O
antagonistic	O
functions	O
,	O
namely	O
,	O
Znt1	B-GGP
and	O
Slc39a10	B-GGP
.	O

Specific	O
binding	O
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
was	O
observed	O
for	O
an	O
MRE	O
located	O
just	O
downstream	O
of	O
the	O
Slc39a10	B-GGP
transcription	B-SO
start	I-SO
.	O

In	O
a	O
simple	O
model	O
,	O
such	O
a	O
binding	O
could	O
interfere	O
with	O
the	O
accessibility	O
of	O
the	O
transcriptional	B-SO
start	I-SO
site	I-SO
for	O
RNA	B-GO
polymerase	I-GO
II	I-GO
and	O
/	O
or	O
general	O
transcription	O
factors	O
,	O
thus	O
preventing	O
transcription	O
initiation	O
of	O
the	O
gene	B-SO
.	O

Indeed	O
,	O
such	O
a	O
mechanism	O
has	O
been	O
described	O
in	O
yeast	B-Taxon
for	O
the	O
zinc	B-GGP
-	I-GGP
responsive	I-GGP
activator	I-GGP
protein	I-GGP
1	I-GGP
(	O
Zap1	B-GGP
)	O
and	O
its	O
target	O
gene	B-SO
,	O
zinc	B-GGP
-	I-GGP
regulated	I-GGP
transporter	I-GGP
2	I-GGP
(	O
ZRT2	B-GGP
)	O
(	O
64	O
)	O
.	O

However	O
,	O
the	O
inhibition	O
of	O
Slc39a10	B-GGP
expression	O
by	O
MTF	B-GGP
-	I-GGP
1	I-GGP
may	O
well	O
be	O
more	O
complex	O
than	O
a	O
competition	O
for	O
promoter	B-SO
binding	O
.	O

Independent	O
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
,	O
cadmium	B-CHEBI
treatment	O
also	O
leads	O
to	O
downregulation	O
of	O
Slc39a10	B-GGP
transcripts	B-SO
,	O
suggesting	O
that	O
some	O
other	O
factor	O
is	O
mediating	O
this	O
response	O
.	O

A	O
previous	O
target	O
gene	B-SO
search	O
for	O
MTF	B-GGP
-	I-GGP
1	I-GGP
with	O
mouse	B-Taxon
embryos	O
of	O
conventional	O
Mtf1	B-GGP
knockout	O
phenotype	O
revealed	O
,	O
besides	O
metallothionein	O
genes	B-SO
,	O
the	O
multifunctional	O
alpha	B-GGP
-	I-GGP
fetoprotein	I-GGP
(	O
Afp	B-GGP
)	O
and	O
the	O
liver	O
-	O
enriched	O
transcription	O
factor	O
CCAAT	B-GGP
/	I-GGP
enhancer	I-GGP
binding	I-GGP
protein	I-GGP
alpha	I-GGP
(	O
Cebpa	B-GGP
)	O
as	O
prime	O
candidates	O
(	O
65	O
)	O
.	O

After	O
an	O
early	O
onset	O
during	O
hepatogenesis	O
,	O
Afp	B-GGP
expression	O
is	O
repressed	O
postnatally	O
and	O
replaced	O
by	O
albumin	B-GGP
(	O
66	O
)	O
.	O

Thus	O
,	O
our	O
adult	O
Mtf1Mx	O
-	O
cre	O
mice	B-Taxon
lacking	O
MTF	B-GGP
-	I-GGP
1	I-GGP
were	O
not	O
suitable	O
to	O
analyze	O
Afp	B-GGP
expression	O
.	O

Cebpa	B-GGP
is	O
expressed	O
in	O
the	O
adult	O
liver	O
as	O
well	O
as	O
in	O
other	O
tissues	O
(	O
67	O
)	O
,	O
but	O
the	O
present	O
microarray	O
data	O
revealed	O
no	O
significant	O
expression	O
differences	O
in	O
livers	O
from	O
adult	O
Mtf1loxP	O
and	O
Mtf1Mx	O
-	O
cre	O
mice	B-Taxon
(	O
data	O
not	O
shown	O
)	O
.	O

Therefore	O
,	O
MTF	B-GGP
-	I-GGP
1	I-GGP
may	O
affect	O
Cebpa	B-GGP
expression	O
only	O
during	O
embryonal	O
development	O
,	O
perhaps	O
in	O
combination	O
with	O
as	O
yet	O
unidentified	O
factors	O
.	O

The	O
present	O
study	O
confirms	O
and	O
extends	O
the	O
role	O
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
as	O
an	O
important	O
stress	O
response	O
regulator	O
.	O

We	O
have	O
identified	O
and	O
preliminarily	O
characterized	O
four	O
target	O
genes	B-SO
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
in	O
the	O
adult	O
mouse	B-Taxon
liver	O
:	O
in	O
the	O
case	O
of	O
Sepw1	B-GGP
,	O
MTF	B-GGP
-	I-GGP
1	I-GGP
is	O
required	O
to	O
maintain	O
basal	O
expression	O
,	O
supporting	O
a	O
role	O
of	O
mouse	B-GGP
MTF	I-GGP
-	I-GGP
1	I-GGP
in	O
oxidative	O
stress	O
response	O
.	O

In	O
addition	O
,	O
MTF	B-GGP
-	I-GGP
1	I-GGP
contributes	O
to	O
the	O
cadmium	B-CHEBI
-	O
induced	O
expression	O
of	O
Ndrg1	B-GGP
and	O
Csrp1	B-GGP
.	O

Furthermore	O
,	O
MTF	B-GGP
-	I-GGP
1	I-GGP
helps	O
to	O
repress	O
the	O
basal	O
expression	O
of	O
Slc39a10	B-GGP
,	O
in	O
contrast	O
to	O
its	O
role	O
as	O
transcriptional	O
activator	O
for	O
genes	B-SO
like	O
Mt1	B-GGP
,	O
Mt2	B-GGP
or	O
Znt1	B-GGP
.	O

Thus	O
the	O
same	O
transcription	O
factor	O
apparently	O
serves	O
as	O
an	O
activator	O
or	O
repressor	O
,	O
depending	O
on	O
the	O
target	O
gene	B-SO
.	O

The	O
comparison	O
of	O
liver	O
gene	B-SO
expression	O
of	O
cadmium	B-CHEBI
-	O
and	O
mock	O
-	O
treated	O
mice	B-Taxon
also	O
revealed	O
a	O
number	O
of	O
genes	B-SO
that	O
were	O
responsive	O
to	O
cadmium	B-CHEBI
exposure	O
,	O
independent	O
of	O
the	O
presence	O
or	O
absence	O
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
.	O

Evidence	O
suggests	O
that	O
the	O
production	O
of	O
reactive	B-CHEBI
oxygen	I-CHEBI
species	I-CHEBI
is	O
a	O
major	O
effect	O
of	O
acute	O
cadmium	B-CHEBI
toxicity	O
(	O
68	O
,	O
69	O
)	O
,	O
and	O
exposure	O
of	O
cultured	O
cells	B-CL
or	O
animals	B-Taxon
to	O
cadmium	B-CHEBI
is	O
associated	O
with	O
depletion	O
of	O
reduced	B-CHEBI
glutathione	I-CHEBI
,	O
lipid	B-CHEBI
peroxidation	O
and	O
DNA	B-SO
damage	O
(	O
70	O
-	O
73	O
)	O
.	O

Oxidative	O
stress	O
and	O
the	O
subsequent	O
restoration	O
of	O
cellular	B-CL
homeostasis	O
have	O
been	O
shown	O
to	O
induce	O
the	O
expression	O
of	O
genes	B-SO
encoding	O
acute	O
-	O
phase	O
proteins	B-CHEBI
and	O
antioxidant	B-CHEBI
enzymes	B-SO
(	O
74	O
)	O
.	O

In	O
mammals	B-Taxon
,	O
cadmium	B-CHEBI
tends	O
to	O
accumulate	O
in	O
the	O
kidney	O
and	O
liver	O
as	O
a	O
cadmium	B-CHEBI
-	O
metallothionein	O
complex	O
that	O
has	O
an	O
extremely	O
slow	O
turnover	O
(	O
75	O
,	O
76	O
)	O
.	O

Furthermore	O
,	O
metallothioneins	O
provide	O
protection	O
against	O
oxidative	O
stress	O
(	O
1	O
,	O
17	O
)	O
.	O

In	O
addition	O
to	O
metallothioneins	O
,	O
glutathione	B-CHEBI
was	O
postulated	O
as	O
a	O
first	O
line	O
of	O
defense	O
against	O
cadmium	B-CHEBI
toxicity	O
(	O
77	O
)	O
.	O

Glutathione	B-CHEBI
efficiently	O
complexes	O
cadmium	B-CHEBI
(	O
78	O
)	O
and	O
scavenges	O
free	B-CHEBI
radicals	I-CHEBI
and	O
other	O
reactive	B-CHEBI
oxygen	I-CHEBI
species	I-CHEBI
directly	O
,	O
and	O
indirectly	O
via	O
enzymatic	B-SO
reactions	O
(	O
45	O
)	O
.	O

In	O
such	O
reactions	O
,	O
glutathione	B-CHEBI
is	O
oxidized	O
and	O
has	O
to	O
be	O
regenerated	O
by	O
glutathione	B-GGP
reductase	I-GGP
.	O

Also	O
,	O
glutathione	B-GGP
-	I-GGP
S	I-GGP
-	I-GGP
transferases	I-GGP
mediate	O
the	O
conjugation	O
of	O
various	O
electrophiles	O
to	O
glutathione	B-CHEBI
.	O

The	O
observed	O
cadmium	B-CHEBI
-	O
induced	O
upregulation	O
of	O
Gclc	B-GGP
,	O
Gsr	B-GGP
and	O
Gstm4	B-GGP
supports	O
the	O
importance	O
of	O
glutathione	B-CHEBI
in	O
the	O
cellular	B-CL
cadmium	B-CHEBI
response	O
.	O

The	O
enhanced	O
sensitivity	O
to	O
cadmium	B-CHEBI
toxicity	O
that	O
we	O
found	O
for	O
mouse	B-Taxon
embryonic	O
fibroblasts	B-CL
upon	O
a	O
combination	O
of	O
Mtf1	B-GGP
deletion	B-SO
and	O
depletion	O
of	O
glutathione	B-CHEBI
further	O
corroborates	O
the	O
importance	O
of	O
MTF	B-GGP
-	I-GGP
1	I-GGP
and	O
its	O
target	O
genes	B-SO
as	O
well	O
as	O
reduced	B-CHEBI
glutathione	I-CHEBI
for	O
an	O
efficient	O
anti	O
-	O
cadmium	B-CHEBI
defense	O
.	O

Our	O
data	O
provide	O
strong	O
evidence	O
for	O
at	O
least	O
two	O
branches	O
of	O
cellular	B-CL
anti	O
-	O
cadmium	B-CHEBI
defense	O
,	O
one	O
via	O
MTF	B-GGP
-	I-GGP
1	I-GGP
and	O
its	O
target	O
genes	B-SO
,	O
notably	O
metallothioneins	O
,	O
the	O
other	O
via	O
glutathione	B-CHEBI
,	O
with	O
an	O
apparent	O
overlap	O
in	O
Sepw1	B-GGP
.	O

SUPPLEMENTARY	O
DATA	O

Supplementary	O
data	O
are	O
available	O
at	O
NAR	O
online	O
.	O

Supplementary	O
Material	O

[	O
Supplementary	O
Material	O
]	O

Acknowledgements	O

We	O
are	O
indebted	O
to	O
the	O
Functional	O
Genomics	O
Center	O
Zurich	O
(	O
Zurich	O
,	O
CH	O
)	O
for	O
financial	O
as	O
well	O
as	O
technical	O
support	O
(	O
thanks	O
especially	O
to	O
Andrea	O
Patrignani	O
,	O
Dr	O
Ulrich	O
Wagner	O
,	O
and	O
Dr	O
Hubert	O
Rehrauer	O
for	O
their	O
assistance	O
in	O
data	O
generation	O
and	O
evaluation	O
)	O
,	O
and	O
to	O
Dr	O
Michael	O
Leviten	O
(	O
San	O
Carlos	O
,	O
CA	O
)	O
for	O
the	O
help	O
in	O
generating	O
Mtf1	B-GGP
conditional	O
knockout	O
mice	B-Taxon
.	O

We	O
also	O
thank	O
Prof	O
.	O

Ueli	O
Schibler	O
(	O
Geneva	O
,	O
CH	O
)	O
for	O
his	O
advice	O
on	O
the	O
ADDER	O
technique	O
,	O
Prof	O
.	O

Michel	O
Aguet	O
(	O
Epalinges	O
-	O
Lausanne	O
,	O
CH	O
)	O
for	O
the	O
gift	O
of	O
Mx	B-GGP
-	O
Cre	O
mice	B-Taxon
,	O
Dr	O
George	O
Hausmann	O
and	O
Dr	O
Michael	O
Fetchko	O
for	O
critical	O
reading	O
of	O
the	O
manuscript	O
,	O
and	O
Fritz	O
Ochsenbein	O
for	O
preparing	O
the	O
figures	O
.	O

Funding	O
to	O
pay	O
the	O
Open	O
Access	O
publication	O
charges	O
for	O
this	O
article	O
was	O
provided	O
by	O
the	O
Kanton	O
Zurich	O
.	O

Conflict	O
of	O
interest	O
statement	O
.	O

None	O
declared	O
.	O

Figures	O
and	O
Tables	O

Figure	O
1	O

Deletion	B-SO
of	O
Mtf1	B-GGP
in	O
adult	O
mouse	B-Taxon
liver	O
.	O

(	O
a	O
)	O
Generation	O
of	O
Mtf1	B-GGP
conditional	O
knockout	O
mice	B-Taxon
.	O

The	O
targeted	O
allele	B-SO
was	O
obtained	O
by	O
homologous	O
recombination	O
of	O
wild	B-SO
-	I-SO
type	I-SO
(	O
wt	B-SO
)	O
allele	B-SO
and	O
targeting	O
vector	B-SO
in	O
ES	O
cells	B-CL
.	O

Removal	B-SO
of	O
the	O
neomycin	O
cassette	B-SO
(	O
NEO	O
)	O
by	O
Cre	O
recombinase	O
led	O
to	O
the	O
conditional	O
knockout	O
allele	B-SO
Mtf1loxP	O
.	O

Conditional	O
Cre	O
-	O
mediated	O
deletion	B-SO
of	O
exons	B-SO
3	O
and	O
4	O
(	O
Mtf1	O
Delta	O
)	O
results	O
in	O
loss	O
of	O
function	O
via	O
loss	B-SO
of	O
an	O
essential	O
part	B-SO
of	O
the	O
DNA	B-SO
-	O
binding	O
domain	B-SO
and	O
the	O
generation	O
of	O
a	O
new	O
stop	B-SO
codon	I-SO
right	O
after	O
exon	B-SO
2	O
.	O

Exons	B-SO
3	O
to	O
7	O
of	O
Mtf1	B-GGP
are	O
indicated	O
by	O
grey	O
boxes	O
,	O
loxP	B-SO
sites	I-SO
by	O
black	O
triangles	O
.	O

TK	O
,	O
thymidine	B-CHEBI
kinase	O
cassette	B-SO
.	O

Restriction	O
enzymes	B-SO
:	O
San	O
,	O
SanDI	O
;	O
B	O
,	O
BbvCI	O
;	O
S	O
,	O
SrfI	O
;	O
H	O
,	O
HpaI	O
.	O

The	O
HpaI	O
site	B-SO
indicated	O
by	O
the	O
crossed	O
H	O
was	O
lost	B-SO
during	O
the	O
cloning	O
procedure	O
for	O
the	O
targeting	O
vector	B-SO
.	O

(	O
b	O
)	O
RT	O
-	O
PCRs	O
with	O
total	O
liver	O
RNA	B-SO
from	O
pI	O
-	O
pC	O
-	O
induced	O
male	O
Mtf1Mx	O
-	O
cre	O
or	O
Mtf1loxP	O
mice	B-Taxon
.	O

The	O
used	O
primer	B-SO
pair	O
results	O
in	O
products	B-SO
of	O
589	O
bp	B-SO
and	O
218	O
bp	B-SO
with	O
full	O
-	O
length	O
mRNA	B-CHEBI
and	O
mRNA	B-CHEBI
without	O
exons	B-SO
3	O
and	O
4	O
,	O
respectively	O
.	O

(	O
c	O
)	O
EMSA	O
with	O
liver	O
protein	B-CHEBI
extract	O
of	O
a	O
pI	O
-	O
pC	O
-	O
induced	O
male	O
Mtf1Mx	O
-	O
cre	O
or	O
Mtf1loxP	O
mouse	B-Taxon
.	O

MTF	B-GGP
-	I-GGP
1	I-GGP
protein	B-GO
-	I-GO
DNA	I-GO
complex	I-GO
formation	O
was	O
tested	O
with	O
32P	B-CHEBI
-	O
labeled	O
MRE	O
consensus	B-SO
oligonucleotide	B-SO
MRE	O
-	O
s	O
.	O

Specificity	O
of	O
binding	O
was	O
verified	O
with	O
excess	O
of	O
unlabeled	O
competitor	O
MREd	O
or	O
unrelated	O
Gal4	O
oligonucleotide	B-SO
;	O
Sp1	B-GGP
bandshifts	O
with	O
32P	B-CHEBI
-	O
labeled	O
Sp1	B-GGP
consensus	B-SO
oligonucleotide	B-SO
were	O
included	O
as	O
a	O
loading	O
control	O
.	O

Figure	O
2	O

Sepw1	B-GGP
basal	O
expression	O
depends	O
on	O
MTF	B-GGP
-	I-GGP
1	I-GGP
.	O

(	O
a	O
)	O
Semiquantitative	O
RT	O
-	O
PCRs	O
for	O
Sepw1	B-GGP
mRNA	B-CHEBI
using	O
total	O
liver	O
RNA	B-SO
from	O
pI	O
-	O
pC	O
-	O
induced	O
male	O
Mtf1Mx	O
-	O
cre	O
or	O
Mtf1loxP	O
mice	B-Taxon
.	O

The	O
animals	B-Taxon
had	O
obtained	O
either	O
mock	O
s	O
.	O
c	O
.	O
injections	O
(	O
-	O
Cd	B-CHEBI
)	O
or	O
s	O
.	O
c	O
.	O
injections	O
with	O
20	O
micro	O
mol	O
/	O
kg	O
body	O
weight	O
CdSO4	O
(	O
+	O
Cd	B-CHEBI
)	O
6	O
h	O
before	O
sacrificing	O
them	O
.	O

RT	O
-	O
PCRs	O
for	O
Hprt	B-GGP
mRNA	B-CHEBI
were	O
used	O
as	O
internal	O
control	O
to	O
adjust	O
the	O
amount	O
of	O
total	O
RNA	B-SO
used	O
.	O

(	O
b	O
)	O
S1	O
analysis	O
for	O
Sepw1	B-GGP
mRNA	B-CHEBI
with	O
RNA	B-SO
described	O
in	O
(	O
a	O
)	O
,	O
using	O
a	O
32P	B-CHEBI
-	O
labeled	O
Sepw1	B-GGP
S1	O
probe	B-SO
.	O

A	O
32P	B-CHEBI
-	O
labeled	O
S1	O
probe	B-SO
for	O
Hprt	B-GGP
mRNA	B-CHEBI
was	O
used	O
to	O
adjust	O
the	O
amount	O
of	O
RNA	B-SO
used	O
.	O

(	O
c	O
)	O
MRE	O
core	O
consensus	B-SO
sequences	I-SO
TGCRCNC	O
(	O
bold	O
letters	O
)	O
and	O
flanking	B-SO
sequences	I-SO
found	O
in	O
a	O
region	B-SO
of	O
1000	O
bp	B-SO
upstream	O
from	O
Sepw1	B-GGP
transcription	B-SO
start	I-SO
;	O
the	O
position	B-SO
of	I-SO
each	I-SO
core	I-SO
sequence	I-SO
is	O
indicated	O
.	O

(	O
d	O
)	O
EMSA	O
with	O
liver	O
protein	B-CHEBI
extracts	O
of	O
a	O
male	O
Mtf1loxP	O
or	O
a	O
pI	O
-	O
pC	O
-	O
induced	O
,	O
male	O
Mtf1Mx	O
-	O
cre	O
mouse	B-Taxon
,	O
both	O
mock	O
-	O
treated	O
.	O

MTF	B-GGP
-	I-GGP
1	I-GGP
protein	B-GO
-	I-GO
DNA	I-GO
complex	I-GO
formation	O
was	O
tested	O
with	O
32P	B-CHEBI
-	O
labeled	O
Sepw1	B-GGP
MRE1	O
or	O
MRE2	O
oligonucleotide	B-SO
,	O
respectively	O
.	O

Specificity	O
of	O
binding	O
was	O
verified	O
with	O
excess	O
of	O
unlabeled	O
competitor	O
MREd	O
or	O
unrelated	O
Gal4	O
oligonucleotide	B-SO
.	O

32P	B-CHEBI
-	O
labeled	O
MRE	O
-	O
s	O
was	O
included	O
to	O
indicate	O
the	O
position	O
of	O
an	O
MTF	B-GGP
-	I-GGP
1	I-GGP
-	O
DNA	B-SO
complex	B-GO
;	O
bandshifts	O
for	O
the	O
common	O
transcription	O
factor	O
Sp1	B-GGP
with	O
32P	B-CHEBI
-	O
labeled	O
Sp1	B-GGP
consensus	B-SO
oligonucleotide	B-SO
were	O
obtained	O
as	O
protein	B-CHEBI
loading	O
control	O
.	O

Figure	O
3	O

Cadmium	B-CHEBI
response	O
of	O
Ndrg1	B-GGP
depends	O
on	O
MTF	B-GGP
-	I-GGP
1	I-GGP
.	O

(	O
a	O
)	O
Semiquantitative	O
RT	O
-	O
PCRs	O
for	O
Ndrg1	B-GGP
mRNA	B-CHEBI
using	O
total	O
liver	O
RNA	B-SO
from	O
pI	O
-	O
pC	O
-	O
induced	O
male	O
Mtf1Mx	O
-	O
cre	O
or	O
Mtf1loxP	O
mice	B-Taxon
.	O

The	O
animals	B-Taxon
had	O
obtained	O
either	O
mock	O
s	O
.	O
c	O
.	O
injections	O
(	O
-	O
Cd	B-CHEBI
)	O
or	O
s	O
.	O
c	O
.	O
injections	O
with	O
20	O
micro	O
mol	O
/	O
kg	O
body	O
weight	O
CdSO4	O
(	O
+	O
Cd	B-CHEBI
)	O
6	O
h	O
before	O
sacrificing	O
them	O
.	O

RT	O
-	O
PCRs	O
for	O
Hprt	B-GGP
mRNA	B-CHEBI
were	O
used	O
as	O
internal	O
control	O
to	O
adjust	O
the	O
amount	O
of	O
total	O
RNA	B-SO
used	O
.	O

(	O
b	O
)	O
MRE	O
core	O
consensus	B-SO
sequences	I-SO
TGCRCNC	O
(	O
bold	O
letters	O
)	O
and	O
flanking	B-SO
sequences	I-SO
found	O
in	O
a	O
region	B-SO
of	O
1000	O
bp	B-SO
upstream	O
from	O
Ndrg1	B-GGP
transcription	B-SO
start	I-SO
;	O
the	O
position	B-SO
of	I-SO
each	I-SO
core	I-SO
sequence	I-SO
is	O
indicated	O
.	O

(	O
c	O
)	O
EMSA	O
with	O
liver	O
protein	B-CHEBI
extracts	O
of	O
a	O
male	O
Mtf1loxP	O
or	O
a	O
pI	O
-	O
pC	O
-	O
induced	O
,	O
male	O
Mtf1Mx	O
-	O
cre	O
mouse	B-Taxon
,	O
both	O
mock	O
-	O
treated	O
.	O

MTF	B-GGP
-	I-GGP
1	I-GGP
protein	B-GO
-	I-GO
DNA	I-GO
complex	I-GO
formation	O
was	O
tested	O
with	O
32P	B-CHEBI
-	O
labeled	O
Ndrg1	B-GGP
MRE1	O
or	O
MRE2	O
oligonucleotide	B-SO
,	O
or	O
a	O
32P	B-CHEBI
-	O
labeled	O
oligonucleotide	B-SO
including	O
both	O
MRE3	O
and	O
MRE4	O
(	O
MRE3	O
,	O
4	O
)	O
.	O

Specificity	O
of	O
binding	O
was	O
verified	O
with	O
excess	O
of	O
unlabeled	O
competitor	O
MREd	O
or	O
unrelated	O
Gal4	O
oligonucleotide	B-SO
.	O

32P	B-CHEBI
-	O
labeled	O
MRE	O
-	O
s	O
was	O
included	O
to	O
indicate	O
the	O
position	O
of	O
an	O
MTF	B-GGP
-	I-GGP
1	I-GGP
-	O
DNA	B-SO
complex	B-GO
;	O
Sp1	B-GGP
bandshifts	O
with	O
32P	B-CHEBI
-	O
labeled	O
Sp1	B-GGP
consensus	B-SO
oligonucleotide	B-SO
were	O
obtained	O
as	O
protein	B-CHEBI
loading	O
control	O
.	O

Figure	O
4	O

Cadmium	B-CHEBI
response	O
of	O
Csrp1	B-GGP
depends	O
on	O
MTF	B-GGP
-	I-GGP
1	I-GGP
.	O

(	O
a	O
)	O
Semiquantitative	O
RT	O
-	O
PCRs	O
for	O
Csrp1	B-GGP
mRNA	B-CHEBI
using	O
total	O
liver	O
RNA	B-SO
from	O
pI	O
-	O
pC	O
-	O
induced	O
male	O
Mtf1Mx	O
-	O
cre	O
or	O
Mtf1loxP	O
mice	B-Taxon
.	O

The	O
animals	B-Taxon
had	O
obtained	O
either	O
mock	O
s	O
.	O
c	O
.	O
injections	O
(	O
-	O
Cd	B-CHEBI
)	O
or	O
s	O
.	O
c	O
.	O
injections	O
with	O
20	O
micro	O
mol	O
/	O
kg	O
body	O
weight	O
CdSO4	O
(	O
+	O
Cd	B-CHEBI
)	O
6	O
h	O
before	O
sacrificing	O
them	O
.	O

RT	O
-	O
PCRs	O
for	O
Hprt	B-GGP
mRNA	B-CHEBI
were	O
used	O
as	O
internal	O
control	O
to	O
adjust	O
the	O
amount	O
of	O
total	O
RNA	B-SO
used	O
.	O

(	O
b	O
)	O
MRE	O
core	O
consensus	B-SO
sequences	I-SO
TGCRCNC	O
(	O
bold	O
letters	O
)	O
and	O
flanking	B-SO
sequences	I-SO
found	O
in	O
a	O
region	B-SO
of	O
1000	O
bp	B-SO
upstream	O
from	O
Csrp1	B-GGP
transcription	B-SO
start	I-SO
;	O
the	O
position	B-SO
of	I-SO
each	I-SO
core	I-SO
sequence	I-SO
is	O
indicated	O
.	O

(	O
c	O
)	O
EMSA	O
with	O
liver	O
protein	B-CHEBI
extracts	O
of	O
a	O
male	O
Mtf1loxP	O
or	O
a	O
pI	O
-	O
pC	O
-	O
induced	O
,	O
male	O
Mtf1Mx	O
-	O
cre	O
mouse	B-Taxon
,	O
both	O
mock	O
-	O
treated	O
.	O

MTF	B-GGP
-	I-GGP
1	I-GGP
protein	B-GO
-	I-GO
DNA	I-GO
complex	I-GO
formation	O
was	O
tested	O
with	O
32P	B-CHEBI
-	O
labeled	O
Csrp1	B-GGP
MRE1	O
,	O
MRE2	O
,	O
MRE3	O
or	O
MRE4	O
oligonucleotide	B-SO
,	O
respectively	O
.	O

Specificity	O
of	O
binding	O
was	O
verified	O
with	O
excess	O
of	O
unlabeled	O
competitor	O
MREd	O
or	O
unrelated	O
Gal4	O
oligonucleotide	B-SO
.	O

32P	B-CHEBI
-	O
labeled	O
MRE	O
-	O
s	O
was	O
included	O
to	O
indicate	O
the	O
position	O
of	O
an	O
MTF	B-GGP
-	I-GGP
1	I-GGP
-	O
DNA	B-SO
complex	B-GO
;	O
Sp1	B-GGP
bandshifts	O
with	O
32P	B-CHEBI
-	O
labeled	O
Sp1	B-GGP
consensus	B-SO
oligonucleotide	B-SO
were	O
obtained	O
as	O
protein	B-CHEBI
loading	O
control	O
.	O

Figure	O
5	O

MTF	B-GGP
-	I-GGP
1	I-GGP
represses	O
basal	O
expression	O
of	O
Slc39a10	B-GGP
.	O

(	O
a	O
)	O
Semiquantitative	O
RT	O
-	O
PCRs	O
for	O
Slc39a10	B-GGP
mRNA	B-CHEBI
using	O
total	O
liver	O
RNA	B-SO
from	O
pI	O
-	O
pC	O
-	O
induced	O
male	O
Mtf1Mx	O
-	O
cre	O
or	O
Mtf1loxP	O
mice	B-Taxon
.	O

The	O
animals	B-Taxon
had	O
obtained	O
either	O
mock	O
s	O
.	O
c	O
.	O
injections	O
(	O
-	O
Cd	B-CHEBI
)	O
or	O
s	O
.	O
c	O
.	O
injections	O
with	O
20	O
micro	O
mol	O
/	O
kg	O
body	O
weight	O
CdSO4	O
(	O
+	O
Cd	B-CHEBI
)	O
6	O
h	O
before	O
sacrificing	O
them	O
.	O

RT	O
-	O
PCRs	O
for	O
Hprt	B-GGP
mRNA	B-CHEBI
were	O
used	O
as	O
internal	O
control	O
to	O
adjust	O
the	O
amount	O
of	O
total	O
RNA	B-SO
used	O
.	O

(	O
b	O
)	O
MRE	O
core	O
consensus	B-SO
sequences	I-SO
TGCRCNC	O
(	O
bold	O
letters	O
)	O
and	O
flanking	B-SO
sequences	I-SO
found	O
in	O
a	O
region	B-SO
of	O
1000	O
bp	B-SO
upstream	O
from	O
Slc39a10	B-GGP
transcription	B-SO
start	I-SO
;	O
the	O
position	B-SO
of	I-SO
each	I-SO
core	I-SO
sequence	I-SO
is	O
indicated	O
.	O

(	O
c	O
)	O
EMSA	O
with	O
liver	O
protein	B-CHEBI
extracts	O
of	O
a	O
male	O
Mtf1loxP	O
or	O
a	O
pI	O
-	O
pC	O
-	O
induced	O
,	O
male	O
Mtf1Mx	O
-	O
cre	O
mouse	B-Taxon
,	O
both	O
mock	O
-	O
treated	O
.	O

MTF	B-GGP
-	I-GGP
1	I-GGP
protein	B-GO
-	I-GO
DNA	I-GO
complex	I-GO
formation	O
was	O
tested	O
with	O
32P	B-CHEBI
-	O
labeled	O
Slc39a10	B-GGP
MRE1	O
or	O
MRE2	O
oligonucleotide	B-SO
,	O
respectively	O
.	O

Specificity	O
of	O
binding	O
was	O
verified	O
with	O
excess	O
of	O
unlabeled	O
competitor	O
MREd	O
or	O
unrelated	O
Gal4	O
oligonucleotide	B-SO
.	O

32P	B-CHEBI
-	O
labeled	O
MRE	O
-	O
s	O
was	O
included	O
to	O
indicate	O
the	O
position	O
of	O
an	O
MTF	B-GGP
-	I-GGP
1	I-GGP
-	O
DNA	B-SO
complex	B-GO
;	O
Sp1	B-GGP
bandshifts	O
with	O
32P	B-CHEBI
-	O
labeled	O
Sp1	B-GGP
consensus	B-SO
oligonucleotide	B-SO
were	O
obtained	O
as	O
protein	B-CHEBI
loading	O
control	O
.	O

Figure	O
6	O

Cells	B-CL
with	O
reduced	B-CHEBI
glutathione	I-CHEBI
level	O
that	O
also	O
lack	O
MTF	B-GGP
-	I-GGP
1	I-GGP
are	O
hypersensitive	O
to	O
cadmium	B-CHEBI
.	O

The	O
viability	O
of	O
cells	B-CL
was	O
assessed	O
with	O
the	O
so	O
-	O
called	O
MTT	O
assay	O
.	O

Mouse	B-Taxon
embryonic	O
fibroblasts	B-CL
with	O
(	O
ckoC	O
)	O
and	O
without	O
(	O
delC19	O
,	O
delC21	O
and	O
delC23	O
)	O
functional	O
Mtf1	B-GGP
were	O
compared	O
.	O

Cells	B-CL
were	O
pre	O
-	O
incubated	O
in	O
medium	O
containing	O
0	O
,	O
5	O
,	O
10	O
,	O
25	O
or	O
50	O
micro	O
M	O
BSO	O
for	O
24	O
h	O
and	O
further	O
exposed	O
to	O
0	O
,	O
5	O
,	O
10	O
or	O
20	O
micro	O
M	O
CdCl2	B-CHEBI
(	O
Cd	B-CHEBI
)	O
in	O
the	O
specified	O
pre	O
-	O
incubation	O
medium	O
for	O
an	O
additional	O
24	O
h	O
.	O

Results	O
are	O
expressed	O
as	O
mean	O
values	O
+/-	O
SD	O
(	O
n	O
=	O
3	O
)	O
normalized	O
to	O
the	O
respective	O
value	O
of	O
untreated	O
cells	B-CL
.	O

Table	O
1	O

Comparison	O
of	O
liver	O
gene	B-SO
expression	O
for	O
pI	O
-	O
pC	O
-	O
induced	O
Mtf1Mx	O
-	O
cre	O
and	O
Mtf1loxP	O
mice	B-Taxon
(	O
up	O
-	O
or	O
downregulation	O
at	O
least	O
2	O
-	O
fold	O
,	O
P	O
<=	O
0	O
.	O
05	O
)	O

The	O
animals	B-Taxon
had	O
obtained	O
either	O
mock	O
s	O
.	O
c	O
.	O
injections	O
(	O
-	O
Cd	B-CHEBI
)	O
or	O
s	O
.	O
c	O
.	O
injections	O
with	O
20	O
micro	O
mol	O
/	O
kg	O
body	O
weight	O
CdSO4	O
(	O
+	O
Cd	B-CHEBI
)	O
6	O
h	O
before	O
sacrificing	O
them	O
.	O

The	O
expression	O
values	O
for	O
each	O
gene	B-SO
are	O
given	O
as	O
mean	O
value	O
of	O
three	O
animals	B-Taxon
per	O
group	O
,	O
normalized	O
to	O
the	O
mean	O
value	O
of	O
group	O
Mtf1loxP	O
-	O
Cd	B-CHEBI
(	O
relative	O
activity	O
)	O
.	O

Grey	O
shading	O
indicates	O
the	O
two	O
groups	O
of	O
animals	B-Taxon
compared	O
,	O
relative	O
activities	O
for	O
the	O
other	O
two	O
groups	O
are	O
shown	O
for	O
a	O
complete	O
overview	O
.	O

The	O
number	O
of	O
MRE	O
core	O
consensus	B-SO
sequences	I-SO
TGCRCNC	O
in	O
a	O
region	B-SO
of	O
1000	O
bp	B-SO
upstream	O
from	O
the	O
annotated	O
transcription	B-SO
start	I-SO
is	O
indicated	O
.	O

aOnly	O
incomplete	B-SO
region	B-SO
up	O
to	O
-	O
1000	O
bp	B-SO
from	O
transcription	B-SO
start	I-SO
is	O
available	O
in	O
database	O
.	O

bMean	O
values	O
of	O
two	O
independent	O
Affymetrix	O
probe	B-SO
sets	O
.	O

cMean	O
value	O
of	O
four	O
independent	O
Affymetrix	O
probe	B-SO
sets	O
.	O

Table	O
2	O

Comparison	O
of	O
liver	O
gene	B-SO
expression	O
for	O
cadmium	B-CHEBI
-	O
and	O
mock	O
-	O
treated	O
mice	B-Taxon
(	O
up	O
-	O
or	O
downregulation	O
at	O
least	O
2	O
-	O
fold	O
,	O
P	O
<=	O
0	O
.	O
05	O
)	O

The	O
animals	B-Taxon
had	O
obtained	O
either	O
mock	O
s	O
.	O
c	O
.	O
injections	O
(	O
-	O
Cd	O
)	O
or	O
s	O
.	O
c	O
.	O
injections	O
with	O
20	O
micro	O
mol	O
/	O
kg	O
body	O
weight	O
CdSO4	O
(	O
+	O
Cd	O
)	O
6	O
h	O
before	O
sacrificing	O
them	O
.	O

The	O
expression	O
values	O
for	O
each	O
gene	B-SO
are	O
given	O
as	O
mean	O
value	O
of	O
three	O
animals	B-Taxon
per	O
group	O
,	O
normalized	O
to	O
the	O
mean	O
value	O
of	O
group	O
Mtf1loxP	O
-	O
Cd	O
(	O
relative	O
activity	O
)	O
.	O

aMean	O
values	O
of	O
three	O
independent	O
Affymetrix	O
probe	B-SO
sets	O
.	O

bMean	O
value	O
of	O
six	O
independent	O
Affymetrix	O
probe	B-SO
sets	O
.	O

cMean	O
value	O
of	O
two	O
independent	O
Affymetrix	O
probe	B-SO
sets	O
.	O

CEBPG	B-GGP
transcription	I-GGP
factor	I-GGP
correlates	O
with	O
antioxidant	B-CHEBI
and	O
DNA	B-SO
repair	O
genes	B-SO
in	O
normal	O
bronchial	O
epithelial	B-CL
cells	I-CL
but	O
not	O
in	O
individuals	B-Taxon
with	O
bronchogenic	O
carcinoma	O

Abstract	O

Background	O

Cigarette	O
smoking	O
is	O
the	O
primary	O
cause	O
of	O
bronchogenic	O
carcinoma	O
(	O
BC	O
)	O
,	O
yet	O
only	O
10	O
-	O
15	O
%	O
of	O
heavy	O
smokers	O
develop	O
BC	O
and	O
it	O
is	O
likely	O
that	O
this	O
variation	O
in	O
risk	O
is	O
,	O
in	O
part	O
,	O
genetically	B-SO
determined	O
.	O

We	O
previously	O
reported	O
a	O
set	O
of	O
antioxidant	B-CHEBI
genes	B-SO
for	O
which	O
transcript	B-SO
abundance	O
was	O
lower	O
in	O
normal	O
bronchial	O
epithelial	B-CL
cells	I-CL
(	O
NBEC	O
)	O
of	O
BC	O
individuals	B-Taxon
compared	O
to	O
non	O
-	O
BC	O
individuals	B-Taxon
.	O

In	O
unpublished	O
studies	O
of	O
the	O
same	O
NBEC	O
samples	O
,	O
transcript	B-SO
abundance	O
values	O
for	O
several	O
DNA	B-SO
repair	O
genes	B-SO
were	O
correlated	O
with	O
these	O
antioxidant	B-CHEBI
genes	B-SO
.	O

From	O
these	O
data	O
,	O
we	O
hypothesized	O
that	O
antioxidant	B-CHEBI
and	O
DNA	B-SO
repair	O
genes	B-SO
are	O
co	O
-	O
regulated	O
by	O
one	O
or	O
more	O
transcription	O
factors	O
and	O
that	O
inter	O
-	O
individual	B-Taxon
variation	O
in	O
expression	O
and	O
/	O
or	O
function	O
of	O
one	O
or	O
more	O
of	O
these	O
transcription	O
factors	O
is	O
responsible	O
for	O
inter	O
-	O
individual	B-Taxon
variation	O
in	O
risk	O
for	O
BC	O
.	O

Methods	O

The	O
putative	O
transcription	B-SO
factor	I-SO
recognition	I-SO
sites	I-SO
common	O
to	O
six	O
of	O
the	O
antioxidant	B-CHEBI
genes	B-SO
were	O
identified	O
through	O
in	O
silico	O
DNA	B-SO
sequence	I-SO
analysis	O
.	O

The	O
transcript	B-SO
abundance	O
values	O
of	O
these	O
transcription	O
factors	O
(	O
n	O
=	O
6	O
)	O
and	O
an	O
expanded	O
group	O
of	O
antioxidant	B-CHEBI
and	O
DNA	B-SO
repair	O
genes	B-SO
(	O
n	O
=	O
16	O
)	O
were	O
measured	O
simultaneously	O
by	O
quantitative	O
PCR	O
in	O
NBEC	O
of	O
24	O
non	O
-	O
BC	O
and	O
25	O
BC	O
individuals	B-Taxon
.	O

Results	O

CEBPG	B-GGP
transcription	I-GGP
factor	I-GGP
was	O
significantly	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
correlated	O
with	O
eight	O
of	O
the	O
antioxidant	B-CHEBI
or	O
DNA	B-SO
repair	O
genes	B-SO
in	O
non	O
-	O
BC	O
individuals	B-Taxon
but	O
not	O
in	O
BC	O
individuals	B-Taxon
.	O

In	O
BC	O
individuals	B-Taxon
the	O
correlation	O
with	O
CEBPG	B-GGP
was	O
significantly	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
lower	O
than	O
that	O
of	O
non	O
-	O
BC	O
individuals	B-Taxon
for	O
four	O
of	O
the	O
genes	B-SO
(	O
XRCC1	B-GGP
,	O
ERCC5	B-GGP
,	O
GSTP1	B-GGP
,	O
and	O
SOD1	B-GGP
)	O
and	O
the	O
difference	O
was	O
nearly	O
significant	O
for	O
GPX1	B-GGP
.	O

The	O
only	O
other	O
transcription	O
factor	O
correlated	O
with	O
any	O
of	O
these	O
five	O
target	O
genes	B-SO
in	O
non	O
-	O
BC	O
individuals	B-Taxon
was	O
E2F1	B-GGP
.	O

E2F1	B-GGP
was	O
correlated	O
with	O
GSTP1	B-GGP
among	O
non	O
-	O
BC	O
individuals	B-Taxon
,	O
but	O
in	O
contrast	O
to	O
CEBPG	B-GGP
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
this	O
correlation	O
in	O
non	O
-	O
BC	O
individuals	B-Taxon
compared	O
to	O
BC	O
individuals	B-Taxon
.	O

Conclusion	O

We	O
conclude	O
that	O
CEBPG	B-GGP
is	O
the	O
transcription	O
factor	O
primarily	O
responsible	O
for	O
regulating	O
transcription	O
of	O
key	O
antioxidant	B-CHEBI
and	O
DNA	B-SO
repair	O
genes	B-SO
in	O
non	O
-	O
BC	O
individuals	B-Taxon
.	O

Further	O
,	O
we	O
conclude	O
that	O
the	O
heavy	O
smokers	O
selected	O
for	O
development	O
of	O
BC	O
are	O
those	O
who	O
have	O
sub	O
-	O
optimal	O
regulation	O
of	O
antioxidant	B-CHEBI
and	O
DNA	B-SO
repair	O
genes	B-SO
by	O
CEBPG	B-GGP
.	O

Background	O

BC	O
is	O
currently	O
the	O
leading	O
cause	O
of	O
cancer	O
-	O
related	O
death	O
in	O
the	O
United	O
States	O
,	O
causing	O
28	O
%	O
of	O
all	O
cancer	O
deaths	O
[	O
1	O
]	O
.	O

Although	O
cigarette	O
smoking	O
is	O
the	O
primary	O
risk	O
factor	O
,	O
only	O
10	O
-	O
15	O
%	O
of	O
heavy	O
smokers	O
(	O
greater	O
than	O
20	O
pack	O
years	O
)	O
develop	O
BC	O
[	O
1	O
-	O
3	O
]	O
.	O

Antioxidant	B-CHEBI
and	O
DNA	B-SO
repair	O
enzymes	B-SO
that	O
provide	O
protection	O
from	O
the	O
effects	O
of	O
cigarette	O
smoke	O
are	O
expressed	O
in	O
the	O
progenitor	O
cells	B-CL
for	O
BC	O
,	O
normal	O
bronchial	O
epithelial	B-CL
cells	I-CL
(	O
NBEC	O
)	O
[	O
1	O
]	O
.	O

Inherited	O
inter	O
-	O
individual	B-Taxon
variation	O
in	O
the	O
function	O
of	O
these	O
genes	B-SO
plays	O
a	O
role	O
in	O
determining	O
risk	O
for	O
BC	O
[	O
4	O
-	O
6	O
]	O
.	O

Antioxidant	B-CHEBI
enzymes	B-SO
protect	O
NBEC	O
from	O
reactive	B-CHEBI
oxygen	I-CHEBI
species	I-CHEBI
produced	O
by	O
interaction	O
with	O
and	O
metabolism	O
of	O
xenobiotics	B-CHEBI
such	O
as	O
pollution	O
and	O
cigarette	O
smoke	O
[	O
4	O
-	O
7	O
]	O
as	O
well	O
as	O
those	O
produced	O
by	O
normal	O
cellular	B-CL
metabolism	O
.	O

Reactive	B-CHEBI
oxygen	I-CHEBI
species	I-CHEBI
cause	O
many	O
damaging	O
reactions	O
including	O
denaturation	O
of	O
proteins	B-CHEBI
,	O
cross	O
-	O
linking	O
of	O
lipids	B-CHEBI
and	O
proteins	B-CHEBI
and	O
modification	B-SO
of	O
nucleic	B-CHEBI
acid	I-CHEBI
bases	B-SO
,	O
which	O
can	O
lead	O
to	O
cancer	O
[	O
7	O
]	O
.	O

DNA	B-SO
repair	O
enzymes	B-SO
repair	O
the	O
frequent	O
damage	O
to	O
DNA	B-SO
caused	O
by	O
oxidant	O
stress	O
as	O
well	O
as	O
other	O
stresses	O
,	O
including	O
bulky	O
adducts	O
derived	O
from	O
carcinogens	O
in	O
cigarette	O
smoke	O
[	O
8	O
]	O
.	O

We	O
previously	O
reported	O
that	O
an	O
interactive	O
transcript	B-SO
abundance	O
index	O
comprising	O
antioxidant	B-CHEBI
genes	B-SO
was	O
lower	O
in	O
NBEC	O
of	O
BC	O
individuals	B-Taxon
compared	O
to	O
non	O
-	O
BC	O
individuals	B-Taxon
,	O
suggesting	O
that	O
BC	O
individuals	B-Taxon
are	O
selected	O
on	O
the	O
basis	O
of	O
poor	O
antioxidant	B-CHEBI
protection	O
[	O
9	O
]	O
.	O

In	O
that	O
study	O
,	O
there	O
was	O
a	O
tendency	O
towards	O
correlation	O
in	O
transcript	B-SO
abundance	O
between	O
several	O
pairs	O
of	O
antioxidant	B-CHEBI
or	O
DNA	B-SO
repair	O
genes	B-SO
in	O
non	O
-	O
BC	O
individuals	B-Taxon
,	O
but	O
not	O
in	O
BC	O
individuals	B-Taxon
.	O

Gene	B-SO
pairs	O
included	O
in	O
that	O
observation	O
were	O
GSTP1	B-GGP
/	O
GPX1	B-GGP
,	O
CAT	B-GGP
/	O
GPX3	B-GGP
,	O
and	O
GPX3	B-GGP
/	O
SOD1	B-GGP
.	O

Correlation	O
is	O
one	O
typical	O
characteristic	O
of	O
co	O
-	O
regulated	O
genes	B-SO
.	O

Another	O
is	O
shared	O
transcription	B-SO
factor	I-SO
recognition	I-SO
sites	I-SO
in	O
the	O
regulatory	B-SO
regions	I-SO
of	O
those	O
genes	B-SO
[	O
10	O
]	O
.	O

Based	O
on	O
the	O
above	O
findings	O
,	O
it	O
was	O
hypothesized	O
first	O
,	O
that	O
there	O
is	O
inter	O
-	O
individual	B-Taxon
variation	O
in	O
regulation	O
of	O
key	O
antioxidant	B-CHEBI
and	O
DNA	B-SO
repair	O
genes	B-SO
by	O
one	O
or	O
more	O
transcription	O
factors	O
and	O
second	O
,	O
that	O
individuals	B-Taxon
with	O
sub	O
-	O
optimal	O
regulation	O
are	O
selected	O
for	O
development	O
of	O
BC	O
if	O
they	O
smoke	O
cigarettes	O
.	O

To	O
test	O
these	O
hypotheses	O
,	O
transcription	B-SO
factor	I-SO
recognition	I-SO
sites	I-SO
common	O
to	O
the	O
regulatory	B-SO
regions	I-SO
of	O
the	O
above	O
correlated	O
gene	B-SO
pairs	O
were	O
identified	O
through	O
in	O
silico	O
DNA	B-SO
sequence	I-SO
analysis	O
,	O
and	O
their	O
transcript	B-SO
abundance	O
measured	O
simultaneously	O
with	O
an	O
expanded	O
group	O
of	O
ten	O
antioxidant	B-CHEBI
and	O
six	O
DNA	B-SO
repair	O
genes	B-SO
.	O

Methods	O

NBEC	O
sample	O
procurement	O

Brush	O
biopsy	O
samples	O
of	O
normal	O
bronchial	O
epithelium	O
were	O
obtained	O
for	O
research	O
studies	O
at	O
the	O
time	O
of	O
diagnostic	O
bronchoscopy	O
according	O
to	O
previously	O
described	O
methods	O
[	O
9	O
,	O
11	O
]	O
.	O

Normal	O
bronchial	O
epithelium	O
in	O
the	O
lung	O
not	O
involved	O
with	O
cancer	O
was	O
brushed	O
prior	O
to	O
biopsy	O
of	O
the	O
suspected	O
cancerous	O
area	O
.	O

Samples	O
were	O
collected	O
in	O
a	O
manner	O
satisfying	O
all	O
requirements	O
of	O
the	O
Institutional	O
Review	O
Board	O
for	O
the	O
Medical	O
University	O
of	O
Ohio	O
.	O

Each	O
BC	O
diagnosis	O
and	O
subtype	O
identification	O
was	O
determined	O
by	O
histopathological	O
examination	O
in	O
the	O
Department	O
of	O
Pathology	O
at	O
the	O
Medical	O
University	O
of	O
Ohio	O
.	O

NBEC	O
samples	O
from	O
a	O
total	O
of	O
49	O
individuals	B-Taxon
,	O
including	O
24	O
non	O
-	O
BC	O
individuals	B-Taxon
and	O
25	O
BC	O
individuals	B-Taxon
,	O
were	O
evaluated	O
in	O
this	O
study	O
.	O

The	O
biographical	O
characteristics	O
of	O
these	O
individuals	B-Taxon
are	O
presented	O
in	O
Table	O
1	O
.	O

Transcript	B-SO
abundance	O
measurement	O

Total	O
RNA	B-SO
samples	O
extracted	O
from	O
NBEC	O
were	O
reverse	O
transcribed	O
using	O
M	B-GGP
-	I-GGP
MLV	I-GGP
reverse	I-GGP
transcriptase	I-GGP
and	O
oligo	B-SO
dT	O
primers	B-SO
as	O
previously	O
described	O
[	O
9	O
,	O
11	O
]	O
.	O

Standardized	O
RT	O
(	O
StaRT	O
)	O
-	O
PCR	O
was	O
used	O
for	O
transcript	B-SO
abundance	O
measurement	O
in	O
these	O
studies	O
.	O

With	O
StaRT	O
-	O
PCR	O
,	O
an	O
internal	O
standard	O
for	O
each	O
gene	B-SO
within	O
a	O
standardized	O
mixture	O
of	O
internal	O
standards	O
(	O
SMIS	O
)	O
is	O
included	O
in	O
each	O
PCR	O
reaction	O
.	O

After	O
amplification	O
,	O
products	B-SO
were	O
electrophoresed	O
on	O
an	O
Agilent	O
2100	O
Bioanalyzer	O
using	O
DNA	B-SO
Chips	O
with	O
DNA	B-SO
1000	O
Kit	O
reagents	B-CHEBI
for	O
visualization	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
(	O
Agilent	O
Technologies	O
Deutschland	O
GmbH	O
,	O
Waldbronn	O
,	O
Germany	O
)	O
.	O

The	O
StaRT	O
-	O
PCR	O
technology	O
is	O
licensed	O
to	O
Gene	B-SO
Express	O
,	O
Inc	O
.	O

(	O
Toledo	O
,	O
OH	O
)	O
.	O

Many	O
of	O
the	O
reagents	B-CHEBI
are	O
available	O
commercially	O
and	O
were	O
obtained	O
through	O
Gene	B-SO
Express	O
,	O
Inc	O
.	O
for	O
this	O
study	O
.	O

StaRT	O
-	O
PCR	O
reagents	B-CHEBI
for	O
each	O
of	O
the	O
measured	O
genes	B-SO
that	O
were	O
not	O
commercially	O
available	O
,	O
including	O
primers	B-SO
and	O
SMIS	O
,	O
were	O
prepared	O
according	O
to	O
previously	O
described	O
methods	O
[	O
11	O
,	O
12	O
]	O
.	O

Sequence	B-SO
information	O
for	O
the	O
primers	B-SO
is	O
provided	O
in	O
Table	O
2	O
.	O

Including	O
an	O
internal	O
standard	O
within	O
a	O
SMIS	O
in	O
each	O
measurement	O
controls	O
for	O
all	O
known	O
sources	O
of	O
variation	O
during	O
PCR	O
,	O
including	O
inhibitors	B-CHEBI
in	O
samples	O
,	O
and	O
generates	O
virtually	O
-	O
multiplexed	O
transcript	B-SO
abundance	O
data	O
that	O
are	O
directly	O
comparable	O
across	O
multiple	O
experiments	O
and	O
institutions	O
[	O
13	O
]	O
.	O

The	O
performance	O
characteristics	O
of	O
StaRT	O
-	O
PCR	O
are	O
superior	O
to	O
other	O
forms	O
of	O
commercially	O
available	O
quantitative	O
PCR	O
technology	O
in	O
the	O
areas	O
critical	O
to	O
this	O
study	O
.	O

With	O
respect	O
to	O
these	O
studies	O
,	O
the	O
key	O
property	O
of	O
a	O
quantitative	O
PCR	O
method	O
is	O
not	O
whether	O
the	O
PCR	B-SO
products	I-SO
are	O
measured	O
kinetically	O
or	O
at	O
endpoint	O
,	O
but	O
rather	O
whether	O
there	O
are	O
internal	O
standards	O
in	O
each	O
measurement	O
or	O
not	O
.	O

The	O
overall	O
performance	O
characteristics	O
of	O
StaRT	O
-	O
PCR	O
,	O
including	O
extensive	O
validation	O
of	O
the	O
method	O
in	O
independent	O
laboratories	O
have	O
been	O
presented	O
in	O
several	O
recent	O
articles	O
and	O
chapters	O
[	O
13	O
-	O
15	O
]	O
.	O

With	O
respect	O
to	O
the	O
genes	B-SO
measured	O
in	O
this	O
study	O
,	O
for	O
each	O
gene	B-SO
the	O
StaRT	O
-	O
PCR	O
reagents	B-CHEBI
had	O
lower	O
detection	O
threshold	O
of	O
less	O
than	O
10	O
molecules	B-CHEBI
,	O
linear	O
dynamic	O
range	O
of	O
more	O
than	O
six	O
orders	O
of	O
magnitude	O
(	O
less	O
than	O
10	O
to	O
over	O
107	O
molecules	B-CHEBI
)	O
,	O
and	O
signal	O
-	O
to	O
-	O
analyte	O
response	O
of	O
100	O
%	O
.	O

In	O
addition	O
,	O
the	O
presence	O
of	O
an	O
internal	O
standard	O
controls	O
for	O
inter	O
-	O
sample	O
variation	O
in	O
presence	O
of	O
PCR	O
inhibitors	B-CHEBI
(	O
which	O
often	O
are	O
gene	B-SO
-	O
specific	O
)	O
and	O
ensures	O
no	O
false	O
negatives	O
(	O
if	O
the	O
PCR	O
fails	O
the	O
internal	O
standard	O
PCR	B-SO
product	I-SO
is	O
not	O
observed	O
and	O
there	O
are	O
no	O
data	O
to	O
report	O
)	O
.	O

False	O
positives	O
are	O
eliminated	O
through	O
use	O
of	O
a	O
control	O
PCR	O
reaction	O
with	O
no	O
cDNA	B-SO
in	O
it	O
.	O

Statistical	O
analysis	O

More	O
than	O
6	O
,	O
000	O
transcript	B-SO
abundance	O
measurements	O
were	O
conducted	O
in	O
multiple	O
experiments	O
over	O
two	O
years	O
to	O
assess	O
the	O
six	O
transcription	O
factors	O
and	O
sixteen	O
antioxidant	B-CHEBI
and	O
DNA	B-SO
repair	O
genes	B-SO
in	O
NBEC	O
samples	O
from	O
49	O
individuals	B-Taxon
(	O
24	O
non	O
-	O
BC	O
individuals	B-Taxon
and	O
25	O
BC	O
individuals	B-Taxon
)	O
.	O

Correlation	O
of	O
each	O
of	O
the	O
six	O
transcription	O
factors	O
with	O
each	O
of	O
the	O
antioxidant	B-CHEBI
or	O
DNA	B-SO
repair	O
genes	B-SO
was	O
determined	O
by	O
Pearson	O
'	O
s	O
correlation	O
following	O
logarithmic	O
transformation	O
.	O

The	O
transformation	O
was	O
necessary	O
due	O
to	O
the	O
wide	O
biological	O
variation	O
in	O
expression	O
of	O
each	O
gene	B-SO
among	O
the	O
individuals	B-Taxon
.	O

Significance	O
level	O
was	O
defined	O
as	O
p	O
<	O
0	O
.	O
01	O
following	O
Bonferroni	O
adjustment	O
for	O
multiple	O
comparison	O
,	O
specifically	O
comparison	O
of	O
each	O
of	O
six	O
transcription	O
factors	O
to	O
each	O
of	O
the	O
antioxidant	B-CHEBI
or	O
DNA	B-SO
repair	O
genes	B-SO
.	O

Comparison	O
for	O
significant	O
differences	O
between	O
pairs	O
of	O
correlation	O
coefficients	O
was	O
done	O
by	O
Fisher	O
'	O
s	O
Z	O
-	O
transformation	O
test	O
[	O
16	O
]	O
.	O

Analysis	O
of	O
the	O
relationship	O
between	O
virtually	O
-	O
multiplexed	O
transcript	B-SO
abundance	O
data	O
for	O
each	O
gene	B-SO
with	O
age	O
was	O
assessed	O
by	O
Pearson	O
'	O
s	O
correlation	O
,	O
with	O
gender	O
by	O
t	O
-	O
test	O
,	O
and	O
with	O
smoking	O
history	O
by	O
ANOVA	O
followed	O
by	O
Duncan	O
'	O
s	O
test	O
.	O

Transcription	B-SO
factor	I-SO
recognition	I-SO
site	I-SO
analysis	O

The	O
El	O
Dorado	O
(	O
Build	O
35	O
)	O
program	O
from	O
the	O
Genomatix	O
software	O
package	O
was	O
used	O
to	O
locate	O
the	O
correlated	O
genes	B-SO
within	O
the	O
genome	B-SO
and	O
define	O
1101	O
base	B-SO
pairs	I-SO
of	O
the	O
promoter	B-SO
regions	I-SO
(	O
1000	O
base	B-SO
pairs	I-SO
upstream	O
of	O
and	O
100	O
base	B-SO
pairs	I-SO
into	O
the	O
transcription	B-SO
start	I-SO
site	I-SO
)	O
for	O
each	O
gene	B-SO
(	O
Genomatix	O
Software	O
GmbH	O
,	O
Munich	O
,	O
Germany	O
,	O
[	O
17	O
]	O
)	O
.	O

The	O
1101	O
base	B-SO
pair	I-SO
sequences	B-SO
obtained	O
from	O
the	O
El	O
Dorado	O
program	O
then	O
were	O
used	O
as	O
the	O
target	O
sequences	B-SO
for	O
putative	O
transcription	B-SO
factor	I-SO
recognition	I-SO
site	I-SO
identification	O
using	O
the	O
MatInspector	O
Version	O
4	O
.	O
2	O
program	O
,	O
which	O
yielded	O
sites	B-SO
for	I-SO
11	I-SO
transcription	I-SO
factors	I-SO
(	O
Genomatix	O
Software	O
GmbH	O
,	O
Munich	O
,	O
Germany	O
,	O
[	O
17	O
]	O
)	O
.	O

The	O
parameters	O
used	O
were	O
the	O
standard	O
(	O
0	O
.	O
75	O
)	O
core	O
similarity	O
and	O
the	O
optimized	O
matrix	O
similarity	O
[	O
18	O
]	O
.	O

StaRT	O
-	O
PCR	O
reagents	B-CHEBI
were	O
optimized	O
for	O
ten	O
of	O
these	O
transcription	O
factors	O
,	O
including	O
CEBPB	B-GGP
,	O
CEBPE	B-GGP
,	O
CEBPG	B-GGP
,	O
E2F1	B-GGP
,	O
E2F3	B-GGP
,	O
E2F4	B-GGP
,	O
E2F5	B-GGP
,	O
E2F6	B-GGP
,	O
EVI1	B-GGP
,	O
and	O
PAX5	B-GGP
.	O

Four	O
transcription	O
factors	O
were	O
expressed	O
at	O
low	O
and	O
invariant	O
levels	O
among	O
multiple	O
NBEC	O
samples	O
and	O
were	O
therefore	O
excluded	O
from	O
the	O
study	O
.	O

The	O
remaining	O
six	O
,	O
CEBPB	B-GGP
,	O
CEBPG	B-GGP
,	O
E2F1	B-GGP
,	O
E2F3	B-GGP
,	O
E2F6	B-GGP
,	O
and	O
EVI	B-GGP
,	O
were	O
evaluated	O
for	O
correlation	O
with	O
an	O
expanded	O
group	O
of	O
ten	O
antioxidant	B-CHEBI
and	O
six	O
DNA	B-SO
repair	O
genes	B-SO
.	O

Results	O

Virtually	O
-	O
multiplexed	O
transcript	B-SO
abundance	O
data	O
were	O
obtained	O
for	O
each	O
gene	B-SO
in	O
each	O
of	O
the	O
49	O
samples	O
,	O
except	O
for	O
E2F1	B-GGP
measurement	O
in	O
sample	O
147	O
(	O
Table	O
3	O
)	O
.	O

A	O
gene	B-SO
-	O
specific	O
inhibitor	B-CHEBI
in	O
sample	O
147	O
prevented	O
amplification	O
of	O
E2F1	B-GGP
.	O

Neither	O
the	O
internal	O
standard	O
,	O
nor	O
the	O
native	O
cDNA	B-SO
PCR	B-SO
product	I-SO
was	O
observed	O
.	O

The	O
presence	O
of	O
gene	B-SO
-	O
specific	O
PCR	O
inhibition	O
was	O
observable	O
in	O
some	O
other	O
samples	O
as	O
reduction	O
in	O
peak	O
heights	O
in	O
internal	O
standard	O
PCR	B-SO
products	I-SO
relative	O
to	O
that	O
expected	O
for	O
the	O
number	O
of	O
internal	O
standard	O
molecules	B-CHEBI
present	O
at	O
the	O
beginning	O
of	O
the	O
PCR	O
reaction	O
.	O

However	O
,	O
in	O
each	O
such	O
case	O
,	O
the	O
PCR	O
amplification	O
was	O
efficient	O
enough	O
to	O
enable	O
quantification	O
.	O

Bivariate	O
analysis	O

In	O
non	O
-	O
BC	O
individuals	B-Taxon
there	O
was	O
significant	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
correlation	O
between	O
CEBPG	B-GGP
and	O
eight	O
of	O
the	O
16	O
antioxidant	B-CHEBI
or	O
DNA	B-SO
repair	O
genes	B-SO
,	O
specifically	O
XRCC1	B-GGP
,	O
ERCC5	B-GGP
,	O
GSTP1	B-GGP
,	O
SOD1	B-GGP
,	O
GPX1	B-GGP
,	O
ERCC1	B-GGP
,	O
CAT	B-GGP
and	O
ERCC2	B-GGP
(	O
Table	O
4	O
)	O
.	O

In	O
contrast	O
,	O
in	O
BC	O
individuals	B-Taxon
samples	O
CEBPG	B-GGP
was	O
not	O
correlated	O
with	O
any	O
of	O
the	O
antioxidant	B-CHEBI
or	O
DNA	B-SO
repair	O
genes	B-SO
.	O

These	O
relationships	O
were	O
not	O
observed	O
with	O
any	O
of	O
the	O
other	O
transcription	O
factors	O
studied	O
.	O

For	O
XRCC1	B-GGP
,	O
ERCC5	B-GGP
,	O
GSTP1	B-GGP
,	O
and	O
SOD1	B-GGP
the	O
correlation	O
with	O
CEBPG	B-GGP
was	O
significantly	O
lower	O
in	O
BC	O
individuals	B-Taxon
compared	O
to	O
non	O
-	O
BC	O
individuals	B-Taxon
and	O
the	O
difference	O
was	O
nearly	O
significant	O
for	O
GPX1	B-GGP
(	O
Fig	O
.	O
1b	O
)	O
.	O

Scatter	O
plots	O
of	O
the	O
relationship	O
between	O
CEBPG	B-GGP
and	O
XRCC1	B-GGP
in	O
non	O
-	O
BC	O
individuals	B-Taxon
or	O
BC	O
individuals	B-Taxon
(	O
Fig	O
.	O
2a	O
,	O
b	O
)	O
are	O
representative	O
of	O
the	O
other	O
four	O
genes	B-SO
.	O

Neither	O
CEBPG	B-GGP
,	O
nor	O
XRCC1	B-GGP
,	O
ERCC5	B-GGP
,	O
GSTP1	B-GGP
,	O
SOD1	B-GGP
or	O
GPX1	B-GGP
was	O
significantly	O
correlated	O
with	O
age	O
,	O
gender	O
,	O
or	O
smoking	O
history	O
in	O
non	O
-	O
BC	O
individuals	B-Taxon
,	O
BC	O
individuals	B-Taxon
,	O
or	O
the	O
combined	O
group	O
.	O

In	O
non	O
-	O
BC	O
individuals	B-Taxon
,	O
based	O
on	O
the	O
r2	O
values	O
from	O
Pearson	O
'	O
s	O
correlation	O
analysis	O
,	O
CEBPG	B-GGP
accounts	O
for	O
much	O
of	O
the	O
variance	O
in	O
expression	O
of	O
XRCC1	B-GGP
(	O
69	O
%	O
)	O
,	O
ERCC5	B-GGP
(	O
62	O
%	O
)	O
,	O
GSTP1	B-GGP
(	O
55	O
%	O
)	O
,	O
SOD1	B-GGP
(	O
44	O
%	O
)	O
,	O
and	O
GPX1	B-GGP
(	O
52	O
%	O
)	O
.	O

E2F1	B-GGP
accounts	O
for	O
some	O
of	O
the	O
remaining	O
variance	O
.	O

For	O
example	O
,	O
when	O
samples	O
from	O
all	O
49	O
non	O
-	O
BC	O
individuals	B-Taxon
and	O
BC	O
individuals	B-Taxon
were	O
assessed	O
as	O
a	O
single	O
group	O
,	O
E2F1	B-GGP
was	O
significantly	O
correlated	O
with	O
ERCC5	B-GGP
,	O
GSTP1	B-GGP
and	O
SOD1	B-GGP
(	O
Table	O
4	O
)	O
.	O

Further	O
,	O
in	O
non	O
-	O
BC	O
individuals	B-Taxon
,	O
E2F1	B-GGP
was	O
correlated	O
with	O
GSTP1	B-GGP
(	O
Fig	O
.	O
1c	O
)	O
and	O
the	O
correlation	O
was	O
lower	O
in	O
BC	O
individuals	B-Taxon
.	O

However	O
,	O
the	O
difference	O
in	O
correlation	O
between	O
non	O
-	O
BC	O
individuals	B-Taxon
and	O
BC	O
individuals	B-Taxon
was	O
not	O
significant	O
.	O

None	O
of	O
the	O
other	O
transcription	O
factors	O
were	O
correlated	O
with	O
XRCC1	B-GGP
,	O
ERCC5	B-GGP
,	O
GSTP1	B-GGP
,	O
SOD1	B-GGP
,	O
or	O
GPX1	B-GGP
(	O
Fig	O
.	O
1a	O
,	O
d	O
,	O
e	O
,	O
f	O
)	O
.	O

Comparison	O
of	O
gene	B-SO
expression	O
with	O
demographic	O
characteristics	O

E2F1	B-GGP
and	O
GSTZ1	B-GGP
each	O
were	O
positively	O
correlated	O
with	O
age	O
.	O

GSTM1	B-GGP
-	O
5	O
was	O
the	O
only	O
gene	B-SO
with	O
a	O
difference	O
in	O
expression	O
by	O
gender	O
.	O

There	O
was	O
a	O
difference	O
in	O
ERCC2	B-GGP
expression	O
between	O
former	O
and	O
never	O
smokers	O
.	O

Discussion	O

In	O
this	O
study	O
,	O
we	O
tested	O
two	O
hypotheses	O
.	O

First	O
,	O
that	O
there	O
is	O
inter	O
-	O
individual	B-Taxon
variation	O
in	O
regulation	O
of	O
key	O
antioxidant	B-CHEBI
and	O
DNA	B-SO
repair	O
genes	B-SO
by	O
one	O
or	O
more	O
transcription	O
factors	O
.	O

Second	O
,	O
that	O
individuals	B-Taxon
with	O
sub	O
-	O
optimal	O
regulation	O
are	O
selected	O
for	O
development	O
of	O
BC	O
if	O
they	O
smoke	O
cigarettes	O
.	O

These	O
hypotheses	O
are	O
supported	O
by	O
the	O
findings	O
that	O
a	O
)	O
there	O
was	O
large	O
inter	O
-	O
individual	B-Taxon
variation	O
in	O
transcript	B-SO
levels	O
of	O
CEBPG	B-GGP
and	O
each	O
of	O
the	O
target	O
genes	B-SO
and	O
in	O
non	O
-	O
BC	O
individuals	B-Taxon
,	O
b	O
)	O
CEBPG	B-GGP
transcript	B-SO
abundance	O
values	O
were	O
significantly	O
correlated	O
by	O
bivariate	O
analysis	O
with	O
the	O
transcript	B-SO
abundance	O
values	O
of	O
four	O
key	O
antioxidant	B-CHEBI
and	O
DNA	B-SO
repair	O
genes	B-SO
in	O
non	O
-	O
BC	O
individuals	B-Taxon
,	O
and	O
c	O
)	O
that	O
there	O
was	O
no	O
correlation	O
between	O
CEBPG	B-GGP
and	O
these	O
genes	B-SO
in	O
BC	O
individuals	B-Taxon
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
each	O
of	O
the	O
antioxidant	B-CHEBI
or	O
DNA	B-SO
repair	O
genes	B-SO
correlated	O
with	O
CEBPG	B-GGP
in	O
non	O
-	O
BC	O
individuals	B-Taxon
is	O
regulated	O
by	O
CEBPG	B-GGP
.	O

This	O
is	O
supported	O
by	O
the	O
specificity	O
of	O
the	O
CEBPG	B-GGP
correlation	O
.	O

That	O
is	O
,	O
there	O
was	O
lack	O
of	O
correlation	O
between	O
any	O
of	O
the	O
other	O
five	O
transcription	O
factors	O
assessed	O
and	O
these	O
target	O
genes	B-SO
.	O

Of	O
particular	O
note	O
is	O
the	O
lack	O
of	O
correlation	O
of	O
the	O
target	O
genes	B-SO
with	O
CEBPB	B-GGP
,	O
which	O
binds	O
to	O
the	O
same	O
recognition	B-SO
site	I-SO
as	O
CEBPG	B-GGP
,	O
and	O
shares	O
its	O
recognition	B-SO
site	I-SO
within	O
each	O
of	O
the	O
antioxidant	B-CHEBI
or	O
DNA	B-SO
repair	O
genes	B-SO
.	O

However	O
,	O
there	O
are	O
alternative	O
explanations	O
for	O
the	O
observed	O
correlation	O
of	O
CEBPG	B-GGP
with	O
antioxidant	B-CHEBI
and	O
DNA	B-SO
repair	O
genes	B-SO
in	O
non	O
-	O
BC	O
individuals	B-Taxon
.	O

One	O
possibility	O
is	O
that	O
CEBPG	B-GGP
and	O
each	O
of	O
the	O
correlated	O
antioxidant	B-CHEBI
or	O
DNA	B-SO
repair	O
genes	B-SO
is	O
regulated	O
by	O
a	O
transcription	O
factor	O
that	O
is	O
as	O
yet	O
undiscovered	O
,	O
and	O
/	O
or	O
has	O
a	O
recognition	B-SO
site	I-SO
that	O
is	O
not	O
yet	O
known	O
and	O
was	O
not	O
in	O
the	O
Genomatix	O
software	O
database	O
.	O

There	O
also	O
is	O
more	O
than	O
one	O
possible	O
explanation	O
for	O
the	O
observed	O
lack	O
of	O
correlation	O
between	O
CEBPG	B-GGP
and	O
antioxidant	B-CHEBI
or	O
DNA	B-SO
repair	O
genes	B-SO
in	O
BC	O
individuals	B-Taxon
.	O

For	O
example	O
,	O
the	O
non	O
-	O
BC	O
individual	B-Taxon
and	O
BC	O
individual	B-Taxon
groups	O
are	O
not	O
perfectly	O
matched	O
with	O
respect	O
to	O
age	O
,	O
gender	O
or	O
smoking	O
history	O
(	O
Table	O
1	O
)	O
and	O
each	O
of	O
these	O
factors	O
could	O
contribute	O
to	O
the	O
observed	O
difference	O
in	O
correlation	O
between	O
groups	O
.	O

However	O
,	O
the	O
lack	O
of	O
association	O
of	O
transcript	B-SO
abundance	O
level	O
for	O
CEBPG	B-GGP
,	O
XRCC1	B-GGP
,	O
ERCC5	B-GGP
,	O
GSTP1	B-GGP
,	O
SOD1	B-GGP
,	O
or	O
GPX1	B-GGP
with	O
age	O
,	O
gender	O
or	O
smoking	O
history	O
argues	O
against	O
such	O
an	O
explanation	O
.	O

One	O
way	O
to	O
examine	O
this	O
possibility	O
is	O
through	O
additional	O
,	O
larger	O
,	O
more	O
closely	O
matched	O
studies	O
.	O

Another	O
possible	O
explanation	O
is	O
that	O
any	O
differences	O
in	O
NBEC	O
from	O
BC	O
individuals	B-Taxon
compared	O
to	O
non	O
-	O
BC	O
individuals	B-Taxon
resulted	O
from	O
development	O
of	O
BC	O
,	O
instead	O
of	O
being	O
a	O
hereditary	O
cause	O
of	O
increased	O
risk	O
for	O
cancer	O
.	O

The	O
best	O
way	O
to	O
determine	O
this	O
will	O
be	O
to	O
conduct	O
a	O
prospective	O
study	O
.	O

In	O
such	O
a	O
study	O
,	O
individuals	B-Taxon
matched	O
for	O
smoking	O
history	O
will	O
be	O
monitored	O
for	O
development	O
of	O
BC	O
over	O
time	O
.	O

The	O
correlation	O
of	O
transcript	B-SO
abundance	O
values	O
for	O
CEBPG	B-GGP
relative	O
to	O
transcript	B-SO
abundance	O
values	O
for	O
each	O
of	O
the	O
antioxidant	B-CHEBI
or	O
DNA	B-SO
repair	O
genes	B-SO
will	O
be	O
assessed	O
.	O

It	O
is	O
expected	O
that	O
the	O
greatest	O
incidence	O
of	O
BC	O
will	O
be	O
among	O
the	O
heaviest	O
smokers	O
.	O

Among	O
the	O
matched	O
heaviest	O
smokers	O
,	O
it	O
is	O
expected	O
that	O
CEBPG	B-GGP
will	O
be	O
significantly	O
correlated	O
with	O
each	O
of	O
the	O
antioxidant	B-CHEBI
or	O
DNA	B-SO
repair	O
genes	B-SO
among	O
the	O
non	O
-	O
BC	O
individuals	B-Taxon
but	O
not	O
correlated	O
in	O
BC	O
individuals	B-Taxon
.	O

Thus	O
,	O
there	O
are	O
multiple	O
possible	O
explanations	O
for	O
the	O
observed	O
findings	O
.	O

However	O
,	O
based	O
on	O
the	O
preponderance	O
of	O
data	O
thus	O
far	O
available	O
,	O
we	O
conclude	O
that	O
CEBPG	B-GGP
is	O
responsible	O
for	O
optimal	O
transcriptional	O
regulation	O
of	O
key	O
antioxidant	B-CHEBI
or	O
DNA	B-SO
repair	O
genes	B-SO
in	O
NBEC	O
and	O
that	O
there	O
is	O
inter	O
-	O
individual	B-Taxon
variation	O
in	O
the	O
regulation	O
of	O
each	O
of	O
these	O
genes	B-SO
by	O
CEBPG	B-GGP
.	O

If	O
this	O
conclusion	O
is	O
correct	O
,	O
the	O
individuals	B-Taxon
at	O
greatest	O
risk	O
for	O
BC	O
will	O
be	O
those	O
with	O
the	O
most	O
extreme	O
smoking	O
history	O
combined	O
with	O
sub	O
-	O
optimal	O
regulation	O
of	O
the	O
largest	O
number	O
of	O
antioxidant	B-CHEBI
and	O
DNA	B-SO
repair	O
genes	B-SO
.	O

This	O
,	O
in	O
turn	O
,	O
leads	O
to	O
increased	O
representation	O
among	O
BC	O
individuals	B-Taxon
of	O
individuals	B-Taxon
with	O
lack	O
of	O
correlation	O
between	O
CEBPG	B-GGP
and	O
each	O
of	O
the	O
affected	O
antioxidant	B-CHEBI
and	O
/	O
or	O
DNA	B-SO
repair	O
genes	B-SO
.	O

CEBPG	B-GGP
is	O
a	O
truncated	O
CEBP	O
transcription	O
factor	O
[	O
19	O
]	O
and	O
possesses	O
the	O
sequences	B-SO
necessary	O
for	O
DNA	B-SO
binding	O
and	O
heterodimer	O
formation	O
,	O
but	O
lacks	O
the	O
sequences	B-SO
necessary	O
for	O
transactivation	O
[	O
20	O
]	O
.	O

CEBPG	B-GGP
forms	O
heterodimers	O
with	O
other	O
CEBP	O
family	O
members	O
and	O
in	O
other	O
tissues	O
this	O
leads	O
to	O
increased	O
[	O
21	O
]	O
or	O
decreased	O
[	O
20	O
]	O
transcription	O
of	O
the	O
regulated	O
gene	B-SO
.	O

CEBPG	B-GGP
is	O
known	O
to	O
have	O
stimulatory	O
effect	O
on	O
the	O
IL	B-GGP
-	I-GGP
6	I-GGP
and	O
IL	B-GGP
-	I-GGP
8	I-GGP
promoters	B-SO
in	O
B	B-CL
cell	I-CL
lines	O
[	O
21	O
]	O
,	O
and	O
can	O
also	O
act	O
as	O
a	O
dominant	O
negative	O
regulator	O
of	O
CEBPA	B-GGP
and	O
CEBPB	B-GGP
in	O
fibroblast	B-CL
and	O
B	B-CL
cell	I-CL
lines	O
[	O
20	O
]	O
.	O

The	O
data	O
from	O
CEBPG	B-GGP
knockout	O
mice	B-Taxon
support	O
a	O
role	O
for	O
CEBPG	B-GGP
in	O
protecting	O
lungs	O
from	O
oxidant	O
damage	O
.	O

CEBPG	B-GGP
-	O
/	O
-	O
knockout	O
mice	B-Taxon
are	O
healthy	O
at	O
birth	O
but	O
begin	O
to	O
die	O
within	O
24	O
hours	O
,	O
and	O
histological	O
examination	O
reveals	O
emphysematous	O
lungs	O
[	O
22	O
]	O
.	O

In	O
humans	B-Taxon
,	O
risk	O
for	O
emphysema	O
is	O
associated	O
with	O
antioxidant	B-CHEBI
capacity	O
[	O
23	O
]	O
,	O
and	O
there	O
is	O
a	O
strong	O
correlation	O
between	O
risk	O
for	O
emphysema	O
and	O
risk	O
for	O
BC	O
.	O

However	O
,	O
it	O
will	O
be	O
important	O
to	O
obtain	O
direct	O
experimental	O
evidence	O
in	O
NBECs	O
for	O
the	O
role	O
of	O
CEBPG	B-GGP
in	O
regulating	O
the	O
antioxidant	B-CHEBI
and	O
DNA	B-SO
repair	O
genes	B-SO
included	O
in	O
this	O
study	O
.	O

Correlation	O
between	O
CEBPG	B-GGP
and	O
target	O
gene	B-SO
transcript	B-SO
levels	O
may	O
not	O
be	O
associated	O
with	O
correlation	O
at	O
the	O
protein	B-CHEBI
level	O
.	O

In	O
this	O
study	O
,	O
E2F1	B-GGP
correlation	O
with	O
DNA	B-SO
repair	O
and	O
antioxidant	B-CHEBI
genes	B-SO
was	O
less	O
than	O
the	O
correlation	O
observed	O
with	O
CEBPG	B-GGP
,	O
and	O
the	O
E2F1	B-GGP
correlation	O
was	O
observed	O
in	O
both	O
non	O
-	O
BC	O
individuals	B-Taxon
as	O
well	O
as	O
BC	O
individuals	B-Taxon
.	O

The	O
maintained	O
correlation	O
of	O
E2F1	B-GGP
with	O
DNA	B-SO
repair	O
and	O
antioxidant	B-CHEBI
genes	B-SO
in	O
BC	O
individuals	B-Taxon
suggests	O
that	O
this	O
function	O
is	O
more	O
tightly	O
controlled	O
in	O
the	O
population	O
and	O
does	O
not	O
play	O
a	O
role	O
in	O
determination	O
of	O
risk	O
for	O
BC	O
.	O

E2F1	B-GGP
has	O
previously	O
been	O
reported	O
to	O
regulate	O
transcription	O
of	O
DNA	B-SO
repair	O
enzyme	B-SO
genes	B-SO
in	O
other	O
cell	B-CL
types	O
,	O
including	O
primary	O
human	B-Taxon
fibroblasts	B-CL
and	O
mouse	B-Taxon
epidermal	B-CL
cells	I-CL
[	O
24	O
,	O
25	O
]	O
.	O

Clearly	O
this	O
would	O
have	O
survival	O
value	O
since	O
DNA	B-SO
repair	O
gene	B-SO
up	O
-	O
regulation	O
in	O
response	O
to	O
E2F1	B-GGP
provides	O
additional	O
DNA	B-SO
repair	O
when	O
the	O
DNA	B-SO
is	O
replicating	O
and	O
is	O
particularly	O
vulnerable	O
to	O
damage	O
.	O

Epidemiologic	O
assessment	O
of	O
the	O
correlation	O
between	O
a	O
particular	O
variation	B-SO
in	I-SO
DNA	I-SO
sequence	I-SO
,	O
or	O
polymorphism	B-SO
,	O
and	O
risk	O
for	O
BC	O
has	O
been	O
a	O
dominant	O
paradigm	O
for	O
many	O
years	O
.	O

Thus	O
far	O
,	O
these	O
efforts	O
have	O
met	O
with	O
scant	O
success	O
[	O
26	O
]	O
.	O

A	O
common	O
limitation	O
in	O
design	O
of	O
such	O
studies	O
is	O
that	O
they	O
involve	O
assessment	O
of	O
a	O
single	O
polymorphism	B-SO
or	O
occasionally	O
,	O
a	O
few	O
polymorphisms	B-SO
.	O

Further	O
,	O
although	O
the	O
polymorphism	B-SO
assessed	O
typically	O
resides	O
within	O
a	O
gene	B-SO
known	O
to	O
protect	O
bronchial	O
epithelium	O
from	O
carcinogens	O
,	O
oxidants	O
,	O
or	O
DNA	B-SO
damage	O
,	O
the	O
selection	O
of	O
the	O
particular	O
polymorphism	B-SO
for	O
study	O
is	O
largely	O
empiric	O
,	O
and	O
not	O
based	O
on	O
known	O
functional	O
properties	O
.	O

These	O
are	O
problems	O
because	O
multiple	O
infrequent	O
polymorphisms	B-SO
at	O
different	O
sites	B-SO
may	O
all	O
contribute	O
to	O
risk	O
and	O
unless	O
the	O
key	O
polymorphisms	B-SO
can	O
be	O
identified	O
through	O
a	O
functional	O
test	O
,	O
a	O
statistically	O
valid	O
assessment	O
would	O
require	O
much	O
larger	O
study	O
populations	O
[	O
27	O
]	O
.	O

The	O
findings	O
of	O
this	O
study	O
support	O
a	O
novel	O
approach	O
to	O
identifying	O
clinically	O
useful	O
biomarkers	O
.	O

According	O
to	O
the	O
paradigm	O
used	O
in	O
this	O
study	O
,	O
a	O
)	O
a	O
normal	O
phenotype	O
results	O
from	O
regulated	O
transcription	O
of	O
a	O
group	O
of	O
genes	B-SO
by	O
one	O
or	O
more	O
transcription	O
factors	O
,	O
b	O
)	O
the	O
corresponding	O
risk	O
-	O
conferring	O
or	O
disease	O
phenotype	O
results	O
from	O
sub	O
-	O
optimal	O
interaction	O
among	O
those	O
same	O
genes	B-SO
,	O
and	O
c	O
)	O
each	O
phenotype	O
is	O
identifiable	O
and	O
distinguishable	O
through	O
virtually	O
-	O
multiplexed	O
transcript	B-SO
abundance	O
analysis	O
.	O

The	O
data	O
presented	O
here	O
support	O
the	O
utility	O
of	O
this	O
paradigm	O
in	O
identifying	O
genes	B-SO
associated	O
with	O
risk	O
for	O
BC	O
.	O

The	O
next	O
step	O
will	O
be	O
to	O
identify	O
polymorphisms	B-SO
that	O
affect	O
regulation	O
of	O
XRCC1	B-GGP
,	O
ERCC5	B-GGP
,	O
GSTP1	B-GGP
,	O
SOD1	B-GGP
,	O
and	O
GPX1	B-GGP
by	O
CEBPG	B-GGP
.	O

Such	O
polymorphisms	B-SO
should	O
yield	O
biomarkers	O
suitable	O
for	O
more	O
readily	O
accessible	O
samples	O
,	O
such	O
as	O
peripheral	O
blood	O
or	O
buccal	O
smears	O
.	O

A	O
biomarker	O
combining	O
polymorphisms	B-SO
that	O
affect	O
regulation	O
with	O
those	O
that	O
affect	O
function	O
of	O
antioxidant	B-CHEBI
and	O
DNA	B-SO
repair	O
genes	B-SO
is	O
likely	O
to	O
be	O
the	O
most	O
accurate	O
for	O
identifying	O
individuals	B-Taxon
at	O
risk	O
for	O
BC	O
.	O

Biomarkers	O
that	O
accurately	O
identify	O
individuals	B-Taxon
at	O
risk	O
for	O
BC	O
will	O
improve	O
efficacy	O
of	O
chemoprevention	O
and	O
early	O
detection	O
clinical	O
trials	O
.	O

The	O
observed	O
inter	O
-	O
sample	O
variation	O
in	O
the	O
presence	O
of	O
gene	B-SO
-	O
specific	O
inhibitors	B-CHEBI
of	O
PCR	O
provides	O
evidence	O
supporting	O
the	O
need	O
for	O
inclusion	O
of	O
an	O
internal	O
standard	O
in	O
each	O
quantitative	O
PCR	O
transcript	B-SO
abundance	O
measurement	O
.	O

Including	O
such	O
internal	O
standards	O
in	O
the	O
form	O
of	O
standardized	O
mixtures	O
of	O
internal	O
standards	O
improves	O
the	O
reproducibility	O
of	O
transcript	B-SO
abundance	O
measurement	O
and	O
enables	O
development	O
of	O
a	O
standardized	O
database	O
comprising	O
virtually	O
-	O
multiplexed	O
transcript	B-SO
abundance	O
data	O
.	O

Virtually	O
-	O
multiplexed	O
transcript	B-SO
abundance	O
data	O
are	O
highly	O
suited	O
to	O
identification	O
of	O
genes	B-SO
that	O
have	O
correlated	O
transcript	B-SO
abundance	O
values	O
.	O

Correlation	O
at	O
the	O
transcript	B-SO
abundance	O
level	O
is	O
an	O
important	O
property	B-SO
of	O
genes	B-SO
that	O
are	O
co	O
-	O
regulated	O
at	O
the	O
transcription	O
level	O
.	O

Conclusion	O

We	O
conclude	O
that	O
in	O
non	O
-	O
BC	O
individuals	B-Taxon
,	O
CEBPG	B-GGP
regulates	O
transcription	O
of	O
key	O
antioxidant	B-CHEBI
or	O
DNA	B-SO
repair	O
genes	B-SO
in	O
NBEC	O
and	O
that	O
in	O
smokers	O
who	O
develop	O
BC	O
,	O
CEBPG	B-GGP
regulation	O
is	O
sub	O
-	O
optimal	O
for	O
a	O
sufficient	O
number	O
of	O
antioxidant	B-CHEBI
and	O
/	O
or	O
DNA	B-SO
repair	O
genes	B-SO
to	O
cause	O
increased	O
risk	O
.	O

Competing	O
interests	O

JCW	O
and	O
ELC	O
each	O
have	O
significant	O
equity	O
interest	O
in	O
Gene	B-SO
Express	O
,	O
Inc	O
.	O
,	O
which	O
produces	O
and	O
markets	O
StaRT	O
-	O
PCR	O
(TM)	O
reagents	B-CHEBI
used	O
in	O
this	O
study	O
.	O

Authors	O
'	O
contributions	O

DNM	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
,	O
performed	O
the	O
TF	O
identification	O
,	O
carried	O
out	O
TA	O
measurements	O
,	O
coordinated	O
and	O
participated	O
in	O
the	O
statistical	O
analysis	O
and	O
drafted	O
the	O
manuscript	O
.	O

ELC	O
contributed	O
the	O
preliminary	O
data	O
,	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
and	O
carried	O
out	O
TA	O
measurements	O
.	O

SAK	O
performed	O
the	O
statistical	O
analysis	O
for	O
interpretation	O
of	O
data	O
.	O

DAH	O
and	O
YY	O
consented	O
patients	O
and	O
obtained	O
the	O
primary	O
samples	O
necessary	O
for	O
the	O
study	O
according	O
to	O
IRB	O
regulations	O
.	O

JCW	O
conceived	O
of	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
,	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

Acknowledgements	O

These	O
studies	O
and	O
manuscript	O
preparation	O
were	O
supported	O
by	O
grants	O
from	O
the	O
National	O
Cancer	O
Institute	O
(	O
NCI	O
)	O
,	O
including	O
CA85147	O
and	O
CA	O
95806	O
,	O
and	O
the	O
George	O
Isaac	O
Cancer	O
Research	O
Fund	O
.	O

StaRT	O
-	O
PCR	O
reagents	B-CHEBI
for	O
measurement	O
of	O
some	O
of	O
the	O
genes	B-SO
were	O
provided	O
at	O
no	O
cost	O
by	O
Gene	B-SO
Express	O
,	O
Inc	O
.	O

Neither	O
the	O
NCI	O
nor	O
Gene	B-SO
Express	O
,	O
Inc	O
.	O
had	O
any	O
role	O
in	O
study	O
design	O
,	O
collection	O
,	O
analysis	O
,	O
or	O
interpretation	O
of	O
data	O
,	O
writing	O
of	O
the	O
manuscript	O
,	O
or	O
in	O
the	O
decision	O
to	O
submit	O
the	O
manuscript	O
for	O
publication	O
.	O

Figures	O
and	O
Tables	O

Figure	O
1	O

Correlation	O
of	O
each	O
transcription	O
factor	O
with	O
XRCC1	B-GGP
,	O
ERCC5	B-GGP
,	O
GSTP1	B-GGP
,	O
SOD1	B-GGP
,	O
or	O
GPX1	B-GGP
.	O

(	O
a	O
-	O
f	O
)	O
Each	O
panel	O
presents	O
the	O
correlation	O
coefficients	O
(	O
r	O
values	O
)	O
for	O
one	O
transcription	O
factor	O
in	O
relation	O
to	O
each	O
of	O
the	O
five	O
genes	B-SO
:	O
(	O
a	O
)	O
CEBPB	B-GGP
,	O
(	O
b	O
)	O
CEBPG	B-GGP
,	O
(	O
c	O
)	O
E2F1	B-GGP
,	O
(	O
d	O
)	O
E2F3	B-GGP
,	O
(	O
e	O
)	O
E2F6	B-GGP
,	O
(	O
f	O
)	O
EVI1	B-GGP
.	O

The	O
p	O
value	O
for	O
each	O
significant	O
correlation	O
is	O
provided	O
above	O
the	O
bar	O
.	O

For	O
CEBPG	B-GGP
,	O
presented	O
in	O
panel	O
b	O
,	O
the	O
difference	O
in	O
r	O
value	O
between	O
non	O
-	O
BC	O
individuals	B-Taxon
and	O
BC	O
individuals	B-Taxon
was	O
significant	O
or	O
nearly	O
significant	O
for	O
each	O
correlated	O
gene	B-SO
,	O
and	O
the	O
p	O
value	O
for	O
each	O
comparison	O
is	O
provided	O
below	O
the	O
corresponding	O
pair	O
of	O
bars	O
.	O

Figure	O
2	O

Scatter	O
plot	O
representation	O
of	O
bivariate	O
correlation	O
of	O
CEBPG	B-GGP
with	O
XRCC1	B-GGP
.	O

(	O
a	O
,	O
b	O
)	O
CEBPG	B-GGP
/	O
XRCC1	B-GGP
data	O
from	O
Figure	O
1b	O
presented	O
as	O
scatter	O
plots	O
:	O
(	O
a	O
)	O
non	O
-	O
BC	O
individuals	B-Taxon
,	O
(	O
b	O
)	O
BC	O
individuals	B-Taxon
.	O

Table	O
1	O

Demographic	O
data	O
of	O
patients	O
from	O
whom	O
the	O
NBEC	O
samples	O
were	O
obtained	O
.	O

1Pack	O
years	O
;	O
2Non	O
-	O
bronchogenic	O
carcinoma	O
individual	B-Taxon
;	O
3White	O
;	O
4African	O
-	O
American	O
;	O
5Non	O
-	O
smoker	O
;	O
6Not	O
available	O
;	O
7Hispanic	O
;	O
8Bronchogenic	O
carcinoma	O
individual	B-Taxon
;	O
9Non	O
-	O
small	O
cell	B-CL
lung	O
cancer	O
;	O
10Squamous	O
carcinoma	O
;	O
11Small	O
cell	B-CL
lung	O
cancer	O
;	O
12Carcinoma	O
-	O
in	O
-	O
situ	O
;	O
13Adenocarcinoma	O
;	O
14Bronchogenic	O
Cancer	O
,	O
histology	O
not	O
specified	O
;	O
15Poorly	O
differentiated	O
carcinoma	O
.	O

Table	O
2	O

Sequence	B-SO
for	O
each	O
primer	B-SO
used	O
for	O
StaRT	O
-	O
PCR	O
virtually	O
-	O
multiplexed	O
transcript	B-SO
abundance	O
measurement	O
or	O
for	O
internal	O
standard	O
preparation	O
(	O
CT	O
)	O
[	O
15	O
]	O
.	O

Table	O
3	O

Virtually	O
-	O
multiplexed	O
transcript	B-SO
abundance	O
data	O
.	O

Virtually	O
-	O
multiplexed	O
transcript	B-SO
abundance	O
data	O
for	O
each	O
gene	B-SO
(	O
in	O
the	O
form	O
of	O
molecules	B-CHEBI
/	O
106	O
beta	B-GGP
-	I-GGP
actin	I-GGP
molecules	B-CHEBI
)	O
from	O
all	O
experiments	O
were	O
included	O
in	O
the	O
same	O
Standardized	O
Expression	O
Database	O
(	O
SED	O
)	O
.	O

These	O
data	O
are	O
now	O
directly	O
comparable	O
to	O
previously	O
published	O
virtually	O
-	O
multiplexed	O
transcript	B-SO
abundance	O
data	O
from	O
this	O
laboratory	O
[	O
15	O
]	O
,	O
or	O
to	O
Virtually	O
-	O
multiplexed	O
transcript	B-SO
abundance	O
data	O
collected	O
by	O
others	O
who	O
use	O
the	O
NCI	O
-	O
funded	O
(	O
R24	O
CA	O
95806	O
)	O
Standardized	O
Expression	O
Measurement	O
(	O
SEM	O
)	O
Center	O
.	O

The	O
data	O
presented	O
here	O
represent	O
more	O
than	O
6	O
,	O
000	O
Virtually	O
-	O
multiplexed	O
transcript	B-SO
abundance	O
measurements	O
conducted	O
in	O
multiple	O
experiments	O
.	O

The	O
sixteen	O
antioxidant	B-CHEBI
or	O
DNA	B-SO
repair	O
genes	B-SO
and	O
each	O
of	O
the	O
six	O
transcription	O
factors	O
except	O
for	O
E2F1	B-GGP
were	O
measured	O
in	O
each	O
NBEC	O
sample	O
from	O
49	O
individuals	B-Taxon
(	O
24	O
non	O
-	O
BC	O
individuals	B-Taxon
and	O
25	O
BC	O
individuals	B-Taxon
)	O
.	O

1ND	O
,	O
Not	O
detectable	O
(	O
When	O
60	O
molecules	B-CHEBI
of	O
Competitive	O
Template	O
(	O
CT	O
)	O
were	O
added	O
to	O
the	O
reaction	O
,	O
CT	O
was	O
detected	O
but	O
native	O
template	O
was	O
not	O
.	O
)	O

2NA	O
,	O
Not	O
available	O
.	O

E2F1	B-GGP
was	O
measured	O
in	O
all	O
of	O
the	O
samples	O
except	O
for	O
one	O
BC	O
individual	B-Taxon
(	O
24	O
non	O
-	O
BC	O
individuals	B-Taxon
and	O
24	O
BC	O
individuals	B-Taxon
)	O
.	O

Table	O
4	O

Bivariate	O
analysis	O
of	O
virtually	O
-	O
multiplexed	O
transcript	B-SO
abundance	O
data	O
values	O
for	O
each	O
antioxidant	B-CHEBI
or	O
DNA	B-SO
repair	O
gene	B-SO
versus	O
each	O
transcription	O
factor	O
.	O

The	O
correlation	O
of	O
logarithmically	O
transformed	O
virtually	O
-	O
multiplexed	O
transcript	B-SO
abundance	O
data	O
(	O
Table	O
3	O
)	O
from	O
each	O
of	O
the	O
six	O
transcription	O
factors	O
with	O
each	O
of	O
the	O
sixteen	O
antioxidant	O
or	O
DNA	B-SO
repair	O
genes	B-SO
was	O
determined	O
.	O

The	O
transformation	O
was	O
necessary	O
due	O
to	O
the	O
wide	O
range	O
of	O
expression	O
of	O
each	O
gene	B-SO
among	O
the	O
samples	O
.	O

The	O
correlation	O
coefficient	O
(	O
r	O
value	O
)	O
and	O
level	O
of	O
significance	O
(	O
p	O
value	O
)	O
for	O
each	O
correlation	O
are	O
presented	O
.	O

Significance	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
was	O
determined	O
using	O
a	O
two	O
-	O
tailed	O
test	O
following	O
Bonferroni	O
adjustment	O
for	O
six	O
multiple	O
comparisons	O
(	O
comparison	O
of	O
each	O
of	O
six	O
transcription	O
factors	O
to	O
each	O
of	O
the	O
antioxidant	O
or	O
DNA	B-SO
repair	O
genes	B-SO
)	O
.	O

*	O
values	O
for	O
E2F1	B-GGP
obtained	O
in	O
all	O
but	O
one	O
BC	O
individuals	B-Taxon
.	O

Persistent	O
Amyloidosis	O
following	O
Suppression	O
of	O
A	B-GGP
beta	I-GGP
Production	O
in	O
a	O
Transgenic	B-SO
Model	O
of	O
Alzheimer	O
Disease	O

Abstract	O

Background	O

The	O
proteases	O
(	O
secretases	O
)	O
that	O
cleave	O
amyloid	B-GGP
-	I-GGP
beta	I-GGP
(	O
A	B-GGP
beta	I-GGP
)	O
peptide	B-SO
from	O
the	O
amyloid	B-GGP
precursor	I-GGP
protein	I-GGP
(	O
APP	B-GGP
)	O
have	O
been	O
the	O
focus	O
of	O
considerable	O
investigation	O
in	O
the	O
development	O
of	O
treatments	O
for	O
Alzheimer	O
disease	O
.	O

The	O
prediction	O
has	O
been	O
that	O
reducing	O
A	B-GGP
beta	I-GGP
production	O
in	O
the	O
brain	O
,	O
even	O
after	O
the	O
onset	O
of	O
clinical	O
symptoms	O
and	O
the	O
development	O
of	O
associated	O
pathology	O
,	O
will	O
facilitate	O
the	O
repair	O
of	O
damaged	O
tissue	O
and	O
removal	O
of	O
amyloid	O
lesions	O
.	O

However	O
,	O
no	O
long	O
-	O
term	O
studies	O
using	O
animal	B-Taxon
models	O
of	O
amyloid	O
pathology	O
have	O
yet	O
been	O
performed	O
to	O
test	O
this	O
hypothesis	O
.	O

Methods	O
and	O
Findings	O

We	O
have	O
generated	O
a	O
transgenic	B-SO
mouse	B-Taxon
model	O
that	O
genetically	B-SO
mimics	O
the	O
arrest	O
of	O
A	B-GGP
beta	I-GGP
production	O
expected	O
from	O
treatment	O
with	O
secretase	O
inhibitors	B-CHEBI
.	O

These	O
mice	B-Taxon
overexpress	O
mutant	B-SO
APP	B-GGP
from	O
a	O
vector	B-SO
that	O
can	O
be	O
regulated	O
by	O
doxycycline	O
.	O

Under	O
normal	O
conditions	O
,	O
high	O
-	O
level	O
expression	O
of	O
APP	B-GGP
quickly	O
induces	O
fulminant	O
amyloid	O
pathology	O
.	O

We	O
show	O
that	O
doxycycline	O
administration	O
inhibits	O
transgenic	B-SO
APP	B-GGP
expression	O
by	O
greater	O
than	O
95	O
%	O
and	O
reduces	O
A	B-GGP
beta	I-GGP
production	O
to	O
levels	O
found	O
in	O
nontransgenic	O
mice	B-Taxon
.	O

Suppression	O
of	O
transgenic	B-SO
A	B-GGP
beta	I-GGP
synthesis	O
in	O
this	O
model	O
abruptly	O
halts	O
the	O
progression	O
of	O
amyloid	O
pathology	O
.	O

However	O
,	O
formation	O
and	O
disaggregation	O
of	O
amyloid	O
deposits	O
appear	O
to	O
be	O
in	O
disequilibrium	O
as	O
the	O
plaques	O
require	O
far	O
longer	O
to	O
disperse	O
than	O
to	O
assemble	O
.	O

Mice	B-Taxon
in	O
which	O
APP	B-GGP
synthesis	O
was	O
suppressed	O
for	O
as	O
long	O
as	O
6	O
mo	O
after	O
the	O
formation	O
of	O
A	B-GGP
beta	I-GGP
deposits	O
retain	O
a	O
considerable	O
amyloid	O
load	O
,	O
with	O
little	O
sign	O
of	O
active	O
clearance	O
.	O

Conclusion	O

This	O
study	O
demonstrates	O
that	O
amyloid	O
lesions	O
in	O
transgenic	B-SO
mice	B-Taxon
are	O
highly	O
stable	O
structures	O
in	O
vivo	O
that	O
are	O
slow	O
to	O
disaggregate	O
.	O

Our	O
findings	O
suggest	O
that	O
arresting	O
A	B-GGP
beta	I-GGP
production	O
in	O
patients	O
with	O
Alzheimer	O
disease	O
should	O
halt	O
the	O
progression	O
of	O
pathology	O
,	O
but	O
that	O
early	O
treatment	O
may	O
be	O
imperative	O
,	O
as	O
it	O
appears	O
that	O
amyloid	O
deposits	O
,	O
once	O
formed	O
,	O
will	O
require	O
additional	O
intervention	O
to	O
clear	O
.	O

Introduction	O

Over	O
a	O
decade	O
ago	O
the	O
amyloid	O
cascade	O
hypothesis	O
predicted	O
that	O
increased	O
levels	O
of	O
amyloid	B-GGP
-	I-GGP
beta	I-GGP
(	O
A	B-GGP
beta	I-GGP
)	O
peptide	B-SO
lead	O
to	O
secondary	O
pathologies	O
that	O
ultimately	O
culminate	O
in	O
the	O
onset	O
of	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
[	O
1	O
]	O
.	O

Early	O
support	O
for	O
this	O
hypothesis	O
came	O
from	O
genetic	B-SO
studies	O
linking	O
early	O
-	O
onset	O
AD	O
to	O
mutations	B-SO
in	O
the	O
amyloid	B-GGP
precursor	I-GGP
protein	I-GGP
(	O
APP	B-GGP
)	O
,	O
from	O
which	O
A	B-GGP
beta	I-GGP
is	O
derived	O
,	O
and	O
presenilins	B-GGP
1	I-GGP
and	I-GGP
2	I-GGP
,	O
which	O
are	O
interchangeable	O
components	O
of	O
a	O
endoprotease	O
complex	B-GO
that	O
releases	O
A	B-GGP
beta	I-GGP
from	O
APP	B-GGP
(	O
for	O
review	O
see	O
[	O
2	O
,	O
3	O
]	O
)	O
.	O

If	O
,	O
as	O
predicted	O
,	O
overproduction	O
of	O
A	B-GGP
beta	I-GGP
initiates	O
the	O
cascade	O
of	O
events	O
leading	O
to	O
disease	O
,	O
then	O
therapeutic	O
strategies	O
that	O
lower	O
A	B-GGP
beta	I-GGP
levels	O
should	O
either	O
arrest	O
or	O
reverse	O
the	O
progression	O
from	O
peptide	B-SO
to	O
dementia	O
.	O

Early	O
evidence	O
from	O
clinical	O
trials	O
of	O
antibody	B-GO
-	O
mediated	O
clearance	O
,	O
one	O
of	O
the	O
first	O
A	B-GGP
beta	I-GGP
-	O
lowering	O
approaches	O
tested	O
in	O
humans	B-Taxon
,	O
suggested	O
that	O
treatments	O
designed	O
to	O
reduce	O
amyloid	O
burden	O
may	O
indeed	O
be	O
beneficial	O
.	O

Although	O
the	O
trials	O
were	O
halted	O
because	O
of	O
adverse	O
effects	O
in	O
a	O
subset	O
of	O
volunteers	O
[	O
4	O
,	O
5	O
]	O
,	O
further	O
analysis	O
of	O
several	O
patients	O
found	O
evidence	O
that	O
amyloid	O
pathology	O
,	O
and	O
to	O
a	O
lesser	O
degree	O
cognitive	O
function	O
,	O
was	O
improved	O
in	O
proportion	O
to	O
the	O
patient	O
'	O
s	O
titer	O
of	O
A	B-GGP
beta	I-GGP
-	O
specific	O
antibody	B-GO
[	O
6	O
,	O
7	O
]	O
.	O

While	O
this	O
approach	O
is	O
promising	O
,	O
constant	O
exposure	O
to	O
antibodies	B-GO
that	O
recognize	O
an	O
epitope	B-SO
highly	O
enriched	O
in	O
the	O
brain	O
may	O
have	O
unexpected	O
side	O
effects	O
that	O
will	O
limit	O
its	O
long	O
-	O
term	O
use	O
.	O

An	O
alternative	O
approach	O
that	O
is	O
being	O
actively	O
pursued	O
for	O
future	O
treatment	O
of	O
AD	O
seeks	O
to	O
lower	O
A	B-GGP
beta	I-GGP
levels	O
by	O
limiting	O
its	O
production	O
from	O
the	O
precursor	O
protein	B-CHEBI
APP	B-GGP
.	O

Peptide	B-SO
A	B-GGP
beta	I-GGP
is	O
released	O
from	O
APP	B-GGP
by	O
the	O
action	O
of	O
two	O
enzymes	B-SO
,	O
the	O
beta	B-GGP
-	I-GGP
APP	I-GGP
cleaving	I-GGP
enzyme	I-GGP
1	I-GGP
(	O
BACE1	B-GGP
)	O
and	O
gamma	O
-	O
secretase	O
,	O
which	O
cleave	O
the	O
holoprotein	O
at	O
the	O
N	B-SO
-	I-SO
and	I-SO
C	I-SO
-	I-SO
termini	I-SO
of	O
A	B-GGP
beta	I-GGP
,	O
respectively	O
.	O

Several	O
inhibitors	B-CHEBI
of	O
gamma	O
-	O
secretase	O
have	O
already	O
been	O
produced	O
[	O
8	O
,	O
9	O
]	O
,	O
and	O
small	O
molecule	B-CHEBI
inhibitors	B-CHEBI
of	O
beta	B-GGP
-	I-GGP
APP	I-GGP
cleaving	I-GGP
enzyme	I-GGP
1	I-GGP
are	O
currently	O
being	O
developed	O
[	O
10	O
,	O
11	O
]	O
.	O

The	O
long	O
-	O
term	O
effectiveness	O
of	O
this	O
approach	O
in	O
either	O
humans	B-Taxon
or	O
model	O
systems	O
,	O
however	O
,	O
has	O
not	O
been	O
reported	O
.	O

Although	O
loss	O
of	O
beta	B-GGP
-	I-GGP
APP	I-GGP
cleaving	I-GGP
enzyme	I-GGP
1	I-GGP
function	O
can	O
prevent	O
the	O
development	O
of	O
plaques	O
in	O
transgenic	B-SO
mouse	B-Taxon
models	O
for	O
AD	O
(	O
F	O
.	O
Laird	O
,	O
H	O
.	O
Cai	O
,	O
P	O
.	O
C	O
.	O
Wong	O
,	O
personal	O
communication	O
)	O
,	O
it	O
is	O
not	O
known	O
whether	O
the	O
brain	O
can	O
clear	O
pre	O
-	O
existing	O
amyloid	O
deposits	O
once	O
production	O
of	O
A	B-GGP
beta	I-GGP
has	O
been	O
suppressed	O
.	O

Clearly	O
,	O
the	O
amyloid	O
-	O
lowering	O
approach	O
should	O
be	O
rigorously	O
examined	O
in	O
animal	B-Taxon
models	O
before	O
these	O
reagents	B-CHEBI
are	O
tested	O
in	O
patients	O
.	O

However	O
,	O
the	O
chemical	B-CHEBI
secretase	I-CHEBI
inhibitors	I-CHEBI
most	O
likely	O
to	O
reach	O
human	B-Taxon
trials	O
are	O
still	O
in	O
development	O
.	O

Therefore	O
,	O
we	O
developed	O
a	O
mouse	B-Taxon
model	O
of	O
Alzheimer	O
-	O
type	O
amyloid	O
that	O
expresses	O
a	O
controllable	O
APP	B-GGP
transgene	B-SO
.	O

This	O
system	O
,	O
commonly	O
known	O
as	O
the	O
tet	O
-	O
off	O
system	O
,	O
can	O
be	O
regulated	O
by	O
analogs	O
of	O
tetracycline	B-CHEBI
administered	O
in	O
food	B-CHEBI
or	O
water	B-CHEBI
[	O
12	O
,	O
13	O
]	O
.	O

The	O
strong	O
expression	O
levels	O
produced	O
with	O
the	O
tet	O
-	O
off	O
vectors	B-SO
,	O
combined	O
with	O
the	O
ability	O
to	O
reduce	O
this	O
expression	O
by	O
several	O
orders	O
of	O
magnitude	O
with	O
tetracycline	B-CHEBI
[	O
14	O
]	O
,	O
allowed	O
for	O
a	O
stringent	O
test	O
of	O
how	O
a	O
highly	O
effective	O
pharmaceutical	B-CHEBI
inhibitor	B-CHEBI
of	O
A	B-GGP
beta	I-GGP
production	O
would	O
impact	O
the	O
progression	O
of	O
amyloid	O
pathology	O
and	O
whether	O
reversal	O
of	O
these	O
lesions	O
might	O
be	O
possible	O
following	O
such	O
treatment	O
.	O

Methods	O

Transgene	B-SO
Construction	O

We	O
created	O
a	O
tetracycline	B-CHEBI
-	O
responsive	O
chimeric	O
mouse	B-Taxon
/	O
human	B-Taxon
APP695Swedish	O
/	O
Indiana	B-GGP
(	O
swe	B-GGP
/	O
ind	B-GGP
)	O
vector	B-SO
by	O
replacing	B-SO
the	O
promoter	B-SO
region	I-SO
of	O
the	O
moPrP	B-GGP
.	O
XhoI	O
vector	B-SO
(	O
also	O
known	O
as	O
pPrPpE1	O
/	O
E2	O
,	O
3sal	O
[	O
15	O
]	O
)	O
with	O
the	O
tetracycline	B-CHEBI
-	O
responsive	O
promoter	B-SO
of	O
pTetSplice	O
(	O
Life	O
Technologies	O
,	O
Rockville	O
,	O
Maryland	O
,	O
United	O
States	O
)	O
,	O
and	O
then	O
ligating	O
mouse	B-GGP
APP	I-GGP
with	O
a	O
humanized	O
A	B-GGP
beta	I-GGP
domain	B-SO
(	O
mo	B-Taxon
/	O
huAPP695	B-GGP
)	O
cDNA	B-SO
into	O
the	O
new	O
vector	B-SO
.	O

We	O
began	O
by	O
cloning	O
the	O
tetracycline	B-CHEBI
-	O
responsive	O
promoter	B-SO
(	O
bp	B-SO
6	O
-	O
481	O
)	O
from	O
pTetSplice	O
by	O
PCR	O
using	O
primers	B-SO
that	O
added	O
external	O
BamHI	O
and	O
NotI	O
sites	B-SO
to	O
the	O
5	O
'	O
end	O
and	O
a	O
BamHI	O
site	B-SO
to	O
the	O
3	O
'	O
end	O
,	O
while	O
destroying	O
XhoI	O
and	O
BamHI	O
sites	B-SO
within	O
the	O
promoter	B-SO
(	O
forward	B-SO
:	O
GCC	O
GGA	O
TCC	O
GCG	O
GCC	O
GCC	O
GTC	O
GAG	O
TTT	O
ACC	O
ACT	O
CCC	O
TAT	O
C	B-CHEBI
;	O
reverse	B-SO
:	O
GCC	O
GGA	O
TCC	O
ACT	O
CTA	O
GAA	O
GAT	O
CCC	O
CGG	O
GTA	O
CCG	O
)	O
.	O

We	O
then	O
isolated	O
the	O
moPrP	B-GGP
.	O
XhoI	O
intron	B-SO
by	O
amplification	O
with	O
primers	B-SO
that	O
added	O
an	O
external	O
BamHI	O
site	B-SO
to	O
the	O
5	O
'	O
end	O
of	O
exon	B-SO
1	O
and	O
ran	O
through	O
the	O
Asp718	O
site	B-SO
of	I-SO
exon	I-SO
2	O
(	O
forward	B-SO
:	O
GCC	O
GGA	O
TCC	O
GAT	O
CAG	O
CAG	O
ACC	O
GAT	O
TCT	O
GG	O
;	O
reverse	B-SO
:	O
GCC	O
GGT	O
ACC	O
ACT	O
AGG	O
AAG	O
GCA	O
GAA	O
TGC	O
)	O
.	O

This	O
2	O
-	O
kb	O
intron	B-SO
fragment	B-SO
was	O
cloned	O
into	O
a	O
TA	O
cloning	O
vector	B-SO
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
California	O
,	O
United	O
States	O
)	O
,	O
then	O
excised	B-SO
by	O
Asp718	O
digestion	O
and	O
ligated	O
to	O
the	O
6	O
.	O
8	O
-	O
kb	O
Asp718	O
fragment	B-SO
of	O
moPrP	B-GGP
.	O
XhoI	O
containing	O
exon	B-SO
2	O
,	O
exon	B-SO
3	O
,	O
the	O
3	B-SO
'	I-SO
UTR	I-SO
,	O
and	O
pBluescript	O
to	O
generate	O
an	O
intermediate	B-SO
vector	B-SO
with	O
all	O
three	O
exons	B-SO
and	O
a	O
central	O
intron	B-SO
but	O
no	O
promoter	B-SO
.	O

This	O
vector	B-SO
was	O
then	O
opened	O
at	O
the	O
BamHI	O
site	B-SO
introduced	B-SO
by	O
the	O
intron	B-SO
cloning	O
primer	B-SO
,	O
and	O
ligated	O
to	O
the	O
0	O
.	O
5	O
-	O
kb	O
BamHI	O
-	O
cut	O
tetracycline	O
promoter	B-SO
fragment	B-SO
.	O

This	O
ligation	O
generated	O
a	O
9	O
.	O
3	O
-	O
kb	O
vector	B-SO
encoding	O
the	O
tetracycline	O
promoter	B-SO
from	O
pTetSplice	O
with	O
two	O
exons	B-SO
,	O
one	O
intron	B-SO
,	O
and	O
the	O
original	O
3	B-SO
'	I-SO
UTR	I-SO
of	O
the	O
moPrP	B-GGP
.	O
XhoI	O
vector	B-SO
,	O
all	O
carried	O
in	O
the	O
pBluescript	O
cloning	O
vector	B-SO
.	O

We	O
incorporated	O
the	O
Swedish	B-GGP
(	O
KM570	O
/	O
571NL	O
)	O
and	O
Indiana	B-GGP
(	O
V617F	O
)	O
mutations	B-SO
into	O
the	O
mo	B-Taxon
/	O
huAPP695	B-GGP
cDNA	B-SO
(	O
in	O
BS	O
-	O
KS	O
)	O
by	O
PCR	O
using	O
a	O
four	O
-	O
primer	B-SO
strategy	O
:	O
first	O
,	O
two	O
partially	O
overlapping	B-SO
products	B-SO
were	O
generated	O
in	O
separate	O
reactions	O
using	O
primers	B-SO
that	O
encode	O
the	O
desired	O
mutations	B-SO
(	O
Swedish	B-GGP
forward	B-SO
:	O
GGA	O
GAT	O
CTC	O
TGA	O
AGT	O
GAA	O
TCT	O
GGA	O
TGC	O
AGA	O
ATT	O
CCG	O
/	O
Indiana	B-GGP
reverse	B-SO
:	O
GGG	O
TGA	O
TGA	O
AAA	O
TCA	O
CGG	O
TTG	O
C	B-CHEBI
;	O
Indiana	B-GGP
forward	B-SO
:	O
CAA	O
CCG	O
TGA	O
TTT	O
TCA	O
TCA	O
CCC	O
TGG	O
/	O
M13	O
reverse	B-SO
)	O
.	O

The	O
two	O
PCR	B-SO
products	I-SO
were	O
ligated	O
,	O
digested	O
with	O
BglII	O
and	O
ApaI	O
and	O
cloned	O
back	O
into	O
the	O
original	O
mo	B-Taxon
/	O
huAPP695	B-GGP
-	O
BS	O
-	O
KS	O
vector	B-SO
.	O

Finally	O
,	O
the	O
new	O
APP695swe	O
/	O
ind	B-GGP
was	O
subcloned	O
into	O
the	O
XhoI	O
site	B-SO
of	O
the	O
moPrP	B-GGP
-	O
tetP	O
vector	B-SO
from	O
above	O
to	O
complete	O
the	O
construct	B-SO
.	O

Pronuclear	B-GO
Injection	O
,	O
Screening	O
of	O
Founders	O
,	O
and	O
Maintenance	O
of	O
the	O
Lines	O

The	O
moPrP	B-GGP
-	O
tetP	O
-	O
mo	B-Taxon
/	O
huAPP695swe	O
/	O
ind	B-GGP
vector	B-SO
was	O
linearized	O
and	O
the	O
pBluescript	O
domain	B-SO
excised	B-SO
by	O
digestion	O
with	O
NotI	O
.	O

The	O
purified	O
vector	B-SO
was	O
injected	O
into	O
the	O
pronucleus	B-GO
of	O
fertilized	O
eggs	B-CL
from	O
C57BL	O
/	O
6J	O
x	O
C3HeJ	O
F1	O
matings	O
.	O

Founder	O
animals	B-Taxon
were	O
screened	O
for	O
the	O
presence	O
of	O
the	O
transgene	B-SO
by	O
three	O
-	O
way	O
PCR	O
using	O
the	O
S36	O
and	O
PrP	B-GGP
-	O
S	O
/	O
PrP	B-GGP
-	O
AS	O
primers	B-SO
described	O
below	O
.	O

Transgene	B-SO
-	O
positive	O
founders	O
were	O
bred	O
to	O
animals	B-Taxon
expressing	O
the	O
tetracycline	B-CHEBI
transactivator	O
(	O
tTA	O
)	O
under	O
control	O
of	O
the	O
calcium	B-GGP
-	I-GGP
calmodulin	I-GGP
kinase	I-GGP
II	I-GGP
alpha	I-GGP
(	O
CaMKII	B-GGP
alpha	I-GGP
)	O
promoter	B-SO
obtained	O
from	O
Jackson	O
Laboratory	O
[	O
16	O
]	O
(	O
Bar	O
Harbor	O
,	O
Maine	O
,	O
United	O
States	O
;	O
stock	O
#	O
3010	O
;	O
B6	O
;	O
CBA	O
-	O
TgN	O
[	O
Camk2a	B-GGP
-	O
tTA	O
]	O
1Mmay	O
)	O
.	O

The	O
colony	O
was	O
thereafter	O
maintained	O
by	O
crossing	O
single	O
transgenic	B-SO
tTA	O
and	O
APP	B-GGP
offspring	O
for	O
each	O
of	O
the	O
four	O
APP	B-GGP
lines	O
.	O

All	O
mice	B-Taxon
were	O
provided	O
fresh	O
food	B-CHEBI
and	O
water	B-CHEBI
ad	O
libitum	O
.	O

Animal	B-Taxon
protocols	O
were	O
approved	O
by	O
both	O
the	O
Johns	O
Hopkins	O
University	O
and	O
the	O
California	O
Institute	O
of	O
Technology	O
Institutional	O
Animal	B-Taxon
Care	O
and	O
Use	O
Committees	O
.	O

Doxycycline	O
Administration	O

Doxycycline	O
(	O
dox	O
)	O
was	O
administered	O
through	O
commercially	O
available	O
dox	O
-	O
containing	O
chow	O
(	O
BioServ	O
,	O
Frenchtown	O
,	O
New	O
Jersey	O
,	O
United	O
States	O
)	O
.	O

The	O
chow	O
contained	O
200	O
mg	O
/	O
kg	O
of	O
antibiotic	B-CHEBI
;	O
based	O
on	O
estimated	O
consumption	O
of	O
5	O
g	O
per	O
mouse	B-Taxon
per	O
day	O
,	O
the	O
expected	O
dose	O
to	O
each	O
animal	B-Taxon
was	O
1	O
mg	O
dox	O
per	O
day	O
.	O

The	O
average	O
25	O
-	O
g	O
animal	B-Taxon
therefore	O
received	O
40	O
mu	O
g	O
of	O
dox	O
per	O
gram	O
body	O
weight	O
per	O
day	O
.	O

Chow	O
was	O
changed	O
1	O
-	O
2	O
times	O
per	O
week	O
to	O
prevent	O
breakdown	O
of	O
the	O
antibiotic	B-CHEBI
.	O

Genotyping	O

Offspring	O
were	O
genotyped	O
for	O
the	O
presence	O
of	O
each	O
transgene	B-SO
by	O
PCR	O
amplification	O
of	O
genomic	B-SO
DNA	I-SO
extracted	O
from	O
a	O
5	O
-	O
mm	O
tail	O
biopsy	O
.	O

Tails	O
were	O
heated	O
to	O
95	O
degrees	O
C	O
for	O
45	O
min	O
in	O
250	O
mu	O
l	O
of	O
50	O
mM	O
NaOH	B-CHEBI
,	O
vortexed	O
,	O
then	O
neutralized	O
with	O
an	O
equal	O
volume	O
of	O
0	O
.	O
5	O
M	O
Tris	B-CHEBI
-	O
HCl	B-CHEBI
(	O
pH	O
5	O
.	O
5	O
)	O
.	O

Debris	O
was	O
sedimented	O
by	O
centrifugation	O
,	O
and	O
3	O
mu	O
l	O
of	O
supernatant	O
was	O
used	O
for	O
amplification	O
.	O

Genotyping	O
for	O
APP	B-GGP
and	O
tTA	O
transgenes	B-SO
was	O
performed	O
in	O
the	O
same	O
PCR	O
reaction	O
,	O
using	O
five	O
separate	O
primers	B-SO
.	O

APP	B-GGP
was	O
amplified	O
using	O
forward	B-SO
primer	I-SO
S36	O
located	O
in	O
the	O
3	O
'	O
end	O
of	O
the	O
APP	B-GGP
cDNA	B-SO
(	O
CCG	O
AGA	O
TCT	O
CTG	O
AAG	O
TGA	O
AGA	O
TGG	O
ATG	O
)	O
and	O
reverse	B-SO
primer	I-SO
PrP	B-GGP
-	O
AS	O
-	O
J	O
located	O
in	O
the	O
3	B-SO
'	I-SO
UTR	I-SO
of	O
the	O
vector	B-SO
(	O
CCA	O
AGC	O
CTA	O
GAC	O
CAC	O
GAG	O
AAT	O
GC	O
)	O
.	O

The	O
tTA	O
transgene	B-SO
was	O
detected	O
using	O
a	O
primer	B-SO
set	O
that	O
amplified	O
across	O
its	O
two	O
subdomains	O
with	O
tet	O
forward	B-SO
located	O
within	O
the	O
Tn10	O
tetracycline	O
repressor	O
(	O
CGC	O
TGT	O
GGG	O
GCA	O
TTT	O
TAC	O
TTT	O
AG	O
)	O
and	O
tet	O
reverse	B-SO
within	O
the	O
HSV1	B-GGP
VP16	I-GGP
(	O
CAT	O
GTC	O
CAG	O
ATC	O
GAA	O
ATC	O
GTC	O
)	O
.	O

All	O
reactions	O
,	O
whether	O
transgene	B-SO
-	O
positive	O
or	O
not	O
,	O
amplified	O
a	O
segment	B-SO
of	I-SO
the	I-SO
endogenous	I-SO
prion	I-SO
protein	I-SO
gene	I-SO
as	O
a	O
control	O
for	O
DNA	B-SO
quality	O
using	O
a	O
forward	B-SO
primer	I-SO
,	O
PrP	B-GGP
-	O
S	O
-	O
J	O
,	O
specific	O
to	O
the	O
mouse	B-GGP
PrP	I-GGP
open	B-SO
reading	I-SO
frame	I-SO
(	O
GGG	O
ACT	O
ATG	O
TGG	O
ACT	O
GAT	O
GTC	O
GG	O
)	O
and	O
a	O
reverse	B-SO
primer	I-SO
,	O
PrP	B-GGP
-	O
AS	O
-	O
J	O
,	O
shared	O
by	O
the	O
3	B-SO
'	I-SO
UTR	I-SO
of	O
the	O
endogenous	O
PrP	B-GGP
gene	B-SO
and	O
the	O
transgene	B-SO
vector	B-SO
.	O

Amplification	O
reactions	O
were	O
run	O
for	O
37	O
cycles	O
at	O
94	O
degrees	O
C	O
for	O
30	O
s	O
,	O
64	O
degrees	O
C	O
for	O
1	O
min	O
,	O
and	O
72	O
degrees	O
C	O
for	O
1	O
min	O
.	O

All	O
samples	O
,	O
transgenic	B-SO
and	O
wild	B-SO
-	I-SO
type	I-SO
,	O
gave	O
a	O
750	O
-	O
bp	B-SO
product	B-SO
from	O
the	O
endogenous	O
PrP	B-GGP
gene	B-SO
.	O

The	O
APP	B-GGP
transgene	B-SO
yielded	O
an	O
additional	O
band	O
at	O
400	O
bp	B-SO
;	O
the	O
tTA	O
product	B-SO
fell	O
in	O
between	O
at	O
480	O
bp	B-SO
.	O

Immunoblotting	O
/	O
Quantitation	O

Frozen	O
cortical	O
or	O
whole	O
forebrain	O
tissue	O
was	O
homogenized	O
by	O
sonication	O
in	O
five	O
volumes	O
of	O
phosphate	B-CHEBI
-	O
buffered	B-CHEBI
saline	O
(	O
PBS	O
)	O
with	O
5	O
mM	O
EDTA	B-CHEBI
and	O
protease	B-CHEBI
inhibitors	I-CHEBI
(	O
Mammalian	B-Taxon
cell	B-CL
cocktail	O
,	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
Missouri	O
,	O
United	O
States	O
)	O
,	O
using	O
a	O
probe	B-SO
sonicator	O
set	O
to	O
50	O
%	O
output	O
(	O
TEKMAR	O
,	O
Cincinnati	O
,	O
Ohio	O
,	O
United	O
States	O
)	O
.	O

After	O
dilution	O
with	O
an	O
equal	O
volume	O
of	O
PBS	O
/	O
EDTA	B-CHEBI
/	O
protease	B-CHEBI
inhibitor	I-CHEBI
,	O
the	O
samples	O
were	O
centrifuged	O
briefly	O
and	O
the	O
supernatant	O
used	O
for	O
analysis	O
.	O

Fifty	O
micrograms	O
(	O
6E10	O
and	O
CT15	O
)	O
or	O
5	O
mu	O
g	O
(	O
22C11	O
)	O
of	O
brain	O
homogenate	O
was	O
loaded	O
per	O
lane	O
onto	O
7	O
.	O
5	O
%	O
,	O
10	O
%	O
-	O
20	O
%	O
,	O
or	O
4	O
%	O
-	O
20	O
%	O
Tris	B-CHEBI
-	O
HCl	B-CHEBI
PAGE	O
gels	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
,	O
Hercules	O
,	O
California	O
,	O
United	O
States	O
)	O
and	O
electrophoresed	O
for	O
several	O
hours	O
in	O
1	O
x	O
Tris	B-CHEBI
-	O
glycine	B-CHEBI
-	O
sodium	B-CHEBI
dodecyl	I-CHEBI
sulfate	I-CHEBI
(	O
1	O
x	O
TG	O
-	O
SDS	B-CHEBI
)	O
buffer	O
(	O
6E10	O
and	O
22C11	O
;	O
Amresco	O
,	O
Solon	O
,	O
Ohio	O
,	O
United	O
States	O
)	O
or	O
1	O
x	O
Tris	B-CHEBI
-	O
tricine	B-CHEBI
-	O
SDS	B-CHEBI
buffer	O
(	O
CT15	O
;	O
Invitrogen	O
,	O
Carlsbad	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

Proteins	B-CHEBI
were	O
transferred	O
overnight	O
to	O
0	O
.	O
45	O
-	O
mu	O
m	O
Optitran	O
nitrocellulose	O
(	O
Schleicher	O
and	O
Schuell	O
,	O
Keene	O
,	O
New	O
Hampshire	O
,	O
United	O
States	O
)	O
in	O
1	O
x	O
TG	O
buffer	O
(	O
Amresco	O
)	O
.	O

Blots	O
were	O
blocked	O
in	O
PBS	O
containing	O
5	O
%	O
nonfat	O
dry	O
milk	O
powder	O
,	O
and	O
incubated	O
for	O
3	O
h	O
at	O
room	O
temperature	O
in	O
blocking	O
solution	O
with	O
one	O
of	O
the	O
following	O
antibodies	B-GO
:	O
mouse	B-Taxon
monoclonal	O
22C11	O
(	O
kind	O
gift	O
of	O
Konrad	O
Beyreuther	O
and	O
Andreas	O
Weidemann	O
;	O
[	O
17	O
]	O
)	O
diluted	O
1	O
:	O
1	O
,	O
000	O
,	O
mouse	B-Taxon
monoclonal	O
6E10	O
(	O
Signet	O
Laboratories	O
,	O
Dedham	O
,	O
Massachusetts	O
,	O
United	O
States	O
)	O
diluted	O
1	O
:	O
2	O
,	O
500	O
,	O
rabbit	B-Taxon
polyclonal	O
anti	O
-	O
superoxide	B-GGP
dismutase	I-GGP
1	I-GGP
(	O
m	O
/	O
hSOD1	B-GGP
)	O
[	O
18	O
]	O
diluted	O
1	O
:	O
2	O
,	O
500	O
to	O
1	O
:	O
4	O
,	O
000	O
,	O
or	O
rabbit	B-Taxon
polyclonal	O
CT15	O
(	O
kind	O
gift	O
of	O
Ed	O
Koo	O
;	O
[	O
19	O
]	O
)	O
diluted	O
1	O
:	O
1	O
,	O
000	O
.	O

Subsequently	O
,	O
the	O
blots	O
were	O
washed	O
with	O
PBS	O
containing	O
0	O
.	O
1	O
%	O
Tween	O
-	O
20	O
,	O
and	O
then	O
incubated	O
with	O
either	O
goat	B-Taxon
anti	O
-	O
mouse	B-Taxon
-	O
or	O
goat	B-Taxon
anti	O
-	O
rabbit	B-Taxon
-	O
HRP	O
conjugated	O
secondary	O
antibody	B-GO
diluted	O
1	O
:	O
1	O
,	O
000	O
in	O
blocking	O
solution	O
.	O

After	O
several	O
additional	O
rinses	O
in	O
PBS	O
with	O
0	O
.	O
1	O
%	O
Tween	O
-	O
20	O
,	O
blots	O
were	O
developed	O
with	O
enhanced	O
chemiluminescence	O
reagent	B-CHEBI
and	O
imaged	O
with	O
the	O
Bio	O
-	O
Rad	O
Molecular	B-CHEBI
Imager	O
FX	O
system	O
.	O

Staining	O
intensity	O
within	O
each	O
lane	O
was	O
quantified	O
using	O
the	O
Quantity	O
One	O
image	O
analysis	O
software	O
(	O
Molecular	B-CHEBI
Imager	O
FX	O
,	O
Bio	O
-	O
Rad	O
Laboratories	O
)	O
.	O

Background	O
was	O
calculated	O
from	O
across	O
the	O
image	O
and	O
subtracted	O
from	O
the	O
entire	O
file	O
.	O

The	O
signal	O
intensity	O
for	O
each	O
band	O
(	O
corrected	O
signal	O
intensity	O
x	O
pixel	O
number	O
)	O
was	O
then	O
calculated	O
using	O
the	O
Volume	O
report	O
tool	O
.	O

Slot	O
Blot	O
mRNA	B-CHEBI
Analysis	O

Five	O
micrograms	O
per	O
sample	O
of	O
total	O
RNA	B-SO
extracted	O
from	O
fresh	O
-	O
frozen	O
brain	O
,	O
liver	O
,	O
kidney	O
,	O
heart	O
,	O
lung	O
,	O
spleen	O
,	O
and	O
skeletal	O
muscle	O
was	O
vacuum	O
-	O
filtered	O
through	O
0	O
.	O
45	O
-	O
mu	O
m	O
Optitran	O
nitrocellulose	O
.	O

After	O
several	O
washes	O
through	O
the	O
manifold	O
with	O
10	O
x	O
SSC	O
,	O
blots	O
were	O
UV	O
-	O
cross	O
-	O
linked	O
and	O
probed	O
with	O
a	O
radiolabeled	B-CHEBI
~	O
350	O
-	O
bp	B-SO
BglII	O
-	O
XhoI	O
cDNA	B-SO
fragment	B-SO
of	O
mo	B-Taxon
/	O
huAPP695	B-GGP
cDNA	B-SO
.	O

After	O
hybridizing	O
overnight	O
at	O
65	O
degrees	O
C	O
in	O
1	O
%	O
BSA	B-GGP
/	O
1	O
mM	O
EDTA	B-CHEBI
/	O
0	O
.	O
5	O
M	O
sodium	B-CHEBI
phosphate	I-CHEBI
buffer	O
(	O
pH	O
7	O
.	O
2	O
)	O
/	O
7	O
%	O
SDS	B-CHEBI
[	O
20	O
]	O
,	O
the	O
blots	O
were	O
washed	O
twice	O
at	O
65	O
degrees	O
C	O
for	O
30	O
min	O
each	O
in	O
0	O
.	O
1	O
%	O
BSA	B-GGP
/	O
1	O
mM	O
EDTA	B-CHEBI
/	O
40	O
mM	O
sodium	B-CHEBI
phosphate	I-CHEBI
buffer	O
(	O
pH	O
7	O
.	O
2	O
)	O
/	O
5	O
%	O
SDS	B-CHEBI
before	O
two	O
final	O
30	O
-	O
min	O
washes	O
at	O
65	O
degrees	O
C	O
with	O
1	O
mM	O
EDTA	B-CHEBI
/	O
40	O
mM	O
sodium	B-CHEBI
phosphate	I-CHEBI
buffer	O
(	O
pH	O
7	O
.	O
2	O
)	O
/	O
1	O
%	O
SDS	B-CHEBI
.	O

Blots	O
were	O
wrapped	O
wet	O
and	O
exposed	O
to	O
phosphorscreens	O
overnight	O
at	O
room	O
temperature	O
.	O

Amyloid	O
Histology	O

Mice	B-Taxon
were	O
euthanized	O
by	O
ether	O
inhalation	O
and	O
brains	O
removed	O
for	O
immersion	O
fixation	O
in	O
4	O
%	O
paraformaldehyde	O
/	O
1	O
x	O
PBS	O
.	O

After	O
48	O
h	O
in	O
fixative	O
at	O
4	O
degrees	O
C	O
,	O
brains	O
were	O
transferred	O
to	O
PBS	O
,	O
dehydrated	O
in	O
alcohols	B-CHEBI
,	O
treated	O
with	O
cedarwood	O
oil	O
and	O
methylsalicylate	O
,	O
and	O
embedded	O
in	O
paraffin	O
for	O
sectioning	O
.	O

Hirano	O
silver	B-CHEBI
stain	O

Silver	B-CHEBI
impregnation	O
histology	O
was	O
performed	O
on	O
10	O
-	O
mu	O
m	O
paraffin	O
-	O
embedded	O
sections	O
by	O
Hirano	O
'	O
s	O
modification	O
of	O
the	O
Bielschowsky	O
method	O
[	O
21	O
]	O
.	O

Briefly	O
,	O
sections	O
were	O
deparaffinized	O
through	O
xylene	B-CHEBI
and	O
alcohols	B-CHEBI
into	O
tap	O
water	B-CHEBI
before	O
being	O
placed	O
into	O
fresh	O
20	O
%	O
silver	B-CHEBI
nitrate	I-CHEBI
solution	O
for	O
20	O
min	O
.	O

After	O
being	O
washed	O
thoroughly	O
with	O
distilled	O
water	B-CHEBI
,	O
slides	O
were	O
immersed	O
in	O
20	O
%	O
silver	B-CHEBI
nitrate	I-CHEBI
solution	O
titrated	O
with	O
fresh	O
ammonium	B-CHEBI
hydroxide	I-CHEBI
.	O

After	O
20	O
min	O
,	O
slides	O
were	O
washed	O
with	O
ammonia	B-CHEBI
water	I-CHEBI
before	O
being	O
individually	O
developed	O
with	O
100	O
mu	O
l	O
of	O
developer	O
(	O
20	O
ml	O
of	O
37	O
%	O
formaldehyde	B-CHEBI
,	O
100	O
ml	O
of	O
distilled	O
water	B-CHEBI
,	O
50	O
mu	O
l	O
of	O
concentrated	O
nitric	B-CHEBI
acid	I-CHEBI
,	O
and	O
0	O
.	O
5	O
g	O
of	O
citric	B-CHEBI
acid	I-CHEBI
)	O
added	O
to	O
50	O
ml	O
of	O
titrated	O
silver	B-CHEBI
nitrate	I-CHEBI
solution	O
.	O

Slides	O
were	O
then	O
rinsed	O
in	O
tap	O
water	B-CHEBI
,	O
fixed	O
in	O
5	O
%	O
sodium	B-CHEBI
thiosulfate	B-CHEBI
,	O
and	O
dehydrated	O
through	O
alcohols	B-CHEBI
and	O
xylene	B-CHEBI
.	O

Thioflavin	O
-	O
S	O
staining	O

Following	O
deparaffinization	O
of	O
sections	O
through	O
xylene	B-CHEBI
and	O
alcohols	B-CHEBI
,	O
amyloid	O
impregnation	O
with	O
thioflavin	O
-	O
S	O
was	O
performed	O
according	O
to	O
the	O
Guntern	O
modification	O
of	O
the	O
standard	O
protocol	O
.	O

Slides	O
holding	O
10	O
-	O
mu	O
m	O
paraffin	O
sections	O
were	O
washed	O
twice	O
in	O
distilled	O
water	B-CHEBI
,	O
then	O
immersed	O
for	O
5	O
min	O
in	O
a	O
0	O
.	O
25	O
%	O
potassium	B-CHEBI
permanganate	B-CHEBI
solution	O
,	O
followed	O
by	O
5	O
min	O
in	O
a	O
1	O
%	O
potassium	B-CHEBI
metabisulfate	B-CHEBI
/	O
1	O
%	O
oxalic	B-CHEBI
acid	I-CHEBI
solution	O
.	O

After	O
this	O
preparation	O
,	O
slides	O
were	O
placed	O
into	O
a	O
filtered	O
aqueous	B-CHEBI
0	O
.	O
02	O
%	O
thioflavin	O
-	O
S	O
solution	O
(	O
Chroma	O
-	O
Gesellschaft	O
Schmid	O
,	O
Kongen	O
,	O
Germany	O
)	O
for	O
8	O
min	O
.	O

Excess	O
stain	O
was	O
removed	O
by	O
two	O
brief	O
rinses	O
in	O
80	O
%	O
ethanol	B-CHEBI
,	O
then	O
two	O
in	O
distilled	O
water	B-CHEBI
,	O
after	O
which	O
slides	O
were	O
finished	O
in	O
aqueous	B-CHEBI
mounting	O
medium	O
for	O
florescence	O
photomicrography	O
.	O

Ubiquitin	O
,	O
glial	B-GGP
fibrillary	I-GGP
acidic	I-GGP
protein	I-GGP
,	O
and	O
A	B-GGP
beta	I-GGP
immunohistochemistry	O

Prior	O
to	O
immunostaining	O
,	O
slides	O
were	O
deparaffinized	O
by	O
oven	O
heating	O
followed	O
by	O
immersion	O
in	O
xylene	B-CHEBI
.	O

After	O
rehydration	O
through	O
graded	O
alcohols	B-CHEBI
into	O
tap	O
water	B-CHEBI
,	O
endogenous	O
peroxidase	O
activity	O
was	O
quenched	O
by	O
incubation	O
with	O
3	O
%	O
hydrogen	B-CHEBI
peroxide	I-CHEBI
in	O
methanol	B-CHEBI
.	O

Slides	O
were	O
microwaved	O
for	O
5	O
-	O
7	O
min	O
in	O
water	B-CHEBI
,	O
cooled	O
for	O
5	O
min	O
,	O
then	O
washed	O
in	O
TBS	O
.	O

Nonspecific	O
staining	O
was	O
blocked	O
for	O
1	O
h	O
with	O
3	O
%	O
normal	O
goat	B-Taxon
serum	O
and	O
0	O
.	O
1	O
%	O
Triton	O
-	O
X	O
100	O
in	O
TBS	O
.	O

Slides	O
were	O
then	O
placed	O
into	O
primary	O
antibody	B-GO
(	O
rabbit	B-Taxon
anti	O
-	O
A	B-GGP
beta	I-GGP
peptide	B-SO
polyclonal	O
antibody	B-GO
,	O
Zymed	O
Laboratories	O
,	O
South	O
San	O
Francisco	O
,	O
California	O
,	O
United	O
States	O
;	O
rabbit	B-Taxon
anti	O
-	O
ubiquitin	O
and	O
rabbit	B-Taxon
anti	O
-	O
glial	B-GGP
fibrillary	I-GGP
acidic	I-GGP
protein	I-GGP
(	O
GFAP	B-GGP
)	O
polyclonal	O
antibodies	B-GO
,	O
Dako	O
,	O
Carpinteria	O
,	O
California	O
,	O
United	O
States	O
)	O
diluted	O
1	O
:	O
500	O
in	O
TBS	O
with	O
2	O
%	O
normal	O
goat	B-Taxon
serum	O
and	O
incubated	O
overnight	O
at	O
room	O
temperature	O
.	O

After	O
being	O
washed	O
of	O
excess	O
primary	O
antibody	B-GO
with	O
several	O
changes	O
of	O
TBS	O
,	O
slides	O
were	O
incubated	O
with	O
either	O
the	O
Vectastain	O
Elite	O
anti	O
-	O
rabbit	B-Taxon
secondary	O
system	O
(	O
anti	O
-	O
A	B-GGP
beta	I-GGP
;	O
Vector	O
Laboratories	O
,	O
Burlingame	O
,	O
California	O
,	O
United	O
States	O
)	O
or	O
peroxidase	O
/	O
anti	O
-	O
peroxidase	O
reagents	B-CHEBI
(	O
anti	O
-	O
ubitquitin	O
and	O
anti	O
-	O
GFAP	B-GGP
;	O
Sternberger	O
Monoclonals	O
,	O
Lutherville	O
,	O
Maryland	O
,	O
United	O
States	O
)	O
according	O
to	O
the	O
manufacturers	O
'	O
directions	O
.	O

Antibody	B-GO
binding	O
was	O
visualized	O
with	O
diaminobenzidene	O
,	O
and	O
sections	O
were	O
counterstained	O
with	O
hematoxylin	O
.	O

Filter	O
Trap	O
Assay	O

An	O
aliquot	O
of	O
each	O
cortical	O
homogenate	O
used	O
for	O
Western	O
blotting	O
above	O
was	O
partially	O
solubilized	O
by	O
the	O
addition	O
of	O
SDS	B-CHEBI
to	O
a	O
final	O
concentration	O
of	O
1	O
%	O
.	O

Serial	O
1	O
:	O
2	O
dilutions	O
were	O
made	O
with	O
1	O
x	O
PBS	O
/	O
1	O
%	O
SDS	B-CHEBI
,	O
and	O
100	O
mu	O
l	O
of	O
each	O
dilution	O
was	O
then	O
vacuum	O
-	O
filtered	O
through	O
a	O
pre	O
-	O
wet	O
0	O
.	O
22	O
-	O
mu	O
m	O
cellulose	O
acetate	B-CHEBI
membrane	O
(	O
Schleicher	O
and	O
Schuell	O
)	O
[	O
22	O
]	O
.	O

Each	O
well	O
was	O
washed	O
several	O
times	O
with	O
PBS	O
,	O
after	O
which	O
blots	O
were	O
incubated	O
overnight	O
with	O
polyclonal	O
anti	O
-	O
A	B-GGP
beta	I-GGP
antibody	B-GO
(	O
Zymed	O
Laboratories	O
)	O
diluted	O
1	O
:	O
600	O
in	O
a	O
blocking	O
solution	O
of	O
1	O
x	O
TBS	O
/	O
5	O
%	O
nonfat	O
dry	O
milk	O
powder	O
.	O

After	O
washing	O
the	O
blots	O
three	O
times	O
for	O
10	O
min	O
each	O
in	O
1	O
x	O
TBS	O
/	O
0	O
.	O
1	O
%	O
Tween	O
-	O
20	O
,	O
the	O
membrane	O
was	O
incubated	O
for	O
1	O
h	O
with	O
HRP	O
-	O
conjugated	O
protein	B-CHEBI
A	O
(	O
Sigma	O
)	O
diluted	O
1	O
:	O
5	O
,	O
000	O
in	O
blocking	O
solution	O
.	O

The	O
membranes	O
were	O
again	O
washed	O
three	O
times	O
with	O
1	O
x	O
TBS	O
/	O
0	O
.	O
1	O
%	O
Tween	O
-	O
20	O
,	O
before	O
antibody	B-GO
binding	O
was	O
detected	O
with	O
enhanced	O
chemiluminescence	O
(	O
PerkinElmer	O
,	O
Boston	O
,	O
Massachusetts	O
,	O
United	O
States	O
)	O
.	O

Digital	O
images	O
of	O
each	O
blot	O
were	O
captured	O
with	O
a	O
Molecular	B-CHEBI
Imager	O
FX	O
gel	O
documentation	O
system	O
,	O
and	O
the	O
intensity	O
of	O
A	B-GGP
beta	I-GGP
staining	O
was	O
quantified	O
using	O
Quantity	O
One	O
image	O
analysis	O
software	O
.	O

A	B-GGP
beta	I-GGP
ELISA	O

An	O
aliquot	O
of	O
cortical	O
homogenate	O
generated	O
for	O
Western	O
analysis	O
described	O
above	O
was	O
subjected	O
to	O
a	O
three	O
-	O
step	O
sequential	O
extraction	O
using	O
PBS	O
,	O
2	O
%	O
SDS	B-CHEBI
,	O
and	O
70	O
%	O
formic	B-CHEBI
acid	I-CHEBI
(	O
FA	B-CHEBI
)	O
.	O

At	O
each	O
step	O
,	O
the	O
sample	O
was	O
sonicated	O
in	O
appropriate	O
buffer	O
and	O
centrifuged	O
at	O
100	O
,	O
000g	O
for	O
30	O
min	O
(	O
1	O
-	O
to	O
1	O
.	O
5	O
-	O
mo	O
samples	O
)	O
or	O
60	O
min	O
(	O
6	O
-	O
to	O
12	O
-	O
mo	O
samples	O
)	O
at	O
4	O
degrees	O
C	O
as	O
previously	O
described	O
[	O
23	O
-	O
25	O
]	O
.	O

The	O
supernatant	O
was	O
removed	O
for	O
analysis	O
,	O
and	O
the	O
pellet	O
was	O
sonicated	O
in	O
the	O
next	O
solution	O
in	O
sequence	O
.	O

The	O
2	O
%	O
SDS	B-CHEBI
extracts	O
were	O
diluted	O
in	O
EC	O
buffer	O
,	O
and	O
the	O
FA	B-CHEBI
extracts	O
neutralized	O
with	O
1M	O
Tris	B-CHEBI
-	O
phosphate	B-CHEBI
buffer	O
(	O
pH	O
11	O
)	O
then	O
diluted	O
with	O
EC	O
buffer	O
prior	O
to	O
testing	O
.	O

Human	B-Taxon
A	B-GGP
beta	I-GGP
was	O
measured	O
in	O
each	O
fraction	O
using	O
BAN50	O
for	O
capture	O
(	O
epitope	B-SO
A	O
beta	O
1	O
-	O
16	O
)	O
and	O
BA27	O
and	O
BC05	O
for	O
detection	O
(	O
A	B-GGP
beta	I-GGP
40	I-GGP
and	O
A	B-GGP
beta	I-GGP
42	I-GGP
,	O
respectively	O
)	O
(	O
Takeda	O
Chemical	B-CHEBI
Industries	O
,	O
Osaka	O
,	O
Japan	O
)	O
.	O

Total	O
A	B-GGP
beta	I-GGP
(	O
mouse	B-Taxon
+	O
human	B-Taxon
;	O
1	O
-	O
to	O
1	O
.	O
5	O
-	O
mo	O
samples	O
only	O
)	O
was	O
measured	O
in	O
each	O
fraction	O
using	O
BNT77	O
for	O
capture	O
(	O
epitope	B-SO
A	O
beta	O
11	O
-	O
28	O
)	O
and	O
BA27	O
and	O
BC05	O
for	O
detection	O
.	O

All	O
values	O
were	O
calculated	O
as	O
picomoles	O
per	O
gram	O
based	O
on	O
the	O
initial	O
weight	O
of	O
cortical	O
tissue	O
.	O

Activity	O
Monitoring	O

Daily	O
basal	O
activity	O
was	O
studied	O
in	O
28	O
CaMKII	B-GGP
alpha	I-GGP
-	O
tTA	O
x	O
tet	O
-	O
APPswe	O
/	O
ind	B-GGP
line	O
107	O
mice	B-Taxon
between	O
4	O
and	O
5	O
mo	O
of	O
age	O
.	O

Animals	B-Taxon
were	O
separated	O
into	O
individual	O
cages	O
immediately	O
before	O
the	O
start	O
of	O
each	O
experiment	O
(	O
n	O
=	O
3	O
-	O
6	O
per	O
genotype	B-SO
untreated	O
,	O
2	O
-	O
5	O
per	O
genotype	B-SO
dox	O
-	O
reared	O
)	O
.	O

The	O
cages	O
were	O
placed	O
inside	O
activity	O
-	O
monitoring	O
frames	O
designed	O
to	O
count	O
every	O
time	O
the	O
animal	B-Taxon
passed	O
through	O
one	O
of	O
three	O
photobeams	O
spanning	O
the	O
width	O
of	O
the	O
cage	O
(	O
San	O
Diego	O
Instruments	O
,	O
San	O
Diego	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

Experiments	O
were	O
started	O
midway	O
through	O
the	O
light	O
phase	O
of	O
the	O
day	O
,	O
and	O
data	O
were	O
collected	O
in	O
1	O
-	O
h	O
bins	O
for	O
the	O
following	O
48	O
h	O
.	O

Testing	O
rooms	O
were	O
maintained	O
on	O
the	O
same	O
13	O
:	O
11	O
h	O
day	O
:	O
night	O
cycle	O
as	O
the	O
main	O
animal	B-Taxon
housing	O
areas	O
and	O
were	O
closed	O
to	O
entry	O
during	O
the	O
experiment	O
.	O

Statistical	O
Analyses	O

Statistical	O
analyses	O
of	O
protein	B-CHEBI
expression	O
,	O
ELISA	O
data	O
,	O
and	O
filter	O
trap	O
assays	O
were	O
performed	O
by	O
ANOVA	O
with	O
Tukey	O
'	O
s	O
honest	O
significant	O
difference	O
post	O
-	O
hoc	O
test	O
applied	O
to	O
significant	O
main	O
effects	O
or	O
interactions	O
(	O
Statistica	O
6	O
.	O
0	O
,	O
StatSoft	O
,	O
Tulsa	O
,	O
Oklahoma	O
,	O
United	O
States	O
)	O
.	O

In	O
cases	O
of	O
positively	O
skewed	O
data	O
distribution	O
,	O
log10	O
(	O
x	O
+	O
0	O
.	O
5	O
)	O
transformation	O
was	O
applied	O
to	O
the	O
raw	O
data	O
before	O
submitting	O
them	O
to	O
ANOVA	O
.	O

Results	O

We	O
used	O
the	O
tet	O
-	O
off	O
transgene	B-SO
system	O
to	O
express	O
a	O
double	O
mutant	B-SO
version	B-SO
of	O
chimeric	O
mo	B-Taxon
/	O
huAPP695	B-GGP
(	O
swe	B-GGP
/	O
ind	B-GGP
KM570	O
,	O
571NL	O
,	O
and	O
V617F	O
)	O
from	O
a	O
tetracycline	B-CHEBI
-	O
responsive	O
promoter	B-SO
[	O
12	O
,	O
13	O
]	O
.	O

Transgenic	B-SO
APP	B-GGP
expression	O
was	O
activated	O
by	O
crossing	O
the	O
APPswe	O
/	O
ind	B-GGP
mice	B-Taxon
to	O
animals	B-Taxon
producing	O
tTA	O
under	O
control	O
of	O
the	O
CaMKII	B-GGP
alpha	I-GGP
promoter	B-SO
[	O
16	O
]	O
.	O

After	O
initial	O
screening	O
of	O
founders	O
,	O
we	O
identified	O
four	O
lines	O
of	O
tet	O
-	O
APPswe	O
/	O
ind	B-GGP
mice	B-Taxon
that	O
produced	O
very	O
high	O
levels	O
of	O
transgene	B-SO
product	O
in	O
offspring	O
coexpressing	O
tTA	O
(	O
Figures	O
1	O
and	O
Figure	O
S1	O
)	O
.	O

Compared	O
to	O
a	O
standard	O
APP	B-GGP
transgenic	B-SO
line	O
used	O
for	O
previous	O
amyloid	O
studies	O
by	O
our	O
laboratory	O
(	O
line	O
C3	O
-	O
3	O
;	O
[	O
15	O
,	O
26	O
,	O
27	O
]	O
)	O
,	O
we	O
estimated	O
that	O
the	O
four	O
controllable	O
lines	O
produce	O
transgenic	B-SO
APP	B-GGP
protein	B-CHEBI
at	O
10	O
-	O
to	O
30	O
-	O
fold	O
over	O
endogenous	O
levels	O
(	O
Figure	O
S1	O
)	O
.	O

This	O
estimate	O
was	O
confirmed	O
by	O
direct	O
comparison	O
of	O
APP	B-GGP
levels	O
in	O
nontransgenic	O
and	O
tet	O
-	O
off	O
APP	B-GGP
mice	B-Taxon
using	O
an	O
antibody	B-GO
that	O
recognizes	O
both	O
endogenous	O
APP	B-GGP
(	O
and	O
amyloid	B-GGP
precursor	I-GGP
-	I-GGP
like	I-GGP
protein	I-GGP
2	I-GGP
)	O
and	O
the	O
transgenic	B-SO
protein	B-CHEBI
(	O
monoclonal	O
antibody	B-GO
22C11	O
;	O
Figure	O
1D	O
)	O
.	O

Importantly	O
,	O
all	O
four	O
new	O
lines	O
of	O
tet	O
-	O
off	O
APP	B-GGP
mice	B-Taxon
showed	O
nearly	O
complete	O
suppression	O
of	O
the	O
transgene	B-SO
following	O
dox	O
treatment	O
(	O
Figures	O
1	O
and	O
Figure	O
S1	O
)	O
.	O

We	O
focused	O
on	O
one	O
of	O
the	O
four	O
lines	O
,	O
line	O
107	O
,	O
to	O
examine	O
in	O
more	O
detail	O
the	O
time	O
dependence	O
and	O
extent	O
of	O
transgene	B-SO
suppression	O
following	O
either	O
acute	O
or	O
chronic	O
treatment	O
with	O
dox	O
.	O

Two	O
dox	O
-	O
treated	O
groups	O
were	O
compared	O
to	O
two	O
untreated	O
groups	O
:	O
one	O
group	O
of	O
mice	B-Taxon
was	O
born	O
and	O
raised	O
on	O
dox	O
,	O
a	O
second	O
group	O
was	O
treated	O
with	O
dox	O
for	O
2	O
wk	O
starting	O
at	O
1	O
mo	O
of	O
age	O
(	O
4	O
wk	O
+	O
2	O
wk	O
dox	O
)	O
;	O
two	O
untreated	O
groups	O
kept	O
on	O
normal	O
chow	O
were	O
harvested	O
at	O
either	O
4	O
or	O
6	O
wk	O
of	O
age	O
.	O

Animals	B-Taxon
born	O
and	O
raised	O
on	O
dox	O
harbored	O
no	O
transgenic	B-SO
APP	B-GGP
(	O
Figure	O
1A	O
)	O
.	O

Following	O
as	O
little	O
as	O
2	O
wk	O
of	O
dox	O
treatment	O
,	O
transgenic	B-SO
APP	B-GGP
expression	O
was	O
reduced	O
by	O
more	O
than	O
95	O
%	O
compared	O
to	O
pre	O
-	O
dox	O
levels	O
.	O

The	O
residual	O
expression	O
remaining	O
in	O
acutely	O
treated	O
mice	B-Taxon
represents	O
less	O
than	O
4	O
%	O
of	O
the	O
transgenic	B-SO
protein	B-CHEBI
produced	O
in	O
the	O
absence	O
of	O
dox	O
(	O
Figure	O
1C	O
)	O
,	O
and	O
likely	O
results	O
from	O
slight	O
leakage	O
at	O
the	O
level	O
of	O
transcription	O
(	O
data	O
not	O
shown	O
)	O
.	O

Importantly	O
,	O
the	O
total	O
amount	O
of	O
APP	B-GGP
(	O
endogenous	O
plus	O
transgenic	B-SO
)	O
and	O
related	O
APLPs	O
in	O
both	O
acute	O
and	O
chronically	O
treated	O
animals	B-Taxon
was	O
statistically	O
indistinguishable	O
from	O
that	O
in	O
nontransgenic	O
mice	B-Taxon
(	O
Figure	O
1D	O
;	O
statistical	O
analyses	O
for	O
experiments	O
throughout	O
the	O
study	O
are	O
presented	O
in	O
the	O
accompanying	O
figure	O
legends	O
)	O
.	O

To	O
ensure	O
that	O
A	B-GGP
beta	I-GGP
production	O
was	O
suppressed	O
in	O
concert	O
with	O
the	O
dox	O
-	O
mediated	O
inhibition	O
of	O
its	O
precursor	O
APPswe	O
/	O
ind	B-GGP
,	O
we	O
measured	O
A	B-GGP
beta	I-GGP
40	I-GGP
and	O
A	B-GGP
beta	I-GGP
42	I-GGP
levels	O
by	O
ELISA	O
in	O
forebrain	O
homogenates	O
from	O
young	O
tet	O
-	O
off	O
animals	B-Taxon
.	O

At	O
1	O
mo	O
of	O
age	O
,	O
the	O
mice	B-Taxon
lacked	O
visible	O
amyloid	O
aggregates	O
that	O
might	O
act	O
as	O
an	O
intractable	O
reservoir	O
of	O
peptide	B-SO
remaining	O
in	O
the	O
brain	O
after	O
the	O
transgene	B-SO
had	O
been	O
suppressed	O
.	O

To	O
further	O
ensure	O
we	O
could	O
detect	O
any	O
such	O
insoluble	O
aggregates	O
that	O
might	O
bias	O
our	O
measure	O
of	O
changes	O
in	O
peptide	B-SO
synthesis	O
,	O
we	O
performed	O
a	O
sequential	O
three	O
-	O
step	O
extraction	O
with	O
PBS	O
,	O
2	O
%	O
SDS	B-CHEBI
,	O
and	O
70	O
%	O
FA	B-CHEBI
that	O
would	O
separate	O
peptides	B-SO
by	O
solubility	O
.	O

We	O
compared	O
the	O
levels	O
of	O
human	B-Taxon
transgene	B-SO
-	O
derived	O
A	B-GGP
beta	I-GGP
40	I-GGP
and	O
A	B-GGP
beta	I-GGP
42	I-GGP
in	O
untreated	O
mice	B-Taxon
at	O
4	O
and	O
6	O
wk	O
of	O
age	O
to	O
animals	B-Taxon
that	O
had	O
either	O
been	O
born	O
and	O
raised	O
on	O
dox	O
or	O
that	O
had	O
been	O
left	O
untreated	O
for	O
4	O
wk	O
and	O
then	O
placed	O
on	O
dox	O
chow	O
for	O
2	O
wk	O
prior	O
to	O
harvest	O
(	O
the	O
same	O
groups	O
described	O
above	O
for	O
immunoblot	O
analysis	O
of	O
APPswe	O
/	O
ind	B-GGP
levels	O
,	O
line	O
107	O
)	O
.	O

Consistent	O
with	O
the	O
reduction	O
in	O
full	O
-	O
length	O
APPswe	O
/	O
ind	B-GGP
synthesis	O
shown	O
by	O
immunoblot	O
(	O
see	O
Figure	O
1	O
)	O
,	O
we	O
found	O
that	O
transgene	B-SO
-	O
derived	O
A	B-GGP
beta	I-GGP
levels	O
were	O
completely	O
suppressed	O
in	O
animals	B-Taxon
born	O
and	O
raised	O
on	O
dox	O
,	O
and	O
were	O
sharply	O
reduced	O
following	O
acute	O
(	O
2	O
wk	O
)	O
antibiotic	B-CHEBI
treatment	O
.	O

Compared	O
to	O
the	O
levels	O
in	O
untreated	O
4	O
-	O
wk	O
-	O
old	O
mice	B-Taxon
,	O
PBS	O
-	O
soluble	O
A	B-GGP
beta	I-GGP
42	I-GGP
dropped	O
by	O
95	O
.	O
2	O
%	O
following	O
2	O
wk	O
of	O
dox	O
treatment	O
and	O
by	O
99	O
.	O
2	O
%	O
with	O
chronic	O
treatment	O
(	O
Figure	O
2A	O
)	O
.	O

Similarly	O
,	O
SDS	B-CHEBI
-	O
soluble	O
A	B-GGP
beta	I-GGP
42	I-GGP
decreased	O
by	O
75	O
.	O
2	O
%	O
and	O
94	O
.	O
8	O
%	O
following	O
2	O
-	O
wk	O
or	O
lifelong	O
dox	O
treatment	O
(	O
Figure	O
2B	O
)	O
.	O

Only	O
the	O
FA	B-CHEBI
fraction	B-GO
revealed	O
a	O
small	O
dox	O
-	O
resistant	O
pool	O
of	O
peptide	B-SO
in	O
acutely	O
treated	O
animals	B-Taxon
that	O
we	O
believe	O
represents	O
stable	O
predeposit	O
aggregates	O
that	O
have	O
already	O
accumulated	O
by	O
4	O
wk	O
of	O
age	O
when	O
treatment	O
was	O
begun	O
(	O
Figure	O
2C	O
)	O
.	O

Indeed	O
,	O
animals	B-Taxon
that	O
were	O
born	O
and	O
raised	O
on	O
dox	O
did	O
not	O
harbor	O
this	O
reservoir	O
of	O
treatment	O
-	O
resistant	O
peptide	B-SO
,	O
with	O
96	O
.	O
3	O
%	O
less	O
A	B-GGP
beta	I-GGP
42	I-GGP
than	O
untreated	O
4	O
-	O
wk	O
-	O
old	O
mice	B-Taxon
.	O

Measurement	O
of	O
total	O
A	B-GGP
beta	I-GGP
in	O
chronically	O
treated	O
mice	B-Taxon
,	O
including	O
endogenous	O
and	O
transgene	B-SO
-	O
derived	O
peptide	B-SO
,	O
demonstrated	O
that	O
A	B-GGP
beta	I-GGP
levels	O
in	O
tet	O
-	O
off	O
APP	B-GGP
mice	B-Taxon
were	O
reduced	O
to	O
the	O
level	O
of	O
endogenous	O
peptide	B-SO
found	O
in	O
nontransgenic	O
animals	B-Taxon
(	O
Figure	O
2D	O
)	O
.	O

Taken	O
together	O
with	O
the	O
immunoblotting	O
data	O
for	O
full	O
-	O
length	O
APPswe	O
/	O
ind	B-GGP
,	O
the	O
ELISA	O
measurements	O
indicate	O
that	O
dox	O
-	O
mediated	O
suppression	O
of	O
transgenic	B-SO
APPswe	O
/	O
ind	B-GGP
synthesis	O
leads	O
to	O
parallel	O
reduction	O
of	O
A	B-GGP
beta	I-GGP
levels	O
.	O

The	O
ELISA	O
data	O
also	O
confirmed	O
that	O
incorporation	O
of	O
the	O
Swedish	B-GGP
and	O
Indiana	B-GGP
mutations	B-SO
led	O
to	O
high	O
levels	O
of	O
A	B-GGP
beta	I-GGP
42	I-GGP
,	O
which	O
we	O
predicted	O
would	O
induce	O
rapid	O
plaque	O
formation	O
in	O
untreated	O
animals	B-Taxon
.	O

Histological	O
characterization	O
of	O
double	O
transgenic	B-SO
(	O
CaMKII	B-GGP
alpha	I-GGP
-	O
tTA	O
x	O
tet	O
-	O
APPswe	O
/	O
ind	B-GGP
)	O
mice	B-Taxon
revealed	O
early	O
-	O
onset	O
amyloid	O
formation	O
in	O
all	O
four	O
new	O
lines	O
.	O

Amyloid	O
plaques	O
were	O
seen	O
in	O
mice	B-Taxon
as	O
young	O
as	O
8	O
wk	O
of	O
age	O
(	O
data	O
not	O
shown	O
)	O
.	O

Plaques	O
were	O
limited	O
to	O
the	O
forebrain	O
,	O
including	O
the	O
cortex	O
,	O
hippocampus	O
,	O
olfactory	O
bulb	O
,	O
and	O
striatum	O
,	O
where	O
the	O
CaMKII	B-GGP
alpha	I-GGP
promoter	B-SO
is	O
known	O
to	O
be	O
most	O
active	O
[	O
16	O
,	O
28	O
]	O
(	O
Figure	O
S2	O
)	O
.	O

By	O
6	O
mo	O
of	O
age	O
,	O
amyloid	O
burden	O
became	O
severe	O
,	O
covering	O
large	O
areas	O
of	O
the	O
cortex	O
and	O
hippocampus	O
(	O
Figure	O
S3	O
)	O
.	O

No	O
lesions	O
were	O
seen	O
in	O
the	O
cerebellum	O
or	O
brain	O
stem	O
even	O
at	O
late	O
ages	O
,	O
consistent	O
with	O
CaMKII	B-GGP
alpha	I-GGP
-	O
controlled	O
transgene	B-SO
expression	O
.	O

Unlike	O
what	O
is	O
thought	O
to	O
occur	O
in	O
the	O
human	B-Taxon
disease	O
,	O
the	O
first	O
visible	O
plaques	O
in	O
the	O
tet	O
-	O
off	O
APP	B-GGP
mice	B-Taxon
are	O
fibrillar	O
-	O
cored	O
deposits	O
.	O

We	O
have	O
noted	O
the	O
same	O
early	O
appearance	O
of	O
cored	O
deposits	O
in	O
other	O
lines	O
of	O
APP	B-GGP
transgenic	B-SO
mice	B-Taxon
that	O
harbor	O
the	O
Swedish	B-GGP
mutation	B-SO
[	O
27	O
]	O
.	O

Diffuse	O
plaques	O
were	O
apparent	O
in	O
6	O
-	O
mo	O
-	O
old	O
tTA	O
/	O
APP	B-GGP
mice	B-Taxon
,	O
and	O
became	O
relatively	O
abundant	O
by	O
9	O
mo	O
of	O
age	O
.	O

At	O
older	O
ages	O
(	O
9	O
-	O
12	O
mo	O
)	O
amyloid	O
deposits	O
were	O
visible	O
in	O
the	O
thalamus	O
,	O
which	O
has	O
also	O
been	O
observed	O
in	O
mice	B-Taxon
expressing	O
mutant	B-SO
APP	B-GGP
via	O
the	O
Thy	B-GGP
-	I-GGP
1	I-GGP
promoter	B-SO
.	O

The	O
presence	O
of	O
amyloid	O
pathology	O
in	O
this	O
region	O
has	O
been	O
attributed	O
to	O
axonal	B-GO
transport	O
of	O
APP	B-GGP
/	O
A	B-GGP
beta	I-GGP
to	O
the	O
terminals	B-GO
of	I-GO
cortical	I-GO
neurons	I-GO
in	O
the	O
thalamus	O
[	O
29	O
]	O
.	O

Most	O
importantly	O
,	O
only	O
double	O
transgenic	B-SO
mice	B-Taxon
,	O
expressing	O
both	O
the	O
tTA	O
and	O
APP	B-GGP
transgenes	B-SO
,	O
developed	O
amyloid	O
lesions	O
.	O

Single	O
transgenic	B-SO
mice	B-Taxon
up	O
to	O
15	O
mo	O
of	O
age	O
showed	O
no	O
sign	O
of	O
pathology	O
(	O
Figure	O
S3	O
)	O
.	O

Similarly	O
,	O
amyloid	O
pathology	O
can	O
be	O
completely	O
prevented	O
in	O
double	O
transgenic	B-SO
animals	B-Taxon
born	O
and	O
raised	O
on	O
dox	O
.	O

Animals	B-Taxon
from	O
our	O
highest	O
expressing	O
line	O
(	O
line	O
885	O
)	O
maintained	O
on	O
dox	O
for	O
up	O
to	O
1	O
y	O
harbored	O
no	O
amyloid	O
pathology	O
(	O
data	O
not	O
shown	O
)	O
,	O
indicating	O
that	O
residual	O
leakage	O
of	O
transgene	B-SO
expression	O
in	O
the	O
presence	O
of	O
dox	O
does	O
not	O
provide	O
sufficient	O
A	B-GGP
beta	I-GGP
peptide	B-SO
to	O
induce	O
amyloid	O
formation	O
even	O
over	O
long	O
periods	O
.	O

To	O
mimic	O
therapeutic	O
intervention	O
with	O
inhibitors	B-CHEBI
of	O
A	B-GGP
beta	I-GGP
production	O
,	O
we	O
raised	O
a	O
group	O
of	O
25	O
double	O
transgenic	B-SO
mice	B-Taxon
(	O
CaMKII	B-GGP
alpha	I-GGP
-	O
tTA	O
x	O
APP	B-GGP
line	O
107	O
)	O
on	O
normal	O
food	B-CHEBI
until	O
6	O
mo	O
of	O
age	O
,	O
when	O
we	O
knew	O
amyloid	O
formation	O
was	O
already	O
well	O
underway	O
in	O
the	O
brain	O
.	O

At	O
6	O
mo	O
,	O
half	O
of	O
the	O
animals	B-Taxon
were	O
switched	O
from	O
normal	O
chow	O
to	O
food	B-CHEBI
containing	O
dox	O
at	O
200	O
mg	O
/	O
kg	O
until	O
they	O
were	O
sacrificed	O
at	O
9	O
or	O
12	O
mo	O
of	O
age	O
.	O

The	O
remaining	O
control	O
animals	B-Taxon
were	O
kept	O
on	O
standard	O
chow	O
(	O
untreated	O
)	O
.	O

In	O
all	O
,	O
four	O
cohorts	O
were	O
created	O
:	O
6	O
mo	O
untreated	O
(	O
n	O
=	O
7	O
)	O
,	O
9	O
mo	O
untreated	O
(	O
n	O
=	O
5	O
)	O
,	O
6	O
mo	O
+	O
3	O
mo	O
treated	O
(	O
n	O
=	O
8	O
)	O
,	O
and	O
6	O
mo	O
+	O
6	O
mo	O
treated	O
(	O
n	O
=	O
5	O
)	O
.	O

Full	O
suppression	O
(	O
>	O
95	O
%	O
)	O
of	O
transgenic	B-SO
APPswe	O
/	O
ind	B-GGP
levels	O
in	O
the	O
dox	O
-	O
treated	O
animals	B-Taxon
was	O
confirmed	O
by	O
immunoblot	O
(	O
Figure	O
3	O
)	O
.	O

To	O
ensure	O
that	O
the	O
transgene	B-SO
could	O
be	O
suppressed	O
as	O
rapidly	O
in	O
6	O
-	O
mo	O
-	O
old	O
mice	B-Taxon
with	O
fulminant	O
pathology	O
as	O
it	O
can	O
in	O
young	O
,	O
predeposit	O
animals	B-Taxon
,	O
we	O
treated	O
an	O
additional	O
set	O
of	O
6	O
-	O
mo	O
-	O
old	O
animals	B-Taxon
with	O
dox	O
for	O
1	O
wk	O
prior	O
to	O
harvest	O
.	O

Importantly	O
,	O
both	O
APPswe	O
/	O
ind	B-GGP
and	O
APP	B-GGP
-	O
C	B-SO
-	I-SO
terminal	I-SO
fragment	B-SO
levels	O
were	O
fully	O
suppressed	O
after	O
only	O
1	O
wk	O
of	O
treatment	O
,	O
indicating	O
that	O
the	O
in	O
vivo	O
half	O
-	O
life	O
of	O
APPswe	O
/	O
ind	B-GGP
and	O
its	O
processed	O
C	B-SO
-	I-SO
terminal	I-SO
fragments	B-SO
are	O
relatively	O
short	O
(	O
Figure	O
3D	O
)	O
.	O

Tissue	O
sections	O
from	O
each	O
animal	B-Taxon
in	O
the	O
four	O
treatment	O
groups	O
were	O
stained	O
for	O
amyloid	O
pathology	O
by	O
Hirano	O
silver	B-CHEBI
,	O
Campbell	O
-	O
Switzer	O
silver	B-CHEBI
,	O
thioflavin	O
-	O
S	O
,	O
and	O
A	B-GGP
beta	I-GGP
immunohistochemistry	O
.	O

As	O
expected	O
,	O
the	O
6	O
mo	O
untreated	O
cohort	O
displayed	O
moderate	O
amyloid	O
pathology	O
,	O
and	O
the	O
9	O
mo	O
untreated	O
cohort	O
progressed	O
to	O
a	O
severe	O
amyloid	O
burden	O
.	O

In	O
contrast	O
,	O
the	O
extent	O
of	O
amyloid	O
pathology	O
in	O
mice	B-Taxon
from	O
the	O
6	O
mo	O
+	O
3	O
mo	O
treated	O
or	O
6	O
mo	O
+	O
6	O
mo	O
treated	O
cohorts	O
closely	O
resembled	O
that	O
of	O
the	O
6	O
mo	O
untreated	O
cohort	O
,	O
despite	O
the	O
significant	O
age	O
difference	O
between	O
the	O
treated	O
and	O
untreated	O
groups	O
(	O
Figures	O
4	O
and	O
Figure	O
S3	O
)	O
.	O

Well	O
-	O
formed	O
plaques	O
remained	O
in	O
the	O
treated	O
animals	B-Taxon
after	O
6	O
mo	O
of	O
transgene	B-SO
suppression	O
,	O
even	O
though	O
as	O
much	O
time	O
was	O
given	O
to	O
clear	O
the	O
lesions	O
as	O
they	O
had	O
taken	O
to	O
form	O
.	O

Moreover	O
,	O
both	O
types	O
of	O
amyloid	O
,	O
diffuse	O
and	O
fibrillar	O
,	O
remained	O
intact	O
throughout	O
treatment	O
.	O

Using	O
the	O
Campbell	O
-	O
Switzer	O
silver	B-CHEBI
stain	O
to	O
distinguish	O
different	O
forms	O
of	O
amyloid	O
,	O
we	O
found	O
diffuse	O
plaques	O
were	O
as	O
persistent	O
as	O
cored	O
deposits	O
(	O
Figure	O
S4	O
)	O
.	O

It	O
was	O
nevertheless	O
clear	O
that	O
dox	O
-	O
induced	O
suppression	O
of	O
transgenic	B-SO
APP	B-GGP
had	O
completely	O
halted	O
the	O
progression	O
of	O
pathology	O
.	O

To	O
confirm	O
that	O
the	O
arrest	O
of	O
plaques	O
without	O
any	O
sign	O
of	O
clearance	O
was	O
not	O
unique	O
to	O
the	O
line	O
107	O
mice	B-Taxon
,	O
we	O
repeated	O
the	O
dox	O
-	O
suppression	O
experiment	O
in	O
a	O
second	O
line	O
of	O
tet	O
-	O
off	O
APP	B-GGP
mice	B-Taxon
(	O
CaMKII	B-GGP
alpha	I-GGP
-	O
tTA	O
x	O
tet	O
-	O
APPswe	O
/	O
ind	B-GGP
line	O
18	O
;	O
n	O
=	O
22	O
)	O
.	O

Again	O
,	O
long	O
-	O
term	O
dox	O
treatment	O
was	O
begun	O
at	O
6	O
mo	O
of	O
age	O
,	O
and	O
mice	B-Taxon
were	O
harvested	O
after	O
3	O
mo	O
of	O
transgene	B-SO
suppression	O
(	O
6	O
mo	O
untreated	O
,	O
n	O
=	O
8	O
;	O
9	O
mo	O
untreated	O
,	O
n	O
=	O
6	O
;	O
6	O
mo	O
+	O
3	O
mo	O
treated	O
,	O
n	O
=	O
8	O
)	O
.	O

Immunoblotting	O
for	O
APP	B-GGP
confirmed	O
full	O
transgene	B-SO
suppression	O
in	O
the	O
treated	O
animals	B-Taxon
(	O
Figure	O
S5	O
)	O
.	O

As	O
in	O
the	O
line	O
107	O
mice	B-Taxon
described	O
above	O
,	O
amyloid	O
burden	O
worsened	O
substantially	O
in	O
the	O
untreated	O
mice	B-Taxon
between	O
6	O
and	O
9	O
mo	O
of	O
age	O
.	O

Suppression	O
of	O
transgene	B-SO
expression	O
abruptly	O
arrested	O
progression	O
of	O
pathology	O
(	O
Figure	O
S6	O
)	O
,	O
but	O
again	O
without	O
any	O
sign	O
of	O
reduction	O
.	O

Both	O
silver	B-CHEBI
-	O
and	O
thioflavin	O
-	O
S	O
-	O
positive	O
plaques	O
could	O
still	O
be	O
found	O
in	O
each	O
of	O
the	O
dox	O
-	O
treated	O
animals	B-Taxon
.	O

We	O
biochemically	O
measured	O
the	O
amount	O
of	O
aggregated	O
A	B-GGP
beta	I-GGP
in	O
the	O
brains	O
of	O
our	O
mice	B-Taxon
before	O
and	O
after	O
transgene	B-SO
suppression	O
using	O
filter	O
trap	O
analysis	O
of	O
cortical	O
tissue	O
from	O
each	O
animal	B-Taxon
.	O

In	O
this	O
assay	O
,	O
serial	O
dilutions	O
of	O
protein	B-CHEBI
homogenate	O
are	O
passed	O
through	O
a	O
cellulose	O
acetate	B-CHEBI
filter	O
;	O
particles	O
larger	O
than	O
the	O
pore	O
size	O
of	O
the	O
filter	O
become	O
trapped	O
in	O
the	O
membrane	O
and	O
are	O
revealed	O
by	O
immunoblotting	O
[	O
22	O
]	O
.	O

Consistent	O
with	O
our	O
visual	O
analysis	O
of	O
the	O
histological	O
sections	O
,	O
line	O
107	O
tTA	O
/	O
APP	B-GGP
mice	B-Taxon
treated	O
with	O
dox	O
for	O
3	O
or	O
6	O
mo	O
had	O
the	O
same	O
amount	O
of	O
aggregated	O
A	B-GGP
beta	I-GGP
as	O
when	O
they	O
started	O
treatment	O
at	O
6	O
mo	O
of	O
age	O
(	O
Figure	O
4A	O
and	O
4B	O
)	O
.	O

In	O
contrast	O
,	O
untreated	O
9	O
-	O
mo	O
-	O
old	O
mice	B-Taxon
had	O
almost	O
twice	O
as	O
much	O
aggregated	O
A	B-GGP
beta	I-GGP
as	O
either	O
of	O
the	O
treated	O
groups	O
.	O

Filter	O
trap	O
analysis	O
of	O
line	O
18	O
tTA	O
/	O
APP	B-GGP
mice	B-Taxon
yielded	O
similar	O
results	O
:	O
the	O
increase	O
in	O
aggregated	O
A	B-GGP
beta	I-GGP
observed	O
in	O
untreated	O
animals	B-Taxon
between	O
6	O
and	O
9	O
mo	O
of	O
age	O
was	O
completely	O
arrested	O
by	O
transgene	B-SO
suppression	O
(	O
Figure	O
S5C	O
and	O
S5D	O
)	O
.	O

We	O
next	O
used	O
ELISA	O
to	O
measure	O
total	O
A	B-GGP
beta	I-GGP
in	O
the	O
brains	O
of	O
each	O
group	O
to	O
determine	O
whether	O
any	O
change	O
in	O
the	O
amount	O
or	O
solubility	O
of	O
peptide	B-SO
occurred	O
while	O
APPswe	O
/	O
ind	B-GGP
expression	O
was	O
suppressed	O
.	O

Cortical	O
homogenates	O
were	O
sequentially	O
extracted	O
to	O
separate	O
peptide	B-SO
into	O
PBS	O
-	O
,	O
SDS	B-CHEBI
-	O
,	O
and	O
FA	B-CHEBI
-	O
soluble	O
fractions	B-GO
,	O
then	O
transgene	B-SO
-	O
derived	O
A	B-GGP
beta	I-GGP
40	I-GGP
and	O
A	B-GGP
beta	I-GGP
42	I-GGP
were	O
measured	O
by	O
human	B-Taxon
-	O
specific	O
ELISA	O
[	O
23	O
]	O
.	O

In	O
all	O
animals	B-Taxon
harboring	O
amyloid	O
deposits	O
,	O
we	O
found	O
that	O
the	O
vast	O
majority	O
of	O
A	B-GGP
beta	I-GGP
(	O
>	O
99	O
%	O
)	O
was	O
extracted	O
into	O
the	O
SDS	B-CHEBI
and	O
FA	B-CHEBI
fractions	B-GO
(	O
Figure	O
5A	O
and	O
5B	O
)	O
.	O

Consistent	O
with	O
the	O
filter	O
trap	O
results	O
presented	O
above	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
SDS	B-CHEBI
-	O
or	O
FA	B-CHEBI
-	O
soluble	O
A	B-GGP
beta	I-GGP
between	O
the	O
6	O
mo	O
untreated	O
cohort	O
and	O
either	O
the	O
6	O
mo	O
+	O
3	O
mo	O
treated	O
or	O
6	O
mo	O
+	O
6	O
mo	O
treated	O
cohorts	O
.	O

However	O
,	O
brains	O
of	O
both	O
6	O
mo	O
+	O
3	O
mo	O
and	O
6	O
mo	O
+	O
6	O
mo	O
treated	O
cohorts	O
contained	O
roughly	O
twice	O
as	O
much	O
PBS	O
-	O
soluble	O
A	B-GGP
beta	I-GGP
40	I-GGP
as	O
untreated	O
6	O
-	O
mo	O
-	O
old	O
mice	B-Taxon
(	O
Figure	O
5C	O
)	O
.	O

Levels	O
of	O
A	B-GGP
beta	I-GGP
42	I-GGP
showed	O
a	O
similar	O
trend	O
,	O
but	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

In	O
fact	O
,	O
levels	O
of	O
PBS	O
-	O
soluble	O
A	B-GGP
beta	I-GGP
40	I-GGP
and	O
A	B-GGP
beta	I-GGP
42	I-GGP
in	O
the	O
6	O
mo	O
+	O
3	O
mo	O
and	O
6	O
mo	O
+	O
6	O
mo	O
treated	O
cohorts	O
were	O
most	O
similar	O
to	O
that	O
of	O
the	O
9	O
mo	O
untreated	O
cohort	O
,	O
suggesting	O
that	O
age	O
,	O
as	O
opposed	O
to	O
synthetic	O
rate	O
(	O
which	O
would	O
be	O
negligible	O
in	O
the	O
treated	O
animals	B-Taxon
)	O
,	O
may	O
determine	O
the	O
fraction	O
of	O
PBS	O
-	O
soluble	O
A	B-GGP
beta	I-GGP
in	O
these	O
animals	B-Taxon
.	O

We	O
also	O
assessed	O
neuritic	O
and	O
glial	B-CL
pathology	O
surrounding	O
the	O
plaques	O
to	O
determine	O
whether	O
there	O
were	O
any	O
changes	O
in	O
nearby	O
tissue	O
following	O
long	O
-	O
term	O
transgene	B-SO
suppression	O
.	O

Both	O
Hirano	O
silver	B-CHEBI
stain	O
and	O
ubiquitin	O
immunostaining	O
showed	O
neuritic	O
pathology	O
in	O
all	O
treatment	O
groups	O
(	O
Figure	O
6	O
)	O
.	O

Similarly	O
,	O
activated	O
astrocytes	B-CL
immunostained	O
for	O
GFAP	B-GGP
were	O
found	O
near	O
plaques	O
in	O
all	O
animals	B-Taxon
(	O
Figure	O
6	O
)	O
.	O

Neuritic	O
and	O
glial	B-CL
pathology	O
were	O
more	O
severe	O
in	O
the	O
older	O
untreated	O
mice	B-Taxon
.	O

In	O
contrast	O
,	O
transgene	B-SO
suppression	O
prevented	O
the	O
growth	O
of	O
individual	O
deposits	O
apparent	O
in	O
untreated	O
mice	B-Taxon
,	O
and	O
limited	O
the	O
surrounding	O
pathology	O
to	O
what	O
was	O
already	O
present	O
when	O
treatment	O
began	O
.	O

An	O
obvious	O
question	O
we	O
sought	O
to	O
address	O
was	O
whether	O
the	O
deposition	O
of	O
A	B-GGP
beta	I-GGP
diminished	O
cognitive	O
ability	O
in	O
untreated	O
mice	B-Taxon
,	O
and	O
what	O
might	O
happen	O
to	O
cognition	O
when	O
the	O
process	O
was	O
interrupted	O
.	O

Unfortunately	O
,	O
efforts	O
to	O
characterize	O
cognitive	O
behavior	O
were	O
compromised	O
by	O
severe	O
hyperactivity	O
in	O
untreated	O
double	O
transgenic	B-SO
mice	B-Taxon
.	O

The	O
tTA	O
/	O
APP	B-GGP
animals	B-Taxon
were	O
often	O
seen	O
running	O
in	O
circles	O
around	O
the	O
perimeter	O
of	O
their	O
cages	O
,	O
and	O
a	O
similar	O
swimming	O
pattern	O
was	O
noted	O
when	O
the	O
mice	B-Taxon
were	O
tested	O
in	O
the	O
Morris	O
water	B-CHEBI
maze	O
.	O

In	O
the	O
radial	O
water	B-CHEBI
maze	O
,	O
repetitive	O
swim	O
patterns	O
were	O
noted	O
with	O
no	O
evidence	O
of	O
choice	O
-	O
motivated	O
actions	O
.	O

Other	O
studies	O
have	O
dealt	O
with	O
similar	O
problems	O
by	O
excluding	O
animals	B-Taxon
that	O
do	O
not	O
show	O
adequate	O
attention	O
to	O
the	O
task	O
,	O
retaining	O
only	O
those	O
mice	B-Taxon
that	O
meet	O
certain	O
performance	O
criteria	O
[	O
30	O
]	O
.	O

In	O
our	O
case	O
,	O
the	O
penetrance	O
of	O
hyperactivity	O
was	O
close	O
to	O
100	O
%	O
,	O
leaving	O
us	O
with	O
no	O
testable	O
animals	B-Taxon
.	O

This	O
phenotype	O
has	O
not	O
affected	O
previous	O
lines	O
of	O
APPswe	O
mice	B-Taxon
we	O
have	O
produced	O
,	O
such	O
as	O
lines	O
E1	O
-	O
2	O
or	O
C3	O
-	O
3	O
,	O
that	O
express	O
lower	O
levels	O
of	O
transgenic	B-SO
protein	B-CHEBI
.	O

Indeed	O
,	O
in	O
past	O
studies	O
where	O
hyperactivity	O
was	O
not	O
a	O
factor	O
,	O
we	O
established	O
a	O
clear	O
relationship	O
between	O
amyloid	O
load	O
and	O
cognitive	O
ability	O
[	O
31	O
]	O
.	O

However	O
,	O
in	O
the	O
current	O
study	O
,	O
we	O
feel	O
that	O
although	O
the	O
poor	O
performance	O
of	O
the	O
tTA	O
/	O
APP	B-GGP
mice	B-Taxon
in	O
the	O
maze	O
tests	O
could	O
technically	O
be	O
scored	O
as	O
cognitive	O
impairment	O
,	O
the	O
animals	B-Taxon
'	O
severe	O
hyperactivity	O
made	O
interpretation	O
of	O
the	O
cognitive	O
tasks	O
impossible	O
.	O

In	O
order	O
to	O
understand	O
the	O
nature	O
and	O
extent	O
of	O
hyperactivity	O
in	O
the	O
tTA	O
/	O
APP	B-GGP
mice	B-Taxon
,	O
we	O
quantified	O
daily	O
activity	O
levels	O
in	O
double	O
transgenic	B-SO
animals	B-Taxon
along	O
with	O
their	O
single	O
transgenic	B-SO
and	O
nontransgenic	O
siblings	O
using	O
four	O
-	O
beam	O
frames	O
designed	O
to	O
monitor	O
ambulation	O
within	O
an	O
enclosed	O
cage	O
.	O

As	O
shown	O
in	O
Figure	O
7	O
,	O
the	O
double	O
transgenic	B-SO
mice	B-Taxon
were	O
up	O
to	O
10	O
-	O
fold	O
more	O
active	O
during	O
the	O
dark	O
phase	O
of	O
the	O
day	O
-	O
night	O
cycle	O
than	O
any	O
of	O
the	O
control	O
groups	O
.	O

Activity	O
levels	O
appeared	O
to	O
follow	O
a	O
relatively	O
normal	O
diurnal	O
cycle	O
,	O
decreasing	O
substantially	O
during	O
the	O
daylight	O
hours	O
.	O

However	O
,	O
even	O
during	O
the	O
light	O
phase	O
,	O
the	O
tTA	O
/	O
APP	B-GGP
mice	B-Taxon
remained	O
many	O
-	O
fold	O
more	O
active	O
than	O
normal	O
controls	O
.	O

This	O
behavior	O
was	O
partially	O
,	O
but	O
not	O
consistently	O
,	O
reversed	O
by	O
1	O
mo	O
of	O
transgene	B-SO
suppression	O
beginning	O
at	O
4	O
-	O
5	O
mo	O
of	O
age	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
contrast	O
,	O
hyperactivity	O
was	O
completely	O
abolished	O
by	O
rearing	O
tTA	O
/	O
APP	B-GGP
mice	B-Taxon
on	O
dox	O
.	O

Animals	B-Taxon
born	O
and	O
raised	O
on	O
dox	O
showed	O
activity	O
levels	O
similar	O
to	O
the	O
untreated	O
controls	O
(	O
Figure	O
7C	O
)	O
.	O

Intriguingly	O
,	O
all	O
of	O
the	O
dox	O
-	O
reared	O
animals	B-Taxon
,	O
both	O
transgenic	B-SO
and	O
wild	B-SO
-	I-SO
type	I-SO
,	O
showed	O
altered	O
circadian	O
rhythms	O
with	O
far	O
less	O
distinction	O
between	O
their	O
day	O
-	O
and	O
nighttime	O
activity	O
levels	O
.	O

Discussion	O

We	O
present	O
a	O
new	O
mouse	B-Taxon
model	O
for	O
AD	O
that	O
was	O
designed	O
to	O
test	O
the	O
consequences	O
of	O
inhibiting	O
A	B-GGP
beta	I-GGP
production	O
after	O
the	O
onset	O
of	O
amyloid	O
pathology	O
.	O

New	O
lines	O
of	O
transgenic	B-SO
mice	B-Taxon
were	O
developed	O
for	O
this	O
study	O
that	O
express	O
high	O
levels	O
of	O
APPswe	O
/	O
ind	B-GGP
under	O
the	O
control	O
of	O
a	O
tetracycline	B-CHEBI
-	O
responsive	O
promoter	B-SO
.	O

We	O
demonstrate	O
that	O
treatment	O
with	O
dox	O
suppresses	O
steady	O
-	O
state	O
levels	O
of	O
both	O
APPswe	O
/	O
ind	B-GGP
and	O
its	O
C	B-SO
-	I-SO
terminal	I-SO
fragments	B-SO
,	O
indicating	O
that	O
the	O
mutant	B-SO
proteins	B-CHEBI
have	O
a	O
relatively	O
short	O
half	O
-	O
life	O
in	O
vivo	O
.	O

Transgenic	B-SO
expression	O
of	O
APPswe	O
/	O
ind	B-GGP
and	O
consequent	O
overproduction	O
of	O
A	B-GGP
beta	I-GGP
42	I-GGP
cause	O
early	O
-	O
onset	O
amyloid	O
deposition	O
in	O
untreated	O
mice	B-Taxon
,	O
in	O
which	O
deposits	O
appear	O
as	O
early	O
as	O
2	O
mo	O
of	O
age	O
.	O

Amyloid	O
burden	O
worsens	O
significantly	O
with	O
age	O
,	O
and	O
by	O
9	O
mo	O
,	O
the	O
hippocampus	O
and	O
cortex	O
of	O
untreated	O
mice	B-Taxon
are	O
largely	O
filled	O
with	O
aggregated	O
peptide	B-SO
.	O

We	O
find	O
that	O
suppression	O
of	O
transgenic	B-SO
APP	B-GGP
by	O
more	O
than	O
95	O
%	O
abruptly	O
halts	O
the	O
progression	O
of	O
amyloid	O
pathology	O
.	O

Importantly	O
,	O
this	O
outcome	O
occurs	O
in	O
animals	B-Taxon
already	O
harboring	O
considerable	O
amyloid	O
pathology	O
,	O
a	O
situation	O
similar	O
to	O
what	O
might	O
be	O
expected	O
in	O
patients	O
to	O
be	O
treated	O
with	O
secretase	O
inhibitors	B-CHEBI
.	O

Somewhat	O
unexpectedly	O
,	O
we	O
observe	O
no	O
appreciable	O
clearance	O
of	O
deposited	O
amyloid	O
even	O
following	O
periods	O
of	O
transgene	B-SO
suppression	O
equal	O
to	O
the	O
time	O
taken	O
for	O
plaques	O
to	O
form	O
.	O

This	O
latter	O
finding	O
indicates	O
that	O
compared	O
to	O
other	O
disease	O
-	O
associated	O
protein	B-CHEBI
aggregates	O
such	O
as	O
mutant	B-SO
huntingtin	B-GGP
,	O
which	O
clear	O
in	O
less	O
than	O
3	O
mo	O
[	O
32	O
]	O
,	O
the	O
disaggregation	O
of	O
extracellular	B-GO
amyloid	O
is	O
relatively	O
slow	O
.	O

Notably	O
,	O
pharmaceutical	B-CHEBI
gamma	O
-	O
secretase	O
inhibitors	B-CHEBI
published	O
to	O
date	O
show	O
less	O
strict	O
regulation	O
of	O
A	B-GGP
beta	I-GGP
production	O
following	O
chronic	O
administration	O
than	O
we	O
have	O
attained	O
here	O
.	O

Two	O
independent	O
compounds	B-CHEBI
tested	O
in	O
Tg2576	O
[	O
33	O
]	O
and	O
TgCRND8	O
[	O
34	O
]	O
transgenic	B-SO
mice	B-Taxon
show	O
no	O
more	O
than	O
85	O
%	O
suppression	O
of	O
A	B-GGP
beta	I-GGP
40	I-GGP
levels	O
,	O
and	O
where	O
measured	O
,	O
even	O
less	O
suppression	O
of	O
A	B-GGP
beta	I-GGP
42	I-GGP
(	O
approximately	O
60	O
%	O
)	O
[	O
35	O
,	O
36	O
]	O
.	O

Thus	O
,	O
even	O
after	O
accounting	O
for	O
the	O
much	O
higher	O
APP	B-GGP
expression	O
levels	O
in	O
our	O
mice	B-Taxon
than	O
in	O
the	O
Tg2576	O
and	O
TgCRND8	O
lines	O
,	O
we	O
have	O
achieved	O
better	O
absolute	O
suppression	O
of	O
A	B-GGP
beta	I-GGP
production	O
with	O
the	O
tet	O
-	O
off	O
system	O
than	O
is	O
currently	O
possible	O
with	O
published	O
gamma	O
-	O
secretase	O
inhibitors	B-CHEBI
.	O

Since	O
even	O
the	O
most	O
advanced	O
future	O
pharmaceutical	B-CHEBI
agents	I-CHEBI
are	O
unlikely	O
to	O
attain	O
more	O
complete	O
control	O
of	O
A	B-GGP
beta	I-GGP
production	O
than	O
achieved	O
here	O
,	O
this	O
system	O
provides	O
a	O
salient	O
test	O
of	O
therapeutic	O
intervention	O
with	O
A	B-GGP
beta	I-GGP
-	O
lowering	O
compounds	B-CHEBI
.	O

Although	O
the	O
progression	O
of	O
amyloid	O
deposition	O
was	O
sharply	O
arrested	O
by	O
this	O
approach	O
,	O
we	O
found	O
that	O
a	O
substantial	O
amyloid	O
burden	O
remained	O
even	O
after	O
long	O
periods	O
of	O
transgene	B-SO
suppression	O
.	O

We	O
examined	O
a	O
small	O
number	O
of	O
animals	B-Taxon
after	O
12	O
mo	O
of	O
dox	O
treatment	O
(	O
beginning	O
at	O
6	O
mo	O
of	O
age	O
)	O
,	O
and	O
found	O
that	O
amyloid	O
deposits	O
were	O
still	O
relatively	O
abundant	O
.	O

Longer	O
-	O
term	O
treatments	O
are	O
now	O
in	O
progress	O
.	O

At	O
the	O
latest	O
treatment	O
interval	O
analyzed	O
by	O
ELISA	O
,	O
animals	B-Taxon
administered	O
dox	O
for	O
6	O
mo	O
showed	O
elevated	O
levels	O
of	O
PBS	O
-	O
soluble	O
A	B-GGP
beta	I-GGP
(	O
see	O
Figure	O
5	O
)	O
that	O
could	O
be	O
interpreted	O
as	O
an	O
indication	O
that	O
the	O
plaques	O
are	O
slowly	O
releasing	O
peptide	B-SO
(	O
or	O
oligomeric	O
A	O
beta	O
)	O
into	O
the	O
soluble	O
pool	O
and	O
might	O
eventually	O
dissolve	O
.	O

Whether	O
inhibiting	O
A	B-GGP
beta	I-GGP
production	O
longer	O
than	O
6	O
(	O
or	O
12	O
)	O
mo	O
may	O
ultimately	O
result	O
in	O
clearance	O
of	O
amyloid	O
is	O
under	O
investigation	O
;	O
unfortunately	O
,	O
the	O
life	O
span	O
of	O
the	O
model	O
eventually	O
limits	O
this	O
experiment	O
.	O

Therapeutics	O
used	O
in	O
humans	B-Taxon
will	O
have	O
considerably	O
more	O
time	O
to	O
act	O
than	O
is	O
possible	O
within	O
the	O
life	O
span	O
of	O
rodent	B-Taxon
models	O
.	O

Long	O
-	O
term	O
treatments	O
would	O
certainly	O
be	O
possible	O
and	O
could	O
be	O
a	O
key	O
to	O
effective	O
therapy	O
.	O

Overall	O
,	O
however	O
,	O
we	O
interpret	O
our	O
findings	O
as	O
evidence	O
that	O
AD	O
therapies	O
that	O
significantly	O
lower	O
the	O
production	O
of	O
A	B-GGP
beta	I-GGP
(	O
by	O
either	O
inhibiting	O
secretase	O
activity	O
or	O
inhibiting	O
APP	B-GGP
expression	O
)	O
may	O
not	O
quickly	O
reverse	O
preexisting	O
pathology	O
,	O
but	O
should	O
effectively	O
halt	O
further	O
deposition	O
of	O
amyloid	O
.	O

In	O
interpreting	O
our	O
study	O
,	O
it	O
should	O
be	O
remembered	O
that	O
the	O
earliest	O
plaques	O
to	O
appear	O
in	O
these	O
mice	B-Taxon
,	O
like	O
other	O
APP	B-GGP
transgenics	B-SO
harboring	O
the	O
Swedish	B-GGP
mutation	B-SO
[	O
27	O
]	O
,	O
are	O
predominantly	O
fibrillar	O
deposits	O
,	O
which	O
may	O
be	O
less	O
tractable	O
than	O
the	O
diffuse	O
aggregates	O
thought	O
to	O
come	O
first	O
in	O
the	O
course	O
of	O
the	O
human	B-Taxon
disease	O
.	O

However	O
,	O
our	O
data	O
suggest	O
that	O
once	O
diffuse	O
deposits	O
are	O
formed	O
in	O
these	O
mice	B-Taxon
,	O
they	O
are	O
no	O
more	O
easily	O
cleared	O
in	O
our	O
system	O
than	O
cored	O
plaques	O
(	O
see	O
Figure	O
S4	O
)	O
.	O

An	O
additional	O
consideration	O
we	O
recognize	O
is	O
that	O
a	O
small	O
amount	O
of	O
transgene	B-SO
expression	O
continues	O
in	O
the	O
presence	O
of	O
dox	O
and	O
that	O
endogenous	O
mouse	B-Taxon
A	B-GGP
beta	I-GGP
continues	O
to	O
be	O
produced	O
.	O

It	O
is	O
possible	O
that	O
the	O
combined	O
low	O
levels	O
of	O
endogenous	O
mouse	B-Taxon
A	B-GGP
beta	I-GGP
and	O
nonsuppressed	O
human	B-Taxon
peptide	B-SO
are	O
sufficient	O
to	O
maintain	O
existing	O
deposits	O
.	O

However	O
,	O
these	O
low	O
levels	O
of	O
peptide	B-SO
are	O
not	O
sufficient	O
to	O
induce	O
new	O
amyloid	O
formation	O
,	O
as	O
CaMKII	B-GGP
alpha	I-GGP
-	O
tTA	O
x	O
tetAPPswe	O
/	O
ind	B-GGP
mice	B-Taxon
raised	O
on	O
dox	O
for	O
up	O
to	O
a	O
year	O
do	O
not	O
develop	O
amyloid	O
lesions	O
(	O
data	O
not	O
shown	O
)	O
.	O

It	O
is	O
also	O
clear	O
that	O
in	O
this	O
genetic	B-SO
system	O
,	O
we	O
have	O
raised	O
the	O
production	O
of	O
A	B-GGP
beta	I-GGP
to	O
levels	O
not	O
found	O
in	O
humans	B-Taxon
to	O
accelerate	O
pathology	O
into	O
an	O
experimentally	O
feasible	O
time	O
frame	O
.	O

This	O
system	O
allowed	O
us	O
to	O
create	O
an	O
approximately	O
20	O
-	O
fold	O
differential	O
between	O
APP	B-GGP
/	O
A	B-GGP
beta	I-GGP
synthetic	O
rates	O
before	O
and	O
after	O
treatment	O
,	O
yet	O
the	O
in	O
vivo	O
equilibrium	O
between	O
aggregated	O
and	O
disaggregated	O
states	O
of	O
A	B-GGP
beta	I-GGP
still	O
favored	O
the	O
maintenance	O
of	O
amyloid	O
deposits	O
.	O

In	O
our	O
opinion	O
,	O
it	O
seems	O
unlikely	O
that	O
amyloid	O
deposits	O
in	O
human	B-Taxon
brain	O
would	O
be	O
inherently	O
any	O
less	O
stable	O
than	O
those	O
formed	O
in	O
mouse	B-Taxon
brain	O
.	O

However	O
,	O
the	O
human	B-Taxon
brain	O
may	O
harbor	O
clearance	O
mechanisms	O
not	O
shared	O
by	O
mice	B-Taxon
that	O
would	O
allow	O
more	O
efficient	O
removal	O
of	O
preexisting	O
amyloid	O
.	O

One	O
potential	O
mechanism	O
by	O
which	O
amyloid	O
may	O
be	O
more	O
efficiently	O
removed	O
in	O
the	O
human	B-Taxon
disease	O
than	O
in	O
the	O
mouse	B-Taxon
models	O
is	O
through	O
microglial	B-CL
phagocytosis	O
.	O

Resident	O
microglia	B-CL
in	O
transgenic	B-SO
mouse	B-Taxon
models	O
localize	O
to	O
tissue	O
surrounding	O
plaques	O
but	O
show	O
little	O
evidence	O
of	O
amyloid	O
engulfment	O
[	O
37	O
-	O
40	O
]	O
.	O

In	O
contrast	O
,	O
microglia	B-CL
surrounding	O
amyloid	O
plaques	O
in	O
human	B-Taxon
brain	O
show	O
a	O
much	O
higher	O
state	O
of	O
activation	O
with	O
greater	O
expression	O
of	O
complement	O
receptor	O
[	O
40	O
]	O
.	O

Thus	O
,	O
the	O
role	O
of	O
microglia	B-CL
in	O
amyloid	O
metabolism	O
is	O
minor	O
in	O
transgenic	B-SO
models	O
compared	O
to	O
the	O
human	B-Taxon
condition	O
.	O

Somewhat	O
paradoxically	O
,	O
several	O
studies	O
further	O
demonstrate	O
that	O
treatment	O
with	O
anti	O
-	O
inflammatory	O
drugs	O
to	O
reduce	O
microglial	B-CL
activation	O
actually	O
lowers	O
amyloid	O
load	O
in	O
APP	B-GGP
transgenic	B-SO
mice	B-Taxon
,	O
suggesting	O
a	O
role	O
for	O
mouse	B-Taxon
microglia	B-CL
in	O
the	O
formation	O
and	O
maintenance	O
of	O
amyloid	O
aggregates	O
[	O
41	O
-	O
43	O
]	O
.	O

However	O
,	O
this	O
outcome	O
may	O
be	O
alternatively	O
explained	O
by	O
direct	O
effects	O
of	O
many	O
anti	B-CHEBI
-	I-CHEBI
inflammatory	I-CHEBI
drugs	I-CHEBI
on	O
gamma	O
-	O
secretase	O
cleavage	O
[	O
44	O
-	O
47	O
]	O
.	O

Nonetheless	O
,	O
the	O
role	O
of	O
microglia	B-CL
in	O
both	O
the	O
human	B-Taxon
condition	O
and	O
the	O
mouse	B-Taxon
models	O
is	O
poorly	O
understood	O
,	O
and	O
differences	O
in	O
microglial	B-CL
reactivity	O
between	O
the	O
two	O
could	O
lead	O
to	O
significantly	O
faster	O
amyloid	O
clearance	O
in	O
the	O
brains	O
of	O
patients	O
with	O
AD	O
than	O
we	O
observe	O
in	O
the	O
tet	O
-	O
off	O
APP	B-GGP
mice	B-Taxon
.	O

Given	O
the	O
relatively	O
minor	O
role	O
played	O
by	O
microglia	B-CL
in	O
other	O
mouse	B-Taxon
models	O
of	O
amyloidosis	O
,	O
we	O
think	O
it	O
unlikely	O
that	O
these	O
cells	B-CL
have	O
influenced	O
the	O
rate	O
of	O
amyloid	O
clearance	O
in	O
the	O
tet	O
-	O
off	O
APP	B-GGP
mice	B-Taxon
.	O

Even	O
so	O
,	O
we	O
considered	O
the	O
possibility	O
that	O
chronic	O
dox	O
treatment	O
may	O
have	O
altered	O
the	O
activation	O
state	O
of	O
microglia	B-CL
in	O
our	O
treated	O
mice	B-Taxon
.	O

Dox	O
is	O
structurally	O
similar	O
to	O
minocycline	O
,	O
a	O
reported	O
anti	B-CHEBI
-	I-CHEBI
inflammatory	I-CHEBI
drug	I-CHEBI
and	O
inhibitor	B-CHEBI
of	O
microglial	B-CL
activation	O
[	O
48	O
]	O
.	O

However	O
,	O
if	O
dox	O
does	O
have	O
anti	O
-	O
inflammatory	O
activity	O
,	O
then	O
,	O
based	O
on	O
previous	O
studies	O
with	O
other	O
anti	B-CHEBI
-	I-CHEBI
inflammatories	I-CHEBI
,	O
we	O
would	O
have	O
expected	O
to	O
find	O
less	O
amyloid	O
in	O
the	O
dox	O
-	O
treated	O
animals	B-Taxon
.	O

Clearly	O
,	O
that	O
was	O
not	O
the	O
case	O
.	O

While	O
it	O
is	O
possible	O
that	O
dox	O
acts	O
in	O
some	O
other	O
way	O
to	O
slow	O
amyloid	O
clearance	O
,	O
data	O
from	O
multiple	O
studies	O
demonstrate	O
that	O
microglial	B-CL
responses	O
are	O
normally	O
weak	O
in	O
the	O
mouse	B-Taxon
AD	O
models	O
[	O
37	O
-	O
40	O
]	O
,	O
and	O
thus	O
it	O
is	O
doubtful	O
that	O
dox	O
-	O
mediated	O
microglial	B-CL
inhibition	O
affected	O
the	O
outcome	O
of	O
our	O
study	O
.	O

The	O
persistence	O
and	O
stability	O
of	O
amyloid	O
deposits	O
in	O
our	O
system	O
is	O
unexpected	O
given	O
the	O
speed	O
with	O
which	O
A	B-GGP
beta	I-GGP
aggregates	O
are	O
cleared	O
in	O
other	O
mouse	B-Taxon
models	O
of	O
therapeutic	O
intervention	O
.	O

Anti	O
-	O
A	B-GGP
beta	I-GGP
antibodies	B-GO
injected	O
directly	O
into	O
the	O
brain	O
have	O
been	O
shown	O
to	O
eliminate	O
amyloid	O
deposits	O
in	O
as	O
little	O
as	O
1	O
wk	O
after	O
treatment	O
[	O
49	O
-	O
51	O
]	O
.	O

Peripheral	O
antibody	B-GO
injection	O
decreases	O
amyloid	O
load	O
more	O
broadly	O
,	O
and	O
although	O
it	O
does	O
not	O
appear	O
to	O
act	O
as	O
quickly	O
as	O
local	O
injection	O
,	O
can	O
significantly	O
reduce	O
amyloid	O
load	O
within	O
2	O
mo	O
of	O
initial	O
treatment	O
[	O
52	O
,	O
53	O
]	O
.	O

More	O
recently	O
,	O
an	O
alternative	O
approach	O
has	O
shown	O
that	O
lentiviral	B-Taxon
transfer	O
of	O
neprilysin	B-GGP
can	O
also	O
reduce	O
the	O
number	O
of	O
aggregates	O
in	O
the	O
area	O
of	O
the	O
injection	O
site	O
[	O
54	O
]	O
.	O

Careful	O
study	O
of	O
the	O
mechanism	O
behind	O
several	O
of	O
the	O
antibody	B-GO
-	O
mediated	O
therapies	O
has	O
suggested	O
that	O
activated	O
microglia	B-CL
play	O
an	O
important	O
role	O
in	O
the	O
removal	O
of	O
fibrillar	O
plaques	O
after	O
immunization	O
[	O
50	O
,	O
52	O
,	O
55	O
]	O
.	O

However	O
,	O
it	O
has	O
been	O
noted	O
that	O
deletion	B-SO
of	O
the	O
Fc	O
receptor	O
(	O
the	O
primary	O
receptor	O
for	O
microglial	B-CL
opsinization	O
of	O
antibody	B-GO
-	O
antigen	O
complexes	B-GO
)	O
in	O
APP	B-GGP
transgenic	B-SO
mouse	B-Taxon
models	O
has	O
no	O
impact	O
on	O
the	O
effectiveness	O
of	O
antibody	B-GO
-	O
mediated	O
therapy	O
[	O
56	O
,	O
57	O
]	O
.	O

It	O
is	O
,	O
nevertheless	O
,	O
possible	O
that	O
lack	O
of	O
microglia	B-CL
activation	O
is	O
the	O
major	O
difference	O
between	O
the	O
slow	O
clearance	O
described	O
here	O
,	O
where	O
no	O
perturbation	O
of	O
the	O
immune	O
system	O
is	O
expected	O
,	O
and	O
the	O
rapid	O
clearance	O
described	O
in	O
studies	O
involving	O
antibody	B-GO
or	O
viral	B-Taxon
injection	O
.	O

In	O
isolation	O
,	O
mild	O
activation	O
of	O
microglia	B-CL
by	O
injection	O
damage	O
or	O
opsinization	O
may	O
not	O
be	O
adequate	O
to	O
induce	O
substantial	O
phagocytosis	O
,	O
but	O
when	O
combined	O
with	O
an	O
A	B-GGP
beta	I-GGP
-	O
lowering	O
agent	O
,	O
such	O
as	O
neprilysin	B-GGP
or	O
A	B-GGP
beta	I-GGP
-	O
targeted	O
antibodies	B-GO
,	O
the	O
two	O
may	O
work	O
in	O
concert	O
to	O
clear	O
peptide	B-SO
deposits	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
strong	O
activation	O
of	O
microglia	B-CL
through	O
transgenic	B-SO
expression	O
of	O
TGF	B-GGP
beta	I-GGP
[	O
58	O
]	O
or	O
central	O
injection	O
of	O
lipopolysaccharide	B-CHEBI
[	O
59	O
,	O
60	O
]	O
can	O
by	O
itself	O
substantially	O
reduce	O
plaque	O
burden	O
in	O
APP	B-GGP
transgenic	B-SO
mice	B-Taxon
.	O

But	O
in	O
the	O
case	O
of	O
acute	O
antibody	B-GO
-	O
and	O
/	O
or	O
injury	O
-	O
mediated	O
activation	O
,	O
once	O
the	O
inflammation	O
has	O
passed	O
,	O
and	O
the	O
antibody	B-GO
and	O
bound	O
peptide	B-SO
have	O
been	O
cleared	O
and	O
degraded	O
,	O
the	O
remaining	O
A	B-GGP
beta	I-GGP
quickly	O
reaggregates	O
and	O
amyloid	O
pathology	O
is	O
reestablished	O
[	O
49	O
]	O
.	O

This	O
finding	O
reinforces	O
the	O
notion	O
that	O
without	O
continued	O
stimulation	O
,	O
microglia	B-CL
in	O
mouse	B-Taxon
models	O
do	O
not	O
maintain	O
the	O
same	O
level	O
of	O
sustained	O
activation	O
that	O
may	O
occur	O
in	O
humans	B-Taxon
.	O

SantaCruz	O
et	O
al	O
.	O
recently	O
published	O
a	O
study	O
of	O
mice	B-Taxon
that	O
express	O
P301L	O
human	B-GGP
tau	I-GGP
via	O
a	O
similar	O
vector	B-SO
system	O
[	O
61	O
]	O
.	O

As	O
in	O
our	O
tet	O
-	O
off	O
APP	B-GGP
mice	B-Taxon
,	O
SantaCruz	O
et	O
al	O
.	O
found	O
that	O
tau	B-GGP
neurofibrillary	O
tangles	O
,	O
like	O
amyloid	O
plaques	O
,	O
are	O
not	O
cleared	O
efficiently	O
following	O
transgene	B-SO
suppression	O
.	O

The	O
lack	O
of	O
clearance	O
in	O
both	O
models	O
of	O
AD	O
pathology	O
comes	O
as	O
a	O
stark	O
contrast	O
to	O
the	O
rapid	O
removal	O
of	O
protein	B-CHEBI
aggregates	O
found	O
in	O
similar	O
tet	O
-	O
off	O
mouse	B-Taxon
models	O
of	O
Huntington	O
[	O
32	O
]	O
and	O
prion	O
disease	O
[	O
62	O
]	O
.	O

In	O
these	O
cases	O
,	O
disrupting	O
the	O
input	O
of	O
new	O
monomer	O
to	O
the	O
system	O
via	O
dox	O
-	O
mediated	O
transgene	B-SO
suppression	O
led	O
to	O
relatively	O
rapid	O
clearance	O
of	O
protein	B-CHEBI
aggregates	O
.	O

By	O
contrast	O
,	O
our	O
study	O
and	O
that	O
of	O
SantaCruz	O
et	O
al	O
.	O
suggest	O
that	O
protein	B-CHEBI
aggregates	O
in	O
AD	O
may	O
be	O
more	O
tenacious	O
than	O
in	O
other	O
neurodegenerative	O
disorders	O
.	O

Perhaps	O
once	O
aggregated	O
,	O
A	B-GGP
beta	I-GGP
and	O
tau	B-GGP
are	O
either	O
inherently	O
more	O
stable	O
than	O
other	O
protein	B-CHEBI
aggregates	O
or	O
more	O
resistant	O
to	O
intra	O
-	O
and	O
extracellular	B-GO
clearance	O
mechanisms	O
.	O

One	O
question	O
we	O
were	O
not	O
able	O
to	O
address	O
in	O
this	O
study	O
is	O
whether	O
abrogating	O
synthesis	O
of	O
new	O
A	B-GGP
beta	I-GGP
halts	O
the	O
progression	O
of	O
cognitive	O
decline	O
.	O

Studies	O
from	O
the	O
tet	O
-	O
off	O
tau	B-GGP
mice	B-Taxon
suggest	O
that	O
protein	B-CHEBI
clearance	O
may	O
in	O
fact	O
not	O
be	O
required	O
for	O
cognitive	O
improvement	O
following	O
transgene	B-SO
suppression	O
[	O
61	O
]	O
.	O

At	O
present	O
,	O
because	O
of	O
unexpected	O
noncognitive	O
behavioral	O
abnormalities	O
,	O
it	O
is	O
not	O
clear	O
whether	O
the	O
tet	O
-	O
off	O
APP	B-GGP
mice	B-Taxon
can	O
be	O
used	O
to	O
address	O
the	O
same	O
question	O
in	O
the	O
context	O
of	O
amyloid	O
pathology	O
.	O

Both	O
lines	O
of	O
tTA	O
/	O
APP	B-GGP
mice	B-Taxon
we	O
studied	O
here	O
display	O
extreme	O
hyperactivity	O
visible	O
as	O
cage	O
circling	O
and	O
quantified	O
by	O
activity	O
monitoring	O
(	O
see	O
Figure	O
7	O
)	O
.	O

Many	O
of	O
the	O
double	O
transgenic	B-SO
mice	B-Taxon
showed	O
similar	O
circular	O
patterns	O
of	O
swimming	O
near	O
the	O
edge	O
of	O
the	O
tank	O
when	O
tested	O
in	O
the	O
Morris	O
water	B-CHEBI
maze	O
.	O

Expression	O
of	O
this	O
phenotype	O
makes	O
standard	O
tests	O
of	O
learning	O
and	O
memory	O
uninterpretable	O
.	O

Hyperactivity	O
nonspecifically	O
inhibits	O
choice	O
-	O
driven	O
changes	O
in	O
movement	O
,	O
the	O
key	O
element	O
behind	O
all	O
cognitive	O
behavioral	O
paradigms	O
.	O

We	O
are	O
currently	O
working	O
to	O
determine	O
whether	O
hyperactivity	O
correlates	O
with	O
expression	O
of	O
the	O
APPswe	O
/	O
ind	B-GGP
holoprotein	O
or	O
its	O
proteolytic	O
derivatives	O
.	O

Preliminary	O
studies	O
suggest	O
that	O
hyperactivity	O
does	O
not	O
appear	O
quickly	O
when	O
dox	O
-	O
reared	O
mice	B-Taxon
are	O
shifted	O
to	O
nonmedicated	O
diets	O
(	O
J	O
.	O
L	O
.	O
J	O
.	O
,	O
unpublished	O
data	O
)	O
.	O

These	O
data	O
may	O
indicate	O
that	O
the	O
neuroactive	O
culprit	O
is	O
not	O
immediately	O
present	O
after	O
transgenic	B-SO
APP	B-GGP
synthesis	O
is	O
initiated	O
,	O
but	O
requires	O
additional	O
time	O
to	O
develop	O
.	O

Alternatively	O
,	O
hyperactivity	O
may	O
be	O
caused	O
by	O
neuronal	B-CL
alterations	O
due	O
to	O
transgene	B-SO
expression	O
during	O
early	O
postnatal	O
development	O
.	O

Further	O
experiments	O
are	O
needed	O
to	O
distinguish	O
between	O
these	O
possibilities	O
.	O

In	O
summary	O
,	O
we	O
demonstrate	O
that	O
abrogating	O
A	B-GGP
beta	I-GGP
production	O
halts	O
the	O
progression	O
of	O
pathologic	O
changes	O
in	O
a	O
transgenic	B-SO
mouse	B-Taxon
model	O
of	O
Alzheimer	O
-	O
type	O
amyloidosis	O
.	O

However	O
,	O
despite	O
dramatic	O
reductions	O
in	O
A	B-GGP
beta	I-GGP
synthesis	O
,	O
neuritic	O
plaques	O
are	O
stable	O
structures	O
in	O
vivo	O
that	O
do	O
not	O
quickly	O
disaggregate	O
.	O

It	O
is	O
possible	O
that	O
a	O
combination	O
of	O
therapies	O
to	O
limit	O
A	B-GGP
beta	I-GGP
production	O
,	O
increase	O
A	B-GGP
beta	I-GGP
degradation	O
,	O
and	O
enhance	O
phagocytosis	O
of	O
deposited	O
amyloid	O
may	O
be	O
required	O
to	O
reverse	O
damage	O
associated	O
with	O
AD	O
.	O

However	O
,	O
if	O
started	O
early	O
enough	O
in	O
the	O
course	O
of	O
disease	O
,	O
secretase	O
inhibitors	B-CHEBI
alone	O
could	O
provide	O
substantial	O
benefit	O
in	O
slowing	O
pathogenic	O
processes	O
linked	O
to	O
amyloid	O
deposition	O
.	O

Even	O
at	O
later	O
stages	O
in	O
the	O
disease	O
,	O
the	O
presence	O
of	O
substantial	O
microglial	B-CL
activation	O
in	O
human	B-Taxon
AD	O
[	O
40	O
]	O
suggests	O
that	O
simply	O
slowing	O
the	O
formation	O
of	O
new	O
amyloid	O
deposits	O
may	O
allow	O
ongoing	O
phagocytosis	O
to	O
diminish	O
preexisting	O
lesions	O
.	O

However	O
,	O
the	O
development	O
of	O
safe	O
and	O
effective	O
secretase	O
inhibitors	B-CHEBI
will	O
ultimately	O
be	O
required	O
to	O
determine	O
whether	O
the	O
human	B-Taxon
brain	O
has	O
the	O
capacity	O
to	O
repair	O
amyloid	O
-	O
associated	O
damage	O
of	O
AD	O
once	O
the	O
progression	O
of	O
pathology	O
is	O
arrested	O
.	O

Supporting	O
Information	O

Figure	O
S1	O

Transgenic	B-SO
APP	B-GGP
Expression	O
and	O
Suppression	O
by	O
Dox	O
in	O
the	O
Four	O
New	O
Tet	O
-	O
Off	O
APP	B-GGP
Lines	O

Western	O
blotting	O
with	O
human	B-Taxon
-	O
specific	O
antibody	B-GO
6E10	O
reveals	O
transgene	B-SO
-	O
derived	O
full	O
-	O
length	O
APP	B-GGP
in	O
cortical	O
homogenates	O
from	O
untreated	O
animals	B-Taxon
(	O
left	O
lanes	O
of	O
each	O
panel	O
)	O
.	O

The	O
new	O
lines	O
produce	O
exceptionally	O
high	O
levels	O
of	O
transgene	B-SO
expression	O
;	O
an	O
equal	O
amount	O
of	O
brain	O
homogenate	O
from	O
a	O
standard	O
transgenic	B-SO
APP	B-GGP
line	O
is	O
shown	O
for	O
comparison	O
(	O
extreme	O
left	O
lane	O
,	O
Standard	O
Tg	B-SO
line	O
C3	O
-	O
3	O
;	O
[	O
15	O
,	O
63	O
]	O
)	O
.	O

After	O
1	O
mo	O
of	O
dox	O
treatment	O
,	O
transgenic	B-SO
protein	B-CHEBI
in	O
all	O
four	O
new	O
tet	O
-	O
off	O
APP	B-GGP
lines	O
is	O
reduced	O
to	O
residual	O
levels	O
(	O
+	O
dox	O
;	O
right	O
lanes	O
of	O
each	O
panel	O
)	O
.	O

(	O
474	O
KB	O
TIF	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Figure	O
S2	O

Transgenic	B-SO
APP	B-GGP
mRNA	B-CHEBI
Is	O
Brain	O
-	O
Specific	O

A	O
slot	O
blot	O
of	O
mRNA	B-CHEBI
harvested	O
from	O
various	O
tissues	O
in	O
three	O
of	O
the	O
four	O
new	O
tet	O
-	O
off	O
APP	B-GGP
lines	O
and	O
a	O
nontransgenic	O
control	O
was	O
used	O
to	O
examine	O
transgenic	B-SO
mRNA	B-CHEBI
expression	O
.	O

Hybridization	O
is	O
seen	O
only	O
in	O
the	O
brain	O
;	O
no	O
signal	O
above	O
background	O
is	O
seen	O
in	O
any	O
other	O
tissue	O
.	O

(	O
781	O
KB	O
PSD	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Figure	O
S3	O

Amyloid	O
Pathology	O
in	O
the	O
Cortex	O
Reiterates	O
That	O
in	O
the	O
Hippocampus	O

Amyloid	O
histology	O
was	O
performed	O
on	O
sections	O
from	O
line	O
107	O
double	O
transgenic	B-SO
mice	B-Taxon
by	O
Hirano	O
silver	B-CHEBI
stain	O
(	O
top	O
row	O
)	O
,	O
thioflavin	O
-	O
S	O
(	O
middle	O
row	O
)	O
,	O
and	O
A	B-GGP
beta	I-GGP
immunohistochemistry	O
(	O
bottom	O
row	O
)	O
to	O
examine	O
the	O
persistence	O
of	O
pathology	O
following	O
transgene	B-SO
suppression	O
.	O

As	O
in	O
the	O
hippocampus	O
(	O
see	O
Figure	O
4	O
and	O
text	O
)	O
,	O
the	O
progression	O
of	O
amyloid	O
pathology	O
in	O
the	O
cortex	O
worsens	O
substantially	O
between	O
6	O
and	O
9	O
mo	O
of	O
age	O
in	O
untreated	O
mice	B-Taxon
.	O

This	O
progression	O
is	O
completely	O
prevented	O
by	O
suppression	O
of	O
the	O
transgene	B-SO
with	O
dox	O
.	O

For	O
comparison	O
,	O
normal	O
neurohistology	O
is	O
shown	O
in	O
an	O
age	O
-	O
matched	O
single	O
transgenic	B-SO
(	O
tTA	O
only	O
)	O
animal	B-Taxon
.	O

No	O
amyloid	O
pathology	O
has	O
been	O
detected	O
in	O
either	O
APP	B-GGP
or	O
tTA	O
single	O
transgenic	B-SO
animals	B-Taxon
up	O
to	O
15	O
mo	O
of	O
age	O
.	O

(	O
4	O
.	O
8	O
MB	O
PSD	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Figure	O
S4	O

Diffuse	O
Deposits	O
Do	O
Not	O
Disperse	O
During	O
A	B-GGP
beta	I-GGP
Suppression	O

Campbell	O
-	O
Switzer	O
silver	B-CHEBI
stain	O
was	O
used	O
to	O
differentiate	O
cored	O
(	O
brown	O
)	O
from	O
diffuse	O
(	O
black	O
)	O
deposits	O
in	O
line	O
107	O
tTA	O
/	O
APP	B-GGP
mice	B-Taxon
.	O

This	O
stain	O
demonstrates	O
that	O
both	O
types	O
of	O
deposit	O
persist	O
throughout	O
long	O
periods	O
of	O
transgene	B-SO
suppression	O
.	O

The	O
lower	O
panels	O
,	O
showing	O
low	O
-	O
power	O
images	O
(	O
10	O
x	O
)	O
of	O
frontal	O
cortex	O
from	O
each	O
condition	O
,	O
reveal	O
little	O
change	O
in	O
the	O
extent	O
of	O
diffuse	O
amyloid	O
following	O
up	O
to	O
6	O
mo	O
of	O
A	B-GGP
beta	I-GGP
suppression	O
.	O

High	O
-	O
power	O
images	O
(	O
40	O
x	O
)	O
in	O
the	O
upper	O
panels	O
show	O
that	O
the	O
diffuse	O
halo	O
surrounding	O
individual	O
cored	O
deposits	O
remains	O
relatively	O
unchanged	O
in	O
treated	O
mice	B-Taxon
.	O

Untreated	O
tTA	O
single	O
transgenic	B-SO
animals	B-Taxon
are	O
shown	O
as	O
a	O
negative	O
control	O
.	O

Protocol	O
for	O
the	O
Campbell	O
-	O
Switzer	O
Alzheimer	O
'	O
s	O
Method	O
was	O
kindly	O
shared	O
by	O
Robert	O
Switzer	O
,	O
III	O
(	O
NeuroScience	O
Associates	O
,	O
Knoxville	O
,	O
Tennessee	O
,	O
United	O
States	O
)	O
,	O
and	O
can	O
be	O
downloaded	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
nsalabs	O
.	O
com	O
/	O
Documents	O
/	O
publications	O
/	O
campbell	O
-	O
switzer	O
_	O
protocol	O
.	O
htm	O
[	O
64	O
,	O
65	O
]	O
.	O

(	O
923	O
KB	O
JPG	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Figure	O
S5	O

Chronic	O
Transgene	B-SO
Suppression	O
and	O
Arrest	O
of	O
A	B-GGP
beta	I-GGP
Aggregate	O
Formation	O
in	O
an	O
Independent	O
Line	O
of	O
Tet	O
-	O
Off	O
APP	B-GGP
Mice	B-Taxon
(	O
CaMKII	B-GGP
alpha	I-GGP
-	O
tTA	O
x	O
tet	O
-	O
APPswe	O
/	O
ind	B-GGP
Line	O
18	O
)	O

(	O
A	O
)	O
The	O
experiment	O
presented	O
in	O
the	O
text	O
for	O
line	O
107	O
tet	O
-	O
off	O
APP	B-GGP
was	O
repeated	O
with	O
a	O
second	O
tet	O
-	O
off	O
APP	B-GGP
line	O
(	O
line	O
18	O
)	O
to	O
control	O
for	O
integration	B-SO
site	I-SO
artifacts	O
.	O

Cortical	O
homogenates	O
from	O
untreated	O
control	O
and	O
dox	O
-	O
treated	O
double	O
transgenic	B-SO
mice	B-Taxon
were	O
immunoblotted	O
for	O
full	O
-	O
length	O
APP	B-GGP
with	O
the	O
human	B-Taxon
-	O
specific	O
antibody	B-GO
6E10	O
to	O
confirm	O
transgene	B-SO
suppression	O
at	O
the	O
time	O
of	O
harvest	O
.	O

Immunostaining	O
for	O
endogenous	O
superoxide	B-GGP
dismutase	I-GGP
(	O
SOD1	B-GGP
)	O
was	O
included	O
as	O
a	O
loading	O
control	O
.	O

(	O
B	O
)	O
Quantitation	O
of	O
signal	O
intensity	O
from	O
the	O
Western	O
blot	O
in	O
(	O
A	O
)	O
shows	O
transgenic	B-SO
APP	B-GGP
levels	O
in	O
line	O
18	O
are	O
suppressed	O
by	O
more	O
than	O
98	O
%	O
following	O
3	O
mo	O
of	O
dox	O
treatment	O
(	O
significant	O
effect	O
of	O
group	O
ANOVA	O
F2	O
,	O
8	O
=	O
1559	O
.	O
7	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

This	O
level	O
of	O
suppression	O
was	O
equal	O
to	O
or	O
better	O
than	O
that	O
attained	O
in	O
line	O
107	O
(	O
see	O
Figure	O
3B	O
)	O
.	O

(	O
C	O
)	O
Serial	O
dilution	O
filter	O
trap	O
assay	O
was	O
used	O
to	O
quantify	O
aggregated	O
A	B-GGP
beta	I-GGP
in	O
cortical	O
homogenates	O
.	O

(	O
D	O
)	O
Quantitation	O
of	O
signal	O
intensity	O
in	O
the	O
linear	O
range	O
of	O
the	O
dilution	O
series	O
shown	O
in	O
(	O
C	O
)	O
.	O

Consistent	O
with	O
the	O
amyloid	O
histology	O
shown	O
in	O
Figure	O
S5	O
,	O
aggregate	O
formation	O
was	O
significantly	O
increased	O
between	O
6	O
and	O
9	O
mo	O
of	O
age	O
in	O
untreated	O
mice	B-Taxon
(	O
significant	O
effect	O
of	O
group	O
ANOVA	O
F2	O
,	O
18	O
=	O
12	O
.	O
14	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Aggregate	O
formation	O
was	O
completely	O
arrested	O
by	O
transgene	B-SO
suppression	O
,	O
and	O
is	O
identical	O
in	O
9	O
-	O
mo	O
-	O
old	O
mice	B-Taxon
treated	O
with	O
dox	O
for	O
3	O
mo	O
as	O
in	O
untreated	O
animals	B-Taxon
harvested	O
when	O
treatment	O
began	O
(	O
p	O
>	O
0	O
.	O
5	O
,	O
Tukey	O
post	O
-	O
hoc	O
test	O
)	O
.	O

*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
005	O
;	O
*	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
001	O
versus	O
9	O
-	O
mo	O
-	O
old	O
untreated	O
mice	B-Taxon
,	O
Tukey	O
post	O
-	O
hoc	O
test	O
.	O

(	O
962	O
KB	O
TIF	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Figure	O
S6	O

Arrest	O
of	O
Amyloid	O
Progression	O
by	O
Chronic	O
Transgene	B-SO
Suppression	O
in	O
Line	O
18	O
Tet	O
-	O
Off	O
APP	B-GGP
Mice	B-Taxon

Amyloid	O
histology	O
in	O
cortical	O
(	O
first	O
and	O
third	O
rows	O
)	O
and	O
hippocampal	O
(	O
second	O
and	O
fourth	O
rows	O
)	O
sections	O
from	O
untreated	O
tTA	O
/	O
APP	B-GGP
mice	B-Taxon
shows	O
a	O
dramatic	O
progression	O
of	O
pathology	O
between	O
6	O
and	O
9	O
mo	O
of	O
age	O
.	O

Suppression	O
of	O
transgenic	B-SO
APP	B-GGP
expression	O
arrests	O
this	O
progression	O
,	O
although	O
without	O
any	O
sign	O
of	O
plaque	O
clearance	O
(	O
6	O
mo	O
+	O
3	O
mo	O
dox	O
)	O
.	O

Hirano	O
silver	B-CHEBI
stain	O
(	O
top	O
panels	O
)	O
;	O
thioflavin	O
-	O
S	O
(	O
bottom	O
panels	O
)	O
.	O

(	O
5	O
.	O
8	O
MB	O
PSD	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Patient	O
Summary	O

Background	O

Patients	O
with	O
Alzheimer	O
disease	O
(	O
AD	O
)	O
have	O
elevated	O
levels	O
of	O
a	O
small	O
protein	B-CHEBI
called	O
amyloid	B-GGP
-	I-GGP
beta	I-GGP
peptide	B-SO
that	O
sticks	O
together	O
to	O
form	O
what	O
are	O
known	O
as	O
amyloid	O
plaques	O
in	O
their	O
brains	O
.	O

This	O
peptide	B-SO
is	O
normally	O
made	O
at	O
low	O
levels	O
in	O
healthy	O
individuals	B-Taxon
,	O
and	O
is	O
made	O
when	O
a	O
larger	O
protein	B-CHEBI
called	O
amyloid	B-GGP
precursor	I-GGP
protein	I-GGP
(	O
APP	B-GGP
)	O
is	O
cut	O
down	O
in	O
size	O
.	O

New	O
treatments	O
are	O
now	O
being	O
developed	O
that	O
will	O
decrease	O
the	O
amount	O
of	O
A	B-GGP
beta	I-GGP
produced	O
from	O
APP	B-GGP
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
whether	O
lowering	O
the	O
production	O
of	O
A	B-GGP
beta	I-GGP
will	O
allow	O
the	O
brain	O
to	O
heal	O
itself	O
by	O
clearing	O
the	O
amyloid	O
plaques	O
.	O

The	O
answer	O
to	O
this	O
question	O
may	O
be	O
important	O
for	O
deciding	O
when	O
A	B-GGP
beta	I-GGP
-	O
lowering	O
drugs	B-CHEBI
should	O
be	O
started	O
,	O
and	O
may	O
also	O
determine	O
how	O
effective	O
they	O
are	O
in	O
reversing	O
the	O
mental	O
symptoms	O
of	O
AD	O
.	O

What	O
Did	O
the	O
Researchers	O
Do	O
and	O
Find	O
?	O

Because	O
new	O
drugs	B-CHEBI
designed	O
to	O
lower	O
A	B-GGP
beta	I-GGP
levels	O
are	O
still	O
in	O
development	O
,	O
they	O
are	O
not	O
available	O
for	O
testing	O
in	O
animal	B-Taxon
models	O
of	O
the	O
disease	O
.	O

Instead	O
,	O
basic	O
questions	O
about	O
the	O
effectiveness	O
of	O
this	O
type	O
of	O
treatment	O
must	O
be	O
answered	O
using	O
systems	O
that	O
mimic	O
how	O
the	O
drugs	B-CHEBI
work	O
.	O

To	O
do	O
this	O
,	O
the	O
authors	O
created	O
mice	B-Taxon
that	O
produce	O
too	O
much	O
APP	B-GGP
and	O
that	O
develop	O
the	O
same	O
amyloid	O
lesions	O
as	O
do	O
human	B-Taxon
patients	O
with	O
AD	O
.	O

Unlike	O
normal	O
mice	B-Taxon
,	O
these	O
mice	B-Taxon
also	O
carried	O
a	O
"	O
switch	O
"	O
gene	B-SO
that	O
allowed	O
the	O
researchers	O
to	O
turn	O
off	O
APP	B-GGP
by	O
feeding	O
the	O
mice	B-Taxon
special	O
food	B-CHEBI
.	O

Turning	O
off	O
APP	B-GGP
in	O
these	O
mice	B-Taxon
had	O
the	O
same	O
effect	O
as	O
treating	O
them	O
with	O
A	B-GGP
beta	I-GGP
-	O
lowering	O
drugs	B-CHEBI
,	O
and	O
so	O
the	O
researchers	O
were	O
able	O
to	O
ask	O
what	O
happened	O
to	O
the	O
amyloid	O
plaques	O
after	O
A	B-GGP
beta	I-GGP
production	O
was	O
shut	O
down	O
.	O

They	O
showed	O
that	O
lowering	O
A	B-GGP
beta	I-GGP
production	O
prevents	O
the	O
amyloid	O
lesions	O
from	O
getting	O
worse	O
as	O
the	O
disease	O
progresses	O
.	O

This	O
means	O
that	O
treatment	O
with	O
A	B-GGP
beta	I-GGP
-	O
lowering	O
drugs	B-CHEBI
may	O
be	O
able	O
to	O
stop	O
the	O
disease	O
from	O
filling	O
the	O
brain	O
with	O
plaques	O
.	O

However	O
,	O
the	O
researchers	O
also	O
found	O
that	O
the	O
amyloid	O
lesions	O
that	O
had	O
formed	O
before	O
treatment	O
was	O
started	O
remained	O
intact	O
throughout	O
the	O
experiment	O
.	O

What	O
Do	O
These	O
Findings	O
Mean	O
?	O

These	O
results	O
indicate	O
that	O
treatments	O
designed	O
to	O
lower	O
the	O
production	O
of	O
A	B-GGP
beta	I-GGP
may	O
be	O
an	O
important	O
part	O
of	O
future	O
AD	O
treatment	O
,	O
as	O
this	O
approach	O
seems	O
to	O
prevents	O
additional	O
amyloid	O
plaques	O
from	O
forming	O
in	O
the	O
mouse	B-Taxon
brain	O
.	O

However	O
,	O
by	O
itself	O
,	O
this	O
strategy	O
may	O
not	O
be	O
able	O
to	O
rid	O
the	O
brain	O
of	O
plaques	O
that	O
have	O
already	O
formed	O
in	O
the	O
brain	O
before	O
treatment	O
is	O
started	O
.	O

The	O
findings	O
suggest	O
that	O
early	O
treatment	O
may	O
be	O
important	O
for	O
this	O
approach	O
to	O
succeed	O
.	O

Where	O
Can	O
I	O
Get	O
More	O
Information	O
Online	O
?	O

MedlinePlus	O
has	O
several	O
Web	O
pages	O
of	O
information	O
on	O
Alzheimer	O
disease	O
:	O

http	O
:	O
/	O
/	O
www	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
medlineplus	O
/	O
alzheimersdisease	O
.	O
html	O

The	O
ADEAR	O
Center	O
of	O
the	O
US	O
Government	O
'	O
s	O
National	O
Institute	O
on	O
Aging	O
also	O
has	O
information	O
on	O
Alzheimer	O
disease	O
:	O

http	O
:	O
/	O
/	O
www	O
.	O
alzheimers	O
.	O
org	O
/	O

The	O
Alzheimer	O
'	O
s	O
Association	O
Web	O
site	O
contains	O
information	O
on	O
both	O
caregiving	O
and	O
research	O
:	O

http	O
:	O
/	O
/	O
www	O
.	O
alz	O
.	O
org	O

Acknowledgements	O

We	O
thank	O
Patrick	O
Tremblay	O
for	O
helpful	O
advice	O
on	O
the	O
tet	O
system	O
at	O
a	O
critical	O
time	O
in	O
the	O
project	O
,	O
and	O
Mark	O
Mayford	O
for	O
sharing	O
the	O
CaMKII	B-GGP
alpha	I-GGP
-	O
tTA	O
mice	B-Taxon
through	O
Jackson	O
Laboratory	O
.	O

We	O
also	O
thank	O
Fraser	O
Moss	O
for	O
saving	O
several	O
immunoblots	O
with	O
last	O
-	O
minute	O
shipments	O
,	O
Andy	O
Groves	O
for	O
many	O
thoughtful	O
discussions	O
,	O
Neil	O
Segil	O
for	O
generously	O
sharing	O
his	O
laboratory	O
and	O
equipment	O
,	O
Beth	O
Olson	O
,	O
Natasha	O
Bouey	O
,	O
and	O
Yolanda	O
Jackson	O
for	O
outstanding	O
animal	B-Taxon
care	O
,	O
Debbie	O
Swing	O
for	O
expert	O
microinjection	O
,	O
and	O
Dave	O
Fromholt	O
for	O
genotyping	O
and	O
dissection	O
.	O

We	O
gratefully	O
acknowledge	O
Takeda	O
Chemical	B-CHEBI
Industries	O
for	O
providing	O
antibodies	B-GO
BAN50	O
,	O
BA27	O
,	O
and	O
BC05	O
,	O
Konrad	O
Beyreuther	O
and	O
Andreas	O
Weidemann	O
for	O
providing	O
22C11	O
antibody	B-GO
,	O
and	O
Ed	O
Koo	O
for	O
sharing	O
CT15	O
antibody	B-GO
.	O

This	O
work	O
was	O
supported	O
by	O
grants	O
from	O
the	O
Johns	O
Hopkins	O
Alzheimer	O
'	O
s	O
Disease	O
Research	O
Center	O
(	O
JLJ	O
)	O
,	O
the	O
National	O
Alliance	O
for	O
Research	O
on	O
Schizophrenia	O
and	O
Depression	O
(	O
Young	O
Investigator	O
Award	O
[	O
JLJ	O
]	O
)	O
,	O
the	O
Rose	O
Hills	O
Foundation	O
(	O
JLJ	O
)	O
,	O
the	O
Alzheimer	O
'	O
s	O
Association	O
(	O
Zenith	O
Award	O
[	O
DRB	O
]	O
)	O
,	O
the	O
National	O
Institute	O
of	O
Aging	O
(	O
K01	O
AG26144	O
-	O
01	O
[	O
JLJ	O
]	O
,	O
P50	O
AGO5146	O
-	O
20	O
[	O
DRB	O
]	O
,	O
R01	O
AG006656	O
-	O
16	O
[	O
SGY	O
]	O
,	O
and	O
P01	O
AG015453	O
[	O
SGY	O
]	O
)	O
,	O
the	O
National	O
Institute	O
of	O
Neurologic	O
Disease	O
and	O
Stoke	O
(	O
R01	O
NS	O
047225	O
[	O
DRB	O
]	O
)	O
,	O
and	O
the	O
National	O
Cancer	O
Institute	O
(	O
NAJ	O
and	O
NGC	O
)	O
.	O

The	O
funding	O
agencies	O
generously	O
provided	O
for	O
research	O
supplies	O
,	O
animal	B-Taxon
care	O
,	O
and	O
salary	O
support	O
;	O
the	O
funders	O
of	O
this	O
work	O
had	O
no	O
role	O
in	O
study	O
design	O
,	O
data	O
collection	O
and	O
analysis	O
,	O
decision	O
to	O
publish	O
,	O
or	O
preparation	O
of	O
the	O
manuscript	O
.	O

Abbreviations	O

A	B-GGP
beta	I-GGP
-	O
amyloid	B-GGP
-	I-GGP
beta	I-GGP

AD	O
-	O
Alzheimer	O
disease	O

APLP	O
-	O
amyloid	B-GGP
precursor	I-GGP
-	O
like	O
protein	B-CHEBI

APP	B-GGP
-	O
amyloid	B-GGP
precursor	I-GGP
protein	I-GGP

CaMKII	B-GGP
alpha	I-GGP
-	O
calcium	B-GGP
-	I-GGP
calmodulin	I-GGP
kinase	I-GGP
II	I-GGP
alpha	I-GGP

dox	O
-	O
doxycycline	O

FA	B-CHEBI
-	O
formic	B-CHEBI
acid	I-CHEBI

GFAP	B-GGP
-	O
glial	B-GGP
fibrillary	I-GGP
acidic	I-GGP
protein	I-GGP

mo	B-Taxon
/	O
huAPP695	B-GGP
-	O
mouse	B-GGP
APP	I-GGP
with	O
a	O
humanized	O
A	B-GGP
beta	I-GGP
domain	B-SO

PBS	O
-	O
phosphate	B-CHEBI
-	O
buffered	B-CHEBI
saline	O

SDS	B-CHEBI
-	O
sodium	B-CHEBI
dodecyl	I-CHEBI
sulfate	I-CHEBI

swe	B-GGP
/	O
ind	B-GGP
-	O
Swedish	B-GGP
/	O
Indiana	B-GGP

tTA	O
-	O
tetracycline	B-CHEBI
transactivator	O

Figures	O
and	O
Tables	O

Figure	O
1	O

Control	O
of	O
Transgenic	B-SO
APP	B-GGP
Expression	O
by	O
Dox	O

(	O
A	O
)	O
Western	O
blotting	O
for	O
transgenic	B-SO
APP	B-GGP
using	O
the	O
human	B-Taxon
-	O
specific	O
6E10	O
antibody	B-GO
shows	O
expression	O
of	O
full	O
-	O
length	O
protein	B-CHEBI
in	O
forebrain	O
tissue	O
from	O
young	O
predeposit	O
double	O
transgenic	B-SO
animals	B-Taxon
(	O
line	O
107	O
)	O
and	O
its	O
suppression	O
following	O
dox	O
treatment	O
.	O

Untreated	O
animals	B-Taxon
show	O
high	O
levels	O
of	O
transgene	B-SO
expression	O
;	O
protein	B-CHEBI
levels	O
drop	O
dramatically	O
in	O
animals	B-Taxon
acutely	O
treated	O
with	O
dox	O
for	O
2	O
wk	O
.	O

A	O
faint	O
,	O
but	O
detectable	O
band	O
of	O
full	O
-	O
length	O
protein	B-CHEBI
remains	O
in	O
acutely	O
treated	O
animals	B-Taxon
that	O
can	O
be	O
eliminated	O
in	O
mice	B-Taxon
born	O
and	O
raised	O
on	O
dox	O
.	O

(	O
B	O
)	O
Immunoblotting	O
with	O
the	O
N	B-SO
-	I-SO
terminal	I-SO
antibody	B-GO
22C11	O
to	O
detect	O
both	O
transgenic	B-SO
and	O
endogenous	O
protein	B-CHEBI
shows	O
that	O
dox	O
treatment	O
reduces	O
APP	B-GGP
/	O
APLP	O
to	O
levels	O
found	O
in	O
nontransgenic	O
mice	B-Taxon
.	O

(	O
C	O
)	O
Measurement	O
of	O
signal	O
intensity	O
from	O
the	O
Western	O
blot	O
in	O
(	O
A	O
)	O
shows	O
transgenic	B-SO
APP	B-GGP
levels	O
are	O
decreased	O
more	O
than	O
95	O
%	O
by	O
dox	O
in	O
both	O
acutely	O
and	O
chronically	O
treated	O
animals	B-Taxon
(	O
97	O
.	O
2	O
%	O
for	O
4	O
wk	O
+	O
2	O
wk	O
dox	O
,	O
98	O
.	O
0	O
%	O
for	O
reared	O
on	O
dox	O
versus	O
4	O
wk	O
untreated	O
;	O
ANOVA	O
effect	O
of	O
treatment	O
group	O
F4	O
,	O
15	O
=	O
85	O
.	O
55	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

APP	B-GGP
levels	O
in	O
4	O
wk	O
+	O
2	O
wk	O
dox	O
,	O
reared	O
on	O
dox	O
,	O
and	O
nontransgenic	O
(	O
NTg	O
)	O
were	O
not	O
significantly	O
different	O
(	O
p	O
>	O
0	O
.	O
9	O
,	O
Tukey	O
post	O
-	O
hoc	O
test	O
)	O
.	O

(	O
D	O
)	O
Measurement	O
of	O
signal	O
intensity	O
from	O
the	O
Western	O
blot	O
in	O
(	O
B	O
)	O
shows	O
total	O
APP	B-GGP
/	O
APLP	O
levels	O
in	O
dox	O
-	O
treated	O
tTA	O
/	O
APP	B-GGP
mice	B-Taxon
are	O
significantly	O
lower	O
than	O
in	O
4	O
-	O
wk	O
-	O
old	O
untreated	O
mice	B-Taxon
(	O
ANOVA	O
effect	O
of	O
treatment	O
group	O
F4	O
,	O
15	O
=	O
84	O
.	O
41	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
indistinguishable	O
from	O
those	O
of	O
nontransgenic	O
animals	B-Taxon
(	O
p	O
>	O
0	O
.	O
9	O
,	O
Tukey	O
post	O
-	O
hoc	O
test	O
)	O
.	O

*	O
,	O
p	O
<	O
0	O
.	O
001	O
versus	O
untreated	O
4	O
-	O
wk	O
-	O
old	O
mice	B-Taxon
,	O
Tukey	O
post	O
-	O
hoc	O
test	O
applied	O
to	O
significant	O
effect	O
of	O
group	O
ANOVA	O
.	O

Figure	O
2	O

A	B-GGP
beta	I-GGP
Levels	O
Are	O
Dramatically	O
Reduced	O
by	O
Transgene	B-SO
Suppression	O

Cortical	O
homogenates	O
from	O
young	O
,	O
predeposit	O
tTA	O
/	O
APP	B-GGP
mice	B-Taxon
used	O
for	O
Western	O
blot	O
in	O
Figure	O
1	O
(	O
line	O
107	O
)	O
were	O
fractionated	O
by	O
sequential	O
multi	O
-	O
step	O
extraction	O
with	O
PBS	O
,	O
2	O
%	O
SDS	B-CHEBI
,	O
and	O
70	O
%	O
FA	B-CHEBI
followed	O
by	O
human	B-Taxon
-	O
specific	O
A	B-GGP
beta	I-GGP
ELISA	O
to	O
measure	O
transgene	B-SO
-	O
derived	O
peptide	B-SO
in	O
each	O
fraction	B-GO
.	O

A	B-GGP
beta	I-GGP
40	I-GGP
is	O
shown	O
in	O
white	O
,	O
A	B-GGP
beta	I-GGP
42	I-GGP
in	O
black	O
.	O

(	O
A	O
)	O
PBS	O
-	O
soluble	O
A	B-GGP
beta	I-GGP
levels	O
are	O
substantially	O
reduced	O
by	O
both	O
acute	O
and	O
chronic	O
dox	O
treatment	O
(	O
ANOVA	O
,	O
effect	O
of	O
treatment	O
group	O
F4	O
,	O
24	O
=	O
137	O
.	O
10	O
and	O
386	O
.	O
01	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
for	O
A	B-GGP
beta	I-GGP
40	I-GGP
and	O
A	B-GGP
beta	I-GGP
42	I-GGP
,	O
respectively	O
)	O
.	O

A	B-GGP
beta	I-GGP
levels	O
in	O
treated	O
animals	B-Taxon
are	O
indistinguishable	O
from	O
nontransgenic	O
(	O
NTg	O
)	O
animals	B-Taxon
(	O
p	O
>	O
0	O
.	O
3	O
,	O
Tukey	O
post	O
-	O
hoc	O
test	O
)	O
.	O

(	O
B	O
)	O
In	O
the	O
young	O
animals	B-Taxon
tested	O
here	O
prior	O
to	O
the	O
formation	O
of	O
visible	O
amyloid	O
deposits	O
,	O
most	O
A	B-GGP
beta	I-GGP
is	O
extracted	O
into	O
the	O
SDS	B-CHEBI
fraction	B-GO
(	O
84	O
%	O
and	O
76	O
%	O
of	O
all	O
transgene	B-SO
-	O
derived	O
A	B-GGP
beta	I-GGP
40	I-GGP
and	O
A	B-GGP
beta	I-GGP
42	I-GGP
,	O
respectively	O
)	O
.	O

As	O
in	O
the	O
PBS	O
-	O
soluble	O
fraction	B-GO
,	O
A	B-GGP
beta	I-GGP
levels	O
in	O
the	O
SDS	B-CHEBI
fraction	B-GO
are	O
significantly	O
lowered	O
by	O
dox	O
treatment	O
compared	O
to	O
untreated	O
animals	B-Taxon
(	O
ANOVA	O
effect	O
of	O
group	O
F4	O
,	O
24	O
=	O
197	O
.	O
57	O
and	O
163	O
.	O
48	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
for	O
A	B-GGP
beta	I-GGP
40	I-GGP
and	O
A	B-GGP
beta	I-GGP
42	I-GGP
,	O
respectively	O
)	O
.	O

Acutely	O
treated	O
animals	B-Taxon
retained	O
a	O
small	O
(	O
although	O
significant	O
)	O
amount	O
of	O
residual	O
peptide	B-SO
(	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
nontransgeinc	O
,	O
Tukey	O
post	O
-	O
hoc	O
test	O
)	O
,	O
whereas	O
A	B-GGP
beta	I-GGP
levels	O
in	O
mice	B-Taxon
born	O
and	O
raised	O
on	O
dox	O
were	O
reduced	O
to	O
levels	O
indistinguishable	O
from	O
nontransgenic	O
(	O
p	O
>	O
0	O
.	O
8	O
,	O
Tukey	O
post	O
-	O
hoc	O
test	O
)	O
.	O

(	O
C	O
)	O
The	O
FA	B-CHEBI
-	O
soluble	O
fraction	B-GO
already	O
contains	O
a	O
small	O
but	O
significant	O
pool	O
of	O
aggregated	O
A	B-GGP
beta	I-GGP
42	I-GGP
in	O
untreated	O
animals	B-Taxon
by	O
4	O
wk	O
of	O
age	O
(	O
p	O
<	O
0	O
.	O
05	O
versus	O
nontransgenic	O
;	O
Tukey	O
post	O
-	O
hoc	O
test	O
applied	O
to	O
significant	O
effect	O
of	O
group	O
ANOVA	O
F4	O
,	O
24	O
=	O
17	O
.	O
11	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

By	O
6	O
wk	O
of	O
age	O
,	O
the	O
amount	O
of	O
A	B-GGP
beta	I-GGP
in	O
the	O
FA	B-CHEBI
fraction	B-GO
is	O
increased	O
significantly	O
preceding	O
the	O
appearance	O
of	O
visible	O
deposits	O
2	O
wk	O
later	O
.	O

The	O
FA	B-CHEBI
pool	O
is	O
the	O
only	O
peptide	B-SO
fraction	B-GO
not	O
lowered	O
by	O
acute	O
dox	O
treatment	O
(	O
4	O
wk	O
untreated	O
=	O
4	O
wk	O
+	O
2	O
wk	O
dox	O
,	O
p	O
>	O
0	O
.	O
9	O
,	O
Tukey	O
post	O
-	O
hoc	O
test	O
)	O
,	O
consistent	O
with	O
poor	O
turnover	O
of	O
aggregated	O
A	B-GGP
beta	I-GGP
species	B-SO
.	O

(	O
D	O
)	O
Measurements	O
of	O
total	O
A	B-GGP
beta	I-GGP
,	O
including	O
both	O
endogenous	O
and	O
transgene	B-SO
-	O
derived	O
peptides	B-SO
,	O
show	O
that	O
animals	B-Taxon
born	O
and	O
raised	O
on	O
dox	O
harbor	O
A	B-GGP
beta	I-GGP
levels	O
identical	O
to	O
nontransgenic	O
animals	B-Taxon
(	O
p	O
>	O
0	O
.	O
9	O
,	O
Tukey	O
post	O
-	O
hoc	O
test	O
,	O
effect	O
of	O
group	O
ANOVA	O
F4	O
,	O
24	O
=	O
39	O
.	O
13	O
and	O
35	O
.	O
29	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
for	O
A	B-GGP
beta	I-GGP
40	I-GGP
and	O
A	B-GGP
beta	I-GGP
42	I-GGP
,	O
respectively	O
)	O
.	O

Whereas	O
chronic	O
transgene	B-SO
suppression	O
fully	O
prevents	O
synthesis	O
of	O
both	O
peptides	B-SO
,	O
acute	O
dox	O
treatment	O
fully	O
suppresses	O
A	B-GGP
beta	I-GGP
40	I-GGP
levels	O
(	O
p	O
>	O
0	O
.	O
8	O
,	O
Tukey	O
post	O
-	O
hoc	O
test	O
)	O
,	O
but	O
leaves	O
a	O
small	O
amount	O
of	O
nonsuppressed	O
A	B-GGP
beta	I-GGP
42	I-GGP
.	O

The	O
residual	O
A	B-GGP
beta	I-GGP
42	I-GGP
observed	O
in	O
acutely	O
treated	O
young	O
animals	B-Taxon
derives	O
from	O
uncleared	O
aggregates	O
extracted	O
in	O
the	O
SDS	B-CHEBI
and	O
FA	B-CHEBI
fractions	B-GO
.	O

*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
005	O
;	O
*	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
001	O
versus	O
4	O
-	O
wk	O
-	O
old	O
untreated	O
mice	B-Taxon
,	O
Tukey	O
post	O
-	O
hoc	O
applied	O
to	O
significant	O
effect	O
of	O
group	O
ANOVA	O
.	O

Figure	O
3	O

Robust	O
Transgene	B-SO
Suppression	O
in	O
Older	O
Mice	B-Taxon
with	O
Preexisting	O
Amyloid	O
Pathology	O

(	O
A	O
)	O
Cortical	O
homogenates	O
from	O
6	O
-	O
to	O
12	O
-	O
mo	O
-	O
old	O
animals	B-Taxon
used	O
for	O
pathology	O
studies	O
described	O
below	O
(	O
line	O
107	O
)	O
were	O
immunoblotted	O
with	O
human	B-Taxon
-	O
specific	O
antibody	B-GO
6E10	O
to	O
examine	O
transgene	B-SO
suppression	O
following	O
3	O
or	O
6	O
mo	O
of	O
dox	O
treatment	O
.	O

The	O
blot	O
was	O
co	O
-	O
immunostained	O
for	O
endogenous	O
superoxide	B-GGP
dismutase	I-GGP
1	I-GGP
(	O
SOD1	B-GGP
)	O
as	O
a	O
control	O
for	O
loading	O
.	O

(	O
B	O
)	O
Quantitation	O
of	O
signal	O
intensity	O
from	O
the	O
Western	O
blot	O
shown	O
in	O
(	O
A	O
)	O
.	O

Transgenic	B-SO
APP	B-GGP
levels	O
are	O
significantly	O
suppressed	O
following	O
3	O
or	O
6	O
mo	O
of	O
dox	O
treatment	O
(	O
96	O
.	O
9	O
%	O
and	O
97	O
.	O
6	O
%	O
,	O
respectively	O
)	O
.	O

*	O
,	O
p	O
<	O
0	O
.	O
001	O
compared	O
to	O
6	O
-	O
mo	O
-	O
old	O
untreated	O
animals	B-Taxon
,	O
Tukey	O
post	O
-	O
hoc	O
test	O
applied	O
to	O
significant	O
effect	O
of	O
group	O
ANOVA	O
F3	O
,	O
12	O
=	O
107	O
.	O
22	O
,	O
p	O
<	O
0	O
.	O
001	O
.	O

These	O
data	O
demonstrate	O
that	O
strong	O
transgene	B-SO
suppression	O
is	O
attained	O
both	O
before	O
and	O
after	O
the	O
onset	O
of	O
amyloid	O
pathology	O
(	O
see	O
Figure	O
1	O
for	O
predeposit	O
experiments	O
)	O
.	O

(	O
C	O
)	O
Experimental	O
design	O
.	O

To	O
examine	O
the	O
effects	O
of	O
chronic	O
A	B-GGP
beta	I-GGP
suppression	O
on	O
amyloid	O
pathology	O
after	O
the	O
onset	O
of	O
deposition	O
,	O
we	O
compared	O
untreated	O
controls	O
harvested	O
at	O
6	O
and	O
9	O
mo	O
of	O
age	O
to	O
animals	B-Taxon
placed	O
on	O
dox	O
at	O
6	O
mo	O
of	O
age	O
and	O
harvested	O
after	O
3	O
or	O
6	O
mo	O
of	O
treatment	O
.	O

(	O
D	O
)	O
Dox	O
treatment	O
leads	O
to	O
rapid	O
transgene	B-SO
suppression	O
even	O
in	O
6	O
-	O
mo	O
-	O
old	O
tTA	O
/	O
APP	B-GGP
mice	B-Taxon
.	O

Immunostaining	O
with	O
6E10	O
shows	O
APPswe	O
/	O
ind	B-GGP
levels	O
are	O
dramatically	O
reduced	O
in	O
6	O
-	O
mo	O
-	O
old	O
mice	B-Taxon
treated	O
for	O
1	O
wk	O
with	O
dox	O
(	O
upper	O
panel	O
)	O
.	O

A	O
separate	O
blot	O
was	O
immunostained	O
for	O
APP	B-GGP
C	B-SO
-	I-SO
terminal	I-SO
fragments	B-SO
with	O
CT15	O
antibody	B-GO
to	O
show	O
that	O
the	O
precursors	O
to	O
A	B-GGP
beta	I-GGP
cleavage	O
are	O
decreased	O
in	O
parallel	O
with	O
the	O
full	O
-	O
length	O
protein	B-CHEBI
(	O
middle	O
panel	O
)	O
.	O

Costaining	O
for	O
superoxide	B-GGP
dismutase	I-GGP
1	I-GGP
was	O
used	O
as	O
an	O
internal	O
control	O
for	O
loading	O
(	O
lower	O
panel	O
,	O
taken	O
from	O
bottom	O
half	O
of	O
6E10	O
blot	O
)	O
.	O

Figure	O
4	O

Suppression	O
of	O
Transgenic	B-SO
APP	B-GGP
Arrests	O
Progression	O
of	O
Amyloid	O
Pathology	O

(	O
A	O
)	O
Aggregated	O
A	B-GGP
beta	I-GGP
was	O
quantified	O
in	O
cortical	O
tissue	O
from	O
dox	O
-	O
treated	O
and	O
control	O
tTA	O
/	O
APP	B-GGP
mice	B-Taxon
(	O
line	O
107	O
)	O
using	O
a	O
filter	O
trap	O
assay	O
.	O

Serial	O
dilutions	O
of	O
protein	B-CHEBI
homogenate	O
were	O
passed	O
through	O
a	O
cellulose	O
acetate	B-CHEBI
filter	O
;	O
protein	B-CHEBI
aggregates	O
larger	O
than	O
the	O
pore	O
size	O
were	O
trapped	O
and	O
immunostained	O
for	O
A	B-GGP
beta	I-GGP
.	O

(	O
B	O
)	O
Quantitation	O
of	O
signal	O
intensity	O
in	O
the	O
linear	O
range	O
of	O
each	O
filter	O
trap	O
dilution	O
series	O
(	O
arrow	O
in	O
[	O
A	O
]	O
)	O
was	O
used	O
to	O
compare	O
aggregate	O
load	O
across	O
treatment	O
groups	O
.	O

Aggregated	O
A	B-GGP
beta	I-GGP
increased	O
significantly	O
between	O
6	O
and	O
9	O
mo	O
of	O
age	O
in	O
untreated	O
mice	B-Taxon
(	O
significant	O
effect	O
of	O
group	O
ANOVA	O
F3	O
,	O
18	O
=	O
7	O
.	O
85	O
,	O
p	O
<	O
0	O
.	O
002	O
)	O
.	O

This	O
progression	O
of	O
pathology	O
was	O
completely	O
prevented	O
by	O
transgene	B-SO
suppression	O
.	O

The	O
amount	O
of	O
aggregated	O
A	B-GGP
beta	I-GGP
was	O
identical	O
in	O
untreated	O
mice	B-Taxon
at	O
6	O
mo	O
of	O
age	O
to	O
that	O
in	O
9	O
-	O
or	O
12	O
-	O
mo	O
-	O
old	O
animals	B-Taxon
treated	O
with	O
dox	O
(	O
p	O
>	O
0	O
.	O
9	O
,	O
Tukey	O
post	O
-	O
hoc	O
test	O
)	O
.	O

Single	O
transgenic	B-SO
tTA	O
samples	O
were	O
included	O
as	O
negative	O
controls	O
and	O
showed	O
no	O
signal	O
above	O
background	O
.	O

*	O
,	O
p	O
<	O
0	O
.	O
01	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
005	O
versus	O
9	O
-	O
mo	O
-	O
old	O
untreated	O
mice	B-Taxon
,	O
Tukey	O
post	O
-	O
hoc	O
test	O
;	O
*	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
001	O
versus	O
9	O
-	O
mo	O
-	O
old	O
untreated	O
mice	B-Taxon
,	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

(	O
C	O
)	O
Amyloid	O
pathology	O
in	O
the	O
hippocampus	O
of	O
representative	O
mice	B-Taxon
from	O
each	O
treatment	O
group	O
:	O
Hirano	O
silver	B-CHEBI
stain	O
(	O
top	O
row	O
)	O
,	O
thioflavin	O
-	O
S	O
(	O
middle	O
row	O
)	O
,	O
and	O
A	B-GGP
beta	I-GGP
immunohistochemistry	O
(	O
bottom	O
row	O
)	O
.	O

Amyloid	O
burden	O
increases	O
dramatically	O
between	O
6	O
and	O
9	O
mo	O
of	O
age	O
in	O
untreated	O
animals	B-Taxon
,	O
but	O
remains	O
stable	O
in	O
transgene	B-SO
-	O
suppressed	O
mice	B-Taxon
over	O
the	O
same	O
period	O
(	O
6	O
mo	O
+	O
3	O
mo	O
dox	O
and	O
6	O
mo	O
+	O
6	O
mo	O
dox	O
)	O
.	O

Single	O
transgenic	B-SO
animals	B-Taxon
(	O
tTA	O
only	O
shown	O
here	O
)	O
show	O
no	O
sign	O
of	O
amyloid	O
pathology	O
at	O
any	O
age	O
tested	O
.	O

Figure	O
5	O

A	B-GGP
beta	I-GGP
ELISA	O
Confirms	O
Arrest	O
of	O
Progression	O
without	O
Clearance	O
of	O
Peptide	B-SO
in	O
Mice	B-Taxon
with	O
Preexisting	O
Aggregates	O

A	B-GGP
beta	I-GGP
levels	O
in	O
untreated	O
6	O
-	O
and	O
9	O
-	O
mo	O
-	O
old	O
tTA	O
/	O
APP	B-GGP
line	O
107	O
mice	B-Taxon
(	O
shown	O
in	O
Figure	O
4	O
)	O
were	O
compared	O
to	O
those	O
in	O
9	O
-	O
and	O
12	O
-	O
mo	O
-	O
old	O
animals	B-Taxon
treated	O
with	O
dox	O
from	O
the	O
age	O
of	O
6	O
mo	O
.	O

Single	O
transgenic	B-SO
APP	B-GGP
samples	O
were	O
included	O
as	O
negative	O
controls	O
.	O

Cortical	O
homogenates	O
were	O
fractionated	O
by	O
sequential	O
multi	O
-	O
step	O
extraction	O
with	O
PBS	O
,	O
2	O
%	O
SDS	B-CHEBI
,	O
and	O
70	O
%	O
FA	B-CHEBI
followed	O
by	O
human	B-Taxon
-	O
specific	O
A	B-GGP
beta	I-GGP
ELISA	O
to	O
measure	O
transgene	B-SO
-	O
derived	O
peptide	B-SO
in	O
each	O
fraction	B-GO
.	O

A	B-GGP
beta	I-GGP
40	I-GGP
is	O
shown	O
in	O
white	O
,	O
A	B-GGP
beta	I-GGP
42	I-GGP
in	O
black	O
.	O

(	O
A	O
and	O
B	O
)	O
Most	O
A	B-GGP
beta	I-GGP
in	O
the	O
brains	O
of	O
plaque	O
-	O
bearing	O
mice	B-Taxon
is	O
extracted	O
into	O
the	O
FA	B-CHEBI
and	O
SDS	B-CHEBI
fractions	B-GO
.	O

Consistent	O
with	O
amyloid	O
burden	O
(	O
Figures	O
4	O
and	O
Figure	O
S3	O
)	O
,	O
SDS	B-CHEBI
-	O
and	O
FA	B-CHEBI
-	O
extracted	O
A	B-GGP
beta	I-GGP
levels	O
in	O
untreated	O
9	O
-	O
mo	O
-	O
old	O
mice	B-Taxon
were	O
significantly	O
higher	O
than	O
in	O
untreated	O
6	O
-	O
mo	O
-	O
old	O
mice	B-Taxon
(	O
Tukey	O
post	O
-	O
hoc	O
test	O
applied	O
to	O
significant	O
effect	O
of	O
group	O
ANOVA	O
for	O
SDS	B-CHEBI
and	O
FA	B-CHEBI
fractions	B-GO
F3	O
,	O
18	O
=	O
4	O
.	O
72	O
-	O
12	O
.	O
92	O
,	O
p	O
<	O
0	O
.	O
02	O
)	O
.	O

In	O
contrast	O
,	O
3	O
or	O
6	O
mo	O
of	O
transgene	B-SO
suppression	O
held	O
A	B-GGP
beta	I-GGP
at	O
levels	O
equivalent	O
to	O
those	O
harbored	O
when	O
treatment	O
was	O
started	O
(	O
p	O
>	O
0	O
.	O
2	O
compared	O
to	O
6	O
mo	O
untreated	O
mice	B-Taxon
,	O
Tukey	O
post	O
-	O
hoc	O
test	O
)	O
.	O

*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
005	O
;	O
*	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
001	O
versus	O
9	O
-	O
mo	O
-	O
old	O
untreated	O
mice	B-Taxon
,	O
Tukey	O
post	O
-	O
hoc	O
test	O
.	O

Significance	O
for	O
APP	B-GGP
versus	O
9	O
-	O
mo	O
-	O
old	O
untreated	O
mice	B-Taxon
is	O
based	O
on	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

(	O
C	O
)	O
The	O
PBS	O
fraction	B-GO
represents	O
less	O
than	O
0	O
.	O
1	O
%	O
of	O
total	O
A	B-GGP
beta	I-GGP
(	O
note	O
the	O
change	O
in	O
y	O
-	O
axis	O
from	O
[	O
A	O
]	O
and	O
[	O
B	O
]	O
)	O
,	O
but	O
only	O
here	O
do	O
A	B-GGP
beta	I-GGP
levels	O
in	O
the	O
dox	O
-	O
treated	O
mice	B-Taxon
differ	O
from	O
those	O
in	O
younger	O
untreated	O
mice	B-Taxon
.	O

Although	O
both	O
peptides	B-SO
appear	O
elevated	O
in	O
the	O
treated	O
groups	O
compared	O
to	O
the	O
untreated	O
6	O
-	O
mo	O
-	O
old	O
mice	B-Taxon
,	O
only	O
A	B-GGP
beta	I-GGP
40	I-GGP
reaches	O
statistical	O
significance	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
Tukey	O
post	O
-	O
hoc	O
test	O
applied	O
to	O
significant	O
effect	O
of	O
group	O
ANOVA	O
for	O
A	B-GGP
beta	I-GGP
40	I-GGP
F3	O
,	O
18	O
=	O
4	O
.	O
60	O
,	O
p	O
<	O
0	O
.	O
02	O
)	O
.	O

A	O
similar	O
trend	O
was	O
seen	O
for	O
A	B-GGP
beta	I-GGP
42	I-GGP
,	O
where	O
ANOVA	O
yielded	O
a	O
significant	O
effect	O
of	O
group	O
for	O
PBS	O
-	O
soluble	O
A	B-GGP
beta	I-GGP
42	I-GGP
(	O
F3	O
,	O
18	O
=	O
3	O
.	O
75	O
,	O
p	O
<	O
0	O
.	O
03	O
)	O
,	O
however	O
this	O
was	O
due	O
only	O
to	O
differences	O
between	O
the	O
untreated	O
6	O
-	O
and	O
9	O
-	O
mo	O
-	O
old	O
groups	O
.	O

*	O
,	O
p	O
<	O
0	O
.	O
05	O
versus	O
6	O
-	O
mo	O
-	O
old	O
untreated	O
mice	B-Taxon
,	O
Tukey	O
post	O
-	O
hoc	O
test	O
;	O
*	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
001	O
versus	O
6	O
-	O
mo	O
-	O
old	O
untreated	O
mice	B-Taxon
,	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

Figure	O
6	O

Neuritic	O
and	O
Glial	B-CL
Pathology	O
Are	O
Unchanged	O
following	O
Transgene	B-SO
Suppression	O

Dystrophic	O
neurites	O
and	O
activated	O
astrocytes	B-CL
surround	O
most	O
compact	O
plaques	O
in	O
tet	O
-	O
off	O
APP	B-GGP
mice	B-Taxon
(	O
line	O
107	O
)	O
.	O

Dark	O
-	O
stained	O
,	O
ubiquitin	O
-	O
filled	O
neurites	O
and	O
reactive	O
astrocytes	B-CL
form	O
a	O
halo	O
around	O
cored	O
,	O
fibrillar	O
deposits	O
by	O
6	O
mo	O
of	O
age	O
that	O
worsens	O
with	O
time	O
in	O
untreated	O
mice	B-Taxon
.	O

Both	O
plaque	O
-	O
associated	O
pathologies	O
are	O
arrested	O
,	O
although	O
not	O
reversed	O
,	O
by	O
transgene	B-SO
suppression	O
.	O

Hirano	O
silver	B-CHEBI
stain	O
(	O
top	O
row	O
)	O
;	O
GFAP	B-GGP
immunohistochemistry	O
(	O
middle	O
row	O
)	O
;	O
ubiquitin	O
immunohistochemistry	O
(	O
bottom	O
row	O
)	O
.	O

Figure	O
7	O

Transgene	B-SO
Suppression	O
Attenuates	O
Hyperactivity	O
in	O
tTA	O
/	O
APP	B-GGP
Mice	B-Taxon

(	O
A	O
)	O
A	O
48	O
-	O
h	O
measure	O
of	O
ambulation	O
records	O
extreme	O
hyperactivity	O
in	O
untreated	O
double	O
transgenic	B-SO
mice	B-Taxon
compared	O
to	O
single	O
transgenic	B-SO
and	O
nontransgenic	O
controls	O
(	O
line	O
107	O
)	O
.	O

This	O
phenotype	O
is	O
completely	O
eliminated	O
by	O
rearing	O
the	O
double	O
transgenic	B-SO
mice	B-Taxon
on	O
dox	O
.	O

(	O
B	O
)	O
The	O
same	O
data	O
shown	O
in	O
(	O
A	O
)	O
are	O
replotted	O
to	O
magnify	O
data	O
from	O
untreated	O
control	O
and	O
dox	O
-	O
treated	O
groups	O
.	O

(	O
C	O
and	O
D	O
)	O
Activity	O
levels	O
in	O
the	O
combined	O
control	O
groups	O
of	O
(	O
A	O
)	O
and	O
(	O
B	O
)	O
are	O
here	O
separated	O
by	O
genotype	B-SO
.	O

None	O
of	O
the	O
single	O
transgenic	B-SO
or	O
nontransgenic	O
control	O
groups	O
display	O
the	O
hyperactivity	O
present	O
in	O
untreated	O
tTA	O
/	O
APP	B-GGP
animals	B-Taxon
.	O

Again	O
,	O
note	O
the	O
y	O
-	O
axes	O
have	O
been	O
enlarged	O
for	O
detail	O
compared	O
to	O
(	O
A	O
)	O
.	O

Footnotes	O

Citation	O
:	O
Jankowsky	O
JL	O
,	O
Slunt	O
HH	O
,	O
Gonzales	O
V	O
,	O
Savonenko	O
AV	O
,	O
Wen	O
JC	O
,	O
et	O
al	O
.	O

(	O
2005	O
)	O
Persistent	O
amyloidosis	O
following	O
suppression	O
of	O
A	B-GGP
beta	I-GGP
production	O
in	O
a	O
transgenic	B-SO
model	O
of	O
Alzheimer	O
disease	O
.	O

PLoS	O
Med	O
2	O
(	O
12	O
)	O
:	O
e355	O
.	O

Genetic	B-SO
and	O
Genomic	B-SO
Analysis	O
of	O
a	O
Fat	O
Mass	O
Trait	O
with	O
Complex	O
Inheritance	O
Reveals	O
Marked	O
Sex	O
Specificity	O

Abstract	O

The	O
integration	O
of	O
expression	O
profiling	O
with	O
linkage	O
analysis	O
has	O
increasingly	O
been	O
used	O
to	O
identify	O
genes	B-SO
underlying	O
complex	O
phenotypes	O
.	O

The	O
effects	O
of	O
gender	O
on	O
the	O
regulation	O
of	O
many	O
physiological	O
traits	O
are	O
well	O
documented	O
;	O
however	O
,	O
"	O
genetical	B-SO
genomic	B-SO
"	O
analyses	O
have	O
not	O
yet	O
addressed	O
the	O
degree	O
to	O
which	O
their	O
conclusions	O
are	O
affected	O
by	O
sex	O
.	O

We	O
constructed	O
and	O
densely	O
genotyped	O
a	O
large	O
F2	O
intercross	O
derived	O
from	O
the	O
inbred	O
mouse	B-Taxon
strains	O
C57BL	O
/	O
6J	O
and	O
C3H	O
/	O
HeJ	O
on	O
an	O
apolipoprotein	B-GGP
E	I-GGP
null	O
(	O
ApoE	B-GGP
-	O
/	O
-	O
)	O
background	O
.	O

This	O
BXH	O
.	O
ApoE	B-GGP
-	O
/	O
-	O
population	O
recapitulates	O
several	O
"	O
metabolic	O
syndrome	O
"	O
phenotypes	O
.	O

The	O
cross	O
consists	O
of	O
334	O
animals	B-Taxon
of	O
both	O
sexes	O
,	O
allowing	O
us	O
to	O
specifically	O
test	O
for	O
the	O
dependence	O
of	O
linkage	O
on	O
sex	O
.	O

We	O
detected	O
several	O
thousand	O
liver	O
gene	B-SO
expression	O
quantitative	B-SO
trait	I-SO
loci	I-SO
,	O
a	O
significant	O
proportion	O
of	O
which	O
are	O
sex	O
-	O
biased	O
.	O

We	O
used	O
these	O
analyses	O
to	O
dissect	O
the	O
genetics	O
of	O
gonadal	O
fat	O
mass	O
,	O
a	O
complex	O
trait	O
with	O
sex	O
-	O
specific	O
regulation	O
.	O

We	O
present	O
evidence	O
for	O
a	O
remarkably	O
high	O
degree	O
of	O
sex	O
-	O
dependence	O
on	O
both	O
the	O
cis	O
and	O
trans	O
regulation	O
of	O
gene	B-SO
expression	O
.	O

We	O
demonstrate	O
how	O
these	O
analyses	O
can	O
be	O
applied	O
to	O
the	O
study	O
of	O
the	O
genetics	O
underlying	O
gonadal	O
fat	O
mass	O
,	O
a	O
complex	O
trait	O
showing	O
significantly	O
female	O
-	O
biased	O
heritability	O
.	O

These	O
data	O
have	O
implications	O
on	O
the	O
potential	O
effects	O
of	O
sex	O
on	O
the	O
genetic	B-SO
regulation	O
of	O
other	O
complex	O
traits	O
.	O

Synopsis	O

Although	O
their	O
genomes	B-SO
are	O
nearly	O
identical	O
,	O
the	O
males	O
and	O
females	O
of	O
a	O
species	O
exhibit	O
striking	O
differences	O
in	O
many	O
traits	O
,	O
including	O
complex	O
traits	O
such	O
as	O
obesity	O
.	O

This	O
study	O
combines	O
genetic	B-SO
and	O
genomic	B-SO
tools	O
to	O
identify	O
in	O
parallel	O
quantitative	B-SO
trait	I-SO
loci	I-SO
(	O
QTLs	B-SO
)	O
for	O
a	O
measure	O
of	O
gonadal	O
fat	O
mass	O
and	O
for	O
expression	O
of	O
transcripts	B-SO
in	O
the	O
liver	O
.	O

The	O
results	O
are	O
used	O
to	O
explore	O
the	O
relationship	O
between	O
genetic	B-SO
variation	O
,	O
sexual	O
differentiation	O
,	O
and	O
obesity	O
in	O
the	O
mouse	B-Taxon
model	O
.	O

Using	O
over	O
300	O
intercross	O
progeny	O
of	O
two	O
inbred	O
mouse	B-Taxon
strains	O
,	O
five	O
loci	B-SO
in	O
the	O
genome	B-SO
were	O
found	O
to	O
be	O
highly	O
correlated	O
with	O
abdominal	O
fat	O
mass	O
.	O

Four	O
of	O
the	O
five	O
loci	B-SO
exhibited	O
opposite	O
effects	O
on	O
obesity	O
in	O
the	O
two	O
sexes	O
,	O
a	O
phenomenon	O
known	O
as	O
sexual	O
antagonism	O
.	O

To	O
identify	O
candidate	O
genes	B-SO
that	O
may	O
be	O
involved	O
in	O
obesity	O
through	O
their	O
expression	O
in	O
the	O
liver	O
,	O
global	O
gene	B-SO
expression	O
analysis	O
was	O
employed	O
using	O
microarrays	O
.	O

Many	O
of	O
these	O
expression	O
QTLs	B-SO
also	O
show	O
sex	O
-	O
specific	O
effects	O
on	O
transcription	O
.	O

A	O
hotspot	O
for	O
trans	O
-	O
acting	O
QTLs	B-SO
regulating	O
the	O
expression	O
of	O
transcripts	B-SO
whose	O
abundance	O
is	O
correlated	O
with	O
gonadal	O
fat	O
mass	O
was	O
identified	O
on	O
Chromosome	B-GO
19	O
.	O

This	O
region	B-SO
of	O
the	O
genome	B-SO
colocalizes	O
with	O
a	O
clinical	O
QTL	B-SO
for	O
gonadal	O
fat	O
mass	O
,	O
suggesting	O
that	O
it	O
harbors	O
a	O
good	O
candidate	O
gene	B-SO
for	O
obesity	O
.	O

Introduction	O

Females	O
and	O
males	O
share	O
nearly	O
identical	O
genetic	B-SO
information	O
,	O
but	O
vary	O
widely	O
with	O
respect	O
to	O
disease	O
susceptibility	O
[	O
1	O
,	O
2	O
]	O
.	O

Apart	O
from	O
the	O
obvious	O
gender	O
-	O
specific	O
diseases	O
such	O
as	O
cervical	O
or	O
prostate	O
cancer	O
,	O
sex	O
influences	O
susceptibility	O
to	O
nearly	O
all	O
highly	O
prevalent	O
diseases	O
that	O
affect	O
both	O
women	O
and	O
men	O
,	O
including	O
atherosclerosis	O
and	O
diabetes	O
and	O
their	O
precursor	O
conditions	O
of	O
hyperlipidemia	O
,	O
obesity	O
,	O
and	O
insulin	B-GGP
resistance	O
.	O

These	O
are	O
multifactorial	O
in	O
their	O
pathogenesis	O
,	O
encompassing	O
environmental	O
and	O
behavioral	O
aspects	O
,	O
as	O
well	O
as	O
significant	O
genetic	B-SO
determination	O
,	O
on	O
which	O
these	O
other	O
factors	O
interact	O
.	O

The	O
genetic	B-SO
component	O
is	O
multigenic	O
,	O
with	O
the	O
heritability	O
embedded	O
in	O
the	O
genetic	B-SO
variation	O
intrinsic	O
to	O
our	O
population	O
.	O

Although	O
the	O
sex	O
differences	O
in	O
disease	O
susceptibility	O
are	O
recognized	O
,	O
the	O
interplay	O
between	O
sex	O
and	O
gene	B-SO
expression	O
that	O
is	O
at	O
the	O
basis	O
of	O
these	O
differences	O
is	O
not	O
well	O
understood	O
.	O

Females	O
and	O
males	O
inherit	O
(	O
on	O
average	O
)	O
the	O
same	O
genes	B-SO
that	O
may	O
be	O
risk	O
factors	O
,	O
but	O
their	O
expression	O
and	O
effect	O
on	O
disease	O
risk	O
varies	O
significantly	O
.	O

An	O
understanding	O
and	O
recognition	O
of	O
the	O
significance	O
of	O
specific	O
disease	O
-	O
associated	O
polymorphisms	B-SO
/	O
mutations	B-SO
in	O
the	O
context	O
of	O
sex	O
is	O
therefore	O
of	O
critical	O
clinical	O
importance	O
.	O

We	O
have	O
utilized	O
the	O
mouse	B-Taxon
as	O
a	O
model	O
system	O
to	O
study	O
the	O
genetics	O
of	O
metabolic	O
and	O
vascular	O
diseases	O
[	O
3	O
-	O
5	O
]	O
.	O

Rather	O
than	O
focus	O
initially	O
on	O
natural	B-SO
or	O
induced	O
mutants	B-SO
of	O
single	O
genes	B-SO
,	O
we	O
utilize	O
the	O
complex	O
endogenous	O
genetic	B-SO
variation	O
between	O
strains	O
in	O
genetic	B-SO
crosses	O
to	O
identify	O
causative	O
genetic	B-SO
loci	I-SO
and	O
ultimately	O
the	O
underlying	O
variations	B-SO
responsible	O
for	O
trait	O
differences	O
[	O
6	O
]	O
.	O

This	O
design	O
more	O
closely	O
reflects	O
the	O
situation	O
faced	O
when	O
studying	O
human	B-Taxon
populations	O
.	O

The	O
genetic	B-SO
composition	O
of	O
each	O
individual	O
mouse	B-Taxon
is	O
restricted	O
to	O
that	O
of	O
the	O
two	O
parental	O
strains	O
and	O
is	O
defined	O
at	O
every	O
locus	B-SO
across	O
the	O
genome	B-SO
.	O

The	O
application	O
of	O
quantitative	B-SO
trait	I-SO
locus	I-SO
(	O
QTL	B-SO
)	O
analysis	O
allows	O
the	O
identification	O
of	O
those	O
chromosomal	B-SO
regions	I-SO
that	O
contain	O
a	O
genetic	B-SO
variation	O
that	O
influences	O
trait	O
expression	O
(	O
for	O
a	O
comprehensive	O
review	O
on	O
QTLs	B-SO
see	O
[	O
7	O
]	O
)	O
.	O

We	O
[	O
5	O
,	O
8	O
]	O
,	O
and	O
others	O
[	O
9	O
-	O
17	O
]	O
,	O
have	O
recently	O
extended	O
the	O
power	O
of	O
this	O
approach	O
by	O
incorporating	O
genome	B-SO
-	O
wide	O
gene	B-SO
expression	O
array	O
analysis	O
,	O
which	O
allows	O
us	O
to	O
model	O
the	O
"	O
genetics	O
of	O
gene	B-SO
expression	O
"	O
using	O
similar	O
methods	O
.	O

An	O
immediate	O
extension	O
of	O
this	O
approach	O
is	O
toward	O
dissecting	O
the	O
genetic	B-SO
regulation	O
of	O
complex	O
phenotypes	O
,	O
which	O
would	O
greatly	O
improve	O
the	O
progression	O
from	O
candidate	O
locus	B-SO
to	O
candidate	O
gene	B-SO
.	O

Here	O
we	O
report	O
the	O
application	O
of	O
this	O
integrated	O
approach	O
to	O
study	O
the	O
significance	O
of	O
sex	O
on	O
the	O
genetic	B-SO
determinants	O
of	O
obesity	O
and	O
the	O
associated	O
regulation	O
of	O
liver	O
gene	B-SO
expression	O
in	O
an	O
F2	O
intercross	O
derived	O
from	O
the	O
inbred	O
strains	O
C57BL	O
/	O
6J	O
(	O
B6	O
)	O
and	O
C3H	O
/	O
HeJ	O
(	O
C3H	O
)	O
on	O
an	O
apolipoprotein	B-GGP
E	I-GGP
null	O
(	O
ApoE	B-GGP
-	O
/	O
-	O
)	O
background	O
.	O

The	O
BXH	O
.	O
ApoE	B-GGP
-	O
/	O
-	O
population	O
was	O
designed	O
to	O
recapitulate	O
several	O
of	O
the	O
phenotypes	O
associated	O
with	O
the	O
so	O
-	O
called	O
metabolic	O
syndrome	O
.	O

The	O
cross	O
consists	O
of	O
334	O
animals	B-Taxon
of	O
both	O
sexes	O
,	O
allowing	O
us	O
to	O
specifically	O
test	O
for	O
the	O
dependence	O
of	O
QTLs	B-SO
on	O
sex	O
.	O

We	O
detected	O
several	O
thousand	O
gene	B-SO
expression	O
QTLs	B-SO
(	O
eQTLs	O
)	O
,	O
a	O
significant	O
proportion	O
of	O
which	O
were	O
sex	O
-	O
biased	O
.	O

We	O
used	O
these	O
analyses	O
to	O
dissect	O
the	O
genetic	B-SO
regulation	O
of	O
the	O
gonadal	O
fat	O
mass	O
trait	O
and	O
to	O
identify	O
genes	B-SO
associated	O
with	O
the	O
trait	O
.	O

Results	O

QTLs	B-SO
Associated	O
with	O
Gonadal	O
Fat	O
Mass	O

Characteristics	O
of	O
the	O
B6	O
.	O
ApoE	B-GGP
-	O
/	O
-	O
and	O
C3H	O
.	O
ApoE	B-GGP
-	O
/	O
-	O
parents	O
and	O
the	O
F2	O
BXH	O
.	O
ApoE	B-GGP
-	O
/	O
-	O
generation	O
on	O
a	O
Western	O
diet	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

Gonadal	O
fat	O
mass	O
differed	O
significantly	O
between	O
the	O
sexes	O
in	O
F2	O
(	O
p	O
<	O
10	O
-	O
4	O
)	O
and	O
in	O
the	O
parental	O
C3H	O
.	O
ApoE	B-GGP
-	O
/	O
-	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
but	O
not	O
in	O
B6	O
.	O
ApoE	B-GGP
-	O
/	O
-	O
mice	B-Taxon
.	O

Gonadal	O
fat	O
mass	O
was	O
the	O
fat	O
pad	O
collection	O
that	O
represented	O
the	O
most	O
animals	B-Taxon
and	O
the	O
most	O
accurate	O
collections	O
and	O
was	O
thus	O
chosen	O
for	O
further	O
analysis	O
.	O

Broad	O
sense	O
heritability	O
(	O
h2	O
)	O
calculated	O
as	O
(	O
sigma	O
2Total	O
-	O
sigma	O
2Parental	O
)	O
/	O
sigma	O
2Total	O
for	O
the	O
gonadal	O
fat	O
mass	O
trait	O
was	O
54	O
%	O
for	O
females	O
and	O
36	O
%	O
for	O
males	O
,	O
which	O
is	O
in	O
close	O
agreement	O
with	O
previous	O
reports	O
[	O
18	O
,	O
19	O
]	O
and	O
demonstrates	O
significant	O
heritability	O
of	O
gonadal	O
fat	O
mass	O
.	O

A	O
total	O
of	O
334	O
F2	O
mice	B-Taxon
were	O
genotyped	O
at	O
an	O
average	O
1	O
.	O
5	O
cM	O
density	O
using	O
1	O
,	O
032	O
single	B-SO
nucleotide	I-SO
polymorphisms	I-SO
(	O
SNPs	B-SO
)	O
spanning	O
all	O
19	O
autosomes	B-GO
.	O

QTL	B-SO
analysis	O
for	O
several	O
clinical	O
traits	O
(	O
clinical	O
QTLs	B-SO
[	O
cQTLs	O
]	O
)	O
,	O
including	O
the	O
unadjusted	O
raw	O
values	O
for	O
gonadal	O
fat	O
mass	O
,	O
was	O
performed	O
using	O
a	O
single	O
marker	O
regression	O
approach	O
(	O
justified	O
by	O
the	O
high	O
-	O
density	O
of	O
markers	O
,	O
making	O
interval	B-SO
mapping	O
unnecessary	O
)	O
.	O

In	O
order	O
to	O
test	O
specifically	O
for	O
sex	O
effects	O
of	O
linkage	O
,	O
we	O
included	O
additive	O
,	O
dominant	O
,	O
sex	O
,	O
sex	O
-	O
additive	O
,	O
and	O
sex	O
-	O
dominant	O
parameters	O
in	O
our	O
calculations	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
.	O

A	O
stepwise	O
regression	O
procedure	O
was	O
used	O
to	O
determine	O
whether	O
the	O
addition	O
of	O
the	O
final	O
two	O
terms	O
significantly	O
improved	O
the	O
linear	O
regression	O
model	O
,	O
conditional	O
on	O
realizing	O
a	O
significant	O
additive	O
QTL	B-SO
effect	O
.	O

We	O
performed	O
permutation	O
analyses	O
over	O
all	O
gene	B-SO
expression	O
traits	O
,	O
estimating	O
false	O
discovery	O
rates	O
(	O
FDRs	O
)	O
at	O
different	O
logarithm	O
of	O
odds	O
(	O
LOD	O
)	O
score	O
thresholds	O
and	O
assessing	O
the	O
overall	O
rate	O
of	O
QTL	B-SO
detection	O
.	O

From	O
these	O
analyses	O
we	O
constructed	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
-	O
like	O
curves	O
to	O
demonstrate	O
that	O
our	O
straightforward	O
method	O
has	O
significantly	O
increased	O
power	O
to	O
detect	O
QTLs	B-SO
compared	O
to	O
QTL	B-SO
mapping	O
methods	O
that	O
do	O
not	O
incorporate	O
sex	O
and	O
genotype	B-SO
-	O
sex	O
interactions	O
(	O
Figure	O
S1	O
)	O
.	O

It	O
is	O
clear	O
from	O
the	O
ROC	O
curves	O
that	O
the	O
sex	O
and	O
sex	O
-	O
interaction	O
terms	O
add	O
significantly	O
to	O
the	O
detection	O
of	O
QTL	B-SO
for	O
the	O
gene	B-SO
expression	O
traits	O
.	O

Using	O
previously	O
described	O
conventions	O
[	O
20	O
]	O
,	O
QTL	B-SO
models	O
without	O
the	O
final	O
two	O
interaction	O
terms	O
(	O
sex	O
*	O
add	O
and	O
sex	O
*	O
dom	O
)	O
have	O
a	O
suggestive	O
threshold	O
of	O
3	O
.	O
0	O
(	O
p	O
<	O
1	O
x	O
10	O
-	O
3	O
)	O
and	O
a	O
significant	O
threshold	O
of	O
4	O
.	O
3	O
(	O
p	O
<	O
5	O
x	O
10	O
-	O
5	O
,	O
genome	B-SO
-	O
wide	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

QTL	B-SO
models	O
incorporating	O
only	O
the	O
sex	O
*	O
add	O
interaction	O
term	O
in	O
addition	O
to	O
the	O
additive	O
terms	O
have	O
one	O
extra	O
degree	O
of	O
freedom	O
that	O
leads	O
to	O
a	O
corresponding	O
increase	O
in	O
the	O
LOD	O
score	O
thresholds	O
to	O
3	O
.	O
5	O
(	O
suggestive	O
)	O
and	O
4	O
.	O
9	O
(	O
significant	O
)	O
for	O
the	O
0	O
.	O
001	O
and	O
0	O
.	O
00005	O
p	O
-	O
value	O
thresholds	O
,	O
respectively	O
.	O

QTL	B-SO
models	O
incorporating	O
both	O
sex	O
*	O
add	O
and	O
sex	O
*	O
dom	O
interaction	O
terms	O
possess	O
two	O
extra	O
degrees	O
of	O
freedom	O
,	O
with	O
a	O
corresponding	O
increase	O
in	O
LOD	O
score	O
thresholds	O
to	O
4	O
.	O
0	O
(	O
suggestive	O
)	O
and	O
5	O
.	O
4	O
(	O
significant	O
)	O
for	O
the	O
0	O
.	O
001	O
and	O
0	O
.	O
00005	O
p	O
-	O
value	O
thresholds	O
,	O
respectively	O
.	O

One	O
suggestive	O
(	O
Chromosome	B-GO
1	O
)	O
and	O
four	O
significant	O
(	O
Chromosomes	B-GO
3	O
,	O
5	O
,	O
11	O
,	O
and	O
19	O
)	O
cQTLs	O
for	O
the	O
gonadal	O
fat	O
mass	O
trait	O
were	O
identified	O
(	O
Figure	O
1A	O
;	O
Table	O
2	O
)	O
.	O

Four	O
out	O
of	O
the	O
five	O
cQTLs	O
showed	O
statistically	O
significant	O
better	O
fits	O
with	O
the	O
full	O
model	O
incorporating	O
the	O
interaction	O
terms	O
sex	O
*	O
add	O
and	O
sex	O
*	O
dom	O
,	O
compared	O
to	O
the	O
model	O
including	O
only	O
the	O
additive	O
terms	O
.	O

Interestingly	O
,	O
the	O
cQTL	O
over	O
Chromosome	B-GO
11	O
did	O
not	O
improve	O
,	O
suggesting	O
that	O
the	O
additional	O
terms	O
did	O
not	O
contribute	O
to	O
improved	O
detection	O
of	O
this	O
locus	B-SO
.	O

Table	O
2	O
summarizes	O
the	O
position	O
and	O
LOD	O
score	O
of	O
maximal	O
linkage	O
for	O
each	O
cQTL	O
.	O

While	O
the	O
focus	O
of	O
this	O
study	O
was	O
the	O
gonadal	O
fat	O
mass	O
trait	O
,	O
it	O
is	O
noted	O
that	O
a	O
genome	B-SO
scan	O
for	O
the	O
adiposity	O
trait	O
resulted	O
in	O
cQTLs	O
at	O
the	O
same	O
locations	O
,	O
with	O
very	O
similar	O
LOD	O
scores	O
and	O
sex	O
dependence	O
(	O
unpublished	O
data	O
)	O
.	O

Results	O
from	O
the	O
various	O
regression	O
models	O
used	O
to	O
determine	O
linkage	O
for	O
the	O
Chromosome	B-GO
5	O
cQTL	O
are	O
depicted	O
in	O
Figure	O
1B	O
.	O

Analysis	O
of	O
all	O
animals	B-Taxon
with	O
and	O
without	O
sex	O
as	O
a	O
covariate	O
failed	O
to	O
demonstrate	O
evidence	O
of	O
linkage	O
on	O
Chromosome	B-GO
5	O
.	O

When	O
females	O
were	O
analyzed	O
alone	O
,	O
a	O
suggestive	O
LOD	O
score	O
of	O
3	O
.	O
7	O
was	O
realized	O
(	O
p	O
=	O
2	O
x	O
10	O
-	O
4	O
)	O
;	O
males	O
analyzed	O
alone	O
did	O
not	O
demonstrate	O
evidence	O
for	O
linkage	O
.	O

However	O
,	O
using	O
all	O
334	O
animals	B-Taxon
and	O
adding	O
the	O
interaction	O
terms	O
to	O
the	O
QTL	B-SO
model	O
significantly	O
improved	O
sensitivity	O
,	O
and	O
a	O
cQTL	O
with	O
a	O
maximum	O
LOD	O
of	O
7	O
.	O
56	O
(	O
p	O
=	O
1	O
.	O
7	O
x	O
10	O
-	O
6	O
)	O
was	O
realized	O
.	O

Given	O
the	O
improved	O
detection	O
of	O
four	O
of	O
the	O
five	O
cQTLs	O
when	O
sex	O
-	O
additive	O
and	O
sex	O
-	O
dominant	O
interaction	O
terms	O
were	O
considered	O
,	O
we	O
hypothesized	O
that	O
the	O
main	O
genotype	B-SO
effect	O
of	O
these	O
cQTLs	O
on	O
the	O
gonadal	O
fat	O
mass	O
trait	O
would	O
differ	O
between	O
the	O
sexes	O
(	O
Figure	O
2	O
)	O
.	O

Indeed	O
,	O
cQTLs	O
located	O
on	O
Chromosomes	B-GO
1	O
,	O
3	O
,	O
and	O
5	O
showed	O
opposing	O
effects	O
on	O
fat	O
mass	O
,	O
or	O
sex	O
antagonism	O
.	O

The	O
effect	O
of	O
the	O
cQTL	O
on	O
Chromosome	B-GO
11	O
was	O
in	O
the	O
same	O
direction	O
in	O
both	O
males	O
and	O
females	O
,	O
but	O
was	O
sex	O
-	O
biased	O
toward	O
a	O
larger	O
effect	O
in	O
females	O
(	O
R2	O
=	O
0	O
.	O
091	O
in	O
females	O
versus	O
R2	O
=	O
0	O
.	O
046	O
in	O
males	O
)	O
,	O
confirming	O
the	O
minimal	O
sex	O
specificity	O
of	O
this	O
cQTL	O
.	O

The	O
cQTL	O
on	O
Chromosome	B-GO
19	O
showed	O
a	O
sex	O
-	O
specific	O
effect	O
in	O
females	O
,	O
with	O
no	O
effect	O
in	O
males	O
.	O

Overall	O
,	O
all	O
five	O
cQTLs	O
for	O
gonadal	O
fat	O
mass	O
were	O
biased	O
toward	O
a	O
larger	O
effect	O
in	O
females	O
.	O

Assuming	O
purely	O
additive	O
effects	O
of	O
each	O
genotype	B-SO
,	O
these	O
cQTLs	O
account	O
for	O
approximately	O
42	O
%	O
of	O
the	O
variation	O
in	O
female	O
F2	O
mice	B-Taxon
and	O
13	O
%	O
in	O
males	O
,	O
consistent	O
with	O
the	O
narrow	O
sense	O
heritability	O
estimates	O
for	O
this	O
trait	O
and	O
again	O
demonstrating	O
significant	O
differences	O
in	O
the	O
regulation	O
and	O
heritability	O
of	O
the	O
gonadal	O
fat	O
trait	O
between	O
the	O
sexes	O
.	O

Liver	O
eQTLs	O

Livers	O
from	O
312	O
F2	O
animals	B-Taxon
(	O
156	O
female	O
,	O
156	O
male	O
)	O
were	O
profiled	O
using	O
oligonucleotide	B-SO
microarrays	O
manufactured	O
by	O
Agilent	O
Technologies	O
(	O
Palo	O
Alto	O
,	O
California	O
,	O
United	O
States	O
)	O
,	O
which	O
included	O
probes	B-SO
for	O
23	O
,	O
574	O
mouse	B-Taxon
transcripts	B-SO
.	O

Individual	O
transcript	B-SO
intensities	O
were	O
corrected	O
for	O
experimental	O
variation	O
and	O
normalized	O
and	O
are	O
reported	O
as	O
the	O
mean	O
log10	O
ratio	O
(	O
mlratio	O
)	O
of	O
an	O
individual	O
experiment	O
relative	O
to	O
a	O
pool	O
composed	O
of	O
150	O
mice	B-Taxon
randomly	O
selected	O
from	O
the	O
F2	O
population	O
[	O
21	O
]	O
.	O

Each	O
measurement	O
was	O
fitted	O
to	O
an	O
error	O
model	O
and	O
assigned	O
a	O
significance	O
measurement	O
(	O
type	O
I	O
error	O
)	O
.	O

A	O
heat	O
map	O
of	O
the	O
2	O
,	O
320	O
transcripts	B-SO
most	O
differentially	O
expressed	O
(	O
p	O
<	O
0	O
.	O
05	O
in	O
10	O
%	O
or	O
more	O
of	O
animals	B-Taxon
)	O
relative	O
to	O
the	O
pool	O
is	O
depicted	O
in	O
Figure	O
3	O
.	O

This	O
selection	O
of	O
genes	B-SO
was	O
not	O
biased	O
on	O
a	O
priori	O
known	O
differential	O
expression	O
between	O
the	O
sexes	O
,	O
linkage	O
,	O
or	O
correlation	O
with	O
a	O
clinical	O
phenotype	O
.	O

This	O
is	O
noteworthy	O
because	O
hierarchical	O
clustering	O
of	O
these	O
transcripts	B-SO
against	O
the	O
312	O
F2	O
mice	B-Taxon
shows	O
an	O
almost	O
perfect	O
clustering	O
into	O
male	O
and	O
female	O
subgroups	O
,	O
emphasizing	O
striking	O
effects	O
of	O
sex	O
on	O
liver	O
gene	B-SO
expression	O
levels	O
and	O
suggesting	O
that	O
sex	O
is	O
controlling	O
more	O
variance	O
in	O
these	O
transcripts	B-SO
'	O
expression	O
than	O
any	O
other	O
parameter	O
.	O

The	O
expression	O
values	O
of	O
the	O
23	O
,	O
574	O
transcripts	B-SO
were	O
treated	O
as	O
quantitative	O
traits	O
and	O
fitted	O
to	O
the	O
same	O
linear	O
regression	O
models	O
used	O
to	O
compute	O
LOD	O
scores	O
for	O
clinical	O
traits	O
(	O
eQTLs	O
)	O
.	O

The	O
FDR	O
at	O
each	O
threshold	O
was	O
determined	O
by	O
permuting	O
the	O
data	O
100	O
times	O
and	O
taking	O
the	O
mean	O
number	O
of	O
QTLs	B-SO
detected	O
over	O
all	O
of	O
the	O
permuted	O
datasets	O
at	O
a	O
given	O
threshold	O
,	O
and	O
dividing	O
this	O
count	O
by	O
the	O
number	O
of	O
QTLs	B-SO
detected	O
at	O
the	O
same	O
threshold	O
in	O
the	O
observed	O
data	O
.	O

At	O
the	O
threshold	O
for	O
significant	O
linkage	O
(	O
p	O
<	O
5	O
x	O
10	O
-	O
5	O
,	O
genome	B-SO
-	O
wide	O
p	O
<	O
0	O
.	O
05	O
,	O
based	O
on	O
a	O
single	O
trait	O
)	O
,	O
the	O
FDR	O
was	O
estimated	O
at	O
3	O
.	O
4	O
%	O
for	O
the	O
standard	O
QTL	B-SO
model	O
not	O
accounting	O
for	O
any	O
sex	O
terms	O
,	O
3	O
.	O
1	O
%	O
for	O
the	O
QTL	B-SO
model	O
accounting	O
for	O
additive	O
sex	O
effects	O
,	O
and	O
3	O
.	O
2	O
%	O
for	O
the	O
QTL	B-SO
model	O
accounting	O
for	O
additive	O
sex	O
effects	O
and	O
allowing	O
for	O
the	O
sex	O
interaction	O
terms	O
to	O
enter	O
the	O
model	O
.	O

A	O
list	O
of	O
all	O
detected	O
suggestive	O
(	O
p	O
<	O
1	O
x	O
10	O
-	O
3	O
)	O
and	O
significant	O
eQTLs	O
(	O
p	O
<	O
5	O
x	O
10	O
-	O
5	O
)	O
detected	O
in	O
the	O
BXH	O
.	O
ApoE	B-GGP
-	O
/	O
-	O
intercross	O
is	O
provided	O
in	O
Table	O
S1	O
.	O

Characteristics	O
of	O
the	O
eQTLs	O
at	O
different	O
significance	O
levels	O
are	O
summarized	O
in	O
Table	O
3	O
and	O
shown	O
graphically	O
in	O
Figure	O
4	O
.	O

We	O
detected	O
6	O
,	O
676	O
eQTLs	O
representing	O
4	O
,	O
998	O
transcripts	B-SO
at	O
the	O
5	O
x	O
10	O
-	O
5	O
significant	O
level	O
.	O

Of	O
these	O
,	O
2	O
,	O
118	O
eQTLs	O
were	O
located	O
within	O
20	O
Mb	O
(	O
roughly	O
10	O
cM	O
)	O
of	O
the	O
corresponding	O
gene	B-SO
,	O
likely	O
representing	O
eQTLs	O
regulated	O
by	O
cis	O
-	O
acting	O
variation	O
within	O
the	O
gene	B-SO
itself	O
.	O

Of	O
the	O
6	O
,	O
676	O
significant	O
eQTLs	O
,	O
1	O
,	O
166	O
(	O
17	O
%	O
)	O
demonstrated	O
a	O
sex	O
bias	O
and	O
were	O
subsequently	O
significantly	O
improved	O
with	O
the	O
addition	O
of	O
the	O
sex	O
-	O
additive	O
and	O
sex	O
-	O
dominant	O
terms	O
.	O

The	O
distribution	O
of	O
all	O
6	O
,	O
676	O
significant	O
eQTLs	O
(	O
p	O
<	O
5	O
x	O
10	O
-	O
5	O
)	O
across	O
the	O
genome	B-SO
in	O
2	O
cM	O
bins	O
is	O
shown	O
in	O
Figure	O
4A	O
.	O

Evidence	O
for	O
eQTL	O
hotspots	O
is	O
clear	O
on	O
Chromosomes	B-GO
1	O
,	O
2	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
and	O
7	O
where	O
significant	O
fractions	O
of	O
the	O
6	O
,	O
676	O
eQTLs	O
colocalize	O
within	O
2	O
cM	O
regions	B-SO
on	I-SO
each	I-SO
chromosome	I-SO
.	O

Approximately	O
67	O
%	O
of	O
eQTLs	O
at	O
this	O
threshold	O
are	O
trans	O
,	O
and	O
these	O
eQTL	O
hotspots	O
consist	O
primarily	O
of	O
trans	O
-	O
acting	O
effects	O
on	O
transcriptional	O
variation	O
.	O

Distribution	O
of	O
the	O
1	O
,	O
166	O
eQTLs	O
with	O
significant	O
sex	O
effects	O
,	O
of	O
which	O
852	O
(	O
73	O
%	O
)	O
are	O
trans	O
,	O
showed	O
enrichment	O
on	O
Chromosome	B-GO
5	O
at	O
approximately	O
49	O
cM	O
(	O
Figure	O
4B	O
)	O
as	O
assessed	O
using	O
the	O
Fisher	O
exact	O
test	O
(	O
p	O
=	O
8	O
.	O
7	O
x	O
10	O
-	O
25	O
after	O
Bonferroni	O
correction	O
)	O
.	O

At	O
this	O
locus	B-SO
there	O
were	O
250	O
eQTLs	O
,	O
140	O
of	O
which	O
exhibited	O
genotype	B-SO
-	O
sex	O
interactions	O
.	O

At	O
increasing	O
thresholds	O
for	O
linkage	O
,	O
a	O
higher	O
fraction	O
of	O
detected	O
eQTLs	O
were	O
cis	O
-	O
acting	O
(	O
Figure	O
4C	O
)	O
.	O

The	O
increased	O
proportion	O
of	O
cis	O
-	O
eQTLs	O
with	O
increasing	O
LOD	O
score	O
thresholds	O
has	O
been	O
reported	O
before	O
[	O
5	O
,	O
15	O
]	O
and	O
confirms	O
what	O
is	O
likely	O
to	O
be	O
our	O
increased	O
power	O
to	O
detect	O
first	O
-	O
order	O
cis	O
-	O
acting	O
variations	B-SO
affecting	O
transcription	O
.	O

The	O
proportion	O
of	O
eQTLs	O
with	O
significant	O
sex	O
effects	O
remained	O
relatively	O
constant	O
at	O
all	O
thresholds	O
(	O
Figure	O
4C	O
)	O
.	O

Furthermore	O
,	O
the	O
majority	O
of	O
these	O
sex	O
-	O
specific	O
eQTLs	O
(	O
73	O
%	O
)	O
are	O
acting	O
in	O
trans	O
on	O
a	O
given	O
gene	B-SO
'	O
s	O
expression	O
(	O
Figure	O
4D	O
)	O
,	O
and	O
similar	O
proportions	O
of	O
sex	O
-	O
specific	O
eQTLs	O
(	O
26	O
%	O
)	O
are	O
cis	O
compared	O
to	O
the	O
proportion	O
of	O
all	O
liver	O
cis	O
-	O
eQTLs	O
(	O
32	O
%	O
)	O
.	O

These	O
data	O
demonstrate	O
the	O
profound	O
effects	O
of	O
sex	O
on	O
the	O
genetic	B-SO
regulation	O
of	O
gene	B-SO
expression	O
.	O

Cis	O
-	O
eQTLs	O
Are	O
Candidate	O
Genes	B-SO
for	O
the	O
Gonadal	O
Fat	O
Mass	O
Trait	O

Given	O
the	O
marked	O
effects	O
of	O
sex	O
on	O
liver	O
gene	B-SO
expression	O
and	O
the	O
genetic	B-SO
regulation	O
of	O
gonadal	O
fat	O
mass	O
,	O
we	O
reasoned	O
that	O
cis	O
-	O
eQTLs	O
with	O
significant	O
"	O
sex	O
-	O
additive	O
"	O
and	O
"	O
sex	O
-	O
dominant	O
"	O
interactions	O
would	O
be	O
potential	O
candidate	O
genes	B-SO
for	O
our	O
trait	O
.	O

Of	O
the	O
2	O
,	O
118	O
significant	O
cis	O
-	O
eQTLs	O
,	O
304	O
(	O
14	O
%	O
)	O
were	O
improved	O
by	O
the	O
sex	O
-	O
interaction	O
terms	O
.	O

Cis	O
-	O
eQTLs	O
overlapping	B-SO
the	O
confidence	O
interval	O
for	O
the	O
fat	O
mass	O
cQTL	O
are	O
candidate	O
genes	B-SO
for	O
the	O
trait	O
.	O

Those	O
genes	B-SO
with	O
significant	O
sex	O
interactions	O
receive	O
increased	O
consideration	O
as	O
potential	O
candidates	O
(	O
Tables	O
4	O
and	O
5	O
)	O
.	O

Thousands	O
of	O
Genes	B-SO
Show	O
a	O
Sex	O
-	O
Specific	O
Correlation	O
with	O
Gonadal	O
Fat	O
Mass	O

For	O
each	O
of	O
the	O
23	O
,	O
574	O
oligonucleotides	B-SO
represented	O
on	O
the	O
array	O
,	O
we	O
computed	O
a	O
linear	O
regression	O
analysis	O
to	O
test	O
for	O
association	O
between	O
the	O
trait	O
"	O
gonadal	O
fat	O
mass	O
"	O
and	O
each	O
transcript	B-SO
abundance	O
measure	O
,	O
incorporating	O
the	O
terms	O
"	O
gene	B-SO
,	O
"	O
"	O
sex	O
,	O
"	O
and	O
"	O
gene	B-SO
-	O
by	O
-	O
sex	O
,	O
"	O
where	O
the	O
"	O
gene	B-SO
-	O
by	O
-	O
sex	O
"	O
parameter	O
tests	O
for	O
sex	O
-	O
specific	O
correlation	O
between	O
a	O
gene	B-SO
and	O
the	O
trait	O
.	O

As	O
before	O
,	O
a	O
stepwise	O
regression	O
procedure	O
was	O
used	O
to	O
determine	O
if	O
the	O
addition	O
of	O
the	O
interaction	O
term	O
significantly	O
improved	O
the	O
model	O
fit	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
.	O

Multiple	O
testing	O
was	O
addressed	O
by	O
controlling	O
for	O
the	O
FDR	O
.	O

Distribution	O
of	O
the	O
p	O
-	O
values	O
obtained	O
from	O
these	O
23	O
,	O
574	O
correlations	O
is	O
shown	O
in	O
Figure	O
5A	O
.	O

At	O
FDR	O
=	O
0	O
.	O
01	O
,	O
4	O
,	O
613	O
genes	B-SO
were	O
significantly	O
correlated	O
with	O
gonadal	O
fat	O
mass	O
.	O

Of	O
these	O
genes	B-SO
,	O
4	O
,	O
524	O
(	O
98	O
%	O
)	O
showed	O
significant	O
"	O
gene	B-SO
-	O
by	O
-	O
sex	O
"	O
effects	O
,	O
supporting	O
the	O
high	O
degree	O
of	O
sex	O
specificity	O
in	O
the	O
genetic	B-SO
regulation	O
of	O
this	O
trait	O
.	O

A	O
complete	O
list	O
of	O
all	O
genes	B-SO
correlated	O
with	O
gonadal	O
fat	O
mass	O
is	O
provided	O
in	O
Table	O
S2	O
.	O

Of	O
the	O
4	O
,	O
613	O
genes	B-SO
correlated	O
with	O
gonadal	O
fat	O
mass	O
,	O
1	O
,	O
130	O
generate	O
1	O
,	O
478	O
significant	O
eQTLs	O
(	O
Figure	O
5B	O
)	O
.	O

The	O
colocalization	O
of	O
eQTLs	O
for	O
these	O
correlated	O
genes	B-SO
with	O
the	O
cQTL	O
for	O
the	O
fat	O
mass	O
trait	O
provides	O
useful	O
implications	O
for	O
the	O
possible	O
role	O
of	O
these	O
genes	B-SO
.	O

Whether	O
the	O
eQTLs	O
are	O
cis	O
or	O
trans	O
determines	O
what	O
that	O
role	O
may	O
be	O
.	O

Genes	B-SO
that	O
show	O
significant	O
correlation	O
with	O
the	O
gonadal	O
fat	O
mass	O
trait	O
and	O
that	O
have	O
cis	O
-	O
eQTLs	O
coincident	O
with	O
the	O
fat	O
mass	O
cQTLs	O
are	O
potential	O
candidate	O
genes	B-SO
for	O
the	O
trait	O
(	O
i	O
.	O
e	O
.	O
,	O
they	O
may	O
contain	O
a	O
genetic	B-SO
variation	B-SO
in	O
that	O
gene	B-SO
that	O
is	O
the	O
cause	O
of	O
the	O
trait	O
cQTL	O
)	O
.	O

Table	O
5	O
summarizes	O
the	O
genes	B-SO
that	O
possess	O
these	O
properties	B-SO
for	O
each	O
cQTL	O
,	O
increasing	O
evidence	O
for	O
these	O
genes	B-SO
as	O
potential	O
candidates	O
.	O

As	O
addressed	O
below	O
,	O
given	O
the	O
complex	O
multiorgan	O
regulation	O
of	O
adipose	O
tissue	O
mass	O
,	O
it	O
is	O
unlikely	O
that	O
the	O
genetic	B-SO
regulation	O
of	O
all	O
five	O
loci	B-SO
resides	O
in	O
the	O
liver	O
.	O

However	O
,	O
some	O
may	O
involve	O
the	O
liver	O
,	O
and	O
even	O
for	O
those	O
that	O
do	O
not	O
,	O
the	O
liver	O
transcriptional	O
variation	O
may	O
reflect	O
that	O
of	O
the	O
relevant	O
tissue	O
.	O

Genes	B-SO
that	O
show	O
significant	O
correlation	O
with	O
gonadal	O
fat	O
mass	O
and	O
have	O
trans	O
-	O
eQTLs	O
coincident	O
with	O
the	O
fat	O
mass	O
cQTL	O
cannot	O
be	O
candidates	O
directly	O
responsible	O
for	O
the	O
trait	O
,	O
as	O
they	O
are	O
physically	O
located	O
elsewhere	O
in	O
the	O
genome	B-SO
.	O

However	O
,	O
they	O
are	O
potentially	O
involved	O
in	O
the	O
pathway	O
(	O
s	O
)	O
leading	O
from	O
the	O
causative	O
gene	B-SO
to	O
the	O
expression	O
of	O
the	O
fat	O
mass	O
trait	O
(	O
i	O
.	O
e	O
.	O
,	O
their	O
transcription	O
is	O
closely	O
regulated	O
by	O
the	O
causative	O
gene	B-SO
at	O
the	O
locus	B-SO
)	O
.	O

All	O
of	O
the	O
five	O
fat	O
mass	O
cQTLs	O
have	O
colocalizing	O
trans	O
-	O
eQTLs	O
for	O
correlated	O
genes	B-SO
.	O

However	O
,	O
for	O
a	O
trait	O
such	O
as	O
fat	O
mass	O
that	O
is	O
regulated	O
by	O
multiple	O
tissues	O
and	O
organs	O
,	O
it	O
is	O
unlikely	O
that	O
all	O
five	O
fat	O
mass	O
cQTLs	O
are	O
primarily	O
driven	O
by	O
liver	O
gene	B-SO
expression	O
.	O

As	O
an	O
approach	O
to	O
this	O
problem	O
,	O
we	O
hypothesized	O
that	O
those	O
cQTLs	O
that	O
are	O
most	O
closely	O
associated	O
with	O
liver	O
gene	B-SO
expression	O
would	O
show	O
an	O
overrepresentation	O
of	O
colocalized	O
eQTL	O
for	O
correlated	O
genes	B-SO
,	O
while	O
those	O
loci	B-SO
primarily	O
controlled	O
by	O
other	O
tissues	O
would	O
not	O
have	O
shown	O
this	O
pattern	O
.	O

To	O
assess	O
this	O
,	O
we	O
first	O
determined	O
the	O
distribution	O
of	O
these	O
1	O
,	O
478	O
eQTLs	O
across	O
the	O
genome	B-SO
in	O
2	O
-	O
cM	O
bins	O
as	O
shown	O
in	O
Figure	O
5C	O
.	O

In	O
order	O
to	O
see	O
if	O
there	O
exist	O
any	O
hotspots	O
for	O
these	O
eQTLs	O
,	O
we	O
tested	O
eQTLs	O
with	O
p	O
<	O
0	O
.	O
001	O
for	O
enrichment	O
along	O
the	O
genome	B-SO
in	O
overlapping	B-SO
2	O
-	O
cM	O
bins	O
against	O
the	O
distribution	O
of	O
all	O
liver	O
eQTLs	O
(	O
Figure	O
4A	O
)	O
using	O
a	O
Fisher	O
exact	O
test	O
.	O

Figure	O
5D	O
shows	O
the	O
significance	O
of	O
enrichment	O
reported	O
as	O
-	O
log10	O
of	O
the	O
enrichment	O
p	O
-	O
value	O
across	O
the	O
genome	B-SO
.	O

One	O
locus	B-SO
on	I-SO
Chromosome	I-SO
19	O
was	O
significantly	O
enriched	O
for	O
eQTLs	O
of	O
transcripts	B-SO
correlated	O
with	O
the	O
gonadal	O
fat	O
mass	O
trait	O
.	O

As	O
anticipated	O
,	O
there	O
was	O
an	O
overlap	O
of	O
a	O
correlated	O
eQTL	O
hotspot	O
and	O
a	O
fat	O
mass	O
cQTL	O
,	O
specifically	O
Chromosome	B-GO
19	O
at	O
40	O
cM	O
.	O

This	O
suggests	O
that	O
the	O
genetic	B-SO
regulation	O
of	O
fat	O
mass	O
for	O
the	O
Chromosome	B-SO
19	I-SO
locus	I-SO
is	O
more	O
closely	O
tied	O
to	O
liver	O
gene	B-SO
expression	O
than	O
are	O
the	O
other	O
four	O
fat	O
mass	O
cQTLs	O
.	O

The	O
effect	O
of	O
the	O
trans	O
-	O
eQTLs	O
at	O
the	O
Chromosome	B-SO
19	I-SO
locus	I-SO
on	O
gene	B-SO
expression	O
is	O
summarized	O
in	O
Figure	O
6	O
.	O

Twenty	O
-	O
nine	O
trans	O
-	O
eQTLs	O
colocalize	O
to	O
Chromosome	B-GO
9	O
at	O
40	O
cM	O
,	O
suggesting	O
that	O
29	O
genes	B-SO
correlated	O
with	O
gonadal	O
fat	O
mass	O
are	O
regulated	O
in	O
trans	O
by	O
a	O
polymorphism	B-SO
at	O
this	O
position	B-SO
.	O

The	O
proportion	O
of	O
gene	B-SO
expression	O
levels	O
controlled	O
by	O
this	O
locus	B-SO
(	O
approximated	O
as	O
the	O
coefficients	O
of	O
determination	O
R2	O
)	O
differs	O
between	O
males	O
and	O
females	O
for	O
the	O
majority	O
of	O
the	O
transcripts	B-SO
(	O
as	O
in	O
Figure	O
6A	O
)	O
,	O
and	O
for	O
Chromosome	B-GO
19	O
(	O
Figure	O
6B	O
)	O
,	O
females	O
demonstrated	O
greater	O
genetic	B-SO
regulation	O
of	O
gene	B-SO
expression	O
than	O
males	O
.	O

This	O
substantial	O
female	O
bias	O
is	O
significantly	O
higher	O
than	O
would	O
be	O
expected	O
to	O
arise	O
by	O
chance	O
for	O
the	O
Chromosome	B-SO
19	I-SO
locus	I-SO
(	O
p	O
<	O
0	O
.	O
001	O
by	O
chi	O
2	O
)	O
.	O

This	O
locus	B-SO
corresponds	O
to	O
one	O
of	O
the	O
four	O
sex	O
-	O
biased	O
cQTLs	O
for	O
gonadal	O
fat	O
mass	O
reported	O
in	O
this	O
study	O
,	O
and	O
the	O
significant	O
sex	O
specificity	O
of	O
both	O
the	O
cis	O
and	O
trans	O
genetic	B-SO
regulation	O
of	O
liver	O
genes	B-SO
correlated	O
with	O
fat	O
mass	O
supports	O
the	O
functional	O
significance	O
of	O
this	O
locus	B-SO
in	O
this	O
organ	O
.	O

Discussion	O

In	O
this	O
study	O
,	O
we	O
described	O
a	O
large	O
,	O
densely	O
mapped	O
,	O
segregating	O
F2	O
mouse	B-Taxon
population	O
designed	O
to	O
study	O
the	O
genetic	B-SO
regulation	O
of	O
several	O
traits	O
associated	O
with	O
the	O
so	O
-	O
called	O
metabolic	O
syndrome	O
.	O

Several	O
groups	O
,	O
including	O
ours	O
,	O
have	O
reported	O
the	O
advantage	O
of	O
combining	O
traditional	O
genetics	O
with	O
genome	B-SO
-	O
wide	O
gene	B-SO
expression	O
analysis	O
for	O
the	O
dissection	O
of	O
complex	O
traits	O
.	O

This	O
study	O
improved	O
on	O
past	O
models	O
by	O
including	O
over	O
300	O
animals	B-Taxon
(	O
three	O
times	O
the	O
size	O
of	O
previous	O
studies	O
)	O
of	O
both	O
sexes	O
,	O
allowing	O
for	O
the	O
incorporation	O
of	O
sex	O
-	O
specific	O
effects	O
on	O
underlying	O
genetic	B-SO
regulation	O
.	O

Significant	O
Sex	O
Bias	O
in	O
the	O
Regulation	O
of	O
Both	O
Complex	O
Traits	O
and	O
Gene	B-SO
Expression	O

Given	O
the	O
known	O
dichotomy	O
between	O
females	O
and	O
males	O
in	O
the	O
susceptibility	O
and	O
control	O
of	O
obesity	O
,	O
this	O
study	O
was	O
designed	O
to	O
sufficiently	O
power	O
the	O
detection	O
of	O
significant	O
QTLs	B-SO
for	O
this	O
and	O
other	O
traits	O
with	O
sex	O
-	O
dependent	O
effects	O
.	O

Note	O
,	O
however	O
,	O
that	O
these	O
effects	O
can	O
extend	O
to	O
traits	O
without	O
overall	O
mean	O
differences	O
between	O
the	O
sexes	O
.	O

Previous	O
studies	O
have	O
described	O
the	O
advantages	O
of	O
performing	O
QTL	B-SO
analysis	O
both	O
with	O
and	O
without	O
sex	O
as	O
an	O
interactive	O
covariate	O
[	O
22	O
-	O
25	O
]	O
.	O

Analyzing	O
the	O
sexes	O
separately	O
is	O
suboptimal	O
since	O
it	O
reduces	O
sample	O
size	O
in	O
both	O
groups	O
,	O
thus	O
reducing	O
power	O
to	O
detect	O
main	O
QTL	B-SO
effects	O
,	O
as	O
demonstrated	O
by	O
our	O
genome	B-SO
scan	O
of	O
Chromosome	B-GO
5	O
(	O
Figure	O
1B	O
)	O
.	O

Furthermore	O
,	O
separate	O
analyses	O
would	O
not	O
allow	O
for	O
the	O
detection	O
of	O
QTLs	B-SO
that	O
have	O
opposing	O
,	O
or	O
sex	O
-	O
antagonistic	O
,	O
effects	O
in	O
females	O
and	O
males	O
and	O
would	O
hinder	O
the	O
detection	O
of	O
QTLs	B-SO
specific	O
to	O
one	O
sex	O
.	O

Accordingly	O
,	O
we	O
detected	O
five	O
cQTLs	O
for	O
the	O
gonadal	O
fat	O
mass	O
trait	O
on	O
Chromosomes	B-GO
1	O
,	O
3	O
,	O
5	O
,	O
11	O
,	O
and	O
19	O
.	O

The	O
detection	O
of	O
all	O
five	O
cQTLs	O
was	O
"	O
driven	O
"	O
by	O
the	O
larger	O
effect	O
in	O
females	O
,	O
with	O
significant	O
improvement	O
by	O
the	O
incorporation	O
of	O
sex	O
*	O
additive	O
and	O
sex	O
*	O
dominant	O
parameters	O
.	O

QTLs	B-SO
associated	O
with	O
obesity	O
,	O
gonadal	O
fat	O
,	O
and	O
abdominal	O
fat	O
have	O
been	O
reported	O
before	O
overlapping	B-SO
with	O
cQTLs	O
on	O
Chromosomes	B-GO
1	O
[	O
26	O
-	O
28	O
]	O
,	O
5	O
[	O
26	O
,	O
29	O
]	O
,	O
and	O
11	O
[	O
19	O
,	O
29	O
]	O
reported	O
here	O
,	O
whereas	O
the	O
cQTL	O
on	O
Chromosome	B-GO
3	O
represents	O
a	O
novel	O
QTL	B-SO
for	O
this	O
trait	O
.	O

The	O
Chromosome	B-GO
19	O
cQTL	O
for	O
fat	O
mass	O
was	O
recently	O
reported	O
by	O
us	O
[	O
5	O
]	O
in	O
the	O
BXD	O
intercross	O
F2	O
progeny	O
from	O
the	O
strains	O
B6	O
and	O
DBA	O
(	O
which	O
shares	O
the	O
same	O
haplotype	B-SO
at	O
this	O
region	B-SO
as	O
the	O
C3H	O
strain	O
used	O
in	O
this	O
study	O
)	O
.	O

Interestingly	O
,	O
significant	O
heritability	O
and	O
genetic	B-SO
regulation	O
was	O
seen	O
in	O
this	O
F2	O
population	O
despite	O
the	O
hyperlipidemic	O
,	O
proinflammatory	O
ApoE	B-GGP
-	O
/	O
-	O
background	O
and	O
the	O
high	O
-	O
fat	O
Western	O
diet	O
.	O

This	O
background	O
possesses	O
several	O
advantages	O
,	O
such	O
as	O
allowing	O
the	O
modeling	O
of	O
human	B-Taxon
-	O
like	O
disease	O
states	O
.	O

The	O
predominantly	O
female	O
-	O
driven	O
effects	O
of	O
the	O
five	O
cQTLs	O
likely	O
reflect	O
the	O
significant	O
effect	O
of	O
differential	O
gonadal	O
hormone	B-CHEBI
secretions	O
on	O
the	O
genetic	B-SO
regulation	O
of	O
this	O
complex	O
trait	O
.	O

The	O
identification	O
of	O
genes	B-SO
underlying	O
cQTLs	O
remains	O
a	O
challenge	O
.	O

The	O
widespread	O
availability	O
of	O
genome	B-SO
-	O
wide	O
expression	O
analysis	O
has	O
begun	O
to	O
address	O
this	O
by	O
providing	O
a	O
snapshot	O
of	O
transcription	O
in	O
relevant	O
organs	O
and	O
thus	O
providing	O
initial	O
information	O
for	O
which	O
genes	B-SO
can	O
differentiate	O
a	O
given	O
trait	O
.	O

Furthermore	O
,	O
by	O
treating	O
transcript	B-SO
levels	O
as	O
quantitative	O
traits	O
,	O
we	O
can	O
map	O
the	O
genetic	B-SO
regulation	O
underlying	O
differential	O
gene	B-SO
expression	O
(	O
eQTLs	O
)	O
.	O

Those	O
eQTLs	O
that	O
have	O
cis	O
-	O
acting	O
variations	B-SO
affecting	O
their	O
transcription	O
are	O
potential	O
candidate	O
genes	B-SO
for	O
the	O
trait	O
.	O

At	O
a	O
single	O
trait	O
,	O
genome	B-SO
-	O
wide	O
significance	O
level	O
of	O
0	O
.	O
05	O
,	O
we	O
detected	O
6	O
,	O
676	O
eQTLs	O
representing	O
4	O
,	O
998	O
genes	B-SO
,	O
of	O
which	O
2	O
,	O
118	O
were	O
cis	O
-	O
acting	O
.	O

At	O
increased	O
thresholds	O
,	O
the	O
proportion	O
of	O
cis	O
-	O
eQTLs	O
increased	O
,	O
which	O
is	O
in	O
good	O
agreement	O
with	O
previous	O
studies	O
[	O
5	O
,	O
15	O
]	O
and	O
likely	O
reflects	O
the	O
increased	O
power	O
to	O
detect	O
cis	O
-	O
acting	O
variations	B-SO
affecting	O
transcription	O
.	O

Of	O
all	O
6	O
,	O
676	O
significant	O
eQTLs	O
,	O
1	O
,	O
166	O
possessed	O
significant	O
sex	O
interactions	O
.	O

Of	O
these	O
,	O
304	O
were	O
cis	O
and	O
852	O
were	O
trans	O
,	O
suggesting	O
that	O
only	O
a	O
minority	O
of	O
the	O
sex	O
-	O
specific	O
effects	O
on	O
the	O
regulation	O
of	O
gene	B-SO
expression	O
occur	O
through	O
polymorphisms	B-SO
within	O
the	O
gene	B-SO
itself	O
.	O

Rather	O
,	O
underlying	O
genetic	B-SO
regulation	O
of	O
most	O
transcripts	B-SO
is	O
the	O
result	O
of	O
interactions	O
between	O
trans	O
loci	B-SO
and	O
sex	O
-	O
specific	O
factors	O
(	O
e	O
.	O
g	O
.	O
,	O
hormones	B-CHEBI
)	O
.	O

As	O
with	O
cQTLs	O
,	O
sex	O
bias	O
in	O
the	O
predominantly	O
trans	O
genetic	B-SO
regulation	O
of	O
gene	B-SO
expression	O
is	O
likely	O
secondary	O
to	O
different	O
sex	O
hormone	B-CHEBI
profiles	O
.	O

Recently	O
,	O
using	O
a	O
similar	O
dataset	O
,	O
our	O
group	O
demonstrated	O
that	O
significant	O
cis	O
-	O
eQTLs	O
(	O
p	O
<	O
5	O
x	O
10	O
-	O
5	O
)	O
largely	O
represent	O
true	O
positives	O
[	O
30	O
]	O
and	O
are	O
enriched	O
for	O
highly	O
polymorphic	B-SO
regions	I-SO
over	O
the	O
mouse	B-Taxon
genome	B-SO
.	O

The	O
cis	O
-	O
eQTLs	O
presented	O
in	O
Table	O
5	O
overlap	O
with	O
one	O
of	O
the	O
gonadal	O
fat	O
mass	O
cQTLs	O
and	O
should	O
be	O
considered	O
potential	O
candidates	O
.	O

Given	O
the	O
sex	O
effects	O
in	O
the	O
gonadal	O
fat	O
mass	O
cQTLs	O
,	O
we	O
reasoned	O
that	O
the	O
cis	O
-	O
eQTLs	O
with	O
significant	O
sex	O
*	O
additive	O
and	O
sex	O
*	O
dominant	O
effects	O
should	O
receive	O
priority	O
consideration	O
.	O

The	O
use	O
of	O
eQTLs	O
to	O
dissect	O
cQTLs	O
is	O
a	O
method	O
still	O
in	O
its	O
infancy	O
,	O
with	O
uncertain	O
efficacy	O
and	O
applicability	O
.	O

Nevertheless	O
,	O
application	O
of	O
this	O
analysis	O
to	O
this	O
dataset	O
provides	O
some	O
tantalizingly	O
attractive	O
candidate	O
genes	B-SO
.	O

One	O
shortcoming	O
of	O
this	O
approach	O
,	O
however	O
,	O
is	O
that	O
candidate	O
genes	B-SO
are	O
limited	O
to	O
those	O
whose	O
transcript	B-SO
expression	O
levels	O
vary	O
in	O
association	O
with	O
a	O
nearby	O
polymorphism	B-SO
that	O
differs	O
between	O
the	O
parental	O
strains	O
--	O
in	O
other	O
words	O
,	O
genes	B-SO
with	O
significant	O
and	O
detectable	O
cis	O
-	O
eQTLs	O
.	O

However	O
,	O
it	O
is	O
not	O
strictly	O
necessary	O
for	O
candidate	O
genes	B-SO
to	O
have	O
evidence	O
of	O
such	O
linkage	O
:	O
polymorphisms	B-SO
underlying	O
a	O
trait	O
cQTL	O
can	O
affect	O
gene	B-SO
function	O
or	O
posttranslational	O
modifications	B-SO
.	O

Nevertheless	O
,	O
several	O
phenotypes	O
are	O
known	O
to	O
be	O
regulated	O
,	O
at	O
least	O
partly	O
,	O
at	O
the	O
level	O
of	O
transcription	O
or	O
mRNA	B-CHEBI
stability	O
,	O
which	O
is	O
exactly	O
what	O
our	O
methods	O
are	O
designed	O
to	O
detect	O
.	O

A	O
separate	O
problem	O
is	O
that	O
organ	O
-	O
specific	O
gene	B-SO
expression	O
differences	O
may	O
preclude	O
one	O
from	O
detecting	O
the	O
relevant	O
causative	O
gene	B-SO
if	O
the	O
tissue	O
arrayed	O
is	O
not	O
the	O
tissue	O
where	O
the	O
control	O
is	O
exerted	O
.	O

This	O
is	O
particularly	O
relevant	O
for	O
a	O
trait	O
such	O
as	O
adipose	O
tissue	O
mass	O
,	O
which	O
is	O
controlled	O
by	O
multiple	O
tissues	O
.	O

We	O
propose	O
that	O
analysis	O
of	O
correlated	O
genes	B-SO
can	O
provide	O
guidance	O
as	O
discussed	O
below	O
.	O

Genes	B-SO
Correlated	O
with	O
Gonadal	O
Fat	O
Mass	O
Illustrate	O
Tissue	O
-	O
Specific	O
Regulation	O
of	O
the	O
Trait	O

In	O
an	O
effort	O
to	O
identify	O
genes	B-SO
associated	O
with	O
the	O
fat	O
mass	O
trait	O
,	O
but	O
not	O
necessarily	O
candidate	O
genes	B-SO
underlying	O
the	O
trait	O
cQTLs	O
,	O
we	O
fitted	O
linear	O
models	O
to	O
assess	O
the	O
degree	O
of	O
association	O
between	O
transcripts	B-SO
and	O
gonadal	O
fat	O
mass	O
.	O

As	O
with	O
QTLs	B-SO
,	O
sex	O
-	O
specific	O
correlations	O
were	O
modeled	O
.	O

At	O
an	O
FDR	O
of	O
1	O
%	O
,	O
4	O
,	O
613	O
genes	B-SO
were	O
found	O
to	O
be	O
significantly	O
correlated	O
with	O
gonadal	O
fat	O
mass	O
,	O
of	O
which	O
4	O
,	O
254	O
(	O
98	O
%	O
)	O
showed	O
sex	O
-	O
biased	O
correlation	O
.	O

As	O
indicated	O
in	O
Tables	O
4	O
and	O
5	O
,	O
several	O
genes	B-SO
with	O
detectable	O
cis	O
-	O
eQTLs	O
are	O
also	O
significantly	O
correlated	O
with	O
the	O
trait	O
and	O
are	O
even	O
further	O
prioritized	O
as	O
candidate	O
genes	B-SO
.	O

Thus	O
far	O
,	O
studies	O
that	O
have	O
examined	O
the	O
"	O
genetics	O
of	O
gene	B-SO
expression	O
"	O
are	O
in	O
good	O
agreement	O
regarding	O
the	O
increased	O
power	O
to	O
detect	O
cis	O
-	O
eQTLs	O
relative	O
to	O
trans	O
[	O
5	O
,	O
9	O
,	O
15	O
,	O
16	O
,	O
31	O
]	O
.	O

It	O
is	O
unclear	O
at	O
this	O
time	O
,	O
however	O
,	O
what	O
exactly	O
is	O
the	O
significance	O
of	O
trans	O
-	O
eQTLs	O
and	O
the	O
nature	O
of	O
the	O
underlying	O
polymorphisms	B-SO
associated	O
with	O
them	O
.	O

Furthermore	O
,	O
the	O
eQTL	O
hotspots	O
reported	O
in	O
this	O
and	O
previous	O
studies	O
[	O
5	O
,	O
9	O
,	O
10	O
]	O
largely	O
represent	O
trans	O
-	O
eQTLs	O
.	O

This	O
localization	O
suggests	O
some	O
functional	O
significance	O
to	O
these	O
regions	B-SO
.	O

Of	O
the	O
4	O
,	O
613	O
genes	B-SO
correlated	O
with	O
gonadal	O
fat	O
mass	O
,	O
1	O
,	O
130	O
generate	O
1	O
,	O
478	O
significant	O
eQTLs	O
,	O
of	O
which	O
1	O
,	O
023	O
(	O
69	O
%	O
)	O
are	O
trans	O
-	O
acting	O
.	O

These	O
eQTLs	O
are	O
significantly	O
enriched	O
at	O
one	O
locus	B-SO
(	O
Chromosome	B-GO
19	O
)	O
.	O

Interestingly	O
,	O
this	O
hotspot	O
was	O
coincident	O
with	O
a	O
cQTL	O
associated	O
with	O
fat	O
mass	O
reported	O
in	O
this	O
study	O
.	O

Since	O
these	O
transcripts	B-SO
represent	O
those	O
significantly	O
correlated	O
with	O
gonadal	O
fat	O
mass	O
,	O
the	O
localization	O
of	O
their	O
eQTLs	O
to	O
these	O
regions	B-SO
strongly	O
supports	O
the	O
notion	O
that	O
the	O
genes	B-SO
with	O
trans	O
-	O
eQTLs	O
represent	O
downstream	O
targets	O
of	O
candidate	O
regulatory	O
genes	B-SO
located	O
at	O
the	O
position	B-SO
of	O
significant	O
linkage	O
.	O

This	O
means	O
that	O
the	O
genes	B-SO
may	O
be	O
causal	O
but	O
downstream	O
of	O
the	O
gene	B-SO
responsible	O
for	O
the	O
cQTLs	O
,	O
or	O
they	O
may	O
be	O
reacting	O
to	O
the	O
increased	O
gonadal	O
fat	O
mass	O
and	O
associated	O
metabolic	O
changes	O
.	O

These	O
data	O
also	O
suggest	O
that	O
identifying	O
such	O
loci	B-SO
that	O
show	O
overrepresentation	O
of	O
highly	O
correlated	O
genes	B-SO
is	O
a	O
means	O
to	O
identify	O
which	O
of	O
the	O
trait	O
cQTLs	O
are	O
more	O
likely	O
controlled	O
by	O
the	O
tissue	O
arrayed	O
.	O

As	O
expected	O
,	O
the	O
Chromosome	B-SO
19	I-SO
locus	I-SO
was	O
enriched	O
for	O
trans	O
-	O
eQTLs	O
with	O
substantially	O
greater	O
effects	O
in	O
females	O
.	O

Functional	O
and	O
promoter	B-SO
analysis	O
of	O
genes	B-SO
with	O
a	O
common	O
trans	O
-	O
eQTL	O
may	O
prove	O
enlightening	O
.	O

Furthermore	O
,	O
gene	B-SO
expression	O
network	O
construction	O
and	O
analysis	O
may	O
be	O
improved	O
by	O
the	O
incorporation	O
of	O
experimentally	O
demonstrated	O
cis	O
versus	O
trans	O
regulation	O
.	O

Conclusion	O

The	O
integration	O
of	O
traditional	O
genetics	O
with	O
genome	B-SO
-	O
wide	O
expression	O
analysis	O
was	O
first	O
proposed	O
by	O
Jansen	O
and	O
Nap	O
4	O
y	O
ago	O
[	O
32	O
]	O
.	O

Advances	O
in	O
genomic	B-SO
technology	O
and	O
bioinformatic	O
resources	O
since	O
then	O
have	O
vastly	O
improved	O
the	O
applicability	O
of	O
these	O
methods	O
to	O
the	O
dissection	O
of	O
complex	O
traits	O
.	O

Taking	O
into	O
account	O
sex	O
-	O
specific	O
effects	O
will	O
similarly	O
improve	O
the	O
sensitivity	O
to	O
detect	O
underlying	O
genetic	B-SO
regulation	O
,	O
especially	O
for	O
phenotypes	O
known	O
to	O
be	O
affected	O
by	O
sex	O
.	O

Furthermore	O
,	O
network	O
analyses	O
are	O
increasingly	O
being	O
applied	O
to	O
complex	O
phenotypes	O
[	O
11	O
,	O
33	O
]	O
.	O

Regardless	O
of	O
which	O
variables	O
are	O
used	O
in	O
the	O
construction	O
of	O
these	O
networks	O
,	O
whether	O
they	O
measure	O
gene	B-SO
expression	O
or	O
protein	B-CHEBI
interactions	O
,	O
accounting	O
for	O
sex	O
specificity	O
,	O
hormonal	B-CHEBI
status	O
,	O
or	O
construction	O
of	O
different	O
networks	O
for	O
females	O
and	O
males	O
would	O
likely	O
more	O
accurately	O
represent	O
the	O
complexity	O
associated	O
with	O
these	O
phenotypes	O
.	O

We	O
reported	O
here	O
on	O
the	O
initial	O
genetic	B-SO
and	O
genomic	B-SO
analysis	O
of	O
an	O
F2	O
intercross	O
population	O
designed	O
to	O
recapitulate	O
several	O
traits	O
associated	O
with	O
human	B-Taxon
metabolic	O
syndrome	O
.	O

Using	O
334	O
mice	B-Taxon
of	O
both	O
sexes	O
genotyped	O
at	O
high	O
density	O
,	O
this	O
is	O
the	O
largest	O
study	O
of	O
its	O
kind	O
to	O
date	O
designed	O
,	O
and	O
it	O
is	O
strongly	O
powered	O
to	O
detect	O
subtle	O
effects	O
of	O
genetic	B-SO
regulation	O
and	O
sex	O
specificity	O
.	O

We	O
identified	O
five	O
cQTLs	O
for	O
the	O
gonadal	O
fat	O
mass	O
trait	O
,	O
all	O
with	O
greater	O
effects	O
in	O
females	O
.	O

We	O
also	O
detected	O
several	O
thousand	O
significant	O
liver	O
eQTLs	O
,	O
a	O
significant	O
fraction	O
of	O
which	O
are	O
sex	O
-	O
biased	O
,	O
demonstrating	O
how	O
meaningful	O
effects	O
of	O
sex	O
on	O
gene	B-SO
expression	O
extend	O
beyond	O
overall	O
mean	O
differences	O
.	O

We	O
demonstrated	O
the	O
application	O
of	O
linkage	O
and	O
correlation	O
methods	O
to	O
identify	O
candidate	O
genes	B-SO
.	O

Finally	O
,	O
we	O
showed	O
that	O
localization	O
of	O
a	O
subset	O
of	O
liver	O
genes	B-SO
linked	O
in	O
trans	O
to	O
a	O
cQTL	O
region	B-SO
can	O
identify	O
relative	O
tissue	O
contributions	O
to	O
the	O
genetic	B-SO
regulation	O
of	O
a	O
complex	O
trait	O
.	O

We	O
anticipate	O
that	O
the	O
application	O
of	O
these	O
and	O
similar	O
methods	O
would	O
significantly	O
improve	O
the	O
elucidation	O
of	O
the	O
genetic	B-SO
regulation	O
underlying	O
complex	O
phenotypes	O
.	O

Materials	O
and	O
Methods	O

Animals	B-Taxon
and	O
tissue	O
collection	O
.	O

C57BL	O
/	O
6J	O
ApoE	B-GGP
-	O
/	O
-	O
(	O
B6	O
.	O
ApoE	B-GGP
-	O
/	O
-	O
)	O
were	O
purchased	O
from	O
Jackson	O
Laboratory	O
(	O
Bar	O
Harbor	O
,	O
Maine	O
,	O
United	O
States	O
)	O
.	O

C3H	O
/	O
HeJ	O
ApoE	B-GGP
-	O
/	O
-	O
(	O
C3H	O
.	O
ApoE	B-GGP
-	O
/	O
-	O
)	O
were	O
generated	O
by	O
backcrossing	O
B6	O
.	O
ApoE	B-GGP
-	O
/	O
-	O
to	O
C3H	O
for	O
ten	O
generations	O
.	O

F1	O
mice	B-Taxon
were	O
generated	O
from	O
reciprocal	O
intercrossing	O
between	O
B6	O
.	O
ApoE	B-GGP
-	O
/	O
-	O
and	O
C3H	O
.	O
ApoE	B-GGP
-	O
/	O
-	O
,	O
and	O
F2	O
mice	B-Taxon
were	O
subsequently	O
bred	O
by	O
intercrossing	O
F1	O
mice	B-Taxon
.	O

A	O
total	O
of	O
334	O
mice	B-Taxon
(	O
169	O
female	O
,	O
165	O
male	O
)	O
were	O
produced	O
.	O

All	O
mice	B-Taxon
were	O
fed	O
Purina	O
Chow	O
containing	O
4	O
%	O
fat	O
until	O
8	O
wk	O
of	O
age	O
and	O
then	O
transferred	O
to	O
a	O
"	O
Western	O
"	O
diet	O
containing	O
42	O
%	O
fat	O
and	O
0	O
.	O
15	O
%	O
cholesterol	B-CHEBI
for	O
16	O
wk	O
.	O

Mice	B-Taxon
were	O
sacrificed	O
at	O
24	O
wk	O
of	O
age	O
.	O

At	O
death	O
,	O
livers	O
were	O
immediately	O
collected	O
and	O
flash	O
-	O
frozen	O
in	O
liquid	O
N2	B-CHEBI
,	O
and	O
gonadal	O
fat	O
pads	O
were	O
extracted	O
and	O
weighed	O
.	O

RNA	B-SO
sample	O
preparation	O
,	O
microarray	O
hybridization	O
,	O
and	O
expression	O
analysis	O
.	O

RNA	B-SO
preparation	O
and	O
array	O
hybridizations	O
were	O
performed	O
at	O
Rosetta	O
Inpharmatics	O
(	O
Seattle	O
,	O
Washington	O
,	O
United	O
States	O
)	O
.	O

The	O
custom	O
ink	O
-	O
jet	O
microarrays	O
used	O
in	O
this	O
study	O
(	O
Agilent	O
Technologies	O
,	O
previously	O
described	O
[	O
21	O
,	O
34	O
]	O
)	O
contain	O
2	O
,	O
186	O
control	O
probes	B-SO
and	O
23	O
,	O
574	O
noncontrol	O
oligonucleotides	B-SO
extracted	O
from	O
mouse	B-Taxon
UniGene	O
clusters	O
and	O
combined	O
with	O
RefSeq	O
sequences	B-SO
and	O
RIKEN	O
full	O
-	O
length	O
clones	B-SO
.	O

Mouse	B-Taxon
livers	O
were	O
homogenized	O
and	O
total	O
RNA	B-SO
extracted	O
using	O
TRIzol	O
reagent	B-CHEBI
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
California	O
,	O
United	O
States	O
)	O
according	O
to	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Three	O
micrograms	O
of	O
total	O
RNA	B-SO
was	O
reverse	O
transcribed	O
and	O
labeled	O
with	O
either	O
Cy3	O
or	O
Cy5	O
fluorochrome	O
.	O

Purified	O
Cy3	O
or	O
Cy5	O
complementary	O
RNA	B-SO
was	O
hybridized	O
to	O
at	O
least	O
two	O
microarray	O
slides	O
with	O
fluor	O
reversal	O
for	O
24	O
h	O
in	O
a	O
hybridization	O
chamber	O
,	O
washed	O
,	O
and	O
scanned	O
using	O
a	O
laser	O
confocal	O
scanner	O
.	O

Arrays	O
were	O
quantified	O
on	O
the	O
basis	O
of	O
spot	O
intensity	O
relative	O
to	O
background	O
,	O
adjusted	O
for	O
experimental	O
variation	O
between	O
arrays	O
using	O
average	O
intensity	O
over	O
multiple	O
channels	O
,	O
and	O
fitted	O
to	O
an	O
error	O
model	O
to	O
determine	O
significance	O
(	O
type	O
I	O
error	O
)	O
.	O

Gene	B-SO
expression	O
is	O
reported	O
as	O
the	O
mlratio	O
relative	O
to	O
the	O
pool	O
derived	O
from	O
150	O
mice	B-Taxon
randomly	O
selected	O
from	O
the	O
F2	O
population	O
.	O

For	O
subsequent	O
analyses	O
,	O
mlratio	O
data	O
are	O
assumed	O
to	O
be	O
normally	O
distributed	O
,	O
a	O
valid	O
assumption	O
as	O
previously	O
demonstrated	O
[	O
21	O
,	O
30	O
]	O
.	O

The	O
error	O
model	O
used	O
to	O
assess	O
whether	O
a	O
given	O
gene	B-SO
is	O
significantly	O
differentially	O
expressed	O
in	O
a	O
single	O
sample	O
relative	O
to	O
a	O
pool	O
comprised	O
of	O
a	O
randomly	O
selected	O
subset	O
of	O
150	O
samples	O
has	O
been	O
extensively	O
described	O
and	O
tested	O
in	O
a	O
number	O
of	O
publications	O
[	O
35	O
,	O
36	O
]	O
.	O

Genotyping	O
and	O
linkage	O
statistics	O
.	O

Genomic	B-SO
DNA	I-SO
was	O
isolated	O
from	O
kidney	O
by	O
phenol	B-CHEBI
-	O
chloroform	B-CHEBI
extraction	O
.	O

An	O
examination	O
of	O
existing	O
databases	O
identified	O
over	O
1	O
,	O
300	O
SNPs	B-SO
that	O
showed	O
variation	O
between	O
the	O
B6	O
and	O
C3H	O
strains	O
,	O
and	O
a	O
complete	O
linkage	O
map	B-SO
for	O
all	O
19	O
autosomes	B-GO
was	O
constructed	O
using	O
1	O
,	O
032	O
of	O
these	O
SNPs	B-SO
at	O
an	O
average	O
density	O
of	O
1	O
.	O
5	O
cM	O
.	O

Genotyping	O
was	O
conducted	O
by	O
ParAllele	O
(	O
South	O
San	O
Francisco	O
,	O
California	O
,	O
United	O
States	O
)	O
using	O
the	O
molecular	B-CHEBI
-	O
inversion	O
probe	B-SO
(	O
MIB	O
)	O
multiplex	O
technique	O
[	O
37	O
]	O
.	O

Testing	O
for	O
linkage	O
of	O
both	O
clinical	O
traits	O
and	O
gene	B-SO
expression	O
(	O
using	O
mlratio	O
)	O
was	O
conducted	O
using	O
a	O
linear	O
model	O
.	O

Consider	O
a	O
phenotype	O
denoted	O
by	O
y	O
.	O

The	O
linear	O
model	O
that	O
relates	O
variation	O
in	O
y	O
to	O
QTLs	B-SO
and	O
other	O
covariates	O
(	O
e	O
.	O
g	O
.	O
,	O
sex	O
)	O
is	O
given	O
by	O
the	O
general	O
form	O

where	O
mu	O
is	O
the	O
trait	O
mean	O
,	O
X	O
'	O
a	O
vector	O
of	O
covariates	O
,	O
beta	O
being	O
the	O
associated	O
vector	O
of	O
regression	O
coefficients	O
,	O
and	O
e	O
the	O
residual	O
error	O
.	O

Linkage	O
was	O
computed	O
for	O
over	O
20	O
clinical	O
traits	O
as	O
well	O
as	O
23	O
,	O
574	O
liver	O
transcripts	B-SO
.	O

Standard	O
genome	B-SO
scans	O
calculate	O
linkage	O
by	O
comparing	O
the	O
linear	O
model	O

to	O
the	O
null	O
model	O

where	O
beta	O
1	O
and	O
beta	O
2	O
are	O
the	O
regression	O
coefficients	O
of	O
the	O
additive	O
and	O
dominant	O
parameters	O
,	O
respectively	O
.	O

The	O
LOD	O
score	O
represents	O
the	O
difference	O
in	O
the	O
log10	O
of	O
the	O
likelihood	O
of	O
the	O
above	O
two	O
equations	O
,	O
where	O
the	O
individual	O
model	O
likelihoods	O
are	O
maximized	O
with	O
respect	O
to	O
the	O
model	O
parameters	O
,	O
given	O
the	O
marker	O
genotype	B-SO
and	O
phenotype	O
data	O
.	O

If	O
a	O
trait	O
y	O
differs	O
on	O
average	O
between	O
the	O
two	O
sexes	O
but	O
the	O
QTL	B-SO
has	O
the	O
same	O
effect	O
in	O
both	O
males	O
and	O
females	O
,	O
we	O
can	O
model	O
this	O
interaction	O
by	O
including	O
sex	O
as	O
an	O
additive	O
covariate	O
in	O
the	O
above	O
models	O
,	O
resulting	O
in	O
the	O
new	O
model	O

which	O
is	O
then	O
compared	O
to	O
the	O
null	O
model	O

where	O
beta	O
3	O
is	O
the	O
regression	O
coefficient	O
of	O
the	O
sex	O
parameter	O
.	O

The	O
effect	O
of	O
a	O
QTL	B-SO
may	O
be	O
dependent	O
on	O
the	O
state	O
of	O
a	O
covariate	O
;	O
for	O
instance	O
,	O
a	O
QTL	B-SO
may	O
have	O
an	O
effect	O
specific	O
to	O
one	O
sex	O
,	O
or	O
may	O
have	O
opposite	O
effects	O
in	O
the	O
two	O
sexes	O
.	O

This	O
interaction	O
can	O
be	O
modeled	O
using	O
a	O
full	O
model	O
,	O
which	O
accounts	O
for	O
all	O
additive	O
covariates	O
,	O
as	O
well	O
as	O
interactions	O
between	O
the	O
covariates	O
:	O

which	O
is	O
compared	O
to	O
the	O
above	O
null	O
model	O
(	O
Equation	O
5	O
)	O
.	O

The	O
full	O
model	O
(	O
Equation	O
6	O
)	O
allows	O
us	O
to	O
model	O
all	O
heritable	O
and	O
sex	O
-	O
specific	O
interactions	O
in	O
a	O
single	O
equation	O
and	O
maximally	O
powers	O
us	O
to	O
detect	O
significant	O
QTLs	B-SO
when	O
the	O
sex	O
and	O
sex	O
-	O
interaction	O
terms	O
are	O
significant	O
,	O
given	O
all	O
334	O
animals	B-Taxon
are	O
included	O
in	O
the	O
analysis	O
.	O

Furthermore	O
,	O
using	O
the	O
full	O
model	O
obviates	O
the	O
need	O
for	O
modeling	O
QTLs	B-SO
in	O
one	O
sex	O
only	O
,	O
a	O
procedure	O
that	O
could	O
decrease	O
our	O
power	O
by	O
halving	O
the	O
sample	O
size	O
,	O
rendering	O
it	O
impossible	O
to	O
detect	O
interactions	O
between	O
QTLs	B-SO
and	O
sex	O
.	O

However	O
,	O
because	O
the	O
full	O
model	O
contains	O
two	O
more	O
parameters	O
than	O
the	O
model	O
that	O
treats	O
sex	O
as	O
an	O
additive	O
covariate	O
(	O
Equation	O
4	O
)	O
,	O
the	O
LOD	O
score	O
threshold	O
for	O
significant	O
linkage	O
is	O
higher	O
(	O
using	O
the	O
convention	O
of	O
Lander	O
and	O
Kruglyak	O
[	O
20	O
]	O
)	O
,	O
with	O
QTL	B-SO
-	O
specific	O
significance	O
levels	O
of	O
2	O
x	O
10	O
-	O
3	O
and	O
5	O
x	O
10	O
-	O
5	O
equivalent	O
to	O
LOD	O
scores	O
of	O
4	O
.	O
0	O
(	O
suggestive	O
linkage	O
)	O
and	O
5	O
.	O
4	O
(	O
significant	O
linkage	O
,	O
equivalent	O
to	O
genome	B-SO
-	O
wide	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
respectively	O
.	O

As	O
a	O
result	O
,	O
if	O
there	O
are	O
no	O
significant	O
sex	O
-	O
additive	O
or	O
sex	O
-	O
dominant	O
interactions	O
,	O
the	O
full	O
model	O
will	O
actually	O
reduce	O
power	O
to	O
detect	O
linkage	O
.	O

To	O
minimize	O
the	O
loss	O
in	O
power	O
of	O
fitting	O
the	O
full	O
model	O
when	O
the	O
sex	O
-	O
interaction	O
terms	O
are	O
not	O
significant	O
,	O
we	O
employed	O
a	O
model	O
selection	O
procedure	O
that	O
introduces	O
sex	O
-	O
interaction	O
terms	O
only	O
if	O
they	O
add	O
significantly	O
to	O
the	O
overall	O
QTL	B-SO
model	O
.	O

The	O
model	O
selection	O
procedure	O
makes	O
use	O
of	O
forward	O
stepwise	O
regression	O
techniques	O
to	O
determine	O
whether	O
it	O
is	O
beneficial	O
to	O
include	O
the	O
sex	O
-	O
interaction	O
terms	O
,	O
conditional	O
on	O
realizing	O
a	O
significant	O
additive	O
effect	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

That	O
is	O
,	O
the	O
data	O
are	O
fitted	O
to	O
Equation	O
4	O
for	O
a	O
given	O
marker	O
,	O
and	O
if	O
the	O
add	O
term	O
is	O
significant	O
at	O
the	O
0	O
.	O
001	O
significance	O
level	O
,	O
then	O
we	O
attempt	O
to	O
add	O
the	O
sex	O
*	O
add	O
term	O
into	O
the	O
model	O
.	O

The	O
sex	O
*	O
add	O
term	O
is	O
retained	O
in	O
the	O
model	O
if	O
the	O
Bayesian	O
information	O
criterion	O
(	O
BIC	O
)	O
for	O
this	O
model	O
is	O
smaller	O
than	O
the	O
BIC	O
for	O
Equation	O
4	O
.	O

If	O
sex	O
*	O
add	O
is	O
included	O
in	O
the	O
model	O
as	O
a	O
result	O
of	O
this	O
procedure	O
,	O
then	O
we	O
again	O
use	O
BIC	O
to	O
consider	O
including	O
the	O
sex	O
*	O
dom	O
term	O
in	O
the	O
model	O
.	O

To	O
determine	O
which	O
of	O
the	O
four	O
models	O
(	O
Equations	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
the	O
model	O
selection	O
)	O
is	O
optimal	O
,	O
we	O
empirically	O
estimated	O
the	O
FDR	O
for	O
each	O
model	O
over	O
a	O
set	O
of	O
3	O
,	O
000	O
genes	B-SO
randomly	O
selected	O
from	O
the	O
set	O
of	O
all	O
genes	B-SO
detected	O
as	O
expressed	O
in	O
the	O
liver	O
samples	O
.	O

For	O
each	O
gene	B-SO
and	O
for	O
each	O
marker	O
we	O
fitted	O
each	O
of	O
the	O
four	O
models	O
to	O
the	O
data	O
.	O

We	O
performed	O
this	O
same	O
analysis	O
on	O
ten	O
separate	O
permutation	O
sets	O
in	O
which	O
each	O
of	O
the	O
3	O
,	O
000	O
gene	B-SO
expression	O
trait	O
vectors	O
was	O
permuted	O
such	O
that	O
the	O
correlation	O
structure	O
among	O
the	O
genes	B-SO
was	O
preserved	O
.	O

The	O
FDR	O
for	O
a	O
given	O
LOD	O
score	O
threshold	O
was	O
then	O
computed	O
as	O
the	O
ratio	O
of	O
the	O
mean	O
number	O
of	O
QTL	B-SO
detected	O
in	O
the	O
permuted	O
datasets	O
(	O
the	O
mean	O
taken	O
over	O
the	O
ten	O
permuted	O
datasets	O
)	O
and	O
the	O
total	O
number	O
of	O
QTL	B-SO
detected	O
in	O
the	O
observed	O
3	O
,	O
000	O
-	O
gene	B-SO
dataset	O
.	O

We	O
then	O
generated	O
ROC	O
-	O
like	O
curves	O
by	O
varying	O
the	O
LOD	O
score	O
threshold	O
,	O
resulting	O
in	O
a	O
range	O
of	O
FDRs	O
(	O
from	O
0	O
%	O
to	O
more	O
than	O
50	O
%	O
)	O
.	O

To	O
simplify	O
this	O
type	O
of	O
summary	O
,	O
we	O
considered	O
no	O
more	O
than	O
one	O
QTL	B-SO
per	O
chromosome	B-GO
per	O
gene	B-SO
expression	O
trait	O
by	O
considering	O
only	O
the	O
QTL	B-SO
with	O
the	O
max	O
LOD	O
score	O
on	O
each	O
chromosome	B-GO
for	O
each	O
trait	O
.	O

The	O
ROC	O
curves	O
for	O
each	O
of	O
the	O
four	O
models	O
are	O
shown	O
in	O
Figure	O
S1	O
,	O
with	O
the	O
black	O
curve	O
corresponding	O
to	O
Equation	O
2	O
,	O
the	O
blue	O
curve	O
corresponding	O
to	O
Equation	O
4	O
,	O
the	O
red	O
curve	O
corresponding	O
to	O
Equation	O
6	O
,	O
and	O
the	O
green	O
curve	O
corresponding	O
to	O
the	O
model	O
selection	O
procedure	O
.	O

It	O
is	O
clear	O
from	O
the	O
ROC	O
curves	O
that	O
the	O
sex	O
and	O
sex	O
-	O
interaction	O
terms	O
are	O
significant	O
in	O
the	O
gene	B-SO
expression	O
dataset	O
.	O

For	O
example	O
,	O
at	O
an	O
FDR	O
of	O
5	O
%	O
we	O
note	O
that	O
800	O
QTLs	B-SO
were	O
detected	O
in	O
the	O
set	O
of	O
3	O
,	O
000	O
genes	B-SO
for	O
model	O
1	O
,	O
while	O
968	O
(	O
21	O
%	O
increase	O
)	O
and	O
1	O
,	O
159	O
(	O
45	O
%	O
increase	O
)	O
QTLs	B-SO
were	O
detected	O
for	O
Equations	O
4	O
and	O
6	O
,	O
respectively	O
.	O

These	O
results	O
demonstrate	O
significantly	O
increased	O
power	O
to	O
detect	O
QTLs	B-SO
when	O
sex	O
is	O
taken	O
into	O
account	O
.	O

We	O
further	O
note	O
that	O
the	O
stepwise	O
selection	O
procedure	O
captures	O
more	O
information	O
than	O
Equation	O
4	O
,	O
indicating	O
a	O
significant	O
interaction	O
signature	O
in	O
this	O
dataset	O
and	O
also	O
demonstrating	O
that	O
this	O
simple	O
statistical	O
procedure	O
is	O
capable	O
of	O
identifying	O
significant	O
interaction	O
events	O
even	O
at	O
conservative	O
FDR	O
thresholds	O
.	O

Finally	O
,	O
it	O
is	O
of	O
particular	O
note	O
that	O
Equation	O
4	O
performed	O
better	O
than	O
Equation	O
6	O
,	O
the	O
model	O
that	O
incorporated	O
the	O
interaction	O
terms	O
at	O
all	O
times	O
.	O

That	O
is	O
,	O
despite	O
there	O
being	O
a	O
significant	O
interaction	O
signature	O
,	O
the	O
signature	O
was	O
not	O
large	O
enough	O
to	O
justify	O
including	O
interaction	O
terms	O
for	O
every	O
expression	O
trait	O
and	O
at	O
every	O
marker	O
tested	O
.	O

This	O
fact	O
motivated	O
the	O
need	O
to	O
employ	O
the	O
forward	O
regression	O
procedure	O
,	O
and	O
these	O
results	O
further	O
motivate	O
the	O
need	O
to	O
explore	O
sex	O
effects	O
by	O
employing	O
even	O
more	O
sophisticated	O
QTL	B-SO
detection	O
methods	O
,	O
such	O
as	O
that	O
recently	O
described	O
by	O
Yi	O
et	O
al	O
.	O

[	O
38	O
]	O
.	O

Additional	O
statistics	O
.	O

For	O
each	O
23	O
,	O
574	O
oligonucleotides	B-SO
represented	O
on	O
the	O
array	O
,	O
we	O
computed	O
a	O
linear	O
regression	O
analysis	O
to	O
test	O
for	O
a	O
correlation	O
between	O
the	O
trait	O
"	O
gonadal	O
fat	O
mass	O
"	O
and	O
each	O
transcript	B-SO
.	O

Similar	O
to	O
our	O
method	O
of	O
calculating	O
linkage	O
,	O
we	O
employed	O
a	O
stepwise	O
linear	O
regression	O
procedure	O
using	O
equations	O
of	O
the	O
form	O

or	O

compared	O
to	O
the	O
null	O
model	O

where	O
beta	O
0	O
is	O
the	O
intercept	O
,	O
and	O
beta	O
1	O
,	O
beta	O
2	O
,	O
and	O
beta	O
3	O
represent	O
the	O
regression	O
coefficients	O
of	O
their	O
respective	O
terms	O
.	O

As	O
before	O
,	O
the	O
parameter	O
"	O
sex	O
*	O
gene	B-SO
"	O
is	O
only	O
retained	O
if	O
it	O
significantly	O
improves	O
the	O
fit	O
of	O
the	O
model	O
.	O

The	O
p	O
-	O
value	O
threshold	O
for	O
significant	O
correlation	O
is	O
calculated	O
by	O
an	O
F	O
test	O
,	O
which	O
compares	O
the	O
appropriate	O
model	O
(	O
Equation	O
7	O
or	O
8	O
)	O
to	O
the	O
null	O
model	O
(	O
Equation	O
9	O
)	O
.	O

As	O
before	O
,	O
multiple	O
testing	O
was	O
addressed	O
with	O
use	O
of	O
the	O
FDR	O
,	O
ranking	O
the	O
p	O
-	O
values	O
obtained	O
from	O
the	O
above	O
F	O
tests	O
and	O
setting	O
alpha	O
=	O
0	O
.	O
01	O
.	O

Genes	B-SO
correlated	O
with	O
the	O
gonadal	O
fat	O
mass	O
trait	O
generated	O
several	O
significant	O
eQTLs	O
.	O

In	O
order	O
to	O
determine	O
if	O
eQTLs	O
generated	O
by	O
these	O
genes	B-SO
were	O
enriched	O
in	O
any	O
locus	B-SO
or	O
if	O
they	O
were	O
distributed	O
randomly	O
,	O
we	O
compared	O
the	O
distribution	O
of	O
these	O
eQTLs	O
against	O
the	O
distribution	O
of	O
all	O
liver	O
eQTLs	O
in	O
overlapping	B-SO
6	O
-	O
cM	O
bins	O
across	O
the	O
genome	B-SO
using	O
the	O
Fisher	O
exact	O
test	O
.	O

This	O
test	O
is	O
based	O
on	O
exact	O
probabilities	O
from	O
a	O
specific	O
distribution	O
(	O
hypergeometric	O
distribution	O
)	O
.	O

p	O
-	O
Values	O
obtained	O
from	O
this	O
test	O
were	O
corrected	O
for	O
multiple	O
comparisons	O
using	O
a	O
simple	O
Bonferonni	O
correction	O
(	O
given	O
that	O
we	O
performed	O
772	O
tests	O
across	O
the	O
genome	B-SO
,	O
0	O
.	O
05	O
/	O
772	O
)	O
.	O

Loci	B-SO
with	O
p	O
<	O
6	O
.	O
5	O
x	O
10	O
-	O
5	O
by	O
Fisher	O
exact	O
test	O
were	O
considered	O
significantly	O
enriched	O
for	O
eQTLs	O
correlated	O
with	O
gonadal	O
fat	O
mass	O
.	O

Supporting	O
Information	O

Figure	O
S1	O

ROC	O
Curves	O
for	O
Each	O
of	O
the	O
Four	O
Models	O

(	O
21	O
KB	O
DOC	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Table	O
S1	O

Suggestive	O
and	O
Significant	O
eQTLs	O

(	O
3	O
.	O
7	O
MB	O
XLS	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Table	O
S2	O

Transcripts	B-SO
Significantly	O
Correlated	O
with	O
Gonadal	O
Fat	O
Mass	O

(	O
716	O
KB	O
XLS	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Acknowledgements	O

The	O
authors	O
wish	O
to	O
thank	O
Steve	O
Horvath	O
,	O
Desmond	O
Smith	O
,	O
Xia	O
Yang	O
,	O
Sudheer	O
Doss	O
,	O
Anatole	O
Ghazalpour	O
,	O
Pek	O
Lum	O
,	O
and	O
John	O
Lamb	O
for	O
valuable	O
discussions	O
and	O
insights	O
.	O

We	O
thank	O
Leslie	O
Ingram	O
-	O
Drake	O
for	O
work	O
on	O
data	O
preparation	O
.	O

Initial	O
work	O
on	O
construction	O
of	O
the	O
BXH	O
.	O
ApoE	B-GGP
-	O
/	O
-	O
cross	O
was	O
done	O
by	O
Weibin	O
Shi	O
.	O

Abbreviations	O

ApoE	B-GGP
-	O
/	O
-	O
-	O
apolipoprotein	B-GGP
E	I-GGP
null	O

cQTL	O
-	O
clinical	O
QTL	B-SO

eQTL	O
-	O
gene	B-SO
expression	O
QTL	B-SO

FDR	O
-	O
false	O
discovery	O
rate	O

LOD	O
-	O
logarithm	O
of	O
odds	O

mlratio	O
-	O
mean	O
log10	O
ratio	O

QTL	B-SO
-	O
quantitative	B-SO
trait	I-SO
locus	I-SO

ROC	O
-	O
receiver	O
operating	O
characteristic	O

SNP	B-SO
-	O
single	B-SO
nucleotide	I-SO
polymorphism	I-SO

Figures	O
and	O
Tables	O

Figure	O
1	O

Genome	B-SO
Scan	O
for	O
Gonadal	O
Fat	O
Mass	O

(	O
A	O
)	O
Animals	B-Taxon
were	O
genotyped	O
at	O
an	O
average	O
1	O
.	O
5	O
cM	O
density	O
using	O
1	O
,	O
032	O
SNPs	B-SO
polymorphic	B-SO
between	O
the	O
parental	O
strains	O
.	O

LOD	O
scores	O
computed	O
using	O
sex	O
as	O
an	O
additive	O
covariate	O
(	O
black	O
)	O
failed	O
to	O
detect	O
significant	O
linkage	O
.	O

A	O
genome	B-SO
scan	O
accounting	O
for	O
interactions	O
between	O
sex	O
and	O
QTL	B-SO
(	O
red	O
)	O
showed	O
evidence	O
for	O
suggestive	O
linkage	O
on	O
Chromosome	B-GO
1	O
and	O
significant	O
linkage	O
on	O
Chromosomes	B-GO
3	O
,	O
5	O
,	O
11	O
,	O
and	O
19	O
.	O

Dashed	O
and	O
solid	O
lines	O
are	O
thresholds	O
for	O
suggestive	O
(	O
p	O
<	O
1	O
x	O
10	O
-	O
3	O
)	O
and	O
significant	O
linkage	O
(	O
p	O
<	O
5	O
x	O
10	O
-	O
5	O
)	O
,	O
respectively	O
.	O

(	O
B	O
)	O
Genome	B-SO
scans	O
for	O
gonadal	O
fat	O
mass	O
using	O
different	O
models	O
over	O
mouse	B-Taxon
Chromosome	B-GO
5	O
.	O

Scans	O
for	O
fat	O
mass	O
using	O
all	O
animals	B-Taxon
with	O
(	O
black	O
)	O
and	O
without	O
(	O
green	O
)	O
sex	O
as	O
an	O
additive	O
covariate	O
failed	O
to	O
detect	O
significant	O
linkage	O
.	O

Females	O
analyzed	O
alone	O
(	O
magenta	O
)	O
showed	O
evidence	O
for	O
suggestive	O
linkage	O
(	O
p	O
<	O
2	O
x	O
10	O
-	O
4	O
)	O
.	O

When	O
both	O
sexes	O
were	O
analyzed	O
to	O
account	O
for	O
sex	O
effects	O
(	O
red	O
)	O
,	O
a	O
significant	O
QTL	B-SO
was	O
realized	O
(	O
p	O
<	O
10	O
-	O
6	O
)	O
.	O

For	O
clarity	O
,	O
only	O
the	O
model	O
incorporating	O
both	O
the	O
"	O
sex	O
*	O
add	O
"	O
and	O
"	O
sex	O
*	O
dom	O
"	O
terms	O
is	O
shown	O
in	O
red	O
,	O
although	O
additional	O
models	O
incorporating	O
the	O
terms	O
separately	O
were	O
also	O
computed	O
.	O

Figure	O
2	O

Effect	O
of	O
Genotype	B-SO
on	O
Fat	O
Mass	O

Homozygous	O
B6	O
(	O
BB	O
)	O
,	O
C3H	O
(	O
CC	O
)	O
,	O
or	O
heterozygous	O
(	O
BC	O
)	O
genotype	B-SO
at	O
all	O
five	O
QTL	B-SO
positions	I-SO
,	O
separated	O
by	O
sex	O
,	O
are	O
shown	O
.	O

The	O
underlying	O
genotypic	B-SO
effects	O
of	O
the	O
QTLs	B-SO
on	O
fat	O
mass	O
differ	O
between	O
the	O
sexes	O
.	O

Coefficients	O
of	O
determination	O
(	O
R2	O
)	O
are	O
shown	O
along	O
with	O
associated	O
ANOVAs	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
*	O
*	O
p	O
<	O
0	O
.	O
01	O
,	O
*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
.	O

Figure	O
3	O

Heat	O
Map	O
of	O
Liver	O
Gene	B-SO
Expression	O

Over	O
2	O
,	O
300	O
of	O
the	O
most	O
differentially	O
expressed	O
genes	B-SO
in	O
liver	O
hierarchically	O
clustered	O
by	O
animals	B-Taxon
(	O
x	O
-	O
axis	O
)	O
against	O
transcript	B-SO
levels	O
(	O
y	O
-	O
axis	O
)	O
.	O

Expression	O
is	O
reported	O
as	O
mlratio	O
of	O
individual	O
experiment	O
against	O
a	O
common	O
pool	O
.	O

Red	O
is	O
over	O
-	O
and	O
green	O
underrepresented	O
relative	O
to	O
pool	O
.	O

Figure	O
4	O

Properties	B-SO
of	O
All	O
Liver	O
eQTLs	O

(	O
A	O
)	O
Distribution	O
of	O
all	O
significant	O
liver	O
eQTLs	O
across	O
the	O
genome	B-SO
in	O
2	O
-	O
cM	O
bins	O
.	O

A	O
total	O
of	O
6	O
,	O
676	O
significant	O
eQTLs	O
were	O
realized	O
,	O
representing	O
4	O
,	O
998	O
liver	O
transcripts	B-SO
.	O

Hotspots	O
of	O
nonrandom	O
eQTL	O
colocalization	O
are	O
clearly	O
evident	O
.	O

(	O
B	O
)	O
Distribution	O
of	O
eQTLs	O
with	O
significant	O
sex	O
-	O
specific	O
effects	O
.	O

A	O
total	O
of	O
1	O
,	O
166	O
eQTLs	O
representing	O
1	O
,	O
044	O
transcripts	B-SO
show	O
an	O
eQTL	O
hotspot	O
on	O
Chromosome	B-GO
5	O
.	O

(	O
C	O
)	O
Properties	B-SO
of	O
eQTLs	O
at	O
increasing	O
significance	O
levels	O
.	O

As	O
the	O
threshold	O
for	O
significant	O
linkage	O
increases	O
(	O
p	O
-	O
value	O
decreases	O
,	O
or	O
LOD	O
score	O
increases	O
)	O
,	O
the	O
proportion	O
of	O
cis	O
-	O
eQTLs	O
(	O
black	O
)	O
increases	O
.	O

The	O
fraction	O
of	O
all	O
eQTLs	O
with	O
sex	O
effects	O
(	O
red	O
)	O
and	O
cis	O
-	O
eQTLs	O
with	O
sex	O
effects	O
(	O
blue	O
)	O
remains	O
relatively	O
constant	O
at	O
increasing	O
thresholds	O
.	O

The	O
dashed	O
line	O
indicates	O
the	O
genome	B-SO
-	O
wide	O
significance	O
threshold	O
(	O
p	O
<	O
5	O
x	O
10	O
-	O
5	O
;	O
genome	B-SO
-	O
wide	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

(	O
D	O
)	O
Properties	B-SO
of	O
sex	O
-	O
specific	O
eQTLs	O
at	O
increasing	O
significance	O
levels	O
.	O

For	O
eQTLs	O
with	O
significant	O
sex	O
effects	O
,	O
as	O
with	O
all	O
eQTLs	O
,	O
the	O
proportion	O
of	O
cis	O
-	O
eQTLs	O
(	O
black	O
)	O
increases	O
and	O
trans	O
(	O
blue	O
)	O
decreases	O
as	O
the	O
threshold	O
for	O
significance	O
increases	O
.	O

At	O
the	O
genome	B-SO
-	O
wide	O
threshold	O
for	O
significance	O
(	O
dashed	O
line	O
)	O
,	O
over	O
70	O
%	O
of	O
eQTLs	O
with	O
significant	O
sex	O
effects	O
are	O
trans	O
.	O

Figure	O
5	O

Properties	B-SO
of	O
Transcripts	B-SO
Significantly	O
Correlated	O
with	O
Gonadal	O
Fat	O
Mass	O

(	O
A	O
)	O
Distribution	O
of	O
p	O
-	O
values	O
for	O
trait	O
-	O
gene	B-SO
correlations	O
between	O
transcripts	B-SO
and	O
gonadal	O
fat	O
mass	O
.	O

At	O
FDR	O
=	O
0	O
.	O
01	O
,	O
4	O
,	O
613	O
transcripts	B-SO
are	O
significantly	O
correlated	O
with	O
the	O
trait	O
.	O

(	O
B	O
)	O
Number	O
of	O
eQTLs	O
generated	O
by	O
the	O
4	O
,	O
613	O
genes	B-SO
significantly	O
correlated	O
with	O
gonadal	O
fat	O
mass	O
.	O

Of	O
these	O
,	O
1	O
,	O
130	O
genes	B-SO
possessed	O
at	O
least	O
one	O
significant	O
eQTL	O
.	O

(	O
C	O
)	O
Distribution	O
of	O
1	O
,	O
478	O
eQTLs	O
significantly	O
correlated	O
with	O
gonadal	O
fat	O
mass	O
across	O
the	O
genome	B-SO
in	O
2	O
-	O
cM	O
bins	O
.	O

(	O
D	O
)	O
Identification	O
of	O
genomic	B-SO
regions	I-SO
enriched	O
for	O
eQTLs	O
correlated	O
with	O
gonadal	O
fat	O
mass	O
.	O

The	O
x	O
-	O
axis	O
represents	O
genome	B-SO
position	B-SO
in	O
2	O
-	O
cM	O
bins	O
,	O
and	O
the	O
y	O
-	O
axis	O
represents	O
the	O
-	O
log10	O
Fisher	O
exact	O
test	O
p	O
-	O
value	O
for	O
enrichment	O
of	O
eQTLs	O
in	O
overlapping	B-SO
6	O
-	O
cM	O
bins	O
.	O

The	O
dashed	O
line	O
corresponds	O
to	O
p	O
=	O
0	O
.	O
05	O
after	O
correction	O
for	O
multiple	O
comparisons	O
.	O

One	O
significantly	O
enriched	O
region	B-SO
on	I-SO
Chromosome	I-SO
19	O
is	O
shown	O
.	O

The	O
Chromosome	B-GO
19	O
(	O
40	O
-	O
cM	O
)	O
hotspot	O
is	O
coincident	O
with	O
a	O
cQTL	O
for	O
gonadal	O
fat	O
mass	O
and	O
is	O
highlighted	O
in	O
red	O
.	O

Figure	O
6	O

The	O
Effects	O
of	O
Sex	O
on	O
Trans	O
-	O
eQTL	O
Correlated	O
with	O
Gonadal	O
Fat	O
Mass	O

(	O
A	O
)	O
Example	O
of	O
the	O
effect	O
of	O
genotype	B-SO
at	O
a	O
trans	O
locus	B-SO
on	O
gene	B-SO
expression	O
.	O

Presence	O
of	O
homozygous	O
B6	O
(	O
BB	O
)	O
,	O
C3H	O
(	O
CC	O
)	O
,	O
or	O
heterozygous	O
(	O
BC	O
)	O
genotype	B-SO
at	O
a	O
trans	O
locus	B-SO
affects	O
transcript	B-SO
MMT00016118	O
levels	O
(	O
reported	O
as	O
mlratio	O
)	O
in	O
a	O
sex	O
-	O
specific	O
manner	O
,	O
with	O
effects	O
detectable	O
only	O
in	O
females	O
.	O

Coefficients	O
of	O
determination	O
(	O
R2	O
,	O
or	O
proportion	O
variance	O
explained	O
)	O
are	O
shown	O
along	O
with	O
associated	O
ANOVA	O
p	O
-	O
values	O
.	O

Several	O
trans	O
-	O
eQTLs	O
correlated	O
with	O
gonadal	O
fat	O
mass	O
localize	O
to	O
regions	B-SO
overlapping	B-SO
with	O
cQTLs	O
for	O
this	O
trait	O
,	O
specifically	O
,	O
to	O
Chromosome	B-GO
19	O
,	O
40	O
cM	O
.	O

(	O
B	O
)	O
For	O
Chromosome	B-GO
19	O
,	O
the	O
vast	O
majority	O
of	O
these	O
correlated	O
trans	O
-	O
eQTLs	O
are	O
biased	O
toward	O
larger	O
effects	O
on	O
gene	B-SO
expression	O
in	O
females	O
(	O
red	O
lines	O
)	O
.	O

The	O
effect	O
of	O
any	O
given	O
trans	O
-	O
eQTL	O
is	O
approximated	O
as	O
R2	O
determined	O
in	O
a	O
manner	O
similar	O
to	O
that	O
depicted	O
in	O
(	O
A	O
)	O
.	O

Table	O
1	O

Characteristics	O
of	O
the	O
BXH	O
.	O
ApoE	B-GGP
-	O
/	O
-	O
Cross	O

Table	O
2	O

cQTLs	O
for	O
Gonadal	O
Fat	O
Mass	O

Table	O
3	O

Characteristics	O
of	O
Liver	O
eQTLs	O

Table	O
4	O

Properties	B-SO
of	O
Genes	B-SO
Coincident	O
with	O
the	O
Gonadal	O
Fat	O
Mass	O
cQTL	O

Table	O
5	O

Transcripts	B-SO
Coincident	O
with	O
cQTLs	O
with	O
Significant	O
Sex	O
Effects	O
and	O
Correlated	O
with	O
Gonadal	O
Fat	O
Mass	O
Are	O
Strong	O
Candidate	O
Genes	B-SO
for	O
the	O
Trait	O

Footnotes	O

Author	O
contributions	O
.	O

SW	O
,	O
TAD	O
,	O
and	O
AJL	O
conceived	O
and	O
designed	O
the	O
experiments	O
.	O

SW	O
,	O
NY	O
,	O
and	O
EES	O
performed	O
the	O
experiments	O
.	O

SW	O
,	O
NY	O
,	O
HW	O
,	O
and	O
TAD	O
analyzed	O
the	O
data	O
.	O

EES	O
and	O
HW	O
contributed	O
reagents	B-CHEBI
/	O
materials	O
/	O
analysis	O
tools	O
.	O

HW	O
designed	O
script	O
and	O
code	O
to	O
analyze	O
data	O
.	O

SW	O
,	O
NY	O
,	O
EES	O
,	O
TAD	O
,	O
and	O
AJL	O
wrote	O
the	O
paper	O
.	O

Funding	O
.	O

Work	O
was	O
supported	O
in	O
part	O
by	O
National	O
Institutes	O
of	O
Health	O
grants	O
HL	O
-	O
30568	O
and	O
HL	O
-	O
28481	O
to	O
AJL	O
,	O
Public	O
Health	O
Services	O
Training	O
Grant	O
HD07228	O
-	O
24	O
to	O
SW	O
,	O
the	O
Iris	O
Cantor	O
-	O
UCLA	O
Women	O
'	O
s	O
Health	O
Center	O
,	O
UCLA	O
National	O
Center	O
for	O
Excellence	O
in	O
Women	O
'	O
s	O
Health	O
Grant	O
to	O
TAD	O
,	O
and	O
by	O
an	O
American	O
Heart	O
Association	O
Medical	O
Student	O
Research	O
Grant	O
to	O
NY	O
.	O

Competing	O
interests	O
.	O

The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Citation	O
:	O
Wang	O
S	O
,	O
Yehya	O
N	O
,	O
Schadt	O
EE	O
,	O
Wang	O
H	O
,	O
Drake	O
TA	O
,	O
et	O
al	O
.	O

(	O
2006	O
)	O
Genetic	B-SO
and	O
genomic	B-SO
analysis	O
of	O
a	O
fat	O
mass	O
trait	O
with	O
complex	O
inheritance	O
reveals	O
marked	O
sex	O
specificity	O
.	O

PLoS	O
Genet	O
2	O
(	O
2	O
)	O
:	O
e15	O
.	O

Identification	O
and	O
targeted	O
disruption	O
of	O
the	O
mouse	B-Taxon
gene	B-SO
encoding	O
ESG1	B-GGP
(	O
PH34	B-GGP
/	O
ECAT2	B-GGP
/	O
DPPA5	B-GGP
)	O

Abstract	O

Background	O

Embryonic	B-GGP
stem	I-GGP
cell	I-GGP
-	I-GGP
specific	I-GGP
gene	I-GGP
(	I-GGP
ESG	I-GGP
)	I-GGP
1	I-GGP
,	O
which	O
encodes	O
a	O
KH	O
-	O
domain	B-SO
containing	O
protein	B-CHEBI
,	O
is	O
specifically	O
expressed	O
in	O
early	O
embryos	O
,	O
germ	B-CL
cells	I-CL
,	O
and	O
embryonic	O
stem	B-CL
(	I-CL
ES	I-CL
)	I-CL
cells	I-CL
.	O

Previous	O
studies	O
identified	O
genomic	B-SO
clones	I-SO
containing	O
the	O
mouse	B-GGP
ESG1	I-GGP
gene	B-SO
and	O
five	O
pseudogenes	B-SO
.	O

However	O
,	O
their	O
chromosomal	B-SO
localizations	I-SO
or	O
physiological	O
functions	O
have	O
not	O
been	O
determined	O
.	O

Results	O

A	O
Blast	O
search	O
of	O
mouse	B-Taxon
genomic	B-SO
databases	O
failed	O
to	O
locate	O
the	O
ESG1	B-GGP
gene	B-SO
.	O

We	O
identified	O
several	O
bacterial	B-SO
artificial	I-SO
clones	I-SO
containing	O
the	O
mouse	B-GGP
ESG1	I-GGP
gene	B-SO
and	O
an	O
additional	O
ESG1	B-GGP
-	O
like	O
sequence	B-SO
with	O
a	O
similar	O
gene	B-SO
structure	O
from	O
chromosome	B-GO
9	O
.	O

The	O
ESG1	B-GGP
-	O
like	O
sequence	B-SO
contained	O
a	O
multiple	O
critical	O
mutations	B-SO
,	O
indicating	O
that	O
it	O
was	O
a	O
duplicated	O
pseudogene	B-SO
.	O

The	O
5	B-SO
'	I-SO
flanking	I-SO
region	I-SO
of	O
the	O
ESG1	B-GGP
gene	B-SO
,	O
but	O
not	O
that	O
of	O
the	O
pseudogene	B-SO
,	O
exhibited	O
strong	O
enhancer	B-SO
and	O
promoter	B-SO
activity	O
in	O
undifferentiated	O
ES	O
cells	B-CL
by	O
luciferase	O
reporter	O
assay	O
.	O

To	O
study	O
the	O
physiological	O
functions	O
of	O
the	O
ESG1	B-GGP
gene	B-SO
,	O
we	O
replaced	B-SO
this	O
sequence	B-SO
in	O
ES	O
cells	B-CL
with	O
a	O
beta	O
-	O
geo	O
cassette	B-SO
by	O
homologous	O
recombination	O
.	O

Despite	O
specific	O
expression	O
in	O
early	O
embryos	O
and	O
germ	B-CL
cells	I-CL
,	O
ESG1	B-GGP
-	O
/	O
-	O
mice	B-Taxon
developed	O
normally	O
and	O
were	O
fertile	O
.	O

We	O
also	O
generated	O
ESG1	B-GGP
-	O
/	O
-	O
ES	O
cells	B-CL
both	O
by	O
a	O
second	O
independent	O
homologous	O
recombination	O
and	O
directly	O
from	O
blastocysts	O
derived	O
from	O
heterozygous	O
intercrosses	O
.	O

Northern	O
blot	O
and	O
western	O
blot	O
analyses	O
confirmed	O
the	O
absence	O
of	O
ESG1	B-GGP
in	O
these	O
cells	B-CL
.	O

These	O
ES	O
cells	B-CL
demonstrated	O
normal	O
morphology	O
,	O
proliferation	O
,	O
and	O
differentiation	O
.	O

Conclusion	O

The	O
mouse	B-GGP
ESG1	I-GGP
gene	B-SO
,	O
together	O
with	O
a	O
duplicated	O
pseudogene	B-SO
,	O
is	O
located	O
on	O
chromosome	B-GO
9	O
.	O

Despite	O
its	O
specific	O
expression	O
in	O
pluripotent	O
cells	B-CL
and	O
germ	B-CL
cells	I-CL
,	O
ESG1	B-GGP
is	O
dispensable	O
for	O
self	O
-	O
renewal	O
of	O
ES	O
cells	B-CL
and	O
establishment	O
of	O
germcells	B-CL
.	O

Background	O

Embryonic	O
stem	B-CL
(	I-CL
ES	I-CL
)	I-CL
cells	I-CL
were	O
first	O
derived	O
from	O
the	O
blastocysts	O
of	O
mice	B-Taxon
in	O
1981	O
[	O
1	O
,	O
2	O
]	O
and	O
humans	B-Taxon
in	O
1998	O
[	O
3	O
]	O
.	O

ES	O
cells	B-CL
have	O
two	O
important	O
properties	O
:	O
theability	O
to	O
maintain	O
pluripotency	O
,	O
which	O
is	O
the	O
ability	O
to	O
differentiate	O
into	O
a	O
wide	O
variety	O
of	O
cells	B-CL
,	O
and	O
rapid	O
proliferation	O
.	O

These	O
characteristics	O
make	O
mouse	B-Taxon
ES	O
cells	B-CL
an	O
essential	O
component	O
of	O
gene	B-SO
targeting	O
technology	O
.	O

These	O
qualitiesalso	O
make	O
human	B-Taxon
ES	O
cells	B-CL
attractive	O
sources	O
for	O
cell	B-CL
transplantation	O
therapy	O
to	O
treat	O
various	O
diseases	O
,	O
including	O
spinal	O
cord	O
injuries	O
and	O
juvenile	O
diabetes	O
.	O

The	O
molecular	B-CHEBI
mechanisms	O
underlying	O
the	O
pluripotency	O
and	O
rapid	O
proliferation	O
of	O
ES	O
cells	B-CL
are	O
currently	O
a	O
major	O
focus	O
of	O
the	O
field	O
of	O
stem	B-CL
cell	I-CL
biology	O
[	O
4	O
-	O
6	O
]	O
.	O

To	O
identify	O
molecules	B-CHEBI
essential	O
in	O
ES	O
cells	B-CL
for	O
these	O
properties	O
,	O
several	O
groups	O
have	O
utilized	O
transcriptome	O
analyses	O
to	O
identify	O
genes	B-SO
specifically	O
expressed	O
in	O
ES	O
cells	B-CL
and	O
early	O
embryos	O
.	O

These	O
analyses	O
,	O
including	O
DNA	B-SO
microarray	O
analyses	O
[	O
7	O
]	O
and	O
expressed	B-SO
sequence	I-SO
tag	I-SO
analyses	O
[	O
8	O
-	O
12	O
]	O
,	O
identified	O
several	O
common	O
transcripts	B-SO
,	O
including	O
ESG1	B-GGP
that	O
was	O
also	O
designated	O
dppa5	B-GGP
or	O
ECAT2	B-GGP
.	O

ESG1	B-GGP
was	O
originally	O
identified	O
as	O
a	O
transcript	B-SO
Ph34	B-GGP
that	O
was	O
down	O
-	O
regulated	O
by	O
retinoic	B-CHEBI
acid	I-CHEBI
in	O
embryonic	O
carcinoma	O
cells	B-CL
[	O
13	O
]	O
.	O

The	O
expression	O
of	O
this	O
gene	B-SO
was	O
confined	O
in	O
mice	B-Taxon
to	O
early	O
embryos	O
and	O
germ	B-CL
cells	I-CL
[	O
14	O
]	O
.	O

It	O
is	O
also	O
expressed	O
in	O
pluripotent	O
cells	B-CL
,	O
including	O
ES	O
cells	B-CL
,	O
embryonic	O
germ	B-CL
cells	I-CL
,	O
and	O
multipotent	B-CL
germline	I-CL
stem	I-CL
cells	I-CL
[	O
15	O
]	O
.	O

ESG1	B-GGP
encodes	O
a	O
polypeptide	B-SO
of	O
118	O
amino	B-CHEBI
acids	I-CHEBI
that	O
contains	O
a	O
single	O
KH	O
domain	B-SO
,	O
which	O
is	O
an	O
RNA	B-SO
-	O
binding	O
domain	B-SO
[	O
16	O
]	O
.	O

It	O
remains	O
unclear	O
,	O
however	O
,	O
if	O
ESG1	B-GGP
functions	O
as	O
an	O
RNA	B-SO
-	O
binding	O
protein	B-CHEBI
or	O
the	O
roles	O
it	O
plays	O
in	O
ES	O
cells	B-CL
and	O
mice	B-Taxon
.	O

Previous	O
genomic	B-SO
library	O
screening	O
by	O
identified	O
genomic	B-SO
clones	I-SO
containing	O
the	O
mouse	B-GGP
ESG1	I-GGP
gene	B-SO
and	O
seven	O
pseudogenes	B-SO
[	O
17	O
]	O
.	O

Two	O
of	O
these	O
pseudogenes	B-SO
exhibit	O
a	O
similar	O
exon	B-SO
-	O
intron	B-SO
structure	O
as	O
the	O
ESG1	B-GGP
gene	B-SO
,	O
indicating	O
their	O
generation	O
by	O
gene	B-SO
duplication	O
.	O

The	O
five	O
remaining	O
pseudogenes	B-SO
did	O
not	O
contain	O
any	O
introns	B-SO
,	O
indicating	O
that	O
these	O
were	O
generated	O
by	O
retrotransposition	O
of	O
ESG1	B-GGP
transcripts	B-SO
.	O

The	O
chromosomal	B-SO
localizations	I-SO
of	O
the	O
mouse	B-GGP
ESG1	I-GGP
gene	B-SO
and	O
pseudogenes	B-SO
,	O
however	O
,	O
have	O
not	O
been	O
reported	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
structure	O
of	O
the	O
mouse	B-Taxon
gene	B-SO
encoding	O
this	O
protein	B-CHEBI
and	O
related	O
pseudogenes	B-SO
.	O

We	O
also	O
performed	O
gene	B-SO
targeting	O
to	O
determine	O
the	O
physiological	O
function	O
of	O
ESG1	B-GGP
.	O

Results	O
and	O
discussion	O

Chromosomal	B-SO
localization	I-SO
and	O
structures	O
of	O
mouse	B-GGP
ESG1	I-GGP
gene	B-SO
and	O
psedogenes	B-SO

To	O
determine	O
the	O
chromosomal	B-SO
localizations	I-SO
of	O
the	O
mouse	B-GGP
ESG1	I-GGP
gene	B-SO
and	O
pseudogenes	B-SO
,	O
we	O
performed	O
a	O
Blast	O
analysis	O
of	O
the	O
mouse	B-Taxon
genomic	B-SO
database	O
with	O
the	O
ESG1	B-GGP
cDNA	B-SO
sequence	I-SO
as	O
a	O
query	O
.	O

We	O
identified	O
several	O
putative	O
pseudogenes	B-SO
without	O
introns	B-SO
on	O
chromosomes	B-GO
1	O
,	O
5	O
,	O
11	O
,	O
12	O
,	O
14	O
,	O
16	O
,	O
17	O
,	O
and	O
X	O
(	O
Figure	O
1	O
)	O
.	O

In	O
addition	O
,	O
two	O
intron	B-SO
-	O
less	O
pseudogenes	B-SO
were	O
identified	O
in	O
DNA	B-SO
fragments	B-SO
for	O
which	O
the	O
chromosomal	B-SO
localization	I-SO
remained	O
unmapped	O
.	O

While	O
these	O
pseudodgenes	B-SO
have	O
significant	O
homology	B-SO
to	O
ESG1	B-GGP
cDNA	B-SO
,	O
they	O
could	O
not	O
produce	O
functional	O
proteins	B-CHEBI
,	O
because	O
of	O
critical	O
mutations	B-SO
.	O

This	O
result	O
suggests	O
that	O
there	O
are	O
a	O
larger	O
number	O
of	O
intron	B-SO
-	O
less	O
pseudogenes	B-SO
than	O
previously	O
anticipated	O
.	O

Existence	O
of	O
multiple	O
retropseudogenes	B-SO
is	O
a	O
hallmark	O
of	O
pluripotent	O
cell	B-CL
-	O
specific	O
genes	B-SO
[	O
18	O
]	O
.	O

Figure	O
1	O

ESG1pseudogenes	O
identified	O
by	O
a	O
Blast	O
search	O
of	O
mouse	B-Taxon
genomic	B-SO
databases	O
.	O

Substitution	B-SO
mutations	I-SO
are	O
indicated	O
by	O
black	O
lines	O
.	O

Intron	B-SO
-	O
like	O
gap	B-SO
sequences	B-SO
are	O
indicated	O
with	O
triangles	O
.	O

Chromosomal	B-SO
localizations	I-SO
are	O
shown	O
on	O
the	O
right	O
.	O

On	O
chromosome	B-GO
9	O
,	O
we	O
identified	O
a	O
DNA	B-SO
fragment	B-SO
similar	O
to	O
the	O
ESG1	B-GGP
gene	B-SO
that	O
included	O
two	O
putative	O
introns	B-SO
.	O

These	O
putative	O
first	O
and	O
second	O
exons	B-SO
,	O
however	O
,	O
contained	O
(	O
4	O
)	O
multiple	O
mutations	B-SO
of	O
the	O
ESG1	B-GGP
cDNA	B-SO
sequence	I-SO
.	O

The	O
putative	O
third	O
exon	B-SO
was	O
identical	O
to	O
that	O
of	O
the	O
previously	O
reported	O
ESG1	B-GGP
gene	B-SO
.	O

Also	O
on	O
chromosome	B-GO
9	O
,	O
we	O
identified	O
another	O
DNA	B-SO
fragment	B-SO
that	O
was	O
similar	O
,	O
but	O
not	O
identical	O
,	O
to	O
the	O
third	O
exon	B-SO
of	O
the	O
ESG1	B-GGP
gene	B-SO
.	O

These	O
findings	O
suggest	O
that	O
these	O
ESG1	B-GGP
-	O
like	O
sequences	B-SO
on	I-SO
chromosome	I-SO
9	O
have	O
not	O
been	O
correctly	O
assembled	O
.	O

To	O
obtain	O
DNA	B-SO
fragments	B-SO
containing	O
the	O
ESG1	B-GGP
gene	B-SO
,	O
we	O
screened	O
the	O
bacterial	B-SO
artificial	I-SO
chromosome	I-SO
(	O
BAC	B-SO
)	O
DNA	B-SO
pool	O
by	O
PCR	O
using	O
primer	B-SO
pairs	O
that	O
would	O
only	O
amplify	O
the	O
real	O
gene	B-SO
,	O
not	O
the	O
pseudogenes	B-SO
.	O

We	O
obtained	O
two	O
independent	O
,	O
but	O
overlapping	B-SO
BAC	B-SO
clones	B-SO
.	O

Southern	O
blot	O
analyses	O
and	O
sequencing	O
demonstrated	O
that	O
these	O
clones	B-SO
contained	O
a	O
sequence	B-SO
exhibiting	O
complete	O
identity	O
with	O
ESG1	B-GGP
cDNA	B-SO
that	O
was	O
interrupted	O
by	O
two	O
putative	O
introns	B-SO
(	O
Figure	O
2A	O
)	O
.	O

The	O
two	O
intron	B-SO
sequences	I-SO
begin	O
with	O
GT	O
and	O
terminate	O
with	O
AG	O
,	O
fulfilling	O
the	O
GT	O
-	O
AG	O
rule	O
of	O
exon	B-SO
-	I-SO
intron	I-SO
junctions	I-SO
[	O
19	O
]	O
.	O

The	O
5	B-SO
'	I-SO
flanking	I-SO
region	I-SO
of	O
this	O
DNA	B-SO
fragment	B-SO
exhibited	O
strong	O
promoter	B-SO
/	O
enhancer	B-SO
activity	O
by	O
luciferase	O
reporter	O
assays	O
in	O
undifferentiated	O
ES	O
cells	B-CL
,	O
but	O
not	O
in	O
somatic	O
cells	B-CL
(	O
Figure	O
3	O
)	O
.	O

The	O
same	O
fragment	B-SO
showed	O
much	O
weaker	O
activity	O
after	O
induction	O
of	O
differentiation	O
by	O
retinoic	B-CHEBI
acid	I-CHEBI
.	O

We	O
concluded	O
that	O
this	O
sequence	B-SO
is	O
the	O
ESG1	B-GGP
gene	B-SO
.	O

Figure	O
2	O

BAC	B-SO
clones	B-SO
containing	O
the	O
ESG1	B-GGP
gene	B-SO
and	O
a	O
duplication	B-SO
pseudogene	B-SO
(	O
PS	B-SO
)	O
.	O

A	O
)	O
Localization	B-SO
of	O
the	O
gene	B-SO
and	O
PS	B-SO
on	O
chromosome	B-GO
9	O
.	O

B	O
)	O
Sequence	B-SO
comparison	O
of	O
the	O
gene	B-SO
and	O
PS	B-SO
revealed	O
that	O
these	O
are	O
homologous	B-SO
from	O
eight	O
base	B-SO
pairs	I-SO
upstream	O
of	O
the	O
first	O
exon	B-SO
to	O
675	O
bp	B-SO
downstream	O
of	O
the	O
third	O
exon	B-SO
.	O

Substitution	B-SO
mutations	I-SO
are	O
indicated	O
by	O
black	O
lines	O
.	O

The	O
insertion	B-SO
is	O
indicated	O
by	O
an	O
open	O
triangle	O
.	O

Figure	O
3	O

Promoter	B-SO
/	O
enhancer	B-SO
activity	O
of	O
the	O
ESG1	B-GGP
gene	B-SO
and	O
pseudogene	B-SO
.	O

DNA	B-SO
fragments	B-SO
of	O
~	O
6	O
kbp	O
isolated	O
from	O
the	O
5	B-SO
'	I-SO
flanking	I-SO
regions	I-SO
of	O
the	O
gene	B-SO
and	O
PS	B-SO
were	O
transferred	B-SO
into	O
luciferase	O
reporter	O
plasmids	B-SO
.	O

We	O
introduced	O
the	O
reporter	O
genes	B-SO
into	O
undifferentiated	O
ES	O
cells	B-CL
(	O
open	O
columns	O
)	O
,	O
retinoic	B-CHEBI
acid	I-CHEBI
-	O
treated	O
ES	O
cells	B-CL
(	O
grey	O
columns	O
)	O
,	O
and	O
NIH3T3	O
cells	B-CL
(	O
closed	O
columns	O
)	O
.	O

Data	O
represent	O
the	O
averages	O
and	O
standard	O
deviations	O
of	O
three	O
independent	O
experiments	O
.	O

We	O
also	O
found	O
that	O
the	O
two	O
BAC	B-SO
clones	B-SO
contained	O
another	O
ESG1	B-GGP
-	O
like	O
sequence	B-SO
(	O
Figure	O
2A	O
)	O
.	O

The	O
two	O
sequences	B-SO
,	O
separated	O
by	O
a	O
68	O
kbp	O
intergenic	B-SO
sequence	I-SO
,	O
were	O
oriented	O
in	O
opposite	O
directions	O
.	O

The	O
ESG1	B-GGP
-	O
like	O
sequence	B-SO
exhibited	O
greater	O
than	O
95	O
%	O
identity	O
to	O
the	O
exons	B-SO
and	O
introns	B-SO
of	O
the	O
ESG1	B-GGP
gene	B-SO
.	O

This	O
sequence	B-SO
,	O
however	O
,	O
contained	O
critical	O
nucleotide	B-CHEBI
substitutions	B-SO
in	O
all	O
of	O
the	O
exons	B-SO
and	O
one	O
nucleotide	B-SO
insertion	I-SO
in	O
exon	B-SO
2	O
(	O
Figure	O
2B	O
)	O
.	O

Although	O
675	O
base	B-SO
pairs	I-SO
of	O
the	O
3	B-SO
'	I-SO
flanking	I-SO
regions	I-SO
were	O
conserved	B-SO
between	O
the	O
ESG1	B-GGP
gene	B-SO
and	O
the	O
pseudogene	B-SO
,	O
only	O
five	O
base	B-SO
pairs	I-SO
of	O
the	O
5	B-SO
'	I-SO
flanking	I-SO
region	I-SO
were	O
identical	O
.	O

This	O
5	B-SO
'	I-SO
flanking	I-SO
region	I-SO
(	O
~	O
6	O
kbp	O
)	O
did	O
not	O
possess	O
any	O
promoter	B-SO
/	O
enhancer	B-SO
activity	O
in	O
luciferase	O
reporter	O
assays	O
(	O
Figure	O
3	O
)	O
.	O

It	O
is	O
thus	O
unlikely	O
that	O
this	O
sequence	B-SO
is	O
transcribed	O
or	O
translated	O
into	O
a	O
functional	O
protein	B-CHEBI
.	O

This	O
sequence	B-SO
likely	O
represents	O
a	O
duplication	B-SO
pseudogene	B-SO
.	O

Bierbaum	O
previously	O
reported	O
the	O
existence	O
of	O
two	O
pseudogenes	B-SO
with	O
similar	O
exon	B-SO
-	O
intron	B-SO
organization	O
as	O
the	O
ESG1	B-GGP
gene	B-SO
[	O
17	O
]	O
.	O

We	O
could	O
not	O
determine	O
which	O
of	O
these	O
two	O
pseudogenes	B-SO
corresponds	O
to	O
the	O
one	O
we	O
identified	O
or	O
the	O
location	B-SO
of	O
the	O
remaining	O
pseudogene	B-SO
.	O

Targeted	O
disruption	O
of	O
the	O
mouse	B-GGP
ESG1	I-GGP
gene	B-SO

To	O
study	O
the	O
function	O
of	O
ESG1	B-GGP
,	O
we	O
deleted	B-SO
the	O
gene	B-SO
by	O
homologous	O
recombination	O
in	O
mouse	B-Taxon
ES	O
cells	B-CL
.	O

We	O
replaced	B-SO
the	O
three	O
exons	B-SO
with	O
either	O
a	O
fusion	B-SO
of	I-SO
the	I-SO
neomycin	I-SO
-	I-SO
resistance	I-SO
and	I-SO
beta	I-SO
-	I-SO
galactosidase	I-SO
genes	I-SO
(	O
beta	O
-	O
geo	O
)	O
or	O
the	O
hygromycin	B-CHEBI
resistant	O
gene	B-SO
(	O
HygR	O
)	O
using	O
two	O
targeting	O
vectors	B-SO
(	O
Figure	O
4A	O
)	O
introduced	O
into	O
RF8	O
ES	O
cells	B-CL
by	O
electroporation	O
.	O

We	O
obtained	O
eight	O
ES	O
cell	B-CL
clones	O
with	O
correct	O
homologous	O
recombination	O
of	O
the	O
beta	O
-	O
geo	O
targeting	O
vector	B-SO
,	O
which	O
was	O
confirmed	O
by	O
Southern	O
blot	O
analysis	O
(	O
Figure	O
4B	O
)	O
.	O

We	O
obtained	O
only	O
one	O
clone	O
with	O
correct	O
homologous	O
recombination	O
of	O
the	O
HygR	O
targeting	O
vector	B-SO
.	O

Figure	O
4	O

Targeted	O
disruption	O
of	O
the	O
mouse	B-GGP
ESG1	I-GGP
gene	B-SO
.	O

A	O
)	O
Targeting	O
strategy	O
.	O

Homologous	O
regions	O
are	O
indicated	O
by	O
thick	O
lines	O
.	O

Recognition	B-SO
sites	I-SO
of	O
PstI	O
(	O
P	O
)	O
and	O
SpeI	O
(	O
S	O
)	O
,	O
which	O
were	O
used	O
for	O
Southern	O
blot	O
analyses	O
,	O
are	O
shown	O
.	O

The	O
gene	B-SO
encoding	O
diphtheria	B-GGP
toxin	I-GGP
A	O
(	O
DTA	O
)	O
was	O
inserted	B-SO
at	O
the	O
3	O
'	O
end	O
of	O
the	O
targeting	O
vectors	B-SO
to	O
facilitate	O
negative	O
selection	O
.	O

B	O
)	O
Southern	O
blot	O
analyses	O
confirming	O
homologous	O
recombination	O
.	O

WT	B-SO
,	O
wild	B-SO
-	I-SO
type	I-SO
ES	O
cells	B-CL
;	O
beta	O
,	O
beta	O
-	O
geo	O
+	B-SO
/	O
-	O
ES	O
cells	B-CL
;	O
H	O
,	O
HygR	O
+	B-SO
/	O
-	O
ES	O
cells	B-CL
;	O
-	O
/	O
-	O
,	O
ESG1	B-GGP
-	O
null	O
ES	O
cells	B-CL
.	O

Numbers	O
indicate	O
clone	O
numbers	O
.	O

C	O
)	O
Northern	O
blot	O
(	O
upper	O
)	O
and	O
western	O
blot	O
(	O
lower	O
)	O
analyses	O
of	O
wild	B-SO
-	I-SO
type	I-SO
ES	O
cells	B-CL
(	O
WT	B-SO
)	O
,	O
ESG1	B-GGP
-	O
null	O
ES	O
cells	B-CL
(	O
-	O
/	O
-	O
,	O
three	O
clones	O
)	O
and	O
heterozygous	O
ES	O
cells	B-CL
(	O
+	B-SO
/	O
-	O
)	O
.	O

Northern	O
blot	O
was	O
performed	O
as	O
previously	O
described	O
[	O
20	O
]	O
.	O

To	O
confirm	O
the	O
loading	O
of	O
equal	O
amounts	O
of	O
RNA	B-SO
,	O
ethidium	B-CHEBI
bromide	I-CHEBI
staining	O
of	O
ribosomal	B-CHEBI
RNA	I-CHEBI
is	O
also	O
shown	O
(	O
middle	O
)	O
.	O

To	O
obtain	O
homozygous	O
mutant	B-SO
ES	O
cells	B-CL
,	O
we	O
introduced	O
the	O
beta	O
-	O
geo	O
vector	B-SO
into	O
HygR	O
heterozygous	O
ES	O
cells	B-CL
.	O

Of	O
105	O
G418	O
-	O
resistant	O
colonies	O
tested	O
,	O
49	O
were	O
homozygous	O
for	O
ESG1	B-GGP
deletion	B-SO
.	O

Northern	O
blot	O
and	O
western	O
blot	O
analyses	O
confirmed	O
the	O
absence	O
of	O
ESG1	B-GGP
in	O
these	O
cells	B-CL
(	O
Figure	O
4C	O
)	O
.	O

In	O
29	O
clones	O
,	O
the	O
beta	O
-	O
geo	O
vector	B-SO
had	O
replaced	B-SO
the	O
HygR	O
vector	B-SO
,	O
such	O
that	O
the	O
cells	B-CL
remained	O
heterozygous	O
.	O

In	O
the	O
remaining	O
27	O
clones	O
,	O
the	O
beta	O
-	O
geo	O
vector	B-SO
was	O
integrated	B-SO
at	O
non	O
-	O
homologous	O
sites	O
.	O

ESG1	B-GGP
-	O
/	O
-	O
ES	O
cells	B-CL
exhibited	O
normal	O
morphology	O
(	O
Figure	O
5A	O
)	O
.	O

These	O
cells	B-CL
also	O
proliferated	O
at	O
a	O
speed	O
comparable	O
to	O
that	O
of	O
the	O
control	O
(	O
heterozygous	O
and	O
wild	B-SO
-	I-SO
type	I-SO
)	O
cells	B-CL
(	O
Figure	O
5B	O
)	O
.	O

ESG1	B-GGP
-	O
/	O
-	O
cells	B-CL
differentiated	O
normally	O
after	O
the	O
removal	O
of	O
leukemia	B-GGP
inhibitory	I-GGP
factor	I-GGP
(	O
Figure	O
5B	O
)	O
or	O
retinoic	B-CHEBI
acid	I-CHEBI
treatment	O
(	O
not	O
shown	O
)	O
.	O

When	O
transplanted	O
into	O
hind	O
flanks	O
of	O
nude	O
mice	B-Taxon
,	O
these	O
cells	B-CL
produced	O
teratomas	O
,	O
tumors	O
containing	O
components	O
of	O
all	O
three	O
germ	O
layers	O
(	O
Figure	O
5C	O
)	O
.	O

These	O
results	O
indicate	O
that	O
ESG1	B-GGP
is	O
dispensable	O
for	O
the	O
self	O
-	O
renewal	O
properties	O
and	O
pluripotency	O
of	O
ES	O
cells	B-CL
.	O

Figure	O
5	O

Analyses	O
of	O
ESG1	B-GGP
-	O
null	O
ES	O
cells	B-CL
.	O

A	O
)	O
The	O
morphology	O
of	O
ESG1	B-GGP
-	O
null	O
ES	O
cell	B-CL
colonies	O
grown	O
on	O
STO	O
feeder	O
cells	B-CL
.	O

B	O
)	O
Growth	O
curve	O
of	O
wild	B-SO
-	I-SO
type	I-SO
(	O
WT	B-SO
)	O
,	O
ESG1	B-GGP
-	O
null	O
(	O
-	O
/	O
-	O
)	O
and	O
heterozygous	O
(	O
+	B-SO
/	O
-	O
)	O
ES	O
cells	B-CL
.	O

Each	O
clone	O
(	O
1	O
x	O
104	O
cells	B-CL
/	O
well	O
)	O
was	O
plated	O
in	O
24	O
-	O
well	O
plates	O
.	O

Cell	B-CL
numbers	O
were	O
determined	O
with	O
a	O
Coulter	O
counter	O
at	O
2	O
,	O
4	O
,	O
and	O
6	O
days	O
.	O

Data	O
of	O
+	B-SO
/	O
-	O
and	O
-	O
/	O
-	O
cells	B-CL
are	O
shown	O
as	O
averages	O
and	O
standard	O
deviations	O
of	O
three	O
independent	O
clones	O
.	O

C	O
)	O
A	O
section	O
of	O
teratoma	O
derived	O
from	O
ESG1	B-GGP
-	O
null	O
ES	O
cells	B-CL
(	O
hematoxylin	O
&	O
eosin	O
staining	O
)	O
.	O

We	O
examined	O
the	O
gene	B-SO
expression	O
profiles	O
of	O
ESG1	B-GGP
-	O
/	O
-	O
ES	O
cells	B-CL
using	O
oligonucleotide	B-SO
-	O
based	O
DNA	B-SO
microarrays	O
representing	O
~	O
20	O
,	O
000	O
genes	B-SO
.	O

In	O
comparison	O
to	O
control	O
ES	O
cells	B-CL
,	O
ESG1	B-GGP
was	O
identified	O
as	O
the	O
gene	B-SO
reduced	O
to	O
the	O
greatest	O
extent	O
in	O
ESG1	B-GGP
-	O
/	O
-	O
ES	O
cells	B-CL
(	O
Figure	O
6A	O
)	O
.	O

The	O
expression	O
of	O
ES	O
cell	B-CL
marker	O
genes	B-SO
,	O
such	O
as	O
Nanog	B-GGP
and	O
Oct3	B-GGP
/	I-GGP
4	I-GGP
,	O
was	O
normal	O
in	O
ESG1	B-GGP
-	O
/	O
-	O
ES	O
cells	B-CL
.	O

We	O
confirmed	O
normal	O
Oct3	B-GGP
/	I-GGP
4	I-GGP
expression	O
at	O
protein	B-CHEBI
levels	O
by	O
Western	O
blot	O
(	O
Figure	O
6B	O
)	O
.	O

The	O
overall	O
gene	B-SO
expression	O
profiles	O
were	O
similar	O
between	O
control	O
ES	O
cells	B-CL
and	O
ESG1	B-GGP
-	O
/	O
-	O
ES	O
cells	B-CL
.	O

Several	O
genes	B-SO
exhibited	O
a	O
greater	O
than	O
two	O
-	O
fold	O
reduction	O
in	O
ESG1	B-GGP
-	O
/	O
-	O
cells	B-CL
,	O
including	O
Krt1	B-GGP
-	O
8	O
,	O
Pem	B-GGP
,	O
Ctgf	B-GGP
,	O
Ptgs2	B-GGP
,	O
Igf2	B-GGP
and	O
Inhba	B-GGP
.	O

These	O
genes	B-SO
might	O
be	O
regulated	O
directly	O
or	O
indirectly	O
by	O
ESG1	B-GGP
.	O

Since	O
ESG1	B-GGP
contains	O
a	O
KH	O
-	O
type	O
RNA	B-SO
-	O
binding	O
domain	B-SO
,	O
it	O
may	O
stabilize	O
mRNA	B-CHEBI
of	O
these	O
genes	B-SO
.	O

Further	O
studied	O
are	O
required	O
to	O
clarify	O
this	O
possibility	O
.	O

Figure	O
6	O

Gene	B-SO
expression	O
analyses	O
of	O
ESG1	B-GGP
-	O
null	O
ES	O
cells	B-CL
.	O

A	O
)	O
DNA	B-SO
microarray	O
analyses	O
.	O

Total	O
RNA	B-SO
from	O
wild	B-SO
-	I-SO
type	I-SO
ES	O
cells	B-CL
and	O
ESG1	B-GGP
-	O
null	O
ES	O
cells	B-CL
were	O
labeled	O
with	O
Cy3	O
and	O
Cy5	O
,	O
respectively	O
.	O

Samples	O
were	O
hybridized	O
to	O
Agilent	O
Mouse	B-Taxon
Developmental	O
Microarrays	O
.	O

The	O
averages	O
of	O
two	O
independent	O
clones	O
are	O
shown	O
.	O

B	O
)	O
Western	O
blot	O
analyses	O
.	O

Cell	B-CL
lysates	O
from	O
ESG1	B-GGP
+	B-SO
/	O
-	O
and	O
ESG1	B-GGP
-	O
/	O
-	O
cells	B-CL
were	O
examined	O
for	O
expression	O
of	O
ESG1	B-GGP
,	O
Oct3	B-GGP
/	I-GGP
4	I-GGP
and	O
CDK4	B-GGP
with	O
immunoblotting	O
.	O

To	O
generate	O
ESG1	B-GGP
-	O
knockout	O
mice	B-Taxon
,	O
we	O
injected	O
beta	O
-	O
geo	O
-	O
ESG1	B-GGP
+	B-SO
/	O
-	O
ES	O
cell	B-CL
clones	O
into	O
the	O
blastocysts	O
of	O
C57BL6	O
mice	B-Taxon
.	O

We	O
obtained	O
germline	O
transmission	O
from	O
three	O
clones	O
.	O

We	O
obtained	O
ESG1	B-GGP
-	O
/	O
-	O
mice	B-Taxon
at	O
the	O
Mendelian	O
ratios	O
(	O
36	O
wild	B-SO
-	I-SO
type	I-SO
,	O
69	O
ESG1	B-GGP
+	B-SO
/	O
-	O
,	O
and	O
45	O
ESG1	B-GGP
-	O
/	O
-	O
)	O
from	O
intercrosses	O
of	O
ESG1	B-GGP
+	B-SO
/	O
-	O
mice	B-Taxon
.	O

These	O
animals	B-Taxon
exhibited	O
normal	O
development	O
,	O
gross	O
appearance	O
,	O
and	O
fertility	O
(	O
not	O
shown	O
)	O
.	O

Histological	O
examination	O
of	O
testis	O
and	O
ovary	O
could	O
not	O
identify	O
any	O
abnormalities	O
(	O
not	O
shown	O
)	O
.	O

These	O
data	O
demonstrated	O
that	O
ESG1	B-GGP
is	O
dispensable	O
for	O
both	O
mouse	B-Taxon
development	O
and	O
germ	B-CL
cell	I-CL
formation	O
.	O

We	O
also	O
generated	O
ES	O
cells	B-CL
from	O
blastocysts	O
obtained	O
by	O
intercrosses	O
of	O
ESG1	B-GGP
+	B-SO
/	O
-	O
males	O
and	O
ESG1	B-GGP
-	O
/	O
-	O
females	O
.	O

Of	O
the	O
eight	O
ES	O
cell	B-CL
lines	O
established	O
,	O
two	O
clones	O
were	O
ESG1	B-GGP
-	O
/	O
-	O
.	O

These	O
ESG1	B-GGP
-	O
null	O
ES	O
cells	B-CL
demonstrated	O
normal	O
morphology	O
,	O
proliferation	O
,	O
and	O
differentiation	O
(	O
not	O
shown	O
)	O
,	O
confirming	O
that	O
ESG1	B-GGP
is	O
dispensable	O
in	O
ES	O
cells	B-CL
.	O

Conclusion	O

To	O
analyze	O
the	O
physiological	O
roles	O
of	O
ESG1	B-GGP
,	O
we	O
identified	O
the	O
mouse	B-Taxon
gene	B-SO
on	O
chromosome	B-GO
9	O
and	O
deleted	B-SO
it	O
by	O
homologous	O
recombination	O
in	O
ES	O
cells	B-CL
.	O

Despite	O
specific	O
expression	O
in	O
early	O
embryos	O
,	O
germ	B-CL
cells	I-CL
,	O
and	O
pluripotent	O
cells	B-CL
,	O
our	O
data	O
demonstrated	O
that	O
ESG1	B-GGP
is	O
dispensable	O
for	O
mouse	B-Taxon
development	O
,	O
germ	B-CL
cell	I-CL
formation	O
,	O
and	O
ES	O
cell	B-CL
self	O
-	O
renewal	O
.	O

Methods	O

Identification	O
and	O
analyses	O
of	O
BAC	B-SO
clones	B-SO
containing	O
the	O
mouse	B-GGP
ESG1	I-GGP
gene	B-SO

To	O
identify	O
bacterial	B-SO
artificial	I-SO
chromosome	I-SO
(	O
BAC	B-SO
)	O
clones	B-SO
containing	O
mouse	B-GGP
ESG1	I-GGP
gene	B-SO
,	O
we	O
performed	O
PCR	O
-	O
based	O
screening	O
of	O
mouse	B-Taxon
BAC	B-SO
library	O
DNA	B-SO
pools	O
(	O
Research	O
Genetics	O
)	O
using	O
the	O
pH34	B-GGP
-	O
u38	O
(	O
5	O
'	O
-	O
GAAGTCTGGTTCCTTGGCAGG	O
-	O
3	O
'	O
)	O
and	O
pH34	B-GGP
-	O
L394	O
(	O
5	O
'	O
-	O
ACTCGATACACTGGCCTAGC	O
-	O
3	O
'	O
)	O
primers	B-SO
.	O

Following	O
restriction	O
enzyme	B-SO
digestion	O
,	O
we	O
performed	O
Southern	O
blot	O
analyses	O
of	O
BAC	B-SO
clones	B-SO
as	O
described	O
[	O
20	O
]	O
using	O
the	O
pH34	B-GGP
-	O
U258	O
(	O
5	O
'	O
-	O
CTCGAGTGTACAGTCAAGTGGTTGCTGGGA	O
-	O
3	O
'	O
)	O
,	O
pH34	B-GGP
-	O
U65	O
(	O
5	O
'	O
-	O
GTGACCCTCGTGACCCGTAA	O
-	O
3	O
'	O
)	O
,	O
pH34	B-GGP
-	O
intron1L	O
(	O
5	O
'	O
-	O
CTGCGTGAGAGAAACACCAAACAGGC	O
-	O
3	O
'	O
)	O
,	O
pH34	B-GGP
-	O
L545	O
(	O
5	O
'	O
-	O
TGTGAATGGGAAGGTTACCACTCT	O
-	O
3	O
'	O
)	O
and	O
pH34	B-GGP
-	O
SCL1	O
(	O
5	O
'	O
-	O
GCCCTCTTCTGGTTTGTCTCGAAAT	O
-	O
3	O
'	O
)	O
probes	B-SO
.	O

Hybridization	O
with	O
these	O
probes	B-SO
revealed	O
bands	O
containing	O
either	O
the	O
ESG1	B-GGP
gene	B-SO
or	O
pseudogenes	B-SO
.	O

To	O
sequence	O
the	O
region	B-SO
containing	O
the	O
mouse	B-GGP
ESG1	I-GGP
gene	B-SO
and	O
the	O
3	B-SO
'	I-SO
flanking	I-SO
region	I-SO
,	O
we	O
subcloned	O
a	O
~	O
15	O
kbp	O
XhoI	O
-	O
SalI	O
fragment	B-SO
into	O
the	O
pZERO	O
-	O
2	O
vector	B-SO
(	O
Invitrogen	O
)	O
.	O

HindIII	O
-	O
or	O
EcoRI	O
-	O
digested	O
fragments	B-SO
of	O
this	O
vector	B-SO
were	O
then	O
cloned	O
into	O
pBluescript	O
KS	O
(	O
-	O
)	O
for	O
sequencing	O
.	O

To	O
sequence	O
the	O
ESG1	B-GGP
pseudogene	B-SO
and	O
the	O
3	B-SO
'	I-SO
flanking	I-SO
region	I-SO
,	O
an	O
8	O
kbp	O
NotI	O
/	O
XhoI	O
fragment	B-SO
was	O
cloned	O
into	O
pBluescript	O
KS	O
(	O
-	O
)	O
.	O

BamHI	O
-	O
or	O
PstI	O
-	O
fragments	B-SO
of	O
this	O
vector	B-SO
were	O
also	O
cloned	O
into	O
pBluescript	O
KS	O
(	O
-	O
)	O
.	O

To	O
identify	O
the	O
sequence	B-SO
containing	O
the	O
5	B-SO
'	I-SO
flanking	I-SO
regions	I-SO
of	O
the	O
ESG1	B-GGP
gene	B-SO
and	O
the	O
related	O
pseudogenes	B-SO
,	O
we	O
used	O
a	O
TOPO	O
walker	O
kit	O
(	O
Invitrogen	O
)	O
with	O
the	O
pH34	B-GGP
-	O
T2L	O
(	O
5	O
'	O
-	O
ACTAGTCGCAGCAGGGATCCAGGAATATCT	O
-	O
3	O
'	O
)	O
and	O
pH34	B-GGP
-	O
L394	O
primers	B-SO
.	O

The	O
resulting	O
sequence	B-SO
was	O
cloned	O
into	O
pCR2	O
.	O
1	O
(	O
Invitrogen	O
)	O
.	O

We	O
obtained	O
a	O
~	O
6	O
kbp	O
band	O
from	O
the	O
NsiI	O
-	O
digensted	O
library	O
;	O
XbaI	O
-	O
,	O
SpeI	O
-	O
,	O
EcoRI	O
-	O
,	O
and	O
PstI	O
-	O
digested	O
fragments	B-SO
of	O
this	O
band	O
were	O
cloned	O
into	O
pBluescript	O
KS	O
(	O
-	O
)	O
for	O
sequencing	O
.	O

This	O
fragment	B-SO
contained	O
the	O
5	B-SO
'	I-SO
flanking	I-SO
region	I-SO
of	O
the	O
ESG1	B-GGP
gene	B-SO
.	O

A	O
~	O
3	O
kbp	O
fragment	B-SO
,	O
obtained	O
from	O
the	O
SacI	O
-	O
digested	O
library	O
,	O
was	O
cloned	O
into	O
pCR2	O
.	O
1	O
for	O
sequencing	O
.	O

This	O
fragment	B-SO
was	O
contained	O
the	O
5	O
'	O
region	B-SO
flanking	O
the	O
pseudogene	B-SO
.	O

Construction	O
of	O
ESG1	B-GGP
targeting	O
vectors	B-SO

We	O
replaced	B-SO
all	O
of	O
the	O
ESG1	B-GGP
exons	B-SO
with	O
two	O
targeting	O
vectors	B-SO
containing	O
either	O
an	O
IRES	B-SO
-	O
beta	O
-	O
geo	O
cassette	B-SO
[	O
21	O
]	O
or	O
an	O
IRES	B-SO
-	O
HygR	O
cassette	B-SO
by	O
promoter	B-SO
trap	O
selection	O
.	O

We	O
amplified	O
the	O
5	O
'	O
arm	O
(	O
1	O
.	O
8	O
kbp	O
)	O
using	O
KOD	O
plus	O
(	O
TOYOBO	O
)	O
with	O
the	O
pH34	B-GGP
-	O
targetpair5	O
-	O
U	O
(	O
5	O
'	O
-	O
CCGCGGAAAGTCAAGAGATTGGGTGG	O
-	O
3	O
'	O
)	O
and	O
pH34	B-GGP
-	O
targetpair5	O
-	O
L	O
(	O
5	O
'	O
-	O
GCGGCCGCCTTTACGGGTCACGAGGGTCAC	O
-	O
3	O
'	O
)	O
primers	B-SO
.	O

The	O
3	O
'	O
arm	O
(	O
5	O
.	O
8	O
kbp	O
)	O
was	O
amplified	O
using	O
the	O
pH34	B-GGP
-	O
targetpair3	O
-	O
U	O
(	O
5	O
'	O
-	O
TGTGGCCAGTGTTTGGTTCTGGCGGG	O
-	O
3	O
'	O
)	O
and	O
pH34	B-GGP
-	O
targetpair3	O
-	O
L	O
(	O
5	O
'	O
-	O
CTCGAGGACTCGCCATTCTAGCCAAG	O
-	O
3	O
'	O
)	O
primers	B-SO
.	O

The	O
IRES	B-SO
beta	O
-	O
geo	O
or	O
IRES	B-SO
HygR	O
cassettes	B-SO
were	O
ligated	O
in	O
between	O
the	O
two	O
PCR	O
fragments	B-SO
.	O

The	O
diphtheria	B-GGP
toxin	I-GGP
A	O
cassette	B-SO
was	O
placed	O
downstream	O
of	O
the	O
3	O
'	O
arm	O
.	O

After	O
linearization	O
with	O
SacII	O
,	O
these	O
targeting	O
vectors	B-SO
were	O
electroporated	O
into	O
2	O
.	O
0	O
x	O
107	O
RF8	O
ES	O
cells	B-CL
[	O
22	O
]	O
using	O
a	O
Gene	B-SO
pulser	O
(	O
BIORAD	O
)	O
.	O

Transfected	O
cells	B-CL
were	O
selected	O
with	O
250	O
mu	O
g	O
/	O
mL	O
G418	O
or	O
100	O
mu	O
g	O
/	O
mL	O
hygromycin	B-CHEBI
B	I-CHEBI
,	O
respectively	O
.	O

Genomic	B-SO
DNA	I-SO
from	O
G418	O
-	O
or	O
hygromycin	B-CHEBI
B	I-CHEBI
-	O
resistant	O
colonies	O
was	O
screened	O
for	O
homologous	O
recombination	O
by	O
Southern	O
blotting	O
.	O

Southern	O
blot	O
screening	O
for	O
homologous	O
recombination	O

ES	O
cells	B-CL
genomic	B-SO
DNA	I-SO
was	O
extracted	O
with	O
PUREGENE	O
(TM)	O
Cell	B-CL
Lysis	O
Solution	O
(	O
Gentra	O
systems	O
)	O
.	O

For	O
5	O
'	O
Southern	O
blot	O
analysis	O
,	O
genomic	B-SO
DNA	I-SO
was	O
first	O
digested	O
with	O
PstI	O
,	O
then	O
separated	O
on	O
an	O
0	O
.	O
8	O
%	O
agarose	B-CHEBI
gel	O
and	O
transferred	O
to	O
a	O
nylon	B-CHEBI
membrane	O
as	O
described	O
[	O
20	O
]	O
.	O

A	O
560	O
bp	B-SO
5	O
'	O
probe	B-SO
was	O
amplified	O
using	O
the	O
ESG1S5	O
(	O
5	O
'	O
-	O
GATGGTGGTGGTGACTCAGAG	O
-	O
3	O
'	O
)	O
and	O
ESG1AS5	O
as	O
(	O
5	O
'	O
-	O
CCTCCATTGCCTCTATATCAG	O
-	O
3	O
'	O
)	O
primers	B-SO
.	O

The	O
probe	B-SO
specifically	O
labeled	O
an	O
18	O
kbp	O
band	O
from	O
the	O
wild	B-SO
-	I-SO
type	I-SO
locus	B-SO
,	O
a	O
15	O
kbp	O
band	O
from	O
the	O
beta	O
-	O
geo	O
locus	B-SO
,	O
and	O
a	O
12	O
kbp	O
band	O
from	O
the	O
HygR	O
locus	B-SO
.	O

Genomic	B-SO
DNA	I-SO
was	O
also	O
digested	O
with	O
SpeI	O
for	O
3	O
'	O
Southern	O
blot	O
analysis	O
.	O

A	O
1	O
,	O
010	O
bp	B-SO
3	O
'	O
probe	B-SO
was	O
amplified	O
with	O
the	O
pH34U	O
-	O
8000	O
(	O
5	O
'	O
-	O
CCAACCAGCCAGAGTTTCAGTTAT	O
-	O
3	O
'	O
)	O
and	O
pH34L	O
-	O
9000	O
(	O
5	O
'	O
-	O
GATAAGCTGCTGCCAAAAGACAAG	O
-	O
3	O
'	O
)	O
primers	B-SO
.	O

The	O
probe	B-SO
hybridized	O
to	O
an	O
11	O
.	O
5	O
kbp	O
band	O
from	O
the	O
wild	B-SO
-	I-SO
type	I-SO
locus	B-SO
,	O
a	O
12	O
.	O
5	O
kbp	O
band	O
from	O
the	O
beta	O
-	O
geo	O
locus	B-SO
,	O
and	O
a	O
9	O
.	O
5	O
kbp	O
band	O
from	O
the	O
HygR	O
locus	B-SO
.	O

Generation	O
of	O
anti	O
-	O
ESG1	B-GGP
polyclonal	O
antibodies	B-GO

The	O
coding	B-SO
sequence	I-SO
of	O
Esg1	B-GGP
was	O
amplified	O
by	O
PCR	O
with	O
the	O
pH34	B-GGP
-	O
gw	O
-	O
s	O
(	O
5	O
'	O
-	O
AAAAAGCAGGCTGGATGATGGTGACCCTCGTGA	O
-	O
3	O
'	O
)	O
and	O
pH34	B-GGP
-	O
gw	O
-	O
as	O
(	O
5	O
'	O
-	O
AGAAAGCTGGGTCTGCATCCAGGTCGGAGACA	O
-	O
3	O
'	O
)	O
primers	B-SO
.	O

To	O
construct	O
pDONR	O
-	O
pH34	B-GGP
,	O
the	O
resulting	O
PCR	B-SO
product	I-SO
was	O
subcloned	O
into	O
pDONR201	O
(	O
Invitrogen	O
)	O
.	O

pDONR	O
-	O
pH34	B-GGP
was	O
interacted	O
with	O
pDEST17	O
(	O
Invitrogen	O
)	O
by	O
LR	O
recombination	O
.	O

After	O
introduction	O
of	O
the	O
resulting	O
expression	O
vector	B-SO
pDEST17	O
-	O
pH34	B-GGP
into	O
BL21	O
-	O
AI	O
E	B-Taxon
.	I-Taxon
coli	I-Taxon
(	O
Invitrogen	O
)	O
,	O
recombinant	O
protein	B-CHEBI
production	O
was	O
induced	O
according	O
to	O
the	O
manufacture	O
'	O
s	O
protocol	O
.	O

Histidine	B-CHEBI
-	O
tagged	O
ESG1	B-GGP
was	O
purified	O
using	O
Ni	B-CHEBI
-	O
nitrilotriacetic	B-CHEBI
acid	I-CHEBI
agarose	B-CHEBI
(	O
Qiagen	O
)	O
under	O
denaturing	O
conditions	O
in	O
the	O
presence	O
of	O
8	O
M	O
urea	B-CHEBI
.	O

After	O
dialysis	O
against	O
6	O
M	O
urea	B-CHEBI
,	O
the	O
recombinant	O
proteins	B-CHEBI
were	O
injected	O
into	O
New	O
Zealand	O
White	O
rabbits	B-Taxon
to	O
generate	O
anti	O
-	O
ESG1	B-GGP
polyclonal	O
antibodies	B-GO
.	O

Western	O
blot	O

After	O
preparation	O
of	O
ES	O
cell	B-CL
extracts	O
with	O
M	O
-	O
Per	O
(	O
Pierce	O
)	O
,	O
cellular	B-CL
proteins	B-CHEBI
were	O
separated	O
on	O
sodium	B-CHEBI
dodecyl	I-CHEBI
sulfate	I-CHEBI
(	O
SDS	B-CHEBI
)	O
-	O
14	O
%	O
polyacrylamide	O
gels	O
and	O
transferred	O
to	O
nitrocellulose	O
membranes	O
(	O
Millipore	O
)	O
.	O

Membranes	O
were	O
incubated	O
with	O
anti	O
-	O
ESG1	B-GGP
(	O
1	O
/	O
500	O
dilution	O
)	O
,	O
anti	O
-	O
Oct3	B-GGP
/	I-GGP
4	I-GGP
(	O
1	O
/	O
500	O
;	O
Santa	O
Cruz	O
Biotechnology	O
)	O
,	O
anti	O
-	O
CDK4	B-GGP
(	O
1	O
/	O
200	O
;	O
Santa	O
Cruz	O
Biotechnology	O
)	O
,	O
and	O
anti	O
-	O
GFP	O
(	O
1	O
/	O
1000	O
;	O
MBL	O
)	O
primary	O
antibodies	B-GO
.	O

Horseradish	B-Taxon
peroxidase	O
-	O
conjugated	O
anti	O
-	O
rabbit	B-Taxon
and	O
anti	O
-	O
mouse	B-Taxon
immunoglobulins	B-GO
(	O
1	O
/	O
5000	O
;	O
Cell	B-CL
Signaling	O
)	O
were	O
used	O
to	O
detect	O
antibody	B-GO
binding	O
.	O

We	O
visualized	O
bound	O
antibody	B-GO
with	O
an	O
ECL	O
Western	O
Blotting	O
Detection	O
System	O
(	O
Amersham	O
)	O
.	O

Derivation	O
of	O
ESG1	B-GGP
-	O
deficient	O
ES	O
cells	B-CL
from	O
blastocysts	O

Esg1	B-GGP
+	B-SO
/	O
-	O
or	O
ESG1	B-GGP
-	O
/	O
-	O
mutant	B-SO
female	O
mice	B-Taxon
were	O
injected	O
with	O
Tamoxifen	B-CHEBI
(	O
10	O
mu	O
g	O
)	O
and	O
Depo	O
-	O
provera	O
(	O
1	O
mg	O
)	O
subcutaneously	O
on	O
the	O
third	O
day	O
of	O
pregnancy	O
.	O

Four	O
days	O
later	O
,	O
embryos	O
in	O
diapause	O
were	O
flushed	O
out	O
of	O
the	O
uterus	O
and	O
cultured	O
on	O
STO	O
feeder	O
cells	B-CL
in	O
four	O
-	O
well	O
plates	O
in	O
Dulbecco	O
'	O
s	O
Modified	O
Eagle	O
Medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
20	O
%	O
Fetal	O
Bovine	B-Taxon
Serum	O
(	O
Hyclone	O
)	O
,	O
0	O
.	O
1	O
mM	O
Non	O
-	O
Essential	O
Amino	B-CHEBI
Acids	I-CHEBI
(	O
Invitrogen	O
)	O
,	O
2	O
mM	O
L	B-CHEBI
-	I-CHEBI
glutamine	I-CHEBI
(	O
Invitrogen	O
)	O
,	O
50	O
U	O
/	O
ml	O
Penicillin	B-CHEBI
-	O
Streptomysin	B-CHEBI
(	O
Invitrogen	O
)	O
,	O
and	O
0	O
.	O
11	O
mM	O
2	B-CHEBI
-	I-CHEBI
mercaptoethanol	I-CHEBI
(	O
Invitrogen	O
)	O
.	O

After	O
six	O
days	O
,	O
the	O
central	O
mass	O
of	O
each	O
explant	O
was	O
harvested	O
,	O
rinsed	O
in	O
PBS	O
,	O
and	O
placed	O
in	O
a	O
drop	O
of	O
trypsin	O
for	O
a	O
few	O
minutes	O
.	O

The	O
cell	B-CL
mass	O
was	O
collected	O
with	O
a	O
finely	O
drawn	O
-	O
out	O
Pasteur	O
pipette	O
preloaded	O
with	O
medium	O
,	O
ensuring	O
minimal	O
carryover	O
of	O
the	O
trypsin	O
.	O

The	O
cells	B-CL
were	O
gently	O
transfered	O
into	O
a	O
fresh	O
well	O
with	O
20	O
%	O
FBS	O
-	O
containing	O
medium	O
.	O

The	O
resulting	O
primary	O
ES	O
cell	B-CL
colonies	O
were	O
individually	O
passaged	O
into	O
wells	O
of	O
four	O
-	O
well	O
plates	O
containing	O
STO	O
feeder	O
cell	B-CL
layers	O
.	O

Thereafter	O
,	O
cells	B-CL
were	O
expanded	O
by	O
trypsinization	O
of	O
the	O
entire	O
culture	O
.	O

Microarrays	O

Total	O
RNA	B-SO
from	O
wild	B-SO
-	I-SO
type	I-SO
ES	O
cells	B-CL
and	O
ESG1	B-GGP
-	O
/	O
-	O
ES	O
cells	B-CL
was	O
labeled	O
with	O
Cy3	O
and	O
Cy5	O
,	O
respectively	O
.	O

The	O
samples	O
were	O
hybridized	O
to	O
a	O
Mouse	B-Taxon
Development	O
Microarray	O
(	O
Algilent	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Arrays	O
were	O
scanned	O
with	O
a	O
G2565BA	O
Microarray	O
Scanner	O
System	O
(	O
Agilent	O
)	O
.	O

Hybridization	O
was	O
repeated	O
with	O
two	O
independent	O
clones	O
.	O

Data	O
were	O
analyzed	O
with	O
GeneSprings	O
software	O
(	O
Silico	O
Genetics	O
)	O
.	O

Authors	O
'	O
contributions	O

HA	O
carried	O
out	O
the	O
phenotypic	O
studies	O
of	O
ESG1	B-GGP
knockout	O
mice	B-Taxon
.	O

KI	O
determined	O
the	O
chromosomal	B-SO
localizations	I-SO
of	O
the	O
ESG1	B-GGP
gene	B-SO
and	O
pseudogenes	B-SO
and	O
constructed	O
the	O
targeting	O
vector	B-SO
.	O

TI	O
carried	O
out	O
mouse	B-Taxon
embryo	O
manipulation	O
.	O

MM	O
and	O
MN	O
carried	O
out	O
ES	O
cell	B-CL
culture	O
.	O

SY	O
conceived	O
of	O
the	O
study	O
,	O
and	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Acknowledgements	O

We	O
thank	O
Chihiro	O
Takigawa	O
,	O
Junko	O
Iida	O
,	O
Masako	O
Shirasaka	O
,	O
Yumi	O
Ohuchi	O
,	O
and	O
Megumi	O
Narita	O
for	O
their	O
technical	O
and	O
administrative	O
assistance	O
.	O

We	O
are	O
grateful	O
to	O
Drs	O
.	O

Minoru	O
Ko	O
and	O
Azim	O
Surani	O
for	O
sharing	O
helpful	O
data	O
prior	O
to	O
publication	O
,	O
Dr	O
.	O
Hitoshi	O
Niwa	O
for	O
generously	O
providing	O
various	O
vectors	B-SO
,	O
and	O
Dr	O
.	O
Robert	O
Farese	O
Jr	O
.	O
for	O
his	O
kind	O
gift	O
of	O
the	O
RF8	O
ES	O
cells	B-CL
.	O

This	O
work	O
was	O
supported	O
in	O
part	O
by	O
research	O
grants	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Culture	O
,	O
Sports	O
,	O
Science	O
,	O
and	O
Technology	O
of	O
Japan	O
,	O
the	O
Uehara	O
Memorial	O
Foundation	O
,	O
the	O
Naito	O
Foundation	O
,	O
the	O
Sumitomo	O
Research	O
Foundation	O
,	O
the	O
Mitsubishi	O
Foundation	O
.	O

S	O
.	O
Y	O
.	O
was	O
supported	O
by	O
a	O
Toray	O
Science	O
and	O
Technology	O
Grant	O
(	O
to	O
S	O
.	O
Y	O
.	O
)	O
.	O

This	O
work	O
was	O
also	O
supported	O
in	O
part	O
by	O
a	O
Grant	O
-	O
in	O
-	O
Aid	O
for	O
21st	O
Century	O
COE	O
(	O
Center	O
of	O
Excellence	O
)	O
Research	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Culture	O
,	O
Sports	O
,	O
Science	O
,	O
and	O
Technology	O
.	O

Identification	O
of	O
collagen	B-GGP
-	O
induced	O
arthritis	O
loci	B-SO
in	O
aged	O
multiparous	O
female	O
mice	B-Taxon

Abstract	O

Collagen	B-GGP
-	O
induced	O
arthritis	O
in	O
mice	B-Taxon
is	O
one	O
of	O
the	O
most	O
commonly	O
used	O
autoimmune	O
experimental	O
models	O
,	O
with	O
many	O
similarities	O
to	O
rheumatoid	O
arthritis	O
.	O

Since	O
collagen	B-GGP
-	O
induced	O
arthritis	O
is	O
a	O
complex	O
polygenic	O
disease	O
there	O
is	O
a	O
need	O
for	O
identification	O
of	O
several	O
major	O
disease	O
-	O
controlling	O
genes	B-SO
.	O

Because	O
rheumatoid	O
arthritis	O
particularly	O
affects	O
aged	O
women	O
,	O
we	O
have	O
in	O
the	O
present	O
study	O
identified	O
new	O
genetic	B-SO
regions	B-SO
critical	O
for	O
collagen	B-GGP
-	O
induced	O
arthritis	O
by	O
studying	O
aged	O
female	O
mice	B-Taxon
of	O
a	O
cross	O
between	O
NFR	O
/	O
N	O
and	O
B10	O
.	O
Q	O
(	O
H	O
-	O
2q	O
haplotype	B-SO
)	O
.	O

The	O
mice	B-Taxon
in	O
the	O
present	O
study	O
had	O
different	O
reproductive	O
histories	O
,	O
which	O
did	O
not	O
significantly	O
affect	O
the	O
onset	O
,	O
incidence	O
or	O
severity	O
of	O
the	O
disease	O
.	O

A	O
total	O
of	O
200	O
female	O
mice	B-Taxon
were	O
used	O
in	O
a	O
total	O
genome	B-SO
-	O
wide	O
screening	O
with	O
125	O
microsatellite	B-SO
markers	I-SO
.	O

We	O
found	O
one	O
new	O
significant	O
quantitative	B-SO
trait	I-SO
locus	I-SO
affecting	O
the	O
arthritis	O
incidence	O
,	O
severity	O
and	O
day	O
of	O
onset	O
on	O
chromosome	B-GO
11	O
(	O
denoted	O
Cia40	B-GGP
)	O
,	O
which	O
colocalizes	O
with	O
a	O
locus	B-SO
controlling	O
pregnancy	O
failure	O
.	O

Furthermore	O
,	O
a	O
quantitative	B-SO
trait	I-SO
locus	I-SO
of	O
suggestive	O
significance	O
associated	O
with	O
the	O
incidence	O
,	O
severity	O
and	O
day	O
of	O
onset	O
was	O
identified	O
on	O
chromosome	B-GO
1	O
.	O

Finally	O
,	O
a	O
suggestively	O
significant	O
quantitative	B-SO
trait	I-SO
locus	I-SO
associated	O
with	O
collagen	B-GGP
type	I-GGP
II	I-GGP
antibody	B-GO
titers	O
was	O
identified	O
on	O
chromosome	B-GO
13	O
.	O

This	O
study	O
indicates	O
that	O
several	O
gene	B-SO
loci	B-SO
control	O
arthritis	O
in	O
aged	O
multiparous	O
females	O
,	O
and	O
that	O
at	O
least	O
one	O
of	O
these	O
loci	B-SO
coincides	O
with	O
pregnancy	O
failure	O
.	O

Introduction	O

The	O
similarities	O
between	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
in	O
man	B-Taxon
and	O
collagen	B-GGP
-	O
induced	O
arthritis	O
(	O
CIA	O
)	O
in	O
mice	B-Taxon
are	O
well	O
established	O
,	O
although	O
differences	O
in	O
the	O
disease	O
pattern	O
exist	O
[	O
1	O
-	O
3	O
]	O
.	O

Characteristic	O
of	O
RA	O
is	O
the	O
fact	O
that	O
women	O
of	O
reproductive	O
age	O
are	O
more	O
susceptible	O
to	O
the	O
disease	O
than	O
men	O
[	O
4	O
]	O
.	O

It	O
has	O
also	O
been	O
reported	O
that	O
75	O
%	O
of	O
female	O
patients	O
(	O
23	O
out	O
of	O
31	O
females	O
)	O
with	O
RA	O
exhibit	O
clinical	O
remission	O
during	O
the	O
course	O
of	O
pregnancy	O
[	O
5	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
it	O
has	O
been	O
suggested	O
that	O
the	O
onset	O
of	O
RA	O
is	O
postponed	O
by	O
parity	O
.	O

The	O
risk	O
of	O
onset	O
is	O
reduced	O
during	O
pregnancy	O
,	O
while	O
in	O
the	O
first	O
year	O
postpartum	O
the	O
chance	O
of	O
onset	O
is	O
increased	O
[	O
6	O
,	O
7	O
]	O
.	O

The	O
results	O
of	O
a	O
recent	O
study	O
of	O
RA	O
in	O
women	O
,	O
however	O
,	O
indicate	O
that	O
pregnancy	O
history	O
does	O
not	O
increase	O
the	O
incidence	O
of	O
the	O
disease	O
later	O
in	O
life	O
[	O
8	O
]	O
.	O

Adequate	O
animal	B-Taxon
models	O
are	O
useful	O
tools	O
for	O
the	O
identification	O
of	O
genes	B-SO
involved	O
in	O
complex	O
human	B-Taxon
diseases	O
.	O

CIA	O
in	O
mice	B-Taxon
shares	O
both	O
immunological	O
and	O
pathological	O
characteristics	O
with	O
human	B-Taxon
RA	O
and	O
is	O
one	O
of	O
the	O
most	O
used	O
models	O
for	O
the	O
identification	O
of	O
genes	B-SO
and	O
mechanisms	O
involved	O
in	O
arthritis	O
.	O

The	O
incidence	O
of	O
CIA	O
is	O
sex	O
dependent	O
,	O
like	O
the	O
incidence	O
in	O
RA	O
,	O
although	O
different	O
species	O
and	O
different	O
variants	O
of	O
the	O
disease	O
could	O
lead	O
to	O
both	O
male	O
and	O
female	O
predominance	O
.	O

Male	O
mice	B-Taxon
are	O
more	O
often	O
affected	O
than	O
females	O
.	O

Gender	O
differences	O
in	O
CIA	O
susceptibility	O
are	O
dependent	O
on	O
many	O
factors	O
,	O
including	O
genetic	B-SO
,	O
hormonal	O
and	O
behavioral	O
influences	O
[	O
9	O
]	O
.	O

However	O
,	O
isolated	O
factors	O
are	O
remarkably	O
consistent	O
between	O
RA	O
and	O
the	O
different	O
animal	B-Taxon
models	O
[	O
3	O
,	O
9	O
]	O
.	O

Pregnancy	O
in	O
mice	B-Taxon
,	O
like	O
pregnancy	O
in	O
women	O
,	O
normally	O
causes	O
remission	O
of	O
arthritis	O
[	O
5	O
,	O
10	O
]	O
,	O
while	O
exacerbation	O
often	O
occurs	O
postpartum	O
[	O
7	O
,	O
10	O
,	O
11	O
]	O
.	O

Pregnancy	O
-	O
induced	O
remission	O
of	O
CIA	O
in	O
mice	B-Taxon
appears	O
to	O
be	O
caused	O
by	O
the	O
increase	O
in	O
estrogen	O
levels	O
,	O
while	O
the	O
postpartum	O
exacerbation	O
can	O
be	O
explained	O
by	O
the	O
dramatic	O
drop	O
in	O
estrogen	O
[	O
10	O
]	O
,	O
possibly	O
together	O
with	O
increased	O
prolactin	B-GGP
levels	O
[	O
11	O
]	O
.	O

To	O
what	O
extent	O
the	O
pregnancy	O
history	O
(	O
parity	O
)	O
affects	O
the	O
incidence	O
of	O
CIA	O
later	O
in	O
life	O
has	O
,	O
to	O
our	O
knowledge	O
,	O
not	O
previously	O
been	O
studied	O
.	O

Importantly	O
,	O
RA	O
occurs	O
predominantly	O
in	O
women	O
,	O
many	O
of	O
which	O
have	O
had	O
several	O
children	O
,	O
and	O
it	O
is	O
therefore	O
appropriate	O
to	O
also	O
mimic	O
this	O
situation	O
using	O
animal	B-Taxon
models	O
.	O

In	O
the	O
present	O
paper	O
we	O
have	O
analyzed	O
female	O
mice	B-Taxon
that	O
previously	O
had	O
undergone	O
a	O
reproductive	O
study	O
(	O
Liljander	O
M	O
,	O
S	O
a	O
llstr	O
o	O
m	O
MA	O
,	O
Andersson	O
S	O
,	O
Wernhoff	O
P	O
,	O
Andersson	O
A	O
,	O
Holmdahl	O
R	O
,	O
Mattsson	O
R	O
,	O
unpublished	O
data	O
)	O
.	O

A	O
total	O
of	O
200	O
female	O
mice	B-Taxon
(	O
ten	O
months	O
of	O
age	O
)	O
of	O
the	O
N2	O
backcross	O
between	O
NFR	O
/	O
N	O
and	O
C57BL	O
/	O
B10	O
.	O
Q	O
(	O
B10	O
.	O
Q	O
)	O
were	O
used	O
to	O
analyze	O
the	O
genetic	B-SO
control	O
of	O
CIA	O
in	O
aged	O
females	O
with	O
a	O
multiparous	O
history	O
.	O

Materials	O
and	O
methods	O

Mice	B-Taxon

Inbred	O
NFR	O
/	O
N	O
mice	B-Taxon
were	O
originally	O
obtained	O
from	O
the	O
National	O
Institute	O
of	O
Health	O
(	O
Bethesda	O
,	O
MD	O
,	O
USA	O
)	O
and	O
the	O
B10	O
.	O
Q	O
mice	B-Taxon
were	O
originally	O
bought	O
from	O
The	O
Jackson	O
Laboratory	O
(	O
Bar	O
Harbor	O
,	O
ME	O
,	O
USA	O
)	O
.	O

(	O
B10Q	O
x	O
NFR	O
/	O
N	O
)	O
F1	O
hybrids	O
and	O
(	O
B10	O
.	O
Q	O
x	O
NFR	O
/	O
N	O
)	O
x	O
B10	O
.	O
Q	O
N2	O
mice	B-Taxon
were	O
bred	O
in	O
individual	O
ventilated	O
cages	O
in	O
the	O
BMC	O
Barrier	O
animal	B-Taxon
facility	O
and	O
at	O
the	O
animal	B-Taxon
house	O
of	O
the	O
Department	O
of	O
Pathology	O
,	O
Lund	O
University	O
,	O
Sweden	O
.	O

The	O
animals	B-Taxon
were	O
fed	O
ad	O
libitum	O
with	O
standard	O
rodent	B-Taxon
chow	B-CHEBI
(	O
LAB	O
FOR	O
R36	O
,	O
irradiated	O
breeding	O
food	B-CHEBI
for	O
rats	B-Taxon
and	O
mice	B-Taxon
;	O
Lactamin	O
AB	O
,	O
Stockholm	O
,	O
Sweden	O
)	O
and	O
water	B-CHEBI
in	O
a	O
photoperiod	O
of	O
12	O
hours	O
:	O
12	O
hours	O
light	O
:	O
dark	O
.	O

The	O
mice	B-Taxon
used	O
in	O
the	O
present	O
study	O
had	O
clean	O
health	O
monitoring	O
protocols	O
according	O
to	O
the	O
Federation	O
of	O
European	O
Laboratory	O
Animal	B-Taxon
Sciences	O
Association	O
recommendations	O
.	O

Ethical	O
permissions	O
were	O
M125	O
-	O
04	O
(	O
embryo	O
transfer	O
)	O
and	O
M290	O
-	O
03	O
(	O
reproduction	O
and	O
arthritis	O
)	O
.	O

Experimental	O
design	O

A	O
total	O
of	O
200	O
female	O
mice	B-Taxon
(	O
approximately	O
ten	O
months	O
old	O
)	O
of	O
N2	O
backcross	O
(	O
B10	O
.	O
Q	O
x	O
NFR	O
/	O
N	O
)	O
x	O
B10	O
.	O
Q	O
were	O
used	O
.	O

The	O
mice	B-Taxon
had	O
earlier	O
undergone	O
a	O
reproductive	O
study	O
where	O
each	O
animal	B-Taxon
had	O
four	O
mating	O
opportunities	O
.	O

First	O
,	O
the	O
female	O
mice	B-Taxon
were	O
allowed	O
to	O
mate	O
twice	O
with	O
B10	O
.	O
RIII	O
males	O
(	O
allogeneic	O
mating	O
by	O
means	O
of	O
MHC	B-GO
(	O
major	B-GO
histocompatibility	I-GO
complex	I-GO
)	O
and	O
finally	O
to	O
mate	O
twice	O
with	O
B10	O
.	O
Q	O
males	O
(	O
syngeneic	O
mating	O
by	O
means	O
of	O
MHC	B-GO
)	O
.	O

After	O
four	O
possible	O
pregnancies	O
CIA	O
was	O
induced	O
to	O
the	O
female	O
mice	B-Taxon
.	O

Induction	O
and	O
evaluation	O
of	O
CIA	O

To	O
induce	O
CIA	O
,	O
the	O
mice	B-Taxon
were	O
immunized	O
subcutaneously	O
at	O
the	O
base	O
of	O
the	O
tail	O
with	O
100	O
mu	O
g	O
rat	B-GGP
collagen	I-GGP
type	I-GGP
II	I-GGP
(	O
CII	B-GGP
)	O
emulsified	O
in	O
0	O
.	O
1	O
M	O
acetic	B-CHEBI
acid	I-CHEBI
combined	O
with	O
an	O
equal	O
amount	O
of	O
complete	O
Freud	O
'	O
s	O
adjuvant	O
(	O
Difco	O
Laboratories	O
,	O
Detroit	O
,	O
MI	O
,	O
USA	O
)	O
.	O

A	O
booster	O
injection	O
containing	O
50	O
mu	O
g	O
CII	B-GGP
emulsified	O
in	O
0	O
.	O
1	O
M	O
acetic	B-CHEBI
acid	I-CHEBI
combined	O
with	O
an	O
equal	O
amount	O
of	O
Freud	O
'	O
s	O
incomplete	O
adjuvant	O
(	O
Difco	O
Laboratories	O
)	O
was	O
given	O
after	O
30	O
days	O
.	O

The	O
clinical	O
scoring	O
of	O
arthritis	O
commenced	O
25	O
days	O
after	O
the	O
first	O
immunization	O
.	O

Animals	B-Taxon
were	O
examined	O
for	O
clinical	O
signs	O
of	O
CIA	O
three	O
times	O
per	O
week	O
and	O
were	O
graded	O
on	O
a	O
12	O
-	O
point	O
scale	O
.	O

The	O
arthritis	O
index	O
was	O
assigned	O
to	O
each	O
mouse	B-Taxon
using	O
the	O
following	O
criteria	O
:	O
0	O
=	O
no	O
visible	O
sign	O
of	O
arthritis	O
,	O
1	O
=	O
redness	O
and	O
swelling	O
in	O
a	O
single	O
joint	O
,	O
2	O
=	O
inflammation	O
in	O
multiple	O
joints	O
,	O
and	O
3	O
=	O
severe	O
inflammation	O
in	O
the	O
entire	O
paw	O
and	O
/	O
or	O
anklebone	O
.	O

Each	O
paw	O
was	O
given	O
the	O
scores	O
0	O
-	O
3	O
,	O
with	O
the	O
index	O
being	O
the	O
sum	O
of	O
all	O
four	O
paws	O
.	O

The	O
severity	O
trait	O
is	O
the	O
maximum	O
score	O
observed	O
in	O
each	O
individual	O
female	O
.	O

The	O
onset	O
is	O
the	O
number	O
of	O
days	O
calculated	O
from	O
the	O
first	O
immunization	O
to	O
the	O
first	O
clinical	O
signs	O
of	O
arthritis	O
excluding	O
unaffected	O
animals	B-Taxon
.	O

Microsatellite	B-SO
genotyping	O
and	O
linkage	O
analysis	O

Tail	O
biopsies	O
were	O
collected	O
from	O
all	O
N2	O
females	O
and	O
the	O
F0	O
generation	O
.	O

DNA	B-SO
was	O
isolated	O
according	O
to	O
a	O
previously	O
described	O
protocol	O
[	O
12	O
]	O
.	O

After	O
screening	O
of	O
parental	O
DNA	B-SO
with	O
approximately	O
450	O
mouse	B-Taxon
fluorescence	B-CHEBI
-	I-CHEBI
labeled	I-CHEBI
microsatellite	B-SO
markers	I-SO
(	O
INTERACTIVA	O
,	O
Ulm	O
,	O
Germany	O
)	O
,	O
125	O
informative	O
markers	O
were	O
selected	O
covering	O
the	O
genome	B-SO
.	O

Two	O
hundred	O
and	O
thirty	O
-	O
seven	O
N2	O
mice	B-Taxon
were	O
genotyped	O
with	O
markers	O
covering	O
all	O
chromosomes	B-GO
except	O
for	O
the	O
Y	B-GO
chromosome	I-GO
.	O

PCR	O
amplification	O
for	O
the	O
markers	O
was	O
performed	O
in	O
a	O
final	O
volume	O
of	O
10	O
mu	O
l	O
in	O
a	O
96	O
-	O
well	O
V	O
-	O
bottom	O
microtiter	O
plate	O
using	O
20	O
ng	O
DNA	B-SO
,	O
10	O
mM	O
KCl	B-CHEBI
,	O
20	O
mM	O
Tris	B-CHEBI
-	O
HCl	B-CHEBI
,	O
10	O
mM	O
(	O
NH4	B-CHEBI
)	O
2SO4	O
,	O
2	O
mM	O
MgCl2	B-CHEBI
,	O
0	O
.	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
pH	O
8	O
.	O
8	O
(	O
New	O
England	O
BioLabs	O
Inc	O
.	O
,	O
Ipswich	O
,	O
MA	O
,	O
USA	O
)	O
,	O
3	O
mu	O
M	O
(	O
10	O
pmol	O
)	O
each	O
primer	B-SO
,	O
2	O
mM	O
dNTPs	B-CHEBI
(	O
Advanced	O
Biotechnologies	O
,	O
Epsom	O
,	O
Surrey	O
,	O
UK	O
)	O
and	O
0	O
.	O
25	O
U	O
Taq	B-Taxon
DNA	B-SO
Polymerase	O
(	O
New	O
England	O
BioLabs	O
Inc	O
.	O
)	O
.	O

The	O
following	O
program	O
was	O
used	O
to	O
amplify	O
the	O
DNA	B-SO
:	O
denaturation	O
at	O
95	O
degrees	O
C	O
for	O
3	O
minutes	O
,	O
annealing	O
at	O
56	O
degrees	O
C	O
for	O
45	O
seconds	O
,	O
polymerization	O
at	O
72	O
degrees	O
C	O
for	O
1	O
minute	O
,	O
30	O
cycles	O
of	O
95	O
degrees	O
C	O
for	O
30	O
seconds	O
,	O
56	O
degrees	O
C	O
for	O
45	O
seconds	O
and	O
72	O
degrees	O
C	O
for	O
1	O
minute	O
,	O
and	O
a	O
final	O
extension	O
step	O
of	O
7	O
minutes	O
at	O
72	O
degrees	O
C	O
.	O

The	O
PCR	B-SO
products	I-SO
were	O
analyzed	O
on	O
a	O
MegaBACE	O
(TM)	O
1000	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
Inc	O
Piscataway	O
,	O
NJ	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Data	O
were	O
analyzed	O
with	O
Genetic	B-SO
Profiler	O
1	O
.	O
1	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
Inc	O
)	O
.	O

Map	B-SO
Manager	O
QTXb20	O
free	O
software	O
[	O
13	O
]	O
was	O
used	O
to	O
perform	O
linkage	O
analysis	O
and	O
the	O
permutation	O
test	O
.	O

Ninety	O
percent	O
of	O
the	O
mouse	B-Taxon
genome	B-SO
was	O
within	O
a	O
20	O
cM	O
intermarker	O
distance	O
.	O

The	O
marker	O
map	B-SO
was	O
generated	O
using	O
the	O
Kosambis	O
map	O
function	O
and	O
1	O
,	O
000	O
permutations	O
were	O
performed	O
for	O
every	O
phenotype	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
permutation	O
tests	O
were	O
carried	O
out	O
to	O
establish	O
empirical	O
significance	O
thresholds	O
for	O
the	O
interactions	O
.	O

A	O
threshold	O
equal	O
to	O
or	O
above	O
the	O
37th	O
percentile	O
(	O
P	O
=	O
0	O
.	O
63	O
)	O
was	O
considered	O
suggestively	O
significant	O
,	O
and	O
the	O
level	O
for	O
the	O
significant	O
threshold	O
was	O
set	O
to	O
the	O
95th	O
percentile	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

Interval	B-SO
mapping	O
was	O
made	O
with	O
a	O
2	O
cM	O
increase	O
under	O
the	O
additive	O
regression	O
model	O
in	O
order	O
to	O
calculate	O
the	O
test	O
statistics	O
.	O

Enzyme	B-SO
-	O
linked	O
immunosorbent	O
assay	O

The	O
adult	O
female	O
mice	B-Taxon
were	O
sacrificed	O
at	O
15	O
months	O
of	O
age	O
and	O
sera	O
were	O
collected	O
.	O

Anti	O
-	O
CII	B-GGP
antibody	B-GO
titers	O
in	O
sera	O
were	O
analyzed	O
by	O
a	O
sandwich	O
ELISA	O
technique	O
[	O
14	O
]	O
.	O

In	O
brief	O
,	O
CII	B-GGP
(	O
10	O
mu	O
g	O
/	O
ml	O
)	O
was	O
coupled	O
to	O
immunosorbent	O
plates	O
overnight	O
at	O
4	O
degrees	O
C	O
.	O

Bovine	B-GGP
serum	I-GGP
albumin	I-GGP
(	O
Sigma	O
Chemical	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
was	O
used	O
for	O
blocking	O
,	O
and	O
thereafter	O
different	O
dilutions	O
of	O
control	O
sera	O
(	O
purified	O
mouse	B-Taxon
anti	O
-	O
CII	B-GGP
antibodies	B-GO
)	O
,	O
test	O
sera	O
,	O
and	O
positive	O
and	O
negative	O
controls	O
were	O
added	O
.	O

The	O
presence	O
of	O
CII	B-GGP
-	O
specific	O
IgG	B-GO
was	O
visualized	O
by	O
means	O
of	O
peroxidase	O
-	O
conjugated	O
goat	B-Taxon
antimouse	O
IgG	B-GO
.	O

Statistical	O
analysis	O

Statistical	O
comparison	O
between	O
the	O
different	O
experimental	O
groups	O
was	O
performed	O
using	O
the	O
Mann	O
-	O
Whitney	O
U	O
test	O
or	O
Student	O
'	O
s	O
unpaired	O
t	O
test	O
.	O

Results	O

NFR	O
/	O
N	O
female	O
mice	B-Taxon
show	O
delayed	O
onset	O
and	O
lower	O
incidence	O
of	O
CIA	O
compared	O
with	O
B10	O
.	O
Q	O
females	O

The	O
onset	O
of	O
the	O
disease	O
was	O
significantly	O
delayed	O
in	O
NFR	O
/	O
N	O
mice	B-Taxon
,	O
which	O
resulted	O
in	O
lower	O
incidence	O
in	O
the	O
initial	O
phase	O
of	O
the	O
disease	O
(	O
Table	O
1	O
and	O
Figure	O
1	O
)	O
.	O

The	O
appearance	O
of	O
the	O
arthritis	O
was	O
slightly	O
different	O
between	O
the	O
two	O
strains	O
,	O
NFR	O
/	O
N	O
mice	B-Taxon
showing	O
a	O
higher	O
frequency	O
of	O
swelling	O
of	O
the	O
entire	O
paw	O
than	O
B10	O
.	O
Q	O
mice	B-Taxon
.	O

Later	O
in	O
the	O
disease	O
course	O
the	O
differences	O
in	O
CIA	O
frequency	O
and	O
severity	O
between	O
the	O
strains	O
were	O
less	O
obvious	O
.	O

However	O
,	O
the	O
anti	O
-	O
CII	B-GGP
titers	O
100	O
days	O
after	O
primary	O
immunization	O
(	O
and	O
70	O
days	O
after	O
the	O
booster	O
)	O
differed	O
significantly	O
between	O
NFR	O
/	O
N	O
and	O
B10	O
.	O
Q	O
female	O
mice	B-Taxon
(	O
see	O
Table	O
1	O
)	O
.	O

Pregnancy	O
history	O
does	O
not	O
significantly	O
affect	O
incidence	O
or	O
severity	O
of	O
CIA	O
in	O
female	O
mice	B-Taxon
of	O
mixed	O
genetic	B-SO
background	O

Table	O
2	O
presents	O
the	O
results	O
of	O
arthritic	O
incidence	O
,	O
arthritis	O
onset	O
and	O
maximum	O
arthritic	O
score	O
for	O
the	O
female	O
mice	B-Taxon
of	O
the	O
N2	O
generation	O
,	O
(	O
NFR	O
/	O
N	O
x	O
B10	O
.	O
Q	O
)	O
x	O
B10	O
.	O
Q	O
,	O
grouped	O
according	O
to	O
the	O
number	O
of	O
pregnancies	O
they	O
had	O
experienced	O
prior	O
to	O
immunization	O
with	O
CII	B-GGP
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
incidence	O
or	O
severity	O
of	O
arthritis	O
depending	O
on	O
the	O
number	O
of	O
pregnancies	O
that	O
had	O
been	O
passed	O
prior	O
to	O
the	O
induction	O
of	O
the	O
disease	O
.	O

We	O
observed	O
a	O
trend	O
towards	O
lower	O
severity	O
in	O
multiparous	O
mice	B-Taxon
compared	O
with	O
mice	B-Taxon
with	O
a	O
history	O
of	O
zero	O
to	O
two	O
pregnancies	O
.	O

The	O
onset	O
of	O
diseases	O
,	O
however	O
,	O
was	O
earlier	O
in	O
mice	B-Taxon
that	O
had	O
passed	O
more	O
than	O
one	O
pregnancy	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
development	O
of	O
the	O
disease	O
between	O
female	O
mice	B-Taxon
that	O
have	O
only	O
been	O
pregnant	O
with	O
MHC	B-GO
mismatched	O
males	O
(	O
B10	O
.	O
RIII	O
)	O
and	O
female	O
mice	B-Taxon
that	O
only	O
have	O
been	O
pregnant	O
with	O
MHC	B-GO
matched	O
males	O
(	O
B10	O
.	O
Q	O
)	O
.	O

New	O
loci	B-SO
associated	O
with	O
CIA	O
in	O
identified	O
old	O
female	O
mice	B-Taxon

The	O
genetic	B-SO
linkage	O
analysis	O
revealed	O
one	O
significant	O
quantitative	B-SO
trait	I-SO
locus	I-SO
(	O
QTL	B-SO
)	O
located	O
at	O
64	O
-	O
70	O
cM	O
on	O
chromosome	B-GO
11	O
(	O
Table	O
3	O
and	O
Figure	O
2	O
)	O
.	O

This	O
locus	B-SO
(	O
denoted	O
Cia40	B-GGP
)	O
gave	O
significant	O
LOD	O
scores	O
for	O
the	O
traits	O
incidence	O
(	O
LOD	O
=	O
4	O
.	O
1	O
)	O
and	O
'	O
day	O
of	O
onset	O
'	O
(	O
LOD	O
=	O
4	O
.	O
0	O
)	O
,	O
and	O
a	O
suggestive	O
LOD	O
score	O
for	O
the	O
trait	O
'	O
arthritis	O
score	O
'	O
(	O
LOD	O
=	O
3	O
.	O
3	O
)	O
.	O

Another	O
QTL	B-SO
of	O
suggestive	O
significance	O
for	O
the	O
incidence	O
of	O
disease	O
was	O
identified	O
around	O
27	O
cM	O
on	O
chromosome	B-GO
1	O
(	O
Figure	O
2	O
)	O
.	O

Finally	O
,	O
a	O
suggestive	O
QTL	B-SO
for	O
the	O
trait	O
anti	O
-	O
CII	B-GGP
antibody	B-GO
titer	O
was	O
identified	O
on	O
chromosome	B-GO
13	O
(	O
Figure	O
2	O
)	O
.	O

Discussion	O

Although	O
carrying	O
the	O
same	O
CIA	O
-	O
susceptible	O
MHC	B-GO
region	B-SO
,	O
the	O
NFR	O
/	O
N	O
and	O
B10	O
.	O
Q	O
mice	B-Taxon
are	O
different	O
in	O
several	O
respects	O
.	O

The	O
NFR	O
/	O
N	O
mouse	B-Taxon
,	O
which	O
is	O
an	O
inbred	O
NMRI	O
mouse	B-Taxon
of	O
the	O
H	O
-	O
2q	O
haplotype	B-SO
,	O
is	O
larger	O
in	O
size	O
than	O
the	O
B10	O
.	O
Q	O
mouse	B-Taxon
and	O
is	O
also	O
known	O
for	O
its	O
extraordinarily	O
good	O
breeding	O
properties	O
.	O

The	O
mice	B-Taxon
used	O
in	O
the	O
present	O
study	O
,	O
(	O
NFR	O
/	O
N	O
x	O
B10	O
.	O
Q	O
)	O
x	O
B10	O
.	O
Q	O
females	O
,	O
first	O
underwent	O
a	O
genetic	B-SO
study	O
of	O
reproduction	O
,	O
in	O
which	O
a	O
number	O
of	O
loci	B-SO
associated	O
with	O
breeding	O
performance	O
were	O
identified	O
(	O
Liljander	O
M	O
,	O
S	O
a	O
llstr	O
o	O
m	O
MA	O
,	O
Andersson	O
S	O
,	O
Wernhoff	O
P	O
,	O
Andersson	O
A	O
,	O
Holmdahl	O
R	O
,	O
Mattsson	O
R	O
;	O
unpublished	O
data	O
)	O
.	O

Since	O
the	O
parental	O
strains	O
differ	O
in	O
susceptibility	O
to	O
CIA	O
,	O
in	O
spite	O
of	O
both	O
having	O
the	O
MHC	B-GGP
class	I-GGP
II	I-GGP
A	I-GGP
beta	I-GGP
genes	B-SO
[	O
15	O
]	O
,	O
we	O
wanted	O
to	O
test	O
the	O
susceptibility	O
to	O
inflammatory	O
disease	O
in	O
mice	B-Taxon
from	O
this	O
cross	O
.	O

In	O
fact	O
,	O
this	O
situation	O
gave	O
an	O
opportunity	O
to	O
study	O
the	O
genetic	B-SO
control	O
of	O
arthritis	O
in	O
aged	O
multiparous	O
females	O
,	O
a	O
common	O
situation	O
in	O
human	B-Taxon
RA	O
.	O

This	O
susceptibility	O
was	O
important	O
to	O
investigate	O
for	O
various	O
reasons	O
.	O

The	O
fact	O
that	O
the	O
mice	B-Taxon
differed	O
in	O
their	O
reproductive	O
history	O
made	O
it	O
possible	O
to	O
analyze	O
whether	O
this	O
would	O
significantly	O
affect	O
the	O
incidence	O
or	O
severity	O
of	O
CIA	O
.	O

Second	O
,	O
almost	O
all	O
the	O
linkage	O
analyses	O
performed	O
for	O
detection	O
of	O
CIA	O
-	O
associated	O
loci	B-SO
in	O
mice	B-Taxon
have	O
been	O
carried	O
out	O
with	O
male	O
mice	B-Taxon
.	O

Another	O
reason	O
is	O
that	O
the	O
use	O
of	O
old	O
multiparous	O
mice	B-Taxon
mimicked	O
the	O
RA	O
situation	O
(	O
older	O
women	O
is	O
the	O
major	O
risk	O
group	O
)	O
.	O

Finally	O
,	O
the	O
NFR	O
/	O
N	O
strain	O
had	O
not	O
previously	O
been	O
used	O
in	O
linkage	O
analyses	O
for	O
detection	O
of	O
CIA	O
-	O
associated	O
loci	B-SO
,	O
which	O
opened	O
(	O
up	O
)	O
the	O
possibility	O
of	O
detecting	O
new	O
polymorphic	B-SO
genes	B-SO
of	O
importance	O
in	O
this	O
disease	O
.	O

The	O
first	O
conclusion	O
from	O
the	O
present	O
paper	O
is	O
that	O
multiparity	O
does	O
not	O
negatively	O
influence	O
the	O
incidence	O
or	O
severity	O
of	O
CIA	O
induced	O
later	O
in	O
life	O
(	O
Table	O
2	O
)	O
.	O

This	O
is	O
in	O
agreement	O
with	O
results	O
from	O
a	O
recent	O
study	O
of	O
RA	O
in	O
women	O
,	O
which	O
similarly	O
indicates	O
that	O
previous	O
experience	O
of	O
pregnancy	O
does	O
not	O
negatively	O
affect	O
the	O
incidence	O
or	O
severity	O
of	O
RA	O
later	O
in	O
life	O
[	O
8	O
]	O
.	O

It	O
is	O
worth	O
noting	O
that	O
the	O
situation	O
is	O
quite	O
different	O
if	O
pregnancy	O
is	O
entered	O
during	O
ongoing	O
arthritis	O
.	O

This	O
will	O
normally	O
lead	O
to	O
a	O
temporary	O
remission	O
of	O
the	O
disease	O
in	O
both	O
mice	B-Taxon
and	O
humans	B-Taxon
,	O
followed	O
by	O
an	O
exacerbation	O
phase	O
after	O
delivery	O
[	O
7	O
,	O
10	O
,	O
11	O
]	O
.	O

The	O
second	O
conclusion	O
from	O
this	O
study	O
is	O
that	O
loci	B-SO
of	O
possible	O
importance	O
for	O
CIA	O
have	O
been	O
detected	O
,	O
two	O
associated	O
with	O
arthritis	O
susceptibility	O
(	O
chromosomes	B-GO
1	O
and	O
11	O
)	O
and	O
one	O
associated	O
with	O
anti	O
-	O
CII	B-GGP
titers	O
(	O
chromosome	B-GO
13	O
)	O
.	O

Some	O
arthritis	O
loci	B-SO
have	O
previously	O
been	O
identified	O
on	O
chromosome	B-GO
1	O
:	O
Cia15	B-GGP
at	O
8	O
cM	O
[	O
16	O
]	O
,	O
Cia20	B-GGP
at	O
44	O
cM	O
[	O
16	O
]	O
and	O
Cia9	B-GGP
at	O
92	O
cM	O
[	O
17	O
]	O
.	O

However	O
,	O
none	O
of	O
these	O
loci	B-SO
appears	O
to	O
be	O
close	O
to	O
the	O
locus	B-SO
found	O
on	O
chromosome	B-GO
1	O
in	O
the	O
present	O
study	O
.	O

The	O
newly	O
identified	O
Cia40	B-GGP
locus	B-SO
includes	O
the	O
Ctla4	B-GGP
(	O
CD152	B-GGP
)	O
gene	B-SO
,	O
which	O
is	O
a	O
strong	O
candidate	O
associated	O
with	O
spontaneous	O
diabetes	O
identified	O
in	O
crosses	O
between	O
C57Bl	O
and	O
nonobese	O
diabetic	O
strains	O
[	O
18	O
]	O
.	O

Analyses	O
of	O
CIA	O
in	O
crosses	O
of	O
the	O
same	O
backgrounds	O
,	O
however	O
,	O
did	O
not	O
identify	O
a	O
linkage	O
to	O
this	O
locus	B-SO
,	O
suggesting	O
that	O
the	O
polymorphism	B-SO
underlying	O
Cia40	B-GGP
differs	O
from	O
the	O
genes	B-SO
associated	O
with	O
diabetes	O
[	O
18	O
]	O
.	O

Interestingly	O
,	O
Bauer	O
and	O
colleagues	O
previously	O
identified	O
a	O
locus	B-SO
(	O
Cia28	B-GGP
)	O
associated	O
with	O
anti	O
-	O
CII	B-GGP
antibody	B-GO
production	O
at	O
53	O
cM	O
on	O
chromosome	B-GO
13	O
[	O
19	O
]	O
,	O
which	O
is	O
approximately	O
at	O
the	O
same	O
position	B-SO
as	O
where	O
we	O
find	O
the	O
linkage	O
for	O
this	O
trait	O
in	O
the	O
present	O
study	O
.	O

It	O
is	O
therefore	O
most	O
likely	O
that	O
the	O
QTL	B-SO
we	O
have	O
identified	O
on	O
chromosome	B-GO
13	O
is	O
the	O
same	O
as	O
Cia28	B-GGP
.	O

Since	O
the	O
possible	O
new	O
locus	B-SO
of	O
potential	O
interest	O
on	O
chromosome	B-GO
1	O
was	O
of	O
suggestive	O
significance	O
,	O
and	O
since	O
the	O
locus	B-SO
identified	O
on	O
chromosome	B-GO
13	O
probably	O
is	O
Cia28	B-GGP
,	O
we	O
are	O
now	O
paying	O
special	O
attention	O
to	O
the	O
significant	O
QTL	B-SO
for	O
CIA	O
incidence	O
detected	O
at	O
60	O
-	O
70	O
cM	O
on	O
chromosome	B-GO
11	O
(	O
denoted	O
Cia40	B-GGP
)	O
.	O

No	O
other	O
CIA	O
genes	B-SO
have	O
previously	O
been	O
typed	O
in	O
this	O
region	B-SO
,	O
but	O
the	O
central	O
part	B-SO
of	I-SO
chromosome	I-SO
11	O
is	O
known	O
to	O
contain	O
a	O
number	O
of	O
inflammation	O
loci	B-SO
,	O
such	O
as	O
Eae22	B-GGP
,	O
Eae6b	B-GGP
,	O
Eae23	B-GGP
and	O
Eae7	B-GGP
[	O
20	O
-	O
22	O
]	O
.	O

One	O
QTL	B-SO
for	O
proteoglycan	B-CHEBI
-	O
induced	O
arthritis	O
,	O
which	O
was	O
female	O
specific	O
for	O
disease	O
onset	O
,	O
have	O
also	O
been	O
found	O
on	O
chromosome	B-GO
11	O
.	O

Although	O
this	O
locus	B-SO
(	O
Pgia28	B-GGP
)	O
is	O
not	O
located	O
in	O
the	O
vicinity	O
of	O
Cia40	B-GGP
,	O
it	O
is	O
worth	O
noting	O
[	O
23	O
]	O
.	O

The	O
mouse	B-Taxon
chromosome	B-GO
11	O
contains	O
several	O
genes	B-SO
that	O
are	O
highly	O
conserved	B-SO
with	O
human	B-Taxon
chromosome	B-GO
17	O
.	O

Linkages	O
for	O
human	B-Taxon
RA	O
have	O
been	O
found	O
in	O
this	O
particular	O
region	B-SO
[	O
24	O
]	O
.	O

Another	O
interesting	O
locus	B-SO
is	O
Cia5	B-GGP
on	O
the	O
homolog	B-SO
rat	B-Taxon
chromosome	B-GO
10	O
,	O
which	O
regulates	O
the	O
severity	O
of	O
CIA	O
and	O
pristane	O
-	O
induced	O
arthritis	O
[	O
25	O
]	O
.	O

Interestingly	O
,	O
from	O
studies	O
with	O
the	O
same	O
cross	O
,	O
we	O
have	O
previously	O
detected	O
a	O
significant	O
QTL	B-SO
denoted	O
Pregq2	B-GGP
for	O
the	O
trait	O
'	O
pregnancy	O
frequency	O
'	O
in	O
the	O
very	O
same	O
region	B-SO
as	O
Cia40	B-GGP
(	O
peak	O
at	O
64	O
-	O
70	O
cM	O
on	O
chromosome	B-GO
11	O
)	O
(	O
Liljander	O
M	O
,	O
S	O
a	O
llstr	O
o	O
m	O
MA	O
,	O
Andersson	O
S	O
,	O
Wernhoff	O
P	O
,	O
Andersson	O
A	O
,	O
Holmdahl	O
R	O
,	O
Mattsson	O
R	O
,	O
unpublished	O
data	O
)	O
.	O

This	O
means	O
that	O
this	O
region	B-SO
contains	O
genes	B-SO
affecting	O
the	O
CIA	O
incidence	O
in	O
multiparous	O
mice	B-Taxon
in	O
addition	O
to	O
the	O
rate	O
of	O
successful	O
deliveries	O
in	O
female	O
mice	B-Taxon
.	O

The	O
'	O
pregnancy	O
rate	O
'	O
in	O
mice	B-Taxon
is	O
defined	O
as	O
successful	O
pregnancies	O
per	O
detected	O
vaginal	O
plug	O
,	O
a	O
phenotype	O
associated	O
with	O
early	O
pregnancy	O
failure	O
,	O
which	O
in	O
turn	O
possibly	O
could	O
have	O
an	O
inflammatory	O
cause	O
.	O

We	O
cannot	O
exclude	O
that	O
the	O
same	O
gene	B-SO
(	I-SO
s	I-SO
)	I-SO
are	O
affecting	O
both	O
these	O
traits	O
.	O

Conclusion	O

Our	O
results	O
show	O
that	O
multiparity	O
does	O
not	O
negatively	O
influence	O
the	O
incidence	O
or	O
severity	O
of	O
CIA	O
induced	O
later	O
in	O
life	O
.	O

Furthermore	O
,	O
two	O
new	O
loci	B-SO
linked	O
to	O
CIA	O
susceptibility	O
were	O
detected	O
on	O
chromosome	B-GO
11	O
(	O
Cia40	B-GGP
)	O
and	O
on	O
chromosome	B-GO
1	O
.	O

We	O
detected	O
on	O
chromosome	B-GO
13	O
a	O
locus	B-SO
associated	O
with	O
anti	O
-	O
CII	B-GGP
titers	O
,	O
which	O
probably	O
is	O
the	O
same	O
as	O
the	O
recently	O
reported	O
Cia28	B-GGP
[	O
19	O
]	O
.	O

Abbreviations	O

CIA	O
=	O
collagen	B-GGP
-	O
induced	O
arthritis	O
;	O
CII	B-GGP
=	O
collagen	B-GGP
type	I-GGP
II	I-GGP
;	O
LOD	O
=	O
logarithm	O
of	O
the	O
odds	O
;	O
MHC	B-GO
=	O
major	B-GO
histocompatibility	I-GO
complex	I-GO
;	O
PCR	O
=	O
polymerase	O
chain	O
reaction	O
;	O
QTL	B-SO
=	O
quantitative	B-SO
trait	I-SO
locus	I-SO
;	O
RA	O
=	O
rheumatoid	O
arthritis	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interest	O
.	O

Authors	O
'	O
contributions	O

ML	O
is	O
responsible	O
for	O
genotyping	O
,	O
phenotyping	O
,	O
analyses	O
and	O
,	O
together	O
with	O
RM	O
,	O
for	O
interpretation	O
and	O
for	O
writing	O
the	O
manuscript	O
.	O

M	O
-	O
AS	O
and	O
SA	O
have	O
contributed	O
to	O
collection	O
of	O
phenotype	O
data	O
.	O

RM	O
,	O
A	O
A	O
,	O
RH	O
and	O
ML	O
designed	O
the	O
study	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Acknowledgements	O

This	O
study	O
was	O
supported	O
by	O
O	O
sterlund	O
'	O
s	O
fund	O
,	O
Crafoord	O
'	O
s	O
fund	O
,	O
the	O
Gustav	O
V	O
80	O
Year	O
Foundation	O
,	O
the	O
Royal	O
Physiographic	O
Society	O
in	O
Lund	O
and	O
by	O
Swegene	O
.	O

Figures	O
and	O
Tables	O

Figure	O
1	O

The	O
accumulated	O
incidence	O
of	O
arthritis	O
in	O
the	O
parental	O
strains	O
(	O
NFR	O
/	O
N	O
and	O
B10	O
.	O
Q	O
)	O
of	O
female	O
mice	B-Taxon
.	O

Figure	O
2	O

Chromosomal	B-SO
locations	I-SO
of	O
the	O
quantitative	B-SO
trait	I-SO
loci	I-SO
(	O
QTL	B-SO
)	O
for	O
collagen	B-GGP
-	O
induced	O
arthritis	O
incidence	O
on	O
chromosomes	B-GO
1	O
and	O
11	O
.	O

QTL	B-SO
for	O
collagen	B-GGP
type	I-GGP
II	I-GGP
(	O
CII	B-GGP
)	O
antibody	B-GO
titers	O
are	O
illustrated	O
on	O
chromosome	B-GO
13	O
.	O

*	O
Suggestive	O
level	O
threshold	O
(	O
P	O
=	O
0	O
.	O
63	O
)	O
according	O
to	O
the	O
permutation	O
test	O
(	O
n	O
=	O
1	O
,	O
000	O
)	O
.	O

*	O
*	O
Significance	O
level	O
threshold	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
according	O
to	O
the	O
permutation	O
test	O
(	O
n	O
=	O
1	O
,	O
000	O
)	O
.	O

Table	O
1	O

Severity	O
of	O
arthritis	O
and	O
anti	O
-	O
collagen	B-GGP
type	I-GGP
II	I-GGP
(	O
anti	O
-	O
CII	B-GGP
)	O
titers	O
in	O
(	O
NFR	O
/	O
N	O
x	O
B10	O
.	O
Q	O
)	O
x	O
B10	O
.	O
Q	O
female	O
mice	B-Taxon
and	O
parental	O
strains	O

aMedian	O
value	O
on	O
the	O
days	O
of	O
onset	O
when	O
calculated	O
in	O
all	O
arthritic	O
mice	B-Taxon
in	O
the	O
group	O
on	O
day	O
100	O
(	O
maximum	O
-	O
minimum	O
values	O
in	O
the	O
series	O
)	O
.	O

bMean	O
+/-	O
standard	O
error	O
of	O
the	O
maximum	O
score	O
from	O
all	O
arthritic	O
mice	B-Taxon
in	O
the	O
respective	O
group	O
.	O

cSignificantly	O
higher	O
than	O
in	O
B10	O
.	O
Q	O
mice	B-Taxon
(	O
P	O
=	O
0	O
.	O
02	O
in	O
Student	O
'	O
s	O
unpaired	O
t	O
test	O
)	O
.	O

Table	O
2	O

Incidence	O
,	O
onset	O
and	O
maximum	O
score	O
in	O
(	O
NFR	O
/	O
N	O
x	O
B10	O
.	O
Q	O
)	O
x	O
B10	O
.	O
Q	O
female	O
mice	B-Taxon

aMedian	O
value	O
on	O
the	O
days	O
of	O
onset	O
when	O
calculated	O
in	O
all	O
arthritic	O
mice	B-Taxon
in	O
the	O
group	O
(	O
maximum	O
-	O
minimum	O
values	O
in	O
the	O
series	O
)	O
.	O

bMean	O
(	O
+/-	O
standard	O
error	O
)	O
of	O
the	O
maximum	O
score	O
from	O
all	O
arthritic	O
mice	B-Taxon
in	O
the	O
respective	O
group	O
on	O
day	O
100	O
.	O

Table	O
3	O

Distribution	O
of	O
genotypes	B-SO
between	O
affected	O
and	O
unaffected	O
N2	O
mice	B-Taxon
at	O
different	O
loci	B-SO
linked	O
to	O
clinical	O
phenotypes	O
of	O
collagen	B-GGP
-	O
induced	O
arthritis	O

*	O
Suggestive	O
significance	O
,	O
*	O
*	O
significant	O
.	O

Cloning	O
and	O
characterization	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
,	O
a	O
novel	O
SAM	O
domain	B-SO
protein	B-CHEBI
,	O
predominantly	O
expressed	O
in	O
retinal	B-CL
photoreceptor	I-CL
cells	I-CL

Abstract	O

Background	O

Sterile	O
alpha	O
motif	O
(	O
SAM	O
)	O
domains	B-SO
are	O
~	O
70	O
residues	B-CHEBI
long	O
and	O
have	O
been	O
reported	O
as	O
common	O
protein	B-CHEBI
-	O
protein	B-CHEBI
interaction	O
modules	B-SO
.	O

This	O
domain	B-SO
is	O
found	O
in	O
a	O
large	O
number	O
of	O
proteins	B-CHEBI
,	O
including	O
Polycomb	O
group	O
(	O
PcG	O
)	O
proteins	B-CHEBI
and	O
ETS	O
family	O
transcription	O
factors	O
.	O

In	O
this	O
work	O
,	O
we	O
report	O
the	O
cloning	O
and	O
functional	O
characterization	O
of	O
a	O
novel	O
SAM	O
domain	B-SO
-	O
containing	O
protein	B-CHEBI
,	O
which	O
is	O
predominantly	O
expressed	O
in	O
retinal	B-CL
photoreceptors	I-CL
and	O
the	O
pineal	O
gland	O
and	O
is	O
designated	O
mouse	B-GGP
mr	I-GGP
-	I-GGP
s	I-GGP
(	I-GGP
major	I-GGP
retinal	I-GGP
SAM	I-GGP
domain	I-GGP
protein	I-GGP
)	O
.	O

Results	O

mr	B-GGP
-	I-GGP
s	I-GGP
is	O
evolutionarily	B-SO
conserved	I-SO
from	O
zebrafish	B-Taxon
through	O
human	B-Taxon
,	O
organisms	B-Taxon
through	O
which	O
the	O
mechanism	O
of	O
photoreceptor	B-CL
development	O
is	O
also	O
highly	O
conserved	O
.	O

Phylogenetic	O
analysis	O
suggests	O
that	O
the	O
SAM	O
domain	B-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
most	O
closely	O
related	O
to	O
a	O
mouse	B-Taxon
polyhomeotic	B-GGP
(	O
ph	B-GGP
)	O
ortholog	B-SO
,	O
Mph1	B-GGP
/	O
Rae28	B-GGP
,	O
which	O
is	O
known	O
as	O
an	O
epigenetic	O
molecule	B-CHEBI
involved	O
in	O
chromatin	B-GO
modifications	O
.	O

These	O
findings	O
provide	O
the	O
possibility	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
may	O
play	O
a	O
critical	O
role	O
by	O
regulating	O
gene	B-SO
expression	O
in	O
photoreceptor	B-CL
development	O
.	O

mr	B-GGP
-	I-GGP
s	I-GGP
is	O
preferentially	O
expressed	O
in	O
the	O
photoreceptors	B-CL
at	O
postnatal	O
day	O
3	O
-	O
6	O
(	O
P3	O
-	O
6	O
)	O
,	O
when	O
photoreceptors	B-CL
undergo	O
terminal	O
differentiation	O
,	O
and	O
in	O
the	O
adult	O
pineal	O
gland	O
.	O

Transcription	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
directly	O
regulated	O
by	O
the	O
cone	B-CL
-	O
rod	B-CL
homeodomain	O
protein	B-CHEBI
Crx	B-GGP
.	O

Immunoprecipitation	O
assay	O
showed	O
that	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
self	O
-	O
associates	O
mainly	O
through	O
the	O
SAM	O
domain	B-SO
-	O
containing	O
region	B-SO
as	O
well	O
as	O
ph	B-GGP
.	O

The	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
localizes	O
mainly	O
in	O
the	O
nucleus	B-GO
,	O
when	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
overexpressed	O
in	O
HEK293T	O
cells	B-CL
.	O

Moreover	O
,	O
in	O
the	O
luciferase	O
assays	O
,	O
we	O
found	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
fused	O
to	O
GAL4	B-GGP
DNA	B-SO
-	O
binding	O
domain	B-SO
functions	O
as	O
a	O
transcriptional	O
repressor	O
.	O

We	O
revealed	O
that	O
the	O
repression	O
activity	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
not	O
due	O
to	O
a	O
homophilic	O
interaction	O
through	O
its	O
SAM	O
domain	B-SO
but	O
to	O
the	O
C	B-SO
-	I-SO
terminal	I-SO
region	I-SO
.	O

Conclusion	O

We	O
identified	O
a	O
novel	O
gene	B-SO
,	O
mr	B-GGP
-	I-GGP
s	I-GGP
,	O
which	O
is	O
predominantly	O
expressed	O
in	O
retinal	B-CL
photoreceptors	I-CL
and	O
pineal	O
gland	O
.	O

Based	O
on	O
its	O
expression	O
pattern	O
and	O
biochemical	O
analysis	O
,	O
we	O
predict	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
may	O
function	O
as	O
a	O
transcriptional	O
repressor	O
in	O
photoreceptor	B-CL
cells	I-CL
and	O
in	O
pinealocytes	B-CL
of	O
the	O
pineal	O
gland	O
.	O

Background	O

In	O
the	O
development	O
of	O
the	O
mammalian	B-Taxon
retina	O
,	O
a	O
diverse	O
range	O
of	O
cell	B-CL
types	O
is	O
generated	O
from	O
a	O
pool	O
of	O
multipotent	B-CL
retinal	I-CL
progenitor	I-CL
cells	I-CL
.	O

Among	O
these	O
cell	B-CL
types	O
,	O
photoreceptors	B-CL
account	O
for	O
over	O
70	O
%	O
of	O
all	O
cells	B-CL
in	O
the	O
retina	O
.	O

In	O
vertebrates	B-Taxon
,	O
there	O
are	O
two	O
classes	O
of	O
photoreceptors	B-CL
,	O
rods	B-CL
and	O
cones	B-CL
.	O

Rods	B-CL
are	O
sensors	O
of	O
dim	O
light	O
,	O
while	O
cones	B-CL
function	O
in	O
bright	O
light	O
and	O
are	O
responsible	O
for	O
color	O
vision	O
.	O

Phototransduction	O
,	O
a	O
series	O
of	O
signal	O
amplifications	O
detecting	O
a	O
single	O
photon	B-CHEBI
of	O
light	O
,	O
is	O
initiated	O
by	O
the	O
capture	O
of	O
light	O
with	O
11	O
-	O
cis	O
-	O
retinal	O
,	O
a	O
chromophore	B-CHEBI
bound	O
by	O
the	O
opsin	B-GGP
proteins	B-CHEBI
:	O
rhodopsin	B-GGP
in	O
rods	B-CL
and	O
cone	B-CL
opsins	B-GGP
in	O
cones	B-CL
.	O

The	O
proteins	B-CHEBI
that	O
carry	O
out	O
phototransduction	O
are	O
located	O
in	O
an	O
elaborate	O
and	O
highly	O
specialized	O
membranous	B-GO
structure	O
,	O
the	O
outer	B-GO
segment	I-GO
.	O

The	O
outer	B-GO
segment	I-GO
appears	O
to	O
be	O
relatively	O
fragile	O
,	O
degenerating	O
in	O
response	O
to	O
many	O
environmental	O
and	O
/	O
or	O
genetic	B-SO
perturbations	O
.	O

In	O
the	O
rodent	B-Taxon
retina	O
,	O
the	O
production	O
of	O
specific	O
cell	B-CL
types	O
during	O
development	O
progresses	O
in	O
a	O
general	O
order	O
[	O
1	O
,	O
2	O
]	O
.	O

Rod	B-CL
photoreceptor	I-CL
generation	O
peaks	O
around	O
the	O
time	O
of	O
birth	O
.	O

Cone	B-CL
photoreceptors	I-CL
,	O
ganglion	B-CL
cells	I-CL
,	O
horizontal	B-CL
cells	I-CL
and	O
amacrine	B-CL
cells	I-CL
are	O
generated	O
earlier	O
,	O
while	O
M	B-CL
u	I-CL
ller	I-CL
glia	I-CL
and	O
bipolar	B-CL
cells	I-CL
are	O
generated	O
later	O
.	O

This	O
production	O
of	O
different	O
cell	B-CL
types	O
at	O
different	O
times	O
appears	O
to	O
derive	O
from	O
differences	O
in	O
the	O
intrinsic	O
properties	O
of	O
progenitor	O
cells	B-CL
involved	O
in	O
the	O
transcription	O
or	O
chromatin	B-GO
modification	O
.	O

Recent	O
studies	O
identified	O
several	O
important	O
transcription	O
factors	O
of	O
photoreceptor	B-CL
development	O
[	O
3	O
-	O
7	O
]	O
.	O

Two	O
Otx	O
family	O
homeobox	O
genes	B-SO
,	O
Otx2	B-GGP
and	O
Crx	B-GGP
,	O
play	O
essential	O
roles	O
in	O
early	O
cell	B-CL
fate	O
determination	O
and	O
terminal	O
differentiation	O
of	O
photoreceptors	B-CL
[	O
3	O
,	O
8	O
,	O
9	O
]	O
.	O

In	O
the	O
absence	O
of	O
Otx2	B-GGP
function	O
,	O
differentiating	O
photoreceptor	B-CL
cells	I-CL
are	O
converted	O
to	O
amacrine	B-CL
-	O
like	O
neurons	B-CL
[	O
9	O
]	O
.	O

Crx	B-GGP
,	O
a	O
downstream	O
target	O
of	O
Otx2	B-GGP
,	O
controls	O
the	O
transcription	O
of	O
various	O
photoreceptor	B-CL
cell	I-CL
-	O
specific	O
genes	B-SO
and	O
is	O
essential	O
for	O
the	O
formation	O
of	O
outer	B-GO
segments	I-GO
,	O
synaptic	B-GO
terminals	B-GO
,	O
and	O
phototransduction	O
pathways	O
[	O
8	O
,	O
10	O
]	O
.	O

Crx	B-GGP
transcripts	B-SO
begin	O
to	O
be	O
expressed	O
in	O
developing	O
photoreceptors	B-CL
at	O
embryonic	O
day	O
12	O
.	O
5	O
(	O
E12	O
.	O
5	O
)	O
in	O
the	O
mouse	B-Taxon
and	O
a	O
strong	O
upregulation	O
of	O
Crx	B-GGP
transcription	O
is	O
apparent	O
across	O
the	O
differentiating	O
photoreceptors	B-CL
at	O
postnatal	O
day	O
6	O
(	O
P6	O
)	O
.	O

Photoreceptor	B-CL
cells	I-CL
in	O
the	O
Crx	B-GGP
knockout	O
(	O
KO	O
)	O
mice	B-Taxon
exhibit	O
a	O
dramatic	O
reduction	O
of	O
many	O
photoreceptor	B-CL
molecules	B-CHEBI
including	O
visual	O
pigments	B-CHEBI
and	O
develop	O
neither	O
photoreceptor	B-GO
outer	I-GO
segments	I-GO
nor	O
a	O
synaptic	B-GO
terminus	B-GO
[	O
8	O
,	O
10	O
]	O
.	O

In	O
addition	O
,	O
mutations	B-SO
of	O
human	B-GGP
CRX	I-GGP
have	O
been	O
demonstrated	O
to	O
be	O
associated	O
with	O
three	O
types	O
of	O
photoreceptor	B-CL
diseases	O
:	O
autosomal	B-GO
dominant	O
cone	B-CL
-	O
rod	B-CL
dystrophy	O
2	O
,	O
autosomal	B-GO
dominant	O
-	O
type	O
retinitis	O
pigmentosa	O
,	O
and	O
Leber	O
'	O
s	O
congenital	O
amaurosis	O
(	O
LCA	O
)	O
[	O
11	O
-	O
14	O
]	O
.	O

While	O
Otx2	B-GGP
and	O
Crx	B-GGP
control	O
general	O
photoreceptor	B-CL
development	O
,	O
three	O
other	O
transcription	O
factors	O
,	O
TR	B-GGP
beta	I-GGP
2	I-GGP
,	O
Nrl	B-GGP
,	O
and	O
Nr2e3	B-GGP
regulate	O
the	O
specification	O
of	O
photoreceptor	B-CL
cell	I-CL
types	O
[	O
4	O
,	O
5	O
,	O
7	O
]	O
.	O

SAM	O
domains	B-SO
(	O
also	O
known	O
as	O
Pointed	O
,	O
HLH	O
,	O
or	O
SPM	O
domains	B-SO
)	O
are	O
~	O
70	O
residues	B-CHEBI
long	O
and	O
have	O
been	O
reported	O
as	O
common	O
protein	B-CHEBI
-	O
protein	B-CHEBI
interaction	O
modules	B-SO
[	O
15	O
-	O
17	O
]	O
.	O

This	O
domain	B-SO
is	O
found	O
in	O
a	O
large	O
number	O
of	O
proteins	B-CHEBI
,	O
including	O
Polycomb	O
group	O
(	O
PcG	O
)	O
proteins	B-CHEBI
[	O
18	O
]	O
,	O
serine	B-CHEBI
threonine	B-CHEBI
kinases	O
[	O
19	O
]	O
,	O
Eph	B-GGP
family	I-GGP
receptor	I-GGP
tyrosine	I-GGP
kinases	I-GGP
[	O
20	O
]	O
,	O
the	O
p73	B-GGP
tumor	I-GGP
suppressor	I-GGP
[	O
21	O
]	O
,	O
the	O
RNA	B-SO
-	O
binding	O
protein	B-CHEBI
Smaug	O
[	O
22	O
]	O
,	O
diacylglycerol	B-CHEBI
kinases	O
[	O
23	O
,	O
24	O
]	O
,	O
yeast	B-Taxon
mating	O
type	O
signaling	O
proteins	B-CHEBI
[	O
19	O
,	O
25	O
]	O
and	O
ETS	O
family	O
transcription	O
factors	O
[	O
26	O
,	O
27	O
]	O
.	O

The	O
PcG	O
proteins	B-CHEBI
are	O
transcriptional	O
repressors	O
that	O
maintain	O
gene	B-SO
silencing	O
during	O
development	O
[	O
28	O
-	O
30	O
]	O
.	O

In	O
mammals	B-Taxon
,	O
PcG	O
proteins	B-CHEBI
are	O
also	O
implicated	O
in	O
Hox	O
gene	B-SO
regulation	O
.	O

Their	O
biological	O
activity	O
lies	O
in	O
stable	O
silencing	O
of	O
specific	O
sets	O
of	O
genes	B-SO
through	O
chromatin	B-GO
modifications	O
.	O

A	O
member	O
of	O
polycomb	B-GO
repressive	I-GO
complex	I-GO
1	I-GO
(	O
PRC1	B-GO
)	O
,	O
ph	B-GGP
,	O
contains	O
a	O
SAM	O
domain	B-SO
at	O
the	O
C	B-SO
-	I-SO
terminal	I-SO
,	O
and	O
PRC1	B-GO
complex	I-GO
is	O
known	O
to	O
form	O
helical	B-SO
,	O
head	O
-	O
to	O
-	O
tail	O
polymers	B-CHEBI
through	O
its	O
SAM	O
domain	B-SO
[	O
31	O
]	O
.	O

These	O
polymeric	B-CHEBI
structures	O
mediate	O
the	O
formation	O
of	O
a	O
higher	O
order	O
chromatin	B-GO
structure	I-GO
and	O
possibly	O
stabilize	O
the	O
repressed	O
state	O
of	O
Hox	O
genes	B-SO
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
a	O
novel	O
gene	B-SO
,	O
mr	B-GGP
-	I-GGP
s	I-GGP
,	O
which	O
encodes	O
a	O
SAM	O
domain	B-SO
-	O
containing	O
protein	B-CHEBI
.	O

The	O
SAM	O
domain	B-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
most	O
closely	O
related	O
to	O
that	O
of	O
ph	B-GGP
mouse	B-Taxon
ortholog	B-SO
,	O
MPH1	B-GGP
/	O
Rae28	B-GGP
.	O

mr	B-GGP
-	I-GGP
s	I-GGP
is	O
predominantly	O
expressed	O
in	O
retinal	B-CL
photoreceptors	I-CL
when	O
they	O
undergo	O
terminal	O
differentiation	O
,	O
and	O
adult	O
pineal	O
gland	O
.	O

The	O
expression	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
directly	O
regulated	O
by	O
Crx	B-GGP
.	O

Moreover	O
,	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
localized	O
in	O
the	O
nucleus	B-GO
and	O
can	O
self	O
-	O
associate	O
through	O
its	O
SAM	O
domain	B-SO
-	O
containing	O
region	B-SO
.	O

We	O
also	O
found	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
fused	O
to	O
GAL4	B-GGP
DNA	B-SO
-	O
binding	O
domain	B-SO
functions	O
as	O
a	O
transcriptional	O
repressor	O
.	O

These	O
findings	O
suggest	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
functions	O
as	O
a	O
member	O
of	O
a	O
transcriptional	B-GO
repressor	I-GO
complex	I-GO
in	O
retinal	B-CL
photoreceptor	I-CL
development	O
.	O

Results	O

Cloning	O
of	O
mouse	B-GGP
mr	I-GGP
-	I-GGP
s	I-GGP

In	O
order	O
to	O
identify	O
novel	O
mouse	B-Taxon
genes	B-SO
preferentially	O
expressed	O
in	O
the	O
developing	O
retina	O
,	O
we	O
screened	O
the	O
National	O
Institute	O
for	O
Biotechnology	O
Information	O
(	O
NCBI	O
)	O
database	O
,	O
UniGene	O
,	O
using	O
Digital	O
Differential	O
Display	O
(	O
DDD	O
)	O
and	O
found	O
EST	B-SO
fragments	B-SO
which	O
are	O
frequently	O
present	O
in	O
mouse	B-Taxon
retinal	O
cDNA	B-SO
libraries	O
.	O

We	O
found	O
that	O
one	O
clone	B-SO
in	O
these	O
cDNAs	B-SO
encodes	O
a	O
protein	B-CHEBI
containing	O
a	O
SAM	O
domain	B-SO
related	O
to	O
that	O
of	O
polyhomeotic	B-GGP
protein	I-GGP
.	O

A	O
PCR	O
fragment	B-SO
corresponding	O
to	O
this	O
mouse	B-Taxon
clone	B-SO
was	O
used	O
to	O
screen	O
a	O
mouse	B-Taxon
P0	O
-	O
P3	O
retinal	O
cDNA	B-SO
library	O
to	O
obtain	O
a	O
full	O
-	O
length	O
cDNA	B-SO
clone	I-SO
.	O

Sequence	B-SO
analysis	O
showed	O
that	O
this	O
cDNA	B-SO
was	O
a	O
novel	O
gene	B-SO
encoding	O
a	O
SAM	O
domain	B-SO
-	O
containing	O
protein	B-CHEBI
.	O

We	O
referred	O
to	O
this	O
protein	B-CHEBI
as	O
mr	B-GGP
-	I-GGP
s	I-GGP
(	O
major	B-GGP
retinal	I-GGP
SAM	I-GGP
domain	I-GGP
protein	I-GGP
)	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

1A	O
,	O
a	O
translation	B-SO
initiation	I-SO
codon	I-SO
is	O
present	O
in	O
the	O
same	O
open	B-SO
reading	I-SO
frame	I-SO
as	O
the	O
SAM	O
domain	B-SO
.	O

This	O
initiation	B-SO
site	I-SO
shows	O
similarity	O
to	O
the	O
consensus	B-SO
sequence	I-SO
proposed	O
by	O
Kozak	O
[	O
32	O
]	O
including	O
the	O
presence	O
of	O
the	O
highly	O
conserved	B-SO
purine	O
at	O
position	B-SO
-	O
3	O
.	O

The	O
stop	B-SO
codon	I-SO
of	O
the	O
predicted	B-SO
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
is	O
also	O
indicated	O
in	O
Fig	O
.	O

1A	O
.	O

The	O
amino	B-SO
acid	I-SO
sequence	I-SO
of	O
the	O
SAM	O
domain	B-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
(	O
Fig	O
.	O
1A	O
,	O
boxed	O
sequence	B-SO
)	O
exhibits	O
homology	B-SO
with	O
SAM	O
domains	B-SO
of	O
EphB2	B-GGP
,	O
EphA4	B-GGP
,	O
MPH1	B-GGP
,	O
TEL	B-GGP
and	O
Smaug	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

By	O
phylogenetic	O
analysis	O
,	O
the	O
SAM	O
domain	B-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
most	O
closely	O
related	O
to	O
that	O
of	O
Mph1	B-GGP
/	O
Rae28	B-GGP
,	O
a	O
mouse	B-Taxon
homolog	B-SO
of	O
ph	B-GGP
(	O
Fig	O
.	O
1C	O
)	O
.	O

Mouse	B-GGP
mr	I-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
is	O
conserved	B-SO
in	O
rat	B-Taxon
,	O
human	B-Taxon
,	O
chick	B-Taxon
and	O
zebrafish	B-Taxon
,	O
which	O
display	O
91	O
%	O
,	O
70	O
%	O
,	O
36	O
%	O
and	O
26	O
%	O
identity	O
with	O
mouse	B-GGP
mr	I-GGP
-	I-GGP
s	I-GGP
,	O
respectively	O
(	O
Fig	O
.	O
1D	O
)	O
.	O

The	O
SAM	O
domains	B-SO
of	O
rat	B-GGP
,	I-GGP
human	I-GGP
,	I-GGP
chick	I-GGP
and	I-GGP
zebrafish	I-GGP
mr	I-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
are	O
highly	O
conserved	B-SO
and	O
display	O
96	O
%	O
,	O
90	O
%	O
,	O
76	O
%	O
and	O
72	O
%	O
identity	O
with	O
the	O
SAM	O
domain	B-SO
of	O
mouse	B-GGP
mr	I-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
.	O

The	O
chromosomal	B-SO
localizations	I-SO
of	O
mouse	B-GGP
and	I-GGP
human	I-GGP
mr	I-GGP
-	I-GGP
s	I-GGP
genes	B-SO
were	O
determined	O
by	O
searching	O
the	O
mouse	B-Taxon
and	O
human	B-Taxon
genome	B-SO
databases	O
(	O
NCBI	O
)	O
,	O
respectively	O
.	O

Mouse	B-GGP
mr	I-GGP
-	I-GGP
s	I-GGP
is	O
mapped	O
to	O
chromosome	B-GO
4E2	O
,	O
and	O
human	B-GGP
MR	I-GGP
-	I-GGP
S	I-GGP
is	O
mapped	O
to	O
chromosome	B-GO
1p36	O
.	O
33	O
.	O

LCA	O
is	O
the	O
most	O
common	O
cause	O
of	O
inherited	O
childhood	O
blindness	O
.	O

Human	B-GGP
MR	I-GGP
-	I-GGP
S	I-GGP
maps	O
in	O
the	O
vicinity	O
region	B-SO
of	O
the	O
LCA9	B-GGP
,	O
recently	O
identified	O
as	O
a	O
new	O
locus	B-SO
for	O
LCA	O
[	O
33	O
]	O
.	O

Figure	O
1	O

mr	B-GGP
-	I-GGP
s	I-GGP
nucleotide	B-SO
and	I-SO
amino	I-SO
acid	I-SO
sequences	I-SO
.	O

(	O
A	O
)	O
mr	B-GGP
-	I-GGP
s	I-GGP
nucleotide	B-SO
and	I-SO
amino	I-SO
acids	I-SO
sequences	I-SO
.	O

Boxed	O
amino	B-CHEBI
acids	I-CHEBI
are	O
the	O
SAM	O
domain	B-SO
sequence	I-SO
and	O
the	O
dashed	O
box	O
indicates	O
a	O
putative	O
nuclear	B-GO
localization	O
signal	B-SO
.	O

The	O
underline	O
indicates	O
a	O
putative	O
polyadenylation	B-SO
termination	I-SO
signal	I-SO
.	O

(	O
B	O
)	O
Alignment	O
of	O
SAM	O
domain	B-SO
sequences	I-SO
for	O
SAM	O
domain	B-SO
-	O
containing	O
proteins	B-CHEBI
.	O

The	O
five	O
alpha	B-SO
helices	I-SO
are	O
marked	O
H1	O
-	O
H5	O
.	O

Conserved	B-SO
amino	B-CHEBI
acid	I-CHEBI
residues	I-CHEBI
are	O
shown	O
with	O
a	O
dark	O
shadow	O
and	O
functionally	O
similar	O
residues	B-CHEBI
are	O
shown	O
with	O
a	O
light	O
shadow	O
.	O

The	O
sites	B-SO
that	O
were	O
targeted	O
for	O
mutagenesis	B-SO
are	O
indicated	O
by	O
arrows	O
.	O

(	O
C	O
)	O
Phylogenetic	O
tree	O
of	O
SAM	O
domain	B-SO
-	O
containing	O
proteins	B-CHEBI
.	O

Amino	B-SO
acid	I-SO
sequences	I-SO
were	O
analyzed	O
by	O
the	O
neighbor	O
-	O
joining	O
method	O
in	O
MacVector	O
7	O
.	O
2	O
.	O

Branch	O
lengths	O
reflect	O
the	O
mean	O
number	O
of	O
substitutions	B-SO
per	O
site	B-SO
.	O

(	O
D	O
)	O
Schematic	O
comparison	O
of	O
the	O
amino	B-SO
acid	I-SO
sequences	I-SO
for	O
mouse	B-GGP
,	I-GGP
rat	I-GGP
,	I-GGP
human	I-GGP
,	I-GGP
chick	I-GGP
and	I-GGP
zebrafish	I-GGP
mr	I-GGP
-	I-GGP
s	I-GGP
proteins	B-CHEBI
.	O

The	O
percent	O
similarity	O
of	O
the	O
SAM	O
domains	B-SO
and	O
other	O
regions	B-SO
to	O
the	O
corresponding	O
regions	B-SO
of	O
the	O
mouse	B-Taxon
protein	B-CHEBI
is	O
shown	O
.	O

Overall	O
sequence	B-SO
similarity	O
with	O
the	O
mouse	B-Taxon
protein	B-CHEBI
is	O
shown	O
on	O
the	O
right	O
.	O

Expression	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
in	O
the	O
developing	O
retina	O
and	O
the	O
pineal	O
gland	O

To	O
investigate	O
mr	B-GGP
-	I-GGP
s	I-GGP
expression	O
,	O
we	O
first	O
performed	O
whole	O
mount	O
in	O
situ	O
hybridization	O
in	O
mouse	B-Taxon
embryos	O
.	O

No	O
hybridization	O
signal	O
was	O
detected	O
at	O
E9	O
.	O
5	O
,	O
E10	O
.	O
5	O
and	O
E11	O
.	O
5	O
with	O
an	O
mr	B-GGP
-	I-GGP
s	I-GGP
probe	B-SO
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
then	O
investigated	O
the	O
expression	O
of	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
gene	B-SO
in	O
the	O
developing	O
retina	O
by	O
section	O
in	O
situ	O
hybridization	O
(	O
Fig	O
.	O
1A	O
-	O
G	O
)	O
.	O

No	O
significant	O
signal	O
was	O
detected	O
in	O
the	O
developing	O
retina	O
at	O
E13	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

A	O
weak	O
signal	O
was	O
initially	O
detected	O
in	O
the	O
outer	O
aspect	O
of	O
the	O
neuroblastic	O
layer	O
(	O
NBL	O
)	O
,	O
a	O
presumptive	O
photoreceptor	B-CL
layer	O
at	O
E18	O
(	O
Fig	O
.	O
2B	O
,	O
arrow	O
)	O
.	O

At	O
P3	O
,	O
an	O
mr	B-GGP
-	I-GGP
s	I-GGP
transcript	B-SO
was	O
clearly	O
detected	O
in	O
the	O
developing	O
photoreceptor	B-CL
layer	O
(	O
Fig	O
.	O
2E	O
)	O
.	O

At	O
P6	O
,	O
mr	B-GGP
-	I-GGP
s	I-GGP
showed	O
peak	O
expression	O
in	O
the	O
photoreceptor	B-CL
layer	O
(	O
Fig	O
.	O
2F	O
)	O
.	O

This	O
pattern	O
correlates	O
with	O
the	O
rapid	O
increase	O
in	O
cells	B-CL
expressing	O
rhodopsin	B-GGP
and	O
other	O
phototransduction	O
genes	B-SO
between	O
P6	O
-	O
P8	O
[	O
34	O
-	O
37	O
]	O
.	O

At	O
P9	O
,	O
the	O
intensity	O
of	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
signal	O
was	O
significantly	O
reduced	O
but	O
was	O
localized	O
to	O
the	O
outer	O
nuclear	O
layer	O
(	O
ONL	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

Faint	O
expression	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
mRNA	B-CHEBI
was	O
observed	O
in	O
mature	O
photoreceptors	B-CL
in	I-CL
the	I-CL
adult	I-CL
retina	I-CL
(	O
Fig	O
.	O
2G	O
)	O
.	O

Figure	O
2	O

mr	B-GGP
-	I-GGP
s	I-GGP
expression	O
in	O
developing	O
mouse	B-Taxon
retina	O
and	O
pineal	O
gland	O
.	O

(	O
A	O
-	O
G	O
)	O
mr	B-GGP
-	I-GGP
s	I-GGP
expression	O
during	O
development	O
of	O
the	O
mouse	B-Taxon
retina	O
.	O

The	O
in	O
situ	O
hybridization	O
signal	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
was	O
not	O
detected	O
at	O
E13	O
(	O
A	O
)	O
.	O

The	O
signal	O
(	O
arrow	O
)	O
was	O
first	O
detected	O
in	O
the	O
outer	O
aspect	O
of	O
NBL	O
at	O
E18	O
(	O
B	O
)	O
.	O

A	O
strong	O
mr	B-GGP
-	I-GGP
s	I-GGP
signal	O
was	O
detected	O
in	O
outer	O
layer	O
of	O
the	O
retina	O
at	O
P3	O
-	O
P6	O
,	O
and	O
then	O
the	O
signal	O
decreased	O
in	O
the	O
adult	O
retina	O
(	O
E	O
-	O
G	O
)	O
.	O

Control	O
with	O
the	O
sense	O
probe	B-SO
in	O
E18	O
retina	O
is	O
shown	O
(	O
C	O
)	O
.	O

Scale	O
bar	O
,	O
100	O
mu	O
m	O
.	O

(	O
H	O
)	O
Northern	O
blot	O
analysis	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
expression	O
in	O
adult	O
mouse	B-Taxon
organs	O
.	O

The	O
arrow	O
corresponds	O
to	O
2	O
.	O
2kb	O
mr	B-GGP
-	I-GGP
s	I-GGP
transcript	B-SO
.	O

(	O
I	O
)	O
RT	O
-	O
PCR	O
analysis	O
of	O
total	O
RNAs	B-SO
extracted	O
from	O
E13	O
whole	O
embryo	O
,	O
P0	O
whole	O
body	O
(	O
except	O
for	O
the	O
eye	O
)	O
,	O
P7	O
retina	O
,	O
P7	O
pineal	O
gland	O
,	O
P7	O
brain	O
,	O
P7	O
liver	O
,	O
adult	O
retina	O
,	O
adult	O
pineal	O
gland	O
,	O
adult	O
brain	O
and	O
adult	O
liver	O
,	O
respectively	O
.	O

RPE	O
,	O
retinal	O
pigment	O
epithelium	O
;	O
NR	O
,	O
neural	O
retina	O
;	O
NBL	O
,	O
neuroblastic	O
layer	O
;	O
GCL	O
,	O
ganglion	B-CL
cell	I-CL
layer	O
;	O
ONL	O
,	O
outer	O
nuclear	O
layer	O
;	O
INL	O
,	O
inner	O
nuclear	O
layer	O
.	O

To	O
determine	O
the	O
tissue	O
specificity	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
expression	O
,	O
the	O
expression	O
of	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
gene	B-SO
in	O
various	O
adult	O
tissues	O
was	O
examined	O
by	O
Northern	O
hybridization	O
(	O
Fig	O
.	O
2H	O
)	O
.	O

As	O
a	O
control	O
,	O
P7	O
retinal	O
RNA	B-SO
was	O
used	O
.	O

Four	O
bands	O
corresponding	O
to	O
7	O
.	O
2	O
-	O
kb	O
,	O
4	O
.	O
0	O
-	O
kb	O
,	O
2	O
.	O
5	O
-	O
kb	O
and	O
2	O
.	O
2	O
-	O
kb	O
were	O
detected	O
in	O
P7	O
retina	O
.	O

The	O
2	O
.	O
2	O
-	O
kb	O
band	O
corresponds	O
to	O
the	O
cDNA	B-SO
characterized	O
in	O
this	O
study	O
.	O

The	O
larger	O
bands	O
,	O
possibly	O
alternative	B-SO
spliced	I-SO
transcripts	I-SO
,	O
have	O
not	O
yet	O
been	O
characterized	O
.	O

The	O
mr	B-GGP
-	I-GGP
s	I-GGP
probe	B-SO
did	O
not	O
detect	O
a	O
band	O
in	O
the	O
adult	O
tissues	O
examined	O
,	O
indicating	O
that	O
these	O
tissues	O
do	O
not	O
express	O
mr	B-GGP
-	I-GGP
s	I-GGP
at	O
a	O
level	O
comparable	O
to	O
that	O
of	O
the	O
developing	O
retina	O
.	O

Previous	O
reports	O
revealed	O
that	O
many	O
photoreceptor	B-CL
-	O
specific	O
genes	B-SO
are	O
also	O
expressed	O
in	O
the	O
pineal	O
gland	O
[	O
38	O
]	O
.	O

We	O
examined	O
the	O
expression	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
transcripts	B-SO
in	O
the	O
whole	O
embryo	O
,	O
whole	O
body	O
,	O
retina	O
,	O
pineal	O
gland	O
,	O
brain	O
,	O
liver	O
and	O
other	O
organs	O
at	O
various	O
stages	O
by	O
RT	O
-	O
PCR	O
(	O
Fig	O
.	O
2I	O
and	O
data	O
not	O
shown	O
)	O
.	O

We	O
amplified	O
PCR	O
fragments	B-SO
of	I-SO
292	I-SO
bp	I-SO
and	I-SO
452	I-SO
bp	I-SO
with	I-SO
primer	I-SO
pairs	I-SO
for	I-SO
genes	I-SO
encoding	O
mouse	B-GGP
mr	I-GGP
-	I-GGP
s	I-GGP
and	I-GGP
G3PDH	I-GGP
,	O
respectively	O
.	O

In	O
E13	O
whole	O
embryo	O
and	O
P0	O
whole	O
body	O
(	O
except	O
for	O
the	O
eye	O
)	O
,	O
no	O
mr	B-GGP
-	I-GGP
s	I-GGP
signal	O
was	O
detected	O
.	O

As	O
expected	O
,	O
we	O
observed	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
expressed	O
in	O
the	O
P7	O
and	O
adult	O
pineal	O
gland	O
.	O

In	O
the	O
P7	O
and	O
adult	O
brain	O
,	O
liver	O
and	O
several	O
other	O
organs	O
,	O
the	O
RT	O
-	O
PCR	O
amplified	O
band	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
was	O
not	O
detected	O
(	O
Fig	O
.	O
2I	O
and	O
data	O
not	O
shown	O
)	O
.	O

Our	O
data	O
showed	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
predominantly	O
expressed	O
in	O
developing	O
photoreceptors	B-CL
and	O
the	O
pineal	O
gland	O
.	O

Regulation	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
transcription	O
by	O
Crx	B-GGP
homeodomain	I-GGP
protein	I-GGP

Transcription	O
factors	O
Otx2	B-GGP
and	O
Crx	B-GGP
are	O
known	O
to	O
be	O
key	O
regulators	O
of	O
retinal	B-CL
photoreceptor	I-CL
development	O
[	O
3	O
,	O
8	O
,	O
9	O
]	O
.	O

Although	O
both	O
Otx2	B-GGP
and	O
Crx	B-GGP
are	O
expressed	O
in	O
developing	O
photoreceptor	B-CL
cells	I-CL
in	I-CL
the	I-CL
embryonic	I-CL
retina	I-CL
,	O
only	O
Crx	B-GGP
is	O
highly	O
expressed	O
in	O
the	O
postnatal	O
photoreceptors	B-CL
,	O
suggesting	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
may	O
be	O
regulated	O
by	O
Crx	B-GGP
.	O

To	O
test	O
whether	O
Crx	B-GGP
regulates	O
mr	B-GGP
-	I-GGP
s	I-GGP
transcription	O
,	O
we	O
performed	O
in	O
situ	O
hybridization	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
mRNA	B-CHEBI
on	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Crx	B-GGP
KO	O
P5	O
retinas	O
(	O
Fig	O
.	O
3A	O
,	O
B	O
)	O
.	O

In	O
the	O
Crx	B-GGP
KO	O
retina	O
,	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
transcript	B-SO
was	O
dramatically	O
reduced	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

This	O
indicates	O
that	O
Crx	B-GGP
is	O
essential	O
for	O
transactivation	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
.	O

Moreover	O
,	O
to	O
test	O
whether	O
the	O
transcription	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
also	O
regulated	O
by	O
Crx	B-GGP
in	O
the	O
pineal	O
gland	O
,	O
RT	O
-	O
PCR	O
analysis	O
was	O
used	O
to	O
compare	O
transcriptional	O
levels	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
in	O
P28	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Crx	B-GGP
KO	O
pineal	O
gland	O
(	O
Fig	O
.	O
3C	O
)	O
.	O

The	O
results	O
revealed	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
transcription	O
was	O
significantly	O
downregulated	O
in	O
the	O
Crx	B-GGP
KO	O
pineal	O
gland	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
transcription	O
is	O
regulated	O
by	O
Crx	B-GGP
in	O
the	O
developing	O
photoreceptors	B-CL
and	O
pineal	O
gland	O
.	O

Figure	O
3	O

The	O
transcription	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
regulated	O
by	O
Crx	B-GGP
.	O

(	O
A	O
,	O
B	O
)	O
In	O
situ	O
hybridization	O
using	O
a	O
probe	B-SO
for	O
mouse	B-GGP
mr	I-GGP
-	I-GGP
s	I-GGP
was	O
performed	O
on	O
the	O
wild	B-SO
-	I-SO
type	I-SO
(	O
A	O
)	O
and	O
Crx	B-GGP
KO	O
retinas	O
(	O
B	O
)	O
at	O
P5	O
.	O

mr	B-GGP
-	I-GGP
s	I-GGP
expression	O
was	O
drastically	O
reduced	O
in	O
the	O
Crx	B-GGP
KO	O
retina	O
(	O
B	O
)	O
.	O

Scale	O
bar	O
,	O
100	O
mu	O
m	O
.	O

(	O
C	O
)	O
RT	O
-	O
PCR	O
analysis	O
of	O
total	O
RNAs	B-SO
extracted	O
from	O
the	O
pineal	O
glands	O
of	O
P5	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Crx	B-GGP
KO	O
mouse	B-Taxon
.	O

The	O
upper	O
and	O
lower	O
lanes	O
show	O
PCR	B-SO
products	I-SO
amplified	O
by	O
the	O
primer	B-SO
pairs	O
specific	O
for	O
mr	B-GGP
-	I-GGP
s	I-GGP
and	O
G3PDH	B-GGP
cDNAs	B-SO
,	O
respectively	O
.	O

Water	B-CHEBI
was	O
used	O
for	O
control	O
RT	O
-	O
PCR	O
reaction	O
.	O

(	O
D	O
-	O
F	O
)	O
Crx	B-GGP
transactivates	O
mr	B-GGP
-	I-GGP
s	I-GGP
transcription	O
.	O

Reporter	O
plasmids	B-SO
for	O
the	O
luciferase	O
assay	O
are	O
shown	O
.	O

Blue	O
boxes	O
represent	O
Crx	B-GGP
binding	B-SO
sites	I-SO
(	O
D	O
)	O
.	O

Relative	O
activity	O
of	O
the	O
luciferase	O
is	O
indicated	O
when	O
Pro1	O
.	O
2k	O
was	O
co	O
-	O
transfected	O
with	O
Crx	B-GGP
,	O
Otx2	B-GGP
,	O
Nrl	B-GGP
,	O
and	O
Crx	B-GGP
+	O
Nrl	B-GGP
,	O
respectively	O
(	O
E	O
)	O
.	O

Fold	O
activation	O
is	O
indicated	O
when	O
Pro1	O
.	O
2k	O
,	O
mut1259	O
,	O
mut198	O
,	O
mut72	O
and	O
mut	B-SO
all	O
were	O
co	O
-	O
transfected	O
with	O
the	O
Crx	B-GGP
expression	O
vector	B-SO
(	O
Crx	B-GGP
+	O
)	O
or	O
the	O
empty	O
vector	B-SO
(	O
Crx	B-GGP
-	O
)	O
into	O
HEK293T	O
cells	B-CL
(	O
F	O
)	O
.	O

Error	O
bars	O
represent	O
standard	O
error	O
of	O
mean	O
.	O

To	O
further	O
examine	O
whether	O
Crx	B-GGP
regulates	O
mr	B-GGP
-	I-GGP
s	I-GGP
transcription	O
directly	O
or	O
not	O
,	O
we	O
next	O
performed	O
a	O
luciferase	O
assay	O
using	O
the	O
1	O
.	O
2	O
-	O
kb	O
proximal	O
promoter	B-SO
region	B-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
fused	O
to	O
a	O
luciferase	O
gene	B-SO
as	O
a	O
luciferase	O
reporter	O
(	O
Fig	O
.	O
3D	O
,	O
Pro1	O
.	O
2k	O
)	O
and	O
the	O
Crx	B-GGP
,	O
Otx2	B-GGP
,	O
Nrl	B-GGP
expression	O
vectors	B-SO
,	O
respectively	O
.	O

This	O
1	O
.	O
2	O
-	O
kb	O
region	B-SO
of	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
upstream	O
sequence	B-SO
contains	O
three	O
Crx	B-GGP
binding	B-SO
consensus	I-SO
sequences	I-SO
.	O

As	O
shown	O
in	O
Fig	O
.	O

3E	O
,	O
the	O
luciferase	O
activity	O
was	O
significantly	O
upregulated	O
when	O
the	O
Crx	B-GGP
or	O
Otx2	B-GGP
expression	O
vector	B-SO
was	O
co	O
-	O
introduced	O
with	O
Pro1	O
.	O
2k	O
into	O
HEK293T	O
cells	B-CL
,	O
while	O
the	O
luciferase	O
activity	O
was	O
not	O
altered	O
when	O
the	O
Nrl	B-GGP
expression	O
vector	B-SO
was	O
co	O
-	O
introduced	O
.	O

A	O
previous	O
report	O
suggested	O
that	O
the	O
transcriptional	O
activity	O
of	O
Crx	B-GGP
is	O
augmented	O
with	O
Nrl	B-GGP
when	O
the	O
rhodopsin	B-GGP
promoter	B-SO
was	O
used	O
as	O
a	O
reporter	O
gene	B-SO
[	O
6	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
our	O
present	O
data	O
showed	O
that	O
the	O
luciferase	O
gene	B-SO
expression	O
was	O
not	O
upregulated	O
when	O
both	O
Crx	B-GGP
and	O
Nrl	B-GGP
expression	O
vectors	B-SO
were	O
co	O
-	O
introduced	O
with	O
Pro1	O
.	O
2k	O
compared	O
to	O
the	O
activity	O
when	O
the	O
Crx	B-GGP
only	O
expression	O
vector	B-SO
was	O
introduced	O
.	O

This	O
may	O
be	O
due	O
to	O
cell	B-CL
type	O
differences	O
because	O
a	O
cell	B-CL
type	O
of	O
retinal	O
/	O
pineal	O
origin	O
was	O
not	O
used	O
in	O
our	O
luciferase	O
assay	O
.	O

In	O
addition	O
,	O
our	O
present	O
data	O
showed	O
that	O
Otx2	B-GGP
,	O
which	O
is	O
reported	O
to	O
have	O
the	O
same	O
binding	O
consensus	B-SO
as	O
Crx	B-GGP
,	O
also	O
transactivated	O
mr	B-GGP
-	I-GGP
s	I-GGP
expression	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

2A	O
-	O
F	O
,	O
the	O
expression	O
pattern	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
correlates	O
with	O
that	O
of	O
Crx	B-GGP
.	O

In	O
contrast	O
,	O
the	O
transcripts	B-SO
of	O
Otx2	B-GGP
are	O
mainly	O
detected	O
in	O
the	O
photoreceptor	B-CL
layer	O
at	O
embryonic	O
stages	O
.	O

Therefore	O
,	O
we	O
concluded	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
transcription	O
is	O
directly	O
regulated	O
mainly	O
by	O
Crx	B-GGP
.	O

We	O
also	O
constructed	O
reporter	O
vectors	B-SO
in	O
which	O
mutations	B-SO
were	O
introduced	O
at	O
the	O
three	O
Crx	B-GGP
binding	B-SO
sites	I-SO
(	O
Fig	O
.	O
3D	O
,	O
mut1259	O
,	O
mut198	O
,	O
mut72	O
,	O
mut	B-SO
all	O
)	O
.	O

Then	O
the	O
Crx	B-GGP
expression	O
vector	B-SO
was	O
co	O
-	O
introduced	O
with	O
mut1259	O
,	O
mut198	O
,	O
mut72	O
and	O
mut	B-SO
all	O
,	O
respectively	O
(	O
Fig	O
.	O
3F	O
)	O
.	O

The	O
transactivaton	O
activity	O
by	O
Crx	B-GGP
was	O
clearly	O
reduced	O
when	O
mut198	O
or	O
mut72	O
was	O
co	O
-	O
introduced	O
.	O

On	O
the	O
other	O
hand	O
,	O
when	O
mut1259	O
was	O
co	O
-	O
transfected	O
,	O
the	O
transactivation	O
activity	O
by	O
Crx	B-GGP
was	O
not	O
altered	O
.	O

These	O
results	O
suggest	O
that	O
the	O
Crx	B-GGP
binding	B-SO
sites	I-SO
72	O
-	O
bp	B-SO
and	O
198	O
-	O
bp	B-SO
upstream	O
from	O
the	O
transcription	B-SO
initiation	I-SO
site	I-SO
are	O
crucial	O
for	O
the	O
direct	O
regulation	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
transcription	O
by	O
Crx	B-GGP
.	O

Self	O
-	O
association	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI

SAM	O
domains	B-SO
are	O
known	O
to	O
function	O
as	O
protein	B-CHEBI
-	O
protein	B-CHEBI
interaction	O
modules	B-SO
[	O
15	O
-	O
17	O
]	O
.	O

Although	O
SAM	O
domains	B-SO
can	O
bind	O
to	O
various	O
non	O
-	O
SAM	O
domain	B-SO
-	O
containing	O
proteins	B-CHEBI
,	O
many	O
homo	O
-	O
SAM	O
and	O
hetero	O
-	O
SAM	O
domain	B-SO
interactions	O
have	O
been	O
reported	O
.	O

To	O
investigate	O
whether	O
the	O
SAM	O
domain	B-SO
of	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
can	O
also	O
function	O
as	O
a	O
protein	B-CHEBI
-	O
protein	B-CHEBI
interaction	O
module	B-SO
,	O
we	O
performed	O
yeast	B-Taxon
two	O
-	O
hybrid	O
screening	O
using	O
full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
as	O
the	O
bait	O
.	O

Using	O
this	O
bait	O
,	O
we	O
screened	O
the	O
transcriptional	O
activator	O
fusion	B-SO
protein	B-CHEBI
library	O
in	O
which	O
mouse	B-Taxon
P0	O
-	O
P3	O
retinal	O
cDNAs	B-SO
were	O
fused	O
to	O
the	O
GAL4	B-GGP
activation	O
domain	B-SO
.	O

The	O
most	O
frequent	O
positive	O
clones	B-SO
(	O
5	O
out	O
of	O
28	O
)	O
were	O
cDNA	B-SO
fragments	B-SO
containing	O
the	O
SAM	O
domain	B-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
(	O
Fig	O
.	O
4A	O
)	O
.	O

This	O
result	O
strongly	O
suggests	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
self	O
-	O
associates	O
through	O
SAM	O
domain	B-SO
-	O
containing	O
regions	B-SO
.	O

We	O
then	O
directly	O
tested	O
this	O
self	O
-	O
association	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
in	O
yeast	B-Taxon
.	O

We	O
fused	O
full	O
-	O
length	O
or	O
truncated	O
portions	B-SO
of	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
to	O
the	O
DNA	B-SO
-	O
binding	O
domain	B-SO
of	O
the	O
yeast	B-Taxon
transcription	O
factor	O
GAL4	B-GGP
to	O
make	O
bait	O
constructs	B-SO
.	O

We	O
fused	O
full	O
-	O
length	O
or	O
truncated	O
portions	B-SO
of	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
to	O
the	O
GAL4	B-GGP
transcriptional	O
activation	O
domain	B-SO
to	O
make	O
prey	O
constructs	B-SO
(	O
Fig	O
.	O
4B	O
)	O
.	O

These	O
constructs	B-SO
were	O
transformed	O
into	O
yeast	B-Taxon
that	O
contain	O
a	O
transgene	B-SO
with	O
GAL4	B-GGP
binding	B-SO
sites	I-SO
upstream	O
of	O
the	O
lacZ	O
gene	B-SO
.	O

We	O
found	O
that	O
the	O
full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
bait	O
construct	B-SO
induced	O
lacZ	O
expression	O
with	O
the	O
full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
prey	O
construct	B-SO
(	O
Fig	O
.	O
4B	O
,	O
full	O
x	O
full	O
)	O
.	O

The	O
N	B-SO
-	I-SO
terminus	I-SO
400	I-SO
amino	I-SO
acid	I-SO
(	I-SO
aa	I-SO
)	I-SO
stretch	I-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
,	O
which	O
does	O
not	O
contain	O
a	O
SAM	O
domain	B-SO
,	O
does	O
weakly	O
activate	O
transcription	O
of	O
lacZ	O
(	O
Fig	O
.	O
4B	O
,	O
full	O
x	O
N	B-SO
)	O
.	O

The	O
N	B-SO
-	I-SO
terminus	I-SO
400	I-SO
aa	I-SO
stretch	I-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
was	O
able	O
to	O
induce	O
transcription	O
of	O
lacZ	O
weakly	O
with	O
the	O
same	O
N	B-SO
-	I-SO
terminus	I-SO
400	I-SO
aa	I-SO
stretch	I-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
(	O
Fig	O
.	O
4B	O
,	O
N	B-SO
x	O
N	B-SO
)	O
.	O

Although	O
the	O
N	B-SO
-	I-SO
terminus	I-SO
400	O
aa	B-CHEBI
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
weakly	O
activates	O
lacZ	O
transcription	O
with	O
the	O
same	O
N	B-SO
-	I-SO
terminus	I-SO
portion	I-SO
,	O
a	O
much	O
stronger	O
activation	O
of	O
lacZ	O
expression	O
was	O
observed	O
with	O
a	O
C	B-SO
-	I-SO
terminus	I-SO
portion	I-SO
encoding	O
the	O
391	O
-	O
542	O
aa	B-CHEBI
stretch	B-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
(	O
Fig	O
.	O
4B	O
,	O
full	O
x	O
C	B-SO
,	O
C	B-SO
x	O
C	B-SO
)	O
.	O

Our	O
GAL4	B-GGP
assay	O
indicated	O
that	O
the	O
signal	O
when	O
the	O
full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
was	O
present	O
in	O
both	O
the	O
bait	O
and	O
prey	O
contexts	O
was	O
weaker	O
than	O
when	O
isolated	O
SAM	O
domains	B-SO
were	O
used	O
.	O

This	O
may	O
simply	O
reflect	O
the	O
tendency	O
for	O
the	O
small	O
fusion	B-SO
proteins	B-CHEBI
to	O
enter	O
the	O
yeast	B-Taxon
nucleus	B-GO
and	O
occupy	O
GAL4	B-GGP
binding	B-SO
sites	I-SO
.	O

Alternatively	O
,	O
the	O
SAM	O
domain	B-SO
may	O
be	O
less	O
accessible	O
for	O
interaction	O
in	O
the	O
full	O
-	O
length	O
protein	B-CHEBI
context	O
as	O
previously	O
reported	O
[	O
39	O
]	O
.	O

Figure	O
4	O

Summary	O
of	O
yeast	B-Taxon
two	O
-	O
hybrid	O
screening	O
and	O
GAL4	B-GGP
assay	O
.	O

(	O
A	O
)	O
Full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
as	O
a	O
bait	O
used	O
in	O
the	O
yeast	B-Taxon
two	O
-	O
hybrid	O
screening	O
and	O
positive	O
clones	B-SO
are	O
indicated	O
.	O

Note	O
that	O
all	O
of	O
five	O
mr	B-GGP
-	I-GGP
s	I-GGP
clones	B-SO
identified	O
in	O
the	O
screening	O
contain	O
SAM	O
domains	B-SO
.	O

(	O
B	O
)	O
Schematic	O
diagram	O
of	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
fusion	B-SO
proteins	B-CHEBI
used	O
in	O
the	O
yeast	B-GGP
GAL4	I-GGP
assay	O
.	O

Black	O
boxes	O
represent	O
the	O
position	B-SO
of	I-SO
SAM	I-SO
domains	I-SO
.	O

Relative	O
levels	O
of	O
LacZ	O
expression	O
are	O
shown	O
on	O
the	O
right	O
,	O
respectively	O
.	O

Note	O
;	O
+	O
+	O
indicates	O
an	O
intense	O
blue	O
signal	O
visible	O
after	O
12hr	O
of	O
incubation	O
at	O
37	O
degrees	O
C	O
,	O
+	O
indicates	O
a	O
blue	O
signal	O
visible	O
after	O
24hr	O
of	O
incubation	O
.	O

BD	B-SO
,	O
binding	O
domain	B-SO
;	O
AD	O
,	O
activation	O
domain	B-SO
;	O
full	O
,	O
full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
;	O
N	B-SO
,	O
N	B-SO
-	I-SO
terminal	I-SO
portion	I-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
(	O
amino	B-CHEBI
acids	I-CHEBI
1	O
to	O
400	O
)	O
;	O
C	B-SO
,	O
C	B-SO
-	I-SO
terminal	I-SO
portion	I-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
(	O
amino	B-CHEBI
acids	I-CHEBI
391	O
to	O
542	O
)	O
.	O

To	O
confirm	O
self	O
-	O
association	O
of	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
in	O
mammalian	B-Taxon
cells	B-CL
,	O
we	O
next	O
performed	O
co	O
-	O
immunoprecipitation	O
studies	O
in	O
HEK293T	O
cells	B-CL
by	O
co	O
-	O
transfection	O
of	O
HA	O
-	O
tagged	O
full	O
-	O
length	O
/	O
truncated	O
mr	B-GGP
-	I-GGP
s	I-GGP
and	O
Flag	O
-	O
tagged	O
full	O
-	O
length	O
/	O
truncated	O
mr	B-GGP
-	I-GGP
s	I-GGP
(	O
Fig	O
.	O
5A	O
)	O
.	O

As	O
a	O
negative	O
control	O
,	O
we	O
constructed	O
Flag	O
-	O
tagged	O
Sonic	B-GGP
hedgehog	I-GGP
(	O
Shh	B-GGP
)	O
(	O
lane	O
2	O
and	O
7	O
)	O
.	O

In	O
accordance	O
with	O
the	O
result	O
of	O
the	O
yeast	B-Taxon
two	O
-	O
hybrid	O
GAL4	B-GGP
assay	O
,	O
HA	O
-	O
tagged	O
full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
(	O
full	O
-	O
HA	O
)	O
was	O
co	O
-	O
immunoprecipitated	O
with	O
Flag	O
-	O
tagged	O
full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
(	O
Flag	O
-	O
mrs	B-GGP
)	O
and	O
the	O
Flag	O
-	O
tagged	O
C	B-SO
-	I-SO
terminus	I-SO
portion	I-SO
containing	O
the	O
SAM	O
domain	B-SO
(	O
Flag	O
-	O
SAM	O
)	O
,	O
respectively	O
(	O
Fig	O
5B	O
,	O
lane3	O
and	O
lane5	O
)	O
.	O

We	O
also	O
found	O
a	O
weak	O
co	O
-	O
immunoprecipitation	O
band	O
in	O
co	O
-	O
transfection	O
of	O
full	O
-	O
HA	O
and	O
Flag	O
-	O
tagged	O
N	B-SO
-	I-SO
terminus	I-SO
portion	I-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
(	O
Flag	O
-	O
Delta	O
SAM	O
,	O
Fig	O
.	O
5B	O
,	O
lane	O
4	O
)	O
.	O

When	O
Delta	O
SAM	O
-	O
HA	O
and	O
Flag	O
-	O
tagged	O
deletion	B-SO
mutants	B-SO
were	O
co	O
-	O
transfected	O
,	O
Delta	O
SAM	O
-	O
HA	O
was	O
co	O
-	O
immunoprecipitated	O
with	O
Flag	O
-	O
mrs	B-GGP
and	O
Flag	O
-	O
Delta	O
SAM	O
(	O
Fig	O
.	O
5B	O
,	O
lane	O
8	O
and	O
lane	O
9	O
)	O
,	O
while	O
Delta	O
SAM	O
-	O
HA	O
was	O
not	O
co	O
-	O
immunoprecipitated	O
with	O
Flag	O
-	O
SAM	O
(	O
Fig	O
.	O
5B	O
,	O
lane	O
10	O
)	O
.	O

Figure	O
5	O

The	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
can	O
self	O
-	O
associate	O
in	O
mammalian	B-Taxon
cells	B-CL
.	O

(	O
A	O
)	O
Schematic	O
drawing	O
of	O
the	O
constructs	B-SO
used	O
for	O
immunoprecipitation	O
assay	O
.	O

HA	O
-	O
tagged	O
or	O
Flag	O
-	O
tagged	O
full	O
-	O
length	O
(	O
amino	B-CHEBI
acids	I-CHEBI
1	O
to	O
542	O
)	O
,	O
Delta	O
SAM	O
(	O
amino	B-CHEBI
acids	I-CHEBI
1	O
to	O
400	O
)	O
and	O
SAM	O
(	O
amino	B-CHEBI
acids	I-CHEBI
401	O
to	O
542	O
)	O
regions	B-SO
were	O
inserted	B-SO
into	O
pcDNA3	O
vector	B-SO
,	O
respectively	O
.	O

(	O
B	O
)	O
The	O
constructs	B-SO
indicated	O
above	O
were	O
transfected	O
into	O
HEK293T	O
cells	B-CL
.	O

Each	O
lane	O
was	O
co	O
-	O
immunoprecipitated	O
by	O
anti	O
-	O
Flag	O
antibody	B-GO
and	O
detected	O
by	O
anti	O
-	O
HA	O
antibody	B-GO
.	O

Input	O
protein	B-CHEBI
lysates	O
are	O
shown	O
in	O
the	O
lower	O
panels	O
.	O

(	O
C	O
)	O
Flag	O
-	O
tagged	O
two	O
site	B-SO
-	O
directed	O
mr	B-GGP
-	I-GGP
s	I-GGP
mutants	B-SO
,	O
Flag	O
-	O
W404A	O
and	O
Flag	O
-	O
G453A	O
were	O
generated	O
and	O
co	O
-	O
transfected	O
with	O
full	O
-	O
HA	O
.	O

Each	O
lane	O
was	O
co	O
-	O
immunoprecipitated	O
by	O
anti	O
-	O
HA	O
antibody	B-GO
and	O
detected	O
by	O
anti	O
-	O
Flag	O
antibody	B-GO
.	O

To	O
investigate	O
whether	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
self	O
-	O
associates	O
mainly	O
through	O
the	O
SAM	O
domain	B-SO
,	O
two	O
site	B-SO
-	O
directed	O
mutations	B-SO
were	O
generated	O
in	O
the	O
SAM	O
domain	B-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
(	O
Fig	O
.	O
1B	O
,	O
arrows	O
)	O
.	O

These	O
mutations	B-SO
alter	B-SO
residues	B-CHEBI
that	O
are	O
conserved	B-SO
in	O
the	O
SAM	O
domain	B-SO
of	O
ph	B-GGP
and	O
previous	O
report	O
indicates	O
that	O
these	O
mutations	B-SO
of	O
ph	B-GGP
-	O
SAM	O
cause	O
significant	O
reduction	O
in	O
binding	O
activity	O
to	O
the	O
other	O
SAM	O
domain	B-SO
-	O
containing	O
protein	B-CHEBI
,	O
Sex	B-GGP
comb	I-GGP
on	I-GGP
midleg	I-GGP
(	O
Scm	B-GGP
)	O
(	O
41	O
)	O
.	O

Based	O
on	O
this	O
result	O
,	O
we	O
introduced	O
two	O
types	O
of	O
site	B-SO
-	O
directed	O
mutations	B-SO
,	O
which	O
correspond	O
to	O
the	O
mutations	B-SO
introduced	O
in	O
ph	B-GGP
protein	B-CHEBI
,	O
into	O
Flag	O
-	O
tagged	O
full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
(	O
Flag	O
-	O
W404A	O
and	O
Flag	O
-	O
G453A	O
)	O
.	O

We	O
found	O
that	O
Flag	O
-	O
W404A	O
binding	O
activity	O
was	O
significantly	O
reduced	O
and	O
Flag	O
-	O
G453A	O
binding	O
activity	O
was	O
also	O
slightly	O
reduced	O
compared	O
to	O
Flag	O
-	O
mrs	B-GGP
(	O
Fig	O
.	O
5C	O
)	O
.	O

These	O
results	O
,	O
together	O
with	O
yeast	O
two	O
-	O
hybrid	O
GAL4	B-GGP
assay	O
,	O
indicate	O
that	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
self	O
-	O
associates	O
strongly	O
through	O
its	O
SAM	O
domain	B-SO
and	O
weakly	O
through	O
the	O
N	B-SO
-	I-SO
terminus	I-SO
portion	I-SO
lacking	O
SAM	O
domain	B-SO
.	O

The	O
subcellular	O
localization	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
in	O
mammalian	B-Taxon
cells	B-CL

The	O
putative	O
nuclear	B-GO
localization	O
signal	B-SO
at	O
the	O
N	B-SO
-	I-SO
terminus	I-SO
of	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
(	O
Fig	O
.	O
1A	O
,	O
dashed	O
box	O
)	O
suggests	O
that	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
localizes	O
in	O
the	O
nucleus	B-GO
.	O

To	O
determine	O
the	O
subcellular	O
localization	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
in	O
mammalian	B-Taxon
cells	B-CL
,	O
we	O
introduced	O
an	O
HA	O
-	O
tagged	O
full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
plasmid	B-SO
into	O
HEK293T	O
cells	B-CL
.	O

Confocal	O
microscopy	O
showed	O
that	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
localized	O
mainly	O
in	O
the	O
nucleus	B-GO
of	O
HEK293T	O
cells	B-CL
(	O
Fig	O
.	O
6A	O
,	O
B	O
)	O
.	O

To	O
confirm	O
the	O
precise	O
localization	O
of	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
,	O
full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
was	O
co	O
-	O
immunostained	O
with	O
DAPI	O
(	O
Fig	O
.	O
6C	O
-	O
E	O
)	O
.	O

These	O
data	O
showed	O
that	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
localizes	O
preferentially	O
to	O
the	O
nucleus	B-GO
in	O
mammalian	B-Taxon
cells	B-CL
,	O
supporting	O
the	O
idea	O
that	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
is	O
involved	O
in	O
transcriptional	O
regulation	O
as	O
are	O
ph	B-GGP
and	O
/	O
or	O
TEL	B-GGP
.	O

Figure	O
6	O

Subcellular	O
localization	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
in	O
mammalian	B-Taxon
cells	B-CL
.	O

(	O
A	O
,	O
B	O
)	O
HA	O
-	O
tagged	O
full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
was	O
transfected	O
into	O
HEK293T	O
(	O
B	O
)	O
and	O
detected	O
by	O
anti	O
-	O
HA	O
antibody	B-GO
(	O
A	O
)	O
.	O

Scale	O
bar	O
,	O
20	O
mu	O
m	O
.	O

(	O
C	O
-	O
E	O
)	O
HEK293T	O
cells	B-CL
immunostained	O
with	O
anti	O
-	O
HA	O
antibody	B-GO
(	O
C	O
)	O
,	O
DAPI	O
(	O
D	O
)	O
,	O
and	O
merged	O
image	O
(	O
E	O
)	O
.	O

Scale	O
bar	O
,	O
50	O
mu	O
m	O
.	O

The	O
GAL4	B-GGP
-	O
mr	B-GGP
-	I-GGP
s	I-GGP
fusion	B-SO
protein	B-CHEBI
functions	O
as	O
transcriptional	O
repressor	O

A	O
member	O
of	O
PcG	O
proteins	B-CHEBI
,	O
ph	B-GGP
,	O
does	O
not	O
contain	O
an	O
obvious	O
sequence	B-SO
-	O
specific	O
DNA	B-SO
binding	O
motif	O
(	O
16	O
)	O
.	O

Ph	B-GGP
functions	O
as	O
a	O
transcriptional	O
repressor	O
through	O
its	O
polymerization	O
and	O
protein	B-CHEBI
-	O
protein	B-CHEBI
interaction	O
with	O
other	O
sequence	B-SO
-	O
specific	O
transcriptional	O
repressors	O
,	O
which	O
can	O
form	O
a	O
higher	O
order	O
chromatin	B-GO
structure	I-GO
.	O

The	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
also	O
does	O
not	O
have	O
an	O
obvious	O
DNA	B-SO
-	O
binding	O
domain	B-SO
.	O

To	O
characterize	O
the	O
biochemical	O
activity	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
,	O
we	O
next	O
performed	O
a	O
luciferase	O
assay	O
.	O

We	O
generated	O
effector	O
plasmids	B-SO
,	O
which	O
express	O
various	O
deletion	B-SO
constructs	B-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
fused	O
to	O
the	O
GAL4	B-GGP
DNA	B-SO
-	O
binding	O
domain	B-SO
(	O
Fig	O
.	O
7A	O
)	O
.	O

We	O
first	O
confirmed	O
that	O
full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
fused	O
to	O
GAL4	B-GGP
DNA	B-SO
binding	O
domain	B-SO
(	O
DBD	O
-	O
mrs	B-GGP
)	O
had	O
no	O
effect	O
on	O
the	O
pGL3	O
promoter	B-SO
plasmid	B-SO
lacking	O
GAL4	B-GGP
binding	B-SO
sites	I-SO
(	O
data	O
not	O
shown	O
)	O
.	O

When	O
the	O
5xGAL4	O
-	O
pGL3	O
reporter	O
plasmid	B-SO
was	O
co	O
-	O
transfected	O
,	O
DBD	O
-	O
mrs	B-GGP
repressed	O
luciferase	O
activity	O
by	O
about	O
90	O
%	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Fig	O
.	O
7B	O
)	O
.	O

As	O
a	O
control	O
,	O
GAL4	B-GGP
DNA	B-SO
-	O
binding	O
domain	B-SO
(	O
DBD	O
)	O
had	O
no	O
significant	O
effect	O
on	O
the	O
5xGAL4	O
-	O
pGL3	O
reporter	O
plasmid	B-SO
.	O

In	O
addition	O
,	O
we	O
confirmed	O
that	O
full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
without	O
GAL4	B-GGP
DBD	O
had	O
no	O
effect	O
on	O
the	O
same	O
reporter	O
plasmid	B-SO
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
next	O
analyzed	O
deletion	B-SO
constructs	B-SO
in	O
which	O
the	O
N	B-SO
-	I-SO
terminus	I-SO
400	I-SO
aa	I-SO
stretch	I-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
(	O
amino	B-CHEBI
acids	I-CHEBI
1	O
to	O
400	O
)	O
or	O
the	O
C	B-SO
-	I-SO
terminus	I-SO
portion	I-SO
(	O
amino	B-CHEBI
acids	I-CHEBI
391	O
to	O
542	O
)	O
were	O
fused	O
to	O
the	O
GAL4	B-GGP
DBD	O
(	O
Fig	O
.	O
7A	O
,	O
DBD	O
-	O
N	B-SO
,	O
DBD	O
-	O
C	B-SO
)	O
.	O

While	O
DBD	O
-	O
N	B-SO
had	O
no	O
repressive	O
effect	O
on	O
this	O
reporter	O
activity	O
,	O
DBD	O
-	O
C	B-SO
repressed	O
luciferase	O
gene	B-SO
expression	O
by	O
about	O
65	O
%	O
.	O

This	O
result	O
suggested	O
to	O
us	O
the	O
possibility	O
that	O
DBD	O
-	O
mrs	B-GGP
exerts	O
transcriptional	O
repressive	O
activity	O
via	O
self	O
-	O
association	O
through	O
its	O
SAM	O
domain	B-SO
.	O

To	O
investigate	O
whether	O
the	O
homophilic	O
association	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
required	O
for	O
transcriptional	O
repression	O
,	O
two	O
site	B-SO
-	O
directed	O
mutants	B-SO
,	O
DBD	O
-	O
W404A	O
and	O
DBD	O
-	O
G453A	O
,	O
either	O
of	O
which	O
may	O
reduce	O
self	O
-	O
binding	O
ability	O
,	O
were	O
analyzed	O
(	O
Fig	O
.	O
7C	O
)	O
.	O

Compared	O
to	O
DBD	O
-	O
mrs	B-GGP
,	O
DBD	O
-	O
W404A	O
and	O
DBD	O
-	O
G453A	O
had	O
repression	O
activity	O
of	O
72	O
%	O
and	O
87	O
%	O
,	O
respectively	O
.	O

While	O
the	O
ability	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
self	O
-	O
association	O
partially	O
correlates	O
with	O
transcriptional	O
repressive	O
activity	O
,	O
these	O
mutants	B-SO
do	O
not	O
compromise	O
the	O
ability	O
to	O
repress	O
transcription	O
critically	O
.	O

To	O
determine	O
the	O
regions	B-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
involved	O
in	O
transcriptional	O
repression	O
more	O
precisely	O
,	O
the	O
C	B-SO
-	I-SO
terminus	I-SO
portion	I-SO
was	O
divided	O
into	O
two	O
regions	B-SO
and	O
each	O
was	O
fused	O
to	O
the	O
GAL4	B-GGP
DBD	O
(	O
Fig	O
.	O
7A	O
,	O
DBD	O
-	O
tail	O
,	O
DBD	O
-	O
SAM	O
)	O
.	O

As	O
a	O
consequence	O
,	O
DBD	O
-	O
SAM	O
(	O
amino	B-CHEBI
acids	I-CHEBI
384	O
to	O
462	O
)	O
did	O
not	O
have	O
a	O
repressive	O
effect	O
on	O
the	O
5xGAL4	O
-	O
pGL3	O
reporter	O
plasmid	B-SO
.	O

On	O
the	O
other	O
hand	O
,	O
luciferase	O
activity	O
was	O
repressed	O
by	O
55	O
%	O
when	O
DBD	O
-	O
tail	O
(	O
amino	B-CHEBI
acids	I-CHEBI
459	O
to	O
542	O
)	O
was	O
co	O
-	O
transfected	O
with	O
this	O
reporter	O
plasmid	B-SO
(	O
Fig	O
.	O
7D	O
)	O
.	O

To	O
assess	O
the	O
transcriptional	O
repressive	O
activity	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
in	O
cells	B-CL
of	O
retinal	O
origin	O
,	O
we	O
performed	O
similar	O
experiments	O
using	O
human	B-Taxon
Y79	O
retinoblastoma	O
cells	B-CL
.	O

The	O
results	O
indicated	O
that	O
DBD	O
-	O
mrs	B-GGP
also	O
reduced	O
luciferase	O
activity	O
significantly	O
in	O
Y79	O
retinoblastoma	O
cells	B-CL
(	O
Fig	O
.	O
7E	O
)	O
.	O

However	O
,	O
luciferase	O
activity	O
was	O
repressed	O
by	O
about	O
30	O
%	O
in	O
Y79	O
cells	B-CL
,	O
while	O
it	O
was	O
repressed	O
by	O
90	O
%	O
in	O
HEK293T	O
cells	B-CL
.	O

This	O
might	O
be	O
due	O
to	O
the	O
difference	O
in	O
transfection	O
efficiency	O
between	O
these	O
cell	B-CL
lines	O
.	O

Another	O
possibility	O
is	O
that	O
intracellular	B-GO
environment	I-GO
in	O
Y79	O
cells	B-CL
,	O
a	O
retinoblastoma	O
cell	B-CL
line	O
,	O
is	O
insufficient	O
for	O
recapitulating	O
developing	O
photoreceptors	B-CL
.	O

In	O
this	O
study	O
,	O
we	O
did	O
not	O
address	O
the	O
question	O
whether	O
or	O
not	O
our	O
in	O
vitro	O
data	O
reflect	O
native	O
mr	B-GGP
-	I-GGP
s	I-GGP
transcriptional	O
repression	O
in	O
vivo	O
.	O

However	O
,	O
these	O
in	O
vitro	O
experiments	O
using	O
HEK293T	O
and	O
Y79	O
cells	B-CL
strongly	O
support	O
our	O
hypothesis	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
functions	O
as	O
a	O
transcriptional	O
repressor	O
in	O
developing	O
photoreceptors	B-CL
.	O

Our	O
results	O
suggested	O
that	O
the	O
C	B-SO
-	I-SO
terminal	I-SO
region	I-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
(	O
amino	B-CHEBI
acids	I-CHEBI
463	O
to	O
542	O
)	O
is	O
required	O
for	O
transcriptional	O
repression	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
and	O
the	O
SAM	O
domain	B-SO
appears	O
to	O
be	O
dispensable	O
for	O
this	O
repressive	O
activity	O
.	O

This	O
C	B-SO
-	I-SO
terminal	I-SO
region	I-SO
of	O
mouse	B-GGP
mr	I-GGP
-	I-GGP
s	I-GGP
is	O
highly	O
conserved	B-SO
among	O
species	O
(	O
Fig	O
.	O
7F	O
)	O
.	O

The	O
sequence	B-SO
identity	O
of	O
the	O
region	B-SO
was	O
93	O
%	O
,	O
73	O
%	O
,	O
41	O
%	O
and	O
40	O
%	O
for	O
rat	B-Taxon
,	O
human	B-Taxon
,	O
chick	B-Taxon
and	O
zebrafish	B-Taxon
,	O
respectively	O
(	O
Fig	O
.	O
1D	O
)	O
.	O

This	O
strongly	O
suggests	O
that	O
the	O
C	B-SO
-	I-SO
terminal	I-SO
region	I-SO
of	O
mouse	B-GGP
mr	I-GGP
-	I-GGP
s	I-GGP
functions	O
as	O
a	O
transcriptional	O
repressive	O
domain	B-SO
in	O
photoreceptor	B-CL
development	O
.	O

However	O
,	O
this	O
region	B-SO
does	O
not	O
contain	O
characteristic	O
amino	B-CHEBI
acid	I-CHEBI
motifs	O
and	O
the	O
mechanism	O
through	O
which	O
the	O
region	B-SO
achieves	O
and	O
/	O
or	O
maintains	O
gene	B-SO
repression	O
remains	O
to	O
be	O
clarified	O
in	O
the	O
future	O
.	O

Figure	O
7	O

mr	B-GGP
-	I-GGP
s	I-GGP
fused	O
to	O
GAL4	B-GGP
DNA	B-SO
binding	O
domain	B-SO
functions	O
as	O
a	O
transcriptional	O
repressor	O
in	O
HEK293T	O
cells	B-CL
.	O

(	O
A	O
)	O
Schematic	O
drawing	O
of	O
the	O
constructs	B-SO
used	O
for	O
the	O
luciferase	O
assay	O
.	O

5xGAL4	O
-	O
pGL3	O
reporter	O
plasmid	B-SO
was	O
co	O
-	O
transfected	O
into	O
HEK293T	O
cells	B-CL
with	O
effector	O
plasmids	B-SO
expressing	O
various	O
deletion	B-SO
mutants	B-SO
fused	O
to	O
GAL4	B-GGP
-	O
DBD	O
.	O

(	O
B	O
)	O
Various	O
amounts	O
of	O
DBD	O
,	O
DBD	O
-	O
mrs	B-GGP
,	O
DBD	O
-	O
N	B-SO
or	O
DBD	O
-	O
C	B-SO
plasmids	B-SO
were	O
transfected	O
with	O
0	O
.	O
1	O
mu	O
g	O
of	O
5xGAL4	O
-	O
pGL3	O
reporter	O
plasmid	B-SO
.	O

The	O
reporter	O
activity	O
in	O
the	O
presence	O
of	O
the	O
pcDNA3	O
vector	B-SO
(	O
pcDNA3	O
)	O
was	O
designated	O
as	O
1	O
.	O

Error	O
bars	O
represent	O
standard	O
error	O
of	O
mean	O
.	O

(	O
C	O
)	O
DBD	O
-	O
W404A	O
and	O
DBD	O
-	O
G453A	O
were	O
co	O
-	O
transfected	O
into	O
HEK293T	O
cells	B-CL
with	O
5xGAL4	O
-	O
pGL3	O
reporter	O
plasmid	B-SO
.	O

Fold	O
repression	O
was	O
calculated	O
as	O
the	O
fold	O
decrease	O
in	O
luciferase	O
activity	O
compared	O
with	O
DBD	O
-	O
mrs	B-GGP
.	O

Error	O
bars	O
represent	O
standard	O
deviation	O
.	O

(	O
D	O
)	O
Various	O
amounts	O
of	O
DBD	O
-	O
tail	O
or	O
DBD	O
-	O
SAM	O
were	O
transfected	O
with	O
5xGAL4	O
-	O
pGL3	O
reporter	O
plasmid	B-SO
.	O

Error	O
bars	O
represent	O
standard	O
error	O
of	O
mean	O
.	O

(	O
E	O
)	O
pcDNA3	O
or	O
DBD	O
-	O
mrs	B-GGP
(	O
5	O
mu	O
g	O
)	O
was	O
co	O
-	O
transfected	O
into	O
Y79	O
retinoblastoma	O
cells	B-CL
with	O
0	O
.	O
5	O
mu	O
g	O
of	O
5xGAL4	O
-	O
pGL3	O
reporter	O
plasmid	B-SO
.	O

The	O
reporter	O
activity	O
in	O
the	O
presence	O
of	O
pcDNA3	O
was	O
designated	O
as	O
1	O
.	O

Error	O
bars	O
represent	O
standard	O
deviation	O
.	O

Asterisk	O
marks	O
statistically	O
significant	O
difference	O
(	O
Student	O
'	O
s	O
t	O
test	O
:	O
p	O
<	O
0	O
.	O
03	O
)	O
.	O

(	O
F	O
)	O
Alignment	O
of	O
the	O
C	B-SO
-	I-SO
terminal	I-SO
regions	I-SO
for	O
mouse	B-GGP
,	I-GGP
rat	I-GGP
,	I-GGP
human	I-GGP
,	I-GGP
chick	I-GGP
and	I-GGP
zebrafish	I-GGP
mr	I-GGP
-	I-GGP
s	I-GGP
proteins	B-CHEBI
.	O

Conserved	B-SO
amino	B-CHEBI
acid	I-CHEBI
residues	I-CHEBI
are	O
shown	O
with	O
a	O
dark	O
shadow	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
DBD	O
-	O
mrs	B-GGP
functions	O
as	O
a	O
transcriptional	O
repressor	O
and	O
that	O
the	O
repression	O
activity	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
not	O
due	O
to	O
a	O
homophilic	O
interaction	O
through	O
its	O
SAM	O
domain	B-SO
but	O
to	O
the	O
C	B-SO
-	I-SO
terminal	I-SO
region	I-SO
(	O
amino	B-CHEBI
acids	I-CHEBI
463	O
to	O
542	O
)	O
.	O

Discussion	O

In	O
the	O
present	O
study	O
,	O
we	O
identified	O
a	O
novel	O
gene	B-SO
,	O
mr	B-GGP
-	I-GGP
s	I-GGP
,	O
which	O
is	O
predominantly	O
expressed	O
in	O
retinal	B-CL
photoreceptors	I-CL
and	O
the	O
pineal	O
gland	O
.	O

The	O
peak	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
expression	O
in	O
the	O
developing	O
retina	O
is	O
around	O
P6	O
.	O

This	O
expression	O
pattern	O
correlates	O
with	O
the	O
rapid	O
increase	O
of	O
Crx	B-GGP
,	O
rhodopsin	B-GGP
and	O
other	O
photoreceptor	B-CL
genes	B-SO
around	O
P6	O
-	O
P8	O
.	O

Around	O
P6	O
,	O
the	O
outer	O
plexiform	O
layer	O
becomes	O
visible	O
and	O
the	O
outer	O
layer	O
of	O
retina	O
separates	O
into	O
two	O
layers	O
,	O
ONL	O
and	O
INL	O
.	O

At	O
the	O
same	O
time	O
,	O
photoreceptors	B-CL
begin	O
to	O
undergo	O
terminal	O
differentiation	O
,	O
forming	O
the	O
outer	B-GO
segment	I-GO
.	O

We	O
therefore	O
hypothesized	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
a	O
key	O
molecule	B-CHEBI
in	O
the	O
late	O
development	O
of	O
photoreceptors	B-CL
.	O

We	O
previously	O
reported	O
that	O
Otx2	B-GGP
and	O
Crx	B-GGP
have	O
a	O
critical	O
role	O
in	O
photoreceptor	B-CL
development	O
and	O
that	O
Otx2	B-GGP
directly	O
regulates	O
Crx	B-GGP
transcription	O
[	O
3	O
,	O
9	O
]	O
.	O

In	O
situ	O
hybridization	O
and	O
RT	O
-	O
PCR	O
showed	O
significant	O
reduction	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
signal	O
in	O
the	O
Crx	B-GGP
KO	O
retina	O
and	O
pineal	O
gland	O
.	O

Furthermore	O
,	O
the	O
luciferase	O
assay	O
demonstrated	O
that	O
Otx2	B-GGP
and	O
Crx	B-GGP
may	O
directly	O
upregulate	O
the	O
transcription	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
in	O
mammalian	B-Taxon
cells	B-CL
.	O

In	O
retinal	B-CL
photoreceptor	I-CL
cells	I-CL
,	O
the	O
Otx2	B-GGP
transcripts	B-SO
are	O
not	O
highly	O
expressed	O
at	O
P6	O
-	O
P9	O
,	O
while	O
the	O
Crx	B-GGP
transcripts	B-SO
are	O
strongly	O
detected	O
around	O
P6	O
.	O

Therefore	O
,	O
our	O
results	O
strongly	O
suggest	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
transcription	O
is	O
directly	O
regulated	O
by	O
Crx	B-GGP
.	O

In	O
the	O
present	O
study	O
,	O
Nrl	B-GGP
,	O
a	O
photoreceptor	B-CL
-	O
specific	O
transcription	O
factor	O
that	O
is	O
highly	O
expressed	O
in	O
photoreceptors	B-CL
at	O
the	O
postnatal	O
stage	O
,	O
did	O
not	O
affect	O
the	O
transcription	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
.	O

This	O
finding	O
is	O
actually	O
consistent	O
with	O
the	O
analysis	O
of	O
the	O
Nrl	B-GGP
KO	O
mouse	B-Taxon
which	O
was	O
recently	O
reported	O
[	O
40	O
]	O
.	O

The	O
expression	O
profiles	O
of	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Nrl	B-GGP
KO	O
retinas	O
at	O
P2	O
,	O
P10	O
and	O
2	O
months	O
were	O
analyzed	O
and	O
mr	B-GGP
-	I-GGP
s	I-GGP
was	O
not	O
included	O
in	O
161	O
differentially	O
expressed	O
genes	B-SO
in	O
the	O
Nrl	B-GGP
KO	O
retina	O
.	O

Previous	O
reports	O
suggested	O
that	O
the	O
SAM	O
domain	B-SO
is	O
a	O
protein	B-CHEBI
-	O
protein	B-CHEBI
interaction	O
module	B-SO
.	O

The	O
SAM	O
domain	B-SO
of	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
is	O
closely	O
related	O
to	O
that	O
of	O
ph	B-GGP
and	O
TEL	B-GGP
,	O
whose	O
SAM	O
domains	B-SO
can	O
form	O
a	O
helical	B-SO
,	O
head	O
-	O
to	O
-	O
tail	O
polymeric	B-CHEBI
structure	O
and	O
mediate	O
the	O
formation	O
of	O
a	O
higher	O
order	O
chromatin	B-GO
structure	O
.	O

To	O
characterize	O
the	O
biochemical	O
function	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
,	O
we	O
performed	O
yeast	B-Taxon
two	O
-	O
hybrid	O
screening	O
using	O
full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
as	O
the	O
bait	O
.	O

As	O
a	O
result	O
,	O
the	O
most	O
frequent	O
positive	O
clones	B-SO
(	O
5	O
/	O
28	O
)	O
in	O
the	O
screening	O
were	O
the	O
cDNA	B-SO
fragments	B-SO
containing	O
the	O
SAM	O
domain	B-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
.	O

This	O
strongly	O
suggests	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
self	O
-	O
associates	O
through	O
its	O
SAM	O
domain	B-SO
.	O

An	O
immunoprecipitation	O
assay	O
,	O
using	O
two	O
site	B-SO
-	O
directed	O
mutants	B-SO
of	O
the	O
SAM	O
domain	B-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
,	O
demonstrated	O
that	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
can	O
self	O
-	O
associate	O
through	O
its	O
SAM	O
domain	B-SO
in	O
mammalian	B-Taxon
cells	B-CL
.	O

While	O
we	O
did	O
not	O
address	O
the	O
question	O
whether	O
the	O
SAM	O
domain	B-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
forms	O
a	O
polymeric	B-CHEBI
structure	O
in	O
the	O
present	O
study	O
,	O
the	O
phylogenetic	O
analysis	O
of	O
SAM	O
domain	B-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
and	O
other	O
SAM	O
domain	B-SO
-	O
containing	O
molecules	B-CHEBI
suggests	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
can	O
form	O
head	O
-	O
to	O
-	O
tail	O
polymer	B-CHEBI
and	O
mediate	O
gene	B-SO
silencing	O
by	O
spreading	O
repressive	B-GO
complexes	I-GO
along	O
the	O
chromatin	B-GO
similar	O
to	O
ph	B-GGP
and	O
/	O
or	O
TEL	B-GGP
.	O

Although	O
our	O
results	O
in	O
the	O
immunoprecipitation	O
assay	O
demonstrated	O
that	O
the	O
N	B-SO
-	I-SO
terminal	I-SO
constructs	B-SO
lacking	O
a	O
SAM	O
domain	B-SO
still	O
interact	O
with	O
each	O
other	O
,	O
these	O
results	O
do	O
not	O
fit	O
into	O
the	O
head	O
-	O
to	O
-	O
tail	O
polymer	B-CHEBI
model	O
.	O

We	O
cannot	O
exclude	O
the	O
possibility	O
that	O
the	O
resulting	O
protein	B-CHEBI
-	O
protein	B-CHEBI
interaction	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
an	O
artifact	O
of	O
the	O
overexpression	O
conditions	O
.	O

The	O
issue	O
of	O
whether	O
or	O
not	O
mr	B-GGP
-	I-GGP
s	I-GGP
forms	O
a	O
polymer	B-CHEBI
awaits	O
future	O
analysis	O
.	O

A	O
previous	O
report	O
indicated	O
that	O
TEL	B-GGP
contains	O
a	O
sequence	B-SO
-	O
specific	O
DNA	B-SO
binding	O
domain	B-SO
,	O
namely	O
the	O
ETS	O
domain	B-SO
,	O
and	O
binds	O
to	O
specific	O
sites	B-SO
via	O
its	O
ETS	O
domain	B-SO
[	O
41	O
]	O
.	O

TEL	B-GGP
could	O
serve	O
to	O
nucleate	O
a	O
polymer	B-CHEBI
,	O
which	O
would	O
spread	O
by	O
oligomerization	O
of	O
the	O
SAM	O
domain	B-SO
.	O

In	O
contrast	O
to	O
TEL	B-GGP
,	O
ph	B-GGP
does	O
not	O
contain	O
an	O
obvious	O
sequence	B-SO
-	O
specific	O
DNA	B-SO
binding	O
motif	O
(	O
16	O
)	O
.	O

Therefore	O
,	O
its	O
initial	O
binding	O
to	O
the	O
template	O
may	O
require	O
protein	B-CHEBI
-	O
protein	B-CHEBI
interactions	O
with	O
other	O
sequence	B-SO
-	O
specific	O
transcriptional	O
repressors	O
.	O

The	O
segmentation	O
gene	B-SO
-	O
encoding	O
transcriptional	O
repressors	O
such	O
as	O
Hunchback	B-GGP
have	O
a	O
role	O
in	O
recruiting	O
SAM	O
domain	B-SO
-	O
containing	O
PcG	O
proteins	B-CHEBI
,	O
which	O
can	O
spread	O
along	O
the	O
template	O
via	O
polymerization	O
[	O
42	O
]	O
.	O

Since	O
mr	B-GGP
-	I-GGP
s	I-GGP
does	O
not	O
contain	O
obvious	O
DNA	B-SO
binding	O
motifs	O
,	O
we	O
suppose	O
that	O
there	O
is	O
a	O
sequence	B-SO
-	O
specific	O
transcription	O
factor	O
(	O
s	O
)	O
which	O
interacts	O
with	O
mr	B-GGP
-	I-GGP
s	I-GGP
.	O

However	O
,	O
we	O
did	O
not	O
find	O
any	O
transcription	O
factors	O
in	O
the	O
present	O
yeast	B-Taxon
two	O
-	O
hybrid	O
screening	O
.	O

We	O
also	O
found	O
that	O
full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
fused	O
to	O
the	O
GAL4	B-GGP
DNA	B-SO
binding	O
domain	B-SO
(	O
DBD	O
-	O
mrs	B-GGP
)	O
functions	O
as	O
a	O
transcriptional	O
repressor	O
.	O

This	O
may	O
support	O
the	O
idea	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
involved	O
in	O
repressive	B-GO
complexes	I-GO
similar	O
to	O
other	O
SAM	O
domain	B-SO
-	O
containing	O
proteins	B-CHEBI
.	O

Our	O
results	O
,	O
however	O
,	O
showed	O
that	O
the	O
self	O
-	O
association	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
through	O
its	O
SAM	O
domain	B-SO
is	O
not	O
essential	O
for	O
the	O
transcriptional	O
repressive	O
activity	O
.	O

Polymerization	O
of	O
the	O
SAM	O
domain	B-SO
has	O
been	O
previously	O
reported	O
to	O
be	O
essential	O
for	O
the	O
repressive	O
functions	O
of	O
ph	B-GGP
and	O
TEL	B-GGP
[	O
43	O
,	O
44	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
human	B-GGP
lethal	I-GGP
(	I-GGP
3	I-GGP
)	I-GGP
malignant	I-GGP
brain	I-GGP
tumor	I-GGP
(	O
H	B-GGP
-	I-GGP
L	I-GGP
(	I-GGP
3	I-GGP
)	I-GGP
MBT	I-GGP
)	O
protein	B-CHEBI
,	O
which	O
also	O
contains	O
a	O
SAM	O
domain	B-SO
at	O
the	O
C	B-SO
-	I-SO
terminus	I-SO
,	O
was	O
reported	O
as	O
a	O
transcriptional	O
repressor	O
and	O
the	O
repressor	O
activity	O
of	O
H	B-GGP
-	I-GGP
L	I-GGP
(	I-GGP
3	I-GGP
)	I-GGP
MBT	I-GGP
required	O
mainly	O
the	O
presence	O
of	O
the	O
MBT	O
repeats	B-SO
but	O
not	O
the	O
SAM	O
domain	B-SO
[	O
45	O
]	O
.	O

To	O
determine	O
the	O
transcriptional	O
repressor	O
region	B-SO
of	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
,	O
we	O
performed	O
a	O
luciferase	O
assay	O
using	O
site	B-SO
-	O
directed	O
mutants	B-SO
(	O
DBD	O
-	O
W404A	O
and	O
DBD	O
-	O
G453A	O
)	O
.	O

The	O
result	O
showed	O
that	O
the	O
reduced	O
binding	O
ability	O
of	O
self	O
-	O
association	O
partially	O
compromises	O
the	O
transcriptional	O
repressive	O
activity	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
(	O
Fig	O
.	O
7D	O
)	O
.	O

However	O
,	O
the	O
repressive	O
effect	O
was	O
more	O
significant	O
when	O
DBD	O
-	O
tail	O
,	O
which	O
does	O
not	O
contain	O
SAM	O
domain	B-SO
,	O
was	O
co	O
-	O
introduced	O
with	O
the	O
5xGAL4	O
-	O
pGL3	O
reporter	O
plasmid	B-SO
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
a	O
region	B-SO
from	O
amino	B-CHEBI
acids	I-CHEBI
463	O
to	O
542	O
is	O
mainly	O
responsible	O
for	O
the	O
repressor	O
activity	O
in	O
the	O
case	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
.	O

Evolutionary	B-SO
conservation	I-SO
of	O
the	O
C	B-SO
-	I-SO
terminal	I-SO
80	I-SO
aa	I-SO
region	I-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
from	O
zebrafish	B-Taxon
through	O
human	B-Taxon
may	O
underlie	O
the	O
functional	O
importance	O
of	O
this	O
region	B-SO
.	O

Two	O
distinct	O
multiprotein	O
PcG	B-GO
complexes	I-GO
,	O
PRC1	B-GO
and	O
PRC2	O
,	O
have	O
been	O
identified	O
.	O

PRC2	O
is	O
involved	O
in	O
the	O
initiation	O
of	O
silencing	O
and	O
contains	O
histone	B-CHEBI
deacetylases	O
(	O
HDACs	O
)	O
and	O
histone	B-CHEBI
methyltransferases	O
,	O
which	O
can	O
methylate	O
histone	B-CHEBI
H3	O
lysine	B-CHEBI
9	O
and	O
27	O
,	O
marks	O
of	O
silenced	O
chromatin	B-GO
.	O

PRC1	B-GO
,	O
including	O
ph	B-GGP
,	O
recognizes	O
the	O
histone	B-CHEBI
H3	O
lysine	B-CHEBI
27	O
mark	O
set	O
by	O
PRC2	O
and	O
maintains	O
a	O
stable	O
state	O
of	O
gene	B-SO
repression	O
in	O
which	O
PRC1	B-GO
blocks	O
chromatin	B-GO
remodeling	O
by	O
the	O
trithorax	O
group	O
-	O
related	O
SWI	B-GO
-	I-GO
SNF	I-GO
complex	I-GO
[	O
46	O
,	O
47	O
]	O
.	O

Therefore	O
,	O
the	O
mechanism	O
of	O
repression	O
by	O
PRC2	O
is	O
thought	O
to	O
be	O
HDAC	O
-	O
dependent	O
while	O
the	O
mechanism	O
of	O
repression	O
by	O
PRC1	B-GO
appears	O
to	O
be	O
HDAC	O
-	O
independent	O
.	O

Our	O
luciferase	O
assay	O
also	O
showed	O
that	O
transcriptional	O
repression	O
of	O
DBD	O
-	O
mrs	B-GGP
was	O
not	O
affected	O
by	O
the	O
addition	O
of	O
various	O
concentrations	O
of	O
trichostatin	B-CHEBI
A	I-CHEBI
,	O
a	O
potent	O
HDAC	O
inhibitor	B-CHEBI
(	O
data	O
not	O
shown	O
)	O
.	O

Therefore	O
,	O
we	O
speculate	O
that	O
the	O
mechanism	O
of	O
repression	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
may	O
be	O
HDAC	O
-	O
independent	O
and	O
more	O
similar	O
to	O
that	O
of	O
PRC1	B-GO
complex	I-GO
.	O

In	O
the	O
present	O
study	O
,	O
the	O
biochemical	O
experiments	O
demonstrate	O
that	O
the	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
functions	O
as	O
a	O
transcriptional	O
repressor	O
and	O
possibly	O
down	O
-	O
regulates	O
the	O
spatial	O
and	O
temporal	O
expression	O
of	O
the	O
target	O
genes	B-SO
during	O
retinal	B-CL
photoreceptor	I-CL
development	O
.	O

Our	O
data	O
also	O
revealed	O
that	O
the	O
repressive	O
activity	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
mainly	O
due	O
to	O
the	O
C	B-SO
-	I-SO
terminal	I-SO
region	I-SO
(	O
amino	B-CHEBI
acids	I-CHEBI
463	O
to	O
542	O
)	O
.	O

However	O
,	O
downstream	O
targets	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
still	O
remain	O
unclear	O
.	O

In	O
situ	O
hybridization	O
showed	O
that	O
the	O
peak	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
expression	O
is	O
around	O
P6	O
,	O
when	O
retinal	B-CL
photoreceptors	I-CL
undergo	O
terminal	O
differentiation	O
.	O

We	O
hypothesize	O
that	O
the	O
target	O
genes	B-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
might	O
be	O
non	O
-	O
photoreceptor	B-CL
genes	B-SO
.	O

In	O
this	O
case	O
,	O
mr	B-GGP
-	I-GGP
s	I-GGP
may	O
suppress	O
the	O
expression	O
of	O
non	O
-	O
photoreceptor	B-CL
genes	B-SO
in	O
rod	B-CL
and	I-CL
cone	I-CL
photoreceptors	I-CL
.	O

There	O
may	O
be	O
another	O
possibility	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
involved	O
in	O
cell	B-CL
fate	O
determination	O
of	O
rod	B-CL
photoreceptors	I-CL
versus	O
cone	B-CL
photoreceptors	I-CL
.	O

While	O
cone	B-CL
photoreceptors	I-CL
are	O
born	O
during	O
the	O
early	O
embryonic	O
stages	O
of	O
mouse	B-Taxon
retinogenesis	O
,	O
rod	B-CL
photoreceptors	I-CL
are	O
born	O
primarily	O
in	O
the	O
late	O
embryonic	O
and	O
early	O
postnatal	O
period	O
[	O
48	O
]	O
.	O

The	O
expression	O
pattern	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
may	O
suggest	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
expressed	O
in	O
rod	B-CL
photoreceptors	I-CL
but	O
not	O
in	O
cone	B-CL
photoreceptors	I-CL
as	O
well	O
as	O
Nr2e3	B-GGP
,	O
which	O
is	O
known	O
as	O
a	O
transcriptional	O
repressor	O
and	O
is	O
thought	O
to	O
down	O
-	O
regulate	O
cone	B-CL
photoreceptor	I-CL
-	O
specific	O
genes	B-SO
.	O

To	O
clarify	O
the	O
biological	O
function	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
,	O
analysis	O
of	O
mice	B-Taxon
with	O
targeted	O
disruptions	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
will	O
be	O
very	O
important	O
.	O

Conclusion	O

Here	O
we	O
identified	O
mouse	B-GGP
mr	I-GGP
-	I-GGP
s	I-GGP
,	O
which	O
is	O
predominantly	O
expressed	O
in	O
retinal	B-CL
photoreceptors	I-CL
and	O
the	O
pineal	O
gland	O
.	O

mr	B-GGP
-	I-GGP
s	I-GGP
is	O
evolutionarily	B-SO
conserved	I-SO
from	O
zebrafish	B-Taxon
through	O
to	O
human	B-Taxon
,	O
suggesting	O
a	O
significant	O
role	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
in	O
photoreceptor	B-CL
development	O
.	O

Our	O
present	O
data	O
suggest	O
that	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
localizes	O
in	O
the	O
nucleus	B-GO
and	O
can	O
self	O
-	O
associated	O
mainly	O
through	O
the	O
SAM	O
domain	B-SO
.	O

Moreover	O
,	O
mr	B-GGP
-	I-GGP
s	I-GGP
protein	B-CHEBI
fused	O
to	O
GAL4	B-GGP
DBD	O
functions	O
as	O
a	O
transcriptional	O
repressor	O
.	O

The	O
repressive	O
activity	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
due	O
to	O
its	O
C	B-SO
-	I-SO
terminal	I-SO
region	I-SO
(	O
amino	B-CHEBI
acid	I-CHEBI
463	O
to	O
542	O
)	O
.	O

Taken	O
together	O
,	O
mr	B-GGP
-	I-GGP
s	I-GGP
is	O
a	O
novel	O
repressor	O
molecule	B-CHEBI
possibly	O
involved	O
in	O
the	O
development	O
of	O
retinal	B-CL
photoreceptors	I-CL
and	O
pineal	O
gland	O
.	O

Methods	O

Isolation	O
of	O
mouse	B-GGP
mr	I-GGP
-	I-GGP
s	I-GGP
cDNA	B-SO

We	O
used	O
the	O
bioinformatics	O
method	O
Digital	O
Differential	O
Display	O
(	O
NCBI	O
,	O
UniGene	O
)	O
to	O
screen	O
novel	O
mouse	B-Taxon
genes	B-SO
expressed	O
preferentially	O
in	O
the	O
retina	O
.	O

Some	O
of	O
the	O
clusters	O
in	O
the	O
UniGene	O
database	O
were	O
mainly	O
from	O
mouse	B-Taxon
retinal	O
cDNAs	B-SO
.	O

One	O
clone	B-SO
in	O
these	O
clusters	O
(	O
#	O
Mm	B-Taxon
.	I-Taxon
246385	O
)	O
has	O
a	O
weak	O
homology	B-SO
with	O
the	O
polyhomeotic	O
family	O
genes	B-SO
.	O

A	O
735	O
-	O
bp	B-SO
cDNA	B-SO
fragment	B-SO
of	O
this	O
clone	B-SO
,	O
encoding	O
amino	B-CHEBI
acids	I-CHEBI
140	O
-	O
384	O
was	O
amplified	O
by	O
RT	O
-	O
PCR	O
from	O
mouse	B-Taxon
P0	O
retinal	O
cDNA	B-SO
.	O

This	O
fragment	B-SO
was	O
used	O
as	O
the	O
probe	B-SO
for	O
library	O
screening	O
,	O
in	O
situ	O
hybridization	O
and	O
Northern	O
hybridization	O
.	O

A	O
mouse	B-Taxon
P0	O
-	O
P3	O
retinal	O
cDNA	B-SO
library	O
was	O
screened	O
using	O
this	O
mouse	B-Taxon
cDNA	B-SO
fragment	B-SO
.	O

Positive	O
bacteriophage	O
clones	B-SO
were	O
isolated	O
and	O
the	O
full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
fragment	B-SO
was	O
inserted	B-SO
into	O
pBluescriptII	O
(	O
Stratagene	O
)	O
.	O

DNA	B-SO
sequencing	O
was	O
performed	O
on	O
both	O
strands	B-SO
by	O
the	O
cycle	O
sequencing	O
method	O
.	O

The	O
nucleotide	B-SO
sequence	I-SO
for	O
mr	B-GGP
-	I-GGP
s	I-GGP
gene	B-SO
has	O
been	O
deposited	O
in	O
the	O
GenBank	O
database	O
under	O
GenBank	O
Accession	O
Number	O
#	O
AY458844	O
.	O

In	O
situ	O
hybridization	O

The	O
735	O
-	O
bp	B-SO
cDNA	B-SO
fragment	B-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
amplified	O
by	O
RT	O
-	O
PCR	O
was	O
used	O
as	O
a	O
probe	B-SO
for	O
in	O
situ	O
hybridization	O
.	O

In	O
situ	O
hybridization	O
was	O
performed	O
as	O
described	O
previously	O
[	O
49	O
]	O
.	O

Cell	B-CL
culture	O
and	O
transfection	O

HEK293T	O
cells	B-CL
were	O
maintained	O
at	O
37	O
degrees	O
C	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	B-Taxon
serum	O
(	O
Sigma	O
)	O
,	O
100	O
IU	O
/	O
ml	O
penicillin	B-CHEBI
and	O
100	O
mu	O
g	O
/	O
ml	O
streptomycin	B-CHEBI
.	O

Transient	O
transfection	O
of	O
HEK293T	O
cells	B-CL
was	O
carried	O
out	O
using	O
calcium	B-CHEBI
phosphate	I-CHEBI
method	O
or	O
Fugene6	O
transfection	O
reagent	B-CHEBI
(	O
Roche	O
)	O
.	O

Y79	O
retinoblastoma	O
cells	B-CL
were	O
maintained	O
in	O
Iscove	O
'	O
s	O
modified	O
Dulbecco	O
'	O
s	O
medium	O
with	O
4	O
mM	O
L	B-CHEBI
-	I-CHEBI
glutamine	I-CHEBI
adjusted	O
to	O
contain	O
1	O
.	O
5	O
g	O
/	O
L	O
sodium	B-CHEBI
bicarbonate	I-CHEBI
,	O
20	O
%	O
FBS	O
.	O

Transient	O
transfection	O
was	O
carried	O
out	O
using	O
TransIt	O
LT1	O
(	O
Mirus	O
)	O
.	O

Northern	O
-	O
blot	O
analysis	O

RNA	B-SO
was	O
extracted	O
from	O
the	O
tissues	O
of	O
adult	O
mice	B-Taxon
using	O
Trizol	O
(	O
Invitrogen	O
)	O
.	O

A	O
5	O
mu	O
g	O
of	O
total	O
RNA	B-SO
was	O
electrophoresed	O
in	O
a	O
1	O
.	O
0	O
%	O
agarose	B-CHEBI
-	O
formaldehyde	B-CHEBI
gel	O
and	O
transferred	O
to	O
a	O
nylon	B-CHEBI
membrane	O
(	O
Zeta	O
-	O
Probe	O
GT	O
,	O
Bio	O
-	O
Rad	O
)	O
.	O

The	O
735	O
-	O
bp	B-SO
cDNA	B-SO
fragment	B-SO
encoding	O
the	O
SAM	O
domain	B-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
was	O
used	O
as	O
a	O
probe	B-SO
for	O
hybridization	O
.	O

Hybridization	O
was	O
performed	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Washes	O
with	O
increasing	O
stringency	O
were	O
performed	O
,	O
the	O
last	O
being	O
at	O
50	O
degrees	O
C	O
in	O
0	O
.	O
1	O
x	O
standard	O
saline	B-CHEBI
citrate	B-CHEBI
/	O
0	O
.	O
1	O
%	O
sodium	B-CHEBI
dodecyl	I-CHEBI
sulfate	I-CHEBI
(	O
SDS	B-CHEBI
)	O
.	O

RT	O
-	O
PCR	O
analysis	O

Total	O
RNA	B-SO
was	O
isolated	O
from	O
each	O
tissue	O
using	O
Trizol	O
.	O

A	O
1	O
mu	O
g	O
of	O
total	O
RNA	B-SO
was	O
reverse	O
transcribed	O
using	O
SuperscriptII	O
(	O
Invitrogen	O
)	O
.	O

RT	O
-	O
PCR	O
primers	B-SO
,	O
which	O
span	O
introns	B-SO
,	O
for	O
detection	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
cDNA	B-SO
were	O
5	O
'	O
-	O
TGTCCAGCCCAGCCAACCCAAGGAGACGACA	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
TGTGGTCTCCTCATCAGTGAAGA	O
-	O
3	O
'	O
.	O

Product	B-SO
size	O
was	O
292	O
bp	B-SO
(	O
positions	B-SO
965	O
-	O
1256	O
of	O
Genbank	O
Accession	O
Number	O
#	O
AY458844	O
)	O
.	O

Primer	B-SO
pairs	O
for	O
mouse	B-GGP
G3PDH	I-GGP
were	O
5	O
'	O
-	O
ACCACAGTCCATGCCATCAC	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
TCCACCACCCTGTTGCTGTA	O
-	O
3	O
'	O
which	O
amplified	O
a	O
452	O
-	O
bp	B-SO
product	B-SO
(	O
positions	B-SO
587	O
-	O
1038	O
of	O
Genbank	O
Accession	O
Number	O
#	O
BC85275	O
)	O
.	O

Yeast	B-Taxon
two	O
-	O
hybrid	O
screening	O
and	O
GAL4	B-GGP
assay	O

We	O
carried	O
out	O
yeast	B-Taxon
two	O
-	O
hybrid	O
experiments	O
using	O
the	O
MATCHMAKER	O
GAL4	B-GGP
two	O
-	O
hybrid	O
system	O
3	O
(	O
BD	O
Bioscience	O
)	O
as	O
recommended	O
by	O
the	O
manufacturer	O
.	O

We	O
cloned	O
the	O
full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
into	O
the	O
pGBKT7	O
vector	B-SO
and	O
used	O
it	O
to	O
screen	O
a	O
library	O
of	O
mouse	B-Taxon
P0	O
-	O
P3	O
retinal	O
cDNAs	B-SO
in	O
the	O
pGADT7	O
vector	B-SO
.	O

Transformants	O
that	O
conferred	O
growth	O
were	O
picked	O
,	O
isolated	O
and	O
re	O
-	O
introduced	O
with	O
the	O
bait	O
into	O
AH109	O
to	O
confirm	O
interaction	O
.	O

Plasmid	B-SO
DNA	B-SO
was	O
isolated	O
from	O
yeast	B-Taxon
using	O
RPM	O
Yeast	B-Taxon
Plasmid	B-SO
Isolation	O
Kit	O
(	O
Qbiogene	O
)	O
.	O

In	O
order	O
to	O
confirm	O
the	O
protein	B-CHEBI
interactions	O
,	O
single	O
colonies	O
were	O
picked	O
and	O
grown	O
individually	O
in	O
synthetic	O
complete	O
media	O
lacking	O
leucine	B-CHEBI
,	O
tryptophan	B-CHEBI
and	O
containing	O
X	O
-	O
gal	O
.	O

After	O
4	O
-	O
5	O
days	O
,	O
X	O
-	O
gal	O
positive	O
clones	B-SO
were	O
selected	O
and	O
analyzed	O
.	O

To	O
test	O
self	O
-	O
interaction	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
,	O
we	O
subcloned	O
the	O
full	O
-	O
length	O
,	O
N	B-SO
-	I-SO
terminus	I-SO
(	O
amino	B-CHEBI
acids	I-CHEBI
1	O
-	O
400	O
)	O
and	O
C	B-SO
-	I-SO
terminus	I-SO
(	O
amino	B-CHEBI
acids	I-CHEBI
391	O
-	O
542	O
)	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
into	O
pGBKT7	O
and	O
pGADT7	O
vectors	B-SO
.	O

We	O
assessed	O
interactions	O
by	O
scoring	O
blue	O
color	O
on	O
plates	O
of	O
medium	O
containing	O
X	O
-	O
gal	O
.	O

Immunoprecipitation	O
assay	O

For	O
immunoprecipitation	O
assay	O
,	O
4	O
x	O
hemagglutinin	O
(	O
HA	O
)	O
or	O
3	O
x	O
Flag	O
tagged	O
cDNA	B-SO
fragment	B-SO
encoding	O
full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
(	O
full	O
-	O
HA	O
and	O
Flag	O
-	O
mrs	B-GGP
)	O
,	O
a	O
cDNA	B-SO
fragment	B-SO
encoding	O
amino	B-CHEBI
acids	I-CHEBI
1	O
-	O
400	O
(	O
Delta	O
SAM	O
-	O
HA	O
and	O
Flag	O
-	O
Delta	O
SAM	O
)	O
,	O
and	O
a	O
cDNA	B-SO
fragment	B-SO
encoding	O
amino	B-CHEBI
acids	I-CHEBI
400	O
-	O
542	O
(	O
Flag	O
-	O
SAM	O
)	O
were	O
subcloned	O
into	O
the	O
pcDNA3	O
(	O
Invitrogen	O
)	O
expression	O
vector	B-SO
.	O

We	O
also	O
constructed	O
two	O
site	B-SO
-	O
directed	O
mutants	B-SO
,	O
Flag	O
-	O
W404A	O
and	O
Flag	O
-	O
G453A	O
,	O
using	O
PCR	O
.	O

Each	O
of	O
these	O
mutations	B-SO
was	O
also	O
introduced	O
into	O
Flag	O
-	O
mr	B-GGP
-	I-GGP
s	I-GGP
.	O

We	O
transfected	O
HEK293T	O
cells	B-CL
with	O
5	O
mu	O
g	O
of	O
plasmid	B-SO
DNA	B-SO
per	O
6	O
cm	O
dish	O
by	O
calcium	B-CHEBI
phosphate	I-CHEBI
method	O
.	O

Approximately	O
48	O
hr	O
after	O
transfection	O
,	O
cells	B-CL
were	O
harvested	O
in	O
immunoprecipitation	O
buffer	O
(	O
50	O
mM	O
Tris	B-CHEBI
-	O
HCl	B-CHEBI
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
1	O
mM	O
EDTA	B-CHEBI
,	O
2	O
mM	O
MgCl2	B-CHEBI
,	O
150	O
mM	O
NaCl	B-CHEBI
,	O
1	O
mM	O
phenylmethylsulfonyl	B-CHEBI
fluoride	I-CHEBI
[	O
Wako	O
]	O
,	O
1	O
%	O
Nonidet	O
P	O
-	O
40	O
,	O
10	O
%	O
glycerol	B-CHEBI
)	O
in	O
the	O
presence	O
of	O
protease	B-CHEBI
inhibitor	I-CHEBI
cocktail	O
tablets	O
(	O
Roche	O
)	O
.	O

For	O
each	O
reaction	O
,	O
1	O
mg	O
of	O
cell	B-CL
lysate	O
was	O
mixed	O
with	O
0	O
.	O
5	O
mu	O
g	O
of	O
anti	O
-	O
Flag	O
antibody	B-GO
(	O
SIGMA	O
,	O
F3165	O
)	O
and	O
15	O
mu	O
l	O
of	O
protein	B-CHEBI
G	O
-	O
Sepharose	O
(	O
Amersham	O
)	O
on	O
a	O
rotating	O
wheel	O
at	O
4	O
degrees	O
C	O
for	O
2	O
hrs	O
.	O

Protein	B-CHEBI
concentration	O
was	O
determined	O
by	O
the	O
BCA	O
protein	B-CHEBI
assay	O
system	O
(	O
Pierce	O
)	O
.	O

The	O
beads	O
were	O
then	O
washed	O
three	O
times	O
with	O
immunoprecipitation	O
buffer	O
and	O
followed	O
by	O
three	O
times	O
with	O
wash	O
buffer	O
(	O
50	O
mM	O
Tris	B-CHEBI
-	O
HCl	B-CHEBI
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
150	O
mM	O
NaCl	B-CHEBI
,	O
20	O
mM	O
MgCl2	B-CHEBI
)	O
.	O

Proteins	B-CHEBI
were	O
then	O
boiled	O
for	O
5	O
min	O
in	O
SDS	B-CHEBI
sample	O
buffer	O
(	O
1	O
%	O
SDS	B-CHEBI
,	O
1	O
mM	O
Tris	B-CHEBI
[	O
pH	O
6	O
.	O
8	O
]	O
,	O
40	O
mM	O
DTT	B-CHEBI
,	O
4	O
%	O
glycerol	B-CHEBI
,	O
0	O
.	O
01	O
%	O
pyronine	O
Y	O
)	O
.	O

The	O
supernatants	O
were	O
fractionated	O
by	O
sodium	B-CHEBI
dodecyl	I-CHEBI
sulfate	I-CHEBI
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	B-CHEBI
-	O
PAGE	O
)	O
and	O
transferred	O
to	O
the	O
nitrocellulose	O
membrane	O
(	O
Trans	O
-	O
Blot	O
Transfer	O
Medium	O
,	O
Bio	O
-	O
Rad	O
)	O
.	O

Western	O
blotting	O
was	O
performed	O
with	O
rabbit	B-Taxon
polyclonal	O
anti	O
-	O
HA	O
antibody	B-GO
(	O
Santa	O
Cruz	O
,	O
#	O
sc	O
-	O
805	O
)	O
.	O

Signals	O
were	O
detected	O
with	O
horseradish	B-Taxon
peroxidase	O
-	O
conjugated	O
goat	B-Taxon
anti	O
-	O
rabbit	B-Taxon
IgG	O
and	O
ECL	O
plus	O
Western	O
Blotting	O
Detection	O
System	O
(	O
Amersham	O
)	O
.	O

Subcellular	O
localization	O
analysis	O

We	O
transfected	O
the	O
plasmid	B-SO
encoding	O
HA	O
-	O
tagged	O
full	O
-	O
length	O
mr	B-GGP
-	I-GGP
s	I-GGP
into	O
HEK293T	O
cells	B-CL
,	O
seeded	O
cells	B-CL
on	O
coverslips	O
coated	O
with	O
collagen	B-GGP
48	O
hr	O
after	O
transfection	O
,	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
in	O
phosphate	B-CHEBI
-	O
buffered	B-CHEBI
saline	O
(	O
PBS	O
)	O
at	O
room	O
temperature	O
for	O
20	O
min	O
,	O
and	O
washed	O
with	O
PBS	O
.	O

Then	O
we	O
permeabilized	O
cells	B-CL
in	O
PBS	O
containing	O
0	O
.	O
1	O
%	O
Triton	O
X	O
-	O
100	O
for	O
15	O
min	O
,	O
washed	O
again	O
with	O
PBS	O
,	O
and	O
incubated	O
in	O
PBS	O
containing	O
0	O
.	O
1	O
%	O
bovine	B-GGP
serum	I-GGP
albumin	I-GGP
(	O
BSA	B-GGP
)	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

We	O
incubated	O
cells	B-CL
with	O
anti	O
-	O
HA	O
antibody	B-GO
overnight	O
at	O
4	O
degrees	O
C	O
(	O
1	O
:	O
200	O
in	O
PBS	O
containing	O
0	O
.	O
2	O
%	O
BSA	B-GGP
)	O
.	O

The	O
following	O
day	O
,	O
we	O
washed	O
cells	B-CL
three	O
times	O
with	O
PBS	O
and	O
incubated	O
with	O
a	O
Cy3	O
-	O
conjugated	O
goat	B-Taxon
IgG	O
against	O
rabbit	B-Taxon
IgG	O
(	O
1	O
:	O
400	O
in	O
PBS	O
,	O
Jackson	O
ImmunoReseach	O
Laboratories	O
)	O
for	O
30	O
min	O
.	O

We	O
rinsed	O
cells	B-CL
three	O
times	O
with	O
PBS	O
,	O
followed	O
by	O
observation	O
using	O
a	O
confocal	O
microscope	O
FV300	O
(	O
Olympus	O
)	O
equipped	O
with	O
a	O
60	O
x	O
objective	O
lens	O
.	O

Luciferase	O
assay	O

For	O
transcriptional	O
analysis	O
of	O
the	O
1	O
.	O
2	O
-	O
kb	O
promoter	B-SO
region	B-SO
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
,	O
we	O
constructed	O
a	O
reporter	O
plasmid	B-SO
(	O
pro1	O
.	O
2k	O
)	O
by	O
subcloning	O
a	O
1	O
.	O
2	O
-	O
kb	O
upstream	O
genomic	B-SO
fragment	B-SO
of	I-SO
mr	I-SO
-	I-SO
s	I-SO
gene	I-SO
into	O
a	O
pGL3	O
luciferase	O
reporter	O
plasmid	B-SO
(	O
Promega	O
)	O
.	O

The	O
expression	O
vectors	B-SO
were	O
constructed	O
by	O
subcloning	O
full	O
-	O
length	O
Crx	B-GGP
,	O
Otx2	B-GGP
,	O
Nrl	B-GGP
genes	B-SO
into	O
a	O
pMIK	O
expression	O
vector	B-SO
(	O
a	O
gift	O
from	O
Dr	O
.	O
K	O
.	O
Maruyama	O
)	O
,	O
respectively	O
.	O

For	O
the	O
"	O
mut1259	O
"	O
vector	B-SO
,	O
the	O
Crx	B-GGP
binding	B-SO
site	I-SO
at	O
the	O
-	O
1259	O
bp	B-SO
position	B-SO
was	O
mutated	B-SO
by	O
replacing	B-SO
GGATTA	O
with	O
AGATCT	O
.	O

For	O
the	O
"	O
mut198	O
"	O
vector	B-SO
,	O
the	O
Crx	B-GGP
binding	B-SO
site	I-SO
at	O
the	O
-	O
198	O
bp	B-SO
position	B-SO
was	O
mutated	B-SO
by	O
replacing	B-SO
TAATCC	O
with	O
GAATTC	O
.	O

For	O
the	O
"	O
mut72	O
"	O
vector	B-SO
,	O
the	O
Crx	B-GGP
binding	B-SO
site	I-SO
at	O
the	O
-	O
72	O
bp	B-SO
position	B-SO
was	O
mutated	B-SO
by	O
replacing	B-SO
GGATTA	O
with	O
GAATTC	O
.	O

For	O
the	O
"	O
mut	B-SO
all	O
"	O
vector	B-SO
,	O
all	O
of	O
three	O
Crx	B-GGP
binding	B-SO
sites	I-SO
were	O
mutated	B-SO
.	O

5xGAL4	O
-	O
pGL3	O
Control	O
reporter	O
plasmid	B-SO
,	O
which	O
contains	O
five	O
copies	O
of	O
the	O
GAL4	B-GGP
DNA	B-SO
recognition	B-SO
sequence	I-SO
positioned	O
immediately	O
upstream	O
of	O
SV40	B-Taxon
minimal	O
promoter	B-SO
,	O
was	O
kindly	O
gifted	O
from	O
Dr	O
.	O
T	O
.	O

Noguchi	O
and	O
used	O
for	O
analysis	O
of	O
the	O
transcriptional	O
activity	O
of	O
mr	B-GGP
-	I-GGP
s	I-GGP
[	O
50	O
]	O
.	O

To	O
generate	O
effector	O
plasmids	B-SO
,	O
various	O
deletion	B-SO
fragments	B-SO
were	O
produced	O
by	O
PCR	O
reaction	O
and	O
subcloned	O
into	O
pGBKT7	O
vector	B-SO
,	O
respectively	O
.	O

These	O
fragments	B-SO
were	O
digested	O
with	O
the	O
sequence	B-SO
,	O
which	O
encodes	O
GAL4	B-GGP
DNA	B-SO
binding	O
domain	B-SO
,	O
and	O
inserted	B-SO
into	O
pcDNA3	O
.	O

We	O
transfected	O
0	O
.	O
1	O
mu	O
g	O
of	O
reporter	O
plasmid	B-SO
DNA	B-SO
and	O
2	O
mu	O
g	O
of	O
the	O
expression	O
vector	B-SO
DNA	B-SO
per	O
6	O
cm	O
dish	O
into	O
HEK293T	O
cells	B-CL
using	O
Fugene6	O
transfection	O
reagent	B-CHEBI
.	O

We	O
analyzed	O
luciferase	O
activity	O
48	O
hr	O
after	O
transfection	O
.	O

List	O
of	O
abbreviations	O

Crx	B-GGP
,	O
cone	B-GGP
-	I-GGP
rod	I-GGP
homeobox	I-GGP
;	O
Otx2	B-GGP
,	O
orthodenticle	B-GGP
-	I-GGP
related	I-GGP
homeobox	I-GGP
2	I-GGP
;	O
TR	B-GGP
beta	I-GGP
2	I-GGP
,	O
thyroid	B-GGP
hormone	I-GGP
receptor	I-GGP
beta	I-GGP
2	I-GGP
;	O
Nrl	B-GGP
,	O
neural	B-GGP
retina	I-GGP
leucine	I-GGP
zipper	I-GGP
;	O
Nr2e3	B-GGP
,	O
nuclear	B-GGP
receptor	I-GGP
subfamily	I-GGP
2	I-GGP
group	I-GGP
E	I-GGP
member	I-GGP
3	I-GGP
;	O
EST	B-SO
,	O
expressed	B-SO
sequence	I-SO
tag	I-SO
;	O
EphB2	B-GGP
,	O
ephrin	B-GGP
receptor	I-GGP
B2	I-GGP
;	O
EphA4	B-GGP
,	O
ephrin	B-GGP
receptor	I-GGP
A4	I-GGP
;	O
TEL	B-GGP
,	O
translocation	B-GGP
ETS	I-GGP
leukemia	I-GGP
.	O

Authors	O
'	O
contributions	O

TI	O
and	O
KT	O
performed	O
most	O
of	O
the	O
experiments	O
,	O
interpreted	O
the	O
data	O
and	O
wrote	O
the	O
first	O
draft	O
of	O
the	O
manuscript	O
.	O

AF	O
prepared	O
retinal	O
tissues	O
and	O
their	O
sections	O
of	O
wild	B-SO
-	I-SO
type	I-SO
and	O
Crx	B-GGP
mutant	B-SO
mice	B-Taxon
.	O

CK	O
performed	O
luciferase	O
assay	O
using	O
Y79	O
retinoblastoma	O
cells	B-CL
.	O

YT	O
,	O
MA	O
and	O
TF	O
have	O
made	O
substantial	O
contributions	O
to	O
conception	O
and	O
design	O
of	O
the	O
experiments	O
and	O
drafting	O
of	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Acknowledgements	O

We	O
thank	O
T	O
.	O

Noguchi	O
for	O
5xGAL4	O
-	O
pGL3	O
reporter	O
plasmid	B-SO
;	O
A	O
.	O

Nishida	O
for	O
discussion	O
and	O
critical	O
reading	O
of	O
the	O
manuscript	O
;	O
A	O
.	O

Yoshimura	O
for	O
advice	O
on	O
confocal	O
microscopy	O
;	O
A	O
.	O

Tani	O
,	O
Y	O
.	O

Kambara	O
,	O
M	O
.	O

Murai	O
,	O
Y	O
.	O

Hirao	O
and	O
H	O
.	O

Yoshii	O
for	O
technical	O
assistance	O
.	O

This	O
work	O
was	O
supported	O
by	O
Precursory	O
Research	O
for	O
Embryonic	O
Science	O
and	O
Technology	O
(	O
PRESTO	O
)	O
,	O
Dynamics	O
of	O
Development	O
Systems	O
Molecular	B-CHEBI
Brain	O
Science	O
,	O
Grant	O
-	O
in	O
Aid	O
for	O
Scientific	O
Research	O
(	O
B	O
)	O
,	O
Senri	O
Life	O
Science	O
Foundation	O
,	O
and	O
Uehara	O
Foundation	O
.	O

Rescue	O
of	O
Progeria	O
in	O
Trichothiodystrophy	O
by	O
Homozygous	O
Lethal	O
Xpd	B-GGP
Alleles	B-SO

Abstract	O

Although	O
compound	O
heterozygosity	O
,	O
or	O
the	O
presence	O
of	O
two	O
different	O
mutant	B-SO
alleles	B-SO
of	O
the	O
same	O
gene	B-SO
,	O
is	O
common	O
in	O
human	B-Taxon
recessive	O
disease	O
,	O
its	O
potential	O
to	O
impact	O
disease	O
outcome	O
has	O
not	O
been	O
well	O
documented	O
.	O

This	O
is	O
most	O
likely	O
because	O
of	O
the	O
inherent	O
difficulty	O
in	O
distinguishing	O
specific	O
biallelic	O
effects	O
from	O
differences	O
in	O
environment	O
or	O
genetic	B-SO
background	O
.	O

We	O
addressed	O
the	O
potential	O
of	O
different	O
recessive	O
alleles	B-SO
to	O
contribute	O
to	O
the	O
enigmatic	O
pleiotropy	O
associated	O
with	O
XPD	B-GGP
recessive	O
disorders	O
in	O
compound	O
heterozygous	O
mouse	B-Taxon
models	O
.	O

Alterations	B-SO
in	O
this	O
essential	O
helicase	O
,	O
with	O
functions	O
in	O
both	O
DNA	B-SO
repair	O
and	O
basal	O
transcription	O
,	O
result	O
in	O
diverse	O
pathologies	O
ranging	O
from	O
elevated	O
UV	O
sensitivity	O
and	O
cancer	O
predisposition	O
to	O
accelerated	O
segmental	O
progeria	O
.	O

We	O
report	O
a	O
variety	O
of	O
biallelic	O
effects	O
on	O
organismal	B-Taxon
phenotype	O
attributable	O
to	O
combinations	O
of	O
recessive	O
Xpd	B-GGP
alleles	B-SO
,	O
including	O
the	O
following	O
:	O
(	O
i	O
)	O
the	O
ability	O
of	O
homozygous	O
lethal	O
Xpd	B-GGP
alleles	B-SO
to	O
ameliorate	O
a	O
variety	O
of	O
disease	O
symptoms	O
when	O
their	O
essential	O
basal	O
transcription	O
function	O
is	O
supplied	O
by	O
a	O
different	O
disease	O
-	O
causing	O
allele	B-SO
,	O
(	O
ii	O
)	O
differential	O
developmental	O
and	O
tissue	O
-	O
specific	O
functions	O
of	O
distinct	O
Xpd	B-GGP
allele	B-SO
products	O
,	O
and	O
(	O
iii	O
)	O
interallelic	O
complementation	O
,	O
a	O
phenomenon	O
rarely	O
reported	O
at	O
clinically	O
relevant	O
loci	B-SO
in	O
mammals	B-Taxon
.	O

Our	O
data	O
suggest	O
a	O
re	O
-	O
evaluation	O
of	O
the	O
contribution	O
of	O
"	O
null	O
"	O
alleles	B-SO
to	O
XPD	B-GGP
disorders	O
and	O
highlight	O
the	O
potential	O
of	O
combinations	O
of	O
recessive	O
alleles	B-SO
to	O
affect	O
both	O
normal	O
and	O
pathological	O
phenotypic	O
plasticity	O
in	O
mammals	B-Taxon
.	O

Introduction	O

Interallelic	O
complementation	O
is	O
defined	O
as	O
the	O
ability	O
of	O
two	O
differentially	O
mutated	B-SO
alleles	B-SO
to	O
function	O
better	O
together	O
than	O
either	O
can	O
on	O
its	O
own	O
.	O

Despite	O
its	O
near	O
universality	O
in	O
lower	O
organisms	B-Taxon
[	O
1	O
]	O
,	O
its	O
potential	O
to	O
contribute	O
to	O
clinical	O
heterogeneity	O
in	O
human	B-Taxon
disease	O
is	O
seldom	O
considered	O
.	O

Evidence	O
of	O
interallelic	O
complementation	O
at	O
clinically	O
relevant	O
loci	B-SO
is	O
limited	O
to	O
biochemical	O
and	O
cell	B-CL
-	O
based	O
studies	O
of	O
a	O
handful	O
of	O
metabolic	O
disorders	O
with	O
defects	O
in	O
enzymes	B-SO
including	O
propinyl	B-CHEBI
-	I-CHEBI
CoA	I-CHEBI
carboxylase	O
[	O
2	O
]	O
,	O
argininosuccinate	B-GGP
lyase	I-GGP
[	O
3	O
]	O
,	O
galactose	B-GGP
-	I-GGP
1	I-GGP
-	I-GGP
phosphate	I-GGP
uridylyltransferase	I-GGP
[	O
4	O
]	O
,	O
and	O
methylmalonyl	B-GGP
CoA	I-GGP
mutase	I-GGP
[	O
5	O
]	O
.	O

Compound	O
heterozygotes	O
are	O
individuals	B-Taxon
carrying	O
two	O
different	O
mutant	B-SO
alleles	B-SO
of	O
the	O
same	O
gene	B-SO
.	O

In	O
the	O
absence	O
of	O
a	O
dominant	O
(	O
wild	B-SO
-	I-SO
type	I-SO
[	O
wt	B-SO
]	O
)	O
allele	B-SO
,	O
genetic	B-SO
interactions	O
between	O
recessive	O
alleles	B-SO
(	O
referred	O
to	O
here	O
as	O
"	O
biallelic	O
"	O
effects	O
)	O
could	O
result	O
in	O
different	O
phenotypic	O
outcomes	O
including	O
interallelic	O
complementation	O
.	O

Although	O
amelioration	O
of	O
disease	O
symptoms	O
by	O
interallelic	O
complementation	O
would	O
create	O
an	O
ascertainment	O
bias	O
in	O
the	O
clinic	O
,	O
the	O
lack	O
of	O
evidence	O
concerning	O
interallelic	O
complementation	O
or	O
other	O
biallelic	O
effects	O
in	O
human	B-Taxon
disease	O
is	O
likely	O
caused	O
by	O
the	O
difficulty	O
in	O
distinguishing	O
such	O
effects	O
from	O
environment	O
and	O
genetic	B-SO
background	O
.	O

XPD	B-GGP
encodes	O
one	O
of	O
the	O
two	O
helicase	O
components	O
of	O
basal	B-GO
transcription	I-GO
/	I-GO
DNA	I-GO
repair	I-GO
factor	I-GO
IIH	I-GO
(	O
TFIIH	B-GO
)	O
,	O
a	O
ten	O
-	O
subunit	O
,	O
multifunctional	O
complex	B-GO
that	O
is	O
essential	O
for	O
multiple	O
processes	O
,	O
including	O
basal	O
transcription	O
initiation	O
and	O
DNA	B-SO
damage	O
repair	O
via	O
the	O
nucleotide	B-CHEBI
excision	B-SO
repair	O
(	O
NER	O
)	O
pathway	O
[	O
6	O
,	O
7	O
]	O
.	O

Alterations	B-SO
in	O
XPD	B-GGP
resulting	O
in	O
defective	O
TFIIH	B-GO
function	O
are	O
associated	O
with	O
UV	O
-	O
sensitive	O
,	O
multisystem	O
disorders	O
including	O
xeroderma	O
pigmentosum	O
(	O
XP	O
)	O
,	O
XP	O
combined	O
with	O
Cockayne	O
syndrome	O
(	O
CS	O
)	O
,	O
and	O
trichothiodystrophy	O
(	O
TTD	O
)	O
[	O
8	O
-	O
10	O
]	O
.	O

XP	O
is	O
marked	O
by	O
sun	O
-	O
induced	O
pigmentation	O
anomalies	O
and	O
a	O
greater	O
than	O
1	O
,	O
000	O
-	O
fold	O
elevation	O
in	O
skin	O
cancer	O
risk	O
.	O

Severe	O
cases	O
can	O
also	O
present	O
with	O
growth	O
retardation	O
and	O
primary	O
neurodegeneration	O
[	O
11	O
]	O
.	O

CS	O
and	O
TTD	O
,	O
on	O
the	O
other	O
hand	O
,	O
are	O
segmental	O
progeroid	O
disorders	O
characterised	O
by	O
progressive	O
post	O
-	O
natal	O
growth	O
failure	O
and	O
primary	O
demyelination	O
resulting	O
in	O
severe	O
neurodysfunction	O
,	O
but	O
without	O
a	O
clear	O
cancer	O
predisposition	O
[	O
12	O
-	O
15	O
]	O
.	O

Patients	O
with	O
TTD	O
additionally	O
display	O
hallmark	O
sulphur	B-CHEBI
-	O
deficient	O
brittle	O
hair	O
and	O
nails	O
and	O
scaling	O
skin	O
[	O
13	O
]	O
,	O
resulting	O
from	O
a	O
basal	O
transcription	O
defect	O
in	O
specific	O
cell	B-CL
types	O
[	O
16	O
,	O
17	O
]	O
.	O

A	O
related	O
disorder	O
with	O
the	O
cancer	O
predisposition	O
of	O
XP	O
combined	O
with	O
the	O
neurodevelopmental	O
complications	O
of	O
CS	O
(	O
XPCS	O
)	O
,	O
although	O
rare	O
,	O
has	O
also	O
been	O
described	O
[	O
18	O
]	O
.	O

Many	O
XPD	B-GGP
mutations	B-SO
are	O
associated	O
with	O
an	O
exclusive	O
disease	O
phenotype	O
(	O
e	O
.	O
g	O
.	O
,	O
XPDR722W	O
with	O
TTD	O
and	O
XPDR683W	O
with	O
XP	O
)	O
and	O
are	O
thus	O
viewed	O
as	O
causative	O
of	O
the	O
corresponding	O
syndromes	O
.	O

Alleles	B-SO
not	O
associated	O
exclusively	O
with	O
one	O
disorder	O
are	O
considered	O
"	O
likely	O
null	O
"	O
alleles	B-SO
[	O
19	O
,	O
20	O
]	O
.	O

Some	O
of	O
these	O
alleles	B-SO
fail	O
to	O
support	O
viability	O
in	O
a	O
haploid	O
Schizosaccharomyces	B-Taxon
pombe	I-Taxon
yeast	I-Taxon
strain	O
with	O
a	O
null	O
mutation	B-SO
in	O
the	O
XPD	B-GGP
homologue	B-SO
rad15	B-GGP
and	O
are	O
thus	O
considered	O
devoid	O
of	O
significant	O
biological	O
activity	O
[	O
19	O
]	O
.	O

This	O
classification	O
of	O
alleles	B-SO
as	O
either	O
causative	O
or	O
null	O
currently	O
defines	O
what	O
we	O
refer	O
to	O
as	O
a	O
"	O
monoallelic	O
"	O
paradigm	O
of	O
XPD	B-GGP
disease	O
.	O

However	O
,	O
the	O
identification	O
in	O
recent	O
years	O
of	O
XP	O
complementation	O
group	O
D	O
patients	O
with	O
atypical	O
disease	O
presentation	O
,	O
including	O
symptoms	O
of	O
both	O
XP	O
and	O
TTD	O
[	O
8	O
]	O
,	O
casts	O
doubt	O
on	O
the	O
ability	O
of	O
such	O
a	O
monoallelic	O
paradigm	O
to	O
explain	O
clinical	O
heterogeneity	O
in	O
compound	O
heterozygotes	O
.	O

Previously	O
,	O
we	O
generated	O
a	O
TTD	O
mouse	B-Taxon
model	O
(	O
XPDR722W	O
)	O
that	O
phenocopies	O
the	O
human	B-Taxon
syndrome	O
[	O
15	O
,	O
21	O
]	O
.	O

Here	O
we	O
report	O
the	O
generation	O
of	O
additional	O
mutant	B-SO
Xpd	B-GGP
alleles	B-SO
that	O
fail	O
to	O
support	O
viability	O
on	O
their	O
own	O
but	O
nevertheless	O
ameliorate	O
TTD	O
-	O
associated	O
premature	O
segmental	O
ageing	O
,	O
cutaneous	O
features	O
,	O
cellular	B-CL
DNA	B-SO
repair	O
capacity	O
,	O
and	O
UV	O
survival	O
when	O
present	O
in	O
a	O
compound	O
heterozygote	O
state	O
.	O

Results	O

Generation	O
of	O
Xpd	B-GGP
Compound	O
Heterozygotes	O

We	O
generated	O
an	O
Xpd	B-GGP
knock	O
-	O
in	O
allele	B-SO
with	O
a	O
point	B-SO
mutation	I-SO
encoding	O
a	O
single	O
amino	B-CHEBI
acid	I-CHEBI
change	B-SO
(	O
XPDG602D	O
)	O
found	O
in	O
the	O
XPCS	O
patient	O
XPCS2	O
(	O
Figure	O
1A	O
-	O
1C	O
)	O
.	O

mRNA	B-CHEBI
expression	O
from	O
the	O
targeted	O
allele	B-SO
could	O
be	O
detected	O
in	O
embryonic	O
stem	B-CL
cells	I-CL
by	O
RT	O
-	O
PCR	O
(	O
Figure	O
1D	O
)	O
,	O
although	O
expression	O
was	O
reduced	O
approximately	O
5	O
-	O
fold	O
relative	O
to	O
wt	B-SO
mRNA	B-CHEBI
transcript	I-CHEBI
levels	O
as	O
determined	O
by	O
Northern	O
blotting	O
of	O
RNA	B-SO
from	O
the	O
testis	O
of	O
heterozygous	O
animals	B-Taxon
(	O
Figure	O
1E	O
)	O
.	O

Because	O
patient	O
XPCS2	O
was	O
a	O
hemizygote	O
with	O
mutant	B-SO
XPD	B-GGP
protein	B-CHEBI
(	O
XPDG602D	O
)	O
expressed	O
from	O
a	O
single	O
allele	B-SO
,	O
the	O
corresponding	O
mutation	B-SO
was	O
expected	O
to	O
be	O
viable	O
in	O
the	O
homozygous	O
state	O
.	O

However	O
,	O
homozygous	O
mutant	B-SO
mice	B-Taxon
were	O
not	O
observed	O
,	O
neither	O
amongst	O
live	O
births	O
nor	O
embryonic	O
day	O
13	O
.	O
5	O
(	O
E13	O
.	O
5	O
)	O
or	O
E3	O
.	O
5	O
embryos	O
(	O
Table	O
1	O
)	O
.	O

The	O
corresponding	O
hypomorphic	O
,	O
mutant	B-SO
allele	B-SO
was	O
thus	O
designated	O
as	O
homozygous	O
lethal	O
(	O
+	O
XPCS	O
)	O
.	O

Homozygous	O
lethality	O
of	O
the	O
XPCS	O
allele	B-SO
is	O
likely	O
due	O
to	O
reduced	O
levels	O
of	O
expression	O
of	O
this	O
essential	O
protein	B-CHEBI
as	O
a	O
result	O
of	O
gene	B-SO
targeting	O
(	O
Figure	O
1A	O
)	O
rather	O
than	O
to	O
the	O
mutation	B-SO
itself	O
.	O

Xpd	B-GGP
ablation	O
(	O
XpdKO	O
/	O
KO	O
)	O
is	O
similarly	O
incompatible	O
with	O
life	O
beyond	O
the	O
earliest	O
stages	O
of	O
embryogenesis	O
[	O
22	O
]	O
.	O

Consistent	O
with	O
this	O
interpretation	O
,	O
a	O
different	O
targeted	O
Xpd	B-GGP
mutation	B-SO
encoding	O
XPDR683W	O
,	O
which	O
is	O
associated	O
with	O
XP	O
in	O
the	O
homozygous	O
state	O
in	O
humans	B-Taxon
,	O
was	O
similarly	O
underexpressed	O
and	O
lethal	O
in	O
the	O
homozygous	O
state	O
(	O
designated	O
as	O
+	O
XP	O
allele	B-SO
)	O
(	O
Figure	O
1A	O
-	O
1C	O
;	O
Table	O
1	O
;	O
unpublished	O
data	O
)	O
.	O

Also	O
,	O
a	O
different	O
targeting	O
approach	O
leading	O
to	O
the	O
use	O
of	O
the	O
native	B-SO
3	B-SO
'	I-SO
UTR	I-SO
and	O
removal	B-SO
of	O
the	O
neo	O
gene	B-SO
resulted	O
in	O
normalisation	O
of	O
XpdXPCS	O
mRNA	B-CHEBI
levels	O
and	O
viable	O
homozygous	O
XpdXPCS	O
/	O
XPCS	O
(	O
XPDG602D	O
/	O
G602D	O
)	O
animals	B-Taxon
[	O
23	O
]	O
.	O

Figure	O
1	O

Targeting	O
of	O
the	O
Mouse	B-GGP
Xpd	I-GGP
Gene	B-SO

(	O
A	O
)	O
Schematic	O
representation	O
of	O
the	O
genomic	B-SO
structure	O
and	O
partial	B-SO
restriction	B-SO
map	I-SO
of	O
the	O
wt	B-SO
and	O
targeted	O
mouse	B-GGP
Xpd	I-GGP
loci	B-SO
.	O

For	O
the	O
wt	B-SO
Xpd	B-GGP
allele	B-SO
,	O
shaded	O
boxes	O
represent	O
coding	B-SO
regions	I-SO
of	I-SO
exons	I-SO
12	O
and	O
19	O
-	O
23	O
;	O
the	O
3	B-SO
'	I-SO
UTR	I-SO
is	O
represented	O
by	O
an	O
open	O
box	O
.	O

TGA	O
indicates	O
the	O
translational	B-SO
stop	I-SO
codon	I-SO
;	O
PolyA	B-SO
indicates	O
the	O
polyadenylation	B-SO
signal	I-SO
.	O

For	O
the	O
XpdTTD	O
targeted	O
allele	B-SO
,	O
the	O
194	O
-	O
base	B-SO
pair	I-SO
(	O
bp	B-SO
)	O
human	B-GGP
XPD	I-GGP
cDNA	B-SO
fragment	B-SO
fused	O
to	O
exon	B-SO
22	O
is	O
indicated	O
as	O
a	O
striped	O
box	O
including	O
the	O
TTD	O
(	O
R722W	O
)	O
mutation	B-SO
indicated	O
by	O
a	O
vertical	O
arrow	O
.	O

Chicken	B-Taxon
beta	B-GGP
-	I-GGP
globin	I-GGP
exons	B-SO
2	O
and	O
3	O
including	O
the	O
3	B-SO
'	I-SO
UTR	I-SO
are	O
indicated	O
as	O
black	O
boxes	O
with	O
corresponding	O
Roman	O
numerals	O
followed	O
by	O
the	O
beta	B-GGP
-	I-GGP
globin	I-GGP
polyadenylation	B-SO
signal	I-SO
(	O
PolyA	B-SO
*	I-SO
)	O
.	O

For	O
the	O
Xpd	B-GGP
+	O
XP	O
and	O
Xpd	B-GGP
+	O
XPCS	O
targeted	O
alleles	B-SO
,	O
vertical	O
arrows	O
indicate	O
XPCS	O
(	O
G602D	O
-	O
encoding	O
)	O
and	O
XP	O
(	O
R683W	O
-	O
encoding	O
)	O
mutations	B-SO
in	O
exons	B-SO
19	O
and	O
22	O
,	O
respectively	O
.	O

The	O
unique	O
3	O
'	O
probe	B-SO
located	O
outside	O
the	O
targeting	O
construct	B-SO
is	O
marked	O
by	O
a	O
thick	O
black	O
line	O
.	O

Restriction	B-SO
sites	I-SO
:	O
B	O
,	O
BamHI	O
;	O
C	O
,	O
ClaI	O
;	O
E	O
,	O
EcoRI	O
;	O
H	B-GGP
,	O
HindIII	B-GGP
;	O
Hp	O
,	O
HpaI	O
;	O
Sf	O
,	O
SfiI	O
.	O

(	O
B	O
)	O
Southern	O
blot	O
analysis	O
of	O
EcoRI	O
-	O
digested	O
genomic	B-SO
DNA	I-SO
from	O
wt	B-SO
,	O
Xpd	B-GGP
+	O
XPCS	O
/	O
wt	B-SO
,	O
and	O
Xpd	B-GGP
+	O
XP	O
/	O
wt	B-SO
recombinant	O
embryonic	O
stem	B-CL
cell	I-CL
clones	O
hybridised	O
with	O
the	O
3	O
'	O
probe	B-SO
depicted	O
in	O
(	O
A	O
)	O
.	O

The	O
wt	B-SO
allele	B-SO
yields	O
a	O
6	O
.	O
5	O
-	O
kilobase	O
(	O
kb	O
)	O
fragment	B-SO
,	O
whereas	O
both	O
targeted	O
Xpd	B-GGP
+	O
XP	O
and	O
Xpd	B-GGP
+	O
XPCS	O
alleles	B-SO
yield	O
a	O
5	O
.	O
1	O
-	O
kb	O
fragment	B-SO
.	O

(	O
C	O
)	O
Genotyping	O
of	O
wt	B-SO
and	O
targeted	O
alleles	B-SO
by	O
PCR	O
using	O
primers	B-SO
F2	O
,	O
R1	O
,	O
and	O
mR	O
as	O
indicated	O
in	O
(	O
A	O
)	O
yields	O
fragments	B-SO
of	O
399	O
bp	B-SO
and	O
468	O
bp	B-SO
,	O
respectively	O
.	O

(	O
D	O
)	O
RT	O
-	O
PCR	O
detection	O
of	O
mRNA	B-CHEBI
expression	O
originating	O
from	O
the	O
targeted	O
+	O
XP	O
and	O
+	O
XPCS	O
alleles	B-SO
in	O
embryonic	O
stem	B-CL
cell	I-CL
clones	O
using	O
primers	B-SO
F1	O
(	O
hybridising	O
outside	O
the	O
targeting	O
construct	B-SO
)	O
and	O
mR	O
as	O
indicated	O
in	O
(	O
A	O
)	O
results	O
in	O
a	O
1	O
,	O
416	O
-	O
bp	B-SO
fragment	B-SO
.	O

(	O
E	O
)	O
Northern	O
blot	O
analysis	O
of	O
total	O
RNA	B-SO
isolated	O
from	O
testis	O
of	O
homozygous	O
wt	B-SO
and	O
XpdTTD	O
/	O
TTD	O
,	O
heterozygous	O
Xpd	B-GGP
+	O
XPCS	O
/	O
wt	B-SO
and	O
XpdTTD	O
/	O
wt	B-SO
,	O
and	O
compound	O
heterozygous	O
Xpd	B-GGP
+	O
XPCS	O
/	O
TTD	O
mice	B-Taxon
as	O
indicated	O
.	O

Hybridisation	O
with	O
a	O
1	O
.	O
4	O
-	O
kb	O
mouse	B-GGP
Xpd	I-GGP
cDNA	B-SO
probe	B-SO
detects	O
mRNAs	B-CHEBI
of	O
4	O
,	O
3	O
.	O
3	O
,	O
and	O
2	O
.	O
7	O
kb	O
from	O
wt	B-SO
,	O
Xpd	B-GGP
+	O
XPCS	O
,	O
and	O
XpdTTD	O
alleles	B-SO
,	O
respectively	O
.	O

An	O
ethidium	B-CHEBI
bromide	I-CHEBI
(	O
EtBr	B-CHEBI
)	O
-	O
stained	O
gel	O
showing	O
the	O
amount	O
of	O
total	O
RNA	B-SO
loaded	O
is	O
shown	O
below	O
.	O

Table	O
1	O

Frequency	O
of	O
Xpd	B-GGP
+	O
XP	O
/	O
+	O
XP	O
,	O
Xpd	B-GGP
+	O
XPCS	O
/	O
+	O
XPCS	O
,	O
and	O
Compound	O
Heterozygous	O
Xpd	B-GGP
+	O
XP	O
/	O
+	O
XPCS	O
Embryos	O
and	O
Offspring	O

"	O
Null	O
"	O
Allele	B-SO
Can	O
Alleviate	O
Developmental	O
Delay	O
,	O
Skin	O
,	O
and	O
Hair	O
Features	O
of	O
TTD	O

To	O
test	O
the	O
potential	O
of	O
a	O
homozygous	O
lethal	O
"	O
null	O
"	O
allele	B-SO
to	O
nevertheless	O
contribute	O
to	O
organismal	B-Taxon
phenotype	O
,	O
we	O
combined	O
an	O
Xpd	B-GGP
+	O
XPCS	O
allele	B-SO
with	O
a	O
viable	O
XpdTTD	O
allele	B-SO
by	O
crossing	O
the	O
corresponding	O
heterozygous	O
animals	B-Taxon
.	O

Similar	O
to	O
hemizygous	O
TTD	O
mice	B-Taxon
carrying	O
one	O
true	O
Xpd	B-GGP
knockout	O
allele	B-SO
(	O
XpdTTD	O
/	O
KO	O
)	O
,	O
compound	O
heterozygous	O
XpdTTD	O
/	O
+	O
XPCS	O
mice	B-Taxon
were	O
born	O
at	O
the	O
expected	O
Mendelian	O
frequencies	O
.	O

Expression	O
from	O
the	O
Xpd	B-GGP
+	O
XPCS	O
allele	B-SO
was	O
also	O
reduced	O
in	O
the	O
testis	O
of	O
compound	O
heterozygous	O
animals	B-Taxon
,	O
whereas	O
expression	O
from	O
the	O
XpdTTD	O
allele	B-SO
was	O
increased	O
relative	O
to	O
wt	B-SO
by	O
~	O
5	O
-	O
fold	O
(	O
Figure	O
1E	O
)	O
.	O

Because	O
of	O
a	O
lack	O
of	O
available	O
antibodies	B-GO
and	O
the	O
inability	O
to	O
distinguish	O
amongst	O
various	O
mutant	B-SO
forms	I-SO
of	O
XPD	B-GGP
differing	O
only	O
by	O
single	O
amino	B-CHEBI
acid	I-CHEBI
substitutions	B-SO
,	O
we	O
were	O
unable	O
to	O
ascertain	O
the	O
relative	O
amount	O
of	O
XPD	B-GGP
protein	B-CHEBI
from	O
the	O
different	O
alleles	B-SO
.	O

Despite	O
reduced	O
levels	O
of	O
mRNA	B-CHEBI
expression	O
,	O
the	O
homozygous	O
lethal	O
Xpd	B-GGP
+	O
XPCS	O
allele	B-SO
ameliorated	O
multiple	O
XpdTTD	O
-	O
associated	O
disease	O
symptoms	O
in	O
compound	O
heterozygous	O
XpdTTD	O
/	O
+	O
XPCS	O
animals	B-Taxon
including	O
the	O
hallmark	O
brittle	O
hair	O
and	O
cutaneous	O
features	O
fully	O
penetrant	O
in	O
homo	O
-	O
and	O
hemizygous	O
TTD	O
mice	B-Taxon
(	O
Figure	O
2A	O
-	O
2C	O
)	O
.	O

In	O
marked	O
contrast	O
to	O
XpdTTD	O
/	O
TTD	O
(	O
and	O
XpdTTD	O
/	O
KO	O
)	O
mice	B-Taxon
,	O
which	O
display	O
complete	O
hair	O
loss	O
in	O
the	O
first	O
hair	O
cycle	O
and	O
partial	O
hair	O
loss	O
in	O
subsequent	O
cycles	O
throughout	O
their	O
lives	O
[	O
21	O
]	O
,	O
compound	O
heterozygous	O
XpdTTD	O
/	O
+	O
XPCS	O
mice	B-Taxon
displayed	O
some	O
hair	O
loss	O
only	O
during	O
the	O
first	O
hair	O
cycle	O
and	O
only	O
locally	O
at	O
the	O
back	O
(	O
Figure	O
2A	O
)	O
.	O

Scanning	O
electron	B-CHEBI
microscope	O
analysis	O
of	O
XpdTTD	O
/	O
+	O
XPCS	O
hair	O
revealed	O
an	O
almost	O
normal	O
appearance	O
,	O
with	O
TTD	O
-	O
like	O
features	O
such	O
as	O
broken	O
hairs	O
found	O
only	O
at	O
very	O
low	O
frequency	O
(	O
unpublished	O
data	O
)	O
.	O

Amino	B-CHEBI
acid	I-CHEBI
analysis	O
confirmed	O
that	O
cysteine	B-CHEBI
levels	O
in	O
the	O
hair	O
of	O
the	O
XpdTTD	O
/	O
+	O
XPCS	O
mice	B-Taxon
were	O
significantly	O
higher	O
than	O
in	O
XpdTTD	O
/	O
TTD	O
animals	B-Taxon
,	O
but	O
remained	O
below	O
the	O
wt	B-SO
level	O
(	O
Figure	O
2C	O
)	O
.	O

TTD	O
hemizygotes	O
(	O
XpdTTD	O
/	O
KO	O
)	O
do	O
not	O
display	O
significant	O
differences	O
in	O
cutaneous	O
features	O
and	O
longevity	O
relative	O
to	O
homozygous	O
XpdTTD	O
/	O
TTD	O
mice	B-Taxon
[	O
21	O
]	O
.	O

Figure	O
2	O

Partial	O
Rescue	O
of	O
TTD	O
Cutaneous	O
,	O
Blood	O
,	O
and	O
Developmental	O
Phenotypes	O
in	O
Compound	O
Heterozygous	O
XpdTTD	O
/	O
+	O
XPCS	O
Mice	B-Taxon

(	O
A	O
)	O
Photographs	O
of	O
5	O
-	O
mo	O
-	O
old	O
homozygous	O
XpdTTD	O
/	O
TTD	O
,	O
compound	O
heterozygous	O
XpdTTD	O
/	O
+	O
XPCS	O
,	O
and	O
wt	B-SO
mice	B-Taxon
.	O

Insets	O
:	O
images	O
of	O
first	O
-	O
round	O
hair	O
loss	O
.	O

(	O
B	O
)	O
Histological	O
analysis	O
of	O
the	O
skin	O
of	O
XpdTTD	O
/	O
TTD	O
,	O
XpdTTD	O
/	O
+	O
XPCS	O
,	O
and	O
wt	B-SO
mice	B-Taxon
.	O

TTD	O
-	O
associated	O
acanthosis	O
(	O
thicker	O
epidermis	O
,	O
indicated	O
by	O
solid	O
vertical	O
line	O
)	O
,	O
pronounced	O
granular	O
layer	O
(	O
indicated	O
by	O
arrows	O
)	O
,	O
and	O
sebacious	O
gland	O
hyperplasia	O
(	O
indicated	O
by	O
dotted	O
vertical	O
line	O
)	O
were	O
absent	O
in	O
the	O
epidermis	O
of	O
XpdTTD	O
/	O
+	O
XPCS	O
and	O
wt	B-SO
mice	B-Taxon
.	O

Magnification	O
400	O
x	O
.	O

(	O
C	O
)	O
Cysteine	B-CHEBI
content	O
of	O
hair	O
from	O
wt	B-SO
,	O
XpdTTD	O
/	O
TTD	O
,	O
and	O
XpdTTD	O
/	O
+	O
XPCS	O
mice	B-Taxon
.	O

The	O
p	O
-	O
value	O
indicates	O
significant	O
differences	O
between	O
mutants	B-SO
and	O
wt	B-SO
,	O
as	O
well	O
as	O
between	O
XpdTTD	O
/	O
TTD	O
and	O
XpdTTD	O
/	O
+	O
XPCS	O
mice	B-Taxon
.	O

Error	O
bars	O
indicate	O
standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
)	O
.	O

(	O
D	O
)	O
Hematocrit	O
values	O
from	O
blood	O
of	O
XpdTTD	O
/	O
TTD	O
and	O
XpdTTD	O
/	O
+	O
XPCS	O
mice	B-Taxon
.	O

The	O
p	O
-	O
values	O
indicate	O
the	O
significance	O
of	O
the	O
difference	O
relative	O
to	O
wt	B-SO
.	O

Error	O
bars	O
indicate	O
SEM	O
.	O

(	O
E	O
)	O
Body	O
weights	O
of	O
developing	O
XpdTTD	O
/	O
TTD	O
and	O
XpdTTD	O
/	O
+	O
XPCS	O
mice	B-Taxon
after	O
weaning	O
plotted	O
as	O
a	O
percentage	O
of	O
the	O
weight	O
of	O
age	O
-	O
matched	O
control	O
wt	B-SO
and	O
heterozygote	O
(	O
hz	O
)	O
littermates	O
(	O
set	O
at	O
100	O
%	O
)	O
.	O

Error	O
bars	O
indicate	O
SEM	O
.	O

Other	O
prominent	O
TTD	O
features	O
in	O
the	O
epidermis	O
,	O
including	O
acanthosis	O
(	O
thickening	O
of	O
the	O
layer	O
of	O
the	O
nucleated	B-GO
cells	B-CL
)	O
,	O
hyperkeratosis	O
(	O
prominent	O
thickening	O
of	O
the	O
cornified	O
layer	O
)	O
,	O
and	O
pronounced	O
granular	O
layer	O
and	O
sebacious	O
gland	O
hyperplasia	O
(	O
causing	O
greasy	O
appearance	O
of	O
the	O
hair	O
)	O
,	O
were	O
absent	O
in	O
the	O
skin	O
of	O
XpdTTD	O
/	O
+	O
XPCS	O
mice	B-Taxon
,	O
as	O
established	O
by	O
blind	O
microscopic	O
examination	O
of	O
skin	O
sections	O
(	O
Figure	O
2B	O
)	O
.	O

Furthermore	O
,	O
anaemia	O
and	O
developmental	O
delay	O
present	O
in	O
patients	O
with	O
TTD	O
[	O
24	O
]	O
and	O
in	O
XpdTTD	O
/	O
TTD	O
mice	B-Taxon
[	O
15	O
]	O
were	O
both	O
partially	O
rescued	O
in	O
compound	O
heterozygous	O
XpdTTD	O
/	O
+	O
XPCS	O
mice	B-Taxon
(	O
Figure	O
2D	O
and	O
2E	O
)	O
.	O

Rescue	O
of	O
Progeroid	O
Features	O
in	O
TTD	O
Mice	B-Taxon
by	O
Homozygous	O
Lethal	O
Xpd	B-GGP
Alleles	B-SO

Because	O
patients	O
with	O
TTD	O
,	O
XPCS	O
,	O
and	O
CS	O
(	O
but	O
not	O
XP	O
)	O
and	O
the	O
corresponding	O
mouse	B-Taxon
models	O
share	O
similar	O
accelerated	O
progeroid	O
symptoms	O
[	O
12	O
,	O
13	O
,	O
15	O
,	O
23	O
]	O
,	O
we	O
next	O
addressed	O
ageing	O
-	O
related	O
parameters	O
in	O
compound	O
heterozygous	O
mice	B-Taxon
(	O
Figure	O
3	O
)	O
.	O

Whereas	O
XpdTTD	O
/	O
TTD	O
animals	B-Taxon
show	O
reduced	O
bone	O
mineral	B-CHEBI
density	O
as	O
an	O
indication	O
of	O
the	O
early	O
onset	O
of	O
osteoporosis	O
before	O
~	O
14	O
mo	O
of	O
age	O
[	O
15	O
]	O
,	O
tail	O
vertebrae	O
from	O
compound	O
heterozygous	O
XpdTTD	O
/	O
+	O
XPCS	O
mice	B-Taxon
were	O
comparable	O
to	O
wt	B-SO
even	O
at	O
20	O
mo	O
of	O
age	O
(	O
Figure	O
3B	O
and	O
3C	O
)	O
.	O

Furthermore	O
,	O
whereas	O
XpdTTD	O
/	O
TTD	O
mice	B-Taxon
developed	O
kyphosis	O
earlier	O
than	O
wt	B-SO
animals	B-Taxon
(	O
onset	O
~	O
3	O
mo	O
versus	O
12	O
-	O
20	O
mo	O
)	O
,	O
compound	O
heterozygous	O
XpdTTD	O
/	O
+	O
XPCS	O
mice	B-Taxon
did	O
not	O
(	O
Figure	O
3B	O
)	O
.	O

Overall	O
appearance	O
and	O
body	O
weight	O
curves	O
revealed	O
that	O
TTD	O
-	O
associated	O
age	O
-	O
related	O
premature	O
cachexia	O
and	O
lack	O
of	O
general	O
fitness	O
were	O
fully	O
rescued	O
in	O
compound	O
heterozygous	O
XpdTTD	O
/	O
+	O
XPCS	O
mice	B-Taxon
(	O
Figure	O
3A	O
and	O
3D	O
)	O
.	O

Finally	O
,	O
the	O
life	O
span	O
of	O
compound	O
heterozygotes	O
was	O
extended	O
relative	O
to	O
XpdTTD	O
/	O
TTD	O
mice	B-Taxon
(	O
Table	O
2	O
)	O
.	O

Figure	O
3	O

Rescue	O
of	O
TTD	O
-	O
Associated	O
Segmental	O
Progeroid	O
Features	O
in	O
Compound	O
Heterozygous	O
Xpd	B-GGP
TTD	O
/	O
+	O
XPCS	O
Mice	B-Taxon

(	O
A	O
)	O
Photographs	O
of	O
20	O
-	O
mo	O
-	O
old	O
wt	B-SO
,	O
compound	O
heterozygous	O
XpdTTD	O
/	O
+	O
XPCS	O
,	O
and	O
homozygous	O
XpdTTD	O
/	O
TTD	O
mice	B-Taxon
.	O

Note	O
the	O
extreme	O
cachexia	O
(	O
lack	O
of	O
subcutaneous	O
fat	O
)	O
in	O
the	O
XpdTTD	O
/	O
TTD	O
mouse	B-Taxon
and	O
the	O
absence	O
of	O
this	O
phenotype	O
in	O
wt	B-SO
and	O
XpdTTD	O
/	O
+	O
XPCS	O
mice	B-Taxon
.	O

(	O
B	O
)	O
Radiographs	O
of	O
20	O
-	O
mo	O
-	O
old	O
male	O
wt	B-SO
,	O
XpdTTD	O
/	O
+	O
XPCS	O
,	O
and	O
XpdTTD	O
/	O
TTD	O
mice	B-Taxon
.	O

Ageing	O
XpdTTD	O
/	O
TTD	O
mice	B-Taxon
develop	O
kyphosis	O
(	O
curvature	O
of	O
the	O
spinal	O
column	O
)	O
and	O
reduction	O
of	O
bone	O
mineral	B-CHEBI
density	O
as	O
shown	O
in	O
the	O
6	O
-	O
8	O
segment	O
of	O
the	O
tail	O
vertebrae	O
counted	O
from	O
the	O
pelvis	O
(	O
see	O
close	O
-	O
up	O
at	O
right	O
)	O
.	O

Note	O
the	O
absence	O
of	O
these	O
features	O
in	O
the	O
XpdTTD	O
/	O
+	O
XPCS	O
mouse	B-Taxon
.	O

(	O
C	O
)	O
Quantification	O
of	O
relative	O
bone	O
mineral	B-CHEBI
density	O
of	O
tail	O
vertebrae	O
from	O
20	O
-	O
mo	O
-	O
old	O
male	O
wt	B-SO
(	O
n	O
=	O
3	O
)	O
,	O
XpdTTD	O
/	O
+	O
XPCS	O
(	O
n	O
=	O
4	O
)	O
,	O
and	O
XpdTTD	O
/	O
TTD	O
(	O
n	O
=	O
3	O
)	O
mice	B-Taxon
.	O

The	O
p	O
-	O
values	O
indicate	O
the	O
significance	O
of	O
the	O
difference	O
relative	O
to	O
XpdTTD	O
/	O
TTD	O
.	O

Error	O
bars	O
indicate	O
SEM	O
.	O

(	O
D	O
)	O
Body	O
weight	O
curves	O
as	O
a	O
function	O
of	O
time	O
.	O

Note	O
that	O
the	O
age	O
-	O
dependent	O
cachexia	O
observed	O
in	O
XpdTTD	O
/	O
TTD	O
mice	B-Taxon
was	O
rescued	O
in	O
both	O
male	O
and	O
female	O
XpdTTD	O
/	O
+	O
XPCS	O
mice	B-Taxon
.	O

Significant	O
differences	O
between	O
wt	B-SO
and	O
XpdTTD	O
/	O
TTD	O
but	O
not	O
between	O
wt	B-SO
and	O
XpdTTD	O
/	O
+	O
XPCS	O
mice	B-Taxon
were	O
observed	O
at	O
9	O
and	O
18	O
mo	O
of	O
age	O
as	O
indicated	O
by	O
asterisks	O
.	O

Error	O
bars	O
indicate	O
SEM	O
.	O

Table	O
2	O

Pleiotropic	O
Xpd	B-GGP
Biallelic	O
Effects	O
in	O
Mice	B-Taxon
and	O
Cells	B-CL

To	O
determine	O
whether	O
the	O
homozygous	O
lethal	O
Xpd	B-GGP
+	O
XPCS	O
allele	B-SO
was	O
unique	O
in	O
its	O
ability	O
to	O
ameliorate	O
symptoms	O
associated	O
with	O
the	O
XpdTTD	O
allele	B-SO
,	O
we	O
generated	O
compound	O
heterozygous	O
XpdTTD	O
/	O
+	O
XP	O
mice	B-Taxon
by	O
crossing	O
the	O
corresponding	O
heterozygous	O
animals	B-Taxon
.	O

Similar	O
to	O
the	O
Xpd	B-GGP
+	O
XPCS	O
allele	B-SO
,	O
the	O
homozygous	O
lethal	O
Xpd	B-GGP
+	O
XP	O
allele	B-SO
rescued	O
cutaneous	O
symptoms	O
including	O
hair	O
loss	O
(	O
except	O
locally	O
during	O
the	O
first	O
round	O
;	O
unpublished	O
data	O
)	O
,	O
reduced	O
cysteine	B-CHEBI
content	O
(	O
cysteine	B-CHEBI
index	O
9	O
.	O
3	O
+/-	O
0	O
.	O
9	O
standard	O
deviation	O
[	O
87	O
%	O
of	O
wt	B-SO
]	O
,	O
p	O
=	O
0	O
.	O
01	O
versus	O
TTD	O
)	O
,	O
ageing	O
-	O
associated	O
premature	O
cachexia	O
(	O
males	O
and	O
females	O
were	O
36	O
.	O
1	O
+/-	O
6	O
.	O
4	O
g	O
[	O
93	O
%	O
of	O
wt	B-SO
]	O
and	O
39	O
.	O
2	O
+/-	O
3	O
.	O
2	O
g	O
[	O
116	O
%	O
of	O
wt	B-SO
]	O
,	O
respectively	O
)	O
,	O
and	O
reduced	O
life	O
span	O
(	O
Table	O
2	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
two	O
independent	O
alleles	B-SO
,	O
which	O
on	O
their	O
own	O
are	O
unable	O
to	O
support	O
viability	O
(	O
Table	O
1	O
)	O
,	O
were	O
nonetheless	O
able	O
to	O
ameliorate	O
TTD	O
-	O
associated	O
phenotypes	O
in	O
vivo	O
(	O
Table	O
2	O
)	O
.	O

Molecular	B-CHEBI
Mechanisms	O
of	O
Biallelic	O
Effects	O

We	O
next	O
turned	O
to	O
UV	O
-	O
based	O
cellular	B-CL
assays	O
including	O
unscheduled	O
DNA	B-SO
synthesis	O
after	O
UV	O
irradiation	O
(	O
UV	O
-	O
UDS	O
)	O
,	O
recovery	O
of	O
RNA	B-SO
synthesis	O
after	O
UV	O
irradiation	O
(	O
UV	O
-	O
RRS	O
)	O
,	O
and	O
UV	O
survival	O
,	O
which	O
report	O
on	O
the	O
NER	O
subpathways	O
(	O
global	O
genome	B-SO
NER	O
and	O
transcription	O
-	O
coupled	O
NER	O
)	O
and	O
total	O
NER	O
,	O
respectively	O
.	O

In	O
none	O
of	O
these	O
assays	O
was	O
the	O
response	O
to	O
UV	O
improved	O
in	O
compound	O
heterozygotes	O
relative	O
to	O
TTD	O
homozygotes	O
(	O
Figure	O
4A	O
-	O
4C	O
)	O
.	O

However	O
,	O
unlike	O
the	O
in	O
vivo	O
TTD	O
phenotypes	O
described	O
above	O
,	O
in	O
which	O
XpdTTD	O
/	O
TTD	O
and	O
XpdTTD	O
/	O
KO	O
animals	B-Taxon
were	O
indistinguishable	O
,	O
XpdTTD	O
dosage	O
effects	O
were	O
observed	O
in	O
UV	O
survival	O
,	O
UV	O
-	O
UDS	O
,	O
and	O
UV	O
-	O
RRS	O
,	O
indicating	O
that	O
cellular	B-CL
parameters	O
as	O
measured	O
in	O
fibroblasts	B-CL
here	O
do	O
not	O
always	O
correlate	O
with	O
the	O
phenotype	O
at	O
the	O
level	O
of	O
the	O
intact	O
organism	B-Taxon
.	O

XpdTTD	O
/	O
KO	O
hemizygous	O
cells	B-CL
were	O
thus	O
used	O
as	O
the	O
baseline	O
on	O
which	O
to	O
compare	O
the	O
activity	O
of	O
compound	O
heterozygous	O
cells	B-CL
.	O

Relative	O
to	O
XpdTTD	O
/	O
KO	O
hemizygote	O
cells	B-CL
,	O
UV	O
survival	O
was	O
improved	O
by	O
the	O
homozygous	O
lethal	O
Xpd	B-GGP
+	O
XPCS	O
allele	B-SO
in	O
XpdTTD	O
/	O
+	O
XPCS	O
compound	O
heterozygous	O
cells	B-CL
and	O
to	O
a	O
lesser	O
degree	O
by	O
the	O
Xpd	B-GGP
+	O
XP	O
allele	B-SO
(	O
Figure	O
4A	O
)	O
.	O

Because	O
of	O
embryonic	O
and	O
cellular	B-CL
lethality	O
,	O
we	O
were	O
unable	O
to	O
test	O
UV	O
survival	O
associated	O
exclusively	O
with	O
the	O
Xpd	B-GGP
+	O
XPCS	O
or	O
Xpd	B-GGP
+	O
XP	O
alleles	B-SO
.	O

However	O
,	O
homozygous	O
XPDXP	O
(	O
XPDR683W	O
)	O
and	O
hemizygous	O
XPDXPCS	O
(	O
XPDG602D	O
)	O
human	B-Taxon
cells	B-CL
are	O
known	O
to	O
be	O
highly	O
sensitive	O
to	O
UV	O
[	O
19	O
,	O
25	O
]	O
,	O
as	O
are	O
cells	B-CL
from	O
a	O
homozygous	O
viable	O
XpdXPCS	O
/	O
XPCS	O
(	O
XPDG602D	O
/	O
G602D	O
)	O
mouse	B-Taxon
model	O
(	O
Figure	O
4A	O
,	O
dotted	O
line	O
)	O
[	O
23	O
]	O
.	O

Thus	O
,	O
the	O
survival	O
of	O
XpdTTD	O
/	O
+	O
XPCS	O
(	O
and	O
XpdTTD	O
/	O
+	O
XP	O
)	O
cells	B-CL
likely	O
represents	O
a	O
level	O
of	O
UV	O
resistance	O
that	O
neither	O
mutant	B-SO
allele	B-SO
can	O
impart	O
on	O
its	O
own	O
(	O
Table	O
2	O
)	O
.	O

Significant	O
effects	O
of	O
compound	O
heterozygosity	O
on	O
NER	O
subpathways	O
relative	O
to	O
XpdTTD	O
/	O
KO	O
cells	B-CL
were	O
observed	O
in	O
XpdTTD	O
/	O
+	O
XP	O
cells	B-CL
but	O
only	O
for	O
UV	O
-	O
UDS	O
activity	O
.	O

Finally	O
,	O
none	O
of	O
the	O
mutant	B-SO
TFIIH	B-GO
combinations	O
(	O
carrying	O
alterations	B-SO
associated	O
with	O
TTD	O
[	O
XPDR722W	O
]	O
,	O
XPCS	O
[	O
XPDG602D	O
]	O
,	O
or	O
XP	O
[	O
XPDR683W	O
]	O
)	O
exhibited	O
synergism	O
in	O
an	O
in	O
vitro	O
NER	O
reaction	O
reconstituted	O
with	O
different	O
mutant	B-SO
TFIIH	B-GO
complexes	I-GO
(	O
Figure	O
4D	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
are	O
consistent	O
with	O
interallelic	O
complementation	O
of	O
UV	O
sensitivity	O
in	O
cells	B-CL
but	O
underscore	O
the	O
lack	O
of	O
any	O
correlation	O
between	O
UV	O
-	O
related	O
repair	O
characteristics	O
and	O
TTD	O
progeroid	O
phenotypes	O
in	O
animal	B-Taxon
models	O
.	O

Figure	O
4	O

TFIIH	B-GO
Functions	O
and	O
Mechanisms	O
of	O
XPD	B-GGP
-	O
Associated	O
Disease	O
Pleiotropy	O

(	O
A	O
)	O
Cellular	B-CL
survival	O
after	O
UV	O
irradiation	O
.	O

Rescue	O
of	O
hemizygous	O
XpdTTD	O
/	O
KO	O
survival	O
by	O
Xpd	B-GGP
+	O
XPCS	O
and	O
Xpd	B-GGP
+	O
XP	O
alleles	B-SO
is	O
illustrated	O
by	O
arrows	O
marked	O
A	O
and	O
B	O
,	O
respectively	O
.	O

UV	O
survival	O
of	O
homozygous	O
XpdXPCS	O
/	O
XPCS	O
cells	B-CL
(	O
asterisk	O
)	O
from	O
the	O
normally	O
expressed	O
viable	O
allele	B-SO
(	O
XpdXPCS	O
)	O
is	O
depicted	O
by	O
a	O
dotted	O
line	O
.	O

Survival	O
curves	O
represent	O
an	O
average	O
of	O
four	O
independent	O
experiments	O
;	O
1	O
-	O
2	O
cell	B-CL
lines	O
per	O
genotype	B-SO
were	O
included	O
in	O
each	O
experiment	O
.	O

Error	O
bars	O
indicate	O
SEM	O
between	O
experiments	O
.	O

(	O
B	O
)	O
UV	O
-	O
UDS	O
,	O
a	O
measure	O
of	O
global	O
genome	B-SO
repair	O
.	O

Number	O
of	O
experiments	O
:	O
n	O
=	O
15	O
(	O
XpdTTD	O
/	O
TTD	O
)	O
,	O
n	O
=	O
6	O
(	O
XpdTTD	O
/	O
KO	O
)	O
,	O
n	O
=	O
4	O
(	O
XpdTTD	O
/	O
+	O
XPCS	O
)	O
,	O
n	O
=	O
2	O
(	O
XpdTTD	O
/	O
+	O
XP	O
)	O
;	O
1	O
-	O
2	O
cell	B-CL
lines	O
per	O
genotype	B-SO
were	O
included	O
in	O
each	O
experiment	O
.	O

The	O
asterisk	O
indicates	O
significant	O
difference	O
with	O
XpdTTD	O
/	O
TTD	O
;	O
crosses	O
indicate	O
significant	O
differences	O
with	O
XpdTTD	O
/	O
KO	O
.	O

(	O
C	O
)	O
UV	O
-	O
RRS	O
,	O
a	O
measure	O
of	O
transcription	O
-	O
coupled	O
repair	O
of	O
UV	O
-	O
induced	O
lesions	O
.	O

Number	O
of	O
experiments	O
:	O
n	O
=	O
7	O
(	O
XpdTTD	O
/	O
TTD	O
)	O
,	O
n	O
=	O
2	O
(	O
XpdTTD	O
/	O
KO	O
)	O
,	O
n	O
=	O
4	O
(	O
XpdTTD	O
/	O
+	O
XPCS	O
)	O
,	O
n	O
=	O
2	O
(	O
XpdTTD	O
/	O
+	O
XP	O
)	O
;	O
1	O
-	O
2	O
cell	B-CL
lines	O
per	O
genotype	B-SO
were	O
included	O
in	O
each	O
experiment	O
.	O

(	O
D	O
)	O
Incision	O
/	O
excision	B-SO
activity	O
of	O
combinations	O
of	O
altered	B-SO
TFIIH	B-GO
complexes	I-GO
in	O
a	O
reconstituted	O
NER	O
reaction	O
.	O

Equal	O
amounts	O
of	O
single	O
or	O
mixed	O
populations	O
of	O
recombinant	O
TFIIHs	B-GO
(	O
containing	O
XPD	B-GGP
,	O
XPB	B-GGP
,	O
p62	B-GGP
,	O
p52	B-GGP
,	O
His	B-SO
-	O
p44	B-GGP
,	O
Flag	O
-	O
p34	B-GGP
,	O
cdk7	B-GGP
,	O
cyclin	B-GGP
H	I-GGP
,	O
Mat1	B-GGP
,	O
and	O
p8	B-GGP
)	O
were	O
mixed	O
with	O
recombinant	O
XPG	B-GGP
,	O
XPF	B-GGP
/	O
ERCC1	B-GGP
,	O
XPC	B-GGP
/	O
hHR23B	B-GGP
,	O
RPA	O
,	O
and	O
a	O
radiolabelled	B-CHEBI
synthetic	B-SO
NER	O
substrate	O
.	O

The	O
excision	B-SO
products	O
(	O
26	O
-	O
34	O
nucleotides	B-CHEBI
in	O
length	O
)	O
were	O
visualised	O
at	O
nucleotide	B-CHEBI
resolution	O
on	O
a	O
denaturing	O
polyacrylamide	O
gel	O
as	O
indicated	O
.	O

Note	O
the	O
weak	O
activity	O
corresponding	O
to	O
each	O
single	O
and	O
combined	O
TFIIH	B-GO
complex	I-GO
(	O
lanes	O
3	O
-	O
8	O
)	O
relative	O
to	O
the	O
wt	B-SO
(	O
lane	O
1	O
)	O
and	O
negative	O
controls	O
(	O
lane	O
2	O
)	O
.	O

(	O
E	O
)	O
Xpd	B-GGP
dose	O
-	O
dependent	O
reduction	O
of	O
TFIIH	B-GO
in	O
homozygous	O
XpdTTD	O
/	O
TTD	O
,	O
hemizygous	O
XpdTTD	O
/	O
KO	O
,	O
and	O
compound	O
heterozygous	O
XpdTTD	O
/	O
+	O
XPCS	O
and	O
XpdTTD	O
/	O
+	O
XP	O
cells	B-CL
by	O
comparative	O
immunofluorescence	O
of	O
the	O
p62	B-GGP
subunit	I-GGP
of	I-GGP
TFIIH	I-GGP
.	O

Roman	O
numerals	O
represent	O
different	O
microscopic	O
slides	O
and	O
Arabic	O
numerals	O
different	O
cell	B-CL
lines	O
labelled	O
as	O
follows	O
:	O
(	O
I	O
)	O
wt	B-SO
cells	B-CL
(	O
1	O
)	O
labelled	O
with	O
2	O
-	O
mu	O
m	O
beads	O
,	O
XpdTTD	O
/	O
TTD	O
cells	B-CL
(	O
2	O
)	O
with	O
0	O
.	O
79	O
-	O
mu	O
m	O
beads	O
,	O
and	O
XpdTTD	O
/	O
KO	O
cells	B-CL
(	O
3	O
)	O
with	O
no	O
beads	O
;	O
(	O
II	O
)	O
wt	B-SO
cells	B-CL
(	O
1	O
)	O
labelled	O
with	O
0	O
.	O
79	O
-	O
mu	O
m	O
beads	O
and	O
XpdTTD	O
/	O
+	O
XPCS	O
cells	B-CL
(	O
4	O
)	O
with	O
no	O
beads	O
;	O
and	O
(	O
III	O
)	O
wt	B-SO
cells	B-CL
(	O
1	O
)	O
labelled	O
with	O
0	O
.	O
79	O
-	O
mu	O
m	O
beads	O
and	O
XpdTTD	O
/	O
+	O
XP	O
cells	B-CL
(	O
5	O
)	O
with	O
no	O
beads	O
.	O

(	O
F	O
)	O
Quantification	O
of	O
immunofluorescent	O
signal	O
from	O
at	O
least	O
50	O
nuclei	B-GO
per	O
cell	B-CL
line	O
and	O
2	O
-	O
6	O
experiments	O
per	O
genotype	B-SO
.	O

Bars	O
representing	O
cells	B-CL
analysed	O
on	O
the	O
same	O
microscopic	O
slide	O
are	O
depicted	O
side	O
by	O
side	O
,	O
with	O
wt	B-SO
set	O
at	O
100	O
%	O
.	O

The	O
p	O
-	O
value	O
indicates	O
minimum	O
significant	O
difference	O
between	O
wt	B-SO
and	O
the	O
indicated	O
cell	B-CL
lines	O
analysed	O
on	O
the	O
same	O
microscopic	O
slide	O
within	O
one	O
experiment	O
.	O

Next	O
we	O
asked	O
whether	O
the	O
Xpd	B-GGP
+	O
XPCS	O
and	O
Xpd	B-GGP
+	O
XP	O
alleles	B-SO
,	O
despite	O
decreased	O
mRNA	B-CHEBI
levels	O
,	O
ameliorated	O
TTD	O
symptoms	O
by	O
increasing	O
overall	O
TFIIH	B-GO
levels	O
in	O
compound	O
heterozygous	O
XpdTTD	O
/	O
+	O
XPCS	O
and	O
XpdTTD	O
/	O
+	O
XP	O
cells	B-CL
.	O

Previously	O
,	O
using	O
comparative	O
immunohistochemistry	O
,	O
we	O
and	O
others	O
have	O
shown	O
an	O
up	O
to	O
70	O
%	O
reduction	O
of	O
TFIIH	B-GO
levels	O
in	O
primary	O
fibroblasts	B-CL
from	O
patients	O
with	O
TTD	O
compared	O
with	O
wt	B-SO
controls	O
due	O
to	O
reduced	O
stability	O
[	O
16	O
,	O
17	O
]	O
.	O

Despite	O
overexpression	O
of	O
mRNA	B-CHEBI
from	O
the	O
XpdTTD	O
allele	B-SO
relative	O
to	O
the	O
wt	B-SO
allele	B-SO
(	O
Figure	O
1E	O
)	O
,	O
TFIIH	B-GO
protein	B-CHEBI
levels	O
were	O
reduced	O
by	O
50	O
%	O
in	O
primary	O
mouse	B-Taxon
XpdTTD	O
/	O
TTD	O
fibroblasts	B-CL
(	O
Figure	O
4E	O
and	O
4F	O
)	O
,	O
thereby	O
mimicking	O
the	O
situation	O
in	O
human	B-Taxon
patients	O
with	O
TTD	O
.	O

In	O
accordance	O
with	O
the	O
gene	B-SO
dosage	O
,	O
a	O
further	O
reduction	O
of	O
up	O
to	O
70	O
%	O
of	O
the	O
wt	B-SO
level	O
was	O
observed	O
in	O
hemizygous	O
XpdTTD	O
/	O
KO	O
cells	B-CL
.	O

Consistent	O
with	O
low	O
mRNA	B-CHEBI
expression	O
levels	O
,	O
neither	O
the	O
Xpd	B-GGP
+	O
XPCS	O
nor	O
the	O
Xpd	B-GGP
+	O
XP	O
allele	B-SO
was	O
able	O
to	O
restore	O
TFIIH	B-GO
abundance	O
to	O
wt	B-SO
levels	O
in	O
XpdTTD	O
compound	O
heterozygote	O
cells	B-CL
(	O
Figure	O
4E	O
and	O
4F	O
)	O
.	O

Thus	O
,	O
the	O
improved	O
UV	O
survival	O
observed	O
in	O
compound	O
heterozygote	O
cells	B-CL
(	O
Figure	O
4A	O
)	O
and	O
likely	O
the	O
rescue	O
of	O
TTD	O
progeroid	O
symptoms	O
(	O
Figure	O
3	O
)	O
were	O
not	O
due	O
to	O
normalisation	O
of	O
TFIIH	B-GO
levels	O
,	O
suggesting	O
a	O
qualitative	O
rather	O
than	O
a	O
quantitative	O
effect	O
on	O
these	O
phenotypes	O
in	O
vivo	O
.	O

In	O
contrast	O
,	O
the	O
level	O
of	O
XPCS	O
mRNA	B-CHEBI
expression	O
did	O
affect	O
the	O
ability	O
of	O
the	O
encoded	O
protein	B-CHEBI
(	O
XPDG602D	O
)	O
to	O
restore	O
the	O
TTD	O
hair	O
phenotype	O
to	O
normal	O
.	O

Notably	O
,	O
XpdTTD	O
/	O
+	O
XPCS	O
animals	B-Taxon
had	O
a	O
partial	O
TTD	O
hair	O
phenotype	O
,	O
correlating	O
with	O
low	O
levels	O
of	O
Xpd	B-GGP
+	O
XPCS	O
expression	O
,	O
whereas	O
XpdTTD	O
/	O
XPCS	O
animals	B-Taxon
had	O
wt	B-SO
hair	O
,	O
correlating	O
with	O
normal	O
expression	O
levels	O
from	O
the	O
viable	O
XpdXPCS	O
allele	B-SO
(	O
Table	O
2	O
and	O
unpublished	O
data	O
)	O
.	O

Thus	O
,	O
the	O
range	O
of	O
expression	O
levels	O
from	O
these	O
two	O
mutant	B-SO
alleles	B-SO
affected	O
their	O
ability	O
to	O
complement	O
some	O
phenotypes	O
(	O
hair	O
)	O
.	O

An	O
overview	O
of	O
the	O
functional	O
relationships	O
between	O
Xpd	B-GGP
alleles	B-SO
,	O
phenotypes	O
,	O
and	O
the	O
presumed	O
underlying	O
TFIIH	B-GO
function	O
in	O
mice	B-Taxon
and	O
cells	B-CL
is	O
presented	O
in	O
Table	O
2	O
.	O

Discussion	O

Dissection	O
of	O
Biallelic	O
Effects	O
from	O
other	O
Determinants	O
of	O
Phenotype	O

Although	O
phenotypic	O
consequences	O
,	O
referred	O
to	O
here	O
as	O
biallelic	O
effects	O
,	O
resulting	O
from	O
two	O
different	O
mutant	B-SO
alleles	B-SO
in	O
compound	O
heterozygote	O
patients	O
have	O
been	O
postulated	O
,	O
such	O
effects	O
have	O
historically	O
been	O
difficult	O
to	O
distinguish	O
from	O
the	O
influence	O
of	O
environment	O
and	O
genetic	B-SO
background	O
.	O

We	O
used	O
a	O
genetically	B-SO
defined	O
mammalian	B-Taxon
model	O
system	O
under	O
controlled	O
environmental	O
conditions	O
to	O
reveal	O
phenotypic	O
effects	O
attributable	O
specifically	O
to	O
combinations	O
of	O
differentially	O
mutated	B-SO
Xpd	B-GGP
alleles	B-SO
.	O

The	O
observed	O
biallelic	O
effects	O
were	O
of	O
three	O
general	O
types	O
.	O

In	O
the	O
first	O
,	O
the	O
allele	B-SO
associated	O
in	O
a	O
homozygous	O
state	O
with	O
a	O
phenotype	O
closer	O
to	O
wt	B-SO
singularly	O
determined	O
the	O
phenotypic	O
outcome	O
,	O
a	O
phenomenon	O
widely	O
known	O
in	O
human	B-Taxon
recessive	O
disease	O
.	O

Because	O
these	O
Xpd	B-GGP
alleles	B-SO
functioned	O
at	O
or	O
near	O
wt	B-SO
levels	O
with	O
respect	O
to	O
a	O
particular	O
function	O
,	O
we	O
call	O
these	O
effects	O
"	O
dominant	O
"	O
.	O

Such	O
alleles	B-SO
can	O
also	O
be	O
referred	O
to	O
as	O
"	O
separation	O
of	O
function	O
"	O
alleles	B-SO
,	O
because	O
they	O
allow	O
dissection	O
of	O
the	O
roles	O
of	O
multifunctional	O
proteins	B-CHEBI
in	O
specific	O
phenotypes	O
.	O

Secondly	O
,	O
highlighting	O
the	O
potential	O
relevance	O
of	O
current	O
findings	O
to	O
all	O
diploid	O
organisms	B-Taxon
including	O
humans	B-Taxon
was	O
the	O
observation	O
that	O
in	O
one	O
compound	O
heterozygous	O
animal	B-Taxon
,	O
the	O
Xpd	B-GGP
allelic	B-SO
relationship	O
could	O
shift	O
from	O
Adominant	O
|	O
arecessive	O
to	O
Arecessive	O
|	O
adominant	O
with	O
respect	O
to	O
different	O
phenotypes	O
in	O
a	O
time	O
-	O
dependent	O
and	O
tissue	O
-	O
specific	O
manner	O
(	O
see	O
below	O
and	O
Table	O
2	O
)	O
.	O

In	O
the	O
third	O
type	O
of	O
biallelic	O
effect	O
,	O
known	O
as	O
interallelic	O
complementation	O
,	O
two	O
mutant	B-SO
alleles	B-SO
produced	O
a	O
phenotype	O
closer	O
to	O
wt	B-SO
than	O
either	O
could	O
alone	O
in	O
a	O
homo	O
-	O
or	O
hemizygous	O
state	O
.	O

As	O
summarised	O
in	O
Table	O
2	O
,	O
examples	O
of	O
all	O
types	O
of	O
biallelic	O
effects	O
were	O
observed	O
in	O
a	O
variety	O
of	O
Xpd	B-GGP
-	O
associated	O
phenotypes	O
,	O
ranging	O
from	O
brittle	O
hair	O
to	O
segmental	O
progeria	O
.	O

TFIIH	B-GO
in	O
Transcription	O
and	O
Repair	O
:	O
Mechanisms	O
of	O
XPD	B-GGP
Disease	O
Pleiotropy	O

We	O
observed	O
differences	O
in	O
the	O
ability	O
of	O
XpdTTD	O
versus	O
homozygous	O
lethal	O
Xpd	B-GGP
+	O
XPCS	O
and	O
Xpd	B-GGP
+	O
XP	O
alleles	B-SO
to	O
function	O
in	O
two	O
transcription	O
-	O
related	O
phenotypes	O
separated	O
in	O
the	O
organism	B-Taxon
by	O
both	O
time	O
and	O
space	O
:	O
embryonic	O
lethality	O
and	O
terminal	O
differentiation	O
of	O
enucleating	B-CL
skin	I-CL
and	I-CL
blood	I-CL
cells	I-CL
.	O

The	O
preblastocyst	O
-	O
stage	O
homozygous	O
lethality	O
shared	O
by	O
the	O
XpdKO	O
,	O
Xpd	B-GGP
+	O
XPCS	O
,	O
and	O
Xpd	B-GGP
+	O
XP	O
alleles	B-SO
most	O
likely	O
reflects	O
a	O
defect	O
in	O
basal	O
transcription	O
that	O
is	O
incompatible	O
with	O
life	O
.	O

In	O
XpdTTD	O
/	O
+	O
XPCS	O
and	O
XpdTTD	O
/	O
+	O
XP	O
compound	O
heterozygous	O
mice	B-Taxon
,	O
embryonic	O
lethality	O
was	O
fully	O
rescued	O
by	O
the	O
XpdTTD	O
allele	B-SO
.	O

Because	O
embryonic	O
lethality	O
was	O
also	O
fully	O
rescued	O
in	O
XpdTTD	O
/	O
KO	O
hemizygous	O
mice	B-Taxon
,	O
the	O
XpdTTD	O
allele	B-SO
can	O
be	O
considered	O
as	O
wt	B-SO
and	O
thus	O
dominant	O
to	O
each	O
of	O
the	O
homozygous	O
lethal	O
alleles	B-SO
(	O
XpdKO	O
,	O
Xpd	B-GGP
+	O
XPCS	O
,	O
and	O
Xpd	B-GGP
+	O
XP	O
)	O
with	O
respect	O
to	O
this	O
particular	O
phenotype	O
(	O
Table	O
2	O
)	O
.	O

TTD	O
-	O
specific	O
cutaneous	O
and	O
anaemic	O
features	O
,	O
on	O
the	O
other	O
hand	O
,	O
are	O
thought	O
to	O
result	O
from	O
a	O
specific	O
kind	O
of	O
transcriptional	O
insufficiency	O
caused	O
by	O
depletion	O
of	O
unstable	O
TFIIH	B-GO
during	O
the	O
terminal	O
differentiation	O
of	O
skin	O
,	O
hair	O
-	O
shaft	O
,	O
and	O
blood	B-CL
cells	I-CL
[	O
16	O
,	O
24	O
]	O
.	O

In	O
compound	O
heterozygous	O
mice	B-Taxon
,	O
both	O
homozygous	O
lethal	O
Xpd	B-GGP
+	O
XPCS	O
and	O
Xpd	B-GGP
+	O
XP	O
alleles	B-SO
were	O
able	O
to	O
alleviate	O
XpdTTD	O
-	O
specific	O
cutaneous	O
and	O
anaemic	O
features	O
and	O
can	O
thus	O
be	O
defined	O
as	O
dominant	O
over	O
the	O
XpdTTD	O
allele	B-SO
with	O
respect	O
to	O
these	O
phenotypes	O
.	O

We	O
conclude	O
that	O
the	O
defects	O
leading	O
to	O
embryonic	O
lethality	O
and	O
aberrant	O
terminal	O
differentiation	O
of	O
the	O
skin	O
,	O
hair	O
,	O
and	O
blood	O
represent	O
two	O
qualitatively	O
and	O
/	O
or	O
quantitatively	O
different	O
transcriptional	O
deficiencies	O
.	O

During	O
early	O
embryonic	O
development	O
,	O
XpdTTD	O
is	O
dominant	O
over	O
the	O
Xpd	B-GGP
+	O
XPCS	O
and	O
Xpd	B-GGP
+	O
XP	O
alleles	B-SO
,	O
whereas	O
later	O
in	O
the	O
ontogenesis	O
of	O
skin	O
,	O
hair	O
-	O
shaft	O
,	O
and	O
blood	B-CL
cells	I-CL
,	O
the	O
situation	O
is	O
reversed	O
.	O

In	O
its	O
role	O
in	O
the	O
repair	O
of	O
UV	O
photolesions	O
,	O
the	O
Xpd	B-GGP
+	O
XPCS	O
allele	B-SO
imparted	O
a	O
clear	O
UV	O
survival	O
benefit	O
over	O
a	O
single	O
XpdTTD	O
allele	B-SO
or	O
two	O
XpdXPCS	O
alleles	B-SO
independent	O
of	O
expression	O
levels	O
,	O
which	O
is	O
consistent	O
with	O
interallelic	O
complementation	O
.	O

However	O
,	O
the	O
observation	O
that	O
no	O
other	O
cellular	B-CL
or	O
biochemical	O
UV	O
-	O
related	O
parameters	O
were	O
improved	O
in	O
XpdTTD	O
/	O
+	O
XPCS	O
argues	O
against	O
complementation	O
of	O
this	O
repair	O
activity	O
in	O
the	O
rescue	O
of	O
TTD	O
progeroid	O
symptoms	O
in	O
vivo	O
.	O

Interallelic	O
Complementation	O
and	O
XPD	B-GGP
Function	O

What	O
does	O
interallelic	O
complementation	O
tell	O
us	O
about	O
the	O
mechanism	O
of	O
XPD	B-GGP
function	O
?	O

Interallelic	O
complementation	O
is	O
most	O
often	O
observed	O
in	O
multimeric	O
proteins	B-CHEBI
with	O
multiple	O
functional	O
domains	B-SO
.	O

Unfortunately	O
,	O
the	O
structure	O
-	O
function	O
relationship	O
between	O
disease	O
-	O
causing	O
mutations	B-SO
and	O
XPD	B-GGP
functional	O
domains	B-SO
,	O
including	O
detailed	O
structural	O
information	O
on	O
XPD	B-GGP
or	O
even	O
its	O
stoichiometry	O
within	O
TFIIH	B-GO
,	O
remains	O
unknown	O
.	O

However	O
,	O
based	O
on	O
the	O
ability	O
of	O
cell	B-CL
extracts	O
that	O
are	O
defective	O
in	O
two	O
different	O
TFIIH	B-GO
components	O
(	O
XPD	B-GGP
and	O
XPB	B-GGP
)	O
to	O
complement	O
NER	O
activity	O
in	O
vitro	O
[	O
26	O
]	O
,	O
it	O
is	O
likely	O
that	O
TFIIH	B-GO
(	O
or	O
its	O
components	O
)	O
can	O
either	O
multimerise	O
or	O
exchange	O
at	O
least	O
during	O
the	O
NER	O
reaction	O
.	O

Furthermore	O
,	O
XPD	B-GGP
is	O
known	O
to	O
be	O
a	O
"	O
loosely	O
bound	O
"	O
subunit	O
of	O
TFIIH	B-GO
[	O
27	O
]	O
.	O

We	O
thus	O
envisage	O
the	O
molecular	B-CHEBI
mechanism	O
of	O
interallelic	O
complementation	O
to	O
involve	O
the	O
exchange	O
of	O
XPD	B-GGP
molecules	B-CHEBI
within	O
the	O
TFIIH	B-GO
complex	I-GO
or	O
turnover	O
of	O
TFIIH	B-GO
complexes	I-GO
containing	O
different	O
XPD	B-GGP
molecules	B-CHEBI
at	O
the	O
site	B-SO
of	O
DNA	B-SO
damage	O
during	O
the	O
course	O
of	O
the	O
global	O
genome	B-SO
as	O
well	O
as	O
transcription	O
-	O
coupled	O
repair	O
of	O
either	O
UV	O
-	O
induced	O
or	O
endogenous	O
DNA	B-SO
damage	O
.	O

A	O
Biallelic	O
Paradigm	O
for	O
XPD	B-GGP
Disorders	O

Recently	O
,	O
proteins	B-CHEBI
originating	O
from	O
presumed	O
null	O
alleles	B-SO
were	O
biochemically	O
characterised	O
as	O
inactive	O
in	O
basal	O
transcription	O
[	O
27	O
]	O
,	O
providing	O
an	O
explanation	O
as	O
to	O
why	O
these	O
alleles	B-SO
failed	O
to	O
rescue	O
lethality	O
in	O
haploid	O
S	B-Taxon
.	I-Taxon
pombe	I-Taxon
with	O
a	O
null	O
mutation	B-SO
in	O
the	O
XPD	B-GGP
homologue	B-SO
rad15	B-GGP
[	O
19	O
]	O
.	O

Our	O
data	O
suggest	O
that	O
certain	O
presumed	O
null	O
alleles	B-SO
,	O
although	O
unable	O
on	O
their	O
own	O
to	O
support	O
basal	O
transcription	O
,	O
may	O
in	O
fact	O
have	O
a	O
substantial	O
impact	O
on	O
disease	O
outcome	O
in	O
compound	O
heterozygous	O
humans	B-Taxon
,	O
as	O
they	O
do	O
in	O
mouse	B-Taxon
models	O
.	O

Clinical	O
evidence	O
in	O
support	O
of	O
this	O
hypothesis	O
comes	O
from	O
a	O
number	O
of	O
XP	O
complementation	O
group	O
D	O
patients	O
that	O
do	O
not	O
fit	O
within	O
the	O
framework	O
of	O
the	O
current	O
monoallelic	O
paradigm	O
of	O
XPD	B-GGP
disorders	O
(	O
Figure	O
5	O
)	O
.	O

In	O
contrast	O
to	O
two	O
hemizygous	O
XPDXPCS	O
patients	O
carrying	O
the	O
XPDG47R	O
-	O
or	O
XPDR666W	O
-	O
encoding	O
alleles	B-SO
who	O
died	O
of	O
the	O
disease	O
before	O
2	O
y	O
of	O
age	O
,	O
two	O
compound	O
heterozygous	O
XPDXPCS	O
patients	O
carrying	O
the	O
same	O
XPDG47R	O
-	O
or	O
XPDR666W	O
-	O
encoding	O
alleles	B-SO
in	O
addition	O
to	O
the	O
presumed	O
null	O
XPDL461V	O
+	O
del716	O
-	O
730	O
both	O
had	O
considerably	O
milder	O
disease	O
symptoms	O
and	O
survived	O
more	O
than	O
ten	O
times	O
longer	O
(	O
A	O
.	O
Lehmann	O
,	O
personal	O
communication	O
)	O
(	O
Figure	O
5	O
)	O
.	O

Compound	O
heterozygosity	O
is	O
also	O
associated	O
with	O
the	O
recently	O
reported	O
combination	O
XP	O
and	O
TTD	O
(	O
XPTTD	O
)	O
syndrome	O
[	O
8	O
]	O
.	O

Similar	O
to	O
the	O
XpdTTD	O
/	O
+	O
XPCS	O
and	O
XpdTTD	O
/	O
+	O
XP	O
mice	B-Taxon
described	O
here	O
,	O
both	O
patients	O
with	O
XPTTD	O
described	O
so	O
far	O
had	O
intermediate	O
hair	O
cysteine	B-CHEBI
values	O
.	O

Furthermore	O
,	O
XPTTD	O
patient	O
XP38BR	O
carried	O
a	O
"	O
causative	O
"	O
TTD	O
mutation	B-SO
in	O
one	O
allele	B-SO
and	O
a	O
novel	O
point	B-SO
mutation	I-SO
encoding	O
XPDL485P	O
in	O
the	O
other	O
.	O

Although	O
the	O
XPDL485P	O
-	O
encoding	O
allele	B-SO
fails	O
to	O
complement	O
viability	O
in	O
the	O
haploid	O
S	B-GGP
.	I-GGP
pombe	I-GGP
rad15	I-GGP
deletion	B-SO
strain	O
and	O
is	O
thus	O
interpretable	O
as	O
a	O
null	O
allele	B-SO
[	O
8	O
]	O
,	O
we	O
nonetheless	O
suggest	O
that	O
the	O
combined	O
XPTTD	O
phenotype	O
in	O
this	O
patient	O
involves	O
phenotypic	O
contributions	O
from	O
both	O
alleles	B-SO
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
a	O
shift	O
to	O
a	O
biallelic	O
paradigm	O
for	O
compound	O
heterozygous	O
patients	O
in	O
XP	O
complementation	O
group	O
D	O
.	O

Figure	O
5	O

Genotype	O
-	O
Phenotype	O
Relationships	O
in	O
XPD	B-GGP
Disorders	O

According	O
to	O
the	O
current	O
monoallelic	O
hypothesis	O
,	O
phenotype	O
is	O
determined	O
solely	O
by	O
the	O
causative	O
allele	B-SO
product	O
.	O

If	O
a	O
second	O
,	O
different	O
allele	B-SO
is	O
present	O
,	O
it	O
is	O
considered	O
a	O
functional	O
null	O
.	O

There	O
is	O
a	O
lack	O
of	O
any	O
correlation	O
between	O
the	O
site	B-SO
of	O
the	O
XPD	B-GGP
mutation	B-SO
and	O
the	O
resulting	O
disorder	O
.	O

We	O
propose	O
a	O
biallelic	O
hypothesis	O
for	O
compound	O
heterozygotes	O
in	O
which	O
both	O
alleles	B-SO
can	O
contribute	O
to	O
the	O
phenotype	O
.	O

Examples	O
of	O
compound	O
heterozygous	O
patients	O
in	O
which	O
a	O
second	O
,	O
presumed	O
null	O
allele	B-SO
is	O
likely	O
to	O
contribute	O
to	O
disease	O
outcome	O
are	O
provided	O
above	O
in	O
comparison	O
to	O
corresponding	O
homo	O
-	O
or	O
hemizygous	O
patients	O
with	O
the	O
same	O
causative	O
allele	B-SO
.	O

Numbers	O
in	O
the	O
schematic	O
of	O
the	O
protein	B-CHEBI
indicate	O
the	O
helicase	O
domains	B-SO
.	O

Potential	O
of	O
Combined	O
Recessive	O
Alleles	B-SO
to	O
Affect	O
Phenotypic	O
Diversity	O
in	O
Mammals	B-Taxon

In	O
humans	B-Taxon
,	O
the	O
clinical	O
relevance	O
of	O
biallelic	O
effects	O
such	O
as	O
interallelic	O
complementation	O
remains	O
unknown	O
.	O

Although	O
interallelic	O
complementation	O
between	O
two	O
endogenous	O
mutant	B-SO
alleles	B-SO
has	O
been	O
described	O
in	O
cells	B-CL
from	O
a	O
compound	O
heterozygous	O
patient	O
with	O
methylmalonic	O
acidaemia	O
,	O
no	O
observable	O
effects	O
on	O
disease	O
outcome	O
were	O
noted	O
in	O
the	O
patient	O
[	O
28	O
]	O
.	O

Thus	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
amelioration	O
of	O
progeroid	O
features	O
observed	O
here	O
is	O
the	O
first	O
in	O
vivo	O
demonstration	O
in	O
compound	O
heterozygous	O
animals	B-Taxon
of	O
interallelic	O
complementation	O
relevant	O
to	O
a	O
human	B-Taxon
disease	O
.	O

Keeping	O
in	O
mind	O
that	O
the	O
~	O
1	O
,	O
200	O
alleles	B-SO
known	O
to	O
exist	O
for	O
the	O
CTRF	B-GGP
gene	B-SO
implicated	O
in	O
the	O
common	O
autosomal	B-GO
recessive	O
disorder	O
cystic	O
fibrosis	O
alone	O
[	O
29	O
]	O
can	O
theoretically	O
result	O
in	O
~	O
700	O
,	O
000	O
different	O
allelic	B-SO
combinations	O
,	O
the	O
potential	O
number	O
of	O
allelic	B-SO
combinations	O
of	O
different	O
recessive	O
mutations	B-SO
and	O
single	B-SO
nucleotide	I-SO
polymorphisms	I-SO
genome	B-SO
-	O
wide	O
is	O
currently	O
incalculable	O
.	O

We	O
suggest	O
biallelic	O
effects	O
as	O
a	O
previously	O
underestimated	O
yet	O
important	O
variable	O
in	O
considering	O
genotype	B-SO
-	O
phenotype	O
relationships	O
from	O
autosomal	B-GO
recessive	O
disease	O
to	O
normal	O
phenotypic	O
diversity	O
in	O
mammals	B-Taxon
.	O

Extension	O
of	O
the	O
above	O
concept	O
implies	O
that	O
recessive	O
mutations	B-SO
can	O
enter	O
evolutionary	O
selection	O
in	O
F1	O
provided	O
that	O
the	O
second	O
allele	B-SO
carries	O
a	O
different	O
recessive	O
alteration	B-SO
.	O

Finally	O
,	O
our	O
data	O
highlight	O
the	O
potential	O
of	O
clinically	O
relevant	O
alleles	B-SO
previously	O
designated	O
as	O
null	O
,	O
with	O
little	O
or	O
no	O
detectable	O
expression	O
or	O
activity	O
,	O
to	O
nonetheless	O
contribute	O
to	O
phenotype	O
.	O

Materials	O
and	O
Methods	O

Derivation	O
and	O
analysis	O
of	O
mutant	B-SO
mice	B-Taxon
.	O

Generation	O
of	O
XpdTTD	O
(	O
XPDR722W	O
)	O
and	O
XpdTTD	O
/	O
KO	O
mice	B-Taxon
has	O
been	O
described	O
previously	O
[	O
21	O
,	O
22	O
]	O
.	O

A	O
detailed	O
description	O
of	O
the	O
generation	O
of	O
targeting	O
constructs	B-SO
for	O
Xpd	B-GGP
+	O
XPCS	O
and	O
Xpd	B-GGP
+	O
XP	O
alleles	B-SO
carrying	O
mutations	B-SO
encoding	O
the	O
G602D	O
and	O
R683W	O
alterations	B-SO
will	O
be	O
provided	O
upon	O
request	O
.	O

Chimeric	O
mice	B-Taxon
and	O
mouse	B-Taxon
embryonic	O
fibroblasts	B-CL
were	O
generated	O
according	O
to	O
standard	O
procedures	O
.	O

Haematoxylin	O
and	O
eosin	O
staining	O
was	O
performed	O
according	O
to	O
standard	O
procedures	O
.	O

Amino	B-CHEBI
acid	I-CHEBI
analysis	O
was	O
conducted	O
as	O
described	O
in	O
[	O
21	O
]	O
.	O

Blood	O
values	O
were	O
analysed	O
using	O
Animal	B-Taxon
Blood	O
Counter	O
Vet	O
(	O
ABX	O
Diagnostix	O
,	O
Montpellier	O
,	O
France	O
)	O
.	O

Radiographs	O
were	O
taken	O
,	O
and	O
relative	O
bone	O
mineral	B-CHEBI
density	O
was	O
calculated	O
as	O
described	O
in	O
[	O
15	O
]	O
.	O

Mice	B-Taxon
used	O
in	O
this	O
study	O
were	O
in	O
a	O
129Ola	O
/	O
C57BL6	O
mixed	O
background	O
unless	O
noted	O
differently	O
.	O

All	O
experiments	O
involving	O
mice	B-Taxon
were	O
judged	O
and	O
approved	O
by	O
the	O
national	O
committee	O
for	O
genetic	B-SO
identification	O
of	O
organisms	B-Taxon
and	O
the	O
animal	B-Taxon
ethical	O
committee	O
,	O
and	O
were	O
conducted	O
according	O
to	O
national	O
and	O
international	O
guidelines	O
.	O

UV	O
sensitivity	O
,	O
UV	O
-	O
UDS	O
,	O
UV	O
-	O
RRS	O
,	O
and	O
TFIIH	B-GO
incision	O
/	O
excision	B-SO
activity	O
.	O

UV	O
survival	O
,	O
UV	O
-	O
UDS	O
,	O
and	O
UV	O
-	O
RRS	O
assays	O
were	O
performed	O
as	O
described	O
previously	O
[	O
21	O
,	O
30	O
]	O
.	O

For	O
UV	O
-	O
RRS	O
,	O
average	O
values	O
from	O
the	O
representative	O
experiment	O
containing	O
two	O
wt	B-SO
,	O
three	O
XpdTTD	O
/	O
TTD	O
,	O
two	O
XpdTTD	O
/	O
XPCS	O
,	O
and	O
one	O
XpdTTD	O
/	O
XP	O
cell	B-CL
line	O
are	O
presented	O
.	O

The	O
~	O
48	O
%	O
UV	O
-	O
UDS	O
value	O
presented	O
in	O
this	O
study	O
for	O
XpdTTD	O
/	O
TTD	O
cells	B-CL
differs	O
from	O
our	O
previously	O
published	O
data	O
of	O
25	O
%	O
UV	O
-	O
UDS	O
[	O
21	O
]	O
,	O
possibly	O
because	O
of	O
the	O
high	O
variability	O
intrinsic	O
to	O
the	O
assay	O
or	O
routine	O
variations	O
in	O
the	O
cell	B-CL
culture	O
conditions	O
.	O

For	O
the	O
incision	O
/	O
excision	B-SO
activity	O
assay	O
,	O
recombinant	O
TFIIH	B-GO
was	O
prepared	O
and	O
assayed	O
as	O
described	O
previously	O
[	O
27	O
]	O
.	O

Comparative	O
immunofluorescence	O
.	O

Latex	O
bead	O
labelling	O
and	O
comparative	O
immunofluorescence	O
analysis	O
of	O
the	O
p62	B-GGP
subunit	I-GGP
of	I-GGP
the	I-GGP
TFIIH	I-GGP
was	O
performed	O
as	O
described	O
previously	O
[	O
16	O
,	O
17	O
]	O
using	O
primary	O
mouse	B-Taxon
embryonic	O
fibroblasts	B-CL
at	O
passages	O
2	O
-	O
5	O
.	O

Two	O
or	O
more	O
cell	B-CL
lines	O
per	O
genotype	B-SO
(	O
except	O
for	O
the	O
XpdTTD	O
/	O
+	O
XP	O
cells	B-CL
,	O
in	O
which	O
only	O
one	O
cell	B-CL
line	O
was	O
used	O
in	O
repeated	O
experiments	O
)	O
were	O
used	O
,	O
and	O
experiments	O
were	O
repeated	O
2	O
-	O
6	O
times	O
per	O
genotype	B-SO
.	O

Acknowledgements	O

We	O
are	O
very	O
grateful	O
to	O
Steven	O
Bergink	O
,	O
Koos	O
Jaspers	O
,	O
and	O
Bjorn	O
Schumacher	O
for	O
thoughtful	O
discussions	O
and	O
critical	O
reading	O
of	O
the	O
manuscript	O
and	O
to	O
Ruud	O
Koppenol	O
and	O
Tom	O
de	O
Vries	O
for	O
photography	O
.	O

Author	O
contributions	O
.	O

JOA	O
,	O
JJ	O
,	O
JHJH	O
,	O
GTJvdH	O
,	O
and	O
JRM	O
conceived	O
and	O
designed	O
the	O
experiments	O
.	O

JOA	O
,	O
JJ	O
,	O
JdW	O
,	O
FC	O
,	O
DH	O
,	O
MvdV	O
,	O
WT	O
,	O
JH	O
,	O
WJvL	O
,	O
and	O
JRM	O
performed	O
the	O
experiments	O
.	O

JOA	O
,	O
JJ	O
,	O
JdW	O
,	O
FC	O
,	O
DH	O
,	O
MvdV	O
,	O
JH	O
,	O
HBT	O
,	O
WJvL	O
,	O
JME	O
,	O
JHJH	O
,	O
and	O
JRM	O
analyzed	O
the	O
data	O
.	O

JdB	O
and	O
GTJvdH	O
contributed	O
reagents	B-CHEBI
/	O
materials	O
/	O
analysis	O
tools	O
.	O

JOA	O
,	O
JHJH	O
,	O
and	O
JRM	O
wrote	O
the	O
paper	O
.	O

Funding	O
.	O

This	O
research	O
was	O
supported	O
by	O
the	O
Netherlands	O
Organization	O
for	O
Scientific	O
Research	O
(	O
NWO	O
)	O
through	O
the	O
foundation	O
of	O
the	O
Research	O
Institute	O
for	O
Diseases	O
of	O
the	O
Elderly	O
,	O
as	O
well	O
as	O
grants	O
from	O
the	O
National	O
Institutes	O
of	O
Health	O
(	O
1PO1	O
AG17242	O
-	O
02	O
)	O
,	O
National	O
Institute	O
of	O
Environmental	O
Health	O
Sciences	O
(	O
1UO1	O
ES011044	O
)	O
,	O
European	O
Commission	O
(	O
QRTL	O
-	O
1999	O
-	O
02002	O
)	O
,	O
and	O
the	O
Dutch	O
Cancer	O
Society	O
(	O
EUR	O
99	O
-	O
2004	O
)	O
.	O

JRM	O
was	O
a	O
fellow	O
of	O
the	O
Damon	O
Runyon	O
Cancer	O
Research	O
Fund	O
(	O
DRG	O
1677	O
)	O
.	O

Abbreviations	O

bp	B-SO
-	O
base	B-SO
pair	I-SO

CS	O
-	O
Cockayne	O
syndrome	O

E	O
[	O
number	O
]	O
-	O
embryonic	O
day	O
[	O
number	O
]	O

kb	O
-	O
kilobase	O

NER	O
-	O
nucleotide	B-CHEBI
excision	B-SO
repair	O

SEM	O
-	O
standard	O
error	O
of	O
the	O
mean	O

TFIIH	B-GO
-	O
basal	B-GO
transcription	I-GO
/	I-GO
DNA	I-GO
repair	I-GO
factor	I-GO
IIH	I-GO

TTD	O
-	O
trichothiodystrophy	O

UV	O
-	O
RRS	O
-	O
recovery	O
of	O
RNA	B-SO
synthesis	O
after	O
ultraviolet	O
irradiation	O

UV	O
-	O
UDS	O
-	O
unscheduled	O
DNA	B-SO
synthesis	O
after	O
ultraviolet	O
irradiation	O

wt	B-SO
-	O
wild	B-SO
-	I-SO
type	I-SO

XP	O
-	O
xeroderma	O
pigmentosum	O

XPCS	O
-	O
xeroderma	O
pigmentosum	O
combined	O
with	O
Cockayne	O
syndrome	O

XPTTD	O
-	O
combination	O
xeroderma	O
pigmentosum	O
and	O
trichothiodystrophy	O

Footnotes	O

Competing	O
interests	O
.	O

The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

currency	O
a	O
Current	O
address	O
:	O
Institute	O
of	O
Biotechnology	O
,	O
University	O
of	O
Helsinki	O
,	O
Helsinki	O
,	O
Finland	O

currency	O
b	O
Current	O
address	O
:	O
Department	O
of	O
Molecular	B-CHEBI
and	O
Cell	B-CL
Biology	O
,	O
University	O
of	O
California	O
Berkeley	O
,	O
Berkeley	O
,	O
California	O
,	O
United	O
States	O
of	O
America	O

currency	O
c	O
Current	O
address	O
:	O
Institute	O
for	O
Biomedical	O
Technology	O
,	O
University	O
of	O
Twente	O
,	O
Bilthoven	O
,	O
Netherlands	O

Genetic	B-SO
background	O
determines	O
response	O
to	O
hemostasis	O
and	O
thrombosis	O

Abstract	O

Background	O

Thrombosis	O
is	O
the	O
fatal	O
and	O
disabling	O
consequence	O
of	O
cardiovascular	O
diseases	O
,	O
the	O
leading	O
cause	O
of	O
mortality	O
and	O
morbidity	O
in	O
Western	O
countries	O
.	O

Two	O
inbred	O
mouse	B-Taxon
strains	O
,	O
C57BL	O
/	O
6J	O
and	O
A	O
/	O
J	O
,	O
have	O
marked	O
differences	O
in	O
susceptibility	O
to	O
obesity	O
,	O
atherosclerosis	O
,	O
and	O
vessel	O
remodeling	O
.	O

However	O
,	O
it	O
is	O
unclear	O
how	O
these	O
diverse	O
genetic	B-SO
backgrounds	O
influence	O
pathways	O
known	O
to	O
regulate	O
thrombosis	O
and	O
hemostasis	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
thrombosis	O
and	O
hemostasis	O
in	O
these	O
two	O
inbred	O
strains	O
and	O
determine	O
the	O
phenotypic	O
response	O
of	O
A	O
/	O
J	O
chromosomes	B-GO
in	O
the	O
C57BL	O
/	O
6J	O
background	O
.	O

Methods	O

A	O
/	O
J	O
and	O
C57Bl	O
/	O
6J	O
mice	B-Taxon
were	O
evaluated	O
for	O
differences	O
in	O
thrombosis	O
and	O
hemostasis	O
.	O

A	O
thrombus	O
was	O
induced	O
in	O
the	O
carotid	O
artery	O
by	O
application	O
of	O
the	O
exposed	O
carotid	O
to	O
ferric	B-CHEBI
chloride	I-CHEBI
and	O
blood	O
flow	O
measured	O
until	O
the	O
vessel	O
occluded	O
.	O

Bleeding	O
and	O
rebleeding	O
times	O
,	O
as	O
surrogate	O
markers	O
for	O
thrombosis	O
and	O
hemostasis	O
,	O
were	O
determined	O
after	O
clipping	O
the	O
tail	O
and	O
placing	O
in	O
warm	O
saline	O
.	O

Twenty	O
-	O
one	O
chromosome	B-GO
substitution	B-SO
strains	O
,	O
A	O
/	O
J	O
chromosomes	B-GO
in	O
a	O
C57BL	O
/	O
6J	O
background	O
,	O
were	O
screened	O
for	O
response	O
to	O
the	O
tail	O
bleeding	O
assay	O
.	O

Results	O

Thrombus	O
occlusion	O
time	O
was	O
markedly	O
decreased	O
in	O
the	O
A	O
/	O
J	O
mice	B-Taxon
compared	O
to	O
C57BL	O
/	O
6J	O
mice	B-Taxon
.	O

Tail	O
bleeding	O
time	O
was	O
similar	O
in	O
the	O
two	O
strains	O
,	O
but	O
rebleeding	O
time	O
was	O
markedly	O
increased	O
in	O
the	O
A	O
/	O
J	O
mice	B-Taxon
compared	O
to	O
C57BL	O
/	O
6J	O
mice	B-Taxon
.	O

Coagulation	O
times	O
and	O
tail	O
morphology	O
were	O
similar	O
,	O
but	O
tail	O
collagen	B-GO
content	O
was	O
higher	O
in	O
A	O
/	O
J	O
than	O
C57BL	O
/	O
6J	O
mice	B-Taxon
.	O

Three	O
chromosome	B-GO
substitution	B-SO
strains	O
,	O
B6	O
-	O
Chr5A	O
/	O
J	O
,	O
B6	O
-	O
Chr11A	O
/	O
J	O
,	O
and	O
B6	O
-	O
Chr17A	O
/	O
J	O
,	O
were	O
identified	O
with	O
increased	O
rebleeding	O
time	O
,	O
a	O
phenotype	O
similar	O
to	O
A	O
/	O
J	O
mice	B-Taxon
.	O

Mice	B-Taxon
heterosomic	O
for	O
chromosomes	B-GO
5	O
or	O
17	O
had	O
rebleeding	O
times	O
similar	O
to	O
C57BL	O
/	O
6J	O
mice	B-Taxon
,	O
but	O
when	O
these	O
two	O
chromosome	B-GO
substitution	B-SO
strains	O
,	O
B6	O
-	O
Chr5A	O
/	O
J	O
and	O
B6	O
-	O
Chr17A	O
/	O
J	O
,	O
were	O
crossed	O
,	O
the	O
A	O
/	O
J	O
phenotype	O
was	O
restored	O
in	O
these	O
doubly	O
heterosomic	O
progeny	O
.	O

Conclusion	O

These	O
results	O
indicate	O
that	O
susceptibility	O
to	O
arterial	O
thrombosis	O
and	O
haemostasis	O
is	O
remarkably	O
different	O
in	O
C57BL	O
/	O
and	O
A	O
/	O
J	O
mice	B-Taxon
.	O

Three	O
A	O
/	O
J	O
chromosome	B-GO
substitution	B-SO
strains	O
were	O
identified	O
that	O
expressed	O
a	O
phenotype	O
similar	O
to	O
A	O
/	O
J	O
for	O
rebleeding	O
,	O
the	O
C57Bl	O
/	O
6J	O
background	O
could	O
modify	O
the	O
A	O
/	O
J	O
phenotype	O
,	O
and	O
the	O
combination	O
of	O
two	O
A	O
/	O
J	O
QTL	B-SO
could	O
restore	O
the	O
phenotype	O
.	O

The	O
diverse	O
genetic	B-SO
backgrounds	O
and	O
differences	O
in	O
response	O
to	O
vascular	O
injury	O
induced	O
thrombosis	O
and	O
the	O
tail	O
bleeding	O
assay	O
,	O
suggest	O
the	O
potential	O
for	O
identifying	O
novel	O
genetic	B-SO
determinants	O
of	O
thrombotic	O
risk	O
.	O

Background	O

Family	O
history	O
[	O
1	O
]	O
is	O
the	O
strongest	O
risk	O
factor	O
for	O
cardiovascular	O
diseases	O
(	O
CVD	O
)	O
.	O

While	O
a	O
number	O
of	O
genetic	B-SO
mutations	B-SO
have	O
been	O
identified	O
,	O
these	O
account	O
for	O
only	O
a	O
small	O
percentage	O
of	O
the	O
CVD	O
in	O
human	B-Taxon
populations	O
.	O

Thrombus	O
formation	O
on	O
fissured	O
atherosclerotic	O
plaques	O
is	O
the	O
precipitating	O
event	O
in	O
the	O
transition	O
from	O
a	O
stable	O
or	O
subclinical	O
atherosclerotic	O
disease	O
and	O
leads	O
to	O
acute	O
myocardial	O
infarction	O
,	O
ischemic	O
stroke	O
or	O
peripheral	O
arterial	O
occlusion	O
.	O

Arterial	O
and	O
venous	O
thrombosis	O
are	O
complex	O
responses	O
and	O
are	O
influenced	O
by	O
multiple	O
genetic	B-SO
and	O
environmental	O
factors	O
[	O
2	O
-	O
5	O
]	O
.	O

Polymorphisms	B-SO
and	O
mutations	B-SO
in	O
coagulation	O
factors	O
,	O
fibrinolytic	O
factors	O
,	O
platelet	B-CL
surface	O
receptors	O
,	O
methylenetetrahydrofalate	B-GGP
reductase	I-GGP
,	O
endothelial	B-GGP
nitric	I-GGP
oxide	I-GGP
synthase	I-GGP
,	O
and	O
antioxidant	B-CHEBI
enzymes	B-SO
have	O
been	O
implicated	O
as	O
genetic	B-SO
determinants	O
of	O
susceptibility	O
to	O
thrombosis	O
[	O
6	O
,	O
7	O
]	O
.	O

Great	O
strides	O
have	O
been	O
made	O
in	O
the	O
diagnosis	O
and	O
treatment	O
of	O
thrombosis	O
in	O
the	O
last	O
decade	O
.	O

However	O
,	O
strategies	O
to	O
prevent	O
thrombosis	O
have	O
lagged	O
far	O
behind	O
due	O
,	O
in	O
part	O
,	O
to	O
the	O
contribution	O
of	O
multiple	O
,	O
and	O
as	O
yet	O
undefined	O
,	O
genetic	B-SO
factors	O
that	O
lead	O
to	O
thrombotic	O
risk	O
.	O

Moreover	O
,	O
it	O
remains	O
unclear	O
how	O
genetic	B-SO
background	O
influences	O
the	O
function	O
of	O
molecules	B-CHEBI
and	O
pathways	O
known	O
to	O
regulate	O
thrombus	O
formation	O
and	O
lysis	O
and	O
,	O
thereby	O
,	O
contributes	O
to	O
the	O
risk	O
of	O
thrombotic	O
disease	O
.	O

Many	O
of	O
the	O
available	O
inbred	O
mouse	B-Taxon
strains	O
,	O
such	O
as	O
C57BL	O
/	O
6J	O
(	O
B6	O
)	O
and	O
A	O
/	O
J	O
,	O
have	O
been	O
classified	O
as	O
resistant	O
or	O
susceptible	O
to	O
particular	O
complex	O
diseases	O
(	O
Table	O
1	O
)	O
.	O

These	O
two	O
strains	O
have	O
diverse	O
responses	O
to	O
diet	O
-	O
induced	O
obesity	O
[	O
8	O
]	O
(	O
B6	O
susceptible	O
;	O
A	O
/	O
J	O
resistant	O
)	O
,	O
diet	O
-	O
induced	O
atherosclerosis	O
(	O
B6	O
susceptible	O
;	O
A	O
/	O
J	O
resistant	O
)	O
[	O
9	O
]	O
,	O
arterial	O
ligation	O
-	O
induced	O
neointimal	O
hyperplasia	O
(	O
B6	O
resistant	O
;	O
A	O
/	O
J	O
resistant	O
)	O
,	O
and	O
ligation	O
induced	O
vessel	O
remodeling	O
(	O
B6	O
resistant	O
;	O
A	O
/	O
J	O
susceptible	O
)	O
[	O
10	O
]	O
.	O

These	O
conditions	O
are	O
predisposing	O
to	O
thrombosis	O
per	O
se	O
,	O
but	O
these	O
mice	B-Taxon
have	O
not	O
been	O
systematically	O
evaluated	O
for	O
thrombosis	O
.	O

Clot	O
formation	O
and	O
lysis	O
,	O
which	O
ultimately	O
determine	O
thrombosis	O
,	O
requires	O
platelet	B-CL
aggregation	O
,	O
coagulation	O
,	O
and	O
fibrinolytic	O
functions	O
.	O

Interactions	O
among	O
these	O
pathways	O
may	O
occur	O
and	O
additional	O
factors	O
may	O
modulate	O
these	O
processes	O
.	O

Identification	O
of	O
novel	O
modulators	O
and	O
factors	O
of	O
these	O
pathways	O
can	O
be	O
identified	O
by	O
associating	O
the	O
phenotype	O
with	O
a	O
location	B-SO
(	I-SO
s	I-SO
)	I-SO
on	I-SO
a	I-SO
specific	I-SO
chromosome	I-SO
,	O
a	O
quantitative	B-SO
trait	I-SO
locus	I-SO
(	O
QTL	B-SO
)	O
.	O

Table	O
1	O

Identification	O
of	O
mice	B-Taxon
susceptible	O
or	O
resistant	O
to	O
obesity	O
,	O
atherosclerosis	O
,	O
and	O
vascular	O
injury	O

R	O
:	O
resistant	O
;	O
S	O
:	O
susceptible	O
.	O

Reference	O
provided	O
by	O
number	O
in	O
parenthesis	O
.	O

Lepob	O
,	O
Plg	B-GGP
-	O
/	O
-	O
,	O
and	O
PAI	B-GGP
-	I-GGP
F1	I-GGP
-	O
/	O
-	O
mice	B-Taxon
were	O
in	O
a	O
B6	O
background	O
.	O

A	O
panel	O
of	O
chromosome	B-GO
substitution	B-SO
strains	O
(	O
CSS	O
)	O
was	O
generated	O
[	O
11	O
]	O
by	O
a	O
"	O
marker	O
-	O
assisted	O
"	O
breeding	O
program	O
where	O
the	O
progeny	O
of	O
a	O
B6	O
x	O
A	O
/	O
J	O
cross	O
were	O
successively	O
backcrossed	O
to	O
the	O
B6	O
mice	B-Taxon
.	O

Genetic	B-SO
markers	O
were	O
used	O
to	O
identify	O
homozygosity	O
in	O
the	O
background	O
(	O
B6	O
)	O
and	O
the	O
individual	O
A	O
/	O
J	O
chromosome	B-GO
.	O

These	O
strains	O
have	O
one	O
chromosome	B-GO
from	O
A	O
/	O
J	O
mice	B-Taxon
in	O
a	O
B6	O
background	O
.	O

This	O
allows	O
the	O
identification	O
of	O
a	O
trait	O
in	O
one	O
or	O
more	O
CSS	O
and	O
implies	O
that	O
at	O
least	O
one	O
QTL	B-SO
resides	O
on	O
this	O
chromosome	B-GO
.	O

Use	O
of	O
this	O
panel	O
requires	O
fewer	O
mice	B-Taxon
to	O
determine	O
the	O
QTL	B-SO
than	O
does	O
a	O
genome	B-SO
-	O
wide	O
scan	O
.	O

Another	O
advantage	O
is	O
the	O
ability	O
for	O
detection	O
of	O
QTL	B-SO
in	O
the	O
presence	O
of	O
other	O
QTL	B-SO
.	O

In	O
addition	O
,	O
initial	O
screens	O
with	O
the	O
CSS	O
simplify	O
the	O
fine	O
-	O
mapping	O
of	O
QTL	B-SO
.	O

Several	O
studies	O
of	O
this	O
CSS	O
panel	O
,	O
B6	O
Chr1	O
-	O
19	O
,	O
X	O
,	O
YA	O
/	O
J	O
,	O
have	O
been	O
reported	O
for	O
behavior	O
[	O
12	O
]	O
,	O
weight	O
gain	O
[	O
13	O
]	O
,	O
sterols	B-CHEBI
[	O
13	O
]	O
,	O
and	O
plasma	O
amino	B-CHEBI
acids	I-CHEBI
levels	O
[	O
13	O
,	O
14	O
]	O
,	O
and	O
have	O
identified	O
many	O
more	O
QTL	B-SO
than	O
studies	O
of	O
the	O
same	O
traits	O
using	O
a	O
genome	B-SO
-	O
wide	O
scan	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
two	O
inbred	O
strains	O
of	O
mice	B-Taxon
for	O
prothrombotic	O
risk	O
,	O
utilizing	O
a	O
ferric	B-CHEBI
chloride	I-CHEBI
vascular	O
injury	O
model	O
,	O
tail	O
bleeding	O
assay	O
,	O
and	O
measures	O
of	O
coagulation	O
and	O
fibrinolysis	O
.	O

The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
the	O
two	O
inbred	O
strains	O
,	O
B6	O
and	O
A	O
/	O
J	O
mice	B-Taxon
,	O
have	O
diverse	O
prothrombotic	O
phenotypes	O
,	O
unrelated	O
to	O
coagulation	O
or	O
platelet	B-CL
aggregation	O
.	O

In	O
addition	O
,	O
in	O
the	O
CSS	O
,	O
expression	O
of	O
the	O
A	O
/	O
J	O
phenotypes	O
,	O
rebleeding	O
time	O
and	O
arterial	O
occlusion	O
,	O
was	O
modified	O
in	O
the	O
B6	O
background	O
,	O
and	O
suggested	O
that	O
interactions	O
occurred	O
among	O
the	O
A	O
/	O
J	O
QTL	B-SO
.	O

Thus	O
,	O
it	O
should	O
be	O
possible	O
to	O
identify	O
independent	O
genetic	B-SO
determinants	O
of	O
susceptibility	O
to	O
pathological	O
haemostasis	O
and	O
thrombosis	O
.	O

Methods	O

Mice	B-Taxon

The	O
inbred	O
strains	O
,	O
B6	O
(	O
#	O
000664	O
)	O
,	O
Lepob	O
(	O
#	O
000632	O
)	O
,	O
A	O
/	O
J	O
(	O
#	O
000646	O
)	O
and	O
gene	B-SO
-	O
targeted	O
plasminogen	B-GGP
(	I-GGP
Plg	I-GGP
)	I-GGP
activator	I-GGP
inhibitor	I-GGP
deficient	O
mice	B-Taxon
(	O
PAI	B-GGP
-	I-GGP
1	I-GGP
-	O
/	O
-	O
)	O
(	O
#	O
002507	O
)	O
[	O
15	O
]	O
mice	B-Taxon
in	O
a	O
B6	O
background	O
were	O
obtained	O
from	O
Jackson	O
Laboratory	O
(	O
Bar	O
Harbor	O
,	O
Maine	O
)	O
at	O
6	O
wks	O
-	O
of	O
-	O
age	O
.	O

The	O
Plg	B-GGP
-	O
/	O
-	O
mice	B-Taxon
were	O
generated	O
as	O
previously	O
described	O
[	O
16	O
]	O
and	O
maintained	O
in	O
the	O
B6	O
background	O
,	O
generated	O
by	O
crossing	O
mice	B-Taxon
from	O
the	O
original	O
mixed	O
(	O
B6	O
:	O
129	O
)	O
background	O
for	O
eight	O
generations	O
with	O
B6	O
mice	B-Taxon
.	O

The	O
Plg	B-GGP
-	O
/	O
-	O
mice	B-Taxon
do	O
not	O
reproduce	O
well	O
and	O
Plg	B-GGP
heterozygous	O
pairs	O
were	O
used	O
for	O
breeding	O
.	O

Genotypes	B-SO
(	O
Plg	B-GGP
+	B-SO
/	O
+	B-SO
,	O
Plg	B-GGP
+	B-SO
/	O
-	O
,	O
Plg	B-GGP
-	O
/	O
-	O
)	O
of	O
the	O
offspring	O
were	O
determined	O
by	O
a	O
PCR	O
assay	O
at	O
3	O
-	O
4	O
weeks	O
-	O
of	O
-	O
age	O
from	O
an	O
ear	O
punch	O
[	O
17	O
]	O
.	O

Breeding	O
pairs	O
of	O
the	O
CSS	O
mice	B-Taxon
were	O
transferred	O
from	O
Dr	O
.	O
Nadeau	O
'	O
s	O
laboratory	O
.	O

All	O
mice	B-Taxon
were	O
housed	O
and	O
bred	O
in	O
the	O
Biological	O
Resource	O
Unit	O
at	O
the	O
Cleveland	O
Clinic	O
Foundation	O
(	O
CCF	O
)	O
.	O

Mice	B-Taxon
were	O
housed	O
in	O
sterilized	O
isolator	O
cages	O
,	O
maintained	O
on	O
a	O
14	O
hr	O
light	O
/	O
10	O
hr	O
dark	O
cycle	O
,	O
and	O
were	O
provided	O
sterilized	O
food	B-CHEBI
and	O
water	B-CHEBI
ad	O
libitum	O
.	O

Mice	B-Taxon
were	O
fed	O
a	O
standard	O
autoclavable	O
laboratory	O
diet	O
consisting	O
of	O
:	O
23	O
%	O
protein	B-CHEBI
,	O
4	O
.	O
5	O
%	O
fat	O
,	O
6	O
%	O
fiber	O
,	O
(	O
Purina	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
,	O
and	O
tested	O
between	O
7	O
and	O
9	O
wks	O
-	O
of	O
-	O
age	O
.	O

All	O
animal	B-Taxon
experiments	O
were	O
performed	O
in	O
accordance	O
with	O
a	O
protocol	O
approved	O
by	O
the	O
Institutional	O
Animal	B-Taxon
Care	O
and	O
Research	O
Advisory	O
Committee	O
at	O
CCF	O
.	O

Vascular	O
injury	O

To	O
induce	O
thrombosis	O
formation	O
in	O
the	O
carotid	O
artery	O
,	O
a	O
ferric	B-CHEBI
chloride	I-CHEBI
(	O
FeCl3	B-CHEBI
)	O
model	O
of	O
vessel	O
injury	O
[	O
18	O
,	O
19	O
]	O
was	O
employed	O
.	O

Mice	B-Taxon
were	O
anesthetized	O
with	O
ketamine	O
/	O
xylazine	O
(	O
80	O
mg	O
/	O
kg	O
,	O
5	O
mg	O
/	O
kg	O
)	O
,	O
a	O
midline	O
cervical	O
incision	O
was	O
made	O
and	O
the	O
left	O
common	O
carotid	O
artery	O
isolated	O
by	O
blunt	O
dissection	O
.	O

The	O
flow	O
probe	O
(	O
Transonic	O
Systems	O
,	O
model	O
0	O
.	O
5PSB	O
)	O
was	O
placed	O
under	O
the	O
artery	O
and	O
when	O
a	O
stable	O
baseline	O
was	O
reached	O
,	O
a	O
0	O
.	O
5	O
x	O
2	O
mm	O
strip	O
of	O
filter	O
paper	O
saturated	O
with	O
10	O
%	O
FeCl3	B-CHEBI
solution	O
was	O
applied	O
to	O
the	O
surface	O
of	O
the	O
carotid	O
artery	O
for	O
3	O
min	O
.	O

Occlusion	O
time	O
was	O
determined	O
from	O
the	O
addition	O
of	O
the	O
FeCl3	B-CHEBI
solution	O
to	O
the	O
occlusion	O
of	O
the	O
artery	O
(	O
minimum	O
blood	O
flow	O
)	O
.	O

The	O
flow	O
probe	O
was	O
in	O
place	O
from	O
the	O
establishment	O
of	O
the	O
baseline	O
until	O
several	O
min	O
after	O
the	O
stable	O
occlusion	O
had	O
been	O
reached	O
or	O
stopped	O
at	O
30	O
min	O
if	O
it	O
had	O
not	O
occluded	O
.	O

Blood	O
flow	O
was	O
recorded	O
every	O
10	O
sec	O
(	O
Transonic	O
Systems	O
,	O
model	O
TS420	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
body	O
weight	O
among	O
the	O
mice	B-Taxon
that	O
were	O
tested	O
in	O
the	O
vascular	O
injury	O
model	O
.	O

Bleeding	O
and	O
rebleeding	O
assay	O

For	O
the	O
tail	O
bleeding	O
assay	O
,	O
mice	B-Taxon
were	O
anesthetized	O
with	O
ketamine	O
/	O
xylazine	O
(	O
80	O
mg	O
/	O
kg	O
,	O
5	O
mg	O
/	O
kg	O
)	O
,	O
the	O
tail	O
prewarmed	O
for	O
5	O
min	O
in	O
10	O
mL	O
of	O
saline	O
at	O
37	O
degrees	O
C	O
in	O
a	O
water	B-CHEBI
bath	O
.	O

The	O
tail	O
was	O
lifted	O
from	O
the	O
saline	O
and	O
a	O
5	O
mm	O
tail	O
segment	O
amputated	O
and	O
immediately	O
returned	O
to	O
the	O
saline	O
.	O

Bleeding	O
time	O
was	O
measured	O
as	O
the	O
time	O
between	O
the	O
start	O
of	O
bleeding	O
to	O
cessation	O
of	O
bleeding	O
.	O

With	O
the	O
tail	O
remaining	O
in	O
the	O
same	O
saline	O
solution	O
,	O
the	O
rebleeding	O
time	O
was	O
measured	O
from	O
the	O
time	O
between	O
bleeding	O
cessation	O
and	O
the	O
start	O
of	O
the	O
second	O
bleeding	O
.	O

Coagulation	O
,	O
Plg	B-GGP
,	O
alpha	B-GGP
2	I-GGP
-	I-GGP
antiplasmin	I-GGP
,	O
fibrinogen	B-GO
,	O
fibrinolytic	O
and	O
PAI	B-GGP
-	I-GGP
1	I-GGP
assays	O

Mice	B-Taxon
were	O
anesthetized	O
with	O
Isoflurane	O
(	O
Abbott	O
)	O
,	O
bled	O
from	O
the	O
orbital	O
sinus	O
into	O
uncoated	O
capillary	O
tubes	O
,	O
and	O
a	O
drop	O
of	O
blood	O
immediately	O
placed	O
on	O
a	O
reagent	B-CHEBI
strip	O
(	O
Synbiotics	O
)	O
for	O
prothrombin	B-GGP
time	O
(	O
PT	O
)	O
or	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
aPTT	O
)	O
determinations	O
and	O
inserted	O
into	O
the	O
precalibrated	O
Coagulation	O
Analyzer	O
(	O
SCA2000	O
,	O
Synbiotics	O
)	O
.	O

PAI	B-GGP
-	I-GGP
1	I-GGP
activity	O
was	O
determined	O
according	O
to	O
the	O
method	O
of	O
Chandler	O
et	O
al	O
[	O
20	O
]	O
.	O

PAI	B-GGP
-	I-GGP
1	I-GGP
antigen	O
concentration	O
was	O
determined	O
by	O
ELISA	O
[	O
21	O
]	O
using	O
sheep	B-Taxon
-	O
anti	O
mouse	B-GGP
PAI	I-GGP
-	I-GGP
1	I-GGP
(	O
American	O
Diagnostica	O
)	O
as	O
the	O
capture	O
antibody	B-GO
and	O
mouse	B-GGP
PAI	I-GGP
-	I-GGP
1	I-GGP
(	O
American	O
Diagnostica	O
)	O
as	O
the	O
standard	O
(	O
0	O
-	O
3	O
.	O
5	O
ng	O
/	O
mL	O
)	O
.	O

Plg	B-GGP
was	O
determined	O
with	O
a	O
chromogenic	O
assay	O
[	O
22	O
]	O
and	O
the	O
fibrinolytic	O
activity	O
determined	O
by	O
fibrin	O
degradation	O
[	O
23	O
]	O
.	O

For	O
the	O
negative	O
controls	O
in	O
these	O
assays	O
,	O
plasma	O
from	O
PAI	B-GGP
-	I-GGP
1	I-GGP
or	O
Plg	B-GGP
deficient	O
mice	B-Taxon
was	O
used	O
.	O

Functionally	O
active	O
mouse	B-GGP
alpha	I-GGP
2	I-GGP
-	I-GGP
antiplasmin	I-GGP
was	O
determined	O
with	O
a	O
plasmin	B-GGP
capture	O
assay	O
and	O
detection	O
with	O
a	O
mouse	B-Taxon
antibody	B-GO
(	O
Molecular	B-CHEBI
Innovations	O
,	O
Southfield	O
,	O
MI	O
)	O
,	O
and	O
fibrinogen	B-GO
with	O
an	O
ELISA	O
assay	O
with	O
antibodies	B-GO
that	O
recognize	O
mouse	B-Taxon
fibrinogen	B-GO
(	O
Hyphen	O
BioMed	O
,	O
France	O
)	O
.	O

Histochemical	O
and	O
immunohistochemistry	O
analysis	O

The	O
frozen	O
tails	O
or	O
injured	O
carotids	O
in	O
OCT	O
were	O
sectioned	O
at	O
5	O
mu	O
m	O
thickness	O
and	O
stained	O
with	O
Masson	O
'	O
s	O
Trichrome	O
(	O
HT	O
15	O
,	O
Sigma	O
Diagnostics	O
)	O
.	O

For	O
quantitative	O
analysis	O
of	O
collagen	B-GO
area	O
in	O
the	O
tail	O
sections	O
,	O
four	O
sections	O
from	O
2	O
-	O
3	O
sites	O
were	O
measured	O
using	O
computer	O
assisted	O
image	O
analysis	O
(	O
Image	O
-	O
Pro	O
Plus	O
,	O
Cybernetics	O
)	O
.	O

For	O
the	O
area	O
determination	O
of	O
the	O
injured	O
carotid	O
lumen	O
,	O
3	O
-	O
4	O
sections	O
from	O
different	O
sites	O
approximately	O
100	O
mu	O
m	O
apart	O
were	O
analyzed	O
and	O
averaged	O
for	O
each	O
mouse	B-Taxon
.	O

Statistics	O

Data	O
are	O
presented	O
as	O
mean	O
+/-	O
SEM	O
.	O

The	O
statistical	O
analysis	O
for	O
comparisons	O
between	O
A	O
/	O
J	O
and	O
B6	O
mice	B-Taxon
and	O
between	O
wild	B-SO
-	I-SO
type	I-SO
(	O
WT	B-SO
)	O
and	O
Plg	B-GGP
-	O
/	O
-	O
littermates	O
was	O
compared	O
with	O
a	O
two	O
-	O
tailed	O
t	O
-	O
test	O
.	O

Differences	O
among	O
B6	O
,	O
Lepob	O
,	O
PAI	B-GGP
-	I-GGP
1	I-GGP
-	O
/	O
-	O
mice	B-Taxon
were	O
determined	O
by	O
a	O
one	O
-	O
way	O
ANOVA	O
and	O
a	O
Newman	O
-	O
Keuls	O
post	O
-	O
test	O
.	O

A	O
value	O
of	O
P	O
<	O
0	O
.	O
05	O
was	O
considered	O
significant	O
.	O

The	O
statistical	O
analysis	O
for	O
comparisons	O
between	O
B6	O
mice	B-Taxon
and	O
CSS	O
were	O
determined	O
with	O
two	O
-	O
tail	O
t	O
-	O
tests	O
and	O
the	O
level	O
of	O
the	O
significant	O
P	O
-	O
values	O
(	O
see	O
figure	O
legends	O
)	O
determined	O
with	O
a	O
Bonferroni	O
correction	O
to	O
account	O
for	O
multihypothesis	O
testing	O
[	O
13	O
]	O
.	O

Results	O

Marked	O
differences	O
in	O
arterial	O
thrombus	O
formation	O
in	O
B6	O
and	O
A	O
/	O
J	O
mice	B-Taxon

The	O
FeCl3	B-CHEBI
cartoid	O
artery	O
injury	O
model	O
[	O
24	O
]	O
,	O
a	O
well	O
-	O
characterized	O
arterial	O
thrombosis	O
model	O
,	O
was	O
used	O
to	O
induce	O
an	O
occlusive	O
thrombus	O
in	O
the	O
B6	O
and	O
A	O
/	O
J	O
mouse	B-Taxon
strains	O
under	O
investigation	O
.	O

A	O
marked	O
difference	O
in	O
arterial	O
thrombus	O
occlusion	O
time	O
was	O
found	O
between	O
the	O
B6	O
and	O
the	O
A	O
/	O
J	O
mice	B-Taxon
(	O
Figure	O
1A	O
)	O
.	O

The	O
occlusion	O
time	O
in	O
the	O
A	O
/	O
J	O
mice	B-Taxon
was	O
2	O
-	O
fold	O
less	O
than	O
for	O
the	O
B6	O
mice	B-Taxon
.	O

A	O
5	O
%	O
dose	O
of	O
FeCl3	B-CHEBI
was	O
tested	O
in	O
the	O
A	O
/	O
J	O
and	O
B6	O
mice	B-Taxon
and	O
the	O
occlusion	O
time	O
was	O
lower	O
in	O
the	O
A	O
/	O
J	O
than	O
the	O
B6	O
mice	B-Taxon
,	O
the	O
same	O
results	O
as	O
with	O
the	O
10	O
%	O
dose	O
.	O

The	O
occlusion	O
time	O
(	O
min	O
for	O
both	O
B6	O
(	O
15	O
+/-	O
3	O
,	O
n	O
=	O
3	O
)	O
and	O
A	O
/	O
J	O
(	O
8	O
+/-	O
1	O
,	O
n	O
=	O
3	O
)	O
at	O
5	O
%	O
were	O
longer	O
than	O
at	O
10	O
%	O
for	O
B6	O
(	O
10	O
+/-	O
1	O
,	O
n	O
=	O
17	O
and	O
A	O
/	O
J	O
(	O
5	O
+/-	O
2	O
,	O
n	O
=	O
14	O
)	O
.	O

The	O
curves	O
of	O
blood	O
flow	O
after	O
FeCl3	B-CHEBI
application	O
indicated	O
a	O
pattern	O
with	O
a	O
gradual	O
decrease	O
before	O
occlusion	O
for	O
the	O
B6	O
mice	B-Taxon
(	O
Figure	O
1B	O
)	O
,	O
but	O
for	O
the	O
A	O
/	O
J	O
mice	B-Taxon
the	O
blood	O
flow	O
decreased	O
abruptly	O
to	O
zero	O
(	O
Figure	O
1C	O
)	O
,	O
demonstrating	O
a	O
marked	O
difference	O
from	O
the	O
B6	O
strain	O
.	O

The	O
mean	O
occlusion	O
times	O
were	O
significantly	O
different	O
between	O
the	O
two	O
strains	O
(	O
Figure	O
1A	O
)	O
.	O

The	O
size	O
of	O
the	O
carotids	O
in	O
the	O
two	O
strains	O
was	O
noticeably	O
different	O
.	O

The	O
area	O
(	O
mm2	O
)	O
of	O
the	O
lumen	O
(	O
0	O
.	O
066	O
+/-	O
0	O
.	O
007	O
,	O
n	O
=	O
6	O
)	O
was	O
significantly	O
less	O
in	O
the	O
A	O
/	O
J	O
mice	B-Taxon
than	O
for	O
B6	O
mice	B-Taxon
(	O
0	O
.	O
128	O
+/-	O
0	O
.	O
007	O
,	O
n	O
=	O
6	O
)	O
.	O

However	O
,	O
the	O
ratio	O
of	O
the	O
thrombus	O
to	O
lumen	O
was	O
similar	O
for	O
A	O
/	O
J	O
(	O
0	O
.	O
63	O
+/-	O
0	O
.	O
03	O
)	O
compared	O
to	O
B6	O
mice	B-Taxon
(	O
0	O
.	O
67	O
+/-	O
0	O
.	O
09	O
)	O
.	O

Calculated	O
sheer	O
stress	O
rates	O
[	O
25	O
]	O
were	O
14	O
%	O
less	O
in	O
the	O
A	O
/	O
J	O
mice	B-Taxon
when	O
compared	O
to	O
B6	O
mice	B-Taxon
.	O

Figure	O
1	O

Arterial	O
occlusion	O
time	O
in	O
B6	O
and	O
A	O
/	O
J	O
mice	B-Taxon
.	O

Panels	O
A	O
and	O
B	O
are	O
representative	O
occlusion	O
curves	O
from	O
each	O
genotype	B-SO
.	O

Red	O
arrows	O
indicate	O
duration	O
of	O
ferric	B-CHEBI
chloride	I-CHEBI
application	O
to	O
the	O
carotid	O
.	O

Panel	O
A	O
:	O
B6	O
mice	B-Taxon
,	O
Panel	O
B	O
:	O
A	O
/	O
J	O
mice	B-Taxon
.	O

Panel	O
C	O
:	O
Arterial	O
occlusion	O
time	O
,	O
mean	O
+/-	O
SEM	O
of	O
14	O
-	O
17	O
mice	B-Taxon
per	O
genotype	B-SO
.	O

Symbol	O
indicates	O
a	O
significant	O
difference	O
(	O
*	O
*	O
P	O
<	O
0	O
.	O
01	O
)	O
between	O
B6	O
mice	B-Taxon
determined	O
with	O
a	O
t	O
-	O
test	O
.	O

Marked	O
differences	O
in	O
rebleeding	O
time	O
in	O
B6	O
and	O
A	O
/	O
J	O
mice	B-Taxon

The	O
bleeding	O
time	O
,	O
an	O
indicator	O
of	O
hemostatic	O
activity	O
,	O
was	O
determined	O
after	O
prewarming	O
the	O
tail	O
,	O
clipping	O
a	O
5	O
mm	O
segment	O
,	O
placing	O
the	O
tail	O
in	O
warm	O
saline	O
and	O
measuring	O
the	O
time	O
for	O
the	O
bleeding	O
to	O
stop	O
.	O

We	O
found	O
this	O
procedure	O
was	O
consistent	O
and	O
reproducible	O
in	O
different	O
mouse	B-Taxon
strains	O
and	O
was	O
not	O
gender	O
dependent	O
.	O

Bleeding	O
time	O
was	O
not	O
different	O
in	O
A	O
/	O
J	O
mice	B-Taxon
compared	O
to	O
B6	O
mice	B-Taxon
(	O
Figure	O
2A	O
)	O
.	O

In	O
order	O
to	O
determine	O
if	O
specific	O
pathways	O
were	O
altered	O
in	O
the	O
B6	O
and	O
A	O
/	O
J	O
strains	O
,	O
mice	B-Taxon
with	O
known	O
alterations	O
in	O
hemostasis	O
,	O
Lepob	O
mice	B-Taxon
,	O
or	O
thrombosis	O
,	O
Plg	B-GGP
-	O
/	O
-	O
and	O
PAI	B-GGP
-	O
/	O
-	O
mice	B-Taxon
,	O
were	O
also	O
tested	O
.	O

The	O
Lepob	O
mice	B-Taxon
have	O
impaired	O
platelet	B-CL
aggregation	O
[	O
26	O
]	O
and	O
were	O
evaluated	O
as	O
a	O
reference	O
for	O
platelet	B-CL
function	O
.	O

In	O
the	O
Lepob	O
mice	B-Taxon
(	O
Figure	O
2A	O
)	O
there	O
was	O
nearly	O
a	O
10	O
-	O
fold	O
increase	O
in	O
bleeding	O
time	O
compared	O
to	O
B6	O
mice	B-Taxon
.	O

Bleeding	O
time	O
was	O
also	O
significantly	O
(	O
P	O
=	O
0	O
.	O
0001	O
)	O
increased	O
by	O
66	O
%	O
in	O
the	O
Plg	B-GGP
-	O
/	O
-	O
mice	B-Taxon
compared	O
to	O
WT	B-SO
mice	B-Taxon
littermates	O
.	O

Bleeding	O
time	O
was	O
not	O
different	O
in	O
PAI	B-GGP
-	I-GGP
1	I-GGP
-	O
/	O
-	O
mice	B-Taxon
compared	O
to	O
B6	O
mice	B-Taxon
.	O

In	O
contrast	O
to	O
the	O
Lepob	O
mice	B-Taxon
with	O
a	O
platelet	B-CL
defect	O
and	O
10	O
-	O
fold	O
increase	O
in	O
bleeding	O
time	O
,	O
there	O
was	O
no	O
difference	O
in	O
the	O
bleeding	O
time	O
between	O
B6	O
and	O
A	O
/	O
J	O
mice	B-Taxon
and	O
suggested	O
platelet	B-CL
aggregation	O
is	O
not	O
altered	O
in	O
these	O
two	O
strains	O
.	O

Figure	O
2	O

Bleeding	O
and	O
rebleeding	O
time	O
in	O
B6	O
,	O
A	O
/	O
J	O
,	O
Lepob	O
,	O
Plg	B-GGP
-	O
/	O
-	O
and	O
PAI	B-GGP
-	I-GGP
1	I-GGP
-	O
/	O
-	O
mice	B-Taxon
.	O

Panel	O
A	O
,	O
B	O
:	O
Bleeding	O
time	O
(	O
seconds	O
)	O
and	O
Panel	O
C	O
,	O
D	O
:	O
Rebleeding	O
time	O
(	O
seconds	O
)	O
.	O

To	O
determine	O
statistical	O
differences	O
,	O
values	O
from	O
B6	O
and	O
A	O
/	O
J	O
and	O
from	O
WT	B-SO
and	O
Plg	B-GGP
-	O
/	O
-	O
littermates	O
were	O
compared	O
with	O
a	O
t	O
-	O
test	O
,	O
and	O
values	O
from	O
B6	O
,	O
PAI	B-GGP
-	I-GGP
1	I-GGP
-	O
/	O
-	O
and	O
Lepob	O
were	O
compared	O
by	O
a	O
one	O
-	O
way	O
ANOVA	O
and	O
a	O
Newman	O
-	O
Keuls	O
post	O
-	O
test	O
.	O

Symbols	O
indicate	O
a	O
significant	O
difference	O
(	O
*	O
P	O
<	O
0	O
.	O
05	O
,	O
*	O
*	O
P	O
<	O
0	O
.	O
01	O
,	O
*	O
*	O
*	O
P	O
<	O
0	O
.	O
001	O
)	O
between	O
B6	O
or	O
WT	B-SO
mice	B-Taxon
.	O

Values	O
are	O
the	O
mean	O
+/-	O
SEM	O
of	O
10	O
-	O
34	O
mice	B-Taxon
per	O
genotype	B-SO
.	O

Rebleeding	O
time	O
,	O
an	O
indicator	O
of	O
thrombus	O
stability	O
,	O
was	O
measured	O
as	O
the	O
time	O
between	O
the	O
cessation	O
of	O
bleeding	O
and	O
the	O
start	O
of	O
the	O
second	O
bleeding	O
(	O
Figure	O
2B	O
)	O
.	O

Rebleeding	O
times	O
were	O
significantly	O
higher	O
in	O
A	O
/	O
J	O
(	O
2	O
.	O
6	O
-	O
fold	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
mice	B-Taxon
than	O
the	O
B6	O
mice	B-Taxon
.	O

In	O
contrast	O
,	O
the	O
rebleeding	O
time	O
was	O
nearly	O
8	O
.	O
5	O
-	O
fold	O
less	O
in	O
the	O
Lepob	O
mice	B-Taxon
than	O
the	O
B6	O
mice	B-Taxon
.	O

To	O
determine	O
how	O
alterations	O
in	O
the	O
fibrinolytic	O
system	O
may	O
affect	O
rebleeding	O
time	O
,	O
Plg	B-GGP
-	O
/	O
-	O
and	O
PAI	B-GGP
-	I-GGP
1	I-GGP
-	O
/	O
-	O
mice	B-Taxon
were	O
also	O
tested	O
(	O
Figure	O
2B	O
)	O
.	O

Rebleeding	O
time	O
was	O
not	O
different	O
in	O
Plg	B-GGP
-	O
/	O
-	O
mice	B-Taxon
compared	O
to	O
WT	B-SO
littermates	O
,	O
but	O
PAI	B-GGP
-	I-GGP
1	I-GGP
-	O
/	O
-	O
mice	B-Taxon
had	O
a	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
reduced	O
rebleeding	O
time	O
,	O
which	O
was	O
1	O
.	O
8	O
-	O
fold	O
lower	O
than	O
for	O
the	O
B6	O
mice	B-Taxon
.	O

Although	O
a	O
Plg	B-GGP
deficiency	O
did	O
not	O
result	O
in	O
a	O
prolonged	O
rebleeding	O
time	O
as	O
anticipated	O
,	O
a	O
PAI	B-GGP
-	I-GGP
1	I-GGP
deficiency	O
resulted	O
in	O
a	O
shortened	O
time	O
.	O

The	O
markedly	O
increased	O
rebleeding	O
time	O
in	O
the	O
A	O
/	O
J	O
may	O
suggest	O
differences	O
in	O
the	O
regulation	O
of	O
the	O
Plg	B-GGP
network	O
.	O

No	O
difference	O
in	O
blood	O
coagulation	O
between	O
B6	O
and	O
A	O
/	O
J	O
mice	B-Taxon

To	O
determine	O
if	O
differences	O
in	O
coagulation	O
were	O
contributing	O
factors	O
to	O
the	O
bleeding	O
and	O
rebleeding	O
results	O
,	O
prothrombin	B-GGP
time	O
(	O
PT	O
)	O
and	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
aPTT	O
)	O
were	O
measured	O
.	O

PT	O
is	O
a	O
measurement	O
of	O
the	O
extrinsic	O
coagulation	O
pathway	O
(	O
activation	O
of	O
Factor	B-GGP
VII	I-GGP
by	O
tissue	B-GGP
factor	I-GGP
)	O
while	O
aPTT	O
is	O
a	O
measurement	O
of	O
the	O
intrinsic	O
pathway	O
(	O
activation	O
of	O
Factors	B-GGP
XII	I-GGP
,	I-GGP
XI	I-GGP
,	I-GGP
IX	I-GGP
and	I-GGP
VIII	I-GGP
)	O
.	O

The	O
products	O
of	O
both	O
pathways	O
activate	O
Factor	B-GGP
X	I-GGP
,	O
which	O
initiates	O
the	O
common	O
pathway	O
leading	O
to	O
thrombin	O
generation	O
and	O
fibrin	O
clot	O
formation	O
.	O

PT	O
and	O
aPTT	O
were	O
measured	O
in	O
the	O
B6	O
and	O
A	O
/	O
J	O
mice	B-Taxon
and	O
values	O
were	O
not	O
different	O
between	O
the	O
two	O
mouse	B-Taxon
strains	O
(	O
Table	O
2	O
)	O
.	O

These	O
results	O
suggest	O
that	O
the	O
coagulation	O
pathway	O
is	O
not	O
different	O
in	O
the	O
two	O
inbred	O
strains	O
.	O

Table	O
2	O

Coagulation	O
and	O
Plasminogen	B-GGP
System	O
Parameters	O
in	O
B6	O
and	O
A	O
/	O
J	O
inbred	O
mouse	B-Taxon
strains	O

Values	O
are	O
the	O
mean	O
+/-	O
SEM	O
.	O

*	O
P	O
<	O
0	O
.	O
05	O
,	O
*	O
*	O
P	O
<	O
0	O
.	O
01	O
.	O

n	O
=	O
5	O
-	O
8	O
.	O

Plg	B-GGP
and	O
PAI	B-GGP
-	I-GGP
1	I-GGP
higher	O
in	O
A	O
/	O
J	O
than	O
B6	O
mice	B-Taxon

Plg	B-GGP
concentration	O
was	O
34	O
%	O
higher	O
in	O
the	O
A	O
/	O
J	O
mice	B-Taxon
than	O
in	O
B6	O
mice	B-Taxon
.	O

In	O
addition	O
,	O
fibrinolytic	O
activity	O
,	O
PAI	B-GGP
-	I-GGP
1	I-GGP
activity	O
,	O
and	O
alpha	B-GGP
2	I-GGP
-	I-GGP
anitplasmin	I-GGP
were	O
also	O
increased	O
in	O
the	O
A	O
/	O
J	O
mice	B-Taxon
when	O
compared	O
to	O
the	O
B6	O
mice	B-Taxon
(	O
Table	O
2	O
)	O
.	O

The	O
functional	O
consequences	O
of	O
these	O
differences	O
are	O
not	O
clear	O
,	O
since	O
fibrinogen	B-GO
is	O
also	O
higher	O
in	O
the	O
A	O
/	O
J	O
mice	B-Taxon
.	O

To	O
determine	O
whether	O
there	O
were	O
protein	B-CHEBI
structure	O
changes	O
of	O
Plg	B-GGP
from	O
the	O
A	O
/	O
J	O
mice	B-Taxon
,	O
plasma	O
from	O
the	O
B6	O
and	O
the	O
A	O
/	O
J	O
mice	B-Taxon
were	O
subjected	O
to	O
electrophoresis	O
under	O
reduced	O
,	O
non	O
-	O
reduced	O
,	O
and	O
non	O
-	O
denaturing	O
conditions	O
.	O

No	O
difference	O
in	O
migration	O
for	O
immunostained	O
Plg	B-GGP
under	O
these	O
conditions	O
was	O
observed	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
density	O
of	O
the	O
Western	O
blot	O
from	O
SDS	B-CHEBI
-	O
PAGE	O
under	O
reducing	O
conditions	O
of	O
plasma	O
of	O
varying	O
volumes	O
from	O
B6	O
and	O
A	O
/	O
J	O
mice	B-Taxon
was	O
compared	O
and	O
the	O
density	O
of	O
the	O
bands	O
was	O
56	O
%	O
higher	O
in	O
the	O
A	O
/	O
J	O
than	O
the	O
B6	O
mice	B-Taxon
(	O
six	O
individual	O
mice	B-Taxon
were	O
tested	O
on	O
at	O
least	O
two	O
occasions	O
)	O
from	O
the	O
same	O
amount	O
of	O
plasma	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

Thus	O
,	O
the	O
concentration	O
of	O
Plg	B-GGP
in	O
plasma	O
from	O
the	O
A	O
/	O
J	O
mice	B-Taxon
was	O
higher	O
than	O
plasma	O
from	O
the	O
B6	O
mice	B-Taxon
as	O
determined	O
by	O
two	O
methods	O
and	O
no	O
difference	O
in	O
migration	O
after	O
electrophoresis	O
was	O
observed	O
,	O
suggesting	O
no	O
marked	O
changes	O
in	O
the	O
structure	O
of	O
Plg	B-GGP
in	O
the	O
two	O
mouse	B-Taxon
strains	O
.	O

Tail	O
morphology	O
in	O
B6	O
and	O
A	O
/	O
J	O

The	O
tails	O
of	O
the	O
mice	B-Taxon
were	O
examined	O
for	O
differences	O
that	O
might	O
account	O
for	O
the	O
variations	O
in	O
the	O
bleeding	O
and	O
rebleeding	O
values	O
.	O

Sections	O
of	O
the	O
tail	O
from	O
the	O
B6	O
and	O
A	O
/	O
J	O
mice	B-Taxon
were	O
stained	O
with	O
Hematoxylin	O
/	O
Eosin	O
or	O
Masson	O
'	O
s	O
Trichrome	O
and	O
representative	O
sections	O
are	O
shown	O
in	O
Figure	O
3	O
.	O

No	O
obvious	O
qualitative	O
differences	O
were	O
observed	O
in	O
hair	O
follicles	O
,	O
sebaceous	O
glands	O
,	O
or	O
center	O
bone	O
/	O
cartilage	O
in	O
Hematoxylin	O
/	O
Eosin	O
(	O
Figure	O
3A	O
)	O
stained	O
sections	O
.	O

Sections	O
of	O
the	O
tails	O
were	O
stained	O
with	O
Masson	O
'	O
s	O
Trichrome	O
(	O
Figure	O
3B	O
)	O
that	O
detects	O
collagen	B-GO
,	O
the	O
major	O
platelet	B-CL
adhesive	O
substratum	O
for	O
initiation	O
of	O
thrombus	O
formation	O
.	O

Collagen	B-GO
content	O
(	O
%	O
tail	O
area	O
)	O
was	O
quantified	O
(	O
Figure	O
3C	O
)	O
from	O
3	O
-	O
4	O
sections	O
from	O
2	O
-	O
3	O
areas	O
/	O
mouse	O
.	O

The	O
amount	O
of	O
collagen	B-GO
was	O
greater	O
in	O
the	O
A	O
/	O
J	O
than	O
the	O
B6	O
mice	B-Taxon
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Collagen	B-GO
in	O
vessels	O
in	O
adipose	O
tissue	O
in	O
the	O
A	O
/	O
J	O
mice	B-Taxon
is	O
also	O
increased	O
compared	O
to	O
the	O
B6	O
mice	B-Taxon
(	O
data	O
not	O
shown	O
)	O
.	O

Figure	O
3	O

Tail	O
morphology	O
and	O
collagen	B-GO
.	O

Tails	O
were	O
excised	O
,	O
embedded	O
in	O
OCT	O
,	O
sectioned	O
,	O
and	O
stained	O
with	O
Hematoxylin	O
/	O
Eosin	O
or	O
Masson	O
'	O
s	O
Trichrome	O
.	O

Panel	O
A	O
:	O
Representative	O
sections	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
from	O
B6	O
and	O
A	O
/	O
J	O
mice	B-Taxon
.	O

Panel	O
B	O
:	O
Representative	O
sections	O
stained	O
with	O
Masson	O
'	O
s	O
Trichrome	O
from	O
B6	O
and	O
A	O
/	O
J	O
mice	B-Taxon
.	O

The	O
blue	O
color	O
identifies	O
the	O
collagen	B-GO
.	O

Panel	O
C	O
:	O
The	O
percentage	O
of	O
the	O
collagen	B-GO
area	O
(	O
excluding	O
center	O
bone	O
/	O
cartilage	O
)	O
of	O
the	O
total	O
tail	O
area	O
of	O
each	O
section	O
was	O
determined	O
in	O
3	O
-	O
4	O
sections	O
at	O
2	O
-	O
3	O
sites	O
for	O
each	O
tail	O
and	O
averaged	O
for	O
each	O
mouse	B-Taxon
.	O

Values	O
are	O
the	O
mean	O
+/-	O
SEM	O
of	O
4	O
-	O
8	O
mice	B-Taxon
per	O
genotype	B-SO
.	O

Symbol	O
indicates	O
a	O
significant	O
difference	O
(	O
*	O
P	O
<	O
0	O
.	O
05	O
)	O
between	O
B6	O
mice	B-Taxon
determined	O
by	O
t	O
-	O
test	O
.	O

Tail	O
bleeding	O
assay	O
identifies	O
three	O
chromosomes	B-GO
with	O
QTL	B-SO
for	O
rebleeding	O
in	O
CSS	O

Using	O
the	O
tail	O
bleeding	O
/	O
rebleeding	O
assay	O
as	O
a	O
surrogate	O
marker	O
for	O
hemostasis	O
and	O
thrombosis	O
,	O
the	O
CSS	O
were	O
screened	O
.	O

The	O
bleeding	O
times	O
(	O
Figure	O
4A	O
)	O
for	O
the	O
B6	O
and	O
the	O
A	O
/	O
J	O
mice	B-Taxon
were	O
not	O
different	O
,	O
but	O
6six	O
of	O
the	O
strains	O
,	O
B6	O
-	O
Chr5	O
,	O
6	O
,	O
8	O
,	O
14	O
,	O
15	O
,	O
and	O
YA	O
/	O
J	O
,	O
had	O
lower	O
(	O
P	O
<	O
0	O
.	O
002	O
)	O
bleeding	O
times	O
(	O
49	O
-	O
79	O
seconds	O
)	O
compared	O
to	O
the	O
value	O
for	O
the	O
B6	O
mice	B-Taxon
(	O
121	O
sec	O
)	O
.	O

The	O
rebleeding	O
time	O
(	O
Figure	O
4B	O
)	O
,	O
determined	O
as	O
the	O
time	O
between	O
bleeding	O
cessation	O
and	O
initiation	O
of	O
the	O
second	O
bleeding	O
,	O
was	O
markedly	O
increased	O
in	O
the	O
A	O
/	O
J	O
mice	B-Taxon
compared	O
to	O
the	O
B6	O
mice	B-Taxon
and	O
two	O
strains	O
,	O
B6	O
-	O
Chr11A	O
/	O
J	O
(	O
CSS	O
-	O
11	O
)	O
and	O
B6	O
-	O
Chr17A	O
/	O
J	O
(	O
CSS	O
-	O
17	O
)	O
,	O
had	O
significantly	O
(	O
P	O
<	O
0	O
.	O
002	O
)	O
longer	O
rebleeding	O
times	O
compared	O
to	O
the	O
B6	O
mice	B-Taxon
that	O
were	O
similar	O
to	O
values	O
from	O
the	O
A	O
/	O
J	O
mice	B-Taxon
.	O

Another	O
strain	O
,	O
B6	O
-	O
Chr5A	O
/	O
J	O
(	O
CSS	O
-	O
5	O
)	O
,	O
approached	O
significance	O
at	O
P	O
<	O
0	O
.	O
008	O
.	O

The	O
rebleeding	O
time	O
was	O
stopped	O
at	O
600	O
sec	O
,	O
and	O
the	O
percentage	O
of	O
mice	B-Taxon
with	O
this	O
value	O
determined	O
for	O
the	O
three	O
strains	O
:	O
CSS	O
-	O
5	O
-	O
60	O
%	O
,	O
CSS	O
-	O
11	O
-	O
60	O
%	O
and	O
CSS	O
-	O
A17	O
-	O
46	O
%	O
.	O

The	O
percentage	O
of	O
B6	O
mice	B-Taxon
with	O
a	O
rebleeding	O
time	O
of	O
600	O
sec	O
was	O
7	O
%	O
and	O
for	O
the	O
A	O
/	O
J	O
mice	B-Taxon
the	O
percentage	O
was	O
85	O
%	O
.	O

Figure	O
4	O

Bleeding	O
and	O
rebleeding	O
time	O
in	O
the	O
CSS	O
.	O

Panel	O
A	O
:	O
Bleeding	O
Time	O
(	O
seconds	O
)	O
.	O

Panel	O
B	O
:	O
Rebleeding	O
Time	O
(	O
seconds	O
)	O
.	O

Bars	O
are	O
the	O
mean	O
+/-	O
SEM	O
of	O
7	O
-	O
28	O
mice	B-Taxon
.	O

Statistical	O
differences	O
between	O
B6	O
mice	B-Taxon
and	O
CSS	O
were	O
determined	O
with	O
a	O
t	O
-	O
test	O
,	O
and	O
a	O
Bonferroni	O
correction	O
was	O
made	O
to	O
determine	O
significance	O
value	O
(	O
P	O
<	O
0	O
.	O
002	O
)	O
.	O

Symbols	O
indicate	O
a	O
significant	O
difference	O
between	O
B6	O
values	O
.	O

*	O
P	O
<	O
0	O
.	O
002	O
.	O

Rebleeding	O
time	O
in	O
the	O
parent	O
strains	O
and	O
CSS	O
were	O
compared	O
to	O
values	O
from	O
the	O
progeny	O
of	O
mice	B-Taxon
that	O
were	O
crossed	O
with	O
B6	O
mice	B-Taxon
to	O
produce	O
heterosomic	O
mice	B-Taxon
for	O
the	O
CSS	O
-	O
5	O
,	O
(	O
B6xCSS	O
-	O
5	O
)	O
F1	O
and	O
CSS	O
-	O
17	O
(	O
B6xCSS	O
-	O
17	O
)	O
F1	O
strains	O
(	O
Figure	O
5	O
)	O
.	O

The	O
rebleeding	O
values	O
for	O
CSS	O
-	O
5F1	O
and	O
CSS	O
-	O
17F1	O
mice	B-Taxon
were	O
similar	O
to	O
the	O
B6	O
rather	O
than	O
the	O
A	O
/	O
J	O
mice	B-Taxon
,	O
suggesting	O
the	O
A	O
/	O
J	O
trait	O
is	O
recessive	O
.	O

Bleeding	O
and	O
rebleeding	O
in	O
the	O
progeny	O
of	O
the	O
cross	O
,	O
B6	O
-	O
Chr5A	O
/	O
J	O
x	O
B6	O
-	O
Chr17A	O
/	O
J	O
(	O
CSS	O
-	O
5	O
x	O
CSS	O
-	O
17	O
)	O
resulted	O
in	O
the	O
recovery	O
of	O
the	O
A	O
/	O
J	O
phenotype	O
in	O
the	O
progeny	O
of	O
these	O
double	O
heterosomic	O
strains	O
.	O

Thus	O
,	O
despite	O
the	O
heterosomic	O
chromosomes	B-GO
of	O
5	O
and	O
17	O
in	O
the	O
progeny	O
of	O
the	O
CSS	O
-	O
5	O
x	O
CSS	O
-	O
17	O
,	O
the	O
phenotype	O
was	O
now	O
similar	O
to	O
A	O
/	O
J	O
.	O

This	O
suggested	O
that	O
traits	O
on	O
the	O
A	O
/	O
J	O
chromosomes	B-GO
were	O
interacting	O
to	O
produce	O
the	O
phenotype	O
.	O

Figure	O
5	O

Bleeding	O
and	O
rebleeding	O
time	O
in	O
the	O
CSS	O
backcrosses	O
.	O

Panel	O
A	O
:	O
Bleeding	O
Time	O
(	O
seconds	O
)	O
and	O
Panel	O
B	O
:	O
Rebleeding	O
Time	O
(	O
seconds	O
)	O
were	O
tested	O
in	O
heterosomic	O
mice	B-Taxon
,	O
(	O
B6xCSS	O
-	O
5	O
)	O
F1	O
(	O
5F1	O
)	O
and	O
(	O
B6xCSS	O
-	O
17	O
)	O
F1	O
(	O
17F1	O
)	O
and	O
doubly	O
heterosomic	O
mice	B-Taxon
for	O
chromosomes	B-GO
5	O
and	O
17	O
(	O
5	O
x	O
17	O
)	O
.	O

Bars	O
are	O
the	O
mean	O
+/-	O
SEM	O
of	O
5	O
-	O
28	O
mice	B-Taxon
.	O

Statistical	O
differences	O
between	O
B6	O
mice	B-Taxon
and	O
the	O
CSS	O
were	O
determined	O
with	O
a	O
t	O
-	O
test	O
,	O
and	O
a	O
Bonferroni	O
correction	O
was	O
made	O
to	O
determine	O
significance	O
value	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Symbols	O
indicate	O
a	O
significant	O
difference	O
between	O
B6	O
values	O
.	O

*	O
P	O
<	O
0	O
.	O
01	O
.	O

Interactions	O
of	O
CSS	O
for	O
PAI	B-GGP
-	I-GGP
1	I-GGP
antigen	O
and	O
activity	O

Components	O
of	O
the	O
Plg	B-GGP
system	O
reside	O
on	O
chromosomes	B-GO
CSS	O
-	O
5	O
(	O
PAI	B-GGP
-	I-GGP
1	I-GGP
)	O
,	O
CSS	O
-	O
11	O
(	O
alpha	B-GGP
2	I-GGP
-	I-GGP
antiplasmin	I-GGP
)	O
,	O
and	O
CSS	O
-	O
17	O
(	O
Plg	B-GGP
)	O
.	O

As	O
reported	O
in	O
Table	O
2	O
,	O
the	O
A	O
/	O
J	O
mice	B-Taxon
had	O
increased	O
Plg	B-GGP
antigen	O
,	O
fibrinolytic	O
activity	O
,	O
alpha	B-GGP
2	I-GGP
-	I-GGP
antiplasmin	I-GGP
,	O
PAI	B-GGP
-	I-GGP
1	I-GGP
activity	O
and	O
fibrinogen	B-GO
when	O
compared	O
to	O
B6	O
mice	B-Taxon
.	O

In	O
CSS	O
-	O
17	O
mice	B-Taxon
,	O
the	O
Plg	B-GGP
antigen	O
was	O
also	O
significantly	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O
increased	O
(	O
152	O
+/-	O
6	O
,	O
n	O
=	O
12	O
)	O
when	O
compared	O
to	O
the	O
B6	O
mice	B-Taxon
,	O
but	O
for	O
CSS	O
-	O
5	O
and	O
CSS	O
-	O
5	O
x	O
17	O
,	O
the	O
Plg	B-GGP
antigen	O
was	O
similar	O
to	O
values	O
for	O
the	O
B6	O
mice	B-Taxon
.	O

Fibrinolytic	O
activity	O
was	O
not	O
different	O
in	O
the	O
CSS	O
-	O
5	O
or	O
CSS	O
-	O
17	O
strains	O
compared	O
to	O
the	O
B6	O
mice	B-Taxon
.	O

alpha	B-GGP
2	I-GGP
-	I-GGP
antiplasmin	I-GGP
was	O
significantly	O
(	O
P	O
=	O
<	O
0	O
.	O
01	O
)	O
reduced	O
in	O
CSS	O
-	O
5	O
mice	B-Taxon
(	O
142	O
+/-	O
4	O
mu	O
g	O
/	O
mL	O
,	O
n	O
=	O
5	O
)	O
,	O
significantly	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
higher	O
in	O
the	O
CSS	O
-	O
11	O
(	O
201	O
+/-	O
6	O
,	O
n	O
=	O
8	O
)	O
,	O
but	O
not	O
different	O
in	O
CSS	O
-	O
17	O
or	O
CSS	O
-	O
5	O
x	O
17	O
mice	B-Taxon
compared	O
to	O
the	O
B6	O
mice	B-Taxon
.	O

PAI	B-GGP
-	I-GGP
1	I-GGP
antigen	O
and	O
activity	O
were	O
determined	O
in	O
the	O
CSS	O
with	O
increased	O
rebleeding	O
times	O
,	O
CSS	O
-	O
5	O
,	O
CSS	O
-	O
11	O
,	O
and	O
CSS	O
-	O
17	O
(	O
Figure	O
6	O
)	O
,	O
the	O
heterosomic	O
,	O
CSS	O
-	O
5F1	O
,	O
CSS	O
-	O
17F1	O
,	O
and	O
double	O
hetersomic	O
,	O
CSS	O
-	O
5	O
x	O
17	O
.	O

CSS	O
-	O
5	O
,	O
CSS	O
-	O
17	O
,	O
CSS	O
-	O
5F1	O
,	O
and	O
CSS	O
-	O
17F1	O
generally	O
had	O
reduced	O
PAI	B-GGP
-	I-GGP
1	I-GGP
antigen	O
when	O
compared	O
to	O
B6	O
mice	B-Taxon
.	O

The	O
reduced	O
PAI	B-GGP
-	I-GGP
1	I-GGP
antigen	O
was	O
a	O
dominant	O
trait	O
due	O
to	O
the	O
fact	O
that	O
the	O
values	O
were	O
similar	O
in	O
the	O
homosomic	O
and	O
heterosomic	O
CSS	O
-	O
5	O
and	O
CSS	O
-	O
17	O
.	O

The	O
CSS	O
-	O
5	O
x	O
CSS	O
-	O
17	O
double	O
heterosomic	O
strains	O
had	O
values	O
similar	O
to	O
the	O
B6	O
and	O
A	O
/	O
J	O
parent	O
strains	O
.	O

PAI	B-GGP
-	I-GGP
1	I-GGP
activity	O
was	O
significantly	O
reduced	O
in	O
the	O
CSS	O
-	O
5	O
and	O
CSS	O
-	O
17F1	O
mice	B-Taxon
,	O
but	O
again	O
in	O
the	O
CSS	O
-	O
5	O
x	O
CSS	O
-	O
17	O
strain	O
the	O
value	O
for	O
PAI	B-GGP
-	I-GGP
1	I-GGP
activity	O
was	O
restored	O
to	O
the	O
value	O
of	O
the	O
B6	O
and	O
A	O
/	O
J	O
parent	O
strains	O
.	O

The	O
PAI	B-GGP
-	I-GGP
1	I-GGP
antigen	O
(	O
5	O
.	O
4	O
ng	O
/	O
mL	O
+/-	O
0	O
.	O
5	O
,	O
n	O
=	O
7	O
)	O
and	O
activity	O
(	O
170	O
U	O
/	O
mL	O
+/-	O
20	O
,	O
n	O
=	O
6	O
)	O
in	O
the	O
CSS	O
-	O
11	O
mice	B-Taxon
was	O
not	O
different	O
than	O
for	O
B6	O
mice	B-Taxon
.	O

Figure	O
6	O

PAI	B-GGP
-	I-GGP
1	I-GGP
in	O
the	O
CSS	O
backcrosses	O
.	O

Panel	O
A	O
:	O
Plasma	O
PAI	B-GGP
-	I-GGP
1	I-GGP
antigen	O
(	O
ng	O
/	O
mL	O
)	O
and	O
Panel	O
B	O
:	O
Plasma	O
PAI	B-GGP
-	I-GGP
1	I-GGP
activity	O
(	O
U	O
/	O
mL	O
)	O
were	O
tested	O
in	O
heterosomic	O
mice	B-Taxon
,	O
(	O
B6xCSS	O
-	O
5	O
)	O
F1	O
(	O
5F1	O
)	O
and	O
(	O
B6xCSS	O
-	O
17	O
)	O
F1	O
(	O
17F1	O
)	O
and	O
doubly	O
heterosomic	O
mice	B-Taxon
for	O
chromosomes	B-GO
5	O
and	O
17	O
(	O
5	O
x	O
17	O
)	O
.	O

Bars	O
are	O
the	O
mean	O
+/-	O
SEM	O
of	O
5	O
-	O
18	O
mice	B-Taxon
.	O

Statistical	O
differences	O
between	O
B6	O
mice	B-Taxon
and	O
CSS	O
were	O
determined	O
with	O
a	O
t	O
-	O
test	O
,	O
and	O
a	O
Bonferroni	O
correction	O
was	O
made	O
to	O
determine	O
significance	O
value	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Symbols	O
indicate	O
a	O
significant	O
difference	O
between	O
B6	O
values	O
.	O

*	O
P	O
<	O
0	O
.	O
01	O
.	O

Interactions	O
of	O
CSS	O
for	O
arterial	O
thrombus	O
formation	O

The	O
tail	O
bleeding	O
assay	O
was	O
rapid	O
and	O
facilitated	O
the	O
screening	O
of	O
the	O
21	O
CSS	O
strains	O
,	O
and	O
subsequently	O
the	O
identified	O
strains	O
were	O
tested	O
for	O
arterial	O
occlusion	O
after	O
the	O
FeCl3	B-CHEBI
injury	O
(	O
Figure	O
7	O
)	O
.	O

The	O
CSS	O
-	O
5	O
and	O
CSS	O
-	O
17	O
had	O
occlusion	O
times	O
similar	O
to	O
the	O
B6	O
mice	B-Taxon
,	O
but	O
the	O
doubly	O
heterosomic	O
CSS	O
-	O
5	O
x	O
CSS	O
-	O
17	O
progeny	O
had	O
occlusion	O
times	O
higher	O
than	O
either	O
the	O
B6	O
mice	B-Taxon
or	O
the	O
heterosomic	O
CSS	O
-	O
5F1	O
and	O
CSS	O
-	O
17F1	O
or	O
the	O
A	O
/	O
J	O
strains	O
.	O

In	O
double	O
heterosomic	O
CSS	O
-	O
5	O
x	O
CSS	O
-	O
17	O
mice	B-Taxon
,	O
only	O
one	O
or	O
three	O
mice	B-Taxon
tested	O
had	O
occluded	O
by	O
30	O
min	O
;	O
the	O
other	O
two	O
mice	B-Taxon
did	O
not	O
occlude	O
by	O
30	O
min	O
.	O

While	O
only	O
a	O
small	O
number	O
of	O
CSS	O
mice	B-Taxon
have	O
been	O
tested	O
for	O
the	O
arterial	O
occlusion	O
,	O
the	O
results	O
suggest	O
that	O
interaction	O
of	O
the	O
genes	B-SO
on	O
chromosome	B-GO
5	O
and	O
17	O
also	O
determines	O
arterial	O
occlusion	O
time	O
.	O

Figure	O
7	O

Arterial	O
occlusion	O
time	O
in	O
the	O
CSS	O
backcrosses	O
.	O

Occlusion	O
time	O
was	O
determined	O
in	O
heterosomic	O
mice	B-Taxon
,	O
(	O
B6xCSS	O
-	O
5	O
)	O
F1	O
(	O
5F1	O
)	O
and	O
(	O
B6xCSS	O
-	O
17	O
)	O
F1	O
(	O
17F1	O
)	O
,	O
and	O
doubly	O
heterosomic	O
mice	B-Taxon
for	O
chromosomes	B-GO
5	O
and	O
17	O
(	O
5	O
x	O
17	O
)	O
.	O

Bars	O
are	O
the	O
mean	O
+/-	O
SEM	O
of	O
5	O
-	O
18	O
mice	B-Taxon
.	O

Statistical	O
differences	O
between	O
B6	O
mice	B-Taxon
and	O
CSS	O
were	O
determined	O
with	O
a	O
t	O
-	O
test	O
,	O
and	O
a	O
Bonferroni	O
correction	O
was	O
made	O
to	O
determine	O
significance	O
value	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

Symbols	O
indicate	O
a	O
significant	O
difference	O
between	O
B6	O
values	O
.	O

*	O
P	O
<	O
0	O
.	O
0001	O
.	O

Discussion	O

In	O
this	O
study	O
,	O
thrombotic	O
risk	O
was	O
systematically	O
assessed	O
in	O
two	O
inbred	O
strains	O
of	O
mice	B-Taxon
that	O
have	O
marked	O
differences	O
in	O
susceptibility	O
to	O
diet	O
-	O
induced	O
obesity	O
,	O
diet	O
-	O
induced	O
atherosclerosis	O
,	O
and	O
ligation	O
-	O
induced	O
neointimal	O
hyperplasia	O
and	O
vessel	O
remodeling	O
.	O

Arterial	O
occlusion	O
time	O
,	O
tail	O
bleeding	O
and	O
rebleeding	O
time	O
were	O
evaluated	O
as	O
potential	O
predictors	O
of	O
thrombotic	O
response	O
.	O

Assessments	O
of	O
the	O
two	O
inbred	O
strains	O
were	O
compared	O
to	O
values	O
from	O
gene	B-SO
targeted	O
mice	B-Taxon
of	O
the	O
Plg	B-GGP
network	O
with	O
altered	O
fibrinolytic	O
responses	O
,	O
as	O
well	O
as	O
in	O
leptin	B-GGP
deficient	O
mice	B-Taxon
with	O
a	O
reduced	O
platelet	B-CL
function	O
.	O

Marked	O
differences	O
were	O
found	O
in	O
the	O
thrombotic	O
response	O
among	O
the	O
two	O
inbred	O
strains	O
,	O
B6	O
and	O
A	O
/	O
J	O
,	O
and	O
the	O
observed	O
differences	O
were	O
not	O
correlated	O
with	O
change	O
in	O
coagulation	O
or	O
platelet	B-CL
function	O
.	O

Screening	O
the	O
CSS	O
identified	O
three	O
chromosomes	B-GO
that	O
harbored	O
genes	B-SO
which	O
contributed	O
to	O
the	O
A	O
/	O
J	O
phenotype	O
of	O
increased	O
rebleeding	O
time	O
.	O

Mice	B-Taxon
homosomic	O
for	O
these	O
chromosomes	B-GO
or	O
doubly	O
heterosomic	O
for	O
two	O
of	O
the	O
chromosomes	B-GO
,	O
5	O
and	O
17	O
,	O
were	O
required	O
to	O
express	O
the	O
A	O
/	O
J	O
phenotype	O
,	O
elevated	O
rebleeding	O
time	O
.	O

PAI	B-GGP
-	I-GGP
1	I-GGP
antigen	O
and	O
activity	O
were	O
decreased	O
in	O
both	O
CSS	O
-	O
5	O
and	O
CSS	O
-	O
17	O
and	O
the	O
heterosomic	O
mice	B-Taxon
,	O
CSS	O
-	O
5F1	O
and	O
CSS	O
-	O
17F1	O
,	O
but	O
not	O
in	O
the	O
CSS	O
-	O
11	O
strain	O
.	O

Values	O
were	O
restored	O
in	O
the	O
doubly	O
heterosomic	O
for	O
two	O
of	O
chromosomes	B-GO
,	O
5	O
and	O
17	O
.	O

Arterial	O
occlusion	O
time	O
was	O
similar	O
to	O
B6	O
in	O
the	O
CSS	O
-	O
5	O
and	O
CSS	O
-	O
17	O
homozygous	O
strains	O
,	O
but	O
increased	O
in	O
doubly	O
heterosomic	O
for	O
two	O
of	O
chromosomes	B-GO
,	O
5	O
and	O
17	O
.	O

The	O
FeCl3	B-CHEBI
-	O
induced	O
model	O
of	O
vascular	O
injury	O
and	O
thrombosis	O
in	O
mice	B-Taxon
is	O
now	O
widely	O
used	O
to	O
evaluate	O
genetic	B-SO
and	O
pharmacological	O
interventions	O
[	O
24	O
]	O
.	O

The	O
two	O
inbred	O
strains	O
had	O
marked	O
differences	O
in	O
the	O
time	O
for	O
occlusion	O
of	O
the	O
carotid	O
artery	O
after	O
FeCl3	B-CHEBI
injury	O
.	O

After	O
FeCl3	B-CHEBI
treatment	O
,	O
thrombus	O
formation	O
and	O
occlusion	O
was	O
remarkably	O
shortened	O
in	O
the	O
A	O
/	O
J	O
mice	B-Taxon
compared	O
to	O
the	O
B6	O
mice	B-Taxon
.	O

These	O
results	O
have	O
not	O
previously	O
been	O
reported	O
.	O

A	O
recent	O
study	O
[	O
25	O
]	O
of	O
sheer	O
stress	O
in	O
rats	B-Taxon
,	O
found	O
that	O
the	O
magnitude	O
of	O
changes	O
in	O
sheer	O
stress	O
with	O
increased	O
blood	O
flow	O
varied	O
with	O
the	O
different	O
strains	O
.	O

Further	O
investigation	O
,	O
beyond	O
the	O
scope	O
of	O
this	O
study	O
would	O
be	O
necessary	O
to	O
determine	O
the	O
contribution	O
in	O
the	O
differences	O
in	O
size	O
and	O
sheer	O
stress	O
of	O
the	O
carotids	O
to	O
arterial	O
occlusion	O
rates	O
in	O
the	O
B6	O
and	O
A	O
/	O
J	O
mice	B-Taxon
.	O

In	O
preliminary	O
studies	O
,	O
we	O
have	O
noted	O
differences	O
in	O
the	O
composition	O
of	O
the	O
thrombus	O
in	O
B6	O
and	O
A	O
/	O
J	O
mice	B-Taxon
.	O

The	O
pattern	O
of	O
blood	O
flow	O
cessation	O
for	O
the	O
two	O
inbred	O
strains	O
was	O
different	O
than	O
for	O
the	O
Lepob	O
mice	B-Taxon
[	O
26	O
]	O
with	O
impaired	O
platelet	B-CL
function	O
,	O
and	O
coagulation	O
time	O
was	O
similar	O
in	O
the	O
two	O
strains	O
.	O

In	O
the	O
mice	B-Taxon
with	O
deficiencies	O
of	O
the	O
Plg	B-GGP
network	O
[	O
27	O
]	O
,	O
thrombus	O
formation	O
time	O
was	O
reduced	O
in	O
the	O
Plg	B-GGP
-	O
/	O
-	O
mice	B-Taxon
,	O
but	O
increased	O
in	O
the	O
PAI	B-GGP
-	O
/	O
-	O
mice	B-Taxon
,	O
suggesting	O
that	O
alterations	O
in	O
plasmin	B-GGP
activity	O
that	O
affect	O
the	O
rate	O
of	O
clot	O
lysis	O
,	O
can	O
modulate	O
the	O
events	O
leading	O
to	O
occlusive	O
thrombus	O
formation	O
.	O

The	O
tail	O
-	O
bleeding	O
assay	O
has	O
been	O
used	O
extensively	O
in	O
mice	B-Taxon
to	O
assess	O
the	O
impact	O
of	O
deficiencies	O
and	O
over	O
expression	O
of	O
platelet	B-CL
and	O
coagulation	O
proteins	B-CHEBI
in	O
mice	B-Taxon
.	O

Sweeny	O
et	O
al	O
[	O
28	O
]	O
screened	O
25	O
strains	O
of	O
mice	B-Taxon
and	O
found	O
only	O
the	O
RIIS	O
/	O
J	O
mice	B-Taxon
to	O
have	O
increased	O
bleeding	O
time	O
due	O
to	O
reduced	O
von	B-GGP
Willebrand	I-GGP
antigen	I-GGP
.	O

Broze	O
et	O
al	O
[	O
29	O
]	O
evaluated	O
mice	B-Taxon
with	O
gene	B-SO
deletions	B-SO
of	O
the	O
coagulation	O
pathway	O
and	O
found	O
that	O
while	O
bleeding	O
time	O
was	O
not	O
increased	O
,	O
rebleeding	O
persisted	O
despite	O
electrocautery	O
of	O
the	O
tail	O
in	O
FVIII	B-GGP
and	O
FIX	B-GGP
deficient	O
mice	B-Taxon
.	O

This	O
observation	O
raised	O
the	O
possibility	O
that	O
rebleeding	O
time	O
may	O
be	O
a	O
sensitive	O
reporter	O
of	O
genetic	B-SO
influences	O
on	O
thrombus	O
formation	O
and	O
stability	O
.	O

Mice	B-Taxon
that	O
are	O
deficient	O
in	O
factors	O
required	O
for	O
normal	O
platelet	B-CL
function	O
,	O
platelet	B-CL
glycoprotein	O
Ib	O
[	O
30	O
]	O
,	O
and	O
protease	B-GGP
-	I-GGP
activated	I-GGP
receptor	I-GGP
-	I-GGP
4	I-GGP
,	O
[	O
31	O
]	O
have	O
increased	O
tail	O
bleeding	O
time	O
.	O

The	O
leptin	B-GGP
deficiency	O
with	O
reduced	O
platelet	B-CL
aggregation	O
clearly	O
shows	O
a	O
marked	O
increase	O
in	O
bleeding	O
time	O
and	O
the	O
increased	O
bleeding	O
time	O
in	O
Plg	B-GGP
-	O
/	O
-	O
and	O
uPA	B-GGP
-	O
/	O
-	O
mice	B-Taxon
suggests	O
that	O
Plg	B-GGP
and	O
uPA	B-GGP
may	O
exert	O
an	O
influence	O
on	O
platelet	B-CL
response	O
to	O
promote	O
normal	O
thrombus	O
formation	O
.	O

Overall	O
,	O
the	O
marked	O
increase	O
in	O
rebleeding	O
times	O
observed	O
in	O
certain	O
mouse	B-Taxon
strains	O
suggests	O
genetic	B-SO
factors	O
other	O
than	O
coagulation	O
may	O
play	O
a	O
role	O
in	O
the	O
stability	O
of	O
a	O
thrombus	O
.	O

In	O
the	O
tail	O
bleeding	O
assay	O
,	O
A	O
/	O
J	O
mice	B-Taxon
did	O
not	O
have	O
changes	O
in	O
bleeding	O
time	O
,	O
but	O
rebleeding	O
time	O
was	O
higher	O
compared	O
to	O
B6	O
mice	B-Taxon
.	O

In	O
our	O
study	O
,	O
Plg	B-GGP
-	O
/	O
-	O
mice	B-Taxon
had	O
increased	O
bleeding	O
time	O
,	O
PAI	B-GGP
-	I-GGP
1	I-GGP
-	O
/	O
-	O
had	O
decreased	O
rebleeding	O
time	O
,	O
and	O
uPA	B-GGP
-	O
/	O
-	O
mice	B-Taxon
had	O
an	O
increased	O
bleeding	O
time	O
similar	O
to	O
the	O
Plg	B-GGP
-	O
/	O
-	O
mice	B-Taxon
(	O
J	O
.	O
Hoover	O
-	O
Plow	O
,	O
A	O
.	O
Shchurin	O
,	O
and	O
E	O
.	O
Hart	O
,	O
unpublished	O
results	O
)	O
.	O

Increased	O
bleeding	O
or	O
rebleeding	O
times	O
have	O
not	O
been	O
reported	O
in	O
any	O
of	O
the	O
Plg	B-GGP
network	O
targeted	O
mice	B-Taxon
.	O

Matsuno	O
et	O
al	O
[	O
32	O
]	O
reported	O
no	O
difference	O
in	O
bleeding	O
time	O
for	O
tPA	B-GGP
-	O
/	O
-	O
,	O
uPA	B-GGP
-	O
/	O
-	O
,	O
PAI	B-GGP
-	I-GGP
1	I-GGP
-	O
/	O
-	O
mice	B-Taxon
compared	O
to	O
WT	B-SO
mice	B-Taxon
,	O
and	O
the	O
assay	O
was	O
similar	O
,	O
but	O
the	O
tail	O
clip	O
segment	O
was	O
considerably	O
shorter	O
and	O
bleeding	O
times	O
reduced	O
compared	O
to	O
the	O
times	O
reported	O
in	O
our	O
study	O
.	O

Bleeding	O
time	O
has	O
not	O
been	O
previously	O
reported	O
for	O
Plg	B-GGP
-	O
/	O
-	O
mice	B-Taxon
.	O

We	O
have	O
found	O
similar	O
values	O
for	O
Plg	B-GGP
-	O
/	O
-	O
mice	B-Taxon
in	O
a	O
50	O
%	O
B6	O
:	O
50	O
%	O
129	O
background	O
(	O
J	O
.	O
Hoover	O
-	O
Plow	O
,	O
A	O
.	O
Shchurin	O
,	O
and	O
E	O
.	O
Hart	O
,	O
unpublished	O
results	O
)	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
not	O
only	O
is	O
bleeding	O
time	O
genetically	B-SO
determined	O
by	O
background	O
,	O
but	O
also	O
that	O
tail	O
rebleeding	O
time	O
is	O
genetically	B-SO
determined	O
.	O

While	O
blood	O
pressure	O
could	O
conceivably	O
be	O
higher	O
in	O
mice	B-Taxon
with	O
elevated	O
tail	O
bleeding	O
time	O
,	O
several	O
studies	O
suggest	O
that	O
this	O
is	O
not	O
the	O
case	O
.	O

Studies	O
of	O
A	O
/	O
J	O
[	O
33	O
-	O
36	O
]	O
mice	B-Taxon
have	O
reported	O
either	O
decreased	O
blood	O
pressure	O
or	O
no	O
difference	O
compared	O
to	O
the	O
B6	O
mice	B-Taxon
.	O

Blood	O
pressure	O
was	O
measured	O
in	O
the	O
Plg	B-GGP
-	O
/	O
-	O
mice	B-Taxon
(	O
D	O
.	O
Hellard	O
,	O
J	O
.	O
Hoover	O
-	O
Plow	O
,	O
and	O
E	O
.	O
Plow	O
,	O
unpublished	O
results	O
)	O
,	O
and	O
these	O
mice	B-Taxon
have	O
reduced	O
blood	O
pressure	O
when	O
compared	O
to	O
WT	B-SO
littermates	O
,	O
and	O
uPA	B-GGP
-	O
/	O
-	O
[	O
37	O
]	O
and	O
Lepob	O
[	O
38	O
,	O
39	O
]	O
mice	B-Taxon
also	O
have	O
reduced	O
blood	O
pressure	O
,	O
but	O
there	O
is	O
no	O
correspondence	O
between	O
blood	O
pressure	O
and	O
tail	O
bleeding	O
or	O
rebleeding	O
times	O
.	O

Morphometric	O
analysis	O
of	O
the	O
tail	O
indicated	O
a	O
difference	O
in	O
the	O
collagen	B-GO
content	O
of	O
the	O
tail	O
in	O
the	O
A	O
/	O
J	O
mice	B-Taxon
.	O

Differences	O
in	O
the	O
structure	O
and	O
/	O
or	O
metabolism	O
of	O
collagen	B-GO
or	O
extracellular	B-GO
matrix	I-GO
proteins	B-CHEBI
may	O
contribute	O
to	O
the	O
increased	O
rebleeding	O
and	O
reduced	O
occlusion	O
time	O
in	O
the	O
A	O
/	O
J	O
mice	B-Taxon
and	O
warrant	O
further	O
investigation	O
.	O

The	O
genes	B-SO
for	O
Plg	B-GGP
,	O
PAI	B-GGP
-	I-GGP
1	I-GGP
,	O
and	O
alpha	B-GGP
2	I-GGP
-	I-GGP
antiplasmin	I-GGP
reside	O
on	O
the	O
three	O
chromosomes	B-GO
identified	O
for	O
QTL	B-SO
for	O
rebleeding	O
time	O
and	O
may	O
or	O
may	O
not	O
be	O
coincidental	O
to	O
the	O
observed	O
phenotypes	O
found	O
in	O
the	O
A	O
/	O
J	O
mice	B-Taxon
and	O
CSS	O
.	O

It	O
is	O
not	O
likely	O
that	O
merely	O
the	O
concentration	O
of	O
these	O
components	O
explains	O
the	O
increased	O
rebleeding	O
time	O
and	O
reduced	O
arterial	O
occlusion	O
time	O
in	O
the	O
A	O
/	O
J	O
mice	B-Taxon
.	O

When	O
compared	O
to	O
the	O
B6	O
mice	B-Taxon
,	O
the	O
A	O
/	O
J	O
mice	B-Taxon
and	O
the	O
three	O
strains	O
with	O
elevated	O
rebleeding	O
time	O
had	O
variable	O
Plg	B-GGP
,	O
PAI	B-GGP
-	I-GGP
1	I-GGP
,	O
and	O
alpha	B-GGP
2	I-GGP
-	I-GGP
antiplasmin	I-GGP
.	O

Two	O
allelic	B-SO
forms	I-SO
of	O
the	O
mouse	B-GGP
Plg	I-GGP
gene	B-SO
have	O
been	O
reported	O
for	O
B6	O
and	O
A	O
/	O
J	O
mice	B-Taxon
[	O
40	O
]	O
.	O

Plg	B-GGP
concentration	O
was	O
increased	O
in	O
A	O
/	O
J	O
mice	B-Taxon
compared	O
to	O
B6	O
mice	B-Taxon
.	O

Although	O
we	O
did	O
not	O
detect	O
differences	O
in	O
Plg	B-GGP
structure	O
,	O
this	O
would	O
not	O
exclude	O
possible	O
functional	O
differences	O
.	O

A	O
congenic	O
strain	O
(	O
specific	O
for	O
a	O
homosomic	O
region	B-SO
from	O
A	O
/	O
J	O
and	O
the	O
remaining	O
Chr	B-GO
and	O
background	O
is	O
from	O
B6	O
mice	B-Taxon
)	O
of	O
A	O
/	O
J	O
chromosome	B-GO
17	O
that	O
includes	O
the	O
Plg	B-GGP
gene	B-SO
was	O
tested	O
in	O
the	O
bleeding	O
assay	O
.	O

Values	O
for	O
bleeding	O
and	O
rebleeding	O
in	O
this	O
congenic	O
strain	O
were	O
similar	O
to	O
values	O
from	O
B6	O
mice	B-Taxon
,	O
indicating	O
that	O
the	O
QTL	B-SO
is	O
not	O
Plg	B-GGP
.	O

There	O
are	O
genes	B-SO
for	O
other	O
proteases	O
and	O
matrix	O
proteins	B-CHEBI
that	O
reside	O
on	O
chromosome	B-GO
17	O
in	O
addition	O
to	O
unknown	O
genes	B-SO
.	O

DNA	B-SO
base	I-SO
pair	I-SO
sequence	I-SO
data	O
for	O
the	O
PAI	B-GGP
-	I-GGP
1	I-GGP
gene	B-SO
or	O
the	O
alpha	B-GGP
2	I-GGP
-	I-GGP
antiplasmin	I-GGP
gene	B-SO
in	O
B6	O
and	O
A	O
/	O
J	O
mice	B-Taxon
have	O
reported	O
no	O
differences	O
[	O
51	O
]	O
,	O
but	O
regulatory	O
genes	B-SO
upstream	O
of	O
the	O
coding	B-SO
region	I-SO
may	O
be	O
important	O
.	O

Our	O
results	O
suggest	O
that	O
novel	O
or	O
unknown	O
genes	B-SO
may	O
interact	O
with	O
the	O
Plg	B-GGP
system	O
components	O
to	O
modify	O
their	O
function	O
.	O

In	O
summary	O
,	O
this	O
study	O
reports	O
marked	O
differences	O
in	O
two	O
inbred	O
strains	O
of	O
mice	B-Taxon
,	O
B6	O
and	O
A	O
/	O
J	O
,	O
in	O
arterial	O
thrombosis	O
formation	O
in	O
a	O
FeCl3	B-CHEBI
vascular	O
injury	O
model	O
,	O
rebleeding	O
time	O
in	O
a	O
tail	O
bleeding	O
assay	O
,	O
plasminogen	B-GGP
function	O
,	O
and	O
tissue	O
and	O
vessel	O
collagen	B-GO
deposition	O
.	O

Three	O
chromosomes	B-GO
from	O
A	O
/	O
J	O
mice	B-Taxon
were	O
identified	O
that	O
had	O
QTL	B-SO
for	O
rebleeding	O
time	O
.	O

The	O
genes	B-SO
may	O
interact	O
with	O
components	O
in	O
the	O
Plg	B-GGP
network	O
and	O
modulate	O
arterial	O
occlusion	O
time	O
.	O

Conclusion	O

The	O
marked	O
independent	O
differences	O
demonstrated	O
in	O
the	O
B6	O
and	O
A	O
/	O
J	O
mice	B-Taxon
can	O
be	O
exploited	O
to	O
identify	O
genetic	B-SO
determinants	O
of	O
thrombosis	O
and	O
haemostasis	O
.	O

Our	O
results	O
of	O
the	O
CSS	O
screening	O
suggest	O
that	O
novel	O
or	O
unknown	O
genes	B-SO
can	O
be	O
used	O
to	O
identify	O
the	O
genes	B-SO
responsible	O
for	O
the	O
traits	O
related	O
to	O
arterial	O
thrombosis	O
,	O
tail	O
bleeding	O
/	O
rebleeding	O
and	O
vessel	O
extracellular	B-GO
matrix	I-GO
.	O

Identification	O
of	O
differences	O
in	O
the	O
parent	O
strains	O
,	O
such	O
as	O
those	O
described	O
in	O
this	O
study	O
,	O
and	O
screening	O
of	O
the	O
CSS	O
is	O
a	O
first	O
-	O
step	O
in	O
the	O
discovery	O
of	O
new	O
genetic	B-SO
determinants	O
of	O
thrombotic	O
risk	O
.	O

Abbreviations	O

B6	O
=	O
C57BL	O
/	O
6J	O

CSS	O
=	O
chromosome	B-GO
substitution	B-SO
strains	O

CSS	O
-	O
#	O
=	O
B6	O
-	O
Chr	B-SO
#	O
A	O
/	O
J	O

CSS	O
-	O
#	O
F1	O
=	O
(	O
B6	O
x	O
CSS	O
-	O
#	O
)	O
F1	O

WT	B-SO
=	O
wild	B-SO
-	I-SO
type	I-SO

-	O
/	O
-	O
=	O
deficient	O

Plg	B-GGP
=	O
plasminogen	B-GGP

PAI	B-GGP
-	I-GGP
1	I-GGP
=	O
plasminogen	B-GGP
activator	I-GGP
inhibitor	I-GGP
-	I-GGP
1	I-GGP

tPA	B-GGP
=	O
tissue	B-GGP
plasminogen	I-GGP
activator	I-GGP

uPA	B-GGP
=	O
urokinase	B-GGP
plasminogen	I-GGP
activator	I-GGP

SEM	O
=	O
standard	O
error	O
of	O
the	O
mean	O

QTL	B-SO
=	O
quantitative	B-SO
trait	I-SO
locus	I-SO

Competing	O
interests	O

The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

JHP	O
conceived	O
and	O
designed	O
the	O
study	O
,	O
coordinated	O
the	O
experiments	O
and	O
drafted	O
the	O
manuscript	O
.	O

AS	O
developed	O
and	O
performed	O
the	O
tail	O
bleeding	O
assay	O
and	O
participated	O
in	O
drafting	O
the	O
manuscript	O
.	O

EH	O
carried	O
out	O
the	O
vascular	O
injury	O
model	O
and	O
analyses	O
and	O
the	O
tail	O
bleeding	O
assay	O
,	O
participated	O
in	O
the	O
tail	O
collagen	B-GO
analyses	O
,	O
and	O
coordination	O
of	O
the	O
mouse	B-Taxon
breeding	O
.	O

JS	O
participated	O
in	O
the	O
analysis	O
of	O
the	O
vascular	O
injury	O
model	O
results	O
and	O
collagen	B-GO
analyses	O
.	O

JHN	O
and	O
AHE	O
provided	O
the	O
CSS	O
breeding	O
pairs	O
,	O
JHN	O
participated	O
in	O
discussions	O
of	O
the	O
results	O
,	O
and	O
JBS	O
and	O
JHN	O
developed	O
the	O
CSS	O
.	O

All	O
the	O
authors	O
have	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

Acknowledgements	O

The	O
authors	O
thank	O
Dr	O
.	O
A	O
.	O

Vasanji	O
,	O
Shiyang	O
Wang	O
,	O
and	O
Jenna	O
Saraniti	O
for	O
assistance	O
with	O
image	O
analyses	O
,	O
David	O
Hellard	O
for	O
performing	O
the	O
blood	O
pressure	O
measurements	O
,	O
Dr	O
.	O
Y	O
.	O
Shchurina	O
for	O
the	O
plasminogen	B-GGP
analyses	O
,	O
Drs	O
.	O

Lindsey	O
Burrage	O
and	O
Jonathan	O
Smith	O
for	O
helpful	O
discussions	O
,	O
and	O
Robin	O
Lewis	O
for	O
assistance	O
with	O
manuscript	O
preparation	O
.	O

This	O
study	O
was	O
supported	O
by	O
grants	O
from	O
NIH	O
,	O
HL17964	O
,	O
HL65204	O
,	O
HL078701	O
(	O
JHP	O
)	O
,	O
T32	O
HL07914	O
(	O
AS	O
)	O
,	O
and	O
RR12305	O
(	O
JHN	O
)	O
.	O

CAF	B-GO
-	I-GO
1	I-GO
Is	O
Essential	O
for	O
Heterochromatin	B-GO
Organization	O
in	O
Pluripotent	O
Embryonic	O
Cells	B-CL

Abstract	O

During	O
mammalian	B-Taxon
development	O
,	O
chromatin	B-GO
dynamics	O
and	O
epigenetic	O
marking	O
are	O
important	O
for	O
genome	B-SO
reprogramming	O
.	O

Recent	O
data	O
suggest	O
an	O
important	O
role	O
for	O
the	O
chromatin	B-GO
assembly	O
machinery	O
in	O
this	O
process	O
.	O

To	O
analyze	O
the	O
role	O
of	O
chromatin	B-GO
assembly	I-GO
factor	I-GO
1	I-GO
(	O
CAF	B-GO
-	I-GO
1	I-GO
)	O
during	O
pre	O
-	O
implantation	O
development	O
,	O
we	O
generated	O
a	O
mouse	B-Taxon
line	O
carrying	O
a	O
targeted	O
mutation	B-SO
in	O
the	O
gene	B-SO
encoding	O
its	O
large	O
subunit	O
,	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
.	O

Loss	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
in	O
homozygous	O
mutants	B-SO
leads	O
to	O
developmental	O
arrest	O
at	O
the	O
16	O
-	O
cell	B-CL
stage	O
.	O

Absence	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
in	O
these	O
embryos	O
results	O
in	O
severe	O
alterations	O
in	O
the	O
nuclear	B-GO
organization	O
of	O
constitutive	O
heterochromatin	B-GO
.	O

We	O
provide	O
evidence	O
that	O
in	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
,	O
heterochromatin	B-GO
domains	I-GO
are	O
extensively	O
reorganized	O
between	O
the	O
two	O
-	O
cell	B-CL
and	O
blastocyst	O
stages	O
.	O

In	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
mutant	B-SO
16	O
-	O
cell	B-CL
stage	O
embryos	O
,	O
the	O
altered	O
organization	O
of	O
heterochromatin	B-GO
displays	O
similarities	O
to	O
the	O
structure	O
of	O
heterochromatin	B-GO
in	O
two	O
-	O
to	O
four	O
-	O
cell	B-CL
stage	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
,	O
suggesting	O
that	O
CAF	B-GO
-	I-GO
1	I-GO
is	O
required	O
for	O
the	O
maturation	O
of	O
heterochromatin	B-GO
during	O
preimplantation	O
development	O
.	O

In	O
embryonic	O
stem	B-CL
cells	I-CL
,	O
depletion	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
using	O
RNA	B-SO
interference	O
results	O
in	O
the	O
mislocalization	O
,	O
loss	O
of	O
clustering	O
,	O
and	O
decondensation	O
of	O
pericentric	B-GO
heterochromatin	I-GO
domains	I-GO
.	O

Furthermore	O
,	O
loss	O
of	O
CAF	B-GO
-	I-GO
1	I-GO
in	O
these	O
cells	B-CL
results	O
in	O
the	O
alteration	O
of	O
epigenetic	O
histone	B-CHEBI
methylation	O
marks	O
at	O
the	O
level	O
of	O
pericentric	B-GO
heterochromatin	I-GO
.	O

These	O
alterations	O
of	O
heterochromatin	B-GO
are	O
not	O
found	O
in	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
mouse	B-Taxon
embryonic	O
fibroblasts	B-CL
,	O
which	O
are	O
cells	B-CL
that	O
are	O
already	O
lineage	O
committed	O
,	O
suggesting	O
that	O
CAF	B-GO
-	I-GO
1	I-GO
is	O
specifically	O
required	O
for	O
heterochromatin	B-GO
organization	O
in	O
pluripotent	O
embryonic	O
cells	B-CL
.	O

Our	O
findings	O
underline	O
the	O
role	O
of	O
the	O
chromatin	B-GO
assembly	O
machinery	O
in	O
controlling	O
the	O
spatial	O
organization	O
and	O
epigenetic	O
marking	O
of	O
the	O
genome	B-SO
in	O
early	O
embryos	O
and	O
embryonic	O
stem	B-CL
cells	I-CL
.	O

Synopsis	O

Chromatin	B-GO
is	O
the	O
support	O
of	O
our	O
genetic	B-SO
information	O
.	O

It	O
is	O
composed	O
of	O
numerous	O
repeated	O
units	O
called	O
nucleosomes	B-GO
,	O
in	O
which	O
DNA	B-SO
wraps	O
around	O
a	O
core	O
of	O
histone	B-CHEBI
proteins	I-CHEBI
.	O

Modifications	O
in	O
the	O
composition	O
and	O
biochemical	O
properties	O
of	O
nucleosomes	B-GO
play	O
major	O
roles	O
in	O
the	O
regulation	O
of	O
genome	B-SO
function	O
.	O

Such	O
modifications	O
are	O
termed	O
"	O
epigenetic	O
"	O
when	O
they	O
are	O
inherited	O
across	O
cell	B-CL
divisions	O
and	O
confer	O
new	O
information	O
to	O
chromatin	B-GO
,	O
in	O
addition	O
to	O
the	O
genetic	B-SO
information	O
provided	O
by	O
DNA	B-SO
.	O

It	O
is	O
usually	O
believed	O
that	O
during	O
genome	B-SO
replication	O
,	O
the	O
basic	O
chromatin	B-GO
assembly	O
machinery	O
builds	O
up	O
"	O
na	O
i	O
ve	O
"	O
nucleosomes	B-GO
,	O
and	O
,	O
in	O
a	O
subsequent	O
step	O
,	O
nucleosomes	B-GO
are	O
selectively	O
modified	B-SO
by	O
a	O
series	O
of	O
enzymes	B-SO
to	O
acquire	O
epigenetic	O
information	O
.	O

Here	O
,	O
the	O
authors	O
studied	O
the	O
role	O
of	O
a	O
basic	O
chromatin	B-GO
assembly	O
factor	O
(	O
CAF	B-GO
-	I-GO
1	I-GO
)	O
in	O
mouse	B-Taxon
embryonic	O
stem	B-CL
cells	I-CL
and	O
early	O
embryos	O
.	O

Surprisingly	O
,	O
they	O
show	O
that	O
CAF	B-GO
-	I-GO
1	I-GO
confers	O
epigenetic	O
information	O
to	O
specific	O
genomic	B-SO
regions	I-SO
.	O

In	O
addition	O
,	O
this	O
study	O
revealed	O
that	O
CAF	B-GO
-	I-GO
1	I-GO
is	O
required	O
for	O
the	O
proper	O
spatial	O
organization	O
of	O
chromosomes	B-GO
in	I-GO
the	I-GO
nucleus	I-GO
.	O

This	O
new	O
knowledge	O
may	O
contribute	O
to	O
better	O
understanding	O
the	O
role	O
of	O
chromatin	B-GO
in	O
the	O
maintenance	O
of	O
embryonic	O
stem	B-CL
cell	I-CL
identity	O
and	O
plasticity	O
.	O

Introduction	O

During	O
mouse	B-Taxon
pre	O
-	O
implantation	O
development	O
,	O
the	O
genome	B-SO
undergoes	O
a	O
series	O
of	O
major	O
epigenetic	O
changes	O
required	O
for	O
embryonic	O
gene	B-SO
expression	O
,	O
the	O
maintenance	O
of	O
totipotency	O
,	O
and	O
the	O
first	O
differentiation	O
events	O
[	O
1	O
,	O
2	O
]	O
.	O

While	O
many	O
studies	O
have	O
established	O
the	O
importance	O
of	O
DNA	B-SO
methylation	O
in	O
epigenetic	O
reprogramming	O
,	O
recent	O
data	O
point	O
to	O
a	O
crucial	O
role	O
of	O
chromatin	B-GO
in	O
this	O
process	O
[	O
3	O
-	O
5	O
]	O
.	O

Yet	O
we	O
know	O
very	O
little	O
about	O
the	O
role	O
of	O
histone	B-CHEBI
modifying	B-SO
enzymes	B-SO
,	O
chromatin	B-GO
remodeling	O
factors	O
,	O
and	O
histone	B-CHEBI
chaperones	O
during	O
pre	O
-	O
implantation	O
development	O
,	O
or	O
in	O
stem	B-CL
cells	I-CL
derived	O
from	O
early	O
embryos	O
[	O
6	O
]	O
.	O

A	O
subset	O
of	O
identified	O
histone	B-CHEBI
chaperones	O
and	O
chromatin	B-GO
remodeling	I-GO
complexes	I-GO
can	O
collaborate	O
to	O
promote	O
nucleosome	B-GO
assembly	O
in	O
vitro	O
and	O
are	O
therefore	O
in	O
a	O
strategic	O
position	O
to	O
control	O
chromatin	B-GO
assembly	O
and	O
maturation	O
during	O
development	O
[	O
7	O
,	O
8	O
]	O
.	O

Among	O
histone	B-CHEBI
chaperones	O
,	O
chromatin	B-GO
assembly	I-GO
factor	I-GO
1	I-GO
(	O
CAF	B-GO
-	I-GO
1	I-GO
)	O
is	O
a	O
three	O
-	O
subunit	O
(	O
p150	B-GGP
,	O
p60	B-GGP
,	O
and	O
p48	B-GGP
)	O
complex	B-GO
which	O
promotes	O
histone	B-CHEBI
H3	O
and	O
H4	O
deposition	O
onto	O
newly	O
synthesized	O
DNA	B-SO
during	O
replication	O
or	O
DNA	B-SO
repair	O
[	O
9	O
,	O
10	O
]	O
.	O

Specifically	O
,	O
CAF	B-GO
-	I-GO
1	I-GO
deposits	O
the	O
histone	B-CHEBI
H3	O
variant	B-SO
H3	O
.	O
1	O
into	O
chromatin	B-GO
,	O
in	O
a	O
pathway	O
coupled	O
to	O
DNA	B-SO
synthesis	O
,	O
whereas	O
a	O
second	O
histone	B-CHEBI
chaperone	O
,	O
HIRA	B-GGP
,	O
is	O
involved	O
in	O
the	O
deposition	O
of	O
the	O
H3	O
.	O
3	O
variant	B-SO
in	O
a	O
DNA	B-SO
synthesis	O
independent	O
pathway	O
[	O
11	O
,	O
12	O
]	O
.	O

In	O
addition	O
to	O
this	O
specific	O
chromatin	B-GO
assembly	O
activity	O
,	O
CAF	B-GO
-	I-GO
1	I-GO
interacts	O
with	O
several	O
proteins	B-CHEBI
present	O
in	O
heterochromatin	B-GO
,	O
including	O
heterochromatin	B-GO
protein	B-CHEBI
1	O
(	O
HP1	O
)	O
and	O
MBD1	B-GGP
,	O
a	O
methyl	B-CHEBI
-	O
CpG	O
binding	O
domain	B-SO
protein	B-CHEBI
that	O
recruits	O
histone	B-CHEBI
deacetylase	O
and	O
repressive	O
histone	B-CHEBI
methyltransferase	O
activities	O
[	O
13	O
-	O
15	O
]	O
.	O

Furthermore	O
,	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
is	O
required	O
to	O
ensure	O
a	O
replication	O
-	O
specific	O
pool	O
of	O
HP1	O
molecules	B-CHEBI
at	O
replication	B-SO
sites	I-SO
in	O
pericentric	B-GO
heterochromatin	I-GO
during	O
mid	O
-	O
late	O
S	O
phase	O
[	O
16	O
]	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
roles	O
for	O
CAF	B-GO
-	I-GO
1	I-GO
in	O
the	O
formation	O
of	O
heterochromatin	B-GO
and	O
in	O
the	O
heritability	O
of	O
epigenetic	O
traits	O
.	O

While	O
the	O
function	O
of	O
this	O
evolutionary	B-SO
conserved	I-SO
histone	B-CHEBI
chaperone	O
has	O
been	O
studied	O
extensively	O
biochemically	O
,	O
we	O
still	O
lack	O
information	O
concerning	O
its	O
importance	O
during	O
early	O
development	O
in	O
mammals	B-Taxon
and	O
in	O
pluripotent	O
cells	B-CL
such	O
as	O
embryonic	O
stem	B-CL
(	I-CL
ES	I-CL
)	I-CL
cells	I-CL
.	O

Here	O
,	O
we	O
have	O
analyzed	O
the	O
importance	O
of	O
CAF	B-GO
-	I-GO
1	I-GO
during	O
early	O
mouse	B-Taxon
development	O
by	O
genetic	B-SO
ablation	O
and	O
in	O
ES	O
cells	B-CL
by	O
depletion	O
using	O
RNA	B-SO
interference	O
(	O
RNAi	O
)	O
.	O

We	O
show	O
that	O
CAF	B-GO
-	I-GO
1	I-GO
is	O
essential	O
for	O
viability	O
in	O
early	O
mouse	B-Taxon
embryos	O
and	O
ES	O
cells	B-CL
.	O

We	O
provide	O
evidence	O
that	O
CAF	B-GO
-	I-GO
1	I-GO
is	O
required	O
for	O
the	O
spatial	O
organization	O
and	O
epigenetic	O
marking	O
of	O
heterochromatin	B-GO
domains	I-GO
in	O
pluripotent	O
embryonic	O
cells	B-CL
.	O

Results	O

We	O
used	O
gene	B-SO
targeting	O
in	O
ES	O
cells	B-CL
to	O
delete	B-SO
exon	B-SO
3	O
in	O
the	O
Chaf1a	B-GGP
gene	B-SO
,	O
which	O
encodes	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
(	O
Figure	O
1A	O
)	O
.	O

Chaf1a	B-GGP
+	B-SO
/	O
-	O
mice	B-Taxon
were	O
born	O
at	O
a	O
Mendelian	O
frequency	O
,	O
were	O
of	O
normal	O
size	O
and	O
weight	O
,	O
displayed	O
no	O
obvious	O
abnormalities	O
,	O
and	O
were	O
fertile	O
.	O

Crossing	O
heterozygous	O
mice	B-Taxon
failed	O
to	O
generate	O
viable	O
newborn	O
Chaf1a	B-GGP
-	O
/	O
-	O
mice	B-Taxon
.	O

Furthermore	O
,	O
no	O
homozygous	O
Chaf1a	B-GGP
-	O
/	O
-	O
embryos	O
were	O
detected	O
at	O
any	O
of	O
the	O
post	O
-	O
implantation	O
stages	O
.	O

However	O
,	O
we	O
could	O
detect	O
Chaf1a	B-GGP
-	O
/	O
-	O
embryos	O
at	O
embryonic	O
day	O
4	O
(	O
E4	O
)	O
using	O
a	O
PCR	O
strategy	O
(	O
Figure	O
1B	O
)	O
.	O

They	O
represent	O
only	O
10	O
%	O
of	O
E4	O
embryos	O
obtained	O
from	O
Chaf1a	B-GGP
+	B-SO
/	O
-	O
mice	B-Taxon
intercrosses	O
,	O
suggesting	O
that	O
more	O
than	O
half	O
of	O
the	O
homozygous	O
mutant	B-SO
embryos	O
had	O
degenerated	O
before	O
this	O
stage	O
.	O

Moreover	O
,	O
mutant	B-SO
embryos	O
contained	O
only	O
eight	O
to	O
16	O
cells	B-CL
at	O
the	O
E4	O
stage	O
,	O
instead	O
of	O
32	O
cells	B-CL
observed	O
for	O
wild	B-SO
-	I-SO
type	I-SO
or	O
heterozygous	O
blastocysts	O
(	O
Figure	O
1C	O
and	O
1D	O
)	O
.	O

Further	O
analysis	O
by	O
light	O
microscopy	O
using	O
immunofluorescence	O
(	O
IF	O
)	O
allowed	O
us	O
to	O
compare	O
wild	B-SO
-	I-SO
type	I-SO
and	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
embryos	O
.	O

A	O
loss	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
staining	O
could	O
not	O
be	O
detected	O
before	O
the	O
eight	O
-	O
cell	B-CL
stage	O
(	O
unpublished	O
data	O
)	O
suggesting	O
that	O
maternally	O
contributed	O
protein	B-CHEBI
is	O
present	O
in	O
the	O
embryo	O
up	O
to	O
the	O
four	O
-	O
cell	B-CL
stage	O
.	O

Thus	O
,	O
depletion	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
protein	B-CHEBI
from	O
this	O
stage	O
allows	O
a	O
maximum	O
of	O
two	O
additional	O
cell	B-CL
divisions	O
before	O
developmental	O
arrest	O
.	O

Strikingly	O
,	O
we	O
found	O
that	O
the	O
nuclear	B-GO
organization	O
of	O
heterochromatin	B-GO
appeared	O
abnormal	O
in	O
the	O
nuclei	B-GO
of	O
Chaf1a	B-GGP
-	O
/	O
-	O
embryos	O
.	O

Pericentric	B-GO
heterochromatin	I-GO
,	O
the	O
major	O
component	O
of	O
constitutive	O
heterochromatin	B-GO
,	O
can	O
easily	O
be	O
visualized	O
in	O
interphase	O
nuclei	B-GO
by	O
the	O
fluorochrome	O
DAPI	O
and	O
by	O
immunostaining	O
with	O
HP1	B-GGP
alpha	I-GGP
[	O
16	O
,	O
17	O
-	O
19	O
]	O
.	O

In	O
wild	B-SO
-	I-SO
type	I-SO
blastocysts	O
and	O
in	O
mouse	B-Taxon
somatic	O
cells	B-CL
,	O
pericentric	B-GO
heterochromatin	I-GO
domains	I-GO
cluster	O
together	O
and	O
form	O
higher	O
-	O
order	O
chromatin	B-GO
structures	I-GO
called	O
chromocenters	B-GO
[	O
20	O
]	O
,	O
which	O
are	O
visualized	O
as	O
DAPI	O
-	O
dense	O
foci	O
(	O
Figure	O
1C	O
)	O
.	O

These	O
structures	O
were	O
not	O
detected	O
in	O
Chaf1a	B-GGP
-	O
/	O
-	O
embryos	O
(	O
Figure	O
1D	O
)	O
.	O

Since	O
chromatin	B-GO
architecture	O
and	O
higher	O
-	O
order	O
structures	O
are	O
important	O
for	O
genome	B-SO
function	O
[	O
21	O
]	O
,	O
we	O
decided	O
to	O
characterize	O
this	O
phenotype	O
in	O
more	O
detail	O
.	O

For	O
this	O
purpose	O
,	O
we	O
examined	O
the	O
status	O
of	O
heterochromatin	B-GO
organization	O
between	O
the	O
two	O
-	O
cell	B-CL
and	O
blastocyst	O
stages	O
.	O

In	O
two	O
-	O
cell	B-CL
stage	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
,	O
DAPI	O
staining	O
is	O
diffuse	O
and	O
fibrillar	O
,	O
with	O
regions	O
of	O
higher	O
density	O
around	O
the	O
nucleolar	B-GO
precursor	I-GO
bodies	I-GO
(	O
Figure	O
1E	O
)	O
.	O

Heterochromatin	B-GO
domains	I-GO
are	O
progressively	O
assembled	O
into	O
DAPI	O
-	O
dense	O
foci	O
between	O
the	O
four	O
-	O
cell	B-CL
and	O
32	O
-	O
cell	B-CL
blastocyst	O
stages	O
(	O
Figure	O
1F	O
)	O
.	O

Localization	O
of	O
HP1	B-GGP
alpha	I-GGP
confirmed	O
that	O
the	O
structures	O
visualized	O
by	O
DAPI	O
staining	O
correspond	O
to	O
constitutive	O
heterochromatin	B-GO
(	O
Figure	O
1E	O
)	O
.	O

Thus	O
,	O
the	O
nuclear	B-GO
organization	O
of	O
heterochromatin	B-GO
is	O
dramatically	O
modified	O
during	O
pre	O
-	O
implantation	O
development	O
,	O
between	O
the	O
two	O
-	O
cell	B-CL
and	O
blastocyst	O
stages	O
.	O

In	O
Chaf1a	B-GGP
-	O
/	O
-	O
E4	O
embryos	O
,	O
which	O
are	O
arrested	O
between	O
the	O
eight	O
-	O
and	O
16	O
-	O
cell	B-CL
stage	O
,	O
DAPI	O
-	O
dense	O
foci	O
were	O
barely	O
detectable	O
(	O
Figure	O
1D	O
)	O
.	O

Instead	O
,	O
DAPI	O
staining	O
was	O
diffuse	O
within	O
the	O
nucleus	B-GO
,	O
with	O
regions	O
of	O
higher	O
density	O
around	O
the	O
nucleoli	B-GO
and	O
at	O
the	O
periphery	O
of	O
the	O
nuclei	B-GO
(	O
Figure	O
1D	O
)	O
.	O

Localization	O
of	O
HP1	B-GGP
alpha	I-GGP
showed	O
a	O
diffuse	O
pattern	O
similar	O
to	O
the	O
DAPI	O
,	O
with	O
some	O
enrichment	O
at	O
the	O
nuclear	B-GO
periphery	O
,	O
and	O
around	O
the	O
nucleoli	B-GO
(	O
Figure	O
1D	O
)	O
.	O

This	O
abnormal	O
organization	O
of	O
heterochromatin	B-GO
in	O
Chaf1a	B-GGP
-	O
/	O
-	O
embryos	O
is	O
reminiscent	O
of	O
the	O
heterochromatin	B-GO
organization	O
found	O
in	O
two	O
-	O
to	O
four	O
-	O
cell	B-CL
stage	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
(	O
compare	O
Figure	O
1D	O
and	O
1F	O
)	O
.	O

These	O
data	O
evidence	O
a	O
key	O
role	O
for	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
during	O
pre	O
-	O
implantation	O
development	O
,	O
and	O
reveal	O
that	O
this	O
protein	B-CHEBI
is	O
required	O
for	O
the	O
proper	O
3	O
-	O
D	O
organization	O
of	O
heterochromatin	B-GO
within	I-GO
embryonic	I-GO
cell	I-GO
nuclei	I-GO
.	O

Next	O
,	O
we	O
wondered	O
whether	O
a	O
similar	O
requirement	O
for	O
CAF	B-GO
-	I-GO
1	I-GO
could	O
also	O
be	O
observed	O
in	O
ES	O
cells	B-CL
,	O
which	O
are	O
derived	O
from	O
the	O
blastocyst	O
inner	O
cell	B-CL
mass	O
.	O

Given	O
the	O
early	O
developmental	O
arrest	O
observed	O
in	O
Chaf1a	B-GGP
-	O
/	O
-	O
embryos	O
,	O
such	O
cells	B-CL
could	O
not	O
be	O
derived	O
directly	O
from	O
null	O
embryos	O
,	O
and	O
we	O
thus	O
used	O
an	O
RNAi	O
strategy	O
(	O
Figure	O
2A	O
)	O
.	O

p150CAF	B-GGP
-	I-GGP
1	I-GGP
knockdown	O
in	O
ES	O
cells	B-CL
was	O
quantified	O
by	O
Western	O
blot	O
analysis	O
and	O
IF	O
.	O

(	O
Figure	O
S1	O
)	O
.	O

p150CAF	B-GGP
-	I-GGP
1	I-GGP
RNAi	O
-	O
depleted	O
ES	O
cells	B-CL
displayed	O
a	O
phenotype	O
very	O
similar	O
to	O
the	O
cells	B-CL
of	O
Chaf1a	B-GGP
-	O
/	O
-	O
E4	O
mice	B-Taxon
.	O

DAPI	O
-	O
dense	O
foci	O
were	O
lost	O
,	O
and	O
we	O
observed	O
diffuse	O
HP1	B-GGP
alpha	I-GGP
and	O
DAPI	O
staining	O
around	O
the	O
nucleoli	B-GO
and	O
at	O
the	O
periphery	O
of	O
the	O
nucleus	B-GO
(	O
Figure	O
2B	O
)	O
.	O

This	O
result	O
indicates	O
that	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
is	O
essential	O
for	O
nuclear	B-GO
organization	O
of	O
heterochromatin	B-GO
in	O
ES	O
cells	B-CL
in	O
a	O
similar	O
way	O
to	O
early	O
pre	O
-	O
implantation	O
embryos	O
.	O

Surprisingly	O
,	O
we	O
did	O
not	O
observe	O
this	O
severe	O
alteration	O
in	O
heterochromatin	B-GO
organization	O
in	O
primary	O
mouse	B-Taxon
embryonic	O
fibroblasts	B-CL
(	O
MEFs	O
)	O
following	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
depletion	O
by	O
RNAi	O
.	O

p150CAF	B-GGP
-	I-GGP
1	I-GGP
depletion	O
in	O
MEFs	O
resulted	O
in	O
a	O
strong	O
inhibition	O
of	O
cell	B-CL
proliferation	O
(	O
unpublished	O
data	O
)	O
,	O
but	O
did	O
not	O
alter	O
the	O
clustering	O
of	O
heterochromatin	B-GO
domains	I-GO
(	O
Figures	O
2C	O
and	O
S2	O
)	O
.	O

Similarly	O
,	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
depletion	O
in	O
3T3	O
cells	B-CL
did	O
not	O
affect	O
heterochromatin	B-GO
organization	O
[	O
16	O
]	O
.	O

These	O
observations	O
reveal	O
a	O
specific	O
function	O
for	O
CAF	B-GO
-	I-GO
1	I-GO
in	O
the	O
early	O
embryo	O
and	O
ES	O
cells	B-CL
.	O

We	O
also	O
wondered	O
whether	O
loss	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
in	O
ES	O
cells	B-CL
specifically	O
affects	O
the	O
heterochromatin	B-GO
nuclear	B-GO
subcompartment	I-GO
,	O
or	O
whether	O
it	O
might	O
result	O
in	O
a	O
more	O
global	O
loss	O
of	O
nuclear	B-GO
organization	O
and	O
architecture	O
.	O

We	O
used	O
a	O
specific	O
antibody	B-GO
against	O
the	O
promyelocytic	B-GGP
leukemia	I-GGP
(	O
PML	B-GGP
)	O
protein	B-CHEBI
to	O
study	O
the	O
fate	O
of	O
the	O
PML	B-GO
nuclear	I-GO
bodies	I-GO
,	O
which	O
are	O
well	O
-	O
characterized	O
subnuclear	B-GO
structures	I-GO
[	O
22	O
]	O
.	O

We	O
could	O
not	O
detect	O
any	O
significant	O
difference	O
in	O
the	O
distribution	O
and	O
aspect	O
of	O
PML	B-GO
nuclear	I-GO
bodies	I-GO
between	O
control	O
and	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
ES	O
cells	B-CL
(	O
Figure	O
2D	O
)	O
.	O

These	O
data	O
show	O
that	O
nuclear	B-GO
architecture	O
is	O
not	O
globally	O
altered	O
following	O
CAF	B-GO
-	I-GO
1	I-GO
loss	O
-	O
of	O
-	O
function	O
.	O

In	O
addition	O
,	O
Western	O
blot	O
analysis	O
revealed	O
that	O
CAF	B-GO
-	I-GO
1	I-GO
depletion	O
did	O
not	O
result	O
in	O
altered	O
levels	O
of	O
chromatin	B-GO
architectural	O
proteins	B-CHEBI
such	O
as	O
histone	B-CHEBI
H3	O
and	O
HP1	B-GGP
alpha	I-GGP
(	O
Figure	O
S1	O
)	O
.	O

Thus	O
,	O
CAF	B-GO
-	I-GO
1	I-GO
is	O
specifically	O
required	O
in	O
early	O
embryos	O
and	O
in	O
ES	O
cells	B-CL
for	O
the	O
proper	O
organization	O
of	O
the	O
heterochromatin	B-GO
subnuclear	B-GO
compartment	I-GO
.	O

Previous	O
studies	O
performed	O
in	O
mammalian	B-Taxon
cell	B-CL
lines	O
showed	O
that	O
CAF	B-GO
-	I-GO
1	I-GO
activity	O
is	O
required	O
for	O
S	O
phase	O
progression	O
[	O
16	O
,	O
23	O
,	O
24	O
]	O
.	O

We	O
show	O
here	O
that	O
3	O
d	O
after	O
transfection	O
of	O
the	O
RNAi	O
vector	B-SO
,	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
cells	B-CL
(	O
identified	O
by	O
a	O
complete	O
absence	O
of	O
CAF	B-GO
-	I-GO
1	I-GO
IF	O
signal	O
)	O
appear	O
still	O
active	O
for	O
replication	O
,	O
as	O
revealed	O
by	O
incorporation	B-SO
of	O
the	O
thymidine	B-CHEBI
analog	B-CHEBI
bromodeoxyuridine	O
(	O
BrdU	O
)	O
(	O
Figure	O
3A	O
)	O
,	O
the	O
PCNA	B-GGP
(	O
proliferating	B-GGP
cell	I-GGP
nuclear	I-GGP
antigen	I-GGP
)	O
pattern	O
(	O
Figure	O
3B	O
)	O
,	O
and	O
flow	O
cytometry	O
analysis	O
(	O
Figure	O
3C	O
)	O
.	O

Hence	O
,	O
in	O
these	O
cells	B-CL
,	O
DNA	B-SO
replication	O
persists	O
despite	O
the	O
drastic	O
changes	O
in	O
heterochromatin	B-GO
organization	O
.	O

However	O
,	O
24	O
h	O
later	O
,	O
ES	O
cells	B-CL
cease	O
to	O
proliferate	O
and	O
die	O
,	O
revealing	O
that	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
is	O
required	O
for	O
an	O
essential	O
cellular	B-CL
process	O
,	O
as	O
in	O
embryos	O
.	O

Altogether	O
,	O
our	O
data	O
demonstrate	O
that	O
loss	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
function	O
in	O
ES	O
cells	B-CL
and	O
early	O
embryos	O
alters	O
first	O
the	O
organization	O
of	O
heterochromatin	B-GO
in	I-GO
the	I-GO
nucleus	I-GO
and	O
,	O
in	O
a	O
subsequent	O
step	O
,	O
cell	B-CL
cycle	O
and	O
viability	O
.	O

In	O
order	O
to	O
better	O
characterize	O
the	O
defects	O
in	O
heterochromatin	B-GO
organization	O
,	O
we	O
performed	O
two	O
-	O
color	O
DNA	B-SO
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
experiments	O
to	O
reveal	O
the	O
spatial	O
distribution	O
of	O
pericentric	B-GO
and	I-GO
centric	I-GO
chromosomal	I-GO
regions	I-GO
,	O
which	O
in	O
mouse	B-Taxon
are	O
mainly	O
composed	O
of	O
large	O
blocks	O
of	O
major	O
and	O
minor	O
satellite	B-SO
repeats	I-SO
,	O
respectively	O
[	O
20	O
]	O
.	O

Pericentric	B-GO
domains	I-GO
from	I-GO
different	I-GO
chromosomes	I-GO
form	O
clusters	O
,	O
which	O
are	O
revealed	O
by	O
FISH	O
as	O
large	O
spots	O
that	O
coincide	O
with	O
DAPI	O
-	O
dense	O
foci	O
in	O
the	O
interphase	O
nucleus	B-GO
(	O
Figure	O
4A	O
)	O
.	O

At	O
the	O
periphery	O
of	O
each	O
pericentric	B-GO
domain	I-GO
,	O
centric	O
regions	B-SO
form	O
individual	O
entities	O
(	O
Figure	O
4A	O
)	O
.	O

In	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
RNAi	O
-	O
depleted	O
cells	B-CL
,	O
we	O
observed	O
a	O
disruption	O
of	O
pericentric	B-GO
heterochromatin	I-GO
clusters	O
that	O
coincides	O
with	O
the	O
disappearance	O
of	O
DAPI	O
-	O
dense	O
foci	O
(	O
Figure	O
4B	O
)	O
.	O

Individual	O
pericentric	B-GO
domains	I-GO
from	I-GO
single	I-GO
chromosomes	I-GO
are	O
now	O
found	O
either	O
isolated	O
or	O
aggregated	O
in	O
a	O
pattern	O
less	O
dense	O
than	O
the	O
regular	O
clusters	O
observed	O
in	O
control	O
cells	B-CL
(	O
Figure	O
4B	O
)	O
.	O

Such	O
aggregates	O
,	O
which	O
are	O
often	O
found	O
at	O
the	O
nuclear	B-GO
periphery	O
,	O
are	O
also	O
revealed	O
by	O
DAPI	O
staining	O
as	O
a	O
typical	O
signature	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
loss	O
-	O
of	O
-	O
function	O
.	O

Quantification	O
of	O
fluorescence	O
along	O
a	O
line	O
randomly	O
drawn	O
across	O
the	O
nucleus	B-GO
revealed	O
lower	O
fluorescence	O
intensity	O
and	O
a	O
broader	O
distribution	O
of	O
DAPI	O
and	O
major	O
satellite	B-SO
hybridization	O
signals	O
in	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
cells	B-CL
(	O
Figure	O
4C	O
and	O
4D	O
)	O
,	O
indicating	O
decondensation	O
of	O
pericentric	B-GO
heterochromatin	I-GO
domains	I-GO
.	O

In	O
contrast	O
,	O
centric	O
domains	B-SO
showed	O
an	O
intensity	O
and	O
shape	O
similar	O
to	O
control	O
cells	B-CL
,	O
suggesting	O
that	O
they	O
remain	O
unaffected	O
by	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
depletion	O
(	O
Figure	O
4C	O
and	O
4D	O
)	O
.	O

In	O
conclusion	O
,	O
these	O
results	O
show	O
that	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
is	O
required	O
for	O
the	O
proper	O
condensation	O
and	O
clustering	O
of	O
pericentric	B-GO
heterochromatin	I-GO
domains	I-GO
.	O

Given	O
the	O
known	O
role	O
of	O
CAF	B-GO
-	I-GO
1	I-GO
in	O
the	O
deposition	O
of	O
histone	B-CHEBI
H3	O
.	O
1	O
and	O
H4	O
associated	O
with	O
DNA	B-SO
synthesis	O
[	O
11	O
,	O
12	O
]	O
,	O
we	O
wondered	O
whether	O
this	O
defect	O
in	O
higher	O
-	O
order	O
chromatin	B-GO
organization	O
could	O
reflect	O
an	O
aberrant	O
nucleosomal	B-GO
organization	O
.	O

Using	O
DNase	B-GGP
I	I-GGP
and	O
micrococcal	O
nuclease	O
(	O
MNase	O
)	O
assays	O
,	O
we	O
could	O
not	O
observe	O
any	O
significant	O
difference	O
between	O
control	O
and	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
ES	O
cells	B-CL
at	O
the	O
level	O
of	O
bulk	O
genome	B-SO
chromatin	B-GO
or	O
at	O
pericentric	B-GO
repeats	B-SO
(	O
Figure	O
5	O
)	O
.	O

In	O
a	O
second	O
series	O
of	O
experiments	O
,	O
we	O
compared	O
the	O
association	O
of	O
histone	B-CHEBI
H3	O
with	O
chromatin	B-GO
in	I-GO
nuclei	I-GO
isolated	O
from	O
cells	B-CL
transfected	O
with	O
control	O
and	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
RNAi	O
plasmid	B-SO
vectors	I-SO
.	O

Nuclei	B-GO
were	O
incubated	O
in	O
buffers	O
with	O
different	O
salt	B-CHEBI
concentrations	O
ranging	O
from	O
100	O
mM	O
NaCl	B-CHEBI
to	O
1	O
M	O
NaCl	B-CHEBI
.	O

In	O
all	O
conditions	O
,	O
the	O
amount	O
of	O
histone	B-CHEBI
H3	O
remaining	O
associated	O
with	O
chromatin	B-GO
was	O
indistinguishable	O
in	O
control	O
and	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
ES	O
cells	B-CL
(	O
unpublished	O
data	O
)	O
.	O

Therefore	O
,	O
the	O
loss	O
of	O
clustering	O
and	O
decondensation	O
of	O
pericentric	B-GO
heterochromatin	I-GO
are	O
unlikely	O
to	O
be	O
the	O
consequence	O
of	O
severe	O
defects	O
in	O
nucleosomal	B-GO
organization	O
.	O

Our	O
findings	O
showed	O
that	O
the	O
nuclear	B-GO
localization	O
of	O
HP1	B-GGP
alpha	I-GGP
is	O
severely	O
altered	O
in	O
Chaf1a	B-GGP
-	O
/	O
-	O
embryos	O
and	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
ES	O
cells	B-CL
.	O

We	O
therefore	O
examined	O
the	O
status	O
of	O
other	O
epigenetic	O
marks	O
previously	O
shown	O
to	O
characterize	O
pericentric	B-GO
heterochromatin	I-GO
.	O

We	O
first	O
tested	O
DNA	B-SO
CpG	O
methylation	O
[	O
25	O
]	O
at	O
major	O
satellite	B-SO
repeats	I-SO
and	O
found	O
no	O
significant	O
difference	O
between	O
control	O
and	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
cells	B-CL
(	O
Figure	O
6	O
)	O
.	O

As	O
the	O
LTM7	O
ES	O
cell	B-CL
line	O
that	O
we	O
used	O
in	O
our	O
RNAi	O
experiments	O
is	O
a	O
female	O
(	O
XX	O
)	O
cell	B-CL
line	O
,	O
DNA	B-SO
methylation	O
is	O
globally	O
reduced	O
in	O
these	O
cells	B-CL
[	O
26	O
]	O
.	O

To	O
rule	O
out	O
the	O
possibility	O
that	O
hypomethylation	O
of	O
pericentric	B-GO
repeats	B-SO
might	O
contribute	O
to	O
the	O
destabilization	O
of	O
heterochromatin	B-GO
domains	I-GO
in	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
ES	O
cells	B-CL
,	O
we	O
tested	O
our	O
RNAi	O
plasmid	B-SO
vector	I-SO
in	O
a	O
XY	O
ES	O
cell	B-CL
line	O
,	O
and	O
confirmed	O
that	O
loss	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
leads	O
to	O
disruption	O
of	O
heterochromatin	B-GO
organization	O
independently	O
of	O
the	O
degree	O
of	O
DNA	B-SO
methylation	O
at	O
pericentric	B-GO
repeats	B-SO
(	O
unpublished	O
data	O
)	O
.	O

We	O
next	O
analyzed	O
specific	O
histone	B-CHEBI
modifications	B-SO
[	O
27	O
]	O
in	O
chromatin	B-GO
immunoprecipitation	O
(	O
ChIP	O
)	O
experiments	O
using	O
native	O
chromatin	B-GO
[	O
28	O
]	O
.	O

We	O
found	O
that	O
pericentric	B-GO
DNA	I-GO
was	O
immunoprecipitated	O
with	O
a	O
2	O
-	O
fold	O
lower	O
efficiency	O
with	O
H4K20me3	O
[	O
29	O
,	O
30	O
]	O
antibodies	B-GO
following	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
depletion	O
(	O
Figure	O
7A	O
and	O
7B	O
)	O
.	O

Immunoprecipitation	O
of	O
minor	O
satellite	B-SO
repeats	I-SO
in	O
the	O
same	O
experiment	O
was	O
less	O
affected	O
(	O
Figure	O
7B	O
)	O
,	O
showing	O
that	O
loss	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
function	O
mainly	O
affects	O
H4K20me3	O
at	O
pericentric	B-GO
heterochromatin	I-GO
.	O

Moreover	O
,	O
no	O
significant	O
difference	O
in	O
immunoprecipitation	O
efficiency	O
was	O
detected	O
at	O
intracisternal	O
A	O
particle	O
(	O
IAP	O
)	O
elements	B-SO
(	O
Figure	O
7B	O
)	O
,	O
which	O
are	O
noncentromeric	O
repeated	B-SO
DNA	I-SO
elements	I-SO
also	O
enriched	O
in	O
H4K20me3	O
[	O
31	O
]	O
.	O

This	O
result	O
shows	O
that	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
contributes	O
to	O
normal	O
levels	O
of	O
H4K20me3	O
at	O
pericentric	B-GO
heterochromatin	I-GO
,	O
but	O
not	O
necessarily	O
at	O
other	O
loci	B-SO
.	O

The	O
H3K9me3	O
mark	O
[	O
32	O
]	O
was	O
also	O
significantly	O
reduced	O
in	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
cells	B-CL
,	O
though	O
to	O
a	O
lesser	O
extent	O
than	O
H4K20me3	O
(	O
Figure	O
7A	O
and	O
7B	O
)	O
.	O

In	O
wild	B-SO
-	I-SO
type	I-SO
cells	B-CL
,	O
most	O
of	O
H4K20me3	O
and	O
H3K9me3	O
signals	O
are	O
present	O
at	O
the	O
level	O
of	O
DAPI	O
-	O
dense	O
domains	O
when	O
visualized	O
by	O
IF	O
[	O
29	O
]	O
(	O
Figures	O
7C	O
and	O
7D	O
)	O
.	O

H3K9me3	O
was	O
severely	O
perturbed	O
in	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
cells	B-CL
,	O
displaying	O
a	O
diffuse	O
pattern	O
similar	O
to	O
HP1	B-GGP
alpha	I-GGP
(	O
Figure	O
7C	O
)	O
.	O

The	O
H4K20me3	O
pattern	O
was	O
even	O
more	O
severely	O
altered	O
,	O
showing	O
both	O
a	O
loss	O
of	O
the	O
typical	O
dots	O
revealed	O
in	O
control	O
cells	B-CL
and	O
a	O
reduction	O
in	O
signal	O
intensity	O
(	O
Figure	O
7D	O
)	O
.	O

Consistent	O
with	O
our	O
ChIP	O
experiments	O
,	O
residual	O
H4K20me3	O
epitopes	B-SO
were	O
detected	O
at	O
the	O
level	O
of	O
relocated	O
DAPI	O
-	O
dense	O
material	O
.	O

Altogether	O
,	O
our	O
results	O
show	O
that	O
depletion	O
of	O
CAF	B-GO
-	I-GO
1	I-GO
in	O
ES	O
cells	B-CL
leads	O
to	O
a	O
simultaneous	O
disruption	O
of	O
heterochromatin	B-GO
3	O
-	O
D	O
organization	O
and	O
an	O
alteration	O
in	O
epigenetic	O
marking	O
.	O

Discussion	O

Here	O
,	O
we	O
provide	O
evidence	O
that	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
has	O
a	O
crucial	O
function	O
during	O
mouse	B-Taxon
early	O
embryogenesis	O
and	O
in	O
ES	O
cells	B-CL
.	O

Previous	O
studies	O
showed	O
that	O
CAF	B-GO
-	I-GO
1	I-GO
is	O
essential	O
for	O
the	O
progression	O
of	O
DNA	B-SO
replication	O
in	O
vertebrates	B-Taxon
.	O

In	O
Xenopus	B-Taxon
laevis	I-Taxon
,	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
function	O
is	O
required	O
for	O
the	O
rapid	O
cell	B-CL
divisions	O
that	O
occur	O
during	O
early	O
development	O
[	O
33	O
]	O
.	O

Similarly	O
,	O
CAF	B-GO
-	I-GO
1	I-GO
is	O
essential	O
in	O
mammalian	B-Taxon
cell	B-CL
lines	O
for	O
the	O
progression	O
of	O
DNA	B-SO
replication	O
[	O
16	O
,	O
23	O
,	O
24	O
,	O
34	O
]	O
.	O

Our	O
findings	O
reveal	O
a	O
role	O
for	O
CAF	B-GO
-	I-GO
1	I-GO
in	O
the	O
nuclear	B-GO
organization	O
of	O
heterochromatin	B-GO
domains	I-GO
during	O
early	O
development	O
and	O
in	O
ES	O
cells	B-CL
.	O

We	O
show	O
that	O
in	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
ES	O
cells	B-CL
,	O
while	O
DNA	B-SO
replication	O
initially	O
persists	O
without	O
significant	O
perturbation	O
in	O
nucleosomal	B-GO
organization	O
,	O
severe	O
heterochromatin	B-GO
organization	O
defects	O
can	O
be	O
observed	O
.	O

Loss	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
did	O
not	O
affect	O
PML	B-GO
bodies	I-GO
in	O
ES	O
cell	B-CL
nuclei	B-GO
,	O
showing	O
that	O
nuclear	B-GO
architecture	O
is	O
not	O
generally	O
altered	O
.	O

Ultimately	O
,	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
depletion	O
results	O
in	O
the	O
arrest	O
of	O
ES	O
cell	B-CL
division	O
and	O
cell	B-CL
death	O
.	O

Given	O
the	O
major	O
defects	O
observed	O
in	O
heterochromatin	B-GO
organization	O
,	O
it	O
is	O
tempting	O
to	O
speculate	O
that	O
these	O
defects	O
cause	O
the	O
developmental	O
arrest	O
in	O
the	O
embryos	O
and	O
death	O
in	O
ES	O
cells	B-CL
.	O

The	O
role	O
of	O
CAF	B-GO
-	I-GO
1	I-GO
in	O
the	O
nuclear	B-GO
organization	O
of	O
heterochromatin	B-GO
includes	O
spatial	O
localization	O
,	O
condensation	O
,	O
and	O
clustering	O
of	O
pericentric	B-GO
domains	I-GO
.	O

This	O
important	O
function	O
of	O
CAF	B-GO
-	I-GO
1	I-GO
was	O
not	O
revealed	O
in	O
primary	O
MEFs	O
,	O
3T3	O
cells	B-CL
,	O
or	O
human	B-Taxon
cell	B-CL
lines	O
,	O
suggesting	O
that	O
it	O
is	O
specific	O
of	O
pluripotent	O
embryonic	O
cells	B-CL
.	O

Alternatively	O
,	O
early	O
embryos	O
and	O
ES	O
cells	B-CL
,	O
whose	O
genome	B-SO
is	O
more	O
plastic	O
than	O
somatic	O
cells	B-CL
,	O
might	O
represent	O
a	O
particularly	O
sensitive	O
context	O
in	O
which	O
the	O
importance	O
of	O
CAF	B-GO
-	I-GO
1	I-GO
in	O
heterochromatin	B-GO
organization	O
is	O
exacerbated	O
.	O

In	O
ES	O
cells	B-CL
,	O
major	O
architectural	O
chromatin	B-GO
proteins	B-CHEBI
are	O
hyperdynamic	O
and	O
bind	O
relatively	O
loosely	O
to	O
chromatin	B-GO
[	O
35	O
]	O
.	O

In	O
this	O
cellular	B-CL
context	O
,	O
our	O
findings	O
show	O
that	O
proper	O
heterochromatin	B-GO
nuclear	B-GO
architecture	O
relies	O
on	O
CAF	B-GO
-	I-GO
1	I-GO
function	O
.	O

In	O
contrast	O
,	O
in	O
undifferentiated	O
cells	B-CL
that	O
are	O
already	O
lineage	O
committed	O
(	O
such	O
as	O
MEFs	O
)	O
genome	B-SO
architecture	O
might	O
be	O
more	O
stable	O
than	O
in	O
ES	O
cells	B-CL
and	O
thus	O
cannot	O
be	O
disrupted	O
by	O
CAF	B-GO
-	I-GO
1	I-GO
depletion	O
.	O

This	O
important	O
function	O
of	O
CAF	B-GO
-	I-GO
1	I-GO
in	O
pluripotent	O
embryonic	O
cells	B-CL
could	O
be	O
partially	O
conserved	B-SO
during	O
evolution	O
.	O

Indeed	O
,	O
in	O
Arabidopsis	B-Taxon
thaliana	I-Taxon
,	O
in	O
which	O
CAF	B-GO
-	I-GO
1	I-GO
is	O
not	O
essential	O
for	O
viability	O
[	O
36	O
]	O
,	O
loss	O
of	O
CAF	B-GO
-	I-GO
1	I-GO
is	O
associated	O
with	O
a	O
mild	O
alteration	O
in	O
chromocenter	B-GO
size	O
[	O
37	O
]	O
.	O

This	O
phenotype	O
is	O
somehow	O
reminiscent	O
of	O
loss	O
of	O
CAF	B-GO
-	I-GO
1	I-GO
-	O
mediated	O
defects	O
in	O
heterochromatin	B-GO
organization	O
in	O
early	O
mouse	B-Taxon
embryos	O
.	O

In	O
mouse	B-Taxon
ES	O
cells	B-CL
,	O
we	O
show	O
that	O
CAF	B-GO
-	I-GO
1	I-GO
is	O
also	O
required	O
for	O
regular	O
levels	O
of	O
H4K20me3	O
at	O
pericentric	B-GO
repeats	B-SO
,	O
but	O
not	O
at	O
IAP	O
elements	B-SO
,	O
which	O
are	O
repeated	B-SO
sequences	I-SO
spread	O
all	O
over	O
the	O
mouse	B-Taxon
genome	B-SO
.	O

These	O
data	O
suggest	O
that	O
proper	O
nuclear	B-GO
organization	O
and	O
epigenetic	O
marking	O
of	O
pericentric	B-GO
heterochromatin	I-GO
are	O
coupled	O
in	O
ES	O
cells	B-CL
.	O

Alternatively	O
,	O
3	O
-	O
D	O
organization	O
of	O
heterochromatin	B-GO
and	O
epigenetic	O
marking	O
might	O
represent	O
two	O
independent	O
functions	O
of	O
CAF	B-GO
-	I-GO
1	I-GO
.	O

The	O
variable	O
requirement	O
for	O
CAF	B-GO
-	I-GO
1	I-GO
across	O
species	O
might	O
reflect	O
the	O
acquisition	O
of	O
new	O
properties	O
affecting	O
the	O
function	O
of	O
histone	B-CHEBI
H3	O
variants	B-SO
during	O
evolution	O
of	O
eukaryotes	B-Taxon
.	O

CAF	B-GO
-	I-GO
1	I-GO
is	O
essential	O
in	O
mammals	B-Taxon
but	O
dispensable	O
in	O
Saccharomyces	B-Taxon
cerevisiae	I-Taxon
[	O
38	O
]	O
.	O

Interestingly	O
,	O
the	O
budding	B-Taxon
yeast	I-Taxon
genome	B-SO
does	O
not	O
contain	O
heterochromatin	B-GO
regions	I-GO
equivalent	O
to	O
those	O
of	O
higher	O
eukaryotes	B-Taxon
,	O
and	O
several	O
hallmark	O
features	B-SO
of	O
heterochromatin	B-GO
such	O
as	O
di	O
-	O
and	O
trimethylation	O
at	O
H3K9	O
,	O
H3K27	O
,	O
and	O
H4K20	O
are	O
not	O
observed	O
in	O
the	O
silent	O
chromatin	B-GO
of	O
S	B-Taxon
.	I-Taxon
cerevisiae	I-Taxon
.	O

In	O
mammals	B-Taxon
,	O
H3K9	O
dimethylation	O
is	O
predominantly	O
associated	O
with	O
H3	O
.	O
1	O
,	O
but	O
not	O
with	O
H3	O
.	O
3	O
,	O
which	O
carries	O
modifications	B-SO
typically	O
found	O
in	O
transcribed	O
chromatin	B-GO
regions	I-GO
[	O
39	O
]	O
.	O

Outside	O
of	O
the	O
centromeric	O
H3	O
variant	B-SO
,	O
S	B-Taxon
.	I-Taxon
cerevisiae	I-Taxon
possesses	O
only	O
H3	O
.	O
3	O
,	O
which	O
is	O
expressed	O
and	O
incorporated	O
into	O
chromatin	B-GO
in	O
a	O
replication	O
-	O
independent	O
fashion	O
in	O
higher	O
eukaryotes	B-Taxon
[	O
12	O
]	O
.	O

These	O
data	O
suggest	O
a	O
specific	O
role	O
for	O
H3	O
.	O
1	O
in	O
heterochromatin	B-GO
regions	I-GO
.	O

We	O
show	O
here	O
that	O
CAF	B-GO
-	I-GO
1	I-GO
,	O
which	O
is	O
a	O
H3	O
.	O
1	O
replication	O
-	O
dependent	O
loading	O
complex	B-GO
[	O
11	O
]	O
,	O
is	O
specifically	O
required	O
for	O
the	O
nuclear	B-GO
organization	O
of	O
pericentric	B-GO
heterochromatin	I-GO
in	O
embryos	O
and	O
ES	O
cells	B-CL
.	O

One	O
possibility	O
would	O
be	O
a	O
scenario	O
in	O
which	O
incorporation	O
of	O
H3	O
.	O
1	O
into	O
chromatin	B-GO
is	O
required	O
for	O
the	O
proper	O
nuclear	B-GO
organization	O
of	O
constitutive	O
heterochromatin	B-GO
in	O
an	O
embryonic	O
context	O
.	O

While	O
this	O
has	O
to	O
be	O
addressed	O
experimentally	O
,	O
it	O
is	O
worthwhile	O
to	O
mention	O
an	O
alternate	O
possible	O
mechanism	O
that	O
might	O
explain	O
the	O
disruption	O
of	O
heterochromatin	B-GO
domains	I-GO
in	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
null	O
embryos	O
and	O
ES	O
cells	B-CL
.	O

CAF	B-GO
-	I-GO
1	I-GO
could	O
be	O
required	O
for	O
the	O
loading	O
,	O
into	O
heterochromatin	B-GO
,	O
of	O
an	O
interacting	O
partner	O
required	O
for	O
the	O
clustering	O
of	O
pericentric	B-GO
domains	I-GO
.	O

Following	O
one	O
or	O
two	O
rounds	O
of	O
DNA	B-SO
replication	O
in	O
the	O
absence	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
,	O
heterochromatin	B-GO
would	O
become	O
deprived	O
of	O
this	O
molecule	B-CHEBI
,	O
which	O
would	O
cause	O
the	O
disruption	O
of	O
its	O
3	O
-	O
D	O
organization	O
.	O

A	O
potential	O
candidate	O
is	O
the	O
HP1	B-GGP
protein	B-CHEBI
,	O
which	O
interacts	O
with	O
CAF	B-GO
-	I-GO
1	I-GO
[	O
13	O
,	O
16	O
]	O
.	O

In	O
agreement	O
with	O
a	O
recent	O
report	O
[	O
40	O
]	O
,	O
our	O
analysis	O
of	O
heterochromatin	B-GO
in	O
pre	O
-	O
implantation	O
embryos	O
has	O
revealed	O
drastic	O
changes	O
in	O
nuclear	B-GO
organization	O
between	O
the	O
two	O
-	O
cell	B-CL
and	O
blastocyst	O
stages	O
.	O

Cloning	O
experiments	O
in	O
mouse	B-Taxon
revealed	O
that	O
the	O
nuclear	B-GO
organization	O
of	O
heterochromatin	B-GO
in	I-GO
ES	I-GO
cell	I-GO
nuclei	I-GO
was	O
quickly	O
reverted	O
into	O
the	O
one	O
-	O
cell	B-CL
stage	O
-	O
specific	O
form	O
after	O
nuclear	B-GO
transfer	O
[	O
40	O
]	O
.	O

Hence	O
,	O
remodeling	O
of	O
heterochromatin	B-GO
3	O
-	O
D	O
organization	O
parallels	O
nuclear	B-GO
reprogramming	O
toward	O
an	O
early	O
embryonic	O
status	O
in	O
cloned	O
embryos	O
.	O

This	O
drastic	O
reorganization	O
of	O
heterochromatin	B-GO
organization	O
is	O
similar	O
to	O
that	O
observed	O
in	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
ES	O
cells	B-CL
,	O
and	O
in	O
developmentally	O
arrested	O
16	O
-	O
cell	B-CL
stage	O
Chaf1a	B-GGP
-	O
/	O
-	O
embryos	O
.	O

These	O
data	O
show	O
that	O
CAF	B-GO
-	I-GO
1	I-GO
is	O
involved	O
in	O
setting	O
up	O
proper	O
heterochromatin	B-GO
architecture	O
during	O
the	O
first	O
cell	B-CL
divisions	O
of	O
embryonic	O
life	O
.	O

Given	O
the	O
importance	O
of	O
nuclear	B-GO
organization	O
in	O
the	O
control	O
of	O
gene	B-SO
expression	O
[	O
21	O
,	O
41	O
]	O
,	O
this	O
finding	O
suggests	O
that	O
CAF	B-GO
-	I-GO
1	I-GO
contributes	O
to	O
the	O
coordinated	O
programs	O
of	O
gene	B-SO
expression	O
during	O
early	O
embryogenesis	O
.	O

Our	O
findings	O
open	O
new	O
perspectives	O
in	O
the	O
understanding	O
of	O
chromatin	B-GO
dynamics	O
during	O
early	O
development	O
and	O
in	O
pluripotent	O
embryonic	O
cells	B-CL
.	O

While	O
most	O
studies	O
focused	O
on	O
the	O
role	O
of	O
DNA	B-SO
methylation	O
and	O
histone	B-CHEBI
modifying	B-SO
enzymes	B-SO
[	O
3	O
]	O
,	O
our	O
data	O
point	O
to	O
the	O
importance	O
of	O
the	O
chromatin	B-GO
assembly	O
machinery	O
.	O

We	O
show	O
that	O
in	O
addition	O
to	O
assembling	O
nucleosomes	B-GO
,	O
CAF	B-GO
-	I-GO
1	I-GO
provides	O
spatial	O
and	O
epigenetic	O
information	O
to	O
heterochromatin	B-GO
domains	I-GO
in	O
early	O
embryos	O
and	O
ES	O
cells	B-CL
.	O

Materials	O
and	O
Methods	O

Generation	O
of	O
Chaf1a	B-GGP
mutant	B-SO
mice	B-Taxon
and	O
embryos	O
.	O

Using	O
PCR	O
,	O
we	O
amplified	O
two	O
genomic	B-SO
fragments	B-SO
(	O
about	O
3	O
kb	O
each	O
)	O
flanking	O
Chaf1a	B-GGP
exon	B-SO
3	O
.	O

These	O
DNA	B-SO
fragments	B-SO
were	O
assembled	O
by	O
conventional	O
cloning	O
with	O
the	O
neomycin	O
and	O
DT	B-GGP
(	O
diphtheria	B-GGP
toxin	I-GGP
)	O
cassettes	B-SO
,	O
as	O
described	O
in	O
Figure	O
1A	O
.	O

The	O
construct	B-SO
was	O
transfected	O
in	O
ES	O
cells	B-CL
by	O
electroporation	O
.	O

We	O
identified	O
recombinant	O
ES	O
cells	B-CL
carrying	O
the	O
mutant	B-SO
Chaf1atm1Ger	O
(	O
abbreviated	O
Chaf1a	B-GGP
-	O
in	O
the	O
manuscript	O
)	O
allele	B-SO
by	O
Southern	O
blot	O
(	O
Figure	O
1A	O
)	O
.	O

We	O
derived	O
Chaf1a	B-GGP
+	B-SO
/	O
-	O
mice	B-Taxon
by	O
injecting	O
recombined	O
ES	O
cells	B-CL
into	O
C57BL	O
/	O
6N	O
blastocysts	O
.	O

E4	O
embryos	O
obtained	O
from	O
the	O
intercross	O
of	O
Chaf1a	B-GGP
+	B-SO
/	O
-	O
mice	B-Taxon
were	O
genotyped	O
by	O
nested	O
-	O
PCR	O
amplification	O
.	O

Embryos	O
were	O
collected	O
in	O
a	O
PCR	O
reaction	O
mix	O
containing	O
oligonucleotide	B-SO
primers	B-SO
1	O
,	O
2	O
,	O
and	O
3	O
(	O
Figure	O
1A	O
)	O
that	O
amplify	O
the	O
wild	B-SO
-	I-SO
type	I-SO
and	O
mutant	B-SO
alleles	B-SO
.	O

After	O
30	O
cycles	O
of	O
amplification	O
,	O
1	O
mu	O
l	O
of	O
each	O
PCR	O
reaction	O
was	O
used	O
in	O
a	O
second	O
round	O
of	O
PCR	O
amplification	O
with	O
a	O
new	O
set	O
of	O
oligonucleotide	B-SO
primers	B-SO
.	O

After	O
30	O
cycles	O
of	O
amplification	O
,	O
PCR	O
reactions	O
were	O
run	O
onto	O
an	O
agarose	B-CHEBI
gel	O
,	O
which	O
revealed	O
the	O
presence	O
of	O
the	O
wild	B-SO
-	I-SO
type	I-SO
(	O
150	O
bp	B-SO
)	O
and	O
recombinant	O
(	O
200	O
bp	B-SO
)	O
alleles	B-SO
.	O

P150CAF	B-GGP
-	I-GGP
1	I-GGP
depletion	O
by	O
RNAi	O
.	O

The	O
RNAi	O
plasmid	B-SO
vector	I-SO
that	O
we	O
used	O
in	O
this	O
study	O
contains	O
the	O
mouse	B-Taxon
H1	O
promoter	B-SO
and	O
a	O
puromycin	B-CHEBI
selection	O
gene	B-SO
(	O
SB	O
and	O
MG	O
,	O
unpublished	O
data	O
)	O
.	O

We	O
characterized	O
in	O
detail	O
the	O
properties	O
of	O
this	O
new	O
vector	B-SO
using	O
a	O
GFP	O
target	O
gene	B-SO
and	O
FACS	O
:	O
Extinction	O
of	O
target	O
genes	B-SO
in	O
ES	O
cells	B-CL
is	O
highly	O
efficient	O
in	O
70	O
%	O
of	O
the	O
cells	B-CL
,	O
of	O
intermediate	O
efficiency	O
in	O
15	O
%	O
,	O
and	O
inefficient	O
in	O
the	O
remaining	O
15	O
%	O
of	O
cells	B-CL
analysis	O
.	O

The	O
sequence	B-SO
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
siRNA	B-SO
(	O
short	B-SO
interfering	I-SO
RNA	I-SO
)	O
duplex	O
[	O
16	O
]	O
was	O
cloned	O
into	O
this	O
plasmid	B-SO
.	O

The	O
control	O
vector	B-SO
expressed	O
a	O
siRNA	B-SO
that	O
targets	O
GFP	O
RNA	B-SO
degradation	O
.	O

ES	O
cells	B-CL
were	O
transfected	O
by	O
electroporation	O
with	O
the	O
RNA	B-SO
plasmid	B-SO
vector	I-SO
,	O
seeded	O
onto	O
gelatin	O
-	O
coated	O
slides	O
,	O
and	O
cultured	O
for	O
24	O
h	O
in	O
the	O
absence	O
of	O
selection	O
.	O

Puromycin	B-CHEBI
(	O
2	O
mu	O
g	O
/	O
ml	O
)	O
was	O
added	O
to	O
the	O
culture	O
medium	O
and	O
cells	B-CL
were	O
cultured	O
for	O
an	O
additional	O
48	O
-	O
h	O
period	O
.	O

Using	O
the	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
RNAi	O
vector	B-SO
,	O
IF	O
microscopy	O
quantification	O
reveals	O
a	O
complete	O
CAF	B-GO
-	I-GO
1	I-GO
depletion	O
in	O
most	O
cells	B-CL
(	O
Figure	O
S1B	O
)	O
.	O

Western	O
blot	O
analysis	O
(	O
Figure	O
S1A	O
)	O
reveals	O
residual	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
expression	O
,	O
as	O
expected	O
from	O
the	O
15	O
%	O
of	O
cells	B-CL
that	O
do	O
not	O
inhibit	O
the	O
target	O
gene	B-SO
.	O

MEFs	O
(	O
passage	O
3	O
,	O
90	O
%	O
confluence	O
)	O
were	O
transfected	O
during	O
4	O
h	O
with	O
the	O
RNAi	O
plasmid	B-SO
vector	I-SO
using	O
Lipofectamine	O
2000	O
(	O
Invitrogene	O
,	O
Carlsbad	O
,	O
California	O
,	O
United	O
States	O
)	O
according	O
to	O
manufacturer	O
'	O
s	O
conditions	O
.	O

Cells	B-CL
were	O
trypsinized	O
,	O
plated	O
at	O
1	O
/	O
3	O
dilution	O
,	O
and	O
cultured	O
for	O
48	O
h	O
in	O
the	O
presence	O
of	O
puromycin	B-CHEBI
.	O

Cell	B-CL
lines	O
.	O

AT	O
-	O
1	O
ES	O
cells	B-CL
[	O
42	O
]	O
(	O
a	O
gift	O
of	O
M	O
.	O
Vernet	O
)	O
were	O
used	O
for	O
gene	B-SO
targeting	O
.	O

LTM7	O
ES	O
cells	B-CL
were	O
used	O
in	O
all	O
RNAi	O
experiments	O
.	O

We	O
derived	O
this	O
cell	B-CL
line	O
from	O
(	O
C57BL	O
/	O
6	O
x	O
129	O
)	O
F1	O
females	O
bred	O
with	O
C3H	O
/	O
HeJ	O
males	O
.	O

LTM7	O
are	O
XX	O
ES	O
cells	B-CL
,	O
competent	O
for	O
germ	O
line	O
transmission	O
.	O

Primary	O
MEFs	O
were	O
derived	O
from	O
E13	O
embryos	O
as	O
described	O
in	O
[	O
43	O
]	O
.	O

Immunofluorescence	O
.	O

Cells	B-CL
were	O
fixed	O
for	O
20	O
min	O
in	O
PBS	O
with	O
4	O
%	O
paraformaldehyde	O
,	O
and	O
immunodetection	O
was	O
performed	O
as	O
previously	O
described	O
[	O
44	O
]	O
.	O

E4	O
embryos	O
were	O
collected	O
and	O
treated	O
with	O
tyrode	O
acid	B-CHEBI
to	O
remove	O
the	O
zona	O
pellucida	O
,	O
deposited	O
onto	O
microscope	O
slides	O
,	O
and	O
processed	O
for	O
immunostaining	O
as	O
described	O
for	O
ES	O
cells	B-CL
.	O

Antibodies	B-GO
anti	O
-	O
HP1	B-GGP
alpha	I-GGP
(	O
2HP1H5	O
,	O
Euromedex	O
,	O
France	O
)	O
,	O
anti	O
-	O
H4K20me3	O
(	O
Abcam	O
,	O
Cambridge	O
,	O
United	O
Kingdom	O
)	O
,	O
anti	O
-	O
BrdU	O
(	O
DakoCytomation	O
,	O
Glostrup	O
,	O
Denmark	O
)	O
,	O
anti	O
-	O
PCNA	B-GGP
(	O
DakoCytomation	O
)	O
,	O
and	O
anti	O
-	O
PML	B-GGP
(	O
Upstate	O
Biotechnology	O
,	O
Lake	O
Placid	O
,	O
New	O
York	O
,	O
United	O
States	O
)	O
were	O
all	O
used	O
at	O
1	O
/	O
1000	O
dilution	O
.	O

Antibodies	B-GO
anti	O
-	O
mouse	B-GGP
p150CAF1	I-GGP
[	O
16	O
]	O
and	O
anti	O
-	O
H3K9me3	O
(	O
Upstate	O
Biotechnology	O
)	O
were	O
used	O
at	O
1	O
/	O
250	O
and	O
1	O
/	O
500	O
,	O
respectively	O
.	O

All	O
secondary	O
antibodies	B-GO
were	O
purchased	O
from	O
Molecular	B-CHEBI
Probes	O
(	O
Sunnyvale	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

Western	O
blot	O
analysis	O
.	O

Cells	B-CL
were	O
lysed	O
in	O
Laemli	O
buffer	O
and	O
run	O
onto	O
a	O
4	O
%	O
-	O
12	O
%	O
SDS	B-CHEBI
PAGE	O
gradient	O
gel	O
.	O

We	O
used	O
antibodies	B-GO
against	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
(	O
[	O
16	O
]	O
;	O
dilution	O
1	O
/	O
500	O
)	O
,	O
HP1	B-GGP
alpha	I-GGP
(	O
2G9	O
,	O
Euromedex	O
;	O
1	O
/	O
500	O
)	O
,	O
Histone	B-CHEBI
H3	O
(	O
Abcam	O
;	O
1	O
/	O
500	O
)	O
,	O
H3K9me3	O
(	O
Upstate	O
;	O
1	O
/	O
500	O
)	O
and	O
beta	B-GGP
-	I-GGP
actin	I-GGP
(	O
Upstate	O
;	O
1	O
/	O
40	O
000	O
)	O
.	O

DNA	B-SO
FISH	O
.	O

Probes	B-SO
were	O
described	O
previously	O
[	O
20	O
]	O
.	O

Biotin	B-CHEBI
-	O
16	O
-	O
dUTP	B-CHEBI
or	O
Digoxigenin	B-CHEBI
-	O
11	O
-	O
dUTP	B-CHEBI
(	O
Roche	O
,	O
Basel	O
,	O
Switzerland	O
)	O
labeled	O
probes	B-SO
were	O
generated	O
by	O
nick	O
translation	O
(	O
Roche	O
)	O
and	O
FISH	O
performed	O
as	O
described	O
[	O
20	O
]	O
.	O

Image	O
acquisition	O
was	O
performed	O
with	O
the	O
Deltavision	O
RT	O
microscope	O
(	O
100	O
x	O
,	O
1	O
.	O
4	O
NA	O
objective	O
)	O
,	O
images	O
were	O
deconvoluted	O
,	O
and	O
fluorescence	O
profiles	O
measured	O
along	O
an	O
arbitrary	O
line	O
using	O
SoftWorx	O
.	O

Nuclei	B-GO
preparation	O
,	O
nuclease	O
digestion	O
,	O
and	O
biochemical	O
analysis	O
of	O
chromatin	B-GO
.	O

ES	O
cells	B-CL
were	O
incubated	O
on	O
ice	O
for	O
10	O
min	O
in	O
buffer	O
1	O
(	O
15	O
mM	O
Tris	B-CHEBI
-	O
HCl	B-CHEBI
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
0	O
.	O
3	O
M	O
sucrose	B-CHEBI
,	O
60	O
mM	O
KCl	B-CHEBI
,	O
15	O
mM	O
NaCl	B-CHEBI
,	O
5	O
mM	O
MgCl2	B-CHEBI
,	O
0	O
.	O
1	O
mM	O
EGTA	B-CHEBI
)	O
with	O
0	O
.	O
15	O
%	O
IGEPAL	O
(	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
Missouri	O
,	O
United	O
States	O
)	O
.	O

Nuclei	B-GO
were	O
purified	O
by	O
centrifugation	O
(	O
10	O
,	O
000	O
x	O
g	O
for	O
30	O
min	O
,	O
at	O
4	O
degrees	O
C	O
)	O
on	O
sucrose	B-CHEBI
cushions	O
(	O
buffer	O
1	O
with	O
1	O
.	O
2	O
M	O
sucrose	O
)	O
and	O
resuspended	O
in	O
nuclease	O
buffer	O
(	O
50	O
mM	O
Tris	B-CHEBI
-	O
HCl	B-CHEBI
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
20	O
mM	O
NaCl	B-CHEBI
,	O
0	O
.	O
32	O
M	O
sucrose	B-CHEBI
,	O
4	O
mM	O
MgCl2	B-CHEBI
,	O
1	O
mM	O
CaCl2	B-CHEBI
)	O
.	O

About	O
2	O
.	O
106	O
nuclei	B-GO
were	O
incubated	O
with	O
increasing	O
quantities	O
of	O
MNase	O
(	O
0	O
.	O
04	O
-	O
1	O
.	O
6	O
units	O
)	O
or	O
DNase	B-GGP
I	I-GGP
(	O
0	O
.	O
25	O
-	O
16	O
units	O
)	O
.	O

Digestion	O
time	O
at	O
37	O
degrees	O
C	O
was	O
10	O
min	O
for	O
MNase	O
and	O
2	O
min	O
for	O
DNase	B-GGP
I	I-GGP
.	O

Digestions	O
were	O
stopped	O
by	O
adding	O
SDS	B-CHEBI
to	O
1	O
%	O
and	O
EDTA	B-CHEBI
to	O
50	O
mM	O
.	O

DNAs	B-SO
were	O
prepared	O
by	O
proteinase	O
K	O
digestion	O
followed	O
by	O
phenol	B-CHEBI
-	O
chloroform	B-CHEBI
extraction	O
and	O
isopropanol	B-CHEBI
precipitation	O
.	O

To	O
test	O
the	O
association	O
of	O
histone	B-CHEBI
H3	O
with	O
chromatin	B-GO
in	O
control	O
and	O
p150	B-GGP
-	O
depleted	O
cells	B-CL
,	O
isolated	O
nuclei	B-GO
were	O
incubated	O
on	O
ice	O
for	O
30	O
min	O
in	O
buffer	O
2	O
(	O
50	O
mM	O
Hepes	B-CHEBI
[	O
pH7	O
.	O
9	O
]	O
,	O
20	O
%	O
Glycerol	B-CHEBI
,	O
3	O
mM	O
MgCl2	B-CHEBI
,	O
0	O
.	O
1	O
%	O
IGEPAL	O
,	O
0	O
.	O
5	O
mM	O
DTT	B-CHEBI
,	O
0	O
.	O
5	O
mM	O
PMSF	B-CHEBI
)	O
supplemented	O
with	O
either	O
0	O
.	O
1	O
M	O
,	O
0	O
.	O
3	O
M	O
,	O
0	O
.	O
45	O
M	O
,	O
0	O
.	O
7	O
M	O
,	O
or	O
1	O
M	O
NaCl	B-CHEBI
.	O

After	O
centrifugation	O
at	O
15	O
,	O
000	O
g	O
,	O
pellets	O
and	O
supernants	O
were	O
analyzed	O
by	O
Western	O
blot	O
using	O
a	O
histone	B-CHEBI
H3	O
antibody	B-GO
(	O
Abcam	O
)	O
.	O

ChIP	O
.	O

We	O
prepared	O
native	O
chromatin	B-GO
fragments	B-SO
of	O
two	O
to	O
six	O
nucleosomes	B-GO
in	O
length	O
as	O
described	O
[	O
28	O
]	O
.	O

5	O
mu	O
g	O
of	O
chromatin	B-GO
were	O
incubated	O
overnight	O
with	O
10	O
mu	O
l	O
of	O
commercial	O
antibodies	B-GO
.	O

After	O
incubation	O
with	O
protein	B-CHEBI
-	O
G	O
sepharose	O
and	O
three	O
washes	O
,	O
immunoprecipitated	O
DNA	B-SO
was	O
purified	O
,	O
sized	O
onto	O
an	O
agarose	B-CHEBI
gel	O
,	O
and	O
analyzed	O
by	O
Southern	O
blot	O
.	O

Hybridization	O
signals	O
were	O
quantified	O
using	O
an	O
Instant	O
Imager	O
(	O
PerkinElmer	O
,	O
Wellesley	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

Antibodies	B-GO
specific	O
for	O
H4K20me3	O
were	O
purchased	O
from	O
Abcam	O
.	O

Antibodies	B-GO
for	O
H3K9me3	O
were	O
purchased	O
from	O
both	O
Abcam	O
and	O
Upstate	O
Biotechnology	O
and	O
gave	O
similar	O
results	O
.	O

For	O
Southern	O
blot	O
analysis	O
,	O
we	O
used	O
a	O
240	O
-	O
bp	B-SO
EcoRI	O
/	O
BamHI	O
fragment	B-SO
from	O
pSAT	O
(	O
major	O
satellite	B-SO
probe	B-SO
)	O
[	O
45	O
-	O
47	O
]	O
and	O
a	O
360	O
-	O
bp	B-SO
EcoRI	O
/	O
HindIII	O
fragment	B-SO
from	O
R198	O
,	O
corresponding	O
to	O
three	O
copies	O
of	O
the	O
120	O
-	O
bp	B-SO
minor	O
satellite	B-SO
repeat	I-SO
[	O
49	O
]	O
.	O

Probes	B-SO
used	O
in	O
FISH	O
experiments	O
were	O
described	O
in	O
[	O
46	O
-	O
48	O
]	O
.	O

The	O
probe	B-SO
for	O
IAP	O
elements	B-SO
was	O
described	O
in	O
[	O
50	O
]	O
.	O

Supporting	O
Information	O

Figure	O
S1	O

Analysis	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
Depletion	O
by	O
RNAi	O
with	O
Western	O
Blot	O
and	O
IF	O

(	O
A	O
)	O
Western	O
blot	O
analysis	O
of	O
ES	O
cells	B-CL
transfected	O
with	O
control	O
(	O
cont	O
)	O
or	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
(	O
p150	B-GGP
)	O
RNAi	O
plasmid	B-SO
vectors	I-SO
.	O

beta	B-GGP
-	I-GGP
actin	I-GGP
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

Amount	O
of	O
cells	B-CL
used	O
in	O
each	O
lane	O
is	O
indicated	O
.	O

p150CAF	B-GGP
-	I-GGP
1	I-GGP
knockdown	O
does	O
not	O
significantly	O
affect	O
HP1	B-GGP
alpha	I-GGP
,	O
histone	B-CHEBI
H3	O
,	O
or	O
H3K9me3	O
levels	O
.	O

(	O
B	O
)	O
IF	O
analysis	O
.	O

ES	O
cells	B-CL
transfected	O
with	O
control	O
(	O
cont	O
)	O
or	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
(	O
p150	B-GGP
)	O
siRNA	B-SO
vector	B-SO
were	O
immunostained	O
with	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
antibody	B-GO
(	O
green	O
)	O
and	O
DAPI	O
(	O
blue	O
)	O
.	O

Scale	O
bar	O
=	O
5	O
mu	O
m	O
.	O

Fluorescence	O
was	O
quantified	O
along	O
a	O
line	O
drawn	O
across	O
the	O
nucleus	B-GO
and	O
data	O
were	O
plotted	O
,	O
revealing	O
efficient	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
depletion	O
by	O
RNAi	O
.	O

The	O
apparent	O
difference	O
in	O
the	O
efficiency	O
of	O
CAF	B-GO
-	I-GO
1	I-GO
knockdown	O
revealed	O
by	O
Western	O
blot	O
and	O
IF	O
likely	O
reflects	O
the	O
observation	O
that	O
the	O
RNAi	O
plasmid	B-SO
vector	I-SO
used	O
in	O
this	O
study	O
is	O
efficient	O
in	O
85	O
%	O
of	O
the	O
transfected	O
ES	O
cell	B-CL
population	O
,	O
whereas	O
15	O
%	O
of	O
cells	B-CL
display	O
no	O
inhibition	O
of	O
the	O
target	O
gene	B-SO
(	O
see	O
Materials	O
and	O
Methods	O
)	O
.	O

(	O
1	O
.	O
3	O
MB	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Figure	O
S2	O

CAF	B-GO
-	I-GO
1	I-GO
-	O
Depleted	O
Embryonic	O
Fibroblasts	B-CL
Active	O
for	O
DNA	B-SO
Replication	O
Do	O
Not	O
Display	O
an	O
Altered	O
Heterochromatin	B-GO
Nuclear	B-GO
Architecture	O

Immunodetection	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
(	O
green	O
)	O
and	O
BrdU	O
(	O
red	O
)	O
in	O
MEFs	O
transfected	O
with	O
control	O
(	O
cont	O
)	O
or	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
RNAi	O
vectors	B-SO
.	O

MEFs	O
were	O
pulse	O
-	O
labeled	O
for	O
1	O
h	O
with	O
BrdU	O
prior	O
to	O
fixation	O
and	O
IF	O
analysis	O
.	O

The	O
p150	B-GGP
+	O
BrdU	O
image	O
shows	O
the	O
merge	O
between	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
and	O
BrdU	O
fluorescence	O
.	O

DAPI	O
staining	O
is	O
shown	O
in	O
the	O
right	O
-	O
hand	O
panel	O
.	O

The	O
cytoplasmic	B-GO
CAF	B-GO
-	I-GO
1	I-GO
IF	O
pattern	O
is	O
non	O
-	O
specific	O
.	O

(	O
343	O
KB	O
TIF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Acknowledgements	O

We	O
thank	O
E	O
.	O

Heard	O
and	O
S	O
.	O

Khochbin	O
for	O
critical	O
reading	O
and	O
suggestions	O
;	O
S	O
.	O

Jounier	O
and	O
H	O
.	O

Humbertclaude	O
for	O
cell	B-CL
culture	O
;	O
J	O
.	O

Mitja	O
,	O
S	O
.	O

Thessier	O
,	O
and	O
J	O
.	O

C	O
.	O

Robillard	O
for	O
animal	B-Taxon
care	O
;	O
M	O
.	O

Vernet	O
for	O
AT	O
-	O
1	O
cells	B-CL
;	O
K	O
.	O

Nacerddine	O
for	O
the	O
PML	B-GGP
antibody	B-GO
;	O
N	O
.	O

Gilbert	O
and	O
T	O
.	O

Bestor	O
for	O
probes	B-SO
;	O
G	O
.	O

Hamard	O
for	O
advice	O
on	O
blastocyst	O
injection	O
;	O
P	O
.	O

Le	O
Baccon	O
for	O
help	O
on	O
image	O
analysis	O
;	O
and	O
C	O
.	O

Mann	O
,	O
A	O
.	O

Sentenac	O
,	O
and	O
E	O
.	O

Moustacchi	O
for	O
their	O
support	O
.	O

Abbreviations	O

BrdU	O
-	O
bromodeoxyuridine	O

CAF	B-GO
-	I-GO
1	I-GO
-	O
chromatin	B-GO
assembly	I-GO
factor	I-GO
1	I-GO

ChIP	O
-	O
chromatin	B-GO
immunoprecipitation	O

E4	O
-	O
embryonic	O
day	O
4	O

ES	O
-	O
embryonic	O
stem	O

FISH	O
-	O
fluorescence	O
in	O
situ	O
hybridization	O

IAP	O
-	O
intracisternal	O
A	O
particle	O

IF	O
-	O
immunofluorescence	O

MEF	O
-	O
mouse	B-Taxon
embryonic	O
fibroblast	B-CL

PCNA	B-GGP
-	O
proliferating	B-GGP
cell	I-GGP
nuclear	I-GGP
antigen	I-GGP

PML	B-GGP
-	O
promyelocytic	B-GGP
leukemia	I-GGP

RNAi	O
-	O
RNA	B-SO
interference	O

siRNA	B-SO
-	O
short	B-SO
interfering	I-SO
RNA	I-SO

Figures	O
and	O
Tables	O

Figure	O
1	O

Loss	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
Function	O
Leads	O
to	O
Early	O
Developmental	O
Arrest	O
and	O
Alteration	O
of	O
Heterochromatin	B-GO
Organization	O

(	O
A	O
)	O
Generation	O
of	O
Chaf1a	B-GGP
+	B-SO
/	O
-	O
mice	B-Taxon
by	O
homologous	O
recombination	O
in	O
ES	O
cells	B-CL
.	O

(	O
Top	O
)	O
Scheme	O
of	O
the	O
p150CAF1	B-GGP
protein	B-CHEBI
indicating	O
the	O
interacting	O
domains	B-SO
(	O
ID	O
)	O
for	O
HP1	B-GGP
and	O
p60CAF	B-GGP
-	I-GGP
1	I-GGP
,	O
and	O
the	O
acidic	B-CHEBI
domain	B-SO
(	O
AD	O
)	O
.	O

(	O
Middle	O
)	O
Structure	O
of	O
the	O
murine	B-Taxon
Chaf1a	B-GGP
gene	B-SO
.	O

Blocks	O
and	O
lines	O
represent	O
exons	B-SO
and	O
introns	B-SO
,	O
respectively	O
.	O

A	O
star	O
indicates	O
the	O
translation	B-SO
initiation	I-SO
site	I-SO
.	O

Below	O
is	O
shown	O
the	O
Chaf1a	B-GGP
targeting	O
vector	B-SO
,	O
which	O
includes	O
genomic	B-SO
DNA	I-SO
homology	I-SO
regions	I-SO
(	O
5	O
HR	O
and	O
3	O
HR	O
)	O
,	O
the	O
diphtheria	B-GGP
toxin	I-GGP
(	O
DT	B-GGP
)	O
,	O
and	O
neomycin	B-CHEBI
selection	O
genes	B-SO
.	O

Recombined	O
(	O
Rec	O
)	O
ES	O
cells	B-CL
and	O
mice	B-Taxon
were	O
identified	O
by	O
Southern	O
blot	O
using	O
ScaI	O
(	O
S	O
)	O
and	O
the	O
indicated	O
probe	B-SO
.	O

(	O
B	O
)	O
Breeding	O
strategy	O
used	O
for	O
the	O
production	O
of	O
E4	O
Chaf1a	B-GGP
-	O
/	O
-	O
embryos	O
.	O

Genotyping	O
was	O
performed	O
by	O
PCR	O
using	O
the	O
three	O
oligonucleotide	B-SO
primers	B-SO
indicated	O
in	O
(	O
A	O
)	O
(	O
1	O
,	O
2	O
,	O
and	O
3	O
)	O
.	O

An	O
example	O
of	O
the	O
result	O
of	O
a	O
genotyping	O
experiment	O
is	O
shown	O
.	O

(	O
C	O
)	O
Immunodetection	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
(	O
green	O
)	O
and	O
HP1	B-GGP
alpha	I-GGP
(	O
red	O
)	O
in	O
E4	O
embryos	O
derived	O
from	O
Chaf1a	B-GGP
+	B-SO
/	O
-	O
intercrosses	O
.	O

Because	O
Chaf1a	B-GGP
+	B-SO
/	O
+	B-SO
and	O
Chaf1a	B-GGP
+	B-SO
/	O
-	O
embryos	O
both	O
stain	O
positively	O
for	O
the	O
presence	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
,	O
they	O
are	O
both	O
designated	O
as	O
wild	B-SO
-	I-SO
type	I-SO
.	O

p150CAF	B-GGP
-	I-GGP
1	I-GGP
expression	O
,	O
which	O
indicates	O
ongoing	O
S	O
phase	O
,	O
can	O
be	O
detected	O
in	O
most	O
cells	B-CL
within	O
the	O
wild	B-SO
-	I-SO
type	I-SO
blastocyst	O
(	O
upper	O
panel	O
)	O
.	O

The	O
lower	O
panel	O
shows	O
a	O
12	O
-	O
cell	B-CL
embryo	O
labeling	O
negatively	O
for	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
.	O

Only	O
nonspecific	O
background	O
labeling	O
can	O
be	O
observed	O
.	O

In	O
each	O
panel	O
,	O
the	O
right	O
-	O
hand	O
image	O
shows	O
the	O
merge	O
between	O
the	O
HP1	B-GGP
alpha	I-GGP
fluorescence	O
and	O
DAPI	O
-	O
stained	O
DNA	B-SO
in	O
blue	O
.	O

Pink	O
color	O
indicates	O
the	O
association	O
of	O
HP1	B-GGP
with	O
DAPI	O
-	O
dense	O
material	O
.	O

The	O
bottom	O
of	O
each	O
panel	O
shows	O
the	O
magnification	O
of	O
a	O
nucleus	B-GO
selected	O
from	O
the	O
above	O
embryo	O
(	O
white	O
square	O
)	O
.	O

The	O
arrowhead	O
indicates	O
the	O
typical	O
heterochromatin	B-GO
foci	I-GO
revealed	O
by	O
DAPI	O
and	O
HP1	B-GGP
alpha	I-GGP
staining	O
in	O
wild	B-SO
-	I-SO
type	I-SO
embryos	O
.	O

These	O
foci	O
are	O
not	O
visible	O
in	O
Chaf1a	B-GGP
-	O
/	O
-	O
embryos	O
.	O

DAPI	O
and	O
HP1	B-GGP
alpha	I-GGP
staining	O
are	O
diffuse	O
within	O
the	O
nucleus	B-GO
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
embryos	O
,	O
with	O
enrichment	O
at	O
the	O
nuclear	B-GO
periphery	O
,	O
revealing	O
abnormal	O
heterochromatin	B-GO
organization	O
.	O

Scale	O
bars	O
represent	O
10	O
mu	O
m	O
.	O

(	O
E	O
)	O
Wild	B-SO
-	I-SO
type	I-SO
embryos	O
isolated	O
at	O
embryonic	O
day	O
2	O
(	O
E2	O
,	O
two	O
cells	B-CL
)	O
,	O
E2	O
.	O
5	O
(	O
four	O
cells	B-CL
)	O
,	O
E3	O
(	O
eight	O
cells	B-CL
)	O
,	O
E3	O
.	O
5	O
(	O
16	O
cells	B-CL
)	O
,	O
and	O
E4	O
(	O
32	O
cells	B-CL
)	O
are	O
shown	O
.	O

Heterochromatin	B-GO
was	O
monitored	O
by	O
DAPI	O
staining	O
(	O
upper	O
panel	O
)	O
and	O
HP1	B-GGP
immunolabeling	O
(	O
in	O
red	O
,	O
lower	O
panel	O
)	O
.	O

(	O
F	O
)	O
Magnification	O
of	O
a	O
nucleus	B-GO
(	O
DAPI	O
-	O
stained	O
)	O
representative	O
of	O
each	O
stage	O
.	O

The	O
right	O
-	O
hand	O
panel	O
shows	O
the	O
nucleus	B-GO
of	O
an	O
ES	O
cell	B-CL
.	O

Scale	O
bar	O
represents	O
10	O
mu	O
m	O
.	O

Figure	O
2	O

Depletion	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
in	O
ES	O
Cells	B-CL
Results	O
in	O
a	O
Severe	O
Alteration	O
of	O
Heterochromatin	B-GO
Organization	O

(	O
A	O
)	O
Strategy	O
used	O
to	O
deplete	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
by	O
RNAi	O
in	O
ES	O
cells	B-CL
.	O

The	O
siRNA	B-SO
expression	O
vector	B-SO
includes	O
a	O
puromycin	B-CHEBI
selection	O
cassette	B-SO
(	O
Puro	O
)	O
,	O
the	O
mouse	B-Taxon
H1	O
promoter	B-SO
,	O
and	O
the	O
siRNA	B-SO
encoding	O
sequence	B-SO
.	O

ES	O
cells	B-CL
were	O
kept	O
under	O
puromycin	B-CHEBI
selection	O
during	O
48	O
h	O
following	O
transfection	O
.	O

(	O
B	O
)	O
Abnormal	O
heterochromatin	B-GO
organization	O
in	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
ES	O
cells	B-CL
.	O

Immunodetection	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
(	O
green	O
)	O
and	O
HP1	B-GGP
alpha	I-GGP
(	O
red	O
)	O
in	O
ES	O
cells	B-CL
transfected	O
with	O
control	O
(	O
cont	O
)	O
and	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
siRNA	B-SO
.	O

siRNA	B-SO
expression	O
results	O
in	O
efficient	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
depletion	O
.	O

The	O
right	O
-	O
hand	O
image	O
shows	O
the	O
merge	O
between	O
HP1	B-GGP
alpha	I-GGP
fluorescence	O
and	O
DAPI	O
-	O
stained	O
DNA	B-SO
in	O
blue	O
.	O

Scale	O
bar	O
=	O
10	O
mu	O
m	O
.	O

(	O
C	O
)	O
Heterochromatin	B-GO
organization	O
is	O
not	O
altered	O
in	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
MEFs	O
.	O

Immunodetection	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
(	O
green	O
)	O
and	O
HP1	B-GGP
alpha	I-GGP
(	O
red	O
)	O
in	O
MEFs	O
transfected	O
with	O
control	O
(	O
cont	O
)	O
or	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
siRNA	B-SO
.	O

The	O
right	O
-	O
hand	O
image	O
shows	O
the	O
merge	O
between	O
HP1	B-GGP
alpha	I-GGP
fluorescence	O
and	O
DAPI	O
-	O
stained	O
DNA	B-SO
in	O
blue	O
.	O

(	O
D	O
)	O
PML	B-GO
bodies	I-GO
are	O
not	O
altered	O
in	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
ES	O
cells	B-CL
.	O

Immunodetection	O
of	O
PML	B-GGP
(	O
red	O
)	O
in	O
ES	O
cells	B-CL
transfected	O
with	O
control	O
(	O
cont	O
)	O
or	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
siRNA	B-SO
.	O

The	O
right	O
-	O
hand	O
image	O
shows	O
the	O
merge	O
between	O
PML	B-GGP
fluorescence	O
and	O
DAPI	O
-	O
stained	O
DNA	B-SO
in	O
blue	O
.	O

Figure	O
3	O

p150CAF	B-GGP
-	I-GGP
1	I-GGP
Depletion	O
and	O
Loss	O
of	O
Heterochromatin	B-GO
Organization	O
Are	O
Compatible	O
with	O
Active	O
DNA	B-SO
Replication	O
in	O
ES	O
Cells	B-CL

(	O
A	O
)	O
ES	O
cells	B-CL
were	O
transfected	O
with	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
or	O
control	O
siRNA	B-SO
vectors	B-SO
.	O

After	O
3	O
d	O
under	O
puromycin	B-CHEBI
selection	O
,	O
cells	B-CL
were	O
pulse	O
-	O
labeled	O
for	O
10	O
min	O
with	O
BrdU	O
and	O
immediately	O
analyzed	O
by	O
IF	O
.	O

No	O
significant	O
difference	O
in	O
BrdU	O
incorporation	B-SO
could	O
be	O
detected	O
between	O
control	O
and	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
cells	B-CL
.	O

The	O
right	O
-	O
hand	O
image	O
shows	O
the	O
merge	O
between	O
the	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
and	O
BrdU	O
fluorescence	O
.	O

Scale	O
bar	O
=	O
10	O
mu	O
m	O
.	O

(	O
B	O
)	O
Immunodetection	O
of	O
PCNA	B-GGP
(	O
red	O
)	O
revealed	O
no	O
significant	O
difference	O
in	O
the	O
formation	O
of	O
replication	O
foci	O
between	O
control	O
and	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
ES	O
cells	B-CL
.	O

Immunodetection	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
is	O
shown	O
in	O
green	O
and	O
the	O
merging	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
and	O
PCNA	B-GGP
appears	O
in	O
yellow	O
.	O

(	O
C	O
)	O
Flow	O
cytometry	O
analysis	O
showed	O
a	O
similar	O
cell	B-CL
-	O
cycle	O
profile	O
for	O
control	O
and	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
ES	O
cells	B-CL
.	O

Results	O
are	O
presented	O
as	O
the	O
percentage	O
of	O
cells	B-CL
in	O
each	O
phase	O
of	O
the	O
cell	B-CL
cycle	O
(	O
G1	O
,	O
S	O
,	O
G2	O
/	O
M	O
)	O
,	O
as	O
defined	O
by	O
BrdU	O
incorporation	B-SO
and	O
DNA	B-SO
content	O
.	O

Data	O
presented	O
are	O
the	O
mean	O
of	O
three	O
independent	O
experiments	O
;	O
error	O
bars	O
indicate	O
the	O
standard	O
deviation	O
.	O

All	O
experiments	O
were	O
performed	O
3	O
d	O
after	O
transfection	O
of	O
the	O
siRNA	B-SO
vectors	B-SO
.	O

Figure	O
4	O

Depletion	O
of	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
Leads	O
to	O
Loss	O
of	O
Clustering	O
,	O
Altered	O
Localization	O
,	O
and	O
Decondensation	O
of	O
Pericentric	B-GO
Heterochromatin	I-GO
Domains	I-GO

Distribution	O
of	O
pericentric	B-GO
(	I-GO
red	I-GO
)	I-GO
and	I-GO
centric	I-GO
(	I-GO
green	I-GO
)	I-GO
domains	I-GO
was	O
analyzed	O
in	O
the	O
interphase	O
nuclei	B-GO
of	O
mouse	B-Taxon
ES	O
cells	B-CL
by	O
DNA	B-SO
FISH	O
,	O
using	O
major	O
satellite	B-SO
(	I-SO
pSAT	I-SO
)	I-SO
[	I-SO
47	I-SO
]	I-SO
and	I-SO
minor	I-SO
satellite	I-SO
(	I-SO
pMR150	I-SO
)	I-SO
[	I-SO
48	I-SO
]	I-SO
DNA	I-SO
probes	B-SO
,	O
respectively	O
.	O

(	O
A	O
)	O
In	O
ES	O
cells	B-CL
expressing	O
control	O
(	O
cont	O
)	O
siRNA	B-SO
,	O
pericentric	B-GO
regions	I-GO
from	I-GO
several	I-GO
chromosomes	I-GO
associate	O
in	O
clusters	O
(	O
red	O
)	O
.	O

These	O
chromocenters	B-GO
form	O
foci	O
as	O
revealed	O
by	O
DAPI	O
staining	O
(	O
left	O
-	O
hand	O
image	O
)	O
,	O
while	O
centric	O
regions	B-SO
(	O
green	O
)	O
remain	O
independent	O
entities	O
at	O
the	O
periphery	O
of	O
these	O
domains	B-SO
.	O

The	O
right	O
-	O
hand	O
image	O
shows	O
the	O
merge	O
between	O
the	O
pericentric	B-GO
and	O
centric	O
FISH	O
signals	O
.	O

(	O
B	O
)	O
The	O
organization	O
of	O
pericentric	B-GO
domains	I-GO
was	O
altered	O
in	O
cells	B-CL
expressing	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
siRNA	B-SO
.	O

Instead	O
of	O
forming	O
well	O
-	O
defined	O
chromocenters	B-GO
,	O
pericentric	B-GO
domains	I-GO
were	O
found	O
either	O
isolated	O
or	O
associated	O
in	O
heterogeneous	O
aggregates	O
of	O
various	O
sizes	O
,	O
often	O
at	O
the	O
nuclear	B-GO
periphery	O
.	O

Scale	O
bar	O
=	O
10	O
mu	O
m	O
.	O

(	O
C	O
)	O
Control	O
ES	O
cells	B-CL
.	O

Fluorescence	O
was	O
quantified	O
along	O
a	O
line	O
randomly	O
drawn	O
across	O
the	O
nucleus	B-GO
in	O
the	O
merged	O
image	O
and	O
data	O
were	O
plotted	O
.	O

One	O
can	O
distinguish	O
clear	O
peaks	O
corresponding	O
to	O
chromocenters	B-GO
(	O
red	O
)	O
and	O
the	O
condensed	O
minor	O
satellites	B-SO
(	O
green	O
)	O
.	O

(	O
D	O
)	O
ES	O
cells	B-CL
expressing	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
siRNA	B-SO
.	O

p150CAF	B-GGP
-	I-GGP
1	I-GGP
depletion	O
led	O
to	O
a	O
lower	O
fluorescence	O
intensity	O
and	O
a	O
broader	O
distribution	O
of	O
signals	O
corresponding	O
to	O
DAPI	O
(	O
blue	O
)	O
and	O
major	O
satellite	B-SO
hybridization	O
(	O
red	O
,	O
plot	O
)	O
while	O
the	O
organization	O
of	O
the	O
minor	O
satellites	B-SO
remained	O
unaffected	O
.	O

Insets	O
in	O
the	O
right	O
-	O
hand	O
images	O
show	O
a	O
typical	O
chromocenter	B-GO
in	O
control	O
cells	B-CL
(	O
C	O
)	O
and	O
a	O
disrupted	O
chromocenter	B-GO
in	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
cells	B-CL
(	O
D	O
)	O
.	O

Figure	O
5	O

Nucleosomal	B-GO
Organization	O
Is	O
Not	O
Altered	O
in	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
Depleted	O
ES	O
Cells	B-CL

Nuclei	O
were	O
prepared	O
from	O
ES	O
cells	B-CL
transfected	O
with	O
control	O
or	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
siRNA	B-SO
vector	B-SO
.	O

Nuclei	B-GO
were	O
digested	O
with	O
increasing	O
amounts	O
of	O
DNase	B-GGP
I	I-GGP
or	O
MNase	O
.	O

(	O
A	O
)	O
After	O
digestion	O
with	O
the	O
indicated	O
nucleases	O
,	O
total	O
DNA	B-SO
was	O
prepared	O
and	O
run	O
onto	O
an	O
agarose	B-CHEBI
gel	O
which	O
was	O
stained	O
with	O
ethidium	B-CHEBI
bromide	I-CHEBI
to	O
reveal	O
bulk	O
genomic	B-SO
DNA	I-SO
.	O

(	O
B	O
)	O
The	O
DNA	B-SO
was	O
blotted	O
onto	O
a	O
nylon	B-CHEBI
membrane	O
,	O
which	O
was	O
then	O
hybridized	O
with	O
the	O
alpha	O
-	O
32P	B-CHEBI
-	O
labeled	O
pSAT	O
major	O
satellite	B-SO
repeat	I-SO
probe	B-SO
[	O
47	O
]	O
.	O

Figure	O
6	O

DNA	B-SO
CpG	O
Methylation	O
at	O
Pericentric	B-GO
Heterochromatin	I-GO
Is	O
Not	O
Altered	B-SO
in	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
Depleted	O
ES	O
Cells	B-CL

Total	O
DNA	B-SO
was	O
isolated	O
from	O
cells	B-CL
transfected	O
with	O
a	O
control	O
or	O
the	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
siRNA	B-SO
vector	B-SO
and	O
digested	O
with	O
MaeII	O
,	O
whose	O
recognition	B-SO
sequence	I-SO
is	O
present	O
in	O
major	O
satellite	B-SO
repeats	I-SO
.	O

Digested	O
DNA	B-SO
was	O
run	O
onto	O
an	O
agarose	B-CHEBI
gel	O
and	O
analyzed	O
by	O
Southern	O
blotting	O
using	O
the	O
pSAT	O
major	O
satellite	B-SO
probe	B-SO
[	O
47	O
]	O
.	O

Figure	O
7	O

Alteration	O
of	O
Epigenetic	O
Marking	O
at	O
Pericentric	B-GO
Heterochromatin	I-GO
in	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
Depleted	O
Cells	B-CL

(	O
A	O
)	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
depletion	O
leads	O
to	O
reduced	O
H4K20me3	O
and	O
H3K9me3	O
at	O
pericentric	B-GO
heterochromatin	I-GO
.	O

Enrichment	O
of	O
histone	B-CHEBI
marks	O
at	O
major	O
satellite	B-SO
repeats	I-SO
was	O
determined	O
by	O
ChIP	O
from	O
control	O
(	O
cont	O
)	O
and	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
(	O
p150	B-GGP
)	O
siRNA	B-SO
-	O
expressing	O
ES	O
cells	B-CL
.	O

DNA	B-SO
prepared	O
from	O
the	O
input	O
and	O
the	O
antibody	B-GO
-	O
bound	O
fraction	B-GO
were	O
run	O
onto	O
an	O
agarose	B-CHEBI
gel	O
and	O
analyzed	O
by	O
Southern	O
blot	O
with	O
the	O
pSAT	O
major	O
satellite	B-SO
repeat	I-SO
probe	B-SO
[	O
47	O
]	O
.	O

(	O
B	O
)	O
Hybridization	O
signals	O
were	O
quantified	O
using	O
an	O
Instant	O
Imager	O
.	O

After	O
autoradiography	O
,	O
the	O
membrane	O
was	O
stripped	O
and	O
rehybridized	O
with	O
a	O
minor	O
satellite	B-SO
probe	B-SO
[	O
49	O
]	O
.	O

After	O
quantification	O
,	O
the	O
membrane	O
was	O
stripped	O
and	O
rehybridized	O
with	O
an	O
IAP	O
LTR	B-SO
probe	B-SO
[	O
50	O
]	O
.	O

Results	O
are	O
presented	O
as	O
the	O
amount	O
of	O
DNA	B-SO
immunoprecipitated	O
from	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
ES	O
cells	B-CL
divided	O
by	O
the	O
DNA	B-SO
obtained	O
from	O
control	O
cells	B-CL
.	O

The	O
figure	O
shows	O
the	O
mean	O
value	O
and	O
standard	O
deviation	O
of	O
three	O
independent	O
ChIP	O
experiments	O
.	O

(	O
C	O
and	O
D	O
)	O
H3K9me3	O
and	O
H4K20me3	O
fluorescence	O
patterns	O
are	O
severely	O
altered	O
in	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
-	O
depleted	O
ES	O
cells	B-CL
.	O

Immunodetection	O
of	O
H3K9me3	O
(	O
C	O
,	O
green	O
)	O
,	O
H4K20me3	O
(	O
D	O
,	O
green	O
)	O
,	O
and	O
HP1	B-GGP
alpha	I-GGP
(	O
red	O
)	O
in	O
control	O
and	O
p150CAF	B-GGP
-	I-GGP
1	I-GGP
siRNA	B-SO
-	O
expressing	O
ES	O
cells	B-CL
.	O

Merging	O
of	O
HP1	B-GGP
alpha	I-GGP
with	O
H3K9me3	O
(	O
C	O
)	O
and	O
H4K20me3	O
(	O
D	O
)	O
is	O
shown	O
in	O
yellow	O
.	O

Scale	O
bars	O
represent	O
10	O
mu	O
m	O
.	O

Footnotes	O

currency	O
Current	O
address	O
:	O
Unit	O
e	O
de	O
G	O
e	O
n	O
e	O
tique	O
Fonctionnelle	O
de	O
la	O
Souris	O
,	O
Centre	O
National	O
de	O
la	O
Recherche	O
Scientifique	O
URA	O
2578	O
,	O
Institut	O
Pasteur	O
,	O
Paris	O
,	O
France	O

Competing	O
interests	O
.	O

The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

A	O
previous	O
version	O
of	O
this	O
article	O
appeared	O
as	O
an	O
Early	O
Online	O
Release	O
on	O
September	O
11	O
,	O
2006	O
(	O
doi	O
:	O
10	O
.	O
1371	O
/	O
journal	O
.	O
pgen	O
.	O
0020181	O
.	O
eor	O
)	O
.	O

Author	O
contributions	O
.	O

MH	O
,	O
SB	O
,	O
AVP	O
,	O
JPQ	O
,	O
GA	O
,	O
and	O
MG	O
conceived	O
and	O
designed	O
the	O
experiments	O
.	O

MH	O
,	O
SB	O
,	O
AVP	O
,	O
and	O
PH	O
performed	O
the	O
experiments	O
.	O

MH	O
,	O
SB	O
,	O
AVP	O
,	O
and	O
JPQ	O
analyzed	O
the	O
data	O
.	O

MG	O
wrote	O
the	O
paper	O
.	O

Funding	O
.	O

This	O
study	O
was	O
funded	O
by	O
grants	O
from	O
the	O
Association	O
Pour	O
la	O
Recherche	O
Sur	O
le	O
Cancer	O
and	O
the	O
Fondation	O
Pour	O
la	O
Recherche	O
Medicale	O
to	O
MG	O
,	O
and	O
grants	O
from	O
a	O
Collaborative	O
Programme	O
Curie	O
Institute	O
/	O
Commissariat	O
a	O
l	O
'	O
Energie	O
Atomique	O
to	O
MG	O
and	O
GA	O
.	O

GA	O
'	O
s	O
team	O
is	O
labelized	O
by	O
la	O
Ligue	O
Contre	O
le	O
Cancer	O
,	O
and	O
part	O
of	O
the	O
Epigenome	O
Network	O
.	O

AVP	O
has	O
been	O
supported	O
by	O
the	O
Curie	O
Institute	O
and	O
the	O
Fondation	O
Franco	O
Norv	O
e	O
gienne	O
;	O
MH	O
by	O
the	O
CEA	O
,	O
the	O
Curie	O
Institute	O
,	O
and	O
the	O
Canceropole	O
IdF	O
.	O

Rb	B-GGP
-	O
Mediated	O
Neuronal	B-CL
Differentiation	O
through	O
Cell	B-CL
-	O
Cycle	O
-	O
Independent	O
Regulation	O
of	O
E2f3a	O

Abstract	O

It	O
has	O
long	O
been	O
known	O
that	O
loss	O
of	O
the	O
retinoblastoma	B-GGP
protein	I-GGP
(	O
Rb	B-GGP
)	O
perturbs	O
neural	O
differentiation	O
,	O
but	O
the	O
underlying	O
mechanism	O
has	O
never	O
been	O
solved	O
.	O

Rb	B-GGP
absence	O
impairs	O
cell	B-CL
cycle	O
exit	O
and	O
triggers	O
death	O
of	O
some	O
neurons	B-CL
,	O
so	O
differentiation	O
defects	O
may	O
well	O
be	O
indirect	O
.	O

Indeed	O
,	O
we	O
show	O
that	O
abnormalities	O
in	O
both	O
differentiation	O
and	O
light	O
-	O
evoked	O
electrophysiological	O
responses	O
in	O
Rb	B-GGP
-	O
deficient	O
retinal	O
cells	B-CL
are	O
rescued	O
when	O
ectopic	O
division	O
and	O
apoptosis	O
are	O
blocked	O
specifically	O
by	O
deleting	B-SO
E2f	B-GGP
transcription	I-GGP
factor	I-GGP
(	I-GGP
E2f	I-GGP
)	I-GGP
1	I-GGP
.	O

However	O
,	O
comprehensive	O
cell	B-CL
-	O
type	O
analysis	O
of	O
the	O
rescued	O
double	O
-	O
null	O
retina	O
exposed	O
cell	B-CL
-	O
cycle	O
-	O
independent	O
differentiation	O
defects	O
specifically	O
in	O
starburst	O
amacrine	B-CL
cells	I-CL
(	O
SACs	O
)	O
,	O
cholinergic	B-CHEBI
interneurons	B-CL
critical	O
in	O
direction	O
selectivity	O
and	O
developmentally	O
important	O
rhythmic	O
bursts	O
.	O

Typically	O
,	O
Rb	B-GGP
is	O
thought	O
to	O
block	O
division	O
by	O
repressing	O
E2fs	O
,	O
but	O
to	O
promote	O
differentiation	O
by	O
potentiating	O
tissue	O
-	O
specific	O
factors	O
.	O

Remarkably	O
,	O
however	O
,	O
Rb	B-GGP
promotes	O
SAC	O
differentiation	O
by	O
inhibiting	O
E2f3	B-GGP
activity	O
.	O

Two	O
E2f3	B-GGP
isoforms	B-SO
exist	O
,	O
and	O
we	O
find	O
both	O
in	O
the	O
developing	O
retina	O
,	O
although	O
intriguingly	O
they	O
show	O
distinct	O
subcellular	O
distribution	O
.	O

E2f3b	O
is	O
thought	O
to	O
mediate	O
Rb	B-GGP
function	O
in	O
quiescent	O
cells	B-CL
.	O

However	O
,	O
in	O
what	O
is	O
to	O
our	O
knowledge	O
the	O
first	O
work	O
to	O
dissect	O
E2f	O
isoform	B-SO
function	O
in	O
vivo	O
we	O
show	O
that	O
Rb	B-GGP
promotes	O
SAC	O
differentiation	O
through	O
E2f3a	O
.	O

These	O
data	O
reveal	O
a	O
mechanism	O
through	O
which	O
Rb	B-GGP
regulates	O
neural	O
differentiation	O
directly	O
,	O
and	O
,	O
unexpectedly	O
,	O
it	O
involves	O
inhibition	O
of	O
E2f3a	O
,	O
not	O
potentiation	O
of	O
tissue	O
-	O
specific	O
factors	O
.	O

Author	O
Summary	O

The	O
retinoblastoma	B-GGP
protein	I-GGP
(	O
Rb	B-GGP
)	O
,	O
an	O
important	O
tumor	O
suppressor	O
,	O
blocks	O
division	O
and	O
death	O
by	O
inhibiting	O
the	O
E2f	O
transcription	O
factor	O
family	O
.	O

In	O
contrast	O
,	O
Rb	B-GGP
is	O
thought	O
to	O
promote	O
differentiation	O
by	O
potentiating	O
tissue	O
-	O
specific	O
transcription	O
factors	O
,	O
although	O
differentiation	O
defects	O
in	O
Rb	B-GGP
null	O
cells	B-CL
could	O
be	O
an	O
indirect	O
consequence	O
of	O
E2f	O
-	O
driven	O
division	O
and	O
death	O
.	O

Here	O
,	O
we	O
resolve	O
different	O
mechanisms	O
by	O
which	O
Rb	B-GGP
controls	O
division	O
,	O
death	O
,	O
and	O
differentiation	O
in	O
the	O
retina	O
.	O

Removing	O
E2f1	B-GGP
rescues	O
aberrant	O
division	O
of	O
differentiating	O
Rb	B-GGP
-	O
deficient	O
retinal	O
neurons	B-CL
,	O
as	O
well	O
as	O
death	O
in	O
cells	B-CL
prone	O
to	O
apoptosis	O
,	O
and	O
restores	O
both	O
normal	O
differentiation	O
and	O
function	O
of	O
major	O
cell	B-CL
types	O
,	O
such	O
as	O
photoreceptors	O
.	O

However	O
,	O
Rb	B-GGP
-	O
deficient	O
starburst	O
amacrine	B-CL
neurons	I-CL
differentiate	O
abnormally	O
even	O
when	O
E2f1	B-GGP
is	O
removed	O
,	O
providing	O
an	O
unequivocal	O
example	O
of	O
a	O
direct	O
role	O
for	O
Rb	B-GGP
in	O
neuronal	B-CL
differentiation	O
.	O

Rather	O
than	O
potentiating	O
a	O
cell	B-CL
-	O
specific	O
factor	O
,	O
Rb	B-GGP
promotes	O
starburst	O
cell	B-CL
differentiation	O
by	O
inhibiting	O
another	O
E2f	O
,	O
E2f3a	O
.	O

This	O
cell	B-CL
-	O
cycle	O
-	O
independent	O
activity	O
broadens	O
the	O
importance	O
of	O
the	O
Rb	B-GGP
-	O
E2f	O
pathway	O
,	O
and	O
suggests	O
we	O
should	O
reassess	O
its	O
role	O
in	O
the	O
differentiation	O
of	O
other	O
cell	B-CL
types	O
.	O

Introduction	O

The	O
simplicity	O
of	O
the	O
retina	O
makes	O
it	O
an	O
ideal	O
tissue	O
to	O
study	O
neurogenesis	O
.	O

Its	O
development	O
proceeds	O
through	O
three	O
overlapping	O
steps	O
starting	O
with	O
retinal	O
progenitor	O
cell	B-CL
(	O
RPC	O
)	O
proliferation	O
,	O
followed	O
by	O
birth	O
of	O
post	O
-	O
mitotic	O
retinal	O
transition	O
cells	B-CL
(	O
RTCs	O
,	O
also	O
referred	O
to	O
as	O
precursors	O
)	O
,	O
and	O
ending	O
with	O
terminal	O
differentiation	O
of	O
seven	O
major	O
cell	B-CL
types	O
(	O
Figure	O
1A	O
)	O
[	O
1	O
]	O
.	O

RPCs	O
are	O
multipotent	O
and	O
exit	O
the	O
cell	B-CL
cycle	O
to	O
generate	O
different	O
RTCs	O
at	O
specific	O
time	O
periods	O
in	O
development	O
[	O
1	O
]	O
.	O

This	O
process	O
of	O
RTC	O
"	O
birth	O
"	O
requires	O
coupling	O
of	O
differentiation	O
and	O
cell	B-CL
cycle	O
exit	O
.	O

Once	O
born	O
,	O
post	O
-	O
mitotic	O
RTCs	O
migrate	O
and	O
form	O
different	O
retinal	O
layers	O
.	O

Rods	B-CL
and	O
cones	B-CL
make	O
up	O
the	O
outer	O
nuclear	O
layer	O
(	O
ONL	O
)	O
;	O
horizontal	B-CL
,	I-CL
bipolar	I-CL
,	I-CL
and	I-CL
amacrine	I-CL
cells	I-CL
,	O
as	O
well	O
as	O
M	B-CL
u	I-CL
ller	I-CL
glia	I-CL
cell	I-CL
bodies	O
,	O
reside	O
in	O
the	O
inner	O
nuclear	O
layer	O
(	O
INL	O
)	O
;	O
and	O
ganglion	B-CL
and	I-CL
displaced	I-CL
amacrine	I-CL
cells	I-CL
form	O
the	O
ganglion	B-CL
cell	I-CL
layer	O
(	O
GCL	O
)	O
(	O
Figure	O
1A	O
)	O
.	O

The	O
outer	O
plexiform	O
layer	O
(	O
OPL	O
)	O
and	O
inner	O
plexiform	O
layer	O
(	O
IPL	O
)	O
house	O
synaptic	B-GO
connections	I-GO
separating	O
the	O
ONL	O
/	O
INL	O
and	O
INL	O
/	O
GCL	O
,	O
respectively	O
.	O

Figure	O
1	O

E2f1	B-GGP
,	O
but	O
Not	O
E2f2	B-GGP
or	O
E2f3	B-GGP
,	O
Loss	O
Rescues	O
Ectopic	O
Division	O
and	O
Cell	B-CL
Death	O
in	O
the	O
Rb	B-GGP
KO	O
Retina	O

(	O
A	O
)	O
Retinal	O
development	O
.	O

At	O
E11	O
the	O
retina	O
is	O
a	O
NBL	O
of	O
dividing	O
RPCs	O
(	O
white	O
circle	O
,	O
green	O
nuclei	B-GO
)	O
.	O

RPC	O
cell	B-GO
bodies	I-GO
oscillate	O
along	O
processes	B-GO
as	O
they	O
progress	O
through	O
the	O
cell	B-CL
cycle	O
.	O

By	O
P0	O
the	O
NBL	O
contains	O
both	O
RPCs	O
and	O
post	O
-	O
mitotic	O
RTCs	O
(	O
coloured	O
circles	O
,	O
red	O
nuclei	B-GO
)	O
and	O
is	O
separated	O
from	O
the	O
GCL	O
by	O
the	O
IPL	O
.	O

By	O
P8	O
there	O
are	O
no	O
RPCs	O
,	O
fewer	O
RTCs	O
,	O
an	O
OPL	O
,	O
and	O
more	O
differentiated	O
rods	B-CL
(	O
r	B-CL
)	O
and	O
cones	B-CL
(	O
c	B-CL
)	O
in	O
the	O
ONL	O
;	O
horizontal	B-CL
(	I-CL
h	I-CL
)	I-CL
,	I-CL
bipolar	I-CL
(	I-CL
b	I-CL
)	I-CL
,	I-CL
M	I-CL
u	I-CL
ller	I-CL
(	I-CL
m	I-CL
)	I-CL
,	I-CL
and	I-CL
amacrine	I-CL
(	I-CL
a	I-CL
)	I-CL
cells	I-CL
in	O
the	O
INL	O
;	O
and	O
ganglion	B-CL
(	I-CL
g	I-CL
)	I-CL
and	I-CL
displaced	I-CL
amacrine	I-CL
cells	I-CL
in	O
the	O
GCL	O
.	O

Development	O
is	O
complete	O
by	O
~	O
P18	O
.	O

(	O
B	O
)	O
Rb	B-GGP
is	O
thought	O
to	O
regulate	O
cell	B-CL
cycle	O
and	O
apoptosis	O
by	O
repressing	O
E2fs	O
,	O
but	O
to	O
promote	O
differentiation	O
by	O
potentiating	O
tissue	O
-	O
specific	O
transcription	O
factors	O
.	O

However	O
,	O
Rb	B-GGP
loss	O
could	O
also	O
perturb	O
differentiation	O
through	O
the	O
indirect	O
effects	O
of	O
abnormal	O
division	O
or	O
death	O
,	O
and	O
/	O
or	O
through	O
direct	O
regulation	O
of	O
differentiation	O
genes	B-SO
by	O
E2fs	O
.	O

(	O
C	O
and	O
D	O
)	O
Horizontal	O
retinal	O
sections	O
of	O
the	O
indicated	O
genotypes	B-SO
and	O
ages	O
were	O
stained	O
for	O
nuclei	B-GO
(	O
DAPI	O
,	O
blue	O
)	O
,	O
and	O
(	O
C	O
)	O
S	O
-	O
phase	O
(	O
anti	O
-	O
BrdU	O
,	O
red	O
)	O
or	O
(	O
D	O
)	O
apoptosis	O
(	O
TUNEL	O
,	O
red	O
)	O
.	O

Scale	O
bars	O
are	O
50	O
mu	O
m	O
.	O

(	O
E	O
-	O
G	O
)	O
Quantification	O
of	O
(	O
E	O
)	O
all	O
BrdU	O
+	O
cells	B-CL
,	O
(	O
F	O
)	O
ectopic	O
BrdU	O
+	O
cells	B-CL
in	O
GCL	O
at	O
P0	O
,	O
and	O
(	O
G	O
)	O
total	O
TUNEL	O
+	O
cells	B-CL
.	O

(	O
H	O
)	O
Real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
of	O
E2fs	O
and	O
E2f	O
target	O
genes	B-SO
in	O
P8	O
retinas	O
of	O
the	O
indicated	O
genotypes	B-SO
.	O

Error	O
bars	O
represent	O
SD	O
of	O
measurements	O
from	O
three	O
animals	B-Taxon
,	O
and	O
asterisks	O
indicate	O
a	O
significant	O
difference	O
between	O
the	O
WT	B-SO
and	O
indicated	O
genotypes	B-SO
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
;	O
p	O
<	O
0	O
.	O
01	O
;	O
ANOVA	O
and	O
Tukey	O
HSD	O
test	O
for	O
[	O
E	O
-	O
G	O
]	O
and	O
Fisher	O
test	O
for	O
[	O
H	O
]	O
)	O
.	O

The	O
retinoblastoma	B-GGP
protein	I-GGP
(	O
Rb	B-GGP
)	O
is	O
critical	O
for	O
cell	B-CL
cycle	O
exit	O
during	O
retinal	O
transition	O
cell	B-CL
birth	O
.	O

Rb	B-GGP
knockout	O
(	O
KO	O
)	O
RTCs	O
continue	O
to	O
proliferate	O
inappropriately	O
and	O
some	O
(	O
rod	B-CL
,	I-CL
ganglion	I-CL
,	I-CL
and	I-CL
bipolar	I-CL
cells	I-CL
)	O
die	O
by	O
apoptosis	O
[	O
2	O
,	O
3	O
]	O
.	O

Rb	B-GGP
controls	O
the	O
cell	B-CL
cycle	O
by	O
binding	O
and	O
inhibiting	O
E2f	O
transcription	O
factors	O
(	O
E2fs	O
)	O
(	O
Figure	O
1B	O
)	O
,	O
first	O
defined	O
as	O
transcription	O
factors	O
that	O
bind	O
adenoviral	B-Taxon
E2	O
regulatory	B-SO
elements	I-SO
and	O
subsequently	O
shown	O
to	O
be	O
critical	O
cell	B-CL
cycle	O
regulators	O
[	O
4	O
,	O
5	O
]	O
.	O

E2fs	O
bind	O
to	O
DNA	B-SO
as	O
heterodimers	O
with	O
proteins	B-CHEBI
of	O
the	O
related	O
Tfdp	O
family	O
.	O

E2f1	B-GGP
,	O
E2f2	B-GGP
,	O
and	O
E2f3a	O
are	O
"	O
activating	O
E2fs	O
"	O
that	O
are	O
required	O
for	O
fibroblast	B-CL
division	O
.	O

They	O
are	O
strong	O
transcriptional	O
activators	O
that	O
can	O
drive	O
G0	O
fibroblasts	B-CL
into	O
cycle	O
,	O
and	O
are	O
inhibited	O
when	O
bound	O
to	O
Rb	B-GGP
[	O
4	O
,	O
5	O
]	O
.	O

Ectopic	O
division	O
in	O
Rb	B-GGP
KO	O
embryos	O
can	O
be	O
rescued	O
to	O
various	O
extents	O
in	O
different	O
tissues	O
by	O
knocking	O
out	O
E2f1	B-GGP
,	O
E2f2	B-GGP
,	O
or	O
E2f3	B-GGP
[	O
6	O
-	O
9	O
]	O
,	O
but	O
which	O
member	O
(	O
s	O
)	O
drive	O
division	O
in	O
Rb	B-GGP
KO	O
RTCs	O
is	O
unknown	O
.	O

Other	O
members	O
of	O
the	O
family	O
,	O
such	O
as	O
E2f4	B-GGP
and	O
E2f5	B-GGP
,	O
are	O
known	O
as	O
"	O
repressive	O
E2fs	O
"	O
because	O
they	O
are	O
weak	O
activators	O
and	O
appear	O
to	O
be	O
primarily	O
involved	O
in	O
gene	B-SO
silencing	O
in	O
quiescent	O
or	O
differentiated	O
cells	B-CL
.	O

Activating	O
E2fs	O
may	O
also	O
promote	O
apoptosis	O
in	O
the	O
Rb	B-GGP
KO	O
retina	O
(	O
Figure	O
1B	O
)	O
.	O

Originally	O
,	O
E2f1	B-GGP
was	O
considered	O
the	O
primary	O
pro	O
-	O
apoptotic	O
member	O
of	O
the	O
family	O
[	O
10	O
]	O
.	O

However	O
,	O
this	O
view	O
was	O
reevaluated	O
when	O
it	O
was	O
shown	O
that	O
either	O
E2f1	B-GGP
or	O
E2f3	B-GGP
deletion	B-SO
rescues	O
apoptosis	O
in	O
the	O
developing	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
of	O
Rb	B-GGP
KO	O
embryos	O
[	O
6	O
,	O
11	O
]	O
.	O

Subsequently	O
,	O
CNS	O
apoptosis	O
was	O
shown	O
to	O
be	O
an	O
indirect	O
result	O
of	O
placental	O
defects	O
and	O
probable	O
hypoxia	O
[	O
12	O
-	O
14	O
]	O
.	O

Indeed	O
,	O
E2f3	B-GGP
-	O
induced	O
apoptosis	O
in	O
fibroblasts	B-CL
has	O
recently	O
been	O
shown	O
to	O
require	O
E2f1	B-GGP
[	O
15	O
]	O
.	O

Thus	O
,	O
it	O
is	O
controversial	O
whether	O
E2f3	B-GGP
is	O
required	O
for	O
apoptosis	O
of	O
any	O
Rb	B-GGP
KO	O
cell	B-CL
type	O
.	O

Determining	O
which	O
activating	O
E2fs	O
promote	O
death	O
in	O
distinct	O
Rb	B-GGP
KO	O
tissues	O
requires	O
conditional	O
rather	O
than	O
germ	O
line	O
models	O
of	O
Rb	B-GGP
deletion	B-SO
to	O
avoid	O
secondary	O
indirect	O
effects	O
(	O
such	O
as	O
hypoxia	O
)	O
.	O

E2f	O
family	O
diversity	O
is	O
expanded	O
by	O
E2f3	B-GGP
isoforms	B-SO
.	O

Alternative	O
promoters	B-SO
generate	O
two	O
forms	B-SO
(	O
a	O
and	O
b	O
)	O
that	O
are	O
identical	O
except	O
for	O
distinct	O
first	O
exons	B-SO
[	O
16	O
]	O
.	O

E2f3a	O
is	O
a	O
strong	O
activator	O
,	O
and	O
,	O
like	O
other	O
activating	O
E2fs	O
,	O
its	O
expression	O
is	O
induced	O
when	O
quiescent	O
cells	B-CL
are	O
stimulated	O
to	O
divide	O
[	O
16	O
]	O
.	O

E2f3b	O
,	O
like	O
repressive	O
E2fs	O
,	O
is	O
present	O
in	O
both	O
quiescent	O
and	O
dividing	O
cells	B-CL
,	O
and	O
in	O
quiescent	O
fibroblasts	B-CL
it	O
associates	O
primarily	O
with	O
Rb	B-GGP
,	O
suggesting	O
that	O
it	O
mediates	O
repression	O
[	O
16	O
-	O
18	O
]	O
.	O

Indeed	O
,	O
silencing	O
the	O
Cdkn2d	B-GGP
(	O
p19Arf	B-GGP
)	O
locus	B-SO
in	O
unstressed	O
cells	B-CL
relies	O
on	O
E2f3b	O
[	O
19	O
]	O
.	O

Other	O
E2fs	O
may	O
also	O
exist	O
in	O
isoforms	B-SO
since	O
at	O
least	O
two	O
mRNA	B-CHEBI
species	B-SO
have	O
been	O
detected	O
for	O
E2f1	B-GGP
and	O
E2f2	B-GGP
[	O
16	O
]	O
.	O

The	O
roles	O
of	O
E2f	O
isoforms	B-SO
in	O
vivo	O
are	O
unknown	O
.	O

E2fs	O
are	O
also	O
regulated	O
by	O
subcellular	O
localization	O
.	O

Although	O
this	O
feature	O
has	O
been	O
best	O
characterized	O
for	O
repressive	O
E2fs	O
[	O
20	O
-	O
22	O
]	O
,	O
it	O
also	O
affects	O
activating	O
E2fs	O
[	O
23	O
-	O
25	O
]	O
.	O

The	O
distribution	O
of	O
E2f	O
isoforms	B-SO
has	O
never	O
been	O
assessed	O
.	O

It	O
has	O
been	O
known	O
for	O
many	O
years	O
that	O
Rb	B-GGP
loss	O
perturbs	O
neuronal	B-CL
differentiation	O
[	O
26	O
-	O
29	O
]	O
.	O

However	O
,	O
prior	O
work	O
could	O
not	O
exclude	O
the	O
possibility	O
that	O
differentiation	O
defects	O
are	O
simply	O
an	O
indirect	O
consequence	O
of	O
abnormal	O
division	O
and	O
death	O
.	O

If	O
Rb	B-GGP
does	O
regulate	O
differentiation	O
directly	O
it	O
is	O
unclear	O
whether	O
it	O
does	O
so	O
in	O
all	O
or	O
a	O
subset	O
of	O
neurons	B-CL
.	O

Moreover	O
,	O
the	O
mechanism	O
has	O
never	O
been	O
solved	O
.	O

In	O
other	O
cell	B-CL
types	O
where	O
Rb	B-GGP
may	O
promote	O
differentiation	O
directly	O
,	O
such	O
as	O
muscle	O
and	O
bone	O
,	O
it	O
seems	O
to	O
do	O
so	O
through	O
E2f	O
-	O
independent	O
means	O
by	O
potentiating	O
tissue	O
-	O
specific	O
transcription	O
factors	O
(	O
Figure	O
1B	O
)	O
[	O
30	O
-	O
33	O
]	O
.	O

In	O
the	O
retina	O
,	O
others	O
have	O
noted	O
abnormally	O
shaped	O
Rb	B-GGP
KO	O
rods	B-CL
and	O
have	O
suggested	O
Rb	B-GGP
may	O
directly	O
promote	O
their	O
morphogenesis	O
by	O
activating	O
retina	O
-	O
specific	O
factors	O
[	O
29	O
]	O
.	O

However	O
,	O
differentiation	O
defects	O
in	O
any	O
Rb	B-GGP
KO	O
neuron	B-CL
could	O
be	O
an	O
indirect	O
effect	O
of	O
ectopic	O
division	O
and	O
/	O
or	O
apoptosis	O
(	O
Figure	O
1B	O
)	O
.	O

Thus	O
,	O
it	O
is	O
critical	O
to	O
study	O
differentiation	O
of	O
Rb	B-GGP
KO	O
cells	B-CL
in	O
the	O
absence	O
of	O
ectopic	O
proliferation	O
and	O
death	O
.	O

Here	O
,	O
we	O
establish	O
that	O
Rb	B-GGP
suppresses	O
RTC	O
division	O
and	O
death	O
by	O
inhibiting	O
E2f1	B-GGP
,	O
not	O
E2f2	B-GGP
or	O
E2f3	B-GGP
.	O

When	O
these	O
defects	O
were	O
rescued	O
,	O
most	O
retinal	O
neurons	B-CL
,	O
including	O
rods	B-CL
,	O
survived	O
,	O
differentiated	O
,	O
and	O
functioned	O
normally	O
.	O

Thus	O
,	O
unexpectedly	O
,	O
retina	O
-	O
specific	O
differentiation	O
factors	O
function	O
independently	O
of	O
Rb	B-GGP
.	O

However	O
,	O
comprehensive	O
assessment	O
of	O
the	O
Rb	B-GGP
/	O
E2f1	B-GGP
double	O
-	O
null	O
rescued	O
retina	O
revealed	O
a	O
differentiation	O
defect	O
in	O
cholinergic	B-CHEBI
starburst	O
amacrine	B-CL
cells	I-CL
(	O
SACs	O
)	O
.	O

Recent	O
breakthroughs	O
have	O
revealed	O
that	O
these	O
interneurons	B-CL
are	O
critical	O
for	O
direction	O
selectivity	O
and	O
developmentally	O
important	O
rhythmic	O
bursts	O
[	O
34	O
-	O
36	O
]	O
.	O

However	O
,	O
their	O
differentiation	O
is	O
poorly	O
understood	O
.	O

Contrary	O
to	O
the	O
prevailing	O
view	O
that	O
Rb	B-GGP
promotes	O
differentiation	O
through	O
E2f	O
-	O
independent	O
tissue	O
-	O
specific	O
transcription	O
factors	O
,	O
we	O
show	O
that	O
Rb	B-GGP
facilitates	O
SAC	O
development	O
through	O
E2f3	B-GGP
.	O

Defects	O
in	O
Rb	B-GGP
null	O
SACs	O
correlated	O
with	O
specific	O
E2f3	B-GGP
expression	O
in	O
these	O
cells	B-CL
,	O
and	O
E2f3	B-GGP
expression	O
was	O
absent	O
in	O
neurons	B-CL
that	O
differentiated	O
without	O
Rb	B-GGP
.	O

E2f3	B-GGP
is	O
also	O
present	O
in	O
a	O
specific	O
subset	O
of	O
other	O
CNS	B-CL
neurons	I-CL
,	O
implying	O
that	O
this	O
may	O
be	O
a	O
general	O
mechanism	O
by	O
which	O
Rb	B-GGP
facilitates	O
neurogenesis	O
.	O

To	O
define	O
the	O
mechanism	O
in	O
even	O
more	O
detail	O
,	O
we	O
determined	O
which	O
E2f3	B-GGP
isoform	B-SO
Rb	B-GGP
targets	O
to	O
control	O
SAC	O
differentiation	O
.	O

E2f3b	O
mediates	O
Rb	B-GGP
function	O
in	O
quiescent	O
fibroblasts	B-CL
[	O
19	O
]	O
,	O
yet	O
no	O
prior	O
studies	O
to	O
our	O
knowledge	O
have	O
dissected	O
E2f3a	O
or	O
E2f3b	O
functions	O
in	O
vivo	O
.	O

Using	O
an	O
isoform	B-SO
-	O
specific	O
null	O
mouse	B-Taxon
we	O
show	O
that	O
Rb	B-GGP
drives	O
SAC	O
differentiation	O
through	O
E2f3a	O
.	O

Thus	O
,	O
independent	O
of	O
E2f1	B-GGP
-	O
mediated	O
effects	O
on	O
division	O
and	O
death	O
,	O
Rb	B-GGP
does	O
regulate	O
neuronal	B-CL
differentiation	O
,	O
but	O
only	O
in	O
specific	O
neurons	B-CL
and	O
,	O
unexpectedly	O
,	O
through	O
E2f3a	O
,	O
not	O
tissue	O
-	O
specific	O
differentiation	O
factors	O
.	O

Results	O

Rb	B-GGP
Regulates	O
Division	O
and	O
Death	O
through	O
E2f1	B-GGP

We	O
used	O
the	O
alpha	O
-	O
Cre	O
transgene	B-SO
to	O
delete	B-SO
floxed	B-SO
Rb	B-GGP
exon	B-SO
19	O
at	O
embryonic	O
day	O
(	O
E	O
)	O
10	O
in	O
peripheral	O
retina	O
[	O
2	O
]	O
.	O

RbloxP	O
/	O
loxP	B-SO
;	O
alpha	O
-	O
Cre	O
mice	B-Taxon
were	O
bred	O
with	O
strains	O
lacking	O
E2f1	B-GGP
or	O
E2f2	B-GGP
in	O
the	O
germ	O
line	O
,	O
or	O
a	O
strain	O
carrying	O
a	O
floxed	B-SO
E2f3	B-GGP
allele	B-SO
[	O
5	O
]	O
.	O

RbloxP	O
/	O
loxP	B-SO
;	O
E2f1	B-GGP
+	B-SO
/	O
-	O
and	O
RbloxP	O
/	O
loxP	B-SO
;	O
E2f1	B-GGP
+	B-SO
/	O
-	O
;	O
alpha	O
-	O
Cre	O
mice	B-Taxon
were	O
bred	O
to	O
produce	O
RbloxP	O
/	O
loxP	B-SO
;	O
E2f1	B-GGP
-	O
/	O
-	O
;	O
alpha	O
-	O
Cre	O
mice	B-Taxon
at	O
a	O
frequency	O
of	O
1	O
/	O
8	O
and	O
littermate	O
controls	O
at	O
the	O
same	O
or	O
higher	O
(	O
1	O
/	O
4	O
)	O
frequency	O
.	O

For	O
simplicity	O
we	O
will	O
refer	O
to	O
the	O
RbloxP	O
/	O
loxP	B-SO
;	O
E2f1	B-GGP
-	O
/	O
-	O
;	O
alpha	O
-	O
Cre	O
peripheral	O
retina	O
as	O
the	O
Rb	B-GGP
/	O
E2f1	B-GGP
double	O
knockout	O
(	O
DKO	O
)	O
retina	O
.	O

Similar	O
strategies	O
were	O
employed	O
in	O
the	O
case	O
of	O
E2f2	B-GGP
or	O
E2f3	B-GGP
.	O

Cre	O
-	O
mediated	O
excision	B-SO
of	O
Rb	B-GGP
and	O
E2f3	B-GGP
alleles	B-SO
in	O
the	O
retina	O
was	O
confirmed	O
by	O
PCR	O
as	O
described	O
previously	O
[	O
2	O
,	O
5	O
]	O
.	O

To	O
measure	O
ectopic	O
cell	B-CL
division	O
,	O
mice	B-Taxon
were	O
pulse	O
-	O
labelled	O
with	O
bromodeoxyuridine	O
(	O
BrdU	O
)	O
2	O
h	O
before	O
sacrifice	O
and	O
the	O
peripheral	O
retina	O
analyzed	O
for	O
BrdU	O
incorporation	B-SO
by	O
immunofluorescence	O
.	O

As	O
reported	O
before	O
[	O
2	O
,	O
3	O
]	O
,	O
Rb	B-GGP
KO	O
retinas	O
exhibited	O
both	O
spatial	O
and	O
temporal	O
ectopic	O
DNA	B-SO
synthesis	O
(	O
Figures	O
1C	O
and	O
S1A	O
)	O
.	O

This	O
is	O
easily	O
detected	O
at	O
E14	O
,	O
E16	O
,	O
and	O
postnatal	O
day	O
(	O
P	O
)	O
0	O
in	O
the	O
inner	O
retina	O
where	O
abnormal	O
BrdU	O
+	O
ganglion	B-CL
and	O
amacrine	B-CL
RTCs	O
are	O
located	O
,	O
or	O
on	O
the	O
outermost	O
region	O
of	O
the	O
P0	O
retina	O
,	O
where	O
BrdU	O
+	O
photoreceptor	B-CL
RTCs	O
reside	O
(	O
Figures	O
S1A	O
and	O
S2	O
,	O
arrows	O
)	O
[	O
2	O
]	O
.	O

Ectopic	O
RTC	O
division	O
in	O
Rb	B-GGP
KO	O
retinas	O
is	O
even	O
more	O
obvious	O
at	O
P8	O
or	O
P18	O
,	O
when	O
division	O
is	O
completed	O
in	O
wild	B-SO
-	I-SO
type	I-SO
(	O
WT	B-SO
)	O
retina	O
(	O
Figures	O
1C	O
and	O
S1A	O
)	O
.	O

Strikingly	O
,	O
the	O
ectopically	O
positioned	O
S	O
-	O
phase	O
cells	B-CL
at	O
E14	O
,	O
E16	O
,	O
and	O
P0	O
and	O
all	O
the	O
abnormal	O
division	O
at	O
P8	O
and	O
P18	O
were	O
completely	O
suppressed	O
in	O
the	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
retina	O
(	O
Figures	O
1C	O
,	O
1E	O
,	O
1F	O
,	O
S1A	O
,	O
and	O
S2	O
)	O
.	O

In	O
contrast	O
,	O
deletion	B-SO
of	O
E2f2	B-GGP
or	O
E2f3	B-GGP
had	O
no	O
effect	O
at	O
any	O
stage	O
of	O
development	O
.	O

Analysis	O
of	O
mitotic	O
cells	B-CL
with	O
anti	O
-	O
phosphohistone	O
3	O
(	O
PH3	O
)	O
-	O
specific	O
antibodies	B-GO
confirmed	O
that	O
loss	O
of	O
E2f1	B-GGP
,	O
but	O
not	O
E2f2	B-GGP
or	O
E2f3	B-GGP
,	O
suppressed	O
ectopic	O
division	O
(	O
Figure	O
S3	O
)	O
.	O

Deleting	B-SO
one	O
E2f1	B-GGP
allele	B-SO
partially	O
suppressed	O
ectopic	O
S	O
-	O
phase	O
and	O
mitosis	O
in	O
Rb	B-GGP
KO	O
RTCs	O
(	O
Figures	O
1C	O
,	O
1E	O
,	O
1F	O
,	O
S1A	O
,	O
S2	O
,	O
and	O
S3	O
)	O
,	O
suggesting	O
that	O
E2f1	B-GGP
drives	O
ectopic	O
division	O
in	O
Rb	B-GGP
KO	O
RTCs	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

These	O
data	O
contrast	O
with	O
previous	O
findings	O
in	O
the	O
lens	O
and	O
CNS	O
of	O
Rb	B-GGP
KO	O
embryos	O
,	O
where	O
deletion	B-SO
of	O
any	O
activating	O
E2f	O
suppresses	O
ectopic	O
division	O
to	O
some	O
extent	O
[	O
6	O
-	O
9	O
]	O
.	O

Loss	O
of	O
Rb	B-GGP
in	O
the	O
retina	O
results	O
in	O
considerable	O
RTC	O
apoptosis	O
,	O
eliminating	O
most	O
bipolar	B-CL
and	I-CL
ganglion	I-CL
cells	I-CL
as	O
well	O
as	O
many	O
rods	B-CL
(	O
Figure	O
2A	O
-	O
2D	O
)	O
[	O
2	O
,	O
3	O
]	O
.	O

The	O
loss	O
of	O
Rb	B-GGP
KO	O
rods	B-CL
is	O
evident	O
from	O
the	O
thinner	O
ONL	O
,	O
and	O
the	O
death	O
of	O
these	O
cells	B-CL
as	O
well	O
as	O
bipolar	B-CL
and	I-CL
ganglion	I-CL
neurons	I-CL
can	O
be	O
detected	O
directly	O
by	O
double	O
labelling	O
for	O
apoptotic	O
and	O
cell	B-CL
-	O
type	O
-	O
specific	O
markers	O
[	O
2	O
]	O
(	O
M	O
.	O
P	O
.	O
and	O
R	O
.	O
B	O
.	O
,	O
unpublished	O
data	O
)	O
.	O

Loss	O
of	O
peripheral	O
Rb	B-GGP
KO	O
ganglion	B-CL
cells	I-CL
is	O
also	O
evident	O
from	O
thinning	O
of	O
the	O
optic	O
nerve	O
(	O
D	O
.	O
C	O
.	O
and	O
R	O
.	O
B	O
.	O
,	O
unpublished	O
data	O
)	O
.	O

Deleting	B-SO
E2f1	B-GGP
,	O
but	O
not	O
E2f2	B-GGP
or	O
E2f3	B-GGP
,	O
blocked	O
this	O
ectopic	O
cell	B-CL
death	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
(	O
Figures	O
1D	O
,	O
1G	O
,	O
and	O
S1B	O
)	O
.	O

Figure	O
2	O

E2f1	B-GGP
Deletion	B-SO
Rescues	O
Ganglion	B-CL
,	I-CL
Rod	I-CL
,	I-CL
and	I-CL
Bipolar	I-CL
Cells	I-CL
in	I-CL
the	I-CL
Rb	I-CL
KO	I-CL
Retina	I-CL

(	O
A	O
)	O
Horizontal	O
retinal	O
sections	O
from	O
mice	B-Taxon
of	O
the	O
indicated	O
ages	O
and	O
genotypes	B-SO
were	O
stained	O
for	O
nuclei	B-GO
(	O
DAPI	O
,	O
blue	O
)	O
and	O
markers	O
that	O
detect	O
ganglion	B-CL
cells	I-CL
(	O
Pou4f2	B-GGP
,	O
red	O
)	O
,	O
rods	B-CL
and	O
cones	B-CL
(	O
Sag	B-GGP
[	O
rod	B-GGP
arrestin	I-GGP
]	O
,	O
green	O
)	O
,	O
and	O
rod	B-CL
bipolar	I-CL
cells	I-CL
(	O
Prkca	B-GGP
,	O
green	O
,	O
and	O
Cabp5	B-GGP
,	O
red	O
)	O
.	O

Scale	O
bars	O
are	O
50	O
mu	O
m	O
.	O

(	O
B	O
)	O
Quantification	O
of	O
Pou4f2	B-GGP
+	O
ganglion	B-CL
cells	I-CL
.	O

(	O
C	O
)	O
Quantification	O
of	O
Prkca	B-GGP
+	O
and	O
Cabp5	B-GGP
+	O
bipolar	B-CL
cells	I-CL
.	O

(	O
D	O
)	O
Thickness	O
of	O
the	O
ONL	O
,	O
which	O
represents	O
the	O
number	O
of	O
rods	B-CL
.	O

Error	O
bars	O
represent	O
SD	O
of	O
measurements	O
from	O
three	O
animals	B-Taxon
,	O
and	O
asterisks	O
indicate	O
a	O
significant	O
difference	O
between	O
retinas	O
of	O
WT	B-SO
and	O
the	O
indicated	O
genotypes	B-SO
,	O
unless	O
indicated	O
otherwise	O
by	O
connecting	O
lines	O
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
;	O
p	O
<	O
0	O
.	O
01	O
;	O
ANOVA	O
and	O
Tukey	O
HSD	O
test	O
)	O
.	O

(	O
E	O
and	O
F	O
)	O
ERGs	O
were	O
recorded	O
from	O
the	O
indicated	O
genotypes	B-SO
under	O
dark	O
-	O
adapted	O
(	O
scotopic	O
)	O
conditions	O
,	O
and	O
(	O
E	O
)	O
intensity	O
series	O
and	O
(	O
F	O
)	O
b	O
-	O
wave	O
amplitudes	O
as	O
a	O
function	O
of	O
the	O
logarithm	O
of	O
the	O
flash	O
intensity	O
were	O
determined	O
.	O

(	O
F	O
)	O
Further	O
illustrates	O
that	O
the	O
relative	O
influence	O
of	O
the	O
mutations	B-SO
on	O
the	O
photoreceptors	B-CL
(	O
indicated	O
by	O
the	O
saturated	O
a	O
-	O
wave	O
amplitude	O
,	O
right	O
graph	O
)	O
was	O
not	O
substantially	O
different	O
from	O
their	O
effect	O
on	O
the	O
b	O
-	O
wave	O
response	O
(	O
dominated	O
by	O
the	O
bipolars	B-CL
,	O
left	O
graph	O
)	O
at	O
the	O
same	O
intensity	O
of	O
10	O
cd	O
.	O
s	O
/	O
m2	O
.	O

To	O
investigate	O
the	O
molecular	B-CHEBI
mechanism	O
that	O
underlies	O
the	O
unique	O
role	O
of	O
E2f1	B-GGP
,	O
we	O
assessed	O
the	O
expression	O
of	O
known	B-SO
E2f	O
targets	O
as	O
well	O
as	O
other	O
genes	B-SO
that	O
regulate	O
the	O
cell	B-CL
cycle	O
and	O
apoptosis	O
.	O

Numerous	O
positive	O
and	O
negative	O
cell	B-CL
cycle	O
and	O
apoptotic	O
regulators	O
were	O
up	O
-	O
regulated	O
in	O
the	O
Rb	B-GGP
KO	O
retina	O
(	O
Figure	O
1H	O
)	O
.	O

Among	O
the	O
E2f	O
family	O
,	O
E2f1	B-GGP
,	O
E2f2	B-GGP
,	O
E2f3a	O
,	O
and	O
E2f7	B-GGP
were	O
induced	O
following	O
Rb	B-GGP
loss	O
,	O
but	O
E2f3b	O
,	O
E2f4	B-GGP
,	O
and	O
E2f5	B-GGP
were	O
unaffected	O
.	O

Consistent	O
with	O
the	O
BrdU	O
and	O
terminal	O
dUTP	B-CHEBI
nick	O
-	O
end	O
labelling	O
(	O
TUNEL	O
)	O
analyses	O
,	O
E2f1	B-GGP
deletion	B-SO
specifically	O
reversed	O
all	O
these	O
molecular	B-CHEBI
defects	O
,	O
but	O
E2f3	B-GGP
deletion	B-SO
had	O
no	O
effect	O
(	O
Figure	O
1H	O
)	O
.	O

Normal	O
Differentiation	O
in	O
the	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
Retina	O

Because	O
E2f1	B-GGP
deletion	B-SO
blocks	O
abnormal	O
division	O
and	O
death	O
in	O
the	O
Rb	B-GGP
KO	O
retina	O
,	O
the	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
retina	O
provided	O
a	O
unique	O
opportunity	O
to	O
evaluate	O
whether	O
Rb	B-GGP
controls	O
differentiation	O
independent	O
of	O
cell	B-CL
cycle	O
effects	O
.	O

The	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
retina	O
had	O
many	O
Sag	B-GGP
+	O
(	O
S	B-GGP
-	I-GGP
antigen	I-GGP
/	O
rod	B-GGP
arrestin	I-GGP
)	O
photoreceptors	B-CL
,	O
Pou4f2	B-GGP
+	O
(	O
Brn3b	B-GGP
)	O
ganglion	B-CL
cells	I-CL
,	O
and	O
numerous	O
Prkca	B-GGP
+	O
/	O
Cabp5	B-GGP
+	O
bipolar	B-CL
neurons	I-CL
(	O
Figure	O
2A	O
-	O
2D	O
)	O
.	O

In	O
contrast	O
,	O
there	O
was	O
no	O
such	O
rescue	O
of	O
cell	B-CL
types	O
in	O
Rb	B-GGP
/	O
E2f2	B-GGP
or	O
Rb	B-GGP
/	O
E2f3	B-GGP
DKO	O
retinas	O
(	O
Figure	O
S4	O
)	O
.	O

Analysis	O
with	O
general	O
neuronal	B-CL
markers	O
Mtap2	B-GGP
(	O
MAP2	B-GGP
)	O
and	O
Snap25	B-GGP
,	O
as	O
well	O
as	O
other	O
markers	O
expressed	O
in	O
bipolar	B-CL
cells	I-CL
(	O
Chx10	B-GGP
,	O
Rcvrn	B-GGP
,	O
Vsx1	B-GGP
,	O
Tacr3	B-GGP
,	O
and	O
Atp2b1	B-GGP
)	O
and	O
rod	B-CL
photoreceptors	I-CL
(	O
Rho	B-GGP
and	O
Rcvrn	B-GGP
)	O
confirmed	O
rescue	O
of	O
the	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
retina	O
(	O
Table	O
S1	O
)	O
.	O

Moreover	O
,	O
neurons	B-CL
exhibited	O
the	O
same	O
complex	O
morphology	O
as	O
in	O
WT	B-SO
retina	O
.	O

Bipolar	B-CL
cell	I-CL
bodies	O
were	O
located	O
in	O
the	O
INL	O
and	O
had	O
ascending	O
and	O
descending	O
processes	B-GO
ending	O
in	O
the	O
OPL	O
and	O
IPL	O
,	O
respectively	O
(	O
Figure	O
2A	O
)	O
.	O

In	O
addition	O
,	O
the	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
retina	O
had	O
a	O
healthy	O
appearing	O
ONL	O
consisting	O
of	O
morphologically	O
normal	O
rods	B-CL
with	O
descending	O
processes	B-GO
ending	O
in	O
the	O
OPL	O
and	O
ascending	O
processes	B-GO
that	O
terminated	O
in	O
inner	B-GO
and	I-GO
outer	I-GO
segments	I-GO
(	O
Figure	O
2A	O
)	O
.	O

It	O
was	O
suggested	O
that	O
Rb	B-GGP
might	O
regulate	O
photoreceptor	B-CL
differentiation	O
,	O
possibly	O
through	O
rod	B-CL
-	O
specific	O
transcription	O
factors	O
(	O
Figure	O
1B	O
)	O
[	O
29	O
]	O
.	O

However	O
,	O
if	O
Rb	B-GGP
does	O
regulate	O
photoreceptor	B-CL
differentiation	O
,	O
it	O
does	O
so	O
by	O
inhibiting	O
E2f1	B-GGP
,	O
not	O
by	O
potentiating	O
rod	B-CL
differentiation	O
factors	O
,	O
such	O
as	O
Otx2	B-GGP
,	O
Crx	B-GGP
,	O
or	O
Nrl	B-GGP
.	O

It	O
is	O
impossible	O
to	O
tell	O
whether	O
E2f1	B-GGP
perturbs	O
differentiation	O
directly	O
,	O
by	O
affecting	O
the	O
expression	O
of	O
genes	B-SO
that	O
modulate	O
maturation	O
,	O
and	O
/	O
or	O
indirectly	O
through	O
its	O
effects	O
on	O
proliferation	O
and	O
survival	O
(	O
Figure	O
1B	O
)	O
.	O

As	O
with	O
ectopic	O
division	O
and	O
apoptosis	O
(	O
Figure	O
1C	O
and	O
1D	O
)	O
,	O
the	O
rescue	O
of	O
Rb	B-GGP
KO	O
retinal	B-CL
bipolar	I-CL
,	I-CL
ganglion	I-CL
,	I-CL
and	I-CL
rod	I-CL
cells	I-CL
was	O
dependent	O
on	O
E2f1	B-GGP
dose	O
(	O
Figure	O
2A	O
-	O
2D	O
)	O
.	O

Separate	O
from	O
its	O
role	O
in	O
driving	O
ectopic	O
division	O
of	O
Rb	B-GGP
KO	O
RTCs	O
,	O
E2f1	B-GGP
also	O
promotes	O
normal	O
RPC	O
division	O
since	O
in	O
its	O
absence	O
RPC	O
proliferation	O
drops	O
~	O
2	O
-	O
fold	O
(	O
D	O
.	O
C	O
.	O
and	O
R	O
.	O
B	O
.	O
,	O
unpublished	O
data	O
)	O
.	O

This	O
modest	O
reduction	O
of	O
RPC	O
numbers	O
in	O
the	O
absence	O
of	O
E2f1	B-GGP
accounts	O
for	O
the	O
slight	O
reduction	O
in	O
the	O
number	O
of	O
ganglion	B-CL
cells	I-CL
at	O
P0	O
,	O
in	O
the	O
number	O
of	O
bipolar	B-CL
cells	I-CL
at	O
P18	O
or	O
P30	O
,	O
and	O
in	O
the	O
thickness	O
of	O
the	O
ONL	O
at	O
P18	O
or	O
P30	O
in	O
the	O
E2f1	B-GGP
KO	O
and	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
retina	O
(	O
Figure	O
2B	O
-	O
2D	O
)	O
.	O

The	O
morphology	O
of	O
E2f1	B-GGP
KO	O
neurons	B-CL
was	O
WT	B-SO
(	O
Figure	O
2A	O
)	O
.	O

Despite	O
a	O
slight	O
drop	O
in	O
absolute	O
cell	B-CL
numbers	O
,	O
the	O
proportion	O
of	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
and	O
E2f1	B-GGP
KO	O
bipolar	B-CL
cells	I-CL
was	O
the	O
same	O
as	O
WT	B-SO
(	O
data	O
not	O
shown	O
)	O
.	O

Slightly	O
reduced	O
cell	B-CL
numbers	O
were	O
not	O
due	O
to	O
residual	O
RTC	O
death	O
since	O
we	O
have	O
not	O
observed	O
ectopic	O
apoptosis	O
at	O
any	O
embryonic	O
or	O
postnatal	O
stage	O
in	O
the	O
developing	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
retina	O
(	O
Figures	O
1D	O
,	O
1G	O
,	O
and	O
S2	O
)	O
.	O

Moreover	O
,	O
deleting	B-SO
Ccnd1	B-GGP
,	O
which	O
acts	O
upstream	O
of	O
Rb	B-GGP
proteins	B-CHEBI
,	O
also	O
reduces	O
RPC	O
number	O
,	O
but	O
does	O
not	O
suppress	O
any	O
defect	O
in	O
the	O
Rb	B-GGP
KO	O
retina	O
(	O
D	O
.	O
C	O
.	O
and	O
R	O
.	O
B	O
.	O
,	O
unpublished	O
data	O
)	O
.	O

Thus	O
,	O
slightly	O
reduced	O
RPC	O
division	O
and	O
dramatic	O
rescue	O
of	O
severe	O
defects	O
in	O
Rb	B-GGP
KO	O
RTCs	O
are	O
distinct	O
effects	O
stemming	O
from	O
the	O
deletion	B-SO
of	O
E2f1	B-GGP
.	O

Normal	O
Function	O
of	O
the	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
Retina	O

The	O
discovery	O
that	O
E2f1	B-GGP
loss	O
rescues	O
even	O
the	O
morphology	O
of	O
Rb	B-GGP
KO	O
neurons	B-CL
is	O
surprising	O
because	O
Rb	B-GGP
is	O
thought	O
to	O
regulate	O
differentiation	O
primarily	O
through	O
E2f	O
-	O
independent	O
pathways	O
[	O
30	O
-	O
33	O
]	O
.	O

However	O
,	O
normal	O
morphology	O
may	O
not	O
equate	O
to	O
completely	O
normal	O
differentiation	O
.	O

Thus	O
,	O
we	O
compared	O
the	O
electroretinograms	O
(	O
ERGs	O
)	O
of	O
adult	O
WT	B-SO
(	O
alpha	O
-	O
Cre	O
)	O
,	O
E2f1	B-GGP
-	O
/	O
-	O
,	O
alpha	O
-	O
Cre	O
;	O
RbloxP	O
/	O
loxP	B-SO
,	O
and	O
alpha	O
-	O
Cre	O
;	O
RbloxP	O
/	O
loxP	B-SO
;	O
E2f1	B-GGP
-	O
/	O
-	O
mice	B-Taxon
.	O

ERGs	O
functionally	O
assess	O
visual	O
signalling	O
in	O
the	O
mammalian	B-Taxon
retina	O
from	O
photoreceptors	B-CL
to	O
amacrine	B-CL
cells	I-CL
(	O
but	O
usually	O
not	O
gangion	B-CL
cells	I-CL
)	O
,	O
and	O
are	O
dominated	O
by	O
rod	B-CL
and	I-CL
cone	I-CL
bipolar	I-CL
cells	I-CL
.	O

Typically	O
,	O
an	O
ERG	O
signal	O
begins	O
with	O
a	O
negative	O
deflection	O
initiated	O
by	O
the	O
photoreceptors	B-CL
(	O
the	O
a	O
-	O
wave	O
)	O
,	O
which	O
is	O
terminated	O
by	O
a	O
large	O
positive	O
deflection	O
due	O
to	O
the	O
activation	O
of	O
ON	B-CL
bipolar	I-CL
cells	I-CL
(	O
the	O
b	O
-	O
wave	O
)	O
.	O

Responses	O
to	O
dim	O
light	O
in	O
dark	O
-	O
adapted	O
(	O
scotopic	O
)	O
conditions	O
specifically	O
assess	O
the	O
rod	B-CL
system	O
,	O
and	O
were	O
defective	O
in	O
the	O
Rb	B-GGP
KO	O
retina	O
(	O
Figure	O
2E	O
)	O
.	O

The	O
substantial	O
reduction	O
of	O
both	O
a	O
-	O
and	O
b	O
-	O
waves	O
is	O
consistent	O
with	O
rod	B-CL
and	I-CL
bipolar	I-CL
cell	I-CL
apoptosis	O
[	O
2	O
]	O
.	O

The	O
sensitivity	O
of	O
the	O
residual	O
response	O
appeared	O
unchanged	O
,	O
suggesting	O
it	O
arose	O
from	O
the	O
Cre	O
-	O
negative	O
portions	O
of	O
the	O
retina	O
.	O

Responses	O
were	O
about	O
the	O
same	O
in	O
the	O
WT	B-SO
and	O
E2f1	B-GGP
KO	O
retina	O
,	O
and	O
,	O
most	O
importantly	O
,	O
also	O
the	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
response	O
median	O
lay	O
at	O
the	O
lower	O
end	O
of	O
the	O
normal	O
range	O
for	O
most	O
intensities	O
(	O
Figure	O
2F	O
)	O
.	O

Thus	O
,	O
E2f1	B-GGP
deletion	B-SO
almost	O
completely	O
rescued	O
the	O
rod	B-CL
system	O
in	O
the	O
Rb	B-GGP
KO	O
retina	O
.	O

Light	O
-	O
adapted	O
(	O
photopic	O
)	O
recordings	O
to	O
specifically	O
assess	O
the	O
cone	B-CL
system	O
yielded	O
comparable	O
results	O
.	O

Cones	B-CL
represent	O
only	O
3	O
%	O
of	O
photoreceptors	B-CL
and	O
,	O
unlike	O
rods	B-CL
,	O
develop	O
without	O
Rb	B-GGP
,	O
but	O
they	O
require	O
rods	B-CL
for	O
survival	O
,	O
and	O
in	O
the	O
Rb	B-GGP
KO	O
retina	O
,	O
they	O
have	O
abnormal	O
morphology	O
and	O
their	O
synaptic	B-GO
targets	O
,	O
bipolar	B-CL
cells	I-CL
,	O
are	O
much	O
depleted	O
[	O
2	O
]	O
.	O

The	O
photopic	O
response	O
,	O
a	O
product	O
of	O
cone	B-CL
and	O
mainly	O
bipolar	B-CL
activity	O
,	O
was	O
much	O
reduced	O
by	O
Rb	B-GGP
loss	O
,	O
but	O
was	O
rescued	O
considerably	O
in	O
the	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
retina	O
(	O
Figure	O
S5	O
)	O
.	O

Again	O
,	O
the	O
median	O
amplitude	O
lay	O
at	O
the	O
lower	O
end	O
of	O
the	O
E2f1	B-GGP
KO	O
range	O
.	O

The	O
photopic	O
response	O
in	O
E2f1	B-GGP
KO	O
mice	B-Taxon
was	O
slightly	O
reduced	O
relative	O
to	O
WT	B-SO
(	O
Figure	O
S5B	O
)	O
,	O
possibly	O
because	O
E2f1	B-GGP
is	O
required	O
for	O
maximal	O
expansion	O
of	O
embryonic	O
RPCs	O
,	O
and	O
the	O
E2f1	B-GGP
KO	O
retina	O
has	O
,	O
as	O
noted	O
earlier	O
,	O
slightly	O
fewer	O
cells	B-CL
than	O
the	O
WT	B-SO
retina	O
,	O
although	O
cell	B-CL
type	O
proportions	O
are	O
unaffected	O
(	O
D	O
.	O
C	O
.	O
and	O
R	O
.	O
B	O
.	O
,	O
unpublished	O
data	O
)	O
.	O

Thus	O
,	O
marginally	O
subnormal	O
photopic	O
responses	O
in	O
the	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
retina	O
can	O
be	O
attributed	O
to	O
both	O
a	O
reduction	O
of	O
cone	B-CL
numbers	O
in	O
E2f1	B-GGP
KO	O
mice	B-Taxon
alone	O
,	O
and	O
a	O
"	O
genuine	O
"	O
slight	O
reduction	O
in	O
cone	B-CL
function	O
attributable	O
to	O
Rb	B-GGP
loss	O
relative	O
to	O
WT	B-SO
.	O

This	O
slight	O
effect	O
may	O
relate	O
to	O
a	O
true	O
differentiation	O
defect	O
in	O
a	O
subset	O
of	O
amacrine	B-CL
cells	I-CL
discussed	O
below	O
.	O

This	O
discussion	O
should	O
not	O
obscure	O
the	O
major	O
outcome	O
that	O
E2f1	B-GGP
deletion	B-SO
recovers	O
most	O
of	O
the	O
ERG	O
response	O
.	O

Thus	O
,	O
E2f1	B-GGP
deletion	B-SO
not	O
only	O
rescues	O
morphology	O
but	O
also	O
both	O
rod	B-CL
and	O
cone	B-CL
system	O
function	O
in	O
the	O
Rb	B-GGP
KO	O
retina	O
.	O

Abnormal	O
SAC	O
Differentiation	O
Independent	O
of	O
Cell	B-CL
Cycle	O
and	O
Survival	O
Defects	O

ERGs	O
primarily	O
assess	O
photoreceptor	B-CL
and	O
bipolar	B-CL
cell	I-CL
function	O
,	O
but	O
may	O
miss	O
differentiation	O
defects	O
in	O
other	O
cells	B-CL
.	O

To	O
test	O
for	O
subtle	O
differences	O
we	O
stained	O
the	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
retina	O
with	O
43	O
markers	O
(	O
Table	O
S1	O
)	O
.	O

Thirty	O
-	O
two	O
proteins	B-CHEBI
displayed	O
identical	O
patterns	O
in	O
WT	B-SO
,	O
E2f1	B-GGP
KO	O
,	O
and	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
retina	O
(	O
Table	O
S1	O
)	O
.	O

The	O
other	O
11	O
markers	O
revealed	O
a	O
cell	B-CL
-	O
cycle	O
-	O
and	O
apoptosis	O
-	O
independent	O
differentiation	O
defect	O
in	O
SACs	O
.	O

We	O
first	O
studied	O
Calb2	B-GGP
(	O
calretinin	B-GGP
)	O
,	O
which	O
marks	O
a	O
subset	O
of	O
amacrine	B-CL
and	I-CL
ganglion	I-CL
cell	I-CL
bodies	O
as	O
well	O
as	O
three	O
tracks	O
corresponding	O
to	O
their	O
processes	B-GO
in	O
the	O
IPL	O
(	O
Figure	O
3A	O
)	O
.	O

Normal	O
Calb2	B-GGP
staining	O
was	O
seen	O
in	O
the	O
E2f1	B-GGP
KO	O
IPL	O
(	O
data	O
not	O
shown	O
)	O
.	O

However	O
,	O
only	O
one	O
Calb2	B-GGP
+	O
track	O
was	O
evident	O
in	O
the	O
Rb	B-GGP
KO	O
IPL	O
,	O
and	O
this	O
defect	O
was	O
not	O
rescued	O
in	O
the	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
retina	O
(	O
Figure	O
3A	O
)	O
.	O

We	O
quantified	O
Calb2	B-GGP
+	O
cell	B-GO
bodies	I-GO
in	O
the	O
Rb	B-GGP
KO	O
INL	O
(	O
corresponding	O
to	O
amacrine	B-CL
cell	I-CL
staining	O
only	O
)	O
and	O
observed	O
a	O
reduction	O
from	O
P8	O
onwards	O
(	O
Figures	O
3C	O
and	O
S6	O
)	O
.	O

Figure	O
3	O

Differentiation	O
Defects	O
in	O
Rb	B-GGP
KO	O
SACs	O

(	O
A	O
)	O
P18	O
horizontal	O
sections	O
of	O
WT	B-SO
,	O
Rb	B-GGP
KO	O
,	O
and	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
retina	O
were	O
stained	O
for	O
nuclei	B-GO
(	O
DAPI	O
,	O
blue	O
)	O
,	O
Calb2	B-GGP
(	O
green	O
)	O
,	O
and	O
Slc18a3	B-GGP
(	O
red	O
)	O
.	O

(	O
B	O
)	O
Confocal	O
images	O
of	O
P30	O
horizontal	O
sections	O
of	O
WT	B-SO
and	O
Rb	B-GGP
KO	O
retina	O
were	O
stained	O
for	O
nuclei	B-GO
(	O
DAPI	O
,	O
blue	O
)	O
,	O
Chat	B-GGP
and	O
Slc18a3	B-GGP
(	O
both	O
red	O
)	O
,	O
and	O
Camk2a	B-GGP
(	O
green	O
)	O
.	O

In	O
the	O
Rb	B-GGP
KO	O
section	O
,	O
the	O
red	O
stain	O
is	O
Chat	B-GGP
only	O
,	O
as	O
Slc18a3	B-GGP
is	O
missing	O
(	O
see	O
[	O
A	O
]	O
)	O
.	O

(	O
C	O
)	O
Quantification	O
of	O
dense	O
Calb2	B-GGP
+	O
cell	B-GO
bodies	I-GO
in	O
the	O
INL	O
,	O
total	O
Slc18a3	B-GGP
+	O
cell	B-GO
bodies	I-GO
,	O
and	O
Camk2a	B-GGP
+	O
cell	B-GO
bodies	I-GO
in	O
the	O
INL	O
.	O

Error	O
bars	O
represent	O
SD	O
of	O
measurements	O
from	O
three	O
animals	B-Taxon
,	O
and	O
asterisks	O
indicate	O
significant	O
differences	O
between	O
retinas	O
of	O
WT	B-SO
and	O
the	O
indicated	O
genotypes	B-SO
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
;	O
p	O
<	O
0	O
.	O
01	O
;	O
ANOVA	O
and	O
Tukey	O
HSD	O
test	O
)	O
.	O

Scale	O
bars	O
are	O
50	O
mu	O
m	O
in	O
(	O
A	O
)	O
and	O
20	O
mu	O
m	O
in	O
(	O
B	O
)	O
.	O

Of	O
the	O
three	O
Calb2	B-GGP
+	O
tracks	O
in	O
the	O
IPL	O
,	O
the	O
two	O
outer	O
tracks	O
are	O
from	O
SACs	O
,	O
named	O
after	O
their	O
extensive	O
dendritic	B-GO
-	I-GO
tree	I-GO
-	O
like	O
morphology	O
[	O
37	O
]	O
.	O

SACs	O
are	O
cholinergic	B-CHEBI
,	O
represent	O
~	O
5	O
.	O
2	O
%	O
of	O
amacrine	B-CL
neurons	I-CL
[	O
38	O
]	O
,	O
and	O
are	O
critical	O
for	O
both	O
direction	O
selectivity	O
[	O
34	O
,	O
35	O
]	O
and	O
spontaneous	O
rhythmic	O
activity	O
that	O
occurs	O
during	O
normal	O
retinal	O
development	O
[	O
36	O
]	O
.	O

SACs	O
in	O
the	O
INL	O
synapse	B-GO
in	O
the	O
OFF	O
layer	O
of	O
the	O
IPL	O
that	O
responds	O
to	O
decreasing	O
light	O
,	O
while	O
displaced	O
SACs	O
in	O
the	O
GCL	O
have	O
processes	B-GO
that	O
synapse	O
in	O
the	O
nearby	O
ON	O
layer	O
of	O
the	O
IPL	O
that	O
responds	O
to	O
increasing	O
light	O
(	O
reviewed	O
in	O
[	O
39	O
]	O
)	O
.	O

Mature	O
SAC	O
processes	B-GO
stain	O
specifically	O
for	O
Slc18a3	B-GGP
(	O
vesicular	B-GGP
acetyl	I-GGP
choline	I-GGP
transporter	I-GGP
,	O
VAChT	B-GGP
)	O
[	O
37	O
]	O
,	O
and	O
,	O
significantly	O
,	O
this	O
marker	O
was	O
absent	O
in	O
the	O
peripheral	O
Rb	B-GGP
KO	O
or	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
P18	O
retina	O
(	O
Figures	O
3A	O
and	O
S7B	O
)	O
.	O

Chat	B-GGP
,	O
expressed	O
from	O
the	O
same	O
locus	B-SO
,	O
is	O
also	O
SAC	O
specific	O
,	O
but	O
marks	O
both	O
cell	B-GO
bodies	I-GO
and	O
processes	B-GO
of	O
mature	O
SACs	O
[	O
37	O
]	O
.	O

Chat	B-GGP
was	O
seen	O
in	O
fewer	O
cells	B-CL
in	O
the	O
mature	O
Rb	B-GGP
KO	O
retina	O
,	O
and	O
was	O
present	O
in	O
the	O
soma	B-GO
but	O
absent	O
from	O
processes	B-GO
(	O
Figure	O
3B	O
)	O
.	O

We	O
obtained	O
similar	O
results	O
for	O
Sv2c	B-GGP
,	O
a	O
synaptic	B-GO
vesicle	I-GO
protein	B-CHEBI
found	O
in	O
SACs	O
[	O
40	O
]	O
;	O
Kcnc1b	B-GGP
and	O
Kcnc2	B-GGP
,	O
potassium	B-CHEBI
channels	O
expressed	O
on	O
SAC	O
soma	B-GO
and	O
dendrites	B-GO
as	O
well	O
as	O
a	O
very	O
small	O
number	O
of	O
ganglion	B-CL
cells	I-CL
[	O
41	O
]	O
;	O
gamma	B-CHEBI
-	I-CHEBI
aminobutyric	I-CHEBI
acid	I-CHEBI
(	O
GABA	B-CHEBI
)	O
,	O
an	O
inhibitory	O
neurotransmitter	B-CHEBI
present	O
in	O
about	O
half	O
of	O
amacrine	B-CL
cells	I-CL
including	O
SACs	O
,	O
as	O
well	O
as	O
horizontal	B-CL
and	I-CL
some	I-CL
bipolar	I-CL
neurons	I-CL
[	O
37	O
]	O
;	O
and	O
Calb1	B-GGP
(	O
calbindin	B-GGP
)	O
,	O
which	O
is	O
expressed	O
in	O
many	O
amacrine	B-CL
cells	I-CL
and	O
labels	O
SAC	O
process	B-GO
faintly	O
(	O
Figure	O
S7A	O
and	O
S7B	O
;	O
Table	O
S1	O
;	O
and	O
data	O
not	O
shown	O
)	O
.	O

Finally	O
,	O
we	O
also	O
examined	O
the	O
effect	O
of	O
Rb	B-GGP
deletion	B-SO
on	O
SAC	O
differentiation	O
using	O
a	O
Chx10	B-GGP
-	O
Cre	O
transgene	B-SO
that	O
is	O
expressed	O
in	O
a	O
mosaic	O
pattern	O
across	O
the	O
retina	O
,	O
generating	O
patches	O
of	O
Cre	O
-	O
expressing	O
cells	B-CL
[	O
42	O
]	O
.	O

Consistent	O
with	O
the	O
mosaic	O
deletion	B-SO
pattern	O
,	O
we	O
observed	O
markedly	O
reduced	O
Chat	B-GGP
/	O
Slc18a3	B-GGP
staining	O
in	O
the	O
IPL	O
of	O
Chx10	B-GGP
-	O
Cre	O
;	O
RbloxP	O
/	O
loxP	B-SO
retina	O
compared	O
to	O
WT	B-SO
(	O
Figure	O
S7C	O
)	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
a	O
role	O
for	O
Rb	B-GGP
in	O
SAC	O
differentiation	O
.	O

The	O
above	O
findings	O
could	O
indicate	O
a	O
defect	O
in	O
SAC	O
specification	O
,	O
SAC	O
survival	O
,	O
or	O
the	O
levels	O
and	O
/	O
or	O
transport	O
of	O
the	O
markers	O
described	O
above	O
.	O

Camk2a	B-GGP
marks	O
both	O
SACs	O
and	O
ganglion	B-CL
cells	I-CL
[	O
37	O
]	O
,	O
but	O
because	O
ganglion	B-CL
cells	I-CL
are	O
eliminated	O
in	O
the	O
Rb	B-GGP
KO	O
retina	O
,	O
Camk2a	B-GGP
is	O
a	O
specific	O
SAC	O
marker	O
in	O
this	O
context	O
.	O

Importantly	O
,	O
Camk2a	B-GGP
+	O
tracks	O
and	O
dendrites	B-GO
were	O
present	O
in	O
both	O
the	O
WT	B-SO
and	O
Rb	B-GGP
KO	O
retina	O
(	O
Figure	O
3B	O
)	O
,	O
and	O
the	O
number	O
of	O
Camk2a	B-GGP
+	O
soma	B-GO
was	O
similar	O
in	O
WT	B-SO
and	O
Rb	B-GGP
KO	O
retina	O
at	O
P30	O
and	O
beyond	O
,	O
although	O
fewer	O
cells	B-CL
stained	O
in	O
Rb	B-GGP
KO	O
retina	O
at	O
P18	O
,	O
suggesting	O
a	O
delay	O
in	O
its	O
appearance	O
(	O
Figures	O
3C	O
and	O
S6B	O
)	O
.	O

Thus	O
,	O
Rb	B-GGP
is	O
not	O
required	O
for	O
SAC	O
survival	O
or	O
for	O
process	B-GO
outgrowth	O
,	O
but	O
rather	O
it	O
seems	O
to	O
regulate	O
the	O
expression	O
and	O
/	O
or	O
stability	O
of	O
Calb2	B-GGP
,	O
Calb1	B-GGP
,	O
Chat	B-GGP
,	O
Slc18a3	B-GGP
,	O
Sv2c	B-GGP
,	O
Kcnc1b	B-GGP
,	O
Kcnc2	B-GGP
,	O
and	O
GABA	B-CHEBI
in	O
SACs	O
,	O
but	O
leaves	O
Camk2a	B-GGP
expression	O
virtually	O
unaffected	O
.	O

The	O
presence	O
of	O
Chat	B-GGP
in	O
some	O
cell	B-GO
bodies	I-GO
but	O
never	O
in	O
processes	B-GO
(	O
Figure	O
3B	O
)	O
also	O
suggests	O
a	O
transport	O
defect	O
.	O

The	O
developmental	O
pattern	O
of	O
Slc18a3	B-GGP
expression	O
also	O
supported	O
this	O
notion	O
.	O

In	O
mature	O
WT	B-SO
SACs	O
Slc18a3	B-GGP
is	O
only	O
in	O
processes	B-GO
,	O
but	O
in	O
early	O
postnatal	O
SACs	O
,	O
it	O
is	O
found	O
in	O
the	O
cell	B-GO
body	I-GO
,	O
and	O
moves	O
into	O
emerging	O
processes	B-GO
at	O
approximately	O
P4	O
-	O
P6	O
.	O

As	O
noted	O
above	O
,	O
Slc18a3	B-GGP
was	O
absent	O
at	O
P18	O
in	O
the	O
Rb	B-GGP
KO	O
retina	O
(	O
Figure	O
3A	O
)	O
;	O
at	O
P4	O
or	O
P5	O
it	O
was	O
in	O
cell	B-GO
bodies	I-GO
,	O
yet	O
was	O
rarely	O
present	O
in	O
Rb	B-GGP
KO	O
processes	B-GO
(	O
Figures	O
4A	O
and	O
S6	O
)	O
.	O

Slc18a3	B-GGP
became	O
virtually	O
undetectable	O
in	O
Rb	B-GGP
KO	O
SACs	O
by	O
P8	O
(	O
Figures	O
3C	O
and	O
S6C	O
)	O
.	O

These	O
data	O
suggest	O
that	O
Rb	B-GGP
affects	O
both	O
the	O
synthesis	O
/	O
stability	O
and	O
transport	O
of	O
SAC	O
markers	O
.	O

Figure	O
4	O

E2f3	B-GGP
Loss	O
Rescues	O
Differentiation	O
of	O
Rb	B-GGP
KO	O
SACs	O

(	O
A	O
)	O
Horizontal	O
retinal	O
sections	O
of	O
the	O
indicated	O
ages	O
and	O
genotypes	B-SO
were	O
stained	O
for	O
nuclei	B-GO
(	O
DAPI	O
,	O
blue	O
)	O
,	O
mitosis	O
marker	O
PH3	O
(	O
green	O
)	O
,	O
and	O
Slc18a3	B-GGP
(	O
red	O
)	O
,	O
which	O
marks	O
SAC	O
soma	B-GO
at	O
early	O
stages	O
and	O
processes	B-GO
from	O
~	O
P5	O
onwards	O
.	O

Arrows	O
show	O
mitotic	O
PH3	O
+	O
nuclei	B-GO
in	O
Rb	B-GGP
KO	O
,	O
Rb	B-GGP
/	O
E2f2	B-GGP
DKO	O
,	O
and	O
Rb	B-GGP
/	O
E2f3	B-GGP
DKO	O
retinas	O
.	O

E2f1	B-GGP
loss	O
rescues	O
the	O
ectopic	O
mitosis	O
and	O
cell	B-CL
death	O
defects	O
,	O
but	O
not	O
the	O
SAC	O
defect	O
.	O

E2f2	B-GGP
loss	O
has	O
no	O
effect	O
.	O

E2f3	B-GGP
loss	O
does	O
not	O
rescue	O
the	O
ectopic	O
mitosis	O
and	O
cell	B-CL
loss	O
defects	O
,	O
but	O
rescues	O
the	O
SAC	O
defect	O
.	O

Inactivating	O
E2f1	B-GGP
and	O
E2f3	B-GGP
together	O
rescues	O
the	O
ectopic	O
mitosis	O
,	O
cell	B-CL
death	O
,	O
and	O
SAC	O
defects	O
.	O

(	O
B	O
)	O
The	O
fraction	O
of	O
Camk2a	B-GGP
+	O
cells	B-CL
that	O
are	O
Chat	B-GGP
+	O
and	O
Slc18a3	B-GGP
+	O
in	O
the	O
P30	O
retina	O
.	O

(	O
C	O
)	O
Horizontal	O
P5	O
retinal	O
sections	O
were	O
stained	O
for	O
nuclei	B-GO
(	O
DAPI	O
,	O
blue	O
)	O
,	O
Slc18a3	B-GGP
(	O
green	O
)	O
,	O
and	O
Isl1	B-GGP
(	O
red	O
)	O
.	O

Arrows	O
show	O
double	O
-	O
labelled	O
Isl1	B-GGP
+	O
/	O
Slc18a3	B-GGP
+	O
cells	B-CL
in	O
the	O
inner	O
INL	O
.	O

(	O
D	O
)	O
Horizontal	O
P0	O
retinal	O
sections	O
of	O
the	O
indicated	O
genotypes	B-SO
were	O
stained	O
for	O
nuclei	B-GO
(	O
DAPI	O
,	O
blue	O
)	O
,	O
cell	B-CL
division	O
marker	O
Mki67	B-GGP
(	O
green	O
)	O
,	O
and	O
Isl1	B-GGP
(	O
red	O
)	O
.	O

Arrows	O
show	O
double	O
-	O
labelled	O
dividing	O
SACs	O
.	O

(	O
E	O
)	O
The	O
fraction	O
of	O
Isl1	B-GGP
+	O
cells	B-CL
in	O
the	O
inner	O
NBL	O
(	O
INBL	O
)	O
of	O
P0	O
retinas	O
that	O
are	O
dividing	O
(	O
Mki67	B-GGP
+	O
)	O
.	O

Error	O
bars	O
represent	O
SD	O
of	O
measurements	O
from	O
three	O
animals	B-Taxon
,	O
and	O
asterisks	O
indicate	O
significant	O
differences	O
between	O
retinas	O
of	O
WT	B-SO
and	O
the	O
indicated	O
genotypes	B-SO
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
;	O
p	O
<	O
0	O
.	O
01	O
;	O
ANOVA	O
and	O
Tukey	O
HSD	O
test	O
)	O
.	O

Scale	O
bars	O
in	O
(	O
A	O
)	O
,	O
(	O
C	O
)	O
,	O
and	O
(	O
D	O
)	O
are	O
50	O
mu	O
m	O
.	O

Rb	B-GGP
Regulates	O
SAC	O
Differentiation	O
through	O
E2f3	B-GGP

Rb	B-GGP
binds	O
more	O
than	O
100	O
proteins	B-CHEBI
[	O
43	O
]	O
and	O
in	O
some	O
non	O
-	O
neuronal	B-CL
cells	B-CL
,	O
such	O
as	O
skeletal	O
muscle	O
,	O
adipocytes	B-CL
,	O
and	O
bone	O
,	O
Rb	B-GGP
is	O
thought	O
to	O
bind	O
and	O
potentiate	O
tissue	O
-	O
specific	O
transcription	O
factors	O
that	O
promote	O
differentiation	O
[	O
31	O
-	O
33	O
]	O
.	O

Thus	O
,	O
we	O
expected	O
that	O
Rb	B-GGP
might	O
interact	O
with	O
retina	O
-	O
specific	O
factors	O
to	O
facilitate	O
SAC	O
differentiation	O
.	O

A	O
direct	O
role	O
for	O
E2f	O
in	O
mediating	O
Rb	B-GGP
-	O
dependent	O
differentiation	O
defects	O
(	O
independent	O
of	O
cell	B-CL
cycle	O
or	O
death	O
defects	O
)	O
has	O
to	O
our	O
knowledge	O
not	O
been	O
described	O
,	O
but	O
because	O
E2f	O
can	O
regulate	O
some	O
differentiation	O
genes	B-SO
[	O
44	O
-	O
48	O
]	O
,	O
we	O
first	O
tested	O
whether	O
E2f2	B-GGP
or	O
E2f3	B-GGP
might	O
perturb	O
Rb	B-GGP
KO	O
SAC	O
maturation	O
.	O

At	O
multiple	O
time	O
points	O
,	O
E2f1	B-GGP
deletion	B-SO
suppressed	O
ectopic	O
mitosis	O
(	O
PH3	O
+	O
cells	B-CL
)	O
,	O
but	O
did	O
not	O
reverse	O
the	O
SAC	O
defect	O
,	O
and	O
E2f2	B-GGP
deletion	B-SO
had	O
no	O
effect	O
on	O
either	O
defect	O
(	O
Figure	O
4A	O
)	O
.	O

Remarkably	O
,	O
although	O
E2f3	B-GGP
deletion	B-SO
did	O
not	O
reverse	O
ectopic	O
mitosis	O
,	O
it	O
rescued	O
Calb2	B-GGP
,	O
Slc18a3	B-GGP
,	O
Chat	B-GGP
,	O
GABA	B-CHEBI
,	O
Kcnc1b	B-GGP
,	O
Kcnc2	B-GGP
,	O
and	O
Sv2c	B-GGP
staining	O
at	O
multiple	O
times	O
(	O
Figure	O
4A	O
and	O
data	O
not	O
shown	O
)	O
.	O

Rb	B-GGP
/	O
E2f3	B-GGP
DKO	O
SAC	O
tracks	O
were	O
slightly	O
more	O
disordered	O
than	O
in	O
WT	B-SO
retina	O
,	O
most	O
likely	O
because	O
of	O
the	O
absence	O
of	O
synaptic	B-GO
partner	O
cells	B-CL
,	O
which	O
are	O
killed	O
by	O
E2f1	B-GGP
.	O

Indeed	O
,	O
this	O
minor	O
defect	O
was	O
rescued	O
in	O
the	O
Rb	B-GGP
/	O
E2f1	B-GGP
/	O
E2f3	B-GGP
triple	O
knockout	O
retina	O
,	O
where	O
bipolar	B-CL
and	I-CL
ganglion	I-CL
cell	I-CL
death	O
was	O
rescued	O
and	O
SAC	O
differentiation	O
was	O
restored	O
(	O
Figure	O
4A	O
)	O
.	O

E2f3	B-GGP
deletion	B-SO
alone	O
did	O
not	O
affect	O
SAC	O
differentiation	O
(	O
Figure	O
4A	O
)	O
;	O
thus	O
,	O
it	O
is	O
unleashed	O
E2f3	B-GGP
activity	O
that	O
is	O
detrimental	O
,	O
and	O
the	O
critical	O
role	O
for	O
Rb	B-GGP
is	O
to	O
inhibit	O
E2f3	B-GGP
.	O

We	O
quantified	O
the	O
fraction	O
of	O
Camk2a	B-GGP
+	O
SACs	O
in	O
different	O
genotypes	B-SO
and	O
found	O
that	O
60	O
%	O
of	O
WT	B-SO
P30	O
Camk2a	B-GGP
+	O
cells	B-CL
expressed	O
Chat	B-GGP
and	O
Slc18a3	B-GGP
,	O
which	O
dropped	O
to	O
only	O
5	O
.	O
6	O
%	O
in	O
the	O
Rb	B-GGP
KO	O
retina	O
,	O
and	O
remained	O
low	O
at	O
3	O
.	O
7	O
%	O
in	O
the	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
retina	O
,	O
but	O
rose	O
to	O
91	O
%	O
in	O
the	O
Rb	B-GGP
/	O
E2f3	B-GGP
DKO	O
retina	O
(	O
Figure	O
4B	O
)	O
.	O

The	O
latter	O
fraction	O
is	O
higher	O
than	O
WT	B-SO
because	O
ganglion	B-CL
cells	I-CL
,	O
which	O
normally	O
make	O
up	O
~	O
40	O
%	O
of	O
Camk2a	B-GGP
+	O
cells	B-CL
,	O
are	O
killed	O
by	O
apoptosis	O
.	O

To	O
quantify	O
the	O
effect	O
of	O
different	O
E2fs	O
on	O
ectopic	O
division	O
specifically	O
in	O
SACs	O
,	O
we	O
exploited	O
Isl1	B-GGP
(	O
Islet1	B-GGP
)	O
.	O

This	O
marker	O
is	O
expressed	O
in	O
both	O
SACs	O
and	O
ganglion	B-CL
cells	I-CL
,	O
thus	O
Isl1	B-GGP
+	O
cells	B-CL
in	O
the	O
INL	O
are	O
exclusively	O
SACs	O
[	O
49	O
]	O
.	O

We	O
found	O
that	O
98	O
.	O
2	O
%	O
+/-	O
1	O
.	O
8	O
%	O
of	O
Isl1	B-GGP
+	O
cells	B-CL
in	O
the	O
forming	O
inner	O
INL	O
at	O
P5	O
were	O
also	O
Slc18a3	B-GGP
+	O
,	O
confirming	O
that	O
Isl1	B-GGP
is	O
an	O
excellent	O
SAC	O
marker	O
(	O
Figure	O
4C	O
)	O
.	O

Moreover	O
,	O
Isl1	B-GGP
,	O
unlike	O
Slc18a3	B-GGP
,	O
is	O
nuclear	B-GO
,	O
which	O
facilitates	O
scoring	O
of	O
Isl1	B-GGP
+	O
/	O
Mki67	B-GGP
+	O
cells	B-CL
.	O

It	O
is	O
also	O
expressed	O
earlier	O
than	O
Slc18a3	B-GGP
,	O
permitting	O
analysis	O
of	O
SACs	O
soon	O
after	O
their	O
birth	O
at	O
~	O
E15	O
;	O
thus	O
,	O
we	O
could	O
study	O
retina	O
at	O
P0	O
,	O
a	O
time	O
when	O
ectopic	O
division	O
is	O
high	O
in	O
the	O
inner	O
retina	O
and	O
prior	O
to	O
Rb	B-GGP
-	O
independent	O
cell	B-CL
cycle	O
exit	O
associated	O
with	O
terminal	O
differentiation	O
[	O
2	O
]	O
.	O

At	O
P0	O
,	O
no	O
WT	B-SO
Isl1	B-GGP
+	O
cells	B-CL
in	O
the	O
inner	O
neuroblastic	O
layer	O
(	O
NBL	O
)	O
(	O
which	O
is	O
the	O
future	O
INL	O
)	O
were	O
dividing	O
,	O
but	O
57	O
+/-	O
14	O
Isl1	B-GGP
+	O
/	O
Mki67	B-GGP
+	O
cells	B-CL
were	O
detected	O
in	O
the	O
Rb	B-GGP
KO	O
inner	O
NBL	O
(	O
Figure	O
4D	O
)	O
.	O

Indeed	O
,	O
about	O
one	O
-	O
third	O
of	O
all	O
Isl1	B-GGP
+	O
cells	B-CL
in	O
the	O
entire	O
inner	O
NBL	O
were	O
dividing	O
in	O
the	O
Rb	B-GGP
KO	O
retina	O
,	O
or	O
~	O
50	O
%	O
in	O
the	O
periphery	O
where	O
Cre	O
is	O
expressed	O
(	O
Figure	O
4E	O
and	O
data	O
not	O
shown	O
)	O
.	O

This	O
defect	O
was	O
suppressed	O
in	O
the	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
retina	O
,	O
where	O
we	O
detected	O
only	O
1	O
+/-	O
1	O
dividing	O
SAC	O
,	O
but	O
not	O
the	O
Rb	B-GGP
/	O
E2f3	B-GGP
DKO	O
retina	O
,	O
where	O
there	O
were	O
53	O
+/-	O
8	O
dividing	O
SACs	O
(	O
Figure	O
4D	O
and	O
4E	O
)	O
.	O

We	O
observed	O
similar	O
effects	O
at	O
P0	O
with	O
Calb2	B-GGP
,	O
which	O
marks	O
newborn	O
SACs	O
and	O
other	O
amacrine	B-CL
cells	I-CL
(	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
,	O
in	O
Rb	B-GGP
KO	O
SACs	O
,	O
E2f1	B-GGP
deletion	B-SO
suppresses	O
ectopic	O
division	O
but	O
not	O
aberrant	O
differentiation	O
,	O
whereas	O
E2f3	B-GGP
deletion	B-SO
suppresses	O
aberrant	O
differentiation	O
but	O
not	O
ectopic	O
division	O
.	O

Specific	O
Expression	O
of	O
E2f3	B-GGP
in	O
SACs	O
and	O
Other	O
Subsets	O
of	O
CNS	B-CL
Neurons	I-CL

The	O
unique	O
effect	O
of	O
E2f3	B-GGP
in	O
disrupting	O
the	O
differentiation	O
of	O
SACs	O
but	O
not	O
other	O
retinal	O
neurons	B-CL
might	O
be	O
due	O
to	O
cell	B-CL
-	O
type	O
-	O
specific	O
expression	O
or	O
cell	B-CL
-	O
type	O
-	O
specific	O
activity	O
of	O
E2f3	B-GGP
.	O

Determining	O
between	O
these	O
two	O
possibilities	O
is	O
not	O
easy	O
,	O
as	O
E2f	O
immunostaining	O
in	O
mouse	B-Taxon
tissues	O
is	O
problematic	O
.	O

We	O
did	O
not	O
solve	O
this	O
issue	O
for	O
E2f1	B-GGP
or	O
E2f2	B-GGP
,	O
but	O
used	O
a	O
modified	O
protocol	O
[	O
50	O
]	O
to	O
successfully	O
track	O
E2f3	B-GGP
expression	O
(	O
Figure	O
5	O
)	O
.	O

At	O
P0	O
,	O
E2f3	B-GGP
was	O
detected	O
in	O
RPCs	O
,	O
consistent	O
with	O
a	O
putative	O
role	O
in	O
normal	O
proliferation	O
(	O
Figure	O
5A	O
)	O
.	O

The	O
signal	O
was	O
specific	O
as	O
it	O
was	O
absent	O
in	O
the	O
E2f3	B-GGP
KO	O
peripheral	O
retina	O
(	O
Figure	O
5A	O
)	O
.	O

As	O
the	O
retina	O
differentiated	O
and	O
RPC	O
division	O
diminished	O
,	O
the	O
number	O
of	O
E2f3	B-GGP
+	O
cells	B-CL
also	O
dropped	O
,	O
and	O
by	O
P8	O
,	O
when	O
division	O
is	O
virtually	O
over	O
,	O
only	O
a	O
subset	O
of	O
post	O
-	O
mitotic	O
cells	B-CL
in	O
the	O
inner	O
retina	O
expressed	O
E2f3	B-GGP
(	O
Figure	O
5A	O
)	O
.	O

By	O
P18	O
,	O
E2f3	B-GGP
was	O
also	O
detected	O
in	O
two	O
tracks	O
in	O
the	O
IPL	O
(	O
Figure	O
5A	O
and	O
5B	O
)	O
,	O
reminiscent	O
of	O
SAC	O
markers	O
such	O
as	O
Chat	B-GGP
and	O
Slc18a3	B-GGP
(	O
c	O
.	O
f	O
.	O
Figures	O
3	O
and	O
4	O
)	O
.	O

This	O
cytoplasmic	B-GO
E2f3	B-GGP
staining	O
was	O
also	O
specific	O
,	O
as	O
it	O
was	O
absent	O
in	O
the	O
E2f3	B-GGP
KO	O
peripheral	O
retina	O
of	O
alpha	O
-	O
Cre	O
;	O
E2f3loxP	O
/	O
loxP	B-SO
mice	B-Taxon
(	O
Figure	O
5A	O
)	O
.	O

Indeed	O
,	O
double	O
labelling	O
with	O
E2f3	B-GGP
(	O
red	O
)	O
and	O
Chat	B-GGP
plus	O
Slc18a3	B-GGP
(	O
green	O
)	O
confirmed	O
that	O
E2f3	B-GGP
is	O
present	O
in	O
both	O
SAC	O
soma	B-GO
and	O
dendrites	B-GO
(	O
Figure	O
5B	O
)	O
.	O

Rb	B-GGP
protein	B-CHEBI
was	O
also	O
detected	O
in	O
the	O
inner	O
retina	O
(	O
Figure	O
5A	O
)	O
,	O
and	O
showed	O
a	O
similar	O
distribution	O
as	O
E2f3	B-GGP
in	O
SACs	O
(	O
Figure	O
5B	O
)	O
,	O
and	O
was	O
also	O
present	O
in	O
mature	O
ganglion	B-CL
cells	I-CL
and	O
M	B-CL
u	I-CL
ller	I-CL
cells	I-CL
as	O
reported	O
[	O
51	O
]	O
.	O

Rb	B-GGP
staining	O
in	O
SAC	O
processes	B-GO
was	O
specific	O
as	O
it	O
was	O
absent	O
in	O
the	O
peripheral	O
retina	O
of	O
alpha	O
Cre	O
;	O
RbloxP	O
/	O
loxP	B-SO
mice	B-Taxon
(	O
Figure	O
5A	O
)	O
.	O

These	O
data	O
suggest	O
that	O
Rb	B-GGP
and	O
E2f3	B-GGP
colocalize	O
in	O
SACs	O
and	O
that	O
E2f3	B-GGP
triggers	O
defects	O
in	O
SAC	O
differentiation	O
because	O
it	O
is	O
specifically	O
expressed	O
in	O
these	O
retinal	O
neurons	B-CL
.	O

Figure	O
5	O

E2f3	B-GGP
and	O
Rb	B-GGP
Expression	O
in	O
SACs	O

(	O
A	O
)	O
Left	O
panels	O
:	O
horizontal	O
P0	O
,	O
P8	O
,	O
and	O
P18	O
retinal	O
sections	O
of	O
the	O
indicated	O
genotypes	B-SO
were	O
stained	O
for	O
E2f3	B-GGP
(	O
red	O
)	O
and	O
DAPI	O
(	O
blue	O
)	O
.	O

The	O
arrow	O
indicates	O
the	O
junction	O
between	O
the	O
E2f3	B-GGP
null	O
peripheral	O
and	O
WT	B-SO
central	O
P0	O
retina	O
.	O

Note	O
the	O
absence	O
of	O
E2f3	B-GGP
protein	B-CHEBI
in	O
the	O
peripheral	O
E2f3	B-GGP
KO	O
RPCs	O
at	O
P0	O
and	O
in	O
peripheral	O
inner	O
retinal	O
neurons	B-CL
at	O
P18	O
.	O

Far	O
right	O
panel	O
:	O
P18	O
retinal	O
sections	O
of	O
the	O
indicated	O
genotypes	B-SO
were	O
stained	O
for	O
Rb	B-GGP
(	O
red	O
)	O
and	O
DAPI	O
(	O
blue	O
)	O
.	O

Note	O
the	O
absence	O
of	O
Rb	B-GGP
protein	B-CHEBI
in	O
the	O
peripheral	O
Rb	B-GGP
KO	O
inner	O
retinal	O
neurons	B-CL
.	O

(	O
B	O
)	O
WT	B-SO
P18	O
retinal	O
sections	O
were	O
stained	O
for	O
nuclei	B-GO
(	O
DAPI	O
,	O
blue	O
)	O
,	O
E2f3	B-GGP
(	O
red	O
)	O
or	O
Rb	B-GGP
(	O
red	O
)	O
,	O
and	O
Chat	B-GGP
plus	O
Slc18a3	B-GGP
(	O
green	O
)	O
.	O

Arrows	O
indicate	O
double	O
-	O
labelled	O
soma	B-GO
.	O

Note	O
that	O
the	O
IPL	O
processes	B-GO
are	O
also	O
double	O
-	O
labelled	O
.	O

Scale	O
bars	O
are	O
50	O
mu	O
m	O
.	O

We	O
also	O
found	O
that	O
E2f3	B-GGP
is	O
present	O
in	O
a	O
specific	O
subset	O
of	O
mature	O
neurons	B-CL
in	O
various	O
brain	O
regions	O
(	O
data	O
not	O
shown	O
)	O
.	O

For	O
example	O
,	O
in	O
the	O
P20	O
amygdala	O
,	O
E2f3	B-GGP
colocalized	O
with	O
the	O
general	O
neuronal	B-CL
markers	O
Mtap2	B-GGP
and	O
Mecp2	B-GGP
[	O
52	O
]	O
,	O
but	O
not	O
with	O
Calb2	B-GGP
,	O
which	O
marks	O
a	O
subset	O
of	O
neurons	B-CL
,	O
or	O
with	O
the	O
glial	B-CL
marker	O
Gfap	B-GGP
(	O
data	O
not	O
shown	O
)	O
.	O

Unlike	O
in	O
retinal	O
SACs	O
,	O
E2f3	B-GGP
was	O
not	O
coexpressed	O
in	O
Chat	B-GGP
+	O
or	O
Slc18a3	B-GGP
+	O
cholinergic	B-CL
neurons	I-CL
located	O
in	O
various	O
regions	O
of	O
the	O
brain	O
and	O
spinal	O
cord	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
agreement	O
,	O
we	O
could	O
not	O
detect	O
defects	O
in	O
cholinergic	B-CL
Rb	I-CL
KO	I-CL
neurons	I-CL
in	O
the	O
developing	O
forebrain	O
,	O
but	O
other	O
Rb	B-GGP
KO	O
neurons	B-CL
in	O
this	O
region	O
showed	O
differentiation	O
defects	O
that	O
were	O
rescued	O
by	O
deleting	B-SO
E2f3	B-GGP
[	O
53	O
]	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
common	O
mechanism	O
by	O
which	O
Rb	B-GGP
promotes	O
neural	O
differentiation	O
is	O
through	O
E2f3	B-GGP
inhibition	O
.	O

Distinct	O
Localization	O
of	O
E2f3	B-GGP
Isoforms	B-SO

As	O
noted	O
above	O
,	O
E2f3	B-GGP
and	O
Rb	B-GGP
staining	O
in	O
SACs	O
was	O
both	O
nuclear	B-GO
and	O
cytoplasmic	B-GO
(	O
Figure	O
5A	O
and	O
5B	O
)	O
.	O

The	O
antibody	B-GO
that	O
worked	O
in	O
immunostaining	O
recognizes	O
a	O
C	B-SO
-	I-SO
terminal	I-SO
region	I-SO
and	O
thus	O
,	O
does	O
not	O
distinguish	O
a	O
/	O
b	O
isoforms	B-SO
.	O

To	O
our	O
knowledge	O
,	O
the	O
subcellular	O
location	O
of	O
E2f3	B-GGP
isoforms	B-SO
has	O
not	O
been	O
determined	O
in	O
any	O
cell	B-CL
type	O
.	O

To	O
verify	O
the	O
dual	O
locations	O
of	O
E2f3	B-GGP
and	O
to	O
determine	O
which	O
isoforms	B-SO
were	O
present	O
in	O
retina	O
,	O
we	O
analyzed	O
nuclear	B-GO
and	O
cytoplasmic	B-GO
fractions	B-GO
by	O
Western	O
blot	O
at	O
different	O
times	O
during	O
development	O
.	O

Analysis	O
with	O
the	O
pan	O
-	O
E2f3	B-GGP
antibody	B-GO
(	O
sc	O
-	O
878	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
detected	O
a	O
55	O
-	O
kD	O
E2f3a	O
species	B-SO
and	O
a	O
40	O
-	O
kD	O
E2f3b	O
polypeptide	B-SO
(	O
Figure	O
6	O
)	O
.	O

To	O
confirm	O
that	O
the	O
upper	O
species	B-SO
in	O
our	O
retinal	O
lysates	O
was	O
E2f3a	O
,	O
we	O
exploited	O
novel	O
mice	B-Taxon
that	O
lack	O
E2f3	B-GGP
exon	B-SO
1a	O
and	O
thus	O
express	O
E2f3b	O
exclusively	O
(	O
R	O
.	O
O	O
.	O
and	O
G	O
.	O
L	O
.	O
,	O
unpublished	O
data	O
)	O
.	O

The	O
genotyping	O
strategy	O
is	O
discussed	O
in	O
detail	O
later	O
and	O
is	O
outlined	O
in	O
Figure	O
7A	O
.	O

Western	O
analysis	O
confirmed	O
that	O
the	O
upper	O
band	O
was	O
absent	O
in	O
E2f3a	O
-	O
/	O
-	O
mice	B-Taxon
(	O
Figures	O
6	O
and	O
S8	O
)	O
.	O

Consistent	O
with	O
the	O
drop	O
in	O
E2f3	B-GGP
-	O
expressing	O
cells	B-CL
during	O
WT	B-SO
retinal	O
maturation	O
(	O
Figure	O
5A	O
)	O
,	O
the	O
total	O
amount	O
of	O
E2f3a	O
was	O
less	O
at	O
P18	O
compared	O
to	O
P0	O
(	O
Figure	O
6	O
)	O
.	O

E2f3b	O
was	O
present	O
in	O
similar	O
amounts	O
at	O
both	O
time	O
points	O
.	O

At	O
P0	O
and	O
P18	O
,	O
E2f3a	O
was	O
present	O
in	O
both	O
nuclear	B-GO
and	O
cytoplasmic	B-GO
fractions	B-GO
,	O
but	O
in	O
marked	O
contrast	O
,	O
E2f3b	O
was	O
exclusively	O
nuclear	B-GO
at	O
both	O
times	O
(	O
Figure	O
6	O
)	O
.	O

Two	O
closely	O
migrating	O
E2f3a	O
bands	O
were	O
detected	O
,	O
more	O
clearly	O
evident	O
at	O
P18	O
,	O
of	O
which	O
the	O
faster	O
migrating	O
species	B-SO
was	O
dominant	O
in	O
nuclear	B-GO
and	O
the	O
slower	O
species	B-SO
was	O
dominant	O
in	O
cytoplasm	B-GO
(	O
Figure	O
6	O
)	O
.	O

The	O
identity	O
of	O
both	O
as	O
E2f3a	O
species	B-SO
was	O
confirmed	O
by	O
their	O
absence	O
in	O
the	O
P18	O
E2f3a	O
KO	O
retina	O
(	O
Figure	O
S8	O
)	O
.	O

Analysis	O
of	O
Pou4f2	B-GGP
,	O
a	O
nuclear	B-GO
transcription	O
factor	O
expressed	O
in	O
ganglion	B-CL
cells	I-CL
,	O
showed	O
that	O
nuclear	B-GO
proteins	B-CHEBI
had	O
not	O
contaminated	O
the	O
cytoplasmic	B-GO
fraction	B-GO
,	O
and	O
analysis	O
of	O
Slc18a3	B-GGP
,	O
a	O
cytoplasmic	B-GO
SAC	O
marker	O
,	O
confirmed	O
that	O
the	O
reverse	O
had	O
also	O
not	O
occurred	O
(	O
Figure	O
6	O
)	O
.	O

These	O
data	O
show	O
,	O
to	O
our	O
knowledge	O
for	O
the	O
first	O
time	O
,	O
that	O
E2f3a	O
and	O
E2f3b	O
exhibit	O
distinct	O
patterns	O
of	O
subcellular	O
distribution	O
,	O
and	O
raise	O
the	O
possibility	O
that	O
E2f3a	O
localization	O
may	O
be	O
regulated	O
by	O
as	O
yet	O
unknown	O
post	O
-	O
translational	O
modifications	B-SO
.	O

Figure	O
6	O

Subcellular	O
Distribution	O
of	O
E2f3	B-GGP
Isoforms	B-SO
and	O
Other	O
Cell	B-CL
Cycle	O
Proteins	B-CHEBI
in	O
the	O
Developing	O
Retina	O

Nuclear	O
and	O
cytoplasmic	B-GO
extracts	O
from	O
an	O
equivalent	O
number	O
of	O
retinal	O
cells	B-CL
from	O
mice	B-Taxon
of	O
the	O
indicated	O
genotypes	B-SO
and	O
ages	O
were	O
analyzed	O
by	O
Western	O
blotting	O
to	O
detect	O
the	O
indicated	O
proteins	B-CHEBI
.	O

Lysate	O
from	O
E2f3a	O
-	O
/	O
-	O
mice	B-Taxon
was	O
used	O
as	O
a	O
control	O
to	O
confirm	O
the	O
location	O
of	O
E2f3a	O
protein	B-CHEBI
.	O

C	B-GO
,	O
cytoplasmic	B-GO
extracts	O
;	O
N	B-GO
,	O
nuclear	B-GO
extracts	O
.	O

Figure	O
7	O

The	O
E2f3a	O
Isoform	B-SO
Drives	O
the	O
Differentiation	O
Defect	O
in	O
Rb	B-GGP
KO	O
SACs	O

(	O
A	O
)	O
Schematic	O
diagrams	O
of	O
the	O
mouse	B-Taxon
WT	B-SO
,	O
E2f3a	O
-	O
/	O
-	O
,	O
and	O
the	O
Cre	O
-	O
recombined	O
floxed	B-SO
E2f3	B-GGP
loci	B-SO
(	O
indicated	O
here	O
as	O
E2f3	B-GGP
-	O
/	O
-	O
for	O
simplicity	O
)	O
.	O

E2f3a	O
-	O
/	O
-	O
mice	B-Taxon
lack	O
most	O
of	O
E2f3	B-GGP
exon	B-SO
1a	O
and	O
part	O
of	O
intron	B-SO
1a	O
(	O
red	O
dotted	O
box	O
)	O
.	O

Arrows	O
indicate	O
PCR	O
primers	B-SO
.	O

Genotyping	O
of	O
an	O
E2f3a	O
+	B-SO
/	O
-	O
mouse	B-Taxon
is	O
shown	O
on	O
the	O
right	O
.	O

(	O
B	O
)	O
RT	O
-	O
PCR	O
detection	O
of	O
E2f3a	O
and	O
E2f3b	O
mRNA	B-CHEBI
in	O
the	O
retina	O
.	O

The	O
sequences	B-SO
of	O
primers	B-SO
are	O
1aF	O
(	O
5	O
'	O
-	O
GCCTCTACACCACGCCACAAG	O
-	O
3	O
'	O
)	O
,	O
1bF	O
(	O
5	O
'	O
-	O
CGGAAATGCCCTTACAGC	O
-	O
3	O
'	O
)	O
,	O
and	O
4R	O
(	O
5	O
'	O
-	O
CTCAGTCACTTCTTTGGACAG	O
-	O
3	O
'	O
)	O
.	O

WT	B-SO
retina	O
expresses	O
both	O
E2f3a	O
and	O
E2f3b	O
mRNA	B-CHEBI
.	O

As	O
expected	O
,	O
E2f3a	O
-	O
/	O
-	O
retina	O
lacks	O
E2f3a	O
mRNA	B-CHEBI
and	O
still	O
expresses	O
E2f3b	O
mRNA	B-CHEBI
.	O

E2f3	B-GGP
-	O
/	O
-	O
retina	O
lacks	O
full	O
-	O
length	O
E2f3a	O
and	O
E2f3b	O
mRNAs	B-CHEBI
,	O
and	O
instead	O
expresses	O
a	O
truncated	O
mRNA	B-CHEBI
lacking	O
exon	B-SO
3	O
.	O

(	O
C	O
)	O
Real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
of	O
E2f	O
genes	B-SO
in	O
P8	O
retinas	O
of	O
the	O
indicated	O
genotypes	B-SO
.	O

Error	O
bars	O
represent	O
SD	O
of	O
measurements	O
from	O
three	O
animals	B-Taxon
,	O
and	O
asterisks	O
indicate	O
a	O
significant	O
difference	O
between	O
WT	B-SO
and	O
the	O
indicated	O
genotypes	B-SO
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
;	O
p	O
<	O
0	O
.	O
01	O
;	O
ANOVA	O
and	O
Tukey	O
HSD	O
test	O
)	O
.	O

(	O
D	O
)	O
Rescue	O
of	O
Rb	B-GGP
KO	O
SACs	O
by	O
E2f3a	O
deletion	B-SO
.	O

Horizontal	O
retinal	O
sections	O
of	O
the	O
indicated	O
genotypes	B-SO
and	O
ages	O
were	O
stained	O
for	O
nuclei	B-GO
(	O
DAPI	O
,	O
blue	O
)	O
,	O
M	O
-	O
phase	O
(	O
PH3	O
,	O
green	O
)	O
,	O
and	O
the	O
SAC	O
marker	O
Slc18a3	B-GGP
(	O
red	O
)	O
.	O

E2f3a	O
deletion	B-SO
does	O
not	O
suppress	O
ectopic	O
division	O
,	O
but	O
rescues	O
the	O
SAC	O
defect	O
.	O

Scale	O
bars	O
are	O
50	O
mu	O
m	O
.	O

M	O
,	O
molecular	B-CHEBI
size	O
marker	O
.	O

We	O
also	O
examined	O
the	O
distribution	O
of	O
other	O
cell	B-CL
cycle	O
regulators	O
during	O
retinal	O
development	O
.	O

Like	O
E2f3a	O
,	O
Rb	B-GGP
was	O
present	O
in	O
both	O
the	O
WT	B-SO
cytoplasm	B-GO
and	O
nucleus	B-GO
at	O
P0	O
,	O
but	O
at	O
P18	O
,	O
when	O
the	O
levels	O
of	O
Rb	B-GGP
had	O
increased	O
,	O
it	O
was	O
primarily	O
nuclear	B-GO
(	O
Figure	O
6	O
)	O
.	O

A	O
very	O
faint	O
cytoplasmic	B-GO
Rb	B-GGP
signal	O
was	O
evident	O
at	O
P18	O
,	O
which	O
is	O
consistent	O
with	O
Rb	B-GGP
staining	O
of	O
SAC	O
processes	B-GO
(	O
Figure	O
5B	O
)	O
,	O
and	O
with	O
the	O
very	O
small	O
proportion	O
of	O
SACs	O
in	O
the	O
retina	O
[	O
38	O
]	O
.	O

E2f1	B-GGP
was	O
also	O
detected	O
in	O
both	O
nuclear	B-GO
and	O
cytoplasmic	B-GO
fractions	B-GO
,	O
although	O
unlike	O
E2f3a	O
it	O
was	O
predominantly	O
nuclear	B-GO
both	O
at	O
P0	O
and	O
P18	O
(	O
Figure	O
6	O
)	O
.	O

The	O
E2f	O
dimerization	O
partner	O
,	O
Tfdp1	B-GGP
,	O
which	O
lacks	O
a	O
nuclear	B-GO
localization	O
signal	B-SO
[	O
54	O
]	O
,	O
was	O
primarily	O
cytoplasmic	B-GO
at	O
both	O
P0	O
and	O
P18	O
,	O
and	O
the	O
Cdk	O
inhibitors	B-CHEBI
Cdkn1a	B-GGP
and	O
Cdkn1b	B-GGP
showed	O
a	O
similar	O
pattern	O
of	O
distribution	O
(	O
Figure	O
6	O
)	O
.	O

Thus	O
,	O
among	O
the	O
cell	B-CL
cycle	O
regulators	O
we	O
examined	O
,	O
most	O
showed	O
bivalent	O
distribution	O
,	O
and	O
E2f3b	O
was	O
unusual	O
in	O
its	O
solely	O
nuclear	B-GO
compartmentalization	O
.	O

Rb	B-GGP
Regulates	O
SAC	O
Differentiation	O
through	O
E2f3a	O

To	O
test	O
which	O
E2f3	B-GGP
isoform	B-SO
is	O
responsible	O
for	O
aberrant	O
Rb	B-GGP
KO	O
SAC	O
differentiation	O
we	O
exploited	O
E2f3a	O
-	O
/	O
-	O
mice	B-Taxon
(	O
Figure	O
7A	O
)	O
.	O

The	O
genotyping	O
strategy	O
outlined	O
in	O
Figure	O
7A	O
was	O
used	O
to	O
distinguish	O
the	O
E2f3a	O
,	O
WT	B-SO
,	O
and	O
null	O
alleles	B-SO
.	O

Reverse	O
transcriptase	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
confirmed	O
the	O
presence	O
of	O
both	O
E2f3a	O
and	O
E2f3b	O
RNA	B-SO
species	B-SO
in	O
the	O
developing	O
WT	B-SO
retina	O
,	O
and	O
the	O
specific	O
absence	O
of	O
E2f3a	O
RNA	B-SO
in	O
the	O
E2f3a	O
-	O
/	O
-	O
retina	O
(	O
Figure	O
7B	O
)	O
.	O

E2f3a	O
protein	B-CHEBI
was	O
absent	O
in	O
E2f3a	O
-	O
/	O
-	O
retinal	O
lysate	O
(	O
Figures	O
6	O
and	O
S8	O
)	O
.	O

Importantly	O
,	O
the	O
levels	O
of	O
E2f3b	O
message	B-SO
were	O
similar	O
in	O
the	O
Rb	B-GGP
KO	O
and	O
Rb	B-GGP
/	O
E2f3a	O
DKO	O
retina	O
,	O
ruling	O
out	O
the	O
possibility	O
that	O
any	O
effects	O
of	O
E2f3a	O
deletion	B-SO
we	O
might	O
observe	O
were	O
due	O
to	O
down	O
-	O
regulation	O
of	O
E2f3b	O
(	O
Figure	O
7C	O
)	O
.	O

Also	O
,	O
the	O
levels	O
of	O
other	O
E2fs	O
were	O
the	O
same	O
in	O
the	O
Rb	B-GGP
KO	O
,	O
Rb	B-GGP
/	O
E2f3	B-GGP
DKO	O
,	O
and	O
Rb	B-GGP
/	O
E2f3a	O
DKO	O
retina	O
,	O
ruling	O
out	O
any	O
cross	O
-	O
regulatory	O
effects	O
(	O
Figure	O
7C	O
)	O
[	O
55	O
]	O
.	O

E2f3a	O
can	O
trigger	O
cell	B-CL
cycle	O
induction	O
,	O
but	O
because	O
SAC	O
defects	O
are	O
not	O
linked	O
to	O
cell	B-CL
cycle	O
perturbation	O
(	O
Figures	O
3A	O
and	O
4	O
)	O
,	O
and	O
in	O
view	O
of	O
the	O
predominant	O
association	O
between	O
E2f3b	O
and	O
Rb	B-GGP
in	O
quiescent	O
cells	B-CL
[	O
16	O
,	O
19	O
]	O
,	O
we	O
suspected	O
that	O
E2f3b	O
may	O
perturb	O
differentiation	O
in	O
Rb	B-GGP
KO	O
SACs	O
.	O

Unexpectedly	O
,	O
however	O
,	O
E2f3a	O
deletion	B-SO
suppressed	O
the	O
Rb	B-GGP
KO	O
SAC	O
defect	O
(	O
Figure	O
7D	O
)	O
.	O

Thus	O
,	O
separate	O
from	O
its	O
role	O
in	O
cell	B-CL
cycle	O
control	O
,	O
Rb	B-GGP
regulation	O
of	O
E2f3a	O
is	O
critical	O
to	O
ensure	O
proper	O
neuronal	B-CL
differentiation	O
.	O

Discussion	O

Rb	B-GGP
Controls	O
Retinal	O
Cell	B-CL
Division	O
and	O
Death	O
through	O
E2f1	B-GGP

Work	O
in	O
the	O
early	O
1990s	O
showed	O
that	O
Rb	B-GGP
loss	O
triggers	O
defects	O
in	O
neuronal	B-CL
cell	B-CL
cycle	O
exit	O
,	O
survival	O
,	O
and	O
differentiation	O
[	O
26	O
-	O
28	O
]	O
.	O

Much	O
of	O
the	O
death	O
is	O
an	O
indirect	O
consequence	O
of	O
probable	O
hypoxia	O
linked	O
to	O
placental	O
defects	O
[	O
12	O
-	O
14	O
]	O
.	O

However	O
,	O
targeted	O
KO	O
and	O
chimeric	O
studies	O
reveal	O
that	O
Rb	B-GGP
autonomously	O
promotes	O
cell	B-CL
cycle	O
exit	O
in	O
newborn	O
neurons	B-CL
,	O
and	O
is	O
required	O
for	O
survival	O
of	O
a	O
subset	O
of	O
neurons	B-CL
,	O
particularly	O
in	O
the	O
retina	O
[	O
2	O
,	O
3	O
,	O
13	O
,	O
14	O
,	O
56	O
-	O
59	O
]	O
.	O

However	O
,	O
whether	O
Rb	B-GGP
also	O
regulates	O
differentiation	O
is	O
obscured	O
by	O
potentially	O
indirect	O
effects	O
of	O
ectopic	O
division	O
and	O
death	O
.	O

Moreover	O
,	O
a	O
mechanism	O
though	O
which	O
Rb	B-GGP
may	O
regulate	O
neuronal	B-CL
maturation	O
has	O
not	O
been	O
elucidated	O
.	O

Here	O
,	O
deleting	B-SO
E2f1	B-GGP
specifically	O
rescued	O
ectopic	O
division	O
and	O
death	O
in	O
the	O
Rb	B-GGP
KO	O
retina	O
.	O

Importantly	O
,	O
major	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
neurons	B-CL
differentiated	O
normally	O
,	O
and	O
ERGs	O
revealed	O
the	O
rescue	O
of	O
rod	B-CL
-	O
and	O
cone	B-CL
-	O
mediated	O
function	O
,	O
implicating	O
a	O
regular	O
signal	O
flow	O
from	O
photoreceptors	B-CL
to	O
bipolar	B-CL
and	I-CL
amacrine	I-CL
cells	I-CL
.	O

Division	O
and	O
death	O
genes	B-SO
were	O
induced	O
in	O
Rb	B-GGP
KO	O
cells	B-CL
,	O
and	O
deleting	B-SO
E2f1	B-GGP
,	O
but	O
not	O
E2f2	B-GGP
or	O
E2f3	B-GGP
,	O
reversed	O
these	O
molecular	B-CHEBI
events	O
.	O

E2f1	B-GGP
may	O
also	O
regulate	O
differentiation	O
targets	O
,	O
but	O
whether	O
this	O
contributes	O
to	O
defects	O
in	O
retinal	O
cell	B-CL
maturation	O
is	O
impossible	O
to	O
separate	O
from	O
potentially	O
indirect	O
consequences	O
of	O
deregulated	O
division	O
and	O
death	O
.	O

In	O
any	O
case	O
,	O
it	O
is	O
clear	O
that	O
in	O
most	O
retinal	O
cells	B-CL
,	O
including	O
photoreceptors	B-CL
[	O
29	O
]	O
,	O
transcription	O
factors	O
that	O
promote	O
differentiation	O
function	O
independently	O
of	O
Rb	B-GGP
.	O

We	O
have	O
also	O
found	O
that	O
E2f1	B-GGP
deletion	B-SO
rescues	O
cell	B-CL
-	O
autonomous	O
ectopic	O
division	O
,	O
death	O
,	O
and	O
differentiation	O
defects	O
in	O
sporadic	O
Rb	B-GGP
KO	O
clones	O
generated	O
using	O
a	O
Cre	O
retrovirus	B-Taxon
vector	B-SO
(	O
M	O
.	O
P	O
.	O
and	O
R	O
.	O
B	O
.	O
,	O
unpublished	O
data	O
)	O
.	O

These	O
data	O
are	O
consistent	O
with	O
the	O
observation	O
that	O
E2f1	B-GGP
overexpression	O
in	O
newborn	O
photoreceptors	B-CL
drives	O
ectopic	O
division	O
and	O
apoptosis	O
[	O
60	O
]	O
,	O
and	O
add	O
to	O
the	O
growing	O
evidence	O
indicating	O
that	O
E2f1	B-GGP
is	O
the	O
major	O
,	O
and	O
perhaps	O
only	O
,	O
member	O
of	O
the	O
three	O
activating	O
E2fs	O
required	O
to	O
induce	O
apoptosis	O
in	O
Rb	B-GGP
KO	O
cells	B-CL
[	O
10	O
,	O
15	O
]	O
.	O

Thus	O
,	O
deregulated	O
E2f1	B-GGP
activity	O
in	O
the	O
retina	O
,	O
whether	O
resulting	O
from	O
the	O
inactivation	O
of	O
Rb	B-GGP
or	O
from	O
overexpression	O
,	O
promotes	O
unscheduled	O
cell	B-CL
division	O
and	O
triggers	O
apoptosis	O
in	O
susceptible	O
RTCs	O
.	O

E2f1	B-GGP
,	O
rather	O
than	O
other	O
E2fs	O
,	O
may	O
be	O
a	O
potential	O
target	O
for	O
novel	O
therapeutics	O
to	O
prevent	O
retinoblastoma	O
in	O
RB1	B-GGP
+	B-SO
/	O
-	O
humans	B-Taxon
.	O

Our	O
ERG	O
studies	O
revealed	O
rescue	O
of	O
the	O
Rb	B-GGP
KO	O
rod	B-CL
-	O
bipolar	B-CL
system	O
,	O
and	O
almost	O
complete	O
restoration	O
of	O
the	O
cone	B-CL
-	O
bipolar	B-CL
system	O
following	O
E2f1	B-GGP
deletion	B-SO
.	O

There	O
was	O
a	O
slightly	O
lower	O
response	O
in	O
the	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
retina	O
relative	O
to	O
the	O
E2f1	B-GGP
KO	O
control	O
retina	O
.	O

This	O
difference	O
might	O
reflect	O
a	O
role	O
for	O
Rb	B-GGP
in	O
the	O
development	O
of	O
cones	B-CL
,	O
bipolar	B-CL
cells	I-CL
,	O
or	O
other	O
cells	B-CL
that	O
may	O
contribute	O
to	O
the	O
photopic	O
ERG	O
,	O
including	O
potentially	O
SACs	O
,	O
which	O
do	O
have	O
a	O
serious	O
defect	O
in	O
the	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
retina	O
.	O

Rb	B-GGP
Controls	O
SAC	O
Differentiation	O
through	O
E2f3a	O

Comprehensive	O
marker	O
analysis	O
revealed	O
that	O
,	O
in	O
striking	O
contrast	O
to	O
other	O
retinal	O
neurons	B-CL
,	O
E2f1	B-GGP
deletion	B-SO
did	O
not	O
suppress	O
defects	O
in	O
Rb	B-GGP
KO	O
cholinergic	B-CHEBI
SACs	O
.	O

Instead	O
,	O
we	O
observed	O
E2f1	B-GGP
-	O
independent	O
defects	O
in	O
the	O
synthesis	O
and	O
transport	O
of	O
a	O
large	O
cohort	O
of	O
SAC	O
proteins	B-CHEBI
.	O

These	O
data	O
expand	O
insight	O
into	O
the	O
development	O
of	O
these	O
important	O
interneurons	B-CL
,	O
but	O
more	O
critically	O
,	O
provide	O
to	O
our	O
knowledge	O
the	O
first	O
unambiguous	O
evidence	O
that	O
Rb	B-GGP
regulates	O
neurogenesis	O
beyond	O
terminal	O
mitosis	O
.	O

Rb	B-GGP
binds	O
more	O
than	O
100	O
factors	O
[	O
43	O
]	O
,	O
and	O
in	O
several	O
non	O
-	O
neuronal	B-CL
cells	B-CL
,	O
such	O
as	O
skeletal	O
muscle	O
,	O
adipocytes	B-CL
,	O
and	O
bone	O
,	O
it	O
binds	O
and	O
potentiates	O
tissue	O
-	O
specific	O
transcription	O
factors	O
that	O
promote	O
differentiation	O
[	O
31	O
-	O
33	O
]	O
.	O

The	O
idea	O
that	O
Rb	B-GGP
promotes	O
muscle	O
differentiation	O
by	O
potentiating	O
Myod1	B-GGP
activity	O
was	O
contested	O
[	O
61	O
]	O
,	O
and	O
other	O
mechanisms	O
proposed	O
[	O
62	O
,	O
63	O
]	O
,	O
but	O
not	O
involving	O
E2f	O
repression	O
.	O

Strikingly	O
,	O
however	O
,	O
we	O
discovered	O
that	O
Rb	B-GGP
promotes	O
SAC	O
differentiation	O
through	O
E2f3	B-GGP
(	O
Figure	O
8	O
)	O
.	O

Figure	O
8	O

Rb	B-GGP
Regulates	O
Distinct	O
Processes	O
through	O
E2f1	B-GGP
and	O
E2f3a	O

Red	O
text	O
and	O
arrows	O
indicate	O
Rb	B-GGP
-	O
dependent	O
events	O
.	O

Black	O
text	O
and	O
arrows	O
indicate	O
events	O
for	O
which	O
there	O
is	O
no	O
direct	O
evidence	O
of	O
Rb	B-GGP
involvement	O
.	O

Rb	B-GGP
does	O
not	O
appear	O
to	O
temper	O
RPC	O
expansion	O
and	O
is	O
not	O
required	O
for	O
differentiation	O
of	O
RPCs	O
into	O
RTCs	O
,	O
but	O
is	O
essential	O
to	O
couple	O
RTC	O
birth	O
to	O
terminal	O
mitosis	O
,	O
thus	O
locking	O
them	O
out	O
of	O
cycle	O
.	O

Rb	B-GGP
performs	O
this	O
function	O
by	O
inhibiting	O
E2f1	B-GGP
.	O

Rb	B-GGP
is	O
also	O
required	O
for	O
SAC	O
differentiation	O
,	O
and	O
in	O
this	O
case	O
,	O
acts	O
by	O
inhibiting	O
E2f3a	O
.	O

There	O
is	O
no	O
direct	O
evidence	O
that	O
Rb	B-GGP
is	O
required	O
for	O
terminal	O
differentiation	O
of	O
other	O
cell	B-CL
types	O
.	O

Colour	O
codes	O
and	O
abbreviations	O
as	O
in	O
Figure	O
1A	O
.	O

Rb	B-GGP
regulation	O
of	O
SAC	O
differentiation	O
through	O
E2f3	B-GGP
was	O
independent	O
of	O
its	O
role	O
in	O
controlling	O
division	O
or	O
death	O
:	O
E2f3	B-GGP
deletion	B-SO
rescued	O
Rb	B-GGP
KO	O
SAC	O
defects	O
but	O
did	O
not	O
suppress	O
aberrant	O
proliferation	O
or	O
death	O
,	O
whereas	O
E2f1	B-GGP
deletion	B-SO
reversed	O
abnormal	O
proliferation	O
and	O
death	O
but	O
did	O
not	O
rescue	O
SAC	O
differentiation	O
.	O

Double	O
labelling	O
confirmed	O
that	O
E2f1	B-GGP
but	O
not	O
E2f3	B-GGP
deletion	B-SO
reversed	O
Rb	B-GGP
KO	O
SAC	O
division	O
.	O

Moreover	O
,	O
deleting	B-SO
E2f1	B-GGP
,	O
but	O
not	O
E2f3	B-GGP
,	O
reversed	O
deregulated	O
expression	O
of	O
cell	B-CL
cycle	O
and	O
apoptotic	O
genes	B-SO
in	O
the	O
Rb	B-GGP
KO	O
retina	O
.	O

E2f3	B-GGP
is	O
expressed	O
in	O
a	O
subset	O
of	O
CNS	B-CL
neurons	I-CL
(	O
this	O
work	O
)	O
and	O
drives	O
specific	O
cell	B-CL
-	O
cycle	O
-	O
independent	O
defects	O
in	O
Rb	B-GGP
KO	O
forebrain	O
neurons	B-CL
[	O
53	O
]	O
.	O

Thus	O
,	O
E2f3	B-GGP
inhibition	O
is	O
the	O
first	O
,	O
and	O
may	O
be	O
the	O
only	O
,	O
mechanism	O
by	O
which	O
Rb	B-GGP
participates	O
directly	O
in	O
neuronal	B-CL
differentiation	O
.	O

To	O
further	O
dissect	O
the	O
mechanism	O
of	O
action	O
of	O
Rb	B-GGP
in	O
SACs	O
we	O
determined	O
the	O
E2f3	B-GGP
isoform	B-SO
it	O
targets	O
to	O
promote	O
differentiation	O
.	O

E2f3b	O
was	O
the	O
primary	O
candidate	O
,	O
since	O
Rb	B-GGP
and	O
E2f3b	O
collaborate	O
to	O
repress	O
targets	O
in	O
quiescent	O
cells	B-CL
in	O
vitro	O
[	O
19	O
]	O
.	O

However	O
,	O
in	O
the	O
first	O
work	O
to	O
our	O
knowledge	O
to	O
examine	O
the	O
function	O
of	O
any	O
E2f	O
protein	B-CHEBI
isoform	B-SO
in	O
vivo	O
,	O
we	O
made	O
the	O
surprising	O
observation	O
that	O
Rb	B-GGP
regulates	O
SAC	O
differentiation	O
through	O
E2f3a	O
(	O
Figure	O
8	O
)	O
.	O

Formally	O
,	O
we	O
cannot	O
exclude	O
the	O
possibility	O
that	O
deleting	B-SO
E2f3b	O
might	O
also	O
rescue	O
SAC	O
differentiation	O
,	O
but	O
definitive	O
proof	O
will	O
require	O
analysis	O
of	O
E2f3b	O
null	O
mice	B-Taxon
.	O

Nevertheless	O
,	O
our	O
data	O
prove	O
that	O
Rb	B-GGP
definitely	O
regulates	O
SAC	O
differentiation	O
through	O
the	O
activating	O
E2f3	B-GGP
isoform	B-SO
.	O

Distinct	O
E2f3a	O
and	O
E2f3b	O
Localization	O

The	O
subcellular	O
location	O
of	O
E2f	O
isoforms	B-SO
has	O
not	O
to	O
our	O
knowledge	O
been	O
addressed	O
before	O
.	O

E2f3a	O
and	O
E2f3b	O
share	O
110	O
C	B-SO
-	I-SO
terminal	I-SO
amino	B-CHEBI
acids	I-CHEBI
that	O
encode	O
the	O
NLS	O
,	O
DNA	B-SO
-	O
binding	O
,	O
marked	O
box	O
,	O
transactivation	O
,	O
and	O
Rb	B-GGP
-	O
binding	B-SO
domains	I-SO
[	O
16	O
]	O
,	O
yet	O
they	O
exhibit	O
different	O
subcellular	O
distribution	O
in	O
developing	O
retinal	O
cells	B-CL
.	O

E2f3a	O
is	O
both	O
nuclear	B-GO
and	O
cytoplasmic	B-GO
,	O
but	O
E2f3b	O
is	O
always	O
nuclear	B-GO
.	O

The	O
unique	O
121	O
-	O
and	O
six	O
-	O
residue	B-SO
N	B-SO
-	I-SO
termini	I-SO
of	O
E2f3a	O
and	O
E2f3b	O
,	O
respectively	O
,	O
likely	O
mediate	O
this	O
difference	O
.	O

This	O
region	B-SO
in	O
E2f1	B-GGP
,	O
E2f2	B-GGP
,	O
and	O
E2f3a	O
binds	O
Ccna2	B-GGP
,	O
establishing	O
a	O
negative	O
regulatory	O
loop	O
that	O
deactivates	O
E2fs	O
in	O
mid	O
-	O
late	O
S	O
-	O
phase	O
[	O
64	O
,	O
65	O
]	O
.	O

However	O
,	O
even	O
E2f3b	O
,	O
which	O
lacks	O
this	O
domain	B-SO
,	O
binds	O
and	O
is	O
regulated	O
by	O
Ccna2	B-GGP
[	O
18	O
]	O
,	O
so	O
the	O
domain	B-SO
difference	O
may	O
not	O
explain	O
the	O
unique	O
distributions	O
we	O
observed	O
.	O

Rb	B-GGP
family	O
and	O
Tfdp	O
proteins	B-CHEBI
can	O
also	O
determine	O
E2f	O
localization	O
[	O
20	O
-	O
22	O
]	O
,	O
and	O
we	O
found	O
that	O
a	O
portion	O
of	O
both	O
Rb	B-GGP
and	O
Tfdp1	B-GGP
proteins	B-CHEBI
are	O
cytoplasmic	B-GO
in	O
retinal	O
cells	B-CL
.	O

Indeed	O
,	O
immunostaining	O
revealed	O
that	O
Rb	B-GGP
and	O
E2f3	B-GGP
colocalize	O
to	O
SAC	O
processes	B-GO
.	O

The	O
nuclear	B-GO
localization	O
of	O
E2f3b	O
contrasts	O
with	O
that	O
of	O
other	O
repressive	O
E2fs	O
in	O
differentiating	O
muscle	O
,	O
where	O
E2f5	B-GGP
switches	O
from	O
the	O
nucleus	B-GO
to	O
cytoplasm	B-GO
,	O
while	O
E2f4	B-GGP
remains	O
in	O
both	O
compartments	O
[	O
23	O
]	O
.	O

The	O
distinct	O
compartmentalization	O
of	O
E2f3a	O
and	O
E2f3b	O
in	O
the	O
retina	O
suggests	O
temporally	O
and	O
functionally	O
distinct	O
activities	O
.	O

Rb	B-GGP
distribution	O
matches	O
that	O
of	O
E2f3a	O
,	O
consistent	O
with	O
its	O
critical	O
role	O
in	O
supporting	O
SAC	O
differentiation	O
through	O
E2f3a	O
.	O

Ectopic	O
Division	O
and	O
Differentiation	O

Rb	B-GGP
is	O
critical	O
to	O
ensure	O
that	O
many	O
types	O
of	O
terminally	O
differentiating	O
cells	B-CL
leave	O
the	O
cell	B-CL
cycle	O
(	O
e	O
.	O
g	O
.	O
,	O
neurons	B-CL
,	O
gut	O
and	O
skin	O
epithelia	O
,	O
muscle	O
,	O
and	O
lens	O
fibres	O
)	O
(	O
reviewed	O
in	O
[	O
66	O
]	O
)	O
.	O

Early	O
overexpression	O
studies	O
in	O
vitro	O
suggested	O
Rb	B-GGP
might	O
temper	O
expansion	O
of	O
cycling	O
cells	B-CL
,	O
but	O
KO	O
studies	O
in	O
vivo	O
indicate	O
that	O
its	O
major	O
role	O
is	O
to	O
block	O
division	O
in	O
terminally	O
differentiating	O
cells	B-CL
.	O

In	O
its	O
absence	O
,	O
many	O
(	O
but	O
clearly	O
not	O
all	O
)	O
aspects	O
of	O
differentiation	O
go	O
ahead	O
relatively	O
unperturbed	O
.	O

In	O
the	O
retina	O
,	O
differentiating	O
transition	O
cells	B-CL
are	O
born	O
in	O
the	O
absence	O
of	O
Rb	B-GGP
,	O
migrate	O
to	O
the	O
correct	O
layer	O
,	O
and	O
express	O
appropriate	O
markers	O
(	O
[	O
2	O
]	O
and	O
this	O
work	O
)	O
.	O

In	O
brain	O
,	O
Rb	B-GGP
KO	O
neurons	B-CL
migrate	O
away	O
from	O
the	O
ventricular	O
zone	O
and	O
switch	O
on	O
Tubb3	B-GGP
(	O
beta	B-GGP
III	I-GGP
-	I-GGP
tubulin	I-GGP
)	O
,	O
but	O
continue	O
to	O
incorporate	B-SO
BrdU	O
[	O
13	O
]	O
,	O
and	O
in	O
gut	O
epithelia	O
,	O
differentiated	O
enterocytes	B-CL
migrate	O
up	O
the	O
villi	O
and	O
activate	O
expression	O
of	O
serotonin	B-CHEBI
,	O
yet	O
continue	O
to	O
incorporate	B-SO
BrdU	O
[	O
67	O
]	O
.	O

In	O
the	O
case	O
of	O
SACs	O
,	O
the	O
differentiation	O
defects	O
we	O
observed	O
(	O
e	O
.	O
g	O
.	O
,	O
loss	O
of	O
Slc18a3	B-GGP
and	O
Chat	B-GGP
)	O
were	O
not	O
due	O
to	O
aberrant	O
division	O
,	O
but	O
it	O
is	O
possible	O
there	O
are	O
other	O
problems	O
with	O
these	O
cells	B-CL
that	O
are	O
caused	O
by	O
ectopic	O
division	O
.	O

Nevertheless	O
,	O
it	O
is	O
clear	O
that	O
many	O
aspects	O
of	O
differentiation	O
in	O
multiple	O
cell	B-CL
types	O
are	O
compatible	O
with	O
ectopic	O
division	O
.	O

However	O
,	O
division	O
of	O
terminally	O
differentiating	O
cells	B-CL
is	O
dangerous	O
,	O
since	O
it	O
may	O
facilitate	O
transformation	O
,	O
as	O
is	O
the	O
case	O
in	O
retinoblastoma	O
(	O
reviewed	O
in	O
[	O
66	O
]	O
)	O
.	O

How	O
Does	O
E2f3a	O
Perturb	O
SAC	O
Differentiation	O
?	O

E2f3a	O
could	O
disrupt	O
SAC	O
differentiation	O
through	O
its	O
well	O
known	O
role	O
as	O
a	O
transcriptional	O
activator	O
,	O
or	O
,	O
in	O
view	O
of	O
the	O
discovery	O
that	O
it	O
is	O
partially	O
cytoplasmic	B-GO
,	O
E2f3a	O
may	O
affect	O
processes	O
other	O
than	O
gene	B-SO
regulation	O
.	O

Both	O
scenarios	O
are	O
feasible	O
since	O
E2fs	O
regulate	O
differentiation	O
genes	B-SO
[	O
44	O
-	O
48	O
]	O
,	O
and	O
cell	B-CL
cycle	O
regulators	O
,	O
such	O
as	O
Cdkn1b	B-GGP
,	O
have	O
cytoplasmic	B-GO
activities	O
that	O
influence	O
differentiation	O
[	O
68	O
,	O
69	O
]	O
.	O

Many	O
transcription	O
factors	O
shuttle	O
between	O
nucleus	B-GO
and	O
cytoplasm	B-GO
during	O
neurogenesis	O
(	O
e	O
.	O
g	O
.	O
,	O
[	O
70	O
]	O
and	O
references	O
therein	O
)	O
.	O

It	O
may	O
be	O
difficult	O
to	O
identify	O
E2f3a	O
-	O
specific	O
target	O
genes	B-SO
or	O
cytoplasmic	B-GO
proteins	B-CHEBI
in	O
SACs	O
since	O
these	O
neurons	B-CL
are	O
a	O
small	O
proportion	O
(	O
<	O
1	O
%	O
)	O
of	O
the	O
total	O
retina	O
and	O
only	O
~	O
5	O
.	O
2	O
%	O
of	O
amacrine	B-CL
neurons	I-CL
[	O
38	O
]	O
.	O

Do	O
E2fs	O
Mediate	O
All	O
Rb	B-GGP
Functions	O
?	O

Others	O
have	O
suggested	O
that	O
Rb	B-GGP
promotes	O
differentiation	O
in	O
non	O
-	O
neuronal	B-CL
cells	B-CL
through	O
E2f	O
-	O
independent	O
means	O
[	O
31	O
-	O
33	O
]	O
.	O

However	O
,	O
these	O
studies	O
did	O
not	O
assess	O
whether	O
these	O
cell	B-CL
types	O
differentiate	O
normally	O
if	O
Rb	B-GGP
is	O
deleted	B-SO
along	O
with	O
one	O
or	O
more	O
E2f	O
family	O
members	O
.	O

One	O
study	O
reported	O
that	O
Rb	B-GGP
mutants	B-SO
that	O
do	O
not	O
bind	O
E2f	O
still	O
induce	O
differentiation	O
[	O
30	O
]	O
.	O

However	O
,	O
the	O
binding	O
assays	O
were	O
performed	O
in	O
solution	O
,	O
and	O
we	O
have	O
found	O
that	O
several	O
of	O
these	O
mutants	B-SO
do	O
bind	O
E2f	O
,	O
albeit	O
weakly	O
,	O
on	O
chromatin	B-GO
(	O
T	O
.	O
Yu	O
and	O
R	O
.	O
B	O
.	O
,	O
unpublished	O
data	O
)	O
.	O

It	O
is	O
possible	O
that	O
Rb	B-GGP
-	O
mediated	O
potentiation	O
of	O
tissue	O
-	O
specific	O
transcription	O
factors	O
may	O
,	O
at	O
least	O
in	O
some	O
cases	O
,	O
be	O
a	O
redundant	O
activity	O
,	O
and	O
that	O
the	O
only	O
critical	O
Rb	B-GGP
function	O
is	O
to	O
inhibit	O
E2f	O
.	O

Our	O
study	O
is	O
the	O
first	O
to	O
our	O
knowledge	O
to	O
assess	O
comprehensively	O
whether	O
Rb	B-GGP
KO	O
cells	B-CL
can	O
differentiate	O
in	O
the	O
absence	O
of	O
different	O
E2fs	O
.	O

In	O
light	O
of	O
our	O
findings	O
,	O
it	O
will	O
be	O
important	O
to	O
reassess	O
differentiation	O
defects	O
in	O
other	O
Rb	B-GGP
KO	O
tissues	O
in	O
the	O
absence	O
of	O
individual	O
and	O
combined	O
activating	O
E2f	O
family	O
members	O
.	O

Materials	O
and	O
Methods	O

Mouse	B-Taxon
strains	O
and	O
genotyping	O
.	O

Mice	B-Taxon
were	O
treated	O
according	O
to	O
institutional	O
and	O
national	O
guidelines	O
.	O

alpha	O
-	O
Cre	O
mice	B-Taxon
(	O
P	O
.	O
Gruss	O
)	O
,	O
Chx10	B-GGP
-	O
Cre	O
mice	B-Taxon
(	O
C	O
.	O
Cepko	O
)	O
,	O
RbloxP	O
/	O
loxP	B-SO
mice	B-Taxon
(	O
A	O
.	O
Berns	O
)	O
,	O
E2f1	B-GGP
-	O
/	O
-	O
mice	B-Taxon
,	O
E2f2	B-GGP
-	O
/	O
-	O
mice	B-Taxon
,	O
E2f3loxP	O
/	O
loxP	B-SO
mice	B-Taxon
,	O
and	O
E2f3a	O
-	O
/	O
-	O
mice	B-Taxon
were	O
maintained	O
on	O
a	O
mixed	O
(	O
NMRI	O
x	O
C57	O
/	O
Bl	O
x	O
FVB	O
/	O
N	O
x	O
129sv	O
)	O
background	O
.	O

A	O
detailed	O
description	O
of	O
E2f3a	O
-	O
/	O
-	O
mice	B-Taxon
will	O
be	O
published	O
elsewhere	O
.	O

Mice	B-Taxon
of	O
different	O
genotypes	B-SO
were	O
compared	O
within	O
the	O
same	O
litter	O
and	O
across	O
a	O
minimum	O
of	O
three	O
litters	O
.	O

We	O
have	O
not	O
noted	O
any	O
phenotypic	O
differences	O
in	O
separate	O
litters	O
.	O

Genotyping	O
was	O
performed	O
as	O
before	O
[	O
2	O
,	O
5	O
]	O
,	O
and	O
the	O
primers	B-SO
used	O
for	O
genotyping	O
E2f3a	O
-	O
/	O
-	O
mice	B-Taxon
were	O
E2f3a	O
KL	O
(	O
5	O
'	O
-	O
CTCCAGACCCCCGATTATTT	O
-	O
3	O
'	O
)	O
,	O
E2f3a	O
KR1	O
(	O
5	O
'	O
-	O
TCCAGTGCACTACTCCCTCC	O
-	O
3	O
'	O
)	O
,	O
and	O
E2f3a	O
KM	O
(	O
5	O
'	O
-	O
GCTAGCAGTGCCCTTTTGTC	O
-	O
3	O
'	O
)	O
.	O

Histology	O
,	O
immunofluorescence	O
,	O
and	O
measurements	O
.	O

Eyeballs	O
were	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
for	O
1	O
h	O
at	O
4	O
degrees	O
C	O
,	O
embedded	O
in	O
OCT	O
(	O
TissueTek	O
4583	O
,	O
Sakura	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
sakuraeu	O
.	O
com	O
)	O
,	O
frozen	O
on	O
dry	O
ice	O
,	O
and	O
cut	O
into	O
12	O
-	O
mu	O
m	O
sections	O
on	O
Superfrost	O
plus	O
slides	O
(	O
VWR	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
vwr	O
.	O
com	O
)	O
.	O

For	O
S	O
-	O
phase	O
analysis	O
,	O
BrdU	O
(	O
100	O
mu	O
g	O
/	O
g	O
of	O
body	O
weight	O
)	O
was	O
injected	O
intraperitoneally	O
2	O
h	O
prior	O
to	O
sacrifice	O
.	O

BrdU	O
+	O
cells	B-CL
were	O
detected	O
using	O
a	O
biotin	B-CHEBI
-	O
conjugated	O
sheep	B-Taxon
polyclonal	O
antibody	B-GO
(	O
1	O
:	O
500	O
,	O
Maine	O
Biotechnology	O
Services	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
mainebiotechnology	O
.	O
com	O
)	O
.	O

All	O
other	O
antibodies	B-GO
are	O
described	O
in	O
Table	O
S1	O
.	O

For	O
E2f3	B-GGP
,	O
Mki67	B-GGP
,	O
and	O
Rb	B-GGP
staining	O
,	O
antigen	O
retrieval	O
was	O
performed	O
by	O
boiling	O
sections	O
in	O
citric	B-CHEBI
acid	I-CHEBI
solution	O
for	O
15	O
min	O
according	O
to	O
Ino	O
[	O
50	O
]	O
,	O
except	O
on	O
frozen	O
sections	O
.	O

TUNEL	O
was	O
performed	O
as	O
described	O
[	O
13	O
]	O
.	O

Briefly	O
,	O
sections	O
were	O
incubated	O
for	O
1	O
h	O
at	O
37	O
degrees	O
C	O
with	O
75	O
mu	O
l	O
of	O
mixture	O
solution	O
consisting	O
of	O
0	O
.	O
5	O
mu	O
l	O
of	O
terminal	B-GGP
deoxynucleotide	I-GGP
transferase	I-GGP
,	O
1	O
mu	O
l	O
of	O
biotin	B-CHEBI
-	O
16	O
-	O
dUTP	B-CHEBI
,	O
7	O
.	O
5	O
mu	O
l	O
of	O
CoCl2	B-CHEBI
,	O
15	O
mu	O
l	O
of	O
5	O
x	O
terminal	B-GGP
deoxynucleotide	I-GGP
transferase	I-GGP
buffer	O
,	O
and	O
51	O
mu	O
l	O
of	O
distilled	O
water	B-CHEBI
.	O

After	O
three	O
washes	O
in	O
4	O
x	O
SSC	O
buffer	O
,	O
sections	O
were	O
incubated	O
with	O
Alexa	O
488	O
-	O
or	O
Alexa	O
568	O
-	O
streptavidin	O
(	O
1	O
:	O
1	O
,	O
000	O
;	O
Molecular	B-CHEBI
Probes	O
,	O
http	O
:	O
/	O
/	O
probes	O
.	O
invitrogen	O
.	O
com	O
)	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

Primary	O
antibodies	B-GO
or	O
labelled	O
cells	B-CL
were	O
visualized	O
using	O
donkey	B-Taxon
anti	O
-	O
mouse	B-Taxon
Alexa	O
488	O
or	O
Alexa	O
568	O
,	O
donkey	B-Taxon
anti	O
-	O
rabbit	B-Taxon
Alexa	O
488	O
or	O
Alexa	O
568	O
,	O
donkey	B-Taxon
anti	O
-	O
goat	B-Taxon
Alexa	O
488	O
or	O
Alexa	O
568	O
,	O
and	O
streptavidin	O
Alexa	O
488	O
or	O
Alexa	O
568	O
(	O
1	O
:	O
1	O
,	O
000	O
;	O
Molecular	B-CHEBI
Probes	O
)	O
.	O

Nuclei	B-GO
were	O
counter	O
-	O
stained	O
with	O
4	O
,	O
6	O
-	O
diamidino	O
-	O
2	O
-	O
phenyindole	B-CHEBI
(	O
DAPI	O
;	O
Sigma	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
sigmaaldrich	O
.	O
com	O
)	O
.	O

Labelled	O
cells	B-CL
were	O
visualized	O
using	O
a	O
Zeiss	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
zeiss	O
.	O
com	O
)	O
Axioplan	O
-	O
2	O
microscope	O
with	O
Plan	O
Neofluar	O
objectives	O
and	O
images	O
captured	O
with	O
a	O
Zeiss	O
AxionCam	O
camera	O
.	O

For	O
double	O
-	O
labelled	O
samples	O
,	O
confocal	O
images	O
were	O
obtained	O
with	O
a	O
Zeiss	O
LSM	O
5	O
.	O
0	O
laser	O
scanning	O
microscope	O
.	O

The	O
retina	O
was	O
separated	O
into	O
three	O
bins	O
by	O
dividing	O
the	O
ventricular	O
edge	O
of	O
the	O
retina	O
into	O
equal	O
parts	O
and	O
extending	O
a	O
line	O
to	O
the	O
vitreal	O
edge	O
[	O
2	O
]	O
.	O

Bin	O
1	O
contains	O
only	O
cells	B-CL
that	O
expressed	O
Cre	O
as	O
progenitors	O
;	O
bin	O
3	O
is	O
at	O
central	O
retina	O
and	O
contains	O
cells	B-CL
derived	O
from	O
progenitors	O
that	O
did	O
not	O
express	O
Cre	O
.	O

For	O
cell	B-CL
counts	O
or	O
thickness	O
measurement	O
we	O
used	O
a	O
region	O
0	O
-	O
100	O
mu	O
m	O
peripheral	O
to	O
the	O
boundary	O
separating	O
bins	O
1	O
and	O
2	O
.	O

Measurements	O
were	O
performed	O
on	O
an	O
Axioplan	O
-	O
2	O
microscope	O
using	O
Axiovison	O
software	O
.	O

Quantification	O
of	O
S	O
-	O
phase	O
,	O
M	O
-	O
phase	O
,	O
and	O
apoptotic	B-CL
cells	I-CL
was	O
performed	O
on	O
horizontal	O
sections	O
that	O
included	O
the	O
optic	O
nerve	O
.	O

Quantification	O
of	O
differentiated	O
cell	B-CL
types	O
was	O
performed	O
using	O
horizontal	O
sections	O
at	O
equal	O
distances	O
from	O
the	O
optic	O
nerve	O
.	O

A	O
minimum	O
of	O
three	O
sections	O
per	O
eye	O
and	O
three	O
eyes	O
from	O
different	O
litters	O
were	O
counted	O
.	O

RNA	B-SO
extraction	O
,	O
reverse	O
transcription	O
,	O
and	O
PCR	O
.	O

Total	O
RNA	B-SO
was	O
isolated	O
from	O
dissected	O
peripheral	O
retina	O
using	O
TRIzol	O
reagent	B-CHEBI
(	O
Invitrogen	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
invitrogen	O
.	O
com	O
)	O
followed	O
by	O
digestion	O
with	O
RNase	O
-	O
free	O
DNase	O
(	O
DNA	B-SO
-	O
free	O
,	O
Ambion	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
ambion	O
.	O
com	O
)	O
to	O
remove	O
DNA	B-SO
contamination	O
.	O

First	O
-	O
strand	B-SO
cDNA	B-SO
was	O
synthesized	O
from	O
0	O
.	O
2	O
-	O
0	O
.	O
5	O
mu	O
g	O
of	O
total	O
RNA	B-SO
using	O
the	O
SuperScript	O
II	O
first	O
-	O
strand	B-SO
synthesis	O
system	O
(	O
Invitrogen	O
)	O
.	O

PCR	O
primers	B-SO
are	O
listed	O
in	O
Table	O
S2	O
.	O

Real	O
-	O
time	O
quantitative	O
PCR	O
was	O
performed	O
using	O
an	O
Applied	O
Biosystems	O
(	O
http	O
:	O
/	O
/	O
appliedbiosystems	O
.	O
com	O
)	O
PRISM	O
7900HT	O
.	O

Tests	O
were	O
run	O
in	O
duplicate	O
on	O
three	O
separate	O
biological	O
samples	O
with	O
SYBR	O
Green	O
PCR	O
Master	O
Mix	O
(	O
Applied	O
Biosystems	O
)	O
exactly	O
as	O
we	O
described	O
previously	O
[	O
71	O
]	O
.	O

Briefly	O
,	O
master	O
stocks	O
were	O
prepared	O
such	O
that	O
each	O
10	O
-	O
mu	O
l	O
reaction	O
contained	O
5	O
mu	O
l	O
of	O
SYBR	O
Green	O
PCR	O
Master	O
Mix	O
,	O
0	O
.	O
1	O
mu	O
l	O
of	O
each	O
forward	B-SO
and	I-SO
reverse	I-SO
primer	I-SO
(	O
stock	O
50	O
mu	O
M	O
)	O
,	O
0	O
.	O
8	O
mu	O
l	O
of	O
blue	O
H2O	B-CHEBI
(	O
0	O
.	O
73	O
%	O
Blue	O
Food	B-CHEBI
Colour	O
;	O
McCormick	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
mccormick	O
.	O
com	O
)	O
,	O
2	O
mu	O
l	O
of	O
diluted	O
cDNA	B-SO
template	O
,	O
and	O
2	O
mu	O
l	O
of	O
yellow	O
H2O	B-CHEBI
(	O
0	O
.	O
73	O
%	O
Yellow	O
Food	B-CHEBI
Colour	O
)	O
.	O

PCR	O
consisted	O
of	O
40	O
cycles	O
of	O
denaturation	O
at	O
95	O
degrees	O
C	O
for	O
15	O
s	O
and	O
annealing	O
and	O
extension	O
at	O
55	O
degrees	O
C	O
for	O
30	O
s	O
.	O

An	O
additional	O
cycle	O
(	O
95	O
degrees	O
C	O
,	O
15	O
s	O
,	O
60	O
degrees	O
C	O
)	O
generated	O
a	O
dissociation	O
curve	O
to	O
confirm	O
a	O
single	O
product	B-SO
.	O

The	O
cycle	O
quantity	O
required	O
to	O
reach	O
a	O
threshold	O
in	O
the	O
linear	O
range	O
was	O
determined	O
and	O
compared	O
to	O
a	O
standard	O
curve	O
for	O
each	O
primer	B-SO
set	O
generated	O
by	O
five	O
3	O
-	O
fold	O
dilutions	O
of	O
genomic	B-SO
DNA	I-SO
or	O
cDNA	B-SO
samples	O
of	O
known	O
concentration	O
.	O

Values	O
obtained	O
for	O
test	O
RNAs	B-SO
were	O
normalized	O
to	O
Hprt1	B-GGP
mRNA	B-CHEBI
levels	O
.	O

Western	O
blots	O
.	O

Mouse	B-Taxon
retinas	O
were	O
homogenized	O
by	O
passing	O
them	O
through	O
a	O
30	O
-	O
gauge	O
BD	O
9	O
http	O
:	O
/	O
/	O
www	O
.	O
bd	O
.	O
com	O
)	O
needle	O
5	O
-	O
10	O
times	O
in	O
1	O
x	O
PBS	O
solution	O
.	O

Nuclear	B-GO
and	O
cytoplasmic	B-GO
proteins	B-CHEBI
were	O
extracted	O
using	O
the	O
NE	O
-	O
PER	O
Nuclear	B-GO
and	O
Cytoplasmic	B-GO
Extraction	O
Kit	O
(	O
Product	O
#	O
78833	O
,	O
Pierce	O
Biotechnology	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
piercenet	O
.	O
com	O
)	O
.	O

Proteins	B-CHEBI
were	O
separated	O
by	O
10	O
%	O
SDS	B-CHEBI
-	O
PAGE	O
and	O
transferred	O
to	O
nitrocellulose	O
.	O

After	O
blocking	O
overnight	O
at	O
4	O
degrees	O
C	O
in	O
5	O
%	O
skim	O
milk	O
,	O
membranes	O
were	O
incubated	O
in	O
the	O
primary	O
antibody	B-GO
for	O
2	O
h	O
at	O
room	O
temperature	O
.	O

After	O
three	O
10	O
-	O
min	O
washes	O
in	O
TPBS	O
(	O
100	O
mM	O
Na2HPO4	B-CHEBI
,	O
100	O
mM	O
NaH2PO4	B-CHEBI
,	O
0	O
.	O
5	O
N	O
NaCl	B-CHEBI
,	O
0	O
.	O
1	O
%	O
Tween	O
-	O
20	O
)	O
,	O
membranes	O
were	O
incubated	O
for	O
30	O
min	O
at	O
room	O
temperature	O
in	O
the	O
secondary	O
horseradish	B-Taxon
peroxidase	O
-	O
conjugated	O
antibody	B-GO
(	O
Jackson	O
ImmunoResearch	O
Laboratories	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
jacksonimmuno	O
.	O
com	O
)	O
.	O

Blots	O
were	O
developed	O
using	O
the	O
ECL	O
-	O
Plus	O
chemiluminescent	O
detection	O
system	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
pharmacia	O
.	O
ca	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
following	O
primary	O
antibodies	B-GO
were	O
used	O
:	O
E2f	B-GGP
-	I-GGP
1	I-GGP
(	O
SC	O
-	O
193	O
)	O
,	O
E2f	B-GGP
-	I-GGP
3	I-GGP
(	O
SC	O
-	O
878	O
)	O
,	O
Cdkn1a	B-GGP
(	O
p21	B-GGP
,	O
SC	O
-	O
471	O
)	O
,	O
Cdkn1b	B-GGP
(	O
p27	B-GGP
,	O
SC	O
-	O
528	O
)	O
,	O
Pou4f2	B-GGP
(	O
Brn3b	B-GGP
,	O
SC	O
-	O
6062	O
)	O
,	O
and	O
Tfdp1	B-GGP
(	O
Dp1	B-GGP
,	O
SC	O
-	O
610	O
)	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
scbt	O
.	O
com	O
)	O
,	O
pRB	O
(	O
554136	O
)	O
from	O
BD	O
Science	O
-	O
Pharmingen	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
bdbiosciences	O
.	O
com	O
)	O
,	O
and	O
Slc18a3	B-GGP
(	O
VAChT	B-GGP
,	O
G448A	O
)	O
from	O
Promega	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
promega	O
.	O
com	O
)	O
.	O

Electroretinography	O
.	O

ERGs	O
were	O
recorded	O
from	O
dark	O
-	O
adapted	O
mice	B-Taxon
as	O
described	O
[	O
72	O
]	O
.	O

Briefly	O
,	O
mice	B-Taxon
were	O
dark	O
-	O
adapted	O
overnight	O
and	O
anaesthetized	O
by	O
subcutaneous	O
injection	O
of	O
ketamine	O
(	O
66	O
.	O
7	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
and	O
xylazine	O
(	O
11	O
.	O
7	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
.	O

The	O
pupils	O
were	O
dilated	O
and	O
single	O
-	O
flash	O
ERG	O
recordings	O
were	O
obtained	O
under	O
dark	O
-	O
adapted	O
(	O
scotopic	O
)	O
and	O
light	O
-	O
adapted	O
(	O
photopic	O
)	O
conditions	O
.	O

Light	O
adaptation	O
was	O
accomplished	O
with	O
a	O
background	O
illumination	O
of	O
30	O
candela	O
(	O
cd	O
)	O
per	O
square	O
meter	O
starting	O
10	O
min	O
before	O
recording	O
.	O

Single	O
white	O
-	O
flash	O
stimulation	O
ranged	O
from	O
10	O
-	O
4	O
to	O
25	O
cd	O
.	O
s	O
/	O
m2	O
,	O
divided	O
into	O
ten	O
steps	O
of	O
0	O
.	O
5	O
and	O
1	O
log	O
cd	O
.	O
s	O
/	O
m2	O
.	O

Ten	O
responses	O
were	O
averaged	O
with	O
an	O
inter	O
-	O
stimulus	O
interval	O
of	O
either	O
5	O
s	O
(	O
for	O
10	O
-	O
4	O
,	O
10	O
-	O
3	O
,	O
10	O
-	O
2	O
,	O
3	O
x	O
10	O
-	O
2	O
,	O
10	O
-	O
1	O
,	O
and	O
3	O
x	O
10	O
-	O
1	O
cd	O
.	O
s	O
/	O
m2	O
)	O
or	O
17	O
s	O
(	O
for	O
1	O
,	O
3	O
,	O
10	O
,	O
and	O
25	O
cd	O
.	O
s	O
/	O
m2	O
)	O
.	O

Band	O
-	O
pass	O
filter	O
cut	O
-	O
off	O
frequencies	O
were	O
0	O
.	O
1	O
and	O
3	O
,	O
000	O
Hz	O
.	O

Statistics	O
.	O

Different	O
genotypes	B-SO
were	O
evaluated	O
using	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
followed	O
by	O
the	O
Tukey	O
honestly	O
significant	O
difference	O
(	O
HSD	O
)	O
test	O
or	O
Fisher	O
test	O
(	O
XLSTAT	O
program	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
xlstat	O
.	O
com	O
)	O
.	O

Supporting	O
Information	O

Figure	O
S1	O

Deleting	B-SO
E2f1	B-GGP
,	O
but	O
Not	O
E2f2	B-GGP
or	O
E2f3	B-GGP
,	O
Rescues	O
Ectopic	O
Division	O
and	O
Cell	B-CL
Death	O
in	O
P0	O
and	O
P18	O
Rb	B-GGP
KO	O
Retina	O

Horizontal	O
sections	O
of	O
the	O
indicated	O
genotypes	B-SO
and	O
ages	O
were	O
stained	O
for	O
nuclei	B-GO
(	O
DAPI	O
,	O
blue	O
)	O
,	O
and	O
(	O
A	O
)	O
S	O
-	O
phase	O
(	O
anti	O
-	O
BrdU	O
,	O
red	O
)	O
or	O
(	O
B	O
)	O
apoptosis	O
(	O
TUNEL	O
,	O
red	O
)	O
.	O

In	O
Rb	B-GGP
-	O
/	O
-	O
retinas	O
,	O
BrdU	O
+	O
cells	B-CL
extend	O
beyond	O
the	O
normal	O
boundaries	O
at	O
P0	O
(	O
arrows	O
)	O
,	O
and	O
ectopic	O
DNA	B-SO
synthesis	O
continues	O
in	O
multiple	O
layers	O
at	O
later	O
stages	O
.	O

Scale	O
bar	O
is	O
50	O
mu	O
m	O
.	O

The	O
NBL	O
is	O
where	O
dividing	O
RPCs	O
are	O
located	O
.	O

(	O
815	O
KB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Figure	O
S2	O

Deleting	B-SO
E2f1	B-GGP
Rescues	O
Ectopic	O
Division	O
and	O
Apoptosis	O
in	O
the	O
Embryonic	O
Rb	B-GGP
KO	O
Retina	O

Horizontal	O
sections	O
of	O
the	O
indicated	O
genotypes	B-SO
and	O
ages	O
(	O
E14	O
and	O
E16	O
,	O
the	O
period	O
during	O
which	O
SACs	O
are	O
born	O
)	O
were	O
stained	O
for	O
nuclei	B-GO
(	O
DAPI	O
,	O
blue	O
)	O
,	O
and	O
either	O
S	O
-	O
phase	O
(	O
upper	O
two	O
panels	O
,	O
anti	O
-	O
BrdU	O
,	O
red	O
)	O
or	O
apoptosis	O
(	O
lower	O
two	O
panels	O
,	O
TUNEL	O
,	O
red	O
)	O
.	O

In	O
Rb	B-GGP
-	O
/	O
-	O
retinas	O
,	O
BrdU	O
+	O
and	O
TUNEL	O
+	O
cells	B-CL
can	O
be	O
seen	O
in	O
the	O
inner	O
retina	O
(	O
arrows	O
)	O
.	O

Inactivation	O
of	O
E2f1	B-GGP
rescued	O
these	O
defects	O
.	O

Scale	O
bar	O
is	O
50	O
mu	O
m	O
.	O

The	O
NBL	O
is	O
where	O
dividing	O
RPCs	O
are	O
located	O
.	O

(	O
754	O
KB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Figure	O
S3	O

Deleting	B-SO
E2f1	B-GGP
,	O
but	O
Not	O
E2f2	B-GGP
or	O
E2f3	B-GGP
,	O
Rescues	O
Ectopic	O
Mitosis	O
in	O
the	O
Rb	B-GGP
KO	O
Retina	O

(	O
A	O
)	O
Horizontal	O
retinal	O
sections	O
of	O
the	O
indicated	O
genotypes	B-SO
and	O
ages	O
were	O
stained	O
for	O
nuclei	B-GO
(	O
DAPI	O
,	O
blue	O
)	O
and	O
M	O
-	O
phase	O
(	O
anti	O
-	O
PH3	O
,	O
red	O
)	O
.	O

Scale	O
bar	O
is	O
50	O
mu	O
m	O
.	O

(	O
B	O
)	O
Quantification	O
of	O
all	O
PH3	O
+	O
cells	B-CL
.	O

(	O
C	O
)	O
Quantification	O
of	O
ectopic	O
PH3	O
+	O
cells	B-CL
.	O

Error	O
bars	O
represent	O
standard	O
deviation	O
(	O
SD	O
)	O
,	O
and	O
asterisks	O
indicate	O
significant	O
difference	O
between	O
retina	O
of	O
WT	B-SO
and	O
indicated	O
genotypes	B-SO
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
01	O
;	O
ANOVA	O
and	O
Tukey	O
HSD	O
test	O
)	O
.	O

(	O
628	O
KB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Figure	O
S4	O

Deleting	B-SO
E2f2	B-GGP
or	O
E2f3	B-GGP
Does	O
Not	O
Rescue	O
Ganglion	B-CL
,	I-CL
Rod	I-CL
,	I-CL
or	I-CL
Bipolar	I-CL
Cell	I-CL
Death	O
in	O
the	O
Rb	B-GGP
KO	O
Retina	O

(	O
A	O
)	O
Horizontal	O
retinal	O
sections	O
from	O
mice	B-Taxon
of	O
the	O
indicated	O
ages	O
and	O
genotypes	B-SO
were	O
stained	O
for	O
nuclei	B-GO
(	O
DAPI	O
,	O
blue	O
)	O
and	O
markers	O
that	O
detect	O
ganglion	B-CL
cells	I-CL
(	O
Pou4f2	B-GGP
,	O
red	O
)	O
,	O
rods	B-CL
and	O
cones	B-CL
(	O
Sag	B-GGP
[	O
rod	B-GGP
arrestin	I-GGP
]	O
,	O
green	O
)	O
,	O
and	O
rod	B-CL
bipolar	I-CL
cells	I-CL
(	O
Prkca	B-GGP
,	O
green	O
)	O
.	O

Scale	O
bar	O
is	O
50	O
mu	O
m	O
.	O

(	O
B	O
)	O
Quantification	O
of	O
total	O
ganglion	B-CL
(	I-CL
Pou4f2	I-CL
+	I-CL
)	I-CL
cells	I-CL
.	O

(	O
C	O
)	O
Quantification	O
of	O
total	O
rod	B-CL
bipolar	I-CL
(	I-CL
Prkca	I-CL
+	I-CL
)	I-CL
cells	I-CL
.	O

(	O
D	O
)	O
Thickness	O
of	O
the	O
ONL	O
,	O
which	O
represents	O
the	O
number	O
of	O
rods	B-CL
.	O

Error	O
bars	O
represent	O
SD	O
,	O
and	O
asterisks	O
indicate	O
significant	O
difference	O
between	O
retina	O
of	O
WT	B-SO
and	O
indicated	O
genotypes	B-SO
(	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
01	O
;	O
ANOVA	O
and	O
Tukey	O
HSD	O
test	O
)	O
.	O

(	O
488	O
KB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Figure	O
S5	O

E2f1	B-GGP
Deletion	B-SO
Rescues	O
alpha	O
-	O
Cre	O
;	O
RbloxP	O
/	O
loxP	O
Retinal	O
Function	O

ERGs	O
were	O
recorded	O
from	O
the	O
indicated	O
genotypes	B-SO
under	O
light	O
adapted	O
(	O
photopic	O
)	O
conditions	O
.	O

(	O
A	O
)	O
Intensity	O
series	O
.	O

(	O
B	O
)	O
The	O
b	O
-	O
wave	O
amplitudes	O
as	O
a	O
function	O
of	O
the	O
logarithm	O
of	O
the	O
flash	O
intensity	O
.	O

(	O
383	O
KB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Figure	O
S6	O

Differentiation	O
Defects	O
in	O
Rb	B-GGP
KO	O
SACs	O

Horizontal	O
retinal	O
sections	O
of	O
indicated	O
genotypes	B-SO
and	O
ages	O
were	O
stained	O
for	O
nuclei	B-GO
(	O
DAPI	O
,	O
blue	O
)	O
and	O
Calb2	B-GGP
(	O
[	O
A	O
]	O
,	O
red	O
;	O
only	O
densely	O
stained	O
cells	B-CL
were	O
counted	O
for	O
Figure	O
3C	O
)	O
,	O
Camk2a	B-GGP
(	O
[	O
B	O
]	O
,	O
green	O
)	O
,	O
and	O
Slc18a3	B-GGP
(	O
[	O
C	O
]	O
,	O
red	O
)	O
.	O

Scale	O
bars	O
are	O
50	O
mu	O
m	O
.	O

(	O
564	O
KB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Figure	O
S7	O

GABA	B-CHEBI
Neurotransmitter	I-CHEBI
in	O
the	O
Rb	B-GGP
KO	O
Retina	O
and	O
Abnormal	O
SACs	O
in	O
Chx10	B-GGP
-	O
Cre	O
;	O
RbloxP	O
/	O
loxP	B-SO
Retina	O

Horizontal	O
sections	O
of	O
the	O
indicated	O
genotypes	B-SO
and	O
ages	O
of	O
retina	O
were	O
stained	O
for	O
nuclei	B-GO
(	O
DAPI	O
,	O
blue	O
)	O
,	O
and	O
(	O
A	O
and	O
B	O
)	O
GABA	B-CHEBI
(	O
red	O
)	O
and	O
Slc18a3	B-GGP
(	O
green	O
)	O
or	O
(	O
C	O
)	O
Chat	B-GGP
and	O
Slc18a3	B-GGP
(	O
red	O
)	O
.	O

(	O
A	O
)	O
In	O
P18	O
WT	B-SO
retina	O
,	O
GABA	B-CHEBI
labelled	O
four	O
IPL	O
tracks	O
,	O
of	O
which	O
the	O
two	O
inner	O
tracks	O
co	O
-	O
stained	O
with	O
Slc18a3	B-GGP
.	O

The	O
latter	O
tracks	O
disappeared	O
in	O
the	O
Rb	B-GGP
KO	O
retina	O
,	O
and	O
were	O
rescued	O
by	O
E2f3	B-GGP
KO	O
but	O
not	O
E2f1	B-GGP
KO	O
.	O

(	O
B	O
)	O
At	O
the	O
boundary	O
of	O
the	O
WT	B-SO
(	O
central	O
)	O
and	O
Rb	B-GGP
KO	O
area	O
(	O
peripheral	O
retina	O
)	O
the	O
inner	O
GABA	B-CHEBI
+	O
SAC	O
tracks	O
can	O
be	O
seen	O
disappearing	O
towards	O
the	O
periphery	O
(	O
left	O
)	O
.	O

(	O
C	O
)	O
Slc18a3	B-GGP
staining	O
in	O
the	O
IPL	O
of	O
Chx10	B-GGP
-	O
Cre	O
;	O
RbloxP	O
/	O
loxP	B-SO
retina	O
is	O
consistent	O
with	O
the	O
mosaic	O
pattern	O
of	O
Rb	B-GGP
inactivation	O
.	O

Scale	O
bars	O
are	O
50	O
mu	O
m	O
.	O

(	O
633	O
KB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Figure	O
S8	O

Subcellular	O
Distribution	O
of	O
E2f3a	O
Isoform	B-SO
in	O
the	O
Developing	O
Retina	O

Nuclear	B-GO
and	O
cytoplasmic	B-GO
extracts	O
from	O
an	O
equivalent	O
number	O
of	O
retinal	O
cells	B-CL
from	O
mice	B-Taxon
of	O
the	O
indicated	O
genotypes	B-SO
and	O
ages	O
were	O
analyzed	O
by	O
Western	O
blotting	O
to	O
detect	O
the	O
E2f3a	O
protein	B-CHEBI
.	O

Lysates	O
from	O
E2f3a	O
-	O
/	O
-	O
mice	B-Taxon
of	O
matched	O
ages	O
were	O
used	O
as	O
a	O
control	O
to	O
confirm	O
the	O
location	O
of	O
E2f3a	O
protein	B-CHEBI
.	O

C	B-GO
,	O
cytoplasmic	B-GO
extracts	O
;	O
N	B-GO
,	O
nuclear	B-GO
extracts	O
.	O

(	O
115	O
KB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Table	O
S1	O

List	O
of	O
Antibodies	B-GO
and	O
Marker	O
Patterns	O
in	O
Rb	B-GGP
/	O
E2f1	B-GGP
DKO	O
SACs	O

(	O
97	O
KB	O
DOC	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Table	O
S2	O

Real	O
-	O
Time	O
RT	O
-	O
PCR	O
Primers	B-SO

(	O
49	O
KB	O
DOC	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Accession	O
Numbers	O

The	O
GenBank	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
genbank	O
)	O
accession	O
numbers	O
for	O
the	O
major	O
genes	B-SO
and	O
gene	B-SO
products	O
discussed	O
in	O
this	O
paper	O
are	O
Camk2a	B-GGP
(	O
NM	O
_	O
009792	O
)	O
,	O
Chat	B-GGP
(	O
NM	O
_	O
009891	O
)	O
,	O
E2f1	B-GGP
(	O
NM	O
_	O
007891	O
)	O
,	O
E2f2	B-GGP
(	O
NM	O
_	O
177733	O
)	O
,	O
E2f3	B-GGP
(	O
NM	O
_	O
010093	O
)	O
,	O
Rb	B-GGP
(	O
NM	O
_	O
009029	O
)	O
,	O
and	O
Slc18a3	B-GGP
(	O
NM	O
_	O
021712	O
)	O
.	O

Acknowledgements	O

We	O
thank	O
K	O
.	O

McClellan	O
and	O
R	O
.	O

Slack	O
for	O
sharing	O
unpublished	O
data	O
,	O
L	O
.	O

Galli	O
-	O
Resta	O
for	O
suggesting	O
Isl1	B-GGP
(	O
Islet1	B-GGP
)	O
as	O
an	O
early	O
SAC	O
marker	O
,	O
J	O
.	O

Eubanks	O
for	O
advice	O
on	O
immunostaining	O
,	O
A	O
.	O

Berns	O
,	O
C	O
.	O

Cepko	O
,	O
and	O
P	O
.	O

Gruss	O
for	O
mice	B-Taxon
,	O
and	O
T	O
.	O

Edlund	O
,	O
F	O
.	O

Haeseleer	O
,	O
R	O
.	O

Janz	O
,	O
S	O
.	O

Sugita	O
,	O
P	O
.	O

A	O
.	O

Hargrave	O
,	O
C	O
.	O

M	O
.	O

Craft	O
,	O
X	O
.	O

Zhu	O
,	O
R	O
.	O

McInnes	O
,	O
R	O
.	O

L	O
.	O

Chow	O
,	O
and	O
J	O
.	O

Saari	O
for	O
antibodies	B-GO
.	O

Abbreviations	O

ANOVA	O
-	O
analysis	O
of	O
variance	O

BrdU	O
-	O
bromodeoxyuridine	O

cd	O
-	O
candela	O

CNS	O
-	O
central	O
nervous	O
system	O

DAPI	O
-	O
4	O
,	O
6	O
-	O
diamidino	O
-	O
2	O
-	O
phenyindole	B-CHEBI

DKO	O
-	O
double	O
knockout	O

E	O
[	O
number	O
]	O
-	O
embryonic	O
day	O
[	O
number	O
]	O

E2f	O
-	O
E2f	O
transcription	O
factor	O

ERG	O
-	O
electroretinogram	O

HSD	O
-	O
honestly	O
significant	O
difference	O

GABA	B-CHEBI
-	O
gamma	B-CHEBI
-	I-CHEBI
aminobutyric	I-CHEBI
acid	I-CHEBI

GCL	O
-	O
ganglion	B-CL
cell	I-CL
layer	O

INL	O
-	O
inner	O
nuclear	O
layer	O

IPL	O
-	O
inner	O
plexiform	O
layer	O

KO	O
-	O
knockout	O

NBL	O
-	O
neuroblastic	O
layer	O

ONL	O
-	O
outer	O
nuclear	O
layer	O

OPL	O
-	O
outer	O
plexiform	O
layer	O

P	O
[	O
number	O
]	O
-	O
postnatal	O
day	O
[	O
number	O
]	O

PH3	O
-	O
phosphohistone	O
3	O

Rb	B-GGP
-	O
retinoblastoma	B-GGP
protein	I-GGP

RPC	O
-	O
retinal	O
progenitor	O
cell	B-CL

RTC	O
-	O
retinal	O
transition	O
cell	B-CL

RT	O
-	O
PCR	O
-	O
reverse	O
transcriptase	O
PCR	O

SAC	O
-	O
starburst	O
amacrine	B-CL
cell	I-CL

SD	O
-	O
standard	O
deviation	O

TUNEL	O
-	O
terminal	O
dUTP	B-CHEBI
nick	O
-	O
end	O
labelling	O

WT	B-SO
-	O
wild	B-SO
-	I-SO
type	I-SO

Footnotes	O

Author	O
contributions	O
.	O

DC	O
and	O
RB	O
conceived	O
and	O
designed	O
the	O
experiments	O
.	O

DC	O
performed	O
most	O
of	O
the	O
experiments	O
.	O

RO	O
,	O
PW	O
,	O
and	O
GL	O
provided	O
the	O
E2f3	B-GGP
floxed	B-SO
and	O
E2f3a	O
KO	O
mice	B-Taxon
.	O

DC	O
and	O
RB	O
analyzed	O
the	O
data	O
.	O

MP	O
,	O
NT	O
,	O
and	O
MWS	O
performed	O
the	O
ERG	O
analysis	O
.	O

DC	O
and	O
RB	O
wrote	O
the	O
paper	O
.	O

Funding	O
.	O

This	O
work	O
was	O
supported	O
by	O
grants	O
from	O
the	O
Canadian	O
Institute	O
for	O
Health	O
Research	O
and	O
Foundation	O
Fighting	O
Blindness	O
Canada	O
to	O
RB	O
,	O
and	O
by	O
the	O
German	O
Research	O
Council	O
(	O
DFG	O
Se837	O
/	O
4	O
-	O
1	O
and	O
5	O
-	O
1	O
)	O
and	O
the	O
European	O
Union	O
(	O
IP	O
"	O
EVI	O
-	O
GenoRet	O
"	O
LSHG	O
-	O
CT	O
-	O
512036	O
)	O
to	O
MWS	O
.	O

Competing	O
interests	O
.	O

The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

Caracterización	O
morfológica	O
de	O
la	O
AlphaA	B-Protein
-	I-Protein
y	I-Protein
AlphaB	I-Protein
-	I-Protein
cristalino	I-Protein
doble	O
nocaut	O
ratón	B-Taxon
lente	O

Resumen	O

Antecedentes	O

Un	O
enfoque	O
para	O
resolver	O
algunas	O
de	O
las	O
funciones	O
in	O
vivo	O
de	O
la	O
alfa-cristalina	O
es	O
generar	O
animal	B-Taxon
modelos	O
en	O
los	O
que	O
uno	O
o	O
ambos	O
alfa	O
-	O
cristalino	O
gene	B-Sequence
Los	O
productos	O
han	O
sido	O
eliminados	O
.	O

en	O
el	O
soltero	O
alfa	B-Protein
-	I-Protein
cristalino	I-Protein
knockear	O
ratones	B-Taxon
,	O
el	O
restante	O
alfa	B-Protein
-	I-Protein
cristalino	I-Protein
puede	O
compensar	O
total	O
o	O
parcialmente	O
algunas	O
de	O
las	O
funciones	O
de	O
la	O
falta	O
proteína	B-Chemical
,	O
especialmente	O
en	O
la	O
lente	O
,	O
donde	O
ambos	O
alfaA	B-Protein
y	O
alfab	B-Protein
se	O
expresan	O
normalmente	O
en	O
niveles	O
altos	O
.	O

El	O
propósito	O
de	O
este	O
estudio	O
fue	O
caracterizar	O
la	O
morfología	O
lenticular	O
macroscópica	O
en	O
ratones	B-Taxon
y	O
ratones	B-Taxon
con	O
la	O
interrupción	O
selectiva	O
de	O
alfaA	B-Protein
-	I-Protein
y	I-Protein
alfaB	I-Protein
-	I-Protein
cristalino	I-Protein
genes	B-Sequence
(	O
alfaA	B-Protein
/BKO	O
)	O
.	O

Métodos	O

Lentes	O
de	O
129SvEvTac	O
ratones	B-Taxon
y	O
alfaA	B-Protein
/	O
BKO	O
ratones	B-Taxon
fueron	O
examinados	O
por	O
escaneo	O
estándar	O
electrón	B-Chemical
Metodologías	O
de	O
microscopía	O
y	O
microscopía	O
confocal	O
.	O

Resultados	O

Dimensiones	O
ecuatoriales	O
y	O
axiales	O
(	O
sagitales	O
)	O
de	O
lentes	O
para	O
alfaA	B-Protein
/	O
BKO	O
ratones	B-Taxon
fueron	O
significativamente	O
más	O
pequeños	O
que	O
la	O
edad	O
-	O
emparejados	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O

Sin	O
suturas	O
posteriores	O
ni	O
fibra	O
células	B-Cell
extendiéndose	O
a	O
la	O
cápsula	O
posterior	O
del	O
cristalino	O
se	O
encontraron	O
en	O
alfaA	B-Protein
/Objetivos	O
BKO	O
.	O

ectópico	O
ácido	B-Chemical
nucleico	I-Chemical
se	O
observó	O
tinción	O
en	O
la	O
región	O
subcapsular	O
posterior	O
de	O
5	O
semanas	O
y	O
la	O
corteza	O
subcapsular	O
anterior	O
de	O
54	O
semanas	O
alfaA	B-Protein
/Objetivos	O
BKO	O
.	O

También	O
se	O
observaron	O
grandes	O
diferencias	O
morfológicas	O
en	O
las	O
regiones	O
ecuatorial	O
/	O
arco	O
,	O
posterior	O
y	O
anterior	O
de	O
los	O
lentes	O
de	O
alfaA	B-Protein
/	O
BKO	O
ratones	B-Taxon
en	O
comparación	O
con	O
salvaje	B-Sequence
ratones	B-Taxon
.	O

Conclusión	O

Estos	O
resultados	O
indicaron	O
que	O
ambos	O
alfaA	B-Protein
-	I-Protein
y	I-Protein
alfaB	I-Protein
-	I-Protein
cristalino	I-Protein
son	O
necesarios	O
para	O
la	O
fibra	O
adecuada	O
célula	B-Cell
formación	O
,	O
y	O
que	O
la	O
ausencia	O
de	O
alfa	B-Protein
-	I-Protein
cristalino	I-Protein
puede	O
conducir	O
a	O
la	O
formación	O
de	O
cataratas	O
.	O

Antecedentes	O

Alpha	O
-	O
Crystallin	O
se	O
compone	O
de	O
dos	O
polipéptidos	B-Sequence
,	O
alfaA	B-Protein
-	I-Protein
cristalino	I-Protein
(	O
alfaA	B-Protein
)	O
y	O
alfaB	B-Protein
-	I-Protein
cristalina	I-Protein
(	O
alfab	B-Protein
)	O
,	O
que	O
comparten	O
el	O
55	O
%	O
homología	B-Sequence
de	I-Sequence
secuencia	I-Sequence
de	I-Sequence
aminoácidos	I-Sequence
[	O
1	O
]	O
.	O

son	O
los	O
mas	O
abundantes	O
proteinas	B-Chemical
en	O
fibra	O
de	O
lente	O
células	B-Cell
[	O
2	O
,	O
3	O
]	O
y	O
existen	O
como	O
heteroagregados	O
de	O
aproximadamente	O
800	O
kDa	O
que	O
pueden	O
sufrir	O
un	O
intercambio	O
de	O
subunidades	O
entre	O
agregados	O
[	O
4	O
]	O
.	O

La	O
expresión	O
de	O
estos	O
dos	O
proteinas	B-Chemical
en	O
el	O
epitelio	O
del	O
cristalino	O
,	O
sin	O
embargo	O
,	O
no	O
es	O
uniforme	O
en	O
las	O
diferentes	O
regiones	O
del	O
epitelio	O
anterior	O
.	O

AlfaB	B-Protein
la	O
expresión	O
se	O
detecta	O
en	O
el	O
epitelio	O
central	O
y	O
aumenta	O
desde	O
el	O
centro	O
hasta	O
las	O
zonas	O
de	O
elongación	O
,	O
donde	O
células	B-Cell
epiteliales	I-Cell
diferenciarse	O
en	O
fibra	O
células	B-Cell
.	O

AlfaA	B-Protein
sin	O
embargo	O
,	O
no	O
se	O
detecta	O
en	O
el	O
epitelio	O
central	O
.	O

La	O
proporción	O
relativa	O
de	O
alfaA	B-Protein
y	O
alfab	B-Protein
cambia	O
de	O
una	O
relación	O
molar	O
de	O
1	O
:	O
3	O
en	O
las	O
zonas	O
pericentral	O
y	O
germinativa	O
a	O
una	O
relación	O
molar	O
de	O
3	O
:	O
1	O
en	O
la	O
zona	O
de	O
elongación	O
y	O
fibra	O
células	B-Cell
[	O
2	O
,	O
3	O
]	O
.	O

Estas	O
diferencias	O
en	O
las	O
proporciones	O
relativas	O
de	O
alfaA	B-Protein
y	O
alfab	B-Protein
dentro	O
de	O
la	O
lente	O
sugieren	O
diferentes	O
funciones	O
para	O
las	O
dos	O
subunidades	O
en	O
la	O
lente	O
en	O
desarrollo	O
.	O

Antes	O
de	O
la	O
década	O
de	O
1990	O
,	O
se	O
pensaba	O
que	O
la	O
alfa-cristalina	O
era	O
un	O
componente	O
estructural	O
proteína	B-Chemical
cuya	O
mayor	O
celular	B-Cell
La	O
función	O
era	O
producir	O
una	O
solución	O
densa	O
necesaria	O
para	O
la	O
refracción	O
de	O
la	O
luz	O
en	O
la	O
lente	O
.	O

A	O
principios	O
de	O
la	O
década	O
de	O
1990	O
,	O
se	O
demostró	O
que	O
la	O
alfa-cristalina	O
actuaba	O
como	O
un	O
molecular	B-Chemical
acompañante	O
,	O
unión	O
a	O
parcialmente	O
desnaturalizado	O
proteinas	B-Chemical
,	O
tanto	O
in	O
vitro	O
[	O
5	O
]	O
como	O
probablemente	O
in	O
vivo	O
[	O
6	O
]	O
,	O
para	O
inhibir	O
una	O
mayor	O
desnaturalización	O
y	O
agregación	O
del	O
cristalino	O
proteinas	B-Chemical
.	O

AlfaA	B-Protein
y	O
alfab	B-Protein
también	O
se	O
demostró	O
que	O
tenían	O
homología	B-Sequence
de	I-Sequence
secuencia	I-Sequence
con	O
varios	O
otros	O
proteinas	B-Chemical
que	O
son	O
miembros	O
de	O
la	O
pequeña	B-Protein
proteína	I-Protein
de	I-Protein
choque	I-Protein
térmico	I-Protein
(	O
hsp	O
)	O
familia	O
[	O
7	O
]	O
.	O

Además	O
,	O
la	O
expresión	O
de	O
alfa	O
-	O
cristalina	O
,	O
particularmente	O
alfab	B-Protein
,	O
se	O
demostró	O
que	O
no	O
se	O
restringe	O
a	O
la	O
lente	O
.	O

AlfaB	B-Protein
se	O
encontró	O
que	O
se	O
expresaba	O
en	O
niveles	O
significativos	O
en	O
una	O
variedad	O
de	O
tejidos	O
no	O
lenticulares	O
,	O
mientras	O
que	O
alfaA	B-Protein
sólo	O
se	O
ha	O
detectado	O
en	O
pequeñas	O
cantidades	O
en	O
algunos	O
otros	O
tejidos	O
,	O
como	O
la	O
retina	O
,	O
el	O
bazo	O
y	O
el	O
timo	O
[	O
8-12	O
]	O
.	O

Colectivamente	O
,	O
estos	O
hallazgos	O
han	O
desafiado	O
el	O
dogma	O
de	O
que	O
la	O
alfa-cristalina	O
es	O
puramente	O
un	O
componente	O
estructural	O
.	O
proteína	B-Chemical
necesarios	O
para	O
la	O
refracción	O
de	O
la	O
luz	O
,	O
y	O
han	O
llevado	O
a	O
la	O
conclusión	O
de	O
que	O
la	O
alfa-cristalina	O
puede	O
tener	O
una	O
variedad	O
de	O
funciones	O
biológicas	O
en	O
el	O
cristalino	O
.	O

Un	O
ámbito	O
mucho	O
más	O
amplio	O
de	O
celular	B-Cell
Las	O
funciones	O
de	O
la	O
alfa-cristalina	O
en	O
el	O
cristalino	O
se	O
deducen	O
de	O
las	O
observaciones	O
in	O
vitro	O
.	O

Ambas	O
cosas	O
alfaA	B-Protein
y	O
alfab	B-Protein
puede	O
unirse	O
específicamente	O
a	O
la	O
actina	O
,	O
in	O
vitro	O
[	O
13	O
]	O
e	O
in	O
vivo	O
[	O
14	O
]	O
.	O

Aunque	O
filamento	B-GENE
de	I-GENE
actina	I-GENE
Se	O
ha	O
demostrado	O
que	O
la	O
formación	O
es	O
necesaria	O
para	O
la	O
diferenciación	O
del	O
cristalino	O
.	O
células	B-Cell
epiteliales	I-Cell
[	O
15	O
]	O
,	O
se	O
desconoce	O
la	O
importancia	O
de	O
la	O
interacción	O
de	O
la	O
alfa-cristalina	O
con	O
la	O
actina	O
en	O
la	O
diferenciación	O
.	O

En	O
el	O
cristalino	O
,	O
la	O
alfa-cristalina	O
también	O
se	O
asocia	O
con	O
filamento	B-GENE
intermedio	I-GENE
tipo	I-GENE
III	I-GENE
proteinas	B-Chemical
y	O
el	O
filamento	O
de	O
cuentas	O
proteinas	B-Chemical
CP49	B-Protein
y	O
CP115	B-Protein
,	O
y	O
se	O
ha	O
demostrado	O
que	O
el	O
ensamblaje	O
correcto	O
de	O
los	O
filamentos	O
rebordeados	O
depende	O
de	O
la	O
presencia	O
de	O
alfa	O
-	O
cristalina	O
[	O
16	O
]	O
.	O

Filamento	O
con	O
cuentas	O
ARNm	B-Chemical
los	O
niveles	O
aumentan	O
considerablemente	O
en	O
la	O
diferenciación	O
del	O
epitelio	O
del	O
cristalino	O
y	O
se	O
han	O
sugerido	O
como	O
un	O
marcador	O
panespecífico	O
para	O
el	O
desarrollo	O
de	O
la	O
fibra	O
del	O
cristalino	O
[	O
17	O
]	O
.	O

También	O
se	O
ha	O
demostrado	O
que	O
la	O
alfa-cristalina	O
interactúa	O
directamente	O
con	O
ADN	B-Sequence
[	O
18	O
]	O
.	O

En	O
CHO	O
transfectado	O
células	B-Cell
,	O
alfab	B-Protein
también	O
se	O
ha	O
demostrado	O
que	O
se	O
localiza	O
ectópicamente	O
en	O
la	O
interfase	O
núcleos	B-GENE
,	O
sugiriendo	O
un	O
papel	O
para	O
este	O
proteína	B-Chemical
en	O
el	O
núcleo	B-GENE
[	O
19	O
]	O
.	O

A	O
nuclear	B-GENE
papel	O
para	O
alfab	B-Protein
en	O
la	O
lente	O
fue	O
apoyado	O
por	O
los	O
hallazgos	O
de	O
que	O
un	O
subconjunto	O
de	O
lentes	O
células	B-Cell
epiteliales	I-Cell
derivado	O
de	O
alfab	B-Protein
knockear	O
ratones	B-Taxon
mostró	O
hiperproliferación	O
y	O
genómico	B-Sequence
inestabilidad	O
[	O
20	O
]	O
.	O

Además	O
,	O
la	O
administración	O
de	O
alfa	O
-	O
cristalina	O
exógena	O
a	O
los	O
bovino	B-Taxon
lente	O
Célula	B-Cell
epitelial	I-Cell
cultivos	O
resultaron	O
en	O
la	O
formación	O
de	O
cuerpos	O
lentoides	O
,	O
consistente	O
con	O
un	O
papel	O
para	O
estos	O
proteinas	B-Chemical
en	O
la	O
diferenciación	O
de	O
lentes	O
[	O
21	O
]	O
.	O

Estos	O
hallazgos	O
indican	O
que	O
la	O
alfa-cristalina	O
puede	O
tener	O
una	O
multitud	O
de	O
funciones	O
in	O
vivo	O
.	O

Un	O
enfoque	O
para	O
resolver	O
algunas	O
de	O
las	O
funciones	O
in	O
vivo	O
de	O
la	O
alfa-cristalina	O
es	O
generar	O
animal	B-Taxon
modelos	O
en	O
los	O
que	O
uno	O
o	O
ambos	O
alfa	O
-	O
cristalino	O
gene	B-Sequence
Los	O
productos	O
han	O
sido	O
eliminados	O
.	O

Brady	O
et	O
al	O
.	O

22	O
]	O
demostrado	O
,	O
mediante	O
la	O
interrupción	O
selectiva	O
del	O
ratón	B-Protein
alfaA	I-Protein
gene	B-Sequence
,	O
que	O
este	O
proteína	B-Chemical
era	O
esencial	O
para	O
el	O
mantenimiento	O
de	O
la	O
transparencia	O
de	O
la	O
lente	O
,	O
posiblemente	O
manteniendo	O
la	O
solubilidad	O
de	O
alfab	B-Protein
,	O
o	O
asociado	O
proteinas	B-Chemical
,	O
en	O
la	O
lente	O
.	O

También	O
se	O
informó	O
que	O
estas	O
lentes	O
eran	O
más	O
pequeñas	O
en	O
dimensiones	O
ecuatoriales	O
y	O
axiales	O
ligeras	O
que	O
las	O
correspondientes	O
a	O
la	O
edad	O
.	O
tipo	B-Sequence
salvaje	I-Sequence
lente	O

No	O
fue	O
posible	O
utilizar	O
las	O
técnicas	O
empleadas	O
en	O
el	O
estudio	O
para	O
determinar	O
si	O
las	O
lentes	O
más	O
pequeñas	O
se	O
debieron	O
a	O
la	O
reducción	O
del	O
volumen	O
o	O
del	O
número	O
de	O
fibras	O
.	O
células	B-Cell
.	O

Interrupción	O
dirigida	O
de	O
la	O
ratón	B-Protein
alfab	I-Protein
gene	B-Sequence
resultó	O
en	O
lentes	O
de	O
tamaño	O
similar	O
a	O
los	O
envejecidos	O
-	O
emparejados	O
tipo	B-Sequence
salvaje	I-Sequence
lente	O

Además	O
,	O
no	O
se	O
observó	O
formación	O
de	O
cataratas	O
en	O
el	O
alfab	B-Protein
lentes	O
ciegos	O
.	O

Estas	O
animales	B-Taxon
tener	O
celula	B-Cell
muscular	I-Cell
anormalidades	O
,	O
anomalías	O
posturales	O
severas	O
,	O
degeneración	O
muscular	O
selectiva	O
y	O
esperanza	O
de	O
vida	O
más	O
corta	O
en	O
comparación	O
con	O
los	O
controles	O
normales	O
[	O
23	O
]	O
.	O

en	O
el	O
soltero	O
alfa	B-Protein
-	I-Protein
cristalino	I-Protein
knockear	O
ratones	B-Taxon
,	O
el	O
restante	O
alfa	B-Protein
-	I-Protein
cristalino	I-Protein
puede	O
compensar	O
total	O
o	O
parcialmente	O
algunas	O
de	O
las	O
funciones	O
de	O
la	O
falta	O
proteína	B-Chemical
,	O
especialmente	O
en	O
la	O
lente	O
,	O
donde	O
ambos	O
alfaA	B-Protein
y	O
alfab	B-Protein
se	O
expresan	O
normalmente	O
en	O
niveles	O
altos	O
.	O

Los	O
objetivos	O
del	O
informe	O
actual	O
fueron	O
caracterizar	O
la	O
morfología	O
macroscópica	O
de	O
jóvenes	O
(	O
5	O
semanas	O
)	O
y	O
viejos	O
(	O
54	O
semanas	O
)	O
ratón	B-Taxon
lentes	O
con	O
interrupción	O
dirigida	O
tanto	O
de	O
la	O
alfaA	B-Protein
y	O
alfab	B-Protein
genes	B-Sequence
,	O
en	O
comparación	O
con	O
la	O
edad	O
emparejada	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O
,	O
usando	O
escaneo	O
electrón	B-Chemical
microscopía	O
(	O
SEM	O
)	O
y	O
microscopía	O
confocal	O
,	O
para	O
dilucidar	O
las	O
posibles	O
funciones	O
de	O
alfa	B-Protein
-	I-Protein
cristalino	I-Protein
en	O
la	O
lente	O

Los	O
resultados	O
indican	O
que	O
alfa	B-Protein
-	I-Protein
cristalino	I-Protein
es	O
necesario	O
para	O
la	O
fibra	O
adecuada	O
célula	B-Cell
formación	O
y	O
transparencia	O
de	O
la	O
lente	O
resultante	O
.	O

Métodos	O

Lentes	O

los	O
tipo	B-Sequence
salvaje	I-Sequence
ratón	B-Taxon
cepa	O
utilizada	O
en	O
este	O
estudio	O
fue	O
la	O
129SvEvTac	O
ratón	B-Taxon
.	O

Los	O
lentes	O
examinados	O
tenían	O
5	O
(	O
8	O
lentes	O
)	O
,	O
46	O
(	O
8	O
lentes	O
)	O
y	O
72	O
(	O
6	O
lentes	O
)	O
semanas	O
de	O
edad	O
ratones	B-Taxon
.	O

AlfaA	B-Protein
/	O
BKO	O
se	O
generó	O
cruzando	O
alphaAKO	O
-	O
127	O
[	O
22	O
]	O
y	O
alphaBKO	O
-	O
168	O
ratones	B-Taxon
[	O
23	O
]	O
,	O
también	O
en	O
un	O
fondo	O
de	O
129Sv	O
.	O

Estas	O
ratones	B-Taxon
también	O
falta	O
el	O
HSPB2	B-Protein
gene	B-Sequence
producto	O
[	O
23	O
]	O
.	O

Los	O
lentes	O
examinados	O
tenían	O
5	O
semanas	O
(	O
6	O
lentes	O
)	O
y	O
54	O
semanas	O
(	O
16	O
lentes	O
)	O
de	O
edad	O
ratones	B-Taxon
.	O

Todos	O
animales	B-Taxon
fueron	O
tratados	O
de	O
acuerdo	O
con	O
la	O
Declaración	O
de	O
la	O
Asociación	O
para	O
la	O
Investigación	O
de	O
la	O
Visión	O
y	O
la	O
Oftalmología	O
para	O
el	O
uso	O
de	O
animales	B-Taxon
en	O
Investigación	O
Oftalmológica	O
y	O
de	O
la	O
Visión	O
.	O

Inmediatamente	O
después	O
de	O
la	O
eutanasia	O
animales	B-Taxon
,	O
los	O
ojos	O
fueron	O
enucleados	O
.	O

Luego	O
se	O
usó	O
una	O
hoja	O
de	O
bisturí	O
para	O
hacer	O
una	O
pequeña	O
incisión	O
en	O
la	O
cámara	O
anterior	O
cerca	O
del	O
ecuador	O
y	O
luego	O
en	O
ambos	O
ojos	O
de	O
forma	O
individual	O
.	O
animales	B-Taxon
se	O
sumergieron	O
en	O
5	O
ml	O
de	O
fijador	O
(	O
2	O
%	O
(	O
p	O
/	O
v	O
)	O
de	O
paraformaldehído	O
y	O
2	O
%	O
de	O
glutaraldehído	O
(	O
v	O
/	O
v	O
)	O
en	O
0	O
,	O
1	O
M	O
cacodilato	B-Chemical
de	I-Chemical
sodio	I-Chemical
tampón	O
,	O
pH	O
7	O
.	O
2	O
)	O
.	O

Los	O
ojos	O
se	O
fijaron	O
durante	O
al	O
menos	O
24	O
horas	O
a	O
temperatura	O
ambiente	O
(	O
RT	O
)	O
antes	O
de	O
la	O
disección	O
de	O
las	O
lentes	O
.	O

En	O
este	O
momento	O
,	O
se	O
registraron	O
las	O
dimensiones	O
ecuatoriales	O
y	O
axiales	O
de	O
las	O
lentes	O
y	O
la	O
apariencia	O
lenticular	O
macroscópica	O
.	O

Los	O
análisis	O
estadísticos	O
de	O
los	O
datos	O
consistieron	O
en	O
la	O
prueba	O
t	O
de	O
Student	O
,	O
medias	O
y	O
desviación	O
estándar	O
,	O
utilizando	O
el	O
paquete	O
de	O
software	O
estadístico	O
StatMost	O
(	O
Dataxiom	O
Software	O
Inc.	O
,	O
Los	O
Ángeles	O
,	O
CA	O
)	O
.	O

Microscopia	O
confocal	O

Las	O
lentes	O
se	O
seccionaron	O
con	O
vibratomo	O
en	O
secciones	O
de	O
100-200	O
µm	O
de	O
espesor	O
a	O
lo	O
largo	O
de	O
los	O
ejes	O
óptico	O
(	O
anterior	O
a	O
posterior	O
)	O
o	O
ecuatorial	O
.	O

Las	O
secciones	O
gruesas	O
se	O
fijaron	O
en	O
paraformaldehído	O
al	O
2	O
%	O
(	O
p	O
/	O
v	O
)	O
y	O
glutaraldehído	O
al	O
2	O
%	O
(	O
v	O
/	O
v	O
)	O
en	O
O	O
.	O
1M	O
cacodilato	B-Chemical
de	I-Chemical
sodio	I-Chemical
tampón	O
pH	O
7	O
.	O
2	O
a	O
temperatura	O
ambiente	O
durante	O
24	O
horas	O
,	O
luego	O
se	O
lavó	O
varias	O
veces	O
en	O
Tris	B-Chemical
amortiguado	I-Chemical
solución	O
salina	O
(	O
0,5	O
M	O
tris	B-Chemical
,	O
150	O
mm	O
NaCl	B-Chemical
,	O
pH	O
7	O
.	O
4	O
)	O
.	O

Visualizar	O
lípido	B-Chemical
membranas	B-GENE
,	O
las	O
secciones	O
se	O
tiñeron	O
con	O
1	O
,	O
1	O
'	O
-	O
dioctadecil	O
-	O
3	O
,	O
3	O
,	O
3	O
'	O
,	O
3	O
'	O
-	O
tetrametilindocarbocianina	O
perclorato	B-Chemical
(	O
'DiI	O
'	O
;	O
DiIC18	O
;	O
Molecular	B-Chemical
Sondas	O
)	O
como	O
se	O
ha	O
descrito	O
anteriormente	O
[	O
24	O
]	O
.	O

A	O
continuación	O
,	O
las	O
secciones	O
se	O
lavaron	O
varias	O
veces	O
con	O
Tris	B-Chemical
amortiguado	I-Chemical
salino	O
,	O
y	O
ácidos	B-Chemical
nucleicos	I-Chemical
se	O
tiñeron	O
incubando	O
secciones	O
en	O
TBS	O
que	O
contenía	O
SYTOX	O
Green	O
1	O
mu	O
M	O
(	O
Molecular	B-Chemical
Sondas	O
)	O
durante	O
10	O
min	O
a	O
temperatura	O
ambiente	O
seguido	O
de	O
varios	O
lavados	O
con	O
TBS	O
antes	O
de	O
la	O
imagen	O
confocal	O
.	O

Las	O
secciones	O
de	O
la	O
lente	O
se	O
observaron	O
en	O
un	O
microscopio	O
confocal	O
de	O
barrido	O
láser	O
Zeiss	O
modelo	O
LSM	O
410	O
equipado	O
con	O
un	O
microscopio	O
invertido	O
Axiovert	O
100	O
,	O
un	O
Argón	B-Chemical
-	O
Criptón	B-Chemical
488/568/647	O
láser	O
,	O
un	O
filtro	O
de	O
selección	O
de	O
línea	O
KP	O
,	O
un	O
divisor	O
de	O
haz	O
dicroico	O
FT	O
488/568	O
,	O
un	O
divisor	O
de	O
haz	O
dicroico	O
FT	O
560	O
,	O
un	O
filtro	O
de	O
emisión	O
LP	O
590	O
para	O
ver	O
DiI	O
,	O
un	O
filtro	O
de	O
emisión	O
BP	O
515-540	O
para	O
ver	O
SYTOX	O
verde	O
,	O
y	O
el	O
paquete	O
de	O
software	O
LSM	O
3	O
.	O
993	O
.	O

Exploración	O
electrón	B-Chemical
microscopía	O

Las	O
lentes	O
divididas	O
en	O
dos	O
a	O
lo	O
largo	O
de	O
los	O
ejes	O
ópticos	O
se	O
fijaron	O
por	O
inmersión	O
en	O
paraformaldehído	O
al	O
2	O
%	O
(	O
p	O
/	O
v	O
)	O
y	O
glutaraldehído	O
al	O
2	O
%	O
(	O
v	O
/	O
v	O
)	O
en	O
O	O
.	O
1M	O
cacodilato	B-Chemical
de	I-Chemical
sodio	I-Chemical
tampón	O
pH	O
7	O
.	O
2	O
a	O
temperatura	O
ambiente	O
durante	O
24	O
horas	O
.	O

A	O
continuación	O
,	O
las	O
muestras	O
se	O
lavaron	O
varias	O
veces	O
con	O
agua	O
destilada	O
.	O
agua	B-Chemical
y	O
postfijado	O
en	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
osmio	B-Chemical
acuoso	I-Chemical
tetróxido	O
a	O
temperatura	O
ambiente	O
durante	O
1	O
hora	O
.	O

Las	O
mitades	O
de	O
las	O
lentes	O
se	O
deshidrataron	O
en	O
forma	O
ascendente	O
etanol	B-Chemical
serie	O
del	O
50	O
-	O
100	O
%	O
.	O

Una	O
vez	O
que	O
las	O
mitades	O
de	O
la	O
lente	O
estaban	O
al	O
100	O
%	O
etanol	B-Chemical
,	O
fueron	O
secados	O
en	O
punto	O
crítico	O
en	O
dióxido	B-Chemical
de	I-Chemical
carbono	I-Chemical
en	O
un	O
Samdri-790B	O
(	O
Tousimis	O
Research	O
Corp.	O
,	O
Rockville	O
,	O
MD	O
)	O
.	O

Las	O
mitades	O
de	O
lentes	O
secadas	O
en	O
el	O
punto	O
crítico	O
se	O
aseguraron	O
en	O
aluminio	B-Chemical
talones	O
con	O
cinta	O
de	O
doble	O
cara	O
.	O

continuación	O
,	O
las	O
muestras	O
montadas	O
se	O
recubrieron	O
por	O
pulverización	O
con	O
oro	B-Chemical
y	O
visto	O
en	O
un	O
escáner	O
Hitachi	O
S	O
-	O
3500N	O
electrón	B-Chemical
microscopio	O
(	O
Tokio	O
,	O
Japón	O
)	O
a	O
1-5	O
kV	O
.	O

``	O
Este	O
microscopio	O
está	O
equipado	O
con	O
el	O
sistema	O
``	O
''	O
Dual-Bias	O
''	O
''	O
patentado	O
de	O
Hitachi	O
que	O
permite	O
corrientes	O
de	O
emisión	O
extremadamente	O
altas	O
a	O
voltajes	O
de	O
aceleración	O
de	O
5	O
kV	O
e	O
inferiores	O
.	O
''	O

Resultados	O

Se	O
registraron	O
las	O
dimensiones	O
ecuatoriales	O
y	O
axiales	O
(	O
sagital	O
)	O
de	O
las	O
lentes	O
y	O
la	O
apariencia	O
lenticular	O
macroscópica	O
(	O
Tabla	O
1	O
)	O
.	O

AlfaA	B-Protein
/	O
Los	O
lentes	O
BKO	O
a	O
las	O
5	O
semanas	O
de	O
edad	O
eran	O
significativamente	O
más	O
pequeños	O
(	O
p	O
<	O
0,05	O
)	O
,	O
tanto	O
ecuatorial	O
como	O
axialmente	O
,	O
que	O
los	O
de	O
5	O
semanas	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O
y	O
permanecen	O
más	O
pequeños	O
durante	O
toda	O
la	O
vida	O
.	O

Cincuenta	O
y	O
cuatro	O
semanas	O
de	O
edad	O
alfaA	B-Protein
/	O
Los	O
lentes	O
BKO	O
eran	O
mucho	O
más	O
pequeños	O
que	O
los	O
lentes	O
normales	O
de	O
edad	O
similar	O
y	O
tenían	O
un	O
tamaño	O
similar	O
al	O
de	O
5	O
semanas	O
de	O
antigüedad	O
.	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O

Tanto	O
los	O
de	O
5	O
semanas	O
de	O
edad	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O
y	O
las	O
54	O
semanas	O
de	O
edad	O
alfaA	B-Protein
/	O
Los	O
lentes	O
BKO	O
fueron	O
significativamente	O
más	O
pequeños	O
(	O
p	O
<	O
0.01	O
)	O
que	O
los	O
de	O
46	O
o	O
72	O
semanas	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O

AlfaA	B-Protein
/	O
Lentes	O
BKO	O
a	O
las	O
5	O
semanas	O
de	O
edad	O
expuestas	O
vacuolas	B-GENE
en	O
la	O
región	O
ecuatorial	O
(	O
Figura	O
1A	O
,	O
ver	O
flechas	O
)	O
y	O
un	O
área	O
de	O
ligera	O
dispersión	O
de	O
luz	O
en	O
las	O
regiones	O
subcapsulares	O
posteriores	O
(	O
Figura	O
1B	O
,	O
ver	O
puntas	O
de	O
flecha	O
)	O
.	O

A	O
las	O
54	O
semanas	O
de	O
edad	O
,	O
alfaA	B-Protein
Los	O
lentes	O
BKO	O
exhibieron	O
densas	O
cataratas	O
corticales	O
y	O
nucleares	O
(	O
Figura	O
1C	O
)	O
.	O

No	O
se	O
observaron	O
suturas	O
posteriores	O
en	O
ninguno	O
de	O
los	O
alfaA	B-Protein
/	O
Lentes	O
BKO	O
examinadas	O
.	O

Todos	O
tipo	B-Sequence
salvaje	I-Sequence
Los	O
lentes	O
eran	O
transparentes	O
al	O
retirarlos	O
del	O
ojo	O
(	O
Figura	O
1D	O
,	O
1E	O
y	O
1F	O
)	O
y	O
tenían	O
suturas	O
posteriores	O
bien	O
definidas	O
.	O

Figura	O
1	O

Micrografías	O
ópticas	O
de	O
lentes	O
disecados	O
de	O
ojos	O
fijos	O
de	O
alfaA	B-Protein
/	O
BKO	O
(	O
A-C	O
)	O
y	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
D	O
-	O
F	O
)	O
ratones	B-Taxon
.	O

Todas	O
las	O
micrografías	O
se	O
generaron	O
utilizando	O
un	O
4	O
x	O
/	O
0	O
.	O
10	O
en	O
un	O
Zeiss	O
LSM	O
410	O
usando	O
el	O
modo	O
de	O
luz	O
transmitida	O
.	O

Las	O
imágenes	O
en	O
(	O
A	O
y	O
B	O
)	O
se	O
ampliaron	O
en	O
comparación	O
con	O
las	O
imágenes	O
(	O
C-F	O
)	O
(	O
ver	O
barras	O
de	O
escala	O
)	O
.	O

Para	O
todas	O
las	O
micrografías	O
excepto	O
(	O
B	O
)	O
,	O
el	O
punto	O
focal	O
del	O
objetivo	O
se	O
fijó	O
en	O
el	O
plano	O
ecuatorial	O
de	O
la	O
lente	O
,	O
mientras	O
que	O
(	O
B	O
)	O
se	O
fijó	O
en	O
el	O
polo	O
posterior	O
de	O
la	O
lente	O
.	O

(	O
A	O
y	O
B	O
)	O
Micrografías	O
representativas	O
de	O
lentes	O
de	O
5	O
semanas	O
alfaA	B-Protein
/	O
BKO	O
ratones	B-Taxon
,	O
mostrando	O
cambios	O
en	O
las	O
regiones	O
ecuatorial	O
(	O
A	O
)	O
y	O
subcapsular	O
posterior	O
(	O
B	O
)	O
.	O

(	O
C	O
)	O
Micrografía	O
representativa	O
de	O
54	O
semanas	O
alfaA	B-Protein
/	O
BKO	O
ratón	B-Taxon
cristalino	O
que	O
muestra	O
una	O
catarata	O
densa	O
del	O
cristalino	O
entero	O
.	O

(	O
D	O
-	O
F	O
)	O
Lentes	O
transparentes	O
representativos	O
de	O
la	O
semana	O
5	O
(	O
D	O
)	O
,	O
semana	O
46	O
(	O
E	O
)	O
y	O
semana	O
72	O
(	O
F	O
)	O
tipo	B-Sequence
salvaje	I-Sequence
ratones	B-Taxon
.	O

Las	O
flechas	O
(	O
A	O
)	O
indican	O
vacuolas	B-GENE
en	O
la	O
región	O
ecuatorial	O
de	O
un	O
representante	O
5	O
semanas	O
alfaA	B-Protein
/Objetivo	O
BKO	O
.	O

Las	O
puntas	O
de	O
flecha	O
(	O
B	O
)	O
indican	O
un	O
área	O
de	O
dispersión	O
de	O
luz	O
menor	O
en	O
lo	O
profundo	O
de	O
la	O
cápsula	O
posterior	O
en	O
un	O
período	O
representativo	O
de	O
5	O
semanas	O
.	O
alfaA	B-Protein
/Objetivo	O
BKO	O
.	O

tabla	O
1	O

Dimensiones	O
y	O
aspecto	O
lenticular	O
bruto	O
de	O
las	O
lentes	O
.	O

El	O
examen	O
de	O
las	O
secciones	O
axiales	O
medias	O
teñidas	O
con	O
DiI	O
y	O
SYTOX	O
green	O
reveló	O
diferencias	O
únicas	O
en	O
la	O
morfología	O
macroscópica	O
y	O
ácido	B-Chemical
nucleico	I-Chemical
tinción	O
entre	O
alfaA	B-Protein
/	O
Lentes	O
BKO	O
y	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O
(	O
Figura	O
2	O
)	O
.	O

En	O
cinco	O
semanas	O
de	O
edad	O
alfaA	B-Protein
/	O
Lentes	O
BKO	O
,	O
tinte	O
verde	O
Sytox	O
núcleos	B-GENE
(	O
verde	O
)	O
en	O
las	O
regiones	O
del	O
epitelio	O
anterior	O
,	O
ecuatorial/arco	O
y	O
subcapsular	O
posterior	O
(	O
Figura	O
2A	O
)	O
.	O

Célula	B-Cell
núcleos	B-GENE
localizados	O
en	O
la	O
región	O
ecuatorial	O
/	O
proa	O
estaban	O
desorganizados	O
en	O
comparación	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
.	O

se	O
agrandaron	O
espacios	B-GENE
extracelulares	I-GENE
Entre	O
células	B-Cell
en	O
la	O
región	O
ecuatorial/del	O
arco	O
a	O
las	O
5	O
semanas	O
de	O
edad	O
alfaA	B-Protein
/Objetivos	O
BKO	O
.	O

Cincuenta	O
y	O
cuatro	O
semanas	O
de	O
edad	O
alfaA	B-Protein
/	O
Los	O
lentes	O
BKO	O
(	O
Figura	O
2B	O
)	O
no	O
se	O
mancharon	O
durante	O
ácido	B-Chemical
nucleico	I-Chemical
en	O
la	O
región	O
subcapsular	O
posterior	O
,	O
sin	O
embargo	O
,	O
toda	O
la	O
región	O
del	O
cristalino	O
subcapsular	O
anterior	O
se	O
tiñó	O
para	O
ácido	B-Chemical
nucleico	I-Chemical
(	O
Consulte	O
la	O
Figura	O
3I	O
para	O
obtener	O
una	O
imagen	O
de	O
alta	O
resolución/ampliación	O
de	O
esta	O
área	O
)	O
.	O

No	O
se	O
observó	O
una	O
región	O
ecuatorial/arco	O
definida	O
en	O
estos	O
lentes	O
más	O
antiguos	O
,	O
y	O
la	O
fibra	O
células	B-Cell
no	O
se	O
encontraron	O
extendiéndose	O
a	O
la	O
cápsula	O
posterior	O
del	O
cristalino	O
.	O

Desestructurado	O
celular	B-Cell
el	O
material	O
cubría	O
la	O
región	O
anterior	O
del	O
núcleo	O
embrionario/fetal	O
,	O
y	O
una	O
indentación	O
distintiva	O
de	O
la	O
masa	O
del	O
cristalino	O
en	O
la	O
región	O
ecuatorial	O
era	O
evidente	O
en	O
secciones	O
axiales	O
medias	O
así	O
como	O
en	O
lentes	O
completos	O
.	O

En	O
alfaA	B-Protein
/BKO	O
el	O
núcleo	O
embrionario/fetal	O
(	O
fibras	O
primarias	O
del	O
cristalino	O
)	O
había	O
migrado	O
posteriormente	O
y	O
parecía	O
estar	O
en	O
contacto	O
con	O
la	O
cápsula	O
posterior	O
.	O

En	O
5	O
semanas	O
,	O
46	O
semanas	O
o	O
72	O
semanas	O
de	O
edad	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O
(	O
Figura	O
2C	O
,	O
2D	O
y	O
2E	O
)	O
,	O
sin	O
embargo	O
,	O
no	O
había	O
subcapsular	O
posterior	O
o	O
anterior	O
ácido	B-Chemical
nucleico	I-Chemical
tinción	O
y	O
el	O
núcleo	O
embrionario-fetal	O
se	O
localizaba	O
centralmente	O
,	O
no	O
en	O
contacto	O
con	O
la	O
cápsula	O
posterior	O
.	O

Figura	O
2	O

Secciones	O
ópticas	O
confocales	O
representativas	O
tomadas	O
de	O
secciones	O
de	O
vibratomo	O
axial	O
medio	O
de	O
alfaA	B-Protein
/	O
BKO	O
(	O
A	O
y	O
B	O
)	O
y	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
C-E	O
)	O
lentes	O
.	O

Todas	O
las	O
secciones	O
ópticas	O
se	O
generaron	O
utilizando	O
un	O
4	O
x	O
/	O
0	O
.	O
10	O
objetivos	O
en	O
un	O
Zeiss	O
LSM	O
410	O
.	O

El	O
color	O
rojo	O
representa	O
la	O
tinción	O
DiI	O
(	O
membrana	B-GENE
)	O
,	O
mientras	O
que	O
el	O
color	O
verde	O
representa	O
la	O
tinción	O
verde	O
SYTOX	O
(	O
ADN	B-Sequence
)	O
.	O

(	O
A	O
y	O
B	O
)	O
se	O
tomaron	O
de	O
5	O
semanas	O
y	O
54	O
semanas	O
alfaA	B-Protein
/	O
Lentes	O
BKO	O
,	O
respectivamente	O
.	O

(	O
C	O
-	O
E	O
)	O
se	O
tomaron	O
de	O
5	O
semanas	O
,	O
46	O
semanas	O
y	O
72	O
semanas	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O
,	O
respectivamente	O
.	O

Las	O
puntas	O
de	O
flecha	O
indican	O
el	O
epitelio	O
anterior	O
representativo	O
núcleos	B-GENE
teñido	O
con	O
verde	O
SYTOX	O
.	O

figura	O
3	O

Secciones	O
ópticas	O
confocales	O
representativas	O
de	O
alfaA	B-Protein
/	O
BKO	O
(	O
A	O
-	O
J	O
)	O
y	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
K-T	O
)	O
lentes	O
.	O

Todas	O
las	O
secciones	O
ópticas	O
se	O
generaron	O
utilizando	O
un	O
63	O
x	O
/	O
1	O
.	O
4	O
objetivos	O
en	O
un	O
Zeiss	O
LSM	O
410	O
.	O

El	O
color	O
rojo	O
representa	O
la	O
tinción	O
DiI	O
(	O
membrana	B-GENE
)	O
,	O
mientras	O
que	O
el	O
color	O
verde	O
representa	O
la	O
tinción	O
verde	O
SYTOX	O
(	O
ADN	B-Sequence
)	O
.	O

(	O
A	O
-	O
E	O
)	O
son	O
de	O
5	O
semanas	O
alfaA	B-Protein
/Objetivos	O
BKO	O
.	O

(	O
F	O
-	O
J	O
)	O
son	O
de	O
54	O
semanas	O
alfaA	B-Protein
/Objetivos	O
BKO	O
.	O

(	O
K	O
-	O
O	O
)	O
son	O
de	O
5	O
semanas	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O

(	O
P	O
-	O
T	O
)	O
son	O
de	O
46	O
semanas	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O

(	O
A	O
,	O
F	O
,	O
K	O
y	O
P	O
)	O
son	O
la	O
corteza	O
central	O
anterior	O
y	O
el	O
epitelio	O
.	O

(	O
B	O
,	O
G	O
,	O
L	O
y	O
Q	O
)	O
son	O
la	O
región	O
del	O
arco	O
ecuatorial	O
.	O

(	O
C	O
,	O
H	O
,	O
M	O
y	O
R	O
)	O
son	O
núcleo	O
embrionario/fetal	O
.	O

(	O
D	O
,	O
I	O
,	O
N	O
y	O
S	O
)	O
son	O
la	O
corteza	O
anterior	O
profunda	O
.	O

(	O
E	O
,	O
J	O
,	O
O	O
y	O
T	O
)	O
son	O
la	O
región	O
subcapsular	O
posterior	O
.	O

(	O
*	O
)	O
indica	O
áreas	O
desprovistas	O
de	O
celular	B-Cell
material	O
(	O
B	O
y	O
G	O
)	O
.	O

La	O
flecha	O
indica	O
sutura	O
posterior	O
(	O
O	O
)	O
.	O

Las	O
puntas	O
de	O
flecha	O
indican	O
representante	O
núcleos	B-GENE
teñido	O
con	O
verde	O
SYTOX	O
(	O
A	O
,	O
B	O
,	O
E	O
,	O
F	O
,	O
G	O
,	O
I	O
,	O
K	O
,	O
L	O
,	O
P	O
y	O
Q	O
)	O
.	O

A	O
mayor	O
aumento	O
,	O
el	O
examen	O
de	O
las	O
secciones	O
teñidas	O
con	O
DiI	O
y	O
SYTOX	O
green	O
reveló	O
diferencias	O
ultraestructurales	O
entre	O
alfaA	B-Protein
/	O
Lentes	O
BKO	O
y	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O
(	O
Figura	O
3	O
)	O
.	O

Tinción	O
epitelial	O
anterior	O
en	O
5	O
semanas	O
de	O
edad	O
alfaA	B-Protein
/	O
BKO	O
(	O
Figura	O
3A	O
)	O
y	O
5	O
semanas	O
de	O
edad	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O
eran	O
similares	O
(	O
Figura	O
3K	O
)	O
con	O
respecto	O
a	O
nuclear	B-GENE
tinción	O
con	O
verde	O
SYTOX	O
.	O

Sin	O
embargo	O
,	O
algunas	O
diferencias	O
en	O
54	O
semanas	O
de	O
edad	O
alfaA	B-Protein
/	O
Se	O
observaron	O
lentes	O
BKO	O
(	O
Figura	O
3F	O
)	O
en	O
el	O
epitelio	O
anterior	O
central	O
en	O
comparación	O
con	O
5	O
semanas	O
(	O
Figura	O
3K	O
)	O
,	O
46	O
semanas	O
(	O
Figura	O
3P	O
)	O
y	O
72	O
semanas	O
(	O
datos	O
no	O
mostrados	O
)	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O

Estas	O
diferencias	O
incluyeron	O
cambios	O
en	O
el	O
epitelio	O
central	O
nuclear	B-GENE
tinción	O
,	O
nuclear	B-GENE
forma	O
y	O
grosor	O
epitelial	O
y	O
continuidad	O
.	O

La	O
tinción	O
cortical	O
anterior	O
superficial	O
y	O
profunda	O
fue	O
muy	O
diferente	O
entre	O
alfaA	B-Protein
/BKO	O
(	O
Figura	O
3A	O
,	O
3D	O
,	O
3F	O
y	O
3I	O
)	O
y	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O
(	O
Figura	O
3K	O
,	O
3N	O
,	O
3P	O
y	O
3S	O
)	O
.	O

En	O
5	O
y	O
54	O
semanas	O
de	O
edad	O
alfaA	B-Protein
/	O
Lentes	O
BKO	O
,	O
regiones	O
corticales	O
anteriores	O
superficiales	O
y	O
profundas	O
,	O
teñidas	O
para	O
lípido	B-Chemical
membranas	B-GENE
,	O
no	O
reveló	O
ningún	O
patrón	O
típico	O
de	O
fibra	O
células	B-Cell
corte	O
en	O
sección	O
transversal	O
o	O
sección	O
longitudinal	O
.	O

en	O
5	O
semanas	O
alfaA	B-Protein
/	O
Lentes	O
BKO	O
hubo	O
una	O
alta	O
densidad	O
de	O
manchado	O
membranas	B-GENE
por	O
unidad	O
de	O
área	O
en	O
toda	O
la	O
corteza	O
,	O
sin	O
ácido	B-Chemical
nucleico	I-Chemical
tinción	O
en	O
estas	O
regiones	O
.	O

en	O
54	O
semanas	O
alfaA	B-Protein
Lentes	O
BKO	O
,	O
grandes	O
,	O
de	O
forma	O
irregular	O
células	B-Cell
fueron	O
observados	O
,	O
intercalados	O
entre	O
regiones	O
de	O
alta	O
membrana	B-GENE
densidad	O
de	O
tinción	O
por	O
unidad	O
de	O
área	O
.	O

Estos	O
grandes	O
objetos	O
no	O
eran	O
vacuolas	B-GENE
,	O
porque	O
el	O
examen	O
del	O
interior	O
de	O
estas	O
estructuras	O
por	O
microscopía	O
de	O
luz	O
transmitida	O
y	O
reflejada	O
mostró	O
que	O
el	O
membranas	B-GENE
abarcado	O
celular	B-Cell
material	O
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Además	O
,	O
ácido	B-Chemical
nucleico	I-Chemical
se	O
observó	O
tinción	O
(	O
Figura	O
3F	O
y	O
3I	O
)	O
dentro	O
de	O
muchos	O
de	O
estos	O
células	B-Cell
exhibiendo	O
grandes	O
perfiles	O
transversales	O
.	O

En	O
el	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O
,	O
patrones	O
típicos	O
de	O
sección	O
transversal	O
de	O
fibra	O
células	B-Cell
se	O
observaron	O
organizados	O
en	O
columnas	O
radiales	O
(	O
Figura	O
3K	O
,	O
3N	O
,	O
3P	O
y	O
3S	O
)	O
.	O

También	O
se	O
observaron	O
diferencias	O
ultraestructurales	O
en	O
la	O
región	O
ecuatorial/del	O
arco	O
entre	O
alfaA	B-Protein
/	O
Lentes	O
BKO	O
(	O
Figura	O
3B	O
y	O
3G	O
)	O
y	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O
(	O
Figura	O
3L	O
y	O
3Q	O
)	O
.	O

En	O
contraste	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O
(	O
Figura	O
3L	O
y	O
3Q	O
)	O
,	O
el	O
alfaA	B-Protein
/	O
Las	O
lentes	O
BKO	O
(	O
Figura	O
3B	O
y	O
3G	O
)	O
contenían	O
grandes	O
áreas	O
desprovistas	O
de	O
celular	B-Cell
material	O
,	O
su	O
núcleos	B-GENE
no	O
se	O
limitaban	O
a	O
una	O
región	O
ecuatorial/arco	O
bien	O
definida	O
,	O
y	O
ordenadas	O
columnas	O
radiales	O
de	O
fibra	O
alargada	O
células	B-Cell
no	O
se	O
observaron	O
extendiéndose	O
desde	O
la	O
cápsula	O
posterior	O
al	O
epitelio	O
anterior	O
.	O

Además	O
de	O
la	O
región	O
ecuatorial	O
,	O
las	O
diferencias	O
ultraestructurales	O
entre	O
alfaA	B-Protein
/	O
Lentes	O
BKO	O
(	O
Figura	O
3C	O
y	O
3H	O
)	O
y	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O
(	O
Figura	O
3M	O
y	O
3R	O
)	O
se	O
observaron	O
en	O
fibra	O
células	B-Cell
del	O
núcleo	O
embrionario	O
y	O
fetal	O
.	O

en	O
5	O
semanas	O
alfaA	B-Protein
/	O
lentes	O
BKO	O
(	O
Figura	O
3C	O
)	O
,	O
se	O
observó	O
una	O
mayor	O
variación	O
en	O
el	O
diámetro	O
de	O
la	O
sección	O
transversal	O
,	O
con	O
célula	B-Cell
diámetros	O
que	O
van	O
desde	O
menos	O
de	O
2	O
micras	O
hasta	O
aproximadamente	O
25	O
micras	O
,	O
en	O
comparación	O
con	O
las	O
5	O
y	O
46	O
semanas	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O
,	O
cuyos	O
diámetros	O
iban	O
desde	O
menos	O
de	O
2	O
micras	O
hasta	O
aproximadamente	O
10	O
micras	O
(	O
Figura	O
3M	O
y	O
3R	O
)	O
.	O

A	O
las	O
54	O
semanas	O
,	O
estos	O
células	B-Cell
en	O
el	O
alfaA	B-Protein
/	O
Las	O
lentes	O
BKO	O
eran	O
más	O
grandes	O
en	O
diámetro	O
de	O
sección	O
transversal	O
que	O
tipo	B-Sequence
salvaje	I-Sequence
,	O
y	O
exhibió	O
una	O
variación	O
mucho	O
mayor	O
en	O
el	O
tamaño	O
de	O
la	O
sección	O
transversal	O
y	O
célula	B-Cell
forma	O
.	O

Células	B-Cell
adyacente	O
a	O
la	O
cápsula	O
posterior	O
de	O
5	O
semanas	O
alfaA	B-Protein
Lentes	O
BKO	O
(	O
Figura	O
3E	O
)	O
expuestas	O
ácido	B-Chemical
nucleico	I-Chemical
tinción	O
,	O
eran	O
pequeños	O
y	O
no	O
alargados	O
,	O
con	O
numerosos	O
proyecciones	B-GENE
de	I-GENE
membrana	I-GENE
.	O
Sin	O
embargo	O
,	O
estos	O
no	O
se	O
observaron	O
en	O
54	O
semanas	O
alfaA	B-Protein
/Objetivos	O
BKO	O
.	O

en	O
5	O
semanas	O
alfaA	B-Protein
/	O
Lentes	O
BKO	O
,	O
profundas	O
a	O
la	O
cápsula	O
posterior	O
,	O
mayor	O
diámetro	O
células	B-Cell
,	O
similares	O
a	O
los	O
observados	O
en	O
el	O
núcleo	O
embrionario/fetal	O
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Fibra	O
células	B-Cell
de	O
dimensiones	O
y	O
apariencia	O
similares	O
a	O
las	O
fibras	O
nucleares	O
embrionarias/fetales	O
se	O
observaron	O
en	O
la	O
cápsula	O
posterior	O
en	O
54	O
semanas	O
alfaA	B-Protein
/	O
Lentes	O
BKO	O
(	O
Figura	O
3J	O
)	O
.	O

Tanto	O
en	O
5	O
como	O
en	O
54	O
semanas	O
alfaA	B-Protein
/	O
Lentes	O
BKO	O
,	O
no	O
se	O
pudieron	O
encontrar	O
suturas	O
posteriores	O
en	O
ninguna	O
de	O
las	O
secciones	O
de	O
vibratomo	O
ecuatoriales	O
o	O
axiales	O
examinadas	O
.	O

Las	O
suturas	O
posteriores	O
se	O
encontraron	O
fácilmente	O
en	O
las	O
secciones	O
de	O
vibratome	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O
(	O
Figura	O
3O	O
,	O
flecha	O
)	O
.	O

Fibra	O
células	B-Cell
adherido	O
a	O
la	O
cápsula	O
posterior	O
y	O
extendiéndose	O
anteriormente	O
se	O
observaron	O
en	O
5	O
semanas	O
(	O
Figura	O
3O	O
)	O
,	O
46	O
semanas	O
(	O
Figura	O
3T	O
)	O
y	O
72	O
semanas	O
(	O
datos	O
no	O
mostrados	O
)	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O

SEM	O
confirmó	O
muchas	O
de	O
las	O
observaciones	O
realizadas	O
por	O
microscopía	O
confocal	O
.	O

En	O
la	O
región	O
ecuatorial	O
/	O
arco	O
,	O
una	O
serie	O
desorganizada	O
de	O
relativamente	O
pequeños	O
de	O
forma	O
irregular	O
células	B-Cell
se	O
observaron	O
en	O
5	O
semanas	O
(	O
Figura	O
4A	O
)	O
y	O
54	O
semanas	O
(	O
Figura	O
4D	O
)	O
alfaA	B-Protein
/	O
Lentes	O
BKO	O
,	O
mientras	O
que	O
fibra	O
alargada	O
células	B-Cell
organizados	O
en	O
columnas	O
radiales	O
,	O
con	O
interdigitaciones	O
de	O
bola	O
y	O
cavidad	O
,	O
se	O
observaron	O
en	O
5	O
semanas	O
(	O
Figura	O
4G	O
)	O
,	O
46	O
semanas	O
(	O
Figura	O
4J	O
)	O
y	O
72	O
semanas	O
(	O
datos	O
no	O
mostrados	O
)	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O

En	O
la	O
región	O
cortical	O
anterior	O
de	O
5	O
semanas	O
alfaA	B-Protein
/	O
Lentes	O
BKO	O
,	O
columnas	O
radiales	O
de	O
células	B-Cell
con	O
numerosos	O
proyecciones	B-GENE
de	I-GENE
la	I-GENE
superficie	I-GENE
celular	I-GENE
(	O
Figura	O
4B	O
)	O
,	O
pero	O
estas	O
columnas	O
radiales	O
ya	O
no	O
estaban	O
presentes	O
a	O
las	O
54	O
semanas	O
de	O
edad	O
(	O
Figura	O
4E	O
)	O
.	O

En	O
estas	O
lentes	O
más	O
antiguas	O
,	O
de	O
forma	O
irregular	O
,	O
enrevesadas	O
células	B-Cell
,	O
sin	O
un	O
patrón	O
de	O
organización	O
reconocible	O
,	O
estaban	O
presentes	O
.	O

En	O
contraste	O
,	O
columnas	O
radiales	O
de	O
fibra	O
alargada	O
células	B-Cell
de	O
tamaño	O
y	O
forma	O
uniforme	O
,	O
con	O
interdigitación	O
de	O
bola	O
y	O
cavidad	O
,	O
estuvieron	O
presentes	O
en	O
la	O
región	O
cortical	O
anterior	O
de	O
5	O
semanas	O
(	O
Figura	O
4H	O
)	O
,	O
46	O
semanas	O
(	O
Figura	O
4K	O
)	O
y	O
72	O
semanas	O
(	O
datos	O
no	O
mostrados	O
)	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O

Las	O
regiones	O
subcapsulares	O
posteriores	O
de	O
5	O
semanas	O
(	O
Figura	O
4C	O
)	O
y	O
54	O
semanas	O
(	O
Figura	O
4F	O
)	O
alfaA	B-Protein
/	O
Los	O
lentes	O
BKO	O
se	O
llenaron	O
con	O
formas	O
irregulares	O
células	B-Cell
con	O
numerosos	O
proyecciones	B-GENE
de	I-GENE
la	I-GENE
superficie	I-GENE
celular	I-GENE
.	O

En	O
el	O
núcleo	O
fetal/embrionario	O
,	O
fibra	O
alargada	O
células	B-Cell
con	O
numerosas	O
proyecciones	O
largas	O
en	O
forma	O
de	O
dedos	O
y	O
con	O
surcos	O
membranas	B-GENE
eran	O
evidentes	O
(	O
no	O
se	O
muestran	O
)	O
.	O

sin	O
alargar	O
células	B-Cell
que	O
se	O
extiende	O
desde	O
la	O
región	O
del	O
arco	O
hasta	O
la	O
cápsula	O
posterior	O
de	O
alfaA	B-Protein
/	O
Se	O
observaron	O
lentes	O
BKO	O
.	O

En	O
contraste	O
,	O
columnas	O
radiales	O
de	O
fibra	O
alargada	O
células	B-Cell
de	O
tamaño	O
y	O
forma	O
uniformes	O
que	O
contenían	O
interdigitaciones	O
de	O
bola	O
y	O
cavidad	O
se	O
observaron	O
en	O
la	O
región	O
subcapsular	O
posterior	O
en	O
5	O
semanas	O
(	O
Figura	O
4I	O
)	O
,	O
46	O
semanas	O
(	O
Figura	O
4L	O
)	O
y	O
72	O
semanas	O
(	O
datos	O
no	O
mostrados	O
)	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O
y	O
fibra	O
células	B-Cell
en	O
contacto	O
con	O
la	O
cápsula	O
posterior	O
podría	O
rastrearse	O
hasta	O
la	O
región	O
del	O
arco	O
ecuatorial	O
y	O
el	O
epitelio	O
anterior	O
.	O

Figura	O
4	O

Escaneo	O
representativo	O
electrón	B-Chemical
micrografías	O
de	O
alfaA	B-Protein
/	O
BKO	O
(	O
A	O
-	O
F	O
)	O
y	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
G-L	O
)	O
lentes	O
.	O

(	O
A	O
-	O
C	O
)	O
Imágenes	O
representativas	O
de	O
la	O
semana	O
5	O
alfaA	B-Protein
/Objetivos	O
BKO	O
.	O

(	O
D	O
-	O
F	O
)	O
Imágenes	O
representativas	O
de	O
la	O
semana	O
54	O
alfaA	B-Protein
/Objetivos	O
BKO	O
.	O

(	O
G	O
-	O
I	O
)	O
Imágenes	O
representativas	O
de	O
la	O
semana	O
5	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O

J	O
-	O
L	O
)	O
Imágenes	O
representativas	O
de	O
la	O
semana	O
46	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O

(	O
A	O
,	O
D	O
,	O
G	O
y	O
J	O
)	O
Región	O
ecuatorial/arco	O
.	O

(	O
B	O
,	O
E	O
,	O
H	O
y	O
K	O
)	O
Corteza	O
anterior	O
.	O

C	O
,	O
(	O
F	O
,	O
I	O
y	O
L	O
)	O
Región	O
subcapsular	O
posterior	O
.	O

Discusión	O

Un	O
enfoque	O
para	O
resolver	O
algunas	O
de	O
las	O
funciones	O
in	O
vivo	O
de	O
la	O
alfa-cristalina	O
es	O
generar	O
animal	B-Taxon
modelos	O
en	O
los	O
que	O
uno	O
o	O
ambos	O
alfa	O
-	O
cristalino	O
gene	B-Sequence
Los	O
productos	O
han	O
sido	O
eliminados	O
.	O

Brady	O
et	O
al	O
.	O

22	O
]	O
demostrado	O
,	O
mediante	O
la	O
interrupción	O
selectiva	O
del	O
ratón	B-Protein
alfaA	I-Protein
gene	B-Sequence
,	O
que	O
este	O
proteína	B-Chemical
era	O
esencial	O
para	O
el	O
mantenimiento	O
de	O
la	O
transparencia	O
de	O
la	O
lente	O
,	O
posiblemente	O
manteniendo	O
la	O
solubilidad	O
de	O
alfab	B-Protein
,	O
o	O
asociado	O
proteinas	B-Chemical
,	O
en	O
la	O
lente	O
.	O

También	O
se	O
informó	O
que	O
estos	O
lentes	O
eran	O
más	O
pequeños	O
en	O
dimensiones	O
ecuatoriales	O
y	O
axiales	O
que	O
los	O
de	O
la	O
misma	O
edad	O
.	O
tipo	B-Sequence
salvaje	I-Sequence
lente	O
,	O
que	O
fue	O
muy	O
similar	O
a	O
la	O
que	O
se	O
observó	O
con	O
la	O
lente	O
doble	O
knockout	O
.	O

Interrupción	O
dirigida	O
de	O
la	O
ratón	B-Protein
alfab	I-Protein
gene	B-Sequence
,	O
sin	O
embargo	O
,	O
resultó	O
en	O
lentes	O
de	O
tamaño	O
similar	O
a	O
los	O
de	O
edad	O
tipo	B-Sequence
salvaje	I-Sequence
cristalino	O
sin	O
cataratas	O
reportadas	O
[	O
23	O
]	O
.	O

Esto	O
indica	O
que	O
alfaA	B-Protein
puede	O
desempeñar	O
un	O
papel	O
más	O
importante	O
en	O
el	O
mantenimiento	O
de	O
la	O
transparencia	O
de	O
la	O
lente	O
que	O
alfab	B-Protein
.	O

en	O
el	O
soltero	O
alfa	B-Protein
-	I-Protein
cristalino	I-Protein
knockear	O
ratones	B-Taxon
,	O
el	O
restante	O
alfa	B-Protein
-	I-Protein
cristalino	I-Protein
puede	O
compensar	O
total	O
o	O
parcialmente	O
algunas	O
de	O
las	O
funciones	O
de	O
la	O
falta	O
proteína	B-Chemical
,	O
especialmente	O
en	O
la	O
lente	O
,	O
donde	O
ambos	O
alfaA	B-Protein
y	O
alfab	B-Protein
se	O
expresan	O
normalmente	O
en	O
niveles	O
altos	O
.	O

Esto	O
fue	O
respaldado	O
por	O
la	O
observación	O
morfológica	O
realizada	O
en	O
este	O
estudio	O
de	O
ausencia	O
de	O
suturas	O
posteriores	O
o	O
fibra	O
células	B-Cell
extendiéndose	O
a	O
la	O
cápsula	O
posterior	O
del	O
cristalino	O
,	O
tinción	O
ectópica	O
ácidos	B-Chemical
nucleicos	I-Chemical
en	O
la	O
región	O
subcapsular	O
posterior	O
de	O
5	O
semanas	O
y	O
la	O
corteza	O
subcapsular	O
anterior	O
de	O
54	O
semanas	O
,	O
grandes	O
diferencias	O
morfológicas	O
en	O
las	O
regiones	O
ecuatorial	O
/	O
arco	O
,	O
posterior	O
y	O
anterior	O
de	O
lentes	O
de	O
alfaA	B-Protein
/	O
BKO	O
ratones	B-Taxon
en	O
comparación	O
con	O
salvaje	B-Sequence
ratones	B-Taxon
.	O

Ninguna	O
de	O
estas	O
diferencias	O
morfológicas	O
ha	O
sido	O
reportada	O
en	O
un	O
único	O
alfaA	B-Protein
o	O
alfab	B-Protein
knockear	O
ratones	B-Taxon
.	O

Debe	O
notarse	O
,	O
sin	O
embargo	O
,	O
que	O
el	O
alfaA	B-Protein
/	O
BKO	O
ratones	B-Taxon
también	O
falta	O
el	O
HSPB2	B-Protein
gene	B-Sequence
producto	O
[	O
23	O
]	O
y	O
la	O
contribución	O
de	O
este	O
proteína	B-Chemical
No	O
debe	O
pasarse	O
por	O
alto	O
la	O
morfología	O
y	O
las	O
funciones	O
normales	O
del	O
cristalino	O
.	O

Los	O
estudios	O
futuros	O
deben	O
abordar	O
las	O
posibles	O
funciones	O
de	O
HSPB2	B-Protein
en	O
lentes	O
normales	O
.	O

Los	O
resultados	O
del	O
presente	O
estudio	O
apoyan	O
la	O
hipótesis	O
de	O
que	O
alfa	B-Protein
-	I-Protein
cristalino	I-Protein
juega	O
un	O
papel	O
activo	O
en	O
la	O
diferenciación	O
y	O
el	O
crecimiento	O
de	O
la	O
fibra	O
del	O
cristalino	O
células	B-Cell
.	O

Diferenciación	O
normal	O
de	O
la	O
fibra	O
del	O
cristalino	O
.	O
células	B-Cell
consiste	O
en	O
una	O
progresión	O
de	O
un	O
cuboide	O
simple	O
Célula	B-Cell
epitelial	I-Cell
,	O
que	O
contiene	O
un	O
núcleo	B-GENE
y	O
un	O
número	O
mínimo	O
de	O
orgánulos	B-GENE
,	O
a	O
una	O
capa	O
estratificada	O
de	O
fibra	O
alargada	O
-	O
como	O
células	B-Cell
,	O
desprovisto	O
de	O
núcleos	B-GENE
y	O
orgánulos	B-GENE
.	O

Diferenciación	O
de	O
células	B-Cell
epiteliales	I-Cell
se	O
produce	O
en	O
la	O
región	O
ecuatorial/arco	O
del	O
cristalino	O
,	O
donde	O
células	B-Cell
epiteliales	I-Cell
comienzan	O
a	O
alargarse	O
y	O
diferenciarse	O
en	O
fibra	O
células	B-Cell
de	O
uniforme	O
celular	B-Cell
forma	O
,	O
dispuestas	O
en	O
columnas	O
radiales	O
de	O
células	B-Cell
Se	O
extiende	O
desde	O
el	O
epitelio	O
anterior	O
hasta	O
la	O
cápsula	O
posterior	O
.	O

Este	O
proceso	O
no	O
parece	O
haber	O
procedido	O
normalmente	O
en	O
lentes	O
que	O
carecen	O
alfaA	B-Protein
y	O
alfab	B-Protein
.	O

Las	O
observaciones	O
morfológicas	O
presentadas	O
en	O
este	O
estudio	O
demuestran	O
que	O
la	O
fibra	O
células	B-Cell
en	O
lentes	O
que	O
faltan	O
alfaA	B-Protein
y	O
alfab	B-Protein
``	O
no	O
se	O
alargan	O
simétricamente	O
desde	O
la	O
región	O
del	O
arco	O
y	O
,	O
por	O
lo	O
tanto	O
,	O
no	O
establecen	O
la	O
conformación	O
típica	O
de	O
``	O
''	O
piel	O
de	O
cebolla	O
''	O
''	O
en	O
la	O
que	O
''	O
células	B-Cell
Se	O
extienden	O
desde	O
el	O
epitelio	O
anterior	O
hasta	O
la	O
cápsula	O
posterior	O
.	O

Adicionalmente	O
,	O
en	O
lentes	O
a	O
partir	O
de	O
las	O
54	O
semanas	O
alfaA	B-Protein
/	O
Lentes	O
BKO	O
,	O
hubo	O
una	O
persistencia	O
de	O
célula	B-Cell
núcleos	B-GENE
en	O
regiones	O
corticales	O
más	O
profundas	O
y	O
ectópicas	O
célula	B-Cell
núcleos	B-GENE
estaban	O
presentes	O
en	O
gran	O
número	O
en	O
la	O
corteza	O
central	O
anterior	O
.	O

A	O
las	O
5	O
semanas	O
de	O
edad	O
célula	B-Cell
núcleos	B-GENE
estaban	O
presentes	O
,	O
adyacentes	O
a	O
la	O
cápsula	O
posterior	O
.	O

Estas	O
observaciones	O
morfológicas	O
son	O
consistentes	O
con	O
un	O
defecto	O
en	O
la	O
vía	O
de	O
diferenciación	O
normal	O
del	O
cristalino	O
.	O
células	B-Cell
epiteliales	I-Cell
en	O
fibra	O
células	B-Cell
.	O

Es	O
poco	O
probable	O
que	O
estas	O
alteraciones	O
en	O
alfaA	B-Protein
/	O
BKO	O
ratón	B-Taxon
Los	O
lentes	O
resultan	O
de	O
una	O
mayor	O
susceptibilidad	O
de	O
estos	O
lentes	O
al	O
daño	O
inducido	O
por	O
la	O
luz	O
en	O
ausencia	O
del	O
molecular	B-Chemical
protección	O
de	O
chaperona	O
proporcionada	O
por	O
alfaA	B-Protein
y	O
alfab	B-Protein
en	O
lentes	O
normales	O
.	O

Con	O
el	O
tiempo	O
normal	O
de	O
apertura	O
de	O
los	O
ojos	O
aproximadamente	O
a	O
los	O
14	O
días	O
después	O
del	O
nacimiento	O
,	O
el	O
bebé	O
de	O
5	O
semanas	O
ratones	B-Taxon
tenían	O
los	O
ojos	O
abiertos	O
y	O
los	O
cristalinos	O
expuestos	O
a	O
la	O
luz	O
durante	O
sólo	O
unas	O
3	O
semanas	O
antes	O
del	O
análisis	O
morfológico	O
.	O

Además	O
,	O
estos	O
animales	B-Taxon
había	O
estado	O
expuesto	O
sólo	O
animal	B-Taxon
instalación	O
de	O
iluminación	O
fluorescente	O
y	O
fueron	O
protegidos	O
de	O
la	O
luz	O
ultravioleta	O
por	O
jaulas	O
de	O
plástico	O
.	O

Si	O
la	O
falta	O
de	O
protección	O
contra	O
el	O
daño	O
inducido	O
por	O
la	O
luz	O
fue	O
el	O
principal	O
factor	O
que	O
afectó	O
los	O
cambios	O
en	O
estos	O
lentes	O
,	O
entonces	O
la	O
mayor	O
parte	O
del	O
daño	O
debería	O
haber	O
residido	O
a	O
lo	O
largo	O
del	O
eje	O
visual	O
,	O
particularmente	O
en	O
el	O
epitelio	O
anterior	O
central	O
y	O
la	O
corteza	O
subcapsular	O
en	O
los	O
lentes	O
de	O
5	O
semanas	O
,	O
pero	O
este	O
no	O
era	O
el	O
caso	O
.	O

En	O
estos	O
lentes	O
,	O
los	O
cambios	O
morfológicos	O
macroscópicos	O
eran	O
evidentes	O
en	O
las	O
regiones	O
ecuatorial	O
y	O
subcapsular	O
posterior	O
.	O

Estos	O
cambios	O
incluyeron	O
subcapsular	O
posterior	O
ácido	B-Chemical
nucleico	I-Chemical
tinción	O
,	O
ausencia	O
de	O
suturas	O
posteriores	O
y	O
pequeños	O
de	O
forma	O
irregular	O
células	B-Cell
,	O
no	O
dispuesto	O
en	O
ningún	O
patrón	O
perceptible	O
,	O
en	O
la	O
región	O
ecuatorial	O
/	O
proa	O
.	O

Factores	O
de	O
estrés	O
sistémico	O
que	O
cruzan	O
la	O
sangre	O
/	O
acuoso	B-Chemical
barrera	O
podría	O
explicar	O
algunos	O
cambios	O
morfológicos	O
en	O
la	O
región	O
ecuatorial	O
,	O
pero	O
esto	O
no	O
explicaría	O
ácido	B-Chemical
nucleico	I-Chemical
tinción	O
en	O
la	O
región	O
subcapsular	O
posterior	O
.	O

en	O
las	O
5	O
semanas	O
alfaA	B-Protein
/	O
Lentes	O
BKO	O
,	O
ácido	B-Chemical
nucleico	I-Chemical
la	O
tinción	O
en	O
la	O
región	O
subcapsular	O
posterior	O
es	O
compatible	O
con	O
la	O
anterior	O
células	B-Cell
epiteliales	I-Cell
migrando	O
de	O
forma	O
aberrante	O
al	O
polo	O
posterior	O
o	O
fibra	O
primaria	O
células	B-Cell
no	O
diferenciarse	O
completamente	O
a	O
las	O
5	O
semanas	O
de	O
edad	O
.	O

Estas	O
dos	O
posibilidades	O
no	O
se	O
pudieron	O
diferenciar	O
en	O
los	O
métodos	O
empleados	O
,	O
y	O
estaban	O
más	O
allá	O
de	O
los	O
objetivos	O
del	O
presente	O
estudio	O
.	O

Se	O
están	O
diseñando	O
estudios	O
futuros	O
para	O
abordar	O
cuál	O
de	O
estos	O
dos	O
procesos	O
podría	O
explicar	O
ácido	B-Chemical
nucleico	I-Chemical
tinción	O
en	O
la	O
región	O
subcapsular	O
posterior	O
.	O

La	O
tinción	O
en	O
esta	O
región	O
no	O
se	O
observó	O
en	O
mayores	O
alfaA	B-Protein
/	O
Lentes	O
BKO	O
,	O
lo	O
que	O
sugiere	O
que	O
este	O
patrón	O
fue	O
transitorio	O
.	O

el	O
destino	O
de	O
la	O
ácido	B-Chemical
nucleico	I-Chemical
#	O
¿NOMBRE	O
?	O
células	B-Cell
en	O
la	O
región	O
capsular	O
posterior	O
de	O
los	O
lentes	O
más	O
jóvenes	O
no	O
se	O
conoce	O
en	O
este	O
momento	O
,	O
ni	O
tampoco	O
la	O
morfología	O
de	O
los	O
lentes	O
en	O
etapas	O
más	O
tempranas	O
.	O

Se	O
están	O
diseñando	O
estudios	O
futuros	O
con	O
objetivos	O
definidos	O
para	O
abordar	O
el	O
desarrollo	O
y	O
la	O
progresión	O
de	O
los	O
cambios	O
morfológicos	O
observados	O
en	O
este	O
estudio	O
.	O

Las	O
diferencias	O
morfológicas	O
en	O
alfaA	B-Protein
/	O
Lentes	O
BKO	O
,	O
en	O
comparación	O
con	O
la	O
edad	O
correspondiente	O
tipo	B-Sequence
salvaje	I-Sequence
lentes	O
,	O
eran	O
consistentes	O
con	O
la	O
hipótesis	O
de	O
que	O
alfa	B-Protein
-	I-Protein
cristalino	I-Protein
juega	O
un	O
papel	O
activo	O
en	O
la	O
diferenciación	O
y	O
el	O
crecimiento	O
de	O
la	O
fibra	O
del	O
cristalino	O
células	B-Cell
.	O

Además	O
,	O
era	O
claramente	O
evidente	O
que	O
alfa	B-Protein
-	I-Protein
cristalino	I-Protein
es	O
necesario	O
para	O
la	O
transparencia	O
de	O
la	O
lente	O
.	O

El	O
evento	O
biológico	O
final	O
en	O
una	O
lente	O
.	O
Célula	B-Cell
epitelial	I-Cell
La	O
vida	O
de	O
s	O
es	O
la	O
transformación	O
de	O
un	O
Célula	B-Cell
epitelial	I-Cell
en	O
una	O
fibra	O
célula	B-Cell
,	O
que	O
ocurre	O
en	O
la	O
región	O
ecuatorial	O
/	O
arco	O
de	O
la	O
lente	O
.	O

La	O
fibra	O
recién	O
formada	O
célula	B-Cell
continúa	O
diferenciándose	O
en	O
la	O
corteza	O
hasta	O
que	O
una	O
fibra	O
madura	O
célula	B-Cell
desprovisto	O
de	O
orgánulos	B-GENE
con	O
formación	O
de	O
sutura	O
en	O
los	O
extremos	O
de	O
la	O
célula	B-Cell
se	O
forma	O

Todo	O
este	O
proceso	O
desde	O
Célula	B-Cell
epitelial	I-Cell
para	O
madurar	O
la	O
fibra	O
célula	B-Cell
se	O
define	O
como	O
diferenciación	O
del	O
cristalino	O
.	O

La	O
precisa	O
expresión	O
espacial	O
y	O
temporal	O
del	O
cristalino	O
proteinas	B-Chemical
en	O
el	O
cristalino	O
en	O
desarrollo	O
puede	O
no	O
ser	O
simplemente	O
una	O
consecuencia	O
del	O
proceso	O
de	O
diferenciación	O
,	O
sino	O
que	O
puede	O
desempeñar	O
un	O
papel	O
importante	O
,	O
si	O
no	O
esencial	O
,	O
en	O
el	O
propio	O
proceso	O
de	O
diferenciación	O
.	O

Los	O
resultados	O
del	O
presente	O
estudio	O
apoyan	O
esta	O
hipótesis	O
.	O

El	O
exacto	O
en	O
vivo	O
molecular	B-Chemical
mecanismos	O
,	O
por	O
los	O
cuales	O
la	O
alfa	O
-	O
cristalina	O
podría	O
influir	O
en	O
la	O
lente	O
Célula	B-Cell
epitelial	I-Cell
la	O
diferenciación	O
y	O
el	O
mantenimiento	O
de	O
la	O
transparencia	O
del	O
cristalino	O
quedan	O
por	O
determinar	O
.	O

AlfaA	B-Protein
y	O
alfab	B-Protein
son	O
miembros	O
de	O
la	O
shsp	B-Protein
familia	O
[	O
7	O
]	O
.	O

Estudios	O
previos	O
han	O
demostrado	O
que	O
la	O
alfa-cristalina	O
posee	O
molecular	B-Chemical
actividad	O
chaperona	O
,	O
uniéndose	O
a	O
parcialmente	O
desnaturalizado	O
proteinas	B-Chemical
,	O
tanto	O
in	O
vitro	O
[	O
5	O
]	O
como	O
probablemente	O
in	O
vivo	O
[	O
6	O
]	O
,	O
para	O
inhibir	O
una	O
mayor	O
desnaturalización	O
.	O

Aunque	O
esta	O
propiedad	O
puede	O
contribuir	O
de	O
manera	O
importante	O
al	O
mantenimiento	O
de	O
la	O
claridad	O
de	O
la	O
lente	O
,	O
los	O
primeros	O
cambios	O
en	O
la	O
alfaA	B-Protein
/	O
Las	O
lentes	O
BKO	O
indican	O
una	O
visión	O
mucho	O
más	O
amplia	O
celular	B-Cell
función	O
para	O
alfa	B-Protein
-	I-Protein
cristalino	I-Protein
.	O

Estrés	O
proteinas	B-Chemical
se	O
ha	O
demostrado	O
que	O
se	O
expresan	O
en	O
no	O
acentuado	O
células	B-Cell
durante	O
el	O
desarrollo	O
y	O
la	O
diferenciación	O
[	O
25	O
]	O
.	O

Se	O
demostró	O
que	O
las	O
Hsp	O
se	O
expresaban	O
durante	O
la	O
diferenciación	O
de	O
mamífero	B-Taxon
osteoblastos	B-Cell
y	O
leucemia	O
promelocítica	O
células	B-Cell
[	O
26	O
]	O
.	O

Además	O
,	O
se	O
ha	O
demostrado	O
que	O
la	O
expresión	O
de	O
hsp	O
acompaña	O
a	O
la	O
detención	O
del	O
crecimiento	O
en	O
humano	B-Taxon
linfocitos	B-Cell
B	I-Cell
[	O
27	O
]	O
y	O
macrófago	B-Cell
diferenciación	O
de	O
HL	O
60	O
células	B-Cell
[	O
28	O
]	O
.	O

Durante	O
la	O
diferenciación	O
miogénica	O
,	O
ARNm	B-Chemical
por	O
alfab	B-Protein
aumenta	O
junto	O
con	O
la	O
inducción	O
de	O
ARNm	B-Chemical
por	O
miogenina	B-Protein
,	O
el	O
evento	O
más	O
antiguo	O
conocido	O
en	O
la	O
miogénesis	O
[	O
29	O
]	O
.	O

La	O
adición	O
de	O
alfa-cristalina	O
exógena	O
a	O
la	O
primaria	O
bovino	B-Taxon
Se	O
demostró	O
que	O
el	O
epitelio	O
del	O
cristalino	O
induce	O
cambios	O
rápidos	O
en	O
célula	B-Cell
forma	O
,	O
lo	O
que	O
lleva	O
a	O
la	O
formación	O
de	O
cuerpos	O
lentoides	O
[	O
21	O
]	O
.	O

Estos	O
estudios	O
sugieren	O
fuertemente	O
que	O
la	O
familia	O
hsp	O
de	O
proteinas	B-Chemical
tiene	O
otras	O
funciones	O
además	O
de	O
proteger	O
proteinas	B-Chemical
y	O
células	B-Cell
durante	O
el	O
estrés	O
.	O

La	O
alfa-cristalina	O
puede	O
desempeñar	O
un	O
papel	O
funcional	O
en	O
la	O
célula	B-Cell
núcleo	B-GENE
y	O
puede	O
tener	O
un	O
papel	O
en	O
la	O
regulación	O
de	O
la	O
célula	B-Cell
ciclo	O

Varios	O
golpes	O
de	O
calor	O
proteinas	B-Chemical
han	O
sido	O
encontrados	O
en	O
célula	B-Cell
núcleos	B-GENE
en	O
ausencia	O
de	O
estrés	O
[	O
30	O
]	O
,	O
y	O
se	O
ha	O
demostrado	O
que	O
la	O
alfa	O
-	O
cristalina	O
interactúa	O
directamente	O
con	O
ADN	B-Sequence
[	O
18	O
]	O
.	O

AlfaB	B-Protein
,	O
expresado	O
en	O
CHO	O
transfectado	O
células	B-Cell
,	O
se	O
ha	O
demostrado	O
que	O
se	O
localiza	O
ectópicamente	O
en	O
la	O
interfase	O
núcleos	B-GENE
,	O
lo	O
que	O
sugiere	O
un	O
papel	O
regulador	O
para	O
este	O
proteína	B-Chemical
en	O
el	O
núcleo	B-GENE
[	O
19	O
]	O
.	O

Un	O
subconjunto	O
de	O
lente	O
inmortalizado	O
células	B-Cell
epiteliales	I-Cell
de	O
alfaBKO	O
ratones	B-Taxon
se	O
ha	O
demostrado	O
que	O
hiperproliferan	O
[	O
20	O
]	O
,	O
lo	O
que	O
sugiere	O
que	O
alfab	B-Protein
puede	O
ser	O
importante	O
para	O
mantener	O
genómico	B-Sequence
estabilidad	O

En	O
el	O
epitelio	O
del	O
cristalino	O
derivado	O
de	O
lentes	O
alphaAKO	O
,	O
célula	B-Cell
Se	O
informó	O
que	O
las	O
tasas	O
de	O
crecimiento	O
eran	O
un	O
50	O
%	O
más	O
bajas	O
en	O
comparación	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
[	O
31	O
]	O
,	O
sugiriendo	O
un	O
papel	O
para	O
alfaA	B-Protein
en	O
la	O
regulación	O
de	O
la	O
célula	B-Cell
ciclo	O

Todos	O
estos	O
hallazgos	O
plantean	O
muchas	O
preguntas	O
en	O
cuanto	O
a	O
la	O
(	O
s	O
)	O
posible	O
(	O
s	O
)	O
función	O
(	O
es	O
)	O
de	O
la	O
alfa-cristalina	O
en	O
la	O
núcleo	B-GENE
y	O
en	O
célula	B-Cell
regulación	O
del	O
ciclo	O
durante	O
la	O
diferenciación	O
.	O

En	O
el	O
estudio	O
actual	O
,	O
la	O
observación	O
de	O
un	O
patrón	O
desorganizado	O
de	O
núcleos	B-GENE
localizado	O
en	O
la	O
región	O
del	O
arco	O
ecuatorial	O
de	O
alfaA	B-Protein
/	O
Lentes	O
BKO	O
,	O
y	O
ácido	B-Chemical
nucleico	I-Chemical
tinción	O
de	O
estructuras	O
a	O
lo	O
largo	O
de	O
la	O
corteza	O
anterior	O
de	O
54	O
semanas	O
alfaA	B-Protein
Lentes	O
BKO	O
,	O
es	O
consistente	O
con	O
un	O
papel	O
para	O
alfa	B-Protein
-	I-Protein
cristalino	I-Protein
en	O
el	O
núcleo	B-GENE
.	O

Existe	O
amplia	O
evidencia	O
de	O
estudios	O
previos	O
que	O
demuestran	O
que	O
la	O
alfa-cristalina	O
juega	O
un	O
papel	O
en	O
la	O
citoesquelético	B-GENE
organización	O

Ambas	O
cosas	O
alfaA	B-Protein
y	O
alfab	B-Protein
puede	O
unirse	O
específicamente	O
a	O
la	O
actina	O
,	O
tanto	O
in	O
vitro	O
[	O
13	O
]	O
como	O
in	O
vivo	O
[	O
14	O
]	O
.	O

filamento	B-GENE
de	I-GENE
actina	I-GENE
Se	O
ha	O
demostrado	O
que	O
la	O
formación	O
es	O
necesaria	O
para	O
la	O
diferenciación	O
de	O
la	O
lente	O
.	O
células	B-Cell
epiteliales	I-Cell
[	O
15	O
]	O
,	O
sin	O
embargo	O
,	O
se	O
desconoce	O
la	O
importancia	O
de	O
la	O
interacción	O
de	O
alfa	O
-	O
cristalina	O
con	O
la	O
actina	O
en	O
la	O
diferenciación	O
.	O

En	O
el	O
cristalino	O
,	O
la	O
alfa-cristalina	O
también	O
forma	O
un	O
complejo	O
con	O
filamento	B-GENE
intermedio	I-GENE
tipo	I-GENE
III	I-GENE
proteinas	B-Chemical
y	O
la	O
lente	O
-	O
filamento	O
perlado	O
específico	O
proteinas	B-Chemical
CP49	B-Protein
y	O
CP115	B-Protein
,	O
que	O
puede	O
ser	O
fundamental	O
para	O
el	O
ensamblaje	O
adecuado	O
del	O
filamento	O
[	O
16	O
]	O
.	O

Filamento	O
con	O
cuentas	O
ARNm	B-Chemical
los	O
niveles	O
aumentan	O
mucho	O
en	O
la	O
diferenciación	O
de	O
lentes	O
células	B-Cell
epiteliales	I-Cell
,	O
y	O
se	O
ha	O
sugerido	O
como	O
un	O
marcador	O
pan-específico	O
para	O
fibra	O
de	O
lente	O
células	B-Cell
[	O
17	O
]	O
.	O

Por	O
lo	O
tanto	O
,	O
es	O
posible	O
que	O
el	O
aumento	O
de	O
la	O
síntesis	O
de	O
alfa-cristalina	O
en	O
células	B-Cell
epiteliales	I-Cell
temprano	O
en	O
el	O
proceso	O
de	O
diferenciación	O
puede	O
tener	O
efectos	O
profundos	O
sobre	O
el	O
citoesqueleto	B-GENE
que	O
a	O
su	O
vez	O
puede	O
afectar	O
profundamente	O
célula	B-Cell
forma	O
y	O
migración	O
.	O

La	O
falta	O
de	O
organización	O
y	O
uniformidad	O
de	O
la	O
bodega	O
.	O
célula	B-Cell
forma	O
en	O
la	O
región	O
ecuatorial	O
observada	O
en	O
alfaA	B-Protein
Los	O
lentes	O
/BKO	O
respaldan	O
esta	O
hipótesis	O
.	O

Actualmente	O
se	O
están	O
realizando	O
estudios	O
para	O
caracterizar	O
citoesquelético	B-GENE
organización	O
en	O
el	O
alfaA	B-Protein
/Objetivo	O
BKO	O
.	O

Conflicto	O
de	O
intereses	O

Ninguno	O
declarado	O

Contribuciones	O
de	O
los	O
autores	O

DLB	O
concibió	O
y	O
diseñó	O
el	O
estudio	O
,	O
llevó	O
a	O
cabo	O
la	O
preparación	O
de	O
muestras	O
,	O
microscopía	O
confocal	O
,	O
escaneo	O
electrón	B-Chemical
microscopía	O
,	O
análisis	O
estadístico	O
,	O
y	O
redactó	O
el	O
manuscrito	O
.	O

JPB	O
ayudó	O
en	O
la	O
producción	O
del	O
Alfa	B-Protein
/	O
BKO	O
ratones	B-Taxon
.	O

EFW	O
colaboró	O
en	O
la	O
producción	O
del	O
AlfaA	B-Protein
/	O
BKO	O
ratones	B-Taxon
,	O
diseño	O
experimental	O
y	O
fijación	O
inicial	O
de	O
muestras	O
.	O

Todos	O
los	O
autores	O
leyeron	O
y	O
aprobaron	O
el	O
manuscrito	O
final	O
.	O

Historial	O
previo	O
a	O
la	O
publicación	O

Se	O
puede	O
acceder	O
al	O
historial	O
previo	O
a	O
la	O
publicación	O
de	O
este	O
artículo	O
aquí	O
:	O

Agradecimientos	O

Esta	O
investigación	O
fue	O
financiada	O
en	O
parte	O
por	O
una	O
subvención	O
NIH	O
para	O
la	O
investigación	O
de	O
la	O
visión	O
EY02932	O
otorgada	O
a	O
LT	O
.	O

un	O
modelo	O
de	O
tripeptidil	B-Protein
-	I-Protein
peptidasa	I-Protein
I	I-Protein
(	O
CLN2	B-Protein
)	O
,	O
un	O
ubicuo	O
y	O
altamente	O
conservado	B-Sequence
miembro	O
de	O
la	O
familia	O
de	O
las	O
sedolisinas	O
serina	B-Chemical
-	O
carboxilo	B-Chemical
peptidasas	O

Resumen	O

Antecedentes	O

Tripeptidil	B-Protein
-	I-Protein
peptidasa	I-Protein
I	I-Protein
,	O
también	O
conocido	O
como	O
CLN2	B-Protein
,	O
es	O
un	O
miembro	O
de	O
la	O
familia	O
de	O
las	O
sedolisinas	O
(	O
serina	B-Chemical
-	O
carboxilo	B-Chemical
peptidasas	O
)	O
.	O

En	O
humanos	B-Taxon
,	O
defectos	O
en	O
la	O
expresión	O
de	O
este	O
enzima	B-Sequence
conducir	O
a	O
una	O
enfermedad	O
neurodegenerativa	O
fatal	O
,	O
clásica	O
infantil	O
tardía	O
neuronales	B-Cell
lipofuscinosis	O
ceroide	O
.	O

Similar	O
enzimas	B-Sequence
se	O
han	O
encontrado	O
en	O
el	O
secuencias	B-Sequence
genómicas	I-Sequence
de	O
varias	O
especies	O
,	O
pero	O
no	O
se	O
han	O
intentado	O
previamente	O
análisis	O
sistemáticos	O
de	O
su	O
distribución	O
ni	O
modelado	O
de	O
sus	O
estructuras	O
.	O

Resultados	O

Hemos	O
analizado	O
la	O
presencia	O
de	O
ortólogos	B-Sequence
de	O
CLN2	B-Protein
humano	I-Protein
en	O
el	O
secuencias	B-Sequence
genómicas	I-Sequence
de	O
un	O
número	O
de	O
eucariota	B-Taxon
especies	O

Enzimas	B-Sequence
con	O
secuencias	B-Sequence
compartiendo	O
más	O
del	O
80	O
%	O
de	O
identidad	O
se	O
han	O
encontrado	O
en	O
el	O
genomas	B-Sequence
de	O
macaco	B-Taxon
,	O
ratón	B-Taxon
,	O
rata	B-Taxon
,	O
perro	B-Taxon
,	O
y	O
vaca	B-Taxon
.	O

Estrechamente	O
relacionado	O
,	O
aunque	O
claramente	O
distinto	O
,	O
enzimas	B-Sequence
están	O
presentes	O
en	O
pez	B-Taxon
(	O
fugu	B-Taxon
y	O
cebra	B-Taxon
)	O
,	O
así	O
como	O
en	O
ranas	B-Taxon
(	O
Xenopus	B-Taxon
tropicalis	I-Taxon
)	O
.	O

Un	O
modelo	O
tridimensional	O
de	O
CLN2	B-Protein
humano	I-Protein
fue	O
construido	O
en	O
base	O
principalmente	O
a	O
la	O
homología	B-Sequence
con	O
Pseudomonas	B-Taxon
sp	O
.	O

101	O
sedolisina	O
.	O

Conclusión	O

CLN2	B-Protein
es	O
muy	O
altamente	O
conservado	B-Sequence
y	O
ampliamente	O
distribuido	O
entre	O
los	O
más	O
altos	O
organismos	B-Taxon
y	O
pueden	O
jugar	O
un	O
papel	O
importante	O
en	O
sus	O
ciclos	O
de	O
vida	O
.	O

El	O
modelo	O
presentado	O
aquí	O
indica	O
una	O
muy	O
abierta	O
y	O
accesible	O
sitio	B-Sequence
activo	I-Sequence
eso	O
es	O
casi	O
completamente	O
conservado	B-Sequence
entre	O
todos	O
conocido	B-Sequence
CLN2	B-Protein
enzimas	B-Sequence
.	O

Este	O
resultado	O
es	O
algo	O
sorprendente	O
para	O
una	O
tripeptidasa	O
en	O
la	O
que	O
se	O
anticipó	O
la	O
presencia	O
de	O
un	O
bolsillo	O
de	O
unión	O
más	O
limitado	O
.	O

Este	O
modelo	O
estructural	O
debería	O
ser	O
útil	O
en	O
la	O
búsqueda	O
de	O
los	O
sustratos	O
fisiológicos	O
de	O
estos	O
enzimas	B-Sequence
y	O
en	O
el	O
diseño	O
de	O
más	O
específicos	O
inhibidores	B-Chemical
de	O
CLN2	B-Protein
.	O

Antecedentes	O

Aunque	O
la	O
existencia	O
de	O
tripeptidil	B-Protein
-	I-Protein
peptidasa	I-Protein
I	I-Protein
(	O
TPP-yo	B-Protein
se	O
observó	O
por	O
primera	O
vez	O
hace	O
más	O
de	O
40	O
años	O
[	O
1	O
]	O
,	O
la	O
base	O
estructural	O
y	O
mecanicista	O
de	O
su	O
actividad	O
se	O
ha	O
malinterpretado	O
en	O
gran	O
medida	O
hasta	O
hace	O
muy	O
poco	O
.	O

La	O
situación	O
cambió	O
después	O
de	O
que	O
se	O
demostró	O
que	O
TPP-yo	B-Protein
es	O
idéntico	O
a	O
un	O
caracterizado	O
independientemente	O
enzima	B-Sequence
llamado	O
CLN2	B-Protein
.	O

También	O
se	O
demostró	O
que	O
mutaciones	B-Sequence
que	O
lleva	O
a	O
la	O
abolición	O
de	O
la	O
enzimático	B-Sequence
actividad	O
de	O
CLN2	B-Protein
fueron	O
la	O
causa	O
directa	O
de	O
una	O
enfermedad	O
neurodegenerativa	O
hereditaria	O
fatal	O
,	O
clásica	O
infantil	O
tardía	O
neuronales	B-Cell
lipofuscinosis	O
ceroide	O
[	O
2	O
]	O
.	O

Esta	O
importante	O
observación	O
fue	O
seguida	O
por	O
la	O
identificación	O
de	O
CLN2	B-Protein
como	O
un	O
serina	B-Chemical
peptidasa	O
[	O
3	O
,	O
4	O
]	O
,	O
sin	O
especificar	O
,	O
sin	O
embargo	O
,	O
su	O
plegamiento	O
estructural	O
y	O
los	O
detalles	O
de	O
la	O
sitio	B-Sequence
catalítico	I-Sequence
.	O

Colocación	O
más	O
precisa	O
de	O
CLN2	B-Protein
dentro	O
del	O
contexto	O
de	O
una	O
familia	O
de	O
parientes	O
enzimas	B-Sequence
se	O
hizo	O
posible	O
sólo	O
después	O
de	O
estructuras	O
cristalinas	O
de	O
alta	O
resolución	O
de	O
dos	O
bacteriano	B-Taxon
enzimas	B-Sequence
con	O
un	O
limitado	O
secuencia	B-Sequence
similitud	O
con	O
CLN2	B-Protein
sedolisina	O
y	O
kumamolisina	O
,	O
estuvieron	O
disponibles	O
[	O
5	O
-	O
7	O
]	O
.	O

Estas	O
estructuras	O
definieron	O
una	O
nueva	O
familia	O
de	O
enzimas	B-Sequence
,	O
ahora	O
llamados	O
sedolisinas	O
o	O
serina	B-Chemical
-	O
carboxilo	B-Chemical
peptidasas	O
,	O
que	O
se	O
caracteriza	O
por	O
la	O
utilización	O
de	O
un	O
conservado	B-Sequence
tríada	O
catalítica	O
(	O
Ser	B-Chemical
,	O
Glú	B-Chemical
,	O
Áspid	B-Chemical
)	O
y	O
por	O
la	O
presencia	O
de	O
un	O
Áspid	B-Chemical
en	O
el	O
oxianión	B-Chemical
agujero	O
[	O
8	O
]	O
.	O

Sedolisina	O
y	O
sus	O
varios	O
variantes	B-Sequence
(	O
p	O
.	O
ej	O
.	O
,	O
kumamolisin	O
,	O
aorsin	O
[	O
9	O
]	O
y	O
physarolisin	O
[	O
10	O
]	O
)	O
ahora	O
se	O
han	O
encontrado	O
en	O
arqueas	B-Taxon
,	O
bacterias	B-Taxon
,	O
hongos	B-Taxon
y	O
amebas	B-Taxon
,	O
mientras	O
que	O
cuanto	O
mayor	O
sea	O
organismos	B-Taxon
parecen	O
contener	O
solo	O
variantes	B-Sequence
de	O
CLN2	B-Protein
[	O
8	O
]	O
.	O

El	O
papel	O
fisiológico	O
de	O
las	O
sedolisinas	O
en	O
la	O
parte	O
inferior	O
organismos	B-Taxon
aún	O
no	O
ha	O
sido	O
dilucidado	O
.	O

A	O
pesar	O
de	O
la	O
potencial	O
importancia	O
médica	O
de	O
CLN2	B-Protein
y	O
relacionado	O
enzimas	B-Sequence
,	O
no	O
hay	O
estudios	O
sistemáticos	O
de	O
su	O
genómico	B-Sequence
distribución	O
se	O
han	O
publicado	O
hasta	O
la	O
fecha	O
.	O

Tampoco	O
hay	O
informes	O
publicados	O
de	O
la	O
cristalización	O
de	O
este	O
enzima	B-Sequence
.	O

En	O
ausencia	O
de	O
una	O
estructura	O
experimental	O
obtenida	O
por	O
cristalografía	O
o	O
RMN	O
,	O
a	O
veces	O
es	O
necesario	O
recurrir	O
a	O
molecular	B-Chemical
modelado	O
con	O
el	O
fin	O
de	O
proporcionar	O
una	O
base	O
estructural	O
para	O
la	O
explicación	O
de	O
las	O
propiedades	O
biológicas	O
de	O
un	O
enzima	B-Sequence
,	O
y	O
,	O
en	O
particular	O
,	O
iniciar	O
el	O
diseño	O
de	O
sus	O
inhibidores	B-Chemical
.	O

Ejemplos	O
de	O
tales	O
esfuerzos	O
de	O
modelado	O
muy	O
exitosos	O
y	O
útiles	O
son	O
proporcionados	O
por	O
VIH	B-Taxon
proteasa	O
[	O
11	O
]	O
,	O
o	O
muy	O
recientemente	O
por	O
la	O
peptidasa	O
de	O
un	O
coronavirus	B-Taxon
involucrados	O
en	O
el	O
síndrome	O
respiratorio	O
agudo	O
severo	O
[	O
12	O
]	O
,	O
entre	O
otros	O
.	O

Ahora	O
hemos	O
aplicado	O
las	O
herramientas	O
de	O
molecular	B-Chemical
homología	B-Sequence
modelado	O
para	O
predecir	O
una	O
estructura	O
de	O
CLN2	B-Protein
que	O
podría	O
ser	O
utilizado	O
como	O
base	O
para	O
una	O
búsqueda	O
de	O
los	O
sustratos	O
biológicos	O
de	O
esta	O
familia	O
de	O
enzimas	B-Sequence
y	O
para	O
el	O
diseño	O
de	O
inhibidores	B-Chemical
.	O

Resultados	O
y	O
discusión	O

Secuencia	B-Sequence
comparaciones	O
de	O
los	O
CLN2	B-Protein
#	O
¿NOMBRE	O
?	O
enzimas	B-Sequence

Mamífero	B-Taxon
enzimas	B-Sequence
homólogas	I-Sequence
para	O
CLN2	B-Protein
humano	I-Protein
[	O
2	O
,	O
4	O
]	O
forman	O
una	O
subfamilia	O
de	O
sedolisinas	O
con	O
secuencias	B-Sequence
conservadas	I-Sequence
(	O
Figura	O
1	O
)	O
.	O

Estas	O
enzimas	B-Sequence
se	O
expresan	O
con	O
un	O
prosegmento	B-Sequence
compuesto	O
por	O
195	O
residuos	B-Chemical
que	O
se	O
escinde	O
durante	O
la	O
maduración	O
,	O
produciendo	O
el	O
catalizador	O
activo	O
dominio	B-Sequence
.	O

Completo	O
secuencias	B-Sequence
están	O
disponibles	O
para	O
CLN2	B-Protein
de	O
seis	O
especies	O
en	O
las	O
que	O
se	O
ha	O
encontrado	O
hasta	O
ahora	O
(	O
humano	B-Taxon
,	O
macaco	B-Taxon
,	O
perro	B-Taxon
,	O
ratón	B-Taxon
,	O
rata	B-Taxon
,	O
y	O
vaca	B-Taxon
)	O
.	O

La	O
longitud	O
completa	O
enzimas	B-Sequence
consta	O
de	O
563	O
aminoácidos	B-Chemical
ordenados	O
en	O
un	O
solo	O
cadena	B-Sequence
polipeptídica	I-Sequence
que	O
contiene	O
tanto	O
el	O
prosegmento	B-Sequence
y	O
el	O
catalitico	O
dominio	B-Sequence
,	O
con	O
la	O
excepción	O
de	O
ratón	B-Protein
CLN2	I-Protein
que	O
tiene	O
un	O
solo	O
supresión	B-Sequence
en	O
el	O
prosegmento	B-Sequence
.	O

El	O
general	O
secuencia	B-Sequence
identidad	O
para	O
estos	O
enzimas	B-Sequence
es	O
del	O
81	O
%	O
,	O
mientras	O
que	O
la	O
similitud	O
es	O
del	O
92	O
%	O
.	O

Una	O
comparación	O
por	O
pares	O
de	O
los	O
humano	B-Taxon
y	O
ratón	B-Taxon
enzimas	B-Sequence
arroja	O
88	O
%	O
de	O
identidad	O
y	O
94	O
%	O
de	O
similitud	O
,	O
considerablemente	O
superior	O
a	O
la	O
mediana	O
78	O
.	O
5	O
%	O
de	O
identidad	O
reportada	O
para	O
todos	O
los	O
identificados	O
ratón	B-Taxon
-	O
humano	B-Taxon
ortólogos	B-Sequence
[	O
13	O
]	O
.	O

Por	O
lo	O
tanto	O
,	O
mamífero	B-Taxon
CLN2	B-Protein
parece	O
ser	O
altamente	O
enzima	B-Sequence
conservada	I-Sequence
.	O

Figura	O
1	O

Secuencia	B-Sequence
comparaciones	O
de	O
mamífero	B-Taxon
CLN2	B-Protein
#	O
¿NOMBRE	O
?	O
enzimas	B-Sequence
.	O
Estas	O
secuencias	B-Sequence
corresponde	O
al	O
completo	O
enzimas	B-Sequence
,	O
incluyendo	O
el	O
prosegmento	B-Sequence
.	O

residuos	B-Chemical
formando	O
el	O
sitio	B-Sequence
activo	I-Sequence
se	O
muestran	O
en	O
amarillo	O
sobre	O
fondo	O
rojo	O
,	O
otros	O
conservado	B-Sequence
residuos	B-Chemical
identificados	O
como	O
importantes	O
para	O
la	O
estabilidad	O
de	O
la	O
enzima	B-Sequence
están	O
marcados	O
con	O
fondo	O
amarillo	O
,	O
residuos	B-Chemical
idénticos	O
en	O
al	O
menos	O
5	O
de	O
las	O
estructuras	O
son	O
verdes	O
,	O
y	O
residuos	B-Chemical
similares	O
en	O
su	O
carácter	O
se	O
muestran	O
en	O
magenta	O
.	O

El	O
punto	O
de	O
división	O
de	O
la	O
maduración	O
que	O
genera	O
la	O
terminal	B-Sequence
N	I-Sequence
del	O
activo	O
enzima	B-Sequence
está	O
marcado	O
con	O
triángulos	O
negros	O
.	O

Además	O
de	O
mamíferos	B-Taxon
,	O
CLN2	B-Protein
#	O
¿NOMBRE	O
?	O
enzimas	B-Sequence
también	O
se	O
encuentran	O
en	O
fugu	B-Taxon
(	O
pez	B-Taxon
globo	I-Taxon
#	O
¿NOMBRE	O
?	O
fugu	B-Taxon
secuencia	B-Sequence
base	O
de	O
datos	O
,	O
)	O
y	O
pez	B-Taxon
cebra	I-Taxon
(	O
contiguo	B-Sequence
wz4596	O
.	O
2	O
en	O
el	O
pez	B-Taxon
cebra	I-Taxon
est	B-Sequence
base	O
de	O
datos	O
,	O
)	O
.	O

solo	O
un	O
fragmento	B-Sequence
de	O
El	O
secuencia	B-Sequence
del	O
último	O
enzima	B-Sequence
coincidió	O
con	O
el	O
primero	O
.	O

Sin	O
embargo	O
,	O
algunos	O
relativamente	O
menores	O
modificaciones	B-Sequence
puede	O
traer	O
el	O
pez	B-Taxon
cebra	I-Taxon
secuencia	B-Sequence
en	O
buen	O
acuerdo	O
con	O
el	O
de	O
la	O
fugu	B-Taxon
CLN2	B-Protein
.	O

Estas	O
modificaciones	B-Sequence
Incluir	O
un	O
supresión	B-Sequence
de	O
un	O
solo	O
nucleótido	B-Chemical
de	O
una	O
racha	O
de	O
tres	O
,	O
así	O
como	O
de	O
tres	O
inserciones	B-Sequence
de	O
pares	B-Sequence
de	I-Sequence
nucleótidos	I-Sequence
repetidos	I-Sequence
(	O
Figura	O
2	O
)	O
.	O

Hay	O
que	O
subrayar	O
que	O
estos	O
modificaciones	B-Sequence
son	O
especulativos	O
y	O
pueden	O
conducir	O
a	O
la	O
predicción	O
de	O
varios	O
errores	O
aminoácidos	B-Chemical
sin	O
embargo	O
,	O
traen	O
los	O
dos	O
secuencias	B-Sequence
en	O
un	O
buen	O
acuerdo	O
global	O
(	O
69	O
%	O
de	O
identidades	O
y	O
83	O
%	O
de	O
similitudes	O
)	O
.	O

Figura	O
2	O

corregido	O
secuencia	B-Sequence
de	I-Sequence
genes	I-Sequence
de	O
El	O
pez	B-Protein
cebra	I-Protein
CLN2	I-Protein
.	O
este	O
putativo	O
secuencia	B-Sequence
muestra	O
las	O
correcciones	O
manuales	O
que	O
lo	O
alinean	O
con	O
el	O
secuencia	B-Sequence
de	O
El	O
fugu	B-Taxon
enzima	B-Sequence
.	O

Insertado	B-Sequence
nucleótidos	B-Chemical
están	O
marcados	O
en	O
verde	O
y	O
un	O
eliminado	B-Sequence
uno	O
en	O
rojo	O
.	O

El	O
disponible	O
secuencia	B-Sequence
de	I-Sequence
aminoácidos	I-Sequence
de	O
El	O
fugu	B-Taxon
CLN2	B-Protein
análogo	O
,	O
llamado	O
por	O
nosotros	O
sedolisin-TPP	O
[	O
8	O
]	O
,	O
también	O
está	O
en	O
buen	O
acuerdo	O
con	O
el	O
secuencias	B-Sequence
de	O
El	O
mamífero	B-Taxon
ortólogos	B-Sequence
(	O
Figura	O
3	O
)	O
.	O

La	O
única	O
diferencia	O
importante	O
en	O
la	O
traducción	O
secuencia	B-Sequence
de	I-Sequence
aminoácidos	I-Sequence
en	O
comparación	O
con	O
el	O
mamífero	B-Taxon
y	O
pez	B-Taxon
cebra	I-Taxon
enzimas	B-Sequence
está	O
en	O
el	O
término	B-Sequence
amino	I-Sequence
de	O
El	O
región	B-Sequence
propéptido	I-Sequence
eso	O
es	O
mas	O
corto	O
por	O
30	O
aminoácidos	B-Chemical
(	O
no	O
mostrado	O
)	O
.	O

Es	O
muy	O
probable	O
que	O
esto	O
represente	O
una	O
falla	O
en	O
el	O
secuencia	B-Sequence
ensamblada	I-Sequence
en	O
lugar	O
de	O
un	O
verdadero	O
variación	B-Sequence
,	O
desde	O
el	O
actual	O
marco	B-Sequence
de	I-Sequence
codificación	I-Sequence
no	O
se	O
inicia	O
con	O
un	O
metionina	B-Chemical
,	O
y	O
algunos	O
extra	O
residuos	B-Chemical
están	O
presentes	O
en	O
su	O
totalidad	O
secuencia	B-Sequence
genómica	I-Sequence
disponible	O
desde	O
el	O
fugu	B-Taxon
consorcio	O
de	O
secuenciación	O
.	O

figura	O
3	O

Secuencias	B-Sequence
del	O
catalitico	O
dominios	B-Sequence
de	O
CLN2	B-Protein
.	O

Completo	O
secuencias	B-Sequence
se	O
muestran	O
para	O
CLN2	B-Protein
de	I-Protein
humano	I-Protein
,	I-Protein
fugu	I-Protein
y	I-Protein
pez	I-Protein
cebra	I-Protein
,	O
junto	O
con	O
la	O
secuencia	B-Sequence
parcial	I-Sequence
de	O
putativo	O
CLN2	B-Protein
en	I-Protein
Xenopus	I-Protein
tropicalis	I-Protein
.	O

residuos	B-Chemical
idénticos	O
en	O
los	O
cuatro	O
enzimas	B-Sequence
son	O
de	O
color	O
verde	O
y	O
los	O
similares	O
son	O
de	O
color	O
magenta	O
.	O

Residuos	B-Sequence
del	I-Sequence
sitio	I-Sequence
activo	I-Sequence
están	O
marcados	O
como	O
en	O
la	O
Figura	O
1	O
.	O

CLN2	B-Protein
está	O
presente	O
no	O
sólo	O
en	O
pez	B-Taxon
,	O
pero	O
también	O
en	O
anfibios	B-Taxon
,	O
en	O
particular	O
en	O
Xenopus	B-Taxon
tropicalis	I-Taxon
(	O
una	O
especie	O
de	O
rana	B-Taxon
)	O
.	O

A	O
secuencia	B-Sequence
parcial	I-Sequence
de	O
su	O
sedolisina	O
-	O
TPP	O
(	O
AL594774	O
)	O
que	O
se	O
encuentra	O
en	O
el	O
est	B-Sequence
La	O
base	O
de	O
datos	O
abarca	O
la	O
parte	O
media	O
del	O
catalítico	O
.	O
dominio	B-Sequence
,	O
sin	O
llegar	O
a	O
la	O
parte	O
del	O
sitio	B-Sequence
activo	I-Sequence
más	O
cerca	O
de	O
la	O
terminal	B-Sequence
N	I-Sequence
que	O
contiene	O
el	O
ácidos	B-Chemical
aspártico	I-Chemical
y	I-Chemical
glutámico	I-Chemical
que	O
pertenecen	O
a	O
la	O
tríada	O
catalítica	O
.	O

Sin	O
embargo	O
,	O
la	O
secuencia	O
parte	B-Sequence
de	O
El	O
enzima	B-Sequence
muestra	O
un	O
75	O
%	O
de	O
identidad	O
con	O
el	O
fugu	B-Taxon
sedolisina	O
-	O
TPP	O
,	O
y	O
69	O
%	O
identidad	O
con	O
CLN2	B-Protein
humano	I-Protein
(	O
Figura	O
3	O
)	O
.	O

Secuencia	B-Sequence
similitud	O
con	O
bacteriano	B-Taxon
o	O
hongos	B-Taxon
sedolisinas	O
es	O
mucho	O
menor	O
,	O
lo	O
que	O
indica	O
que	O
la	O
enzima	B-Sequence
encontrado	O
en	O
ranas	B-Taxon
también	O
podría	O
compartir	O
las	O
propiedades	O
funcionales	O
de	O
la	O
CLN2	B-Protein
subfamilia	O

El	O
descubrimiento	O
de	O
altamente	O
conservado	B-Sequence
CLN2	B-Protein
#	O
¿NOMBRE	O
?	O
enzimas	B-Sequence
no	O
solo	O
en	O
mamíferos	B-Taxon
pero	O
también	O
en	O
dos	O
pez	B-Taxon
especie	O
y	O
una	O
de	O
ranas	B-Taxon
puede	O
indicar	O
que	O
estas	O
peptidasas	O
están	O
universalmente	O
presentes	O
en	O
el	O
vertebrados	B-Taxon
,	O
y	O
que	O
su	O
importante	O
papel	O
identificado	O
en	O
humanos	B-Taxon
[	O
2	O
]	O
y	O
ratones	B-Taxon
[	O
14	O
]	O
podría	O
ser	O
una	O
característica	O
más	O
general	O
.	O

Modelado	O
de	O
la	O
estructura	O
de	O
CLN2	B-Protein
humano	I-Protein

La	O
importancia	O
médica	O
de	O
CLN2	B-Protein
y	O
la	O
falta	O
de	O
una	O
estructura	O
cristalina	O
inspiró	O
intentos	O
de	O
proteína	B-Chemical
modelado	O

El	O
primer	O
modelo	O
de	O
este	O
tipo	O
asumía	O
que	O
este	O
enzima	B-Sequence
es	O
membrana	B-GENE
-	O
atado	O
,	O
con	O
el	O
secuencia	B-Sequence
271	O
-	O
294	O
(	O
numeración	O
correspondiente	O
a	O
la	O
madura	O
enzima	B-Sequence
,	O
Figura	O
1	O
)	O
formando	O
el	O
putativo	O
transmembrana	B-GENE
ancla	O
[	O
15	O
]	O
.	O

Sin	O
embargo	O
,	O
en	O
vista	O
de	O
las	O
estructuras	O
obtenidas	O
posteriormente	O
de	O
la	O
totalidad	O
agua	B-Chemical
-sedolisinas	O
solubles	O
,	O
este	O
modelo	O
era	O
claramente	O
incorrecto	O
.	O

explotando	O
el	O
secuencia	B-Sequence
similitud	O
entre	O
CLN2	B-Protein
,	O
sedolisina	O
y	O
kumamolisina	O
(	O
Figura	O
4	O
)	O
,	O
ahora	O
hemos	O
utilizado	O
el	O
obtenido	B-Sequence
experimentalmente	I-Sequence
estructuras	O
de	O
los	O
dos	O
últimos	O
enzimas	B-Sequence
para	O
formar	O
una	O
nueva	O
,	O
homología	B-Sequence
#	O
¿NOMBRE	O
?	O
CLN2	B-Protein
humano	I-Protein
.	O

La	O
base	O
primaria	O
de	O
la	O
homología	B-Sequence
modelo	O
era	O
la	O
estructura	O
de	O
un	O
complejo	O
de	O
sedolisina	O
con	O
un	O
enlace	O
covalente	O
inhibidor	B-Chemical
,	O
pseudo	O
-	O
yodotirostatina	O
.	O

Aunque	O
no	O
se	O
ha	O
demostrado	O
directamente	O
que	O
este	O
compuesto	B-Chemical
puede	O
inhibir	O
CLN2	B-Protein
humano	I-Protein
,	O
otros	O
similares	O
péptidos	B-Sequence
con	O
un	O
aldehído	B-Chemical
``	O
funcionalidad	O
en	O
su	O
``	O
''	O
''	O
C	B-Sequence
-	I-Sequence
terminales	I-Sequence
son	O
débiles	O
,	O
pero	O
detectables	O
,	O
inhibidores	B-Chemical
de	I-Chemical
esta	I-Chemical
enzima	I-Chemical
(	O
Oda	O
,	O
inédito	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
es	O
probable	O
que	O
la	O
pseudo-yodotirostatina	O
o	O
un	O
medicamento	O
similar	O
inhibidor	B-Chemical
podría	O
funcionar	O
para	O
CLN2	B-Protein
también	O
,	O
aunque	O
los	O
contactos	O
reales	O
entre	O
los	O
inhibidor	B-Chemical
y	O
el	O
enzima	B-Sequence
que	O
se	O
ven	O
en	O
el	O
modelo	O
deben	O
ser	O
tratados	O
con	O
cautela	O
.	O

Otra	O
razón	O
para	O
el	O
modelado	O
de	O
un	O
complejo	O
de	O
pseudo-yodotirostatina	O
es	O
que	O
CLN2	B-Protein
es	O
una	O
tripeptidasa	O
,	O
y	O
que	O
esta	O
inhibidor	B-Chemical
representa	O
la	O
única	O
estructura	O
experimental	O
de	O
un	O
análogo	O
de	O
tripéptido	O
unido	O
a	O
la	O
sedolisina	O
.	O

Figura	O
4	O

Secuencia	B-Sequence
alineación	O
de	O
bacteriano	B-Taxon
y	O
mamífero	B-Taxon
enzimas	B-Sequence
.	O

Alineación	O
de	O
la	O
secuencias	B-Sequence
de	O
sedolisina	O
,	O
kumamolisina	O
y	O
CLN2	B-Protein
humano	I-Protein
utilizado	O
en	O
la	O
construcción	O
del	O
modelo	O
de	O
este	O
último	O
enzima	B-Sequence
.	O

El	O
esquema	O
de	O
colores	O
es	O
el	O
mismo	O
que	O
en	O
la	O
Figura	O
2	O
.	O

El	O
r	O
.	O
m	O
s	O
.	O
desviación	O
entre	O
las	O
correspondientes	O
coordenadas	O
C	O
alfa	O
del	O
modelo	O
de	O
CLN2	B-Protein
(	O
Figura	O
5	O
)	O
y	O
la	O
estructura	O
experimental	O
de	O
la	O
sedolisina	O
es	O
de	O
aproximadamente	O
1	O
.	O
75	O
A	O
,	O
no	O
mucho	O
mayor	O
que	O
la	O
diferencia	O
experimental	O
entre	O
sedolisina	O
y	O
kumamolisina	O
.	O

Curiosamente	O
,	O
el	O
Cys327	O
y	O
Cys342	O
residuos	B-Chemical
en	O
el	O
modelo	O
se	O
encontró	O
que	O
estaban	O
en	O
una	O
posición	O
ideal	O
para	O
formar	O
un	O
enlace	O
disulfuro	O
a	O
pesar	O
de	O
que	O
esto	O
no	O
era	O
parte	O
de	O
la	O
estrategia	O
de	O
diseño	O
.	O

Que	O
este	O
vínculo	O
probablemente	O
ocurra	O
en	O
el	O
mundo	O
real	O
.	O
proteína	B-Chemical
se	O
sugiere	O
por	O
el	O
hecho	O
de	O
que	O
estos	O
dos	O
cisteínas	B-Chemical
son	O
estrictamente	O
conservado	B-Sequence
en	O
todo	O
lo	O
conocido	O
animal	B-Taxon
especies	O
de	O
CLN2	B-Protein
(	O
Figuras	O
1	O
y	O
3	O
)	O
,	O
aunque	O
están	O
ausentes	O
en	O
todos	O
secuencias	B-Sequence
conocidas	I-Sequence
de	O
bacteriano	B-Taxon
sedolisinas	O
.	O

Por	O
lo	O
tanto	O
,	O
si	O
se	O
encontrara	O
experimentalmente	O
que	O
este	O
disulfuro	O
existe	O
en	O
CLN2	B-Protein
proporcionaría	O
apoyo	O
para	O
la	O
corrección	O
del	O
modelo	O
.	O

Figura	O
5	O

A	O
homología	B-Sequence
#	O
¿NOMBRE	O
?	O
CLN2	B-Protein
humano	I-Protein
.	O

Diagrama	O
de	O
cinta	O
de	O
la	O
traza	O
C	O
alfa	O
de	O
CLN2	B-Protein
,	O
con	O
el	O
segmentos	B-Sequence
que	O
fueron	O
modelados	O
en	O
base	O
a	O
los	O
altamente	O
conservado	B-Sequence
núcleo	O
de	O
sedolisina	O
y	O
kumamolisina	O
(	O
r	O
.	O
m	O
.	O
s	O
.	O
desviación	O
de	O
1	O
A	O
)	O
coloreado	O
en	O
rojo	O
.	O

Cadenas	O
laterales	O
de	O
la	O
residuos	B-Chemical
que	O
resultaron	O
ser	O
mutado	B-Sequence
en	O
el	O
genes	B-Sequence
de	O
familias	O
de	O
pacientes	O
con	O
tardío	O
-	O
infantil	O
neuronales	B-Cell
lipofuscinosis	O
ceroide	O
[	O
17	O
]	O
están	O
marcados	O
en	O
bola	O
y	O
palo	O
.	O

Comparaciones	O
de	O
los	O
bolsillos	O
de	O
unión	O
del	O
sustrato	O
de	O
CLN2	B-Protein
y	O
sedolisina	O

Dado	O
que	O
la	O
principal	O
actividad	O
conocida	O
de	O
CLN2	B-Protein
es	O
el	O
de	O
una	O
tripeptidasa	O
,	O
se	O
espera	O
que	O
sean	O
discernibles	O
tres	O
bolsillos	O
de	O
unión	O
al	O
sustrato	O
,	O
S1	O
a	O
S3	O
(	O
usando	O
la	O
nomenclatura	O
de	O
Schechter	O
y	O
Berger	O
[	O
16	O
]	O
)	O
.	O

residuos	B-Chemical
P1	O
-	O
P3	O
de	O
la	O
inhibidor	B-Chemical
que	O
deben	O
ocupar	O
estos	O
bolsillos	O
se	O
muestran	O
en	O
la	O
Figura	O
6	O
.	O

Todas	O
las	O
estructuras	O
disponibles	O
de	O
los	O
complejos	O
de	O
sedolisina	O
o	O
kumamolisina	O
con	O
inhibidores	B-Chemical
contener	O
un	O
tirosina	B-Chemical
o	O
un	O
fenilalanina	B-Chemical
ocupando	O
el	O
bolsillo	O
S1	O
.	O

Partes	O
de	O
este	O
bolsillo	O
están	O
completamente	O
conservado	B-Sequence
entre	O
diferentes	O
sedolisinas	O
,	O
mientras	O
que	O
otras	O
partes	O
difieren	O
.	O

El	O
lado	O
derecho	O
de	O
la	O
cajera	O
(	O
en	O
la	O
vista	O
utilizada	O
en	O
la	O
Figura	O
6	O
)	O
está	O
formado	O
por	O
la	O
parte	O
principal	O
cadena	B-Sequence
incluso	O
residuos	B-Chemical
164	O
-	O
165	O
(	O
a	O
menos	O
que	O
se	O
indique	O
lo	O
contrario	O
,	O
la	O
numeración	O
se	O
refiere	O
a	O
la	O
secuencia	B-Sequence
de	O
los	O
maduros	O
CLN2	B-Protein
humano	I-Protein
)	O
.	O

Esta	O
parte	O
de	O
la	O
principal	O
cadena	B-Sequence
se	O
mantiene	O
en	O
su	O
lugar	O
a	O
través	O
de	O
un	O
hidrógeno	B-Chemical
-	O
interacción	O
unida	O
con	O
la	O
cadena	O
lateral	O
de	O
Thr279	O
,	O
parte	O
de	O
la	O
firma	O
secuencia	B-Sequence
SGTSAS	O
que	O
rodea	O
el	O
catalítico	O
Ser280	O
y	O
sus	O
equivalentes	O
en	O
el	O
otro	O
enzimas	B-Sequence
.	O

Asp165	O
en	O
sí	O
también	O
es	O
conservado	B-Sequence
desde	O
eso	O
residuo	B-Chemical
proporciona	O
el	O
revestimiento	O
de	O
la	O
oxianión	B-Chemical
orificio	O
,	O
por	O
lo	O
que	O
se	O
puede	O
suponer	O
con	O
seguridad	O
que	O
esta	O
parte	O
del	O
bolsillo	O
S1	O
es	O
prácticamente	O
idéntica	O
.	O

Sin	O
embargo	O
,	O
ninguna	O
cadena	O
lateral	O
apunta	O
al	O
bolsillo	O
desde	O
allí	O
,	O
por	O
lo	O
que	O
su	O
importancia	O
se	O
limita	O
a	O
proporcionar	O
una	O
barrera	O
estérica	O
y	O
excluir	O
solvente	B-Chemical
.	O

Otra	O
pared	O
del	O
bolsillo	O
se	O
compone	O
de	O
la	O
principal	O
cadena	B-Sequence
de	I-Sequence
residuos	I-Sequence
130	O
-	O
132	O
que	O
flanquean	O
el	O
conservado	B-Sequence
Gly131	O
.	O

De	O
nuevo	O
,	O
esta	O
parte	O
del	O
cadena	B-Sequence
no	O
proporciona	O
ninguna	O
interacción	O
específica	O
con	O
el	O
P1	O
residuo	B-Chemical
del	O
sustrato	O
.	O

Figura	O
6	O

Un	O
modelo	O
de	O
la	O
sitio	B-Sequence
activo	I-Sequence
de	O
CLN2	B-Protein
humano	I-Protein
.	O

los	O
enzima	B-Sequence
se	O
muestra	O
en	O
complejo	O
con	O
pseudo-yodotirostatina	O
,	O
un	O
buen	O
inhibidor	B-Chemical
de	O
la	O
familia	O
de	O
peptidasas	O
de	O
las	O
sedolisinas	O
.	O

Solo	O
seleccionados	O
residuos	B-Chemical
de	O
El	O
enzima	B-Sequence
se	O
muestran	O
explícitamente	O
en	O
el	O
fondo	O
que	O
consiste	O
en	O
el	O
molecular	B-Chemical
superficie	O
.	O

El	O
modelo	O
de	O
palo	O
de	O
la	O
inhibidor	B-Chemical
es	O
de	O
color	O
dorado	O
y	O
el	O
P1	O
-	O
P3	O
residuos	B-Chemical
están	O
etiquetados	O
en	O
negro	O
.	O

Previamente	O
se	O
han	O
publicado	O
puntos	O
de	O
vista	O
similares	O
para	O
el	O
determinado	B-Sequence
experimentalmente	I-Sequence
estructuras	O
de	O
sedolisin	O
y	O
kumamolisin	O
[	O
8	O
]	O
.	O

La	O
figura	O
fue	O
preparada	O
usando	O
el	O
programa	O
DINO	O
.	O

Sin	O
embargo	O
,	O
se	O
observan	O
diferencias	O
considerables	O
en	O
el	O
fondo	O
de	O
la	O
bolsa	O
,	O
donde	O
las	O
cadenas	O
laterales	O
de	O
Asp179	O
en	O
kumamolisina	O
y	O
el	O
equivalente	O
Ser190	O
en	O
sedolisina	O
forman	O
hidrógeno	B-Chemical
se	O
une	O
al	O
P1	O
tirosina	B-Chemical
de	O
El	O
inhibidor	B-Chemical
(	O
si	O
está	O
presente	O
)	O
.	O

El	O
equivalente	O
residuo	B-Chemical
en	O
CLN2	B-Protein
es	O
Thr182	O
,	O
pero	O
es	O
muy	O
poco	O
probable	O
que	O
pueda	O
asumir	O
una	O
orientación	O
que	O
le	O
permita	O
hacer	O
una	O
hidrógeno	B-Chemical
enlace	O
a	O
un	O
P1	O
tirosina	B-Chemical
.	O

Otros	O
polares	O
residuos	B-Chemical
en	O
la	O
vecindad	O
se	O
encuentran	O
Glu175	O
en	O
sedolisina	O
y	O
el	O
correspondiente	O
Asp169	O
en	O
kumamolisina	O
.	O

Sin	O
embargo	O
,	O
el	O
residuo	B-Chemical
encontrado	O
aquí	O
en	O
CLN2	B-Protein
es	O
Cys170	O
,	O
mucho	O
menos	O
polar	O
que	O
su	O
contrapartes	B-Sequence
.	O

Tampoco	O
existe	O
un	O
equivalente	O
a	O
la	O
interacción	O
polar	O
entre	O
Glu175	O
y	O
Glu171	O
en	O
la	O
sedolisina	O
,	O
ya	O
que	O
el	O
equivalente	O
de	O
este	O
último	O
residuo	B-Chemical
en	O
CLN2	B-Protein
es	O
Ser166	O
,	O
mucho	O
más	O
pequeño	O
y	O
apuntando	O
hacia	O
afuera	O
.	O

El	O
lado	O
del	O
bolsillo	O
S1	O
creado	O
por	O
la	O
cadena	O
lateral	O
muy	O
flexible	O
de	O
Arg179	O
en	O
sedolisina	O
contiene	O
solo	O
un	O
Ser174	O
mucho	O
más	O
pequeño	O
en	O
CLN2	B-Protein
,	O
y	O
por	O
lo	O
tanto	O
es	O
mucho	O
más	O
abierto	O
en	O
este	O
último	O
proteína	B-Chemical
.	O

Esta	O
parte	O
del	O
bolsillo	O
,	O
con	O
el	O
principal	O
cadena	B-Chemical
de	I-Chemical
la	I-Chemical
proteina	I-Chemical
bastante	O
distante	O
del	O
sustrato	O
,	O
de	O
hecho	O
no	O
está	O
bien	O
conservado	B-Sequence
en	O
estos	O
proteinas	B-Chemical
,	O
faltando	O
la	O
kumamolisina	O
por	O
completo	O
debido	O
a	O
una	O
supresión	B-Sequence
en	O
el	O
correspondiente	O
secuencia	B-Sequence
posición	O
.	O

En	O
resumen	O
,	O
el	O
bolsillo	O
S1	O
en	O
CLN2	B-Protein
tiene	O
menos	O
carácter	O
polar	O
que	O
el	O
bolsillo	O
equivalente	O
en	O
el	O
relacionado	O
proteinas	B-Chemical
carece	O
de	O
anclajes	O
polares	O
directos	O
para	O
cualquier	O
cadena	O
lateral	O
que	O
pueda	O
estar	O
presente	O
en	O
el	O
sustrato	O
.	O

El	O
bolsillo	O
S2	O
en	O
CLN2	B-Protein
también	O
es	O
bastante	O
abierto	O
y	O
accesible	O
para	O
solvente	B-Chemical
.	O

Lo	O
más	O
probable	O
es	O
que	O
sea	O
más	O
grande	O
que	O
los	O
bolsillos	O
equivalentes	O
en	O
sedolisina	O
o	O
kumamolisina	O
,	O
ya	O
que	O
estos	O
están	O
limitados	O
por	O
Trp81	O
en	O
el	O
primero	O
y	O
Trp129	O
en	O
el	O
segundo	O
(	O
estos	O
residuos	B-Chemical
se	O
originan	O
en	O
diferentes	O
partes	O
de	O
la	O
columna	O
vertebral	O
en	O
los	O
dos	O
enzimas	B-Sequence
y	O
no	O
están	O
relacionados	O
topológicamente	O
)	O
.	O

Tyr130	O
,	O
un	O
equivalente	O
de	O
este	O
último	O
residuo	B-Chemical
en	O
CLN2	B-Protein
,	O
es	O
poco	O
probable	O
que	O
entre	O
en	O
contacto	O
directo	O
con	O
el	O
P2	O
residuo	B-Chemical
del	O
sustrato	O
debido	O
a	O
su	O
mayor	O
distancia	O
(	O
casi	O
4	O
A	O
para	O
el	O
más	O
cercano	O
átomos	B-Chemical
)	O
.	O

Un	O
rompecabezas	O
restante	O
importante	O
es	O
que	O
el	O
predicho	B-Sequence
estructura	O
de	O
CLN2	B-Protein
no	O
muestra	O
limitaciones	O
claras	O
del	O
bolsillo	O
S3	O
que	O
puedan	O
explicar	O
la	O
actividad	O
tripeptidasa	O
de	O
este	O
enzima	B-Sequence
.	O

La	O
ubicación	O
de	O
la	O
cadena	O
lateral	O
P3	O
del	O
sustrato	O
es	O
ambigua	O
,	O
ya	O
que	O
podría	O
apuntar	O
en	O
cualquiera	O
de	O
las	O
dos	O
direcciones	O
por	O
intercambio	O
con	O
el	O
N-terminal	B-Sequence
amina	B-Chemical
.	O

El	O
único	O
cargado	O
negativamente	O
residuo	B-Chemical
de	O
CLN2	B-Protein
que	O
se	O
encuentra	O
en	O
esta	O
vecindad	O
es	O
Asp132	O
.	O

Aunque	O
en	O
el	O
modelo	O
actual	O
la	O
distancia	O
entre	O
sus	O
carboxilato	B-Chemical
y	O
el	O
nitrógeno	B-Chemical
de	O
El	O
N	B-Sequence
-	I-Sequence
terminal	I-Sequence
del	O
sustrato	O
modelado	O
es	O
de	O
aproximadamente	O
6	O
A	O
,	O
estos	O
dos	O
grupos	B-Chemical
podría	O
ser	O
llevado	O
a	O
hidrógeno	B-Chemical
#	O
¿NOMBRE	O
?	O
proteína	B-Chemical
.	O

Tal	O
cambio	O
conformacional	O
implicaría	O
la	O
ruptura	O
del	O
hidrógeno	B-Chemical
enlace	O
entre	O
Asp132	O
y	O
Ser139	O
.	O

Sin	O
embargo	O
,	O
no	O
es	O
probable	O
que	O
esta	O
última	O
interacción	O
sea	O
estructuralmente	O
crucial	O
ya	O
que	O
la	O
serina	B-Chemical
no	O
es	O
absolutamente	O
conservado	B-Sequence
en	O
todo	O
CLN2	B-Protein
#	O
¿NOMBRE	O
?	O
enzimas	B-Sequence
.	O

Ubicación	O
de	O
mutaciones	B-Sequence
implicado	O
en	O
la	O
enfermedad	O

Ubicación	O
de	O
mutaciones	B-Sequence
encontrado	O
a	O
través	O
de	O
un	O
genético	B-Sequence
encuesta	O
a	O
familias	O
de	O
clásico	O
tardío	O
-	O
infantil	O
neuronales	B-Cell
pacientes	O
con	O
lipofuscinosis	O
ceroide	O
se	O
ha	O
descrito	O
previamente	O
[	O
17	O
]	O
.	O

La	O
mayoría	O
de	O
tales	O
mutaciones	B-Sequence
dar	O
como	O
resultado	O
la	O
expresión	O
de	O
cualquiera	O
truncado	O
enzima	B-Sequence
o	O
en	O
forma	O
incorrecta	O
intrón	B-Sequence
-	O
exón	B-Sequence
empalmes	O

Sin	O
embargo	O
,	O
algunos	O
de	O
los	O
mutaciones	B-Sequence
conducir	O
a	O
soltero	O
aminoácidos	B-Chemical
sustituciones	B-Sequence
en	O
la	O
madurez	O
enzima	B-Sequence
.	O

Tal	O
mutaciones	B-Sequence
incluyen	O
I92N	O
,	O
E148K	O
,	O
C170R	O
y	O
C170Y	O
,	O
V190D	O
,	O
G194E	O
,	O
Q227H	O
,	O
R252H	O
,	O
A259E	O
y	O
S280L	O
(	O
Figura	O
5	O
)	O
.	O

Sólo	O
el	O
papel	O
de	O
este	O
último	O
mutación	B-Sequence
es	O
completamente	O
claro	O
,	O
ya	O
que	O
reemplaza	B-Sequence
el	O
catalítico	O
serina	B-Chemical
de	O
CLN2	B-Protein
con	O
una	O
cadena	O
lateral	O
que	O
no	O
puede	O
soportar	O
su	O
enzimático	B-Sequence
actividad	O
.	O

Ninguna	O
otra	O
residuos	B-Chemical
parecen	O
estar	O
ubicados	O
en	O
las	O
inmediaciones	O
del	O
sustrato	O
.	O

residuos	B-Chemical
Val190	O
,	O
Gly194	O
y	O
Arg252	O
son	O
muy	O
altamente	O
conservado	B-Sequence
no	O
solo	O
en	O
CLN2	B-Protein
pero	O
también	O
en	O
otras	O
sedolisinas	O
y	O
debe	O
jugar	O
un	O
papel	O
estructural	O
importante	O
.	O

Las	O
razones	O
por	O
las	O
que	O
el	O
resto	O
mutaciones	B-Sequence
llevaría	O
a	O
la	O
pérdida	O
de	O
enzimático	B-Sequence
actividad	O
son	O
mucho	O
menos	O
claros	O
,	O
pero	O
la	O
amplia	O
distribución	O
de	O
estos	O
mutaciones	B-Sequence
en	O
la	O
estructura	O
apoya	O
la	O
conclusión	O
de	O
que	O
cualquier	O
modificaciones	B-Sequence
para	O
CLN2	B-Protein
que	O
aboliría	O
o	O
perjudicaría	O
su	O
función	O
podría	O
conducir	O
al	O
desarrollo	O
de	O
la	O
enfermedad	O
.	O

Sustratos	O
y	O
inhibidores	B-Chemical
de	O
CLN2	B-Protein

Poco	O
se	O
sabe	O
en	O
este	O
momento	O
acerca	O
de	O
los	O
sustratos	O
biológicamente	O
relevantes	O
de	O
CLN2	B-Protein
.	O

Varios	O
defectos	O
que	O
incluyen	O
truncamientos	O
y	O
mutaciones	B-Sequence
de	I-Sequence
sitio	I-Sequence
único	I-Sequence
en	O
CLN2	B-Protein
se	O
han	O
encontrado	O
en	O
el	O
genes	B-Sequence
de	O
pacientes	O
que	O
presentan	O
síntomas	O
de	O
tardío	O
-	O
infantil	O
neuronales	B-Cell
lipofuscinosis	O
ceroide	O
[	O
17	O
]	O
.	O

Uno	O
de	O
los	O
síntomas	O
de	O
la	O
enfermedad	O
es	O
la	O
acumulación	O
de	O
un	O
material	O
autofluorescente	O
,	O
ceroide-lipofuscina	O
,	O
en	O
cuerpos	B-GENE
de	I-GENE
almacenamiento	I-GENE
lisosomales	I-GENE
en	O
varios	O
célula	B-Cell
tipos	O
,	O
principalmente	O
en	O
el	O
sistema	O
nervioso	O
.	O

Dado	O
que	O
un	O
componente	O
principal	O
de	O
tales	O
cuerpos	O
parece	O
estar	O
intacto	O
subunidad	B-Protein
c	I-Protein
de	I-Protein
la	I-Protein
ATP	I-Protein
sintasa	I-Protein
mitocondrial	I-Protein
,	O
esta	O
proteína	B-Chemical
ha	O
sido	O
implicado	O
como	O
un	O
objetivo	O
biológico	O
potencial	O
de	O
la	O
proteasa	O
.	O

Recientemente	O
se	O
ha	O
demostrado	O
que	O
CLN2	B-Protein
de	O
hecho	O
puede	O
degradar	O
esta	O
subunidad	O
en	O
su	O
terminal	B-Sequence
N	I-Sequence
[	O
18	O
]	O
,	O
pero	O
aún	O
falta	O
la	O
prueba	O
inequívoca	O
de	O
que	O
este	O
es	O
de	O
hecho	O
el	O
objetivo	O
más	O
importante	O
.	O

CLN2	B-Protein
es	O
capaz	O
de	O
procesar	O
un	O
número	O
de	O
diferentes	O
angiotensina	B-Chemical
#	O
¿NOMBRE	O
?	O
péptidos	B-Sequence
[	O
19	O
]	O
,	O
con	O
la	O
eficiencia	O
de	O
la	O
escisión	O
dependiendo	O
de	O
la	O
longitud	O
de	O
tal	O
péptidos	B-Sequence
.	O

El	O
más	O
eficientemente	O
procesado	O
péptido	B-Sequence
constaba	O
de	O
14	O
aminoácidos	B-Chemical
,	O
con	O
el	O
tripéptido	O
Áspid	B-Chemical
-	O
Argentina	B-Chemical
-	O
valle	B-Chemical
remoto	B-Sequence
de	O
su	O
terminal	B-Sequence
N	I-Sequence
.	O

el	O
modelo	O
de	O
CLN2	B-Protein
presentado	O
aquí	O
puede	O
acomodar	O
fácilmente	O
este	O
péptido	B-Sequence
en	O
el	O
lado	O
P	O
del	O
sustrato	O
-	O
sitio	B-Sequence
de	I-Sequence
unión	I-Sequence
,	O
aunque	O
el	O
modo	O
exacto	O
de	O
unión	O
de	O
la	O
porción	O
larga	O
P	O
'	O
del	O
sustrato	O
permanece	O
oscuro	O
.	O

La	O
observación	O
de	O
que	O
un	O
análogo	O
péptido	B-Sequence
acetilado	O
en	O
su	O
terminal	B-Sequence
N	I-Sequence
no	O
puede	O
ser	O
procesado	O
apoya	O
el	O
postulado	O
de	O
que	O
las	O
interacciones	O
de	O
los	O
N-terminal	B-Sequence
grupo	B-Chemical
amino	I-Chemical
con	O
la	O
cadena	O
lateral	O
de	O
Asp132	O
puede	O
ser	O
la	O
característica	O
más	O
importante	O
que	O
define	O
la	O
especificidad	O
de	O
tripeptidasa	O
de	O
CLN2	B-Protein
.	O

Se	O
pueden	O
procesar	O
en	O
serie	O
varios	O
tripéptidos	O
diferentes	O
a	O
partir	O
de	O
glucagón	B-Protein
,	O
con	O
su	O
secuencias	B-Sequence
variando	O
ampliamente	O
[	O
20	O
]	O
.	O

De	O
nuevo	O
,	O
sin	O
embargo	O
,	O
todos	O
estos	O
tripéptidos	O
pueden	O
acomodarse	O
fácilmente	O
en	O
el	O
sustrato	O
.	O
sitio	B-Sequence
de	I-Sequence
unión	I-Sequence
de	O
El	O
CLN2	B-Protein
modelo	O

Otros	O
sustratos	O
potencialmente	O
biológicamente	O
relevantes	O
incluyen	O
colecistoquinina	B-Protein
y	O
posiblemente	O
otros	O
neuropéptidos	O
[	O
21	O
]	O
.	O

Una	O
propiedad	O
intrigante	O
de	O
CLN2	B-Protein
es	O
su	O
capacidad	O
reportada	O
para	O
escindir	O
colágeno	B-Protein
#	O
¿NOMBRE	O
?	O
péptidos	B-Sequence
[	O
22	O
]	O
.	O

Los	O
tripéptidos	O
resultantes	O
de	O
tal	O
procesamiento	O
incluyen	O
gly	B-Chemical
-	O
Pro	B-Chemical
-	O
Reunió	B-Chemical
,	O
gly	B-Chemical
-	O
Pro	B-Chemical
-	O
Argentina	B-Chemical
,	O
y	O
gly	B-Chemical
-	O
Pro	B-Chemical
-	O
ala	B-Chemical
.	O

Recientemente	O
se	O
informó	O
que	O
la	O
kumamolisina	O
y	O
,	O
en	O
particular	O
,	O
un	O
proteína	B-Chemical
desde	O
Aliciclobacillus	B-Taxon
sendaiensis	I-Taxon
(	O
kumamolisina	O
-	O
Como	B-Taxon
)	O
puede	O
escindir	O
eficientemente	O
no	O
solo	O
colágeno	B-Protein
#	O
¿NOMBRE	O
?	O
péptidos	B-Sequence
,	O
pero	O
también	O
nativo	B-Sequence
colágeno	B-Protein
tipo	I-Protein
I	I-Protein
[	O
23	O
]	O
.	O

Con	O
el	O
sustrato	O
-	O
sitio	B-Sequence
de	I-Sequence
unión	I-Sequence
de	O
CLN2	B-Protein
más	O
parecido	O
al	O
de	O
la	O
kumamolisina	O
que	O
al	O
de	O
la	O
sedolisina	O
(	O
esta	O
última	O
enzima	B-Sequence
tiene	O
actividad	O
de	O
colagenasa	O
baja	O
,	O
si	O
es	O
que	O
tiene	O
alguna	O
)	O
,	O
el	O
potencial	O
colágeno	B-Protein
#	O
¿NOMBRE	O
?	O
CLN2	B-Protein
podría	O
justificar	O
una	O
mayor	O
investigación	O
.	O

Conclusiones	O

Dado	O
que	O
la	O
maquinaria	O
catalítica	O
de	O
CLN2	B-Protein
coincide	O
estrechamente	O
con	O
la	O
de	O
sedolisina	O
,	O
kumamolisina	O
y	O
otros	O
miembros	O
de	O
la	O
familia	O
de	O
serina	B-Chemical
-	O
carboxilo	B-Chemical
peptidasas	O
,	O
la	O
enzimático	B-Sequence
mecanismo	O
de	O
todos	O
estos	O
enzimas	B-Sequence
lo	O
más	O
probable	O
es	O
que	O
sea	O
lo	O
mismo	O
.	O

Diseño	O
de	O
inhibidores	B-Chemical
específico	O
para	O
CLN2	B-Protein
debe	O
incorporar	O
la	O
caracteristicas	B-Sequence
que	O
han	O
demostrado	O
ser	O
importantes	O
para	O
los	O
relacionados	O
enzimas	B-Sequence
,	O
como	O
la	O
colocación	O
de	O
un	O
aldehído	B-Chemical
funcionalidad	O
capaz	O
de	O
realizar	O
interacciones	O
covalentes	O
con	O
el	O
catalizador	O
serina	B-Chemical
o	O
la	O
utilización	O
de	O
clorometilo	O
cetona	B-Chemical
para	O
el	O
mismo	O
fin	O
.	O

Desde	O
los	O
pocos	O
inhibidores	B-Chemical
que	O
se	O
han	O
utilizado	O
con	O
éxito	O
en	O
los	O
estudios	O
de	O
sedolisinas	O
son	O
más	O
largos	O
que	O
los	O
tripéptidos	O
o	O
contienen	O
bloqueo	O
grupos	B-Chemical
en	O
su	O
N	B-Sequence
terminales	I-Sequence
,	O
nuevo	O
tripéptido	O
basado	O
inhibidores	B-Chemical
con	O
gratis	O
N	B-Sequence
terminales	I-Sequence
ahora	O
se	O
están	O
sintetizando	O
(	O
Oda	O
,	O
inédito	O
)	O
.	O

Será	O
necesario	O
probar	O
las	O
propiedades	O
de	O
unión	O
de	O
diferentes	O
sustratos	O
para	O
determinar	O
el	O
más	O
prometedor	O
.	O
secuencias	B-Sequence
peptídicas	I-Sequence
.	O

Análisis	O
del	O
modelo	O
de	O
CLN2	B-Protein
sugiere	O
que	O
el	O
tamaño	O
del	O
subsitio	O
S1	O
es	O
mucho	O
mayor	O
que	O
en	O
la	O
sedolisina	O
o	O
la	O
kumamolisina	O
y	O
,	O
por	O
lo	O
tanto	O
,	O
el	O
uso	O
de	O
un	O
P1	O
grande	O
grupo	B-Chemical
podría	O
estar	O
indicado	O
.	O

Por	O
supuesto	O
,	O
la	O
disponibilidad	O
de	O
una	O
estructura	O
cristalina	O
experimental	O
hará	O
que	O
el	O
diseño	O
de	O
inhibidores	B-Chemical
más	O
fácil	O
y	O
continuamos	O
nuestros	O
esfuerzos	O
para	O
cristalizar	O
CLN2	B-Protein
de	O
diferentes	O
fuentes	O
.	O

Métodos	O

Homología	B-Sequence
modelado	O

tridimensional	O
,	O
atómico	B-Chemical
#	O
¿NOMBRE	O
?	O
CLN2	B-Protein
se	O
desarrollaron	O
aprovechando	O
la	O
secuencia	B-Sequence
similitud	O
con	O
la	O
sedolisina	O
y	O
la	O
kumamolisina	O
proteinas	B-Chemical
(	O
r	O
.	O
m	O
.	O
s	O
.	O
desviación	O
de	O
1	O
.	O
0	O
A	O
para	O
273	O
pares	O
de	O
C	O
alfa	O
átomos	B-Chemical
en	O
el	O
núcleo	O
de	O
la	O
enzimas	B-Sequence
)	O
.	O

Actualmente	O
,	O
estos	O
dos	O
enzimas	B-Sequence
son	O
los	O
únicos	O
miembros	O
de	O
la	O
recién	O
definida	O
sedolisina	O
/	O
serina	B-Chemical
-	O
carboxilo	B-Chemical
familia	O
de	O
peptidasas	O
[	O
8	O
]	O
para	O
las	O
que	O
se	O
han	O
publicado	O
las	O
estructuras	O
cristalinas	O
[	O
5	O
-	O
7	O
]	O
.	O

El	O
actual	O
Proteína	B-Chemical
Banco	O
de	O
datos	O
[	O
24	O
]	O
:	O
)	O
Las	O
entradas	O
utilizadas	O
en	O
el	O
modelado	O
fueron	O
1GA4	O
.	O
pdb	O
y	O
1GT9	O
.	O
pdb	O
para	O
sedolisina	O
y	O
kumamolisina	O
,	O
respectivamente	O
.	O

El	O
primer	O
paso	O
fue	O
formar	O
una	O
red	O
global	O
,	O
múltiple	O
secuencia	B-Sequence
alineación	O
entre	O
todos	O
conocido	B-Sequence
miembros	O
de	O
la	O
familia	O
de	O
las	O
sedolisinas	O
.	O

Los	O
estudios	O
han	O
demostrado	O
que	O
incorporar	O
los	O
patrones	O
específicos	O
de	O
residuo	B-Chemical
de	I-Chemical
aminoácido	I-Chemical
#	O
¿NOMBRE	O
?	O
conservación	B-Sequence
entre	O
una	O
familia	O
de	O
homólogo	B-Sequence
proteinas	B-Chemical
proporciona	O
resultados	O
superiores	O
a	O
los	O
simples	O
,	O
por	O
pares	O
secuencia	B-Sequence
alineación	O
[	O
25	O
]	O
.	O

Secuencia	B-Sequence
Los	O
archivos	O
que	O
representan	O
las	O
diferentes	O
subfamilias	O
se	O
extrajeron	O
de	O
la	O
base	O
de	O
datos	O
GenBank	O
no	O
redundante	O
[	O
26	O
]	O
utilizando	O
sedolisina	O
,	O
kumamolisina	O
y	O
el	O
CLN2	B-Protein
humano	I-Protein
secuencias	B-Sequence
como	O
consultas	O
a	O
la	O
versión	O
web	O
del	O
programa	O
BLAST	O
[	O
27	O
]	O
:	O
.	O

múltiplo	O
inicial	O
secuencia	B-Sequence
las	O
alineaciones	O
se	O
formaron	O
con	O
el	O
programa	O
informático	O
ClustalX	O
[	O
28	O
]	O
.	O

Como	O
es	O
de	O
esperar	O
para	O
una	O
familia	O
de	O
proteinas	B-Chemical
,	O
muy	O
-	O
segmentos	B-Sequence
conservados	I-Sequence
se	O
encontraron	O
alineados	O
con	O
la	O
estructura	O
cristalina	O
-	O
núcleo	O
identificado	O
regiones	B-Sequence
de	O
la	O
sedolisina	O
y	O
la	O
kumamolisina	O
secuencias	B-Sequence
.	O

Posteriormente	O
,	O
el	O
secuencias	B-Sequence
se	O
dividieron	O
en	O
dos	O
grupos	O
:	O
los	O
más	O
cercanos	O
a	O
la	O
sedolisina	O
que	O
a	O
la	O
kumamolisina	O
y	O
viceversa	O
.	O

Luego	O
,	O
la	O
alineación	O
de	O
estos	O
dos	O
grupos	O
se	O
estableció	O
manualmente	O
mediante	O
la	O
alineación	O
estructural	O
observada	O
de	O
la	O
sedolisina	O
y	O
la	O
kumamolisina	O
.	O
proteinas	B-Chemical
.	O

Finalmente	O
,	O
se	O
requirió	O
algún	O
ajuste	O
adicional	O
para	O
corregir	O
los	O
pocos	O
lugares	O
donde	O
conservado	B-Sequence
residuos	B-Chemical
del	O
núcleo	O
regiones	B-Sequence
estaban	O
ligeramente	O
desalineados	O
entre	O
las	O
diferentes	O
subfamilias	O
de	O
secuencias	B-Sequence
.	O

el	O
modelo	O
de	O
CLN2	B-Protein
humano	I-Protein
fue	O
construido	O
utilizando	O
la	O
estructura	O
de	O
la	O
sedolisina	O
complejada	O
con	O
el	O
inhibidor	B-Chemical
pseudo-tyrostatin	O
[	O
5	O
,	O
6	O
]	O
como	O
plantilla	O
.	O

La	O
razón	O
de	O
esta	O
elección	O
es	O
que	O
,	O
aunque	O
diferentes	O
proteína	B-Chemical
los	O
modelos	O
eran	O
generalmente	O
comparables	O
,	O
el	O
elegido	O
inhibidor	B-Chemical
era	O
más	O
compatible	O
con	O
el	O
carácter	O
tripeptidasa	O
de	O
CLN2	B-Protein
.	O

con	O
la	O
correspondencia	O
de	O
residuos	B-Chemical
especificado	O
en	O
las	O
alineaciones	O
,	O
atómico	B-Chemical
las	O
coordenadas	O
fueron	O
transferidas	O
al	O
objetivo	O
secuencia	B-Sequence
por	O
una	O
variedad	O
de	O
métodos	O
,	O
incluyendo	O
el	O
homología	B-Sequence
módulos	O
de	O
modelado	O
de	O
los	O
paquetes	O
de	O
programas	O
informáticos	O
Look/GeneMine	O
[	O
29	O
]	O
y	O
DeepView	O
[	O
30	O
]	O
.	O

Para	O
el	O
núcleo	O
y	O
sitio	B-Sequence
activo	I-Sequence
de	I-Sequence
la	I-Sequence
proteina	I-Sequence
,	O
coordenadas	O
para	O
idéntico	O
residuos	B-Chemical
simplemente	O
fueron	O
transferidos	O
sin	O
cambios	O
;	O
Considerando	O
que	O
se	O
requería	O
un	O
cuidado	O
especial	O
para	O
colocar	O
las	O
cadenas	O
laterales	O
de	O
residuos	B-Chemical
diferente	O
a	O
la	O
plantilla	O
.	O

Esto	O
se	O
logró	O
primero	O
automáticamente	O
por	O
los	O
dos	O
paquetes	O
de	O
computadora	O
,	O
luego	O
se	O
ajustó	O
manualmente	O
en	O
el	O
Quanta	O
molecular	B-Chemical
paquete	O
de	O
modelado	O
(	O
Accelrys	O
,	O
Inc.	O
)	O
para	O
imitar	O
mejor	O
las	O
plantillas	O
y	O
optimizar	O
las	O
interacciones	O
con	O
los	O
alrededores	O
residuos	B-Chemical
.	O

Se	O
utilizó	O
un	O
enfoque	O
similar	O
de	O
dos	O
pasos	O
para	O
manifestar	O
el	O
inserciones	B-Sequence
y	O
eliminaciones	B-Sequence
en	O
la	O
variable	O
,	O
bucle	O
regiones	B-Sequence
de	O
El	O
proteína	B-Chemical
donde	O
fue	O
necesario	O
crear	O
una	O
nueva	O
columna	O
vertebral	O
así	O
como	O
coordenadas	O
de	O
cadenas	O
laterales	O
para	O
los	O
modelos	O
.	O

Cabe	O
señalar	O
que	O
,	O
por	O
razones	O
obvias	O
,	O
la	O
conformación	O
de	O
mal	O
regiones	B-Sequence
de	I-Sequence
bucle	I-Sequence
conservadas	I-Sequence
es	O
generalmente	O
el	O
aspecto	O
menos	O
preciso	O
de	O
un	O
homología	B-Sequence
modelo	O

Afortunadamente	O
,	O
estos	O
bucles	O
problemáticos	O
no	O
afectarán	O
significativamente	O
la	O
sitio	B-Sequence
activo	I-Sequence
del	O
modelo	O
,	O
ya	O
que	O
sólo	O
dos	O
de	O
ellos	O
inciden	O
en	O
el	O
Perímetro	B-Sequence
de	O
esto	O
altamente	O
región	B-Sequence
funcional	I-Sequence
conservada	I-Sequence
.	O

Refinamiento	O
y	O
análisis	O
del	O
modelo	O

El	O
modelo	O
se	O
terminó	O
realizando	O
la	O
minimización	O
de	O
energía	O
en	O
vacío	O
con	O
el	O
programa	O
informático	O
CHARMM	O
[	O
31	O
]	O
.	O

Esto	O
refinó	O
la	O
estructura	O
poniendo	O
la	O
geometría	O
covalente	O
y	O
las	O
interacciones	O
no	O
enlazadas	O
de	O
acuerdo	O
con	O
los	O
valores	O
calculados	O
y	O
observados	O
experimentalmente	O
.	O

Dichas	O
optimizaciones	O
incluyeron	O
el	O
ajuste	O
de	O
las	O
longitudes	O
de	O
los	O
enlaces	O
,	O
los	O
ángulos	O
de	O
3	O
puntos	O
y	O
los	O
ángulos	O
diédricos	O
de	O
4	O
puntos	O
,	O
así	O
como	O
la	O
eliminación	O
atómico	B-Chemical
superposición	O
y	O
formación	O
sal	B-Chemical
#	O
¿NOMBRE	O
?	O
hidrógeno	B-Chemical
bonos	O

Dado	O
que	O
actualmente	O
las	O
funciones	O
de	O
energía	O
potencial	O
utilizadas	O
para	O
describir	O
la	O
atómico	B-Chemical
-	O
los	O
modelos	O
a	O
escala	O
no	O
son	O
lo	O
suficientemente	O
completos	O
y	O
precisos	O
,	O
la	O
energía	O
final	O
del	O
modelo	O
no	O
se	O
utilizó	O
como	O
indicador	O
de	O
la	O
calidad	O
realista	O
de	O
la	O
estructura	O
.	O

La	O
calidad	O
final	O
de	O
la	O
estructura	O
se	O
analizó	O
con	O
el	O
programa	O
informático	O
PROCHECK	O
[	O
32	O
]	O
.	O

La	O
estructura	O
se	O
depositó	O
en	O
el	O
PDB	O
con	O
el	O
código	O
de	O
acceso	O
1R60	O
.	O

Contribuciones	O
de	O
los	O
autores	O

AW	O
inició	O
este	O
proyecto	O
y	O
analizó	O
la	O
genómico	B-Sequence
distribución	O
de	O
esta	O
familia	O
de	O
enzimas	B-Sequence
.	O

SRD	O
aportó	O
el	O
modelado	O
de	O
la	O
estructura	O
tridimensional	O
de	O
CLN2	B-Protein
.	O

ML	O
analizó	O
el	O
modelo	O
y	O
lo	O
comparó	O
con	O
las	O
estructuras	O
cristalinas	O
de	O
las	O
sedolisinas	O
.	O

HO	O
,	O
KO	O
y	O
BMD	O
contribuyeron	O
con	O
su	O
experiencia	O
adquirida	O
en	O
estudios	O
de	O
serina	B-Chemical
-	O
carboxilo	B-Chemical
peptidasas	O
y	O
el	O
diseño	O
de	O
sus	O
inhibidores	B-Chemical
,	O
dirigido	O
al	O
análisis	O
de	O
sustrato	O
-	O
enzima	B-Sequence
interacciones	O
y	O
enzima	B-Sequence
especificidad	O

Todos	O
los	O
autores	O
leyeron	O
y	O
aprobaron	O
el	O
manuscrito	O
final	O
.	O

Agradecimientos	O

Discusiones	O
extensas	O
con	O
el	O
Dr	O
.	O
UN	O
.	O

Barrett	O
(	O
Wellcome	O
Trust	O
Sanger	O
Institute	O
,	O
Hinxton	O
,	O
Reino	O
Unido	O
)	O
son	O
reconocidos	O
con	O
gratitud	O
.	O

Los	O
esfuerzos	O
de	O
modelado	O
fueron	O
facilitados	O
por	O
el	O
Dr	O
.	O
Robert	O
Jernigan	O
(	O
Universidad	O
Estatal	O
de	O
Iowa	O
)	O
.	O

Este	O
trabajo	O
fue	O
apoyado	O
en	O
parte	O
por	O
una	O
subvención	O
en	O
ayuda	O
para	O
la	O
investigación	O
científica	O
(	O
B	O
)	O
,	O
15380072	O
,	O
del	O
Ministerio	O
de	O
Educación	O
,	O
Cultura	O
,	O
Deportes	O
,	O
Ciencia	O
y	O
Tecnología	O
de	O
Japón	O
(	O
a	O
K	O
.	O
O	O
.	O
)	O
;	O
por	O
NIH	O
otorga	O
DK18865	O
y	O
AI39211	O
(	O
a	O
B	O
.	O
M	O
.	O
D	O
.	O
)	O
;	O
y	O
en	O
parte	O
con	O
fondos	O
Federales	O
del	O
Instituto	O
Nacional	O
del	O
Cáncer	O
,	O
Institutos	O
Nacionales	O
de	O
Salud	O
,	O
bajo	O
el	O
contrato	O
No	O
.	O

NO1-CO-12400	O
.	O

El	O
contenido	O
de	O
esta	O
publicación	O
no	O
refleja	O
necesariamente	O
los	O
puntos	O
de	O
vista	O
o	O
las	O
políticas	O
del	O
Departamento	O
de	O
Salud	O
y	O
Humano	B-Taxon
Servicios	O
,	O
ni	O
la	O
mención	O
de	O
nombres	O
comerciales	O
,	O
productos	O
comerciales	O
u	O
organizaciones	O
implica	O
respaldo	O
por	O
parte	O
de	O
los	O
EE	O
.	O

S	O
.	O

Gobierno	O
.	O

los	O
Aguardiente	B-Protein
de	I-Protein
pez	I-Protein
cebra	I-Protein
Gene	B-Sequence
codifica	O
Factor	B-Protein
intermediario	I-Protein
transcripcional	I-Protein
1	I-Protein
gamma	I-Protein
,	O
un	O
regulador	O
esencial	O
de	O
la	O
hematopoyesis	O

Resumen	O

La	O
hematopoyesis	O
está	O
precisamente	O
orquestada	O
por	O
el	O
linaje	O
:	O
ADN	B-Sequence
#	O
¿NOMBRE	O
?	O
proteinas	B-Chemical
que	O
regulan	O
la	O
transcripción	O
en	O
conjunto	O
con	O
coactivadores	O
y	O
correpresores	O
.	O

Mutaciones	B-Sequence
en	O
el	O
luz	B-Protein
de	I-Protein
la	I-Protein
luna	I-Protein
de	I-Protein
pez	I-Protein
cebra	I-Protein
(	O
Lun	B-Protein
)	O
gene	B-Sequence
interrumpir	O
específicamente	O
tanto	O
la	O
hematopoyesis	O
embrionaria	O
como	O
la	O
adulta	O
,	O
lo	O
que	O
resulta	O
en	O
graves	O
glóbulo	B-Cell
rojo	I-Cell
aplasia	O

informamos	O
que	O
Lun	B-Protein
codifica	O
el	O
pez	B-Taxon
cebra	I-Taxon
ortólogo	B-Sequence
de	O
mamífero	B-Taxon
intermediario	B-Protein
transcripcional	I-Protein
factor	I-Protein
1	I-Protein
gamma	I-Protein
(	O
gama	B-Protein
TIF1	I-Protein
)	O
(	O
o	O
TRIM33	B-Protein
)	O
,	O
miembro	O
de	O
la	O
familia	O
TIF1	O
de	O
coactivadores	O
y	O
correpresores	O
.	O

Durante	O
el	O
desarrollo	O
,	O
células	B-Cell
progenitoras	I-Cell
hematopoyéticas	I-Cell
en	O
Lun	B-Protein
mutantes	B-Sequence
no	O
expresan	O
niveles	O
normales	O
de	O
factores	O
de	O
transcripción	O
hematopoyéticos	O
,	O
incluidos	O
gata1	B-Protein
y	O
sufren	O
apoptosis	O
.	O

tres	O
diferentes	O
Lun	B-Protein
alelos	B-Sequence
mutantes	I-Sequence
cada	O
codificar	O
prematura	O
codones	B-Sequence
de	I-Sequence
parada	I-Sequence
y	O
expresión	O
forzada	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
gama	B-Protein
tif1	I-Protein
ARNm	B-Chemical
rescata	O
la	O
hematopoyesis	O
embrionaria	O
en	O
homocigotos	O
Lun	B-Protein
mutantes	B-Sequence
.	O

Sorprendentemente	O
,	O
un	O
alto	O
nivel	O
de	O
cigóticos	O
gama	B-Protein
tif1	I-Protein
ARNm	B-Chemical
expresión	O
delinea	O
el	O
mesodermo	O
ventral	O
durante	O
célula	B-Cell
madre	I-Cell
hematopoyética	I-Cell
y	O
la	O
formación	O
de	O
progenitores	O
antes	O
de	O
gata1	B-Protein
expresión	O
.	O

Los	O
estudios	O
de	O
trasplante	O
revelan	O
que	O
gama	B-Protein
tif1	I-Protein
funciones	O
en	O
un	O
célula	B-Cell
#	O
¿NOMBRE	O
?	O
eritroide	B-Cell
precursores	O

Estudios	O
en	O
murino	B-Taxon
célula	B-Cell
eritroide	I-Cell
las	O
líneas	O
demuestran	O
que	O
gama	B-Protein
tif1	I-Protein
proteína	B-Chemical
está	O
localizado	O
dentro	O
de	O
la	O
novela	O
nuclear	B-GENE
focos	O
,	O
y	O
la	O
expresión	O
disminuye	O
durante	O
célula	B-Cell
eritroide	I-Cell
maduración	O

Nuestros	O
resultados	O
establecen	O
un	O
papel	O
importante	O
para	O
este	O
factor	O
intermediario	O
transcripcional	O
en	O
la	O
diferenciación	O
de	O
células	B-Cell
hematopoyéticas	I-Cell
en	O
vertebrados	B-Taxon
.	O

Introducción	O

La	O
hematopoyesis	O
implica	O
los	O
procesos	O
coordinados	O
de	O
célula	B-Cell
proliferación	O
y	O
diferenciación	O
de	O
un	O
número	O
relativamente	O
pequeño	O
de	O
progenitores	O
células	B-Cell
en	O
miles	O
de	O
millones	O
de	O
circulante	O
glóbulos	B-Cell
rojos	I-Cell
y	I-Cell
blancos	I-Cell
(	O
Thisse	O
y	O
Zon	O
2002	O
)	O
.	O

Hematopoyesis	O
en	O
vertebrados	B-Taxon
,	O
desde	O
pez	B-Taxon
cebra	I-Taxon
para	O
humanos	B-Taxon
,	O
es	O
un	O
programa	O
conservado	O
evolutivamente	O
que	O
produce	O
dos	O
ondas	O
de	O
células	B-Cell
madre	I-Cell
o	I-Cell
progenitoras	I-Cell
que	O
difieren	O
tanto	O
en	O
sus	O
orígenes	O
embrionarios	O
como	O
en	O
los	O
linajes	O
de	O
células	B-Cell
de	I-Cell
sangre	I-Cell
producido	O
(	O
Palis	O
y	O
Yoder	O
2001	O
;	O
Orkin	O
y	O
Zon	O
2002	O
;	O
Galloway	O
y	O
Zon	O
2003	O
)	O
.	O

La	O
primera	O
ola	O
de	O
hematopoyesis	O
,	O
o	O
primitiva	O
,	O
se	O
origina	O
en	O
el	O
mesodermo	O
ventral	O
y	O
da	O
lugar	O
al	O
progenitor	O
.	O
células	B-Cell
que	O
se	O
diferencian	O
en	O
islas	O
de	O
sangre	O
embrionaria	O
.	O

La	O
onda	O
primitiva	O
de	O
hematopoyesis	O
produce	O
un	O
estallido	O
de	O
embriones	O
eritrocitos	B-Cell
y	O
macrófagos	B-Cell
.	O

La	O
segunda	O
,	O
o	O
definitiva	O
,	O
ola	O
de	O
hematopoyesis	O
surge	O
de	O
la	O
auto-renovación	O
Células	B-Cell
madre	I-Cell
que	O
se	O
desarrollan	O
principalmente	O
en	O
la	O
región	O
intraembrionaria	O
de	O
la	O
aorta-gónada-mesonefros	O
.	O

estos	O
definitivos	O
células	B-Cell
madre	I-Cell
hematopoyéticas	I-Cell
sembrar	O
los	O
espacios	O
medulares	O
que	O
se	O
desarrollan	O
más	O
tarde	O
,	O
para	O
producir	O
todos	O
los	O
linajes	O
de	O
adultos	O
células	B-Cell
de	I-Cell
sangre	I-Cell
,	O
incluida	O
la	O
definitiva	O
eritrocitos	B-Cell
,	O
células	B-Cell
mieloides	I-Cell
,	O
y	O
linfocitos	B-Cell
.	O

hemos	O
emprendido	O
un	O
genético	B-Sequence
enfoque	O
para	O
caracterizar	O
genes	B-Sequence
que	O
controlan	O
la	O
hematopoyesis	O
mediante	O
el	O
pez	B-Taxon
cebra	I-Taxon
como	O
sistema	O
modelo	O
(	O
Thisse	O
y	O
Zon	O
2002	O
)	O
.	O

Como	O
parte	O
de	O
un	O
avance	O
a	O
gran	O
escala	O
genético	B-Sequence
pantalla	O
,	O
identificamos	O
previamente	O
sin	O
sangre	O
pez	B-Taxon
cebra	I-Taxon
mutantes	B-Sequence
que	O
no	O
logró	O
expresar	O
la	O
eritroide	B-Cell
factor	O
de	O
transcripcion	O
gata1	B-Protein
normalmente	O
en	O
precursores	O
hematopoyéticos	O
embrionarios	O
(	O
Ransom	O
et	O
al	O
.	O
1996	O
)	O
.	O

Nombramos	O
a	O
uno	O
de	O
estos	O
pez	B-Taxon
cebra	I-Taxon
genes	B-Sequence
luz	B-Protein
de	I-Protein
la	I-Protein
luna	I-Protein
(	O
Lun	B-Protein
)	O
,	O
y	O
otro	O
grupo	O
nombró	O
un	O
no	O
complementario	O
alelo	B-Sequence
vampiro	B-Protein
(	O
Weinstein	O
y	O
col.	O
1996	O
)	O
.	O

Aquí	O
hemos	O
determinado	O
que	O
mutaciones	B-Sequence
en	O
el	O
Lun	B-Protein
gene	B-Sequence
causar	O
una	O
interrupción	O
en	O
la	O
hematopoyesis	O
tanto	O
del	O
embrión	O
primitivo	O
como	O
del	O
adulto	O
definitivo	O
,	O
lo	O
que	O
resulta	O
en	O
una	O
pérdida	O
severa	O
de	O
células	B-Cell
eritroides	I-Cell
.	O

Células	B-Cell
progenitoras	I-Cell
eritroides	I-Cell
en	O
Lun	B-Protein
mutantes	B-Sequence
inicialmente	O
están	O
presentes	O
,	O
pero	O
no	O
expresan	O
niveles	O
normales	O
de	O
factores	O
de	O
transcripción	O
hematopoyéticos	O
y	O
sufren	O
apoptosis	O
.	O

posicional	B-Sequence
la	O
clonación	O
identifica	O
el	O
Lun	B-Protein
gene	B-Sequence
como	O
el	O
pez	B-Taxon
cebra	I-Taxon
ortólogo	B-Sequence
de	O
mamífero	B-Taxon
intermediario	B-Protein
transcripcional	I-Protein
factor	I-Protein
1	I-Protein
gamma	I-Protein
(	O
gama	B-Protein
TIF1	I-Protein
)	O
,	O
un	O
miembro	O
de	O
la	O
familia	O
TIF1	O
de	O
coactivadores	O
y	O
correpresores	O
transcripcionales	O
(	O
Le	O
Douarin	O
et	O
al	O
.	O
1995	O
;	O
Friedman	O
et	O
al	O
.	O
1996	O
;	O
Kim	O
et	O
al	O
.	O
1996	O
;	O
Venturini	O
et	O
al	O
.	O
1999	O
;	O
Peng	O
et	O
al	O
.	O
2002	O
)	O
.	O

Los	O
tres	O
miembros	O
de	O
la	O
vertebrado	B-Taxon
La	O
familia	O
TIF1	O
(	O
alfa	O
,	O
beta	O
y	O
gamma	O
)	O
son	O
grandes	O
nuclear	B-GENE
proteinas	B-Chemical
que	O
cada	O
uno	O
contiene	O
un	O
N	B-Sequence
-	I-Sequence
terminal	I-Sequence
RBCC	I-Sequence
o	I-Sequence
dominio	I-Sequence
TRIM	I-Sequence
(	O
Reymond	O
et	O
al	O
.	O
2001	O
)	O
compuesto	O
por	O
un	O
dedo	O
ANULAR	O
,	O
dos	O
B	B-Sequence
-	I-Sequence
cajas	I-Sequence
,	O
y	O
un	O
enrollado	B-Sequence
-	I-Sequence
dominio	I-Sequence
de	I-Sequence
la	I-Sequence
bobina	I-Sequence
.	O

Los	O
miembros	O
de	O
la	O
familia	O
TIF1	O
también	O
contienen	O
un	O
C-terminal	B-Sequence
planta	B-Taxon
homeodominio	O
dedo	O
y	O
bromodominio	O
que	O
son	O
característicos	O
de	O
cromatina	B-GENE
factores	O
de	O
remodelación	O
.	O

TIF1	B-Protein
alfa	I-Protein
se	O
ha	O
demostrado	O
que	O
se	O
asocia	O
con	O
una	O
variedad	O
de	O
ligandos	O
unidos	O
nuclear	B-GENE
hormona	B-Chemical
receptores	O
(	O
Le	O
Douarin	O
et	O
al	O
.	O
1995	O
)	O
y	O
funcionan	O
como	O
un	O
coactivador	O
para	O
ácido	B-Chemical
retinoico	I-Chemical
receptores	O
(	O
Zhong	O
et	O
al	O
.	O
1999	O
)	O
.	O

TIF1	B-Protein
beta	I-Protein
se	O
ha	O
demostrado	O
que	O
actúa	O
como	O
un	O
correpresor	O
de	O
la	O
gran	O
familia	O
de	O
cajas	O
asociadas	O
a	O
Kruppel	O
(	O
KRAB	O
)	O
dominio	B-Sequence
zinc	B-Chemical
-	O
factores	O
de	O
transcripción	O
de	O
dedo	O
(	O
Friedman	O
et	O
al	O
.	O
1996	O
;	O
Abrink	O
et	O
al	O
.	O
2001	O
)	O
.	O

A	O
diferencia	O
de	O
,	O
gama	B-Protein
TIF1	I-Protein
no	O
se	O
asocia	O
directamente	O
con	O
ninguno	O
nuclear	B-GENE
receptores	O
o	O
KRAB	O
dominios	B-Sequence
que	O
se	O
unen	O
a	O
los	O
otros	O
miembros	O
de	O
la	O
familia	O
TIF1	O
(	O
Venturini	O
et	O
al	O
.	O
1999	O
;	O
Abrink	O
et	O
al	O
.	O
2001	O
)	O
.	O

Los	O
estudios	O
bioquímicos	O
también	O
demuestran	O
que	O
gama	B-Protein
TIF1	I-Protein
forma	O
homo	O
-	O
oligómeros	O
y	O
hetero	O
-	O
oligómeros	O
con	O
TIF1	B-Protein
alfa	I-Protein
pero	O
no	O
con	O
TIF1	B-Protein
beta	I-Protein
(	O
Peng	O
et	O
al	O
.	O
2002	O
)	O
.	O

los	O
murino	B-Taxon
tif1	B-Protein
alfa	I-Protein
y	O
gama	B-Protein
tif1	I-Protein
genes	B-Sequence
aún	O
no	O
han	O
sido	O
sometidos	O
gene	B-Sequence
experimentos	O
de	O
focalización	O
,	O
mientras	O
que	O
el	O
análisis	O
de	O
ratón	B-Taxon
mutantes	B-Sequence
demuestra	O
que	O
beta	B-Protein
tif1	I-Protein
se	O
requiere	O
para	O
la	O
embriogénesis	O
posterior	O
a	O
la	O
implantación	O
y	O
la	O
inducción	O
del	O
mesodermo	O
en	O
particular	O
(	O
Cammas	O
et	O
al	O
.	O
2000	O
)	O
.	O

En	O
conjunto	O
,	O
estos	O
estudios	O
sugieren	O
que	O
una	O
función	O
importante	O
de	O
los	O
miembros	O
de	O
la	O
familia	O
TIF1	O
es	O
vincular	O
ADN	B-Sequence
#	O
¿NOMBRE	O
?	O
proteinas	B-Chemical
con	O
otros	O
coactivadores	O
o	O
correpresores	O
durante	O
el	O
desarrollo	O
.	O

Nuestros	O
estudios	O
establecen	O
que	O
gama	B-Protein
tif1	I-Protein
funciona	O
como	O
un	O
regulador	O
esencial	O
de	O
la	O
hematopoyesis	O
embrionaria	O
y	O
adulta	O
en	O
vertebrados	B-Taxon
.	O

Célula	B-Cell
estudios	O
de	O
trasplante	O
demuestran	O
que	O
gama	B-Protein
tif1	I-Protein
actúa	O
en	O
un	O
célula	B-Cell
#	O
¿NOMBRE	O
?	O

los	O
gama	B-Protein
tif1	I-Protein
gene	B-Sequence
se	O
expresa	O
específicamente	O
en	O
el	O
mesodermo	O
ventral	O
y	O
progenitores	B-Cell
hematopoyéticos	I-Cell
,	O
luego	O
regulado	O
a	O
la	O
baja	O
como	O
eritroide	B-Cell
se	O
produce	O
la	O
maduración	O
.	O

gama	B-Protein
tif1	I-Protein
proteína	B-Chemical
se	O
localiza	O
en	O
una	O
nueva	O
clase	O
de	O
cuerpos	B-GENE
nucleares	I-GENE
en	O
ambas	O
primarias	O
ratón	B-Taxon
embrión	O
fibroblastos	B-Cell
y	O
eritroleucemia	O
célula	B-Cell
líneas	O
.	O

En	O
conjunto	O
,	O
nuestros	O
estudios	O
demuestran	O
que	O
gama	B-Protein
tif1	I-Protein
se	O
requiere	O
para	O
la	O
normalidad	O
célula	B-Cell
eritroide	I-Cell
desarrollo	O
y	O
supervivencia	O
.	O

Resultados	O

los	O
Mon	B-Protein
pez	I-Protein
cebra	I-Protein
Gene	B-Sequence
Es	O
esencial	O
tanto	O
para	O
la	O
eritropoyesis	O
primitiva	O
como	O
para	O
la	O
definitiva	O

Para	O
determinar	O
cuándo	O
el	O
Lun	B-Protein
gene	B-Sequence
se	O
requiere	O
en	O
el	O
desarrollo	O
,	O
primero	O
examinamos	O
hematopoyético	O
gene	B-Sequence
expresión	O
y	O
apoptosis	O
en	O
pez	B-Taxon
cebra	I-Taxon
homocigoto	O
Lun	B-Protein
mutante	B-Sequence
embriones	O

Durante	O
la	O
embriogénesis	O
,	O
homocigotos	O
pez	B-Protein
cebra	I-Protein
mon	I-Protein
mutantes	B-Sequence
No	O
tienen	O
las	B-Cell
células	I-Cell
rojas	I-Cell
de	I-Cell
la	I-Cell
sangre	I-Cell
(	O
glóbulos	B-Cell
rojos	I-Cell
)	O
visible	O
en	O
circulación	O
(	O
Ransom	O
et	O
al	O
.	O
1996	O
;	O
Weinstein	O
et	O
al	O
.	O
1996	O
)	O
.	O

los	O
Lun	B-Protein
mutantes	B-Sequence
iniciar	O
la	O
expresión	O
de	O
gata1	B-Protein
en	O
células	B-Cell
hematopoyéticas	I-Cell
alrededor	O
de	O
la	O
etapa	O
de	O
cinco	O
somitas	O
,	O
similar	O
a	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
(	O
datos	O
no	O
mostrados	O
)	O
;	O
sin	O
embargo	O
,	O
según	O
la	O
tinción	O
de	O
TUNEL	O
,	O
la	O
diferenciación	O
células	B-Cell
eritroides	I-Cell
someterse	O
a	O
programa	O
célula	B-Cell
muerte	O
desde	O
el	O
estadio	O
de	O
12	O
somitas	O
hasta	O
las	O
22	O
h	O
postfertilización	O
(	O
hpf	O
)	O
(	O
Figura	O
1A	O
y	O
1B	O
,	O
flechas	O
)	O
.	O

A	O
las	O
12	O
somitas	O
,	O
gata1	B-Protein
la	O
expresión	O
se	O
reduce	O
sólo	O
ligeramente	O
.	O

A	O
las	O
18	O
-	O
22	O
hpf	O
,	O
marcadores	O
hematopoyéticos	O
específicos	O
como	O
gata1	B-Protein
,	O
scl	B-Protein
,	O
gata2	B-Protein
,	O
y	O
ícaros	B-Protein
no	O
se	O
detectan	O
en	O
la	O
isla	O
de	O
sangre	O
embrionaria	O
(	O
Figura	O
1A	O
y	O
1B	O
;	O
datos	O
no	O
publicados	O
)	O
.	O

los	O
células	B-Cell
hematopoyéticas	I-Cell
por	O
lo	O
tanto	O
,	O
se	O
especifican	O
correctamente	O
al	O
principio	O
del	O
desarrollo	O
de	O
Lun	B-Protein
mutante	B-Sequence
embriones	O
,	O
pero	O
estos	O
precursores	O
sufren	O
célula	B-Cell
muerte	O
.	O

Basado	O
en	O
la	O
expresión	O
de	O
c	B-Protein
-	I-Protein
mib	I-Protein
y	O
trapo1	B-Protein
(	O
Figura	O
1B	O
,	O
flechas	O
)	O
,	O
Lun	B-Protein
mutantes	B-Sequence
tener	O
normalidad	O
mieloide	B-Cell
y	O
desarrollo	O
linfoide	O
,	O
respectivamente	O
.	O

Además	O
del	O
déficit	O
de	O
glóbulos	B-Cell
rojos	I-Cell
en	O
Lun	B-Protein
mutantes	B-Sequence
,	O
hay	O
una	O
pérdida	O
importante	O
del	O
mesénquima	O
del	O
pliegue	O
de	O
la	O
aleta	O
y	O
la	O
cola	O
(	O
Ransom	O
et	O
al	O
.	O
1996	O
)	O
.	O

tinción	O
TUNEL	O
de	O
Lun	B-Protein
mutantes	B-Sequence
demuestra	O
una	O
extensa	O
apoptosis	O
de	O
células	B-Cell
mesenquimales	I-Cell
en	O
las	O
regiones	O
del	O
tronco	O
y	O
la	O
cola	O
(	O
Figura	O
1A	O
y	O
1B	O
,	O
flechas	O
)	O
.	O

los	O
Lun	B-Protein
gene	B-Sequence
por	O
lo	O
tanto	O
,	O
se	O
requiere	O
para	O
el	O
desarrollo	O
normal	O
y	O
la	O
supervivencia	O
de	O
ambos	O
comprometidos	O
células	B-Cell
progenitoras	I-Cell
eritroides	I-Cell
y	O
posteriores	O
células	B-Cell
mesenquimales	I-Cell
.	O

Luego	O
examinamos	O
la	O
hematopoyesis	O
definitiva	O
en	O
adultos	O
homocigotos	O
sobrevivientes	O
raros	O
pez	B-Protein
cebra	I-Protein
mon	I-Protein
mutantes	B-Sequence
.	O

Mutaciones	B-Sequence
en	O
Lun	B-Protein
son	O
generalmente	O
letales	O
a	O
los	O
10	O
a	O
14	O
días	O
de	O
desarrollo	O
(	O
Ransom	O
et	O
al	O
.	O
1996	O
)	O
,	O
aunque	O
es	O
raro	O
Lun	B-Protein
homocigoto	O
mutantes	B-Sequence
(	O
aproximadamente	O
1	O
de	O
cada	O
500	O
embriones	O
sin	O
sangre	O
)	O
de	O
todos	O
los	O
probados	O
alelos	B-Sequence
sobrevivir	O
hasta	O
la	O
edad	O
adulta	O
.	O

Adulto	O
Lun	B-Protein
mutantes	B-Sequence
muestran	O
hipertrofia	O
cardíaca	O
,	O
presumiblemente	O
debido	O
a	O
la	O
anemia	O
severa	O
que	O
conduce	O
a	O
un	O
estado	O
de	O
alto	O
gasto	O
(	O
Figura	O
2	O
)	O
.	O

En	O
tipo	B-Sequence
salvaje	I-Sequence
pez	B-Taxon
cebra	I-Taxon
,	O
el	O
sitio	O
adulto	O
de	O
hematopoyesis	O
es	O
el	O
riñón	O
(	O
Al	O
Adhami	O
y	O
Kunz	O
1977	O
)	O
,	O
que	O
contiene	O
eritroide	B-Cell
,	O
linfoide	O
y	O
mieloide	B-Cell
poblaciones	O
en	O
varias	O
etapas	O
de	O
diferenciación	O
(	O
Bennett	O
et	O
al	O
.	O
2001	O
)	O
.	O

En	O
Lun	B-Protein
homocigoto	O
mutantes	B-Sequence
,	O
hay	O
un	O
bloqueo	O
severo	O
en	O
la	O
maduración	O
en	O
el	O
proeritroblasto	B-Cell
(	O
Figura	O
2	O
)	O
,	O
mientras	O
que	O
la	O
diferenciación	O
de	O
células	B-Cell
mieloides	I-Cell
es	O
normal	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Esto	O
demuestra	O
que	O
el	O
Lun	B-Protein
gene	B-Sequence
El	O
producto	O
actúa	O
durante	O
la	O
eritropoyesis	O
tanto	O
primitiva	O
como	O
definitiva	O
.	O

posicional	B-Sequence
La	O
clonación	O
identifica	O
Lun	B-Protein
como	O
el	O
pez	B-Taxon
cebra	I-Taxon
Ortólogo	B-Sequence
de	O
Mamífero	B-Taxon
gama	B-Protein
TIF1	I-Protein

Identificamos	O
el	O
Lun	B-Protein
gene	B-Sequence
por	O
posicional	B-Sequence
clonación	O
usando	O
un	O
panel	O
de	O
2	O
,	O
200	O
diploides	O
mutantes	B-Sequence
recolectado	O
de	O
T	O
u	O
bingen	O
background	O
(	O
TU	O
)	O
/	O
padres	O
híbridos	O
de	O
la	O
cepa	O
WIK	O
que	O
llevan	O
el	O
montg234	O
alelo	B-Sequence
.	O

los	O
Lun	B-Protein
gen	B-Sequence
mutante	I-Sequence
se	O
colocó	O
en	O
Cromosoma	B-GENE
8	O
entre	O
marcadores	B-Sequence
de	I-Sequence
microsatélites	I-Sequence
z987	O
y	O
z11001	O
(	O
Figura	O
3A	O
)	O
(	O
Knapik	O
et	O
al	O
.	O
1998	O
)	O
.	O

Para	O
posicional	B-Sequence
fines	O
de	O
clonación	O
,	O
más	O
de	O
12	O
000	O
polimórfico	B-Sequence
Los	O
marcadores	O
se	O
examinaron	O
utilizando	O
amplificado	O
fragmento	B-Sequence
longitud	O
polimorfismo	B-Sequence
(	O
AFLP	O
)	O
(	O
Ransom	O
y	O
Zon	O
1999	O
)	O
,	O
y	O
36	O
marcadores	O
dentro	O
del	O
intervalo	B-Sequence
estaban	O
aislados	O
.	O

Se	O
encontró	O
que	O
uno	O
de	O
estos	O
,	O
MA3	O
,	O
era	O
0	O
.	O
3cm	O
de	O
la	O
gene	B-Sequence
(	O
Figura	O
3A	O
)	O
y	O
se	O
utilizó	O
como	O
punto	O
de	O
partida	O
punto	B-Sequence
de	O
un	O
cromosómico	B-GENE
andar	O
.	O

Un	O
crítico	O
Clon	B-Sequence
cromosómico	I-Sequence
artificial	I-Sequence
bacteriano	I-Sequence
P1	I-Sequence
(	O
PAC	B-Sequence
)	O
,	O
107N19	O
,	O
que	O
abarcó	O
el	O
intervalo	B-Sequence
genético	I-Sequence
.	O

dos	O
simples	O
secuencia	B-Sequence
conformación	O
polimorfismo	B-Sequence
(	O
SSCP	O
)	O
marcadores	O
encontrados	O
en	O
este	O
clon	B-Sequence
de	I-Sequence
PAC	I-Sequence
flanquear	O
a	O
la	O
crítica	O
intervalo	B-Sequence
genético	I-Sequence
.	O

El	O
marcador	O
80M12	O
-	O
T7	O
mapea	O
dos	O
recombinantes	O
de	O
4	O
400	O
meiosis	O
telomérico	B-Sequence
de	O
El	O
mutación	B-Sequence
,	O
y	O
el	O
marcador	O
157J23	O
-	O
T7	O
mapea	O
un	O
recombinante	O
centrómico	B-Sequence
de	O
El	O
mutación	B-Sequence
(	O
Figura	O
3A	O
)	O
.	O

El	O
fin	O
secuencias	B-Sequence
y	O
marcadores	O
SSCP	O
de	O
PAC	B-Sequence
107N19	O
se	O
encuentran	O
en	O
el	O
pez	B-Taxon
cebra	I-Taxon
secuencia	B-Sequence
genómica	I-Sequence
contig	I-Sequence
ctg23107	O
(	O
http	O
:	O
//	O
www	O
.	O
ensembl	O
.	O
org	O
/	O
Danio	O
_	O
rerio	O
/	O
)	O
que	O
contiene	O
un	O
gen	B-Sequence
predicho	I-Sequence
de	I-Sequence
la	I-Sequence
familia	I-Sequence
TIF1	I-Sequence
del	I-Sequence
pez	I-Sequence
cebra	I-Sequence
.	O

Esta	O
PAC	B-Sequence
se	O
hibridó	O
a	O
un	O
riñón	O
ADNc	B-Sequence
biblioteca	O
,	O
lo	O
que	O
resultó	O
en	O
el	O
aislamiento	O
de	O
cuatro	O
clones	B-Sequence
que	O
representaba	O
lo	O
mismo	O
gene	B-Sequence
.	O

los	O
Lun	B-Protein
gene	B-Sequence
codifica	O
un	O
miembro	O
de	O
la	O
familia	O
TIF1	O
de	O
transcripcional	O
cofactores	B-Chemical
(	O
Figura	O
3B	O
y	O
3C	O
)	O
.	O

los	O
secuencia	B-Sequence
de	I-Sequence
codificación	I-Sequence
de	O
Lun	B-Protein
es	O
más	O
similar	O
a	O
gamma	B-Protein
TIF	I-Protein
humano	I-Protein
(	O
Le	O
Douarin	O
et	O
al	O
.	O
1995	O
;	O
Friedman	O
et	O
al	O
.	O
1996	O
;	O
Venturini	O
et	O
al	O
.	O
1999	O
)	O
,	O
y	O
el	O
ubicaciones	B-Sequence
de	O
límites	B-Sequence
del	I-Sequence
exón	I-Sequence
están	O
conservado	B-Sequence
Entre	O
los	O
pez	B-Taxon
cebra	I-Taxon
y	O
humano	B-Taxon
genes	B-Sequence
(	O
datos	O
no	O
publicados	O
)	O
.	O

los	O
Lun	B-Protein
locus	B-Sequence
en	I-Sequence
el	I-Sequence
cromosoma	I-Sequence
del	I-Sequence
pez	I-Sequence
cebra	I-Sequence
8	O
también	O
se	O
prevé	O
que	O
sea	O
sintético	B-Sequence
al	O
región	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
humano	I-Sequence
1p	O
que	O
contiene	O
el	O
gama	B-Protein
TIF1	I-Protein
gene	B-Sequence
basado	O
en	O
el	O
ubicaciones	B-Sequence
conservadas	I-Sequence
de	O
12	O
otros	O
gen	B-Sequence
ortólogo	I-Sequence
pares	O
,	O
incluyendo	O
SNA	B-Protein
,	O
asignado	O
a	O
estos	O
regiones	B-Sequence
en	O
humano	B-Taxon
y	O
pez	B-Taxon
cebra	I-Taxon
(	O
Barbazuk	O
et	O
al	O
.	O
2000	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
en	O
base	O
a	O
secuencia	B-Sequence
similitud	O
y	O
ubicación	B-Sequence
cromosómica	I-Sequence
,	O
los	O
pez	B-Protein
cebra	I-Protein
mon	I-Protein
gene	B-Sequence
es	O
probable	O
ortólogo	B-Sequence
de	O
El	O
gamma	B-Protein
TIF1	I-Protein
humano	I-Protein
gene	B-Sequence
.	O

Hemos	O
identificado	O
etil	B-Chemical
-	I-Chemical
nitrosourea	I-Chemical
(	O
ENU	B-Chemical
)	O
-	O
inducido	O
mutaciones	B-Sequence
puntuales	I-Sequence
en	O
tres	O
alelos	B-Sequence
de	O
Lun	B-Protein
(	O
Figura	O
3C	O
y	O
3D	O
)	O
,	O
cada	O
uno	O
de	O
los	O
cuales	O
genera	O
una	O
prematura	O
codón	B-Sequence
de	I-Sequence
parada	I-Sequence
.	O

El	O
montb222b	O
y	O
montg234	O
alelos	B-Sequence
tienen	O
un	O
fenotipo	O
severo	O
sin	O
circulación	O
células	B-Cell
de	I-Cell
sangre	I-Cell
.	O

Por	O
el	O
contrario	O
,	O
el	O
monm262	O
alelo	B-Sequence
tiene	O
10	O
-	O
100	O
circulando	O
células	B-Cell
de	I-Cell
sangre	I-Cell
por	O
48	O
hpf	O
,	O
en	O
comparación	O
con	O
los	O
aproximadamente	O
3	O
000	O
glóbulos	B-Cell
rojos	I-Cell
en	O
la	O
circulación	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
o	O
embriones	O
heterocigotos	O
al	O
mismo	O
tiempo	O
.	O

el	O
monm262	O
alelo	B-Sequence
se	O
encontró	O
que	O
codifica	O
un	O
prematuro	O
codón	B-Sequence
de	I-Sequence
parada	I-Sequence
en	O
posición	B-Sequence
E40	O
,	O
que	O
codificaría	O
un	O
supuesto	O
proteína	B-Chemical
de	O
solo	O
40	O
aminoácidos	B-Chemical
.	O

Aunque	O
esto	O
mutación	B-Sequence
se	O
esperaría	O
que	O
condujera	O
a	O
una	O
pérdida	O
completa	O
de	O
Lun	B-Protein
gene	B-Sequence
producto	O
,	O
otro	O
metionina	B-Chemical
se	O
encuentra	O
aguas	O
abajo	O
en	O
posición	B-Sequence
de	I-Sequence
aminoácido	I-Sequence
104	O
.	O

Experimentos	O
de	O
traducción	O
in	O
vitro	O
en	O
reticulocito	B-Cell
los	O
lisados	O
demuestran	O
el	O
reinicio	O
de	O
la	O
traducción	O
de	O
este	O
metionina	B-Chemical
(	O
datos	O
no	O
publicados	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
el	O
fenotipo	O
larval	O
hipomórfico	O
de	O
monm262	O
alelo	B-Sequence
probablemente	O
se	O
deba	O
a	O
la	O
pérdida	O
parcial	O
de	O
Lun	B-Protein
función	O
o	O
expresión	O
.	O

La	O
presencia	O
de	O
mutaciones	B-Sequence
en	O
cada	O
uno	O
de	O
los	O
Lun	B-Protein
alelos	B-Sequence
indica	O
que	O
defectuoso	O
gama	B-Protein
tif1	I-Protein
La	O
función	O
es	O
la	O
causa	O
de	O
la	O
Lun	B-Protein
fenotipo	O

Para	O
determinar	O
si	O
gama	B-Protein
tif1	I-Protein
se	O
expresa	O
en	O
el	O
mesodermo	O
hematopoyético	O
,	O
a	O
continuación	O
examinamos	O
pez	B-Taxon
cebra	I-Taxon
embriones	O
por	O
hibridación	O
in	O
situ	O
de	O
montaje	O
completo	O
(	O
Figura	O
4A	O
)	O
.	O

gama	B-Protein
tif1	I-Protein
ARNm	B-Chemical
se	O
expresa	O
por	O
vía	O
materna	O
y	O
se	O
encuentra	O
en	O
todo	O
el	O
embrión	O
durante	O
las	O
etapas	O
de	O
blástula	O
.	O

Durante	O
las	O
etapas	O
de	O
gastrulación	O
y	O
epibolia	O
,	O
la	O
expresión	O
cigótica	O
de	O
Lun	B-Protein
es	O
más	O
alto	O
en	O
el	O
mesendodermo	O
del	O
anillo	O
germinal	O
.	O

En	O
la	O
yema	O
de	O
la	O
cola	O
y	O
en	O
las	O
primeras	O
etapas	O
de	O
somita	O
,	O
un	O
alto	O
nivel	O
de	O
gama	B-Protein
tif1	I-Protein
expresión	O
delinea	O
una	O
población	O
en	O
forma	O
de	O
herradura	O
de	O
mesodermo	O
ventral	O
/	O
lateral	O
que	O
dará	O
lugar	O
a	O
la	O
sangre	O
y	O
también	O
expresa	O
leucemia	B-Protein
de	I-Protein
células	I-Protein
madrefactor	I-Protein
de	I-Protein
transcripción	I-Protein
hematopoyético	I-Protein
(	O
scl	B-Protein
)	O
(	O
Liao	O
et	O
al	O
.	O
1997	O
)	O
.	O

este	O
grupo	O
de	O
células	B-Cell
continúa	O
expresando	O
gama	B-Protein
tif1	I-Protein
y	O
scl	B-Protein
mientras	O
que	O
converge	O
y	O
forma	O
la	O
isla	O
de	O
sangre	O
embrionaria	O
(	O
Detrich	O
et	O
al	O
.	O
1995	O
)	O
.	O

los	O
gama	B-Protein
tif1	I-Protein
gene	B-Sequence
también	O
está	O
altamente	O
expresado	O
en	O
el	O
sistema	O
nervioso	O
central	O
así	O
como	O
en	O
el	O
mesénquima	O
del	O
tronco	O
y	O
la	O
cola	O
.	O

Homocigoto	O
montg234	O
mutantes	B-Sequence
tener	O
una	O
cantidad	O
muy	O
reducida	O
de	O
gama	B-Protein
tif1	I-Protein
ARNm	B-Chemical
en	O
todos	O
los	O
tejidos	O
consistente	O
con	O
tonterías	O
-	O
mediada	O
mensaje	B-Sequence
decaer	O

Por	O
lo	O
tanto	O
,	O
pez	B-Protein
cebra	I-Protein
tif1	I-Protein
gamma	I-Protein
se	O
expresa	O
específicamente	O
en	O
el	O
mesodermo	O
ventral	O
y	O
los	O
hemangioblastos	O
putativos	O
antes	O
y	O
durante	O
las	O
etapas	O
embrionarias	O
cuando	O
progenitores	B-Cell
hematopoyéticos	I-Cell
están	O
experimentando	O
apoptosis	O
en	O
Lun	B-Protein
mutantes	B-Sequence
.	O

También	O
comparamos	O
la	O
expresión	O
de	O
pez	B-Protein
cebra	I-Protein
mon	I-Protein
para	O
ratón	B-Protein
tif1	I-Protein
gama	I-Protein
(	O
Figura	O
4A	O
y	O
4B	O
)	O
.	O

Ratón	B-Protein
Tif1	I-Protein
gama	I-Protein
está	O
muy	O
expresado	O
en	O
eritroide	B-Cell
islas	O
de	O
sangre	O
del	O
saco	O
vitelino	O
,	O
y	O
posteriormente	O
se	O
expresa	O
en	O
el	O
hígado	O
fetal	O
en	O
un	O
alto	O
nivel	O
,	O
y	O
en	O
otros	O
tejidos	O
,	O
incluido	O
el	O
sistema	O
nervioso	O
central	O
.	O

Tomados	O
en	O
conjunto	O
,	O
estos	O
resultados	O
sugieren	O
fuertemente	O
que	O
pez	B-Protein
cebra	I-Protein
mon	I-Protein
y	O
ratón	B-Protein
tif1	I-Protein
gama	I-Protein
están	O
ortólogos	B-Sequence
que	O
funcionan	O
durante	O
la	O
hematopoyesis	O
.	O

Dado	O
que	O
mamífero	B-Taxon
gama	B-Protein
TIF1	I-Protein
se	O
ha	O
demostrado	O
que	O
forma	O
hetero	O
-	O
oligómeros	O
con	O
tif1	B-Protein
alfa	I-Protein
(	O
Peng	O
et	O
al	O
.	O
2002	O
)	O
,	O
buscamos	O
miembros	O
adicionales	O
de	O
la	O
familia	O
TIF1	O
en	O
pez	B-Taxon
cebra	I-Taxon
para	O
comparar	O
con	O
gama	B-Protein
tif1	I-Protein
.	O

Utilizando	O
pez	B-Taxon
cebra	I-Taxon
secuencias	B-Sequence
de	I-Sequence
etiquetas	I-Sequence
de	I-Sequence
secuencia	I-Sequence
expresada	I-Sequence
(	I-Sequence
EST	I-Sequence
)	I-Sequence
,	O
diseñamos	O
cebadores	B-Sequence
a	O
RT	O
-	O
PCR	O
amplificar	O
un	O
TIF1	O
-	O
relacionado	O
ADNc	B-Sequence
de	O
embrionario	O
10	O
-	O
hpf	O
y	O
24	O
-	O
hpf	O
ARN	B-Sequence
.	O

Esta	O
ADNc	B-Sequence
codifica	O
un	O
predicho	B-Sequence
pez	B-Taxon
cebra	I-Taxon
ortólogo	B-Sequence
de	O
humano	B-Protein
TIF1	I-Protein
alfa	I-Protein
Residencia	O
en	O
secuencias	B-Sequence
de	I-Sequence
aminoácidos	I-Sequence
predichas	I-Sequence
(	O
ver	O
Figura	O
3B	O
)	O
.	O

Además	O
,	O
pez	B-Protein
cebra	I-Protein
tif1	I-Protein
alfa	I-Protein
EST	B-Sequence
asignar	O
a	O
LG4	O
en	O
un	O
región	B-Sequence
predicha	I-Sequence
ser	O
sintético	B-Sequence
al	O
región	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
humano	I-Sequence
7	O
que	O
contiene	O
el	O
TIF1	B-Protein
alfa	I-Protein
gene	B-Sequence
basado	O
en	O
el	O
ubicaciones	B-Sequence
conservadas	I-Sequence
de	O
otros	O
ocho	O
gen	B-Sequence
ortólogo	I-Sequence
pares	O
,	O
incluyendo	O
SEMA3A	B-Protein
,	O
asignado	O
a	O
estos	O
regiones	B-Sequence
en	O
humano	B-Taxon
y	O
pez	B-Taxon
cebra	I-Taxon
(	O
Barbazuk	O
et	O
al	O
.	O
2000	O
)	O
.	O

Luego	O
comparamos	O
el	O
patrón	O
de	O
expresión	O
embrionario	O
de	O
tif1	B-Protein
alfa	I-Protein
ARNm	B-Chemical
para	O
gama	B-Protein
tif1	I-Protein
por	O
hibridación	O
in	O
situ	O
.	O

Me	O
gusta	O
mamífero	B-Taxon
TIF1	B-Protein
alfa	I-Protein
(	O
Le	O
Douarin	O
et	O
al	O
.	O
1995	O
;	O
Niederreither	O
et	O
al	O
.	O
1999	O
)	O
,	O
el	O
gen	B-Sequence
gamma	I-Sequence
tif1	I-Sequence
predicho	I-Sequence
del	I-Sequence
pez	I-Sequence
cebra	I-Sequence
se	O
expresa	O
ampliamente	O
(	O
ver	O
Figura	O
4A	O
)	O
.	O

A	O
las	O
cinco	O
somitas	O
,	O
pez	B-Protein
cebra	I-Protein
tif1	I-Protein
alfa	I-Protein
no	O
muestra	O
la	O
expresión	O
relativamente	O
alta	O
en	O
la	O
región	O
en	O
forma	O
de	O
herradura	O
del	O
mesodermo	O
hematopoyético	O
visto	O
con	O
gama	B-Protein
tif1	I-Protein
.	O

En	O
etapas	O
posteriores	O
,	O
tif1	B-Protein
alfa	I-Protein
se	O
expresa	O
uniformemente	O
en	O
la	O
mayor	O
parte	O
del	O
embrión	O
,	O
incluidas	O
las	O
islas	O
de	O
sangre	O
en	O
desarrollo	O
.	O

Por	O
lo	O
tanto	O
,	O
tif1	B-Protein
alfa	I-Protein
se	O
coexpresa	O
en	O
el	O
mismo	O
células	B-Cell
con	O
gama	B-Protein
tif1	I-Protein
y	O
por	O
lo	O
tanto	O
puede	O
estar	O
disponible	O
para	O
formar	O
hetero	O
-	O
oligómeros	O
in	O
vivo	O
.	O

Expresión	O
forzada	O
de	O
gama	B-Protein
tif1	I-Protein
Rescata	O
Hematopoyesis	O
en	O
Lun	B-Protein
mutantes	B-Sequence

Para	O
confirmar	O
aún	O
más	O
que	O
un	O
mutación	B-Sequence
en	O
el	O
pez	B-Protein
cebra	I-Protein
tif1	I-Protein
gamma	I-Protein
gene	B-Sequence
es	O
responsable	O
de	O
la	O
Lun	B-Protein
mutante	B-Sequence
fenotipo	O
realizamos	O
experimentos	O
de	O
rescate	O
de	O
embriones	O
(	O
Figura	O
5A	O
;	O
Tabla	O
1	O
)	O
.	O

Microinyección	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
sintético	I-Sequence
Lun	B-Protein
ARNm	B-Chemical
en	O
el	O
uno	O
-	O
célula	B-Cell
etapa	O
rescata	O
la	O
formación	O
de	O
embriones	O
eritrocitos	B-Cell
en	O
genotipado	O
mutante	B-Sequence
embriones	O
sin	O
causar	O
defectos	O
evidentes	O
en	O
el	O
patrón	O
embrionario	O
o	O
la	O
organogénesis	O
.	O

los	O
4	O
d	O
de	O
desarrollo	O
,	O
70	O
%	O
(	O
n	O
=	O
10	O
)	O
de	O
montg234	O
mutantes	B-Sequence
mostrar	O
significativo	O
(	O
más	O
de	O
200	O
células	B-Cell
en	O
comparación	O
con	O
un	O
tipo	B-Sequence
salvaje	I-Sequence
estimación	O
de	O
3	O
000	O
células	B-Cell
)	O
rescate	O
de	O
circulantes	O
hemoglobinizados	O
glóbulos	B-Cell
rojos	I-Cell
en	O
comparación	O
con	O
el	O
hermano	O
de	O
control	O
mutantes	B-Sequence
(	O
n	O
=	O
75	O
)	O
.	O

Con	O
base	O
en	O
la	O
corrección	O
del	O
fenotipo	O
de	O
pliegue	O
de	O
aleta	O
dentado	O
(	O
Ransom	O
et	O
al	O
.	O
1996	O
)	O
,	O
el	O
células	B-Cell
mesenquimales	I-Cell
se	O
rescatan	O
en	O
una	O
medida	O
similar	O
a	O
la	O
anemia	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Sobreexpresión	O
de	O
Lun	B-Protein
no	O
dio	O
como	O
resultado	O
una	O
expansión	O
globulo	B-Cell
números	O
en	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
y	O
no	O
era	O
tóxico	B-Chemical
a	O
dosis	O
que	O
rescatan	O
el	O
fenotipo	O
de	O
Lun	B-Protein
mutantes	B-Sequence
(	O
datos	O
no	O
publicados	O
)	O
.	O

Dado	O
que	O
no	O
hubo	O
poblaciones	O
de	O
sangre	O
expandida	O
o	O
ectópica	O
en	O
los	O
embriones	O
,	O
estos	O
experimentos	O
de	O
rescate	O
sugieren	O
que	O
Lun	B-Protein
funciona	O
como	O
un	O
factor	O
permisivo	O
requerido	O
para	O
la	O
hematopoyesis	O
.	O

El	O
trasplante	O
de	O
médula	O
rescata	O
la	O
eritropoyesis	O
en	O
Lun	B-Protein
mutantes	B-Sequence

Los	O
altos	O
niveles	O
de	O
gama	B-Protein
tif1	I-Protein
expresión	O
en	O
células	B-Cell
eritroides	I-Cell
sugieren	O
que	O
funciona	O
como	O
un	O
célula	B-Cell
#	O
¿NOMBRE	O
?	O
gene	B-Sequence
expresión	O
en	O
células	B-Cell
hematopoyéticas	I-Cell
.	O

Para	O
probar	O
esta	O
hipótesis	O
,	O
trasplantamos	O
tipo	B-Sequence
salvaje	I-Sequence
adulto	O
pez	B-Taxon
cebra	I-Taxon
médula	O
renal	O
células	B-Cell
llevando	O
una	O
gata1	B-Protein
verde	O
fluorescente	O
proteína	B-Chemical
(	O
GFP	O
)	O
transgén	B-Sequence
en	O
48	O
-	O
hpf	O
Lun	B-Protein
mutante	B-Sequence
embriones	O
(	O
Figura	O
5B	O
;	O
Tabla	O
2	O
)	O
.	O

los	O
gata1	B-Protein
:	O
GFP	O
transgén	B-Sequence
hace	O
uso	O
de	O
la	O
gata1	B-Protein
promotor	B-Sequence
para	O
impulsar	O
la	O
expresión	O
de	O
GFP	O
y	O
,	O
por	O
lo	O
tanto	O
,	O
se	O
puede	O
utilizar	O
para	O
marcar	O
donantes	O
derivados	O
células	B-Cell
eritroides	I-Cell
(	O
Long	O
et	O
al	O
.	O
1997	O
)	O
.	O

no	O
trasplantado	O
mutante	B-Sequence
los	O
embriones	O
no	O
tienen	O
embriones	O
células	B-Cell
de	I-Cell
sangre	I-Cell
En	O
circulación	O
.	O

Después	O
del	O
trasplante	O
,	O
mutante	B-Sequence
embriones	O
huésped	O
se	O
observaron	O
diariamente	O
durante	O
2	O
semanas	O
.	O

de	O
191	O
mutante	B-Sequence
embriones	O
inyectados	O
,	O
129	O
(	O
68	O
%	O
)	O
mostraron	O
GFP	O
+	O
células	B-Cell
en	O
circulación	O
2	O
d	O
después	O
.	O

Muchos	O
receptores	O
mostraron	O
aumentos	O
sólidos	O
en	O
los	O
beneficios	O
derivados	O
de	O
donantes	O
.	O
células	B-Cell
durante	O
el	O
período	O
de	O
observación	O
.	O

De	O
81	O
destinatarios	O
inicialmente	O
calificados	O
con	O
menos	O
de	O
diez	O
GFP	O
+	O
células	B-Cell
en	O
el	O
día	O
2	O
postrasplante	O
,	O
13	O
(	O
16	O
%	O
)	O
de	O
estos	O
demostraron	O
un	O
aumento	O
marcado	O
en	O
células	B-Cell
eritroides	I-Cell
con	O
100	O
-	O
1	O
000	O
GFP	O
+	O
células	B-Cell
en	O
circulación	O
6	O
d	O
después	O
.	O

Para	O
el	O
día	O
10	O
,	O
estos	O
embriones	O
trasplantados	O
mostraban	O
aproximadamente	O
3	O
000	O
células	B-Cell
en	O
circulación	O
,	O
similar	O
al	O
número	O
de	O
células	B-Cell
de	I-Cell
sangre	I-Cell
en	O
embriones	O
normales	O
.	O

pesar	O
de	O
la	O
sólida	O
reconstitución	O
de	O
células	B-Cell
de	I-Cell
sangre	I-Cell
,	O
mutante	B-Sequence
los	O
receptores	O
no	O
inflaron	O
sus	O
vejigas	O
natatorias	O
y	O
,	O
por	O
lo	O
tanto	O
,	O
no	O
lograron	O
sobrevivir	O
más	O
tiempo	O
que	O
los	O
controles	O
hermanos	O
no	O
trasplantados	O
,	O
y	O
todos	O
murieron	O
a	O
las	O
3	O
semanas	O
de	O
edad	O
.	O

Por	O
el	O
contrario	O
,	O
13/35	O
(	O
37	O
%	O
)	O
trasplantes	O
heterocigotos	O
montg234	O
sobrevivieron	O
hasta	O
la	O
edad	O
adulta	O
temprana	O
.	O

Trasplantes	O
similares	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
células	B-Cell
puede	O
rescatar	O
completamente	O
vlad	B-Protein
tepes	I-Protein
(	O
gata1	B-Protein
)	O
mutantes	B-Sequence
(	O
Traver	O
et	O
al	O
.	O
2003	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
los	O
resultados	O
de	O
célula	B-Cell
trasplantes	O
sugiere	O
que	O
gama	B-Protein
tif1	I-Protein
juega	O
un	O
célula	B-Cell
#	O
¿NOMBRE	O
?	O
células	B-Cell
eritroides	I-Cell
y	O
su	O
papel	O
en	O
los	O
tejidos	O
no	O
hematopoyéticos	O
,	O
como	O
el	O
mesénquima	O
del	O
tronco	O
o	O
el	O
sistema	O
nervioso	O
,	O
también	O
es	O
necesario	O
para	O
la	O
supervivencia	O
del	O
embrión	O
.	O

gama	B-Protein
tif1	I-Protein
en	O
punteado	O
Nuclear	B-GENE
Los	O
focos	O
están	O
regulados	O
por	O
el	O
desarrollo	O

Para	O
examinar	O
la	O
distribución	O
subcelular	O
de	O
gama	B-Protein
tif1	I-Protein
proteína	B-Chemical
,	O
generamos	O
una	O
afinidad	O
-	O
purificada	O
Conejo	B-Taxon
antisuero	O
policlonal	O
dirigido	O
contra	O
el	O
C-terminal	B-Sequence
15	O
aminoácidos	B-Chemical
conservado	B-Sequence
en	O
gamma	B-Protein
TIF1	I-Protein
humano	I-Protein
y	O
ratón	B-Protein
tif1	I-Protein
gama	I-Protein
.	O

Inmunofluorescencia	O
de	O
ratón	B-Taxon
embrión	O
fibroblasto	B-Cell
núcleos	B-GENE
con	O
el	O
anti-	O
gama	B-Protein
tif1	I-Protein
antisuero	O
demuestra	O
que	O
gama	B-Protein
tif1	I-Protein
se	O
localiza	O
en	O
pequeños	O
nuclear	B-GENE
focos	O
(	O
Figura	O
6A	O
)	O
.	O

La	O
localización	O
de	O
gama	B-Protein
tif1	I-Protein
proteína	B-Chemical
aparece	O
diferente	O
del	O
más	O
difuso	O
nuclear	B-GENE
patrones	O
típicamente	O
vistos	O
en	O
los	O
estudios	O
de	O
tif1	B-Protein
alfa	I-Protein
(	O
Remboutsika	O
et	O
al	O
.	O
2002	O
)	O
o	O
TIF1	B-Protein
beta	I-Protein
(	O
Cammas	O
et	O
al	O
.	O
2002	O
)	O
.	O

Un	O
informe	O
reciente	O
demuestra	O
que	O
TIF1	B-Protein
beta	I-Protein
se	O
asocia	O
con	O
heterocromatina	B-GENE
#	O
¿NOMBRE	O
?	O
ácido	B-Chemical
retinoico	I-Chemical
tratamiento	O
o	O
privación	O
de	O
suero	O
(	O
Cammas	O
et	O
al	O
.	O
2002	O
)	O
.	O

Así	O
,	O
la	O
localización	O
o	O
expresión	O
del	O
TIF1	O
proteinas	B-Chemical
puede	O
ser	O
regulada	O
durante	O
distintos	O
procesos	O
de	O
desarrollo	O
o	O
por	O
señales	O
ambientales	O
.	O

los	O
nuclear	B-GENE
focos	O
que	O
contienen	O
gama	B-Protein
tif1	I-Protein
no	O
colocalizar	O
con	O
dos	O
marcadores	O
de	O
heterocromatina	B-GENE
,	O
HP1	B-Protein
alfa	I-Protein
proteína	B-Chemical
y	O
tinción	O
DAPI	O
de	O
ADN	B-Sequence
(	O
Figura	O
6A	O
)	O
.	O

Es	O
más	O
,	O
gama	B-Protein
tif1	I-Protein
no	O
se	O
colocaliza	O
con	O
Cuerpos	B-GENE
nucleares	I-GENE
del	I-GENE
producto	I-GENE
del	I-GENE
gen	I-GENE
de	I-GENE
la	I-GENE
leucemia	I-GENE
promielocítica	I-GENE
(	I-GENE
PML	I-GENE
)	I-GENE
,	O
ADN	B-Sequence
reparar	O
complejos	B-GENE
que	O
contienen	O
mre11	B-Protein
,	O
o	O
complejos	B-GENE
transcripcionales	I-GENE
que	O
contiene	O
TFII	B-Protein
-	I-Protein
B	I-Protein
(	O
datos	O
no	O
publicados	O
)	O
.	O

A	O
continuación	O
examinamos	O
la	O
expresión	O
de	O
gama	B-Protein
tif1	I-Protein
proteína	B-Chemical
durante	O
la	O
diferenciación	O
de	O
G1E	O
células	B-Cell
,	O
a	O
murino	B-Taxon
eritroleucemia	O
célula	B-Cell
línea	O
que	O
puede	O
diferenciarse	O
terminalmente	O
en	O
eritrocitos	B-Cell
cuando	O
una	O
gata1	B-Protein
:	O
receptor	B-Protein
de	I-Protein
estrógeno	I-Protein
fusión	B-Sequence
proteína	B-Chemical
se	O
estabiliza	O
en	O
respuesta	O
a	O
la	O
exposición	O
al	O
estrógeno	O
(	O
Weiss	O
et	O
al	O
.	O
1997	O
)	O
.	O

El	O
análisis	O
de	O
Western	O
blot	O
demostró	O
que	O
gama	B-Protein
tif1	I-Protein
proteína	B-Chemical
expresión	O
disminuye	O
con	O
terminal	O
eritroide	B-Cell
diferenciación	O
(	O
Figura	O
6B	O
)	O
.	O

De	O
acuerdo	O
con	O
este	O
hallazgo	O
,	O
después	O
de	O
24	O
hpf	O
,	O
pez	B-Protein
cebra	I-Protein
mon	I-Protein
ARNm	B-Chemical
expresión	O
cae	O
durante	O
la	O
maduración	O
terminal	O
de	O
la	O
primitiva	O
células	B-Cell
eritroides	I-Cell
(	O
datos	O
no	O
publicados	O
)	O
.	O

en	O
dos	O
diferentes	O
murino	B-Taxon
eritroleucemia	O
célula	B-Cell
líneas	O
(	O
MEL	O
y	O
G1E	O
)	O
,	O
gama	B-Protein
tif1	I-Protein
también	O
se	O
expresa	O
en	O
nuclear	B-GENE
focos	O
,	O
y	O
aunque	O
el	O
conjunto	O
gama	B-Protein
tif1	I-Protein
proteína	B-Chemical
se	O
reduce	O
el	O
nivel	O
,	O
esto	O
nuclear	B-GENE
la	O
localización	O
de	O
los	O
focos	O
no	O
cambia	O
con	O
la	O
diferenciación	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Esto	O
proporciona	O
más	O
apoyo	O
a	O
la	O
hipótesis	O
de	O
que	O
gama	B-Protein
tif1	I-Protein
actos	O
dentro	O
de	O
la	O
novela	O
nuclear	B-GENE
focos	O
,	O
durante	O
eritroide	B-Cell
diferenciación	O

Discusión	O

los	O
pez	B-Taxon
cebra	I-Taxon
es	O
un	O
excelente	O
sistema	O
modelo	O
para	O
dilucidar	O
la	O
molecular	B-Chemical
control	O
de	O
maquinaria	O
gene	B-Sequence
expresión	O
durante	O
la	O
hematopoyesis	O
(	O
Thisse	O
y	O
Zon	O
2002	O
;	O
Galloway	O
y	O
Zon	O
2003	O
)	O
.	O

Como	O
parte	O
de	O
un	O
avance	O
a	O
gran	O
escala	O
genético	B-Sequence
pantalla	O
,	O
originalmente	O
identificamos	O
un	O
grupo	O
complementario	O
de	O
independientes	O
alelos	B-Sequence
mutantes	I-Sequence
en	O
el	O
pez	B-Taxon
cebra	I-Taxon
gene	B-Sequence
que	O
nombramos	O
luz	B-Protein
de	I-Protein
la	I-Protein
luna	I-Protein
(	O
Ransom	O
et	O
al	O
.	O
1996	O
)	O
.	O

posicional	B-Sequence
La	O
clonación	O
se	O
usó	O
para	O
identificar	O
el	O
Lun	B-Protein
gene	B-Sequence
,	O
estableciendo	O
un	O
papel	O
crítico	O
para	O
un	O
factor	O
intermediario	O
transcripcional	O
,	O
gama	B-Protein
tif1	I-Protein
,	O
durante	O
el	O
desarrollo	O
hematopoyético	O
.	O

los	O
Lun	B-Protein
Gene	B-Sequence
Codifica	O
el	O
pez	B-Taxon
cebra	I-Taxon
Ortólogo	B-Sequence
de	O
Mamífero	B-Taxon
gama	B-Protein
TIF1	I-Protein

Nuestros	O
resultados	O
apoyan	O
fuertemente	O
la	O
conclusión	O
de	O
que	O
tenemos	O
posicionalmente	B-Sequence
clonado	O
el	O
pez	B-Protein
cebra	I-Protein
mon	I-Protein
gene	B-Sequence
correctamente	O
,	O
y	O
es	O
el	O
ortólogo	B-Sequence
de	O
mamífero	B-Taxon
gama	B-Protein
tif1	I-Protein
.	O

gama	B-Protein
tif1	I-Protein
está	O
presente	O
en	O
la	O
crítica	O
intervalo	B-Sequence
genético	I-Sequence
que	O
abarca	O
un	O
solo	O
aproximadamente	O
50	O
-	O
kb	O
clon	B-Sequence
de	I-Sequence
PAC	I-Sequence
definido	O
por	O
análisis	O
de	O
ligamiento	O
(	O
ver	O
Figura	O
3	O
)	O
.	O

Secuencia	B-Sequence
análisis	O
indica	O
que	O
pez	B-Protein
cebra	I-Protein
tif1	I-Protein
gamma	I-Protein
es	O
más	O
similar	O
en	O
secuencia	B-Sequence
de	I-Sequence
aminoácidos	I-Sequence
predicha	I-Sequence
y	O
intrón	B-Sequence
/	O
exón	B-Sequence
estructura	O
en	O
comparación	O
con	O
la	O
genes	B-Sequence
humanos	I-Sequence
y	I-Sequence
de	I-Sequence
ratón	I-Sequence
ortólogos	I-Sequence
predichos	I-Sequence
.	O

Pez	B-Protein
cebra	I-Protein
tif1	I-Protein
gamma	I-Protein
se	O
encuentra	O
en	O
un	O
región	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
del	I-Sequence
pez	I-Sequence
cebra	I-Sequence
8	O
sintético	B-Sequence
al	O
región	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
humano	I-Sequence
1	O
que	O
contiene	O
gama	B-Protein
TIF1	I-Protein
.	O

Nosotros	O
identificamos	O
mutaciones	B-Sequence
puntuales	I-Sequence
en	O
gama	B-Protein
tif1	I-Protein
de	O
tres	O
diferentes	O
alelos	B-Sequence
de	O
Lun	B-Protein
que	O
cada	O
resultado	O
en	O
prematura	O
codones	B-Sequence
de	I-Sequence
parada	I-Sequence
y	O
ARNm	B-Chemical
decaer	O

Además	O
,	O
gama	B-Protein
tif1	I-Protein
/	O
gama	B-Protein
tif1	I-Protein
está	O
muy	O
expresado	O
en	O
células	B-Cell
hematopoyéticas	I-Cell
a	O
lo	O
largo	O
de	O
la	O
embriogénesis	O
en	O
ambos	O
pez	B-Taxon
cebra	I-Taxon
y	O
ratón	B-Taxon
(	O
ver	O
Figura	O
4	O
)	O
.	O

Y	O
como	O
predijo	O
,	O
forzada	O
expresión	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
gama	B-Protein
tif1	I-Protein
ARNm	B-Chemical
rescata	O
eficientemente	O
la	O
hematopoyesis	O
en	O
Lun	B-Protein
mutantes	B-Sequence
no	O
perturba	O
la	O
hematopoyesis	O
en	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
(	O
ver	O
Figura	O
5	O
)	O
.	O

También	O
hemos	O
clonado	O
el	O
predicho	B-Sequence
pez	B-Taxon
cebra	I-Taxon
ortólogo	B-Sequence
de	O
tif1	B-Protein
alfa	I-Protein
,	O
que	O
se	O
expresa	O
más	O
uniformemente	O
en	O
pez	B-Taxon
cebra	I-Taxon
embriones	O
como	O
mamífero	B-Taxon
TIF1	B-Protein
alfa	I-Protein
(	O
Le	O
Douarin	O
et	O
al	O
.	O
1995	O
;	O
Niederreither	O
et	O
al	O
.	O
1999	O
)	O
(	O
véanse	O
las	O
Figuras	O
3A	O
y	O
4A	O
)	O
y	O
por	O
lo	O
tanto	O
puede	O
estar	O
disponible	O
para	O
formar	O
hetero	O
-	O
oligómeros	O
con	O
gama	B-Protein
tif1	I-Protein
proteína	B-Chemical
en	O
desarrollo	O
células	B-Cell
hematopoyéticas	I-Cell
.	O

Comparando	O
disponible	O
pez	B-Taxon
cebra	I-Taxon
y	O
mamífero	B-Taxon
TIF1-	O
secuencias	B-Sequence
de	I-Sequence
aminoácidos	I-Sequence
predichas	I-Sequence
,	O
parece	O
que	O
el	O
gama	B-Protein
tif1	I-Protein
ortólogos	B-Sequence
son	O
los	O
más	O
altamente	O
conservado	B-Sequence
miembros	O
de	O
la	O
familia	O
mientras	O
el	O
tif1	B-Protein
alfa	I-Protein
secuencias	B-Sequence
son	O
relativamente	O
más	O
divergentes	O
.	O

no	O
hemos	O
encontrado	O
un	O
beta	B-Protein
tif1	I-Protein
ortólogo	B-Sequence
,	O
hasta	O
el	O
momento	O
,	O
en	O
el	O
pez	B-Taxon
cebra	I-Taxon
o	O
fugu	B-Taxon
genoma	B-Sequence
o	O
secuencias	B-Sequence
EST	I-Sequence
.	O

Es	O
posible	O
que	O
beta	B-Protein
tif1	I-Protein
,	O
como	O
el	O
KRAB	O
dominio	B-Sequence
factores	O
de	O
transcripción	O
a	O
los	O
que	O
se	O
une	O
,	O
pueden	O
estar	O
presentes	O
sólo	O
en	O
tetrápodos	B-Taxon
(	O
Urrutia	O
2003	O
)	O
.	O

Sin	O
embargo	O
,	O
más	O
completa	O
secuencias	B-Sequence
del	I-Sequence
genoma	I-Sequence
será	O
necesario	O
para	O
confirmar	O
esta	O
hipótesis	O
.	O

Con	O
base	O
en	O
nuestro	O
análisis	O
de	O
pez	B-Protein
cebra	I-Protein
mon	I-Protein
mutantes	B-Sequence
,	O
es	O
razonable	O
predecir	O
que	O
gama	B-Protein
tif1	I-Protein
,	O
el	O
más	O
conservado	B-Sequence
evolutivamente	I-Sequence
miembro	O
de	O
la	O
familia	O
TIF1	O
,	O
juega	O
un	O
papel	O
igualmente	O
esencial	O
en	O
humano	B-Taxon
y	O
ratón	B-Taxon
hematopoyesis	O

Mutaciones	B-Sequence
en	O
gama	B-Protein
tif1	I-Protein
Causa	O
Apoptosis	O
de	O
Progenitores	B-Cell
eritroides	I-Cell

Nuestro	O
examen	O
de	O
hematopoyética	O
gene	B-Sequence
expresión	O
,	O
apoptosis	O
e	O
histología	O
de	O
la	O
médula	O
en	O
Lun	B-Protein
mutantes	B-Sequence
demuestra	O
que	O
temprano	O
progenitores	B-Cell
eritroides	I-Cell
se	O
forman	O
en	O
homocigotos	O
mutantes	B-Sequence
,	O
pero	O
no	O
logran	O
diferenciar	O
adecuadamente	O
y	O
en	O
su	O
lugar	O
se	O
someten	O
a	O
cambios	O
programados	O
.	O
célula	B-Cell
muerte	O
(	O
ver	O
Figura	O
1	O
)	O
.	O

la	O
expresión	O
de	O
gata1	B-Protein
parece	O
iniciar	O
normalmente	O
en	O
el	O
cometido	O
células	B-Cell
eritroides	I-Cell
de	O
Lun	B-Protein
mutantes	B-Sequence
.	O

Sin	O
embargo	O
,	O
el	O
células	B-Cell
son	O
anormales	O
antes	O
de	O
la	O
pérdida	O
completa	O
de	O
gata1	B-Protein
expresión	O
.	O

TUNEL	O
-	O
positivo	O
células	B-Cell
apoptóticas	I-Cell
son	O
abundantes	O
en	O
la	O
etapa	O
de	O
desarrollo	O
de	O
12	O
somitas	O
y	O
en	O
22	O
hpf	O
todas	O
las	O
células	O
hematopoyéticas	O
gene	B-Sequence
la	O
expresión	O
se	O
extingue	O
.	O

La	O
expresión	O
del	O
marcador	O
.	O
genes	B-Sequence
,	O
incluyendo	O
scl	B-Protein
y	O
gata2	B-Protein
,	O
caracteristico	O
de	O
células	B-Cell
madre	I-Cell
hematopoyéticas	I-Cell
y	O
primitivo	O
progenitores	B-Cell
hematopoyéticos	I-Cell
,	O
tampoco	O
se	O
detectan	O
en	O
las	O
islas	O
de	O
sangre	O
embrionaria	O
de	O
mutantes	B-Sequence
a	O
22	O
cvf	O
.	O

Esto	O
indica	O
que	O
el	O
mutante	B-Sequence
células	B-Cell
hematopoyéticas	I-Cell
no	O
están	O
bloqueados	O
antes	O
del	O
compromiso	O
con	O
el	O
eritroide	B-Cell
linaje	O
,	O
sino	O
que	O
se	O
desarrollan	O
como	O
anormales	O
células	B-Cell
eritroides	I-Cell
y	O
sufren	O
apoptosis	O
,	O
similar	O
a	O
gata1	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
eritroides	I-Cell
(	O
Fujiwara	O
et	O
al	O
.	O
1996	O
;	O
Lyons	O
et	O
al	O
.	O
2002	O
)	O
.	O

También	O
se	O
observaron	O
eritropoyesis	O
defectuosa	O
y	O
anemia	O
severa	O
en	O
homocigotos	O
sobrevivientes	O
raros	O
.	O
mutante	B-Sequence
Lun	B-Protein
adultos	O
,	O
demostrando	O
que	O
gama	B-Protein
tif1	I-Protein
también	O
se	O
requiere	O
en	O
la	O
hematopoyesis	O
definitiva	O
(	O
ver	O
Figura	O
2	O
)	O
.	O

Los	O
fenotipos	O
cigóticos	O
de	O
Lun	B-Protein
mutantes	B-Sequence
puede	O
no	O
revelar	O
la	O
función	O
de	O
herencia	O
materna	O
gama	B-Protein
tif1	I-Protein
.	O

Expresado	O
maternalmente	O
pez	B-Protein
cebra	I-Protein
tif1	I-Protein
gamma	I-Protein
pueden	O
desempeñar	O
funciones	O
en	O
la	O
hematopoyesis	O
u	O
otros	O
aspectos	O
de	O
la	O
organogénesis	O
que	O
no	O
son	O
detectables	O
debido	O
a	O
la	O
presencia	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
ARNm	B-Chemical
en	O
huevos	B-Cell
puestas	O
por	O
madres	O
heterocigotas	O
.	O

Análisis	O
de	O
la	O
descendencia	O
de	O
homocigotos	O
Lun	B-Protein
mutante	B-Sequence
mujer	O
pez	B-Taxon
cebra	I-Taxon
ayudará	O
a	O
definir	O
la	O
función	O
de	O
este	O
maternal	O
ARNm	B-Chemical
.	O

El	O
presente	O
análisis	O
de	O
zygotic	O
Lun	B-Protein
mutantes	B-Sequence
proporciona	O
datos	O
que	O
son	O
consistentes	O
con	O
la	O
conclusión	O
de	O
que	O
gama	B-Protein
tif1	I-Protein
es	O
esencial	O
para	O
la	O
eritropoyesis	O
pero	O
no	O
se	O
descartan	O
funciones	O
esenciales	O
en	O
otros	O
linajes	O
hematopoyéticos	O
.	O

El	O
fenotipo	O
hematopoyético	O
de	O
Lun	B-Protein
mutantes	B-Sequence
se	O
asemeja	O
a	O
la	O
pérdida	O
de	O
células	B-Cell
eritroides	I-Cell
visto	O
en	O
ambos	O
raton	B-Protein
gata1	I-Protein
embriones	O
knockout	O
y	O
pez	B-Protein
cebra	I-Protein
vlad	I-Protein
tepes	I-Protein
(	I-Protein
gata1	I-Protein
)	O
mutante	B-Sequence
embriones	O
(	O
Fujiwara	O
et	O
al	O
.	O
1996	O
;	O
Lyons	O
et	O
al	O
.	O
2002	O
)	O
.	O

En	O
un	O
esfuerzo	O
por	O
determinar	O
si	O
existe	O
una	O
genético	B-Sequence
relación	O
entre	O
Lun	B-Protein
y	O
gata1	B-Protein
,	O
probamos	O
su	O
capacidad	O
para	O
rescatar	O
la	O
eritropoyesis	O
.	O

Tanto	O
la	O
inyección	O
de	O
gata1	B-Protein
ARNm	B-Chemical
dentro	O
Lun	B-Protein
homocigoto	O
mutante	B-Sequence
embriones	O
e	O
inyección	O
de	O
gama	B-Protein
tif1	I-Protein
ARNm	B-Chemical
dentro	O
gata1	B-Protein
los	O
embriones	O
derribados	O
no	O
lograron	O
rescatar	O
la	O
hematopoyesis	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

También	O
probamos	O
una	O
interacción	O
directa	O
entre	O
gama	B-Protein
tif1	I-Protein
y	O
gata1	B-Protein
proteinas	B-Chemical
por	O
coinmunoprecipitación	O
y	O
levadura	B-Taxon
ensayos	O
de	O
dos	O
híbridos	O
y	O
no	O
encontraron	O
asociación	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Aunque	O
el	O
mutaciones	B-Sequence
en	O
cada	O
uno	O
de	O
estos	O
genes	B-Sequence
arrestar	O
células	B-Cell
en	O
una	O
etapa	O
similar	O
de	O
desarrollo	O
,	O
nuestros	O
resultados	O
sugieren	O
que	O
gata1	B-Protein
y	O
gama	B-Protein
tif1	I-Protein
actuar	O
de	O
forma	O
independiente	O
.	O

Esto	O
no	O
descarta	O
la	O
posibilidad	O
de	O
que	O
en	O
paralelo	O
genético	B-Sequence
caminos	O
que	O
involucran	O
gata1	B-Protein
y	O
gama	B-Protein
tif1	I-Protein
,	O
operando	O
juntos	O
,	O
regulando	O
gene	B-Sequence
transcripción	O
dentro	O
células	B-Cell
de	I-Cell
sangre	I-Cell
.	O

El	O
rol	O
de	O
gama	B-Protein
tif1	I-Protein
en	O
Eritropoyesis	O
Primitiva	O
y	O
Definitiva	O

En	O
conjunto	O
,	O
nuestros	O
datos	O
sugieren	O
que	O
gama	B-Protein
tif1	I-Protein
se	O
requiere	O
como	O
permisivo	O
cofactor	B-Chemical
Para	O
el	O
eritroide	B-Cell
linaje	O
-	O
control	O
específico	O
de	O
la	O
hematopoyética	O
gene	B-Sequence
expresión	O
.	O

Predecimos	O
razonablemente	O
que	O
gama	B-Protein
tif1	I-Protein
proteína	B-Chemical
funciona	O
como	O
un	O
factor	O
intermediario	O
transcripcional	O
en	O
células	B-Cell
progenitoras	I-Cell
hematopoyéticas	I-Cell
dado	O
que	O
ambos	O
TIF1	B-Protein
alfa	I-Protein
(	O
Zhong	O
et	O
al	O
.	O
1999	O
)	O
y	O
TIF1	B-Protein
beta	I-Protein
(	O
Friedman	O
et	O
al	O
.	O
1996	O
;	O
Abrink	O
et	O
al	O
.	O
2001	O
)	O
actúan	O
como	O
factores	O
intermediarios	O
que	O
regulan	O
positiva	O
o	O
negativamente	O
gene	B-Sequence
transcripción	O

Estos	O
estudios	O
indican	O
que	O
TIF1	B-Protein
alfa	I-Protein
y	O
TIF1	B-Protein
beta	I-Protein
actúan	O
como	O
andamios	O
que	O
unen	O
diferentes	O
clases	O
de	O
ADN	B-Sequence
#	O
¿NOMBRE	O
?	O
proteinas	B-Chemical
y	O
cromatina	B-GENE
#	O
¿NOMBRE	O
?	O
proteinas	B-Chemical
en	O
regulaciones	O
más	O
grandes	O
complejos	B-GENE
.	O

gama	B-Protein
tif1	I-Protein
se	O
detecta	O
dentro	O
nuclear	B-GENE
focos	O
(	O
ver	O
Figura	O
6	O
)	O
,	O
que	O
,	O
según	O
nuestro	O
análisis	O
,	O
no	O
parecen	O
corresponder	O
a	O
varios	O
tipos	O
de	O
cuerpos	B-GENE
nucleares	I-GENE
,	O
incluyendo	O
cuerpos	B-GENE
de	I-GENE
LMP	I-GENE
.	O

Localización	O
de	O
gama	B-Protein
tif1	I-Protein
a	O
estos	O
cuerpos	B-GENE
nucleares	I-GENE
puede	O
ser	O
regulada	O
por	O
la	O
modificación	O
postraduccional	O
como	O
la	O
modificación	O
SUMO	O
que	O
se	O
requiere	O
para	O
LMP	B-Protein
formar	O
Dominios	B-GENE
nucleares	I-GENE
de	I-GENE
PML	I-GENE
(	O
Zhong	O
et	O
al	O
.	O
2000a	O
,	O
2000b	O
;	O
Best	O
et	O
al	O
.	O
2002	O
)	O
.	O

Estos	O
focos	O
pueden	O
servir	O
como	O
puntos	O
de	O
reunión	O
donde	O
gama	B-Protein
tif1	I-Protein
formas	O
multisubunidad	O
complejos	B-GENE
con	O
ADN	B-Sequence
factores	O
de	O
transcripción	O
vinculantes	O
y	O
sus	O
otros	O
coactivadores	O
o	O
correpresores	O
esenciales	O
,	O
durante	O
las	O
primeras	O
etapas	O
de	O
eritroide	B-Cell
diferenciación	O

Será	O
importante	O
determinar	O
la	O
identidad	O
de	O
gama	B-Protein
tif1	I-Protein
#	O
¿NOMBRE	O
?	O
proteinas	B-Chemical
en	O
nuclear	B-GENE
focos	O
y	O
establecer	O
cómo	O
funcionan	O
con	O
gama	B-Protein
tif1	I-Protein
regular	O
globulo	B-Cell
desarrollo	O
.	O

Materiales	O
y	O
métodos	O

pez	B-Taxon
cebra	I-Taxon
y	O
ratón	B-Taxon
cepas	O
y	O
estudios	O

pez	B-Taxon
cebra	I-Taxon
se	O
mantuvieron	O
y	O
organizaron	O
como	O
se	O
describe	O
(	O
Westerfield	O
1998	O
)	O
.	O

los	O
alelos	B-Sequence
montb222b	O
y	O
montg234	O
se	O
generaron	O
en	O
una	O
pantalla	O
a	O
gran	O
escala	O
para	O
ENU	B-Chemical
#	O
¿NOMBRE	O
?	O
mutaciones	B-Sequence
(	O
Ransom	O
et	O
al	O
.	O
1996	O
)	O
en	O
el	O
TU	O
,	O
mientras	O
que	O
el	O
monm262	O
alelo	B-Sequence
se	O
derivó	O
de	O
la	O
cepa	O
AB	O
y	O
originalmente	O
se	O
llamó	O
vampiro	O
(	O
Weinstein	O
et	O
al	O
.	O
1996	O
)	O
.	O

Las	O
cepas	O
de	O
mapeo	O
se	O
construyeron	O
apareándose	O
con	O
WIK	O
o	O
SJD	O
polimórfico	B-Sequence
cepas	O

El	O
análisis	O
de	O
ligamiento	O
se	O
realizó	O
en	O
embriones	O
haploides	O
o	O
diploides	O
obtenidos	O
de	O
híbridos	O
TU/SJD	O
o	O
TU/WIK	O
.	O

La	O
hibridación	O
in	O
situ	O
y	O
las	O
tinciones	O
de	O
embriones	O
se	O
realizaron	O
como	O
se	O
describe	O
(	O
Thompson	O
et	O
al	O
.	O
1998	O
;	O
Liao	O
et	O
al	O
.	O
2002	O
)	O
.	O

Hibridación	O
in	O
situ	O
de	O
ratón	B-Taxon
embriones	O
se	O
realizó	O
como	O
se	O
describe	O
(	O
Kingsley	O
et	O
al	O
.	O
2001	O
)	O
.	O

ADN	B-Sequence
genómico	I-Sequence
aislamiento	O
,	O
genotipado	O
,	O
análisis	O
AFLP	O
y	O
cromosómico	B-GENE
caminar	O
se	O
realizaron	O
como	O
se	O
describió	O
previamente	O
(	O
Browlie	O
et	O
al	O
.	O
1998	O
;	O
Ransom	O
y	O
Zon	O
1999	O
)	O
.	O

Una	O
lista	O
completa	O
de	O
cebadores	B-Sequence
por	O
genético	B-Sequence
mapeo	O
,	O
RT-PCR	O
y	O
secuenciación	O
de	O
Lun	B-Protein
están	O
disponibles	O
bajo	O
petición	O
.	O

ARNm	B-Chemical
expresión	O
construcciones	B-Sequence
,	O
morfolinos	B-Sequence
y	O
microinyección	O

La	O
longitud	O
completa	O
Lun	B-Protein
ADNc	B-Sequence
fue	O
subclonado	O
en	O
EcoRI	O
y	O
XhoI	O
sitios	B-Sequence
en	O
el	O
PCS2	O
+	O
vector	B-Sequence
.	O

Sintético	B-Sequence
ARNm	B-Chemical
se	O
transcribió	O
in	O
vitro	O
,	O
y	O
la	O
microinyección	O
se	O
realizó	O
esencialmente	O
como	O
se	O
describe	O
(	O
Liao	O
et	O
al	O
.	O
2002	O
)	O
.	O

Célula	B-Cell
trasplante	O

médula	O
renal	O
entera	O
células	B-Cell
fueron	O
aislados	O
de	O
adultos	O
gata1	B-Protein
:	O
EGFP	O
transgénico	B-Sequence
donantes	O
,	O
resuspendido	O
en	O
0	O
.	O
9X	O
fosfato	B-Chemical
-	O
amortiguado	B-Chemical
solución	O
salina	O
+	O
5	O
%	O
fetal	O
bovino	B-Taxon
suero	O
,	O
y	O
se	O
inyectó	O
en	O
el	O
seno	O
venoso	O
de	O
embriones	O
de	O
control	O
y	O
montg234-/-	O
de	O
2	O
días	O
de	O
edad	O
.	O

Entre	O
102	O
y	O
103	O
médula	O
renal	O
células	B-Cell
fueron	O
inyectados	O
por	O
embrión	O
.	O

Los	O
embriones	O
trasplantados	O
individuales	O
fueron	O
anestesiados	O
y	O
visualizados	O
diariamente	O
bajo	O
un	O
microscopio	O
fluorescente	O
invertido	O
(	O
DM-IRE2	O
;	O
Leica	O
,	O
Wetzlar	O
,	O
Alemania	O
)	O
para	O
GFP+	O
células	B-Cell
en	O
un	O
lapso	O
de	O
12	O
d	O
.	O

El	O
día	O
13	O
después	O
del	O
trasplante	O
,	O
todas	O
las	O
larvas	O
supervivientes	O
(	O
12/129	O
;	O
9	O
%	O
)	O
se	O
colocaron	O
en	O
tanques	O
y	O
se	O
controló	O
su	O
supervivencia	O
.	O

anticuerpos	B-GENE
,	O
inmunotinción	O
e	O
inmunoblots	O

Antisueros	O
contra	O
el	O
humano	B-Taxon
C	B-Sequence
-	I-Sequence
secuencia	I-Sequence
terminal	I-Sequence
TIF1	I-Sequence
gamma	I-Sequence
RRKRLKSDERPVHIK	O
se	O
generó	O
en	O
conejos	B-Taxon
(	O
Genemed	O
Synthesis	O
,	O
South	O
San	O
Francisco	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
y	O
purificado	O
por	O
afinidad	O
.	O

Ratón	B-Taxon
embrionario	O
fibroblastos	B-Cell
cultivadas	O
en	O
cubreobjetos	O
fueron	O
inmunoteñidas	O
con	O
HP1	B-Protein
alfa	I-Protein
(	O
Chemicon	O
,	O
Temecula	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
y	O
gama	B-Protein
tif1	I-Protein
antisueros	O
simultáneamente	O
.	O

En	O
breve	O
,	O
células	B-Cell
se	O
fijaron	O
en	O
paraformaldehído	O
al	O
4	O
%	O
durante	O
5	O
min	O
,	O
se	O
lavaron	O
con	O
fosfato	B-Chemical
-	O
amortiguado	B-Chemical
solución	O
salina	O
y	O
bloqueado	O
con	O
suero	O
al	O
5	O
%	O
(	O
PBST	O
)	O
durante	O
30	O
min	O
.	O

Después	O
de	O
la	O
incubación	O
con	O
el	O
primario	O
anticuerpos	B-GENE
(	O
PBST	O
,	O
60	O
minutos	O
)	O
células	B-Cell
se	O
lavaron	O
tres	O
veces	O
con	O
PBST	O
y	O
se	O
incubaron	O
con	O
anticuerpos	B-GENE
(	O
Laboratorio	O
Jackson	O
,	O
Bar	O
Harbor	O
,	O
Maine	O
,	O
Estados	O
Unidos	O
)	O
seguido	O
de	O
tres	O
lavados	O
en	O
PBST	O
.	O

Células	B-Cell
se	O
incluyeron	O
con	O
Vectashield/DAPI	O
y	O
se	O
analizaron	O
con	O
un	O
microscopio	O
Axioplan	O
2	O
(	O
Zeiss	O
,	O
Jena	O
,	O
Alemania	O
)	O
.	O

Las	O
imágenes	O
digitales	O
se	O
procesaron	O
utilizando	O
el	O
Volocity	O
1	O
.	O
0	O
software	O
(	O
Improvision	O
,	O
Lexington	O
,	O
Massachusetts	O
,	O
Estados	O
Unidos	O
)	O
.	O

G1E	O
célula	B-Cell
los	O
experimentos	O
de	O
diferenciación	O
se	O
realizaron	O
esencialmente	O
como	O
se	O
describe	O
(	O
Weiss	O
et	O
al	O
.	O
1997	O
)	O
.	O

información	O
de	O
soporte	O

Trasplante	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
pez	B-Taxon
cebra	I-Taxon
médula	O
células	B-Cell
llevando	O
una	O
gata1	B-Protein
:	O
GFP	O
transgén	B-Sequence
en	O
embriones	O
de	O
2	O
días	O
de	O
edad	O
reconstituye	O
la	O
eritropoyesis	O
,	O
pero	O
no	O
la	O
viabilidad	O
,	O
en	O
montg234	O
homocigotos	O
mutantes	B-Sequence
.	O

Las	O
películas	O
de	O
embriones	O
vivos	O
en	O
el	O
día	O
3	O
después	O
del	O
trasplante	O
destacan	O
menos	O
de	O
100	O
GFP	O
+	O
glóbulos	B-Cell
rojos	I-Cell
En	O
circulación	O
.	O

trasplantado	O
células	B-Cell
se	O
observó	O
que	O
proliferaban	O
,	O
dando	O
como	O
resultado	O
miles	O
de	O
células	O
derivadas	O
de	O
donantes	O
eritrocitos	B-Cell
7	O
días	O
después	O
.	O

Películas	O
presentan	O
GFP	O
-	O
imágenes	O
fluorescentes	O
de	O
vivo	O
pez	B-Taxon
cebra	I-Taxon
larvas	O

Vídeo	O
S1	O

Control	O
no	O
trasplantado	O
montg234	O
Homocigoto	O
mutantes	B-Sequence
No	O
tenía	O
fluorescente	O
Células	B-Cell
en	O
circulación	O
a	O
los	O
3	O
días	O
de	O
desarrollo	O

(	O
13	O
.	O
7	O
MB	O
MOV	O
)	O
.	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Vídeo	O
S2	O

Un	O
día	O
después	O
del	O
trasplante	O
,	O
menos	O
de	O
100	O
GFP	O
+	O
eritrocitos	B-Cell
eran	O
visibles	O
en	O
la	O
circulación	O
de	O
tres	O
montg234	O
homocigotos	O
mutantes	B-Sequence

(	O
11	O
.	O
3	O
MB	O
MOV	O
)	O
.	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Vídeo	O
S3	O

Control	O
no	O
trasplantado	O
montg234	O
Homocigoto	O
mutantes	B-Sequence
No	O
tenía	O
fluorescente	O
Células	B-Cell
en	O
circulación	O
a	O
los	O
9	O
días	O
de	O
desarrollo	O

(	O
7	O
.	O
9	O
MB	O
MOV	O
)	O
.	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Vídeo	O
S4	O

Siete	O
días	O
después	O
del	O
trasplante	O
,	O
miles	O
de	O
donantes	O
derivados	O
eritrocitos	B-Cell
Eran	O
Visibles	O
en	O
la	O
Circulación	O
de	O
un	O
Representante	O
montg234	O
Homocigoto	O
mutante	B-Sequence

(	O
11	O
.	O
2	O
MB	O
MOV	O
)	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Números	O
de	O
acceso	O

Los	O
números	O
de	O
acceso	O
de	O
GenBank	O
(	O
http	O
:	O
//	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
Genbank	O
)	O
para	O
el	O
genes	B-Sequence
y	O
gene	B-Sequence
Los	O
productos	O
discutidos	O
en	O
este	O
documento	O
son	O
bono	B-Protein
de	I-Protein
vuelo	I-Protein
(	O
AAF19646	O
)	O
,	O
humano	B-Protein
TIF1	I-Protein
alfa	I-Protein
(	O
015164	O
)	O
,	O
humano	B-Protein
TIF1	I-Protein
beta	I-Protein
(	O
Q13263	O
)	O
,	O
gamma	B-Protein
TIF	I-Protein
humano	I-Protein
(	O
Q9UPN9	O
)	O
,	O
gamma	B-Protein
TIF1	I-Protein
humano	I-Protein
(	O
Q9UPN9	O
)	O
,	O
Lun	B-Protein
(	O
AY59853	O
)	O
,	O
ratón	B-Protein
Tif1	I-Protein
alfa	I-Protein
(	O
Q64127	O
)	O
,	O
ratón	B-Protein
tif1	I-Protein
beta	I-Protein
(	O
AAH58391	O
)	O
,	O
y	O
ratón	B-Protein
tif1	I-Protein
gama	I-Protein
(	O
NP444400	O
)	O
.	O

los	O
Secuencias	B-Protein
de	I-Protein
ADNc	I-Protein
de	I-Protein
pez	I-Protein
cebra	I-Protein
mon/tif1	I-Protein
gamma	I-Protein
y	I-Protein
tif1	I-Protein
alfa	I-Protein
han	O
sido	O
depositados	O
en	O
GenBank	O
con	O
los	O
números	O
de	O
acceso	O
AY598453	O
y	O
AY598454	O
,	O
respectivamente	O
.	O

Agradecimientos	O

Agradecemos	O
a	O
A	O
.	O

Davidson	O
,	O
J	O
.	O

Amatruda	O
y	O
J	O
.	O

Christian	O
por	O
la	O
revisión	O
crítica	O
de	O
este	O
manuscrito	O
;	O
j	O

Postlethwait	O
y	O
W	O
.	O

Talbot	O
por	O
sus	O
útiles	O
debates	O
y	O
consejos	O
experimentales	O
;	O
B	O
.	O

Weinstein	O
por	O
el	O
regalo	O
del	O
m262	O
alelo	B-Sequence
de	O
Lun	B-Protein
;	O
y	O
D	O
.	O

Giarla	O
por	O
la	O
asistencia	O
administrativa	O
.	O

DGR	O
fue	O
financiado	O
por	O
la	O
Sociedad	O
Americana	O
del	O
Cáncer	O
y	O
un	O
premio	O
a	O
la	O
Universidad	O
de	O
Ciencias	O
y	O
Salud	O
de	O
Oregón	O
por	O
parte	O
del	O
Programa	O
de	O
Apoyo	O
a	O
la	O
Investigación	O
Biomédica	O
para	O
Escuelas	O
de	O
Medicina	O
del	O
Instituto	O
Médico	O
Howard	O
Hughes	O
(	O
HHMI	O
)	O
.	O

LIZ	O
y	O
SHO	O
son	O
investigadores	O
del	O
HHMI	O
.	O

Este	O
trabajo	O
fue	O
apoyado	O
por	O
subvenciones	O
de	O
los	O
Institutos	O
Nacionales	O
de	O
Salud	O
.	O

abreviaturas	O

AFLP	O
-	O
amplificado	O
fragmento	B-Sequence
longitud	O
polimorfismo	B-Sequence

ENU	B-Chemical
-	O
etil	B-Chemical
-	I-Chemical
nitrosourea	I-Chemical

est	B-Sequence
-	O
etiqueta	B-Sequence
de	I-Sequence
secuencia	I-Sequence
expresada	I-Sequence

GFP	O
-	O
verde	O
fluorescente	O
proteína	B-Chemical

hpf	O
-	O
horas	O
postfecundación	O

KRAB	O
-	O
Kr	O
uppel	O
-	O
caja	O
asociada	O

Lun	B-Protein
-	O
luz	B-Protein
de	I-Protein
la	I-Protein
luna	I-Protein
;	O
PAC	B-Sequence

LMP	B-Protein
-	O
leucemia	B-Protein
promielocítica	I-Protein
gene	B-Sequence
producto	O

glóbulos	B-Cell
rojos	I-Cell
-	O
las	B-Cell
células	I-Cell
rojas	I-Cell
de	I-Cell
la	I-Cell
sangre	I-Cell

scl	B-Protein
-	O
leucemia	B-Protein
de	I-Protein
células	I-Protein
madre	I-Protein
;	O
SSCP	O

TIF	O
-	O
factor	O
intermediario	O
transcripcional	O

TU	O
-	O
Tu	O
bingen	O
fondo	O

Figuras	O
y	O
Tablas	O

Figura	O
1	O

Mon	B-Protein
pez	I-Protein
cebra	I-Protein
mutantes	B-Sequence
Tienen	O
defectos	O
graves	O
en	O
la	O
hematopoyesis	O
primitiva	O

(	O
A	O
)	O
Los	O
ensayos	O
TUNEL	O
de	O
montaje	O
completo	O
revelan	O
que	O
el	O
células	B-Cell
mesodérmicas	I-Cell
sufrir	O
apoptosis	O
en	O
homocigotos	O
montg234	O
mutante	B-Sequence
embriones	O

Hibridación	O
in	O
situ	O
de	O
montaje	O
completo	O
de	O
gata1	B-Protein
detectado	O
en	O
la	O
etapa	O
de	O
12	O
y	O
18	O
somitas	O
en	O
embriones	O
genotipados	O
.	O

Vistas	O
posteriores	O
,	O
anterior	O
a	O
la	O
izquierda	O
.	O

(	O
B	O
)	O
La	O
apoptosis	O
extensa	O
es	O
visible	O
en	O
el	O
tronco	O
y	O
la	O
cola	O
(	O
punta	O
de	O
flecha	O
)	O
y	O
también	O
en	O
células	B-Cell
hematopoyéticas	I-Cell
de	O
la	O
isla	O
de	O
sangre	O
embrionaria	O
a	O
las	O
22	O
h	O
de	O
desarrollo	O
(	O
flecha	O
)	O
.	O

Hibridación	O
in	O
situ	O
de	O
montaje	O
completo	O
a	O
22	O
hpf	O
que	O
incluye	O
scl	B-Protein
,	O
gata2	B-Protein
,	O
gata1	B-Protein
,	O
ícaros	B-Protein
,	O
y	O
mi	B-Protein
b	I-Protein
en	O
montg234	O
mutantes	B-Sequence
.	O

Expresión	O
de	O
mi	B-Protein
b	I-Protein
se	O
reduce	O
en	O
gran	O
medida	O
en	O
las	O
islas	O
de	O
sangre	O
debido	O
a	O
una	O
prdida	O
de	O
células	B-Cell
eritroides	I-Cell
,	O
pero	O
embrionario	O
macrófagos	B-Cell
todavía	O
están	O
presentes	O
(	O
flechas	O
)	O
.	O

la	O
expresión	O
de	O
trapo1	B-Protein
en	O
timo	O
células	B-Cell
T	I-Cell
parece	O
normal	O
en	O
Lun	B-Protein
mutantes	B-Sequence
a	O
los	O
5	O
d	O
postfecundación	O
(	O
puntas	O
de	O
flecha	O
)	O
.	O

Vistas	O
laterales	O
de	O
22	O
hpf	O
y	O
embriones	O
de	O
5	O
días	O
de	O
edad	O
.	O

Figura	O
2	O

Mon	B-Protein
pez	I-Protein
cebra	I-Protein
mutantes	B-Sequence
También	O
tienen	O
defectos	O
graves	O
en	O
la	O
hematopoyesis	O
definitiva	O

Fenotipo	O
adulto	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
Lun	B-Protein
mutantes	B-Sequence
.	O

Un	O
raro	O
adulto	O
homocigoto	O
montb222	O
sobreviviente	O
muestra	O
cardiomegalia	O
significativa	O
en	O
comparación	O
con	O
un	O
tipo	B-Sequence
salvaje	I-Sequence
control	O
emparejado	O
por	O
edad	O
.	O

Wright	O
-	O
Médula	O
teñida	O
con	O
Giemsa	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
adulto	O
en	O
comparación	O
con	O
un	O
homocigoto	O
mutante	B-Sequence
.	O

Nótese	O
la	O
drástica	O
reducción	O
de	O
diferenciados	O
terminalmente	O
células	B-Cell
eritroides	I-Cell
y	O
la	O
presencia	O
de	O
megaloblastos	O
anormalmente	O
grandes	O
proeritroblastos	B-Cell
en	O
el	O
montb222	O
mutante	B-Sequence
tuétano	O

figura	O
3	O

posicional	B-Sequence
La	O
clonación	O
identifica	O
el	O
Lun	B-Protein
Gene	B-Sequence
como	O
Pez	B-Protein
cebra	I-Protein
tif1	I-Protein
gamma	I-Protein

(	O
A	O
)	O
Mapa	B-Sequence
físico	I-Sequence
de	O
El	O
Lun	B-Protein
locus	B-Sequence
en	I-Sequence
el	I-Sequence
cromosoma	I-Sequence
del	I-Sequence
pez	I-Sequence
cebra	I-Sequence
8	O

Marcadores	B-Sequence
de	I-Sequence
microsatélites	I-Sequence
z987	O
y	O
z11001	O
se	O
usaron	O
para	O
identificar	O
inicialmente	O
los	O
recombinantes	O
en	O
un	O
panel	O
de	O
2	O
,	O
200	O
diploides	O
montg234	O
homocigotos	O
mutantes	B-Sequence
.	O

El	O
marcador	O
AFLP	O
MA3	O
se	O
utilizó	O
para	O
iniciar	O
un	O
cromosómico	B-GENE
entrar	O
PAC	B-Sequence
bibliotecas	O

El	O
critico	O
PACS	B-Sequence
que	O
fueron	O
aislados	O
para	O
abarcar	O
el	O
Lun	B-Protein
lugar	B-Sequence
se	O
indican	O
mediante	O
números	O
encima	O
de	O
la	O
barra	O
.	O

los	O
PAC	B-Sequence
107N19	O
define	O
la	O
crítica	O
intervalo	B-Sequence
Para	O
el	O
Lun	B-Protein
gene	B-Sequence
.	O

Esta	O
PAC	B-Sequence
fue	O
utilizado	O
como	O
un	O
Investigacion	B-Sequence
a	O
la	O
pantalla	O
ADNc	B-Sequence
bibliotecas	O
e	O
identificar	O
pez	B-Protein
cebra	I-Protein
tif1	I-Protein
gamma	I-Protein
ADNc	B-Sequence
.	O

Los	O
números	O
debajo	O
de	O
la	O
barra	O
indican	O
el	O
número	O
de	O
recombinantes	O
identificados	O
por	O
análisis	O
SSCP	O
.	O

(	O
B	O
)	O
Clustal	O
-	O
W	O
-	O
árbol	O
filogenético	O
generado	O
de	O
pez	B-Protein
cebra	I-Protein
(	I-Protein
Danio	I-Protein
rerio	I-Protein
[	I-Protein
Dr	I-Protein
]	I-Protein
)	I-Protein
Tif1	I-Protein
gamma	I-Protein
y	I-Protein
Tif1	I-Protein
alfa	I-Protein
secuencias	B-Sequence
peptídicas	I-Sequence
en	O
comparación	O
con	O
los	O
miembros	O
de	O
la	O
familia	O
TIF1	O
:	O
humanos	B-Protein
(	I-Protein
Hs	I-Protein
)	I-Protein
TIF1	I-Protein
alfa	I-Protein
,	I-Protein
TIF1	I-Protein
beta	I-Protein
y	I-Protein
TIF1	I-Protein
gamma	I-Protein
;	O
ratón	B-Protein
(	I-Protein
Mm	I-Protein
)	I-Protein
Tif1	I-Protein
alfa	I-Protein
,	I-Protein
Tif1	I-Protein
beta	I-Protein
y	I-Protein
Tif1	I-Protein
gamma	I-Protein
;	O
;	O
y	O
bono	B-Protein
de	I-Protein
mosca	I-Protein
(	I-Protein
Dm	I-Protein
)	I-Protein
.	O

(	O
C	O
)	O
Diagramas	O
que	O
ilustran	O
la	O
estructura	O
del	O
gama	B-Protein
tif1	I-Protein
-	O
péptido	B-Sequence
predicho	I-Sequence
y	O
los	O
tres	O
puntos	O
identificados	O
mutantes	B-Sequence
.	O

dedo	O
ANULAR	O
(	O
ANILLO	O
)	O
,	O
B	B-Sequence
-	I-Sequence
cajas	I-Sequence
(	O
B1	O
y	O
B2	O
)	O
,	O
planta	B-Taxon
dedo	O
de	O
homeodominio	O
(	O
PHD	O
)	O
y	O
bromodominio	O
(	O
BROMO	O
)	O
.	O

Los	O
números	O
debajo	O
del	O
primer	O
diagrama	O
indican	O
el	O
porcentaje	O
de	O
identidad	O
compartido	O
entre	O
cada	O
uno	O
de	O
estos	O
dominios	B-Sequence
en	O
pez	B-Protein
cebra	I-Protein
y	I-Protein
gamma	I-Protein
TIF1	I-Protein
humana	I-Protein
.	O

los	O
predicho	B-Sequence
truncado	O
proteinas	B-Chemical
se	O
indican	O
.	O

(	O
D	O
)	O
secuencia	B-Sequence
de	I-Sequence
ADN	I-Sequence
cromatogramas	O
que	O
muestran	O
los	O
tres	O
ENU	B-Chemical
#	O
¿NOMBRE	O
?	O
mutantes	B-Sequence
en	O
comparación	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
control	O
secuencias	B-Sequence

Figura	O
4	O

los	O
Lun	B-Protein
/	O
gama	B-Protein
tif1	I-Protein
Gene	B-Sequence
está	O
altamente	O
expresado	O
en	O
el	O
mesodermo	O
hematopoyético	O

(	O
A	O
)	O
Hibridación	O
in	O
situ	O
de	O
pez	B-Taxon
cebra	I-Taxon
embriones	O
que	O
demuestran	O
la	O
expresión	O
embrionaria	O
de	O
gama	B-Protein
tif1	I-Protein
.	O

gama	B-Protein
tif1	I-Protein
se	O
expresa	O
inicialmente	O
como	O
maternal	O
ARNm	B-Chemical
.	O

Aumento	O
de	O
la	O
expresión	O
de	O
gama	B-Protein
tif1	I-Protein
en	O
el	O
mesodermo	O
ventral-lateral	O
comienza	O
entre	O
las	O
etapas	O
de	O
uno	O
a	O
tres	O
somitas	O
y	O
aumenta	O
a	O
lo	O
largo	O
del	O
desarrollo	O
temprano	O
.	O

Por	O
cinco	O
somitas	O
,	O
gama	B-Protein
tif1	I-Protein
se	O
expresa	O
fuertemente	O
en	O
franjas	O
laterales	O
de	O
mesodermo	O
que	O
también	O
expresan	O
scl	B-Protein
.	O

A	O
22	O
HPF	O
gama	B-Protein
tif1	I-Protein
se	O
expresa	O
ampliamente	O
en	O
el	O
cerebro	O
,	O
la	O
médula	O
espinal	O
,	O
el	O
tronco	O
y	O
el	O
mesénquima	O
de	O
la	O
cola	O
,	O
pero	O
se	O
encuentra	O
en	O
niveles	O
mucho	O
más	O
altos	O
en	O
células	B-Cell
hematopoyéticas	I-Cell
de	O
la	O
isla	O
de	O
sangre	O
.	O

Pez	B-Protein
cebra	I-Protein
tif1	I-Protein
alfa	I-Protein
también	O
se	O
expresa	O
ampliamente	O
pero	O
es	O
relativamente	O
más	O
uniforme	O
en	O
la	O
mayoría	O
de	O
los	O
tejidos	O
,	O
en	O
comparación	O
con	O
gama	B-Protein
tif1	I-Protein
.	O

tif1	B-Protein
alfa	I-Protein
se	O
expresa	O
débilmente	O
en	O
las	O
primeras	O
etapas	O
de	O
somita	O
en	O
el	O
mesodermo	O
hematopoyético	O
y	O
se	O
expresa	O
uniformemente	O
a	O
las	O
22	O
hpf	O
,	O
incluida	O
la	O
expresión	O
en	O
los	O
islotes	O
sanguíneos	O
.	O

Expresión	O
de	O
scl	B-Protein
en	O
cinco	O
somitas	O
y	O
22	O
hpf	O
resalta	O
la	O
isla	O
de	O
sangre	O
embrionaria	O
en	O
comparación	O
con	O
gama	B-Protein
tif1	I-Protein
expresión	O
.	O

(	O
B	O
)	O
Hibridación	O
in	O
situ	O
de	O
ratón	B-Taxon
embriones	O
detecta	O
una	O
amplia	O
expresión	O
de	O
gama	B-Protein
tif1	I-Protein
en	O
el	O
día	O
8	O
embrionario	O
.	O
5	O
incluyendo	O
los	O
islotes	O
de	O
sangre	O
del	O
saco	O
vitelino	O
(	O
flecha	O
)	O
.	O

En	O
el	O
día	O
12	O
embrionario	O
.	O
5	O
,	O
hay	O
un	O
alto	O
nivel	O
de	O
expresión	O
en	O
el	O
hígado	O
fetal	O
(	O
flecha	O
)	O
y	O
una	O
amplia	O
expresión	O
en	O
el	O
cerebro	O
embrionario	O
,	O
la	O
médula	O
espinal	O
,	O
el	O
intestino	O
y	O
el	O
músculo	O
.	O

Figura	O
5	O

Sobreexpresión	O
de	O
Tipo	B-Sequence
salvaje	I-Sequence
gama	B-Protein
tif1	I-Protein
ARNm	B-Chemical
o	O
el	O
trasplante	O
de	O
médula	O
rescata	O
la	O
hematopoyesis	O
embrionaria	O
en	O
Lun	B-Protein
mutantes	B-Sequence

(	O
A	O
)	O
montg234	O
mutantes	B-Sequence
son	O
rescatados	O
por	O
inyección	O
de	O
ARNm	B-Chemical
#	O
¿NOMBRE	O
?	O
tipo	B-Sequence
salvaje	I-Sequence
gama	B-Protein
tif1	I-Protein
proteína	B-Chemical
.	O

A	O
los	O
4	O
días	O
de	O
desarrollo	O
,	O
un	O
gran	O
número	O
de	O
glóbulos	B-Cell
rojos	I-Cell
son	O
visibles	O
en	O
la	O
circulación	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
pez	B-Taxon
cebra	I-Taxon
,	O
que	O
se	O
muestra	O
aquí	O
mediante	O
la	O
tinción	O
con	O
o	O
-	O
dianisidina	O
de	O
hemoglobina	B-GENE
.	O

Homocigoto	O
monttg234	O
no	O
inyectado	O
mutantes	B-Sequence
son	O
completamente	O
sin	O
sangre	O
.	O

Inyección	O
de	O
100	O
pg	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
gama	B-Protein
tif1	I-Protein
ARNm	B-Chemical
rescata	O
la	O
eritropoyesis	O
en	O
mutante	B-Sequence
embriones	O

Las	O
larvas	O
teñidas	O
con	O
o-dianisidina	O
se	O
muestran	O
en	O
vistas	O
ventrales	O
para	O
resaltar	O
la	O
sangre	O
en	O
los	O
vasos	O
.	O

(	O
B	O
)	O
Trasplante	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
pez	B-Taxon
cebra	I-Taxon
médula	O
células	B-Cell
llevando	O
una	O
gata1	B-Protein
:	O
GFP	O
transgén	B-Sequence
en	O
embriones	O
de	O
2	O
días	O
de	O
edad	O
reconstituye	O
la	O
eritropoyesis	O
,	O
pero	O
no	O
la	O
viabilidad	O
,	O
en	O
montg234	O
homocigotos	O
mutantes	B-Sequence
.	O

Los	O
fotogramas	O
de	O
películas	O
de	O
embriones	O
vivos	O
en	O
el	O
día	O
3	O
después	O
del	O
trasplante	O
resaltan	O
menos	O
de	O
100	O
GFP	O
+	O
glóbulos	B-Cell
rojos	I-Cell
en	O
circulación	O
(	O
arriba	O
)	O
.	O

trasplantado	O
células	B-Cell
se	O
observó	O
que	O
proliferaban	O
dando	O
como	O
resultado	O
miles	O
de	O
donantes	O
derivados	O
eritrocitos	B-Cell
7	O
d	O
después	O
(	O
abajo	O
)	O
.	O

Las	O
flechas	O
indican	O
los	O
corazones	O
de	O
control	O
y	O
trasplantados	O
pez	B-Taxon
cebra	I-Taxon
.	O

Ver	O
vídeos	O
S1-S4	O
.	O

Figura	O
6	O

Mamífero	B-Taxon
gama	B-Protein
tif1	I-Protein
Proteína	B-Chemical
Localiza	O
a	O
cuerpos	B-GENE
nucleares	I-GENE
Distinto	O
de	O
heterocromatina	B-GENE

(	O
A	O
)	O
Imágenes	O
de	O
inmunofluorescencia	O
desconvolucionadas	O
de	O
un	O
ratón	B-Taxon
embrionario	O
célula	B-Cell
de	I-Cell
fibroblasto	I-Cell
núcleo	B-GENE
manchado	O
con	O
un	O
anti	O
-	O
gama	B-Protein
tif1	I-Protein
anticuerpo	B-GENE
y	O
teñido	O
con	O
un	O
monoclonal	O
anticuerpo	B-GENE
dirigido	O
contra	O
HP1	B-Protein
alfa	I-Protein
.	O

Esto	O
también	O
se	O
compara	O
con	O
la	O
tinción	O
DAPI	O
.	O

Las	O
imágenes	O
fusionadas	O
de	O
la	O
núcleo	B-GENE
muestra	O
esa	O
gama	B-Protein
tif1	I-Protein
no	O
se	O
colocaliza	O
con	O
el	O
HP1	B-Protein
alfa	I-Protein
o	O
tinción	O
DAPI	O
de	O
heterocromatina	B-GENE
tiempo	O
HP1	B-Protein
alfa	I-Protein
y	O
superposición	O
de	O
tinción	O
DAPI	O
.	O

(	O
B	O
)	O
G1ER	O
ratón	B-Taxon
eritroleucemia	O
células	B-Cell
expresar	O
altos	O
niveles	O
de	O
gama	B-Protein
tif1	I-Protein
proteína	B-Chemical
según	O
lo	O
detectado	O
por	O
análisis	O
de	O
transferencia	O
Western	O
.	O

Expresión	O
de	O
gama	B-Protein
tif1	I-Protein
disminuye	O
durante	O
gata1	B-Protein
#	O
¿NOMBRE	O
?	O
eritroide	B-Cell
maduración	O
inducida	O
por	O
beta-estradiol	B-Chemical
tratamiento	O
para	O
inducir	O
un	O
gata1	B-Protein
-	O
Urgencias	B-Protein
fusión	B-Sequence
proteína	B-Chemical
.	O

tabla	O
1	O

Sobreexpresión	O
de	O
gama	B-Protein
tif1	I-Protein
ARNm	B-Chemical
Rescates	O
Lun	B-Protein
mutantes	B-Sequence
Fenotipos	O
hematopoyéticos	O

Sintético	B-Sequence
gama	B-Protein
tif1	I-Protein
ARNm	B-Chemical
(	O
100	O
pg	O
)	O
se	O
inyectó	O
en	O
el	O
-	O
célula	B-Cell
etapa	O
en	O
embriones	O
de	O
los	O
indicados	O
genotipos	B-Sequence
.	O

Para	O
el	O
Lun	B-Protein
embriones	O
,	O
células	B-Cell
circulantes	I-Cell
donde	O
se	O
contaron	O
cada	O
día	O
a	O
través	O
de	O
4	O
d	O
,	O
cuando	O
los	O
embriones	O
fueron	O
fijados	O
y	O
teñidos	O
con	O
o	O
-	O
dianisidina	O
para	O
detectar	O
hemoglobina	B-Chemical
en	O
maduro	O
glóbulos	B-Cell
rojos	I-Cell
.	O

Los	O
embriones	O
normales	O
contienen	O
aproximadamente	O
3	O
000	O
células	B-Cell
circulantes	I-Cell
en	O
estos	O
momentos	O
.	O

Los	O
resultados	O
se	O
dan	O
como	O
número	O
de	O
embriones	O
con	O
el	O
fenotipo	O
indicado	O
.	O

Los	O
números	O
entre	O
paréntesis	O
representan	O
el	O
porcentaje	O
del	O
total	O
de	O
embriones	O
analizados	O

Tabla	O
2	O

El	O
trasplante	O
de	O
médula	O
rescata	O
la	O
hematopoyesis	O
pero	O
no	O
la	O
supervivencia	O
en	O
Lun	B-Protein
mutantes	B-Sequence
:	O
Embriones	O
con	O
Trasplantados	O
Células	B-Cell
eritroides	I-Cell

Entre	O
100	O
y	O
1	O
000	O
médula	O
renal	O
células	B-Cell
de	O
adulto	O
gata1	B-Protein
:	O
EGFP	O
transgénico	B-Sequence
los	O
donantes	O
fueron	O
inyectados	O
por	O
pez	B-Taxon
cebra	I-Taxon
embrión	O
a	O
las	O
48	O
hpf	O
.	O

Los	O
embriones	O
trasplantados	O
individuales	O
fueron	O
anestesiados	O
y	O
visualizados	O
para	O
GFP	O
+	O
células	B-Cell
eritroides	I-Cell
.	O

A	O
los	O
10	O
días	O
posteriores	O
al	O
trasplante	O
,	O
el	O
número	O
indicado	O
de	O
embriones	O
tenía	O
un	O
estimado	O
de	O
100	O
a	O
3	O
000	O
GFP	O
+	O
células	B-Cell
En	O
circulación	O
.	O

los	O
3	O
meses	O
el	O
número	O
indicado	O
de	O
pez	B-Taxon
estaban	O
vivos	O

El	O
porcentaje	O
relativo	O
de	O
embriones	O
se	O
muestra	O
entre	O
paréntesis	O
.	O

notas	O
al	O
pie	O

Conflictos	O
de	O
interés	O
.	O

Los	O
autores	O
han	O
declarado	O
que	O
no	O
existen	O
conflictos	O
de	O
interés	O
.	O

Contribuciones	O
de	O
autor	O
.	O

DGR	O
,	O
NB	O
,	O
KN	O
,	O
DT	O
,	O
CB	O
,	O
NST	O
,	O
YZ	O
,	O
JP	O
,	O
SHO	O
y	O
LIZ	O
concibieron	O
y	O
diseñaron	O
los	O
experimentos	O
.	O

DGR	O
,	O
NB	O
,	O
KN	O
,	O
DT	O
,	O
CB	O
,	O
NST	O
,	O
NPL	O
,	O
WJS	O
,	O
CAL	O
,	O
CH	O
,	O
BAB	O
y	O
PDK	O
realizaron	O
los	O
experimentos	O
.	O

DGR	O
,	O
NB	O
,	O
KN	O
,	O
DT	O
,	O
CB	O
,	O
NST	O
,	O
NPL	O
,	O
YZ	O
,	O
JP	O
,	O
SHO	O
y	O
LIZ	O
analizaron	O
los	O
datos	O
.	O

DGR	O
,	O
NB	O
,	O
KN	O
,	O
DT	O
,	O
NST	O
,	O
YZ	O
,	O
BAB	O
,	O
SL	O
y	O
JP	O
contribuyeron	O
reactivos	B-Chemical
/	O
materiales	O
/	O
herramientas	O
de	O
análisis	O
.	O

DGR	O
,	O
NB	O
,	O
KN	O
,	O
DT	O
y	O
LIZ	O
escribieron	O
el	O
artículo	O
.	O

Editor	O
académico	O
:	O
William	O
Talbot	O
,	O
Universidad	O
de	O
Stanford	O

moneda	O
Dirección	O
actual	O
:	O
Departamento	O
de	O
Célula	B-Cell
y	O
Biología	O
del	O
Desarrollo	O
,	O
Universidad	O
de	O
Ciencias	O
y	O
Salud	O
de	O
Oregón	O
,	O
Portland	O
,	O
Oregón	O
,	O
Estados	O
Unidos	O
de	O
América	O

Cita	O
:	O
Ransom	O
DG	O
,	O
Bahary	O
N	O
,	O
Niss	O
K	O
,	O
Traver	O
D	O
,	O
Burns	O
C	O
,	O
et	O
al	O
.	O

(	O
2004	O
)	O
El	O
luz	B-Protein
de	I-Protein
la	I-Protein
luna	I-Protein
de	I-Protein
pez	I-Protein
cebra	I-Protein
gene	B-Sequence
codifica	O
intermediario	B-Protein
transcripcional	I-Protein
factor	I-Protein
1	I-Protein
gamma	I-Protein
,	O
un	O
regulador	O
esencial	O
de	O
la	O
hematopoyesis	O
.	O

PLoS	O
Biol	O
2	O
(	O
8	O
)	O
:	O
e237	O
.	O

Autoinmunidad	O
espontánea	O
en	O
129	O
y	O
C57BL/6	O
Ratones	B-Taxon
#	O
¿NOMBRE	O
?	O
Gene	B-Sequence
#	O
¿NOMBRE	O
?	O
Ratones	B-Taxon

Resumen	O

El	O
lupus	O
eritematoso	O
sistémico	O
(	O
LES	O
)	O
es	O
un	O
trastorno	O
autoinmune	O
multisistémico	O
en	O
el	O
que	O
se	O
genético	B-Sequence
factores	O
juegan	O
un	O
papel	O
importante	O
.	O

Varias	O
cepas	O
de	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
se	O
ha	O
informado	O
que	O
desarrollan	O
LES	O
,	O
lo	O
que	O
implica	O
la	O
nula	O
genes	B-Sequence
en	O
la	O
causalidad	O
de	O
la	O
enfermedad	O
.	O

Sin	O
embargo	O
,	O
las	O
cepas	O
híbridas	O
entre	O
129	O
y	O
C57BL	O
/	O
6	O
ratones	B-Taxon
,	O
ampliamente	O
utilizado	O
en	O
la	O
generación	O
de	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
,	O
desarrollar	O
autoinmunidad	O
espontánea	O
.	O

Además	O
,	O
el	O
genético	B-Sequence
fondo	O
influye	O
notablemente	O
en	O
el	O
fenotipo	O
autoinmune	O
de	O
LES	O
en	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
.	O

Esto	O
sugiere	O
un	O
papel	O
importante	O
en	O
la	O
expresión	O
de	O
la	O
autoinmunidad	O
de	O
antecedentes	O
aún	O
no	O
caracterizados	O
.	O
genes	B-Sequence
procedente	O
de	O
estos	O
padres	O
ratón	B-Taxon
cepas	O

Utilizando	O
genoma	B-Sequence
-	O
amplio	O
análisis	O
de	O
ligamiento	O
,	O
identificamos	O
varias	O
susceptibilidades	O
lugares	B-Sequence
,	O
derivado	O
de	O
129	O
y	O
C57BL/6	O
ratones	B-Taxon
mapeado	O
en	O
el	O
modelo	O
híbrido	O
propenso	O
al	O
lupus	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
.	O

Al	O
crear	O
una	O
cepa	O
congénica	O
C57BL	O
/	O
6	O
que	O
lleva	O
un	O
derivado	O
de	O
129	O
Segmento	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
1	I-Sequence
,	O
encontramos	O
que	O
este	O
129	O
intervalo	B-Sequence
fue	O
suficiente	O
para	O
mediar	O
la	O
pérdida	O
de	O
tolerancia	O
a	O
nuclear	B-GENE
antígenos	O
,	O
que	O
previamente	O
se	O
habían	O
atribuido	O
a	O
una	O
alteración	O
gene	B-Sequence
.	O

Estos	O
resultados	O
demuestran	O
importantes	O
modificadores	O
epistáticos	O
de	O
la	O
autoinmunidad	O
en	O
129	O
y	O
C57BL/6	O
ratón	B-Taxon
cepas	O
,	O
muy	O
utilizadas	O
en	O
gene	B-Sequence
apuntando	O

estos	O
antecedentes	O
gene	B-Sequence
influencias	O
pueden	O
explicar	O
algunos	O
,	O
o	O
incluso	O
todos	O
,	O
los	O
rasgos	O
autoinmunes	O
descritos	O
en	O
algunos	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O

Introducción	O

El	O
lupus	O
eritematoso	O
sistémico	O
(	O
LES	O
)	O
es	O
una	O
enfermedad	O
autoinmune	O
crónica	O
caracterizada	O
por	O
la	O
producción	O
de	O
autoanticuerpos	O
(	O
auto-	O
Abdominales	B-GENE
)	O
contra	O
un	O
amplio	O
espectro	O
de	O
autoantígenos	O
,	O
principalmente	O
de	O
compartimentos	O
subcelulares	O
,	O
especialmente	O
el	O
célula	B-Cell
núcleo	B-GENE
.	O

Genético	B-Sequence
La	O
predisposición	O
es	O
un	O
contribuyente	O
importante	O
a	O
la	O
susceptibilidad	O
al	O
LES	O
en	O
ambos	O
humanos	B-Taxon
y	O
animales	B-Taxon
(	O
Vyse	O
y	O
Todd	O
1996	O
;	O
Harley	O
et	O
al	O
.	O
1998	O
;	O
Theofilopoulos	O
y	O
Kono	O
1999	O
;	O
Wakeland	O
et	O
al	O
.	O
2001	O
)	O
.	O

genes	B-Sequence
en	O
múltiples	O
vías	O
participan	O
en	O
la	O
mediación	O
de	O
la	O
patogénesis	O
de	O
la	O
enfermedad	O
y	O
las	O
interacciones	O
epistáticas	O
entre	O
estos	O
genes	B-Sequence
influir	O
en	O
la	O
expresión	O
de	O
la	O
enfermedad	O
.	O

En	O
este	O
contexto	O
,	O
ambos	O
genético	B-Sequence
estudios	O
de	O
ligamiento	O
en	O
lupus	O
espontáneo	O
-	O
modelos	O
propensos	O
y	O
sintéticos	O
murino	B-Taxon
modelos	O
de	O
autoinmunidad	O
generados	O
por	O
la	O
interrupción	O
dirigida	O
de	O
específicos	O
genes	B-Sequence
moduladores	O
del	O
sistema	O
inmunitario	O
se	O
han	O
utilizado	O
ampliamente	O
para	O
investigar	O
la	O
complejidad	O
del	O
LES	O
.	O

Las	O
cepas	O
mejor	O
estudiadas	O
de	O
ratones	B-Taxon
que	O
desarrollan	O
espontáneamente	O
una	O
patología	O
similar	O
al	O
lupus	O
son	O
la	O
cepa	O
híbrida	O
New	O
Zealand	O
Black/New	O
Zealand	O
White	O
(	O
NZB/WF1	O
)	O
;	O
la	O
cepa	O
MRL	O
/	O
Mp	O
lpr	O
/	O
lpr	O
,	O
que	O
porta	O
la	O
cepa	O
lpr	O
mutación	B-Sequence
de	O
El	O
receptor	B-Protein
FAS	I-Protein
gene	B-Sequence
;	O
y	O
la	O
cepa	O
BXSB	O
,	O
que	O
lleva	O
la	O
Acelerador	B-Protein
autoinmune	I-Protein
del	I-Protein
cromosoma	I-Protein
Y	I-Protein
(	O
Yaa	B-Protein
)	O
gene	B-Sequence
(	O
Theofilopoulos	O
y	O
Dixon	O
1985	O
)	O
.	O

Extenso	O
genético	B-Sequence
estudios	O
de	O
mapeo	O
en	O
las	O
tres	O
cepas	O
han	O
identificado	O
múltiples	O
intervalos	B-Sequence
asociado	O
con	O
la	O
susceptibilidad	O
a	O
la	O
enfermedad	O
.	O

Curiosamente	O
,	O
la	O
mayoría	O
de	O
los	O
intervalos	B-Sequence
detectados	O
son	O
específicos	O
de	O
la	O
cepa	O
,	O
lo	O
que	O
confirma	O
la	O
genético	B-Sequence
complejidad	O
de	O
la	O
enfermedad	O
e	O
indicando	O
la	O
presencia	O
de	O
una	O
amplia	O
heterogeneidad	O
en	O
la	O
genes	B-Sequence
contribuyendo	O
a	O
la	O
patogenia	O
de	O
la	O
enfermedad	O
.	O

Sin	O
embargo	O
,	O
cierta	O
susceptibilidad	O
lugares	B-Sequence
han	O
sido	O
mapeados	O
a	O
similares	O
ubicaciones	B-Sequence
cromosómicas	I-Sequence
en	O
diferentes	O
cepas	O
,	O
lo	O
que	O
sugiere	O
que	O
al	O
menos	O
alguna	O
susceptibilidad	O
puede	O
ser	O
compartida	O
entre	O
las	O
cepas	O
propensas	O
al	O
lupus	O
.	O

Entre	O
estas	O
susceptibilidades	O
compartidas	O
lugares	B-Sequence
,	O
las	O
más	O
llamativas	O
son	O
loci	B-Sequence
en	I-Sequence
el	I-Sequence
cromosoma	I-Sequence
distal	I-Sequence
1	O
,	O
para	O
el	O
cual	O
contribuye	O
importante	O
genes	B-Sequence
se	O
han	O
encontrado	O
en	O
modelos	O
de	O
Nueva	O
Zelanda	O
y	O
BXSB	O
(	O
Theofilopoulos	O
y	O
Kono	O
1999	O
;	O
Wakeland	O
et	O
al	O
.	O
2001	O
)	O
.	O

Aunque	O
se	O
han	O
hecho	O
esfuerzos	O
considerables	O
para	O
identificar	O
los	O
genes	B-Sequence
responsable	O
del	O
desarrollo	O
de	O
la	O
enfermedad	O
,	O
a	O
excepción	O
de	O
la	O
lpr	O
mutación	B-Sequence
,	O
ninguno	O
de	O
los	O
genético	B-Sequence
contribuciones	O
a	O
la	O
enfermedad	O
en	O
los	O
tres	O
bien	O
documentados	O
murino	B-Taxon
Las	O
cepas	O
de	O
LES	O
aún	O
se	O
han	O
resuelto	O
por	O
completo	O
en	O
el	O
molecular	B-Chemical
o	O
proteína	B-Chemical
nivel	O
.	O

Así	O
,	O
dirigido	O
genético	B-Sequence
interrupción	O
del	O
candidato	O
genes	B-Sequence
codificación	O
proteinas	B-Chemical
del	O
sistema	O
inmunitario	O
se	O
ha	O
utilizado	O
ampliamente	O
para	O
examinar	O
su	O
papel	O
en	O
la	O
regulación	O
inmunitaria	O
.	O

Sin	O
embargo	O
,	O
el	O
resultado	O
más	O
sorprendente	O
de	O
este	O
poderoso	O
enfoque	O
ha	O
sido	O
la	O
alta	O
frecuencia	O
con	O
la	O
que	O
tales	O
mutaciones	B-Sequence
se	O
han	O
asociado	O
con	O
un	O
fenotipo	O
autoinmune	O
.	O

En	O
este	O
sentido	O
,	O
cabe	O
destacar	O
que	O
las	O
cepas	O
híbridas	O
entre	O
129	O
y	O
C57BL/6	O
ratones	B-Taxon
,	O
ampliamente	O
utilizado	O
en	O
la	O
generación	O
de	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
,	O
están	O
espontáneamente	O
predispuestos	O
al	O
desarrollo	O
de	O
autoinmunidad	O
humoral	O
con	O
niveles	O
bajos	O
de	O
glomerulonefritis	O
(	O
Obata	O
et	O
al	O
.	O
1979	O
;	O
Botto	O
et	O
al	O
.	O
1998	O
;	O
Bickerstaff	O
et	O
al	O
.	O
1999	O
;	O
Santiago	O
-	O
Raber	O
et	O
al	O
.	O
2001	O
)	O
.	O

Además	O
,	O
el	O
genético	B-Sequence
fondo	O
influye	O
notablemente	O
en	O
el	O
fenotipo	O
autoinmune	O
en	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
(	O
Bolland	O
y	O
Ravetch	O
2000	O
;	O
Santiago-Raber	O
et	O
al	O
.	O
2001	O
;	O
Mitchell	O
et	O
al	O
.	O
2002	O
)	O
.	O

Estas	O
observaciones	O
llevaron	O
a	O
la	O
hipótesis	O
de	O
que	O
el	O
fenotipo	O
autoinmune	O
descrito	O
en	O
algunos	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
podría	O
deberse	O
principalmente	O
a	O
combinaciones	O
de	O
antecedentes	O
aún	O
no	O
caracterizados	O
genes	B-Sequence
,	O
con	O
origen	O
en	O
129	O
y	O
C57BL	O
/	O
6	O
ratones	B-Taxon
cepas	O
,	O
interactuando	O
o	O
no	O
con	O
el	O
alelo	B-Sequence
mutado	I-Sequence
.	O

Para	O
probar	O
esto	O
,	O
llevamos	O
a	O
cabo	O
un	O
genoma	B-Sequence
-	O
análisis	O
de	O
escaneo	O
amplio	O
de	O
dos	O
grandes	O
cohortes	O
de	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
ratones	B-Taxon
,	O
uno	O
de	O
los	O
cuales	O
llevaba	O
un	O
mutación	B-Sequence
en	O
el	O
componente	B-Protein
amiloide	I-Protein
P	I-Protein
sérico	I-Protein
gene	B-Sequence
(	O
APC	B-Protein
)	O
.	O

los	O
APC	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
(	O
APC	B-Protein
-	O
/	O
-	O
)	O
fueron	O
elegidos	O
como	O
ejemplo	O
de	O
un	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
genético	B-Sequence
fondo	O
(	O
129	O
x	O
C57BL/6	O
)	O
;	O
autoinmunidad	O
en	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
persiste	O
incluso	O
después	O
de	O
retrocruzar	O
el	O
gen	B-Sequence
mutado	I-Sequence
sobre	O
C57BL/6	O
(	O
Bickerstaff	O
et	O
al	O
.	O
1999	O
)	O
.	O

Elegimos	O
este	O
objetivo	O
gene	B-Sequence
en	O
particular	O
para	O
estudiar	O
desde	O
el	O
APC	B-Protein
gene	B-Sequence
se	O
encuentra	O
en	O
Cromosoma	B-GENE
1	O
,	O
aproximadamente	O
a	O
94	O
cm	O
del	O
centrómero	B-Sequence
,	O
dentro	O
de	O
una	O
región	B-Sequence
donde	O
varios	O
lupus	O
-	O
susceptibilidad	O
lugares	B-Sequence
,	O
designado	O
Sle1	B-Protein
(	O
Morel	O
et	O
al	O
.	O
2001	O
)	O
,	O
Nba2	B-Protein
(	O
Drake	O
et	O
al	O
.	O
1995	O
;	O
Vyse	O
et	O
al	O
.	O
1997	O
)	O
,	O
y	O
Bxs3	B-Protein
Hogarth	O
et	O
al	O
.	O
1998	O
;	O
Haywood	O
et	O
al	O
.	O
2000	O
)	O
,	O
se	O
han	O
mapeado	O
en	O
cepas	O
propensas	O
al	O
lupus	O
NZW	O
,	O
NZB	O
y	O
BXSB	O
,	O
respectivamente	O
.	O

Esta	O
región	B-Sequence
contiene	O
varios	O
genes	B-Sequence
,	O
incluidos	O
los	O
que	O
codifican	O
Fc	B-Protein
gamma	I-Protein
RII	I-Protein
,	O
el	O
receptor	O
del	O
complemento	O
CR1	B-Protein
/	O
2	O
(	O
CD35	B-Protein
/	O
CD21	B-Protein
)	O
,	O
y	O
el	O
factor	O
de	O
aceleración	O
del	O
decaimiento	O
CD55	B-Protein
(	O
Prodeus	O
et	O
al	O
.	O
1998	O
;	O
Bolland	O
y	O
Ravetch	O
2000	O
;	O
Miwa	O
et	O
al	O
.	O
2002	O
;	O
Wu	O
et	O
al	O
.	O
2002	O
)	O
,	O
cada	O
uno	O
de	O
los	O
cuales	O
ha	O
sido	O
implicado	O
en	O
la	O
causalidad	O
del	O
LES	O
cuando	O
es	O
inactivado	O
por	O
gene	B-Sequence
-	O
focalización	O
en	O
129	O
embrionarios	O
Células	B-Cell
madre	I-Cell
.	O

Aquí	O
mostramos	O
que	O
hay	O
múltiples	O
locus	B-Sequence
genéticos	I-Sequence
,	O
derivado	O
tanto	O
de	O
129	O
como	O
de	O
C57BL/6	O
ratones	B-Taxon
,	O
contribuyendo	O
a	O
la	O
autoinmunidad	O
.	O

Además	O
,	O
un	O
derivado	O
de	O
129	O
intervalo	B-Sequence
en	I-Sequence
el	I-Sequence
cromosoma	I-Sequence
distal	I-Sequence
1	O
,	O
cuando	O
transferido	B-Sequence
en	O
el	O
C57BL	O
/	O
6	O
genoma	B-Sequence
,	O
una	O
combinación	O
comúnmente	O
creada	O
por	O
retrocruzamiento	O
en	O
C57BL	O
/	O
6	O
a	O
gene	B-Sequence
que	O
ha	O
sido	O
inactivado	O
en	O
129	O
embriones	O
Células	B-Cell
madre	I-Cell
fue	O
suficiente	O
para	O
causar	O
autoinmunidad	O
humoral	O
por	O
derecho	O
propio	O
,	O
independientemente	O
de	O
la	O
presencia	O
del	O
mutado	B-Sequence
APC	B-Protein
gene	B-Sequence
.	O

Estos	O
resultados	O
demuestran	O
importantes	O
interacciones	O
epistáticas	O
entre	O
genes	B-Sequence
de	O
129	O
y	O
C57BL/6	O
genomas	B-Sequence
sobre	O
el	O
desarrollo	O
de	O
la	O
autoinmunidad	O
e	O
ilustrar	O
los	O
efectos	O
importantes	O
de	O
antecedentes	O
genes	B-Sequence
en	O
el	O
análisis	O
e	O
interpretación	O
de	O
fenotipos	O
autoinmunes	O
asociados	O
con	O
genético	B-Sequence
interrupciones	O

Resultados	O

Rasgos	O
de	O
enfermedad	O
en	O
(	O
129	O
x	O
C57BL/6	O
)	O
F2	O
y	O
(	O
129	O
x	O
C57BL/6	O
)	O
F2	O
.	O
APC	B-Protein
-	O
/	O
-	O
Ratones	B-Taxon

para	O
investigar	O
el	O
genético	B-Sequence
base	O
de	O
la	O
enfermedad	O
similar	O
al	O
lupus	O
observada	O
en	O
el	O
híbrido	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
ratones	B-Taxon
,	O
generamos	O
dos	O
grandes	O
cohortes	O
de	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
animales	B-Taxon
,	O
uno	O
que	O
lleva	O
un	O
mutación	B-Sequence
en	O
el	O
APC	B-Protein
gene	B-Sequence
y	O
los	O
supervisó	O
durante	O
1	O
año	O
en	O
condiciones	O
ambientales	O
idénticas	O
.	O

Desde	O
mujer	O
ratones	B-Taxon
en	O
los	O
informes	O
originales	O
mostró	O
una	O
mayor	O
penetración	O
de	O
la	O
enfermedad	O
,	O
el	O
presente	O
estudio	O
se	O
realizó	O
solo	O
en	O
mujeres	O
ratones	B-Taxon
.	O

Los	O
resultados	O
del	O
análisis	O
fenotípico	O
al	O
año	O
de	O
edad	O
se	O
resumen	O
en	O
las	O
Tablas	O
1	O
y	O
2	O
.	O

Como	O
se	O
informó	O
previamente	O
(	O
Botto	O
et	O
al	O
.	O
1998	O
)	O
,	O
el	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
ratones	B-Taxon
desarrolló	O
rasgos	O
de	O
lupus	O
con	O
niveles	O
elevados	O
de	O
auto	O
-	O
Abdominales	B-GENE
,	O
a	O
partir	O
de	O
los	O
6	O
meses	O
de	O
edad	O
(	O
datos	O
no	O
mostrados	O
)	O
y	O
evidencia	O
histológica	O
de	O
glomerulonefritis	O
proliferativa	O
.	O

De	O
acuerdo	O
con	O
nuestras	O
observaciones	O
previas	O
(	O
Bickerstaff	O
et	O
al	O
.	O
1999	O
)	O
,	O
los	O
títulos	O
de	O
anti	O
-	O
abdominales	B-GENE
nucleares	I-GENE
(	O
ANA	O
)	O
y	O
anti-	O
cromatina	B-GENE
Ab	I-GENE
fueron	O
considerablemente	O
mayores	O
en	O
el	O
(	O
129	O
x	O
C57BL/6	O
)	O
F2	O
.	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
en	O
comparación	O
con	O
los	O
controles	O
emparejados	O
por	O
cepas	O
.	O

Sin	O
embargo	O
,	O
a	O
diferencia	O
de	O
nuestros	O
hallazgos	O
originales	O
,	O
los	O
niveles	O
de	O
los	O
otros	O
dos	O
marcadores	O
serológicos	O
de	O
enfermedad	O
analizados	O
(	O
anti-	O
ADN	B-Sequence
monocatenario	I-Sequence
[	O
ssDNA	O
]	O
y	O
anti-	O
ADN	B-Sequence
de	I-Sequence
doble	I-Sequence
cadena	I-Sequence
[	O
dsADN	O
]	O
Abdominales	B-GENE
)	O
y	O
la	O
gravedad	O
de	O
la	O
patología	O
renal	O
no	O
fueron	O
diferentes	O
entre	O
los	O
dos	O
grupos	O
experimentales	O
.	O

Ante	O
la	O
posibilidad	O
de	O
una	O
asociación	O
entre	O
el	O
fijo	O
129	O
-	O
derivado	O
segmento	B-Sequence
flanqueando	O
el	O
mutado	B-Sequence
APC	B-Protein
gene	B-Sequence
los	O
rasgos	O
autoinmunes	O
observados	O
,	O
la	O
genoma	B-Sequence
Se	O
llevó	O
a	O
cabo	O
por	O
separado	O
un	O
amplio	O
análisis	O
de	O
vinculación	O
de	O
las	O
dos	O
cohortes	O
experimentales	O
.	O

Mapeo	O
de	O
lugares	B-Sequence
Predisposición	O
al	O
Lupus	O
en	O
la	O
Cepa	O
Híbrida	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O

Ratones	B-Taxon
fueron	O
genotipados	O
con	O
143	O
marcadores	B-Sequence
de	I-Sequence
microsatélites	I-Sequence
distribuidos	O
por	O
todo	O
el	O
autosomas	B-GENE
tal	O
que	O
el	O
98	O
%	O
de	O
los	O
genes	B-Sequence
estaban	O
dentro	O
de	O
los	O
20	O
cm	O
de	O
un	O
marcador	O
informativo	O
.	O

un	O
resumen	O
de	O
la	O
genoma	B-Sequence
En	O
la	O
Tabla	O
3	O
se	O
muestra	O
un	O
amplio	O
análisis	O
de	O
vinculación	O
para	O
cada	O
uno	O
de	O
los	O
rasgos	O
de	O
enfermedad	O
medidos	O
.	O

los	O
áreas	B-Sequence
de	I-Sequence
vinculación	I-Sequence
se	O
definieron	O
según	O
el	O
origen	O
parental	O
,	O
129	O
o	O
C57BL	O
/	O
6	O
.	O

Solo	O
los	O
vínculos	O
identificados	O
en	O
ambos	O
grupos	O
experimentales	O
se	O
informan	O
en	O
la	O
Tabla	O
3	O
,	O
con	O
la	O
excepción	O
de	O
los	O
Segmento	B-Sequence
distal	I-Sequence
del	I-Sequence
cromosoma	I-Sequence
1	I-Sequence
,	O
donde	O
el	O
análisis	O
de	O
ligamiento	O
no	O
se	O
pudo	O
aplicar	O
al	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
.	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
como	O
este	O
región	B-Sequence
era	O
de	O
origen	O
fijo	O
129	O
.	O

cromosomas	B-GENE
donde	O
los	O
vínculos	O
estaban	O
presentes	O
sólo	O
en	O
una	O
de	O
las	O
dos	O
cohortes	O
se	O
muestran	O
en	O
las	O
Figuras	O
1-3	O
.	O

los	O
vinculación	B-Sequence
de	I-Sequence
rasgos	I-Sequence
cuantitativos	I-Sequence
(	O
QTL	B-Sequence
)	O
análisis	O
identificó	O
varios	O
intervalos	B-Sequence
en	I-Sequence
el	I-Sequence
cromosoma	I-Sequence
1	O
con	O
enlace	O
a	O
marcadores	O
serológicos	O
de	O
enfermedad	O
,	O
y	O
estos	O
regiones	B-Sequence
todos	O
se	O
derivaron	O
del	O
129	O
ratón	B-Taxon
cepa	O
(	O
ver	O
Tabla	O
3	O
;	O
Figuras	O
4	O
y	O
5	O
)	O
.	O

Curiosamente	O
,	O
mientras	O
que	O
ANA	O
y	O
anti-	O
cromatina	B-GENE
Ab	I-GENE
niveles	O
mostraron	O
vínculos	O
sugestivos	O
o	O
significativos	O
sólo	O
con	O
el	O
región	B-GENE
telomérica	I-GENE
del	I-GENE
cromosoma	I-GENE
1	O
,	O
con	O
un	O
pico	O
estimado	O
que	O
ocurre	O
en	O
un	O
posición	B-Sequence
aproximadamente	O
90	O
cm	O
cerca	O
del	O
APC	B-Protein
gene	B-Sequence
,	O
anti	O
-	O
dsDNA	O
o	O
anti	O
-	O
ssDNA	O
AB	B-GENE
la	O
producción	O
también	O
estaba	O
vinculada	O
a	O
otros	O
segmentos	B-Sequence
en	I-Sequence
el	I-Sequence
cromosoma	I-Sequence
1	O
,	O
indicando	O
una	O
más	O
compleja	O
genético	B-Sequence
aporte	O
del	O
129	O
ratón	B-Taxon
tensión	O
.	O

Guiados	O
por	O
estas	O
observaciones	O
,	O
investigamos	O
si	O
los	O
niveles	O
elevados	O
de	O
ANA	O
y	O
anti-	O
cromatina	B-GENE
Ab	I-GENE
observado	O
en	O
el	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
fueron	O
causados	O
por	O
un	O
gen	B-Sequence
(	I-Sequence
es	I-Sequence
)	I-Sequence
dentro	O
del	O
fijo	O
129	O
región	B-Sequence
rodeando	O
el	O
mutado	B-Sequence
APC	B-Protein
gene	B-Sequence
,	O
en	O
lugar	O
de	O
ser	O
causada	O
por	O
la	O
mutado	B-Sequence
APC	B-Protein
gene	B-Sequence
sí	O
mismo	O
.	O

Comparamos	O
los	O
niveles	O
de	O
estos	O
auto	O
-	O
Abdominales	B-GENE
entre	O
todos	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
.	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
y	O
un	O
grupo	O
de	O
33	O
tipo	B-Sequence
salvaje	I-Sequence
ratones	B-Taxon
que	O
fueron	O
seleccionados	O
por	O
ser	O
homocigotos	O
129	O
en	O
el	O
región	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
1	O
entre	O
microsatélites	B-Sequence
D1Mit105	O
y	O
D1Mit	O
223	O
(	O
80-106	O
cm	O
)	O
(	O
Figura	O
6A-6D	O
)	O
.	O

En	O
contraste	O
con	O
los	O
resultados	O
informados	O
en	O
la	O
Tabla	O
1	O
,	O
esta	O
comparación	O
no	O
mostró	O
diferencias	O
significativas	O
entre	O
los	O
dos	O
grupos	O
experimentales	O
.	O

Este	O
resultado	O
demuestra	O
que	O
,	O
muy	O
probablemente	O
,	O
el	O
derivado	O
de	O
129	O
región	B-Sequence
y	O
no	O
la	O
falta	O
de	O
APC	B-Protein
estaba	O
mediando	O
la	O
producción	O
de	O
ANA	O
y	O
anti	O
-	O
cromatina	B-GENE
Ab	I-GENE
.	O

De	O
acuerdo	O
con	O
esta	O
explicación	O
,	O
encontramos	O
que	O
el	O
129	O
ratones	B-Taxon
tienen	O
niveles	O
significativamente	O
más	O
altos	O
de	O
APC	B-Protein
en	O
circulación	O
en	O
comparación	O
con	O
el	O
C57BL	O
/	O
6	O
ratones	B-Taxon
(	O
mediana	O
,	O
83	O
mg	O
/	O
l	O
;	O
rango	O
,	O
25	O
-	O
208	O
;	O
n	O
=	O
16	O
versus	O
mediana	O
,	O
5	O
mg	O
/	O
l	O
;	O
rango	O
,	O
4	O
-	O
9	O
;	O
n	O
=	O
10	O
,	O
respectivamente	O
;	O
p	O
<	O
0,0001	O
)	O
.	O

Se	O
ha	O
informado	O
previamente	O
que	O
la	O
cepa	O
C57BL/6	O
es	O
una	O
de	O
las	O
murino	B-Taxon
cepas	O
definidas	O
como	O
bajas	O
APC	B-Protein
productores	O
(	O
Pepys	O
et	O
al	O
.	O
1979	O
;	O
Baltz	O
et	O
al	O
.	O
1980	O
)	O
.	O

Además	O
,	O
secuencia	B-Sequence
análisis	O
de	O
la	O
totalidad	O
APC	B-Protein
región	B-Sequence
de	I-Sequence
codificación	I-Sequence
en	O
ambas	O
cepas	O
no	O
pudieron	O
identificar	O
ninguna	O
polimorfismos	B-Sequence
de	I-Sequence
secuencia	I-Sequence
codificante	I-Sequence
en	O
el	O
APC	B-Protein
gene	B-Sequence
(	O
datos	O
no	O
mostrados	O
)	O
,	O
lo	O
que	O
indica	O
que	O
una	O
estructura	O
variante	B-Sequence
de	O
El	O
proteína	B-Chemical
es	O
poco	O
probable	O
que	O
sea	O
la	O
explicación	O
de	O
nuestros	O
hallazgos	O
.	O

Esto	O
es	O
consistente	O
con	O
un	O
informe	O
anterior	O
de	O
Drake	O
et	O
al	O
.	O

(	O
1996	O
)	O
que	O
no	O
mostró	O
APC	B-Protein
secuencia	B-Sequence
de	I-Sequence
codificación	I-Sequence
diferencias	O
entre	O
varios	O
autoinmunes	O
y	O
no	O
autoinmunes	O
murino	B-Taxon
cepas	O

Además	O
del	O
129	O
-	O
derivado	O
segmentos	B-Sequence
,	O
en	O
ambas	O
cohortes	O
la	O
cepa	O
C57BL/6	O
contribuyó	O
a	O
los	O
rasgos	O
autoinmunes	O
con	O
una	O
mayor	O
susceptibilidad	O
locus	B-Sequence
en	I-Sequence
el	I-Sequence
cromosoma	I-Sequence
3	O
.	O

A	O
región	B-Sequence
genómica	I-Sequence
entre	O
D3Mit40	O
y	O
D3Mit13	O
,	O
con	O
un	O
pico	O
estimado	O
en	O
posición	B-Sequence
aproximadamente	O
51	O
cM	O
,	O
mostró	O
un	O
vínculo	O
significativo	O
con	O
la	O
producción	O
de	O
ANA	O
y	O
vínculos	O
más	O
débiles	O
con	O
anti	O
-	O
ssDNA	O
y	O
anti	O
-	O
cromatina	B-GENE
producción	O
(	O
ver	O
Tabla	O
3	O
;	O
Figura	O
7	O
)	O
.	O

La	O
alta	O
frecuencia	O
de	O
fenotipo	O
autoinmune	O
en	O
el	O
híbrido	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
genético	B-Sequence
antecedentes	O
y	O
su	O
ausencia	O
en	O
cualquiera	O
de	O
las	O
cepas	O
parentales	O
endogámicas	O
implican	O
que	O
existen	O
interacciones	O
esenciales	O
entre	O
129	O
y	O
C57BL	O
/	O
6	O
derivados	O
alelos	B-Sequence
para	O
la	O
expresión	O
de	O
la	O
autoinmunidad	O
.	O

Investigamos	O
más	O
a	O
fondo	O
los	O
efectos	O
de	O
genes	B-Sequence
del	O
fondo	O
C57BL/6	O
repitiendo	O
el	O
análisis	O
de	O
ligamiento	O
en	O
(	O
129	O
x	O
C57BL/6	O
)	O
F2	O
ratones	B-Taxon
,	O
mientras	O
se	O
controla	O
por	O
el	O
efecto	O
129	O
muy	O
fuerte	O
en	O
distal	O
Cromosoma	B-GENE
1	O
,	O
como	O
se	O
describió	O
anteriormente	O
(	O
Zeng	O
1994	O
)	O
.	O

Los	O
resultados	O
de	O
este	O
análisis	O
mostraron	O
que	O
el	O
soporte	O
estadístico	O
para	O
la	O
vinculación	O
del	O
C57BL/6	O
locus	B-Sequence
en	I-Sequence
el	I-Sequence
cromosoma	I-Sequence
3	O
para	O
ANA	O
aumentado	O
a	O
partir	O
del	O
logaritmo	O
de	O
probabilidades	O
(	O
LOD	O
)	O
5	O
.	O
4	O
a	O
LOD	O
6	O
.	O
4	O
.	O

En	O
contraste	O
con	O
estas	O
fuertes	O
asociaciones	O
con	O
marcadores	O
serológicos	O
de	O
enfermedades	O
,	O
el	O
QTL	B-Sequence
El	O
análisis	O
identificó	O
solo	O
dos	O
vínculos	O
potenciales	O
con	O
la	O
glomerulonefritis	O
:	O
uno	O
en	O
el	O
tipo	B-Sequence
salvaje	I-Sequence
ratones	B-Taxon
en	O
Cromosoma	B-GENE
7	O
a	O
través	O
de	O
10	O
cm	O
región	B-Sequence
entre	O
D7Mit246	O
(	O
15	O
cM	O
)	O
y	O
D7Mit145	O
(	O
26	O
.	O
5	O
cM	O
)	O
de	O
origen	O
129	O
(	O
LOD	O
2	O
.	O
86	O
,	O
p	O
=	O
0	O
.	O
0013	O
)	O
,	O
y	O
uno	O
en	O
Cromosoma	B-GENE
17	O
entre	O
D17Mit100	O
(	O
11	O
,	O
7	O
cM	O
)	O
y	O
D17Mit216	O
(	O
29	O
,	O
4	O
cM	O
)	O
de	O
la	O
cepa	O
C57BL	O
/	O
6	O
(	O
LOD	O
1	O
,	O
3	O
,	O
p	O
=	O
0	O
,	O
049	O
y	O
LOD	O
1	O
,	O
67	O
,	O
p	O
=	O
0	O
,	O
021	O
en	O
el	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
,	O
respectivamente	O
)	O
.	O

Solo	O
se	O
encontró	O
evidencia	O
histológica	O
de	O
glomerulonefritis	O
en	O
aproximadamente	O
el	O
20	O
%	O
de	O
los	O
ratones	B-Taxon
en	O
cada	O
cohorte	O
,	O
lo	O
que	O
reduce	O
el	O
poder	O
de	O
la	O
QTL	B-Sequence
análisis	O
para	O
este	O
rasgo	O
de	O
la	O
enfermedad	O
.	O

Producción	O
de	O
un	O
C57BL	O
/	O
6	O
.	O
129	O
Cromosoma	B-GENE
1	O
Línea	O
Congénica	O
y	O
su	O
Análisis	O
Fenotípico	O

Generamos	O
una	O
línea	O
congénica	O
C57BL/6	O
que	O
lleva	O
el	O
región	B-GENE
telomérica	I-GENE
del	I-GENE
cromosoma	I-GENE
1	O
de	O
los	O
129	O
ratón	B-Taxon
cepa	O
,	O
con	O
el	O
fin	O
de	O
diseccionar	O
el	O
fenotipo	O
de	O
enfermedad	O
poligénica	O
compleja	O
de	O
la	O
cepa	O
híbrida	O
F2	O
(	O
C57BL	O
/	O
6	O
x	O
129	O
/	O
Sv	O
)	O
en	O
su	O
individuo	O
genético	B-Sequence
componentes	O

El	O
intervalo	O
129	O
se	O
retrocruzó	O
siete	O
veces	O
con	O
C57BL/6	O
y	O
,	O
en	O
cada	O
generación	O
,	O
la	O
presencia	O
o	O
ausencia	O
del	O
Intervalo	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
1	I-Sequence
se	O
determinó	O
con	O
varios	O
marcadores	B-Sequence
de	I-Sequence
microsatélites	I-Sequence
.	O

Cada	O
generación	O
retrocruzada	O
se	O
cribó	O
con	O
más	O
de	O
tres	O
marcadores	O
por	O
cromosoma	B-GENE
para	O
facilitar	O
la	O
eliminación	B-Sequence
de	O
no	O
seleccionados	O
129	O
regiones	B-Sequence
genómicas	I-Sequence
.	O

Al	O
final	O
del	O
retrocruzamiento	O
,	O
el	O
derivado	O
129	O
Intervalo	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
1	I-Sequence
en	O
el	O
congénico	O
ratones	B-Taxon
extendido	O
desde	O
marcador	B-Sequence
de	I-Sequence
microsatélites	I-Sequence
D1Mit105	O
a	O
D1Mit223	O
(	O
80	O
-	O
106	O
cM	O
)	O
,	O
que	O
abarca	O
los	O
129	O
más	O
importantes	O
intervalo	B-Sequence
identificado	O
por	O
los	O
estudios	O
de	O
ligamiento	O
en	O
el	O
(	O
C57BL	O
/	O
6	O
x	O
129	O
/	O
Sv	O
)	O
F2	O
ratones	B-Taxon
.	O

Mujer	O
Cromosoma	B-GENE
1	O
congénico	O
ratones	B-Taxon
(	O
C57BL	O
/	O
6	O
.	O
129	O
[	O
D1Mit105	O
-	O
223	O
]	O
)	O
,	O
junto	O
con	O
emparejamiento	O
por	O
sexo	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
retrocruzado	O
con	O
C57BL/6	O
durante	O
diez	O
generaciones	O
(	O
C57BL/6	O
.	O
APC	B-Protein
-/-	O
)	O
y	O
controles	O
C57BL/6	O
,	O
fueron	O
monitoreados	O
para	O
detectar	O
la	O
presencia	O
de	O
lupus	O
.	O

En	O
el	O
C57BL/6	O
.	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
,	O
el	O
129	O
genoma	B-Sequence
alrededor	O
de	O
APC	B-Protein
lugar	B-Sequence
fue	O
mapeado	O
como	O
un	O
tramo	B-Sequence
de	O
aproximadamente	O
17	O
cm	O
,	O
posicionado	O
desde	O
87	O
.	O
9	O
cm	O
(	O
D1Mit15	O
)	O
a	O
105	O
cm	O
(	O
D1Mit17	O
)	O
.	O

Así	O
,	O
la	O
línea	O
congénica	O
llevó	O
un	O
129	O
similar	O
región	B-Sequence
(	O
80	O
-	O
106	O
cM	O
)	O
al	O
presente	O
en	O
el	O
C57BL	O
/	O
6	O
.	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
(	O
87	O
,	O
9	O
-	O
105	O
cm	O
)	O
.	O

Al	O
año	O
de	O
edad	O
,	O
todos	O
animales	B-Taxon
fueron	O
sacrificados	O
,	O
el	O
auto	O
-	O
Abdominales	B-GENE
evaluado	O
,	O
y	O
la	O
histología	O
renal	O
examinada	O
.	O

Los	O
resultados	O
de	O
este	O
análisis	O
se	O
muestran	O
en	O
la	O
Figura	O
8	O
.	O

Como	O
se	O
informó	O
previamente	O
(	O
Bickerstaff	O
et	O
al	O
.	O
1999	O
)	O
,	O
los	O
niveles	O
de	O
auto-	O
Abdominales	B-GENE
aumentaron	O
notablemente	O
en	O
el	O
C57BL/6	O
.	O
APC	B-Protein
-	O
/	O
-	O
en	O
comparación	O
con	O
el	O
tipo	B-Sequence
salvaje	I-Sequence
C57BL/6	O
mandos	O
.	O

Sin	O
embargo	O
,	O
el	O
C57BL/6	O
.	O
129	O
(	O
D1Mit105	O
-	O
223	O
)	O
animales	B-Taxon
también	O
expresó	O
altos	O
niveles	O
de	O
auto	O
-	O
Abdominales	B-GENE
,	O
y	O
estos	O
títulos	O
no	O
fueron	O
diferentes	O
de	O
los	O
detectados	O
en	O
los	O
congénicos	O
emparejados	O
ratones	B-Taxon
que	O
contiene	O
un	O
nulo	O
mutación	B-Sequence
de	O
El	O
APC	B-Protein
gene	B-Sequence
.	O

Estos	O
resultados	O
demostraron	O
claramente	O
que	O
las	O
interacciones	O
epistáticas	O
entre	O
129	O
loci	B-Sequence
en	I-Sequence
el	I-Sequence
cromosoma	I-Sequence
1	O
y	O
C57BL/6	O
genes	B-Sequence
fueron	O
suficientes	O
para	O
mediar	O
la	O
pérdida	O
de	O
tolerancia	O
a	O
nuclear	B-GENE
autoantígenos	O

Sin	O
embargo	O
,	O
en	O
contraste	O
con	O
los	O
datos	O
serológicos	O
,	O
la	O
evaluación	O
histológica	O
de	O
los	O
riñones	O
mostró	O
evidencia	O
de	O
glomerulonefritis	O
marcadamente	O
aumentada	O
en	O
el	O
C57BL/6	O
.	O
APC	B-Protein
-	O
/	O
-	O
en	O
comparación	O
con	O
ambos	O
grupos	O
de	O
control	O
(	O
Figura	O
9	O
)	O
,	O
lo	O
que	O
sugiere	O
que	O
la	O
falta	O
de	O
APC	B-Protein
,	O
cuando	O
se	O
combina	O
con	O
otros	O
C57BL	O
/	O
6	O
susceptibilidad	O
alelos	B-Sequence
puede	O
inducir	O
el	O
desarrollo	O
de	O
daño	O
renal	O
severo	O
.	O

Discusión	O

Cada	O
vez	O
hay	O
más	O
pruebas	O
de	O
que	O
los	O
antecedentes	O
genes	B-Sequence
puede	O
influir	O
en	O
la	O
expresión	O
de	O
la	O
autoinmunidad	O
en	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
.	O

Aquí	O
informamos	O
lo	O
que	O
es	O
,	O
según	O
nuestro	O
conocimiento	O
,	O
el	O
primer	O
estudio	O
sistemático	O
que	O
ha	O
examinado	O
esto	O
en	O
el	O
129	O
y	O
C57BL	O
/	O
6	O
ratón	B-Taxon
cepas	O
,	O
muy	O
utilizadas	O
para	O
gene	B-Sequence
apuntando	O

Nuestros	O
resultados	O
demuestran	O
la	O
interacción	O
lugares	B-Sequence
entre	O
129	O
y	O
C57BL/6	O
ratones	B-Taxon
que	O
puede	O
provocar	O
la	O
expresión	O
de	O
un	O
potente	O
fenotipo	O
autoinmune	O
en	O
estos	O
animales	B-Taxon
,	O
en	O
ausencia	O
de	O
cualquier	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
mutaciones	B-Sequence
.	O

También	O
desarrollamos	O
un	O
congénico	O
ratón	B-Taxon
tensión	O
soportando	O
un	O
porción	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
129	I-Sequence
1	O
en	O
un	O
fondo	O
C57BL	O
/	O
6	O
y	O
demostró	O
que	O
este	O
tipo	B-Sequence
salvaje	I-Sequence
línea	O
congénica	O
expresó	O
llamativo	O
anti	O
-	O
nuclear	B-GENE
autoinmunidad	O

Al	O
comparar	O
esto	O
Cromosoma	B-GENE
1	O
cepa	O
congénica	O
con	O
congénica	O
emparejada	O
ratones	B-Taxon
careciendo	O
de	O
la	O
APC	B-Protein
gene	B-Sequence
,	O
demostramos	O
que	O
componente	B-Protein
amiloide	I-Protein
P	I-Protein
sérico	I-Protein
la	O
deficiencia	O
influye	O
en	O
la	O
gravedad	O
de	O
la	O
glomerulonefritis	O
,	O
pero	O
no	O
es	O
el	O
motor	O
principal	O
en	O
la	O
inducción	O
de	O
anti-	O
nuclear	B-GENE
autoinmunidad	O
,	O
contrariamente	O
a	O
nuestra	O
propia	O
interpretación	O
original	O
de	O
nuestros	O
datos	O
(	O
Bickerstaff	O
et	O
al	O
.	O
1999	O
)	O
.	O

La	O
misma	O
consideración	O
se	O
aplica	O
a	O
otros	O
genes	B-Sequence
ubicado	O
en	O
el	O
mismo	O
Región	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
1	I-Sequence
que	O
han	O
sido	O
implicados	O
en	O
el	O
desarrollo	O
de	O
LES	O
cuando	O
son	O
inactivados	O
por	O
gene	B-Sequence
-	O
focalización	O
en	O
129	O
embrionarios	O
Células	B-Cell
madre	I-Cell
y	O
luego	O
retrocruzado	O
en	O
un	O
puro	O
genético	B-Sequence
antecedentes	O
(	O
Bolland	O
y	O
Ravetch	O
2000	O
;	O
Miwa	O
et	O
al	O
.	O
2002	O
;	O
Wu	O
et	O
al	O
.	O
2002	O
)	O
.	O

Para	O
cada	O
uno	O
,	O
tiene	O
que	O
haber	O
una	O
pregunta	O
sobre	O
si	O
el	O
anti-	O
nuclear	B-GENE
La	O
autoinmunidad	O
se	O
debe	O
a	O
la	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
gen	B-Sequence
mutante	I-Sequence
o	O
a	O
lo	O
normal	O
129	O
genes	B-Sequence
expresado	O
en	O
el	O
mismo	O
región	B-Sequence
como	O
objetivo	O
gene	B-Sequence
.	O

La	O
influencia	O
del	O
fondo	O
.	O
genes	B-Sequence
sobre	O
el	O
desarrollo	O
de	O
la	O
enfermedad	O
autoinmune	O
espontánea	O
es	O
bien	O
conocido	O
,	O
especialmente	O
con	O
respecto	O
a	O
la	O
lpr	O
y	O
Yaa	B-Protein
enfermedad	O
-	O
susceptibilidad	O
genes	B-Sequence
.	O

En	O
LMR	O
/	O
Mp	O
ratones	B-Taxon
,	O
la	O
presencia	O
de	O
la	O
lpr	O
gene	B-Sequence
acelera	O
el	O
desarrollo	O
de	O
alto	O
nivel	O
y	O
amplio	O
-	O
espectro	O
auto	O
-	O
AB	B-GENE
producción	O
y	O
glomerulonefritis	O
letal	O
,	O
además	O
de	O
marcada	O
enfermedad	O
linfoproliferativa	O
.	O

Por	O
el	O
contrario	O
,	O
la	O
homocigosidad	O
de	O
la	O
lpr	O
gene	B-Sequence
en	O
otras	O
cepas	O
como	O
C57BL	O
/	O
6	O
,	O
AKR	O
,	O
LG	O
/	O
J	O
y	O
C3H	O
conduce	O
solo	O
a	O
auto	O
-	O
AB	B-GENE
producción	O
(	O
Izui	O
et	O
al	O
.	O
1984	O
)	O
.	O

Del	O
mismo	O
modo	O
,	O
el	O
Y	B-GENE
-	I-GENE
cromosoma	I-GENE
#	O
¿NOMBRE	O
?	O
Yaa	B-Protein
gene	B-Sequence
en	O
BXSB	O
y	O
MRL	O
/	O
Mp	O
machos	O
mejora	O
el	O
rápido	O
desarrollo	O
de	O
auto	O
-	O
Abdominales	B-GENE
y	O
glomerulonefritis	O
(	O
Izui	O
et	O
al	O
.	O
1988	O
;	O
Merino	O
et	O
al	O
.	O
1989	O
)	O
.	O

Sin	O
embargo	O
,	O
en	O
el	O
fondo	O
C57BL/6	O
,	O
el	O
Yaa	B-Protein
gene	B-Sequence
no	O
conduce	O
a	O
un	O
fenotipo	O
autoinmune	O
(	O
Izui	O
et	O
al	O
.	O
1988	O
)	O
.	O

No	O
es	O
sorprendente	O
que	O
los	O
efectos	O
importantes	O
de	O
la	O
genético	B-Sequence
antecedentes	O
sobre	O
la	O
expresión	O
de	O
la	O
autoinmunidad	O
también	O
se	O
han	O
informado	O
en	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
(	O
Bolland	O
y	O
Ravetch	O
2000	O
;	O
Santiago-Raber	O
et	O
al	O
.	O
2001	O
;	O
Mitchell	O
et	O
al	O
.	O
2002	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
el	O
LES	O
existe	O
como	O
un	O
trastorno	O
de	O
rasgos	O
complejos	O
en	O
el	O
que	O
se	O
combinan	O
combinaciones	O
específicas	O
de	O
susceptibilidad	O
.	O
alelos	B-Sequence
son	O
necesarios	O
para	O
la	O
expresión	O
del	O
fenotipo	O
completo	O
.	O

Mediante	O
el	O
uso	O
de	O
marcador	B-Sequence
de	I-Sequence
microsatélites	I-Sequence
mapas	O
,	O
la	O
identificación	O
de	O
murino	B-Taxon
susceptibilidad	O
al	O
LES	O
intervalos	B-Sequence
en	O
cruces	O
experimentales	O
ha	O
sido	O
posible	O
.	O

Estos	O
estudios	O
de	O
mapeo	O
han	O
demostrado	O
que	O
la	O
expresión	O
de	O
la	O
enfermedad	O
en	O
relación	O
con	O
la	O
herencia	O
de	O
los	O
diferentes	O
alelos	B-Sequence
siguió	O
un	O
patrón	O
de	O
umbral	O
de	O
responsabilidad	O
en	O
el	O
que	O
un	O
fenotipo	O
positivo	O
dependía	O
de	O
la	O
presencia	O
de	O
múltiples	O
susceptibilidades	O
discretas	O
lugares	B-Sequence
sin	O
soltero	O
lugar	B-Sequence
siendo	O
un	O
factor	O
previo	O
.	O

Hemos	O
empleado	O
el	O
mismo	O
enfoque	O
para	O
analizar	O
la	O
genético	B-Sequence
herencia	O
de	O
la	O
enfermedad	O
en	O
la	O
cepa	O
híbrida	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
,	O
la	O
más	O
común	O
genético	B-Sequence
fondo	O
en	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
.	O

Aunque	O
no	O
se	O
ha	O
documentado	O
autoinmunidad	O
espontánea	O
en	O
ninguna	O
de	O
las	O
cepas	O
puras	O
129	O
o	O
C57BL/6	O
,	O
se	O
ha	O
descrito	O
un	O
fenotipo	O
espontáneo	O
similar	O
al	O
lupus	O
en	O
cepas	O
híbridas	O
(	O
129	O
x	O
C57BL/6	O
)	O
(	O
Obata	O
et	O
al	O
.	O
1979	O
;	O
Botto	O
et	O
al	O
.	O
1998	O
)	O
.	O
;	O
Bickerstaff	O
et	O
al	O
.	O
1999	O
;	O
Santiago	O
-	O
Raber	O
et	O
al	O
.	O
2001	O
)	O
,	O
lo	O
que	O
sugiere	O
que	O
la	O
predisposición	O
en	O
estos	O
híbridos	O
ratones	B-Taxon
pueden	O
surgir	O
como	O
resultado	O
de	O
la	O
interacción	O
entre	O
combinaciones	O
específicas	O
de	O
alelos	B-Sequence
heredado	O
de	O
las	O
cepas	O
parentales	O
129	O
y	O
C57BL/6	O
.	O

Esto	O
fue	O
confirmado	O
por	O
el	O
estudio	O
de	O
mapeo	O
reportado	O
aquí	O
.	O

Demostramos	O
que	O
hay	O
múltiples	O
locus	B-Sequence
genéticos	I-Sequence
que	O
contribuyen	O
a	O
la	O
enfermedad	O
y	O
estos	O
se	O
derivan	O
tanto	O
de	O
129	O
como	O
de	O
C57BL	O
/	O
6	O
ratones	B-Taxon
.	O

Demostramos	O
que	O
un	O
129	O
-	O
derivado	O
segmento	B-Sequence
de	I-Sequence
cromosoma	I-Sequence
1	O
estaba	O
fuertemente	O
ligado	O
a	O
la	O
expresión	O
de	O
auto	O
-	O
Abdominales	B-GENE
.	O

Esta	O
región	B-Sequence
es	O
probablemente	O
capaz	O
de	O
causar	O
el	O
inicio	O
de	O
una	O
respuesta	O
autoinmune	O
humoral	O
a	O
nuclear	B-GENE
antígenos	O
;	O
sin	O
embargo	O
,	O
esta	O
respuesta	O
no	O
ocurre	O
en	O
ausencia	O
de	O
C57BL/6	O
genes	B-Sequence
.	O

En	O
apoyo	O
de	O
esto	O
,	O
identificamos	O
un	O
C57BL/6	O
segmento	B-Sequence
en	I-Sequence
cromosoma	I-Sequence
3	O
,	O
que	O
puede	O
interactuar	O
con	O
el	O
129	O
genes	B-Sequence
en	O
Cromosoma	B-GENE
1	O
para	O
mediar	O
la	O
pérdida	O
de	O
tolerancia	O
.	O

Curiosamente	O
,	O
aunque	O
el	O
C57BL	O
/	O
6	O
SLE	O
-	O
susceptibilidad	O
región	B-Sequence
en	I-Sequence
el	I-Sequence
cromosoma	I-Sequence
3	O
es	O
nuevo	O
,	O
modificador	O
de	O
la	O
enfermedad	O
alelos	B-Sequence
derivados	O
de	O
las	O
cepas	O
C57BL/10	O
y	O
C57BL/6	O
han	O
sido	O
mapeados	O
a	O
un	O
porción	B-Sequence
de	I-Sequence
cromosoma	I-Sequence
3	O
cerca	O
de	O
la	O
región	B-Sequence
identificadas	O
en	O
este	O
estudio	O
(	O
Morel	O
et	O
al	O
.	O
1999	O
;	O
Haywood	O
et	O
al	O
.	O
2000	O
)	O
.	O

Además	O
,	O
el	O
región	B-Sequence
en	I-Sequence
el	I-Sequence
cromosoma	I-Sequence
asociado	O
con	O
el	O
desarrollo	O
de	O
nefritis	O
lúpica	O
se	O
ha	O
relacionado	O
con	O
el	O
mismo	O
rasgo	O
en	O
otros	O
murino	B-Taxon
modelos	O
de	O
LES	O
(	O
Santiago	O
et	O
al	O
.	O
1998	O
;	O
Morel	O
et	O
al	O
.	O
1999	O
;	O
Xie	O
et	O
al	O
.	O
2002	O
)	O
,	O
lo	O
que	O
sugiere	O
la	O
posibilidad	O
de	O
una	O
susceptibilidad	O
compartida	O
lugares	B-Sequence
.	O

En	O
conjunto	O
,	O
nuestros	O
resultados	O
sugieren	O
un	O
complejo	O
genético	B-Sequence
contribución	O
del	O
fondo	O
híbrido	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
genoma	B-Sequence
,	O
tanto	O
potenciadores	O
como	O
inhibidores	O
lugares	B-Sequence
del	O
129	O
ratón	B-Taxon
,	O
además	O
de	O
genes	B-Sequence
promoviendo	O
la	O
autoinmunidad	O
del	O
C57BL/6	O
ratones	B-Taxon
.	O

El	O
impacto	O
que	O
estas	O
interacciones	O
lugares	B-Sequence
puede	O
tener	O
en	O
el	O
lupus	O
-	O
enfermedad	O
similar	O
presente	O
en	O
varios	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
animales	B-Taxon
se	O
evaluó	O
aún	O
más	O
comparando	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
con	O
Cromosoma	B-GENE
1	O
genéticamente	B-Sequence
controles	O
emparejados	O
.	O

En	O
el	O
contexto	O
de	O
la	O
susceptibilidad	O
al	O
LES	O
,	O
uno	O
de	O
los	O
no	O
-	O
CMH	B-GENE
regiones	B-Sequence
de	O
El	O
ratón	B-Taxon
genoma	B-Sequence
es	O
el	O
Segmento	B-GENE
telomérico	I-GENE
del	I-GENE
cromosoma	I-GENE
1	I-GENE
,	O
donde	O
varias	O
enfermedades	O
lugares	B-Sequence
,	O
designado	O
Sle1	B-Protein
(	O
Morel	O
et	O
al	O
.	O
2001	O
)	O
,	O
Nba2	B-Protein
(	O
Drake	O
et	O
al	O
.	O
1995	O
;	O
Rozzo	O
et	O
al	O
.	O
1996	O
;	O
Vyse	O
et	O
al	O
.	O
1997	O
)	O
,	O
y	O
Bxs3	B-Protein
(	O
Hogarth	O
et	O
al	O
.	O
1998	O
)	O
,	O
se	O
han	O
mapeado	O
en	O
cepas	O
propensas	O
al	O
lupus	O
.	O

Además	O
,	O
esto	O
región	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
de	I-Sequence
ratón	I-Sequence
1	O
es	O
ortólogo	B-Sequence
a	O
un	O
región	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
humano	I-Sequence
1q22	O
-	O
1q25	O
,	O
que	O
también	O
se	O
ha	O
relacionado	O
con	O
humano	B-Taxon
LES	O
(	O
Moser	O
et	O
al	O
.	O
1998	O
)	O
.	O

los	O
APC	B-Protein
gene	B-Sequence
es	O
uno	O
de	O
los	O
candidatos	O
genes	B-Sequence
conocido	O
por	O
estar	O
dentro	O
de	O
este	O
región	B-Sequence
.	O

los	O
componente	B-Protein
amiloide	I-Protein
P	I-Protein
sérico	I-Protein
humano	I-Protein
se	O
une	O
con	O
avidez	O
a	O
ADN	B-Sequence
,	O
cromatina	B-GENE
,	O
y	O
células	B-Cell
apoptóticas	I-Cell
en	O
condiciones	O
fisiológicas	O
in	O
vitro	O
(	O
Pepys	O
1974	O
;	O
Pepys	O
y	O
Butler	O
1987	O
;	O
Butler	O
et	O
al	O
.	O
1990	O
)	O
y	O
también	O
a	O
expuestos	O
cromatina	B-GENE
y	O
células	B-Cell
apoptóticas	I-Cell
in	O
vivo	O
(	O
Hintner	O
et	O
al	O
.	O
1988	O
;	O
Breathnach	O
et	O
al	O
.	O
1989	O
;	O
Familian	O
et	O
al	O
.	O
2001	O
)	O
.	O

Hemos	O
informado	O
anteriormente	O
que	O
(	O
129	O
x	O
C57BL/6	O
)	O
.	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
producen	O
espontáneamente	O
una	O
amplia	O
gama	O
de	O
ANA	O
y	O
desarrollan	O
importantes	O
complejo	B-GENE
inmune	I-GENE
glomerulonefritis	O
(	O
Bickerstaff	O
et	O
al	O
.	O
1999	O
)	O
.	O

Sobre	O
la	O
base	O
de	O
estas	O
observaciones	O
,	O
se	O
postuló	O
que	O
APC	B-Protein
,	O
alterando	O
la	O
holgura	O
de	O
cromatina	B-GENE
,	O
contribuye	O
a	O
la	O
patogenia	O
del	O
LES	O
.	O

Sin	O
embargo	O
,	O
en	O
este	O
estudio	O
encontramos	O
que	O
sólo	O
ANA	O
y	O
anti-	O
cromatina	B-GENE
Ab	I-GENE
los	O
niveles	O
aumentaron	O
significativamente	O
en	O
el	O
(	O
129	O
x	O
C57BL/6	O
)	O
F2	O
.	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
.	O

Una	O
posible	O
explicación	O
de	O
esta	O
discrepancia	O
puede	O
residir	O
en	O
el	O
hecho	O
de	O
que	O
la	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
analizados	O
en	O
el	O
estudio	O
original	O
se	O
generaron	O
a	O
partir	O
de	O
un	O
número	O
limitado	O
de	O
fundadores	O
y	O
que	O
esto	O
puede	O
haber	O
causado	O
una	O
herencia	O
no	O
aleatoria	O
de	O
los	O
lugares	B-Sequence
de	O
las	O
cepas	O
parentales	O
.	O

Además	O
,	O
todo	O
-	O
genoma	B-Sequence
análisis	O
identificó	O
los	O
129	O
región	B-Sequence
rodeando	O
el	O
APC	B-Protein
gene	B-Sequence
como	O
el	O
principal	O
lugar	B-Sequence
contribuyendo	O
al	O
desarrollo	O
de	O
ANA	O
y	O
anti	O
-	O
cromatina	B-GENE
Ab	I-GENE
.	O

De	O
acuerdo	O
con	O
esto	O
,	O
cuando	O
realizamos	O
una	O
comparación	O
selectiva	O
entre	O
el	O
(	O
129	O
x	O
C57BL/6	O
)	O
F2	O
.	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
y	O
Cromosoma	B-GENE
1	O
genéticamente	B-Sequence
controles	O
emparejados	O
,	O
no	O
pudimos	O
detectar	O
ninguna	O
diferencia	O
significativa	O
en	O
los	O
niveles	O
de	O
estos	O
dos	O
auto-	O
Abdominales	B-GENE
.	O

Estos	O
hallazgos	O
,	O
tomados	O
en	O
conjunto	O
,	O
indicaron	O
que	O
el	O
fenotipo	O
asociado	O
con	O
APC	B-Protein
deficiencia	O
fue	O
causada	O
por	O
la	O
presencia	O
de	O
129	O
inalterados	O
genes	B-Sequence
desde	O
el	O
región	B-GENE
telomérica	I-GENE
del	I-GENE
cromosoma	I-GENE
1	O
operando	O
en	O
el	O
C57BL/6	O
genómico	B-Sequence
antecedentes	O
.	O

El	O
análisis	O
del	O
C57BL	O
/	O
6	O
proporcionó	O
una	O
fuerte	O
evidencia	O
de	O
apoyo	O
para	O
esto	O
.	O
ratones	B-Taxon
congénico	O
para	O
este	O
129	O
región	B-Sequence
.	O

La	O
generación	O
y	O
el	O
análisis	O
de	O
cepas	O
congénicas	O
se	O
han	O
utilizado	O
con	O
éxito	O
para	O
diseccionar	O
la	O
contribución	O
de	O
la	O
susceptibilidad	O
individual	O
alelos	B-Sequence
a	O
un	O
rasgo	O
multigénico	O
como	O
el	O
LES	O
.	O

Adoptamos	O
la	O
misma	O
estrategia	O
para	O
investigar	O
la	O
contribución	O
relativa	O
de	O
los	O
129	O
Segmento	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
1	I-Sequence
y	O
el	O
APC	B-Protein
gene	B-Sequence
a	O
cada	O
característica	O
de	O
la	O
enfermedad	O
.	O

Usando	O
este	O
enfoque	O
,	O
demostramos	O
que	O
el	O
129	O
intervalo	B-Sequence
en	I-Sequence
el	I-Sequence
cromosoma	I-Sequence
distal	I-Sequence
1	O
,	O
cuando	O
transferido	B-Sequence
en	O
el	O
C57BL	O
/	O
6	O
genoma	B-Sequence
,	O
una	O
combinación	O
comúnmente	O
creada	O
por	O
retrocruzamiento	O
en	O
C57BL	O
/	O
6	O
a	O
gen	B-Sequence
mutado	I-Sequence
ubicado	O
en	O
ese	O
región	B-Sequence
cromosómica	I-Sequence
,	O
fue	O
suficiente	O
para	O
mediar	O
en	O
la	O
producción	O
de	O
auto	O
-	O
Abdominales	B-GENE
.	O

En	O
este	O
contexto	O
,	O
cabe	O
señalar	O
que	O
varias	O
cepas	O
de	O
ratones	B-Taxon
con	O
objetivo	O
mutaciones	B-Sequence
de	O
genes	B-Sequence
codificado	O
en	O
este	O
región	B-Sequence
se	O
ha	O
informado	O
que	O
expresan	O
una	O
enfermedad	O
similar	O
al	O
lupus	O
,	O
incluyendo	O
ratones	B-Taxon
carente	O
Fc	B-Protein
gamma	I-Protein
RIIB	I-Protein
(	O
Bolland	O
y	O
Ravetch	O
2000	O
)	O
,	O
receptores	O
del	O
complemento	O
(	O
CR1	B-Protein
/	O
2	O
)	O
(	O
Prodeus	O
et	O
al	O
.	O
1998	O
;	O
Wu	O
et	O
al	O
.	O
2002	O
)	O
,	O
y	O
decaimiento	B-Protein
-	I-Protein
factor	I-Protein
acelerador	I-Protein
(	O
CD55	B-Protein
)	O
(	O
Miwa	O
et	O
al	O
.	O
2002	O
)	O
.	O

En	O
cada	O
caso	O
,	O
el	O
fenotipo	O
autoinmune	O
se	O
describió	O
en	O
ratones	B-Taxon
en	O
el	O
que	O
el	O
nulo	O
mutación	B-Sequence
se	O
generó	O
en	O
129	O
embrionarios	O
Células	B-Cell
madre	I-Cell
luego	O
se	O
retrocruza	O
con	O
el	O
C57BL/6	O
u	O
otro	O
genético	B-Sequence
antecedentes	O
.	O

Así	O
,	O
a	O
la	O
vista	O
de	O
nuestros	O
hallazgos	O
,	O
se	O
puede	O
postular	O
que	O
en	O
cada	O
uno	O
de	O
estos	O
murino	B-Taxon
modelos	O
de	O
LES	O
,	O
los	O
efectos	O
del	O
objetivo	O
nulo	O
gene	B-Sequence
eran	O
irrelevantes	O
.	O

Conclusiones	O
similares	O
pueden	O
aplicarse	O
a	O
otros	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
animales	B-Taxon
que	O
lleva	O
mutaciones	B-Sequence
de	O
genes	B-Sequence
mapeado	O
en	O
el	O
129	O
-	O
susceptibilidad	O
derivada	O
alelo	B-Sequence
en	O
Cromosoma	B-GENE
7	O
(	O
O'Keefe	O
et	O
al	O
.	O
1996	O
,	O
1999	O
)	O
.	O

La	O
expresión	O
de	O
anti	O
-	O
nuclear	B-GENE
la	O
autoinmunidad	O
fue	O
idéntica	O
comparando	O
la	O
congénica	O
con	O
la	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
.	O

La	O
única	O
diferencia	O
en	O
el	O
fenotipo	O
entre	O
estos	O
ratones	B-Taxon
fue	O
en	O
la	O
expresión	O
de	O
glomerulonefritis	O
,	O
que	O
fue	O
más	O
pronunciada	O
en	O
la	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
en	O
comparación	O
con	O
los	O
congénitos	O
ratones	B-Taxon
.	O

Aunque	O
estos	O
hallazgos	O
demuestran	O
que	O
APC	B-Protein
no	O
está	O
implicada	O
en	O
el	O
procesamiento	O
de	O
autoantígenos	O
,	O
como	O
se	O
había	O
sugerido	O
anteriormente	O
,	O
indican	O
que	O
APC	B-Protein
todavía	O
podría	O
desempeñar	O
un	O
papel	O
protector	O
importante	O
en	O
la	O
nefritis	O
lúpica	O
.	O

En	O
apoyo	O
de	O
esto	O
,	O
la	O
expresión	O
de	O
la	O
proteína	B-Protein
C	I-Protein
humana	I-Protein
reactiva	I-Protein
,	O
una	O
fase	O
aguda	O
proteína	B-Chemical
relacionado	O
cercanamente	O
a	O
APC	B-Protein
se	O
ha	O
demostrado	O
que	O
retrasa	O
la	O
aparición	O
y	O
la	O
gravedad	O
de	O
la	O
nefritis	O
lúpica	O
en	O
la	O
cepa	O
NZB/W	O
al	O
prevenir	O
el	O
depósito	O
de	O
complejos	B-GENE
inmunes	I-GENE
en	O
la	O
corteza	O
renal	O
(	O
Szalai	O
et	O
al	O
.	O
2003	O
)	O
.	O

En	O
concordancia	O
con	O
esto	O
,	O
un	O
polimorfismo	B-Sequence
asociado	O
con	O
un	O
nivel	O
basal	O
reducido	O
de	O
Proteína	B-Protein
C-reactiva	I-Protein
se	O
ha	O
informado	O
que	O
está	O
relacionado	O
con	O
el	O
LES	O
en	O
humanos	B-Taxon
(	O
Russell	O
et	O
al	O
.	O
2004	O
)	O
.	O

Sin	O
embargo	O
,	O
como	O
la	O
congénita	O
ratones	B-Taxon
y	O
el	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
llevado	O
similar	O
pero	O
no	O
idéntico	O
129	O
regiones	B-Sequence
en	I-Sequence
el	I-Sequence
cromosoma	I-Sequence
1	O
,	O
una	O
explicación	O
alternativa	O
para	O
nuestros	O
hallazgos	O
aún	O
puede	O
residir	O
en	O
las	O
numerosas	O
y	O
complejas	O
interacciones	O
sinérgicas	O
y	O
contrarrestantes	O
entre	O
129	O
y	O
C57BL	O
/	O
6	O
genes	B-Sequence
involucrada	O
en	O
la	O
autotolerancia	O
y	O
el	O
daño	O
de	O
órganos	O
diana	O
.	O

Así	O
,	O
mientras	O
que	O
la	O
falta	O
de	O
nefritis	O
lúpica	O
en	O
los	O
congénitos	O
ratones	B-Taxon
es	O
consistente	O
con	O
la	O
necesidad	O
de	O
susceptibilidad	O
múltiple	O
genes	B-Sequence
para	O
la	O
expresión	O
completa	O
del	O
lupus	O
,	O
se	O
requerirán	O
más	O
estudios	O
para	O
dilucidar	O
completamente	O
el	O
papel	O
de	O
APC	B-Protein
en	O
la	O
patogénesis	O
del	O
daño	O
renal	O
.	O

En	O
resumen	O
,	O
nuestros	O
hallazgos	O
demuestran	O
el	O
impacto	O
de	O
las	O
interacciones	O
epistáticas	O
entre	O
129	O
y	O
C57BL/6	O
genomas	B-Sequence
sobre	O
el	O
desarrollo	O
del	O
LES	O
e	O
ilustrar	O
cómo	O
estos	O
antecedentes	O
gene	B-Sequence
efectos	O
pueden	O
dar	O
lugar	O
a	O
interpretaciones	O
incorrectas	O
al	O
analizar	O
el	O
fenotipo	O
autoinmune	O
de	O
determinados	O
genético	B-Sequence
interrupciones	O

Materiales	O
y	O
métodos	O

Ratones	B-Taxon
.	O

Todos	O
ratones	B-Taxon
eran	O
hembras	O
.	O

Tipo	B-Sequence
salvaje	I-Sequence
C57BL/6	O
y	O
129/Sv	O
(	O
129S6	O
,	O
según	O
la	O
nomenclatura	O
revisada	O
)	O
fueron	O
criados	O
y	O
mantenidos	O
en	O
el	O
animal	B-Taxon
centro	O
de	O
atención	O
en	O
el	O
Imperial	O
College	O
,	O
Londres	O
,	O
Reino	O
Unido	O
.	O

(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F1	O
ratones	B-Taxon
se	O
generaron	O
entrecruzando	O
los	O
dos	O
tipo	B-Sequence
salvaje	I-Sequence
cepas	O
y	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
ratones	B-Taxon
cruzando	O
el	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F1	O
ratones	B-Taxon
.	O

los	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
se	O
generaron	O
como	O
se	O
informó	O
anteriormente	O
(	O
Botto	O
et	O
al	O
.	O
1997	O
)	O
,	O
y	O
el	O
(	O
129	O
x	O
C57BL/6	O
)	O
F2	O
.	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
fueron	O
generados	O
por	O
entrecruzamiento	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
en	O
el	O
129	O
genético	B-Sequence
fondo	O
con	O
APC	B-Protein
-	O
/	O
-	O
animales	B-Taxon
retrocruzada	O
con	O
C57BL/6	O
durante	O
diez	O
generaciones	O
.	O

Un	O
total	O
de	O
141	O
(	O
129	O
x	O
C57BL/6	O
)	O
F2	O
y	O
158	O
(	O
129	O
x	O
C57BL/6	O
)	O
F2	O
.	O
APC	B-Protein
-	O
/	O
-	O
mujer	O
ratones	B-Taxon
fueron	O
producidos	O
y	O
monitoreados	O
durante	O
1	O
año	O
.	O

Tipo	B-Sequence
salvaje	I-Sequence
congénico	O
C57BL/6	O
.	O
129	O
(	O
D1Mit105	O
-	O
223	O
)	O
ratones	B-Taxon
se	O
generaron	O
retrocruzando	O
los	O
129	O
intervalo	B-Sequence
Entre	O
microsatélites	B-Sequence
D1Mit105	O
y	O
D1Mit223	O
(	O
80	O
cM	O
a	O
106	O
cM	O
)	O
en	O
la	O
cepa	O
C57BL/6	O
.	O

heredado	O
129	O
regiones	B-Sequence
fueron	O
mapeados	O
con	O
marcadores	B-Sequence
de	I-Sequence
microsatélites	I-Sequence
polimórficos	I-Sequence
entre	O
129	O
y	O
C57BL/6	O
ratones	B-Taxon
(	O
vea	O
abajo	O
)	O
.	O

Después	O
de	O
siete	O
generaciones	O
de	O
retrocruzamiento	O
,	O
se	O
cruzaron	O
hermanos	O
para	O
generar	O
C57BL/6	O
.	O
129	O
(	O
D1Mit105	O
-	O
223	O
)	O
congénico	O
ratones	B-Taxon
homocigoto	O
para	O
el	O
129	O
Intervalo	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
1	I-Sequence
.	O

Dentro	O
de	O
129	O
marcadores	O
en	O
posiciones	B-Sequence
81	O
.	O
6	O
cM	O
(	O
D1Mit159	O
)	O
y	O
105	O
cM	O
(	O
D1Mit17	O
)	O
,	O
respectivamente	O
,	O
y	O
un	O
marcador	O
exterior	O
C57BL	O
/	O
6	O
en	O
posición	B-Sequence
74	O
.	O
3cM	O
(	O
D1Mit159	O
)	O
se	O
utilizaron	O
para	O
definir	O
aún	O
más	O
el	O
intervalo	B-Sequence
.	O

En	O
el	O
C57BL/6	O
.	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
(	O
retrocruzado	O
con	O
C57BL	O
/	O
6	O
durante	O
diez	O
generaciones	O
)	O
,	O
el	O
129	O
genoma	B-Sequence
alrededor	O
de	O
APC	B-Protein
lugar	B-Sequence
fue	O
mapeado	O
como	O
un	O
segmento	B-Sequence
de	O
87	O
.	O
9	O
cm	O
(	O
D1Mit15	O
)	O
a	O
105	O
cm	O
(	O
D1Mit17	O
)	O
.	O

En	O
este	O
análisis	O
,	O
los	O
129	O
marcadores	O
internos	O
estaban	O
en	O
posiciones	B-Sequence
93	O
cm	O
(	O
D1Mit36	O
)	O
y	O
99	O
.	O
7	O
cM	O
(	O
D1Mit115	O
)	O
y	O
los	O
marcadores	O
C57BL	O
/	O
6	O
exteriores	O
en	O
posiciones	B-Sequence
81	O
.	O
6	O
cm	O
(	O
D1Mit159	O
)	O
y	O
106	O
cm	O
(	O
D1Mit223	O
)	O
.	O

Junto	O
con	O
28	O
C57BL/6	O
.	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
y	O
30	O
C57BL/6	O
tipo	B-Sequence
salvaje	I-Sequence
animales	B-Taxon
,	O
26	O
C57BL	O
/	O
6	O
.	O
129	O
(	O
D1Mit105	O
-	O
223	O
)	O
hembra	O
ratones	B-Taxon
-	O
/	O
-	O
fueron	O
seguidos	O
hasta	O
1	O
año	O
de	O
edad	O
.	O

animales	B-Taxon
se	O
mantuvieron	O
en	O
condiciones	O
libres	O
de	O
patógenos	O
específicos	O
.	O

Todos	O
animal	B-Taxon
los	O
procedimientos	O
se	O
ajustaron	O
a	O
las	O
directrices	O
institucionales	O
.	O

Análisis	O
serológicos	O
.	O

Los	O
sueros	O
,	O
recogidos	O
a	O
los	O
6	O
y	O
12	O
meses	O
de	O
edad	O
,	O
se	O
analizaron	O
para	O
determinar	O
la	O
presencia	O
de	O
auto	O
-	O
Abdominales	B-GENE
.	O

Los	O
niveles	O
de	O
ANA	O
IgG	O
se	O
buscaron	O
por	O
inmunofluorescencia	O
indirecta	O
usando	O
Hep	O
-	O
2	O
células	B-Cell
,	O
y	O
anti	O
-	O
dsDNA	O
Abdominales	B-GENE
fueron	O
detectados	O
por	O
inmunofluorescencia	O
indirecta	O
en	O
Crithidia	B-Taxon
luciliae	I-Taxon
como	O
se	O
describió	O
previamente	O
(	O
Mitchell	O
et	O
al	O
.	O
2002	O
)	O
.	O

Las	O
muestras	O
de	O
suero	O
se	O
examinaron	O
a	O
una	O
dilución	O
de	O
1:80	O
(	O
ANA	O
)	O
o	O
1:20	O
(	O
anti-dsDNA	O
)	O
y	O
las	O
muestras	O
positivas	O
se	O
titularon	O
hasta	O
el	O
punto	O
final	O
.	O

Abdominales	B-GENE
a	O
ssDNA	O
y	O
anti	O
-	O
cromatina	B-GENE
fueron	O
medidos	O
por	O
ELISA	O
,	O
como	O
se	O
describió	O
previamente	O
(	O
Mitchell	O
et	O
al	O
.	O
2002	O
)	O
.	O

Las	O
muestras	O
se	O
examinaron	O
a	O
una	O
dilución	O
de	O
1:100	O
y	O
los	O
resultados	O
se	O
expresaron	O
en	O
unidades	O
ELISA	O
arbitrarias	O
(	O
AEU	O
)	O
en	O
relación	O
con	O
una	O
muestra	O
positiva	O
estándar	O
(	O
derivada	O
de	O
un	O
MRL/Mp	O
.	O
lpr	B-Protein
/	O
lpr	B-Protein
ratón	B-Taxon
)	O
,	O
al	O
que	O
se	O
le	O
asignó	O
un	O
valor	O
de	O
100	O
.	O

Para	O
la	O
comparación	O
entre	O
placas	O
,	O
se	O
incluyeron	O
diluciones	O
en	O
serie	O
de	O
una	O
muestra	O
de	O
suero	O
de	O
control	O
positivo	O
en	O
cada	O
placa	O
.	O

APC	B-Protein
Los	O
niveles	O
fueron	O
evaluados	O
por	O
ELISA	O
utilizando	O
oveja	B-Taxon
anti	O
-	O
ratón	B-Protein
y	O
Conejo	B-Taxon
anti	O
-	O
ratón	B-Protein
Abdominales	B-GENE
(	O
Calbiochem	O
,	O
Nottigham	O
,	O
Reino	O
Unido	O
)	O
.	O

Las	O
muestras	O
se	O
examinaron	O
a	O
una	O
dilución	O
de	O
1:3.000	O
y	O
los	O
resultados	O
se	O
expresaron	O
en	O
miligramos	O
por	O
litro	O
,	O
en	O
referencia	O
a	O
una	O
curva	O
estándar	O
derivada	O
de	O
un	O
suero	O
de	O
fase	O
aguda	O
con	O
una	O
concentración	O
conocida	O
de	O
APC	B-Protein
(	O
Calbioquímica	O
)	O
.	O

APC	B-Protein
-	O
/	O
-	O
ratón	B-Taxon
el	O
suero	O
se	O
incluyó	O
como	O
control	O
negativo	O
.	O

Análisis	O
histológico	O
.	O

Todos	O
ratones	B-Taxon
,	O
excepto	O
los	O
pocos	O
que	O
murieron	O
antes	O
del	O
final	O
del	O
experimento	O
,	O
se	O
sacrificaron	O
al	O
año	O
de	O
edad	O
,	O
y	O
las	O
porciones	O
de	O
riñón	O
se	O
fijaron	O
en	O
solución	O
de	O
Bouin	O
y	O
se	O
incluyeron	O
en	O
parafina	O
,	O
y	O
las	O
secciones	O
se	O
tiñeron	O
con	O
ácido	B-Chemical
periódico	I-Chemical
#	O
¿NOMBRE	O
?	O
reactivo	B-Chemical
.	O

La	O
histología	O
glomerular	O
se	O
calificó	O
de	O
manera	O
ciega	O
de	O
la	O
siguiente	O
manera	O
:	O
grado	O
0	O
,	O
normal	O
;	O
grado	O
1	O
,	O
hipercelularidad	O
que	O
afecta	O
a	O
más	O
del	O
50	O
%	O
del	O
penacho	O
glomerular	O
en	O
el	O
25	O
%	O
-50	O
%	O
de	O
los	O
glomérulos	O
;	O
grado	O
2	O
,	O
hipercelularidad	O
que	O
afecta	O
a	O
más	O
del	O
50	O
%	O
del	O
penacho	O
glomerular	O
en	O
el	O
50	O
%	O
-75	O
%	O
de	O
los	O
glomérulos	O
;	O
grado	O
3	O
,	O
hipercelularidad	O
glomerular	O
en	O
más	O
del	O
75	O
%	O
de	O
los	O
glomérulos	O
o	O
semilunas	O
en	O
más	O
del	O
25	O
%	O
de	O
los	O
glomérulos	O
.	O

análisis	O
estadístico	O

Los	O
datos	O
no	O
paramétricos	O
se	O
expresan	O
como	O
mediana	O
con	O
rango	O
de	O
valores	O
entre	O
paréntesis	O
.	O

Todas	O
las	O
estadísticas	O
se	O
calcularon	O
utilizando	O
GraphPad	O
PrismTM	O
versión	O
3	O
.	O
0	O
para	O
Windows	O
(	O
Software	O
GraphPad	O
,	O
San	O
Diego	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
.	O

En	O
todo	O
momento	O
se	O
aplicaron	O
pruebas	O
no	O
paramétricas	O
,	O
considerándose	O
diferencias	O
significativas	O
para	O
valores	O
de	O
p	O
<	O
0	O
.	O
05	O
.	O

Se	O
utilizó	O
la	O
prueba	O
de	O
Mann-Whitney	O
para	O
la	O
comparación	O
de	O
dos	O
grupos	O
,	O
mientras	O
que	O
para	O
el	O
análisis	O
de	O
tres	O
grupos	O
se	O
utilizó	O
la	O
prueba	O
de	O
Kruskal-Wallis	O
con	O
la	O
prueba	O
de	O
comparación	O
múltiple	O
de	O
Dunn	O
.	O

Análisis	O
genotípico	O

El	O
genotipado	O
se	O
llevó	O
a	O
cabo	O
por	O
PCR	O
de	O
ADN	B-Sequence
genómico	I-Sequence
usando	O
143	O
polimórfico	B-Sequence
marcadores	O
(	O
lista	O
disponible	O
a	O
pedido	O
)	O
distribuidos	O
a	O
lo	O
largo	O
de	O
los	O
19	O
autosomas	B-GENE
.	O

PCR	O
se	O
realizaron	O
utilizando	O
estándar	O
reactivos	B-Chemical
que	O
contiene	O
1	O
.	O
5	O
mm	O
MgCl2	B-Chemical
y	O
0	O
4	O
muM	O
cebadores	B-Sequence
.	O

Marcadores	B-Sequence
de	I-Sequence
microsatélites	I-Sequence
fueron	O
examinados	O
para	O
el	O
tamaño	O
polimorfismos	B-Sequence
entre	O
129	O
y	O
C57BL/6	O
ratones	B-Taxon
.	O

Solamente	O
cebadores	B-Sequence
con	O
diferencias	O
detectables	O
en	O
bromuro	B-Chemical
de	I-Chemical
etidio	I-Chemical
#	O
¿NOMBRE	O
?	O
agarosa	B-Chemical
geles	O
o	O
en	O
SDS	B-Chemical
#	O
¿NOMBRE	O
?	O

Análisis	O
de	O
vinculación	O

los	O
QTL	B-Sequence
programa	O
ADMINISTRADOR	O
DE	O
MAPAS	O
.	O
QTL	B-Sequence
(	O
ftp	O
:	O
//	O
mcbio	O
.	O
med	O
.	O
buffalo	O
.	O
edu	O
/	O
pub	O
/	O
MapMgr	O
/	O
)	O
y	O
los	O
dos	O
grupos	O
experimentales	O
se	O
examinaron	O
de	O
forma	O
independiente	O
.	O

Solo	O
datos	O
de	O
ratones	B-Taxon
a	O
los	O
12	O
meses	O
de	O
edad	O
se	O
analizaron	O
.	O

Log	O
transformaciones	O
de	O
auto	O
-	O
Abdominales	B-GENE
niveles	O
dieron	O
como	O
resultado	O
una	O
distribución	O
más	O
normalizada	O
y	O
se	O
utilizaron	O
en	O
QTL	B-Sequence
mapeo	O

Los	O
umbrales	O
de	O
LOD	O
para	O
los	O
vínculos	O
sugestivos	O
y	O
significativos	O
se	O
determinaron	O
mediante	O
una	O
prueba	O
de	O
permutación	O
específica	O
de	O
rasgos	O
y	O
cohortes	O
(	O
1	O
000	O
permutaciones	O
)	O
.	O

El	O
umbral	O
promedio	O
para	O
los	O
vínculos	O
sugestivos	O
,	O
significativos	O
y	O
altamente	O
significativos	O
fue	O
LOD	O
>	O
=	O
2	O
.	O
1	O
(	O
p	O
<	O
=	O
7	O
.	O
8	O
x	O
10	O
-	O
3	O
)	O
,	O
LOD	O
>	O
=	O
3	O
.	O
6	O
(	O
p	O
<	O
=	O
2	O
.	O
4	O
x	O
10	O
-	O
4	O
)	O
,	O
y	O
LOD	O
>	O
=	O
5	O
(	O
p	O
<	O
=	O
1	O
x	O
10	O
-	O
5	O
)	O
,	O
respectivamente	O
(	O
Manly	O
y	O
Olson	O
1999	O
)	O
.	O

información	O
de	O
soporte	O

Números	O
de	O
acceso	O

Los	O
números	O
de	O
identificación	O
de	O
LocusLink	O
(	O
http	O
:	O
//	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
LocusLink	O
/	O
)	O
para	O
el	O
genes	B-Sequence
y	O
gene	B-Sequence
Los	O
productos	O
discutidos	O
en	O
este	O
documento	O
son	O
APC	B-Protein
(	O
ID	O
de	O
LocusLink	O
20219	O
)	O
,	O
CD35	B-Protein
/	O
CD21	B-Protein
(	O
ID	O
de	O
LocusLink	O
12902	O
)	O
,	O
CD55	B-Protein
(	O
LocusLink	O
ID	O
13136	O
)	O
,	O
el	O
receptor	B-Protein
FAS	I-Protein
gene	B-Sequence
(	O
ID	O
de	O
LocusLink	O
14102	O
)	O
,	O
y	O
Fc	B-Protein
gamma	I-Protein
RII	I-Protein
(	O
ID	O
de	O
LocusLink	O
14130	O
)	O
.	O

Agradecimientos	O

Agradecemos	O
a	O
M	O
.	O

Lewis	O
por	O
el	O
procesamiento	O
de	O
las	O
muestras	O
para	O
histología	O
ya	O
F	O
.	O

Reid	O
y	O
D	O
.	O

Mitchell	O
por	O
su	O
ayuda	O
.	O

Agradecemos	O
a	O
todo	O
el	O
personal	O
de	O
la	O
animal	B-Taxon
facilidad	O
para	O
su	O
asistencia	O
técnica	O
.	O

Este	O
trabajo	O
fue	O
apoyado	O
por	O
Wellcome	O
Trust	O
(	O
subvención	O
número	O
061438	O
)	O
.	O

JCH	O
recibió	O
una	O
beca	O
del	O
Instituto	O
Nacional	O
de	O
Salud	O
de	O
España	O
(	O
BEFI	O
99/9212	O
)	O
.	O

abreviaturas	O

AB	B-GENE
-	O
anticuerpo	B-GENE

ANA	O
-	O
anti	O
-	O
nuclear	O
anticuerpo	B-GENE

AEU	O
-	O
unidad	O
ELISA	O
arbitraria	O

APC	B-Protein
-	O
/	O
-	O
-	O
APC	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon

APC	B-Protein
-	O
componente	B-Protein
amiloide	I-Protein
P	I-Protein
sérico	I-Protein
gene	B-Sequence

dsADN	O
-	O
ADN	B-Sequence
de	I-Sequence
doble	I-Sequence
cadena	I-Sequence

LOD	O
-	O
logaritmo	O
de	O
probabilidades	O

QTL	B-Sequence
-	O
vinculación	B-Sequence
de	I-Sequence
rasgos	I-Sequence
cuantitativos	I-Sequence

LES	O
-	O
lupus	O
eritematoso	O
sistémico	O

ssDNA	O
-	O
anti	O
-	O
ADN	B-Sequence
monocatenario	I-Sequence

Figuras	O
y	O
Tablas	O

Figura	O
1	O

Vinculación	O
de	O
Cromosoma	B-GENE
2	O
con	O
ANA	O
y	O
Anti	O
-	O
Abdominales	B-GENE
de	I-GENE
cromatina	I-GENE
en	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
.	O
APC	B-Protein
-	O
/	O
-	O
Ratones	B-Taxon

Estas	O
asociaciones	O
no	O
se	O
detectaron	O
en	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
animales	B-Taxon
.	O

Centimorgan	O
posiciones	B-Sequence
fueron	O
deducidos	O
por	O
intervalo	B-Sequence
mapeo	O
,	O
marcador	O
de	O
anclaje	O
ubicaciones	B-Sequence
a	O
datos	O
de	O
http	O
:	O
//www	O
.	O
informatica	O
jax	O
org	O
.	O

Las	O
líneas	O
punteadas	O
y	O
la	O
línea	O
punteada	O
indican	O
el	O
umbral	O
sobre	O
el	O
cual	O
los	O
vínculos	O
se	O
consideraron	O
sugestivos	O
o	O
significativos	O
,	O
respectivamente	O
,	O
según	O
se	O
define	O
en	O
Materiales	O
y	O
Métodos	O
.	O

figura	O
3	O

Vinculación	O
de	O
Cromosoma	B-GENE
4	O
con	O
Anti	O
-	O
dsDNA	O
Abdominales	B-GENE

El	O
pico	O
estimado	O
en	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
ratones	B-Taxon
estaba	O
en	O
posición	B-Sequence
51	O
.	O
3	O
cM	O
,	O
mientras	O
que	O
en	O
el	O
(	O
129	O
x	O
C57BL/6	O
)	O
F2	O
.	O
APC	B-Protein
-	O
/	O
-	O
animales	B-Taxon
fue	O
en	O
posición	B-Sequence
71	O
cM	O
,	O
lo	O
que	O
indica	O
que	O
lo	O
más	O
probable	O
es	O
que	O
se	O
tratara	O
de	O
dos	O
independientes	O
lugares	B-Sequence
.	O

Centimorgan	O
posiciones	B-Sequence
fueron	O
deducidos	O
por	O
intervalo	B-Sequence
mapeo	O
,	O
marcador	O
de	O
anclaje	O
ubicaciones	B-Sequence
a	O
datos	O
de	O
http	O
:	O
//www	O
.	O
informatica	O
jax	O
org	O
.	O

Las	O
líneas	O
punteadas	O
indican	O
el	O
umbral	O
por	O
encima	O
del	O
cual	O
se	O
consideró	O
sugerente	O
la	O
vinculación	O
,	O
tal	O
como	O
se	O
define	O
en	O
Materiales	O
y	O
Métodos	O
.	O

Figura	O
4	O

Intervalo	B-Sequence
Mapeo	O
de	O
escaneos	O
que	O
muestran	O
QTL	B-Sequence
en	O
Cromosoma	B-GENE
1	O
con	O
Anti	O
-	O
dsDNA	O
y	O
Anti	O
-	O
ssDNA	O
Abdominales	B-GENE

Centimorgan	O
posiciones	B-Sequence
fueron	O
deducidos	O
por	O
intervalo	B-Sequence
mapeo	O
,	O
marcador	O
de	O
anclaje	O
ubicaciones	B-Sequence
a	O
datos	O
de	O
http	O
:	O
//www	O
.	O
informatica	O
jax	O
org	O
.	O

Las	O
líneas	O
punteadas	O
indican	O
el	O
umbral	O
por	O
encima	O
del	O
cual	O
la	O
vinculación	O
se	O
consideró	O
sugestiva	O
,	O
las	O
líneas	O
discontinuas	O
indican	O
el	O
umbral	O
por	O
encima	O
del	O
cual	O
la	O
vinculación	O
se	O
consideró	O
significativa	O
y	O
las	O
líneas	O
punteadas/discontinuas	O
indican	O
una	O
vinculación	O
altamente	O
significativa	O
,	O
tal	O
como	O
se	O
define	O
en	O
Materiales	O
y	O
Métodos	O
.	O

Consulte	O
la	O
Tabla	O
3	O
para	O
obtener	O
detalles	O
adicionales	O
.	O

Figura	O
5	O

Intervalo	B-Sequence
Mapeo	O
de	O
escaneos	O
que	O
muestran	O
QTL	B-Sequence
en	O
Cromosoma	B-GENE
1	O
con	O
ANA	O
y	O
Anti	O
-	O
Abdominales	B-GENE
de	I-GENE
cromatina	I-GENE

Centimorgan	O
posiciones	B-Sequence
fueron	O
deducidos	O
por	O
intervalo	B-Sequence
mapeo	O
,	O
marcador	O
de	O
anclaje	O
ubicaciones	B-Sequence
a	O
datos	O
de	O
http	O
:	O
//www	O
.	O
informatica	O
jax	O
org	O
.	O

Las	O
líneas	O
punteadas	O
indican	O
el	O
umbral	O
por	O
encima	O
del	O
cual	O
la	O
vinculación	O
se	O
consideró	O
sugestiva	O
y	O
las	O
líneas	O
discontinuas	O
indican	O
el	O
umbral	O
por	O
encima	O
del	O
cual	O
la	O
vinculación	O
se	O
consideró	O
significativa	O
,	O
tal	O
como	O
se	O
define	O
en	O
Materiales	O
y	O
Métodos	O
.	O

Consulte	O
la	O
Tabla	O
3	O
para	O
obtener	O
detalles	O
adicionales	O
.	O

Figura	O
6	O

automático	O
-	O
AB	B-GENE
Perfiles	O

(	O
A	O
)	O
Títulos	O
de	O
ANA	O
en	O
el	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
.	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
y	O
(	O
129	O
x	O
C57BL/6	O
)	O
F2	O
al	O
año	O
de	O
edad	O
.	O

Un	O
pequeño	O
círculo	O
representa	O
uno	O
ratón	B-Taxon
;	O
un	O
círculo	O
grande	O
,	O
un	O
número	O
variable	O
de	O
animales	B-Taxon
,	O
como	O
se	O
indica	O
entre	O
paréntesis	O
.	O

Las	O
muestras	O
de	O
suero	O
se	O
valoraron	O
hasta	O
el	O
punto	O
final	O
.	O

(	O
B	O
)	O
títulos	O
de	O
ANA	O
en	O
el	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
.	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
y	O
un	O
número	O
seleccionado	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
animales	B-Taxon
llevando	O
el	O
Región	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
1	I-Sequence
entre	O
D1Mit105	O
y	O
D1Mit223	O
(	O
80-106	O
cM	O
)	O
de	O
origen	O
129	O
.	O

Los	O
símbolos	O
son	O
como	O
en	O
(	O
A	O
)	O
.	O

(	O
C	O
y	O
D	O
)	O
Anti-	O
cromatina	B-GENE
Ab	I-GENE
niveles	O
expresados	O
en	O
AEU	O
relacionados	O
con	O
una	O
muestra	O
positiva	O
estándar	O
,	O
a	O
la	O
que	O
se	O
le	O
asignó	O
un	O
valor	O
de	O
100	O
AEU	O
.	O

La	O
comparación	O
es	O
entre	O
los	O
mismos	O
grupos	O
de	O
ratones	B-Taxon
como	O
en	O
(	O
A	O
)	O
y	O
(	O
B	O
)	O
,	O
respectivamente	O
.	O

Los	O
símbolos	O
son	O
como	O
en	O
(	O
A	O
)	O
.	O

Figura	O
7	O

Intervalo	B-Sequence
Mapeo	O
de	O
escaneos	O
que	O
muestran	O
QTL	B-Sequence
en	O
Cromosoma	B-GENE
3	O
con	O
ANA	O
,	O
Anti-	O
cromatina	B-GENE
y	O
anti-ssDNA	O
Abdominales	B-GENE

Consulte	O
la	O
Tabla	O
3	O
para	O
obtener	O
detalles	O
adicionales	O
.	O

Centimorgan	O
posiciones	B-Sequence
fueron	O
deducidos	O
por	O
intervalo	B-Sequence
mapeo	O
,	O
marcador	O
de	O
anclaje	O
ubicaciones	B-Sequence
a	O
datos	O
de	O
http	O
:	O
//www	O
.	O
informatica	O
jax	O
org	O
.	O

Las	O
líneas	O
punteadas	O
indican	O
el	O
umbral	O
por	O
encima	O
del	O
cual	O
la	O
vinculación	O
se	O
consideró	O
sugestiva	O
,	O
la	O
línea	O
discontinua	O
indica	O
el	O
umbral	O
por	O
encima	O
del	O
cual	O
la	O
vinculación	O
se	O
consideró	O
significativa	O
,	O
y	O
las	O
líneas	O
punteadas/discontinuas	O
indican	O
una	O
vinculación	O
altamente	O
significativa	O
,	O
tal	O
como	O
se	O
define	O
en	O
Materiales	O
y	O
Métodos	O
.	O

Figura	O
8	O

automático	O
-	O
AB	B-GENE
Perfiles	O

(	O
A	O
)	O
Títulos	O
de	O
ANA	O
en	O
C57BL	O
/	O
6	O
ratones	B-Taxon
,	O
C57BL	O
/	O
6	O
.	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
y	O
C57BL/6	O
.	O
129	O
(	O
D1Mit105	O
-	O
223	O
)	O
congénico	O
ratones	B-Taxon
a	O
1	O
año	O
de	O
edad	O
.	O

Los	O
símbolos	O
pequeños	O
representan	O
uno	O
ratón	B-Taxon
;	O
símbolos	O
grandes	O
,	O
un	O
número	O
variable	O
de	O
animales	B-Taxon
como	O
se	O
indica	O
entre	O
paréntesis	O
.	O

La	O
muestra	O
de	O
suero	O
se	O
tituló	O
hasta	O
el	O
punto	O
final	O
.	O

(	O
B	O
y	O
C	O
)	O
Anti	O
-	O
ssDNA	O
(	O
B	O
)	O
y	O
anti	O
-	O
cromatina	B-GENE
(	O
C	O
)	O
AB	B-GENE
niveles	O
en	O
las	O
mismas	O
cohortes	O
de	O
ratones	B-Taxon
como	O
en	O
(	O
A	O
)	O
.	O

los	O
AB	B-GENE
los	O
niveles	O
se	O
expresan	O
en	O
AEU	O
en	O
relación	O
con	O
una	O
muestra	O
positiva	O
estándar	O
,	O
a	O
la	O
que	O
se	O
le	O
asignó	O
un	O
valor	O
de	O
100	O
AEU	O
.	O

(	O
D	O
)	O
Anti	O
-	O
dsADN	O
AB	B-GENE
niveles	O

Las	O
muestras	O
de	O
suero	O
se	O
rastrearon	O
a	O
1:20	O
.	O

Las	O
muestras	O
que	O
dieron	O
positivo	O
se	O
titularon	O
hasta	O
el	O
punto	O
final	O
.	O

Los	O
símbolos	O
son	O
como	O
en	O
(	O
A	O
)	O
.	O

Figura	O
9	O

Evaluación	O
histológica	O
renal	O

C57BL	O
/	O
6	O
ratones	B-Taxon
,	O
C57BL	O
/	O
6	O
.	O
APC	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
y	O
C57BL/6	O
.	O
129	O
(	O
D1Mit105	O
-	O
223	O
)	O
congénico	O
ratones	B-Taxon
fueron	O
sacrificados	O
al	O
año	O
de	O
edad	O
para	O
obtener	O
especímenes	O
de	O
autopsia	O
de	O
la	O
misma	O
edad	O
.	O

Las	O
secciones	O
de	O
riñón	O
fijadas	O
de	O
Bouin	O
se	O
puntuaron	O
enmascaradas	O
para	O
la	O
glomerulonefritis	O
.	O

La	O
glomerulonefritis	O
se	O
calificó	O
en	O
una	O
escala	O
de	O
0	O
a	O
3	O
(	O
ver	O
Materiales	O
y	O
Métodos	O
para	O
más	O
detalles	O
)	O
.	O

Figura	O
2	O

Vinculación	O
de	O
Cromosoma	B-GENE
8	O
con	O
Anti	O
-	O
cromatina	B-GENE
y	O
Anti	O
-	O
dsDNA	O
Abdominales	B-GENE
en	O
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
Ratones	B-Taxon

Estos	O
enlaces	O
no	O
se	O
detectaron	O
en	O
(	O
129	O
x	O
C57BL/6	O
)	O
F2	O
.	O
APC	B-Protein
-	O
/	O
-	O
animales	B-Taxon
.	O

Centimorgan	O
posiciones	B-Sequence
fueron	O
deducidos	O
por	O
intervalo	B-Sequence
mapeo	O
,	O
marcador	O
de	O
anclaje	O
ubicaciones	B-Sequence
a	O
datos	O
de	O
http	O
:	O
//www	O
.	O
informatica	O
jax	O
org	O
.	O

Las	O
líneas	O
punteadas	O
indican	O
el	O
umbral	O
por	O
encima	O
del	O
cual	O
se	O
consideró	O
sugerente	O
la	O
vinculación	O
,	O
tal	O
como	O
se	O
define	O
en	O
Materiales	O
y	O
Métodos	O
.	O

tabla	O
1	O

Auto	O
Espontáneo	O
-	O
Abdominales	B-GENE
en	O
APC	B-Protein
-	O
/	O
-	O
y	O
Tipo	B-Sequence
salvaje	I-Sequence
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
Hembra	O
Ratones	B-Taxon

Diferencias	O
significativas	O
entre	O
APC	B-Protein
-	O
/	O
-	O
y	O
tipo	B-Sequence
salvaje	I-Sequence
controles	O
por	O
prueba	O
U	O
de	O
Mann-Whitney	O
.	O

Los	O
números	O
probados	O
para	O
diferentes	O
fenotipos	O
no	O
son	O
iguales	O
debido	O
a	O
la	O
cantidad	O
limitada	O
de	O
suero	O
o	O
muerte	O
del	O
ratones	B-Taxon
antes	O
del	O
final	O
del	O
experimento	O
.	O

NS	O
,	O
no	O
significativo	O

Tabla	O
2	O

Evaluación	O
histológica	O
de	O
secciones	O
de	O
riñón	O
en	O
APC	B-Protein
-	O
/	O
-	O
y	O
Tipo	B-Sequence
salvaje	I-Sequence
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
Hembra	O
Ratones	B-Taxon

Las	O
secciones	O
renales	O
se	O
puntuaron	O
en	O
una	O
escala	O
de	O
0	O
a	O
3	O
sobre	O
la	O
intensidad	O
y	O
extensión	O
de	O
los	O
cambios	O
histopatológicos	O
como	O
se	O
describe	O
en	O
Materiales	O
y	O
Métodos	O
.	O

La	O
diferencia	O
entre	O
los	O
dos	O
grupos	O
experimentales	O
no	O
fue	O
significativa	O
.	O

Tabla	O
3	O

Resumen	O
de	O
genoma	B-Sequence
#	O
¿NOMBRE	O
?	O
APC	B-Protein
-	O
/	O
-	O
y	O
Tipo	B-Sequence
salvaje	I-Sequence
(	O
129	O
x	O
C57BL	O
/	O
6	O
)	O
F2	O
Hembra	O
Ratones	B-Taxon

un	O
vínculo	O
sugerente	O

b	O
Vinculación	O
significativa	O

c	O
Relación	O
altamente	O
significativa	O
como	O
se	O
define	O
en	O
la	O
sección	O
de	O
material	O
y	O
método	O

cr	B-GENE
,	O
Cromosoma	B-GENE
;	O
Est	O
.	O

Pico	O
,	O
pico	O
estimado	O
;	O
LOD	O
,	O
logaritmo	O
de	O
probabilidades	O
;	O
N/A	O
,	O
no	O
aplicable	O

cromosomas	B-GENE
donde	O
los	O
enlaces	O
no	O
estaban	O
presentes	O
en	O
ambos	O
grupos	O
experimentales	O
no	O
se	O
ilustran	O
.	O

Ver	O
Materiales	O
y	O
Métodos	O
para	O
más	O
detalles	O
.	O

los	O
secuencias	B-Sequence
de	I-Sequence
oligonucleótidos	I-Sequence
y	O
aproximado	O
posiciones	B-Sequence
de	O
El	O
marcadores	B-Sequence
de	I-Sequence
microsatélites	I-Sequence
utilizados	O
fueron	O
tomados	O
de	O
la	O
Ratón	B-Taxon
genoma	B-Sequence
base	O
de	O
datos	O
,	O
Ratón	B-Taxon
genoma	B-Sequence
Informática	O
,	O
Jackson	O
Laboratory	O
,	O
Bar	O
Harbor	O
,	O
Maine	O
,	O
Estados	O
Unidos	O
(	O
http	O
:	O
//	O
www	O
.	O
informatics	O
.	O
jax	O
.	O
org	O
)	O

notas	O
al	O
pie	O

Conflictos	O
de	O
interés	O
.	O

Los	O
autores	O
han	O
declarado	O
que	O
no	O
existen	O
conflictos	O
de	O
interés	O
.	O

Contribuciones	O
de	O
autor	O
.	O

MJW	O
,	O
TJV	O
y	O
MB	O
concibieron	O
y	O
diseñaron	O
los	O
experimentos	O
.	O

AEB	O
,	O
KLR	O
,	O
JW	O
,	O
JC-H	O
y	O
RJR	O
realizaron	O
los	O
experimentos	O
.	O

AEB	O
,	O
KLR	O
,	O
RJR	O
y	O
HTC	O
analizaron	O
los	O
datos	O
.	O

MB	O
escribió	O
el	O
documento	O
.	O

Editor	O
académico	O
:	O
David	O
Nemazee	O
,	O
Instituto	O
de	O
Investigación	O
Scripps	O

moneda	O
Dirección	O
actual	O
:	O
The	O
Wellcome	O
Trust	O
,	O
Londres	O
,	O
Reino	O
Unido	O

Cita	O
:	O
Bygrave	O
AE	O
,	O
Rose	O
KL	O
,	O
Cortes-Hernandez	O
J	O
,	O
Warren	O
J	O
,	O
Rigby	O
RJ	O
,	O
et	O
al	O
.	O

(	O
2004	O
)	O
Autoinmunidad	O
espontánea	O
en	O
129	O
y	O
C57BL/6	O
ratones	B-Taxon
#	O
¿NOMBRE	O
?	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
.	O

PLoS	O
Biol	O
2	O
(	O
8	O
)	O
:	O
e243	O
.	O

los	O
receptor	B-Protein
de	I-Protein
fosfatidilserina	I-Protein
tiene	O
funciones	O
esenciales	O
durante	O
la	O
embriogénesis	O
pero	O
no	O
en	O
célula	B-Cell
apoptótica	I-Cell
eliminación	O

Resumen	O

Antecedentes	O

Fagocitosis	O
de	O
células	B-Cell
apoptóticas	I-Cell
es	O
fundamental	O
para	O
animal	B-Taxon
desarrollo	O
,	O
función	O
inmunológica	O
y	O
celular	B-Cell
homeostasis	O

los	O
receptor	B-Protein
de	I-Protein
fosfatidilserina	I-Protein
(	O
ptdsr	B-Protein
)	O
en	O
fagocitos	B-Cell
ha	O
estado	O
implicado	O
en	O
el	O
reconocimiento	O
y	O
engullimiento	O
de	O
células	B-Cell
apoptóticas	I-Cell
y	O
en	O
la	O
señalización	O
antiinflamatoria	O
.	O

Para	O
determinar	O
la	O
función	O
biológica	O
de	O
la	O
receptor	B-Protein
de	I-Protein
fosfatidilserina	I-Protein
in	O
vivo	O
,	O
inactivamos	O
el	O
ptdsr	B-Protein
gene	B-Sequence
en	O
el	O
ratón	B-Taxon
.	O

Resultados	O

Ablación	O
de	O
ptdsr	B-Protein
función	O
en	O
ratones	B-Taxon
causa	O
letalidad	O
perinatal	O
,	O
retraso	O
en	O
el	O
crecimiento	O
y	O
retraso	O
en	O
la	O
diferenciación	O
terminal	O
del	O
riñón	O
,	O
intestino	O
,	O
hígado	O
y	O
pulmones	O
durante	O
la	O
embriogénesis	O
.	O

Además	O
,	O
el	O
desarrollo	O
de	O
los	O
ojos	O
puede	O
verse	O
gravemente	O
alterado	O
,	O
desde	O
defectos	O
en	O
la	O
diferenciación	O
de	O
la	O
retina	O
hasta	O
la	O
ausencia	O
total	O
de	O
ojos	O
unilateral	O
o	O
bilateral	O
.	O

ptdsr	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
con	O
anoftalmía	O
desarrollan	O
nuevas	O
lesiones	O
,	O
con	O
inducción	O
de	O
epitelio	O
ectópico	O
pigmentado	O
en	O
la	O
retina	O
en	O
las	O
cavidades	O
nasales	O
.	O

Una	O
investigación	O
exhaustiva	O
de	O
célula	B-Cell
apoptótica	I-Cell
aclaramiento	O
in	O
vivo	O
e	O
in	O
vitro	O
demostró	O
que	O
la	O
absorción	O
de	O
células	B-Cell
apoptóticas	I-Cell
era	O
normal	O
en	O
ptdsr	B-Protein
knockear	O
ratones	B-Taxon
,	O
pero	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
macrófagos	B-Cell
se	O
vieron	O
afectados	O
en	O
la	O
señalización	O
de	O
citocinas	O
pro	O
y	O
antiinflamatorias	O
después	O
de	O
la	O
estimulación	O
con	O
células	B-Cell
apoptóticas	I-Cell
o	O
con	O
lipopolisacárido	B-Chemical
.	O

Conclusión	O

ptdsr	B-Protein
es	O
esencial	O
para	O
el	O
desarrollo	O
y	O
diferenciación	O
de	O
múltiples	O
órganos	O
durante	O
la	O
embriogénesis	O
pero	O
no	O
para	O
célula	B-Cell
apoptótica	I-Cell
remoción	O

ptdsr	B-Protein
Por	O
lo	O
tanto	O
,	O
puede	O
tener	O
una	O
función	O
de	O
desarrollo	O
novedosa	O
e	O
inesperada	O
como	O
una	O
importante	O
promoción	O
de	O
la	O
diferenciación	O
.	O
gene	B-Sequence
.	O

Es	O
más	O
,	O
ptdsr	B-Protein
no	O
se	O
requiere	O
para	O
célula	B-Cell
apoptótica	I-Cell
liquidación	O
por	O
macrófagos	B-Cell
pero	O
parece	O
ser	O
necesario	O
para	O
la	O
regulación	O
de	O
macrófago	B-Cell
respuestas	O
de	O
citocinas	O
.	O

Estos	O
resultados	O
contradicen	O
claramente	O
la	O
opinión	O
actual	O
de	O
que	O
la	O
receptor	B-Protein
de	I-Protein
fosfatidilserina	I-Protein
funciona	O
principalmente	O
en	O
célula	B-Cell
apoptótica	I-Cell
autorización	O
.	O

Antecedentes	O

Programado	O
célula	B-Cell
Se	O
requiere	O
la	O
muerte	O
o	O
apoptosis	O
para	O
el	O
desarrollo	O
normal	O
de	O
casi	O
todas	O
las	O
células	O
multicelulares	O
.	O
organismos	B-Taxon
y	O
es	O
un	O
mecanismo	O
fisiológico	O
para	O
controlar	O
célula	B-Cell
número	O
;	O
como	O
resultado	O
,	O
las	O
estructuras	O
que	O
ya	O
no	O
son	O
necesarias	O
se	O
eliminan	O
durante	O
el	O
desarrollo	O
y	O
anormal	O
células	B-Cell
son	O
eliminados	O
[	O
1	O
,	O
2	O
]	O
.	O

La	O
mayoría	O
de	O
células	B-Cell
producido	O
durante	O
mamífero	B-Taxon
el	O
desarrollo	O
embrionario	O
pasa	O
por	O
procesos	O
fisiológicos	O
célula	B-Cell
muerte	O
antes	O
del	O
final	O
del	O
período	O
perinatal	O
[	O
3	O
]	O
.	O

Células	B-Cell
apoptóticas	I-Cell
se	O
eliminan	O
rápida	O
y	O
eficientemente	O
como	O
intactos	O
células	B-Cell
o	O
cuerpos	O
apoptóticos	O
por	O
profesionales	O
fagocitos	B-Cell
o	O
por	O
vecinos	O
células	B-Cell
.	O

Este	O
proceso	O
altamente	O
regulado	O
evita	O
la	O
liberación	O
de	O
sustancias	O
potencialmente	O
nocivas	O
o	O
inmunogénicas	O
.	O
intracelular	B-GENE
materiales	O
y	O
constituye	O
el	O
destino	O
de	O
la	O
mayoría	O
de	O
los	O
moribundos	O
células	B-Cell
a	O
lo	O
largo	O
de	O
la	O
vida	O
de	O
un	O
organismo	B-Taxon
[	O
4	O
,	O
5	O
]	O
.	O

Fagocitosis	O
de	O
células	B-Cell
apoptóticas	I-Cell
es	O
muy	O
distinto	O
de	O
otros	O
procesos	O
de	O
engullimiento	O
que	O
resultan	O
,	O
por	O
ejemplo	O
,	O
en	O
la	O
eliminación	O
de	O
microorganismos	O
,	O
porque	O
el	O
engullimiento	O
de	O
células	B-Cell
apoptóticas	I-Cell
desencadena	O
la	O
secreción	O
de	O
potentes	O
mediadores	B-Chemical
antiinflamatorios	I-Chemical
e	I-Chemical
inmunosupresores	I-Chemical
,	O
mientras	O
que	O
el	O
reconocimiento	O
de	O
patógenos	O
provoca	O
la	O
liberación	O
de	O
señales	O
proinflamatorias	O
[	O
6	O
]	O
.	O

Casi	O
todos	O
célula	B-Cell
tipos	O
pueden	O
reconocer	O
,	O
responder	O
e	O
ingerir	O
células	B-Cell
apoptóticas	I-Cell
mediante	O
el	O
uso	O
de	O
conjuntos	O
específicos	O
de	O
receptores	O
fagocíticos	O
que	O
se	O
unen	O
a	O
ligandos	O
específicos	O
en	O
células	B-Cell
apoptóticas	I-Cell
.	O

Detallado	O
genético	B-Sequence
estudios	O
en	O
drosófila	B-Taxon
y	O
Caenorhabditis	B-Taxon
elegans	I-Taxon
recientemente	O
han	O
arrojado	O
evidencia	O
de	O
que	O
los	O
mecanismos	O
fagocíticos	O
básicos	O
y	O
las	O
vías	O
para	O
el	O
reconocimiento	O
y	O
la	O
absorción	O
de	O
células	B-Cell
apoptóticas	I-Cell
están	O
altamente	O
conservados	O
a	O
lo	O
largo	O
de	O
la	O
filogenia	O
[	O
7	O
,	O
8	O
]	O
.	O

En	O
vertebrados	B-Taxon
,	O
se	O
han	O
identificado	O
varios	O
receptores	O
que	O
pueden	O
mediar	O
la	O
fagocitosis	O
de	O
células	B-Cell
apoptóticas	I-Cell
.	O

Estos	O
incluyen	O
,	O
por	O
ejemplo	O
,	O
receptores	O
carroñeros	O
y	O
receptores	O
de	O
reconocimiento	O
de	O
patrones	O
tales	O
como	O
CD36	B-Protein
,	O
SR-A	B-Protein
y	O
CD14	B-Protein
,	O
integrinas	B-GENE
como	O
el	O
receptor	O
de	O
vitronectina	O
alfa	O
v	O
beta	O
3	O
y	O
miembros	O
de	O
la	O
familia	O
de	O
las	O
colectinas	O
y	O
sus	O
receptores	O
CD91	B-Protein
y	O
calreticulina	B-Protein
[	O
9	O
-	O
13	O
]	O
.	O

Los	O
roles	O
individuales	O
de	O
estos	O
moléculas	B-Chemical
en	O
la	O
unión	O
,	O
fagocitosis	O
o	O
transducción	O
de	O
señales	O
antiinflamatorias	O
sobre	O
célula	B-Cell
apoptótica	I-Cell
sin	O
embargo	O
,	O
el	O
reconocimiento	O
no	O
ha	O
sido	O
bien	O
definido	O
[	O
5	O
,	O
6	O
,	O
14	O
]	O
.	O

La	O
importancia	O
de	O
mecanismos	O
eficientes	O
para	O
célula	B-Cell
apoptótica	I-Cell
eliminación	O
in	O
vivo	O
está	O
respaldada	O
por	O
la	O
observación	O
de	O
que	O
las	O
respuestas	O
autoinmunes	O
pueden	O
ser	O
provocadas	O
en	O
ratones	B-Taxon
cuando	O
clave	O
moléculas	B-Chemical
por	O
célula	B-Cell
apoptótica	I-Cell
Falta	O
reconocimiento	O
y	O
aceptación	O
.	O

Esto	O
ha	O
sido	O
reportado	O
por	O
nocaut	O
ratones	B-Taxon
falta	O
el	O
complemento	O
proteína	B-Chemical
C1q	B-Protein
[	O
15	O
]	O
,	O
por	O
ratones	B-Taxon
con	O
un	O
mutación	B-Sequence
en	O
el	O
receptor	B-Protein
de	I-Protein
tirosina	I-Protein
quinasa	I-Protein
gene	B-Sequence
Mer	B-Protein
[	O
16	O
]	O
y	O
,	O
más	O
recientemente	O
,	O
en	O
ratones	B-Taxon
carente	O
transglutaminasa	B-Protein
2	I-Protein
o	O
factor	B-Protein
de	I-Protein
crecimiento	I-Protein
epidérmico	I-Protein
8	I-Protein
del	I-Protein
glóbulo	I-Protein
de	I-Protein
grasa	I-Protein
láctea	I-Protein
(	O
MFG-E8	B-Protein
)	O
[	O
17	O
,	O
18	O
]	O
.	O

La	O
exposición	O
de	O
la	O
fosfolípido	B-Chemical
fosfatidilserina	I-Chemical
(	O
PD	B-Chemical
)	O
en	O
el	O
prospecto	O
exterior	O
del	O
membrana	B-GENE
de	I-GENE
plasma	I-GENE
de	O
células	B-Cell
apoptóticas	I-Cell
ha	O
sido	O
descrito	O
como	O
uno	O
de	O
los	O
sellos	O
distintivos	O
de	O
la	O
inducción	O
de	O
la	O
apoptosis	O
y	O
se	O
considera	O
que	O
es	O
una	O
de	O
las	O
señales	O
más	O
importantes	O
requeridas	O
para	O
célula	B-Cell
apoptótica	I-Cell
reconocimiento	O
y	O
remoción	O
[	O
19	O
]	O
.	O

Un	O
numero	O
de	O
superficie	B-GENE
celular	I-GENE
y	O
puente	O
moléculas	B-Chemical
puede	O
interactuar	O
con	O
expuestos	O
PD	B-Chemical
en	O
células	B-Cell
apoptóticas	I-Cell
.	O

Estos	O
incluyen	O
el	O
suero	O
proteinas	B-Chemical
beta	B-Protein
2	I-Protein
-	I-Protein
glicoproteína	I-Protein
1	I-Protein
y	O
proteína	B-Protein
S	I-Protein
[	O
20	O
,	O
21	O
]	O
,	O
la	O
detención	O
del	O
crecimiento	O
específica	O
gene	B-Sequence
producto	O
GAS-6	B-Protein
[	O
22	O
]	O
,	O
productos	O
de	O
activación	O
del	O
complemento	O
[	O
23	O
]	O
,	O
el	O
glóbulo	O
de	O
grasa	O
láctea	O
proteína	B-Chemical
MFG-E8	B-Protein
[	O
24	O
]	O
,	O
y	O
anexina	B-Protein
I	I-Protein
[	O
25	O
]	O
.	O

En	O
la	O
mayoría	O
de	O
los	O
casos	O
,	O
los	O
receptores	O
de	O
fagocitos	B-Cell
que	O
reconocen	O
estos	O
PD	B-Chemical
#	O
¿NOMBRE	O
?	O
moléculas	B-Chemical
no	O
han	O
sido	O
definidos	O
,	O
pero	O
se	O
ha	O
informado	O
que	O
GAS-6	B-Protein
es	O
un	O
ligando	O
para	O
el	O
receptor	B-Protein
de	I-Protein
tirosina	I-Protein
quinasa	I-Protein
Mer	I-Protein
y	O
eso	O
MFG-E8	B-Protein
puede	O
unirse	O
al	O
receptor	O
de	O
vitronectina	O
alfa	O
v	O
beta	O
3	O
[	O
16	O
,	O
24	O
]	O
.	O

Otro	O
moléculas	B-Chemical
que	O
unen	O
PD	B-Chemical
con	O
diferente	O
especificidad	O
son	O
los	O
lectina	B-Protein
-	I-Protein
como	I-Protein
receptor	I-Protein
de	I-Protein
lipoproteínas	I-Protein
de	I-Protein
baja	I-Protein
densidad	I-Protein
oxidado	I-Protein
-	I-Protein
1	I-Protein
(	O
LOX	B-Protein
-	I-Protein
1	I-Protein
)	O
y	O
los	O
receptores	O
carroñeros	O
CD36	B-Protein
y	O
CD68	B-Protein
(	O
para	O
revisión	O
ver	O
[	O
5	O
]	O
y	O
referencias	O
allí	O
)	O
.	O

El	O
mejor	O
-	O
caracterizado	O
molécula	B-Chemical
hasta	O
ahora	O
que	O
se	O
une	O
PD	B-Chemical
en	O
un	O
estéreo	O
-	O
manera	O
específica	O
es	O
el	O
receptor	B-Protein
de	I-Protein
fosfatidilserina	I-Protein
(	O
ptdsr	B-Protein
)	O
[	O
26	O
]	O
.	O

In	O
vitro	O
,	O
se	O
ha	O
demostrado	O
que	O
la	O
ptdsr	B-Protein
puede	O
mediar	O
en	O
la	O
captación	O
de	O
células	B-Cell
apoptóticas	I-Cell
y	O
que	O
tal	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
PD	B-Chemical
liposomas	O
,	O
el	O
PD	B-Chemical
#	O
¿NOMBRE	O
?	O
molécula	B-Chemical
anexina	B-Protein
V	I-Protein
o	O
un	O
anti-	O
ptdsr	B-Protein
anticuerpo	B-GENE
[	O
26	O
]	O
.	O

Además	O
,	O
la	O
vinculación	O
de	O
ptdsr	B-Protein
para	O
PD	B-Chemical
en	O
células	B-Cell
apoptóticas	I-Cell
se	O
ha	O
informado	O
que	O
es	O
importante	O
para	O
la	O
liberación	O
de	O
mediadores	B-Chemical
antiinflamatorios	I-Chemical
,	O
incluyendo	O
factor	B-Protein
de	I-Protein
crecimiento	I-Protein
transformante	I-Protein
-	I-Protein
beta	I-Protein
1	I-Protein
(	O
TGF-beta	B-Protein
1	I-Protein
)	O
,	O
plaqueta	B-Cell
-	O
factor	O
activador	O
(	O
PAF	O
)	O
,	O
y	O
prostaglandina	B-Chemical
E2	I-Chemical
[	O
26	O
,	O
27	O
]	O
.	O

Estos	O
datos	O
apoyaron	O
la	O
hipótesis	O
de	O
que	O
ptdsr	B-Protein
cumple	O
un	O
papel	O
como	O
un	O
interruptor	O
de	O
señalización	O
crucial	O
después	O
de	O
la	O
participación	O
de	O
macrófagos	B-Cell
con	O
células	B-Cell
apoptóticas	I-Cell
y	O
por	O
lo	O
tanto	O
es	O
fundamental	O
para	O
prevenir	O
respuestas	O
inmunitarias	O
locales	O
a	O
células	B-Cell
apoptóticas	I-Cell
antes	O
de	O
su	O
autorización	O
[	O
28	O
]	O
.	O

Muy	O
recientemente	O
,	O
ptdsr	B-Protein
se	O
ha	O
encontrado	O
en	O
el	O
célula	B-Cell
núcleo	B-GENE
.	O

Su	O
nuclear	B-GENE
la	O
localización	O
está	O
mediada	O
por	O
cinco	O
nuclear	B-GENE
localización	O
señales	B-Sequence
,	O
cada	O
uno	O
de	O
los	O
cuales	O
por	O
sí	O
solo	O
es	O
capaz	O
de	O
apuntar	O
ptdsr	B-Protein
al	O
célula	B-Cell
núcleo	B-GENE
[	O
29	O
]	O
.	O

Además	O
,	O
un	O
estudio	O
adicional	O
realizado	O
recientemente	O
en	O
Hidra	B-Taxon
mostró	O
de	O
forma	O
exclusiva	O
nuclear	B-GENE
localización	O
para	O
el	O
ptdsr	B-Protein
proteína	B-Chemical
[	O
30	O
]	O
.	O

Lo	O
más	O
interesante	O
,	O
el	O
nuclear	B-GENE
localización	O
de	O
ptdsr	B-Protein
en	O
Hidra	B-Taxon
células	B-Cell
epiteliales	I-Cell
no	O
cambió	O
con	O
la	O
fagocitosis	O
de	O
células	B-Cell
apoptóticas	I-Cell
.	O

Estos	O
informes	O
desafían	O
la	O
hipótesis	O
original	O
,	O
según	O
la	O
cual	O
ptdsr	B-Protein
es	O
un	O
exclusivo	O
transmembrana	B-GENE
receptor	O
para	O
célula	B-Cell
apoptótica	I-Cell
reconocimiento	O
y	O
señalización	O
antiinflamatoria	O
.	O

Para	O
examinar	O
más	O
a	O
fondo	O
el	O
papel	O
de	O
ptdsr	B-Protein
en	O
vivo	O
,	O
realizamos	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
.	O

Se	O
observó	O
un	O
fenotipo	O
perinatalmente	O
letal	O
en	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
,	O
y	O
ptdsr	B-Protein
los	O
embriones	O
deficientes	O
presentaban	O
múltiples	O
defectos	O
en	O
la	O
diferenciación	O
de	O
tejidos	O
y	O
órganos	O
.	O

Mientras	O
este	O
trabajo	O
estaba	O
en	O
progreso	O
,	O
tanto	O
Li	O
et	O
al	O
.	O

[	O
31	O
]	O
y	O
Kunisaki	O
et	O
al	O
.	O

[	O
32	O
]	O
también	O
reportaron	O
la	O
generación	O
y	O
caracterización	O
fenotípica	O
de	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
.	O

Cabe	O
destacar	O
que	O
,	O
aunque	O
algunos	O
de	O
sus	O
resultados	O
se	O
confirmaron	O
en	O
nuestro	O
estudio	O
,	O
encontramos	O
un	O
fenotipo	O
fundamentalmente	O
diferente	O
con	O
respecto	O
a	O
la	O
eliminación	O
de	O
células	B-Cell
apoptóticas	I-Cell
.	O

Además	O
,	O
nuestro	O
estudio	O
reveló	O
hallazgos	O
marcados	O
e	O
inesperados	O
en	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
que	O
no	O
están	O
relacionados	O
con	O
la	O
apoptosis	O
.	O

Resultados	O

Generación	O
de	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon

Investigar	O
in	O
vivo	O
las	O
funciones	O
de	O
los	O
receptor	B-Protein
de	I-Protein
fosfatidilserina	I-Protein
Ptdsr	I-Protein
,	O
generamos	O
un	O
nulo	O
alelo	B-Sequence
en	O
el	O
ratón	B-Taxon
por	O
gene	B-Sequence
focalización	O
(	O
Figura	O
1a	O
,	O
1b	O
,	O
1c	O
)	O
.	O

A	O
diferencia	O
de	O
lo	O
descrito	O
anteriormente	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
[	O
31	O
,	O
32	O
]	O
,	O
usamos	O
Bruce4	O
embrionario	O
células	B-Cell
madre	I-Cell
(	I-Cell
ES	I-Cell
)	I-Cell
por	O
gene	B-Sequence
focalización	O
[	O
33	O
]	O
,	O
generando	O
así	O
una	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
alelo	B-Sequence
en	O
un	O
C57BL	O
/	O
6J	O
isogénico	O
puro	O
genético	B-Sequence
antecedentes	O
.	O

El	O
nocaut	O
recién	O
establecido	O
ratón	B-Taxon
línea	O
se	O
denominó	O
Ptdsrtm1Gbf	O
(	O
en	O
lo	O
sucesivo	O
,	O
ptdsr	B-Protein
-/-	O
)	O
.	O

heterocigoto	O
ptdsr	B-Protein
+	B-Sequence
/	O
-	O
ratones	B-Taxon
eran	O
viables	O
y	O
fértiles	O
y	O
no	O
mostraban	O
anormalidades	O
obvias	O
.	O

ptdsr	B-Protein
+	B-Sequence
/	O
-	O
ratones	B-Taxon
se	O
entrecruzaron	O
para	O
generar	O
homocigotos	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
.	O

La	O
ausencia	O
de	O
ptdsr	B-Protein
expresión	O
en	O
ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
fue	O
confirmado	O
por	O
RT	O
-	O
PCR	O
(	O
datos	O
no	O
mostrados	O
)	O
,	O
y	O
por	O
análisis	O
de	O
transferencia	O
Northern	O
y	O
Western	O
(	O
Figura	O
1d	O
,	O
e	O
)	O
.	O

Cruzamiento	O
de	O
heterocigotos	O
ratones	B-Taxon
mostró	O
que	O
el	O
mutación	B-Sequence
fue	O
letal	O
,	O
ya	O
que	O
no	O
se	O
detectaron	O
mutantes	O
homocigóticos	O
en	O
más	O
de	O
100	O
camadas	O
analizadas	O
al	O
destete	O
.	O

Determinar	O
las	O
etapas	O
del	O
desarrollo	O
embrionario	O
afectadas	O
por	O
el	O
Ptdsrtm1Gbf	O
mutación	B-Sequence
,	O
las	O
inseminaciones	O
cronometradas	O
fueron	O
seguidas	O
por	O
el	O
genotipado	O
por	O
PCR	O
(	O
Figura	O
1c	O
)	O
de	O
los	O
embriones	O
.	O

Recuperamos	O
menos	O
del	O
número	O
esperado	O
de	O
embriones	O
homocigotos	O
de	O
cruces	O
de	O
ptdsr	B-Protein
+	B-Sequence
/	O
-	O
ratones	B-Taxon
.	O

De	O
un	O
total	O
de	O
1	O
031	O
embriones	O
analizados	O
entre	O
el	O
día	O
gestacional	O
(	O
E	O
)	O
9	O
.	O
5	O
y	O
E18	O
.	O
5	O
,	O
198	O
(	O
19	O
.	O
2	O
%	O
)	O
ptdsr	B-Protein
-	O
se	O
recogieron	O
embriones	O
homocigóticos	O
deficientes	O
,	O
lo	O
que	O
indica	O
que	O
los	O
embriones	O
introducidos	O
mutación	B-Sequence
se	O
asocia	O
con	O
una	O
baja	O
tasa	O
de	O
letalidad	O
embrionaria	O
en	O
el	O
útero	O
.	O

De	O
E9	O
.	O
5	O
a	O
E12	O
.	O
5	O
,	O
ptdsr	B-Protein
-/-	O
los	O
embriones	O
eran	O
viables	O
y	O
de	O
tamaño	O
normal	O
.	O

En	O
E13	O
.	O
5	O
y	O
posteriormente	O
,	O
sin	O
embargo	O
,	O
la	O
mayoría	O
ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
mostraron	O
anomalías	O
morfológicas	O
(	O
Tabla	O
1	O
)	O
.	O

Todos	O
los	O
embriones	O
homocigóticos	O
recogidos	O
tenían	O
retraso	O
en	O
el	O
crecimiento	O
de	O
E13	O
.	O
5	O
en	O
adelante	O
,	O
tenía	O
una	O
apariencia	O
pálida	O
y	O
mostraba	O
múltiples	O
dismorfologías	O
de	O
desarrollo	O
.	O

Estos	O
incluyeron	O
varias	O
malformaciones	O
craneofaciales	O
y	O
de	O
la	O
cabeza	O
,	O
como	O
exencefalia	O
,	O
paladar	O
hendido	O
y	O
forma	O
anormal	O
de	O
la	O
cabeza	O
(	O
Figura	O
1f	O
,	O
g	O
)	O
.	O

La	O
inspección	O
macroscópica	O
reveló	O
que	O
el	O
desarrollo	O
de	O
los	O
ojos	O
se	O
vio	O
gravemente	O
afectado	O
en	O
14	O
.	O
1	O
%	O
de	O
embriones	O
homocigóticos	O
.	O

Los	O
afectados	O
animales	B-Taxon
mostró	O
una	O
completa	O
ausencia	O
unilateral	O
o	O
bilateral	O
de	O
los	O
ojos	O
(	O
Tabla	O
1	O
)	O
que	O
nunca	O
se	O
detectó	O
en	O
ptdsr	B-Protein
+	B-Sequence
/	O
+	B-Sequence
o	O
ptdsr	B-Protein
+	B-Sequence
/	O
-	O
compañeros	O
de	O
camada	O
.	O

Además	O
,	O
los	O
embriones	O
homocigóticos	O
recolectados	O
entre	O
E12	O
.	O
5	O
y	O
E15	O
.	O
5	O
tenían	O
edema	O
subcutáneo	O
(	O
Figura	O
1f	O
,	O
g	O
)	O
.	O

Porque	O
pudimos	O
recuperarnos	O
ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
hasta	O
E18	O
.	O
5	O
,	O
investigamos	O
si	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
podría	O
nacer	O
vivo	O
.	O

La	O
observación	O
cuidadosa	O
de	O
los	O
apareamientos	O
cronometrados	O
nos	O
permitió	O
recuperar	O
ptdsr	B-Protein
-	O
/	O
-	O
neonatos	O
,	O
pero	O
las	O
crías	O
homocigóticas	O
murieron	O
durante	O
el	O
parto	O
o	O
minutos	O
después	O
del	O
nacimiento	O
.	O

ptdsr	B-Protein
-	O
Los	O
neonatos	O
deficientes	O
también	O
presentaban	O
retraso	O
en	O
el	O
crecimiento	O
,	O
tenían	O
un	O
aspecto	O
pálido	O
y	O
presentaban	O
diversas	O
malformaciones	O
.	O

Estos	O
incluyeron	O
paladar	O
hendido	O
,	O
forma	O
anormal	O
de	O
la	O
cabeza	O
,	O
ausencia	O
de	O
ojos	O
y	O
piel	O
edematosa	O
(	O
Figura	O
1h	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
supresión	B-Sequence
de	O
El	O
ptdsr	B-Protein
gene	B-Sequence
resultó	O
en	O
letalidad	O
perinatal	O
con	O
severidad	O
variable	O
y	O
penetrancia	O
de	O
fenotipos	O
.	O

Expresión	O
de	O
ptdsr	B-Protein
durante	O
la	O
embriogénesis	O
y	O
en	O
tejidos	O
adultos	O

La	O
letalidad	O
perinatal	O
observada	O
indica	O
que	O
ptdsr	B-Protein
juega	O
un	O
papel	O
importante	O
durante	O
el	O
desarrollo	O
.	O

El	O
análisis	O
por	O
RT-PCR	O
(	O
datos	O
no	O
mostrados	O
)	O
mostró	O
que	O
ptdsr	B-Protein
se	O
expresa	O
temprano	O
en	O
el	O
desarrollo	O
,	O
porque	O
pudimos	O
detectar	O
ptdsr	B-Protein
transcripciones	B-Sequence
en	O
ES	O
células	B-Cell
y	O
embriones	O
en	O
todas	O
las	O
etapas	O
de	O
desarrollo	O
.	O

Analizar	O
con	O
más	O
detalle	O
los	O
patrones	O
de	O
expresión	O
temporal	O
y	O
espacial	O
de	O
ptdsr	B-Protein
,	O
y	O
para	O
correlacionar	O
los	O
patrones	O
de	O
expresión	O
con	O
las	O
malformaciones	O
patológicas	O
observadas	O
,	O
hicimos	O
uso	O
de	O
un	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
ratón	B-Taxon
línea	O
generada	O
a	O
partir	O
de	O
un	O
ptdsr	B-Protein
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
célula	B-Cell
clon	O

Esta	O
línea	O
tiene	O
un	O
inserción	B-Sequence
de	O
beta	O
-	O
galactosidasa	O
en	O
los	O
3	O
'	O
región	B-Sequence
del	I-Sequence
gen	I-Sequence
(	O
Figura	O
2a	O
)	O
.	O

Primero	O
examinamos	O
ptdsr	B-Protein
expresión	O
por	O
tinción	O
de	O
X-Gal	O
en	O
embriones	O
heterocigotos	O
estadificados	O
a	O
partir	O
de	O
E9	O
.	O
5	O
a	O
E12	O
.	O
5	O
.	O

Estas	O
etapas	O
de	O
desarrollo	O
fueron	O
elegidas	O
para	O
investigar	O
ptdsr	B-Protein
expresión	O
en	O
los	O
órganos	O
afectados	O
antes	O
de	O
la	O
aparición	O
de	O
malformaciones	O
patológicas	O
en	O
ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
.	O

En	O
E9	O
.	O
5	O
encontramos	O
ptdsr	B-Protein
expresión	O
en	O
el	O
tubo	O
neural	O
en	O
desarrollo	O
,	O
somitas	O
,	O
corazón	O
,	O
intestino	O
y	O
arcos	O
branquiales	O
(	O
Figura	O
2b	O
)	O
.	O

En	O
E10	O
.	O
5	O
,	O
ptdsr	B-Protein
la	O
expresión	O
permaneció	O
alta	O
en	O
el	O
sistema	O
nervioso	O
en	O
desarrollo	O
,	O
con	O
una	O
tinción	O
más	O
intensa	O
en	O
el	O
prosencéfalo	O
,	O
el	O
rombencéfalo	O
y	O
el	O
tubo	O
neural	O
.	O

En	O
esta	O
etapa	O
de	O
la	O
embriogénesis	O
,	O
los	O
altos	O
niveles	O
de	O
ptdsr	B-Protein
la	O
expresión	O
también	O
podría	O
detectarse	O
en	O
las	O
yemas	O
de	O
las	O
extremidades	O
y	O
los	O
ojos	O
en	O
desarrollo	O
(	O
Figura	O
2b	O
)	O
.	O

ptdsr	B-Protein
la	O
expresión	O
se	O
alteró	O
en	O
E12	O
.	O
5	O
,	O
con	O
la	O
tinción	O
más	O
intensa	O
de	O
beta-galactosidasa	O
en	O
los	O
ojos	O
,	O
desarrollando	O
condensaciones	O
de	O
las	O
yemas	O
de	O
las	O
extremidades	O
,	O
el	O
tubo	O
neural	O
y	O
el	O
cerebro	O
(	O
Figura	O
2b	O
)	O
.	O

Secciones	O
transversales	O
de	O
embriones	O
teñidos	O
con	O
X-Gal	O
en	O
E12	O
.	O
5	O
mostró	O
un	O
patrón	O
de	O
expresión	O
asimétrica	O
en	O
el	O
tubo	O
neural	O
con	O
tinción	O
intensa	O
de	O
la	O
capa	O
central	O
del	O
manto	O
pero	O
sin	O
expresión	O
en	O
la	O
parte	O
dorsal	O
del	O
tubo	O
neural	O
(	O
por	O
ejemplo	O
,	O
la	O
placa	O
del	O
techo	O
;	O
Figura	O
2c	O
)	O
.	O

Se	O
observó	O
expresión	O
en	O
los	O
ganglios	O
de	O
la	O
raíz	O
dorsal	O
lateral	O
al	O
tubo	O
neural	O
y	O
en	O
los	O
somitas	O
;	O
ptdsr	B-Protein
se	O
expresó	O
en	O
toda	O
la	O
estructura	O
somita	O
(	O
miotoma	O
,	O
dermatoma	O
y	O
esclerotomo	O
;	O
Figura	O
2d	O
)	O
.	O

Los	O
límites	O
de	O
expresión	O
entre	O
los	O
somitas	O
eran	O
evidentes	O
,	O
sin	O
expresión	O
en	O
las	O
interzonas	O
segmentarias	O
,	O
que	O
corresponden	O
a	O
los	O
futuros	O
discos	O
intervertebrales	O
(	O
Figura	O
2d	O
)	O
.	O

Secciones	O
transversales	O
del	O
ojo	O
en	O
desarrollo	O
en	O
E12	O
.	O
5	O
revelado	O
fuerte	O
ptdsr	B-Protein
expresión	O
en	O
la	O
capa	O
interna	O
de	O
la	O
copa	O
neural	O
,	O
que	O
luego	O
se	O
convertirá	O
en	O
la	O
retina	O
neural	O
.	O

Es	O
más	O
,	O
ptdsr	B-Protein
se	O
detectó	O
expresión	O
en	O
la	O
fibra	O
primaria	O
del	O
cristalino	O
células	B-Cell
del	O
cristalino	O
en	O
desarrollo	O
(	O
Figura	O
2e	O
)	O
.	O

Investigamos	O
cuidadosamente	O
si	O
ptdsr	B-Protein
se	O
expresa	O
a	O
partir	O
de	O
E10	O
.	O
5	O
a	O
E12	O
.	O
5	O
en	O
el	O
riñón	O
y	O
los	O
pulmones	O
en	O
desarrollo	O
,	O
pero	O
no	O
se	O
pudo	O
detectar	O
ninguna	O
expresión	O
que	O
indique	O
que	O
ptdsr	B-Protein
la	O
expresión	O
sólo	O
se	O
requiere	O
en	O
etapas	O
posteriores	O
del	O
desarrollo	O
de	O
estos	O
órganos	O
(	O
ver	O
más	O
abajo	O
)	O
.	O

La	O
hibridación	O
de	O
un	O
Northern	O
blot	O
de	O
tejido	O
múltiple	O
reveló	O
un	O
solo	O
transcripción	B-Sequence
de	O
aproximadamente	O
1	O
.	O
8	O
kb	O
en	O
casi	O
todos	O
los	O
tejidos	O
analizados	O
en	O
adultos	O
ratones	B-Taxon
(	O
Figura	O
2f	O
)	O
.	O

La	O
expresión	O
más	O
destacada	O
se	O
observó	O
en	O
testículos	O
,	O
timo	O
,	O
riñón	O
,	O
hígado	O
y	O
piel	O
,	O
con	O
una	O
expresión	O
de	O
moderada	O
a	O
baja	O
en	O
pulmón	O
,	O
intestino	O
delgado	O
,	O
bazo	O
,	O
estómago	O
y	O
músculo	O
esquelético	O
.	O

Por	O
lo	O
tanto	O
,	O
ptdsr	B-Protein
se	O
expresa	O
de	O
manera	O
ubicua	O
a	O
lo	O
largo	O
de	O
la	O
embriogénesis	O
y	O
en	O
tejidos	O
adultos	O
,	O
aunque	O
en	O
diferentes	O
niveles	O
.	O

ptdsr	B-Protein
se	O
requiere	O
para	O
la	O
diferenciación	O
normal	O
de	O
tejidos	O
y	O
órganos	O

continuación	O
examinamos	O
el	O
papel	O
de	O
ptdsr	B-Protein
en	O
el	O
desarrollo	O
de	O
órganos	O
.	O

Secciones	O
histológicas	O
seriadas	O
de	O
ptdsr	B-Protein
-/-	O
y	O
se	O
tomaron	O
embriones	O
de	O
control	O
para	O
realizar	O
un	O
análisis	O
morfológico	O
detallado	O
de	O
todos	O
los	O
sistemas	O
de	O
órganos	O
durante	O
el	O
desarrollo	O
.	O

Se	O
observó	O
un	O
retraso	O
significativo	O
en	O
la	O
diferenciación	O
de	O
órganos	O
y	O
tejidos	O
en	O
E16	O
.	O
5	O
en	O
pulmones	O
,	O
riñones	O
e	O
intestino	O
.	O

Los	O
pulmones	O
de	O
los	O
compañeros	O
de	O
camada	O
de	O
control	O
se	O
desarrollaron	O
adecuadamente	O
con	O
alvéolos	O
en	O
expansión	O
(	O
Figura	O
3a	O
)	O
.	O

Los	O
bronquios	O
terminales	O
y	O
los	O
bronquiolos	O
ya	O
estaban	O
bien	O
desarrollados	O
y	O
diferenciados	O
terminalmente	O
.	O
células	B-Cell
epiteliales	I-Cell
con	O
cilios	B-GENE
en	O
el	O
luminal	O
superficie	B-GENE
celular	I-GENE
estuvieron	O
presentes	O
.	O

Por	O
el	O
contrario	O
,	O
casi	O
no	O
había	O
alvéolos	O
ni	O
bronquiolos	O
en	O
ptdsr	B-Protein
-/-pulmones	O
,	O
lo	O
que	O
indica	O
un	O
retraso	O
o	O
detención	O
en	O
la	O
saculación	O
y	O
expansión	O
pulmonar	O
.	O

En	O
cambio	O
,	O
observamos	O
una	O
abundancia	O
de	O
mesénquima	O
que	O
parecía	O
muy	O
inmaduro	O
(	O
Figura	O
3g	O
)	O
.	O

Un	O
retraso	O
similar	O
en	O
la	O
diferenciación	O
tisular	O
de	O
ptdsr	B-Protein
-	O
/	O
-	O
se	O
encontraron	O
embriones	O
en	O
los	O
riñones	O
(	O
Figura	O
3h	O
)	O
.	O

Riñones	O
de	O
ptdsr	B-Protein
+	B-Sequence
/	O
+	B-Sequence
los	O
embriones	O
estaban	O
bien	O
desarrollados	O
en	O
E16	O
.	O
5	O
,	O
que	O
muestra	O
glomérulos	O
diferenciados	O
terminalmente	O
con	O
cápsula	O
de	O
Bowman	O
y	O
túbulos	O
colectores	O
revestidos	O
con	O
cuboide	O
células	B-Cell
epiteliales	I-Cell
(	O
Figura	O
3b	O
)	O
.	O

A	O
diferencia	O
de	O
,	O
ptdsr	B-Protein
-	O
los	O
riñones	O
deficientes	O
tenían	O
sólo	O
glomérulos	O
primitivos	O
en	O
E16	O
.	O
5	O
,	O
y	O
los	O
túbulos	O
colectores	O
estaban	O
menos	O
desarrollados	O
.	O

En	O
cambio	O
,	O
una	O
gran	O
cantidad	O
de	O
mesénquima	O
indiferenciado	O
estaba	O
presente	O
en	O
ptdsr	B-Protein
-	O
/	O
-	O
riñones	O
(	O
Figura	O
3h	O
)	O
.	O

También	O
se	O
encontró	O
un	O
retraso	O
en	O
la	O
diferenciación	O
de	O
tejidos	O
en	O
el	O
intestino	O
en	O
esta	O
etapa	O
de	O
desarrollo	O
.	O

ptdsr	B-Protein
-/-	O
los	O
embriones	O
mostraban	O
vellosidades	O
mal	O
desarrolladas	O
y	O
una	O
submucosa	O
subdesarrollada	O
o	O
ausente	O
(	O
Figura	O
3i	O
)	O
.	O

En	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
(	O
Figura	O
3c	O
)	O
,	O
intestino	O
celular	B-Cell
la	O
diferenciación	O
ya	O
estaba	O
muy	O
organizada	O
,	O
con	O
ganglio	O
intramural	O
células	B-Cell
entre	O
las	O
capas	O
musculares	O
externa	O
e	O
interna	O
.	O

Tal	O
células	B-Cell
neuronales	I-Cell
estaban	O
ausentes	O
del	O
intestino	O
de	O
ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
(	O
Figura	O
3i	O
)	O
,	O
sin	O
embargo	O
.	O

Algunos	O
ptdsr	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
4	O
,	O
5	O
%	O
)	O
también	O
mostraban	O
malformaciones	O
cerebrales	O
extensas	O
que	O
resultaban	O
en	O
anomalías	O
visibles	O
externamente	O
en	O
la	O
cabeza	O
,	O
con	O
tejido	O
ectópico	O
ocasional	O
fuera	O
del	O
cráneo	O
o	O
exencefalia	O
(	O
Figura	O
1f	O
,	O
h	O
)	O
.	O

El	O
análisis	O
histológico	O
reveló	O
una	O
hiperplasia	O
extensa	O
del	O
tejido	O
cerebral	O
con	O
herniación	O
del	O
tejido	O
cerebral	O
a	O
través	O
del	O
casquete	O
craneal	O
oa	O
través	O
de	O
la	O
parte	O
ventral	O
del	O
cráneo	O
(	O
Figura	O
3d	O
,	O
j	O
)	O
.	O

En	O
los	O
casos	O
más	O
severos	O
,	O
la	O
expansión	O
del	O
tejido	O
cerebral	O
en	O
mutante	B-Sequence
ratones	B-Taxon
resultó	O
en	O
más	O
perturbaciones	O
de	O
las	O
estructuras	O
corticales	O
(	O
Figura	O
3d	O
,	O
j	O
)	O
.	O

Cabe	O
destacar	O
que	O
se	O
observó	O
un	O
fenotipo	O
cerebral	O
similar	O
en	O
el	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratón	B-Taxon
línea	O
generada	O
por	O
Li	O
y	O
colegas	O
[	O
31	O
]	O
.	O

En	O
contraste	O
con	O
el	O
estudio	O
de	O
Li	O
et	O
al	O
.	O

[	O
31	O
]	O
,	O
sin	O
embargo	O
,	O
encontramos	O
pulmones	O
casi	O
normalmente	O
desarrollados	O
al	O
nacer	O
.	O

ptdsr	B-Protein
-	O
/	O
-	O
los	O
pulmones	O
mostraron	O
,	O
en	O
comparación	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
,	O
sólo	O
un	O
ligero	O
retraso	O
en	O
la	O
maduración	O
y	O
fueron	O
ventilados	O
completamente	O
en	O
los	O
recién	O
nacidos	O
en	O
la	O
mayoría	O
de	O
los	O
casos	O
(	O
Figura	O
3e	O
,	O
k	O
)	O
.	O

Esto	O
demuestra	O
que	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
puede	O
superar	O
el	O
retraso	O
en	O
la	O
diferenciación	O
pulmonar	O
embrionaria	O
y	O
mostrar	O
una	O
morfología	O
pulmonar	O
normal	O
al	O
nacer	O
.	O

Por	O
lo	O
tanto	O
,	O
parecería	O
muy	O
poco	O
probable	O
que	O
ptdsr	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
morir	O
por	O
insuficiencia	O
respiratoria	O
.	O

De	O
acuerdo	O
con	O
las	O
observaciones	O
de	O
Kunisaki	O
y	O
colegas	O
[	O
32	O
]	O
,	O
encontramos	O
una	O
diferenciación	O
eritropoyética	O
severamente	O
bloqueada	O
en	O
un	O
eritroblasto	B-Cell
temprano	I-Cell
etapa	O
en	O
el	O
hígado	O
(	O
Figura	O
3f	O
,	O
3l	O
)	O
,	O
lo	O
que	O
sugiere	O
una	O
explicación	O
para	O
la	O
apariencia	O
groseramente	O
anémica	O
que	O
observamos	O
en	O
nuestro	O
ptdsr	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
.	O

Pérdida	O
de	O
ptdsr	B-Protein
la	O
actividad	O
se	O
asocia	O
con	O
defectos	O
en	O
el	O
desarrollo	O
ocular	O
y	O
puede	O
conducir	O
a	O
la	O
formación	O
de	O
estructuras	O
oculares	O
ectópicas	O

Por	O
morfología	O
general	O
podríamos	O
diferenciar	O
dos	O
clases	O
de	O
ptdsr	B-Protein
mutantes	B-Sequence
:	O
los	O
que	O
parecían	O
normales	O
con	O
ambos	O
ojos	O
presentes	O
(	O
Figura	O
4	O
)	O
y	O
los	O
que	O
estaban	O
gravemente	O
afectados	O
y	O
mostraban	O
anoftalmía	O
uni	O
o	O
bilateral	O
(	O
Figura	O
5	O
)	O
.	O

El	O
análisis	O
de	O
embriones	O
normales	O
o	O
levemente	O
afectados	O
no	O
reveló	O
diferencias	O
entre	O
mutante	B-Sequence
y	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
en	O
la	O
diferenciación	O
del	O
ojo	O
en	O
desarrollo	O
hasta	O
E16	O
.	O
5	O
.	O

En	O
ambos	O
genotipos	B-Sequence
las	O
capas	O
interna	O
y	O
externa	O
de	O
la	O
retina	O
mostraron	O
un	O
estado	O
de	O
diferenciación	O
comparable	O
,	O
como	O
se	O
muestra	O
,	O
por	O
ejemplo	O
,	O
en	O
E12	O
.	O
5	O
(	O
Figura	O
4a	O
,	O
e	O
)	O
.	O

En	O
el	O
día	O
E16	O
.	O
5	O
,	O
sin	O
embargo	O
,	O
las	O
capas	O
de	O
la	O
retina	O
en	O
ptdsr	B-Protein
-	O
/	O
-	O
los	O
embriones	O
eran	O
mucho	O
más	O
delgados	O
que	O
en	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
,	O
contenía	O
menos	O
células	B-Cell
y	O
fueron	O
muy	O
reducidos	O
en	O
tamaño	O
(	O
Figura	O
4b	O
,	O
f	O
)	O
.	O

Comparación	O
de	O
las	O
estructuras	O
retinianas	O
de	O
ptdsr	B-Protein
+	B-Sequence
/	O
+	B-Sequence
y	O
ptdsr	B-Protein
-	O
/	O
-	O
los	O
embriones	O
revelaron	O
que	O
las	O
cuatro	O
capas	O
de	O
la	O
retina	O
estaban	O
presentes	O
en	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
en	O
E16	O
.	O
5	O
(	O
Figura	O
4b	O
,	O
f	O
)	O
.	O

En	O
E18	O
.	O
5	O
(	O
Figura	O
4c	O
,	O
g	O
)	O
y	O
en	O
neonatos	O
animales	B-Taxon
(	O
día	O
postnatal	O
P0	O
;	O
Figura	O
4d	O
,	O
h	O
)	O
,	O
las	O
diferencias	O
en	O
la	O
diferenciación	O
retiniana	O
entre	O
ptdsr	B-Protein
+	B-Sequence
/	O
+	B-Sequence
y	O
ptdsr	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
todavía	O
eran	O
evidentes	O
,	O
pero	O
la	O
reducción	O
del	O
tamaño	O
de	O
las	O
capas	O
de	O
la	O
retina	O
fue	O
menos	O
pronunciada	O
en	O
el	O
golpe	O
de	O
gracia	O
ratones	B-Taxon
.	O

ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
animales	B-Taxon
parece	O
haber	O
compensado	O
el	O
marcado	O
retraso	O
en	O
celular	B-Cell
diferenciación	O
y	O
expansión	O
de	O
las	O
capas	O
de	O
la	O
retina	O
.	O

Un	O
examen	O
minucioso	O
de	O
las	O
estructuras	O
de	O
la	O
retina	O
reveló	O
que	O
la	O
capa	O
granular	O
interna	O
estaba	O
aún	O
menos	O
expandida	O
en	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
animales	B-Taxon
,	O
sin	O
embargo	O
,	O
y	O
que	O
contenía	O
menos	O
células	B-Cell
todavía	O
estaba	O
severamente	O
subdesarrollado	O
en	O
comparación	O
con	O
la	O
capa	O
retiniana	O
correspondiente	O
en	O
el	O
control	O
animales	B-Taxon
(	O
Figura	O
4c	O
,	O
4g	O
y	O
4d	O
,	O
4h	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
incluso	O
levemente	O
afectados	O
ptdsr	B-Protein
-	O
/	O
-	O
mutantes	B-Sequence
tenía	O
malformaciones	O
oculares	O
con	O
defectos	O
en	O
la	O
diferenciación	O
de	O
las	O
estructuras	O
retinianas	O
.	O

A	O
continuación	O
examinamos	O
ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
que	O
mostraban	O
ausencia	O
unilateral	O
o	O
bilateral	O
de	O
ojos	O
(	O
Figura	O
5a	O
)	O
mediante	O
cortes	O
en	O
serie	O
de	O
embriones	O
completos	O
.	O

Estos	O
embriones	O
presentaban	O
malformaciones	O
complejas	O
de	O
la	O
copa	O
óptica	O
,	O
incluida	O
la	O
ausencia	O
del	O
cristalino	O
(	O
Figura	O
5b	O
)	O
.	O

Lo	O
más	O
sorprendente	O
es	O
que	O
encontramos	O
células	B-Cell
epiteliales	I-Cell
pigmentadas	I-Cell
en	O
la	O
cavidad	O
nasal	O
de	O
todos	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
con	O
anoftalmía	O
que	O
fueron	O
analizados	O
histopatológicamente	O
.	O

Podríamos	O
identificar	O
negro	O
-	O
de	O
color	O
células	B-Cell
pigmentadas	I-Cell
incrustado	O
en	O
el	O
epitelio	O
del	O
seno	O
maxilar	O
que	O
parecía	O
un	O
presunto	O
epitelio	O
pigmentado	O
de	O
la	O
retina	O
(	O
Figura	O
5b	O
,	O
c	O
)	O
.	O

El	O
examen	O
de	O
secciones	O
seriadas	O
consecutivas	O
reveló	O
la	O
formación	O
de	O
una	O
estructura	O
ocular	O
primitiva	O
,	O
con	O
inducción	O
y	O
posterior	O
proliferación	O
de	O
tejido	O
mesenquimatoso	O
ectópico	O
inmediatamente	O
adyacente	O
al	O
epitelio	O
pigmentado	O
desplazado	O
(	O
Figura	O
5d	O
)	O
.	O

Esta	O
estructura	O
fue	O
claramente	O
inducida	O
ectópicamente	O
y	O
no	O
logramos	O
identificar	O
cambios	O
similares	O
en	O
ninguno	O
de	O
los	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O

En	O
resumen	O
,	O
observamos	O
una	O
amplia	O
gama	O
de	O
malformaciones	O
oculares	O
en	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
que	O
iban	O
desde	O
defectos	O
de	O
diferenciación	O
en	O
la	O
retina	O
célula	B-Cell
capas	O
(	O
por	O
ejemplo	O
,	O
la	O
capa	O
granular	O
interna	O
)	O
en	O
homocigotos	O
levemente	O
afectados	O
a	O
la	O
anoftalmía	O
en	O
los	O
gravemente	O
afectados	O
ptdsr	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
que	O
se	O
asoció	O
con	O
la	O
inducción	O
de	O
estructuras	O
oculares	O
ectópicas	O
en	O
las	O
cavidades	O
nasales	O
.	O

Fagocitosis	O
y	O
aclaramiento	O
de	O
células	B-Cell
apoptóticas	I-Cell
es	O
normal	O
en	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon

A	O
continuación	O
probamos	O
si	O
ptdsr	B-Protein
es	O
funcionalmente	O
necesario	O
para	O
la	O
autorización	O
de	O
células	B-Cell
apoptóticas	I-Cell
.	O

Comenzamos	O
con	O
una	O
investigación	O
de	O
célula	B-Cell
muerte	O
in	O
vivo	O
en	O
las	O
áreas	O
interdigitales	O
de	O
las	O
extremidades	O
en	O
desarrollo	O
.	O

Apoptosis	O
de	O
los	O
interdigitales	O
células	B-Cell
en	I-Cell
el	I-Cell
mesénquima	I-Cell
distal	I-Cell
de	O
las	O
yemas	O
de	O
las	O
extremidades	O
ocurre	O
de	O
manera	O
más	O
prominente	O
a	O
partir	O
de	O
las	O
etapas	O
de	O
desarrollo	O
E12	O
.	O
0	O
a	O
E13	O
.	O
5	O
y	O
se	O
puede	O
examinar	O
fácilmente	O
in	O
situ	O
mediante	O
montaje	O
completo	O
desoxinucleótido	B-Protein
transferasa	I-Protein
terminal	I-Protein
#	O
¿NOMBRE	O
?	O
UTP	B-Chemical
etiquetado	O
final	O
(	O
TUNEL	O
)	O
.	O

Comparamos	O
el	O
patrón	O
de	O
interdigital	O
célula	B-Cell
muerte	O
en	O
yemas	O
de	O
las	O
extremidades	O
anteriores	O
y	O
posteriores	O
por	O
ptdsr	B-Protein
-	O
/	O
-	O
(	O
n	O
=	O
3	O
)	O
y	O
ptdsr	B-Protein
+	B-Sequence
/	O
+	B-Sequence
(	O
norte	O
=	O
3	O
)	O
ratones	B-Taxon
en	O
E12	O
.	O
5	O
y	O
E13	O
.	O
5	O
.	O

Sin	O
diferencias	O
en	O
la	O
acumulación	O
de	O
TUNEL	O
-	O
positivo	O
célula	B-Cell
se	O
observaron	O
cadáveres	O
entre	O
los	O
dos	O
genotipos	B-Sequence
(	O
Figura	O
6a	O
)	O
.	O

La	O
cinética	O
de	O
célula	B-Cell
La	O
ocurrencia	O
de	O
muertes	O
y	O
la	O
regresión	O
de	O
la	O
red	O
interdigital	O
fue	O
similar	O
en	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
mutante	B-Sequence
compañeros	O
de	O
camada	O
,	O
sin	O
proporcionar	O
evidencia	O
de	O
que	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
interdigitales	I-Cell
apoptóticas	I-Cell
durante	O
el	O
desarrollo	O
de	O
las	O
extremidades	O
.	O

Para	O
investigar	O
más	O
a	O
fondo	O
si	O
la	O
eliminación	O
de	O
células	B-Cell
apoptóticas	I-Cell
está	O
deteriorado	O
en	O
ptdsr	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
,	O
teñimos	O
inmunohistoquímicamente	O
para	O
caspasa	B-Protein
activada	I-Protein
3	I-Protein
(	O
acasp3	B-Protein
)	O
y	O
analizó	O
órganos	O
y	O
tejidos	O
adicionales	O
en	O
los	O
que	O
la	O
apoptosis	O
juega	O
un	O
papel	O
crucial	O
en	O
la	O
remodelación	O
de	O
tejidos	O
durante	O
el	O
desarrollo	O
.	O

partir	O
de	O
E12	O
.	O
5	O
,	O
analizamos	O
y	O
comparamos	O
el	O
número	O
y	O
la	O
distribución	O
de	O
acasp3	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
en	O
más	O
de	O
140	O
secciones	O
en	O
serie	O
de	O
tres	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
seis	O
ptdsr	B-Protein
-/-	O
embriones	O
en	O
secciones	O
consecutivas	O
y	O
correspondientes	O
.	O

Las	O
secciones	O
sagitales	O
fueron	O
separadas	O
por	O
5	O
µm	O
,	O
lo	O
que	O
permitió	O
un	O
análisis	O
detallado	O
de	O
la	O
apoptosis	O
en	O
varios	O
órganos	O
y	O
tejidos	O
.	O

Reestructuración	O
de	O
tejidos	O
por	O
programa	O
célula	B-Cell
la	O
muerte	O
ocurrió	O
más	O
notablemente	O
dentro	O
de	O
la	O
parte	O
ventral	O
del	O
tubo	O
neural	O
(	O
Figura	O
6b	O
,	O
f	O
)	O
y	O
en	O
los	O
ganglios	O
paravertebrales	O
en	O
desarrollo	O
(	O
Figura	O
6d	O
,	O
h	O
)	O
con	O
muchos	O
células	B-Cell
apoptóticas	I-Cell
Estar	O
presente	O
.	O

En	O
estos	O
tejidos	O
ptdsr	B-Protein
se	O
expresa	O
altamente	O
en	O
E12	O
.	O
5	O
(	O
Figura	O
2c	O
)	O
,	O
pero	O
no	O
observamos	O
ninguna	O
diferencia	O
en	O
el	O
número	O
o	O
distribución	O
de	O
células	B-Cell
apoptóticas	I-Cell
en	O
ptdsr	B-Protein
+	B-Sequence
/	O
+	B-Sequence
y	O
ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
.	O

Lo	O
mismo	O
era	O
cierto	O
para	O
el	O
riñón	O
en	O
desarrollo	O
:	O
células	B-Cell
apoptóticas	I-Cell
estuvieron	O
presentes	O
en	O
ptdsr	B-Protein
+	B-Sequence
/	O
+	B-Sequence
y	O
ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
,	O
en	O
números	O
limitados	O
,	O
pero	O
no	O
pudimos	O
detectar	O
ninguna	O
diferencia	O
en	O
el	O
número	O
de	O
células	B-Cell
apoptóticas	I-Cell
Entre	O
los	O
genotipos	B-Sequence
(	O
Figura	O
6c	O
,	O
6g	O
)	O
.	O

Además	O
,	O
cuando	O
continuamos	O
nuestro	O
análisis	O
de	O
célula	B-Cell
apoptótica	I-Cell
aclaramiento	O
in	O
vivo	O
en	O
E16	O
.	O
5	O
,	O
E17	O
.	O
5	O
y	O
E18	O
.	O
5	O
del	O
desarrollo	O
embrionario	O
así	O
como	O
en	O
el	O
neonatal	O
ratones	B-Taxon
,	O
el	O
número	O
y	O
la	O
distribución	O
de	O
células	B-Cell
apoptóticas	I-Cell
fue	O
similar	O
en	O
ambos	O
genotipos	B-Sequence
.	O

Como	O
ya	O
se	O
observó	O
en	O
E12	O
.	O
5	O
,	O
análisis	O
de	O
acasp3	B-Protein
-	O
las	O
secciones	O
teñidas	O
del	O
timo	O
en	O
desarrollo	O
,	O
el	O
corazón	O
,	O
el	O
diafragma	O
,	O
la	O
cresta	O
genital	O
,	O
los	O
ojos	O
y	O
la	O
retina	O
mostraron	O
de	O
manera	O
convincente	O
que	O
no	O
había	O
deterioro	O
en	O
célula	B-Cell
apoptótica	I-Cell
eliminación	O
en	O
ptdsr	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
.	O

Además	O
,	O
debido	O
a	O
que	O
Li	O
y	O
sus	O
colegas	O
[	O
31	O
]	O
informaron	O
una	O
eliminación	O
alterada	O
de	O
los	O
células	B-Cell
durante	O
el	O
desarrollo	O
pulmonar	O
en	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
,	O
examinamos	O
la	O
tasa	O
de	O
inducción	O
de	O
apoptosis	O
y	O
célula	B-Cell
autorización	O
en	O
nuestro	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
en	O
el	O
pulmón	O

Análisis	O
de	O
acasp3	B-Protein
#	O
¿NOMBRE	O
?	O
ptdsr	B-Protein
+	B-Sequence
/	O
+	B-Sequence
y	O
ptdsr	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
en	O
E17	O
.	O
5	O
y	O
P0	O
demostraron	O
que	O
la	O
apoptosis	O
era	O
un	O
evento	O
extremadamente	O
raro	O
durante	O
la	O
morfogénesis	O
pulmonar	O
en	O
esta	O
etapa	O
.	O

Además	O
,	O
no	O
hubo	O
diferencias	O
en	O
el	O
número	O
o	O
distribución	O
de	O
células	B-Cell
apoptóticas	I-Cell
en	O
ptdsr	B-Protein
-	O
/	O
-	O
y	O
ptdsr	B-Protein
+	B-Sequence
/	O
+	B-Sequence
ratones	B-Taxon
.	O

Además	O
,	O
no	O
pudimos	O
detectar	O
ninguna	O
evidencia	O
de	O
necrosis	O
tisular	O
en	O
los	O
pulmones	O
de	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
.	O

En	O
contraste	O
con	O
el	O
informe	O
de	O
Li	O
et	O
al	O
.	O

[	O
31	O
]	O
,	O
nunca	O
observamos	O
el	O
reclutamiento	O
de	O
neutrófilos	B-Cell
u	O
otros	O
signos	O
de	O
inflamación	O
pulmonar	O
en	O
cualquier	O
etapa	O
de	O
desarrollo	O
en	O
nuestro	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
.	O

Para	O
analizar	O
si	O
macrófagos	B-Cell
son	O
reclutados	O
en	O
áreas	O
donde	O
la	O
apoptosis	O
es	O
prominente	O
durante	O
la	O
embriogénesis	O
,	O
teñimos	O
secciones	O
en	O
serie	O
consecutivas	O
con	O
el	O
macrófago	B-Cell
superficie	B-GENE
marcador	O
F4	B-Protein
/	I-Protein
80	I-Protein
o	O
con	O
acasp3	B-Protein
.	O

Sorprendentemente	O
,	O
no	O
hubo	O
co-localización	O
de	O
macrófagos	B-Cell
con	O
células	B-Cell
apoptóticas	I-Cell
.	O

En	O
prácticamente	O
todos	O
los	O
tejidos	O
embrionarios	O
,	O
células	B-Cell
apoptóticas	I-Cell
y	O
macrófagos	B-Cell
se	O
localizaron	O
en	O
diferentes	O
compartimentos	O
(	O
Figura	O
6e	O
,	O
6i	O
;	O
y	O
ver	O
también	O
Archivo	O
de	O
datos	O
adicional	O
1	O
,	O
Figura	O
S1	O
)	O
.	O

Esto	O
sugiere	O
que	O
en	O
esta	O
etapa	O
de	O
desarrollo	O
es	O
principalmente	O
vecino	O
células	B-Cell
que	O
intervienen	O
en	O
la	O
eliminación	O
de	O
células	B-Cell
apoptóticas	I-Cell
,	O
en	O
lugar	O
de	O
profesional	O
macrófagos	B-Cell
.	O

En	O
resumen	O
,	O
nuestro	O
análisis	O
in	O
vivo	O
no	O
reveló	O
ningún	O
deterioro	O
en	O
célula	B-Cell
apoptótica	I-Cell
autorización	O
en	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
apoptóticas	I-Cell
está	O
mediado	O
principalmente	O
por	O
un	O
'espectador	O
'	O
no	O
profesional	O
células	B-Cell
.	O

Para	O
determinar	O
si	O
macrófagos	B-Cell
desde	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
se	O
vieron	O
afectados	O
en	O
la	O
eficacia	O
de	O
célula	B-Cell
apoptótica	I-Cell
captación	O
in	O
vitro	O
,	O
realizamos	O
ensayos	O
de	O
fagocitosis	O
con	O
derivados	O
de	O
hígado	O
fetal	O
macrófagos	B-Cell
(	O
FLDM	O
)	O
y	O
cuantificaron	O
sus	O
tasas	O
de	O
fagocitosis	O
.	O

Se	O
investigó	O
la	O
fagocitosis	O
de	O
los	O
timocitos	O
apoptóticos	O
a	O
los	O
60	O
,	O
90	O
y	O
120	O
minutos	O
después	O
de	O
la	O
adición	O
del	O
objetivo	O
células	B-Cell
en	O
ausencia	O
de	O
suero	O
.	O

El	O
análisis	O
de	O
las	O
tasas	O
de	O
fagocitosis	O
mediante	O
análisis	O
de	O
citometría	O
de	O
flujo	O
(	O
FACS	O
)	O
no	O
reveló	O
diferencias	O
en	O
la	O
eficacia	O
de	O
célula	B-Cell
apoptótica	I-Cell
absorción	O
entre	O
ptdsr	B-Protein
-	O
/	O
-	O
y	O
ptdsr	B-Protein
+	B-Sequence
/	O
+	B-Sequence
macrófagos	B-Cell
y	O
no	O
demostró	O
diferencias	O
en	O
célula	B-Cell
apoptótica	I-Cell
inmersión	O
entre	O
puntos	O
de	O
tiempo	O
seleccionados	O
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Para	O
volver	O
a	O
examinar	O
y	O
luego	O
validar	O
independientemente	O
el	O
resultado	O
de	O
normal	O
célula	B-Cell
apoptótica	I-Cell
captación	O
por	O
ptdsr	B-Protein
-	O
/	O
-	O
macrófagos	B-Cell
,	O
realizamos	O
ensayos	O
de	O
fagocitosis	O
durante	O
60	O
min	O
y	O
determinamos	O
el	O
porcentaje	O
de	O
macrófagos	B-Cell
que	O
había	O
engullido	O
células	B-Cell
apoptóticas	I-Cell
,	O
en	O
un	O
total	O
de	O
al	O
menos	O
300	O
macrófagos	B-Cell
contados	O
por	O
microscopía	O
de	O
fluorescencia	O
.	O

Fagocitado	O
,	O
5	O
-	O
carboxitetrametilrodamina	O
-	O
(	O
TAMRA	O
-	O
)	O
marcado	O
células	B-Cell
apoptóticas	I-Cell
fueron	O
identificados	O
como	O
engullidos	O
por	O
la	O
inclusión	O
en	O
F4	B-Protein
/	I-Protein
80	I-Protein
#	O
¿NOMBRE	O
?	O
macrófagos	B-Cell
.	O

El	O
análisis	O
fue	O
realizado	O
de	O
forma	O
independiente	O
por	O
tres	O
investigadores	O
que	O
desconocían	O
macrófago	B-Cell
genotipos	B-Sequence
(	O
ptdsr	B-Protein
-	O
/	O
-	O
o	O
ptdsr	B-Protein
+	B-Sequence
/	O
+	B-Sequence
)	O
.	O

De	O
nuevo	O
,	O
no	O
se	O
encontraron	O
diferencias	O
en	O
el	O
porcentaje	O
de	O
macrófagos	B-Cell
que	O
había	O
engullido	O
células	B-Cell
apoptóticas	I-Cell
(	O
Figura	O
7a	O
,	O
c	O
,	O
e	O
)	O
o	O
en	O
el	O
número	O
relativo	O
de	O
fagocitados	O
células	B-Cell
apoptóticas	I-Cell
por	O
macrófago	B-Cell
(	O
índice	O
fagocítico	O
;	O
Figura	O
7f	O
)	O
.	O

Además	O
,	O
soltero	O
ptdsr	B-Protein
-	O
/	O
-	O
macrófagos	B-Cell
podría	O
identificarse	O
que	O
había	O
engullido	O
aún	O
más	O
células	B-Cell
diana	I-Cell
apoptóticas	I-Cell
que	O
tenía	O
tipo	B-Sequence
salvaje	I-Sequence
macrófagos	B-Cell
(	O
Figura	O
7b	O
,	O
d	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
macrófagos	B-Cell
tenía	O
una	O
capacidad	O
normal	O
para	O
ingerir	O
células	B-Cell
apoptóticas	I-Cell
y	O
no	O
se	O
vieron	O
afectados	O
en	O
el	O
reconocimiento	O
o	O
la	O
fagocitosis	O
de	O
células	B-Cell
que	O
había	O
sido	O
programado	O
célula	B-Cell
muerte	O
.	O

ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
macrófago	B-Cell
estímulo	O

Además	O
de	O
su	O
importancia	O
sugerida	O
para	O
la	O
fagocitosis	O
de	O
células	B-Cell
apoptóticas	I-Cell
,	O
se	O
ha	O
propuesto	O
que	O
ptdsr	B-Protein
cumple	O
un	O
segundo	O
papel	O
crucial	O
en	O
la	O
regulación	O
y	O
el	O
mantenimiento	O
de	O
un	O
entorno	O
no	O
inflamatorio	O
tras	O
el	O
reconocimiento	O
de	O
células	B-Cell
apoptóticas	I-Cell
por	O
macrófagos	B-Cell
[	O
26	O
]	O
.	O

Por	O
lo	O
tanto	O
,	O
probamos	O
si	O
ptdsr	B-Protein
-	O
/	O
-	O
macrófagos	B-Cell
fueron	O
capaces	O
de	O
liberar	O
citocinas	O
antiinflamatorias	O
después	O
de	O
la	O
ingestión	O
de	O
células	B-Cell
apoptóticas	I-Cell
.	O

Examinamos	O
los	O
niveles	O
de	O
TGF-beta	B-Protein
1	I-Protein
y	O
interleucina	B-Protein
-	I-Protein
10	I-Protein
(	O
IL	B-Protein
-	I-Protein
10	I-Protein
)	O
después	O
de	O
la	O
estimulación	O
de	O
FLDM	O
con	O
lipopolisacárido	B-Chemical
(	O
LPS	B-Chemical
)	O
,	O
con	O
y	O
sin	O
cocultivo	O
de	O
células	B-Cell
apoptóticas	I-Cell
.	O

Cuantificación	O
de	O
TGF-beta	B-Protein
1	I-Protein
y	O
IL	B-Protein
-	I-Protein
10	I-Protein
los	O
niveles	O
después	O
de	O
22	O
horas	O
de	O
cultivo	O
demostraron	O
que	O
ptdsr	B-Protein
-	O
/	O
-	O
macrófagos	B-Cell
fueron	O
capaces	O
de	O
secretar	O
estas	O
citocinas	O
antiinflamatorias	O
tras	O
la	O
ingestión	O
de	O
células	B-Cell
apoptóticas	I-Cell
,	O
aunque	O
a	O
un	O
nivel	O
ligeramente	O
inferior	O
al	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
Figura	O
8a	O
,	O
b	O
)	O
.	O

Esto	O
indica	O
que	O
la	O
ablación	O
de	O
ptdsr	B-Protein
función	O
no	O
compromete	O
en	O
general	O
la	O
capacidad	O
de	O
macrófagos	B-Cell
para	O
liberar	O
citocinas	O
inmunosupresoras	O
después	O
del	O
reconocimiento	O
y	O
engullimiento	O
de	O
células	B-Cell
apoptóticas	I-Cell
.	O

Analizar	O
si	O
la	O
señalización	O
proinflamatoria	O
se	O
ve	O
afectada	O
en	O
ptdsr	B-Protein
-	O
/	O
-	O
macrófagos	B-Cell
,	O
estimulamos	O
los	O
FLDM	O
de	O
ptdsr	B-Protein
+	B-Sequence
/	O
+	B-Sequence
y	O
ptdsr	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
con	O
LPS	B-Chemical
y	O
niveles	O
medidos	O
de	O
factor	B-Protein
de	I-Protein
necrosis	I-Protein
tumoral	I-Protein
-	I-Protein
alfa	I-Protein
(	O
TNF-alfa	B-Protein
)	O
en	O
diferentes	O
momentos	O
después	O
de	O
la	O
estimulación	O
(	O
Figura	O
8c	O
)	O
.	O

ptdsr	B-Protein
-	O
/	O
-	O
macrófagos	B-Cell
produjo	O
significativamente	O
menos	O
TNF-alfa	B-Protein
que	O
lo	O
hizo	O
tipo	B-Sequence
salvaje	I-Sequence
macrófagos	B-Cell
.	O

La	O
diferencia	O
en	O
TNF-alfa	B-Protein
La	O
secreción	O
fue	O
visible	O
por	O
primera	O
vez	O
después	O
de	O
3	O
h	O
de	O
LPS	B-Chemical
estimulación	O
y	O
se	O
hizo	O
más	O
prominente	O
durante	O
el	O
transcurso	O
del	O
experimento	O
(	O
por	O
ejemplo	O
,	O
después	O
de	O
9	O
h	O
y	O
12	O
h	O
de	O
LPS	B-Chemical
estimulación	O
;	O
Figura	O
8c	O
)	O
.	O

Para	O
analizar	O
si	O
TNF-alfa	B-Protein
liberación	O
por	O
ptdsr	B-Protein
-	O
/	O
-	O
macrófagos	B-Cell
puede	O
verse	O
afectado	O
por	O
el	O
hundimiento	O
de	O
células	B-Cell
apoptóticas	I-Cell
,	O
estimulamos	O
los	O
FLDM	O
con	O
LPS	B-Chemical
,	O
células	B-Cell
apoptóticas	I-Cell
o	O
ambos	O
.	O

Cuantificación	O
de	O
TNF-alfa	B-Protein
Los	O
niveles	O
por	O
ELISA	O
después	O
de	O
22	O
h	O
mostraron	O
que	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
macrófagos	B-Cell
liberar	O
menos	O
TNF-alfa	B-Protein
después	O
de	O
la	O
estimulación	O
con	O
LPS	B-Chemical
solo	O
,	O
y	O
también	O
después	O
de	O
la	O
doble	O
estimulación	O
de	O
macrófagos	B-Cell
con	O
LPS	B-Chemical
y	O
células	B-Cell
apoptóticas	I-Cell
(	O
Figura	O
8d	O
)	O
.	O

Además	O
,	O
la	O
doble	O
estimulación	O
demostró	O
que	O
el	O
LPS	B-Chemical
#	O
¿NOMBRE	O
?	O
TNF-alfa	B-Protein
liberación	O
por	O
ptdsr	B-Protein
-	O
/	O
-	O
macrófagos	B-Cell
podría	O
ser	O
inhibida	O
por	O
la	O
administración	O
conjunta	O
de	O
células	B-Cell
apoptóticas	I-Cell
en	O
una	O
medida	O
comparable	O
a	O
la	O
observada	O
en	O
tipo	B-Sequence
salvaje	I-Sequence
macrófagos	B-Cell
.	O

Se	O
obtuvieron	O
resultados	O
similares	O
cuando	O
otras	O
citocinas	O
proinflamatorias	O
,	O
como	O
interleucina	B-Protein
-	I-Protein
6	I-Protein
y	O
proteína	B-Protein
quimioatrayente	I-Protein
de	I-Protein
monocitos	I-Protein
-	I-Protein
1	I-Protein
,	O
fueron	O
analizados	O
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Estos	O
resultados	O
indican	O
que	O
ptdsr	B-Protein
no	O
se	O
requiere	O
en	O
macrófagos	B-Cell
para	O
la	O
inhibición	O
de	O
la	O
señalización	O
proinflamatoria	O
después	O
del	O
reconocimiento	O
y	O
engullimiento	O
de	O
células	B-Cell
apoptóticas	I-Cell
.	O

ptdsr	B-Protein
-	O
la	O
deficiencia	O
,	O
sin	O
embargo	O
,	O
afecta	O
la	O
liberación	O
global	O
de	O
citocinas	O
proinflamatorias	O
y	O
antiinflamatorias	O
después	O
de	O
la	O
estimulación	O
con	O
LPS	B-Chemical
y	O
después	O
del	O
doble	O
tratamiento	O
con	O
LPS	B-Chemical
y	O
células	B-Cell
apoptóticas	I-Cell
,	O
Indicando	O
que	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
macrófagos	B-Cell
tienen	O
una	O
capacidad	O
reducida	O
para	O
producir	O
o	O
secretar	O
citocinas	O
pro	O
y	O
antiinflamatorias	O
.	O

Discusión	O

ptdsr	B-Protein
se	O
requiere	O
para	O
la	O
diferenciación	O
de	O
múltiples	O
sistemas	O
de	O
órganos	O
durante	O
el	O
desarrollo	O

En	O
este	O
estudio	O
,	O
hemos	O
generado	O
un	O
valor	O
nulo	O
mutación	B-Sequence
en	O
el	O
receptor	B-Protein
de	I-Protein
fosfatidilserina	I-Protein
(	O
ptdsr	B-Protein
)	O
gene	B-Sequence
en	O
C57BL	O
/	O
6J	O
ratones	B-Taxon
.	O

Demostramos	O
que	O
la	O
ablación	O
de	O
ptdsr	B-Protein
produce	O
defectos	O
profundos	O
de	O
diferenciación	O
en	O
múltiples	O
órganos	O
y	O
tejidos	O
durante	O
la	O
embriogénesis	O
,	O
aunque	O
con	O
penetrancia	O
variable	O
.	O

Mientras	O
este	O
trabajo	O
estaba	O
en	O
progreso	O
,	O
otros	O
dos	O
grupos	O
reportaron	O
la	O
generación	O
de	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
[	O
31	O
,	O
32	O
]	O
.	O

En	O
los	O
tres	O
nocauts	O
ratón	B-Taxon
lineas	O
,	O
las	O
dos	O
primeras	O
exones	B-Sequence
(	O
[	O
31	O
]	O
y	O
este	O
estudio	O
)	O
o	O
exones	B-Sequence
uno	O
a	O
tres	O
[	O
32	O
]	O
fueron	O
eliminado	B-Sequence
por	O
reemplazo	B-Sequence
con	O
un	O
neomicina	B-Chemical
#	O
¿NOMBRE	O
?	O
casete	B-Sequence
.	O

los	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratón	B-Taxon
Las	O
líneas	O
difieren	O
en	O
el	O
genético	B-Sequence
fondo	O
en	O
el	O
que	O
el	O
mutación	B-Sequence
fue	O
generado	O
y	O
mantenido	O
,	O
sin	O
embargo	O
.	O

En	O
nuestro	O
caso	O
,	O
el	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
alelo	B-Sequence
se	O
generó	O
en	O
un	O
fondo	O
isogénico	O
C57BL/6J	O
,	O
mientras	O
que	O
Li	O
et	O
al	O
.	O

[	O
31	O
]	O
y	O
Kunisaki	O
et	O
al	O
.	O

[	O
32	O
]	O
investigó	O
el	O
fenotipo	O
de	O
sus	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
en	O
un	O
fondo	O
mixto	O
de	O
129	O
x	O
C57BL/6	O
.	O

la	O
ablación	O
de	O
ptdsr	B-Protein
La	O
función	O
resulta	O
en	O
letalidad	O
perinatal	O
en	O
todos	O
los	O
casos	O
,	O
pero	O
existen	O
diferencias	O
interesantes	O
en	O
la	O
severidad	O
o	O
expresividad	O
de	O
los	O
fenotipos	O
entre	O
los	O
diferentes	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratón	B-Taxon
líneas	O
.	O

Esto	O
puede	O
deberse	O
a	O
diferencias	O
en	O
genético	B-Sequence
antecedentes	O
o	O
porque	O
los	O
fenotipos	O
que	O
se	O
han	O
investigado	O
en	O
este	O
estudio	O
no	O
se	O
han	O
analizado	O
con	O
tanto	O
detalle	O
antes	O
.	O

En	O
el	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratón	B-Taxon
línea	O
reportada	O
aquí	O
,	O
el	O
retraso	O
del	O
crecimiento	O
comenzó	O
a	O
partir	O
de	O
E12	O
.	O
5	O
en	O
adelante	O
y	O
se	O
asoció	O
con	O
retraso	O
en	O
la	O
diferenciación	O
en	O
varios	O
órganos	O
en	O
los	O
que	O
ptdsr	B-Protein
se	O
expresa	O
ya	O
sea	O
durante	O
la	O
embriogénesis	O
o	O
más	O
tarde	O
en	O
la	O
edad	O
adulta	O
.	O

En	O
E16	O
.	O
5	O
casi	O
no	O
se	O
observó	O
morfogénesis	O
ramificada	O
del	O
epitelio	O
pulmonar	O
en	O
ptdsr	B-Protein
-	O
/	O
-	O
pulmones	O
.	O

De	O
manera	O
similar	O
,	O
las	O
estructuras	O
epiteliales	O
solo	O
se	O
desarrollaron	O
parcialmente	O
en	O
mutante	B-Sequence
riñones	O
,	O
sin	O
diferenciación	O
terminal	O
de	O
la	O
cápsula	O
de	O
Bowman	O
y	O
con	O
una	O
severa	O
reducción	O
en	O
el	O
número	O
de	O
túbulos	O
colectores	O
diferenciados	O
.	O

Asimismo	O
,	O
la	O
diferenciación	O
del	O
intestino	O
también	O
se	O
retrasó	O
severamente	O
en	O
esta	O
etapa	O
de	O
desarrollo	O
.	O

Cuando	O
se	O
compara	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
controles	O
,	O
tejidos	O
intestinales	O
de	O
ptdsr	B-Protein
knockear	O
ratones	B-Taxon
aparecían	O
desestructurados	O
,	O
con	O
ausencia	O
de	O
ganglios	O
entéricos	O
y	O
de	O
tejido	O
muscular	O
liso	O
diferenciado	O
.	O

Curiosamente	O
,	O
los	O
defectos	O
en	O
la	O
diferenciación	O
de	O
riñón	O
e	O
intestino	O
no	O
se	O
describieron	O
en	O
el	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O

[	O
31	O
]	O
y	O
Kunisaki	O
et	O
al	O
.	O

[	O
32	O
]	O
.	O

Sorprendentemente	O
,	O
cuando	O
examinamos	O
ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
poco	O
antes	O
del	O
nacimiento	O
(	O
E18	O
.	O
5	O
)	O
o	O
neonatalmente	O
,	O
encontramos	O
sólo	O
leves	O
retrasos	O
en	O
la	O
diferenciación	O
en	O
órganos	O
que	O
parecían	O
gravemente	O
afectados	O
a	O
mitad	O
de	O
la	O
gestación	O
.	O

Esta	O
'recuperación	O
'	O
fue	O
más	O
visible	O
en	O
ptdsr	B-Protein
-	O
/	O
-	O
pulmones	O
:	O
en	O
P0	O
encontramos	O
pulmones	O
expandidos	O
en	O
el	O
golpe	O
de	O
gracia	O
ratones	B-Taxon
que	O
mostró	O
patrones	O
de	O
ramificación	O
normales	O
,	O
con	O
alvéolos	O
y	O
bronquiolos	O
diferenciados	O
.	O

Investigamos	O
la	O
ocurrencia	O
de	O
eventos	O
programados	O
.	O
célula	B-Cell
muerte	O
durante	O
el	O
desarrollo	O
pulmonar	O
en	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
a	O
lo	O
largo	O
de	O
la	O
embriogénesis	O
(	O
E16.5	O
a	O
P0	O
)	O
.	O

Inmunohistoquímica	O
comparativa	O
para	O
acasp3	B-Protein
reveló	O
que	O
la	O
apoptosis	O
es	O
un	O
evento	O
raro	O
durante	O
la	O
morfogénesis	O
pulmonar	O
.	O

Además	O
,	O
no	O
pudimos	O
detectar	O
ninguna	O
diferencia	O
en	O
el	O
número	O
de	O
células	B-Cell
apoptóticas	I-Cell
en	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
tipo	B-Sequence
salvaje	I-Sequence
animales	B-Taxon
en	O
los	O
raros	O
casos	O
en	O
los	O
que	O
pudimos	O
detectar	O
células	B-Cell
apoptóticas	I-Cell
dentro	O
de	O
los	O
tejidos	O
pulmonares	O
.	O

Estos	O
hallazgos	O
son	O
contrarios	O
a	O
los	O
resultados	O
informados	O
por	O
Li	O
et	O
al	O
.	O

[	O
31	O
]	O
,	O
quien	O
sugirió	O
que	O
la	O
eliminación	O
deficiente	O
de	O
células	B-Cell
mesenquimales	I-Cell
y	I-Cell
epiteliales	I-Cell
apoptóticas	I-Cell
provoca	O
un	O
fallo	O
en	O
la	O
morfogénesis	O
pulmonar	O
en	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
.	O

Por	O
el	O
contrario	O
,	O
nuestros	O
resultados	O
están	O
en	O
consonancia	O
con	O
la	O
opinión	O
actual	O
sobre	O
el	O
desarrollo	O
de	O
los	O
pulmones	O
durante	O
la	O
embriogénesis	O
.	O

En	O
consecuencia	O
,	O
la	O
formación	O
del	O
pulmón	O
epitelial	O
a	O
través	O
de	O
la	O
morfogénesis	O
ramificada	O
se	O
puede	O
subdividir	O
en	O
una	O
serie	O
de	O
pasos	O
secuenciales	O
que	O
implican	O
:	O
primero	O
,	O
la	O
formación	O
del	O
esbozo	O
del	O
órgano	O
en	O
forma	O
de	O
placoda	O
;	O
en	O
segundo	O
lugar	O
,	O
la	O
formación	O
de	O
yemas	O
primarias	O
por	O
invaginación	O
de	O
placodas	O
;	O
tercero	O
,	O
iniciación	O
de	O
ramas	O
y	O
crecimiento	O
de	O
ramas	O
;	O
cuarto	O
,	O
una	O
mayor	O
reiteración	O
del	O
proceso	O
de	O
ramificación	O
;	O
y	O
quinto	O
,	O
diferenciación	O
terminal	O
de	O
estructuras	O
proximales	O
y	O
distales	O
específicas	O
de	O
órganos	O
[	O
34	O
,	O
35	O
]	O
.	O

diferencia	O
de	O
otros	O
procesos	O
de	O
invaginación	O
durante	O
la	O
embriogénesis	O
,	O
como	O
la	O
formación	O
de	O
glándulas	O
mamarias	O
,	O
la	O
luz	O
de	O
los	O
pulmones	O
se	O
expande	O
por	O
eventos	O
de	O
ramificación	O
sucesivos	O
,	O
crecimiento	O
y	O
alargamiento	O
de	O
ramas	O
,	O
en	O
lugar	O
de	O
por	O
apoptosis	O
[	O
34	O
,	O
36	O
]	O
.	O

Finalmente	O
,	O
porque	O
los	O
pulmones	O
de	O
ptdsr	B-Protein
-	O
/	O
-	O
los	O
recién	O
nacidos	O
estaban	O
casi	O
completamente	O
expandidos	O
y	O
parecían	O
de	O
estructura	O
normal	O
en	O
comparación	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
compañeros	O
de	O
camada	O
,	O
es	O
muy	O
poco	O
probable	O
que	O
ptdsr	B-Protein
mutantes	B-Sequence
morir	O
de	O
insuficiencia	O
respiratoria	O
pulmonar	O
.	O

Además	O
,	O
Li	O
y	O
sus	O
colegas	O
[	O
31	O
]	O
demostraron	O
que	O
surfactante	B-Chemical
la	O
expresión	O
es	O
normal	O
en	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
animales	B-Taxon
,	O
apoyando	O
la	O
idea	O
de	O
una	O
maduración	O
normal	O
de	O
surfactante	B-Chemical
#	O
¿NOMBRE	O
?	O
células	B-Cell
epiteliales	I-Cell
y	O
función	O
pulmonar	O
.	O

Por	O
lo	O
tanto	O
,	O
otros	O
defectos	O
deben	O
ser	O
responsables	O
de	O
la	O
muerte	O
de	O
ptdsr	B-Protein
-	O
mutante	B-Sequence
ratones	B-Taxon
.	O

El	O
edema	O
subcutáneo	O
de	O
varios	O
grados	O
observado	O
con	O
frecuencia	O
en	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O

De	O
hecho	O
,	O
muy	O
recientemente	O
hemos	O
obtenido	O
pruebas	O
sólidas	O
de	O
que	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
morir	O
como	O
resultado	O
de	O
defectos	O
en	O
el	O
desarrollo	O
del	O
corazón	O
que	O
están	O
asociados	O
con	O
malformaciones	O
cardiopulmonares	O
específicas	O
;	O
(	O
J	O
.	O
E	O
.	O
Schneider	O
,	O
J	O
.	O
B	O
.	O
,	O
S	O
.	O
D	O
.	O
Bamfort	O
,	O
A	O
.	O
D	O
.	O
G	O
.	O
,	O
C	O
.	O
Broadbent	O
,	O
K	O
.	O
Clarke	O
,	O
S	O
.	O
Neubauer	O
,	O
A	O
.	O
L	O
.	O
y	O
S	O
.	O
Battacharya	O
,	O
observaciones	O
no	O
publicadas	O
)	O
.	O

Además	O
,	O
demostramos	O
que	O
el	O
desarrollo	O
de	O
los	O
ojos	O
requiere	O
un	O
desarrollo	O
funcional	O
ptdsr	B-Protein
gene	B-Sequence
.	O

ptdsr	B-Protein
Los	O
embriones	O
deficientes	O
se	O
pueden	O
dividir	O
aproximadamente	O
en	O
dos	O
categorías	O
.	O

El	O
primer	O
grupo	O
,	O
gravemente	O
afectado	O
,	O
desarrolla	O
anoftalmía	O
que	O
se	O
correlaciona	O
con	O
la	O
formación	O
de	O
epitelio	O
pigmentado	O
de	O
la	O
retina	O
ectópico	O
y	O
la	O
inducción	O
de	O
la	O
proliferación	O
del	O
mesénquima	O
subyacente	O
en	O
la	O
cavidad	O
nasal	O
.	O

Este	O
fenotipo	O
representa	O
una	O
lesión	O
completamente	O
nueva	O
que	O
,	O
hasta	O
donde	O
sabemos	O
,	O
no	O
ha	O
sido	O
descrita	O
antes	O
en	O
ningún	O
otro	O
ratón	B-Taxon
mutante	B-Sequence
.	O

El	O
segundo	O
grupo	O
muestra	O
estructuras	O
oculares	O
externas	O
normales	O
,	O
aunque	O
en	O
este	O
caso	O
el	O
desarrollo	O
de	O
la	O
retina	O
se	O
retrasa	O
temporalmente	O
durante	O
la	O
mitad	O
de	O
la	O
gestación	O
,	O
con	O
morfogénesis	O
anormal	O
persistente	O
de	O
la	O
capa	O
granular	O
interna	O
de	O
la	O
retina	O
en	O
etapas	O
posteriores	O
de	O
la	O
embriogénesis	O
.	O

Una	O
posible	O
explicación	O
para	O
estos	O
dos	O
fenotipos	O
se	O
puede	O
encontrar	O
en	O
el	O
patrón	O
de	O
expresión	O
del	O
ptdsr	B-Protein
gene	B-Sequence
.	O

Inicialmente	O
,	O
ptdsr	B-Protein
se	O
expresa	O
a	O
lo	O
largo	O
de	O
todo	O
el	O
sistema	O
nervioso	O
en	O
desarrollo	O
,	O
con	O
niveles	O
excepcionalmente	O
altos	O
en	O
la	O
parte	O
anterior	O
del	O
prosencéfalo	O
.	O

La	O
expresión	O
posterior	O
se	O
vuelve	O
más	O
restringida	O
a	O
la	O
retina	O
y	O
el	O
cristalino	O
en	O
desarrollo	O
.	O

Por	O
lo	O
tanto	O
,	O
ptdsr	B-Protein
podría	O
desempeñar	O
un	O
papel	O
importante	O
en	O
los	O
primeros	O
eventos	O
de	O
la	O
morfogénesis	O
ocular	O
,	O
como	O
el	O
establecimiento	O
y	O
la	O
bisección	O
de	O
los	O
campos	O
oculares	O
y	O
la	O
formación	O
de	O
copas	O
ópticas	O
.	O

Estos	O
primeros	O
pasos	O
de	O
formación	O
del	O
ojo	O
están	O
estrechamente	O
interconectados	O
con	O
el	O
desarrollo	O
del	O
cerebro	O
anterior	O
[	O
37	O
,	O
38	O
]	O
y	O
la	O
nariz	O
[	O
39-41	O
]	O
.	O

Curiosamente	O
,	O
ocasionalmente	O
observamos	O
malformaciones	O
graves	O
del	O
prosencéfalo	O
y	O
las	O
estructuras	O
nasales	O
en	O
ptdsr	B-Protein
embriones	O
knockout	O
que	O
se	O
asociaron	O
con	O
anoftalmía	O
bilateral	O
(	O
ver	O
por	O
ejemplo	O
el	O
mutante	B-Sequence
embrión	O
en	O
la	O
Figura	O
1g	O
)	O
.	O

Esto	O
sugiere	O
que	O
ptdsr	B-Protein
está	O
involucrado	O
en	O
la	O
regulación	O
de	O
los	O
procesos	O
de	O
diferenciación	O
dentro	O
de	O
las	O
regiones	O
del	O
cerebro	O
anterior	O
,	O
y	O
que	O
la	O
ablación	O
de	O
ptdsr	B-Protein
la	O
función	O
podría	O
afectar	O
secundariamente	O
la	O
formación	O
temprana	O
del	O
ojo	O
.	O

Li	O
et	O
al	O
.	O

[	O
31	O
]	O
encontró	O
lentes	O
más	O
pequeñas	O
en	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
y	O
describió	O
la	O
formación	O
de	O
protuberancias	O
retinianas	O
,	O
aunque	O
la	O
anoftalmía	O
y	O
los	O
defectos	O
de	O
diferenciación	O
específicos	O
de	O
la	O
retina	O
célula	B-Cell
las	O
capas	O
no	O
fueron	O
reportadas	O
en	O
su	O
estudio	O
.	O

Li	O
et	O
al	O
.	O
propusieron	O
[	O
31	O
]	O
que	O
el	O
fenotipo	O
del	O
ojo	O
que	O
observaron	O
podría	O
explicarse	O
por	O
la	O
eliminación	O
fallida	O
de	O
células	B-Cell
apoptóticas	I-Cell
durante	O
el	O
desarrollo	O
del	O
ojo	O
,	O
pero	O
creemos	O
que	O
los	O
defectos	O
observados	O
no	O
están	O
relacionados	O
con	O
una	O
falla	O
de	O
célula	B-Cell
apoptótica	I-Cell
autorización	O
.	O

Un	O
análisis	O
cinético	O
completo	O
reciente	O
de	O
la	O
inducción	O
de	O
la	O
apoptosis	O
durante	O
ratón	B-Taxon
El	O
desarrollo	O
de	O
la	O
retina	O
describió	O
cuatro	O
picos	O
principales	O
de	O
célula	B-Cell
apoptótica	I-Cell
muerte	O
[	O
42	O
]	O
.	O

Este	O
estudio	O
demostró	O
que	O
existe	O
una	O
fase	O
inicial	O
de	O
célula	B-Cell
muerte	O
durante	O
la	O
invaginación	O
de	O
la	O
copa	O
óptica	O
(	O
E10.5	O
)	O
,	O
seguida	O
de	O
ondas	O
posteriores	O
de	O
inducción	O
de	O
apoptosis	O
inmediatamente	O
antes	O
y	O
después	O
del	O
nacimiento	O
(	O
E18.5	O
al	O
día	O
postnatal	O
P2	O
)	O
,	O
y	O
desde	O
los	O
días	O
postnatales	O
P9	O
a	O
P10	O
y	O
P14	O
a	O
P16	O
[	O
42	O
]	O
.	O

Por	O
lo	O
tanto	O
,	O
además	O
de	O
la	O
formación	O
de	O
las	O
capas	O
interna	O
y	O
externa	O
de	O
la	O
copa	O
óptica	O
en	O
el	O
desarrollo	O
temprano	O
del	O
ojo	O
,	O
otras	O
fases	O
importantes	O
de	O
la	O
retina	O
célula	B-Cell
La	O
apoptosis	O
tiene	O
lugar	O
solo	O
después	O
del	O
nacimiento	O
y	O
corresponde	O
a	O
períodos	O
importantes	O
en	O
el	O
establecimiento	O
de	O
neuronales	B-Cell
conexiones	O

Es	O
más	O
,	O
célula	B-Cell
la	O
muerte	O
durante	O
el	O
desarrollo	O
normal	O
de	O
la	O
retina	O
ocurre	O
en	O
capas	O
retinales	O
distintas	O
de	O
la	O
capa	O
granular	O
interna	O
donde	O
observamos	O
los	O
defectos	O
de	O
diferenciación	O
más	O
pronunciados	O
en	O
el	O
ptdsr	B-Protein
-	O
/	O
-	O
mutantes	B-Sequence
descrito	O
aquí	O
.	O

Otros	O
estudios	O
que	O
relacionan	O
la	O
eliminación	O
posnatal	O
de	O
células	B-Cell
fotorreceptoras	I-Cell
apoptóticas	I-Cell
para	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
macrófago	B-Cell
engullimiento	O
[	O
43	O
]	O
debe	O
interpretarse	O
con	O
extrema	O
precaución	O
ya	O
que	O
estos	O
estudios	O
se	O
basaron	O
en	O
el	O
anti	O
-	O
monoclonal	O
ptdsr	B-Protein
anticuerpo	B-GENE
mAb	O
217G8E9	O
[	O
26	O
,	O
43	O
]	O
(	O
ver	O
más	O
abajo	O
)	O
.	O

De	O
acuerdo	O
con	O
los	O
resultados	O
de	O
Li	O
et	O
al	O
.	O

31	O
]	O
,	O
encontramos	O
malformaciones	O
cerebrales	O
particulares	O
en	O
nuestro	O
ptdsr	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
.	O

Se	O
observaron	O
exencefalia	O
y	O
fenotipos	O
cerebrales	O
hiperplásicos	O
a	O
baja	O
penetrancia	O
en	O
ptdsr	B-Protein
-	O
mutante	B-Sequence
ratones	B-Taxon
(	O
menos	O
del	O
4	O
,	O
5	O
%	O
de	O
los	O
homocigotos	O
)	O
,	O
pero	O
estos	O
no	O
se	O
parecen	O
en	O
nada	O
a	O
los	O
fenotipos	O
de	O
crecimiento	O
excesivo	O
del	O
cerebro	O
de	O
la	O
caspasa	O
-	O
o	O
apaf1	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
(	O
[	O
44	O
]	O
,	O
y	O
referencias	O
allí	O
)	O
en	O
el	O
sentido	O
de	O
que	O
no	O
logramos	O
identificar	O
ninguna	O
diferencia	O
en	O
el	O
número	O
o	O
distribución	O
de	O
células	B-Cell
apoptóticas	I-Cell
o	O
picnótico	O
célula	B-Cell
cúmulos	O
en	O
el	O
neuroepitelio	O
de	O
ptdsr	B-Protein
-	O
/	O
-	O
y	O
ptdsr	B-Protein
+	B-Sequence
/	O
+	B-Sequence
ratones	B-Taxon
.	O

Así	O
,	O
reducido	O
célula	B-Cell
muerte	O
o	O
eliminación	O
disminuida	O
de	O
células	B-Cell
progenitoras	I-Cell
neurales	I-Cell
apoptóticas	I-Cell
es	O
poco	O
probable	O
que	O
sea	O
la	O
causa	O
de	O
la	O
hiperplasia	O
cerebral	O
.	O

En	O
resumen	O
,	O
nuestros	O
estudios	O
demuestran	O
que	O
ptdsr	B-Protein
es	O
necesaria	O
para	O
la	O
diferenciación	O
tisular	O
normal	O
,	O
especialmente	O
durante	O
la	O
mitad	O
del	O
período	O
de	O
gestación	O
,	O
cuando	O
observamos	O
los	O
retrasos	O
de	O
diferenciación	O
más	O
graves	O
en	O
varios	O
órganos	O
de	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
.	O

Los	O
múltiples	O
defectos	O
en	O
la	O
diferenciación	O
tisular	O
no	O
pueden	O
explicarse	O
por	O
el	O
fracaso	O
de	O
célula	B-Cell
apoptótica	I-Cell
liquidación	O
,	O
ya	O
que	O
este	O
proceso	O
es	O
normal	O
en	O
nuestro	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O

Por	O
tanto	O
,	O
este	O
resultado	O
indica	O
que	O
ptdsr	B-Protein
tiene	O
un	O
papel	O
novedoso	O
,	O
hasta	O
ahora	O
inesperado	O
,	O
en	O
la	O
promoción	O
de	O
la	O
maduración	O
tisular	O
y	O
la	O
diferenciación	O
terminal	O
.	O

Estudios	O
adicionales	O
con	O
objetivos	O
condicionales	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
están	O
obligados	O
a	O
investigar	O
el	O
papel	O
de	O
las	O
relaciones	O
espaciales	O
y	O
temporales	O
ptdsr	B-Protein
expresión	O
y	O
función	O
durante	O
la	O
diferenciación	O
tisular	O
.	O

ptdsr	B-Protein
no	O
es	O
indispensable	O
para	O
la	O
liquidación	O
de	O
células	B-Cell
apoptóticas	I-Cell

Nuestros	O
estudios	O
demuestran	O
que	O
ptdsr	B-Protein
no	O
es	O
un	O
receptor	O
primario	O
para	O
la	O
captación	O
de	O
células	B-Cell
apoptóticas	I-Cell
.	O

Investigación	O
de	O
célula	B-Cell
apoptótica	I-Cell
aclaramiento	O
in	O
vivo	O
en	O
ptdsr	B-Protein
-	O
/	O
-	O
los	O
embriones	O
demostraron	O
de	O
manera	O
concluyente	O
que	O
la	O
eliminación	O
de	O
células	B-Cell
apoptóticas	I-Cell
no	O
se	O
ve	O
comprometida	O
por	O
la	O
ablación	O
de	O
ptdsr	B-Protein
función	O

Análisis	O
comparativo	O
de	O
diez	O
tejidos	O
y	O
órganos	O
diferentes	O
en	O
ptdsr	B-Protein
+	B-Sequence
/	O
+	B-Sequence
y	O
ptdsr	B-Protein
-	O
/	O
-	O
animales	B-Taxon
en	O
varias	O
etapas	O
del	O
desarrollo	O
embrionario	O
y	O
en	O
recién	O
nacidos	O
no	O
pudo	O
identificar	O
la	O
absorción	O
alterada	O
de	O
células	B-Cell
apoptóticas	I-Cell
en	O
cualquier	O
momento	O
durante	O
el	O
desarrollo	O
.	O

Además	O
,	O
los	O
ensayos	O
de	O
fagocitosis	O
in	O
vitro	O
demostraron	O
una	O
captación	O
completamente	O
normal	O
de	O
células	B-Cell
apoptóticas	I-Cell
por	O
ptdsr	B-Protein
-	O
/	O
-	O
macrófagos	B-Cell
,	O
con	O
algún	O
nocaut	O
macrófagos	B-Cell
mostrando	O
cargas	O
aún	O
más	O
altas	O
que	O
tipo	B-Sequence
salvaje	I-Sequence
de	O
muertos	O
hundidos	O
células	B-Cell
.	O

Estos	O
resultados	O
son	O
contrarios	O
al	O
papel	O
esperado	O
de	O
ptdsr	B-Protein
en	O
célula	B-Cell
apoptótica	I-Cell
aclaramiento	O
ya	O
los	O
hallazgos	O
informados	O
por	O
Li	O
et	O
al	O
.	O

[	O
31	O
]	O
y	O
Kunisaki	O
et	O
al	O
.	O

[	O
32	O
]	O
,	O
así	O
como	O
a	O
un	O
estudio	O
realizado	O
con	O
un	O
receptor	B-Protein
de	I-Protein
fosfatidilserina	I-Protein
nulo	O
alelo	B-Sequence
en	O
C	B-Taxon
.	I-Taxon
elegantes	I-Taxon
[	O
45	O
]	O
.	O

En	O
estudios	O
previos	O
en	O
el	O
ratón	B-Taxon
,	O
la	O
distribución	O
y	O
cantidad	O
de	O
células	B-Cell
apoptóticas	I-Cell
en	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
animales	B-Taxon
se	O
investigaron	O
sólo	O
en	O
unos	O
pocos	O
tejidos	O
y	O
en	O
una	O
[	O
31	O
]	O
o	O
dos	O
[	O
32	O
]	O
etapas	O
de	O
desarrollo	O
.	O

Li	O
et	O
al	O
.	O

[	O
31	O
]	O
examinaron	O
los	O
pulmones	O
,	O
el	O
mesencéfalo	O
y	O
la	O
retina	O
el	O
día	O
E17	O
.	O
5	O
de	O
gestación	O
e	O
identificados	O
células	B-Cell
apoptóticas	I-Cell
por	O
tinción	O
de	O
TUNEL	O
.	O

Sus	O
hallazgos	O
deben	O
interpretarse	O
con	O
cautela	O
porque	O
la	O
remodelación	O
de	O
celular	B-Cell
Se	O
sabe	O
que	O
las	O
estructuras	O
por	O
apoptosis	O
en	O
capas	O
específicas	O
de	O
la	O
retina	O
ocurren	O
principalmente	O
después	O
del	O
nacimiento	O
[	O
42	O
]	O
,	O
y	O
la	O
apoptosis	O
juega	O
un	O
papel	O
fisiológico	O
importante	O
en	O
el	O
mantenimiento	O
y	O
la	O
homeostasis	O
del	O
epitelio	O
pulmonar	O
después	O
del	O
nacimiento	O
o	O
en	O
condiciones	O
patológicas	O
que	O
involucran	O
inflamación	O
pulmonar	O
y	O
no	O
durante	O
el	O
desarrollo	O
pulmonar	O
[	O
46	O
]	O
.	O

Este	O
papel	O
posnatal	O
de	O
la	O
apoptosis	O
está	O
de	O
acuerdo	O
con	O
nuestros	O
datos	O
,	O
ya	O
que	O
rara	O
vez	O
observamos	O
células	B-Cell
apoptóticas	I-Cell
en	O
retina	O
o	O
tejido	O
pulmonar	O
a	O
lo	O
largo	O
de	O
la	O
embriogénesis	O
en	O
ptdsr	B-Protein
+	B-Sequence
/	O
+	B-Sequence
y	O
ptdsr	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
.	O

Kunisaki	O
et	O
al	O
.	O

[	O
32	O
]	O
analizaron	O
secciones	O
de	O
hígado	O
y	O
timo	O
teñidas	O
con	O
TUNEL	O
en	O
los	O
días	O
E13	O
.	O
5	O
y	O
E16	O
.	O
5	O
de	O
desarrollo	O
en	O
ptdsr	B-Protein
+	B-Sequence
/	O
-	O
y	O
ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
y	O
se	O
encontró	O
un	O
número	O
reducido	O
en	O
lugar	O
de	O
aumentado	O
de	O
TUNEL	O
-	O
positivo	O
células	B-Cell
en	O
ptdsr	B-Protein
-	O
embriones	O
deficientes	O
.	O

Uso	O
de	O
co	O
-	O
localización	O
de	O
TUNEL	O
-	O
positivo	O
células	B-Cell
con	O
F4	B-Protein
/	I-Protein
80	I-Protein
#	O
¿NOMBRE	O
?	O
macrófagos	B-Cell
sugirieron	O
que	O
ptdsr	B-Protein
-	O
/	O
-	O
los	O
embriones	O
exhibieron	O
un	O
aumento	O
de	O
tres	O
veces	O
en	O
la	O
frecuencia	O
de	O
TUNEL	O
no	O
fagocitado	O
-	O
positivo	O
células	B-Cell
junto	O
con	O
un	O
número	O
muy	O
reducido	O
de	O
F4	B-Protein
/	I-Protein
80	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
.	O

Sin	O
embargo	O
,	O
estos	O
resultados	O
deben	O
interpretarse	O
con	O
mucho	O
cuidado	O
,	O
ya	O
que	O
es	O
técnicamente	O
difícil	O
identificar	O
sin	O
ambigüedades	O
el	O
objetivo	O
sumergido	O
.	O
células	B-Cell
en	O
particular	O
macrófagos	B-Cell
en	O
tejidos	O
sólidos	O
por	O
microscopía	O
de	O
fluorescencia	O
.	O

Además	O
,	O
nuestros	O
datos	O
sugieren	O
que	O
durante	O
la	O
embriogénesis	O
,	O
macrófago	B-Cell
#	O
¿NOMBRE	O
?	O
células	B-Cell
apoptóticas	I-Cell
no	O
es	O
el	O
único	O
-	O
ni	O
siquiera	O
el	O
principal	O
-	O
mecanismo	O
para	O
la	O
eliminación	O
de	O
células	B-Cell
apoptóticas	I-Cell
.	O

En	O
muchos	O
tejidos	O
donde	O
programado	O
célula	B-Cell
la	O
muerte	O
ocurre	O
como	O
un	O
evento	O
destacado	O
durante	O
la	O
embriogénesis	O
,	O
como	O
la	O
remodelación	O
de	O
la	O
cresta	O
genital	O
durante	O
la	O
morfogénesis	O
de	O
las	O
gónadas	O
y	O
la	O
diferenciación	O
del	O
tubo	O
neural	O
,	O
casi	O
no	O
encontramos	O
co	O
-	O
localización	O
de	O
células	B-Cell
apoptóticas	I-Cell
y	O
macrófagos	B-Cell
.	O

Esto	O
indica	O
que	O
en	O
estos	O
casos	O
la	O
liquidación	O
de	O
células	B-Cell
apoptóticas	I-Cell
está	O
mediado	O
directamente	O
por	O
el	O
'espectador	O
'	O
vecino	O
células	B-Cell
en	O
lugar	O
de	O
por	O
macrófagos	B-Cell
que	O
han	O
sido	O
reclutados	O
en	O
áreas	O
donde	O
ocurre	O
la	O
apoptosis	O
.	O

Obviamente	O
,	O
estos	O
mecanismos	O
de	O
eliminación	O
in	O
vivo	O
no	O
se	O
ven	O
comprometidos	O
por	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
mutante	B-Sequence
.	O

Este	O
hallazgo	O
está	O
en	O
línea	O
con	O
los	O
estudios	O
en	O
macrófagos	O
Sfpi1	B-Protein
#	O
¿NOMBRE	O
?	O
pu	B-Protein
.	I-Protein
1	I-Protein
.	O

Aquí	O
,	O
la	O
fagocitosis	O
de	O
células	B-Cell
apoptóticas	I-Cell
durante	O
la	O
embriogénesis	O
es	O
asumido	O
por	O
vecinos	O
mesenquimales	O
'	O
suplentes	O
'	O
[	O
47	O
]	O
.	O

como	O
reconocimiento	O
de	O
fosfatidilserina	B-Chemical
se	O
cree	O
que	O
es	O
un	O
mecanismo	O
de	O
inmersión	O
universal	O
para	O
todos	O
células	B-Cell
que	O
son	O
capaces	O
de	O
fagocitar	O
células	B-Cell
apoptóticas	I-Cell
,	O
es	O
muy	O
llamativo	O
que	O
célula	B-Cell
apoptótica	I-Cell
autorización	O
mediada	O
por	O
un	O
transeúnte	O
no	O
profesional	O
células	B-Cell
tampoco	O
está	O
comprometido	O
por	O
ptdsr	B-Protein
-	O
deficiencia	O
.	O

En	O
contraste	O
con	O
Li	O
et	O
al	O
.	O

[	O
31	O
]	O
,	O
no	O
observamos	O
ningún	O
deterioro	O
en	O
la	O
absorción	O
de	O
células	B-Cell
apoptóticas	I-Cell
por	O
ptdsr	B-Protein
-	O
/	O
-	O
macrófagos	B-Cell
in	O
vitro	O

Realizamos	O
ensayos	O
de	O
fagocitosis	O
in	O
vitro	O
con	O
derivados	O
de	O
hígado	O
fetal	O
macrófagos	B-Cell
,	O
mientras	O
que	O
en	O
sus	O
ensayos	O
,	O
Li	O
y	O
sus	O
colegas	O
utilizaron	O
tioglicolato	B-Chemical
#	O
¿NOMBRE	O
?	O
macrófagos	B-Cell
peritoneales	I-Cell
después	O
de	O
la	O
transferencia	O
adoptiva	O
de	O
ptdsr	B-Protein
-	O
/	O
-	O
células	B-Cell
madre	I-Cell
hematopoyéticas	I-Cell
.	O

Los	O
diferentes	O
resultados	O
obtenidos	O
en	O
los	O
dos	O
estudios	O
son	O
desconcertantes	O
;	O
pueden	O
deberse	O
al	O
uso	O
de	O
diferentes	O
macrófago	B-Cell
o	O
célula	B-Cell
poblaciones	O

Nosotros	O
y	O
Kunisaki	O
et	O
al	O
.	O

[	O
32	O
]	O
descubrió	O
que	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O

Por	O
tanto	O
,	O
parece	O
posible	O
que	O
el	O
reclutamiento	O
y	O
la	O
activación	O
/	O
diferenciación	O
de	O
macrófagos	B-Cell
después	O
de	O
la	O
transferencia	O
adoptiva	O
y	O
tioglicolato	B-Chemical
la	O
elicitación	O
se	O
ve	O
afectada	O
por	O
ptdsr	B-Protein
-	O
deficiencia	O
.	O

No	O
creemos	O
que	O
los	O
diferentes	O
resultados	O
observados	O
en	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
en	O
un	O
fondo	O
mixto	O
C57BL	O
/	O
6	O
x	O
129	O
y	O
en	O
un	O
fondo	O
puro	O
C57BL	O
/	O
6J	O
se	O
puede	O
atribuir	O
a	O
genético	B-Sequence
efectos	O
de	O
fondo	O
:	O
comparación	O
de	O
célula	B-Cell
apoptótica	I-Cell
eficacias	O
de	O
absorción	O
de	O
tioglicolato	B-Chemical
#	O
¿NOMBRE	O
?	O
macrófagos	B-Cell
de	O
129P2/OlaHsd	O
y	O
C57BL/6J	O
ratones	B-Taxon
no	O
mostró	O
diferencias	O
en	O
célula	B-Cell
apoptótica	I-Cell
absorción	O
(	O
J	O
.	O
B	O
.	O
y	O
A	O
.	O
L	O
.	O
,	O
observaciones	O
no	O
publicadas	O
)	O
.	O

Además	O
,	O
a	O
diferencia	O
de	O
nuestros	O
estudios	O
,	O
ni	O
Li	O
et	O
al	O
.	O

[	O
31	O
]	O
ni	O
Kunisaki	O
et	O
al	O
.	O

[	O
32	O
]	O
determinaron	O
los	O
índices	O
fagocíticos	O
de	O
absorción	O
para	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
macrófagos	B-Cell
.	O

Curiosamente	O
,	O
observamos	O
diferencias	O
entre	O
ptdsr	B-Protein
+	B-Sequence
/	O
+	B-Sequence
y	O
ptdsr	B-Protein
-	O
/	O
-	O
macrófagos	B-Cell
en	O
la	O
secreción	O
de	O
citocinas	O
pro	O
y	O
antiinflamatorias	O
después	O
de	O
la	O
estimulación	O
con	O
LPS	B-Chemical
y	O
células	B-Cell
apoptóticas	I-Cell
.	O

Esto	O
proporciona	O
evidencia	O
de	O
que	O
celular	B-Cell
activación	O
y	O
efector	B-Chemical
Los	O
mecanismos	O
están	O
dañados	O
en	O
ptdsr	B-Protein
-	O
eliminado	B-Sequence
macrófagos	B-Cell
.	O

Queda	O
por	O
determinar	O
qué	O
vías	O
clásicas	O
de	O
macrófago	B-Cell
la	O
activación	O
y	O
la	O
función	O
implican	O
ptdsr	B-Protein
.	O

Esto	O
es	O
especialmente	O
importante	O
a	O
la	O
luz	O
de	O
hallazgos	O
recientes	O
que	O
demostraron	O
nuclear	B-GENE
localización	O
de	O
la	O
ptdsr	B-Protein
proteína	B-Chemical
[	O
29	O
]	O
.	O

Lo	O
más	O
sorprendente	O
es	O
que	O
los	O
datos	O
publicados	O
recientemente	O
sobre	O
la	O
genético	B-Sequence
ablación	O
o	O
perturbación	O
de	O
receptor	B-Protein
de	I-Protein
fosfatidilserina	I-Protein
función	O
en	O
C	B-Taxon
.	I-Taxon
elegantes	I-Taxon
también	O
son	O
contradictorios	O
.	O

Wang	O
et	O
al	O
.	O

[	O
45	O
]	O
informó	O
que	O
psr	B-Protein
-	I-Protein
1	I-Protein
,	O
los	O
C	B-Taxon
.	I-Taxon
elegantes	I-Taxon
homólogo	B-Sequence
de	O
ptdsr	B-Protein
,	O
es	O
importante	O
para	O
célula	B-Cell
-	O
hundimiento	O
del	O
cadáver	O
,	O
mientras	O
que	O
psr	B-Protein
-	I-Protein
1	I-Protein
Los	O
estudios	O
de	O
ARNi	O
realizados	O
por	O
Arur	O
et	O
al	O
.	O

25	O
]	O
arrojó	O
,	O
a	O
este	O
respecto	O
,	O
ningún	O
fenotipo	O
.	O

Además	O
,	O
Wang	O
y	O
sus	O
colegas	O
plantearon	O
la	O
hipótesis	O
sobre	O
la	O
base	O
de	O
sus	O
datos	O
de	O
que	O
psr	B-Protein
-	I-Protein
1	I-Protein
podría	O
actuar	O
para	O
transducir	O
una	O
señal	O
envolvente	O
aguas	O
arriba	O
de	O
Ced	B-Protein
-	I-Protein
2	I-Protein
(	O
Crk	B-Protein
II	I-Protein
)	O
,	O
ced	B-Protein
-	I-Protein
5	I-Protein
(	O
Muelle	B-Protein
180	I-Protein
)	O
,	O
Ced	B-Protein
-	I-Protein
10	I-Protein
(	O
Carrera	B-Protein
1	I-Protein
)	O
y	O
ced	B-Protein
-	I-Protein
12	I-Protein
(	O
Elmo	O
)	O
en	O
uno	O
de	O
los	O
dos	O
célula	B-Cell
#	O
¿NOMBRE	O
?	O
gusano	B-Taxon
[	O
45	O
]	O
.	O

Pero	O
el	O
fenotipo	O
de	O
pérdida	O
de	O
función	O
de	O
psr	B-Protein
-	I-Protein
1	I-Protein
mutantes	B-Sequence
y	O
los	O
fenotipos	O
de	O
complementación	O
en	O
la	O
sobreexpresión	O
transgénico	B-Sequence
gusanos	B-Taxon
mostrado	O
por	O
Wang	O
et	O
al	O
.	O

[	O
45	O
]	O
son	O
bastante	O
débiles	O
en	O
comparación	O
con	O
los	O
clásicos	O
C	B-Taxon
.	I-Taxon
elegantes	I-Taxon
hundimiento	O
mutantes	B-Sequence
[	O
8	O
]	O
.	O

Muchos	O
estudios	O
funcionales	O
previos	O
que	O
reportaron	O
un	O
requerimiento	O
de	O
ptdsr	B-Protein
por	O
la	O
fagocitosis	O
de	O
células	B-Cell
apoptóticas	I-Cell
utilizó	O
el	O
anti	O
monoclonal	O
-	O
ptdsr	B-Protein
anticuerpo	B-GENE
mAb	O
217G8E9	O
[	O
26	O
]	O
.	O

Esta	O
anticuerpo	B-GENE
fue	O
usado	O
en	O
ptdsr	B-Protein
experimentos	O
de	O
unión	O
y	O
bloqueo	O
,	O
así	O
como	O
en	O
estudios	O
de	O
localización	O
subcelular	O
,	O
lo	O
que	O
llevó	O
a	O
la	O
conclusión	O
de	O
que	O
ptdsr	B-Protein
es	O
un	O
transmembrana	B-GENE
receptor	O
crítico	O
para	O
la	O
transducción	O
de	O
señales	O
en	O
la	O
interfaz	O
de	O
inmersión	O
.	O

Más	O
recientemente	O
,	O
se	O
utilizó	O
en	O
ensayos	O
de	O
unión	O
para	O
demostrar	O
que	O
el	O
humano	B-Protein
y	I-Protein
gusano	I-Protein
Ptdsr	I-Protein
moléculas	B-Chemical
puede	O
reconocer	O
fosfatidilserina	B-Chemical
[	O
45	O
]	O
.	O

En	O
el	O
curso	O
del	O
estudio	O
presentado	O
aquí	O
,	O
teñimos	O
inmunohistoquímicamente	O
para	O
ptdsr	B-Protein
con	O
mAb	O
217G8E9	O
activado	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
macrófagos	B-Cell
y	O
fibroblastos	B-Cell
(	O
ver	O
Archivo	O
de	O
datos	O
adicional	O
1	O
,	O
Figura	O
S2	O
y	O
datos	O
no	O
mostrados	O
)	O
.	O

Para	O
nuestra	O
sorpresa	O
,	O
observamos	O
patrones	O
de	O
tinción	O
similares	O
con	O
células	B-Cell
de	O
ambos	O
genotipos	B-Sequence
.	O

Además	O
,	O
utilizando	O
un	O
ptdsr	B-Protein
-	O
péptido	B-Sequence
matriz	O
encontramos	O
que	O
mAb	O
217G8E9	O
puede	O
unirse	O
débilmente	O
a	O
un	O
ptdsr	B-Protein
péptido	B-Sequence
,	O
explicando	O
el	O
aislamiento	O
original	O
de	O
ptdsr	B-Protein
clones	B-Sequence
de	I-Sequence
ADNc	I-Sequence
por	O
exhibición	O
de	O
fagos	O
[	O
26	O
]	O
;	O
pero	O
el	O
anticuerpo	B-GENE
reconoce	O
principalmente	O
información	O
adicional	O
,	O
aún	O
desconocida	O
,	O
membrana	B-GENE
#	O
¿NOMBRE	O
?	O
proteina	B-Chemical
(	I-Chemical
s	I-Chemical
)	I-Chemical
(	O
ver	O
Archivo	O
de	O
datos	O
adicional	O
1	O
,	O
Figura	O
S2	O
)	O
.	O

Experimentos	O
que	O
han	O
utilizado	O
este	O
anticuerpo	B-GENE
por	O
lo	O
tanto	O
,	O
deben	O
interpretarse	O
con	O
mucha	O
cautela	O
,	O
ya	O
que	O
podrían	O
llegar	O
a	O
ser	O
vistos	O
bajo	O
una	O
luz	O
diferente	O
.	O

Conclusión	O

Nuestros	O
resultados	O
demuestran	O
que	O
ptdsr	B-Protein
es	O
esencial	O
para	O
la	O
diferenciación	O
y	O
maduración	O
de	O
múltiples	O
tejidos	O
durante	O
la	O
embriogénesis	O
.	O

Ablación	O
de	O
ptdsr	B-Protein
la	O
función	O
resulta	O
en	O
letalidad	O
neonatal	O
y	O
defectos	O
severos	O
en	O
la	O
morfogénesis	O
de	O
varios	O
órganos	O
.	O

Las	O
malformaciones	O
del	O
desarrollo	O
no	O
pueden	O
explicarse	O
por	O
una	O
depuración	O
deficiente	O
de	O
células	B-Cell
apoptóticas	I-Cell
,	O
un	O
proceso	O
que	O
resultó	O
ser	O
normal	O
en	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
.	O

Esto	O
abre	O
la	O
posibilidad	O
de	O
que	O
haya	O
un	O
-todavía	O
desconocido	O
ptdsr	B-Protein
receptor	O
,	O
que	O
podría	O
actuar	O
como	O
un	O
receptor	O
primario	O
fosfatidilserina	B-Chemical
receptor	O
de	O
reconocimiento	O
,	O
o	O
que	O
el	O
reconocimiento	O
de	O
fosfatidilserina	B-Chemical
y	O
posteriores	O
célula	B-Cell
apoptótica	I-Cell
el	O
hundimiento	O
y	O
la	O
señalización	O
antiinflamatoria	O
están	O
mediados	O
principalmente	O
a	O
través	O
de	O
fosfatidilserina	B-Chemical
puente	O
proteinas	B-Chemical
y	O
sus	O
receptores	O
afines	O
.	O

Aunque	O
ptdsr	B-Protein
-	O
/	O
-	O
macrófagos	B-Cell
no	O
se	O
vieron	O
afectadas	O
en	O
su	O
capacidad	O
para	O
fagocitar	O
células	B-Cell
apoptóticas	I-Cell
,	O
mostraron	O
respuestas	O
reducidas	O
de	O
citoquinas	O
después	O
de	O
la	O
estimulación	O
.	O

Será	O
necesario	O
seguir	O
trabajando	O
para	O
determinar	O
la	O
molecular	B-Chemical
mecanismos	O
de	O
estos	O
recién	O
reconocidos	O
ptdsr	B-Protein
Funciones	O
durante	O
el	O
desarrollo	O
.	O

Materiales	O
y	O
métodos	O

Construcción	O
de	O
la	O
focalización	O
vector	B-Sequence
y	O
generación	O
de	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon

Orientación	O
vector	B-Sequence

A	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
cromosoma	B-Sequence
artificial	I-Sequence
bacteriano	I-Sequence
(	O
BAC	B-Sequence
)	O
clon	B-Sequence
(	O
Número	O
de	O
acceso	O
de	O
GenBank	O
AC091694	O
;	O
RP-23-316F3	O
)	O
fue	O
aislado	O
por	O
secuencia	B-Sequence
homología	O
de	O
un	O
C57BL	O
/	O
6J	O
BAC	B-Sequence
genómico	I-Sequence
biblioteca	O
(	O
RP-23	O
;	O
BACPAC	O
Resources	O
,	O
Oakland	O
,	O
EE.UU	O
.	O
)	O
.	O

un	O
14	O
5	O
kb	O
KpnI	O
/	O
BamHI	O
fragmento	B-Sequence
que	O
contiene	O
la	O
totalidad	O
ptdsr	B-Protein
lugar	B-Sequence
y	O
5	B-Sequence
'	I-Sequence
y	I-Sequence
3	I-Sequence
'	I-Sequence
regiones	I-Sequence
flanqueantes	I-Sequence
fue	O
subclonado	O
de	O
este	O
clon	B-Sequence
BAC	I-Sequence
y	O
un	O
1	O
9	O
kb	O
RsrII	O
/	O
AatII	O
fragmento	B-Sequence
que	O
contiene	O
exones	B-Sequence
I	O
y	O
II	O
de	O
la	O
ptdsr	B-Protein
gene	B-Sequence
era	O
sustituido	B-Sequence
por	O
un	O
1	O
.	O
2	O
KB	O
loxP	B-Sequence
-	I-Sequence
flanqueado	I-Sequence
neomicina	B-Chemical
#	O
¿NOMBRE	O
?	O
casete	B-Sequence
de	I-Sequence
genes	I-Sequence
(	O
neo	O
)	O
.	O

Recombinación	O
homóloga	O
en	O
ES	O
células	B-Cell
y	O
generación	O
de	O
quimeras	O
de	O
línea	O
germinal	O

Bruce4	O
ES	O
células	B-Cell
fueron	O
transfectados	O
con	O
KpnI	O
-	O
direccionamiento	O
linealizado	O
vector	B-Sequence
y	O
seleccionado	O
con	O
G418	O
.	O

ES-	O
célula	B-Cell
clones	B-Sequence
resistentes	O
a	O
G418	O
fueron	O
aislados	O
y	O
analizados	O
por	O
análisis	O
de	O
transferencia	O
de	O
Southern	O
para	O
eventos	O
de	O
recombinación	O
homóloga	O
dentro	O
del	O
ptdsr	B-Protein
lugar	B-Sequence
.	O

quimérico	O
ratones	B-Taxon
fueron	O
producidos	O
por	O
microinyección	O
de	O
dos	O
recombinantes	O
homólogos	O
independientes	O
(	O
ptdsr	B-Protein
+	B-Sequence
/	O
-	O
)	O
ES	O
células	B-Cell
en	O
blastocistos	O
BALB/c	O
y	O
transferencia	O
a	O
madres	O
adoptivas	O
pseudoembarazadas	O
seguidas	O
de	O
desarrollo	O
a	O
término	O
.	O

Los	O
machos	O
quiméricos	O
se	O
aparearon	O
con	O
hembras	O
C57BL/6J	O
.	O

De	O
los	O
dos	O
ES	O
seleccionados	O
-	O
célula	B-Cell
clones	B-Sequence
uno	O
contribuyó	O
con	O
éxito	O
a	O
la	O
línea	O
germinal	O
.	O

Línea	O
germinal	O
de	O
transmisión	O
del	O
alelo	B-Sequence
mutante	I-Sequence
fue	O
verificado	O
por	O
PCR	O
y	O
Southern	O
blot	O
de	O
ADN	B-Sequence
genómico	I-Sequence
de	O
crías	O
F1	O
de	O
pelaje	O
negro	O
.	O

ptdsr	B-Protein
gene	B-Sequence
#	O
¿NOMBRE	O
?	O

un	O
ES-	O
célula	B-Cell
línea	O
que	O
lleva	O
una	O
beta	O
-	O
geo	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
vector	B-Sequence
en	O
el	O
ptdsr	B-Protein
lugar	B-Sequence
se	O
identificó	O
al	O
buscar	O
en	O
la	O
base	O
de	O
datos	O
de	O
BayGenomics	O
(	O
BayGenomics	O
,	O
San	O
Francisco	O
,	O
EE	O
.	O
UU	O
.	O
;	O
[	O
48	O
]	O
)	O
con	O
la	O
longitud	O
completa	O
ptdsr	B-Protein
ADNc	B-Sequence
.	O

Un	O
solo	O
ES	O
-	O
célula	B-Cell
se	O
identificó	O
la	O
línea	O
que	O
lleva	O
el	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
intrón	B-Sequence
entre	O
exones	B-Sequence
V	O
y	O
VI	O
de	O
la	O
ptdsr	B-Protein
gene	B-Sequence
.	O

quimérico	O
ratones	B-Taxon
fueron	O
generados	O
por	O
microinyección	O
en	O
blastocistos	O
CB20	O
y	O
transferidos	O
a	O
madres	O
adoptivas	O
pseudoembarazadas	O
.	O

Los	O
machos	O
quiméricos	O
se	O
aparearon	O
con	O
hembras	O
129P2/OlaHsd	O
.	O

Línea	O
germinal	O
de	O
transmisión	O
del	O
gen	B-Sequence
mutante	I-Sequence
#	O
¿NOMBRE	O
?	O
alelo	B-Sequence
se	O
verificó	O
mediante	O
análisis	O
de	O
expresión	O
mediante	O
tinción	O
con	O
beta-galactosidasa	O
y	O
RT-PCR	O
.	O

Genotipo	B-Sequence
análisis	O

los	O
genotipos	B-Sequence
de	O
embriones	O
o	O
animales	B-Taxon
se	O
determinaron	O
mediante	O
análisis	O
PCR	O
y	O
se	O
confirmaron	O
mediante	O
transferencia	O
Southern	O
.	O

ADN	B-Sequence
genómico	I-Sequence
para	O
PCR	O
se	O
preparó	O
a	O
partir	O
de	O
membranas	O
extraembrionarias	O
o	O
clips	O
de	O
cola	O
usando	O
un	O
no	O
-	O
orgánico	B-Chemical
cola	O
-	O
ADN	B-Sequence
protocolo	O
de	O
extracción	O
[	O
49	O
]	O
.	O

Elevado	O
molecular	B-Chemical
peso	O
ADN	B-Sequence
genómico	I-Sequence
para	O
la	O
transferencia	O
de	O
Southern	O
se	O
preparó	O
de	O
acuerdo	O
con	O
los	O
protocolos	O
estándar	O
.	O

Para	O
el	O
análisis	O
de	O
PCR	O
,	O
el	O
tipo	B-Sequence
salvaje	I-Sequence
ptdsr	B-Protein
alelo	B-Sequence
fue	O
detectado	O
utilizando	O
cartilla	B-Sequence
delantera	I-Sequence
1	O
(	O
5	O
'	O
-	O
GACACTGTCCATGGCAAACAC	O
-	O
3	O
'	O
)	O
y	O
imprimación	B-Sequence
inversa	I-Sequence
2	O
(	O
5	O
'	O
-	O
TAAAGTCGCCTTCCAGAAGATT	O
-	O
3	O
'	O
)	O
.	O

los	O
cartilla	B-Sequence
1	I-Sequence
sitio	I-Sequence
se	O
encuentra	O
a	O
5	O
'	O
al	O
supresión	B-Sequence
y	O
el	O
primer	B-Sequence
sitio	I-Sequence
2	I-Sequence
dentro	O
de	O
supresión	B-Sequence
.	O

Esta	O
cebador	B-Sequence
par	O
amplificado	O
un	O
fragmento	B-Sequence
de	O
aproximadamente	O
300	O
pb	B-Sequence
desde	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
ptdsr	B-Protein
+	B-Sequence
/	O
-	O
ratones	B-Taxon
pero	O
no	O
de	O
ptdsr	B-Protein
-	O
/	O
-	O
mutantes	B-Sequence
.	O

Para	O
detectar	O
el	O
mutante	B-Sequence
ptdsr	B-Protein
alelo	B-Sequence
,	O
ADN	B-Sequence
genómico	I-Sequence
también	O
se	O
amplificó	O
utilizando	O
cebador	B-Sequence
1	O
y	O
imprimación	B-Sequence
inversa	I-Sequence
3	O
(	O
5	O
'	O
-	O
CCACACGCGTCACCTTAATA	O
-	O
3	O
'	O
)	O
,	O
que	O
corresponde	O
a	O
un	O
secuencia	B-Sequence
en	O
el	O
neo	O
casete	B-Sequence
.	O

En	O
este	O
caso	O
,	O
un	O
500	O
fragmento	B-Sequence
pb	I-Sequence
fue	O
detectado	O
en	O
ratones	B-Taxon
heterocigoto	O
u	O
homocigoto	O
para	O
el	O
alelo	B-Sequence
mutante	I-Sequence
,	O
mientras	O
que	O
no	O
se	O
detectó	O
ninguna	O
señal	O
en	O
tipo	B-Sequence
salvaje	I-Sequence
ratones	B-Taxon
.	O

Para	O
el	O
análisis	O
de	O
transferencia	O
de	O
Southern	O
,	O
ADN	B-Sequence
genómico	I-Sequence
(	O
30	O
?	O
g	O
)	O
se	O
digirió	O
durante	O
la	O
noche	O
con	O
BamHI	O
(	O
30	O
U	O
;	O
Roche	O
Diagnostics	O
GmbH	O
,	O
Mannheim	O
,	O
Alemania	O
)	O
y	O
ScaI	O
(	O
30	O
U	O
;	O
Roche	O
)	O
,	O
se	O
fraccionó	O
en	O
un	O
0	O
.	O
8	O
%	O
agarosa	B-Chemical
gel	O
,	O
transferido	O
a	O
un	O
nylon	B-Chemical
membrana	O
(	O
Hybond	O
N	O
;	O
Amersham	O
Biosciences	O
Europe	O
GmbH	O
,	O
Friburgo	O
,	O
Alemania	O
)	O
e	O
hibridada	O
con	O
5	O
'	O
y	O
3	O
'	O
flanqueantes	O
sondas	B-Sequence
.	O

El	O
digesto	O
de	O
BamHI	O
se	O
hibridó	O
con	O
un	O
ptdsr	B-Protein
-	O
flanqueo	O
específico	O
5	O
'	O
Investigacion	B-Sequence
,	O
y	O
Southern	O
blot	O
dio	O
un	O
solo	O
17	O
.	O
banda	O
de	O
2	O
kb	O
para	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
+	B-Sequence
/	O
+	B-Sequence
)	O
,	O
un	O
11	O
.	O
banda	O
de	O
6	O
kb	O
para	O
homocigotos	O
(	O
-	O
/	O
-	O
)	O
y	O
ambas	O
bandas	O
para	O
heterocigotos	O
(	O
+	B-Sequence
/	O
-	O
)	O
ratones	B-Taxon
.	O

El	O
digerido	O
de	O
ScaI	O
se	O
hibridó	O
usando	O
un	O
3	O
'	O
flanqueante	O
Investigacion	B-Sequence
,	O
y	O
Southern	O
blot	O
dio	O
un	O
solo	O
12	O
.	O
banda	O
de	O
4	O
kb	O
para	O
tipo	B-Sequence
salvaje	I-Sequence
,	O
un	O
17	O
.	O
banda	O
de	O
2	O
kb	O
para	O
homocigotos	O
y	O
ambas	O
bandas	O
para	O
heterocigotos	O
ratones	B-Taxon
.	O

Análisis	O
de	O
transferencia	O
Northern	O

Total	O
ARN	B-Sequence
se	O
aisló	O
de	O
embriones	O
homogeneizados	O
usando	O
TRIZOL	O
reactivo	B-Chemical
(	O
Invitrogen	O
GmbH	O
,	O
Karlsruhe	O
,	O
Alemania	O
)	O
.	O

Para	O
transferencias	O
Northern	O
,	O
ya	O
sea	O
total	O
ARN	B-Sequence
(	O
30	O
mu	O
g	O
)	O
se	O
extrajo	O
de	O
los	O
embriones	O
,	O
se	O
sometió	O
a	O
electroforesis	O
y	O
se	O
transfirió	O
a	O
un	O
nylon	B-Chemical
membrana	O
(	O
Hybond	O
N	O
;	O
Amersham	O
)	O
o	O
una	O
poliA	B-Sequence
+	I-Sequence
ARN	I-Sequence
Northern	O
blot	O
(	O
OriGene	O
Technologies	O
Inc.	O
,	O
Rockville	O
,	O
EE	O
.	O
UU	O
.	O
)	O
se	O
hibridó	O
utilizando	O
como	O
Investigacion	B-Sequence
a	O
ptdsr	B-Protein
fragmento	B-Sequence
amplificado	O
de	O
ADNc	B-Sequence
de	I-Sequence
tipo	I-Sequence
salvaje	I-Sequence
utilizando	O
cartilla	B-Sequence
delantera	I-Sequence
5	O
'	O
-	O
GTTCCAGCTCGTCAGACTCG	O
-	O
3	O
'	O
y	O
imprimación	B-Sequence
inversa	I-Sequence
5'-TGCCCCTAAGACATGACCAC-3	O
'	O
.	O

En	O
todos	O
los	O
experimentos	O
se	O
volvió	O
a	O
hibridar	O
la	O
misma	O
membrana	O
con	O
un	O
beta	B-Protein
-	I-Protein
actina	I-Protein
Investigacion	B-Sequence
(	O
OriGene	O
)	O
para	O
confirmar	O
ese	O
equivalente	O
ARN	B-Sequence
los	O
niveles	O
estaban	O
presentes	O
en	O
cada	O
carril	O
.	O

La	O
transferencia	O
Northern	O
indicó	O
que	O
los	O
homocigotos	O
mutante	B-Sequence
embriones	O
no	O
expresaron	O
ptdsr	B-Protein
ARNm	B-Chemical
y	O
heterocigoto	O
mutante	B-Sequence
los	O
embriones	O
expresaron	O
solo	O
cantidades	O
reducidas	O
de	O
ptdsr	B-Protein
ARNm	B-Chemical
.	O

Análisis	O
de	O
Western	O
Blot	O

Embriones	O
(	O
E13	O
.	O
5	O
)	O
para	O
proteína	B-Chemical
aislamiento	O
se	O
homogeneizaron	O
en	O
tampón	O
de	O
lisis	O
que	O
contenía	O
1	O
x	O
PBS	O
,	O
1	O
%	O
Nonidet	O
P	O
-	O
40	O
,	O
0	O
.	O
5	O
%	O
desoxicolato	B-Chemical
de	I-Chemical
sodio	I-Chemical
,	O
0	O
.	O
1	O
%	O
SDS	B-Chemical
y	O
inhibidor	B-Chemical
de	I-Chemical
la	I-Chemical
proteasa	I-Chemical
cóctel	O
(	O
CompleteMini	O
;	O
Roche	O
)	O
.	O

Cantidades	O
iguales	O
(	O
25	O
mu	O
g	O
)	O
de	O
proteína	B-Chemical
lisado	O
fueron	O
separados	O
por	O
SDS	B-Chemical
-electroforesis	O
en	O
gel	O
de	O
poliacrilamida	O
y	O
transferida	O
a	O
una	O
membrana	O
de	O
PVDF	O
(	O
Millipore	O
,	O
Billerica	O
,	O
EE	O
.	O
UU	O
.	O
)	O
según	O
protocolos	O
estándar	O
.	O

Los	O
Western	O
blot	O
se	O
realizaron	O
utilizando	O
un	O
anticuerpo	B-GENE
para	O
ptdsr	B-Protein
(	O
PSR	B-Protein
N-20	O
,	O
sc-11632	O
;	O
Santa	O
Cruz	O
Biotecnología	O
Inc.	O
,	O
Santa	O
Cruz	O
,	O
Estados	O
Unidos	O
)	O
y	O
beta	B-Protein
-	I-Protein
actina	I-Protein
(	O
ab-6276	O
;	O
Abcam	O
,	O
Cambridge	O
,	O
Reino	O
Unido	O
)	O
tal	O
como	O
lo	O
describe	O
el	O
proveedor	O
.	O

Secundario	O
anticuerpos	B-GENE
conjugado	O
a	O
Rábano	B-Taxon
picante	I-Taxon
peroxidasa	O
eran	O
de	O
Santa	O
Cruz	O
y	O
Abcam	O
,	O
se	O
utilizaron	O
según	O
lo	O
descrito	O
por	O
el	O
proveedor	O
,	O
y	O
la	O
detección	O
se	O
realizó	O
con	O
un	O
sistema	O
mejorado	O
de	O
quimioluminiscencia	O
(	O
ECLPlus	O
;	O
Amersham	O
)	O
.	O

Animal	B-Taxon
experimentos	O

Tipo	B-Sequence
salvaje	I-Sequence
C57BL/6J	O
y	O
129P2/OlaHsd	O
ratones	B-Taxon
se	O
obtuvieron	O
de	O
Jackson	O
Laboratories	O
(	O
Bar	O
Harbor	O
,	O
EE	O
.	O
UU	O
.	O
)	O
y	O
Harlan	O
UK	O
(	O
Bicester	O
,	O
Reino	O
Unido	O
)	O
,	O
respectivamente	O
.	O

Todos	O
ratones	B-Taxon
fueron	O
alojados	O
en	O
jaulas	O
ventiladas	O
individualmente	O
en	O
un	O
ambiente	O
libre	O
de	O
patógenos	O
específicos	O
con	O
un	O
ciclo	O
de	O
luz-oscuridad	O
de	O
12	O
horas	O
y	O
fueron	O
alimentados	O
con	O
una	O
dieta	O
regular	O
sin	O
restricciones	O
.	O

El	O
programa	O
de	O
vigilancia	O
de	O
rutina	O
del	O
GBF	O
evaluó	O
patógenos	O
seleccionados	O
.	O

El	O
Ptdsrtm1Gbf	O
mutante	B-Sequence
se	O
cruzó	O
a	O
C57BL/6J	O
ratones	B-Taxon
para	O
establecer	O
el	O
co	O
-	O
isogénico	O
C57BL/6J	O
-	O
Ptdsrtm1Gbf	O
ratón	B-Taxon
línea	O
.	O

Todos	O
los	O
estudios	O
fueron	O
aprobados	O
por	O
las	O
autoridades	O
correspondientes	O
.	O

Aislamiento	O
de	O
embriones	O

Heterocigoto	O
masculino	O
y	O
femenino	O
ratones	B-Taxon
se	O
entrecruzaron	O
para	O
obtener	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O

Las	O
hembras	O
fueron	O
monitoreadas	O
diariamente	O
en	O
busca	O
de	O
tapones	O
vaginales	O
,	O
y	O
el	O
mediodía	O
del	O
día	O
de	O
la	O
detección	O
del	O
tapón	O
se	O
definió	O
como	O
E0	O
.	O
5	O
.	O

Los	O
embriones	O
en	O
los	O
puntos	O
de	O
tiempo	O
indicados	O
se	O
diseccionaron	O
en	O
PBS	O
estéril	O
,	O
se	O
lavaron	O
en	O
PBS	O
enfriado	O
con	O
hielo	O
y	O
se	O
transfirieron	O
a	O
fijador	O
frío	O
.	O

Se	O
conservaron	O
membranas	O
extraembrionarias	O
y	O
se	O
usaron	O
para	O
el	O
genotipado	O
.	O

ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
y	O
sus	O
tipo	B-Sequence
salvaje	I-Sequence
Se	O
utilizaron	O
compañeros	O
de	O
camada	O
para	O
los	O
experimentos	O
.	O

Histología	O
,	O
tinción	O
TUNEL	O
e	O
inmunohistoquímica	O

Se	O
recolectaron	O
embriones	O
para	O
histología	O
e	O
inmunohistoquímica	O
y	O
se	O
fijaron	O
en	O
10	O
%	O
neutral	O
-	O
amortiguado	B-Chemical
formalina	O
,	O
deshidratada	O
a	O
través	O
de	O
una	O
serie	O
graduada	O
de	O
alcohol	B-Chemical
,	O
incluidas	O
en	O
parafina	O
,	O
seccionadas	O
sagitalmente	O
a	O
intervalos	O
de	O
5	O
µm	O
,	O
y	O
cada	O
quinta	O
sección	O
se	O
procesó	O
para	O
tinción	O
con	O
hematoxilina	O
y	O
eosina	O
(	O
H	O
&	O
E	O
)	O
según	O
protocolos	O
estándar	O
.	O

secciones	O
restantes	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
ptdsr	B-Protein
/	O
-	O
se	O
utilizaron	O
muestras	O
para	O
inmunohistoquímica	O
.	O

Para	O
la	O
detección	O
de	O
células	B-Cell
apoptóticas	I-Cell
y	O
macrófagos	B-Cell
,	O
contra	O
-	O
acasp3	B-Protein
(	O
un	O
anticuerpo	B-GENE
específico	O
para	O
caspasa	B-Protein
activada	I-Protein
3	I-Protein
;	O
R	O
&	O
D	O
Systems	O
,	O
Minneapolis	O
,	O
EE.UU	O
.	O
)	O
y	O
anti	O
-	O
F4	B-Protein
/	I-Protein
80	I-Protein
(	O
Serotec	O
GmBH	O
,	O
Düsseldorf	O
,	O
Alemania	O
;	O
#	O
MCA	O
1957	O
)	O
anticuerpos	B-GENE
se	O
usaron	O
según	O
lo	O
descrito	O
por	O
el	O
proveedor	O
.	O

La	O
detección	O
se	O
realizó	O
utilizando	O
estreptavidina	O
indirecta	O
con	O
biotinilado	O
secundario	O
anticuerpos	B-GENE
y	O
cobalto	B-Chemical
#	O
¿NOMBRE	O
?	O

Las	O
secciones	O
se	O
contrastaron	O
con	O
hematoxilina	O
.	O

Para	O
montaje	O
completo	O
desoxinucleotidil	B-Protein
transferasa	I-Protein
terminal	I-Protein
#	O
¿NOMBRE	O
?	O
UTP	B-Chemical
marca	O
final	O
(	O
TUNEL	O
)	O
,	O
yemas	O
de	O
las	O
extremidades	O
fueron	O
diseccionadas	O
de	O
E12	O
.	O
5	O
y	O
E13	O
.	O
5	O
embriones	O
,	O
fijados	O
en	O
paraformaldehído	O
al	O
4	O
%	O
y	O
procesados	O
para	O
su	O
análisis	O
como	O
se	O
ha	O
descrito	O
anteriormente	O
[	O
50	O
]	O
.	O

Preparación	O
de	O
hígado	O
fetal	O
-	O
derivado	O
macrófagos	B-Cell
(	O
FLDM	O
)	O

Los	O
hígados	O
fetales	O
se	O
extirparon	O
de	O
los	O
embriones	O
en	O
E12	O
.	O
5	O
y	O
E13	O
.	O
5	O
,	O
respectivamente	O
,	O
lavadas	O
en	O
PBS	O
y	O
disociadas	O
enzimáticamente	B-Sequence
durante	O
60	O
minutos	O
a	O
37	O
grados	O
C	O
.	O

El	O
tampón	O
de	O
digestión	O
(	O
150	O
mu	O
l	O
por	O
hígado	O
)	O
comprendía	O
0	O
.	O
6	O
U	O
/	O
ml	O
dispasa	O
I	O
(	O
Roche	O
)	O
,	O
0	O
.	O
1	O
%	O
colagenasa	O
D	O
(	O
Roche	O
)	O
,	O
10	O
U	O
DNasa	O
(	O
Roche	O
)	O
y	O
20	O
%	O
FCS	O
en	O
PBS	O
.	O

Se	O
añadió	O
medio	O
X-Vivo	O
15	O
(	O
Cambrex	O
,	O
East	O
Rutherford	O
,	O
EE	O
.	O
UU	O
.	O
)	O
al	O
producto	O
resultante	O
.	O
célula	B-Cell
suspensión	O
,	O
y	O
después	O
de	O
la	O
centrifugación	O
(	O
200	O
xg	O
;	O
3	O
min	O
)	O
células	B-Cell
se	O
resuspendieron	O
en	O
medio	O
X	O
-	O
Vivo	O
15	O
suplementado	O
con	O
50	O
ng/ml	O
colonia	B-Protein
de	I-Protein
macrófagos	I-Protein
-	I-Protein
factor	I-Protein
estimulante	I-Protein
(	O
M	B-Protein
-	I-Protein
LCR	I-Protein
;	O
Sigma-Aldrich	O
,	O
St.	O
Louis	O
,	O
EE	O
.	O
UU	O
.	O
)	O
y	O
cultivadas	O
en	O
placas	O
de	O
cultivo	O
de	O
tejidos	O
no	O
tratadas	O
a	O
37	O
grados	O
C	O
con	O
5	O
%	O
CO2	B-Chemical
.	O

Cada	O
dos	O
o	O
tres	O
días	O
se	O
cambió	O
el	O
medio	O
por	O
centrifugación	O
.	O

Tras	O
la	O
retirada	O
de	O
M	B-Protein
-	I-Protein
LCR	I-Protein
el	O
día	O
6	O
después	O
de	O
la	O
escisión	O
,	O
adherente	O
células	B-Cell
se	O
cultivaron	O
durante	O
24-48	O
horas	O
adicionales	O
en	O
medio	O
X-Vivo	O
15	O
.	O

macrófago	B-Cell
ensayos	O
de	O
fagocitosis	O

Para	O
la	O
preparación	O
de	O
cultivos	O
monocapa	O
de	O
macrófagos	B-Cell
,	O
los	O
FLDM	O
se	O
sembraron	O
en	O
cubreobjetos	O
de	O
vidrio	O
en	O
placas	O
de	O
24	O
pocillos	O
(	O
2	O
x	O
105	O
células	B-Cell
por	O
pocillo	O
)	O
en	O
medio	O
X-Vivo	O
15	O
.	O

Para	O
preparación	O
de	O
células	B-Cell
diana	I-Cell
apoptóticas	I-Cell
,	O
se	O
recolectaron	O
timocitos	O
primarios	O
del	O
timo	O
de	O
C57BL	O
/	O
6J	O
de	O
4	O
a	O
8	O
semanas	O
de	O
edad	O
ratones	B-Taxon
,	O
se	O
tiñeron	O
con	O
TAMRA	O
durante	O
15	O
min	O
,	O
y	O
se	O
indujo	O
la	O
apoptosis	O
mediante	O
el	O
tratamiento	O
células	B-Cell
con	O
5	O
muM	O
estaurosporina	B-Chemical
en	O
medio	O
durante	O
4	O
horas	O
a	O
37	O
grados	O
C	O
o	O
cultivando	O
células	B-Cell
en	O
medio	O
durante	O
la	O
noche	O
.	O

Se	O
comparó	O
la	O
eficacia	O
de	O
la	O
inducción	O
de	O
apoptosis	O
en	O
diana	O
tímica	O
células	B-Cell
y	O
controles	O
por	O
análisis	O
FACS	O
.	O

En	O
promedio	O
,	O
el	O
60	O
%	O
de	O
los	O
células	B-Cell
de	O
la	O
población	O
resultante	O
fueron	O
apoptóticos	O
,	O
con	O
exposición	O
PD	B-Chemical
en	O
su	O
superficie	B-GENE
,	O
y	O
menos	O
del	O
5	O
%	O
de	O
la	O
células	B-Cell
estaban	O
necróticos	O
,	O
como	O
lo	O
confirmó	O
FITC	B-Chemical
-	O
anexina	B-Protein
V	I-Protein
y	O
propidio	O
yoduro	B-Chemical
tinción	O

Los	O
timocitos	O
apoptóticos	O
obtenidos	O
se	O
lavaron	O
con	O
PBS	O
y	O
se	O
añadieron	O
a	O
los	O
cultivos	O
FLDM	O
preparados	O
(	O
proporción	O
10:1	O
)	O
.	O

Luego	O
se	O
permitió	O
que	O
prosiguiera	O
la	O
fagocitosis	O
a	O
37	O
grados	O
C	O
y	O
5	O
%	O
CO2	B-Chemical
.	O

Después	O
de	O
los	O
períodos	O
de	O
tiempo	O
indicados	O
,	O
la	O
absorción	O
de	O
células	B-Cell
apoptóticas	I-Cell
por	O
FLDM	O
se	O
detuvo	O
mediante	O
un	O
lavado	O
intensivo	O
de	O
co	O
-	O
cultivos	O
con	O
PBS	O
frío	O
para	O
eliminar	O
no	O
fagocitados	O
células	B-Cell
.	O

Para	O
medir	O
la	O
fagocitosis	O
de	O
los	O
timocitos	O
apoptóticos	O
,	O
macrófagos	B-Cell
fueron	O
procesados	O
adicionalmente	O
para	O
el	O
análisis	O
de	O
inmunofluorescencia	O
.	O

Células	B-Cell
se	O
fijaron	O
en	O
paraformaldehído	O
al	O
4	O
%	O
,	O
se	O
bloquearon	O
en	O
0	O
.	O
5	O
%	O
BSA/PBS	O
y	O
teñido	O
con	O
un	O
anti	O
-	O
F4	B-Protein
/	I-Protein
80	I-Protein
anticuerpo	B-GENE
(	O
Serotec	O
)	O
seguido	O
de	O
un	O
secundario	O
anticuerpo	B-GENE
acoplado	O
a	O
Alexa	O
488	O
(	O
Molecular	B-Chemical
Sondas	O
Inc.	O
,	O
Eugene	O
,	O
Estados	O
Unidos	O
)	O
.	O

Los	O
cubreobjetos	O
se	O
montaron	O
en	O
portaobjetos	O
y	O
los	O
timocitos	O
engullidos	O
se	O
enumeraron	O
mediante	O
microscopía	O
de	O
fluorescencia	O
.	O

El	O
porcentaje	O
de	O
fagocitosis	O
se	O
calculó	O
contando	O
al	O
menos	O
300	O
macrófagos	B-Cell
y	O
determinar	O
el	O
número	O
de	O
macrófagos	B-Cell
que	O
había	O
engullido	O
timocitos	O
apoptóticos	O
.	O

El	O
índice	O
fagocítico	O
se	O
calculó	O
de	O
acuerdo	O
con	O
la	O
siguiente	O
fórmula	O
:	O
índice	O
fagocítico	O
=	O
(	O
número	O
total	O
de	O
engullidos	O
células	B-Cell
/	O
número	O
total	O
de	O
contados	O
macrófagos	B-Cell
)	O
x	O
(	O
número	O
de	O
macrófagos	B-Cell
conteniendo	O
engullido	O
células	B-Cell
/	O
número	O
total	O
de	O
contados	O
macrófagos	B-Cell
)	O
×	O
100	O
.	O

Los	O
experimentos	O
se	O
realizaron	O
al	O
menos	O
tres	O
veces	O
,	O
cada	O
vez	O
por	O
triplicado	O
,	O
y	O
el	O
conteo	O
fue	O
realizado	O
por	O
tres	O
investigadores	O
diferentes	O
.	O

Medida	O
de	O
macrófago	B-Cell
producción	O
de	O
citoquinas	O

Se	O
prepararon	O
cultivos	O
en	O
monocapa	O
de	O
FLDM	O
y	O
timocitos	O
apoptóticos	O
como	O
se	O
describe	O
anteriormente	O
.	O

Los	O
FLDM	O
se	O
incubaron	O
con	O
medio	O
,	O
LPS	B-Chemical
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
células	B-Cell
apoptóticas	I-Cell
(	O
relación	O
1	O
:	O
10	O
)	O
o	O
ambos	O
para	O
la	O
determinación	O
de	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
TGF-beta	B-Protein
1	I-Protein
o	O
TNF-alfa	B-Protein
niveles	O
después	O
del	O
co	O
-	O
cultivo	O
durante	O
22	O
h	O
.	O

Para	O
TNF-alfa	B-Protein
cuantificación	O
en	O
varios	O
puntos	O
de	O
tiempo	O
,	O
los	O
FLDM	O
se	O
cultivaron	O
con	O
una	O
alta	O
concentración	O
de	O
LPS	B-Chemical
(	O
100	O
ng/ml	O
)	O
.	O

Se	O
recogieron	O
los	O
sobrenadantes	O
del	O
cultivo	O
y	O
TNF-alfa	B-Protein
(	O
Ratón	B-Protein
TNF	I-Protein
-	I-Protein
alfa	I-Protein
conjunto	O
OptEIA	O
;	O
BD	O
Biosciences	O
,	O
Heidelberg	O
,	O
Alemania	O
)	O
y	O
TGF-beta	B-Protein
1	I-Protein
(	O
Cuantiquina	O
,	O
TGF-beta	B-Protein
1	I-Protein
inmunoensayo	O
;	O
R	O
&	O
D	O
Systems	O
)	O
fueron	O
medidos	O
por	O
ELISA	O
como	O
lo	O
describe	O
el	O
proveedor	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
en	O
sobrenadantes	O
de	O
cultivo	O
se	O
determinó	O
mediante	O
un	O
ensayo	O
de	O
perlas	O
citométricas	O
(	O
Ratón	B-Taxon
inflamación	O
CBA	O
;	O
BD	O
Biosciences	O
)	O
como	O
se	O
indica	O
en	O
el	O
manual	O
.	O

Los	O
datos	O
se	O
presentan	O
como	O
media	O
+/-	O
SEM	O
de	O
al	O
menos	O
tres	O
experimentos	O
independientes	O
,	O
cada	O
uno	O
realizado	O
por	O
triplicado	O
.	O

El	O
análisis	O
de	O
los	O
resultados	O
utilizó	O
la	O
prueba	O
de	O
rango	O
con	O
signo	O
de	O
Wilcoxon	O
;	O
valores	O
de	O
p	O
por	O
debajo	O
de	O
0	O
.	O
05	O
fueron	O
considerados	O
significativos	O
.	O

Archivos	O
de	O
datos	O
adicionales	O

El	O
archivo	O
de	O
datos	O
adicional	O
1	O
contiene	O
:	O
Figura	O
S1	O
que	O
muestra	O
la	O
localización	O
de	O
células	B-Cell
apoptóticas	I-Cell
y	O
macrófagos	B-Cell
en	O
el	O
tejido	O
subcutáneo	O
de	O
embriones	O
en	O
desarrollo	O
;	O
y	O
la	O
Figura	O
S2	O
que	O
muestra	O
la	O
tinción	O
inmunohistoquímica	O
de	O
la	O
ptdsr	B-Protein
proteína	B-Chemical
en	O
macrófagos	B-Cell
derivado	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
.	O

Material	O
suplementario	O

Archivo	O
de	O
datos	O
adicionales	O
1	O

Figura	O
S1	O
que	O
muestra	O
la	O
localización	O
de	O
células	B-Cell
apoptóticas	I-Cell
y	O
macrófagos	B-Cell
en	O
el	O
tejido	O
subcutáneo	O
de	O
embriones	O
en	O
desarrollo	O
;	O
y	O
la	O
Figura	O
S2	O
que	O
muestra	O
la	O
tinción	O
inmunohistoquímica	O
de	O
la	O
ptdsr	B-Protein
proteína	B-Chemical
en	O
macrófagos	B-Cell
derivado	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O

Agradecimientos	O

Agradecemos	O
a	O
Rudi	O
Balling	O
(	O
Centro	O
de	O
Investigación	O
GBF	O
)	O
y	O
Shoumo	O
Bhattacharya	O
(	O
Universidad	O
de	O
Oxford	O
)	O
por	O
muchas	O
discusiones	O
útiles	O
y	O
estimulantes	O
.	O

Agradecemos	O
a	O
Evi	O
Wollscheid	O
-	O
Lengeling	O
(	O
GBF	O
)	O
por	O
su	O
ayuda	O
con	O
la	O
recolección	O
de	O
neonatos	O
ratones	B-Taxon
,	O
Ronald	O
Frank	O
(	O
GBF	O
)	O
por	O
proporcionar	O
ptdsr	B-Protein
péptido	B-Sequence
arreglos	O
,	O
Maria	O
Ebel	O
(	O
GBF	O
)	O
para	O
ES	O
célula	B-Cell
inyecciones	O
de	O
blastocisto	O
,	O
Manfred	O
Rohde	O
(	O
GBF	O
)	O
para	O
electrón	B-Chemical
microscopía	O
,	O
Kurt	O
Dittmar	O
(	O
GBF	O
)	O
por	O
su	O
ayuda	O
con	O
la	O
microscopía	O
confocal	O
y	O
Bastian	O
Pasche	O
(	O
GBF	O
)	O
por	O
la	O
lectura	O
crítica	O
del	O
manuscrito	O
.	O

Agradecemos	O
a	O
BayGenomics	O
,	O
una	O
genómico	B-Sequence
consorcio	O
financiado	O
por	O
el	O
Instituto	O
Nacional	O
del	O
Corazón	O
,	O
los	O
Pulmones	O
y	O
la	O
Sangre	O
de	O
EE	O
.	O
UU.	O
,	O
para	O
proporcionar	O
el	O
ES	O
célula	B-Cell
gene	B-Sequence
-	O
linea	O
trampa	O
RRJ099	O
.	O

``	O
Este	O
trabajo	O
fue	O
apoyado	O
en	O
parte	O
por	O
el	O
proyecto	O
de	O
la	O
UE	O
EUMORPHIA	O
,	O
``	O
''	O
Entendiendo	O
''	O
humano	B-Taxon
molecular	B-Chemical
fisiología	O
y	O
patología	O
a	O
través	O
de	O
la	O
genómica	O
funcional	O
integrada	O
en	O
el	O
ratón	B-Taxon
``	O
modelo	O
``	O
''	O
(	O
QLG2	O
-	O
CT	O
-	O
2002	O
-	O
00930	O
)	O
.	O
''	O

Figuras	O
y	O
Tablas	O

Figura	O
1	O

Inactivación	O
dirigida	O
de	O
la	O
receptor	B-Protein
de	I-Protein
fosfatidilserina	I-Protein
gene	B-Sequence
.	O

(	O
a	O
)	O
ptdsr	B-Protein
gene	B-Sequence
#	O
¿NOMBRE	O
?	O

Recombinación	O
homóloga	O
en	O
ES	O
células	B-Cell
resultados	O
en	O
el	O
supresión	B-Sequence
de	O
exones	B-Sequence
I	O
y	O
II	O
de	O
la	O
ptdsr	B-Protein
murino	I-Protein
gene	B-Sequence
a	O
través	O
de	O
reemplazo	B-Sequence
de	O
un	O
loxP	B-Sequence
-	I-Sequence
flanqueado	I-Sequence
neomicina	B-Chemical
fosfotransferasa	O
gene	B-Sequence
(	O
neo	O
)	O
,	O
con	O
lo	O
que	O
se	O
ablaciona	O
el	O
marco	B-Sequence
de	I-Sequence
lectura	I-Sequence
de	O
lo	O
codificado	O
proteína	B-Chemical
.	O

Codificación	B-Sequence
de	I-Sequence
exones	I-Sequence
I	I-Sequence
-	O
VI	O
se	O
muestran	O
como	O
casillas	O
llenas	O
,	O
y	O
exones	B-Sequence
eliminados	I-Sequence
son	O
de	O
color	O
verde	O
.	O

Sitios	B-Sequence
de	I-Sequence
restricción	I-Sequence
son	O
:	O
A	O
,	O
AatII	O
;	O
B	O
,	O
BamHI	O
;	O
IE	O
,	O
EcoRI	O
;	O
vehículo	O
eléctrico	O
,	O
EcoRV	O
;	O
K	O
,	O
KpnI	O
;	O
R	O
,	O
RsrII	O
;	O
S	O
,	O
SacII	O
;	O
Sc	O
,	O
ScaI	O
,	O
X	O
,	O
XhoI	O
.	O

los	O
sitios	B-Sequence
de	I-Sequence
sondeo	I-Sequence
son	O
cajas	O
rojas	O
etiquetadas	O
:	O
C	O
,	O
5	O
'	O
afuera	O
Investigacion	B-Sequence
;	O
D	O
,	O
3	O
'	O
afuera	O
Investigacion	B-Sequence
.	O

(	O
b	O
)	O
Análisis	O
de	O
transferencia	O
Southern	O
de	O
ADN	B-Sequence
genómico	I-Sequence
extraído	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
+	B-Sequence
/	O
+	B-Sequence
)	O
y	O
ptdsr	B-Protein
+	B-Sequence
/	O
-	O
(	O
+	B-Sequence
/	O
-	O
)	O
animales	B-Taxon
,	O
digerido	O
con	O
BamHI	O
e	O
hibridado	O
con	O
el	O
5	O
'	O
exterior	O
Investigacion	B-Sequence
para	O
confirmar	O
la	O
transmisión	O
de	O
la	O
línea	O
germinal	O
del	O
mutante	B-Sequence
ptdsr	B-Protein
alelo	B-Sequence
.	O

'	O
Tipo	B-Sequence
salvaje	I-Sequence
'	O
indica	O
el	O
BamHI	O
fragmento	B-Sequence
de	O
17	O
2	O
kb	O
de	O
la	O
tipo	B-Sequence
salvaje	I-Sequence
ptdsr	B-Protein
alelo	B-Sequence
;	O
'	O
mutante	B-Sequence
'	O
indica	O
el	O
BamHI	O
fragmento	B-Sequence
de	O
11	O
6	O
kb	O
del	O
objetivo	O
ptdsr	B-Protein
alelo	B-Sequence
.	O

(	O
c	O
)	O
Genotipado	O
por	O
PCR	O
de	O
embriones	O
y	O
animales	B-Taxon
de	O
cruces	O
de	O
heterocigotos	O
ptdsr	B-Protein
+	B-Sequence
/	O
-	O
usando	O
un	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
un	O
alelo	B-Sequence
mutante	I-Sequence
#	O
¿NOMBRE	O
?	O
cebador	B-Sequence
combinación	O
,	O
respectivamente	O
.	O

(	O
d	O
)	O
Análisis	O
de	O
transferencia	O
Northern	O
del	O
total	O
ARN	B-Sequence
aislado	O
de	O
E13	O
.	O
5	O
tipo	B-Sequence
salvaje	I-Sequence
,	O
ptdsr	B-Protein
+	B-Sequence
/	O
-	O
y	O
ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
.	O

(	O
e	O
)	O
Análisis	O
de	O
transferencia	O
Western	O
de	O
proteína	B-Chemical
a	O
partir	O
de	O
homogeneizados	O
de	O
E13	O
.	O
5	O
tipo	B-Sequence
salvaje	I-Sequence
,	O
ptdsr	B-Protein
+	B-Sequence
/	O
-	O
y	O
ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
usando	O
un	O
ptdsr	B-Protein
#	O
¿NOMBRE	O
?	O
anticuerpo	B-GENE
.	O

Anomalías	O
del	O
desarrollo	O
en	O
(	O
f	O
,	O
g	O
)	O
E15	O
.	O
5	O
y	O
(	O
h	O
)	O
nacimiento	O
;	O
en	O
esta	O
y	O
todas	O
las	O
figuras	O
subsiguientes	O
tipo	B-Sequence
salvaje	I-Sequence
los	O
compañeros	O
de	O
camada	O
se	O
ubican	O
a	O
la	O
izquierda	O
y	O
son	O
homocigotos	O
mutante	B-Sequence
ratones	B-Taxon
a	O
la	O
derecha	O
.	O

los	O
ptdsr	B-Protein
-	O
/	O
-	O
los	O
embriones	O
muestran	O
exencefalia	O
(	O
f	O
)	O
o	O
hernia	O
prosencefálica	O
en	O
la	O
región	O
del	O
cerebro	O
anterior	O
(	O
punta	O
de	O
flecha	O
,	O
neonato	O
2	O
;	O
h	O
)	O
,	O
ausencia	O
uni	O
o	O
bilateral	O
de	O
los	O
ojos	O
(	O
f	O
,	O
g	O
y	O
neonato	O
2	O
en	O
h	O
,	O
y	O
flecha	O
,	O
neonato	O
3	O
en	O
h	O
)	O
,	O
una	O
forma	O
anormal	O
de	O
la	O
cabeza	O
con	O
probóscide	O

Figura	O
2	O

Análisis	O
de	O
expresión	O
de	O
ptdsr	B-Protein
durante	O
el	O
desarrollo	O
embrionario	O
.	O

(	O
a	O
)	O
Representación	O
esquemática	O
de	O
la	O
construcción	O
del	O
ptdsr	B-Protein
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
ratón	B-Taxon
línea	O
utilizada	O
para	O
el	O
análisis	O
de	O
expresión	O
en	O
diferentes	O
etapas	O
embrionarias	O
.	O

Los	O
cuadros	O
grises	O
y	O
azules	O
brillantes	O
representan	O
elementos	B-Sequence
regulatorios	I-Sequence
de	O
El	O
gene	B-Sequence
-trap	O
,	O
y	O
beta-geo	O
,	O
la	O
beta-galactosidasa/	O
neomicina	B-Chemical
fosfotransferasa	O
fusión	B-Sequence
proteína	B-Chemical
#	O
¿NOMBRE	O
?	O
casete	B-Sequence
[	O
48	O
,	O
51	O
]	O
.	O

Restricción	O
enzima	B-Sequence
la	O
nomenclatura	O
es	O
como	O
en	O
la	O
Figura	O
1	O
(	O
b	O
)	O
Tinción	O
de	O
beta	O
-	O
galactosidasa	O
de	O
montaje	O
completo	O
de	O
heterocigotos	O
ptdsr	B-Protein
gene	B-Sequence
#	O
¿NOMBRE	O
?	O

Expresión	O
de	O
ptdsr	B-Protein
es	O
mayor	O
en	O
los	O
tejidos	O
neurales	O
y	O
somitas	O
,	O
en	O
los	O
arcos	O
branquiales	O
,	O
las	O
extremidades	O
en	O
desarrollo	O
,	O
el	O
corazón	O
,	O
el	O
intestino	O
primitivo	O
y	O
el	O
ojo	O
en	O
desarrollo	O
.	O

(	O
c	O
-	O
e	O
)	O
Seccionamiento	O
de	O
E12	O
.	O
Los	O
embriones	O
teñidos	O
con	O
5	O
beta	O
-	O
galactosidasa	O
confirman	O
la	O
expresión	O
de	O
ptdsr	B-Protein
en	O
(	O
c	O
)	O
el	O
tubo	O
neural	O
;	O
(	O
recuadro	O
en	O
c	O
)	O
epitelio	O
neural	O
;	O
(	O
d	O
)	O
somitas	O
;	O
y	O
(	O
e	O
)	O
ojos	O
.	O

La	O
expresión	O
en	O
el	O
ojo	O
está	O
restringida	O
al	O
desarrollo	O
de	O
la	O
retina	O
neural	O
y	O
el	O
cristalino	O
.	O
células	B-Cell
.	O

(	O
f	O
)	O
Análisis	O
de	O
expresión	O
de	O
tejidos	O
adultos	O
por	O
transferencia	O
Northern	O
.	O

Expresión	O
de	O
ptdsr	B-Protein
en	O
el	O
músculo	O
(	O
asterisco	O
)	O
se	O
detectó	O
sólo	O
en	O
exposiciones	O
a	O
largo	O
plazo	O
del	O
filtro	O
(	O
>	O
48	O
h	O
)	O
.	O

A	O
beta	B-Protein
-	I-Protein
actina	I-Protein
hibridación	O
se	O
utilizó	O
para	O
confirmar	O
la	O
carga	O
igual	O
de	O
ARN	B-Sequence
muestras	O

Barra	O
de	O
escala	O
,	O
100	O
mu	O
m	O
.	O

figura	O
3	O

Análisis	O
histológico	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
ptdsr	B-Protein
-	O
/	O
-	O
órganos	O
durante	O
la	O
embriogénesis	O
.	O

(	O
a-f	O
)	O
Tipo	B-Sequence
salvaje	I-Sequence
embriones	O
y	O
(	O
g	O
-	O
l	O
)	O
ptdsr	B-Protein
Los	O
compañeros	O
de	O
camada	O
-/-	O
se	O
aislaron	O
en	O
varias	O
etapas	O
embrionarias	O
,	O
se	O
seccionaron	O
en	O
serie	O
sagitalmente	O
y	O
se	O
analizaron	O
en	O
busca	O
de	O
anormalidades	O
de	O
desarrollo	O
en	O
detalle	O
después	O
de	O
la	O
tinción	O
con	O
H	O
&	O
E	O
.	O

En	O
E16	O
.	O
5	O
,	O
los	O
pulmones	O
de	O
(	O
g	O
)	O
ptdsr	B-Protein
-	O
/	O
-	O
los	O
embriones	O
tenían	O
saculación	O
apenas	O
comenzando	O
,	O
y	O
los	O
alvéolos	O
bien	O
formados	O
(	O
asteriscos	O
)	O
o	O
los	O
bronquiolos	O
revestidos	O
de	O
epitelio	O
(	O
flechas	O
)	O
eran	O
escasos	O
en	O
comparación	O
con	O
(	O
a	O
)	O
tipo	B-Sequence
salvaje	I-Sequence
pulmones	O
.	O

En	O
E16	O
.	O
5	O
,	O
los	O
glomérulos	O
(	O
flechas	O
)	O
en	O
el	O
riñón	O
de	O
(	O
h	O
)	O
ptdsr	B-Protein
-	O
/	O
-	O
los	O
embriones	O
estaban	O
subdesarrollados	O
en	O
comparación	O
con	O
(	O
b	O
)	O
tipo	B-Sequence
salvaje	I-Sequence
faltaban	O
túbulos	O
colectores	O
(	O
puntas	O
de	O
flecha	O
)	O
y	O
eran	O
más	O
abundantes	O
los	O
blastemas	O
indiferenciados	O
(	O
asteriscos	O
)	O
.	O

El	O
yeyuno	O
no	O
tenía	O
ganglios	O
intramurales	O
en	O
ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
(	O
i	O
;	O
y	O
flechas	O
en	O
c	O
)	O
;	O
y	O
faltaba	O
una	O
submucosa	O
bien	O
desarrollada	O
(	O
asterisco	O
en	O
c	O
)	O
.	O

Secciones	O
del	O
cerebro	O
en	O
E18	O
.	O
5	O
muestra	O
que	O
(	O
j	O
)	O
ptdsr	B-Protein
-	O
/	O
-	O
los	O
embriones	O
pueden	O
tener	O
una	O
hernia	O
(	O
flecha	O
)	O
del	O
hipotálamo	O
a	O
través	O
de	O
la	O
parte	O
ventral	O
del	O
cráneo	O
(	O
paladar	O
secundario	O
)	O
,	O
muy	O
probablemente	O
a	O
través	O
de	O
la	O
bolsa	O
de	O
Rathke	O
,	O
y	O
una	O
grave	O
malformación	O
de	O
la	O
corteza	O
(	O
asteriscos	O
)	O
en	O
comparación	O
con	O
(	O
d	O
)	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O

En	O
E18	O
.	O
5	O
,	O
(	O
e	O
)	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
(	O
k	O
)	O
ptdsr	B-Protein
-/-	O
los	O
pulmones	O
mostraron	O
saculación	O
normal	O
y	O
formación	O
de	O
alvéolos	O
(	O
asteriscos	O
)	O
y	O
bronquiolos	O
(	O
flecha	O
)	O
.	O

(	O
F	O
)	O
Tipo	B-Sequence
salvaje	I-Sequence
hígado	O
neonatal	O
tenía	O
un	O
número	O
significativo	O
de	O
megacariocitos	B-Cell
(	O
flechas	O
)	O
,	O
en	O
comparación	O
con	O
(	O
l	O
)	O
homocigoto	O
mutante	B-Sequence
compañeros	O
de	O
camada	O
,	O
y	O
un	O
mayor	O
número	O
de	O
islas	O
eritropoyéticas	O
y	O
de	O
maduros	O
eritrocitos	B-Cell
.	O

Las	O
vacuolas	O
hepatocelulares	O
se	O
deben	O
a	O
glucógeno	B-Chemical
reservas	O
(	O
asteriscos	O
)	O
que	O
no	O
se	O
metabolizaron	O
en	O
la	O
muerte	O
perinatal	O
ptdsr	B-Protein
-	O
/	O
-	O
animales	B-Taxon
,	O
en	O
contraste	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
recién	O
nacidos	O

Barra	O
de	O
escala	O
,	O
100	O
mu	O
m	O
,	O
excepto	O
(	O
d	O
)	O
y	O
(	O
j	O
)	O
,	O
1	O
mm	O
.	O

Figura	O
4	O

Morfología	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
ptdsr	B-Protein
-	O
/	O
-	O
retinas	O
.	O

Secciones	O
sagitales	O
seriadas	O
de	O
(	O
a	O
-	O
d	O
)	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
(	O
e	O
-	O
h	O
)	O
ptdsr	B-Protein
/	O
-	O
la	O
retina	O
se	O
analizó	O
en	O
busca	O
de	O
anomalías	O
del	O
desarrollo	O
en	O
(	O
a	O
,	O
e	O
)	O
E12	O
.	O
5	O
,	O
(	O
segundo	O
,	O
f	O
)	O
E16	O
.	O
5	O
,	O
(	O
c	O
,	O
g	O
)	O
E18	O
.	O
5	O
,	O
y	O
(	O
d	O
,	O
h	O
)	O
P0	O
.	O

Se	O
observó	O
un	O
patrón	O
normal	O
de	O
la	O
retina	O
en	O
ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
,	O
con	O
una	O
capa	O
granular	O
externa	O
(	O
OGL	O
)	O
,	O
capa	O
plexiforme	O
externa	O
(	O
OPL	O
)	O
,	O
capa	O
granular	O
interna	O
(	O
IGL	O
)	O
y	O
capa	O
plexiforme	O
interna	O
(	O
IPL	O
)	O
.	O

Tenga	O
en	O
cuenta	O
que	O
el	O
IGL	O
en	O
ptdsr	B-Protein
-	O
/	O
-	O
retinas	O
es	O
menos	O
gruesa	O
que	O
la	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
compañeros	O
de	O
camada	O
al	O
comparar	O
(	O
c	O
,	O
g	O
)	O
y	O
(	O
d	O
,	O
h	O
)	O
.	O

Análisis	O
morfométrico	O
(	O
líneas	O
numeradas	O
)	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
ptdsr	B-Protein
-	O
/	O
-	O
retinas	O
confirmó	O
el	O
hallazgo	O
inicial	O
de	O
una	O
retina	O
más	O
delgada	O
en	O
ptdsr	B-Protein
-	O
/	O
-	O
animales	B-Taxon
que	O
en	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
todos	O
los	O
valores	O
en	O
mu	O
m	O
)	O
.	O

Barra	O
de	O
escala	O
,	O
50	O
mu	O
m	O
.	O

Figura	O
5	O

Análisis	O
histológico	O
del	O
desarrollo	O
ocular	O
en	O
personas	O
sin	O
ojos	O
severamente	O
afectadas	O
ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
.	O

(	O
a	O
)	O
En	O
anoftálmica	O
ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
,	O
se	O
puede	O
detectar	O
la	O
ausencia	O
unilateral	O
o	O
bilateral	O
de	O
los	O
ojos	O
.	O

(	O
b	O
-	O
d	O
)	O
Secciones	O
sagitales	O
teñidas	O
con	O
H	O
y	O
E	O
en	O
serie	O
de	O
homocigotos	O
mutante	B-Sequence
embriones	O
en	O
(	O
b	O
)	O
E17	O
.	O
5	O
y	O
(	O
c	O
,	O
d	O
)	O
E18	O
.	O
5	O
muestran	O
una	O
malformación	O
compleja	O
de	O
la	O
copa	O
óptica	O
y	O
falta	O
de	O
cualquier	O
estructura	O
de	O
lente	O
.	O

El	O
examen	O
cuidadoso	O
de	O
las	O
secciones	O
adyacentes	O
(	O
b-d	O
)	O
revela	O
una	O
mala	O
ubicación	O
ectópica	O
del	O
epitelio	O
pigmentado	O
de	O
la	O
retina	O
en	O
el	O
seno	O
maxilar	O
.	O

No	O
sólo	O
es	O
claramente	O
visible	O
el	O
depósito	O
de	O
pigmento	O
(	O
recuadros	O
de	O
mayor	O
aumento	O
)	O
,	O
sino	O
también	O
la	O
inducción	O
de	O
la	O
proliferación	O
de	O
los	O
tejidos	O
subyacentes	O
y	O
el	O
cambio	O
en	O
la	O
morfología	O
del	O
seno	O
maxilar	O
(	O
d	O
)	O
.	O

Barra	O
de	O
escala	O
,	O
100	O
mu	O
m	O
en	O
(	O
b-d	O
)	O
.	O

Figura	O
6	O

Análisis	O
de	O
programado	O
célula	B-Cell
muerte	O
y	O
participación	O
de	O
macrófagos	B-Cell
en	O
la	O
eliminación	O
de	O
células	B-Cell
apoptóticas	I-Cell
en	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
.	O

(	O
a	O
)	O
Tinción	O
TUNEL	O
de	O
montaje	O
completo	O
(	O
azul	O
)	O
de	O
yemas	O
de	O
extremidades	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
en	O
E13	O
.	O
5	O
no	O
muestran	O
diferencias	O
en	O
la	O
cantidad	O
o	O
localización	O
de	O
células	B-Cell
apoptóticas	I-Cell
durante	O
el	O
comienzo	O
de	O
la	O
regresión	O
de	O
la	O
red	O
interdigital	O
.	O

Secciones	O
sagitales	O
seriadas	O
teñidas	O
para	O
caspasa	B-Protein
activada	I-Protein
3	I-Protein
(	O
acasp3	B-Protein
;	O
rojo	O
)	O
en	O
(	O
b-d	O
)	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
(	O
f-h	O
)	O
ptdsr	B-Protein
-	O
/	O
-	O
embriones	O
en	O
E12	O
.	O
5	O
mostrar	O
células	B-Cell
apoptóticas	I-Cell
en	O
el	O
tubo	O
neural	O
(	O
b	O
,	O
f	O
)	O
,	O
el	O
mesonefros	O
(	O
c	O
,	O
g	O
)	O
y	O
los	O
ganglios	O
paravertebrales	O
en	O
desarrollo	O
(	O
d	O
,	O
h	O
)	O
.	O

Distribución	O
de	O
tejidos	O
y	O
número	O
total	O
de	O
células	B-Cell
apoptóticas	I-Cell
era	O
indistinguible	O
entre	O
genotipos	B-Sequence
y	O
fue	O
confirmado	O
por	O
la	O
comparación	O
de	O
secciones	O
consecutivas	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
ptdsr	B-Protein
-/-	O
embriones	O
de	O
diferentes	O
etapas	O
de	O
desarrollo	O
.	O

Análisis	O
de	O
macrófago	B-Cell
números	O
y	O
ubicación	O
por	O
F4	B-Protein
/	I-Protein
80	I-Protein
tinción	O
(	O
marrón	O
)	O
de	O
secciones	O
consecutivas	O
en	O
ganglios	O
paravertebrales	O
de	O
(	O
e	O
)	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
(	O
i	O
)	O
homocigoto	O
mutante	B-Sequence
embriones	O
revelaron	O
que	O
macrófagos	B-Cell
(	O
flechas	O
)	O
no	O
se	O
encuentran	O
cerca	O
de	O
células	B-Cell
apoptóticas	I-Cell
durante	O
el	O
desarrollo	O
embrionario	O
.	O

(	O
A	O
modo	O
de	O
comparación	O
,	O
consulte	O
también	O
el	O
archivo	O
de	O
datos	O
adicionales	O
1	O
,	O
Figura	O
S1	O
,	O
con	O
la	O
versión	O
en	O
línea	O
de	O
este	O
artículo	O
)	O
.	O

Barra	O
de	O
escala	O
,	O
100	O
mu	O
m	O
.	O

Figura	O
7	O

Fagocitosis	O
de	O
células	B-Cell
apoptóticas	I-Cell
por	O
hígado	O
fetal	O
-	O
derivado	O
macrófagos	B-Cell
(	O
FLDM	O
)	O
.	O

FLDM	O
de	O
(	O
a	O
,	O
b	O
)	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
(	O
c	O
,	O
d	O
)	O
ptdsr	B-Protein
-	O
/	O
-	O
los	O
embriones	O
se	O
cultivaron	O
durante	O
60	O
minutos	O
con	O
timocitos	O
apoptóticos	O
teñidos	O
con	O
TAMRA	O
(	O
rojo	O
)	O
(	O
tratados	O
con	O
estaurosporina	B-Chemical
)	O
de	O
C57BL	O
/	O
6J	O
ratones	B-Taxon
y	O
luego	O
teñido	O
con	O
F4	B-Protein
/	I-Protein
80	I-Protein
(	O
verde	O
)	O
.	O

Macrófagos	B-Cell
de	O
ambos	O
genotipos	B-Sequence
han	O
fagocitado	O
células	B-Cell
apoptóticas	I-Cell
(	O
puntas	O
de	O
flecha	O
)	O
.	O

e	O
)	O
Cuantificación	O
de	O
la	O
fagocitosis	O
de	O
células	B-Cell
apoptóticas	I-Cell
por	O
tipo	B-Sequence
salvaje	I-Sequence
o	O
ptdsr	B-Protein
-	O
/	O
-	O
macrófagos	B-Cell
no	O
reveló	O
diferencias	O
en	O
el	O
porcentaje	O
de	O
macrófagos	B-Cell
que	O
había	O
engullido	O
células	B-Cell
apoptóticas	I-Cell
,	O
ya	O
sea	O
que	O
la	O
apoptosis	O
haya	O
sido	O
o	O
no	O
inducida	O
por	O
estaurosporina	B-Chemical
.	O

Análisis	O
microscópico	O
(	O
b	O
,	O
d	O
)	O
y	O
cuantificación	O
del	O
número	O
de	O
células	B-Cell
apoptóticas	I-Cell
fagocitada	O
por	O
un	O
solo	O
macrófagos	B-Cell
y	O
(	O
f	O
)	O
cálculo	O
del	O
número	O
promedio	O
de	O
células	B-Cell
fagocitado	O
por	O
macrófago	B-Cell
no	O
pudo	O
revelar	O
diferencias	O
en	O
la	O
eficacia	O
de	O
la	O
eliminación	O
de	O
células	B-Cell
apoptóticas	I-Cell
Entre	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
ptdsr	B-Protein
-	O
/	O
-	O
FLDM	O
.	O

Figura	O
8	O

Producción	O
de	O
citocinas	O
por	O
FLDM	O
tras	O
la	O
estimulación	O
con	O
lipopolisacárido	B-Chemical
(	O
LPS	B-Chemical
)	O
y	O
células	B-Cell
apoptóticas	I-Cell
.	O

FLDM	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
ptdsr	B-Protein
-	O
/	O
-	O
los	O
embriones	O
fueron	O
incubados	O
(	O
a	O
,	O
b	O
,	O
d	O
)	O
con	O
medio	O
(	O
0	O
)	O
,	O
LPS	B-Chemical
(	O
10	O
ng	O
/	O
ml	O
)	O
,	O
células	B-Cell
apoptóticas	I-Cell
(	O
relación	O
1	O
:	O
10	O
)	O
o	O
en	O
combinación	O
con	O
LPS	B-Chemical
y	O
células	B-Cell
apoptóticas	I-Cell
o	O
(	O
c	O
)	O
con	O
LPS	B-Chemical
(	O
100	O
ng/ml	O
)	O
solo	O
.	O

Los	O
sobrenadantes	O
de	O
cultivo	O
se	O
recogieron	O
después	O
de	O
22	O
h	O
(	O
a	O
,	O
b	O
,	O
d	O
)	O
o	O
en	O
los	O
puntos	O
de	O
tiempo	O
indicados	O
(	O
c	O
)	O
.	O

TNF-alfa	B-Protein
y	O
TGF-beta	B-Protein
1	I-Protein
fueron	O
cuantificados	O
por	O
ELISA	O
y	O
IL	B-Protein
-	I-Protein
10	I-Protein
mediante	O
ensayo	O
de	O
matriz	O
de	O
perlas	O
citométricas	O
(	O
CBA	O
)	O
.	O

Los	O
datos	O
se	O
presentan	O
como	O
media	O
+/-	O
SEM	O
de	O
al	O
menos	O
tres	O
experimentos	O
independientes	O
,	O
cada	O
uno	O
realizado	O
por	O
triplicado	O
.	O

*	O
,	O
diferencia	O
significativa	O
entre	O
genotipos	B-Sequence
,	O
pag	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
diferencia	O
significativa	O
entre	O
genotipos	B-Sequence
,	O
pag	O
<	O
0	O
.	O
01	O
;	O
Prueba	O
de	O
rango	O
con	O
signo	O
de	O
Wilcoxon	O
.	O

tabla	O
1	O

Penetración	O
de	O
fenotipos	O
en	O
ptdsr	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
de	O
E9	O
.	O
5	O
a	O
E18	O
.	O
5	O
,	O
detectado	O
por	O
morfología	O
macroscópica	O

Los	O
subconjuntos	O
de	O
las	O
principales	O
categorías	O
de	O
malformaciones	O
se	O
indican	O
mediante	O
sangría	O
.	O

BMP	B-Protein
La	O
señalización	O
del	O
receptor	O
es	O
necesaria	O
para	O
el	O
mantenimiento	O
posnatal	O
del	O
cartílago	O
articular	O

Resumen	O

El	O
cartílago	O
articular	O
juega	O
un	O
papel	O
esencial	O
en	O
la	O
salud	O
y	O
la	O
movilidad	O
,	O
pero	O
con	O
frecuencia	O
se	O
daña	O
o	O
se	O
pierde	O
en	O
millones	O
de	O
gente	B-Taxon
que	O
desarrollan	O
artritis	O
.	O

los	O
molecular	B-Chemical
Los	O
mecanismos	O
que	O
crean	O
y	O
mantienen	O
esta	O
fina	O
capa	O
de	O
cartílago	O
que	O
cubre	O
la	O
superficie	O
de	O
los	O
huesos	O
en	O
las	O
regiones	O
articulares	O
son	O
poco	O
conocidos	O
,	O
en	O
parte	O
porque	O
las	O
herramientas	O
para	O
manipular	O
gene	B-Sequence
la	O
expresión	O
específicamente	O
en	O
este	O
tejido	O
no	O
ha	O
estado	O
disponible	O
.	O

Aquí	O
utilizamos	O
información	O
reglamentaria	O
de	O
la	O
ratón	B-Protein
gdf5	I-Protein
gene	B-Sequence
(	O
a	O
proteína	B-Protein
morfogenética	I-Protein
ósea	I-Protein
[	O
BMP	B-Protein
]	O
miembro	O
de	O
la	O
familia	O
)	O
para	O
desarrollar	O
nuevos	O
ratón	B-Taxon
líneas	O
que	O
se	O
pueden	O
utilizar	O
para	O
activar	O
o	O
desactivar	O
genes	B-Sequence
específicamente	O
en	O
el	O
desarrollo	O
de	O
las	O
articulaciones	O
.	O

Expresión	O
de	O
Cre	O
recombinasa	O
de	O
gdf5	B-Protein
clones	B-Sequence
de	I-Sequence
cromosomas	I-Sequence
artificiales	I-Sequence
bacterianos	I-Sequence
conduce	O
a	O
la	O
activación	O
o	O
inactivación	O
específica	O
de	O
genes	B-Sequence
objetivo	I-Sequence
floxed	I-Sequence
en	O
las	O
articulaciones	O
en	O
desarrollo	O
,	O
incluidas	O
las	O
interzonas	O
articulares	O
tempranas	O
,	O
el	O
cartílago	O
articular	O
adulto	O
y	O
la	O
cápsula	O
articular	O
.	O

Hemos	O
utilizado	O
este	O
sistema	O
para	O
probar	O
el	O
papel	O
de	O
BMP	B-Protein
Señalización	O
del	O
receptor	O
en	O
el	O
desarrollo	O
conjunto	O
.	O

Ratones	B-Taxon
con	O
nulo	O
mutaciones	B-Sequence
en	O
Bmpr1a	B-Protein
se	O
sabe	O
que	O
mueren	O
temprano	O
en	O
la	O
embriogénesis	O
con	O
múltiples	O
defectos	O
.	O

Sin	O
embargo	O
,	O
combinar	O
un	O
flojo	B-Sequence
Bmpr1a	B-Protein
alelo	B-Sequence
con	O
el	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
extrañando	O
el	O
Bmpr1a	B-Protein
gene	B-Sequence
en	O
las	O
regiones	O
articulares	O
.	O

La	O
mayoría	O
de	O
las	O
articulaciones	O
del	O
cuerpo	O
se	O
forman	O
normalmente	O
en	O
ausencia	O
de	O
receptor	B-Protein
bmpr1a	I-Protein
función	O

Sin	O
embargo	O
,	O
el	O
cartílago	O
articular	O
dentro	O
de	O
las	O
articulaciones	O
se	O
desgasta	O
gradualmente	O
en	O
personas	O
con	O
deficiencia	O
de	O
receptores	O
.	O
ratones	B-Taxon
después	O
del	O
nacimiento	O
en	O
un	O
proceso	O
similar	O
humano	B-Taxon
artrosis	O

gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
proporcionar	O
un	O
sistema	O
general	O
que	O
se	O
puede	O
utilizar	O
para	O
probar	O
el	O
papel	O
de	O
genes	B-Sequence
en	O
las	O
regiones	O
articulares	O
.	O

BMP	B-Protein
la	O
señalización	O
del	O
receptor	O
es	O
necesaria	O
no	O
sólo	O
para	O
el	O
desarrollo	O
temprano	O
y	O
la	O
creación	O
de	O
múltiples	O
tejidos	O
,	O
sino	O
también	O
para	O
el	O
mantenimiento	O
continuo	O
del	O
cartílago	O
articular	O
después	O
del	O
nacimiento	O
.	O

Genético	B-Sequence
variación	O
en	O
la	O
fuerza	O
de	O
BMP	B-Protein
la	O
señalización	O
del	O
receptor	O
puede	O
ser	O
un	O
factor	O
de	O
riesgo	O
importante	O
en	O
humano	B-Taxon
osteoartritis	O
y	O
tratamientos	O
que	O
imitan	O
o	O
aumentan	O
BMP	B-Protein
la	O
señalización	O
del	O
receptor	O
debe	O
investigarse	O
como	O
una	O
posible	O
estrategia	O
terapéutica	O
para	O
mantener	O
la	O
salud	O
de	O
los	O
revestimientos	O
de	O
las	O
articulaciones	O
.	O

Introducción	O

Capas	O
delgadas	O
de	O
cartílago	O
articular	O
recubren	O
los	O
huesos	O
de	O
las	O
articulaciones	O
sinoviales	O
y	O
brindan	O
una	O
estructura	O
suave	O
y	O
resistente	O
al	O
desgaste	O
que	O
reduce	O
la	O
fricción	O
y	O
absorbe	O
las	O
fuerzas	O
de	O
impacto	O
(	O
Brandt	O
et	O
al	O
.	O
1998	O
)	O
.	O

La	O
pérdida	O
o	O
daño	O
del	O
cartílago	O
articular	O
es	O
un	O
sello	O
distintivo	O
de	O
las	O
enfermedades	O
artríticas	O
y	O
es	O
una	O
de	O
las	O
razones	O
más	O
comunes	O
por	O
las	O
que	O
tanto	O
los	O
adultos	O
jóvenes	O
como	O
los	O
adultos	O
mayores	O
buscan	O
atención	O
médica	O
.	O

Millones	O
de	O
gente	B-Taxon
sufren	O
de	O
artritis	O
y	O
,	O
en	O
última	O
instancia	O
,	O
afecta	O
a	O
más	O
de	O
la	O
mitad	O
de	O
gente	B-Taxon
mayores	O
de	O
65	O
años	O
(	O
Badley	O
1995	O
;	O
Yelin	O
y	O
Callahan	O
1995	O
)	O
.	O

Una	O
mejor	O
comprensión	O
de	O
la	O
molecular	B-Chemical
Los	O
mecanismos	O
que	O
crean	O
y	O
mantienen	O
el	O
cartílago	O
articular	O
son	O
cruciales	O
para	O
descubrir	O
las	O
causas	O
de	O
los	O
trastornos	O
articulares	O
y	O
proporcionar	O
tratamientos	O
médicos	O
útiles	O
.	O

La	O
formación	O
de	O
articulaciones	O
comienza	O
durante	O
la	O
embriogénesis	O
,	O
cuando	O
las	O
franjas	O
de	O
alta	O
célula	B-Cell
densidad	O
denominada	O
interzonas	O
se	O
forman	O
a	O
través	O
de	O
precursores	O
esqueléticos	O
en	O
desarrollo	O
(	O
Haines	O
1947	O
)	O
.	O

Programado	O
célula	B-Cell
la	O
muerte	O
ocurre	O
dentro	O
de	O
la	O
interzona	O
,	O
y	O
se	O
forma	O
una	O
interzona	O
de	O
tres	O
capas	O
que	O
tiene	O
dos	O
capas	O
de	O
mayor	O
célula	B-Cell
densidad	O
que	O
flanquea	O
una	O
región	O
de	O
menor	O
célula	B-Cell
densidad	O

Los	O
precursores	O
no	O
articulares	O
del	O
esqueleto	O
normalmente	O
se	O
convierten	O
en	O
cartílago	O
,	O
que	O
se	O
hipertrofia	O
y	O
es	O
reemplazado	O
por	O
hueso	O
.	O

Sin	O
embargo	O
,	O
células	B-Cell
dentro	O
de	O
las	O
capas	O
de	O
alta	O
densidad	O
de	O
la	O
interzona	O
quedan	O
excluidas	O
de	O
este	O
proceso	O
y	O
se	O
desarrollan	O
en	O
las	O
capas	O
permanentes	O
de	O
cartílago	O
articular	O
que	O
se	O
encuentran	O
en	O
la	O
articulación	O
madura	O
(	O
Mitrovic	O
1978	O
)	O
.	O

Los	O
estudios	O
de	O
los	O
últimos	O
10	O
años	O
han	O
comenzado	O
a	O
dilucidar	O
algunas	O
de	O
las	O
vías	O
de	O
señalización	O
que	O
contribuyen	O
a	O
las	O
primeras	O
etapas	O
de	O
la	O
formación	O
de	O
articulaciones	O
.	O

Wnt14	B-Protein
se	O
expresa	O
en	O
franjas	O
en	O
los	O
sitios	O
donde	O
se	O
formarán	O
las	O
articulaciones	O
,	O
y	O
es	O
capaz	O
de	O
inducir	O
la	O
expresión	O
de	O
otros	O
marcadores	O
articulares	O
cuando	O
se	O
expresa	O
incorrectamente	O
en	O
nuevas	O
ubicaciones	O
en	O
la	O
extremidad	O
(	O
Hartmann	O
y	O
Tabin	O
2001	O
)	O
.	O

Varios	O
miembros	O
de	O
la	O
proteína	B-Protein
morfogenética	I-Protein
ósea	I-Protein
(	O
BMP	B-Protein
)	O
familia	O
de	O
señalización	O
secretada	O
moléculas	B-Chemical
también	O
se	O
expresan	O
en	O
franjas	O
en	O
los	O
sitios	O
donde	O
se	O
formarán	O
las	O
uniones	O
,	O
incluidas	O
las	O
codificadas	O
por	O
el	O
genes	B-Sequence
gdf5	B-Protein
,	O
gdf6	B-Protein
,	O
gdf7	B-Protein
,	O
Bmp2	B-Protein
,	O
y	O
Bmp4	B-Protein
(	O
Storm	O
y	O
Kingsley	O
1996	O
;	O
Wolfman	O
et	O
al	O
.	O
1997	O
;	O
Francis-West	O
et	O
al	O
.	O
1999	O
;	O
Settle	O
et	O
al	O
.	O
2003	O
)	O
.	O

De	O
estos	O
,	O
gdf5	B-Protein
La	O
expresión	O
se	O
limita	O
de	O
manera	O
más	O
llamativa	O
a	O
las	O
regiones	O
donde	O
se	O
desarrollarán	O
las	O
articulaciones	O
y	O
es	O
una	O
de	O
las	O
primeras	O
conocido	B-Sequence
marcadores	O
de	O
formación	O
de	O
articulaciones	O
.	O

Mutaciones	B-Sequence
en	O
cualquiera	O
gdf5	B-Protein
o	O
los	O
estrechamente	O
relacionados	O
gdf6	B-Protein
gene	B-Sequence
también	O
bloquean	O
la	O
formación	O
de	O
uniones	O
en	O
lugares	O
específicos	O
,	O
proporcionando	O
una	O
fuerte	O
evidencia	O
de	O
que	O
estas	O
moléculas	O
son	O
esenciales	O
para	O
el	O
proceso	O
de	O
formación	O
de	O
uniones	O
(	O
Storm	O
et	O
al	O
.	O
1994	O
;	O
Settle	O
et	O
al	O
.	O
2003	O
)	O
.	O

Sin	O
embargo	O
,	O
mutaciones	B-Sequence
en	O
Bmp2	B-Protein
o	O
Bmp4	B-Protein
causan	O
letalidad	O
embrionaria	O
temprana	O
,	O
lo	O
que	O
dificulta	O
probar	O
su	O
papel	O
en	O
la	O
formación	O
de	O
articulaciones	O
(	O
Winnier	O
et	O
al	O
.	O
1995	O
;	O
Zhang	O
y	O
Bradley	O
1996	O
)	O
.	O

Se	O
sabe	O
mucho	O
menos	O
acerca	O
de	O
cómo	O
funcionan	O
las	O
vías	O
de	O
señalización	O
durante	O
la	O
posterior	O
maduración	O
y	O
mantenimiento	O
de	O
las	O
estructuras	O
articulares	O
adultas	O
.	O

Es	O
importante	O
destacar	O
que	O
BMP	B-Protein
Los	O
componentes	O
de	O
señalización	O
están	O
presentes	O
en	O
el	O
cartílago	O
articular	O
adulto	O
,	O
lo	O
que	O
sugiere	O
que	O
pueden	O
funcionar	O
durante	O
el	O
desarrollo	O
tardío	O
o	O
el	O
mantenimiento	O
de	O
esta	O
estructura	O
crítica	O
(	O
Erlacher	O
et	O
al	O
.	O
1998	O
;	O
Chubinskaya	O
et	O
al	O
.	O
2000	O
;	O
Muehleman	O
et	O
al	O
.	O
2002	O
;	O
Bau	O
et	O
al	O
.	O
2002	O
;	O
Bobacz	O
)	O
.	O
et	O
al.	O
,	O
2003	O
)	O
.	O

BMP	B-Protein
enlazar	O
tetramérico	O
complejos	B-GENE
de	O
dos	O
tipo	O
I	O
y	O
dos	O
tipo	O
II	O
transmembrana	B-GENE
serina	B-Chemical
-	O
treonina	B-Chemical
receptores	O
de	O
cinasa	O
.	O

Sobre	O
BMP	B-Protein
vinculante	O
,	O
estos	O
complejos	B-GENE
transducir	O
una	O
señal	O
mediante	O
la	O
fosforilación	O
de	O
miembros	O
del	O
Smad	B-Protein
familia	O
de	O
factores	O
de	O
transcripción	O
(	O
Massague	O
1996	O
)	O
.	O

Experimentos	O
recientes	O
han	O
implicado	O
a	O
dos	O
diferentes	O
BMP	B-Protein
receptores	O
tipo	O
I	O
en	O
el	O
patrón	O
esquelético	O
,	O
BMPR1A	B-Protein
y	O
BMPR1B	B-Protein
.	O

Ambos	O
receptores	O
pueden	O
unirse	O
BMP2	B-Protein
,	O
BMP4	B-Protein
,	O
y	O
GDF5	B-Protein
,	O
aunque	O
GDF5	B-Protein
muestra	O
mayor	O
afinidad	O
por	O
BMPR1B	B-Protein
(	O
Koenig	O
y	O
col.	O
1994	O
;	O
ten	O
Dijke	O
y	O
col.	O
1994	O
;	O
Yamaji	O
y	O
col.	O
1994	O
;	O
Nishitoh	O
y	O
col.	O
1996	O
;	O
Chalaux	O
y	O
col.	O
1998	O
)	O
.	O

Ambos	O
receptores	O
también	O
se	O
expresan	O
en	O
patrones	O
dinámicos	O
durante	O
el	O
desarrollo	O
normal	O
.	O

en	O
las	O
extremidades	O
,	O
Bmpr1a	B-Protein
la	O
expresión	O
se	O
restringe	O
a	O
interzonas	O
articulares	O
,	O
pericondrio	O
,	O
cartílago	O
periarticular	O
,	O
condrocitos	B-Cell
hipertróficos	I-Cell
y	O
mesénquima	O
de	O
las	O
extremidades	O
interdigitales	O
.	O

En	O
comparación	O
,	O
Bmpr1b	B-Protein
expresión	O
se	O
ve	O
principalmente	O
en	O
condensación	O
precartilaginosa	O
células	B-Cell
mesenquimales	I-Cell
,	O
regiones	O
que	O
flanquean	O
las	O
interzonas	O
articulares	O
,	O
el	O
pericondrio	O
y	O
el	O
cartílago	O
periarticular	O
(	O
Dewulf	O
et	O
al	O
.	O
1995	O
;	O
Mishina	O
et	O
al	O
.	O
1995	O
;	O
Zou	O
et	O
al	O
.	O
1997	O
;	O
Baur	O
et	O
al	O
.	O
2000	O
)	O
.	O

Nulo	O
mutaciones	B-Sequence
en	O
el	O
Bmpr1b	B-Protein
gene	B-Sequence
producir	O
viable	O
ratones	B-Taxon
con	O
defectos	O
en	O
la	O
formación	O
de	O
huesos	O
y	O
articulaciones	O
que	O
se	O
parecen	O
mucho	O
a	O
los	O
observados	O
en	O
ratones	B-Taxon
desaparecido	O
gdf5	B-Protein
(	O
Storm	O
y	O
Kingsley	O
1996	O
;	O
Baur	O
et	O
al	O
.	O
2000	O
;	O
Yi	O
et	O
al	O
.	O
2000	O
)	O
.	O

Nulo	O
mutaciones	B-Sequence
en	O
Bmpr1a	B-Protein
causar	O
letalidad	O
embrionaria	O
temprana	O
,	O
con	O
defectos	O
en	O
la	O
gastrulación	O
similares	O
a	O
los	O
observados	O
en	O
ratones	B-Taxon
con	O
mutaciones	B-Sequence
en	O
Bmp4	B-Protein
(	O
Mishina	O
y	O
col.	O
1995	O
;	O
Winnier	O
y	O
col.	O
1995	O
)	O
.	O

Estudios	O
recientes	O
con	O
alelos	B-Sequence
flojos	I-Sequence
sugerir	O
que	O
Bmpr1a	B-Protein
también	O
se	O
requiere	O
para	O
muchos	O
eventos	O
de	O
desarrollo	O
posteriores	O
,	O
pero	O
aún	O
no	O
se	O
ha	O
probado	O
su	O
papel	O
en	O
la	O
formación	O
de	O
huesos	O
y	O
articulaciones	O
(	O
Mishina	O
2003	O
)	O
.	O

A	O
genético	B-Sequence
sistema	O
de	O
activación	O
o	O
desactivación	O
genes	B-Sequence
específicamente	O
en	O
los	O
tejidos	O
de	O
las	O
articulaciones	O
sería	O
particularmente	O
útil	O
para	O
futuros	O
estudios	O
de	O
formación	O
y	O
mantenimiento	O
de	O
las	O
articulaciones	O
.	O

Aquí	O
aprovechamos	O
el	O
patrón	O
de	O
expresión	O
específico	O
de	O
tejido	O
de	O
la	O
gdf5	B-Protein
gene	B-Sequence
diseñar	O
un	O
sistema	O
Cre/loxP	O
(	O
Nagy	O
2000	O
)	O
,	O
gdf5	B-Protein
-	O
Cre	O
,	O
que	O
se	O
puede	O
utilizar	O
para	O
eliminar	O
o	O
expresar	O
ectópicamente	O
genes	B-Sequence
en	O
articulaciones	O
.	O

Pruebas	O
con	O
reportero	O
ratones	B-Taxon
demostrar	O
que	O
este	O
sistema	O
es	O
capaz	O
de	O
modificando	B-Sequence
genes	I-Sequence
en	O
todas	O
las	O
estructuras	O
de	O
la	O
articulación	O
sinovial	O
madura	O
,	O
incluidos	O
los	O
ligamentos	O
de	O
la	O
cápsula	O
articular	O
,	O
la	O
membrana	O
sinovial	O
y	O
el	O
cartílago	O
articular	O
.	O

gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
mutaciones	B-Sequence
en	O
Bmpr1a	B-Protein
y	O
muestra	O
que	O
este	O
receptor	O
es	O
necesario	O
para	O
la	O
formación	O
temprana	O
de	O
articulaciones	O
en	O
algunos	O
lugares	O
y	O
para	O
el	O
inicio	O
de	O
la	O
formación	O
programada	O
célula	B-Cell
muerte	O
en	O
membranas	O
entre	O
los	O
dedos	O
.	O

Curiosamente	O
,	O
Bmpr1a	B-Protein
también	O
se	O
requiere	O
para	O
el	O
mantenimiento	O
posnatal	O
del	O
cartílago	O
articular	O
en	O
la	O
mayor	O
parte	O
del	O
esqueleto	O
.	O

En	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
El	O
cartílago	O
articular	O
inicialmente	O
se	O
forma	O
normalmente	O
,	O
pero	O
posteriormente	O
pierde	O
la	O
expresión	O
de	O
varios	O
marcadores	O
clave	O
del	O
cartílago	O
después	O
del	O
nacimiento	O
.	O

Finalmente	O
se	O
fibrila	O
y	O
degenera	O
,	O
dando	O
como	O
resultado	O
osteoartritis	O
severa	O
y	O
pérdida	O
de	O
movilidad	O
.	O

Estos	O
experimentos	O
sugieren	O
que	O
BMP	B-Protein
se	O
requiere	O
señalización	O
para	O
el	O
mantenimiento	O
normal	O
del	O
cartílago	O
articular	O
postnatal	O
,	O
y	O
esa	O
modulación	O
de	O
la	O
BMP	B-Protein
vía	O
de	O
señalización	O
puede	O
jugar	O
un	O
papel	O
importante	O
en	O
la	O
enfermedad	O
de	O
las	O
articulaciones	O
.	O

Resultados	O

Genético	B-Sequence
Sistema	O
para	O
probar	O
la	O
función	O
de	O
genes	B-Sequence
en	O
Desarrollo	O
Conjunto	O

Generar	O
un	O
sistema	O
general	O
capaz	O
de	O
probar	O
específicamente	O
genes	B-Sequence
para	O
funciones	O
en	O
el	O
desarrollo	O
de	O
las	O
articulaciones	O
esqueléticas	O
,	O
diseñamos	O
transgénico	B-Sequence
ratones	B-Taxon
para	O
expresar	O
la	O
recombinasa	O
Cre	O
en	O
articulaciones	O
en	O
desarrollo	O
(	O
Figura	O
1	O
)	O
.	O

gdf5	B-Protein
es	O
un	O
gene	B-Sequence
fuertemente	O
expresada	O
en	O
franjas	O
a	O
través	O
de	O
elementos	O
esqueléticos	O
en	O
desarrollo	O
durante	O
la	O
formación	O
de	O
articulaciones	O
embrionarias	O
.	O

A	O
cromosoma	B-Sequence
artificial	I-Sequence
bacteriano	I-Sequence
(	O
BAC	B-Sequence
)	O
que	O
contiene	O
el	O
gdf5	B-Protein
lugar	B-Sequence
era	O
modificado	B-Sequence
por	O
recombinación	O
homóloga	O
en	O
bacterias	B-Taxon
para	O
insertar	B-Sequence
a	O
casete	B-Sequence
codificación	O
Cre	O
-	O
sitio	B-Sequence
interno	I-Sequence
de	I-Sequence
entrada	I-Sequence
al	I-Sequence
ribosoma	I-Sequence
(	O
ires	B-Sequence
)	O
-	O
fosfatasa	B-Protein
alcalina	I-Protein
placentaria	I-Protein
humana	I-Protein
(	O
hPLAP	B-Protein
)	O
en	O
el	O
sitio	B-Sequence
de	I-Sequence
inicio	I-Sequence
de	I-Sequence
traducción	I-Sequence
de	O
gdf5	B-Protein
(	O
Figura	O
1A	O
)	O
.	O

Esta	O
BAC	B-Sequence
modificado	I-Sequence
luego	O
se	O
usó	O
para	O
hacer	O
líneas	O
de	O
transgénico	B-Sequence
ratones	B-Taxon
.	O

La	O
resultante	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
transgénico	B-Sequence
ratones	B-Taxon
fueron	O
probados	O
para	O
transgén	B-Sequence
expresión	O
y	O
actividad	O
de	O
la	O
recombinasa	O
Cre	O
al	O
cruzarlos	O
con	O
el	O
reportero	O
R26R	O
ratones	B-Taxon
que	O
activan	O
la	O
expresión	O
de	O
lacZ	O
después	O
de	O
Cre	O
-	O
mediada	O
eliminación	B-Sequence
de	O
secuencias	B-Sequence
de	I-Sequence
parada	I-Sequence
transcripcional	I-Sequence
(	O
Soriano	O
1999	O
)	O
.	O

La	O
progenie	O
resultante	O
se	O
analizó	O
tanto	O
para	O
la	O
expresión	O
de	O
la	O
transgén	B-Sequence
ensayando	O
HPLAP	B-Protein
actividad	O
y	O
para	O
la	O
recombinación	O
de	O
ADN	B-Sequence
analizando	O
la	O
actividad	O
de	O
LACZ	O
.	O

La	O
progenie	O
de	O
las	O
tres	O
líneas	O
mostró	O
una	O
fuerte	O
expresión	O
de	O
LACZ	O
principalmente	O
en	O
las	O
articulaciones	O
y	O
en	O
dos	O
de	O
las	O
tres	O
líneas	O
.	O
HPLAP	B-Protein
la	O
expresión	O
también	O
se	O
podía	O
ver	O
en	O
las	O
regiones	O
conjuntas	O
.	O

Curiosamente	O
,	O
HPLAP	B-Protein
expresión	O
en	O
la	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
transgénico	B-Sequence
Se	O
observó	O
que	O
la	O
línea	O
GAC	O
(	O
A	O
)	O
utilizada	O
para	O
todos	O
los	O
experimentos	O
de	O
reproducción	O
posteriores	O
precede	O
a	O
la	O
expresión	O
de	O
LACZ	O
durante	O
el	O
desarrollo	O
sucesivo	O
de	O
articulaciones	O
en	O
los	O
dedos	O
(	O
Figura	O
1C	O
)	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Estos	O
experimentos	O
demuestran	O
claramente	O
que	O
el	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
transgén	B-Sequence
expresa	O
Cre	O
recombinasa	O
y	O
causa	O
ADN	B-Sequence
recombinación	O
en	O
el	O
desarrollo	O
de	O
regiones	O
conjuntas	O
.	O

CAG	O
(	O
A	O
)	O
ratones	B-Taxon
se	O
cruzaron	O
con	O
la	O
cepa	O
informadora	O
lacZ	O
ROSA26	O
Cre	O
(	O
R26R	O
)	O
ratones	B-Taxon
analizar	O
el	O
patrón	O
de	O
recombinación	O
lacZ	O
mediada	O
por	O
Cre	O
a	O
lo	O
largo	O
del	O
desarrollo	O
.	O

Las	O
articulaciones	O
en	O
las	O
extremidades	O
en	O
desarrollo	O
comienzan	O
a	O
formarse	O
en	O
un	O
patrón	O
proximal-distal	O
,	O
de	O
modo	O
que	O
la	O
articulación	O
del	O
hombro	O
se	O
forma	O
antes	O
que	O
la	O
articulación	O
del	O
codo	O
.	O

Además	O
,	O
la	O
histología	O
ha	O
definido	O
tres	O
etapas	O
principales	O
del	O
desarrollo	O
articular	O
temprano	O
como	O
(	O
1	O
)	O
formación	O
de	O
interzona	O
,	O
(	O
2	O
)	O
formación	O
de	O
interzona	O
de	O
tres	O
capas	O
y	O
(	O
3	O
)	O
cavitación	O
(	O
Mitrovic	O
1978	O
)	O
.	O

De	O
acuerdo	O
con	O
el	O
patrón	O
proximal	O
-	O
distal	O
de	O
desarrollo	O
articular	O
en	O
las	O
extremidades	O
,	O
la	O
actividad	O
de	O
LACZ	O
se	O
observa	O
en	O
el	O
día	O
embrionario	O
12	O
.	O
5	O
(	O
E12	O
.	O
5	O
)	O
en	O
las	O
articulaciones	O
más	O
proximales	O
,	O
incluidos	O
el	O
hombro	O
y	O
la	O
rodilla	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Por	O
E14	O
.	O
5	O
,	O
la	O
expresión	O
de	O
LACZ	O
se	O
ve	O
típicamente	O
en	O
todas	O
las	O
articulaciones	O
de	O
las	O
extremidades	O
excepto	O
en	O
las	O
más	O
distales	O
(	O
Figura	O
1B	O
y	O
1C	O
)	O
,	O
pero	O
con	O
cierta	O
variabilidad	O
tanto	O
en	O
la	O
fuerza	O
como	O
en	O
el	O
grado	O
de	O
expresión	O
de	O
embrión	O
a	O
embrión	O
.	O

Los	O
embriones	O
que	O
se	O
tiñen	O
más	O
intensamente	O
a	O
menudo	O
tienen	O
tinción	O
adicional	O
en	O
las	O
yemas	O
de	O
los	O
dedos	O
(	O
no	O
se	O
ve	O
en	O
el	O
embrión	O
E14.5	O
de	O
la	O
Figura	O
1C	O
,	O
pero	O
es	O
claramente	O
detectable	O
en	O
el	O
embrión	O
E13.5	O
que	O
se	O
muestra	O
en	O
la	O
Figura	O
2	O
)	O
.	O

Las	O
secciones	O
a	O
través	O
de	O
las	O
articulaciones	O
en	O
desarrollo	O
muestran	O
que	O
LACZ	O
está	O
presente	O
en	O
muchos	O
células	B-Cell
en	O
la	O
etapa	O
interzonal	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Sin	O
embargo	O
,	O
la	O
expresión	O
de	O
LACZ	O
en	O
casi	O
el	O
100	O
%	O
de	O
las	O
articulaciones	O
células	B-Cell
no	O
se	O
logra	O
hasta	O
la	O
etapa	O
de	O
interzona	O
de	O
tres	O
capas	O
(	O
por	O
ejemplo	O
,	O
en	O
la	O
articulación	O
de	O
la	O
rodilla	O
en	O
E14.5	O
o	O
en	O
cualquiera	O
de	O
las	O
articulaciones	O
de	O
las	O
falanges	O
en	O
E16.5	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Dentro	O
del	O
esqueleto	O
en	O
desarrollo	O
,	O
la	O
expresión	O
de	O
LACZ	O
mediada	O
por	O
Cre	O
sigue	O
siendo	O
sorprendentemente	O
específica	O
de	O
las	O
articulaciones	O
a	O
lo	O
largo	O
del	O
desarrollo	O
.	O

Además	O
,	O
se	O
observa	O
en	O
todas	O
las	O
estructuras	O
de	O
las	O
articulaciones	O
sinoviales	O
posnatales	O
,	O
incluido	O
el	O
cartílago	O
articular	O
,	O
la	O
cápsula	O
articular	O
y	O
la	O
membrana	O
sinovial	O
(	O
Figura	O
1D	O
y	O
1E	O
)	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Estos	O
patrones	O
son	O
consistentes	O
con	O
la	O
expresión	O
bien	O
establecida	O
de	O
gdf5	B-Protein
en	O
regiones	O
interzonales	O
durante	O
el	O
desarrollo	O
embrionario	O
(	O
Storm	O
y	O
Kingsley	O
1996	O
)	O
.	O

Patrones	O
de	O
expresión	O
adulta	O
de	O
la	O
gdf5	B-Protein
gene	B-Sequence
no	O
están	O
tan	O
bien	O
caracterizados	O
,	O
pero	O
gdf5	B-Protein
la	O
expresión	O
se	O
ha	O
detectado	O
previamente	O
en	O
cartílago	O
articular	O
adulto	O
usando	O
RT-PCR	O
e	O
inmunocitoquímica	O
(	O
Chang	O
et	O
al	O
.	O
1994	O
;	O
Erlacher	O
et	O
al	O
.	O
1998	O
;	O
Bobacz	O
et	O
al	O
.	O
2002	O
)	O
.	O

Otros	O
sitios	O
además	O
de	O
las	O
articulaciones	O
de	O
las	O
extremidades	O
también	O
tienen	O
expresión	O
de	O
lacZ	O
mediada	O
por	O
Cre	O
.	O

A	O
partir	O
de	O
E13	O
.	O
5	O
,	O
se	O
detecta	O
actividad	O
de	O
LACZ	O
en	O
un	O
dominio	O
anterior	O
y	O
posterior	O
del	O
brote	O
de	O
la	O
extremidad	O
(	O
Figura	O
2C	O
)	O
.	O

En	O
E14	O
.	O
5	O
,	O
la	O
actividad	O
de	O
LACZ	O
es	O
detectable	O
en	O
las	O
orejas	O
en	O
desarrollo	O
,	O
las	O
costillas	O
,	O
el	O
esternón	O
,	O
los	O
tejidos	O
de	O
la	O
cara	O
y	O
algunas	O
regiones	O
del	O
cerebro	O
y	O
la	O
médula	O
espinal	O
(	O
Figura	O
1B	O
)	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Al	O
nacer	O
,	O
la	O
LACZ	O
también	O
se	O
expresa	O
en	O
tendones	O
que	O
recorren	O
la	O
columna	O
vertebral	O
,	O
regiones	O
de	O
tendones	O
en	O
la	O
muñeca	O
y	O
el	O
tobillo	O
,	O
y	O
algunas	O
inserciones	O
de	O
tendones	O
(	O
Figura	O
1D	O
)	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Hacia	O
las	O
5	O
semanas	O
de	O
edad	O
,	O
LACZ	O
también	O
se	O
expresa	O
en	O
los	O
folículos	O
pilosos	O
,	O
el	O
cartílago	O
de	O
la	O
oreja	O
,	O
algunos	O
células	B-Cell
en	O
la	O
placa	O
de	O
crecimiento	O
de	O
los	O
huesos	O
largos	O
y	O
porciones	O
del	O
cerebro	O
y	O
la	O
médula	O
espinal	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Sorprendentemente	O
,	O
23	O
de	O
63	O
,	O
o	O
el	O
37	O
%	O
de	O
transgénico	B-Sequence
ratones	B-Taxon
``	O
analizados	O
también	O
muestran	O
cierto	O
grado	O
de	O
expresión	O
LACZ	O
``	O
''	O
ectópica	O
''	O
''	O
más	O
amplia	O
,	O
que	O
puede	O
extenderse	O
a	O
lo	O
largo	O
de	O
muchos	O
tejidos	O
diferentes	O
en	O
el	O
''	O
animal	B-Taxon
.	O

Sin	O
embargo	O
,	O
la	O
expresión	O
sostenida	O
de	O
la	O
transgén	B-Sequence
en	O
sí	O
mismo	O
,	O
según	O
lo	O
analizado	O
por	O
HPLAP	B-Protein
actividad	O
,	O
todavía	O
está	O
restringida	O
principalmente	O
a	O
las	O
articulaciones	O
en	O
animales	B-Taxon
que	O
muestran	O
evidencia	O
de	O
una	O
recombinación	O
más	O
generalizada	O
basada	O
en	O
la	O
expresión	O
LACZ	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Esto	O
sugiere	O
que	O
en	O
una	O
fracción	O
de	O
animales	B-Taxon
,	O
la	O
expresión	O
esporádica	O
de	O
Cre	O
en	O
algún	O
momento	O
temprano	O
en	O
el	O
desarrollo	O
es	O
suficiente	O
para	O
conducir	O
tanto	O
a	O
la	O
recombinación	O
ectópica	O
como	O
a	O
la	O
expresión	O
de	O
LACZ	O
.	O

Mientras	O
que	O
la	O
fracción	O
de	O
animales	B-Taxon
con	O
patrones	O
de	O
recombinación	O
más	O
amplios	O
deben	O
ser	O
rastreados	O
y	O
contabilizados	O
durante	O
los	O
experimentos	O
,	O
estos	O
animales	B-Taxon
ofrecen	O
el	O
beneficio	O
potencial	O
de	O
revelar	O
nuevas	O
funciones	O
adicionales	O
de	O
destino	O
genes	B-Sequence
que	O
podrían	O
ser	O
posteriormente	O
estudiados	O
con	O
sitio	B-Sequence
#	O
¿NOMBRE	O
?	O

gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
animales	B-Taxon
Sobrevivir	O
hasta	O
la	O
edad	O
adulta	O
con	O
defectos	O
en	O
los	O
oídos	O
,	O
membranas	O
y	O
articulaciones	O

A	O
continuación	O
usamos	O
el	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
BMP	B-Protein
Señalización	O
durante	O
el	O
desarrollo	O
normal	O
de	O
las	O
articulaciones	O
.	O

gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
transgénico	B-Sequence
ratones	B-Taxon
fueron	O
criados	O
para	O
animales	B-Taxon
llevando	O
un	O
condicional	O
alelo	B-Sequence
flojo	I-Sequence
de	O
El	O
Bmpr1a	B-Protein
lugar	B-Sequence
(	O
Mishina	O
et	O
al	O
.	O
2002	O
)	O
,	O
generalmente	O
en	O
presencia	O
del	O
reportero	O
R26R	O
alelo	B-Sequence
para	O
facilitar	O
la	O
visualización	O
simultánea	O
de	O
patrones	O
de	O
recombinación	O
mediada	O
por	O
Cre	O
(	O
ver	O
cruce	O
típico	O
en	O
la	O
Figura	O
3	O
)	O
.	O

La	O
amplificación	O
por	O
PCR	O
confirmó	O
que	O
una	O
clave	O
exón	B-Sequence
de	O
El	O
Bmpr1a	B-Protein
gene	B-Sequence
era	O
eliminado	B-Sequence
en	O
ratones	B-Taxon
que	O
también	O
llevaba	O
el	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
transgén	B-Sequence
(	O
datos	O
no	O
publicados	O
)	O
.	O

Estudios	O
previos	O
han	O
demostrado	O
que	O
la	O
Bmpr1afloxP	O
recombinada	O
alelo	B-Sequence
imita	O
un	O
nulo	O
alelo	B-Sequence
de	O
El	O
Bmpr1a	B-Protein
lugar	B-Sequence
cuando	O
se	O
transmite	O
a	O
través	O
de	O
la	O
línea	O
germinal	O
(	O
Mishina	O
et	O
al	O
.	O
2002	O
)	O
.	O

los	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
eran	O
viables	O
y	O
sobrevivieron	O
hasta	O
la	O
edad	O
adulta	O
,	O
lo	O
que	O
demuestra	O
que	O
la	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
animales	B-Taxon
con	O
un	O
nulo	O
mutación	B-Sequence
en	O
el	O
Bmpr1a	B-Protein
lugar	B-Sequence
(	O
Mishina	O
y	O
col.	O
1995	O
)	O
.	O

el	O
viable	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
mostró	O
varios	O
fenotipos	O
.	O

Primero	O
,	O
el	O
nocaut	O
condicional	O
.	O
ratones	B-Taxon
tenían	O
orejas	O
más	O
cortas	O
que	O
a	O
menudo	O
quedaban	O
más	O
planas	O
contra	O
la	O
cabeza	O
que	O
los	O
controles	O
(	O
controles	O
13,1	O
+/-	O
0,1	O
mm	O
de	O
largo	O
,	O
n	O
=	O
38	O
;	O
mutantes	B-Sequence
11	O
8	O
+/-	O
0	O
.	O
2	O
mm	O
,	O
n	O
=	O
11	O
;	O
pag	O
<	O
0	O
.	O
0001	O
)	O
.	O

BMP	B-Protein
Se	O
sabe	O
que	O
la	O
señalización	O
es	O
necesaria	O
para	O
el	O
crecimiento	O
del	O
oído	O
externo	O
de	O
ratones	B-Taxon
(	O
Kingsley	O
et	O
al	O
.	O
1992	O
)	O
,	O
y	O
este	O
fenotipo	O
probablemente	O
refleja	O
la	O
pérdida	O
de	O
Bmpr1a	B-Protein
función	O
en	O
la	O
fracción	O
del	O
oído	O
células	B-Cell
que	O
expresan	O
la	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
transgén	B-Sequence
.	O

Más	O
mutante	B-Sequence
ratones	B-Taxon
también	O
mostraron	O
sindactilia	O
de	O
tejidos	O
blandos	O
o	O
retención	O
de	O
membranas	O
interdigitales	O
entre	O
el	O
primer	O
y	O
segundo	O
dedo	O
de	O
los	O
pies	O
,	O
un	O
fenotipo	O
que	O
fue	O
más	O
frecuente	O
y	O
más	O
severo	O
en	O
las	O
extremidades	O
anteriores	O
(	O
201	O
de	O
220	O
,	O
o	O
91	O
%	O
,	O
de	O
las	O
patas	O
delanteras	O
y	O
109	O
de	O
220	O
,	O
o	O
50	O
%	O
,	O
de	O
patas	O
traseras	O
)	O
.	O

Finalmente	O
,	O
mutante	B-Sequence
animales	B-Taxon
mostró	O
cambios	O
esqueléticos	O
obvios	O
en	O
preparaciones	O
esqueléticas	O
de	O
montaje	O
completo	O
.	O

En	O
algunos	O
sitios	O
de	O
los	O
tobillos	O
,	O
las	O
articulaciones	O
parecían	O
faltar	O
por	O
completo	O
,	O
con	O
fusión	O
de	O
huesos	O
que	O
normalmente	O
estarían	O
separados	O
.	O

Por	O
ejemplo	O
,	O
el	O
segundo	O
tarso	O
distal	O
se	O
fusionó	O
con	O
el	O
hueso	O
del	O
tarso	O
central	O
en	O
cada	O
golpe	O
de	O
gracia	O
condicional	O
.	O
animal	B-Taxon
examinados	O
(	O
18	O
de	O
18	O
)	O
,	O
un	O
fenotipo	O
no	O
observado	O
en	O
los	O
controles	O
(	O
cero	O
de	O
18	O
)	O
(	O
Figura	O
3B	O
y	O
3C	O
)	O
.	O

En	O
otros	O
lugares	O
,	O
las	O
articulaciones	O
se	O
habían	O
formado	O
claramente	O
pero	O
mostraban	O
una	O
pérdida	O
dramática	O
de	O
tinción	O
con	O
el	O
cartílago	O
.	O
matriz	B-GENE
marcador	O
azul	O
alcián	O
(	O
Figura	O
3B-3E	O
)	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Se	O
observó	O
una	O
tinción	O
normal	O
con	O
azul	O
alcián	O
en	O
regiones	O
no	O
articulares	O
,	O
como	O
la	O
placa	O
de	O
crecimiento	O
cartilaginosa	O
(	O
Figura	O
3D	O
y	O
3E	O
,	O
asterisco	O
)	O
.	O

Estos	O
datos	O
sugieren	O
que	O
Bmpr1a	B-Protein
La	O
función	O
es	O
necesaria	O
para	O
la	O
formación	O
de	O
articulaciones	O
específicas	O
en	O
la	O
región	O
del	O
tobillo	O
y	O
para	O
la	O
generación	O
o	O
el	O
mantenimiento	O
del	O
cartílago	O
articular	O
en	O
la	O
mayoría	O
de	O
las	O
demás	O
articulaciones	O
de	O
la	O
extremidad	O
.	O

Origen	O
del	O
desarrollo	O
del	O
fenotipo	O
de	O
tejido	O

El	O
mesénquima	O
interdigital	O
normalmente	O
se	O
elimina	O
por	O
apoptosis	O
durante	O
el	O
desarrollo	O
embrionario	O
,	O
un	O
proceso	O
que	O
puede	O
ser	O
estimulado	O
por	O
BMP	B-Protein
perlas	O
,	O
inhibidas	O
por	O
Noggin	O
,	O
o	O
bloqueadas	O
por	O
la	O
sobreexpresión	O
de	O
dominante	O
-	O
negativo	O
BMP	B-Protein
receptores	O
(	O
García-Martinez	O
et	O
al	O
.	O
1993	O
;	O
Yokouchi	O
et	O
al	O
.	O
1996	O
;	O
Zou	O
y	O
Niswander	O
1996	O
;	O
Guha	O
et	O
al	O
.	O
2002	O
)	O
.	O

extremidades	O
de	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
mutante	B-Sequence
los	O
embriones	O
mostraron	O
una	O
retención	O
evidente	O
de	O
la	O
membrana	O
interdigital	O
entre	O
el	O
primer	O
y	O
el	O
segundo	O
dedo	O
de	O
E14	O
,	O
pero	O
no	O
los	O
demás	O
.	O
5	O
extremidades	O
anteriores	O
(	O
Figura	O
2A	O
y	O
2B	O
)	O
,	O
un	O
patrón	O
que	O
corresponde	O
a	O
la	O
presencia	O
o	O
ausencia	O
de	O
membranas	O
observadas	O
en	O
la	O
extremidad	O
adulta	O
.	O

También	O
mostraron	O
exceso	O
de	O
tejido	O
en	O
el	O
margen	O
posterior	O
del	O
quinto	O
dedo	O
(	O
Figura	O
2B	O
,	O
flecha	O
)	O
.	O

Análisis	O
de	O
la	O
expresión	O
de	O
LACZ	O
en	O
gdf5	B-Protein
Los	O
embriones	O
indicadores	O
Cre/R26R	O
mostraron	O
que	O
E13	O
había	O
producido	O
una	O
recombinación	O
mediada	O
por	O
Cre	O
.	O
5	O
en	O
las	O
articulaciones	O
metacarpiano-falángicas	O
y	O
en	O
la	O
región	O
interdigital	O
entre	O
el	O
primer	O
y	O
el	O
segundo	O
dedo	O
,	O
pero	O
no	O
en	O
otros	O
dedos	O
.	O

Además	O
,	O
también	O
se	O
observa	O
de	O
manera	O
reproducible	O
un	O
dominio	O
de	O
recombinación	O
y	O
expresión	O
de	O
LACZ	O
en	O
la	O
mitad	O
posterior	O
del	O
quinto	O
dígito	O
(	O
Figura	O
2C	O
)	O
.	O

Desoxinucleotidil	B-Protein
transferasa	I-Protein
terminal	I-Protein
#	O
¿NOMBRE	O
?	O
trifosfato	B-Chemical
de	I-Chemical
desoxiuridina	I-Chemical
La	O
tinción	O
con	O
marcaje	O
del	O
extremo	O
de	O
la	O
mella	O
(	O
TUNEL	O
)	O
del	O
mesénquima	O
interdigital	O
entre	O
el	O
primer	O
y	O
el	O
segundo	O
dígito	O
(	O
Figura	O
2D	O
y	O
2E	O
)	O
y	O
el	O
mesénquima	O
que	O
flanquea	O
el	O
quinto	O
dígito	O
mostró	O
una	O
disminución	O
en	O
el	O
número	O
de	O
muertes	O
.	O
células	B-Cell
en	O
las	O
regiones	O
donde	O
el	O
exceso	O
de	O
tejido	O
se	O
retiene	O
en	O
el	O
mutante	B-Sequence
extremidades	O

Números	O
de	O
fosforilados	O
histona	B-Chemical
H3	O
-	O
marcado	O
en	O
proliferación	O
células	B-Cell
también	O
fueron	O
elevados	O
en	O
estas	O
regiones	O
(	O
Figura	O
2F	O
)	O
.	O

Más	O
células	B-Cell
se	O
encuentra	O
en	O
la	O
región	O
palmeada	O
entre	O
el	O
primer	O
y	O
el	O
segundo	O
dígito	O
en	O
E15	O
.	O
5	O
expresaron	O
fuertemente	O
LACZ	O
en	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
mutante	B-Sequence
embriones	O
(	O
Figura	O
2H	O
)	O
.	O

Estos	O
datos	O
sugieren	O
que	O
la	O
pérdida	O
regional	O
de	O
receptor	B-Protein
BMPR1A	I-Protein
bloques	O
de	O
señalización	O
programados	O
célula	B-Cell
muerte	O
en	O
el	O
mesénquima	O
interdigital	O
,	O
y	O
que	O
la	O
recombinación	O
células	B-Cell
sobrevivir	O
y	O
proliferar	O
en	O
ausencia	O
de	O
BMPR1A	B-Protein
señalización	O

Fracaso	O
de	O
la	O
formación	O
articular	O
temprana	O
en	O
las	O
regiones	O
del	O
tobillo	O

los	O
Bmpr1a	B-Protein
gene	B-Sequence
se	O
expresa	O
en	O
la	O
región	O
interzonal	O
de	O
las	O
juntas	O
en	O
desarrollo	O
en	O
E13	O
.	O
5	O
(	O
Baur	O
et	O
al	O
.	O
2000	O
)	O
.	O

La	O
hibridación	O
in	O
situ	O
mostró	O
que	O
la	O
gene	B-Sequence
también	O
se	O
expresa	O
en	O
las	O
interzonas	O
de	O
las	O
articulaciones	O
del	O
tobillo	O
y	O
las	O
posibles	O
regiones	O
de	O
cartílago	O
articular	O
de	O
las	O
articulaciones	O
de	O
los	O
dedos	O
en	O
E15	O
.	O
5	O
(	O
Figura	O
4	O
)	O
.	O

La	O
tinción	O
con	O
LACZ	O
indicó	O
que	O
la	O
recombinación	O
mediada	O
por	O
Cre	O
comienza	O
a	O
ocurrir	O
en	O
las	O
articulaciones	O
del	O
tobillo	O
alrededor	O
de	O
E14	O
.	O
5	O
,	O
y	O
es	O
extenso	O
por	O
E15	O
.	O
5	O
(	O
Figura	O
4G	O
y	O
4J	O
)	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

En	O
las	O
regiones	O
de	O
la	O
articulación	O
del	O
tobillo	O
que	O
obviamente	O
se	O
fusionaron	O
en	O
el	O
postnatal	O
mutante	B-Sequence
animales	B-Taxon
E15	O
también	O
podría	O
observar	O
alteraciones	O
en	O
la	O
expresión	O
temprana	O
de	O
marcadores	O
articulares	O
.	O
5	O
.	O

En	O
esta	O
etapa	O
,	O
el	O
gdf5	B-Protein
gene	B-Sequence
normalmente	O
se	O
expresa	O
en	O
franjas	O
que	O
marcan	O
los	O
sitios	O
de	O
formación	O
conjunta	O
(	O
Figura	O
4F	O
)	O
,	O
y	O
el	O
gene	B-Sequence
para	O
el	O
mayor	O
colágeno	B-Protein
proteína	B-Chemical
de	O
cartílago	O
matriz	B-GENE
(	O
Col2a1	B-Protein
)	O
está	O
regulado	O
a	O
la	O
baja	O
en	O
la	O
región	O
interzona	O
(	O
Figura	O
4E	O
)	O
.	O

A	O
diferencia	O
de	O
,	O
Col2a1	B-Protein
tinción	O
extendida	O
completamente	O
a	O
través	O
de	O
la	O
región	O
articular	O
entre	O
el	O
segundo	O
tarso	O
y	O
el	O
central	O
de	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
mutantes	B-Sequence
(	O
Figura	O
4H	O
,	O
flecha	O
negra	O
)	O
,	O
y	O
gdf5	B-Protein
la	O
expresión	O
se	O
vio	O
sólo	O
como	O
una	O
pequeña	O
muesca	O
que	O
se	O
extendía	O
hacia	O
donde	O
debería	O
estar	O
formándose	O
la	O
unión	O
(	O
Figura	O
4I	O
,	O
paréntesis	O
)	O
.	O

Estos	O
datos	O
sugieren	O
que	O
las	O
fusiones	O
observadas	O
entre	O
los	O
huesos	O
del	O
tobillo	O
en	O
el	O
postnatal	O
mutante	B-Sequence
Los	O
esqueletos	O
son	O
el	O
resultado	O
de	O
una	O
segmentación	O
incompleta	O
de	O
los	O
precursores	O
del	O
esqueleto	O
durante	O
el	O
desarrollo	O
embrionario	O
,	O
un	O
defecto	O
limitado	O
a	O
algunos	O
lugares	O
del	O
tobillo	O
.	O

Falta	O
de	O
mantenimiento	O
del	O
cartílago	O
articular	O
en	O
otras	O
articulaciones	O

En	O
la	O
mayoría	O
de	O
las	O
articulaciones	O
de	O
Bmpr1a	B-Protein
nocaut	O
condicional	O
ratones	B-Taxon
,	O
la	O
segmentación	O
embrionaria	O
de	O
los	O
precursores	O
del	O
esqueleto	O
ocurrió	O
normalmente	O
.	O

Aunque	O
gdf5	B-Protein
La	O
recombinación	O
mediada	O
por	O
Cre	O
se	O
observó	O
ya	O
en	O
E13	O
.	O
5	O
en	O
regiones	O
interzonales	O
de	O
dígitos	O
(	O
ver	O
Figura	O
2C	O
)	O
,	O
sin	O
cambios	O
en	O
célula	B-Cell
muerte	O
o	O
célula	B-Cell
la	O
proliferación	O
podía	O
verse	O
en	O
las	O
articulaciones	O
metacarpiano-falángicas	O
o	O
metatarso-falángicas	O
en	O
E13	O
.	O
5	O
o	O
E14	O
.	O
5	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

De	O
manera	O
similar	O
,	O
aunque	O
E15	O
vio	O
una	O
expresión	O
clara	O
de	O
LACZ	O
.	O
5	O
en	O
articulaciones	O
interfalángicas	O
y	O
regiones	O
periarticulares	O
(	O
Figura	O
4D	O
)	O
,	O
sin	O
diferencia	O
en	O
la	O
morfología	O
o	O
expresión	O
de	O
Col2a1	B-Protein
,	O
gdf5	B-Protein
,	O
o	O
Bmpr1b	B-Protein
se	O
observó	O
en	O
las	O
regiones	O
articulares	O
de	O
las	O
falanges	O
en	O
estas	O
etapas	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Al	O
nacer	O
,	O
las	O
articulaciones	O
de	O
los	O
dedos	O
eran	O
generalmente	O
indistinguibles	O
de	O
las	O
de	O
control	O
.	O
animales	B-Taxon
;	O
condrocitos	B-Cell
eran	O
abundantes	O
en	O
las	O
regiones	O
articulares	O
y	O
estaban	O
rodeadas	O
de	O
cartílago	O
típico	O
matriz	B-GENE
con	O
tinción	O
normal	O
por	O
Safranin	O
O	O
,	O
una	O
tinción	O
histológica	O
para	O
proteoglicanos	B-Chemical
(	O
Figura	O
5	O
)	O
.	O

En	O
esta	O
etapa	O
,	O
ambos	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
mutante	B-Sequence
células	B-Cell
en	O
las	O
regiones	O
articulares	O
también	O
expresaron	O
altos	O
niveles	O
de	O
Col2a1	B-Protein
y	O
agrecano	B-Protein
(	O
agregado	B-Protein
)	O
,	O
los	O
genes	B-Sequence
codificar	O
la	O
estructura	O
principal	O
proteinas	B-Chemical
de	O
cartílago	O
matriz	B-GENE
(	O
Figura	O
5B	O
y	O
5G	O
)	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Sin	O
alteraciones	O
en	O
celular	B-Cell
se	O
observó	O
apoptosis	O
o	O
proliferación	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Para	O
determinar	O
si	O
es	O
articular	O
células	B-Cell
fueron	O
debidamente	O
especificados	O
en	O
mutantes	B-Sequence
,	O
también	O
analizamos	O
la	O
expresión	O
de	O
Matrilín	B-Protein
-	I-Protein
4	I-Protein
(	O
Mat4	B-Protein
)	O
,	O
a	O
gene	B-Sequence
se	O
expresa	O
específicamente	O
en	O
las	O
regiones	O
periarticulares	O
y	O
pericondrales	O
de	O
las	O
articulaciones	O
en	O
desarrollo	O
(	O
Klatt	O
et	O
al	O
.	O
2001	O
)	O
.	O

Tanto	O
en	O
el	O
control	O
como	O
mutante	B-Sequence
animales	B-Taxon
,	O
transcripción	O
de	O
Mat4	B-Protein
era	O
claramente	O
detectable	O
en	O
las	O
capas	O
de	O
cartílago	O
articular	O
de	O
las	O
articulaciones	O
recién	O
nacidas	O
(	O
Figura	O
5D	O
y	O
5I	O
)	O
.	O

En	O
todos	O
los	O
experimentos	O
,	O
la	O
expresión	O
de	O
LACZ	O
en	O
las	O
regiones	O
articulares	O
indicó	O
que	O
se	O
había	O
producido	O
una	O
recombinación	O
mediada	O
por	O
Cre	O
en	O
todas	O
las	O
regiones	O
articulares	O
(	O
Figura	O
5C	O
,	O
5H	O
,	O
5E	O
y	O
5J	O
)	O
.	O

El	O
aspecto	O
histológico	O
normal	O
,	O
las	O
propiedades	O
de	O
tinción	O
y	O
el	O
marcador	O
gene	B-Sequence
patrones	O
de	O
expresión	O
sugieren	O
que	O
Bmpr1a	B-Protein
no	O
se	O
requiere	O
para	O
la	O
formación	O
inicial	O
o	O
especificación	O
del	O
cartílago	O
articular	O
.	O

Una	O
semana	O
después	O
del	O
nacimiento	O
,	O
comenzaron	O
a	O
detectarse	O
diferencias	O
obvias	O
en	O
las	O
regiones	O
articulares	O
de	O
mutante	B-Sequence
animales	B-Taxon
.	O

la	O
expresión	O
de	O
Col2a1	B-Protein
se	O
redujo	O
a	O
lo	O
largo	O
de	O
las	O
superficies	O
articulares	O
de	O
los	O
carpianos	O
,	O
metacarpianos	O
y	O
falanges	O
de	O
los	O
pies	O
anteriores	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

También	O
se	O
observaron	O
reducciones	O
menos	O
severas	O
en	O
la	O
articulación	O
células	B-Cell
de	O
tarsianos	O
y	O
metatarsianos	O
en	O
las	O
patas	O
traseras	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

A	O
las	O
2	O
semanas	O
de	O
edad	O
,	O
Col2a1	B-Protein
la	O
expresión	O
se	O
redujo	O
en	O
la	O
mayoría	O
células	B-Cell
de	O
la	O
región	O
articular	O
(	O
Figura	O
5L	O
y	O
5Q	O
)	O
,	O
acompañada	O
de	O
tinción	O
marcadamente	O
reducida	O
de	O
Safranina	O
O	O
(	O
Figura	O
5K	O
y	O
5P	O
)	O
y	O
disminución	O
de	O
la	O
expresión	O
de	O
agregado	B-Protein
y	O
dos	O
genes	B-Sequence
normalmente	O
expresado	O
en	O
articulares	O
más	O
maduros	O
células	B-Cell
de	I-Cell
cartílago	I-Cell
,	O
Colágeno	B-Protein
3	I-Protein
(	O
Col3a1	B-Protein
)	O
y	O
Colágeno	B-Protein
10	I-Protein
(	O
Col10a1	B-Protein
)	O
(	O
Figura	O
5M	O
y	O
5R	O
)	O
(	O
datos	O
no	O
publicados	O
)	O
(	O
Eyre	O
2002	O
)	O
.	O

Inhibición	O
de	O
BMP	B-Protein
señalización	O
en	O
culto	O
condrocitos	B-Cell
previamente	O
se	O
ha	O
informado	O
que	O
induce	O
Colágeno	B-Protein
1	I-Protein
(	O
Col1a1	B-Protein
)	O
expresión	O
,	O
aumentar	O
la	O
proliferación	O
y	O
dar	O
como	O
resultado	O
células	B-Cell
con	O
aplanado	O
,	O
fibroblasto	B-Cell
como	O
morfología	O
(	O
Enomoto	O
-	O
Iwamoto	O
et	O
al	O
.	O
1998	O
)	O
.	O

Sin	O
embargo	O
,	O
no	O
vimos	O
ningún	O
aumento	O
en	O
la	O
expresión	O
de	O
Col1a1	B-Protein
en	O
mutante	B-Sequence
cartílago	O
articular	O
,	O
y	O
no	O
se	O
detectó	O
proliferación	O
en	O
articular	O
células	B-Cell
de	O
cualquiera	O
de	O
las	O
mutante	B-Sequence
o	O
controlar	O
animales	B-Taxon
(	O
datos	O
no	O
publicados	O
)	O
.	O

Si	O
bien	O
se	O
detectó	O
la	O
expresión	O
del	O
marcador	O
LACZ	O
recombinado	O
en	O
la	O
mayoría	O
de	O
los	O
células	B-Cell
de	I-Cell
cartílago	I-Cell
,	O
también	O
se	O
observó	O
en	O
subarticulares	O
dispersos	O
condrocitos	B-Cell
,	O
placa	O
de	O
crecimiento	O
condrocitos	B-Cell
,	O
y	O
osteoblastos	B-Cell
(	O
Figura	O
5O	O
y	O
5T	O
)	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Aunque	O
esto	O
implica	O
que	O
BMP	B-Protein
la	O
señalización	O
era	O
defectuosa	O
en	O
múltiples	O
célula	B-Cell
tipos	O
,	O
los	O
defectos	O
observados	O
se	O
limitaron	O
al	O
cartílago	O
articular	O
.	O

Por	O
ejemplo	O
,	O
osteocalcina	B-Protein
y	O
Col1a1	B-Protein
expresión	O
parecía	O
normal	O
en	O
osteoblastos	B-Cell
(	O
datos	O
no	O
publicados	O
)	O
.	O

Juntos	O
,	O
estos	O
datos	O
sugieren	O
que	O
BMPR1A	B-Protein
Se	O
requiere	O
actividad	O
en	O
el	O
cartílago	O
articular	O
de	O
la	O
articulación	O
posnatal	O
para	O
mantener	O
la	O
expresión	O
de	O
muchos	O
genes	B-Sequence
codificación	O
estructural	O
componentes	B-GENE
de	I-GENE
la	I-GENE
matriz	I-GENE
del	I-GENE
cartílago	I-GENE
.	O

Estudios	O
previos	O
han	O
demostrado	O
que	O
medias9	B-Protein
se	O
requiere	O
para	O
la	O
diferenciación	O
normal	O
del	O
cartílago	O
,	O
para	O
la	O
expresión	O
del	O
cartílago	O
la	B-GENE
matriz	I-GENE
extracelular	I-GENE
(	O
ECM	B-GENE
)	O
genes	B-Sequence
incluso	O
agregado	B-Protein
y	O
es	O
un	O
regulador	O
transcripcional	O
directo	O
del	O
cartílago	O
clave	O
matriz	B-GENE
gene	B-Sequence
Col2a1	B-Protein
(	O
Bell	O
et	O
al	O
.	O
1997	O
;	O
Lefebvre	O
et	O
al	O
.	O
1997	O
;	O
Bi	O
et	O
al	O
.	O
1999	O
;	O
Sekiya	O
et	O
al	O
.	O
2000	O
)	O
.	O

En	O
particular	O
,	O
a	O
pesar	O
de	O
la	O
expresión	O
reducida	O
de	O
muchos	O
cartílagos	O
matriz	B-GENE
marcador	O
genes	B-Sequence
en	O
Bmpr1a	B-Protein
mutante	B-Sequence
ratones	B-Taxon
,	O
los	O
SOX9	B-Protein
proteína	B-Chemical
estuvo	O
presente	O
en	O
niveles	O
normales	O
en	O
las	O
regiones	O
articulares	O
en	O
todas	O
las	O
etapas	O
examinadas	O
,	O
incluido	O
el	O
recién	O
nacido	O
,	O
2	O
semanas	O
de	O
edad	O
,	O
7	O
semanas	O
de	O
edad	O
y	O
9	O
meses	O
de	O
edad	O
ratones	B-Taxon
(	O
Figura	O
5N	O
y	O
5S	O
)	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Hipertrofia	O
sinovial	O
,	O
erosión	O
del	O
cartílago	O
y	O
maduración	O
acelerada	O
del	O
cartílago	O

Pérdida	O
condicional	O
de	O
Bmpr1a	B-Protein
condujo	O
a	O
una	O
marcada	O
hipertrofia	O
de	O
la	O
membrana	O
sinovial	O
en	O
la	O
cápsula	O
articular	O
de	O
algunas	O
articulaciones	O
,	O
particularmente	O
en	O
la	O
región	O
del	O
tobillo	O
.	O

En	O
las	O
articulaciones	O
más	O
severamente	O
afectadas	O
,	O
la	O
membrana	O
sinovial	O
expandida	O
creció	O
dentro	O
del	O
espacio	O
articular	O
y	O
se	O
asoció	O
con	O
pérdida	O
o	O
erosión	O
obvia	O
del	O
cartílago	O
articular	O
(	O
Figura	O
6A	O
y	O
6B	O
,	O
asteriscos	O
,	O
flechas	O
)	O
.	O

Maduración	O
acelerada	O
del	O
cartílago	O
y	O
aumento	O
de	O
la	O
expresión	O
de	O
Col10a1	B-Protein
se	O
veía	O
con	O
frecuencia	O
en	O
el	O
condrocitos	B-Cell
subyacentes	O
a	O
las	O
erosiones	O
articulares	O
(	O
Figura	O
6C	O
y	O
6D	O
,	O
corchetes	O
)	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Curiosamente	O
,	O
las	O
regiones	O
de	O
mayor	O
Col10a1	B-Protein
la	O
expresión	O
no	O
correspondía	O
a	O
las	O
regiones	O
que	O
habían	O
sufrido	O
recombinación	O
mediada	O
por	O
Cre	O
.	O

En	O
cambio	O
,	O
una	O
mayor	O
expresión	O
de	O
Col10a1	B-Protein
fue	O
visto	O
en	O
una	O
zona	O
de	O
mayor	O
parte	O
de	O
LACZ	O
-	O
negativo	O
células	B-Cell
que	O
se	O
extiende	O
desde	O
el	O
cartílago	O
adyacente	O
al	O
frente	O
de	O
osificación	O
(	O
donde	O
Col10a1	B-Protein
normalmente	O
se	O
expresa	O
en	O
la	O
maduración	O
células	B-Cell
de	I-Cell
cartílago	I-Cell
)	O
,	O
hacia	O
las	O
regiones	O
donde	O
el	O
cartílago	O
articular	O
superficial	O
estaba	O
severamente	O
erosionado	O
o	O
faltaba	O
(	O
Figura	O
6A	O
y	O
6B	O
,	O
puntas	O
de	O
flecha	O
)	O
.	O

Estudios	O
previos	O
sugieren	O
que	O
hormona	B-Protein
paratiroidea	I-Protein
-	I-Protein
proteína	I-Protein
relacionada	I-Protein
,	O
una	O
señal	O
difusible	O
hecha	O
en	O
la	O
superficie	O
articular	O
,	O
normalmente	O
puede	O
inhibir	O
la	O
maduración	O
del	O
cartílago	O
subyacente	O
(	O
Vortkamp	O
et	O
al	O
.	O
1996	O
;	O
Weir	O
et	O
al	O
.	O
1996	O
)	O
.	O

La	O
pérdida	O
local	O
de	O
la	O
superficie	O
articular	O
podría	O
eliminar	O
esta	O
inhibición	O
y	O
dar	O
lugar	O
a	O
una	O
célula	B-Cell
#	O
¿NOMBRE	O
?	O
condrocitos	B-Cell
puntos	O
subyacentes	O
de	O
erosión	O
articular	O
.	O

Esta	O
hipertrofia	O
sinovial	O
se	O
asocia	O
con	O
un	O
mayor	O
número	O
de	O
células	B-Cell
mononucleares	I-Cell
parecido	O
a	O
sinoviocitos	B-Cell
o	O
macrófagos	B-Cell
,	O
célula	B-Cell
tipos	O
que	O
son	O
difíciles	O
de	O
distinguir	O
incluso	O
con	O
superficie	B-GENE
marcadores	O
en	O
etapas	O
postnatales	O
tempranas	O
.	O

Sin	O
embargo	O
,	O
no	O
neutrófilos	B-Cell
se	O
observaron	O
,	O
lo	O
que	O
sugiere	O
que	O
hay	O
poca	O
inflamación	O
.	O

En	O
etapas	O
posteriores	O
se	O
reduce	O
la	O
hipertrofia	O
sinovial	O
.	O

Será	O
necesario	O
seguir	O
trabajando	O
para	O
determinar	O
si	O
el	O
desarrollo	O
sinovial	O
está	O
regulado	O
por	O
BMP	B-Protein
señalización	O
,	O
o	O
si	O
la	O
membrana	O
sinovial	O
aumenta	O
de	O
tamaño	O
como	O
respuesta	O
a	O
malformaciones	O
esqueléticas	O
cercanas	O
(	O
como	O
la	O
fusión	O
de	O
los	O
tarsianos	O
segundo	O
y	O
central	O
o	O
defectos	O
en	O
el	O
cartílago	O
articular	O
)	O
.	O

Degeneración	O
no	O
inflamatoria	O
del	O
cartílago	O
articular	O
en	O
las	O
articulaciones	O
de	O
los	O
dedos	O
y	O
la	O
rodilla	O

Fuera	O
de	O
la	O
región	O
del	O
tobillo	O
,	O
se	O
observó	O
poca	O
o	O
ninguna	O
evidencia	O
de	O
expansión	O
de	O
la	O
membrana	O
sinovial	O
.	O

En	O
lugar	O
de	O
,	O
mutante	B-Sequence
ratones	B-Taxon
mostró	O
signos	O
histológicos	O
de	O
artrosis	O
,	O
como	O
fibrilación	O
de	O
la	O
superficie	O
articular	O
(	O
Figura	O
7	O
)	O
.	O

Como	O
se	O
vio	O
anteriormente	O
en	O
1	O
-	O
y	O
2	O
-	O
wk	O
-	O
old	O
animales	B-Taxon
,	O
tinción	O
con	O
safranina	O
O	O
y	O
agregado	B-Protein
y	O
Col10	B-Protein
expresión	O
se	O
redujeron	O
en	O
mutante	B-Sequence
regiones	O
articulares	O
de	O
las	O
patas	O
delanteras	O
y	O
traseras	O
a	O
las	O
7	O
semanas	O
de	O
edad	O
,	O
y	O
se	O
observaron	O
los	O
primeros	O
signos	O
de	O
pérdida	O
de	O
cartílago	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

A	O
los	O
9	O
meses	O
de	O
edad	O
,	O
muchas	O
regiones	O
del	O
cartílago	O
articular	O
faltaban	O
por	O
completo	O
o	O
estaban	O
extremadamente	O
fibriladas	O
,	O
dejando	O
regiones	O
de	O
hueso	O
expuesto	O
en	O
la	O
superficie	O
(	O
Figura	O
7A-7D	O
)	O
.	O

No	O
se	O
observaron	O
alteraciones	O
en	O
la	O
expresión	O
de	O
osteocalcina	B-Protein
,	O
Col1a1	B-Protein
,	O
o	O
metaloproteasa	B-Protein
de	I-Protein
matriz	I-Protein
-	I-Protein
13	I-Protein
a	O
las	O
7	O
semanas	O
o	O
a	O
los	O
9	O
meses	O
.	O

La	O
principal	O
articulación	O
que	O
soporta	O
el	O
peso	O
de	O
la	O
pata	O
trasera	O
,	O
la	O
rodilla	O
,	O
mostró	O
cambios	O
muy	O
parecidos	O
a	O
los	O
observados	O
en	O
las	O
articulaciones	O
de	O
los	O
pies	O
.	O

Todos	O
los	O
marcadores	O
de	O
cartílago	O
matriz	B-GENE
parecía	O
similar	O
a	O
los	O
controles	O
en	O
E16	O
.	O
5	O
,	O
lo	O
que	O
sugiere	O
que	O
las	O
primeras	O
etapas	O
de	O
formación	O
conjunta	O
no	O
se	O
interrumpieron	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Para	O
el	O
día	O
7	O
posnatal	O
,	O
tinción	O
con	O
safranina	O
O	O
y	O
Col2a1	B-Protein
y	O
agregado	B-Protein
expresión	O
se	O
redujeron	O
claramente	O
en	O
el	O
mutante	B-Sequence
,	O
a	O
pesar	O
de	O
la	O
continua	O
expresión	O
de	O
medias9	B-Protein
(	O
datos	O
no	O
publicados	O
)	O
.	O

La	O
forma	O
general	O
de	O
mutante	B-Sequence
Los	O
elementos	O
del	O
esqueleto	O
de	O
la	O
rodilla	O
parecían	O
similares	O
a	O
los	O
controles	O
,	O
aunque	O
el	O
menisco	O
fibrocartilaginoso	O
que	O
reside	O
entre	O
el	O
fémur	O
y	O
la	O
tibia	O
parecía	O
mucho	O
menos	O
denso	O
en	O
los	O
controles	O
.	O
mutantes	B-Sequence
en	O
E16	O
.	O
5	O
.	O

Se	O
formó	O
algo	O
de	O
cartílago	O
en	O
la	O
región	O
del	O
menisco	O
,	O
pero	O
el	O
tamaño	O
de	O
estos	O
elementos	O
se	O
redujo	O
mucho	O
y	O
contenía	O
abundante	O
células	B-Cell
con	O
apariencia	O
fibrosa	O
,	O
no	O
cartilaginosa	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Esta	O
reducción	O
del	O
menisco	O
también	O
se	O
puede	O
ver	O
en	O
secciones	O
de	O
7	O
semanas	O
y	O
9	O
meses	O
de	O
edad	O
.	O
animales	B-Taxon
(	O
Figura	O
7E	O
,	O
7H	O
,	O
7K	O
y	O
7N	O
,	O
flechas	O
)	O
.	O

A	O
las	O
7	O
semanas	O
de	O
edad	O
,	O
la	O
epífisis	O
tibial	O
normalmente	O
abovedada	O
estaba	O
aplanada	O
y	O
deprimida	O
en	O
las	O
rodillas	O
de	O
mutante	B-Sequence
animales	B-Taxon
,	O
reduciendo	O
notablemente	O
la	O
distancia	O
entre	O
la	O
placa	O
de	O
crecimiento	O
y	O
la	O
superficie	O
articular	O
(	O
Figura	O
7E	O
y	O
7H	O
,	O
barra	O
vertical	O
)	O
.	O

El	O
cartílago	O
articular	O
también	O
era	O
más	O
delgado	O
que	O
en	O
el	O
control	O
animales	B-Taxon
,	O
mostró	O
una	O
ausencia	O
casi	O
completa	O
de	O
tinción	O
con	O
safranina	O
O	O
y	O
era	O
acelular	O
o	O
comenzaba	O
a	O
fibrilar	O
en	O
muchas	O
regiones	O
(	O
Figura	O
7F	O
y	O
7I	O
)	O
.	O

Los	O
pocos	O
grandes	O
Safranin	O
O	O
-	O
teñidos	O
células	B-Cell
aún	O
evidente	O
en	O
mutante	B-Sequence
regiones	O
articulares	O
parecían	O
corresponder	O
en	O
posición	O
a	O
LACZ	O
raro	O
-	O
negativo	O
células	B-Cell
en	O
secciones	O
adyacentes	O
,	O
sugiriendo	O
que	O
Bmpr1a	B-Protein
es	O
requerido	O
célula	B-Cell
-	O
de	O
forma	O
autónoma	O
en	O
el	O
cartílago	O
articular	O
(	O
Figura	O
7I	O
y	O
7J	O
,	O
puntas	O
de	O
flecha	O
blancas	O
)	O
.	O

A	O
los	O
9	O
meses	O
,	O
grandes	O
áreas	O
de	O
mutante	B-Sequence
las	O
rodillas	O
estaban	O
desprovistas	O
de	O
articulación	O
células	B-Cell
,	O
y	O
los	O
huesos	O
del	O
fémur	O
y	O
la	O
tibia	O
parecían	O
frotarse	O
directamente	O
uno	O
contra	O
el	O
otro	O
.	O

Además	O
,	O
la	O
epífisis	O
de	O
la	O
tibia	O
estaba	O
extremadamente	O
deprimida	O
,	O
hasta	O
el	O
punto	O
de	O
que	O
el	O
cartílago	O
de	O
la	O
placa	O
de	O
crecimiento	O
estaba	O
casi	O
expuesto	O
a	O
través	O
de	O
la	O
superficie	O
del	O
hueso	O
(	O
Figura	O
7K	O
,	O
7L	O
,	O
7N	O
y	O
7O	O
)	O
.	O

Además	O
,	O
mutantes	B-Sequence
a	O
las	O
7	O
semanas	O
y	O
9	O
meses	O
mostró	O
esclerosis	O
subcondral	O
,	O
especialmente	O
en	O
la	O
epífisis	O
del	O
fémur	O
(	O
Figura	O
7E	O
,	O
7H	O
,	O
7K	O
y	O
7N	O
,	O
asteriscos	O
)	O
.	O

Si	O
bien	O
la	O
esclerosis	O
subcondral	O
se	O
observa	O
comúnmente	O
en	O
casos	O
de	O
osteoartritis	O
,	O
no	O
está	O
claro	O
en	O
este	O
caso	O
si	O
la	O
esclerosis	O
es	O
principalmente	O
una	O
respuesta	O
de	O
la	O
formación	O
ósea	O
para	O
compensar	O
la	O
disminución	O
del	O
cartílago	O
articular	O
,	O
o	O
si	O
es	O
el	O
efecto	O
de	O
la	O
pérdida	O
de	O
Bmpr1a	B-Protein
señalización	O
en	O
algunos	O
LACZ	O
-	O
positivo	O
células	B-Cell
que	O
también	O
se	O
observan	O
en	O
estas	O
regiones	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Los	O
signos	O
histológicos	O
de	O
la	O
artritis	O
articular	O
se	O
acompañaron	O
de	O
deficiencias	O
funcionales	O
tanto	O
en	O
la	O
capacidad	O
de	O
agarre	O
como	O
en	O
el	O
rango	O
de	O
movimiento	O
en	O
mutante	B-Sequence
animales	B-Taxon
.	O

gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
mutante	B-Sequence
animales	B-Taxon
mostró	O
una	O
capacidad	O
muy	O
significativamente	O
reducida	O
para	O
agarrar	O
y	O
permanecer	O
suspendido	O
en	O
una	O
barra	O
delgada	O
(	O
tiempo	O
medio	O
de	O
suspensión	O
:	O
controles	O
38	O
+/-	O
6	O
s	O
,	O
n	O
=	O
39	O
;	O
mutantes	B-Sequence
6	O
+/-	O
3	O
s	O
,	O
n	O
=	O
11	O
;	O
pag	O
<	O
0	O
.	O
0001	O
)	O
.	O

mutante	B-Sequence
ratones	B-Taxon
también	O
mostró	O
una	O
clara	O
disminución	O
en	O
el	O
rango	O
máximo	O
de	O
movilidad	O
de	O
dos	O
articulaciones	O
diferentes	O
en	O
los	O
dedos	O
,	O
según	O
lo	O
evaluado	O
por	O
manipulación	O
pasiva	O
(	O
articulación	O
MT/P1	O
:	O
controles	O
100	O
+/-	O
0	O
grados	O
,	O
n	O
=	O
26	O
;	O
mutantes	B-Sequence
82	O
+/-	O
3	O
grados	O
,	O
n	O
=	O
8	O
;	O
pag	O
<	O
0	O
.	O
0003	O
;	O
Articulación	O
P1/P2	O
:	O
controles	O
152	O
+/-	O
1	O
grados	O
,	O
n	O
=	O
23	O
;	O
mutantes	B-Sequence
140	O
+/-	O
5	O
grados	O
,	O
n	O
=	O
6	O
;	O
pag	O
<	O
0	O
.	O
05	O
)	O
.	O

El	O
marcador	O
estructural	O
,	O
histológico	O
.	O
gene	B-Sequence
expresión	O
y	O
cambios	O
funcionales	O
en	O
mutante	B-Sequence
ratones	B-Taxon
demostrar	O
que	O
BMPR1A	B-Protein
se	O
requiere	O
para	O
el	O
mantenimiento	O
posnatal	O
normal	O
del	O
cartílago	O
articular	O
.	O

Discusión	O

Estudios	O
previos	O
sugieren	O
que	O
BMP	B-Protein
la	O
señalización	O
está	O
involucrada	O
en	O
un	O
gran	O
número	O
de	O
eventos	O
de	O
desarrollo	O
.	O

Muchos	O
de	O
estos	O
eventos	O
ocurren	O
temprano	O
en	O
la	O
embriogénesis	O
y	O
la	O
inactivación	O
completa	O
de	O
BMP	B-Protein
Los	O
receptores	O
causan	O
la	O
muerte	O
por	O
E9	O
.	O
5	O
(	O
Mishina	O
et	O
al	O
.	O
1995	O
)	O
.	O

los	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
Bmpr1a	B-Protein
mutaciones	B-Sequence
,	O
y	O
proporciona	O
nueva	O
información	O
importante	O
sobre	O
el	O
papel	O
de	O
este	O
receptor	O
en	O
el	O
desarrollo	O
de	O
las	O
extremidades	O
y	O
el	O
esqueleto	O
.	O

Los	O
tres	O
principales	O
fenotipos	O
de	O
las	O
extremidades	O
revelados	O
por	O
eliminando	B-Sequence
Bmpr1a	B-Protein
con	O
gdf5	B-Protein
Las	O
Cre	O
impulsadas	O
incluyen	O
membranas	O
entre	O
los	O
dedos	O
,	O
falta	O
de	O
formación	O
de	O
articulaciones	O
en	O
lugares	O
específicos	O
del	O
tobillo	O
y	O
falta	O
de	O
mantenimiento	O
del	O
cartílago	O
articular	O
después	O
del	O
nacimiento	O
,	O
lo	O
que	O
resulta	O
en	O
artritis	O
severa	O
.	O

Estudios	O
previos	O
han	O
demostrado	O
que	O
la	O
manipulación	O
de	O
BMP	B-Protein
la	O
señalización	O
altera	O
la	O
apoptosis	O
interdigital	O
durante	O
el	O
desarrollo	O
de	O
la	O
extremidad	O
,	O
pero	O
ningún	O
experimento	O
ha	O
identificado	O
a	O
un	O
miembro	O
específico	O
de	O
la	O
BMP	B-Protein
vía	O
de	O
señalización	O
que	O
se	O
requiere	O
para	O
este	O
proceso	O
(	O
Yokouchi	O
et	O
al	O
.	O
1996	O
;	O
Zou	O
y	O
Niswander	O
1996	O
;	O
Zou	O
et	O
al	O
.	O
1997	O
;	O
Guha	O
et	O
al	O
.	O
2002	O
)	O
.	O

Nuestros	O
nuevos	O
datos	O
de	O
pérdida	O
de	O
función	O
confirman	O
que	O
BMP	B-Protein
se	O
requiere	O
señalización	O
para	O
la	O
apoptosis	O
interdigital	O
y	O
sugiere	O
que	O
Bmpr1a	B-Protein
es	O
un	O
componente	O
crítico	O
para	O
mediar	O
esta	O
señal	O
.	O

En	O
algunos	O
sitios	O
,	O
la	O
pérdida	O
de	O
Bmpr1a	B-Protein
La	O
función	O
conduce	O
a	O
un	O
defecto	O
en	O
las	O
primeras	O
etapas	O
de	O
la	O
formación	O
de	O
la	O
articulación	O
,	O
lo	O
que	O
resulta	O
en	O
una	O
falla	O
total	O
para	O
formar	O
una	O
articulación	O
y	O
la	O
fusión	O
de	O
los	O
huesos	O
en	O
el	O
tobillo	O
.	O

Mutaciones	B-Sequence
en	O
dos	O
ligandos	O
diferentes	O
en	O
el	O
BMP	B-Protein
familia	O
,	O
gdf5	B-Protein
y	O
gdf6	B-Protein
,	O
los	O
Bmpr1b	B-Protein
receptor	O
y	O
en	O
el	O
cabeza	B-Protein
humana	I-Protein
lugar	B-Sequence
(	O
Storm	O
y	O
Kingsley	O
1996	O
;	O
Gong	O
et	O
al	O
.	O
1999	O
;	O
Baur	O
et	O
al	O
.	O
2000	O
;	O
Yi	O
et	O
al	O
.	O
2000	O
;	O
Settle	O
et	O
al	O
.	O
2003	O
)	O
también	O
producen	O
defectos	O
en	O
la	O
formación	O
de	O
articulaciones	O
en	O
lugares	O
específicos	O
de	O
las	O
extremidades	O
.	O

Los	O
defectos	O
articulares	O
asociados	O
con	O
múltiples	O
componentes	O
del	O
BMP	B-Protein
camino	O
proporcionan	O
una	O
fuerte	O
evidencia	O
de	O
que	O
BMP	B-Protein
la	O
señalización	O
es	O
necesaria	O
para	O
las	O
primeras	O
etapas	O
de	O
la	O
formación	O
de	O
articulaciones	O
en	O
algunas	O
ubicaciones	O
anatómicas	O
.	O

La	O
mayoría	O
de	O
las	O
articulaciones	O
todavía	O
se	O
forman	O
normalmente	O
cuando	O
Bmpr1a	B-Protein
es	O
noqueado	O
en	O
gdf5	B-Protein
dominios	O
de	O
expresión	O
.	O

La	O
falta	O
de	O
fusiones	O
articulares	O
fuera	O
de	O
la	O
región	O
del	O
tobillo	O
podría	O
deberse	O
a	O
diferencias	O
en	O
los	O
requisitos	O
para	O
BMP	B-Protein
señalización	O
en	O
diferentes	O
articulaciones	O
,	O
para	O
compensar	O
la	O
expresión	O
de	O
otras	O
BMP	B-Protein
receptores	O
fuera	O
de	O
los	O
tobillos	O
,	O
o	O
a	O
diferencias	O
en	O
el	O
momento	O
detallado	O
de	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
gene	B-Sequence
inactivación	O
en	O
tobillos	O
y	O
otras	O
regiones	O
articulares	O
.	O

Comparación	O
de	O
la	O
expresión	O
de	O
la	O
HPLAP	B-Protein
marcador	O
(	O
impulsado	O
directamente	O
por	O
gdf5	B-Protein
elementos	O
de	O
control	O
)	O
y	O
el	O
marcador	O
R26R	O
LACZ	O
(	O
expresado	O
a	O
continuación	O
gdf5	B-Protein
-	O
Cre	O
recombination	O
)	O
sugiere	O
que	O
la	O
recombinación	O
-	O
estimuló	O
cambios	O
en	O
gene	B-Sequence
la	O
expresión	O
puede	O
retrasarse	O
por	O
un	O
0	O
.	O
5	O
-	O
1	O
d	O
en	O
la	O
región	O
de	O
dígitos	O
(	O
ver	O
Figura	O
1C	O
)	O
.	O

Además	O
,	O
los	O
niveles	O
de	O
Bmpr1a	B-Protein
ARNm	B-Chemical
y	O
proteína	B-Chemical
puede	O
persistir	O
durante	O
algún	O
tiempo	O
después	O
gdf5	B-Protein
-	O
Cre	O
estimuló	O
la	O
recombinación	O
,	O
lo	O
que	O
hizo	O
posible	O
eludir	O
un	O
requisito	O
temprano	O
para	O
Bmpr1a	B-Protein
en	O
formación	O
conjunta	O
en	O
algunos	O
lugares	O
.	O

Tras	O
la	O
decadencia	O
de	O
Bmpr1a	B-Protein
ARNm	B-Chemical
y	O
proteína	B-Chemical
,	O
los	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
Bmpr1a	B-Protein
función	O
en	O
recombinado	O
células	B-Cell
.	O

Este	O
sistema	O
proporciona	O
así	O
uno	O
de	O
los	O
primeros	O
fuertes	O
genético	B-Sequence
pruebas	O
de	O
Bmpr1a	B-Protein
función	O
en	O
etapas	O
posteriores	O
del	O
desarrollo	O
conjunto	O
.	O

A	O
pesar	O
de	O
la	O
apariencia	O
normal	O
de	O
las	O
regiones	O
articulares	O
y	O
gene	B-Sequence
expresión	O
inmediatamente	O
después	O
del	O
nacimiento	O
,	O
Bmpr1a	B-Protein
#	O
¿NOMBRE	O
?	O
animales	B-Taxon
son	O
incapaces	O
de	O
mantener	O
el	O
estado	O
diferenciado	O
normal	O
del	O
cartílago	O
articular	O
a	O
medida	O
que	O
continúan	O
desarrollándose	O
y	O
envejeciendo	O
.	O

Estos	O
resultados	O
sugieren	O
que	O
BMP	B-Protein
la	O
señalización	O
del	O
receptor	O
es	O
esencial	O
para	O
la	O
salud	O
e	O
integridad	O
continuas	O
del	O
cartílago	O
articular	O
en	O
el	O
período	O
posnatal	O
.	O

El	O
cartílago	O
articular	O
es	O
un	O
componente	O
clave	O
de	O
las	O
articulaciones	O
sinoviales	O
y	O
es	O
una	O
de	O
las	O
pocas	O
regiones	O
del	O
esqueleto	O
donde	O
el	O
cartílago	O
se	O
mantiene	O
hasta	O
la	O
edad	O
adulta	O
.	O

A	O
pesar	O
de	O
la	O
importancia	O
del	O
cartílago	O
articular	O
en	O
la	O
salud	O
y	O
la	O
movilidad	O
de	O
las	O
articulaciones	O
,	O
se	O
sabe	O
poco	O
sobre	O
los	O
factores	O
que	O
lo	O
crean	O
y	O
lo	O
mantienen	O
en	O
capas	O
delgadas	O
en	O
los	O
extremos	O
de	O
los	O
huesos	O
largos	O
.	O

En	O
nuestros	O
experimentos	O
,	O
cartílago	O
articular	O
carente	O
Bmpr1a	B-Protein
conserva	O
algunas	O
características	O
normales	O
,	O
en	O
el	O
sentido	O
de	O
que	O
mantiene	O
una	O
tasa	O
de	O
proliferación	O
muy	O
baja	O
,	O
no	O
expresa	O
Col1a1	B-Protein
,	O
y	O
sigue	O
expresando	O
SOX9	B-Protein
,	O
un	O
importante	O
factor	O
de	O
transcripción	O
que	O
regula	O
la	O
expresión	O
de	O
estructuras	O
componentes	B-GENE
de	I-GENE
la	I-GENE
matriz	I-GENE
del	I-GENE
cartílago	I-GENE
.	O

Sin	O
embargo	O
,	O
varios	O
de	O
los	O
elementos	O
estructurales	O
más	O
prominentes	O
componentes	B-GENE
de	I-GENE
la	I-GENE
matriz	I-GENE
del	I-GENE
cartílago	I-GENE
no	O
se	O
mantiene	O
en	O
mutante	B-Sequence
animales	B-Taxon
,	O
lo	O
que	O
resulta	O
en	O
una	O
disminución	O
de	O
la	O
síntesis	O
de	O
Col2a1	B-Protein
,	O
agregado	B-Protein
,	O
y	O
proteoglicanos	B-Chemical
.	O

Por	O
lo	O
tanto	O
,	O
BMPR1A	B-Protein
parece	O
mantener	O
el	O
cartílago	O
articular	O
principalmente	O
a	O
través	O
de	O
la	O
inducción	O
de	O
la	O
expresión	O
de	O
clave	O
Componentes	B-GENE
del	I-GENE
ECM	I-GENE
.	O

Es	O
interesante	O
que	O
el	O
factor	B-Protein
de	I-Protein
transcripción	I-Protein
SOX9	I-Protein
se	O
sigue	O
expresando	O
en	O
mutante	B-Sequence
cartílago	O
a	O
pesar	O
de	O
la	O
pérdida	O
de	O
Col2a1	B-Protein
,	O
un	O
objetivo	O
directo	O
de	O
este	O
factor	O
de	O
transcripción	O
(	O
Bell	O
et	O
al	O
.	O
1997	O
;	O
Lefebvre	O
et	O
al	O
.	O
1997	O
)	O
.	O

Estudios	O
previos	O
sugieren	O
que	O
SOX9	B-Protein
La	O
actividad	O
puede	O
ser	O
modificada	O
por	O
proteína	B-Chemical
dependiente	O
de	O
cinasa	O
A	O
(	O
PKA	O
)	O
proteína	B-Chemical
fosforilación	O
,	O
o	O
por	O
coexpresión	O
de	O
dos	O
relacionados	O
proteinas	B-Chemical
,	O
L-SOX5	B-Protein
y	O
SOX6	B-Protein
(	O
Lefebvre	O
et	O
al	O
.	O
1998	O
;	O
Huang	O
et	O
al	O
.	O
2000	O
)	O
.	O

Además	O
,	O
un	O
examen	O
minucioso	O
del	O
orden	O
de	O
genes	B-Sequence
inducido	O
durante	O
pollo	B-Taxon
La	O
formación	O
de	O
dígitos	O
revela	O
que	O
medias9	B-Protein
se	O
enciende	O
primero	O
,	O
seguido	O
de	O
Bmpr1b	B-Protein
con	O
L	B-Protein
-	I-Protein
Medias5	I-Protein
,	O
y	O
luego	O
medias6	B-Protein
y	O
el	O
cartílago	O
componentes	B-GENE
estructurales	I-GENE
de	I-GENE
la	I-GENE
matriz	I-GENE
Col2a1	B-Protein
y	O
agregado	B-Protein
(	O
Chimal-Monroy	O
et	O
al	O
.	O
2003	O
)	O
.	O

Estos	O
resultados	O
,	O
junto	O
con	O
el	O
patrón	O
alterado	O
de	O
gene	B-Sequence
expresión	O
vista	O
en	O
nuestro	O
Bmpr1a	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
,	O
sugerir	O
que	O
BMPR1A	B-Protein
la	O
señalización	O
normalmente	O
puede	O
actuar	O
para	O
estimular	O
SOX9	B-Protein
por	O
correo	O
-	O
traducción	O
proteína	B-Chemical
modificación	O
,	O
o	O
para	O
inducir	O
L	B-Protein
-	I-Protein
Medias5	I-Protein
o	O
medias6	B-Protein
en	O
el	O
cartílago	O
para	O
mantener	O
la	O
expresión	O
de	O
Componentes	B-GENE
del	I-GENE
ECM	I-GENE
.	O

Estos	O
modelos	O
son	O
consistentes	O
con	O
la	O
capacidad	O
de	O
BMP2	B-Protein
tanto	O
para	O
aumentar	O
la	O
actividad	O
de	O
PKA	O
como	O
para	O
inducir	O
la	O
expresión	O
de	O
medias6	B-Protein
en	O
cultivo	O
de	O
tejidos	O
células	B-Cell
(	O
Lee	O
y	O
Chuong	O
1997	O
;	O
Fernández-Lloris	O
et	O
al	O
.	O
2003	O
)	O
.	O

Aunque	O
hemos	O
tratado	O
de	O
monitorear	O
la	O
expresión	O
de	O
L	B-Protein
-	I-Protein
Medias5	I-Protein
o	O
medias6	B-Protein
en	O
el	O
cartílago	O
articular	O
postnatal	O
,	O
y	O
probar	O
el	O
estado	O
de	O
fosforilación	O
de	O
SOX9	B-Protein
usando	O
lo	O
descrito	O
anteriormente	O
reactivos	B-Chemical
(	O
Lefebvre	O
et	O
al	O
.	O
1998	O
;	O
Huang	O
et	O
al	O
.	O
2000	O
)	O
,	O
no	O
hemos	O
podido	O
obtener	O
una	O
señal	O
específica	O
requerida	O
en	O
las	O
últimas	O
etapas	O
posnatales	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Además	O
,	O
nulo	O
mutaciones	B-Sequence
en	O
L	B-Protein
-	I-Protein
Medias5	I-Protein
o	O
Medias	B-Protein
-	I-Protein
6	I-Protein
causan	O
letalidad	O
en	O
el	O
momento	O
del	O
nacimiento	O
o	O
poco	O
después	O
,	O
y	O
no	O
se	O
ha	O
informado	O
ningún	O
efecto	O
sobre	O
el	O
mantenimiento	O
del	O
cartílago	O
(	O
Smits	O
et	O
al	O
.	O
2001	O
)	O
.	O

Sin	O
embargo	O
,	O
parece	O
probable	O
que	O
estos	O
u	O
otros	O
procesos	O
regulados	O
por	O
BMP	B-Protein
señalización	O
cooperar	O
con	O
SOX9	B-Protein
para	O
inducir	O
objetivo	O
genes	B-Sequence
en	O
cartílago	O
articular	O
.	O

Mutación	B-Sequence
de	O
Smad3	B-Protein
o	O
expresión	O
de	O
dominante	O
negativo	O
receptor	B-Protein
del	I-Protein
factor	I-Protein
de	I-Protein
crecimiento	I-Protein
transformante	I-Protein
beta	I-Protein
(	I-Protein
TGF-beta	I-Protein
)	I-Protein
tipo	I-Protein
II	I-Protein
también	O
altera	O
el	O
mantenimiento	O
normal	O
del	O
cartílago	O
articular	O
(	O
Serra	O
et	O
al	O
.	O
1997	O
;	O
Yang	O
et	O
al	O
.	O
2001	O
)	O
.	O

Ambas	O
manipulaciones	O
deberían	O
interrumpir	O
TGF	B-Protein
beta	I-Protein
en	O
vez	O
de	O
BMP	B-Protein
señalización	O
,	O
y	O
ambas	O
manipulaciones	O
hacen	O
que	O
el	O
cartílago	O
articular	O
se	O
hipertrofie	O
y	O
sea	O
reemplazado	O
por	O
hueso	O
.	O

Por	O
el	O
contrario	O
,	O
nuestro	O
análisis	O
de	O
Bmpr1a	B-Protein
mutante	B-Sequence
cartílago	O
articular	O
mostró	O
una	O
pérdida	O
de	O
Componentes	B-GENE
del	I-GENE
ECM	I-GENE
,	O
pero	O
sin	O
signos	O
de	O
hipertrofia	O
o	O
reemplazo	O
óseo	O
.	O

Por	O
lo	O
tanto	O
,	O
TGF	B-Protein
beta	I-Protein
y	O
BMP	B-Protein
la	O
señalización	O
está	O
desempeñando	O
papeles	O
distintos	O
pero	O
necesarios	O
para	O
mantener	O
el	O
cartílago	O
articular	O
.	O

Aunque	O
BMP	B-Protein
se	O
aislaron	O
originalmente	O
sobre	O
la	O
base	O
de	O
su	O
capacidad	O
para	O
inducir	O
la	O
formación	O
de	O
hueso	O
ectópico	O
,	O
su	O
presencia	O
en	O
el	O
cartílago	O
articular	O
y	O
su	O
fuerte	O
efecto	O
sobre	O
la	O
formación	O
de	O
cartílago	O
ha	O
estimulado	O
el	O
interés	O
en	O
usarlos	O
para	O
reparar	O
o	O
regenerar	O
defectos	O
del	O
cartílago	O
en	O
adultos	O
animales	B-Taxon
(	O
Chang	O
et	O
al	O
.	O
1994	O
;	O
Erlacher	O
et	O
al	O
.	O
1998	O
;	O
Edwards	O
y	O
Francis-West	O
2001	O
;	O
Chubinskaya	O
y	O
Kuettner	O
2003	O
)	O
.	O

La	O
incapacidad	O
para	O
mantener	O
el	O
cartílago	O
articular	O
en	O
ausencia	O
de	O
normal	O
BMPR1A	B-Protein
función	O
sugiere	O
que	O
ligandos	O
o	O
pequeños	O
agonistas	B-Chemical
de	I-Chemical
moléculas	I-Chemical
que	O
interactúan	O
específicamente	O
con	O
este	O
subtipo	O
de	O
receptor	O
pueden	O
ser	O
particularmente	O
buenos	O
candidatos	O
para	O
diseñar	O
nuevos	O
enfoques	O
para	O
mantener	O
o	O
sanar	O
el	O
cartílago	O
articular	O
en	O
las	O
etapas	O
posnatales	O
.	O

Falta	O
de	O
Bmpr1a	B-Protein
La	O
función	O
en	O
el	O
cartílago	O
articular	O
da	O
como	O
resultado	O
fibrilación	O
severa	O
de	O
la	O
superficie	O
articular	O
y	O
pérdida	O
de	O
movilidad	O
articular	O
.	O

El	O
desarrollo	O
de	O
síntomas	O
severos	O
de	O
artritis	O
en	O
Bmpr1a	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
plantea	O
la	O
posibilidad	O
de	O
que	O
los	O
defectos	O
en	O
BMP	B-Protein
La	O
señalización	O
también	O
contribuye	O
a	O
humano	B-Taxon
enfermedad	O
de	O
las	O
articulaciones	O

Se	O
sabe	O
que	O
la	O
osteoartritis	O
tiene	O
un	O
importante	O
genético	B-Sequence
componente	O
,	O
pero	O
es	O
probable	O
que	O
involucre	O
múltiples	O
genético	B-Sequence
factores	O
que	O
han	O
sido	O
difíciles	O
de	O
identificar	O
(	O
Spector	O
et	O
al	O
.	O
1996	O
;	O
Felson	O
et	O
al	O
.	O
1998	O
;	O
Hirsch	O
et	O
al	O
.	O
1998	O
)	O
.	O

humanos	B-Taxon
que	O
son	O
heterocigotos	O
para	O
la	O
pérdida	O
de	O
función	O
mutaciones	B-Sequence
en	O
BMPR1A	B-Protein
se	O
sabe	O
que	O
están	O
en	O
riesgo	O
de	O
poliposis	O
juvenil	O
(	O
Howe	O
et	O
al	O
.	O
2001	O
;	O
Zhou	O
et	O
al	O
.	O
2001	O
)	O
,	O
pero	O
el	O
riesgo	O
de	O
osteoartritis	O
para	O
estos	O
gente	B-Taxon
no	O
ha	O
sido	O
reportado	O
.	O

Sin	O
embargo	O
,	O
el	O
mando	O
ratones	B-Taxon
utilizados	O
en	O
este	O
estudio	O
fueron	O
heterocigotos	O
para	O
un	O
nulo	O
alelo	B-Sequence
de	O
Bmpr1a	B-Protein
,	O
y	O
mostraron	O
pocas	O
señales	O
de	O
osteoartritis	O
incluso	O
en	O
etapas	O
avanzadas	O
de	O
la	O
vida	O
.	O

Varios	O
regiones	B-Sequence
cromosómicas	I-Sequence
se	O
han	O
relacionado	O
previamente	O
con	O
fenotipos	O
de	O
artritis	O
en	O
humanos	B-Taxon
mediante	O
estudios	O
de	O
asociación	O
en	O
poblaciones	O
o	O
estudios	O
de	O
ligamiento	O
en	O
familias	O
.	O

Es	O
interesante	O
notar	O
que	O
varios	O
de	O
estos	O
regiones	B-Sequence
cromosómicas	I-Sequence
Contiene	O
genes	B-Sequence
codificar	O
diferentes	O
miembros	O
de	O
la	O
BMP	B-Protein
vía	O
de	O
señalización	O
,	O
incluida	O
la	O
BMP5	B-Protein
gene	B-Sequence
en	O
humano	B-Taxon
cromosoma	B-GENE
6p12	O
(	O
Loughlin	O
et	O
al	O
.	O
2002	O
)	O
,	O
el	O
MADH1	B-Protein
gene	B-Sequence
en	O
humano	B-Taxon
cromosoma	B-GENE
4q26-4q31	O
(	O
Leppavuori	O
et	O
al	O
.	O
1999	O
;	O
Kent	O
et	O
al	O
.	O
2002	O
)	O
,	O
y	O
el	O
receptor	B-Protein
BMPR2	I-Protein
en	O
humano	B-Taxon
cromosoma	B-GENE
2q33	O
(	O
Wright	O
y	O
col.	O
1996	O
)	O
.	O

La	O
naturaleza	O
compleja	O
de	O
humano	B-Taxon
osteoartritis	O
sugiere	O
que	O
las	O
interacciones	O
entre	O
múltiples	O
genes	B-Sequence
puede	O
estar	O
involucrado	O
en	O
la	O
modificación	O
de	O
la	O
susceptibilidad	O
a	O
la	O
enfermedad	O
.	O

los	O
inclusión	B-Sequence
de	O
genético	B-Sequence
marcadores	O
cerca	O
BMP	B-Protein
los	O
componentes	O
de	O
señalización	O
pueden	O
ayudar	O
a	O
identificar	O
la	O
susceptibilidad	O
adicional	O
a	O
la	O
osteoartritis	O
lugares	B-Sequence
y	O
facilitar	O
la	O
búsqueda	O
de	O
causas	O
mutaciones	B-Sequence
.	O

Los	O
procesos	O
de	O
desarrollo	O
y	O
enfermedad	O
en	O
las	O
articulaciones	O
sinoviales	O
han	O
sido	O
difíciles	O
de	O
estudiar	O
genéticamente	B-Sequence
,	O
porque	O
las	O
articulaciones	O
sinoviales	O
se	O
generan	O
y	O
funcionan	O
en	O
etapas	O
relativamente	O
tardías	O
de	O
vertebrado	B-Taxon
desarrollo	O
.	O

los	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
gene	B-Sequence
expresión	O
o	O
inactivación	O
principalmente	O
a	O
las	O
regiones	O
articulares	O
,	O
evitando	O
así	O
las	O
funciones	O
pleiotrópicas	O
de	O
muchos	O
genes	B-Sequence
en	O
otros	O
tejidos	O
.	O

Dependiendo	O
de	O
la	O
configuración	O
del	O
gen	B-Sequence
objetivo	I-Sequence
floxado	I-Sequence
,	O
este	O
sistema	O
se	O
puede	O
utilizar	O
para	O
activar	O
la	O
expresión	O
de	O
un	O
gene	B-Sequence
principalmente	O
en	O
el	O
desarrollo	O
de	O
articulaciones	O
(	O
ver	O
Figura	O
1B-1D	O
)	O
,	O
o	O
para	O
inactivar	O
gene	B-Sequence
funcionan	O
en	O
las	O
regiones	O
articulares	O
(	O
ver	O
Figura	O
3	O
)	O
.	O

Los	O
estudios	O
adicionales	O
con	O
este	O
sistema	O
deberían	O
mejorar	O
en	O
gran	O
medida	O
nuestro	O
conocimiento	O
del	O
desarrollo	O
,	O
la	O
función	O
y	O
los	O
mecanismos	O
de	O
enfermedad	O
de	O
las	O
articulaciones	O
,	O
y	O
pueden	O
acercarnos	O
a	O
una	O
mejor	O
prevención	O
y	O
tratamiento	O
de	O
las	O
enfermedades	O
de	O
las	O
articulaciones	O
.	O

Materiales	O
y	O
métodos	O

Generación	O
de	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
transgénico	B-Sequence
ratones	B-Taxon

A	O
ratón	B-Taxon
129x1	O
/	O
SvJ	O
BAC	B-Sequence
biblioteca	O
(	O
Invitrogen	O
)	O
fue	O
examinada	O
para	O
identificar	O
un	O
140	O
-	O
kb	O
BAC	B-Sequence
desde	O
el	O
gdf5	B-Protein
lugar	B-Sequence
.	O

Esta	O
BAC	B-Sequence
era	O
modificado	B-Sequence
utilizando	O
un	O
sistema	O
de	O
recombinación	O
homóloga	O
en	O
mi	B-Taxon
coli	I-Taxon
(	O
Yang	O
et	O
al	O
.	O
1997	O
)	O
para	O
colocar	O
nuclear	B-GENE
-	O
recombinasa	O
Cre	O
localizada	O
(	O
de	O
plásmido	B-Sequence
pML78	O
,	O
regalo	O
de	O
Gail	O
Martin	O
)	O
seguido	O
de	O
ires	B-Sequence
-	O
hPLAP	B-Protein
(	O
desde	O
plásmido	B-Sequence
1726	O
,	O
regalo	O
de	O
Oliver	O
Bogler	O
)	O
directamente	O
detrás	O
del	O
Sitio	B-Sequence
de	I-Sequence
inicio	I-Sequence
de	I-Sequence
ATG	I-Sequence
de	O
gdf5	B-Protein
.	O

En	O
proceso	O
,	O
583	O
pb	B-Sequence
del	O
primero	O
exón	B-Sequence
de	O
gdf5	B-Protein
era	O
remoto	B-Sequence
y	O
no	O
funcional	O
GDF5	B-Protein
proteína	B-Chemical
se	O
prevé	O
que	O
se	O
produzca	O
.	O

El	O
brazo	O
de	O
homología	O
5	O
'	O
fue	O
subclonado	O
a	O
partir	O
de	O
un	O
producto	B-Sequence
PCR	I-Sequence
atado	O
con	O
XhoI	O
y	O
Bsp120I	O
sitios	B-Sequence
de	I-Sequence
restricción	I-Sequence
que	O
contiene	O
781	O
pb	B-Sequence
de	O
5	O
'	O
secuencia	B-Sequence
genómica	I-Sequence
Gdf5	I-Sequence
terminando	O
en	O
el	O
Sitio	B-Sequence
de	I-Sequence
inicio	I-Sequence
de	I-Sequence
traducción	I-Sequence
ATG	I-Sequence
(	O
cartilla	B-Sequence
delantera	I-Sequence
5'-CTTGTCTCGAGATGAGGTGGAGGTGAAGACCCC-3	O
'	O
;	O
contrarrestar	B-Sequence
5	O
'	O
-	O
GTTTGGGCCCATCCTCTGGCCAGCCGCTG	O
-	O
3	O
'	O
)	O
.	O

Cre	O
fue	O
subclonado	O
de	O
un	O
1	O
.	O
1	O
-	O
kb	O
Bsp120I	O
/	O
EcoRI	O
fragmento	B-Sequence
de	O
pML78	O
.	O

ires	B-Sequence
hPLAP	B-Protein
fue	O
subclonado	O
de	O
un	O
2	O
.	O
1	O
kb	O
producto	B-Sequence
PCR	I-Sequence
junto	O
con	O
EcoRI	O
y	O
SpeI	O
sitios	B-Sequence
que	O
contiene	O
el	O
hPLAP	B-Protein
sitio	B-Sequence
de	I-Sequence
parada	I-Sequence
de	I-Sequence
traducción	I-Sequence
(	O
cartilla	B-Sequence
delantera	I-Sequence
5'-ATCTCTCGAGGAATTCTCCACCATATTGCCGTCTTTTG-3	O
'	O
;	O
contrarrestar	B-Sequence
5	O
'	O
-	O
AGAACTCGAGACTAGTCGGGACACTCAGGGAGTAGTGG	O
-	O
3	O
'	O
)	O
.	O

El	O
brazo	O
de	O
homología	O
3	O
'	O
se	O
subclonó	O
a	O
partir	O
de	O
un	O
0	O
.	O
8	O
kb	O
producto	B-Sequence
PCR	I-Sequence
amplificado	O
desde	O
0	O
.	O
9	O
-	O
kb	O
XhoI	O
gdf5	B-Protein
genómico	B-Sequence
subclon	O
que	O
contiene	O
parte	B-Sequence
del	I-Sequence
primer	I-Sequence
exón	I-Sequence
y	I-Sequence
el	I-Sequence
intrón	I-Sequence
aguas	I-Sequence
abajo	I-Sequence
.	O

los	O
cartilla	B-Sequence
delantera	I-Sequence
contiene	O
el	O
3	O
'	O
final	O
del	O
primero	O
exón	B-Sequence
y	O
es	O
seguido	O
por	O
un	O
SpeI	O
sitio	B-Sequence
;	O
los	O
imprimación	B-Sequence
inversa	I-Sequence
es	O
de	O
la	O
T7	B-Taxon
promotor	B-Sequence
de	O
El	O
vector	B-Sequence
que	O
contiene	O
el	O
0.	O
subclon	O
de	O
9	O
kb	O
y	O
flanquea	O
al	O
sitio	B-Sequence
intronic	I-Sequence
XhoI	I-Sequence
(	O
cartilla	B-Sequence
delantera	I-Sequence
5'-CTAAACTAGTCACCAGCTTTATTGACAAAGG-3	O
'	O
;	O
contrarrestar	B-Sequence
5	O
'	O
-	O
GATTTCTAGAGTAATACGACTCACTATAGGGC	O
-	O
3	O
'	O
)	O
.	O

la	O
focalización	O
construir	B-Sequence
fue	O
construido	O
y	O
verificado	O
en	O
pBSSK	O
(	O
Stratagene	O
,	O
La	O
Jolla	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
,	O
luego	O
digerido	O
con	O
XhoI	O
y	O
subclonado	O
en	O
pSV1	O
,	O
el	O
vector	B-Sequence
utilizado	O
para	O
la	O
recombinación	O
homóloga	O
(	O
Yang	O
et	O
al	O
.	O
1997	O
)	O
.	O

Southern	O
Blot	O
,	O
PCR	O
y	O
secuencia	B-Sequence
de	I-Sequence
ADN	I-Sequence
análisis	O
confirmó	O
la	O
focalización	O
adecuada	O
construir	B-Sequence
y	O
modificaciones	B-Sequence
BAC	I-Sequence
se	O
realizaron	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Antes	O
de	O
BAC	B-Sequence
modificado	I-Sequence
fue	O
inyectado	O
para	O
producir	O
transgénico	B-Sequence
animales	B-Taxon
,	O
a	O
sitio	B-Sequence
loxP	I-Sequence
presente	O
en	O
el	O
BAC	B-Sequence
vectorial	I-Sequence
,	O
pBeloBAC11	O
,	O
fue	O
remoto	B-Sequence
para	O
evitar	O
la	O
adición	O
de	O
objetivos	O
Cre	O
no	O
deseados	O
sitios	B-Sequence
en	O
el	O
genoma	B-Sequence
.	O

Para	O
hacer	O
esto	O
,	O
ADN	B-Sequence
BAC	I-Sequence
fue	O
preparado	O
por	O
separación	O
de	O
CsCl	O
,	O
digerido	O
con	O
NotI	O
para	O
liberar	O
el	O
insertar	B-Sequence
desde	O
el	O
vector	B-Sequence
,	O
y	O
tamaño	O
-	O
fraccionada	O
en	O
un	O
sacarosa	B-Chemical
degradado	O
.	O

Se	O
corrieron	O
alícuotas	O
de	O
fracciones	O
en	O
un	O
gel	O
de	O
campo	O
pulsado	O
y	O
se	O
sometieron	O
a	O
transferencia	O
Southern	O
usando	O
vector	B-Sequence
#	O
¿NOMBRE	O
?	O
ADN	B-Sequence
como	O
un	O
Investigacion	B-Sequence
.	O

Fracciones	O
que	O
contienen	O
sin	O
cortar	O
insertar	B-Sequence
y	O
casi	O
no	O
detectable	O
vector	B-Sequence
de	I-Sequence
ADN	I-Sequence
fueron	O
dializados	O
en	O
tampón	O
de	O
microinyección	O
(	O
10	O
mM	O
tris	B-Chemical
[	O
pH	O
7	O
.	O
4	O
]	O
con	O
0	O
.	O
15	O
mm	O
EDTA	B-Chemical
pH	O
8	O
.	O
0	O
]	O
)	O
utilizando	O
concentradores	O
Centriprep	O
-	O
30	O
(	O
Millipore	O
,	O
Billerica	O
,	O
Massachusetts	O
,	O
Estados	O
Unidos	O
)	O
.	O

esta	O
purificada	O
insertar	B-Sequence
ADN	I-Sequence
se	O
ajustó	O
a	O
1	O
ng/mu	O
l	O
y	O
se	O
inyectó	O
en	O
el	O
pronúcleo	B-GENE
de	O
fertilizado	O
huevos	B-Cell
de	O
FVB/N	O
ratones	B-Taxon
por	O
Stanford	O
transgénico	B-Sequence
Instalaciones	O
.	O

transgénico	B-Sequence
fundador	O
ratones	B-Taxon
fueron	O
identificados	O
por	O
PCR	O
usando	O
Cre	O
-	O
específico	O
cebadores	B-Sequence
5	O
'	O
-	O
GCCTGCATTACCGGTCGATGCAACGA	O
-	O
3	O
'	O
y	O
5	O
'	O
-	O
GTGGCAGATGGCGCGGCAACACCATT	O
-	O
3	O
'	O
,	O
que	O
amplifican	O
un	O
725	O
-	O
producto	B-Sequence
pb	I-Sequence
,	O
y	O
fueron	O
evaluados	O
por	O
la	O
ausencia	O
de	O
BAC	B-Sequence
vectorial	I-Sequence
utilizando	O
vector	B-Sequence
#	O
¿NOMBRE	O
?	O
cebadores	B-Sequence
5	O
'	O
-	O
CGGAGTCTGATGCGGTTGCGATG	O
-	O
3	O
'	O
y	O
5	O
'	O
-	O
AGTGCTGTTCCCTGGTGCTTCCTC	O
-	O
3	O
'	O
,	O
que	O
amplifican	O
un	O
465	O
-	O
producto	B-Sequence
pb	I-Sequence
.	O

tres	O
lineas	O
de	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
se	O
establecieron	O
y	O
mantuvieron	O
en	O
el	O
fondo	O
FVB	O
.	O

Apareamientos	O
con	O
R26R	O
Cre	O
-	O
reportero	O
LACZ	O
inducible	O
ratones	B-Taxon
(	O
Soriano	O
1999	O
)	O
para	O
evaluar	O
la	O
actividad	O
de	O
Cre	O
.	O

Tinción	O
para	O
LACZ	O
y	O
HPLAP	B-Protein
en	O
embriones	O
completos	O
o	O
secciones	O
de	O
embriones	O
se	O
logró	O
siguiendo	O
protocolos	O
establecidos	O
(	O
Lobe	O
et	O
al	O
.	O
1999	O
)	O
.	O

El	O
sustrato	O
LACZ	O
rojo	O
(	O
ver	O
Figura	O
1E	O
)	O
es	O
6	O
-	O
cloro	B-Chemical
-	O
3	O
-	O
indoxil	O
-	O
beta	O
-	O
D	O
-	O
galactopiranósido	O
(	O
Biosynth	O
International	O
,	O
Naperville	O
,	O
Illinois	O
,	O
Estados	O
Unidos	O
)	O
.	O

Caracterización	O
general	O
de	O
Bmpr1a	B-Protein
mutante	B-Sequence
ratones	B-Taxon

Bmpr1a	B-Protein
nulo	O
y	O
alelos	B-Sequence
flojos	I-Sequence
(	O
Ahn	O
et	O
al	O
.	O
2001	O
;	O
Mishina	O
et	O
al	O
.	O
2002	O
)	O
se	O
obtuvieron	O
en	O
un	O
fondo	O
mixto	O
129	O
y	O
C57BL	O
/	O
6	O
y	O
se	O
mantuvieron	O
mediante	O
mejoramiento	O
aleatorio	O
.	O

Ratones	B-Taxon
llevando	O
el	O
nulo	O
y	O
alelos	B-Sequence
flojos	I-Sequence
eran	O
típicamente	O
apareados	O
con	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
como	O
se	O
muestra	O
en	O
la	O
Figura	O
3	O
.	O

La	O
resultante	O
ratones	B-Taxon
están	O
en	O
un	O
129	O
mixto	O
;	O
C57Bl/6	O
;	O
Fondo	O
FVB/N	O
,	O
con	O
ambos	O
controles	O
y	O
mutante	B-Sequence
animales	B-Taxon
generados	O
como	O
compañeros	O
de	O
camada	O
de	O
los	O
mismos	O
apareamientos	O
.	O

Se	O
hicieron	O
preparaciones	O
esqueléticas	O
de	O
montaje	O
completo	O
de	O
34	O
-	O
a	O
36	O
-	O
d	O
-	O
de	O
edad	O
ratones	B-Taxon
(	O
Lufkin	O
y	O
col.	O
1992	O
)	O
.	O

Pares	O
de	O
orejas	O
de	O
6	O
meses	O
sacrificados	O
animales	B-Taxon
fueron	O
removidos	O
,	O
fijados	O
,	O
fotografiados	O
,	O
proyectados	O
y	O
medidos	O
desde	O
la	O
base	O
de	O
la	O
curva	O
formada	O
entre	O
el	O
trago	O
y	O
el	O
antitrago	O
hasta	O
el	O
punto	O
más	O
lejano	O
en	O
el	O
borde	O
de	O
las	O
pinnas	O
.	O

Capacidad	O
de	O
agarre	O
a	O
los	O
6	O
meses	O
de	O
edad	O
ratones	B-Taxon
se	O
midió	O
colocando	O
animales	B-Taxon
sobre	O
una	O
varilla	O
delgada	O
y	O
cronometrando	O
cuanto	O
tiempo	O
pueden	O
permanecer	O
suspendidos	O
en	O
la	O
varilla	O
,	O
hasta	O
un	O
tiempo	O
máximo	O
permitido	O
de	O
2	O
min	O
.	O

Datos	O
de	O
cinco	O
ensayos	O
consecutivos	O
para	O
cada	O
ratón	B-Taxon
fueron	O
promediados	O
.	O

Se	O
realizaron	O
ensayos	O
de	O
rango	O
de	O
movimiento	O
en	O
las	O
articulaciones	O
MT	O
/	O
P1	O
y	O
P1	O
/	O
P2	O
del	O
segundo	O
dedo	O
de	O
la	O
pata	O
trasera	O
de	O
18	O
semanas	O
de	O
edad	O
sacrificadas	O
.	O
animales	B-Taxon
.	O

Se	O
usaron	O
fórceps	O
para	O
doblar	O
la	O
articulación	O
hasta	O
su	O
posición	O
de	O
parada	O
natural	O
y	O
el	O
ángulo	O
resultante	O
se	O
midió	O
con	O
una	O
precisión	O
de	O
10	O
grados	O
por	O
debajo	O
de	O
12	O
.	O
Aumento	O
de	O
5x	O
usando	O
una	O
retícula	O
de	O
360	O
grados	O
.	O

El	O
análisis	O
descrito	O
en	O
esta	O
sección	O
ocurrió	O
en	O
animales	B-Taxon
falta	O
R26R	O
.	O

Control	O
ratones	B-Taxon
incluido	O
todo	O
no	O
mutante	O
genotipos	B-Sequence
generado	O
por	O
Parent	O
1	O
siendo	O
heterocigoto	O
para	O
gdf5	B-Protein
Cre	O
y	O
Bmpr1anull	O
y	O
Parent	O
2	O
siendo	O
heterocigotos	O
para	O
Bmpr1afloxP	O
(	O
ver	O
Figura	O
3	O
)	O
.	O

Todos	O
los	O
análisis	O
estadísticos	O
utilizaron	O
la	O
prueba	O
de	O
la	O
t	O
de	O
Student	O
o	O
la	O
prueba	O
de	O
la	O
t	O
de	O
Welch	O
,	O
y	O
los	O
valores	O
enumerados	O
son	O
la	O
media	O
+/-	O
el	O
error	O
estándar	O
de	O
la	O
media	O
.	O

Célula	B-Cell
ensayos	O
de	O
muerte	O
y	O
proliferación	O

extremidades	O
de	O
mutante	B-Sequence
y	O
control	O
animales	B-Taxon
en	O
E13	O
.	O
5	O
y	O
E14	O
.	O
5	O
fueron	O
disecados	O
y	O
congelados	O
en	O
OCT	O
(	O
Sakura	O
Finetek	O
,	O
Torrence	O
,	O
CA	O
,	O
Estados	O
Unidos	O
)	O
.	O

Las	O
criosecciones	O
de	O
tejido	O
fueron	O
analizadas	O
por	O
TUNEL	O
usando	O
el	O
In	O
Situ	O
Célula	B-Cell
Kit	O
de	O
Detección	O
de	O
Muerte	O
,	O
Fluoresceína	O
(	O
Roche	O
,	O
Basilea	O
,	O
Suiza	O
)	O
.	O

Después	O
de	O
TUNEL	O
,	O
los	O
portaobjetos	O
se	O
lavaron	O
en	O
PBS	O
,	O
se	O
bloquearon	O
con	O
PBS	O
+	O
0	O
.	O
05	O
%	O
Interpolación	O
-	O
20	O
+	O
5	O
%	O
cabra	B-Taxon
suero	O
,	O
lavado	O
nuevamente	O
e	O
incubado	O
con	O
una	O
dilución	O
1	O
:	O
200	O
de	O
un	O
Conejo	B-Taxon
anti	O
-	O
fosfo	B-Chemical
-	O
histona	B-Chemical
0	O
anticuerpo	B-GENE
llamado	O
Mitosis	O
Marker	O
(	O
Upstate	O
Biotechnology	O
,	O
Lake	O
Placid	O
,	O
Nueva	O
York	O
,	O
Estados	O
Unidos	O
)	O
para	O
identificar	O
células	B-Cell
en	O
mitosis	O
.	O

Cy3	O
-	O
etiquetado	O
anti	O
-	O
Conejo	B-Taxon
secundario	O
anticuerpo	B-GENE
se	O
utilizó	O
para	O
detectar	O
la	O
anticuerpo	B-GENE
.	O

Célula	B-Cell
núcleos	B-GENE
se	O
etiquetaron	O
con	O
DAPI	O
y	O
los	O
portaobjetos	O
se	O
montaron	O
en	O
Vectamount	O
(	O
Vector	O
Laboratories	O
,	O
Burlingame	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
y	O
se	O
visualizaron	O
con	O
un	O
aumento	O
de	O
100x	O
.	O

Se	O
midió	O
el	O
área	O
de	O
los	O
sitios	O
anatómicos	O
seleccionados	O
y	O
se	O
midió	O
el	O
número	O
de	O
TUNEL	O
marcados	O
.	O
fragmentos	B-GENE
nucleares	I-GENE
y	O
el	O
número	O
de	O
Cy3	O
-	O
etiquetados	O
núcleos	B-GENE
se	O
contaron	O
a	O
partir	O
de	O
tres	O
secciones	O
de	O
10	O
mu	O
m	O
que	O
abarcan	O
50	O
mu	O
m	O
,	O
de	O
tres	O
de	O
control	O
y	O
tres	O
mutante	B-Sequence
animales	B-Taxon
.	O

El	O
número	O
de	O
etiquetado	O
células	B-Cell
en	O
las	O
articulaciones	O
metacarpiano-falángicas	O
y	O
metatarso-falángicas	O
se	O
contó	O
en	O
un	O
rectángulo	O
de	O
290	O
mu	O
mx	O
365	O
mu	O
m	O
colocado	O
alrededor	O
del	O
centro	O
de	O
la	O
articulación	O
.	O

La	O
región	O
posterior	O
del	O
quinto	O
dedo	O
se	O
definió	O
dibujando	O
una	O
línea	O
desde	O
la	O
punta	O
del	O
dedo	O
hacia	O
abajo	O
2	O
.	O
15	O
mm	O
y	O
transversal	O
al	O
borde	O
lateral	O
del	O
tejido	O
.	O

Para	O
este	O
análisis	O
,	O
el	O
reportero	O
R26R	O
Cre	O
no	O
estuvo	O
presente	O
.	O

Histología	O
e	O
histoquímica	O

tejido	O
de	O
animales	B-Taxon
que	O
van	O
desde	O
las	O
etapas	O
E14	O
.	O
5	O
a	O
P14	O
se	O
preparó	O
para	O
el	O
análisis	O
fijándolo	O
en	O
paraformaldehído	O
(	O
PFA	O
)	O
al	O
4	O
%	O
en	O
PBS	O
durante	O
45	O
min	O
a	O
4	O
h	O
dependiendo	O
de	O
la	O
etapa	O
;	O
lavado	O
tres	O
veces	O
en	O
PBS	O
,	O
una	O
vez	O
en	O
PBS	O
+	O
15	O
%	O
sacarosa	B-Chemical
durante	O
1	O
h	O
,	O
y	O
una	O
vez	O
en	O
PBS	O
+	O
30	O
%	O
sacarosa	B-Chemical
de	O
2	O
h	O
a	O
toda	O
la	O
noche	O
dependiendo	O
de	O
la	O
etapa	O
;	O
y	O
luego	O
congelando	O
en	O
OCT	O
.	O

tejido	O
de	O
animales	B-Taxon
de	O
7	O
semanas	O
a	O
9	O
meses	O
de	O
edad	O
se	O
procesó	O
de	O
manera	O
similar	O
a	O
las	O
etapas	O
anteriores	O
excepto	O
que	O
se	O
descalcificó	O
en	O
0	O
.	O
5M	O
EDTA	B-Chemical
(	O
pH	O
7	O
.	O
4	O
)	O
durante	O
4	O
d	O
antes	O
de	O
incubar	O
en	O
sacarosa	B-Chemical
.	O

Todas	O
las	O
soluciones	O
se	O
preenfriaron	O
y	O
se	O
usaron	O
a	O
4	O
°C	O
con	O
agitación	O
y	O
piel	O
de	O
tejidos	O
de	O
P0	O
o	O
más	O
.	O
ratones	B-Taxon
fue	O
lacerado	O
o	O
removido	O
antes	O
del	O
procesamiento	O
.	O

A	O
continuación	O
,	O
se	O
criosectó	O
el	O
tejido	O
a	O
12	O
µm	O
y	O
se	O
procesó	O
.	O

La	O
tinción	O
de	O
las	O
secciones	O
con	O
Safranina	O
O	O
,	O
Fast	O
Green	O
y	O
hematoxilina	O
de	O
Harris	O
se	O
llevó	O
a	O
cabo	O
usando	O
procedimientos	O
histológicos	O
estándar	O
.	O

La	O
detección	O
de	O
la	O
actividad	O
LACZ	O
con	O
X-Gal	O
se	O
realizó	O
como	O
se	O
describe	O
(	O
Lobe	O
et	O
al	O
.	O
1999	O
)	O
y	O
fue	O
seguida	O
por	O
una	O
nueva	O
fijación	O
en	O
PFA	O
al	O
4	O
%	O
,	O
enjuague	O
con	O
agua	O
desionizada	O
.	O
agua	B-Chemical
contratinción	O
con	O
Nuclear	B-GENE
Fast	O
Red	O
(	O
Vector	O
Labs	O
)	O
,	O
aclarado	O
con	O
agua	B-Chemical
nuevamente	O
,	O
y	O
luego	O
montaje	O
en	O
Aquamount	O
(	O
Lerner	O
Labs	O
,	O
Pittsburgh	O
,	O
Pensilvania	O
,	O
Estados	O
Unidos	O
)	O
.	O

ARN	B-Sequence
la	O
hibridación	O
in	O
situ	O
se	O
realizó	O
como	O
se	O
describe	O
(	O
Storm	O
y	O
Kingsley	O
1996	O
)	O
,	O
con	O
las	O
siguientes	O
modificaciones	O
:	O
(	O
1	O
)	O
Antes	O
del	O
paso	O
de	O
acetilación	O
,	O
las	O
secciones	O
se	O
incubaron	O
con	O
10	O
-	O
20	O
µg	O
/	O
ml	O
de	O
proteinasa	O
K	O
durante	O
30	O
s	O
a	O
7	O
min	O
a	O
temperatura	O
ambiente	O
(	O
dependiendo	O
de	O
la	O
etapa	O
de	O
desarrollo	O
)	O
,	O
seguido	O
de	O
una	O
nueva	O
fijación	O
en	O
PFA	O
al	O
4	O
%	O
y	O
un	O
lavado	O
tres	O
veces	O
en	O
PBS	O
;	O
(	O
2	O
)	O
se	O
omitió	O
el	O
paso	O
de	O
prehibridación	O
y	O
(	O
3	O
)	O
las	O
secciones	O
de	O
tejido	O
embrionario	O
utilizaron	O
una	O
mezcla	O
de	O
desarrollo	O
de	O
color	O
diferente	O
(	O
Thut	O
et	O
al	O
.	O
2001	O
)	O
.	O

Sondas	B-Sequence
para	O
el	O
siguiente	O
genes	B-Sequence
han	O
sido	O
publicados	O
anteriormente	O
:	O
Bmpr1a	B-Protein
(	O
Mishina	O
et	O
al	O
.	O
1995	O
)	O
,	O
Col2a1	B-Protein
(	O
Metsaranta	O
et	O
al	O
.	O
1991	O
)	O
,	O
Col10a1	B-Protein
(	O
Apte	O
et	O
al	O
.	O
1992	O
)	O
,	O
gdf5	B-Protein
(	O
Storm	O
y	O
Kingsley	O
1996	O
)	O
,	O
osteocalcina	O
(	O
Celeste	O
et	O
al	O
.	O
1986	O
)	O
y	O
medias5	B-Protein
y	O
medias6	B-Protein
(	O
Lefebvre	O
et	O
al	O
.	O
1998	O
)	O
.	O

La	O
siguiente	O
Investigacion	B-Sequence
las	O
plantillas	O
fueron	O
regalos	O
:	O
agregado	B-Protein
,	O
Dr	O
.	O
Vicki	O
Rosen	O
,	O
Instituto	O
de	O
Genética	O
;	O
Bmp2	B-Protein
y	O
Bmp4	B-Protein
,	O
Arend	O
Sidow	O
,	O
Universidad	O
de	O
Stanford	O
;	O
Col1a1	B-Protein
,	O
Bjorn	O
Olsen	O
,	O
Facultad	O
de	O
Medicina	O
de	O
Harvard	O
;	O
Bmpr1b	B-Protein
,	O
Col3a1	B-Protein
,	O
y	O
Mat4	B-Protein
sondas	B-Sequence
fueron	O
hechos	O
de	O
EST	B-Sequence
con	O
IMAGEN	O
clon	B-Sequence
números	O
5056341	O
,	O
478480	O
y	O
406027	O
,	O
respectivamente	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
.	O

Las	O
secciones	O
para	O
inmunohistoquímica	O
se	O
fijaron	O
en	O
PFA	O
al	O
4	O
%	O
,	O
luego	O
se	O
digirieron	O
con	O
942	O
-	O
2	O
000	O
U	O
/	O
ml	O
tipo	O
IV	O
-	O
S	O
bovino	B-Taxon
hialuronindasa	O
(	O
Sigma	O
,	O
St.	O
Louis	O
,	O
Missouri	O
,	O
Estados	O
Unidos	O
)	O
en	O
PBS	O
(	O
pH	O
5	O
)	O
a	O
37	O
grados	O
C	O
durante	O
30	O
min	O
a	O
2	O
h	O
dependiendo	O
del	O
estadio	O
.	O

Luego	O
se	O
lavaron	O
los	O
portaobjetos	O
en	O
PBS	O
,	O
se	O
trataron	O
con	O
O	O
.	O
3	O
%	O
peróxido	B-Chemical
de	I-Chemical
hidrógeno	I-Chemical
en	O
100	O
%	O
metanol	B-Chemical
durante	O
30	O
min	O
,	O
lavado	O
,	O
bloqueado	O
con	O
PBS	O
+	O
0	O
.	O
05	O
%	O
interpolación	O
20	O
+	O
5	O
%	O
cabra	B-Taxon
o	O
fetal	O
bovino	B-Taxon
suero	O
,	O
lavado	O
de	O
nuevo	O
e	O
incubado	O
con	O
primario	O
anticuerpos	B-GENE
en	O
PBS+0	O
.	O
05	O
%	O
interpolación	O
20	O
+	O
1	O
%	O
cabra	B-Taxon
o	O
fetal	O
bovino	B-Taxon
suero	O
durante	O
la	O
noche	O
a	O
4	O
grados	O
C	O
.	O

biotina	B-Chemical
#	O
¿NOMBRE	O
?	O
anticuerpos	B-GENE
(	O
Vector	O
Labs	O
)	O
se	O
marcaron	O
con	O
HRP	O
usando	O
el	O
kit	O
Vectastain	O
Elite	O
ABC	O
(	O
Vector	O
Labs	O
)	O
seguido	O
de	O
detección	O
con	O
DAB	O
(	O
Vector	O
Labs	O
)	O
.	O

Primario	O
anticuerpos	B-GENE
y	O
las	O
diluciones	O
utilizadas	O
fueron	O
:	O
cabra	B-Taxon
anti	O
-	O
ratón	B-Protein
MMP13	I-Protein
,	O
1	O
:	O
100	O
(	O
Chemicon	O
International	O
,	O
Temecula	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
;	O
Conejo	B-Taxon
anti	O
-	O
humano	B-Protein
SOX9	I-Protein
,	O
1	O
:	O
500	O
(	O
Morais	O
da	O
Silva	O
et	O
al	O
.	O
1996	O
)	O
;	O
Conejo	B-Taxon
anti	O
-	O
fosforilado	O
-	O
SOX9	B-Protein
(	O
SOX9	B-Protein
.	O
P	O
)	O
,	O
1:10-1:250	O
(	O
Huang	O
et	O
al	O
.	O
2000	O
)	O
.	O

información	O
de	O
soporte	O

Números	O
de	O
acceso	O

GenBank	O
(	O
http	O
:	O
//	O
www	O
.	O
ncbi	O
.	O
nih	O
.	O
gov	O
/	O
Genbank	O
/	O
)	O
números	O
de	O
acceso	O
para	O
el	O
genes	B-Sequence
discutidos	O
en	O
este	O
trabajo	O
son	O
gdf5	B-Protein
(	O
AC084323	O
)	O
y	O
Bmpr1a	B-Protein
(	O
NM_009758	O
)	O
.	O

Agradecimientos	O

Agradecemos	O
a	O
Gail	O
Martin	O
por	O
la	O
Cre	O
construir	B-Sequence
(	O
plásmido	B-Sequence
pML78	O
)	O
y	O
Oliver	O
Bogler	O
por	O
el	O
ires	B-Sequence
-	O
hPLAP	B-Protein
construir	B-Sequence
(	O
plásmido	B-Sequence
1726	O
)	O
;	O
Bjorn	O
Olsen	O
y	O
Benoit	O
de	O
Crombrugghe	O
por	O
anticuerpos	B-GENE
;	O
la	O
siguiente	O
individuos	B-Taxon
para	O
in	O
situ	O
Investigacion	B-Sequence
plantillas	O
:	O
Sophie	O
Candille	O
,	O
Arend	O
Sidow	O
(	O
Bmp2	B-Protein
y	O
Bmp4	B-Protein
)	O
,	O
Vicki	O
Rosen	O
(	O
Agg	O
)	O
y	O
Bjorn	O
Olsen	O
(	O
Col1a1	B-Protein
)	O
;	O
Véronique	O
Lefebvre	O
por	O
medias5	B-Protein
y	O
medias6	B-Protein
Investigacion	B-Sequence
plantillas	O
y	O
debates	O
útiles	O
;	O
Michelle	O
Johnson	O
por	O
su	O
ayuda	O
con	O
los	O
ensayos	O
fenotípicos	O
en	O
ratones	B-Taxon
;	O
Dr	O
.	O
Corrine	O
Davis	O
por	O
su	O
ayuda	O
en	O
la	O
evaluación	O
de	O
las	O
secciones	O
sinoviales	O
;	O
Rebecca	O
Rountree	O
por	O
los	O
consejos	O
de	O
Adobe	O
Photoshop	O
e	O
Illustrator	O
;	O
y	O
miembros	O
del	O
laboratorio	O
de	O
Kingsley	O
por	O
sus	O
valiosos	O
comentarios	O
sobre	O
el	O
manuscrito	O
.	O

Este	O
trabajo	O
fue	O
apoyado	O
por	O
una	O
subvención	O
de	O
formación	O
predoctoral	O
(	O
RR	O
)	O
del	O
NIH	O
,	O
una	O
beca	O
posdoctoral	O
de	O
la	O
Arthritis	O
Foundation	O
(	O
MS	O
)	O
y	O
subvenciones	O
de	O
los	O
Institutos	O
Nacionales	O
de	O
Salud	O
(	O
DK	O
)	O
.	O

Dr	O
.	O
Kingsley	O
es	O
investigador	O
asociado	O
del	O
Instituto	O
Médico	O
Howard	O
Hughes	O
.	O

abreviaturas	O

BAC	B-Sequence
-	O
cromosoma	B-Sequence
artificial	I-Sequence
bacteriano	I-Sequence

Bmpr1a	B-Protein
-	O
receptor	B-Protein
de	I-Protein
proteína	I-Protein
morfogenética	I-Protein
ósea	I-Protein
1a	I-Protein

E	O
[	O
número	O
]	O
-	O
día	O
embrionario	O
[	O
número	O
]	O

ECM	B-GENE
-	O
la	B-GENE
matriz	I-GENE
extracelular	I-GENE

GAC-	O
transgénico	B-Sequence
transporte	O
de	O
línea	O
gdf5	B-Protein
-	O
alcalino	B-Chemical
fosfatasa	O
-	O
Cre	O
construir	B-Sequence

gdf5	B-Protein
-	O
factor	B-Protein
de	I-Protein
diferenciación	I-Protein
de	I-Protein
crecimiento	I-Protein
5	I-Protein

hPLAP	B-Protein
-	O
fosfatasa	B-Protein
alcalina	I-Protein
placentaria	I-Protein
humana	I-Protein

ires	B-Sequence
-	O
sitio	B-Sequence
interno	I-Sequence
de	I-Sequence
entrada	I-Sequence
al	I-Sequence
ribosoma	I-Sequence

PFA	O
-	O
paraformaldehído	O

R26R	O
-	O
lacZ	O
ROSA26	B-Protein
Cre	O
cepa	O
reportera	O

TGF-beta	B-Protein
-	O
factor	B-Protein
de	I-Protein
crecimiento	I-Protein
transformante	I-Protein
beta	I-Protein

TUNEL	O
-	O
desoxinucleotidil	B-Protein
transferasa	I-Protein
terminal	I-Protein
#	O
¿NOMBRE	O
?	O
trifosfato	B-Chemical
de	I-Chemical
desoxiuridina	I-Chemical
etiquetado	O
del	O
extremo	O
de	O
la	O
muesca	O

Figuras	O
y	O
Tablas	O

Figura	O
1	O

A	O
Genético	B-Sequence
Sistema	O
para	O
conducir	O
Gene	B-Sequence
Recombinación	O
en	O
articulaciones	O
en	O
desarrollo	O

A	O
)	O
A	O
140	O
-	O
kb	O
BAC	B-Sequence
desde	O
el	O
gdf5	B-Protein
lugar	B-Sequence
era	O
modificado	B-Sequence
por	O
insertando	B-Sequence
cre-	O
ires	B-Sequence
-	O
hPLAP	B-Protein
en	O
el	O
sitio	B-Sequence
de	I-Sequence
inicio	I-Sequence
de	I-Sequence
traducción	I-Sequence
de	O
gdf5	B-Protein
y	O
solía	O
hacer	O
transgénico	B-Sequence
ratones	B-Taxon
.	O

No	O
a	O
escala	O
.	O

Ver	O
Materiales	O
y	O
Métodos	O
para	O
más	O
detalles	O
.	O

(	O
B	O
-	O
E	O
)	O
Visualización	O
de	O
gdf5	B-Protein
-	O
Patrones	O
de	O
recombinación	O
impulsados	O
por	O
Cre	O
basados	O
en	O
la	O
activación	O
de	O
la	O
expresión	O
lacZ	O
del	O
reportero	O
R26R	O
Cre	O
alelo	B-Sequence
.	O

(	O
B	O
)	O
La	O
actividad	O
de	O
LACZ	O
es	O
visible	O
como	O
tinción	O
azul	O
en	O
el	O
oído	O
(	O
ea	O
)	O
y	O
las	O
articulaciones	O
del	O
hombro	O
(	O
s	O
)	O
,	O
codo	O
(	O
eb	O
)	O
,	O
muñeca	O
(	O
w	O
)	O
,	O
rodilla	O
(	O
k	O
)	O
,	O
tobillo	O
(	O
a	O
)	O
,	O
vértebra	O
(	O
vj	O
)	O
y	O
falanges	O
(	O
puntas	O
de	O
flecha	O
negras	O
)	O
de	O
un	O
E14	O
.	O
5	O
ratón	B-Taxon
embrión	O

(	O
C	O
)	O
E14	O
.	O
5	O
patas	O
traseras	O
dobles	O
-	O
teñidas	O
para	O
mostrar	O
ambas	O
HPLAP	B-Protein
expresión	O
de	O
la	O
transgén	B-Sequence
(	O
tinción	O
gris	O
/	O
púrpura	O
)	O
y	O
expresión	O
LACZ	O
del	O
R26R	O
reorganizado	O
alelo	B-Sequence
(	O
tinción	O
azul	O
)	O
.	O

Tenga	O
en	O
cuenta	O
que	O
ambos	O
marcadores	O
son	O
visibles	O
en	O
la	O
articulación	O
interfalángica	O
proximal	O
más	O
antigua	O
(	O
punta	O
de	O
flecha	O
negra	O
)	O
,	O
sólo	O
HPLAP	B-Protein
la	O
actividad	O
es	O
visible	O
en	O
la	O
articulación	O
interfalángica	O
medial	O
formada	O
más	O
recientemente	O
(	O
flecha	O
negra	O
)	O
,	O
y	O
tampoco	O
HPLAP	B-Protein
ni	O
la	O
expresión	O
de	O
LACZ	O
es	O
visible	O
en	O
la	O
articulación	O
más	O
joven	O
y	O
más	O
distal	O
del	O
dedo	O
(	O
punta	O
de	O
flecha	O
blanca	O
)	O
.	O

D	O
)	O
Miembro	O
anterior	O
del	O
recién	O
nacido	O
(	O
P0	O
)	O
con	O
piel	O
parcialmente	O
extirpada	O
que	O
muestra	O
actividad	O
LACZ	O
expresada	O
en	O
todas	O
las	O
articulaciones	O
falángicas	O
(	O
tinción	O
roja	O
Salmon	O
gal	O
,	O
puntas	O
de	O
flecha	O
negras	O
)	O
y	O
regiones	O
de	O
algunos	O
tendones	O
(	O
asterisco	O
)	O
.	O

(	O
E	O
)	O
Sección	O
a	O
través	O
de	O
la	O
articulación	O
falángica	O
más	O
distal	O
de	O
una	O
pata	O
trasera	O
P0	O
teñida	O
con	O
azul	O
alcián	O
para	O
marcar	O
el	O
cartílago	O
que	O
muestra	O
la	O
expresión	O
LACZ	O
(	O
teñida	O
de	O
rojo	O
)	O
en	O
todos	O
los	O
tejidos	O
de	O
las	O
articulaciones	O
en	O
desarrollo	O
:	O
cartílago	O
articular	O
(	O
punta	O
de	O
flecha	O
negra	O
)	O
,	O
precursores	O
de	O
ligamentos	O
y	O
membranas	O
sinoviales	O
(	O
punta	O
de	O
flecha	O
negra	O
)	O
flecha	O
)	O
,	O
y	O
células	B-Cell
donde	O
está	O
ocurriendo	O
la	O
cavitación	O
(	O
asterisco	O
)	O
.	O

Figura	O
2	O

Bmpr1a	B-Protein
es	O
necesario	O
para	O
la	O
regresión	O
de	O
membrana	O
y	O
la	O
apoptosis	O
en	O
regiones	O
específicas	O
de	O
la	O
extremidad	O

(	O
A	O
y	O
B	O
)	O
Mando	O
E14	O
.	O
5	O
miembro	O
anterior	O
(	O
A	O
)	O
comparado	O
con	O
a	O
,	O
E14	O
.	O
5	O
mutante	B-Sequence
miembro	O
anterior	O
(	O
B	O
)	O
que	O
muestra	O
una	O
membrana	O
entre	O
los	O
dedos	O
1	O
y	O
2	O
(	O
puntas	O
de	O
flecha	O
)	O
y	O
tejido	O
adicional	O
en	O
la	O
parte	O
posterior	O
del	O
dedo	O
5	O
(	O
flechas	O
)	O
.	O

(	O
C	O
)	O
gdf5	B-Protein
Expresión	O
de	O
lacZ	O
inducida	O
por	O
Cre	O
a	O
partir	O
de	O
R26R	O
en	O
un	O
E13	O
.	O
5	O
miembro	O
anterior	O
que	O
muestra	O
tinción	O
LACZ	O
(	O
azul	O
)	O
en	O
las	O
articulaciones	O
metacarpiano-falángicas	O
,	O
entre	O
los	O
dedos	O
1	O
y	O
2	O
(	O
punta	O
de	O
flecha	O
)	O
,	O
y	O
en	O
una	O
región	O
posterior	O
al	O
dedo	O
5	O
(	O
flecha	O
)	O
.	O

(	O
D	O
y	O
E	O
)	O
Secciones	O
de	O
E14	O
.	O
5	O
patas	O
traseras	O
que	O
muestran	O
apoptosis	O
visualizada	O
por	O
tinción	O
TUNEL	O
(	O
verde	O
)	O
y	O
proliferación	O
visualizada	O
por	O
tinción	O
para	O
histona	B-Chemical
Fosforilación	O
de	O
H3	O
(	O
rojo	O
)	O
.	O

Los	O
controles	O
muestran	O
una	O
tinción	O
fuerte	O
y	O
uniforme	O
de	O
TUNEL	O
entre	O
los	O
dígitos	O
1	O
y	O
2	O
(	O
D	O
,	O
punta	O
de	O
flecha	O
)	O
mientras	O
mutantes	B-Sequence
muestran	O
tinción	O
irregular	O
de	O
TUNEL	O
intercalada	O
con	O
mitosis	O
células	B-Cell
en	O
regiones	O
similares	O
(	O
E	O
)	O
.	O

Barra	O
de	O
escala	O
=	O
200	O
mu	O
m	O
.	O

(	O
F	O
)	O
Cuantificación	O
de	O
tinción	O
TUNEL	O
y	O
mitosis	O
células	B-Cell
en	O
la	O
región	O
posterior	O
del	O
quinto	O
dígito	O
muestra	O
que	O
la	O
apoptosis	O
se	O
reduce	O
en	O
un	O
30	O
%	O
mientras	O
que	O
la	O
proliferación	O
aumenta	O
en	O
un	O
20	O
%	O
(	O
los	O
asteriscos	O
indican	O
una	O
diferencia	O
estadísticamente	O
significativa	O
)	O
.	O

(	O
G	O
y	O
H	O
)	O
Por	O
E15	O
.	O
5	O
,	O
el	O
tejido	O
interdigital	O
ha	O
retrocedido	O
en	O
los	O
controles	O
(	O
G	O
,	O
punta	O
de	O
flecha	O
)	O
.	O

Por	O
el	O
contrario	O
,	O
el	O
tejido	O
permanece	O
en	O
mutantes	B-Sequence
en	O
este	O
lugar	O
,	O
derivado	O
principalmente	O
de	O
células	B-Cell
que	O
han	O
sufrido	O
gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
Bmpr1a	B-Protein
función	O
y	O
activa	O
la	O
expresión	O
de	O
LACZ	O
(	O
H	O
)	O
.	O

Barra	O
de	O
escala	O
=	O
75	O
mu	O
m	O
.	O

figura	O
3	O

gdf5	B-Protein
#	O
¿NOMBRE	O
?	O
Supresión	B-Sequence
de	O
Bmpr1a	B-Protein

(	O
A	O
)	O
Estrategia	O
de	O
cría	O
simultáneamente	O
elimina	B-Sequence
Bmpr1afloxP	O
y	O
permite	O
la	O
visualización	O
de	O
gdf5	B-Protein
-	O
Recombinación	O
mediada	O
por	O
Cre	O
por	O
expresión	O
de	O
lacZ	O
de	O
R26R	O
.	O

(	O
B	O
-	O
E	O
)	O
5	O
semanas	O
de	O
edad	O
mutante	B-Sequence
y	O
control	O
ratones	B-Taxon
teñido	O
con	O
azul	O
alcián	O
para	O
marcar	O
el	O
cartílago	O
y	O
alizarina	B-Chemical
roja	I-Chemical
para	O
marcar	O
hueso	O
.	O

(	O
B	O
)	O
Tobillo	O
de	O
control	O
con	O
una	O
fuerte	O
tinción	O
azul	O
que	O
recubre	O
cada	O
articulación	O
(	O
puntas	O
de	O
flecha	O
)	O
.	O

(	O
C	O
)	O
Tobillo	O
de	O
mutante	B-Sequence
mostrando	O
una	O
ausencia	O
de	O
tinción	O
azul	O
en	O
la	O
mayoría	O
de	O
las	O
regiones	O
(	O
puntas	O
de	O
flecha	O
)	O
y	O
una	O
fusión	O
conjunta	O
entre	O
el	O
tarso	O
central	O
(	O
c	O
)	O
y	O
el	O
segundo	O
(	O
2	O
)	O
(	O
flecha	O
)	O
.	O

(	O
D	O
)	O
Control	O
y	O
(	O
E	O
)	O
mutante	B-Sequence
articulación	O
metatarsal/falángica	O
que	O
carece	O
de	O
tinción	O
azul	O
en	O
las	O
regiones	O
articulares	O
(	O
puntas	O
de	O
flecha	O
)	O
pero	O
retiene	O
la	O
tinción	O
en	O
la	O
placa	O
de	O
crecimiento	O
(	O
asteriscos	O
)	O
.	O

(	O
F	O
)	O
Miembro	O
anterior	O
de	O
control	O
.	O

(	O
G	O
)	O
mutante	B-Sequence
miembro	O
anterior	O
con	O
una	O
membrana	O
entre	O
el	O
primer	O
y	O
el	O
segundo	O
dedo	O
(	O
punta	O
de	O
flecha	O
negra	O
)	O
.	O

Figura	O
4	O

Bmpr1a	B-Protein
Se	O
expresa	O
en	O
las	O
articulaciones	O
y	O
se	O
requiere	O
para	O
la	O
formación	O
continua	O
de	O
articulaciones	O
en	O
la	O
región	O
del	O
tobillo	O

(	O
A	O
)	O
Diagrama	O
de	O
los	O
huesos	O
del	O
tobillo	O
de	O
un	O
tipo	B-Sequence
salvaje	I-Sequence
ratón	B-Taxon
;	O
huesos	O
fusionados	O
en	O
mutante	B-Sequence
son	O
de	O
color	O
rojo	O
.	O

números	O
romanos	O
II-IV	O
,	O
metatarsianos	O
;	O
2	O
,	O
3	O
y	O
4/5	O
,	O
fila	O
distal	O
de	O
huesos	O
del	O
tarso	O
;	O
c	O
,	O
hueso	O
tarsal	O
central	O
;	O
ta	O
,	O
astrágalo	O
;	O
ca	O
,	O
calcáneo	O
.	O

(	O
B	O
y	O
C	O
)	O
Hibridación	O
in	O
situ	O
en	O
E15	O
.	O
5	O
mostrando	O
que	O
Bmpr1a	B-Protein
se	O
expresa	O
en	O
las	O
interzonas	O
de	O
la	O
articulación	O
del	O
tobillo	O
(	O
B	O
,	O
puntas	O
de	O
flecha	O
)	O
y	O
en	O
las	O
regiones	O
articulares	O
formadoras	O
de	O
las	O
articulaciones	O
falángicas	O
(	O
C	O
,	O
puntas	O
de	O
flecha	O
)	O
.	O

(	O
D	O
)	O
Cerca	O
de	O
la	O
sección	O
adyacente	O
a	O
(	O
C	O
)	O
mostrando	O
gdf5	B-Protein
-	O
Expresión	O
de	O
LACZ	O
inducida	O
por	O
Cre	O
de	O
R26R	O
en	O
las	O
uniones	O
de	O
formación	O
de	O
los	O
dígitos	O
(	O
puntas	O
de	O
flecha	O
)	O
.	O

(	O
E	O
-	O
J	O
)	O
Marcador	O
gene	B-Sequence
expresión	O
y	O
patrones	O
de	O
tinción	O
R26R	O
LACZ	O
en	O
secciones	O
adyacentes	O
cercanas	O
de	O
control	O
y	O
mutante	B-Sequence
embriones	O

En	O
control	O
ratones	B-Taxon
en	O
E15	O
.	O
5	O
articulaciones	O
del	O
tobillo	O
están	O
claramente	O
delineadas	O
como	O
regiones	O
que	O
han	O
regulado	O
hacia	O
abajo	O
Col2	B-Protein
E	O
)	O
,	O
expreso	O
gdf5	B-Protein
a	O
lo	O
largo	O
de	O
(	O
F	O
)	O
,	O
y	O
expresan	O
LACZ	O
en	O
la	O
mayoría	O
células	B-Cell
(	O
G	O
;	O
puntas	O
de	O
flecha	O
blancas	O
y	O
flechas	O
negras	O
)	O
.	O

En	O
mutante	B-Sequence
embriones	O
en	O
la	O
misma	O
etapa	O
,	O
la	O
formación	O
conjunta	O
es	O
incompleta	O
.	O

Desmayarse	O
Col2	B-Protein
la	O
expresión	O
se	O
puede	O
ver	O
conectando	O
una	O
región	O
medial	O
del	O
tarso	O
2	O
con	O
el	O
metatarsiano	O
II	O
(	O
H	O
,	O
punta	O
de	O
flecha	O
blanca	O
)	O
,	O
y	O
gdf5	B-Protein
la	O
expresión	O
no	O
se	O
extiende	O
por	O
toda	O
la	O
articulación	O
en	O
esta	O
ubicación	O
(	O
I	O
,	O
punta	O
de	O
flecha	O
blanca	O
)	O
.	O

Entre	O
los	O
tarsianos	O
c	O
y	O
2	O
,	O
mutantes	B-Sequence
Rápido	O
Col2	B-Protein
a	O
través	O
de	O
la	O
región	O
normal	O
de	O
formación	O
de	O
articulaciones	O
(	O
H	O
,	O
flecha	O
negra	O
)	O
y	O
carecen	O
de	O
expresión	O
de	O
gdf5	B-Protein
en	O
los	O
sitios	O
donde	O
se	O
observan	O
fusiones	O
esqueléticas	O
(	O
I	O
,	O
flecha	O
negra	O
y	O
paréntesis	O
)	O
.	O

(	O
J	O
)	O
Barra	O
de	O
escala	O
=	O
100	O
mu	O
m	O
.	O

Figura	O
5	O

Bmpr1a	B-Protein
Se	O
requiere	O
para	O
mantener	O
la	O
expresión	O
de	O
Componentes	B-GENE
ECM	I-GENE
en	O
cartílago	O
articular	O

Hibridación	O
in	O
situ	O
o	O
tinción	O
LACZ	O
en	O
secciones	O
adyacentes	O
cercanas	O
de	O
las	O
articulaciones	O
metacarpiano-falángicas	O
(	O
A-C	O
y	O
F-H	O
)	O
y	O
la	O
articulación	O
tarsiana	O
2-metatarsiana	O
II	O
(	O
D-E	O
e	O
I-J	O
)	O
de	O
P0	O
ratones	B-Taxon
.	O

Al	O
nacer	O
,	O
cartílago	O
articular	O
de	O
los	O
controles	O
(	O
A	O
-	O
E	O
)	O
y	O
mutantes	B-Sequence
(	O
F-J	O
)	O
parece	O
similar	O
por	O
tinción	O
con	O
safranina	O
O	O
(	O
A	O
y	O
F	O
)	O
,	O
y	O
Col2	B-Protein
expresión	O
(	O
B	O
,	O
G	O
)	O
.	O

Mat4	B-Protein
expresión	O
confirma	O
que	O
el	O
cartílago	O
articular	O
se	O
especifica	O
inicialmente	O
en	O
mutantes	B-Sequence
(	O
D	O
e	O
I	O
,	O
corchetes	O
)	O
.	O

La	O
expresión	O
de	O
LACZ	O
confirma	O
que	O
se	O
ha	O
producido	O
una	O
recombinación	O
mediada	O
por	O
Cre	O
en	O
el	O
cartílago	O
articular	O
(	O
C	O
,	O
H	O
,	O
E	O
y	O
J	O
)	O
.	O

(	O
K	O
-	O
T	O
)	O
Cerca	O
de	O
secciones	O
adyacentes	O
de	O
las	O
articulaciones	O
metacarpiano	O
-	O
falángicas	O
de	O
P14	O
ratones	B-Taxon
.	O

Dos	O
semanas	O
después	O
del	O
nacimiento	O
,	O
el	O
cartílago	O
articular	O
de	O
los	O
controles	O
se	O
tiñe	O
con	O
Safranina	O
O	O
pericelular	O
(	O
tinción	O
naranja	O
,	O
K	O
)	O
y	O
expresa	O
Col2	B-Protein
(	O
I	O
)	O
,	O
agregado	B-Protein
(	O
M	O
)	O
,	O
y	O
SOX9	B-Protein
(	O
N	O
)	O
.	O

A	O
diferencia	O
de	O
,	O
mutante	B-Sequence
articular	O
células	B-Cell
son	O
más	O
pequeños	O
y	O
más	O
densamente	O
empaquetados	O
,	O
carecen	O
de	O
tinción	O
pericelular	O
con	O
Safranina	O
O	O
(	O
P	O
)	O
,	O
tienen	O
expresión	O
reducida	O
de	O
Col2	B-Protein
(	O
Q	O
)	O
y	O
agregado	B-Protein
(	O
R	O
)	O
,	O
pero	O
conservan	O
los	O
niveles	O
normales	O
de	O
SOX9	B-Protein
proteína	B-Chemical
(	O
S	O
,	O
corchetes	O
;	O
la	O
línea	O
discontinua	O
marca	O
los	O
bordes	O
débiles	O
de	O
las	O
superficies	O
articulares	O
)	O
.	O

La	O
expresión	O
de	O
LACZ	O
confirma	O
que	O
se	O
ha	O
producido	O
una	O
recombinación	O
mediada	O
por	O
Cre	O
en	O
articular	O
células	B-Cell
(	O
O	O
y	O
T	O
,	O
corchetes	O
)	O
.	O

(	O
A	O
y	O
K	O
)	O
Barra	O
de	O
escala	O
=	O
75	O
mu	O
m	O
.	O

Figura	O
6	O

Expansión	O
de	O
la	O
membrana	O
sinovial	O
,	O
erosión	O
de	O
la	O
superficie	O
articular	O
y	O
maduración	O
acelerada	O
del	O
cartílago	O
subyacente	O
en	O
los	O
tobillos	O
de	O
Bmpr1a	B-Protein
mutante	B-Sequence
Ratones	B-Taxon

Cerca	O
de	O
secciones	O
adyacentes	O
de	O
la	O
articulación	O
tarsal	O
2	O
-	O
metatarsal	O
II	O
de	O
7	O
-	O
d	O
-	O
viejo	O
ratones	B-Taxon
.	O

(	O
A	O
y	O
B	O
)	O
La	O
tinción	O
LACZ	O
(	O
azul	O
)	O
muestra	O
que	O
la	O
recombinación	O
mediada	O
por	O
Cre	O
está	O
en	O
gran	O
parte	O
restringida	O
a	O
articular	O
(	O
puntas	O
de	O
flecha	O
)	O
y	O
células	B-Cell
sinoviales	I-Cell
(	O
asteriscos	O
)	O
tanto	O
en	O
los	O
controles	O
como	O
en	O
mutantes	B-Sequence
.	O

(	O
C	O
y	O
D	O
)	O
La	O
hibridación	O
in	O
situ	O
muestra	O
Col10	B-Protein
la	O
expresión	O
se	O
expande	O
en	O
mutantes	B-Sequence
hacia	O
regiones	O
de	O
expansión	O
de	O
la	O
membrana	O
sinovial	O
y	O
erosión	O
de	O
la	O
superficie	O
articular	O
(	O
paréntesis	O
y	O
flechas	O
)	O
.	O

Esto	O
puede	O
ser	O
un	O
célula	B-Cell
efecto	O
no	O
autónomo	O
del	O
daño	O
articular	O
,	O
ya	O
que	O
la	O
LACZ	O
expresa	O
células	B-Cell
en	O
la	O
superficie	O
articular	O
no	O
muestran	O
upregulation	O
de	O
Col10	B-Protein
(	O
puntas	O
de	O
flecha	O
)	O
y	O
la	O
región	O
de	O
expansión	O
Col10	B-Protein
La	O
expresión	O
se	O
compone	O
en	O
gran	O
parte	O
de	O
células	B-Cell
que	O
no	O
han	O
sufrido	O
recombinación	O
mediada	O
por	O
Cre	O
.	O

Nótese	O
la	O
formación	O
de	O
un	O
puente	O
cartilaginoso	O
a	O
lo	O
largo	O
de	O
la	O
cápsula	O
articular	O
del	O
mutante	B-Sequence
donde	O
la	O
formación	O
de	O
juntas	O
se	O
interrumpe	O
en	O
etapas	O
anteriores	O
(	O
B	O
,	O
punta	O
de	O
flecha	O
blanca	O
y	O
Figura	O
3	O
,	O
puntas	O
de	O
flecha	O
blancas	O
)	O
.	O

(	O
A	O
)	O
Barra	O
de	O
escala	O
=	O
75	O
mu	O
m	O
.	O

Figura	O
7	O

Pérdida	O
de	O
Bmpr1a	B-Protein
La	O
señalización	O
conduce	O
a	O
la	O
fibrilación	O
y	O
degeneración	O
del	O
cartílago	O
articular	O
en	O
los	O
dedos	O
y	O
las	O
rodillas	O
del	O
envejecimiento	O
Ratones	B-Taxon

(	O
A	O
-	O
D	O
)	O
Cerca	O
de	O
las	O
secciones	O
adyacentes	O
de	O
las	O
articulaciones	O
metatarso	O
-	O
falángicas	O
a	O
partir	O
de	O
los	O
9	O
meses	O
de	O
edad	O
ratones	B-Taxon
.	O

El	O
cartílago	O
articular	O
de	O
los	O
controles	O
está	O
completo	O
y	O
se	O
tiñe	O
intensamente	O
con	O
safranina	O
O	O
(	O
A	O
,	O
tinción	O
naranja	O
)	O
.	O

En	O
cambio	O
,	O
articular	O
células	B-Cell
de	O
mutantes	B-Sequence
están	O
gravemente	O
fibrilados	O
o	O
ausentes	O
con	O
una	O
tinción	O
muy	O
reducida	O
de	O
safranina	O
O	O
(	O
C	O
,	O
puntas	O
de	O
flecha	O
)	O
.	O

La	O
expresión	O
de	O
LACZ	O
confirma	O
que	O
se	O
ha	O
producido	O
una	O
recombinación	O
mediada	O
por	O
Cre	O
en	O
articular	O
células	B-Cell
(	O
B	O
y	O
D	O
)	O
.	O

(	O
E	O
-	O
P	O
)	O
Secciones	O
sagitales	O
a	O
través	O
de	O
las	O
articulaciones	O
de	O
la	O
rodilla	O
de	O
7	O
semanas	O
(	O
E	O
-	O
J	O
)	O
o	O
9	O
meses	O
de	O
edad	O
animales	B-Taxon
(	O
K-P	O
)	O
;	O
fe	O
,	O
fémur	O
;	O
ti	O
,	O
tibia	O
;	O
gp	O
,	O
placa	O
de	O
crecimiento	O
.	O

Siete	O
semanas	O
después	O
del	O
nacimiento	O
,	O
la	O
altura	O
de	O
la	O
epífisis	O
tibial	O
se	O
reduce	O
en	O
mutantes	B-Sequence
(	O
E	O
y	O
H	O
,	O
barras	O
)	O
,	O
y	O
su	O
capa	O
articular	O
se	O
tiñe	O
mal	O
con	O
safranina	O
O	O
,	O
está	O
fibrilada	O
y	O
es	O
llamativamente	O
más	O
delgada	O
(	O
F	O
e	O
I	O
,	O
punta	O
de	O
flecha	O
negra	O
y	O
corchetes	O
)	O
.	O

Cerca	O
de	O
secciones	O
adyacentes	O
con	O
tinción	O
LACZ	O
confirman	O
que	O
se	O
ha	O
producido	O
recombinación	O
mediada	O
por	O
Cre	O
en	O
articular	O
células	B-Cell
(	O
G	O
y	O
J	O
)	O
.	O

Tenga	O
en	O
cuenta	O
que	O
en	O
mutantes	B-Sequence
,	O
LACZ	O
está	O
ausente	O
en	O
células	B-Cell
adyacentes	O
a	O
los	O
que	O
se	O
tiñen	O
con	O
safranina	O
O	O
,	O
lo	O
que	O
sugiere	O
Bmpr1a	B-Protein
puede	O
actuar	O
célula	B-Cell
de	O
forma	O
autónoma	O
(	O
I	O
y	O
J	O
,	O
puntas	O
de	O
flecha	O
blancas	O
)	O
.	O

A	O
los	O
9	O
meses	O
de	O
edad	O
,	O
el	O
mutante	B-Sequence
la	O
epífisis	O
tibial	O
es	O
extremadamente	O
delgada	O
(	O
K	O
y	O
N	O
,	O
barras	O
)	O
,	O
y	O
la	O
capa	O
articular	O
está	O
completamente	O
ausente	O
,	O
dejando	O
que	O
el	O
hueso	O
roce	O
directamente	O
con	O
el	O
hueso	O
(	O
L	O
y	O
O	O
,	O
soporte	O
)	O
.	O

La	O
tinción	O
LACZ	O
muestra	O
que	O
se	O
produjo	O
una	O
recombinación	O
mediada	O
por	O
Cre	O
en	O
articular	O
células	B-Cell
de	O
controles	O
(	O
M	O
)	O
y	O
en	O
algunos	O
restos	O
de	O
tejido	O
esquelético	O
de	O
mutantes	B-Sequence
(	O
PAGS	O
)	O
.	O

Obsérvese	O
también	O
el	O
cartílago	O
meniscal	O
formado	O
de	O
forma	O
aberrante	O
en	O
mutantes	B-Sequence
(	O
E	O
,	O
H	O
,	O
K	O
y	O
N	O
,	O
flechas	O
)	O
,	O
y	O
aumento	O
de	O
la	O
esclerosis	O
en	O
mutante	B-Sequence
epífisis	O
(	O
E	O
,	O
H	O
,	O
K	O
y	O
N	O
,	O
asteriscos	O
)	O
.	O

(	O
A	O
y	O
K	O
)	O
Barra	O
de	O
escala	O
=	O
50	O
mu	O
m	O
;	O
(	O
I	O
)	O
barra	O
de	O
escala	O
=	O
300	O
mu	O
m	O
.	O

notas	O
al	O
pie	O

Conflictos	O
de	O
interés	O
.	O

Los	O
autores	O
han	O
declarado	O
que	O
no	O
existen	O
conflictos	O
de	O
interés	O
.	O

Contribuciones	O
de	O
autor	O
.	O

RBR	O
,	O
MS	O
y	O
DMK	O
concibieron	O
y	O
diseñaron	O
los	O
experimentos	O
.	O

RBR	O
y	O
MEM	O
realizaron	O
los	O
experimentos	O
.	O

RBR	O
,	O
HC	O
y	O
DMK	O
analizaron	O
los	O
datos	O
.	O

MS	O
,	O
HC	O
,	O
VH	O
y	O
YM	O
contribuyeron	O
reactivos	B-Chemical
/	O
materiales	O
/	O
herramientas	O
de	O
análisis	O
.	O

RBR	O
y	O
DMK	O
escribieron	O
el	O
artículo	O
.	O

Editor	O
académico	O
:	O
Lee	O
Niswander	O
,	O
Centro	O
de	O
Ciencias	O
de	O
la	O
Salud	O
de	O
la	O
Universidad	O
de	O
Colorado	O

moneda	O
Dirección	O
actual	O
:	O
ARTEMIS	O
productos	B-Chemical
farmaceuticos	I-Chemical
,	O
an	O
Exelixis	O
Company	O
,	O
K	O
o	O
ln	O
,	O
Alemania	O

Cita	O
:	O
Rountree	O
RB	O
,	O
Schoor	O
M	O
,	O
Chen	O
H	O
,	O
Marks	O
ME	O
,	O
Harley	O
V	O
,	O
et	O
al	O
.	O

-2004	O
BMP	B-Protein
la	O
señalización	O
del	O
receptor	O
es	O
necesaria	O
para	O
el	O
mantenimiento	O
posnatal	O
del	O
cartílago	O
articular	O
.	O

PLoS	O
Biol	O
2	O
(	O
11	O
)	O
:	O
e355	O
.	O

Un	O
papel	O
quimioatrayente	O
para	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
en	O
propioceptivo	O
axón	B-GENE
Guia	O

Resumen	O

Neurotrofina	B-Protein
-	I-Protein
3	I-Protein
(	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
)	O
es	O
necesario	O
para	O
la	O
propiocepción	O
neurona	B-Cell
supervivencia	O

Supresión	B-Sequence
de	O
la	O
proapoptótica	O
gene	B-Sequence
bax	B-Protein
en	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
knockear	O
ratones	B-Taxon
rescata	O
a	O
estos	O
neuronas	B-Cell
y	O
permite	O
el	O
examen	O
de	O
sus	O
axón	B-GENE
crecimiento	O
en	O
ausencia	O
de	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
señalización	O

TrkC	B-Protein
#	O
¿NOMBRE	O
?	O
axones	B-GENE
desde	O
los	O
ganglios	O
de	O
la	O
raíz	O
dorsal	O
siguen	O
trayectorias	O
apropiadas	O
y	O
llegan	O
muy	O
cerca	O
de	O
sus	O
objetivos	O
pero	O
no	O
logran	O
inervarlos	O
.	O

Periféricamente	O
,	O
los	O
husos	O
musculares	O
están	O
ausentes	O
y	O
TrkC	B-Protein
#	O
¿NOMBRE	O
?	O
axones	B-GENE
no	O
entre	O
en	O
sus	O
músculos	O
objetivo	O
.	O

Centralmente	O
,	O
propioceptivo	O
axones	B-GENE
se	O
ramifican	O
en	O
regiones	O
ectópicas	O
de	O
la	O
médula	O
espinal	O
,	O
incluso	O
cruzando	O
la	O
línea	O
media	O
.	O

Ensayos	O
in	O
vitro	O
revelan	O
efectos	O
quimioatrayentes	O
de	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
en	O
el	O
ganglio	O
de	O
la	O
raíz	O
dorsal	O
axones	B-GENE
.	O

Nuestros	O
resultados	O
muestran	O
que	O
el	O
factor	O
de	O
supervivencia	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
actúa	O
como	O
una	O
distancia	O
corta	O
axón	B-GENE
Guia	O
molécula	B-Chemical
para	O
los	O
aferentes	O
sensoriales	O
musculares	O
a	O
medida	O
que	O
se	O
acercan	O
a	O
sus	O
objetivos	O
adecuados	O
.	O

Introducción	O

Neurotrofina	B-Protein
-	I-Protein
3	I-Protein
(	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
)	O
es	O
un	O
requisito	O
clave	O
para	O
el	O
desarrollo	O
de	O
entradas	O
propioceptivas	O
para	O
neuronas	B-Cell
motoras	I-Cell
(	O
Chen	O
y	O
Frank	O
1999	O
;	O
Chen	O
et	O
al	O
.	O
2003	O
)	O
.	O

Ratones	B-Taxon
deficiente	O
en	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
,	O
su	O
receptor	B-Protein
de	I-Protein
tirosina	I-Protein
quinasa	I-Protein
,	O
TrkC	B-Protein
,	O
o	O
en	O
TrkC	B-Protein
#	O
¿NOMBRE	O
?	O
neurona	B-Cell
#	O
¿NOMBRE	O
?	O
Ejecutarx3	B-Protein
muestran	O
ataxia	O
severa	O
asociada	O
con	O
la	O
ausencia	O
de	O
husos	O
musculares	O
y	O
pérdida	O
de	O
la	O
función	O
propioceptiva	O
neuronas	B-Cell
en	O
los	O
ganglios	O
de	O
la	O
raíz	O
dorsal	O
(	O
GRD	O
)	O
o	O
sus	O
axones	B-GENE
(	O
Ernfors	O
et	O
al	O
.	O
1994	O
;	O
Klein	O
et	O
al	O
.	O
1994	O
;	O
Tessarollo	O
et	O
al	O
.	O
1994	O
;	O
Fari	O
n	O
as	O
et	O
al	O
.	O
1996	O
;	O
Liebl	O
et	O
al	O
.	O
1997	O
;	O
Inoue	O
et	O
al	O
.	O
2002	O
;	O
Levanon	O
et	O
al	O
.	O
2002	O
)	O
.	O

Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
se	O
expresa	O
en	O
la	O
médula	O
espinal	O
ventral	O
,	O
en	O
las	O
yemas	O
de	O
las	O
extremidades	O
en	O
desarrollo	O
y	O
en	O
las	O
fibras	O
de	O
la	O
bolsa	O
intrafusal	O
de	O
los	O
husos	O
musculares	O
más	O
adelante	O
en	O
el	O
desarrollo	O
(	O
Copray	O
y	O
Brouwer	O
1994	O
;	O
Fari	O
n	O
as	O
et	O
al	O
.	O
1996	O
;	O
Tojo	O
et	O
al	O
.	O
1996	O
)	O
.	O

cuando	O
sensorial	O
axones	B-GENE
entran	O
en	O
contacto	O
con	O
los	O
miotubos	O
en	O
desarrollo	O
,	O
inducen	O
la	O
diferenciación	O
del	O
huso	O
muscular	O
,	O
formando	O
una	O
espiral	O
en	O
forma	O
de	O
anillo	O
terminaciones	B-GENE
nerviosas	I-GENE
alrededor	O
de	O
ellos	O
.	O

En	O
el	O
pollo	B-Taxon
embrión	O
,	O
ablaciones	O
de	O
extremidades	O
o	O
anti	O
-	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
anticuerpo	B-GENE
las	O
inyecciones	O
en	O
los	O
brotes	O
de	O
las	O
extremidades	O
conducen	O
a	O
la	O
eliminación	O
de	O
TrkC	B-Protein
#	O
¿NOMBRE	O
?	O
neuronas	B-Cell
y	O
disminución	O
de	O
la	O
inervación	O
de	O
neuronas	B-Cell
motoras	I-Cell
(	O
Oakley	O
y	O
col.	O
1995	O
,	O
1997	O
)	O
.	O

Es	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
¿sólo	O
un	O
factor	O
de	O
supervivencia	O
quimiotrófico	O
para	O
los	O
aferentes	O
sensoriales	O
musculares	O
,	O
o	O
tiene	O
funciones	O
adicionales	O
en	O
el	O
desarrollo	O
de	O
los	O
propioceptores	O
y	O
el	O
establecimiento	O
del	O
arco	O
reflejo	O
monosináptico	O
?	O

Aquí	O
proporcionamos	O
evidencia	O
de	O
que	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
actúa	O
como	O
un	O
quimioatrayente	O
para	O
los	O
sentidos	O
axones	B-GENE
durante	O
la	O
fase	O
final	O
de	O
su	O
orientación	O
dirigida	O
al	O
objetivo	O
.	O

Resultados	O

TrkC	B-Protein
#	O
¿NOMBRE	O
?	O
neuronas	B-Cell
son	O
rescatados	O
en	O
bax	B-Protein
/	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
Doble	O
nocaut	O
Ratones	B-Taxon

Ratones	B-Taxon
carente	O
de	O
proapoptótico	O
proteína	B-Chemical
bax	B-Protein
permiten	O
distinguir	O
los	O
efectos	O
de	O
supervivencia	O
de	O
neurotrofinas	B-Protein
de	O
otros	O
efectos	O
.	O

bax	B-Protein
#	O
¿NOMBRE	O
?	O
neuronas	B-Cell
sensoriales	I-Cell
ya	O
no	O
requiere	O
neurotrofinas	B-Protein
para	O
la	O
supervivencia	O
(	O
White	O
et	O
al	O
.	O
1998	O
;	O
Patel	O
et	O
al	O
.	O
2000	O
)	O
,	O
por	O
lo	O
que	O
pueden	O
utilizarse	O
para	O
examinar	O
axonal	B-GENE
efectos	O

criamos	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
heterocigoto	O
y	O
bax	B-Protein
nocaut	O
(	O
KO	O
)	O
ratones	B-Taxon
para	O
obtener	O
ratones	B-Taxon
con	O
doble	O
KO	O
de	O
ambos	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
y	O
bax	B-Protein
genes	B-Sequence
,	O
y	O
examinó	O
propioceptivo	O
proyecciones	B-GENE
axonales	I-GENE
.	O

Todos	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
y	O
los	O
KO	O
dobles	O
morían	O
dentro	O
de	O
las	O
48	O
h	O
posteriores	O
al	O
nacimiento	O
(	O
Tessarollo	O
et	O
al	O
.	O
1994	O
)	O
.	O

Actuamos	O
TrkA	B-Protein
/	O
TrkC	B-Protein
inmunohistoquímica	O
doble	O
(	O
Huang	O
et	O
al	O
.	O
1999	O
)	O
,	O
que	O
permite	O
la	O
detección	O
de	O
ambos	O
proteinas	B-Chemical
en	O
la	O
misma	O
muestra	O
.	O

TrkC	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
(	O
Figura	O
1A	O
)	O
y	O
fibras	O
(	O
Figura	O
1E	O
)	O
estaban	O
ausentes	O
en	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
KOs	O
en	O
el	O
día	O
embrionario	O
(	O
E	O
)	O
15	O
.	O

Dos	O
subconjuntos	O
de	O
DRG	O
células	B-Cell
expresando	O
cualquiera	O
TrkA	B-Protein
o	O
TrkC	B-Protein
fueron	O
detectados	O
en	O
dobles	O
KOs	O
,	O
similar	O
a	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
peso	B-Sequence
)	O
o	O
bax	B-Protein
KO	O
animales	B-Taxon
.	O

Sorprendentemente	O
,	O
en	O
el	O
día	O
postnatal	O
(	O
P	O
)	O
0	O
,	O
algunos	O
células	B-Cell
expresado	O
TrkC	B-Protein
incluso	O
en	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
KO	O
animales	B-Taxon
en	O
el	O
bax	B-Protein
+	B-Sequence
/	O
#	B-Sequence
¿NOMBRE	I-Sequence
?	I-Sequence
antecedentes	O
y	O
algunos	O
células	B-Cell
co	O
-	O
expresado	O
TrkA	B-Protein
y	O
TrkC	B-Protein
a	O
pesar	O
de	O
genotipo	B-Sequence
(	O
Figura	O
1B	O
)	O
.	O

Para	O
cuantificar	O
nuestros	O
resultados	O
,	O
analizamos	O
el	O
ratio	O
de	O
TrkA	B-Protein
y	O
TrkC	B-Protein
inmunopositivo	O
células	B-Cell
de	O
cuatro	O
GRD	O
diferentes	O
de	O
animales	B-Taxon
de	O
diferente	O
genotipos	B-Sequence
.	O

En	O
todas	O
las	O
edades	O
estudiadas	O
,	O
bax	B-Protein
/	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
los	O
DRG	O
dobles	O
nulos	O
tenían	O
TrkA	B-Protein
/	O
TrkC	B-Protein
proporciones	O
similares	O
a	O
las	O
de	O
bax	B-Protein
GRD	O
nulos	O
,	O
y	O
superiores	O
a	O
los	O
de	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
GRD	O
nulos	O
(	O
Figura	O
1D	O
)	O
.	O

TrkC	B-Protein
#	O
¿NOMBRE	O
?	O
neuronas	B-Cell
rescatado	O
por	O
bax	B-Protein
supresión	B-Sequence
,	O
sin	O
embargo	O
,	O
no	O
pudo	O
diferenciar	O
adecuadamente	O
,	O
como	O
lo	O
demuestra	O
la	O
falta	O
de	O
expresión	O
del	O
propioceptivo	O
molecular	B-Chemical
marcador	O
parvalbúmina	B-Protein
(	O
fotovoltaica	B-Protein
)	O
(	O
Figura	O
1C	O
)	O
.	O

Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
es	O
necesario	O
para	O
la	O
inervación	O
adecuada	O
de	O
Neuronas	B-Cell
motoras	I-Cell

TrkA	B-Protein
/	O
TrkC	B-Protein
-Se	O
pudieron	O
detectar	O
fibras	O
positivas	O
en	O
la	O
médula	O
espinal	O
en	O
E15	O
(	O
Figura	O
1E	O
)	O
.	O

TrkA	B-Protein
-	O
Las	O
fibras	O
positivas	O
estaban	O
restringidas	O
y	O
terminaban	O
en	O
la	O
médula	O
espinal	O
dorsolateral	O
,	O
mientras	O
que	O
TrkC	B-Protein
Las	O
fibras	O
positivas	O
entraron	O
en	O
el	O
cordón	O
dorsomedialmente	O
y	O
descendieron	O
a	O
los	O
cuernos	O
ventrales	O
en	O
peso	B-Sequence
(	O
Ozaki	O
y	O
Snider	O
1997	O
)	O
y	O
bax	B-Protein
Embriones	O
KO	O
.	O

No	O
se	O
detectó	O
TrkC	B-Protein
expresión	O
en	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
Médula	O
espinal	O
KO	O
,	O
lo	O
que	O
indica	O
ausencia	O
completa	O
de	O
fibras	O
propioceptivas	O
.	O

En	O
doble	O
KO	O
de	O
médula	O
espinal	O
,	O
TrkC	B-Protein
#	O
¿NOMBRE	O
?	O
peso	B-Sequence
o	O
bax	B-Protein
Casos	O
KO	O
.	O

Sin	O
embargo	O
,	O
no	O
fue	O
posible	O
seguir	O
TrkC	B-Protein
fibras	O
inmunomarcadas	O
hasta	O
sus	O
zonas	O
terminales	O
en	O
cualquiera	O
de	O
los	O
casos	O
.	O

A	O
continuación	O
examinamos	O
el	O
centro	O
proyecciones	B-GENE
de	O
GRD	O
axones	B-GENE
con	O
el	O
trazador	O
lipofílico	O
DiI	O
en	O
P0	O
.	O

En	O
peso	B-Sequence
y	O
bax	B-Protein
Cachorros	O
KO	O
,	O
los	O
aferentes	O
propioceptivos	O
entraron	O
en	O
la	O
médula	O
espinal	O
dorsal	O
y	O
siguieron	O
un	O
curso	O
medial	O
hacia	O
el	O
asta	O
ventral	O
.	O

Luego	O
giraron	O
lateralmente	O
hacia	O
neuronas	B-Cell
motoras	I-Cell
en	O
la	O
columna	O
motora	O
lateral	O
,	O
donde	O
se	O
ramificaban	O
y	O
terminaban	O
(	O
Figura	O
2A	O
)	O
.	O

El	O
marcaje	O
de	O
DiI	O
se	O
limitó	O
a	O
la	O
médula	O
espinal	O
dorsal	O
en	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
KO	O
(	O
Figura	O
2A	O
)	O
,	O
como	O
se	O
informó	O
anteriormente	O
,	O
consistente	O
con	O
una	O
ausencia	O
total	O
de	O
inervación	O
propioceptiva	O
(	O
Ernfors	O
et	O
al	O
.	O
1994	O
;	O
Tessarollo	O
et	O
al	O
.	O
1994	O
)	O
.	O

En	O
los	O
KO	O
dobles	O
,	O
los	O
aferentes	O
propioceptivos	O
inicialmente	O
siguieron	O
una	O
trayectoria	O
similar	O
a	O
la	O
de	O
peso	B-Sequence
contrapartes	O
,	O
pero	O
la	O
mayoría	O
de	O
ellos	O
no	O
lograron	O
proyectarse	O
hasta	O
el	O
cordón	O
ventral	O
y	O
la	O
columna	O
motora	O
lateral	O
.	O

En	O
cambio	O
,	O
arborizaron	O
cerca	O
de	O
la	O
línea	O
media	O
ventral	O
;	O
algunos	O
cruzaron	O
la	O
línea	O
media	O
y	O
se	O
extendieron	O
hacia	O
el	O
cordón	O
ventral	O
contralateral	O
(	O
Figura	O
2A	O
y	O
2C	O
)	O
.	O

Con	O
el	O
fin	O
de	O
distinguir	O
entre	O
un	O
papel	O
para	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
en	O
iniciación	O
de	O
neurona	B-Cell
motora	I-Cell
inervación	O
y	O
un	O
papel	O
para	O
el	O
mantenimiento	O
,	O
repetimos	O
el	O
etiquetado	O
DiI	O
en	O
E17	O
.	O

Los	O
patrones	O
de	O
inervación	O
de	O
las	O
médulas	O
espinales	O
E17	O
(	O
Figura	O
3	O
)	O
fueron	O
similares	O
a	O
los	O
de	O
P0	O
(	O
Figura	O
2	O
)	O
.	O

Cuernos	O
dorsales	O
de	O
todos	O
genotipos	B-Sequence
se	O
llenaron	O
con	O
fibras	O
marcadas	O
con	O
DiI	O
correspondientes	O
a	O
factor	B-Protein
de	I-Protein
crecimiento	I-Protein
nervioso	I-Protein
#	O
¿NOMBRE	O
?	O
axones	B-GENE
.	O

En	O
peso	B-Sequence
y	O
bax	B-Protein
Embriones	O
KO	O
,	O
fibras	O
propioceptivas	O
extendidas	O
hacia	O
el	O
cuerno	O
ventral	O
neuronas	B-Cell
motoras	I-Cell
(	O
Figura	O
3A	O
y	O
3B	O
)	O
,	O
mientras	O
que	O
los	O
cuernos	O
ventrales	O
del	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
Los	O
embriones	O
KO	O
estaban	O
desprovistos	O
de	O
inervación	O
(	O
Figura	O
3C	O
)	O
.	O

En	O
el	O
bax	B-Protein
/	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
KO	O
dobles	O
,	O
las	O
fibras	O
marcadas	O
con	O
DiI	O
entraron	O
en	O
la	O
médula	O
espinal	O
ventral	O
,	O
pero	O
se	O
extendieron	O
hacia	O
la	O
línea	O
media	O
en	O
lugar	O
del	O
asta	O
ventral	O
(	O
Figura	O
3D	O
)	O
,	O
en	O
un	O
patrón	O
similar	O
al	O
observado	O
en	O
P0	O
.	O

Nuestros	O
datos	O
apuntan	O
a	O
una	O
ausencia	O
total	O
de	O
inervación	O
propioceptiva	O
del	O
asta	O
ventral	O
del	O
bax	B-Protein
/	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
médula	O
espinal	O
nula	O
a	O
lo	O
largo	O
de	O
las	O
etapas	O
de	O
desarrollo	O
investigadas	O
.	O

como	O
lo	O
sensorial	O
axones	B-GENE
nunca	O
alcanzar	O
neurona	B-Cell
motora	I-Cell
dendritas	B-GENE
en	O
el	O
asta	O
ventral	O
(	O
Figura	O
S1	O
)	O
,	O
no	O
se	O
establece	O
el	O
circuito	O
del	O
arco	O
reflejo	O
de	O
estiramiento	O
.	O

La	O
falla	O
en	O
iniciar	O
el	O
contacto	O
entre	O
los	O
sentidos	O
axones	B-GENE
y	O
neuronas	B-Cell
motoras	I-Cell
en	O
ausencia	O
de	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
sugiere	O
un	O
requisito	O
para	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
para	O
el	O
correcto	O
axón	B-GENE
focalización	O
además	O
de	O
un	O
papel	O
en	O
los	O
sentidos	O
axón	B-GENE
mantenimiento	O
.	O

Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
es	O
necesario	O
para	O
la	O
inervación	O
periférica	O
adecuada	O

Para	O
estudiar	O
la	O
inervación	O
periférica	O
en	O
doble	O
KO	O
animales	B-Taxon
,	O
investigamos	O
el	O
desarrollo	O
del	O
huso	O
en	O
el	O
músculo	O
gastrocnemio	O
.	O

Los	O
husos	O
musculares	O
podrían	O
identificarse	O
fácilmente	O
en	O
P0	O
peso	B-Sequence
y	O
bax	B-Protein
KO	O
animales	B-Taxon
por	O
su	O
morfología	O
característica	O
(	O
Figura	O
4A	O
y	O
4B	O
)	O
.	O

Fibras	O
propioceptivas	O
marcadas	O
con	O
neurofilamento	B-Protein
-	I-Protein
M	I-Protein
(	O
NF-M	B-Protein
)	O
anticuerpo	B-GENE
forma	O
de	O
anillo	O
-	O
como	O
terminaciones	O
en	O
espiral	O
envueltas	O
alrededor	O
de	O
las	O
fibras	O
de	O
la	O
bolsa	O
intrafusal	O
etiquetadas	O
con	O
S46	O
anticuerpo	B-GENE
,	O
específico	O
para	O
el	O
desarrollo	O
lento	O
miosina	B-GENE
pesado	O
cadena	B-Sequence
proteína	B-Chemical
(	O
Miller	O
y	O
col.	O
1985	O
)	O
.	O

Como	O
se	O
informó	O
anteriormente	O
,	O
no	O
había	O
husos	O
musculares	O
en	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
KO	O
animales	B-Taxon
(	O
Ernfors	O
et	O
al	O
.	O
1994	O
)	O
.	O

Por	O
otro	O
lado	O
,	O
bax	B-Protein
KO	O
animales	B-Taxon
tenía	O
más	O
husos	O
que	O
peso	B-Sequence
,	O
y	O
los	O
husos	O
estaban	O
en	O
grupos	O
similares	O
a	O
animales	B-Taxon
sobre	O
-	O
expresando	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
en	O
el	O
músculo	O
(	O
Wright	O
et	O
al	O
.	O
1997	O
)	O
.	O

Aunque	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
fueron	O
rescatados	O
,	O
no	O
se	O
detectaron	O
husos	O
musculares	O
en	O
las	O
extremidades	O
de	O
los	O
KO	O
dobles	O
(	O
Figura	O
4A	O
y	O
4B	O
)	O
.	O

Los	O
husos	O
musculares	O
se	O
pueden	O
observar	O
con	O
TrkC	B-Protein
anticuerpo	B-GENE
en	O
peso	B-Sequence
y	O
bax	B-Protein
KO	O
animales	B-Taxon
,	O
pero	O
no	O
en	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
o	O
dobles	O
KO	O
(	O
Figura	O
4E	O
)	O
.	O

En	O
ambos	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
y	O
doble	O
KO	O
animales	B-Taxon
,	O
NF-M	B-Protein
-	O
Las	O
fibras	O
marcadas	O
se	O
pueden	O
detectar	O
en	O
los	O
músculos	O
,	O
por	O
lo	O
que	O
los	O
músculos	O
de	O
estos	O
animales	B-Taxon
no	O
estaban	O
completamente	O
desprovistos	O
de	O
fibras	O
nerviosas	O
.	O

Como	O
no	O
había	O
TrkC	B-Protein
-	O
fibras	O
positivas	O
en	O
estos	O
músculos	O
,	O
pensamos	O
que	O
estos	O
NF-M	B-Protein
#	O
¿NOMBRE	O
?	O
axones	B-GENE
.	O

La	O
ausencia	O
de	O
husos	O
musculares	O
puede	O
deberse	O
a	O
un	O
fallo	O
en	O
el	O
inicio	O
de	O
la	O
diferenciación	O
por	O
propiocepción	O
.	O
axones	B-GENE
,	O
o	O
una	O
falta	O
de	O
maduración	O
y	O
mantenimiento	O
en	O
ausencia	O
de	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
.	O

Para	O
distinguir	O
entre	O
estas	O
dos	O
posibilidades	O
,	O
investigamos	O
el	O
desarrollo	O
del	O
huso	O
muscular	O
en	O
E15	O
y	O
E17	O
con	O
S46/	O
NF-M	B-Protein
inmunotinción	O
así	O
como	O
marcaje	O
con	O
DiI	O
.	O

No	O
se	O
detectaron	O
estructuras	O
con	O
la	O
forma	O
característica	O
del	O
huso	O
muscular	O
en	O
ninguno	O
de	O
los	O
genotipos	B-Sequence
en	O
E15	O
(	O
Figura	O
S2	O
)	O
.	O

Sin	O
embargo	O
,	O
se	O
pudieron	O
identificar	O
numerosos	O
husillos	O
de	O
revelado	O
en	O
E17	O
en	O
peso	B-Sequence
y	O
bax	B-Protein
KOs	O
,	O
pero	O
no	O
en	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
Embriones	O
KO	O
(	O
Figura	O
4C	O
)	O
.	O

bax	B-Protein
/	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
los	O
músculos	O
nulos	O
dobles	O
estaban	O
desprovistos	O
de	O
husos	O
(	O
Figura	O
4C	O
)	O
,	O
excepto	O
por	O
una	O
estructura	O
similar	O
a	O
un	O
huso	O
observada	O
en	O
una	O
pata	O
de	O
un	O
embrión	O
(	O
Figura	O
4C	O
,	O
recuadro	O
,	O
indicado	O
por	O
el	O
asterisco	O
)	O
.	O

El	O
marcaje	O
de	O
DiI	O
a	O
través	O
de	O
los	O
GRD	O
en	O
E17	O
arrojó	O
resultados	O
similares	O
,	O
con	O
husos	O
musculares	O
identificados	O
en	O
secciones	O
paralelas	O
en	O
peso	B-Sequence
y	O
bax	B-Protein
músculos	O
nulos	O
(	O
Figura	O
4D	O
)	O
,	O
pero	O
no	O
en	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
o	O
doble	O
KO	O
animales	B-Taxon
.	O

Aunque	O
las	O
fibras	O
marcadas	O
con	O
DiI	O
podían	O
detectarse	O
en	O
músculos	O
doblemente	O
nulos	O
,	O
nunca	O
formaron	O
estructuras	O
anulares	O
características	O
de	O
los	O
husos	O
musculares	O
.	O

También	O
examinamos	O
TrkA	B-Protein
/	O
TrkC	B-Protein
expresión	O
en	O
P0	O
en	O
el	O
nervio	O
tibial	O
,	O
que	O
transporta	O
fibras	O
sensoriales	O
al	O
músculo	O
gastrocnemio	O
así	O
como	O
a	O
la	O
piel	O
de	O
la	O
parte	O
inferior	O
de	O
la	O
pierna	O
.	O

En	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
KO	O
,	O
TrkA	B-Protein
#	O
¿NOMBRE	O
?	O
axones	B-GENE
podía	O
verse	O
en	O
el	O
nervio	O
tibial	O
pero	O
no	O
había	O
TrkC	B-Protein
#	O
¿NOMBRE	O
?	O
axones	B-GENE
;	O
a	O
diferencia	O
de	O
,	O
TrkA	B-Protein
#	O
¿NOMBRE	O
?	O
TrkC	B-Protein
#	O
¿NOMBRE	O
?	O
axones	B-GENE
ambos	O
están	O
presentes	O
en	O
peso	B-Sequence
,	O
bax	B-Protein
KO	O
y	O
doble	O
KO	O
animales	B-Taxon
(	O
Figura	O
4F	O
)	O
.	O

Estos	O
resultados	O
sugieren	O
que	O
aunque	O
propioceptivo	O
axones	B-GENE
siguen	O
trayectorias	O
adecuadas	O
en	O
los	O
nervios	O
periféricos	O
distales	O
,	O
no	O
logran	O
inervar	O
sus	O
músculos	O
objetivo	O
en	O
ausencia	O
de	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
.	O

Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
Es	O
un	O
quimioatrayente	O
para	O
DRG	O
axones	B-GENE
in	O
vitro	O

Para	O
probar	O
la	O
hipótesis	O
de	O
que	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
actúa	O
como	O
un	O
quimioatrayente	O
para	O
los	O
sentidos	O
axones	B-GENE
,	O
realizamos	O
una	O
serie	O
de	O
ensayos	O
in	O
vitro	O
.	O

propioceptivo	O
axones	B-GENE
en	O
ratones	B-Taxon
entrar	O
en	O
la	O
materia	O
gris	O
en	O
la	O
médula	O
espinal	O
y	O
avanzar	O
ventralmente	O
paralelo	O
a	O
la	O
línea	O
media	O
por	O
E13	O
y	O
llegar	O
a	O
la	O
neuronas	B-Cell
motoras	I-Cell
por	O
E15	O
(	O
Ozaki	O
y	O
Snider	O
1994	O
)	O
.	O

Nosotros	O
co-cultivamos	O
colágeno	B-Protein
#	O
¿NOMBRE	O
?	O
peso	B-Sequence
Explantes	O
de	O
DRG	O
con	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
-	O
perlas	O
de	O
sefarosa	O
empapadas	O
(	O
n	O
=	O
26	O
)	O
.	O

Los	O
cultivos	O
de	O
control	O
se	O
establecieron	O
utilizando	O
albúmina	B-Protein
de	I-Protein
suero	I-Protein
bovino	I-Protein
(	O
BSA	B-Protein
)	O
-	O
o	O
fosfato	B-Chemical
Perlas	O
empapadas	O
en	O
tampón	O
salino	O
(	O
PBS	O
)	O
(	O
n	O
=	O
12	O
)	O
.	O

GRD	O
axones	B-GENE
comenzó	O
a	O
extenderse	O
hacia	O
el	O
localizado	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
fuente	O
al	O
final	O
del	O
primer	O
día	O
y	O
mostraron	O
consistentemente	O
una	O
fuerte	O
quimioatracción	O
por	O
3	O
d	O
in	O
vitro	O
,	O
mientras	O
que	O
no	O
mostraron	O
tal	O
preferencia	O
por	O
BSA	B-Protein
microesferas	O
de	O
control	O
cargadas	O
(	O
Figura	O
5A	O
y	O
5B	O
)	O
.	O

Esta	O
atracción	O
no	O
se	O
debió	O
al	O
apoyo	O
de	O
supervivencia	O
de	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
porque	O
bax	B-Protein
los	O
ganglios	O
nulos	O
mostraron	O
la	O
misma	O
quimioatracción	O
(	O
Figura	O
5C	O
;	O
n	O
=	O
16	O
)	O
.	O

Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
puede	O
actuar	O
a	O
través	O
de	O
TrkC	B-Protein
,	O
o	O
la	O
p75NTR	B-Protein
.	O

Repetimos	O
los	O
experimentos	O
de	O
cocultivo	O
con	O
explantes	O
de	O
DRG	O
derivados	O
de	O
p75NTR	B-Protein
KO	O
ratones	B-Taxon
(	O
n	O
=	O
18	O
)	O
.	O

axones	B-GENE
de	O
estos	O
ganglios	O
también	O
mostró	O
una	O
fuerte	O
quimioatracción	O
hacia	O
el	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
perlas	O
(	O
Figura	O
5D	O
)	O
.	O

Finalmente	O
,	O
usamos	O
difusible	O
receptores	B-Protein
TrkC	I-Protein
conjugado	O
a	O
IgG	O
constante	O
regiones	B-Sequence
(	O
TrkC	B-Protein
Fc	O
)	O
añadido	O
al	O
medio	O
(	O
n	O
=	O
6	O
)	O
para	O
agotar	O
soluble	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
desde	O
el	O
colágeno	B-Protein
geles	O
(	O
Figura	O
5E	O
)	O
.	O

En	O
la	O
presencia	O
de	O
TrkC	B-Protein
-	O
Fc	O
la	O
quimioatracción	O
fue	O
completamente	O
bloqueada	O
,	O
demostrando	O
que	O
el	O
efecto	O
que	O
vemos	O
es	O
específico	O
para	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
.	O

Para	O
investigar	O
el	O
rango	O
activo	O
de	O
nuestras	O
perlas	O
,	O
hemos	O
repetido	O
los	O
cultivos	O
con	O
peso	B-Sequence
E13	O
GRD	O
colocando	O
las	O
perlas	O
a	O
distancias	O
crecientes	O
de	O
los	O
ganglios	O
(	O
n	O
=	O
4	O
cada	O
uno	O
)	O
(	O
Figura	O
5F	O
)	O
.	O

Todavía	O
hubo	O
un	O
crecimiento	O
preferencial	O
hacia	O
el	O
cordón	O
a	O
1200	O
mu	O
m	O
,	O
la	O
distancia	O
más	O
larga	O
estudiada	O
,	O
aunque	O
el	O
número	O
de	O
axones	B-GENE
y	O
el	O
grado	O
de	O
crecimiento	O
no	O
fue	O
tan	O
sólido	O
.	O

A	O
continuación	O
,	O
configuramos	O
cultivos	O
de	O
explantes	O
de	O
médula	O
espinal	O
E13	O
DRG	O
usando	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
#	O
¿NOMBRE	O
?	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
fuente	O
(	O
n	O
=	O
15	O
)	O
.	O

Los	O
cultivos	O
de	O
control	O
se	O
establecieron	O
utilizando	O
perlas	O
cargadas	O
con	O
PBS	O
(	O
n	O
=	O
6	O
)	O
.	O

El	O
marcaje	O
de	O
DiI	O
a	O
través	O
de	O
los	O
GRD	O
reveló	O
numerosas	O
fibras	O
que	O
ingresan	O
a	O
la	O
médula	O
espinal	O
en	O
regiones	O
ectópicas	O
y	O
crecen	O
hacia	O
el	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
cuentas	O
(	O
Figura	O
6A	O
)	O
,	O
rodeando	O
las	O
cuentas	O
y	O
formando	O
paquetes	O
alrededor	O
de	O
ellas	O
(	O
Figura	O
6C-6E	O
)	O
.	O

En	O
los	O
cultivos	O
de	O
control	O
,	O
todas	O
las	O
fibras	O
marcadas	O
se	O
dirigieron	O
hacia	O
la	O
médula	O
espinal	O
dorsal	O
y	O
terminaron	O
allí	O
,	O
donde	O
normalmente	O
ingresan	O
a	O
la	O
materia	O
gris	O
en	O
E13	O
(	O
Figura	O
6B	O
)	O
.	O

No	O
axones	B-GENE
se	O
observaron	O
alrededor	O
de	O
las	O
perlas	O
de	O
control	O
cargadas	O
con	O
PBS	O
(	O
Figura	O
6F	O
)	O
.	O

axones	B-GENE
que	O
normalmente	O
ingresan	O
a	O
la	O
sustancia	O
gris	O
a	O
través	O
de	O
la	O
médula	O
espinal	O
dorsal	O
crecen	O
hacia	O
la	O
línea	O
media	O
cuando	O
se	O
presentan	O
con	O
un	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
fuente	O
y	O
nueva	O
axón	B-GENE
crecimiento	O
hacia	O
el	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
la	O
perla	O
se	O
inicia	O
desde	O
los	O
GRD	O
y	O
entra	O
en	O
la	O
médula	O
espinal	O
en	O
lugares	O
ectópicos	O
en	O
la	O
parte	O
media	O
lateral	O
de	O
la	O
médula	O
espinal	O
(	O
Figura	O
6G	O
)	O
.	O

Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
por	O
lo	O
tanto	O
,	O
es	O
capaz	O
de	O
actuar	O
como	O
un	O
quimioatrayente	O
para	O
DRG	O
axones	B-GENE
.	O

Discusión	O

Relativamente	O
pocos	O
estudios	O
han	O
implicado	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
como	O
un	O
agente	O
quimioatrayente	O
para	O
sensorial	O
y	O
motor	O
axones	B-GENE
.	O

Acción	O
quimioatrayente	O
previamente	O
notada	O
del	O
embrión	O
ratón	B-Taxon
proceso	O
maxilar	O
en	O
el	O
ganglio	O
del	O
trigémino	O
neuronas	B-Cell
(	O
Lumsden	O
y	O
Davies	O
1986	O
)	O
ahora	O
se	O
atribuye	O
a	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
y	O
factor	B-Protein
neurotrófico	I-Protein
derivado	I-Protein
del	I-Protein
cerebro	I-Protein
(	O
BDNF	B-Protein
)	O
(	O
O	O
'	O
Connor	O
et	O
al	O
.	O
1999	O
)	O
.	O

Recientemente	O
,	O
Tucker	O
et	O
al	O
.	O

(	O
2001	O
)	O
mostró	O
que	O
el	O
desarrollo	O
sensorial	O
y	O
motor	O
axones	B-GENE
en	O
cultivos	O
de	O
corte	O
de	O
extremidades	O
crecen	O
preferentemente	O
hacia	O
neurotrofina	B-Protein
#	O
¿NOMBRE	O
?	O

Por	O
el	O
contrario	O
,	O
las	O
cuentas	O
empapadas	O
con	O
neurotrofina	B-Protein
función	O
-	O
bloqueo	O
anticuerpos	B-GENE
condujo	O
a	O
la	O
reducción	O
de	O
la	O
sensibilidad	O
y	O
el	O
motor	O
axón	B-GENE
crecimiento	O
hacia	O
la	O
extremidad	O
.	O

En	O
transgénico	B-Sequence
ratones	B-Taxon
,	O
que	O
sobre	O
-	O
expresan	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
bajo	O
la	O
anidando	B-Protein
promotor	B-Sequence
en	O
el	O
sistema	O
nervioso	O
central	O
,	O
el	O
curso	O
de	O
los	O
aferentes	O
propioceptivos	O
se	O
altera	O
y	O
se	O
dirige	O
hacia	O
las	O
regiones	O
con	O
altos	O
niveles	O
de	O
ectópico	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
expresión	O
en	O
la	O
médula	O
espinal	O
(	O
Ringstedt	O
et	O
al	O
.	O
1997	O
)	O
.	O

Ringstedt	O
et	O
al	O
.	O
consideró	O
la	O
posibilidad	O
de	O
que	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
puede	O
jugar	O
un	O
papel	O
quimioatrayente	O
durante	O
la	O
inervación	O
de	O
los	O
cuernos	O
ventrales	O
por	O
aferentes	O
propioceptivos	O
.	O

Sin	O
embargo	O
,	O
hallazgos	O
anteriores	O
de	O
trayectorias	O
aferentes	O
propioceptivas	O
normales	O
en	O
pollo	B-Taxon
embriones	O
a	O
pesar	O
de	O
la	O
inyección	O
de	O
función	O
-	O
bloqueo	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
anticuerpo	B-GENE
en	O
la	O
médula	O
espinal	O
(	O
Oakley	O
et	O
al	O
.	O
1995	O
)	O
los	O
llevó	O
a	O
descartar	O
esta	O
posibilidad	O
.	O

En	O
ese	O
estudio	O
,	O
sin	O
embargo	O
,	O
los	O
ensayos	O
sobre	O
la	O
eficacia	O
de	O
anticuerpo	B-GENE
perturbación	O
en	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
#	O
¿NOMBRE	O
?	O
célula	B-Cell
la	O
supervivencia	O
mostró	O
que	O
la	O
efectividad	O
era	O
significativa	O
(	O
aproximadamente	O
90	O
%	O
)	O
pero	O
no	O
completa	O
(	O
Oakley	O
et	O
al	O
.	O
1995	O
)	O
.	O

Ringstedt	O
et	O
al	O
.	O

(	O
1997	O
)	O
argumentan	O
que	O
mientras	O
que	O
el	O
sensor	O
central	O
axones	B-GENE
todavía	O
puede	O
navegar	O
correctamente	O
en	O
ausencia	O
de	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
,	O
expresión	O
ectópica	O
de	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
interrumpe	O
su	O
orientación	O
.	O

Recientemente	O
,	O
otro	O
miembro	O
de	O
la	O
neurotrofina	B-Protein
familia	O
,	O
BDNF	B-Protein
,	O
se	O
ha	O
sugerido	O
para	O
actuar	O
como	O
un	O
quimioatrayente	O
para	O
sensorial	O
axones	B-GENE
inervando	O
el	O
oído	O
(	O
Tessarollo	O
et	O
al	O
.	O
2004	O
)	O
.	O

en	O
un	O
gene	B-Sequence
estrategia	O
de	O
sustitución	O
en	O
la	O
que	O
BDNF	B-Protein
expresión	O
fue	O
impulsada	O
por	O
la	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
promotor	B-Sequence
,	O
vestíbulo	O
axones	B-GENE
desviado	O
hacia	O
fuentes	O
ectópicas	O
de	O
BDNF	B-Protein
en	O
la	O
cóclea	O
que	O
normalmente	O
expresa	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
y	O
no	O
estaban	O
inervados	O
por	O
estos	O
axones	B-GENE
.	O

Ectópico	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
suministrado	O
mediante	O
bombas	O
osmóticas	O
y	O
adenovirus	B-Taxon
#	O
¿NOMBRE	O
?	O
axón	B-GENE
crecimiento	O
durante	O
la	O
regeneración	O
(	O
Zhang	O
et	O
al	O
.	O
1998	O
,	O
Bradbury	O
et	O
al	O
.	O
1999	O
,	O
Oudega	O
et	O
al	O
.	O
1999	O
,	O
Ramer	O
et	O
al	O
.	O
2002	O
)	O
,	O
e	O
inducir	O
axonal	B-GENE
plasticidad	O
de	O
corticoespinal	O
axones	B-GENE
en	O
la	O
médula	O
espinal	O
adulta	O
lesionada	O
(	O
Zhou	O
et	O
al	O
.	O
2003	O
)	O
,	O
donde	O
el	O
brote	O
axones	B-GENE
desde	O
el	O
sitio	O
intacto	O
cruzar	O
la	O
línea	O
media	O
hacia	O
el	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
fuente	O
en	O
el	O
lado	O
de	O
la	O
lesión	O
de	O
la	O
médula	O
espinal	O
.	O

Nuestros	O
resultados	O
actuales	O
están	O
de	O
acuerdo	O
con	O
estas	O
observaciones	O
y	O
proporcionan	O
evidencia	O
adicional	O
de	O
que	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
actúa	O
como	O
un	O
quimioatrayente	O
para	O
los	O
aferentes	O
sensoriales	O
.	O

antes	O
normal	O
neurona	B-Cell
motora	I-Cell
se	O
rescató	O
la	O
inervación	O
en	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
KO	O
animales	B-Taxon
por	O
sobre-expresar	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
selectivamente	O
en	O
sus	O
músculos	O
(	O
Wright	O
et	O
al	O
.	O
1997	O
)	O
.	O

Parece	O
que	O
los	O
periféricos	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
solo	O
es	O
suficiente	O
para	O
rescatar	O
propioceptiva	O
neuronas	B-Cell
en	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
KO	O
animales	B-Taxon
y	O
apropiado	O
axonal	B-GENE
búsqueda	O
de	O
caminos	O
en	O
la	O
médula	O
espinal	O
.	O

Sin	O
embargo	O
,	O
no	O
está	O
claro	O
si	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
está	O
ausente	O
de	O
la	O
médula	O
espinal	O
ventral	O
de	O
estos	O
animales	B-Taxon
.	O

Se	O
ha	O
planteado	O
la	O
posibilidad	O
de	O
que	O
neuronas	B-Cell
motoras	I-Cell
puede	O
transportar	O
retrógradamente	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
en	O
el	O
músculo	O
a	O
la	O
médula	O
espinal	O
(	O
Chen	O
y	O
Frank	O
1999	O
)	O
.	O

Ensayos	O
para	O
determinar	O
si	O
alguna	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
está	O
presente	O
en	O
los	O
cuernos	O
ventrales	O
de	O
estos	O
ratones	B-Taxon
seria	O
informativo	O
.	O

Recientemente	O
,	O
Patel	O
et	O
al	O
.	O

(	O
2003	O
)	O
reportaron	O
sus	O
observaciones	O
sobre	O
bax	B-Protein
/	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
doble	O
KO	O
ratones	B-Taxon
ellos	O
criaron	O

Sus	O
resultados	O
son	O
significativamente	O
diferentes	O
a	O
los	O
nuestros	O
.	O

No	O
ven	O
aferentes	O
propioceptivos	O
en	O
la	O
periferia	O
de	O
los	O
dobles	O
knockouts	O
y	O
notan	O
que	O
los	O
aferentes	O
propioceptivos	O
centrales	O
terminan	O
en	O
la	O
médula	O
espinal	O
intermedia	O
sin	O
extenderse	O
ventralmente	O
.	O

Sus	O
observaciones	O
se	O
basan	O
en	O
fotovoltaica	B-Protein
inmunotinción	O
y	O
marcaje	O
DiI	O
de	O
los	O
nervios	O
periféricos	O
.	O

Notamos	O
que	O
fotovoltaica	B-Protein
el	O
inmunomarcaje	O
está	O
disminuido	O
en	O
nuestro	O
bax	B-Protein
/	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
doble	O
KO	O
.	O

En	O
diversas	O
manipulaciones	O
de	O
la	O
neurotrofinas	B-Protein
se	O
ha	O
notado	O
que	O
molecular	B-Chemical
marcadores	O
de	O
propiocepción	O
axones	B-GENE
tal	O
como	O
fotovoltaica	B-Protein
o	O
gen	B-Protein
de	I-Protein
la	I-Protein
calcitonina	I-Protein
-	I-Protein
péptido	I-Protein
relacionado	I-Protein
por	O
factor	B-Protein
de	I-Protein
crecimiento	I-Protein
nervioso	I-Protein
#	O
¿NOMBRE	O
?	O
axones	B-GENE
están	O
comprometidos	O
(	O
Ringstedt	O
et	O
al	O
.	O
1997	O
;	O
Patel	O
et	O
al	O
.	O
2000	O
)	O
,	O
por	O
lo	O
que	O
fotovoltaica	B-Protein
inmunotinción	O
en	O
bax	B-Protein
/	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
los	O
dobles	O
KO	O
no	O
pueden	O
revelar	O
el	O
grado	O
de	O
propiocepción	O
axones	B-GENE
en	O
la	O
periferia	O

Se	O
informó	O
que	O
el	O
setenta	O
y	O
tres	O
por	O
ciento	O
de	O
los	O
aferentes	O
del	O
músculo	O
gastrocnemio	O
marcados	O
retrógradamente	O
estaban	O
expresando	O
TrkC	B-Protein
ARN	B-Sequence
en	O
el	O
adulto	O
rata	B-Taxon
GRD	O
,	O
aunque	O
algunos	O
de	O
estos	O
(	O
alrededor	O
del	O
10	O
%	O
)	O
pueden	O
representar	O
inervación	O
cutánea	O
(	O
McMahon	O
et	O
al	O
.	O
1994	O
)	O
.	O

Actualmente	O
,	O
no	O
está	O
claro	O
si	O
TrkC	B-Protein
proteína	B-Chemical
también	O
es	O
producido	O
por	O
aferentes	O
cutáneos	O
y	O
,	O
de	O
ser	O
así	O
,	O
en	O
qué	O
etapa	O
del	O
desarrollo	O
este	O
receptor	O
es	O
expresado	O
por	O
aferentes	O
cutáneos	O
.	O
axones	B-GENE
.	O

Con	O
base	O
en	O
la	O
evidencia	O
disponible	O
que	O
muestra	O
que	O
todas	O
las	O
técnicas	O
propioceptivas	O
neuronas	B-Cell
se	O
eliminan	O
en	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
o	O
TrkC	B-Protein
nulo	O
ratones	B-Taxon
,	O
pensamos	O
eso	O
TrkC	B-Protein
tinción	O
en	O
el	O
nervio	O
tibial	O
en	O
su	O
mayoría	O
representa	O
propioceptivo	O
axones	B-GENE
en	O
las	O
cercanías	O
de	O
su	O
objetivo	O
periférico	O
.	O

En	O
conjunto	O
,	O
nuestros	O
hallazgos	O
sugieren	O
un	O
papel	O
para	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
en	O
el	O
inicio	O
de	O
la	O
inervación	O
muscular	O
y	O
la	O
diferenciación	O
del	O
huso	O
por	O
el	O
propioceptivo	O
axones	B-GENE
.	O

Patel	O
et	O
al	O
.	O

(	O
2003	O
)	O
examinó	O
DRG	O
central	O
marcado	O
con	O
DiI	O
axones	B-GENE
en	O
la	O
médula	O
espinal	O
de	O
tres	O
casos	O
E17	O
y	O
dos	O
P0	O
,	O
e	O
informan	O
que	O
la	O
propiocepción	O
central	O
axones	B-GENE
se	O
detiene	O
en	O
las	O
láminas	O
intermedias	O
,	O
sin	O
entrar	O
nunca	O
en	O
el	O
cordón	O
ventral	O
.	O

Hemos	O
examinado	O
nueve	O
bax	B-Protein
/	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
casos	O
de	O
doble	O
KO	O
,	O
y	O
el	O
etiquetado	O
DiI	O
a	O
menudo	O
incompleto	O
da	O
la	O
impresión	O
de	O
que	O
no	O
hay	O
axones	B-GENE
llegando	O
a	O
la	O
médula	O
espinal	O
ventral	O
.	O

También	O
hemos	O
visto	O
casos	O
similares	O
al	O
de	O
ellos	O
(	O
n	O
=	O
4	O
)	O
,	O
pero	O
a	O
mayor	O
aumento	O
estos	O
axones	B-GENE
no	O
tenía	O
botones	B-GENE
terminales	I-GENE
y	O
no	O
estaban	O
completamente	O
etiquetados	O
.	O

Sin	O
embargo	O
,	O
con	O
rellenos	O
completos	O
(	O
n	O
=	O
5	O
)	O
,	O
fue	O
posible	O
rastrear	O
estos	O
axones	B-GENE
en	O
la	O
línea	O
media	O
ventral	O
y	O
a	O
través	O
del	O
lado	O
contralateral	O
,	O
y	O
visualizar	O
botones	B-GENE
terminales	I-GENE
en	O
sus	O
puntas	O
(	O
ver	O
Figura	O
3C	O
)	O
.	O

Previamente	O
,	O
Arber	O
et	O
al	O
.	O

(	O
2000	O
)	O
informó	O
que	O
los	O
miembros	O
de	O
la	O
familia	O
Ets	O
de	O
factores	O
de	O
transcripción	O
,	O
Er81	B-Protein
y	O
Guisante3	B-Protein
,	O
se	O
expresan	O
por	O
GRD	O
neuronas	B-Cell
así	O
como	O
también	O
neuronas	B-Cell
motoras	I-Cell
y	O
sus	O
fibras	O
musculares	O
diana	O
.	O

Descubrieron	O
que	O
en	O
la	O
médula	O
espinal	O
de	O
Er81	B-Protein
KO	O
ratones	B-Taxon
,	O
ventral	O
proyecciones	B-GENE
de	O
propioceptivo	O
axones	B-GENE
estuvieron	O
ausentes	O
en	O
su	O
mayoría	O
,	O
y	O
muy	O
pocos	O
axones	B-GENE
llegó	O
al	O
cordón	O
ventral	O
.	O

Patel	O
et	O
al	O
.	O

(	O
2003	O
)	O
señalan	O
que	O
el	O
fenotipo	O
que	O
observaron	O
en	O
sus	O
bax	B-Protein
/	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
doble	O
KO	O
ratones	B-Taxon
es	O
bastante	O
similar	O
a	O
la	O
de	O
Er81	B-Protein
KO	O
ratones	B-Taxon
.	O

Proporcionan	O
evidencia	O
de	O
que	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
induce	O
Er81	B-Protein
expresión	O
en	O
explantes	O
de	O
DRG	O
in	O
vitro	O
.	O

Patel	O
et	O
al	O
.	O

(	O
2003	O
)	O
reportan	O
que	O
Er81	B-Protein
ARNm	B-Chemical
expresión	O
es	O
disminuida	O
(	O
pero	O
no	O
abolida	O
)	O
en	O
ambos	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
KO	O
y	O
bax	B-Protein
/	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
doble	O
KO	O
ratones	B-Taxon
,	O
mientras	O
que	O
su	O
inmunohistoquímica	O
muestra	O
mucho	O
menos	O
proteína	B-Chemical
expresión	O
en	O
el	O
doble	O
KO	O
ratones	B-Taxon
.	O

Es	O
muy	O
posible	O
que	O
un	O
número	O
pequeño	O
pero	O
considerable	O
de	O
DRG	O
células	B-Cell
expresar	O
el	O
factor	O
de	O
transcripción	O
Er81	B-Protein
y	O
que	O
su	O
axones	B-GENE
crecer	O
más	O
allá	O
de	O
los	O
niveles	O
intermedios	O
de	O
la	O
médula	O
espinal	O
en	O
bax	B-Protein
/	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
doble	O
KO	O
ratones	B-Taxon
.	O

Mientras	O
que	O
el	O
fenotipo	O
de	O
Er81	B-Protein
KO	O
ratones	B-Taxon
es	O
bastante	O
dramático	O
,	O
y	O
más	O
propioceptivo	O
axones	B-GENE
detenerse	O
dentro	O
de	O
la	O
médula	O
espinal	O
intermedia	O
,	O
es	O
importante	O
tener	O
en	O
cuenta	O
que	O
algunos	O
axones	B-GENE
todavía	O
encuentran	O
su	O
camino	O
hacia	O
la	O
médula	O
espinal	O
ventral	O
y	O
apuntan	O
adecuadamente	O
a	O
la	O
neuronas	B-Cell
motoras	I-Cell
(	O
Arber	O
et	O
al	O
.	O
2000	O
)	O
.	O

Patel	O
et	O
al	O
.	O

(	O
2003	O
)	O
también	O
presentan	O
observaciones	O
de	O
islet2DTA	O
ratones	B-Taxon
,	O
que	O
carecen	O
de	O
una	O
parte	O
significativa	O
de	O
la	O
neuronas	B-Cell
motoras	I-Cell
en	O
el	O
cordón	O
ventral	O
.	O

En	O
estos	O
ratones	B-Taxon
fotovoltaica	B-Protein
espectáculos	O
de	O
inmunotinción	O
axones	B-GENE
en	O
los	O
cuernos	O
ventrales	O
.	O

Patel	O
et	O
al	O
.	O
argumentar	O
que	O
desde	O
neuronas	B-Cell
motoras	I-Cell
están	O
ausentes	O
en	O
estos	O
ratones	B-Taxon
,	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
secretada	O
por	O
ellos	O
no	O
podría	O
ser	O
una	O
señal	O
de	O
propiocepción	O
axones	B-GENE
para	O
entrar	O
en	O
las	O
columnas	O
motoras	O
laterales	O
.	O

Sin	O
embargo	O
,	O
no	O
hay	O
evidencia	O
que	O
demuestre	O
que	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
ARNm	B-Chemical
o	O
proteína	B-Chemical
expresada	O
en	O
la	O
médula	O
espinal	O
ventral	O
proviene	O
exclusivamente	O
de	O
neuronas	B-Cell
motoras	I-Cell
,	O
y	O
no	O
hay	O
datos	O
disponibles	O
que	O
indiquen	O
que	O
en	O
islet2DTA	O
ratones	B-Taxon
,	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
se	O
suprime	O
la	O
expresión	O
en	O
la	O
médula	O
espinal	O
ventral	O
(	O
Yang	O
et	O
al	O
.	O
2001	O
;	O
Pun	O
et	O
al	O
.	O
2002	O
)	O
.	O

Estudios	O
en	O
embrionario	O
ratones	B-Taxon
reportado	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
ARNm	B-Chemical
en	O
los	O
cuernos	O
ventrales	O
de	O
la	O
médula	O
espinal	O
,	O
pero	O
no	O
es	O
definitivo	O
que	O
ambos	O
ARNm	B-Chemical
y	O
proteína	B-Chemical
se	O
expresan	O
únicamente	O
por	O
neuronas	B-Cell
motoras	I-Cell
.	O

En	O
la	O
médula	O
espinal	O
adulta	O
,	O
mientras	O
que	O
neuronas	B-Cell
motoras	I-Cell
expresar	O
altos	O
niveles	O
de	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
,	O
otro	O
células	B-Cell
,	O
incluyendo	O
glía	B-Cell
,	O
también	O
lo	O
expresan	O
(	O
Zhou	O
y	O
Rush	O
1994	O
;	O
Dreyfus	O
et	O
al	O
.	O
1999	O
;	O
Buck	O
et	O
al	O
.	O
2000	O
)	O
.	O

Nuestros	O
resultados	O
actuales	O
,	O
junto	O
con	O
los	O
de	O
transgénico	B-Sequence
ratones	B-Taxon
con	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
sobreexpresión	O
en	O
regiones	O
ectópicas	O
de	O
la	O
médula	O
espinal	O
(	O
Ringstedt	O
et	O
al	O
.	O
1997	O
)	O
,	O
abogan	O
por	O
un	O
papel	O
de	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
en	O
quimioatrayente	O
axón	B-GENE
guía	O
de	O
propiocepción	O
axones	B-GENE
en	O
la	O
médula	O
espinal	O
.	O

Finalmente	O
,	O
en	O
ensayos	O
de	O
cultivo	O
,	O
vemos	O
una	O
fuerte	O
quimioatracción	O
de	O
DRG	O
neuronas	B-Cell
a	O
fuentes	O
localizadas	O
de	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
.	O

Esta	O
respuesta	O
se	O
ve	O
en	O
peso	B-Sequence
,	O
bax	B-Protein
nulo	O
y	O
en	O
p75	B-Protein
explantes	O
de	O
DRG	O
nulos	O
,	O
y	O
en	O
ausencia	O
de	O
cualquier	O
otro	O
neurotrofinas	B-Protein
o	O
objetivo	O
-	O
derivado	O
axón	B-GENE
Guia	O
moléculas	B-Chemical
.	O

Además	O
,	O
in	O
vitro	O
,	O
sensorial	O
axón	B-GENE
respuesta	O
a	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
no	O
parece	O
depender	O
de	O
la	O
dosis	O
(	O
Ringstedt	O
et	O
al	O
.	O
1997	O
;	O
Tucker	O
et	O
al	O
.	O
2001	O
)	O
.	O

Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
es	O
capaz	O
de	O
atraer	O
axones	B-GENE
a	O
lo	O
largo	O
de	O
distancias	O
de	O
hasta	O
1	O
mm	O
en	O
colágeno	B-Protein
matriz	O
de	O
gel	O
,	O
cubriendo	O
el	O
rango	O
fisiológico	O
que	O
necesita	O
para	O
atraer	O
axones	B-GENE
durante	O
el	O
desarrollo	O
.	O

Estudios	O
previos	O
con	O
aplicaciones	O
exógenas	O
o	O
locales	O
de	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
al	O
desarrollo	O
sensorial	O
primario	O
axones	B-GENE
han	O
indicado	O
que	O
esto	O
neurotrofina	B-Protein
puede	O
atraer	O
e	O
inducir	O
axonal	B-GENE
ramificación	O
(	O
Ulup	O
i	O
nar	O
et	O
al	O
.	O
2000	O
;	O
O	O
zdinler	O
y	O
Erzurumlu	O
2001	O
,	O
O	O
zdinler	O
et	O
al	O
.	O
2004	O
)	O
.	O

A	O
lo	O
largo	O
de	O
la	O
vía	O
del	O
reflejo	O
de	O
estiramiento	O
monosináptico	O
,	O
sólo	O
Wnt	B-Protein
-	I-Protein
3	I-Protein
ha	O
sido	O
implicado	O
como	O
axón	B-GENE
factor	O
de	O
arborización	O
en	O
la	O
médula	O
espinal	O
(	O
Krylova	O
et	O
al	O
.	O
2002	O
)	O
.	O

Otro	O
molécula	B-Chemical
,	O
Hendidura2	B-Protein
,	O
expresada	O
en	O
la	O
línea	O
media	O
y	O
por	O
neuronas	B-Cell
motoras	I-Cell
(	O
Wang	O
et	O
al	O
.	O
1999	O
)	O
es	O
capaz	O
de	O
inducir	O
axonal	B-GENE
ramificación	O
(	O
Nguyen	O
Ba-Charvet	O
et	O
al	O
.	O
2001	O
;	O
O	O
zdinler	O
y	O
Erzurumlu	O
2002	O
)	O
.	O

GRD	O
neuronas	B-Cell
expresan	O
receptores	O
Robo	O
,	O
que	O
se	O
unen	O
a	O
Slits	O
,	O
y	O
propioceptivos	O
axones	B-GENE
son	O
por	O
lo	O
tanto	O
capaces	O
de	O
responder	O
a	O
las	O
señales	O
de	O
Slit	O
(	O
Wang	O
et	O
al	O
.	O
1999	O
)	O
.	O

Hendidura2	B-Protein
no	O
causa	O
repulsión	O
de	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
#	O
¿NOMBRE	O
?	O
axones	B-GENE
in	O
vitro	O
(	O
Nguyen	O
Ba-Charvet	O
et	O
al	O
.	O
2001	O
)	O
,	O
pero	O
causa	O
ramificación	O
ectópica	O
y	O
arborización	O
del	O
trigémino	O
axones	B-GENE
en	O
el	O
tronco	O
encefálico	O
(	O
O	O
zdinler	O
y	O
Erzurumlu	O
2002	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
Hendidura2	B-Protein
también	O
podría	O
estar	O
involucrado	O
en	O
la	O
ramificación	O
terminal	O
de	O
propioceptivo	O
axones	B-GENE
en	O
el	O
cordón	O
ventral	O
y	O
en	O
la	O
línea	O
media	O
la	O
ramificación	O
observada	O
en	O
nuestros	O
dobles	O
KO	O
.	O

Falta	O
de	O
fotovoltaica	B-Protein
expresión	O
en	O
bax	B-Protein
/	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
KO	O
ratones	B-Taxon
sugiere	O
que	O
fotovoltaica	B-Protein
expresión	O
podría	O
ser	O
responsable	O
de	O
la	O
correcta	O
axón	B-GENE
Orientación	O
y	O
diferenciación	O
del	O
huso	O
muscular	O
.	O

Actualmente	O
no	O
podemos	O
descartar	O
por	O
completo	O
esta	O
posibilidad	O
.	O

Sin	O
embargo	O
,	O
no	O
hay	O
defectos	O
en	O
axón	B-GENE
Pathfinding	O
a	O
lo	O
largo	O
del	O
arco	O
reflejo	O
monosináptico	O
o	O
en	O
la	O
diferenciación	O
del	O
huso	O
muscular	O
se	O
han	O
observado	O
en	O
fotovoltaica	B-Protein
KO	O
ratones	B-Taxon
que	O
se	O
desarrollan	O
normalmente	O
y	O
no	O
muestran	O
cambios	O
aparentes	O
en	O
su	O
comportamiento	O
o	O
actividad	O
física	O
(	O
Schwaller	O
et	O
al	O
.	O
1999	O
)	O
.	O

Estas	O
observaciones	O
sugieren	O
que	O
axonal	B-GENE
apuntando	O
a	O
defectos	O
en	O
bax	B-Protein
/	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
doble	O
KO	O
ratones	B-Taxon
no	O
puede	O
deberse	O
simplemente	O
a	O
la	O
falta	O
de	O
fotovoltaica	B-Protein
expresión	O
en	O
propioceptiva	O
células	B-Cell
.	O

Nuestros	O
resultados	O
actuales	O
sugieren	O
que	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
actúa	O
como	O
un	O
corto	O
-	O
alcance	O
axón	B-GENE
señal	O
de	O
orientación	O
para	O
propioceptivo	O
axones	B-GENE
central	O
y	O
periféricamente	O
,	O
mientras	O
navegan	O
hacia	O
sus	O
objetivos	O
utilizando	O
otros	O
axón	B-GENE
señales	O
de	O
orientación	O
.	O

En	O
su	O
ausencia	O
,	O
estos	O
axones	B-GENE
terminan	O
en	O
lugares	O
inapropiados	O
.	O

Sin	O
embargo	O
,	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
Puede	O
que	O
no	O
sea	O
el	O
único	O
molécula	B-Chemical
que	O
juega	O
un	O
papel	O
en	O
la	O
orientación	O
y	O
la	O
ramificación	O
terminal	O
de	O
los	O
sentidos	O
axones	B-GENE
en	O
la	O
médula	O
espinal	O
ventral	O
.	O

Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
lo	O
más	O
probable	O
es	O
que	O
actúe	O
en	O
cooperación	O
con	O
otros	O
axón	B-GENE
Guia	O
moléculas	B-Chemical
o	O
regulando	O
la	O
expresión	O
de	O
propioceptivo	O
aún	O
por	O
identificar	O
neurona	B-Cell
#	O
¿NOMBRE	O
?	O
axón	B-GENE
señales	O
de	O
orientación	O
.	O

Materiales	O
y	O
métodos	O

Generación	O
de	O
dobles	O
KOs	O
.	O

cruzamos	O
bax	B-Protein
Hembras	O
KO	O
en	O
un	O
fondo	O
C57BL/6	O
(	O
Laboratorio	O
Jackson	O
,	O
Bar	O
Harbor	O
,	O
Maine	O
,	O
Estados	O
Unidos	O
)	O
para	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
machos	O
heterocigotos	O
en	O
un	O
fondo	O
de	O
129	O
Sv	O
para	O
generar	O
doble	O
heterocigoto	O
animales	B-Taxon
.	O

La	O
progenie	O
fue	O
genotipada	O
con	O
PCR	O
,	O
y	O
animales	B-Taxon
heterocigoto	O
para	O
ambos	O
genes	B-Sequence
fueron	O
criados	O
para	O
obtener	O
los	O
dobles	O
KOs	O
.	O

imprimaciones	B-Sequence
utilizado	O
para	O
el	O
bax	B-Protein
lugar	B-Sequence
fueron	O
R661	O
,	O
GTT	O
GAC	O
CAG	O
AGT	O
GGC	O
GTA	O
GG	O
;	O
R662	O
,	O
CCG	O
CTT	O
CCA	O
TTG	O
CTC	O
AGC	O
GG	O
;	O
y	O
R663	O
,	O
GAG	O
CTG	O
ATC	O
AGA	O
ACC	O
ATC	O
ATG	O
.	O

imprimaciones	B-Sequence
utilizado	O
para	O
el	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
lugar	B-Sequence
fueron	O
NT3A	O
,	O
CGT	O
GGT	O
GAG	O
GTT	O
CTA	O
TTG	O
GCT	O
AC	O
;	O
NT3B	O
,	O
CAG	O
AGC	O
ACC	O
CTG	O
CCC	O
AAA	O
GCA	O
GAG	O
;	O
NT3R	O
,	O
TCC	O
TGA	O
CAA	O
TAC	O
TGA	O
ATG	O
CC	O
;	O
y	O
NEOF	O
,	O
GGG	O
AAC	O
TTC	O
CTG	O
ACT	O
AGG	O
.	O

peso	B-Sequence
,	O
bax	B-Protein
KO	O
,	O
y	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
Se	O
usaron	O
compañeros	O
de	O
camada	O
KO	O
como	O
controles	O
.	O

Un	O
total	O
de	O
11	O
bax	B-Protein
/	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
doble	O
KO	O
ratones	B-Taxon
fueron	O
analizados	O
,	O
de	O
estos	O
nueve	O
eran	O
cachorros	O
P0	O
.	O

los	O
p75	B-Protein
Se	O
recibió	O
una	O
colonia	O
en	O
un	O
fondo	O
de	O
129	O
S1	O
de	O
Jackson	O
Laboratory	O
.	O

usamos	O
la	O
cola	O
ADN	B-Sequence
al	O
genotipo	O
animales	B-Taxon
utilizando	O
el	O
cebadores	B-Sequence
IMR0013	O
,	O
CTT	O
GGG	O
TGG	O
AGA	O
GGC	O
TAT	O
TC	O
;	O
IMR0014	O
,	O
AGG	O
TGA	O
GAT	O
GAC	O
AGG	O
AGA	O
TC	O
(	O
neo	O
genérico	O
cebadores	B-Sequence
)	O
;	O
IMR0710	O
,	O
TGT	O
TAC	O
GTT	O
CTC	O
TGA	O
CGT	O
GGT	O
GAG	O
;	O
y	O
IMR0711	O
,	O
TCA	O
GCC	O
CAG	O
GGT	O
GTG	O
CAC	O
TC	O
(	O
p75	B-Protein
lugar	B-Sequence
)	O
.	O

Para	O
los	O
experimentos	O
con	O
embriones	O
,	O
el	O
día	O
de	O
positividad	O
del	O
plug	O
se	O
consideró	O
E0	O
.	O

Todos	O
los	O
protocolos	O
utilizados	O
en	O
este	O
estudio	O
fueron	O
aprobados	O
por	O
el	O
Centro	O
Institucional	O
de	O
Ciencias	O
de	O
la	O
Salud	O
de	O
la	O
Universidad	O
Estatal	O
de	O
Luisiana	O
.	O
Animal	B-Taxon
Comité	O
de	O
Cuidado	O
y	O
Uso	O
y	O
cumplió	O
con	O
las	O
pautas	O
de	O
los	O
Institutos	O
Nacionales	O
de	O
Salud	O
para	O
el	O
uso	O
de	O
animales	B-Taxon
.	O

TrkA	B-Protein
/	O
TrkC	B-Protein
inmunohistoquímica	O
.	O

Secciones	O
de	O
médula	O
espinal	O
congeladas	O
(	O
10	O
µm	O
de	O
espesor	O
)	O
fueron	O
bloqueadas	O
e	O
incubadas	O
en	O
un	O
cóctel	O
de	O
Conejo	B-Taxon
anti	O
-	O
TrkA	B-Protein
y	O
cabra	B-Taxon
anti	O
-	O
TrkC	B-Protein
anticuerpos	B-GENE
(	O
obsequio	O
del	O
Dr.	O
Reichardt	O
;	O
Huang	O
et	O
al	O
.	O
1999	O
)	O
,	O
seguido	O
de	O
un	O
cóctel	O
de	O
CY3	O
conjugado	O
Burro	B-Taxon
anti	O
-	O
Conejo	B-Taxon
y	O
FITC	B-Chemical
conjugado	O
Burro	B-Taxon
anti	O
-	O
cabra	B-Taxon
anticuerpos	B-GENE
(	O
Chemicon	O
,	O
Temecula	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
en	O
presencia	O
de	O
0	O
.	O
3	O
%	O
TritonX	O
-	O
100	O
y	O
10	O
%	O
normal	O
Burro	B-Taxon
suero	O

Para	O
fotovoltaica	B-Protein
inmunohistoquímica	O
,	O
las	O
secciones	O
se	O
hicieron	O
reaccionar	O
con	O
monoclonal	O
ratón	B-Taxon
anti	O
-	O
fotovoltaica	B-Protein
anticuerpo	B-GENE
(	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
Missouri	O
,	O
Estados	O
Unidos	O
)	O
,	O
y	O
desarrollado	O
por	O
Vector	O
fluoresceína	B-Chemical
ratón	B-Taxon
en	O
ratón	B-Taxon
kit	O
(	O
Vector	O
Laboratories	O
,	O
Burlingame	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
.	O

A	O
efectos	O
de	O
cuantificación	O
,	O
TrkA	B-Protein
#	O
¿NOMBRE	O
?	O
TrkC	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
de	O
cuatro	O
GRD	O
diferentes	O
de	O
cada	O
genotipo	B-Sequence
la	O
edad	O
estudiada	O
se	O
contaron	O
y	O
las	O
proporciones	O
se	O
trazaron	O
.	O

Detección	O
de	O
huso	O
muscular	O
.	O

Se	O
diseccionó	O
el	O
músculo	O
gastrocnemio	O
en	O
cachorros	O
P0	O
y	O
se	O
seccionó	O
longitudinalmente	O
o	O
,	O
en	O
algunos	O
casos	O
,	O
se	O
seccionó	O
transversalmente	O
toda	O
la	O
pierna	O
al	O
nivel	O
del	O
músculo	O
gastrocnemio	O
con	O
el	O
nervio	O
tibial	O
.	O

Las	O
secciones	O
se	O
incubaron	O
con	O
monoclonal	O
S46	O
anticuerpo	B-GENE
(	O
obsequio	O
del	O
Dr.	O
Stockdale	O
)	O
reactivo	O
al	O
tónico	O
lento	O
específico	O
del	O
huso	O
miosina	B-GENE
pesado	O
isoforma	B-Sequence
de	I-Sequence
cadena	I-Sequence
y	O
desarrollado	O
por	O
Vector	O
ratón	B-Taxon
en	O
ratón	B-Taxon
kit	O
como	O
se	O
describe	O
arriba	O
,	O
seguido	O
de	O
Conejo	B-Taxon
anti	O
-	O
NF-M	B-Protein
anticuerpo	B-GENE
(	O
Chemicon	O
)	O
y	O
CY3	O
conjugado	O
cabra	B-Taxon
anti	O
-	O
Conejo	B-Taxon
anticuerpo	B-GENE
(	O
Chemicon	O
)	O
en	O
un	O
protocolo	O
secuencial	O
de	O
doble	O
marcaje	O
.	O

En	O
otro	O
método	O
,	O
se	O
colocaron	O
cristales	O
de	O
DiI	O
en	O
GRD	O
de	O
embriones	O
E17	O
de	O
diferentes	O
genotipos	B-Sequence
(	O
n	O
=	O
2	O
)	O
,	O
y	O
el	O
músculo	O
gastrocnemio	O
se	O
aisló	O
y	O
seccionó	O
en	O
rodajas	O
de	O
40	O
µm	O
de	O
espesor	O
en	O
un	O
vibratomo	O
.	O

Etiquetado	O
DiI	O
.	O

Se	O
disecaron	O
las	O
médulas	O
espinales	O
con	O
los	O
DRG	O
adjuntos	O
,	O
se	O
cortó	O
la	O
raíz	O
motora	O
para	O
evitar	O
el	O
relleno	O
de	O
neuronas	B-Cell
motoras	I-Cell
y	O
cristales	O
de	O
1	O
,	O
1	O
'	O
-	O
dioctadecil	O
-	O
3	O
,	O
3	O
,	O
3	O
'	O
,	O
3	O
'	O
-	O
tetrametilindocarbocianina	O
perclorato	B-Chemical
(	O
Dil	O
;	O
Molecular	B-Chemical
Probes	O
,	O
Eugene	O
,	O
Oregón	O
,	O
Estados	O
Unidos	O
)	O
se	O
insertaron	O
en	O
GRD	O
.	O

Las	O
médulas	O
espinales	O
marcadas	O
se	O
incubaron	O
a	O
37	O
grados	O
C	O
durante	O
8	O
días	O
y	O
se	O
seccionaron	O
en	O
un	O
vibrotomo	O
a	O
100	O
µm	O
.	O

Las	O
secciones	O
se	O
observaron	O
bajo	O
el	O
microscopio	O
fluorescente	O
y	O
se	O
fotografiaron	O
,	O
y	O
las	O
imágenes	O
se	O
transfirieron	O
a	O
Adobe	O
Photoshop	O
,	O
se	O
invirtieron	O
y	O
se	O
ajustaron	O
en	O
brillo	O
y	O
contraste	O
.	O

Fotoconvertido	O
en	O
0	O
.	O
15	O
%	O
DAB	O
(	O
3	O
,	O
3	O
'	O
-	O
diaminobencidina	O
;	O
Sigma	O
)	O
en	O
0	O
.	O
1M	O
tris	B-Chemical
tampón	O
(	O
pH	O
8,2	O
)	O
.	O

Ensayo	O
de	O
cocultivo	O
in	O
vitro	O
.	O

Los	O
explantes	O
de	O
DRG	O
se	O
derivaron	O
de	O
Swiss	O
Webster	O
,	O
bax	B-Protein
nulo	O
,	O
y	O
p75	B-Protein
nulo	O
ratón	B-Taxon
embriones	O
(	O
E13	O
)	O
.	O

Para	O
colágeno	B-Protein
ensayos	O
de	O
matriz	O
,	O
los	O
DRG	O
se	O
diseccionaron	O
bajo	O
un	O
estereomicroscopio	O
usando	O
tungsteno	B-Chemical
agujas	O

Colágeno	B-Protein
matriz	O
se	O
preparó	O
con	O
430	O
mu	O
l	O
de	O
colágeno	B-Protein
(	O
3	O
mg	O
/	O
ml	O
disueltos	O
en	O
0	O
.	O
1M	O
ácido	B-Chemical
acético	I-Chemical
Sigma	O
)	O
,	O
50	O
mu	O
l	O
de	O
medio	O
10X	O
DMEM	O
,	O
y	O
2	O
.	O
5	O
mu	O
l	O
de	O
0	O
.	O
NaCa2	O
8	O
M	O
y	O
el	O
pH	O
se	O
ajustó	O
a	O
7	O
.	O
5	O
.	O

Se	O
colocaron	O
explantes	O
de	O
ganglios	O
individuales	O
en	O
placas	O
de	O
24	O
pocillos	O
y	O
se	O
cubrieron	O
con	O
colágeno	B-Protein
.	O

Se	O
utilizaron	O
perlas	O
de	O
sefarosa	O
con	O
un	O
diámetro	O
medio	O
de	O
150	O
µm	O
.	O

Las	O
perlas	O
se	O
lavaron	O
dos	O
veces	O
con	O
PBS	O
,	O
se	O
secaron	O
al	O
aire	O
y	O
se	O
cargaron	O
con	O
10	O
,	O
20	O
,	O
50	O
o	O
100	O
ng	O
/	O
mu	O
l	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
(	O
Investigación	O
Colaborativa	O
,	O
Chemicon	O
)	O
a	O
4	O
grados	O
C	O
durante	O
la	O
noche	O
con	O
agitación	O
constante	O
.	O

Para	O
el	O
control	O
negativo	O
,	O
las	O
perlas	O
se	O
cargaron	O
con	O
BSA	B-Protein
(	O
10	O
-	O
100	O
ng	O
/	O
mu	O
l	O
)	O
o	O
PBS	O
.	O

O	O
un	O
solo	O
neurotrofina	B-Protein
#	O
¿NOMBRE	O
?	O
BSA	B-Protein
(	O
o	O
PBS	O
)	O
se	O
implantó	O
una	O
perla	O
cargada	O
aproximadamente	O
a	O
200-1	O
,	O
200	O
mu	O
m	O
del	O
explante	O
del	O
ganglio	O
.	O

Colágeno	B-Protein
A	O
continuación	O
,	O
los	O
cultivos	O
integrados	O
se	O
colocaron	O
a	O
33	O
grados	O
C	O
durante	O
15	O
minutos	O
para	O
que	O
la	O
matriz	O
se	O
endureciera	O
.	O

A	O
continuación	O
,	O
se	O
añadió	O
medio	O
de	O
cultivo	O
sin	O
suero	O
a	O
cada	O
pocillo	O
.	O

En	O
culturas	O
con	O
peso	B-Sequence
DRG	O
y	O
perlas	O
de	O
control	O
,	O
se	O
añadió	O
suero	O
al	O
10	O
%	O
para	O
asegurar	O
la	O
viabilidad	O
de	O
los	O
explantes	O
.	O

TrkC	B-Protein
-	O
Fc	O
(	O
Regeneron	O
productos	B-Chemical
farmaceuticos	I-Chemical
Tarrytown	O
,	O
Nueva	O
York	O
,	O
Estados	O
Unidos	O
)	O
(	O
20	O
µg	O
/	O
ml	O
)	O
al	O
medio	O
de	O
cultivo	O
.	O

Cocultivos	O
de	O
explantes	O

Las	O
médulas	O
espinales	O
con	O
DRG	O
adjuntos	O
se	O
diseccionaron	O
de	O
Swiss	O
Webster	O
ratón	B-Taxon
embriones	O
en	O
E13	O
,	O
y	O
seccionados	O
en	O
rodajas	O
de	O
300	O
mu	O
m	O
de	O
espesor	O
.	O

Los	O
cortes	O
de	O
tejido	O
se	O
colocaron	O
en	O
insertos	O
de	O
cultivo	O
de	O
tejidos	O
Millicell	O
(	O
Millipore	O
,	O
Billrica	O
,	O
Massachusetts	O
,	O
Estados	O
Unidos	O
)	O
.	O

Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
Se	O
prepararon	O
perlas	O
de	O
sefarosa	O
cargadas	O
(	O
n	O
=	O
15	O
)	O
o	O
cargadas	O
con	O
PBS	O
(	O
n	O
=	O
6	O
)	O
como	O
se	O
describe	O
anteriormente	O
,	O
y	O
se	O
colocaron	O
en	O
la	O
línea	O
media	O
a	O
nivel	O
de	O
la	O
médula	O
espinal	O
media	O
.	O

Los	O
insertos	O
se	O
colocaron	O
en	O
placas	O
de	O
seis	O
pocillos	O
con	O
medio	O
sin	O
suero	O
en	O
el	O
fondo	O
de	O
los	O
pocillos	O
y	O
se	O
mantuvieron	O
a	O
33	O
grados	O
C	O
durante	O
3	O
días	O
en	O
presencia	O
de	O
5	O
%	O
CO2	B-Chemical
.	O

A	O
continuación	O
,	O
los	O
cultivos	O
se	O
fijaron	O
con	O
paraformaldehído	O
al	O
4	O
%	O
en	O
PBS	O
y	O
se	O
colocaron	O
pequeños	O
cristales	O
de	O
DiI	O
en	O
los	O
DRG	O
.	O

Las	O
muestras	O
se	O
incubaron	O
en	O
una	O
incubadora	O
a	O
37	O
grados	O
C	O
,	O
lo	O
que	O
permitió	O
que	O
la	O
teñir	B-Chemical
para	O
difundir	O
,	O
y	O
fotografiado	O
bajo	O
un	O
microscopio	O
de	O
epifluorescencia	O
invertida	O
Nikon	O
(	O
Tokio	O
,	O
Japón	O
)	O
.	O

información	O
de	O
soporte	O

Figura	O
S1	O

Neurona	B-Cell
motora	I-Cell
Inervación	O
iniciada	O
en	O
peso	B-Sequence
E17	O
Los	O
embriones	O
no	O
se	O
pueden	O
detectar	O
en	O
bax	B-Protein
/	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
Doble	O
KO	O

En	O
algunas	O
de	O
las	O
muestras	O
,	O
neuronas	B-Cell
motoras	I-Cell
fueron	O
etiquetados	O
por	O
relleno	O
a	O
través	O
de	O
la	O
raíz	O
ventral	O
además	O
de	O
la	O
sensorial	O
axones	B-GENE
etiquetados	O
a	O
través	O
de	O
los	O
GRD	O
.	O

(	O
A	O
)	O
peso	B-Sequence
embrión	O
mostrando	O
propioceptivo	O
axones	B-GENE
contactando	O
neurona	B-Cell
motora	I-Cell
dendritas	B-GENE
en	O
el	O
asta	O
ventral	O
,	O
formando	O
sinapsis	B-GENE
.	O

(	O
B	O
)	O
bax	B-Protein
/	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
médula	O
espinal	O
doble	O
nula	O
.	O

Aunque	O
las	O
fibras	O
marcadas	O
entran	O
en	O
la	O
médula	O
espinal	O
ventral	O
,	O
se	O
extienden	O
hacia	O
la	O
línea	O
media	O
en	O
lugar	O
del	O
asta	O
ventral	O
y	O
nunca	O
entran	O
en	O
contacto	O
con	O
la	O
médula	O
espinal	O
.	O
neurona	B-Cell
motora	I-Cell
dendritas	B-GENE
.	O

(	O
C	O
)	O
Imagen	O
de	O
alta	O
potencia	O
del	O
recuadro	O
en	O
(	O
A	O
)	O
.	O

Las	O
flechas	O
apuntan	O
a	O
las	O
fibras	O
propioceptivas	O
en	O
contacto	O
neuronas	B-Cell
motoras	I-Cell
(	O
asterisco	O
)	O
.	O

(	O
D	O
)	O
Imagen	O
de	O
alta	O
potencia	O
del	O
recuadro	O
en	O
(	O
B	O
)	O
.	O

Tenga	O
en	O
cuenta	O
que	O
no	O
hay	O
sensores	O
axones	B-GENE
contactando	O
etiquetado	O
neuronas	B-Cell
motoras	I-Cell
(	O
asterisco	O
)	O
.	O

Barra	O
de	O
escala	O
:	O
100	O
mu	O
m	O
(	O
A	O
y	O
B	O
)	O
,	O
50	O
mu	O
m	O
(	O
C	O
y	O
D	O
)	O
.	O

(	O
24MB	O
TIF	O
)	O
.	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Figura	O
S2	O

S46	O
/	O
NF-M	B-Protein
Inmunohistoquímica	O
en	O
el	O
músculo	O
gastrocnemio	O
E15	O

Aunque	O
se	O
etiquetaron	O
numerosas	O
fibras	O
musculares	O
y	O
nerviosas	O
,	O
no	O
se	O
pudo	O
identificar	O
ningún	O
huso	O
muscular	O
porque	O
la	O
morfología	O
característica	O
de	O
la	O
terminación	O
nerviosa	O
sensorial	O
envuelta	O
alrededor	O
de	O
la	O
fibra	O
de	O
la	O
bolsa	O
muscular	O
no	O
había	O
comenzado	O
a	O
desarrollarse	O
en	O
ninguno	O
de	O
los	O
genotipos	B-Sequence
aún	O
.	O

Barra	O
de	O
escala	O
:	O
25	O
mu	O
m	O
.	O

(	O
13MB	O
TIF	O
)	O
.	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Agradecimientos	O

Agradecemos	O
a	O
L	O
.	O

Tessarollo	O
por	O
proporcionar	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
KO	O
animales	B-Taxon
,	O
l	O

Reichardt	O
para	O
TrkA	B-Protein
y	O
TrkC	B-Protein
anticuerpos	B-GENE
,	O
F	O
.	O

Stockdale	O
para	O
el	O
S46	O
anticuerpo	B-GENE
,	O
K	O
.	O

Muneoka	O
para	O
perlas	O
de	O
sefarosa	O
y	O
B	O
.	O

Rey	O
para	O
el	O
mantenimiento	O
de	O
animales	B-Taxon
utilizado	O
en	O
este	O
estudio	O
.	O

Agradecemos	O
especialmente	O
a	O
E	O
.	O

Frank	O
por	O
sus	O
valiosos	O
comentarios	O
y	O
debates	O
sobre	O
este	O
estudio	O
y	O
por	O
compartir	O
datos	O
inéditos	O
de	O
su	O
laboratorio	O
.	O

Con	O
el	O
apoyo	O
de	O
los	O
Institutos	O
Nacionales	O
de	O
Salud/Instituto	O
Nacional	O
de	O
Investigación	O
Dental	O
y	O
Craneofacial	O
subvención	O
P01	O
DE07734	O
.	O

abreviaturas	O

BDNF	B-Protein
-	O
factor	B-Protein
neurotrófico	I-Protein
derivado	I-Protein
del	I-Protein
cerebro	I-Protein

BSA	B-Protein
-	O
albúmina	B-Protein
de	I-Protein
suero	I-Protein
bovino	I-Protein

DRG	O
-	O
ganglio	O
de	O
la	O
raíz	O
dorsal	O

E	O
-	O
día	O
embrionario	O

KO	O
-	O
nocaut	O

NF-M	B-Protein
-	O
neurofilamento	B-Protein
-	I-Protein
M	I-Protein

Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
-	O
neurotrofina	B-Protein
-	I-Protein
3	I-Protein

P	O
-	O
día	O
postnatal	O

PBS	O
-	O
fosfato	B-Chemical
tampón	O
salino	O

fotovoltaica	B-Protein
-	O
parvalbúmina	B-Protein

TrkC	B-Protein
-	O
Fc	O
-	O
difusible	O
receptores	B-Protein
TrkC	I-Protein
conjugado	O
a	O
IgG	O
constante	O
regiones	B-Sequence

peso	B-Sequence
-	O
tipo	B-Sequence
salvaje	I-Sequence

Figuras	O
y	O
Tablas	O

Figura	O
1	O

TrkA	B-Protein
/	O
TrkC	B-Protein
y	O
fotovoltaica	B-Protein
Inmunohistoquímica	O
en	O
GRD	O
y	O
Médula	O
Espinal	O

El	O
rojo	O
representa	O
TrkA	B-Protein
,	O
el	O
verde	O
representa	O
TrkC	B-Protein
(	O
y	O
fotovoltaica	B-Protein
en	O
[	O
C	O
]	O
)	O
,	O
y	O
el	O
amarillo	O
representa	O
la	O
coexpresión	O
.	O

(	O
A	O
)	O
TrkA	B-Protein
/	O
TrkC	B-Protein
inmunotinción	O
en	O
E15	O
DRG	O
.	O

TrkC	B-Protein
#	O
¿NOMBRE	O
?	O
neuronas	B-Cell
normalmente	O
eliminado	O
en	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
Los	O
KO	O
se	O
rescatan	O
en	O
doble	O
KO	O
.	O

(	O
B	O
)	O
TrkA	B-Protein
/	O
TrkC	B-Protein
inmunotinción	O
en	O
P0	O
en	O
DRG	O
.	O

(	O
C	O
)	O
fotovoltaica	B-Protein
inmunotinción	O
en	O
P0	O
DRG	O
.	O

Rescatados	O
TrkC	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
fallar	O
en	O
expresar	O
fotovoltaica	B-Protein
.	O

(	O
D	O
)	O
Relación	O
de	O
TrkA	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
para	O
TrkC	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
en	O
los	O
GRD	O
E15	O
y	O
P0	O
.	O

Los	O
datos	O
se	O
presentan	O
como	O
porcentaje	O
de	O
células	B-Cell
con	O
desviación	O
estándar	O
.	O

Los	O
KO	O
dobles	O
siempre	O
tuvieron	O
proporciones	O
similares	O
a	O
bax	B-Protein
KO	O
,	O
y	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
Los	O
KO	O
tenían	O
la	O
menor	O
cantidad	O
de	O
TrkC	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
,	O
Si	O
alguna	O
.	O

(	O
mi	O
)	O
TrkA	B-Protein
/	O
TrkC	B-Protein
inmunotinción	O
en	O
médula	O
espinal	O
E15	O
.	O

La	O
flecha	O
apunta	O
al	O
grupo	O
de	O
fibras	O
Ia	O
.	O

El	O
dorsal	O
está	O
arriba	O
.	O

Barra	O
de	O
escala	O
:	O
50	O
mu	O
m	O
(	O
A-C	O
)	O
,	O
1	O
mm	O
(	O
E	O
)	O
.	O

Figura	O
2	O

Proyecciones	B-GENE
axonales	I-GENE
en	O
la	O
médula	O
espinal	O
después	O
del	O
etiquetado	O
DiI	O
de	O
DRG	O
en	O
P0	O

(	O
A	O
)	O
propioceptivo	O
DRG	O
rescatado	O
neuronas	B-Cell
no	O
inervar	O
adecuadamente	O
neuronas	B-Cell
motoras	I-Cell
en	O
doble	O
KO	O
.	O

En	O
cambio	O
,	O
algunos	O
axones	B-GENE
se	O
dirigen	O
hacia	O
la	O
línea	O
media	O
ventral	O
;	O
cruzan	O
la	O
línea	O
media	O
y	O
se	O
ramifican	O
.	O

(	O
B	O
)	O
Dibujo	O
esquemático	O
del	O
arco	O
reflejo	O
monosináptico	O
tal	O
como	O
se	O
desarrolla	O
normalmente	O
.	O

Los	O
pequeños	O
puntos	O
negros	O
representan	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
liberado	O
centralmente	O
por	O
el	O
neuronas	B-Cell
motoras	I-Cell
y	O
periféricamente	O
por	O
los	O
husos	O
musculares	O
.	O

(	O
C	O
)	O
Ampliación	O
de	O
alta	O
potencia	O
del	O
inserto	O
en	O
(	O
A	O
)	O
.	O

La	O
flecha	O
apunta	O
a	O
la	O
línea	O
media	O
y	O
las	O
puntas	O
de	O
flecha	O
apuntan	O
a	O
botón	B-GENE
sináptico	I-GENE
-	O
como	O
estructuras	O
.	O

Barra	O
de	O
escala	O
:	O
1	O
mm	O
(	O
A	O
)	O
,	O
400	O
mu	O
m	O
(	O
C	O
)	O
.	O

figura	O
3	O

Sensorial	O
axones	B-GENE
Etiquetado	O
con	O
DiI	O
a	O
través	O
del	O
DRG	O
en	O
E17	O

(	O
A	O
)	O
Fibras	O
marcadas	O
con	O
DiI	O
en	O
peso	B-Sequence
médula	O
espinal	O
.	O

Aviso	O
propioceptivo	O
axones	B-GENE
extendiéndose	O
hacia	O
el	O
neuronas	B-Cell
motoras	I-Cell
Situado	O
en	O
el	O
asta	O
ventral	O
de	O
la	O
médula	O
espinal	O
en	O
corte	O
transversal	O
.	O

(	O
B	O
)	O
bax	B-Protein
médula	O
espinal	O
nula	O
.	O

(	O
C	O
)	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
médula	O
espinal	O
nula	O
.	O

Las	O
fibras	O
teñidas	O
están	O
restringidas	O
al	O
nociceptivo	O
.	O
axones	B-GENE
en	O
el	O
asta	O
dorsal	O
,	O
como	O
lo	O
demuestra	O
la	O
ausencia	O
total	O
de	O
marcaje	O
en	O
la	O
médula	O
espinal	O
ventral	O
.	O

(	O
D	O
)	O
bax	B-Protein
/	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
médula	O
espinal	O
doble	O
nula	O
.	O

Aunque	O
las	O
fibras	O
se	O
extienden	O
hacia	O
la	O
médula	O
espinal	O
ventral	O
,	O
nunca	O
crecen	O
hacia	O
la	O
neuronas	B-Cell
motoras	I-Cell
sino	O
que	O
se	O
dirigen	O
hacia	O
la	O
línea	O
media	O
en	O
su	O
lugar	O
.	O

Barra	O
de	O
escala	O
:	O
100	O
mu	O
m	O
.	O

Figura	O
4	O

Husos	O
musculares	O
en	O
el	O
músculo	O
gastrocnemio	O
y	O
TrkA	B-Protein
/	O
TrkC	B-Protein
Tinción	O
en	O
el	O
Nervio	O
Tibial	O
en	O
P0	O

(	O
A	O
)	O
NF-M	B-Protein
(	O
rojo	O
)	O
y	O
S46	O
(	O
verde	O
)	O
inmunotinción	O
en	O
sección	O
transversal	O
del	O
músculo	O
gastrocnemio	O
en	O
P0	O
.	O

No	O
se	O
detectan	O
husos	O
musculares	O
en	O
los	O
KO	O
dobles	O
.	O

(	O
B	O
)	O
NF-M	B-Protein
(	O
rojo	O
)	O
y	O
S46	O
(	O
verde	O
)	O
inmunotinción	O
en	O
secciones	O
paralelas	O
de	O
músculo	O
gastrocnemio	O
en	O
P0	O
.	O

(	O
C	O
)	O
NF-M	B-Protein
(	O
rojo	O
)	O
y	O
S46	O
(	O
verde	O
)	O
inmunotinción	O
en	O
secciones	O
paralelas	O
del	O
músculo	O
gastrocnemio	O
en	O
E17	O
.	O

Los	O
músculos	O
nulos	O
dobles	O
están	O
en	O
su	O
mayoría	O
desprovistos	O
de	O
husos	O
musculares	O
,	O
a	O
excepción	O
de	O
una	O
estructura	O
similar	O
a	O
un	O
huso	O
detectada	O
(	O
que	O
se	O
muestra	O
en	O
el	O
recuadro	O
,	O
indicada	O
con	O
un	O
asterisco	O
)	O
.	O

(	O
D	O
)	O
Husos	O
musculares	O
detectados	O
por	O
marcaje	O
DiI	O
a	O
través	O
del	O
DRG	O
.	O

El	O
músculo	O
gastrocnemio	O
se	O
secciona	O
a	O
40	O
µm	O
de	O
espesor	O
en	O
un	O
plano	O
paralelo	O
a	O
las	O
fibras	O
musculares	O
.	O

(	O
E	O
)	O
Husos	O
musculares	O
detectados	O
por	O
TrkC	B-Protein
tinción	O
en	O
sección	O
transversal	O
del	O
músculo	O
gastrocnemio	O
en	O
P0	O
.	O

(	O
F	O
)	O
TrkA	B-Protein
(	O
rojo	O
y	O
TrkC	B-Protein
(	O
verde	O
)	O
inmunotinción	O
en	O
la	O
sección	O
transversal	O
del	O
nervio	O
tibial	O
en	O
P0	O
.	O

TrkC	B-Protein
#	O
¿NOMBRE	O
?	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
KO	O
.	O

La	O
superposición	O
rojo-verde	O
(	O
amarillo	O
)	O
se	O
debe	O
al	O
grosor	O
de	O
la	O
sección	O
y	O
la	O
superposición	O
de	O
etiquetas	O
rojas	O
y	O
verdes	O
(	O
TrkA	B-Protein
y	O
TrkC	B-Protein
)	O
fibras	O
presentes	O
a	O
diferentes	O
profundidades	O
focales	O
,	O
en	O
lugar	O
de	O
colocalización	O
.	O

Las	O
flechas	O
indican	O
los	O
husos	O
musculares	O
.	O

Barra	O
de	O
escala	O
:	O
50	O
mu	O
m	O
(	O
A	O
,	O
B	O
,	O
D	O
)	O
,	O
25	O
mu	O
m	O
(	O
C	O
,	O
E	O
)	O
,	O
75	O
mu	O
m	O
(	O
F	O
)	O
.	O

Figura	O
5	O

Quimioatracción	O
de	O
E13	O
DRG	O
axones	B-GENE
a	O
locales	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
Observado	O
por	O
In	O
Vitro	O
Co	O
-	O
Ensayos	O
de	O
cultivo	O

(	O
A	O
)	O
peso	B-Sequence
GRD	O
con	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
#	O
¿NOMBRE	O
?	O

(	O
B	O
)	O
peso	B-Sequence
DRG	O
con	O
cordón	O
cargado	O
con	O
BSA	O
.	O

(	O
C	O
)	O
bax	B-Protein
GRD	O
nulo	O
con	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
#	O
¿NOMBRE	O
?	O

(	O
D	O
)	O
p75	B-Protein
GRD	O
nulo	O
con	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
#	O
¿NOMBRE	O
?	O

(	O
mi	O
)	O
peso	B-Sequence
GRD	O
con	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
#	O
¿NOMBRE	O
?	O
TrkC	B-Protein
-	O
Fc	O
en	O
el	O
medio	O
.	O

(	O
F	O
)	O
peso	B-Sequence
GRD	O
con	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
perlas	O
cargadas	O
colocadas	O
a	O
distancias	O
crecientes	O
de	O
los	O
ganglios	O
(	O
rango	O
,	O
500-1	O
,	O
200	O
mu	O
m	O
)	O
.	O

Barra	O
de	O
escala	O
:	O
150	O
mu	O
m	O
(	O
A-E	O
)	O
,	O
350	O
mu	O
m	O
(	O
F	O
)	O
.	O

Figura	O
6	O

Quimioatracción	O
hacia	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
Cuentas	O
colocadas	O
en	O
la	O
médula	O
espinal	O
E13	O
DRG	O
Explant	O
Co	O
-	O
Cultures	O

(	O
A	O
)	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
cuenta	O
colocada	O
en	O
la	O
línea	O
media	O
de	O
E13	O
peso	B-Sequence
médula	O
espinal	O
.	O

Aviso	O
axones	B-GENE
etiquetados	O
a	O
través	O
de	O
los	O
GRD	O
(	O
en	O
un	O
círculo	O
con	O
líneas	O
discontinuas	O
negras	O
)	O
que	O
crecen	O
hacia	O
el	O
cordón	O
(	O
en	O
un	O
círculo	O
con	O
líneas	O
discontinuas	O
blancas	O
)	O
ingresan	O
a	O
la	O
médula	O
espinal	O
en	O
lugares	O
ectópicos	O
en	O
lugar	O
de	O
la	O
médula	O
espinal	O
dorsal	O
.	O

(	O
B	O
)	O
Perla	O
cargada	O
con	O
PBS	O
en	O
la	O
médula	O
espinal	O
E13	O
.	O

Todo	O
etiquetado	O
axones	B-GENE
se	O
extienden	O
a	O
lo	O
largo	O
de	O
la	O
médula	O
espinal	O
dorsal	O
,	O
donde	O
terminan	O
.	O

(	O
C	O
)	O
Imagen	O
de	O
alta	O
potencia	O
de	O
la	O
perla	O
en	O
(	O
A	O
)	O
.	O

Aviso	O
etiquetado	O
axones	B-GENE
que	O
rodea	O
la	O
cuenta	O
.	O

(	O
D	O
)	O
Imagen	O
de	O
alta	O
potencia	O
de	O
un	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
#	O
¿NOMBRE	O
?	O

Aviso	O
axones	B-GENE
agrupado	O
alrededor	O
de	O
la	O
cuenta	O
.	O

(	O
E	O
)	O
Imagen	O
de	O
alta	O
potencia	O
de	O
un	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
#	O
¿NOMBRE	O
?	O

Observe	O
la	O
axones	B-GENE
acercándose	O
a	O
la	O
cuenta	O
a	O
través	O
de	O
la	O
médula	O
espinal	O
dorsal	O
.	O

(	O
F	O
)	O
Imagen	O
de	O
alta	O
potencia	O
de	O
una	O
perla	O
cargada	O
con	O
PBS	O
.	O

No	O
se	O
observaron	O
fibras	O
marcadas	O
alrededor	O
de	O
las	O
perlas	O
de	O
control	O
.	O

(	O
G	O
)	O
Resumen	O
de	O
nuestras	O
observaciones	O
de	O
cultivos	O
organotípicos	O
DRG	O
de	O
médula	O
espinal	O
E13	O
.	O

En	O
cultivos	O
de	O
control	O
,	O
las	O
fibras	O
se	O
extienden	O
a	O
lo	O
largo	O
de	O
la	O
médula	O
espinal	O
dorsal	O
,	O
donde	O
normalmente	O
ingresan	O
a	O
la	O
materia	O
gris	O
en	O
E13	O
.	O

En	O
presencia	O
de	O
un	O
ectópico	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
fuente	O
localizada	O
en	O
la	O
línea	O
media	O
,	O
estos	O
axones	B-GENE
crecer	O
hacia	O
el	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
perla	O

Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
también	O
inicia	O
el	O
crecimiento	O
del	O
axón	O
a	O
partir	O
de	O
los	O
GRD	O
,	O
entrando	O
en	O
la	O
médula	O
espinal	O
en	O
los	O
loci	O
laterales	O
ectópicos	O
,	O
creciendo	O
hacia	O
el	O
cordón	O
,	O
rodeándolo	O
,	O
formando	O
haces	O
de	O
nervios	O
y	O
ramificándose	O
a	O
su	O
alrededor	O
.	O

Barra	O
de	O
escala	O
,	O
175	O
mu	O
m	O
(	O
A	O
y	O
B	O
)	O
,	O
100	O
mu	O
m	O
(	O
C-F	O
)	O
.	O

notas	O
al	O
pie	O

Conflictos	O
de	O
interés	O
.	O

Los	O
autores	O
han	O
declarado	O
que	O
no	O
existen	O
conflictos	O
de	O
interés	O
.	O

Contribuciones	O
de	O
autor	O
.	O

BG	O
y	O
RE	O
concibieron	O
y	O
diseñaron	O
los	O
experimentos	O
.	O

BG	O
,	O
AEM	O
y	O
PHO	O
realizaron	O
los	O
experimentos	O
.	O

BG	O
,	O
PHO	O
y	O
RE	O
analizaron	O
los	O
datos	O
.	O

BG	O
y	O
RE	O
escribieron	O
el	O
documento	O
.	O

Editor	O
Académico	O
:	O
Joshua	O
R.	O
Sanes	O
,	O
Universidad	O
de	O
Harvard	O

moneda	O
Dirección	O
actual	O
:	O
Hospital	O
General	O
de	O
Massachusetts	O
,	O
Centro	O
de	O
Reparación	O
del	O
Sistema	O
Nervioso	O
de	O
la	O
Facultad	O
de	O
Medicina	O
de	O
Harvard	O
,	O
Boston	O
,	O
Massachusetts	O
,	O
Estados	O
Unidos	O
de	O
América	O

Cita	O
:	O
Gen	O
c	O
B	O
,	O
O	O
zdinler	O
PH	O
,	O
Mendoza	O
AE	O
,	O
Erzurumlu	O
RS	O
(	O
2004	O
)	O
A	O
chemoattractant	O
role	O
for	O
Nuevo	B-Protein
Testamento	I-Protein
-	I-Protein
3	I-Protein
en	O
propioceptivo	O
axón	B-GENE
Guia	O
.	O

PLoS	O
Biol	O
2	O
(	O
12	O
)	O
:	O
e403	O
.	O

ADN	B-Sequence
acciones	O
de	O
unión	O
y	O
helicasa	O
de	O
ratón	B-Protein
MCM4	I-Protein
/	O
6	O
/	O
7	O
helicasa	O

Resumen	O

Las	O
helicasas	O
juegan	O
un	O
papel	O
central	O
en	O
la	O
iniciación	O
y	O
elongación	O
de	O
ADN	B-Sequence
replicación	O

Anteriormente	O
informamos	O
que	O
las	O
actividades	O
de	O
helicasa	O
y	O
ATPasa	O
del	O
mamífero	B-Taxon
Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejo	B-GENE
son	O
activados	O
específicamente	O
por	O
timina	B-Chemical
#	O
¿NOMBRE	O
?	O
ADN	B-Sequence
monocatenario	I-Sequence
.	O

Aquí	O
,	O
examinamos	O
su	O
preferencia	O
de	O
sustrato	O
y	O
las	O
acciones	O
de	O
helicasa	O
usando	O
varios	O
ADN	B-Sequence
sintético	I-Sequence
.	O

Sobre	O
un	O
sustrato	O
de	O
burbujas	O
,	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
hace	O
contactos	O
duales	O
simétricos	O
con	O
el	O
5	O
'	O
-	O
proximal	O
25	O
Nuevo	B-Chemical
Testamento	I-Chemical
segmentos	B-Sequence
monocatenarios	I-Sequence
adyacente	O
a	O
los	O
puntos	O
de	O
ramificación	O
,	O
presumiblemente	O
generando	O
doble	O
hexámero	O
.	O

Pérdida	O
de	O
residuos	B-Chemical
de	I-Chemical
timina	I-Chemical
de	O
uno	O
solo	O
-	O
hebra	B-Sequence
da	O
como	O
resultado	O
una	O
disminución	O
significativa	O
de	O
la	O
eficacia	O
de	O
desenrollado	O
,	O
lo	O
que	O
sugiere	O
que	O
el	O
desenrollado	O
bidireccional	O
concurrente	O
por	O
un	O
solo	O
hexámero	O
doble	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
puede	O
jugar	O
un	O
papel	O
en	O
el	O
desenrollado	O
eficiente	O
de	O
la	O
burbuja	O
.	O

Mcm4	B-Protein
/	O
6	O
/	O
7	O
ata	O
y	O
desenrolla	O
varios	O
tenedor	B-GENE
y	O
estructuras	O
de	O
extensión	O
que	O
llevan	O
un	O
monocatenario	B-Sequence
3	O
'	O
-	O
cola	O
ADN	B-Sequence
.	O

El	O
grado	O
de	O
activación	O
de	O
la	O
helicasa	O
depende	O
de	O
la	O
secuencia	B-Sequence
contexto	O
de	O
la	O
cola	O
de	O
3	O
'	O
,	O
y	O
el	O
nivel	O
máximo	O
se	O
logra	O
mediante	O
ADN	B-Sequence
con	O
50	O
%	O
o	O
más	O
timina	B-Chemical
contenido	O
.	O

Hebra	B-Sequence
desplazamiento	O
por	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
está	O
inhibido	O
,	O
ya	O
que	O
el	O
contenido	O
de	O
GC	O
del	O
región	B-Sequence
dúplex	I-Sequence
aumenta	O

Reemplazo	B-Sequence
de	O
citosina	B-Chemical
-	O
guanina	B-Chemical
pares	O
con	O
citosina	B-Chemical
-	O
inosina	B-Chemical
pares	O
en	O
el	O
dúplex	O
restaurado	O
desenrollado	O
,	O
lo	O
que	O
sugiere	O
que	O
mamífero	B-Taxon
Mcm4	B-Protein
/	O
6	O
/	O
7	O
la	O
helicasa	O
tiene	O
dificultades	O
para	O
desenrollarse	O
de	O
forma	O
estable	O
base	B-Sequence
-	I-Sequence
emparejado	I-Sequence
dúplex	O

Tomados	O
en	O
conjunto	O
,	O
estos	O
hallazgos	O
revelan	O
características	O
importantes	O
sobre	O
la	O
activación	O
y	O
la	O
preferencia	O
de	O
sustrato	O
del	O
eucariota	B-Taxon
helicasa	O
replicativa	O
.	O

INTRODUCCIÓN	O

ADN	B-Sequence
Las	O
helicasas	O
acoplan	O
la	O
hidrólisis	O
de	O
trifosfato	B-Chemical
de	I-Chemical
nucleótidos	I-Chemical
o	I-Chemical
desoxinucleótidos	I-Chemical
al	O
desenrollado	O
dúplex	O
(	O
1	O
)	O
.	O

Coordinación	O
de	O
un	O
conjunto	O
de	O
subactividades	O
que	O
incluyen	O
nucleótido	B-Chemical
Unión	O
,	O
ADN	B-Sequence
vinculante	O
y	O
atp	B-Chemical
Se	O
requiere	O
hidrólisis	O
para	O
desenrollar	O
ADN	B-Sequence
dúplex	I-Sequence
(	O
1	O
,	O
2	O
)	O
.	O

Las	O
helicasas	O
hexaméricas	O
,	O
a	O
las	O
que	O
helicasa	B-GENE
de	I-GENE
mantenimiento	I-GENE
de	I-GENE
minicromosomas	I-GENE
(	I-GENE
Mcm	I-GENE
)	I-GENE
pertenece	O
,	O
se	O
sabe	O
que	O
ensamblan	O
una	O
estructura	O
en	O
forma	O
de	O
anillo	O
(	O
3-5	O
)	O
.	O

Mientras	O
que	O
la	O
mayoría	O
de	O
ADN	B-Sequence
helicasas	O
de	O
este	O
grupo	O
,	O
incluyendo	O
virus	B-Protein
simio	I-Protein
40	I-Protein
T	I-Protein
grande	I-Protein
-	I-Protein
antígeno	I-Protein
(	O
6	O
)	O
,	O
Escherichia	B-Taxon
coli	I-Taxon
ADNB	B-Protein
(	O
7	O
)	O
y	O
Arqueal	B-Taxon
Mcm	O
(	O
4	O
,	O
8	O
,	O
9	O
)	O
,	O
se	O
componen	O
de	O
una	O
sola	O
subunidad	O
,	O
la	O
activa	O
eucariota	B-Taxon
Mcm	B-GENE
helicasas	I-GENE
se	O
componen	O
de	O
dos	O
triméricos	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
proteinas	B-Chemical
(	O
10	O
-	O
14	O
)	O
.	O

Todos	O
los	O
seis	O
Mcm	B-Protein
2	I-Protein
-	I-Protein
7	I-Protein
proteinas	B-Chemical
contener	O
altamente	O
ADN	B-Sequence
conservado	I-Sequence
#	O
¿NOMBRE	O
?	O
regiones	B-Sequence
(	O
15	O
,	O
16	O
)	O
.	O

Entre	O
los	O
varios	O
subcomplejos	O
estables	O
que	O
MCM	B-GENE
proteinas	B-Chemical
puede	O
generar	O
,	O
sólo	O
el	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejo	B-GENE
se	O
ha	O
demostrado	O
que	O
posee	O
un	O
intrínseco	O
ADN	B-Sequence
actividad	O
helicasa	O
(	O
10-14	O
,	O
17-18	O
)	O
.	O

Tiempo	O
Mcm4	B-Protein
,	O
Mcm6	B-Protein
y	O
Mcm7	B-Protein
proteinas	B-Chemical
hacer	O
una	O
contribución	O
distinta	O
a	O
su	O
actividad	O
helicasa	O
(	O
11	O
-	O
13	O
)	O
,	O
Mcm2	B-Protein
o	O
Mcm3	B-Protein
/	O
5	O
inhibir	O
la	O
actividad	O
helicasa	O
del	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejo	B-GENE
convirtiendo	O
su	O
estructura	O
de	O
doble	O
trímero	O
en	O
un	O
heterotetrámero	O
o	O
heteropentámero	O
,	O
respectivamente	O
(	O
3	O
,	O
11	O
)	O
.	O

cromatina	B-GENE
ensayos	O
de	O
inmunoprecipitación	O
y	O
genético	B-Sequence
caracterización	O
en	O
Saccharomyces	B-Taxon
cerevisiae	I-Taxon
sugirió	O
fuertemente	O
que	O
Mcm	B-GENE
está	O
involucrada	O
no	O
sólo	O
en	O
la	O
iniciación	O
sino	O
también	O
en	O
la	O
cadena	B-Sequence
de	I-Sequence
ADN	I-Sequence
etapa	O
de	O
elongación	O
como	O
una	O
helicasa	O
replicativa	O
(	O
19	O
,	O
20	O
)	O
.	O

De	O
acuerdo	O
con	O
esta	O
noción	O
,	O
la	O
procesividad	O
de	O
la	O
Schizosaccharomyces	B-Protein
pombe	I-Protein
y	I-Protein
ratón	I-Protein
Mcm4	I-Protein
/	O
6	O
/	O
7	O
complejos	B-GENE
se	O
estimula	O
significativamente	O
en	O
ahorquillado	B-GENE
ADN	B-Sequence
estructuras	O
y	O
puede	O
desenrollarse	O
ADN	B-Sequence
dúplex	I-Sequence
de	O
400	O
-	O
500	O
pb	B-Sequence
(	O
13	O
,	O
14	O
)	O
.	O

Mcm4	B-Protein
/	O
6	O
/	O
7	O
se	O
une	O
a	O
estructuras	B-GENE
de	I-GENE
horquilla	I-GENE
y	I-GENE
burbuja	I-GENE
en	O
un	O
atp	B-Chemical
-	O
manera	O
dependiente	O
,	O
y	O
genera	O
un	O
doble	O
-	O
hexamerico	O
complejo	B-GENE
,	O
como	O
se	O
mostró	O
para	O
T	B-Protein
-	I-Protein
antígeno	I-Protein
(	O
13	O
,	O
14	O
,	O
21	O
)	O
.	O

Recientemente	O
,	O
informamos	O
que	O
la	O
helicasa	O
y	O
atp	B-Chemical
actividades	O
de	O
hidrólisis	O
de	O
mamífero	B-Taxon
Mcm4	B-Protein
/	O
6	O
/	O
7	O
son	O
específicamente	O
activados	O
por	O
ADN	B-Sequence
monocatenario	I-Sequence
que	O
contiene	O
tramos	O
de	O
residuos	B-Chemical
de	I-Chemical
timina	I-Chemical
y	O
propuso	O
un	O
modelo	O
novedoso	O
que	O
Mcm	B-GENE
puede	O
jugar	O
un	O
papel	O
crucial	O
en	O
la	O
selección	O
de	O
orígenes	B-Sequence
de	I-Sequence
replicación	I-Sequence
en	O
alto	O
eucariotas	B-Taxon
(	O
13	O
)	O
.	O

En	O
este	O
informe	O
,	O
con	O
el	O
fin	O
de	O
aclarar	O
el	O
modo	O
de	O
acción	O
de	O
la	O
Mcm	B-GENE
helicasa	I-GENE
y	O
obtener	O
una	O
idea	O
de	O
cómo	O
puede	O
funcionar	O
en	O
el	O
horquillas	B-GENE
de	I-GENE
replicación	I-GENE
in	O
vivo	O
,	O
hemos	O
realizado	O
análisis	O
detallados	O
de	O
la	O
acción	O
de	O
la	O
helicasa	O
y	O
ADN	B-Sequence
Unión	O
de	O
ratón	B-Protein
mcm4	I-Protein
/	O
6	O
/	O
7	O
helicasa	O
usando	O
varios	O
ahorquillado	B-GENE
y	O
sustrato	O
de	O
burbujas	O
ADN	B-Sequence
.	O

Nos	O
dirigimos	O
específicamente	O
secuencia	B-Sequence
requisito	O
para	O
el	O
Mcm	B-GENE
helicasa	I-GENE
activación	O
,	O
modo	O
de	O
interacción	O
con	O
ADN	B-Sequence
sustratos	O
y	O
si	O
la	O
timina	O
secuencias	B-Sequence
son	O
necesarios	O
para	O
la	O
activación	O
continua	O
de	O
Mcm	B-GENE
helicasa	I-GENE
durante	O
el	O
proceso	O
de	O
desenrollado	O
.	O

Los	O
resultados	O
indican	O
que	O
mamífero	B-Taxon
Mcm4	B-Protein
/	O
6	O
/	O
7	O
se	O
une	O
principalmente	O
a	O
región	B-Sequence
de	I-Sequence
ADN	I-Sequence
monocatenario	I-Sequence
,	O
y	O
que	O
el	O
grado	O
de	O
activación	O
de	O
la	O
helicasa	O
está	O
relacionado	O
con	O
el	O
contenido	O
de	O
timina	O
de	O
la	O
segmento	B-Sequence
monocatenario	I-Sequence
.	O

Inesperadamente	O
,	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
helicasa	O
no	O
es	O
capaz	O
de	O
desenrollar	O
eficientemente	O
el	O
GC	O
-	O
rico	O
segmento	B-Sequence
dúplex	I-Sequence
lo	O
que	O
sugiere	O
que	O
se	O
puede	O
requerir	O
algún	O
otro	O
mecanismo	O
para	O
completar	O
la	O
replicación	O
de	O
todo	O
el	O
genoma	B-Sequence
.	O

MATERIALES	O
Y	O
MÉTODOS	O

reactivos	B-Chemical

Etiquetado	O
y	O
sin	O
etiquetar	O
dNTP	B-Chemical
/	O
rNTP	B-Chemical
y	O
Sequenase	O
se	O
adquirieron	O
de	O
Amersham	O
Pharmacia	O
.	O

M13mp18	O
y	O
M13mp19	O
ADN	B-Sequence
circular	I-Sequence
monocatenario	I-Sequence
,	O
T4	B-Protein
polinucleótido	I-Protein
quinasa	I-Protein
,	O
ADNasa	B-Protein
I	I-Protein
y	O
el	O
klenow	O
fragmento	B-Sequence
eran	O
de	O
TAKARA	O
,	O
Nuclease	O
P1	O
era	O
de	O
Roche	O
y	O
anti	O
-	O
FLAG	O
M2	O
AB	B-GENE
(	O
anticuerpo	B-GENE
)	O
-	O
agarosa	B-Chemical
y	O
BANDERA	O
péptido	B-Sequence
eran	O
de	O
Sigma	O
.	O

SV40	B-Protein
T	I-Protein
-	I-Protein
antígeno	I-Protein
fue	O
purificado	O
de	O
baculovirus	B-Taxon
#	O
¿NOMBRE	O
?	O
insecto	B-Taxon
células	B-Cell
como	O
se	O
informó	O
(	O
22	O
)	O
.	O

PriA	B-Protein
helicasa	I-Protein
proteína	B-Chemical
fue	O
proporcionada	O
por	O
el	O
Dr.	O
Taku	O
Tanaka	O
(	O
23	O
)	O
.	O

oligonucleótidos	B-Sequence
se	O
adquirieron	O
de	O
Hokkaido	O
system	O
science	O
Co.	O
,	O
Ltd	O
(	O
Hokkaido	O
,	O
Japón	O
)	O
,	O
y	O
se	O
purificaron	O
en	O
gel	O
de	O
poliacrilamida	O
,	O
seguido	O
de	O
purificación	O
mediante	O
columna	O
de	O
cartucho	O
Sep	O
-	O
Pak	O
Plus	O
C18	O
(	O
Waters	O
)	O
.	O

Expresión	O
y	O
purificación	O
de	O
ratón	B-Protein
mcm4	I-Protein
/	O
6	O
/	O
7	O
complejo	B-GENE

el	O
recombinante	O
baculovirus	B-Taxon
expresando	O
His6	O
-	O
Mcm4	B-Protein
/	O
Mcm6	B-Protein
o	O
Mcm7	B-Protein
#	O
¿NOMBRE	O
?	O
proteinas	B-Chemical
fueron	O
descritas	O
previamente	O
(	O
11	O
)	O
.	O

Sf9	O
y	O
choca	O
esos	O
cinco	O
insecto	B-Taxon
células	B-Cell
fueron	O
cultivadas	O
a	O
27	O
grados	O
C	O
en	O
Sf-900	O
II	O
SFM	O
(	O
Life	O
Technologies	O
,	O
Inc.	O
)	O
y	O
EX-	O
CÉLULA	B-Cell
405	O
medio	O
(	O
JRH	O
Biosciences	O
)	O
,	O
respectivamente	O
.	O

Para	O
expresión	O
de	O
la	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
proteinas	B-Chemical
,	O
Cinco	O
altos	O
células	B-Cell
fueron	O
coinfectados	O
con	O
recombinante	O
baculovirus	B-Taxon
expresando	O
el	O
His6	O
-	O
Mcm4	B-Protein
/	O
Mcm6	B-Protein
proteinas	B-Chemical
y	O
los	O
que	O
expresan	O
la	O
Mcm7	B-Protein
-FLAG	O
,	O
y	O
se	O
recogieron	O
a	O
las	O
48	O
h	O
después	O
de	O
la	O
infección	O
.	O

el	O
recombinante	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejos	B-GENE
se	O
purificaron	O
como	O
se	O
describió	O
previamente	O
(	O
12	O
)	O
.	O

ADN	B-Sequence
sustratos	O

los	O
secuencias	B-Sequence
para	O
todos	O
los	O
oligonucleótidos	B-Sequence
utilizado	O
para	O
construcciones	O
de	O
ADN	B-Sequence
los	O
sustratos	O
se	O
enumeran	O
en	O
las	O
Tablas	O
1	O
y	O
2	O
.	O

Los	O
sustratos	O
heterodúplex	O
parciales	O
se	O
construyeron	O
recociendo	O
etiquetados	O
oligonucleótidos	B-Sequence
con	O
M13mp18	O
ADN	B-Sequence
circular	I-Sequence
monocatenario	I-Sequence
o	O
su	O
derivado	O
.	O

Los	O
sustratos	O
marcados	O
se	O
purificaron	O
mediante	O
cromatografía	O
en	O
columna	O
Sepharose	O
CL4B	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
)	O
.	O

los	O
ADN	B-Sequence
sustratos	O
de	O
burbujas	O
se	O
ensamblaron	O
a	O
partir	O
de	O
dos	O
parcialmente	O
complementarios	O
oligonucleótidos	B-Sequence
con	O
arriba	O
y	O
abajo	O
secuencias	B-Sequence
de	I-Sequence
hebras	I-Sequence
(	O
Tabla	O
1	O
)	O
.	O

T	O
-	O
cola	O
Y	O
-	O
tenedor	B-GENE
Los	O
sustratos	O
se	O
prepararon	O
recociendo	O
dos	O
oligonucleótidos	B-Sequence
(	O
series	O
dT30	O
y	O
dT60	O
)	O
.	O

Para	O
construir	O
el	O
arrestado	O
tenedor	B-GENE
y	O
sustratos	O
de	O
extensión	O
de	O
3	O
'	O
o	O
5	O
'	O
,	O
varias	O
combinaciones	O
de	O
oligonucleótidos	B-Sequence
mostrados	O
en	O
la	O
Tabla	O
1	O
fueron	O
recocidos	O
.	O

Bub	O
-	O
82	O
/	O
lámina	B-Protein
B2	I-Protein
que	O
contiene	O
el	O
T	B-Chemical
#	O
¿NOMBRE	O
?	O
hebra	B-Sequence
de	O
El	O
lámina	B-Protein
B2	I-Protein
región	B-Sequence
de	I-Sequence
origen	I-Sequence
se	O
construyó	O
como	O
se	O
describió	O
previamente	O
(	O
13	O
)	O
.	O

El	O
sustrato	O
de	O
la	O
burbuja	O
,	O
c-myc	B-Protein
/	O
VENCIDO	O
o	O
c-myc	B-Protein
/	O
VENCIDO	O
-	O
C	O
,	O
contiene	O
secuencias	B-Sequence
(	O
Número	O
de	O
acceso	O
de	O
GenBank	O
K01908	O
)	O
de	O
nucleótidos	B-Sequence
722	O
a	O
853	O
o	O
los	O
del	O
828	O
al	O
747	O
(	O
complementarios	O
hebra	B-Sequence
)	O
,	O
respectivamente	O
,	O
en	O
el	O
centro	O
fundido	O
región	B-Sequence
.	O

Para	O
cada	O
sustrato	O
,	O
etiquetado	O
oligonucleótido	B-Sequence
(	O
3	O
pmol	O
)	O
se	O
recoció	O
con	O
el	O
no	O
marcado	O
oligonucleótido	B-Sequence
(	O
6	O
pmol	O
)	O
en	O
una	O
mezcla	O
de	O
reacción	O
(	O
50	O
mu	O
l	O
)	O
que	O
contiene	O
20	O
mM	O
tris	B-Chemical
-	O
HCl	B-Chemical
(	O
pH	O
7	O
,	O
5	O
)	O
,	O
10	O
mM	O
MgCl2	B-Chemical
y	O
25	O
mm	O
NaCl	B-Chemical
,	O
que	O
se	O
calentaron	O
a	O
95	O
grados	O
C	O
,	O
se	O
mantuvieron	O
a	O
67	O
grados	O
C	O
durante	O
1	O
hora	O
y	O
luego	O
se	O
dejaron	O
enfriar	O
lentamente	O
a	O
37	O
grados	O
C	O
.	O

Los	O
sustratos	O
ensamblados	O
se	O
purificaron	O
a	O
partir	O
de	O
gel	O
de	O
poliacrilamida	O
por	O
elución	O
en	O
tampón	O
TE	O
(	O
24	O
)	O
.	O

Los	O
sustratos	O
heterodúplex	O
parciales	O
en	O
un	O
ADN	B-Sequence
circular	I-Sequence
monocatenario	I-Sequence
con	O
longitudes	O
variadas	O
de	O
regiones	B-Sequence
dúplex	I-Sequence
fueron	O
preparados	O
extendiendo	O
cadenas	B-Sequence
de	I-Sequence
ADN	I-Sequence
desde	O
el	O
extremo	O
3	O
'	O
del	O
dT40	O
-	O
37mer	O
(	O
37mer	O
región	B-Sequence
hibridando	O
en	O
posiciones	B-Sequence
6289	O
-	O
6326	O
de	O
M13mp18	O
vector	B-Sequence
)	O
recocido	O
al	O
ADN	B-Sequence
circular	I-Sequence
monocatenario	I-Sequence
.	O

cadenas	B-Sequence
de	I-Sequence
ADN	I-Sequence
se	O
alargaron	O
con	O
Sequenase	O
en	O
presencia	O
de	O
[	O
alfa	O
-	O
32P	B-Chemical
]	O
dGTP	B-Chemical
,	O
seguido	O
de	O
extensión	O
después	O
de	O
agregar	O
ddGTP	O
y	O
los	O
cuatro	O
dNTP	B-Chemical
,	O
lo	O
que	O
da	O
como	O
resultado	O
sustratos	O
que	O
contienen	O
etiquetas	O
regiones	B-Sequence
dúplex	I-Sequence
de	O
longitudes	O
variadas	O
(	O
13	O
)	O
.	O

El	O
sustrato	O
(	O
5	O
fmol	O
)	O
se	O
incubó	O
primero	O
con	O
la	O
cantidad	O
indicada	O
del	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejo	B-GENE
a	O
37	O
grados	O
C	O
durante	O
1	O
h	O
en	O
la	O
mezcla	O
de	O
reacción	O
como	O
se	O
describe	O
(	O
11	O
)	O
,	O
y	O
luego	O
las	O
reacciones	O
se	O
detuvieron	O
mediante	O
la	O
adición	O
de	O
EDTA	B-Chemical
(	O
20	O
mM	O
)	O
,	O
SDS	B-Chemical
(	O
0,1	O
%	O
)	O
y	O
2	O
µg	O
de	O
proteinasa	O
K	O
,	O
seguido	O
de	O
incubación	O
durante	O
20	O
min	O
.	O

Las	O
alícuotas	O
se	O
sometieron	O
a	O
electroforesis	O
en	O
un	O
6	O
.	O
Gel	O
de	O
poliacrilamida	O
al	O
5	O
%	O
en	O
1	O
x	O
TBE	O
a	O
300	O
V	O
para	O
2	O
.	O
5	O
horas	O

los	O
ADN	B-Sequence
circular	I-Sequence
monocatenario	I-Sequence
se	O
usaron	O
M13mp18	O
y	O
M13mp19	O
+	O
ricos	O
en	O
G	O
.	O

Este	O
último	O
fue	O
construido	O
por	O
insertando	B-Sequence
a	O
GRAMO	B-Chemical
#	O
¿NOMBRE	O
?	O
repetir	B-Sequence
secuencia	I-Sequence
(	O
GGGGCGTGGGC	O
)	O
6	O
,	O
preparado	O
por	O
recocido	O
de	O
dos	O
oligonucleótidos	B-Sequence
(	O
5	O
'	O
-	O
GATCC	O
-	O
[	O
GGGGCGTGGGC	O
]	O
6	O
-	O
3	O
'	O
/	O
5	O
'	O
-	O
GATCC	O
-	O
[	O
GCCCACGCCCC	O
]	O
6	O
-	O
3	O
'	O
)	O
en	O
el	O
BamHI	O
sitio	B-Sequence
de	O
M13mp19	O
y	O
el	O
secuencias	B-Sequence
de	O
El	O
insertar	B-Sequence
fueron	O
confirmados	O
.	O

ADN	B-Sequence
Ensayos	O
de	O
cambio	O
de	O
gel	O
y	O
helicasa	O

En	O
los	O
ensayos	O
de	O
cambio	O
de	O
gel	O
,	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
proteinas	B-Chemical
se	O
incubaron	O
a	O
30	O
grados	O
C	O
durante	O
30	O
min	O
en	O
mezclas	O
de	O
reacción	O
(	O
15	O
mu	O
l	O
)	O
que	O
contenían	O
25	O
mM	O
HEPES	B-Chemical
-	O
NaOH	B-Chemical
(	O
pH	O
7	O
,	O
5	O
)	O
,	O
50	O
mM	O
acetato	B-Chemical
de	I-Chemical
sodio	I-Chemical
,	O
10	O
mm	O
magnesio	B-Chemical
(	O
CH3COO	B-Chemical
)	O
2	O
,	O
1	O
mM	O
TDT	B-Chemical
,	O
0	O
.	O
25	O
ug/ml	O
BSA	B-Protein
,	O
0	O
.	O
5	O
mm	O
ATP-gamma-S	B-Chemical
y	O
sustratos	O
etiquetados	O
en	O
la	O
cantidad	O
indicada	O
.	O

Después	O
de	O
la	O
adición	O
de	O
2	O
mu	O
l	O
de	O
50	O
%	O
glicerol	B-Chemical
,	O
las	O
mezclas	O
de	O
reacción	O
se	O
aplicaron	O
directamente	O
sobre	O
un	O
gel	O
de	O
poliacrilamida	O
que	O
contenía	O
6	O
mM	O
acetato	B-Chemical
de	I-Chemical
magnesio	I-Chemical
y	O
5	O
%	O
glicerol	B-Chemical
en	O
0	O
5	O
x	O
TBE	O
,	O
y	O
la	O
electroforesis	O
se	O
realizó	O
a	O
temperatura	O
ambiente	O
.	O

Para	O
ADN	B-Sequence
ensayos	O
de	O
helicasa	O
,	O
las	O
mezclas	O
de	O
reacción	O
de	O
los	O
ensayos	O
de	O
cambio	O
de	O
gel	O
,	O
como	O
se	O
describe	O
anteriormente	O
,	O
se	O
incubaron	O
a	O
30	O
grados	O
C	O
durante	O
15	O
minutos	O
,	O
y	O
luego	O
se	O
atp	B-Chemical
se	O
añadió	O
a	O
10	O
mM	O
,	O
seguido	O
de	O
incubación	O
a	O
37	O
grados	O
C	O
durante	O
30	O
min	O
adicionales	O
.	O

Las	O
reacciones	O
se	O
terminaron	O
mediante	O
la	O
adición	O
de	O
EDTA	B-Chemical
(	O
20	O
mM	O
)	O
,	O
SDS	B-Chemical
(	O
0,1	O
%	O
)	O
y	O
2	O
µg	O
de	O
proteinasa	O
K	O
,	O
y	O
se	O
incubaron	O
durante	O
15	O
min	O
adicionales	O
.	O

Las	O
muestras	O
se	O
separaron	O
por	O
electroforesis	O
en	O
gel	O
de	O
poliacrilamida	O
no	O
desnaturalizante	O
en	O
1	O
x	O
TBE	O
.	O

Ensayos	O
de	O
protección	O
de	O
nucleasa	O

Las	O
mezclas	O
de	O
reacción	O
(	O
25	O
mu	O
l	O
)	O
contenían	O
25	O
mM	O
HEPES	B-Chemical
-	O
NaOH	B-Chemical
(	O
pH	O
7	O
,	O
5	O
)	O
,	O
50	O
mM	O
acetato	B-Chemical
de	I-Chemical
sodio	I-Chemical
,	O
10	O
mm	O
magnesio	B-Chemical
(	O
CH3COO	B-Chemical
)	O
2	O
,	O
1	O
mM	O
TDT	B-Chemical
,	O
0	O
.	O
25	O
mg/ml	O
BSA	B-Protein
,	O
0	O
.	O
5	O
mm	O
ATP-gamma-S	B-Chemical
,	O
0	O
.	O
5	O
mm	O
CaCl2	B-Chemical
,	O
10	O
fmol	O
de	O
32P	B-Chemical
-	O
sustrato	O
de	O
burbujas	O
etiquetado	O
,	O
y	O
la	O
cantidad	O
indicada	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
proteinas	B-Chemical
.	O

Después	O
de	O
la	O
incubación	O
a	O
30	O
grados	O
C	O
durante	O
30	O
min	O
,	O
la	O
cantidad	O
indicada	O
de	O
ADNasa	B-Protein
I	I-Protein
(	O
TAKARA	O
Biomedical	O
,	O
Japón	O
)	O
y	O
las	O
mezclas	O
se	O
incubaron	O
a	O
temperatura	O
ambiente	O
durante	O
1	O
min	O
.	O

ADNasa	B-Protein
I	I-Protein
fue	O
inactivado	O
por	O
la	O
adición	O
de	O
250	O
l	O
de	O
solución	O
de	O
parada	O
(	O
20	O
mM	O
EDTA	B-Chemical
0	O
.	O
2M	O
cloruro	B-Chemical
de	I-Chemical
sodio	I-Chemical
,	O
1	O
%	O
SDS	B-Chemical
y	O
12	O
.	O
5	O
ug/ml	O
levadura	B-Taxon
ARN	B-Sequence
)	O
.	O

Para	O
el	O
ensayo	O
de	O
huella	O
de	O
nucleasa	O
P1	O
,	O
las	O
reacciones	O
de	O
unión	O
se	O
llevaron	O
a	O
cabo	O
en	O
las	O
mismas	O
condiciones	O
excepto	O
que	O
CaCl2	B-Chemical
fue	O
omitido	O

Se	O
añadió	O
nucleasa	O
P1	O
(	O
0,3	O
U	O
,	O
Roche	O
)	O
y	O
se	O
continuó	O
la	O
incubación	O
a	O
37	O
grados	O
C	O
durante	O
1	O
min	O
.	O

La	O
escisión	O
se	O
detuvo	O
mediante	O
la	O
adición	O
de	O
50	O
µl	O
de	O
25	O
mM	O
EDTA	B-Chemical
y	O
0	O
4M	O
NaOH	B-Chemical
;	O
la	O
mezcla	O
se	O
incubó	O
a	O
temperatura	O
ambiente	O
durante	O
10	O
min	O
seguido	O
de	O
la	O
adición	O
de	O
12	O
mu	O
l	O
de	O
3	O
M	O
acetato	B-Chemical
de	I-Chemical
sodio	I-Chemical
(	O
pH	O
4	O
.	O
8	O
)	O
.	O

Proteínas	B-Chemical
fueron	O
eliminados	O
por	O
fenol	B-Chemical
-	O
cloroformo	B-Chemical
extracción	O
,	O
y	O
ADN	B-Sequence
fueron	O
recogidos	O
por	O
etanol	B-Chemical
precipitación	O
seguida	O
de	O
lavado	O
con	O
70	O
%	O
etanol	B-Chemical
.	O

el	O
digerido	O
ADN	B-Sequence
fue	O
sometido	O
a	O
electroforesis	O
a	O
través	O
de	O
un	O
gel	O
de	O
secuenciación	O
de	O
poliacrilamida	O
al	O
10	O
o	O
12	O
%	O
que	O
contenía	O
7	O
M	O
urea	B-Chemical
,	O
seguido	O
de	O
autorradiografía	O
.	O

RESULTADOS	O

Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejo	B-GENE
interactúa	O
principalmente	O
con	O
el	O
segmento	B-Sequence
de	I-Sequence
ADN	I-Sequence
monocatenario	I-Sequence

Mcm4	B-Protein
/	O
6	O
/	O
7	O
se	O
une	O
a	O
'burbuja	O
'	O
ADN	B-Sequence
sustratos	O
y	O
desenrolla	O
el	O
segmentos	B-Sequence
dúplex	I-Sequence
cuando	O
el	O
central	O
segmento	B-Sequence
monocatenario	I-Sequence
contiene	O
timina	B-Chemical
se	B-Sequence
estira	I-Sequence
(	O
13	O
)	O
.	O

Para	O
examinar	O
el	O
modo	O
de	O
vinculación	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
en	O
burbuja	O
ADN	B-Sequence
,	O
realizamos	O
ensayos	O
de	O
protección	O
de	O
nucleasas	O
utilizando	O
sustrato	O
de	O
burbujas	O
marcado	O
ADN	B-Sequence
y	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
en	O
presencia	O
de	O
ATP-gamma-S	B-Chemical
que	O
permite	O
la	O
unión	O
al	O
sustrato	O
ADN	B-Sequence
pero	O
no	O
moviliza	O
la	O
helicasa	O
.	O

A	O
una	O
concentración	O
óptima	O
de	O
ADNasa	B-Protein
I	I-Protein
,	O
se	O
detectaron	O
fuertes	O
clivajes	O
el	O
21	O
regiones	B-Sequence
dúplex	I-Sequence
pb	I-Sequence
en	O
ambos	O
extremos	O
de	O
los	O
sustratos	O
,	O
mientras	O
que	O
se	O
detectaron	O
clivajes	O
más	O
débiles	O
en	O
el	O
centro	O
región	B-Sequence
monocatenaria	I-Sequence
,	O
consistente	O
con	O
la	O
preferencia	O
de	O
ADNasa	B-Protein
I	I-Protein
para	O
ADN	B-Sequence
de	I-Sequence
doble	I-Sequence
cadena	I-Sequence
.	O

Con	O
el	O
Bub66	O
/	O
T	B-Chemical
-	O
sustrato	O
rico	O
,	O
se	O
detectó	O
una	O
fuerte	O
protección	O
en	O
todo	O
el	O
regiones	B-Sequence
monocatenarias	I-Sequence
tanto	O
de	O
arriba	O
como	O
de	O
abajo	O
hebras	B-Sequence
con	O
el	O
aumento	O
de	O
la	O
concentración	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
,	O
consistente	O
con	O
alta	O
afinidad	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
a	O
T	B-Chemical
#	O
¿NOMBRE	O
?	O
secuencias	B-Sequence
(	O
Figura	O
1A	O
)	O
.	O

Se	O
detectó	O
una	O
protección	O
similar	O
,	O
pero	O
menos	O
significativa	O
,	O
en	O
el	O
segmento	B-Sequence
de	I-Sequence
ADN	I-Sequence
monocatenario	I-Sequence
con	O
nucleasas	O
P1	O
(	O
Figura	O
1A	O
)	O
,	O
que	O
es	O
específico	O
de	O
ADN	B-Sequence
monocatenario	I-Sequence
.	O

Los	O
resultados	O
indican	O
que	O
la	O
complejo	B-GENE
mcm	I-GENE
se	O
carga	O
en	O
la	O
burbuja	O
ADN	B-Sequence
a	O
través	O
de	O
la	O
unión	O
a	O
ambos	O
hebras	B-Sequence
de	O
El	O
región	B-Sequence
monocatenaria	I-Sequence
.	O

Examen	O
cuidadoso	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
huellas	O
en	O
una	O
burbuja	O
indicaron	O
una	O
fuerte	O
protección	O
en	O
el	O
5	O
'	O
-	O
la	O
mitad	O
de	O
la	O
parte	O
superior	O
hebra	B-Sequence
y	O
protección	O
moderada	O
en	O
los	O
3	O
'	O
-	O
medios	O
restantes	O
,	O
así	O
como	O
en	O
varios	O
base	B-Sequence
-	I-Sequence
segmento	I-Sequence
dúplex	I-Sequence
par	I-Sequence
adyacente	O
al	O
punto	O
de	O
bifurcación	O
(	O
Figura	O
1A	O
y	O
datos	O
no	O
mostrados	O
)	O
.	O

También	O
se	O
observó	O
un	O
patrón	O
similar	O
de	O
protección	O
en	O
la	O
parte	O
inferior	O
.	O
hebra	B-Sequence
.	O

Esto	O
sugiere	O
que	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
puede	O
unirse	O
a	O
un	O
sustrato	O
de	O
burbuja	O
de	O
replicación	O
con	O
una	O
simetría	O
doble	O
como	O
un	O
hexámero	O
doble	O
(	O
Figura	O
1A	O
,	O
ver	O
el	O
esquema	O
inferior	O
)	O
,	O
de	O
manera	O
similar	O
a	O
SV40	B-Protein
T	I-Protein
-	I-Protein
antígeno	I-Protein
(	O
21	O
)	O
.	O

Los	O
ensayos	O
de	O
protección	O
de	O
nucleasa	O
también	O
se	O
realizaron	O
en	O
una	O
estructura	O
de	O
horquilla	O
en	O
Y	O
con	O
cola	O
en	O
T	O
(	O
Figura	O
1B	O
)	O
.	O

No	O
solo	O
el	O
monocatenario	B-Sequence
cola	O
región	B-Sequence
pero	O
también	O
el	O
7	O
ADN	B-Sequence
dúplex	I-Sequence
pb	I-Sequence
adyacente	O
a	O
la	O
dúplex	B-Sequence
-	O
para	O
-	O
unión	B-Sequence
de	I-Sequence
una	I-Sequence
sola	I-Sequence
hebra	I-Sequence
fueron	O
protegidos	O
por	O
Mcm	B-GENE
vinculante	O
de	O
ADNaseI	B-Protein
digestión	O
.	O

Estos	O
resultados	O
indican	O
que	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
proteína	B-Chemical
interactúa	O
principalmente	O
con	O
región	B-Sequence
de	I-Sequence
ADN	I-Sequence
monocatenario	I-Sequence
y	O
que	O
la	O
interacción	O
también	O
abarca	O
el	O
segmentos	B-Sequence
dúplex	I-Sequence
cerca	O
del	O
punto	O
de	O
bifurcación	O
del	O
horquilla	B-GENE
de	I-GENE
replicación	I-GENE
.	O

Formación	O
de	O
doble	O
hexamérica	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejos	B-GENE
facilita	O
las	O
acciones	O
de	O
helicasa	O
en	O
sustratos	O
de	O
burbujas	O

Los	O
resultados	O
anteriores	O
sugieren	O
que	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
genera	O
un	O
doble	O
hexamérico	O
complejo	B-GENE
en	O
una	O
burbuja	O
,	O
cada	O
hexámero	O
del	O
cual	O
hace	O
contacto	O
simétrico	O
con	O
el	O
centro	O
proximal	O
5	O
'	O
segmento	B-Sequence
monocatenario	I-Sequence
.	O

Esto	O
predice	O
que	O
el	O
segmento	B-Sequence
monocatenario	I-Sequence
debe	O
tener	O
una	O
longitud	O
suficiente	O
para	O
acomodar	O
el	O
complejo	B-GENE
mcm	I-GENE
.	O

De	O
hecho	O
,	O
mostramos	O
anteriormente	O
que	O
el	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
forma	O
principalmente	O
un	O
solo	O
hexamérica	O
complejo	B-GENE
en	O
burbuja	O
-	O
20	O
(	O
un	O
sustrato	O
de	O
burbuja	O
con	O
20	O
Nuevo	B-Sequence
Testamento	I-Sequence
centro	O
largo	O
segmento	B-Sequence
monocatenario	I-Sequence
)	O
y	O
un	O
doble	O
hexamerico	O
complejo	B-GENE
en	O
burbuja	O
-	O
60	O
ADN	B-Sequence
(	O
13	O
)	O
.	O

Con	O
el	O
fin	O
de	O
determinar	O
el	O
requisito	O
mínimo	O
para	O
la	O
formación	O
de	O
doble	O
hexámero	O
,	O
un	O
conjunto	O
de	O
sintético	B-Sequence
sustratos	O
similares	O
a	O
burbujas	O
(	O
Bub	O
-	O
T10	O
,	O
Bub	O
-	O
T20	O
,	O
Bub	O
-	O
T30	O
,	O
Bub	O
-	O
T40	O
y	O
Bub	O
-	O
T50	O
)	O
que	O
diferían	O
en	O
la	O
longitud	O
del	O
centro	O
segmento	B-Sequence
no	I-Sequence
emparejado	I-Sequence
fueron	O
construidos	O
,	O
y	O
las	O
actividades	O
de	O
unión	O
y	O
helicasa	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
sobre	O
estos	O
sustratos	O
fueron	O
examinados	O
.	O

Mcm4	B-Protein
/	O
6	O
/	O
7	O
fue	O
incubado	O
con	O
un	O
radiomarcado	B-Chemical
sintético	B-Sequence
sustrato	O
de	O
burbujas	O
en	O
presencia	O
de	O
0	O
.	O
5	O
mm	O
ATP-gamma-S	B-Chemical
permitir	O
complejo	B-GENE
formación	O

La	O
mitad	O
de	O
estas	O
mezclas	O
de	O
reacción	O
se	O
analizaron	O
para	O
ADN	B-Sequence
unión	O
en	O
ensayos	O
de	O
cambio	O
de	O
gel	O
(	O
Figura	O
2A	O
)	O
,	O
y	O
el	O
resto	O
se	O
incubó	O
adicionalmente	O
en	O
presencia	O
de	O
10	O
mM	O
atp	B-Chemical
para	O
medir	O
ADN	B-Sequence
actividad	O
helicasa	O
(	O
Figura	O
2B	O
)	O
.	O

Bub	O
-	O
10	O
generó	O
solo	O
un	O
bajo	O
nivel	O
de	O
complejos	B-GENE
con	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
,	O
y	O
Bub	O
-	O
20	O
generaron	O
principalmente	O
una	O
única	O
forma	O
de	O
movilidad	O
desplazada	O
,	O
que	O
puede	O
contener	O
un	O
solo	O
hexámero	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
.	O

En	O
Bub-30	O
,	O
una	O
cantidad	O
significativa	O
de	O
complejos	B-GENE
que	O
contenían	O
un	O
doble	O
hexámero	O
además	O
de	O
los	O
que	O
contenían	O
un	O
solo	O
hexámero	O
(	O
Figura	O
2A	O
)	O
(	O
13	O
,	O
21	O
)	O
.	O

Las	O
cantidades	O
de	O
doble	O
hexámero	O
complejos	B-GENE
aumentado	O
en	O
Bub	O
-	O
T40	O
y	O
Bub	O
-	O
T50	O
con	O
disminución	O
concomitante	O
de	O
hexámero	O
único	O
complejos	B-GENE
(	O
Figura	O
2A	O
)	O
.	O

Los	O
resultados	O
indican	O
que	O
un	O
segmento	B-Sequence
monocatenario	I-Sequence
de	O
al	O
menos	O
40	O
Nuevo	B-Sequence
Testamento	I-Sequence
de	O
largo	O
es	O
necesario	O
para	O
la	O
carga	O
eficiente	O
del	O
doble	O
-	O
hexamérica	O
Mcm	B-GENE
helicasa	I-GENE
sobre	O
un	O
sustrato	O
de	O
burbujas	O
.	O

En	O
ADN	B-Sequence
ensayos	O
de	O
helicasa	O
,	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejo	B-GENE
no	O
mostró	O
actividad	O
helicasa	O
ni	O
en	O
el	O
sustrato	O
Bub-10	O
ni	O
en	O
el	O
Bub-20	O
.	O

La	O
eficiencia	O
del	O
desplazamiento	O
mejoró	O
ligeramente	O
a	O
medida	O
que	O
la	O
longitud	O
del	O
segmento	B-Sequence
monocatenario	I-Sequence
aumentó	O
hasta	O
30	O
Nuevo	B-Sequence
Testamento	I-Sequence
.	O

En	O
Bub-T40	O
y	O
Bub-T50	O
,	O
por	O
otro	O
lado	O
,	O
se	O
observó	O
un	O
desplazamiento	O
significativo	O
,	O
lo	O
que	O
indica	O
que	O
un	O
segmento	B-Sequence
monocatenario	I-Sequence
de	O
al	O
menos	O
40	O
Nuevo	B-Sequence
Testamento	I-Sequence
Se	O
requiere	O
mucho	O
tiempo	O
para	O
acciones	O
eficientes	O
de	O
helicasa	O
sobre	O
sustratos	O
de	O
burbujas	O
(	O
Figura	O
2B	O
)	O
.	O

Tomados	O
en	O
conjunto	O
,	O
los	O
resultados	O
anteriores	O
son	O
consistentes	O
con	O
la	O
noción	O
de	O
que	O
el	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejo	B-GENE
,	O
cargado	O
en	O
ADN	B-Sequence
como	O
un	O
doble	O
hexamerico	O
complejo	B-GENE
,	O
desenrolla	O
eficientemente	O
el	O
región	B-Sequence
dúplex	I-Sequence
del	O
sustrato	O
ADN	B-Sequence
.	O

Ambas	O
cosas	O
hebras	B-Sequence
de	O
timina	B-Chemical
#	O
¿NOMBRE	O
?	O
segmentos	B-Sequence
monocatenarios	I-Sequence
son	O
necesarios	O
para	O
el	O
desenrollado	O
eficiente	O
de	O
la	O
burbuja	O
ADN	B-Sequence
por	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O

Unión	O
simétrica	O
de	O
la	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
doble	O
hexámero	O
a	O
burbuja	O
sugiere	O
que	O
cada	O
hexámero	O
cataliza	O
el	O
desenrollado	O
de	O
uno	O
de	O
los	O
dos	O
segmentos	B-Sequence
dúplex	I-Sequence
.	O

Preguntamos	O
si	O
se	O
requiere	O
la	O
activación	O
de	O
ambos	O
hexámeros	O
para	O
desenrollar	O
el	O
sustrato	O
de	O
la	O
burbuja	O
.	O

El	O
sustrato	O
de	O
burbujas	O
preferido	O
que	O
se	O
desenrolla	O
eficientemente	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
contiene	O
timina	B-Chemical
se	B-Sequence
estira	I-Sequence
en	O
ambos	O
hebras	B-Sequence
de	O
El	O
segmento	B-Sequence
monocatenario	I-Sequence
.	O

Construimos	O
una	O
hetero-burbuja	O
(	O
Bub66/	O
T	B-Chemical
-	O
GRAMO	B-Chemical
-	O
rico	O
)	O
en	O
el	O
que	O
uno	O
hebra	B-Sequence
es	O
T	B-Chemical
-	O
rico	O
(	O
igual	O
que	O
Bub66	O
/	O
T	B-Chemical
-	O
rico	O
)	O
y	O
el	O
otro	O
hebra	B-Sequence
es	O
GRAMO	B-Chemical
-	O
rico	O
(	O
igual	O
que	O
Bub66	O
/	O
GRAMO	B-Chemical
rico	O
)	O
(	O
13	O
)	O
,	O
y	O
los	O
ensayos	O
de	O
helicasa	O
se	O
realizaron	O
con	O
una	O
cantidad	O
creciente	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
.	O

Solo	O
se	O
detectó	O
un	O
desenrollado	O
débil	O
en	O
este	O
sustrato	O
en	O
comparación	O
con	O
Bub66	O
/	O
T	B-Chemical
-	O
rico	O
(	O
Figura	O
3A	O
)	O
.	O

Ya	O
que	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
puede	O
unirse	O
a	O
Bub66	O
/	O
T	B-Chemical
-	O
GRAMO	B-Chemical
#	O
¿NOMBRE	O
?	O
complejo	B-GENE
(	O
datos	O
no	O
mostrados	O
)	O
,	O
el	O
desenrollado	O
defectuoso	O
no	O
se	O
debe	O
a	O
una	O
carga	O
ineficaz	O
de	O
la	O
helicasa	O
sobre	O
el	O
sustrato	O
.	O

Si	O
un	O
hexámero	O
interactúa	O
con	O
el	O
timina	B-Chemical
#	O
¿NOMBRE	O
?	O
hebra	B-Sequence
se	O
disocia	O
del	O
otro	O
hexámero	O
y	O
desplaza	O
sólo	O
uno	O
de	O
los	O
segmentos	B-Sequence
dúplex	I-Sequence
,	O
entonces	O
resultaría	O
en	O
la	O
generación	O
de	O
Y	O
-	O
estructuras	B-GENE
de	I-GENE
horquilla	I-GENE
que	O
no	O
pudo	O
ser	O
desplazada	O
más	O
debido	O
a	O
la	O
presencia	O
de	O
GRAMO	B-Chemical
-	O
rico	O
3	O
'	O
-	O
cola	O
y	O
aparecería	O
en	O
el	O
gel	O
.	O

Sin	O
embargo	O
,	O
no	O
detectamos	O
tales	O
intermediarios	O
durante	O
el	O
transcurso	O
del	O
experimento	O
(	O
Figura	O
3B	O
)	O
,	O
lo	O
que	O
sugiere	O
que	O
la	O
burbuja	O
se	O
puede	O
desplazar	O
eficientemente	O
solo	O
cuando	O
dos	O
moléculas	B-Chemical
de	O
El	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
hexámeros	O
se	O
activan	O
simultáneamente	O
.	O

Acciones	O
de	O
unión	O
y	O
helicasa	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
en	O
ahorquillado	B-GENE
y	O
3	O
'	O
-	O
o	O
5	O
'	O
-	O
sustratos	O
de	O
extensión	O

Para	O
examinar	O
con	O
mayor	O
precisión	O
la	O
interacción	O
y	O
las	O
acciones	O
de	O
la	O
helicasa	O
con	O
ahorquillado	B-GENE
sustratos	O
,	O
Y	O
-	O
tenedor	B-GENE
sustratos	O
que	O
contienen	O
un	O
líder	O
naciente	O
hebra	B-Sequence
(	O
A	O
-	O
tenedor	B-GENE
[	O
3	O
'	O
]	O
)	O
,	O
retraso	O
naciente	O
hebra	B-Sequence
(	O
A	O
-	O
tenedor	B-GENE
[	O
5	O
'	O
]	O
)	O
,	O
o	O
ambos	O
(	O
A	O
-	O
tenedor	B-GENE
[	O
3	O
'	O
,	O
5	O
'	O
]	O
)	O
,	O
así	O
como	O
estructuras	O
de	O
5	O
'	O
o	O
3	O
'	O
de	O
extensión	O
.	O

Mcm4	B-Protein
/	O
6	O
/	O
7	O
ligado	O
a	O
A	O
-	O
tenedor	B-GENE
[	O
3	O
'	O
]	O
o	O
A-	O
tenedor	B-GENE
[	O
5	O
'	O
]	O
con	O
afinidad	O
similar	O
a	O
la	O
de	O
una	O
simple	O
Y	O
-	O
tenedor	B-GENE
(	O
Figura	O
4A	O
y	O
datos	O
no	O
mostrados	O
)	O
.	O

A	O
diferencia	O
de	O
,	O
PriA	B-Protein
helicasa	I-Protein
,	O
usado	O
como	O
control	O
,	O
ligado	O
a	O
A	O
-	O
tenedor	B-GENE
[	O
3	O
'	O
]	O
más	O
eficientemente	O
que	O
a	O
A	O
-	O
tenedor	B-GENE
[	O
5	O
'	O
]	O
,	O
como	O
se	O
informó	O
anteriormente	O
(	O
23	O
,	O
25	O
)	O
.	O

Mcm4	B-Protein
6	O
/	O
7	O
unido	O
también	O
a	O
5	O
'	O
-	O
extensión	O
y	O
3	O
'	O
-	O
extensión	O
,	O
aunque	O
con	O
una	O
afinidad	O
ligeramente	O
reducida	O
en	O
comparación	O
con	O
A	O
-	O
tenedor	B-GENE
[	O
3	O
'	O
]	O
y	O
A-	O
tenedor	B-GENE
[	O
5	O
'	O
]	O
(	O
Figura	O
4A	O
)	O
.	O

Mcm4	B-Protein
/	O
6	O
/	O
7	O
ligado	O
a	O
A	O
-	O
tenedor	B-GENE
[	O
3	O
'	O
,	O
5	O
'	O
]	O
con	O
mucha	O
menor	O
afinidad	O
,	O
y	O
el	O
complejo	B-GENE
dio	O
origen	O
a	O
una	O
sola	O
banda	O
.	O

Estos	O
hallazgos	O
indican	O
que	O
la	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejo	B-GENE
se	O
carga	O
en	O
ADN	B-Sequence
preferencial	O
y	O
eficientemente	O
a	O
través	O
de	O
región	B-Sequence
monocatenaria	I-Sequence
,	O
independientemente	O
de	O
la	O
presencia	O
de	O
terminales	O
de	O
3	O
'	O
o	O
5	O
'	O
.	O

Por	O
el	O
contrario	O
,	O
sólo	O
el	O
sustrato	O
que	O
contiene	O
un	O
3	O
'	O
ADN	B-Sequence
monocatenario	I-Sequence
cola	O
(	O
A-	O
tenedor	B-GENE
[	O
5	O
'	O
]	O
)	O
fue	O
desenrollado	O
eficientemente	O
y	O
A	O
-	O
tenedor	B-GENE
[	O
3	O
'	O
]	O
o	O
A-	O
tenedor	B-GENE
[	O
3	O
'	O
,	O
5	O
'	O
]	O
,	O
no	O
fue	O
desenrollado	O
por	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
(	O
Figura	O
4B	O
)	O
.	O

Ausencia	O
de	O
acciones	O
de	O
helicasa	O
en	O
A	O
-	O
tenedor	B-GENE
[	O
3	O
'	O
,	O
5	O
'	O
]	O
compuesto	O
únicamente	O
por	O
regiones	B-Sequence
dúplex	I-Sequence
se	O
espera	O
desde	O
ADN	B-Sequence
de	I-Sequence
doble	I-Sequence
cadena	I-Sequence
no	O
es	O
capaz	O
de	O
activar	O
la	O
actividad	O
ATPasa	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
(	O
10	O
)	O
.	O

En	O
contraste	O
,	O
el	O
PriA	B-Protein
,	O
una	O
helicasa	O
de	O
estructura	O
específica	O
utilizada	O
como	O
control	O
,	O
se	O
une	O
en	O
el	O
tenedor	B-GENE
unión	B-Sequence
y	O
desenrolla	O
el	O
tenedor	B-GENE
el	O
rezago	O
naciente	O
cadena	B-Sequence
de	I-Sequence
ADN	I-Sequence
en	O
un	O
-	O
tenedor	B-GENE
[	O
5	O
'	O
]	O
,	O
o	O
desenrolla	O
el	O
retraso	O
naciente	O
hebra	B-Sequence
en	O
un	O
-	O
tenedor	B-GENE
[	O
3	O
'	O
,	O
5	O
'	O
]	O
,	O
como	O
se	O
informó	O
antes	O
(	O
25	O
)	O
.	O

Estos	O
resultados	O
indican	O
que	O
la	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejo	B-GENE
se	O
une	O
a	O
ADN	B-Sequence
monocatenario	I-Sequence
y	O
que	O
su	O
helicasa	O
se	O
activa	O
sólo	O
en	O
presencia	O
de	O
un	O
monocatenario	B-Sequence
3	O
'	O
-	O
cola	O
.	O

3	O
'	O
-	O
extensión	O
con	O
poli	O
(	O
dT	O
)	O
la	O
cola	O
se	O
desplaza	O
por	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O

Se	O
ha	O
informado	O
que	O
la	O
extensión	O
de	O
3	O
'-	O
puede	O
ser	O
desenrollada	O
por	O
el	O
archaeal	B-Taxon
Mcm	B-GENE
homohexámero	O
pero	O
no	O
por	O
fisión	B-Taxon
y	I-Taxon
levadura	I-Taxon
en	I-Taxon
ciernes	I-Taxon
complejos	B-GENE
mcm	I-GENE
(	O
14	O
,	O
26	O
,	O
27	O
)	O
.	O

Hemos	O
construido	O
sustratos	O
de	O
extensión	O
de	O
3	O
'	O
que	O
contienen	O
colas	O
de	O
poli	O
(	O
dT	O
)	O
,	O
poli	O
(	O
dA	O
)	O
,	O
poli	O
(	O
dC	O
)	O
y	O
poli	O
(	O
dG	O
)	O
3	O
'	O
para	O
examinar	O
si	O
ratón	B-Protein
mcm4	I-Protein
/	O
6	O
/	O
7	O
puede	O
desplazar	O
estos	O
sustratos	O
.	O

Primero	O
encontramos	O
que	O
Mcm4	B-Protein
/6/7	O
se	O
une	O
a	O
la	O
extensión	O
dT-	O
,	O
dC-	O
y	O
dG-3	O
'	O
con	O
una	O
afinidad	O
similar	O
,	O
ya	O
la	O
extensión	O
dA-3	O
'	O
con	O
una	O
afinidad	O
mucho	O
menor	O
(	O
Figura	O
5A	O
)	O
.	O

Esto	O
es	O
consistente	O
con	O
los	O
resultados	O
anteriores	O
que	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
se	O
une	O
a	O
50mer	O
oligo	B-Sequence
-	O
dT	O
,	O
-	O
dC	O
y	O
-	O
dG	O
,	O
pero	O
no	O
a	O
50mer	O
oligo	B-Sequence
-dA	O
(	O
13	O
)	O
.	O

Encontramos	O
que	O
la	O
extensión	O
3	O
'de	O
cola	O
dT	O
fue	O
desplazada	O
eficientemente	O
por	O
Mcm	B-Protein
4	I-Protein
/	I-Protein
6	I-Protein
/	I-Protein
7	I-Protein
mientras	O
que	O
casi	O
ninguna	O
o	O
muy	O
poca	O
actividad	O
se	O
detectó	O
en	O
otros	O
sustratos	O
(	O
Figura	O
5B	O
y	O
C	O
)	O
.	O

Esto	O
contrasta	O
fuertemente	O
con	O
levadura	B-Taxon
Mcm4	B-Protein
/	O
6	O
/	O
7	O
helicasas	O
que	O
no	O
son	O
capaces	O
de	O
desenrollar	O
sustratos	O
de	O
3	O
'	O
de	O
extensión	O
.	O

Además	O
,	O
la	O
extensión	O
5	O
'	O
con	O
cola	O
dT	O
,	O
a	O
la	O
que	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
pudo	O
enlazar	O
,	O
no	O
fue	O
desplazado	O
por	O
el	O
Mcm	B-GENE
helicasa	I-GENE
.	O

La	O
adición	O
de	O
la	O
cola	O
de	O
5	O
'	O
a	O
la	O
extensión	O
de	O
3	O
'	O
de	O
la	O
cola	O
dT	O
estimuló	O
aún	O
más	O
el	O
desplazamiento	O
(	O
Figura	O
5D	O
)	O
,	O
lo	O
que	O
confirma	O
el	O
informe	O
anterior	O
de	O
que	O
la	O
estructuras	B-GENE
de	I-GENE
horquilla	I-GENE
facilitar	O
la	O
acción	O
de	O
la	O
helicasa	O
.	O

Por	O
lo	O
tanto	O
,	O
estos	O
resultados	O
fortalecen	O
aún	O
más	O
nuestra	O
conclusión	O
de	O
que	O
el	O
mamífero	B-Taxon
Mcm	B-GENE
helicasa	I-GENE
generalmente	O
es	O
activado	O
por	O
la	O
timina	B-Chemical
-	O
tramo	B-Sequence
en	O
el	O
3	O
'	O
-	O
monocatenario	B-Sequence
cola	O
.	O

los	O
efectos	O
de	O
la	O
timina	B-Chemical
contenido	O
de	O
los	O
3	O
'	O
-	O
tail	O
on	O
Mcm	B-GENE
helicasa	I-GENE
actividad	O

A	O
continuación	O
examinamos	O
más	O
sistemáticamente	O
el	O
efecto	O
de	O
las	O
composiciones	O
de	O
los	O
residuos	B-Chemical
de	I-Chemical
timina	I-Chemical
de	O
los	O
3	O
'	O
-	O
cola	O
en	O
el	O
Mcm	B-GENE
helicasa	I-GENE
actividad	O
.	O

Un	O
heterodúplex	O
parcial	O
M13	O
ADN	B-Sequence
monocatenario	I-Sequence
que	O
contiene	O
un	O
37	O
región	B-Sequence
dúplex	I-Sequence
pb	I-Sequence
en	O
presencia	O
o	O
ausencia	O
de	O
los	O
50	O
Nuevo	B-Chemical
Testamento	I-Chemical
largo	O
3	O
'	O
-	O
cola	O
de	O
varios	O
nucleótido	B-Chemical
las	O
composiciones	O
fueron	O
construidas	O
y	O
el	O
desenrollado	O
por	O
ratón	B-Protein
mcm4	I-Protein
/	O
6	O
/	O
7	O
fue	O
examinado	O
(	O
Figura	O
6A	O
)	O
.	O

Debido	O
a	O
su	O
baja	O
procesividad	O
,	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
apenas	O
desplazó	O
al	O
37mer	O
recocido	O
oligonucleótido	B-Sequence
sin	O
una	O
cola	O
de	O
3	O
'	O
(	O
37mer	O
;	O
Figura	O
6A	O
)	O
.	O

Sólo	O
se	O
observó	O
actividad	O
helicasa	O
débil	O
en	O
el	O
sustrato	O
que	O
lleva	O
la	O
cola	O
3	O
'	O
de	O
25	O
repite	B-Sequence
de	O
dinucleótido	O
TA	O
(	O
37-TA25	O
;	O
Figura	O
6A	O
)	O
,	O
mientras	O
que	O
se	O
observó	O
una	O
fuerte	O
actividad	O
de	O
helicasa	O
en	O
37-TTA17	O
.	O

Aumento	O
de	O
timina	B-Chemical
contenido	O
en	O
la	O
cola	O
de	O
3	O
'	O
no	O
aumentó	O
más	O
el	O
grado	O
de	O
desenrollado	O
(	O
37	O
-	O
TTTA13	O
,	O
37	O
-	O
TTTTA10	O
y	O
37	O
-	O
T50	O
;	O
Figura	O
6A	O
)	O
,	O
lo	O
que	O
sugiere	O
que	O
17	O
repite	B-Sequence
de	O
dinucleótidos	O
TT	O
(	O
67	O
%	O
timina	B-Chemical
)	O
puede	O
ser	O
suficiente	O
para	O
la	O
activación	O
de	O
Mcm	B-GENE
helicasa	I-GENE
.	O

Cabe	O
señalar	O
que	O
la	O
cola	O
TA25	O
se	O
autorrecocería	O
y	O
esto	O
evitaría	O
la	O
carga	O
de	O
Mcm	B-GENE
,	O
dado	O
que	O
la	O
cola	O
de	O
3	O
'	O
que	O
contenía	O
TTAA13	O
o	O
TTTAAA8	O
tampoco	O
mejoraba	O
el	O
desenrollado	O
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
a	O
continuación	O
examinamos	O
los	O
efectos	O
de	O
secuencias	B-Sequence
repetitivas	I-Sequence
de	O
timina	B-Chemical
y	O
citosina	B-Chemical
(	O
Figura	O
6B	O
)	O
.	O

Los	O
sustratos	O
heterodúplex	O
parciales	O
que	O
contenían	O
la	O
cola	O
3	O
'	O
de	O
TC25	O
,	O
TTCC13	O
,	O
TTTCCC8	O
,	O
TTTTCCCC6	O
,	O
TTCC17	O
fueron	O
desplazados	O
por	O
el	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejo	B-GENE
en	O
una	O
medida	O
similar	O
a	O
la	O
lograda	O
por	O
TTA17	O
,	O
lo	O
que	O
sugiere	O
que	O
el	O
50	O
%	O
timina	B-Chemical
el	O
contenido	O
es	O
suficiente	O
para	O
la	O
activación	O
completa	O
de	O
Mcm	B-GENE
helicasa	I-GENE
.	O

TTCC13	O
y	O
TTCC17	O
se	O
desplazaron	O
en	O
una	O
medida	O
similar	O
,	O
en	O
consonancia	O
con	O
el	O
resultado	O
anterior	O
de	O
que	O
un	O
40	O
Nuevo	B-Chemical
Testamento	I-Chemical
la	O
cola	O
es	O
suficiente	O
para	O
la	O
activación	O
(	O
13	O
)	O
.	O

Sin	O
embargo	O
,	O
la	O
eficiencia	O
del	O
desplazamiento	O
disminuyó	O
significativamente	O
a	O
medida	O
que	O
timina	B-Chemical
el	O
contenido	O
de	O
la	O
cola	O
3	O
'	O
se	O
redujo	O
al	O
33	O
%	O
,	O
como	O
en	O
TAA17	O
o	O
TCC17	O
(	O
Figura	O
6B	O
y	O
C	O
)	O
.	O

Así	O
,	O
el	O
mínimo	O
timina	B-Chemical
contenido	O
requerido	O
para	O
la	O
activación	O
del	O
Mcm	B-GENE
helicasa	I-GENE
puede	O
estar	O
entre	O
el	O
33	O
y	O
el	O
50	O
%	O
.	O

VENCER	O
secuencias	B-Sequence
desde	O
el	O
c-myc	B-Protein
origen	B-Sequence
activar	O
Mcm	B-GENE
helicasa	I-GENE

Nuestros	O
estudios	O
previos	O
han	O
demostrado	O
que	O
el	O
secuencias	B-Sequence
que	O
contiene	O
periódico	O
(	O
dT	O
)	O
n	O
tratados	B-Sequence
derivado	O
de	O
la	O
lamina	B-Protein
humana	I-Protein
B2	I-Protein
origen	B-Sequence
(	O
48	O
%	O
timina	B-Chemical
contenido	O
)	O
puede	O
servir	O
como	O
un	O
activador	O
eficiente	O
para	O
el	O
Mcm	B-GENE
helicasa	I-GENE
en	O
una	O
burbuja	O
y	O
reemplazo	B-Sequence
de	O
timinas	B-Chemical
con	O
guaninas	B-Chemical
abolió	O
la	O
activación	O
de	O
la	O
helicasa	O
(	O
13	O
,	O
28	O
)	O
.	O

Para	O
examinar	O
otros	O
orígenes	B-Sequence
de	I-Sequence
replicación	I-Sequence
natural	I-Sequence
con	O
diferente	O
timina	B-Chemical
contenidos	O
para	O
la	O
capacidad	O
de	O
activar	O
Mcm	B-GENE
helicasa	I-GENE
sobre	O
un	O
sustrato	O
de	O
burbujas	O
,	O
construimos	O
nuevos	O
sustratos	O
de	O
burbujas	O
,	O
Bub82	O
/	O
c-myc	B-Protein
,	O
que	O
contiene	O
secuencias	B-Sequence
derivados	O
del	O
VENCIMIENTO	O
(	O
ADN	B-Sequence
elemento	O
de	O
desenrollado	O
)	O
región	B-Sequence
de	O
El	O
humano	B-Protein
c-myc	I-Protein
origen	B-Sequence
que	O
es	O
esencial	O
para	O
c-myc	B-Protein
actividad	O
replicadora	O
(	O
29	O
,	O
30	O
)	O
.	O

los	O
segmento	B-Sequence
no	I-Sequence
emparejado	I-Sequence
en	O
Bub82	O
/	O
c-myc	B-Protein
/	O
DUE	O
contiene	O
uno	O
hebra	B-Sequence
de	O
DUE	O
y	O
que	O
en	O
Bub82	O
/	O
c-myc	B-Protein
/	O
DUE	O
-	O
C	O
contiene	O
otro	O
hebra	B-Sequence
.	O

Se	O
cree	O
que	O
este	O
DUE	O
coincide	O
con	O
el	O
inicialmente	O
desenrollado	O
región	B-Sequence
de	O
El	O
c-myc	B-Protein
origen	B-Sequence
(	O
29	O
)	O
,	O
y	O
su	O
supresión	B-Sequence
redujo	O
sustancialmente	O
la	O
actividad	O
del	O
replicador	O
(	O
30	O
)	O
.	O

Mcm4	B-Protein
/	O
6	O
/	O
7	O
Bub82	O
desenrollado	O
/	O
lámina	B-Protein
B2	I-Protein
(	O
timina	B-Chemical
48	O
%	O
)	O
,	O
Bub82	O
/	O
c-myc	B-Protein
/	O
DUE	O
(	O
37	O
%	O
)	O
y	O
Bub82	O
/	O
c-myc	B-Protein
/	O
DUE	O
-	O
C	O
(	O
39	O
%	O
)	O
con	O
eficiencia	O
similar	O
(	O
Figura	O
7A	O
)	O
,	O
indicando	O
que	O
el	O
secuencias	B-Sequence
desde	O
el	O
c-myc	B-Protein
origen	B-Sequence
también	O
pueden	O
servir	O
como	O
activadores	O
eficientes	O
de	O
la	O
Mcm	B-GENE
helicasa	I-GENE
.	O

Este	O
resultado	O
también	O
indica	O
que	O
secuencias	B-Sequence
con	O
37	O
%	O
timina	B-Chemical
el	O
contenido	O
puede	O
activar	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
para	O
desplazar	O
24	O
Nuevo	B-Chemical
Testamento	I-Chemical
dúplex	O
en	O
ambos	O
lados	O
en	O
un	O
sustrato	O
de	O
burbujas	O
,	O
lo	O
que	O
sugiere	O
que	O
no	O
solo	O
timina	B-Chemical
contenido	O
sino	O
también	O
el	O
secuencia	B-Sequence
contexto	O
puede	O
afectar	O
la	O
Mcm	B-GENE
helicasa	I-GENE
activación	O

En	O
los	O
ensayos	O
de	O
cambio	O
de	O
gel	O
,	O
MCM4	B-Protein
/	O
6	O
/	O
7	O
unido	O
a	O
las	O
tres	O
burbujas	O
,	O
aunque	O
la	O
afinidad	O
con	O
Bub82	O
/	O
c-myc	B-Protein
/	O
DEBIDO	O
y	O
a	O
Bub82	O
/	O
c-myc	B-Protein
/	O
DUE	O
-	O
C	O
es	O
ligeramente	O
más	O
bajo	O
que	O
el	O
de	O
Bub	O
-	O
82	O
/	O
lámina	B-Protein
B2	I-Protein
(	O
Figura	O
7B	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
helicasa	O
y	O
ADN	B-Sequence
las	O
actividades	O
vinculantes	O
no	O
se	O
correlacionan	O
necesariamente	O
entre	O
sí	O
.	O

Esto	O
también	O
fue	O
indicado	O
por	O
nuestros	O
resultados	O
previos	O
de	O
que	O
guanina	B-Chemical
y	O
citosina	B-Chemical
se	B-Sequence
estira	I-Sequence
puede	O
unirse	O
a	O
Mcm	B-GENE
pero	O
no	O
puede	O
activar	O
la	O
helicasa	O
(	O
13	O
)	O
.	O

ADN	B-Sequence
relajarse	O
por	O
Mcm4	B-Protein
6	O
/	O
7	O
es	O
inhibido	O
por	O
el	O
GC	O
-	O
rico	O
secuencias	B-Sequence
sobre	O
el	O
segmento	B-Sequence
dúplex	I-Sequence

Nuestros	O
resultados	O
indican	O
que	O
timina	B-Chemical
#	O
¿NOMBRE	O
?	O
ADN	B-Sequence
monocatenario	I-Sequence
se	O
requiere	O
para	O
la	O
carga	O
inicial	O
y	O
la	O
activación	O
del	O
Mcm	B-GENE
helicasa	I-GENE
.	O

Sin	O
embargo	O
,	O
no	O
se	O
sabe	O
si	O
timina	B-Chemical
secuencias	B-Sequence
son	O
necesarios	O
para	O
el	O
desenrollado	O
procesual	O
de	O
ADN	B-Sequence
dúplex	I-Sequence
.	O

Por	O
lo	O
tanto	O
,	O
hemos	O
examinado	O
si	O
la	O
nucleótido	B-Chemical
composición	O
de	O
la	O
región	B-Sequence
dúplex	I-Sequence
afecta	O
su	O
actividad	O
de	O
desenrollado	O
.	O

Para	O
solucionar	O
este	O
problema	O
,	O
construimos	O
una	O
serie	O
de	O
Y	O
-	O
colas	O
en	O
T	O
estructuras	B-GENE
de	I-GENE
horquilla	I-GENE
(	O
T-	O
tenedor	B-GENE
)	O
que	O
contiene	O
varios	O
secuencias	B-Sequence
en	O
el	O
segmento	B-Sequence
dúplex	I-Sequence
.	O

Llevaban	O
contenidos	O
variados	O
de	O
residuos	B-Chemical
de	I-Chemical
citosina	I-Chemical
en	O
el	O
3	O
'	O
-	O
cola	O
hebra	B-Sequence
.	O

En	O
los	O
ensayos	O
de	O
cambio	O
de	O
gel	O
,	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
enlazado	O
a	O
estos	O
Y	O
-	O
tenedor	B-GENE
sustratos	O
con	O
afinidad	O
idéntica	O
(	O
Figura	O
8A	O
)	O
,	O
consistente	O
con	O
la	O
noción	O
de	O
que	O
el	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
se	O
une	O
a	O
monocatenario	B-Sequence
colas	O

Sin	O
embargo	O
,	O
en	O
ADN	B-Sequence
ensayos	O
de	O
helicasa	O
,	O
T	O
-	O
tenedor	B-GENE
/	O
(	O
C	O
:	O
G	O
)	O
49	O
apenas	O
fue	O
desplazado	O
por	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
,	O
pero	O
fue	O
fácilmente	O
desplazado	O
por	O
SV40	B-Protein
T	I-Protein
-	I-Protein
antígeno	I-Protein
ADN	I-Protein
helicasa	I-Protein
(	O
Figura	O
8B	O
)	O
.	O

Cuándo	O
timina	B-Chemical
o	O
adenina	B-Chemical
es	O
insertado	B-Sequence
como	O
cada	O
tercio	O
nucleótido	B-Chemical
(	O
repite	B-Sequence
de	O
CCT	O
o	O
CCA	O
)	O
,	O
el	O
grado	O
de	O
desenrollado	O
aumentó	O
(	O
T-	O
tenedor	B-GENE
(	O
CCT	O
:	O
GGA	O
)	O
16	O
y	O
T-	O
tenedor	B-GENE
/	O
(	O
CCA	O
:	O
GGT	O
)	O
16	O
)	O
.	O

La	O
eficiencia	O
del	O
desenrollado	O
se	O
correlaciona	O
aproximadamente	O
con	O
el	O
contenido	O
de	O
pares	O
GC	O
en	O
el	O
segmento	B-Sequence
dúplex	I-Sequence
[	O
T	O
-	O
tenedor	B-GENE
/	O
(	O
CCAA	O
:	O
GGTT	O
)	O
12	O
,	O
T	O
-	O
tenedor	B-GENE
/	O
(	O
CCTT	O
:	O
GGAA	O
)	O
12	O
,	O
T	O
-	O
tenedor	B-GENE
/	O
(	O
CAAA	O
:	O
GTTT	O
)	O
12	O
y	O
T-	O
tenedor	B-GENE
/	O
(	O
CTTT	O
:	O
GAAA	O
)	O
12	O
;	O
Figura	O
8B	O
]	O
.	O

parece	O
que	O
el	O
segmento	B-Sequence
dúplex	I-Sequence
que	O
contiene	O
<	O
50	O
%	O
de	O
pares	O
GC	O
se	O
desenrolla	O
eficientemente	O
(	O
Figura	O
8C	O
)	O
.	O

Luego	O
examinamos	O
el	O
efecto	O
de	O
GC	O
-	O
rico	O
segmentos	B-Sequence
en	O
un	O
heterodúplex	O
parcial	O
ADN	B-Sequence
en	O
un	O
ADN	B-Sequence
circular	I-Sequence
monocatenario	I-Sequence
.	O

Hemos	O
construido	O
dos	O
conjuntos	O
de	O
heterodúplex	O
parciales	O
de	O
cola	O
5	O
'	O
ADN	B-Sequence
sustratos	O
que	O
contienen	O
regiones	B-Sequence
dúplex	I-Sequence
de	O
longitudes	O
variables	O
;	O
uno	O
en	O
M13mp18	O
vector	B-Sequence
y	O
el	O
otro	O
en	O
M13mp19	O
que	O
contiene	O
un	O
66	O
Nuevo	B-Sequence
Testamento	I-Sequence
largo	O
GRAMO	B-Chemical
#	O
¿NOMBRE	O
?	O
segmento	B-Sequence
aguas	O
abajo	O
de	O
la	O
hibridación	O
oligonucleótido	B-Sequence
.	O

Encontramos	O
que	O
el	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
helicasa	O
puede	O
desplazar	O
ADN	B-Sequence
dúplex	I-Sequence
hasta	O
350	O
Nuevo	B-Sequence
Testamento	I-Sequence
de	O
largo	O
por	O
sí	O
solo	O
en	O
el	O
sustrato	O
anterior	O
(	O
Figura	O
8D	O
,	O
izquierda	O
)	O
,	O
consistente	O
con	O
resultados	O
previos	O
(	O
13	O
)	O
.	O

Por	O
el	O
contrario	O
,	O
el	O
desplazamiento	O
se	O
inhibió	O
sobre	O
la	O
rica	O
en	O
GC	O
segmentos	B-Sequence
en	O
el	O
último	O
sustrato	O
(	O
Figura	O
8D	O
,	O
panel	O
derecho	O
)	O
,	O
aunque	O
el	O
desplazamiento	O
hasta	O
250	O
Nuevo	B-Sequence
Testamento	I-Sequence
de	O
longitud	O
,	O
aunque	O
a	O
un	O
nivel	O
reducido	O
,	O
se	O
observó	O
en	O
una	O
alta	O
concentración	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejo	B-GENE
.	O

Este	O
resultado	O
es	O
consistente	O
con	O
el	O
de	O
Y	O
-	O
tenedor	B-GENE
e	O
indica	O
que	O
GC	O
-	O
rico	O
segmento	B-Sequence
dúplex	I-Sequence
es	O
inhibitorio	O
para	O
relajarse	O
por	O
el	O
Mcm	B-GENE
helicasa	I-GENE
.	O

Estos	O
resultados	O
pueden	O
indicar	O
que	O
la	O
presencia	O
de	O
timina	B-Chemical
-	O
adenina	B-Chemical
parejas	B-Sequence
con	O
cierta	O
frecuencia	O
en	O
el	O
región	B-Sequence
dúplex	I-Sequence
puede	O
facilitar	O
el	O
desenrollado	O
continuo	O
por	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
.	O

Alternativamente	O
,	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
no	O
es	O
lo	O
suficientemente	O
eficiente	O
para	O
desplazar	O
GC	O
termodinámicamente	O
estable	O
-	O
base	B-Sequence
-	I-Sequence
segmento	I-Sequence
emparejado	I-Sequence
.	O

Para	O
distinguir	O
estas	O
dos	O
posibilidades	O
,	O
diseñamos	O
un	O
nuevo	O
T-	O
tenedor	B-GENE
sustrato	O
que	O
contiene	O
residuo	B-Sequence
de	I-Sequence
inosina	I-Sequence
(	I-Sequence
I	I-Sequence
)	I-Sequence
en	O
lugar	O
de	O
residuo	B-Chemical
de	I-Chemical
guanosina	I-Chemical
.	O

La	O
estabilidad	O
térmica	O
de	O
la	O
I	B-Chemical
:	O
C	B-Chemical
Base	B-Sequence
par	I-Sequence
es	O
inferior	O
a	O
la	O
del	O
GRAMO	B-Chemical
:	O
C	B-Chemical
Base	B-Sequence
par	I-Sequence
en	O
ADN	B-Sequence
dúplex	I-Sequence
por	O
la	O
pérdida	O
de	O
uno	O
hidrógeno	B-Chemical
bono	O
y	O
es	O
incluso	O
más	O
bajo	O
que	O
A	B-Chemical
:	O
T	B-Chemical
Base	B-Sequence
par	I-Sequence
(	O
31	O
)	O
.	O

Construimos	O
la	O
cola	O
en	O
T	O
tenedor	B-GENE
sustratos	O
que	O
contienen	O
(	O
GCC	O
:	O
CGG	O
)	O
10	O
,	O
(	O
GCC	O
:	O
CIG	O
)	O
10	O
o	O
(	O
GAA	O
:	O
CTT	O
)	O
10	O
segmento	B-Sequence
de	I-Sequence
ADN	I-Sequence
dúplex	I-Sequence
(	O
Figura	O
8E	O
)	O
.	O

Mcm4	B-Protein
/	O
6	O
/	O
7	O
apenas	O
desplazó	O
al	O
31	O
Nuevo	B-Chemical
Testamento	I-Chemical
dúplex	O
largo	O
de	O
GCC	O
:	O
CGG	O
repite	B-Sequence
,	O
mientras	O
que	O
la	O
T	O
-	O
tenedor	B-GENE
/	O
(	O
GAA	O
:	O
CTT	O
)	O
10	O
se	O
desplazó	O
de	O
manera	O
eficiente	O
,	O
como	O
se	O
describe	O
anteriormente	O
.	O

T-	O
tenedor	B-GENE
/	O
(	O
GCC	O
:	O
CIG	O
)	O
10	O
fue	O
desplazado	O
con	O
una	O
eficiencia	O
mucho	O
mayor	O
que	O
la	O
de	O
T	O
-	O
tenedor	B-GENE
/	O
(	O
GCC	O
:	O
CGG	O
)	O
10	O
,	O
indicando	O
que	O
la	O
termoestabilidad	O
del	O
segmento	B-Sequence
dúplex	I-Sequence
,	O
no	O
la	O
falta	O
de	O
TA	O
Base	B-Sequence
par	I-Sequence
,	O
es	O
responsable	O
de	O
la	O
incapacidad	O
de	O
Mcm4	B-Protein
/6/7	O
para	O
desplazar	O
el	O
dúplex	O
.	O

DISCUSIÓN	O

ADN	B-Sequence
helicasa	O
es	O
un	O
factor	O
central	O
para	O
el	O
funcionamiento	O
de	O
horquillas	B-GENE
de	I-GENE
replicación	I-GENE
.	O

También	O
juega	O
un	O
papel	O
crucial	O
en	O
el	O
paso	O
de	O
iniciación	O
en	O
el	O
orígenes	B-Sequence
de	I-Sequence
replicación	I-Sequence
.	O

Por	O
lo	O
tanto	O
,	O
la	O
elucidación	O
de	O
cómo	O
interactúan	O
las	O
helicasas	O
replicativas	O
con	O
ADN	B-Sequence
sustrato	O
y	O
cómo	O
se	O
activan	O
es	O
crucial	O
para	O
entender	O
el	O
molecular	B-Chemical
base	O
de	O
iniciación	O
de	O
ADN	B-Sequence
replicación	O

Ahora	O
se	O
cree	O
que	O
Mcm	B-GENE
es	O
un	O
componente	O
importante	O
de	O
la	O
eucariota	B-Taxon
helicasa	O
replicativa	O
.	O

En	O
este	O
informe	O
,	O
hemos	O
realizado	O
análisis	O
detallados	O
sobre	O
las	O
acciones	O
de	O
unión	O
y	O
helicasa	O
de	O
ratón	B-Protein
mcm4	I-Protein
/	O
6	O
/	O
7	O
usando	O
varios	O
sustratos	O
incluyendo	O
estructuras	B-GENE
de	I-GENE
horquilla	I-GENE
y	I-GENE
burbuja	I-GENE
.	O

Modos	O
de	O
unión	O
y	O
activación	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
helicasa	O
sobre	O
estructura	O
de	O
burbuja	O

Iniciación	O
de	O
ADN	B-Sequence
la	O
replicación	O
está	O
asociada	O
con	O
la	O
fusión	O
localizada	O
de	O
ADN	B-Sequence
dúplex	I-Sequence
cerca	O
orígenes	B-Sequence
de	I-Sequence
replicación	I-Sequence
.	O

Las	O
helicasas	O
se	O
cargan	O
en	O
horquillas	B-GENE
de	I-GENE
replicación	I-GENE
a	O
través	O
del	O
derretido	O
región	B-Sequence
,	O
inducida	O
por	O
la	O
unión	O
del	O
iniciador	O
,	O
en	O
bacterias	B-Taxon
(	O
32	O
)	O
.	O

Anteriormente	O
informamos	O
que	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
se	O
puede	O
cargar	O
en	O
una	O
estructura	O
similar	O
a	O
una	O
burbuja	O
y	O
puede	O
servir	O
como	O
ADN	B-Sequence
helicasa	O
en	O
el	O
tenedores	B-GENE
(	O
13	O
)	O
.	O

la	O
habilidad	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
para	O
desenrollar	O
el	O
sustrato	O
burbuja	O
pero	O
no	O
el	O
convencional	O
ADN	B-Sequence
dúplex	I-Sequence
(	O
Figuras	O
2	O
y	O
13	O
)	O
indica	O
que	O
Mcm	B-GENE
se	O
puede	O
cargar	O
a	O
través	O
de	O
la	O
segmento	B-Sequence
monocatenario	I-Sequence
de	O
la	O
burbuja	O
.	O

Además	O
,	O
el	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejo	B-GENE
muestra	O
marcada	O
preferencia	O
por	O
timina	B-Chemical
#	O
¿NOMBRE	O
?	O
secuencias	B-Sequence
dentro	O
de	O
segmento	B-Sequence
monocatenario	I-Sequence
para	O
activación	O
de	O
helicasa	O
(	O
13	O
)	O
.	O

Los	O
resultados	O
de	O
este	O
informe	O
indican	O
que	O
la	O
acción	O
helicasa	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
en	O
sintético	B-Sequence
burbujas	O
pueden	O
depender	O
de	O
la	O
presencia	O
de	O
un	O
región	B-Sequence
no	I-Sequence
apareada	I-Sequence
de	O
longitud	O
suficiente	O
(	O
al	O
menos	O
40	O
Nuevo	B-Chemical
Testamento	I-Chemical
)	O
,	O
que	O
puede	O
permitir	O
el	O
montaje	O
de	O
un	O
doble	O
hexamerico	O
complejo	B-GENE
en	O
el	O
sustrato	O
ADN	B-Sequence
,	O
Similar	O
a	O
SV40	B-Protein
T	I-Protein
-	I-Protein
antígeno	I-Protein
proteína	B-Chemical
(	O
Figura	O
2A	O
)	O
(	O
21	O
)	O
.	O

Cuando	O
uno	O
hebra	B-Sequence
de	O
El	O
segmento	B-Sequence
monocatenario	I-Sequence
en	O
T	B-Chemical
#	O
¿NOMBRE	O
?	O
sustituido	B-Sequence
por	O
guanina	B-Chemical
#	O
¿NOMBRE	O
?	O
secuencias	B-Sequence
,	O
la	O
eficacia	O
del	O
desenrollado	O
se	O
redujo	O
significativamente	O
.	O

Nuestros	O
análisis	O
de	O
huellas	O
mostraron	O
que	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
protege	O
fuertemente	O
25	O
nt	B-Sequence
segmento	I-Sequence
de	I-Sequence
ADN	I-Sequence
monocatenario	I-Sequence
adyacente	O
a	O
cada	O
punto	O
de	O
ramificación	O
y	O
proximal	O
a	O
los	O
extremos	O
5	O
'	O
de	O
ambos	O
hebras	B-Sequence
de	O
la	O
burbuja	O
.	O

En	O
cada	O
tenedor	B-GENE
,	O
una	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejo	B-GENE
es	O
probable	O
que	O
rodee	O
el	O
hebra	B-Sequence
de	I-Sequence
ADN	I-Sequence
monocatenario	I-Sequence
y	O
dos	O
hexámeros	O
pueden	O
unirse	O
simétricamente	O
al	O
sustrato	O
de	O
la	O
burbuja	O
,	O
formando	O
una	O
estructura	O
hexámera	O
doble	O
en	O
la	O
burbuja	O
(	O
véase	O
el	O
dibujo	O
esquemático	O
de	O
la	O
Figura	O
1A	O
)	O
.	O

El	O
desenrollado	O
eficiente	O
en	O
ambas	O
direcciones	O
puede	O
requerir	O
la	O
activación	O
simultánea	O
de	O
ambos	O
hexámeros	O
que	O
pueden	O
sentarse	O
en	O
el	O
centro	O
mientras	O
se	O
extruye	O
el	O
desenrollado	O
.	O
ADN	B-Sequence
monocatenario	I-Sequence
a	O
través	O
de	O
los	O
anillos	O
.	O

Esto	O
puede	O
parecerse	O
mucho	O
a	O
los	O
modos	O
propuestos	O
de	O
unión	O
y	O
acciones	O
de	O
helicasa	O
de	O
T	B-Protein
-	I-Protein
antígeno	I-Protein
(	O
21	O
)	O
.	O

Aunque	O
no	O
podemos	O
excluir	O
totalmente	O
la	O
posibilidad	O
de	O
que	O
uno	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
hexámeros	O
en	O
cada	O
uno	O
tenedor	B-GENE
desenrolla	O
el	O
dúplex	O
de	O
forma	O
independiente	O
,	O
estructuras	O
en	O
forma	O
de	O
anillo	O
de	O
ratón	B-Taxon
y	O
arquea	B-Taxon
MCM	B-GENE
,	O
tal	O
como	O
lo	O
revelan	O
electrón	B-Chemical
microscopía	O
,	O
tienen	O
mucha	O
similitud	O
con	O
la	O
estructura	O
resuelta	O
recientemente	O
de	O
la	O
SV40	B-Protein
gran	I-Protein
T	I-Protein
-	I-Protein
antígeno	I-Protein
(	O
4	O
,	O
6	O
)	O
,	O
y	O
están	O
a	O
favor	O
de	O
la	O
estructura	O
hexamérica	O
doble	O
de	O
ratón	B-Taxon
Mcm	B-GENE
en	O
una	O
burbuja	O
ADN	B-Sequence
.	O

Sustrato	O
y	O
secuencia	B-Sequence
requerimiento	O
para	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
activación	O
helicasa	O

ADN	B-Sequence
Los	O
ensayos	O
de	O
unión	O
indican	O
que	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
se	O
une	O
a	O
aquellos	O
sustratos	O
que	O
contienen	O
regiones	B-Sequence
de	I-Sequence
ADN	I-Sequence
monocatenario	I-Sequence
independientemente	O
de	O
la	O
presencia	O
o	O
ausencia	O
de	O
monocatenario	B-Sequence
Extremo	O
3	O
'	O
o	O
5	O
'	O
.	O

desenrollado	O
de	O
la	O
ADN	B-Sequence
dúplex	I-Sequence
depende	O
de	O
translocación	B-Sequence
de	O
ADN	B-Sequence
monocatenario	I-Sequence
de	O
3	O
'	O
a	O
5	O
'	O
de	O
dirección	O
.	O

Esto	O
se	O
muestra	O
más	O
claramente	O
por	O
su	O
acción	O
de	O
helicasa	O
en	O
A	O
-	O
tenedor	B-GENE
[	O
5	O
'	O
]	O
y	O
3	O
'	O
-	O
extensión	O
pero	O
no	O
en	O
A	O
-	O
tenedor	B-GENE
[	O
3	O
'	O
]	O
,	O
A	O
-	O
tenedor	B-GENE
[	O
3	O
'	O
,	O
5	O
'	O
]	O
ni	O
5	O
'	O
-	O
extensión	O
.	O

Sin	O
embargo	O
,	O
no	O
requiere	O
necesariamente	O
3	O
'	O
final	O
de	O
ADN	B-Sequence
monocatenario	I-Sequence
,	O
ya	O
que	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
puede	O
desplazar	O
el	O
recocido	O
oligonucleótido	B-Sequence
en	O
un	O
ADN	B-Sequence
monocatenario	I-Sequence
circular	I-Sequence
.	O

La	O
habilidad	O
del	O
ratón	B-Protein
mcm4	I-Protein
/	O
6	O
/	O
7	O
para	O
relajarse	O
3	O
'	O
-	O
la	O
extensión	O
es	O
compartida	O
por	O
el	O
archaeal	B-Taxon
Mcm	B-GENE
helicasa	I-GENE
pero	O
no	O
por	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
desde	O
S	B-Taxon
.	I-Taxon
bomba	I-Taxon
y	O
S	B-Taxon
.	I-Taxon
cerevisias	I-Taxon
(	O
14	O
,	O
26	O
,	O
27	O
)	O
.	O

los	O
archaeal	B-Taxon
Mcm	B-GENE
puede	O
relajarse	O
A	O
-	O
tenedor	B-GENE
[	O
3	O
'	O
]	O
pero	O
eucariota	B-Taxon
Mcm4	B-Protein
/	O
6	O
/	O
7	O
no	O
puede	O
,	O
ya	O
que	O
el	O
primero	O
se	O
une	O
a	O
ADN	B-Sequence
de	I-Sequence
doble	I-Sequence
cadena	I-Sequence
pero	O
este	O
último	O
no	O
(	O
5	O
,	O
27	O
)	O
.	O

Tiempo	O
levadura	B-Taxon
Mcm	B-GENE
helicasas	I-GENE
lata	O
translocar	B-Sequence
en	O
ADN	B-Sequence
dúplex	I-Sequence
,	O
dicha	O
actividad	O
no	O
se	O
observó	O
con	O
mamífero	B-Taxon
Mcm4	B-Protein
/	O
6	O
/	O
7	O
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Ocurrencia	O
de	O
AT	O
-	O
rico	O
secuencias	B-Sequence
,	O
con	O
distribución	O
asimétrica	O
de	O
adenina	B-Chemical
y	O
timina	B-Chemical
,	O
cerca	O
de	O
orígenes	B-Sequence
de	I-Sequence
replicación	I-Sequence
,	O
nos	O
llevan	O
a	O
proponer	O
que	O
Mcm	B-GENE
puede	O
desempeñar	O
un	O
papel	O
en	O
la	O
selección	O
de	O
la	O
iniciación	O
sitios	B-Sequence
de	O
mamífero	B-Taxon
ADN	B-Sequence
replicación	O
,	O
y	O
nos	O
llevó	O
a	O
examinar	O
la	O
capacidad	O
de	O
secuencias	B-Sequence
desde	O
humano	B-Taxon
orígenes	B-Sequence
de	I-Sequence
replicación	I-Sequence
Activar	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
helicasa	O
.	O

Ambas	O
cosas	O
lamina	B-Protein
-	I-Protein
B2	I-Protein
y	O
c-myc	B-Protein
orígenes	B-Sequence
sirvió	O
como	O
activador	O
eficaz	O
para	O
Mcm	B-GENE
helicasa	I-GENE
in	O
vitro	O

En	O
consonancia	O
con	O
ello	O
,	O
sitio	B-Sequence
#	O
¿NOMBRE	O
?	O
Mcm	B-GENE
en	O
el	O
ADN	B-Sequence
iniciación	O
de	O
la	O
replicación	O
zona	B-Sequence
de	O
El	O
c-myc	B-Protein
se	O
informó	O
recientemente	O
(	O
33	O
)	O
.	O

Hemos	O
examinado	O
en	O
detalle	O
el	O
efecto	O
de	O
secuencia	B-Sequence
contexto	O
de	O
la	O
ADN	B-Sequence
monocatenario	I-Sequence
sobre	O
la	O
actividad	O
helicasa	O
de	O
Mcm	B-GENE
.	O

Los	O
resultados	O
indican	O
que	O
timina	B-Chemical
un	O
contenido	O
del	O
50	O
%	O
es	O
suficiente	O
para	O
la	O
máxima	O
actividad	O
helicasa	O
.	O

La	O
eficiencia	O
del	O
desplazamiento	O
disminuyó	O
a	O
medida	O
que	O
timina	B-Chemical
el	O
contenido	O
de	O
la	O
cola	O
3	O
'	O
cayó	O
al	O
33	O
%	O
(	O
Figura	O
6	O
)	O
.	O

los	O
se	B-Sequence
estira	I-Sequence
de	O
residuos	B-Chemical
de	I-Chemical
timina	I-Chemical
puede	O
no	O
ser	O
necesariamente	O
necesario	O
,	O
ya	O
que	O
repite	B-Sequence
de	O
dinucleótidos	O
TC	O
sirvió	O
como	O
un	O
potente	O
activador	O
para	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
.	O

También	O
notamos	O
que	O
la	O
presencia	O
de	O
un	O
estructura	B-Sequence
secundaria	I-Sequence
dentro	O
de	O
ADN	B-Sequence
monocatenario	I-Sequence
es	O
inhibidor	O
de	O
la	O
acción	O
de	O
la	O
helicasa	O
.	O

Los	O
ensayos	O
de	O
huella	O
de	O
nucleasa	O
indicaron	O
que	O
la	O
unión	O
fue	O
interferida	O
por	O
el	O
estructura	B-Sequence
secundaria	I-Sequence
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Así	O
,	O
hemos	O
concluido	O
que	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
la	O
helicasa	O
se	O
activa	O
de	O
forma	O
más	O
eficaz	O
mediante	O
ADN	B-Sequence
monocatenario	I-Sequence
con	O
timina	B-Chemical
contenido	O
del	O
50	O
%	O
o	O
más	O
,	O
aunque	O
también	O
se	O
observa	O
una	O
estimulación	O
significativa	O
por	O
ADN	B-Sequence
con	O
menos	O
timina	B-Chemical
contenido	O
(	O
Figura	O
7	O
)	O
,	O
lo	O
que	O
sugiere	O
que	O
el	O
secuencia	B-Sequence
especificidad	O
para	O
Mcm	B-GENE
helicasa	I-GENE
activación	O
es	O
bastante	O
relajada	O
y	O
que	O
el	O
grado	O
de	O
activación	O
puede	O
depender	O
de	O
la	O
secuencia	B-Sequence
contexto	O

Esto	O
sería	O
razonable	O
dada	O
la	O
flexibilidad	O
y	O
regulación	O
diferencial	O
de	O
sitio	B-Sequence
selección	O
para	O
el	O
inicio	O
de	O
ADN	B-Sequence
replicación	O
durante	O
el	O
desarrollo	O
o	O
en	O
varios	O
célula	B-Cell
tipos	O
,	O
así	O
como	O
la	O
variabilidad	O
en	O
el	O
potencial	O
de	O
iniciación	O
de	O
cada	O
origen	B-Sequence
de	I-Sequence
replicación	I-Sequence
sobre	O
el	O
genoma	B-Sequence
incluso	O
dentro	O
del	O
solo	O
célula	B-Cell
escribe	O
.	O

Mcm4	B-Protein
/	O
6	O
/	O
7	O
helicasa	O
durante	O
el	O
desenrollado	O
procesivo	O
en	O
el	O
tenedor	B-GENE

El	O
requisito	O
específico	O
de	O
monocatenario	B-Sequence
residuos	B-Chemical
de	I-Chemical
timina	I-Chemical
para	O
activación	O
de	O
Mcm	B-GENE
helicasa	I-GENE
nos	O
impulsó	O
a	O
examinar	O
si	O
también	O
son	O
necesarios	O
para	O
el	O
desenrollado	O
ADN	B-Sequence
dúplex	I-Sequence
.	O

Nuestros	O
resultados	O
indicaron	O
que	O
el	O
aumento	O
de	O
GC	O
par	B-Sequence
en	O
el	O
segmento	B-Sequence
dúplex	I-Sequence
inhibió	O
significativamente	O
la	O
Mcm	B-GENE
helicasa	I-GENE
actividad	O
.	O

ADN	B-Sequence
dúplex	I-Sequence
compuesto	O
solo	O
de	O
GC	O
parejas	B-Sequence
(	O
10	O
repite	B-Sequence
de	O
CGG	O
)	O
en	O
una	O
Y	O
-	O
tenedor	B-GENE
no	O
fue	O
desplazado	O
en	O
absoluto	O
,	O
mientras	O
que	O
la	O
misma	O
plantilla	O
fue	O
fácilmente	O
desplazada	O
por	O
SV40	B-Protein
T	I-Protein
-	I-Protein
antígeno	I-Protein
(	O
Figura	O
8B	O
)	O
.	O

Mcm	B-GENE
helicasa	I-GENE
fue	O
inhibida	O
por	O
la	O
presencia	O
de	O
GC	O
-	O
rico	O
segmento	B-Sequence
dúplex	I-Sequence
también	O
en	O
un	O
circular	B-Sequence
monocatenario	I-Sequence
sustrato	O
heterodúplex	O
parcial	O
.	O

Sin	O
embargo	O
,	O
en	O
este	O
sustrato	O
,	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
pudo	O
desplazar	O
ADN	B-Sequence
pasado	O
el	O
GC	O
-	O
rico	O
región	B-Sequence
,	O
aunque	O
de	O
forma	O
limitada	O
,	O
cuando	O
se	O
añadía	O
a	O
una	O
concentración	O
elevada	O
.	O

En	O
la	O
plantilla	O
heterodúplex	O
parcial	O
,	O
Mcm	B-GENE
se	O
carga	O
en	O
el	O
ADN	B-Sequence
monocatenario	I-Sequence
circular	I-Sequence
de	O
6	O
4	O
kb	O
,	O
mientras	O
se	O
carga	O
en	O
el	O
50	O
Nuevo	B-Chemical
Testamento	I-Chemical
largo	O
3	O
'	O
-	O
cola	O
ADN	B-Sequence
en	O
la	O
Y-	O
tenedor	B-GENE
.	O

Por	O
lo	O
tanto	O
,	O
la	O
diferencia	O
de	O
acciones	O
de	O
helicasa	O
puede	O
reflejar	O
la	O
eficiencia	O
de	O
Mcm	B-GENE
cargando	O
.	O

Alternativamente	O
,	O
la	O
presencia	O
de	O
'	O
aleatorio	B-Sequence
'	O
secuencia	B-Sequence
en	O
el	O
inicialmente	O
desenrollado	O
segmento	B-Sequence
dúplex	I-Sequence
en	O
la	O
plantilla	O
anterior	O
puede	O
comprometer	O
el	O
Mcm	B-GENE
helicasa	I-GENE
en	O
una	O
conformación	O
más	O
activa	O
que	O
puede	O
desplazar	O
el	O
GC	O
-	O
rico	O
segmento	B-Sequence
dúplex	I-Sequence
.	O

En	O
Y-	O
tenedor	B-GENE
sustratos	O
,	O
aumento	O
de	O
AT	O
pares	B-Sequence
de	I-Sequence
bases	I-Sequence
en	O
el	O
dúplex	O
(	O
10	O
repite	B-Sequence
de	O
CTT	O
)	O
restauró	O
el	O
desenrollado	O
.	O

Estos	O
resultados	O
indican	O
que	O
residuos	B-Chemical
de	I-Chemical
timina	I-Chemical
se	O
requieren	O
en	O
el	O
ADN	B-Sequence
dúplex	I-Sequence
para	O
desenrollado	O
continuo	O
,	O
o	O
que	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
simplemente	O
no	O
es	O
lo	O
suficientemente	O
eficiente	O
para	O
desenrollar	O
el	O
GC	O
estable	O
parejas	B-Sequence
.	O

Reemplazo	B-Sequence
del	O
central	O
guanosina	B-Chemical
con	O
inosina	B-Chemical
en	O
el	O
CGG	O
repetición	B-Sequence
de	I-Sequence
ADN	I-Sequence
dúplex	I-Sequence
resultó	O
en	O
el	O
desplazamiento	O
(	O
Figura	O
8E	O
)	O
(	O
31	O
)	O
,	O
lo	O
que	O
sugiere	O
que	O
la	O
presencia	O
continua	O
de	O
AT	O
Base	B-Sequence
par	I-Sequence
puede	O
no	O
ser	O
esencial	O
para	O
el	O
Mcm	B-GENE
helicasa	I-GENE
función	O
y	O
que	O
la	O
termoestabilidad	O
de	O
GC	O
pares	B-Sequence
de	I-Sequence
bases	I-Sequence
Inhibe	O
la	O
acción	O
de	O
la	O
helicasa	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
.	O

Los	O
resultados	O
descritos	O
en	O
este	O
manuscrito	O
revelan	O
características	O
potencialmente	O
importantes	O
de	O
mamífero	B-Taxon
Mcm4	B-Protein
/	O
6	O
/	O
7	O
helicasa	O
,	O
que	O
probablemente	O
sea	O
un	O
componente	O
clave	O
de	O
la	O
eucariota	B-Taxon
helicasa	O
replicativa	O
.	O

Antes	O
del	O
inicio	O
de	O
ADN	B-Sequence
replicación	O
,	O
Mcm	B-GENE
helicasa	I-GENE
puede	O
adoptar	O
un	O
doble	O
hexámero	O
complejo	B-GENE
en	O
el	O
parcialmente	O
derretido	O
región	B-Sequence
de	I-Sequence
origen	I-Sequence
,	O
y	O
puede	O
catalizar	O
el	O
desenrollado	O
concurrente	O
de	O
ADN	B-Sequence
dúplex	I-Sequence
en	O
ambas	O
direcciones	O
,	O
mientras	O
que	O
está	O
asociado	O
de	O
forma	O
estable	O
con	O
el	O
orígenes	B-Sequence
de	I-Sequence
la	I-Sequence
replicación	I-Sequence
del	I-Sequence
ADN	I-Sequence
.	O

Esto	O
es	O
similar	O
a	O
la	O
T	B-Protein
-	I-Protein
antígeno	I-Protein
modelo	O
originalmente	O
propuesto	O
por	O
Smelkova	O
y	O
Borowiec	O
(	O
21	O
)	O
.	O

Proponemos	O
que	O
,	O
solo	O
cuando	O
ambos	O
hexámeros	O
son	O
activados	O
por	O
la	O
interacción	O
timina	B-Chemical
#	O
¿NOMBRE	O
?	O
secuencias	B-Sequence
presente	O
dentro	O
del	O
derretido	O
región	B-Sequence
,	O
los	O
Mcm	B-GENE
helicasa	I-GENE
se	O
moviliza	O
y	O
tiene	O
lugar	O
la	O
iniciación	O
.	O

Una	O
pregunta	O
crucial	O
es	O
cómo	O
estos	O
doble	O
hexamérica	O
complejos	B-GENE
de	I-GENE
helicasa	I-GENE
se	O
generan	O
y	O
se	O
convierten	O
en	O
helicasas	O
activas	O
en	O
el	O
orígenes	B-Sequence
.	O

Este	O
proceso	O
implicaría	O
la	O
fusión	O
de	O
ADN	B-Sequence
dúplex	I-Sequence
,	O
que	O
puede	O
facilitarse	O
mediante	O
la	O
vinculación	O
de	O
PreRC	B-GENE
componentes	O
en	O
el	O
contexto	O
de	O
estructuras	B-GENE
de	I-GENE
cromatina	I-GENE
o	O
por	O
otros	O
factores	O
desencadenantes	O
,	O
incluida	O
una	O
topoisomerasa	O
o	O
una	O
nueva	O
Helicasa	B-Protein
Mcm8	I-Protein
(	O
34	O
-	O
36	O
)	O
.	O

También	O
puede	O
requerir	O
la	O
asociación	O
de	O
tenedor	B-GENE
#	O
¿NOMBRE	O
?	O
proteinas	B-Chemical
tal	O
como	O
cd45	B-Protein
(	O
37	O
,	O
38	O
)	O
así	O
como	O
eventos	O
de	O
fosforilación	O
por	O
Cdk	O
y	O
Cdc7	B-Protein
quinasas	I-Protein
(	O
39	O
,	O
40	O
)	O
.	O

Un	O
hallazgo	O
inesperado	O
de	O
este	O
estudio	O
es	O
la	O
baja	O
actividad	O
helicasa	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
en	O
GC	O
-	O
rico	O
ADN	B-Sequence
dúplex	I-Sequence
.	O

Esto	O
,	O
junto	O
con	O
la	O
baja	O
procesividad	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
helicasa	O
,	O
indica	O
fuertemente	O
que	O
la	O
helicasa	O
replicativa	O
en	O
el	O
horquillas	B-GENE
de	I-GENE
replicación	I-GENE
requeriría	O
más	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejo	B-GENE
.	O

Durante	O
el	O
desenrollado	O
procesual	O
de	O
dúplex	B-Sequence
horquillas	B-GENE
de	I-GENE
replicación	I-GENE
de	I-GENE
ADN	I-GENE
,	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
puede	O
ser	O
estimulado	O
aún	O
más	O
por	O
la	O
interacción	O
con	O
otros	O
proteinas	B-Chemical
,	O
incluyendo	O
el	O
resto	O
Mcm	B-GENE
subunidades	O
,	O
cd45	B-Protein
(	O
37	O
,	O
38	O
)	O
,	O
GINEBRAS	B-GENE
(	O
41	O
,	O
42	O
)	O
,	O
ADN	B-GENE
polimerasa	I-GENE
subunidades	O
(	O
43	O
)	O
,	O
Mcm8	B-Protein
(	O
35	O
,	O
36	O
)	O
,	O
etc	O
.	O
convertirse	O
en	O
una	O
helicasa	O
verdaderamente	O
procesiva	O
y	O
potente	O
capaz	O
de	O
replicar	O
todo	O
el	O
genoma	B-Sequence
.	O

Agradecimientos	O

Agradecemos	O
al	O
Dr.	O
Taku	O
Tanaka	O
por	O
la	O
preparación	O
de	O
algunos	O
de	O
los	O
sustratos	O
.	O
ADN	B-Sequence
utilizado	O
en	O
este	O
estudio	O
y	O
para	O
sugerencias	O
útiles	O
,	O
y	O
también	O
los	O
miembros	O
de	O
nuestro	O
laboratorio	O
para	O
discusiones	O
útiles	O
.	O

Este	O
trabajo	O
fue	O
apoyado	O
en	O
parte	O
por	O
subvenciones	O
para	O
investigación	O
científica	O
del	O
Ministerio	O
de	O
Educación	O
,	O
Cultura	O
,	O
Deportes	O
,	O
Ciencia	O
y	O
Tecnología	O
de	O
Japón	O
(	O
MEXT	O
)	O
otorgadas	O
a	O
Z.	O
Y	O
.	O
y	O
H.	O
m	O

El	O
financiamiento	O
para	O
pagar	O
los	O
cargos	O
de	O
publicación	O
de	O
acceso	O
abierto	O
de	O
este	O
artículo	O
fue	O
proporcionado	O
por	O
MEXT	O
.	O

Declaracion	O
de	O
conflicto	O
de	O
interes	O
.	O

Ninguno	O
declarado	O
.	O

Figuras	O
y	O
Tablas	O

Figura	O
1	O

Análisis	O
de	O
protección	O
de	O
nucleasa	O
de	O
unión	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
proteína	B-Chemical
para	O
sintético	B-Sequence
burbuja	O
y	O
tenedor	B-GENE
sustratos	O

(	O
A	O
)	O
El	O
Bub66	O
/	O
T	B-Chemical
-	O
sustrato	O
rico	O
(	O
4	O
fmol	O
)	O
,	O
la	O
parte	O
superior	O
hebra	B-Sequence
o	O
abajo	O
hebra	B-Sequence
de	O
los	O
cuales	O
fueron	O
32P	B-Chemical
-	O
marcados	O
en	O
el	O
extremo	O
5	O
'	O
,	O
se	O
incubaron	O
con	O
0	O
(	O
carril	O
1	O
)	O
,	O
25	O
ng	O
(	O
carril	O
2	O
)	O
,	O
50	O
ng	O
(	O
carril	O
3	O
)	O
o	O
75	O
ng	O
(	O
carril	O
4	O
)	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
proteína	B-Chemical
.	O

A	O
continuación	O
,	O
las	O
mezclas	O
de	O
reacción	O
se	O
trataron	O
con	O
O	O
.	O
11U	O
de	O
ADNasa	B-Protein
I	I-Protein
o	O
0	O
.	O
3	O
U	O
de	O
nucleasa	O
P1	O
.	O

(	O
B	O
)	O
La	O
T-cola	O
Y-	O
tenedor	B-GENE
/	O
aleatorio	B-Sequence
sustrato	O
(	O
4	O
fmol	O
)	O
se	O
incubó	O
con	O
0	O
(	O
carril	O
1	O
)	O
,	O
15	O
ng	O
(	O
carril	O
2	O
)	O
,	O
30	O
ng	O
(	O
carril	O
3	O
)	O
,	O
60	O
ng	O
(	O
carril	O
4	O
)	O
o	O
120	O
ng	O
(	O
carril	O
5	O
)	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
proteína	B-Chemical
,	O
y	O
luego	O
se	O
trata	O
con	O
0	O
.	O
037	O
U	O
de	O
ADNasa	B-Protein
I	I-Protein
o	O
0	O
.	O
3	O
U	O
de	O
nucleasa	O
P1	O
.	O

Los	O
productos	O
de	O
reacción	O
se	O
separaron	O
en	O
PAGE	O
desnaturalizante	O
.	O

Monocatenario	B-Sequence
y	O
regiones	B-Sequence
dúplex	I-Sequence
de	O
los	O
sustratos	O
utilizados	O
en	O
los	O
ensayos	O
se	O
indican	O
a	O
lo	O
largo	O
del	O
gel	O
.	O

En	O
(	O
A	O
)	O
,	O
arriba	O
y	O
abajo	O
hebras	B-Sequence
se	O
indican	O
con	O
negrita	O
y	O
líneas	O
normales	O
,	O
respectivamente	O
.	O

Regiones	B-Sequence
de	O
protección	O
fuerte	O
y	O
moderada	O
se	O
indican	O
mediante	O
líneas	O
grises	O
normales	O
y	O
gruesas	O
,	O
respectivamente	O
,	O
a	O
lo	O
largo	O
de	O
la	O
estructura	O
del	O
sustrato	O
.	O

El	O
dibujo	O
en	O
la	O
parte	O
inferior	O
de	O
(	O
A	O
)	O
muestra	O
un	O
resumen	O
del	O
patrón	O
de	O
protección	O
(	O
protegido	O
regiones	B-Sequence
indicado	O
por	O
líneas	O
grises	O
en	O
negrita	O
)	O
y	O
modos	O
de	O
unión	O
predichos	O
del	O
doble	O
hexámero	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
(	O
mostrado	O
por	O
óvalos	O
de	O
color	O
gris	O
pálido	O
)	O
en	O
el	O
sustrato	O
de	O
la	O
burbuja	O
.	O

Las	O
marcas	O
de	O
estrella	O
representan	O
los	O
extremos	O
5	O
'	O
radiactivos	O
del	O
recocido	O
oligonucleótidos	B-Sequence
.	O

M	O
,	O
radiomarcado	B-Chemical
10	O
y	O
50	O
pb	B-Sequence
escalera	O
.	O

Figura	O
2	O

Acciones	O
de	O
unión	O
y	O
helicasa	O
de	O
ratón	B-Protein
mcm4	I-Protein
/	O
6	O
/	O
7	O
en	O
sustratos	O
de	O
burbujas	O
que	O
contienen	O
segmentos	B-Sequence
monocatenarios	I-Sequence
de	O
longitudes	O
variadas	O
.	O

Desplazamiento	O
de	O
gel	O
(	O
A	O
)	O
y	O
ADN	B-Sequence
Los	O
ensayos	O
de	O
helicasa	O
(	O
B	O
)	O
se	O
realizaron	O
con	O
ratón	B-Protein
mcm4	I-Protein
/	O
6	O
/	O
7	O
en	O
sintético	B-Sequence
burbuja	O
ADN	B-Sequence
(	O
4	O
fmol	O
)	O
,	O
Bub-T10	O
,	O
Bub-T20	O
,	O
Bub-T30	O
,	O
Bub-T40	O
y	O
Bub-T50	O
(	O
Tabla	O
1	O
)	O
.	O

Los	O
carriles	O
1	O
-	O
4	O
contienen	O
0	O
,	O
25	O
,	O
50	O
y	O
100	O
ng	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
proteína	B-Chemical
,	O
respectivamente	O
.	O

B	O
,	O
sustrato	O
hervido	O
.	O

El	O
dibujo	O
en	O
(	O
A	O
)	O
muestra	O
una	O
representación	O
esquemática	O
de	O
los	O
sustratos	O
utilizados	O
.	O

El	O
asterisco	O
indica	O
32P	B-Chemical
-	O
terminal	O
5	O
'	O
etiquetado	O
.	O

figura	O
3	O

Efecto	O
de	O
la	O
pérdida	O
de	O
timina	B-Chemical
#	O
¿NOMBRE	O
?	O
secuencias	B-Sequence
de	O
uno	O
único	B-Sequence
-	O
hebra	B-Sequence
de	O
El	O
T	B-Chemical
#	O
¿NOMBRE	O
?	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
.	O

(	O
A	O
)	O
El	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
actividad	O
de	O
helicasa	O
se	O
midió	O
usando	O
burbuja	O
ADN	B-Sequence
sustrato	O
(	O
4	O
fmol	O
)	O
que	O
contiene	O
un	O
segmento	B-Sequence
no	I-Sequence
emparejado	I-Sequence
de	O
dos	O
timina	B-Chemical
#	O
¿NOMBRE	O
?	O
secuencias	B-Sequence
(	O
Bub66	O
/	O
T	B-Chemical
-	O
rico	O
)	O
o	O
que	O
contiene	O
timina	B-Chemical
#	O
¿NOMBRE	O
?	O
guanina	B-Chemical
#	O
¿NOMBRE	O
?	O
secuencia	B-Sequence
en	O
cada	O
hebra	B-Sequence
(	O
Bub66	O
/	O
T	O
-	O
G	O
-	O
rico	O
)	O
.	O

Los	O
dibujos	O
debajo	O
de	O
los	O
paneles	O
muestran	O
representaciones	O
esquemáticas	O
de	O
los	O
sustratos	O
utilizados	O
en	O
este	O
ensayo	O
.	O

B	O
,	O
sustrato	O
hervido	O
;	O
carril	O
1	O
,	O
no	O
proteína	B-Chemical
;	O
los	O
carriles	O
2	O
-	O
4	O
contienen	O
25	O
,	O
50	O
y	O
100	O
ng	O
del	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejo	B-GENE
,	O
respectivamente	O
.	O

(	O
B	O
)	O
Los	O
ensayos	O
de	O
helicasa	O
se	O
realizaron	O
con	O
Mcm4	B-Protein
6	O
/	O
7	O
(	O
50	O
ng	O
)	O
sobre	O
los	O
sustratos	O
de	O
burbujas	O
indicados	O
durante	O
varios	O
tiempos	O
.	O

La	O
cuantificación	O
de	O
los	O
sustratos	O
desplazados	O
se	O
presenta	O
en	O
los	O
gráficos	O
.	O

Figura	O
4	O

ADN	B-Sequence
acciones	O
de	O
unión	O
y	O
helicasa	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
en	O
varios	O
tenedor	B-GENE
sustratos	O

(	O
A	O
)	O
Los	O
ensayos	O
de	O
cambio	O
de	O
gel	O
se	O
realizaron	O
con	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
en	O
específico	O
tenedor	B-GENE
y	O
sustratos	O
de	O
extensión	O
(	O
3	O
fmol	O
)	O
como	O
se	O
indica	O
.	O

(	O
B	O
)	O
ADN	B-Sequence
Los	O
ensayos	O
de	O
helicasa	O
se	O
realizaron	O
en	O
varios	O
sustratos	O
(	O
3	O
fmol	O
)	O
usados	O
en	O
(	O
A	O
)	O
.	O

las	O
cantidades	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
agregados	O
fueron	O
0	O
(	O
carril	O
1	O
)	O
,	O
25	O
(	O
carril	O
2	O
)	O
,	O
50	O
(	O
carril	O
3	O
)	O
y	O
100	O
ng	O
(	O
carril	O
4	O
)	O
.	O

carril	O
5	O
,	O
PriA	B-Protein
helicasa	I-Protein
a	O
10	O
nM	O
.	O

B	O
,	O
sustrato	O
hervido	O
.	O

Los	O
dibujos	O
muestran	O
una	O
representación	O
esquemática	O
de	O
los	O
sustratos	O
utilizados	O
en	O
los	O
ensayos	O
.	O

Las	O
flechas	O
a-d	O
indican	O
productos	O
desplazados	O
,	O
y	O
sus	O
estructuras	O
se	O
indican	O
debajo	O
del	O
panel	O
.	O

los	O
posiciones	B-Sequence
de	O
El	O
complejos	B-GENE
que	O
contienen	O
un	O
solo	O
hexámero	O
o	O
doble	O
hexámero	O
están	O
indicados	O
.	O

En	O
los	O
dibujos	O
esquemáticos	O
de	O
los	O
sustratos	O
,	O
el	O
etiquetado	O
oligonucleótidos	B-Sequence
se	O
muestran	O
como	O
líneas	O
en	O
negrita	O
y	O
los	O
asteriscos	O
indican	O
32P	B-Chemical
-	O
etiquetado	O
5	O
'	O
-	O
terminales	O
.	O

Figura	O
5	O

ADN	B-Sequence
acciones	O
de	O
unión	O
y	O
helicasa	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
en	O
sustratos	O
de	O
extensión	O
de	O
5	O
'	O
y	O
3	O
'	O
.	O

ADN	B-Sequence
#	O
¿NOMBRE	O
?	O
Mcm4	B-Protein
6	O
/	O
7	O
se	O
examinaron	O
en	O
varios	O
sustratos	O
de	O
extensión	O
3	O
'	O
(	O
4	O
fmol	O
)	O
como	O
se	O
muestra	O
.	O

(	O
C	O
)	O
Cuantificación	O
de	O
los	O
sustratos	O
desplazados	O
en	O
(	O
B	O
)	O
.	O

(	O
D	O
)	O
ADN	B-Sequence
ensayos	O
de	O
helicasa	O
en	O
5	O
'	O
-	O
extensión	O
,	O
3	O
'	O
-	O
extensión	O
y	O
Y	O
-	O
ahorquillado	B-GENE
sustratos	O

Los	O
carriles	O
1	O
-	O
4	O
son	O
reacciones	O
con	O
0	O
,	O
25	O
,	O
50	O
y	O
100	O
ng	O
del	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejo	B-GENE
,	O
respectivamente	O
.	O

También	O
se	O
muestran	O
dibujos	O
esquemáticos	O
de	O
los	O
sustratos	O
utilizados	O
en	O
los	O
ensayos	O
.	O

Las	O
marcas	O
de	O
estrellas	O
indican	O
32P	B-Chemical
-	O
etiquetado	O
5	O
'	O
-	O
terminales	O
.	O

Figura	O
6	O

los	O
efectos	O
de	O
la	O
nucleótido	B-Chemical
composiciones	O
de	O
la	O
cola	O
3	O
'-	O
en	O
el	O
desplazamiento	O
de	O
sustratos	O
heterodúplex	O
parciales	O
por	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
.	O

(	O
A	O
)	O
ADN	B-Sequence
Los	O
ensayos	O
de	O
helicasa	O
se	O
realizaron	O
con	O
sustratos	O
de	O
helicasa	O
heterodúplex	O
parcial	O
de	O
cola	O
3	O
'	O
(	O
en	O
un	O
ADN	B-Sequence
circular	I-Sequence
monocatenario	I-Sequence
;	O
4	O
fmol	O
)	O
llevando	O
varios	O
secuencias	B-Sequence
de	I-Sequence
nucleótidos	I-Sequence
en	O
la	O
cola	O
de	O
3	O
'	O
como	O
se	O
muestra	O
.	O

Los	O
asteriscos	O
representan	O
la	O
32P	B-Chemical
-	O
rotulados	O
5	O
'	O
extremos	O
del	O
recocido	O
oligonucleótidos	B-Sequence
.	O

(	O
B	O
)	O
ADN	B-Sequence
Los	O
ensayos	O
de	O
helicasa	O
se	O
realizaron	O
con	O
conjuntos	O
similares	O
de	O
sustratos	O
de	O
helicasa	O
heterodúplex	O
parciales	O
que	O
portaban	O
las	O
colas	O
3	O
'	O
como	O
se	O
muestra	O
.	O

(	O
C	O
)	O
Cuantificación	O
de	O
desplazados	O
oligonucleótidos	B-Sequence
en	O
(	O
B	O
)	O
.	O

Los	O
carriles	O
1	O
-	O
4	O
contienen	O
0	O
,	O
25	O
,	O
50	O
y	O
100	O
ng	O
del	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejo	B-GENE
,	O
respectivamente	O
.	O

B	O
,	O
sustrato	O
hervido	O
.	O

Figura	O
7	O

Activación	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
ADN	B-Sequence
helicasa	O
por	O
secuencias	B-Sequence
derivado	O
de	O
la	O
humano	B-Protein
c-myc	I-Protein
origen	B-Sequence
.	O

(	O
A	O
)	O
ADN	B-Sequence
ensayos	O
de	O
helicasa	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
se	O
realizaron	O
usando	O
sustratos	O
de	O
burbujas	O
Bub	O
-	O
82	O
(	O
6	O
fmol	O
)	O
que	O
contenían	O
c-myc	B-Protein
/	O
VENCER	O
,	O
Lamina	B-Protein
B2	I-Protein
y	O
c-myc	B-Protein
/	O
VENCE	O
-	O
C	O
secuencias	B-Sequence
en	O
el	O
segmento	B-Sequence
no	I-Sequence
emparejado	I-Sequence
,	O
los	O
timina	B-Chemical
cuyos	O
contenidos	O
son	O
48	O
,	O
37	O
y	O
39	O
%	O
,	O
respectivamente	O
.	O

La	O
cuantificación	O
de	O
los	O
sustratos	O
desplazados	O
se	O
presenta	O
en	O
el	O
gráfico	O
.	O

(	O
B	O
)	O
ADN	B-Sequence
Unión	O
de	O
Mcm4	B-Protein
/6/7	O
se	O
examinó	O
en	O
ensayos	O
de	O
cambio	O
de	O
gel	O
utilizando	O
el	O
mismo	O
conjunto	O
de	O
sustratos	O
.	O

Los	O
carriles	O
1	O
-	O
4	O
son	O
reacciones	O
con	O
0	O
,	O
25	O
,	O
50	O
y	O
100	O
ng	O
del	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
complejo	B-GENE
,	O
respectivamente	O
.	O

B	O
,	O
sustrato	O
hervido	O
.	O

Figura	O
8	O

Efecto	O
de	O
nucleótido	B-Chemical
composiciones	O
de	O
la	O
segmentos	B-Sequence
dúplex	I-Sequence
sobre	O
la	O
acción	O
de	O
la	O
helicasa	O
de	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
.	O

ADN	B-Sequence
actividades	O
de	O
unión	O
(	O
A	O
)	O
y	O
helicasa	O
(	O
B	O
,	O
D	O
y	O
E	O
)	O
del	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
helicasas	O
fueron	O
examinadas	O
en	O
varios	O
Y	O
-	O
tenedor	B-GENE
ADN	B-Sequence
(	O
3	O
fmol	O
)	O
llevando	O
diferentes	O
nucleótidos	B-Chemical
en	O
el	O
región	B-Sequence
dúplex	I-Sequence
como	O
se	O
muestra	O
(	O
A	O
,	O
B	O
y	O
E	O
)	O
o	O
en	O
circular	B-Sequence
monocatenario	I-Sequence
heterodúplex	O
parcial	O
ADN	B-Sequence
sustratos	O
(	O
5	O
fmol	O
)	O
(	O
D	O
)	O
.	O

(	O
A	O
,	O
B	O
y	O
E	O
)	O
Carril	O
1	O
,	O
no	O
proteína	B-Chemical
agregado	O
;	O
los	O
carriles	O
2	O
-	O
4	O
contienen	O
25	O
,	O
50	O
y	O
100	O
ng	O
del	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
proteína	B-Chemical
,	O
respectivamente	O
;	O
carril	O
5	O
[	O
en	O
(	O
B	O
)	O
]	O
,	O
50	O
ng	O
de	O
SV40	B-Protein
T	I-Protein
-	I-Protein
antígeno	I-Protein
.	O

(	O
C	O
)	O
Cuantificación	O
de	O
los	O
sustratos	O
desplazados	O
en	O
(	O
B	O
)	O
.	O

D	O
)	O
Ensayos	O
de	O
helicasa	O
en	O
dT40	O
-	O
Nmer	O
/	O
M13mp18	O
y	O
dT40	O
-	O
Nmer	O
/	O
M13mp19	O
+	O
G	O
-	O
ricos	O
que	O
llevan	O
la	O
marca	O
regiones	B-Sequence
dúplex	I-Sequence
de	O
longitudes	O
variadas	O
.	O

carril	O
1	O
,	O
no	O
proteína	B-Chemical
agregado	O
;	O
los	O
carriles	O
2	O
-	O
7	O
contienen	O
25	O
,	O
50	O
,	O
75	O
,	O
125	O
,	O
200	O
y	O
300	O
ng	O
del	O
Mcm4	B-Protein
/	O
6	O
/	O
7	O
proteína	B-Chemical
,	O
respectivamente	O
.	O

Carriles	O
8	O
y	O
9	O
,	O
hervidos	O
M13mp18	O
y	O
M13mp19	O
+	O
GRAMO	B-Chemical
-sustratos	O
ricos	O
,	O
respectivamente	O
.	O

Los	O
dibujos	O
muestran	O
representaciones	O
esquemáticas	O
de	O
los	O
sustratos	O
utilizados	O
en	O
los	O
ensayos	O
.	O

El	O
rojo	O
segmento	B-Sequence
en	O
negrita	O
en	O
(	O
D	O
)	O
indica	O
el	O
66	O
Nuevo	B-Chemical
Testamento	I-Chemical
largo	O
GRAMO	B-Chemical
#	O
¿NOMBRE	O
?	O
segmento	B-Sequence
.	O

Los	O
asteriscos	O
representan	O
radioactivo	O
[	O
alfa	O
-	O
32P	B-Chemical
]	O
dGTP	B-Chemical
incorporado	B-Sequence
en	O
el	O
segmento	B-Sequence
dúplex	I-Sequence
o	O
32P	B-Chemical
-	O
rotulados	O
5	O
'	O
extremos	O
del	O
recocido	O
oligonucleótidos	B-Sequence
.	O

M	O
[	O
en	O
(	O
D	O
)	O
]	O
,	O
desnaturalizado	O
50	O
pb	B-Sequence
escalera	O
ADN	B-Sequence
marcador	O
;	O
y	O
I	B-Chemical
[	O
en	O
(	O
E	O
)	O
]	O
,	O
inosina	B-Chemical
.	O

B	O
,	O
sustrato	O
hervido	O
.	O

tabla	O
1	O

Construcciones	O
de	O
sustratos	O
de	O
helicasa	O
utilizados	O
en	O
este	O
estudio	O
.	O

Los	O
números	O
con	O
'	O
#	O
'	O
se	O
refieren	O
a	O
oligonucleótidos	B-Sequence
cuyo	O
secuencias	B-Sequence
se	O
dan	O
en	O
la	O
Tabla	O
2	O
.	O

Tabla	O
2	O

Lista	O
de	O
oligonucleótidos	B-Sequence
utilizado	O
en	O
este	O
estudio	O

Inactivación	O
de	O
la	O
Gen	B-Protein
de	I-Protein
la	I-Protein
enfermedad	I-Protein
de	I-Protein
Huntington	I-Protein
(	O
hd	B-Protein
)	O
afecta	O
la	O
formación	O
de	O
la	O
estría	O
anterior	O
y	O
el	O
patrón	O
temprano	O
de	O
la	O
ratón	B-Taxon
embrión	O

Resumen	O

Antecedentes	O

Huntingtin	B-Protein
,	O
los	O
alta	B-Protein
definición	I-Protein
gene	B-Sequence
codificado	O
proteína	B-Chemical
mutado	B-Sequence
por	O
la	O
expansión	O
de	O
poliglutamina	O
en	O
la	O
enfermedad	O
de	O
Huntington	O
,	O
se	O
requiere	O
en	O
los	O
tejidos	O
extraembrionarios	O
para	O
la	O
gastrulación	O
adecuada	O
,	O
lo	O
que	O
implica	O
sus	O
actividades	O
en	O
la	O
nutrición	O
o	O
el	O
patrón	O
del	O
embrión	O
en	O
desarrollo	O
.	O

Para	O
probar	O
estas	O
posibilidades	O
,	O
hemos	O
utilizado	O
hibridación	O
in	O
situ	O
de	O
montaje	O
completo	O
para	O
examinar	O
el	O
patrón	O
embrionario	O
y	O
la	O
morfogénesis	O
en	O
homocigotos	O
Hdhex4/5	O
cazatin	B-Protein
embriones	O
deficientes	O
.	O

Resultados	O

En	O
ausencia	O
de	O
cazatin	B-Protein
,	O
expresión	O
de	O
lo	O
nutritivo	O
genes	B-Sequence
parece	O
normal	O
pero	O
E7	O
.	O
0	O
-	O
7	O
.	O
5	O
embriones	O
exhiben	O
una	O
combinación	O
única	O
de	O
defectos	O
de	O
patrón	O
.	O

Son	O
notables	O
una	O
racha	O
primitiva	O
acortada	O
,	O
ausencia	O
de	O
un	O
nodo	O
propio	O
y	O
producción	O
disminuida	O
de	O
derivados	O
de	O
la	O
racha	O
anterior	O
.	O

Reducido	O
Wnt3a	B-Protein
,	O
Tbx6	B-Protein
y	O
dll1	B-Protein
expresión	O
significa	O
disminución	O
del	O
mesodermo	O
paraxial	O
y	O
reducción	O
Otx2	B-Protein
la	O
expresión	O
y	O
la	O
falta	O
de	O
pliegues	O
denotan	O
una	O
falla	O
en	O
el	O
desarrollo	O
de	O
la	O
cabeza	O
.	O

Además	O
,	O
genes	B-Sequence
inicialmente	O
ampliamente	O
expresados	O
no	O
están	O
propiamente	O
restringidos	O
a	O
la	O
parte	O
posterior	O
,	O
como	O
lo	O
demuestra	O
la	O
expresión	O
ectópica	O
de	O
Nodal	B-Protein
,	O
Fgf8	B-Protein
y	O
gsc	B-Protein
en	O
el	O
epiblasto	O
y	O
T	B-Protein
(	O
braquiuria	B-Protein
)	O
y	O
Evx1	B-Protein
en	O
derivados	O
del	O
mesodermo	O
proximal	O
.	O

A	O
pesar	O
de	O
la	O
restricción	O
posterior	O
alterada	O
y	O
los	O
déficits	O
de	O
la	O
raya	O
anterior	O
,	O
se	O
establece	O
la	O
polaridad	O
general	O
anterior/posterior	O
.	O

Se	O
forma	O
una	O
única	O
raya	O
primitiva	O
y	O
la	O
expresión	O
del	O
marcador	O
muestra	O
que	O
se	O
especifican	O
el	O
epiblasto	O
anterior	O
y	O
el	O
endodermo	O
visceral	O
anterior	O
(	O
AVE	O
)	O
.	O

Conclusión	O

Huntingtin	B-Protein
es	O
esencial	O
en	O
el	O
patrón	O
temprano	O
del	O
embrión	O
para	O
la	O
formación	O
de	O
la	O
región	O
anterior	O
de	O
la	O
línea	O
primitiva	O
y	O
para	O
la	O
regulación	O
a	O
la	O
baja	O
de	O
un	O
subconjunto	O
de	O
crecimiento	O
dinámico	O
y	O
factor	O
de	O
transcripción	O
genes	B-Sequence
.	O

Estos	O
hallazgos	O
proporcionan	O
puntos	O
de	O
partida	O
fundamentales	O
para	O
identificar	O
la	O
novela	O
celular	B-Cell
y	O
molecular	B-Chemical
actividades	O
de	O
cazatin	B-Protein
en	O
los	O
tejidos	O
extraembrionarios	O
que	O
gobiernan	O
el	O
desarrollo	O
normal	O
de	O
la	O
raya	O
anterior	O
.	O

Este	O
conocimiento	O
puede	O
resultar	O
importante	O
para	O
comprender	O
el	O
mecanismo	O
por	O
el	O
cual	O
la	O
expansión	O
poliglutamina	O
dominante	O
en	O
cazatin	B-Protein
determina	O
la	O
pérdida	O
de	O
neuronas	B-Cell
en	O
la	O
enfermedad	O
de	O
Huntington	O
.	O

Antecedentes	O

La	O
enfermedad	O
de	O
Huntington	O
(	O
EH	O
)	O
es	O
un	O
trastorno	O
neurodegenerativo	O
de	O
herencia	O
dominante	O
causado	O
por	O
CAG	O
repite	B-Sequence
en	O
el	O
alta	B-Protein
definición	I-Protein
lugar	B-Sequence
que	O
extienden	O
una	O
poliglutamina	O
tracto	B-Sequence
en	O
un	O
CALOR	O
ubicuo	O
dominio	B-Sequence
proteína	B-Chemical
llamado	O
cazatin	B-Protein
[	O
1	O
]	O
.	O

los	O
molecular	B-Chemical
mecanismo	O
por	O
el	O
cual	O
el	O
nuevo	O
propiedad	B-Sequence
que	O
se	O
le	O
confiere	O
cazatin	B-Protein
por	O
la	O
expansión	O
de	O
poliglutamina	O
conduce	O
a	O
la	O
pérdida	O
distintiva	O
de	O
estriatal	O
neuronas	B-Cell
en	O
HD	O
no	O
se	O
conoce	O
.	O

Sin	O
embargo	O
,	O
las	O
expansiones	O
de	O
poliglutamina	O
en	O
no	O
relacionados	O
proteinas	B-Chemical
ese	O
objetivo	O
distinto	O
célula	B-Cell
neuronal	I-Cell
poblaciones	O
causan	O
distintos	O
trastornos	O
neurodegenerativos	O
de	O
'poliglutamina	O
'	O
.	O

Esta	O
observación	O
sugiere	O
fuertemente	O
que	O
el	O
estriado	O
célula	B-Cell
especificidad	O
de	O
la	O
expansión	O
de	O
poliglutamina	O
en	O
el	O
contexto	O
de	O
cazatin	B-Protein
debe	O
estar	O
determinado	O
por	O
algún	O
aspecto	O
de	O
cazatin	B-Protein
estructura	O
,	O
ubicación	O
subcelular	O
o	O
actividades	O
[	O
2	O
]	O
.	O

Huntingtin	B-Protein
se	O
postula	O
para	O
funcionar	O
como	O
un	O
HEAT	O
flexible	O
de	O
~	O
350	O
kDa	O
dominio	B-Sequence
andamio	O
que	O
puede	O
facilitar	O
el	O
montaje	O
y	O
posiblemente	O
la	O
ubicación	O
subcelular	O
de	O
grandes	O
complejos	B-GENE
proteicos	I-GENE
[	O
3	O
-	O
7	O
]	O
.	O

Huntingtin	B-Protein
's	O
gran	O
número	O
de	O
diversos	O
citoplasmático	B-GENE
y	O
nuclear	B-GENE
proteína	B-Chemical
socios	O
vinculantes	O
sugieren	O
fuertemente	O
que	O
cazatin	B-Protein
puede	O
participar	O
en	O
una	O
variedad	O
de	O
celular	B-Cell
procesos	O
que	O
van	O
desde	O
el	O
tráfico	O
de	O
factor	O
de	O
crecimiento	O
complejos	B-GENE
para	O
gene	B-Sequence
transcripción	O
(	O
revisada	O
en	O
[	O
5	O
,	O
8	O
,	O
9	O
]	O
.	O

Sin	O
embargo	O
,	O
a	O
pesar	O
de	O
la	O
importancia	O
potencial	O
de	O
cazatin	B-Protein
'	O
función	O
normal	O
para	O
nuestra	O
comprensión	O
de	O
cómo	O
la	O
poliglutamina	O
dominante	O
mutación	B-Sequence
causa	O
patología	O
HD	O
,	O
cazatin	B-Protein
es	O
preciso	O
molecular	B-Chemical
y	O
celular	B-Cell
las	O
actividades	O
no	O
han	O
sido	O
definidas	O
.	O

Por	O
lo	O
tanto	O
,	O
nosotros	O
y	O
otros	O
nos	O
propusimos	O
descubrir	O
cazatin	B-Protein
actividades	O
esenciales	O
mediante	O
el	O
estudio	O
de	O
los	O
efectos	O
de	O
cazatin	B-Protein
deficiencia	O
en	O
el	O
ratón	B-Taxon
.	O

Inactivación	O
de	O
la	O
gen	B-Protein
de	I-Protein
EH	I-Protein
de	I-Protein
ratón	I-Protein
(	O
hd	B-Protein
)	O
ha	O
demostrado	O
que	O
cazatin	B-Protein
no	O
se	O
requiere	O
para	O
célula	B-Cell
viabilidad	O
,	O
como	O
lo	O
demuestra	O
la	O
supervivencia	O
de	O
ratón	B-Taxon
embrionario	O
Células	B-Cell
madre	I-Cell
y	O
neuronas	B-Cell
esa	O
falta	O
cazatin	B-Protein
[	O
10	O
-	O
12	O
]	O
.	O

Sin	O
embargo	O
,	O
cazatin	B-Protein
se	O
necesita	O
a	O
nivel	O
de	O
organismo	B-Taxon
para	O
el	O
correcto	O
mamífero	B-Taxon
desarrollo	O
embrionario	O
[	O
10	O
,	O
13	O
,	O
14	O
]	O
.	O

Falta	O
completa	O
de	O
cazatin	B-Protein
resulta	O
en	O
una	O
detención	O
del	O
desarrollo	O
durante	O
la	O
gastrulación	O
,	O
mientras	O
que	O
la	O
reducción	O
severa	O
de	O
cazatin	B-Protein
los	O
niveles	O
dan	O
como	O
resultado	O
neurogénesis	O
anormal	O
y	O
letalidad	O
perinatal	O
[	O
15	O
]	O
.	O

Análisis	O
de	O
cazatin	B-Protein
embriones	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
deficientes	O
revela	O
que	O
la	O
inactivación	O
homocigota	O
del	O
gen	B-Protein
de	I-Protein
EH	I-Protein
de	I-Protein
ratón	I-Protein
no	O
afecta	O
abiertamente	O
el	O
desarrollo	O
hasta	O
E7	O
.	O
0	O

Por	O
E7	O
.	O
5	O
,	O
mutante	B-Sequence
los	O
embriones	O
exhiben	O
una	O
racha	O
primitiva	O
acortada	O
,	O
tamaño	O
reducido	O
y	O
,	O
por	O
morfología	O
,	O
carecen	O
de	O
un	O
nudo	O
y	O
pliegues	O
de	O
la	O
cabeza	O
.	O

mutantes	B-Sequence
son	O
rápidamente	O
reabsorbidos	O
por	O
E8	O
.	O
0	O
[	O
10	O
]	O
.	O

Es	O
importante	O
destacar	O
que	O
la	O
expresión	O
de	O
cazatin	B-Protein
sólo	O
en	O
tejidos	O
extraembrionarios	O
en	O
quimeras	O
se	O
rescata	O
este	O
fenotipo	O
de	O
gastrulación	O
,	O
sugiriendo	O
que	O
cazatin	B-Protein
se	O
requiere	O
solo	O
en	O
células	B-Cell
del	O
linaje	O
extraembrionario	O
y	O
actúa	O
en	O
un	O
célula	B-Cell
manera	O
no	O
autónoma	O
en	O
esta	O
etapa	O
[	O
16	O
]	O
.	O

Los	O
tejidos	O
extraembrionarios	O
son	O
esenciales	O
para	O
el	O
suministro	O
nutrientes	B-Chemical
y	O
señales	O
que	O
dirigen	O
la	O
formación	O
y	O
el	O
patrón	O
del	O
eje	O
anterior/posterior	O
en	O
el	O
embrión	O
en	O
desarrollo	O
(	O
revisado	O
en	O
[	O
17	O
]	O
)	O
,	O
lo	O
que	O
implica	O
cazatin	B-Protein
en	O
cualquiera	O
de	O
estos	O
procesos	O
o	O
en	O
ambos	O
.	O

De	O
estas	O
posibilidades	O
,	O
el	O
papel	O
nutritivo	O
ha	O
sido	O
investigado	O
más	O
extensamente	O
.	O

Sin	O
embargo	O
,	O
cazatin	B-Protein
embriones	O
deficientes	O
no	O
muestran	O
defectos	O
evidentes	O
del	O
endodermo	O
visceral	O
,	O
con	O
la	O
notable	O
excepción	O
de	O
compromiso	O
planchar	B-Chemical
transporte	O
en	O
etapa	O
posterior	O
mutantes	B-Sequence
,	O
aunque	O
planchar	B-Chemical
la	O
captación	O
no	O
se	O
altera	O
[	O
16	O
]	O
y	O
la	O
endocitosis	O
no	O
se	O
altera	O
en	O
cazatin	B-Protein
embriones	O
deficientes	O
o	O
embrionarios	O
Células	B-Cell
madre	I-Cell
[	O
16	O
,	O
18	O
]	O
.	O

De	O
la	O
misma	O
manera	O
,	O
cazatin	B-Protein
lanzaderas	O
a	O
través	O
de	O
la	O
núcleo	B-GENE
,	O
donde	O
se	O
requiere	O
para	O
la	O
adecuada	O
nuclear	B-GENE
localización	O
de	O
sus	O
socios	O
del	O
factor	O
de	O
transcripción	O
,	O
lo	O
que	O
sugiere	O
que	O
cazatin	B-Protein
puede	O
desempeñar	O
un	O
papel	O
en	O
las	O
cascadas	O
de	O
transcripción	O
en	O
los	O
tejidos	O
extraembrionarios	O
que	O
modelan	O
el	O
embrión	O
[	O
18	O
]	O
.	O

Por	O
lo	O
tanto	O
,	O
hemos	O
examinado	O
esta	O
hipótesis	O
,	O
monitoreando	O
la	O
expresión	O
de	O
genes	B-Sequence
que	O
determinan	O
el	O
patrón	O
embrionario	O
normal	O
y	O
la	O
morfogénesis	O
en	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
cazatin	B-Protein
embriones	O
deficientes	O
.	O

Nuestros	O
resultados	O
apoyan	O
y	O
refinan	O
la	O
hipótesis	O
,	O
indicando	O
que	O
cazatin	B-Protein
se	O
requiere	O
para	O
el	O
patrón	O
adecuado	O
del	O
mesodermo	O
y	O
para	O
la	O
restricción	O
regional	O
normal	O
de	O
la	O
expresión	O
de	O
un	O
subconjunto	O
de	O
factores	O
de	O
crecimiento	O
y	O
transcripción	O
.	O

Resultados	O

Huntingtin	B-Protein
#	O
¿NOMBRE	O
?	O

Dado	O
que	O
los	O
tejidos	O
extraembrionarios	O
suministran	O
nutrientes	B-Chemical
al	O
embrión	O
en	O
desarrollo	O
,	O
probamos	O
la	O
posibilidad	O
de	O
que	O
cazatin	B-Protein
deficiencia	O
puede	O
perturbar	O
esta	O
función	O
mediante	O
la	O
realización	O
de	O
análisis	O
RT-PCR	O
para	O
examinar	O
la	O
expresión	O
de	O
un	O
panel	O
de	O
'nutritivo	O
'	O
genes	B-Sequence
en	O
E7	O
.	O
5	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
cazatin	B-Protein
embriones	O
deficientes	O
.	O

``	O
De	O
acuerdo	O
con	O
un	O
informe	O
anterior	O
[	O
16	O
]	O
,	O
no	O
se	O
encontraron	O
diferencias	O
obvias	O
en	O
la	O
expresión	O
de	O
``	O
''	O
nutritivo	O
``	O
''	O
''	O
genes	B-Sequence
(	O
Hnf4	B-Protein
,	O
Afp	B-Protein
,	O
Tfn	B-Protein
,	O
ApoAI	B-Protein
,	O
Apo	B-Protein
-	I-Protein
AIV	I-Protein
,	O
y	O
ApoB	B-Protein
)	O
o	O
genes	B-Sequence
involucrada	O
en	O
la	O
hematopoyesis	O
o	O
vasculogénesis	O
del	O
saco	O
vitelino	O
(	O
Ttr	B-Protein
,	O
Rbp	B-Protein
,	O
Flt1	B-Protein
,	O
Flk1	B-Protein
,	O
Tal1	B-Protein
,	O
Rbtn2	B-Protein
,	O
GATA1	B-Protein
)	O
(	O
datos	O
no	O
mostrados	O
)	O
,	O
lo	O
que	O
sugiere	O
que	O
cazatin	B-Protein
no	O
es	O
esencial	O
para	O
la	O
correcta	O
expresión	O
de	O
genes	B-Sequence
necesarios	O
para	O
la	O
función	O
nutritiva	O
de	O
los	O
tejidos	O
extraembrionarios	O
.	O

Investigar	O
cazatin	B-Protein
actividades	O
de	O
desarrollo	O
de	O
s	O
,	O
luego	O
analizamos	O
la	O
expresión	O
de	O
genes	B-Sequence
que	O
modelan	O
el	O
embrión	O
temprano	O
o	O
marcan	O
hitos	O
morfogénicos	O
en	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
embriones	O
Hdhex4/5/Hdhex4/5	O
mediante	O
hibridación	O
in	O
situ	O
de	O
montaje	O
completo	O
y	O
sección	O
.	O

Las	O
disecciones	O
confirmaron	O
datos	O
morfológicos	O
previos	O
en	O
E7	O
.	O
0	O
-	O
7	O
.	O
5	O
que	O
todos	O
los	O
homocigotos	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
presentan	O
una	O
morfología	O
anormal	O
,	O
incluida	O
una	O
racha	O
primitiva	O
acortada	O
y	O
una	O
falta	O
de	O
pliegues	O
o	O
nódulos	O
morfológicos	O
de	O
la	O
cabeza	O
[	O
10	O
,	O
13	O
]	O
.	O

Los	O
resultados	O
del	O
análisis	O
de	O
hibridación	O
in	O
situ	O
también	O
confirmaron	O
que	O
las	O
tres	O
capas	O
germinales	O
y	O
el	O
tejido	O
extraembrionario	O
se	O
forman	O
en	O
cazatin	B-Protein
embriones	O
deficientes	O
.	O

Otx2	B-Protein
,	O
normalmente	O
expresado	O
en	O
el	O
neuroectodermo	O
anterior	O
y	O
el	O
endodermo	O
visceral	O
anterior	O
[	O
19	O
]	O
,	O
se	O
expresa	O
en	O
mutante	B-Sequence
embriones	O
en	O
E7	O
.	O
5	O
(	O
Fig	O
.	O
1A	O
,	O
B	O
)	O
aunque	O
el	O
dominio	O
de	O
expresión	O
parece	O
reducido	O
.	O

Similar	O
,	O
Hex1	B-Protein
la	O
expresión	O
es	O
muy	O
normal	O
en	O
mutante	B-Sequence
embriones	O
,	O
con	O
expresión	O
localizada	O
en	O
AVE	O
y	O
neuroectodermo	O
(	O
Fig	O
.	O
1C-F	O
,	O
[	O
20	O
]	O
)	O
,	O
aunque	O
el	O
dominio	O
de	O
expresión	O
también	O
aparece	O
reducido	O
.	O

Estos	O
resultados	O
indican	O
una	O
especificación	O
y	O
un	O
movimiento	O
apropiados	O
de	O
la	O
visceral	O
anterior	O
.	O
células	B-Cell
del	I-Cell
endodermo	I-Cell
(	I-Cell
AVE	I-Cell
)	I-Cell
desde	O
la	O
punta	O
distal	O
y	O
sugieren	O
que	O
el	O
neuroectodermo	O
es	O
inducido	O
en	O
el	O
mutante	B-Sequence
embriones	O

Figura	O
1	O

El	O
desplazamiento	O
del	O
AVE	O
y	O
la	O
inducción	O
del	O
neurectodermo	O
anterior	O
ocurren	O
normalmente	O
en	O
ausencia	O
de	O
cazatin	B-Protein
.	O

Análisis	O
de	O
hibridación	O
in	O
situ	O
de	O
montaje	O
completo	O
de	O
Otx2	B-Protein
(	O
Una	O
banda	O
Hex	B-Protein
(	O
C-F	O
)	O
en	O
E7	O
.	O
5	O
normales	O
(	O
A	O
,	O
C	O
,	O
E	O
)	O
y	O
mutante	B-Sequence
(	O
B	O
,	O
D	O
,	O
F	O
)	O
revela	O
que	O
el	O
neuroectodermo	O
y	O
el	O
endodermo	O
visceral	O
anterior	O
(	O
AVE	O
)	O
se	O
desarrollan	O
normalmente	O
en	O
cazatin	B-Protein
embriones	O
deficientes	O
,	O
aunque	O
el	O
dominio	O
de	O
expresión	O
del	O
neuroectodermo	O
está	O
reducido	O
.	O

Expresión	O
asimétrica	O
de	O
Hex	B-Protein
en	O
mutante	B-Sequence
embriones	O
(	O
F	O
)	O
sugiere	O
que	O
se	O
mantiene	O
el	O
control	O
transcripcional	O
izquierdo-derecho	O
.	O

hnf3	B-Protein
beta	I-Protein
la	O
expresión	O
en	O
el	O
endodermo	O
definitivo	O
se	O
extiende	O
alrededor	O
de	O
la	O
punta	O
distal	O
y	O
se	O
reduce	O
en	O
el	O
AVE	O
(	O
*	O
)	O
tanto	O
en	O
normal	O
(	O
G	O
,	O
I	O
)	O
como	O
en	O
mutante	B-Sequence
embriones	O
(	O
H	O
,	O
J	O
)	O
.	O

En	O
conjunto	O
,	O
estos	O
resultados	O
sugieren	O
una	O
inducción	O
y	O
localización	O
normal	O
del	O
ectodermo	O
y	O
el	O
endodermo	O
en	O
embriones	O
Hdhex4/5/Hdhex4/5	O
.	O

Los	O
embriones	O
se	O
muestran	O
en	O
vistas	O
laterales	O
,	O
con	O
el	O
anterior	O
a	O
la	O
izquierda	O
en	O
todas	O
las	O
imágenes	O
con	O
la	O
excepción	O
de	O
E	O
y	O
F	O
.	O

Los	O
embriones	O
se	O
ven	O
desde	O
el	O
aspecto	O
anterior	O
en	O
E	O
y	O
F	O
.	O

Para	O
examinar	O
la	O
formación	O
definitiva	O
del	O
endodermo	O
,	O
la	O
expresión	O
de	O
hnf3	B-Protein
beta	I-Protein
(	O
ZorroA2	B-Protein
)	O
en	O
mutante	B-Sequence
y	O
tipo	B-Sequence
salvaje	I-Sequence
Se	O
analizaron	O
los	O
embriones	O
.	O

En	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
,	O
hnf3	B-Protein
beta	I-Protein
la	O
expresión	O
se	O
limita	O
al	O
nódulo	O
y	O
al	O
endodermo	O
definitivo	O
anterior	O
(	O
Fig	O
.	O
1G	O
,	O
I	O
[	O
21	O
]	O
)	O
.	O

mutante	B-Sequence
exhibición	O
de	O
embriones	O
hnf3	B-Protein
beta	I-Protein
-	O
endodermo	O
definitivo	O
reactivo	O
sobre	O
la	O
región	O
de	O
la	O
estría	O
anterior	O
desorganizada	O
y	O
avanzando	O
rostralmente	O
alrededor	O
de	O
la	O
punta	O
distal	O
(	O
Fig	O
.	O
1H	O
,	O
J	O
)	O
.	O

Tanto	O
en	O
normalidad	O
como	O
en	O
mutante	B-Sequence
embriones	O
,	O
el	O
AVE	O
exhibe	O
poca	O
hnf3	B-Protein
beta	I-Protein
expresión	O
.	O

Por	O
lo	O
tanto	O
,	O
cazatin	B-Protein
la	O
deficiencia	O
no	O
afecta	O
mucho	O
hnf3	B-Protein
beta	I-Protein
regulación	O
o	O
la	O
reorganización	O
del	O
endodermo	O
visceral	O
.	O

La	O
falta	O
de	O
un	O
nódulo	O
morfológico	O
y	O
la	O
presencia	O
de	O
una	O
raya	O
acortada	O
,	O
junto	O
con	O
un	O
neuroectodermo	O
reducido	O
y	O
la	O
falta	O
de	O
pliegues	O
craneales	O
,	O
sugieren	O
que	O
la	O
formación	O
de	O
la	O
raya	O
anterior	O
puede	O
verse	O
afectada	O
en	O
cazatin	B-Protein
embriones	O
deficientes	O
.	O

Para	O
investigar	O
esta	O
posibilidad	O
,	O
examinamos	O
la	O
formación	O
de	O
mesodermo	O
en	O
mutante	B-Sequence
embriones	O

El	O
mesodermo	O
se	O
especifica	O
en	O
el	O
mutante	B-Sequence
embriones	O
,	O
marcados	O
por	O
la	O
expresión	O
de	O
T	B-Protein
(	O
braquiuria	B-Protein
)	O
y	O
Evx1	B-Protein
(	O
Fig	O
.	O
2A-F	O
)	O
.	O

Sin	O
embargo	O
,	O
una	O
inspección	O
minuciosa	O
de	O
los	O
datos	O
revela	O
patrones	O
anormales	O
dentro	O
de	O
este	O
tejido	O
y	O
sus	O
derivados	O
.	O
T	B-Protein
,	O
normalmente	O
expresado	O
en	O
la	O
racha	O
primitiva	O
,	O
el	O
nodo	O
y	O
el	O
proceso	O
de	O
la	O
cabeza	O
axial	O
/	O
mesodermo	O
notocordal	O
[	O
22	O
]	O
,	O
se	O
detecta	O
en	O
la	O
racha	O
acortada	O
y	O
el	O
mesodermo	O
axial	O
en	O
embriones	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
,	O
que	O
se	O
extiende	O
rostralmente	O
desde	O
una	O
región	O
de	O
débilmente	O
positivo	O
células	B-Cell
(	O
Fig	O
.	O
2A	O
,	O
B	O
)	O
.	O

T	B-Protein
expresión	O
aparece	O
más	O
débil	O
,	O
sin	O
embargo	O
,	O
en	O
la	O
raya	O
anterior	O
,	O
correspondiente	O
a	O
células	B-Cell
que	O
dará	O
lugar	O
al	O
mesodermo	O
axial	O
(	O
Fig	O
.	O
2D	O
)	O
.	O

T	B-Protein
también	O
se	O
expresa	O
ectópicamente	O
en	O
mutante	B-Sequence
mesodermo	O
extraembrionario	O
en	O
la	O
unión	O
embrionaria	O
anterior	O
ya	O
lo	O
largo	O
del	O
corion	O
(	O
Fig	O
.	O
2B	O
,	O
D	O
)	O
.	O

Similar	O
,	O
Evx1	B-Protein
,	O
normalmente	O
expresado	O
en	O
mesodermo	O
de	O
estrías	O
primitivas	O
en	O
E7	O
.	O
5	O
con	O
niveles	O
más	O
altos	O
en	O
proximal	O
células	B-Cell
[	O
23	O
]	O
,	O
se	O
expresa	O
en	O
la	O
estría	O
acortada	O
proximal	O
pero	O
también	O
se	O
expresa	O
de	O
manera	O
aberrante	O
en	O
todo	O
el	O
mesodermo	O
extraembrionario	O
,	O
alantoides	O
y	O
corion	O
(	O
Fig	O
.	O
2E	O
,	O
F	O
)	O
.	O

El	O
mesodermo	O
extraembrionario	O
,	O
derivado	O
de	O
la	O
estría	O
proximal	O
,	O
normalmente	O
no	O
expresa	O
T	B-Protein
o	O
Evx1	B-Protein
en	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
[	O
22	O
]	O
.	O

Por	O
lo	O
tanto	O
,	O
la	O
expresión	O
inapropiada	O
de	O
T	B-Protein
y	O
Evx1	B-Protein
,	O
la	O
racha	O
primitiva	O
acortada	O
y	O
la	O
ausencia	O
de	O
un	O
nódulo	O
morfológico	O
sugieren	O
que	O
la	O
racha	O
primitiva	O
anterior	O
es	O
deficiente	O
en	O
el	O
mutante	B-Sequence
embriones	O

Figura	O
2	O

Huntingtin	B-Protein
Se	O
requiere	O
para	O
la	O
formación	O
de	O
la	O
línea	O
primitiva	O
anterior	O
y	O
el	O
mesodermo	O
paraxial	O
.	O

Hibridaciones	O
in	O
situ	O
de	O
montaje	O
completo	O
y	O
sección	O
de	O
E7	O
.	O
5	O
espectáculos	O
de	O
embriones	O
T	B-Protein
(	O
braquiuria	B-Protein
)	O
(	O
A	O
-	O
D	O
)	O
se	O
expresa	O
en	O
la	O
estría	O
primitiva	O
,	O
nudo	O
,	O
mesodermo	O
axial	O
y	O
Evx1	B-Protein
(	O
E	O
-	O
F	O
)	O
se	O
expresa	O
en	O
la	O
raya	O
primitiva	O
,	O
más	O
fuertemente	O
en	O
la	O
raya	O
proximal	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O

Sin	O
embargo	O
,	O
en	O
mutante	B-Sequence
embriones	O
,	O
ambos	O
T	B-Protein
(	O
B	O
,	O
D	O
)	O
y	O
Evx1	B-Protein
(	O
F	O
)	O
se	O
expresan	O
ectópicamente	O
en	O
la	O
región	O
extraembrionaria	O
.	O

Wnt3A	B-Protein
la	O
expresión	O
se	O
reduce	O
en	O
mutante	B-Sequence
embriones	O
(	O
H	O
)	O
,	O
aunque	O
la	O
localización	O
de	O
su	O
expresión	O
en	O
la	O
raya	O
proximal	O
es	O
la	O
misma	O
que	O
en	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
(	O
G	O
)	O
.	O

Análisis	O
de	O
marcadores	O
de	O
mesodermo	O
paraxial	O
Tbx6	B-Protein
(	O
yo	O
,	O
j	O
)	O
y	O
dll1	B-Protein
K	O
,	O
L	O
)	O
,	O
revela	O
que	O
estos	O
marcadores	O
se	O
reducen	O
en	O
mutante	B-Sequence
embriones	O
(	O
J	O
,	O
L	O
)	O
,	O
lo	O
que	O
sugiere	O
una	O
producción	O
alterada	O
del	O
mesodermo	O
paraxial	O
en	O
ausencia	O
de	O
cazatin	B-Protein
.	O

Los	O
embriones	O
en	O
A-H	O
se	O
muestran	O
en	O
una	O
vista	O
lateral	O
con	O
el	O
anterior	O
orientado	O
hacia	O
la	O
izquierda	O
.	O

Los	O
embriones	O
en	O
I-L	O
se	O
muestran	O
en	O
una	O
vista	O
posterior	O
(	O
I	O
,	O
K	O
)	O
o	O
casi	O
posterior	O
(	O
J	O
,	O
L	O
)	O
con	O
la	O
orientación	O
proximal	O
hacia	O
la	O
parte	O
superior	O
.	O

En	O
(	O
C	O
,	O
D	O
)	O
,	O
al	O
=	O
alantoides	O
,	O
a	O
=	O
amnios	O
,	O
ch	O
=	O
corion	O
,	O
ee	O
=	O
nódulo	O
embrionario	O
(	O
N	O
)	O
,	O
em	O
=	O
mesodermo	O
extraembrionario	O
,	O
n	O
=	O
nódulo	O
,	O
ps	O
=	O
estría	O
primitiva	O
.	O

En	O
lugar	O
de	O
un	O
nodo	O
,	O
mutante	B-Sequence
embriones	O
exhiben	O
una	O
región	O
desorganizada	O
células	B-Cell
(	O
*	O
)	O
en	O
la	O
extensión	O
distal	O
de	O
la	O
raya	O
primitiva	O
corta	O
.	O

La	O
estría	O
anterior	O
genera	O
mesodermo	O
paraxial	O
.	O

Por	O
lo	O
tanto	O
,	O
examinamos	O
la	O
formación	O
de	O
mesodermo	O
paraxial	O
en	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
mutante	B-Sequence
embriones	O
,	O
revelando	O
déficits	O
en	O
el	O
patrón	O
del	O
mesodermo	O
.	O

A	O
partir	O
de	O
E.	O
7	O
.	O
5	O
,	O
Wnt3A	B-Protein
se	O
expresa	O
en	O
la	O
racha	O
primitiva	O
en	O
células	B-Cell
destinado	O
a	O
convertirse	O
en	O
mesodermo	O
paraxial	O
.	O

En	O
cazatin	B-Protein
deficiente	O
mutantes	B-Sequence
,	O
Wnt3a	B-Protein
se	O
induce	O
en	O
la	O
línea	O
proximal	O
(	O
Fig	O
.	O
2G	O
,	O
H	O
)	O
,	O
lo	O
que	O
confirma	O
el	O
desarrollo	O
posterior	O
apropiado	O
para	O
la	O
etapa	O
,	O
en	O
contraste	O
con	O
la	O
ausencia	O
de	O
pliegues	O
anteriores	O
de	O
la	O
cabeza	O
.	O

Sin	O
embargo	O
,	O
expresión	O
de	O
Wnt3a	B-Protein
se	O
reduce	O
notablemente	O
en	O
los	O
embriones	O
Hdhex4/5/Hdhex4/5	O
,	O
lo	O
que	O
sugiere	O
un	O
defecto	O
en	O
el	O
desarrollo	O
del	O
mesodermo	O
paraxial	O
(	O
Fig	O
.	O
2H	O
)	O
.	O

Expresión	O
reducida	O
de	O
Tbx6	B-Protein
en	O
el	O
mesodermo	O
lateral	O
a	O
la	O
racha	O
primitiva	O
en	O
mutante	B-Sequence
embriones	O
confirma	O
esta	O
interpretación	O
(	O
Fig	O
.	O
2I	O
,	O
J	O
)	O
.	O

Además	O
,	O
en	O
mutante	B-Sequence
embriones	O
en	O
E7	O
.	O
5	O
,	O
la	O
expresión	O
de	O
dll1	B-Protein
en	O
la	O
región	O
de	O
la	O
raya	O
distal	O
y	O
en	O
sólo	O
una	O
estrecha	O
franja	O
de	O
células	B-Cell
localizado	O
lateralmente	O
confirma	O
la	O
escasez	O
de	O
mesodermo	O
paraxial	O
(	O
Fig	O
.	O
2K	O
,	O
L	O
,	O
[	O
24	O
]	O
)	O
.	O

Estos	O
resultados	O
sugieren	O
fuertemente	O
que	O
la	O
formación	O
de	O
la	O
estría	O
primitiva	O
anterior	O
está	O
alterada	O
,	O
lo	O
que	O
da	O
como	O
resultado	O
una	O
formación	O
de	O
mesodermo	O
axial	O
y	O
paraxial	O
reducida	O
y	O
un	O
desarrollo	O
neural	O
deteriorado	O
.	O

Alteración	O
de	O
la	O
restricción	O
regional	O
de	O
la	O
expresión	O
del	O
factor	O
de	O
crecimiento	O
en	O
ausencia	O
de	O
cazatin	B-Protein

Para	O
dilucidar	O
los	O
aparentes	O
déficits	O
de	O
patrones	O
,	O
a	O
continuación	O
analizamos	O
la	O
señalización	O
moléculas	B-Chemical
que	O
se	O
requieren	O
para	O
el	O
patrón	O
temprano	O
.	O

Nodal	B-Protein
,	O
miembro	O
de	O
la	O
beta	B-Protein
familia	O
de	O
secretos	O
moléculas	B-Chemical
es	O
necesaria	O
para	O
la	O
formación	O
y	O
mantenimiento	O
de	O
la	O
racha	O
primitiva	O
e	O
inducción	O
del	O
AVE	O
[	O
25-27	O
]	O
.	O

Nodal	B-Protein
normalmente	O
se	O
expresa	O
en	O
todo	O
el	O
epiblasto	O
y	O
el	O
endodermo	O
visceral	O
suprayacente	O
en	O
las	O
primeras	O
etapas	O
posteriores	O
a	O
la	O
implantación	O
[	O
28	O
]	O
,	O
pero	O
luego	O
se	O
restringe	O
a	O
la	O
parte	O
posterior	O
del	O
embrión	O
al	O
sitio	O
de	O
la	O
racha	O
primitiva	O
con	O
expresión	O
asimétrica	O
del	O
endodermo	O
visceral	O
que	O
marca	O
el	O
eje	O
izquierda	O
-	O
derecha	O
.	O

Por	O
E7	O
.	O
5	O
,	O
Nodal	B-Protein
expresión	O
está	O
restringida	O
al	O
nodo	O
.	O

Nodal	B-Protein
expresión	O
se	O
evaluó	O
en	O
embriones	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
heterocigotos	O
para	O
la	O
ndl	B-Protein
lago	O
Z	O
alelo	B-Sequence
[	O
28	O
,	O
29	O
]	O
.	O

En	O
particular	O
,	O
la	O
pérdida	O
heterocigótica	O
de	O
nodal	B-Protein
no	O
altera	O
el	O
fenotipo	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
,	O
determinado	O
por	O
la	O
morfología	O
de	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
:	O
Ndllacz	O
/	O
ndl	B-Protein
embriones	O
en	O
comparación	O
con	O
embriones	O
Hdhex4/5/Hdhex4/5	O
(	O
datos	O
no	O
mostrados	O
)	O
.	O

En	O
contraste	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
,	O
que	O
exhiben	O
una	O
fuerte	O
restricción	O
de	O
Nodal	B-Protein
.	O
Expresión	O
LacZ	O
al	O
nodo	O
,	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
:	O
Ndllacz	O
/	O
ndl	B-Protein
#	O
¿NOMBRE	O
?	O
Nodal	B-Protein
.	O
LacZ	O
en	O
todo	O
el	O
endodermo	O
que	O
recubre	O
el	O
epiblasto	O
,	O
con	O
niveles	O
más	O
altos	O
en	O
la	O
parte	O
posterior	O
en	O
un	O
patrón	O
asimétrico	O
(	O
Fig	O
.	O
3A-D	O
)	O
.	O

La	O
falta	O
de	O
estricta	O
restricción	O
de	O
nodal	B-Protein
la	O
señal	O
es	O
consistente	O
con	O
una	O
falla	O
para	O
formar	O
una	O
estructura	O
de	O
nodo	O
organizada	O
.	O

figura	O
3	O

Deterioro	O
de	O
la	O
restricción	O
regional	O
de	O
gene	B-Sequence
expresión	O
en	O
cazatin	B-Protein
embriones	O
deficientes	O
.	O

Tinción	O
X	O
-	O
gal	O
de	O
Nodal	B-Protein
-	O
Los	O
embriones	O
LacZ	O
muestran	O
tinción	O
en	O
el	O
endodermo	O
cerca	O
del	O
nódulo	O
de	O
los	O
embriones	O
normales	O
(	O
A	O
,	O
C	O
)	O
pero	O
una	O
tinción	O
amplia	O
en	O
mutante	B-Sequence
embriones	O
(	O
B	O
,	O
D	O
)	O
,	O
aunque	O
la	O
expresión	O
es	O
mayor	O
en	O
la	O
parte	O
posterior	O
.	O

La	O
expresión	O
de	O
nodo	O
apretado	O
de	O
Nodal	B-Protein
en	O
embriones	O
normales	O
(	O
C	O
)	O
se	O
pierde	O
en	O
mutante	B-Sequence
embriones	O
(	O
D	O
)	O
,	O
consistente	O
con	O
la	O
pérdida	O
de	O
un	O
nódulo	O
morfológico	O
en	O
ausencia	O
de	O
cazatin	B-Protein
.	O

Montaje	O
completo	O
e	O
hibridación	O
in	O
situ	O
de	O
E7	O
.	O
Embriones	O
de	O
5	O
días	O
revela	O
que	O
Fgf8	B-Protein
se	O
detecta	O
en	O
la	O
racha	O
proximal	O
y	O
se	O
regula	O
a	O
la	O
baja	O
en	O
células	B-Cell
migrando	O
fuera	O
de	O
la	O
línea	O
en	O
embriones	O
normales	O
(	O
E	O
,	O
G	O
)	O
.	O

A	O
diferencia	O
de	O
,	O
Fgf8	B-Protein
queda	O
muy	O
expresada	O
en	O
mutante	B-Sequence
embriones	O
(	O
F	O
,	O
H	O
)	O
.	O

Expresión	O
transitoria	O
de	O
gsc	B-Protein
en	O
el	O
endodermo	O
definitivo	O
que	O
recubre	O
la	O
futura	O
región	O
de	O
la	O
cabeza	O
en	O
embriones	O
normales	O
(	O
I	O
,	O
K	O
)	O
se	O
distingue	O
en	O
otros	O
célula	B-Cell
capas	O
en	O
embriones	O
normales	O
pero	O
permanece	O
sin	O
restricciones	O
en	O
mutante	B-Sequence
embriones	O
(	O
J	O
,	O
L	O
)	O
.	O

Expresión	O
posterior	O
anterior	O
de	O
gsc	B-Protein
también	O
se	O
mantiene	O
en	O
mutante	B-Sequence
embriones	O
(	O
J	O
)	O
mientras	O
que	O
está	O
regulado	O
negativamente	O
en	O
embriones	O
normales	O
(	O
I	O
)	O
.	O

Los	O
embriones	O
(	O
A	O
,	O
B	O
,	O
E	O
,	O
F	O
,	O
G	O
,	O
H	O
,	O
I	O
,	O
K	O
,	O
L	O
)	O
se	O
muestran	O
en	O
una	O
vista	O
lateral	O
con	O
el	O
anterior	O
orientado	O
hacia	O
la	O
izquierda	O
.	O

Los	O
embriones	O
(	O
C	O
,	O
D	O
)	O
están	O
en	O
una	O
vista	O
posterior	O
.	O

Fgf8	B-Protein
la	O
señalización	O
también	O
es	O
esencial	O
para	O
la	O
gastrulación	O
normal	O
en	O
el	O
ratón	B-Taxon
embrión	O

Fgf8	B-Protein
se	O
requiere	O
para	O
célula	B-Cell
migración	O
lejos	O
de	O
la	O
racha	O
primitiva	O
[	O
30	O
]	O
.	O

Expresado	O
justo	O
antes	O
de	O
la	O
formación	O
de	O
estrías	O
en	O
el	O
epiblasto	O
posterior	O
y	O
el	O
endodermo	O
visceral	O
,	O
Fgf8	B-Protein
se	O
restringe	O
al	O
mesodermo	O
de	O
la	O
raya	O
en	O
E7	O
.	O
5	O
en	O
un	O
gradiente	O
proximal	O
-	O
distal	O
decreciente	O
y	O
está	O
regulado	O
a	O
la	O
baja	O
en	O
células	B-Cell
poco	O
después	O
salen	O
de	O
la	O
racha	O
(	O
Fig	O
.	O
3E	O
,	O
G	O
)	O
.	O

En	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
embriones	O
,	O
Fgf8	B-Protein
la	O
expresión	O
se	O
expresa	O
fuertemente	O
en	O
la	O
región	O
posterior	O
en	O
la	O
línea	O
primitiva	O
y	O
ectópicamente	O
en	O
el	O
endodermo	O
que	O
recubre	O
todo	O
el	O
epiblasto	O
(	O
Fig	O
.	O
3F	O
,	O
H	O
)	O
.	O

Sin	O
embargo	O
,	O
los	O
derivados	O
de	O
la	O
raya	O
parecen	O
migrar	O
normalmente	O
,	O
como	O
lo	O
demuestra	O
la	O
expresión	O
anterior	O
adecuada	O
de	O
marcadores	O
como	O
Otx2	B-Protein
,	O
hnf3	B-Protein
beta	I-Protein
y	O
Hex1	B-Protein
anteriormente	O
(	O
Fig	O
.	O
1	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
mutante	B-Sequence
los	O
embriones	O
exhiben	O
una	O
migración	O
normal	O
de	O
los	O
derivados	O
de	O
la	O
raya	O
,	O
pero	O
se	O
muestran	O
alterados	O
Fgf8	B-Protein
represión	O
en	O
mutante	B-Sequence
endodermo	O

Los	O
embriones	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
tampoco	O
logran	O
restringir	O
la	O
expresión	O
de	O
gansoide	B-Protein
(	O
gsc	B-Protein
)	O
.	O

Normalmente	O
,	O
gsc	B-Protein
se	O
expresa	O
inicialmente	O
en	O
el	O
endodermo	O
visceral	O
y	O
la	O
estría	O
posterior	O
proximal	O
donde	O
se	O
formará	O
la	O
estría	O
primitiva	O
antes	O
de	O
la	O
gastrulación	O
.	O

A	O
medida	O
que	O
se	O
forma	O
y	O
se	O
extiende	O
la	O
racha	O
primitiva	O
,	O
gsc	B-Protein
se	O
expresa	O
en	O
la	O
línea	O
distal	O
,	O
el	O
nódulo	O
y	O
el	O
mesodermo	O
axial	O
que	O
se	O
extiende	O
anteriormente	O
desde	O
el	O
nódulo	O
(	O
Fig	O
.	O
3I	O
,	O
K	O
,	O
[	O
31	O
,	O
32	O
]	O
)	O
.	O

Sin	O
embargo	O
,	O
en	O
el	O
mutante	B-Sequence
Hdhex4/5/HDhex4/5	O
embriones	O
,	O
altos	O
niveles	O
de	O
gsc	B-Protein
expresión	O
permanecen	O
sin	O
restricciones	O
en	O
el	O
endodermo	O
que	O
recubre	O
todo	O
el	O
embrión	O
y	O
ectópicamente	O
en	O
células	B-Cell
adyacente	O
al	O
cono	O
ectoplacentario	O
(	O
Fig	O
.	O
3J	O
,	O
L	O
)	O
.	O

Estos	O
resultados	O
sugieren	O
que	O
,	O
en	O
contraste	O
con	O
la	O
adecuada	O
hnf3	B-Protein
beta	I-Protein
regulación	O
,	O
gsc	B-Protein
permanece	O
inapropiadamente	O
activado	O
en	O
mutante	B-Sequence
endodermo	O
visceral	O
y	O
definitivo	O
,	O
implicando	O
cazatin	B-Protein
en	O
la	O
adecuada	O
restricción	O
de	O
este	O
factor	O
de	O
transcripción	O
del	O
homeodominio	O
.	O

Huntingtin	B-Protein
no	O
se	O
requiere	O
para	O
la	O
expresión	O
de	O
la	O
señalización	O
extraembrionaria	O
moléculas	B-Chemical

Estudios	O
previos	O
de	O
embriones	O
quiméricos	O
sugieren	O
que	O
cazatin	B-Protein
se	O
requiere	O
sólo	O
en	O
el	O
tejido	O
extraembrionario	O
para	O
su	O
correcto	O
desarrollo	O
[	O
16	O
]	O
.	O

Las	O
señales	O
del	O
tejido	O
extraembrionario	O
son	O
críticas	O
para	O
la	O
inducción	O
de	O
señales	O
embrionarias	O
y	O
para	O
modelar	O
el	O
epiblasto	O
.	O

En	O
consecuencia	O
,	O
examinamos	O
el	O
desarrollo	O
extraembrionario	O
en	O
cazatin	B-Protein
embriones	O
deficientes	O
.	O

Hnf4	B-Protein
es	O
un	O
factor	O
de	O
transcripción	O
expresado	O
en	O
el	O
endodermo	O
primitivo	O
tan	O
pronto	O
como	O
este	O
tejido	O
se	O
vuelve	O
distinto	O
y	O
es	O
un	O
regulador	O
clave	O
de	O
los	O
factores	O
secretados	O
por	O
el	O
endodermo	O
visceral	O
como	O
alfafetoproteína	B-Protein
,	O
apolipoproteínas	B-Chemical
,	O
y	O
transferrina	B-Protein
.	O

Inactivación	O
de	O
Hnf4	B-Protein
resulta	O
en	O
gastrulación	O
deteriorada	O
[	O
33	O
,	O
34	O
]	O
.	O

En	O
E7	O
.	O
5	O
,	O
Hnf4	B-Protein
se	O
expresa	O
en	O
el	O
visceral	O
columnar	O
células	B-Cell
endodérmicas	I-Cell
en	O
la	O
unión	O
extraembrionaria-ectodérmica	O
(	O
Fig	O
.	O
4A	O
,	O
[	O
33	O
]	O
)	O
.	O

En	O
embriones	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
,	O
compatibles	O
con	O
la	O
diferenciación	O
normal	O
del	O
endodermo	O
primitivo	O
y	O
visceral	O
,	O
Hnf4	B-Protein
expresión	O
parece	O
normal	O
,	O
aunque	O
la	O
señal	O
es	O
más	O
fuerte	O
en	O
mutante	B-Sequence
embriones	O
en	O
comparación	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
(	O
Fig	O
.	O
4B	O
)	O
.	O

Similar	O
,	O
pem	B-Protein
,	O
un	O
factor	O
de	O
transcripción	O
expresado	O
en	O
el	O
endodermo	O
visceral	O
proximal	O
y	O
el	O
cono	O
ectoplacentario	O
en	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
en	O
E7	O
.	O
5	O
,	O
también	O
se	O
expresa	O
en	O
estos	O
tejidos	O
en	O
el	O
mutante	B-Sequence
embriones	O
(	O
Fig	O
.	O
4C	O
,	O
D	O
[	O
35	O
]	O
)	O
.	O

Sin	O
embargo	O
,	O
pem	B-Protein
expresando	O
el	O
endodermo	O
visceral	O
se	O
cierne	O
sobre	O
la	O
parte	O
anterior	O
de	O
la	O
mutante	B-Sequence
embriones	O
,	O
que	O
revelan	O
una	O
ubicación	O
anormal	O
a	O
pesar	O
de	O
la	O
diferenciación	O
macroscópicamente	O
normal	O
.	O

Figura	O
4	O

Expresión	O
normal	O
de	O
marcadores	O
extraembrionarios	O
en	O
cazatin	B-Protein
embriones	O
deficientes	O
.	O

Análisis	O
de	O
hibridación	O
in	O
situ	O
de	O
montaje	O
completo	O
en	O
E7	O
.	O
5	O
de	O
marcadores	O
de	O
los	O
tejidos	O
extraembrionarios	O
revela	O
una	O
expresión	O
muy	O
normal	O
en	O
ausencia	O
de	O
cazatin	B-Protein
.	O

Hnf4	B-Protein
,	O
expresada	O
en	O
el	O
endodermo	O
visceral	O
en	O
la	O
unión	O
del	O
embrión	O
-	O
ectodermo	O
(	O
A	O
)	O
,	O
es	O
normal	O
en	O
mutante	B-Sequence
embriones	O
,	O
aunque	O
la	O
señal	O
es	O
ligeramente	O
superior	O
(	O
B	O
)	O
.	O

Del	O
mismo	O
modo	O
,	O
la	O
expresión	O
de	O
pem	B-Protein
transcripciones	B-Sequence
se	O
mantiene	O
en	O
mutante	B-Sequence
embriones	O
(	O
D	O
)	O
similares	O
a	O
los	O
embriones	O
normales	O
(	O
C	O
)	O
,	O
aunque	O
pem	B-Protein
se	O
expresa	O
en	O
el	O
saliente	O
asimétrico	O
anormal	O
del	O
endodermo	O
visceral	O
sobre	O
la	O
parte	O
anterior	O
de	O
la	O
mutante	B-Sequence
embriones	O

Expresión	O
de	O
señalización	O
extraembrionaria	O
moléculas	B-Chemical
no	O
se	O
ve	O
afectado	O
por	O
la	O
pérdida	O
de	O
cazatin	B-Protein
,	O
como	O
lo	O
demuestra	O
la	O
expresión	O
de	O
Bmp4	B-Protein
(	O
E	O
,	O
F	O
)	O
en	O
el	O
ectodermo	O
extraembrionario	O
,	O
y	O
zurdo1	B-Protein
y	O
Dkk1	B-Protein
(	O
I	O
-	O
L	O
)	O
en	O
el	O
AVE	O
en	O
mutante	B-Sequence
embriones	O

Bmp4	B-Protein
sin	O
embargo	O
,	O
no	O
se	O
localiza	O
en	O
un	O
anillo	O
de	O
ectodermo	O
extraembrionario	O
en	O
mutante	B-Sequence
embriones	O
(	O
F	O
)	O
como	O
en	O
embriones	O
normales	O
(	O
E	O
)	O
.	O

Células	B-Cell
germinales	I-Cell
primitivas	I-Cell
(	I-Cell
PCG	I-Cell
)	I-Cell
)	O
se	O
inducen	O
normalmente	O
en	O
ambos	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
G	O
)	O
y	O
mutante	B-Sequence
embriones	O
(	O
H	O
)	O
,	O
sugiriendo	O
la	O
Bmp4	B-Protein
la	O
señalización	O
del	O
ectodermo	O
extraembrionario	O
al	O
epiblasto	O
es	O
normal	O
.	O

zurdo1	B-Protein
expresión	O
aparece	O
desorganizada	O
en	O
mutante	B-Sequence
embriones	O
(	O
I	O
)	O
en	O
comparación	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
(	O
J	O
)	O
.	O

Por	O
el	O
contrario	O
,	O
la	O
expresión	O
anterior	O
de	O
Dkk1	B-Protein
en	O
el	O
AVE	O
en	O
mutante	B-Sequence
embriones	O
(	O
L	O
)	O
coincide	O
con	O
el	O
tipo	B-Sequence
salvaje	I-Sequence
patrón	O
de	O
expresión	O
(	O
K	O
)	O
.	O

A	O
pesar	O
de	O
la	O
formación	O
normal	O
de	O
AVE	O
,	O
los	O
pliegues	O
de	O
la	O
cabeza	O
no	O
se	O
forman	O
en	O
mutante	B-Sequence
embriones	O
,	O
incluso	O
cuando	O
se	O
cultivan	O
en	O
nutritivo	B-Chemical
medios	O
enriquecidos	O
durante	O
24	O
horas	O
.	O

Tipo	B-Sequence
salvaje	I-Sequence
E7	O
.	O
5	O
embriones	O
,	O
cuando	O
se	O
cultivan	O
en	O
75	O
%	O
rata	B-Taxon
suero	O
,	O
desarrollar	O
somitas	O
(	O
M	O
)	O
,	O
corazón	O
(	O
flecha	O
blanca	O
,	O
N	O
)	O
y	O
pliegues	O
de	O
la	O
cabeza	O
(	O
punta	O
de	O
flecha	O
azul	O
,	O
N	O
)	O
en	O
cultivo	O
.	O

A	O
diferencia	O
de	O
,	O
cazatin	B-Protein
los	O
embriones	O
deficientes	O
continúan	O
viviendo	O
en	O
cultivo	O
pero	O
no	O
forman	O
pliegues	O
de	O
cabeza	O
,	O
corazón	O
o	O
somitas	O
(	O
O	O
)	O
.	O

Los	O
embriones	O
se	O
muestran	O
en	O
una	O
vista	O
lateral	O
(	O
A-F	O
,	O
I-J	O
)	O
con	O
el	O
anterior	O
orientado	O
a	O
la	O
izquierda	O
.	O

Los	O
embriones	O
en	O
(	O
G	O
,	O
H	O
,	O
K	O
,	O
L	O
)	O
se	O
muestran	O
en	O
una	O
vista	O
anterior	O
con	O
la	O
parte	O
proximal	O
orientada	O
hacia	O
arriba	O
.	O

Las	O
señales	O
de	O
los	O
tejidos	O
extraembrionarios	O
,	O
incluidos	O
el	O
endodermo	O
visceral	O
anterior	O
y	O
el	O
ectodermo	O
extraembrionario	O
,	O
son	O
necesarias	O
para	O
la	O
formación	O
y	O
el	O
patrón	O
adecuados	O
del	O
epiblasto	O
[	O
17	O
]	O
.	O

Bmp4	B-Protein
es	O
una	O
señal	O
molécula	B-Chemical
que	O
primero	O
se	O
expresa	O
de	O
manera	O
uniforme	O
en	O
todo	O
el	O
ectodermo	O
extraembrionario	O
y	O
posteriormente	O
se	O
localiza	O
en	O
un	O
anillo	O
de	O
ectodermo	O
extraembrionario	O
adyacente	O
al	O
epiblasto	O
(	O
Fig	O
.	O
4E	O
,	O
[	O
36	O
]	O
)	O
.	O

Un	O
factor	O
clave	O
en	O
la	O
regulación	O
de	O
la	O
formación	O
del	O
nudo	O
y	O
la	O
racha	O
primitiva	O
,	O
Bmp4	B-Protein
se	O
requiere	O
para	O
modelar	O
el	O
embrión	O
a	O
lo	O
largo	O
del	O
eje	O
proximodistal	O
[	O
37	O
-	O
40	O
]	O
.	O

En	O
ausencia	O
de	O
cazatin	B-Protein
,	O
Bmp4	B-Protein
la	O
expresión	O
se	O
mantiene	O
adecuadamente	O
en	O
el	O
ectodermo	O
extraembrionario	O
Hdhex4/5/Hdhex4/5	O
pero	O
también	O
se	O
expresa	O
en	O
todo	O
el	O
ectodermo	O
extraembrionario	O
(	O
Fig	O
.	O
4F	O
)	O
en	O
un	O
patrón	O
que	O
es	O
similar	O
al	O
temprano	O
Bmp4	B-Protein
expresión	O
en	O
lugar	O
de	O
estar	O
restringida	O
a	O
un	O
anillo	O
de	O
ectodermo	O
extraembrionario	O
como	O
se	O
ve	O
en	O
la	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
Para	O
evaluar	O
Bmp4	B-Protein
señalización	O
del	O
ectodermo	O
extraembrionario	O
,	O
evaluamos	O
células	B-Cell
germinales	I-Cell
primordiales	I-Cell
(	O
PGC	B-Cell
)	O
,	O
que	O
requieren	O
Bmp4	B-Protein
para	O
su	O
inducción	O
[	O
37	O
]	O
.	O

PGC	B-Cell
se	O
puede	O
detectar	O
primero	O
en	O
E7	O
.	O
0	O
y	O
subsecuentemente	O
subyacen	O
a	O
la	O
porción	O
posterior	O
de	O
la	O
racha	O
primitiva	O
.	O

Tinción	O
de	O
montaje	O
completo	O
de	O
E7	O
.	O
5	O
mutante	B-Sequence
y	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
para	O
alcalino	B-Chemical
La	O
actividad	O
de	O
la	O
fosfatasa	O
revela	O
que	O
PCG	B-Cell
en	O
embriones	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
,	O
lo	O
que	O
sugiere	O
que	O
Bmp4	B-Protein
La	O
señalización	O
es	O
funcional	O
en	O
ausencia	O
de	O
cazatin	B-Protein
(	O
Fig	O
.	O
4G	O
,	O
H	O
)	O
.	O

El	O
endodermo	O
visceral	O
anterior	O
(	O
AVE	O
)	O
también	O
es	O
una	O
fuente	O
extraembrionaria	O
de	O
señales	O
que	O
son	O
críticas	O
para	O
el	O
patrón	O
temprano	O
.	O

Wnt	O
y	O
nodal	B-Protein
antagonistas	O
,	O
Dkk1	B-Protein
(	O
mdkk	B-Protein
-	I-Protein
1	I-Protein
)	O
y	O
zurdo1	B-Protein
respectivamente	O
,	O
se	O
expresan	O
en	O
el	O
AVE	O
y	O
son	O
importantes	O
para	O
limitar	O
la	O
posteriorización	O
del	O
embrión	O
anterior	O
al	O
restringir	O
Nodal	B-Protein
y	O
señalización	O
Wnt	O
[	O
41-43	O
]	O
.	O

En	O
embriones	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
,	O
ambos	O
Dkk1	B-Protein
(	O
Fig	O
.	O
4I	O
,	O
J	O
)	O
y	O
zurdo1	B-Protein
(	O
Fig	O
.	O
4K	O
,	O
L	O
)	O
se	O
expresan	O
normalmente	O
en	O
el	O
AVE	O
en	O
comparación	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O

Sin	O
embargo	O
,	O
bb	B-Protein
-	I-Protein
1	I-Protein
los	O
niveles	O
parecen	O
aumentar	O
ligeramente	O
en	O
los	O
embriones	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
,	O
aunque	O
el	O
patrón	O
de	O
bb	B-Protein
-	I-Protein
1	I-Protein
expresión	O
permanece	O
sin	O
cambios	O
y	O
este	O
aumento	O
puede	O
reflejar	O
la	O
misma	O
cantidad	O
de	O
expresión	O
en	O
un	O
área	O
más	O
pequeña	O
.	O

Por	O
lo	O
tanto	O
,	O
la	O
expresión	O
ectópica	O
de	O
Nodal	B-Protein
(	O
Fig	O
.	O
3A-D	O
)	O
y	O
la	O
disminución	O
Wnt3a	B-Protein
expresión	O
(	O
Fig	O
.	O
2H	O
)	O
en	O
mutante	B-Sequence
embriones	O
no	O
parecen	O
ser	O
el	O
resultado	O
de	O
cambios	O
en	O
el	O
patrón	O
de	O
expresión	O
de	O
zurdo1	B-Protein
o	O
Dkk1	B-Protein
.	O

A	O
pesar	O
de	O
la	O
formación	O
normal	O
de	O
AVE	O
y	O
la	O
inducción	O
del	O
neuroectodermo	O
,	O
los	O
pliegues	O
de	O
la	O
cabeza	O
no	O
se	O
forman	O
en	O
los	O
embriones	O
Hdhex4/5/Hdhex4/5	O
.	O

Por	O
lo	O
tanto	O
,	O
para	O
determinar	O
si	O
mutante	B-Sequence
los	O
embriones	O
son	O
intrínsecamente	O
capaces	O
de	O
formar	O
pliegues	O
de	O
cabeza	O
,	O
embriones	O
cosechados	O
en	O
la	O
etapa	O
E7	O
.	O
5	O
se	O
dejaron	O
progresar	O
en	O
medio	O
de	O
cultivo	O
rico	O
in	O
vitro	O
durante	O
24	O
horas	O
.	O

Tipo	B-Sequence
salvaje	I-Sequence
los	O
embriones	O
continuaron	O
desarrollando	O
pliegues	O
de	O
cabeza	O
,	O
somitas	O
y	O
corazones	O
(	O
Fig	O
.	O
4M	O
,	O
N	O
)	O
.	O

A	O
diferencia	O
de	O
,	O
mutante	B-Sequence
etapa	O
7	O
5	O
embriones	O
no	O
desarrollaron	O
pliegues	O
de	O
cabeza	O
,	O
corazones	O
o	O
somitas	O
,	O
aunque	O
estos	O
embriones	O
continuaron	O
viviendo	O
(	O
Fig	O
.	O
4O	O
)	O
.	O

Estos	O
resultados	O
sugieren	O
fuertemente	O
que	O
en	O
ausencia	O
de	O
cazatin	B-Protein
,	O
los	O
embriones	O
no	O
pueden	O
someterse	O
a	O
la	O
organogénesis	O
,	O
incluso	O
si	O
continúan	O
viviendo	O
más	O
allá	O
de	O
E7	O
.	O
5	O
en	O
un	O
nutritivo	B-Chemical
entorno	O
rico	O
.	O

Discusión	O

Hemos	O
investigado	O
los	O
procesos	O
embrionarios	O
que	O
requieren	O
cazatin	B-Protein
para	O
delimitar	O
con	O
mayor	O
precisión	O
cazatin	B-Protein
es	O
esencial	O
molecular	B-Chemical
y	O
celular	B-Cell
actividades	O
y	O
proporcionar	O
pistas	O
sobre	O
el	O
mecanismo	O
por	O
el	O
cual	O
la	O
expansión	O
de	O
poliglutamina	O
dominante	O
mutación	B-Sequence
en	O
cazatin	B-Protein
conduce	O
a	O
la	O
patogenia	O
de	O
la	O
EH	O
.	O

En	O
la	O
búsqueda	O
de	O
la	O
conclusión	O
de	O
que	O
cazatin	B-Protein
se	O
necesita	O
solo	O
en	O
tejidos	O
extraembrionarios	O
para	O
la	O
gastrulación	O
normal	O
,	O
nuestros	O
datos	O
no	O
proporcionan	O
evidencia	O
de	O
nutrición	O
anormal	O
gene	B-Sequence
expresión	O
en	O
embriones	O
Hdhex4/5/Hdhex4/5	O
.	O

En	O
cambio	O
,	O
nuestros	O
resultados	O
revelan	O
que	O
cazatin	B-Protein
se	O
requiere	O
para	O
la	O
formación	O
normal	O
de	O
la	O
estría	O
anterior	O
y	O
la	O
consiguiente	O
producción	O
de	O
mesodermo	O
paraxial	O
,	O
con	O
un	O
papel	O
previamente	O
no	O
reconocido	O
para	O
cazatin	B-Protein
en	O
la	O
adecuada	O
extinción	O
de	O
transitoria	O
y/o	O
dinámicamente	O
expresada	O
genes	B-Sequence
.	O

De	O
hecho	O
,	O
el	O
sello	O
distintivo	O
de	O
la	O
cazatin	B-Protein
deficiente	O
molecular	B-Chemical
El	O
fenotipo	O
es	O
la	O
alteración	O
de	O
la	O
regulación	O
negativa	O
de	O
un	O
subconjunto	O
de	O
expresiones	O
dinámicas	O
.	O
genes	B-Sequence
,	O
después	O
del	O
inicio	O
adecuado	O
de	O
la	O
expresión	O
.	O

Este	O
fenómeno	O
no	O
refleja	O
una	O
falta	O
de	O
formación	O
del	O
eje	O
anterior/posterior	O
,	O
como	O
lo	O
demuestra	O
la	O
formación	O
del	O
AVE	O
en	O
la	O
parte	O
anterior	O
y	O
la	O
raya	O
primitiva	O
en	O
la	O
parte	O
posterior	O
.	O

Tampoco	O
puede	O
explicarse	O
simplemente	O
por	O
un	O
retraso	O
en	O
el	O
desarrollo	O
,	O
ya	O
que	O
los	O
marcadores	O
específicos	O
de	O
la	O
etapa	O
,	O
como	O
Wnt3a	B-Protein
y	O
células	B-Cell
germinales	I-Cell
primordiales	I-Cell
,	O
que	O
son	O
detectables	O
en	O
E7	O
.	O
0	O
en	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
,	O
son	O
inducidos	O
apropiadamente	O
.	O

Además	O
,	O
la	O
expresión	O
de	O
T	B-Protein
y	O
Evx1	B-Protein
en	O
el	O
mesodermo	O
extraembrionario	O
de	O
mutante	B-Sequence
embriones	O
no	O
es	O
una	O
característica	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
,	O
incluso	O
en	O
etapas	O
más	O
tempranas	O
.	O

Esto	O
sugiere	O
fuertemente	O
que	O
en	O
cazatin	B-Protein
embriones	O
deficientes	O
,	O
la	O
migración	O
de	O
los	O
derivados	O
de	O
la	O
estría	O
distal	O
al	O
mesodermo	O
extraembrionario	O
ocurre	O
normalmente	O
pero	O
la	O
regulación	O
a	O
la	O
baja	O
de	O
estos	O
genes	B-Sequence
está	O
desemparejado	O
.	O

Este	O
deterioro	O
también	O
puede	O
explicar	O
el	O
fracaso	O
de	O
cazatin	B-Protein
embriones	O
deficientes	O
para	O
restringir	O
adecuadamente	O
la	O
expresión	O
de	O
Fgf8	B-Protein
,	O
Nodal	B-Protein
y	O
gsc	B-Protein
.	O

Por	O
lo	O
tanto	O
,	O
cazatin	B-Protein
puede	O
desempeñar	O
un	O
papel	O
directo	O
en	O
la	O
regulación	O
transcripcional	O
,	O
o	O
ARNm	B-Chemical
estabilidad	O
de	O
estos	O
genes	B-Sequence
o	O
puede	O
actuar	O
indirectamente	O
al	O
cruzarse	O
con	O
otras	O
vías	O
que	O
regulan	O
la	O
expresión	O
de	O
estos	O
genes	B-Sequence
.	O

El	O
requisito	O
para	O
cazatin	B-Protein
en	O
los	O
tejidos	O
extraembrionarios	O
nos	O
había	O
llevado	O
a	O
probar	O
si	O
las	O
señales	O
extraembrionarias	O
deterioradas	O
podrían	O
ser	O
responsables	O
de	O
la	O
desregulación	O
de	O
gene	B-Sequence
expresión	O
dentro	O
del	O
epiblasto	O
que	O
se	O
observa	O
en	O
los	O
embriones	O
Hdhex4/5/Hdhex4/5	O
.	O

El	O
desarrollo	O
extraembrionario	O
en	O
embriones	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
se	O
asocia	O
con	O
niveles	O
levemente	O
elevados	O
de	O
expresión	O
de	O
Hnf4	B-Protein
en	O
el	O
endodermo	O
primitivo	O
y	O
pem	B-Protein
en	O
el	O
corion	O
anterior	O
torcido	O
pero	O
la	O
expresión	O
de	O
otros	O
conocido	B-Sequence
señales	O
,	O
como	O
Bmp4	B-Protein
del	O
ectodermo	O
extraembrionario	O
y	O
Dkk1	B-Protein
y	O
zurdo1	B-Protein
del	O
AVE	O
,	O
parecen	O
normales	O
,	O
aunque	O
el	O
ligero	O
aumento	O
de	O
bb	B-Protein
-	I-Protein
1	I-Protein
la	O
expresión	O
en	O
embriones	O
Hdhex4/5/Hdhex4/5	O
sugiere	O
que	O
se	O
justifica	O
una	O
mayor	O
investigación	O
sobre	O
la	O
señalización	O
de	O
Wnt	O
.	O

Además	O
,	O
extraembrionario	O
Bmp4	B-Protein
la	O
señalización	O
no	O
se	O
ve	O
afectada	O
en	O
ausencia	O
de	O
cazatin	B-Protein
,	O
como	O
la	O
inducción	O
de	O
PCG	B-Cell
en	O
mutante	B-Sequence
embriones	O
es	O
normal	O
,	O
lo	O
que	O
implica	O
un	O
transporte	O
y	O
secreción	O
adecuados	O
de	O
las	O
señales	O
extraembrionarias	O
apropiadas	O
.	O

Sin	O
embargo	O
,	O
Nodal	B-Protein
,	O
Fgf8	B-Protein
y	O
gsc	B-Protein
se	O
expresan	O
ectópicamente	O
en	O
el	O
endodermo	O
visceral	O
de	O
los	O
embriones	O
Hdhex4/5/Hdhex4/5	O
.	O

Ambas	O
cosas	O
Nodal	B-Protein
y	O
Fgf8	B-Protein
,	O
importantes	O
factores	O
de	O
crecimiento	O
necesarios	O
para	O
el	O
desarrollo	O
normal	O
del	O
epiblasto	O
,	O
están	O
estrictamente	O
regulados	O
durante	O
la	O
gastrulación	O
.	O

Por	O
lo	O
tanto	O
,	O
la	O
expresión	O
errónea	O
de	O
uno	O
o	O
ambos	O
de	O
estos	O
factores	O
,	O
o	O
de	O
gansoide	B-Protein
,	O
en	O
el	O
endodermo	O
visceral	O
podría	O
contribuir	O
a	O
la	O
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
mutante	B-Sequence
fenotipo	O

Además	O
,	O
es	O
posible	O
que	O
otra	O
(	O
s	O
)	O
señal	O
(	O
es	O
)	O
extraembrionaria	O
(	O
s	O
)	O
que	O
no	O
hayamos	O
analizado	O
también	O
puedan	O
verse	O
afectadas	O
por	O
la	O
falta	O
de	O
cazatin	B-Protein
actividad	O
en	O
células	B-Cell
extraembrionarias	I-Cell
en	O
mutante	B-Sequence
embriones	O

Huntingtin	B-Protein
los	O
embriones	O
deficientes	O
tampoco	O
logran	O
formar	O
pliegues	O
craneales	O
ni	O
someterse	O
a	O
la	O
organogénesis	O
,	O
incluso	O
después	O
de	O
cultivarlos	O
en	O
nutritivo	B-Chemical
Medios	O
de	O
comunicación	O
ricos	O
.	O

La	O
ausencia	O
de	O
formación	O
de	O
pliegues	O
cefálicos	O
en	O
estos	O
embriones	O
no	O
parece	O
ser	O
el	O
resultado	O
de	O
una	O
falla	O
en	O
la	O
inducción	O
del	O
neurectodermo	O
o	O
una	O
falla	O
en	O
la	O
formación	O
del	O
AVE	O
,	O
ya	O
que	O
mutante	B-Sequence
embriones	O
expresan	O
marcadores	O
como	O
Otx2	B-Protein
,	O
Ddk1	B-Protein
,	O
zurdo1	B-Protein
y	O
Hex1	B-Protein
.	O

Además	O
,	O
dado	O
que	O
la	O
formación	O
de	O
nodos	O
no	O
es	O
necesaria	O
para	O
la	O
inducción	O
neural	O
[	O
44-46	O
]	O
,	O
el	O
hecho	O
de	O
no	O
formar	O
un	O
nodo	O
en	O
cazatin	B-Protein
También	O
es	O
poco	O
probable	O
que	O
los	O
embriones	O
deficientes	O
expliquen	O
la	O
falta	O
de	O
pliegues	O
craneales	O
.	O

La	O
aparente	O
reducción	O
del	O
mesodermo	O
paraxial	O
en	O
los	O
embriones	O
Hdhex4/5/Hdhex4/5	O
podría	O
explicar	O
la	O
falta	O
de	O
pliegues	O
craneales	O
,	O
ya	O
que	O
el	O
mesodermo	O
paraxial	O
es	O
importante	O
para	O
el	O
pleno	O
desarrollo	O
del	O
neuroectodermo	O
y	O
,	O
en	O
consecuencia	O
,	O
de	O
los	O
pliegues	O
craneales	O
.	O

Alternativamente	O
,	O
la	O
incapacidad	O
de	O
manifestar	O
headfolds	O
podría	O
sugerir	O
que	O
cazatin	B-Protein
se	O
requiere	O
en	O
una	O
etapa	O
muy	O
temprana	O
para	O
el	O
desarrollo	O
normal	O
del	O
SNC	O
.	O

Esta	O
conclusión	O
es	O
consistente	O
con	O
el	O
hallazgo	O
de	O
que	O
los	O
niveles	O
severamente	O
reducidos	O
de	O
cazatin	B-Protein
,	O
de	O
un	O
hipomórfico	O
hd	B-Protein
alelo	B-Sequence
,	O
conducen	O
a	O
cerebros	O
anormales	O
más	O
adelante	O
en	O
el	O
desarrollo	O
embrionario	O
[	O
15	O
]	O
.	O

Las	O
características	O
cardinales	O
de	O
la	O
completa	O
hd	B-Protein
inactivación	O
que	O
observamos	O
son	O
similares	O
a	O
los	O
fenotipos	O
que	O
se	O
derivan	O
de	O
la	O
inactivación	O
completa	O
del	O
grupo	O
Polycomb	O
gene	B-Sequence
(	O
Pc-g	O
)	O
Eed	B-Protein
(	O
desarrollo	B-Protein
del	I-Protein
ectodermo	I-Protein
embrionario	I-Protein
)	O
.	O

De	O
hecho	O
,	O
la	O
deficiencia	O
completa	O
para	O
cualquiera	O
cazatin	B-Protein
o	O
la	O
necesidad	B-Protein
proteína	B-Chemical
conduce	O
al	O
desarrollo	O
anormal	O
de	O
rayas	O
,	O
falta	O
de	O
formación	O
de	O
pliegues	O
craneales	O
,	O
ectópico	O
T	B-Protein
,	O
Evx1	B-Protein
y	O
Nodal	B-Protein
la	O
expresión	O
y	O
la	O
interrupción	O
de	O
la	O
producción	O
de	O
mesodermo	O
veta	O
primitivo	O
anterior	O
[	O
47	O
]	O
.	O

Curiosamente	O
,	O
Eed	B-Protein
proteína	B-Chemical
también	O
se	O
requiere	O
para	O
el	O
desarrollo	O
adecuado	O
del	O
trofoblasto	O
y	O
el	O
mantenimiento	O
normal	O
de	O
impreso	O
X	B-GENE
#	O
¿NOMBRE	O
?	O
genómico	B-Sequence
impronta	O
[	O
47	O
-	O
49	O
]	O
,	O
lo	O
que	O
sugiere	O
que	O
estas	O
actividades	O
merecen	O
una	O
investigación	O
en	O
cazatin	B-Protein
embriones	O
deficientes	O
.	O

Así	O
,	O
nuestras	O
observaciones	O
proporcionan	O
puntos	O
de	O
partida	O
inesperados	O
en	O
la	O
búsqueda	O
de	O
cazatin	B-Protein
es	O
preciso	O
molecular	B-Chemical
actividades	O
,	O
que	O
comenzaron	O
con	O
el	O
descubrimiento	O
de	O
que	O
este	O
CALOR	O
dominio	B-Sequence
proteína	B-Chemical
alberga	O
la	O
poliglutamina	O
dominante	O
propiedad	B-Sequence
esa	O
es	O
la	O
base	O
fundamental	O
de	O
la	O
patogenia	O
de	O
la	O
EH	O
.	O

En	O
pacientes	O
en	O
HD	O
y	O
en	O
condiciones	O
precisas	O
genético	B-Sequence
réplicas	O
,	O
alta	B-Protein
definición	I-Protein
golpe	O
de	O
CAG	O
-	O
en	O
ratones	B-Taxon
,	O
el	O
dominante	O
mutación	B-Sequence
Afecta	O
específicamente	O
a	O
la	O
gran	O
población	O
de	O
neuronas	B-Cell
en	O
el	O
cuerpo	O
estriado	O
,	O
sin	O
perjudicar	O
cazatin	B-Protein
actividades	O
esenciales	O
de	O
s	O
en	O
el	O
desarrollo	O
embrionario	O
[	O
50	O
-	O
53	O
]	O
.	O

De	O
hecho	O
,	O
los	O
pacientes	O
homocigóticos	O
con	O
EH	O
no	O
hacen	O
tipo	B-Sequence
salvaje	I-Sequence
cazatin	B-Protein
,	O
y	O
en	O
el	O
ratón	B-Taxon
,	O
un	O
solo	O
mutante	B-Sequence
hd	B-Protein
alelo	B-Sequence
vale	O
la	O
pena	O
mutante	B-Sequence
cazatin	B-Protein
puede	O
rescatar	O
completamente	O
cazatin	B-Protein
fenotipos	O
embrionarios	O
de	O
deficiencia	O
[	O
15	O
,	O
51	O
]	O
.	O

La	O
búsqueda	O
para	O
comprender	O
el	O
mecanismo	O
HD	O
,	O
por	O
lo	O
tanto	O
,	O
tiene	O
como	O
objetivo	O
delinear	O
el	O
cazatin	B-Protein
actividad	O
que	O
puede	O
explicar	O
el	O
estriado	O
célula	B-Cell
especificidad	O
de	O
la	O
poliglutamina	O
versión	B-Sequence
mutante	I-Sequence
de	O
cazatin	B-Protein
.	O

Una	O
hipótesis	O
es	O
que	O
cazatin	B-Protein
normalmente	O
participa	O
en	O
gene	B-Sequence
transcripción	O
,	O
como	O
se	O
propone	O
para	O
NRSF	B-Protein
/	O
DESCANSO	B-Protein
mediado	O
BDNF	B-Protein
expresión	O
[	O
54	O
]	O
.	O

Ahora	O
,	O
nuestro	O
hallazgo	O
de	O
que	O
cazatin	B-Protein
puede	O
ser	O
absolutamente	O
necesario	O
para	O
la	O
adecuada	O
regulación	O
de	O
genes	B-Sequence
con	O
patrones	O
de	O
expresión	O
dinámicos	O
in	O
vivo	O
,	O
proporciona	O
una	O
razón	O
de	O
peso	O
para	O
dilucidar	O
la	O
celular	B-Cell
maquinaria	O
necesaria	O
para	O
cazatin	B-Protein
mediado	O
gene	B-Sequence
reglamento	O

Conclusión	O

Nuestros	O
hallazgos	O
indican	O
que	O
cazatin	B-Protein
se	O
requiere	O
para	O
el	O
patrón	O
adecuado	O
del	O
epiblasto	O
durante	O
la	O
embriogénesis	O
temprana	O
,	O
para	O
la	O
formación	O
adecuada	O
de	O
la	O
estría	O
anterior	O
y	O
el	O
nódulo	O
,	O
la	O
progresión	O
de	O
la	O
estría	O
primitiva	O
,	O
la	O
formación	O
del	O
mesodermo	O
paraxial	O
y	O
el	O
pliegue	O
de	O
la	O
cabeza	O
,	O
así	O
como	O
para	O
la	O
restricción	O
adecuada	O
del	O
factor	O
de	O
transcripción	O
y	O
crecimiento	O
expresado	O
transitoriamente	O
genes	B-Sequence
.	O

conocimiento	O
de	O
la	O
molecular	B-Chemical
base	O
de	O
estos	O
cambios	O
en	O
cazatin	B-Protein
embriones	O
deficientes	O
debe	O
facilitar	O
la	O
identificación	O
de	O
los	O
celular	B-Cell
caminos	O
que	O
dependen	O
de	O
cazatin	B-Protein
actividades	O

Estos	O
serán	O
importantes	O
para	O
implicar	O
a	O
los	O
candidatos	O
a	O
evaluar	O
en	O
las	O
señales	O
extraembrionarias	O
que	O
determinan	O
la	O
progresión	O
de	O
la	O
línea	O
anterior	O
en	O
el	O
embrión	O
en	O
desarrollo	O
y	O
para	O
delinear	O
la	O
actividad	O
dominante	O
de	O
la	O
poliglutamina	O
.	O
tracto	B-Sequence
en	O
cazatin	B-Protein
que	O
determina	O
la	O
especificidad	O
estriatal	O
de	O
la	O
EH	O
.	O

Métodos	O

Ratones	B-Taxon
y	O
genotipado	O

El	O
Hdhex4	O
/	O
5	O
ratones	B-Taxon
llevando	O
un	O
pGKneo	O
inserción	B-Sequence
/	O
reemplazo	B-Sequence
inactivando	O
mutación	B-Sequence
en	O
el	O
homólogo	B-Protein
del	I-Protein
gen	I-Protein
HD	I-Protein
de	I-Protein
ratón	I-Protein
han	O
sido	O
descritos	O
previamente	O
[	O
10	O
]	O
.	O

Los	O
experimentos	O
se	O
realizaron	O
de	O
acuerdo	O
con	O
un	O
protocolo	O
aprobado	O
por	O
IACUC	O
,	O
a	O
través	O
del	O
Subcomité	O
de	O
MGH	O
sobre	O
Animal	B-Taxon
Investigación	O
.	O

mutante	B-Sequence
Hdhex4	O
/	O
5	O
/	O
Hdhex4	O
/	O
5	O
y	O
compañeros	O
de	O
camada	O
normales	O
se	O
obtuvieron	O
en	O
embarazos	O
programados	O
del	O
apareamiento	O
de	O
Hdhex4	O
/	O
5	O
/	O
hd	B-Protein
+	O
heterocigotos	O
,	O
genotipados	O
por	O
ensayo	O
PCR	O
,	O
como	O
se	O
describe	O
[	O
10	O
]	O
.	O

El	O
día	O
del	O
enchufe	O
se	O
tomó	O
como	O
E0	O
.	O
5	O
.	O

Los	O
embriones	O
que	O
eran	O
morfológicamente	O
normales	O
se	O
agruparon	O
por	O
separado	O
de	O
los	O
morfológicamente	O
mutante	B-Sequence
embriones	O
para	O
análisis	O
.	O

Nodal	B-Protein
expresión	O
se	O
determinó	O
en	O
embriones	O
de	O
apareamientos	O
de	O
Hdhex4	O
/	O
5	O
/	O
hd	B-Protein
+	O
;	O
NdllacZ	O
/	O
ndl	B-Protein
+	O
heterocigotos	O
compuestos	O
genotipados	O
por	O
ensayo	O
PCR	O
como	O
se	O
describe	O
en	O
[	O
29	O
]	O
.	O

Montaje	O
completo	O
y	O
sección	O
hibridación	O
in	O
situ	O
y	O
tinción	O
beta	O
-	O
gal	O

Después	O
de	O
la	O
disección	O
en	O
PBS	O
,	O
los	O
embriones	O
se	O
fijaron	O
durante	O
la	O
noche	O
en	O
paraformaldehído	O
al	O
4	O
%	O
a	O
4	O
grados	O
C	O
.	O

Para	O
las	O
secciones	O
,	O
la	O
decidua	O
fijada	O
en	O
paraformaldehído	O
al	O
4	O
%	O
,	O
se	O
embebió	O
en	O
parafina	O
y	O
se	O
seccionó	O
a	O
7	O
micras	O
.	O

ARN	B-Sequence
hibridaciones	O
in	O
situ	O
se	O
realizaron	O
como	O
se	O
describe	O
anteriormente	O
[	O
55	O
]	O
.	O

Nodal	B-Protein
La	O
expresión	O
de	O
lacZ	O
se	O
evaluó	O
mediante	O
tinción	O
con	O
beta-galactosidasa	O
,	O
como	O
se	O
informó	O
[	O
29	O
]	O
,	O
en	O
embriones	O
fijados	O
posteriormente	O
en	O
paraformaldehído	O
al	O
4	O
%	O
.	O

Los	O
embriones	O
fueron	O
montados	O
en	O
80	O
%	O
glicerol	B-Chemical
antes	O
de	O
ser	O
fotografiado	O
.	O

los	O
cazatin	B-Protein
fenotipo	O
deficiente	O
es	O
totalmente	O
penetrante	O
en	O
cada	O
una	O
de	O
las	O
etapas	O
que	O
se	O
evaluaron	O
[	O
10	O
]	O
.	O

Se	O
evaluaron	O
de	O
tres	O
a	O
seis	O
embriones	O
para	O
cada	O
marcador	O
,	O
y	O
cada	O
embrión	O
exhibió	O
el	O
mismo	O
mutante	B-Sequence
fenotipo	O
en	O
cada	O
caso	O
.	O

Alcalino	B-Chemical
tinción	O
con	O
fosfatasa	O
de	O
Células	B-Cell
germinales	I-Cell
primordiales	I-Cell
(	O
PCG	B-Cell
)	O

Después	O
de	O
las	O
disecciones	O
,	O
los	O
embriones	O
se	O
fijaron	O
brevemente	O
en	O
paraformaldehído	O
al	O
4	O
%	O
y	O
se	O
lavaron	O
y	O
almacenaron	O
en	O
1	O
x	O
PBS/0	O
.	O
1	O
%	O
TX	O
-	O
100	O
a	O
4	O
grados	O
C	O
.	O

Los	O
embriones	O
se	O
lavaron	O
una	O
vez	O
con	O
tris	B-Chemical
-	O
maleato	B-Chemical
Tampón	O
(	O
25	O
mM	O
tris	B-Chemical
-	O
maleato	B-Chemical
,	O
pH	O
=	O
9	O
.	O
0	O
,	O
0	O
.	O
8	O
mm	O
MgCl2	B-Chemical
)	O
y	O
posteriormente	O
se	O
incubaron	O
en	O
alcalino	B-Chemical
solución	O
de	O
tinción	O
de	O
fosfatasa	O
(	O
25	O
mM	O
tris	B-Chemical
-	O
maleato	B-Chemical
,	O
pH	O
=	O
9	O
.	O
0	O
,	O
0	O
.	O
8	O
mm	O
MgCl2	B-Chemical
,	O
0	O
.	O
4	O
mg/ml	O
alfa	O
-	O
fosfato	B-Chemical
de	I-Chemical
naftilo	I-Chemical
,	O
1	O
mg	O
/	O
ml	O
Fast	O
-	O
Red	O
)	O
.	O

Los	O
embriones	O
teñidos	O
se	O
lavaron	O
en	O
1	O
x	O
PBS/0	O
.	O
1	O
%	O
TX	O
-	O
100	O
.	O

cultivo	O
de	O
embriones	O
completos	O

Los	O
embriones	O
se	O
diseccionaron	O
en	O
E7	O
.	O
5	O
y	O
lavado	O
en	O
DMEM	O
.	O

A	O
continuación	O
,	O
los	O
embriones	O
se	O
cultivaron	O
individualmente	O
en	O
1	O
ml	O
de	O
medio	O
de	O
cultivo	O
(	O
75	O
%	O
inmediatamente	O
centrifugado	O
rata	B-Taxon
suero	O
y	O
25	O
%	O
de	O
DMEM	O
[	O
56	O
]	O
)	O
durante	O
24	O
horas	O
mientras	O
se	O
rota	O
en	O
una	O
incubadora	O
a	O
37	O
grados	O
C	O
en	O
5	O
%	O
CO2	B-Chemical
.	O

A	O
continuación	O
,	O
los	O
embriones	O
se	O
fijaron	O
en	O
paraformaldehído	O
al	O
4	O
%	O
para	O
su	O
análisis	O
.	O

abreviaturas	O

AVE	O
,	O
endodermo	O
visceral	O
anterior	O
;	O
alta	B-Protein
definición	I-Protein
,	O
Gen	B-Protein
de	I-Protein
la	I-Protein
enfermedad	I-Protein
de	I-Protein
Huntington	I-Protein
;	O
HD	O
,	O
enfermedad	O
de	O
Huntington	O
;	O
hd	B-Protein
,	O
homólogo	B-Protein
del	I-Protein
gen	I-Protein
HD	I-Protein
de	I-Protein
ratón	I-Protein
;	O
PCG	B-Cell
,	O
células	B-Cell
germinales	I-Cell
primordiales	I-Cell

Contribuciones	O
de	O
los	O
autores	O

JMW	O
,	O
TC	O
,	O
PH-M	O
y	O
MD	O
realizaron	O
ensayos	O
de	O
hibridación	O
in	O
situ	O
y	O
de	O
montaje	O
completo	O
.	O

MEM	O
y	O
RC	O
contribuyeron	O
a	O
la	O
concepción	O
de	O
este	O
estudio	O
.	O

JMW	O
,	O
TC	O
,	O
PH-M	O
y	O
MEM	O
redactó	O
el	O
manuscrito	O
y	O
RC	O
contribuyó	O
a	O
su	O
finalización	O
.	O

Todos	O
los	O
autores	O
leyeron	O
y	O
aprobaron	O
el	O
manuscrito	O
final	O
.	O

Agradecimientos	O

Agradecemos	O
a	O
los	O
Dres	O
.	O

UN	O
.	O

Gosler	O
,	O
J	O
.	O

Darnell	O
,	O
Jr.	O
,	O
J	O
Rossant	O
,	O
G	O
.	O

Keller	O
,	O
S	O
.	O

Orquin	O
,	O
G	O
.	O

Martín	O
,	O
T	O
.	O

Yamaguchi	O
,	O
A	O
.	O

McMahon	O
,	O
R	O
.	O

Masas	O
,	O
K.	O
,	O
Muneoka	O
,	O
A	O
.	O

Simeone	O
,	O
Hamada	O
H.	O
y	O
C	O
.	O

Niehrs	O
por	O
los	O
generosos	O
obsequios	O
de	O
clones	B-Sequence
y	O
anticuerpo	B-GENE
reactivos	B-Chemical
y	O
la	O
Dra	O
.	O
mi	O

Robertson	O
para	O
NdllacZ	O
ratones	B-Taxon
.	O

Nos	O
gustaría	O
agradecer	O
a	O
Kathy	O
Molyneaux	O
por	O
sus	O
útiles	O
sugerencias	O
y	O
asistencia	O
técnica	O
.	O

También	O
agradecemos	O
a	O
Vladimir	O
Vrbanac	O
,	O
Janice	O
Espínola	O
y	O
Edith	O
Toral	O
López	O
por	O
su	O
ayuda	O
con	O
animal	B-Taxon
agricultura	O

También	O
agradecemos	O
a	O
los	O
miembros	O
del	O
laboratorio	O
de	O
MacDonald	O
útiles	O
debates	O
durante	O
la	O
realización	O
de	O
este	O
trabajo	O
.	O

Este	O
trabajo	O
fue	O
apoyado	O
por	O
las	O
subvenciones	O
NINDS	O
NS32765	O
y	O
NS16367	O
,	O
y	O
subvenciones	O
de	O
la	O
Fundación	O
para	O
el	O
Cuidado	O
y	O
Curación	O
de	O
la	O
enfermedad	O
de	O
Huntington	O
y	O
con	O
el	O
apoyo	O
de	O
la	O
Coalición	O
para	O
la	O
Cura	O
y	O
la	O
Fundación	O
de	O
Enfermedades	O
Hereditarias	O
de	O
la	O
Huntington	O
's	O
Disease	O
Society	O
of	O
America	O
.	O

juliana	O
m.	O
Woda	O
recibió	O
la	O
Beca	O
Postdoctoral	O
Milton	O
Wexler	O
de	O
la	O
Fundación	O
de	O
Enfermedades	O
Hereditarias	O
.	O

Diabetes	O
insípida	O
en	O
Ratones	B-Taxon
con	O
un	O
Mutación	B-Sequence
en	O
acuaporina	B-Protein
-	I-Protein
2	I-Protein

Resumen	O

La	O
diabetes	O
insípida	O
nefrogénica	O
congénita	O
(	O
NDI	O
)	O
es	O
una	O
enfermedad	O
caracterizada	O
por	O
la	O
incapacidad	O
del	O
riñón	O
para	O
concentrar	O
la	O
orina	O
en	O
respuesta	O
a	O
vasopresina	B-Protein
.	O

Humano	B-Taxon
Se	O
ha	O
descubierto	O
que	O
las	O
familias	O
con	O
diabetes	O
insípida	O
nefrogénica	O
albergan	O
mutaciones	B-Sequence
en	O
el	O
receptor	B-Protein
de	I-Protein
vasopresina	I-Protein
2	I-Protein
(	O
Avpr2	B-Protein
)	O
gene	B-Sequence
o	O
la	O
vasopresina	B-Protein
#	O
¿NOMBRE	O
?	O
agua	B-Chemical
canal	O
acuaporina	B-Protein
-	I-Protein
2	I-Protein
(	O
Aqp2	B-Protein
)	O
gene	B-Sequence
.	O

El	O
desarrollo	O
de	O
un	O
tratamiento	O
se	O
hace	O
difícil	O
debido	O
a	O
la	O
falta	O
de	O
un	O
animal	B-Taxon
modelo	O

A	O
través	O
de	O
adelante	O
genético	B-Sequence
proyección	O
de	O
etilnitrosourea	B-Chemical
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
,	O
reportamos	O
la	O
identificación	O
y	O
caracterización	O
de	O
un	O
ratón	B-Taxon
modelo	O
de	O
NDI	O
,	O
con	O
un	O
F204V	O
mutación	B-Sequence
en	O
el	O
Aqp2	B-Protein
gene	B-Sequence
.	O

A	O
diferencia	O
de	O
lo	O
intentado	O
anteriormente	O
murino	B-Taxon
modelos	O
de	O
NDI	O
,	O
nuestro	O
ratones	B-Taxon
sobrevivir	O
hasta	O
la	O
edad	O
adulta	O
y	O
más	O
exactamente	O
recapitular	O
el	O
humano	B-Taxon
desorden	O

Experimentos	O
in	O
vitro	O
previos	O
usando	O
riñón	O
célula	B-Cell
las	O
líneas	O
sugieren	O
recesivo	O
Aqp2	B-Protein
mutaciones	B-Sequence
resultar	O
en	O
el	O
tráfico	O
indebido	O
de	O
los	O
mutante	B-Sequence
agua	B-Chemical
poro	O

Usando	O
estos	O
animales	B-Taxon
,	O
hemos	O
probado	O
directamente	O
esta	O
hipótesis	O
de	O
impropios	O
AQP2	B-Protein
translocación	O
como	O
el	O
molecular	B-Chemical
defecto	O
en	O
la	O
diabetes	O
insípida	O
nefrogénica	O
en	O
el	O
intacto	O
organismo	B-Taxon
.	O

Además	O
,	O
el	O
uso	O
de	O
un	O
riñón	O
célula	B-Cell
recta	O
mostramos	O
que	O
el	O
mutado	B-Sequence
proteína	B-Chemical
,	O
AQP2	B-Protein
-	O
F204V	O
,	O
queda	O
retenido	O
en	O
el	O
retículo	B-GENE
endoplásmico	I-GENE
que	O
esta	O
localización	O
anormal	O
puede	O
ser	O
rescatada	O
por	O
tipo	B-Sequence
salvaje	I-Sequence
proteína	B-Chemical
.	O

Esta	O
novela	O
ratón	B-Taxon
modelo	O
permite	O
más	O
estudios	O
mecanicistas	O
,	O
así	O
como	O
pruebas	O
de	O
farmacológico	O
y	O
gene	B-Sequence
terapias	O
para	O
NDI	O
.	O

Sinopsis	O

La	O
diabetes	O
insípida	O
nefrogénica	O
(	O
NDI	O
,	O
por	O
sus	O
siglas	O
en	O
inglés	O
)	O
es	O
una	O
enfermedad	O
caracterizada	O
por	O
micción	O
y	O
sed	O
excesivas	O
.	O

Normalmente	O
,	O
el	O
hipotálamo	O
detecta	O
situaciones	O
en	O
las	O
que	O
agua	B-Chemical
es	O
limitada	O
y	O
envía	O
señales	O
al	O
riñón	O
para	O
aumentar	O
agua	B-Chemical
reabsorción	O
de	O
la	O
orina	O
.	O

la	O
señalización	O
molécula	B-Chemical
secretada	O
por	O
el	O
hipotálamo	O
es	O
arginina	B-Protein
vasopresina	I-Protein
(	O
AVP	B-Protein
)	O
,	O
que	O
se	O
une	O
a	O
un	O
determinado	O
proteína	B-Chemical
sobre	O
el	O
superficie	B-GENE
de	I-GENE
las	I-GENE
células	I-GENE
renales	I-GENE
,	O
receptor	B-Protein
de	I-Protein
AVP	I-Protein
(	O
AVPR2	B-Protein
)	O
.	O

AVP	B-Protein
unión	O
a	O
su	O
receptor	O
en	O
el	O
riñón	O
células	B-Cell
comienza	O
una	O
serie	O
de	O
eventos	O
bioquímicos	O
que	O
finalmente	O
resultan	O
en	O
la	O
inserción	O
de	O
un	O
proteína	B-Chemical
,	O
acuaporina	B-Protein
2	I-Protein
(	O
AQP2	B-Protein
)	O
,	O
hacia	O
el	O
exterior	O
superficie	B-GENE
de	I-GENE
la	I-GENE
célula	I-GENE
renal	I-GENE
.	O

Como	O
su	O
nombre	O
lo	O
indica	O
,	O
AQP2	B-Protein
facilita	O
la	O
recaptación	O
de	O
agua	B-Chemical
de	O
la	O
orina	O
espacio	B-GENE
en	O
el	O
célula	B-Cell
,	O
concentrando	O
así	O
la	O
orina	O
y	O
conservando	O
agua	B-Chemical
.	O

La	O
NDI	O
congénita	O
es	O
causada	O
por	O
mutaciones	B-Sequence
en	O
cualquiera	O
de	O
los	O
dos	O
agua	B-Chemical
canal	O
,	O
AQP2	B-Protein
,	O
o	O
en	O
el	O
receptor	O
,	O
AVPR2	B-Protein
.	O

Mientras	O
estos	O
mutaciones	B-Sequence
han	O
sido	O
estudiados	O
extensamente	O
en	O
el	O
laboratorio	O
,	O
trabajan	O
en	O
vivo	O
animales	B-Taxon
ha	O
sido	O
muy	O
limitado	O
.	O

Este	O
informe	O
describe	O
la	O
primera	O
solución	O
viable	O
ratón	B-Taxon
modelo	O
de	O
NDI	O
.	O

Los	O
modelos	O
anteriores	O
han	O
sido	O
intentados	O
por	O
objetivos	O
mutación	B-Sequence
,	O
I	O
.	O
mi	O
.	O
,	O
genes	B-Sequence
que	O
se	O
sabe	O
que	O
están	O
involucrados	O
en	O
la	O
enfermedad	O
han	O
sido	O
alterado	B-Sequence
en	O
el	O
ratón	B-Taxon
,	O
un	O
llamado	O
reverso	O
genético	B-Sequence
Acercarse	O
.	O

Contrarrestar	O
genético	B-Sequence
hasta	O
ahora	O
los	O
enfoques	O
no	O
han	O
logrado	O
producir	O
una	O
solución	O
viable	O
ratón	B-Taxon
modelo	O
de	O
NDI	O
.	O

Aquí	O
los	O
autores	O
dan	O
un	O
paso	O
adelante	O
genético	B-Sequence
enfoque	O
en	O
el	O
que	O
genes	B-Sequence
están	O
mutado	B-Sequence
al	O
azar	O
y	O
animales	B-Taxon
se	O
analizan	O
para	O
detectar	O
propiedades	O
similares	O
a	O
enfermedades	O
.	O

Además	O
de	O
probar	O
hipótesis	O
que	O
provienen	O
de	O
estudios	O
de	O
laboratorio	O
,	O
este	O
modelo	O
abre	O
la	O
puerta	O
a	O
la	O
prueba	O
de	O
gene	B-Sequence
terapia	O
u	O
otras	O
terapias	O
para	O
el	O
tratamiento	O
de	O
NDI	O
.	O

Introducción	O

La	O
diabetes	O
insípida	O
nefrogénica	O
(	O
NDI	O
)	O
es	O
una	O
enfermedad	O
caracterizada	O
por	O
micción	O
y	O
sed	O
excesivas	O
,	O
a	O
pesar	O
de	O
la	O
producción	O
normal	O
del	O
antidiurético	O
hormona	B-Chemical
arginina	B-Protein
vasopresina	I-Protein
(	O
AVP	B-Protein
)	O
[	O
1	O
]	O
.	O

Las	O
formas	O
heredadas	O
son	O
X	B-GENE
#	O
¿NOMBRE	O
?	O
mutación	B-Sequence
de	O
El	O
Avpr2	B-Protein
gene	B-Sequence
[	O
2	O
]	O
,	O
o	O
autosómico	B-GENE
debido	O
a	O
mutación	B-Sequence
de	O
El	O
Aqp2	B-Protein
gene	B-Sequence
[	O
3	O
]	O
.	O

acuaporina	B-Protein
-	I-Protein
2	I-Protein
(	O
AQP2	B-Protein
)	O
es	O
un	O
poro	O
-	O
formando	O
proteína	B-Chemical
perteneciente	O
a	O
una	O
familia	O
de	O
agua	B-Chemical
canales	O
[	O
4	O
]	O
,	O
y	O
se	O
expresa	O
en	O
conducto	O
colector	O
principal	O
células	B-Cell
en	O
el	O
riñón	O
[	O
5	O
]	O
.	O

Generalmente	O
estos	O
proteinas	B-Chemical
permitir	O
el	O
paso	O
de	O
agua	B-Chemical
a	O
través	O
de	O
membrana	B-GENE
de	I-GENE
plasma	I-GENE
(	O
PM	B-GENE
)	O
de	O
células	B-Cell
,	O
varios	O
de	O
los	O
cuales	O
cumplen	O
este	O
rol	O
específicamente	O
en	O
el	O
proceso	O
de	O
agua	B-Chemical
reabsorción	O
de	O
la	O
orina	O
en	O
el	O
riñón	O
.	O

Se	O
ha	O
establecido	O
que	O
las	O
acuaporinas	O
,	O
aunque	O
funcionan	O
como	O
monómero	O
,	O
se	O
tetramerizan	O
antes	O
de	O
su	O
inserción	O
en	O
el	O
membrana	B-GENE
de	I-GENE
plasma	I-GENE
[	O
4	O
,	O
6	O
]	O
.	O

Además	O
estos	O
proteinas	B-Chemical
también	O
puede	O
ser	O
dirigido	O
diferencialmente	O
a	O
distintos	O
regiones	B-GENE
del	I-GENE
PM	I-GENE
;	O
por	O
ejemplo	O
,	O
AQP2	B-Protein
se	O
enruta	O
a	O
la	O
membrana	B-GENE
apical	I-GENE
de	I-GENE
las	I-GENE
células	I-GENE
que	O
rodea	O
el	O
conducto	O
colector	O
,	O
mientras	O
que	O
otras	O
acuaporinas	O
(	O
AQP3	B-Protein
o	O
4	O
)	O
se	O
insertan	O
en	O
la	O
cara	O
basolateral	O
.	O

A	O
diferencia	O
de	O
todos	O
los	O
demás	O
miembros	O
de	O
la	O
familia	O
,	O
AQP2	B-Protein
no	O
se	O
inserta	O
constitutivamente	O
en	O
el	O
membrana	B-GENE
de	I-GENE
plasma	I-GENE
.	O

En	O
condiciones	O
basales	O
,	O
el	O
proteína	B-Chemical
reside	O
en	O
subapical	O
vesículas	B-GENE
intracelulares	I-GENE
;	O
sin	O
embargo	O
,	O
bajo	O
condiciones	O
que	O
requieren	O
agua	B-Chemical
retencion	O
AQP2	B-Protein
se	O
traslada	O
a	O
la	O
membrana	B-GENE
apical	I-GENE
,	O
permitiendo	O
agua	B-Chemical
reabsorción	O
[	O
7	O
,	O
8	O
]	O
.	O

Para	O
que	O
ocurra	O
este	O
proceso	O
,	O
la	O
AVP	O
se	O
une	O
a	O
su	O
receptor	O
,	O
AVPR2	B-Protein
,	O
en	O
la	O
cara	O
basolateral	O
del	O
conducto	O
colector	O
células	B-Cell
,	O
lo	O
que	O
lleva	O
a	O
un	O
aumento	O
de	O
intracelular	B-GENE
acampar	B-Chemical
,	O
resultando	O
finalmente	O
en	O
la	O
fosforilación	O
de	O
AQP2	B-Protein
en	O
serina	B-Chemical
256	O
por	O
acampar	B-Chemical
#	O
¿NOMBRE	O
?	O
proteína	B-Chemical
quinasa	O
[	O
9	O
]	O
y	O
su	O
redistribución	O
al	O
membrana	B-GENE
de	I-GENE
plasma	I-GENE
.	O

La	O
importancia	O
de	O
AQP2	B-Protein
redistribución	O
ha	O
sido	O
destacada	O
por	O
la	O
caracterización	O
funcional	O
de	O
Aqp2	B-Protein
mutaciones	B-Sequence
resultando	O
en	O
NDI	O
severo	O
en	O
humanos	B-Taxon
[	O
3	O
,	O
10	O
]	O
.	O

Recesivo	O
Aqp2	B-Protein
mutaciones	B-Sequence
generalmente	O
se	O
cree	O
que	O
producen	O
una	O
lesión	O
anormalmente	O
localizada	O
y	O
,	O
en	O
la	O
mayoría	O
de	O
los	O
casos	O
,	O
mal	O
plegada	O
.	O
agua	B-Chemical
poro	O
que	O
responde	O
anormalmente	O
a	O
un	O
aumento	O
en	O
acampar	B-Chemical
[	O
6	O
,	O
11	O
]	O
.	O

Además	O
,	O
dominante	O
mutaciones	B-Sequence
han	O
sido	O
descritos	O
y	O
se	O
ha	O
encontrado	O
que	O
desvían	O
tanto	O
el	O
mutante	B-Sequence
y	O
el	O
tipo	B-Sequence
salvaje	I-Sequence
proteína	B-Chemical
al	O
membrana	B-GENE
basolateral	I-GENE
[	O
6	O
,	O
12	O
]	O
.	O

Varios	O
ratón	B-Taxon
se	O
han	O
generado	O
modelos	O
de	O
diabetes	O
insípida	O
[	O
13	O
-	O
17	O
]	O
.	O

En	O
un	O
intento	O
de	O
recapitular	O
humano	B-Taxon
NDI	O
,	O
ratones	B-Taxon
han	O
sido	O
generados	O
con	O
mutaciones	B-Sequence
en	O
Aqp2	B-Protein
y	O
Avpr2	B-Protein
[	O
15	O
,	O
18	O
]	O
.	O

Yang	O
y	O
sus	O
colegas	O
crearon	O
un	O
ratón	B-Taxon
con	O
un	O
golpe	O
T126M	O
-	O
en	O
mutación	B-Sequence
en	O
el	O
Aqp2	B-Protein
gene	B-Sequence
.	O

Inesperadamente	O
,	O
homocigoto	O
mutante	B-Sequence
ratones	B-Taxon
murió	O
dentro	O
de	O
los	O
6	O
días	O
posteriores	O
al	O
nacimiento	O
.	O

Curiosamente	O
,	O
AVPR2	B-Protein
#	O
¿NOMBRE	O
?	O

Juntos	O
,	O
estos	O
modelos	O
sugieren	O
que	O
el	O
ratón	B-Taxon
puede	O
ser	O
muy	O
sensible	O
organismo	B-Taxon
con	O
respecto	O
a	O
agua	B-Chemical
homeostasis	O
,	O
y	O
es	O
incapaz	O
de	O
sobrevivir	O
con	O
poliuria	O
.	O

en	O
un	O
delantero	O
genético	B-Sequence
pantalla	O
,	O
un	O
ratón	B-Taxon
con	O
un	O
Aqp2	B-Protein
mutación	B-Sequence
fue	O
identificado	O
.	O

El	O
propósito	O
de	O
este	O
estudio	O
fue	O
caracterizar	O
este	O
murino	B-Taxon
modelo	O
de	O
DI	O
nefrogénica	O
recesiva	O
.	O

Ahora	O
reportamos	O
un	O
novedoso	O
F204V	O
mutación	B-Sequence
en	O
el	O
Aqp2	B-Protein
gene	B-Sequence
.	O

Esta	O
alelo	B-Sequence
de	O
Aqp2	B-Protein
se	O
descubrió	O
que	O
causaba	O
la	O
primera	O
ratón	B-Taxon
modelo	O
de	O
NDI	O
para	O
sobrevivir	O
más	O
allá	O
de	O
la	O
primera	O
semana	O
de	O
vida	O
.	O

Molecular	B-Chemical
los	O
análisis	O
concluyeron	O
que	O
mutante	B-Sequence
AQP2	B-Protein
adopta	O
una	O
localización	O
subcelular	O
diferente	O
en	O
el	O
conducto	O
colector	O
renal	O
células	B-Cell
,	O
y	O
fue	O
resistente	O
a	O
la	O
translocación	O
inducida	O
por	O
desmopresina	O
,	O
un	O
agonista	B-Chemical
de	O
AVP	O
.	O

Estudios	O
in	O
vitro	O
usando	O
el	O
Madin	O
-	O
Darby	O
canino	B-Taxon
riñón	O
(	O
MDCK	O
)	O
célula	B-Cell
línea	O
demostró	O
una	O
retículo	B-GENE
endoplásmico	I-GENE
patrón	O
para	O
el	O
mutante	B-Sequence
proteína	B-Chemical
y	O
aparente	O
resistencia	O
a	O
la	O
translocación	O
.	O

Estos	O
datos	O
prueban	O
de	O
manera	O
concluyente	O
que	O
autosómico	B-GENE
El	O
NDI	O
recesivo	O
es	O
consecuencia	O
de	O
una	O
mala	O
AQP2	B-Protein
enrutamiento	O
en	O
el	O
intacto	O
mamífero	B-Taxon
.	O

Resultados	O

en	O
un	O
delantero	O
genético	B-Sequence
pantalla	O
que	O
usa	O
etilnitrosourea	B-Chemical
(	O
ENU	B-Chemical
)	O
inducir	O
mutaciones	B-Sequence
en	O
un	O
fundador	O
animal	B-Taxon
cuyos	O
descendientes	O
fueron	O
luego	O
examinados	O
para	O
el	O
metabolismo	O
anormal	O
de	O
todo	O
el	O
cuerpo	O
[	O
19	O
,	O
20	O
]	O
,	O
encontramos	O
una	O
familia	O
de	O
ratones	B-Taxon
que	O
orinaba	O
y	O
bebía	O
en	O
exceso	O
.	O

Los	O
análisis	O
de	O
suero	O
y	O
orina	O
mostraron	O
que	O
el	O
plasma	O
glucosa	B-Chemical
los	O
niveles	O
eran	O
normales	O
y	O
no	O
había	O
glucosa	B-Chemical
en	O
la	O
orina	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
este	O
fue	O
un	O
ejemplo	O
de	O
diabetes	O
insípida	O
.	O

El	O
desorden	O
en	O
estos	O
ratones	B-Taxon
segregado	O
en	O
un	O
monogénico	O
,	O
autosómico	B-GENE
manera	O
recesiva	O
,	O
haciendo	O
Aqp2	B-Protein
un	O
candidato	O
gene	B-Sequence
.	O

Secuenciación	O
de	O
Aqp2	B-Protein
región	B-Sequence
de	I-Sequence
codificación	I-Sequence
de	O
afectados	O
ratones	B-Taxon
identificado	O
un	O
Transversión	B-Sequence
de	I-Sequence
timina	I-Sequence
a	I-Sequence
guanina	I-Sequence
(	I-Sequence
T	I-Sequence
a	I-Sequence
G	I-Sequence
)	I-Sequence
(	O
Figura	O
1A	O
)	O
,	O
que	O
se	O
predice	O
que	O
conducirá	O
a	O
un	O
valina	B-Chemical
por	O
fenilalanina	B-Chemical
sustitución	B-Sequence
en	O
aminoácidos	B-Chemical
204	O
de	O
la	O
proteína	B-Chemical
(	O
F204V	O
)	O
.	O

AQP2	B-Protein
es	O
un	O
seis	O
-	O
transmembrana	B-GENE
agua	B-Chemical
canal	O
,	O
y	O
F204	O
se	O
encuentra	O
cerca	O
del	O
extracelular	B-GENE
cara	O
del	O
sexto	O
membrana	B-GENE
abarcando	O
dominio	B-Sequence
,	O
a	O
región	B-Sequence
rico	O
en	O
hidrófobo	O
aminoácidos	B-Chemical
.	O

esto	O
y	O
lo	O
otro	O
membrana	B-GENE
#	O
¿NOMBRE	O
?	O
dominios	B-Sequence
están	O
conservado	B-Sequence
entre	O
vertebrado	B-Taxon
especies	O

los	O
fenilalanina	B-Chemical
en	O
posición	B-Sequence
204	O
está	O
particularmente	O
bien	O
conservado	B-Sequence
(	O
Figura	O
1B	O
)	O
,	O
no	O
sólo	O
entre	O
vertebrado	B-Taxon
AQP2	B-Protein
proteinas	B-Chemical
,	O
pero	O
también	O
entre	O
otros	O
miembros	O
de	O
esta	O
familia	O
.	O

Aqp2F204V	O
/	O
F204V	O
ratones	B-Taxon
han	O
incrementado	O
dramáticamente	O
la	O
producción	O
de	O
orina	O
,	O
en	O
algunos	O
casos	O
produciendo	O
una	O
cantidad	O
de	O
orina	O
en	O
24	O
h	O
que	O
excede	O
su	O
peso	O
corporal	O
,	O
en	O
comparación	O
con	O
sus	O
heterocigotos	O
o	O
tipo	B-Sequence
salvaje	I-Sequence
compañeros	O
de	O
camada	O

Tal	O
pérdida	O
de	O
agua	B-Chemical
conduciría	O
rápidamente	O
a	O
la	O
deshidratación	O
si	O
no	O
fuera	O
compensada	O
por	O
un	O
aumento	O
agua	B-Chemical
ingesta	O

Por	O
supuesto	O
,	O
mutante	B-Sequence
ratones	B-Taxon
también	O
aumentan	O
dramáticamente	O
su	O
agua	B-Chemical
ingesta	O
(	O
Figura	O
1C	O
)	O
en	O
comparación	O
con	O
sus	O
heterocigotos	O
o	O
tipo	B-Sequence
salvaje	I-Sequence
compañeros	O
de	O
camada	O

Este	O
fenotipo	O
,	O
aumento	O
de	O
la	O
producción	O
de	O
orina	O
y	O
agua	B-Chemical
ingesta	O
--	O
mostró	O
concordancia	O
completa	O
con	O
la	O
homocigosidad	O
del	O
F204V	O
mutación	B-Sequence
en	O
el	O
58	O
animales	B-Taxon
probado	O

La	O
diabetes	O
insípida	O
se	O
puede	O
definir	O
como	O
la	O
incapacidad	O
para	O
concentrar	O
la	O
orina	O
cuando	O
sea	O
apropiado	O
.	O

Comparado	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
o	O
compañeros	O
de	O
camada	O
heterocigotos	O
,	O
Aqp2F204V	O
/	O
F204V	O
ratones	B-Taxon
producir	O
orina	O
muy	O
diluida	O
(	O
Figura	O
1D	O
)	O
.	O

Concentración	O
basal	O
de	O
orina	O
en	O
mutante	B-Sequence
ratones	B-Taxon
es	O
de	O
aproximadamente	O
161	O
mOsm	O
,	O
en	O
comparación	O
con	O
aproximadamente	O
1293	O
mOsm	O
en	O
tipo	B-Sequence
salvaje	I-Sequence
ratones	B-Taxon
(	O
pag	O
<	O
0	O
.	O
001	O
)	O
.	O

Normalmente	O
,	O
la	O
concentración	O
de	O
orina	O
está	O
bajo	O
el	O
control	O
del	O
hipotálamo	O
,	O
el	O
cual	O
,	O
en	O
respuesta	O
a	O
hipovolemia	O
o	O
hipernatremia	O
[	O
21	O
]	O
,	O
secreta	O
AVP	O
.	O

los	O
sintético	B-Sequence
Análogo	O
de	O
AVP	O
,	O
1	O
-	O
deamino	O
-	O
8	O
-	O
D	B-Chemical
-	I-Chemical
arginina	I-Chemical
vasopresina	O
(	O
dDAVP	O
;	O
también	O
llamada	O
desmopresina	O
)	O
,	O
es	O
un	O
potente	O
agonista	B-Chemical
de	O
AVPR2	B-Protein
.	O

Cuando	O
se	O
administra	O
a	O
tipo	B-Sequence
salvaje	I-Sequence
ratones	B-Taxon
,	O
dDAVP	O
lleva	O
a	O
un	O
aumento	O
dramático	O
en	O
la	O
concentración	O
de	O
orina	O
,	O
de	O
1	O
293	O
a	O
5	O
885	O
mOsm	O
(	O
4	O
,	O
6	O
veces	O
;	O
Figura	O
1D	O
)	O
.	O

Con	O
trato	O
similar	O
,	O
mutante	B-Sequence
ratones	B-Taxon
concentran	O
su	O
orina	O
en	O
un	O
grado	O
menor	O
pero	O
aún	O
significativo	O
,	O
de	O
161	O
a	O
470	O
mOsm	O
(	O
2	O
,	O
9	O
veces	O
)	O
,	O
lo	O
que	O
indica	O
que	O
estos	O
animales	B-Taxon
no	O
sólo	O
son	O
incapaces	O
de	O
concentrar	O
la	O
orina	O
adecuadamente	O
,	O
sino	O
que	O
también	O
tienen	O
una	O
respuesta	O
defectuosa	O
a	O
la	O
dDAVP	O
.	O

La	O
menor	O
respuesta	O
a	O
dDAVP	O
indica	O
alguna	O
actividad	O
residual	O
del	O
mutante	B-Sequence
canal	B-Protein
AQP2	I-Protein
,	O
que	O
debe	O
ser	O
suficiente	O
para	O
permitir	O
la	O
supervivencia	O
del	O
individual	B-Taxon
,	O
en	O
contraste	O
con	O
el	O
T126M	O
knock-in	O
ratón	B-Taxon
[	O
18	O
]	O
.	O

Múltiples	O
apareamientos	O
heterocigotos	O
produjeron	O
101	O
animales	B-Taxon
,	O
que	O
apareció	O
en	O
una	O
proporción	O
de	O
26	O
:	O
49	O
:	O
26	O
,	O
cerca	O
del	O
esperado	O
mendeliano	O
tipo	B-Sequence
salvaje	I-Sequence
,	O
heterocigoto	O
y	O
mutante	B-Sequence
frecuencias	O
,	O
respectivamente	O
,	O
lo	O
que	O
indica	O
que	O
no	O
hay	O
viabilidad	O
reducida	O
asociada	O
con	O
este	O
mutación	B-Sequence
.	O

Además	O
del	O
aumento	O
de	O
la	O
producción	O
de	O
orina	O
y	O
agua	B-Chemical
consumo	O
,	O
no	O
hubo	O
un	O
fenotipo	O
manifiesto	O
en	O
mutante	B-Sequence
ratones	B-Taxon
,	O
excepto	O
los	O
riñones	O
distendidos	O
,	O
que	O
aparecieron	O
de	O
forma	O
variable	O
en	O
adultos	O
animales	B-Taxon
(	O
Figura	O
2A	O
)	O
.	O

Aunque	O
no	O
se	O
mide	O
específicamente	O
,	O
mutante	B-Sequence
ratones	B-Taxon
parecen	O
tener	O
una	O
vida	O
útil	O
normal	O
.	O

El	O
único	O
animal	B-Taxon
que	O
se	O
siguió	O
vivió	O
hasta	O
los	O
18	O
meses	O
,	O
típico	O
de	O
animales	B-Taxon
en	O
nuestra	O
colonia	O
.	O

Aqp2F204V	O
/	O
F204V	O
ratones	B-Taxon
sufren	O
de	O
hidronefrosis	O
severa	O
(	O
Figura	O
2A	O
y	O
2B	O
)	O
,	O
presumiblemente	O
como	O
consecuencia	O
de	O
la	O
incapacidad	O
para	O
hacer	O
frente	O
a	O
la	O
poliuria	O
extrema	O
.	O

Encontramos	O
riñones	O
distendidos	O
en	O
todos	O
los	O
Aqp2F204V	O
/	O
F204V	O
ratones	B-Taxon
;	O
sin	O
embargo	O
,	O
el	O
grado	O
de	O
inflación	O
fue	O
variable	O
en	O
los	O
países	O
afectados	O
.	O
ratones	B-Taxon
y	O
empeoró	O
con	O
la	O
edad	O
.	O

Se	O
ha	O
observado	O
previamente	O
hidronefrosis	O
severa	O
en	O
doble	O
Aqp1	B-Protein
/	O
Aqp3	B-Protein
knockear	O
ratones	B-Taxon
[	O
17	O
]	O
,	O
y	O
aparece	O
a	O
las	O
6	O
semanas	O
.	O

Incluso	O
a	O
las	O
4	O
semanas	O
,	O
Aqp2F204V	O
/	O
F204V	O
ratones	B-Taxon
tenía	O
hidronefrosis	O
.	O

Secciones	O
histológicas	O
de	O
Aqp2F204V	O
/	O
F204V	O
ratones	B-Taxon
demostró	O
marcada	O
dilatación	O
de	O
la	O
pelvis	O
renal	O
pero	O
morfología	O
normal	O
del	O
uréter	O
(	O
Figura	O
2C	O
y	O
2D	O
)	O
.	O

En	O
particular	O
,	O
la	O
muscularis	O
propria	O
no	O
estaba	O
ni	O
hipertrofiada	O
ni	O
adelgazada	O
.	O

Había	O
el	O
aspecto	O
festoneado	O
normal	O
del	O
urotelio	O
,	O
y	O
este	O
epitelio	O
de	O
transición	O
tenía	O
un	O
grosor	O
normal	O
.	O

Había	O
adelgazamiento	O
del	O
riñón	O
medido	O
desde	O
la	O
cápsula	O
renal	O
hasta	O
la	O
pelvis	O
renal	O
.	O

Sin	O
embargo	O
,	O
las	O
características	O
morfológicas	O
de	O
los	O
glomérulos	O
y	O
los	O
túbulos	O
proximal/distal	O
no	O
eran	O
destacables	O
(	O
Figura	O
2D	O
)	O
.	O

Como	O
se	O
mostró	O
anteriormente	O
[	O
18	O
,	O
22	O
]	O
,	O
la	O
inmunotransferencia	O
reveló	O
tres	O
diferentes	B-Sequence
formas	I-Sequence
de	O
AQP2	B-Protein
,	O
debido	O
a	O
los	O
diferentes	O
grados	O
y	O
formas	O
de	O
glicosilación	O
(	O
Figura	O
3A	O
)	O
.	O

Informes	O
anteriores	O
han	O
demostrado	O
que	O
no	O
glicosilados	O
proteína	B-Chemical
aparece	O
como	O
una	O
banda	O
de	O
29	O
kDa	O
,	O
mientras	O
que	O
el	O
complejo	O
glicosilado	O
proteína	B-Chemical
corre	O
como	O
un	O
frotis	O
entre	O
35	O
y	O
45	O
kDa	O
.	O

Una	O
vida	O
corta	O
forma	B-Sequence
intermedia	I-Sequence
de	O
31	O
kDa	O
que	O
representa	O
el	O
núcleo	O
,	O
alto	O
-	O
manosa	B-Chemical
glicosilación	O
de	O
AQP2	B-Protein
es	O
evidente	O
a	O
partir	O
de	O
experimentos	O
de	O
etiquetado	O
de	O
persecución	O
de	O
pulsos	O
[	O
22	O
]	O
.	O

Comparado	O
con	O
el	O
de	O
los	O
riñones	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
animales	B-Taxon
,	O
AQP2	B-Protein
desde	O
mutante	B-Sequence
animales	B-Taxon
se	O
redujo	O
tanto	O
en	O
el	O
alto	O
molecular	B-Chemical
peso	O
,	O
difuso	O
formulario	B-Sequence
y	O
el	O
mas	O
bajo	O
molecular	B-Chemical
peso	O
formulario	B-Sequence
,	O
pero	O
enriquecido	O
en	O
el	O
intermedio	B-Sequence
molecular	B-Chemical
peso	O
formulario	B-Sequence
(	O
Figura	O
3A	O
)	O
.	O

heterocigoto	O
animales	B-Taxon
mostró	O
cantidades	O
intermedias	O
de	O
los	O
tres	O
formularios	B-Sequence
.	O

La	O
naturaleza	O
de	O
estos	O
glicosilados	O
formularios	B-Sequence
fue	O
revelado	O
por	O
digestión	O
con	O
endoglicosidasa	B-Protein
H	I-Protein
,	O
que	O
escinde	O
específicamente	O
manosa	B-Chemical
#	O
¿NOMBRE	O
?	O
proteína	B-Chemical
columna	O
vertebral	O
.	O

Tratamiento	O
de	O
endógenos	O
AQP2	B-Protein
de	O
riñones	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
,	O
heterocigotos	O
y	O
mutante	B-Sequence
animales	B-Taxon
afectó	O
específicamente	O
a	O
la	O
intermedio	B-Sequence
molecular	B-Chemical
peso	O
formulario	B-Sequence
(	O
Figura	O
3B	O
)	O
.	O

La	O
presencia	O
de	O
algunos	O
glicosilados	O
maduros	O
proteinas	B-Chemical
(	O
35	O
-	O
45	O
kDa	O
)	O
en	O
Aqp2F204V	O
/	O
F204V	O
ratones	B-Taxon
presumiblemente	O
permite	O
su	O
supervivencia	O
en	O
comparación	O
con	O
Aqp2T126M	O
/	O
T126M	O
ratones	B-Taxon
,	O
y	O
es	O
consistente	O
con	O
una	O
respuesta	O
disminuida	O
a	O
dDAVP	O
.	O

En	O
humanos	B-Taxon
,	O
recesivo	O
alelos	B-Sequence
de	O
Aqp2	B-Protein
se	O
postula	O
que	O
causan	O
NDI	O
porque	O
no	O
se	O
translocan	O
adecuadamente	O
al	O
superficie	B-GENE
celular	I-GENE
apical	I-GENE
en	O
respuesta	O
a	O
AVP	B-Protein
.	O

Este	O
postulado	O
proviene	O
únicamente	O
de	O
estudios	O
in	O
vitro	O
en	O
los	O
que	O
mutante	B-Sequence
Aqp2	B-Protein
ADNc	B-Sequence
correspondiente	O
a	O
humano	B-Taxon
enfermedad	O
mutaciones	B-Sequence
se	O
transfectan	O
en	O
riñón	O
célula	B-Cell
líneas	O
.	O

En	O
general	O
,	O
tales	O
recesivos	O
alelos	B-Sequence
,	O
cuando	O
se	O
visualizan	O
inmunocitoquímicamente	O
,	O
no	O
se	O
localizan	O
en	O
AVP	B-Protein
#	O
¿NOMBRE	O
?	O
vesículas	B-GENE
.	O

Más	O
bien	O
,	O
quedan	O
atrapados	O
en	O
el	O
retículo	B-GENE
endoplásmico	I-GENE
(	O
Urgencias	B-GENE
)	O
.	O

Nuestro	O
ratón	B-Taxon
modelo	O
de	O
NDI	O
ofrece	O
la	O
primera	O
oportunidad	O
de	O
probar	O
esta	O
hipótesis	O
en	O
un	O
maduro	O
animal	B-Taxon
.	O

Como	O
se	O
muestra	O
en	O
la	O
Figura	O
4A	O
(	O
fila	O
superior	O
de	O
microfotografías	O
)	O
,	O
AQP2	B-Protein
(	O
teñido	O
de	O
rojo	O
)	O
normalmente	O
localizado	O
en	O
el	O
subapical	O
región	B-GENE
de	I-GENE
las	I-GENE
células	I-GENE
del	I-GENE
conducto	I-GENE
colector	I-GENE
en	O
riñones	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
ratones	B-Taxon
.	O

Tras	O
la	O
estimulación	O
con	O
dDAVP	O
,	O
AQP2	B-Protein
trasladado	O
hacia	O
o	O
cerca	O
del	O
superficie	B-GENE
celular	I-GENE
(	O
Figura	O
4A	O
,	O
segunda	O
fila	O
)	O
.	O

En	O
riñones	O
tomados	O
de	O
mutante	B-Sequence
animales	B-Taxon
,	O
sin	O
embargo	O
,	O
AQP2	B-Protein
se	O
distribuyó	O
aleatoriamente	O
por	O
todo	O
el	O
célula	B-Cell
en	O
el	O
estado	O
basal	O
(	O
Figura	O
4A	O
,	O
tercera	O
fila	O
)	O
,	O
mientras	O
que	O
AQP3	B-Protein
(	O
verde	O
)	O
apropiadamente	O
localizado	O
en	O
el	O
basolateral	O
superficie	B-GENE
[	O
23	O
]	O
.	O

Además	O
,	O
tras	O
la	O
estimulación	O
con	O
dDAVP	O
,	O
AQP2	B-Protein
-	O
F204V	O
no	O
pudo	O
trasladarse	O
al	O
superficie	B-GENE
celular	I-GENE
(	O
Figura	O
4A	O
,	O
fila	O
inferior	O
)	O
.	O

Para	O
confirmar	O
estos	O
hallazgos	O
,	O
se	O
repitió	O
la	O
tinción	O
en	O
riñones	O
tomados	O
de	O
otros	O
dos	O
ratones	B-Taxon
para	O
cada	O
clase	O
,	O
tipo	B-Sequence
salvaje	I-Sequence
o	O
mutante	B-Sequence
,	O
con	O
o	O
sin	O
tratamiento	O
con	O
dDAVP	O
,	O
con	O
idénticos	O
resultados	O
.	O

Para	O
investigar	O
el	O
mecanismo	O
de	O
translocación	O
defectuosa	O
de	O
AQP2	B-Protein
-	O
F204V	O
,	O
recurrimos	O
a	O
la	O
transfección	O
de	O
MDCK	O
células	B-Cell
.	O

Estable	O
célula	B-Cell
lineas	O
expresando	O
ratón	B-Protein
salvaje	I-Protein
-	I-Protein
tipo	I-Protein
AQP2	I-Protein
y	I-Protein
AQP2	I-Protein
-	O
Se	O
establecieron	O
F204V	O
.	O

inmunotransferencias	O
de	O
proteína	B-Chemical
extractos	O
de	O
establo	O
célula	B-Cell
líneas	O
mostraron	O
que	O
MDCK	O
células	B-Cell
recapitular	O
el	O
defecto	O
de	O
glicosilación	O
visto	O
en	O
mutante	B-Sequence
ratones	B-Taxon
(	O
datos	O
no	O
publicados	O
)	O
.	O

los	O
tipo	B-Sequence
salvaje	I-Sequence
proteína	B-Chemical
volvió	O
a	O
estar	O
presente	O
en	O
tres	O
diferentes	B-Sequence
formas	I-Sequence
.	O

Células	B-Cell
expresando	O
AQP2	B-Protein
-	O
F204V	O
carecía	O
de	O
los	O
35	O
-	O
45	O
kDa	O
formulario	B-Sequence
y	O
fueron	O
enriquecidos	O
en	O
el	O
núcleo	O
-	O
glicosilados	O
de	O
31	O
kDa	O
formulario	B-Sequence
.	O

En	O
MDCK	O
transfectada	O
y	O
no	O
estimulada	O
células	B-Cell
,	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
(	O
teñido	O
de	O
verde	O
)	O
apareció	O
en	O
un	O
patrón	O
punteado	O
distribuido	O
a	O
lo	O
largo	O
de	O
la	O
región	O
subapical	O
(	O
Figura	O
4B	O
,	O
fotomicrografías	O
de	O
la	O
columna	O
izquierda	O
)	O
,	O
consistente	O
con	O
vesicular	B-GENE
compartimentación	O
.	O

AQP2	B-Protein
-	O
F204V	O
,	O
en	O
cambio	O
,	O
aparecía	O
de	O
forma	O
punteada	O
pero	O
perinuclear	B-GENE
patrón	O
(	O
Figura	O
4B	O
,	O
tercera	O
columna	O
)	O
.	O

Tras	O
la	O
estimulación	O
con	O
forskoline	O
,	O
un	O
acampar	B-Chemical
#	O
¿NOMBRE	O
?	O
proteína	B-Chemical
activador	O
de	O
quinasa	O
,	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
trasladado	O
a	O
la	O
superficie	B-GENE
apical	I-GENE
de	I-GENE
células	I-GENE
MDCK	I-GENE
polarizadas	I-GENE
(	O
Figura	O
4B	O
,	O
segunda	O
columna	O
)	O
.	O

A	O
lo	O
largo	O
del	O
eje	O
z	O
,	O
el	O
perinuclear	B-GENE
distribución	O
de	O
AQP2	B-Protein
-F204V	O
se	O
vio	O
claramente	O
,	O
y	O
esta	O
distribución	O
no	O
se	O
ve	O
alterada	O
por	O
la	O
forskoline	O
(	O
Figura	O
4B	O
,	O
fila	O
inferior	O
,	O
dos	O
columnas	O
de	O
la	O
derecha	O
)	O
.	O

los	O
perinuclear	B-GENE
distribución	O
de	O
AQP2	B-Protein
-	O
F204V	O
es	O
consistente	O
con	O
un	O
Urgencias	B-GENE
compartimentación	O
.	O

Para	O
probar	O
la	O
idea	O
de	O
que	O
AQP2	B-Protein
-	O
F204V	O
se	O
localiza	O
en	O
el	O
Urgencias	B-GENE
co-manchamos	O
células	B-Cell
transfectado	O
con	O
Aqp2F204V	O
(	O
ADNc	B-Sequence
)	O
por	O
AQP2	B-Protein
y	O
un	O
Urgencias	B-GENE
marcador	O
,	O
calnexina	B-Protein
(	O
Figura	O
4C	O
)	O
.	O

Colocalización	O
de	O
calnexina	B-Protein
con	O
AQP2	B-Protein
fue	O
investigado	O
directamente	O
,	O
y	O
se	O
encontró	O
que	O
el	O
80	O
%	O
de	O
todos	O
AQP2	B-Protein
-	O
F204V	O
proteína	B-Chemical
colocalizado	O
con	O
calnexina	B-Protein
.	O

El	O
20	O
%	O
restante	O
apareció	O
en	O
la	O
periferia	O
de	O
la	O
Urgencias	B-GENE
,	O
representando	O
AQP2	B-Protein
-	O
F204V	O
que	O
potencialmente	O
había	O
progresado	O
más	O
allá	O
del	O
Urgencias	B-GENE
.	O

``	O
Esta	O
``	O
''	O
''	O
Urgencias	B-GENE
``	O
escape	O
``	O
''	O
fue	O
consistente	O
con	O
la	O
pequeña	O
proporción	O
de	O
glicosilados	O
complejos	O
maduros	O
,	O
''	O
AQP2	B-Protein
-	O
F204V	O
en	O
mutante	B-Sequence
riñones	O
(	O
ver	O
Figura	O
3A	O
)	O
.	O

animales	B-Taxon
heterocigoto	O
para	O
Aqp2F204V	O
mutación	B-Sequence
no	O
se	O
vieron	O
afectados	O
en	O
su	O
producción	O
de	O
orina	O
o	O
la	O
osmolalidad	O
de	O
la	O
orina	O
(	O
ver	O
Figura	O
1C	O
y	O
1D	O
)	O
.	O

También	O
se	O
ha	O
demostrado	O
que	O
un	O
NDI	O
recesivo	O
alelo	B-Sequence
,	O
AQP2	B-Protein
-	O
R187C	O
,	O
no	O
interacciona	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
proteína	B-Chemical
en	O
ovocitos	B-Cell
[	O
24	O
]	O
,	O
ni	O
se	O
homo	O
-	O
oligomeriza	O
en	O
MDCK	O
células	B-Cell
[	O
22	O
]	O
.	O

Por	O
lo	O
tanto	O
,	O
los	O
riñones	O
de	O
heterocigotos	O
animales	B-Taxon
fueron	O
examinados	O
en	O
busca	O
de	O
evidencia	O
de	O
dos	O
poblaciones	O
de	O
AQP2	B-Protein
proteína	B-Chemical
.	O

Sorprendentemente	O
,	O
la	O
tinción	O
inmunohistoquímica	O
de	O
los	O
túbulos	O
colectores	O
renales	O
de	O
Aqp2F204V	O
/	O
+	B-Sequence
ratones	B-Taxon
reveló	O
un	O
patrón	O
notablemente	O
similar	O
a	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
Figura	O
5A	O
)	O
.	O

AQP2	B-Protein
trasladado	O
por	O
completo	O
a	O
la	O
superficie	B-GENE
celular	I-GENE
apical	I-GENE
tras	O
la	O
estimulación	O
con	O
dDAVP	O
.	O

Esta	O
tipo	B-Sequence
salvaje	I-Sequence
patrón	O
de	O
tinción	O
puede	O
reflejar	O
simplemente	O
el	O
hecho	O
de	O
que	O
la	O
disminución	O
de	O
la	O
cantidad	O
de	O
mutante	B-Sequence
proteína	B-Chemical
a	O
la	O
mitad	O
lo	O
hace	O
indetectable	O
por	O
inmunocitoquímica	O
.	O

Alternativamente	O
,	O
la	O
presencia	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
proteína	B-Chemical
puede	O
alterar	O
la	O
localización	O
de	O
la	O
mutante	B-Sequence
proteína	B-Chemical
.	O

``	O
De	O
hecho	O
,	O
Hendriks	O
et	O
al	O
.	O
propuso	O
un	O
mecanismo	O
``	O
''	O
piggy-back	O
''	O
''	O
para	O
explicar	O
el	O
transporte	O
de	O
subunidades	O
no	O
glicosiladas	O
de	O
''	O
AQP2	B-Protein
al	O
superficie	B-GENE
celular	I-GENE
por	O
subunidades	O
glicosiladas	O
[	O
22	O
]	O
.	O

También	O
se	O
ha	O
demostrado	O
que	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
proteína	B-Chemical
puede	O
rescatar	O
una	O
translocación	O
-	O
defectuosa	O
mutante	B-Sequence
proteína	B-Chemical
,	O
AQP2	B-Protein
-	O
P262L	O
,	O
cuando	O
los	O
dos	O
se	O
coexpresan	O
en	O
MDCK	O
células	B-Cell
[	O
25	O
]	O
.	O

En	O
los	O
conductos	O
colectores	O
de	O
Aqp2F204V	O
/	O
+	B-Sequence
ratones	B-Taxon
,	O
los	O
tipo	B-Sequence
salvaje	I-Sequence
puede	O
rescatar	O
a	O
la	O
mutante	B-Sequence
proteína	B-Chemical
como	O
lo	O
sugiere	O
la	O
distribución	O
subcelular	O
de	O
AQP2	B-Protein
proteína	B-Chemical
.	O

Para	O
probar	O
esta	O
idea	O
,	O
primero	O
buscamos	O
una	O
interacción	O
entre	O
mutante	B-Sequence
y	O
tipo	B-Sequence
salvaje	I-Sequence
proteinas	B-Chemical
en	O
MDCK	O
transfectada	O
células	B-Cell
(	O
Figura	O
5B	O
)	O
.	O

MDCK	O
células	B-Cell
expresando	O
de	O
manera	O
estable	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
fueron	O
transfectados	O
transitoriamente	O
con	O
expresión	O
de	O
GFP	O
construcciones	B-Sequence
codificación	O
GFP	O
-	O
etiquetado	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
,	O
AQP2	B-Protein
-F204V	O
,	O
o	O
GFP	O
solo	O
.	O

anticuerpos	B-GENE
contra	O
GFP	O
coinmunoprecipitado	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
Cuándo	O
AQP2	B-Protein
#	O
¿NOMBRE	O
?	O
AQP2	B-Protein
-	O
F204V	O
-	O
GFP	O
se	O
transfectó	O
transitoriamente	O
,	O
pero	O
no	O
cuando	O
GFP	O
por	O
sí	O
mismo	O
se	O
transfectó	O
transitoriamente	O
en	O
MDCK	O
células	B-Cell
expresando	O
de	O
manera	O
estable	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
(	O
Figura	O
5B	O
,	O
transferencias	O
superiores	O
)	O
.	O

Western	O
blot	O
del	O
total	O
membranas	B-GENE
mostró	O
que	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
se	O
expresa	O
de	O
manera	O
equivalente	O
en	O
los	O
tres	O
casos	O
(	O
Figura	O
5B	O
,	O
transferencias	O
inferiores	O
)	O
.	O

Si	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
mutante	B-Sequence
proteinas	B-Chemical
de	O
hecho	O
están	O
interactuando	O
en	O
el	O
célula	B-Cell
,	O
¿es	O
esta	O
interacción	O
suficiente	O
para	O
rescatar	O
la	O
localización	O
de	O
mutante	B-Sequence
proteína	B-Chemical
?	O

Para	O
responder	O
a	O
esta	O
pregunta	O
,	O
usamos	O
MDCK	O
células	B-Cell
establemente	O
transfectado	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
expresando	O
vector	B-Sequence
o	O
con	O
vacío	O
vector	B-Sequence
.	O

Además	O
de	O
estos	O
,	O
transfectamos	O
transitoriamente	O
AQP2	B-Protein
#	O
¿NOMBRE	O
?	O
AQP2	B-Protein
-	O
F204V	O
-	O
expresión	O
GFP	O
construcciones	B-Sequence
.	O

AQP2	B-Protein
#	O
¿NOMBRE	O
?	O
superficie	B-GENE
apical	I-GENE
tras	O
la	O
estimulación	O
con	O
forskoline	O
,	O
si	O
se	O
transfectó	O
transitoriamente	O
en	O
vector	B-Sequence
#	O
¿NOMBRE	O
?	O
células	B-Cell
(	O
Figura	O
5C	O
,	O
imágenes	O
superior	O
izquierda	O
)	O
o	O
en	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
células	B-Cell
(	O
Figura	O
5C	O
,	O
arriba	O
a	O
la	O
derecha	O
)	O
.	O

AQP2	B-Protein
-	O
F204V	O
-	O
GFP	O
,	O
cuando	O
se	O
expresa	O
por	O
transfección	O
transitoria	O
en	O
vector	B-Sequence
solamente	O
células	B-Cell
mostró	O
una	O
difusa	O
citoplasmático	B-GENE
patrón	O
de	O
distribución	O
(	O
Figura	O
5C	O
,	O
abajo	O
a	O
la	O
izquierda	O
)	O
.	O

Cuando	O
se	O
expresa	O
en	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
células	B-Cell
,	O
sin	O
embargo	O
,	O
AQP2	B-Protein
-	O
F204V	O
-	O
GFP	O
localizado	O
en	O
el	O
superficie	B-GENE
apical	I-GENE
en	O
diversos	O
grados	O
(	O
Figura	O
5C	O
,	O
imágenes	O
abajo	O
a	O
la	O
derecha	O
[	O
i-iii	O
]	O
)	O
.	O

Las	O
imágenes	O
inferiores	O
a	O
la	O
derecha	O
de	O
la	O
Figura	O
5C	O
muestran	O
tres	O
células	B-Cell
de	O
una	O
sola	O
transfección	O
.	O

El	O
primero	O
es	O
un	O
no	O
transfectado	O
célula	B-Cell
que	O
muestra	O
la	O
localización	O
de	O
la	O
expresión	O
estable	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
,	O
cual	O
es	O
apical	B-GENE
tras	O
la	O
estimulación	O
con	O
forskoline	O
.	O

Los	O
dos	O
siguientes	O
muestran	O
la	O
expresión	O
tanto	O
del	O
establo	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
y	O
el	O
transitorio	O
AQP2	B-Protein
-F204V-GFP	O
.	O

En	O
célula	B-Cell
(	O
ii	O
)	O
,	O
localización	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
era	O
indistinguible	O
de	O
AQP2	B-Protein
-F204V-GFP	O
;	O
ambos	O
eran	O
apical	B-GENE
tras	O
la	O
estimulación	O
con	O
forskoline	O
.	O

Aunque	O
el	O
efecto	O
fue	O
sutil	O
en	O
célula	B-Cell
(	O
iii	O
)	O
,	O
AQP2	B-Protein
-	O
F204V	O
-	O
GFP	O
se	O
localizó	O
parcialmente	O
en	O
el	O
superficie	B-GENE
apical	I-GENE
.	O

En	O
general	O
,	O
la	O
localización	O
de	O
AQP2	B-Protein
-	O
F204V	O
-	O
GFP	O
fue	O
claramente	O
más	O
apical	B-GENE
Cuándo	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
también	O
se	O
expresó	O
.	O

Para	O
confirmar	O
estos	O
resultados	O
bioquímicamente	O
,	O
transfectamos	O
el	O
mismo	O
célula	B-Cell
líneas	O
(	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
o	O
vector	B-Sequence
)	O
con	O
F204V	O
-	O
GFP	O
,	O
biotinilado	O
superficie	B-GENE
proteinas	B-Chemical
después	O
de	O
la	O
estimulación	O
con	O
forskoline	O
,	O
y	O
precipitó	O
el	O
biotinilado	O
proteinas	B-Chemical
(	O
Figura	O
5D	O
)	O
.	O

AQP2	B-Protein
-	O
F204V	O
-	O
GFP	O
se	O
expresa	O
aproximadamente	O
por	O
igual	O
en	O
ambos	O
célula	B-Cell
líneas	O
(	O
Figura	O
5D	O
,	O
total	O
células	B-Cell
)	O
,	O
pero	O
se	O
biotinila	O
solo	O
cuando	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
también	O
se	O
expresa	O
(	O
Figura	O
5D	O
,	O
superficie	B-GENE
biotinilado	O
)	O
.	O

Ya	O
que	O
solo	O
superficie	B-GENE
celular	I-GENE
proteinas	B-Chemical
son	O
accesibles	O
a	O
biotina	B-Chemical
,	O
estos	O
resultados	O
indican	O
que	O
AQP2	B-Protein
-	O
F204V	O
es	O
transportado	O
al	O
superficie	B-GENE
celular	I-GENE
Cuándo	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
está	O
presente	O
,	O
pero	O
no	O
por	O
sí	O
solo	O
.	O

Discusión	O

Aqp2F204	O
/	O
F204V	O
ratones	B-Taxon
son	O
viables	O
y	O
crecen	O
y	O
se	O
reproducen	O
normalmente	O
.	O

Sin	O
embargo	O
,	O
tienen	O
un	O
defecto	O
grave	O
en	O
su	O
capacidad	O
para	O
concentrar	O
la	O
orina	O
,	O
lo	O
que	O
provoca	O
un	O
aumento	O
de	O
la	O
producción	O
de	O
orina	O
y	O
agua	B-Chemical
ingesta	O
,	O
convirtiéndolos	O
así	O
en	O
los	O
primeros	O
ratón	B-Taxon
modelo	O
de	O
NDI	O
para	O
sobrevivir	O
hasta	O
la	O
madurez	O
.	O

En	O
humanos	B-Taxon
,	O
NDI	O
es	O
causado	O
por	O
mutaciones	B-Sequence
en	O
Avpr2	B-Protein
o	O
Aqp2	B-Protein
.	O

nocaut	O
de	O
la	O
X	B-GENE
#	O
¿NOMBRE	O
?	O
Gen	B-Protein
avpr2	I-Protein
en	I-Protein
ratones	I-Protein
[	O
15	O
]	O
dio	O
un	O
fenotipo	O
similar	O
al	O
NDI	O
en	O
neonatos	O
hemicigóticos	O
masculinos	O
,	O
pero	O
el	O
fenotipo	O
no	O
pudo	O
evaluarse	O
en	O
adultos	O
como	O
el	O
ratones	B-Taxon
murió	O
dentro	O
de	O
1	O
semana	O
de	O
nacimiento	O
.	O

Las	O
hembras	O
heterocigotas	O
adultas	O
mostraron	O
una	O
tendencia	O
leve	O
hacia	O
un	O
aumento	O
de	O
la	O
producción	O
de	O
orina	O
y	O
agua	B-Chemical
ingesta	O
y	O
disminución	O
de	O
la	O
osmolalidad	O
de	O
la	O
orina	O
.	O

nocaut	O
de	O
la	O
ratón	B-Protein
Aqp2	I-Protein
gene	B-Sequence
no	O
ha	O
sido	O
reportado	O
.	O

Un	O
golpe	O
-	O
en	O
de	O
un	O
humano	B-Taxon
enfermedad	O
-	O
causando	O
mutación	B-Sequence
(	O
T126M	O
)	O
,	O
sin	O
embargo	O
,	O
se	O
ha	O
realizado	O
[	O
18	O
]	O
.	O

Estas	O
ratones	B-Taxon
tiene	O
un	O
defecto	O
grave	O
de	O
concentración	O
de	O
orina	O
que	O
resulta	O
en	O
deshidratación	O
y	O
muerte	O
dentro	O
de	O
la	O
primera	O
semana	O
después	O
del	O
nacimiento	O
.	O

curiosamente	O
AQP2	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
.	O

La	O
morfología	O
del	O
conducto	O
colector	O
sumamente	O
anormal	O
hace	O
que	O
sea	O
imposible	O
identificar	O
con	O
precisión	O
el	O
molecular	B-Chemical
defecto	O
en	O
estos	O
golpes	O
-	O
en	O
ratones	B-Taxon
.	O

El	O
toque	O
T126M	O
muestra	O
claramente	O
que	O
Aqp2	B-Protein
es	O
un	O
esencial	O
gene	B-Sequence
[	O
18	O
]	O
.	O

El	O
hecho	O
de	O
que	O
nuestro	O
ratones	B-Taxon
sobrevivir	O
muestra	O
que	O
AQP2	B-Protein
-	O
F204V	O
posee	O
algunos	O
residuos	O
agua	B-Chemical
capacidad	O
de	O
transporte	O
o	O
que	O
hay	O
AVP	B-Protein
#	O
¿NOMBRE	O
?	O
agua	B-Chemical
reabsorción	O

Actividad	O
residual	O
de	O
AQP2	B-Protein
-	O
F204V	O
es	O
probable	O
,	O
ya	O
que	O
mutante	B-Sequence
animales	B-Taxon
muestran	O
una	O
pequeña	O
respuesta	O
a	O
dDAVP	O
,	O
aunque	O
la	O
osmolalidad	O
de	O
la	O
orina	O
estimulada	O
por	O
dDAVP	O
sigue	O
siendo	O
bastante	O
baja	O
.	O

La	O
inmunotinción	O
del	O
riñón	O
muestra	O
que	O
AQP2	B-Protein
-	O
F204V	O
no	O
transporta	O
eficientemente	O
agua	B-Chemical
,	O
porque	O
no	O
se	O
localiza	O
en	O
el	O
superficie	B-GENE
celular	I-GENE
apical	I-GENE
después	O
del	O
tratamiento	O
con	O
dDAVP	O
.	O

Alguna	O
actividad	O
residual	O
de	O
AQP2	B-Protein
implicaría	O
que	O
alguna	O
porción	O
pequeña	O
e	O
indetectable	O
del	O
mutante	B-Sequence
proteína	B-Chemical
está	O
llegando	O
a	O
la	O
superficie	B-GENE
celular	I-GENE
.	O

los	O
superficie	B-GENE
experimento	O
de	O
biotinilación	O
(	O
Figura	O
5D	O
)	O
sugiere	O
que	O
no	O
mutante	B-Sequence
proteína	B-Chemical
llega	O
a	O
la	O
superficie	B-GENE
,	O
pero	O
esto	O
no	O
refleja	O
necesariamente	O
la	O
situación	O
in	O
vivo	O
.	O

Si	O
bien	O
esta	O
pequeña	O
fracción	O
de	O
proteína	B-Chemical
puede	O
no	O
ser	O
detectable	O
por	O
inmunofluorescencia	O
,	O
la	O
transferencia	O
Western	O
muestra	O
que	O
algunos	O
mutante	B-Sequence
proteína	B-Chemical
progresa	O
más	O
allá	O
de	O
la	O
Urgencias	B-GENE
(	O
35	O
-	O
45kDa	O
especies	B-Sequence
en	O
la	O
Figura	O
3A	O
)	O
.	O

Comparado	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
,	O
mutante	B-Sequence
proteína	B-Chemical
se	O
enriquece	O
en	O
lo	O
alto	O
-	O
manosa	B-Chemical
,	O
núcleo	O
-	O
glicosilado	O
formulario	B-Sequence
(	O
31	O
kDa	O
)	O
y	O
deficiente	O
en	O
glicosilados	O
no	O
glicosilados	O
(	O
29	O
kDa	O
)	O
y	O
complejos	O
(	O
35	O
-	O
45	O
kDa	O
)	O
formularios	B-Sequence
.	O

La	O
presencia	O
de	O
una	O
cantidad	O
reducida	O
pero	O
detectable	O
de	O
proteína	B-Chemical
en	O
el	O
rango	O
de	O
35	O
-	O
45	O
kDa	O
indica	O
que	O
mutante	B-Sequence
proteína	B-Chemical
es	O
transportado	O
fuera	O
del	O
Urgencias	B-GENE
,	O
pero	O
con	O
una	O
eficiencia	O
muy	O
reducida	O
.	O

Colocalización	O
de	O
AQP2	B-Protein
-	O
F204V	O
con	O
el	O
Urgencias	B-GENE
proteína	B-Chemical
calnexina	B-Protein
en	O
MDCK	O
transfectada	O
células	B-Cell
muestra	O
que	O
,	O
mientras	O
que	O
la	O
mayoría	O
de	O
los	O
mutante	B-Sequence
proteína	B-Chemical
está	O
atrapado	O
en	O
el	O
Urgencias	B-GENE
,	O
algunos	O
progresan	O
más	O
allá	O
del	O
Urgencias	B-GENE
.	O

Respuesta	O
disminuida	O
a	O
dDAVP	O
,	O
abundancia	O
disminuida	O
de	O
glicosilados	O
maduros	O
proteína	B-Chemical
en	O
mutante	B-Sequence
animales	B-Taxon
,	O
y	O
el	O
transporte	O
de	O
una	O
fracción	O
de	O
mutante	B-Sequence
proteína	B-Chemical
más	O
allá	O
de	O
Urgencias	B-GENE
en	O
MDCK	O
células	B-Cell
son	O
todas	O
consistentes	O
con	O
la	O
noción	O
de	O
que	O
AQP2	B-Protein
-	O
El	O
mal	O
plegado	O
de	O
F204V	O
es	O
limitado	O
y	O
puede	O
retener	O
algunos	O
residuos	O
agua	B-Chemical
actividad	O
de	O
transporte	O
.	O

Evidentemente	O
,	O
esta	O
actividad	O
residual	O
es	O
suficiente	O
para	O
la	O
viabilidad	O
y	O
el	O
crecimiento	O
de	O
mutante	B-Sequence
animales	B-Taxon
.	O

Reducción	O
de	O
la	O
eficiencia	O
al	O
salir	O
del	O
Urgencias	B-GENE
puede	O
explicar	O
por	O
qué	O
AQP2	B-Protein
-	O
F204V	O
está	O
enriquecido	O
en	O
el	O
alto	O
de	O
31	O
kDa	O
-	O
manosa	B-Chemical
glicosilado	O
formulario	B-Sequence
.	O

La	O
altura	O
-	O
manosa	B-Chemical
centro	O
oligosacárido	B-Chemical
se	O
agrega	O
en	O
el	O
Urgencias	B-GENE
y	O
es	O
mas	O
tarde	O
modificado	B-Sequence
y	O
elaborado	O
en	O
el	O
aparato	B-GENE
de	I-GENE
Golgi	I-GENE
[	O
26	O
]	O
.	O

El	O
aumento	O
en	O
el	O
alto	O
-	O
manosa	B-Chemical
glicosilado	O
formulario	B-Sequence
de	O
AQP2	B-Protein
-	O
F204V	O
puede	O
reflejar	O
simplemente	O
su	O
presencia	O
prolongada	O
en	O
el	O
Urgencias	B-GENE
y	O
exposición	O
a	O
oligosacarilo	B-Chemical
transferasa	O

Si	O
bien	O
la	O
localización	O
incorrecta	O
de	O
AQP2	B-Protein
explica	O
el	O
fenotipo	O
del	O
homocigoto	O
mutante	B-Sequence
ratones	B-Taxon
,	O
la	O
falta	O
total	O
de	O
un	O
fenotipo	O
en	O
heterocigotos	O
ratones	B-Taxon
es	O
más	O
difícil	O
de	O
explicar	O
.	O

Fisiológicamente	O
,	O
heterocigoto	O
ratones	B-Taxon
no	O
tienen	O
síntomas	O
(	O
ver	O
Figura	O
1C	O
)	O
,	O
y	O
son	O
indistinguibles	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
sobre	O
inmunotinción	O
de	O
riñones	O
(	O
Figura	O
5A	O
)	O
.	O

La	O
presencia	O
del	O
50	O
%	O
de	O
la	O
cantidad	O
normal	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
proteína	B-Chemical
puede	O
explicar	O
la	O
falta	O
de	O
síntomas	O
,	O
pero	O
no	O
puede	O
explicar	O
la	O
falta	O
de	O
Urgencias	B-GENE
#	O
¿NOMBRE	O
?	O
mutante	B-Sequence
proteína	B-Chemical
.	O

Más	O
bien	O
,	O
el	O
fenotipo	O
del	O
Aqp2F204V	O
/	O
+	B-Sequence
animales	B-Taxon
sugiere	O
que	O
el	O
mutante	B-Sequence
proteína	B-Chemical
está	O
siendo	O
rescatado	O
por	O
el	O
tipo	B-Sequence
salvaje	I-Sequence
proteína	B-Chemical
.	O

De	O
hecho	O
,	O
de	O
Mattia	O
et	O
al	O
.	O

(	O
26	O
)	O
han	O
demostrado	O
que	O
uno	O
recesivo	O
alelo	B-Sequence
de	O
Aqp2	B-Protein
,	O
P262L	O
,	O
no	O
se	O
transloca	O
correctamente	O
cuando	O
se	O
expresa	O
por	O
sí	O
mismo	O
en	O
MDCK	O
células	B-Cell
,	O
pero	O
que	O
en	O
presencia	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
proteína	B-Chemical
,	O
se	O
localiza	O
normalmente	O
.	O

El	O
mismo	O
mecanismo	O
parece	O
aplicarse	O
in	O
vivo	O
con	O
Aqp2F204V	O
/	O
+	B-Sequence
ratones	B-Taxon
.	O

En	O
apoyo	O
de	O
esto	O
,	O
AQP2	B-Protein
-	O
F204V	O
puede	O
interactuar	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
(	O
Figura	O
5B	O
)	O
,	O
y	O
cuando	O
se	O
coexpresa	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
proteína	B-Chemical
,	O
AQP2	B-Protein
-	O
F204V	O
puede	O
alcanzar	O
el	O
superficie	B-GENE
celular	I-GENE
(	O
Figura	O
5C	O
panel	O
inferior	O
derecho	O
y	O
5D	O
)	O
.	O

Aunque	O
se	O
ha	O
demostrado	O
que	O
un	O
recesivo	O
alelo	B-Sequence
(	O
codificación	O
AQP2	B-Protein
-	O
R187C	O
)	O
de	O
NDI	O
no	O
puede	O
interactuar	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
[	O
6	O
]	O
,	O
aquí	O
mostramos	O
que	O
AQP2	B-Protein
-	O
F204V	O
interactúa	O
con	O
el	O
tipo	B-Sequence
salvaje	I-Sequence
proteína	B-Chemical
presumiblemente	O
como	O
parte	O
de	O
los	O
heterotetrámeros	O
,	O
y	O
representa	O
un	O
rescate	O
rescatable	O
alelo	B-Sequence
,	O
tanto	O
in	O
vitro	O
como	O
in	O
vivo	O
.	O

Inmunostinción	O
de	O
los	O
riñones	O
de	O
homocigotos	O
Aqp2F204V/F204V	O
ratones	B-Taxon
muestra	O
que	O
el	O
mutante	B-Sequence
#	O
¿NOMBRE	O
?	O
células	B-Cell
no	O
puede	O
mediar	O
agua	B-Chemical
reabsorción	O
,	O
porque	O
no	O
se	O
inserta	O
en	O
el	O
membrana	B-GENE
plasmática	I-GENE
apical	I-GENE
en	O
respuesta	O
a	O
dDAVP	O
.	O

Esta	O
es	O
la	O
primera	O
prueba	O
in	O
vivo	O
de	O
una	O
hipótesis	O
de	O
larga	O
data	O
que	O
proviene	O
de	O
estudios	O
in	O
vitro	O
con	O
recesivo	O
Aqp2	B-Protein
mutaciones	B-Sequence
.	O

Transfección	O
en	O
MDCK	O
células	B-Cell
de	O
cualquiera	O
de	O
varios	O
Aqp2	B-Protein
mutaciones	B-Sequence
correspondiente	O
a	O
recesivo	O
humano	B-Taxon
alelos	B-Sequence
muestra	O
localización	O
subcelular	O
anormal	O
[	O
25	O
]	O
,	O
[	O
27	O
]	O
y	O
falta	O
de	O
translocación	O
apropiada	O
al	O
membrana	B-GENE
de	I-GENE
plasma	I-GENE
.	O

Así	O
,	O
desdoblamiento	O
,	O
retención	O
en	O
el	O
Urgencias	B-GENE
,	O
y	O
la	O
falta	O
de	O
translocación	O
en	O
respuesta	O
a	O
dDAVP	O
se	O
propusieron	O
como	O
el	O
mecanismo	O
para	O
autosómico	B-GENE
IND	O
recesivo	O
.	O

Aquí	O
no	O
solo	O
probamos	O
esta	O
hipótesis	O
,	O
sino	O
que	O
también	O
establecemos	O
un	O
modelo	O
útil	O
para	O
humano	B-Taxon
NDI	O
.	O

Esta	O
ratón	B-Taxon
modelo	O
de	O
NDI	O
basado	O
en	O
un	O
Aqp2	B-Protein
alelo	B-Sequence
que	O
pueden	O
ser	O
rescatados	O
brinda	O
la	O
oportunidad	O
de	O
probar	O
terapias	O
,	O
incluyendo	O
gene	B-Sequence
terapia	O
,	O
que	O
puede	O
promover	O
la	O
localización	O
subcelular	O
adecuada	O
.	O

Materiales	O
y	O
métodos	O

Generación	O
de	O
ENU	O
ratones	B-Taxon
y	O
vivienda	O

ENU	B-Chemical
mutagenizado	O
C57BL	O
/	O
6	O
ratones	B-Taxon
se	O
generaron	O
como	O
se	O
describe	O
[	O
19	O
]	O
.	O

Ratones	B-Taxon
se	O
mantuvieron	O
por	O
retrocruzamiento	O
afectados	O
animales	B-Taxon
a	O
C57BL/6	O
y	O
alojado	O
en	O
el	O
Instituto	O
de	O
Genómica	O
de	O
la	O
Fundación	O
de	O
Investigación	O
de	O
Novartis	O
Libre	O
de	O
Patógenos	O
Específicos	O
animal	B-Taxon
instalación	O
(	O
La	O
Jolla	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
.	O

Todos	O
los	O
procedimientos	O
fueron	O
aprobados	O
por	O
el	O
Instituto	O
de	O
Genómica	O
de	O
la	O
Fundación	O
de	O
Investigación	O
Novartis	O
Institucional	O
Animal	B-Taxon
Comité	O
de	O
Cuidado	O
y	O
Uso	O
.	O

Construcciones	B-Sequence
.	O

El	O
completo	O
secuencia	B-Sequence
de	I-Sequence
codificación	I-Sequence
de	O
ratón	B-Protein
AQP2	I-Protein
de	O
una	O
IMAGEN	O
clon	B-Sequence
fue	O
digerido	O
del	O
pCMV	O
.	O
DEPORTE6	O
plásmido	B-Sequence
con	O
EcoRI	O
y	O
NotI	O
y	O
ligado	O
en	O
pcDNA3	O
.	O
1	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
.	O

El	O
F204V	O
mutación	B-Sequence
fue	O
presentado	O
por	O
sitio	B-Sequence
#	O
¿NOMBRE	O
?	O
mutagénesis	B-Sequence
(	O
Stratagene	O
,	O
La	O
Jolla	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
,	O
utilizando	O
el	O
sentido	O
oligonucleótido	B-Sequence
5	O
'	O
-	O
GATGATCACTGGGTCGTCTGGATCGGACCCC	O
-	O
3	O
'	O
,	O
y	O
oligonucleótido	B-Sequence
antisentido	I-Sequence
'	O
-	O
GGGGTCCGATCCAGACGACCCAGTGATCATC	O
-	O
3	O
'	O
.	O

Para	O
generar	O
fusiones	O
GFP	O
de	O
AQP2	B-Protein
,	O
el	O
pCMV	O
.	O
DEPORTE6	O
AQP2	B-Protein
construir	B-Sequence
se	O
usó	O
en	O
una	O
reacción	O
de	O
PCR	O
con	O
el	O
cebadores	B-Sequence
Sp6	O
y	O
5	O
'	O
-	O
GACTGGATCCCGGCCTTGCTGCCGCGCGGCAG	O
-	O
3	O
'	O
a	O
retirar	B-Sequence
los	O
codón	B-Sequence
de	I-Sequence
parada	I-Sequence
de	O
AQP2	B-Protein
.	O

los	O
producto	B-Sequence
se	O
digirió	O
con	O
KpnI	O
y	O
BamHI	O
y	O
se	O
ligó	O
en	O
pEGFP-N2	O
(	O
BD	O
Biosciences	O
,	O
San	O
Diego	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
.	O

El	O
F204V	O
mutación	B-Sequence
fue	O
introducido	O
utilizando	O
el	O
mismo	O
mutagénico	B-Chemical
oligonucleótidos	B-Sequence
.	O

Célula	B-Cell
cultura	O
y	O
generación	O
de	O
estable	O
célula	B-Cell
líneas	O
.	O

MDCK	O
células	B-Cell
(	O
CCL	O
-	O
34	O
;	O
ATCC	O
,	O
Manassas	O
,	O
Virginia	O
,	O
Estados	O
Unidos	O
)	O
se	O
cultivaron	O
en	O
DMEM	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St.	O
Louis	O
,	O
Missouri	O
,	O
Estados	O
Unidos	O
)	O
suplementado	O
con	O
FBS	O
al	O
10	O
%	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
,	O
100	O
U	O
/	O
ml	O
de	O
penicilina	B-Chemical
,	O
y	O
100	O
µg/ml	O
de	O
estreptomicina	B-Chemical
a	O
37	O
grados	O
C	O
en	O
5	O
%	O
CO2	O
.	O

Para	O
generar	O
MDCK	O
estable	O
célula	B-Cell
líneas	O
,	O
células	B-Cell
se	O
transfectaron	O
usando	O
Lipofectamine	O
2000	O
(	O
Invitrogen	O
)	O
y	O
el	O
pcDNA3	O
.	O
1	O
expresión	O
construcciones	B-Sequence
(	O
que	O
contiene	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
,	O
AQP2	B-Protein
-	O
F204V	O
,	O
o	O
no	O
insertar	B-Sequence
)	O
y	O
seleccionado	O
con	O
900	O
µg/ml	O
G418	O
(	O
Sigma-Aldrich	O
)	O
.	O

Las	O
colonias	O
individuales	O
se	O
expandieron	O
14	O
días	O
después	O
.	O

Durante	O
la	O
duración	O
de	O
estos	O
experimentos	O
,	O
el	O
antibiótico	B-Chemical
se	O
agregaba	O
continuamente	O
a	O
los	O
medios	O
.	O

Las	O
transfecciones	O
transitorias	O
de	O
GFP	O
se	O
llevaron	O
a	O
cabo	O
en	O
estable	O
subconfluente	O
células	B-Cell
líneas	O
también	O
utilizando	O
Lipofectamine	O
2000	O
.	O

Secuenciación	O
de	O
Aqp2	B-Protein
y	O
genotipado	O
de	O
ratones	B-Taxon
.	O

Todos	O
exones	B-Sequence
de	O
Aqp2	B-Protein
fueron	O
amplificados	O
de	O
ratón	B-Taxon
ADN	B-Sequence
genómico	I-Sequence
y	O
secuenciado	O
.	O

Para	O
el	O
genotipado	O
,	O
exón	B-Sequence
4	O
se	O
amplificó	O
utilizando	O
el	O
cebadores	B-Sequence
5'-TCAGAACTTGCCCACTAGCC-3	O
'	O
y	O
5'-TGTAGAGGAGGGAACCGATG-3	O
'	O
.	O

Mediciones	O
de	O
orina	O
.	O

La	O
producción	O
total	O
de	O
orina	O
se	O
midió	O
alojando	O
por	O
separado	O
a	O
un	O
adulto	O
ratones	B-Taxon
en	O
Jaulas	O
Metabólicas	O
Nalgene	O
(	O
Minimitter	O
,	O
Bend	O
,	O
Oregón	O
,	O
Estados	O
Unidos	O
)	O
durante	O
2-3	O
d	O
y	O
recolectando	O
orina	O
cada	O
24	O
h	O
.	O

Las	O
osmolalidades	O
de	O
la	O
orina	O
se	O
determinaron	O
con	O
un	O
osmómetro	O
(	O
Osmette	O
5004	O
;	O
Precision	O
Systems	O
,	O
Natick	O
,	O
Massachusetts	O
,	O
Estados	O
Unidos	O
)	O
.	O

Los	O
experimentos	O
de	O
concentración	O
de	O
orina	O
se	O
llevaron	O
a	O
cabo	O
mediante	O
inyección	O
intraperitoneal	O
de	O
dDAVP	O
(	O
0,4	O
µg/kg	O
)	O
.	O

Ratones	B-Taxon
fueron	O
inyectados	O
dos	O
veces	O
con	O
dDAVP	O
,	O
una	O
vez	O
en	O
el	O
tiempo	O
0	O
y	O
otra	O
vez	O
a	O
los	O
30	O
min	O
.	O

La	O
orina	O
se	O
recogió	O
al	O
comienzo	O
del	O
experimento	O
y	O
30	O
minutos	O
después	O
de	O
la	O
segunda	O
inyección	O
.	O

Riñón	O
membrana	B-GENE
preparación	O

Entero	O
ratón	B-Taxon
los	O
riñones	O
se	O
homogeneizaron	O
en	O
10	O
mM	O
tris	B-Chemical
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
350	O
mM	O
sacarosa	B-Chemical
,	O
y	O
5	O
mM	O
EDTA	B-Chemical
que	O
contiene	O
Inhibidores	B-Chemical
de	I-Chemical
la	I-Chemical
proteasa	I-Chemical
(	O
Sigma-Aldrich	O
,	O
#	O
P-8340	O
)	O
en	O
un	O
homogeneizador	O
Potter-Elvehjem	O
.	O

El	O
homogeneizado	O
se	O
centrifugó	O
a	O
2	O
000	O
g	O
durante	O
10	O
min	O
y	O
el	O
sobrenadante	O
se	O
sometió	O
a	O
ultracentrifugación	O
a	O
100	O
000	O
g	O
durante	O
1	O
h	O
a	O
4	O
°C	O
.	O

granulado	O
membranas	B-GENE
se	O
resuspendieron	O
en	O
el	O
mismo	O
tampón	O
y	O
proteína	B-Chemical
la	O
concentración	O
se	O
determinó	O
mediante	O
el	O
ensayo	O
de	O
Bradford	O
.	O

inmunotransferencia	O

Riñón	O
fracciones	B-GENE
de	I-GENE
membrana	I-GENE
(	O
60	O
ug	O
)	O
se	O
resolvieron	O
en	O
un	O
12	O
%	O
SDS	B-Chemical
#	O
¿NOMBRE	O
?	O

Las	O
membranas	O
se	O
bloquearon	O
en	O
leche	O
descremada	O
al	O
5	O
%	O
en	O
tris	B-Chemical
-	O
amortiguado	B-Chemical
solución	O
salina	O
con	O
0	O
.	O
Tween	O
20	O
al	O
05	O
%	O
(	O
TBST	O
)	O
,	O
seguido	O
de	O
una	O
incubación	O
durante	O
la	O
noche	O
(	O
a	O
4	O
grados	O
C	O
)	O
con	O
AQP2	B-Protein
policlonal	O
anticuerpo	B-GENE
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
California	O
,	O
Estados	O
Unidos	O
;	O
#	O
sc-9882	O
)	O
.	O

Las	O
membranas	O
se	O
lavaron	O
en	O
TBST	O
y	O
luego	O
se	O
incubaron	O
con	O
HRP	O
-	O
conjugado	O
Burro	B-Taxon
anti	O
-	O
cabra	B-Taxon
anticuerpo	B-GENE
.	O

Las	O
membranas	O
se	O
lavaron	O
más	O
en	O
TBST	O
y	O
las	O
bandas	O
se	O
visualizaron	O
usando	O
ECL	O
reactivo	B-Chemical
(	O
Amersham	O
Biosciences	O
,	O
Little	O
Chalfont	O
,	O
Reino	O
Unido	O
)	O
.	O

Digestión	O
con	O
endoglicosidasa	O
.	O

Riñón	O
membranas	B-GENE
(	O
60	O
µg	O
)	O
se	O
incubaron	O
en	O
50	O
mM	O
fosfato	B-Chemical
de	I-Chemical
sodio	I-Chemical
(	O
pH	O
5	O
.	O
5	O
)	O
,	O
0	O
.	O
1	O
%	O
SDS	B-Chemical
,	O
y	O
50	O
mM	O
beta	B-Chemical
-	I-Chemical
mercaptoetanol	I-Chemical
,	O
calentado	O
a	O
100	O
grados	O
C	O
durante	O
5	O
min	O
,	O
luego	O
enfriado	O
.	O

Endoglicosidasa	B-Protein
H	I-Protein
(	O
0,01	O
unidades	O
;	O
Sigma-Aldrich	O
)	O
y	O
se	O
incubó	O
a	O
37	O
grados	O
C	O
durante	O
2	O
h	O
.	O

La	O
reacción	O
se	O
detuvo	O
hirviendo	O
las	O
muestras	O
en	O
tampón	O
Laemmli	O
.	O

Los	O
reactivos	O
totales	O
se	O
sometieron	O
a	O
inmunotransferencia	O
como	O
se	O
describe	O
anteriormente	O
.	O

Coinmunoprecipitación	O
y	O
biotinilación	O
en	O
MDCK	O
células	B-Cell
.	O

MDCK	O
células	B-Cell
expresando	O
de	O
manera	O
estable	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
(	O
cultivados	O
en	O
placas	O
de	O
10	O
cm	O
)	O
se	O
transfectaron	O
con	O
pEGFP-	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
,	O
pEGFP-	O
AQP2	B-Protein
-	O
F204V	O
,	O
o	O
vector	B-Sequence
solo	O
.	O

los	O
células	B-Cell
fueron	O
homogeneizados	O
en	O
10	O
mM	O
tris	B-Chemical
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
1	O
mM	O
EDTA	B-Chemical
y	O
250	O
mM	O
sacarosa	B-Chemical
40	O
horas	O
después	O
.	O

El	O
sobrenadante	O
clarificado	O
se	O
centrifugó	O
a	O
200	O
000	O
g	O
durante	O
30	O
min	O
.	O

granulado	O
membranas	B-GENE
se	O
resuspendieron	O
en	O
el	O
mismo	O
tampón	O
pero	O
con	O
un	O
4	O
%	O
desoxicolato	B-Chemical
de	I-Chemical
sodio	I-Chemical
y	O
se	O
incubó	O
a	O
37	O
grados	O
C	O
durante	O
1	O
h	O
.	O

De	O
lo	O
disuelto	O
membranas	B-GENE
,	O
se	O
extrajo	O
una	O
muestra	O
de	O
30	O
mu	O
l	O
y	O
se	O
usó	O
como	O
el	O
total	O
fracción	B-GENE
de	I-GENE
membrana	I-GENE
.	O

El	O
restante	O
membranas	B-GENE
se	O
diluyeron	O
con	O
600	O
mu	O
l	O
del	O
tampón	O
de	O
homogeneización	O
y	O
se	O
incubaron	O
con	O
1	O
mu	O
l	O
de	O
antisuero	O
GFP	O
(	O
Invitrogen	O
,	O
#	O
46-0092	O
)	O
y	O
proteína	B-Chemical
A/G	O
sefarosa	O
.	O

Después	O
de	O
la	O
incubación	O
durante	O
la	O
noche	O
,	O
el	O
precipitado	O
proteinas	B-Chemical
se	O
lavaron	O
en	O
tampón	O
RIPA	O
y	O
finalmente	O
se	O
hirvieron	O
en	O
50	O
µl	O
de	O
tampón	O
Laemmli	O
.	O

la	O
mitad	O
del	O
total	O
membrana	B-GENE
y	I-GENE
las	I-GENE
fracciones	I-GENE
IP	I-GENE
fueron	O
procesados	O
para	O
inmunotransferencia	O
.	O

Superficie	B-GENE
celular	I-GENE
la	O
biotinilación	O
se	O
realizó	O
de	O
manera	O
similar	O
.	O

Sin	O
embargo	O
,	O
pEGFP-	O
AQP2	B-Protein
-	O
F204V	O
,	O
fue	O
transfectado	O
en	O
MDCK	O
células	B-Cell
expresando	O
de	O
manera	O
estable	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
y	O
células	B-Cell
hecho	O
estable	O
con	O
vector	B-Sequence
solo	O
.	O

Veinticuatro	O
horas	O
después	O
de	O
la	O
transfección	O
,	O
células	B-Cell
fueron	O
estimulados	O
con	O
forskolina	O
,	O
tripsinizados	O
,	O
resuspendidos	O
en	O
1	O
ml	O
de	O
PBS	O
(	O
2	O
.	O
5	O
x	O
106	O
células	B-Cell
/	O
ml	O
)	O
,	O
y	O
se	O
incubó	O
con	O
0	O
.	O
5	O
mg	O
de	O
SNS	O
-	O
PEO4	O
-	O
biotina	B-Chemical
(	O
Pierce	O
Biotechnology	O
)	O
durante	O
30	O
min	O
a	O
temperatura	O
ambiente	O
.	O

Células	B-Cell
se	O
lavaron	O
una	O
vez	O
en	O
10	O
mM	O
tris	B-Chemical
(	O
pH	O
8	O
)	O
y	O
tres	O
veces	O
en	O
PBS	O
,	O
después	O
de	O
lo	O
cual	O
membranas	B-GENE
se	O
purificaron	O
y	O
solubilizaron	O
como	O
se	O
describe	O
anteriormente	O
.	O

solubilizado	O
membranas	B-GENE
se	O
incubaron	O
con	O
20	O
µl	O
de	O
estreptavidina	O
inmovilizada	O
(	O
Pierce	O
Biotechnology	O
)	O
durante	O
2	O
ha	O
4ºC	O
.	O

Finalmente	O
el	O
precipitado	O
proteinas	B-Chemical
se	O
lavaron	O
en	O
tampón	O
RIPA	O
y	O
se	O
hirvieron	O
en	O
50	O
µl	O
de	O
tampón	O
Laemmli	O
.	O

Total	O
células	B-Cell
y	O
los	O
precipitados	O
biotinilados	O
se	O
inmunotransfirieron	O
usando	O
un	O
anticuerpo	B-GENE
para	O
AQP2	B-Protein
.	O

Inmunohistoquímica	O
renal	O
.	O

Entero	O
ratón	B-Taxon
riñones	O
fueron	O
fijados	O
en	O
10	O
%	O
fosfato	B-Chemical
-	O
amortiguado	B-Chemical
formalina	O
durante	O
24	O
h	O
.	O

Los	O
riñones	O
se	O
incluyeron	O
en	O
parafina	O
y	O
se	O
prepararon	O
secciones	O
de	O
5	O
µm	O
.	O

Después	O
de	O
la	O
recuperación	O
de	O
antígeno	O
usando	O
10	O
mM	O
citrato	B-Chemical
de	I-Chemical
sodio	I-Chemical
(	O
pH	O
8	O
)	O
durante	O
10	O
min	O
a	O
98	O
grados	O
C	O
,	O
las	O
secciones	O
se	O
probaron	O
secuencialmente	O
,	O
primero	O
para	O
AQP3	B-Protein
y	O
luego	O
por	O
AQP2	B-Protein
.	O

Las	O
secciones	O
se	O
incubaron	O
en	O
5	O
%	O
Burro	B-Taxon
suero	O
y	O
luego	O
en	O
cabra	B-Taxon
anti	O
-	O
AQP3	B-Protein
anticuerpo	B-GENE
(	O
1	O
:	O
100	O
;	O
Santa	O
Cruz	O
Biotecnología	O
;	O
#	O
sc	O
-	O
9885	O
)	O
.	O

Los	O
portaobjetos	O
se	O
lavaron	O
con	O
PBS	O
y	O
se	O
incubaron	O
con	O
AlexaFluor	O
488	O
-	O
conjugado	O
Burro	B-Taxon
anti	O
-	O
cabra	B-Taxon
anticuerpo	B-GENE
(	O
Molecular	B-Chemical
Probes	O
,	O
Eugene	O
,	O
Oregón	O
,	O
Estados	O
Unidos	O
)	O
.	O

Los	O
portaobjetos	O
se	O
bloquearon	O
posteriormente	O
en	O
un	O
5	O
%	O
pollo	B-Taxon
suero	O
,	O
incubado	O
con	O
un	O
Conejo	B-Taxon
anti	O
-	O
AQP2	B-Protein
anticuerpo	B-GENE
(	O
1	O
:	O
250	O
;	O
USB	O
,	O
Cleveland	O
,	O
Ohio	O
,	O
Estados	O
Unidos	O
;	O
#	O
A3000	O
-	O
06	O
)	O
,	O
que	O
se	O
detectó	O
con	O
un	O
AlexaFluor	O
594	O
conjugado	O
pollo	B-Taxon
anti	O
-	O
Conejo	B-Taxon
anticuerpo	B-GENE
(	O
1	O
:	O
500	O
;	O
Molecular	B-Chemical
sondas	O
)	O
.	O

Las	O
secciones	O
se	O
tiñeron	O
con	O
DAPI	O
y	O
se	O
montaron	O
en	O
Vectashield	O
(	O
Vector	O
Labs	O
,	O
Burlingame	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
.	O

Inmunocitoquímica	O
en	O
MDCK	O
células	B-Cell
.	O

MDCK	O
estable	O
célula	B-Cell
lineas	O
expresando	O
vector	B-Sequence
solo	O
,	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
,	O
o	O
AQP2	B-Protein
-	O
F204V	O
(	O
y	O
en	O
algunos	O
casos	O
expresando	O
transitoriamente	O
un	O
GFP	O
construir	B-Sequence
)	O
se	O
cultivaron	O
en	O
fibronectina	B-Protein
#	O
¿NOMBRE	O
?	O
juntas	B-GENE
apretadas	I-GENE
formado	O

Células	B-Cell
fueron	O
tratados	O
con	O
o	O
sin	O
forskolina	O
150	O
mu	O
M	O
durante	O
90	O
min	O
y	O
fijados	O
en	O
metanol	B-Chemical
a	O
-20	O
grados	O
C	O
.	O

Posteriormente	O
,	O
células	B-Cell
fueron	O
lavados	O
y	O
permeabilizados	O
en	O
0	O
.	O
2	O
%	O
Triton	O
X	O
-	O
100	O
durante	O
5	O
min	O
,	O
y	O
sondeado	O
secuencialmente	O
para	O
AQP2	B-Protein
y	O
orgánulo	B-GENE
marcadores	O
para	O
el	O
PM	B-GENE
o	O
la	O
Urgencias	B-GENE
.	O

AQP2	B-Protein
fue	O
detectado	O
utilizando	O
cabra	B-Taxon
anti	O
-	O
AQP2	B-Protein
(	O
1	O
:	O
100	O
;	O
Santa	O
Cruz	O
Biotechnology	O
;	O
#	O
sc	O
-	O
9882	O
)	O
y	O
una	O
dilución	O
1	O
:	O
200	O
de	O
AlexaFluor	O
488	O
-	O
conjugado	O
Burro	B-Taxon
anti	O
-	O
cabra	B-Taxon
secundario	O
anticuerpo	B-GENE
.	O

los	O
PM	B-GENE
y	O
Urgencias	B-GENE
fueron	O
probados	O
usando	O
ratón	B-Taxon
anti	O
-	O
na	B-Chemical
+	I-Chemical
/	O
k	B-Chemical
+	I-Chemical
-	O
ATPasa	O
(	O
Upstate	O
,	O
Waltham	O
,	O
Massachusetts	O
,	O
Estados	O
Unidos	O
)	O
o	O
Conejo	B-Taxon
anti	O
-	O
calnexina	B-Protein
(	O
Stressgen	O
Biotechnology	O
,	O
Victoria	O
,	O
Columbia	O
Británica	O
,	O
Canadá	O
)	O
anticuerpos	B-GENE
y	O
el	O
secundario	O
anticuerpos	B-GENE
,	O
Cy3	O
-	O
conjugado	O
cabra	B-Taxon
anti	O
-	O
ratón	B-Taxon
(	O
1	O
:	O
200	O
;	O
Jackson	O
ImmunoResearch	O
,	O
West	O
Grove	O
,	O
Pensilvania	O
,	O
Estados	O
Unidos	O
)	O
o	O
AlexaFluor	O
594	O
conjugado	O
pollo	B-Taxon
anti	O
-	O
Conejo	B-Taxon
(	O
1	O
:	O
200	O
)	O
respectivamente	O
.	O

Células	B-Cell
se	O
lavaron	O
en	O
PBS	O
,	O
se	O
contrastaron	O
con	O
DAPI	O
y	O
se	O
montaron	O
en	O
Vectashield	O
.	O

En	O
experimentos	O
en	O
los	O
que	O
se	O
utilizaron	O
fusiones	O
GFP	O
,	O
AQP2	B-Protein
fue	O
sondeado	O
usando	O
el	O
anticuerpo	B-GENE
combinación	O
utilizada	O
para	O
la	O
inmunohistoquímica	O
renal	O
con	O
el	O
fin	O
de	O
detectar	O
la	O
AQP2	B-Protein
a	O
594	O
nm	O
,	O
para	O
distinguir	O
entre	O
la	O
GFP	O
fusión	B-Sequence
proteinas	B-Chemical
.	O

Microscopia	O
confocal	O
.	O

Las	O
imágenes	O
ópticas	O
de	O
sección	O
z	O
se	O
recogieron	O
en	O
un	O
microscopio	O
confocal	O
de	O
barrido	O
láser	O
Rainbow	O
Radiance	O
2100	O
de	O
BioRad	O
(	O
Hercules	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
.	O

Las	O
pilas	O
de	O
imágenes	O
se	O
aplanaron	O
o	O
seccionaron	O
a	O
lo	O
largo	O
del	O
eje	O
z	O
y	O
luego	O
se	O
procesaron	O
utilizando	O
el	O
software	O
BioRad	O
Laser	O
Sharp	O
2000	O
y	O
el	O
software	O
Image	O
J	O
(	O
v.	O
1	O
.	O
32	O
;	O
Institutos	O
Nacionales	O
de	O
Salud	O
)	O
.	O

La	O
colocalización	O
se	O
realizó	O
utilizando	O
el	O
coeficiente	O
de	O
superposición	O
del	O
software	O
Image	O
J	O
.	O

información	O
de	O
soporte	O

Números	O
de	O
acceso	O

El	O
GenBank	O
(	O
http	O
:	O
//	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
)	O
número	O
de	O
acceso	O
de	O
Aqp2	B-Protein
es	O
NM_009699	O
.	O

El	O
número	O
de	O
acceso	O
de	O
IMAGE	O
(	O
http	O
:	O
//	O
image	O
.	O
llnl	O
.	O
gov	O
)	O
de	O
AQP2	B-Protein
es	O
4222942	O
.	O

Agradecimientos	O

Agradecemos	O
a	O
Debby	O
Stradley	O
por	O
todos	O
los	O
genotipos	O
,	O
a	O
Lacey	O
Kischassey	O
por	O
la	O
reproducción	O
y	O
el	O
cuidado	O
de	O
ratones	B-Taxon
,	O
Karina	O
Ayala	O
y	O
Sandy	O
Bohan	O
por	O
fenotipar	O
el	O
estudio	O
ratones	B-Taxon
,	O
Miah	O
Gilmore	O
por	O
interpretar	O
endoglicosidasa	B-Protein
H	I-Protein
experimentos	O
,	O
James	O
Watson	O
para	O
seccionar	O
tejido	O
,	O
y	O
el	O
Dr	O
.	O
William	O
Kiossis	O
por	O
coleccionar	O
imágenes	O
confocales	O
.	O

abreviaturas	O

AQP	O
[	O
número	O
]	O
-	O
acuaporina	O
-	O
[	O
número	O
]	O

AVPR2	B-Protein
-	O
Receptor	B-Protein
de	I-Protein
AVP	I-Protein
tipo	I-Protein
2	I-Protein

AVP	B-Protein
-	O
arginina	B-Protein
vasopresina	I-Protein

dDAVP	O
-	O
1	O
-	O
deamino	O
-	O
8	O
-	O
D	B-Chemical
-	I-Chemical
arginina	I-Chemical
vasopresina	O

Urgencias	B-GENE
-	O
retículo	B-GENE
endoplásmico	I-GENE

MDCK	O
-	O
Madin	O
-	O
Darby	O
canino	B-Taxon
riñón	O

NDI	O
-	O
diabetes	O
insípida	O
nefrogénica	O

PM	B-GENE
-	O
membrana	B-GENE
de	I-GENE
plasma	I-GENE

Cifras	O

Figura	O
1	O

Análisis	O
de	O
Aqp2	B-Protein
Secuencia	B-Sequence
y	O
fenotipo	O
en	O
mutante	B-Sequence
Ratones	B-Taxon

(	O
A	O
)	O
Rastros	O
cromatográficos	O
de	O
Aqp2	B-Protein
F204V	O
mutación	B-Sequence
.	O

El	O
cuadro	O
muestra	O
el	O
codón	B-Sequence
mutado	I-Sequence
,	O
TTC	O
(	O
fe	B-Chemical
)	O
a	O
GTC	O
(	O
valle	B-Chemical
)	O
en	O
posición	B-Sequence
204	O
.	O

peso	B-Sequence
,	O
tipo	B-Sequence
salvaje	I-Sequence
;	O
Mut	B-Sequence
,	O
mutante	B-Sequence
.	O

(	O
B	O
)	O
Aminoácidos	B-Chemical
conservación	B-Sequence
de	O
ratón	B-Protein
AQP2	I-Protein
(	O
residuos	B-Chemical
194	O
-	O
214	O
)	O
.	O

el	O
en	O
caja	O
residuo	B-Chemical
indica	O
fenilalanina	B-Chemical
en	O
posición	B-Sequence
204	O
.	O

hAQP2	B-Protein
,	O
AQP2	B-Protein
humano	I-Protein
;	O
mAQP1	B-Protein
,	O
ratón	B-Protein
AQP1	I-Protein
;	O
mAQP2	B-Protein
,	O
ratón	B-Protein
AQP2	I-Protein
;	O
rAQP2	B-Protein
,	O
rata	B-Protein
AQP2	I-Protein
;	O
xAQP2	B-Protein
,	O
Xenopus	B-Protein
AQP2	I-Protein
.	O

(	O
C	O
)	O
Producción	O
de	O
orina	O
(	O
ml	O
)	O
y	O
agua	B-Chemical
consumo	O
(	O
ml	O
)	O
de	O
58	O
F2	O
ratones	B-Taxon
durante	O
un	O
período	O
de	O
24	O
h	O
(	O
ambos	O
sexos	O
,	O
de	O
10	O
a	O
22	O
semanas	O
de	O
edad	O
)	O
.	O

mutante	B-Sequence
ratones	B-Taxon
(	O
cuadrados	O
negros	O
)	O
exhiben	O
poliuria	O
y	O
polidipsia	O
manifiestas	O
en	O
comparación	O
con	O
compañeros	O
de	O
camada	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
triángulos	O
blancos	O
)	O
y	O
heterocigotos	O
(	O
círculos	O
grises	O
)	O
ratones	B-Taxon
.	O

(	O
D	O
)	O
Osmolalidad	O
de	O
la	O
orina	O
y	O
capacidad	O
de	O
concentración	O
en	O
Aqp2	B-Protein
mutante	B-Sequence
y	O
sus	O
compañeros	O
de	O
camada	O
(	O
10-22	O
semanas	O
,	O
ambos	O
sexos	O
)	O
,	O
antes	O
(	O
barras	O
blancas	O
)	O
y	O
después	O
(	O
barras	O
negras	O
)	O
del	O
tratamiento	O
con	O
dDAVP	O
.	O

Tipo	B-Sequence
salvaje	I-Sequence
(	O
peso	B-Sequence
n	O
=	O
12	O
)	O
;	O
heterocigoto	O
(	O
Het	O
;	O
n	O
=	O
20	O
)	O
;	O
mutante	B-Sequence
(	O
Mut	B-Sequence
;	O
n	O
=	O
9	O
)	O
.	O

Los	O
datos	O
representan	O
promedios	O
+/-	O
error	O
estándar	O
de	O
la	O
media	O
,	O
*	O
*	O
p	O
<	O
0	O
.	O
01	O
;	O
*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
.	O

Figura	O
2	O

Anatomía	O
e	O
Histología	O
de	O
Ratón	B-Taxon
Riñones	O

(	O
A	O
)	O
Anatomía	O
macroscópica	O
de	O
un	O
afectado	O
ratón	B-Taxon
(	O
macho	O
de	O
8	O
meses	O
)	O
.	O

Esto	O
muestra	O
el	O
agrandamiento	O
y	O
la	O
dilatación	O
quística	O
de	O
la	O
pelvis	O
renal	O
.	O

Hay	O
un	O
adelgazamiento	O
del	O
parénquima	O
renal	O
suprayacente	O
que	O
imparte	O
una	O
apariencia	O
translúcida	O
a	O
porciones	O
del	O
riñón	O
y	O
del	O
sistema	O
colector	O
.	O

La	O
vejiga	O
también	O
está	O
dilatada	O
.	O

(	O
B	O
)	O
Riñón	O
izquierdo	O
de	O
mutante	B-Sequence
ratón	B-Taxon
(	O
derecha	O
)	O
que	O
se	O
muestra	O
en	O
(	O
A	O
)	O
en	O
comparación	O
con	O
un	O
riñón	O
de	O
un	O
compañero	O
de	O
camada	O
no	O
afectado	O
de	O
la	O
misma	O
edad	O
y	O
sexo	O
(	O
izquierda	O
)	O
.	O

(	O
C	O
)	O
Sección	O
de	O
uréter	O
teñida	O
con	O
hematoxilina	O
y	O
eosina	O
de	O
un	O
mutante	B-Sequence
ratón	B-Taxon
,	O
mostrando	O
una	O
histología	O
normal	O
a	O
pesar	O
de	O
la	O
hinchazón	O
del	O
riñón	O
.	O

(	O
D	O
)	O
Sección	O
histológica	O
teñida	O
con	O
hematoxilina	O
y	O
eosina	O
de	O
un	O
riñón	O
de	O
una	O
hembra	O
de	O
4	O
semanas	O
de	O
edad	O
mutante	B-Sequence
ratón	B-Taxon
.	O

los	O
mutante	B-Sequence
El	O
riñón	O
muestra	O
una	O
marcada	O
dilatación	O
de	O
la	O
pelvis	O
renal	O
con	O
embotamiento	O
de	O
la	O
papila	O
.	O

Hay	O
preservación	O
de	O
la	O
corteza	O
y	O
la	O
médula	O
.	O

figura	O
3	O

Análisis	O
de	O
inmunotransferencia	O
de	O
AQP2	B-Protein
desde	O
Ratón	B-Taxon
Riñones	O

(	O
A	O
)	O
Análisis	O
de	O
Western	O
blot	O
de	O
riñón	O
total	O
membranas	B-GENE
de	O
compañero	O
de	O
camada	O
ratones	B-Taxon
.	O

Un	O
forma	B-Sequence
intermedia	I-Sequence
de	O
AQP2	B-Protein
a	O
31	O
kDa	O
se	O
identificó	O
en	O
riñón	O
membranas	B-GENE
a	O
partir	O
de	O
una	O
mutante	B-Sequence
ratón	B-Taxon
(	O
Mut	B-Sequence
)	O
y	O
parcialmente	O
en	O
un	O
heterocigoto	O
ratón	B-Taxon
(	O
Het	O
)	O
.	O

(	O
B	O
)	O
Riñón	O
total	O
membranas	B-GENE
fueron	O
sometidos	O
a	O
endoglicosidasa	B-Protein
H	I-Protein
tratamiento	O
(	O
Endo	B-Protein
H	I-Protein
)	O
antes	O
de	O
la	O
transferencia	O
de	O
Western	O
.	O

Elevado	O
-	O
manosa	B-Chemical
(	O
H	O
.	O
m	B-Chemical
)	O
glicosilado	O
proteinas	B-Chemical
que	O
no	O
han	O
salido	O
de	O
la	O
Urgencias	B-GENE
son	O
sensibles	O
a	O
endoglicosidasa	B-Protein
H	I-Protein
digestión	O
.	O

Figura	O
4	O

AQP2	B-Protein
Localización	O
subcelular	O
y	O
translocación	O
en	O
Ratón	B-Taxon
Conductos	O
colectores	O
renales	O
y	O
MDCK	O
Célula	B-Cell
Líneas	O

(	O
A	O
)	O
Inmunohistoquímica	O
en	O
conductos	O
colectores	O
en	O
secciones	O
de	O
riñón	O
de	O
un	O
AQP2	B-Protein
-	O
F204V	O
mutante	B-Sequence
(	O
Mut	B-Sequence
)	O
ratón	B-Taxon
y	O
una	O
edad	O
-	O
sexo	O
emparejado	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
peso	B-Sequence
)	O
compañero	O
de	O
camada	O
.	O

Ratones	B-Taxon
fueron	O
inyectados	O
intraperitonealmente	O
con	O
PBS	O
(	O
NT	O
)	O
o	O
dDAVP	O
antes	O
del	O
sacrificio	O
y	O
fijación	O
de	O
los	O
riñones	O
.	O

Las	O
secciones	O
de	O
riñón	O
se	O
inmunoteñeron	O
para	O
AQP2	B-Protein
(	O
rojo	O
)	O
y	O
el	O
marcador	O
basolateral	O
AQP3	B-Protein
(	O
verde	O
)	O
.	O

Las	O
imágenes	O
se	O
fusionaron	O
y	O
un	O
área	B-GENE
del	I-GENE
citoplasma	I-GENE
fue	O
ampliada	O
(	O
zoom	O
)	O
.	O

Tenga	O
en	O
cuenta	O
que	O
mutante	B-Sequence
AQP2	B-Protein
no	O
se	O
localiza	O
correctamente	O
en	O
el	O
compartimento	O
subapical	O
ni	O
responde	O
a	O
la	O
dDAVP	O
.	O

(	O
B	O
)	O
MDCK	O
célula	B-Cell
líneas	O
,	O
establemente	O
transfectadas	O
con	O
construcciones	B-Sequence
codificación	O
ratón	B-Protein
WT	I-Protein
o	I-Protein
AQP2	I-Protein
-	O
F204V	O
,	O
fueron	O
tratados	O
con	O
y	O
sin	O
forskolina	O
150	O
mu	O
M	O
durante	O
90	O
min	O
,	O
después	O
de	O
lo	O
cual	O
células	B-Cell
fueron	O
fijados	O
,	O
permeabilizados	O
y	O
sometidos	O
a	O
inmunocitoquímica	O
.	O

AQP2	B-Protein
se	O
muestra	O
en	O
verde	O
,	O
y	O
el	O
marcador	O
basolateral	O
na	B-Chemical
+	I-Chemical
/	O
k	B-Chemical
+	I-Chemical
-	O
La	O
ATPasa	O
se	O
muestra	O
en	O
rojo	O
,	O
junto	O
con	O
la	O
nuclear	B-GENE
tinción	O
DAPI	O
.	O

Las	O
imágenes	O
del	O
perfil	O
z	O
se	O
reconstruyeron	O
a	O
partir	O
de	O
múltiples	O
secciones	O
z	O
,	O
a	O
lo	O
largo	O
de	O
la	O
línea	O
de	O
puntos	O
.	O

mutante	B-Sequence
AQP2	B-Protein
no	O
se	O
localiza	O
en	O
el	O
superficie	B-GENE
celular	I-GENE
tras	O
la	O
estimulación	O
con	O
forskoline	O
.	O

Más	O
bien	O
,	O
el	O
perinuclear	B-GENE
la	O
tinción	O
es	O
consistente	O
con	O
una	O
Urgencias	B-GENE
localización	O
de	O
mutante	B-Sequence
AQP2	B-Protein
.	O

(	O
C	O
)	O
El	O
MDCK	O
célula	B-Cell
línea	O
expresando	O
AQP2	B-Protein
-	O
F204V	O
se	O
cultivó	O
en	O
fibronectina	B-Protein
#	O
¿NOMBRE	O
?	O
juntas	B-GENE
apretadas	I-GENE
formado	O
,	O
momento	O
en	O
el	O
cual	O
el	O
células	B-Cell
fueron	O
tratados	O
con	O
forskolina	O
150	O
mu	O
M	O
durante	O
90	O
min	O
.	O

Células	B-Cell
fueron	O
fijados	O
,	O
permeabilizados	O
y	O
secuencialmente	O
inmunotransferidos	O
para	O
AQP2	B-Protein
(	O
verde	O
)	O
y	O
calnexina	B-Protein
(	O
rojo	O
)	O
,	O
un	O
Urgencias	B-GENE
marcador	O

La	O
imagen	O
fusionada	O
muestra	O
que	O
AQP2	B-Protein
F204V	O
colocaliza	O
con	O
el	O
retículo	B-GENE
endoplásmico	I-GENE
marcador	O

La	O
barra	O
de	O
escala	O
se	O
refiere	O
a	O
10	O
mu	O
m	O
.	O

Figura	O
5	O

AQP2	B-Protein
-	O
F204V	O
Rescate	O
en	O
Heterocigoto	O
Ratón	B-Taxon
Conductos	O
colectores	O
y	O
MDCK	O
cotransfectados	O
Células	B-Cell

(	O
A	O
)	O
En	O
heterocigotos	O
animales	B-Taxon
,	O
AQP2	B-Protein
localiza	O
y	O
responde	O
a	O
dDAVP	O
normalmente	O
.	O

La	O
inmunohistoquímica	O
se	O
llevó	O
a	O
cabo	O
en	O
secciones	O
de	O
riñón	O
de	O
un	O
Aqp2F204V	O
/	O
+	B-Sequence
ratón	B-Taxon
,	O
después	O
de	O
la	O
inyección	O
con	O
dDAVP	O
.	O

Las	O
secciones	O
de	O
riñón	O
se	O
inmunoteñeron	O
secuencialmente	O
para	O
AQP2	B-Protein
(	O
rojo	O
)	O
y	O
el	O
marcador	O
basolateral	O
AQP3	B-Protein
(	O
verde	O
)	O
.	O

(	O
B	O
)	O
mutante	B-Sequence
y	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
interactuar	O
físicamente	O
.	O

MDCK	O
células	B-Cell
expresando	O
de	O
manera	O
estable	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
fueron	O
transfectados	O
transitoriamente	O
con	O
GFP	O
etiquetados	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
,	O
AQP2	B-Protein
-F204V	O
,	O
o	O
GFP	O
solo	O
.	O

solubilizado	O
membranas	B-GENE
fueron	O
inmunoprecipitados	O
con	O
un	O
GFP	O
anticuerpo	B-GENE
.	O

Total	O
membranas	B-GENE
e	O
inmunoprecipitados	O
(	O
GFP-IP	O
)	O
se	O
sometieron	O
a	O
transferencia	O
Western	O
usando	O
un	O
anticuerpo	B-GENE
en	O
contra	O
AQP2	B-Protein
(	O
flecha	O
)	O
o	O
AQP2	B-Protein
-	O
Fusiones	O
GFP	O
(	O
punta	O
de	O
flecha	O
)	O
.	O

(	O
C	O
)	O
Tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
rescata	O
el	O
defecto	O
de	O
localización	O
de	O
mutante	B-Sequence
AQP2	B-Protein
.	O

Fusiones	O
GFP	O
de	O
cualquiera	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
(	O
peso	B-Sequence
-	O
GFP	O
,	O
microfotografías	O
superiores	O
)	O
o	O
F204V	O
AQP2	B-Protein
(	O
F204V-GFP	O
,	O
fotomicrografías	O
inferiores	O
)	O
se	O
expresaron	O
en	O
MDCK	O
polarizada	O
estable	O
célula	B-Cell
lineas	O
expresando	O
vector	B-Sequence
solo	O
(	O
vector	B-Sequence
,	O
microfotografías	O
de	O
la	O
izquierda	O
)	O
o	O
AQP2	B-Protein
-	O
peso	B-Sequence
(	O
microfotografías	O
de	O
la	O
derecha	O
)	O
.	O

Células	B-Cell
se	O
estimularon	O
con	O
forskolina	O
,	O
se	O
procesaron	O
para	O
inmunocitoquímica	O
y	O
se	O
usaron	O
para	O
generar	O
imágenes	O
de	O
corte	O
z	O
.	O

(	O
D	O
)	O
mutante	B-Sequence
AQP2	B-Protein
está	O
presente	O
en	O
el	O
superficie	B-GENE
celular	I-GENE
en	O
células	B-Cell
coexpresando	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
(	O
AQP2	B-Protein
-	O
peso	B-Sequence
)	O
.	O

GFP	O
fusionado	O
a	O
AQP2	B-Protein
-	O
F204V	O
se	O
expresó	O
en	O
MDCK	O
células	B-Cell
expresando	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
o	O
vector	B-Sequence
solo	O
.	O

Células	B-Cell
fueron	O
estimulados	O
con	O
forskoline	O
,	O
y	O
superficie	B-GENE
celular	I-GENE
biotinilado	O
proteinas	B-Chemical
fueron	O
precipitados	O
y	O
luego	O
analizados	O
para	O
detectar	O
la	O
presencia	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
AQP2	B-Protein
(	O
flecha	O
)	O
y	O
AQP2	B-Protein
-F204V	O
(	O
punta	O
de	O
flecha	O
)	O
por	O
Western	O
blot	O
.	O

notas	O
al	O
pie	O

Conflicto	O
de	O
intereses	O
.	O

Los	O
autores	O
han	O
declarado	O
que	O
no	O
existen	O
intereses	O
contrapuestos	O
.	O

Contribuciones	O
de	O
autor	O
.	O

DJL	O
y	O
NG	O
concibieron	O
y	O
diseñaron	O
los	O
experimentos	O
.	O

DJL	O
realizó	O
los	O
experimentos	O
.	O

DJL	O
,	O
FWH	O
y	O
NG	O
analizaron	O
los	O
datos	O
.	O

DJL	O
y	O
LMT	O
contribuyeron	O
reactivos	B-Chemical
/	O
materiales	O
/	O
herramientas	O
de	O
análisis	O
.	O

DJL	O
y	O
NG	O
escribieron	O
el	O
artículo	O
.	O

Cita	O
:	O
Lloyd	O
DJ	O
,	O
Hall	O
FW	O
,	O
Tarantino	O
LM	O
,	O
Gekakis	O
N	O
(	O
2005	O
)	O
Diabetes	O
insipidus	O
in	O
ratones	B-Taxon
con	O
un	O
mutación	B-Sequence
en	O
acuaporina	B-Protein
-	I-Protein
2	I-Protein
.	O

PLoS	O
Genet	O
1	O
(	O
2	O
)	O
:	O
e20	O
.	O

Discriminación	O
de	O
olores	O
mejorada	O
y	O
memoria	O
olfativa	O
deteriorada	O
mediante	O
el	O
cambio	O
controlado	O
espacialmente	O
de	O
los	O
receptores	O
AMPA	O

Resumen	O

Genético	B-Sequence
perturbaciones	O
de	O
alfa	O
-	O
aminado	B-Chemical
-	O
3	O
-	O
hidroxi	B-Chemical
-	O
5	O
-	O
metilo	B-Chemical
#	O
¿NOMBRE	O
?	O
molecular	B-Chemical
mecanismos	O
de	O
codificación	O
sensorial	O
,	O
aprendizaje	O
y	O
memoria	O
.	O

En	O
este	O
estudio	O
,	O
investigamos	O
el	O
papel	O
de	O
Ca2	B-Chemical
+	I-Chemical
#	O
¿NOMBRE	O
?	O

AMPAR	O
modificación	B-Sequence
se	O
obtuvo	O
por	O
agotamiento	O
de	O
la	O
GluR	B-Protein
-	I-Protein
subunidad	I-Protein
B	I-Protein
o	O
expresión	O
de	O
inédito	O
GluR-B	B-Protein
(	O
q	B-Chemical
)	O
,	O
ambos	O
conducen	O
a	O
un	O
aumento	O
Ca2	B-Chemical
+	I-Chemical
permeabilidad	O
de	O
los	O
AMPAR	O
.	O

Ratones	B-Taxon
con	O
este	O
interruptor	O
AMPAR	O
funcional	O
,	O
específicamente	O
en	O
el	O
cerebro	O
anterior	O
,	O
mostró	O
una	O
mayor	O
discriminación	O
olfativa	O
y	O
un	O
aprendizaje	O
más	O
rápido	O
en	O
una	O
tarea	O
de	O
condicionamiento	O
operante	O
pasa/no	O
pasa	O
.	O

La	O
memoria	O
olfativa	O
,	O
sin	O
embargo	O
,	O
estaba	O
dramáticamente	O
dañada	O
.	O

GluR-B	B-Protein
``	O
el	O
agotamiento	O
en	O
el	O
prosencéfalo	O
era	O
ectópicamente	O
variable	O
(	O
``	O
''	O
mosaico	O
''	O
''	O
)	O
entre	O
''	O
individuos	B-Taxon
y	O
fuertemente	O
correlacionado	O
con	O
la	O
disminución	O
de	O
la	O
memoria	O
olfativa	O
en	O
el	O
hipocampo	O
y	O
la	O
corteza	O
.	O

En	O
consecuencia	O
,	O
la	O
memoria	O
fue	O
rescatada	O
por	O
transgénico	B-Sequence
GluR-B	B-Protein
expresión	O
restringida	O
a	O
la	O
corteza	O
piriforme	O
y	O
el	O
hipocampo	O
,	O
mientras	O
que	O
la	O
discriminación	O
de	O
olor	O
mejorada	O
fue	O
independiente	O
de	O
ambos	O
GluR-B	B-Protein
variabilidad	O
y	O
transgénico	B-Sequence
GluR-B	B-Protein
expresión	O
.	O

Así	O
,	O
las	O
diferencias	O
correlacionadas	O
en	O
el	O
comportamiento	O
y	O
los	O
niveles	O
de	O
GluR-B	B-Protein
La	O
expresión	O
permitió	O
una	O
disección	O
mecanicista	O
y	O
espacial	O
del	O
aprendizaje	O
olfativo	O
,	O
la	O
discriminación	O
y	O
las	O
capacidades	O
de	O
memoria	O
.	O

Introducción	O

El	O
sentido	O
del	O
olfato	O
es	O
de	O
suma	O
importancia	O
para	O
roedores	B-Taxon
[	O
1	O
]	O
,	O
para	O
los	O
cuales	O
la	O
rápida	O
discriminación	O
de	O
olores	O
y	O
la	O
memoria	O
olfativa	O
de	O
larga	O
duración	O
permiten	O
respuestas	O
a	O
depredadores	O
y	O
presas	O
críticas	O
para	O
la	O
supervivencia	O
.	O

En	O
consecuencia	O
,	O
los	O
análisis	O
conductuales	O
de	O
las	O
capacidades	O
olfativas	O
en	O
roedores	B-Taxon
son	O
eficientes	O
,	O
cuantitativas	O
y	O
reproducibles	O
[	O
2-4	O
]	O
.	O

Mientras	O
que	O
en	O
la	O
formación	O
y	O
almacenamiento	O
de	O
la	O
memoria	O
olfativa	O
la	O
corteza	O
piriforme	O
[	O
5	O
-	O
7	O
]	O
,	O
el	O
hipocampo	O
[	O
8	O
,	O
9	O
]	O
y	O
el	O
bulbo	O
olfativo	O
[	O
10	O
-	O
12	O
]	O
están	O
todos	O
implicados	O
,	O
el	O
celular	B-Cell
los	O
correlatos	O
para	O
estos	O
procesos	O
no	O
han	O
sido	O
claramente	O
delineados	O
.	O

La	O
contribución	O
del	O
hipocampo	O
a	O
la	O
memoria	O
olfativa	O
es	O
actualmente	O
controvertida	O
[	O
2	O
,	O
13-18	O
]	O
,	O
pero	O
se	O
considera	O
improbable	O
para	O
tareas	O
simples	O
de	O
discriminación	O
olfativa	O
[	O
9	O
,	O
19	O
]	O
.	O

De	O
hecho	O
,	O
los	O
candidatos	O
más	O
probables	O
para	O
un	O
celular	B-Cell
correlato	O
de	O
la	O
memoria	O
olfativa	O
parece	O
ser	O
el	O
neuronales	B-Cell
conexiones	O
en	O
la	O
corteza	O
piriforme	O
debido	O
a	O
la	O
conectividad	O
asociativa	O
[	O
5	O
]	O
y	O
la	O
expresión	O
de	O
varias	O
formas	O
de	O
celular	B-Cell
y	O
sináptico	B-GENE
plasticidad	O
[	O
7	O
,	O
20	O
-	O
23	O
]	O
.	O

En	O
cuanto	O
a	O
la	O
discriminación	O
de	O
olores	O
en	O
sí	O
,	O
celular	B-Cell
Los	O
mecanismos	O
para	O
este	O
proceso	O
a	O
menudo	O
se	O
atribuyen	O
al	O
circuito	O
inhibitorio	O
del	O
bulbo	O
olfatorio	O
(	O
[	O
24-30	O
]	O
;	O
revisado	O
en	O
[	O
31-33	O
]	O
)	O
.	O

Los	O
circuitos	O
inhibidores	O
laterales	O
fueron	O
postulados	O
,	O
en	O
analogía	O
con	O
la	O
retina	O
[	O
34	O
,	O
35	O
]	O
,	O
para	O
mediar	O
el	O
realce	O
de	O
contraste	O
[	O
24	O
]	O
,	O
para	O
lo	O
cual	O
se	O
registraron	O
registros	O
fisiológicos	O
[	O
24	O
,	O
36	O
,	O
37	O
]	O
y	O
datos	O
de	O
modelado	O
,	O
basados	O
en	O
la	O
anatomía	O
bien	O
conocida	O
[	O
29	O
]	O
,	O
proporcionar	O
apoyo	O
adicional	O
.	O

Tal	O
mejora	O
del	O
contraste	O
puede	O
depender	O
en	O
gran	O
parte	O
de	O
las	O
propiedades	O
particulares	O
de	O
las	O
dendrodendríticas	O
.	O
sinapsis	B-GENE
Entre	O
los	O
neuronas	B-Cell
de	I-Cell
salida	I-Cell
principales	I-Cell
(	O
mitral	O
células	B-Cell
)	O
e	O
inhibidores	O
locales	O
neuronas	B-Cell
(	O
células	B-Cell
granulares	I-Cell
)	O
del	O
bulbo	O
olfatorio	O
.	O

En	O
estos	O
distintos	O
sinapsis	B-GENE
,	O
inhibición	O
lateral	O
y	O
recurrente	O
mediada	O
por	O
la	O
ácido	B-Chemical
gamma-aminobutírico	I-Chemical
#	O
¿NOMBRE	O
?	O
glutamatérgico	B-Chemical
parte	O
,	O
tal	O
vez	O
provocando	O
un	O
aumento	O
ácido	B-Chemical
gamma-aminobutírico	I-Chemical
liberación	O
por	O
Ca2	B-Chemical
+	I-Chemical
afluencia	O
a	O
través	O
glutamato	B-Chemical
canales	O
receptores	O
controlados	O
(	O
[	O
38	O
]	O
;	O
véase	O
también	O
[	O
39	O
]	O
)	O
.	O

Dado	O
que	O
neuronales	B-Cell
Los	O
circuitos	O
subyacentes	O
a	O
la	O
discriminación	O
de	O
olores	O
,	O
así	O
como	O
la	O
memoria	O
olfativa	O
,	O
se	O
basan	O
en	O
propiedades	O
de	O
neurotransmisión	O
excitatoria	O
rápida	O
mediada	O
por	O
alfa-	O
aminado	B-Chemical
-	O
3	O
-	O
hidroxi	B-Chemical
-	O
5	O
-	O
metilo	B-Chemical
-	O
4	O
-	O
receptores	O
de	O
propionato	O
de	O
isoxazol	O
(	O
AMPAR	O
)	O
,	O
buscamos	O
alterar	O
,	O
mediante	O
genético	B-Sequence
significa	O
,	O
la	O
contribución	O
funcional	O
específica	O
de	O
alfa	O
-	O
aminado	B-Chemical
-	O
3	O
-	O
hidroxi	B-Chemical
-	O
5	O
-	O
metilo	B-Chemical
#	O
¿NOMBRE	O
?	O
GluR-B	B-Protein
.	O

De	O
los	O
cuatro	O
constituyentes	O
de	O
AMPAR	O
,	O
GluR	B-Protein
-	I-Protein
A	I-Protein
a	I-Protein
D	I-Protein
(	O
GluR1	B-Protein
a	O
4	O
)	O
,	O
que	O
forman	O
canales	O
tetraméricos	O
con	O
diferentes	O
combinaciones	O
de	O
subunidades	O
binarias	O
,	O
GluR-B	B-Protein
está	O
contenido	O
en	O
la	O
mayoría	O
de	O
AMPAR	O
.	O

GluR-B	B-Protein
está	O
críticamente	O
involucrada	O
en	O
la	O
formación	O
y	O
el	O
tráfico	O
de	O
AMPAR	O
,	O
y	O
domina	O
sus	O
ion	B-Chemical
conductancia	O
y	O
propiedades	O
de	O
activación	O
[	O
40	O
-	O
46	O
]	O
.	O

En	O
particular	O
,	O
el	O
normalmente	O
bajo	O
Ca2	B-Chemical
+	I-Chemical
permeabilidad	O
de	O
los	O
canales	O
AMPA	O
en	O
neuronas	B-Cell
principales	I-Cell
está	O
mediada	O
únicamente	O
por	O
GluR-B	B-Protein
,	O
debido	O
a	O
un	O
único	O
residuo	B-Chemical
de	I-Chemical
arginina	I-Chemical
(	O
R587	O
)	O
en	O
el	O
funcionalmente	O
crítico	O
glutamina	B-Chemical
/	O
arginina	B-Chemical
(	O
q	B-Chemical
/	O
R	B-Chemical
)	O
sitio	B-Sequence
del	O
segmento	O
formador	O
de	O
poros	O
M2	O
[	O
44	O
,	O
47	O
,	O
48	O
]	O
,	O
resultante	O
de	O
ARN	B-Sequence
edición	O
de	O
GluR-B	B-Protein
pre	B-Sequence
-	I-Sequence
ARNm	I-Sequence
(	O
[	O
49	O
]	O
;	O
revisado	O
en	O
[	O
50	O
]	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
ya	O
sea	O
GluR-B	B-Protein
deficiencia	O
,	O
o	O
la	O
expresión	O
de	O
q	B-Chemical
/	O
R	B-Chemical
sitio	B-Sequence
#	O
¿NOMBRE	O
?	O
GluR-B	B-Protein
con	O
un	O
residuo	B-Chemical
de	I-Chemical
glutamina	I-Chemical
en	O
el	O
canal	O
crítico	O
sitio	B-Sequence
,	O
conduce	O
a	O
un	O
aumento	O
Ca2	B-Chemical
+	I-Chemical
permeabilidad	O
de	O
los	O
canales	O
AMPA	O
,	O
como	O
se	O
ha	O
demostrado	O
ampliamente	O
en	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
[	O
51	O
,	O
53	O
,	O
58	O
,	O
60	O
]	O
.	O

Así	O
,	O
la	O
ausencia	O
de	O
GluR-B	B-Protein
,	O
o	O
la	O
expresión	O
de	O
GluR-B	B-Protein
(	O
q	B-Chemical
)	O
en	O
el	O
bulbo	O
olfatorio	O
,	O
puede	O
generar	O
una	O
mayor	O
inhibición	O
en	O
la	O
mitral	O
células	B-Cell
.	O

Además	O
,	O
la	O
ablación	O
de	O
GluR-B	B-Protein
,	O
sino	O
también	O
cambios	O
en	O
la	O
extensión	O
de	O
q	B-Chemical
/	O
R	B-Chemical
sitio	B-Sequence
edición	O
de	O
GluR-B	B-Protein
,	O
puede	O
alterar	O
la	O
fuerza	O
de	O
sináptica	B-GENE
excitatoria	I-GENE
transmisión	O
en	O
el	O
genéticamente	B-Sequence
dirigido	O
neuronales	B-Cell
poblaciones	O
[	O
51	O
,	O
58	O
,	O
60	O
]	O
,	O
lo	O
que	O
podría	O
cambiar	O
el	O
equilibrio	O
de	O
la	O
transmisión	O
excitatoria	O
e	O
inhibitoria	O
en	O
los	O
circuitos	O
afectados	O
.	O

Del	O
mismo	O
modo	O
,	O
los	O
cambios	O
en	O
sináptico	B-GENE
plasticidad	O
debido	O
a	O
Ca2	B-Chemical
+	I-Chemical
AMPAR	O
permeables	O
[	O
51	O
,	O
52	O
,	O
60	O
]	O
,	O
e	O
.	O
g.	O
,	O
en	O
la	O
corteza	O
piriforme	O
,	O
podría	O
alterar	O
los	O
procesos	O
de	O
memorización	O
de	O
olores	O
.	O

Por	O
lo	O
tanto	O
,	O
las	O
alteraciones	O
de	O
las	O
propiedades	O
de	O
AMPAR	O
en	O
estas	O
regiones	O
del	O
cerebro	O
permitirán	O
la	O
investigación	O
y	O
posiblemente	O
la	O
separación	O
de	O
los	O
mecanismos	O
subyacentes	O
a	O
estos	O
rasgos	O
de	O
comportamiento	O
.	O

Con	O
respecto	O
a	O
este	O
cambio	O
previsto	O
en	O
las	O
propiedades	O
de	O
AMPAR	O
,	O
ratones	B-Taxon
careciendo	O
de	O
todo	O
GluR-B	B-Protein
,	O
sin	O
embargo	O
,	O
muestran	O
un	O
deterioro	O
generalizado	O
del	O
comportamiento	O
,	O
que	O
incluye	O
letargo	O
,	O
problemas	O
de	O
coordinación	O
motora	O
y	O
déficits	O
en	O
la	O
actividad	O
exploratoria	O
[	O
51	O
]	O
,	O
lo	O
que	O
impide	O
realizar	O
análisis	O
conductuales	O
detallados	O
.	O

Similar	O
,	O
ratones	B-Taxon
expresando	O
(	O
en	O
todo	O
el	O
cerebro	O
)	O
una	O
parte	O
sustancial	O
de	O
la	O
GluR-B	B-Protein
población	O
en	O
el	O
q	B-Chemical
/	O
R	B-Chemical
sitio	B-Sequence
#	O
¿NOMBRE	O
?	O
formulario	B-Sequence
se	O
vuelven	O
propensos	O
a	O
las	O
convulsiones	O
y	O
mueren	O
prematuramente	O
[	O
53	O
]	O
.	O

Algunos	O
de	O
estos	O
problemas	O
pueden	O
superarse	O
parcialmente	O
mediante	O
el	O
uso	O
de	O
sistemas	O
de	O
expresión	O
espacial	O
y	O
temporalmente	O
restringidos	O
[	O
54-56	O
]	O
,	O
en	O
particular	O
el	O
sistema	O
Cre-lox	O
,	O
con	O
expresión	O
de	O
Cre-recombinasa	O
en	O
áreas	O
cerebrales	O
definidas	O
de	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
que	O
lleva	O
GluR-B	B-Protein
alelos	B-Sequence
marcado	O
por	O
sitios	B-Sequence
loxP	I-Sequence
para	O
la	O
recombinación	O
mediada	O
por	O
Cre	O
[	O
55	O
,	O
57	O
]	O
.	O

De	O
hecho	O
,	O
restringir	O
la	O
expresión	O
de	O
q	B-Chemical
/	O
R	B-Chemical
sitio	B-Sequence
#	O
¿NOMBRE	O
?	O
GluR-B	B-Protein
al	O
prosencéfalo	O
dio	O
como	O
resultado	O
una	O
esperanza	O
de	O
vida	O
casi	O
normal	O
y	O
un	O
fenotipo	O
débilmente	O
propenso	O
a	O
las	O
convulsiones	O
[	O
58	O
]	O
.	O

Ratones	B-Taxon
con	O
prosencéfalo	O
-	O
específico	O
GluR-B	B-Protein
el	O
agotamiento	O
parecía	O
casi	O
completamente	O
normal	O
durante	O
toda	O
la	O
vida	O
sin	O
anomalías	O
en	O
el	O
desarrollo	O
,	O
lo	O
que	O
permitió	O
una	O
investigación	O
detallada	O
y	O
cuantitativa	O
del	O
comportamiento	O
olfativo	O
.	O

Para	O
permitir	O
la	O
separación	O
mecanicista	O
del	O
aprendizaje	O
olfativo	O
,	O
la	O
discriminación	O
y	O
la	O
memoria	O
,	O
explotamos	O
un	O
fenómeno	O
bien	O
conocido	O
de	O
transgenes	B-Sequence
,	O
que	O
se	O
refiere	O
a	O
la	O
expresión	O
heterogénea	O
entre	O
diferentes	O
líneas	O
fundadoras	O
e	O
incluso	O
entre	O
genéticamente	B-Sequence
idéntico	O
individuos	B-Taxon
de	O
una	O
línea	O
dada	O
.	O

``	O
Aunque	O
tal	O
expresión	O
de	O
``	O
''	O
mosaico	O
``	O
''	O
no	O
suele	O
ser	O
deseada	O
,	O
aquí	O
la	O
aprovechamos	O
para	O
ablacionar	O
''	O
GluR-B	B-Protein
vía	O
gene	B-Sequence
-	O
apuntado	O
,	O
flojo	B-Sequence
GluR-B	B-Protein
alelos	B-Sequence
con	O
la	O
ayuda	O
de	O
un	O
transgénico	B-Sequence
ratón	B-Taxon
línea	O
con	O
expresión	O
Cre	O
abigarrada	O
en	O
el	O
prosencéfalo	O
.	O

por	O
correlación	O
GluR-B	B-Protein
niveles	O
en	O
regiones	O
cerebrales	O
relacionadas	O
con	O
el	O
olfato	O
con	O
datos	O
conductuales	O
cuantitativos	O
,	O
investigamos	O
la	O
dependencia	O
de	O
GluR-B	B-Protein
de	O
la	O
discriminación	O
olfativa	O
y	O
la	O
memoria	O
.	O

Además	O
,	O
para	O
delinear	O
las	O
áreas	O
del	O
cerebro	O
involucradas	O
en	O
estos	O
procesos	O
olfativos	O
distintivos	O
,	O
usamos	O
transgénico	B-Sequence
rescate	O
de	O
GluR-B	B-Protein
ablación	O
,	O
específicamente	O
en	O
corteza	O
piriforme	O
e	O
hipocampo	O
.	O

Estos	O
esfuerzos	O
nos	O
permitieron	O
diseccionar	O
,	O
tanto	O
espacial	O
como	O
mecánicamente	O
,	O
el	O
papel	O
de	O
GluR-B	B-Protein
propiedades	O
mediadas	O
por	O
AMPAR	O
en	O
regiones	O
cerebrales	O
seleccionadas	O
en	O
el	O
aprendizaje	O
,	O
discriminación	O
y	O
memoria	O
de	O
olores	O
.	O

Resultados	O

GluR-B	B-Protein
(	O
q	B-Chemical
)	O
La	O
expresión	O
en	O
el	O
cerebro	O
anterior	O
aumenta	O
el	O
aprendizaje	O
y	O
la	O
discriminación	O
olfativos	O

Explorar	O
el	O
papel	O
de	O
la	O
neurotransmisión	O
excitatoria	O
rápida	O
llevada	O
a	O
cabo	O
por	O
GluR-B	B-Protein
-	O
que	O
contiene	O
canales	O
AMPA	O
en	O
procesos	O
olfativos	O
,	O
primero	O
analizamos	O
ratones	B-Taxon
que	O
expresan	O
parte	O
de	O
la	O
GluR-B	B-Protein
población	O
en	O
un	O
q	B-Chemical
/	O
R	B-Chemical
sitio	B-Sequence
#	O
¿NOMBRE	O
?	O
formulario	B-Sequence
``	O
(	O
Figura	O
1A	O
;	O
denominado	O
``	O
''	O
GluR-B	O
Delta	O
ECS	O
:	O
FB	O
''	O
''	O
;	O
véase	O
también	O
[	O
58	O
]	O
)	O
.	O
''	O

Estas	O
ratones	B-Taxon
llevar	O
,	O
además	O
de	O
un	O
tipo	B-Sequence
salvaje	I-Sequence
GluR-B	B-Protein
alelo	B-Sequence
,	O
a	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
alelo	B-Sequence
en	O
el	O
que	O
la	O
secuencia	B-Sequence
intrónica	I-Sequence
crítico	O
para	O
GluR-B	B-Protein
pre	B-Sequence
-	I-Sequence
ARNm	I-Sequence
edición	O
en	O
el	O
q	B-Chemical
/	O
R	B-Chemical
sitio	B-Sequence
es	O
sustituido	B-Sequence
por	O
un	O
TK	B-Sequence
floxado	I-Sequence
-	I-Sequence
gen	I-Sequence
neo	I-Sequence
,	O
lo	O
que	O
reduce	O
severamente	O
el	O
empalme	O
del	O
intrón	B-Sequence
modificado	I-Sequence
y	O
por	O
lo	O
tanto	O
atenúa	O
la	O
expresión	O
del	O
GluR	O
-	O
Bneo	O
alelo	B-Sequence
[	O
60	O
]	O
.	O

Dessilenciar	O
el	O
GluR	O
atenuado	O
-	O
Bneo	O
alelo	B-Sequence
,	O
específicamente	O
en	O
el	O
prosencéfalo	O
postnatal	O
,	O
cruzamos	O
en	O
el	O
TgCre4	O
transgén	B-Sequence
,	O
que	O
codifica	O
Cre-recombinasa	O
y	O
es	O
impulsada	O
por	O
la	O
alfa	B-Protein
CaMKII	I-Protein
promotor	B-Sequence
``	O
(	O
[	O
59	O
]	O
;	O
``	O
''	O
Camkcre4	O
``	O
''	O
)	O
.	O
''	O

Por	O
lo	O
tanto	O
,	O
Cre-recombinasa	O
elimina	B-Sequence
en	O
el	O
cerebro	O
anterior	O
neuronas	B-Cell
los	O
intrónico	B-Sequence
TK-neo	O
gene	B-Sequence
,	O
lo	O
que	O
lleva	O
al	O
activo	O
GluR	O
-	O
B	O
Delta	O
ECS	O
alelo	B-Sequence
por	O
q	B-Chemical
/	O
R	B-Chemical
sitio	B-Sequence
#	O
¿NOMBRE	O
?	O
Subunidades	B-Protein
GluR-B	I-Protein
(	I-Protein
Q	I-Protein
)	I-Protein
(	O
Figuras	O
1	O
y	O
S1	O
)	O
.	O

Como	O
era	O
de	O
esperar	O
[	O
53	O
,	O
60	O
]	O
,	O
también	O
en	O
ratones	B-Taxon
expresando	O
el	O
prosencéfalo	O
posnatal	O
-	O
específico	O
q	B-Chemical
/	O
R	B-Chemical
sitio	B-Sequence
#	O
¿NOMBRE	O
?	O
Subunidades	B-Protein
GluR-B	I-Protein
(	I-Protein
Q	I-Protein
)	I-Protein
,	O
Ca2	B-Chemical
+	I-Chemical
se	O
incrementó	O
la	O
permeabilidad	O
a	O
través	O
de	O
AMPAR	O
y	O
las	O
corrientes	O
AMPAR	O
mostraron	O
rectificación	O
(	O
[	O
58	O
]	O
y	O
datos	O
no	O
publicados	O
)	O
.	O

GluR-B	O
Delta	O
ECS	O
:	O
FB	O
ratones	B-Taxon
tenía	O
,	O
en	O
contraste	O
con	O
ratones	B-Taxon
expresando	O
GluR-B	B-Protein
(	O
q	B-Chemical
)	O
globalmente	O
,	O
una	O
vida	O
prolongada	O
y	O
sin	O
alteraciones	O
severas	O
del	O
desarrollo	O
.	O

Sin	O
embargo	O
,	O
todavía	O
eran	O
propensos	O
a	O
las	O
convulsiones	O
[	O
58	O
]	O
y	O
,	O
por	O
lo	O
tanto	O
,	O
el	O
entrenamiento	O
conductual	O
estaba	O
restringido	O
a	O
períodos	O
cortos	O
de	O
tiempo	O
.	O

Entrenamos	O
seis	O
GluR	O
-	O
B	O
Delta	O
ECS	O
:	O
FB	O
ratones	B-Taxon
y	O
seis	O
controles	O
de	O
compañeros	O
de	O
camada	O
en	O
un	O
par	O
de	O
olores	O
en	O
una	O
tarea	O
automatizada	O
de	O
acondicionamiento	O
olfativo	O
pasa	O
/	O
no	O
pasa	O
[	O
3	O
,	O
61	O
]	O
.	O

En	O
esta	O
tarea	O
,	O
agua	B-Chemical
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
están	O
entrenados	O
para	O
distinguir	O
un	O
agua	B-Chemical
-olor	O
recompensado	O
(	O
S+	O
)	O
y	O
un	O
olor	O
no	O
recompensado	O
(	O
S-	O
)	O
por	O
su	O
respuesta	O
de	O
lamido	O
(	O
Figura	O
1B	O
)	O
.	O

Ambos	O
GluR	O
-	O
B	O
Delta	O
ECS	O
:	O
FB	O
y	O
control	O
ratones	B-Taxon
``	O
adquirió	O
la	O
tarea	O
``	O
''	O
simple	O
``	O
''	O
de	O
discriminar	O
entre	O
los	O
olores	O
monomoleculares	O
amilacetato	O
y	O
etilbutirato	O
(	O
porcentaje	O
correcto	O
>	O
70	O
%	O
después	O
de	O
400	O
ensayos	O
)	O
.	O
''	O

Sorprendentemente	O
,	O
GluR-B	O
Delta	O
ECS	O
:	O
FB	O
ratones	B-Taxon
mostraron	O
un	O
aprendizaje	O
más	O
rápido	O
y	O
mejores	O
capacidades	O
de	O
discriminación	O
(	O
Figura	O
1C	O
,	O
efecto	O
de	O
grupo	O
:	O
F	O
(	O
1	O
,	O
10	O
)	O
=	O
10,2	O
,	O
p	O
<	O
0,01	O
)	O
.	O

Esto	O
se	O
confirmó	O
ajustando	O
líneas	O
de	O
tendencia	O
lineal	O
a	O
la	O
parte	O
inicial	O
de	O
la	O
curva	O
de	O
aprendizaje	O
(	O
diferencia	O
de	O
pendiente	O
:	O
p	O
<	O
0,05	O
;	O
véase	O
Materiales	O
y	O
métodos	O
)	O
.	O

El	O
sistema	O
de	O
entrenamiento	O
empleado	O
permite	O
un	O
control	O
cuidadoso	O
de	O
las	O
posiciones	O
de	O
la	O
cabeza	O
[	O
3	O
]	O
.	O

Para	O
pruebas	O
recompensadas	O
(	O
Figura	O
1D	O
,	O
verde	O
)	O
,	O
ya	O
débilmente	O
entrenado	O
animales	B-Taxon
mantuvieron	O
la	O
cabeza	O
en	O
el	O
puerto	O
de	O
muestreo	O
(	O
tubo	O
grande	O
en	O
la	O
Figura	O
1B	O
)	O
durante	O
todo	O
el	O
ensayo	O
de	O
2	O
s	O
,	O
mientras	O
que	O
para	O
los	O
ensayos	O
sin	O
recompensa	O
la	O
cabeza	O
se	O
retrae	O
rápidamente	O
(	O
Figura	O
1D	O
,	O
rojo	O
)	O
.	O

``	O
La	O
diferencia	O
de	O
estas	O
dos	O
curvas	O
(	O
Figura	O
1E	O
,	O
negra	O
)	O
es	O
un	O
ensayo	O
muy	O
sensible	O
para	O
el	O
desempeño	O
de	O
la	O
discriminación	O
;	O
el	O
máximo	O
ajustado	O
de	O
esta	O
curva	O
(	O
Figura	O
1E	O
,	O
azul	O
)	O
se	O
denomina	O
``	O
''	O
índice	O
de	O
discriminación	O
''	O
''	O
en	O
el	O
resto	O
del	O
documento	O
y	O
nuevamente	O
se	O
mejora	O
considerablemente	O
para	O
GluR-B	O
Delta	O
ECS	O
:	O
FB	O
''	O
ratones	B-Taxon
,	O
en	O
comparación	O
con	O
los	O
controles	O
(	O
Figura	O
1F	O
;	O
efecto	O
de	O
grupo	O
:	O
F	O
(	O
1	O
,	O
10	O
)	O
=	O
11	O
,	O
7	O
,	O
p	O
<	O
0	O
,	O
01	O
)	O
.	O

Esto	O
no	O
se	O
debió	O
a	O
cambios	O
en	O
el	O
rendimiento	O
motor	O
general	O
,	O
la	O
atención	O
o	O
la	O
motivación	O
,	O
ya	O
que	O
tanto	O
el	O
intervalo	O
entre	O
pruebas	O
(	O
efecto	O
de	O
grupo	O
:	O
F	O
(	O
1	O
,	O
10	O
)	O
=	O
0,56	O
,	O
p	O
>	O
0,4	O
)	O
como	O
la	O
frecuencia	O
general	O
de	O
lamido	O
(	O
efecto	O
de	O
grupo	O
:	O
F	O
(	O
1	O
,	O
10	O
)	O
=	O
0,72	O
,	O
p	O
>	O
0,4	O
)	O
no	O
se	O
vieron	O
afectados	O
.	O

Así	O
,	O
expresión	O
de	O
Ca2	B-Chemical
+	I-Chemical
Los	O
AMPAR	O
permeables	O
en	O
áreas	O
del	O
cerebro	O
anterior	O
,	O
incluido	O
el	O
bulbo	O
olfativo	O
,	O
dieron	O
como	O
resultado	O
un	O
aprendizaje	O
de	O
olores	O
más	O
rápido	O
y	O
una	O
mejor	O
discriminación	O
olfativa	O
.	O

GluR-B	O
Delta	O
FB	O
Ratones	B-Taxon
Exhibir	O
un	O
mayor	O
rendimiento	O
de	O
discriminación	O
olfativa	O

Para	O
determinar	O
si	O
el	O
aprendizaje	O
olfativo	O
mejorado	O
y	O
la	O
discriminación	O
de	O
olores	O
pueden	O
realmente	O
correlacionarse	O
con	O
el	O
aumento	O
Ca2	B-Chemical
+	I-Chemical
permeabilidad	O
de	O
los	O
canales	O
AMPA	O
en	O
el	O
q	B-Chemical
/	O
R	B-Chemical
sitio	B-Sequence
#	O
¿NOMBRE	O
?	O
formulario	B-Sequence
,	O
a	O
continuación	O
analizamos	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
,	O
que	O
carecen	O
GluR-B	B-Protein
en	O
el	O
cerebro	O
anterior	O
.	O

``	O
Esta	O
ablación	O
específica	O
fue	O
generada	O
por	O
la	O
expresión	O
TgCre4	O
selectiva	O
del	O
prosencéfalo	O
(	O
[	O
59	O
]	O
``	O
''	O
Camkcre4	O
``	O
''	O
)	O
en	O
''	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
llevando	O
,	O
en	O
ambos	O
GluR-B	B-Protein
alelos	B-Sequence
,	O
a	O
exón	B-Sequence
flojo	I-Sequence
11	O
(	O
Figura	O
2A	O
)	O
.	O

Lo	O
especifico	O
GluR-B	B-Protein
agotamiento	O
en	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
puede	O
controlarse	O
mediante	O
inmunohistoquímica	O
(	O
ver	O
más	O
abajo	O
)	O
e	O
inmunotransferencia	O
.	O

En	O
los	O
análisis	O
de	O
inmunotransferencia	O
cuantitativa	O
,	O
encontramos	O
GluR-B	B-Protein
niveles	O
reducidos	O
a	O
28	O
+/-	O
7	O
%	O
,	O
29	O
+/-	O
8	O
%	O
y	O
52	O
+/-	O
9	O
%	O
(	O
+/-	O
SEM	O
;	O
n	O
=	O
10	O
)	O
en	O
el	O
hipocampo	O
,	O
áreas	O
corticales	O
y	O
bulbo	O
olfatorio	O
,	O
respectivamente	O
,	O
en	O
relación	O
con	O
GluR-B	B-Protein
niveles	O
en	O
controles	O
de	O
compañeros	O
de	O
camada	O
GluR-B2lox	O
.	O

En	O
ausencia	O
de	O
GluR-B	B-Protein
,	O
las	O
propiedades	O
electrofisiológicas	O
de	O
los	O
canales	O
AMPA	O
se	O
vuelven	O
similares	O
a	O
las	O
de	O
GluR-B	B-Protein
/	O
GluR-B	B-Protein
(	O
q	B-Chemical
)	O
interruptor	O
[	O
51	O
]	O
que	O
muestra	O
una	O
fuerte	O
rectificación	O
y	O
aumento	O
Ca2	B-Chemical
+	I-Chemical
permeabilidad	O
a	O
través	O
de	O
canales	O
AMPA	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Sin	O
embargo	O
,	O
GluR-B	B-Protein
el	O
agotamiento	O
no	O
es	O
letal	O
y	O
no	O
produce	O
convulsiones	O
.	O

Además	O
,	O
a	O
diferencia	O
del	O
completo	O
GluR-B	B-Protein
nocauts	O
,	O
ratones	B-Taxon
con	O
prosencéfalo	O
-	O
específico	O
GluR-B	B-Protein
el	O
agotamiento	O
parecía	O
normal	O
a	O
lo	O
largo	O
de	O
la	O
vida	O
sin	O
anomalías	O
en	O
el	O
desarrollo	O
o	O
diferencia	O
en	O
el	O
tamaño	O
y	O
el	O
peso	O
corporal	O
en	O
la	O
edad	O
adulta	O
(	O
tipo	B-Sequence
salvaje	I-Sequence
:	O
31	O
.	O
0	O
g	O
+/-	O
1	O
.	O
2	O
;	O
GluR	O
-	O
B	O
Delta	O
FB	O
:	O
28	O
.	O
4	O
+/-	O
0	O
.	O
9	O
;	O
cada	O
n	O
=	O
10	O
)	O
.	O

La	O
actividad	O
exploratoria	O
en	O
una	O
tarea	O
de	O
campo	O
abierto	O
se	O
incrementó	O
ligeramente	O
en	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
(	O
3	O
,	O
480	O
cm	O
+/-	O
180	O
,	O
n	O
=	O
11	O
)	O
,	O
en	O
comparación	O
con	O
tipo	B-Sequence
salvaje	I-Sequence
compañeros	O
de	O
camada	O
(	O
2	O
,	O
512	O
cm	O
+/-	O
96	O
,	O
n	O
=	O
12	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

La	O
coordinación	O
motora	O
medida	O
en	O
un	O
rotarod	O
acelerador	O
estaba	O
algo	O
deteriorada	O
en	O
el	O
mutante	B-Sequence
ratones	B-Taxon
(	O
tipo	B-Sequence
salvaje	I-Sequence
:	O
156	O
s	O
+/-	O
37	O
,	O
n	O
=	O
6	O
;	O
GluR-B	O
Delta	O
FB	O
:	O
37	O
s	O
+/-	O
10	O
,	O
n	O
=	O
6	O
;	O
pag	O
<	O
0	O
.	O
05	O
)	O
.	O

Las	O
pruebas	O
en	O
la	O
caja	O
oscura	O
/	O
clara	O
revelaron	O
una	O
mayor	O
ansiedad	O
de	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
(	O
latencia	O
de	O
la	O
primera	O
salida	O
:	O
tipo	B-Sequence
salvaje	I-Sequence
[	O
17	O
s	O
+/-	O
3	O
]	O
,	O
GluR	O
-	O
B	O
Delta	O
FB	O
[	O
97	O
s	O
+/-	O
42	O
]	O
,	O
p	O
=	O
0	O
.	O
047	O
;	O
cambios	O
de	O
compartimiento	O
:	O
tipo	B-Sequence
salvaje	I-Sequence
[	O
17	O
s	O
+/-	O
3	O
]	O
,	O
GluR	O
-	O
B	O
Delta	O
FB	O
[	O
7	O
+/-	O
2	O
]	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
tiempo	O
pasado	O
en	O
el	O
compartimento	O
iluminado	O
:	O
tipo	B-Sequence
salvaje	I-Sequence
[	O
103	O
s	O
+/-	O
10	O
]	O
,	O
GluR	O
-	O
B	O
Delta	O
FB	O
[	O
59	O
s	O
+/-	O
19	O
]	O
,	O
p	O
=	O
0	O
.	O
051	O
;	O
cada	O
n	O
=	O
6	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
a	O
diferencia	O
del	O
completo	O
GluR-B	B-Protein
agujeros	O
ciegos	O
,	O
GluR-B	O
Delta	O
FB	O
ratones	B-Taxon
muestran	O
sólo	O
cambios	O
muy	O
pequeños	O
en	O
la	O
actividad	O
general	O
y	O
ningún	O
signo	O
de	O
alteración	O
importante	O
del	O
desarrollo	O
,	O
lo	O
que	O
permite	O
investigaciones	O
conductuales	O
detalladas	O
y	O
cuantitativas	O
.	O

Si	O
el	O
GluR-B	B-Protein
/	O
GluR-B	B-Protein
(	O
q	B-Chemical
)	O
cambio	O
-	O
alteraciones	O
inducidas	O
en	O
el	O
Ca2	B-Chemical
+	I-Chemical
La	O
permeabilidad	O
de	O
los	O
canales	O
AMPA	O
está	O
relacionada	O
con	O
una	O
mayor	O
discriminación	O
y	O
aprendizaje	O
de	O
olores	O
,	O
el	O
agotamiento	O
de	O
la	O
GluR	B-Protein
-	I-Protein
subunidad	I-Protein
B	I-Protein
debería	O
conducir	O
a	O
una	O
lectura	O
fenotípica	O
similar	O
.	O

Por	O
lo	O
tanto	O
,	O
entrenamos	O
nueve	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
y	O
nueve	O
controles	O
de	O
compañeros	O
de	O
camada	O
en	O
la	O
misma	O
tarea	O
de	O
acondicionamiento	O
olfativo	O
asociativo	O
automático	O
de	O
tipo	O
pasa/no	O
pasa	O
descrita	O
anteriormente	O
.	O

``	O
Para	O
cubrir	O
incluso	O
pequeños	O
cambios	O
fenotípicos	O
en	O
el	O
olfato	O
,	O
probamos	O
diferentes	O
pares	O
de	O
olores	O
,	O
olores	O
monomoleculares	O
``	O
''	O
simples	O
''	O
''	O
y	O
mezclas	O
binarias	O
``	O
''	O
difíciles	O
''	O
''	O
[	O
3	O
]	O
.	O
''	O

Después	O
de	O
la	O
habituación	O
,	O
GluR-B	O
Delta	O
FB	O
y	O
control	O
ratones	B-Taxon
``	O
fueron	O
entrenados	O
para	O
discriminar	O
entre	O
los	O
olores	O
monomoleculares	O
``	O
''	O
simples	O
''	O
''	O
amilacetato	O
y	O
etilbutirato	O
,	O
y	O
posteriormente	O
adicionalmente	O
en	O
una	O
tarea	O
de	O
discriminación	O
``	O
''	O
difícil	O
''	O
''	O
que	O
consiste	O
en	O
mezclas	O
binarias	O
similares	O
de	O
''	O
cineol	B-Chemical
y	O
eugenol	B-Chemical
``	O
;	O
y	O
finalmente	O
otra	O
vez	O
en	O
una	O
tarea	O
de	O
discriminación	O
``	O
''	O
simple	O
''	O
''	O
con	O
los	O
olores	O
monomoleculares	O
''	O
ácido	B-Chemical
pelargónico	I-Chemical
y	I-Chemical
valérico	I-Chemical
.	O

Similar	O
a	O
GluR-B	O
Delta	O
ECS	O
:	O
FB	O
,	O
GluR-B	O
Delta	O
FB	O
ratones	B-Taxon
también	O
mostró	O
un	O
mayor	O
aprendizaje	O
y	O
discriminación	O
en	O
comparación	O
con	O
los	O
controles	O
(	O
Figura	O
2B	O
;	O
efecto	O
de	O
grupo	O
:	O
F	O
(	O
1	O
,	O
16	O
)	O
=	O
6,55	O
;	O
p	O
<	O
0,05	O
)	O
.	O

``	O
Se	O
espera	O
que	O
un	O
mayor	O
rendimiento	O
de	O
discriminación	O
muestre	O
efectos	O
más	O
pronunciados	O
para	O
olores	O
estrechamente	O
relacionados	O
debido	O
a	O
que	O
la	O
tarea	O
de	O
discriminación	O
``	O
''	O
difícil	O
''	O
''	O
es	O
más	O
desafiante	O
y	O
está	O
más	O
cerca	O
de	O
los	O
límites	O
psicofísicos	O
del	O
sistema	O
[	O
3	O
,	O
4	O
]	O
.	O
''	O

De	O
acuerdo	O
con	O
esta	O
noción	O
,	O
las	O
diferencias	O
entre	O
GluR-B	O
Delta	O
FB	O
y	O
control	O
ratones	B-Taxon
``	O
no	O
sólo	O
eran	O
mayores	O
si	O
se	O
investigaba	O
el	O
patrón	O
de	O
muestreo	O
detallado	O
y	O
el	O
índice	O
de	O
discriminación	O
(	O
Figura	O
2C	O
y	O
2D	O
,	O
efecto	O
de	O
grupo	O
:	O
F	O
(	O
1	O
,	O
16	O
)	O
=	O
29,5	O
;	O
p	O
<	O
10-4	O
)	O
,	O
sino	O
en	O
particular	O
para	O
la	O
discriminación	O
de	O
mezclas	O
binarias	O
con	O
composición	O
similar	O
(	O
efecto	O
de	O
grupo	O
:	O
F	O
(	O
1	O
,	O
16	O
)	O
=	O
27	O
.	O
8	O
;	O
p	O
<	O
10	O
-	O
4	O
para	O
la	O
mezcla	O
;	O
FAA	O
EB	O
(	O
1	O
,	O
16	O
)	O
=	O
7	O
.	O
0	O
;	O
p	O
=	O
0	O
.	O
02	O
,	O
y	O
FPel	O
Val	O
(	O
1	O
,	O
16	O
)	O
=	O
5.8	O
,	O
p	O
=	O
0.03	O
para	O
las	O
tareas	O
de	O
discriminación	O
``	O
''	O
simple	O
``	O
''	O
,	O
ANOVA	O
de	O
3	O
vías	O
:	O
F	O
(	O
6	O
,	O
96	O
)	O
=	O
2.9	O
;	O
p	O
=	O
0.01	O
)	O
.	O
''	O

Como	O
la	O
actividad	O
,	O
medida	O
por	O
el	O
intervalo	O
entre	O
pruebas	O
,	O
no	O
fue	O
significativamente	O
diferente	O
entre	O
genotipos	B-Sequence
(	O
F	O
(	O
1	O
,	O
16	O
)	O
=	O
3	O
.	O
1	O
;	O
p	O
=	O
0	O
.	O
1	O
)	O
,	O
y	O
el	O
análisis	O
de	O
la	O
frecuencia	O
de	O
lamidas	O
mostró	O
una	O
tendencia	O
a	O
la	O
reducción	O
de	O
la	O
motivación	O
de	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
en	O
esta	O
tarea	O
particular	O
(	O
F	O
(	O
1	O
,	O
16	O
)	O
=	O
9	O
.	O
2	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
concluimos	O
que	O
el	O
agotamiento	O
de	O
GluR-B	B-Protein
en	O
las	O
áreas	O
del	O
prosencéfalo	O
de	O
hecho	O
dio	O
como	O
resultado	O
un	O
mayor	O
aprendizaje	O
olfativo	O
y	O
rendimientos	O
de	O
discriminación	O
,	O
en	O
lugar	O
de	O
alteraciones	O
motivacionales	O
.	O

Para	O
evaluar	O
la	O
especificidad	O
del	O
olfato	O
,	O
entrenamos	O
diez	O
GluR-B	O
Delta	O
FB	O
ratones	B-Taxon
y	O
diez	O
controles	O
en	O
una	O
tarea	O
de	O
aprendizaje	O
espacial	O
dependiente	O
del	O
hipocampo	O
no	O
olfativo	O
(	O
laberinto	O
en	O
Y	O
elevado	O
)	O
.	O

El	O
desempeño	O
en	O
esta	O
tarea	O
no	O
mejoró	O
en	O
comparación	O
con	O
los	O
controles	O
(	O
Figura	O
S2	O
)	O
;	O
por	O
el	O
contrario	O
,	O
la	O
adquisición	O
de	O
esta	O
tarea	O
se	O
vio	O
ligeramente	O
afectada	O
,	O
lo	O
que	O
permite	O
concluir	O
que	O
el	O
rendimiento	O
de	O
discriminación	O
olfativa	O
mejorado	O
probablemente	O
sea	O
específico	O
del	O
sentido	O
del	O
olfato	O
y	O
posiblemente	O
esté	O
relacionado	O
con	O
una	O
capacidad	O
de	O
discriminación	O
mejorada	O
,	O
en	O
lugar	O
de	O
un	O
aumento	O
general	O
del	O
estado	O
de	O
alerta	O
.	O

Además	O
,	O
mejora	O
en	O
la	O
discriminación	O
de	O
olores	O
tanto	O
en	O
GluR	O
-	O
B	O
Delta	O
ECS	O
:	O
FB	O
como	O
en	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
hace	O
probable	O
que	O
la	O
mejora	O
en	O
esta	O
tarea	O
resulte	O
del	O
cambio	O
de	O
propiedad	O
AMPAR	O
común	O
mediado	O
por	O
el	O
agotamiento	O
de	O
GluR-B	B-Protein
y	O
la	O
falta	O
de	O
la	O
q	B-Chemical
/	O
R	B-Chemical
sitio	B-Sequence
#	O
¿NOMBRE	O
?	O
GluR	B-Protein
-	I-Protein
subunidad	I-Protein
B	I-Protein
,	O
resultando	O
ambos	O
en	O
Ca2	B-Chemical
+	I-Chemical
#	O
¿NOMBRE	O
?	O

Por	O
lo	O
tanto	O
,	O
esto	O
sugiere	O
que	O
el	O
aumento	O
Ca2	B-Chemical
+	I-Chemical
la	O
afluencia	O
a	O
través	O
de	O
AMPAR	O
conduce	O
a	O
un	O
mayor	O
aprendizaje	O
y	O
discriminación	O
olfativos	O
.	O

La	O
memoria	O
olfativa	O
está	O
significativamente	O
disminuida	O
pero	O
es	O
muy	O
variable	O
en	O
GluR	O
-	O
B	O
Delta	O
FB	O
Ratones	B-Taxon

Para	O
capturar	O
toda	O
la	O
extensión	O
del	O
papel	O
de	O
Ca2	B-Chemical
+	I-Chemical
AMPAR	O
permeables	O
en	O
el	O
comportamiento	O
olfativo	O
,	O
luego	O
evaluamos	O
los	O
efectos	O
de	O
los	O
canales	O
AMPA	O
alterados	O
en	O
la	O
memoria	O
olfativa	O
.	O

Para	O
sondear	O
la	O
memoria	O
olfativa	O
en	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
,	O
seis	O
días	O
después	O
del	O
final	O
de	O
la	O
primera	O
fase	O
de	O
entrenamiento	O
para	O
la	O
discriminación	O
de	O
olores	O
(	O
acetato	O
de	O
amilo	O
versus	O
etilbutirato	O
)	O
,	O
los	O
ensayos	O
de	O
entrenamiento	O
para	O
el	O
tercer	O
par	O
de	O
olores	O
(	O
ácido	B-Chemical
pelargónico	I-Chemical
versus	I-Chemical
ácido	I-Chemical
valérico	I-Chemical
)	O
se	O
intercalaron	O
con	O
ensayos	O
sin	O
recompensa	O
en	O
los	O
que	O
se	O
presentó	O
nuevamente	O
acetato	O
de	O
amil	O
o	O
etilbutirato	O
(	O
barra	O
negra	O
en	O
la	O
Figura	O
2C	O
)	O
.	O

Mientras	O
que	O
el	O
control	O
ratones	B-Taxon
respondió	O
de	O
forma	O
fiable	O
sólo	O
al	O
olor	O
previamente	O
recompensado	O
(	O
memoria	O
de	O
86	O
+/-	O
8	O
%	O
,	O
media	O
+/-	O
SD	O
,	O
n	O
=	O
9	O
,	O
Figura	O
2E	O
)	O
,	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
mostró	O
memoria	O
olfativa	O
reducida	O
(	O
69	O
+/-	O
16	O
%	O
,	O
n	O
=	O
9	O
,	O
p	O
<	O
0,05	O
,	O
Mann-Whitney	O
)	O
.	O

Debido	O
al	O
aprendizaje	O
más	O
rápido	O
observado	O
en	O
GluR-B	O
Delta	O
FB	O
,	O
se	O
podría	O
especular	O
que	O
una	O
disminución	O
en	O
la	O
memoria	O
olfativa	O
podría	O
simplemente	O
reflejar	O
una	O
mayor	O
extinción	O
.	O

Sin	O
embargo	O
,	O
los	O
niveles	O
de	O
extinción	O
fueron	O
bajos	O
en	O
general	O
,	O
no	O
se	O
pudo	O
encontrar	O
una	O
interacción	O
significativa	O
grupo	O
-	O
prueba	O
para	O
las	O
pruebas	O
de	O
memoria	O
(	O
ANOVA	O
de	O
2	O
vías	O
,	O
F	O
(	O
6	O
,	O
90	O
)	O
=	O
1	O
.	O
5	O
,	O
p	O
>	O
0	O
.	O
1	O
)	O
y	O
una	O
restricción	O
de	O
el	O
análisis	O
de	O
las	O
primeras	O
pruebas	O
de	O
memoria	O
mostró	O
esencialmente	O
el	O
mismo	O
patrón	O
(	O
Figura	O
S3A	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
el	O
rendimiento	O
reducido	O
en	O
las	O
pruebas	O
de	O
prueba	O
no	O
se	O
debe	O
a	O
una	O
mayor	O
extinción	O
,	O
sino	O
que	O
refleja	O
un	O
deterioro	O
genuino	O
de	O
la	O
memoria	O
.	O

Además	O
,	O
debido	O
a	O
que	O
la	O
memoria	O
espacial	O
dependiente	O
del	O
hipocampo	O
después	O
de	O
la	O
adquisición	O
de	O
la	O
tarea	O
en	O
el	O
laberinto	O
Y	O
no	O
se	O
vio	O
afectada	O
(	O
Figura	O
S2	O
)	O
,	O
concluimos	O
que	O
el	O
déficit	O
de	O
memoria	O
olfativa	O
observado	O
es	O
bastante	O
específico	O
para	O
el	O
olfato	O
y	O
no	O
se	O
generaliza	O
fácilmente	O
a	O
otras	O
modalidades	O
.	O

Mientras	O
que	O
la	O
discriminación	O
de	O
olores	O
mejorada	O
y	O
el	O
comportamiento	O
de	O
aprendizaje	O
mostraron	O
solo	O
una	O
pequeña	O
variabilidad	O
,	O
el	O
rendimiento	O
de	O
la	O
memoria	O
significativamente	O
deteriorado	O
observado	O
en	O
GluR-B	O
Delta	O
FB	O
ratones	B-Taxon
era	O
muy	O
variable	O
entre	O
los	O
individuos	O
animales	B-Taxon
en	O
comparación	O
con	O
los	O
compañeros	O
de	O
camada	O
de	O
control	O
(	O
Figura	O
2E	O
)	O
.	O

Esta	O
variabilidad	O
en	O
la	O
memoria	O
olfativa	O
se	O
reflejó	O
en	O
el	O
nivel	O
y	O
extensión	O
de	O
la	O
expresión	O
de	O
Cre-recombinasa	O
en	O
el	O
prosencéfalo	O
de	O
transgénico	B-Sequence
TgCre4	O
ratones	B-Taxon
,	O
tal	O
como	O
se	O
visualiza	O
por	O
Cre	O
-	O
actividad	O
en	O
el	O
Cre	O
-	O
indicador	O
ratón	B-Taxon
línea	O
R26R	O
.	O

Observamos	O
que	O
el	O
inicio	O
y	O
el	O
alcance	O
de	O
la	O
expresión	O
de	O
Cre	O
-	O
recombinasa	O
en	O
diferentes	O
regiones	O
del	O
prosencéfalo	O
variaron	O
entre	O
los	O
TgCre4	O
individuales	O
ratones	B-Taxon
(	O
Figura	O
3A	O
)	O
,	O
que	O
también	O
podría	O
visualizarse	O
directamente	O
por	O
inmunohistoquímica	O
con	O
un	O
Cre-	O
anticuerpo	B-GENE
(	O
datos	O
no	O
publicados	O
)	O
.	O

Como	O
esta	O
variabilidad	O
persistió	O
después	O
de	O
varios	O
retrocruzamientos	O
y	O
el	O
análisis	O
de	O
transferencia	O
Southern	O
no	O
reveló	O
diferencias	O
de	O
integración	B-Sequence
transgénica	I-Sequence
o	O
número	O
entre	O
animales	B-Taxon
(	O
Figura	O
3B	O
)	O
,	O
no	O
se	O
puede	O
atribuir	O
a	O
genético	B-Sequence
diferencias	O
sino	O
más	O
bien	O
a	O
mecanismos	O
epigenéticos	O
.	O

Por	O
lo	O
tanto	O
,	O
planteamos	O
la	O
hipótesis	O
de	O
que	O
la	O
variabilidad	O
en	O
la	O
memoria	O
olfativa	O
reflejaba	O
el	O
mosaicismo	O
observado	O
en	O
el	O
transgénico	B-Sequence
Línea	O
TgCre4	O
.	O

La	O
evaluación	O
de	O
las	O
diferencias	O
regionales	O
en	O
el	O
patrón	O
de	O
expresión	O
de	O
animales	B-Taxon
con	O
una	O
memoria	O
olfativa	O
robusta	O
y	O
deficiente	O
podría	O
aplicarse	O
para	O
identificar	O
las	O
áreas	O
del	O
cerebro	O
responsables	O
de	O
los	O
fenotipos	O
observados	O
.	O

La	O
memoria	O
olfativa	O
se	O
correlaciona	O
con	O
la	O
residual	O
GluR-B	B-Protein
Proteína	B-Chemical
Expresión	O
en	O
GluR	O
-	O
B	O
Delta	O
FB	O
Ratones	B-Taxon

Por	O
lo	O
tanto	O
,	O
para	O
examinar	O
si	O
la	O
pronunciada	O
variabilidad	O
de	O
la	O
memoria	O
olfativa	O
en	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
(	O
Figura	O
2E	O
)	O
refleja	O
la	O
variabilidad	O
de	O
GluR-B	B-Protein
niveles	O
en	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
,	O
analizamos	O
la	O
cantidad	O
residual	O
de	O
GluR-B	B-Protein
proteína	B-Chemical
en	O
ratones	B-Taxon
con	O
rendimientos	O
de	O
memoria	O
dispares	O
(	O
Figura	O
4A-C	O
)	O
.	O

En	O
particular	O
,	O
ratones	B-Taxon
con	O
déficits	O
de	O
memoria	O
pronunciados	O
(	O
memoria	O
<	O
70	O
%	O
)	O
mostró	O
esencialmente	O
no	O
detectable	O
GluR-B	B-Protein
proteína	B-Chemical
en	O
hipocampo	O
,	O
amígdala	O
,	O
bulbo	O
olfatorio	O
y	O
corteza	O
piriforme	O
(	O
n	O
=	O
2	O
,	O
Figura	O
4B	O
y	O
datos	O
no	O
publicados	O
)	O
,	O
pero	O
ratones	B-Taxon
con	O
la	O
memoria	O
casi	O
completa	O
muestra	O
residuos	O
sustanciales	O
GluR-B	B-Protein
niveles	O
en	O
todas	O
las	O
áreas	O
cerebrales	O
investigadas	O
(	O
n	O
=	O
2	O
,	O
Figura	O
4B	O
y	O
datos	O
no	O
publicados	O
)	O
.	O

Para	O
cuantificar	O
la	O
relación	O
entre	O
residuos	O
GluR-B	B-Protein
proteína	B-Chemical
y	O
memoria	O
olfativa	O
,	O
el	O
experimento	O
de	O
memoria	O
se	O
repitió	O
con	O
nueve	O
GluR-B	O
Delta	O
FB	O
adicionales	O
ratones	B-Taxon
y	O
dos	O
controles	O
GluR	O
-	O
B2lox	O
animales	B-Taxon
(	O
indicado	O
con	O
símbolos	O
sombreados	O
en	O
la	O
Figura	O
4A	O
)	O
,	O
lo	O
que	O
da	O
como	O
resultado	O
la	O
misma	O
media	O
,	O
variabilidad	O
y	O
rango	O
de	O
rendimiento	O
de	O
la	O
memoria	O
(	O
control	O
:	O
89	O
+/-	O
10	O
%	O
;	O
GluR-B	O
Delta	O
FB	O
:	O
63	O
+/-	O
14	O
%	O
)	O
.	O

Posteriormente	O
,	O
proteína	B-Chemical
se	O
extrajo	O
de	O
bulbos	O
olfativos	O
,	O
áreas	O
corticales	O
e	O
hipocampos	O
de	O
cada	O
ratón	B-Taxon
,	O
y	O
GluR-B	B-Protein
proteína	B-Chemical
fue	O
cuantificado	O
(	O
Figura	O
4C	O
)	O
.	O

Las	O
correlaciones	O
resumidas	O
se	O
representan	O
en	O
la	O
Figura	O
4D	O
(	O
dos	O
animales	B-Taxon
se	O
usaron	O
para	O
el	O
análisis	O
inmunofluorescente	O
que	O
arrojó	O
los	O
mismos	O
resultados	O
que	O
en	O
el	O
primer	O
experimento	O
)	O
.	O

Mientras	O
que	O
ningún	O
parámetro	O
relacionado	O
con	O
el	O
aprendizaje	O
o	O
la	O
discriminación	O
se	O
correlacionó	O
con	O
el	O
residual	O
proteína	B-Chemical
niveles	O
(	O
Figura	O
4D	O
,	O
R2	O
<	O
0.3	O
)	O
,	O
una	O
fuerte	O
correlación	O
entre	O
la	O
memoria	O
y	O
GluR-B	B-Protein
proteína	B-Chemical
se	O
observó	O
en	O
el	O
hipocampo	O
(	O
Figura	O
4D	O
,	O
R2	O
=	O
0,72	O
,	O
p	O
<	O
0,003	O
,	O
n	O
=	O
10	O
)	O
y	O
áreas	O
corticales	O
(	O
Figura	O
4D	O
,	O
R2	O
=	O
0,62	O
,	O
p	O
<	O
0,006	O
,	O
n	O
=	O
10	O
)	O
.	O

Sólo	O
se	O
encontró	O
una	O
correlación	O
débilmente	O
significativa	O
en	O
el	O
bulbo	O
olfativo	O
(	O
Figura	O
4D	O
,	O
R2	O
=	O
0,48	O
,	O
p	O
=	O
0,03	O
,	O
n	O
=	O
10	O
)	O
.	O

GluR-A	B-Protein
los	O
niveles	O
se	O
mantuvieron	O
sin	O
cambios	O
desde	O
tipo	B-Sequence
salvaje	I-Sequence
,	O
lo	O
que	O
indica	O
que	O
la	O
regulación	O
al	O
alza	O
compensatoria	O
de	O
otras	O
subunidades	O
AMPAR	O
es	O
poco	O
probable	O
(	O
GluR-A	B-Protein
niveles	O
relativos	O
al	O
control	O
:	O
1	O
.	O
02	O
+/-	O
0	O
.	O
05	O
,	O
media	O
+/-	O
SEM	O
,	O
n	O
=	O
10	O
)	O
.	O

En	O
resumen	O
,	O
ratones	B-Taxon
con	O
reducido	O
GluR-B	B-Protein
Los	O
niveles	O
en	O
las	O
áreas	O
del	O
cerebro	O
anterior	O
mostraron	O
una	O
disminución	O
de	O
la	O
memoria	O
olfativa	O
,	O
lo	O
que	O
se	O
correlacionó	O
estrechamente	O
con	O
una	O
reducción	O
en	O
GluR-B	B-Protein
niveles	O
en	O
el	O
hipocampo	O
y	O
áreas	O
corticales	O
.	O

El	O
aprendizaje	O
y	O
la	O
discriminación	O
de	O
olores	O
mejorados	O
,	O
por	O
otro	O
lado	O
,	O
fueron	O
independientes	O
de	O
los	O
olores	O
residuales	O
GluR-B	B-Protein
niveles	O
en	O
el	O
bulbo	O
olfatorio	O
y	O
otras	O
áreas	O
del	O
cerebro	O
anterior	O
,	O
lo	O
que	O
indica	O
que	O
GluR-B	B-Protein
las	O
reducciones	O
son	O
suficientes	O
para	O
saturar	O
el	O
aprendizaje	O
y	O
la	O
discriminación	O
de	O
olores	O
mejorados	O
.	O

Así	O
,	O
aunque	O
ambos	O
están	O
mediados	O
por	O
alteraciones	B-Sequence
en	O
la	O
subunidad	O
AMPAR	O
GluR-B	B-Protein
,	O
debido	O
a	O
las	O
curvas	O
de	O
respuesta	O
a	O
la	O
dosis	O
cualitativamente	O
diferentes	O
,	O
los	O
fenotipos	O
relacionados	O
con	O
la	O
memoria	O
olfativa	O
y	O
el	O
aprendizaje	O
/	O
discriminación	O
olfatoria	O
deben	O
ser	O
mecánicamente	O
distintos	O
.	O

Rescate	O
Parcial	O
del	O
Déficit	O
de	O
Memoria	O
Olfatoria	O
por	O
Selectivo	O
transgénico	B-Sequence
GluR-B	B-Protein
Expresión	O
en	O
Hipocampo	O
y	O
Corteza	O
Piriforme	O
en	O
GluR	O
-	O
B	O
Delta	O
FB	O
Ratones	B-Taxon

El	O
efecto	O
de	O
la	O
selectiva	O
GluR-B	B-Protein
agotamiento	O
en	O
ratones	B-Taxon
indicó	O
eso	O
GluR-B	B-Protein
Es	O
probable	O
que	O
los	O
AMPAR	O
que	O
contienen	O
en	O
el	O
hipocampo	O
y/o	O
la	O
corteza	O
(	O
olfatoria	O
)	O
sean	O
importantes	O
para	O
la	O
memoria	O
olfativa	O
.	O

El	O
fenotipo	O
de	O
la	O
memoria	O
olfativa	O
podría	O
deberse	O
al	O
agotamiento	O
de	O
GluR-B	B-Protein
en	O
la	O
corteza	O
olfativa	O
o	O
hipocampo	O
;	O
las	O
capacidades	O
mejoradas	O
de	O
aprendizaje	O
y	O
discriminación	O
podrían	O
más	O
bien	O
ser	O
evocadas	O
por	O
AMPAR	O
que	O
carecen	O
GluR-B	B-Protein
en	O
el	O
bulbo	O
olfatorio	O
.	O

Para	O
obtener	O
evidencia	O
independiente	O
de	O
esta	O
disección	O
espacial	O
y	O
mecanicista	O
de	O
los	O
roles	O
de	O
Ca2	B-Chemical
+	I-Chemical
-	O
AMPAR	O
permeables	O
,	O
expresamos	O
por	O
transgénico	B-Sequence
medio	O
N	B-Sequence
-	I-Sequence
terminalmente	I-Sequence
verde	O
fluorescente	O
proteína	B-Chemical
(	O
GFP	O
)	O
-	O
etiquetado	O
GluR-B	B-Protein
específicamente	O
en	O
hipocampo	O
y	O
corteza	O
piriforme	O
de	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
(	O
Figura	O
5A	O
y	O
5B	O
)	O
.	O

De	O
acuerdo	O
con	O
la	O
región	O
-	O
dependencia	O
propuesta	O
,	O
esperábamos	O
que	O
subunidades	B-Protein
GluR-B	I-Protein
en	O
el	O
hipocampo	O
y/o	O
la	O
corteza	O
piriforme	O
mejoran	O
la	O
memoria	O
de	O
olores	O
pero	O
no	O
alteran	O
el	O
rendimiento	O
de	O
discriminación	O
de	O
olores	O
.	O

los	O
ratón	B-Taxon
línea	O
empleada	O
para	O
este	O
fin	O
,	O
denominada	O
GluR-BRescue	O
,	O
tenía	O
la	O
genético	B-Sequence
fondo	O
de	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
pero	O
además	O
llevaba	O
un	O
módulo	O
bidireccional	O
para	O
la	O
expresión	O
de	O
beta	O
-	O
galactosidasa	O
y	O
GFPGluR	O
-	O
B	O
,	O
que	O
respondía	O
a	O
la	O
tetraciclina	B-Chemical
transactivador	O
transcripcional	O
controlado	O
[	O
62	O
]	O
.	O

El	O
transactivador	O
estaba	O
bajo	O
el	O
control	O
de	O
un	O
modificado	B-Sequence
alfa	B-Protein
CaMKII	I-Protein
-	O
fragmento	B-Sequence
de	I-Sequence
promotor	I-Sequence
para	O
obtener	O
una	O
alta	O
selectividad	O
de	O
expresión	O
(	O
Figura	O
5A	O
;	O
ver	O
también	O
Materiales	O
y	O
Métodos	O
)	O
.	O

los	O
transgénico	B-Sequence
el	O
nivel	O
de	O
expresión	O
de	O
GFPGluR	O
-	O
B	O
fue	O
9	O
.	O
72	O
%	O
+/-	O
1	O
.	O
25	O
(	O
n	O
=	O
3	O
)	O
en	O
el	O
hipocampo	O
,	O
en	O
comparación	O
con	O
endógeno	O
GluR-B	B-Protein
(	O
Figura	O
5C	O
y	O
5D	O
)	O
.	O

Análisis	O
de	O
actividad	O
beta	O
-	O
galactosidasa	O
y	O
expresión	O
de	O
GFPGluR	O
-	O
B	O
en	O
secciones	O
de	O
cerebro	O
de	O
GluR	O
-	O
BRescue	O
ratones	B-Taxon
reveló	O
expresión	O
en	O
el	O
hipocampo	O
y	O
la	O
corteza	O
piriforme	O
,	O
mientras	O
que	O
la	O
corteza	O
,	O
la	O
amígdala	O
y	O
el	O
cuerpo	O
estriado	O
rara	O
vez	O
mostraron	O
resultados	O
positivos	O
.	O
células	B-Cell
(	O
Figura	O
5B	O
)	O
.	O

Es	O
importante	O
destacar	O
que	O
tanto	O
el	O
patrón	O
espacial	O
como	O
la	O
intensidad	O
de	O
la	O
expresión	O
de	O
GFPGluR-B	O
fueron	O
constantes	O
entre	O
todos	O
los	O
GluR-BRescue	O
ratones	B-Taxon
analizados	O
(	O
n	O
=	O
11	O
)	O
.	O

Experimentos	O
de	O
memoria	O
olfativa	O
con	O
GluR-BRescue	O
y	O
GluR-B	O
Delta	O
FB	O
y	O
GluR-B2lox	O
ratones	B-Taxon
como	O
controles	O
,	O
se	O
realizaron	O
como	O
se	O
describe	O
anteriormente	O
(	O
indicado	O
con	O
símbolos	O
sombreados	O
en	O
la	O
Figura	O
6A	O
)	O
.	O

La	O
memoria	O
fue	O
nuevamente	O
altamente	O
reproducible	O
tanto	O
en	O
GluR-B	O
Delta	O
FB	O
(	O
66	O
+/-	O
12	O
%	O
;	O
n	O
=	O
4	O
)	O
como	O
en	O
GluR-B2lox	O
(	O
94	O
+/-	O
2	O
%	O
;	O
n	O
=	O
3	O
)	O
ratones	B-Taxon
,	O
en	O
comparación	O
con	O
experimentos	O
realizados	O
anteriormente	O
(	O
Figuras	O
2E	O
y	O
4A	O
)	O
.	O

Es	O
importante	O
destacar	O
que	O
la	O
memoria	O
olfativa	O
en	O
GluR-BRescue	O
ratones	B-Taxon
fue	O
intermedio	O
(	O
75	O
+/-	O
15	O
%	O
,	O
n	O
=	O
8	O
)	O
,	O
por	O
debajo	O
de	O
los	O
niveles	O
de	O
control	O
de	O
GluR	O
-	O
B2lox	O
,	O
pero	O
mejor	O
que	O
en	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
.	O

La	O
evaluación	O
de	O
la	O
memoria	O
en	O
condiciones	O
libres	O
de	O
extinción	O
,	O
donde	O
cada	O
prueba	O
fue	O
recompensada	O
,	O
confirmó	O
nuevamente	O
que	O
el	O
déficit	O
de	O
memoria	O
era	O
un	O
verdadero	O
déficit	O
de	O
memoria	O
y	O
no	O
debido	O
a	O
una	O
mayor	O
extinción	O
(	O
Figura	O
S3B	O
)	O
.	O

Los	O
datos	O
de	O
los	O
experimentos	O
descritos	O
en	O
las	O
Figuras	O
2	O
y	O
4	O
se	O
combinaron	O
para	O
permitir	O
la	O
comparación	O
estadística	O
(	O
Figura	O
6A	O
y	O
6B	O
)	O
.	O

En	O
resumen	O
,	O
GluR-BRescue	O
ratones	B-Taxon
mostró	O
rendimientos	O
de	O
memoria	O
mejorados	O
en	O
comparación	O
con	O
GluR-B	O
Delta	O
FB	O
(	O
ANOVA	O
general	O
:	O
F	O
(	O
2	O
,	O
41	O
)	O
=	O
13,6	O
,	O
p	O
<	O
10-4	O
;	O
memoryRescue	O
=	O
75	O
+/-	O
15	O
%	O
,	O
n	O
=	O
8	O
;	O
memoria	O
Delta	O
FB	O
=	O
66	O
+/-	O
14	O
%	O
,	O
n	O
=	O
22	O
;	O
p	O
<	O
0	O
,	O
05	O
;	O
Figura	O
6A	O
)	O
,	O
pero	O
aún	O
estaban	O
deteriorados	O
en	O
relación	O
con	O
los	O
controles	O
GluR	O
-	O
B2lox	O
(	O
memory2lox	O
=	O
88	O
+/-	O
8	O
%	O
,	O
n	O
=	O
14	O
;	O
p	O
<	O
0	O
,	O
005	O
)	O
,	O
consistente	O
con	O
un	O
rescate	O
parcial	O
del	O
déficit	O
de	O
memoria	O
por	O
circunscrito	O
transgénico	B-Sequence
Expresión	O
de	O
GFPGluR-B	O
en	O
hipocampo	O
y	O
corteza	O
piriforme	O
.	O

En	O
particular	O
,	O
la	O
memoria	O
parcial	O
está	O
en	O
concordancia	O
numérica	O
con	O
las	O
predicciones	O
de	O
la	O
proteína	B-Chemical
correlación	O
y	O
la	O
medida	O
de	O
transgénico	B-Sequence
proteína	B-Chemical
expresión	O
(	O
ver	O
memoria	O
predicha	O
,	O
línea	O
azul	O
,	O
en	O
la	O
Figura	O
6B	O
)	O
.	O

En	O
los	O
experimentos	O
de	O
memoria	O
olfativa	O
con	O
GluR	O
-	O
B	O
Delta	O
FB	O
animales	B-Taxon
,	O
la	O
memoria	O
olfativa	O
dependía	O
linealmente	O
de	O
GluR-B	B-Protein
expresión	O
en	O
corteza	O
e	O
hipocampo	O
con	O
una	O
pendiente	O
de	O
9	O
.	O
1	O
+/-	O
2	O
.	O
5	O
%	O
(	O
corteza	O
)	O
y	O
8	O
.	O
9	O
+/-	O
2	O
.	O
0	O
%	O
(	O
hipocampo	O
)	O
de	O
aumento	O
en	O
la	O
memoria	O
por	O
10	O
%	O
de	O
aumento	O
en	O
proteína	B-Chemical
(	O
Figura	O
4D	O
)	O
.	O

un	O
9	O
aumento	O
del	O
7	O
%	O
en	O
GluR-B	B-Protein
en	O
estas	O
regiones	O
del	O
cerebro	O
,	O
según	O
lo	O
logrado	O
por	O
GluR-BRescue	O
animales	B-Taxon
(	O
Figura	O
5	O
)	O
,	O
por	O
lo	O
tanto	O
,	O
se	O
predice	O
que	O
aumentará	O
la	O
memoria	O
olfativa	O
en	O
aproximadamente	O
un	O
9	O
%	O
en	O
toda	O
la	O
población	O
heterogénea	O
(	O
línea	O
azul	O
en	O
la	O
Figura	O
6B	O
)	O
.	O

Esto	O
confirma	O
el	O
papel	O
de	O
estas	O
áreas	O
del	O
cerebro	O
como	O
se	O
infiere	O
de	O
la	O
expresión	O
del	O
mosaico	O
y	O
proteína	B-Chemical
análisis	O
de	O
correlación	O
descrito	O
anteriormente	O
(	O
Figura	O
4	O
)	O
.	O

Sin	O
embargo	O
,	O
la	O
discriminación	O
de	O
olores	O
(	O
medida	O
por	O
el	O
índice	O
de	O
discriminación	O
como	O
en	O
las	O
Figuras	O
1	O
,	O
2	O
y	O
4D	O
)	O
fue	O
tan	O
mejorada	O
como	O
en	O
GluR-B	O
Delta	O
FB	O
ratones	B-Taxon
0	O
.	O
79	O
+/-	O
0	O
.	O
05	O
,	O
media	O
+/-	O
SEM	O
en	O
comparación	O
con	O
0	O
.	O
76	O
+/-	O
0	O
.	O
02	O
,	O
p	O
>	O
0	O
.	O
7	O
,	O
Figura	O
6C	O
)	O
y	O
mejoró	O
en	O
relación	O
con	O
los	O
controles	O
GluR	O
-	O
B2lox	O
(	O
0	O
.	O
48	O
+/-	O
0,06	O
,	O
figura	O
6C	O
,	O
ANOVA	O
general	O
:	O
F	O
(	O
2	O
,	O
41	O
)	O
=	O
17,2	O
,	O
p	O
<	O
10-5	O
,	O
Newman	O
Keuls	O
post	O
hoc	O
:	O
p	O
<	O
10-3	O
)	O
,	O
como	O
se	O
esperaba	O
si	O
el	O
fenotipo	O
de	O
discriminación	O
mejorada	O
es	O
debido	O
a	O
Ca2	B-Chemical
+	I-Chemical
#	O
¿NOMBRE	O
?	O
GluR-B	B-Protein
expresión	O
en	O
la	O
corteza	O
piriforme	O
o	O
el	O
hipocampo	O
.	O

Por	O
eso	O
,	O
transgénico	B-Sequence
GluR-B	B-Protein
expresión	O
,	O
específicamente	O
en	O
la	O
corteza	O
piriforme	O
y	O
el	O
hipocampo	O
en	O
el	O
GluR-B	B-Protein
fondo	O
knockout	O
,	O
rescata	O
el	O
déficit	O
de	O
memoria	O
de	O
olores	O
pero	O
deja	O
inalterada	O
la	O
discriminación	O
y	O
el	O
aprendizaje	O
olfativos	O
mejorados	O
.	O

Discusión	O

Aquí	O
presentamos	O
disecciones	O
mecanicistas	O
y	O
espaciales	O
de	O
la	O
discriminación	O
olfativa	O
,	O
el	O
aprendizaje	O
y	O
la	O
memoria	O
.	O

nosotros	O
empleamos	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
transgénico	B-Sequence
ratones	B-Taxon
con	O
región	O
-	O
expresión	O
específica	O
para	O
demostrar	O
que	O
un	O
cambio	O
en	O
GluR-B	B-Protein
#	O
¿NOMBRE	O
?	O
alfa	B-Protein
CaMKII	I-Protein
#	O
¿NOMBRE	O
?	O
neuronas	B-Cell
de	O
ratón	B-Taxon
cerebro	O
anterior	O
,	O
incluidos	O
el	O
bulbo	O
olfatorio	O
mitral	O
y	O
células	B-Cell
granulares	I-Cell
,	O
mejora	O
la	O
discriminación	O
y	O
el	O
aprendizaje	O
olfativos	O
,	O
pero	O
perjudica	O
la	O
memoria	O
olfativa	O
.	O

Estos	O
comportamientos	O
olfativos	O
pertinentes	O
se	O
evaluaron	O
en	O
una	O
tarea	O
de	O
condicionamiento	O
operante	O
go/no-go	O
,	O
que	O
proporciona	O
una	O
herramienta	O
conductual	O
cuantitativa	O
,	O
robusta	O
y	O
reproducible	O
[	O
3	O
]	O
.	O

Observamos	O
entre	O
individuos	O
ratones	B-Taxon
una	O
notable	O
variabilidad	O
en	O
el	O
desempeño	O
de	O
la	O
memoria	O
olfativa	O
pero	O
no	O
en	O
la	O
discriminación	O
de	O
olores	O
.	O

Esta	O
variabilidad	O
podría	O
atribuirse	O
a	O
la	O
variabilidad	O
epigenética	O
en	O
el	O
transgénico	B-Sequence
expresión	O
de	O
Cre-recombinasa	O
,	O
que	O
media	O
la	O
recombinación	O
dentro	O
loxP	B-Sequence
-	I-Sequence
segmentos	I-Sequence
flanqueados	I-Sequence
de	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
alelos	B-Sequence
para	O
la	O
subunidad	O
AMPAR	O
dominante	O
GluR-B	B-Protein
,	O
y	O
por	O
lo	O
tanto	O
operó	O
el	O
interruptor	O
en	O
las	O
propiedades	O
AMPAR	O
hacia	O
GluR-B	B-Protein
ablación	O
y	O
aumento	O
Ca2	B-Chemical
+	I-Chemical
permeabilidad	O

En	O
contraste	O
con	O
la	O
memoria	O
variable	O
,	O
la	O
discriminación	O
olfativa	O
y	O
los	O
rendimientos	O
de	O
aprendizaje	O
parecían	O
ya	O
saturados	O
incluso	O
por	O
grados	O
moderados	O
de	O
expresión	O
de	O
Cre	O
y	O
,	O
por	O
lo	O
tanto	O
,	O
por	O
cambios	O
moderados	O
en	O
las	O
propiedades	O
de	O
AMPAR	O
.	O

El	O
posterior	O
transgén	B-Sequence
#	O
¿NOMBRE	O
?	O
GluR-B	B-Protein
,	O
específicamente	O
en	O
la	O
corteza	O
piriforme	O
y	O
el	O
hipocampo	O
,	O
revirtió	O
la	O
pérdida	O
inducida	O
por	O
Cre	O
de	O
GluR-B	B-Protein
rescató	O
parcialmente	O
el	O
déficit	O
de	O
memoria	O
de	O
olores	O
,	O
pero	O
dejó	O
inalterada	O
la	O
discriminación	O
olfativa	O
mejorada	O
.	O

En	O
pocas	O
palabras	O
,	O
concluimos	O
que	O
la	O
discriminación	O
olfativa	O
se	O
ve	O
reforzada	O
por	O
un	O
aumento	O
de	O
AMPAR	O
mediada	O
por	O
Ca2	B-Chemical
+	I-Chemical
permeabilidad	O
dentro	O
del	O
bulbo	O
olfativo	O
,	O
mientras	O
que	O
la	O
memoria	O
olfativa	O
se	O
deteriora	O
genéticamente	B-Sequence
inducido	O
GluR-B	B-Protein
ablación	O
en	O
centros	O
cerebrales	O
superiores	O
,	O
específicamente	O
en	O
la	O
corteza	O
piriforme	O
.	O

La	O
discriminación	O
olfativa	O
se	O
incrementa	O
en	O
Ratones	B-Taxon
con	O
Prosencéfalo	O
-	O
Específico	O
GluR-B	B-Protein
Ablación	O
o	O
GluR-B	B-Protein
(	O
q	B-Chemical
)	O
Expresión	O

Ambos	O
prosencéfalos	O
-	O
específicos	O
GluR-B	B-Protein
(	O
q	B-Chemical
)	O
expresión	O
y	O
GluR-B	B-Protein
el	O
agotamiento	O
condujo	O
a	O
un	O
mayor	O
aprendizaje	O
olfativo	O
y	O
capacidades	O
de	O
discriminación	O
.	O

Esto	O
fue	O
bastante	O
pronunciado	O
para	O
GluR-B	B-Protein
(	O
q	B-Chemical
)	O
-	O
expresando	O
ratones	B-Taxon
,	O
consistente	O
con	O
las	O
consecuencias	O
fenotípicas	O
más	O
fuertes	O
en	O
general	O
en	O
comparación	O
con	O
GluR-B	B-Protein
agotamiento	O
,	O
tanto	O
cuando	O
el	O
prosencéfalo	O
es	O
selectivo	O
(	O
[	O
58	O
]	O
,	O
y	O
este	O
estudio	O
)	O
o	O
global	O
[	O
53	O
,	O
60	O
]	O
.	O

``	O
Fue	O
necesario	O
un	O
análisis	O
detallado	O
del	O
patrón	O
de	O
muestreo	O
[	O
3	O
]	O
,	O
y	O
en	O
particular	O
el	O
análisis	O
de	O
las	O
tareas	O
de	O
discriminación	O
que	O
involucraron	O
pares	O
de	O
olores	O
monomoleculares	O
diferentes	O
``	O
''	O
simples	O
``	O
''	O
y	O
mezclas	O
binarias	O
``	O
''	O
difíciles	O
``	O
''	O
,	O
para	O
capturar	O
completamente	O
las	O
características	O
del	O
fenotipo	O
de	O
discriminación	O
olfativa	O
para	O
el	O
prosencéfalo	O
-	O
específico	O
''	O
GluR-B	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
.	O

Para	O
mezclas	O
binarias	O
estrechamente	O
relacionadas	O
,	O
las	O
mejoras	O
en	O
la	O
discriminación	O
fueron	O
mayores	O
,	O
en	O
consonancia	O
con	O
una	O
alteración	O
específica	O
en	O
la	O
discriminación	O
de	O
olores	O
,	O
en	O
lugar	O
de	O
una	O
mejora	O
general	O
de	O
las	O
capacidades	O
de	O
aprendizaje	O
.	O

Esto	O
está	O
respaldado	O
por	O
la	O
noción	O
de	O
que	O
no	O
se	O
observó	O
una	O
mejora	O
general	O
en	O
otras	O
tareas	O
conductuales	O
no	O
olfativas	O
,	O
p.	O
g.	O
,	O
tareas	O
de	O
aprendizaje	O
espacial	O
dependientes	O
del	O
hipocampo	O
,	O
como	O
tareas	O
de	O
memoria	O
de	O
referencia	O
espacial	O
de	O
coincidencia	O
con	O
el	O
lugar	O
(	O
Figura	O
S2	O
)	O
.	O

Como	O
no	O
se	O
observó	O
expresión	O
ni	O
actividad	O
de	O
Cre	O
en	O
los	O
principales	O
neuronas	B-Cell
sensoriales	I-Cell
olfativas	I-Cell
en	O
cualquier	O
etapa	O
de	O
desarrollo	O
(	O
Figura	O
S4	O
y	O
datos	O
no	O
publicados	O
)	O
,	O
la	O
función	O
epitelial	O
olfativa	O
no	O
se	O
vio	O
alterada	O
por	O
el	O
modificación	B-Sequence
genética	I-Sequence
.	O

El	O
órgano	O
vomeronasal	O
mostró	O
una	O
expresión	O
de	O
Cre	O
muy	O
débil	O
(	O
datos	O
no	O
publicados	O
)	O
,	O
pero	O
es	O
improbable	O
que	O
esta	O
estructura	O
tenga	O
un	O
papel	O
en	O
el	O
desempeño	O
de	O
la	O
tarea	O
de	O
discriminación	O
olfativa	O
(	O
para	O
una	O
revisión	O
,	O
ver	O
[	O
63	O
]	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
es	O
probable	O
que	O
el	O
fenotipo	O
conductual	O
esté	O
asociado	O
con	O
el	O
procesamiento	O
de	O
la	O
información	O
olfativa	O
más	O
que	O
con	O
la	O
detección	O
de	O
olores	O
.	O

Además	O
,	O
el	O
aumento	O
del	O
rendimiento	O
incluso	O
después	O
de	O
largos	O
periodos	O
de	O
entrenamiento	O
y	O
,	O
en	O
particular	O
,	O
el	O
aumento	O
de	O
las	O
diferencias	O
en	O
los	O
patrones	O
de	O
muestreo	O
(	O
TB	O
y	O
ATS	O
,	O
datos	O
no	O
publicados	O
)	O
respaldaron	O
la	O
idea	O
de	O
que	O
GluR-B	B-Protein
el	O
agotamiento	O
dio	O
como	O
resultado	O
una	O
mayor	O
capacidad	O
de	O
discriminación	O
de	O
olores	O
.	O

Por	O
lo	O
tanto	O
,	O
el	O
fenotipo	O
de	O
aprendizaje	O
podría	O
ser	O
el	O
resultado	O
de	O
esta	O
capacidad	O
de	O
discriminación	O
mejorada	O
o	O
reflejar	O
cambios	O
adicionales	O
en	O
los	O
circuitos	O
que	O
subyacen	O
a	O
la	O
adquisición	O
de	O
tareas	O
.	O

Putativo	O
Celular	B-Cell
Base	O
de	O
discriminación	O
y	O
aprendizaje	O
de	O
olores	O
mejorados	O

Las	O
propiedades	O
de	O
AMPAR	O
se	O
alteraron	O
específicamente	O
en	O
neuronas	B-Cell
de	O
las	O
áreas	O
del	O
prosencéfalo	O
,	O
más	O
notablemente	O
el	O
bulbo	O
olfativo	O
,	O
la	O
corteza	O
olfativa	O
y	O
otras	O
áreas	O
corticales	O
y	O
el	O
hipocampo	O
,	O
lo	O
que	O
conduce	O
a	O
una	O
mejor	O
discriminación	O
y	O
aprendizaje	O
de	O
los	O
olores	O
.	O

Curiosamente	O
,	O
transgénico	B-Sequence
expresión	O
de	O
GFPGluR	O
-	O
B	O
en	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
(	O
genético	B-Sequence
rescate	O
)	O
,	O
específicamente	O
en	O
la	O
corteza	O
piriforme	O
y	O
el	O
hipocampo	O
sin	O
expresión	O
detectable	O
en	O
el	O
bulbo	O
olfativo	O
,	O
no	O
alteró	O
las	O
capacidades	O
mejoradas	O
de	O
discriminación	O
y	O
aprendizaje	O
.	O

Esto	O
es	O
consistente	O
con	O
el	O
papel	O
principal	O
del	O
bulbo	O
olfativo	O
en	O
la	O
discriminación	O
y	O
el	O
aprendizaje	O
olfativos	O
.	O

Alternativamente	O
,	O
transgénico	B-Sequence
proteína	B-Chemical
los	O
niveles	O
podrían	O
haber	O
sido	O
demasiado	O
bajos	O
para	O
alterar	O
las	O
capacidades	O
de	O
discriminación	O
y	O
aprendizaje	O
,	O
aunque	O
la	O
memoria	O
se	O
vio	O
claramente	O
afectada	O
.	O

Esta	O
noción	O
se	O
pondrá	O
a	O
prueba	O
más	O
adelante	O
en	O
ratones	B-Taxon
con	O
corteza	O
piriforme	O
-	O
específico	O
GluR-B	B-Protein
ablación	O

Una	O
contribución	O
directa	O
al	O
fenotipo	O
por	O
Ca2	B-Chemical
+	I-Chemical
afluencia	O
a	O
través	O
genéticamente	B-Sequence
modificado	I-Sequence
Los	O
canales	O
AMPA	O
parecen	O
probables	O
,	O
ya	O
que	O
ratones	B-Taxon
expresando	O
q	B-Chemical
/	O
R	B-Chemical
sitio	B-Sequence
#	O
¿NOMBRE	O
?	O
GluR-B	B-Protein
mostró	O
un	O
rendimiento	O
de	O
aprendizaje	O
y	O
discriminación	O
de	O
olores	O
aún	O
mejor	O
en	O
comparación	O
con	O
ratones	B-Taxon
con	O
agotado	O
GluR-B	B-Protein
.	O

En	O
ambos	O
ratón	B-Taxon
modelos	O
Ca2	B-Chemical
+	I-Chemical
la	O
entrada	O
a	O
través	O
de	O
los	O
canales	O
AMPA	O
aumenta	O
,	O
mientras	O
que	O
el	O
efecto	O
sobre	O
la	O
conductancia	O
macroscópica	O
AMPA	O
es	O
diferente	O
.	O

Las	O
corrientes	O
AMPAR	O
se	O
reducen	O
en	O
ratones	B-Taxon
no	O
expresar	O
GluR-B	B-Protein
[	O
51	O
]	O
,	O
posiblemente	O
debido	O
a	O
menos	O
sináptico	B-GENE
Canalizaciones	O
de	O
AMPA	O
y	O
tráfico	O
y	O
reciclaje	O
de	O
AMPAR	O
deteriorado	O
.	O

En	O
ratones	B-Taxon
expresando	O
lo	O
inédito	O
formulario	B-Sequence
de	O
GluR-B	B-Protein
(	O
q	B-Chemical
)	O
,	O
conductancia	O
macroscópica	O
en	O
su	O
totalidad	O
-	O
célula	B-Cell
parches	O
de	O
CA1	O
piramidales	O
se	O
incrementa	O
[	O
60	O
]	O
,	O
pero	O
la	O
transmisión	O
excitatoria	O
en	O
CA3	O
-	O
a	O
-	O
CA1	O
célula	B-Cell
sinapsis	B-GENE
es	O
algo	O
reducido	O
,	O
a	O
pesar	O
de	O
un	O
umbral	O
más	O
bajo	O
para	O
generar	O
un	O
pico	O
de	O
población	O
[	O
58	O
]	O
,	O
lo	O
que	O
indica	O
un	O
aumento	O
sináptico	B-GENE
excitabilidad	O
por	O
sostenida	O
GluR-B	B-Protein
(	O
q	B-Chemical
)	O
expresión	O
,	O
en	O
consonancia	O
con	O
el	O
fenotipo	O
propenso	O
a	O
las	O
convulsiones	O
.	O

Sin	O
embargo	O
,	O
ambos	O
ratón	B-Taxon
los	O
modelos	O
producen	O
una	O
mejor	O
discriminación	O
y	O
capacidad	O
de	O
aprendizaje	O
.	O

El	O
fenotipo	O
más	O
leve	O
al	O
GluR-B	B-Protein
el	O
agotamiento	O
podría	O
atribuirse	O
a	O
la	O
reducción	O
de	O
las	O
densidades	O
de	O
AMPAR	O
en	O
sinapsis	B-GENE
40	O
,	O
41	O
]	O
y	O
por	O
lo	O
tanto	O
probablemente	O
en	O
menor	O
grado	O
de	O
Ca2	B-Chemical
+	I-Chemical
afluencia	O

Esto	O
está	O
respaldado	O
por	O
kainato	O
-	O
inducido	O
Co2	B-Chemical
+	I-Chemical
captación	O
en	O
cortes	O
cerebrales	O
agudos	O
,	O
revelando	O
considerablemente	O
mayor	O
Co2	B-Chemical
+	I-Chemical
captación	O
vía	O
Ca2	B-Chemical
+	I-Chemical
#	O
¿NOMBRE	O
?	O
neuronas	B-Cell
piramidales	I-Cell
de	O
ratones	B-Taxon
expresando	O
GluR-B	B-Protein
(	O
q	B-Chemical
)	O
,	O
que	O
los	O
que	O
carecen	O
GluR-B	B-Protein
(	O
DRS	O
,	O
RS	O
y	O
PHS	O
,	O
datos	O
no	O
publicados	O
)	O
.	O

Normalmente	O
,	O
GluR-B	B-Protein
#	O
¿NOMBRE	O
?	O
sinapsis	B-GENE
entre	O
mitral	O
y	O
células	B-Cell
granulares	I-Cell
en	O
el	O
bulbo	O
olfatorio	O
[	O
64	O
,	O
65	O
]	O
.	O

Como	O
Ca2	B-Chemical
+	I-Chemical
afluencia	O
a	O
través	O
glutamato	B-Chemical
Se	O
cree	O
que	O
los	O
receptores	O
contribuyen	O
a	O
la	O
inhibición	O
lateral	O
y	O
recurrente	O
(	O
[	O
38	O
]	O
véase	O
también	O
[	O
39	O
]	O
)	O
,	O
la	O
ausencia	O
de	O
GluR-B	B-Protein
,	O
o	O
la	O
presencia	O
de	O
GluR-B	B-Protein
(	O
q	B-Chemical
)	O
en	O
el	O
bulbo	O
olfatorio	O
,	O
es	O
probable	O
que	O
resulte	O
en	O
una	O
mayor	O
inhibición	O
entre	O
el	O
neuronas	B-Cell
principales	I-Cell
en	O
esta	O
estructura	O
.	O

En	O
particular	O
,	O
las	O
capacidades	O
mejoradas	O
de	O
discriminación	O
olfativa	O
fueron	O
evidentes	O
incluso	O
con	O
reducciones	O
relativamente	O
pequeñas	O
en	O
GluR-B	B-Protein
niveles	O

Será	O
interesante	O
ver	O
si	O
GluR-B	B-Protein
+	O
/	O
neo	O
ratones	B-Taxon
también	O
exhiben	O
una	O
mayor	O
discriminación	O
de	O
olores	O
,	O
lo	O
cual	O
es	O
probable	O
dado	O
que	O
los	O
niveles	O
bajos	O
de	O
GluR-B	B-Protein
(	O
q	B-Chemical
)	O
,	O
y	O
por	O
lo	O
tanto	O
un	O
pequeño	O
aumento	O
en	O
Ca2	B-Chemical
+	I-Chemical
AMPARs	O
permeables	O
,	O
surgen	O
del	O
GluR	O
-	O
Bneo	O
atenuado	O
alelo	B-Sequence
[	O
60	O
]	O
,	O
y	O
,	O
además	O
,	O
que	O
GluR-B	B-Protein
los	O
niveles	O
se	O
reducen	O
en	O
estos	O
ratones	B-Taxon
debido	O
a	O
la	O
única	O
copia	O
de	O
la	O
GluR-B	B-Protein
+	O
alelo	B-Sequence
.	O

En	O
prácticamente	O
todos	O
los	O
modelos	O
del	O
bulbo	O
olfativo	O
,	O
la	O
inhibición	O
lateral	O
(	O
y	O
,	O
en	O
menos	O
modelos	O
,	O
también	O
recurrente	O
)	O
juega	O
un	O
papel	O
dominante	O
,	O
ya	O
sea	O
en	O
el	O
establecimiento	O
de	O
la	O
dinámica	O
espacio-temporal	O
[	O
32	O
,	O
66-69	O
]	O
,	O
o	O
en	O
la	O
mejora	O
directa	O
del	O
contraste	O
y	O
,	O
por	O
lo	O
tanto	O
,	O
simplificando	O
la	O
discriminación	O
y	O
el	O
aprendizaje	O
.	O
de	O
olores	O
similares	O
[	O
24	O
,	O
28	O
,	O
29	O
,	O
36	O
]	O
.	O

Por	O
lo	O
tanto	O
,	O
una	O
mayor	O
inhibición	O
mejorará	O
en	O
general	O
la	O
discriminabilidad	O
,	O
en	O
consonancia	O
con	O
las	O
mejoras	O
conductuales	O
observadas	O
con	O
GluR-B	B-Protein
(	O
q	B-Chemical
)	O
expresión	O
,	O
la	O
GluR-B	B-Protein
``	O
nocaut	O
,	O
y	O
el	O
``	O
''	O
rescate	O
''	O
''	O
''	O
ratones	B-Taxon
.	O

Una	O
prueba	O
directa	O
de	O
este	O
vínculo	O
requeriría	O
la	O
medición	O
cuantitativa	O
de	O
la	O
inhibición	O
en	O
la	O
preparación	O
intacta	O
,	O
una	O
tarea	O
que	O
podría	O
ser	O
factible	O
con	O
técnicas	O
electrofisiológicas	O
in	O
vivo	O
mejoradas	O
,	O
tales	O
como	O
registros	O
dirigidos	O
[	O
70	O
,	O
71	O
]	O
o	O
pre	O
y	O
postsinápticos	O
simultáneos	O
.	O
intracelular	B-GENE
mediciones	O
.	O

La	O
memoria	O
olfativa	O
se	O
reduce	O
en	O
GluR-B	B-Protein
Knockear	O
Ratones	B-Taxon
y	O
mejorado	O
por	O
GluR-B	B-Protein
Expresión	O
en	O
Corteza	O
Piriforme	O
e	O
Hipocampo	O

Para	O
evaluar	O
la	O
memoria	O
olfativa	O
de	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
,	O
después	O
de	O
seis	O
días	O
el	O
ratones	B-Taxon
fueron	O
probados	O
con	O
presentaciones	O
de	O
olores	O
sin	O
recompensa	O
que	O
intercalaban	O
una	O
tarea	O
de	O
discriminación	O
simple	O
.	O

Las	O
tareas	O
conductuales	O
prolongadas	O
,	O
como	O
la	O
evaluación	O
de	O
la	O
memoria	O
olfativa	O
a	O
largo	O
plazo	O
,	O
no	O
se	O
realizaron	O
con	O
el	O
GluR-B	O
Delta	O
ECS	O
propenso	O
a	O
las	O
convulsiones	O
:	O
FB	O
ratones	B-Taxon
.	O

Memoria	O
en	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
,	O
sin	O
embargo	O
,	O
se	O
deterioró	O
dramáticamente	O
.	O

Esto	O
no	O
puede	O
atribuirse	O
a	O
un	O
déficit	O
general	O
e	O
inespecífico	O
porque	O
,	O
simultáneamente	O
con	O
los	O
ensayos	O
de	O
memoria	O
,	O
la	O
tarea	O
de	O
discriminación	O
normal	O
y	O
recompensada	O
se	O
realizó	O
incluso	O
mejor	O
que	O
los	O
controles	O
.	O

La	O
memoria	O
olfativa	O
reducida	O
tampoco	O
puede	O
atribuirse	O
simplemente	O
a	O
una	O
mayor	O
extinción	O
,	O
ya	O
que	O
no	O
se	O
observaron	O
interacciones	O
significativas	O
entre	O
el	O
grupo	O
de	O
prueba	O
y	O
también	O
,	O
cuando	O
se	O
restringió	O
a	O
las	O
primeras	O
pruebas	O
de	O
memoria	O
sin	O
recompensa	O
,	O
se	O
observó	O
un	O
deterioro	O
significativo	O
(	O
Figura	O
S3A	O
)	O
.	O

``	O
Además	O
,	O
la	O
investigación	O
del	O
reaprendizaje	O
de	O
la	O
primera	O
tarea	O
de	O
discriminación	O
reveló	O
una	O
correlación	O
significativa	O
con	O
el	O
rendimiento	O
de	O
la	O
memoria	O
,	O
mostrando	O
un	O
déficit	O
de	O
``	O
''	O
memoria	O
''	O
''	O
en	O
condiciones	O
libres	O
de	O
extinción	O
(	O
Figura	O
S3B	O
)	O
.	O
''	O

Finalmente	O
,	O
en	O
otras	O
tareas	O
relacionadas	O
con	O
la	O
memoria	O
,	O
como	O
una	O
tarea	O
de	O
memoria	O
de	O
referencia	O
espacial	O
dependiente	O
del	O
hipocampo	O
(	O
Figura	O
S2	O
)	O
,	O
ratones	B-Taxon
con	O
GluR-B	B-Protein
el	O
agotamiento	O
no	O
se	O
vieron	O
afectados	O
después	O
de	O
la	O
adquisición	O
de	O
la	O
tarea	O
.	O

Por	O
lo	O
tanto	O
,	O
concluimos	O
que	O
el	O
cerebro	O
anterior	O
-	O
ablación	O
específica	O
de	O
GluR-B	B-Protein
resulta	O
en	O
una	O
pérdida	O
específica	O
de	O
la	O
memoria	O
olfativa	O
a	O
largo	O
plazo	O
pero	O
,	O
al	O
mismo	O
tiempo	O
,	O
en	O
una	O
mejor	O
discriminación	O
de	O
olores	O
y	O
capacidades	O
de	O
aprendizaje	O
.	O

Analizar	O
los	O
fenotipos	O
de	O
discriminación	O
,	O
aprendizaje	O
y	O
memoria	O
y	O
,	O
en	O
última	O
instancia	O
,	O
identificar	O
posibles	O
celular	B-Cell
correlatos	O
,	O
hicimos	O
uso	O
de	O
la	O
expresión	O
Cre	O
abigarrada	O
de	O
TgCre4	O
ratones	B-Taxon
.	O

Por	O
lo	O
tanto	O
,	O
residual	O
GluR-B	B-Protein
se	O
determinaron	O
los	O
niveles	O
de	O
cada	O
ratón	B-Taxon
que	O
se	O
había	O
probado	O
en	O
los	O
experimentos	O
de	O
comportamiento	O
,	O
y	O
los	O
niveles	O
se	O
correlacionaron	O
con	O
el	O
aprendizaje	O
de	O
olores	O
,	O
la	O
discriminación	O
y	O
la	O
memoria	O
olfativa	O
.	O

La	O
significativa	O
correlación	O
directa	O
entre	O
residuos	O
GluR-B	B-Protein
niveles	O
en	O
hipocampo	O
y	O
áreas	O
corticales	O
con	O
memoria	O
olfativa	O
sugerida	O
hipocampal	O
y/o	O
cortical	O
neuronas	B-Cell
como	O
mediadores	O
putativos	O
para	O
la	O
memorización	O
y/o	O
almacenamiento	O
de	O
olores	O
.	O

Ninguna	O
medida	O
de	O
discriminación	O
y	O
aprendizaje	O
,	O
por	O
otro	O
lado	O
,	O
se	O
correlacionó	O
con	O
residual	O
GluR-B	B-Protein
niveles	O
;	O
incluso	O
la	O
reducción	O
más	O
pequeña	O
en	O
GluR-B	B-Protein
(	O
alrededor	O
de	O
20	O
%	O
-60	O
%	O
)	O
fue	O
suficiente	O
para	O
establecer	O
y	O
saturar	O
las	O
capacidades	O
mejoradas	O
de	O
discriminación	O
de	O
olores	O
.	O

Juntos	O
,	O
esto	O
permite	O
concluir	O
que	O
distintos	O
mecanismos	O
median	O
la	O
discriminación/aprendizaje	O
y	O
la	O
memoria	O
.	O

Además	O
,	O
esto	O
es	O
consistente	O
con	O
un	O
papel	O
destacado	O
de	O
las	O
áreas	O
corticales	O
o	O
el	O
hipocampo	O
en	O
la	O
memoria	O
olfativa	O
,	O
aunque	O
GluR-B	B-Protein
los	O
niveles	O
en	O
el	O
bulbo	O
olfativo	O
también	O
se	O
correlacionaron	O
débilmente	O
con	O
el	O
rendimiento	O
de	O
la	O
memoria	O
.	O

transgénico	B-Sequence
expresión	O
de	O
GFPGluR-B	O
en	O
la	O
corteza	O
piriforme	O
y	O
el	O
hipocampo	O
de	O
hecho	O
rescató	O
la	O
memoria	O
en	O
una	O
medida	O
sorprendentemente	O
consistente	O
con	O
la	O
transgénico	B-Sequence
proteína	B-Chemical
(	O
aproximadamente	O
el	O
10	O
%	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
GluR-B	B-Protein
)	O
,	O
lo	O
que	O
confirma	O
la	O
fiabilidad	O
del	O
análisis	O
de	O
correlación	O
y	O
la	O
sensibilidad	O
del	O
ensayo	O
de	O
comportamiento	O
.	O

En	O
general	O
,	O
se	O
piensa	O
que	O
el	O
hipocampo	O
está	O
involucrado	O
sólo	O
en	O
aquellas	O
tareas	O
de	O
memoria	O
olfativa	O
que	O
involucran	O
el	O
análisis	O
de	O
secuencias	O
temporales	O
o	O
requieren	O
otras	O
características	O
cognitivas	O
superiores	O
[	O
2	O
,	O
13	O
,	O
72-74	O
]	O
.	O

En	O
particular	O
,	O
las	O
lesiones	O
extensas	O
de	O
la	O
formación	O
del	O
hipocampo	O
en	O
ratas	B-Taxon
no	O
interfieren	O
con	O
la	O
memoria	O
olfativa	O
a	O
largo	O
plazo	O
en	O
las	O
tareas	O
sucesivas	O
de	O
discriminación	O
olfativa	O
[	O
72	O
]	O
,	O
como	O
la	O
descrita	O
.	O

Esto	O
deja	O
a	O
la	O
corteza	O
piriforme	O
como	O
el	O
candidato	O
más	O
prominente	O
para	O
el	O
lugar	O
del	O
déficit	O
de	O
memoria	O
olfativa	O
descrito	O
,	O
de	O
acuerdo	O
con	O
la	O
visión	O
predominante	O
de	O
la	O
corteza	O
piriforme	O
como	O
una	O
estructura	O
de	O
memoria	O
asociativa	O
[	O
75	O
]	O
y	O
los	O
cambios	O
asociados	O
con	O
el	O
aprendizaje	O
en	O
la	O
corteza	O
piriforme	O
[	O
7	O
,	O
20-23	O
]	O
.	O
.	O

Mecanismos	O
potenciales	O
de	O
deterioro	O
específico	O
de	O
la	O
memoria	O
olfativa	O

¿Cuál	O
podría	O
ser	O
el	O
celular	B-Cell
base	O
del	O
déficit	O
de	O
memoria	O
a	O
largo	O
plazo	O
provocado	O
por	O
la	O
falta	O
de	O
GluR-B	B-Protein
#	O
¿NOMBRE	O
?	O

para	O
completar	O
GluR-B	B-Protein
knockouts	O
,	O
se	O
informó	O
un	O
aumento	O
de	O
la	O
plasticidad	O
a	O
largo	O
plazo	O
(	O
LTP	O
)	O
en	O
las	O
grabaciones	O
de	O
campo	O
del	O
hipocampo	O
[	O
51	O
]	O
.	O

Además	O
,	O
en	O
las	O
vías	O
del	O
hipocampo	O
y	O
la	O
amígdala	O
que	O
carecen	O
GluR-B	B-Protein
,	O
dependiente	O
de	O
AMPAR	O
,	O
norte	B-Chemical
-	O
metilo	B-Chemical
-	O
D	B-Chemical
-	I-Chemical
aspartato	I-Chemical
(	O
NMDA	O
)	O
la	O
forma	O
de	O
LTP	O
independiente	O
del	O
receptor	O
puede	O
inducirse	O
fácilmente	O
[	O
51	O
,	O
52	O
]	O
.	O

Mecánicamente	O
,	O
es	O
probable	O
que	O
esto	O
se	O
deba	O
a	O
Ca2	B-Chemical
+	I-Chemical
afluencia	O
a	O
través	O
GluR-B	B-Protein
#	O
¿NOMBRE	O
?	O

Sin	O
embargo	O
,	O
la	O
dependencia	O
hebbiana	O
de	O
la	O
actividad	O
presináptica	O
y	O
postsináptica	O
simultánea	O
suele	O
ser	O
una	O
característica	O
fundamental	O
para	O
el	O
almacenamiento	O
de	O
memoria	O
(	O
revisado	O
,	O
p	O
.	O
ej.	O
,	O
en	O
[	O
76	O
]	O
)	O
;	O
por	O
lo	O
tanto	O
,	O
una	O
forma	O
de	O
plasticidad	O
no	O
hebbiana	O
debería	O
resultar	O
en	O
una	O
mala	O
memorización	O
.	O

Sorprendentemente	O
,	O
en	O
GluR-B	O
Delta	O
FB	O
ratones	B-Taxon
no	O
se	O
pudieron	O
observar	O
cambios	O
de	O
LTP	O
en	O
mediciones	O
de	O
campo	O
en	O
el	O
hipocampo	O
,	O
ni	O
se	O
pudo	O
inducir	O
LTP	O
independiente	O
de	O
NMDA	O
en	O
el	O
hipocampo	O
.	O
sinapsis	B-GENE
entre	O
garantías	O
Schaffer	O
y	O
CA1	O
células	B-Cell
piramidales	I-Cell
en	O
presencia	O
de	O
la	O
NMDA	O
antagonista	B-Chemical
APV	O
(	O
K.	O
Jensen	O
,	O
O.	O
Hvalby	O
,	O
comunicación	O
personal	O
)	O
.	O

Sin	O
embargo	O
,	O
en	O
otras	O
áreas	O
del	O
cerebro	O
que	O
son	O
potencialmente	O
importantes	O
para	O
el	O
procesamiento	O
de	O
la	O
información	O
olfativa	O
,	O
como	O
la	O
corteza	O
piriforme	O
o	O
el	O
bulbo	O
olfativo	O
,	O
aún	O
no	O
se	O
han	O
realizado	O
mediciones	O
de	O
LTP	O
;	O
sinapsis	B-GENE
de	O
estas	O
vías	O
pueden	O
estar	O
reguladas	O
de	O
manera	O
diferente	O
que	O
el	O
hipocampo	O
CA3	O
/	O
CA1	O
sinapsis	B-GENE
.	O

Además	O
,	O
al	O
cambiar	O
el	O
Ca2	B-Chemical
+	I-Chemical
permeabilidad	O
de	O
los	O
AMPAR	O
,	O
Ca2	B-Chemical
+	I-Chemical
la	O
señalización	O
a	O
través	O
de	O
los	O
canales	O
AMPA	O
y	O
NMDA	O
colocalizados	O
podría	O
verse	O
perturbada	O
,	O
lo	O
que	O
perjudicaría	O
la	O
formación	O
de	O
la	O
memoria	O
.	O

Otras	O
formas	O
de	O
plasticidad	O
[	O
77	O
,	O
78	O
]	O
inducidas	O
por	O
Ca2	B-Chemical
+	I-Chemical
Los	O
AMPAR	O
permeables	O
podrían	O
desempeñar	O
un	O
papel	O
predominante	O
en	O
la	O
memoria	O
olfativa	O
.	O

Alternativamente	O
,	O
la	O
estabilización	O
a	O
largo	O
plazo	O
podría	O
involucrar	O
GluR-B	B-Protein
fosforilación	O
similar	O
a	O
la	O
depresión	O
cerebelosa	O
a	O
largo	O
plazo	O
[	O
79	O
]	O
y	O
,	O
por	O
lo	O
tanto	O
,	O
ser	O
afectado	O
selectivamente	O
por	O
GluR-B	B-Protein
agotamiento	O

Idealmente	O
,	O
los	O
experimentos	O
fisiológicos	O
para	O
evaluar	O
estas	O
hipótesis	O
harán	O
uso	O
de	O
métodos	O
aún	O
más	O
restringidos	O
.	O
modificaciones	B-Sequence
geneticas	I-Sequence
con	O
estructuras	O
de	O
entrada	O
completamente	O
inalteradas	O
.	O

Una	O
posibilidad	O
sería	O
mediada	O
por	O
Cre	O
GluR-B	B-Protein
agotamiento	O
y	O
GluR-B	B-Protein
(	O
q	B-Chemical
)	O
expresión	O
en	O
la	O
corteza	O
piriforme	O
como	O
se	O
sugirió	O
anteriormente	O
.	O

Correlación	O
del	O
comportamiento	O
cuantitativo	O
y	O
el	O
mosaico	O
Gene	B-Sequence
Expresión	O
para	O
disección	O
de	O
fenotipos	O

Un	O
paso	O
crítico	O
para	O
discernir	O
los	O
fenotipos	O
de	O
discriminación	O
y	O
aprendizaje	O
del	O
fenotipo	O
de	O
memoria	O
fue	O
la	O
observación	O
de	O
una	O
mayor	O
variabilidad	O
en	O
la	O
memoria	O
del	O
GluR-B	B-Protein
knockear	O
animales	B-Taxon
y	O
,	O
posteriormente	O
,	O
los	O
análisis	O
individuales	O
de	O
proteína	B-Chemical
niveles	O
de	O
expresión	O
.	O

Hicimos	O
uso	O
de	O
la	O
variabilidad	O
epigenética	O
en	O
GluR-B	B-Protein
excisión	B-Sequence
eso	O
podría	O
estar	O
correlacionado	O
con	O
la	O
variabilidad	O
en	O
la	O
memoria	O
pero	O
no	O
mostró	O
correlación	O
con	O
la	O
variabilidad	O
en	O
la	O
discriminación	O
.	O

el	O
analisis	O
de	O
loci	B-Sequence
de	I-Sequence
rasgos	I-Sequence
cuantitativos	I-Sequence
(	O
para	O
revisión	O
,	O
ver	O
[	O
80	O
]	O
)	O
,	O
o	O
clásicamente	O
correlacionando	O
diferentes	O
fenotipos	O
de	O
comportamiento	O
dentro	O
de	O
un	O
verdadero	O
tipo	B-Sequence
salvaje	I-Sequence
población	O
[	O
81	O
-	O
84	O
]	O
,	O
también	O
intenta	O
encontrar	O
común	O
o	O
distinto	O
genético	B-Sequence
Orígenes	O
de	O
diferentes	O
rasgos	O
de	O
comportamiento	O
.	O

Estos	O
intentos	O
,	O
sin	O
duda	O
,	O
contribuyen	O
significativamente	O
a	O
desentrañar	O
el	O
molecular	B-Chemical
base	O
del	O
comportamiento	O
.	O

Debido	O
a	O
diferencias	O
sutiles	O
y	O
multigénicas	O
entre	O
diferentes	O
cepas	O
de	O
roedores	B-Taxon
o	O
diferente	O
individuos	B-Taxon
en	O
un	O
tipo	B-Sequence
salvaje	I-Sequence
``	O
Sin	O
embargo	O
,	O
la	O
población	O
sufre	O
de	O
una	O
relación	O
``	O
''	O
señal-ruido	O
''	O
''	O
bastante	O
baja	O
.	O
''	O

Las	O
diferencias	O
en	O
el	O
individuo	O
genes	B-Sequence
son	O
bastante	O
pequeños	O
en	O
comparación	O
con	O
la	O
gran	O
cantidad	O
de	O
genes	B-Sequence
involucrado	O
.	O

Como	O
resultado	O
,	O
la	O
correlación	O
pura	O
de	O
rasgos	O
de	O
comportamiento	O
dentro	O
de	O
un	O
tipo	B-Sequence
salvaje	I-Sequence
la	O
población	O
por	O
lo	O
general	O
sigue	O
siendo	O
bastante	O
descriptiva	O
,	O
mientras	O
que	O
loci	B-Sequence
de	I-Sequence
rasgos	I-Sequence
cuantitativos	I-Sequence
El	O
análisis	O
es	O
capaz	O
de	O
revelar	O
la	O
base	O
multigénica	O
de	O
los	O
rasgos	O
de	O
comportamiento	O
,	O
pero	O
por	O
lo	O
general	O
carece	O
del	O
poder	O
para	O
identificar	O
al	O
individuo	O
.	O
genes	B-Sequence
ellos	O
mismos	O
.	O

En	O
este	O
documento	O
,	O
describimos	O
una	O
forma	O
de	O
mejorar	O
la	O
relación	O
señal-ruido	O
haciendo	O
uso	O
de	O
la	O
expresión	O
de	O
mosaico	O
a	O
menudo	O
asociada	O
con	O
transgénico	B-Sequence
``	O
enfoques	O
:	O
combinando	O
las	O
ventajas	O
de	O
``	O
''	O
clásico	O
''	O
''	O
''	O
genético	B-Sequence
manipulación	O
-	O
es	O
decir	O
,	O
que	O
el	O
objetivo	O
de	O
la	O
manipulación	O
esté	O
bien	O
definido	O
-	O
con	O
la	O
posibilidad	O
de	O
analizar	O
la	O
variabilidad	O
,	O
también	O
podría	O
en	O
el	O
futuro	O
proporcionar	O
nuevas	O
formas	O
de	O
definir	O
molecular	B-Chemical
y	O
celular	B-Cell
correlatos	O
de	O
rasgos	O
conductuales	O
complejos	O
.	O

En	O
este	O
estudio	O
,	O
combinamos	O
genéticamente	B-Sequence
manipulacin	O
inducida	O
de	O
la	O
composicin	O
de	O
AMPAR	O
con	O
comportamiento	O
cuantitativo	O
y	O
molecular	B-Chemical
analiza	O

Por	O
lo	O
tanto	O
,	O
podríamos	O
proporcionar	O
evidencia	O
de	O
roles	O
opuestos	O
de	O
GluR-B	B-Protein
manipulación	O
y	O
aumento	O
Ca2	B-Chemical
+	I-Chemical
afluencia	O
a	O
través	O
de	O
AMPAR	O
en	O
la	O
discriminación/aprendizaje	O
olfativo	O
y	O
la	O
memoria	O
,	O
potencialmente	O
en	O
el	O
bulbo	O
olfativo	O
y	O
la	O
corteza	O
piriforme	O
,	O
respectivamente	O
.	O

Para	O
lograr	O
esto	O
,	O
hicimos	O
uso	O
de	O
la	O
variabilidad	O
epigenética	O
en	O
la	O
extensión	O
de	O
GluR-B	B-Protein
la	O
ablación	O
,	O
que	O
se	O
correlacionó	O
con	O
la	O
variabilidad	O
en	O
la	O
memoria	O
del	O
olor	O
,	O
pero	O
no	O
en	O
la	O
discriminación	O
y	O
el	O
aprendizaje	O
;	O
este	O
hallazgo	O
fue	O
posteriormente	O
confirmado	O
en	O
GluR-B	B-Protein
rescate	O
ratones	B-Taxon
con	O
corteza	O
piriforme	O
-	O
específico	O
transgénico	B-Sequence
expresión	O
de	O
GluR-B	B-Protein
.	O

Ampliando	O
estos	O
principios	O
de	O
combinar	O
análisis	O
cuantitativos	O
de	O
comportamiento	O
con	O
análisis	O
mínimos	O
y	O
dosificados	O
genético	B-Sequence
la	O
interferencia	O
,	O
junto	O
con	O
otros	O
análisis	O
fisiológicos	O
,	O
finalmente	O
identificará	O
los	O
circuitos	O
neuronales	O
que	O
subyacen	O
a	O
los	O
rasgos	O
conductuales	O
relacionados	O
,	O
pero	O
distintos	O
,	O
en	O
el	O
olfato	O
y	O
otros	O
sistemas	O
.	O

Materiales	O
y	O
métodos	O

Ratón	B-Taxon
líneas	O

La	O
línea	O
R26R	O
[	O
85	O
]	O
se	O
empleó	O
como	O
indicador	O
Cre	O
.	O

GluR-B	O
Delta	O
ECS	O
:	O
FB	O
ratones	B-Taxon
fueron	O
de	O
mezcla	O
C57Bl/6	O
y	O
NMRI	O
genético	B-Sequence
``	O
fondo	O
y	O
generado	O
a	O
partir	O
de	O
TgCre4	O
(	O
``	O
''	O
Camkcre4	O
``	O
''	O
en	O
[	O
59	O
]	O
)	O
y	O
''	O
GluR-B	B-Protein
+	O
/	O
neo	O
[	O
60	O
]	O
ratones	B-Taxon
.	O

GluR-B	B-Protein
+	O
/	O
neo	O
ratones	B-Taxon
cargar	O
una	O
tipo	B-Sequence
salvaje	I-Sequence
GluR-B	B-Protein
alelo	B-Sequence
y	O
un	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
GluR-B	B-Protein
alelo	B-Sequence
en	O
el	O
que	O
la	O
secuencia	B-Sequence
del	I-Sequence
intrón	I-Sequence
11	I-Sequence
crítico	O
para	O
q	B-Chemical
/	O
R	B-Chemical
sitio	B-Sequence
editar	O
es	O
sustituido	B-Sequence
por	O
un	O
TK	O
-	O
neo	O
gen	B-Sequence
flanqueado	I-Sequence
por	O
sitios	B-Sequence
loxP	I-Sequence
``	O
(	O
``	O
''	O
''	O
flojo	B-Sequence
)	O
.	O

GluR-B2lox	O
ratones	B-Taxon
[	O
86	O
]	O
llevar	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
GluR-B	B-Protein
alelos	B-Sequence
en	O
el	O
cual	O
exón	B-Sequence
11	O
es	O
flojo	B-Sequence
.	O

GluR-B	O
Delta	O
FB	O
ratones	B-Taxon
eran	O
de	O
C57Bl/6	O
genético	B-Sequence
fondo	O
y	O
generado	O
a	O
partir	O
de	O
TgCre4	O
y	O
GluR	O
-	O
B2lox	O
ratones	B-Taxon
.	O

TgCN12	O
-	O
itTA	O
ratones	B-Taxon
se	O
generaron	O
como	O
se	O
describe	O
para	O
TgCN10	O
-	O
itTA	O
ratones	B-Taxon
(	O
ver	O
Materiales	O
y	O
Métodos	O
en	O
[	O
58	O
]	O
)	O
,	O
y	O
representan	O
otra	O
línea	O
fundadora	O
obtenida	O
del	O
mismo	O
pronúcleo	B-GENE
inyección	O
,	O
con	O
una	O
expresión	O
más	O
amplia	O
del	O
cerebro	O
anterior	O
.	O

Para	O
la	O
expresión	O
exógena	O
de	O
GFPGluR-B	O
,	O
el	O
ratón	B-Taxon
se	O
generó	O
la	O
línea	O
TgOCN1	O
:	O
un	O
AseI	O
fragmento	B-Sequence
de	O
plásmido	B-Sequence
pnlacZ	O
/	O
GFPGluR	O
-	O
B	O
fue	O
inyectado	O
en	O
el	O
pronúcleo	B-GENE
de	O
ovocitos	B-Cell
obtenido	O
de	O
híbridos	O
DBA1/C57Bl/6	O
F1	O
.	O

Los	O
fundadores	O
positivos	O
se	O
retrocruzaron	O
con	O
C57Bl/6	O
para	O
su	O
posterior	O
análisis	O
.	O

plásmido	B-Sequence
pnlacZ	O
/	O
GFPGluR	O
-	O
B	O
fue	O
construido	O
a	O
partir	O
de	O
pnlacZ	O
/	O
GFPGluR	O
-	O
A	O
[	O
87	O
]	O
por	O
reemplazando	B-Sequence
GluR-A	B-Protein
ADNc	B-Sequence
con	O
el	O
rata	B-Taxon
ADNc	B-Sequence
por	O
GluR-B	B-Protein
.	O

transgénico	B-Sequence
GFPGluR	O
-	O
B	O
proteína	B-Chemical
se	O
midieron	O
los	O
niveles	O
en	O
el	O
hipocampo	O
de	O
TgOCN1	O
ratones	B-Taxon
también	O
llevando	O
un	O
transgén	B-Sequence
para	O
la	O
expresión	O
de	O
tTA	O
homogénea	O
específica	O
del	O
prosencéfalo	O
[	O
88	O
]	O
.	O

Grupos	O
experimentales	O

Ratones	B-Taxon
heterocigoto	O
para	O
TgCre4	O
y	O
heterocigoto	O
para	O
TK	O
-	O
neo	O
casete	B-Sequence
en	O
el	O
GluR-B	B-Protein
alelo	B-Sequence
(	O
GluR-B	O
Delta	O
ECS	O
:	O
FB	O
)	O
u	O
homocigoto	O
para	O
el	O
flojo	B-Sequence
GluR-B	B-Protein
(	O
GluR-B	O
Delta	O
FB	O
)	O
se	O
utilizaron	O
en	O
los	O
experimentos	O
.	O

``	O
El	O
rescate	O
``	O
''	O
''	O
ratones	B-Taxon
GluR	O
-	O
BRescue	O
)	O
fueron	O
positivos	O
para	O
TgCre4	O
,	O
homocigotos	O
para	O
el	O
floxed	B-Sequence
GluR	I-Sequence
-	I-Sequence
gen	I-Sequence
B	I-Sequence
,	O
y	O
positivo	O
para	O
el	O
tet	B-Chemical
#	O
¿NOMBRE	O
?	O
transgén	B-Sequence
TgOCN1	O
y	O
para	O
el	O
activador	O
que	O
expresa	O
itTA	O
transgén	B-Sequence
TgCN12-itTA	O
.	O

Grupos	O
de	O
control	O

Se	O
utilizaron	O
controles	O
de	O
compañeros	O
de	O
camada	O
en	O
todos	O
los	O
experimentos	O
.	O

GluR-B	B-Protein
+	O
/	O
+	O
ratones	B-Taxon
se	O
utilizaron	O
como	O
controles	O
en	O
la	O
tarea	O
descrita	O
en	O
la	O
Figura	O
1	O
.	O

GluR-B	B-Protein
+/2lox	O
y	O
GluR	O
-	O
B2lox/2lox	O
(	O
ambos	O
negativos	O
para	O
TgCre4	O
)	O
ratones	B-Taxon
se	O
usaron	O
como	O
controles	O
en	O
los	O
experimentos	O
descritos	O
en	O
las	O
Figuras	O
2	O
,	O
4	O
y	O
6	O
.	O

Para	O
los	O
experimentos	O
GluR-BRescue	O
(	O
Figura	O
6	O
)	O
,	O
los	O
controles	O
positivos	O
para	O
TgCN12-itTA	O
o	O
TgOCN1	O
en	O
un	O
GluR-B	B-Protein
Se	O
utilizaron	O
los	O
antecedentes	O
+/2lox	O
y	O
GluR-B2lox/2lox	O
(	O
ambos	O
negativos	O
para	O
TgCre4	O
)	O
.	O

genotipado	O

Ratones	B-Taxon
fueron	O
seleccionados	O
por	O
PCR	O
de	O
ratón	B-Taxon
#	O
¿NOMBRE	O
?	O
ADN	B-Sequence
con	O
específico	O
cebadores	B-Sequence
como	O
se	O
describe	O
abajo	O
.	O

Se	O
indican	O
los	O
secuencias	B-Sequence
y	O
la	O
longitud	O
aproximada	O
del	O
amplificado	O
fragmentos	B-Sequence
de	I-Sequence
ADN	I-Sequence
.	O

TgCre4	O
:	O
rspCre1	O
(	O
5	O
'	O
-	O
ACCAGGTTCGTTCACTCATGG	O
-	O
3	O
'	O
)	O
y	O
rspCre2	O
(	O
5	O
'	O
-	O
AGGCTAAGTGCCTTCTCTACAC	O
-	O
3	O
'	O
)	O
,	O
200	O
pares	B-Sequence
de	I-Sequence
bases	I-Sequence
(	O
pb	B-Sequence
)	O
.	O

GluR-Bneo	O
:	O
MH60	O
(	O
5'-CACTCACAGCAATGAAGCAGGAC-3	O
'	O
)	O
,	O
MH53a	O
(	O
5'-GAATGTTGATCATGTGTTTCCCTG-3	O
'	O
)	O
,	O
y	O
MH117	O
(	O
5'-GTTCGAATTCGCCAATGACAAGACG-3	O
'	O
)	O
,	O
tipo	B-Sequence
salvaje	I-Sequence
:	O
500	O
pb	B-Sequence
y	O
mutante	B-Sequence
:	O
400	O
pb	B-Sequence
.	O

GluR	O
-	O
B2lox	O
:	O
VM12	O
(	O
5	O
'	O
-	O
GCGTAAGCCTGTGAAATACCTG	O
-	O
3	O
'	O
)	O
y	O
VM10	O
(	O
5	O
'	O
-	O
GTTGTCTAACAAGTTGTTGACC	O
-	O
3	O
'	O
)	O
,	O
tipo	B-Sequence
salvaje	I-Sequence
:	O
250	O
pb	B-Sequence
y	O
mutante	B-Sequence
:	O
350	O
pb	B-Sequence
.	O

TgOCN1	O
:	O
VM4	O
(	O
5'-CTCCCAGACAACCATTACCTGTCC-3	O
'	O
)	O
y	O
GluR-B882BST	O
(	O
5'-CGAAGTATACTTAATTGTCGCTGTGTG-3	O
'	O
)	O
,	O
600	O
pb	B-Sequence
.	O

TgCN12	O
-	O
itTA	O
:	O
htTA1	O
(	O
5	O
'	O
-	O
AGAGCAAAGTCATCAACTCTG	O
-	O
3	O
'	O
)	O
y	O
htTA2	O
(	O
5	O
'	O
-	O
GTGAGAGCCAGACTCACATTTCA	O
-	O
3	O
'	O
)	O
,	O
1	O
000	O
pb	B-Sequence
.	O

Análisis	O
de	O
transferencia	O
de	O
Southern	O

ADN	B-Sequence
genómico	I-Sequence
desde	O
ratón	B-Taxon
#	O
¿NOMBRE	O
?	O
enzima	B-Sequence
BglII	O
(	O
NEB	O
)	O
,	O
y	O
el	O
Southern	O
blot	O
se	O
realizó	O
con	O
un	O
320	O
-	O
sonda	B-Sequence
de	I-Sequence
pb	I-Sequence
``	O
(	O
``	O
''	O
integ	O
``	O
''	O
)	O
obtenido	O
por	O
PCR	O
detectando	O
el	O
''	O
alfa	B-Protein
CaMKII	I-Protein
promotor	B-Sequence
.	O

Histoquímica	O

La	O
histoquímica	O
se	O
realizó	O
como	O
se	O
describió	O
anteriormente	O
[	O
89	O
]	O
,	O
con	O
las	O
siguientes	O
excepciones	O
:	O
se	O
usaron	O
cortes	O
coronales	O
de	O
vibratomo	O
de	O
70	O
a	O
100	O
mu	O
m	O
para	O
la	O
inmunohistoquímica	O
con	O
GluR-B	B-Protein
(	O
1	O
:	O
60	O
,	O
policlonal	O
;	O
Chemicon	O
,	O
Temecula	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
,	O
GFP	O
(	O
1	O
:	O
8	O
000	O
,	O
policlonal	O
;	O
MobiTech	O
,	O
G	O
o	O
ttingen	O
,	O
Alemania	O
)	O
y	O
Cre	O
(	O
1	O
:	O
8	O
000	O
,	O
policlonal	O
;	O
BAbCO	O
,	O
Berkeley	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
primaria	O
anticuerpos	B-GENE
,	O
y	O
FITC	B-Chemical
-	O
acoplado	O
(	O
1	O
:	O
200	O
;	O
Dianova	O
,	O
Hamburgo	O
,	O
Alemania	O
)	O
y	O
acoplado	O
a	O
peroxidasa	O
(	O
1	O
:	O
600	O
;	O
Vector	O
,	O
Burlingame	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
secundario	O
cabra	B-Taxon
anti	O
-	O
Conejo	B-Taxon
anticuerpos	B-GENE
.	O

El	O
epitelio	O
olfatorio	O
principal	O
se	O
obtuvo	O
mediante	O
corte	O
con	O
criostato	O
y	O
se	O
realizó	O
inmunohistoquímica	O
(	O
primaria	O
anticuerpo	B-GENE
Cre	O
,	O
1:5.000	O
,	O
policlonal	O
;	O
BAbCO	O
)	O
.	O

La	O
tinción	O
con	O
X-gal	O
se	O
realizó	O
como	O
se	O
describe	O
[	O
89	O
]	O
.	O

Análisis	O
de	O
inmunotransferencia	O

Ratón	B-Taxon
se	O
extirparon	O
los	O
cerebros	O
y	O
se	O
aislaron	O
el	O
hipocampo	O
,	O
el	O
bulbo	O
olfatorio	O
y	O
las	O
áreas	O
restantes	O
del	O
cerebro	O
anterior	O
.	O

Total	O
proteína	B-Chemical
se	O
preparó	O
,	O
y	O
se	O
realizaron	O
inmunotransferencias	O
como	O
se	O
describe	O
[	O
87	O
]	O
.	O

anticuerpos	B-GENE
utilizados	O
estaban	O
en	O
contra	O
GluR-B	B-Protein
(	O
1	O
:	O
800	O
,	O
monoclonal	O
;	O
Chemicon	O
)	O
,	O
beta	B-Protein
-	I-Protein
actina	I-Protein
(	O
1	O
:	O
40	O
000	O
,	O
monoclonal	O
;	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
Missouri	O
,	O
Estados	O
Unidos	O
)	O
como	O
patrón	O
interno	O
y	O
secundario	O
cabra	B-Taxon
anti	O
-	O
Conejo	B-Taxon
y	O
cabra	B-Taxon
anti	O
-	O
ratón	B-Taxon
anticuerpos	B-GENE
(	O
Vector	O
,	O
1	O
:	O
15	O
000	O
)	O
.	O

La	O
inmunorreactividad	O
se	O
detectó	O
con	O
ECLplus	O
(	O
Amersham	O
,	O
Little	O
Chalfont	O
,	O
Reino	O
Unido	O
)	O
,	O
y	O
las	O
inmunotransferencias	O
se	O
escanearon	O
y	O
analizaron	O
cuantitativamente	O
con	O
ImageJ	O
.	O

Análisis	O
conductual	O
:	O
Sujetos	O

Todos	O
ratones	B-Taxon
tenían	O
de	O
cuatro	O
a	O
seis	O
semanas	O
de	O
edad	O
al	O
comienzo	O
de	O
los	O
experimentos	O
.	O

Los	O
sujetos	O
se	O
mantuvieron	O
en	O
un	O
ciclo	O
de	O
luz-oscuridad	O
de	O
12	O
h	O
en	O
jaulas	O
aisladas	O
en	O
un	O
ambiente	O
con	O
temperatura	O
y	O
humedad	O
controladas	O
.	O
animal	B-Taxon
instalaciones	O
.	O

Todo	O
el	O
entrenamiento	O
conductual	O
se	O
llevó	O
a	O
cabo	O
durante	O
el	O
día	O
.	O

Durante	O
el	O
período	O
de	O
formación	O
,	O
animales	B-Taxon
se	O
mantuvieron	O
en	O
libertad	O
comida	B-Chemical
pero	O
en	O
un	O
agua	B-Chemical
-	O
programa	O
de	O
restricción	O
diseñado	O
para	O
mantenerlos	O
en	O
>	O
85	O
%	O
de	O
su	O
libre	O
comida	B-Chemical
peso	O
corporal	O
.	O

Continuo	O
agua	B-Chemical
la	O
restricción	O
nunca	O
fue	O
mayor	O
a	O
12	O
h	O
.	O

Todos	O
animal	B-Taxon
La	O
atención	O
y	O
los	O
procedimientos	O
estuvieron	O
de	O
acuerdo	O
con	O
las	O
animal	B-Taxon
lineamientos	O
éticos	O
de	O
la	O
Sociedad	O
Max-Planck	O
.	O

Aparato	O

Todos	O
los	O
experimentos	O
de	O
discriminación	O
olfativa	O
se	O
realizaron	O
utilizando	O
tres	O
olfatómetros	O
de	O
ocho	O
canales	O
modificados	O
(	O
[	O
61	O
]	O
,	O
Knosys	O
,	O
Bethesda	O
,	O
Maryland	O
,	O
Estados	O
Unidos	O
de	O
América	O
)	O
operados	O
por	O
un	O
software	O
personalizado	O
en	O
Igor	O
(	O
Wave	O
Metrics	O
,	O
Lake	O
Oswego	O
,	O
Oregón	O
,	O
Estados	O
Unidos	O
de	O
América	O
)	O
en	O
PC	O
Pentium	O
I	O
,	O
II	O
y	O
III	O
con	O
Microsoft	O
Windows	O
98	O
.	O

Se	O
tuvo	O
mucho	O
cuidado	O
en	O
equilibrar	O
los	O
grupos	O
entre	O
las	O
configuraciones	O
.	O

En	O
breve	O
,	O
animales	B-Taxon
se	O
les	O
presentó	O
el	O
olor	O
de	O
uno	O
de	O
los	O
ocho	O
posibles	O
canales	O
de	O
olor	O
y	O
se	O
les	O
recompensó	O
con	O
una	O
gota	O
de	O
2	O
a	O
4	O
mu	O
l	O
de	O
agua	B-Chemical
en	O
un	O
puerto	O
combinado	O
de	O
olor/recompensa	O
(	O
Figura	O
1B	O
)	O
,	O
asegurando	O
una	O
estrecha	O
asociación	O
de	O
los	O
agua	B-Chemical
#	O
¿NOMBRE	O
?	O

La	O
inserción	O
de	O
la	O
cabeza	O
en	O
el	O
puerto	O
fue	O
monitoreada	O
por	O
un	O
haz	O
de	O
infrarrojos	O
y	O
un	O
fotodiodo	O
(	O
Figura	O
1B	O
)	O
.	O

Los	O
olores	O
utilizados	O
fueron	O
n	O
-	O
amilo	O
acetato	B-Chemical
,	O
butirato	B-Chemical
de	I-Chemical
etilo	I-Chemical
,	O
ácido	B-Chemical
pelargónico	I-Chemical
,	O
ácido	B-Chemical
valérico	I-Chemical
mezclas	O
binarias	O
de	O
cineol	B-Chemical
y	O
eugenol	B-Chemical
.	O

Si	O
no	O
se	O
indica	O
lo	O
contrario	O
,	O
los	O
olores	O
se	O
diluyeron	O
al	O
1	O
%	O
en	O
aceite	O
mineral	O
(	O
Fluka	O
Chemie	O
,	O
Steinheim	O
,	O
Alemania	O
)	O
y	O
luego	O
se	O
diluyeron	O
mediante	O
flujo	O
de	O
aire	O
hasta	O
una	O
concentración	O
final	O
de	O
aproximadamente	O
0	O
.	O
15	O
%	O
.	O

Todas	O
las	O
diluciones	O
en	O
el	O
texto	O
se	O
refieren	O
a	O
la	O
dilución	O
en	O
aceite	O
mineral	O
.	O

Todos	O
productos	B-Chemical
quimicos	I-Chemical
se	O
obtuvieron	O
de	O
Fluka	O
Chemie	O
.	O

Entrenamiento	O
de	O
habituación	O
a	O
la	O
tarea	O

Comenzando	O
1	O
-	O
3	O
d	O
después	O
del	O
inicio	O
de	O
la	O
agua	B-Chemical
horario	O
de	O
restricción	O
,	O
animales	B-Taxon
fueron	O
entrenados	O
utilizando	O
procedimientos	O
estándar	O
de	O
condicionamiento	O
operante	O
[	O
3	O
]	O
.	O

En	O
un	O
primer	O
paso	O
de	O
preentrenamiento	O
,	O
cada	O
lamida	O
en	O
el	O
agua	B-Chemical
tubo	O
de	O
entrega	O
fue	O
recompensado	O
.	O

``	O
Después	O
de	O
20	O
lamidas	O
,	O
se	O
entraba	O
en	O
una	O
segunda	O
etapa	O
en	O
la	O
que	O
la	O
inserción	O
de	O
la	O
cabeza	O
iniciaba	O
una	O
presentación	O
de	O
``	O
''	O
olor	O
''	O
''	O
de	O
2	O
s	O
durante	O
la	O
cual	O
se	O
premiaba	O
con	O
una	O
lamida	O
.	O
''	O

``	O
El	O
``	O
''	O
odorante	O
''	O
''	O
utilizado	O
en	O
el	O
entrenamiento	O
previo	O
fue	O
el	O
aceite	O
mineral	O
portador	O
medio	O
.	O
''	O

Todos	O
animales	B-Taxon
aprendió	O
esta	O
tarea	O
en	O
un	O
día	O
(	O
2-3	O
sesiones	O
de	O
30	O
min	O
cada	O
una	O
)	O
.	O

Estructura	O
de	O
un	O
ensayo	O
individual	O

los	O
ratón	B-Taxon
inicia	O
cada	O
ensayo	O
rompiendo	O
una	O
barrera	O
de	O
luz	O
en	O
la	O
apertura	O
del	O
puerto	O
de	O
muestreo	O
(	O
ver	O
también	O
[	O
3	O
]	O
)	O
.	O

Esto	O
abre	O
una	O
de	O
las	O
ocho	O
válvulas	O
de	O
olor	O
y	O
una	O
válvula	O
de	O
desvío	O
que	O
desvía	O
todo	O
el	O
flujo	O
de	O
aire	O
lejos	O
del	O
animal	B-Taxon
durante	O
típicamente	O
500	O
ms	O
.	O

Después	O
de	O
liberar	O
la	O
válvula	O
de	O
desvío	O
,	O
el	O
olor	O
es	O
accesible	O
al	O
animal	B-Taxon
durante	O
2.000ms	O
.	O

Si	O
lame	O
continuamente	O
en	O
el	O
puerto	O
de	O
lamer	O
durante	O
este	O
tiempo	O
(	O
una	O
vez	O
en	O
al	O
menos	O
tres	O
de	O
los	O
cuatro	O
intervalos	O
de	O
500	O
ms	O
)	O
,	O
puede	O
recibir	O
de	O
2	O
a	O
4	O
mu	O
l	O
agua	B-Chemical
recompensa	O
después	O
del	O
final	O
del	O
período	O
de	O
2.000	O
ms	O
.	O

Si	O
el	O
animal	B-Taxon
no	O
lame	O
continuamente	O
,	O
o	O
si	O
el	O
olor	O
presentado	O
fue	O
un	O
olor	O
no	O
recompensado	O
designado	O
,	O
no	O
se	O
da	O
una	O
recompensa	O
ni	O
ningún	O
tipo	O
de	O
castigo	O
,	O
para	O
minimizar	O
el	O
estrés	O
para	O
el	O
animal	B-Taxon
.	O

Los	O
intentos	O
se	O
cuentan	O
como	O
correctos	O
si	O
el	O
animal	B-Taxon
lame	O
continuamente	O
ante	O
la	O
presentación	O
de	O
un	O
olor	O
recompensado	O
o	O
no	O
lame	O
continuamente	O
con	O
un	O
olor	O
no	O
recompensado	O
.	O

No	O
se	O
puede	O
iniciar	O
una	O
segunda	O
prueba	O
a	O
menos	O
que	O
haya	O
pasado	O
un	O
intervalo	O
entre	O
pruebas	O
de	O
al	O
menos	O
5	O
s	O
.	O

Este	O
intervalo	O
es	O
suficientemente	O
largo	O
para	O
que	O
animales	B-Taxon
por	O
lo	O
general	O
,	O
se	O
retracta	O
rápidamente	O
después	O
del	O
final	O
de	O
la	O
prueba	O
.	O

Los	O
olores	O
se	O
presentan	O
en	O
un	O
esquema	O
pseudoaleatorio	O
(	O
no	O
más	O
de	O
dos	O
presentaciones	O
sucesivas	O
del	O
mismo	O
olor	O
,	O
números	O
iguales	O
dentro	O
de	O
cada	O
bloque	O
de	O
20	O
ensayos	O
)	O
.	O

No	O
se	O
observó	O
preferencia	O
intrínseca	O
hacia	O
ninguno	O
de	O
los	O
olores	O
,	O
pero	O
se	O
controló	O
mediante	O
contrapeso	O
.	O

Se	O
realizaron	O
un	O
total	O
de	O
100	O
a	O
300	O
intentos	O
cada	O
día	O
,	O
separados	O
en	O
tramos	O
de	O
30	O
a	O
40	O
minutos	O
para	O
asegurar	O
la	O
máxima	O
motivación	O
a	O
pesar	O
de	O
la	O
leve	O
agua	B-Chemical
esquema	O
de	O
restricción	O
.	O

Además	O
,	O
la	O
motivación	O
se	O
controló	O
mediante	O
el	O
seguimiento	O
de	O
los	O
intervalos	O
entre	O
pruebas	O
y	O
la	O
frecuencia	O
de	O
respuesta	O
[	O
3	O
]	O
.	O

Medición	O
del	O
desempeño	O

La	O
medida	O
más	O
simple	O
de	O
rendimiento	O
es	O
la	O
fracción	O
de	O
intentos	O
en	O
los	O
que	O
el	O
animal	B-Taxon
responde	O
correctamente	O
,	O
es	O
decir	O
,	O
responde	O
lamiendo	O
a	O
la	O
presentación	O
del	O
olor	O
S+	O
y	O
no	O
lame	O
a	O
la	O
presentación	O
del	O
olor	O
S-	O
.	O

Sin	O
embargo	O
,	O
se	O
demostró	O
anteriormente	O
que	O
el	O
patrón	O
de	O
muestreo	O
detallado	O
es	O
una	O
medida	O
más	O
sensible	O
del	O
rendimiento	O
de	O
la	O
discriminación	O
[	O
3	O
]	O
.	O

Para	O
evitar	O
períodos	O
de	O
entrenamiento	O
prolongados	O
(	O
>	O
3	O
semanas	O
)	O
,	O
decidimos	O
no	O
medir	O
los	O
tiempos	O
de	O
discriminación	O
[	O
3	O
]	O
sino	O
analizar	O
el	O
comportamiento	O
de	O
muestreo	O
promedio	O
en	O
total	O
.	O

Tras	O
la	O
presentación	O
de	O
un	O
olor	O
recompensado	O
,	O
el	O
animal	B-Taxon
por	O
lo	O
general	O
,	O
rompe	O
continuamente	O
el	O
haz	O
,	O
mientras	O
que	O
ante	O
la	O
presentación	O
de	O
un	O
olor	O
no	O
recompensado	O
,	O
la	O
cabeza	O
se	O
retrae	O
rápidamente	O
.	O

La	O
diferencia	O
en	O
la	O
respuesta	O
al	O
olor	O
recompensado	O
y	O
no	O
recompensado	O
es	O
aproximadamente	O
sigmoidea	O
(	O
Figuras	O
1D	O
,	O
1E	O
y	O
2D	O
)	O
y	O
produce	O
una	O
medida	O
sensible	O
del	O
desempeño	O
de	O
la	O
discriminación	O
.	O

A	O
partir	O
de	O
esta	O
diferencia	O
o	O
de	O
un	O
ajuste	O
sigmoidal	O
a	O
la	O
diferencia	O
(	O
Figura	O
1E	O
)	O
,	O
se	O
pueden	O
determinar	O
varias	O
medidas	O
de	O
discriminación	O
:	O
la	O
diferencia	O
media	O
,	O
el	O
pico	O
o	O
máximo	O
,	O
el	O
tiempo	O
de	O
la	O
mitad	O
del	O
máximo	O
y	O
la	O
pendiente	O
del	O
sigmoide	O
ajustado	O
.	O

Mientras	O
que	O
para	O
números	O
de	O
prueba	O
pequeños	O
(	O
<	O
200	O
)	O
la	O
pendiente	O
a	O
menudo	O
no	O
está	O
bien	O
restringida	O
,	O
cualquiera	O
de	O
los	O
otros	O
parámetros	O
arrojó	O
esencialmente	O
los	O
mismos	O
resultados	O
.	O

El	O
índice	O
de	O
discriminación	O
representado	O
en	O
las	O
Figuras	O
1F	O
,	O
2C	O
,	O
4D	O
y	O
6C	O
se	O
refiere	O
al	O
máximo	O
ajustado	O
,	O
que	O
generalmente	O
varía	O
de	O
cero	O
a	O
uno	O
,	O
indicando	O
uno	O
la	O
mejor	O
discriminación	O
.	O

Se	O
obtuvieron	O
resultados	O
idénticos	O
con	O
otras	O
medidas	O
de	O
discriminación	O
,	O
como	O
la	O
diferencia	O
de	O
muestreo	O
promedio	O
.	O

Estructura	O
de	O
la	O
formación	O

Después	O
de	O
la	O
habituación	O
,	O
ratones	B-Taxon
fueron	O
entrenados	O
para	O
discriminar	O
el	O
acetato	O
de	O
amil	O
al	O
1	O
%	O
del	O
butirato	O
de	O
etilo	O
al	O
1	O
%	O
durante	O
500	O
ensayos	O
.	O

Durante	O
los	O
últimos	O
100	O
ensayos	O
,	O
el	O
olor	O
S+	O
fue	O
recompensado	O
en	O
sólo	O
el	O
50	O
%	O
de	O
los	O
casos	O
para	O
aumentar	O
la	O
resistencia	O
a	O
la	O
extinción	O
de	O
la	O
memoria	O
adquirida	O
.	O

Estos	O
ensayos	O
fueron	O
excluidos	O
del	O
análisis	O
estadístico	O
de	O
las	O
curvas	O
de	O
aprendizaje	O
.	O

La	O
inclusión	O
no	O
alteró	O
el	O
resultado	O
del	O
ANOVA	O
;	O
sin	O
embargo	O
,	O
el	O
ajuste	O
lineal	O
de	O
la	O
curva	O
de	O
aprendizaje	O
ya	O
no	O
era	O
apropiado	O
ya	O
que	O
ya	O
se	O
había	O
producido	O
una	O
saturación	O
parcial	O
del	O
rendimiento	O
del	O
aprendizaje	O
.	O

Posteriormente	O
,	O
animales	B-Taxon
``	O
fueron	O
entrenados	O
para	O
500	O
ensayos	O
en	O
la	O
tarea	O
de	O
discriminación	O
``	O
''	O
difícil	O
``	O
''	O
[	O
3	O
]	O
entre	O
las	O
mezclas	O
binarias	O
0	O
.	O
6	O
%	O
''	O
eugenol	B-Chemical
/	O
0	O
.	O
4	O
%	O
cineol	B-Chemical
y	O
0	O
4	O
%	O
eugenol	B-Chemical
/	O
0	O
.	O
6	O
%	O
cineol	B-Chemical
.	O

``	O
Para	O
permitir	O
la	O
comparación	O
,	O
los	O
últimos	O
100	O
ensayos	O
se	O
modificaron	O
como	O
para	O
la	O
tarea	O
de	O
discriminación	O
``	O
''	O
simple	O
''	O
''	O
anterior	O
.	O
''	O

Después	O
de	O
dos	O
días	O
de	O
descanso	O
,	O
animales	B-Taxon
``	O
fueron	O
finalmente	O
entrenados	O
en	O
la	O
tarea	O
de	O
discriminación	O
``	O
''	O
simple	O
''	O
''	O
entre	O
1	O
%	O
''	O
ácido	B-Chemical
pelargónico	I-Chemical
y	O
1	O
%	O
ácido	B-Chemical
valérico	I-Chemical
para	O
otras	O
600	O
pruebas	O
.	O

En	O
todos	O
los	O
experimentos	O
,	O
se	O
aseguró	O
el	O
equilibrio	O
entre	O
los	O
olores	O
y	O
las	O
configuraciones	O
dentro	O
y	O
entre	O
genético	B-Sequence
los	O
grupos	O
o	O
los	O
resultados	O
se	O
compararon	O
con	O
subgrupos	O
contrapesados	O
,	O
que	O
en	O
todos	O
los	O
casos	O
arrojaron	O
resultados	O
idénticos	O
.	O

Durante	O
todo	O
el	O
transcurso	O
del	O
experimento	O
,	O
el	O
persona	B-Taxon
manejando	O
el	O
animales	B-Taxon
y	O
operar	O
los	O
olfatómetros	O
fue	O
ciego	O
a	O
la	O
genotipo	B-Sequence
de	O
El	O
ratones	B-Taxon
.	O

Medida	O
de	O
memoria	O

Para	O
evaluar	O
la	O
memoria	O
,	O
después	O
de	O
280	O
ensayos	O
de	O
entrenamiento	O
para	O
discriminar	O
entre	O
ácido	B-Chemical
pelargónico	I-Chemical
y	O
ácido	B-Chemical
valérico	I-Chemical
,	O
los	O
ensayos	O
de	O
memoria	O
se	O
intercalaron	O
para	O
120	O
ensayos	O
;	O
es	O
decir	O
,	O
dentro	O
de	O
cada	O
bloque	O
de	O
20	O
ensayos	O
se	O
incluyeron	O
dos	O
ensayos	O
de	O
acetato	O
de	O
amilato	O
sin	O
recompensa	O
y	O
dos	O
de	O
butirato	O
de	O
etilo	O
sin	O
recompensa	O
.	O

``	O
Los	O
puntajes	O
de	O
memoria	O
se	O
dan	O
como	O
la	O
fracción	O
de	O
esos	O
intentos	O
sin	O
recompensa	O
que	O
fueron	O
respondidos	O
``	O
''	O
correctamente	O
''	O
''	O
(	O
lamiendo	O
la	O
respuesta	O
al	O
olor	O
que	O
fue	O
recompensada	O
en	O
la	O
sesión	O
de	O
entrenamiento	O
inicial	O
[	O
S	O
+	O
]	O
,	O
sin	O
respuesta	O
al	O
olor	O
que	O
no	O
fue	O
recompensada	O
inicialmente	O
[	O
S-	O
]	O
)	O
.	O
''	O

Debido	O
al	O
fenotipo	O
epiléptico	O
y	O
al	O
ligero	O
aumento	O
de	O
la	O
mortalidad	O
[	O
58	O
]	O
,	O
GluRB	O
Delta	O
ECS	O
:	O
FB	O
ratones	B-Taxon
fueron	O
entrenados	O
sólo	O
para	O
el	O
período	O
inicial	O
de	O
400	O
ensayos	O
.	O

Estadísticas	O

``	O
Las	O
curvas	O
de	O
aprendizaje	O
tanto	O
para	O
el	O
rendimiento	O
correcto	O
(	O
``	O
''	O
porcentaje	O
correcto	O
''	O
''	O
)	O
como	O
para	O
el	O
rendimiento	O
de	O
discriminación	O
se	O
analizaron	O
mediante	O
ANOVA	O
de	O
medidas	O
repetidas	O
.	O
''	O

Además	O
,	O
las	O
curvas	O
de	O
aprendizaje	O
se	O
evaluaron	O
ajustando	O
linealmente	O
las	O
líneas	O
de	O
tendencia	O
a	O
los	O
datos	O
con	O
compensaciones	O
fijas	O
,	O
dejando	O
la	O
pendiente	O
como	O
la	O
única	O
variable	O
.	O

En	O
general	O
,	O
el	O
agrupamiento	O
fue	O
de	O
100	O
ensayos	O
por	O
bloque	O
.	O

Para	O
permitir	O
la	O
investigación	O
de	O
las	O
interacciones	O
de	O
grupo/bloque	O
,	O
el	O
agrupamiento	O
ANOVA	O
de	O
medidas	O
repetidas	O
se	O
redujo	O
a	O
20	O
ensayos	O
por	O
bloque	O
.	O

Para	O
comparar	O
el	O
rendimiento	O
de	O
la	O
memoria	O
en	O
GluR-BRescue	O
(	O
n	O
=	O
8	O
)	O
y	O
GluR-B	O
Delta	O
FB	O
(	O
n	O
=	O
22	O
)	O
ratones	B-Taxon
,	O
debido	O
a	O
la	O
alta	O
variabilidad	O
,	O
se	O
empleó	O
un	O
enfoque	O
de	O
arranque	O
.	O

Subpoblaciones	O
de	O
ocho	O
animales	B-Taxon
fueron	O
seleccionados	O
de	O
la	O
población	O
de	O
22	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
y	O
se	O
determinó	O
la	O
memoria	O
media	O
.	O

En	O
sólo	O
343	O
de	O
20	O
000	O
subpoblaciones	O
,	O
la	O
memoria	O
media	O
superó	O
la	O
memoria	O
media	O
de	O
GluR	O
-	O
BRescue	O
de	O
74	O
.	O
99	O
%	O
,	O
lo	O
que	O
da	O
como	O
resultado	O
un	O
valor	O
de	O
p	O
=	O
343	O
/	O
20	O
,	O
000	O
=	O
0	O
.	O
017	O
.	O

información	O
de	O
soporte	O

Figura	O
S1	O

Prosencéfalo	O
-	O
Específico	O
Gene	B-Sequence
Manipulación	O

(	O
A	O
)	O
Diagramas	O
esquemáticos	O
que	O
representan	O
Cre	O
bajo	O
el	O
alfa	B-Protein
CaMKII	I-Protein
promotor	B-Sequence
control	O
[	O
59	O
]	O
y	O
expresión	O
dependiente	O
de	O
Cre	O
de	O
beta	O
-	O
galactosidasa	O
(	O
LacZ	O
)	O
por	O
el	O
indicador	O
R26R	O
ratón	B-Taxon
[	O
85	O
]	O
.	O

(	O
B	O
)	O
Secciones	O
coronales	O
del	O
prosencéfalo	O
(	O
izquierda	O
)	O
y	O
secciones	O
sagitales	O
del	O
tronco	O
encefálico	O
/	O
cerebelo	O
de	O
ratones	B-Taxon
en	O
P42	O
positivo	O
para	O
TgCre4	O
y	O
R26R	O
Cre-indicador	O
.	O

Cre	O
expresión	O
visualizada	O
por	O
enzimático	B-Sequence
La	O
actividad	O
beta-galactosidasa	O
(	O
azul	O
,	O
X-gal	O
,	O
contratinción	O
por	O
eosina	O
)	O
de	O
R26R	O
y	O
por	O
inmunotinciones	O
anti-Cre	O
(	O
marrón	O
,	O
DAB	O
[	O
diaminobenzadina	O
]	O
)	O
se	O
restringió	O
a	O
las	O
regiones	O
del	O
prosencéfalo	O
.	O

Barras	O
de	O
escala	O
:	O
1	O
mm	O
.	O

A	O
,	O
amígdala	O
;	O
Ce	O
,	O
Cerebelo	O
;	O
Cx	O
,	O
corteza	O
;	O
H	O
,	O
hipocampo	O
;	O
Yo	O
,	O
bulbo	O
raquídeo	O
.	O

(	O
C	O
)	O
Secciones	O
de	O
bulbo	O
olfatorio	O
de	O
la	O
misma	O
ratón	B-Taxon
para	O
visualizar	O
la	O
expresión	O
de	O
Cre	O
por	O
inmunorreactividad	O
de	O
Cre	O
(	O
izquierda	O
,	O
DAB	O
)	O
y	O
por	O
enzimático	B-Sequence
actividad	O
beta	O
-	O
galactosidasa	O
(	O
derecha	O
,	O
X	O
-	O
gal	O
,	O
contratinción	O
con	O
eosina	O
)	O
en	O
células	B-Cell
granulares	I-Cell
(	O
CG	B-Cell
)	O
y	O
mitral	O
células	B-Cell
(	O
MC	O
)	O
como	O
lo	O
indican	O
las	O
flechas	O
.	O

Barras	O
de	O
escala	O
:	O
400	O
mu	O
m	O
(	O
panel	O
superior	O
)	O
,	O
50	O
mu	O
m	O
(	O
panel	O
inferior	O
)	O
.	O

(	O
3	O
.	O
4	O
MB	O
TIF	O
)	O
.	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Figura	O
S2	O

Desempeño	O
de	O
GluR-B	O
Delta	O
FB	O
(	O
n	O
=	O
10	O
)	O
y	O
Littermate	O
Control	O
(	O
n	O
=	O
10	O
)	O
Ratones	B-Taxon
en	O
una	O
tarea	O
de	O
referencia	O
espacial	O
en	O
el	O
laberinto	O
Y	O
elevado	O

Los	O
detalles	O
de	O
la	O
metodología	O
se	O
describen	O
en	O
[	O
90	O
]	O
.	O

*	O
indica	O
p	O
<	O
0	O
.	O
05	O
.	O

(	O
126	O
KB	O
TIF	O
)	O
.	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Figura	O
S3	O

El	O
déficit	O
de	O
memoria	O
no	O
se	O
debe	O
a	O
una	O
mayor	O
extinción	O

(	O
A	O
)	O
Rendimiento	O
de	O
la	O
memoria	O
en	O
función	O
del	O
tiempo	O
para	O
el	O
experimento	O
descrito	O
en	O
la	O
Figura	O
2E	O
(	O
nueve	O
GluR-B	O
Delta	O
FB	O
y	O
nueve	O
GluR-B2lox	O
control	O
animales	B-Taxon
)	O
.	O

``	O
Sólo	O
se	O
agrupan	O
cuatro	O
intentos	O
de	O
``	O
''	O
memoria	O
+	O
''	O
''	O
no	O
recompensados	O
para	O
cada	O
punto	O
de	O
datos	O
.	O
''	O

Memoria	O
de	O
GluR	O
-	O
B	O
Delta	O
FB	O
animales	B-Taxon
se	O
redujo	O
significativamente	O
(	O
F	O
(	O
1	O
,	O
33	O
)	O
=	O
17	O
;	O
p	O
<	O
0,001	O
)	O
.	O

Mientras	O
que	O
se	O
pudo	O
observar	O
un	O
efecto	O
de	O
tiempo	O
general	O
débil	O
(	O
F	O
(	O
2	O
,	O
66	O
)	O
=	O
3	O
.	O
6	O
;	O
p	O
=	O
0	O
.	O
03	O
)	O
,	O
no	O
hubo	O
genotipo	B-Sequence
-	O
efecto	O
de	O
interacción	O
temporal	O
(	O
F	O
(	O
2	O
,	O
66	O
)	O
=	O
0	O
.	O
67	O
;	O
p	O
=	O
0	O
.	O
5	O
)	O
,	O
lo	O
que	O
indica	O
que	O
no	O
existe	O
un	O
efecto	O
diferencial	O
de	O
extinción	O
putativa	O
en	O
el	O
rendimiento	O
de	O
la	O
memoria	O
.	O

indica	O
valores	O
p	O
para	O
una	O
prueba	O
U	O
de	O
Mann-Whitney	O
(	O
*	O
<	O
0,05	O
,	O
*	O
*	O
<	O
0,01	O
)	O
.	O

(	O
B	O
)	O
Después	O
de	O
los	O
experimentos	O
de	O
memoria	O
de	O
la	O
Figura	O
6A	O
,	O
el	O
último	O
conjunto	O
de	O
animales	B-Taxon
(	O
ocho	O
GluR-BRescue	O
,	O
cuatro	O
GluR-B	O
Delta	O
FB	O
y	O
tres	O
controles	O
)	O
fueron	O
entrenados	O
adicionalmente	O
en	O
AA	O
versus	O
EB	O
para	O
900	O
ensayos	O
una	O
semana	O
después	O
del	O
experimento	O
de	O
memoria	O
.	O

Posteriormente	O
,	O
se	O
continuó	O
con	O
el	O
entrenamiento	O
en	O
mezclas	O
AA/EB	O
durante	O
1.200	O
ensayos	O
.	O

Finalmente	O
,	O
el	O
animales	B-Taxon
fueron	O
reentrenados	O
en	O
AA	O
y	O
EB	O
durante	O
100	O
ensayos	O
.	O

El	O
rendimiento	O
de	O
reaprendizaje	O
durante	O
la	O
última	O
tarea	O
de	O
reentrenamiento	O
está	O
altamente	O
correlacionado	O
con	O
el	O
rendimiento	O
de	O
la	O
memoria	O
original	O
(	O
R2	O
=	O
0,46	O
,	O
p	O
=	O
0,006	O
,	O
n	O
=	O
15	O
)	O
.	O

(	O
264	O
KB	O
TIF	O
)	O
.	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Figura	O
S4	O

Ausencia	O
de	O
expresión	O
de	O
Cre	O
en	O
el	O
epitelio	O
olfatorio	O
principal	O
de	O
TgCre4	O
Ratones	B-Taxon

(	O
A	O
)	O
Visión	O
general	O
del	O
epitelio	O
olfatorio	O
principal	O
.	O

(	O
B	O
)	O
Mayor	O
aumento	O
de	O
(	O
A	O
)	O
mostrando	O
todos	O
células	B-Cell
con	O
propidio	O
yoduro	B-Chemical
(	O
rojo	O
)	O
y	O
ausencia	O
de	O
Cre	O
-	O
positivo	O
células	B-Cell
(	O
verde	O
,	O
anti-Cre	O
)	O
.	O

(	O
C	O
)	O
Control	O
positivo	O
que	O
muestra	O
células	B-Cell
granulares	I-Cell
de	O
la	O
circunvolución	O
dentada	O
teñida	O
para	O
nuclear	B-GENE
Cre	O
(	O
verde	O
)	O
de	O
la	O
misma	O
ratón	B-Taxon
.	O

(	O
3	O
.	O
7	O
MB	O
TIF	O
)	O
.	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Agradecimientos	O

Los	O
autores	O
quieren	O
agradecer	O
a	O
Troy	O
Margrie	O
y	O
Bert	O
Sakmann	O
por	O
su	O
apoyo	O
,	O
aliento	O
y	O
discusión	O
;	O
Onyeka	O
Nobuka	O
por	O
su	O
ayuda	O
con	O
el	O
construir	B-Sequence
OCN	O
;	O
Mark	O
Mayford	O
para	O
el	O
alfa	B-Protein
CaMKII	I-Protein
promotor	B-Sequence
;	O
Bettina	O
Suchanek	O
por	O
el	O
NR2C	B-Protein
silenciador	B-Sequence
;	O
Annette	O
Herold	O
,	O
Juliana	O
Kling	O
y	O
Christiane	O
Zacher	O
por	O
el	O
apoyo	O
técnico	O
y	O
experimental	O
;	O
Nixon	O
Abraham	O
por	O
su	O
ayuda	O
con	O
algunos	O
experimentos	O
de	O
comportamiento	O
;	O
ya	O
David	O
Bannerman	O
,	O
Thomas	O
Kuner	O
y	O
Pavel	O
Osten	O
por	O
leer	O
críticamente	O
las	O
primeras	O
versiones	O
del	O
manuscrito	O
.	O

Este	O
trabajo	O
fue	O
apoyado	O
por	O
una	O
subvención	O
de	O
Deutsche	O
Forschungsgemeinschaft	O
(	O
SFB	O
636	O
)	O
a	O
RS	O
,	O
Heidelberger	O
Akademie	O
der	O
Wissenschaften	O
,	O
Boeringer	O
Ingelheim	O
Fonds	O
y	O
Leopoldina	O
Akademie	O
der	O
Wissenschaften	O
a	O
ATS	O
,	O
BMBF	O
y	O
MPG	O
.	O

Conflicto	O
de	O
intereses	O
.	O

Los	O
autores	O
han	O
declarado	O
que	O
no	O
existen	O
intereses	O
contrapuestos	O
.	O

abreviaturas	O

AMPA	O
-	O
alfa	O
-	O
aminado	B-Chemical
-	O
3	O
-	O
hidroxi	B-Chemical
-	O
5	O
-	O
metilo	B-Chemical
#	O
¿NOMBRE	O
?	O

AMPAR	O
-	O
alfa	O
-	O
aminado	B-Chemical
-	O
3	O
-	O
hidroxi	B-Chemical
-	O
5	O
-	O
metilo	B-Chemical
#	O
¿NOMBRE	O
?	O

pb	B-Sequence
-	O
Base	B-Sequence
par	I-Sequence

GFP	O
-	O
verde	O
fluorescente	O
proteína	B-Chemical

LTP	O
-	O
plasticidad	O
a	O
largo	O
plazo	O

NMDA	O
-	O
norte	B-Chemical
-	O
metilo	B-Chemical
-	O
D	B-Chemical
-	I-Chemical
aspartato	I-Chemical

q	B-Chemical
-	O
glutamina	B-Chemical

R	B-Chemical
-	O
arginina	B-Chemical

Figuras	O
y	O
Tablas	O

Figura	O
1	O

El	O
aprendizaje	O
y	O
la	O
discriminación	O
de	O
olores	O
se	O
mejoran	O
en	O
GluR	O
-	O
B	O
Delta	O
ECS	O
:	O
FB	O
Ratones	B-Taxon

(	O
A	O
)	O
Diagrama	O
esquemático	O
que	O
representa	O
la	O
activación	O
mediada	O
por	O
Cre	O
de	O
GluR-B	B-Protein
(	O
q	B-Chemical
)	O
por	O
quitando	B-Sequence
los	O
loxP	B-Sequence
-	I-Sequence
flanqueado	I-Sequence
TK-neo	O
(	O
TK-neo	O
pA	O
,	O
GluR-Bneo	O
)	O
elemento	B-Sequence
en	O
intrón	B-Sequence
11	O
,	O
que	O
actúa	O
como	O
un	O
supresor	O
en	O
la	O
expresión	O
de	O
la	O
q	B-Chemical
/	O
R	B-Chemical
sitio	B-Sequence
edición	O
deficiente	O
GluR	O
-	O
Bneo	O
alelo	B-Sequence
.	O

exón	B-Sequence
10	O
y	O
11	O
codifican	O
membrana	B-Sequence
-	I-Sequence
segmentos	I-Sequence
que	I-Sequence
se	I-Sequence
extienden	I-Sequence
1	O
,	O
2	O
y	O
3	O
(	O
M1	O
,	O
2	O
,	O
3	O
)	O
de	O
la	O
GluR	B-Protein
-	I-Protein
subunidad	I-Protein
B	I-Protein
.	O

los	O
elemento	B-Sequence
intrónico	I-Sequence
necesario	O
para	O
editar	O
el	O
q	B-Chemical
/	O
R	B-Chemical
sitio	B-Sequence
se	O
muestra	O
para	O
el	O
alelo	B-Sequence
de	I-Sequence
tipo	I-Sequence
salvaje	I-Sequence
(	O
+	B-Sequence
)	O
.	O

(	O
B	O
)	O
Esquema	O
de	O
un	O
juicio	O
individual	O
.	O

Rompiendo	O
una	O
barrera	O
de	O
luz	O
,	O
el	O
ratón	B-Taxon
inicia	O
un	O
juicio	O
.	O

Se	O
presenta	O
un	O
olor	O
,	O
y	O
(	O
dependiendo	O
de	O
la	O
denotación	O
del	O
olor	O
y	O
la	O
ratón	B-Taxon
la	O
respuesta	O
de	O
)	O
el	O
ratón	B-Taxon
es	O
recompensado	O
o	O
retrae	O
su	O
cabeza	O
.	O

Un	O
pequeño	O
(	O
2	O
-	O
a	O
4	O
-	O
mu	O
l	O
)	O
agua	B-Chemical
recompensa	O
se	O
da	O
al	O
final	O
de	O
un	O
olor	O
S	O
+	O
si	O
el	O
ratón	B-Taxon
lame	O
continuamente	O
el	O
tubo	O
de	O
entrega	O
durante	O
la	O
prueba	O
de	O
2	O
s	O
.	O

Un	O
ensayo	O
se	O
cuenta	O
como	O
correcto	O
si	O
el	O
ratón	B-Taxon
lame	O
continuamente	O
ante	O
la	O
presentación	O
de	O
un	O
olor	O
recompensado	O
(	O
S	O
+	O
)	O
o	O
no	O
lame	O
continuamente	O
con	O
un	O
olor	O
no	O
recompensado	O
(	O
S	O
-	O
)	O
[	O
3	O
]	O
.	O

(	O
C	O
)	O
Doce	O
experimentalmente	O
ingenuos	O
animales	B-Taxon
(	O
seis	O
GluR-B	O
Delta	O
ECS	O
:	O
FB	O
[	O
naranja	O
]	O
y	O
seis	O
GluR-B	B-Protein
+	B-Sequence
/	O
+	B-Sequence
compañeros	O
de	O
camada	O
de	O
control	O
[	O
negro	O
]	O
)	O
fueron	O
entrenados	O
en	O
AA	O
al	O
1	O
%	O
versus	O
EB	O
al	O
1	O
%	O
para	O
dos	O
tareas	O
de	O
200	O
ensayos	O
cada	O
una	O
.	O

Ambos	O
grupos	O
adquirieron	O
la	O
tarea	O
(	O
>	O
70	O
%	O
correcto	O
)	O
;	O
sin	O
embargo	O
,	O
los	O
GluR-B	O
Delta	O
ECS	O
:	O
FB	O
fueron	O
más	O
rápidos	O
y	O
funcionaron	O
mejor	O
en	O
general	O
que	O
los	O
controles	O
de	O
compañeros	O
de	O
camada	O
(	O
efecto	O
de	O
grupo	O
:	O
F	O
(	O
1	O
,	O
10	O
)	O
=	O
10,2	O
;	O
p	O
<	O
0,01	O
)	O
.	O

AA	O
,	O
acetato	O
de	O
amilo	O
;	O
EB	O
,	O
butirato	O
de	O
etilo	O
.	O

(	O
D	O
)	O
Posición	O
promedio	O
de	O
la	O
cabeza	O
para	O
uno	O
ratón	B-Taxon
y	O
50	O
presentaciones	O
del	O
olor	O
S+	O
(	O
verde	O
)	O
y	O
50	O
presentaciones	O
del	O
S-	O
(	O
rojo	O
)	O
.	O

1	O
indica	O
la	O
interrupción	O
del	O
haz	O
de	O
luz	O
(	O
cabeza	O
en	O
el	O
puerto	O
de	O
muestreo	O
[	O
3	O
]	O
)	O
.	O

Nótese	O
la	O
rápida	O
retracción	O
de	O
la	O
cabeza	O
para	O
el	O
olor	O
S	O
.	O

(	O
E	O
)	O
Diferencia	O
de	O
las	O
posiciones	O
promedio	O
de	O
la	O
cabeza	O
de	O
(	O
D	O
)	O
para	O
olores	O
S	O
+	O
y	O
S	O
-	O
.	O

La	O
línea	O
azul	O
indica	O
ajuste	O
sigmoidal	O
.	O

El	O
índice	O
de	O
discriminación	O
se	O
refiere	O
al	O
máximo	O
del	O
sigmoide	O
ajustado	O
.	O

(	O
F	O
)	O
Como	O
(	O
C	O
)	O
pero	O
representando	O
el	O
índice	O
de	O
discriminación	O
en	O
función	O
del	O
número	O
de	O
prueba	O
(	O
efecto	O
de	O
grupo	O
:	O
F	O
(	O
1	O
,	O
10	O
)	O
=	O
1	O
,	O
7	O
;	O
p	O
<	O
0	O
,	O
01	O
)	O
.	O

Figura	O
2	O

Se	O
mejora	O
el	O
aprendizaje	O
y	O
la	O
discriminación	O
de	O
olores	O
,	O
pero	O
se	O
reduce	O
la	O
memoria	O
de	O
olores	O
en	O
GluR-B	O
Delta	O
FB	O
Ratones	B-Taxon

(	O
A	O
)	O
Diagrama	O
esquemático	O
que	O
representa	O
la	O
ablación	O
mediada	O
por	O
Cre	O
de	O
loxP	B-Sequence
-	I-Sequence
exón	I-Sequence
flanqueado	I-Sequence
11	O
de	O
los	O
GluR-B	B-Protein
alelos	B-Sequence
.	O

(	O
B	O
y	O
C	O
)	O
Nueve	O
GluR	O
-	O
B	O
Delta	O
FB	O
(	O
rojo	O
)	O
y	O
nueve	O
GluRB2lox	O
compañeros	O
de	O
camada	O
controles	O
(	O
negro	O
)	O
fueron	O
entrenados	O
para	O
tareas	O
sucesivas	O
de	O
discriminación	O
de	O
olores	O
en	O
1	O
%	O
AA	O
versus	O
1	O
%	O
EB	O
(	O
400	O
ensayos	O
)	O
,	O
0	O
.	O
4	O
%	O
cin	B-Chemical
/	O
0	O
.	O
6	O
%	O
UE	B-Chemical
contra	O
0	O
.	O
6	O
%	O
cin	B-Chemical
/	O
0	O
.	O
4	O
%	O
UE	B-Chemical
(	O
400	O
ensayos	O
)	O
y	O
1	O
%	O
pela	B-Chemical
frente	O
al	O
1	O
%	O
valle	B-Chemical
.	O

GluR-B	O
Delta	O
FB	O
ratones	B-Taxon
mostró	O
un	O
mayor	O
aprendizaje/discriminación	O
en	O
comparación	O
con	O
los	O
controles	O
,	O
tanto	O
utilizando	O
el	O
rendimiento	O
medido	O
por	O
el	O
porcentaje	O
de	O
intentos	O
correctos	O
(	O
[	O
B	O
]	O
;	O
efecto	O
de	O
grupo	O
:	O
F1	O
,	O
16	O
=	O
6,55	O
,	O
p	O
<	O
0,05	O
)	O
o	O
el	O
índice	O
de	O
discriminación	O
(	O
C	O
)	O
,	O
esa	O
es	O
la	O
diferencia	O
máxima	O
del	O
patrón	O
de	O
muestreo	O
(	O
ver	O
Materiales	O
y	O
Métodos	O
y	O
la	O
Figura	O
1D-1F	O
;	O
F1	O
,	O
16	O
=	O
29	O
.	O
5	O
,	O
p	O
<	O
10-4	O
)	O
.	O

(	O
D	O
)	O
Diferencia	O
de	O
muestreo	O
para	O
los	O
últimos	O
100	O
ensayos	O
de	O
la	O
tarea	O
de	O
discriminación	O
de	O
mezclas	O
(	O
indicada	O
con	O
una	O
flecha	O
negra	O
en	O
[	O
C	O
]	O
)	O
para	O
los	O
18	O
individuos	O
ratones	B-Taxon
.	O

Tenga	O
en	O
cuenta	O
que	O
el	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
muestran	O
una	O
diferencia	O
de	O
muestreo	O
consistentemente	O
mayor	O
.	O

(	O
E	O
)	O
Rendimiento	O
de	O
la	O
memoria	O
olfativa	O
para	O
nueve	O
controles	O
de	O
compañeros	O
de	O
camada	O
(	O
negro	O
)	O
y	O
nueve	O
GluR	O
-	O
B	O
Delta	O
FB	O
(	O
rojo	O
)	O
ratones	B-Taxon
.	O

La	O
memoria	O
olfativa	O
se	O
probó	O
en	O
el	O
momento	O
indicado	O
por	O
la	O
barra	O
negra	O
en	O
(	O
C	O
)	O
intercalando	O
las	O
pela	B-Chemical
y	O
valle	B-Chemical
ensayos	O
con	O
ensayos	O
AA	O
y	O
EB	O
sin	O
recompensa	O
.	O

AA	O
,	O
acetato	O
de	O
amilo	O
;	O
cin	B-Chemical
,	O
cineol	B-Chemical
;	O
EB	O
,	O
butirato	O
de	O
etilo	O
;	O
UE	B-Chemical
,	O
eugenol	B-Chemical
;	O
pela	B-Chemical
,	O
ácido	B-Chemical
pelargónico	I-Chemical
;	O
valle	B-Chemical
,	O
ácido	B-Chemical
valérico	I-Chemical
.	O

figura	O
3	O

Variabilidad	O
de	O
Cre	O
Expresión	O
de	O
Ratón	B-Taxon
Línea	O
TgCre4	O

(	O
A	O
)	O
Expresión	O
variable	O
Cre	O
en	O
prosencéfalos	O
de	O
tres	O
diferentes	O
ratones	B-Taxon
positivo	O
para	O
el	O
indicador	O
TgCre4	O
y	O
R26R	O
Cre	O
(	O
ver	O
Figura	O
S1	O
)	O
en	O
el	O
día	O
12	O
postnatal	O
representado	O
por	O
la	O
actividad	O
beta-galactosidasa	O
dependiente	O
de	O
Cre	O
(	O
azul	O
,	O
X-gal	O
,	O
contratinción	O
por	O
eosina	O
)	O
en	O
cortes	O
coronales	O
de	O
cerebro	O
.	O

Barra	O
de	O
escala	O
:	O
1	O
.	O
25	O
mm	O
.	O

(	O
B	O
)	O
Análisis	O
de	O
transferencia	O
Southern	O
de	O
BglII	O
-	O
digerido	O
ADN	B-Sequence
genómico	I-Sequence
de	I-Sequence
ratón	I-Sequence
de	O
cuatro	O
TgCre4	O
ratones	B-Taxon
que	O
diferían	O
en	O
el	O
patrón	O
de	O
expresión	O
Cre	O
.	O

Meridional	O
Investigacion	B-Sequence
detecta	O
el	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
4	O
.	O
5	O
kpb	O
)	O
y	O
el	O
transgénico	B-Sequence
(	O
7	O
,	O
5	O
,	O
3	O
y	O
2	O
kpb	O
)	O
alelos	B-Sequence
.	O

Figura	O
4	O

La	O
memoria	O
olfativa	O
pero	O
no	O
el	O
aprendizaje/discriminación	O
de	O
olores	O
está	O
correlacionada	O
con	O
residuos	O
GluR-B	B-Protein
Niveles	O
en	O
hipocampo	O
y	O
prosencéfalo	O
de	O
GluR	O
-	O
B	O
Delta	O
FB	O
Ratones	B-Taxon

(	O
A	O
)	O
El	O
rendimiento	O
de	O
la	O
memoria	O
olfativa	O
para	O
18	O
GluR	O
-	O
B	O
Delta	O
FB	O
(	O
rojo	O
)	O
y	O
11	O
control	O
de	O
compañeros	O
de	O
camada	O
(	O
negro	O
)	O
ratones	B-Taxon
se	O
da	O
como	O
media	O
(	O
líneas	O
gruesas	O
+/-	O
SEM	O
)	O
y	O
como	O
rendimiento	O
individual	O
en	O
círculos	O
abiertos	O
y	O
triángulos	O
.	O

Las	O
flechas	O
con	O
números	O
(	O
#	O
)	O
indican	O
aquellos	O
ratones	B-Taxon
utilizado	O
en	O
experimentos	O
(	O
B-C	O
)	O
.	O

Los	O
datos	O
se	O
combinaron	O
de	O
la	O
Figura	O
2	O
(	O
símbolos	O
abiertos	O
)	O
y	O
un	O
experimento	O
adicional	O
con	O
nueve	O
GluR-B	O
Delta	O
FB	O
y	O
dos	O
controles	O
de	O
compañeros	O
de	O
camada	O
(	O
símbolos	O
sombreados	O
)	O
.	O

(	O
B	O
y	O
C	O
)	O
Residual	O
GluR-B	B-Protein
niveles	O
detectados	O
por	O
anti	O
-	O
GluR-B	B-Protein
inmunofluorescencia	O
en	O
hipocampo	O
,	O
amígdala	O
,	O
corteza	O
piriforme	O
y	O
bulbo	O
olfatorio	O
de	O
un	O
control	O
(	O
#	O
1	O
)	O
y	O
dos	O
GluR	O
-	O
B	O
Delta	O
FB	O
(	O
#	O
2	O
y	O
#	O
3	O
)	O
coronal	O
ratón	B-Taxon
secciones	O
de	O
cerebro	O
(	O
B	O
)	O
y	O
por	O
análisis	O
de	O
inmunotransferencia	O
del	O
hipocampo	O
(	O
cadera	O
)	O
,	O
cerebro	O
anterior	O
cortical	O
(	O
FB	O
)	O
y	O
bulbo	O
olfatorio	O
(	O
OB	O
)	O
proteína	B-Chemical
extractos	O
de	O
control	O
(	O
#	O
4	O
)	O
y	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
(	O
#	O
5	O
,	O
#	O
6	O
,	O
#	O
7	O
y	O
#	O
8	O
)	O
probado	O
con	O
anticuerpos	B-GENE
detector	O
GluR-B	B-Protein
y	O
beta	B-Protein
-	I-Protein
actina	I-Protein
como	O
control	O
de	O
carga	O
interna	O
(	O
C	O
)	O
.	O

Barras	O
de	O
escala	O
:	O
200	O
mu	O
m	O
(	O
primer	O
panel	O
)	O
,	O
100	O
mu	O
m	O
(	O
otros	O
paneles	O
)	O
.	O

(	O
D	O
)	O
De	O
diez	O
GluR	O
-	O
B	O
Delta	O
FB	O
ratones	B-Taxon
,	O
se	O
determinó	O
el	O
aprendizaje/discriminación	O
de	O
olores	O
individuales	O
y	O
el	O
rendimiento	O
de	O
la	O
memoria	O
olfativa	O
junto	O
con	O
el	O
rendimiento	O
relativo	O
GluR-B	B-Protein
niveles	O
en	O
inmunotransferencias	O
de	O
hipocampo	O
,	O
prosencéfalo	O
y	O
bulbo	O
olfatorio	O
proteína	B-Chemical
extractos	O

El	O
rendimiento	O
de	O
la	O
memoria	O
(	O
paneles	O
superiores	O
)	O
y	O
la	O
capacidad	O
de	O
discriminación	O
(	O
paneles	O
inferiores	O
;	O
el	O
índice	O
de	O
discriminación	O
se	O
mide	O
para	O
los	O
últimos	O
100	O
intentos	O
de	O
la	O
tarea	O
de	O
discriminación	O
de	O
mezclas	O
como	O
lo	O
indica	O
la	O
flecha	O
en	O
la	O
Figura	O
2C	O
)	O
se	O
trazaron	O
contra	O
GluR-B	B-Protein
niveles	O

La	O
memoria	O
estaba	O
estrechamente	O
relacionada	O
con	O
GluR-B	B-Protein
proteína	B-Chemical
nivel	O
en	O
hipocampo	O
(	O
R2	O
=	O
0	O
.	O
72	O
;	O
p	O
<	O
0	O
.	O
003	O
)	O
y	O
cerebro	O
anterior	O
cortical	O
(	O
R2	O
=	O
0	O
.	O
62	O
;	O
p	O
<	O
0	O
.	O
006	O
)	O
y	O
solo	O
débilmente	O
en	O
el	O
bulbo	O
olfatorio	O
(	O
R2	O
=	O
0	O
.	O
48	O
;	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O

Ninguna	O
medida	O
de	O
aprendizaje/discriminación	O
(	O
índice	O
de	O
discriminación	O
para	O
los	O
últimos	O
100	O
ensayos	O
de	O
mezcla	O
[	O
D	O
]	O
,	O
pendientes	O
de	O
líneas	O
de	O
tendencia	O
,	O
índice	O
de	O
discriminación	O
promedio	O
,	O
diferencias	O
de	O
patrón	O
de	O
muestreo	O
promedio	O
,	O
desempeño	O
correcto	O
,	O
etc	O
.	O
[	O
no	O
mostrado	O
]	O
)	O
mostró	O
correlación	O
alguna	O
(	O
R2	O
<	O
0	O
.	O
3	O
)	O
.	O

Figura	O
5	O

Expresión	O
específica	O
del	O
hipocampo	O
y	O
la	O
corteza	O
piriforme	O
de	O
transgénico	B-Sequence
GFPGluR	O
-	O
B	O

(	O
A	O
)	O
Diagramas	O
esquemáticos	O
que	O
representan	O
el	O
cerebro	O
anterior	O
-	O
específico	O
GluR-B	B-Protein
supresión	B-Sequence
como	O
en	O
la	O
Figura	O
2A	O
y	O
la	O
expresión	O
dependiente	O
de	O
itTA	O
de	O
GFPGluR	O
-	O
B	O
y	O
nuclear	B-GENE
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
(	O
denominado	O
GluR-BRescue	O
)	O
.	O

GFPGluR-B	O
y	O
nLacZ	O
están	O
codificados	O
por	O
TgOCN1	O
,	O
e	O
itTA	O
está	O
controlado	O
por	O
una	O
fusión	O
de	O
NR2C	B-Protein
elemento	B-Sequence
silenciador	I-Sequence
[	O
91	O
]	O
y	O
el	O
alfa	B-Protein
CaMKII	I-Protein
promotor	B-Sequence
(	O
denominado	O
TgCN12-itTA	O
[	O
92	O
]	O
)	O
.	O

(	O
B	O
)	O
En	O
secciones	O
coronales	O
del	O
cerebro	O
de	O
ratones	B-Taxon
positivo	O
para	O
ambos	O
transgenes	B-Sequence
(	O
TgCN12	O
-	O
itTA	O
y	O
TgOCN1	O
)	O
la	O
actividad	O
de	O
beta	O
-	O
galactosidasa	O
(	O
azul	O
,	O
X	O
-	O
gal	O
,	O
contratinción	O
con	O
eosina	O
)	O
está	O
restringida	O
al	O
hipocampo	O
neuronas	B-Cell
en	O
CA1	O
,	O
DG	O
,	O
y	O
neuronas	B-Cell
en	O
la	O
corteza	O
piriforme	O
.	O

Lo	O
mismo	O
neuronas	B-Cell
muestran	O
expresión	O
de	O
GFPGluR	O
-	O
B	O
cuando	O
se	O
analizan	O
en	O
secciones	O
inmunohistoquímicas	O
con	O
un	O
anticuerpo	B-GENE
contra	O
la	O
GFP	O
.	O

Barras	O
de	O
escala	O
:	O
500	O
mu	O
m	O
.	O

(	O
C	O
)	O
Inmunotransferencia	O
que	O
detecta	O
endógeno	O
GluR-B	B-Protein
y	O
transgénico	B-Sequence
GFPGluR	O
-	O
B	O
en	O
el	O
hipocampo	O
de	O
tres	O
diferentes	O
ratones	B-Taxon
(	O
#	O
1	O
,	O
#	O
2	O
,	O
#	O
3	O
)	O
.	O

(	O
D	O
)	O
Cuantificación	O
relativa	O
de	O
(	O
C	O
)	O
de	O
transgénico	B-Sequence
GFPGluR	O
-	O
B	O
comparado	O
con	O
endógeno	O
GluR-B	B-Protein
en	O
el	O
hipocampo	O
.	O

Figura	O
6	O

GluR-B	B-Protein
Expresión	O
en	O
hipocampo	O
y	O
prosencéfalo	O
rescata	O
parcialmente	O
el	O
déficit	O
de	O
memoria	O
de	O
GluR	O
-	O
B	O
Delta	O
FB	O
Ratones	B-Taxon

(	O
A	O
)	O
Los	O
experimentos	O
de	O
memoria	O
olfativa	O
como	O
en	O
la	O
Figura	O
2	O
se	O
realizaron	O
con	O
GluR-BRescue	O
.	O

Individual	O
ratones	B-Taxon
se	O
indican	O
:	O
control	O
GluR-B2lox	O
con	O
círculos	O
negros	O
,	O
GluR-B	O
Delta	O
FB	O
con	O
triángulos	O
rojos	O
,	O
GluR-BRescue	O
con	O
cuadrados	O
verdes	O
.	O

Los	O
datos	O
se	O
combinaron	O
de	O
las	O
Figuras	O
3	O
y	O
4	O
(	O
símbolos	O
abiertos	O
)	O
y	O
un	O
experimento	O
adicional	O
con	O
cuatro	O
GluR-B	O
Delta	O
FB	O
,	O
tres	O
controles	O
de	O
compañeros	O
de	O
camada	O
y	O
ocho	O
GluR-BRescue	O
(	O
símbolos	O
sombreados	O
)	O
.	O

(	O
B	O
)	O
Histograma	O
acumulativo	O
del	O
rendimiento	O
de	O
la	O
memoria	O
.	O

El	O
rendimiento	O
de	O
la	O
memoria	O
se	O
indica	O
como	O
una	O
línea	O
escalonada	O
.	O

El	O
ajuste	O
sigmoidal	O
se	O
indica	O
como	O
una	O
línea	O
continua	O
.	O

El	O
rescate	O
previsto	O
sobre	O
la	O
base	O
de	O
la	O
extensión	O
de	O
transgénico	B-Sequence
Expresión	O
de	O
GFPGluR-B	O
(	O
Figura	O
5D	O
)	O
y	O
la	O
correlación	O
entre	O
memoria	O
y	O
GluR-B	B-Protein
niveles	O
en	O
la	O
corteza	O
piriforme	O
(	O
9	O
.	O
1	O
+/-	O
2	O
.	O
5	O
%	O
de	O
aumento	O
en	O
la	O
memoria	O
para	O
un	O
10	O
%	O
de	O
aumento	O
en	O
proteína	B-Chemical
,	O
Figura	O
4D	O
)	O
se	O
muestra	O
en	O
azul	O
.	O

Tenga	O
en	O
cuenta	O
que	O
el	O
rescate	O
previsto	O
está	O
en	O
perfecta	O
correspondencia	O
numérica	O
con	O
el	O
rendimiento	O
de	O
la	O
memoria	O
de	O
GluR	O
-	O
BRescue	O
ratones	B-Taxon
.	O

C	O
)	O
El	O
índice	O
de	O
discriminación	O
se	O
calculó	O
como	O
en	O
las	O
Figuras	O
1E	O
,	O
2C	O
y	O
4D	O
(	O
últimos	O
100	O
intentos	O
de	O
la	O
tarea	O
de	O
discriminación	O
de	O
mezclas	O
)	O
para	O
GluRBRescue	O
(	O
n	O
=	O
8	O
)	O
,	O
GluR	O
-	O
B	O
Delta	O
FB	O
(	O
n	O
=	O
22	O
)	O
y	O
control	O
(	O
n	O
=	O
14	O
)	O
animales	B-Taxon
.	O

notas	O
al	O
pie	O

Contribuciones	O
de	O
autor	O
.	O

DRS	O
y	O
ATS	O
concibieron	O
y	O
diseñaron	O
la	O
mayoría	O
de	O
los	O
experimentos	O
.	O

El	O
manuscrito	O
fue	O
escrito	O
por	O
DRS	O
,	O
PHS	O
,	O
RS	O
y	O
ATS	O
.	O

Ratón	B-Taxon
las	O
líneas	O
fueron	O
concebidas	O
y	O
diseñadas	O
por	O
DRS	O
,	O
PHS	O
,	O
RS	O
(	O
GluR-B	O
Delta	O
FB	O
,	O
GluR-B	O
Delta	O
ECS	O
:	O
FB	O
)	O
;	O
DRS	O
,	O
PHS	O
,	O
RS	O
,	O
ATS	O
(	O
GluR-BRescue	O
)	O
;	O
JK	O
,	O
PHS	O
,	O
RS	O
(	O
TgCN12-itTA	O
)	O
;	O
y	O
VM	O
,	O
PHS	O
,	O
RS	O
(	O
GluR-B2lox	O
,	O
TgOCN1	O
)	O
.	O

Los	O
experimentos	O
de	O
comportamiento	O
olfativo	O
fueron	O
realizados	O
por	O
TB	O
y	O
ATS	O
;	O
AM	O
realizó	O
las	O
transferencias	O
Western	O
GFPGluR-B	O
;	O
Los	O
experimentos	O
inmunohistoquímicos	O
y	O
otras	O
transferencias	O
Western	O
,	O
así	O
como	O
los	O
experimentos	O
conductuales	O
no	O
olfativos	O
,	O
se	O
realizaron	O
mediante	O
DRS	O
.	O

moneda	O
Dirección	O
actual	O
:	O
Departamento	O
de	O
Fisiología	O
,	O
University	O
College	O
London	O
,	O
Londres	O
,	O
Reino	O
Unido	O

Cita	O
:	O
Shimshek	O
DR	O
,	O
Bus	O
T	O
,	O
Kim	O
J	O
,	O
Mihaljevic	O
A	O
,	O
Mack	O
V	O
,	O
et	O
al	O
.	O

(	O
2005	O
)	O
Discriminación	O
de	O
olores	O
mejorada	O
y	O
deterioro	O
de	O
la	O
memoria	O
olfativa	O
mediante	O
el	O
cambio	O
espacialmente	O
controlado	O
de	O
los	O
receptores	O
AMPA	O
.	O

PLoS	O
Biol	O
3	O
(	O
11	O
)	O
:	O
e354	O
.	O

Dos	O
ramas	O
principales	O
de	O
anti-	O
cadmio	B-Chemical
defensa	O
en	O
el	O
ratón	B-Taxon
:	O
DM	B-Protein
-	I-Protein
1	I-Protein
/	O
metalotioneínas	O
y	O
glutatión	B-Chemical

Resumen	O

Metal	B-Protein
-	I-Protein
factor	I-Protein
de	I-Protein
transcripción	I-Protein
sensible	I-Protein
1	I-Protein
(	O
DM	B-Protein
-	I-Protein
1	I-Protein
)	O
regula	O
la	O
expresión	O
de	O
su	O
objetivo	O
genes	B-Sequence
en	O
respuesta	O
a	O
diversas	O
condiciones	O
de	O
estrés	O
,	O
en	O
particular	O
fuertes	O
metal	B-Chemical
carga	O
,	O
a	O
través	O
de	O
la	O
vinculación	O
a	O
metal	B-Chemical
respuesta	O
elementos	B-Sequence
(	O
MREs	O
)	O
en	O
los	O
respectivos	O
regiones	B-Sequence
potenciadoras/promotoras	I-Sequence
.	O

Además	O
,	O
cumple	O
una	O
función	O
vital	O
en	O
el	O
desarrollo	O
embrionario	O
del	O
hígado	O
.	O

Sin	O
embargo	O
,	O
dirigido	O
supresión	B-Sequence
de	O
mtf1	B-Protein
en	O
el	O
hígado	O
después	O
del	O
nacimiento	O
ya	O
no	O
es	O
letal	O
.	O

Para	O
este	O
estudio	O
,	O
mtf1	B-Protein
nocaut	O
condicional	O
ratones	B-Taxon
y	O
los	O
compañeros	O
de	O
camada	O
de	O
control	O
eran	O
ambos	O
falsos	O
,	O
o	O
cadmio	B-Chemical
Se	O
analizó	O
la	O
transcripción	O
específica	O
de	O
hígado	O
y	O
tratada	O
.	O

Además	O
de	O
la	O
metalotioneína	O
bien	O
caracterizada	O
genes	B-Sequence
,	O
varios	O
nuevos	O
DM	B-Protein
-	I-Protein
1	I-Protein
objetivo	O
genes	B-Sequence
con	O
motivos	O
MRE	O
en	O
el	O
región	B-Sequence
promotora	I-Sequence
surgió	O

DM	B-Protein
-	I-Protein
1	I-Protein
se	O
requiere	O
para	O
la	O
expresión	O
basal	O
de	O
selenoproteína	B-Protein
W	I-Protein
,	I-Protein
músculo	I-Protein
1	I-Protein
gene	B-Sequence
(	O
Sepw1	B-Protein
)	O
que	O
codifica	O
un	O
glutatión	B-Chemical
#	O
¿NOMBRE	O
?	O
proteína	B-Chemical
antioxidante	I-Chemical
,	O
apoyando	O
un	O
papel	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
en	O
la	O
respuesta	O
al	O
estrés	O
oxidativo	O
.	O

Es	O
más	O
,	O
DM	B-Protein
-	I-Protein
1	I-Protein
media	O
el	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
N	B-Protein
-	I-Protein
myc	I-Protein
gen	I-Protein
1	I-Protein
regulado	I-Protein
corriente	I-Protein
abajo	I-Protein
(	O
Ndrg1	B-Protein
)	O
,	O
que	O
es	O
inducida	O
por	O
varias	O
condiciones	O
de	O
estrés	O
y	O
se	O
sobreexpresa	O
en	O
muchos	O
tipos	O
de	O
cáncer	O
.	O

DM	B-Protein
-	I-Protein
1	I-Protein
también	O
está	O
involucrado	O
en	O
la	O
cadmio	B-Chemical
respuesta	O
de	O
proteína	B-Protein
rica	I-Protein
en	I-Protein
cisteína	I-Protein
y	I-Protein
glicina	I-Protein
1	I-Protein
gene	B-Sequence
(	O
Csrp1	B-Protein
)	O
,	O
que	O
está	O
implicado	O
en	O
citoesquelético	B-GENE
organización	O

A	O
diferencia	O
de	O
,	O
DM	B-Protein
-	I-Protein
1	I-Protein
reprime	O
la	O
expresión	O
basal	O
de	O
Slc39a10	B-Protein
,	O
un	O
putativo	O
zinc	B-Chemical
transportador	O

En	O
un	O
camino	O
independiente	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
,	O
cadmio	B-Chemical
también	O
indujo	O
la	O
transcripción	O
de	O
genes	B-Sequence
participan	O
en	O
la	O
síntesis	O
y	O
regeneración	O
de	O
glutatión	B-Chemical
,	O
a	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
antioxidante	B-Chemical
.	O

Estos	O
datos	O
proporcionan	O
una	O
fuerte	O
evidencia	O
de	O
dos	O
ramas	O
principales	O
de	O
celular	B-Cell
anti	O
-	O
cadmio	B-Chemical
defensa	O
,	O
una	O
via	O
DM	B-Protein
-	I-Protein
1	I-Protein
y	O
su	O
objetivo	O
genes	B-Sequence
,	O
en	O
particular	O
las	O
metalotioneínas	O
,	O
la	O
otra	O
vía	O
glutatión	B-Chemical
,	O
con	O
una	O
aparente	O
superposición	O
en	O
selenoproteína	B-Protein
W	I-Protein
.	O

INTRODUCCIÓN	O

Todos	O
organismos	B-Taxon
han	O
desarrollado	O
mecanismos	O
para	O
hacer	O
frente	O
a	O
una	O
variedad	O
de	O
situaciones	O
de	O
estrés	O
.	O

Un	O
tipo	O
de	O
respuesta	O
al	O
estrés	O
es	O
provocada	O
por	O
fuertes	O
rieles	B-Chemical
,	O
tal	O
como	O
zinc	B-Chemical
,	O
cobre	B-Chemical
y	O
cadmio	B-Chemical
(	O
por	O
conveniencia	O
,	O
los	O
términos	O
zinc	B-Chemical
,	O
cobre	B-Chemical
y	O
cadmio	B-Chemical
también	O
se	O
utilizan	O
aquí	O
para	O
denotar	O
Zn2	B-Chemical
+	I-Chemical
,	O
Cu2	B-Chemical
+	I-Chemical
y	O
CD2	B-Chemical
+	I-Chemical
,	O
respectivamente	O
)	O
.	O

Metalotioneínas	O
(	O
MT	O
)	O
,	O
pequeñas	O
,	O
cisteína	B-Chemical
#	O
¿NOMBRE	O
?	O
proteinas	B-Chemical
,	O
juegan	O
un	O
papel	O
importante	O
en	O
metal	B-Chemical
homeostasis	O
y	O
desintoxicación	O
debido	O
a	O
su	O
capacidad	O
para	O
unirse	O
a	O
diferentes	O
iones	B-Chemical
de	I-Chemical
metal	I-Chemical
(	O
1	O
-	O
3	O
)	O
.	O

En	O
el	O
ratón	B-Taxon
,	O
hay	O
cuatro	O
metalotioneínas	O
genes	B-Sequence
,	O
designado	O
como	O
Mt1	B-Protein
para	O
Mt4	B-Protein
.	O

Basal	O
,	O
así	O
como	O
pesado	O
metal	B-Chemical
#	O
¿NOMBRE	O
?	O
Mt1	B-Protein
y	O
mt2	B-Protein
está	O
mediada	O
por	O
metal	B-Protein
-	I-Protein
factor	I-Protein
de	I-Protein
transcripción	I-Protein
sensible	I-Protein
1	I-Protein
(	O
DM	B-Protein
-	I-Protein
1	I-Protein
)	O
(	O
4	O
-	O
7	O
)	O
.	O

Esta	O
zinc	B-Chemical
dedo	O
proteína	B-Chemical
reconoce	O
corto	O
cis	B-Sequence
-	I-Sequence
secuencias	I-Sequence
de	I-Sequence
ADN	I-Sequence
que	I-Sequence
actúan	I-Sequence
,	O
denominado	O
metal	B-Chemical
respuesta	O
elementos	B-Sequence
(	O
MRE	O
;	O
núcleo	O
secuencia	B-Sequence
de	I-Sequence
consenso	I-Sequence
TGCRCNC	O
)	O
,	O
que	O
están	O
presentes	O
en	O
el	O
promotores	B-Sequence
del	O
objetivo	O
genes	B-Sequence
(	O
8	O
,	O
9	O
)	O
.	O

DM	B-Protein
-	I-Protein
1	I-Protein
es	O
conservado	B-Sequence
en	O
evolución	O
,	O
y	O
homólogos	B-Sequence
se	O
han	O
caracterizado	O
en	O
el	O
ratón	B-Taxon
10	O
)	O
,	O
humanos	B-Taxon
(	O
11	O
)	O
,	O
drosófila	B-Taxon
(	O
12	O
-	O
14	O
)	O
y	O
pez	B-Taxon
(	O
15	O
,	O
16	O
)	O
.	O

El	O
rol	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
ha	O
sido	O
estudiada	O
más	O
extensamente	O
en	O
el	O
ratón	B-Taxon
.	O

Además	O
de	O
hacer	O
frente	O
a	O
los	O
pesados	O
metal	B-Chemical
carga	O
,	O
DM	B-Protein
-	I-Protein
1	I-Protein
también	O
puede	O
mediar	O
la	O
inducción	O
de	O
Mt	O
genes	B-Sequence
en	O
respuesta	O
a	O
otras	O
situaciones	O
de	O
estrés	O
,	O
como	O
el	O
estrés	O
oxidativo	O
(	O
5	O
,	O
17	O
)	O
y	O
la	O
hipoxia	O
(	O
18	O
)	O
.	O

Además	O
,	O
se	O
requiere	O
para	O
la	O
metalorregulación	O
de	O
Znt1	B-Protein
,	O
codificando	O
la	O
mayor	O
membrana	B-GENE
de	I-GENE
plasma	I-GENE
#	O
¿NOMBRE	O
?	O
zinc	B-Chemical
transportador	O
de	O
eflujo	O
(	O
19	O
)	O
,	O
la	O
inducción	O
hipóxica	O
/	O
anóxica	O
del	O
gen	B-Protein
del	I-Protein
factor	I-Protein
de	I-Protein
crecimiento	I-Protein
placentario	I-Protein
(	O
por	B-Protein
favor	I-Protein
)	O
,	O
un	O
angiogénico	O
proteína	B-Chemical
de	O
la	O
familia	O
del	O
factor	O
de	O
crecimiento	O
del	O
endotelio	O
vascular	O
(	O
VEGF	O
)	O
(	O
20	O
)	O
,	O
y	O
recientemente	O
se	O
ha	O
invocado	O
en	O
el	O
desarrollo	O
de	O
tumores	O
(	O
21	O
,	O
22	O
)	O
.	O

Es	O
más	O
,	O
DM	B-Protein
-	I-Protein
1	I-Protein
tiene	O
una	O
función	O
esencial	O
durante	O
la	O
embriogénesis	O
:	O
interrupción	O
selectiva	O
de	O
mtf1	B-Protein
resulta	O
en	O
letalidad	O
embrionaria	O
alrededor	O
de	O
14	O
días	O
después	O
del	O
coito	O
debido	O
a	O
hepatocito	B-Cell
necrosis	O
(	O
23	O
)	O
.	O

A	O
diferencia	O
de	O
,	O
ratones	B-Taxon
con	O
nulo	O
mutaciones	B-Sequence
para	O
el	O
estrés	O
-	O
metalotioneína	O
inducible	O
genes	B-Sequence
(	O
Mt1	B-Protein
y	O
mt2	B-Protein
)	O
son	O
viables	O
,	O
aunque	O
sensibles	O
a	O
cadmio	B-Chemical
24	O
,	O
25	O
)	O
,	O
indicando	O
que	O
adicionalmente	O
DM	B-Protein
-	I-Protein
1	I-Protein
objetivo	O
genes	B-Sequence
están	O
involucrados	O
en	O
el	O
fenotipo	O
letal	O
.	O

Con	O
el	O
Cre	O
-	O
loxP	B-Sequence
técnica	O
de	O
nocaut	O
condicional	O
,	O
es	O
posible	O
eludir	O
el	O
fenotipo	O
letal	O
embrionario	O
de	O
convencional	O
mtf1	B-Protein
knockear	O
ratones	B-Taxon
.	O

Experimentos	O
previos	O
con	O
esta	O
técnica	O
revelaron	O
que	O
supresión	B-Sequence
de	O
mtf1	B-Protein
del	O
hígado	O
después	O
del	O
nacimiento	O
ya	O
no	O
es	O
letal	O
en	O
condiciones	O
sin	O
estrés	O
(	O
26	O
)	O
.	O

Para	O
este	O
estudio	O
,	O
un	O
inducible	O
,	O
específico	O
del	O
hígado	O
mtf1	B-Protein
knockear	O
ratón	B-Taxon
línea	O
fue	O
generada	O
para	O
realizar	O
una	O
búsqueda	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
objetivo	O
genes	B-Sequence
y	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
genes	B-Sequence
en	O
el	O
hígado	O
adulto	O
.	O

un	O
numero	O
de	O
objetivo	O
gene	B-Sequence
candidatos	O
surgieron	O
de	O
un	O
análisis	O
transcriptómico	O
de	O
simulacros	O
y	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
mtf1	B-Protein
nocaut	O
condicional	O
ratones	B-Taxon
y	O
compañeros	O
de	O
camada	O
de	O
control	O
y	O
varios	O
de	O
ellos	O
fueron	O
confirmados	O
por	O
RT-PCR	O
semicuantitativa	O
.	O

Además	O
del	O
estrés	O
-	O
metalotioneína	O
inducible	O
genes	B-Sequence
que	O
ya	O
eran	O
conocidos	O
como	O
objetivo	O
genes	B-Sequence
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
,	O
encontramos	O
eso	O
DM	B-Protein
-	I-Protein
1	I-Protein
es	O
importante	O
para	O
la	O
expresión	O
hepática	O
basal	O
de	O
la	O
gene	B-Sequence
por	O
selenoproteína	B-Protein
W	I-Protein
,	I-Protein
músculo	I-Protein
1	I-Protein
(	O
Sepw1	B-Protein
)	O
así	O
como	O
para	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
N	B-Protein
-	I-Protein
myc	I-Protein
gen	I-Protein
1	I-Protein
regulado	I-Protein
corriente	I-Protein
abajo	I-Protein
(	O
Ndrg1	B-Protein
)	O
y	O
el	O
gene	B-Sequence
codificación	O
proteína	B-Protein
rica	I-Protein
en	I-Protein
cisteína	I-Protein
y	I-Protein
glicina	I-Protein
1	I-Protein
(	O
Csrp1	B-Protein
)	O
.	O

Además	O
,	O
DM	B-Protein
-	I-Protein
1	I-Protein
parece	O
reprimir	O
la	O
expresión	O
de	O
soluto	B-Protein
portador	I-Protein
familia	I-Protein
39	I-Protein
,	I-Protein
miembro	I-Protein
10	I-Protein
gene	B-Sequence
(	O
Slc39a10	B-Protein
)	O
,	O
que	O
codifica	O
un	O
supuesto	O
ion	B-Chemical
metálico	I-Chemical
transportador	O

en	O
un	O
DM	B-Protein
-	I-Protein
1	I-Protein
-	O
Respuesta	O
transcriptómica	O
independiente	O
,	O
varias	O
genes	B-Sequence
envuelto	O
en	O
glutatión	B-Chemical
Se	O
induce	O
el	O
metabolismo	O
.	O

Otros	O
estudios	O
confirmaron	O
un	O
doble	O
anti	O
-	O
cadmio	B-Chemical
defensa	O
,	O
una	O
via	O
glutatión	B-Chemical
y	O
otra	O
vía	O
DM	B-Protein
-	I-Protein
1	I-Protein
y	O
su	O
objetivo	O
genes	B-Sequence
,	O
incluidas	O
las	O
metalotioneínas	O
.	O

MATERIALES	O
Y	O
MÉTODOS	O

Generación	O
de	O
mtf1	B-Protein
nocaut	O
condicional	O
ratones	B-Taxon
e	O
hígado	O
-	O
específico	O
supresión	B-Sequence

mtf1	B-Protein
nocaut	O
condicional	O
ratones	B-Taxon
fueron	O
generados	O
en	O
colaboración	O
con	O
el	O
Dr.	O
Michael	O
Leviten	O
(	O
San	O
Carlos	O
,	O
CA	O
)	O
.	O

Dos	O
clones	B-Sequence
genómicos	I-Sequence
que	O
contiene	O
exones	B-Sequence
3	O
a	O
6	O
de	O
mtf1	B-Protein
sirvieron	O
para	O
construir	O
un	O
gene	B-Sequence
apuntando	O
vector	B-Sequence
para	O
recombinación	O
homóloga	O
(	O
datos	O
suplementarios	O
)	O
.	O

A	O
neomicina	B-Chemical
resistencia	O
casete	B-Sequence
(	O
PGK-neo	O
)	O
flanqueado	B-Sequence
por	O
dos	O
sitios	B-Sequence
loxP	I-Sequence
fue	O
clonado	O
en	O
el	O
SacI	O
sitio	B-Sequence
5	O
'	O
de	O
exón	B-Sequence
3	O
de	O
mtf1	B-Protein
,	O
El	O
tercero	O
sitio	B-Sequence
loxP	I-Sequence
fue	O
clonado	O
en	O
el	O
ScaI	O
sitio	B-Sequence
3	O
'	O
de	O
exón	B-Sequence
4	O
.	O

A	O
timidina	B-Chemical
quinasa	O
(	O
TK	O
)	O
casete	B-Sequence
era	O
insertado	B-Sequence
en	O
el	O
HpaI	O
sitio	B-Sequence
3	O
'	O
de	O
exón	B-Sequence
6	O

129	O
ES	O
células	B-Cell
fueron	O
electroporados	O
con	O
la	O
orientación	O
linealizada	O
vector	B-Sequence
,	O
seleccionado	O
en	O
presencia	O
de	O
G418	O
y	O
FIAU	O
,	O
y	O
examinado	O
para	O
la	O
correcta	O
eventos	B-Sequence
de	I-Sequence
integración	I-Sequence
por	O
PCR	O
y	O
análisis	O
de	O
transferencia	O
Southern	O
.	O

La	O
expresión	O
transitoria	O
de	O
la	O
recombinasa	O
Cre	O
condujo	O
a	O
eliminación	B-Sequence
del	O
PGK	O
-	O
neo	O
casete	B-Sequence
,	O
y	O
ratones	B-Taxon
llevando	O
el	O
modificado	B-Sequence
mtf1loxp	O
alelo	B-Sequence
fueron	O
generados	O
por	O
inyección	O
de	O
positivo	O
clones	B-Sequence
en	O
blastocistos	O
C57Bl/6	O
y	O
cruces	O
posteriores	O
.	O

Nocaut	O
condicional	O
homocigoto	O
animales	B-Taxon
(	O
Mtf1loxP	O
/	O
loxP	B-Sequence
)	O
se	O
cruzaron	O
con	O
la	O
recombinasa	O
Cre	O
transgénico	B-Sequence
línea	O
MX	B-Protein
-cre	O
(	O
un	O
regalo	O
del	O
Prof.	O
Michel	O
Aguet	O
)	O
para	O
obtener	O
un	O
inducible	O
,	O
específico	O
del	O
hígado	O
mtf1	B-Protein
línea	O
de	O
nocaut	O
.	O

los	O
ratones	B-Taxon
fueron	O
genotipados	O
por	O
PCR	O
utilizando	O
los	O
siguientes	O
cebadores	B-Sequence
(	O
Microsynth	O
)	O
:	O
Cre	O
recombinasa	O
:	O
5'-CTATCCAGCAACATTTGGGCCAGC-3	O
'	O
;	O
5'-CCAGGTTACGGATATAGTTCATGAC-3	O
'	O
,	O
Mtf1loxP	O
o	O
alelo	B-Sequence
de	I-Sequence
tipo	I-Sequence
salvaje	I-Sequence
:	O
5	O
'	O
-	O
CACACCCAGTTTGTGTATGTCTTC	O
-	O
3	O
'	O
;	O
5'-CAGTCACAAGCAAATTACCAAACACTGCC-3	O
'	O
.	O

Animal	B-Taxon
tratamiento	O

A	O
las	O
8	O
semanas	O
de	O
edad	O
,	O
macho	O
Mtf1loxP	O
/	O
loxP	B-Sequence
ratones	B-Taxon
albergando	O
el	O
MX	B-Protein
#	O
¿NOMBRE	O
?	O
transgén	B-Sequence
(	O
Mtf1loxP	O
/	O
loxP	B-Sequence
MX	B-Protein
-	O
cre	O
,	O
abreviatura	O
.	O
:	O
Mtf1Mx	O
-	O
cre	O
)	O
y	O
controlar	O
compañeros	O
de	O
camada	O
sin	O
transgén	B-Sequence
(	O
Mtf1loxP	O
/	O
loxP	B-Sequence
,	O
abreviatura	O
:	O
Mtf1loxP	O
)	O
recibió	O
cuatro	O
inyecciones	O
intraperitoneales	O
cada	O
una	O
de	O
300	O
micro	O
g	O
ARN	B-Sequence
sintético	I-Sequence
de	I-Sequence
doble	I-Sequence
cadena	I-Sequence
poliinosínico	O
-	O
policitidílico	O
ácido	B-Chemical
[	O
pI-pC	O
;	O
sigma	O
;	O
en	O
un	O
volumen	O
de	O
60	O
micro	O
l	O
fosfato	B-Chemical
-	O
amortiguado	B-Chemical
solución	O
salina	O
(	O
PBS	O
)	O
]	O
a	O
intervalos	O
de	O
3	O
días	O
.	O

Solo	O
en	O
el	O
caso	O
de	O
ADN	B-Sequence
#	O
¿NOMBRE	O
?	O
secuencias	B-Sequence
desde	O
DM	B-Protein
-	I-Protein
1	I-Protein
objetivo	O
gene	B-Sequence
candidatos	O
,	O
el	O
control	O
ratones	B-Taxon
no	O
recibió	O
inyecciones	O
de	O
pI-pC	O
.	O

Para	O
experimentos	O
con	O
metal	B-Chemical
tratamiento	O
,	O
ratones	B-Taxon
recibieron	O
2	O
días	O
después	O
del	O
último	O
tratamiento	O
con	O
pI	O
-	O
pC	O
una	O
inyección	O
subcutánea	O
(	O
s	O
.	O
c	O
.	O
)	O
de	O
20	O
micro	O
mol	O
/	O
kg	O
de	O
peso	O
corporal	O
de	O
CdSO4	O
(	O
2	O
mM	O
CdSO4	O
en	O
H2O	B-Chemical
;	O
cadmio	B-Chemical
tratamiento	O
)	O
o	O
10	O
ml/kg	O
de	O
peso	O
corporal	O
H2O	B-Chemical
(	O
tratamiento	O
simulado	O
)	O
6	O
h	O
antes	O
de	O
sacrificarlos	O
.	O

Análisis	O
de	O
micromatrices	O
y	O
procesamiento	O
de	O
datos	O
.	O

Total	O
ARN	B-Sequence
se	O
aisló	O
del	O
tejido	O
hepático	O
de	O
pI	O
-	O
pC	O
-	O
inducido	O
,	O
simulado	O
-	O
o	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
(	O
n	O
=	O
3	O
por	O
genotipo	B-Sequence
y	O
tratamiento	O
respectivo	O
;	O
todos	O
machos	O
)	O
esencialmente	O
como	O
lo	O
describen	O
Chomczynski	O
y	O
Sacchi	O
(	O
27	O
)	O
.	O

Gene	B-Sequence
el	O
análisis	O
de	O
expresión	O
se	O
realizó	O
en	O
el	O
Centro	O
de	O
Genómica	O
Funcional	O
de	O
Zúrich	O
utilizando	O
GeneChip	O
(	O
R	O
)	O
Ratón	B-Taxon
genoma	B-Sequence
430	O
2	O
.	O
0	O
matrices	O
(	O
Affymetrix	O
)	O
de	O
acuerdo	O
con	O
las	O
instrucciones	O
del	O
fabricante	O
y	O
las	O
siguientes	O
reactivos	B-Chemical
Y	O
condiciones	O
.	O

ADNc	B-Sequence
fue	O
sintetizado	O
con	O
SuperScript	O
(	O
TM	O
)	O
ADNc	B-Sequence
de	I-Sequence
doble	I-Sequence
cadena	I-Sequence
Kit	O
de	O
síntesis	O
(	O
Invitrogen	O
)	O
,	O
usando	O
15	O
micro	O
g	O
en	O
total	O
ARN	B-Sequence
.	O

La	O
transcripción	O
in	O
vitro	O
se	O
realizó	O
con	O
BioArray	O
(	O
TM	O
)	O
High	O
Yield	O
(	O
TM	O
)	O
Transcripción	B-Sequence
de	I-Sequence
ARN	I-Sequence
Kit	O
de	O
etiquetado	O
(	O
Enzo	O
)	O
y	O
3	O
.	O
5	O
a	O
6	O
micro	O
g	O
de	O
cada	O
uno	O
ADNc	B-Sequence
.	O

Limpieza	O
de	O
ambos	O
ADNc	B-Sequence
y	O
las	O
muestras	O
de	O
ARNc	O
se	O
realizaron	O
utilizando	O
el	O
módulo	O
de	O
limpieza	O
de	O
muestras	O
GeneChip	O
(	O
R	O
)	O
(	O
Affymetrix	O
)	O
.	O

Para	O
el	O
lavado	O
y	O
tinción	O
automatizados	O
en	O
la	O
estación	O
fluídica	O
450	O
de	O
Affymetrix	O
se	O
utilizó	O
el	O
protocolo	O
EukGE-Ws2v4_450	O
.	O

los	O
Investigacion	B-Sequence
Las	O
matrices	O
se	O
escanearon	O
con	O
el	O
escáner	O
Affymetrix	O
GS	O
3000	O
.	O

Los	O
datos	O
sin	O
procesar	O
están	O
disponibles	O
en	O
ArrayExpress	O
(	O
,	O
número	O
de	O
acceso	O
E	O
-	O
MEXP	O
-	O
438	O
)	O
.	O

El	O
análisis	O
de	O
datos	O
se	O
realizó	O
con	O
GeneSpring	O
6	O
.	O
1	O
software	O
(	O
Silicon	O
Genetics	O
)	O
,	O
aplicando	O
un	O
nivel	O
de	O
significancia	O
P	O
<	O
=	O
0	O
.	O
05	O
.	O

Además	O
,	O
se	O
utilizó	O
corrección	O
de	O
pruebas	O
múltiples	O
además	O
de	O
obtener	O
cadmio	B-Chemical
-	O
receptivo	O
,	O
DM	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
genes	B-Sequence
.	O

genes	B-Sequence
se	O
consideró	O
que	O
se	O
expresaban	O
diferencialmente	O
si	O
había	O
al	O
menos	O
una	O
diferencia	O
de	O
2	O
veces	O
en	O
los	O
niveles	O
de	O
expresión	O
de	O
los	O
grupos	O
experimentales	O
comparados	O
(	O
genotipo	B-Sequence
y	O
tratamiento	O
respectivo	O
)	O
.	O

El	O
resultado	O
se	O
consideró	O
confiable	O
si	O
los	O
valores	O
de	O
señal	O
para	O
los	O
respectivos	O
gene	B-Sequence
fueron	O
calificados	O
como	O
'presentes	O
'	O
al	O
menos	O
para	O
todos	O
ratones	B-Taxon
en	O
un	O
grupo	O
experimental	O
o	O
para	O
dos	O
ratones	B-Taxon
en	O
cada	O
uno	O
de	O
los	O
dos	O
grupos	O
.	O

Para	O
detectar	O
la	O
presencia	O
del	O
núcleo	O
MRE	O
secuencia	B-Sequence
de	I-Sequence
consenso	I-Sequence
TGCRCNC	O
en	O
el	O
región	B-Sequence
promotora	I-Sequence
,	O
aguas	O
arriba	O
secuencias	B-Sequence
de	O
los	O
respectivos	O
genes	B-Sequence
se	O
obtuvieron	O
de	O
la	O
Universidad	O
de	O
California	O
Santa	O
Cruz	O
(	O
UCSC	O
)	O
genoma	B-Sequence
Base	O
de	O
datos	O
del	O
navegador	O
(	O
;	O
octubre/noviembre	O
de	O
2004	O
)	O
(	O
28	O
)	O
.	O

RT-PCR	O

Todas	O
las	O
RT	O
-	O
PCR	O
se	O
realizaron	O
con	O
el	O
kit	O
QIAGEN	O
(	O
R	O
)	O
OneStep	O
RT	O
-	O
PCR	O
(	O
QIAGEN	O
)	O
de	O
acuerdo	O
con	O
las	O
instrucciones	O
del	O
fabricante	O
,	O
usando	O
150	O
-	O
200	O
ng	O
ADNasa	B-Protein
I	I-Protein
#	O
¿NOMBRE	O
?	O
ARN	B-Sequence
(	O
ARN	B-Sequence
aislamiento	O
véase	O
análisis	O
de	O
micromatrices	O
)	O
.	O

Las	O
reacciones	O
se	O
llevaron	O
a	O
cabo	O
utilizando	O
los	O
siguientes	O
cebadores	B-Sequence
:	O
Csrp1	B-Protein
:	O
5	O
'	O
-	O
TTCCGATGTGCCAAGTGTGGC	O
-	O
3	O
'	O
;	O
5'-AGTAGAGAGTGGACATTCAGC-3	O
'	O
,	O
hipoxantina	B-Protein
-	I-Protein
guanina	I-Protein
-	I-Protein
fosforribosiltransferasa	I-Protein
(	O
Hprt	B-Protein
)	O
:	O
5	O
'	O
-	O
GCTGGTGAAAAGGACCTCTCG	O
-	O
3	O
'	O
;	O
5'-CCACAGGACTAGGACACCTGC-3	O
'	O
,	O
mtf1	B-Protein
:	O
5	O
'	O
-	O
GTGACTTTTGAGACTGTACTGAGTG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
CATGCCAAGAAACATTGAAGGTG	O
-	O
3	O
'	O
,	O
Ndrg1	B-Protein
:	O
5	O
'	O
-	O
AGATACACAACAACGTGGAGG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
TGTGCGAGCGGCTTCGGGGGC	O
-	O
3	O
'	O
,	O
Sepw1	B-Protein
:	O
5	O
'	O
-	O
TAGAGGCAGGGTCCTGAAAGC	O
-	O
3	O
'	O
;	O
5'-ACACCTGGAAACATGGCTGCC-3	O
'	O
,	O
Slc39a10	B-Protein
:	O
5	O
'	O
-	O
GCTGTGGCTGGTAGTAAAAGC	O
-	O
3	O
'	O
;	O
5'-GTGGCATGGGATTGTAAACAGC-3	O
'	O
.	O

Mapeo	O
de	O
nucleasa	O
S1	O
de	O
transcripciones	B-Sequence
(	O
Análisis	O
S1	O
)	O

El	O
análisis	O
S1	O
se	O
realizó	O
como	O
se	O
describió	O
previamente	O
(	O
29	O
)	O
,	O
usando	O
100	O
micro	O
g	O
ADNasa	B-Protein
I	I-Protein
#	O
¿NOMBRE	O
?	O
ARN	B-Sequence
(	O
ARN	B-Sequence
aislamiento	O
véase	O
análisis	O
de	O
micromatrices	O
)	O
.	O

Los	O
geles	O
se	O
revelaron	O
utilizando	O
PhosphorImager	O
(	O
Molecular	B-Chemical
Dinámica	O
)	O
.	O

El	O
análisis	O
S1	O
se	O
realizó	O
con	O
los	O
siguientes	O
32P	B-Chemical
#	O
¿NOMBRE	O
?	O
oligonucleótidos	B-Sequence
:	O
Hprt	B-Protein
S1	O
:	O
5	O
'	O
-	O
TCTTCAGTCTGATAAAATCTACAGTCATAGGAATGGATCTATCACTATTTCTATTCAGTGATTACATTAAAG	O
-	O
3	O
'	O
,	O
Sepw1	B-Protein
S1	O
:	O
5	O
'	O
-	O
TTCAACCGGGAACACCTGGAAACATGGCTGCCTGTCTTCTTGAAGTCTTGAGGTGGAAAGGGAAAGCAAAGCAGGAGGGTTTTCCCACCC	O
-	O
3	O
'	O
.	O

Ensayo	O
de	O
cambio	O
de	O
movilidad	O
electroforética	O
(	O
EMSA	O
)	O

Proteína	B-Chemical
se	O
extrajo	O
de	O
tejido	O
hepático	O
con	O
T	O
-	O
PER	O
(	O
TM	O
)	O
Tissue	O
Proteína	B-Chemical
Extracción	O
Reactivo	B-Chemical
(	O
perforar	O
)	O
de	O
acuerdo	O
con	O
las	O
instrucciones	O
del	O
fabricante	O
,	O
usando	O
una	O
proporción	O
de	O
1	O
:	O
10	O
de	O
ratón	B-Taxon
tejido	O
(	O
mg	O
)	O
a	O
T	O
-	O
PER	O
reactivo	B-Chemical
(	O
micro	O
l	O
)	O
.	O

La	O
EMSA	O
se	O
realizó	O
esencialmente	O
como	O
se	O
describió	O
previamente	O
(	O
10	O
)	O
.	O

Todas	O
las	O
reacciones	O
de	O
unión	O
se	O
llevaron	O
a	O
cabo	O
incubando	O
2	O
-	O
5	O
fmol	O
32P	B-Chemical
#	O
¿NOMBRE	O
?	O
oligonucleótidos	B-Sequence
de	I-Sequence
doble	I-Sequence
cadena	I-Sequence
con	O
100	O
a	O
130	O
micro	O
g	O
de	O
hígado	O
proteína	B-Chemical
extraer	O

Para	O
experimentos	O
de	O
competencia	O
,	O
5	O
pmol	O
de	O
competidor	O
sin	O
marcar	O
oligonucleótido	B-Sequence
se	O
añadió	O
a	O
la	O
reacción	O
de	O
unión	O
antes	O
de	O
la	O
adición	O
del	O
extracto	O
.	O

Todos	O
los	O
geles	O
EMSA	O
se	O
desarrollaron	O
utilizando	O
PhosphorImager	O
(	O
Molecular	B-Chemical
Dinámica	O
)	O
.	O

La	O
siguiente	O
oligonucleótidos	B-Sequence
fueron	O
recocidos	O
y	O
utilizados	O
para	O
las	O
reacciones	O
:	O
Csrp1	B-Protein
MRE1	O
:	O
5	O
'	O
-	O
GGAAACAAAACGGCGCGCACTCCGGCGC	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
GGCTGCGC	O
CGGAGTGCGCGCCGTTTTGT	O
-	O
3	O
'	O
,	O
Csrp1	B-Protein
MRE2	O
:	O
5'-TGTTTGGTGCAGTGTGCAAAGCCTAC-3	O
'	O
;	O
5'-ACCAGTAGGCTTTGCACACTGCACCAC-3	O
'	O
,	O
Csrp1	B-Protein
MRE3	O
:	O
5'-GAGATCGCCATAGGGTGCAAAGAGAAG-3	O
'	O
;	O
5'-GTGACTTCTCTTTGCACCCTAGGCGA-3	O
'	O
,	O
Csrp1	B-Protein
MRE4	O
:	O
5'-TGTCTTATTCTGGAGTGCAAGTTAGTC-3	O
'	O
;	O
5'-AGGGACTAACTTGCACTCCAGAATAA-3	O
'	O
,	O
Gal4	O
:	O
5'-TCCGGAGGACTGTCCTCCGG-3	O
'	O
;	O
5	O
'	O
-	O
GCCGGAGGACAGTCCTCCGG	O
-	O
3	O
'	O
,	O
MREd	O
[	O
MRE	O
derivado	O
de	O
ratón	B-Protein
mt1	I-Protein
promotor	B-Sequence
(	O
10	O
)	O
]	O
:	O
5'-CGAGGGAGCTCTGCACTCCGCCCGAAAAGTG-3	O
'	O
;	O
5	O
'	O
-	O
TCGACACTTTTCGGGCGGAGTGCAGAGCTCCCTCGAGCT	O
-	O
3	O
'	O
,	O
MRE	O
-	O
s	O
[	O
sintético	B-Sequence
MRE	O
secuencia	B-Sequence
de	I-Sequence
consenso	I-Sequence
(	O
10	O
)	O
]	O
:	O
5	O
'	O
-	O
CGAGGGAGCTCTGCACACGGCCCGAAAAGTG	O
-	O
3	O
'	O
;	O
5'-TCGACACTTTTCGGGCCGTGTGCAGAGCTCCCTCGAGCT-3	O
'	O
,	O
Ndrg1	B-Protein
MRE1	O
:	O
5'-CAGCCCAGGCAGGGTGCAGCACGAG-3	O
'	O
;	O
5'-CCGCCTCGTGCTGCACCCTGCCTGG-3	O
'	O
,	O
Ndrg1	B-Protein
MRE2	O
:	O
5'-CACACGTTCGCTGCACACCGCCGCGG-3	O
'	O
;	O
5'-GGGACCGCGGCGTGTGCAGCGAACG-3	O
'	O
,	O
Ndrg1	B-Protein
MRE3	O
,	O
4	O
:	O
5'-GGAGGTCCTTATGCACACGCGCACGAGCGCGCACGGGCAC-3	O
'	O
;	O
5'-TGTGTGCCCGTGCGCGCTCGTGCGCGTGTGCATAAGGAC-3	O
'	O
,	O
Sepw1	B-Protein
MRE1	O
:	O
5'-GAGGCAGTCGGCTGTGCGCACGGCCCCACGCTC-3	O
'	O
;	O
5'-CTCTGAGCGTGGGGCCGTGCGCACAGCCGACTGC-3	O
'	O
,	O
Sepw1	B-Protein
MRE2	O
:	O
5'-ATGGTTTTGGGGGTGCGCAGGGGGTCTG-3	O
'	O
;	O
5'-CGACAGACCCCCTGCGCACCCCCAAAAC-3	O
'	O
,	O
Slc39a10	B-Protein
MRE1	O
:	O
5'-GAATACACGACTGGGTGCAGCCGGGGTTTTGG-3	O
'	O
;	O
5'-GGTACCAAACCCCGGCTGCACCCAGTCGTGTA-3	O
'	O
,	O
Slc39a10	B-Protein
MRE2	O
:	O
5'-GCGGAGAGGAGATGCACACGGCACTCG-3	O
'	O
;	O
5'-CACTCGAGTGCCGTTGCATCTCCTCT-3	O
'	O
,	O
Proteína	B-Protein
de	I-Protein
especificidad	I-Protein
1	I-Protein
(	O
Sp1	B-Protein
)	O
secuencia	B-Sequence
de	I-Sequence
unión	I-Sequence
(	O
10	O
)	O
:	O
5'-CGAGGCCCCGCCCAG-3	O
'	O
;	O
5'-TCGACTGGGCGGGGCCTCGAGct-3	O
'	O
.	O

Célula	B-Cell
cultura	O

embrionario	O
primario	O
fibroblastos	B-Cell
fueron	O
aislados	O
de	O
un	O
12	O
.	O
Mtf1loxP	O
de	O
5	O
días	O
ratón	B-Taxon
embrión	O
y	O
crecido	O
en	O
DMEM	O
suplementado	O
con	O
10	O
%	O
fetal	O
bovino	B-Taxon
suero	O
(	O
ICN	O
)	O
,	O
100	O
U	O
/	O
ml	O
penicilina	B-Chemical
-	O
estreptomicina	B-Chemical
(	O
Gibco	O
BRL	O
)	O
y	O
2	O
mM	O
l	B-Chemical
-	I-Chemical
glutamina	I-Chemical
Gibco	O
BRL	O
)	O
.	O

Placas	O
de	O
100	O
mm	O
con	O
primario	O
células	B-Cell
fueron	O
transfectados	O
con	O
10	O
micro	O
g	O
de	O
una	O
expresión	O
plásmido	B-Sequence
codificando	O
para	O
antígeno	B-Protein
T	I-Protein
grande	I-Protein
del	I-Protein
virus	I-Protein
simio	I-Protein
40	I-Protein
(	I-Protein
SV40	I-Protein
)	I-Protein
impulsado	O
por	O
el	O
citomegalovirus	B-Taxon
(	O
CMV	B-Taxon
)	O
promotor	B-Sequence
,	O
utilizando	O
lipofectamina	O
(	O
TM	O
)	O
reactivo	B-Chemical
(	O
Invitrogen	O
)	O
según	O
las	O
instrucciones	O
del	O
fabricante	O
.	O

Célula	B-Cell
los	O
focos	O
fueron	O
aislados	O
y	O
los	O
inmortalizados	O
ratón	B-Taxon
embrionario	O
célula	B-Cell
de	I-Cell
fibroblasto	I-Cell
la	O
línea	O
ckoC	O
se	O
derivó	O
de	O
uno	O
de	O
ellos	O
.	O

el	O
mtf1loxp	O
genotipo	B-Sequence
de	O
esta	O
línea	O
,	O
así	O
como	O
la	O
integración	B-Sequence
genómica	I-Sequence
del	O
antígeno	O
T	O
fueron	O
confirmados	O
por	O
PCR	O
.	O

Placas	O
de	O
100	O
mm	O
con	O
estos	O
células	B-Cell
fueron	O
transfectados	O
aún	O
más	O
por	O
el	O
Fosfato	B-Chemical
de	I-Chemical
calcio	I-Chemical
método	O
(	O
30	O
)	O
con	O
19	O
.	O
6	O
micro	O
g	O
de	O
una	O
expresión	O
plásmido	B-Sequence
para	O
Cre	O
recombinasa	O
impulsada	O
por	O
el	O
CMV	B-Taxon
promotor	B-Sequence
y	O
0	O
4	O
micro	O
g	O
de	O
una	O
expresión	O
plásmido	B-Sequence
Para	O
el	O
neomicina	B-Chemical
resistencia	O
gene	B-Sequence
bajo	O
el	O
control	O
de	O
los	O
conocimientos	O
tradicionales	O
promotor	B-Sequence
.	O

Transfectado	O
de	O
forma	O
estable	O
células	B-Cell
fueron	O
seleccionados	O
en	O
presencia	O
de	O
0	O
.	O
4	O
micro	O
g	O
/	O
micro	O
l	O
G418	O
(	O
Calbiochem	O
)	O
,	O
clones	O
aislados	O
de	O
resistentes	O
células	B-Cell
fueron	O
cosechados	O
y	O
cultivados	O
de	O
forma	O
independiente	O
,	O
y	O
la	O
expresión	O
de	O
Cre	O
recombinase	O
y	O
excisión	B-Sequence
de	O
exones	B-Sequence
3	O
y	O
4	O
de	O
mtf1	B-Protein
fueron	O
analizados	O
por	O
RT-PCR	O
.	O

los	O
célula	B-Cell
líneas	O
delC19	O
,	O
delC21	O
y	O
delC23	O
con	O
un	O
supresión	B-Sequence
de	O
mtf1	B-Protein
fueron	O
elegidos	O
para	O
otros	O
experimentos	O
.	O

Ensayo	O
de	O
citotoxicidad	O

Muestras	O
de	O
1	O
x	O
104	O
células	B-Cell
/	O
pocillo	O
se	O
sembraron	O
en	O
placas	O
de	O
cultivo	O
tisular	O
de	O
96	O
pocillos	O
y	O
se	O
dejaron	O
adherir	O
durante	O
24	O
h	O
.	O

los	O
células	B-Cell
luego	O
se	O
preincubaron	O
durante	O
24	O
h	O
en	O
un	O
medio	O
que	O
contenía	O
0	O
,	O
5	O
,	O
10	O
,	O
25	O
ó	O
50	O
micro	O
M	O
de	O
l	O
-	O
butionina	O
-	O
[	O
S	O
,	O
R	O
]	O
-	O
sulfoximina	O
(	O
BSO	O
)	O
(	O
Sigma	O
)	O
,	O
un	O
droga	B-Chemical
que	O
inhibe	O
glutatión	B-Chemical
síntesis	O
(	O
31	O
)	O
.	O

Luego	O
,	O
células	B-Cell
fueron	O
expuestos	O
a	O
0	O
,	O
5	O
,	O
10	O
o	O
20	O
micro	O
M	O
CdCl2	B-Chemical
en	O
el	O
medio	O
de	O
preincubación	O
especificado	O
durante	O
24	O
h	O
más	O
.	O

La	O
citotoxicidad	O
se	O
determinó	O
mediante	O
el	O
MTT	O
(	O
3	O
-	O
[	O
4	O
,	O
5	O
-	O
dimetiltiazol	O
-	O
2	O
-	O
il	O
]	O
-	O
2	O
,	O
5	O
-	O
difenil	O
tetrazolio	O
bromuro	B-Chemical
)	O
-	O
establecido	O
Célula	B-Cell
Kit	O
de	O
proliferación	O
I	O
(	O
Roche	O
)	O
según	O
las	O
instrucciones	O
del	O
fabricante	O
.	O

RESULTADOS	O

Generación	O
de	O
un	O
inducible	O
,	O
específico	O
del	O
hígado	O
mtf1	B-Protein
knockear	O
ratón	B-Taxon
línea	O

Utilizando	O
una	O
estrategia	O
de	O
recombinación	O
homóloga	O
,	O
ratones	B-Taxon
se	O
obtuvieron	O
con	O
un	O
modificado	B-Sequence
mtf1	B-Protein
alelo	B-Sequence
mtf1loxp	O
donde	O
exones	B-Sequence
3	O
y	O
4	O
,	O
codificando	O
cuatro	O
de	O
los	O
seis	O
zinc	B-Chemical
dedos	O
de	O
la	O
ADN	B-Sequence
#	O
¿NOMBRE	O
?	O
dominio	B-Sequence
,	O
están	O
flanqueado	B-Sequence
por	O
sitios	B-Sequence
loxP	I-Sequence
(	O
Figura	O
1a	O
)	O
.	O

Ratones	B-Taxon
homocigoto	O
para	O
el	O
Mtf1loxP	O
alelo	B-Sequence
se	O
cruzaron	O
más	O
con	O
animales	B-Taxon
de	O
la	O
recombinasa	O
Cre	O
transgénico	B-Sequence
línea	O
MX	B-Protein
-	O
cre	O
.	O

Cre	O
recombinase	O
se	O
expresa	O
en	O
esta	O
línea	O
bajo	O
el	O
control	O
de	O
la	O
ratón	B-Protein
Mx1	I-Protein
promotor	B-Sequence
de	I-Sequence
genes	I-Sequence
,	O
que	O
es	O
inducible	O
por	O
la	O
administración	O
de	O
interferón	O
alfa	O
o	O
beta	O
,	O
o	O
ARN	B-Sequence
sintético	I-Sequence
de	I-Sequence
doble	I-Sequence
cadena	I-Sequence
pI-pC	O
(	O
32	O
)	O
.	O

Cre	O
-	O
mediado	O
supresión	B-Sequence
se	O
informó	O
que	O
era	O
completa	O
en	O
el	O
hígado	O
,	O
mientras	O
que	O
variaba	O
en	O
otros	O
tejidos	O
,	O
desde	O
el	O
94	O
%	O
en	O
el	O
bazo	O
hasta	O
el	O
8	O
%	O
en	O
el	O
cerebro	O
(	O
32	O
)	O
.	O

Después	O
de	O
Cre	O
-	O
mediado	O
supresión	B-Sequence
de	O
exones	B-Sequence
3	O
y	O
4	O
,	O
lo	O
que	O
da	O
como	O
resultado	O
una	O
cambio	B-Sequence
de	I-Sequence
marco	I-Sequence
y	O
prematuro	O
parada	B-Sequence
de	I-Sequence
traducción	I-Sequence
,	O
no	O
funcional	O
DM	B-Protein
-	I-Protein
1	I-Protein
proteína	B-Chemical
puede	O
ser	O
producido	O
.	O

Para	O
la	O
inducción	O
de	O
la	O
recombinasa	O
Cre	O
,	O
mtf1	B-Protein
nocaut	O
condicional	O
ratones	B-Taxon
albergando	O
el	O
MX	B-Protein
#	O
¿NOMBRE	O
?	O
transgén	B-Sequence
(	O
Mtf1Mx-cre	O
)	O
recibieron	O
cuatro	O
inyecciones	O
intraperitoneales	O
de	O
pI-pC	O
a	O
intervalos	O
de	O
3	O
días	O
(	O
inducción	O
de	O
pI-pC	O
)	O
;	O
controlar	O
a	O
los	O
compañeros	O
de	O
camada	O
sin	O
transgén	B-Sequence
(	O
Mtf1loxP	O
)	O
recibió	O
inyecciones	O
similares	O
.	O

Usando	O
RT	O
-	O
PCR	O
(	O
Figura	O
1b	O
)	O
,	O
una	O
versión	O
abreviada	O
producto	B-Sequence
se	O
obtuvo	O
con	O
ARN	B-Sequence
de	O
Mtf1Mx-cre	O
hígados	O
,	O
lo	O
que	O
indica	O
un	O
éxito	O
excisión	B-Sequence
de	O
exones	B-Sequence
3	O
y	O
4	O
de	O
mtf1	B-Protein
en	O
estos	O
animales	B-Taxon
.	O

En	O
un	O
examen	O
minucioso	O
,	O
también	O
se	O
observó	O
una	O
banda	O
muy	O
tenue	O
similar	O
en	O
tamaño	O
a	O
la	O
señal	O
de	O
longitud	O
completa	O
en	O
aquellos	O
ratones	B-Taxon
,	O
probablemente	O
debido	O
a	O
una	O
baja	O
cantidad	O
de	O
residuos	O
de	O
longitud	O
completa	O
mtf1	B-Protein
ARNm	B-Chemical
.	O

El	O
nivel	O
de	O
funcional	O
DM	B-Protein
-	I-Protein
1	I-Protein
proteína	B-Chemical
fue	O
examinado	O
por	O
EMSA	O
(	O
Figura	O
1c	O
)	O
:	O
DM	B-Protein
-	I-Protein
1	I-Protein
proteína	B-GENE
-	I-GENE
complejo	I-GENE
de	I-GENE
ADN	I-GENE
fue	O
detectable	O
con	O
el	O
hígado	O
proteína	B-Chemical
extracto	O
de	O
un	O
control	O
Mtf1loxP	O
ratón	B-Taxon
,	O
pero	O
sin	O
enlace	O
MRE	O
funcional	O
proteína	B-Chemical
se	O
observó	O
con	O
una	O
muestra	O
Mtf1Mx-cre	O
.	O

Por	O
lo	O
tanto	O
,	O
supresión	B-Sequence
de	O
exones	B-Sequence
3	O
y	O
4	O
de	O
mtf1	B-Protein
en	O
el	O
higado	O
de	O
Mtf1Mx	O
-	O
cre	O
ratones	B-Taxon
estaba	O
virtualmente	O
completo	O
.	O

Todos	O
los	O
hígados	O
examinados	O
-	O
knockout	O
específico	O
ratones	B-Taxon
eran	O
viables	O
en	O
condiciones	O
de	O
laboratorio	O
y	O
parecían	O
normales	O
.	O

DM	B-Protein
-	I-Protein
1	I-Protein
objetivo	O
gene	B-Sequence
búsqueda	O

Para	O
la	O
identificación	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
objetivo	O
genes	B-Sequence
,	O
comparamos	O
el	O
hígado	O
transcripción	B-Sequence
perfiles	O
de	O
ratones	B-Taxon
con	O
y	O
sin	O
funcional	O
mtf1	B-Protein
gene	B-Sequence
que	O
había	O
sido	O
simulado	O
-	O
tratado	O
o	O
expuesto	O
a	O
cadmio	B-Chemical
(	O
n	O
=	O
3	O
por	O
genotipo	B-Sequence
y	O
tratamiento	O
respectivo	O
)	O
.	O

En	O
una	O
primera	O
pantalla	O
,	O
el	O
transcripciones	B-Sequence
fueron	O
analizados	O
con	O
un	O
método	O
basado	O
en	O
visualización	O
diferencial	O
,	O
llamado	O
amplificación	O
de	O
ADNc	B-Sequence
de	I-Sequence
doble	I-Sequence
cadena	I-Sequence
final	O
fragmentos	B-Sequence
de	I-Sequence
restricción	I-Sequence
(	O
ÁMBAR	O
)	O
(	O
33	O
)	O
.	O

De	O
este	O
modo	O
,	O
se	O
obtuvo	O
un	O
número	O
abrumador	O
de	O
señales	O
para	O
las	O
dos	O
metalotioneínas	O
inducibles	O
por	O
estrés	O
(	O
Mt1	B-Protein
y	O
mt2	B-Protein
)	O
,	O
debido	O
a	O
la	O
abundancia	O
de	O
sus	O
transcripciones	B-Sequence
tanto	O
en	O
simulacros	O
de	O
tratamiento	O
como	O
especialmente	O
en	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
DM	B-Protein
-	I-Protein
1	I-Protein
gene	B-Sequence
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Este	O
resultado	O
confirmó	O
la	O
importancia	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
tanto	O
para	O
basales	O
como	O
para	O
metal	B-Chemical
#	O
¿NOMBRE	O
?	O
genes	B-Sequence
.	O

En	O
un	O
segundo	O
enfoque	O
,	O
el	O
gene	B-Sequence
perfil	O
de	O
expresión	O
en	O
hígados	O
de	O
los	O
mencionados	O
ratones	B-Taxon
fue	O
comparado	O
por	O
Affymetrix	O
GeneChip	O
(	O
R	O
)	O
Ratón	B-Taxon
genoma	B-Sequence
430	O
2	O
.	O
0	O
Matrices	O
(	O
Tabla	O
1	O
)	O
.	O

Al	O
analizar	O
el	O
Investigacion	B-Sequence
matriz	O
de	O
datos	O
de	O
hígados	O
de	O
Mtf1Mx	O
-	O
cre	O
y	O
Mtf1loxP	O
tratados	O
de	O
forma	O
simulada	O
ratones	B-Taxon
,	O
se	O
detectó	O
una	O
regulación	O
negativa	O
confiable	O
de	O
la	O
expresión	O
de	O
al	O
menos	O
2	O
veces	O
en	O
hígados	O
Mtf1Mx	O
-	O
cre	O
para	O
13	O
Affymetrix	O
GeneChip	O
(	O
R	O
)	O
Investigacion	B-Sequence
conjuntos	O
correspondientes	O
a	O
11	O
caracterizados	O
genes	B-Sequence
(	O
Cuadro	O
1	O
,	O
a	O
)	O
.	O

siete	O
de	O
estos	O
genes	B-Sequence
contienen	O
uno	O
o	O
más	O
núcleos	O
MRE	O
secuencia	B-Sequence
de	I-Sequence
consenso	I-Sequence
TGCRCNC	O
dentro	O
de	O
un	O
segmento	B-Sequence
de	O
1000	O
pb	B-Sequence
aguas	O
arriba	O
de	O
la	O
comienzo	B-Sequence
de	I-Sequence
la	I-Sequence
transcripción	I-Sequence
.	O

por	O
26	O
Investigacion	B-Sequence
conjuntos	O
correspondientes	O
a	O
24	O
caracteres	O
diferentes	O
genes	B-Sequence
,	O
se	O
detectó	O
una	O
regulación	O
al	O
alza	O
confiable	O
de	O
2	O
veces	O
o	O
más	O
en	O
hígados	O
Mtf1Mx	O
-	O
cre	O
(	O
Tabla	O
1	O
,	O
b	O
)	O
;	O
17	O
de	O
estos	O
24	O
genes	B-Sequence
contienen	O
núcleo	O
MRE	O
secuencias	B-Sequence
de	I-Sequence
consenso	I-Sequence
en	O
el	O
río	O
arriba	O
región	B-Sequence
.	O

El	O
conjunto	O
de	O
datos	O
para	O
hígados	O
de	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
reveló	O
una	O
regulación	O
a	O
la	O
baja	O
confiable	O
de	O
al	O
menos	O
2	O
veces	O
en	O
hígados	O
Mtf1Mx	O
-	O
cre	O
durante	O
21	O
Investigacion	B-Sequence
conjuntos	O
correspondientes	O
a	O
16	O
caracteres	O
diferentes	O
genes	B-Sequence
(	O
Cuadro	O
1	O
,	O
c	O
)	O
;	O
10	O
de	O
estos	O
contienen	O
núcleo	O
MRE	O
secuencias	B-Sequence
de	I-Sequence
consenso	I-Sequence
en	O
su	O
contracorriente	O
región	B-Sequence
.	O

para	O
9	O
Investigacion	B-Sequence
conjuntos	O
correspondientes	O
a	O
9	O
diferentes	O
caracterizados	O
genes	B-Sequence
,	O
se	O
detectó	O
una	O
regulación	O
al	O
alza	O
confiable	O
de	O
al	O
menos	O
2	O
veces	O
(	O
Tabla	O
1	O
,	O
d	O
)	O
;	O
cinco	O
de	O
ellos	O
contienen	O
motivos	O
MRE	O
.	O

Además	O
de	O
caracterizarse	O
genes	B-Sequence
,	O
EST	B-Sequence
y	O
RIKEN	O
secuencias	B-Sequence
de	I-Sequence
ADNc	I-Sequence
también	O
se	O
encontraron	O
en	O
la	O
comparación	O
de	O
hígados	O
Mtf1Mx-cre	O
y	O
Mtf1loxP	O
que	O
se	O
expresaron	O
diferencialmente	O
(	O
Tabla	O
complementaria	O
1	O
)	O
.	O

Regulación	O
a	O
la	O
baja	O
de	O
Mt1	B-Protein
y	O
mt2	B-Protein
se	O
detectó	O
en	O
Mtf1Mx	O
-	O
hígados	O
cre	O
para	O
ambas	O
condiciones	O
(	O
aunque	O
el	O
nivel	O
de	O
importancia	O
para	O
la	O
regulación	O
a	O
la	O
baja	O
de	O
Mt1	B-Protein
en	O
simulacro	O
-	O
tratado	O
animales	B-Taxon
estaba	O
por	O
encima	O
de	O
0	O
.	O
05	O
;	O
datos	O
no	O
mostrados	O
)	O
.	O

Para	O
todos	O
DM	B-Protein
-	I-Protein
1	I-Protein
objetivo	O
genes	B-Sequence
caracterizado	O
hasta	O
ahora	O
,	O
como	O
Mt1	B-Protein
,	O
mt2	B-Protein
y	O
Znt1	B-Protein
,	O
DM	B-Protein
-	I-Protein
1	I-Protein
ejerce	O
su	O
actividad	O
de	O
activación	O
transcripcional	O
a	O
través	O
de	O
MRE	O
estándar	O
secuencias	B-Sequence
situado	O
proximal	O
a	O
la	O
comienzo	B-Sequence
de	I-Sequence
la	I-Sequence
transcripción	I-Sequence
(	O
4	O
,	O
5	O
,	O
8	O
,	O
18	O
,	O
19	O
)	O
.	O

Incluso	O
una	O
búsqueda	O
específica	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
sitios	B-Sequence
de	I-Sequence
unión	I-Sequence
por	O
selección	O
de	O
un	O
grupo	O
de	O
oligonucleótidos	B-Sequence
de	I-Sequence
doble	I-Sequence
cadena	I-Sequence
con	O
secuencias	B-Sequence
aleatorias	I-Sequence
no	O
produjo	O
ningún	O
nuevo	O
motivo	O
de	O
unión	O
para	O
DM	B-Protein
-	I-Protein
1	I-Protein
además	O
de	O
conocido	B-Sequence
MRE	O
(	O
34	O
)	O
.	O

Así	O
,	O
un	O
MRE	O
secuencia	B-Sequence
es	O
hasta	O
la	O
fecha	O
la	O
única	O
indicación	O
de	O
una	O
DM	B-Protein
-	I-Protein
1	I-Protein
objetivo	O
gene	B-Sequence
,	O
y	O
cuatro	O
MRE	O
-	O
objetivo	O
que	O
contiene	O
gene	B-Sequence
los	O
candidatos	O
fueron	O
analizados	O
más	O
a	O
fondo	O
.	O

expresión	O
basal	O
de	O
Sepw1	B-Protein
depende	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein

Sepw1	B-Protein
se	O
encontró	O
en	O
el	O
análisis	O
de	O
microarrays	O
que	O
estaba	O
significativamente	O
regulado	O
a	O
la	O
baja	O
en	O
hígados	O
de	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
(	O
Cuadro	O
1	O
,	O
ayc	O
)	O
.	O

SEPW1	B-Protein
es	O
un	O
selenocisteína	B-Chemical
#	O
¿NOMBRE	O
?	O
proteína	B-Chemical
que	O
une	O
glutatión	B-Chemical
(	O
35	O
)	O
y	O
se	O
piensa	O
que	O
actúa	O
como	O
un	O
antioxidante	B-Chemical
in	O
vivo	O
(	O
36	O
)	O
.	O

Sepw1	B-Protein
expresión	O
en	O
hígados	O
de	O
pI	O
-	O
pC	O
-	O
inducida	O
,	O
simulada	O
-	O
o	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
se	O
analizó	O
más	O
mediante	O
RT-PCR	O
semicuantitativas	O
y	O
análisis	O
S1	O
(	O
Figura	O
2a	O
yb	O
)	O
.	O

De	O
acuerdo	O
con	O
los	O
datos	O
de	O
micromatrices	O
,	O
una	O
regulación	O
positiva	O
leve	O
,	O
si	O
la	O
hay	O
,	O
de	O
Sepw1	B-Protein
se	O
observó	O
transcripción	O
en	O
hígados	O
de	O
Mtf1loxP	O
ratones	B-Taxon
sobre	O
cadmio	B-Chemical
tratamiento	O
.	O

El	O
nivel	O
basal	O
se	O
redujo	O
en	O
hígados	O
de	O
simulacros	O
y	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
,	O
Indicando	O
que	O
DM	B-Protein
-	I-Protein
1	I-Protein
es	O
importante	O
para	O
la	O
expresión	O
basal	O
de	O
Sepw1	B-Protein
.	O

Tres	O
núcleos	O
MRE	O
secuencias	B-Sequence
de	I-Sequence
consenso	I-Sequence
fueron	O
encontrados	O
en	O
el	O
región	B-Sequence
aguas	O
arriba	O
de	O
la	O
ratón	B-Protein
Sepw1	I-Protein
comienzo	B-Sequence
de	I-Sequence
la	I-Sequence
transcripción	I-Sequence
(	O
Figura	O
2c	O
)	O
.	O

Dos	O
de	O
ellos	O
en	O
orientación	O
opuesta	O
se	O
superponen	O
casi	O
completamente	O
proximal	O
a	O
la	O
comienzo	B-Sequence
de	I-Sequence
la	I-Sequence
transcripción	I-Sequence
(	O
MRE1	O
,	O
-	O
40	O
pb	B-Sequence
)	O
,	O
el	O
tercero	O
se	O
encuentra	O
aguas	O
arriba	O
(	O
MRE2	O
,	O
-	O
527	O
pb	B-Sequence
)	O
.	O

Unión	O
específica	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
para	O
Sepw1	B-Protein
MRE1	O
pero	O
no	O
MRE2	O
oligonucleótido	B-Sequence
se	O
observó	O
en	O
EMSA	O
con	O
hígado	O
proteína	B-Chemical
extracto	O
de	O
un	O
control	O
Mtf1loxP	O
ratón	B-Taxon
(	O
Figura	O
2d	O
)	O
.	O

Como	O
control	O
,	O
no	O
se	O
detectó	O
unión	O
a	O
MRE1	O
con	O
extracto	O
de	O
Mtf1Mx	O
-	O
cre	O
inducido	O
por	O
pI	O
-	O
pC	O
ratón	B-Taxon
,	O
lo	O
que	O
confirma	O
que	O
el	O
cambio	O
de	O
banda	O
dependía	O
de	O
hecho	O
de	O
la	O
presencia	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
.	O

Cadmio	B-Chemical
respuesta	O
de	O
Ndrg1	B-Protein
depende	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein

Ndrg1	B-Protein
se	O
reguló	O
significativamente	O
a	O
la	O
baja	O
en	O
microarrays	O
de	O
hígado	O
transcripciones	B-Sequence
desde	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
en	O
comparación	O
con	O
el	O
control	O
Mtf1loxP	O
tratado	O
de	O
manera	O
similar	O
ratones	B-Taxon
(	O
Cuadro	O
1	O
,	O
c	O
)	O
.	O

Ndrg1	B-Protein
probablemente	O
tiene	O
algún	O
papel	O
en	O
la	O
respuesta	O
al	O
estrés	O
ya	O
que	O
varios	O
estímulos	O
,	O
incluyendo	O
la	O
hipoxia	O
y	O
compuestos	B-Chemical
de	I-Chemical
níquel	I-Chemical
,	O
activar	O
la	O
expresión	O
de	O
roedor	B-Taxon
Ndrg1	B-Protein
y/o	O
su	O
humano	B-Taxon
ortólogo	B-Sequence
(	O
37	O
-	O
40	O
)	O
.	O

los	O
Ndrg1	B-Protein
Los	O
resultados	O
de	O
los	O
microarrays	O
se	O
confirmaron	O
con	O
RT-PCR	O
semicuantitativas	O
(	O
Figura	O
3a	O
)	O
:	O
para	O
los	O
hígados	O
de	O
control	O
Mtf1loxP	O
,	O
se	O
observó	O
un	O
claro	O
aumento	O
de	O
Ndrg1	B-Protein
expresión	O
se	O
observó	O
después	O
de	O
cadmio	B-Chemical
exposición	O
;	O
en	O
hígados	O
de	O
Mtf1Mx	O
-	O
cre	O
ratones	B-Taxon
,	O
esta	O
cadmio	B-Chemical
la	O
respuesta	O
no	O
fue	O
detectable	O
,	O
mientras	O
que	O
la	O
expresión	O
basal	O
fue	O
similar	O
a	O
los	O
controles	O
.	O

Esto	O
indica	O
que	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
Ndrg1	B-Protein
depende	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
.	O

Cinco	O
núcleos	O
MRE	O
secuencias	B-Sequence
de	I-Sequence
consenso	I-Sequence
se	O
ubican	O
aguas	O
arriba	O
de	O
la	O
ratón	B-Protein
Ndrg1	I-Protein
comienzo	B-Sequence
de	I-Sequence
la	I-Sequence
transcripción	I-Sequence
(	O
Figura	O
3b	O
)	O
.	O

cuatro	O
de	O
ellos	O
son	O
agrupado	B-Sequence
(	O
MRE1	O
a	O
MRE4	O
,	O
-	O
138	O
a	O
-	O
332	O
pb	B-Sequence
)	O
,	O
el	O
quinto	O
se	O
encuentra	O
aguas	O
arriba	O
(	O
MRE5	O
,	O
-	O
883	O
pb	B-Sequence
)	O
.	O

EMSA	O
se	O
realizó	O
para	O
probar	O
si	O
DM	B-Protein
-	I-Protein
1	I-Protein
está	O
interactuando	O
con	O
algunos	O
o	O
todos	O
los	O
cuatro	O
ERM	O
proximales	O
secuencias	B-Sequence
(	O
Figura	O
3c	O
)	O
.	O

Separar	O
oligonucleótidos	B-Sequence
fueron	O
probados	O
para	O
MRE1	O
y	O
MRE2	O
,	O
mientras	O
que	O
uno	O
oligonucleótido	B-Sequence
abarcando	O
ambos	O
secuencias	B-Sequence
se	O
utilizó	O
para	O
MRE3	O
y	O
MRE4	O
(	O
MRE3	O
,	O
4	O
)	O
.	O

No	O
complejo	B-GENE
fue	O
visto	O
con	O
MRE1	O
,	O
pero	O
específico	O
DM	B-Protein
-	I-Protein
1	I-Protein
complejos	B-GENE
se	O
observaron	O
tanto	O
para	O
el	O
MRE2	O
como	O
para	O
el	O
MRE3	O
,	O
4	O
oligonucleótidos	B-Sequence
con	O
hígado	O
proteína	B-Chemical
extracto	O
de	O
un	O
Mtf1loxP	O
ratón	B-Taxon
.	O

Como	O
era	O
de	O
esperar	O
,	O
no	O
se	O
observó	O
desplazamiento	O
de	O
banda	O
con	O
proteína	B-Chemical
extracto	O
de	O
un	O
ratón	B-Taxon
carente	O
DM	B-Protein
-	I-Protein
1	I-Protein
(	O
Mtf1Mx-cre	O
)	O
.	O

Cadmio	B-Chemical
respuesta	O
de	O
Csrp1	B-Protein
depende	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein

Csrp1	B-Protein
se	O
encontró	O
en	O
análisis	O
de	O
microarrays	O
para	O
estar	O
significativamente	O
regulado	O
a	O
la	O
baja	O
en	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
en	O
comparación	O
con	O
Mtf1loxP	O
ratones	B-Taxon
(	O
Cuadro	O
1	O
,	O
c	O
)	O
.	O

CSRP1	B-Protein
es	O
miembro	O
de	O
la	O
conservado	B-Sequence
evolutivamente	I-Sequence
familia	O
de	O
PCR	O
de	O
proteinas	B-Chemical
que	O
han	O
sido	O
implicados	O
en	O
la	O
miogénesis	O
y	O
citoesquelético	B-GENE
remodelación	O
(	O
41	O
,	O
42	O
)	O
.	O

Las	O
RT-PCR	O
semicuantitativas	O
confirmaron	O
los	O
resultados	O
de	O
los	O
microarrays	O
,	O
es	O
decir	O
,	O
que	O
Csrp1	B-Protein
expresión	O
es	O
elevada	O
en	O
hígados	O
Mtf1loxP	O
sobre	O
cadmio	B-Chemical
exposición	O
(	O
Figura	O
4a	O
)	O
.	O

Por	O
el	O
contrario	O
,	O
sin	O
cadmio	B-Chemical
la	O
respuesta	O
fue	O
detectable	O
en	O
hígados	O
de	O
Mtf1Mx	O
-	O
cre	O
ratones	B-Taxon
,	O
sugiriendo	O
que	O
DM	B-Protein
-	I-Protein
1	I-Protein
se	O
requiere	O
para	O
cadmio	B-Chemical
inducción	O
de	O
Csrp1	B-Protein
.	O

Tres	O
núcleos	O
MRE	O
secuencias	B-Sequence
de	I-Sequence
consenso	I-Sequence
fueron	O
encontrados	O
aguas	O
arriba	O
del	O
Csrp1	B-Protein
comienzo	B-Sequence
de	I-Sequence
la	I-Sequence
transcripción	I-Sequence
(	O
MRE2	O
a	O
MRE4	O
,	O
-	O
56	O
a	O
-	O
366	O
pb	B-Sequence
)	O
,	O
se	O
encontró	O
uno	O
inmediatamente	O
aguas	O
abajo	O
(	O
MRE1	O
,	O
+	O
7	O
pb	B-Sequence
;	O
Figura	O
4b	O
)	O
.	O

Unión	O
específica	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
se	O
observó	O
con	O
EMSA	O
para	O
MRE2	O
oligonucleótido	B-Sequence
y	O
proteína	B-Chemical
extracto	O
de	O
un	O
hígado	O
Mtf1loxP	O
,	O
pero	O
no	O
un	O
extracto	O
de	O
hígado	O
Mtf1Mx	O
-	O
cre	O
carente	O
DM	B-Protein
-	I-Protein
1	I-Protein
,	O
confirmando	O
la	O
participación	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
en	O
el	O
complejo	B-GENE
(	O
Figura	O
4c	O
)	O
.	O

DM	B-Protein
-	I-Protein
1	I-Protein
inhibe	O
la	O
expresión	O
de	O
Slc39a10	B-Protein

Slc39a10	B-Protein
se	O
detectó	O
en	O
el	O
análisis	O
de	O
microarrays	O
que	O
estaba	O
significativamente	O
regulado	O
al	O
alza	O
en	O
hígados	O
tanto	O
de	O
simulacros	O
como	O
de	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
en	O
comparación	O
con	O
el	O
control	O
animales	B-Taxon
(	O
Cuadro	O
1	O
,	O
byd	O
)	O
.	O

SLC39	O
proteinas	B-Chemical
son	O
miembros	O
de	O
Zrt	O
-	O
e	O
Irt	O
-	O
como	O
proteína	B-Chemical
(	O
ZIP	O
)	O
familia	O
de	O
ion	B-Chemical
metálico	I-Chemical
transportistas	O
que	O
transportan	O
,	O
sin	O
excepción	O
conocida	O
,	O
ion	B-Chemical
metálico	I-Chemical
sustratos	O
a	O
través	O
membranas	B-GENE
celulares	I-GENE
en	O
el	O
citoplasma	B-GENE
(	O
43	O
,	O
44	O
)	O
.	O

De	O
acuerdo	O
con	O
los	O
datos	O
de	O
micromatrices	O
,	O
las	O
RT-PCR	O
semicuantitativas	O
mostraron	O
una	O
regulación	O
a	O
la	O
baja	O
de	O
Slc39a10	B-Protein
expresión	O
en	O
hígados	O
de	O
Mtf1loxP	O
ratones	B-Taxon
sobre	O
cadmio	B-Chemical
exposición	O
.	O

En	O
muestras	O
de	O
Mtf1Mx	O
-	O
cre	O
ratones	B-Taxon
,	O
la	O
expresión	O
basal	O
aumentó	O
significativamente	O
;	O
cadmio	B-Chemical
el	O
tratamiento	O
aún	O
resultó	O
en	O
una	O
disminución	O
de	O
Slc39a10	B-Protein
expresión	O
(	O
Figura	O
5a	O
)	O
.	O

No	O
puede	O
ser	O
juzgado	O
por	O
este	O
experimento	O
si	O
el	O
grado	O
de	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
Slc39a10	B-Protein
la	O
transcripción	O
fue	O
idéntica	O
para	O
Mtf1Mx	O
-	O
cre	O
y	O
Mtf1loxP	O
ratones	B-Taxon
o	O
menor	O
en	O
ausencia	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
.	O

En	O
el	O
análisis	O
de	O
micromatrices	O
,	O
el	O
grado	O
de	O
regulación	O
a	O
la	O
baja	O
fue	O
comparable	O
al	O
de	O
los	O
hígados	O
de	O
control	O
o	O
menor	O
,	O
según	O
el	O
Affymetrix	O
GeneChip	O
(	O
R	O
)	O
considerado	O
.	O
Investigacion	B-Sequence
conjunto	O
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Los	O
resultados	O
indican	O
que	O
DM	B-Protein
-	I-Protein
1	I-Protein
participa	O
en	O
la	O
represión	O
de	O
la	O
expresión	O
basal	O
de	O
Slc39a10	B-Protein
.	O

También	O
podría	O
participar	O
en	O
la	O
cadmio	B-Chemical
respuesta	O
de	O
este	O
gene	B-Sequence
,	O
pero	O
aparentemente	O
no	O
es	O
el	O
único	O
responsable	O
.	O

Un	O
núcleo	O
MRE	O
secuencia	B-Sequence
de	I-Sequence
consenso	I-Sequence
fue	O
encontrado	O
aguas	O
arriba	O
del	O
ratón	B-Protein
slc39a10	I-Protein
comienzo	B-Sequence
de	I-Sequence
la	I-Sequence
transcripción	I-Sequence
(	O
MRE1	O
,	O
-	O
21	O
pb	B-Sequence
)	O
,	O
otro	O
directamente	O
aguas	O
abajo	O
(	O
MRE2	O
,	O
+	O
17	O
pb	B-Sequence
;	O
Figura	O
5b	O
)	O
.	O

Unión	O
específica	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
se	O
observó	O
en	O
el	O
análisis	O
EMSA	O
para	O
MRE2	O
con	O
hígado	O
proteína	B-Chemical
extraer	O
de	O
un	O
Mtf1loxP	O
pero	O
no	O
de	O
un	O
Mtf1Mx	O
-	O
cre	O
ratón	B-Taxon
,	O
mientras	O
que	O
no	O
se	O
detectó	O
unión	O
con	O
MRE1	O
(	O
Figura	O
5c	O
)	O
.	O

Cadmio	B-Chemical
-	O
receptivo	O
,	O
DM	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
genes	B-Sequence

Finalmente	O
,	O
también	O
identificamos	O
una	O
serie	O
de	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
genes	B-Sequence
que	O
eran	O
independientes	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
presencia	O
,	O
comparando	O
la	O
Investigacion	B-Sequence
matriz	O
de	O
datos	O
de	O
todos	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
con	O
los	O
datos	O
de	O
todos	O
los	O
simulacros	O
tratados	O
ratones	B-Taxon
,	O
independientemente	O
de	O
la	O
genotipo	B-Sequence
(	O
Tabla	O
2	O
)	O
.	O

Después	O
de	O
cadmio	B-Chemical
exposición	O
durante	O
31	O
Investigacion	B-Sequence
conjuntos	O
correspondientes	O
a	O
21	O
diferentes	O
caracterizados	O
genes	B-Sequence
(	O
Cuadro	O
2	O
,	O
a	O
)	O
.	O

Para	O
2	O
Investigacion	B-Sequence
conjuntos	O
correspondientes	O
a	O
2	O
caracterizados	O
genes	B-Sequence
,	O
se	O
detectó	O
una	O
regulación	O
a	O
la	O
baja	O
de	O
al	O
menos	O
2	O
veces	O
(	O
Tabla	O
2	O
,	O
b	O
)	O
.	O

Varios	O
genes	B-Sequence
involucrados	O
en	O
el	O
metabolismo	O
de	O
los	O
glutatión	B-Chemical
antioxidante	I-Chemical
se	O
encontró	O
que	O
estaban	O
regulados	O
al	O
alza	O
por	O
cadmio	B-Chemical
exposición	O
,	O
es	O
decir	O
,	O
la	O
genes	B-Sequence
codificando	O
el	O
subunidad	B-Protein
catalítica	I-Protein
del	I-Protein
glutamato	I-Protein
-	I-Protein
cisteína	I-Protein
ligasa	I-Protein
(	O
Gclc	B-Protein
)	O
que	O
es	O
el	O
límite	O
de	O
velocidad	O
enzima	B-Sequence
en	O
la	O
síntesis	O
de	O
novo	O
de	O
glutatión	B-Chemical
(	O
45	O
)	O
;	O
glutatión	B-Protein
reductasa	I-Protein
1	I-Protein
(	O
RSG	B-Protein
)	O
,	O
la	O
reducción	O
enzima	B-Sequence
por	O
glutatión	B-Chemical
oxidado	I-Chemical
(	O
45	O
)	O
;	O
y	O
glutatión	B-Protein
-	I-Protein
S	I-Protein
-	I-Protein
transferasa	I-Protein
,	I-Protein
mu	I-Protein
4	I-Protein
(	O
Gstm4	B-Protein
)	O
,	O
que	O
es	O
miembro	O
de	O
la	O
glutatión	B-Chemical
-	O
S	B-Chemical
#	O
¿NOMBRE	O
?	O
enzimas	B-Sequence
(	O
45	O
)	O
.	O

En	O
todos	O
estos	O
casos	O
,	O
la	O
inducción	O
se	O
confirmó	O
mediante	O
RT-PCR	O
semicuantitativas	O
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Gclc	B-Protein
,	O
también	O
conocido	O
como	O
subunidad	B-Protein
de	I-Protein
cadena	I-Protein
pesada	I-Protein
de	I-Protein
gamma	I-Protein
-	I-Protein
glutamilcisteína	I-Protein
sintetasa	I-Protein
(	O
ggcs-hc	B-Protein
)	O
,	O
había	O
sido	O
discutido	O
previamente	O
como	O
un	O
objetivo	O
gene	B-Sequence
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
(	O
6	O
)	O
.	O

Nuestros	O
datos	O
de	O
expresión	O
indican	O
que	O
Gclc	B-Protein
es	O
inducido	O
por	O
cadmio	B-Chemical
pero	O
,	O
al	O
menos	O
en	O
el	O
adulto	O
ratón	B-Taxon
hígado	O
,	O
no	O
dependiente	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
.	O

Para	O
analizar	O
el	O
papel	O
de	O
la	O
glutatión	B-Chemical
sistema	O
en	O
el	O
celular	B-Cell
cadmio	B-Chemical
respuesta	O
,	O
ratón	B-Taxon
embrionario	O
fibroblastos	B-Cell
con	O
y	O
sin	O
funcional	O
mtf1	B-Protein
fueron	O
tratados	O
con	O
cadmio	B-Chemical
en	O
combinación	O
con	O
BSO	O
,	O
un	O
específico	O
inhibidor	B-Chemical
de	O
glutamato	B-Chemical
-	O
cisteína	B-Chemical
ligasa	O
(	O
31	O
)	O
,	O
y	O
célula	B-Cell
la	O
viabilidad	O
se	O
evaluó	O
mediante	O
un	O
ensayo	O
colorimétrico	O
basado	O
en	O
el	O
tetrazolio	O
sal	B-Chemical
MTT	O
(	O
Figura	O
6	O
)	O
.	O

El	O
aumento	O
de	O
las	O
concentraciones	O
de	O
BSO	O
o	O
cadmio	B-Chemical
solos	O
fueron	O
hasta	O
cierto	O
punto	O
citotóxicos	O
para	O
los	O
examinados	O
célula	B-Cell
líneas	O
.	O

El	O
tratamiento	O
con	O
BSO	O
y	O
cadmio	B-Chemical
resultó	O
en	O
una	O
mayor	O
letalidad	O
particularmente	O
para	O
el	O
células	B-Cell
sin	O
funcional	O
mtf1	B-Protein
,	O
indicando	O
que	O
un	O
agotamiento	O
de	O
glutatión	B-Chemical
junto	O
con	O
la	O
falta	O
de	O
mtf1	B-Protein
perjudicar	O
un	O
eficaz	O
anti	O
-	O
cadmio	B-Chemical
defensa	O

Así	O
,	O
adecuado	O
glutatión	B-Chemical
suministro	O
,	O
así	O
como	O
DM	B-Protein
-	I-Protein
1	I-Protein
y	O
su	O
objetivo	O
genes	B-Sequence
son	O
esenciales	O
para	O
la	O
supervivencia	O
de	O
la	O
célula	B-Cell
bajo	O
cadmio	B-Chemical
estrés	O
.	O

además	O
genes	B-Sequence
relacionado	O
a	O
la	O
glutatión	B-Chemical
vía	O
,	O
varios	O
otros	O
relacionados	O
con	O
el	O
estrés	O
genes	B-Sequence
fueron	O
regulados	O
al	O
alza	O
cadmio	B-Chemical
exposición	O
,	O
incluyendo	O
genes	B-Protein
de	I-Protein
la	I-Protein
tiorredoxina	I-Protein
reductasa	I-Protein
1	I-Protein
(	O
Txnrd1	B-Protein
)	O
,	O
uno	O
de	O
los	O
reductores	O
enzimas	B-Sequence
de	O
El	O
tiorredoxina	B-Chemical
antioxidante	I-Chemical
(	O
46	O
)	O
;	O
KDEL	B-Protein
receptor	I-Protein
de	I-Protein
retención	I-Protein
de	I-Protein
proteínas	I-Protein
del	I-Protein
retículo	I-Protein
endoplásmico	I-Protein
2	I-Protein
(	O
Kdelr2	B-Protein
)	O
participando	O
en	O
Urgencias	B-GENE
respuesta	O
al	O
estrés	O
(	O
47	O
)	O
;	O
y	O
el	O
anti-apoptótico	O
Bcl2	B-Protein
-	I-Protein
atanogén	I-Protein
3	I-Protein
asociado	I-Protein
(	O
Bolsa3	B-Protein
)	O
involucrados	O
en	O
la	O
apoptosis	O
inducida	O
por	O
estrés	O
(	O
48	O
)	O
.	O

DISCUSIÓN	O

En	O
este	O
estudio	O
,	O
un	O
estudio	O
virtualmente	O
completo	O
supresión	B-Sequence
de	O
mtf1	B-Protein
en	O
el	O
hígado	O
de	O
adultos	O
,	O
Mtf1Mx	O
-	O
cre	O
inducido	O
por	O
pI	O
-	O
pC	O
ratones	B-Taxon
no	O
afectó	O
de	O
manera	O
detectable	O
el	O
fenotipo	O
de	O
los	O
respectivos	O
ratones	B-Taxon
bajo	O
condiciones	O
de	O
no	O
estrés	O
,	O
confirmando	O
que	O
DM	B-Protein
-	I-Protein
1	I-Protein
es	O
prescindible	O
en	O
el	O
hígado	O
adulto	O
(	O
26	O
)	O
,	O
en	O
contraste	O
con	O
su	O
papel	O
esencial	O
en	O
el	O
desarrollo	O
del	O
hígado	O
embrionario	O
(	O
23	O
)	O
.	O

la	O
comparacion	O
de	O
gene	B-Sequence
expresión	O
en	O
hígados	O
de	O
simulacros	O
-	O
o	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
reveló	O
varios	O
DM	B-Protein
-	I-Protein
1	I-Protein
objetivo	O
gene	B-Sequence
candidatos	O

Transcripciones	B-Sequence
de	O
los	O
dos	O
estrés	O
-	O
metalotioneína	O
sensible	O
genes	B-Sequence
Mt1	B-Protein
y	O
mt2	B-Protein
fueron	O
severamente	O
reducidos	O
,	O
en	O
apoyo	O
de	O
un	O
papel	O
crucial	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
tanto	O
para	O
basales	O
como	O
para	O
metal	B-Chemical
-	O
expresión	O
inducida	O
de	O
metalotioneínas	O
(	O
4	O
,	O
6	O
)	O
.	O

Uno	O
de	O
los	O
objetivos	O
recién	O
encontrados	O
.	O
genes	B-Sequence
es	O
Sepw1	B-Protein
.	O

el	O
exacto	O
molecular	B-Chemical
funcion	O
de	O
SEPW1	B-Protein
proteína	B-Chemical
es	O
desconocido	O
hasta	O
la	O
fecha	O
,	O
pero	O
un	O
papel	O
como	O
antioxidante	B-Chemical
ha	O
sido	O
propuesto	O
debido	O
a	O
su	O
capacidad	O
para	O
unir	O
glutatión	B-Chemical
(	O
35	O
)	O
.	O

De	O
acuerdo	O
con	O
esto	O
,	O
la	O
expresión	O
ectópica	O
de	O
ratón	B-Protein
Sepw1	I-Protein
rinde	O
células	B-Cell
resistente	O
a	O
peróxido	B-Chemical
de	I-Chemical
hidrógeno	I-Chemical
,	O
y	O
esta	O
resistencia	O
depende	O
de	O
que	O
se	O
una	O
glutatión	B-Chemical
(	O
36	O
)	O
.	O

Además	O
,	O
Amantana	O
et	O
al	O
.	O

(	O
49	O
)	O
mostró	O
que	O
la	O
expresión	O
de	O
un	O
reportero	O
gene	B-Sequence
fusionado	O
a	O
un	O
rata	B-Protein
Sepw1	I-Protein
fragmento	B-Sequence
de	I-Sequence
promotor	I-Sequence
puede	O
ser	O
inducido	O
en	O
rata	B-Taxon
células	B-Cell
gliales	I-Cell
por	O
cobre	B-Chemical
y	O
zinc	B-Chemical
,	O
pero	O
no	O
cadmio	B-Chemical
.	O

Esta	O
respuesta	O
dependía	O
de	O
un	O
superposición	B-Sequence
-	O
secuencia	B-Sequence
MRE	I-Sequence
invertida	I-Sequence
situado	O
proximal	O
a	O
la	O
rata	B-Protein
Sepw1	I-Protein
comienzo	B-Sequence
de	I-Sequence
la	I-Sequence
transcripción	I-Sequence
(	O
49	O
)	O
,	O
aunque	O
los	O
estudios	O
iniciales	O
no	O
lograron	O
demostrar	O
DM	B-Protein
-	I-Protein
1	I-Protein
vinculante	O
para	O
eso	O
secuencia	B-Sequence
(	O
50	O
)	O
.	O

Nuestra	O
expresión	O
y	O
ADN	B-Sequence
#	O
¿NOMBRE	O
?	O
DM	B-Protein
-	I-Protein
1	I-Protein
es	O
importante	O
para	O
la	O
expresión	O
basal	O
de	O
ratón	B-Protein
Sepw1	I-Protein
uniéndose	O
a	O
la	O
correspondiente	O
superposición	B-Sequence
-	O
secuencia	B-Sequence
MRE	I-Sequence
invertida	I-Sequence
.	O

Ndrg1	B-Protein
,	O
otro	O
interesante	O
DM	B-Protein
-	I-Protein
1	I-Protein
objetivo	O
gene	B-Sequence
fue	O
nombrado	O
N	B-Protein
-	I-Protein
myc	I-Protein
gen	I-Protein
1	I-Protein
regulado	I-Protein
corriente	I-Protein
abajo	I-Protein
tras	O
el	O
descubrimiento	O
de	O
que	O
el	O
factor	O
de	O
transcripción	O
N-myc	B-Protein
reprime	O
la	O
expresión	O
de	O
ratón	B-Protein
Ndrg1	I-Protein
(	O
51	O
)	O
.	O

Transcripción	O
de	O
Ndrg1	B-Protein
y/o	O
su	O
humano	B-Taxon
ortólogo	B-Sequence
es	O
inducida	O
por	O
diferentes	O
factores	O
fisiológicos	O
y	O
célula	B-Cell
condiciones	O
de	O
estrés	O
,	O
como	O
los	O
andrógenos	O
,	O
compuestos	B-Chemical
de	I-Chemical
níquel	I-Chemical
,	O
ADN	B-Sequence
daños	O
e	O
hipoxia	O
(	O
37-40	O
,	O
52	O
,	O
53	O
)	O
.	O

Además	O
,	O
el	O
proteína	B-Chemical
se	O
sobreexpresa	O
en	O
humano	B-Taxon
cánceres	O
de	O
muchos	O
tejidos	O
,	O
como	O
pulmón	O
,	O
hígado	O
,	O
cerebro	O
,	O
mama	O
,	O
riñón	O
y	O
piel	O
(	O
40	O
)	O
.	O

Aunque	O
Ndrg1	B-Protein
y	O
sobre	O
todo	O
su	O
humano	B-Taxon
ortólogo	B-Sequence
han	O
sido	O
bastante	O
intensamente	O
estudiados	O
,	O
su	O
función	O
sigue	O
sin	O
estar	O
clara	O
;	O
sin	O
embargo	O
,	O
la	O
inducción	O
por	O
estímulos	O
como	O
níquel	B-Chemical
y	O
la	O
hipoxia	O
sugiere	O
una	O
implicación	O
en	O
el	O
célula	B-Cell
respuesta	O
de	O
estrés	O
.	O

Tal	O
papel	O
está	O
fuertemente	O
respaldado	O
por	O
nuestro	O
hallazgo	O
de	O
que	O
Ndrg1	B-Protein
gene	B-Sequence
La	O
expresión	O
también	O
es	O
inducida	O
por	O
cadmio	B-Chemical
,	O
y	O
eso	O
DM	B-Protein
-	I-Protein
1	I-Protein
juega	O
un	O
papel	O
crucial	O
en	O
esta	O
inducción	O
.	O

En	O
el	O
caso	O
de	O
Csrp1	B-Protein
,	O
análisis	O
de	O
expresión	O
y	O
ADN	B-Sequence
#	O
¿NOMBRE	O
?	O
DM	B-Protein
-	I-Protein
1	I-Protein
se	O
requiere	O
para	O
cadmio	B-Chemical
inducción	O
uniéndose	O
a	O
un	O
MRE	O
aguas	O
arriba	O
del	O
comienzo	B-Sequence
de	I-Sequence
la	I-Sequence
transcripción	I-Sequence
.	O

Estudios	O
con	O
humano	B-Protein
,	I-Protein
aviar	I-Protein
y	I-Protein
pollo	I-Protein
CSRP1	I-Protein
han	O
demostrado	O
que	O
esto	O
proteína	B-Chemical
se	O
localiza	O
en	O
placas	B-GENE
de	I-GENE
adherencia	I-GENE
y	O
en	O
asociación	O
con	O
actina	B-GENE
filamentosa	I-GENE
,	O
e	O
interactúa	O
con	O
el	O
placa	B-GENE
de	I-GENE
adherencia	I-GENE
proteína	B-Chemical
zixina	B-Protein
,	O
así	O
como	O
el	O
entrecruzamiento	O
de	O
actina	O
proteína	B-Chemical
alfa-actinina	O
(	O
54-57	O
)	O
.	O

La	O
capacidad	O
de	O
vincular	O
a	O
estos	O
socios	O
sugiere	O
un	O
papel	O
en	O
citoesquelético	B-GENE
organización	O
(	O
58	O
)	O
.	O

Exposición	O
de	O
culto	O
células	B-Cell
para	O
cadmio	B-Chemical
provoca	O
una	O
disminución	O
y	O
destrucción	O
de	O
,	O
celular	B-Cell
contacto	O
proteinas	B-Chemical
y	O
el	O
citoesqueleto	B-GENE
de	I-GENE
actina	I-GENE
(	O
59	O
)	O
.	O

En	O
el	O
túbulo	O
proximal	O
células	B-Cell
de	O
El	O
rata	B-Taxon
riñón	O
,	O
una	O
pérdida	O
parcial	O
de	O
actina	O
y	O
el	O
agrupamiento	O
de	O
actina	O
proteína	B-Chemical
villano	B-Protein
se	O
observa	O
sobre	O
cadmio	B-Chemical
tratamiento	O
,	O
así	O
como	O
el	O
desarreglo	O
y	O
despolimerización	O
de	O
microtúbulos	B-GENE
(	O
60	O
)	O
.	O

Asumiendo	O
que	O
CSRP1	B-Protein
es	O
importante	O
para	O
la	O
organización	O
de	O
elementos	B-GENE
del	I-GENE
citoesqueleto	I-GENE
en	O
el	O
ratón	B-Taxon
,	O
su	O
regulación	O
al	O
alza	O
por	O
cadmio	B-Chemical
podría	O
proteger	O
el	O
organismo	B-Taxon
del	O
daño	O
del	O
citoesqueleto	B-GENE
.	O

Tal	O
mecanismo	O
ampliaría	O
el	O
papel	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
en	O
la	O
respuesta	O
al	O
estrés	O
.	O

Nuestros	O
estudios	O
de	O
expresión	O
también	O
sugieren	O
que	O
DM	B-Protein
-	I-Protein
1	I-Protein
reprime	O
la	O
transcripción	O
basal	O
de	O
Slc39a10	B-Protein
,	O
en	O
contraste	O
con	O
su	O
papel	O
como	O
activador	O
para	O
la	O
expresión	O
de	O
otros	O
objetivos	O
genes	B-Sequence
me	O
gusta	O
Mt1	B-Protein
,	O
mt2	B-Protein
,	O
y	O
Znt1	B-Protein
(	O
4	O
,	O
19	O
)	O
.	O

SLC39A10	B-Protein
es	O
uno	O
de	O
14	O
ratón	B-Taxon
Miembros	O
SLC39	O
,	O
que	O
pertenecen	O
a	O
la	O
familia	O
ZIP	O
de	O
ion	B-Chemical
metálico	I-Chemical
transportadores	O
(	O
43	O
,	O
44	O
)	O
.	O

Todos	O
los	O
miembros	O
de	O
la	O
familia	O
ZIP	O
caracterizados	O
hasta	O
ahora	O
aumentan	O
citoplasmático	B-GENE
intracelular	I-GENE
ion	B-Chemical
metálico	I-Chemical
concentraciones	O
promoviendo	O
extracelular	B-GENE
y	O
vesicular	B-GENE
ion	B-Chemical
transporte	O
en	O
el	O
citoplasma	B-GENE
.	O

CÓDIGO	O
POSTAL	O
proteinas	B-Chemical
han	O
sido	O
reportados	O
como	O
transportadores	O
de	O
zinc	B-Chemical
,	O
planchar	B-Chemical
,	O
manganeso	B-Chemical
y/o	O
cadmio	B-Chemical
(	O
44	O
,	O
61	O
-	O
63	O
)	O
.	O

Aunque	O
SLC39A10	B-Protein
está	O
en	O
gran	O
parte	O
sin	O
caracterizar	O
(	O
44	O
)	O
,	O
en	O
varias	O
bases	O
de	O
datos	O
se	O
le	O
conoce	O
como	O
supuesto	O
zinc	B-Chemical
transportador	O

Anteriormente	O
se	O
ha	O
demostrado	O
que	O
DM	B-Protein
-	I-Protein
1	I-Protein
es	O
importante	O
tanto	O
para	O
la	O
expresión	O
basal	O
como	O
para	O
la	O
metal	B-Chemical
inducción	O
de	O
la	O
ratón	B-Protein
Znt1	I-Protein
gene	B-Sequence
(	O
19	O
)	O
.	O

ZnT	O
proteinas	B-Chemical
representan	O
una	O
familia	O
diferente	O
de	O
transportadores	O
que	O
reducen	O
citoplasmático	B-GENE
intracelular	I-GENE
zinc	B-Chemical
al	O
promover	O
zinc	B-Chemical
salida	O
de	O
células	B-Cell
o	O
en	O
vesículas	B-GENE
intracelulares	I-GENE
.	O

Así	O
,	O
los	O
miembros	O
de	O
la	O
familia	O
ZnT	O
y	O
ZIP	O
con	O
zinc	B-Chemical
como	O
sustrato	O
predominante	O
tienen	O
roles	O
opuestos	O
en	O
celular	B-Cell
zinc	B-Chemical
homeostasis	O
(	O
43	O
)	O
.	O

Asumiendo	O
que	O
SLC39A10	B-Protein
es	O
de	O
hecho	O
un	O
zinc	B-Chemical
transportador	O
,	O
DM	B-Protein
-	I-Protein
1	I-Protein
controlaría	O
la	O
expresión	O
de	O
dos	O
zinc	B-Chemical
transportadores	O
con	O
funciones	O
antagónicas	O
,	O
a	O
saber	O
,	O
Znt1	B-Protein
y	O
Slc39a10	B-Protein
.	O

Unión	O
específica	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
fue	O
observado	O
para	O
un	O
MRE	O
ubicado	O
justo	O
aguas	O
abajo	O
de	O
la	O
Slc39a10	B-Protein
comienzo	B-Sequence
de	I-Sequence
la	I-Sequence
transcripción	I-Sequence
.	O

En	O
un	O
modelo	O
simple	O
,	O
tal	O
encuadernación	O
podría	O
interferir	O
con	O
la	O
accesibilidad	O
del	O
sitio	B-Sequence
de	I-Sequence
inicio	I-Sequence
transcripcional	I-Sequence
por	O
ARN	B-GENE
polimerasa	I-GENE
II	I-GENE
y/o	O
factores	O
de	O
transcripción	O
generales	O
,	O
impidiendo	O
así	O
el	O
inicio	O
de	O
la	O
transcripción	O
del	O
gene	B-Sequence
.	O

De	O
hecho	O
,	O
tal	O
mecanismo	O
ha	O
sido	O
descrito	O
en	O
levadura	B-Taxon
Para	O
el	O
zinc	B-Protein
-	I-Protein
proteína	I-Protein
activadora	I-Protein
de	I-Protein
respuesta	I-Protein
1	I-Protein
(	O
Zap1	B-Protein
)	O
y	O
su	O
destino	O
gene	B-Sequence
,	O
zinc	B-Protein
-	I-Protein
transportador	I-Protein
regulado	I-Protein
2	I-Protein
(	O
ZRT2	B-Protein
)	O
(	O
64	O
)	O
.	O

Sin	O
embargo	O
,	O
la	O
inhibición	O
de	O
Slc39a10	B-Protein
expresión	O
por	O
DM	B-Protein
-	I-Protein
1	I-Protein
bien	O
puede	O
ser	O
más	O
complejo	O
que	O
una	O
competencia	O
por	O
promotor	B-Sequence
Unión	O
.	O

Independiente	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
,	O
cadmio	B-Chemical
El	O
tratamiento	O
también	O
conduce	O
a	O
la	O
regulación	O
a	O
la	O
baja	O
de	O
Slc39a10	B-Protein
transcripciones	B-Sequence
,	O
lo	O
que	O
sugiere	O
que	O
algún	O
otro	O
factor	O
está	O
mediando	O
esta	O
respuesta	O
.	O

Un	O
objetivo	O
anterior	O
gene	B-Sequence
buscar	O
DM	B-Protein
-	I-Protein
1	I-Protein
con	O
ratón	B-Taxon
embriones	O
de	O
convencional	O
mtf1	B-Protein
fenotipo	O
knockout	O
revelado	O
,	O
además	O
de	O
metalotioneína	O
genes	B-Sequence
,	O
el	O
multifuncional	O
alfafetoproteína	B-Protein
(	O
Afp	B-Protein
)	O
y	O
el	O
hígado	O
-	O
factor	O
de	O
transcripción	O
enriquecido	O
CCAAT	B-Protein
/	I-Protein
potenciador	I-Protein
de	I-Protein
proteína	I-Protein
de	I-Protein
unión	I-Protein
alfa	I-Protein
(	O
Cebpa	B-Protein
)	O
como	O
principales	O
candidatos	O
(	O
65	O
)	O
.	O

Después	O
de	O
un	O
inicio	O
temprano	O
durante	O
la	O
hepatogénesis	O
,	O
Afp	B-Protein
expresión	O
es	O
reprimida	O
postnatalmente	O
y	O
reemplazada	O
por	O
albúmina	B-Protein
(	O
66	O
)	O
.	O

Así	O
,	O
nuestro	O
adulto	O
Mtf1Mx	O
-	O
cre	O
ratones	B-Taxon
carente	O
DM	B-Protein
-	I-Protein
1	I-Protein
no	O
eran	O
adecuados	O
para	O
analizar	O
Afp	B-Protein
expresión	O
.	O

Cebpa	B-Protein
se	O
expresa	O
en	O
el	O
hígado	O
adulto	O
así	O
como	O
en	O
otros	O
tejidos	O
(	O
67	O
)	O
,	O
pero	O
los	O
datos	O
de	O
micromatrices	O
actuales	O
no	O
revelaron	O
diferencias	O
de	O
expresión	O
significativas	O
en	O
hígados	O
de	O
adultos	O
Mtf1loxP	O
y	O
Mtf1Mx	O
-	O
cre	O
ratones	B-Taxon
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
DM	B-Protein
-	I-Protein
1	I-Protein
puede	O
afectar	O
Cebpa	B-Protein
expresión	O
sólo	O
durante	O
el	O
desarrollo	O
embrionario	O
,	O
quizás	O
en	O
combinación	O
con	O
factores	O
aún	O
no	O
identificados	O
.	O

El	O
presente	O
estudio	O
confirma	O
y	O
amplía	O
el	O
papel	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
como	O
un	O
importante	O
regulador	O
de	O
la	O
respuesta	O
al	O
estrés	O
.	O

Hemos	O
identificado	O
y	O
caracterizado	O
preliminarmente	O
cuatro	O
objetivos	O
genes	B-Sequence
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
en	O
el	O
adulto	O
ratón	B-Taxon
hígado	O
:	O
en	O
el	O
caso	O
de	O
Sepw1	B-Protein
,	O
DM	B-Protein
-	I-Protein
1	I-Protein
se	O
requiere	O
para	O
mantener	O
la	O
expresión	O
basal	O
,	O
apoyando	O
un	O
papel	O
de	O
ratón	B-Protein
MTF	I-Protein
-	I-Protein
1	I-Protein
en	O
la	O
respuesta	O
al	O
estrés	O
oxidativo	O
.	O

Además	O
,	O
DM	B-Protein
-	I-Protein
1	I-Protein
contribuye	O
a	O
la	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
Ndrg1	B-Protein
y	O
Csrp1	B-Protein
.	O

Es	O
más	O
,	O
DM	B-Protein
-	I-Protein
1	I-Protein
ayuda	O
a	O
reprimir	O
la	O
expresión	O
basal	O
de	O
Slc39a10	B-Protein
,	O
en	O
contraste	O
con	O
su	O
papel	O
como	O
activador	O
transcripcional	O
de	O
genes	B-Sequence
me	O
gusta	O
Mt1	B-Protein
,	O
mt2	B-Protein
o	O
Znt1	B-Protein
.	O

Así	O
,	O
el	O
mismo	O
factor	O
de	O
transcripción	O
aparentemente	O
sirve	O
como	O
activador	O
o	O
represor	O
,	O
dependiendo	O
del	O
objetivo	O
.	O
gene	B-Sequence
.	O

La	O
comparación	O
del	O
hígado	O
gene	B-Sequence
expresión	O
de	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
también	O
reveló	O
una	O
serie	O
de	O
genes	B-Sequence
que	O
respondieron	O
a	O
cadmio	B-Chemical
exposición	O
,	O
independientemente	O
de	O
la	O
presencia	O
o	O
ausencia	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
.	O

La	O
evidencia	O
sugiere	O
que	O
la	O
producción	O
de	O
especies	B-Chemical
de	I-Chemical
oxígeno	I-Chemical
reactivas	I-Chemical
es	O
un	O
efecto	O
importante	O
de	O
la	O
aguda	O
cadmio	B-Chemical
toxicidad	O
(	O
68	O
,	O
69	O
)	O
y	O
exposición	O
de	O
cultivos	O
células	B-Cell
o	O
animales	B-Taxon
para	O
cadmio	B-Chemical
se	O
asocia	O
con	O
el	O
agotamiento	O
de	O
glutatión	B-Chemical
reducido	I-Chemical
,	O
lípido	B-Chemical
peroxidación	O
y	O
ADN	B-Sequence
daño	O
(	O
70	O
-	O
73	O
)	O
.	O

El	O
estrés	O
oxidativo	O
y	O
la	O
posterior	O
restauración	O
de	O
celular	B-Cell
Se	O
ha	O
demostrado	O
que	O
la	O
homeostasis	O
induce	O
la	O
expresión	O
de	O
genes	B-Sequence
codificación	O
de	O
fase	O
aguda	O
proteinas	B-Chemical
y	O
antioxidante	B-Chemical
enzimas	B-Sequence
(	O
74	O
)	O
.	O

En	O
mamíferos	B-Taxon
,	O
cadmio	B-Chemical
tiende	O
a	O
acumularse	O
en	O
el	O
riñón	O
y	O
el	O
hígado	O
como	O
cadmio	B-Chemical
-complejo	O
de	O
metalotioneína	O
que	O
tiene	O
un	O
recambio	O
extremadamente	O
lento	O
(	O
75	O
,	O
76	O
)	O
.	O

Además	O
,	O
las	O
metalotioneínas	O
brindan	O
protección	O
contra	O
el	O
estrés	O
oxidativo	O
(	O
1	O
,	O
17	O
)	O
.	O

Además	O
de	O
las	O
metalotioneínas	O
,	O
glutatión	B-Chemical
se	O
postuló	O
como	O
una	O
primera	O
línea	O
de	O
defensa	O
contra	O
cadmio	B-Chemical
toxicidad	O
(	O
77	O
)	O
.	O

glutatión	B-Chemical
complejos	O
eficientemente	O
cadmio	B-Chemical
(	O
78	O
)	O
y	O
carroñeros	O
radicales	B-Chemical
libres	I-Chemical
y	O
otra	O
especies	B-Chemical
de	I-Chemical
oxígeno	I-Chemical
reactivas	I-Chemical
directa	O
e	O
indirectamente	O
a	O
través	O
de	O
enzimático	B-Sequence
reacciones	O
(	O
45	O
)	O
.	O

En	O
tales	O
reacciones	O
,	O
glutatión	B-Chemical
se	O
oxida	O
y	O
tiene	O
que	O
ser	O
regenerado	O
por	O
glutatión	B-Protein
reductasa	I-Protein
.	O

También	O
,	O
glutatión	B-Protein
-	I-Protein
S	I-Protein
-	I-Protein
transferasas	I-Protein
mediar	O
la	O
conjugación	O
de	O
varios	O
electrófilos	O
para	O
glutatión	B-Chemical
.	O

lo	O
observado	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
Gclc	B-Protein
,	O
RSG	B-Protein
y	O
Gstm4	B-Protein
apoya	O
la	O
importancia	O
de	O
glutatión	B-Chemical
en	O
el	O
celular	B-Cell
cadmio	B-Chemical
respuesta	O
.	O

La	O
mayor	O
sensibilidad	O
a	O
cadmio	B-Chemical
toxicidad	O
que	O
encontramos	O
para	O
ratón	B-Taxon
embrionario	O
fibroblastos	B-Cell
sobre	O
una	O
combinación	O
de	O
mtf1	B-Protein
supresión	B-Sequence
y	O
agotamiento	O
de	O
glutatión	B-Chemical
corrobora	O
aún	O
más	O
la	O
importancia	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
y	O
su	O
objetivo	O
genes	B-Sequence
así	O
como	O
también	O
glutatión	B-Chemical
reducido	I-Chemical
para	O
un	O
eficaz	O
anti	O
-	O
cadmio	B-Chemical
defensa	O

Nuestros	O
datos	O
proporcionan	O
una	O
fuerte	O
evidencia	O
de	O
al	O
menos	O
dos	O
ramas	O
de	O
celular	B-Cell
anti	O
-	O
cadmio	B-Chemical
defensa	O
,	O
una	O
via	O
DM	B-Protein
-	I-Protein
1	I-Protein
y	O
su	O
objetivo	O
genes	B-Sequence
,	O
en	O
particular	O
las	O
metalotioneínas	O
,	O
la	O
otra	O
vía	O
glutatión	B-Chemical
,	O
con	O
una	O
aparente	O
superposición	O
en	O
Sepw1	B-Protein
.	O

DATO	O
SUPLEMENTARIO	O

Los	O
datos	O
complementarios	O
están	O
disponibles	O
en	O
NAR	O
en	O
línea	O
.	O

Material	O
suplementario	O

[	O
Material	O
suplementario	O
]	O

Agradecimientos	O

Estamos	O
en	O
deuda	O
con	O
el	O
Centro	O
de	O
Genómica	O
Funcional	O
de	O
Zúrich	O
(	O
Zúrich	O
,	O
CH	O
)	O
por	O
su	O
apoyo	O
financiero	O
y	O
técnico	O
(	O
gracias	O
especialmente	O
a	O
Andrea	O
Patrignani	O
,	O
Dr.	O
Ulrich	O
Wagner	O
y	O
Dr.	O
Hubert	O
Rehrauer	O
por	O
su	O
asistencia	O
en	O
la	O
generación	O
y	O
evaluación	O
de	O
datos	O
)	O
,	O
y	O
al	O
Dr.	O
Michael	O
Leviten	O
(	O
San	O
Carlos	O
,	O
CA	O
)	O
por	O
la	O
ayuda	O
en	O
la	O
generación	O
mtf1	B-Protein
nocaut	O
condicional	O
ratones	B-Taxon
.	O

También	O
agradecemos	O
al	O
Prof	O
.	O

Ueli	O
Schibler	O
(	O
Ginebra	O
,	O
CH	O
)	O
por	O
su	O
asesoramiento	O
sobre	O
la	O
técnica	O
ADDER	O
,	O
al	O
Prof	O
.	O

Michel	O
Aguet	O
(	O
Epalinges	O
-	O
Lausanne	O
,	O
CH	O
)	O
por	O
el	O
regalo	O
de	O
MX	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
,	O
Dr.	O
George	O
Hausmann	O
y	O
Dr.	O
Michael	O
Fetchko	O
por	O
la	O
lectura	O
crítica	O
del	O
manuscrito	O
,	O
y	O
Fritz	O
Ochsenbein	O
por	O
preparar	O
las	O
figuras	O
.	O

Los	O
fondos	O
para	O
pagar	O
los	O
cargos	O
de	O
publicación	O
de	O
acceso	O
abierto	O
de	O
este	O
artículo	O
fueron	O
proporcionados	O
por	O
Kanton	O
Zurich	O
.	O

Declaracion	O
de	O
conflicto	O
de	O
interes	O
.	O

Ninguno	O
declarado	O
.	O

Figuras	O
y	O
Tablas	O

Figura	O
1	O

Supresión	B-Sequence
de	O
mtf1	B-Protein
en	O
adulto	O
ratón	B-Taxon
hígado	O
.	O

(	O
a	O
)	O
Generación	O
de	O
mtf1	B-Protein
nocaut	O
condicional	O
ratones	B-Taxon
.	O

el	O
objetivo	O
alelo	B-Sequence
se	O
obtuvo	O
por	O
recombinación	O
homóloga	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
peso	B-Sequence
)	O
alelo	B-Sequence
y	O
focalización	O
vector	B-Sequence
en	O
ES	O
células	B-Cell
.	O

Eliminación	B-Sequence
de	O
la	O
neomicina	O
casete	B-Sequence
(	O
NEO	O
)	O
por	O
Cre	O
recombinase	O
condujo	O
al	O
nocaut	O
condicional	O
alelo	B-Sequence
Mtf1loxP	O
.	O

Cre	O
condicional	O
-	O
mediado	O
supresión	B-Sequence
de	O
exones	B-Sequence
3	O
y	O
4	O
(	O
Mtf1	O
Delta	O
)	O
da	O
como	O
resultado	O
la	O
pérdida	O
de	O
función	O
a	O
través	O
de	O
pérdida	B-Sequence
de	O
un	O
esencial	O
parte	B-Sequence
de	O
El	O
ADN	B-Sequence
#	O
¿NOMBRE	O
?	O
dominio	B-Sequence
y	O
la	O
generación	O
de	O
un	O
nuevo	O
codón	B-Sequence
de	I-Sequence
parada	I-Sequence
justo	O
después	O
de	O
exón	B-Sequence
2	O
.	O

exones	B-Sequence
3	O
a	O
7	O
de	O
mtf1	B-Protein
se	O
indican	O
mediante	O
cuadros	O
grises	O
,	O
sitios	B-Sequence
loxP	I-Sequence
por	O
triángulos	O
negros	O
.	O

conocimientos	O
tradicionales	O
,	O
timidina	B-Chemical
quinasa	O
casete	B-Sequence
.	O

Restricción	O
enzimas	B-Sequence
:	O
San	O
,	O
SanDI	O
;	O
B	O
,	O
BbvCI	O
;	O
S	O
,	O
SrfI	O
;	O
H	O
,	O
HpaI	O
.	O

El	O
HpaI	O
sitio	B-Sequence
indicado	O
por	O
la	O
H	O
cruzada	O
fue	O
perdió	B-Sequence
durante	O
el	O
procedimiento	O
de	O
clonación	O
para	O
la	O
focalización	O
vector	B-Sequence
.	O

(	O
b	O
)	O
RT	O
-	O
PCR	O
con	O
hígado	O
total	O
ARN	B-Sequence
de	O
pI	O
-	O
pC	O
-	O
macho	O
inducido	O
Mtf1Mx	O
-	O
cre	O
o	O
Mtf1loxP	O
ratones	B-Taxon
.	O

El	O
usado	O
cebador	B-Sequence
par	O
da	O
como	O
resultado	O
productos	B-Sequence
de	O
589	O
pb	B-Sequence
y	O
218	O
pb	B-Sequence
con	O
longitud	O
completa	O
ARNm	B-Chemical
y	O
ARNm	B-Chemical
sin	O
exones	B-Sequence
3	O
y	O
4	O
,	O
respectivamente	O
.	O

(	O
c	O
)	O
EMSA	O
con	O
hígado	O
proteína	B-Chemical
extracto	O
de	O
un	O
macho	O
pI	O
-	O
pC	O
-	O
inducido	O
Mtf1Mx	O
-	O
cre	O
o	O
Mtf1loxP	O
ratón	B-Taxon
.	O

DM	B-Protein
-	I-Protein
1	I-Protein
proteína	B-GENE
-	I-GENE
complejo	I-GENE
de	I-GENE
ADN	I-GENE
Se	O
probó	O
la	O
formación	O
con	O
32P	B-Chemical
#	O
¿NOMBRE	O
?	O
oligonucleótido	B-Sequence
de	I-Sequence
consenso	I-Sequence
MRE-s	O
.	O

La	O
especificidad	O
de	O
la	O
unión	O
se	O
verificó	O
con	O
exceso	O
de	O
competidor	O
no	O
marcado	O
MREd	O
o	O
Gal4	O
no	O
relacionado	O
oligonucleótido	B-Sequence
;	O
Sp1	B-Protein
cambios	O
de	O
banda	O
con	O
32P	B-Chemical
#	O
¿NOMBRE	O
?	O
Sp1	B-Protein
oligonucleótido	B-Sequence
de	I-Sequence
consenso	I-Sequence
se	O
incluyeron	O
como	O
control	O
de	O
carga	O
.	O

Figura	O
2	O

Sepw1	B-Protein
la	O
expresión	O
basal	O
depende	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
.	O

(	O
a	O
)	O
RT	O
-	O
PCR	O
semicuantitativas	O
para	O
Sepw1	B-Protein
ARNm	B-Chemical
usando	O
hígado	O
total	O
ARN	B-Sequence
de	O
pI	O
-	O
pC	O
-	O
macho	O
inducido	O
Mtf1Mx	O
-	O
cre	O
o	O
Mtf1loxP	O
ratones	B-Taxon
.	O

los	O
animales	B-Taxon
había	O
obtenido	O
cualquiera	O
de	O
los	O
simulacros	O
.	O
C	O
.	O
inyecciones	O
(	O
-	O
Discos	B-Chemical
compactos	I-Chemical
)	O
o	O
s.	O
C	O
.	O
inyecciones	O
con	O
20	O
micro	O
mol/kg	O
peso	O
corporal	O
CdSO4	O
(	O
+	O
Discos	B-Chemical
compactos	I-Chemical
)	O
6	O
h	O
antes	O
de	O
sacrificarlos	O
.	O

RT	O
-	O
PCR	O
para	O
Hprt	B-Protein
ARNm	B-Chemical
se	O
utilizaron	O
como	O
control	O
interno	O
para	O
ajustar	O
la	O
cantidad	O
de	O
ARN	B-Sequence
usado	O
.	O

(	O
b	O
)	O
Análisis	O
S1	O
para	O
Sepw1	B-Protein
ARNm	B-Chemical
con	O
ARN	B-Sequence
descrito	O
en	O
(	O
a	O
)	O
,	O
usando	O
un	O
32P	B-Chemical
#	O
¿NOMBRE	O
?	O
Sepw1	B-Protein
S1	O
Investigacion	B-Sequence
.	O

A	O
32P	B-Chemical
#	O
¿NOMBRE	O
?	O
Investigacion	B-Sequence
por	O
Hprt	B-Protein
ARNm	B-Chemical
se	O
utilizó	O
para	O
ajustar	O
la	O
cantidad	O
de	O
ARN	B-Sequence
usado	O
.	O

(	O
c	O
)	O
Núcleo	O
MRE	O
secuencias	B-Sequence
de	I-Sequence
consenso	I-Sequence
TGCRCNC	O
(	O
letras	O
en	O
negrita	O
)	O
y	O
secuencias	B-Sequence
flanqueantes	I-Sequence
encontrado	O
en	O
un	O
región	B-Sequence
de	O
1000	O
pb	B-Sequence
aguas	O
arriba	O
de	O
Sepw1	B-Protein
comienzo	B-Sequence
de	I-Sequence
la	I-Sequence
transcripción	I-Sequence
;	O
los	O
posición	B-Sequence
de	I-Sequence
cada	I-Sequence
secuencia	I-Sequence
central	I-Sequence
Es	O
indicado	O
.	O

(	O
d	O
)	O
EMSA	O
con	O
hígado	O
proteína	B-Chemical
extractos	O
de	O
un	O
Mtf1loxP	O
macho	O
o	O
un	O
Mtf1Mx	O
-	O
cre	O
macho	O
inducido	O
por	O
pI	O
-	O
pC	O
.	O
ratón	B-Taxon
ambos	O
con	O
tratamiento	O
simulado	O
.	O

DM	B-Protein
-	I-Protein
1	I-Protein
proteína	B-GENE
-	I-GENE
complejo	I-GENE
de	I-GENE
ADN	I-GENE
Se	O
probó	O
la	O
formación	O
con	O
32P	B-Chemical
#	O
¿NOMBRE	O
?	O
Sepw1	B-Protein
MRE1	O
o	O
MRE2	O
oligonucleótido	B-Sequence
,	O
respectivamente	O
.	O

La	O
especificidad	O
de	O
la	O
unión	O
se	O
verificó	O
con	O
exceso	O
de	O
competidor	O
no	O
marcado	O
MREd	O
o	O
Gal4	O
no	O
relacionado	O
oligonucleótido	B-Sequence
.	O

32P	B-Chemical
#	O
¿NOMBRE	O
?	O
DM	B-Protein
-	I-Protein
1	I-Protein
-	O
ADN	B-Sequence
complejo	B-GENE
;	O
desplazamientos	O
de	O
banda	O
para	O
el	O
factor	O
de	O
transcripción	O
común	O
Sp1	B-Protein
con	O
32P	B-Chemical
#	O
¿NOMBRE	O
?	O
Sp1	B-Protein
oligonucleótido	B-Sequence
de	I-Sequence
consenso	I-Sequence
se	O
obtuvieron	O
como	O
proteína	B-Chemical
mando	O
de	O
carga	O
.	O

figura	O
3	O

Cadmio	B-Chemical
respuesta	O
de	O
Ndrg1	B-Protein
depende	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
.	O

(	O
a	O
)	O
RT	O
-	O
PCR	O
semicuantitativas	O
para	O
Ndrg1	B-Protein
ARNm	B-Chemical
usando	O
hígado	O
total	O
ARN	B-Sequence
de	O
pI	O
-	O
pC	O
-	O
macho	O
inducido	O
Mtf1Mx	O
-	O
cre	O
o	O
Mtf1loxP	O
ratones	B-Taxon
.	O

los	O
animales	B-Taxon
había	O
obtenido	O
cualquiera	O
de	O
los	O
simulacros	O
.	O
C	O
.	O
inyecciones	O
(	O
-	O
Discos	B-Chemical
compactos	I-Chemical
)	O
o	O
s.	O
C	O
.	O
inyecciones	O
con	O
20	O
micro	O
mol/kg	O
peso	O
corporal	O
CdSO4	O
(	O
+	O
Discos	B-Chemical
compactos	I-Chemical
)	O
6	O
h	O
antes	O
de	O
sacrificarlos	O
.	O

RT	O
-	O
PCR	O
para	O
Hprt	B-Protein
ARNm	B-Chemical
se	O
utilizaron	O
como	O
control	O
interno	O
para	O
ajustar	O
la	O
cantidad	O
de	O
ARN	B-Sequence
usado	O
.	O

(	O
b	O
)	O
Núcleo	O
MRE	O
secuencias	B-Sequence
de	I-Sequence
consenso	I-Sequence
TGCRCNC	O
(	O
letras	O
en	O
negrita	O
)	O
y	O
secuencias	B-Sequence
flanqueantes	I-Sequence
encontrado	O
en	O
un	O
región	B-Sequence
de	O
1000	O
pb	B-Sequence
aguas	O
arriba	O
de	O
Ndrg1	B-Protein
comienzo	B-Sequence
de	I-Sequence
la	I-Sequence
transcripción	I-Sequence
;	O
los	O
posición	B-Sequence
de	I-Sequence
cada	I-Sequence
secuencia	I-Sequence
central	I-Sequence
Es	O
indicado	O
.	O

(	O
c	O
)	O
EMSA	O
con	O
hígado	O
proteína	B-Chemical
extractos	O
de	O
un	O
Mtf1loxP	O
macho	O
o	O
un	O
Mtf1Mx	O
-	O
cre	O
macho	O
inducido	O
por	O
pI	O
-	O
pC	O
.	O
ratón	B-Taxon
ambos	O
con	O
tratamiento	O
simulado	O
.	O

DM	B-Protein
-	I-Protein
1	I-Protein
proteína	B-GENE
-	I-GENE
complejo	I-GENE
de	I-GENE
ADN	I-GENE
Se	O
probó	O
la	O
formación	O
con	O
32P	B-Chemical
#	O
¿NOMBRE	O
?	O
Ndrg1	B-Protein
MRE1	O
o	O
MRE2	O
oligonucleótido	B-Sequence
,	O
o	O
un	O
32P	B-Chemical
#	O
¿NOMBRE	O
?	O
oligonucleótido	B-Sequence
incluyendo	O
tanto	O
MRE3	O
como	O
MRE4	O
(	O
MRE3	O
,	O
4	O
)	O
.	O

La	O
especificidad	O
de	O
la	O
unión	O
se	O
verificó	O
con	O
exceso	O
de	O
competidor	O
no	O
marcado	O
MREd	O
o	O
Gal4	O
no	O
relacionado	O
oligonucleótido	B-Sequence
.	O

32P	B-Chemical
#	O
¿NOMBRE	O
?	O
DM	B-Protein
-	I-Protein
1	I-Protein
-	O
ADN	B-Sequence
complejo	B-GENE
;	O
Sp1	B-Protein
cambios	O
de	O
banda	O
con	O
32P	B-Chemical
#	O
¿NOMBRE	O
?	O
Sp1	B-Protein
oligonucleótido	B-Sequence
de	I-Sequence
consenso	I-Sequence
se	O
obtuvieron	O
como	O
proteína	B-Chemical
mando	O
de	O
carga	O
.	O

Figura	O
4	O

Cadmio	B-Chemical
respuesta	O
de	O
Csrp1	B-Protein
depende	O
de	O
DM	B-Protein
-	I-Protein
1	I-Protein
.	O

(	O
a	O
)	O
RT	O
-	O
PCR	O
semicuantitativas	O
para	O
Csrp1	B-Protein
ARNm	B-Chemical
usando	O
hígado	O
total	O
ARN	B-Sequence
de	O
pI	O
-	O
pC	O
-	O
macho	O
inducido	O
Mtf1Mx	O
-	O
cre	O
o	O
Mtf1loxP	O
ratones	B-Taxon
.	O

los	O
animales	B-Taxon
había	O
obtenido	O
cualquiera	O
de	O
los	O
simulacros	O
.	O
C	O
.	O
inyecciones	O
(	O
-	O
Discos	B-Chemical
compactos	I-Chemical
)	O
o	O
s.	O
C	O
.	O
inyecciones	O
con	O
20	O
micro	O
mol/kg	O
peso	O
corporal	O
CdSO4	O
(	O
+	O
Discos	B-Chemical
compactos	I-Chemical
)	O
6	O
h	O
antes	O
de	O
sacrificarlos	O
.	O

RT	O
-	O
PCR	O
para	O
Hprt	B-Protein
ARNm	B-Chemical
se	O
utilizaron	O
como	O
control	O
interno	O
para	O
ajustar	O
la	O
cantidad	O
de	O
ARN	B-Sequence
usado	O
.	O

(	O
b	O
)	O
Núcleo	O
MRE	O
secuencias	B-Sequence
de	I-Sequence
consenso	I-Sequence
TGCRCNC	O
(	O
letras	O
en	O
negrita	O
)	O
y	O
secuencias	B-Sequence
flanqueantes	I-Sequence
encontrado	O
en	O
un	O
región	B-Sequence
de	O
1000	O
pb	B-Sequence
aguas	O
arriba	O
de	O
Csrp1	B-Protein
comienzo	B-Sequence
de	I-Sequence
la	I-Sequence
transcripción	I-Sequence
;	O
los	O
posición	B-Sequence
de	I-Sequence
cada	I-Sequence
secuencia	I-Sequence
central	I-Sequence
Es	O
indicado	O
.	O

(	O
c	O
)	O
EMSA	O
con	O
hígado	O
proteína	B-Chemical
extractos	O
de	O
un	O
Mtf1loxP	O
macho	O
o	O
un	O
Mtf1Mx	O
-	O
cre	O
macho	O
inducido	O
por	O
pI	O
-	O
pC	O
.	O
ratón	B-Taxon
ambos	O
con	O
tratamiento	O
simulado	O
.	O

DM	B-Protein
-	I-Protein
1	I-Protein
proteína	B-GENE
-	I-GENE
complejo	I-GENE
de	I-GENE
ADN	I-GENE
Se	O
probó	O
la	O
formación	O
con	O
32P	B-Chemical
#	O
¿NOMBRE	O
?	O
Csrp1	B-Protein
MRE1	O
,	O
MRE2	O
,	O
MRE3	O
o	O
MRE4	O
oligonucleótido	B-Sequence
,	O
respectivamente	O
.	O

La	O
especificidad	O
de	O
la	O
unión	O
se	O
verificó	O
con	O
exceso	O
de	O
competidor	O
no	O
marcado	O
MREd	O
o	O
Gal4	O
no	O
relacionado	O
oligonucleótido	B-Sequence
.	O

32P	B-Chemical
#	O
¿NOMBRE	O
?	O
DM	B-Protein
-	I-Protein
1	I-Protein
-	O
ADN	B-Sequence
complejo	B-GENE
;	O
Sp1	B-Protein
cambios	O
de	O
banda	O
con	O
32P	B-Chemical
#	O
¿NOMBRE	O
?	O
Sp1	B-Protein
oligonucleótido	B-Sequence
de	I-Sequence
consenso	I-Sequence
se	O
obtuvieron	O
como	O
proteína	B-Chemical
mando	O
de	O
carga	O
.	O

Figura	O
5	O

DM	B-Protein
-	I-Protein
1	I-Protein
reprime	O
la	O
expresión	O
basal	O
de	O
Slc39a10	B-Protein
.	O

(	O
a	O
)	O
RT	O
-	O
PCR	O
semicuantitativas	O
para	O
Slc39a10	B-Protein
ARNm	B-Chemical
usando	O
hígado	O
total	O
ARN	B-Sequence
de	O
pI	O
-	O
pC	O
-	O
macho	O
inducido	O
Mtf1Mx	O
-	O
cre	O
o	O
Mtf1loxP	O
ratones	B-Taxon
.	O

los	O
animales	B-Taxon
había	O
obtenido	O
cualquiera	O
de	O
los	O
simulacros	O
.	O
C	O
.	O
inyecciones	O
(	O
-	O
Discos	B-Chemical
compactos	I-Chemical
)	O
o	O
s.	O
C	O
.	O
inyecciones	O
con	O
20	O
micro	O
mol/kg	O
peso	O
corporal	O
CdSO4	O
(	O
+	O
Discos	B-Chemical
compactos	I-Chemical
)	O
6	O
h	O
antes	O
de	O
sacrificarlos	O
.	O

RT	O
-	O
PCR	O
para	O
Hprt	B-Protein
ARNm	B-Chemical
se	O
utilizaron	O
como	O
control	O
interno	O
para	O
ajustar	O
la	O
cantidad	O
de	O
ARN	B-Sequence
usado	O
.	O

(	O
b	O
)	O
Núcleo	O
MRE	O
secuencias	B-Sequence
de	I-Sequence
consenso	I-Sequence
TGCRCNC	O
(	O
letras	O
en	O
negrita	O
)	O
y	O
secuencias	B-Sequence
flanqueantes	I-Sequence
encontrado	O
en	O
un	O
región	B-Sequence
de	O
1000	O
pb	B-Sequence
aguas	O
arriba	O
de	O
Slc39a10	B-Protein
comienzo	B-Sequence
de	I-Sequence
la	I-Sequence
transcripción	I-Sequence
;	O
los	O
posición	B-Sequence
de	I-Sequence
cada	I-Sequence
secuencia	I-Sequence
central	I-Sequence
Es	O
indicado	O
.	O

(	O
c	O
)	O
EMSA	O
con	O
hígado	O
proteína	B-Chemical
extractos	O
de	O
un	O
Mtf1loxP	O
macho	O
o	O
un	O
Mtf1Mx	O
-	O
cre	O
macho	O
inducido	O
por	O
pI	O
-	O
pC	O
.	O
ratón	B-Taxon
ambos	O
con	O
tratamiento	O
simulado	O
.	O

DM	B-Protein
-	I-Protein
1	I-Protein
proteína	B-GENE
-	I-GENE
complejo	I-GENE
de	I-GENE
ADN	I-GENE
Se	O
probó	O
la	O
formación	O
con	O
32P	B-Chemical
#	O
¿NOMBRE	O
?	O
Slc39a10	B-Protein
MRE1	O
o	O
MRE2	O
oligonucleótido	B-Sequence
,	O
respectivamente	O
.	O

La	O
especificidad	O
de	O
la	O
unión	O
se	O
verificó	O
con	O
exceso	O
de	O
competidor	O
no	O
marcado	O
MREd	O
o	O
Gal4	O
no	O
relacionado	O
oligonucleótido	B-Sequence
.	O

32P	B-Chemical
#	O
¿NOMBRE	O
?	O
DM	B-Protein
-	I-Protein
1	I-Protein
-	O
ADN	B-Sequence
complejo	B-GENE
;	O
Sp1	B-Protein
cambios	O
de	O
banda	O
con	O
32P	B-Chemical
#	O
¿NOMBRE	O
?	O
Sp1	B-Protein
oligonucleótido	B-Sequence
de	I-Sequence
consenso	I-Sequence
se	O
obtuvieron	O
como	O
proteína	B-Chemical
mando	O
de	O
carga	O
.	O

Figura	O
6	O

Células	B-Cell
con	O
glutatión	B-Chemical
reducido	I-Chemical
nivel	O
que	O
también	O
falta	O
DM	B-Protein
-	I-Protein
1	I-Protein
son	O
hipersensibles	O
a	O
cadmio	B-Chemical
.	O

La	O
viabilidad	O
de	O
células	B-Cell
se	O
evaluó	O
con	O
el	O
llamado	O
ensayo	O
MTT	O
.	O

Ratón	B-Taxon
embrionario	O
fibroblastos	B-Cell
con	O
(	O
ckoC	O
)	O
y	O
sin	O
(	O
delC19	O
,	O
delC21	O
y	O
delC23	O
)	O
funcionales	O
mtf1	B-Protein
se	O
compararon	O
.	O

Células	B-Cell
se	O
preincubaron	O
en	O
medio	O
que	O
contenía	O
0	O
,	O
5	O
,	O
10	O
,	O
25	O
o	O
50	O
micro	O
M	O
BSO	O
durante	O
24	O
h	O
y	O
luego	O
se	O
expusieron	O
a	O
0	O
,	O
5	O
,	O
10	O
o	O
20	O
micro	O
M	O
CdCl2	B-Chemical
(	O
Discos	B-Chemical
compactos	I-Chemical
)	O
en	O
el	O
medio	O
de	O
preincubación	O
especificado	O
durante	O
24	O
h	O
adicionales	O
.	O

Los	O
resultados	O
se	O
expresan	O
como	O
valores	O
medios	O
+/-	O
SD	O
(	O
n	O
=	O
3	O
)	O
normalizados	O
al	O
valor	O
respectivo	O
de	O
no	O
tratados	O
células	B-Cell
.	O

tabla	O
1	O

Comparación	O
de	O
hígado	O
gene	B-Sequence
expresión	O
para	O
pI	O
-	O
pC	O
-	O
Mtf1Mx	O
-	O
cre	O
y	O
Mtf1loxP	O
inducidos	O
ratones	B-Taxon
(	O
regulación	O
hacia	O
arriba	O
o	O
hacia	O
abajo	O
al	O
menos	O
2	O
veces	O
,	O
P	O
<	O
=	O
0	O
.	O
05	O
)	O

los	O
animales	B-Taxon
había	O
obtenido	O
cualquiera	O
de	O
los	O
simulacros	O
.	O
C	O
.	O
inyecciones	O
(	O
-	O
Discos	B-Chemical
compactos	I-Chemical
)	O
o	O
s.	O
C	O
.	O
inyecciones	O
con	O
20	O
micro	O
mol/kg	O
peso	O
corporal	O
CdSO4	O
(	O
+	O
Discos	B-Chemical
compactos	I-Chemical
)	O
6	O
h	O
antes	O
de	O
sacrificarlos	O
.	O

Los	O
valores	O
de	O
expresión	O
para	O
cada	O
gene	B-Sequence
se	O
dan	O
como	O
valor	O
medio	O
de	O
tres	O
animales	B-Taxon
por	O
grupo	O
,	O
normalizado	O
al	O
valor	O
medio	O
del	O
grupo	O
Mtf1loxP	O
-	O
Discos	B-Chemical
compactos	I-Chemical
(	O
actividad	O
relativa	O
)	O
.	O

El	O
sombreado	O
gris	O
indica	O
los	O
dos	O
grupos	O
de	O
animales	B-Taxon
En	O
comparación	O
,	O
se	O
muestran	O
las	O
actividades	O
relativas	O
de	O
los	O
otros	O
dos	O
grupos	O
para	O
obtener	O
una	O
descripción	O
completa	O
.	O

El	O
número	O
de	O
núcleo	O
MRE	O
secuencias	B-Sequence
de	I-Sequence
consenso	I-Sequence
TGCRCNC	O
en	O
un	O
región	B-Sequence
de	O
1000	O
pb	B-Sequence
aguas	O
arriba	O
de	O
lo	O
anotado	O
comienzo	B-Sequence
de	I-Sequence
la	I-Sequence
transcripción	I-Sequence
Es	O
indicado	O
.	O

aSolo	O
región	B-Sequence
incompleta	I-Sequence
hasta	O
-	O
1000	O
pb	B-Sequence
desde	O
comienzo	B-Sequence
de	I-Sequence
la	I-Sequence
transcripción	I-Sequence
está	O
disponible	O
en	O
la	O
base	O
de	O
datos	O
.	O

bValores	O
medios	O
de	O
dos	O
Affymetrix	O
independientes	O
Investigacion	B-Sequence
conjuntos	O

cValor	O
medio	O
de	O
cuatro	O
Affymetrix	O
independientes	O
Investigacion	B-Sequence
conjuntos	O

Tabla	O
2	O

Comparación	O
de	O
hígado	O
gene	B-Sequence
expresión	O
para	O
cadmio	B-Chemical
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
(	O
regulación	O
hacia	O
arriba	O
o	O
hacia	O
abajo	O
al	O
menos	O
2	O
veces	O
,	O
P	O
<	O
=	O
0	O
.	O
05	O
)	O

los	O
animales	B-Taxon
había	O
obtenido	O
cualquiera	O
de	O
los	O
simulacros	O
.	O
C	O
.	O
inyecciones	O
(	O
-Cd	O
)	O
o	O
s.	O
C	O
.	O
inyecciones	O
con	O
20	O
micro	O
mol/kg	O
peso	O
corporal	O
CdSO4	O
(	O
+Cd	O
)	O
6	O
h	O
antes	O
de	O
sacrificarlas	O
.	O

Los	O
valores	O
de	O
expresión	O
para	O
cada	O
gene	B-Sequence
se	O
dan	O
como	O
valor	O
medio	O
de	O
tres	O
animales	B-Taxon
por	O
grupo	O
,	O
normalizado	O
al	O
valor	O
medio	O
del	O
grupo	O
Mtf1loxP-Cd	O
(	O
actividad	O
relativa	O
)	O
.	O

aValores	O
medios	O
de	O
tres	O
Affymetrix	O
independientes	O
Investigacion	B-Sequence
conjuntos	O

bValor	O
medio	O
de	O
seis	O
Affymetrix	O
independientes	O
Investigacion	B-Sequence
conjuntos	O

cValor	O
medio	O
de	O
dos	O
Affymetrix	O
independientes	O
Investigacion	B-Sequence
conjuntos	O

factor	B-Protein
de	I-Protein
transcripción	I-Protein
CEBPG	I-Protein
se	O
correlaciona	O
con	O
antioxidante	B-Chemical
y	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
en	O
bronquios	O
normales	O
células	B-Cell
epiteliales	I-Cell
pero	O
no	O
en	O
individuos	B-Taxon
con	O
carcinoma	O
broncogénico	O

Resumen	O

Antecedentes	O

El	O
tabaquismo	O
es	O
la	O
causa	O
principal	O
del	O
carcinoma	O
broncogénico	O
(	O
CB	O
)	O
,	O
sin	O
embargo	O
,	O
sólo	O
el	O
10-15	O
%	O
de	O
los	O
fumadores	O
empedernidos	O
desarrollan	O
CB	O
y	O
es	O
probable	O
que	O
esta	O
variación	O
en	O
el	O
riesgo	O
sea	O
,	O
en	O
parte	O
,	O
genéticamente	B-Sequence
determinado	O

Previamente	O
reportamos	O
un	O
conjunto	O
de	O
antioxidante	B-Chemical
genes	B-Sequence
para	O
cual	O
transcripción	B-Sequence
la	O
abundancia	O
fue	O
menor	O
en	O
bronquial	O
normal	O
células	B-Cell
epiteliales	I-Cell
(	O
NBEC	O
)	O
de	O
BC	O
individuos	B-Taxon
en	O
comparación	O
con	O
no	O
-	O
BC	O
individuos	B-Taxon
.	O

En	O
estudios	O
no	O
publicados	O
de	O
las	O
mismas	O
muestras	O
de	O
NBCC	O
,	O
transcripción	B-Sequence
valores	O
de	O
abundancia	O
para	O
varios	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
se	O
correlacionaron	O
con	O
estos	O
antioxidante	B-Chemical
genes	B-Sequence
.	O

A	O
partir	O
de	O
estos	O
datos	O
,	O
planteamos	O
la	O
hipótesis	O
de	O
que	O
antioxidante	B-Chemical
y	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
están	O
co	O
-	O
regulados	O
por	O
uno	O
o	O
más	O
factores	O
de	O
transcripción	O
y	O
que	O
inter	O
-	O
individual	B-Taxon
la	O
variación	O
en	O
la	O
expresión	O
y/o	O
función	O
de	O
uno	O
o	O
más	O
de	O
estos	O
factores	O
de	O
transcripción	O
es	O
responsable	O
de	O
inter	O
-	O
individual	B-Taxon
variación	O
en	O
el	O
riesgo	O
de	O
BC	O
.	O

Métodos	O

el	O
putativo	O
sitios	B-Sequence
de	I-Sequence
reconocimiento	I-Sequence
de	I-Sequence
factores	I-Sequence
de	I-Sequence
transcripción	I-Sequence
común	O
a	O
seis	O
de	O
los	O
antioxidante	B-Chemical
genes	B-Sequence
fueron	O
identificados	O
a	O
través	O
de	O
in	O
silico	O
secuencia	B-Sequence
de	I-Sequence
ADN	I-Sequence
análisis	O

los	O
transcripción	B-Sequence
valores	O
de	O
abundancia	O
de	O
estos	O
factores	O
de	O
transcripción	O
(	O
n	O
=	O
6	O
)	O
y	O
un	O
grupo	O
ampliado	O
de	O
antioxidante	B-Chemical
y	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
(	O
n	O
=	O
16	O
)	O
se	O
midieron	O
simultáneamente	O
por	O
PCR	O
cuantitativa	O
en	O
NBCC	O
de	O
24	O
no	O
BC	O
y	O
25	O
BC	O
individuos	B-Taxon
.	O

Resultados	O

factor	B-Protein
de	I-Protein
transcripción	I-Protein
CEBPG	I-Protein
se	O
correlacionó	O
significativamente	O
(	O
p	O
<	O
0,01	O
)	O
con	O
ocho	O
de	O
los	O
antioxidante	B-Chemical
o	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
en	O
no	O
-	O
BC	O
individuos	B-Taxon
pero	O
no	O
en	O
BC	O
individuos	B-Taxon
.	O

en	O
BC	O
individuos	B-Taxon
la	O
correlación	O
con	O
CEBPG	B-Protein
fue	O
significativamente	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
más	O
bajo	O
que	O
el	O
de	O
los	O
no	O
BC	O
individuos	B-Taxon
por	O
cuatro	O
de	O
los	O
genes	B-Sequence
(	O
XRCC1	B-Protein
,	O
ERCC5	B-Protein
,	O
GSTP1	B-Protein
,	O
y	O
SOD1	B-Protein
)	O
y	O
la	O
diferencia	O
fue	O
casi	O
significativa	O
para	O
GPX1	B-Protein
.	O

El	O
único	O
otro	O
factor	O
de	O
transcripción	O
correlacionado	O
con	O
cualquiera	O
de	O
estos	O
cinco	O
objetivos	O
genes	B-Sequence
en	O
no	O
-	O
BC	O
individuos	B-Taxon
era	O
E2F1	B-Protein
.	O

E2F1	B-Protein
se	O
correlacionó	O
con	O
GSTP1	B-Protein
entre	O
no	O
-	O
BC	O
individuos	B-Taxon
,	O
pero	O
a	O
diferencia	O
de	O
CEBPG	B-Protein
,	O
no	O
hubo	O
diferencia	O
significativa	O
en	O
esta	O
correlación	O
en	O
no	O
-	O
BC	O
individuos	B-Taxon
en	O
comparación	O
con	O
BC	O
individuos	B-Taxon
.	O

Conclusión	O

Concluimos	O
que	O
CEBPG	B-Protein
es	O
el	O
factor	O
de	O
transcripción	O
principalmente	O
responsable	O
de	O
regular	O
la	O
transcripción	O
de	O
claves	O
antioxidante	B-Chemical
y	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
en	O
no	O
-	O
BC	O
individuos	B-Taxon
.	O

Además	O
,	O
concluimos	O
que	O
los	O
grandes	O
fumadores	O
seleccionados	O
para	O
el	O
desarrollo	O
de	O
BC	O
son	O
aquellos	O
que	O
tienen	O
una	O
regulación	O
subóptima	O
de	O
antioxidante	B-Chemical
y	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
por	O
CEBPG	B-Protein
.	O

Antecedentes	O

BC	O
es	O
actualmente	O
la	O
principal	O
causa	O
de	O
muerte	O
relacionada	O
con	O
el	O
cáncer	O
en	O
los	O
Estados	O
Unidos	O
,	O
provocando	O
el	O
28	O
%	O
de	O
todas	O
las	O
muertes	O
por	O
cáncer	O
[	O
1	O
]	O
.	O

Aunque	O
fumar	O
cigarrillos	O
es	O
el	O
principal	O
factor	O
de	O
riesgo	O
,	O
sólo	O
el	O
10-15	O
%	O
de	O
los	O
fumadores	O
empedernidos	O
(	O
más	O
de	O
20	O
paquetes	O
al	O
año	O
)	O
desarrollan	O
BC	O
[	O
1-3	O
]	O
.	O

antioxidante	B-Chemical
y	O
ADN	B-Sequence
reparar	O
enzimas	B-Sequence
que	O
brindan	O
protección	O
contra	O
los	O
efectos	O
del	O
humo	O
del	O
cigarrillo	O
se	O
expresan	O
en	O
el	O
progenitor	O
células	B-Cell
para	O
BC	O
,	O
bronquial	O
normal	O
células	B-Cell
epiteliales	I-Cell
(	O
NBEC	O
)	O
[	O
1	O
]	O
.	O

heredado	O
entre	O
-	O
individual	B-Taxon
variación	O
en	O
la	O
función	O
de	O
estos	O
genes	B-Sequence
desempeña	O
un	O
papel	O
en	O
la	O
determinación	O
del	O
riesgo	O
de	O
BC	O
[	O
4	O
-	O
6	O
]	O
.	O

antioxidante	B-Chemical
enzimas	B-Sequence
proteger	O
a	O
NBCC	O
de	O
especies	B-Chemical
de	I-Chemical
oxígeno	I-Chemical
reactivas	I-Chemical
producido	O
por	O
la	O
interacción	O
y	O
el	O
metabolismo	O
de	O
xenobióticos	B-Chemical
como	O
la	O
contaminación	O
y	O
el	O
humo	O
del	O
cigarrillo	O
[	O
4	O
-	O
7	O
]	O
así	O
como	O
los	O
producidos	O
por	O
celular	B-Cell
metabolismo	O
.	O

Especies	B-Chemical
de	I-Chemical
oxígeno	I-Chemical
reactivas	I-Chemical
causar	O
muchas	O
reacciones	O
perjudiciales	O
,	O
incluida	O
la	O
desnaturalización	O
de	O
proteinas	B-Chemical
,	O
entrecruzamiento	O
de	O
lipidos	B-Chemical
y	O
proteinas	B-Chemical
y	O
modificación	B-Sequence
de	O
ácido	B-Chemical
nucleico	I-Chemical
bases	B-Sequence
,	O
que	O
puede	O
provocar	O
cáncer	O
[	O
7	O
]	O
.	O

ADN	B-Sequence
reparar	O
enzimas	B-Sequence
reparar	O
los	O
frecuentes	O
daños	O
a	O
ADN	B-Sequence
causado	O
por	O
el	O
estrés	O
oxidante	O
,	O
así	O
como	O
por	O
otros	O
tipos	O
de	O
estrés	O
,	O
incluidos	O
los	O
aductos	O
voluminosos	O
derivados	O
de	O
carcinógenos	O
en	O
el	O
humo	O
del	O
cigarrillo	O
[	O
8	O
]	O
.	O

Anteriormente	O
informamos	O
que	O
un	O
interactivo	O
transcripción	B-Sequence
índice	O
de	O
abundancia	O
que	O
comprende	O
antioxidante	B-Chemical
genes	B-Sequence
fue	O
menor	O
en	O
NBCC	O
de	O
BC	O
individuos	B-Taxon
en	O
comparación	O
con	O
no	O
-	O
BC	O
individuos	B-Taxon
,	O
sugiriendo	O
que	O
BC	O
individuos	B-Taxon
se	O
seleccionan	O
sobre	O
la	O
base	O
de	O
los	O
malos	O
antioxidante	B-Chemical
protección	O
[	O
9	O
]	O
.	O

En	O
ese	O
estudio	O
,	O
hubo	O
una	O
tendencia	O
hacia	O
la	O
correlación	O
en	O
transcripción	B-Sequence
abundancia	O
entre	O
varios	O
pares	O
de	O
antioxidante	B-Chemical
o	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
en	O
no	O
-	O
BC	O
individuos	B-Taxon
,	O
pero	O
no	O
en	O
BC	O
individuos	B-Taxon
.	O

Gene	B-Sequence
pares	O
incluidos	O
en	O
esa	O
observación	O
fueron	O
GSTP1	B-Protein
/	O
GPX1	B-Protein
,	O
GATO	B-Protein
/	O
GPX3	B-Protein
,	O
y	O
GPX3	B-Protein
/	O
SOD1	B-Protein
.	O

La	O
correlación	O
es	O
una	O
característica	O
típica	O
de	O
co	O
-	O
regulado	O
genes	B-Sequence
.	O

otra	O
es	O
compartida	O
sitios	B-Sequence
de	I-Sequence
reconocimiento	I-Sequence
de	I-Sequence
factores	I-Sequence
de	I-Sequence
transcripción	I-Sequence
en	O
el	O
regiones	B-Sequence
reguladoras	I-Sequence
de	O
aquellos	O
genes	B-Sequence
[	O
10	O
]	O
.	O

Con	O
base	O
en	O
los	O
hallazgos	O
anteriores	O
,	O
primero	O
se	O
planteó	O
la	O
hipótesis	O
de	O
que	O
existe	O
una	O
inter-	O
individual	B-Taxon
variación	O
en	O
la	O
regulación	O
de	O
la	O
llave	O
antioxidante	B-Chemical
y	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
por	O
uno	O
o	O
más	O
factores	O
de	O
transcripción	O
y	O
segundo	O
,	O
que	O
individuos	B-Taxon
con	O
regulación	O
subóptima	O
son	O
seleccionados	O
para	O
el	O
desarrollo	O
de	O
CB	O
si	O
fuman	O
cigarrillos	O
.	O

Para	O
probar	O
estas	O
hipótesis	O
,	O
sitios	B-Sequence
de	I-Sequence
reconocimiento	I-Sequence
de	I-Sequence
factores	I-Sequence
de	I-Sequence
transcripción	I-Sequence
común	O
a	O
la	O
regiones	B-Sequence
reguladoras	I-Sequence
de	O
lo	O
anterior	O
correlacionado	O
gene	B-Sequence
pares	O
fueron	O
identificados	O
a	O
través	O
de	O
in	O
silico	O
secuencia	B-Sequence
de	I-Sequence
ADN	I-Sequence
análisis	O
y	O
sus	O
transcripción	B-Sequence
abundancia	O
medida	O
simultáneamente	O
con	O
un	O
grupo	O
ampliado	O
de	O
diez	O
antioxidante	B-Chemical
y	O
seis	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
.	O

Métodos	O

Adquisición	O
de	O
muestras	O
de	O
NBCC	O

Se	O
obtuvieron	O
muestras	O
de	O
biopsia	O
por	O
cepillado	O
de	O
epitelio	O
bronquial	O
normal	O
para	O
estudios	O
de	O
investigación	O
en	O
el	O
momento	O
de	O
la	O
broncoscopia	O
diagnóstica	O
según	O
los	O
métodos	O
descritos	O
anteriormente	O
[	O
9	O
,	O
11	O
]	O
.	O

El	O
epitelio	O
bronquial	O
normal	O
en	O
el	O
pulmón	O
que	O
no	O
estaba	O
afectado	O
por	O
el	O
cáncer	O
se	O
cepilló	O
antes	O
de	O
la	O
biopsia	O
del	O
área	O
sospechosa	O
de	O
cáncer	O
.	O

Las	O
muestras	O
se	O
recolectaron	O
de	O
una	O
manera	O
que	O
satisfacía	O
todos	O
los	O
requisitos	O
de	O
la	O
Junta	O
de	O
Revisión	O
Institucional	O
de	O
la	O
Universidad	O
Médica	O
de	O
Ohio	O
.	O

Cada	O
diagnóstico	O
de	O
BC	O
y	O
la	O
identificación	O
del	O
subtipo	O
se	O
determinaron	O
mediante	O
un	O
examen	O
histopatológico	O
en	O
el	O
Departamento	O
de	O
Patología	O
de	O
la	O
Universidad	O
Médica	O
de	O
Ohio	O
.	O

Muestras	O
de	O
NBCC	O
de	O
un	O
total	O
de	O
49	O
individuos	B-Taxon
incluidos	O
24	O
no	O
BC	O
individuos	B-Taxon
y	O
25	O
a.C	O
.	O
individuos	B-Taxon
,	O
fueron	O
evaluados	O
en	O
este	O
estudio	O
.	O

Las	O
características	O
biográficas	O
de	O
estos	O
individuos	B-Taxon
se	O
presentan	O
en	O
la	O
Tabla	O
1	O
.	O

Transcripción	B-Sequence
medición	O
de	O
la	O
abundancia	O

Total	O
ARN	B-Sequence
Las	O
muestras	O
extraídas	O
de	O
NBCC	O
se	O
transcribieron	O
inversamente	O
utilizando	O
M	B-Protein
-	I-Protein
transcriptasa	I-Protein
inversa	I-Protein
MLV	I-Protein
y	O
oligo	B-Sequence
dT	O
cebadores	B-Sequence
como	O
se	O
ha	O
descrito	O
anteriormente	O
[	O
9	O
,	O
11	O
]	O
.	O

Se	O
usó	O
RT	O
estandarizada	O
(	O
StaRT	O
)	O
-	O
PCR	O
para	O
transcripción	B-Sequence
medición	O
de	O
la	O
abundancia	O
en	O
estos	O
estudios	O
.	O

Con	O
StaRT-PCR	O
,	O
un	O
estándar	O
interno	O
para	O
cada	O
gene	B-Sequence
dentro	O
de	O
una	O
mezcla	O
estandarizada	O
de	O
estándares	O
internos	O
(	O
SMIS	O
)	O
se	O
incluye	O
en	O
cada	O
reacción	O
de	O
PCR	O
.	O

Después	O
de	O
la	O
amplificación	O
,	O
productos	B-Sequence
fueron	O
sometidos	O
a	O
electroforesis	O
en	O
un	O
bioanalizador	O
Agilent	O
2100	O
utilizando	O
ADN	B-Sequence
patatas	O
fritas	O
con	O
ADN	B-Sequence
1000	O
equipos	O
reactivos	B-Chemical
para	O
visualización	O
según	O
el	O
protocolo	O
del	O
fabricante	O
(	O
Agilent	O
Technologies	O
Deutschland	O
GmbH	O
,	O
Waldbronn	O
,	O
Alemania	O
)	O
.	O

La	O
tecnología	O
StaRT	O
-	O
PCR	O
tiene	O
licencia	O
para	O
Gene	B-Sequence
expreso	O
,	O
inc	O
.	O

(	O
Toledo	O
,	O
OH	O
)	O
.	O

Mucho	O
de	O
reactivos	B-Chemical
están	O
disponibles	O
comercialmente	O
y	O
se	O
obtuvieron	O
a	O
través	O
de	O
Gene	B-Sequence
expreso	O
,	O
inc.	O
para	O
este	O
estudio	O
.	O

Inicio	O
-	O
PCR	O
reactivos	B-Chemical
para	O
cada	O
uno	O
de	O
los	O
medidos	O
genes	B-Sequence
que	O
no	O
estaban	O
disponibles	O
comercialmente	O
,	O
incluyendo	O
cebadores	B-Sequence
y	O
SMIS	O
,	O
se	O
prepararon	O
de	O
acuerdo	O
con	O
los	O
métodos	O
descritos	O
anteriormente	O
[	O
11	O
,	O
12	O
]	O
.	O

Secuencia	B-Sequence
información	O
para	O
el	O
cebadores	B-Sequence
se	O
proporciona	O
en	O
la	O
Tabla	O
2	O
.	O

Incluir	O
un	O
estándar	O
interno	O
dentro	O
de	O
un	O
SMIS	O
en	O
cada	O
medición	O
controla	O
todas	O
las	O
fuentes	O
conocidas	O
de	O
variación	O
durante	O
la	O
PCR	O
,	O
incluyendo	O
inhibidores	B-Chemical
en	O
muestras	O
,	O
y	O
genera	O
virtualmente	O
multiplexado	O
transcripción	B-Sequence
datos	O
de	O
abundancia	O
que	O
son	O
directamente	O
comparables	O
entre	O
múltiples	O
experimentos	O
e	O
instituciones	O
[	O
13	O
]	O
.	O

Las	O
características	O
de	O
rendimiento	O
de	O
StaRT-PCR	O
son	O
superiores	O
a	O
otras	O
formas	O
de	O
tecnología	O
de	O
PCR	O
cuantitativa	O
disponible	O
comercialmente	O
en	O
las	O
áreas	O
críticas	O
para	O
este	O
estudio	O
.	O

Con	O
respecto	O
a	O
estos	O
estudios	O
,	O
la	O
propiedad	O
clave	O
de	O
un	O
método	O
PCR	O
cuantitativo	O
no	O
es	O
si	O
el	O
productos	B-Sequence
PCR	I-Sequence
se	O
miden	O
cinéticamente	O
o	O
en	O
el	O
punto	O
final	O
,	O
sino	O
si	O
hay	O
estándares	O
internos	O
en	O
cada	O
medición	O
o	O
no	O
.	O

Las	O
características	O
generales	O
de	O
rendimiento	O
de	O
StaRT-PCR	O
,	O
incluida	O
la	O
extensa	O
validación	O
del	O
método	O
en	O
laboratorios	O
independientes	O
,	O
se	O
han	O
presentado	O
en	O
varios	O
artículos	O
y	O
capítulos	O
recientes	O
[	O
13-15	O
]	O
.	O

Con	O
respeto	O
a	O
genes	B-Sequence
medido	O
en	O
este	O
estudio	O
,	O
para	O
cada	O
gene	B-Sequence
el	O
StaRT	O
-	O
PCR	O
reactivos	B-Chemical
tenía	O
un	O
umbral	O
de	O
detección	O
más	O
bajo	O
de	O
menos	O
de	O
10	O
moléculas	B-Chemical
,	O
rango	O
dinámico	O
lineal	O
de	O
más	O
de	O
seis	O
órdenes	O
de	O
magnitud	O
(	O
menos	O
de	O
10	O
a	O
más	O
de	O
107	O
moléculas	B-Chemical
)	O
,	O
y	O
respuesta	O
de	O
señal	O
a	O
analito	O
del	O
100	O
%	O
.	O

Además	O
,	O
la	O
presencia	O
de	O
un	O
estándar	O
interno	O
controla	O
la	O
variación	O
entre	O
muestras	O
en	O
presencia	O
de	O
PCR	O
inhibidores	B-Chemical
(	O
que	O
a	O
menudo	O
son	O
gene	B-Sequence
-	O
específico	O
)	O
y	O
asegura	O
que	O
no	O
haya	O
falsos	O
negativos	O
(	O
si	O
la	O
PCR	O
falla	O
el	O
estándar	O
interno	O
producto	B-Sequence
PCR	I-Sequence
no	O
se	O
observa	O
y	O
no	O
hay	O
datos	O
que	O
reportar	O
)	O
.	O

Los	O
falsos	O
positivos	O
se	O
eliminan	O
mediante	O
el	O
uso	O
de	O
una	O
reacción	O
de	O
PCR	O
de	O
control	O
sin	O
ADNc	B-Sequence
en	O
eso	O
.	O

análisis	O
estadístico	O

Más	O
de	O
6	O
000	O
transcripción	B-Sequence
Se	O
realizaron	O
mediciones	O
de	O
abundancia	O
en	O
múltiples	O
experimentos	O
durante	O
dos	O
años	O
para	O
evaluar	O
los	O
seis	O
factores	O
de	O
transcripción	O
y	O
dieciséis	O
antioxidante	B-Chemical
y	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
en	O
muestras	O
NBCC	O
de	O
49	O
individuos	B-Taxon
(	O
24	O
no	O
-	O
BC	O
individuos	B-Taxon
y	O
25	O
a.C	O
.	O
individuos	B-Taxon
)	O
.	O

Correlación	O
de	O
cada	O
uno	O
de	O
los	O
seis	O
factores	O
de	O
transcripción	O
con	O
cada	O
uno	O
de	O
los	O
antioxidante	B-Chemical
o	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
fue	O
determinado	O
por	O
la	O
correlación	O
de	O
Pearson	O
después	O
de	O
la	O
transformación	O
logarítmica	O
.	O

La	O
transformación	O
fue	O
necesaria	O
debido	O
a	O
la	O
amplia	O
variación	O
biológica	O
en	O
la	O
expresión	O
de	O
cada	O
gene	B-Sequence
entre	O
la	O
individuos	B-Taxon
.	O

El	O
nivel	O
de	O
significación	O
se	O
definió	O
como	O
p	O
<	O
0	O
.	O
01	O
después	O
del	O
ajuste	O
de	O
Bonferroni	O
para	O
la	O
comparación	O
múltiple	O
,	O
específicamente	O
la	O
comparación	O
de	O
cada	O
uno	O
de	O
los	O
seis	O
factores	O
de	O
transcripción	O
con	O
cada	O
uno	O
de	O
los	O
antioxidante	B-Chemical
o	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
.	O

La	O
comparación	O
de	O
diferencias	O
significativas	O
entre	O
pares	O
de	O
coeficientes	O
de	O
correlación	O
se	O
realizó	O
mediante	O
la	O
prueba	O
de	O
transformación	O
Z	O
de	O
Fisher	O
[	O
16	O
]	O
.	O

Análisis	O
de	O
la	O
relación	O
entre	O
virtualmente	O
-	O
multiplexado	O
transcripción	B-Sequence
datos	O
de	O
abundancia	O
para	O
cada	O
gene	B-Sequence
con	O
la	O
edad	O
se	O
evaluó	O
mediante	O
la	O
correlación	O
de	O
Pearson	O
,	O
con	O
el	O
sexo	O
mediante	O
la	O
prueba	O
t	O
y	O
con	O
el	O
historial	O
de	O
tabaquismo	O
mediante	O
ANOVA	O
seguido	O
de	O
la	O
prueba	O
de	O
Duncan	O
.	O

Sitio	B-Sequence
de	I-Sequence
reconocimiento	I-Sequence
de	I-Sequence
factores	I-Sequence
de	I-Sequence
transcripción	I-Sequence
análisis	O

Se	O
utilizó	O
el	O
programa	O
El	O
Dorado	O
(	O
Build	O
35	O
)	O
del	O
paquete	O
de	O
software	O
Genomatix	O
para	O
ubicar	O
la	O
correlación	O
genes	B-Sequence
dentro	O
de	O
genoma	B-Sequence
y	O
definir	O
1101	O
pares	B-Sequence
de	I-Sequence
bases	I-Sequence
de	O
El	O
regiones	B-Sequence
promotoras	I-Sequence
(	O
1000	O
pares	B-Sequence
de	I-Sequence
bases	I-Sequence
aguas	O
arriba	O
de	O
y	O
100	O
pares	B-Sequence
de	I-Sequence
bases	I-Sequence
en	O
el	O
sitio	B-Sequence
de	I-Sequence
inicio	I-Sequence
de	I-Sequence
la	I-Sequence
transcripción	I-Sequence
)	O
para	O
cada	O
gene	B-Sequence
(	O
Genomatix	O
Software	O
GmbH	O
,	O
Múnich	O
,	O
Alemania	O
,	O
[	O
17	O
]	O
)	O
.	O

el	O
1101	O
secuencias	B-Sequence
de	I-Sequence
pares	I-Sequence
de	I-Sequence
bases	I-Sequence
obtenidos	O
del	O
programa	O
El	O
Dorado	O
luego	O
se	O
usaron	O
como	O
el	O
objetivo	O
secuencias	B-Sequence
para	O
putativo	O
sitio	B-Sequence
de	I-Sequence
reconocimiento	I-Sequence
del	I-Sequence
factor	I-Sequence
de	I-Sequence
transcripción	I-Sequence
identificación	O
usando	O
MatInspector	O
Versión	O
4	O
.	O
2	O
programa	O
,	O
que	O
produjo	O
sitios	B-Sequence
para	I-Sequence
11	I-Sequence
factores	I-Sequence
de	I-Sequence
transcripción	I-Sequence
(	O
Genomatix	O
Software	O
GmbH	O
,	O
Múnich	O
,	O
Alemania	O
,	O
[	O
17	O
]	O
)	O
.	O

Los	O
parámetros	O
utilizados	O
fueron	O
el	O
núcleo	O
de	O
similitud	O
estándar	O
(	O
0,75	O
)	O
y	O
la	O
matriz	O
de	O
similitud	O
optimizada	O
[	O
18	O
]	O
.	O

Inicio	O
-	O
PCR	O
reactivos	B-Chemical
fueron	O
optimizados	O
para	O
diez	O
de	O
estos	O
factores	O
de	O
transcripción	O
,	O
incluyendo	O
CEBPB	B-Protein
,	O
CEBPE	B-Protein
,	O
CEBPG	B-Protein
,	O
E2F1	B-Protein
,	O
E2F3	B-Protein
,	O
E2F4	B-Protein
,	O
E2F5	B-Protein
,	O
E2F6	B-Protein
,	O
EVI1	B-Protein
,	O
y	O
PAX5	B-Protein
.	O

Cuatro	O
factores	O
de	O
transcripción	O
se	O
expresaron	O
en	O
niveles	O
bajos	O
e	O
invariantes	O
entre	O
múltiples	O
muestras	O
de	O
NBCC	O
y	O
,	O
por	O
lo	O
tanto	O
,	O
se	O
excluyeron	O
del	O
estudio	O
.	O

Los	O
seis	O
restantes	O
,	O
CEBPB	B-Protein
,	O
CEBPG	B-Protein
,	O
E2F1	B-Protein
,	O
E2F3	B-Protein
,	O
E2F6	B-Protein
,	O
y	O
EVI	B-Protein
,	O
fueron	O
evaluados	O
para	O
la	O
correlación	O
con	O
un	O
grupo	O
ampliado	O
de	O
diez	O
antioxidante	B-Chemical
y	O
seis	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
.	O

Resultados	O

Virtualmente	O
-	O
multiplexado	O
transcripción	B-Sequence
Se	O
obtuvieron	O
datos	O
de	O
abundancia	O
para	O
cada	O
gene	B-Sequence
en	O
cada	O
una	O
de	O
las	O
49	O
muestras	O
,	O
a	O
excepción	O
de	O
E2F1	B-Protein
medición	O
en	O
la	O
muestra	O
147	O
(	O
Tabla	O
3	O
)	O
.	O

A	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
inhibidor	B-Chemical
en	O
la	O
muestra	O
147	O
impidió	O
la	O
amplificación	O
de	O
E2F1	B-Protein
.	O

Ni	O
el	O
patrón	O
interno	O
,	O
ni	O
el	O
nativo	O
Producto	B-Sequence
de	I-Sequence
PCR	I-Sequence
de	I-Sequence
ADNc	I-Sequence
fue	O
observado	O
.	O

La	O
presencia	O
de	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
productos	B-Sequence
PCR	I-Sequence
en	O
relación	O
con	O
lo	O
esperado	O
para	O
el	O
número	O
de	O
patrón	O
interno	O
moléculas	B-Chemical
presentes	O
al	O
comienzo	O
de	O
la	O
reacción	O
de	O
PCR	O
.	O

Sin	O
embargo	O
,	O
en	O
cada	O
uno	O
de	O
estos	O
casos	O
,	O
la	O
amplificación	O
por	O
PCR	O
fue	O
lo	O
suficientemente	O
eficiente	O
como	O
para	O
permitir	O
la	O
cuantificación	O
.	O

Análisis	O
bivariado	O

En	O
no	O
-	O
BC	O
individuos	B-Taxon
hubo	O
una	O
correlación	O
significativa	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
entre	O
CEBPG	B-Protein
y	O
ocho	O
de	O
los	O
16	O
antioxidante	B-Chemical
o	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
,	O
específicamente	O
XRCC1	B-Protein
,	O
ERCC5	B-Protein
,	O
GSTP1	B-Protein
,	O
SOD1	B-Protein
,	O
GPX1	B-Protein
,	O
ERCC1	B-Protein
,	O
GATO	B-Protein
y	O
ERCC2	B-Protein
(	O
Cuadro	O
4	O
)	O
.	O

En	O
cambio	O
,	O
en	O
BC	O
individuos	B-Taxon
muestras	O
CEBPG	B-Protein
no	O
se	O
correlacionó	O
con	O
ninguno	O
de	O
los	O
antioxidante	B-Chemical
o	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
.	O

Estas	O
relaciones	O
no	O
se	O
observaron	O
con	O
ninguno	O
de	O
los	O
otros	O
factores	O
de	O
transcripción	O
estudiados	O
.	O

Para	O
XRCC1	B-Protein
,	O
ERCC5	B-Protein
,	O
GSTP1	B-Protein
,	O
y	O
SOD1	B-Protein
la	O
correlación	O
con	O
CEBPG	B-Protein
fue	O
significativamente	O
menor	O
en	O
BC	O
individuos	B-Taxon
en	O
comparación	O
con	O
no	O
-	O
BC	O
individuos	B-Taxon
y	O
la	O
diferencia	O
fue	O
casi	O
significativa	O
para	O
GPX1	B-Protein
(	O
Fig	O
.	O
1b	O
)	O
.	O

Gráficos	O
de	O
dispersión	O
de	O
la	O
relación	O
entre	O
CEBPG	B-Protein
y	O
XRCC1	B-Protein
en	O
no	O
-	O
BC	O
individuos	B-Taxon
o	O
antes	O
de	O
Cristo	O
individuos	B-Taxon
(	O
Fig	O
.	O
2a	O
,	O
b	O
)	O
son	O
representativos	O
de	O
los	O
otros	O
cuatro	O
genes	B-Sequence
.	O

Ninguno	O
de	O
los	O
dos	O
CEBPG	B-Protein
,	O
ni	O
XRCC1	B-Protein
,	O
ERCC5	B-Protein
,	O
GSTP1	B-Protein
,	O
SOD1	B-Protein
o	O
GPX1	B-Protein
se	O
correlacionó	O
significativamente	O
con	O
la	O
edad	O
,	O
el	O
género	O
o	O
el	O
historial	O
de	O
tabaquismo	O
en	O
pacientes	O
no	O
BC	O
individuos	B-Taxon
,	O
ANTES	O
DE	O
CRISTO	O
individuos	B-Taxon
,	O
o	O
el	O
grupo	O
combinado	O
.	O

En	O
no	O
-	O
BC	O
individuos	B-Taxon
,	O
basado	O
en	O
los	O
valores	O
r2	O
del	O
análisis	O
de	O
correlación	O
de	O
Pearson	O
,	O
CEBPG	B-Protein
explica	O
gran	O
parte	O
de	O
la	O
variación	O
en	O
la	O
expresión	O
de	O
XRCC1	B-Protein
(	O
69	O
%	O
)	O
,	O
ERCC5	B-Protein
(	O
62	O
%	O
)	O
,	O
GSTP1	B-Protein
(	O
55	O
%	O
)	O
,	O
SOD1	B-Protein
(	O
44	O
%	O
)	O
,	O
y	O
GPX1	B-Protein
(	O
52	O
%	O
)	O
.	O

E2F1	B-Protein
representa	O
parte	O
de	O
la	O
varianza	O
restante	O
.	O

Por	O
ejemplo	O
,	O
cuando	O
las	O
muestras	O
de	O
los	O
49	O
países	O
no	O
pertenecientes	O
a	O
BC	O
individuos	B-Taxon
y	O
BC	O
individuos	B-Taxon
fueron	O
evaluados	O
como	O
un	O
solo	O
grupo	O
,	O
E2F1	B-Protein
se	O
correlacionó	O
significativamente	O
con	O
ERCC5	B-Protein
,	O
GSTP1	B-Protein
y	O
SOD1	B-Protein
(	O
Cuadro	O
4	O
)	O
.	O

Además	O
,	O
en	O
fuera	O
de	O
BC	O
individuos	B-Taxon
,	O
E2F1	B-Protein
se	O
correlacionó	O
con	O
GSTP1	B-Protein
(	O
Fig	O
.	O
1c	O
)	O
y	O
la	O
correlación	O
fue	O
menor	O
en	O
BC	O
individuos	B-Taxon
.	O

Sin	O
embargo	O
,	O
la	O
diferencia	O
en	O
la	O
correlación	O
entre	O
no	O
-	O
BC	O
individuos	B-Taxon
y	O
BC	O
individuos	B-Taxon
no	O
fue	O
significativo	O
.	O

Ninguno	O
de	O
los	O
otros	O
factores	O
de	O
transcripción	O
se	O
correlacionó	O
con	O
XRCC1	B-Protein
,	O
ERCC5	B-Protein
,	O
GSTP1	B-Protein
,	O
SOD1	B-Protein
,	O
o	O
GPX1	B-Protein
(	O
Fig	O
.	O
1a	O
,	O
d	O
,	O
e	O
,	O
f	O
)	O
.	O

Comparación	O
de	O
gene	B-Sequence
expresión	O
con	O
características	O
demográficas	O

E2F1	B-Protein
y	O
GSTZ1	B-Protein
cada	O
uno	O
se	O
correlacionó	O
positivamente	O
con	O
la	O
edad	O
.	O

GSTM1	B-Protein
-	O
5	O
fue	O
el	O
único	O
gene	B-Sequence
con	O
una	O
diferencia	O
en	O
la	O
expresión	O
por	O
género	O
.	O

Había	O
una	O
diferencia	O
en	O
ERCC2	B-Protein
expresión	O
entre	O
ex	O
fumadores	O
y	O
nunca	O
fumadores	O
.	O

Discusión	O

En	O
este	O
estudio	O
,	O
probamos	O
dos	O
hipótesis	O
.	O

Primero	O
,	O
que	O
hay	O
inter	O
-	O
individual	B-Taxon
variación	O
en	O
la	O
regulación	O
de	O
la	O
llave	O
antioxidante	B-Chemical
y	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
por	O
uno	O
o	O
más	O
factores	O
de	O
transcripción	O
.	O

segundo	O
,	O
que	O
individuos	B-Taxon
con	O
regulación	O
subóptima	O
son	O
seleccionados	O
para	O
el	O
desarrollo	O
de	O
CB	O
si	O
fuman	O
cigarrillos	O
.	O

Estas	O
hipótesis	O
están	O
respaldadas	O
por	O
los	O
hallazgos	O
de	O
que	O
a	O
)	O
hubo	O
una	O
gran	O
inter	O
-	O
individual	B-Taxon
variación	O
en	O
transcripción	B-Sequence
niveles	O
de	O
CEBPG	B-Protein
y	O
cada	O
uno	O
de	O
los	O
objetivos	O
genes	B-Sequence
y	O
en	O
no	O
-	O
BC	O
individuos	B-Taxon
,	O
B	O
)	O
CEBPG	B-Protein
transcripción	B-Sequence
Los	O
valores	O
de	O
abundancia	O
se	O
correlacionaron	O
significativamente	O
por	O
análisis	O
bivariado	O
con	O
el	O
transcripción	B-Sequence
valores	O
de	O
abundancia	O
de	O
cuatro	O
claves	O
antioxidante	B-Chemical
y	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
en	O
no	O
-	O
BC	O
individuos	B-Taxon
y	O
c	O
)	O
que	O
no	O
hubo	O
correlación	O
entre	O
CEBPG	B-Protein
y	O
estos	O
genes	B-Sequence
en	O
BC	O
individuos	B-Taxon
.	O

Estos	O
resultados	O
apoyan	O
la	O
hipótesis	O
de	O
que	O
cada	O
uno	O
de	O
los	O
antioxidante	B-Chemical
o	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
correlacionado	O
con	O
CEBPG	B-Protein
en	O
no	O
-	O
BC	O
individuos	B-Taxon
está	O
regulado	O
por	O
CEBPG	B-Protein
.	O

Esto	O
está	O
respaldado	O
por	O
la	O
especificidad	O
de	O
la	O
CEBPG	B-Protein
correlación	O

Es	O
decir	O
,	O
hubo	O
falta	O
de	O
correlación	O
entre	O
cualquiera	O
de	O
los	O
otros	O
cinco	O
factores	O
de	O
transcripción	O
evaluados	O
y	O
estos	O
objetivos	O
.	O
genes	B-Sequence
.	O

De	O
particular	O
interés	O
es	O
la	O
falta	O
de	O
correlación	O
del	O
objetivo	O
.	O
genes	B-Sequence
con	O
CEBPB	B-Protein
,	O
que	O
se	O
une	O
al	O
mismo	O
sitio	B-Sequence
de	I-Sequence
reconocimiento	I-Sequence
como	O
CEBPG	B-Protein
y	O
comparte	O
su	O
sitio	B-Sequence
de	I-Sequence
reconocimiento	I-Sequence
dentro	O
de	O
cada	O
uno	O
de	O
los	O
antioxidante	B-Chemical
o	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
.	O

Sin	O
embargo	O
,	O
existen	O
explicaciones	O
alternativas	O
para	O
la	O
correlación	O
observada	O
de	O
CEBPG	B-Protein
con	O
antioxidante	B-Chemical
y	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
en	O
no	O
-	O
BC	O
individuos	B-Taxon
.	O

Una	O
posibilidad	O
es	O
que	O
CEBPG	B-Protein
y	O
cada	O
uno	O
de	O
los	O
relacionados	O
antioxidante	B-Chemical
o	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
está	O
regulado	O
por	O
un	O
factor	O
de	O
transcripción	O
que	O
aún	O
no	O
se	O
ha	O
descubierto	O
y	O
/	O
o	O
tiene	O
un	O
sitio	B-Sequence
de	I-Sequence
reconocimiento	I-Sequence
eso	O
aún	O
no	O
se	O
conoce	O
y	O
no	O
estaba	O
en	O
la	O
base	O
de	O
datos	O
del	O
software	O
Genomatix	O
.	O

También	O
hay	O
más	O
de	O
una	O
explicación	O
posible	O
para	O
la	O
falta	O
de	O
correlación	O
observada	O
entre	O
CEBPG	B-Protein
y	O
antioxidante	B-Chemical
o	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
en	O
BC	O
individuos	B-Taxon
.	O

Por	O
ejemplo	O
,	O
el	O
no	O
-	O
BC	O
individual	B-Taxon
y	O
BC	O
individual	B-Taxon
los	O
grupos	O
no	O
están	O
perfectamente	O
emparejados	O
con	O
respecto	O
a	O
la	O
edad	O
,	O
el	O
sexo	O
o	O
el	O
historial	O
de	O
tabaquismo	O
(	O
Tabla	O
1	O
)	O
y	O
cada	O
uno	O
de	O
estos	O
factores	O
podría	O
contribuir	O
a	O
la	O
diferencia	O
observada	O
en	O
la	O
correlación	O
entre	O
los	O
grupos	O
.	O

Sin	O
embargo	O
,	O
la	O
falta	O
de	O
asociación	O
de	O
transcripción	B-Sequence
nivel	O
de	O
abundancia	O
para	O
CEBPG	B-Protein
,	O
XRCC1	B-Protein
,	O
ERCC5	B-Protein
,	O
GSTP1	B-Protein
,	O
SOD1	B-Protein
,	O
o	O
GPX1	B-Protein
con	O
la	O
edad	O
,	O
el	O
sexo	O
o	O
el	O
historial	O
de	O
tabaquismo	O
argumenta	O
en	O
contra	O
de	O
tal	O
explicación	O
.	O

Una	O
forma	O
de	O
examinar	O
esta	O
posibilidad	O
es	O
a	O
través	O
de	O
estudios	O
adicionales	O
,	O
más	O
amplios	O
y	O
más	O
similares	O
.	O

Otra	O
posible	O
explicación	O
es	O
que	O
cualquier	O
diferencia	O
en	O
NBCC	O
de	O
BC	O
individuos	B-Taxon
en	O
comparación	O
con	O
no	O
-	O
BC	O
individuos	B-Taxon
resultó	O
del	O
desarrollo	O
de	O
BC	O
,	O
en	O
lugar	O
de	O
ser	O
una	O
causa	O
hereditaria	O
de	O
mayor	O
riesgo	O
de	O
cáncer	O
.	O

La	O
mejor	O
manera	O
de	O
determinar	O
esto	O
será	O
realizar	O
un	O
estudio	O
prospectivo	O
.	O

En	O
tal	O
estudio	O
,	O
individuos	B-Taxon
emparejados	O
para	O
el	O
historial	O
de	O
tabaquismo	O
serán	O
monitoreados	O
para	O
el	O
desarrollo	O
de	O
BC	O
a	O
lo	O
largo	O
del	O
tiempo	O
.	O

la	O
correlación	O
de	O
transcripción	B-Sequence
valores	O
de	O
abundancia	O
para	O
CEBPG	B-Protein
relativo	O
a	O
transcripción	B-Sequence
valores	O
de	O
abundancia	O
para	O
cada	O
uno	O
de	O
los	O
antioxidante	B-Chemical
o	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
se	O
evaluará	O
.	O

Se	O
espera	O
que	O
la	O
mayor	O
incidencia	O
de	O
BC	O
sea	O
entre	O
los	O
fumadores	O
más	O
empedernidos	O
.	O

Entre	O
los	O
fumadores	O
empedernidos	O
emparejados	O
,	O
se	O
espera	O
que	O
CEBPG	B-Protein
se	O
correlacionará	O
significativamente	O
con	O
cada	O
uno	O
de	O
los	O
antioxidante	B-Chemical
o	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
entre	O
los	O
no	O
-	O
BC	O
individuos	B-Taxon
pero	O
no	O
correlacionado	O
en	O
BC	O
individuos	B-Taxon
.	O

Por	O
lo	O
tanto	O
,	O
existen	O
múltiples	O
explicaciones	O
posibles	O
para	O
los	O
hallazgos	O
observados	O
.	O

Sin	O
embargo	O
,	O
en	O
base	O
a	O
la	O
preponderancia	O
de	O
los	O
datos	O
disponibles	O
hasta	O
el	O
momento	O
,	O
concluimos	O
que	O
CEBPG	B-Protein
es	O
responsable	O
de	O
la	O
regulación	O
transcripcional	O
óptima	O
de	O
la	O
clave	O
antioxidante	B-Chemical
o	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
en	O
NBCC	O
y	O
que	O
hay	O
inter	O
-	O
individual	B-Taxon
variación	O
en	O
la	O
regulación	O
de	O
cada	O
uno	O
de	O
estos	O
genes	B-Sequence
por	O
CEBPG	B-Protein
.	O

Si	O
esta	O
conclusión	O
es	O
correcta	O
,	O
el	O
individuos	B-Taxon
en	O
mayor	O
riesgo	O
de	O
BC	O
serán	O
aquellos	O
con	O
el	O
historial	O
de	O
tabaquismo	O
más	O
extremo	O
combinado	O
con	O
una	O
regulación	O
subóptima	O
de	O
la	O
mayor	O
cantidad	O
de	O
antioxidante	B-Chemical
y	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
.	O

Esto	O
,	O
a	O
su	O
vez	O
,	O
conduce	O
a	O
una	O
mayor	O
representación	O
entre	O
BC	O
individuos	B-Taxon
de	O
individuos	B-Taxon
con	O
falta	O
de	O
correlación	O
entre	O
CEBPG	B-Protein
y	O
cada	O
uno	O
de	O
los	O
afectados	O
antioxidante	B-Chemical
y/o	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
.	O

CEBPG	B-Protein
es	O
un	O
factor	O
de	O
transcripción	O
CEBP	O
truncado	O
[	O
19	O
]	O
y	O
posee	O
el	O
secuencias	B-Sequence
necesario	O
para	O
ADN	B-Sequence
unión	O
y	O
formación	O
de	O
heterodímeros	O
,	O
pero	O
carece	O
de	O
la	O
secuencias	B-Sequence
necesaria	O
para	O
la	O
transactivación	O
[	O
20	O
]	O
.	O

CEBPG	B-Protein
forma	O
heterodímeros	O
con	O
otros	O
miembros	O
de	O
la	O
familia	O
CEBP	O
y	O
en	O
otros	O
tejidos	O
esto	O
conduce	O
a	O
un	O
aumento	O
[	O
21	O
]	O
o	O
una	O
disminución	O
[	O
20	O
]	O
de	O
la	O
transcripción	O
del	O
compuesto	O
regulado	O
gene	B-Sequence
.	O

CEBPG	B-Protein
Se	O
sabe	O
que	O
tiene	O
un	O
efecto	O
estimulante	O
sobre	O
el	O
IL-6	B-Protein
y	O
IL	B-Protein
-	I-Protein
8	I-Protein
promotores	B-Sequence
en	O
Célula	B-Cell
B	I-Cell
líneas	O
[	O
21	O
]	O
,	O
y	O
también	O
puede	O
actuar	O
como	O
un	O
regulador	O
negativo	O
dominante	O
de	O
CEBPA	B-Protein
y	O
CEBPB	B-Protein
en	O
fibroblasto	B-Cell
y	O
Célula	B-Cell
B	I-Cell
líneas	O
[	O
20	O
]	O
.	O

Los	O
datos	O
de	O
CEBPG	B-Protein
knockear	O
ratones	B-Taxon
apoyar	O
un	O
papel	O
para	O
CEBPG	B-Protein
en	O
la	O
protección	O
de	O
los	O
pulmones	O
del	O
daño	O
oxidante	O
.	O

CEBPG	B-Protein
-	O
/	O
-	O
knockear	O
ratones	B-Taxon
son	O
sanos	O
al	O
nacer	O
pero	O
comienzan	O
a	O
morir	O
dentro	O
de	O
las	O
24	O
horas	O
,	O
y	O
el	O
examen	O
histológico	O
revela	O
pulmones	O
enfisematosos	O
[	O
22	O
]	O
.	O

En	O
humanos	B-Taxon
,	O
el	O
riesgo	O
de	O
enfisema	O
está	O
asociado	O
con	O
antioxidante	B-Chemical
capacidad	O
[	O
23	O
]	O
,	O
y	O
existe	O
una	O
fuerte	O
correlación	O
entre	O
el	O
riesgo	O
de	O
enfisema	O
y	O
el	O
riesgo	O
de	O
BC	O
.	O

Sin	O
embargo	O
,	O
será	O
importante	O
obtener	O
evidencia	O
experimental	O
directa	O
en	O
NBCCs	O
para	O
el	O
papel	O
de	O
CEBPG	B-Protein
en	O
la	O
regulación	O
de	O
la	O
antioxidante	B-Chemical
y	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
incluidos	O
en	O
este	O
estudio	O
.	O

Correlacion	O
entre	O
CEBPG	B-Protein
y	O
objetivo	O
transcripción	B-Sequence
de	I-Sequence
genes	I-Sequence
niveles	O
pueden	O
no	O
estar	O
asociados	O
con	O
la	O
correlación	O
en	O
el	O
proteína	B-Chemical
nivel	O
.	O

En	O
este	O
estudio	O
,	O
E2F1	B-Protein
correlación	O
con	O
ADN	B-Sequence
reparar	O
y	O
antioxidante	B-Chemical
genes	B-Sequence
fue	O
menor	O
que	O
la	O
correlación	O
observada	O
con	O
CEBPG	B-Protein
,	O
y	O
el	O
E2F1	B-Protein
se	O
observó	O
correlación	O
tanto	O
en	O
no	O
-	O
BC	O
individuos	B-Taxon
así	O
como	O
BC	O
individuos	B-Taxon
.	O

La	O
correlación	O
mantenida	O
de	O
E2F1	B-Protein
con	O
ADN	B-Sequence
reparar	O
y	O
antioxidante	B-Chemical
genes	B-Sequence
en	O
BC	O
individuos	B-Taxon
sugiere	O
que	O
esta	O
función	O
está	O
más	O
estrictamente	O
controlada	O
en	O
la	O
población	O
y	O
no	O
juega	O
un	O
papel	O
en	O
la	O
determinación	O
del	O
riesgo	O
de	O
BC	O
.	O

E2F1	B-Protein
previamente	O
se	O
ha	O
informado	O
que	O
regula	O
la	O
transcripción	O
de	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
de	I-Sequence
enzimas	I-Sequence
en	O
otra	O
célula	B-Cell
tipos	O
,	O
incluidos	O
los	O
primarios	O
humano	B-Taxon
fibroblastos	B-Cell
y	O
ratón	B-Taxon
células	B-Cell
epidérmicas	I-Cell
[	O
24	O
,	O
25	O
]	O
.	O

Claramente	O
esto	O
tendría	O
valor	O
de	O
supervivencia	O
ya	O
que	O
ADN	B-Sequence
reparar	O
gene	B-Sequence
up	O
-	O
regulación	O
en	O
respuesta	O
a	O
E2F1	B-Protein
proporciona	O
adicional	O
ADN	B-Sequence
reparar	O
cuando	O
el	O
ADN	B-Sequence
se	O
está	O
replicando	O
y	O
es	O
particularmente	O
vulnerable	O
al	O
daño	O
.	O

Evaluación	O
epidemiológica	O
de	O
la	O
correlación	O
entre	O
un	O
determinado	O
variación	B-Sequence
en	I-Sequence
la	I-Sequence
secuencia	I-Sequence
de	I-Sequence
ADN	I-Sequence
,	O
o	O
polimorfismo	B-Sequence
y	O
el	O
riesgo	O
de	O
BC	O
ha	O
sido	O
un	O
paradigma	O
dominante	O
durante	O
muchos	O
años	O
.	O

Hasta	O
el	O
momento	O
,	O
estos	O
esfuerzos	O
han	O
tenido	O
escaso	O
éxito	O
[	O
26	O
]	O
.	O

Una	O
limitación	O
común	O
en	O
el	O
diseño	O
de	O
tales	O
estudios	O
es	O
que	O
implican	O
la	O
evaluación	O
de	O
un	O
solo	O
polimorfismo	B-Sequence
u	O
ocasionalmente	O
,	O
algunos	O
polimorfismos	B-Sequence
.	O

Además	O
,	O
aunque	O
el	O
polimorfismo	B-Sequence
evaluado	O
típicamente	O
reside	O
dentro	O
de	O
un	O
gene	B-Sequence
Se	O
sabe	O
que	O
protege	O
el	O
epitelio	O
bronquial	O
de	O
carcinógenos	O
,	O
oxidantes	O
o	O
ADN	B-Sequence
daño	O
,	O
la	O
selección	O
del	O
particular	O
polimorfismo	B-Sequence
porque	O
el	O
estudio	O
es	O
en	O
gran	O
medida	O
empírico	O
y	O
no	O
se	O
basa	O
en	O
propiedades	O
funcionales	O
conocidas	O
.	O

Estos	O
son	O
problemas	O
debido	O
a	O
múltiples	O
infrecuentes	O
polimorfismos	B-Sequence
en	O
diferentes	O
sitios	B-Sequence
todos	O
pueden	O
contribuir	O
al	O
riesgo	O
y	O
a	O
menos	O
que	O
la	O
clave	O
polimorfismos	B-Sequence
puede	O
identificarse	O
a	O
través	O
de	O
una	O
prueba	O
funcional	O
,	O
una	O
evaluación	O
estadísticamente	O
válida	O
requeriría	O
poblaciones	O
de	O
estudio	O
mucho	O
más	O
grandes	O
[	O
27	O
]	O
.	O

Los	O
hallazgos	O
de	O
este	O
estudio	O
respaldan	O
un	O
enfoque	O
novedoso	O
para	O
identificar	O
biomarcadores	O
clínicamente	O
útiles	O
.	O

Según	O
el	O
paradigma	O
utilizado	O
en	O
este	O
estudio	O
,	O
a	O
)	O
un	O
fenotipo	O
normal	O
resulta	O
de	O
la	O
transcripción	O
regulada	O
de	O
un	O
grupo	O
de	O
genes	B-Sequence
por	O
uno	O
o	O
más	O
factores	O
de	O
transcripción	O
,	O
b	O
)	O
el	O
correspondiente	O
fenotipo	O
que	O
confiere	O
riesgo	O
o	O
enfermedad	O
resulta	O
de	O
una	O
interacción	O
subóptima	O
entre	O
esos	O
mismos	O
genes	B-Sequence
,	O
y	O
c	O
)	O
cada	O
fenotipo	O
es	O
identificable	O
y	O
distinguible	O
a	O
través	O
de	O
multiplexación	O
virtual	O
transcripción	B-Sequence
analisis	O
de	O
abundancia	O

Los	O
datos	O
presentados	O
aquí	O
apoyan	O
la	O
utilidad	O
de	O
este	O
paradigma	O
para	O
identificar	O
genes	B-Sequence
asociado	O
con	O
el	O
riesgo	O
de	O
BC	O
.	O

El	O
siguiente	O
paso	O
será	O
identificar	O
polimorfismos	B-Sequence
que	O
afectan	O
la	O
regulación	O
de	O
XRCC1	B-Protein
,	O
ERCC5	B-Protein
,	O
GSTP1	B-Protein
,	O
SOD1	B-Protein
,	O
y	O
GPX1	B-Protein
por	O
CEBPG	B-Protein
.	O

Tal	O
polimorfismos	B-Sequence
debe	O
producir	O
biomarcadores	O
adecuados	O
para	O
muestras	O
más	O
fácilmente	O
accesibles	O
,	O
como	O
sangre	O
periférica	O
o	O
frotis	O
bucales	O
.	O

Un	O
biomarcador	O
que	O
combina	O
polimorfismos	B-Sequence
que	O
afectan	O
la	O
regulación	O
con	O
los	O
que	O
afectan	O
la	O
función	O
de	O
antioxidante	B-Chemical
y	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
es	O
probable	O
que	O
sea	O
el	O
más	O
preciso	O
para	O
identificar	O
individuos	B-Taxon
en	O
riesgo	O
de	O
BC	O
.	O

Biomarcadores	O
que	O
identifican	O
con	O
precisión	O
individuos	B-Taxon
en	O
riesgo	O
de	O
BC	O
mejorará	O
la	O
eficacia	O
de	O
los	O
ensayos	O
clínicos	O
de	O
quimioprevención	O
y	O
detección	O
temprana	O
.	O

La	O
variación	O
entre	O
muestras	O
observada	O
en	O
presencia	O
de	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
inhibidores	B-Chemical
de	O
PCR	O
proporciona	O
evidencia	O
que	O
respalda	O
la	O
necesidad	O
de	O
incluir	O
un	O
estándar	O
interno	O
en	O
cada	O
PCR	O
cuantitativa	O
transcripción	B-Sequence
medida	O
de	O
la	O
abundancia	O
.	O

Incluir	O
tales	O
patrones	O
internos	O
en	O
forma	O
de	O
mezclas	O
estandarizadas	O
de	O
patrones	O
internos	O
mejora	O
la	O
reproducibilidad	O
de	O
transcripción	B-Sequence
medición	O
de	O
la	O
abundancia	O
y	O
permite	O
el	O
desarrollo	O
de	O
una	O
base	O
de	O
datos	O
estandarizada	O
que	O
comprende	O
virtualmente	O
-	O
multiplexado	O
transcripción	B-Sequence
datos	O
de	O
abundancia	O
.	O

Virtualmente	O
-	O
multiplexado	O
transcripción	B-Sequence
Los	O
datos	O
de	O
abundancia	O
son	O
muy	O
adecuados	O
para	O
la	O
identificación	O
de	O
genes	B-Sequence
que	O
se	O
han	O
correlacionado	O
transcripción	B-Sequence
valores	O
de	O
abundancia	O
.	O

Correlación	O
en	O
el	O
transcripción	B-Sequence
el	O
nivel	O
de	O
abundancia	O
es	O
un	O
factor	O
importante	O
propiedad	B-Sequence
de	O
genes	B-Sequence
que	O
están	O
co-regulados	O
a	O
nivel	O
de	O
transcripción	O
.	O

Conclusión	O

Concluimos	O
que	O
en	O
no	O
-	O
BC	O
individuos	B-Taxon
,	O
CEBPG	B-Protein
regula	O
la	O
transcripción	O
de	O
claves	O
antioxidante	B-Chemical
o	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
en	O
NBCC	O
y	O
que	O
en	O
fumadores	O
que	O
desarrollan	O
BC	O
,	O
CEBPG	B-Protein
la	O
regulación	O
es	O
subóptima	O
para	O
un	O
número	O
suficiente	O
de	O
antioxidante	B-Chemical
y/o	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
para	O
causar	O
un	O
mayor	O
riesgo	O
.	O

Conflicto	O
de	O
intereses	O

JCW	O
y	O
ELC	O
tienen	O
cada	O
uno	O
una	O
participación	O
accionaria	O
significativa	O
en	O
Gene	B-Sequence
expreso	O
,	O
inc.	O
,	O
que	O
produce	O
y	O
comercializa	O
StaRT	O
-	O
PCR	O
(	O
TM	O
)	O
reactivos	B-Chemical
utilizado	O
en	O
este	O
estudio	O
.	O

Contribuciones	O
de	O
los	O
autores	O

DNM	O
participó	O
en	O
el	O
diseño	O
del	O
estudio	O
,	O
realizó	O
la	O
identificación	O
TF	O
,	O
llevó	O
a	O
cabo	O
las	O
mediciones	O
de	O
TA	O
,	O
coordinó	O
y	O
participó	O
en	O
el	O
análisis	O
estadístico	O
y	O
redactó	O
el	O
manuscrito	O
.	O

ELC	O
contribuyó	O
con	O
los	O
datos	O
preliminares	O
,	O
participó	O
en	O
el	O
diseño	O
del	O
estudio	O
y	O
llevó	O
a	O
cabo	O
las	O
mediciones	O
de	O
TA	O
.	O

SAK	O
realizó	O
el	O
análisis	O
estadístico	O
para	O
la	O
interpretación	O
de	O
los	O
datos	O
.	O

DAH	O
y	O
YY	O
dieron	O
su	O
consentimiento	O
a	O
los	O
pacientes	O
y	O
obtuvieron	O
las	O
muestras	O
primarias	O
necesarias	O
para	O
el	O
estudio	O
de	O
acuerdo	O
con	O
las	O
normas	O
del	O
IRB	O
.	O

JCW	O
concibe	O
el	O
estudio	O
,	O
participó	O
en	O
su	O
diseño	O
y	O
coordinación	O
,	O
y	O
ayudó	O
a	O
redactar	O
el	O
manuscrito	O
.	O

Todos	O
los	O
autores	O
leyeron	O
y	O
aprobaron	O
el	O
manuscrito	O
final	O
.	O

Historial	O
previo	O
a	O
la	O
publicación	O

Se	O
puede	O
acceder	O
al	O
historial	O
previo	O
a	O
la	O
publicación	O
de	O
este	O
artículo	O
aquí	O
:	O

Agradecimientos	O

Estos	O
estudios	O
y	O
la	O
preparación	O
del	O
manuscrito	O
fueron	O
respaldados	O
por	O
subvenciones	O
del	O
Instituto	O
Nacional	O
del	O
Cáncer	O
(	O
NCI	O
)	O
,	O
incluidos	O
los	O
CA85147	O
y	O
CA	O
95806	O
,	O
y	O
el	O
Fondo	O
de	O
Investigación	O
del	O
Cáncer	O
George	O
Isaac	O
.	O

Inicio	O
-	O
PCR	O
reactivos	B-Chemical
para	O
medir	O
algunos	O
de	O
los	O
genes	B-Sequence
fueron	O
proporcionados	O
sin	O
costo	O
por	O
Gene	B-Sequence
expreso	O
,	O
inc	O
.	O

Ni	O
el	O
NCI	O
ni	O
Gene	B-Sequence
expreso	O
,	O
inc.	O
tuvo	O
algún	O
papel	O
en	O
el	O
diseño	O
del	O
estudio	O
,	O
la	O
recopilación	O
,	O
el	O
análisis	O
o	O
la	O
interpretación	O
de	O
los	O
datos	O
,	O
la	O
redacción	O
del	O
manuscrito	O
o	O
la	O
decisión	O
de	O
enviar	O
el	O
manuscrito	O
para	O
su	O
publicación	O
.	O

Figuras	O
y	O
Tablas	O

Figura	O
1	O

Correlación	O
de	O
cada	O
factor	O
de	O
transcripción	O
con	O
XRCC1	B-Protein
,	O
ERCC5	B-Protein
,	O
GSTP1	B-Protein
,	O
SOD1	B-Protein
,	O
o	O
GPX1	B-Protein
.	O

(	O
a-f	O
)	O
Cada	O
panel	O
presenta	O
los	O
coeficientes	O
de	O
correlación	O
(	O
valores	O
r	O
)	O
para	O
un	O
factor	O
de	O
transcripción	O
en	O
relación	O
con	O
cada	O
uno	O
de	O
los	O
cinco	O
genes	B-Sequence
:	O
(	O
a	O
)	O
CEBPB	B-Protein
,	O
(	O
B	O
)	O
CEBPG	B-Protein
,	O
(	O
C	O
)	O
E2F1	B-Protein
,	O
(	O
D	O
)	O
E2F3	B-Protein
,	O
(	O
mi	O
)	O
E2F6	B-Protein
,	O
(	O
f	O
)	O
EVI1	B-Protein
.	O

El	O
valor	O
de	O
p	O
para	O
cada	O
correlación	O
significativa	O
se	O
proporciona	O
encima	O
de	O
la	O
barra	O
.	O

Para	O
CEBPG	B-Protein
,	O
presentado	O
en	O
el	O
panel	O
b	O
,	O
la	O
diferencia	O
en	O
el	O
valor	O
r	O
entre	O
no	O
-	O
BC	O
individuos	B-Taxon
y	O
BC	O
individuos	B-Taxon
fue	O
significativo	O
o	O
casi	O
significativo	O
para	O
cada	O
correlación	O
gene	B-Sequence
y	O
el	O
valor	O
p	O
para	O
cada	O
comparación	O
se	O
proporciona	O
debajo	O
del	O
par	O
de	O
barras	O
correspondiente	O
.	O

Figura	O
2	O

Representación	O
de	O
diagrama	O
de	O
dispersión	O
de	O
la	O
correlación	O
bivariada	O
de	O
CEBPG	B-Protein
con	O
XRCC1	B-Protein
.	O

(	O
un	O
,	O
b	O
)	O
CEBPG	B-Protein
/	O
XRCC1	B-Protein
datos	O
de	O
la	O
Figura	O
1b	O
presentados	O
como	O
diagramas	O
de	O
dispersión	O
:	O
(	O
a	O
)	O
no	O
BC	O
individuos	B-Taxon
,	O
(	O
b	O
)	O
aC	O
individuos	B-Taxon
.	O

tabla	O
1	O

Datos	O
demográficos	O
de	O
los	O
pacientes	O
de	O
los	O
que	O
se	O
obtuvieron	O
las	O
muestras	O
de	O
NBCC	O
.	O

paquete	O
de	O
años	O
;	O
2Carcinoma	O
no	O
broncogénico	O
individual	B-Taxon
;	O
3Blanco	O
;	O
4Afroamericano	O
;	O
5No	O
fumador	O
;	O
6No	O
disponible	O
;	O
7	O
hispano	O
;	O
8	O
Carcinoma	O
broncogénico	O
individual	B-Taxon
;	O
9No	O
-	O
pequeño	O
célula	B-Cell
cáncer	O
de	O
pulmón	O
;	O
10	O
Carcinoma	O
escamoso	O
;	O
11Pequeño	O
célula	B-Cell
cáncer	O
de	O
pulmón	O
;	O
12	O
Carcinoma	O
in	O
situ	O
;	O
13Adenocarcinoma	O
;	O
14	O
Cáncer	O
broncogénico	O
,	O
histología	O
no	O
especificada	O
;	O
15Carcinoma	O
poco	O
diferenciado	O
.	O

Tabla	O
2	O

Secuencia	B-Sequence
para	O
cada	O
cebador	B-Sequence
utilizado	O
para	O
StaRT	O
-	O
PCR	O
virtualmente	O
-	O
multiplexado	O
transcripción	B-Sequence
medición	O
de	O
la	O
abundancia	O
o	O
para	O
la	O
preparación	O
de	O
patrones	O
internos	O
(	O
CT	O
)	O
[	O
15	O
]	O
.	O

Tabla	O
3	O

Virtualmente	O
-	O
multiplexado	O
transcripción	B-Sequence
datos	O
de	O
abundancia	O
.	O

Virtualmente	O
-	O
multiplexado	O
transcripción	B-Sequence
datos	O
de	O
abundancia	O
para	O
cada	O
gene	B-Sequence
(	O
en	O
forma	O
de	O
moléculas	B-Chemical
/	O
106	O
beta	B-Protein
-	I-Protein
actina	I-Protein
moléculas	B-Chemical
)	O
de	O
todos	O
los	O
experimentos	O
se	O
incluyeron	O
en	O
la	O
misma	O
base	O
de	O
datos	O
de	O
expresión	O
estandarizada	O
(	O
SED	O
)	O
.	O

Estos	O
datos	O
ahora	O
son	O
directamente	O
comparables	O
a	O
los	O
previamente	O
publicados	O
virtualmente	O
-	O
multiplexados	O
transcripción	B-Sequence
datos	O
de	O
abundancia	O
de	O
este	O
laboratorio	O
[	O
15	O
]	O
,	O
o	O
virtualmente	O
-	O
multiplexados	O
transcripción	B-Sequence
datos	O
de	O
abundancia	O
recopilados	O
por	O
otros	O
que	O
utilizan	O
el	O
Centro	O
de	O
Medición	O
de	O
Expresión	O
Estandarizada	O
(	O
SEM	O
)	O
financiado	O
por	O
el	O
NCI	O
(	O
R24	O
CA	O
95806	O
)	O
.	O

Los	O
datos	O
presentados	O
aquí	O
representan	O
más	O
de	O
6	O
000	O
Virtualmente	O
-	O
multiplexados	O
transcripción	B-Sequence
mediciones	O
de	O
abundancia	O
realizadas	O
en	O
múltiples	O
experimentos	O
.	O

los	O
dieciséis	O
antioxidante	B-Chemical
o	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
y	O
cada	O
uno	O
de	O
los	O
seis	O
factores	O
de	O
transcripción	O
a	O
excepción	O
de	O
E2F1	B-Protein
se	O
midieron	O
en	O
cada	O
muestra	O
de	O
NBCC	O
de	O
49	O
individuos	B-Taxon
(	O
24	O
no	O
-	O
BC	O
individuos	B-Taxon
y	O
25	O
a.C	O
.	O
individuos	B-Taxon
)	O
.	O

1ND	O
,	O
no	O
detectable	O
(	O
cuando	O
60	O
moléculas	B-Chemical
de	O
plantilla	O
competitiva	O
(	O
CT	O
)	O
se	O
añadieron	O
a	O
la	O
reacción	O
,	O
se	O
detectó	O
CT	O
pero	O
no	O
la	O
plantilla	O
nativa	O
.	O
)	O

2NA	O
,	O
No	O
disponible	O
.	O

E2F1	B-Protein
se	O
midió	O
en	O
todas	O
las	O
muestras	O
excepto	O
en	O
una	O
BC	O
individual	B-Taxon
(	O
24	O
no	O
-	O
BC	O
individuos	B-Taxon
y	O
24	O
a.C	O
.	O
individuos	B-Taxon
)	O
.	O

Tabla	O
4	O

Análisis	O
bivariado	O
de	O
virtualmente	O
-	O
multiplexado	O
transcripción	B-Sequence
valores	O
de	O
datos	O
de	O
abundancia	O
para	O
cada	O
antioxidante	B-Chemical
o	O
ADN	B-Sequence
reparar	O
gene	B-Sequence
frente	O
a	O
cada	O
factor	O
de	O
transcripción	O
.	O

La	O
correlación	O
de	O
virtualmente	O
transformada	O
logarítmicamente	O
-	O
multiplexada	O
transcripción	B-Sequence
datos	O
de	O
abundancia	O
(	O
Tabla	O
3	O
)	O
de	O
cada	O
uno	O
de	O
los	O
seis	O
factores	O
de	O
transcripción	O
con	O
cada	O
uno	O
de	O
los	O
dieciséis	O
antioxidantes	O
o	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
estaba	O
determinado	O
.	O

La	O
transformación	O
fue	O
necesaria	O
debido	O
a	O
la	O
amplia	O
gama	O
de	O
expresión	O
de	O
cada	O
gene	B-Sequence
entre	O
las	O
muestras	O
.	O

Se	O
presentan	O
el	O
coeficiente	O
de	O
correlación	O
(	O
valor	O
r	O
)	O
y	O
el	O
nivel	O
de	O
significancia	O
(	O
valor	O
p	O
)	O
para	O
cada	O
correlación	O
.	O

La	O
significancia	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
se	O
determinó	O
utilizando	O
una	O
prueba	O
de	O
dos	O
colas	O
luego	O
del	O
ajuste	O
de	O
Bonferroni	O
para	O
seis	O
comparaciones	O
múltiples	O
(	O
comparación	O
de	O
cada	O
uno	O
de	O
los	O
seis	O
factores	O
de	O
transcripción	O
con	O
cada	O
uno	O
de	O
los	O
antioxidantes	O
o	O
ADN	B-Sequence
reparar	O
genes	B-Sequence
)	O
.	O

*	O
valores	O
para	O
E2F1	B-Protein
obtenido	O
en	O
todos	O
menos	O
uno	O
BC	O
individuos	B-Taxon
.	O

Amiloidosis	O
persistente	O
después	O
de	O
la	O
supresión	O
de	O
una	B-Protein
beta	I-Protein
producción	O
en	O
un	O
transgénico	B-Sequence
Modelo	O
de	O
la	O
enfermedad	O
de	O
Alzheimer	O

Resumen	O

Antecedentes	O

Las	O
proteasas	O
(	O
secretasas	O
)	O
que	O
escinden	O
amiloide	B-Protein
-	I-Protein
beta	I-Protein
(	O
una	B-Protein
beta	I-Protein
)	O
péptido	B-Sequence
desde	O
el	O
proteína	B-Protein
precursora	I-Protein
de	I-Protein
amiloide	I-Protein
(	O
APLICACIÓN	B-Protein
)	O
han	O
sido	O
objeto	O
de	O
considerable	O
investigación	O
en	O
el	O
desarrollo	O
de	O
tratamientos	O
para	O
la	O
enfermedad	O
de	O
Alzheimer	O
.	O

La	O
predicción	O
ha	O
sido	O
que	O
reducir	O
una	B-Protein
beta	I-Protein
la	O
producción	O
en	O
el	O
cerebro	O
,	O
incluso	O
después	O
de	O
la	O
aparición	O
de	O
los	O
síntomas	O
clínicos	O
y	O
el	O
desarrollo	O
de	O
la	O
patología	O
asociada	O
,	O
facilitará	O
la	O
reparación	O
del	O
tejido	O
dañado	O
y	O
la	O
eliminación	O
de	O
las	O
lesiones	O
amiloides	O
.	O

Sin	O
embargo	O
,	O
no	O
hay	O
estudios	O
a	O
largo	O
plazo	O
que	O
utilicen	O
animal	B-Taxon
todavía	O
se	O
han	O
realizado	O
modelos	O
de	O
patología	O
amiloide	O
para	O
probar	O
esta	O
hipótesis	O
.	O

Métodos	O
y	O
Hallazgos	O

hemos	O
generado	O
un	O
transgénico	B-Sequence
ratón	B-Taxon
modelo	O
que	O
genéticamente	B-Sequence
imita	O
la	O
detención	O
de	O
una	B-Protein
beta	I-Protein
producción	O
esperada	O
del	O
tratamiento	O
con	O
secretasa	O
inhibidores	B-Chemical
.	O

Estas	O
ratones	B-Taxon
sobreexpresar	O
mutante	B-Sequence
APLICACIÓN	B-Protein
a	O
partir	O
de	O
una	O
vector	B-Sequence
que	O
puede	O
ser	O
regulada	O
por	O
la	O
doxiciclina	O
.	O

En	O
condiciones	O
normales	O
,	O
la	O
expresión	O
de	O
alto	O
nivel	O
de	O
APLICACIÓN	B-Protein
induce	O
rápidamente	O
una	O
patología	O
amiloide	O
fulminante	O
.	O

Mostramos	O
que	O
la	O
administración	O
de	O
doxiciclina	O
inhibe	O
transgénico	B-Sequence
APLICACIÓN	B-Protein
expresión	O
en	O
más	O
del	O
95	O
%	O
y	O
reduce	O
una	B-Protein
beta	I-Protein
producción	O
a	O
niveles	O
encontrados	O
en	O
no	O
transgénicos	O
ratones	B-Taxon
.	O

Supresión	O
de	O
transgénico	B-Sequence
una	B-Protein
beta	I-Protein
la	O
síntesis	O
en	O
este	O
modelo	O
detiene	O
abruptamente	O
la	O
progresión	O
de	O
la	O
patología	O
amiloide	O
.	O

Sin	O
embargo	O
,	O
la	O
formación	O
y	O
la	O
disgregación	O
de	O
los	O
depósitos	O
de	O
amiloide	O
parecen	O
estar	O
en	O
desequilibrio	O
ya	O
que	O
las	O
placas	O
requieren	O
mucho	O
más	O
tiempo	O
para	O
dispersarse	O
que	O
para	O
ensamblarse	O
.	O

Ratones	B-Taxon
en	O
el	O
cual	O
APLICACIÓN	B-Protein
la	O
síntesis	O
se	O
suprimió	O
hasta	O
6	O
meses	O
después	O
de	O
la	O
formación	O
de	O
una	B-Protein
beta	I-Protein
los	O
depósitos	O
retienen	O
una	O
carga	O
amiloide	O
considerable	O
,	O
con	O
pocos	O
signos	O
de	O
eliminación	O
activa	O
.	O

Conclusión	O

Este	O
estudio	O
demuestra	O
que	O
las	O
lesiones	O
amiloides	O
en	O
transgénico	B-Sequence
ratones	B-Taxon
son	O
estructuras	O
altamente	O
estables	O
in	O
vivo	O
que	O
se	O
desagregan	O
lentamente	O
.	O

Nuestros	O
hallazgos	O
sugieren	O
que	O
arrestar	O
una	B-Protein
beta	I-Protein
la	O
producción	O
en	O
pacientes	O
con	O
enfermedad	O
de	O
Alzheimer	O
debería	O
detener	O
la	O
progresión	O
de	O
la	O
patología	O
,	O
pero	O
ese	O
tratamiento	O
temprano	O
puede	O
ser	O
imperativo	O
,	O
ya	O
que	O
parece	O
que	O
los	O
depósitos	O
de	O
amiloide	O
,	O
una	O
vez	O
formados	O
,	O
requerirán	O
una	O
intervención	O
adicional	O
para	O
eliminarlos	O
.	O

Introducción	O

Hace	O
más	O
de	O
una	O
década	O
,	O
la	O
hipótesis	O
de	O
la	O
cascada	O
amiloide	O
predijo	O
que	O
los	O
niveles	O
elevados	O
de	O
amiloide	B-Protein
-	I-Protein
beta	I-Protein
(	O
una	B-Protein
beta	I-Protein
)	O
péptido	B-Sequence
conducen	O
a	O
patologías	O
secundarias	O
que	O
finalmente	O
culminan	O
en	O
la	O
aparición	O
de	O
la	O
enfermedad	O
de	O
Alzheimer	O
(	O
EA	O
)	O
[	O
1	O
]	O
.	O

Los	O
primeros	O
apoyos	O
a	O
esta	O
hipótesis	O
provinieron	O
de	O
genético	B-Sequence
estudios	O
que	O
relacionan	O
la	O
EA	O
de	O
inicio	O
temprano	O
con	O
mutaciones	B-Sequence
en	O
el	O
proteína	B-Protein
precursora	I-Protein
de	I-Protein
amiloide	I-Protein
(	O
APLICACIÓN	B-Protein
)	O
,	O
a	O
partir	O
del	O
cual	O
una	B-Protein
beta	I-Protein
se	O
deriva	O
,	O
y	O
presenilinas	B-Protein
1	I-Protein
y	I-Protein
2	I-Protein
,	O
que	O
son	O
componentes	O
intercambiables	O
de	O
una	O
endoproteasa	O
complejo	B-GENE
que	O
libera	O
una	B-Protein
beta	I-Protein
desde	O
APLICACIÓN	B-Protein
(	O
para	O
revisión	O
ver	O
[	O
2	O
,	O
3	O
]	O
)	O
.	O

Si	O
,	O
como	O
se	O
predijo	O
,	O
la	O
sobreproducción	O
de	O
una	B-Protein
beta	I-Protein
inicia	O
la	O
cascada	O
de	O
eventos	O
que	O
conducen	O
a	O
la	O
enfermedad	O
,	O
luego	O
las	O
estrategias	O
terapéuticas	O
que	O
reducen	O
una	B-Protein
beta	I-Protein
niveles	O
deben	O
detener	O
o	O
revertir	O
la	O
progresión	O
de	O
péptido	B-Sequence
a	O
la	O
demencia	O

Las	O
primeras	O
pruebas	O
de	O
los	O
ensayos	O
clínicos	O
de	O
anticuerpo	B-GENE
-	O
aclaramiento	O
mediado	O
,	O
uno	O
de	O
los	O
primeros	O
una	B-Protein
beta	I-Protein
#	O
¿NOMBRE	O
?	O
humanos	B-Taxon
,	O
sugirió	O
que	O
los	O
tratamientos	O
diseñados	O
para	O
reducir	O
la	O
carga	O
de	O
amiloide	O
pueden	O
ser	O
realmente	O
beneficiosos	O
.	O

Aunque	O
los	O
ensayos	O
se	O
detuvieron	O
debido	O
a	O
los	O
efectos	O
adversos	O
en	O
un	O
subconjunto	O
de	O
voluntarios	O
[	O
4	O
,	O
5	O
]	O
,	O
un	O
análisis	O
posterior	O
de	O
varios	O
pacientes	O
encontró	O
evidencia	O
de	O
que	O
la	O
patología	O
amiloide	O
y	O
,	O
en	O
menor	O
grado	O
,	O
la	O
función	O
cognitiva	O
mejoró	O
en	O
proporción	O
al	O
título	O
del	O
paciente	O
de	O
una	B-Protein
beta	I-Protein
#	O
¿NOMBRE	O
?	O
anticuerpo	B-GENE
[	O
6	O
,	O
7	O
]	O
.	O

Si	O
bien	O
este	O
enfoque	O
es	O
prometedor	O
,	O
la	O
exposición	O
constante	O
a	O
anticuerpos	B-GENE
que	O
reconocen	O
un	O
epítopo	B-Sequence
altamente	O
enriquecido	O
en	O
el	O
cerebro	O
puede	O
tener	O
efectos	O
secundarios	O
inesperados	O
que	O
limitarán	O
su	O
uso	O
a	O
largo	O
plazo	O
.	O

Un	O
enfoque	O
alternativo	O
que	O
se	O
está	O
buscando	O
activamente	O
para	O
el	O
tratamiento	O
futuro	O
de	O
la	O
EA	O
busca	O
reducir	O
una	B-Protein
beta	I-Protein
niveles	O
al	O
limitar	O
su	O
producción	O
a	O
partir	O
del	O
precursor	O
proteína	B-Chemical
APLICACIÓN	B-Protein
.	O

péptido	B-Sequence
una	B-Protein
beta	I-Protein
se	O
libera	O
de	O
APLICACIÓN	B-Protein
por	O
la	O
acción	O
de	O
dos	O
enzimas	B-Sequence
,	O
los	O
beta	B-Protein
-	I-Protein
enzima	I-Protein
de	I-Protein
escisión	I-Protein
de	I-Protein
APP	I-Protein
1	I-Protein
(	O
BACE1	B-Protein
)	O
y	O
gamma	O
-	O
secretasa	O
,	O
que	O
escinden	O
la	O
holoproteína	O
en	O
el	O
N	B-Sequence
-	I-Sequence
y	I-Sequence
C	I-Sequence
-	I-Sequence
terminales	I-Sequence
de	O
una	B-Protein
beta	I-Protein
,	O
respectivamente	O
.	O

Varios	O
inhibidores	B-Chemical
de	O
gamma	O
-	O
secretasa	O
ya	O
se	O
han	O
producido	O
[	O
8	O
,	O
9	O
]	O
,	O
y	O
pequeñas	O
inhibidores	B-Chemical
de	I-Chemical
moléculas	I-Chemical
de	O
beta	B-Protein
-	I-Protein
enzima	I-Protein
de	I-Protein
escisión	I-Protein
de	I-Protein
APP	I-Protein
1	I-Protein
se	O
están	O
desarrollando	O
actualmente	O
[	O
10	O
,	O
11	O
]	O
.	O

La	O
eficacia	O
a	O
largo	O
plazo	O
de	O
este	O
enfoque	O
,	O
ya	O
sea	O
en	O
humanos	B-Taxon
o	O
sistemas	O
modelo	O
,	O
sin	O
embargo	O
,	O
no	O
se	O
ha	O
informado	O
.	O

Aunque	O
la	O
pérdida	O
de	O
beta	B-Protein
-	I-Protein
enzima	I-Protein
de	I-Protein
escisión	I-Protein
de	I-Protein
APP	I-Protein
1	I-Protein
función	O
puede	O
prevenir	O
el	O
desarrollo	O
de	O
placas	O
en	O
transgénico	B-Sequence
ratón	B-Taxon
modelos	O
para	O
AD	O
(	O
F.	O
Laird	O
,	O
H.	O
Cai	O
,	O
P.	O
C.	O
Wong	O
,	O
comunicación	O
personal	O
)	O
,	O
no	O
se	O
sabe	O
si	O
el	O
cerebro	O
puede	O
eliminar	O
los	O
depósitos	O
de	O
amiloide	O
preexistentes	O
una	O
vez	O
que	O
la	O
producción	O
de	O
una	B-Protein
beta	I-Protein
ha	O
sido	O
suprimido	O
.	O

Claramente	O
,	O
el	O
enfoque	O
de	O
reducción	O
de	O
amiloide	O
debe	O
examinarse	O
rigurosamente	O
en	O
animal	B-Taxon
modelos	O
anteriores	O
a	O
estos	O
reactivos	B-Chemical
se	O
prueban	O
en	O
pacientes	O
.	O

Sin	O
embargo	O
,	O
el	O
inhibidores	B-Chemical
químicos	I-Chemical
de	I-Chemical
la	I-Chemical
secretasa	I-Chemical
lo	O
más	O
probable	O
es	O
que	O
alcance	O
humano	B-Taxon
los	O
ensayos	O
aún	O
están	O
en	O
desarrollo	O
.	O

Por	O
lo	O
tanto	O
,	O
desarrollamos	O
un	O
ratón	B-Taxon
modelo	O
de	O
Alzheimer	O
-	O
tipo	O
amiloide	O
que	O
expresa	O
un	O
controlable	O
APLICACIÓN	B-Protein
transgén	B-Sequence
.	O

Este	O
sistema	O
,	O
comúnmente	O
conocido	O
como	O
el	O
sistema	O
tet-off	O
,	O
puede	O
ser	O
regulado	O
por	O
análogos	O
de	O
tetraciclina	B-Chemical
administrado	O
en	O
comida	B-Chemical
o	O
agua	B-Chemical
[	O
12	O
,	O
13	O
]	O
.	O

Los	O
fuertes	O
niveles	O
de	O
expresión	O
producidos	O
con	O
el	O
tet	O
-	O
off	O
vectores	B-Sequence
,	O
combinado	O
con	O
la	O
capacidad	O
de	O
reducir	O
esta	O
expresión	O
en	O
varios	O
órdenes	O
de	O
magnitud	O
con	O
tetraciclina	B-Chemical
[	O
14	O
]	O
,	O
permitió	O
una	O
prueba	O
estricta	O
de	O
cómo	O
un	O
altamente	O
efectivo	O
inhibidor	B-Chemical
farmacéutico	I-Chemical
de	O
una	B-Protein
beta	I-Protein
la	O
producción	O
afectaría	O
la	O
progresión	O
de	O
la	O
patología	O
amiloide	O
y	O
si	O
la	O
reversión	O
de	O
estas	O
lesiones	O
podría	O
ser	O
posible	O
después	O
de	O
dicho	O
tratamiento	O
.	O

Métodos	O

Transgén	B-Sequence
Construcción	O

Creamos	O
un	O
tetraciclina	B-Chemical
#	O
¿NOMBRE	O
?	O
ratón	B-Taxon
/	O
humano	B-Taxon
APP695Sueco	O
/	O
Indiana	B-Protein
(	O
sueco	B-Protein
/	O
Indiana	B-Protein
)	O
vector	B-Sequence
por	O
reemplazando	B-Sequence
los	O
región	B-Sequence
promotora	I-Sequence
de	O
El	O
moPrP	B-Protein
.	O
XhoI	O
vector	B-Sequence
(	O
también	O
conocido	O
como	O
pPrPpE1/E2	O
,	O
3sal	O
[	O
15	O
]	O
)	O
con	O
el	O
tetraciclina	B-Chemical
#	O
¿NOMBRE	O
?	O
promotor	B-Sequence
de	O
pTetSplice	O
(	O
Life	O
Technologies	O
,	O
Rockville	O
,	O
Maryland	O
,	O
Estados	O
Unidos	O
)	O
,	O
y	O
luego	O
ligar	O
aplicación	B-Protein
de	I-Protein
ratón	I-Protein
con	O
un	O
humanizado	O
una	B-Protein
beta	I-Protein
dominio	B-Sequence
(	O
mes	B-Taxon
/	O
huAPP695	B-Protein
)	O
ADNc	B-Sequence
en	O
el	O
nuevo	O
vector	B-Sequence
.	O

Comenzamos	O
clonando	O
el	O
tetraciclina	B-Chemical
#	O
¿NOMBRE	O
?	O
promotor	B-Sequence
(	O
pb	B-Sequence
6	O
-	O
481	O
)	O
de	O
pTetSplice	O
por	O
PCR	O
usando	O
cebadores	B-Sequence
que	O
agregó	O
BamHI	O
y	O
NotI	O
externos	O
sitios	B-Sequence
al	O
5	O
'	O
final	O
y	O
un	O
BamHI	O
sitio	B-Sequence
hasta	O
el	O
3	O
'	O
final	O
,	O
mientras	O
destruyen	O
XhoI	O
y	O
BamHI	O
sitios	B-Sequence
dentro	O
de	O
promotor	B-Sequence
(	O
hacia	B-Sequence
adelante	I-Sequence
:	O
GCC	O
GGA	O
TCC	O
GCG	O
GCC	O
GCC	O
GTC	O
GAG	O
TTT	O
ACC	O
ACT	O
CCC	O
TAT	O
C	B-Chemical
;	O
contrarrestar	B-Sequence
:	O
GCC	O
GGA	O
TCC	O
ACT	O
CTA	O
GAA	O
GAT	O
CCC	O
CGG	O
GTA	O
CCG	O
)	O
.	O

Luego	O
aislamos	O
el	O
moPrP	B-Protein
.	O
XhoI	O
intrón	B-Sequence
por	O
amplificación	O
con	O
cebadores	B-Sequence
que	O
agregó	O
un	O
BamHI	O
externo	O
sitio	B-Sequence
al	O
5	O
'	O
final	O
de	O
exón	B-Sequence
1	O
y	O
corrió	O
a	O
través	O
del	O
Asp718	O
sitio	B-Sequence
de	I-Sequence
exón	I-Sequence
2	O
(	O
hacia	B-Sequence
adelante	I-Sequence
:	O
GCC	O
GGA	O
TCC	O
GAT	O
CAG	O
CAG	O
ACC	O
GAT	O
TCT	O
GG	O
;	O
contrarrestar	B-Sequence
:	O
GCC	O
GGT	O
ACC	O
ACT	O
AGG	O
AAG	O
GCA	O
GAA	O
TGC	O
)	O
.	O

Este	O
2	O
-	O
kb	O
fragmento	B-Sequence
de	I-Sequence
intrón	I-Sequence
fue	O
clonado	O
en	O
una	O
clonación	O
TA	O
vector	B-Sequence
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
,	O
luego	O
extirpado	B-Sequence
por	O
digestión	O
con	O
Asp718	O
y	O
ligado	O
al	O
6	O
.	O
8	O
-	O
kb	O
Asp718	O
fragmento	B-Sequence
de	O
moPrP	B-Protein
.	O
XhoI	O
que	O
contiene	O
exón	B-Sequence
2	O
,	O
exón	B-Sequence
3	O
,	O
el	O
3	B-Sequence
'	I-Sequence
UTR	I-Sequence
y	O
pBluescript	O
para	O
generar	O
un	O
vector	B-Sequence
intermedio	I-Sequence
con	O
los	O
tres	O
exones	B-Sequence
y	O
un	O
central	O
intrón	B-Sequence
pero	O
no	O
promotor	B-Sequence
.	O

Esta	O
vector	B-Sequence
luego	O
se	O
inauguró	O
en	O
el	O
BamHI	O
sitio	B-Sequence
introducido	I-Sequence
por	O
el	O
intrón	B-Sequence
clonación	O
cebador	B-Sequence
,	O
y	O
ligado	O
al	O
0	O
.	O
5	O
-	O
kb	O
BamHI	O
-	O
tetraciclina	O
cortada	O
fragmento	B-Sequence
de	I-Sequence
promotor	I-Sequence
.	O

Esta	O
ligadura	O
generó	O
un	O
9	O
.	O
3	O
kilobytes	O
vector	B-Sequence
codificando	O
la	O
tetraciclina	O
promotor	B-Sequence
de	O
pTetSplice	O
con	O
dos	O
exones	B-Sequence
,	O
una	O
intrón	B-Sequence
,	O
y	O
el	O
original	O
3	B-Sequence
'	I-Sequence
UTR	I-Sequence
de	O
El	O
moPrP	B-Protein
.	O
XhoI	O
vector	B-Sequence
,	O
todos	O
llevados	O
en	O
la	O
clonación	O
de	O
pBluescript	O
vector	B-Sequence
.	O

Incorporamos	O
el	O
sueco	B-Protein
(	O
KM570/571NL	O
)	O
y	O
Indiana	B-Protein
(	O
V617F	O
)	O
mutaciones	B-Sequence
en	O
el	O
mes	B-Taxon
/	O
huAPP695	B-Protein
ADNc	B-Sequence
(	O
en	O
BS-KS	O
)	O
por	O
PCR	O
usando	O
un	O
cuatro-	O
cebador	B-Sequence
estrategia	O
:	O
primero	O
,	O
dos	O
parcialmente	O
productos	B-Sequence
superpuestos	I-Sequence
se	O
generaron	O
en	O
reacciones	O
separadas	O
utilizando	O
cebadores	B-Sequence
que	O
codifican	O
lo	O
deseado	O
mutaciones	B-Sequence
(	O
sueco	B-Protein
hacia	B-Sequence
adelante	I-Sequence
:	O
GGA	O
GAT	O
CTC	O
TGA	O
AGT	O
GAA	O
TCT	O
GGA	O
TGC	O
AGA	O
ATT	O
CCG	O
/	O
Indiana	B-Protein
contrarrestar	B-Sequence
:	O
GGG	O
TGA	O
TGA	O
AAA	O
TCA	O
CGG	O
TTG	O
C	B-Chemical
;	O
Indiana	B-Protein
hacia	B-Sequence
adelante	I-Sequence
:	O
CAA	O
CCG	O
TGA	O
TTT	O
TCA	O
TCA	O
CCC	O
TGG	O
/	O
M13	O
contrarrestar	B-Sequence
)	O
.	O

Los	O
dos	O
productos	B-Sequence
PCR	I-Sequence
fueron	O
ligados	O
,	O
digeridos	O
con	O
BglII	O
y	O
ApaI	O
y	O
clonados	O
de	O
nuevo	O
en	O
el	O
original	O
mes	B-Taxon
/	O
huAPP695	B-Protein
#	O
¿NOMBRE	O
?	O
vector	B-Sequence
.	O

Finalmente	O
,	O
el	O
nuevo	O
APP695swe/	O
Indiana	B-Protein
fue	O
subclonado	O
en	O
el	O
XhoI	O
sitio	B-Sequence
de	O
El	O
moPrP	B-Protein
#	O
¿NOMBRE	O
?	O
vector	B-Sequence
desde	O
arriba	O
para	O
completar	O
el	O
construir	B-Sequence
.	O

pronuclear	B-GENE
Inyección	O
,	O
Cribado	O
de	O
Fundadores	O
y	O
Mantenimiento	O
de	O
las	O
Líneas	O

los	O
moPrP	B-Protein
-	O
tetP	O
-	O
mes	B-Taxon
/	O
huAPP695swe	O
/	O
Indiana	B-Protein
vector	B-Sequence
fue	O
linealizado	O
y	O
el	O
pBluescript	O
dominio	B-Sequence
extirpado	I-Sequence
por	O
digestión	O
con	O
NotI	O
.	O

el	O
purificado	O
vector	B-Sequence
fue	O
inyectado	O
en	O
el	O
pronúcleo	B-GENE
de	O
fertilizado	O
huevos	B-Cell
de	O
apareamientos	O
C57BL/6J	O
x	O
C3HeJ	O
F1	O
.	O

Fundador	O
animales	B-Taxon
fueron	O
examinados	O
para	O
detectar	O
la	O
presencia	O
de	O
transgén	B-Sequence
por	O
PCR	O
de	O
tres	O
vías	O
usando	O
el	O
S36	O
y	O
PrP	B-Protein
-	O
S	O
/	O
PrP	B-Protein
#	O
¿NOMBRE	O
?	O
cebadores	B-Sequence
descrito	O
abajo	O
.	O

Transgén	B-Sequence
#	O
¿NOMBRE	O
?	O
animales	B-Taxon
expresando	O
el	O
tetraciclina	B-Chemical
transactivador	O
(	O
tTA	O
)	O
bajo	O
el	O
control	O
del	O
calcio	B-Protein
-	I-Protein
calmodulina	I-Protein
quinasa	I-Protein
II	I-Protein
alfa	I-Protein
(	O
CaMKII	B-Protein
alfa	I-Protein
)	O
promotor	B-Sequence
obtenido	O
de	O
Jackson	O
Laboratory	O
[	O
16	O
]	O
(	O
Bar	O
Harbor	O
,	O
Maine	O
,	O
Estados	O
Unidos	O
;	O
stock	O
#	O
3010	O
;	O
B6	O
;	O
CBA	O
-	O
TgN	O
[	O
camk2a	B-Protein
-	O
tTA	O
]	O
1Mmay	O
)	O
.	O

A	O
partir	O
de	O
entonces	O
,	O
la	O
colonia	O
se	O
mantuvo	O
cruzando	O
solo	O
transgénico	B-Sequence
tTA	O
y	O
APLICACIÓN	B-Protein
descendencia	O
para	O
cada	O
uno	O
de	O
los	O
cuatro	O
APLICACIÓN	B-Protein
líneas	O
.	O

Todos	O
ratones	B-Taxon
fueron	O
proporcionados	O
frescos	O
comida	B-Chemical
y	O
agua	B-Chemical
ad	O
libitum	O
.	O

Animal	B-Taxon
Los	O
protocolos	O
fueron	O
aprobados	O
tanto	O
por	O
la	O
Universidad	O
Johns	O
Hopkins	O
como	O
por	O
el	O
Instituto	O
de	O
Tecnología	O
Institucional	O
de	O
California	O
.	O
Animal	B-Taxon
Comités	O
de	O
Cuidado	O
y	O
Uso	O
.	O

Administración	O
de	O
doxiciclina	O

La	O
doxiciclina	O
(	O
dox	O
)	O
se	O
administró	O
a	O
través	O
de	O
alimentos	O
que	O
contenían	O
dox	O
comercialmente	O
disponibles	O
(	O
BioServ	O
,	O
Frenchtown	O
,	O
Nueva	O
Jersey	O
,	O
Estados	O
Unidos	O
)	O
.	O

El	O
chow	O
contenía	O
200	O
mg/kg	O
de	O
antibiótico	B-Chemical
;	O
basado	O
en	O
un	O
consumo	O
estimado	O
de	O
5	O
g	O
por	O
ratón	B-Taxon
por	O
día	O
,	O
la	O
dosis	O
esperada	O
para	O
cada	O
animal	B-Taxon
fue	O
de	O
1	O
mg	O
dox	O
por	O
día	O
.	O

El	O
promedio	O
25	O
-	O
g	O
animal	B-Taxon
por	O
lo	O
tanto	O
recibió	O
40	O
ug	O
de	O
dox	O
por	O
gramo	O
de	O
peso	O
corporal	O
por	O
día	O
.	O

Chow	O
se	O
cambió	O
1	O
-	O
2	O
veces	O
por	O
semana	O
para	O
evitar	O
la	O
ruptura	O
de	O
la	O
antibiótico	B-Chemical
.	O

genotipado	O

La	O
descendencia	O
fue	O
genotipada	O
para	O
la	O
presencia	O
de	O
cada	O
transgén	B-Sequence
por	O
amplificación	O
por	O
PCR	O
de	O
ADN	B-Sequence
genómico	I-Sequence
extraído	O
de	O
una	O
biopsia	O
de	O
cola	O
de	O
5	O
mm	O
.	O

Las	O
colas	O
se	O
calentaron	O
a	O
95	O
grados	O
C	O
durante	O
45	O
min	O
en	O
250	O
mu	O
l	O
de	O
50	O
mM	O
NaOH	B-Chemical
,	O
agitado	O
,	O
luego	O
neutralizado	O
con	O
un	O
volumen	O
igual	O
a	O
0	O
.	O
5M	O
tris	B-Chemical
-	O
HCl	B-Chemical
(	O
pH	O
5	O
,	O
5	O
)	O
.	O

Los	O
desechos	O
se	O
sedimentaron	O
por	O
centrifugación	O
y	O
se	O
usaron	O
3	O
µl	O
de	O
sobrenadante	O
para	O
la	O
amplificación	O
.	O

Genotipado	O
para	O
APLICACIÓN	B-Protein
y	O
tTA	O
transgenes	B-Sequence
se	O
realizó	O
en	O
la	O
misma	O
reacción	O
de	O
PCR	O
,	O
utilizando	O
cinco	O
cebadores	B-Sequence
.	O

APLICACIÓN	B-Protein
se	O
amplificó	O
usando	O
cartilla	B-Sequence
delantera	I-Sequence
S36	O
ubicado	O
en	O
el	O
extremo	O
3	O
'	O
del	O
APLICACIÓN	B-Protein
ADNc	B-Sequence
(	O
CCG	O
AGA	O
TCT	O
CTG	O
AAG	O
TGA	O
AGA	O
TGG	O
ATG	O
)	O
y	O
imprimación	B-Sequence
inversa	I-Sequence
PrP	B-Protein
#	O
¿NOMBRE	O
?	O
3	B-Sequence
'	I-Sequence
UTR	I-Sequence
de	O
El	O
vector	B-Sequence
(	O
CCA	O
AGC	O
CTA	O
GAC	O
CAC	O
GAG	O
AAT	O
GC	O
)	O
.	O

el	O
tta	O
transgén	B-Sequence
fue	O
detectado	O
utilizando	O
un	O
cebador	B-Sequence
conjunto	O
que	O
amplificó	O
a	O
través	O
de	O
sus	O
dos	O
subdominios	O
con	O
tet	O
hacia	B-Sequence
adelante	I-Sequence
ubicado	O
dentro	O
del	O
represor	O
de	O
tetraciclina	O
Tn10	O
(	O
CGC	O
TGT	O
GGG	O
GCA	O
TTT	O
TAC	O
TTT	O
AG	O
)	O
y	O
tet	O
contrarrestar	B-Sequence
dentro	O
de	O
VHS1	B-Protein
VP16	I-Protein
(	O
CAT	O
GTC	O
CAG	O
ATC	O
GAA	O
ATC	O
GTC	O
)	O
.	O

Todas	O
las	O
reacciones	O
,	O
ya	O
sea	O
transgén	B-Sequence
-	O
positivo	O
o	O
no	O
,	O
amplificado	O
a	O
segmento	B-Sequence
del	I-Sequence
gen	I-Sequence
de	I-Sequence
la	I-Sequence
proteína	I-Sequence
priónica	I-Sequence
endógena	I-Sequence
como	O
control	O
para	O
ADN	B-Sequence
calidad	O
mediante	O
un	O
cartilla	B-Sequence
delantera	I-Sequence
,	O
PrP	B-Protein
-	O
S	O
-	O
J	O
,	O
específico	O
para	O
el	O
PrP	B-Protein
del	I-Protein
ratón	I-Protein
marco	B-Sequence
de	I-Sequence
lectura	I-Sequence
abierto	I-Sequence
(	O
GGG	O
ACT	O
ATG	O
TGG	O
ACT	O
GAT	O
GTC	O
GG	O
)	O
y	O
un	O
imprimación	B-Sequence
inversa	I-Sequence
,	O
PrP	B-Protein
-	O
AS	O
-	O
J	O
,	O
compartido	O
por	O
el	O
3	B-Sequence
'	I-Sequence
UTR	I-Sequence
de	O
lo	O
endógeno	O
PrP	B-Protein
gene	B-Sequence
y	O
el	O
vector	B-Sequence
transgen	I-Sequence
.	O

Las	O
reacciones	O
de	O
amplificación	O
se	O
llevaron	O
a	O
cabo	O
durante	O
37	O
ciclos	O
a	O
94	O
grados	O
C	O
durante	O
30	O
s	O
,	O
64	O
grados	O
C	O
durante	O
1	O
min	O
y	O
72	O
grados	O
C	O
durante	O
1	O
min	O
.	O

Todas	O
las	O
muestras	O
,	O
transgénico	B-Sequence
y	O
tipo	B-Sequence
salvaje	I-Sequence
,	O
dio	O
un	O
750	O
-	O
producto	B-Sequence
pb	I-Sequence
de	O
lo	O
endógeno	O
PrP	B-Protein
gene	B-Sequence
.	O

los	O
APLICACIÓN	B-Protein
transgén	B-Sequence
produjo	O
una	O
banda	O
adicional	O
a	O
400	O
pb	B-Sequence
;	O
el	O
tta	O
producto	B-Sequence
cayó	O
en	O
el	O
medio	O
en	O
480	O
pb	B-Sequence
.	O

Inmunotransferencia	O
/	O
Cuantificación	O

El	O
tejido	O
cortical	O
o	O
del	O
prosencéfalo	O
completo	O
congelado	O
se	O
homogeneizó	O
mediante	O
sonicación	O
en	O
cinco	O
volúmenes	O
de	O
fosfato	B-Chemical
-	O
amortiguado	B-Chemical
solución	O
salina	O
(	O
PBS	O
)	O
con	O
5	O
mM	O
EDTA	B-Chemical
y	O
Inhibidores	B-Chemical
de	I-Chemical
la	I-Chemical
proteasa	I-Chemical
(	O
Mamífero	B-Taxon
célula	B-Cell
coctel	O
,	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
Missouri	O
,	O
Estados	O
Unidos	O
)	O
,	O
utilizando	O
un	O
Investigacion	B-Sequence
sonicador	O
ajustado	O
al	O
50	O
%	O
de	O
salida	O
(	O
TEKMAR	O
,	O
Cincinnati	O
,	O
Ohio	O
,	O
Estados	O
Unidos	O
)	O
.	O

Después	O
de	O
la	O
dilución	O
con	O
un	O
volumen	O
igual	O
de	O
PBS	O
/	O
EDTA	B-Chemical
/	O
inhibidor	B-Chemical
de	I-Chemical
la	I-Chemical
proteasa	I-Chemical
,	O
las	O
muestras	O
se	O
centrifugaron	O
brevemente	O
y	O
el	O
sobrenadante	O
se	O
usó	O
para	O
el	O
análisis	O
.	O

Cincuenta	O
microgramos	O
(	O
6E10	O
y	O
CT15	O
)	O
o	O
5	O
µg	O
(	O
22C11	O
)	O
de	O
homogeneizado	O
de	O
cerebro	O
se	O
cargaron	O
por	O
carril	O
en	O
7	O
.	O
5	O
%	O
,	O
10	O
%	O
-	O
20	O
%	O
,	O
o	O
4	O
%	O
-	O
20	O
%	O
tris	B-Chemical
-	O
HCl	B-Chemical
geles	O
PAGE	O
(	O
Bio-Rad	O
Laboratories	O
,	O
Hercules	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
y	O
sometidos	O
a	O
electroforesis	O
durante	O
varias	O
horas	O
en	O
1	O
x	O
tris	B-Chemical
-	O
glicina	B-Chemical
-	O
dodecil	B-Chemical
sulfato	I-Chemical
de	I-Chemical
sodio	I-Chemical
(	O
1	O
x	O
TG	O
-	O
SDS	B-Chemical
)	O
tampón	O
(	O
6E10	O
y	O
22C11	O
;	O
Amresco	O
,	O
Solon	O
,	O
Ohio	O
,	O
Estados	O
Unidos	O
)	O
o	O
1	O
x	O
tris	B-Chemical
-	O
tricina	B-Chemical
-	O
SDS	B-Chemical
tampón	O
(	O
CT15	O
;	O
Invitrogen	O
,	O
Carlsbad	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
.	O

Proteínas	B-Chemical
fueron	O
transferidos	O
durante	O
la	O
noche	O
a	O
0	O
.	O
Nitrocelulosa	O
Optitran	O
de	O
45	O
mu	O
m	O
(	O
Schleicher	O
and	O
Schuell	O
,	O
Keene	O
,	O
New	O
Hampshire	O
,	O
Estados	O
Unidos	O
)	O
en	O
tampón	O
1	O
x	O
TG	O
(	O
Amresco	O
)	O
.	O

Las	O
transferencias	O
se	O
bloquearon	O
en	O
PBS	O
que	O
contenía	O
leche	O
descremada	O
en	O
polvo	O
al	O
5	O
%	O
y	O
se	O
incubaron	O
durante	O
3	O
h	O
a	O
temperatura	O
ambiente	O
en	O
una	O
solución	O
de	O
bloqueo	O
con	O
uno	O
de	O
los	O
siguientes	O
anticuerpos	B-GENE
:	O
ratón	B-Taxon
22C11	O
monoclonal	O
(	O
amable	O
regalo	O
de	O
Konrad	O
Beyreuther	O
y	O
Andreas	O
Weidemann	O
;	O
[	O
17	O
]	O
)	O
diluido	O
1	O
:	O
1	O
000	O
,	O
ratón	B-Taxon
monoclonal	O
6E10	O
(	O
Signet	O
Laboratories	O
,	O
Dedham	O
,	O
Massachusetts	O
,	O
Estados	O
Unidos	O
)	O
diluido	O
1	O
:	O
2	O
,	O
500	O
,	O
Conejo	B-Taxon
anti	O
policlonal	O
-	O
superóxido	B-Protein
dismutasa	I-Protein
1	I-Protein
(	O
m	O
/	O
hSOD1	B-Protein
)	O
[	O
18	O
]	O
diluido	O
1	O
:	O
2	O
,	O
500	O
a	O
1	O
:	O
4	O
,	O
000	O
,	O
o	O
Conejo	B-Taxon
CT15	O
policlonal	O
(	O
amable	O
regalo	O
de	O
Ed	O
Koo	O
;	O
[	O
19	O
]	O
)	O
diluido	O
1	O
:	O
1	O
000	O
.	O

Posteriormente	O
,	O
las	O
transferencias	O
se	O
lavaron	O
con	O
PBS	O
que	O
contenía	O
0	O
.	O
Tween-20	O
al	O
1	O
%	O
y	O
luego	O
se	O
incuba	O
con	O
cabra	B-Taxon
anti	O
-	O
ratón	B-Taxon
#	O
¿NOMBRE	O
?	O
cabra	B-Taxon
anti	O
-	O
Conejo	B-Taxon
#	O
¿NOMBRE	O
?	O
anticuerpo	B-GENE
diluido	O
1:1	O
,	O
000	O
en	O
solución	O
de	O
bloqueo	O
.	O

Después	O
de	O
varios	O
enjuagues	O
adicionales	O
en	O
PBS	O
con	O
0	O
.	O
1	O
%	O
Tween	O
-	O
20	O
,	O
se	O
desarrollaron	O
transferencias	O
con	O
quimioluminiscencia	O
mejorada	O
reactivo	B-Chemical
y	O
fotografiado	O
con	O
el	O
Bio	O
-	O
Rad	O
Molecular	B-Chemical
Sistema	O
Imager	O
FX	O
.	O

La	O
intensidad	O
de	O
la	O
tinción	O
dentro	O
de	O
cada	O
carril	O
se	O
cuantificó	O
utilizando	O
el	O
software	O
de	O
análisis	O
de	O
imágenes	O
Cantidad	O
Uno	O
(	O
Molecular	B-Chemical
Imager	O
FX	O
,	O
Bio-Rad	O
Laboratories	O
)	O
.	O

El	O
fondo	O
se	O
calculó	O
a	O
lo	O
largo	O
de	O
la	O
imagen	O
y	O
se	O
restó	O
del	O
archivo	O
completo	O
.	O

A	O
continuación	O
,	O
se	O
calculó	O
la	O
intensidad	O
de	O
la	O
señal	O
para	O
cada	O
banda	O
(	O
intensidad	O
de	O
la	O
señal	O
corregida	O
x	O
número	O
de	O
píxeles	O
)	O
mediante	O
la	O
herramienta	O
Informe	O
de	O
volumen	O
.	O

Transferencia	O
de	O
ranura	O
ARNm	B-Chemical
Análisis	O

Cinco	O
microgramos	O
por	O
muestra	O
del	O
total	O
ARN	B-Sequence
extraído	O
de	O
cerebro	O
,	O
hígado	O
,	O
riñón	O
,	O
corazón	O
,	O
pulmón	O
,	O
bazo	O
y	O
músculo	O
esquelético	O
recién	O
congelados	O
se	O
filtró	O
al	O
vacío	O
a	O
través	O
de	O
0	O
.	O
Nitrocelulosa	O
Optitran	O
de	O
45	O
mu	O
m	O
.	O

Después	O
de	O
varios	O
lavados	O
a	O
través	O
del	O
colector	O
con	O
10	O
x	O
SSC	O
,	O
las	O
transferencias	O
se	O
reticularon	O
con	O
UV	O
y	O
se	O
probaron	O
con	O
un	O
radiomarcado	B-Chemical
~	O
350	O
-	O
pb	B-Sequence
BglII	O
-	O
XhoI	O
fragmento	B-Sequence
de	I-Sequence
ADNc	I-Sequence
de	O
mes	B-Taxon
/	O
huAPP695	B-Protein
ADNc	B-Sequence
.	O

Después	O
de	O
hibridar	O
durante	O
la	O
noche	O
a	O
65	O
grados	O
C	O
en	O
1	O
%	O
BSA	B-Protein
/	O
1	O
mm	O
EDTA	B-Chemical
/	O
0	O
.	O
5M	O
fosfato	B-Chemical
de	I-Chemical
sodio	I-Chemical
tampón	O
(	O
pH	O
7	O
.	O
2	O
)	O
/	O
7	O
%	O
SDS	B-Chemical
[	O
20	O
]	O
,	O
las	O
transferencias	O
se	O
lavaron	O
dos	O
veces	O
a	O
65	O
°	O
C	O
durante	O
30	O
min	O
cada	O
una	O
en	O
0	O
.	O
1	O
%	O
BSA	B-Protein
/	O
1	O
mm	O
EDTA	B-Chemical
/	O
40	O
mm	O
fosfato	B-Chemical
de	I-Chemical
sodio	I-Chemical
tampón	O
(	O
pH	O
7	O
,	O
2	O
)	O
/	O
5	O
%	O
SDS	B-Chemical
antes	O
de	O
dos	O
lavados	O
finales	O
de	O
30	O
min	O
a	O
65	O
grados	O
C	O
con	O
1	O
mM	O
EDTA	B-Chemical
/	O
40	O
mm	O
fosfato	B-Chemical
de	I-Chemical
sodio	I-Chemical
tampón	O
(	O
pH	O
7	O
,	O
2	O
)	O
/	O
1	O
%	O
SDS	B-Chemical
.	O

Las	O
transferencias	O
se	O
envolvieron	O
húmedas	O
y	O
se	O
expusieron	O
a	O
pantallas	O
de	O
fósforo	O
durante	O
la	O
noche	O
a	O
temperatura	O
ambiente	O
.	O

Histología	O
amiloide	O

Ratones	B-Taxon
fueron	O
sacrificados	O
por	O
inhalación	O
de	O
éter	O
y	O
se	O
extrajeron	O
los	O
cerebros	O
para	O
su	O
fijación	O
por	O
inmersión	O
en	O
paraformaldehído	O
al	O
4	O
%	O
/	O
1	O
x	O
PBS	O
.	O

Después	O
de	O
48	O
h	O
en	O
fijador	O
a	O
4	O
°C	O
,	O
los	O
cerebros	O
se	O
transfirieron	O
a	O
PBS	O
,	O
se	O
deshidrataron	O
en	O
alcoholes	B-Chemical
,	O
tratada	O
con	O
aceite	O
de	O
madera	O
de	O
cedro	O
y	O
salicilato	O
de	O
metilo	O
,	O
e	O
incrustada	O
en	O
parafina	O
para	O
su	O
seccionamiento	O
.	O

Hirano	O
plata	B-Chemical
Mancha	O

Plata	B-Chemical
La	O
histología	O
de	O
impregnación	O
se	O
realizó	O
en	O
secciones	O
de	O
10	O
µm	O
incluidas	O
en	O
parafina	O
mediante	O
la	O
modificación	O
de	O
Hirano	O
del	O
método	O
de	O
Bielschowsky	O
[	O
21	O
]	O
.	O

Brevemente	O
,	O
las	O
secciones	O
se	O
desparafinizaron	O
a	O
través	O
de	O
xileno	B-Chemical
y	O
alcoholes	B-Chemical
en	O
el	O
grifo	O
agua	B-Chemical
antes	O
de	O
ser	O
colocado	O
en	O
fresco	O
20	O
%	O
nitrato	B-Chemical
de	I-Chemical
plata	I-Chemical
solución	O
durante	O
20	O
min	O
.	O

Después	O
de	O
ser	O
lavado	O
a	O
fondo	O
con	O
agua	O
destilada	O
agua	B-Chemical
,	O
los	O
portaobjetos	O
se	O
sumergieron	O
en	O
un	O
20	O
%	O
nitrato	B-Chemical
de	I-Chemical
plata	I-Chemical
solución	O
titulada	O
con	O
agua	O
fresca	O
hidróxido	B-Chemical
de	I-Chemical
amonio	I-Chemical
.	O

Después	O
de	O
20	O
min	O
,	O
los	O
portaobjetos	O
se	O
lavaron	O
con	O
agua	B-Chemical
de	I-Chemical
amoníaco	I-Chemical
antes	O
de	O
ser	O
revelado	O
individualmente	O
con	O
100	O
mu	O
l	O
de	O
revelador	O
(	O
20	O
ml	O
de	O
37	O
%	O
formaldehído	B-Chemical
,	O
100	O
ml	O
de	O
destilado	O
agua	B-Chemical
,	O
50	O
mu	O
l	O
de	O
concentrado	O
Ácido	B-Chemical
nítrico	I-Chemical
,	O
y	O
0	O
.	O
5	O
g	O
de	O
ácido	B-Chemical
cítrico	I-Chemical
)	O
añadido	O
a	O
50	O
ml	O
de	O
titulado	O
nitrato	B-Chemical
de	I-Chemical
plata	I-Chemical
solución	O

Luego	O
se	O
enjuagaron	O
los	O
portaobjetos	O
en	O
el	O
grifo	O
agua	B-Chemical
,	O
fijo	O
en	O
5	O
%	O
tiosulfato	B-Chemical
de	I-Chemical
sodio	I-Chemical
,	O
y	O
deshidratado	O
por	O
alcoholes	B-Chemical
y	O
xileno	B-Chemical
.	O

Tinción	O
de	O
tioflavina	O
-	O
S	O

Después	O
de	O
la	O
desparafinización	O
de	O
las	O
secciones	O
a	O
través	O
de	O
xileno	B-Chemical
y	O
alcoholes	B-Chemical
,	O
la	O
impregnación	O
de	O
amiloide	O
con	O
tioflavina	O
-	O
S	O
se	O
realizó	O
de	O
acuerdo	O
con	O
la	O
modificación	O
de	O
Guntern	O
del	O
protocolo	O
estándar	O
.	O

Los	O
portaobjetos	O
que	O
contenían	O
secciones	O
de	O
parafina	O
de	O
10	O
µm	O
se	O
lavaron	O
dos	O
veces	O
en	O
agua	O
destilada	O
.	O
agua	B-Chemical
,	O
luego	O
se	O
sumerge	O
durante	O
5	O
min	O
en	O
un	O
0	O
.	O
25	O
%	O
permanganato	B-Chemical
de	I-Chemical
potasio	I-Chemical
solución	O
,	O
seguido	O
de	O
5	O
min	O
en	O
una	O
solución	O
al	O
1	O
%	O
metabisulfato	B-Chemical
de	I-Chemical
potasio	I-Chemical
/	O
1	O
%	O
ácido	B-Chemical
oxálico	I-Chemical
solución	O

Después	O
de	O
esta	O
preparación	O
,	O
los	O
portaobjetos	O
se	O
colocaron	O
en	O
un	O
filtro	O
acuoso	B-Chemical
0	O
solución	O
de	O
tioflavina-S	O
al	O
02	O
%	O
(	O
Chroma-Gesellschaft	O
Schmid	O
,	O
Kongen	O
,	O
Alemania	O
)	O
durante	O
8	O
min	O
.	O

El	O
exceso	O
de	O
tinción	O
se	O
eliminó	O
con	O
dos	O
breves	O
enjuagues	O
en	O
un	O
80	O
%	O
etanol	B-Chemical
,	O
luego	O
dos	O
en	O
destilado	O
agua	B-Chemical
,	O
después	O
de	O
lo	O
cual	O
se	O
terminaron	O
las	O
diapositivas	O
en	O
acuoso	B-Chemical
medio	O
de	O
montaje	O
para	O
fotomicrografía	O
de	O
fluorescencia	O
.	O

Ubiquitina	O
,	O
proteína	B-Protein
ácida	I-Protein
fibrilar	I-Protein
glial	I-Protein
,	O
y	O
una	B-Protein
beta	I-Protein
inmunohistoquímica	O

Antes	O
de	O
la	O
inmunotinción	O
,	O
los	O
portaobjetos	O
se	O
desparafinizaron	O
calentándolos	O
en	O
un	O
horno	O
y	O
luego	O
sumergiéndolos	O
en	O
xileno	B-Chemical
.	O

Después	O
de	O
la	O
rehidratación	O
a	O
través	O
de	O
graduados	O
alcoholes	B-Chemical
en	O
el	O
grifo	O
agua	B-Chemical
,	O
la	O
actividad	O
de	O
peroxidasa	O
endógena	O
se	O
extinguió	O
mediante	O
incubación	O
con	O
3	O
%	O
peróxido	B-Chemical
de	I-Chemical
hidrógeno	I-Chemical
en	O
metanol	B-Chemical
.	O

Los	O
portaobjetos	O
se	O
calentaron	O
en	O
el	O
microondas	O
durante	O
5	O
a	O
7	O
min	O
en	O
agua	B-Chemical
,	O
enfriado	O
durante	O
5	O
min	O
,	O
luego	O
lavado	O
en	O
TBS	O
.	O

La	O
tinción	O
inespecífica	O
se	O
bloqueó	O
durante	O
1	O
h	O
con	O
un	O
3	O
%	O
de	O
normal	O
cabra	B-Taxon
suero	O
y	O
0	O
.	O
1	O
%	O
Triton	O
-	O
X	O
100	O
en	O
TBS	O
.	O

Luego	O
se	O
colocaron	O
los	O
portaobjetos	O
en	O
el	O
primario	O
.	O
anticuerpo	B-GENE
(	O
Conejo	B-Taxon
anti	O
-	O
una	B-Protein
beta	I-Protein
péptido	B-Sequence
policlonal	O
anticuerpo	B-GENE
,	O
Laboratorios	O
Zymed	O
,	O
San	O
Francisco	O
Sur	O
,	O
California	O
,	O
Estados	O
Unidos	O
;	O
Conejo	B-Taxon
anti	O
-	O
ubiquitina	O
y	O
Conejo	B-Taxon
anti	O
-	O
proteína	B-Protein
ácida	I-Protein
fibrilar	I-Protein
glial	I-Protein
(	O
GFAP	B-Protein
)	O
policlonal	O
anticuerpos	B-GENE
,	O
Dako	O
,	O
Carpinteria	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
diluido	O
1	O
:	O
500	O
en	O
TBS	O
con	O
2	O
%	O
normal	O
cabra	B-Taxon
suero	O
y	O
se	O
incubó	O
durante	O
la	O
noche	O
a	O
temperatura	O
ambiente	O
.	O

Después	O
de	O
haber	O
sido	O
lavado	O
del	O
exceso	O
de	O
primaria	O
anticuerpo	B-GENE
con	O
varios	O
cambios	O
de	O
TBS	O
,	O
los	O
portaobjetos	O
se	O
incubaron	O
con	O
Vectastain	O
Elite	O
anti	O
-	O
Conejo	B-Taxon
sistema	O
secundario	O
(	O
anti	O
-	O
una	B-Protein
beta	I-Protein
;	O
Vector	O
Laboratories	O
,	O
Burlingame	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
o	O
peroxidasa	O
/	O
anti	O
-	O
peroxidasa	O
reactivos	B-Chemical
(	O
anti	O
-	O
ubiquitina	O
y	O
anti	O
-	O
GFAP	B-Protein
;	O
Sternberger	O
Monoclonals	O
,	O
Lutherville	O
,	O
Maryland	O
,	O
Estados	O
Unidos	O
)	O
según	O
las	O
instrucciones	O
del	O
fabricante	O
.	O

Anticuerpo	B-GENE
la	O
unión	O
se	O
visualizó	O
con	O
diaminobencideno	O
y	O
las	O
secciones	O
se	O
contrastaron	O
con	O
hematoxilina	O
.	O

Ensayo	O
de	O
trampa	O
de	O
filtro	O

Se	O
solubilizó	O
parcialmente	O
una	O
alícuota	O
de	O
cada	O
homogeneizado	O
cortical	O
utilizado	O
para	O
la	O
transferencia	O
Western	O
anterior	O
mediante	O
la	O
adición	O
de	O
SDS	B-Chemical
hasta	O
una	O
concentración	O
final	O
del	O
1	O
%	O
.	O

Serie	O
1	O
:	O
Se	O
realizaron	O
2	O
diluciones	O
con	O
1	O
x	O
PBS	O
/	O
1	O
%	O
SDS	B-Chemical
y	O
100	O
µl	O
de	O
cada	O
dilución	O
se	O
filtraron	O
luego	O
al	O
vacío	O
a	O
través	O
de	O
un	O
filtro	O
de	O
prehumedecimiento	O
.	O
22	O
-	O
mu	O
m	O
celulosa	O
acetato	B-Chemical
membrana	O
(	O
Schleicher	O
y	O
Schuell	O
)	O
[	O
22	O
]	O
.	O

Cada	O
pocillo	O
se	O
lavó	O
varias	O
veces	O
con	O
PBS	O
,	O
después	O
de	O
lo	O
cual	O
se	O
incubaron	O
las	O
transferencias	O
durante	O
la	O
noche	O
con	O
anti	O
-	O
policlonal	O
una	B-Protein
beta	I-Protein
anticuerpo	B-GENE
(	O
Zymed	O
Laboratories	O
)	O
diluido	O
1:600	O
en	O
una	O
solución	O
de	O
bloqueo	O
de	O
1	O
x	O
TBS/5	O
%	O
de	O
leche	O
en	O
polvo	O
sin	O
grasa	O
.	O

Después	O
de	O
lavar	O
las	O
transferencias	O
tres	O
veces	O
durante	O
10	O
min	O
cada	O
una	O
en	O
1	O
x	O
TBS/0	O
.	O
Tween-20	O
al	O
1	O
%	O
,	O
la	O
membrana	O
se	O
incubó	O
durante	O
1	O
h	O
con	O
HRP-conjugado	O
proteína	B-Chemical
A	O
(	O
Sigma	O
)	O
diluido	O
1:5,000	O
en	O
solución	O
de	O
bloqueo	O
.	O

Las	O
membranas	O
se	O
lavaron	O
de	O
nuevo	O
tres	O
veces	O
con	O
1	O
x	O
TBS/0	O
.	O
1	O
%	O
Tween	O
-	O
20	O
,	O
antes	O
anticuerpo	B-GENE
la	O
unión	O
se	O
detectó	O
con	O
quimioluminiscencia	O
mejorada	O
(	O
PerkinElmer	O
,	O
Boston	O
,	O
Massachusetts	O
,	O
Estados	O
Unidos	O
)	O
.	O

Las	O
imágenes	O
digitales	O
de	O
cada	O
mancha	O
fueron	O
capturadas	O
con	O
un	O
Molecular	B-Chemical
sistema	O
de	O
documentación	O
de	O
gel	O
Imager	O
FX	O
y	O
la	O
intensidad	O
de	O
una	B-Protein
beta	I-Protein
la	O
tinción	O
se	O
cuantificó	O
utilizando	O
el	O
software	O
de	O
análisis	O
de	O
imágenes	O
Cantidad	O
Uno	O
.	O

una	B-Protein
beta	I-Protein
ELISA	O

Una	O
alícuota	O
de	O
homogeneizado	O
cortical	O
generado	O
para	O
el	O
análisis	O
Western	O
descrito	O
anteriormente	O
se	O
sometió	O
a	O
una	O
extracción	O
secuencial	O
de	O
tres	O
pasos	O
usando	O
PBS	O
,	O
2	O
%	O
SDS	B-Chemical
,	O
y	O
70	O
%	O
ácido	B-Chemical
fórmico	I-Chemical
(	O
FA	B-Chemical
)	O
.	O

En	O
cada	O
paso	O
,	O
la	O
muestra	O
se	O
sonicó	O
en	O
un	O
tampón	O
adecuado	O
y	O
se	O
centrifugó	O
a	O
100	O
000	O
g	O
durante	O
30	O
min	O
(	O
muestras	O
de	O
1	O
a	O
1,5	O
meses	O
)	O
o	O
60	O
min	O
(	O
muestras	O
de	O
6	O
a	O
12	O
meses	O
)	O
a	O
4	O
°C	O
como	O
se	O
describió	O
anteriormente	O
[	O
23	O
-	O
25	O
]	O
.	O

El	O
sobrenadante	O
se	O
eliminó	O
para	O
el	O
análisis	O
y	O
el	O
sedimento	O
se	O
sonicó	O
en	O
la	O
siguiente	O
solución	O
en	O
secuencia	O
.	O

El	O
2	O
%	O
SDS	B-Chemical
Los	O
extractos	O
se	O
diluyeron	O
en	O
tampón	O
EC	O
y	O
los	O
FA	B-Chemical
extractos	O
neutralizados	O
con	O
1M	O
tris	B-Chemical
-	O
fosfato	B-Chemical
tampón	O
(	O
pH	O
11	O
)	O
y	O
luego	O
se	O
diluye	O
con	O
tampón	O
EC	O
antes	O
de	O
la	O
prueba	O
.	O

Humano	B-Taxon
una	B-Protein
beta	I-Protein
se	O
midió	O
en	O
cada	O
fracción	O
utilizando	O
BAN50	O
para	O
la	O
captura	O
(	O
epítopo	B-Sequence
A	O
beta	O
1	O
-	O
16	O
)	O
y	O
BA27	O
y	O
BC05	O
para	O
detección	O
(	O
una	B-Protein
beta	I-Protein
40	I-Protein
y	O
una	B-Protein
beta	I-Protein
42	I-Protein
,	O
respectivamente	O
)	O
(	O
Takeda	O
Químico	B-Chemical
Industrias	O
,	O
Osaka	O
,	O
Japón	O
)	O
.	O

Total	O
una	B-Protein
beta	I-Protein
(	O
ratón	B-Taxon
+	O
humano	B-Taxon
;	O
1	O
-	O
a	O
1	O
.	O
muestras	O
de	O
5	O
meses	O
solamente	O
)	O
se	O
midió	O
en	O
cada	O
fracción	O
utilizando	O
BNT77	O
para	O
la	O
captura	O
(	O
epítopo	B-Sequence
A	O
beta	O
11-28	O
)	O
y	O
BA27	O
y	O
BC05	O
para	O
detección	O
.	O

Todos	O
los	O
valores	O
se	O
calcularon	O
como	O
picomoles	O
por	O
gramo	O
en	O
base	O
al	O
peso	O
inicial	O
del	O
tejido	O
cortical	O
.	O

Monitoreo	O
de	O
actividad	O

Se	O
estudió	O
la	O
actividad	O
basal	O
diaria	O
en	O
28	O
CaMKII	B-Protein
alfa	I-Protein
-	O
tTA	O
x	O
tet	O
-	O
APPswe	O
/	O
Indiana	B-Protein
línea	O
107	O
ratones	B-Taxon
entre	O
los	O
4	O
y	O
5	O
meses	O
de	O
edad	O
.	O

animales	B-Taxon
fueron	O
separados	O
en	O
jaulas	O
individuales	O
inmediatamente	O
antes	O
del	O
inicio	O
de	O
cada	O
experimento	O
(	O
n	O
=	O
3	O
-	O
6	O
por	O
genotipo	B-Sequence
sin	O
tratar	O
,	O
2	O
-	O
5	O
por	O
genotipo	B-Sequence
dox	O
-	O
criado	O
)	O
.	O

Las	O
jaulas	O
se	O
colocaron	O
dentro	O
de	O
la	O
actividad	O
-	O
marcos	O
de	O
monitoreo	O
diseñados	O
para	O
contar	O
cada	O
vez	O
que	O
el	O
animal	B-Taxon
pasó	O
a	O
través	O
de	O
uno	O
de	O
los	O
tres	O
haces	O
de	O
luz	O
que	O
abarcan	O
el	O
ancho	O
de	O
la	O
jaula	O
(	O
San	O
Diego	O
Instruments	O
,	O
San	O
Diego	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
.	O

Los	O
experimentos	O
se	O
iniciaron	O
a	O
la	O
mitad	O
de	O
la	O
fase	O
de	O
luz	O
del	O
día	O
y	O
los	O
datos	O
se	O
recopilaron	O
en	O
intervalos	O
de	O
1	O
h	O
durante	O
las	O
siguientes	O
48	O
h	O
.	O

Las	O
salas	O
de	O
prueba	O
se	O
mantuvieron	O
en	O
el	O
mismo	O
ciclo	O
de	O
13:11	O
h	O
día	O
:	O
noche	O
que	O
el	O
principal	O
animal	B-Taxon
áreas	O
de	O
vivienda	O
y	O
fueron	O
cerradas	O
a	O
la	O
entrada	O
durante	O
el	O
experimento	O
.	O

Análisis	O
estadístico	O

Análisis	O
estadísticos	O
de	O
proteína	B-Chemical
Los	O
ensayos	O
de	O
expresión	O
,	O
datos	O
ELISA	O
y	O
trampa	O
de	O
filtro	O
se	O
realizaron	O
mediante	O
ANOVA	O
con	O
la	O
prueba	O
post-hoc	O
de	O
diferencia	O
significativa	O
honesta	O
de	O
Tukey	O
aplicada	O
a	O
efectos	O
o	O
interacciones	O
principales	O
significativos	O
(	O
Statistica	O
6.0	O
,	O
StatSoft	O
,	O
Tulsa	O
,	O
Oklahoma	O
,	O
Estados	O
Unidos	O
)	O
.	O

En	O
los	O
casos	O
de	O
distribución	O
de	O
datos	O
positivamente	O
sesgada	O
,	O
se	O
aplicó	O
la	O
transformación	O
log10	O
(	O
x	O
+	O
0,5	O
)	O
a	O
los	O
datos	O
sin	O
procesar	O
antes	O
de	O
enviarlos	O
a	O
ANOVA	O
.	O

Resultados	O

Usamos	O
el	O
tet	O
-	O
off	O
transgén	B-Sequence
sistema	O
para	O
expresar	O
un	O
doble	O
versión	B-Sequence
mutante	I-Sequence
de	O
quimerico	O
mes	B-Taxon
/	O
huAPP695	B-Protein
(	O
sueco	B-Protein
/	O
Indiana	B-Protein
KM570	O
,	O
571NL	O
y	O
V617F	O
)	O
de	O
un	O
tetraciclina	B-Chemical
#	O
¿NOMBRE	O
?	O
promotor	B-Sequence
[	O
12	O
,	O
13	O
]	O
.	O

transgénico	B-Sequence
APLICACIÓN	B-Protein
expresión	O
se	O
activó	O
cruzando	O
las	O
APPswe	O
/	O
Indiana	B-Protein
ratones	B-Taxon
para	O
animales	B-Taxon
produciendo	O
tTA	O
bajo	O
el	O
control	O
del	O
CaMKII	B-Protein
alfa	I-Protein
promotor	B-Sequence
[	O
dieciséis	O
]	O
.	O

Después	O
de	O
la	O
selección	O
inicial	O
de	O
fundadores	O
,	O
identificamos	O
cuatro	O
líneas	O
de	O
tet	O
-	O
APPswe	O
/	O
Indiana	B-Protein
ratones	B-Taxon
que	O
produjo	O
niveles	O
muy	O
altos	O
de	O
transgén	B-Sequence
producto	O
en	O
la	O
descendencia	O
que	O
coexpresa	O
tTA	O
(	O
Figuras	O
1	O
y	O
Figura	O
S1	O
)	O
.	O

En	O
comparación	O
con	O
un	O
estándar	O
APLICACIÓN	B-Protein
transgénico	B-Sequence
utilizada	O
para	O
estudios	O
previos	O
de	O
amiloide	O
por	O
nuestro	O
laboratorio	O
(	O
línea	O
C3-3	O
;	O
[	O
15	O
,	O
26	O
,	O
27	O
]	O
)	O
,	O
estimamos	O
que	O
las	O
cuatro	O
líneas	O
controlables	O
producen	O
transgénico	B-Sequence
APLICACIÓN	B-Protein
proteína	B-Chemical
de	O
10	O
a	O
30	O
veces	O
por	O
encima	O
de	O
los	O
niveles	O
endógenos	O
(	O
Figura	O
S1	O
)	O
.	O

Esta	O
estimación	O
fue	O
confirmada	O
por	O
comparación	O
directa	O
de	O
APLICACIÓN	B-Protein
niveles	O
en	O
no	O
transgénicos	O
y	O
test	O
-	O
off	O
APLICACIÓN	B-Protein
ratones	B-Taxon
usando	O
un	O
anticuerpo	B-GENE
que	O
reconoce	O
tanto	O
las	O
endógenas	O
APLICACIÓN	B-Protein
(	O
y	O
precursor	B-Protein
amiloide	I-Protein
-	I-Protein
como	I-Protein
la	I-Protein
proteína	I-Protein
2	I-Protein
)	O
y	O
el	O
transgénico	B-Sequence
proteína	B-Chemical
(	O
monoclonal	O
anticuerpo	B-GENE
22C11	O
;	O
Figura	O
1D	O
)	O
.	O

Es	O
importante	O
destacar	O
que	O
las	O
cuatro	O
nuevas	O
líneas	O
de	O
tet-off	O
APLICACIÓN	B-Protein
ratones	B-Taxon
mostró	O
una	O
supresión	O
casi	O
completa	O
de	O
la	O
transgén	B-Sequence
siguiente	O
tratamiento	O
dox	O
(	O
Figuras	O
1	O
y	O
Figura	O
S1	O
)	O
.	O

Nos	O
enfocamos	O
en	O
una	O
de	O
las	O
cuatro	O
líneas	O
,	O
la	O
línea	O
107	O
,	O
para	O
examinar	O
con	O
más	O
detalle	O
la	O
dependencia	O
del	O
tiempo	O
y	O
el	O
alcance	O
de	O
transgén	B-Sequence
supresión	O
después	O
de	O
un	O
tratamiento	O
agudo	O
o	O
crónico	O
con	O
dox	O
.	O

Se	O
compararon	O
dos	O
grupos	O
tratados	O
con	O
dox	O
con	O
dos	O
grupos	O
no	O
tratados	O
:	O
un	O
grupo	O
de	O
ratones	B-Taxon
nació	O
y	O
se	O
crió	O
con	O
dox	O
,	O
un	O
segundo	O
grupo	O
fue	O
tratado	O
con	O
dox	O
durante	O
2	O
semanas	O
a	O
partir	O
del	O
mes	O
de	O
edad	O
(	O
4	O
semanas	O
+	O
2	O
semanas	O
de	O
dox	O
)	O
;	O
dos	O
grupos	O
no	O
tratados	O
mantenidos	O
con	O
comida	O
normal	O
fueron	O
recolectados	O
a	O
las	O
4	O
o	O
6	O
semanas	O
de	O
edad	O
.	O

animales	B-Taxon
nacido	O
y	O
criado	O
en	O
dox	O
no	O
albergaba	O
transgénico	B-Sequence
APLICACIÓN	B-Protein
(	O
Figura	O
1A	O
)	O
.	O

Después	O
de	O
tan	O
solo	O
2	O
semanas	O
de	O
tratamiento	O
con	O
dox	O
,	O
transgénico	B-Sequence
APLICACIÓN	B-Protein
la	O
expresión	O
se	O
redujo	O
en	O
más	O
del	O
95	O
%	O
en	O
comparación	O
con	O
los	O
niveles	O
anteriores	O
a	O
la	O
doxina	O
.	O

La	O
expresión	O
residual	O
que	O
queda	O
en	O
pacientes	O
tratados	O
de	O
forma	O
aguda	O
ratones	B-Taxon
representa	O
menos	O
del	O
4	O
%	O
de	O
la	O
transgénico	B-Sequence
proteína	B-Chemical
producido	O
en	O
ausencia	O
de	O
dox	O
(	O
Figura	O
1C	O
)	O
,	O
y	O
probablemente	O
resulta	O
de	O
una	O
ligera	O
fuga	O
en	O
el	O
nivel	O
de	O
transcripción	O
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Es	O
importante	O
destacar	O
que	O
la	O
cantidad	O
total	O
de	O
APLICACIÓN	B-Protein
(	O
endógeno	O
plus	O
transgénico	B-Sequence
)	O
y	O
APLP	O
relacionados	O
en	O
tratamientos	O
agudos	O
y	O
crónicos	O
.	O
animales	B-Taxon
fue	O
estadísticamente	O
indistinguible	O
de	O
la	O
de	O
los	O
no	O
transgénicos	O
ratones	B-Taxon
(	O
Figura	O
1D	O
;	O
los	O
análisis	O
estadísticos	O
de	O
los	O
experimentos	O
a	O
lo	O
largo	O
del	O
estudio	O
se	O
presentan	O
en	O
las	O
leyendas	O
de	O
las	O
figuras	O
adjuntas	O
)	O
.	O

Para	O
asegurar	O
eso	O
una	B-Protein
beta	I-Protein
la	O
producción	O
fue	O
suprimida	O
en	O
concierto	O
con	O
la	O
inhibición	O
mediada	O
por	O
dox	O
de	O
su	O
precursor	O
APPswe	O
/	O
Indiana	B-Protein
,	O
medimos	O
una	B-Protein
beta	I-Protein
40	I-Protein
y	O
una	B-Protein
beta	I-Protein
42	I-Protein
niveles	O
por	O
ELISA	O
en	O
homogeneizados	O
de	O
prosencéfalo	O
de	O
jóvenes	O
tet	O
-	O
off	O
animales	B-Taxon
.	O

Al	O
mes	O
de	O
edad	O
,	O
el	O
ratones	B-Taxon
carecía	O
de	O
agregados	O
amiloides	O
visibles	O
que	O
podrían	O
actuar	O
como	O
un	O
reservorio	O
intratable	O
de	O
péptido	B-Sequence
permanece	O
en	O
el	O
cerebro	O
después	O
de	O
la	O
transgén	B-Sequence
había	O
sido	O
suprimido	O
.	O

Para	O
garantizar	O
aún	O
más	O
que	O
pudiéramos	O
detectar	O
cualquier	O
agregado	O
insoluble	O
que	O
pudiera	O
sesgar	O
nuestra	O
medida	O
de	O
los	O
cambios	O
en	O
péptido	B-Sequence
síntesis	O
,	O
realizamos	O
una	O
extracción	O
secuencial	O
de	O
tres	O
pasos	O
con	O
PBS	O
,	O
2	O
%	O
SDS	B-Chemical
,	O
y	O
70	O
%	O
FA	B-Chemical
que	O
separaría	O
péptidos	B-Sequence
por	O
solubilidad	O
.	O

Comparamos	O
los	O
niveles	O
de	O
humano	B-Taxon
transgén	B-Sequence
#	O
¿NOMBRE	O
?	O
una	B-Protein
beta	I-Protein
40	I-Protein
y	O
una	B-Protein
beta	I-Protein
42	I-Protein
en	O
no	O
tratado	O
ratones	B-Taxon
a	O
las	O
4	O
y	O
6	O
semanas	O
de	O
edad	O
para	O
animales	B-Taxon
que	O
nacieron	O
y	O
se	O
criaron	O
con	O
dox	O
o	O
que	O
se	O
dejaron	O
sin	O
tratar	O
durante	O
4	O
semanas	O
y	O
luego	O
se	O
colocaron	O
en	O
alimento	O
dox	O
durante	O
2	O
semanas	O
antes	O
de	O
la	O
cosecha	O
(	O
los	O
mismos	O
grupos	O
descritos	O
anteriormente	O
para	O
el	O
análisis	O
de	O
inmunotransferencia	O
de	O
APPswe	O
/	O
Indiana	B-Protein
niveles	O
,	O
línea	O
107	O
)	O
.	O

En	O
consonancia	O
con	O
la	O
reducción	O
de	O
APPswe	O
/	O
Indiana	B-Protein
síntesis	O
mostrada	O
por	O
inmunoblot	O
(	O
ver	O
Figura	O
1	O
)	O
,	O
encontramos	O
que	O
transgén	B-Sequence
#	O
¿NOMBRE	O
?	O
una	B-Protein
beta	I-Protein
los	O
niveles	O
fueron	O
completamente	O
suprimidos	O
en	O
animales	B-Taxon
nacieron	O
y	O
se	O
criaron	O
en	O
dox	O
,	O
y	O
se	O
redujeron	O
drásticamente	O
después	O
de	O
la	O
fase	O
aguda	O
(	O
2	O
semanas	O
)	O
antibiótico	B-Chemical
tratamiento	O
.	O

En	O
comparación	O
con	O
los	O
niveles	O
en	O
pacientes	O
de	O
4	O
semanas	O
sin	O
tratar	O
ratones	B-Taxon
,	O
PBS	O
-	O
soluble	O
una	B-Protein
beta	I-Protein
42	I-Protein
se	O
redujo	O
en	O
95	O
.	O
2	O
%	O
después	O
de	O
2	O
semanas	O
de	O
tratamiento	O
con	O
dox	O
y	O
para	O
el	O
99	O
.	O
2	O
%	O
con	O
tratamiento	O
crónico	O
(	O
Figura	O
2A	O
)	O
.	O

Similar	O
,	O
SDS	B-Chemical
#	O
¿NOMBRE	O
?	O
una	B-Protein
beta	I-Protein
42	I-Protein
disminuyó	O
en	O
75	O
.	O
2	O
%	O
y	O
94	O
.	O
8	O
%	O
después	O
de	O
un	O
tratamiento	O
dox	O
de	O
2	O
semanas	O
o	O
de	O
por	O
vida	O
(	O
Figura	O
2B	O
)	O
.	O

Solo	O
el	O
FA	B-Chemical
fracción	B-GENE
reveló	O
un	O
pequeño	O
dox	O
-	O
grupo	O
resistente	O
de	O
péptido	B-Sequence
en	O
tratamiento	O
agudo	O
animales	B-Taxon
que	O
creemos	O
que	O
representa	O
agregados	O
predepósito	O
estables	O
que	O
ya	O
se	O
han	O
acumulado	O
a	O
las	O
4	O
semanas	O
de	O
edad	O
cuando	O
se	O
inició	O
el	O
tratamiento	O
(	O
Figura	O
2C	O
)	O
.	O

Por	O
supuesto	O
,	O
animales	B-Taxon
que	O
nacieron	O
y	O
se	O
criaron	O
en	O
dox	O
no	O
albergaron	O
esta	O
reserva	O
de	O
tratamiento	O
-	O
resistente	O
péptido	B-Sequence
,	O
con	O
96	O
.	O
3	O
%	O
menos	O
una	B-Protein
beta	I-Protein
42	I-Protein
que	O
sin	O
tratar	O
4	O
semanas	O
de	O
edad	O
ratones	B-Taxon
.	O

Medida	O
de	O
totales	O
una	B-Protein
beta	I-Protein
en	O
tratamiento	O
crónico	O
ratones	B-Taxon
,	O
incluidas	O
las	O
endógenas	O
y	O
transgén	B-Sequence
#	O
¿NOMBRE	O
?	O
péptido	B-Sequence
,	O
demostró	O
que	O
una	B-Protein
beta	I-Protein
niveles	O
en	O
tet	O
-	O
off	O
APLICACIÓN	B-Protein
ratones	B-Taxon
se	O
redujeron	O
al	O
nivel	O
de	O
endógenos	O
péptido	B-Sequence
encontrado	O
en	O
no	O
transgénico	O
animales	B-Taxon
(	O
Figura	O
2D	O
)	O
.	O

Tomado	O
junto	O
con	O
los	O
datos	O
de	O
inmunotransferencia	O
para	O
APPswe	O
de	O
longitud	O
completa	O
/	O
Indiana	B-Protein
,	O
las	O
mediciones	O
de	O
ELISA	O
indican	O
que	O
la	O
supresión	O
mediada	O
por	O
dox	O
de	O
transgénico	B-Sequence
aplicacioneswe	O
/	O
Indiana	B-Protein
la	O
síntesis	O
conduce	O
a	O
la	O
reducción	O
paralela	O
de	O
una	B-Protein
beta	I-Protein
niveles	O

Los	O
datos	O
de	O
ELISA	O
también	O
confirmaron	O
que	O
la	O
incorporación	O
del	O
sueco	B-Protein
y	O
Indiana	B-Protein
mutaciones	B-Sequence
condujo	O
a	O
altos	O
niveles	O
de	O
una	B-Protein
beta	I-Protein
42	I-Protein
,	O
que	O
predijimos	O
induciría	O
la	O
formación	O
rápida	O
de	O
placa	O
en	O
pacientes	O
no	O
tratados	O
animales	B-Taxon
.	O

Caracterización	O
histológica	O
del	O
doble	O
transgénico	B-Sequence
(	O
CaMKII	B-Protein
alfa	I-Protein
-	O
tTA	O
x	O
tet	O
-	O
APPswe	O
/	O
Indiana	B-Protein
)	O
ratones	B-Taxon
reveló	O
la	O
formación	O
de	O
amiloide	O
de	O
aparición	O
temprana	O
en	O
las	O
cuatro	O
líneas	O
nuevas	O
.	O

Se	O
observaron	O
placas	O
de	O
amiloide	O
en	O
ratones	B-Taxon
desde	O
las	O
8	O
semanas	O
de	O
edad	O
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Las	O
placas	O
estaban	O
limitadas	O
al	O
prosencéfalo	O
,	O
incluyendo	O
la	O
corteza	O
,	O
el	O
hipocampo	O
,	O
el	O
bulbo	O
olfatorio	O
y	O
el	O
cuerpo	O
estriado	O
,	O
donde	O
el	O
CaMKII	B-Protein
alfa	I-Protein
promotor	B-Sequence
se	O
sabe	O
que	O
es	O
el	O
más	O
activo	O
[	O
16	O
,	O
28	O
]	O
(	O
Figura	O
S2	O
)	O
.	O

A	O
los	O
6	O
meses	O
de	O
edad	O
,	O
la	O
carga	O
de	O
amiloide	O
se	O
volvió	O
severa	O
,	O
cubriendo	O
grandes	O
áreas	O
de	O
la	O
corteza	O
y	O
el	O
hipocampo	O
(	O
Figura	O
S3	O
)	O
.	O

No	O
se	O
observaron	O
lesiones	O
en	O
el	O
cerebelo	O
ni	O
en	O
el	O
tronco	O
del	O
encéfalo	O
,	O
incluso	O
en	O
edades	O
tardías	O
,	O
lo	O
que	O
concuerda	O
con	O
CaMKII	B-Protein
alfa	I-Protein
#	O
¿NOMBRE	O
?	O
transgén	B-Sequence
expresión	O
.	O

A	O
diferencia	O
de	O
lo	O
que	O
se	O
piensa	O
que	O
ocurre	O
en	O
el	O
humano	B-Taxon
enfermedad	O
,	O
las	O
primeras	O
placas	O
visibles	O
en	O
el	O
tet-off	O
APLICACIÓN	B-Protein
ratones	B-Taxon
son	O
depósitos	O
con	O
núcleo	O
fibrilar	O
.	O

Hemos	O
notado	O
la	O
misma	O
aparición	O
temprana	O
de	O
depósitos	O
con	O
núcleo	O
en	O
otras	O
líneas	O
de	O
APLICACIÓN	B-Protein
transgénico	B-Sequence
ratones	B-Taxon
que	O
albergan	O
el	O
sueco	B-Protein
mutación	B-Sequence
[	O
27	O
]	O
.	O

Se	O
observaron	O
placas	O
difusas	O
en	O
tTA	O
/	O
APLICACIÓN	B-Protein
ratones	B-Taxon
y	O
se	O
volvió	O
relativamente	O
abundante	O
a	O
los	O
9	O
meses	O
de	O
edad	O
.	O

edades	O
más	O
avanzadas	O
(	O
9-12	O
meses	O
)	O
los	O
depósitos	O
de	O
amiloide	O
eran	O
visibles	O
en	O
el	O
tálamo	O
,	O
lo	O
que	O
también	O
se	O
ha	O
observado	O
en	O
ratones	B-Taxon
expresando	O
mutante	B-Sequence
APLICACIÓN	B-Protein
mediante	O
el	O
tu	B-Protein
-	I-Protein
1	I-Protein
promotor	B-Sequence
.	O

La	O
presencia	O
de	O
patología	O
amiloide	O
en	O
esta	O
región	O
se	O
ha	O
atribuido	O
a	O
axonal	B-GENE
transporte	O
de	O
APLICACIÓN	B-Protein
/	O
una	B-Protein
beta	I-Protein
al	O
terminales	B-GENE
de	I-GENE
las	I-GENE
neuronas	I-GENE
corticales	I-GENE
en	O
el	O
tálamo	O
[	O
29	O
]	O
.	O

Lo	O
más	O
importante	O
,	O
solo	O
el	O
doble	O
transgénico	B-Sequence
ratones	B-Taxon
,	O
expresando	O
tanto	O
el	O
tTA	O
como	O
APLICACIÓN	B-Protein
transgenes	B-Sequence
,	O
desarrolló	O
lesiones	O
amiloides	O
.	O

Único	O
transgénico	B-Sequence
ratones	B-Taxon
hasta	O
los	O
15	O
meses	O
de	O
edad	O
no	O
mostraron	O
signos	O
de	O
patología	O
(	O
Figura	O
S3	O
)	O
.	O

Del	O
mismo	O
modo	O
,	O
la	O
patología	O
amiloide	O
se	O
puede	O
prevenir	O
por	O
completo	O
en	O
doble	O
transgénico	B-Sequence
animales	B-Taxon
nacido	O
y	O
criado	O
en	O
dox	O
.	O

animales	B-Taxon
de	O
nuestra	O
línea	O
de	O
expresión	O
más	O
alta	O
(	O
línea	O
885	O
)	O
mantenida	O
en	O
dox	O
por	O
hasta	O
1	O
año	O
no	O
albergaba	O
patología	O
amiloide	O
(	O
datos	O
no	O
mostrados	O
)	O
,	O
lo	O
que	O
indica	O
que	O
la	O
fuga	O
residual	O
de	O
transgén	B-Sequence
expresión	O
en	O
presencia	O
de	O
dox	O
no	O
proporciona	O
suficiente	O
una	B-Protein
beta	I-Protein
péptido	B-Sequence
para	O
inducir	O
la	O
formación	O
de	O
amiloide	O
incluso	O
durante	O
períodos	O
prolongados	O
.	O

Para	O
imitar	O
la	O
intervención	O
terapéutica	O
con	O
inhibidores	B-Chemical
de	O
una	B-Protein
beta	I-Protein
producción	O
,	O
levantamos	O
un	O
grupo	O
de	O
25	O
dobles	O
transgénico	B-Sequence
ratones	B-Taxon
(	O
CaMKII	B-Protein
alfa	I-Protein
#	O
¿NOMBRE	O
?	O
APLICACIÓN	B-Protein
línea	O
107	O
)	O
en	O
normal	O
comida	B-Chemical
hasta	O
los	O
6	O
meses	O
de	O
edad	O
,	O
cuando	O
sabíamos	O
que	O
la	O
formación	O
de	O
amiloide	O
ya	O
estaba	O
en	O
marcha	O
en	O
el	O
cerebro	O
.	O

A	O
los	O
6	O
meses	O
,	O
la	O
mitad	O
de	O
los	O
animales	B-Taxon
fueron	O
cambiados	O
de	O
comida	O
normal	O
a	O
comida	B-Chemical
conteniendo	O
dox	O
a	O
200	O
mg/kg	O
hasta	O
que	O
fueron	O
sacrificados	O
a	O
los	O
9	O
o	O
12	O
meses	O
de	O
edad	O
.	O

El	O
control	O
restante	O
animales	B-Taxon
se	O
mantuvieron	O
con	O
comida	O
estándar	O
(	O
sin	O
tratar	O
)	O
.	O

En	O
total	O
,	O
se	O
crearon	O
cuatro	O
cohortes	O
:	O
6	O
meses	O
sin	O
tratamiento	O
(	O
n	O
=	O
7	O
)	O
,	O
9	O
meses	O
sin	O
tratamiento	O
(	O
n	O
=	O
5	O
)	O
,	O
6	O
meses	O
+	O
3	O
meses	O
con	O
tratamiento	O
(	O
n	O
=	O
8	O
)	O
y	O
6	O
meses	O
+	O
6	O
meses	O
con	O
tratamiento	O
(	O
n	O
=	O
5	O
)	O
.	O

Supresión	O
total	O
(	O
>	O
95	O
%	O
)	O
de	O
transgénico	B-Sequence
aplicacioneswe	O
/	O
Indiana	B-Protein
niveles	O
en	O
el	O
dox	O
-	O
tratados	O
animales	B-Taxon
fue	O
confirmado	O
por	O
inmunoblot	O
(	O
Figura	O
3	O
)	O
.	O

para	O
asegurarse	O
de	O
que	O
el	O
transgén	B-Sequence
podría	O
suprimirse	O
tan	O
rápidamente	O
en	O
6	O
meses	O
de	O
edad	O
ratones	B-Taxon
con	O
patología	O
fulminante	O
como	O
puede	O
en	O
jóvenes	O
,	O
predepósito	O
animales	B-Taxon
,	O
tratamos	O
un	O
conjunto	O
adicional	O
de	O
6	O
meses	O
de	O
edad	O
animales	B-Taxon
con	O
dox	O
durante	O
1	O
semana	O
antes	O
de	O
la	O
cosecha	O
.	O

Es	O
importante	O
destacar	O
que	O
tanto	O
APPswe	O
/	O
Indiana	B-Protein
y	O
APLICACIÓN	B-Protein
-	O
C	B-Sequence
-	I-Sequence
fragmento	I-Sequence
terminal	I-Sequence
los	O
niveles	O
se	O
suprimieron	O
por	O
completo	O
después	O
de	O
sólo	O
1	O
semana	O
de	O
tratamiento	O
,	O
lo	O
que	O
indica	O
que	O
la	O
vida	O
media	O
in	O
vivo	O
de	O
APPswe	O
/	O
Indiana	B-Protein
y	O
es	O
procesado	O
C	B-Sequence
-	I-Sequence
fragmentos	I-Sequence
terminales	I-Sequence
son	O
relativamente	O
cortos	O
(	O
Figura	O
3D	O
)	O
.	O

Secciones	O
de	O
tejido	O
de	O
cada	O
animal	B-Taxon
en	O
los	O
cuatro	O
grupos	O
de	O
tratamiento	O
fueron	O
teñidos	O
para	O
patología	O
amiloide	O
por	O
Hirano	O
plata	B-Chemical
,	O
Campbell	O
-	O
Suiza	O
plata	B-Chemical
,	O
tioflavina	O
-	O
S	O
,	O
y	O
una	B-Protein
beta	I-Protein
inmunohistoquímica	O
.	O

Como	O
era	O
de	O
esperar	O
,	O
la	O
cohorte	O
de	O
6	O
meses	O
sin	O
tratamiento	O
mostró	O
una	O
patología	O
amiloide	O
moderada	O
,	O
y	O
la	O
cohorte	O
de	O
9	O
meses	O
sin	O
tratamiento	O
progresó	O
a	O
una	O
carga	O
de	O
amiloide	O
grave	O
.	O

Por	O
el	O
contrario	O
,	O
la	O
extensión	O
de	O
la	O
patología	O
amiloide	O
en	O
ratones	B-Taxon
de	O
las	O
cohortes	O
de	O
6	O
meses	O
+	O
3	O
meses	O
tratadas	O
o	O
de	O
6	O
meses	O
+	O
6	O
meses	O
tratadas	O
se	O
parecía	O
mucho	O
a	O
la	O
cohorte	O
de	O
6	O
meses	O
sin	O
tratar	O
,	O
a	O
pesar	O
de	O
la	O
diferencia	O
de	O
edad	O
significativa	O
entre	O
los	O
grupos	O
tratados	O
y	O
no	O
tratados	O
(	O
Figuras	O
4	O
y	O
Figura	O
S3	O
)	O
.	O

Placas	O
bien	O
formadas	O
permanecieron	O
en	O
el	O
tratado	O
animales	B-Taxon
después	O
de	O
6	O
meses	O
de	O
transgén	B-Sequence
supresión	O
,	O
aunque	O
se	O
dio	O
tanto	O
tiempo	O
para	O
aclarar	O
las	O
lesiones	O
como	O
habían	O
tardado	O
en	O
formarse	O
.	O

Además	O
,	O
ambos	O
tipos	O
de	O
amiloide	O
,	O
difuso	O
y	O
fibrilar	O
,	O
permanecieron	O
intactos	O
durante	O
todo	O
el	O
tratamiento	O
.	O

Uso	O
de	O
Campbell	O
-	O
Switzer	O
plata	B-Chemical
tinción	O
para	O
distinguir	O
diferentes	O
formas	O
de	O
amiloide	O
,	O
encontramos	O
que	O
las	O
placas	O
difusas	O
eran	O
tan	O
persistentes	O
como	O
los	O
depósitos	O
en	O
núcleo	O
(	O
Figura	O
S4	O
)	O
.	O

No	O
obstante	O
,	O
estaba	O
claro	O
que	O
la	O
supresión	O
inducida	O
por	O
dox	O
de	O
transgénico	B-Sequence
APLICACIÓN	B-Protein
había	O
detenido	O
por	O
completo	O
la	O
progresión	O
de	O
la	O
patología	O
.	O

Confirmar	O
que	O
la	O
detención	O
de	O
placas	O
sin	O
ningún	O
signo	O
de	O
holgura	O
no	O
fue	O
exclusiva	O
de	O
la	O
línea	O
107	O
ratones	B-Taxon
,	O
repetimos	O
el	O
experimento	O
de	O
supresión	O
de	O
dox	O
en	O
una	O
segunda	O
línea	O
de	O
prueba	O
APLICACIÓN	B-Protein
ratones	B-Taxon
(	O
CaMKII	B-Protein
alfa	I-Protein
-	O
tTA	O
x	O
tet	O
-	O
APPswe	O
/	O
Indiana	B-Protein
línea	O
18	O
;	O
n	O
=	O
22	O
)	O
.	O

Una	O
vez	O
más	O
,	O
el	O
tratamiento	O
dox	O
a	O
largo	O
plazo	O
se	O
inició	O
a	O
los	O
6	O
meses	O
de	O
edad	O
y	O
ratones	B-Taxon
fueron	O
cosechados	O
después	O
de	O
3	O
meses	O
de	O
transgén	B-Sequence
supresión	O
(	O
6	O
meses	O
sin	O
tratamiento	O
,	O
n	O
=	O
8	O
;	O
9	O
meses	O
sin	O
tratamiento	O
,	O
n	O
=	O
6	O
;	O
6	O
meses	O
+	O
3	O
meses	O
tratados	O
,	O
n	O
=	O
8	O
)	O
.	O

inmunotransferencia	O
para	O
APLICACIÓN	B-Protein
confirmado	O
lleno	O
transgén	B-Sequence
supresión	O
en	O
el	O
tratado	O
animales	B-Taxon
(	O
Figura	O
S5	O
)	O
.	O

Como	O
en	O
la	O
linea	O
107	O
ratones	B-Taxon
descrito	O
anteriormente	O
,	O
la	O
carga	O
de	O
amiloide	O
empeoró	O
sustancialmente	O
en	O
los	O
no	O
tratados	O
ratones	B-Taxon
entre	O
los	O
6	O
y	O
9	O
meses	O
de	O
edad	O
.	O

Supresión	O
de	O
transgén	B-Sequence
expresión	O
detuvo	O
abruptamente	O
la	O
progresión	O
de	O
la	O
patología	O
(	O
Figura	O
S6	O
)	O
,	O
pero	O
de	O
nuevo	O
sin	O
ningún	O
signo	O
de	O
reducción	O
.	O

Ambas	O
cosas	O
plata	B-Chemical
#	O
¿NOMBRE	O
?	O
animales	B-Taxon
.	O

Medimos	O
bioquímicamente	O
la	O
cantidad	O
de	O
agregados	O
una	B-Protein
beta	I-Protein
en	O
el	O
cerebro	O
de	O
nuestros	O
ratones	B-Taxon
antes	O
y	O
después	O
de	O
transgén	B-Sequence
supresión	O
utilizando	O
análisis	O
de	O
trampa	O
de	O
filtro	O
de	O
tejido	O
cortical	O
de	O
cada	O
animal	B-Taxon
.	O

En	O
este	O
ensayo	O
,	O
diluciones	O
en	O
serie	O
de	O
proteína	B-Chemical
homogeneizado	O
se	O
pasan	O
a	O
través	O
de	O
una	O
celulosa	O
acetato	B-Chemical
filtro	O
;	O
las	O
partículas	O
más	O
grandes	O
que	O
el	O
tamaño	O
de	O
poro	O
del	O
filtro	O
quedan	O
atrapadas	O
en	O
la	O
membrana	O
y	O
se	O
revelan	O
mediante	O
inmunotransferencia	O
[	O
22	O
]	O
.	O

De	O
acuerdo	O
con	O
nuestro	O
análisis	O
visual	O
de	O
las	O
secciones	O
histológicas	O
,	O
la	O
línea	O
107	O
tTA/	O
APLICACIÓN	B-Protein
ratones	B-Taxon
tratados	O
con	O
dox	O
durante	O
3	O
o	O
6	O
meses	O
tenían	O
la	O
misma	O
cantidad	O
de	O
agregado	O
una	B-Protein
beta	I-Protein
como	O
cuando	O
comenzaron	O
el	O
tratamiento	O
a	O
los	O
6	O
meses	O
de	O
edad	O
(	O
Figura	O
4A	O
y	O
4B	O
)	O
.	O

Por	O
el	O
contrario	O
,	O
los	O
niños	O
de	O
9	O
meses	O
sin	O
tratar	O
ratones	B-Taxon
tenía	O
casi	O
el	O
doble	O
de	O
agregado	O
una	B-Protein
beta	I-Protein
como	O
cualquiera	O
de	O
los	O
grupos	O
tratados	O
.	O

Análisis	O
de	O
trampa	O
de	O
filtro	O
de	O
la	O
línea	O
18	O
tTA	O
/	O
APLICACIÓN	B-Protein
ratones	B-Taxon
arrojó	O
resultados	O
similares	O
:	O
el	O
aumento	O
en	O
el	O
agregado	O
una	B-Protein
beta	I-Protein
observado	O
en	O
no	O
tratado	O
animales	B-Taxon
entre	O
6	O
y	O
9	O
meses	O
de	O
edad	O
fue	O
completamente	O
detenido	O
por	O
transgén	B-Sequence
supresión	O
(	O
Figura	O
S5C	O
y	O
S5D	O
)	O
.	O

Luego	O
usamos	O
ELISA	O
para	O
medir	O
el	O
total	O
una	B-Protein
beta	I-Protein
en	O
los	O
cerebros	O
de	O
cada	O
grupo	O
para	O
determinar	O
si	O
algún	O
cambio	O
en	O
la	O
cantidad	O
o	O
solubilidad	O
de	O
péptido	B-Sequence
ocurrió	O
mientras	O
APPswe	O
/	O
Indiana	B-Protein
la	O
expresión	O
fue	O
suprimida	O
.	O

Los	O
homogeneizados	O
corticales	O
se	O
extrajeron	O
secuencialmente	O
para	O
separar	O
péptido	B-Sequence
en	O
PBS-	O
,	O
SDS	B-Chemical
-	O
,	O
y	O
FA	B-Chemical
#	O
¿NOMBRE	O
?	O
fracciones	B-GENE
,	O
luego	O
transgén	B-Sequence
#	O
¿NOMBRE	O
?	O
una	B-Protein
beta	I-Protein
40	I-Protein
y	O
una	B-Protein
beta	I-Protein
42	I-Protein
fueron	O
medidos	O
por	O
humano	B-Taxon
ELISA	O
específico	O
[	O
23	O
]	O
.	O

En	O
todo	O
animales	B-Taxon
albergando	O
depósitos	O
de	O
amiloide	O
,	O
encontramos	O
que	O
la	O
gran	O
mayoría	O
de	O
una	B-Protein
beta	I-Protein
(	O
>	O
99	O
%	O
)	O
se	O
extrajo	O
en	O
el	O
SDS	B-Chemical
y	O
FA	B-Chemical
fracciones	B-GENE
(	O
Figura	O
5A	O
y	O
5B	O
)	O
.	O

De	O
acuerdo	O
con	O
los	O
resultados	O
de	O
la	O
trampa	O
de	O
filtro	O
presentados	O
anteriormente	O
,	O
no	O
hubo	O
diferencias	O
significativas	O
en	O
SDS	B-Chemical
#	O
¿NOMBRE	O
?	O
FA	B-Chemical
#	O
¿NOMBRE	O
?	O
una	B-Protein
beta	I-Protein
entre	O
la	O
cohorte	O
de	O
6	O
meses	O
sin	O
tratar	O
y	O
las	O
cohortes	O
de	O
6	O
meses	O
+	O
3	O
meses	O
tratadas	O
o	O
6	O
meses	O
+	O
6	O
meses	O
tratadas	O
.	O

Sin	O
embargo	O
,	O
los	O
cerebros	O
de	O
las	O
cohortes	O
tratadas	O
tanto	O
de	O
6	O
meses	O
+	O
3	O
meses	O
como	O
de	O
6	O
meses	O
+	O
6	O
meses	O
contenían	O
aproximadamente	O
el	O
doble	O
de	O
PBS	O
soluble	O
una	B-Protein
beta	I-Protein
40	I-Protein
como	O
sin	O
tratar	O
6	O
meses	O
de	O
edad	O
ratones	B-Taxon
(	O
Figura	O
5C	O
)	O
.	O

Niveles	O
de	O
una	B-Protein
beta	I-Protein
42	I-Protein
mostró	O
una	O
tendencia	O
similar	O
,	O
pero	O
no	O
alcanzó	O
significación	O
estadística	O
.	O

De	O
hecho	O
,	O
los	O
niveles	O
de	O
PBS	O
-	O
soluble	O
una	B-Protein
beta	I-Protein
40	I-Protein
y	O
una	B-Protein
beta	I-Protein
42	I-Protein
en	O
las	O
cohortes	O
tratadas	O
de	O
6	O
meses	O
+	O
3	O
meses	O
y	O
6	O
meses	O
+	O
6	O
meses	O
fueron	O
más	O
similares	O
a	O
las	O
de	O
la	O
cohorte	O
no	O
tratada	O
de	O
9	O
meses	O
,	O
lo	O
que	O
sugiere	O
que	O
la	O
edad	O
,	O
a	O
diferencia	O
de	O
la	O
tasa	O
sintética	O
(	O
que	O
sería	O
insignificante	O
en	O
la	O
cohorte	O
tratada	O
)	O
animales	B-Taxon
)	O
,	O
puede	O
determinar	O
la	O
fracción	O
de	O
PBS	O
-	O
soluble	O
una	B-Protein
beta	I-Protein
en	O
estos	O
animales	B-Taxon
.	O

También	O
evaluamos	O
neuríticas	O
y	O
glial	B-Cell
patología	O
que	O
rodea	O
las	O
placas	O
para	O
determinar	O
si	O
hubo	O
algún	O
cambio	O
en	O
el	O
tejido	O
cercano	O
después	O
de	O
un	O
largo	O
plazo	O
transgén	B-Sequence
represión	O

Ambos	O
Hirano	O
plata	B-Chemical
La	O
tinción	O
y	O
la	O
inmunotinción	O
con	O
ubiquitina	O
mostraron	O
patología	O
neurítica	O
en	O
todos	O
los	O
grupos	O
de	O
tratamiento	O
(	O
Figura	O
6	O
)	O
.	O

Del	O
mismo	O
modo	O
,	O
activado	O
astrocitos	B-Cell
inmunoteñido	O
para	O
GFAP	B-Protein
fueron	O
encontrados	O
cerca	O
de	O
placas	O
en	O
todos	O
animales	B-Taxon
(	O
Figura	O
6	O
)	O
.	O

neurítica	O
y	O
glial	B-Cell
patología	O
fueron	O
más	O
graves	O
en	O
los	O
mayores	O
no	O
tratados	O
ratones	B-Taxon
.	O

A	O
diferencia	O
de	O
,	O
transgén	B-Sequence
la	O
supresión	O
impidió	O
el	O
crecimiento	O
de	O
depósitos	O
individuales	O
aparentes	O
en	O
no	O
tratados	O
ratones	B-Taxon
limitó	O
la	O
patología	O
circundante	O
a	O
lo	O
que	O
ya	O
estaba	O
presente	O
cuando	O
comenzó	O
el	O
tratamiento	O
.	O

Una	O
pregunta	O
obvia	O
que	O
buscábamos	O
abordar	O
era	O
si	O
la	O
deposición	O
de	O
una	B-Protein
beta	I-Protein
disminución	O
de	O
la	O
capacidad	O
cognitiva	O
en	O
pacientes	O
no	O
tratados	O
ratones	B-Taxon
y	O
lo	O
que	O
podría	O
sucederle	O
a	O
la	O
cognición	O
cuando	O
se	O
interrumpiera	O
el	O
proceso	O
.	O

Desafortunadamente	O
,	O
los	O
esfuerzos	O
para	O
caracterizar	O
el	O
comportamiento	O
cognitivo	O
se	O
vieron	O
comprometidos	O
por	O
la	O
hiperactividad	O
severa	O
en	O
pacientes	O
dobles	O
no	O
tratados	O
.	O
transgénico	B-Sequence
ratones	B-Taxon
.	O

El	O
tTA	O
/	O
APLICACIÓN	B-Protein
animales	B-Taxon
a	O
menudo	O
se	O
les	O
veía	O
corriendo	O
en	O
círculos	O
alrededor	O
del	O
perímetro	O
de	O
sus	O
jaulas	O
,	O
y	O
se	O
observó	O
un	O
patrón	O
de	O
nado	O
similar	O
cuando	O
el	O
ratones	B-Taxon
fueron	O
probados	O
en	O
el	O
Morris	O
agua	B-Chemical
laberinto	O
.	O

en	O
el	O
radial	O
agua	B-Chemical
En	O
el	O
laberinto	O
,	O
se	O
observaron	O
patrones	O
de	O
nado	O
repetitivos	O
sin	O
evidencia	O
de	O
acciones	O
motivadas	O
por	O
elección	O
.	O

Otros	O
estudios	O
han	O
abordado	O
problemas	O
similares	O
excluyendo	O
animales	B-Taxon
que	O
no	O
muestran	O
la	O
atención	O
adecuada	O
a	O
la	O
tarea	O
,	O
reteniendo	O
sólo	O
aquellos	O
ratones	B-Taxon
que	O
cumplen	O
determinados	O
criterios	O
de	O
rendimiento	O
[	O
30	O
]	O
.	O

En	O
nuestro	O
caso	O
,	O
la	O
penetración	O
de	O
la	O
hiperactividad	O
fue	O
cercana	O
al	O
100	O
%	O
,	O
dejándonos	O
sin	O
resultados	O
comprobables	O
.	O
animales	B-Taxon
.	O

Este	O
fenotipo	O
no	O
ha	O
afectado	O
a	O
líneas	O
anteriores	O
de	O
APPs	O
.	O
ratones	B-Taxon
que	O
hemos	O
producido	O
,	O
como	O
las	O
líneas	O
E1-2	O
o	O
C3-3	O
,	O
que	O
expresan	O
niveles	O
más	O
bajos	O
de	O
transgénico	B-Sequence
proteína	B-Chemical
.	O

De	O
hecho	O
,	O
en	O
estudios	O
anteriores	O
en	O
los	O
que	O
la	O
hiperactividad	O
no	O
era	O
un	O
factor	O
,	O
establecimos	O
una	O
relación	O
clara	O
entre	O
la	O
carga	O
de	O
amiloide	O
y	O
la	O
capacidad	O
cognitiva	O
[	O
31	O
]	O
.	O

Sin	O
embargo	O
,	O
en	O
el	O
estudio	O
actual	O
,	O
creemos	O
que	O
aunque	O
el	O
desempeño	O
deficiente	O
del	O
tTA	O
/	O
APLICACIÓN	B-Protein
ratones	B-Taxon
en	O
las	O
pruebas	O
del	O
laberinto	O
podría	O
calificarse	O
técnicamente	O
como	O
deterioro	O
cognitivo	O
,	O
el	O
animales	B-Taxon
La	O
hiperactividad	O
severa	O
hizo	O
imposible	O
la	O
interpretación	O
de	O
las	O
tareas	O
cognitivas	O
.	O

Para	O
comprender	O
la	O
naturaleza	O
y	O
el	O
alcance	O
de	O
la	O
hiperactividad	O
en	O
el	O
tTA	O
/	O
APLICACIÓN	B-Protein
ratones	B-Taxon
,	O
cuantificamos	O
los	O
niveles	O
de	O
actividad	O
diaria	O
en	O
doble	O
transgénico	B-Sequence
animales	B-Taxon
junto	O
con	O
su	O
sencillo	O
transgénico	B-Sequence
y	O
hermanos	O
no	O
transgénicos	O
que	O
usan	O
marcos	O
de	O
cuatro	O
haces	O
diseñados	O
para	O
monitorear	O
la	O
deambulación	O
dentro	O
de	O
una	O
jaula	O
cerrada	O
.	O

Como	O
se	O
muestra	O
en	O
la	O
Figura	O
7	O
,	O
el	O
doble	O
transgénico	B-Sequence
ratones	B-Taxon
eran	O
hasta	O
10	O
veces	O
más	O
activos	O
durante	O
la	O
fase	O
oscura	O
del	O
ciclo	O
día-noche	O
que	O
cualquiera	O
de	O
los	O
grupos	O
de	O
control	O
.	O

Los	O
niveles	O
de	O
actividad	O
parecían	O
seguir	O
un	O
ciclo	O
diurno	O
relativamente	O
normal	O
,	O
disminuyendo	O
sustancialmente	O
durante	O
las	O
horas	O
del	O
día	O
.	O

Sin	O
embargo	O
,	O
incluso	O
durante	O
la	O
fase	O
de	O
luz	O
,	O
el	O
tTA/	O
APLICACIÓN	B-Protein
ratones	B-Taxon
permanecieron	O
muchas	O
veces	O
más	O
activos	O
que	O
los	O
controles	O
normales	O
.	O

Este	O
comportamiento	O
fue	O
parcialmente	O
,	O
pero	O
no	O
consistentemente	O
,	O
revertido	O
por	O
1	O
mes	O
de	O
transgén	B-Sequence
supresión	O
a	O
partir	O
de	O
los	O
4-5	O
meses	O
de	O
edad	O
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Por	O
el	O
contrario	O
,	O
la	O
hiperactividad	O
se	O
eliminó	O
por	O
completo	O
al	O
criar	O
tTA	O
/	O
APLICACIÓN	B-Protein
ratones	B-Taxon
en	O
dox	O
.	O

animales	B-Taxon
nacidos	O
y	O
criados	O
con	O
dox	O
mostraron	O
niveles	O
de	O
actividad	O
similares	O
a	O
los	O
controles	O
no	O
tratados	O
(	O
Figura	O
7C	O
)	O
.	O

Curiosamente	O
,	O
todos	O
los	O
dox-criados	O
animales	B-Taxon
,	O
ambas	O
cosas	O
transgénico	B-Sequence
y	O
tipo	B-Sequence
salvaje	I-Sequence
,	O
mostraron	O
ritmos	O
circadianos	O
alterados	O
con	O
mucha	O
menos	O
distinción	O
entre	O
sus	O
niveles	O
de	O
actividad	O
diurnos	O
y	O
nocturnos	O
.	O

Discusión	O

Presentamos	O
un	O
nuevo	O
ratón	B-Taxon
modelo	O
para	O
AD	O
que	O
fue	O
diseñado	O
para	O
probar	O
las	O
consecuencias	O
de	O
inhibir	O
una	B-Protein
beta	I-Protein
producción	O
después	O
del	O
inicio	O
de	O
la	O
patología	O
amiloide	O
.	O

nuevas	O
lineas	O
de	O
transgénico	B-Sequence
ratones	B-Taxon
fueron	O
desarrollados	O
para	O
este	O
estudio	O
que	O
expresan	O
altos	O
niveles	O
de	O
APPswe	O
/	O
Indiana	B-Protein
bajo	O
el	O
control	O
de	O
un	O
tetraciclina	B-Chemical
#	O
¿NOMBRE	O
?	O
promotor	B-Sequence
.	O

Demostramos	O
que	O
el	O
tratamiento	O
con	O
dox	O
suprime	O
los	O
niveles	O
de	O
estado	O
estacionario	O
de	O
ambos	O
APPswe	O
/	O
Indiana	B-Protein
y	O
es	O
C	B-Sequence
-	I-Sequence
fragmentos	I-Sequence
terminales	I-Sequence
,	O
indicando	O
que	O
el	O
mutante	B-Sequence
proteinas	B-Chemical
tienen	O
una	O
vida	O
media	O
in	O
vivo	O
relativamente	O
corta	O
.	O

transgénico	B-Sequence
expresión	O
de	O
APPswe	O
/	O
Indiana	B-Protein
y	O
la	O
consiguiente	O
sobreproducción	O
de	O
una	B-Protein
beta	I-Protein
42	I-Protein
causar	O
depósito	O
de	O
amiloide	O
de	O
aparición	O
temprana	O
en	O
pacientes	O
no	O
tratados	O
ratones	B-Taxon
,	O
en	O
el	O
que	O
los	O
depósitos	O
aparecen	O
a	O
los	O
2	O
meses	O
de	O
edad	O
.	O

La	O
carga	O
de	O
amiloide	O
empeora	O
significativamente	O
con	O
la	O
edad	O
,	O
y	O
a	O
los	O
9	O
meses	O
,	O
el	O
hipocampo	O
y	O
la	O
corteza	O
de	O
los	O
pacientes	O
no	O
tratados	O
ratones	B-Taxon
están	O
en	O
gran	O
parte	O
llenos	O
de	O
agregados	O
péptido	B-Sequence
.	O

Encontramos	O
que	O
la	O
supresión	O
de	O
transgénico	B-Sequence
APLICACIÓN	B-Protein
en	O
más	O
del	O
95	O
%	O
detiene	O
abruptamente	O
la	O
progresión	O
de	O
la	O
patología	O
amiloide	O
.	O

Es	O
importante	O
destacar	O
que	O
este	O
resultado	O
se	O
produce	O
en	O
animales	B-Taxon
que	O
ya	O
alberga	O
una	O
patología	O
amiloide	O
considerable	O
,	O
una	O
situación	O
similar	O
a	O
la	O
que	O
cabría	O
esperar	O
en	O
pacientes	O
tratados	O
con	O
secretasa	O
inhibidores	B-Chemical
.	O

De	O
manera	O
un	O
tanto	O
inesperada	O
,	O
no	O
observamos	O
una	O
eliminación	O
apreciable	O
del	O
amiloide	O
depositado	O
incluso	O
después	O
de	O
períodos	O
de	O
transgén	B-Sequence
supresión	O
igual	O
al	O
tiempo	O
que	O
tardan	O
en	O
formarse	O
las	O
placas	O
.	O

Este	O
último	O
hallazgo	O
indica	O
que	O
,	O
en	O
comparación	O
con	O
otras	O
enfermedades	O
asociadas	O
proteína	B-Chemical
agregados	O
tales	O
como	O
mutante	B-Sequence
cazatin	B-Protein
,	O
que	O
despeja	O
en	O
menos	O
de	O
3	O
meses	O
[	O
32	O
]	O
,	O
la	O
desagregación	O
de	O
extracelular	B-GENE
el	O
amiloide	O
es	O
relativamente	O
lento	O
.	O

En	O
particular	O
,	O
farmacéutico	B-Chemical
gamma	O
-	O
secretasa	O
inhibidores	B-Chemical
publicados	O
hasta	O
la	O
fecha	O
muestran	O
una	O
regulación	O
menos	O
estricta	O
de	O
una	B-Protein
beta	I-Protein
producción	O
después	O
de	O
la	O
administración	O
crónica	O
de	O
lo	O
que	O
hemos	O
logrado	O
aquí	O
.	O

dos	O
independientes	O
compuestos	B-Chemical
probado	O
en	O
Tg2576	O
[	O
33	O
]	O
y	O
TgCRND8	O
[	O
34	O
]	O
transgénico	B-Sequence
ratones	B-Taxon
no	O
muestran	O
más	O
del	O
85	O
%	O
de	O
supresión	O
de	O
una	B-Protein
beta	I-Protein
40	I-Protein
niveles	O
,	O
y	O
donde	O
medido	O
,	O
incluso	O
menos	O
supresión	O
de	O
una	B-Protein
beta	I-Protein
42	I-Protein
(	O
aproximadamente	O
60	O
%	O
)	O
[	O
35	O
,	O
36	O
]	O
.	O

Por	O
lo	O
tanto	O
,	O
incluso	O
después	O
de	O
tener	O
en	O
cuenta	O
la	O
mucho	O
mayor	O
APLICACIÓN	B-Protein
niveles	O
de	O
expresión	O
en	O
nuestro	O
ratones	B-Taxon
que	O
en	O
las	O
líneas	O
Tg2576	O
y	O
TgCRND8	O
,	O
hemos	O
logrado	O
una	O
mejor	O
supresión	O
absoluta	O
de	O
una	B-Protein
beta	I-Protein
producción	O
con	O
el	O
sistema	O
tet-off	O
de	O
lo	O
que	O
es	O
actualmente	O
posible	O
con	O
la	O
gamma-secretasa	O
publicada	O
inhibidores	B-Chemical
.	O

Ya	O
que	O
incluso	O
el	O
futuro	O
más	O
avanzado	O
agentes	B-Chemical
farmaceuticos	I-Chemical
es	O
improbable	O
que	O
logren	O
un	O
control	O
más	O
completo	O
de	O
una	B-Protein
beta	I-Protein
producción	O
que	O
la	O
lograda	O
aquí	O
,	O
este	O
sistema	O
proporciona	O
una	O
prueba	O
sobresaliente	O
de	O
intervención	O
terapéutica	O
con	O
una	B-Protein
beta	I-Protein
#	O
¿NOMBRE	O
?	O
compuestos	B-Chemical
.	O

Aunque	O
la	O
progresión	O
de	O
la	O
deposición	O
de	O
amiloide	O
se	O
detuvo	O
bruscamente	O
con	O
este	O
enfoque	O
,	O
encontramos	O
que	O
una	O
carga	O
amiloide	O
sustancial	O
permaneció	O
incluso	O
después	O
de	O
largos	O
períodos	O
de	O
transgén	B-Sequence
represión	O

Examinamos	O
un	O
pequeño	O
número	O
de	O
animales	B-Taxon
después	O
de	O
12	O
meses	O
de	O
tratamiento	O
con	O
dox	O
(	O
comenzando	O
a	O
los	O
6	O
meses	O
de	O
edad	O
)	O
,	O
y	O
encontró	O
que	O
los	O
depósitos	O
de	O
amiloide	O
todavía	O
eran	O
relativamente	O
abundantes	O
.	O

Actualmente	O
se	O
están	O
realizando	O
tratamientos	O
a	O
más	O
largo	O
plazo	O
.	O

En	O
el	O
último	O
intervalo	O
de	O
tratamiento	O
analizado	O
por	O
ELISA	O
,	O
animales	B-Taxon
dox	O
administrado	O
durante	O
6	O
meses	O
mostró	O
niveles	O
elevados	O
de	O
PBS	O
-	O
soluble	O
una	B-Protein
beta	I-Protein
(	O
ver	O
Figura	O
5	O
)	O
que	O
podría	O
interpretarse	O
como	O
una	O
indicación	O
de	O
que	O
las	O
placas	O
se	O
están	O
liberando	O
lentamente	O
péptido	B-Sequence
(	O
u	O
oligómero	O
A	O
beta	O
)	O
en	O
el	O
grupo	O
soluble	O
y	O
eventualmente	O
podría	O
disolverse	O
.	O

Ya	O
sea	O
inhibiendo	O
una	B-Protein
beta	I-Protein
la	O
producción	O
por	O
más	O
de	O
6	O
(	O
o	O
12	O
)	O
meses	O
puede	O
resultar	O
en	O
última	O
instancia	O
en	O
la	O
eliminación	O
de	O
amiloide	O
;	O
se	O
está	O
investigando	O
;	O
desafortunadamente	O
,	O
la	O
vida	O
útil	O
del	O
modelo	O
finalmente	O
limita	O
este	O
experimento	O
.	O

Terapéutica	O
utilizada	O
en	O
humanos	B-Taxon
tendrá	O
considerablemente	O
más	O
tiempo	O
para	O
actuar	O
de	O
lo	O
que	O
es	O
posible	O
dentro	O
de	O
la	O
vida	O
útil	O
de	O
roedor	B-Taxon
modelos	O

Los	O
tratamientos	O
a	O
largo	O
plazo	O
ciertamente	O
serían	O
posibles	O
y	O
podrían	O
ser	O
la	O
clave	O
para	O
una	O
terapia	O
efectiva	O
.	O

En	O
general	O
,	O
sin	O
embargo	O
,	O
interpretamos	O
nuestros	O
hallazgos	O
como	O
evidencia	O
de	O
que	O
las	O
terapias	O
para	O
la	O
DA	O
que	O
reducen	O
significativamente	O
la	O
producción	O
de	O
una	B-Protein
beta	I-Protein
(	O
ya	O
sea	O
inhibiendo	O
la	O
actividad	O
de	O
la	O
secretasa	O
o	O
inhibiendo	O
APLICACIÓN	B-Protein
expresión	O
)	O
no	O
puede	O
revertir	O
rápidamente	O
la	O
patología	O
preexistente	O
,	O
pero	O
debe	O
detener	O
de	O
manera	O
efectiva	O
una	O
mayor	O
deposición	O
de	O
amiloide	O
.	O

Al	O
interpretar	O
nuestro	O
estudio	O
,	O
debe	O
recordarse	O
que	O
las	O
primeras	O
placas	O
que	O
aparecen	O
en	O
estos	O
ratones	B-Taxon
,	O
como	O
otro	O
APLICACIÓN	B-Protein
transgénicos	B-Sequence
albergando	O
el	O
sueco	B-Protein
mutación	B-Sequence
27	O
]	O
,	O
son	O
predominantemente	O
depósitos	O
fibrilares	O
,	O
que	O
pueden	O
ser	O
menos	O
tratables	O
que	O
los	O
agregados	O
difusos	O
que	O
se	O
cree	O
que	O
aparecen	O
primero	O
en	O
el	O
curso	O
de	O
la	O
humano	B-Taxon
enfermedad	O
.	O

Sin	O
embargo	O
,	O
nuestros	O
datos	O
sugieren	O
que	O
una	O
vez	O
que	O
se	O
forman	O
depósitos	O
difusos	O
en	O
estos	O
ratones	B-Taxon
,	O
no	O
se	O
eliminan	O
más	O
fácilmente	O
en	O
nuestro	O
sistema	O
que	O
las	O
placas	O
perforadas	O
(	O
ver	O
Figura	O
S4	O
)	O
.	O

Una	O
consideración	O
adicional	O
que	O
reconocemos	O
es	O
que	O
una	O
pequeña	O
cantidad	O
de	O
transgén	B-Sequence
expresión	O
continúa	O
en	O
presencia	O
de	O
dox	O
y	O
que	O
endógeno	O
ratón	B-Taxon
una	B-Protein
beta	I-Protein
se	O
sigue	O
produciendo	O
.	O

Es	O
posible	O
que	O
los	O
bajos	O
niveles	O
combinados	O
de	O
endógeno	O
ratón	B-Taxon
una	B-Protein
beta	I-Protein
y	O
no	O
reprimido	O
humano	B-Taxon
péptido	B-Sequence
son	O
suficientes	O
para	O
mantener	O
los	O
depósitos	O
existentes	O
.	O

Sin	O
embargo	O
,	O
estos	O
bajos	O
niveles	O
de	O
péptido	B-Sequence
no	O
son	O
suficientes	O
para	O
inducir	O
la	O
formación	O
de	O
nuevo	O
amiloide	O
,	O
como	O
CaMKII	B-Protein
alfa	I-Protein
-	O
tTA	O
x	O
tetAPPswe	O
/	O
Indiana	B-Protein
ratones	B-Taxon
criados	O
en	O
dox	O
por	O
hasta	O
un	O
año	O
no	O
desarrollan	O
lesiones	O
amiloides	O
(	O
datos	O
no	O
mostrados	O
)	O
.	O

También	O
es	O
claro	O
que	O
en	O
este	O
genético	B-Sequence
sistema	O
,	O
hemos	O
elevado	O
la	O
producción	O
de	O
una	B-Protein
beta	I-Protein
a	O
niveles	O
que	O
no	O
se	O
encuentran	O
en	O
humanos	B-Taxon
para	O
acelerar	O
la	O
patología	O
en	O
un	O
marco	O
de	O
tiempo	O
experimentalmente	O
factible	O
.	O

Este	O
sistema	O
nos	O
permitió	O
crear	O
un	O
diferencial	O
de	O
aproximadamente	O
20	O
veces	O
entre	O
APLICACIÓN	B-Protein
/	O
una	B-Protein
beta	I-Protein
tasas	O
sintéticas	O
antes	O
y	O
después	O
del	O
tratamiento	O
,	O
sin	O
embargo	O
,	O
el	O
equilibrio	O
in	O
vivo	O
entre	O
estados	O
agregados	O
y	O
desagregados	O
de	O
una	B-Protein
beta	I-Protein
seguía	O
favoreciendo	O
el	O
mantenimiento	O
de	O
los	O
depósitos	O
de	O
amiloide	O
.	O

En	O
nuestra	O
opinión	O
,	O
parece	O
poco	O
probable	O
que	O
los	O
depósitos	O
de	O
amiloide	O
en	O
humano	B-Taxon
cerebro	O
sería	O
inherentemente	O
menos	O
estable	O
que	O
los	O
formados	O
en	O
ratón	B-Taxon
cerebro	O
.	O

Sin	O
embargo	O
,	O
el	O
humano	B-Taxon
el	O
cerebro	O
puede	O
albergar	O
mecanismos	O
de	O
limpieza	O
no	O
compartidos	O
por	O
ratones	B-Taxon
eso	O
permitiría	O
una	O
eliminación	O
más	O
eficiente	O
del	O
amiloide	O
preexistente	O
.	O

Un	O
mecanismo	O
potencial	O
por	O
el	O
cual	O
el	O
amiloide	O
puede	O
eliminarse	O
más	O
eficientemente	O
en	O
el	O
humano	B-Taxon
enfermedad	O
que	O
en	O
el	O
ratón	B-Taxon
los	O
modelos	O
han	O
terminado	O
microglial	B-Cell
fagocitosis	O

Residente	O
microglía	B-Cell
en	O
transgénico	B-Sequence
ratón	B-Taxon
los	O
modelos	O
se	O
localizan	O
en	O
el	O
tejido	O
que	O
rodea	O
las	O
placas	O
,	O
pero	O
muestran	O
poca	O
evidencia	O
de	O
absorción	O
de	O
amiloide	O
[	O
37-40	O
]	O
.	O

A	O
diferencia	O
de	O
,	O
microglía	B-Cell
placas	O
amiloides	O
circundantes	O
en	O
humano	B-Taxon
el	O
cerebro	O
muestra	O
un	O
estado	O
mucho	O
más	O
alto	O
de	O
activación	O
con	O
una	O
mayor	O
expresión	O
del	O
receptor	O
del	O
complemento	O
[	O
40	O
]	O
.	O

Así	O
,	O
el	O
papel	O
de	O
microglía	B-Cell
en	O
el	O
metabolismo	O
amiloide	O
es	O
menor	O
en	O
transgénico	B-Sequence
modelos	O
en	O
comparación	O
con	O
los	O
humano	B-Taxon
condición	O

Paradójicamente	O
,	O
varios	O
estudios	O
demuestran	O
además	O
que	O
el	O
tratamiento	O
con	O
medicamentos	O
antiinflamatorios	O
para	O
reducir	O
microglial	B-Cell
la	O
activación	O
en	O
realidad	O
reduce	O
la	O
carga	O
amiloide	O
en	O
APLICACIÓN	B-Protein
transgénico	B-Sequence
ratones	B-Taxon
,	O
sugiriendo	O
un	O
papel	O
para	O
ratón	B-Taxon
microglía	B-Cell
en	O
la	O
formación	O
y	O
mantenimiento	O
de	O
agregados	O
amiloides	O
[	O
41	O
-	O
43	O
]	O
.	O

Sin	O
embargo	O
,	O
este	O
resultado	O
puede	O
explicarse	O
alternativamente	O
por	O
los	O
efectos	O
directos	O
de	O
muchos	O
medicamentos	B-Chemical
antiinflamatorios	I-Chemical
sobre	O
la	O
escisión	O
de	O
la	O
gamma	O
-	O
secretasa	O
[	O
44	O
-	O
47	O
]	O
.	O

De	O
todos	O
modos	O
,	O
el	O
papel	O
de	O
microglía	B-Cell
tanto	O
en	O
el	O
humano	B-Taxon
condición	O
y	O
la	O
ratón	B-Taxon
los	O
modelos	O
no	O
se	O
entienden	O
bien	O
y	O
las	O
diferencias	O
en	O
microglial	B-Cell
la	O
reactividad	O
entre	O
los	O
dos	O
podría	O
conducir	O
a	O
una	O
eliminación	O
de	O
amiloide	O
significativamente	O
más	O
rápida	O
en	O
los	O
cerebros	O
de	O
los	O
pacientes	O
con	O
EA	O
de	O
lo	O
que	O
observamos	O
en	O
el	O
test	O
-	O
off	O
APLICACIÓN	B-Protein
ratones	B-Taxon
.	O

Dado	O
el	O
papel	O
relativamente	O
menor	O
desempeñado	O
por	O
microglía	B-Cell
en	O
otra	O
ratón	B-Taxon
modelos	O
de	O
amiloidosis	O
,	O
creemos	O
que	O
es	O
poco	O
probable	O
que	O
estos	O
células	B-Cell
han	O
influido	O
en	O
la	O
tasa	O
de	O
eliminación	O
de	O
amiloide	O
en	O
el	O
test	O
-	O
off	O
APLICACIÓN	B-Protein
ratones	B-Taxon
.	O

Aun	O
así	O
,	O
consideramos	O
la	O
posibilidad	O
de	O
que	O
el	O
tratamiento	O
crónico	O
con	O
dox	O
pudiera	O
haber	O
alterado	O
el	O
estado	O
de	O
activación	O
de	O
microglía	B-Cell
en	O
nuestro	O
tratado	O
ratones	B-Taxon
.	O

Dox	O
es	O
estructuralmente	O
similar	O
a	O
la	O
minociclina	O
,	O
un	O
informe	O
fármaco	B-Chemical
antiinflamatorio	I-Chemical
y	O
inhibidor	B-Chemical
de	O
microglial	B-Cell
activación	O
[	O
48	O
]	O
.	O

Sin	O
embargo	O
,	O
si	O
la	O
dox	O
tiene	O
actividad	O
antiinflamatoria	O
,	O
entonces	O
,	O
según	O
estudios	O
previos	O
con	O
otros	O
antiinflamatorios	B-Chemical
,	O
habríamos	O
esperado	O
encontrar	O
menos	O
amiloide	O
en	O
los	O
pacientes	O
tratados	O
con	O
dox	O
animales	B-Taxon
.	O

Claramente	O
,	O
ese	O
no	O
fue	O
el	O
caso	O
.	O

Si	O
bien	O
es	O
posible	O
que	O
la	O
dox	O
actúe	O
de	O
alguna	O
otra	O
manera	O
para	O
retardar	O
la	O
eliminación	O
de	O
amiloide	O
,	O
los	O
datos	O
de	O
múltiples	O
estudios	O
demuestran	O
que	O
microglial	B-Cell
Las	O
respuestas	O
son	O
normalmente	O
débiles	O
en	O
el	O
ratón	B-Taxon
modelos	O
AD	O
[	O
37-40	O
]	O
,	O
y	O
por	O
lo	O
tanto	O
es	O
dudoso	O
que	O
dox-mediated	O
microglial	B-Cell
la	O
inhibición	O
afectó	O
el	O
resultado	O
de	O
nuestro	O
estudio	O
.	O

La	O
persistencia	O
y	O
estabilidad	O
de	O
los	O
depósitos	O
de	O
amiloide	O
en	O
nuestro	O
sistema	O
es	O
inesperada	O
dada	O
la	O
velocidad	O
con	O
la	O
que	O
una	B-Protein
beta	I-Protein
los	O
agregados	O
se	O
limpian	O
en	O
otros	O
ratón	B-Taxon
modelos	O
de	O
intervención	O
terapéutica	O
.	O

Anti	O
-	O
una	B-Protein
beta	I-Protein
anticuerpos	B-GENE
Se	O
ha	O
demostrado	O
que	O
inyectados	O
directamente	O
en	O
el	O
cerebro	O
eliminan	O
los	O
depósitos	O
de	O
amiloide	O
en	O
tan	O
solo	O
1	O
semana	O
después	O
del	O
tratamiento	O
[	O
49	O
-	O
51	O
]	O
.	O

Periférico	O
anticuerpo	B-GENE
la	O
inyección	O
reduce	O
la	O
carga	O
de	O
amiloide	O
de	O
manera	O
más	O
amplia	O
y	O
,	O
aunque	O
no	O
parece	O
actuar	O
tan	O
rápido	O
como	O
la	O
inyección	O
local	O
,	O
puede	O
reducir	O
significativamente	O
la	O
carga	O
de	O
amiloide	O
en	O
los	O
2	O
meses	O
siguientes	O
al	O
tratamiento	O
inicial	O
[	O
52	O
,	O
53	O
]	O
.	O

Más	O
recientemente	O
,	O
un	O
enfoque	O
alternativo	O
ha	O
demostrado	O
que	O
lentiviral	B-Taxon
transferencia	O
de	O
neprilisina	B-Protein
también	O
puede	O
reducir	O
el	O
número	O
de	O
agregados	O
en	O
el	O
área	O
del	O
sitio	O
de	O
inyección	O
[	O
54	O
]	O
.	O

Un	O
estudio	O
cuidadoso	O
del	O
mecanismo	O
detrás	O
de	O
varios	O
de	O
los	O
anticuerpo	B-GENE
#	O
¿NOMBRE	O
?	O
microglía	B-Cell
juegan	O
un	O
papel	O
importante	O
en	O
la	O
eliminación	O
de	O
las	O
placas	O
fibrilares	O
después	O
de	O
la	O
inmunización	O
[	O
50	O
,	O
52	O
,	O
55	O
]	O
.	O

Sin	O
embargo	O
,	O
se	O
ha	O
señalado	O
que	O
supresión	B-Sequence
del	O
receptor	O
Fc	O
(	O
el	O
principal	O
receptor	O
para	O
microglial	B-Cell
opsinización	O
de	O
anticuerpo	B-GENE
#	O
¿NOMBRE	O
?	O
complejos	B-GENE
)	O
en	O
APLICACIÓN	B-Protein
transgénico	B-Sequence
ratón	B-Taxon
modelos	O
no	O
tiene	O
impacto	O
en	O
la	O
efectividad	O
de	O
anticuerpo	B-GENE
-	O
terapia	O
mediada	O
[	O
56	O
,	O
57	O
]	O
.	O

Sin	O
embargo	O
,	O
es	O
posible	O
que	O
la	O
falta	O
de	O
microglía	B-Cell
la	O
activación	O
es	O
la	O
principal	O
diferencia	O
entre	O
la	O
eliminación	O
lenta	O
descrita	O
aquí	O
,	O
en	O
la	O
que	O
no	O
se	O
espera	O
ninguna	O
perturbación	O
del	O
sistema	O
inmunitario	O
,	O
y	O
la	O
eliminación	O
rápida	O
descrita	O
en	O
estudios	O
que	O
implican	O
anticuerpo	B-GENE
o	O
viral	B-Taxon
inyección	O

De	O
forma	O
aislada	O
,	O
la	O
activación	O
leve	O
de	O
microglía	B-Cell
por	O
daño	O
por	O
inyección	O
u	O
opsinización	O
puede	O
no	O
ser	O
adecuado	O
para	O
inducir	O
una	O
fagocitosis	O
sustancial	O
,	O
pero	O
cuando	O
se	O
combina	O
con	O
un	O
una	B-Protein
beta	I-Protein
-	O
agente	O
reductor	O
,	O
como	O
neprilisina	B-Protein
o	O
una	B-Protein
beta	I-Protein
#	O
¿NOMBRE	O
?	O
anticuerpos	B-GENE
,	O
los	O
dos	O
pueden	O
trabajar	O
en	O
conjunto	O
para	O
despejar	O
péptido	B-Sequence
depósitos	O

De	O
acuerdo	O
con	O
esta	O
hipótesis	O
,	O
una	O
fuerte	O
activación	O
de	O
microglía	B-Cell
a	O
través	O
de	O
transgénico	B-Sequence
expresión	O
de	O
TGF	B-Protein
beta	I-Protein
[	O
58	O
]	O
o	O
inyección	O
central	O
de	O
lipopolisacárido	B-Chemical
[	O
59	O
,	O
60	O
]	O
puede	O
por	O
sí	O
mismo	O
reducir	O
sustancialmente	O
la	O
carga	O
de	O
placa	O
en	O
APLICACIÓN	B-Protein
transgénico	B-Sequence
ratones	B-Taxon
.	O

Pero	O
en	O
el	O
caso	O
de	O
la	O
aguda	O
anticuerpo	B-GENE
-	O
y	O
/	O
o	O
activación	O
mediada	O
por	O
lesión	O
,	O
una	O
vez	O
pasada	O
la	O
inflamación	O
,	O
y	O
la	O
anticuerpo	B-GENE
y	O
atado	O
péptido	B-Sequence
han	O
sido	O
limpiados	O
y	O
degradados	O
,	O
el	O
resto	O
una	B-Protein
beta	I-Protein
se	O
reagrega	O
rápidamente	O
y	O
se	O
restablece	O
la	O
patología	O
amiloide	O
[	O
49	O
]	O
.	O

Este	O
hallazgo	O
refuerza	O
la	O
noción	O
de	O
que	O
sin	O
estimulación	O
continua	O
,	O
microglía	B-Cell
en	O
ratón	B-Taxon
modelos	O
no	O
mantienen	O
el	O
mismo	O
nivel	O
de	O
activación	O
sostenida	O
que	O
puede	O
ocurrir	O
en	O
humanos	B-Taxon
.	O

SantaCruz	O
et	O
al	O
.	O
publicó	O
recientemente	O
un	O
estudio	O
de	O
ratones	B-Taxon
que	O
expresan	O
P301L	O
tau	B-Protein
humano	I-Protein
a	O
través	O
de	O
un	O
similar	O
vector	B-Sequence
sistema	O
[	O
61	O
]	O
.	O

Como	O
en	O
nuestro	O
tet	O
-	O
off	O
APLICACIÓN	B-Protein
ratones	B-Taxon
,	O
Santa	O
Cruz	O
et	O
al	O
.	O
encontrado	O
que	O
Tau	B-Protein
Los	O
ovillos	O
neurofibrilares	O
,	O
como	O
las	O
placas	O
amiloides	O
,	O
no	O
se	O
eliminan	O
de	O
manera	O
eficiente	O
después	O
de	O
transgén	B-Sequence
represión	O

La	O
falta	O
de	O
eliminación	O
en	O
ambos	O
modelos	O
de	O
patología	O
de	O
EA	O
contrasta	O
marcadamente	O
con	O
la	O
rápida	O
eliminación	O
de	O
proteína	B-Chemical
agregados	O
encontrados	O
en	O
pruebas	O
similares	O
ratón	B-Taxon
modelos	O
de	O
Huntington	O
[	O
32	O
]	O
y	O
enfermedad	O
priónica	O
[	O
62	O
]	O
.	O

En	O
estos	O
casos	O
,	O
la	O
interrupción	O
de	O
la	O
entrada	O
de	O
nuevos	O
monómeros	O
al	O
sistema	O
a	O
través	O
de	O
dox-mediated	O
transgén	B-Sequence
la	O
supresión	O
condujo	O
a	O
una	O
eliminación	O
relativamente	O
rápida	O
de	O
proteína	B-Chemical
agregados	O

Por	O
el	O
contrario	O
,	O
nuestro	O
estudio	O
y	O
el	O
de	O
SantaCruz	O
et	O
al	O
.	O
sugerir	O
que	O
proteína	B-Chemical
los	O
agregados	O
en	O
la	O
EA	O
pueden	O
ser	O
más	O
tenaces	O
que	O
en	O
otros	O
trastornos	O
neurodegenerativos	O
.	O

Quizás	O
una	O
vez	O
agregado	O
,	O
una	B-Protein
beta	I-Protein
y	O
Tau	B-Protein
son	O
intrínsecamente	O
más	O
estables	O
que	O
otros	O
proteína	B-Chemical
agregados	O
o	O
más	O
resistentes	O
a	O
intra	O
-	O
y	O
extracelular	B-GENE
mecanismos	O
de	O
liquidación	O
.	O

Una	O
pregunta	O
que	O
no	O
pudimos	O
abordar	O
en	O
este	O
estudio	O
es	O
si	O
la	O
derogación	O
de	O
la	O
síntesis	O
de	O
nuevos	O
una	B-Protein
beta	I-Protein
detiene	O
la	O
progresión	O
del	O
deterioro	O
cognitivo	O
.	O

Estudios	O
desde	O
el	O
tet	O
-	O
off	O
Tau	B-Protein
ratones	B-Taxon
sugerir	O
que	O
proteína	B-Chemical
de	O
hecho	O
,	O
es	O
posible	O
que	O
no	O
se	O
requiera	O
la	O
autorización	O
para	O
la	O
mejora	O
cognitiva	O
después	O
de	O
transgén	B-Sequence
represión	O
[	O
61	O
]	O
.	O

En	O
la	O
actualidad	O
,	O
debido	O
a	O
anormalidades	O
conductuales	O
no	O
cognitivas	O
inesperadas	O
,	O
no	O
está	O
claro	O
si	O
el	O
test-off	O
APLICACIÓN	B-Protein
ratones	B-Taxon
se	O
puede	O
utilizar	O
para	O
abordar	O
la	O
misma	O
pregunta	O
en	O
el	O
contexto	O
de	O
la	O
patología	O
amiloide	O
.	O

Ambas	O
líneas	O
de	O
tTA	O
/	O
APLICACIÓN	B-Protein
ratones	B-Taxon
que	O
estudiamos	O
aquí	O
muestra	O
una	O
hiperactividad	O
extrema	O
visible	O
como	O
una	O
jaula	O
dando	O
vueltas	O
y	O
cuantificada	O
mediante	O
el	O
monitoreo	O
de	O
la	O
actividad	O
(	O
vea	O
la	O
Figura	O
7	O
)	O
.	O

Muchos	O
de	O
los	O
dobles	O
transgénico	B-Sequence
ratones	B-Taxon
mostró	O
patrones	O
circulares	O
similares	O
de	O
natación	O
cerca	O
del	O
borde	O
del	O
tanque	O
cuando	O
se	O
probó	O
en	O
el	O
Morris	O
agua	B-Chemical
laberinto	O
.	O

La	O
expresión	O
de	O
este	O
fenotipo	O
hace	O
que	O
las	O
pruebas	O
estándar	O
de	O
aprendizaje	O
y	O
memoria	O
no	O
sean	O
interpretables	O
.	O

La	O
hiperactividad	O
inhibe	O
de	O
manera	O
no	O
específica	O
los	O
cambios	O
en	O
el	O
movimiento	O
impulsados	O
por	O
la	O
elección	O
,	O
el	O
elemento	O
clave	O
detrás	O
de	O
todos	O
los	O
paradigmas	O
cognitivo-conductuales	O
.	O

Actualmente	O
estamos	O
trabajando	O
para	O
determinar	O
si	O
la	O
hiperactividad	O
se	O
correlaciona	O
con	O
la	O
expresión	O
de	O
las	O
APPswe	O
/	O
Indiana	B-Protein
holoproteína	O
o	O
sus	O
derivados	O
proteolíticos	O
.	O

Los	O
estudios	O
preliminares	O
sugieren	O
que	O
la	O
hiperactividad	O
no	O
aparece	O
rápidamente	O
cuando	O
se	O
cría	O
con	O
dox	O
ratones	B-Taxon
se	O
cambian	O
a	O
dietas	O
no	O
medicadas	O
(	O
J.	O
L.	O
J.	O
,	O
datos	O
no	O
publicados	O
)	O
.	O

Estos	O
datos	O
pueden	O
indicar	O
que	O
el	O
culpable	O
neuroactivo	O
no	O
está	O
presente	O
inmediatamente	O
después	O
transgénico	B-Sequence
APLICACIÓN	B-Protein
se	O
inicia	O
la	O
síntesis	O
,	O
pero	O
requiere	O
tiempo	O
adicional	O
para	O
desarrollarse	O
.	O

Alternativamente	O
,	O
la	O
hiperactividad	O
puede	O
ser	O
causada	O
por	O
neuronales	B-Cell
alteraciones	O
debidas	O
a	O
transgén	B-Sequence
expresión	O
durante	O
el	O
desarrollo	O
posnatal	O
temprano	O
.	O

Se	O
necesitan	O
más	O
experimentos	O
para	O
distinguir	O
entre	O
estas	O
posibilidades	O
.	O

En	O
resumen	O
,	O
demostramos	O
que	O
derogando	O
una	B-Protein
beta	I-Protein
producción	O
detiene	O
la	O
progresión	O
de	O
los	O
cambios	O
patológicos	O
en	O
un	O
transgénico	B-Sequence
ratón	B-Taxon
modelo	O
de	O
amiloidosis	O
tipo	O
Alzheimer	O
.	O

Sin	O
embargo	O
,	O
a	O
pesar	O
de	O
las	O
reducciones	O
dramáticas	O
en	O
una	B-Protein
beta	I-Protein
síntesis	O
,	O
las	O
placas	O
neuríticas	O
son	O
estructuras	O
estables	O
in	O
vivo	O
que	O
no	O
se	O
desagregan	O
rápidamente	O
.	O

Es	O
posible	O
que	O
una	O
combinación	O
de	O
terapias	O
para	O
limitar	O
una	B-Protein
beta	I-Protein
producción	O
,	O
aumento	O
una	B-Protein
beta	I-Protein
puede	O
ser	O
necesaria	O
la	O
degradación	O
y	O
potenciar	O
la	O
fagocitosis	O
del	O
amiloide	O
depositado	O
para	O
revertir	O
el	O
daño	O
asociado	O
con	O
la	O
EA	O
.	O

Sin	O
embargo	O
,	O
si	O
se	O
inicia	O
lo	O
suficientemente	O
temprano	O
en	O
el	O
curso	O
de	O
la	O
enfermedad	O
,	O
la	O
secretasa	O
inhibidores	B-Chemical
por	O
sí	O
solo	O
podría	O
proporcionar	O
un	O
beneficio	O
sustancial	O
en	O
la	O
desaceleración	O
de	O
los	O
procesos	O
patogénicos	O
relacionados	O
con	O
la	O
deposición	O
de	O
amiloide	O
.	O

Incluso	O
en	O
etapas	O
posteriores	O
de	O
la	O
enfermedad	O
,	O
la	O
presencia	O
de	O
microglial	B-Cell
activación	O
en	O
humano	B-Taxon
AD	O
[	O
40	O
]	O
sugiere	O
que	O
simplemente	O
ralentizar	O
la	O
formación	O
de	O
nuevos	O
depósitos	O
de	O
amiloide	O
puede	O
permitir	O
que	O
la	O
fagocitosis	O
en	O
curso	O
disminuya	O
las	O
lesiones	O
preexistentes	O
.	O

Sin	O
embargo	O
,	O
el	O
desarrollo	O
de	O
secretasas	O
seguras	O
y	O
eficaces	O
inhibidores	B-Chemical
en	O
última	O
instancia	O
,	O
será	O
necesario	O
determinar	O
si	O
el	O
humano	B-Taxon
el	O
cerebro	O
tiene	O
la	O
capacidad	O
de	O
reparar	O
el	O
daño	O
de	O
la	O
EA	O
asociado	O
con	O
el	O
amiloide	O
una	O
vez	O
que	O
se	O
detiene	O
la	O
progresión	O
de	O
la	O
patología	O
.	O

información	O
de	O
soporte	O

Figura	O
S1	O

transgénico	B-Sequence
APLICACIÓN	B-Protein
Expression	O
and	O
Suppression	O
de	O
Dox	O
en	O
los	O
Cuatro	O
Nuevos	O
Tet	O
-	O
Off	O
APLICACIÓN	B-Protein
Líneas	O

Western	O
Blot	O
con	O
humano	B-Taxon
#	O
¿NOMBRE	O
?	O
anticuerpo	B-GENE
6E10	O
revela	O
transgén	B-Sequence
#	O
¿NOMBRE	O
?	O
APLICACIÓN	B-Protein
en	O
homogeneizados	O
corticales	O
de	O
no	O
tratados	O
animales	B-Taxon
(	O
carriles	O
izquierdos	O
de	O
cada	O
panel	O
)	O
.	O

Las	O
nuevas	O
líneas	O
producen	O
niveles	O
excepcionalmente	O
altos	O
de	O
transgén	B-Sequence
expresión	O
;	O
una	O
cantidad	O
igual	O
de	O
homogeneizado	O
de	O
cerebro	O
de	O
un	O
estándar	O
transgénico	B-Sequence
APLICACIÓN	B-Protein
línea	O
se	O
muestra	O
para	O
la	O
comparación	O
(	O
carril	O
extremo	O
izquierdo	O
,	O
Estándar	O
Tg	B-Sequence
línea	O
C3-3	O
;	O
[	O
15	O
,	O
63	O
]	O
)	O
.	O

Después	O
de	O
1	O
mes	O
de	O
tratamiento	O
con	O
dox	O
,	O
transgénico	B-Sequence
proteína	B-Chemical
en	O
los	O
cuatro	O
nuevos	O
tet	O
-	O
off	O
APLICACIÓN	B-Protein
líneas	O
se	O
reduce	O
a	O
niveles	O
residuales	O
(	O
+dox	O
;	O
carriles	O
derechos	O
de	O
cada	O
panel	O
)	O
.	O

(	O
474	O
KB	O
TIF	O
)	O
.	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Figura	O
S2	O

transgénico	B-Sequence
APLICACIÓN	B-Protein
ARNm	B-Chemical
Es	O
Cerebro	O
-	O
Específico	O

Una	O
mancha	O
de	O
ranura	O
de	O
ARNm	B-Chemical
cosechado	O
de	O
varios	O
tejidos	O
en	O
tres	O
de	O
los	O
cuatro	O
nuevos	O
tet	O
-	O
off	O
APLICACIÓN	B-Protein
líneas	O
y	O
un	O
control	O
no	O
transgénico	O
se	O
utilizó	O
para	O
examinar	O
transgénico	B-Sequence
ARNm	B-Chemical
expresión	O
.	O

La	O
hibridación	O
se	O
ve	O
sólo	O
en	O
el	O
cerebro	O
;	O
no	O
se	O
ve	O
ninguna	O
señal	O
por	O
encima	O
del	O
fondo	O
en	O
ningún	O
otro	O
tejido	O
.	O

(	O
781	O
KB	O
PSD	O
)	O
.	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Figura	O
S3	O

Patología	O
amiloide	O
en	O
la	O
corteza	O
reitera	O
que	O
en	O
el	O
hipocampo	O

La	O
histología	O
de	O
amiloide	O
se	O
realizó	O
en	O
secciones	O
de	O
la	O
línea	O
107	O
doble	O
transgénico	B-Sequence
ratones	B-Taxon
por	O
Hirano	O
plata	B-Chemical
colorante	O
(	O
fila	O
superior	O
)	O
,	O
tioflavina	O
-	O
S	O
(	O
fila	O
central	O
)	O
y	O
una	B-Protein
beta	I-Protein
inmunohistoquímica	O
(	O
fila	O
inferior	O
)	O
para	O
examinar	O
la	O
persistencia	O
de	O
la	O
patología	O
después	O
transgén	B-Sequence
represión	O

Al	O
igual	O
que	O
en	O
el	O
hipocampo	O
(	O
ver	O
Figura	O
4	O
y	O
texto	O
)	O
,	O
la	O
progresión	O
de	O
la	O
patología	O
amiloide	O
en	O
la	O
corteza	O
empeora	O
sustancialmente	O
entre	O
los	O
6	O
y	O
los	O
9	O
meses	O
de	O
edad	O
en	O
pacientes	O
no	O
tratados	O
.	O
ratones	B-Taxon
.	O

Esta	O
progresión	O
se	O
previene	O
completamente	O
mediante	O
la	O
supresión	O
de	O
la	O
transgén	B-Sequence
con	O
dox	O

A	O
modo	O
de	O
comparación	O
,	O
la	O
neurohistología	O
normal	O
se	O
muestra	O
en	O
un	O
solo	O
caso	O
de	O
la	O
misma	O
edad	O
.	O
transgénico	B-Sequence
(	O
Solo	O
tTA	O
)	O
animal	B-Taxon
.	O

No	O
se	O
ha	O
detectado	O
patología	O
amiloide	O
en	O
ninguno	O
de	O
los	O
APLICACIÓN	B-Protein
o	O
tTA	O
solo	O
transgénico	B-Sequence
animales	B-Taxon
hasta	O
los	O
15	O
meses	O
de	O
edad	O
.	O

(	O
4	O
.	O
8	O
MB	O
PSD	O
)	O
.	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Figura	O
S4	O

Los	O
depósitos	O
difusos	O
no	O
se	O
dispersan	O
durante	O
una	B-Protein
beta	I-Protein
Supresión	O

Campbell	O
-	O
Suiza	O
plata	B-Chemical
Se	O
usó	O
una	O
tinción	O
para	O
diferenciar	O
los	O
depósitos	O
con	O
núcleo	O
(	O
marrón	O
)	O
de	O
los	O
difusos	O
(	O
negros	O
)	O
en	O
la	O
línea	O
107	O
tTA/	O
APLICACIÓN	B-Protein
ratones	B-Taxon
.	O

Esta	O
mancha	O
demuestra	O
que	O
ambos	O
tipos	O
de	O
depósito	O
persisten	O
durante	O
largos	O
periodos	O
de	O
transgén	B-Sequence
represión	O

Los	O
paneles	O
inferiores	O
,	O
que	O
muestran	O
imágenes	O
de	O
bajo	O
aumento	O
(	O
10x	O
)	O
de	O
la	O
corteza	O
frontal	O
de	O
cada	O
condición	O
,	O
revelan	O
pocos	O
cambios	O
en	O
la	O
extensión	O
del	O
amiloide	O
difuso	O
después	O
de	O
hasta	O
6	O
meses	O
de	O
una	B-Protein
beta	I-Protein
represión	O

Las	O
imágenes	O
de	O
alta	O
potencia	O
(	O
40x	O
)	O
en	O
los	O
paneles	O
superiores	O
muestran	O
que	O
el	O
halo	O
difuso	O
que	O
rodea	O
los	O
depósitos	O
de	O
núcleos	O
individuales	O
permanece	O
relativamente	O
sin	O
cambios	O
en	O
los	O
tratados	O
ratones	B-Taxon
.	O

tTA	O
único	O
no	O
tratado	O
transgénico	B-Sequence
animales	B-Taxon
se	O
muestran	O
como	O
un	O
control	O
negativo	O
.	O

El	O
protocolo	O
para	O
el	O
Método	O
Campbell-Switzer	O
Alzheimer	O
fue	O
amablemente	O
compartido	O
por	O
Robert	O
Switzer	O
,	O
III	O
(	O
NeuroScience	O
Associates	O
,	O
Knoxville	O
,	O
Tennessee	O
,	O
Estados	O
Unidos	O
)	O
,	O
y	O
puede	O
descargarse	O
en	O
http	O
:	O
//www	O
.	O
nsalabs	O
.	O
com/Documentos/publicaciones/campbell-switzer_protocolo	O
.	O
htm	O
[	O
64	O
,	O
65	O
]	O
.	O

(	O
923	O
KB	O
JPG	O
)	O
.	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Figura	O
S5	O

Crónico	O
Transgén	B-Sequence
Supresión	O
y	O
Arresto	O
de	O
una	B-Protein
beta	I-Protein
Formación	O
de	O
Agregados	O
en	O
una	O
Línea	O
de	O
Tet	O
Independiente	O
-	O
Off	O
APLICACIÓN	B-Protein
Ratones	B-Taxon
(	O
CaMKII	B-Protein
alfa	I-Protein
-	O
tTA	O
x	O
tet	O
-	O
APPswe	O
/	O
Indiana	B-Protein
Línea	O
18	O
)	O

(	O
A	O
)	O
El	O
experimento	O
presentado	O
en	O
el	O
texto	O
para	O
la	O
línea	O
107	O
tet	O
-	O
off	O
APLICACIÓN	B-Protein
se	O
repitió	O
con	O
un	O
segundo	O
tet	O
-	O
off	O
APLICACIÓN	B-Protein
línea	O
(	O
línea	O
18	O
)	O
para	O
controlar	O
por	O
sitio	B-Sequence
de	I-Sequence
integración	I-Sequence
artefactos	O

Homogeneizados	O
corticales	O
de	O
control	O
no	O
tratado	O
y	O
doble	O
tratado	O
con	O
dox	O
transgénico	B-Sequence
ratones	B-Taxon
fueron	O
inmunotransferidos	O
para	O
longitud	O
completa	O
APLICACIÓN	B-Protein
con	O
el	O
humano	B-Taxon
#	O
¿NOMBRE	O
?	O
anticuerpo	B-GENE
6E10	O
para	O
confirmar	O
transgén	B-Sequence
supresión	O
en	O
el	O
momento	O
de	O
la	O
cosecha	O
.	O

inmunotinción	O
para	O
endógeno	O
superóxido	B-Protein
dismutasa	I-Protein
(	O
SOD1	B-Protein
)	O
se	O
incluyó	O
como	O
control	O
de	O
carga	O
.	O

(	O
B	O
)	O
La	O
cuantificación	O
de	O
la	O
intensidad	O
de	O
la	O
señal	O
del	O
Western	O
blot	O
en	O
(	O
A	O
)	O
muestra	O
transgénico	B-Sequence
APLICACIÓN	B-Protein
los	O
niveles	O
en	O
la	O
línea	O
18	O
se	O
suprimen	O
en	O
más	O
del	O
98	O
%	O
después	O
de	O
3	O
meses	O
de	O
tratamiento	O
con	O
dox	O
(	O
efecto	O
significativo	O
del	O
grupo	O
ANOVA	O
F2	O
,	O
8	O
=	O
1559,7	O
,	O
p	O
<	O
0,001	O
)	O
.	O

Este	O
nivel	O
de	O
supresión	O
fue	O
igual	O
o	O
mejor	O
que	O
el	O
alcanzado	O
en	O
la	O
línea	O
107	O
(	O
ver	O
Figura	O
3B	O
)	O
.	O

(	O
C	O
)	O
Se	O
usó	O
un	O
ensayo	O
de	O
trampa	O
de	O
filtro	O
de	O
dilución	O
en	O
serie	O
para	O
cuantificar	O
una	B-Protein
beta	I-Protein
en	O
homogeneizados	O
corticales	O
.	O

(	O
D	O
)	O
Cuantificación	O
de	O
la	O
intensidad	O
de	O
la	O
señal	O
en	O
el	O
rango	O
lineal	O
de	O
la	O
serie	O
de	O
dilución	O
que	O
se	O
muestra	O
en	O
(	O
C	O
)	O
.	O

De	O
acuerdo	O
con	O
la	O
histología	O
de	O
amiloide	O
que	O
se	O
muestra	O
en	O
la	O
Figura	O
S5	O
,	O
la	O
formación	O
de	O
agregados	O
aumentó	O
significativamente	O
entre	O
los	O
6	O
y	O
los	O
9	O
meses	O
de	O
edad	O
en	O
pacientes	O
no	O
tratados	O
.	O
ratones	B-Taxon
(	O
efecto	O
significativo	O
del	O
grupo	O
ANOVA	O
F2	O
,	O
18	O
=	O
12	O
.	O
14	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

La	O
formación	O
de	O
agregados	O
fue	O
completamente	O
detenida	O
por	O
transgén	B-Sequence
supresión	O
,	O
y	O
es	O
idéntica	O
en	O
9	O
meses	O
de	O
edad	O
ratones	B-Taxon
tratado	O
con	O
dox	O
durante	O
3	O
meses	O
como	O
en	O
no	O
tratado	O
animales	B-Taxon
recolectadas	O
cuando	O
comenzó	O
el	O
tratamiento	O
(	O
p	O
>	O
0.5	O
,	O
prueba	O
post	O
-	O
hoc	O
de	O
Tukey	O
)	O
.	O

*	O
,	O
pag	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
005	O
;	O
*	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
001	O
versus	O
9	O
-	O
mes	O
-	O
viejo	O
sin	O
tratamiento	O
ratones	B-Taxon
,	O
prueba	O
post	O
-	O
hoc	O
de	O
Tukey	O
.	O

(	O
962	O
KB	O
TIF	O
)	O
.	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Figura	O
S6	O

Detención	O
de	O
la	O
progresión	O
amiloide	O
por	O
crónica	O
Transgén	B-Sequence
Supresión	O
en	O
Línea	O
18	O
Tet	O
-	O
Off	O
APLICACIÓN	B-Protein
Ratones	B-Taxon

Histología	O
amiloide	O
en	O
secciones	O
corticales	O
(	O
primera	O
y	O
tercera	O
filas	O
)	O
e	O
hipocampales	O
(	O
segunda	O
y	O
cuarta	O
filas	O
)	O
de	O
tTA	O
sin	O
tratar	O
/	O
APLICACIÓN	B-Protein
ratones	B-Taxon
muestra	O
una	O
progresión	O
dramática	O
de	O
la	O
patología	O
entre	O
los	O
6	O
y	O
los	O
9	O
meses	O
de	O
edad	O
.	O

Supresión	O
de	O
transgénico	B-Sequence
APLICACIÓN	B-Protein
expresión	O
detiene	O
esta	O
progresión	O
,	O
aunque	O
sin	O
ningún	O
signo	O
de	O
eliminación	O
de	O
la	O
placa	O
(	O
6	O
meses	O
+	O
3	O
meses	O
)	O
.	O

Hirano	O
plata	B-Chemical
mancha	O
(	O
paneles	O
superiores	O
)	O
;	O
tioflavina-S	O
(	O
paneles	O
inferiores	O
)	O
.	O

(	O
5	O
.	O
8	O
MB	O
PSD	O
)	O
.	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Resumen	O
del	O
paciente	O

Antecedentes	O

Los	O
pacientes	O
con	O
enfermedad	O
de	O
Alzheimer	O
(	O
EA	O
)	O
tienen	O
niveles	O
elevados	O
de	O
una	O
pequeña	O
proteína	B-Chemical
llamado	O
amiloide	B-Protein
-	I-Protein
beta	I-Protein
péptido	B-Sequence
que	O
se	O
une	O
para	O
formar	O
lo	O
que	O
se	O
conoce	O
como	O
placas	O
amiloides	O
en	O
sus	O
cerebros	O
.	O

Esta	O
péptido	B-Sequence
normalmente	O
se	O
produce	O
en	O
niveles	O
bajos	O
en	O
personas	O
sanas	O
individuos	B-Taxon
,	O
y	O
se	O
hace	O
cuando	O
un	O
mayor	O
proteína	B-Chemical
llamado	O
proteína	B-Protein
precursora	I-Protein
de	I-Protein
amiloide	I-Protein
(	O
APLICACIÓN	B-Protein
)	O
se	O
reduce	O
en	O
tamaño	O
.	O

Ahora	O
se	O
están	O
desarrollando	O
nuevos	O
tratamientos	O
que	O
disminuirán	O
la	O
cantidad	O
de	O
una	B-Protein
beta	I-Protein
producido	O
desde	O
APLICACIÓN	B-Protein
.	O

Sin	O
embargo	O
,	O
no	O
está	O
claro	O
si	O
reducir	O
la	O
producción	O
de	O
una	B-Protein
beta	I-Protein
permitirá	O
que	O
el	O
cerebro	O
se	O
cure	O
por	O
sí	O
mismo	O
limpiando	O
las	O
placas	O
amiloides	O
.	O

La	O
respuesta	O
a	O
esta	O
pregunta	O
puede	O
ser	O
importante	O
para	O
decidir	O
cuándo	O
una	B-Protein
beta	I-Protein
#	O
¿NOMBRE	O
?	O
drogas	B-Chemical
deben	O
iniciarse	O
,	O
y	O
también	O
pueden	O
determinar	O
qué	O
tan	O
efectivos	O
son	O
para	O
revertir	O
los	O
síntomas	O
mentales	O
de	O
la	O
EA	O
.	O

¿Qué	O
hicieron	O
y	O
encontraron	O
los	O
investigadores	O
?	O

porque	O
nuevo	O
drogas	B-Chemical
diseñado	O
para	O
bajar	O
una	B-Protein
beta	I-Protein
los	O
niveles	O
aún	O
están	O
en	O
desarrollo	O
,	O
no	O
están	O
disponibles	O
para	O
probar	O
en	O
animal	B-Taxon
modelos	O
de	O
la	O
enfermedad	O
.	O

En	O
su	O
lugar	O
,	O
las	O
preguntas	O
básicas	O
sobre	O
la	O
eficacia	O
de	O
este	O
tipo	O
de	O
tratamiento	O
deben	O
responderse	O
utilizando	O
sistemas	O
que	O
imiten	O
la	O
forma	O
en	O
que	O
el	O
drogas	B-Chemical
trabajo	O
.	O

Para	O
ello	O
,	O
los	O
autores	O
crearon	O
ratones	B-Taxon
que	O
producen	O
demasiado	O
APLICACIÓN	B-Protein
y	O
que	O
desarrollan	O
las	O
mismas	O
lesiones	O
amiloides	O
que	O
humano	B-Taxon
pacientes	O
con	O
DA	O
.	O

A	O
diferencia	O
de	O
lo	O
normal	O
ratones	B-Taxon
,	O
estas	O
ratones	B-Taxon
``	O
también	O
llevaba	O
un	O
``	O
''	O
interruptor	O
''	O
''	O
''	O
gene	B-Sequence
que	O
permitió	O
a	O
los	O
investigadores	O
apagar	O
APLICACIÓN	B-Protein
al	O
alimentar	O
al	O
ratones	B-Taxon
especial	O
comida	B-Chemical
.	O

Apagando	O
APLICACIÓN	B-Protein
en	O
estos	O
ratones	B-Taxon
tuvo	O
el	O
mismo	O
efecto	O
que	O
tratarlos	O
con	O
una	B-Protein
beta	I-Protein
#	O
¿NOMBRE	O
?	O
drogas	B-Chemical
,	O
por	O
lo	O
que	O
los	O
investigadores	O
pudieron	O
preguntar	O
qué	O
sucedió	O
con	O
las	O
placas	O
de	O
amiloide	O
después	O
una	B-Protein
beta	I-Protein
se	O
cerró	O
la	O
producción	O
.	O

Demostraron	O
que	O
la	O
reducción	O
una	B-Protein
beta	I-Protein
la	O
producción	O
evita	O
que	O
las	O
lesiones	O
de	O
amiloide	O
empeoren	O
a	O
medida	O
que	O
avanza	O
la	O
enfermedad	O
.	O

Esto	O
significa	O
que	O
el	O
tratamiento	O
con	O
una	B-Protein
beta	I-Protein
#	O
¿NOMBRE	O
?	O
drogas	B-Chemical
puede	O
ser	O
capaz	O
de	O
evitar	O
que	O
la	O
enfermedad	O
llene	O
el	O
cerebro	O
de	O
placas	O
.	O

Sin	O
embargo	O
,	O
los	O
investigadores	O
también	O
encontraron	O
que	O
las	O
lesiones	O
amiloides	O
que	O
se	O
habían	O
formado	O
antes	O
de	O
comenzar	O
el	O
tratamiento	O
permanecieron	O
intactas	O
durante	O
todo	O
el	O
experimento	O
.	O

¿Qué	O
significan	O
estos	O
hallazgos	O
?	O

Estos	O
resultados	O
indican	O
que	O
los	O
tratamientos	O
diseñados	O
para	O
disminuir	O
la	O
producción	O
de	O
una	B-Protein
beta	I-Protein
puede	O
ser	O
una	O
parte	O
importante	O
del	O
tratamiento	O
futuro	O
de	O
la	O
EA	O
,	O
ya	O
que	O
este	O
enfoque	O
parece	O
prevenir	O
la	O
formación	O
de	O
placas	O
amiloides	O
adicionales	O
en	O
el	O
ratón	B-Taxon
cerebro	O
.	O

Sin	O
embargo	O
,	O
por	O
sí	O
sola	O
,	O
es	O
posible	O
que	O
esta	O
estrategia	O
no	O
sea	O
capaz	O
de	O
eliminar	O
del	O
cerebro	O
las	O
placas	O
que	O
ya	O
se	O
han	O
formado	O
en	O
el	O
cerebro	O
antes	O
de	O
comenzar	O
el	O
tratamiento	O
.	O

Los	O
hallazgos	O
sugieren	O
que	O
el	O
tratamiento	O
temprano	O
puede	O
ser	O
importante	O
para	O
que	O
este	O
enfoque	O
tenga	O
éxito	O
.	O

¿Dónde	O
puedo	O
obtener	O
más	O
información	O
en	O
línea	O
?	O

MedlinePlus	O
tiene	O
varias	O
páginas	O
web	O
de	O
información	O
sobre	O
la	O
enfermedad	O
de	O
Alzheimer	O
:	O

http	O
:	O
//www	O
.	O
nlm	O
NIH	O
.	O
gov/medlineplus/enfermedad	O
de	O
alzheimer	O
.	O
html	O

El	O
Centro	O
ADEAR	O
del	O
Instituto	O
Nacional	O
sobre	O
el	O
Envejecimiento	O
del	O
Gobierno	O
de	O
los	O
EE	O
.	O
UU	O
.	O
también	O
tiene	O
información	O
sobre	O
la	O
enfermedad	O
de	O
Alzheimer	O
:	O

http	O
:	O
//www	O
.	O
alzheimers	O
org	O
/	O

El	O
sitio	O
web	O
de	O
la	O
Asociación	O
de	O
Alzheimer	O
contiene	O
información	O
sobre	O
el	O
cuidado	O
y	O
la	O
investigación	O
:	O

http	O
:	O
//www	O
.	O
alz	O
.	O
organización	O

Agradecimientos	O

Agradecemos	O
a	O
Patrick	O
Tremblay	O
por	O
sus	O
valiosos	O
consejos	O
sobre	O
el	O
sistema	O
tet	O
en	O
un	O
momento	O
crítico	O
del	O
proyecto	O
y	O
a	O
Mark	O
Mayford	O
por	O
compartir	O
los	O
CaMKII	B-Protein
alfa	I-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
a	O
través	O
del	O
Laboratorio	O
Jackson	O
.	O

También	O
agradecemos	O
a	O
Fraser	O
Moss	O
por	O
guardar	O
varias	O
inmunotransferencias	O
con	O
envíos	O
de	O
última	O
hora	O
,	O
Andy	O
Groves	O
por	O
muchas	O
discusiones	O
reflexivas	O
,	O
Neil	O
Segil	O
por	O
compartir	O
generosamente	O
su	O
laboratorio	O
y	O
equipo	O
,	O
Beth	O
Olson	O
,	O
Natasha	O
Bouey	O
y	O
Yolanda	O
Jackson	O
por	O
su	O
excelente	O
animal	B-Taxon
care	O
,	O
Debbie	O
Swing	O
por	O
microinyección	O
experta	O
y	O
Dave	O
Fromholt	O
por	O
genotipificación	O
y	O
disección	O
.	O

Agradecemos	O
a	O
Takeda	O
Químico	B-Chemical
Industrias	O
para	O
proporcionar	O
anticuerpos	B-GENE
BAN50	O
,	O
BA27	O
y	O
BC05	O
,	O
Konrad	O
Beyreuther	O
y	O
Andreas	O
Weidemann	O
por	O
proporcionar	O
22C11	O
anticuerpo	B-GENE
Ed	O
Koo	O
por	O
compartir	O
CT15	O
anticuerpo	B-GENE
.	O

Este	O
trabajo	O
fue	O
apoyado	O
por	O
becas	O
del	O
Centro	O
de	O
Investigación	O
de	O
la	O
Enfermedad	O
de	O
Alzheimer	O
(	O
JLJ	O
)	O
de	O
Johns	O
Hopkins	O
,	O
la	O
Alianza	O
Nacional	O
para	O
la	O
Investigación	O
sobre	O
la	O
Esquizofrenia	O
y	O
la	O
Depresión	O
(	O
Premio	O
al	O
Investigador	O
Joven	O
[	O
JLJ	O
]	O
)	O
,	O
la	O
Fundación	O
Rose	O
Hills	O
(	O
JLJ	O
)	O
,	O
la	O
Asociación	O
de	O
(	O
Premio	O
Zenith	O
[	O
DRB	O
]	O
)	O
,	O
el	O
Instituto	O
Nacional	O
del	O
Envejecimiento	O
(	O
K01	O
AG26144-01	O
[	O
JLJ	O
]	O
,	O
P50	O
AGO5146-20	O
[	O
DRB	O
]	O
,	O
R01	O
AG006656-16	O
[	O
SGY	O
]	O
y	O
P01	O
AG015453	O
[	O
SGY	O
]	O
)	O
,	O
el	O
Instituto	O
Nacional	O
de	O
Enfermedades	O
Neurológicas	O
y	O
Stoke	O
(	O
R01	O
NS	O
047225	O
[	O
DRB	O
]	O
)	O
,	O
y	O
el	O
Instituto	O
Nacional	O
del	O
Cáncer	O
(	O
NAJ	O
y	O
NGC	O
)	O
.	O

Las	O
agencias	O
de	O
financiación	O
proporcionaron	O
generosamente	O
suministros	O
de	O
investigación	O
,	O
animal	B-Taxon
atención	O
y	O
apoyo	O
salarial	O
;	O
los	O
patrocinadores	O
de	O
este	O
trabajo	O
no	O
tuvieron	O
ningún	O
papel	O
en	O
el	O
diseño	O
del	O
estudio	O
,	O
la	O
recopilación	O
y	O
el	O
análisis	O
de	O
datos	O
,	O
la	O
decisión	O
de	O
publicar	O
o	O
la	O
preparación	O
del	O
manuscrito	O
.	O

abreviaturas	O

una	B-Protein
beta	I-Protein
-	O
amiloide	B-Protein
-	I-Protein
beta	I-Protein

EA	O
-	O
enfermedad	O
de	O
Alzheimer	O

APLP-	O
precursor	B-Protein
de	I-Protein
amiloide	I-Protein
#	O
¿NOMBRE	O
?	O
proteína	B-Chemical

APLICACIÓN	B-Protein
-	O
proteína	B-Protein
precursora	I-Protein
de	I-Protein
amiloide	I-Protein

CaMKII	B-Protein
alfa	I-Protein
-	O
calcio	B-Protein
-	I-Protein
calmodulina	I-Protein
quinasa	I-Protein
II	I-Protein
alfa	I-Protein

dox	O
-	O
doxiciclina	O

FA	B-Chemical
-	O
ácido	B-Chemical
fórmico	I-Chemical

GFAP	B-Protein
-	O
proteína	B-Protein
ácida	I-Protein
fibrilar	I-Protein
glial	I-Protein

mes	B-Taxon
/	O
huAPP695	B-Protein
-	O
aplicación	B-Protein
de	I-Protein
ratón	I-Protein
con	O
un	O
humanizado	O
una	B-Protein
beta	I-Protein
dominio	B-Sequence

PBS	O
-	O
fosfato	B-Chemical
-	O
amortiguado	B-Chemical
salina	O

SDS	B-Chemical
-	O
dodecil	B-Chemical
sulfato	I-Chemical
de	I-Chemical
sodio	I-Chemical

sueco	B-Protein
/	O
Indiana	B-Protein
-	O
sueco	B-Protein
/	O
Indiana	B-Protein

tTA-	O
tetraciclina	B-Chemical
transactivador	O

Figuras	O
y	O
Tablas	O

Figura	O
1	O

Control	O
de	O
transgénico	B-Sequence
APLICACIÓN	B-Protein
Expresión	O
por	O
Dox	O

(	O
A	O
)	O
transferencia	O
Western	O
para	O
transgénico	B-Sequence
APLICACIÓN	B-Protein
utilizando	O
el	O
humano	B-Taxon
-	O
específico	O
6E10	O
anticuerpo	B-GENE
muestra	O
expresión	O
de	O
longitud	O
completa	O
proteína	B-Chemical
en	O
tejido	O
del	O
prosencéfalo	O
de	O
joven	O
predepósito	O
doble	O
transgénico	B-Sequence
animales	B-Taxon
(	O
línea	O
107	O
)	O
y	O
su	O
supresión	O
siguiendo	O
el	O
tratamiento	O
dox	O
.	O

sin	O
tratar	O
animales	B-Taxon
muestran	O
altos	O
niveles	O
de	O
transgén	B-Sequence
expresión	O
;	O
proteína	B-Chemical
los	O
niveles	O
caen	O
dramáticamente	O
en	O
animales	B-Taxon
tratamiento	O
agudo	O
con	O
dox	O
durante	O
2	O
semanas	O
.	O

Una	O
banda	O
tenue	O
pero	O
detectable	O
de	O
longitud	O
completa	O
proteína	B-Chemical
permanece	O
en	O
tratamiento	O
agudo	O
animales	B-Taxon
que	O
se	O
puede	O
eliminar	O
en	O
ratones	B-Taxon
nacido	O
y	O
criado	O
en	O
dox	O
.	O

(	O
B	O
)	O
Inmunotransferencia	O
con	O
el	O
N-terminal	B-Sequence
anticuerpo	B-GENE
22C11	O
para	O
detectar	O
ambos	O
transgénico	B-Sequence
y	O
endógeno	O
proteína	B-Chemical
muestra	O
que	O
el	O
tratamiento	O
con	O
dox	O
reduce	O
APLICACIÓN	B-Protein
/	O
APLP	O
a	O
niveles	O
encontrados	O
en	O
no	O
transgénicos	O
ratones	B-Taxon
.	O

(	O
C	O
)	O
La	O
medición	O
de	O
la	O
intensidad	O
de	O
la	O
señal	O
del	O
Western	O
blot	O
en	O
(	O
A	O
)	O
muestra	O
transgénico	B-Sequence
APLICACIÓN	B-Protein
los	O
niveles	O
se	O
reducen	O
en	O
más	O
del	O
95	O
%	O
por	O
dox	O
tanto	O
en	O
pacientes	O
tratados	O
de	O
forma	O
aguda	O
como	O
crónica	O
.	O
animales	B-Taxon
(	O
97	O
,	O
2	O
%	O
para	O
4	O
semanas	O
+	O
2	O
semanas	O
dox	O
,	O
98	O
,	O
0	O
%	O
para	O
criados	O
con	O
dox	O
versus	O
4	O
semanas	O
sin	O
tratamiento	O
;	O
efecto	O
ANOVA	O
del	O
grupo	O
de	O
tratamiento	O
F4	O
,	O
15	O
=	O
85	O
,	O
55	O
,	O
p	O
<	O
0	O
,	O
001	O
)	O
.	O

APLICACIÓN	B-Protein
los	O
niveles	O
en	O
dox	O
de	O
4	O
semanas	O
+	O
2	O
semanas	O
,	O
criados	O
con	O
dox	O
y	O
no	O
transgénicos	O
(	O
NTg	O
)	O
no	O
fueron	O
significativamente	O
diferentes	O
(	O
p	O
>	O
0,9	O
,	O
prueba	O
post-hoc	O
de	O
Tukey	O
)	O
.	O

(	O
D	O
)	O
La	O
medición	O
de	O
la	O
intensidad	O
de	O
la	O
señal	O
del	O
Western	O
blot	O
en	O
(	O
B	O
)	O
muestra	O
el	O
total	O
APLICACIÓN	B-Protein
/	O
Niveles	O
de	O
APLP	O
en	O
tTA	O
tratados	O
con	O
dox	O
/	O
APLICACIÓN	B-Protein
ratones	B-Taxon
son	O
significativamente	O
más	O
bajos	O
que	O
en	O
4	O
semanas	O
de	O
edad	O
sin	O
tratar	O
ratones	B-Taxon
(	O
Efecto	O
ANOVA	O
del	O
grupo	O
de	O
tratamiento	O
F4	O
,	O
15	O
=	O
84	O
.	O
41	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
e	O
indistinguibles	O
de	O
los	O
de	O
los	O
no	O
transgénicos	O
animales	B-Taxon
(	O
p	O
>	O
0	O
,	O
9	O
,	O
prueba	O
post	O
-	O
hoc	O
de	O
Tukey	O
)	O
.	O

*	O
,	O
pag	O
<	O
0	O
.	O
001	O
versus	O
no	O
tratado	O
4	O
semanas	O
de	O
edad	O
ratones	B-Taxon
,	O
prueba	O
post	O
-	O
hoc	O
de	O
Tukey	O
aplicada	O
al	O
efecto	O
significativo	O
del	O
ANOVA	O
de	O
grupo	O
.	O

Figura	O
2	O

una	B-Protein
beta	I-Protein
Los	O
niveles	O
se	O
reducen	O
drásticamente	O
por	O
Transgén	B-Sequence
Supresión	O

Homogeneizados	O
corticales	O
de	O
jóvenes	O
,	O
predepósito	O
tTA	O
/	O
APLICACIÓN	B-Protein
ratones	B-Taxon
usados	O
para	O
Western	O
blot	O
en	O
la	O
Figura	O
1	O
(	O
línea	O
107	O
)	O
fueron	O
fraccionados	O
por	O
extracción	O
secuencial	O
de	O
múltiples	O
pasos	O
con	O
PBS	O
,	O
2	O
%	O
SDS	B-Chemical
,	O
y	O
70	O
%	O
FA	B-Chemical
seguido	O
por	O
humano	B-Taxon
#	O
¿NOMBRE	O
?	O
una	B-Protein
beta	I-Protein
ELISA	O
a	O
medida	O
transgén	B-Sequence
#	O
¿NOMBRE	O
?	O
péptido	B-Sequence
en	O
cada	O
fracción	B-GENE
.	O

una	B-Protein
beta	I-Protein
40	I-Protein
se	O
muestra	O
en	O
blanco	O
,	O
una	B-Protein
beta	I-Protein
42	I-Protein
en	O
negro	O
.	O

(	O
A	O
)	O
PBS	O
-	O
soluble	O
una	B-Protein
beta	I-Protein
los	O
niveles	O
se	O
reducen	O
sustancialmente	O
con	O
el	O
tratamiento	O
dox	O
agudo	O
y	O
crónico	O
(	O
ANOVA	O
,	O
efecto	O
del	O
grupo	O
de	O
tratamiento	O
F4	O
,	O
24	O
=	O
137	O
.	O
10	O
y	O
386	O
.	O
01	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
para	O
una	B-Protein
beta	I-Protein
40	I-Protein
y	O
una	B-Protein
beta	I-Protein
42	I-Protein
,	O
respectivamente	O
)	O
.	O

una	B-Protein
beta	I-Protein
niveles	O
en	O
tratados	O
animales	B-Taxon
son	O
indistinguibles	O
de	O
los	O
no	O
transgénicos	O
(	O
NTg	O
)	O
animales	B-Taxon
(	O
p	O
>	O
0	O
.	O
3	O
,	O
prueba	O
post	O
-	O
hoc	O
de	O
Tukey	O
)	O
.	O

(	O
B	O
)	O
En	O
los	O
jóvenes	O
animales	B-Taxon
probado	O
aquí	O
antes	O
de	O
la	O
formación	O
de	O
depósitos	O
amiloides	O
visibles	O
,	O
la	O
mayoría	O
una	B-Protein
beta	I-Protein
se	O
extrae	O
en	O
el	O
SDS	B-Chemical
fracción	B-GENE
(	O
84	O
%	O
y	O
76	O
%	O
de	O
todos	O
transgén	B-Sequence
#	O
¿NOMBRE	O
?	O
una	B-Protein
beta	I-Protein
40	I-Protein
y	O
una	B-Protein
beta	I-Protein
42	I-Protein
,	O
respectivamente	O
)	O
.	O

Como	O
en	O
el	O
PBS	O
-	O
soluble	O
fracción	B-GENE
,	O
una	B-Protein
beta	I-Protein
niveles	O
en	O
el	O
SDS	B-Chemical
fracción	B-GENE
se	O
reducen	O
significativamente	O
con	O
el	O
tratamiento	O
con	O
dox	O
en	O
comparación	O
con	O
los	O
no	O
tratados	O
animales	B-Taxon
(	O
Efecto	O
ANOVA	O
del	O
grupo	O
F4	O
,	O
24	O
=	O
197	O
.	O
57	O
y	O
163	O
.	O
48	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
para	O
una	B-Protein
beta	I-Protein
40	I-Protein
y	O
una	B-Protein
beta	I-Protein
42	I-Protein
,	O
respectivamente	O
)	O
.	O

Tratado	O
de	O
forma	O
aguda	O
animales	B-Taxon
retuvo	O
una	O
pequeña	O
(	O
aunque	O
significativa	O
)	O
cantidad	O
de	O
residuos	O
péptido	B-Sequence
(	O
p	O
<	O
0	O
.	O
001	O
en	O
comparación	O
con	O
la	O
prueba	O
post	O
-	O
hoc	O
de	O
Tukey	O
no	O
transgénica	O
)	O
,	O
mientras	O
que	O
una	B-Protein
beta	I-Protein
niveles	O
en	O
ratones	B-Taxon
los	O
nacidos	O
y	O
criados	O
con	O
dox	O
se	O
redujeron	O
a	O
niveles	O
indistinguibles	O
de	O
los	O
no	O
transgénicos	O
(	O
p	O
>	O
0,8	O
,	O
prueba	O
post-hoc	O
de	O
Tukey	O
)	O
.	O

(	O
C	O
)	O
El	O
FA	B-Chemical
#	O
¿NOMBRE	O
?	O
fracción	B-GENE
ya	O
contiene	O
un	O
grupo	O
pequeño	O
pero	O
significativo	O
de	O
datos	O
agregados	O
una	B-Protein
beta	I-Protein
42	I-Protein
en	O
no	O
tratado	O
animales	B-Taxon
a	O
las	O
4	O
semanas	O
de	O
edad	O
(	O
p	O
<	O
0,05	O
versus	O
no	O
transgénicos	O
;	O
prueba	O
post	O
-	O
hoc	O
de	O
Tukey	O
aplicada	O
al	O
efecto	O
significativo	O
del	O
grupo	O
ANOVA	O
F4	O
,	O
24	O
=	O
17,11	O
,	O
p	O
<	O
0,001	O
)	O
.	O

A	O
las	O
6	O
semanas	O
de	O
edad	O
,	O
la	O
cantidad	O
de	O
una	B-Protein
beta	I-Protein
en	O
el	O
FA	B-Chemical
fracción	B-GENE
aumenta	O
significativamente	O
antes	O
de	O
la	O
aparición	O
de	O
depósitos	O
visibles	O
2	O
semanas	O
después	O
.	O

los	O
FA	B-Chemical
la	O
piscina	O
es	O
la	O
única	O
péptido	B-Sequence
fracción	B-GENE
no	O
disminuida	O
por	O
el	O
tratamiento	O
agudo	O
con	O
dox	O
(	O
4	O
semanas	O
sin	O
tratamiento	O
=	O
4	O
semanas	O
+	O
2	O
semanas	O
con	O
dox	O
,	O
p	O
>	O
0.9	O
,	O
prueba	O
post	O
-	O
hoc	O
de	O
Tukey	O
)	O
,	O
consistente	O
con	O
una	O
rotación	O
deficiente	O
de	O
agregados	O
una	B-Protein
beta	I-Protein
especies	B-Sequence
.	O

(	O
D	O
)	O
Medidas	O
de	O
total	O
una	B-Protein
beta	I-Protein
,	O
incluyendo	O
tanto	O
endógenos	O
como	O
transgén	B-Sequence
#	O
¿NOMBRE	O
?	O
péptidos	B-Sequence
,	O
muestra	O
esa	O
animales	B-Taxon
nacido	O
y	O
criado	O
en	O
puerto	O
dox	O
una	B-Protein
beta	I-Protein
niveles	O
idénticos	O
a	O
los	O
no	O
transgénicos	O
animales	B-Taxon
(	O
p	O
>	O
0	O
.	O
9	O
,	O
prueba	O
post	O
-	O
hoc	O
de	O
Tukey	O
,	O
efecto	O
de	O
grupo	O
ANOVA	O
F4	O
,	O
24	O
=	O
39	O
.	O
13	O
y	O
35	O
.	O
29	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
para	O
una	B-Protein
beta	I-Protein
40	I-Protein
y	O
una	B-Protein
beta	I-Protein
42	I-Protein
,	O
respectivamente	O
)	O
.	O

Mientras	O
que	O
crónica	O
transgén	B-Sequence
la	O
supresión	O
impide	O
por	O
completo	O
la	O
síntesis	O
de	O
ambos	O
péptidos	B-Sequence
,	O
el	O
tratamiento	O
agudo	O
con	O
dox	O
suprime	O
por	O
completo	O
una	B-Protein
beta	I-Protein
40	I-Protein
niveles	O
(	O
p	O
>	O
0	O
.	O
8	O
,	O
prueba	O
post	O
-	O
hoc	O
de	O
Tukey	O
)	O
,	O
pero	O
deja	O
una	O
pequeña	O
cantidad	O
de	O
no	O
suprimida	O
una	B-Protein
beta	I-Protein
42	I-Protein
.	O

el	O
residuo	O
una	B-Protein
beta	I-Protein
42	I-Protein
observado	O
en	O
pacientes	O
jóvenes	O
tratados	O
de	O
forma	O
aguda	O
animales	B-Taxon
deriva	O
de	O
áridos	O
no	O
aclarados	O
extraídos	O
en	O
la	O
SDS	B-Chemical
y	O
FA	B-Chemical
fracciones	B-GENE
.	O

*	O
,	O
pag	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
005	O
;	O
*	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
001	O
versus	O
4	O
-	O
semana	O
-	O
antiguo	O
sin	O
tratamiento	O
ratones	B-Taxon
,	O
Tukey	O
post	O
-	O
hoc	O
aplicado	O
al	O
efecto	O
significativo	O
del	O
grupo	O
ANOVA	O
.	O

figura	O
3	O

Robusto	O
Transgén	B-Sequence
Supresión	O
en	O
mayores	O
Ratones	B-Taxon
con	O
patología	O
amiloide	O
preexistente	O

(	O
A	O
)	O
Homogeneizados	O
corticales	O
de	O
6	O
a	O
12	O
meses	O
de	O
edad	O
animales	B-Taxon
utilizados	O
para	O
los	O
estudios	O
de	O
patología	O
que	O
se	O
describen	O
a	O
continuación	O
(	O
línea	O
107	O
)	O
fueron	O
inmunotransferidos	O
con	O
humano	B-Taxon
#	O
¿NOMBRE	O
?	O
anticuerpo	B-GENE
6E10	O
para	O
examinar	O
transgén	B-Sequence
supresión	O
después	O
de	O
3	O
o	O
6	O
meses	O
de	O
tratamiento	O
con	O
dox	O
.	O

El	O
blot	O
fue	O
co	O
-	O
inmunoteñido	O
para	O
endógeno	O
superóxido	B-Protein
dismutasa	I-Protein
1	I-Protein
(	O
SOD1	B-Protein
)	O
como	O
control	O
para	O
la	O
carga	O
.	O

(	O
B	O
)	O
Cuantificación	O
de	O
la	O
intensidad	O
de	O
la	O
señal	O
del	O
Western	O
blot	O
que	O
se	O
muestra	O
en	O
(	O
A	O
)	O
.	O

transgénico	B-Sequence
APLICACIÓN	B-Protein
los	O
niveles	O
se	O
suprimen	O
significativamente	O
después	O
de	O
3	O
o	O
6	O
meses	O
de	O
tratamiento	O
con	O
dox	O
(	O
96	O
,	O
9	O
%	O
y	O
97	O
,	O
6	O
%	O
,	O
respectivamente	O
)	O
.	O

,	O
pag	O
<	O
0	O
.	O
001	O
en	O
comparación	O
con	O
6	O
meses	O
de	O
edad	O
sin	O
tratar	O
animales	B-Taxon
,	O
prueba	O
post	O
-	O
hoc	O
de	O
Tukey	O
aplicada	O
al	O
efecto	O
significativo	O
del	O
grupo	O
ANOVA	O
F3	O
,	O
12	O
=	O
107	O
.	O
22	O
,	O
pag	O
<	O
0	O
.	O
001	O
.	O

Estos	O
datos	O
demuestran	O
que	O
fuerte	O
transgén	B-Sequence
la	O
supresión	O
se	O
logra	O
tanto	O
antes	O
como	O
después	O
del	O
inicio	O
de	O
la	O
patología	O
amiloide	O
(	O
ver	O
la	O
Figura	O
1	O
para	O
los	O
experimentos	O
previos	O
al	O
depósito	O
)	O
.	O

(	O
C	O
)	O
Diseño	O
experimental	O
.	O

Examinar	O
los	O
efectos	O
de	O
la	O
crónica	O
.	O
una	B-Protein
beta	I-Protein
supresión	O
de	O
la	O
patología	O
amiloide	O
después	O
del	O
inicio	O
de	O
la	O
deposición	O
,	O
comparamos	O
controles	O
no	O
tratados	O
recolectados	O
a	O
los	O
6	O
y	O
9	O
meses	O
de	O
edad	O
con	O
animales	B-Taxon
colocado	O
en	O
dox	O
a	O
los	O
6	O
meses	O
de	O
edad	O
y	O
cosechado	O
después	O
de	O
3	O
o	O
6	O
meses	O
de	O
tratamiento	O
.	O

(	O
D	O
)	O
El	O
tratamiento	O
con	O
Dox	O
conduce	O
a	O
una	O
rápida	O
transgén	B-Sequence
supresión	O
incluso	O
en	O
tTA	O
de	O
6	O
meses	O
de	O
edad	O
/	O
APLICACIÓN	B-Protein
ratones	B-Taxon
.	O

La	O
inmunotinción	O
con	O
6E10	O
muestra	O
APPswe	O
/	O
Indiana	B-Protein
los	O
niveles	O
se	O
reducen	O
drásticamente	O
en	O
6	O
meses	O
de	O
edad	O
ratones	B-Taxon
tratado	O
durante	O
1	O
semana	O
con	O
dox	O
(	O
panel	O
superior	O
)	O
.	O

Se	O
inmunotiñó	O
una	O
mancha	O
separada	O
para	O
APLICACIÓN	B-Protein
C	B-Sequence
-	I-Sequence
fragmentos	I-Sequence
terminales	I-Sequence
con	O
CT15	O
anticuerpo	B-GENE
demostrar	O
que	O
los	O
precursores	O
de	O
una	B-Protein
beta	I-Protein
escote	O
se	O
reducen	O
en	O
paralelo	O
con	O
la	O
longitud	O
total	O
proteína	B-Chemical
(	O
panel	O
central	O
)	O
.	O

Costaining	O
para	O
superóxido	B-Protein
dismutasa	I-Protein
1	I-Protein
se	O
utilizó	O
como	O
control	O
interno	O
para	O
la	O
carga	O
(	O
panel	O
inferior	O
,	O
tomado	O
de	O
la	O
mitad	O
inferior	O
de	O
la	O
transferencia	O
6E10	O
)	O
.	O

Figura	O
4	O

Supresión	O
de	O
transgénico	B-Sequence
APLICACIÓN	B-Protein
Detiene	O
la	O
progresión	O
de	O
la	O
patología	O
amiloide	O

(	O
A	O
)	O
Agregado	O
una	B-Protein
beta	I-Protein
se	O
cuantificó	O
en	O
tejido	O
cortical	O
de	O
tTA	O
tratado	O
con	O
dox	O
y	O
de	O
control	O
/	O
APLICACIÓN	B-Protein
ratones	B-Taxon
(	O
línea	O
107	O
)	O
utilizando	O
un	O
ensayo	O
de	O
trampa	O
de	O
filtro	O
.	O

diluciones	O
en	O
serie	O
de	O
proteína	B-Chemical
homogeneizado	O
se	O
pasó	O
a	O
través	O
de	O
una	O
celulosa	O
acetato	B-Chemical
filtro	O
;	O
proteína	B-Chemical
agregados	O
más	O
grandes	O
que	O
el	O
tamaño	O
del	O
poro	O
fueron	O
atrapados	O
e	O
inmunoteñidos	O
para	O
una	B-Protein
beta	I-Protein
.	O

(	O
B	O
)	O
Se	O
utilizó	O
la	O
cuantificación	O
de	O
la	O
intensidad	O
de	O
la	O
señal	O
en	O
el	O
rango	O
lineal	O
de	O
cada	O
serie	O
de	O
dilución	O
de	O
la	O
trampa	O
del	O
filtro	O
(	O
flecha	O
en	O
[	O
A	O
]	O
)	O
para	O
comparar	O
la	O
carga	O
agregada	O
entre	O
los	O
grupos	O
de	O
tratamiento	O
.	O

Agregado	O
una	B-Protein
beta	I-Protein
aumentó	O
significativamente	O
entre	O
los	O
6	O
y	O
los	O
9	O
meses	O
de	O
edad	O
en	O
pacientes	O
no	O
tratados	O
ratones	B-Taxon
(	O
efecto	O
significativo	O
del	O
grupo	O
ANOVA	O
F3	O
,	O
18	O
=	O
7	O
.	O
85	O
,	O
p	O
<	O
0	O
.	O
002	O
)	O
.	O

Esta	O
progresión	O
de	O
la	O
patología	O
fue	O
completamente	O
prevenida	O
por	O
transgén	B-Sequence
represión	O

La	O
cantidad	O
de	O
agregado	O
una	B-Protein
beta	I-Protein
era	O
idéntico	O
en	O
no	O
tratado	O
ratones	B-Taxon
los	O
6	O
meses	O
de	O
edad	O
a	O
la	O
de	O
los	O
9	O
o	O
12	O
meses	O
de	O
edad	O
animales	B-Taxon
tratados	O
con	O
dox	O
(	O
p	O
>	O
0	O
,	O
9	O
,	O
prueba	O
post	O
-	O
hoc	O
de	O
Tukey	O
)	O
.	O

Único	O
transgénico	B-Sequence
Las	O
muestras	O
de	O
tTA	O
se	O
incluyeron	O
como	O
controles	O
negativos	O
y	O
no	O
mostraron	O
ninguna	O
señal	O
por	O
encima	O
del	O
fondo	O
.	O

*	O
,	O
pag	O
<	O
0	O
.	O
01	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
005	O
versus	O
9	O
-	O
mes	O
-	O
viejo	O
sin	O
tratamiento	O
ratones	B-Taxon
,	O
prueba	O
post	O
-	O
hoc	O
de	O
Tukey	O
;	O
*	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
001	O
versus	O
9	O
-	O
mes	O
-	O
viejo	O
sin	O
tratamiento	O
ratones	B-Taxon
,	O
prueba	O
t	O
de	O
Student	O
.	O

(	O
C	O
)	O
Patología	O
amiloide	O
en	O
el	O
hipocampo	O
de	O
representante	O
ratones	B-Taxon
de	O
cada	O
grupo	O
de	O
tratamiento	O
:	O
Hirano	O
plata	B-Chemical
colorante	O
(	O
fila	O
superior	O
)	O
,	O
tioflavina	O
-	O
S	O
(	O
fila	O
central	O
)	O
y	O
una	B-Protein
beta	I-Protein
inmunohistoquímica	O
(	O
fila	O
inferior	O
)	O
.	O

La	O
carga	O
de	O
amiloide	O
aumenta	O
dramáticamente	O
entre	O
los	O
6	O
y	O
los	O
9	O
meses	O
de	O
edad	O
en	O
pacientes	O
no	O
tratados	O
.	O
animales	B-Taxon
,	O
pero	O
permanece	O
estable	O
en	O
transgén	B-Sequence
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
durante	O
el	O
mismo	O
período	O
(	O
6	O
meses	O
+	O
3	O
meses	O
dox	O
y	O
6	O
meses	O
+	O
6	O
meses	O
dox	O
)	O
.	O

Único	O
transgénico	B-Sequence
animales	B-Taxon
(	O
tTA	O
solo	O
se	O
muestra	O
aquí	O
)	O
no	O
muestran	O
signos	O
de	O
patología	O
amiloide	O
a	O
ninguna	O
edad	O
analizada	O
.	O

Figura	O
5	O

una	B-Protein
beta	I-Protein
ELISA	O
confirma	O
la	O
detención	O
de	O
la	O
progresión	O
sin	O
autorización	O
de	O
péptido	B-Sequence
en	O
Ratones	B-Taxon
con	O
agregados	O
preexistentes	O

una	B-Protein
beta	I-Protein
niveles	O
en	O
tTA	O
de	O
6	O
y	O
9	O
meses	O
sin	O
tratar	O
/	O
APLICACIÓN	B-Protein
línea	O
107	O
ratones	B-Taxon
(	O
que	O
se	O
muestra	O
en	O
la	O
Figura	O
4	O
)	O
se	O
compararon	O
con	O
los	O
de	O
9	O
y	O
12	O
meses	O
de	O
edad	O
.	O
animales	B-Taxon
tratados	O
con	O
dox	O
desde	O
los	O
6	O
meses	O
de	O
edad	O
.	O

Único	O
transgénico	B-Sequence
APLICACIÓN	B-Protein
las	O
muestras	O
se	O
incluyeron	O
como	O
controles	O
negativos	O
.	O

Los	O
homogeneizados	O
corticales	O
se	O
fraccionaron	O
mediante	O
extracción	O
secuencial	O
de	O
varios	O
pasos	O
con	O
PBS	O
al	O
2	O
%	O
.	O
SDS	B-Chemical
,	O
y	O
70	O
%	O
FA	B-Chemical
seguido	O
por	O
humano	B-Taxon
#	O
¿NOMBRE	O
?	O
una	B-Protein
beta	I-Protein
ELISA	O
a	O
medida	O
transgén	B-Sequence
#	O
¿NOMBRE	O
?	O
péptido	B-Sequence
en	O
cada	O
fracción	B-GENE
.	O

una	B-Protein
beta	I-Protein
40	I-Protein
se	O
muestra	O
en	O
blanco	O
,	O
una	B-Protein
beta	I-Protein
42	I-Protein
en	O
negro	O
.	O

(	O
A	O
y	O
B	O
)	O
La	O
mayoría	O
una	B-Protein
beta	I-Protein
en	O
los	O
cerebros	O
de	O
placa	O
-	O
teniendo	O
ratones	B-Taxon
se	O
extrae	O
en	O
el	O
FA	B-Chemical
y	O
SDS	B-Chemical
fracciones	B-GENE
.	O

De	O
acuerdo	O
con	O
la	O
carga	O
de	O
amiloide	O
(	O
Figuras	O
4	O
y	O
Figura	O
S3	O
)	O
,	O
SDS	B-Chemical
#	O
¿NOMBRE	O
?	O
FA	B-Chemical
#	O
¿NOMBRE	O
?	O
una	B-Protein
beta	I-Protein
niveles	O
en	O
niños	O
de	O
9	O
meses	O
sin	O
tratar	O
ratones	B-Taxon
fueron	O
significativamente	O
mayores	O
que	O
en	O
los	O
niños	O
de	O
6	O
meses	O
sin	O
tratar	O
ratones	B-Taxon
(	O
Test	O
post-hoc	O
de	O
Tukey	O
aplicado	O
al	O
efecto	O
significativo	O
del	O
grupo	O
ANOVA	O
para	O
SDS	B-Chemical
y	O
FA	B-Chemical
fracciones	B-GENE
F3	O
,	O
18	O
=	O
4	O
.	O
72	O
-	O
12	O
.	O
92	O
,	O
p	O
<	O
0	O
.	O
02	O
)	O
.	O

Por	O
el	O
contrario	O
,	O
3	O
o	O
6	O
meses	O
de	O
transgén	B-Sequence
represión	O
sostenida	O
una	B-Protein
beta	I-Protein
en	O
niveles	O
equivalentes	O
a	O
los	O
albergados	O
cuando	O
se	O
inició	O
el	O
tratamiento	O
(	O
p	O
>	O
0	O
,	O
2	O
en	O
comparación	O
con	O
6	O
meses	O
sin	O
tratamiento	O
ratones	B-Taxon
,	O
prueba	O
post	O
-	O
hoc	O
de	O
Tukey	O
)	O
.	O

*	O
,	O
pag	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
005	O
;	O
*	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
001	O
versus	O
9	O
-	O
mes	O
-	O
viejo	O
sin	O
tratamiento	O
ratones	B-Taxon
,	O
prueba	O
post	O
-	O
hoc	O
de	O
Tukey	O
.	O

Importancia	O
para	O
APLICACIÓN	B-Protein
versus	O
9	O
meses	O
de	O
edad	O
sin	O
tratamiento	O
ratones	B-Taxon
se	O
basa	O
en	O
la	O
prueba	O
t	O
de	O
Student	O
.	O

(	O
C	O
)	O
El	O
PBS	O
fracción	B-GENE
representa	O
menos	O
de	O
0	O
.	O
1	O
%	O
del	O
total	O
una	B-Protein
beta	I-Protein
observe	O
el	O
cambio	O
en	O
el	O
eje	O
y	O
de	O
[	O
A	O
]	O
y	O
[	O
B	O
]	O
)	O
,	O
pero	O
sólo	O
aquí	O
una	B-Protein
beta	I-Protein
niveles	O
en	O
el	O
dox	O
-	O
tratados	O
ratones	B-Taxon
difieren	O
de	O
los	O
de	O
los	O
más	O
jóvenes	O
no	O
tratados	O
ratones	B-Taxon
.	O

Aunque	O
ambos	O
péptidos	B-Sequence
parecen	O
elevados	O
en	O
los	O
grupos	O
tratados	O
en	O
comparación	O
con	O
los	O
de	O
6	O
meses	O
sin	O
tratar	O
ratones	B-Taxon
,	O
solamente	O
una	B-Protein
beta	I-Protein
40	I-Protein
alcanza	O
significación	O
estadística	O
(	O
p	O
<	O
0	O
.	O
05	O
,	O
prueba	O
post	O
-	O
hoc	O
de	O
Tukey	O
aplicada	O
al	O
efecto	O
significativo	O
del	O
grupo	O
ANOVA	O
para	O
una	B-Protein
beta	I-Protein
40	I-Protein
F3	O
,	O
18	O
=	O
4	O
.	O
60	O
,	O
p	O
<	O
0	O
.	O
02	O
)	O
.	O

Se	O
observó	O
una	O
tendencia	O
similar	O
para	O
una	B-Protein
beta	I-Protein
42	I-Protein
,	O
donde	O
ANOVA	O
arrojó	O
un	O
efecto	O
significativo	O
de	O
grupo	O
para	O
PBS	O
-	O
soluble	O
una	B-Protein
beta	I-Protein
42	I-Protein
(	O
F3	O
,	O
18	O
=	O
3	O
,	O
75	O
,	O
p	O
<	O
0	O
,	O
03	O
)	O
,	O
sin	O
embargo	O
,	O
esto	O
se	O
debió	O
únicamente	O
a	O
las	O
diferencias	O
entre	O
los	O
grupos	O
de	O
6	O
y	O
9	O
meses	O
sin	O
tratar	O
.	O

*	O
,	O
pag	O
<	O
0	O
.	O
05	O
versus	O
6	O
-	O
mes	O
-	O
viejo	O
sin	O
tratamiento	O
ratones	B-Taxon
,	O
prueba	O
post	O
-	O
hoc	O
de	O
Tukey	O
;	O
*	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
001	O
versus	O
6	O
-	O
mes	O
-	O
viejo	O
sin	O
tratamiento	O
ratones	B-Taxon
,	O
prueba	O
t	O
de	O
Student	O
.	O

Figura	O
6	O

neurítica	O
y	O
glial	B-Cell
La	O
patología	O
no	O
ha	O
cambiado	O
siguiendo	O
Transgén	B-Sequence
Supresión	O

neuritas	O
distróficas	O
y	O
activadas	O
astrocitos	B-Cell
rodean	O
la	O
mayoría	O
de	O
las	O
placas	O
compactas	O
en	O
tet	O
-	O
off	O
APLICACIÓN	B-Protein
ratones	B-Taxon
(	O
línea	O
107	O
)	O
.	O

Neuritas	O
teñidas	O
de	O
oscuro	O
,	O
llenas	O
de	O
ubiquitina	O
y	O
reactivas	O
astrocitos	B-Cell
forman	O
un	O
halo	O
alrededor	O
de	O
los	O
depósitos	O
fibrilares	O
con	O
núcleo	O
a	O
los	O
6	O
meses	O
de	O
edad	O
que	O
empeora	O
con	O
el	O
tiempo	O
en	O
los	O
no	O
tratados	O
ratones	B-Taxon
.	O

Ambas	O
patologías	O
asociadas	O
a	O
la	O
placa	O
son	O
detenidas	O
,	O
aunque	O
no	O
revertidas	O
,	O
por	O
transgén	B-Sequence
represión	O

Hirano	O
plata	B-Chemical
mancha	O
(	O
fila	O
superior	O
)	O
;	O
GFAP	B-Protein
inmunohistoquímica	O
(	O
fila	O
central	O
)	O
;	O
Inmunohistoquímica	O
de	O
ubiquitina	O
(	O
fila	O
inferior	O
)	O
.	O

Figura	O
7	O

Transgén	B-Sequence
La	O
supresión	O
atenúa	O
la	O
hiperactividad	O
en	O
tTA	O
/	O
APLICACIÓN	B-Protein
Ratones	B-Taxon

(	O
A	O
)	O
Una	O
medida	O
de	O
48	O
h	O
de	O
deambulación	O
registra	O
una	O
hiperactividad	O
extrema	O
en	O
pacientes	O
dobles	O
no	O
tratados	O
.	O
transgénico	B-Sequence
ratones	B-Taxon
comparado	O
con	O
soltero	O
transgénico	B-Sequence
y	O
controles	O
no	O
transgénicos	O
(	O
línea	O
107	O
)	O
.	O

Este	O
fenotipo	O
se	O
elimina	O
por	O
completo	O
al	O
criar	O
el	O
doble	O
transgénico	B-Sequence
ratones	B-Taxon
en	O
dox	O
.	O

(	O
B	O
)	O
Los	O
mismos	O
datos	O
que	O
se	O
muestran	O
en	O
(	O
A	O
)	O
se	O
vuelven	O
a	O
representar	O
para	O
ampliar	O
los	O
datos	O
de	O
los	O
grupos	O
de	O
control	O
no	O
tratados	O
y	O
tratados	O
con	O
dox	O
.	O

(	O
C	O
y	O
D	O
)	O
Los	O
niveles	O
de	O
actividad	O
en	O
los	O
grupos	O
de	O
control	O
combinados	O
de	O
(	O
A	O
)	O
y	O
(	O
B	O
)	O
están	O
aquí	O
separados	O
por	O
genotipo	B-Sequence
.	O

Ninguno	O
de	O
los	O
solteros	O
transgénico	B-Sequence
o	O
los	O
grupos	O
de	O
control	O
no	O
transgénicos	O
muestran	O
la	O
hiperactividad	O
presente	O
en	O
tTA	O
/	O
APLICACIÓN	B-Protein
animales	B-Taxon
.	O

Una	O
vez	O
más	O
,	O
tenga	O
en	O
cuenta	O
que	O
los	O
ejes	O
y	O
se	O
han	O
ampliado	O
para	O
obtener	O
más	O
detalles	O
en	O
comparación	O
con	O
(	O
A	O
)	O
.	O

notas	O
al	O
pie	O

Cita	O
:	O
Jankowsky	O
JL	O
,	O
Slunt	O
HH	O
,	O
Gonzales	O
V	O
,	O
Savonenko	O
AV	O
,	O
Wen	O
JC	O
,	O
et	O
al	O
.	O

(	O
2005	O
)	O
Amiloidosis	O
persistente	O
después	O
de	O
la	O
supresión	O
de	O
una	B-Protein
beta	I-Protein
producción	O
en	O
un	O
transgénico	B-Sequence
modelo	O
de	O
la	O
enfermedad	O
de	O
Alzheimer	O
.	O

PLoS	O
Med	O
2	O
(	O
12	O
)	O
:	O
e355	O
.	O

Genético	B-Sequence
y	O
genómico	B-Sequence
El	O
análisis	O
de	O
un	O
rasgo	O
de	O
masa	O
grasa	O
con	O
herencia	O
compleja	O
revela	O
una	O
marcada	O
especificidad	O
sexual	O

Resumen	O

La	O
integración	O
de	O
perfiles	O
de	O
expresión	O
con	O
análisis	O
de	O
ligamiento	O
se	O
ha	O
utilizado	O
cada	O
vez	O
más	O
para	O
identificar	O
genes	B-Sequence
fenotipos	O
complejos	O
subyacentes	O
.	O

``	O
Los	O
efectos	O
del	O
género	O
en	O
la	O
regulación	O
de	O
muchos	O
rasgos	O
fisiológicos	O
están	O
bien	O
documentados	O
;	O
sin	O
embargo	O
,	O
``	O
''	O
''	O
genético	B-Sequence
genómico	I-Sequence
Los	O
análisis	O
aún	O
no	O
han	O
abordado	O
el	O
grado	O
en	O
que	O
sus	O
conclusiones	O
se	O
ven	O
afectadas	O
por	O
el	O
sexo	O
.	O

Construimos	O
y	O
genotipamos	O
densamente	O
un	O
gran	O
cruce	O
F2	O
derivado	O
del	O
endogamia	O
ratón	B-Taxon
cepas	O
C57BL/6J	O
y	O
C3H/HeJ	O
en	O
un	O
apolipoproteína	B-Protein
E	I-Protein
nulo	O
(	O
ApoE	B-Protein
-	O
/	O
-	O
)	O
antecedentes	O
.	O

Este	O
BXH	O
.	O
ApoE	B-Protein
``	O
/	O
-	O
la	O
población	O
recapitula	O
varios	O
fenotipos	O
del	O
``	O
''	O
síndrome	O
metabólico	O
``	O
''	O
.	O
''	O

La	O
cruz	O
consta	O
de	O
334	O
animales	B-Taxon
de	O
ambos	O
sexos	O
,	O
permitiéndonos	O
probar	O
específicamente	O
la	O
dependencia	O
del	O
ligamiento	O
en	O
el	O
sexo	O
.	O

Detectamos	O
varios	O
miles	O
de	O
hígado	O
gene	B-Sequence
expresión	O
loci	B-Sequence
de	I-Sequence
rasgos	I-Sequence
cuantitativos	I-Sequence
,	O
una	O
proporción	O
significativa	O
de	O
los	O
cuales	O
tienen	O
sesgo	O
sexual	O
.	O

Utilizamos	O
estos	O
análisis	O
para	O
diseccionar	O
la	O
genética	O
de	O
la	O
masa	O
grasa	O
gonadal	O
,	O
un	O
rasgo	O
complejo	O
con	O
regulación	O
específica	O
del	O
sexo	O
.	O

Presentamos	O
evidencia	O
de	O
un	O
grado	O
notablemente	O
alto	O
de	O
dependencia	O
sexual	O
tanto	O
de	O
la	O
regulación	O
cis	O
como	O
trans	O
de	O
gene	B-Sequence
expresión	O
.	O

Demostramos	O
cómo	O
se	O
pueden	O
aplicar	O
estos	O
análisis	O
al	O
estudio	O
de	O
la	O
genética	O
subyacente	O
a	O
la	O
masa	O
grasa	O
gonadal	O
,	O
un	O
rasgo	O
complejo	O
que	O
muestra	O
una	O
heredabilidad	O
significativamente	O
sesgada	O
por	O
las	O
mujeres	O
.	O

Estos	O
datos	O
tienen	O
implicaciones	O
sobre	O
los	O
efectos	O
potenciales	O
del	O
sexo	O
en	O
el	O
genético	B-Sequence
regulación	O
de	O
otros	O
rasgos	O
complejos	O
.	O

Sinopsis	O

Aunque	O
su	O
genomas	B-Sequence
son	O
casi	O
idénticos	O
,	O
los	O
machos	O
y	O
las	O
hembras	O
de	O
una	O
especie	O
exhiben	O
diferencias	O
sorprendentes	O
en	O
muchos	O
rasgos	O
,	O
incluidos	O
rasgos	O
complejos	O
como	O
la	O
obesidad	O
.	O

Este	O
estudio	O
combina	O
genético	B-Sequence
y	O
genómico	B-Sequence
herramientas	O
para	O
identificar	O
en	O
paralelo	O
loci	B-Sequence
de	I-Sequence
rasgos	I-Sequence
cuantitativos	I-Sequence
(	O
QTL	B-Sequence
)	O
para	O
una	O
medida	O
de	O
la	O
masa	O
grasa	O
gonadal	O
y	O
para	O
la	O
expresión	O
de	O
transcripciones	B-Sequence
en	O
el	O
higado	O

Los	O
resultados	O
se	O
utilizan	O
para	O
explorar	O
la	O
relación	O
entre	O
genético	B-Sequence
variación	O
,	O
diferenciación	O
sexual	O
y	O
obesidad	O
en	O
el	O
ratón	B-Taxon
modelo	O

Usando	O
más	O
de	O
300	O
descendientes	O
cruzados	O
de	O
dos	O
consanguíneos	O
ratón	B-Taxon
cepas	O
,	O
cinco	O
lugares	B-Sequence
en	O
el	O
genoma	B-Sequence
se	O
encontró	O
que	O
estaban	O
altamente	O
correlacionados	O
con	O
la	O
masa	O
de	O
grasa	O
abdominal	O
.	O

cuatro	O
de	O
los	O
cinco	O
lugares	B-Sequence
exhibió	O
efectos	O
opuestos	O
sobre	O
la	O
obesidad	O
en	O
los	O
dos	O
sexos	O
,	O
un	O
fenómeno	O
conocido	O
como	O
antagonismo	O
sexual	O
.	O

Para	O
identificar	O
candidato	O
genes	B-Sequence
que	O
pueden	O
estar	O
involucrados	O
en	O
la	O
obesidad	O
a	O
través	O
de	O
su	O
expresión	O
en	O
el	O
hígado	O
,	O
global	O
gene	B-Sequence
Se	O
empleó	O
el	O
análisis	O
de	O
expresión	O
usando	O
micromatrices	O
.	O

Muchas	O
de	O
estas	O
expresiones	O
QTL	B-Sequence
también	O
muestran	O
efectos	O
específicos	O
del	O
sexo	O
en	O
la	O
transcripción	O
.	O

Un	O
punto	O
de	O
acceso	O
para	O
la	O
actuación	O
trans	O
QTL	B-Sequence
regular	O
la	O
expresión	O
de	O
transcripciones	B-Sequence
cuya	O
abundancia	O
se	O
correlaciona	O
con	O
la	O
masa	O
grasa	O
gonadal	O
se	O
identificó	O
en	O
Cromosoma	B-GENE
19	O

Esta	O
región	B-Sequence
de	O
El	O
genoma	B-Sequence
colocaliza	O
con	O
una	O
clínica	O
QTL	B-Sequence
para	O
la	O
masa	O
grasa	O
gonadal	O
,	O
lo	O
que	O
sugiere	O
que	O
alberga	O
un	O
buen	O
candidato	O
gene	B-Sequence
para	O
la	O
obesidad	O

Introducción	O

Las	O
hembras	O
y	O
los	O
machos	O
comparten	O
casi	O
idénticas	O
genético	B-Sequence
información	O
,	O
pero	O
varían	O
ampliamente	O
con	O
respecto	O
a	O
la	O
susceptibilidad	O
a	O
la	O
enfermedad	O
[	O
1	O
,	O
2	O
]	O
.	O

Aparte	O
de	O
las	O
enfermedades	O
obvias	O
específicas	O
de	O
género	O
como	O
el	O
cáncer	O
de	O
cuello	O
uterino	O
o	O
de	O
próstata	O
,	O
el	O
sexo	O
influye	O
en	O
la	O
susceptibilidad	O
a	O
casi	O
todas	O
las	O
enfermedades	O
de	O
alta	O
prevalencia	O
que	O
afectan	O
tanto	O
a	O
mujeres	O
como	O
a	O
hombres	O
,	O
incluidas	O
la	O
aterosclerosis	O
y	O
la	O
diabetes	O
y	O
sus	O
condiciones	O
precursoras	O
de	O
hiperlipidemia	O
,	O
obesidad	O
y	O
insulina	B-Protein
resistencia	O

Estos	O
son	O
multifactoriales	O
en	O
su	O
patogénesis	O
,	O
abarcando	O
aspectos	O
ambientales	O
y	O
de	O
comportamiento	O
,	O
así	O
como	O
importantes	O
genético	B-Sequence
determinación	O
,	O
en	O
la	O
que	O
estos	O
otros	O
factores	O
interactúan	O
.	O

los	O
genético	B-Sequence
componente	O
es	O
multigénico	O
,	O
con	O
la	O
heredabilidad	O
incrustada	O
en	O
el	O
genético	B-Sequence
variación	O
intrínseca	O
a	O
nuestra	O
población	O
.	O

Aunque	O
se	O
reconocen	O
las	O
diferencias	O
de	O
sexo	O
en	O
la	O
susceptibilidad	O
a	O
la	O
enfermedad	O
,	O
la	O
interacción	O
entre	O
sexo	O
y	O
gene	B-Sequence
La	O
expresión	O
que	O
está	O
en	O
la	O
base	O
de	O
estas	O
diferencias	O
no	O
se	O
entiende	O
bien	O
.	O

Mujeres	O
y	O
hombres	O
heredan	O
(	O
en	O
promedio	O
)	O
lo	O
mismo	O
genes	B-Sequence
Esos	O
pueden	O
ser	O
factores	O
de	O
riesgo	O
,	O
pero	O
su	O
expresión	O
y	O
efecto	O
sobre	O
el	O
riesgo	O
de	O
enfermedad	O
varía	O
significativamente	O
.	O

La	O
comprensión	O
y	O
el	O
reconocimiento	O
de	O
la	O
importancia	O
de	O
enfermedades	O
específicas	O
asociadas	O
polimorfismos	B-Sequence
/	O
mutaciones	B-Sequence
en	O
el	O
contexto	O
del	O
sexo	O
es	O
por	O
lo	O
tanto	O
de	O
importancia	O
clínica	O
crítica	O
.	O

hemos	O
utilizado	O
la	O
ratón	B-Taxon
como	O
sistema	O
modelo	O
para	O
estudiar	O
la	O
genética	O
de	O
enfermedades	O
metabólicas	O
y	O
vasculares	O
[	O
3-5	O
]	O
.	O

En	O
lugar	O
de	O
centrarse	O
inicialmente	O
en	O
natural	B-Sequence
o	O
inducido	O
mutantes	B-Sequence
de	O
soltero	O
genes	B-Sequence
,	O
utilizamos	O
el	O
complejo	O
endógeno	O
genético	B-Sequence
variación	O
entre	O
cepas	O
en	O
genético	B-Sequence
cruces	O
para	O
identificar	O
la	O
causa	O
locus	B-Sequence
genéticos	I-Sequence
y	O
en	O
última	O
instancia	O
,	O
el	O
subyacente	O
variaciones	B-Sequence
responsable	O
de	O
las	O
diferencias	O
de	O
rasgos	O
[	O
6	O
]	O
.	O

Este	O
diseño	O
refleja	O
más	O
de	O
cerca	O
la	O
situación	O
que	O
se	O
enfrenta	O
al	O
estudiar	O
humano	B-Taxon
poblaciones	O

los	O
genético	B-Sequence
composición	O
de	O
cada	O
individuo	O
ratón	B-Taxon
se	O
restringe	O
a	O
la	O
de	O
las	O
dos	O
cepas	O
parentales	O
y	O
se	O
define	O
en	O
cada	O
lugar	B-Sequence
a	O
través	O
de	O
genoma	B-Sequence
.	O

La	O
aplicación	O
de	O
locus	B-Sequence
de	I-Sequence
rasgo	I-Sequence
cuantitativo	I-Sequence
(	O
QTL	B-Sequence
)	O
el	O
análisis	O
permite	O
identificar	O
aquellos	O
regiones	B-Sequence
cromosómicas	I-Sequence
que	O
contienen	O
un	O
genético	B-Sequence
variación	O
que	O
influye	O
en	O
la	O
expresión	O
del	O
rasgo	O
(	O
para	O
una	O
revisión	O
completa	O
sobre	O
QTL	B-Sequence
ver	O
[	O
7	O
]	O
)	O
.	O

Nosotros	O
[	O
5	O
,	O
8	O
]	O
y	O
otros	O
[	O
9	O
-	O
17	O
]	O
hemos	O
ampliado	O
recientemente	O
el	O
poder	O
de	O
este	O
enfoque	O
incorporando	O
genoma	B-Sequence
#	O
¿NOMBRE	O
?	O
gene	B-Sequence
``	O
análisis	O
de	O
matriz	O
de	O
expresión	O
,	O
que	O
nos	O
permite	O
modelar	O
la	O
``	O
''	O
genética	O
de	O
''	O
gene	B-Sequence
``	O
expresión	O
``	O
''	O
usando	O
métodos	O
similares	O
.	O
''	O

Una	O
extensión	O
inmediata	O
de	O
este	O
enfoque	O
es	O
hacia	O
la	O
disección	O
del	O
genético	B-Sequence
regulación	O
de	O
fenotipos	O
complejos	O
,	O
lo	O
que	O
mejoraría	O
en	O
gran	O
medida	O
la	O
progresión	O
del	O
candidato	O
lugar	B-Sequence
al	O
candidato	O
gene	B-Sequence
.	O

Aquí	O
informamos	O
la	O
aplicación	O
de	O
este	O
enfoque	O
integrado	O
para	O
estudiar	O
la	O
importancia	O
del	O
sexo	O
en	O
el	O
genético	B-Sequence
determinantes	O
de	O
la	O
obesidad	O
y	O
la	O
regulación	O
asociada	O
del	O
hígado	O
gene	B-Sequence
expresión	O
en	O
un	O
cruce	O
F2	O
derivado	O
de	O
las	O
cepas	O
endogámicas	O
C57BL	O
/	O
6J	O
(	O
B6	O
)	O
y	O
C3H	O
/	O
HeJ	O
(	O
C3H	O
)	O
en	O
un	O
apolipoproteína	B-Protein
E	I-Protein
nulo	O
(	O
ApoE	B-Protein
-	O
/	O
-	O
)	O
antecedentes	O
.	O

El	O
BXH	O
.	O
ApoE	B-Protein
-/-	O
La	O
población	O
fue	O
diseñada	O
para	O
recapitular	O
varios	O
de	O
los	O
fenotipos	O
asociados	O
con	O
el	O
llamado	O
síndrome	O
metabólico	O
.	O

La	O
cruz	O
consta	O
de	O
334	O
animales	B-Taxon
de	O
ambos	O
sexos	O
,	O
lo	O
que	O
nos	O
permite	O
probar	O
específicamente	O
la	O
dependencia	O
de	O
QTL	B-Sequence
sobre	O
el	O
sexo	O

Detectamos	O
varios	O
miles	O
gene	B-Sequence
expresión	O
QTL	B-Sequence
(	O
eQTLs	O
)	O
,	O
una	O
proporción	O
significativa	O
de	O
los	O
cuales	O
estaban	O
sesgados	O
por	O
sexo	O
.	O

Usamos	O
estos	O
análisis	O
para	O
diseccionar	O
el	O
genético	B-Sequence
regulación	O
del	O
rasgo	O
de	O
masa	O
grasa	O
gonadal	O
e	O
identificar	O
genes	B-Sequence
asociado	O
con	O
el	O
rasgo	O
.	O

Resultados	O

QTL	B-Sequence
Asociado	O
con	O
Masa	O
Grasa	O
Gonadal	O

Características	O
del	O
B6	O
.	O
ApoE	B-Protein
-/-	O
y	O
C3H	O
.	O
ApoE	B-Protein
-/-	O
padres	O
y	O
el	O
F2	O
BXH	O
.	O
ApoE	B-Protein
-	O
/	O
-	O
generación	O
en	O
una	O
dieta	O
occidental	O
se	O
resumen	O
en	O
la	O
Tabla	O
1	O
.	O

La	O
masa	O
grasa	O
gonadal	O
difirió	O
significativamente	O
entre	O
sexos	O
en	O
F2	O
(	O
p	O
<	O
10-4	O
)	O
y	O
en	O
el	O
parental	O
C3H	O
.	O
ApoE	B-Protein
-/-	O
(	O
p	O
<	O
0,05	O
)	O
,	O
pero	O
no	O
en	O
B6	O
.	O
ApoE	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
.	O

La	O
masa	O
grasa	O
gonadal	O
fue	O
la	O
colección	O
de	O
almohadillas	O
grasas	O
que	O
representó	O
la	O
mayor	O
parte	O
animales	B-Taxon
y	O
las	O
colecciones	O
más	O
precisas	O
y	O
por	O
lo	O
tanto	O
fue	O
elegido	O
para	O
su	O
posterior	O
análisis	O
.	O

La	O
heredabilidad	O
en	O
sentido	O
amplio	O
(	O
h2	O
)	O
calculada	O
como	O
(	O
sigma	O
2Total	O
-	O
sigma	O
2Parental	O
)	O
/	O
sigma	O
2Total	O
para	O
el	O
rasgo	O
de	O
masa	O
grasa	O
gonadal	O
fue	O
del	O
54	O
%	O
para	O
las	O
mujeres	O
y	O
del	O
36	O
%	O
para	O
los	O
hombres	O
,	O
lo	O
que	O
concuerda	O
estrechamente	O
con	O
informes	O
anteriores	O
[	O
18	O
,	O
19	O
]	O
y	O
demuestra	O
heredabilidad	O
significativa	O
de	O
la	O
masa	O
grasa	O
gonadal	O
.	O

Un	O
total	O
de	O
334	O
F2	O
ratones	B-Taxon
fueron	O
genotipados	O
en	O
un	O
promedio	O
de	O
1	O
.	O
Densidad	O
de	O
5	O
cm	O
usando	O
1	O
,	O
032	O
polimorfismos	B-Sequence
de	I-Sequence
un	I-Sequence
sólo	I-Sequence
nucleótido	I-Sequence
(	O
SNP	B-Sequence
)	O
que	O
abarca	O
los	O
19	O
autosomas	B-GENE
.	O

QTL	B-Sequence
análisis	O
de	O
varios	O
rasgos	O
clínicos	O
(	O
clínico	O
QTL	B-Sequence
[	O
cQTLs	O
]	O
)	O
,	O
incluidos	O
los	O
valores	O
brutos	O
no	O
ajustados	O
para	O
la	O
masa	O
de	O
grasa	O
gonadal	O
,	O
se	O
realizó	O
utilizando	O
un	O
enfoque	O
de	O
regresión	O
de	O
marcador	O
único	O
(	O
justificado	O
por	O
la	O
alta	O
densidad	O
de	O
marcadores	O
,	O
lo	O
que	O
hace	O
intervalo	B-Sequence
mapeo	O
innecesario	O
)	O
.	O

Con	O
el	O
fin	O
de	O
evaluar	O
específicamente	O
los	O
efectos	O
sexuales	O
de	O
la	O
vinculación	O
,	O
incluimos	O
parámetros	O
aditivos	O
,	O
dominantes	O
,	O
sexuales	O
,	O
aditivos	O
sexuales	O
y	O
dominantes	O
sexuales	O
en	O
nuestros	O
cálculos	O
(	O
ver	O
Materiales	O
y	O
Métodos	O
)	O
.	O

Se	O
usó	O
un	O
procedimiento	O
de	O
regresión	O
por	O
pasos	O
para	O
determinar	O
si	O
la	O
suma	O
de	O
los	O
dos	O
términos	O
finales	O
mejoraba	O
significativamente	O
el	O
modelo	O
de	O
regresión	O
lineal	O
,	O
condicionado	O
a	O
la	O
realización	O
de	O
un	O
aditivo	O
significativo	O
.	O
QTL	B-Sequence
efecto	O

Realizamos	O
análisis	O
de	O
permutación	O
sobre	O
todos	O
gene	B-Sequence
rasgos	O
de	O
expresión	O
,	O
estimando	O
las	O
tasas	O
de	O
descubrimiento	O
falso	O
(	O
FDR	O
)	O
en	O
diferentes	O
umbrales	O
de	O
puntaje	O
de	O
logaritmo	O
de	O
probabilidades	O
(	O
LOD	O
)	O
y	O
evaluando	O
la	O
tasa	O
general	O
de	O
QTL	B-Sequence
detección	O

A	O
partir	O
de	O
estos	O
análisis	O
,	O
construimos	O
curvas	O
similares	O
a	O
las	O
características	O
operativas	O
del	O
receptor	O
(	O
ROC	O
)	O
para	O
demostrar	O
que	O
nuestro	O
método	O
sencillo	O
ha	O
aumentado	O
significativamente	O
la	O
potencia	O
para	O
detectar	O
QTL	B-Sequence
comparado	O
con	O
QTL	B-Sequence
métodos	O
de	O
mapeo	O
que	O
no	O
incorporan	O
sexo	O
y	O
genotipo	B-Sequence
-	O
interacciones	O
sexuales	O
(	O
Figura	O
S1	O
)	O
.	O

Está	O
claro	O
a	O
partir	O
de	O
las	O
curvas	O
ROC	O
que	O
los	O
términos	O
sexo	O
y	O
sexo-interacción	O
se	O
suman	O
significativamente	O
a	O
la	O
detección	O
de	O
QTL	B-Sequence
Para	O
el	O
gene	B-Sequence
rasgos	O
de	O
expresión	O
.	O

Utilizando	O
las	O
convenciones	O
descritas	O
previamente	O
[	O
20	O
]	O
,	O
QTL	B-Sequence
los	O
modelos	O
sin	O
los	O
dos	O
últimos	O
términos	O
de	O
interacción	O
(	O
sex	O
*	O
add	O
y	O
sex	O
*	O
dom	O
)	O
tienen	O
un	O
umbral	O
sugestivo	O
de	O
3	O
.	O
0	O
(	O
p	O
<	O
1	O
x	O
10	O
-	O
3	O
)	O
y	O
un	O
umbral	O
significativo	O
de	O
4	O
.	O
3	O
(	O
pag	O
<	O
5	O
x	O
10	O
-	O
5	O
,	O
genoma	B-Sequence
-	O
ancho	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

QTL	B-Sequence
los	O
modelos	O
que	O
incorporan	O
solo	O
el	O
término	O
de	O
interacción	O
sex	O
*	O
add	O
además	O
de	O
los	O
términos	O
aditivos	O
tienen	O
un	O
grado	O
adicional	O
de	O
libertad	O
que	O
conduce	O
a	O
un	O
aumento	O
correspondiente	O
en	O
los	O
umbrales	O
de	O
puntuación	O
LOD	O
a	O
3	O
.	O
5	O
(	O
sugerente	O
)	O
y	O
4	O
.	O
9	O
(	O
significativo	O
)	O
para	O
el	O
0	O
.	O
001	O
y	O
0	O
.	O
00005	O
umbrales	O
de	O
valor	O
p	O
,	O
respectivamente	O
.	O

QTL	B-Sequence
los	O
modelos	O
que	O
incorporan	O
los	O
términos	O
de	O
interacción	O
sex	O
*	O
add	O
y	O
sex	O
*	O
dom	O
poseen	O
dos	O
grados	O
adicionales	O
de	O
libertad	O
,	O
con	O
un	O
aumento	O
correspondiente	O
en	O
los	O
umbrales	O
de	O
puntuación	O
LOD	O
a	O
4	O
.	O
0	O
(	O
sugerente	O
)	O
y	O
5	O
.	O
4	O
(	O
significativo	O
)	O
para	O
el	O
0	O
.	O
001	O
y	O
0	O
.	O
00005	O
umbrales	O
de	O
valor	O
p	O
,	O
respectivamente	O
.	O

Una	O
sugerente	O
(	O
Cromosoma	B-GENE
1	O
)	O
y	O
cuatro	O
significativos	O
(	O
cromosomas	B-GENE
3	O
,	O
5	O
,	O
11	O
y	O
19	O
)	O
se	O
identificaron	O
los	O
cQTL	O
para	O
el	O
rasgo	O
de	O
masa	O
grasa	O
gonadal	O
(	O
Figura	O
1A	O
;	O
Tabla	O
2	O
)	O
.	O

Cuatro	O
de	O
los	O
cinco	O
cQTL	O
mostraron	O
mejores	O
ajustes	O
estadísticamente	O
significativos	O
con	O
el	O
modelo	O
completo	O
que	O
incorporaba	O
los	O
términos	O
de	O
interacción	O
sex	O
*	O
add	O
y	O
sex	O
*	O
dom	O
,	O
en	O
comparación	O
con	O
el	O
modelo	O
que	O
incluía	O
sólo	O
los	O
términos	O
aditivos	O
.	O

Curiosamente	O
,	O
el	O
cQTL	O
sobre	O
Cromosoma	B-GENE
11	O
no	O
mejoró	O
,	O
lo	O
que	O
sugiere	O
que	O
los	O
términos	O
adicionales	O
no	O
contribuyeron	O
a	O
mejorar	O
la	O
detección	O
de	O
este	O
lugar	B-Sequence
.	O

La	O
Tabla	O
2	O
resume	O
la	O
posición	O
y	O
la	O
puntuación	O
LOD	O
de	O
la	O
vinculación	O
máxima	O
para	O
cada	O
cQTL	O
.	O

Si	O
bien	O
el	O
enfoque	O
de	O
este	O
estudio	O
fue	O
el	O
rasgo	O
de	O
la	O
masa	O
grasa	O
gonadal	O
,	O
se	O
observa	O
que	O
un	O
genoma	B-Sequence
la	O
exploración	O
del	O
rasgo	O
de	O
adiposidad	O
dio	O
como	O
resultado	O
cQTL	O
en	O
las	O
mismas	O
ubicaciones	O
,	O
con	O
puntuaciones	O
LOD	O
y	O
dependencia	O
sexual	O
muy	O
similares	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Los	O
resultados	O
de	O
los	O
diversos	O
modelos	O
de	O
regresión	O
utilizados	O
para	O
determinar	O
la	O
vinculación	O
de	O
la	O
Cromosoma	B-GENE
5	O
cQTL	O
se	O
representan	O
en	O
la	O
Figura	O
1B	O
.	O

Análisis	O
de	O
todos	O
animales	B-Taxon
con	O
y	O
sin	O
sexo	O
como	O
covariable	O
no	O
pudo	O
demostrar	O
evidencia	O
de	O
vinculación	O
en	O
Cromosoma	B-GENE
5	O
.	O

Cuando	O
las	O
hembras	O
se	O
analizaron	O
solas	O
,	O
se	O
obtuvo	O
una	O
puntuación	O
LOD	O
sugestiva	O
de	O
3	O
.	O
se	O
realizó	O
7	O
(	O
p	O
=	O
2	O
x	O
10-4	O
)	O
;	O
los	O
machos	O
analizados	O
solos	O
no	O
demostraron	O
evidencia	O
de	O
vinculación	O
.	O

Sin	O
embargo	O
,	O
usando	O
los	O
334	O
animales	B-Taxon
y	O
agregando	O
los	O
términos	O
de	O
interacción	O
a	O
la	O
QTL	B-Sequence
el	O
modelo	O
mejoró	O
significativamente	O
la	O
sensibilidad	O
y	O
un	O
cQTL	O
con	O
un	O
LOD	O
máximo	O
de	O
7	O
.	O
56	O
(	O
p	O
=	O
1	O
,	O
7	O
x	O
10	O
-	O
6	O
)	O
.	O

Dada	O
la	O
detección	O
mejorada	O
de	O
cuatro	O
de	O
los	O
cinco	O
cQTL	O
cuando	O
se	O
consideraron	O
los	O
términos	O
de	O
interacción	O
sexo-aditivo	O
y	O
sexo-dominante	O
,	O
planteamos	O
la	O
hipótesis	O
de	O
que	O
el	O
principal	O
genotipo	B-Sequence
el	O
efecto	O
de	O
estos	O
cQTL	O
en	O
el	O
rasgo	O
de	O
masa	O
grasa	O
gonadal	O
diferiría	O
entre	O
los	O
sexos	O
(	O
Figura	O
2	O
)	O
.	O

De	O
hecho	O
,	O
los	O
cQTL	O
ubicados	O
en	O
cromosomas	B-GENE
1	O
,	O
3	O
y	O
5	O
mostraron	O
efectos	O
opuestos	O
sobre	O
la	O
masa	O
grasa	O
o	O
el	O
antagonismo	O
sexual	O
.	O

El	O
efecto	O
del	O
cQTL	O
en	O
Cromosoma	B-GENE
11	O
estaba	O
en	O
la	O
misma	O
dirección	O
tanto	O
en	O
hombres	O
como	O
en	O
mujeres	O
,	O
pero	O
estaba	O
sesgado	O
por	O
sexo	O
hacia	O
un	O
efecto	O
mayor	O
en	O
mujeres	O
(	O
R2	O
=	O
0,091	O
en	O
mujeres	O
frente	O
a	O
R2	O
=	O
0,046	O
en	O
hombres	O
)	O
,	O
lo	O
que	O
confirma	O
la	O
especificidad	O
sexual	O
mínima	O
de	O
este	O
cQTL	O
.	O

El	O
cQTL	O
en	O
Cromosoma	B-GENE
19	O
mostró	O
un	O
efecto	O
específico	O
del	O
sexo	O
en	O
las	O
mujeres	O
,	O
sin	O
efecto	O
en	O
los	O
hombres	O
.	O

En	O
general	O
,	O
los	O
cinco	O
cQTL	O
para	O
la	O
masa	O
grasa	O
gonadal	O
estaban	O
sesgados	O
hacia	O
un	O
efecto	O
mayor	O
en	O
las	O
mujeres	O
.	O

Suponiendo	O
efectos	O
puramente	O
aditivos	O
de	O
cada	O
genotipo	B-Sequence
,	O
estos	O
cQTL	O
representan	O
aproximadamente	O
el	O
42	O
%	O
de	O
la	O
variación	O
en	O
F2	O
femenino	O
ratones	B-Taxon
y	O
13	O
%	O
en	O
hombres	O
,	O
consistente	O
con	O
las	O
estimaciones	O
de	O
heredabilidad	O
en	O
sentido	O
estricto	O
para	O
este	O
rasgo	O
y	O
nuevamente	O
demostrando	O
diferencias	O
significativas	O
en	O
la	O
regulación	O
y	O
heredabilidad	O
del	O
rasgo	O
de	O
grasa	O
gonadal	O
entre	O
los	O
sexos	O
.	O

eQTL	O
de	O
hígado	O

Hígados	O
de	O
312	O
F2	O
animales	B-Taxon
(	O
156	O
mujeres	O
,	O
156	O
hombres	O
)	O
fueron	O
perfilados	O
usando	O
oligonucleótido	B-Sequence
microarrays	O
fabricados	O
por	O
Agilent	O
Technologies	O
(	O
Palo	O
Alto	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
,	O
que	O
incluían	O
sondas	B-Sequence
para	O
23	O
,	O
574	O
ratón	B-Taxon
transcripciones	B-Sequence
.	O

Individual	O
transcripción	B-Sequence
las	O
intensidades	O
se	O
corrigieron	O
para	O
la	O
variación	O
experimental	O
y	O
se	O
normalizaron	O
y	O
se	O
informan	O
como	O
la	O
relación	O
log10	O
media	O
(	O
mlratio	O
)	O
de	O
un	O
experimento	O
individual	O
en	O
relación	O
con	O
un	O
grupo	O
compuesto	O
por	O
150	O
ratones	B-Taxon
seleccionados	O
al	O
azar	O
de	O
la	O
población	O
F2	O
[	O
21	O
]	O
.	O

Cada	O
medida	O
se	O
ajustó	O
a	O
un	O
modelo	O
de	O
error	O
y	O
se	O
le	O
asignó	O
una	O
medida	O
de	O
significancia	O
(	O
error	O
tipo	O
I	O
)	O
.	O

Un	O
mapa	O
de	O
calor	O
de	O
los	O
2	O
,	O
320	O
transcripciones	B-Sequence
más	O
expresado	O
diferencialmente	O
(	O
p	O
<	O
0,05	O
en	O
el	O
10	O
%	O
o	O
más	O
de	O
animales	B-Taxon
)	O
en	O
relación	O
con	O
el	O
grupo	O
se	O
muestra	O
en	O
la	O
Figura	O
3	O
.	O

Esta	O
selección	O
de	O
genes	B-Sequence
no	O
estaba	O
sesgado	O
por	O
la	O
expresión	O
diferencial	O
conocida	O
a	O
priori	O
entre	O
los	O
sexos	O
,	O
la	O
vinculación	O
o	O
la	O
correlación	O
con	O
un	O
fenotipo	O
clínico	O
.	O

Esto	O
es	O
notable	O
porque	O
el	O
agrupamiento	O
jerárquico	O
de	O
estos	O
transcripciones	B-Sequence
contra	O
el	O
312	O
F2	O
ratones	B-Taxon
muestra	O
una	O
agrupación	O
casi	O
perfecta	O
en	O
subgrupos	O
masculinos	O
y	O
femeninos	O
,	O
lo	O
que	O
enfatiza	O
los	O
efectos	O
sorprendentes	O
del	O
sexo	O
en	O
el	O
hígado	O
gene	B-Sequence
niveles	O
de	O
expresión	O
y	O
lo	O
que	O
sugiere	O
que	O
el	O
sexo	O
está	O
controlando	O
más	O
variación	O
en	O
estos	O
transcripciones	B-Sequence
'	O
expresión	O
que	O
cualquier	O
otro	O
parámetro	O
.	O

Los	O
valores	O
de	O
expresión	O
del	O
23	O
,	O
574	O
transcripciones	B-Sequence
se	O
trataron	O
como	O
rasgos	O
cuantitativos	O
y	O
se	O
ajustaron	O
a	O
los	O
mismos	O
modelos	O
de	O
regresión	O
lineal	O
utilizados	O
para	O
calcular	O
las	O
puntuaciones	O
LOD	O
para	O
los	O
rasgos	O
clínicos	O
(	O
eQTL	O
)	O
.	O

El	O
FDR	O
en	O
cada	O
umbral	O
se	O
determinó	O
permutando	O
los	O
datos	O
100	O
veces	O
y	O
tomando	O
el	O
número	O
medio	O
de	O
QTL	B-Sequence
detectado	O
sobre	O
todos	O
los	O
conjuntos	O
de	O
datos	O
permutados	O
en	O
un	O
umbral	O
dado	O
,	O
y	O
dividiendo	O
este	O
conteo	O
por	O
el	O
número	O
de	O
QTL	B-Sequence
detectado	O
en	O
el	O
mismo	O
umbral	O
en	O
los	O
datos	O
observados	O
.	O

En	O
el	O
umbral	O
de	O
vinculación	O
significativa	O
(	O
p	O
<	O
5	O
x	O
10	O
-	O
5	O
,	O
genoma	B-Sequence
-	O
ancho	O
p	O
<	O
0	O
.	O
05	O
,	O
basado	O
en	O
un	O
solo	O
rasgo	O
)	O
,	O
el	O
FDR	O
se	O
estimó	O
en	O
3	O
.	O
4	O
%	O
para	O
el	O
estándar	O
QTL	B-Sequence
modelo	O
que	O
no	O
tiene	O
en	O
cuenta	O
ningún	O
término	O
sexual	O
,	O
3	O
.	O
1	O
%	O
para	O
el	O
QTL	B-Sequence
modelo	O
que	O
da	O
cuenta	O
de	O
los	O
efectos	O
sexuales	O
aditivos	O
,	O
y	O
3	O
.	O
2	O
%	O
para	O
el	O
QTL	B-Sequence
el	O
modelo	O
tiene	O
en	O
cuenta	O
los	O
efectos	O
sexuales	O
aditivos	O
y	O
permite	O
que	O
los	O
términos	O
de	O
interacción	O
sexual	O
entren	O
en	O
el	O
modelo	O
.	O

Una	O
lista	O
de	O
todos	O
los	O
eQTLs	O
sugestivos	O
(	O
p	O
<	O
1	O
x	O
10-3	O
)	O
y	O
significativos	O
detectados	O
(	O
p	O
<	O
5	O
x	O
10-5	O
)	O
detectados	O
en	O
el	O
BXH	O
.	O
ApoE	B-Protein
-/-	O
el	O
intercruzamiento	O
se	O
proporciona	O
en	O
la	O
Tabla	O
S1	O
.	O

Las	O
características	O
de	O
los	O
eQTL	O
en	O
diferentes	O
niveles	O
de	O
significación	O
se	O
resumen	O
en	O
la	O
Tabla	O
3	O
y	O
se	O
muestran	O
gráficamente	O
en	O
la	O
Figura	O
4	O
.	O

Detectamos	O
6	O
676	O
eQTL	O
que	O
representan	O
4	O
998	O
transcripciones	B-Sequence
en	O
el	O
nivel	O
significativo	O
de	O
5	O
x	O
10-5	O
.	O

De	O
estos	O
,	O
2	O
118	O
eQTL	O
se	O
ubicaron	O
dentro	O
de	O
los	O
20	O
Mb	O
(	O
aproximadamente	O
10	O
cM	O
)	O
del	O
correspondiente	O
gene	B-Sequence
,	O
probablemente	O
representando	O
eQTL	O
regulados	O
por	O
variación	O
de	O
acción	O
cis	O
dentro	O
del	O
gene	B-Sequence
sí	O
mismo	O
.	O

De	O
los	O
6.676	O
eQTLs	O
significativos	O
,	O
1.166	O
(	O
17	O
%	O
)	O
demostraron	O
un	O
sesgo	O
de	O
sexo	O
y	O
posteriormente	O
mejoraron	O
significativamente	O
con	O
la	O
adición	O
de	O
los	O
términos	O
sexo-aditivo	O
y	O
sexo-dominante	O
.	O

La	O
distribución	O
de	O
los	O
6	O
676	O
eQTL	O
significativos	O
(	O
p	O
<	O
5	O
x	O
10	O
-	O
5	O
)	O
en	O
el	O
genoma	B-Sequence
en	O
recipientes	O
de	O
2	O
cm	O
se	O
muestra	O
en	O
la	O
Figura	O
4A	O
.	O

La	O
evidencia	O
de	O
puntos	O
de	O
acceso	O
eQTL	O
es	O
clara	O
en	O
cromosomas	B-GENE
1	O
,	O
2	O
,	O
4	O
,	O
5	O
,	O
6	O
y	O
7	O
donde	O
fracciones	O
significativas	O
de	O
los	O
6	O
676	O
eQTL	O
se	O
colocalizan	O
dentro	O
de	O
2	O
cM	O
regiones	B-Sequence
de	I-Sequence
cada	I-Sequence
cromosoma	I-Sequence
.	O

Aproximadamente	O
el	O
67	O
%	O
de	O
los	O
eQTL	O
en	O
este	O
umbral	O
son	O
trans	O
,	O
y	O
estos	O
puntos	O
críticos	O
de	O
eQTL	O
consisten	O
principalmente	O
en	O
efectos	O
trans	O
que	O
actúan	O
sobre	O
la	O
variación	O
transcripcional	O
.	O

La	O
distribución	O
de	O
los	O
1.166	O
eQTL	O
con	O
efectos	O
sexuales	O
significativos	O
,	O
de	O
los	O
cuales	O
852	O
(	O
73	O
%	O
)	O
son	O
trans	O
,	O
mostró	O
enriquecimiento	O
en	O
Cromosoma	B-GENE
5	O
a	O
aproximadamente	O
49	O
cM	O
(	O
Figura	O
4B	O
)	O
según	O
lo	O
evaluado	O
usando	O
la	O
prueba	O
exacta	O
de	O
Fisher	O
(	O
p	O
=	O
8,7	O
x	O
10-25	O
después	O
de	O
la	O
corrección	O
de	O
Bonferroni	O
)	O
.	O

En	O
este	O
lugar	B-Sequence
hubo	O
250	O
eQTL	O
,	O
140	O
de	O
los	O
cuales	O
exhibieron	O
genotipo	B-Sequence
#	O
¿NOMBRE	O
?	O

A	O
umbrales	O
crecientes	O
para	O
la	O
vinculación	O
,	O
una	O
fracción	O
mayor	O
de	O
eQTL	O
detectados	O
actuaban	O
en	O
cis	O
(	O
Figura	O
4C	O
)	O
.	O

El	O
aumento	O
de	O
la	O
proporción	O
de	O
cis-eQTL	O
con	O
umbrales	O
de	O
puntuación	O
de	O
LOD	O
crecientes	O
se	O
ha	O
informado	O
anteriormente	O
[	O
5	O
,	O
15	O
]	O
y	O
confirma	O
lo	O
que	O
probablemente	O
sea	O
nuestro	O
mayor	O
poder	O
para	O
detectar	O
cis-acting	O
de	O
primer	O
orden	O
.	O
variaciones	B-Sequence
afectando	O
la	O
transcripción	O
.	O

La	O
proporción	O
de	O
eQTL	O
con	O
efectos	O
sexuales	O
significativos	O
se	O
mantuvo	O
relativamente	O
constante	O
en	O
todos	O
los	O
umbrales	O
(	O
Figura	O
4C	O
)	O
.	O

Además	O
,	O
la	O
mayoría	O
de	O
estos	O
eQTL	O
específicos	O
de	O
sexo	O
(	O
73	O
%	O
)	O
actúan	O
en	O
trans	O
sobre	O
un	O
determinado	O
gene	B-Sequence
La	O
expresión	O
de	O
's	O
(	O
Figura	O
4D	O
)	O
,	O
y	O
proporciones	O
similares	O
de	O
eQTL	O
específicos	O
de	O
sexo	O
(	O
26	O
%	O
)	O
son	O
cis	O
en	O
comparación	O
con	O
la	O
proporción	O
de	O
todos	O
los	O
cis-eQTL	O
de	O
hígado	O
(	O
32	O
%	O
)	O
.	O

Estos	O
datos	O
demuestran	O
los	O
profundos	O
efectos	O
del	O
sexo	O
en	O
el	O
genético	B-Sequence
regulación	O
de	O
gene	B-Sequence
expresión	O
.	O

Cis	O
:	O
los	O
eQTL	O
son	O
candidatos	O
genes	B-Sequence
para	O
el	O
rasgo	O
de	O
masa	O
grasa	O
gonadal	O

Dados	O
los	O
marcados	O
efectos	O
del	O
sexo	O
sobre	O
el	O
hígado	O
gene	B-Sequence
expresión	O
y	O
la	O
genético	B-Sequence
``	O
regulación	O
de	O
la	O
masa	O
grasa	O
gonadal	O
,	O
razonamos	O
que	O
los	O
cis-eQTL	O
con	O
interacciones	O
significativas	O
de	O
``	O
''	O
sexo	O
aditivo	O
''	O
''	O
y	O
``	O
''	O
sexo	O
dominante	O
''	O
''	O
serían	O
candidatos	O
potenciales	O
''	O
genes	B-Sequence
por	O
nuestro	O
rasgo	O
.	O

De	O
los	O
2	O
,	O
118	O
cis-eQTLs	O
significativos	O
,	O
304	O
(	O
14	O
%	O
)	O
fueron	O
mejorados	O
por	O
los	O
términos	O
de	O
interacción	O
sexual	O
.	O

Cis	O
-	O
eQTL	O
superposición	B-Sequence
el	O
intervalo	O
de	O
confianza	O
para	O
la	O
masa	O
grasa	O
cQTL	O
son	O
candidatos	O
genes	B-Sequence
por	O
el	O
rasgo	O
.	O

Esos	O
genes	B-Sequence
con	O
interacciones	O
sexuales	O
significativas	O
reciben	O
mayor	O
consideración	O
como	O
candidatos	O
potenciales	O
(	O
Tablas	O
4	O
y	O
5	O
)	O
.	O

Miles	O
de	O
genes	B-Sequence
Mostrar	O
un	O
sexo	O
:	O
correlación	O
específica	O
con	O
la	O
masa	O
de	O
grasa	O
gonadal	O

Para	O
cada	O
uno	O
de	O
los	O
23	O
574	O
oligonucleótidos	B-Sequence
``	O
representada	O
en	O
la	O
matriz	O
,	O
calculamos	O
un	O
análisis	O
de	O
regresión	O
lineal	O
para	O
probar	O
la	O
asociación	O
entre	O
el	O
rasgo	O
``	O
''	O
masa	O
de	O
grasa	O
gonadal	O
''	O
''	O
y	O
cada	O
''	O
transcripción	B-Sequence
``	O
medida	O
de	O
abundancia	O
,	O
incorporando	O
los	O
términos	O
``	O
''	O
''	O
gene	B-Sequence
``	O
,	O
``	O
''	O
``	O
''	O
sexo	O
,	O
``	O
''	O
y	O
``	O
''	O
''	O
gene	B-Sequence
``	O
-	O
por	O
-	O
sexo	O
,	O
``	O
''	O
donde	O
el	O
``	O
''	O
''	O
gene	B-Sequence
``	O
-	O
por	O
-	O
sexo	O
``	O
''	O
pruebas	O
de	O
parámetros	O
para	O
el	O
sexo	O
-	O
correlación	O
específica	O
entre	O
un	O
''	O
gene	B-Sequence
y	O
el	O
rasgo	O
.	O

Como	O
antes	O
,	O
se	O
usó	O
un	O
procedimiento	O
de	O
regresión	O
por	O
pasos	O
para	O
determinar	O
si	O
la	O
adición	O
del	O
término	O
de	O
interacción	O
mejoraba	O
significativamente	O
el	O
ajuste	O
del	O
modelo	O
(	O
ver	O
Materiales	O
y	O
Métodos	O
)	O
.	O

Las	O
pruebas	O
múltiples	O
se	O
abordaron	O
controlando	O
el	O
FDR	O
.	O

La	O
distribución	O
de	O
los	O
valores	O
p	O
obtenidos	O
de	O
estas	O
23	O
574	O
correlaciones	O
se	O
muestra	O
en	O
la	O
Figura	O
5A	O
.	O

En	O
FDR	O
=	O
0	O
.	O
01	O
,	O
4	O
,	O
613	O
genes	B-Sequence
se	O
correlacionaron	O
significativamente	O
con	O
la	O
masa	O
grasa	O
gonadal	O
.	O

De	O
estos	O
genes	B-Sequence
``	O
,	O
4	O
,	O
524	O
(	O
98	O
%	O
)	O
mostró	O
significativa	O
``	O
''	O
''	O
gene	B-Sequence
``	O
``	O
''	O
por	O
-	O
sexo	O
``	O
''	O
efectos	O
,	O
lo	O
que	O
apoya	O
el	O
alto	O
grado	O
de	O
especificidad	O
por	O
sexo	O
en	O
el	O
''	O
genético	B-Sequence
regulación	O
de	O
este	O
rasgo	O
.	O

Una	O
lista	O
completa	O
de	O
todos	O
genes	B-Sequence
correlacionada	O
con	O
la	O
masa	O
de	O
grasa	O
gonadal	O
se	O
proporciona	O
en	O
la	O
Tabla	O
S2	O
.	O

de	O
los	O
4	O
,	O
613	O
genes	B-Sequence
correlacionado	O
con	O
la	O
masa	O
de	O
grasa	O
gonadal	O
,	O
1.130	O
generan	O
1.478	O
eQTL	O
significativos	O
(	O
Figura	O
5B	O
)	O
.	O

La	O
colocalización	O
de	O
eQTLs	O
para	O
estos	O
correlacionados	O
genes	B-Sequence
con	O
el	O
cQTL	O
para	O
el	O
rasgo	O
de	O
masa	O
grasa	O
proporciona	O
implicaciones	O
útiles	O
para	O
el	O
posible	O
papel	O
de	O
estos	O
genes	B-Sequence
.	O

Si	O
los	O
eQTL	O
son	O
cis	O
o	O
trans	O
determina	O
cuál	O
puede	O
ser	O
ese	O
papel	O
.	O

genes	B-Sequence
que	O
muestran	O
una	O
correlación	O
significativa	O
con	O
el	O
rasgo	O
de	O
masa	O
grasa	O
gonadal	O
y	O
que	O
tienen	O
cis	O
-	O
eQTL	O
coincidentes	O
con	O
los	O
cQTL	O
de	O
masa	O
grasa	O
son	O
candidatos	O
potenciales	O
genes	B-Sequence
para	O
el	O
rasgo	O
(	O
es	O
decir	O
,	O
pueden	O
contener	O
un	O
variación	B-Sequence
genética	I-Sequence
en	O
eso	O
gene	B-Sequence
esa	O
es	O
la	O
causa	O
del	O
rasgo	O
cQTL	O
)	O
.	O

La	O
Tabla	O
5	O
resume	O
los	O
genes	B-Sequence
que	O
poseen	O
estos	O
propiedades	B-Sequence
para	O
cada	O
cQTL	O
,	O
aumentando	O
la	O
evidencia	O
de	O
estos	O
genes	B-Sequence
como	O
candidatos	O
potenciales	O
.	O

Como	O
se	O
aborda	O
a	O
continuación	O
,	O
dada	O
la	O
compleja	O
regulación	O
multiorgánica	O
de	O
la	O
masa	O
de	O
tejido	O
adiposo	O
,	O
es	O
poco	O
probable	O
que	O
la	O
genético	B-Sequence
regulación	O
de	O
los	O
cinco	O
lugares	B-Sequence
reside	O
en	O
el	O
hígado	O
.	O

Sin	O
embargo	O
,	O
algunos	O
pueden	O
involucrar	O
al	O
hígado	O
,	O
e	O
incluso	O
para	O
aquellos	O
que	O
no	O
lo	O
hacen	O
,	O
la	O
variación	O
transcripcional	O
del	O
hígado	O
puede	O
reflejar	O
la	O
del	O
tejido	O
relevante	O
.	O

genes	B-Sequence
que	O
muestran	O
una	O
correlación	O
significativa	O
con	O
la	O
masa	O
grasa	O
gonadal	O
y	O
tienen	O
trans	O
-	O
eQTL	O
coincidentes	O
con	O
la	O
masa	O
grasa	O
cQTL	O
no	O
pueden	O
ser	O
candidatos	O
directamente	O
responsables	O
del	O
rasgo	O
,	O
ya	O
que	O
están	O
ubicados	O
físicamente	O
en	O
otra	O
parte	O
del	O
cuerpo	O
.	O
genoma	B-Sequence
.	O

Sin	O
embargo	O
,	O
están	O
potencialmente	O
involucrados	O
en	O
la	O
(	O
s	O
)	O
vía	O
(	O
s	O
)	O
que	O
conduce	O
(	O
n	O
)	O
desde	O
el	O
origen	O
causal	O
.	O
gene	B-Sequence
a	O
la	O
expresión	O
del	O
rasgo	O
de	O
masa	O
grasa	O
(	O
es	O
decir	O
,	O
su	O
transcripción	O
está	O
estrechamente	O
regulada	O
por	O
el	O
factor	O
causal	O
gene	B-Sequence
en	O
el	O
lugar	B-Sequence
)	O
.	O

Los	O
cinco	O
cQTL	O
de	O
masa	O
grasa	O
tienen	O
trans	O
-	O
eQTL	O
colocalizadores	O
para	O
correlación	O
genes	B-Sequence
.	O

Sin	O
embargo	O
,	O
para	O
un	O
rasgo	O
como	O
la	O
masa	O
grasa	O
que	O
está	O
regulada	O
por	O
múltiples	O
tejidos	O
y	O
órganos	O
,	O
es	O
poco	O
probable	O
que	O
los	O
cinco	O
cQTL	O
de	O
masa	O
grasa	O
estén	O
impulsados	O
principalmente	O
por	O
el	O
hígado	O
.	O
gene	B-Sequence
expresión	O
.	O

Como	O
una	O
aproximación	O
a	O
este	O
problema	O
,	O
planteamos	O
la	O
hipótesis	O
de	O
que	O
aquellos	O
cQTL	O
que	O
están	O
más	O
estrechamente	O
asociados	O
con	O
el	O
hígado	O
gene	B-Sequence
expresión	O
mostraría	O
una	O
sobrerrepresentación	O
de	O
eQTL	O
colocalizado	O
para	O
correlacionado	O
genes	B-Sequence
,	O
mientras	O
que	O
aquellos	O
lugares	B-Sequence
controlado	O
principalmente	O
por	O
otros	O
tejidos	O
no	O
habría	O
mostrado	O
este	O
patrón	O
.	O

Para	O
evaluar	O
esto	O
,	O
primero	O
determinamos	O
la	O
distribución	O
de	O
estos	O
1	O
,	O
478	O
eQTL	O
en	O
todo	O
el	O
genoma	B-Sequence
en	O
recipientes	O
de	O
2	O
cm	O
como	O
se	O
muestra	O
en	O
la	O
Figura	O
5C	O
.	O

Para	O
ver	O
si	O
existen	O
puntos	O
críticos	O
para	O
estos	O
eQTL	O
,	O
probamos	O
eQTL	O
con	O
p	O
<	O
0	O
.	O
001	O
para	O
el	O
enriquecimiento	O
a	O
lo	O
largo	O
de	O
la	O
genoma	B-Sequence
en	O
superposición	B-Sequence
Contenedores	O
de	O
2	O
cM	O
contra	O
la	O
distribución	O
de	O
todos	O
los	O
eQTL	O
de	O
hígado	O
(	O
Figura	O
4A	O
)	O
utilizando	O
una	O
prueba	O
exacta	O
de	O
Fisher	O
.	O

La	O
Figura	O
5D	O
muestra	O
la	O
importancia	O
del	O
enriquecimiento	O
informado	O
como	O
-	O
log10	O
del	O
valor	O
p	O
de	O
enriquecimiento	O
en	O
todo	O
el	O
genoma	B-Sequence
.	O

Una	O
locus	B-Sequence
en	I-Sequence
el	I-Sequence
cromosoma	I-Sequence
19	O
se	O
enriqueció	O
significativamente	O
para	O
eQTLs	O
de	O
transcripciones	B-Sequence
correlacionado	O
con	O
el	O
rasgo	O
de	O
masa	O
grasa	O
gonadal	O
.	O

Como	O
se	O
anticipó	O
,	O
hubo	O
una	O
superposición	O
de	O
un	O
punto	O
de	O
acceso	O
eQTL	O
correlacionado	O
y	O
un	O
cQTL	O
de	O
masa	O
grasa	O
,	O
específicamente	O
Cromosoma	B-GENE
19	O
a	O
40cm	O
.	O

Esto	O
sugiere	O
que	O
el	O
genético	B-Sequence
regulación	O
de	O
la	O
masa	O
grasa	O
para	O
el	O
Locus	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
19	I-Sequence
está	O
más	O
estrechamente	O
relacionado	O
con	O
el	O
hígado	O
gene	B-Sequence
expresión	O
que	O
los	O
otros	O
cuatro	O
cQTL	O
de	O
masa	O
grasa	O
.	O

El	O
efecto	O
de	O
los	O
trans	O
-	O
eQTLs	O
en	O
el	O
Locus	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
19	I-Sequence
en	O
gene	B-Sequence
expresión	O
se	O
resume	O
en	O
la	O
Figura	O
6	O
.	O

Veintinueve	O
trans	O
-	O
eQTL	O
colocalizan	O
para	O
Cromosoma	B-GENE
9	O
a	O
40	O
cm	O
,	O
lo	O
que	O
sugiere	O
que	O
29	O
genes	B-Sequence
correlacionados	O
con	O
la	O
masa	O
grasa	O
gonadal	O
están	O
regulados	O
en	O
trans	O
por	O
un	O
polimorfismo	B-Sequence
en	O
esto	O
posición	B-Sequence
.	O

La	O
proporción	O
de	O
gene	B-Sequence
niveles	O
de	O
expresión	O
controlados	O
por	O
este	O
lugar	B-Sequence
(	O
aproximado	O
como	O
los	O
coeficientes	O
de	O
determinación	O
R2	O
)	O
difiere	O
entre	O
hombres	O
y	O
mujeres	O
para	O
la	O
mayoría	O
de	O
los	O
transcripciones	B-Sequence
(	O
como	O
en	O
la	O
Figura	O
6A	O
)	O
,	O
y	O
para	O
Cromosoma	B-GENE
19	O
(	O
Figura	O
6B	O
)	O
,	O
las	O
mujeres	O
demostraron	O
mayor	O
genético	B-Sequence
regulación	O
de	O
gene	B-Sequence
expresión	O
que	O
los	O
hombres	O
.	O

Este	O
sesgo	O
femenino	O
sustancial	O
es	O
significativamente	O
mayor	O
de	O
lo	O
que	O
se	O
esperaría	O
que	O
surja	O
por	O
casualidad	O
para	O
el	O
Locus	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
19	I-Sequence
(	O
p	O
<	O
0	O
.	O
001	O
por	O
chi	O
2	O
)	O
.	O

Esta	O
lugar	B-Sequence
corresponde	O
a	O
uno	O
de	O
los	O
cuatro	O
cQTL	O
sesgados	O
por	O
el	O
sexo	O
para	O
la	O
masa	O
de	O
grasa	O
gonadal	O
informados	O
en	O
este	O
estudio	O
,	O
y	O
la	O
especificidad	O
sexual	O
significativa	O
tanto	O
del	O
cis	O
como	O
del	O
trans	O
genético	B-Sequence
regulación	O
del	O
hígado	O
genes	B-Sequence
correlacionado	O
con	O
la	O
masa	O
grasa	O
apoya	O
la	O
importancia	O
funcional	O
de	O
este	O
lugar	B-Sequence
en	O
este	O
órgano	O
.	O

Discusión	O

En	O
este	O
estudio	O
,	O
describimos	O
un	O
gran	O
F2	O
segregante	O
densamente	O
cartografiado	O
.	O
ratón	B-Taxon
población	O
diseñada	O
para	O
estudiar	O
la	O
genético	B-Sequence
regulación	O
de	O
varios	O
rasgos	O
asociados	O
con	O
el	O
llamado	O
síndrome	O
metabólico	O
.	O

Varios	O
grupos	O
,	O
incluido	O
el	O
nuestro	O
,	O
han	O
reportado	O
la	O
ventaja	O
de	O
combinar	O
genética	O
tradicional	O
con	O
genoma	B-Sequence
#	O
¿NOMBRE	O
?	O
gene	B-Sequence
análisis	O
de	O
expresión	O
para	O
la	O
disección	O
de	O
rasgos	O
complejos	O
.	O

Este	O
estudio	O
mejoró	O
los	O
modelos	O
anteriores	O
al	O
incluir	O
más	O
de	O
300	O
animales	B-Taxon
(	O
tres	O
veces	O
el	O
tamaño	O
de	O
los	O
estudios	O
previos	O
)	O
de	O
ambos	O
sexos	O
,	O
lo	O
que	O
permite	O
la	O
incorporación	O
de	O
efectos	O
específicos	O
de	O
sexo	O
en	O
subyacente	O
genético	B-Sequence
reglamento	O

Sesgo	O
sexual	O
significativo	O
en	O
la	O
regulación	O
de	O
rasgos	O
complejos	O
y	O
Gene	B-Sequence
Expresión	O

Dada	O
la	O
conocida	O
dicotomía	O
entre	O
mujeres	O
y	O
hombres	O
en	O
la	O
susceptibilidad	O
y	O
el	O
control	O
de	O
la	O
obesidad	O
,	O
este	O
estudio	O
fue	O
diseñado	O
para	O
potenciar	O
suficientemente	O
la	O
detección	O
de	O
QTL	B-Sequence
para	O
este	O
y	O
otros	O
rasgos	O
con	O
efectos	O
dependientes	O
del	O
sexo	O
.	O

Tenga	O
en	O
cuenta	O
,	O
sin	O
embargo	O
,	O
que	O
estos	O
efectos	O
pueden	O
extenderse	O
a	O
rasgos	O
sin	O
diferencias	O
medias	O
generales	O
entre	O
los	O
sexos	O
.	O

Estudios	O
previos	O
han	O
descrito	O
las	O
ventajas	O
de	O
realizar	O
QTL	B-Sequence
análisis	O
con	O
y	O
sin	O
sexo	O
como	O
una	O
covariable	O
interactiva	O
[	O
22	O
-	O
25	O
]	O
.	O

Analizar	O
los	O
sexos	O
por	O
separado	O
es	O
subóptimo	O
ya	O
que	O
reduce	O
el	O
tamaño	O
de	O
la	O
muestra	O
en	O
ambos	O
grupos	O
,	O
lo	O
que	O
reduce	O
el	O
poder	O
para	O
detectar	O
los	O
principales	O
QTL	B-Sequence
efectos	O
,	O
como	O
lo	O
demuestra	O
nuestro	O
genoma	B-Sequence
escaneo	O
de	O
Cromosoma	B-GENE
5	O
(	O
Figura	O
1B	O
)	O
.	O

Además	O
,	O
los	O
análisis	O
separados	O
no	O
permitirían	O
la	O
detección	O
de	O
QTL	B-Sequence
que	O
tienen	O
efectos	O
opuestos	O
,	O
o	O
antagónicos	O
al	O
sexo	O
,	O
en	O
mujeres	O
y	O
hombres	O
y	O
dificultarían	O
la	O
detección	O
de	O
QTL	B-Sequence
específico	O
de	O
un	O
sexo	O
.	O

En	O
consecuencia	O
,	O
detectamos	O
cinco	O
cQTL	O
para	O
el	O
rasgo	O
de	O
masa	O
grasa	O
gonadal	O
en	O
cromosomas	B-GENE
1	O
,	O
3	O
,	O
5	O
,	O
11	O
y	O
19	O
.	O

``	O
La	O
detección	O
de	O
los	O
cinco	O
cQTL	O
fue	O
``	O
''	O
impulsada	O
``	O
''	O
por	O
el	O
mayor	O
efecto	O
en	O
las	O
mujeres	O
,	O
con	O
una	O
mejora	O
significativa	O
por	O
la	O
incorporación	O
de	O
los	O
parámetros	O
sexo	O
*	O
aditivo	O
y	O
sexo	O
*	O
dominante	O
.	O
''	O

QTL	B-Sequence
asociados	O
con	O
la	O
obesidad	O
,	O
la	O
grasa	O
gonadal	O
y	O
la	O
grasa	O
abdominal	O
se	O
han	O
informado	O
antes	O
superposición	B-Sequence
con	O
cQTL	O
en	O
cromosomas	B-GENE
1	O
[	O
26	O
-	O
28	O
]	O
,	O
5	O
[	O
26	O
,	O
29	O
]	O
y	O
11	O
[	O
19	O
,	O
29	O
]	O
informados	O
aquí	O
,	O
mientras	O
que	O
el	O
cQTL	O
en	O
Cromosoma	B-GENE
3	O
representa	O
una	O
novela	O
QTL	B-Sequence
por	O
este	O
rasgo	O
.	O

los	O
Cromosoma	B-GENE
19	O
cQTL	O
para	O
la	O
masa	O
grasa	O
fue	O
informado	O
recientemente	O
por	O
nosotros	O
[	O
5	O
]	O
en	O
la	O
progenie	O
BXD	O
intercruzada	O
F2	O
de	O
las	O
cepas	O
B6	O
y	O
DBA	O
(	O
que	O
comparte	O
el	O
mismo	O
haplotipo	B-Sequence
en	O
esto	O
región	B-Sequence
como	O
la	O
cepa	O
C3H	O
utilizada	O
en	O
este	O
estudio	O
)	O
.	O

Curiosamente	O
,	O
la	O
heredabilidad	O
significativa	O
y	O
genético	B-Sequence
regulación	O
se	O
observó	O
en	O
esta	O
población	O
F2	O
a	O
pesar	O
de	O
la	O
hiperlipidemia	O
,	O
proinflamatoria	O
ApoE	B-Protein
-	O
/	O
-	O
antecedentes	O
y	O
la	O
dieta	O
occidental	O
rica	O
en	O
grasas	O
.	O

Este	O
fondo	O
posee	O
varias	O
ventajas	O
,	O
como	O
permitir	O
el	O
modelado	O
de	O
humano	B-Taxon
-	O
como	O
estados	O
de	O
enfermedad	O
.	O

Los	O
efectos	O
predominantemente	O
femeninos	O
de	O
los	O
cinco	O
cQTL	O
probablemente	O
reflejan	O
el	O
efecto	O
significativo	O
de	O
la	O
diferencia	O
gonadal	O
hormona	B-Chemical
secreciones	O
en	O
el	O
genético	B-Sequence
regulación	O
de	O
este	O
complejo	O
rasgo	O
.	O

La	O
identificación	O
de	O
genes	B-Sequence
los	O
cQTL	O
subyacentes	O
siguen	O
siendo	O
un	O
desafío	O
.	O

La	O
disponibilidad	O
generalizada	O
de	O
genoma	B-Sequence
#	O
¿NOMBRE	O
?	O
genes	B-Sequence
puede	O
diferenciar	O
un	O
rasgo	O
dado	O
.	O

Además	O
,	O
al	O
tratar	O
transcripción	B-Sequence
niveles	O
como	O
rasgos	O
cuantitativos	O
,	O
podemos	O
mapear	O
los	O
genético	B-Sequence
regulación	O
subyacente	O
diferencial	O
gene	B-Sequence
expresión	O
(	O
eQTL	O
)	O
.	O

Esos	O
eQTL	O
que	O
tienen	O
cis	O
-	O
actuando	O
variaciones	B-Sequence
afectando	O
su	O
transcripción	O
son	O
candidatos	O
potenciales	O
genes	B-Sequence
por	O
el	O
rasgo	O
.	O

En	O
un	O
solo	O
rasgo	O
,	O
genoma	B-Sequence
-	O
nivel	O
de	O
significación	O
amplio	O
de	O
0	O
.	O
05	O
,	O
detectamos	O
6	O
,	O
676	O
eQTL	O
que	O
representan	O
4	O
,	O
998	O
genes	B-Sequence
,	O
de	O
los	O
cuales	O
2	O
118	O
eran	O
cis	O
-	O
actuantes	O
.	O

umbrales	O
mayores	O
,	O
aumentó	O
la	O
proporción	O
de	O
cis-eQTL	O
,	O
lo	O
que	O
concuerda	O
con	O
estudios	O
previos	O
[	O
5	O
,	O
15	O
]	O
y	O
probablemente	O
refleja	O
el	O
mayor	O
poder	O
para	O
detectar	O
cis-eQTL	O
.	O
variaciones	B-Sequence
afectando	O
la	O
transcripción	O
.	O

De	O
los	O
6.676	O
eQTL	O
significativos	O
,	O
1.166	O
poseían	O
interacciones	O
sexuales	O
significativas	O
.	O

De	O
estos	O
,	O
304	O
eran	O
cis	O
y	O
852	O
eran	O
trans	O
,	O
lo	O
que	O
sugiere	O
que	O
sólo	O
una	O
minoría	O
de	O
los	O
efectos	O
específicos	O
del	O
sexo	O
en	O
la	O
regulación	O
de	O
la	O
gene	B-Sequence
la	O
expresión	O
ocurre	O
a	O
través	O
de	O
polimorfismos	B-Sequence
dentro	O
de	O
gene	B-Sequence
sí	O
mismo	O
.	O

Más	O
bien	O
,	O
subyacente	O
genético	B-Sequence
regulación	O
de	O
la	O
mayoría	O
transcripciones	B-Sequence
es	O
el	O
resultado	O
de	O
interacciones	O
entre	O
trans	O
lugares	B-Sequence
y	O
factores	O
específicos	O
del	O
sexo	O
(	O
p	O
.	O
ej	O
.	O
,	O
hormonas	B-Chemical
)	O
.	O

Al	O
igual	O
que	O
con	O
los	O
cQTL	O
,	O
el	O
sesgo	O
sexual	O
en	O
los	O
predominantemente	O
trans	O
genético	B-Sequence
regulación	O
de	O
gene	B-Sequence
Es	O
probable	O
que	O
la	O
expresión	O
sea	O
secundaria	O
a	O
un	O
sexo	O
diferente	O
.	O
hormona	B-Chemical
perfiles	O

Recientemente	O
,	O
utilizando	O
un	O
conjunto	O
de	O
datos	O
similar	O
,	O
nuestro	O
grupo	O
demostró	O
que	O
los	O
cis	O
-	O
eQTL	O
significativos	O
(	O
p	O
<	O
5	O
x	O
10	O
-	O
5	O
)	O
representan	O
en	O
gran	O
medida	O
verdaderos	O
positivos	O
[	O
30	O
]	O
y	O
están	O
enriquecidos	O
para	O
regiones	B-Sequence
polimórficas	I-Sequence
sobre	O
el	O
ratón	B-Taxon
genoma	B-Sequence
.	O

Los	O
eQTL	O
cis	O
presentados	O
en	O
la	O
Tabla	O
5	O
se	O
superponen	O
con	O
uno	O
de	O
los	O
cQTL	O
de	O
masa	O
grasa	O
gonadal	O
y	O
deben	O
considerarse	O
candidatos	O
potenciales	O
.	O

Dados	O
los	O
efectos	O
del	O
sexo	O
en	O
los	O
cQTL	O
de	O
la	O
masa	O
grasa	O
gonadal	O
,	O
razonamos	O
que	O
los	O
cis-eQTL	O
con	O
efectos	O
sexuales	O
*	O
aditivos	O
y	O
sexuales	O
*	O
dominantes	O
significativos	O
deberían	O
recibir	O
una	O
consideración	O
prioritaria	O
.	O

El	O
uso	O
de	O
eQTLs	O
para	O
diseccionar	O
cQTLs	O
es	O
un	O
método	O
todavía	O
en	O
pañales	O
,	O
con	O
eficacia	O
y	O
aplicabilidad	O
inciertas	O
.	O

Sin	O
embargo	O
,	O
la	O
aplicación	O
de	O
este	O
análisis	O
a	O
este	O
conjunto	O
de	O
datos	O
proporciona	O
un	O
candidato	O
tentadoramente	O
atractivo	O
.	O
genes	B-Sequence
.	O

Una	O
deficiencia	O
de	O
este	O
enfoque	O
,	O
sin	O
embargo	O
,	O
es	O
que	O
el	O
candidato	O
genes	B-Sequence
se	O
limitan	O
a	O
aquellos	O
cuya	O
transcripción	B-Sequence
los	O
niveles	O
de	O
expresión	O
varían	O
en	O
asociación	O
con	O
un	O
cercano	O
polimorfismo	B-Sequence
que	O
difiere	O
entre	O
las	O
cepas	O
parentales	O
;	O
en	O
otras	O
palabras	O
,	O
genes	B-Sequence
con	O
cis-eQTL	O
significativos	O
y	O
detectables	O
.	O

Sin	O
embargo	O
,	O
no	O
es	O
estrictamente	O
necesario	O
que	O
el	O
candidato	O
genes	B-Sequence
para	O
tener	O
evidencia	O
de	O
tal	O
vinculación	O
:	O
polimorfismos	B-Sequence
subyacente	O
a	O
un	O
rasgo	O
cQTL	O
puede	O
afectar	O
gene	B-Sequence
función	O
o	O
postraduccional	O
modificaciones	B-Sequence
.	O

No	O
obstante	O
,	O
se	O
sabe	O
que	O
varios	O
fenotipos	O
están	O
regulados	O
,	O
al	O
menos	O
en	O
parte	O
,	O
a	O
nivel	O
de	O
transcripción	O
o	O
ARNm	B-Chemical
estabilidad	O
,	O
que	O
es	O
exactamente	O
lo	O
que	O
nuestros	O
métodos	O
están	O
diseñados	O
para	O
detectar	O
.	O

Un	O
problema	O
aparte	O
es	O
ese	O
órgano	O
-	O
específico	O
gene	B-Sequence
las	O
diferencias	O
de	O
expresión	O
pueden	O
impedir	O
que	O
uno	O
detecte	O
la	O
causante	O
relevante	O
gene	B-Sequence
si	O
el	O
tejido	O
dispuesto	O
no	O
es	O
el	O
tejido	O
donde	O
se	O
ejerce	O
el	O
control	O
.	O

Esto	O
es	O
particularmente	O
relevante	O
para	O
un	O
rasgo	O
como	O
la	O
masa	O
de	O
tejido	O
adiposo	O
,	O
que	O
está	O
controlada	O
por	O
múltiples	O
tejidos	O
.	O

Proponemos	O
que	O
el	O
análisis	O
de	O
correlación	O
genes	B-Sequence
puede	O
proporcionar	O
orientación	O
como	O
se	O
analiza	O
a	O
continuación	O
.	O

genes	B-Sequence
Correlacionado	O
con	O
Masa	O
Grasa	O
Gonadal	O
Tejido	O
Ilustrado	O
-	O
Regulación	O
Específica	O
del	O
Rasgo	O

En	O
un	O
esfuerzo	O
por	O
identificar	O
genes	B-Sequence
asociado	O
con	O
el	O
rasgo	O
de	O
masa	O
grasa	O
,	O
pero	O
no	O
necesariamente	O
candidato	O
genes	B-Sequence
subyacente	O
al	O
rasgo	O
cQTL	O
,	O
ajustamos	O
modelos	O
lineales	O
para	O
evaluar	O
el	O
grado	O
de	O
asociación	O
entre	O
transcripciones	B-Sequence
y	O
masa	O
grasa	O
gonadal	O
.	O

Al	O
igual	O
que	O
con	O
QTL	B-Sequence
,	O
se	O
modelaron	O
las	O
correlaciones	O
específicas	O
del	O
sexo	O
.	O

un	O
FDR	O
del	O
1	O
%	O
,	O
4	O
,	O
613	O
genes	B-Sequence
se	O
encontró	O
que	O
estaban	O
significativamente	O
correlacionados	O
con	O
la	O
masa	O
de	O
grasa	O
gonadal	O
,	O
de	O
los	O
cuales	O
4	O
,	O
254	O
(	O
98	O
%	O
)	O
mostraron	O
una	O
correlación	O
sesgada	O
por	O
sexo	O
.	O

Como	O
se	O
indica	O
en	O
las	O
Tablas	O
4	O
y	O
5	O
,	O
varios	O
genes	B-Sequence
con	O
cis	O
detectables	O
:	O
los	O
eQTL	O
también	O
se	O
correlacionan	O
significativamente	O
con	O
el	O
rasgo	O
y	O
se	O
priorizan	O
aún	O
más	O
como	O
candidatos	O
genes	B-Sequence
.	O

``	O
Hasta	O
ahora	O
,	O
los	O
estudios	O
que	O
han	O
examinado	O
la	O
``	O
''	O
genética	O
de	O
''	O
gene	B-Sequence
``	O
expresión	O
``	O
''	O
están	O
de	O
acuerdo	O
con	O
respecto	O
a	O
la	O
mayor	O
potencia	O
para	O
detectar	O
cis	O
-	O
eQTLs	O
en	O
relación	O
con	O
trans	O
[	O
5	O
,	O
9	O
,	O
15	O
,	O
16	O
,	O
31	O
]	O
.	O
''	O

No	O
está	O
claro	O
en	O
este	O
momento	O
,	O
sin	O
embargo	O
,	O
cuál	O
es	O
exactamente	O
el	O
significado	O
de	O
trans-eQTLs	O
y	O
la	O
naturaleza	O
de	O
la	O
subyacente	O
.	O
polimorfismos	B-Sequence
asociado	O
con	O
ellos	O
.	O

Además	O
,	O
los	O
hotspots	O
de	O
eQTL	O
informados	O
en	O
este	O
y	O
en	O
estudios	O
anteriores	O
[	O
5	O
,	O
9	O
,	O
10	O
]	O
representan	O
en	O
gran	O
medida	O
trans-eQTL	O
.	O

Esta	O
localización	O
sugiere	O
algún	O
significado	O
funcional	O
para	O
estos	O
regiones	B-Sequence
.	O

de	O
los	O
4	O
,	O
613	O
genes	B-Sequence
correlacionados	O
con	O
la	O
masa	O
de	O
grasa	O
gonadal	O
,	O
1.130	O
generan	O
1.478	O
eQTL	O
significativos	O
,	O
de	O
los	O
cuales	O
1.023	O
(	O
69	O
%	O
)	O
son	O
transacciones	O
.	O

Estos	O
eQTL	O
están	O
significativamente	O
enriquecidos	O
en	O
un	O
lugar	B-Sequence
(	O
Cromosoma	B-GENE
19	O
)	O
.	O

Curiosamente	O
,	O
este	O
punto	O
de	O
acceso	O
coincidió	O
con	O
un	O
cQTL	O
asociado	O
con	O
la	O
masa	O
grasa	O
informado	O
en	O
este	O
estudio	O
.	O

Dado	O
que	O
estos	O
transcripciones	B-Sequence
representan	O
aquellos	O
significativamente	O
correlacionados	O
con	O
la	O
masa	O
de	O
grasa	O
gonadal	O
,	O
la	O
localización	O
de	O
sus	O
eQTLs	O
a	O
estos	O
regiones	B-Sequence
apoya	O
firmemente	O
la	O
noción	O
de	O
que	O
el	O
genes	B-Sequence
con	O
trans	O
-	O
eQTLs	O
representan	O
objetivos	O
aguas	O
abajo	O
de	O
candidatos	O
regulatorios	O
genes	B-Sequence
ubicado	O
en	O
el	O
posición	B-Sequence
de	O
vinculación	O
significativa	O
.	O

Esto	O
significa	O
que	O
el	O
genes	B-Sequence
puede	O
ser	O
causal	O
,	O
pero	O
aguas	O
abajo	O
de	O
la	O
gene	B-Sequence
responsables	O
de	O
los	O
cQTL	O
,	O
o	O
pueden	O
estar	O
reaccionando	O
al	O
aumento	O
de	O
la	O
masa	O
de	O
grasa	O
gonadal	O
y	O
los	O
cambios	O
metabólicos	O
asociados	O
.	O

Estos	O
datos	O
también	O
sugieren	O
que	O
la	O
identificación	O
de	O
tales	O
lugares	B-Sequence
que	O
muestran	O
sobrerrepresentación	O
de	O
altamente	O
correlacionados	O
genes	B-Sequence
es	O
un	O
medio	O
para	O
identificar	O
cuál	O
de	O
los	O
cQTL	O
de	O
rasgo	O
es	O
más	O
probable	O
que	O
esté	O
controlado	O
por	O
el	O
tejido	O
dispuesto	O
.	O

Como	O
era	O
de	O
esperar	O
,	O
el	O
Locus	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
19	I-Sequence
fue	O
enriquecido	O
para	O
trans-eQTLs	O
con	O
efectos	O
sustancialmente	O
mayores	O
en	O
las	O
mujeres	O
.	O

funcional	O
y	O
promotor	B-Sequence
análisis	O
de	O
genes	B-Sequence
con	O
un	O
trans-eQTL	O
común	O
puede	O
resultar	O
esclarecedor	O
.	O

Es	O
más	O
,	O
gene	B-Sequence
la	O
construcción	O
y	O
el	O
análisis	O
de	O
la	O
red	O
de	O
expresión	O
pueden	O
mejorarse	O
mediante	O
la	O
incorporación	O
de	O
la	O
regulación	O
cis	O
versus	O
trans	O
demostrada	O
experimentalmente	O
.	O

Conclusión	O

La	O
integración	O
de	O
la	O
genética	O
tradicional	O
con	O
genoma	B-Sequence
El	O
análisis	O
de	O
expresión	O
amplia	O
fue	O
propuesto	O
por	O
primera	O
vez	O
por	O
Jansen	O
y	O
Nap	O
hace	O
4	O
años	O
[	O
32	O
]	O
.	O

Avances	O
en	O
genómico	B-Sequence
la	O
tecnología	O
y	O
los	O
recursos	O
bioinformáticos	O
desde	O
entonces	O
han	O
mejorado	O
enormemente	O
la	O
aplicabilidad	O
de	O
estos	O
métodos	O
para	O
la	O
disección	O
de	O
rasgos	O
complejos	O
.	O

Teniendo	O
en	O
cuenta	O
el	O
sexo	O
,	O
los	O
efectos	O
específicos	O
mejorarán	O
de	O
manera	O
similar	O
la	O
sensibilidad	O
para	O
detectar	O
genético	B-Sequence
regulación	O
,	O
especialmente	O
para	O
los	O
fenotipos	O
que	O
se	O
sabe	O
que	O
se	O
ven	O
afectados	O
por	O
el	O
sexo	O
.	O

Además	O
,	O
los	O
análisis	O
de	O
redes	O
se	O
aplican	O
cada	O
vez	O
más	O
a	O
fenotipos	O
complejos	O
[	O
11	O
,	O
33	O
]	O
.	O

Independientemente	O
de	O
las	O
variables	O
que	O
se	O
utilicen	O
en	O
la	O
construcción	O
de	O
estas	O
redes	O
,	O
si	O
miden	O
gene	B-Sequence
expresión	O
o	O
proteína	B-Chemical
interacciones	O
,	O
teniendo	O
en	O
cuenta	O
la	O
especificidad	O
del	O
sexo	O
,	O
hormonal	B-Chemical
el	O
estado	O
o	O
la	O
construcción	O
de	O
diferentes	O
redes	O
para	O
hembras	O
y	O
machos	O
probablemente	O
representaría	O
con	O
mayor	O
precisión	O
la	O
complejidad	O
asociada	O
con	O
estos	O
fenotipos	O
.	O

Informamos	O
aquí	O
sobre	O
las	O
primeras	O
genético	B-Sequence
y	O
genómico	B-Sequence
análisis	O
de	O
una	O
población	O
de	O
intercruzamiento	O
F2	O
diseñada	O
para	O
recapitular	O
varios	O
rasgos	O
asociados	O
con	O
humano	B-Taxon
síndrome	O
metabólico	O
.	O

Usando	O
334	O
ratones	B-Taxon
de	O
ambos	O
sexos	O
genotipados	O
a	O
alta	O
densidad	O
,	O
este	O
es	O
el	O
estudio	O
más	O
grande	O
de	O
su	O
tipo	O
diseñado	O
hasta	O
la	O
fecha	O
,	O
y	O
está	O
fuertemente	O
potenciado	O
para	O
detectar	O
efectos	O
sutiles	O
de	O
genético	B-Sequence
regulación	O
y	O
especificidad	O
sexual	O
.	O

Identificamos	O
cinco	O
cQTL	O
para	O
el	O
rasgo	O
de	O
masa	O
grasa	O
gonadal	O
,	O
todos	O
con	O
mayores	O
efectos	O
en	O
las	O
mujeres	O
.	O

También	O
detectamos	O
varios	O
miles	O
de	O
eQTL	O
hepáticos	O
significativos	O
,	O
una	O
fracción	O
significativa	O
de	O
los	O
cuales	O
están	O
sesgados	O
por	O
el	O
sexo	O
,	O
lo	O
que	O
demuestra	O
cómo	O
los	O
efectos	O
significativos	O
del	O
sexo	O
en	O
gene	B-Sequence
la	O
expresión	O
se	O
extiende	O
más	O
allá	O
de	O
las	O
diferencias	O
medias	O
generales	O
.	O

Demostramos	O
la	O
aplicación	O
de	O
métodos	O
de	O
vinculación	O
y	O
correlación	O
para	O
identificar	O
candidatos	O
genes	B-Sequence
.	O

Finalmente	O
,	O
mostramos	O
que	O
la	O
localización	O
de	O
un	O
subconjunto	O
de	O
hígado	O
genes	B-Sequence
vinculado	O
en	O
trans	O
a	O
un	O
cQTL	O
región	B-Sequence
puede	O
identificar	O
las	O
contribuciones	O
relativas	O
de	O
los	O
tejidos	O
a	O
la	O
genético	B-Sequence
regulación	O
de	O
un	O
rasgo	O
complejo	O
.	O

Anticipamos	O
que	O
la	O
aplicación	O
de	O
estos	O
y	O
otros	O
métodos	O
similares	O
mejoraría	O
significativamente	O
la	O
elucidación	O
de	O
la	O
genético	B-Sequence
regulación	O
subyacente	O
a	O
fenotipos	O
complejos	O
.	O

Materiales	O
y	O
métodos	O

animales	B-Taxon
y	O
colección	O
de	O
tejido	O
.	O

C57BL	O
/	O
6J	O
ApoE	B-Protein
-	O
/	O
-	O
(	O
B6	O
.	O
ApoE	B-Protein
-/-	O
)	O
se	O
adquirieron	O
de	O
Jackson	O
Laboratory	O
(	O
Bar	O
Harbor	O
,	O
Maine	O
,	O
Estados	O
Unidos	O
)	O
.	O

C3H	O
/	O
HeJ	O
ApoE	B-Protein
-	O
/	O
-	O
(	O
C3H	O
.	O
ApoE	B-Protein
-/-	O
)	O
se	O
generaron	O
retrocruzando	O
B6	O
.	O
ApoE	B-Protein
-/-	O
a	O
C3H	O
durante	O
diez	O
generaciones	O
.	O

F1	O
ratones	B-Taxon
se	O
generaron	O
a	O
partir	O
del	O
entrecruzamiento	O
recíproco	O
entre	O
B6	O
.	O
ApoE	B-Protein
-/-	O
y	O
C3H	O
.	O
ApoE	B-Protein
-	O
/	O
-	O
y	O
F2	O
ratones	B-Taxon
fueron	O
criados	O
posteriormente	O
cruzando	O
F1	O
ratones	B-Taxon
.	O

Un	O
total	O
de	O
334	O
ratones	B-Taxon
(	O
169	O
mujeres	O
,	O
165	O
hombres	O
)	O
fueron	O
producidos	O
.	O

Todos	O
ratones	B-Taxon
``	O
fueron	O
alimentados	O
con	O
Purina	O
Chow	O
que	O
contenía	O
4	O
%	O
de	O
grasa	O
hasta	O
las	O
8	O
semanas	O
de	O
edad	O
y	O
luego	O
fueron	O
transferidos	O
a	O
una	O
dieta	O
``	O
''	O
occidental	O
``	O
''	O
que	O
contenía	O
42	O
%	O
de	O
grasa	O
y	O
0	O
.	O
15	O
%	O
''	O
colesterol	B-Chemical
durante	O
16	O
semanas	O
.	O

Ratones	B-Taxon
fueron	O
sacrificados	O
a	O
las	O
24	O
semanas	O
de	O
edad	O
.	O

En	O
el	O
momento	O
de	O
la	O
muerte	O
,	O
los	O
hígados	O
se	O
recogieron	O
inmediatamente	O
y	O
se	O
congelaron	O
rápidamente	O
en	O
líquido	O
N2	B-Chemical
y	O
se	O
extrajeron	O
y	O
pesaron	O
las	O
almohadillas	O
de	O
grasa	O
gonadal	O
.	O

ARN	B-Sequence
preparación	O
de	O
muestras	O
,	O
hibridación	O
de	O
micromatrices	O
y	O
análisis	O
de	O
expresión	O
.	O

ARN	B-Sequence
la	O
preparación	O
y	O
las	O
hibridaciones	O
en	O
matriz	O
se	O
realizaron	O
en	O
Rosetta	O
Inpharmatics	O
(	O
Seattle	O
,	O
Washington	O
,	O
Estados	O
Unidos	O
)	O
.	O

Los	O
microarrays	O
de	O
inyección	O
de	O
tinta	O
personalizados	O
utilizados	O
en	O
este	O
estudio	O
(	O
Agilent	O
Technologies	O
,	O
descrito	O
anteriormente	O
[	O
21	O
,	O
34	O
]	O
)	O
contienen	O
2.186	O
controles	O
sondas	B-Sequence
y	O
23	O
574	O
sin	O
control	O
oligonucleótidos	B-Sequence
extraído	O
de	O
ratón	B-Taxon
Clústeres	O
UniGene	O
y	O
combinados	O
con	O
RefSeq	O
secuencias	B-Sequence
y	O
RIKEN	O
de	O
cuerpo	O
entero	O
clones	B-Sequence
.	O

Ratón	B-Taxon
hígados	O
fueron	O
homogeneizados	O
y	O
totales	O
ARN	B-Sequence
extraído	O
usando	O
TRIzol	O
reactivo	B-Chemical
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
según	O
protocolo	O
del	O
fabricante	O
.	O

Tres	O
microgramos	O
de	O
total	O
ARN	B-Sequence
se	O
transcribió	O
inversamente	O
y	O
se	O
marcó	O
con	O
fluorocromo	O
Cy3	O
o	O
Cy5	O
.	O

Complementario	O
Cy3	O
o	O
Cy5	O
purificado	O
ARN	B-Sequence
se	O
hibridó	O
con	O
al	O
menos	O
dos	O
portaobjetos	O
de	O
microarrays	O
con	O
inversión	O
de	O
flúor	O
durante	O
24	O
h	O
en	O
una	O
cámara	O
de	O
hibridación	O
,	O
se	O
lavó	O
y	O
se	O
escaneó	O
con	O
un	O
escáner	O
confocal	O
láser	O
.	O

Las	O
matrices	O
se	O
cuantificaron	O
sobre	O
la	O
base	O
de	O
la	O
intensidad	O
del	O
punto	O
en	O
relación	O
con	O
el	O
fondo	O
,	O
se	O
ajustaron	O
según	O
la	O
variación	O
experimental	O
entre	O
matrices	O
usando	O
la	O
intensidad	O
promedio	O
en	O
múltiples	O
canales	O
y	O
se	O
ajustaron	O
a	O
un	O
modelo	O
de	O
error	O
para	O
determinar	O
la	O
importancia	O
(	O
error	O
tipo	O
I	O
)	O
.	O

Gene	B-Sequence
expresión	O
se	O
reporta	O
como	O
el	O
mlratio	O
relativo	O
al	O
grupo	O
derivado	O
de	O
150	O
ratones	B-Taxon
seleccionados	O
al	O
azar	O
de	O
la	O
población	O
F2	O
.	O

Para	O
los	O
análisis	O
posteriores	O
,	O
se	O
supone	O
que	O
los	O
datos	O
de	O
mlratio	O
se	O
distribuyen	O
normalmente	O
,	O
una	O
suposición	O
válida	O
como	O
se	O
demostró	O
anteriormente	O
[	O
21	O
,	O
30	O
]	O
.	O

El	O
modelo	O
de	O
error	O
utilizado	O
para	O
evaluar	O
si	O
un	O
determinado	O
gene	B-Sequence
se	O
expresa	O
de	O
manera	O
significativamente	O
diferencial	O
en	O
una	O
sola	O
muestra	O
en	O
relación	O
con	O
un	O
grupo	O
compuesto	O
por	O
un	O
subconjunto	O
seleccionado	O
aleatoriamente	O
de	O
150	O
muestras	O
y	O
se	O
ha	O
descrito	O
y	O
probado	O
ampliamente	O
en	O
varias	O
publicaciones	O
[	O
35	O
,	O
36	O
]	O
.	O

Estadísticas	O
de	O
genotipado	O
y	O
ligamiento	O
.	O

ADN	B-Sequence
genómico	I-Sequence
fue	O
aislado	O
del	O
riñón	O
por	O
fenol	B-Chemical
-	O
cloroformo	B-Chemical
extracción	O

Un	O
examen	O
de	O
las	O
bases	O
de	O
datos	O
existentes	O
identificó	O
más	O
de	O
1	O
300	O
SNP	B-Sequence
que	O
mostró	O
variación	O
entre	O
las	O
cepas	O
B6	O
y	O
C3H	O
,	O
y	O
un	O
ligamiento	O
completo	O
mapa	B-Sequence
para	O
todos	O
los	O
19	O
autosomas	B-GENE
fue	O
construido	O
usando	O
1	O
,	O
032	O
de	O
estos	O
SNP	B-Sequence
a	O
una	O
densidad	O
media	O
de	O
1	O
.	O
5cm	O

El	O
genotipado	O
fue	O
realizado	O
por	O
ParAllele	O
(	O
South	O
San	O
Francisco	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
utilizando	O
el	O
molecular	B-Chemical
#	O
¿NOMBRE	O
?	O
Investigacion	B-Sequence
(	O
MIB	O
)	O
técnica	O
multiplexada	O
[	O
37	O
]	O
.	O

Pruebas	O
de	O
vinculación	O
de	O
rasgos	O
clínicos	O
y	O
gene	B-Sequence
La	O
expresión	O
(	O
usando	O
mlratio	O
)	O
se	O
realizó	O
usando	O
un	O
modelo	O
lineal	O
.	O

Considere	O
un	O
fenotipo	O
denotado	O
por	O
y	O
.	O

El	O
modelo	O
lineal	O
que	O
relaciona	O
la	O
variación	O
en	O
y	O
con	O
QTL	B-Sequence
otras	O
covariables	O
(	O
p	O
.	O
ej	O
.	O
,	O
sexo	O
)	O
viene	O
dada	O
por	O
la	O
forma	O
general	O

donde	O
mu	O
es	O
la	O
media	O
del	O
rasgo	O
,	O
X	O
'	O
un	O
vector	O
de	O
covariables	O
,	O
siendo	O
beta	O
el	O
vector	O
asociado	O
de	O
coeficientes	O
de	O
regresión	O
,	O
y	O
e	O
el	O
error	O
residual	O
.	O

Se	O
calculó	O
la	O
vinculación	O
para	O
más	O
de	O
20	O
rasgos	O
clínicos	O
,	O
así	O
como	O
para	O
23	O
574	O
transcripciones	B-Sequence
.	O

Estándar	O
genoma	B-Sequence
los	O
escaneos	O
calculan	O
la	O
vinculación	O
comparando	O
el	O
modelo	O
lineal	O

al	O
modelo	O
nulo	O

donde	O
beta	O
1	O
y	O
beta	O
2	O
son	O
los	O
coeficientes	O
de	O
regresión	O
de	O
los	O
parámetros	O
aditivos	O
y	O
dominantes	O
,	O
respectivamente	O
.	O

La	O
puntuación	O
LOD	O
representa	O
la	O
diferencia	O
en	O
el	O
log10	O
de	O
la	O
probabilidad	O
de	O
las	O
dos	O
ecuaciones	O
anteriores	O
,	O
donde	O
las	O
probabilidades	O
del	O
modelo	O
individual	O
se	O
maximizan	O
con	O
respecto	O
a	O
los	O
parámetros	O
del	O
modelo	O
,	O
dado	O
el	O
marcador	O
genotipo	B-Sequence
y	O
datos	O
de	O
fenotipo	O
.	O

Si	O
un	O
rasgo	O
y	O
difiere	O
en	O
promedio	O
entre	O
los	O
dos	O
sexos	O
pero	O
el	O
QTL	B-Sequence
tiene	O
el	O
mismo	O
efecto	O
tanto	O
en	O
hombres	O
como	O
en	O
mujeres	O
,	O
podemos	O
modelar	O
esta	O
interacción	O
incluyendo	O
el	O
sexo	O
como	O
una	O
covariable	O
aditiva	O
en	O
los	O
modelos	O
anteriores	O
,	O
dando	O
como	O
resultado	O
el	O
nuevo	O
modelo	O

que	O
luego	O
se	O
compara	O
con	O
el	O
modelo	O
nulo	O

donde	O
beta	O
3	O
es	O
el	O
coeficiente	O
de	O
regresión	O
del	O
parámetro	O
sexo	O
.	O

el	O
efecto	O
de	O
un	O
QTL	B-Sequence
puede	O
depender	O
del	O
estado	O
de	O
una	O
covariable	O
;	O
por	O
ejemplo	O
,	O
un	O
QTL	B-Sequence
puede	O
tener	O
un	O
efecto	O
específico	O
para	O
un	O
sexo	O
,	O
o	O
puede	O
tener	O
efectos	O
opuestos	O
en	O
los	O
dos	O
sexos	O
.	O

Esta	O
interacción	O
se	O
puede	O
modelar	O
utilizando	O
un	O
modelo	O
completo	O
,	O
que	O
tiene	O
en	O
cuenta	O
todas	O
las	O
covariables	O
aditivas	O
,	O
así	O
como	O
las	O
interacciones	O
entre	O
las	O
covariables	O
:	O

que	O
se	O
compara	O
con	O
el	O
modelo	O
nulo	O
anterior	O
(	O
Ecuación	O
5	O
)	O
.	O

El	O
modelo	O
completo	O
(	O
Ecuación	O
6	O
)	O
nos	O
permite	O
modelar	O
todas	O
las	O
interacciones	O
hereditarias	O
y	O
específicas	O
del	O
sexo	O
en	O
una	O
sola	O
ecuación	O
y	O
nos	O
permite	O
al	O
máximo	O
detectar	O
interacciones	O
significativas	O
QTL	B-Sequence
cuando	O
los	O
términos	O
sexo	O
y	O
sexo	O
-	O
interacción	O
son	O
significativos	O
,	O
dados	O
todos	O
los	O
334	O
animales	B-Taxon
se	O
incluyen	O
en	O
el	O
análisis	O
.	O

Además	O
,	O
el	O
uso	O
del	O
modelo	O
completo	O
evita	O
la	O
necesidad	O
de	O
modelar	O
QTL	B-Sequence
en	O
un	O
solo	O
sexo	O
,	O
un	O
procedimiento	O
que	O
podría	O
disminuir	O
nuestro	O
poder	O
al	O
reducir	O
a	O
la	O
mitad	O
el	O
tamaño	O
de	O
la	O
muestra	O
,	O
haciendo	O
imposible	O
detectar	O
interacciones	O
entre	O
QTL	B-Sequence
sexo	O

Sin	O
embargo	O
,	O
debido	O
a	O
que	O
el	O
modelo	O
completo	O
contiene	O
dos	O
parámetros	O
más	O
que	O
el	O
modelo	O
que	O
trata	O
el	O
sexo	O
como	O
una	O
covariable	O
aditiva	O
(	O
Ecuación	O
4	O
)	O
,	O
el	O
umbral	O
de	O
puntaje	O
LOD	O
para	O
una	O
vinculación	O
significativa	O
es	O
más	O
alto	O
(	O
usando	O
la	O
convención	O
de	O
Lander	O
y	O
Kruglyak	O
[	O
20	O
]	O
)	O
,	O
con	O
QTL	B-Sequence
-	O
niveles	O
de	O
significación	O
específicos	O
de	O
2	O
x	O
10	O
-	O
3	O
y	O
5	O
x	O
10	O
-	O
5	O
equivalentes	O
a	O
puntuaciones	O
LOD	O
de	O
4	O
.	O
0	O
(	O
vínculo	O
sugestivo	O
)	O
y	O
5	O
.	O
4	O
(	O
enlace	O
significativo	O
,	O
equivalente	O
a	O
genoma	B-Sequence
-	O
ancho	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
respectivamente	O
.	O

Como	O
resultado	O
,	O
si	O
no	O
hay	O
interacciones	O
significativas	O
de	O
sexo	O
aditivo	O
o	O
de	O
sexo	O
dominante	O
,	O
el	O
modelo	O
completo	O
en	O
realidad	O
reducirá	O
el	O
poder	O
para	O
detectar	O
la	O
vinculación	O
.	O

Para	O
minimizar	O
la	O
pérdida	O
de	O
poder	O
de	O
ajuste	O
del	O
modelo	O
completo	O
cuando	O
los	O
términos	O
de	O
interacción	O
sexual	O
no	O
son	O
significativos	O
,	O
empleamos	O
un	O
procedimiento	O
de	O
selección	O
de	O
modelo	O
que	O
introduce	O
términos	O
de	O
interacción	O
sexual	O
solo	O
si	O
se	O
suman	O
significativamente	O
al	O
total	O
.	O
QTL	B-Sequence
modelo	O

El	O
procedimiento	O
de	O
selección	O
del	O
modelo	O
utiliza	O
técnicas	O
de	O
regresión	O
por	O
pasos	O
hacia	O
adelante	O
para	O
determinar	O
si	O
es	O
beneficioso	O
incluir	O
los	O
términos	O
de	O
interacción	O
sexual	O
,	O
condicionados	O
a	O
la	O
realización	O
de	O
un	O
efecto	O
aditivo	O
significativo	O
(	O
p	O
<	O
0,001	O
)	O
.	O

Es	O
decir	O
,	O
los	O
datos	O
se	O
ajustan	O
a	O
la	O
Ecuación	O
4	O
para	O
un	O
marcador	O
dado	O
,	O
y	O
si	O
el	O
término	O
de	O
adición	O
es	O
significativo	O
en	O
el	O
0	O
.	O
001	O
nivel	O
de	O
significación	O
,	O
luego	O
intentamos	O
agregar	O
el	O
término	O
sex	O
*	O
add	O
en	O
el	O
modelo	O
.	O

El	O
término	O
sex	O
*	O
add	O
se	O
retiene	O
en	O
el	O
modelo	O
si	O
el	O
criterio	O
de	O
información	O
bayesiano	O
(	O
BIC	O
)	O
para	O
este	O
modelo	O
es	O
más	O
pequeño	O
que	O
el	O
BIC	O
para	O
la	O
Ecuación	O
4	O
.	O

Si	O
sex	O
*	O
add	O
se	O
incluye	O
en	O
el	O
modelo	O
como	O
resultado	O
de	O
este	O
procedimiento	O
,	O
entonces	O
nuevamente	O
usamos	O
BIC	O
para	O
considerar	O
incluir	O
el	O
término	O
sex	O
*	O
dom	O
en	O
el	O
modelo	O
.	O

Para	O
determinar	O
cuál	O
de	O
los	O
cuatro	O
modelos	O
(	O
ecuaciones	O
2	O
,	O
4	O
,	O
6	O
y	O
la	O
selección	O
del	O
modelo	O
)	O
es	O
óptimo	O
,	O
estimamos	O
empíricamente	O
el	O
FDR	O
para	O
cada	O
modelo	O
sobre	O
un	O
conjunto	O
de	O
3,000	O
genes	B-Sequence
seleccionados	O
al	O
azar	O
del	O
conjunto	O
de	O
todos	O
genes	B-Sequence
detectada	O
como	O
se	O
expresa	O
en	O
las	O
muestras	O
de	O
hígado	O
.	O

Para	O
cada	O
gene	B-Sequence
y	O
para	O
cada	O
marcador	O
ajustamos	O
cada	O
uno	O
de	O
los	O
cuatro	O
modelos	O
a	O
los	O
datos	O
.	O

Realizamos	O
este	O
mismo	O
análisis	O
en	O
diez	O
conjuntos	O
de	O
permutaciones	O
separados	O
en	O
los	O
que	O
cada	O
uno	O
de	O
los	O
3	O
000	O
gene	B-Sequence
Los	O
vectores	O
de	O
rasgos	O
de	O
expresión	O
se	O
permutaron	O
de	O
tal	O
manera	O
que	O
la	O
estructura	O
de	O
correlación	O
entre	O
los	O
genes	B-Sequence
se	O
conservó	O
.	O

Luego	O
se	O
calculó	O
el	O
FDR	O
para	O
un	O
umbral	O
de	O
puntaje	O
LOD	O
dado	O
como	O
la	O
relación	O
entre	O
el	O
número	O
medio	O
de	O
QTL	B-Sequence
detectado	O
en	O
los	O
conjuntos	O
de	O
datos	O
permutados	O
(	O
la	O
media	O
tomada	O
sobre	O
los	O
diez	O
conjuntos	O
de	O
datos	O
permutados	O
)	O
y	O
el	O
número	O
total	O
de	O
QTL	B-Sequence
detectado	O
en	O
el	O
observado	O
3	O
,	O
000	O
-	O
gene	B-Sequence
conjunto	O
de	O
datos	O

Luego	O
generamos	O
curvas	O
similares	O
a	O
ROC	O
variando	O
el	O
umbral	O
de	O
puntaje	O
LOD	O
,	O
lo	O
que	O
resultó	O
en	O
un	O
rango	O
de	O
FDR	O
(	O
de	O
0	O
%	O
a	O
más	O
del	O
50	O
%	O
)	O
.	O

Para	O
simplificar	O
este	O
tipo	O
de	O
resumen	O
,	O
no	O
consideramos	O
más	O
de	O
una	O
QTL	B-Sequence
por	O
cromosoma	B-GENE
por	O
gene	B-Sequence
rasgo	O
de	O
expresión	O
considerando	O
sólo	O
el	O
QTL	B-Sequence
con	O
la	O
puntuación	O
LOD	O
máxima	O
en	O
cada	O
cromosoma	B-GENE
para	O
cada	O
rasgo	O
.	O

Las	O
curvas	O
ROC	O
para	O
cada	O
uno	O
de	O
los	O
cuatro	O
modelos	O
se	O
muestran	O
en	O
la	O
Figura	O
S1	O
,	O
con	O
la	O
curva	O
negra	O
correspondiente	O
a	O
la	O
Ecuación	O
2	O
,	O
la	O
curva	O
azul	O
correspondiente	O
a	O
la	O
Ecuación	O
4	O
,	O
la	O
curva	O
roja	O
correspondiente	O
a	O
la	O
Ecuación	O
6	O
y	O
la	O
curva	O
verde	O
correspondiente	O
al	O
procedimiento	O
de	O
selección	O
del	O
modelo	O
.	O
.	O

Está	O
claro	O
a	O
partir	O
de	O
las	O
curvas	O
ROC	O
que	O
los	O
términos	O
sexo	O
y	O
sexo	O
-	O
interacción	O
son	O
significativos	O
en	O
el	O
gene	B-Sequence
conjunto	O
de	O
datos	O
de	O
expresión	O
.	O

Por	O
ejemplo	O
,	O
a	O
un	O
FDR	O
del	O
5	O
%	O
observamos	O
que	O
800	O
QTL	B-Sequence
fueron	O
detectados	O
en	O
el	O
conjunto	O
de	O
3	O
000	O
genes	B-Sequence
para	O
el	O
modelo	O
1	O
,	O
mientras	O
que	O
968	O
(	O
incremento	O
del	O
21	O
%	O
)	O
y	O
1	O
,	O
159	O
(	O
incremento	O
del	O
45	O
%	O
)	O
QTL	B-Sequence
fueron	O
detectados	O
para	O
las	O
Ecuaciones	O
4	O
y	O
6	O
,	O
respectivamente	O
.	O

Estos	O
resultados	O
demuestran	O
un	O
poder	O
significativamente	O
mayor	O
para	O
detectar	O
QTL	B-Sequence
cuando	O
se	O
tiene	O
en	O
cuenta	O
el	O
sexo	O
.	O

También	O
notamos	O
que	O
el	O
procedimiento	O
de	O
selección	O
paso	O
a	O
paso	O
captura	O
más	O
información	O
que	O
la	O
Ecuación	O
4	O
,	O
lo	O
que	O
indica	O
una	O
firma	O
de	O
interacción	O
significativa	O
en	O
este	O
conjunto	O
de	O
datos	O
y	O
también	O
demuestra	O
que	O
este	O
procedimiento	O
estadístico	O
simple	O
es	O
capaz	O
de	O
identificar	O
eventos	O
de	O
interacción	O
significativos	O
incluso	O
en	O
umbrales	O
de	O
FDR	O
conservadores	O
.	O

Finalmente	O
,	O
cabe	O
destacar	O
que	O
la	O
Ecuación	O
4	O
funcionó	O
mejor	O
que	O
la	O
Ecuación	O
6	O
,	O
el	O
modelo	O
que	O
incorporó	O
los	O
términos	O
de	O
interacción	O
en	O
todo	O
momento	O
.	O

Es	O
decir	O
,	O
a	O
pesar	O
de	O
haber	O
una	O
firma	O
de	O
interacción	O
significativa	O
,	O
la	O
firma	O
no	O
era	O
lo	O
suficientemente	O
grande	O
como	O
para	O
justificar	O
la	O
inclusión	O
de	O
términos	O
de	O
interacción	O
para	O
cada	O
rasgo	O
de	O
expresión	O
y	O
en	O
cada	O
marcador	O
probado	O
.	O

Este	O
hecho	O
motivó	O
la	O
necesidad	O
de	O
emplear	O
el	O
procedimiento	O
de	O
regresión	O
directa	O
,	O
y	O
estos	O
resultados	O
motivan	O
aún	O
más	O
la	O
necesidad	O
de	O
explorar	O
los	O
efectos	O
sexuales	O
empleando	O
procedimientos	O
aún	O
más	O
sofisticados	O
.	O
QTL	B-Sequence
métodos	O
de	O
detección	O
,	O
como	O
el	O
descrito	O
recientemente	O
por	O
Yi	O
et	O
al	O
.	O

[	O
38	O
]	O
.	O

Estadísticas	O
adicionales	O
.	O

Por	O
cada	O
23	O
,	O
574	O
oligonucleótidos	B-Sequence
``	O
representada	O
en	O
la	O
matriz	O
,	O
calculamos	O
un	O
análisis	O
de	O
regresión	O
lineal	O
para	O
probar	O
una	O
correlación	O
entre	O
el	O
rasgo	O
``	O
''	O
masa	O
de	O
grasa	O
gonadal	O
''	O
''	O
y	O
cada	O
''	O
transcripción	B-Sequence
.	O

De	O
manera	O
similar	O
a	O
nuestro	O
método	O
para	O
calcular	O
el	O
vínculo	O
,	O
empleamos	O
un	O
procedimiento	O
de	O
regresión	O
lineal	O
paso	O
a	O
paso	O
usando	O
ecuaciones	O
de	O
la	O
forma	O

o	O

en	O
comparación	O
con	O
el	O
modelo	O
nulo	O

donde	O
beta	O
0	O
es	O
el	O
intercepto	O
,	O
y	O
beta	O
1	O
,	O
beta	O
2	O
y	O
beta	O
3	O
representan	O
los	O
coeficientes	O
de	O
regresión	O
de	O
sus	O
respectivos	O
términos	O
.	O

``	O
Como	O
antes	O
,	O
el	O
parámetro	O
``	O
''	O
sexo	O
*	O
''	O
gene	B-Sequence
sólo	O
se	O
conserva	O
si	O
mejora	O
significativamente	O
el	O
ajuste	O
del	O
modelo	O
.	O

El	O
umbral	O
del	O
valor	O
p	O
para	O
una	O
correlación	O
significativa	O
se	O
calcula	O
mediante	O
una	O
prueba	O
F	O
,	O
que	O
compara	O
el	O
modelo	O
apropiado	O
(	O
Ecuación	O
7	O
u	O
8	O
)	O
con	O
el	O
modelo	O
nulo	O
(	O
Ecuación	O
9	O
)	O
.	O

Como	O
antes	O
,	O
las	O
pruebas	O
múltiples	O
se	O
abordaron	O
con	O
el	O
uso	O
del	O
FDR	O
,	O
clasificando	O
los	O
valores	O
p	O
obtenidos	O
de	O
las	O
pruebas	O
F	O
anteriores	O
y	O
estableciendo	O
alfa	O
=	O
0	O
.	O
01	O
.	O

genes	B-Sequence
correlacionado	O
con	O
el	O
rasgo	O
de	O
masa	O
grasa	O
gonadal	O
generó	O
varios	O
eQTL	O
significativos	O
.	O

Para	O
determinar	O
si	O
los	O
eQTL	O
generados	O
por	O
estos	O
genes	B-Sequence
se	O
enriquecieron	O
en	O
cualquier	O
lugar	B-Sequence
o	O
si	O
se	O
distribuyeron	O
aleatoriamente	O
,	O
comparamos	O
la	O
distribución	O
de	O
estos	O
eQTL	O
con	O
la	O
distribución	O
de	O
todos	O
los	O
eQTL	O
de	O
hígado	O
en	O
superposición	B-Sequence
6	O
-	O
cM	O
contenedores	O
a	O
lo	O
largo	O
del	O
genoma	B-Sequence
utilizando	O
la	O
prueba	O
exacta	O
de	O
Fisher	O
.	O

Esta	O
prueba	O
se	O
basa	O
en	O
probabilidades	O
exactas	O
de	O
una	O
distribución	O
específica	O
(	O
distribución	O
hipergeométrica	O
)	O
.	O

p	O
:	O
los	O
valores	O
obtenidos	O
de	O
esta	O
prueba	O
se	O
corrigieron	O
para	O
comparaciones	O
múltiples	O
utilizando	O
una	O
corrección	O
de	O
Bonferonni	O
simple	O
(	O
dado	O
que	O
realizamos	O
772	O
pruebas	O
en	O
todo	O
el	O
genoma	B-Sequence
,	O
0	O
.	O
05/772	O
)	O
.	O

lugares	B-Sequence
con	O
p	O
<	O
6	O
.	O
5	O
x	O
10-5	O
mediante	O
la	O
prueba	O
exacta	O
de	O
Fisher	O
se	O
consideraron	O
significativamente	O
enriquecidos	O
para	O
los	O
eQTL	O
correlacionados	O
con	O
la	O
masa	O
grasa	O
gonadal	O
.	O

información	O
de	O
soporte	O

Figura	O
S1	O

Curvas	O
ROC	O
para	O
cada	O
uno	O
de	O
los	O
cuatro	O
modelos	O

(	O
21	O
KB	O
DOCUMENTO	O
)	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Tabla	O
S1	O

eQTL	O
sugestivos	O
y	O
significativos	O

(	O
3	O
.	O
7	O
MB	O
XLS	O
)	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Tabla	O
S2	O

Transcripciones	B-Sequence
Significativamente	O
correlacionado	O
con	O
la	O
masa	O
grasa	O
gonadal	O

(	O
716	O
KB	O
XLS	O
)	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Agradecimientos	O

Los	O
autores	O
desean	O
agradecer	O
a	O
Steve	O
Horvath	O
,	O
Desmond	O
Smith	O
,	O
Xia	O
Yang	O
,	O
Sudheer	O
Doss	O
,	O
Anatole	O
Ghazalpour	O
,	O
Pek	O
Lum	O
y	O
John	O
Lamb	O
por	O
sus	O
valiosos	O
debates	O
e	O
ideas	O
.	O

Damos	O
las	O
gracias	O
a	O
Leslie	O
Ingram-Drake	O
por	O
su	O
trabajo	O
en	O
la	O
preparación	O
de	O
datos	O
.	O

Trabajos	O
iniciales	O
de	O
construcción	O
del	O
BXH	O
.	O
ApoE	B-Protein
-/-cross	O
fue	O
realizado	O
por	O
Weibin	O
Shi	O
.	O

abreviaturas	O

ApoE	B-Protein
-	O
/	O
-	O
-	O
apolipoproteína	B-Protein
E	I-Protein
nulo	O

cQTL	O
-	O
clínico	O
QTL	B-Sequence

eQTL	O
-	O
gene	B-Sequence
expresión	O
QTL	B-Sequence

FDR	O
-	O
tasa	O
de	O
descubrimiento	O
falso	O

LOD	O
-	O
logaritmo	O
de	O
probabilidades	O

mlratio	O
-	O
relación	O
log10	O
media	O

QTL	B-Sequence
-	O
locus	B-Sequence
de	I-Sequence
rasgo	I-Sequence
cuantitativo	I-Sequence

ROC	O
-	O
característica	O
de	O
funcionamiento	O
del	O
receptor	O

SNP	B-Sequence
-	O
Polimorfismo	B-Sequence
de	I-Sequence
nucleótido	I-Sequence
simple	I-Sequence

Figuras	O
y	O
Tablas	O

Figura	O
1	O

genoma	B-Sequence
Exploración	O
de	O
masa	O
de	O
grasa	O
gonadal	O

(	O
A	O
)	O
animales	B-Taxon
fueron	O
genotipados	O
en	O
un	O
promedio	O
de	O
1	O
.	O
Densidad	O
de	O
5	O
cm	O
usando	O
1	O
,	O
032	O
SNP	B-Sequence
polimórficos	I-Sequence
entre	O
las	O
cepas	O
parentales	O
.	O

Las	O
puntuaciones	O
LOD	O
calculadas	O
usando	O
el	O
sexo	O
como	O
una	O
covariable	O
aditiva	O
(	O
negro	O
)	O
no	O
pudieron	O
detectar	O
una	O
vinculación	O
significativa	O
.	O

A	O
genoma	B-Sequence
exploración	O
que	O
da	O
cuenta	O
de	O
las	O
interacciones	O
entre	O
sexo	O
y	O
QTL	B-Sequence
(	O
rojo	O
)	O
mostró	O
evidencia	O
de	O
vinculación	O
sugestiva	O
en	O
Cromosoma	B-GENE
1	O
y	O
un	O
vínculo	O
significativo	O
en	O
cromosomas	B-GENE
3	O
,	O
5	O
,	O
11	O
y	O
19	O
.	O

Las	O
líneas	O
discontinuas	O
y	O
continuas	O
son	O
los	O
umbrales	O
de	O
vinculación	O
sugestiva	O
(	O
p	O
<	O
1	O
x	O
10-3	O
)	O
y	O
significativa	O
(	O
p	O
<	O
5	O
x	O
10-5	O
)	O
,	O
respectivamente	O
.	O

(	O
B	O
)	O
genoma	B-Sequence
escanea	O
la	O
masa	O
grasa	O
gonadal	O
usando	O
diferentes	O
modelos	O
sobre	O
ratón	B-Taxon
Cromosoma	B-GENE
5	O
.	O

Escanea	O
en	O
busca	O
de	O
masa	O
grasa	O
usando	O
todos	O
animales	B-Taxon
con	O
(	O
negro	O
)	O
y	O
sin	O
(	O
verde	O
)	O
sexo	O
como	O
una	O
covariable	O
aditiva	O
no	O
logró	O
detectar	O
un	O
vínculo	O
significativo	O
.	O

Las	O
hembras	O
analizadas	O
solas	O
(	O
magenta	O
)	O
mostraron	O
evidencia	O
de	O
vinculación	O
sugestiva	O
(	O
p	O
<	O
2	O
x	O
10-4	O
)	O
.	O

Cuando	O
se	O
analizaron	O
ambos	O
sexos	O
para	O
tener	O
en	O
cuenta	O
los	O
efectos	O
del	O
sexo	O
(	O
rojo	O
)	O
,	O
se	O
observó	O
una	O
QTL	B-Sequence
se	O
realizó	O
(	O
p	O
<	O
10	O
-	O
6	O
)	O
.	O

``	O
Para	O
mayor	O
claridad	O
,	O
sólo	O
se	O
muestra	O
en	O
rojo	O
el	O
modelo	O
que	O
incorpora	O
los	O
términos	O
``	O
''	O
sex	O
*	O
add	O
''	O
''	O
y	O
``	O
''	O
sex	O
*	O
dom	O
''	O
''	O
,	O
aunque	O
también	O
se	O
calcularon	O
modelos	O
adicionales	O
que	O
incorporan	O
los	O
términos	O
por	O
separado	O
.	O
''	O

Figura	O
2	O

Efecto	O
de	O
Genotipo	B-Sequence
sobre	O
la	O
masa	O
grasa	O

Homocigoto	O
B6	O
(	O
BB	O
)	O
,	O
C3H	O
(	O
CC	O
)	O
o	O
heterocigoto	O
(	O
BC	O
)	O
genotipo	B-Sequence
en	O
los	O
cinco	O
Posiciones	B-Sequence
QTL	I-Sequence
,	O
separados	O
por	O
sexo	O
,	O
se	O
muestran	O
.	O

el	O
subyacente	O
genotípico	B-Sequence
efectos	O
de	O
la	O
QTL	B-Sequence
sobre	O
la	O
masa	O
grasa	O
difieren	O
entre	O
los	O
sexos	O
.	O

Los	O
coeficientes	O
de	O
determinación	O
(	O
R2	O
)	O
se	O
muestran	O
junto	O
con	O
los	O
ANOVA	O
asociados	O
*	O
p	O
<	O
0	O
.	O
05	O
,	O
*	O
*	O
pags	O
<	O
0	O
.	O
01	O
,	O
*	O
*	O
*	O
pags	O
<	O
0	O
.	O
001	O
.	O

figura	O
3	O

Mapa	O
de	O
calor	O
del	O
hígado	O
Gene	B-Sequence
Expresión	O

Más	O
de	O
2	O
300	O
de	O
las	O
más	O
diferencialmente	O
expresadas	O
genes	B-Sequence
en	O
el	O
hígado	O
agrupados	O
jerárquicamente	O
por	O
animales	B-Taxon
(	O
eje	O
x	O
)	O
contra	O
transcripción	B-Sequence
niveles	O
(	O
eje	O
y	O
)	O
.	O

La	O
expresión	O
se	O
informa	O
como	O
mlratio	O
del	O
experimento	O
individual	O
frente	O
a	O
un	O
grupo	O
común	O
.	O

El	O
rojo	O
está	O
sobrerrepresentado	O
y	O
el	O
verde	O
subrepresentado	O
en	O
relación	O
con	O
el	O
grupo	O
.	O

Figura	O
4	O

Propiedades	B-Sequence
de	O
todos	O
los	O
eQTL	O
de	O
hígado	O

(	O
A	O
)	O
Distribución	O
de	O
todos	O
los	O
eQTL	O
hepáticos	O
significativos	O
en	O
todo	O
el	O
genoma	B-Sequence
en	O
bins	O
de	O
2	O
cm	O
.	O

Se	O
realizaron	O
un	O
total	O
de	O
6	O
676	O
eQTL	O
significativos	O
,	O
lo	O
que	O
representa	O
4	O
998	O
hígado	O
transcripciones	B-Sequence
.	O

Los	O
puntos	O
críticos	O
de	O
colocalización	O
de	O
eQTL	O
no	O
aleatorios	O
son	O
claramente	O
evidentes	O
.	O

(	O
B	O
)	O
Distribución	O
de	O
eQTLs	O
con	O
efectos	O
significativos	O
específicos	O
del	O
sexo	O
.	O

Un	O
total	O
de	O
1	O
166	O
eQTL	O
que	O
representan	O
1	O
044	O
transcripciones	B-Sequence
mostrar	O
un	O
punto	O
de	O
acceso	O
eQTL	O
en	O
Cromosoma	B-GENE
5	O
.	O

(	O
C	O
)	O
Propiedades	B-Sequence
de	O
eQTLs	O
a	O
niveles	O
crecientes	O
de	O
significancia	O
.	O

medida	O
que	O
aumenta	O
el	O
umbral	O
para	O
un	O
vínculo	O
significativo	O
(	O
disminuye	O
el	O
valor	O
de	O
p	O
o	O
aumenta	O
la	O
puntuación	O
LOD	O
)	O
,	O
aumenta	O
la	O
proporción	O
de	O
cis-eQTL	O
(	O
negro	O
)	O
.	O

La	O
fracción	O
de	O
todos	O
los	O
eQTL	O
con	O
efectos	O
sexuales	O
(	O
rojo	O
)	O
y	O
cis-eQTL	O
con	O
efectos	O
sexuales	O
(	O
azul	O
)	O
permanece	O
relativamente	O
constante	O
en	O
umbrales	O
crecientes	O
.	O

La	O
línea	O
discontinua	O
indica	O
la	O
genoma	B-Sequence
-	O
Umbral	O
de	O
significación	O
amplio	O
(	O
p	O
<	O
5	O
x	O
10	O
-	O
5	O
;	O
genoma	B-Sequence
-	O
ancho	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

(	O
D	O
)	O
Propiedades	B-Sequence
de	O
eQTLs	O
específicos	O
de	O
sexo	O
a	O
niveles	O
crecientes	O
de	O
significación	O
.	O

Para	O
los	O
eQTL	O
con	O
efectos	O
sexuales	O
significativos	O
,	O
como	O
ocurre	O
con	O
todos	O
los	O
eQTL	O
,	O
la	O
proporción	O
de	O
cis-eQTL	O
(	O
negro	O
)	O
aumenta	O
y	O
trans	O
(	O
azul	O
)	O
disminuye	O
a	O
medida	O
que	O
aumenta	O
el	O
umbral	O
de	O
significación	O
.	O

En	O
el	O
genoma	B-Sequence
-	O
amplio	O
umbral	O
de	O
significación	O
(	O
línea	O
discontinua	O
)	O
,	O
más	O
del	O
70	O
%	O
de	O
los	O
eQTL	O
con	O
efectos	O
sexuales	O
significativos	O
son	O
trans	O
.	O

Figura	O
5	O

Propiedades	B-Sequence
de	O
Transcripciones	B-Sequence
Significativamente	O
correlacionado	O
con	O
la	O
masa	O
grasa	O
gonadal	O

(	O
A	O
)	O
Distribución	O
de	O
p	O
-	O
valores	O
para	O
rasgo	O
-	O
gene	B-Sequence
correlaciones	O
entre	O
transcripciones	B-Sequence
y	O
masa	O
grasa	O
gonadal	O
.	O

En	O
FDR	O
=	O
0	O
.	O
01	O
,	O
4	O
,	O
613	O
transcripciones	B-Sequence
se	O
correlacionan	O
significativamente	O
con	O
el	O
rasgo	O
.	O

(	O
B	O
)	O
Número	O
de	O
eQTL	O
generados	O
por	O
el	O
4	O
613	O
genes	B-Sequence
correlacionado	O
significativamente	O
con	O
la	O
masa	O
grasa	O
gonadal	O
.	O

De	O
estos	O
,	O
1	O
,	O
130	O
genes	B-Sequence
Poseía	O
al	O
menos	O
un	O
eQTL	O
significativo	O
.	O

(	O
C	O
)	O
La	O
distribución	O
de	O
1	O
478	O
eQTL	O
se	O
correlacionó	O
significativamente	O
con	O
la	O
masa	O
de	O
grasa	O
gonadal	O
en	O
todo	O
el	O
genoma	B-Sequence
en	O
bins	O
de	O
2	O
cm	O
.	O

(	O
D	O
)	O
Identificación	O
de	O
regiones	B-Sequence
genómicas	I-Sequence
enriquecido	O
para	O
eQTLs	O
correlacionados	O
con	O
la	O
masa	O
de	O
grasa	O
gonadal	O
.	O

El	O
eje	O
x	O
representa	O
posición	B-Sequence
del	I-Sequence
genoma	I-Sequence
en	O
intervalos	O
de	O
2	O
cM	O
,	O
y	O
el	O
eje	O
y	O
representa	O
el	O
valor	O
p	O
de	O
la	O
prueba	O
exacta	O
de	O
Fisher	O
-log10	O
para	O
el	O
enriquecimiento	O
de	O
eQTL	O
en	O
superposición	B-Sequence
Contenedores	O
de	O
6	O
cm	O
.	O

La	O
línea	O
discontinua	O
corresponde	O
a	O
p	O
=	O
0	O
.	O
05	O
después	O
de	O
la	O
corrección	O
por	O
comparaciones	O
múltiples	O
.	O

Uno	O
significativamente	O
enriquecido	O
región	B-Sequence
en	I-Sequence
el	I-Sequence
cromosoma	I-Sequence
19	O
se	O
muestra	O
.	O

los	O
Cromosoma	B-GENE
El	O
punto	O
de	O
acceso	O
19	O
(	O
40-cM	O
)	O
coincide	O
con	O
un	O
cQTL	O
para	O
la	O
masa	O
de	O
grasa	O
gonadal	O
y	O
está	O
resaltado	O
en	O
rojo	O
.	O

Figura	O
6	O

Los	O
efectos	O
del	O
sexo	O
en	O
trans	O
-	O
eQTL	O
correlacionados	O
con	O
la	O
masa	O
de	O
grasa	O
gonadal	O

(	O
A	O
)	O
Ejemplo	O
del	O
efecto	O
de	O
genotipo	B-Sequence
en	O
un	O
trans	O
lugar	B-Sequence
en	O
gene	B-Sequence
expresión	O
.	O

Presencia	O
de	O
homocigotos	O
B6	O
(	O
BB	O
)	O
,	O
C3H	O
(	O
CC	O
)	O
o	O
heterocigotos	O
(	O
BC	O
)	O
genotipo	B-Sequence
en	O
un	O
trans	O
lugar	B-Sequence
afecta	O
transcripción	B-Sequence
Niveles	O
de	O
MMT00016118	O
(	O
informados	O
como	O
mlratio	O
)	O
de	O
manera	O
específica	O
por	O
sexo	O
,	O
con	O
efectos	O
detectables	O
sólo	O
en	O
mujeres	O
.	O

Los	O
coeficientes	O
de	O
determinación	O
(	O
R2	O
,	O
o	O
explicación	O
de	O
la	O
varianza	O
de	O
la	O
proporción	O
)	O
se	O
muestran	O
junto	O
con	O
los	O
valores	O
p	O
de	O
ANOVA	O
asociados	O
.	O

Varios	O
trans	O
-	O
eQTL	O
correlacionados	O
con	O
la	O
masa	O
de	O
grasa	O
gonadal	O
se	O
localizan	O
en	O
regiones	B-Sequence
superpuestas	I-Sequence
con	O
cQTLs	O
para	O
este	O
rasgo	O
,	O
específicamente	O
,	O
para	O
Cromosoma	B-GENE
19	O
,	O
40cm	O
.	O

(	O
B	O
)	O
para	O
Cromosoma	B-GENE
19	O
,	O
la	O
gran	O
mayoría	O
de	O
estos	O
trans	O
-	O
eQTL	O
correlacionados	O
están	O
sesgados	O
hacia	O
efectos	O
más	O
grandes	O
en	O
gene	B-Sequence
expresión	O
en	O
hembras	O
(	O
líneas	O
rojas	O
)	O
.	O

El	O
efecto	O
de	O
cualquier	O
trans-eQTL	O
dado	O
se	O
aproxima	O
como	O
R2	O
determinado	O
de	O
una	O
manera	O
similar	O
a	O
la	O
representada	O
en	O
(	O
A	O
)	O
.	O

tabla	O
1	O

Características	O
del	O
BXH	O
.	O
ApoE	B-Protein
-	O
/	O
-	O
Cruzar	O

Tabla	O
2	O

cQTL	O
para	O
masa	O
grasa	O
gonadal	O

Tabla	O
3	O

Características	O
de	O
los	O
eQTL	O
de	O
hígado	O

Tabla	O
4	O

Propiedades	B-Sequence
de	O
genes	B-Sequence
Coincidente	O
con	O
la	O
Masa	O
Grasa	O
Gonadal	O
cQTL	O

Tabla	O
5	O

Transcripciones	B-Sequence
Coincidentes	O
con	O
cQTL	O
con	O
efectos	O
sexuales	O
significativos	O
y	O
correlacionados	O
con	O
la	O
masa	O
de	O
grasa	O
gonadal	O
son	O
candidatos	O
fuertes	O
genes	B-Sequence
para	O
el	O
rasgo	O

notas	O
al	O
pie	O

Contribuciones	O
de	O
autor	O
.	O

SW	O
,	O
TAD	O
y	O
AJL	O
concibieron	O
y	O
diseñaron	O
los	O
experimentos	O
.	O

SW	O
,	O
NY	O
y	O
EES	O
realizaron	O
los	O
experimentos	O
.	O

SW	O
,	O
NY	O
,	O
HW	O
y	O
TAD	O
analizaron	O
los	O
datos	O
.	O

EES	O
y	O
HW	O
contribuyeron	O
reactivos	B-Chemical
/	O
materiales	O
/	O
herramientas	O
de	O
análisis	O
.	O

HW	O
diseñó	O
el	O
script	O
y	O
el	O
código	O
para	O
analizar	O
los	O
datos	O
.	O

SW	O
,	O
NY	O
,	O
EES	O
,	O
TAD	O
y	O
AJL	O
escribieron	O
el	O
artículo	O
.	O

Financiamiento	O

El	O
trabajo	O
fue	O
financiado	O
en	O
parte	O
por	O
los	O
subsidios	O
HL-30568	O
y	O
HL-28481	O
de	O
los	O
Institutos	O
Nacionales	O
de	O
Salud	O
a	O
AJL	O
,	O
el	O
subsidio	O
de	O
capacitación	O
de	O
servicios	O
de	O
salud	O
pública	O
HD07228-24	O
a	O
SW	O
,	O
el	O
Centro	O
de	O
Salud	O
de	O
la	O
Mujer	O
Iris	O
Cantor-UCLA	O
,	O
el	O
Centro	O
Nacional	O
para	O
la	O
Excelencia	O
en	O
la	O
Mujer	O
de	O
UCLA	O
Health	O
Grant	O
a	O
TAD	O
,	O
y	O
por	O
una	O
beca	O
de	O
investigación	O
para	O
estudiantes	O
de	O
medicina	O
de	O
la	O
American	O
Heart	O
Association	O
a	O
NY	O
.	O

Conflicto	O
de	O
intereses	O
.	O

Los	O
autores	O
han	O
declarado	O
que	O
no	O
existen	O
intereses	O
contrapuestos	O
.	O

Cita	O
:	O
Wang	O
S	O
,	O
Yehya	O
N	O
,	O
Schadt	O
EE	O
,	O
Wang	O
H	O
,	O
Drake	O
TA	O
,	O
et	O
al	O
.	O

-2006	O
Genético	B-Sequence
y	O
genómico	B-Sequence
el	O
análisis	O
de	O
un	O
rasgo	O
de	O
masa	O
grasa	O
con	O
herencia	O
compleja	O
revela	O
una	O
marcada	O
especificidad	O
sexual	O
.	O

PLoS	O
Genet	O
2	O
(	O
2	O
)	O
:	O
e15	O
.	O

Identificación	O
y	O
disrupción	O
dirigida	O
de	O
la	O
ratón	B-Taxon
gene	B-Sequence
codificación	O
ESG1	B-Protein
(	O
PH34	B-Protein
/	O
ECAT2	B-Protein
/	O
DPPA5	B-Protein
)	O

Resumen	O

Antecedentes	O

Gen	B-Protein
específico	I-Protein
de	I-Protein
células	I-Protein
madre	I-Protein
embrionarias	I-Protein
(	I-Protein
ESG	I-Protein
)	I-Protein
1	I-Protein
,	O
que	O
codifica	O
un	O
KH	O
-	O
dominio	B-Sequence
que	O
contiene	O
proteína	B-Chemical
,	O
se	O
expresa	O
específicamente	O
en	O
embriones	O
tempranos	O
,	O
células	B-Cell
germinales	I-Cell
,	O
y	O
embrionario	O
células	B-Cell
madre	I-Cell
(	I-Cell
ES	I-Cell
)	I-Cell
.	O

Estudios	O
previos	O
identificados	O
clones	B-Sequence
genómicos	I-Sequence
que	O
contiene	O
el	O
ratón	B-Protein
ESG1	I-Protein
gene	B-Sequence
y	O
cinco	O
pseudogenes	B-Sequence
.	O

Sin	O
embargo	O
,	O
su	O
localizaciones	B-Sequence
cromosómicas	I-Sequence
o	O
funciones	O
fisiológicas	O
no	O
han	O
sido	O
determinadas	O
.	O

Resultados	O

Una	O
búsqueda	O
explosiva	O
de	O
ratón	B-Taxon
genómico	B-Sequence
las	O
bases	O
de	O
datos	O
no	O
lograron	O
localizar	O
el	O
ESG1	B-Protein
gene	B-Sequence
.	O

Identificamos	O
varios	O
clones	B-Sequence
artificiales	I-Sequence
bacterianos	I-Sequence
que	O
contiene	O
el	O
ratón	B-Protein
ESG1	I-Protein
gene	B-Sequence
y	O
un	O
adicional	O
ESG1	B-Protein
#	O
¿NOMBRE	O
?	O
secuencia	B-Sequence
con	O
un	O
parecido	O
gene	B-Sequence
estructura	O
de	O
cromosoma	B-GENE
9	O

los	O
ESG1	B-Protein
#	O
¿NOMBRE	O
?	O
secuencia	B-Sequence
contenía	O
una	O
crítica	O
múltiple	O
mutaciones	B-Sequence
,	O
indicando	O
que	O
era	O
un	O
duplicado	O
pseudogen	B-Sequence
.	O

los	O
5	B-Sequence
'región	I-Sequence
flanqueante	I-Sequence
de	O
El	O
ESG1	B-Protein
gene	B-Sequence
,	O
pero	O
no	O
la	O
del	O
pseudogen	B-Sequence
,	O
exhibió	O
fuerte	O
potenciador	B-Sequence
y	O
promotor	B-Sequence
actividad	O
en	O
ES	O
indiferenciado	O
células	B-Cell
por	O
ensayo	O
de	O
reportero	O
de	O
luciferasa	O
.	O

Estudiar	O
las	O
funciones	O
fisiológicas	O
del	O
ESG1	B-Protein
gene	B-Sequence
,	O
nosotros	O
sustituido	B-Sequence
esta	O
secuencia	B-Sequence
en	O
ES	O
células	B-Cell
con	O
una	O
beta	O
-	O
geo	O
casete	B-Sequence
por	O
recombinación	O
homóloga	O
.	O

A	O
pesar	O
de	O
la	O
expresión	O
específica	O
en	O
embriones	O
tempranos	O
y	O
células	B-Cell
germinales	I-Cell
,	O
ESG1	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
se	O
desarrollaron	O
normalmente	O
y	O
fueron	O
fértiles	O
.	O

También	O
generamos	O
ESG1	B-Protein
-	O
/	O
-	O
ES	O
células	B-Cell
tanto	O
por	O
una	O
segunda	O
recombinación	O
homóloga	O
independiente	O
como	O
directamente	O
a	O
partir	O
de	O
blastocistos	O
derivados	O
de	O
cruces	O
heterocigóticos	O
.	O

Los	O
análisis	O
de	O
Northern	O
blot	O
y	O
western	O
blot	O
confirmaron	O
la	O
ausencia	O
de	O
ESG1	B-Protein
en	O
estos	O
células	B-Cell
.	O

Estos	O
ES	O
células	B-Cell
demostraron	O
morfología	O
,	O
proliferación	O
y	O
diferenciación	O
normales	O
.	O

Conclusión	O

los	O
ratón	B-Protein
ESG1	I-Protein
gene	B-Sequence
,	O
junto	O
con	O
un	O
duplicado	O
pseudogen	B-Sequence
,	O
se	O
encuentra	O
en	O
cromosoma	B-GENE
9	O

A	O
pesar	O
de	O
su	O
expresión	O
específica	O
en	O
pluripotentes	O
células	B-Cell
y	O
células	B-Cell
germinales	I-Cell
,	O
ESG1	B-Protein
es	O
prescindible	O
para	O
auto	O
-	O
renovación	O
de	O
ES	O
células	B-Cell
y	O
establecimiento	O
de	O
células	B-Cell
germinales	I-Cell
.	O

Antecedentes	O

Embrionario	O
células	B-Cell
madre	I-Cell
(	I-Cell
ES	I-Cell
)	I-Cell
primero	O
se	O
derivaron	O
de	O
los	O
blastocistos	O
de	O
ratones	B-Taxon
en	O
1981	O
[	O
1	O
,	O
2	O
]	O
y	O
humanos	B-Taxon
en	O
1998	O
[	O
3	O
]	O
.	O

ES	O
células	B-Cell
tienen	O
dos	O
propiedades	O
importantes	O
:	O
la	O
capacidad	O
de	O
mantener	O
la	O
pluripotencia	O
,	O
que	O
es	O
la	O
capacidad	O
de	O
diferenciarse	O
en	O
una	O
amplia	O
variedad	O
de	O
células	B-Cell
y	O
rápida	O
proliferación	O
.	O

Estas	O
características	O
hacen	O
ratón	B-Taxon
ES	O
células	B-Cell
un	O
componente	O
esencial	O
de	O
gene	B-Sequence
tecnología	O
de	O
focalización	O
.	O

Estas	O
cualidades	O
también	O
hacen	O
humano	B-Taxon
ES	O
células	B-Cell
fuentes	O
atractivas	O
para	O
célula	B-Cell
terapia	O
de	O
trasplante	O
para	O
tratar	O
diversas	O
enfermedades	O
,	O
incluidas	O
las	O
lesiones	O
de	O
la	O
médula	O
espinal	O
y	O
la	O
diabetes	O
juvenil	O
.	O

los	O
molecular	B-Chemical
mecanismos	O
subyacentes	O
a	O
la	O
pluripotencia	O
y	O
rápida	O
proliferación	O
de	O
SE	O
células	B-Cell
son	O
actualmente	O
un	O
foco	O
importante	O
en	O
el	O
campo	O
de	O
la	O
célula	B-Cell
madre	I-Cell
biología	O
[	O
4	O
-	O
6	O
]	O
.	O

Identificar	O
moléculas	B-Chemical
esencial	O
en	O
ES	O
células	B-Cell
para	O
estas	O
propiedades	O
,	O
varios	O
grupos	O
han	O
utilizado	O
análisis	O
transcriptómicos	O
para	O
identificar	O
genes	B-Sequence
expresado	O
específicamente	O
en	O
ES	O
células	B-Cell
y	O
embriones	O
tempranos	O
.	O

Estos	O
análisis	O
,	O
incluyendo	O
ADN	B-Sequence
análisis	O
de	O
micromatrices	O
[	O
7	O
]	O
y	O
etiqueta	B-Sequence
de	I-Sequence
secuencia	I-Sequence
expresada	I-Sequence
análisis	O
[	O
8	O
-	O
12	O
]	O
,	O
identificó	O
varios	O
transcripciones	B-Sequence
,	O
incluyendo	O
ESG1	B-Protein
que	O
también	O
fue	O
designado	O
dppa5	B-Protein
o	O
ECAT2	B-Protein
.	O

ESG1	B-Protein
originalmente	O
fue	O
identificado	O
como	O
un	O
transcripción	B-Sequence
Ph34	B-Protein
eso	O
estaba	O
abajo	O
-	O
regulado	O
por	O
ácido	B-Chemical
retinoico	I-Chemical
en	O
carcinoma	O
embrionario	O
células	B-Cell
[	O
13	O
]	O
.	O

La	O
expresión	O
de	O
este	O
gene	B-Sequence
estaba	O
confinado	O
en	O
ratones	B-Taxon
a	O
embriones	O
tempranos	O
y	O
células	B-Cell
germinales	I-Cell
[	O
14	O
]	O
.	O

También	O
se	O
expresa	O
en	O
forma	O
pluripotente	O
.	O
células	B-Cell
,	O
incluido	O
ES	O
células	B-Cell
,	O
embrionario	O
células	B-Cell
germinales	I-Cell
,	O
y	O
células	B-Cell
madre	I-Cell
germinales	I-Cell
multipotentes	I-Cell
[	O
15	O
]	O
.	O

ESG1	B-Protein
codifica	O
un	O
polipéptido	B-Sequence
de	O
118	O
aminoácidos	B-Chemical
que	O
contiene	O
un	O
solo	O
KH	O
dominio	B-Sequence
,	O
que	O
es	O
un	O
ARN	B-Sequence
#	O
¿NOMBRE	O
?	O
dominio	B-Sequence
[	O
dieciséis	O
]	O
.	O

No	O
queda	O
claro	O
,	O
sin	O
embargo	O
,	O
si	O
ESG1	B-Protein
funciona	O
como	O
un	O
ARN	B-Sequence
#	O
¿NOMBRE	O
?	O
proteína	B-Chemical
o	O
los	O
roles	O
que	O
juega	O
en	O
ES	O
células	B-Cell
y	O
ratones	B-Taxon
.	O

Anterior	O
genómico	B-Sequence
proyección	O
de	O
biblioteca	O
por	O
identificado	O
clones	B-Sequence
genómicos	I-Sequence
que	O
contiene	O
el	O
ratón	B-Protein
ESG1	I-Protein
gene	B-Sequence
y	O
siete	O
pseudogenes	B-Sequence
[	O
17	O
]	O
.	O

dos	O
de	O
estos	O
pseudogenes	B-Sequence
exhibir	O
una	O
similar	O
exón	B-Sequence
-	O
intrón	B-Sequence
estructura	O
como	O
la	O
ESG1	B-Protein
gene	B-Sequence
,	O
indicando	O
su	O
generación	O
por	O
gene	B-Sequence
duplicación	O

los	O
cinco	O
restantes	O
pseudogenes	B-Sequence
no	O
contenía	O
ninguna	O
intrones	B-Sequence
,	O
indicando	O
que	O
estos	O
fueron	O
generados	O
por	O
retrotransposición	O
de	O
ESG1	B-Protein
transcripciones	B-Sequence
.	O

los	O
localizaciones	B-Sequence
cromosómicas	I-Sequence
de	O
El	O
ratón	B-Protein
ESG1	I-Protein
gene	B-Sequence
y	O
pseudogenes	B-Sequence
,	O
sin	O
embargo	O
,	O
no	O
han	O
sido	O
reportados	O
.	O

En	O
este	O
estudio	O
determinamos	O
la	O
estructura	O
de	O
la	O
ratón	B-Taxon
gene	B-Sequence
codificando	O
esto	O
proteína	B-Chemical
y	O
relacionado	O
pseudogenes	B-Sequence
.	O

también	O
actuamos	O
gene	B-Sequence
para	O
determinar	O
la	O
función	O
fisiológica	O
de	O
ESG1	B-Protein
.	O

Resultados	O
y	O
discusión	O

Localización	B-Sequence
cromosómica	I-Sequence
y	O
estructuras	O
de	O
ratón	B-Protein
ESG1	I-Protein
gene	B-Sequence
y	O
psedógenos	B-Sequence

Para	O
determinar	O
el	O
localizaciones	B-Sequence
cromosómicas	I-Sequence
de	O
El	O
ratón	B-Protein
ESG1	I-Protein
gene	B-Sequence
y	O
pseudogenes	B-Sequence
,	O
realizamos	O
un	O
análisis	O
Blast	O
de	O
la	O
ratón	B-Taxon
genómico	B-Sequence
base	O
de	O
datos	O
con	O
la	O
ESG1	B-Protein
secuencia	B-Sequence
de	I-Sequence
ADNc	I-Sequence
como	O
consulta	O
.	O

Identificamos	O
varios	O
supuestos	O
pseudogenes	B-Sequence
sin	O
intrones	B-Sequence
en	O
cromosomas	B-GENE
1	O
,	O
5	O
,	O
11	O
,	O
12	O
,	O
14	O
,	O
16	O
,	O
17	O
y	O
X	O
(	O
Figura	O
1	O
)	O
.	O

Además	O
,	O
dos	O
intrón	B-Sequence
#	O
¿NOMBRE	O
?	O
pseudogenes	B-Sequence
fueron	O
identificados	O
en	O
fragmentos	B-Sequence
de	I-Sequence
ADN	I-Sequence
para	O
el	O
cual	O
el	O
localización	B-Sequence
cromosómica	I-Sequence
permaneció	O
sin	O
mapear	O
.	O

Mientras	O
estos	O
pseudodgenes	B-Sequence
tener	O
significativo	O
homología	B-Sequence
para	O
ESG1	B-Protein
ADNc	B-Sequence
,	O
no	O
pudieron	O
producir	O
funcional	O
proteinas	B-Chemical
,	O
debido	O
a	O
la	O
crítica	O
mutaciones	B-Sequence
.	O

Este	O
resultado	O
sugiere	O
que	O
existe	O
un	O
mayor	O
número	O
de	O
intrón	B-Sequence
#	O
¿NOMBRE	O
?	O
pseudogenes	B-Sequence
de	O
lo	O
previsto	O
anteriormente	O
.	O

Existencia	O
de	O
múltiples	O
retropseudogenes	B-Sequence
es	O
un	O
sello	O
de	O
pluripotente	O
célula	B-Cell
#	O
¿NOMBRE	O
?	O
genes	B-Sequence
[	O
18	O
]	O
.	O

Figura	O
1	O

Pseudogenes	O
ESG1	O
identificados	O
por	O
una	O
búsqueda	O
Blast	O
de	O
ratón	B-Taxon
genómico	B-Sequence
bases	O
de	O
datos	O

Mutaciones	B-Sequence
de	I-Sequence
sustitución	I-Sequence
se	O
indican	O
con	O
líneas	O
negras	O
.	O

intrón	B-Sequence
#	O
¿NOMBRE	O
?	O
secuencias	B-Sequence
de	I-Sequence
huecos	I-Sequence
se	O
indican	O
con	O
triángulos	O
.	O

Localizaciones	B-Sequence
cromosómicas	I-Sequence
se	O
muestran	O
a	O
la	O
derecha	O
.	O

En	O
cromosoma	B-GENE
9	O
,	O
identificamos	O
un	O
fragmento	B-Sequence
de	I-Sequence
ADN	I-Sequence
Similar	O
a	O
ESG1	B-Protein
gene	B-Sequence
que	O
incluía	O
dos	O
supuestos	O
intrones	B-Sequence
.	O

Estos	O
supuestos	O
primero	O
y	O
segundo	O
exones	B-Sequence
,	O
sin	O
embargo	O
,	O
contenía	O
(	O
4	O
)	O
múltiples	O
mutaciones	B-Sequence
de	O
El	O
ESG1	B-Protein
secuencia	B-Sequence
de	I-Sequence
ADNc	I-Sequence
.	O

El	O
tercero	O
putativo	O
exón	B-Sequence
era	O
idéntica	O
a	O
la	O
reportada	O
anteriormente	O
ESG1	B-Protein
gene	B-Sequence
.	O

También	O
en	O
cromosoma	B-GENE
9	O
,	O
identificamos	O
otro	O
fragmento	B-Sequence
de	I-Sequence
ADN	I-Sequence
que	O
era	O
similar	O
,	O
pero	O
no	O
idéntica	O
,	O
a	O
la	O
tercera	O
exón	B-Sequence
de	O
El	O
ESG1	B-Protein
gene	B-Sequence
.	O

Estos	O
hallazgos	O
sugieren	O
que	O
estos	O
ESG1	B-Protein
#	O
¿NOMBRE	O
?	O
secuencias	B-Sequence
en	I-Sequence
el	I-Sequence
cromosoma	I-Sequence
9	O
no	O
han	O
sido	O
ensamblados	O
correctamente	O
.	O

Para	O
obtener	O
fragmentos	B-Sequence
de	I-Sequence
ADN	I-Sequence
que	O
contiene	O
el	O
ESG1	B-Protein
gene	B-Sequence
,	O
examinamos	O
el	O
cromosoma	B-Sequence
artificial	I-Sequence
bacteriano	I-Sequence
(	O
BAC	B-Sequence
)	O
ADN	B-Sequence
piscina	O
por	O
PCR	O
usando	O
cebador	B-Sequence
pares	O
que	O
solo	O
amplificarían	O
lo	O
real	O
gene	B-Sequence
,	O
no	O
la	O
pseudogenes	B-Sequence
.	O

Obtuvimos	O
dos	O
independientes	O
,	O
pero	O
clones	B-Sequence
BAC	I-Sequence
superpuestos	I-Sequence
.	O

Los	O
análisis	O
de	O
Southern	O
blot	O
y	O
la	O
secuenciación	O
demostraron	O
que	O
estos	O
clones	B-Sequence
contenía	O
un	O
secuencia	B-Sequence
exhibiendo	O
una	O
completa	O
identidad	O
con	O
ESG1	B-Protein
ADNc	B-Sequence
que	O
fue	O
interrumpido	O
por	O
dos	O
supuestos	O
intrones	B-Sequence
(	O
Figura	O
2A	O
)	O
.	O

Los	O
dos	O
secuencias	B-Sequence
de	I-Sequence
intrones	I-Sequence
comienzan	O
con	O
GT	O
y	O
terminan	O
con	O
AG	O
,	O
cumpliendo	O
la	O
regla	O
de	O
GT-AG	O
de	O
uniones	B-Sequence
exón	I-Sequence
-	I-Sequence
intrón	I-Sequence
[	O
19	O
]	O
.	O

los	O
5	B-Sequence
'región	I-Sequence
flanqueante	I-Sequence
de	O
esta	O
fragmento	B-Sequence
de	I-Sequence
ADN	I-Sequence
exhibido	O
fuerte	O
promotor	B-Sequence
/	O
potenciador	B-Sequence
actividad	O
por	O
ensayos	O
de	O
indicador	O
de	O
luciferasa	O
en	O
ES	O
indiferenciado	O
células	B-Cell
,	O
pero	O
no	O
en	O
somática	O
células	B-Cell
(	O
Figura	O
3	O
)	O
.	O

Lo	O
mismo	O
fragmento	B-Sequence
mostró	O
una	O
actividad	O
mucho	O
más	O
débil	O
después	O
de	O
la	O
inducción	O
de	O
la	O
diferenciación	O
por	O
ácido	B-Chemical
retinoico	I-Chemical
.	O

Concluimos	O
que	O
este	O
secuencia	B-Sequence
es	O
el	O
ESG1	B-Protein
gene	B-Sequence
.	O

Figura	O
2	O

clones	B-Sequence
BAC	I-Sequence
que	O
contiene	O
el	O
ESG1	B-Protein
gene	B-Sequence
y	O
un	O
pseudogén	B-Sequence
de	I-Sequence
duplicación	I-Sequence
(	O
PD	B-Sequence
)	O
.	O

A	O
)	O
Localización	B-Sequence
de	O
El	O
gene	B-Sequence
y	O
PD	B-Sequence
en	O
cromosoma	B-GENE
9	O

B	O
)	O
Secuencia	B-Sequence
comparación	O
de	O
los	O
gene	B-Sequence
y	O
PD	B-Sequence
reveló	O
que	O
estos	O
son	O
homólogo	B-Sequence
de	O
ocho	O
pares	B-Sequence
de	I-Sequence
bases	I-Sequence
aguas	O
arriba	O
de	O
la	O
primera	O
exón	B-Sequence
al	O
675	O
pb	B-Sequence
aguas	O
abajo	O
del	O
tercero	O
exón	B-Sequence
.	O

Mutaciones	B-Sequence
de	I-Sequence
sustitución	I-Sequence
se	O
indican	O
con	O
líneas	O
negras	O
.	O

los	O
inserción	B-Sequence
se	O
indica	O
con	O
un	O
triángulo	O
abierto	O
.	O

figura	O
3	O

Promotor	B-Sequence
/	O
potenciador	B-Sequence
actividad	O
de	O
la	O
ESG1	B-Protein
gene	B-Sequence
y	O
pseudogen	B-Sequence
.	O

fragmentos	B-Sequence
de	I-Sequence
ADN	I-Sequence
de	O
~	O
6	O
kbp	O
aislado	O
de	O
la	O
5	B-Sequence
'regiones	I-Sequence
flanqueantes	I-Sequence
de	O
El	O
gene	B-Sequence
y	O
PD	B-Sequence
fueron	O
transferido	B-Sequence
en	O
reportero	O
de	O
luciferasa	O
plásmidos	B-Sequence
.	O

Presentamos	O
al	O
reportero	O
genes	B-Sequence
en	O
ES	O
indiferenciado	O
células	B-Cell
(	O
columnas	O
abiertas	O
)	O
,	O
ácido	B-Chemical
retinoico	I-Chemical
#	O
¿NOMBRE	O
?	O
células	B-Cell
(	O
columnas	O
grises	O
)	O
y	O
NIH3T3	O
células	B-Cell
(	O
columnas	O
cerradas	O
)	O
.	O

Los	O
datos	O
representan	O
los	O
promedios	O
y	O
las	O
desviaciones	O
estándar	O
de	O
tres	O
experimentos	O
independientes	O
.	O

También	O
encontramos	O
que	O
los	O
dos	O
clones	B-Sequence
BAC	I-Sequence
contenía	O
otro	O
ESG1	B-Protein
#	O
¿NOMBRE	O
?	O
secuencia	B-Sequence
(	O
Figura	O
2A	O
)	O
.	O

Los	O
dos	O
secuencias	B-Sequence
,	O
separados	O
por	O
un	O
68	O
kbp	O
secuencia	B-Sequence
intergénica	I-Sequence
,	O
estaban	O
orientados	O
en	O
direcciones	O
opuestas	O
.	O

los	O
ESG1	B-Protein
#	O
¿NOMBRE	O
?	O
secuencia	B-Sequence
exhibió	O
más	O
del	O
95	O
%	O
de	O
identidad	O
con	O
el	O
exones	B-Sequence
y	O
intrones	B-Sequence
de	O
El	O
ESG1	B-Protein
gene	B-Sequence
.	O

Esta	O
secuencia	B-Sequence
,	O
sin	O
embargo	O
,	O
contenía	O
críticas	O
nucleótido	B-Chemical
sustituciones	B-Sequence
en	O
todos	O
los	O
exones	B-Sequence
y	O
uno	O
inserción	B-Sequence
de	I-Sequence
nucleótidos	I-Sequence
en	O
exón	B-Sequence
2	O
(	O
Figura	O
2B	O
)	O
.	O

aunque	O
675	O
pares	B-Sequence
de	I-Sequence
bases	I-Sequence
de	O
El	O
3	B-Sequence
'regiones	I-Sequence
flanqueantes	I-Sequence
fueron	O
conservado	B-Sequence
Entre	O
los	O
ESG1	B-Protein
gene	B-Sequence
y	O
el	O
pseudogen	B-Sequence
,	O
solo	O
cinco	O
pares	B-Sequence
de	I-Sequence
bases	I-Sequence
de	O
El	O
5	B-Sequence
'región	I-Sequence
flanqueante	I-Sequence
eran	O
idénticos	O
.	O

Esta	O
5	B-Sequence
'región	I-Sequence
flanqueante	I-Sequence
(	O
~	O
6	O
kbp	O
)	O
no	O
poseía	O
ninguna	O
promotor	B-Sequence
/	O
potenciador	B-Sequence
actividad	O
en	O
ensayos	O
de	O
indicador	O
de	O
luciferasa	O
(	O
Figura	O
3	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
es	O
poco	O
probable	O
que	O
este	O
secuencia	B-Sequence
se	O
transcribe	O
o	O
traduce	O
a	O
un	O
funcional	O
proteína	B-Chemical
.	O

Esta	O
secuencia	B-Sequence
probablemente	O
representa	O
un	O
pseudogén	B-Sequence
de	I-Sequence
duplicación	I-Sequence
.	O

Bierbaum	O
informó	O
previamente	O
de	O
la	O
existencia	O
de	O
dos	O
pseudogenes	B-Sequence
con	O
similares	O
exón	B-Sequence
-	O
intrón	B-Sequence
organización	O
como	O
la	O
ESG1	B-Protein
gene	B-Sequence
[	O
17	O
]	O
.	O

No	O
pudimos	O
determinar	O
cuál	O
de	O
estos	O
dos	O
pseudogenes	B-Sequence
corresponde	O
al	O
que	O
identificamos	O
o	O
al	O
ubicación	B-Sequence
de	O
los	O
restantes	O
pseudogen	B-Sequence
.	O

Interrupción	O
dirigida	O
de	O
la	O
ratón	B-Protein
ESG1	I-Protein
gene	B-Sequence

Para	O
estudiar	O
la	O
función	O
de	O
ESG1	B-Protein
,	O
nosotros	O
eliminado	B-Sequence
los	O
gene	B-Sequence
por	O
recombinación	O
homóloga	O
en	O
ratón	B-Taxon
ES	O
células	B-Cell
.	O

Nosotros	O
sustituido	B-Sequence
el	O
tres	O
exones	B-Sequence
con	O
un	O
fusión	B-Sequence
de	I-Sequence
los	I-Sequence
genes	I-Sequence
de	I-Sequence
neomicina	I-Sequence
-	I-Sequence
resistencia	I-Sequence
y	I-Sequence
beta	I-Sequence
-	I-Sequence
galactosidasa	I-Sequence
(	O
beta-geo	O
)	O
o	O
el	O
higromicina	B-Chemical
resistente	O
gene	B-Sequence
(	O
HygR	O
)	O
usando	O
dos	O
objetivos	O
vectores	B-Sequence
(	O
Figura	O
4A	O
)	O
introducido	O
en	O
RF8	O
ES	O
células	B-Cell
por	O
electroporación	O
.	O

Obtuvimos	O
ocho	O
ES	O
célula	B-Cell
clones	O
con	O
la	O
recombinación	O
homóloga	O
correcta	O
de	O
la	O
beta	O
-	O
segmentación	O
geográfica	O
vector	B-Sequence
,	O
que	O
fue	O
confirmado	O
por	O
análisis	O
de	O
transferencia	O
Southern	O
(	O
Figura	O
4B	O
)	O
.	O

Obtuvimos	O
solo	O
un	O
clon	O
con	O
recombinación	O
homóloga	O
correcta	O
de	O
la	O
orientación	O
HygR	O
vector	B-Sequence
.	O

Figura	O
4	O

Interrupción	O
dirigida	O
de	O
la	O
ratón	B-Protein
ESG1	I-Protein
gene	B-Sequence
.	O

A	O
)	O
Estrategia	O
de	O
focalización	O
.	O

Las	O
regiones	O
homólogas	O
se	O
indican	O
mediante	O
líneas	O
gruesas	O
.	O

Sitios	B-Sequence
de	I-Sequence
reconocimiento	I-Sequence
de	O
PstI	O
(	O
P	O
)	O
y	O
SpeI	O
(	O
S	O
)	O
,	O
que	O
se	O
usaron	O
para	O
los	O
análisis	O
de	O
transferencia	O
Southern	O
.	O

los	O
gene	B-Sequence
codificación	O
toxina	B-Protein
diftérica	I-Protein
A	O
(	O
DTA	O
)	O
fue	O
insertado	B-Sequence
en	O
el	O
extremo	O
3	O
'de	O
la	O
orientación	O
vectores	B-Sequence
para	O
facilitar	O
la	O
selección	O
negativa	O
.	O

B	O
)	O
Análisis	O
de	O
transferencia	O
Southern	O
que	O
confirman	O
la	O
recombinación	O
homóloga	O
.	O

peso	B-Sequence
,	O
tipo	B-Sequence
salvaje	I-Sequence
ES	O
células	B-Cell
;	O
beta	O
,	O
beta-geo	O
+	B-Sequence
/	O
-	O
ES	O
células	B-Cell
;	O
H	O
,	O
HigR	O
+	B-Sequence
/	O
-	O
ES	O
células	B-Cell
;	O
-	O
/	O
-	O
,	O
ESG1	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
.	O

Los	O
números	O
indican	O
números	O
de	O
clones	O
.	O

C	O
)	O
Análisis	O
de	O
Northern	O
blot	O
(	O
superior	O
)	O
y	O
western	O
blot	O
(	O
inferior	O
)	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
ES	O
células	B-Cell
(	O
peso	B-Sequence
)	O
,	O
ESG1	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
(	O
-	O
/	O
-	O
,	O
tres	O
clones	O
)	O
y	O
ES	O
heterocigotos	O
células	B-Cell
(	O
+	B-Sequence
/	O
-	O
)	O
.	O

Northern	O
blot	O
se	O
realizó	O
como	O
se	O
ha	O
descrito	O
anteriormente	O
[	O
20	O
]	O
.	O

Para	O
confirmar	O
la	O
carga	O
de	O
cantidades	O
iguales	O
de	O
ARN	B-Sequence
,	O
bromuro	B-Chemical
de	I-Chemical
etidio	I-Chemical
tinción	O
de	O
ARN	B-Chemical
ribosomal	I-Chemical
también	O
se	O
muestra	O
(	O
centro	O
)	O
.	O

Para	O
obtener	O
homocigotos	O
mutante	B-Sequence
ES	O
células	B-Cell
,	O
presentamos	O
la	O
versión	O
beta	O
-	O
geo	O
vector	B-Sequence
en	O
HygR	O
heterocigoto	O
ES	O
células	B-Cell
.	O

De	O
105	O
colonias	O
resistentes	O
a	O
G418	O
analizadas	O
,	O
49	O
eran	O
homocigotas	O
para	O
ESG1	B-Protein
supresión	B-Sequence
.	O

Los	O
análisis	O
de	O
Northern	O
blot	O
y	O
western	O
blot	O
confirmaron	O
la	O
ausencia	O
de	O
ESG1	B-Protein
en	O
estos	O
células	B-Cell
(	O
Figura	O
4C	O
)	O
.	O

En	O
29	O
clones	O
,	O
el	O
beta-geo	O
vector	B-Sequence
tenido	O
sustituido	B-Sequence
el	O
HygR	O
vector	B-Sequence
,	O
tal	O
que	O
el	O
células	B-Cell
permaneció	O
heterocigoto	O
.	O

En	O
los	O
27	O
clones	O
restantes	O
,	O
el	O
beta-geo	O
vector	B-Sequence
era	O
integrado	B-Sequence
en	O
sitios	O
no	O
homólogos	O
.	O

ESG1	B-Protein
-	O
/	O
-	O
ES	O
células	B-Cell
presentaba	O
una	O
morfología	O
normal	O
(	O
Figura	O
5A	O
)	O
.	O

Estas	O
células	B-Cell
también	O
proliferó	O
a	O
una	O
velocidad	O
comparable	O
a	O
la	O
del	O
control	O
(	O
heterocigotos	O
y	O
tipo	B-Sequence
salvaje	I-Sequence
)	O
células	B-Cell
(	O
Figura	O
5B	O
)	O
.	O

ESG1	B-Protein
-	O
/	O
-	O
células	B-Cell
diferenciados	O
normalmente	O
después	O
de	O
la	O
eliminación	O
de	O
factor	B-Protein
inhibidor	I-Protein
de	I-Protein
la	I-Protein
leucemia	I-Protein
(	O
Figura	O
5B	O
)	O
o	O
ácido	B-Chemical
retinoico	I-Chemical
tratamiento	O
(	O
no	O
mostrado	O
)	O
.	O

Cuando	O
se	O
trasplanta	O
a	O
los	O
flancos	O
traseros	O
de	O
nude	O
ratones	B-Taxon
,	O
estas	O
células	B-Cell
produjo	O
teratomas	O
,	O
tumores	O
que	O
contienen	O
componentes	O
de	O
las	O
tres	O
capas	O
germinales	O
(	O
Figura	O
5C	O
)	O
.	O

Estos	O
resultados	O
indican	O
que	O
ESG1	B-Protein
es	O
prescindible	O
por	O
las	O
propiedades	O
de	O
auto-renovación	O
y	O
pluripotencia	O
de	O
ES	O
células	B-Cell
.	O

Figura	O
5	O

Análisis	O
de	O
ESG1	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
.	O

A	O
)	O
La	O
morfología	O
de	O
ESG1	B-Protein
#	O
¿NOMBRE	O
?	O
célula	B-Cell
colonias	O
cultivadas	O
en	O
alimentador	O
STO	O
células	B-Cell
.	O

B	O
)	O
Curva	O
de	O
crecimiento	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
peso	B-Sequence
)	O
,	O
ESG1	B-Protein
-	O
nulo	O
(	O
-	O
/	O
-	O
)	O
y	O
heterocigoto	O
(	O
+	B-Sequence
/	O
-	O
)	O
ES	O
células	B-Cell
.	O

Cada	O
clon	O
(	O
1	O
x	O
104	O
células	B-Cell
/	O
pocillo	O
)	O
se	O
sembró	O
en	O
placas	O
de	O
24	O
pocillos	O
.	O

Célula	B-Cell
los	O
números	O
se	O
determinaron	O
con	O
un	O
contador	O
Coulter	O
a	O
los	O
2	O
,	O
4	O
y	O
6	O
días	O
.	O

Datos	O
de	O
+	B-Sequence
/	O
-	O
y	O
-	O
/	O
-	O
células	B-Cell
se	O
muestran	O
como	O
promedios	O
y	O
desviaciones	O
estándar	O
de	O
tres	O
clones	O
independientes	O
.	O

C	O
)	O
Una	O
sección	O
de	O
teratoma	O
derivado	O
de	O
ESG1	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
(	O
tinción	O
de	O
hematoxilina	O
y	O
eosina	O
)	O
.	O

Examinamos	O
el	O
gene	B-Sequence
perfiles	O
de	O
expresión	O
de	O
ESG1	B-Protein
-	O
/	O
-	O
ES	O
células	B-Cell
utilizando	O
oligonucleótido	B-Sequence
#	O
¿NOMBRE	O
?	O
ADN	B-Sequence
microarreglos	O
que	O
representan	O
~	O
20	O
000	O
genes	B-Sequence
.	O

En	O
comparación	O
con	O
el	O
control	O
ES	O
células	B-Cell
,	O
ESG1	B-Protein
fue	O
identificado	O
como	O
el	O
gene	B-Sequence
reducido	O
en	O
su	O
mayor	O
parte	O
en	O
ESG1	B-Protein
-	O
/	O
-	O
ES	O
células	B-Cell
(	O
Figura	O
6A	O
)	O
.	O

La	O
expresión	O
de	O
ES	O
célula	B-Cell
marcador	O
genes	B-Sequence
,	O
tal	O
como	O
Nanog	B-Protein
y	O
oct3	B-Protein
/	I-Protein
4	I-Protein
,	O
era	O
normal	O
en	O
ESG1	B-Protein
-	O
/	O
-	O
ES	O
células	B-Cell
.	O

Confirmamos	O
normalidad	O
oct3	B-Protein
/	I-Protein
4	I-Protein
expresión	O
en	O
proteína	B-Chemical
niveles	O
por	O
Western	O
blot	O
(	O
Figura	O
6B	O
)	O
.	O

El	O
general	O
gene	B-Sequence
los	O
perfiles	O
de	O
expresión	O
fueron	O
similares	O
entre	O
los	O
ES	O
de	O
control	O
células	B-Cell
y	O
ESG1	B-Protein
-	O
/	O
-	O
ES	O
células	B-Cell
.	O

Varios	O
genes	B-Sequence
mostró	O
una	O
reducción	O
de	O
más	O
del	O
doble	O
en	O
ESG1	B-Protein
-	O
/	O
-	O
células	B-Cell
,	O
incluyendo	O
krt1	B-Protein
-	O
8	O
,	O
pem	B-Protein
,	O
ctgf	B-Protein
,	O
Ptgs2	B-Protein
,	O
Igf2	B-Protein
y	O
Inhba	B-Protein
.	O

Estas	O
genes	B-Sequence
puede	O
ser	O
regulada	O
directa	O
o	O
indirectamente	O
por	O
ESG1	B-Protein
.	O

Ya	O
que	O
ESG1	B-Protein
contiene	O
un	O
tipo	O
KH	O
ARN	B-Sequence
#	O
¿NOMBRE	O
?	O
dominio	B-Sequence
,	O
puede	O
estabilizarse	O
ARNm	B-Chemical
de	O
estos	O
genes	B-Sequence
.	O

Se	O
requieren	O
más	O
estudios	O
para	O
aclarar	O
esta	O
posibilidad	O
.	O

Figura	O
6	O

Gene	B-Sequence
análisis	O
de	O
expresión	O
de	O
ESG1	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
.	O

A	O
)	O
ADN	B-Sequence
análisis	O
de	O
micromatrices	O
.	O

Total	O
ARN	B-Sequence
desde	O
tipo	B-Sequence
salvaje	I-Sequence
ES	O
células	B-Cell
y	O
ESG1	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
fueron	O
etiquetados	O
con	O
Cy3	O
y	O
Cy5	O
,	O
respectivamente	O
.	O

Las	O
muestras	O
se	O
hibridaron	O
con	O
Agilent	O
Ratón	B-Taxon
Microarrays	O
de	O
desarrollo	O
.	O

Se	O
muestran	O
los	O
promedios	O
de	O
dos	O
clones	O
independientes	O
.	O

B	O
)	O
Análisis	O
de	O
transferencia	O
Western	O
.	O

Célula	B-Cell
lisados	O
de	O
ESG1	B-Protein
+	B-Sequence
/	O
-	O
y	O
ESG1	B-Protein
-	O
/	O
-	O
células	B-Cell
fueron	O
examinados	O
para	O
la	O
expresión	O
de	O
ESG1	B-Protein
,	O
oct3	B-Protein
/	I-Protein
4	I-Protein
y	O
CDK4	B-Protein
con	O
inmunotransferencia	O
.	O

Para	O
generar	O
ESG1	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
,	O
inyectamos	O
beta	O
-	O
geo	O
-	O
ESG1	B-Protein
+	B-Sequence
/	O
-	O
ES	O
célula	B-Cell
clones	O
en	O
los	O
blastocistos	O
de	O
C57BL6	O
ratones	B-Taxon
.	O

Obtuvimos	O
transmisión	O
de	O
línea	O
germinal	O
de	O
tres	O
clones	O
.	O

Nosotros	O
obtuvimos	O
ESG1	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
en	O
las	O
proporciones	O
mendelianas	O
(	O
36	O
tipo	B-Sequence
salvaje	I-Sequence
,	O
69	O
ESG1	B-Protein
+	B-Sequence
/	O
-	O
,	O
y	O
45	O
ESG1	B-Protein
-	O
/	O
-	O
)	O
de	O
cruces	O
de	O
ESG1	B-Protein
+	B-Sequence
/	O
-	O
ratones	B-Taxon
.	O

Estas	O
animales	B-Taxon
exhibió	O
un	O
desarrollo	O
normal	O
,	O
apariencia	O
macroscópica	O
y	O
fertilidad	O
(	O
no	O
se	O
muestra	O
)	O
.	O

El	O
examen	O
histológico	O
de	O
testículos	O
y	O
ovarios	O
no	O
pudo	O
identificar	O
ninguna	O
anormalidad	O
(	O
no	O
se	O
muestra	O
)	O
.	O

Estos	O
datos	O
demostraron	O
que	O
ESG1	B-Protein
es	O
prescindible	O
para	O
ambos	O
ratón	B-Taxon
desarrollo	O
y	O
Célula	B-Cell
germinal	I-Cell
formación	O

También	O
generamos	O
ES	O
células	B-Cell
de	O
blastocistos	O
obtenidos	O
por	O
cruces	O
de	O
ESG1	B-Protein
+	B-Sequence
/	O
-	O
machos	O
y	O
ESG1	B-Protein
-	O
/	O
-	O
hembras	O
.	O

de	O
los	O
ocho	O
ES	O
célula	B-Cell
líneas	O
establecidas	O
,	O
dos	O
clones	O
fueron	O
ESG1	B-Protein
-	O
/	O
-	O
.	O

Estas	O
ESG1	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
demostró	O
morfología	O
,	O
proliferación	O
y	O
diferenciación	O
normales	O
(	O
no	O
se	O
muestra	O
)	O
,	O
lo	O
que	O
confirma	O
que	O
ESG1	B-Protein
es	O
prescindible	O
en	O
ES	O
células	B-Cell
.	O

Conclusión	O

Analizar	O
las	O
funciones	O
fisiológicas	O
de	O
ESG1	B-Protein
,	O
identificamos	O
la	O
ratón	B-Taxon
gene	B-Sequence
en	O
cromosoma	B-GENE
9	O
y	O
eliminado	B-Sequence
por	O
recombinación	O
homóloga	O
en	O
ES	O
células	B-Cell
.	O

A	O
pesar	O
de	O
la	O
expresión	O
específica	O
en	O
embriones	O
tempranos	O
,	O
células	B-Cell
germinales	I-Cell
y	O
pluripotentes	O
células	B-Cell
,	O
nuestros	O
datos	O
demostraron	O
que	O
ESG1	B-Protein
es	O
prescindible	O
para	O
ratón	B-Taxon
desarrollo	O
,	O
Célula	B-Cell
germinal	I-Cell
formación	O
y	O
ES	O
célula	B-Cell
autorrenovación	O
.	O

Métodos	O

Identificación	O
y	O
análisis	O
de	O
clones	B-Sequence
BAC	I-Sequence
que	O
contiene	O
el	O
ratón	B-Protein
ESG1	I-Protein
gene	B-Sequence

Identificar	O
cromosoma	B-Sequence
artificial	I-Sequence
bacteriano	I-Sequence
(	O
BAC	B-Sequence
)	O
clones	B-Sequence
que	O
contiene	O
ratón	B-Protein
ESG1	I-Protein
gene	B-Sequence
,	O
realizamos	O
un	O
cribado	O
basado	O
en	O
PCR	O
de	O
ratón	B-Taxon
BAC	B-Sequence
Biblioteca	O
ADN	B-Sequence
pools	O
(	O
Research	O
Genetics	O
)	O
usando	O
el	O
pH34	B-Protein
-	O
u38	O
(	O
5	O
'	O
-	O
GAAGTCTGGGTTCCTTGGCAGG	O
-	O
3	O
'	O
)	O
y	O
pH34	B-Protein
-	O
L394	O
(	O
5	O
'	O
-	O
ACTCGATACACTGGCCTAGC	O
-	O
3	O
'	O
)	O
cebadores	B-Sequence
.	O

siguiente	O
restricción	O
enzima	B-Sequence
digestión	O
,	O
realizamos	O
análisis	O
de	O
transferencia	O
Southern	O
de	O
clones	B-Sequence
BAC	I-Sequence
como	O
se	O
describe	O
[	O
20	O
]	O
usando	O
el	O
pH34	B-Protein
-U258	O
(	O
5'-CTCGAGTGTACAGTCAAGTGGTTGCTGGGA-3	O
'	O
)	O
,	O
pH34	B-Protein
-U65	O
(	O
5'-GTGACCCTCGTGACCCGTAA-3	O
'	O
)	O
,	O
pH34	B-Protein
intron1L	O
(	O
5	O
'	O
-	O
CTGCGTGAGAGAAACACCAAACAGGC	O
-	O
3	O
'	O
)	O
,	O
pH34	B-Protein
-	O
L545	O
(	O
5	O
'	O
-	O
TGTGAATGGGAAGGTTACCACTCT	O
-	O
3	O
'	O
)	O
y	O
pH34	B-Protein
-	O
SCL1	O
(	O
5	O
'	O
-	O
GCCCTCTTCTGGTTTGTCTCGAAAT	O
-	O
3	O
'	O
)	O
sondas	B-Sequence
.	O

hibridación	O
con	O
estos	O
sondas	B-Sequence
bandas	O
reveladas	O
que	O
contienen	O
ya	O
sea	O
el	O
ESG1	B-Protein
gene	B-Sequence
o	O
pseudogenes	B-Sequence
.	O

Para	O
secuenciar	O
el	O
región	B-Sequence
que	O
contiene	O
el	O
ratón	B-Protein
ESG1	I-Protein
gene	B-Sequence
y	O
el	O
3	B-Sequence
'región	I-Sequence
flanqueante	I-Sequence
,	O
subclonamos	O
un	O
XhoI	O
-	O
SalI	O
de	O
~	O
15	O
kbp	O
fragmento	B-Sequence
en	O
el	O
pZERO	O
-	O
2	O
vector	B-Sequence
(	O
Invitrogen	O
)	O
.	O

HindIII	O
-	O
o	O
EcoRI	O
-	O
digerido	O
fragmentos	B-Sequence
de	O
esta	O
vector	B-Sequence
luego	O
se	O
clonaron	O
en	O
pBluescript	O
KS	O
(	O
-	O
)	O
para	O
la	O
secuenciación	O
.	O

Para	O
secuenciar	O
el	O
ESG1	B-Protein
pseudogen	B-Sequence
y	O
el	O
3	B-Sequence
'región	I-Sequence
flanqueante	I-Sequence
,	O
un	O
NotI	O
/	O
XhoI	O
de	O
8	O
kbp	O
fragmento	B-Sequence
fue	O
clonado	O
en	O
pBluescript	O
KS	O
(	O
-	O
)	O
.	O

BamHI	O
-	O
o	O
PstI	O
-	O
fragmentos	B-Sequence
de	O
esta	O
vector	B-Sequence
también	O
se	O
clonaron	O
en	O
pBluescript	O
KS	O
(	O
-	O
)	O
.	O

Para	O
identificar	O
el	O
secuencia	B-Sequence
que	O
contiene	O
el	O
5	B-Sequence
'regiones	I-Sequence
flanqueantes	I-Sequence
de	O
El	O
ESG1	B-Protein
gene	B-Sequence
y	O
los	O
relacionados	O
pseudogenes	B-Sequence
,	O
utilizamos	O
un	O
kit	O
de	O
andador	O
TOPO	O
(	O
Invitrogen	O
)	O
con	O
el	O
pH34	B-Protein
-	O
T2L	O
(	O
5	O
'	O
-	O
ACTAGTCGCAGCAGGGATCCAGGAATATCT	O
-	O
3	O
'	O
)	O
y	O
pH34	B-Protein
0	O
cebadores	B-Sequence
.	O

La	O
resultante	O
secuencia	B-Sequence
fue	O
clonado	O
en	O
pCR2	O
.	O
1	O
(	O
Invitrogen	O
)	O
.	O

Obtuvimos	O
una	O
banda	O
de	O
~6	O
kpb	O
de	O
la	O
biblioteca	O
digerida	O
con	O
NsiI	O
;	O
XbaI	O
-	O
,	O
SpeI	O
-	O
,	O
EcoRI	O
-	O
y	O
PstI	O
-	O
digeridos	O
fragmentos	B-Sequence
de	O
esta	O
banda	O
se	O
clonaron	O
en	O
pBluescript	O
KS	O
(	O
-	O
)	O
para	O
la	O
secuenciación	O
.	O

Esta	O
fragmento	B-Sequence
contenía	O
el	O
5	B-Sequence
'región	I-Sequence
flanqueante	I-Sequence
de	O
El	O
ESG1	B-Protein
gene	B-Sequence
.	O

A	O
~	O
3	O
kpb	O
fragmento	B-Sequence
,	O
obtenido	O
de	O
la	O
biblioteca	O
digerida	O
con	O
SacI	O
,	O
se	O
clonó	O
en	O
pCR2	O
.	O
1	O
para	O
la	O
secuenciación	O
.	O

Esta	O
fragmento	B-Sequence
estaba	O
contenido	O
el	O
5	O
'	O
región	B-Sequence
flanqueando	O
el	O
pseudogen	B-Sequence
.	O

Construcción	O
de	O
ESG1	B-Protein
apuntando	O
vectores	B-Sequence

Nosotros	O
sustituido	B-Sequence
toda	O
la	O
ESG1	B-Protein
exones	B-Sequence
con	O
dos	O
objetivos	O
vectores	B-Sequence
que	O
contiene	O
un	O
ires	B-Sequence
#	O
¿NOMBRE	O
?	O
casete	B-Sequence
[	O
21	O
]	O
o	O
un	O
ires	B-Sequence
#	O
¿NOMBRE	O
?	O
casete	B-Sequence
por	O
promotor	B-Sequence
selección	O
de	O
trampas	O
.	O

Amplificamos	O
el	O
brazo	O
de	O
5	O
'	O
(	O
1.8	O
kbp	O
)	O
usando	O
KOD	O
plus	O
(	O
TOYOBO	O
)	O
con	O
el	O
pH34	B-Protein
-	O
targetpair5	O
-	O
U	O
(	O
5	O
'	O
-	O
CCGCGGAAAGTCAAGAGATTGGGTGG	O
-	O
3	O
'	O
)	O
y	O
pH34	B-Protein
-	O
targetpair5	O
-	O
L	O
(	O
5	O
'	O
-	O
GCGGCCGCCTTTACGGGTCACGAGGGTCAC	O
-	O
3	O
'	O
)	O
cebadores	B-Sequence
.	O

El	O
brazo	O
3	O
'	O
(	O
5,8	O
kbp	O
)	O
se	O
amplificó	O
utilizando	O
el	O
pH34	B-Protein
-	O
targetpair3	O
-	O
U	O
(	O
5	O
'	O
-	O
TTGGCCAGTGTTTGGTTCTGGCGGG	O
-	O
3	O
'	O
)	O
y	O
pH34	B-Protein
-	O
targetpair3	O
-	O
L	O
(	O
5	O
'	O
-	O
CTCGAGGACTCGCCATTCTAGCCAAG	O
-	O
3	O
'	O
)	O
cebadores	B-Sequence
.	O

los	O
ires	B-Sequence
beta	O
-	O
geo	O
o	O
ires	B-Sequence
HygR	O
casetes	B-Sequence
fueron	O
ligados	O
entre	O
los	O
dos	O
PCR	O
fragmentos	B-Sequence
.	O

los	O
toxina	B-Protein
diftérica	I-Protein
A	O
casete	B-Sequence
se	O
colocó	O
aguas	O
abajo	O
del	O
brazo	O
de	O
3	O
'	O
.	O

Después	O
de	O
la	O
linealización	O
con	O
SacII	O
,	O
estos	O
objetivos	O
vectores	B-Sequence
fueron	O
electroporados	O
en	O
2	O
.	O
0x107	O
RF8	O
ES	O
células	B-Cell
[	O
22	O
]	O
usando	O
un	O
Gene	B-Sequence
pulsador	O
(	O
BIORAD	O
)	O
.	O

transfectado	O
células	B-Cell
fueron	O
seleccionados	O
con	O
250	O
mu	O
g/mL	O
G418	O
o	O
100	O
mu	O
g/mL	O
higromicina	B-Chemical
B	I-Chemical
,	O
respectivamente	O
.	O

ADN	B-Sequence
genómico	I-Sequence
de	O
G418	O
-	O
o	O
higromicina	B-Chemical
B	I-Chemical
Las	O
colonias	O
resistentes	O
se	O
seleccionaron	O
para	O
determinar	O
la	O
recombinación	O
homóloga	O
mediante	O
transferencia	O
de	O
Southern	O
.	O

Detección	O
de	O
transferencia	O
Southern	O
para	O
recombinación	O
homóloga	O

ES	O
células	B-Cell
ADN	B-Sequence
genómico	I-Sequence
fue	O
extraído	O
con	O
PUREGENE	O
(	O
TM	O
)	O
Célula	B-Cell
Solución	O
de	O
Lisis	O
(	O
sistemas	O
Gentra	O
)	O
.	O

Para	O
el	O
análisis	O
de	O
transferencia	O
Southern	O
de	O
5	O
'	O
,	O
ADN	B-Sequence
genómico	I-Sequence
primero	O
se	O
digirió	O
con	O
PstI	O
,	O
luego	O
se	O
separó	O
en	O
un	O
0	O
.	O
8	O
%	O
agarosa	B-Chemical
gel	O
y	O
se	O
transfiere	O
a	O
un	O
nylon	B-Chemical
membrana	O
como	O
se	O
describe	O
[	O
20	O
]	O
.	O

un	O
560	O
pb	B-Sequence
5	O
'	O
Investigacion	B-Sequence
se	O
amplificó	O
utilizando	O
el	O
ESG1S5	O
(	O
5	O
'	O
-	O
GATGTGTGGTGGTGACTCAGAG	O
-	O
3	O
'	O
)	O
y	O
ESG1AS5	O
como	O
(	O
5	O
'	O
-	O
CCTCCATTGCCTCTATATCAG	O
-	O
3	O
'	O
)	O
cebadores	B-Sequence
.	O

los	O
Investigacion	B-Sequence
etiquetada	O
específicamente	O
una	O
banda	O
de	O
18	O
kbp	O
de	O
la	O
locus	B-Sequence
de	I-Sequence
tipo	I-Sequence
salvaje	I-Sequence
,	O
una	O
banda	O
de	O
15	O
kbp	O
de	O
la	O
beta	O
-	O
geo	O
lugar	B-Sequence
,	O
y	O
una	O
banda	O
de	O
12	O
kbp	O
del	O
HygR	O
lugar	B-Sequence
.	O

ADN	B-Sequence
genómico	I-Sequence
también	O
se	O
digirió	O
con	O
SpeI	O
para	O
el	O
análisis	O
de	O
transferencia	O
Southern	O
3	O
'	O
.	O

10	O
pb	B-Sequence
3	O
'	O
Investigacion	B-Sequence
se	O
amplificó	O
con	O
el	O
pH34U	O
-	O
8000	O
(	O
5	O
'	O
-	O
CCAACCAGCCAGAGAGTTTCAGTTAT	O
-	O
3	O
'	O
)	O
y	O
pH34L	O
-	O
9000	O
(	O
5	O
'	O
-	O
GATAAGCTGCTGCCAAAAGACAAG	O
-	O
3	O
'	O
)	O
cebadores	B-Sequence
.	O

los	O
Investigacion	B-Sequence
hibridado	O
a	O
un	O
11	O
.	O
banda	O
de	O
5	O
kbp	O
de	O
la	O
locus	B-Sequence
de	I-Sequence
tipo	I-Sequence
salvaje	I-Sequence
,	O
un	O
12	O
.	O
Banda	O
de	O
5	O
kbp	O
de	O
la	O
beta	O
-	O
geo	O
lugar	B-Sequence
,	O
y	O
un	O
9	O
.	O
Banda	O
de	O
5	O
kbp	O
del	O
HygR	O
lugar	B-Sequence
.	O

Generación	O
de	O
anti-	O
ESG1	B-Protein
policlonal	O
anticuerpos	B-GENE

los	O
secuencia	B-Sequence
de	I-Sequence
codificación	I-Sequence
de	O
Esg1	B-Protein
fue	O
amplificado	O
por	O
PCR	O
con	O
el	O
pH34	B-Protein
-	O
gw	O
-	O
s	O
(	O
5	O
'	O
-	O
AAAAAGCAGGCTGGATGATGGTGACCCTCGTGA	O
-	O
3	O
'	O
)	O
y	O
pH34	B-Protein
-	O
gw	O
-	O
as	O
(	O
5	O
'	O
-	O
AGAAAGCTGGGTCTGCATCCAGGTCGGACA	O
-	O
3	O
'	O
)	O
cebadores	B-Sequence
.	O

Para	O
construir	O
pDONR	O
-	O
pH34	B-Protein
,	O
la	O
resultante	O
producto	B-Sequence
PCR	I-Sequence
se	O
subclonó	O
en	O
pDONR201	O
(	O
Invitrogen	O
)	O
.	O

pDONR	O
-	O
pH34	B-Protein
interactuó	O
con	O
pDEST17	O
(	O
Invitrogen	O
)	O
mediante	O
recombinación	O
LR	O
.	O

Después	O
de	O
la	O
introducción	O
de	O
la	O
expresión	O
resultante	O
vector	B-Sequence
pDEST17	O
-	O
pH34	B-Protein
en	O
BL21	O
-	O
IA	O
mi	B-Taxon
coli	I-Taxon
(	O
Invitrogen	O
)	O
,	O
recombinante	O
proteína	B-Chemical
la	O
producción	O
se	O
indujo	O
según	O
el	O
protocolo	O
del	O
fabricante	O
.	O

histidina	B-Chemical
#	O
¿NOMBRE	O
?	O
ESG1	B-Protein
se	O
purificó	O
utilizando	O
Ni	B-Chemical
-	O
agarosa	B-Chemical
de	I-Chemical
ácido	I-Chemical
nitrilotriacético	I-Chemical
(	O
Qiagen	O
)	O
en	O
condiciones	O
desnaturalizantes	O
en	O
presencia	O
de	O
8	O
M	O
urea	B-Chemical
.	O

Después	O
de	O
diálisis	O
contra	O
6	O
M	O
urea	B-Chemical
,	O
el	O
recombinante	O
proteinas	B-Chemical
fueron	O
inyectados	O
en	O
Nueva	O
Zelanda	O
White	O
conejos	B-Taxon
para	O
generar	O
anti-	O
ESG1	B-Protein
policlonal	O
anticuerpos	B-GENE
.	O

mancha	O
occidental	O

Después	O
de	O
la	O
preparación	O
de	O
ES	O
célula	B-Cell
extractos	O
con	O
M-Per	O
(	O
Pierce	O
)	O
,	O
celular	B-Cell
proteinas	B-Chemical
fueron	O
separados	O
en	O
dodecil	B-Chemical
sulfato	I-Chemical
de	I-Chemical
sodio	I-Chemical
(	O
SDS	B-Chemical
)	O
-	O
Geles	O
de	O
poliacrilamida	O
al	O
14	O
%	O
y	O
transferidos	O
a	O
membranas	O
de	O
nitrocelulosa	O
(	O
Millipore	O
)	O
.	O

Las	O
membranas	O
se	O
incubaron	O
con	O
anti-	O
ESG1	B-Protein
(	O
dilución	O
1/500	O
)	O
,	O
anti-	O
oct3	B-Protein
/	I-Protein
4	I-Protein
(	O
1	O
/	O
500	O
;	O
Santa	O
Cruz	O
Biotecnología	O
)	O
,	O
anti	O
-	O
CDK4	B-Protein
(	O
1	O
/	O
200	O
;	O
Santa	O
Cruz	O
Biotechnology	O
)	O
,	O
y	O
anti	O
-	O
GFP	O
(	O
1	O
/	O
1000	O
;	O
MBL	O
)	O
primaria	O
anticuerpos	B-GENE
.	O

Rábano	B-Taxon
picante	I-Taxon
peroxidasa	O
-	O
anti	O
conjugado	O
-	O
Conejo	B-Taxon
y	O
anti-	O
ratón	B-Taxon
inmunoglobulinas	B-GENE
(	O
1	O
/	O
5000	O
;	O
Célula	B-Cell
Señalización	O
)	O
se	O
utilizaron	O
para	O
detectar	O
anticuerpo	B-GENE
Unión	O
.	O

Nos	O
visualizamos	O
atados	O
anticuerpo	B-GENE
con	O
un	O
sistema	O
de	O
detección	O
de	O
transferencia	O
Western	O
ECL	O
(	O
Amersham	O
)	O
.	O

Derivación	O
de	O
ESG1	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
de	O
blastocistos	O

Esg1	B-Protein
+	B-Sequence
/	O
-	O
o	O
ESG1	B-Protein
-	O
/	O
-	O
mutante	B-Sequence
mujer	O
ratones	B-Taxon
fueron	O
inyectados	O
con	O
tamoxifeno	B-Chemical
(	O
10	O
mu	O
g	O
)	O
y	O
Depo-provera	O
(	O
1	O
mg	O
)	O
por	O
vía	O
subcutánea	O
al	O
tercer	O
día	O
de	O
embarazo	O
.	O

Cuatro	O
días	O
más	O
tarde	O
,	O
los	O
embriones	O
en	O
diapausa	O
se	O
eliminaron	O
del	O
útero	O
y	O
se	O
cultivaron	O
en	O
un	O
alimentador	O
STO	O
.	O
células	B-Cell
en	O
placas	O
de	O
cuatro	O
pocillos	O
en	O
medio	O
Eagle	O
modificado	O
de	O
Dulbecco	O
(	O
DMEM	O
)	O
complementado	O
con	O
20	O
%	O
de	O
Fetal	O
Bovino	B-Taxon
Suero	O
(	O
Hyclone	O
)	O
,	O
0	O
.	O
1	O
mM	O
no	O
esencial	O
Aminoácidos	B-Chemical
(	O
Invitrogen	O
)	O
,	O
2	O
mM	O
L	B-Chemical
-	I-Chemical
glutamina	I-Chemical
(	O
Invitrogen	O
)	O
,	O
50	O
U	O
/	O
ml	O
Penicilina	B-Chemical
-	O
estreptomisina	B-Chemical
(	O
Invitrogen	O
)	O
,	O
y	O
0	O
.	O
11	O
mm	O
2	B-Chemical
-	I-Chemical
mercaptoetanol	I-Chemical
(	O
Invitrogen	O
)	O
.	O

Después	O
de	O
seis	O
días	O
,	O
se	O
cosechó	O
la	O
masa	O
central	O
de	O
cada	O
explante	O
,	O
se	O
lavó	O
en	O
PBS	O
y	O
se	O
colocó	O
en	O
una	O
gota	O
de	O
tripsina	O
durante	O
unos	O
minutos	O
.	O

los	O
célula	B-Cell
la	O
masa	O
se	O
recogió	O
con	O
una	O
pipeta	O
Pasteur	O
finamente	O
estirada	O
y	O
precargada	O
con	O
medio	O
,	O
asegurando	O
un	O
arrastre	O
mínimo	O
de	O
la	O
tripsina	O
.	O

los	O
células	B-Cell
se	O
transfirieron	O
suavemente	O
a	O
un	O
pocillo	O
nuevo	O
con	O
medio	O
que	O
contenía	O
FBS	O
al	O
20	O
%	O
.	O

El	O
ES	O
primario	O
resultante	O
célula	B-Cell
las	O
colonias	O
se	O
pasaron	O
individualmente	O
a	O
pocillos	O
de	O
placas	O
de	O
cuatro	O
pocillos	O
que	O
contenían	O
alimentador	O
STO	O
célula	B-Cell
capas	O
.	O

Después	O
de	O
eso	O
,	O
células	B-Cell
se	O
expandieron	O
por	O
la	O
tripsinización	O
de	O
todo	O
el	O
cultivo	O
.	O

micromatrices	O

Total	O
ARN	B-Sequence
desde	O
tipo	B-Sequence
salvaje	I-Sequence
ES	O
células	B-Cell
y	O
ESG1	B-Protein
-	O
/	O
-	O
ES	O
células	B-Cell
se	O
marcó	O
con	O
Cy3	O
y	O
Cy5	O
,	O
respectivamente	O
.	O

Las	O
muestras	O
se	O
hibridaron	O
a	O
un	O
Ratón	B-Taxon
Desarrollo	O
Microarray	O
(	O
Algilent	O
)	O
según	O
protocolo	O
del	O
fabricante	O
.	O

Las	O
matrices	O
se	O
escanearon	O
con	O
un	O
sistema	O
de	O
escáner	O
de	O
micromatrices	O
G2565BA	O
(	O
Agilent	O
)	O
.	O

La	O
hibridación	O
se	O
repitió	O
con	O
dos	O
clones	O
independientes	O
.	O

Los	O
datos	O
se	O
analizaron	O
con	O
el	O
software	O
GeneSprings	O
(	O
Silico	O
Genetics	O
)	O
.	O

Contribuciones	O
de	O
los	O
autores	O

HA	O
llevó	O
a	O
cabo	O
los	O
estudios	O
fenotípicos	O
de	O
ESG1	B-Protein
knockear	O
ratones	B-Taxon
.	O

KI	O
determinó	O
el	O
localizaciones	B-Sequence
cromosómicas	I-Sequence
de	O
El	O
ESG1	B-Protein
gene	B-Sequence
y	O
pseudogenes	B-Sequence
y	O
construyó	O
la	O
orientación	O
vector	B-Sequence
.	O

TI	O
llevado	O
a	O
cabo	O
ratón	B-Taxon
manipulación	O
de	O
embriones	O
.	O

MM	O
y	O
MN	O
realizados	O
ES	O
célula	B-Cell
cultura	O
.	O

SY	O
concibe	O
el	O
estudio	O
,	O
y	O
participó	O
en	O
su	O
diseño	O
y	O
coordinación	O
y	O
ayudó	O
a	O
redactar	O
el	O
manuscrito	O
.	O

Todos	O
los	O
autores	O
leyeron	O
y	O
aprobaron	O
el	O
manuscrito	O
final	O
.	O

Agradecimientos	O

Agradecemos	O
a	O
Chihiro	O
Takigawa	O
,	O
Junko	O
Iida	O
,	O
Masako	O
Shirasaka	O
,	O
Yumi	O
Ohuchi	O
y	O
Megumi	O
Narita	O
por	O
su	O
asistencia	O
técnica	O
y	O
administrativa	O
.	O

Agradecemos	O
a	O
los	O
Dres	O
.	O

Minoru	O
Ko	O
y	O
Azim	O
Surani	O
por	O
compartir	O
datos	O
útiles	O
antes	O
de	O
la	O
publicación	O
,	O
Dr.	O
Hitoshi	O
Niwa	O
por	O
proporcionar	O
generosamente	O
varios	O
vectores	B-Sequence
,	O
y	O
la	O
Dra	O
.	O
Roberto	O
Farese	O
Jr.	O
por	O
su	O
amable	O
regalo	O
del	O
RF8	O
ES	O
células	B-Cell
.	O

Este	O
trabajo	O
fue	O
apoyado	O
en	O
parte	O
por	O
becas	O
de	O
investigación	O
del	O
Ministerio	O
de	O
Educación	O
,	O
Cultura	O
,	O
Deportes	O
,	O
Ciencia	O
y	O
Tecnología	O
de	O
Japón	O
,	O
la	O
Fundación	O
Uehara	O
Memorial	O
,	O
la	O
Fundación	O
Naito	O
,	O
la	O
Fundación	O
de	O
Investigación	O
Sumitomo	O
,	O
la	O
Fundación	O
Mitsubishi	O
.	O

S	O
.	O
Y	O
.	O
fue	O
apoyado	O
por	O
una	O
Beca	O
de	O
Ciencia	O
y	O
Tecnología	O
Toray	O
(	O
a	O
S	O
.	O
Y	O
.	O
)	O
.	O

Este	O
trabajo	O
también	O
fue	O
financiado	O
en	O
parte	O
por	O
una	O
subvención	O
de	O
ayuda	O
para	O
la	O
investigación	O
del	O
COE	O
(	O
Centro	O
de	O
Excelencia	O
)	O
del	O
siglo	O
XXI	O
del	O
Ministerio	O
de	O
Educación	O
,	O
Cultura	O
,	O
Deportes	O
,	O
Ciencia	O
y	O
Tecnología	O
.	O

Identificacion	O
de	O
colágeno	B-Protein
#	O
¿NOMBRE	O
?	O
lugares	B-Sequence
en	O
hembra	O
multípara	O
de	O
edad	O
ratones	B-Taxon

Resumen	O

Colágeno	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
es	O
uno	O
de	O
los	O
modelos	O
experimentales	O
autoinmunes	O
más	O
utilizados	O
,	O
con	O
muchas	O
similitudes	O
con	O
la	O
artritis	O
reumatoide	O
.	O

Ya	O
que	O
colágeno	B-Protein
#	O
¿NOMBRE	O
?	O
genes	B-Sequence
.	O

Debido	O
a	O
que	O
la	O
artritis	O
reumatoide	O
afecta	O
particularmente	O
a	O
las	O
mujeres	O
de	O
edad	O
avanzada	O
,	O
en	O
el	O
presente	O
estudio	O
hemos	O
identificado	O
nuevos	O
regiones	B-Sequence
geneticas	I-Sequence
crítico	O
para	O
colágeno	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
de	O
un	O
cruce	O
entre	O
NFR/N	O
y	O
B10	O
.	O
Q	O
(	O
H	O
-	O
2q	O
haplotipo	B-Sequence
)	O
.	O

los	O
ratones	B-Taxon
en	O
el	O
presente	O
estudio	O
tenían	O
diferentes	O
historias	O
reproductivas	O
,	O
lo	O
que	O
no	O
afectó	O
significativamente	O
la	O
aparición	O
,	O
incidencia	O
o	O
severidad	O
de	O
la	O
enfermedad	O
.	O

Un	O
total	O
de	O
200	O
mujeres	O
.	O
ratones	B-Taxon
fueron	O
utilizados	O
en	O
total	O
genoma	B-Sequence
-	O
pantalla	O
ancha	O
con	O
125	O
marcadores	B-Sequence
de	I-Sequence
microsatélites	I-Sequence
.	O

Encontramos	O
un	O
nuevo	O
significativo	O
locus	B-Sequence
de	I-Sequence
rasgo	I-Sequence
cuantitativo	I-Sequence
afectando	O
la	O
incidencia	O
de	O
la	O
artritis	O
,	O
la	O
gravedad	O
y	O
el	O
día	O
de	O
inicio	O
en	O
cromosoma	B-GENE
11	O
(	O
denotado	O
cia40	B-Protein
)	O
,	O
que	O
colocaliza	O
con	O
un	O
lugar	B-Sequence
controlar	O
el	O
fracaso	O
del	O
embarazo	O
.	O

Además	O
,	O
un	O
locus	B-Sequence
de	I-Sequence
rasgo	I-Sequence
cuantitativo	I-Sequence
de	O
significado	O
sugestivo	O
asociado	O
con	O
la	O
incidencia	O
,	O
la	O
gravedad	O
y	O
el	O
día	O
de	O
inicio	O
se	O
identificó	O
en	O
cromosoma	B-GENE
1	O
.	O

Finalmente	O
,	O
un	O
sugerente	O
significado	O
locus	B-Sequence
de	I-Sequence
rasgo	I-Sequence
cuantitativo	I-Sequence
asociado	O
con	O
colágeno	B-Protein
tipo	I-Protein
II	I-Protein
anticuerpo	B-GENE
los	O
títulos	O
se	O
identificaron	O
en	O
cromosoma	B-GENE
13	O

Este	O
estudio	O
indica	O
que	O
varios	O
locus	B-Sequence
de	I-Sequence
genes	I-Sequence
controlar	O
la	O
artritis	O
en	O
hembras	O
multíparas	O
de	O
edad	O
avanzada	O
,	O
y	O
que	O
al	O
menos	O
uno	O
de	O
estos	O
lugares	B-Sequence
Coincide	O
con	O
el	O
fracaso	O
del	O
embarazo	O
.	O

Introducción	O

Las	O
similitudes	O
entre	O
la	O
artritis	O
reumatoide	O
(	O
AR	O
)	O
en	O
hombre	B-Taxon
y	O
colágeno	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
están	O
bien	O
establecidos	O
,	O
aunque	O
existen	O
diferencias	O
en	O
el	O
patrón	O
de	O
la	O
enfermedad	O
[	O
1-3	O
]	O
.	O

La	O
característica	O
de	O
la	O
AR	O
es	O
el	O
hecho	O
de	O
que	O
las	O
mujeres	O
en	O
edad	O
reproductiva	O
son	O
más	O
susceptibles	O
a	O
la	O
enfermedad	O
que	O
los	O
hombres	O
[	O
4	O
]	O
.	O

También	O
se	O
ha	O
informado	O
que	O
el	O
75	O
%	O
de	O
las	O
pacientes	O
femeninas	O
(	O
23	O
de	O
31	O
mujeres	O
)	O
con	O
AR	O
presentan	O
remisión	O
clínica	O
durante	O
el	O
curso	O
del	O
embarazo	O
[	O
5	O
]	O
.	O

Por	O
otro	O
lado	O
,	O
se	O
ha	O
sugerido	O
que	O
el	O
inicio	O
de	O
la	O
AR	O
se	O
pospone	O
por	O
la	O
paridad	O
.	O

El	O
riesgo	O
de	O
aparición	O
se	O
reduce	O
durante	O
el	O
embarazo	O
,	O
mientras	O
que	O
en	O
el	O
primer	O
año	O
posparto	O
aumenta	O
la	O
posibilidad	O
de	O
aparición	O
[	O
6	O
,	O
7	O
]	O
.	O

Sin	O
embargo	O
,	O
los	O
resultados	O
de	O
un	O
estudio	O
reciente	O
de	O
la	O
AR	O
en	O
mujeres	O
indican	O
que	O
los	O
antecedentes	O
de	O
embarazo	O
no	O
aumentan	O
la	O
incidencia	O
de	O
la	O
enfermedad	O
más	O
adelante	O
en	O
la	O
vida	O
[	O
8	O
]	O
.	O

Adecuado	O
animal	B-Taxon
Los	O
modelos	O
son	O
herramientas	O
útiles	O
para	O
la	O
identificación	O
de	O
genes	B-Sequence
involucrado	O
en	O
complejo	O
humano	B-Taxon
enfermedades	O

CIA	O
en	O
ratones	B-Taxon
comparte	O
características	O
tanto	O
inmunológicas	O
como	O
patológicas	O
con	O
humano	B-Taxon
RA	O
y	O
es	O
uno	O
de	O
los	O
modelos	O
más	O
utilizados	O
para	O
la	O
identificación	O
de	O
genes	B-Sequence
y	O
mecanismos	O
implicados	O
en	O
la	O
artritis	O
.	O

La	O
incidencia	O
de	O
la	O
CIA	O
depende	O
del	O
sexo	O
,	O
al	O
igual	O
que	O
la	O
incidencia	O
de	O
la	O
AR	O
,	O
aunque	O
diferentes	O
especies	O
y	O
diferentes	O
variantes	O
de	O
la	O
enfermedad	O
podrían	O
conducir	O
a	O
un	O
predominio	O
tanto	O
masculino	O
como	O
femenino	O
.	O

Masculino	O
ratones	B-Taxon
se	O
ven	O
más	O
afectados	O
que	O
las	O
mujeres	O
.	O

Las	O
diferencias	O
de	O
género	O
en	O
la	O
susceptibilidad	O
a	O
la	O
CIA	O
dependen	O
de	O
muchos	O
factores	O
,	O
que	O
incluyen	O
genético	B-Sequence
,	O
influencias	O
hormonales	O
y	O
conductuales	O
[	O
9	O
]	O
.	O

Sin	O
embargo	O
,	O
los	O
factores	O
aislados	O
son	O
notablemente	O
consistentes	O
entre	O
la	O
AR	O
y	O
los	O
diferentes	O
animal	B-Taxon
modelos	O
[	O
3	O
,	O
9	O
]	O
.	O

Embarazo	O
en	O
ratones	B-Taxon
,	O
al	O
igual	O
que	O
el	O
embarazo	O
en	O
las	O
mujeres	O
,	O
normalmente	O
provoca	O
la	O
remisión	O
de	O
la	O
artritis	O
[	O
5	O
,	O
10	O
]	O
,	O
mientras	O
que	O
la	O
exacerbación	O
a	O
menudo	O
ocurre	O
después	O
del	O
parto	O
[	O
7	O
,	O
10	O
,	O
11	O
]	O
.	O

Embarazo	O
-	O
remisión	O
inducida	O
de	O
CIA	O
en	O
ratones	B-Taxon
parece	O
deberse	O
al	O
aumento	O
de	O
los	O
niveles	O
de	O
estrógeno	O
,	O
mientras	O
que	O
la	O
exacerbación	O
posparto	O
puede	O
explicarse	O
por	O
la	O
drástica	O
caída	O
de	O
los	O
estrógenos	O
[	O
10	O
]	O
,	O
posiblemente	O
junto	O
con	O
un	O
aumento	O
prolactina	B-Protein
niveles	O
[	O
11	O
]	O
.	O

En	O
qué	O
medida	O
la	O
historia	O
del	O
embarazo	O
(	O
paridad	O
)	O
afecta	O
la	O
incidencia	O
de	O
CIA	O
más	O
adelante	O
en	O
la	O
vida	O
,	O
hasta	O
donde	O
sabemos	O
,	O
no	O
se	O
ha	O
estudiado	O
previamente	O
.	O

Es	O
importante	O
destacar	O
que	O
la	O
AR	O
ocurre	O
predominantemente	O
en	O
mujeres	O
,	O
muchas	O
de	O
las	O
cuales	O
han	O
tenido	O
varios	O
hijos	O
y	O
,	O
por	O
lo	O
tanto	O
,	O
es	O
apropiado	O
imitar	O
también	O
esta	O
situación	O
usando	O
animal	B-Taxon
modelos	O

En	O
el	O
presente	O
trabajo	O
hemos	O
analizado	O
a	O
las	O
mujeres	O
ratones	B-Taxon
que	O
previamente	O
se	O
había	O
sometido	O
a	O
un	O
estudio	O
reproductivo	O
(	O
Liljander	O
M	O
,	O
S	O
a	O
llstr	O
om	O
MA	O
,	O
Andersson	O
S	O
,	O
Wernhoff	O
P	O
,	O
Andersson	O
A	O
,	O
Holmdahl	O
R	O
,	O
Mattsson	O
R	O
,	O
datos	O
no	O
publicados	O
)	O
.	O

Un	O
total	O
de	O
200	O
mujeres	O
.	O
ratones	B-Taxon
(	O
diez	O
meses	O
de	O
edad	O
)	O
del	O
retrocruzamiento	O
N2	O
entre	O
NFR/N	O
y	O
C57BL/B10	O
.	O
Q	O
(	O
B10	O
.	O
Q	O
)	O
se	O
utilizaron	O
para	O
analizar	O
la	O
genético	B-Sequence
control	O
de	O
la	O
CIA	O
en	O
hembras	O
ancianas	O
con	O
antecedentes	O
de	O
multíparas	O
.	O

Materiales	O
y	O
métodos	O

Ratones	B-Taxon

NFR	O
consanguíneo	O
/	O
N	O
ratones	B-Taxon
se	O
obtuvieron	O
originalmente	O
del	O
Instituto	O
Nacional	O
de	O
Salud	O
(	O
Bethesda	O
,	O
MD	O
,	O
EUA	O
)	O
y	O
el	O
B10	O
.	O
q	O
ratones	B-Taxon
se	O
compraron	O
originalmente	O
en	O
The	O
Jackson	O
Laboratory	O
(	O
Bar	O
Harbor	O
,	O
ME	O
,	O
EE	O
.	O
UU	O
.	O
)	O
.	O

(	O
B10Q	O
x	O
NFR/N	O
)	O
híbridos	O
F1	O
y	O
(	O
B10	O
.	O
Q	O
x	O
NFR/N	O
)	O
x	O
B10	O
.	O
Q	O
N2	O
ratones	B-Taxon
fueron	O
criados	O
en	O
jaulas	O
individuales	O
ventiladas	O
en	O
la	O
Barrera	O
BMC	O
animal	B-Taxon
establecimiento	O
y	O
en	O
el	O
animal	B-Taxon
casa	O
del	O
Departamento	O
de	O
Patología	O
,	O
Universidad	O
de	O
Lund	O
,	O
Suecia	O
.	O

los	O
animales	B-Taxon
fueron	O
alimentados	O
ad	O
libitum	O
con	O
estándar	O
roedor	B-Taxon
perro	B-Chemical
chino	I-Chemical
(	O
LABORATORIO	O
PARA	O
R36	O
,	O
cultivo	O
irradiado	O
comida	B-Chemical
por	O
ratas	B-Taxon
y	O
ratones	B-Taxon
;	O
Lactamin	O
AB	O
,	O
Estocolmo	O
,	O
Suecia	O
)	O
y	O
agua	B-Chemical
en	O
un	O
fotoperíodo	O
de	O
12	O
horas	O
:	O
12	O
horas	O
luz	O
:	O
oscuridad	O
.	O

los	O
ratones	B-Taxon
utilizados	O
en	O
el	O
presente	O
estudio	O
tenían	O
protocolos	O
de	O
monitoreo	O
de	O
salud	O
limpios	O
de	O
acuerdo	O
con	O
la	O
Federación	O
Europea	O
de	O
Laboratorios	O
Animal	B-Taxon
Recomendaciones	O
de	O
la	O
Asociación	O
de	O
Ciencias	O
.	O

Los	O
permisos	O
éticos	O
fueron	O
M125-04	O
(	O
transferencia	O
de	O
embriones	O
)	O
y	O
M290-03	O
(	O
reproducción	O
y	O
artritis	O
)	O
.	O

Diseño	O
experimental	O

Un	O
total	O
de	O
200	O
mujeres	O
.	O
ratones	B-Taxon
(	O
aproximadamente	O
diez	O
meses	O
de	O
edad	O
)	O
de	O
retrocruzamiento	O
N2	O
(	O
B10	O
.	O
Q	O
x	O
NFR/N	O
)	O
x	O
B10	O
.	O
Se	O
utilizaron	O
Q	O
.	O

los	O
ratones	B-Taxon
anteriormente	O
se	O
había	O
sometido	O
a	O
un	O
estudio	O
reproductivo	O
en	O
el	O
que	O
cada	O
animal	B-Taxon
Tuvo	O
cuatro	O
oportunidades	O
de	O
apareamiento	O
.	O

Primero	O
,	O
la	O
hembra	O
ratones	B-Taxon
se	O
les	O
permitió	O
aparearse	O
dos	O
veces	O
con	O
B10	O
.	O
Machos	O
RIII	O
(	O
apareamiento	O
alogénico	O
mediante	O
CMH	B-GENE
(	O
complejo	B-GENE
mayor	I-GENE
de	I-GENE
histocompatibilidad	I-GENE
)	O
y	O
finalmente	O
aparearse	O
dos	O
veces	O
con	O
B10	O
.	O
Q	O
machos	O
(	O
apareamiento	O
singénico	O
por	O
medio	O
de	O
CMH	B-GENE
)	O
.	O

Tras	O
cuatro	O
posibles	O
embarazos	O
se	O
indujo	O
CIA	O
a	O
la	O
hembra	O
ratones	B-Taxon
.	O

Inducción	O
y	O
evaluación	O
de	O
CIA	O

Para	O
inducir	O
a	O
la	O
CIA	O
,	O
la	O
ratones	B-Taxon
fueron	O
inmunizados	O
por	O
vía	O
subcutánea	O
en	O
la	O
base	O
de	O
la	O
cola	O
con	O
100	O
µg	O
colágeno	B-Protein
de	I-Protein
rata	I-Protein
tipo	I-Protein
II	I-Protein
(	O
ICI	B-Protein
)	O
emulsionado	O
en	O
0	O
.	O
1M	O
ácido	B-Chemical
acético	I-Chemical
combinado	O
con	O
una	O
cantidad	O
igual	O
de	O
adyuvante	O
completo	O
de	O
Freud	O
(	O
Laboratorios	O
Difco	O
,	O
Detroit	O
,	O
MI	O
,	O
EE	O
.	O
UU	O
.	O
)	O
.	O

Una	O
inyección	O
de	O
refuerzo	O
que	O
contiene	O
50	O
mu	O
g	O
ICI	B-Protein
emulsionado	O
en	O
0	O
.	O
1M	O
ácido	B-Chemical
acético	I-Chemical
combinado	O
con	O
una	O
cantidad	O
igual	O
de	O
adyuvante	O
incompleto	O
de	O
Freud	O
(	O
Laboratorios	O
Difco	O
)	O
se	O
administró	O
después	O
de	O
30	O
días	O
.	O

La	O
puntuación	O
clínica	O
de	O
la	O
artritis	O
comenzó	O
25	O
días	O
después	O
de	O
la	O
primera	O
inmunización	O
.	O

animales	B-Taxon
fueron	O
examinados	O
para	O
signos	O
clínicos	O
de	O
CIA	O
tres	O
veces	O
por	O
semana	O
y	O
fueron	O
calificados	O
en	O
una	O
escala	O
de	O
12	O
puntos	O
.	O

El	O
índice	O
de	O
artritis	O
se	O
asignó	O
a	O
cada	O
ratón	B-Taxon
usando	O
los	O
siguientes	O
criterios	O
:	O
0	O
=	O
ningún	O
signo	O
visible	O
de	O
artritis	O
,	O
1	O
=	O
enrojecimiento	O
e	O
hinchazón	O
en	O
una	O
sola	O
articulación	O
,	O
2	O
=	O
inflamación	O
en	O
múltiples	O
articulaciones	O
,	O
y	O
3	O
=	O
inflamación	O
severa	O
en	O
toda	O
la	O
pata	O
y/o	O
el	O
hueso	O
del	O
tobillo	O
.	O

Cada	O
pata	O
recibió	O
puntuaciones	O
de	O
0	O
a	O
3	O
,	O
siendo	O
el	O
índice	O
la	O
suma	O
de	O
las	O
cuatro	O
patas	O
.	O

El	O
rasgo	O
de	O
severidad	O
es	O
la	O
puntuación	O
máxima	O
observada	O
en	O
cada	O
hembra	O
individual	O
.	O

El	O
inicio	O
es	O
el	O
número	O
de	O
días	O
calculados	O
desde	O
la	O
primera	O
inmunización	O
hasta	O
los	O
primeros	O
signos	O
clínicos	O
de	O
artritis	O
,	O
excluyendo	O
a	O
los	O
no	O
afectados	O
.	O
animales	B-Taxon
.	O

microsatélite	B-Sequence
genotipificación	O
y	O
análisis	O
de	O
ligamiento	O

Se	O
recogieron	O
biopsias	O
de	O
cola	O
de	O
todas	O
las	O
hembras	O
N2	O
y	O
de	O
la	O
generación	O
F0	O
.	O

ADN	B-Sequence
fue	O
aislado	O
de	O
acuerdo	O
con	O
un	O
protocolo	O
descrito	O
previamente	O
[	O
12	O
]	O
.	O

Después	O
de	O
la	O
evaluación	O
de	O
los	O
padres	O
ADN	B-Sequence
con	O
aproximadamente	O
450	O
ratón	B-Taxon
fluorescencia	B-Chemical
-	I-Chemical
marcado	I-Chemical
marcadores	B-Sequence
de	I-Sequence
microsatélites	I-Sequence
(	O
INTERACTIVA	O
,	O
Ulm	O
,	O
Alemania	O
)	O
,	O
se	O
seleccionaron	O
125	O
marcadores	O
informativos	O
que	O
cubrían	O
la	O
genoma	B-Sequence
.	O

doscientos	O
treinta	O
y	O
siete	O
N2	O
ratones	B-Taxon
fueron	O
genotipados	O
con	O
marcadores	O
que	O
cubrían	O
todos	O
cromosomas	B-GENE
excepto	O
por	O
el	O
cromosoma	B-GENE
Y	I-GENE
.	O

La	O
amplificación	O
por	O
PCR	O
para	O
los	O
marcadores	O
se	O
realizó	O
en	O
un	O
volumen	O
final	O
de	O
10	O
µl	O
en	O
una	O
placa	O
de	O
microtitulación	O
con	O
fondo	O
en	O
V	O
de	O
96	O
pocillos	O
usando	O
20	O
ng	O
ADN	B-Sequence
,	O
10	O
mm	O
KCl	B-Chemical
,	O
20	O
mm	O
tris	B-Chemical
-	O
HCl	B-Chemical
,	O
10	O
mm	O
(	O
NH4	B-Chemical
)	O
2SO4	O
,	O
2	O
mM	O
MgCl2	B-Chemical
,	O
0	O
.	O
1	O
%	O
Tritón	O
X	O
-	O
100	O
,	O
pH	O
8	O
.	O
8	O
(	O
New	O
England	O
BioLabs	O
Inc	O
.	O
,	O
Ipswich	O
,	O
MA	O
,	O
EE	O
.	O
UU	O
.	O
)	O
,	O
3	O
mu	O
M	O
(	O
10	O
pmol	O
)	O
cada	O
uno	O
cebador	B-Sequence
,	O
2	O
mm	O
dNTP	B-Chemical
(	O
Advanced	O
Biotechnologies	O
,	O
Epsom	O
,	O
Surrey	O
,	O
Reino	O
Unido	O
)	O
y	O
0	O
.	O
25U	O
Taq	B-Taxon
ADN	B-Sequence
Polimerasa	O
(	O
New	O
England	O
BioLabs	O
Inc.	O
)	O
.	O

El	O
siguiente	O
programa	O
se	O
usó	O
para	O
amplificar	O
el	O
ADN	B-Sequence
desnaturalización	O
a	O
95	O
grados	O
C	O
por	O
3	O
minutos	O
,	O
recocido	O
a	O
56	O
grados	O
C	O
por	O
45	O
segundos	O
,	O
polimerización	O
a	O
72	O
grados	O
C	O
por	O
1	O
minuto	O
,	O
30	O
ciclos	O
de	O
95	O
grados	O
C	O
por	O
30	O
segundos	O
,	O
56	O
grados	O
C	O
por	O
45	O
segundos	O
y	O
72	O
grados	O
C	O
por	O
1	O
minuto	O
,	O
y	O
un	O
paso	O
final	O
de	O
extensión	O
de	O
7	O
minutos	O
a	O
72	O
grados	O
C	O
.	O

los	O
productos	B-Sequence
PCR	I-Sequence
se	O
analizaron	O
en	O
un	O
MegaBACE	O
(	O
TM	O
)	O
1000	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
Inc	O
Piscataway	O
,	O
NJ	O
,	O
EE	O
.	O
UU	O
.	O
)	O
de	O
acuerdo	O
con	O
el	O
protocolo	O
del	O
fabricante	O
.	O

Los	O
datos	O
se	O
analizaron	O
con	O
Genético	B-Sequence
perfilador	O
1	O
.	O
1	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
Inc	O
)	O
.	O

Mapa	B-Sequence
Se	O
utilizó	O
el	O
software	O
gratuito	O
Manager	O
QTXb20	O
[	O
13	O
]	O
para	O
realizar	O
el	O
análisis	O
de	O
ligamiento	O
y	O
la	O
prueba	O
de	O
permutación	O
.	O

El	O
noventa	O
por	O
ciento	O
de	O
los	O
ratón	B-Taxon
genoma	B-Sequence
estaba	O
dentro	O
de	O
una	O
distancia	O
entre	O
marcadores	O
de	O
20	O
cm	O
.	O

El	O
marcador	O
mapa	B-Sequence
se	O
generó	O
utilizando	O
la	O
función	O
de	O
mapa	O
de	O
Kosambis	O
y	O
se	O
realizaron	O
1.000	O
permutaciones	O
para	O
cada	O
fenotipo	O
(	O
P	O
<	O
0,05	O
)	O
.	O

Las	O
pruebas	O
de	O
permutación	O
se	O
llevaron	O
a	O
cabo	O
para	O
establecer	O
umbrales	O
de	O
significancia	O
empírica	O
para	O
las	O
interacciones	O
.	O

Un	O
umbral	O
igual	O
o	O
superior	O
al	O
percentil	O
37	O
(	O
P	O
=	O
0,63	O
)	O
se	O
consideró	O
significativamente	O
significativo	O
,	O
y	O
el	O
nivel	O
para	O
el	O
umbral	O
significativo	O
se	O
fijó	O
en	O
el	O
percentil	O
95	O
(	O
P	O
=	O
0,05	O
)	O
.	O

Intervalo	B-Sequence
el	O
mapeo	O
se	O
realizó	O
con	O
un	O
aumento	O
de	O
2	O
cM	O
bajo	O
el	O
modelo	O
de	O
regresión	O
aditiva	O
para	O
calcular	O
las	O
estadísticas	O
de	O
prueba	O
.	O

Enzima	B-Sequence
#	O
¿NOMBRE	O
?	O

la	O
hembra	O
adulta	O
ratones	B-Taxon
se	O
sacrificaron	O
a	O
los	O
15	O
meses	O
de	O
edad	O
y	O
se	O
recogieron	O
los	O
sueros	O
.	O

Anti	O
-	O
ICI	B-Protein
anticuerpo	B-GENE
títulos	O
en	O
sueros	O
fueron	O
analizados	O
por	O
una	O
técnica	O
de	O
sándwich	O
ELISA	O
[	O
14	O
]	O
.	O

En	O
breve	O
,	O
ICI	B-Protein
(	O
10	O
µg/ml	O
)	O
se	O
acopló	O
a	O
placas	O
inmunoabsorbentes	O
durante	O
la	O
noche	O
a	O
4	O
grados	O
C	O
.	O

Albúmina	B-Protein
de	I-Protein
suero	I-Protein
bovino	I-Protein
(	O
Sigma	O
Chemical	O
St	O
Louis	O
,	O
MO	O
,	O
EE	O
.	O
UU	O
.	O
)	O
para	O
el	O
bloqueo	O
,	O
y	O
luego	O
diferentes	O
diluciones	O
de	O
sueros	O
de	O
control	O
(	O
sueros	O
purificados	O
ratón	B-Taxon
anti	O
-	O
ICI	B-Protein
anticuerpos	B-GENE
)	O
,	O
se	O
añadieron	O
sueros	O
de	O
prueba	O
y	O
controles	O
positivos	O
y	O
negativos	O
.	O

La	O
presencia	O
de	O
ICI	B-Protein
#	O
¿NOMBRE	O
?	O
IgG	B-GENE
se	O
visualizó	O
por	O
medio	O
de	O
peroxidasa	O
-	O
conjugada	O
cabra	B-Taxon
anti-ratón	O
IgG	B-GENE
.	O

análisis	O
estadístico	O

La	O
comparación	O
estadística	O
entre	O
los	O
diferentes	O
grupos	O
experimentales	O
se	O
realizó	O
mediante	O
la	O
prueba	O
de	O
la	O
U	O
de	O
Mann-Whitney	O
o	O
la	O
prueba	O
de	O
la	O
t	O
de	O
Student	O
para	O
datos	O
no	O
apareados	O
.	O

Resultados	O

NFR/N	O
hembra	O
ratones	B-Taxon
muestran	O
un	O
inicio	O
tardío	O
y	O
una	O
menor	O
incidencia	O
de	O
CIA	O
en	O
comparación	O
con	O
B10	O
.	O
Q	O
hembras	O

El	O
inicio	O
de	O
la	O
enfermedad	O
se	O
retrasó	O
significativamente	O
en	O
NFR	O
/	O
N	O
ratones	B-Taxon
,	O
lo	O
que	O
se	O
tradujo	O
en	O
una	O
menor	O
incidencia	O
en	O
la	O
fase	O
inicial	O
de	O
la	O
enfermedad	O
(	O
Tabla	O
1	O
y	O
Figura	O
1	O
)	O
.	O

La	O
apariencia	O
de	O
la	O
artritis	O
fue	O
ligeramente	O
diferente	O
entre	O
las	O
dos	O
cepas	O
,	O
NFR/N	O
ratones	B-Taxon
mostrando	O
una	O
mayor	O
frecuencia	O
de	O
hinchazón	O
de	O
toda	O
la	O
pata	O
que	O
B10	O
.	O
q	O
ratones	B-Taxon
.	O

Más	O
adelante	O
en	O
el	O
curso	O
de	O
la	O
enfermedad	O
,	O
las	O
diferencias	O
en	O
la	O
frecuencia	O
y	O
gravedad	O
de	O
la	O
CIA	O
entre	O
las	O
cepas	O
fueron	O
menos	O
obvias	O
.	O

Sin	O
embargo	O
,	O
el	O
anti-	O
ICI	B-Protein
los	O
títulos	O
100	O
días	O
después	O
de	O
la	O
inmunización	O
primaria	O
(	O
y	O
70	O
días	O
después	O
del	O
refuerzo	O
)	O
diferían	O
significativamente	O
entre	O
NFR/N	O
y	O
B10	O
.	O
mujer	O
q	O
ratones	B-Taxon
(	O
ver	O
Tabla	O
1	O
)	O
.	O

El	O
historial	O
de	O
embarazo	O
no	O
afecta	O
significativamente	O
la	O
incidencia	O
o	O
la	O
gravedad	O
de	O
la	O
CIA	O
en	O
mujeres	O
ratones	B-Taxon
de	O
mixto	O
genético	B-Sequence
antecedentes	O

La	O
Tabla	O
2	O
presenta	O
los	O
resultados	O
de	O
la	O
incidencia	O
artrítica	O
,	O
el	O
inicio	O
de	O
la	O
artritis	O
y	O
la	O
puntuación	O
artrítica	O
máxima	O
para	O
las	O
mujeres	O
.	O
ratones	B-Taxon
de	O
la	O
generación	O
N2	O
,	O
(	O
NFR/N	O
x	O
B10	O
.	O
Q	O
)	O
x	O
B10	O
.	O
Q	O
,	O
agrupados	O
según	O
el	O
número	O
de	O
embarazos	O
que	O
habían	O
tenido	O
antes	O
de	O
la	O
inmunización	O
con	O
ICI	B-Protein
.	O

No	O
hubo	O
diferencia	O
significativa	O
en	O
la	O
incidencia	O
o	O
severidad	O
de	O
la	O
artritis	O
dependiendo	O
del	O
número	O
de	O
embarazos	O
que	O
habían	O
pasado	O
antes	O
de	O
la	O
inducción	O
de	O
la	O
enfermedad	O
.	O

Observamos	O
una	O
tendencia	O
hacia	O
una	O
menor	O
severidad	O
en	O
multíparas	O
.	O
ratones	B-Taxon
comparado	O
con	O
ratones	B-Taxon
con	O
antecedentes	O
de	O
cero	O
a	O
dos	O
embarazos	O
.	O

El	O
inicio	O
de	O
las	O
enfermedades	O
,	O
sin	O
embargo	O
,	O
fue	O
más	O
temprano	O
en	O
ratones	B-Taxon
que	O
había	O
pasado	O
más	O
de	O
un	O
embarazo	O
.	O

No	O
hubo	O
diferencia	O
en	O
el	O
desarrollo	O
de	O
la	O
enfermedad	O
entre	O
mujeres	O
ratones	B-Taxon
que	O
solo	O
han	O
estado	O
embarazadas	O
CMH	B-GENE
machos	O
no	O
coincidentes	O
(	O
B10	O
.	O
RIII	O
)	O
y	O
hembras	O
ratones	B-Taxon
que	O
solo	O
han	O
estado	O
embarazadas	O
CMH	B-GENE
machos	O
emparejados	O
(	O
B10	O
.	O
Q	O
)	O
.	O

Nuevo	O
lugares	B-Sequence
asociado	O
con	O
la	O
CIA	O
en	O
anciana	O
identificada	O
ratones	B-Taxon

los	O
genético	B-Sequence
El	O
análisis	O
de	O
vinculación	O
reveló	O
una	O
importante	O
locus	B-Sequence
de	I-Sequence
rasgo	I-Sequence
cuantitativo	I-Sequence
(	O
QTL	B-Sequence
)	O
ubicado	O
a	O
64	O
-	O
70	O
cm	O
en	O
cromosoma	B-GENE
11	O
(	O
Tabla	O
3	O
y	O
Figura	O
2	O
)	O
.	O

Esta	O
lugar	B-Sequence
(	O
denotado	O
cia40	B-Protein
)	O
dieron	O
puntajes	O
LOD	O
significativos	O
para	O
la	O
incidencia	O
de	O
los	O
rasgos	O
(	O
LOD	O
=	O
4.1	O
)	O
y	O
'	O
día	O
de	O
inicio	O
'	O
(	O
LOD	O
=	O
4.0	O
)	O
,	O
y	O
un	O
puntaje	O
LOD	O
sugerente	O
para	O
el	O
rasgo	O
'	O
puntaje	O
de	O
artritis	O
'	O
(	O
LOD	O
=	O
3.3	O
)	O
.	O

Otro	O
QTL	B-Sequence
de	O
importancia	O
sugestiva	O
para	O
la	O
incidencia	O
de	O
la	O
enfermedad	O
se	O
identificó	O
alrededor	O
de	O
27	O
cM	O
en	O
cromosoma	B-GENE
1	O
(	O
Figura	O
2	O
)	O
.	O

Finalmente	O
,	O
una	O
sugerente	O
QTL	B-Sequence
por	O
el	O
rasgo	O
anti-	O
ICI	B-Protein
anticuerpo	B-GENE
se	O
identificó	O
el	O
título	O
en	O
cromosoma	B-GENE
13	O
(	O
Figura	O
2	O
)	O
.	O

Discusión	O

Aunque	O
lleva	O
la	O
misma	O
CIA	O
-	O
susceptible	O
CMH	B-GENE
región	B-Sequence
,	O
el	O
NFR	O
/	O
N	O
y	O
B10	O
.	O
q	O
ratones	B-Taxon
son	O
diferentes	O
en	O
varios	O
aspectos	O
.	O

El	O
NFR/N	O
ratón	B-Taxon
,	O
que	O
es	O
un	O
NMRI	O
endogámico	O
ratón	B-Taxon
de	O
la	O
H	O
-	O
2q	O
haplotipo	B-Sequence
,	O
es	O
de	O
mayor	O
tamaño	O
que	O
el	O
B10	O
.	O
q	O
ratón	B-Taxon
y	O
también	O
es	O
conocida	O
por	O
sus	O
extraordinarias	O
propiedades	O
de	O
reproducción	O
.	O

los	O
ratones	B-Taxon
utilizado	O
en	O
el	O
presente	O
estudio	O
,	O
(	O
NFR/N	O
x	O
B10	O
.	O
Q	O
)	O
x	O
B10	O
.	O
Q	O
hembras	O
,	O
primero	O
se	O
sometieron	O
a	O
un	O
genético	B-Sequence
estudio	O
de	O
la	O
reproducción	O
,	O
en	O
el	O
que	O
una	O
serie	O
de	O
lugares	B-Sequence
asociados	O
con	O
el	O
desempeño	O
reproductivo	O
(	O
Liljander	O
M	O
,	O
S	O
a	O
llstr	O
om	O
MA	O
,	O
Andersson	O
S	O
,	O
Wernhoff	O
P	O
,	O
Andersson	O
A	O
,	O
Holmdahl	O
R	O
,	O
Mattsson	O
R	O
;	O
datos	O
no	O
publicados	O
)	O
.	O

Dado	O
que	O
las	O
cepas	O
parentales	O
difieren	O
en	O
susceptibilidad	O
a	O
la	O
CIA	O
,	O
a	O
pesar	O
de	O
que	O
ambas	O
tienen	O
la	O
MHC	B-Protein
clase	I-Protein
II	I-Protein
A	I-Protein
beta	I-Protein
genes	B-Sequence
[	O
15	O
]	O
,	O
queríamos	O
probar	O
la	O
susceptibilidad	O
a	O
la	O
enfermedad	O
inflamatoria	O
en	O
ratones	B-Taxon
de	O
esta	O
cruz	O
.	O

De	O
hecho	O
,	O
esta	O
situación	O
brindó	O
la	O
oportunidad	O
de	O
estudiar	O
la	O
genético	B-Sequence
control	O
de	O
la	O
artritis	O
en	O
hembras	O
multíparas	O
de	O
edad	O
avanzada	O
,	O
situación	O
común	O
en	O
humano	B-Taxon
RA	O

Esta	O
susceptibilidad	O
fue	O
importante	O
para	O
investigar	O
por	O
varias	O
razones	O
.	O

El	O
hecho	O
de	O
que	O
el	O
ratones	B-Taxon
diferían	O
en	O
su	O
historia	O
reproductiva	O
permitió	O
analizar	O
si	O
esto	O
afectaría	O
significativamente	O
la	O
incidencia	O
o	O
severidad	O
de	O
la	O
CIA	O
.	O

En	O
segundo	O
lugar	O
,	O
casi	O
todos	O
los	O
análisis	O
de	O
vinculación	O
realizados	O
para	O
la	O
detección	O
de	O
CIA	O
asociados	O
lugares	B-Sequence
en	O
ratones	B-Taxon
se	O
han	O
realizado	O
con	O
hombres	O
ratones	B-Taxon
.	O

Otra	O
razón	O
es	O
que	O
el	O
uso	O
de	O
multíparas	O
viejas	O
ratones	B-Taxon
imitaba	O
la	O
situación	O
de	O
la	O
AR	O
(	O
las	O
mujeres	O
mayores	O
son	O
el	O
principal	O
grupo	O
de	O
riesgo	O
)	O
.	O

Por	O
último	O
,	O
la	O
cepa	O
NFR	O
/	O
N	O
no	O
se	O
había	O
utilizado	O
previamente	O
en	O
análisis	O
de	O
ligamiento	O
para	O
la	O
detección	O
de	O
CIA	O
asociada	O
a	O
lugares	B-Sequence
,	O
lo	O
que	O
abrió	O
(	O
up	O
)	O
la	O
posibilidad	O
de	O
detectar	O
nuevos	O
genes	B-Sequence
polimórficos	I-Sequence
de	O
importancia	O
en	O
esta	O
enfermedad	O
.	O

La	O
primera	O
conclusión	O
del	O
presente	O
artículo	O
es	O
que	O
la	O
multiparidad	O
no	O
influye	O
negativamente	O
en	O
la	O
incidencia	O
o	O
gravedad	O
de	O
la	O
CIA	O
inducida	O
más	O
adelante	O
en	O
la	O
vida	O
(	O
Tabla	O
2	O
)	O
.	O

Esto	O
está	O
de	O
acuerdo	O
con	O
los	O
resultados	O
de	O
un	O
estudio	O
reciente	O
de	O
AR	O
en	O
mujeres	O
,	O
que	O
indica	O
de	O
manera	O
similar	O
que	O
la	O
experiencia	O
previa	O
de	O
embarazo	O
no	O
afecta	O
negativamente	O
la	O
incidencia	O
o	O
la	O
gravedad	O
de	O
la	O
AR	O
más	O
adelante	O
en	O
la	O
vida	O
[	O
8	O
]	O
.	O

Vale	O
la	O
pena	O
señalar	O
que	O
la	O
situación	O
es	O
bastante	O
diferente	O
si	O
se	O
inicia	O
el	O
embarazo	O
durante	O
la	O
artritis	O
en	O
curso	O
.	O

Esto	O
normalmente	O
conducirá	O
a	O
una	O
remisión	O
temporal	O
de	O
la	O
enfermedad	O
en	O
ambos	O
ratones	B-Taxon
y	O
humanos	B-Taxon
,	O
seguida	O
de	O
una	O
fase	O
de	O
exacerbación	O
después	O
del	O
parto	O
[	O
7	O
,	O
10	O
,	O
11	O
]	O
.	O

La	O
segunda	O
conclusión	O
de	O
este	O
estudio	O
es	O
que	O
lugares	B-Sequence
de	O
posible	O
importancia	O
para	O
la	O
CIA	O
se	O
han	O
detectado	O
,	O
dos	O
asociados	O
con	O
la	O
susceptibilidad	O
a	O
la	O
artritis	O
(	O
cromosomas	B-GENE
1	O
y	O
11	O
)	O
y	O
uno	O
asociado	O
con	O
anti	O
-	O
ICI	B-Protein
títulos	O
(	O
cromosoma	B-GENE
13	O
)	O
.	O

algo	O
de	O
artritis	O
lugares	B-Sequence
han	O
sido	O
previamente	O
identificados	O
en	O
cromosoma	B-GENE
1:00	O
cia15	B-Protein
a	O
8	O
cm	O
[	O
16	O
]	O
,	O
cia20	B-Protein
a	O
44	O
cm	O
[	O
16	O
]	O
y	O
cia9	B-Protein
a	O
92	O
cm	O
[	O
17	O
]	O
.	O

Sin	O
embargo	O
,	O
ninguno	O
de	O
estos	O
lugares	B-Sequence
parece	O
estar	O
cerca	O
de	O
la	O
lugar	B-Sequence
encontrado	O
en	O
cromosoma	B-GENE
1	O
en	O
el	O
presente	O
estudio	O
.	O

El	O
recién	O
identificado	O
cia40	B-Protein
lugar	B-Sequence
incluye	O
el	O
ctla4	B-Protein
(	O
CD152	B-Protein
)	O
gene	B-Sequence
,	O
que	O
es	O
un	O
fuerte	O
candidato	O
asociado	O
con	O
la	O
diabetes	O
espontánea	O
identificada	O
en	O
cruces	O
entre	O
C57Bl	O
y	O
cepas	O
diabéticas	O
no	O
obesas	O
[	O
18	O
]	O
.	O

Los	O
análisis	O
de	O
CIA	O
en	O
cruces	O
de	O
los	O
mismos	O
antecedentes	O
,	O
sin	O
embargo	O
,	O
no	O
identificaron	O
un	O
vínculo	O
con	O
este	O
lugar	B-Sequence
,	O
sugiriendo	O
que	O
el	O
polimorfismo	B-Sequence
subyacente	O
cia40	B-Protein
difiere	O
de	O
la	O
genes	B-Sequence
asociado	O
con	O
la	O
diabetes	O
[	O
18	O
]	O
.	O

Curiosamente	O
,	O
Bauer	O
y	O
sus	O
colegas	O
identificaron	O
previamente	O
un	O
lugar	B-Sequence
(	O
cia28	B-Protein
)	O
asociado	O
con	O
anti-	O
ICI	B-Protein
anticuerpo	B-GENE
producción	O
a	O
53	O
cm	O
en	O
cromosoma	B-GENE
13	O
[	O
19	O
]	O
,	O
que	O
es	O
aproximadamente	O
al	O
mismo	O
posición	B-Sequence
como	O
donde	O
encontramos	O
el	O
vínculo	O
para	O
este	O
rasgo	O
en	O
el	O
presente	O
estudio	O
.	O

Por	O
lo	O
tanto	O
,	O
lo	O
más	O
probable	O
es	O
que	O
el	O
QTL	B-Sequence
hemos	O
identificado	O
en	O
cromosoma	B-GENE
13	O
es	O
lo	O
mismo	O
que	O
cia28	B-Protein
.	O

Dado	O
que	O
la	O
posible	O
nueva	O
lugar	B-Sequence
de	O
interés	O
potencial	O
en	O
cromosoma	B-GENE
1	O
fue	O
de	O
significado	O
sugerente	O
,	O
y	O
desde	O
el	O
lugar	B-Sequence
identificado	O
en	O
cromosoma	B-GENE
13	O
probablemente	O
es	O
cia28	B-Protein
,	O
ahora	O
estamos	O
prestando	O
especial	O
atención	O
a	O
los	O
importantes	O
QTL	B-Sequence
para	O
incidencia	O
de	O
CIA	O
detectada	O
a	O
60	O
-	O
70	O
cm	O
en	O
cromosoma	B-GENE
11	O
(	O
denotado	O
cia40	B-Protein
)	O
.	O

Ninguna	O
otra	O
CIA	O
genes	B-Sequence
han	O
sido	O
escritos	O
previamente	O
en	O
este	O
región	B-Sequence
,	O
pero	O
el	O
centro	O
parte	B-Sequence
del	I-Sequence
cromosoma	I-Sequence
11	O
se	O
sabe	O
que	O
contiene	O
una	O
serie	O
de	O
inflamaciones	O
lugares	B-Sequence
,	O
tal	O
como	O
Eae22	B-Protein
,	O
Eae6b	B-Protein
,	O
Eae23	B-Protein
y	O
Eae7	B-Protein
[	O
20	O
-	O
22	O
]	O
.	O

Una	O
QTL	B-Sequence
por	O
proteoglicano	B-Chemical
-	O
artritis	O
inducida	O
,	O
que	O
era	O
específica	O
de	O
la	O
mujer	O
para	O
el	O
inicio	O
de	O
la	O
enfermedad	O
,	O
también	O
se	O
ha	O
encontrado	O
en	O
cromosoma	B-GENE
11	O

Aunque	O
esto	O
lugar	B-Sequence
(	O
Pgia28	B-Protein
)	O
no	O
se	O
encuentra	O
en	O
las	O
proximidades	O
de	O
cia40	B-Protein
,	O
vale	O
la	O
pena	O
señalar	O
[	O
23	O
]	O
.	O

los	O
ratón	B-Taxon
cromosoma	B-GENE
11	O
contiene	O
varios	O
genes	B-Sequence
que	O
son	O
altamente	O
conservado	B-Sequence
con	O
humano	B-Taxon
cromosoma	B-GENE
17	O

Enlaces	O
para	O
humano	B-Taxon
RA	O
se	O
han	O
encontrado	O
en	O
este	O
particular	O
región	B-Sequence
[	O
24	O
]	O
.	O

Otro	O
interesante	O
lugar	B-Sequence
es	O
cia5	B-Protein
sobre	O
el	O
homólogo	B-Sequence
rata	B-Taxon
cromosoma	B-GENE
10	O
,	O
que	O
regula	O
la	O
gravedad	O
de	O
la	O
CIA	O
y	O
la	O
artritis	O
inducida	O
por	O
pristano	O
[	O
25	O
]	O
.	O

Curiosamente	O
,	O
a	O
partir	O
de	O
estudios	O
con	O
la	O
misma	O
cruz	O
,	O
hemos	O
detectado	O
previamente	O
una	O
significativa	O
QTL	B-Sequence
denotado	O
Pregq2	B-Protein
para	O
el	O
rasgo	O
'frecuencia	O
de	O
preñez	O
'	O
en	O
el	O
mismo	O
región	B-Sequence
como	O
cia40	B-Protein
(	O
pico	O
a	O
64	O
-	O
70	O
cm	O
en	O
cromosoma	B-GENE
11	O
)	O
(	O
Liljander	O
M	O
,	O
Sallstr	O
om	O
MA	O
,	O
Andersson	O
S	O
,	O
Wernhoff	O
P	O
,	O
Andersson	O
A	O
,	O
Holmdahl	O
R	O
,	O
Mattsson	O
R	O
,	O
datos	O
no	O
publicados	O
)	O
.	O

Esto	O
significa	O
que	O
esto	O
región	B-Sequence
contiene	O
genes	B-Sequence
afectando	O
la	O
incidencia	O
de	O
CIA	O
en	O
multíparas	O
ratones	B-Taxon
además	O
de	O
la	O
tasa	O
de	O
partos	O
exitosos	O
en	O
mujeres	O
ratones	B-Taxon
.	O

La	O
'tasa	O
de	O
embarazo	O
'	O
en	O
ratones	B-Taxon
se	O
define	O
como	O
embarazos	O
exitosos	O
por	O
tapón	O
vaginal	O
detectado	O
,	O
un	O
fenotipo	O
asociado	O
con	O
el	O
fracaso	O
temprano	O
del	O
embarazo	O
,	O
que	O
a	O
su	O
vez	O
podría	O
tener	O
una	O
causa	O
inflamatoria	O
.	O

No	O
podemos	O
excluir	O
que	O
el	O
mismo	O
gen	B-Sequence
(	I-Sequence
es	I-Sequence
)	I-Sequence
están	O
afectando	O
a	O
estos	O
dos	O
rasgos	O
.	O

Conclusión	O

Nuestros	O
resultados	O
muestran	O
que	O
la	O
multiparidad	O
no	O
influye	O
negativamente	O
en	O
la	O
incidencia	O
o	O
gravedad	O
de	O
la	O
CIA	O
inducida	O
más	O
adelante	O
en	O
la	O
vida	O
.	O

Además	O
,	O
dos	O
nuevos	O
lugares	B-Sequence
vinculados	O
a	O
la	O
susceptibilidad	O
a	O
la	O
CIA	O
se	O
detectaron	O
en	O
cromosoma	B-GENE
11	O
(	O
cia40	B-Protein
)	O
y	O
en	O
cromosoma	B-GENE
1	O
.	O

Detectamos	O
en	O
cromosoma	B-GENE
13	O
un	O
lugar	B-Sequence
asociado	O
con	O
anti-	O
ICI	B-Protein
títulos	O
,	O
que	O
probablemente	O
es	O
el	O
mismo	O
que	O
el	O
recientemente	O
informado	O
cia28	B-Protein
[	O
19	O
]	O
.	O

abreviaturas	O

CIA	O
=	O
colágeno	B-Protein
-	O
artritis	O
inducida	O
;	O
ICI	B-Protein
=	O
colágeno	B-Protein
tipo	I-Protein
II	I-Protein
;	O
LOD	O
=	O
logaritmo	O
de	O
las	O
probabilidades	O
;	O
CMH	B-GENE
=	O
complejo	B-GENE
mayor	I-GENE
de	I-GENE
histocompatibilidad	I-GENE
;	O
PCR	O
=	O
reacción	O
en	O
cadena	O
de	O
la	O
polimerasa	O
;	O
QTL	B-Sequence
=	O
locus	B-Sequence
de	I-Sequence
rasgo	I-Sequence
cuantitativo	I-Sequence
;	O
AR	O
=	O
artritis	O
reumatoide	O
.	O

Conflicto	O
de	O
intereses	O

Los	O
autores	O
declaran	O
que	O
no	O
tienen	O
ningún	O
interés	O
en	O
competencia	O
.	O

Contribuciones	O
de	O
los	O
autores	O

ML	O
es	O
responsable	O
de	O
genotipado	O
,	O
fenotipado	O
,	O
análisis	O
y	O
,	O
junto	O
con	O
RM	O
,	O
para	O
la	O
interpretación	O
y	O
redacción	O
del	O
manuscrito	O
.	O

M-AS	O
y	O
SA	O
han	O
contribuido	O
a	O
la	O
recopilación	O
de	O
datos	O
de	O
fenotipo	O
.	O

RM	O
,	O
AA	O
,	O
RH	O
y	O
ML	O
diseñaron	O
el	O
estudio	O
.	O

Todos	O
los	O
autores	O
leyeron	O
y	O
aprobaron	O
el	O
manuscrito	O
final	O
.	O

Agradecimientos	O

Este	O
estudio	O
fue	O
apoyado	O
por	O
el	O
fondo	O
de	O
Osterlund	O
,	O
el	O
fondo	O
de	O
Crafoord	O
,	O
la	O
Fundación	O
Gustav	O
V	O
80	O
Year	O
,	O
la	O
Royal	O
Physiographic	O
Society	O
en	O
Lund	O
y	O
por	O
Swegene	O
.	O

Figuras	O
y	O
Tablas	O

Figura	O
1	O

La	O
incidencia	O
acumulada	O
de	O
artritis	O
en	O
las	O
cepas	O
parentales	O
(	O
NFR	O
/	O
N	O
y	O
B10	O
.	O
Q	O
)	O
de	O
hembras	O
ratones	B-Taxon
.	O

Figura	O
2	O

Ubicaciones	B-Sequence
cromosómicas	I-Sequence
de	O
El	O
loci	B-Sequence
de	I-Sequence
rasgos	I-Sequence
cuantitativos	I-Sequence
(	O
QTL	B-Sequence
)	O
por	O
colágeno	B-Protein
#	O
¿NOMBRE	O
?	O
cromosomas	B-GENE
1	O
y	O
11	O
.	O

QTL	B-Sequence
por	O
colágeno	B-Protein
tipo	I-Protein
II	I-Protein
(	O
ICI	B-Protein
)	O
anticuerpo	B-GENE
los	O
títulos	O
se	O
ilustran	O
en	O
cromosoma	B-GENE
13	O

*	O
Umbral	O
de	O
nivel	O
sugerente	O
(	O
P	O
=	O
0,63	O
)	O
según	O
la	O
prueba	O
de	O
permutación	O
(	O
n	O
=	O
1.000	O
)	O
.	O

*	O
*	O
Umbral	O
de	O
nivel	O
de	O
significación	O
(	O
P	O
=	O
0,05	O
)	O
según	O
la	O
prueba	O
de	O
permutación	O
(	O
n	O
=	O
1.000	O
)	O
.	O

tabla	O
1	O

Severidad	O
de	O
la	O
artritis	O
y	O
anti	O
-	O
colágeno	B-Protein
tipo	I-Protein
II	I-Protein
(	O
anti-	O
ICI	B-Protein
)	O
títulos	O
en	O
(	O
NFR	O
/	O
N	O
x	O
B10	O
.	O
Q	O
)	O
x	O
B10	O
.	O
mujer	O
q	O
ratones	B-Taxon
y	O
cepas	O
parentales	O

aValor	O
de	O
la	O
mediana	O
en	O
los	O
días	O
de	O
inicio	O
cuando	O
se	O
calcula	O
en	O
todas	O
las	O
artritis	O
ratones	B-Taxon
en	O
el	O
grupo	O
el	O
día	O
100	O
(	O
valores	O
máximos-mínimos	O
de	O
la	O
serie	O
)	O
.	O

b	O
Media	O
+/-	O
error	O
estándar	O
de	O
la	O
puntuación	O
máxima	O
de	O
todos	O
los	O
artríticos	O
ratones	B-Taxon
en	O
el	O
grupo	O
respectivo	O
.	O

cSignificativamente	O
mayor	O
que	O
en	O
B10	O
.	O
q	O
ratones	B-Taxon
(	O
P	O
=	O
0,02	O
en	O
la	O
prueba	O
t	O
de	O
Student	O
para	O
datos	O
no	O
apareados	O
)	O
.	O

Tabla	O
2	O

Incidencia	O
,	O
aparición	O
y	O
puntuación	O
máxima	O
en	O
(	O
NFR/N	O
x	O
B10	O
.	O
Q	O
)	O
x	O
B10	O
.	O
mujer	O
q	O
ratones	B-Taxon

aValor	O
de	O
la	O
mediana	O
en	O
los	O
días	O
de	O
inicio	O
cuando	O
se	O
calcula	O
en	O
todas	O
las	O
artritis	O
ratones	B-Taxon
en	O
el	O
grupo	O
(	O
valores	O
máximos-mínimos	O
en	O
la	O
serie	O
)	O
.	O

Media	O
(	O
+/-	O
error	O
estándar	O
)	O
de	O
la	O
puntuación	O
máxima	O
de	O
todos	O
los	O
artríticos	O
ratones	B-Taxon
en	O
el	O
grupo	O
respectivo	O
el	O
día	O
100	O
.	O

Tabla	O
3	O

Distribución	O
de	O
genotipos	B-Sequence
entre	O
N2	O
afectado	O
y	O
no	O
afectado	O
ratones	B-Taxon
en	O
diferentes	O
lugares	B-Sequence
relacionado	O
con	O
los	O
fenotipos	O
clínicos	O
de	O
colágeno	B-Protein
#	O
¿NOMBRE	O
?	O

*	O
significado	O
sugestivo	O
,	O
*	O
significativo	O
.	O

Clonación	O
y	O
caracterización	O
de	O
Señora	B-Protein
,	O
una	O
novela	O
SAM	O
dominio	B-Sequence
proteína	B-Chemical
,	O
expresada	O
predominantemente	O
en	O
células	B-Cell
fotorreceptoras	I-Cell
de	I-Cell
la	I-Cell
retina	I-Cell

Resumen	O

Antecedentes	O

Motivo	O
alfa	O
estéril	O
(	O
SAM	O
)	O
dominios	B-Sequence
son	O
~	O
70	O
residuos	B-Chemical
de	O
largo	O
y	O
han	O
sido	O
reportados	O
como	O
comunes	O
proteína	B-Chemical
-	O
proteína	B-Chemical
Interacción	O
módulos	B-Sequence
.	O

Esta	O
dominio	B-Sequence
se	O
encuentra	O
en	O
un	O
gran	O
número	O
de	O
proteinas	B-Chemical
,	O
incluido	O
el	O
grupo	O
Polycomb	O
(	O
PCG	O
)	O
proteinas	B-Chemical
y	O
factores	O
de	O
transcripción	O
de	O
la	O
familia	O
ETS	O
.	O

En	O
este	O
trabajo	O
,	O
reportamos	O
la	O
clonación	O
y	O
caracterización	O
funcional	O
de	O
un	O
nuevo	O
SAM	O
.	O
dominio	B-Sequence
#	O
¿NOMBRE	O
?	O
proteína	B-Chemical
,	O
que	O
se	O
expresa	O
predominantemente	O
en	O
fotorreceptores	B-Cell
retinales	I-Cell
y	O
la	O
glándula	O
pineal	O
y	O
se	O
designa	O
ratón	B-Protein
mr	I-Protein
-	I-Protein
s	I-Protein
(	I-Protein
proteína	I-Protein
principal	I-Protein
del	I-Protein
dominio	I-Protein
SAM	I-Protein
de	I-Protein
la	I-Protein
retina	I-Protein
)	O
.	O

Resultados	O

Señora	B-Protein
es	O
conservado	B-Sequence
evolutivamente	I-Sequence
desde	O
pez	B-Taxon
cebra	I-Taxon
a	O
través	O
de	O
humano	B-Taxon
,	O
organismos	B-Taxon
a	O
través	O
del	O
cual	O
el	O
mecanismo	O
de	O
fotorreceptor	B-Cell
el	O
desarrollo	O
también	O
está	O
altamente	O
conservado	O
.	O

El	O
análisis	O
filogenético	O
sugiere	O
que	O
el	O
SAM	O
dominio	B-Sequence
de	O
Señora	B-Protein
está	O
más	O
estrechamente	O
relacionado	O
con	O
un	O
ratón	B-Taxon
polihomeótico	B-Protein
(	O
ph	B-Protein
)	O
ortólogo	B-Sequence
,	O
Mph1	B-Protein
/	O
Rae28	B-Protein
,	O
que	O
se	O
conoce	O
como	O
epigenético	O
molécula	B-Chemical
envuelto	O
en	O
cromatina	B-GENE
modificaciones	O

Estos	O
hallazgos	O
brindan	O
la	O
posibilidad	O
de	O
que	O
Señora	B-Protein
puede	O
desempeñar	O
un	O
papel	O
fundamental	O
en	O
la	O
regulación	O
gene	B-Sequence
expresión	O
en	O
fotorreceptor	B-Cell
desarrollo	O
.	O

Señora	B-Protein
se	O
expresa	O
preferentemente	O
en	O
el	O
fotorreceptores	B-Cell
en	O
el	O
día	O
postnatal	O
3	O
-	O
6	O
(	O
P3	O
-	O
6	O
)	O
,	O
cuando	O
fotorreceptores	B-Cell
experimentan	O
diferenciación	O
terminal	O
,	O
y	O
en	O
la	O
glándula	O
pineal	O
adulta	O
.	O

Transcripción	O
de	O
Señora	B-Protein
está	O
directamente	O
regulado	O
por	O
la	O
cono	B-Cell
-	O
vara	B-Cell
homeodominio	O
proteína	B-Chemical
crx	B-Protein
.	O

El	O
ensayo	O
de	O
inmunoprecipitación	O
mostró	O
que	O
la	O
Señora	B-Protein
proteína	B-Chemical
auto-asociados	O
principalmente	O
a	O
través	O
del	O
SAM	O
dominio	B-Sequence
#	O
¿NOMBRE	O
?	O
región	B-Sequence
así	O
como	O
también	O
ph	B-Protein
.	O

los	O
Señora	B-Protein
proteína	B-Chemical
se	O
localiza	O
principalmente	O
en	O
el	O
núcleo	B-GENE
,	O
Cuándo	O
Señora	B-Protein
se	O
sobreexpresa	O
en	O
HEK293T	O
células	B-Cell
.	O

Además	O
,	O
en	O
los	O
ensayos	O
de	O
luciferasa	O
,	O
encontramos	O
que	O
Señora	B-Protein
proteína	B-Chemical
fusionado	O
a	O
GAL4	B-Protein
ADN	B-Sequence
#	O
¿NOMBRE	O
?	O
dominio	B-Sequence
funciona	O
como	O
un	O
represor	O
transcripcional	O
.	O

Revelamos	O
que	O
la	O
actividad	O
represiva	O
de	O
Señora	B-Protein
no	O
se	O
debe	O
a	O
una	O
interacción	O
homófila	O
a	O
través	O
de	O
su	O
SAM	O
dominio	B-Sequence
pero	O
a	O
la	O
C	B-Sequence
-	I-Sequence
región	I-Sequence
terminal	I-Sequence
.	O

Conclusión	O

Identificamos	O
una	O
novela	O
gene	B-Sequence
,	O
Señora	B-Protein
,	O
que	O
se	O
expresa	O
predominantemente	O
en	O
fotorreceptores	B-Cell
retinales	I-Cell
y	O
glándula	O
pineal	O
.	O

Con	O
base	O
en	O
su	O
patrón	O
de	O
expresión	O
y	O
análisis	O
bioquímico	O
,	O
predecimos	O
que	O
Señora	B-Protein
puede	O
funcionar	O
como	O
un	O
represor	O
transcripcional	O
en	O
células	B-Cell
fotorreceptoras	I-Cell
y	O
en	O
pinealocitos	B-Cell
de	O
la	O
glándula	O
pineal	O
.	O

Antecedentes	O

En	O
el	O
desarrollo	O
de	O
la	O
mamífero	B-Taxon
retina	O
,	O
una	O
amplia	O
gama	O
de	O
célula	B-Cell
tipos	O
se	O
genera	O
a	O
partir	O
de	O
un	O
conjunto	O
de	O
células	B-Cell
progenitoras	I-Cell
retinales	I-Cell
multipotentes	I-Cell
.	O

Entre	O
estos	O
célula	B-Cell
tipos	O
,	O
fotorreceptores	B-Cell
representan	O
más	O
del	O
70	O
%	O
de	O
todos	O
células	B-Cell
en	O
la	O
retina	O
.	O

En	O
vertebrados	B-Taxon
,	O
hay	O
dos	O
clases	O
de	O
fotorreceptores	B-Cell
,	O
varillas	B-Cell
y	O
conos	B-Cell
.	O

Varillas	B-Cell
son	O
sensores	O
de	O
luz	O
tenue	O
,	O
mientras	O
que	O
conos	B-Cell
funcionan	O
con	O
luz	O
brillante	O
y	O
son	O
responsables	O
de	O
la	O
visión	O
del	O
color	O
.	O

Fototransducción	O
,	O
una	O
serie	O
de	O
amplificaciones	O
de	O
señal	O
que	O
detectan	O
un	O
solo	O
fotón	B-Chemical
de	O
luz	O
,	O
es	O
iniciado	O
por	O
la	O
captura	O
de	O
luz	O
con	O
11-cis-retinal	O
,	O
un	O
cromóforo	B-Chemical
obligado	O
por	O
el	O
opsina	B-Protein
proteinas	B-Chemical
:	O
rodopsina	B-Protein
en	O
varillas	B-Cell
y	O
cono	B-Cell
opsinas	B-Protein
en	O
conos	B-Cell
.	O

los	O
proteinas	B-Chemical
que	O
llevan	O
a	O
cabo	O
la	O
fototransducción	O
se	O
encuentran	O
en	O
un	O
elaborado	O
y	O
altamente	O
especializado	O
membranoso	B-GENE
estructura	O
,	O
la	O
segmento	B-GENE
exterior	I-GENE
.	O

los	O
segmento	B-GENE
exterior	I-GENE
parece	O
ser	O
relativamente	O
frágil	O
,	O
degenerando	O
en	O
respuesta	O
a	O
muchos	O
factores	O
ambientales	O
y	O
/	O
o	O
genético	B-Sequence
perturbaciones	O

En	O
el	O
roedor	B-Taxon
retina	O
,	O
la	O
producción	O
de	O
célula	B-Cell
tipos	O
durante	O
el	O
desarrollo	O
progresa	O
en	O
un	O
orden	O
general	O
[	O
1	O
,	O
2	O
]	O
.	O

Fotorreceptor	B-Cell
de	I-Cell
varilla	I-Cell
picos	O
de	O
generación	O
alrededor	O
del	O
momento	O
del	O
nacimiento	O
.	O

Fotorreceptores	B-Cell
de	I-Cell
cono	I-Cell
,	O
celulas	B-Cell
ganglionares	I-Cell
,	O
celdas	B-Cell
horizontales	I-Cell
y	O
células	B-Cell
amacrinas	I-Cell
se	O
generan	O
antes	O
,	O
mientras	O
que	O
Müller	B-Cell
glia	I-Cell
y	O
células	B-Cell
bipolares	I-Cell
se	O
generan	O
posteriormente	O
.	O

Esta	O
producción	O
de	O
diferentes	O
célula	B-Cell
tipos	O
en	O
diferentes	O
momentos	O
parece	O
derivar	O
de	O
las	O
diferencias	O
en	O
las	O
propiedades	O
intrínsecas	O
del	O
progenitor	O
células	B-Cell
involucrados	O
en	O
la	O
transcripción	O
o	O
cromatina	B-GENE
modificación	O

Estudios	O
recientes	O
identificaron	O
varios	O
factores	O
de	O
transcripción	O
importantes	O
de	O
fotorreceptor	B-Cell
desarrollo	O
[	O
3	O
-	O
7	O
]	O
.	O

Homeobox	O
de	O
dos	O
familias	O
Otx	O
genes	B-Sequence
,	O
Otx2	B-Protein
y	O
crx	B-Protein
,	O
juegan	O
un	O
papel	O
esencial	O
en	O
los	O
primeros	O
célula	B-Cell
determinación	O
del	O
destino	O
y	O
diferenciación	O
terminal	O
de	O
fotorreceptores	B-Cell
[	O
3	O
,	O
8	O
,	O
9	O
]	O
.	O

En	O
ausencia	O
de	O
Otx2	B-Protein
función	O
,	O
diferenciación	O
células	B-Cell
fotorreceptoras	I-Cell
se	O
convierten	O
en	O
amacrino	B-Cell
#	O
¿NOMBRE	O
?	O
neuronas	B-Cell
[	O
9	O
]	O
.	O

crx	B-Protein
,	O
un	O
objetivo	O
aguas	O
abajo	O
de	O
Otx2	B-Protein
,	O
controla	O
la	O
transcripción	O
de	O
varios	O
célula	B-Cell
fotorreceptora	I-Cell
#	O
¿NOMBRE	O
?	O
genes	B-Sequence
y	O
es	O
fundamental	O
para	O
la	O
formación	O
de	O
segmentos	B-GENE
exteriores	I-GENE
,	O
terminales	B-GENE
sinápticas	I-GENE
,	O
y	O
vías	O
de	O
fototransducción	O
[	O
8	O
,	O
10	O
]	O
.	O

crx	B-Protein
transcripciones	B-Sequence
comienzan	O
a	O
expresarse	O
en	O
el	O
desarrollo	O
fotorreceptores	B-Cell
en	O
el	O
día	O
12	O
embrionario	O
.	O
5	O
(	O
E12	O
.	O
5	O
)	O
en	O
el	O
ratón	B-Taxon
y	O
una	O
fuerte	O
regulación	O
positiva	O
de	O
crx	B-Protein
la	O
transcripción	O
es	O
evidente	O
a	O
través	O
de	O
la	O
diferenciación	O
fotorreceptores	B-Cell
en	O
el	O
día	O
postnatal	O
6	O
(	O
P6	O
)	O
.	O

Células	B-Cell
fotorreceptoras	I-Cell
en	O
el	O
crx	B-Protein
nocaut	O
(	O
KO	O
)	O
ratones	B-Taxon
exhibir	O
una	O
reducción	O
dramática	O
de	O
muchos	O
fotorreceptor	B-Cell
moléculas	B-Chemical
incluyendo	O
visual	O
pigmentos	B-Chemical
y	O
desarrollar	O
ni	O
segmentos	B-GENE
externos	I-GENE
de	I-GENE
los	I-GENE
fotorreceptores	I-GENE
ni	O
un	O
término	B-GENE
sináptico	I-GENE
[	O
8	O
,	O
10	O
]	O
.	O

Además	O
,	O
mutaciones	B-Sequence
de	O
CRX	B-Protein
humano	I-Protein
Se	O
ha	O
demostrado	O
que	O
están	O
asociados	O
con	O
tres	O
tipos	O
de	O
fotorreceptor	B-Cell
enfermedades	O
:	O
autosómico	B-GENE
dominante	O
cono	B-Cell
-	O
vara	B-Cell
distrofia	O
2	O
,	O
autosómico	B-GENE
retinitis	O
pigmentosa	O
de	O
tipo	O
dominante	O
y	O
amaurosis	O
congénita	O
de	O
Leber	O
(	O
LCA	O
)	O
[	O
11-14	O
]	O
.	O

Tiempo	O
Otx2	B-Protein
y	O
crx	B-Protein
controles	O
generales	O
fotorreceptor	B-Cell
desarrollo	O
,	O
otros	O
tres	O
factores	O
de	O
transcripción	O
,	O
TR	B-Protein
beta	I-Protein
2	I-Protein
,	O
NRL	B-Protein
,	O
y	O
nr2e3	B-Protein
regular	O
la	O
especificación	O
de	O
célula	B-Cell
fotorreceptora	I-Cell
tipos	O
[	O
4	O
,	O
5	O
,	O
7	O
]	O
.	O

SAM	O
dominios	B-Sequence
(	O
también	O
conocido	O
como	O
puntiagudo	O
,	O
HLH	O
o	O
SPM	O
)	O
dominios	B-Sequence
)	O
son	O
~	O
70	O
residuos	B-Chemical
de	O
largo	O
y	O
han	O
sido	O
reportados	O
como	O
comunes	O
proteína	B-Chemical
-	O
proteína	B-Chemical
Interacción	O
módulos	B-Sequence
[	O
15	O
-	O
17	O
]	O
.	O

Esta	O
dominio	B-Sequence
se	O
encuentra	O
en	O
un	O
gran	O
número	O
de	O
proteinas	B-Chemical
,	O
incluido	O
el	O
grupo	O
Polycomb	O
(	O
PCG	O
)	O
proteinas	B-Chemical
[	O
18	O
]	O
,	O
serina	B-Chemical
treonina	I-Chemical
quinasas	O
[	O
19	O
]	O
,	O
Tirosina	B-Protein
quinasas	I-Protein
receptoras	I-Protein
de	I-Protein
la	I-Protein
familia	I-Protein
Eph	I-Protein
[	O
20	O
]	O
,	O
el	O
supresor	B-Protein
de	I-Protein
tumores	I-Protein
p73	I-Protein
[	O
21	O
]	O
,	O
el	O
ARN	B-Sequence
#	O
¿NOMBRE	O
?	O
proteína	B-Chemical
smaug	O
[	O
22	O
]	O
,	O
diacilglicerol	B-Chemical
quinasas	O
[	O
23	O
,	O
24	O
]	O
,	O
levadura	B-Taxon
señalización	O
de	O
tipo	O
de	O
apareamiento	O
proteinas	B-Chemical
[	O
19	O
,	O
25	O
]	O
y	O
factores	O
de	O
transcripción	O
de	O
la	O
familia	O
ETS	O
[	O
26	O
,	O
27	O
]	O
.	O

El	O
PCG	O
proteinas	B-Chemical
son	O
represores	O
transcripcionales	O
que	O
mantienen	O
gene	B-Sequence
silenciamiento	O
durante	O
el	O
desarrollo	O
[	O
28	O
-	O
30	O
]	O
.	O

En	O
mamíferos	B-Taxon
,	O
PCG	O
proteinas	B-Chemical
también	O
están	O
implicados	O
en	O
Hox	O
gene	B-Sequence
reglamento	O

Su	O
actividad	O
biológica	O
radica	O
en	O
el	O
silenciamiento	O
estable	O
de	O
conjuntos	O
específicos	O
de	O
genes	B-Sequence
a	O
través	O
de	O
cromatina	B-GENE
modificaciones	O

Un	O
miembro	O
de	O
complejo	B-GENE
represivo	I-GENE
polycomb	I-GENE
1	I-GENE
(	O
PRC1	B-GENE
)	O
,	O
ph	B-Protein
,	O
contiene	O
un	O
SAM	O
dominio	B-Sequence
en	O
el	O
C-terminal	B-Sequence
,	O
y	O
complejo	B-GENE
PRC1	I-GENE
se	O
sabe	O
que	O
forma	O
helicoidal	B-Sequence
,	O
de	O
la	O
cabeza	O
a	O
los	O
pies	O
polímeros	B-Chemical
través	O
de	O
su	O
SAM	O
dominio	B-Sequence
[	O
31	O
]	O
.	O

Estas	O
polimérico	B-Chemical
estructuras	O
median	O
la	O
formación	O
de	O
un	O
orden	O
superior	O
estructura	B-GENE
de	I-GENE
la	I-GENE
cromatina	I-GENE
y	O
posiblemente	O
estabilizar	O
el	O
estado	O
reprimido	O
de	O
Hox	O
genes	B-Sequence
.	O

En	O
este	O
estudio	O
,	O
identificamos	O
una	O
novela	O
gene	B-Sequence
,	O
Señora	B-Protein
,	O
que	O
codifica	O
un	O
SAM	O
dominio	B-Sequence
#	O
¿NOMBRE	O
?	O
proteína	B-Chemical
.	O

El	O
SAM	O
dominio	B-Sequence
de	O
Señora	B-Protein
está	O
más	O
estrechamente	O
relacionado	O
con	O
el	O
de	O
ph	B-Protein
ratón	B-Taxon
ortólogo	B-Sequence
,	O
MPH1	B-Protein
/	O
Rae28	B-Protein
.	O

Señora	B-Protein
se	O
expresa	O
predominantemente	O
en	O
fotorreceptores	B-Cell
retinales	I-Cell
cuando	O
experimentan	O
diferenciación	O
terminal	O
,	O
y	O
glándula	O
pineal	O
adulta	O
.	O

la	O
expresión	O
de	O
Señora	B-Protein
está	O
directamente	O
regulado	O
por	O
crx	B-Protein
.	O

Es	O
más	O
,	O
Señora	B-Protein
se	O
localiza	O
en	O
el	O
núcleo	B-GENE
y	O
puede	O
autoasociarse	O
a	O
través	O
de	O
su	O
SAM	O
dominio	B-Sequence
#	O
¿NOMBRE	O
?	O
región	B-Sequence
.	O

También	O
encontramos	O
que	O
Señora	B-Protein
proteína	B-Chemical
fusionado	O
a	O
GAL4	B-Protein
ADN	B-Sequence
#	O
¿NOMBRE	O
?	O
dominio	B-Sequence
funciona	O
como	O
un	O
represor	O
transcripcional	O
.	O

Estos	O
hallazgos	O
sugieren	O
que	O
Señora	B-Protein
funciona	O
como	O
miembro	O
de	O
un	O
complejo	B-GENE
represor	I-GENE
transcripcional	I-GENE
en	O
fotorreceptor	B-Cell
de	I-Cell
la	I-Cell
retina	I-Cell
desarrollo	O
.	O

Resultados	O

Clonación	O
de	O
ratón	B-Protein
mr	I-Protein
-	I-Protein
s	I-Protein

Para	O
identificar	O
la	O
novela	O
.	O
ratón	B-Taxon
genes	B-Sequence
expresada	O
preferentemente	O
en	O
la	O
retina	O
en	O
desarrollo	O
,	O
examinamos	O
la	O
base	O
de	O
datos	O
del	O
Instituto	O
Nacional	O
de	O
Información	O
Biotecnológica	O
(	O
NCBI	O
)	O
,	O
UniGene	O
,	O
utilizando	O
Visualización	O
diferencial	O
digital	O
(	O
DDD	O
)	O
y	O
encontramos	O
fragmentos	B-Sequence
EST	I-Sequence
que	O
están	O
frecuentemente	O
presentes	O
en	O
ratón	B-Taxon
de	O
retina	O
ADNc	B-Sequence
bibliotecas	O

Encontramos	O
que	O
uno	O
clon	B-Sequence
en	O
estos	O
ADNc	B-Sequence
codifica	O
un	O
proteína	B-Chemical
que	O
contiene	O
un	O
SAM	O
dominio	B-Sequence
relacionado	O
con	O
el	O
de	O
proteína	B-Protein
polihomeótica	I-Protein
.	O

una	O
PCR	O
fragmento	B-Sequence
correspondiente	O
a	O
este	O
ratón	B-Taxon
clon	B-Sequence
se	O
usó	O
para	O
examinar	O
un	O
ratón	B-Taxon
retina	O
P0	O
-	O
P3	O
ADNc	B-Sequence
biblioteca	O
para	O
obtener	O
una	O
imagen	O
completa	O
clon	B-Sequence
de	I-Sequence
ADNc	I-Sequence
.	O

Secuencia	B-Sequence
análisis	O
mostró	O
que	O
este	O
ADNc	B-Sequence
era	O
una	O
novela	O
gene	B-Sequence
codificando	O
un	O
SAM	O
dominio	B-Sequence
#	O
¿NOMBRE	O
?	O
proteína	B-Chemical
.	O

Nos	O
referimos	O
a	O
esto	O
proteína	B-Chemical
como	O
Señora	B-Protein
(	O
principal	B-Protein
proteína	I-Protein
del	I-Protein
dominio	I-Protein
SAM	I-Protein
de	I-Protein
la	I-Protein
retina	I-Protein
)	O
.	O

Como	O
se	O
muestra	O
en	O
la	O
figura	O
.	O

1A	O
,	O
un	O
codón	B-Sequence
de	I-Sequence
iniciación	I-Sequence
de	I-Sequence
la	I-Sequence
traducción	I-Sequence
está	O
presente	O
en	O
el	O
mismo	O
marco	B-Sequence
de	I-Sequence
lectura	I-Sequence
abierto	I-Sequence
como	O
el	O
SAM	O
dominio	B-Sequence
.	O

Esta	O
sitio	B-Sequence
de	I-Sequence
iniciación	I-Sequence
muestra	O
similitud	O
con	O
el	O
secuencia	B-Sequence
de	I-Sequence
consenso	I-Sequence
propuesto	O
por	O
Kozak	O
[	O
32	O
]	O
incluyendo	O
la	O
presencia	O
del	O
altamente	O
conservado	B-Sequence
purina	O
en	O
posición	B-Sequence
-	O
3	O
.	O

los	O
codón	B-Sequence
de	I-Sequence
parada	I-Sequence
de	O
El	O
predicho	B-Sequence
Señora	B-Protein
proteína	B-Chemical
también	O
se	O
indica	O
en	O
la	O
Fig	O
.	O

1A	O
.	O

los	O
secuencia	B-Sequence
de	I-Sequence
aminoácidos	I-Sequence
de	O
la	O
SAM	O
dominio	B-Sequence
de	O
Señora	B-Protein
proteína	B-Chemical
(	O
Fig	O
.	O
1A	O
,	O
recuadro	O
secuencia	B-Sequence
)	O
exhibiciones	O
homología	B-Sequence
con	O
SAM	O
dominios	B-Sequence
de	O
EphB2	B-Protein
,	O
EphA4	B-Protein
,	O
MPH1	B-Protein
,	O
TELÉFONO	B-Protein
y	O
Smaug	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

Por	O
análisis	O
filogenético	O
,	O
el	O
SAM	O
dominio	B-Sequence
de	O
Señora	B-Protein
está	O
más	O
estrechamente	O
relacionado	O
con	O
el	O
de	O
Mph1	B-Protein
/	O
Rae28	B-Protein
,	O
a	O
ratón	B-Taxon
homólogo	B-Sequence
de	O
ph	B-Protein
(	O
Fig	O
.	O
1C	O
)	O
.	O

Ratón	B-Protein
señor	I-Protein
-	I-Protein
s	I-Protein
proteína	B-Chemical
es	O
conservado	B-Sequence
en	O
rata	B-Taxon
,	O
humano	B-Taxon
,	O
polluelo	B-Taxon
y	O
pez	B-Taxon
cebra	I-Taxon
que	O
muestran	O
91	O
%	O
,	O
70	O
%	O
,	O
36	O
%	O
y	O
26	O
%	O
de	O
identidad	O
con	O
ratón	B-Protein
mr	I-Protein
-	I-Protein
s	I-Protein
,	O
respectivamente	O
(	O
Fig	O
.	O
1D	O
)	O
.	O

El	O
SAM	O
dominios	B-Sequence
de	O
rata	B-Protein
,	I-Protein
humano	I-Protein
,	I-Protein
pollito	I-Protein
y	I-Protein
pez	I-Protein
cebra	I-Protein
mr	I-Protein
-	I-Protein
s	I-Protein
proteína	B-Chemical
son	O
altamente	O
conservado	B-Sequence
y	O
mostrar	O
96	O
%	O
,	O
90	O
%	O
,	O
76	O
%	O
y	O
72	O
%	O
de	O
identidad	O
con	O
el	O
SAM	O
dominio	B-Sequence
de	O
ratón	B-Protein
mr	I-Protein
-	I-Protein
s	I-Protein
proteína	B-Chemical
.	O

los	O
localizaciones	B-Sequence
cromosómicas	I-Sequence
de	O
ratón	B-Protein
y	I-Protein
mr	I-Protein
humano	I-Protein
-	I-Protein
s	I-Protein
genes	B-Sequence
se	O
determinaron	O
buscando	O
en	O
el	O
ratón	B-Taxon
y	O
humano	B-Taxon
genoma	B-Sequence
bases	O
de	O
datos	O
(	O
NCBI	O
)	O
,	O
respectivamente	O
.	O

Ratón	B-Protein
señor	I-Protein
-	I-Protein
s	I-Protein
está	O
asignado	O
a	O
cromosoma	B-GENE
4E2	O
,	O
y	O
humano	B-Protein
MR	I-Protein
-	I-Protein
S	I-Protein
está	O
asignado	O
a	O
cromosoma	B-GENE
1p36	O
.	O
33	O
.	O

LCA	O
es	O
la	O
causa	O
más	O
común	O
de	O
ceguera	O
infantil	O
hereditaria	O
.	O

RM	B-Protein
humana	I-Protein
-	I-Protein
S	I-Protein
mapas	O
en	O
los	O
alrededores	O
región	B-Sequence
de	O
El	O
LCA9	B-Protein
,	O
recientemente	O
identificado	O
como	O
un	O
nuevo	O
lugar	B-Sequence
para	O
ACV	O
[	O
33	O
]	O
.	O

Figura	O
1	O

Señora	B-Protein
secuencias	B-Sequence
de	I-Sequence
nucleótidos	I-Sequence
y	I-Sequence
aminoácidos	I-Sequence
.	O

(	O
A	O
)	O
Señora	B-Protein
secuencias	B-Sequence
de	I-Sequence
nucleótidos	I-Sequence
y	I-Sequence
aminoácidos	I-Sequence
.	O

en	O
caja	O
aminoácidos	B-Chemical
son	O
los	O
SAM	O
secuencia	B-Sequence
de	I-Sequence
dominio	I-Sequence
y	O
el	O
cuadro	O
punteado	O
indica	O
un	O
supuesto	O
nuclear	B-GENE
localización	O
señal	B-Sequence
.	O

El	O
subrayado	O
indica	O
un	O
supuesto	O
señal	B-Sequence
de	I-Sequence
terminación	I-Sequence
de	I-Sequence
poliadenilación	I-Sequence
.	O

(	O
B	O
)	O
Alineación	O
de	O
SAM	O
secuencias	B-Sequence
de	I-Sequence
dominio	I-Sequence
para	O
SAM	O
dominio	B-Sequence
#	O
¿NOMBRE	O
?	O
proteinas	B-Chemical
.	O

El	O
cinco	O
hélices	B-Sequence
alfa	I-Sequence
están	O
marcados	O
como	O
H1-H5	O
.	O

Conservado	B-Sequence
residuos	B-Chemical
de	I-Chemical
aminoácidos	I-Chemical
se	O
muestran	O
con	O
una	O
sombra	O
oscura	O
y	O
funcionalmente	O
similares	O
residuos	B-Chemical
se	O
muestran	O
con	O
una	O
ligera	O
sombra	O
.	O

los	O
sitios	B-Sequence
que	O
estaban	O
destinados	O
a	O
mutagénesis	B-Sequence
se	O
indican	O
con	O
flechas	O
.	O

(	O
C	O
)	O
Árbol	O
filogenético	O
de	O
SAM	O
dominio	B-Sequence
#	O
¿NOMBRE	O
?	O
proteinas	B-Chemical
.	O

Secuencias	B-Sequence
de	I-Sequence
aminoácidos	I-Sequence
fueron	O
analizados	O
por	O
el	O
método	O
de	O
unión	O
de	O
vecinos	O
en	O
MacVector	O
7	O
.	O
2	O
.	O

Las	O
longitudes	O
de	O
las	O
ramas	O
reflejan	O
el	O
número	O
medio	O
de	O
sustituciones	B-Sequence
por	O
sitio	B-Sequence
.	O

(	O
D	O
)	O
Comparación	O
esquemática	O
de	O
los	O
secuencias	B-Sequence
de	I-Sequence
aminoácidos	I-Sequence
por	O
ratón	B-Protein
,	I-Protein
rata	I-Protein
,	I-Protein
humano	I-Protein
,	I-Protein
pollito	I-Protein
y	I-Protein
pez	I-Protein
cebra	I-Protein
mr	I-Protein
-	I-Protein
s	I-Protein
proteinas	B-Chemical
.	O

El	O
porcentaje	O
de	O
similitud	O
del	O
SAM	O
dominios	B-Sequence
y	O
otra	O
regiones	B-Sequence
a	O
la	O
correspondiente	O
regiones	B-Sequence
de	O
El	O
ratón	B-Taxon
proteína	B-Chemical
se	O
muestra	O
.	O

En	O
general	O
secuencia	B-Sequence
similitud	O
con	O
el	O
ratón	B-Taxon
proteína	B-Chemical
se	O
muestra	O
a	O
la	O
derecha	O
.	O

Expresión	O
de	O
Señora	B-Protein
en	O
la	O
retina	O
en	O
desarrollo	O
y	O
la	O
glándula	O
pineal	O

Investigar	O
Señora	B-Protein
expresión	O
,	O
primero	O
realizamos	O
hibridación	O
in	O
situ	O
de	O
montaje	O
completo	O
en	O
ratón	B-Taxon
embriones	O

No	O
se	O
detectó	O
señal	O
de	O
hibridación	O
en	O
E9	O
.	O
5	O
,	O
E10	O
.	O
5	O
y	O
E11	O
.	O
5	O
con	O
un	O
Señora	B-Protein
Investigacion	B-Sequence
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Luego	O
investigamos	O
la	O
expresión	O
de	O
la	O
Señora	B-Protein
gene	B-Sequence
en	O
la	O
retina	O
en	O
desarrollo	O
por	O
sección	O
de	O
hibridación	O
in	O
situ	O
(	O
Fig	O
.	O
1A-G	O
)	O
.	O

No	O
se	O
detectó	O
ninguna	O
señal	O
significativa	O
en	O
la	O
retina	O
en	O
desarrollo	O
en	O
E13	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

Inicialmente	O
se	O
detectó	O
una	O
señal	O
débil	O
en	O
el	O
aspecto	O
externo	O
de	O
la	O
capa	O
neuroblástica	O
(	O
NBL	O
)	O
,	O
un	O
presunto	O
fotorreceptor	B-Cell
capa	O
en	O
E18	O
(	O
Fig	O
.	O
2B	O
,	O
flecha	O
)	O
.	O

En	O
P3	O
,	O
un	O
Señora	B-Protein
transcripción	B-Sequence
se	O
detectó	O
claramente	O
en	O
el	O
desarrollo	O
fotorreceptor	B-Cell
capa	O
(	O
Fig	O
.	O
2E	O
)	O
.	O

En	O
P6	O
,	O
Señora	B-Protein
mostró	O
un	O
pico	O
de	O
expresión	O
en	O
el	O
fotorreceptor	B-Cell
capa	O
(	O
Fig	O
.	O
2F	O
)	O
.	O

Este	O
patrón	O
se	O
correlaciona	O
con	O
el	O
rápido	O
aumento	O
de	O
células	B-Cell
expresando	O
rodopsina	B-Protein
y	O
otra	O
fototransducción	O
genes	B-Sequence
entre	O
P6-P8	O
[	O
34-37	O
]	O
.	O

En	O
P9	O
,	O
la	O
intensidad	O
de	O
la	O
Señora	B-Protein
la	O
señal	O
se	O
redujo	O
significativamente	O
pero	O
se	O
localizó	O
en	O
la	O
capa	O
nuclear	O
externa	O
(	O
ONL	O
)	O
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Débil	O
expresión	O
de	O
Señora	B-Protein
ARNm	B-Chemical
se	O
observó	O
en	O
adultos	O
fotorreceptores	B-Cell
en	I-Cell
la	I-Cell
retina	I-Cell
adulta	I-Cell
(	O
Fig	O
.	O
2G	O
)	O
.	O

Figura	O
2	O

Señora	B-Protein
expresión	O
en	O
desarrollo	O
ratón	B-Taxon
retina	O
y	O
glándula	O
pineal	O
.	O

(	O
A-G	O
)	O
Señora	B-Protein
expresión	O
durante	O
el	O
desarrollo	O
de	O
la	O
ratón	B-Taxon
retina	O

La	O
señal	O
de	O
hibridación	O
in	O
situ	O
de	O
Señora	B-Protein
no	O
se	O
detectó	O
en	O
E13	O
(	O
A	O
)	O
.	O

La	O
señal	O
(	O
flecha	O
)	O
se	O
detectó	O
por	O
primera	O
vez	O
en	O
el	O
aspecto	O
exterior	O
de	O
NBL	O
en	O
E18	O
(	O
B	O
)	O
.	O

Un	O
fuerte	O
Señora	B-Protein
la	O
señal	O
se	O
detectó	O
en	O
la	O
capa	O
externa	O
de	O
la	O
retina	O
en	O
P3-P6	O
,	O
y	O
luego	O
la	O
señal	O
disminuyó	O
en	O
la	O
retina	O
adulta	O
(	O
E-G	O
)	O
.	O

Controlar	O
con	O
el	O
sentido	O
Investigacion	B-Sequence
en	O
E18	O
se	O
muestra	O
la	O
retina	O
(	O
C	O
)	O
.	O

Barra	O
de	O
escala	O
,	O
100	O
mu	O
m	O
.	O

(	O
H	O
)	O
Análisis	O
de	O
transferencia	O
Northern	O
de	O
Señora	B-Protein
expresión	O
en	O
adulto	O
ratón	B-Taxon
organos	O

La	O
flecha	O
corresponde	O
a	O
2	O
.	O
2kb	O
Señora	B-Protein
transcripción	B-Sequence
.	O

(	O
I	O
)	O
Análisis	O
RT-PCR	O
del	O
total	O
ARN	B-Sequence
extraído	O
de	O
E13	O
embrión	O
completo	O
,	O
P0	O
cuerpo	O
completo	O
(	O
excepto	O
el	O
ojo	O
)	O
,	O
P7	O
retina	O
,	O
P7	O
glándula	O
pineal	O
,	O
P7	O
cerebro	O
,	O
P7	O
hígado	O
,	O
retina	O
adulta	O
,	O
glándula	O
pineal	O
adulta	O
,	O
cerebro	O
adulto	O
e	O
hígado	O
adulto	O
,	O
respectivamente	O
.	O

EPR	O
,	O
epitelio	O
pigmentario	O
de	O
la	O
retina	O
;	O
NR	O
,	O
retina	O
neural	O
;	O
NBL	O
,	O
capa	O
neuroblástica	O
;	O
GCL	O
,	O
célula	B-Cell
ganglionar	I-Cell
capa	O
;	O
ONL	O
,	O
capa	O
nuclear	O
externa	O
;	O
INL	O
,	O
capa	O
nuclear	O
interna	O
.	O

Para	O
determinar	O
la	O
especificidad	O
tisular	O
de	O
Señora	B-Protein
expresión	O
,	O
la	O
expresión	O
de	O
la	O
Señora	B-Protein
gene	B-Sequence
en	O
varios	O
tejidos	O
adultos	O
se	O
examinó	O
mediante	O
hibridación	O
Northern	O
(	O
Fig	O
.	O
2H	O
)	O
.	O

Como	O
control	O
,	O
retina	O
P7	O
ARN	B-Sequence
se	O
utilizó	O
.	O

Cuatro	O
bandas	O
correspondientes	O
a	O
7	O
.	O
2	O
kb	O
,	O
4	O
.	O
0	O
-	O
kb	O
,	O
2	O
.	O
5	O
kb	O
y	O
2	O
.	O
Se	O
detectaron	O
2	O
kb	O
en	O
la	O
retina	O
P7	O
.	O

El	O
2	O
.	O
La	O
banda	O
de	O
2	O
kb	O
corresponde	O
a	O
la	O
ADNc	B-Sequence
caracterizado	O
en	O
este	O
estudio	O
.	O

Las	O
bandas	O
más	O
grandes	O
,	O
posiblemente	O
transcripciones	B-Sequence
empalmadas	I-Sequence
alternativas	I-Sequence
,	O
aún	O
no	O
han	O
sido	O
caracterizados	O
.	O

los	O
Señora	B-Protein
Investigacion	B-Sequence
no	O
detectó	O
una	O
banda	O
en	O
los	O
tejidos	O
adultos	O
examinados	O
,	O
lo	O
que	O
indica	O
que	O
estos	O
tejidos	O
no	O
expresan	O
Señora	B-Protein
a	O
un	O
nivel	O
comparable	O
al	O
de	O
la	O
retina	O
en	O
desarrollo	O
.	O

Informes	O
anteriores	O
revelaron	O
que	O
muchos	O
fotorreceptor	B-Cell
#	O
¿NOMBRE	O
?	O
genes	B-Sequence
también	O
se	O
expresan	O
en	O
la	O
glándula	O
pineal	O
[	O
38	O
]	O
.	O

Examinamos	O
la	O
expresión	O
de	O
Señora	B-Protein
transcripciones	B-Sequence
en	O
el	O
embrión	O
completo	O
,	O
cuerpo	O
completo	O
,	O
retina	O
,	O
glándula	O
pineal	O
,	O
cerebro	O
,	O
hígado	O
y	O
otros	O
órganos	O
en	O
varias	O
etapas	O
por	O
RT-PCR	O
(	O
Fig	O
.	O
2I	O
y	O
datos	O
no	O
mostrados	O
)	O
.	O

Amplificamos	O
PCR	O
fragmentos	B-Sequence
de	I-Sequence
292	I-Sequence
pb	I-Sequence
y	I-Sequence
452	I-Sequence
pb	I-Sequence
con	I-Sequence
pares	I-Sequence
de	I-Sequence
cebadores	I-Sequence
para	I-Sequence
genes	I-Sequence
codificación	O
ratón	B-Protein
mr	I-Protein
-	I-Protein
s	I-Protein
y	I-Protein
G3PDH	I-Protein
,	O
respectivamente	O
.	O

En	O
E13	O
embrión	O
completo	O
y	O
P0	O
cuerpo	O
completo	O
(	O
excepto	O
el	O
ojo	O
)	O
,	O
no	O
Señora	B-Protein
se	O
detectó	O
la	O
señal	O
.	O

Como	O
era	O
de	O
esperar	O
,	O
observamos	O
que	O
Señora	B-Protein
Se	O
expresa	O
en	O
el	O
P7	O
y	O
en	O
la	O
glándula	O
pineal	O
del	O
adulto	O
.	O

En	O
el	O
P7	O
y	O
el	O
cerebro	O
,	O
el	O
hígado	O
y	O
varios	O
otros	O
órganos	O
adultos	O
,	O
la	O
banda	O
amplificada	O
por	O
RT-PCR	O
de	O
Señora	B-Protein
no	O
fue	O
detectado	O
(	O
Fig	O
.	O
2I	O
y	O
datos	O
no	O
mostrados	O
)	O
.	O

Nuestros	O
datos	O
mostraron	O
que	O
Señora	B-Protein
se	O
expresa	O
predominantemente	O
en	O
el	O
desarrollo	O
fotorreceptores	B-Cell
y	O
la	O
glándula	O
pineal	O
.	O

Regulación	O
de	O
Señora	B-Protein
transcripción	O
por	O
Proteína	B-Protein
con	I-Protein
homeodominio	I-Protein
crx	I-Protein

Factores	O
de	O
transcripción	O
Otx2	B-Protein
y	O
crx	B-Protein
son	O
conocidos	O
por	O
ser	O
reguladores	O
clave	O
de	O
fotorreceptor	B-Cell
de	I-Cell
la	I-Cell
retina	I-Cell
desarrollo	O
[	O
3	O
,	O
8	O
,	O
9	O
]	O
.	O

Aunque	O
ambos	O
Otx2	B-Protein
y	O
crx	B-Protein
se	O
expresan	O
en	O
el	O
desarrollo	O
células	B-Cell
fotorreceptoras	I-Cell
en	I-Cell
la	I-Cell
retina	I-Cell
embrionaria	I-Cell
,	O
solamente	O
crx	B-Protein
se	O
expresa	O
mucho	O
en	O
el	O
posparto	O
fotorreceptores	B-Cell
,	O
sugiriendo	O
que	O
Señora	B-Protein
puede	O
estar	O
regulado	O
por	O
crx	B-Protein
.	O

Para	O
probar	O
si	O
crx	B-Protein
regula	O
Señora	B-Protein
transcripción	O
,	O
realizamos	O
hibridación	O
in	O
situ	O
de	O
Señora	B-Protein
ARNm	B-Chemical
en	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
crx	B-Protein
Retinas	O
KO	O
P5	O
(	O
Fig	O
.	O
3A	O
,	O
B	O
)	O
.	O

En	O
el	O
crx	B-Protein
KO	O
retina	O
,	O
la	O
Señora	B-Protein
transcripción	B-Sequence
se	O
redujo	O
drásticamente	O
(	O
Fig	O
.	O
3B	O
)	O
.	O

Esto	O
indica	O
que	O
crx	B-Protein
es	O
esencial	O
para	O
la	O
transactivación	O
de	O
Señora	B-Protein
.	O

Además	O
,	O
para	O
comprobar	O
si	O
la	O
transcripción	O
de	O
Señora	B-Protein
también	O
está	O
regulado	O
por	O
crx	B-Protein
en	O
la	O
glándula	O
pineal	O
,	O
se	O
utilizó	O
el	O
análisis	O
RT-PCR	O
para	O
comparar	O
los	O
niveles	O
transcripcionales	O
de	O
Señora	B-Protein
en	O
P28	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
crx	B-Protein
Glándula	O
pineal	O
KO	O
(	O
Fig	O
.	O
3C	O
)	O
.	O

Los	O
resultados	O
revelaron	O
que	O
Señora	B-Protein
la	O
transcripción	O
se	O
reguló	O
significativamente	O
en	O
el	O
crx	B-Protein
Glándula	O
pineal	O
KO	O
.	O

En	O
conjunto	O
,	O
estos	O
datos	O
indican	O
que	O
Señora	B-Protein
La	O
transcripción	O
está	O
regulada	O
por	O
crx	B-Protein
en	O
desarrollo	O
fotorreceptores	B-Cell
y	O
glándula	O
pineal	O
.	O

figura	O
3	O

la	O
transcripción	O
de	O
Señora	B-Protein
está	O
regulado	O
por	O
crx	B-Protein
.	O

(	O
A	O
,	O
B	O
)	O
Hibridación	O
in	O
situ	O
utilizando	O
un	O
Investigacion	B-Sequence
por	O
ratón	B-Protein
mr	I-Protein
-	I-Protein
s	I-Protein
se	O
realizó	O
en	O
el	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
A	O
)	O
y	O
crx	B-Protein
Retinas	O
KO	O
(	O
B	O
)	O
en	O
P5	O
.	O

Señora	B-Protein
expresión	O
se	O
redujo	O
drásticamente	O
en	O
el	O
crx	B-Protein
KO	O
retina	O
(	O
B	O
)	O
.	O

Barra	O
de	O
escala	O
,	O
100	O
mu	O
m	O
.	O

(	O
C	O
)	O
RT	O
-	O
Análisis	O
PCR	O
del	O
total	O
ARN	B-Sequence
extraído	O
de	O
las	O
glándulas	O
pineales	O
de	O
P5	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
crx	B-Protein
KO	O
ratón	B-Taxon
.	O

Los	O
carriles	O
superior	O
e	O
inferior	O
muestran	O
productos	B-Sequence
PCR	I-Sequence
amplificado	O
por	O
el	O
cebador	B-Sequence
pares	O
específicos	O
para	O
Señora	B-Protein
y	O
G3PDH	B-Protein
ADNc	B-Sequence
,	O
respectivamente	O
.	O

Agua	B-Chemical
se	O
utilizó	O
para	O
la	O
reacción	O
de	O
RT-PCR	O
de	O
control	O
.	O

(	O
D	O
-	O
F	O
)	O
crx	B-Protein
transactiva	O
Señora	B-Protein
transcripción	O

Reportero	O
plásmidos	B-Sequence
para	O
el	O
ensayo	O
de	O
luciferasa	O
se	O
muestran	O
.	O

Los	O
cuadros	O
azules	O
representan	O
crx	B-Protein
sitios	B-Sequence
de	I-Sequence
unión	I-Sequence
(	O
D	O
)	O
.	O

La	O
actividad	O
relativa	O
de	O
la	O
luciferasa	O
se	O
indica	O
cuando	O
Pro1	O
.	O
2k	O
fue	O
co	O
-	O
transfectado	O
con	O
crx	B-Protein
,	O
Otx2	B-Protein
,	O
NRL	B-Protein
,	O
y	O
crx	B-Protein
+	O
NRL	B-Protein
,	O
respectivamente	O
(	O
E	O
)	O
.	O

La	O
activación	O
del	O
pliegue	O
se	O
indica	O
cuando	O
Pro1	O
.	O
2k	O
,	O
mut1259	O
,	O
mut198	O
,	O
mut72	O
y	O
mudo	B-Sequence
todos	O
fueron	O
co	O
-	O
transfectados	O
con	O
el	O
crx	B-Protein
expresión	O
vector	B-Sequence
(	O
crx	B-Protein
+	O
)	O
o	O
el	O
vacío	O
vector	B-Sequence
(	O
crx	B-Protein
-	O
)	O
en	O
HEK293T	O
células	B-Cell
(	O
F	O
)	O
.	O

Las	O
barras	O
de	O
error	O
representan	O
el	O
error	O
estándar	O
de	O
la	O
media	O
.	O

Para	O
examinar	O
más	O
a	O
fondo	O
si	O
crx	B-Protein
regula	O
Señora	B-Protein
transcripción	O
directa	O
o	O
no	O
,	O
luego	O
realizamos	O
un	O
ensayo	O
de	O
luciferasa	O
usando	O
el	O
1	O
.	O
2	O
-	O
kb	O
proximal	O
región	B-Sequence
promotora	I-Sequence
de	O
Señora	B-Protein
fusionado	O
a	O
una	O
luciferasa	O
gene	B-Sequence
como	O
reportero	O
de	O
luciferasa	O
(	O
Fig	O
.	O
3D	O
,	O
Pro1	O
.	O
2k	O
)	O
y	O
el	O
crx	B-Protein
,	O
Otx2	B-Protein
,	O
NRL	B-Protein
expresión	O
vectores	B-Sequence
,	O
respectivamente	O
.	O

este	O
1	O
.	O
2	O
kilobytes	O
región	B-Sequence
de	O
El	O
Señora	B-Protein
río	O
arriba	O
secuencia	B-Sequence
contiene	O
tres	O
crx	B-Protein
unión	B-Sequence
de	I-Sequence
secuencias	I-Sequence
de	I-Sequence
consenso	I-Sequence
.	O

Como	O
se	O
muestra	O
en	O
la	O
figura	O
.	O

3E	O
,	O
la	O
actividad	O
de	O
la	O
luciferasa	O
aumentó	O
significativamente	O
cuando	O
el	O
crx	B-Protein
o	O
Otx2	B-Protein
expresión	O
vector	B-Sequence
fue	O
presentado	O
conjuntamente	O
con	O
Pro1	O
.	O
2k	O
en	O
HEK293T	O
células	B-Cell
,	O
mientras	O
que	O
la	O
actividad	O
de	O
la	O
luciferasa	O
no	O
se	O
alteró	O
cuando	O
la	O
NRL	B-Protein
expresión	O
vector	B-Sequence
fue	O
co	O
-	O
presentado	O
.	O

Un	O
informe	O
anterior	O
sugirió	O
que	O
la	O
actividad	O
transcripcional	O
de	O
crx	B-Protein
se	O
aumenta	O
con	O
NRL	B-Protein
cuando	O
el	O
rodopsina	B-Protein
promotor	B-Sequence
fue	O
utilizado	O
como	O
reportero	O
gene	B-Sequence
[	O
6	O
]	O
.	O

Por	O
otro	O
lado	O
,	O
nuestros	O
datos	O
actuales	O
mostraron	O
que	O
la	O
luciferasa	O
gene	B-Sequence
expresión	O
no	O
se	O
reguló	O
cuando	O
ambos	O
crx	B-Protein
y	O
NRL	B-Protein
expresión	O
vectores	B-Sequence
se	O
introdujeron	O
conjuntamente	O
con	O
Pro1	O
.	O
2k	O
en	O
comparación	O
con	O
la	O
actividad	O
cuando	O
el	O
crx	B-Protein
única	O
expresión	O
vector	B-Sequence
Fue	O
presentado	O
.	O

Esto	O
puede	O
deberse	O
a	O
célula	B-Cell
diferencias	O
de	O
tipo	O
porque	O
célula	B-Cell
El	O
tipo	O
de	O
origen	O
retinal/pineal	O
no	O
se	O
usó	O
en	O
nuestro	O
ensayo	O
de	O
luciferasa	O
.	O

Además	O
,	O
nuestros	O
datos	O
actuales	O
mostraron	O
que	O
Otx2	B-Protein
,	O
que	O
se	O
informa	O
que	O
tiene	O
el	O
mismo	O
enlace	O
consenso	B-Sequence
como	O
crx	B-Protein
,	O
también	O
transactivado	O
Señora	B-Protein
expresión	O
.	O

Como	O
se	O
muestra	O
en	O
la	O
figura	O
.	O

2A	O
-	O
F	O
,	O
el	O
patrón	O
de	O
expresión	O
de	O
Señora	B-Protein
se	O
correlaciona	O
con	O
la	O
de	O
crx	B-Protein
.	O

En	O
contraste	O
,	O
el	O
transcripciones	B-Sequence
de	O
Otx2	B-Protein
se	O
detectan	O
principalmente	O
en	O
el	O
fotorreceptor	B-Cell
capa	O
en	O
etapas	O
embrionarias	O
.	O

Por	O
lo	O
tanto	O
,	O
concluimos	O
que	O
Señora	B-Protein
La	O
transcripción	O
está	O
directamente	O
regulada	O
principalmente	O
por	O
crx	B-Protein
.	O

También	O
construimos	O
reportero	O
vectores	B-Sequence
en	O
el	O
cual	O
mutaciones	B-Sequence
fueron	O
presentados	O
en	O
los	O
tres	O
crx	B-Protein
sitios	B-Sequence
de	I-Sequence
unión	I-Sequence
(	O
Fig	O
.	O
3D	O
,	O
mut1259	O
,	O
mut198	O
,	O
mut72	O
,	O
mudo	B-Sequence
todos	O
)	O
.	O

Entonces	O
el	O
crx	B-Protein
expresión	O
vector	B-Sequence
fue	O
presentado	O
conjuntamente	O
con	O
mut1259	O
,	O
mut198	O
,	O
mut72	O
y	O
mudo	B-Sequence
todos	O
,	O
respectivamente	O
(	O
Fig	O
.	O
3F	O
)	O
.	O

La	O
actividad	O
de	O
transactivación	O
por	O
crx	B-Protein
se	O
redujo	O
claramente	O
cuando	O
se	O
introdujeron	O
conjuntamente	O
mut198	O
o	O
mut72	O
.	O

Por	O
otro	O
lado	O
,	O
cuando	O
se	O
cotransfectó	O
mut1259	O
,	O
la	O
actividad	O
de	O
transactivación	O
por	O
crx	B-Protein
no	O
fue	O
alterado	O
.	O

Estos	O
resultados	O
sugieren	O
que	O
la	O
crx	B-Protein
sitios	B-Sequence
de	I-Sequence
unión	I-Sequence
-72	O
pb	B-Sequence
y	O
198	O
-	O
pb	B-Sequence
aguas	O
arriba	O
de	O
la	O
sitio	B-Sequence
de	I-Sequence
iniciación	I-Sequence
de	I-Sequence
la	I-Sequence
transcripción	I-Sequence
son	O
cruciales	O
para	O
la	O
regulación	O
directa	O
de	O
Señora	B-Protein
transcripción	O
por	O
crx	B-Protein
.	O

Autoasociación	O
de	O
Señora	B-Protein
proteína	B-Chemical

SAM	O
dominios	B-Sequence
se	O
sabe	O
que	O
funcionan	O
como	O
proteína	B-Chemical
-	O
proteína	B-Chemical
Interacción	O
módulos	B-Sequence
[	O
15	O
-	O
17	O
]	O
.	O

Aunque	O
SAM	O
dominios	B-Sequence
puede	O
unirse	O
a	O
varios	O
no	O
-	O
SAM	O
dominio	B-Sequence
#	O
¿NOMBRE	O
?	O
proteinas	B-Chemical
,	O
muchos	O
homo	O
-	O
SAM	O
y	O
hetero	O
-	O
SAM	O
dominio	B-Sequence
se	O
han	O
reportado	O
interacciones	O
.	O

Para	O
investigar	O
si	O
el	O
SAM	O
dominio	B-Sequence
de	O
El	O
Señora	B-Protein
proteína	B-Chemical
también	O
puede	O
funcionar	O
como	O
un	O
proteína	B-Chemical
-	O
proteína	B-Chemical
Interacción	O
módulo	B-Sequence
,	O
Actuamos	O
levadura	B-Taxon
dos	O
-	O
cribado	O
híbrido	O
utilizando	O
longitud	O
completa	O
Señora	B-Protein
proteína	B-Chemical
como	O
el	O
cebo	O
.	O

Usando	O
este	O
cebo	O
,	O
examinamos	O
el	O
activador	O
transcripcional	O
fusión	B-Sequence
proteína	B-Chemical
biblioteca	O
en	O
la	O
que	O
ratón	B-Taxon
retina	O
P0	O
-	O
P3	O
ADNc	B-Sequence
estaban	O
fusionados	O
con	O
el	O
GAL4	B-Protein
activación	O
dominio	B-Sequence
.	O

Lo	O
positivo	O
más	O
frecuente	O
clones	B-Sequence
(	O
5	O
de	O
28	O
)	O
fueron	O
fragmentos	B-Sequence
de	I-Sequence
ADNc	I-Sequence
que	O
contiene	O
el	O
SAM	O
dominio	B-Sequence
de	O
Señora	B-Protein
(	O
Fig	O
.	O
4A	O
)	O
.	O

Este	O
resultado	O
sugiere	O
fuertemente	O
que	O
Señora	B-Protein
proteína	B-Chemical
autoasociados	O
a	O
través	O
de	O
SAM	O
dominio	B-Sequence
#	O
¿NOMBRE	O
?	O
regiones	B-Sequence
.	O

Luego	O
probamos	O
directamente	O
esta	O
autoasociación	O
de	O
Señora	B-Protein
proteína	B-Chemical
en	O
levadura	B-Taxon
.	O

Fusionamos	O
de	O
cuerpo	O
entero	O
o	O
truncados	O
porciones	B-Sequence
de	O
El	O
Señora	B-Protein
proteína	B-Chemical
al	O
ADN	B-Sequence
#	O
¿NOMBRE	O
?	O
dominio	B-Sequence
de	O
El	O
levadura	B-Taxon
factor	O
de	O
transcripcion	O
GAL4	B-Protein
para	O
hacer	O
cebo	O
construcciones	B-Sequence
.	O

Fusionamos	O
de	O
cuerpo	O
entero	O
o	O
truncados	O
porciones	B-Sequence
de	O
El	O
Señora	B-Protein
proteína	B-Chemical
al	O
GAL4	B-Protein
activación	O
transcripcional	O
dominio	B-Sequence
hacer	O
presa	O
construcciones	B-Sequence
(	O
Figura	O
4B	O
)	O
.	O

Estas	O
construcciones	B-Sequence
fueron	O
transformados	O
en	O
levadura	B-Taxon
que	O
contienen	O
un	O
transgén	B-Sequence
con	O
GAL4	B-Protein
sitios	B-Sequence
de	I-Sequence
unión	I-Sequence
aguas	O
arriba	O
de	O
la	O
lacZ	O
gene	B-Sequence
.	O

Encontramos	O
que	O
la	O
longitud	O
completa	O
Señora	B-Protein
cebo	O
construir	B-Sequence
expresión	O
lacZ	O
inducida	O
con	O
la	O
longitud	O
completa	O
Señora	B-Protein
presa	O
construir	B-Sequence
(	O
Fig	O
.	O
4B	O
,	O
lleno	O
x	O
lleno	O
)	O
.	O

los	O
N	B-Sequence
-	I-Sequence
terminal	I-Sequence
400	I-Sequence
aminoácido	I-Sequence
(	I-Sequence
aa	I-Sequence
)	I-Sequence
tramo	I-Sequence
de	O
Señora	B-Protein
,	O
que	O
no	O
contiene	O
un	O
SAM	O
dominio	B-Sequence
,	O
activa	O
débilmente	O
la	O
transcripción	O
de	O
lacZ	O
(	O
Fig	O
.	O
4B	O
,	O
x	O
completo	O
norte	B-Sequence
)	O
.	O

los	O
N	B-Sequence
-	I-Sequence
tramo	I-Sequence
terminal	I-Sequence
400	I-Sequence
aa	I-Sequence
de	O
Señora	B-Protein
fue	O
capaz	O
de	O
inducir	O
la	O
transcripción	O
de	O
lacZ	O
débilmente	O
con	O
el	O
mismo	O
N	B-Sequence
-	I-Sequence
tramo	I-Sequence
terminal	I-Sequence
400	I-Sequence
aa	I-Sequence
de	O
Señora	B-Protein
(	O
Fig	O
.	O
4B	O
,	O
norte	B-Sequence
X	O
norte	B-Sequence
)	O
.	O

Aunque	O
el	O
N	B-Sequence
-	I-Sequence
terminal	I-Sequence
400	O
Automóvil	B-Chemical
club	I-Chemical
británico	I-Chemical
Señora	B-Protein
proteína	B-Chemical
activa	O
débilmente	O
la	O
transcripción	O
lacZ	O
con	O
el	O
mismo	O
N	B-Sequence
-	I-Sequence
porción	I-Sequence
terminal	I-Sequence
,	O
se	O
observó	O
una	O
activación	O
mucho	O
más	O
fuerte	O
de	O
la	O
expresión	O
de	O
lacZ	O
con	O
un	O
C	B-Sequence
-	I-Sequence
porción	I-Sequence
terminal	I-Sequence
codificando	O
el	O
391	O
-	O
542	O
Automóvil	B-Chemical
club	I-Chemical
británico	I-Chemical
tramo	B-Sequence
de	O
Señora	B-Protein
(	O
Fig	O
.	O
4B	O
,	O
completo	O
x	O
C	B-Sequence
,	O
C	B-Sequence
X	O
C	B-Sequence
)	O
.	O

Nuestro	O
GAL4	B-Protein
ensayo	O
indicó	O
que	O
la	O
señal	O
cuando	O
la	O
longitud	O
completa	O
Señora	B-Protein
estaba	O
presente	O
tanto	O
en	O
el	O
contexto	O
del	O
cebo	O
como	O
en	O
el	O
de	O
la	O
presa	O
era	O
más	O
débil	O
que	O
cuando	O
estaba	O
aislado	O
SAM	O
dominios	B-Sequence
fueron	O
usados	O
.	O

Esto	O
puede	O
reflejar	O
simplemente	O
la	O
tendencia	O
de	O
los	O
pequeños	O
fusión	B-Sequence
proteinas	B-Chemical
para	O
entrar	O
a	O
levadura	B-Taxon
núcleo	B-GENE
y	O
ocupar	O
GAL4	B-Protein
sitios	B-Sequence
de	I-Sequence
unión	I-Sequence
.	O

Alternativamente	O
,	O
el	O
SAM	O
dominio	B-Sequence
puede	O
ser	O
menos	O
accesible	O
para	O
la	O
interacción	O
en	O
toda	O
su	O
longitud	O
proteína	B-Chemical
contexto	O
como	O
se	O
informó	O
anteriormente	O
[	O
39	O
]	O
.	O

Figura	O
4	O

Resumen	O
de	O
levadura	B-Taxon
dos	O
-	O
cribado	O
híbrido	O
y	O
GAL4	B-Protein
ensayo	O

(	O
A	O
)	O
de	O
cuerpo	O
entero	O
Señora	B-Protein
como	O
cebo	O
utilizado	O
en	O
la	O
levadura	B-Taxon
dos	O
-	O
cribado	O
híbrido	O
y	O
positivo	O
clones	B-Sequence
se	O
indican	O
.	O

Tenga	O
en	O
cuenta	O
que	O
los	O
cinco	O
Señora	B-Protein
clones	B-Sequence
identificados	O
en	O
la	O
evaluación	O
contienen	O
SAM	O
dominios	B-Sequence
.	O

(	O
B	O
)	O
Diagrama	O
esquemático	O
del	O
Señora	B-Protein
fusión	B-Sequence
proteinas	B-Chemical
utilizado	O
en	O
el	O
levadura	B-Protein
GAL4	I-Protein
ensayo	O

Los	O
recuadros	O
negros	O
representan	O
el	O
posición	B-Sequence
de	I-Sequence
los	I-Sequence
dominios	I-Sequence
SAM	I-Sequence
.	O

Los	O
niveles	O
relativos	O
de	O
expresión	O
de	O
LacZ	O
se	O
muestran	O
a	O
la	O
derecha	O
,	O
respectivamente	O
.	O

Nota	O
;	O
++	O
indica	O
una	O
señal	O
azul	O
intensa	O
visible	O
después	O
de	O
12	O
horas	O
de	O
incubación	O
a	O
37	O
grados	O
C	O
,	O
+	O
indica	O
una	O
señal	O
azul	O
visible	O
después	O
de	O
24	O
horas	O
de	O
incubación	O
.	O

BD	B-Sequence
Unión	O
dominio	B-Sequence
;	O
ANUNCIO	O
,	O
activación	O
dominio	B-Sequence
;	O
completo	O
,	O
de	O
cuerpo	O
entero	O
Señora	B-Protein
;	O
norte	B-Sequence
,	O
N	B-Sequence
-	I-Sequence
porción	I-Sequence
terminal	I-Sequence
de	O
Señora	B-Protein
(	O
aminoácidos	B-Chemical
1	O
a	O
400	O
)	O
;	O
C	B-Sequence
,	O
C	B-Sequence
-	I-Sequence
porción	I-Sequence
terminal	I-Sequence
de	O
Señora	B-Protein
(	O
aminoácidos	B-Chemical
391	O
a	O
542	O
)	O
.	O

Para	O
confirmar	O
la	O
autoasociación	O
del	O
Señora	B-Protein
proteína	B-Chemical
en	O
mamífero	B-Taxon
células	B-Cell
,	O
luego	O
realizamos	O
estudios	O
de	O
co-inmunoprecipitación	O
en	O
HEK293T	O
células	B-Cell
por	O
co	O
-	O
transfección	O
de	O
HA	O
-	O
etiquetado	O
de	O
longitud	O
completa	O
/	O
truncado	O
Señora	B-Protein
y	O
Marcar	O
-	O
etiquetado	O
de	O
longitud	O
completa	O
/	O
truncado	O
Señora	B-Protein
(	O
Figura	O
5A	O
)	O
.	O

Como	O
control	O
negativo	O
,	O
construimos	O
Flag	O
-	O
tagged	O
erizo	B-Protein
Sonic	I-Protein
(	O
Shh	B-Protein
)	O
(	O
carril	O
2	O
y	O
7	O
)	O
.	O

De	O
acuerdo	O
con	O
el	O
resultado	O
de	O
la	O
levadura	B-Taxon
dos	O
-	O
híbrido	O
GAL4	B-Protein
ensayo	O
,	O
HA	O
-	O
etiquetado	O
de	O
longitud	O
completa	O
Señora	B-Protein
(	O
full	O
-	O
HA	O
)	O
fue	O
co	O
-	O
inmunoprecipitado	O
con	O
Flag	O
-	O
etiquetado	O
de	O
longitud	O
completa	O
Señora	B-Protein
(	O
Bandera	O
-	O
Señora	B-Protein
)	O
y	O
la	O
Bandera	O
-	O
etiquetados	O
C	B-Sequence
-	I-Sequence
porción	I-Sequence
terminal	I-Sequence
que	O
contiene	O
el	O
SAM	O
dominio	B-Sequence
(	O
Bandera-SAM	O
)	O
,	O
respectivamente	O
(	O
Fig	O
.	O
5B	O
,	O
lane3	O
y	O
lane5	O
)	O
.	O

También	O
encontramos	O
una	O
banda	O
débil	O
de	O
co-inmunoprecipitación	O
en	O
la	O
co-transfección	O
de	O
full-HA	O
y	O
Flag-tagged	O
N	B-Sequence
-	I-Sequence
porción	I-Sequence
terminal	I-Sequence
de	O
Señora	B-Protein
(	O
Bandera-Delta	O
SAM	O
,	O
Fig	O
.	O
5B	O
,	O
carril	O
4	O
)	O
.	O

Cuando	O
Delta	O
SAM	O
-	O
HA	O
y	O
Flag	O
-	O
etiquetado	O
mutantes	B-Sequence
por	I-Sequence
deleción	I-Sequence
fueron	O
co	O
-	O
transfectados	O
,	O
Delta	O
SAM	O
-	O
HA	O
fue	O
co	O
-	O
inmunoprecipitado	O
con	O
Flag	O
-	O
Señora	B-Protein
y	O
Flag-Delta	O
SAM	O
(	O
Fig	O
.	O
5B	O
,	O
carril	O
8	O
y	O
carril	O
9	O
)	O
,	O
mientras	O
que	O
Delta	O
SAM-HA	O
no	O
fue	O
co-inmunoprecipitado	O
con	O
Flag-SAM	O
(	O
Fig	O
.	O
5B	O
,	O
carril	O
10	O
)	O
.	O

Figura	O
5	O

los	O
Señora	B-Protein
proteína	B-Chemical
puede	O
auto-asociarse	O
en	O
mamífero	B-Taxon
células	B-Cell
.	O

(	O
A	O
)	O
Dibujo	O
esquemático	O
de	O
la	O
construcciones	B-Sequence
utilizado	O
para	O
el	O
ensayo	O
de	O
inmunoprecipitación	O
.	O

HA	O
-	O
etiquetado	O
o	O
Bandera	O
-	O
etiquetado	O
de	O
longitud	O
completa	O
(	O
aminoácidos	B-Chemical
1	O
a	O
542	O
)	O
,	O
Delta	O
SAM	O
(	O
aminoácidos	B-Chemical
1	O
a	O
400	O
)	O
y	O
SAM	O
(	O
aminoácidos	B-Chemical
401	O
a	O
542	O
)	O
regiones	B-Sequence
fueron	O
insertado	B-Sequence
en	O
pcDNA3	O
vector	B-Sequence
,	O
respectivamente	O
.	O

(	O
B	O
)	O
El	O
construcciones	B-Sequence
indicado	O
anteriormente	O
se	O
transfectaron	O
en	O
HEK293T	O
células	B-Cell
.	O

Cada	O
carril	O
fue	O
co	O
-	O
inmunoprecipitado	O
por	O
anti	O
-	O
Flag	O
anticuerpo	B-GENE
y	O
detectado	O
por	O
anti	O
-	O
HA	O
anticuerpo	B-GENE
.	O

Aporte	O
proteína	B-Chemical
los	O
lisados	O
se	O
muestran	O
en	O
los	O
paneles	O
inferiores	O
.	O

(	O
C	O
)	O
Bandera	O
-	O
etiquetado	O
dos	O
sitio	B-Sequence
#	O
¿NOMBRE	O
?	O
Señora	B-Protein
mutantes	B-Sequence
,	O
Flag-W404A	O
y	O
Flag-G453A	O
se	O
generaron	O
y	O
cotransfectaron	O
con	O
full-HA	O
.	O

Cada	O
carril	O
fue	O
co-inmunoprecipitado	O
por	O
anti-HA	O
anticuerpo	B-GENE
y	O
detectado	O
por	O
anti-Bandera	O
anticuerpo	B-GENE
.	O

Para	O
investigar	O
si	O
el	O
Señora	B-Protein
proteína	B-Chemical
auto-asociados	O
principalmente	O
a	O
través	O
del	O
SAM	O
dominio	B-Sequence
dos	O
sitio	B-Sequence
#	O
¿NOMBRE	O
?	O
mutaciones	B-Sequence
se	O
generaron	O
en	O
el	O
SAM	O
dominio	B-Sequence
de	O
Señora	B-Protein
(	O
Fig	O
.	O
1B	O
,	O
flechas	O
)	O
.	O

Estas	O
las	B-Sequence
mutaciones	I-Sequence
alteran	I-Sequence
residuos	B-Chemical
que	O
son	O
conservado	B-Sequence
en	O
el	O
SAM	O
dominio	B-Sequence
de	O
ph	B-Protein
y	O
el	O
informe	O
anterior	O
indica	O
que	O
estos	O
mutaciones	B-Sequence
de	O
ph	B-Protein
#	O
¿NOMBRE	O
?	O
dominio	B-Sequence
#	O
¿NOMBRE	O
?	O
proteína	B-Chemical
,	O
Peine	B-Protein
sexual	I-Protein
en	I-Protein
la	I-Protein
parte	I-Protein
media	I-Protein
de	I-Protein
la	I-Protein
pierna	I-Protein
.	I-Protein
(	O
scm	B-Protein
)	O
(	O
41	O
)	O
.	O

Con	O
base	O
en	O
este	O
resultado	O
,	O
introdujimos	O
dos	O
tipos	O
de	O
sitio	B-Sequence
#	O
¿NOMBRE	O
?	O
mutaciones	B-Sequence
,	O
que	O
corresponden	O
a	O
la	O
mutaciones	B-Sequence
introducido	O
en	O
ph	B-Protein
proteína	B-Chemical
,	O
en	O
Bandera	O
-	O
etiquetado	O
de	O
longitud	O
completa	O
Señora	B-Protein
(	O
Bandera	O
-	O
W404A	O
y	O
Bandera	O
-	O
G453A	O
)	O
.	O

Descubrimos	O
que	O
la	O
actividad	O
de	O
unión	O
de	O
Flag	O
-	O
W404A	O
se	O
redujo	O
significativamente	O
y	O
la	O
actividad	O
de	O
unión	O
de	O
Flag	O
-	O
G453A	O
también	O
se	O
redujo	O
ligeramente	O
en	O
comparación	O
con	O
Flag	O
-	O
Señora	B-Protein
(	O
Fig	O
.	O
5C	O
)	O
.	O

Estos	O
resultados	O
,	O
junto	O
con	O
la	O
levadura	O
bihíbrida	O
GAL4	B-Protein
ensayo	O
,	O
indican	O
que	O
el	O
Señora	B-Protein
proteína	B-Chemical
auto-se	O
asocia	O
fuertemente	O
a	O
través	O
de	O
su	O
SAM	O
dominio	B-Sequence
y	O
débilmente	O
a	O
través	O
de	O
la	O
N	B-Sequence
-	I-Sequence
porción	I-Sequence
terminal	I-Sequence
sin	O
SAM	O
dominio	B-Sequence
.	O

La	O
localización	O
subcelular	O
de	O
Señora	B-Protein
proteína	B-Chemical
en	O
mamífero	B-Taxon
células	B-Cell

el	O
putativo	O
nuclear	B-GENE
localización	O
señal	B-Sequence
en	O
el	O
N	B-Sequence
-	I-Sequence
terminal	I-Sequence
de	O
El	O
Señora	B-Protein
proteína	B-Chemical
(	O
Fig	O
.	O
1A	O
,	O
cuadro	O
punteado	O
)	O
sugiere	O
que	O
el	O
Señora	B-Protein
proteína	B-Chemical
se	O
localiza	O
en	O
el	O
núcleo	B-GENE
.	O

Para	O
determinar	O
la	O
localización	O
subcelular	O
de	O
Señora	B-Protein
en	O
mamífero	B-Taxon
células	B-Cell
,	O
introdujimos	O
un	O
HA	O
-	O
etiquetado	O
de	O
longitud	O
completa	O
Señora	B-Protein
plásmido	B-Sequence
en	O
HEK293T	O
células	B-Cell
.	O

La	O
microscopía	O
confocal	O
mostró	O
que	O
la	O
Señora	B-Protein
proteína	B-Chemical
localizada	O
principalmente	O
en	O
el	O
núcleo	B-GENE
de	O
HEK293T	O
células	B-Cell
(	O
Fig	O
.	O
6A	O
,	O
B	O
)	O
.	O

Para	O
confirmar	O
la	O
localización	O
precisa	O
del	O
Señora	B-Protein
proteína	B-Chemical
,	O
longitud	O
total	O
Señora	B-Protein
fue	O
co	O
-	O
inmunoteñido	O
con	O
DAPI	O
(	O
Fig	O
.	O
6C	O
-	O
E	O
)	O
.	O

Estos	O
datos	O
mostraron	O
que	O
la	O
Señora	B-Protein
proteína	B-Chemical
se	O
localiza	O
preferentemente	O
en	O
el	O
núcleo	B-GENE
en	O
mamífero	B-Taxon
células	B-Cell
,	O
apoyando	O
la	O
idea	O
de	O
que	O
el	O
Señora	B-Protein
proteína	B-Chemical
participa	O
en	O
la	O
regulación	O
transcripcional	O
al	O
igual	O
que	O
ph	B-Protein
y/o	O
TELÉFONO	B-Protein
.	O

Figura	O
6	O

Localización	O
subcelular	O
de	O
Señora	B-Protein
en	O
mamífero	B-Taxon
células	B-Cell
.	O

(	O
A	O
,	O
B	O
)	O
HA	O
-	O
etiquetado	O
de	O
longitud	O
completa	O
Señora	B-Protein
fue	O
transfectado	O
en	O
HEK293T	O
(	O
B	O
)	O
y	O
detectado	O
por	O
anti	O
-	O
HA	O
anticuerpo	B-GENE
(	O
A	O
)	O
.	O

Barra	O
de	O
escala	O
,	O
20	O
mu	O
m	O
.	O

(	O
C	O
-	O
E	O
)	O
HEK293T	O
células	B-Cell
inmunoteñido	O
con	O
anti	O
-	O
HA	O
anticuerpo	B-GENE
(	O
C	O
)	O
,	O
DAPI	O
(	O
D	O
)	O
e	O
imagen	O
fusionada	O
(	O
E	O
)	O
.	O

Barra	O
de	O
escala	O
,	O
50	O
mu	O
m	O
.	O

los	O
GAL4	B-Protein
-	O
Señora	B-Protein
fusión	B-Sequence
proteína	B-Chemical
funciona	O
como	O
represor	O
transcripcional	O

Un	O
miembro	O
de	O
PCG	O
proteinas	B-Chemical
,	O
ph	B-Protein
,	O
no	O
contiene	O
un	O
obvio	O
secuencia	B-Sequence
#	O
¿NOMBRE	O
?	O
ADN	B-Sequence
motivo	O
de	O
unión	O
(	O
16	O
)	O
.	O

Ph	B-Protein
funciona	O
como	O
un	O
represor	O
transcripcional	O
a	O
través	O
de	O
su	O
polimerización	O
y	O
proteína	B-Chemical
-	O
proteína	B-Chemical
interacción	O
con	O
otros	O
secuencia	B-Sequence
-	O
represores	O
transcripcionales	O
específicos	O
,	O
que	O
pueden	O
formar	O
un	O
orden	O
superior	O
estructura	B-GENE
de	I-GENE
la	I-GENE
cromatina	I-GENE
.	O

los	O
Señora	B-Protein
proteína	B-Chemical
tampoco	O
tiene	O
un	O
obvio	O
ADN	B-Sequence
#	O
¿NOMBRE	O
?	O
dominio	B-Sequence
.	O

Caracterizar	O
la	O
actividad	O
bioquímica	O
de	O
Señora	B-Protein
,	O
luego	O
realizamos	O
un	O
ensayo	O
de	O
luciferasa	O
.	O

Generamos	O
efector	O
plásmidos	B-Sequence
,	O
que	O
expresan	O
diversas	O
construcciones	B-Sequence
de	I-Sequence
eliminación	I-Sequence
de	O
Señora	B-Protein
fusionado	O
a	O
la	O
GAL4	B-Protein
ADN	B-Sequence
#	O
¿NOMBRE	O
?	O
dominio	B-Sequence
(	O
Fig	O
.	O
7A	O
)	O
.	O

Primero	O
confirmamos	O
que	O
de	O
larga	O
duración	O
Señora	B-Protein
fusionado	O
a	O
GAL4	B-Protein
ADN	B-Sequence
Unión	O
dominio	B-Sequence
(	O
DH	O
-	O
Señora	B-Protein
)	O
no	O
tuvo	O
efecto	O
sobre	O
el	O
pGL3	O
plásmido	B-Sequence
promotor	I-Sequence
carente	O
GAL4	B-Protein
sitios	B-Sequence
de	I-Sequence
unión	I-Sequence
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Cuando	O
el	O
reportero	O
5xGAL4	O
-	O
pGL3	O
plásmido	B-Sequence
fue	O
co	O
-	O
transfectado	O
,	O
DBD	O
-	O
Señora	B-Protein
reprimió	O
la	O
actividad	O
de	O
la	O
luciferasa	O
en	O
aproximadamente	O
un	O
90	O
%	O
de	O
una	O
manera	O
dependiente	O
de	O
la	O
dosis	O
(	O
Fig	O
.	O
7B	O
)	O
.	O

Como	O
control	O
,	O
GAL4	B-Protein
ADN	B-Sequence
#	O
¿NOMBRE	O
?	O
dominio	B-Sequence
(	O
DBD	O
)	O
no	O
tuvo	O
un	O
efecto	O
significativo	O
en	O
el	O
reportero	O
5xGAL4	O
-	O
pGL3	O
plásmido	B-Sequence
.	O

Además	O
,	O
confirmamos	O
que	O
los	O
álbumes	O
de	O
larga	O
duración	O
Señora	B-Protein
sin	O
GAL4	B-Protein
DBD	O
no	O
tuvo	O
efecto	O
en	O
el	O
mismo	O
reportero	O
plásmido	B-Sequence
(	O
datos	O
no	O
mostrados	O
)	O
.	O

A	O
continuación	O
analizamos	O
construcciones	B-Sequence
de	I-Sequence
eliminación	I-Sequence
en	O
el	O
que	O
la	O
N	B-Sequence
-	I-Sequence
tramo	I-Sequence
terminal	I-Sequence
400	I-Sequence
aa	I-Sequence
de	O
Señora	B-Protein
(	O
aminoácidos	B-Chemical
1	O
a	O
400	O
)	O
o	O
el	O
C	B-Sequence
-	I-Sequence
porción	I-Sequence
terminal	I-Sequence
(	O
aminoácidos	B-Chemical
391	O
a	O
542	O
)	O
se	O
fusionaron	O
con	O
el	O
GAL4	B-Protein
DBD	O
(	O
Fig	O
.	O
7A	O
,	O
DBD	O
-	O
norte	B-Sequence
,	O
DH-	O
C	B-Sequence
)	O
.	O

Mientras	O
DH	O
-	O
norte	B-Sequence
no	O
tuvo	O
ningún	O
efecto	O
represivo	O
en	O
esta	O
actividad	O
de	O
reportero	O
,	O
DBD-	O
C	B-Sequence
luciferasa	O
reprimida	O
gene	B-Sequence
expresión	O
en	O
aproximadamente	O
un	O
65	O
%	O
.	O

Este	O
resultado	O
nos	O
sugirió	O
la	O
posibilidad	O
de	O
que	O
DBD	O
-	O
Señora	B-Protein
ejerce	O
actividad	O
represiva	O
transcripcional	O
a	O
través	O
de	O
la	O
autoasociación	O
a	O
través	O
de	O
su	O
SAM	O
dominio	B-Sequence
.	O

Investigar	O
si	O
la	O
asociación	O
homófila	O
de	O
Señora	B-Protein
se	O
requiere	O
para	O
la	O
represión	O
transcripcional	O
,	O
dos	O
sitio	B-Sequence
#	O
¿NOMBRE	O
?	O
mutantes	B-Sequence
,	O
DBD	O
-	O
W404A	O
y	O
DBD	O
-	O
G453A	O
,	O
cualquiera	O
de	O
los	O
cuales	O
puede	O
reducir	O
la	O
capacidad	O
de	O
autounión	O
,	O
se	O
analizaron	O
(	O
Fig	O
.	O
7C	O
)	O
.	O

Comparado	O
con	O
DBD	O
-	O
Señora	B-Protein
,	O
DBD	O
-	O
W404A	O
y	O
DBD	O
-	O
G453A	O
tuvieron	O
una	O
actividad	O
de	O
represión	O
del	O
72	O
%	O
y	O
87	O
%	O
,	O
respectivamente	O
.	O

Mientras	O
que	O
la	O
habilidad	O
de	O
Señora	B-Protein
la	O
autoasociación	O
se	O
correlaciona	O
parcialmente	O
con	O
la	O
actividad	O
represiva	O
transcripcional	O
,	O
estos	O
mutantes	B-Sequence
no	O
comprometa	O
la	O
capacidad	O
de	O
reprimir	O
la	O
transcripción	O
críticamente	O
.	O

Para	O
determinar	O
el	O
regiones	B-Sequence
de	O
Señora	B-Protein
involucrados	O
en	O
la	O
represión	O
transcripcional	O
más	O
precisamente	O
,	O
el	O
C	B-Sequence
-	I-Sequence
porción	I-Sequence
terminal	I-Sequence
se	O
dividió	O
en	O
dos	O
regiones	B-Sequence
y	O
cada	O
uno	O
estaba	O
fusionado	O
con	O
el	O
GAL4	B-Protein
DBD	O
(	O
Fig	O
.	O
7A	O
,	O
DBD-cola	O
,	O
DBD-SAM	O
)	O
.	O

Como	O
consecuencia	O
,	O
DBD-SAM	O
(	O
aminoácidos	B-Chemical
384	O
a	O
462	O
)	O
no	O
tuvo	O
un	O
efecto	O
represivo	O
sobre	O
el	O
reportero	O
5xGAL4	O
-	O
pGL3	O
plásmido	B-Sequence
.	O

Por	O
otro	O
lado	O
,	O
la	O
actividad	O
de	O
luciferasa	O
fue	O
reprimida	O
en	O
un	O
55	O
%	O
cuando	O
DBD-tail	O
(	O
aminoácidos	B-Chemical
459	O
a	O
542	O
)	O
fue	O
co-transfectado	O
con	O
este	O
reportero	O
plásmido	B-Sequence
(	O
Fig	O
.	O
7D	O
)	O
.	O

Para	O
evaluar	O
la	O
actividad	O
represiva	O
transcripcional	O
de	O
Señora	B-Protein
en	O
células	B-Cell
de	O
origen	O
retiniano	O
,	O
realizamos	O
experimentos	O
similares	O
utilizando	O
humano	B-Taxon
Y79	O
retinoblastoma	O
células	B-Cell
.	O

Los	O
resultados	O
indicaron	O
que	O
DBD	O
-	O
Señora	B-Protein
también	O
redujo	O
significativamente	O
la	O
actividad	O
de	O
la	O
luciferasa	O
en	O
el	O
retinoblastoma	O
Y79	O
células	B-Cell
(	O
Fig	O
.	O
7E	O
)	O
.	O

Sin	O
embargo	O
,	O
la	O
actividad	O
de	O
la	O
luciferasa	O
fue	O
reprimida	O
en	O
un	O
30	O
%	O
en	O
Y79	O
células	B-Cell
,	O
mientras	O
que	O
fue	O
reprimido	O
en	O
un	O
90	O
%	O
en	O
HEK293T	O
células	B-Cell
.	O

Esto	O
podría	O
deberse	O
a	O
la	O
diferencia	O
en	O
la	O
eficiencia	O
de	O
transfección	O
entre	O
estos	O
célula	B-Cell
líneas	O
.	O

Otra	O
posibilidad	O
es	O
que	O
entorno	B-GENE
intracelular	I-GENE
en	O
Y79	O
células	B-Cell
,	O
un	O
retinoblastoma	O
célula	B-Cell
línea	O
,	O
es	O
insuficiente	O
para	O
recapitular	O
el	O
desarrollo	O
fotorreceptores	B-Cell
.	O

En	O
este	O
estudio	O
,	O
no	O
abordamos	O
la	O
cuestión	O
de	O
si	O
nuestros	O
datos	O
in	O
vitro	O
reflejan	O
o	O
no	O
Señora	B-Protein
represión	O
transcripcional	O
in	O
vivo	O
.	O

Sin	O
embargo	O
,	O
estos	O
experimentos	O
in	O
vitro	O
usando	O
HEK293T	O
y	O
Y79	O
células	B-Cell
apoyan	O
firmemente	O
nuestra	O
hipótesis	O
de	O
que	O
Señora	B-Protein
funciona	O
como	O
un	O
represor	O
transcripcional	O
en	O
el	O
desarrollo	O
fotorreceptores	B-Cell
.	O

Nuestros	O
resultados	O
sugirieron	O
que	O
la	O
C	B-Sequence
-	I-Sequence
región	I-Sequence
terminal	I-Sequence
de	O
Señora	B-Protein
(	O
aminoácidos	B-Chemical
463	O
a	O
542	O
)	O
se	O
requiere	O
para	O
la	O
represión	O
transcripcional	O
de	O
Señora	B-Protein
y	O
el	O
SAM	O
dominio	B-Sequence
parece	O
ser	O
prescindible	O
para	O
esta	O
actividad	O
represiva	O
.	O

Esta	O
C	B-Sequence
-	I-Sequence
región	I-Sequence
terminal	I-Sequence
de	O
ratón	B-Protein
mr	I-Protein
-	I-Protein
s	I-Protein
es	O
altamente	O
conservado	B-Sequence
entre	O
especies	O
(	O
Fig	O
.	O
7F	O
)	O
.	O

los	O
secuencia	B-Sequence
identidad	O
de	O
la	O
región	B-Sequence
fue	O
del	O
93	O
%	O
,	O
73	O
%	O
,	O
41	O
%	O
y	O
40	O
%	O
para	O
rata	B-Taxon
,	O
humano	B-Taxon
,	O
polluelo	B-Taxon
y	O
pez	B-Taxon
cebra	I-Taxon
,	O
respectivamente	O
(	O
Fig	O
.	O
1D	O
)	O
.	O

Esto	O
sugiere	O
fuertemente	O
que	O
el	O
C	B-Sequence
-	I-Sequence
región	I-Sequence
terminal	I-Sequence
de	O
ratón	B-Protein
mr	I-Protein
-	I-Protein
s	I-Protein
funciona	O
como	O
un	O
represor	O
transcripcional	O
dominio	B-Sequence
en	O
fotorreceptor	B-Cell
desarrollo	O
.	O

Sin	O
embargo	O
,	O
esto	O
región	B-Sequence
no	O
contiene	O
característica	O
aminoácidos	B-Chemical
motivos	O
y	O
el	O
mecanismo	O
a	O
través	O
del	O
cual	O
el	O
región	B-Sequence
logra	O
y/o	O
mantiene	O
gene	B-Sequence
la	O
represión	O
queda	O
por	O
aclarar	O
en	O
el	O
futuro	O
.	O

Figura	O
7	O

Señora	B-Protein
fusionado	O
a	O
GAL4	B-Protein
ADN	B-Sequence
Unión	O
dominio	B-Sequence
funciona	O
como	O
un	O
represor	O
transcripcional	O
en	O
HEK293T	O
células	B-Cell
.	O

(	O
A	O
)	O
Dibujo	O
esquemático	O
de	O
la	O
construcciones	B-Sequence
utilizado	O
para	O
el	O
ensayo	O
de	O
luciferasa	O
.	O

5xGAL4	O
-	O
reportero	O
pGL3	O
plásmido	B-Sequence
fue	O
co	O
-	O
transfectado	O
en	O
HEK293T	O
células	B-Cell
con	O
efector	O
plásmidos	B-Sequence
expresando	O
varios	O
mutantes	B-Sequence
por	I-Sequence
deleción	I-Sequence
fusionado	O
a	O
GAL4	B-Protein
#	O
¿NOMBRE	O
?	O

(	O
B	O
)	O
Varias	O
cantidades	O
de	O
DBD	O
,	O
DBD	O
-	O
Señora	B-Protein
,	O
DH-	O
norte	B-Sequence
o	O
DH	O
-	O
C	B-Sequence
plásmidos	I-Sequence
fueron	O
transfectados	O
con	O
0	O
.	O
1	O
mu	O
g	O
de	O
5xGAL4	O
-	O
reportero	O
pGL3	O
plásmido	B-Sequence
.	O

La	O
actividad	O
reportera	O
en	O
presencia	O
del	O
pcDNA3	O
vector	B-Sequence
(	O
pcDNA3	O
)	O
se	O
designó	O
como	O
1	O
.	O

Las	O
barras	O
de	O
error	O
representan	O
el	O
error	O
estándar	O
de	O
la	O
media	O
.	O

(	O
C	O
)	O
DBD	O
-	O
W404A	O
y	O
DBD	O
-	O
G453A	O
se	O
cotransfectaron	O
en	O
HEK293T	O
células	B-Cell
con	O
indicador	O
5xGAL4	O
-	O
pGL3	O
plásmido	B-Sequence
.	O

La	O
represión	O
de	O
veces	O
se	O
calculó	O
como	O
la	O
disminución	O
de	O
veces	O
en	O
la	O
actividad	O
de	O
luciferasa	O
en	O
comparación	O
con	O
DBD	O
-	O
Señora	B-Protein
.	O

Las	O
barras	O
de	O
error	O
representan	O
la	O
desviación	O
estándar	O
.	O

(	O
D	O
)	O
Se	O
transfectaron	O
varias	O
cantidades	O
de	O
DBD	O
-	O
cola	O
o	O
DBD	O
-	O
SAM	O
con	O
el	O
reportero	O
5xGAL4	O
-	O
pGL3	O
plásmido	B-Sequence
.	O

Las	O
barras	O
de	O
error	O
representan	O
el	O
error	O
estándar	O
de	O
la	O
media	O
.	O

(	O
E	O
)	O
pcDNA3	O
o	O
DBD	O
-	O
Señora	B-Protein
(	O
5	O
µg	O
)	O
se	O
cotransfectó	O
en	O
retinoblastoma	O
Y79	O
células	B-Cell
con	O
0	O
5	O
mu	O
g	O
de	O
5xGAL4	O
-	O
reportero	O
pGL3	O
plásmido	B-Sequence
.	O

La	O
actividad	O
indicadora	O
en	O
presencia	O
de	O
pcDNA3	O
se	O
designó	O
como	O
1	O
.	O

Las	O
barras	O
de	O
error	O
representan	O
la	O
desviación	O
estándar	O
.	O

El	O
asterisco	O
marca	O
la	O
diferencia	O
estadísticamente	O
significativa	O
(	O
prueba	O
t	O
de	O
Student	O
:	O
p	O
<	O
0,03	O
)	O
.	O

(	O
F	O
)	O
Alineación	O
del	O
C	B-Sequence
-	I-Sequence
regiones	I-Sequence
terminales	I-Sequence
por	O
ratón	B-Protein
,	I-Protein
rata	I-Protein
,	I-Protein
humano	I-Protein
,	I-Protein
pollito	I-Protein
y	I-Protein
pez	I-Protein
cebra	I-Protein
mr	I-Protein
-	I-Protein
s	I-Protein
proteinas	B-Chemical
.	O

Conservado	B-Sequence
residuos	B-Chemical
de	I-Chemical
aminoácidos	I-Chemical
se	O
muestran	O
con	O
una	O
sombra	O
oscura	O
.	O

Tomados	O
en	O
conjunto	O
,	O
nuestros	O
hallazgos	O
sugieren	O
que	O
DBD-	O
Señora	B-Protein
funciona	O
como	O
un	O
represor	O
transcripcional	O
y	O
que	O
la	O
actividad	O
de	O
represión	O
de	O
Señora	B-Protein
no	O
se	O
debe	O
a	O
una	O
interacción	O
homófila	O
a	O
través	O
de	O
su	O
SAM	O
dominio	B-Sequence
pero	O
a	O
la	O
C	B-Sequence
-	I-Sequence
región	I-Sequence
terminal	I-Sequence
(	O
aminoácidos	B-Chemical
463	O
a	O
542	O
)	O
.	O

Discusión	O

En	O
el	O
presente	O
estudio	O
,	O
identificamos	O
una	O
novela	O
gene	B-Sequence
,	O
Señora	B-Protein
,	O
que	O
se	O
expresa	O
predominantemente	O
en	O
fotorreceptores	B-Cell
retinales	I-Cell
y	O
la	O
glándula	O
pineal	O
.	O

el	O
pico	O
de	O
Señora	B-Protein
la	O
expresión	O
en	O
la	O
retina	O
en	O
desarrollo	O
es	O
alrededor	O
de	O
P6	O
.	O

Este	O
patrón	O
de	O
expresión	O
se	O
correlaciona	O
con	O
el	O
rápido	O
aumento	O
de	O
crx	B-Protein
,	O
rodopsina	B-Protein
y	O
otra	O
fotorreceptor	B-Cell
genes	B-Sequence
alrededor	O
de	O
P6-P8	O
.	O

Alrededor	O
de	O
P6	O
,	O
la	O
capa	O
plexiforme	O
externa	O
se	O
vuelve	O
visible	O
y	O
la	O
capa	O
externa	O
de	O
la	O
retina	O
se	O
separa	O
en	O
dos	O
capas	O
,	O
ONL	O
e	O
INL	O
.	O

Al	O
mismo	O
tiempo	O
,	O
fotorreceptores	B-Cell
comienzan	O
a	O
sufrir	O
una	O
diferenciación	O
terminal	O
,	O
formando	O
el	O
segmento	B-GENE
exterior	I-GENE
.	O

Por	O
lo	O
tanto	O
,	O
planteamos	O
la	O
hipótesis	O
de	O
que	O
Señora	B-Protein
es	O
una	O
clave	O
molécula	B-Chemical
en	O
el	O
desarrollo	O
tardío	O
de	O
fotorreceptores	B-Cell
.	O

Anteriormente	O
informamos	O
que	O
Otx2	B-Protein
y	O
crx	B-Protein
tienen	O
un	O
papel	O
crítico	O
en	O
fotorreceptor	B-Cell
desarrollo	O
y	O
que	O
Otx2	B-Protein
regula	O
directamente	O
crx	B-Protein
transcripción	O
[	O
3	O
,	O
9	O
]	O
.	O

La	O
hibridación	O
in	O
situ	O
y	O
la	O
RT	O
-	O
PCR	O
mostraron	O
una	O
reducción	O
significativa	O
de	O
Señora	B-Protein
señal	O
en	O
el	O
crx	B-Protein
KO	O
retina	O
y	O
glándula	O
pineal	O
.	O

Además	O
,	O
el	O
ensayo	O
de	O
luciferasa	O
demostró	O
que	O
Otx2	B-Protein
y	O
crx	B-Protein
puede	O
aumentar	O
directamente	O
la	O
transcripción	O
de	O
Señora	B-Protein
en	O
mamífero	B-Taxon
células	B-Cell
.	O

En	O
células	B-Cell
fotorreceptoras	I-Cell
de	I-Cell
la	I-Cell
retina	I-Cell
,	O
los	O
Otx2	B-Protein
transcripciones	B-Sequence
no	O
se	O
expresan	O
mucho	O
en	O
P6-P9	O
,	O
mientras	O
que	O
los	O
crx	B-Protein
transcripciones	B-Sequence
se	O
detectan	O
fuertemente	O
alrededor	O
de	O
P6	O
.	O

Por	O
lo	O
tanto	O
,	O
nuestros	O
resultados	O
sugieren	O
fuertemente	O
que	O
Señora	B-Protein
La	O
transcripción	O
está	O
directamente	O
regulada	O
por	O
crx	B-Protein
.	O

En	O
el	O
presente	O
estudio	O
,	O
NRL	B-Protein
,	O
a	O
fotorreceptor	B-Cell
#	O
¿NOMBRE	O
?	O
fotorreceptores	B-Cell
en	O
la	O
etapa	O
postnatal	O
,	O
no	O
afectó	O
la	O
transcripción	O
de	O
Señora	B-Protein
.	O

Este	O
hallazgo	O
es	O
en	O
realidad	O
consistente	O
con	O
el	O
análisis	O
de	O
la	O
NRL	B-Protein
KO	O
ratón	B-Taxon
que	O
se	O
informó	O
recientemente	O
[	O
40	O
]	O
.	O

Los	O
perfiles	O
de	O
expresión	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
NRL	B-Protein
Se	O
analizaron	O
retinas	O
KO	O
en	O
P2	O
,	O
P10	O
y	O
2	O
meses	O
y	O
Señora	B-Protein
no	O
se	O
incluyó	O
en	O
161	O
expresado	O
diferencialmente	O
genes	B-Sequence
en	O
el	O
NRL	B-Protein
KO	O
retina	O
.	O

Informes	O
anteriores	O
sugirieron	O
que	O
la	O
SAM	O
dominio	B-Sequence
es	O
un	O
proteína	B-Chemical
-	O
proteína	B-Chemical
Interacción	O
módulo	B-Sequence
.	O

El	O
SAM	O
dominio	B-Sequence
de	O
El	O
Señora	B-Protein
proteína	B-Chemical
está	O
muy	O
relacionado	O
con	O
el	O
de	O
ph	B-Protein
y	O
TELÉFONO	B-Protein
,	O
cuyo	O
SAM	O
dominios	B-Sequence
puede	O
formar	O
un	O
helicoidal	B-Sequence
,	O
de	O
la	O
cabeza	O
a	O
los	O
pies	O
polimérico	B-Chemical
estructurar	O
y	O
mediar	O
en	O
la	O
formación	O
de	O
un	O
orden	O
superior	O
cromatina	B-GENE
estructura	O
.	O

Caracterizar	O
la	O
función	O
bioquímica	O
de	O
Señora	B-Protein
,	O
Actuamos	O
levadura	B-Taxon
dos	O
-	O
cribado	O
híbrido	O
utilizando	O
longitud	O
completa	O
Señora	B-Protein
como	O
el	O
cebo	O
.	O

Como	O
resultado	O
,	O
los	O
positivos	O
más	O
frecuentes	O
clones	B-Sequence
(	O
5	O
/	O
28	O
)	O
en	O
la	O
proyección	O
estaban	O
los	O
fragmentos	B-Sequence
de	I-Sequence
ADNc	I-Sequence
que	O
contiene	O
el	O
SAM	O
dominio	B-Sequence
de	O
Señora	B-Protein
.	O

Esto	O
sugiere	O
fuertemente	O
que	O
Señora	B-Protein
auto-asociados	O
a	O
través	O
de	O
su	O
SAM	O
dominio	B-Sequence
.	O

Un	O
ensayo	O
de	O
inmunoprecipitación	O
,	O
usando	O
dos	O
sitio	B-Sequence
#	O
¿NOMBRE	O
?	O
mutantes	B-Sequence
de	O
la	O
SAM	O
dominio	B-Sequence
de	O
Señora	B-Protein
demostró	O
que	O
la	O
Señora	B-Protein
proteína	B-Chemical
puede	O
autoasociarse	O
a	O
través	O
de	O
su	O
SAM	O
dominio	B-Sequence
en	O
mamífero	B-Taxon
células	B-Cell
.	O

Si	O
bien	O
no	O
abordamos	O
la	O
cuestión	O
de	O
si	O
el	O
SAM	O
dominio	B-Sequence
de	O
Señora	B-Protein
forma	O
un	O
polimérico	B-Chemical
estructura	O
en	O
el	O
presente	O
estudio	O
,	O
el	O
análisis	O
filogenético	O
de	O
SAM	O
dominio	B-Sequence
de	O
Señora	B-Protein
y	O
otros	O
SAM	O
dominio	B-Sequence
#	O
¿NOMBRE	O
?	O
moléculas	B-Chemical
sugiere	O
que	O
Señora	B-Protein
puede	O
formar	O
de	O
cabeza	O
a	O
cola	O
polímero	B-Chemical
y	O
mediar	O
gene	B-Sequence
silenciar	O
al	O
difundir	O
complejos	B-GENE
represivos	I-GENE
a	O
lo	O
largo	O
de	O
cromatina	B-GENE
Similar	O
a	O
ph	B-Protein
y/o	O
TELÉFONO	B-Protein
.	O

Aunque	O
nuestros	O
resultados	O
en	O
el	O
ensayo	O
de	O
inmunoprecipitación	O
demostraron	O
que	O
la	O
N	B-Sequence
-	I-Sequence
construcciones	I-Sequence
terminales	I-Sequence
sin	O
un	O
SAM	O
dominio	B-Sequence
todavía	O
interactúan	O
entre	O
sí	O
,	O
estos	O
resultados	O
no	O
encajan	O
en	O
la	O
cabeza	O
a	O
la	O
cola	O
polímero	B-Chemical
modelo	O

No	O
podemos	O
excluir	O
la	O
posibilidad	O
de	O
que	O
el	O
resultado	O
proteína	B-Chemical
-	O
proteína	B-Chemical
interacción	O
de	O
Señora	B-Protein
es	O
un	O
artefacto	O
de	O
las	O
condiciones	O
de	O
sobreexpresión	O
.	O

La	O
cuestión	O
de	O
si	O
o	O
no	O
Señora	B-Protein
forma	O
un	O
polímero	B-Chemical
espera	O
futuros	O
análisis	O
.	O

Un	O
informe	O
anterior	O
indicó	O
que	O
TELÉFONO	B-Protein
contiene	O
una	O
secuencia	B-Sequence
#	O
¿NOMBRE	O
?	O
ADN	B-Sequence
Unión	O
dominio	B-Sequence
,	O
a	O
saber	O
,	O
el	O
ETS	O
dominio	B-Sequence
y	O
se	O
une	O
a	O
sitios	B-Sequence
a	O
través	O
de	O
su	O
ETS	O
dominio	B-Sequence
[	O
41	O
]	O
.	O

TELÉFONO	B-Protein
podría	O
servir	O
para	O
nuclear	O
un	O
polímero	B-Chemical
que	O
se	O
propagaría	O
por	O
oligomerización	O
de	O
la	O
SAM	O
dominio	B-Sequence
.	O

En	O
contraste	O
con	O
TELÉFONO	B-Protein
,	O
ph	B-Protein
no	O
contiene	O
un	O
obvio	O
secuencia	B-Sequence
#	O
¿NOMBRE	O
?	O
ADN	B-Sequence
motivo	O
de	O
unión	O
(	O
16	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
su	O
unión	O
inicial	O
a	O
la	O
plantilla	O
puede	O
requerir	O
proteína	B-Chemical
-	O
proteína	B-Chemical
interacciones	O
con	O
otros	O
secuencia	B-Sequence
-	O
represores	O
transcripcionales	O
específicos	O
.	O

la	O
segmentación	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
Jorobado	B-Protein
tienen	O
un	O
papel	O
en	O
el	O
reclutamiento	O
de	O
SAM	O
dominio	B-Sequence
#	O
¿NOMBRE	O
?	O
proteinas	B-Chemical
,	O
que	O
puede	O
extenderse	O
a	O
lo	O
largo	O
de	O
la	O
plantilla	O
a	O
través	O
de	O
la	O
polimerización	O
[	O
42	O
]	O
.	O

Ya	O
que	O
Señora	B-Protein
no	O
contiene	O
obvio	O
ADN	B-Sequence
motivos	O
vinculantes	O
,	O
suponemos	O
que	O
hay	O
un	O
secuencia	B-Sequence
#	O
¿NOMBRE	O
?	O
Señora	B-Protein
.	O

Sin	O
embargo	O
,	O
no	O
encontramos	O
ningún	O
factor	O
de	O
transcripción	O
en	O
el	O
presente	O
levadura	B-Taxon
Cribado	O
de	O
dos	O
híbridos	O
.	O

También	O
encontramos	O
que	O
de	O
cuerpo	O
entero	O
Señora	B-Protein
fusionado	O
a	O
la	O
GAL4	B-Protein
ADN	B-Sequence
Unión	O
dominio	B-Sequence
(	O
DH	O
-	O
Señora	B-Protein
)	O
funciona	O
como	O
un	O
represor	O
transcripcional	O
.	O

Esto	O
puede	O
apoyar	O
la	O
idea	O
de	O
que	O
Señora	B-Protein
está	O
involucrado	O
en	O
complejos	B-GENE
represivos	I-GENE
similar	O
a	O
otros	O
SAM	O
dominio	B-Sequence
#	O
¿NOMBRE	O
?	O
proteinas	B-Chemical
.	O

Nuestros	O
resultados	O
,	O
sin	O
embargo	O
,	O
mostraron	O
que	O
la	O
auto-asociación	O
de	O
Señora	B-Protein
través	O
de	O
su	O
SAM	O
dominio	B-Sequence
no	O
es	O
esencial	O
para	O
la	O
actividad	O
represiva	O
transcripcional	O
.	O

Polimerización	O
de	O
la	O
SAM	O
dominio	B-Sequence
previamente	O
se	O
ha	O
informado	O
que	O
es	O
esencial	O
para	O
las	O
funciones	O
represivas	O
de	O
ph	B-Protein
y	O
TELÉFONO	B-Protein
[	O
43	O
,	O
44	O
]	O
.	O

Por	O
otro	O
lado	O
,	O
tumor	B-Protein
cerebral	I-Protein
maligno	I-Protein
mortal	I-Protein
(	I-Protein
3	I-Protein
)	I-Protein
humano	I-Protein
(	O
H	B-Protein
-	I-Protein
L	I-Protein
(	I-Protein
3	I-Protein
)	I-Protein
MBT	I-Protein
)	O
proteína	B-Chemical
,	O
que	O
también	O
contiene	O
un	O
SAM	O
dominio	B-Sequence
en	O
el	O
C	B-Sequence
-	I-Sequence
terminal	I-Sequence
,	O
fue	O
reportado	O
como	O
un	O
represor	O
transcripcional	O
y	O
la	O
actividad	O
represora	O
de	O
H	B-Protein
-	I-Protein
L	I-Protein
(	I-Protein
3	I-Protein
)	I-Protein
MBT	I-Protein
requería	O
principalmente	O
la	O
presencia	O
del	O
MBT	O
repite	B-Sequence
pero	O
no	O
el	O
SAM	O
dominio	B-Sequence
[	O
45	O
]	O
.	O

Para	O
determinar	O
el	O
represor	O
transcripcional	O
región	B-Sequence
de	O
El	O
Señora	B-Protein
proteína	B-Chemical
,	O
realizamos	O
un	O
ensayo	O
de	O
luciferasa	O
utilizando	O
sitio	B-Sequence
#	O
¿NOMBRE	O
?	O
mutantes	B-Sequence
(	O
DBD-W404A	O
y	O
DBD-G453A	O
)	O
.	O

El	O
resultado	O
mostró	O
que	O
la	O
capacidad	O
de	O
unión	O
reducida	O
de	O
la	O
autoasociación	O
compromete	O
parcialmente	O
la	O
actividad	O
represiva	O
transcripcional	O
de	O
Señora	B-Protein
(	O
Fig	O
.	O
7D	O
)	O
.	O

Sin	O
embargo	O
,	O
el	O
efecto	O
represivo	O
fue	O
más	O
significativo	O
cuando	O
DBD-tail	O
,	O
que	O
no	O
contiene	O
SAM	O
dominio	B-Sequence
,	O
fue	O
presentado	O
conjuntamente	O
con	O
el	O
reportero	O
5xGAL4	O
-	O
pGL3	O
plásmido	B-Sequence
.	O

Por	O
lo	O
tanto	O
,	O
concluimos	O
que	O
un	O
región	B-Sequence
desde	O
aminoácidos	B-Chemical
463	O
a	O
542	O
es	O
el	O
principal	O
responsable	O
de	O
la	O
actividad	O
represora	O
en	O
el	O
caso	O
de	O
Señora	B-Protein
.	O

Conservación	B-Sequence
evolutiva	I-Sequence
de	O
El	O
C	B-Sequence
-	I-Sequence
terminal	I-Sequence
80	I-Sequence
aa	I-Sequence
región	I-Sequence
de	O
Señora	B-Protein
desde	O
pez	B-Taxon
cebra	I-Taxon
a	O
través	O
de	O
humano	B-Taxon
puede	O
subyacer	O
a	O
la	O
importancia	O
funcional	O
de	O
este	O
región	B-Sequence
.	O

Dos	O
multiproteínas	O
distintas	O
complejos	B-GENE
PCG	I-GENE
,	O
PRC1	B-GENE
PRC2	O
,	O
han	O
sido	O
identificados	O
.	O

PRC2	O
participa	O
en	O
el	O
inicio	O
del	O
silenciamiento	O
y	O
contiene	O
histona	B-Chemical
desacetilasas	O
(	O
HDAC	O
)	O
y	O
histona	B-Chemical
metiltransferasas	O
,	O
que	O
pueden	O
metilar	O
histona	B-Chemical
H3	O
lisina	B-Chemical
9	O
y	O
27	O
,	O
marcas	O
de	O
silenciado	O
cromatina	B-GENE
.	O

PRC1	B-GENE
,	O
incluyendo	O
ph	B-Protein
,	O
reconoce	O
la	O
histona	B-Chemical
H3	O
lisina	B-Chemical
27	O
marca	O
establecida	O
por	O
PRC2	O
y	O
mantiene	O
un	O
estado	O
estable	O
de	O
gene	B-Sequence
represión	O
en	O
la	O
que	O
PRC1	B-GENE
bloques	O
cromatina	B-GENE
remodelación	O
por	O
el	O
grupo	O
tritórax	O
-	O
relacionado	O
SWI	B-GENE
-	I-GENE
complejo	I-GENE
SNF	I-GENE
[	O
46	O
,	O
47	O
]	O
.	O

Por	O
lo	O
tanto	O
,	O
se	O
cree	O
que	O
el	O
mecanismo	O
de	O
represión	O
por	O
PRC2	O
depende	O
de	O
HDAC	O
mientras	O
que	O
el	O
mecanismo	O
de	O
represión	O
por	O
PRC1	B-GENE
parece	O
ser	O
independiente	O
de	O
HDAC	O
.	O

Nuestro	O
ensayo	O
de	O
luciferasa	O
también	O
mostró	O
que	O
la	O
represión	O
transcripcional	O
de	O
DBD	O
-	O
Señora	B-Protein
no	O
fue	O
afectado	O
por	O
la	O
adición	O
de	O
varias	O
concentraciones	O
de	O
tricostatina	B-Chemical
A	I-Chemical
,	O
un	O
potente	O
HDAC	O
inhibidor	B-Chemical
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
especulamos	O
que	O
el	O
mecanismo	O
de	O
represión	O
de	O
Señora	B-Protein
puede	O
ser	O
HDAC	O
-	O
independiente	O
y	O
más	O
similar	O
a	O
la	O
de	O
complejo	B-GENE
PRC1	I-GENE
.	O

En	O
el	O
presente	O
estudio	O
,	O
los	O
experimentos	O
bioquímicos	O
demuestran	O
que	O
la	O
Señora	B-Protein
proteína	B-Chemical
funciona	O
como	O
un	O
represor	O
transcripcional	O
y	O
posiblemente	O
regula	O
negativamente	O
la	O
expresión	O
espacial	O
y	O
temporal	O
del	O
objetivo	O
genes	B-Sequence
durante	O
fotorreceptor	B-Cell
de	I-Cell
la	I-Cell
retina	I-Cell
desarrollo	O
.	O

Nuestros	O
datos	O
también	O
revelaron	O
que	O
la	O
actividad	O
represiva	O
de	O
Señora	B-Protein
se	O
debe	O
principalmente	O
a	O
la	O
C	B-Sequence
-	I-Sequence
región	I-Sequence
terminal	I-Sequence
(	O
aminoácidos	B-Chemical
463	O
a	O
542	O
)	O
.	O

Sin	O
embargo	O
,	O
los	O
objetivos	O
aguas	O
abajo	O
de	O
Señora	B-Protein
siguen	O
sin	O
estar	O
claros	O
.	O

La	O
hibridación	O
in	O
situ	O
mostró	O
que	O
el	O
pico	O
de	O
Señora	B-Protein
expresión	O
es	O
alrededor	O
de	O
P6	O
,	O
cuando	O
fotorreceptores	B-Cell
retinales	I-Cell
experimentan	O
diferenciación	O
terminal	O
.	O

Suponemos	O
que	O
el	O
objetivo	O
genes	B-Sequence
de	O
Señora	B-Protein
podría	O
no	O
ser	O
-	O
fotorreceptor	B-Cell
genes	B-Sequence
.	O

En	O
este	O
caso	O
,	O
Señora	B-Protein
puede	O
suprimir	O
la	O
expresión	O
de	O
no	O
-	O
fotorreceptor	B-Cell
genes	B-Sequence
en	O
fotorreceptores	B-Cell
de	I-Cell
conos	I-Cell
y	I-Cell
bastones	I-Cell
.	O

Puede	O
haber	O
otra	O
posibilidad	O
de	O
que	O
Señora	B-Protein
está	O
involucrado	O
en	O
célula	B-Cell
determinación	O
del	O
destino	O
de	O
fotorreceptores	B-Cell
de	I-Cell
varilla	I-Cell
versus	O
fotorreceptores	B-Cell
de	I-Cell
cono	I-Cell
.	O

Tiempo	O
fotorreceptores	B-Cell
de	I-Cell
cono	I-Cell
nacen	O
durante	O
las	O
primeras	O
etapas	O
embrionarias	O
de	O
ratón	B-Taxon
retinogénesis	O
,	O
fotorreceptores	B-Cell
de	I-Cell
varilla	I-Cell
nacen	O
principalmente	O
en	O
el	O
período	O
embrionario	O
tardío	O
y	O
posnatal	O
temprano	O
[	O
48	O
]	O
.	O

El	O
patrón	O
de	O
expresión	O
de	O
Señora	B-Protein
puede	O
sugerir	O
que	O
Señora	B-Protein
se	O
expresa	O
en	O
fotorreceptores	B-Cell
de	I-Cell
varilla	I-Cell
pero	O
no	O
en	O
fotorreceptores	B-Cell
de	I-Cell
cono	I-Cell
así	O
como	O
también	O
nr2e3	B-Protein
que	O
se	O
conoce	O
como	O
represor	O
transcripcional	O
y	O
se	O
cree	O
que	O
regula	O
a	O
la	O
baja	O
fotorreceptor	B-Cell
de	I-Cell
cono	I-Cell
#	O
¿NOMBRE	O
?	O
genes	B-Sequence
.	O

Para	O
aclarar	O
la	O
función	O
biológica	O
de	O
Señora	B-Protein
,	O
análisis	O
de	O
ratones	B-Taxon
con	O
interrupciones	O
específicas	O
de	O
Señora	B-Protein
será	O
muy	O
importante	O
.	O

Conclusión	O

Aquí	O
nos	O
identificamos	O
ratón	B-Protein
mr	I-Protein
-	I-Protein
s	I-Protein
,	O
que	O
se	O
expresa	O
predominantemente	O
en	O
fotorreceptores	B-Cell
retinales	I-Cell
y	O
la	O
glándula	O
pineal	O
.	O

Señora	B-Protein
es	O
conservado	B-Sequence
evolutivamente	I-Sequence
desde	O
pez	B-Taxon
cebra	I-Taxon
a	O
través	O
de	O
humano	B-Taxon
,	O
lo	O
que	O
sugiere	O
un	O
papel	O
significativo	O
de	O
Señora	B-Protein
en	O
fotorreceptor	B-Cell
desarrollo	O
.	O

Nuestros	O
datos	O
actuales	O
sugieren	O
que	O
Señora	B-Protein
proteína	B-Chemical
se	O
localiza	O
en	O
el	O
núcleo	B-GENE
y	O
puede	O
auto-asociarse	O
principalmente	O
a	O
través	O
del	O
SAM	O
dominio	B-Sequence
.	O

Es	O
más	O
,	O
Señora	B-Protein
proteína	B-Chemical
fusionado	O
a	O
GAL4	B-Protein
DBD	O
funciona	O
como	O
un	O
represor	O
transcripcional	O
.	O

La	O
actividad	O
represiva	O
de	O
Señora	B-Protein
se	O
debe	O
a	O
su	O
C	B-Sequence
-	I-Sequence
región	I-Sequence
terminal	I-Sequence
(	O
aminoácidos	B-Chemical
463	O
a	O
542	O
)	O
.	O

Tomados	O
en	O
conjunto	O
,	O
Señora	B-Protein
es	O
un	O
novedoso	O
represor	O
molécula	B-Chemical
posiblemente	O
involucrado	O
en	O
el	O
desarrollo	O
de	O
fotorreceptores	B-Cell
retinales	I-Cell
y	O
glándula	O
pineal	O
.	O

Métodos	O

Aislamiento	O
de	O
ratón	B-Protein
mr	I-Protein
-	I-Protein
s	I-Protein
ADNc	B-Sequence

Usamos	O
el	O
método	O
bioinformático	O
Digital	O
Differential	O
Display	O
(	O
NCBI	O
,	O
UniGene	O
)	O
para	O
seleccionar	O
nuevos	O
ratón	B-Taxon
genes	B-Sequence
se	O
expresa	O
preferentemente	O
en	O
la	O
retina	O
.	O

Algunos	O
de	O
los	O
grupos	O
en	O
la	O
base	O
de	O
datos	O
UniGene	O
eran	O
principalmente	O
de	O
ratón	B-Taxon
de	O
retina	O
ADNc	B-Sequence
.	O

Una	O
clon	B-Sequence
en	O
estos	O
grupos	O
(	O
#	O
mmm	B-Taxon
246385	O
)	O
tiene	O
una	O
débil	O
homología	B-Sequence
con	O
la	O
familia	O
polihomeótica	O
genes	B-Sequence
.	O

Un	O
735-	O
fragmento	B-Sequence
de	I-Sequence
ADNc	I-Sequence
pb	I-Sequence
de	O
esta	O
clon	B-Sequence
,	O
codificación	O
aminoácidos	B-Chemical
140	O
-	O
384	O
fue	O
amplificado	O
por	O
RT	O
-	O
PCR	O
de	O
ratón	B-Taxon
retina	O
P0	O
ADNc	B-Sequence
.	O

Esta	O
fragmento	B-Sequence
fue	O
utilizado	O
como	O
el	O
Investigacion	B-Sequence
para	O
cribado	O
de	O
bibliotecas	O
,	O
hibridación	O
in	O
situ	O
e	O
hibridación	O
Northern	O
.	O

A	O
ratón	B-Taxon
retina	O
P0	O
-	O
P3	O
ADNc	B-Sequence
biblioteca	O
se	O
proyectó	O
utilizando	O
este	O
ratón	B-Taxon
fragmento	B-Sequence
de	I-Sequence
ADNc	I-Sequence
.	O

bacteriófago	O
positivo	O
clones	B-Sequence
fueron	O
aislados	O
y	O
de	O
cuerpo	O
entero	O
Señora	B-Protein
fragmento	B-Sequence
era	O
insertado	B-Sequence
en	O
pBluescriptII	O
(	O
Stratagene	O
)	O
.	O

ADN	B-Sequence
La	O
secuenciación	O
se	O
realizó	O
en	O
ambos	O
hebras	B-Sequence
por	O
el	O
método	O
de	O
secuenciación	O
cíclica	O
.	O

los	O
secuencia	B-Sequence
de	I-Sequence
nucleótidos	I-Sequence
por	O
Señora	B-Protein
gene	B-Sequence
se	O
ha	O
depositado	O
en	O
la	O
base	O
de	O
datos	O
de	O
GenBank	O
con	O
el	O
número	O
de	O
acceso	O
de	O
GenBank	O
#	O
AY458844	O
.	O

Hibridación	O
in	O
situ	O

El	O
735	O
-	O
fragmento	B-Sequence
de	I-Sequence
ADNc	I-Sequence
pb	I-Sequence
de	O
Señora	B-Protein
amplificado	O
por	O
RT	O
-	O
PCR	O
se	O
utilizó	O
como	O
Investigacion	B-Sequence
para	O
hibridación	O
in	O
situ	O
.	O

Hibridación	O
in	O
situ	O
se	O
realizó	O
como	O
se	O
describe	O
anteriormente	O
[	O
49	O
]	O
.	O

Célula	B-Cell
cultivo	O
y	O
transfeccion	O

HEK293T	O
células	B-Cell
se	O
mantuvieron	O
a	O
37	O
grados	O
C	O
en	O
medio	O
de	O
Eagle	O
modificado	O
por	O
Dulbecco	O
(	O
DMEM	O
)	O
suplementado	O
con	O
10	O
%	O
fetal	O
bovino	B-Taxon
suero	O
(	O
Sigma	O
)	O
,	O
100	O
UI	O
/	O
ml	O
penicilina	B-Chemical
y	O
100	O
ug/ml	O
estreptomicina	B-Chemical
.	O

Transfección	O
transitoria	O
de	O
HEK293T	O
células	B-Cell
se	O
llevó	O
a	O
cabo	O
usando	O
Fosfato	B-Chemical
de	I-Chemical
calcio	I-Chemical
método	O
o	O
transfección	O
Fugene6	O
reactivo	B-Chemical
(	O
Roche	O
)	O
.	O

Y79	O
retinoblastoma	O
células	B-Cell
se	O
mantuvieron	O
en	O
medio	O
de	O
Dulbecco	O
modificado	O
de	O
Iscove	O
con	O
4	O
mM	O
L	B-Chemical
-	I-Chemical
glutamina	I-Chemical
ajustado	O
para	O
contener	O
1	O
.	O
5g/L	O
bicarbonato	B-Chemical
de	I-Chemical
sodio	I-Chemical
,	O
20	O
%	O
FBS	O
.	O

La	O
transfección	O
transitoria	O
se	O
llevó	O
a	O
cabo	O
utilizando	O
TransIt	O
LT1	O
(	O
Mirus	O
)	O
.	O

Northern	O
-	O
análisis	O
de	O
transferencia	O

ARN	B-Sequence
fue	O
extraído	O
de	O
los	O
tejidos	O
de	O
adultos	O
ratones	B-Taxon
utilizando	O
Trizol	O
(	O
Invitrogen	O
)	O
.	O

Una	O
taza	O
de	O
5	O
g	O
de	O
total	O
ARN	B-Sequence
se	O
sometió	O
a	O
electroforesis	O
en	O
un	O
1	O
.	O
0	O
%	O
agarosa	B-Chemical
-	O
formaldehído	B-Chemical
gel	O
y	O
se	O
transfiere	O
a	O
un	O
nylon	B-Chemical
membrana	O
(	O
Zeta-Probe	O
GT	O
,	O
Bio-Rad	O
)	O
.	O

El	O
735	O
-	O
fragmento	B-Sequence
de	I-Sequence
ADNc	I-Sequence
pb	I-Sequence
codificando	O
el	O
SAM	O
dominio	B-Sequence
de	O
Señora	B-Protein
fue	O
utilizado	O
como	O
un	O
Investigacion	B-Sequence
por	O
hibridación	O
.	O

La	O
hibridación	O
se	O
realizó	O
de	O
acuerdo	O
con	O
el	O
protocolo	O
del	O
fabricante	O
.	O

Se	O
realizaron	O
lavados	O
con	O
rigurosidad	O
creciente	O
,	O
siendo	O
el	O
último	O
a	O
50	O
grados	O
C	O
en	O
0	O
.	O
1	O
estándar	O
citrato	B-Chemical
salino	I-Chemical
/	O
0	O
.	O
1	O
%	O
dodecil	B-Chemical
sulfato	I-Chemical
de	I-Chemical
sodio	I-Chemical
(	O
SDS	B-Chemical
)	O
.	O

RT	O
-	O
Análisis	O
PCR	O

Total	O
ARN	B-Sequence
se	O
aisló	O
de	O
cada	O
tejido	O
usando	O
Trizol	O
.	O

A	O
1	O
taza	O
g	O
de	O
total	O
ARN	B-Sequence
se	O
transcribió	O
inversamente	O
utilizando	O
SuperscriptII	O
(	O
Invitrogen	O
)	O
.	O

RT-PCR	O
cebadores	B-Sequence
,	O
que	O
abarca	O
intrones	B-Sequence
,	O
para	O
la	O
detección	O
de	O
Señora	B-Protein
ADNc	B-Sequence
fueron	O
5	O
'	O
-	O
TGTCCAGCCCAGCCAACCCAAGGAGACGACA	O
-	O
3	O
'	O
y	O
5	O
'	O
-	O
TGTGGTCTCCTCATCAGTGAAGA	O
-	O
3	O
'	O
.	O

Producto	B-Sequence
el	O
tamaño	O
era	O
292	O
pb	B-Sequence
(	O
posiciones	B-Sequence
965	O
-	O
1256	O
del	O
Número	O
de	O
Acceso	O
de	O
Genbank	O
#	O
AY458844	O
)	O
.	O

Cebador	B-Sequence
pares	O
para	O
ratón	B-Protein
G3PDH	I-Protein
fueron	O
5	O
'	O
-	O
ACCACAGTCCATGCCATCAC	O
-	O
3	O
'	O
y	O
5	O
'	O
-	O
TCCACCACCCTGTTGCTGTA	O
-	O
3	O
'	O
que	O
amplificaron	O
un	O
452	O
-	O
producto	B-Sequence
pb	I-Sequence
(	O
posiciones	B-Sequence
587-1038	O
del	O
Número	O
de	O
Acceso	O
de	O
Genbank	O
#	O
BC85275	O
)	O
.	O

Levadura	B-Taxon
dos	O
-	O
cribado	O
híbrido	O
y	O
GAL4	B-Protein
ensayo	O

llevamos	O
a	O
cabo	O
levadura	B-Taxon
dos	O
-	O
experimentos	O
híbridos	O
usando	O
el	O
MATCHMAKER	O
GAL4	B-Protein
sistema	O
de	O
dos	O
híbridos	O
3	O
(	O
BD	O
Bioscience	O
)	O
según	O
lo	O
recomendado	O
por	O
el	O
fabricante	O
.	O

Clonamos	O
la	O
longitud	O
completa	O
Señora	B-Protein
en	O
el	O
pGBKT7	O
vector	B-Sequence
y	O
lo	O
usó	O
para	O
filtrar	O
una	O
biblioteca	O
de	O
ratón	B-Taxon
retina	O
P0	O
-	O
P3	O
ADNc	B-Sequence
en	O
el	O
pGADT7	O
vector	B-Sequence
.	O

Los	O
transformantes	O
que	O
conferían	O
crecimiento	O
se	O
seleccionaron	O
,	O
aislaron	O
y	O
volvieron	O
a	O
introducir	O
con	O
el	O
cebo	O
en	O
AH109	O
para	O
confirmar	O
la	O
interacción	O
.	O

ADN	B-Sequence
plásmido	I-Sequence
fue	O
aislado	O
de	O
levadura	B-Taxon
usando	O
RPM	O
Levadura	B-Taxon
plásmido	B-Sequence
Kit	O
de	O
aislamiento	O
(	O
Qbiogene	O
)	O
.	O

Para	O
confirmar	O
la	O
proteína	B-Chemical
interacciones	O
,	O
se	O
recogieron	O
colonias	O
individuales	O
y	O
se	O
cultivaron	O
individualmente	O
en	O
medios	O
completos	O
sintéticos	O
que	O
carecían	O
leucina	B-Chemical
,	O
triptófano	B-Chemical
y	O
que	O
contiene	O
X-gal	O
.	O

Después	O
de	O
4	O
a	O
5	O
días	O
,	O
X-gal	O
positivo	O
clones	B-Sequence
fueron	O
seleccionados	O
y	O
analizados	O
.	O

Para	O
probar	O
la	O
autointeracción	O
de	O
Señora	B-Protein
,	O
subclonamos	O
la	O
longitud	O
completa	O
,	O
N	B-Sequence
-	I-Sequence
terminal	I-Sequence
(	O
aminoácidos	B-Chemical
1	O
-	O
400	O
)	O
y	O
C	B-Sequence
-	I-Sequence
terminal	I-Sequence
(	O
aminoácidos	B-Chemical
391	O
-	O
542	O
)	O
de	O
Señora	B-Protein
en	O
pGBKT7	O
y	O
pGADT7	O
vectores	B-Sequence
.	O

Evaluamos	O
las	O
interacciones	O
marcando	O
el	O
color	O
azul	O
en	O
placas	O
de	O
medio	O
que	O
contenía	O
X-gal	O
.	O

Ensayo	O
de	O
inmunoprecipitación	O

Para	O
ensayo	O
de	O
inmunoprecipitación	O
,	O
4	O
x	O
hemaglutinina	O
(	O
HA	O
)	O
o	O
3	O
x	O
marcados	O
con	O
bandera	O
fragmento	B-Sequence
de	I-Sequence
ADNc	I-Sequence
codificación	O
de	O
longitud	O
completa	O
Señora	B-Protein
(	O
completo	O
-	O
HA	O
y	O
Bandera	O
-	O
Señora	B-Protein
)	O
,	O
a	O
fragmento	B-Sequence
de	I-Sequence
ADNc	I-Sequence
codificación	O
aminoácidos	B-Chemical
1-400	O
(	O
Delta	O
SAM-HA	O
y	O
Flag-Delta	O
SAM	O
)	O
,	O
y	O
un	O
fragmento	B-Sequence
de	I-Sequence
ADNc	I-Sequence
codificación	O
aminoácidos	B-Chemical
400	O
-	O
542	O
(	O
Flag	O
-	O
SAM	O
)	O
se	O
subclonaron	O
en	O
la	O
expresión	O
pcDNA3	O
(	O
Invitrogen	O
)	O
vector	B-Sequence
.	O

También	O
construimos	O
dos	O
sitio	B-Sequence
#	O
¿NOMBRE	O
?	O
mutantes	B-Sequence
,	O
Flag	O
-	O
W404A	O
y	O
Flag	O
-	O
G453A	O
,	O
usando	O
PCR	O
.	O

Cada	O
uno	O
de	O
estos	O
mutaciones	B-Sequence
también	O
se	O
introdujo	O
en	O
Flag	O
-	O
Señora	B-Protein
.	O

Transfectamos	O
HEK293T	O
células	B-Cell
con	O
5	O
tazas	O
de	O
ADN	B-Sequence
plásmido	I-Sequence
por	O
plato	O
de	O
6	O
cm	O
por	O
Fosfato	B-Chemical
de	I-Chemical
calcio	I-Chemical
método	O

Aproximadamente	O
48	O
horas	O
después	O
de	O
la	O
transfección	O
,	O
células	B-Cell
se	O
recogieron	O
en	O
tampón	O
de	O
inmunoprecipitación	O
(	O
50	O
mM	O
tris	B-Chemical
-	O
HCl	B-Chemical
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
1	O
mM	O
EDTA	B-Chemical
,	O
2	O
mm	O
MgCl2	B-Chemical
,	O
150	O
mm	O
NaCl	B-Chemical
,	O
1	O
mm	O
fluoruro	B-Chemical
de	I-Chemical
fenilmetilsulfonilo	I-Chemical
[	O
Wako	O
]	O
,	O
1	O
%	O
Nonidet	O
P	O
-	O
40	O
,	O
10	O
%	O
glicerol	B-Chemical
)	O
en	O
la	O
presencia	O
de	O
inhibidor	B-Chemical
de	I-Chemical
la	I-Chemical
proteasa	I-Chemical
tabletas	O
de	O
coctel	O
(	O
Roche	O
)	O
.	O

Para	O
cada	O
reacción	O
,	O
1	O
mg	O
de	O
célula	B-Cell
lisado	O
se	O
mezcló	O
con	O
0	O
.	O
5	O
mu	O
g	O
de	O
anti-Bandera	O
anticuerpo	B-GENE
(	O
SIGMA	O
,	O
F3165	O
)	O
y	O
15	O
mu	O
l	O
de	O
proteína	B-Chemical
G-Sepharose	O
(	O
Amersham	O
)	O
en	O
una	O
rueda	O
giratoria	O
a	O
4	O
grados	O
C	O
durante	O
2	O
horas	O
.	O

Proteína	B-Chemical
concentración	O
fue	O
determinada	O
por	O
el	O
BCA	O
proteína	B-Chemical
sistema	O
de	O
ensayo	O
(	O
Pierce	O
)	O
.	O

Luego	O
,	O
las	O
perlas	O
se	O
lavaron	O
tres	O
veces	O
con	O
tampón	O
de	O
inmunoprecipitación	O
y	O
luego	O
tres	O
veces	O
con	O
tampón	O
de	O
lavado	O
(	O
50	O
mM	O
tris	B-Chemical
-	O
HCl	B-Chemical
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
150	O
mM	O
NaCl	B-Chemical
,	O
20	O
mm	O
MgCl2	B-Chemical
)	O
.	O

Proteínas	B-Chemical
Luego	O
se	O
hirvieron	O
durante	O
5	O
min	O
en	O
SDS	B-Chemical
tampón	O
de	O
muestra	O
(	O
1	O
%	O
SDS	B-Chemical
,	O
1	O
mm	O
tris	B-Chemical
[	O
pH	O
6	O
.	O
8	O
]	O
,	O
40	O
mM	O
TDT	B-Chemical
,	O
4	O
%	O
glicerol	B-Chemical
,	O
0	O
.	O
01	O
%	O
pironina	O
Y	O
)	O
.	O

Los	O
sobrenadantes	O
se	O
fraccionaron	O
por	O
dodecil	B-Chemical
sulfato	I-Chemical
de	I-Chemical
sodio	I-Chemical
-	O
electroforesis	O
en	O
gel	O
de	O
poliacrilamida	O
(	O
SDS	B-Chemical
-PAGE	O
)	O
y	O
se	O
transfirió	O
a	O
la	O
membrana	O
de	O
nitrocelulosa	O
(	O
Trans-Blot	O
Transfer	O
Medium	O
,	O
Bio-Rad	O
)	O
.	O

El	O
Western	O
Blot	O
se	O
realizó	O
con	O
Conejo	B-Taxon
anti-HA	O
policlonal	O
anticuerpo	B-GENE
(	O
Santa	O
Cruz	O
,	O
#	O
sc-805	O
)	O
.	O

Se	O
detectaron	O
señales	O
con	O
Rábano	B-Taxon
picante	I-Taxon
peroxidasa	O
-	O
conjugada	O
cabra	B-Taxon
anti	O
-	O
Conejo	B-Taxon
IgG	O
y	O
ECL	O
más	O
el	O
Sistema	O
de	O
Detección	O
de	O
Transferencia	O
Western	O
(	O
Amersham	O
)	O
.	O

Análisis	O
de	O
localización	O
subcelular	O

Transfectamos	O
el	O
plásmido	B-Sequence
codificación	O
HA	O
-	O
etiquetado	O
de	O
longitud	O
completa	O
Señora	B-Protein
en	O
HEK293T	O
células	B-Cell
,	O
sembrado	O
células	B-Cell
en	O
cubreobjetos	O
recubiertos	O
con	O
colágeno	B-Protein
48	O
h	O
después	O
de	O
la	O
transfección	O
,	O
fijado	O
con	O
paraformaldehído	O
al	O
4	O
%	O
en	O
fosfato	B-Chemical
-	O
amortiguado	B-Chemical
solución	O
salina	O
(	O
PBS	O
)	O
a	O
temperatura	O
ambiente	O
durante	O
20	O
min	O
y	O
se	O
lavó	O
con	O
PBS	O
.	O

Luego	O
permeabilizamos	O
células	B-Cell
en	O
PBS	O
que	O
contiene	O
0	O
.	O
Triton	O
X	O
-	O
100	O
al	O
1	O
%	O
durante	O
15	O
min	O
,	O
se	O
lavó	O
de	O
nuevo	O
con	O
PBS	O
y	O
se	O
incubó	O
en	O
PBS	O
que	O
contenía	O
0	O
.	O
1	O
%	O
albúmina	B-Protein
de	I-Protein
suero	I-Protein
bovino	I-Protein
(	O
BSA	B-Protein
)	O
durante	O
30	O
min	O
a	O
temperatura	O
ambiente	O
.	O

incubamos	O
células	B-Cell
con	O
anti	O
-	O
HA	O
anticuerpo	B-GENE
durante	O
la	O
noche	O
a	O
4	O
grados	O
C	O
(	O
1	O
:	O
200	O
en	O
PBS	O
que	O
contiene	O
0	O
,	O
2	O
%	O
BSA	B-Protein
)	O
.	O

Al	O
día	O
siguiente	O
,	O
nos	O
lavamos	O
células	B-Cell
tres	O
veces	O
con	O
PBS	O
e	O
incubado	O
con	O
Cy3	O
-	O
conjugado	O
cabra	B-Taxon
IgG	O
contra	O
Conejo	B-Taxon
IgG	O
(	O
1:400	O
en	O
PBS	O
,	O
Jackson	O
ImmunoReseach	O
Laboratories	O
)	O
durante	O
30	O
min	O
.	O

enjuagamos	O
células	B-Cell
tres	O
veces	O
con	O
PBS	O
,	O
seguido	O
de	O
observación	O
usando	O
un	O
microscopio	O
confocal	O
FV300	O
(	O
Olympus	O
)	O
equipado	O
con	O
una	O
lente	O
objetivo	O
de	O
60x	O
.	O

Ensayo	O
de	O
luciferasa	O

Para	O
el	O
análisis	O
transcripcional	O
del	O
1	O
.	O
2	O
kilobytes	O
región	B-Sequence
promotora	I-Sequence
de	O
Señora	B-Protein
,	O
construimos	O
un	O
reportero	O
plásmido	B-Sequence
(	O
pro1	O
.	O
2k	O
)	O
subclonando	O
un	O
1	O
.	O
2	O
-	O
kb	O
de	O
subida	O
fragmento	B-Sequence
genómico	I-Sequence
del	I-Sequence
gen	I-Sequence
mr	I-Sequence
-	I-Sequence
s	I-Sequence
en	O
un	O
reportero	O
de	O
luciferasa	O
pGL3	O
plásmido	B-Sequence
(	O
Promega	O
)	O
.	O

La	O
expresion	O
vectores	B-Sequence
fueron	O
construidos	O
por	O
subclonación	O
de	O
longitud	O
completa	O
crx	B-Protein
,	O
Otx2	B-Protein
,	O
NRL	B-Protein
genes	B-Sequence
en	O
una	O
expresión	O
pMIK	O
vector	B-Sequence
(	O
un	O
regalo	O
del	O
Dr.	O
K.	O
Maruyama	O
)	O
,	O
respectivamente	O
.	O

``	O
Para	O
el	O
``	O
''	O
mut1259	O
''	O
''	O
''	O
vector	B-Sequence
,	O
los	O
crx	B-Protein
sitio	B-Sequence
de	I-Sequence
unión	I-Sequence
en	O
el	O
-	O
1259	O
posición	B-Sequence
pb	I-Sequence
era	O
mutado	B-Sequence
por	O
reemplazando	B-Sequence
GGATTA	O
con	O
AGATCT	O
.	O

``	O
Para	O
el	O
``	O
''	O
mut198	O
''	O
''	O
''	O
vector	B-Sequence
,	O
los	O
crx	B-Protein
sitio	B-Sequence
de	I-Sequence
unión	I-Sequence
en	O
el	O
-	O
198	O
posición	B-Sequence
pb	I-Sequence
era	O
mutado	B-Sequence
por	O
reemplazando	B-Sequence
TAATCC	O
con	O
GAATTC	O
.	O

``	O
Para	O
el	O
``	O
''	O
mut72	O
''	O
''	O
''	O
vector	B-Sequence
,	O
los	O
crx	B-Protein
sitio	B-Sequence
de	I-Sequence
unión	I-Sequence
en	O
el	O
-	O
72	O
posición	B-Sequence
pb	I-Sequence
era	O
mutado	B-Sequence
por	O
reemplazando	B-Sequence
GGATTA	O
con	O
GAATTC	O
.	O

``	O
Para	O
el	O
``	O
''	O
''	O
mudo	B-Sequence
``	O
todos	O
``	O
''	O
''	O
vector	B-Sequence
,	O
los	O
tres	O
crx	B-Protein
sitios	B-Sequence
de	I-Sequence
unión	I-Sequence
fueron	O
mutado	B-Sequence
.	O

5xGAL4	O
-	O
Indicador	O
de	O
control	O
pGL3	O
plásmido	B-Sequence
,	O
que	O
contiene	O
cinco	O
copias	O
del	O
GAL4	B-Protein
secuencia	B-Sequence
de	I-Sequence
reconocimiento	I-Sequence
de	I-Sequence
ADN	I-Sequence
colocado	O
inmediatamente	O
aguas	O
arriba	O
de	O
SV40	B-Taxon
mínimo	O
promotor	B-Sequence
,	O
fue	O
gentilmente	O
obsequiado	O
por	O
el	O
Dr	O
.	O
t	O

Noguchi	O
y	O
se	O
utiliza	O
para	O
el	O
análisis	O
de	O
la	O
actividad	O
transcripcional	O
de	O
Señora	B-Protein
[	O
50	O
]	O
.	O

Para	O
generar	O
efector	O
plásmidos	B-Sequence
,	O
varios	O
fragmentos	B-Sequence
de	I-Sequence
borrado	I-Sequence
fueron	O
producidos	O
por	O
reacción	O
PCR	O
y	O
subclonados	O
en	O
pGBKT7	O
vector	B-Sequence
,	O
respectivamente	O
.	O

Estas	O
fragmentos	B-Sequence
fueron	O
digeridos	O
con	O
la	O
secuencia	B-Sequence
,	O
que	O
codifica	O
GAL4	B-Protein
ADN	B-Sequence
Unión	O
dominio	B-Sequence
,	O
y	O
insertado	B-Sequence
en	O
pcDNA3	O
.	O

Transfectamos	O
0	O
.	O
1	O
taza	O
de	O
reportero	O
ADN	B-Sequence
plásmido	I-Sequence
y	O
2	O
mu	O
g	O
de	O
la	O
expresión	O
vector	B-Sequence
de	I-Sequence
ADN	I-Sequence
por	O
plato	O
de	O
6	O
cm	O
en	O
HEK293T	O
células	B-Cell
utilizando	O
la	O
transfección	O
Fugene6	O
reactivo	B-Chemical
.	O

Analizamos	O
la	O
actividad	O
de	O
luciferasa	O
48	O
horas	O
después	O
de	O
la	O
transfección	O
.	O

Lista	O
de	O
abreviaciones	O

crx	B-Protein
,	O
cono	B-Protein
-	I-Protein
varilla	I-Protein
homeobox	I-Protein
;	O
Otx2	B-Protein
,	O
ortodentículo	B-Protein
-	I-Protein
homeobox	I-Protein
relacionado	I-Protein
2	I-Protein
;	O
TR	B-Protein
beta	I-Protein
2	I-Protein
,	O
receptor	B-Protein
beta	I-Protein
2	I-Protein
de	I-Protein
la	I-Protein
hormona	I-Protein
tiroidea	I-Protein
;	O
NRL	B-Protein
,	O
cremallera	B-Protein
de	I-Protein
leucina	I-Protein
de	I-Protein
la	I-Protein
retina	I-Protein
neural	I-Protein
;	O
nr2e3	B-Protein
,	O
subfamilia	B-Protein
de	I-Protein
receptores	I-Protein
nucleares	I-Protein
2	I-Protein
grupo	I-Protein
E	I-Protein
miembro	I-Protein
3	I-Protein
;	O
est	B-Sequence
,	O
etiqueta	B-Sequence
de	I-Sequence
secuencia	I-Sequence
expresada	I-Sequence
;	O
EphB2	B-Protein
,	O
receptor	B-Protein
de	I-Protein
efrina	I-Protein
B2	I-Protein
;	O
EphA4	B-Protein
,	O
receptor	B-Protein
de	I-Protein
efrina	I-Protein
A4	I-Protein
;	O
TELÉFONO	B-Protein
,	O
translocación	B-Protein
ETS	I-Protein
leucemia	I-Protein
.	O

Contribuciones	O
de	O
los	O
autores	O

TI	O
y	O
KT	O
realizaron	O
la	O
mayoría	O
de	O
los	O
experimentos	O
,	O
interpretaron	O
los	O
datos	O
y	O
escribieron	O
el	O
primer	O
borrador	O
del	O
manuscrito	O
.	O

Tejidos	O
retinales	O
preparados	O
por	O
AF	O
y	O
sus	O
secciones	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
crx	B-Protein
mutante	B-Sequence
ratones	B-Taxon
.	O

CK	O
realizó	O
un	O
ensayo	O
de	O
luciferasa	O
usando	O
retinoblastoma	O
Y79	O
células	B-Cell
.	O

YT	O
,	O
MA	O
y	O
TF	O
han	O
hecho	O
contribuciones	O
sustanciales	O
a	O
la	O
concepción	O
y	O
el	O
diseño	O
de	O
los	O
experimentos	O
y	O
la	O
redacción	O
del	O
manuscrito	O
.	O

Todos	O
los	O
autores	O
leyeron	O
y	O
aprobaron	O
el	O
manuscrito	O
final	O
.	O

Agradecimientos	O

Agradecemos	O
a	O
T	O
.	O

Noguchi	O
para	O
5xGAL4	O
-	O
reportero	O
pGL3	O
plásmido	B-Sequence
;	O
UN	O
.	O

Nishida	O
por	O
la	O
discusión	O
y	O
lectura	O
crítica	O
del	O
manuscrito	O
;	O
UN	O
.	O

Yoshimura	O
por	O
su	O
asesoramiento	O
sobre	O
microscopía	O
confocal	O
;	O
UN	O
.	O

Tani	O
,	O
Y	O
.	O

Kambara	O
,	O
M	O
.	O

Murai	O
,	O
Y	O
.	O

Hirao	O
y	O
H	O
.	O

Yoshii	O
por	O
la	O
asistencia	O
técnica	O
.	O

Este	O
trabajo	O
fue	O
apoyado	O
por	O
Precursory	O
Research	O
for	O
Embryonic	O
Science	O
and	O
Technology	O
(	O
PRESTO	O
)	O
,	O
Dynamics	O
of	O
Development	O
Systems	O
Molecular	B-Chemical
Brain	O
Science	O
,	O
Subvenciones	O
para	O
la	O
Investigación	O
Científica	O
(	O
B	O
)	O
,	O
Senri	O
Life	O
Science	O
Foundation	O
y	O
Uehara	O
Foundation	O
.	O

Rescate	O
de	O
Progeria	O
en	O
Trichothiodystrophy	O
por	O
Homozygous	O
Lethal	O
XPD	B-Protein
Alelos	B-Sequence

Resumen	O

Aunque	O
la	O
heterocigosidad	O
compuesta	O
,	O
o	O
la	O
presencia	O
de	O
dos	O
diferentes	O
alelos	B-Sequence
mutantes	I-Sequence
de	O
la	O
misma	O
gene	B-Sequence
,	O
es	O
común	O
en	O
humano	B-Taxon
enfermedad	O
recesiva	O
,	O
su	O
potencial	O
para	O
afectar	O
el	O
resultado	O
de	O
la	O
enfermedad	O
no	O
ha	O
sido	O
bien	O
documentado	O
.	O

Lo	O
más	O
probable	O
es	O
que	O
esto	O
se	O
deba	O
a	O
la	O
dificultad	O
inherente	O
de	O
distinguir	O
los	O
efectos	O
bialélicos	O
específicos	O
de	O
las	O
diferencias	O
en	O
el	O
entorno	O
o	O
genético	B-Sequence
antecedentes	O
.	O

Abordamos	O
el	O
potencial	O
de	O
diferentes	O
recesivos	O
alelos	B-Sequence
contribuir	O
a	O
la	O
pleiotropía	O
enigmática	O
asociada	O
con	O
XPD	B-Protein
trastornos	O
recesivos	O
en	O
heterocigotos	O
compuestos	O
ratón	B-Taxon
modelos	O

Alteraciones	B-Sequence
en	O
esta	O
helicasa	O
esencial	O
,	O
con	O
funciones	O
tanto	O
en	O
ADN	B-Sequence
la	O
reparación	O
y	O
la	O
transcripción	O
basal	O
dan	O
lugar	O
a	O
diversas	O
patologías	O
que	O
van	O
desde	O
una	O
elevada	O
sensibilidad	O
a	O
los	O
rayos	O
UV	O
y	O
una	O
predisposición	O
al	O
cáncer	O
hasta	O
una	O
progeria	O
segmentaria	O
acelerada	O
.	O

Reportamos	O
una	O
variedad	O
de	O
efectos	O
bialélicos	O
en	O
orgánico	B-Taxon
fenotipo	O
atribuible	O
a	O
combinaciones	O
de	O
recesivo	O
XPD	B-Protein
alelos	B-Sequence
incluyendo	O
lo	O
siguiente	O
:	O
(	O
i	O
)	O
la	O
capacidad	O
de	O
letal	O
homocigoto	O
XPD	B-Protein
alelos	B-Sequence
para	O
mejorar	O
una	O
variedad	O
de	O
síntomas	O
de	O
enfermedades	O
cuando	O
su	O
función	O
esencial	O
de	O
transcripción	O
basal	O
es	O
suministrada	O
por	O
una	O
enfermedad	O
diferente	O
,	O
causando	O
alelo	B-Sequence
,	O
(	O
ii	O
)	O
funciones	O
diferenciales	O
de	O
desarrollo	O
y	O
específicas	O
de	O
tejido	O
de	O
distintas	O
XPD	B-Protein
alelo	B-Sequence
productos	O
,	O
y	O
(	O
iii	O
)	O
complementación	O
interalélica	O
,	O
un	O
fenómeno	O
rara	O
vez	O
informado	O
en	O
clínicamente	O
relevante	O
lugares	B-Sequence
en	O
mamíferos	B-Taxon
.	O

``	O
Nuestros	O
datos	O
sugieren	O
una	O
reevaluación	O
de	O
la	O
contribución	O
de	O
``	O
''	O
null	O
''	O
''	O
''	O
alelos	B-Sequence
para	O
XPD	B-Protein
trastornos	O
y	O
resaltar	O
el	O
potencial	O
de	O
combinaciones	O
de	O
recesivo	O
alelos	B-Sequence
afectar	O
la	O
plasticidad	O
fenotípica	O
tanto	O
normal	O
como	O
patológica	O
en	O
mamíferos	B-Taxon
.	O

Introducción	O

La	O
complementación	O
interalélica	O
se	O
define	O
como	O
la	O
capacidad	O
de	O
dos	O
diferencialmente	O
alelos	B-Sequence
mutados	I-Sequence
funcionar	O
mejor	O
juntos	O
que	O
cualquiera	O
de	O
ellos	O
por	O
sí	O
solo	O
.	O

A	O
pesar	O
de	O
su	O
casi	O
universalidad	O
en	O
el	O
bajo	O
organismos	B-Taxon
[	O
1	O
]	O
,	O
su	O
potencial	O
para	O
contribuir	O
a	O
la	O
heterogeneidad	O
clínica	O
en	O
humano	B-Taxon
Rara	O
vez	O
se	O
considera	O
la	O
enfermedad	O
.	O

Evidencia	O
de	O
complementación	O
interalélica	O
en	O
clínicamente	O
relevante	O
lugares	B-Sequence
se	O
limita	O
a	O
bioquímica	O
y	O
célula	B-Cell
#	O
¿NOMBRE	O
?	O
enzimas	B-Sequence
incluso	O
propinilo	B-Chemical
-	I-Chemical
CoA	I-Chemical
carboxilasa	O
[	O
2	O
]	O
,	O
argininosuccinato	B-Protein
liasa	I-Protein
[	O
3	O
]	O
,	O
galactosa	B-Protein
-	I-Protein
1	I-Protein
-	I-Protein
fosfato	I-Protein
uridililtransferasa	I-Protein
[	O
4	O
]	O
,	O
y	O
metilmalonil	B-Protein
CoA	I-Protein
mutasa	I-Protein
[	O
5	O
]	O
.	O

Los	O
heterocigotos	O
compuestos	O
son	O
individuos	B-Taxon
llevando	O
dos	O
diferentes	O
alelos	B-Sequence
mutantes	I-Sequence
de	O
la	O
misma	O
gene	B-Sequence
.	O

En	O
ausencia	O
de	O
un	O
dominante	O
(	O
tipo	B-Sequence
salvaje	I-Sequence
[	O
peso	B-Sequence
]	O
)	O
alelo	B-Sequence
,	O
genético	B-Sequence
interacciones	O
entre	O
recesivo	O
alelos	B-Sequence
``	O
(	O
a	O
los	O
que	O
se	O
hace	O
referencia	O
aquí	O
como	O
efectos	O
``	O
''	O
bialélicos	O
''	O
''	O
)	O
podrían	O
dar	O
lugar	O
a	O
diferentes	O
resultados	O
fenotípicos	O
,	O
incluida	O
la	O
complementación	O
interalélica	O
.	O
''	O

Aunque	O
la	O
mejora	O
de	O
los	O
síntomas	O
de	O
la	O
enfermedad	O
por	O
la	O
complementación	O
interalélica	O
crearía	O
un	O
sesgo	O
de	O
determinación	O
en	O
la	O
clínica	O
,	O
la	O
falta	O
de	O
evidencia	O
sobre	O
la	O
complementación	O
interalélica	O
u	O
otros	O
efectos	O
bialélicos	O
en	O
humano	B-Taxon
Es	O
probable	O
que	O
la	O
enfermedad	O
se	O
deba	O
a	O
la	O
dificultad	O
de	O
distinguir	O
tales	O
efectos	O
del	O
medio	O
ambiente	O
y	O
genético	B-Sequence
antecedentes	O
.	O

XPD	B-Protein
codifica	O
uno	O
de	O
los	O
dos	O
componentes	O
helicasa	O
de	O
transcripción	B-GENE
basal	I-GENE
/	I-GENE
factor	I-GENE
de	I-GENE
reparación	I-GENE
de	I-GENE
ADN	I-GENE
IIH	I-GENE
(	O
TFIIH	B-GENE
)	O
,	O
una	O
subunidad	O
de	O
diez	O
,	O
multifuncional	O
complejo	B-GENE
que	O
es	O
esencial	O
para	O
múltiples	O
procesos	O
,	O
incluyendo	O
el	O
inicio	O
de	O
la	O
transcripción	O
basal	O
y	O
ADN	B-Sequence
reparación	O
de	O
daños	O
a	O
través	O
de	O
la	O
nucleótido	B-Chemical
excisión	B-Sequence
vía	O
de	O
reparación	O
(	O
NER	O
)	O
[	O
6	O
,	O
7	O
]	O
.	O

Alteraciones	B-Sequence
en	O
XPD	B-Protein
dando	O
como	O
resultado	O
un	O
defecto	O
TFIIH	B-GENE
se	O
asocian	O
con	O
trastornos	O
multisistémicos	O
sensibles	O
a	O
los	O
rayos	O
UV	O
,	O
incluidos	O
el	O
xeroderma	O
pigmentoso	O
(	O
XP	O
)	O
,	O
XP	O
combinado	O
con	O
el	O
síndrome	O
de	O
Cockayne	O
(	O
CS	O
)	O
y	O
la	O
tricotiodistrofia	O
(	O
TTD	O
)	O
[	O
8-10	O
]	O
.	O

XP	O
se	O
caracteriza	O
por	O
anomalías	O
de	O
pigmentación	O
inducidas	O
por	O
el	O
sol	O
y	O
una	O
elevación	O
de	O
más	O
de	O
1.000	O
veces	O
en	O
el	O
riesgo	O
de	O
cáncer	O
de	O
piel	O
.	O

Los	O
casos	O
graves	O
también	O
pueden	O
presentarse	O
con	O
retraso	O
del	O
crecimiento	O
y	O
neurodegeneración	O
primaria	O
[	O
11	O
]	O
.	O

CS	O
y	O
TTD	O
,	O
por	O
otro	O
lado	O
,	O
son	O
trastornos	O
progeroides	O
segmentarios	O
caracterizados	O
por	O
una	O
falla	O
progresiva	O
del	O
crecimiento	O
posnatal	O
y	O
desmielinización	O
primaria	O
que	O
resulta	O
en	O
una	O
neurodisfunción	O
severa	O
,	O
pero	O
sin	O
una	O
clara	O
predisposición	O
al	O
cáncer	O
[	O
12-15	O
]	O
.	O

Los	O
pacientes	O
con	O
TTD	O
también	O
muestran	O
un	O
sello	O
distintivo	O
azufre	B-Chemical
-	O
cabello	O
y	O
uñas	O
quebradizos	O
deficientes	O
y	O
piel	O
descamada	O
[	O
13	O
]	O
,	O
como	O
resultado	O
de	O
un	O
defecto	O
de	O
transcripción	O
basal	O
en	O
célula	B-Cell
tipos	O
[	O
16	O
,	O
17	O
]	O
.	O

También	O
se	O
ha	O
descrito	O
un	O
trastorno	O
relacionado	O
con	O
la	O
predisposición	O
al	O
cáncer	O
de	O
XP	O
combinado	O
con	O
las	O
complicaciones	O
del	O
neurodesarrollo	O
de	O
SC	O
(	O
XPCS	O
)	O
,	O
aunque	O
es	O
poco	O
común	O
[	O
18	O
]	O
.	O

Muchos	O
XPD	B-Protein
mutaciones	B-Sequence
están	O
asociados	O
con	O
un	O
fenotipo	O
de	O
enfermedad	O
exclusivo	O
(	O
p	O
.	O
ej.	O
,	O
XPDR722W	O
con	O
TTD	O
y	O
XPDR683W	O
con	O
XP	O
)	O
y	O
,	O
por	O
lo	O
tanto	O
,	O
se	O
consideran	O
causantes	O
de	O
los	O
síndromes	O
correspondientes	O
.	O

Alelos	B-Sequence
``	O
no	O
asociados	O
exclusivamente	O
con	O
un	O
trastorno	O
se	O
consideran	O
``	O
''	O
probablemente	O
nulos	O
''	O
''	O
''	O
alelos	B-Sequence
[	O
19	O
,	O
20	O
]	O
.	O

Algunos	O
de	O
estos	O
alelos	B-Sequence
fallan	O
en	O
apoyar	O
la	O
viabilidad	O
en	O
un	O
haploide	O
levadura	B-Taxon
Schizosaccharomyces	I-Taxon
pombe	I-Taxon
tensión	O
con	O
un	O
nulo	O
mutación	B-Sequence
en	O
el	O
XPD	B-Protein
homólogo	B-Sequence
rad15	B-Protein
y	O
por	O
lo	O
tanto	O
se	O
consideran	O
desprovistos	O
de	O
actividad	O
biológica	O
significativa	O
[	O
19	O
]	O
.	O

Esta	O
clasificación	O
de	O
alelos	B-Sequence
``	O
como	O
causativo	O
o	O
nulo	O
actualmente	O
define	O
lo	O
que	O
llamamos	O
un	O
paradigma	O
``	O
''	O
monoalélico	O
''	O
''	O
de	O
''	O
XPD	B-Protein
enfermedad	O
.	O

Sin	O
embargo	O
,	O
la	O
identificación	O
en	O
los	O
últimos	O
años	O
de	O
pacientes	O
del	O
grupo	O
D	O
con	O
complemento	O
de	O
XP	O
con	O
presentación	O
atípica	O
de	O
la	O
enfermedad	O
,	O
incluidos	O
síntomas	O
tanto	O
de	O
XP	O
como	O
de	O
TTD	O
[	O
8	O
]	O
,	O
arroja	O
dudas	O
sobre	O
la	O
capacidad	O
de	O
dicho	O
paradigma	O
monoalélico	O
para	O
explicar	O
la	O
heterogeneidad	O
clínica	O
en	O
heterocigotos	O
compuestos	O
.	O

Previamente	O
,	O
generamos	O
un	O
TTD	O
ratón	B-Taxon
modelo	O
(	O
XPDR722W	O
)	O
que	O
fenocopia	O
el	O
humano	B-Taxon
síndrome	O
[	O
15	O
,	O
21	O
]	O
.	O

Aquí	O
reportamos	O
la	O
generación	O
de	O
más	O
mutante	B-Sequence
XPD	B-Protein
alelos	B-Sequence
que	O
no	O
respaldan	O
la	O
viabilidad	O
por	O
sí	O
mismos	O
pero	O
que	O
,	O
sin	O
embargo	O
,	O
mejoran	O
el	O
envejecimiento	O
segmentario	O
prematuro	O
asociado	O
con	O
TTD	O
,	O
las	O
características	O
cutáneas	O
,	O
celular	B-Cell
ADN	B-Sequence
capacidad	O
de	O
reparación	O
y	O
supervivencia	O
UV	O
cuando	O
está	O
presente	O
en	O
un	O
estado	O
heterocigoto	O
compuesto	O
.	O

Resultados	O

Generación	O
de	O
XPD	B-Protein
heterocigotos	O
compuestos	O

Generamos	O
un	O
XPD	B-Protein
golpear	O
-	O
en	O
alelo	B-Sequence
con	O
un	O
mutación	B-Sequence
puntual	I-Sequence
codificando	O
un	O
solo	O
aminoácidos	B-Chemical
cambiar	B-Sequence
(	O
XPDG602D	O
)	O
encontrado	O
en	O
el	O
paciente	O
XPCS	O
XPCS2	O
(	O
Figura	O
1A	O
-	O
1C	O
)	O
.	O

ARNm	B-Chemical
expresión	O
del	O
objetivo	O
alelo	B-Sequence
podría	O
detectarse	O
en	O
embriones	O
Células	B-Cell
madre	I-Cell
por	O
RT-PCR	O
(	O
Figura	O
1D	O
)	O
,	O
aunque	O
la	O
expresión	O
se	O
redujo	O
aproximadamente	O
5	O
veces	O
en	O
relación	O
con	O
peso	B-Sequence
transcripción	B-Chemical
de	I-Chemical
ARNm	I-Chemical
niveles	O
determinados	O
por	O
transferencia	O
Northern	O
de	O
ARN	B-Sequence
del	O
testículo	O
de	O
heterocigotos	O
animales	B-Taxon
(	O
Figura	O
1E	O
)	O
.	O

Debido	O
a	O
que	O
el	O
paciente	O
XPCS2	O
era	O
un	O
hemicigoto	O
con	O
mutante	B-Sequence
XPD	B-Protein
proteína	B-Chemical
(	O
XPDG602D	O
)	O
expresado	O
a	O
partir	O
de	O
un	O
solo	O
alelo	B-Sequence
,	O
el	O
correspondiente	O
mutación	B-Sequence
se	O
esperaba	O
que	O
fuera	O
viable	O
en	O
el	O
estado	O
homocigótico	O
.	O

Sin	O
embargo	O
,	O
homocigotos	O
mutante	B-Sequence
ratones	B-Taxon
no	O
se	O
observaron	O
,	O
ni	O
entre	O
los	O
nacidos	O
vivos	O
ni	O
el	O
día	O
13	O
embrionario	O
.	O
5	O
(	O
E13	O
.	O
5	O
)	O
o	O
E3	O
.	O
5	O
embriones	O
(	O
Cuadro	O
1	O
)	O
.	O

El	O
hipomórfico	O
correspondiente	O
,	O
alelo	B-Sequence
mutante	I-Sequence
fue	O
así	O
designado	O
como	O
homocigoto	O
letal	O
(	O
+XPCS	O
)	O
.	O

Letalidad	O
homocigota	O
del	O
XPCS	O
alelo	B-Sequence
es	O
probable	O
que	O
se	O
deba	O
a	O
niveles	O
reducidos	O
de	O
expresión	O
de	O
este	O
esencial	O
proteína	B-Chemical
como	O
resultado	O
de	O
gene	B-Sequence
focalización	O
(	O
Figura	O
1A	O
)	O
en	O
lugar	O
de	O
a	O
la	O
mutación	B-Sequence
sí	O
mismo	O
.	O

XPD	B-Protein
la	O
ablación	O
(	O
XpdKO/KO	O
)	O
es	O
igualmente	O
incompatible	O
con	O
la	O
vida	O
más	O
allá	O
de	O
las	O
primeras	O
etapas	O
de	O
la	O
embriogénesis	O
[	O
22	O
]	O
.	O

De	O
acuerdo	O
con	O
esta	O
interpretación	O
,	O
un	O
objetivo	O
diferente	O
XPD	B-Protein
mutación	B-Sequence
codificando	O
XPDR683W	O
,	O
que	O
está	O
asociado	O
con	O
XP	O
en	O
el	O
estado	O
homocigoto	O
en	O
humanos	B-Taxon
,	O
fue	O
subexpresado	O
de	O
manera	O
similar	O
y	O
letal	O
en	O
el	O
estado	O
homocigoto	O
(	O
designado	O
como	O
+	O
XP	O
alelo	B-Sequence
)	O
(	O
Figura	O
1A	O
-	O
1C	O
;	O
Tabla	O
1	O
;	O
datos	O
no	O
publicados	O
)	O
.	O

Además	O
,	O
un	O
enfoque	O
de	O
focalización	O
diferente	O
que	O
conduce	O
al	O
uso	O
de	O
la	O
nativo	B-Sequence
3	I-Sequence
'	I-Sequence
UTR	I-Sequence
y	O
eliminación	B-Sequence
del	O
neo	O
gene	B-Sequence
resultó	O
en	O
la	O
normalización	O
de	O
XpdXPCS	O
ARNm	B-Chemical
niveles	O
y	O
homocigotos	O
viables	O
XpdXPCS	O
/	O
XPCS	O
(	O
XPDG602D	O
/	O
G602D	O
)	O
animales	B-Taxon
[	O
23	O
]	O
.	O

Figura	O
1	O

Orientación	O
de	O
la	O
Ratón	B-Protein
Xpd	I-Protein
Gene	B-Sequence

(	O
A	O
)	O
Representación	O
esquemática	O
de	O
la	O
genómico	B-Sequence
estructura	O
y	O
mapa	B-Sequence
de	I-Sequence
restricción	I-Sequence
parcial	I-Sequence
de	O
El	O
peso	B-Sequence
y	O
dirigido	O
ratón	B-Protein
xpd	I-Protein
lugares	B-Sequence
.	O

Para	O
el	O
peso	B-Sequence
XPD	B-Protein
alelo	B-Sequence
,	O
los	O
cuadros	O
sombreados	O
representan	O
regiones	B-Sequence
codificantes	I-Sequence
de	I-Sequence
exones	I-Sequence
12	O
y	O
19	O
-	O
23	O
;	O
los	O
3	B-Sequence
'	I-Sequence
UTR	I-Sequence
está	O
representado	O
por	O
una	O
caja	O
abierta	O
.	O

TGA	O
indica	O
el	O
codón	B-Sequence
de	I-Sequence
terminación	I-Sequence
de	I-Sequence
la	I-Sequence
traducción	I-Sequence
;	O
PoliA	B-Sequence
indica	O
el	O
señal	B-Sequence
de	I-Sequence
poliadenilación	I-Sequence
.	O

Para	O
el	O
objetivo	O
XpdTTD	O
alelo	B-Sequence
,	O
el	O
194	O
-	O
Base	B-Sequence
par	I-Sequence
(	O
pb	B-Sequence
)	O
XPD	B-Protein
humano	I-Protein
fragmento	B-Sequence
de	I-Sequence
ADNc	I-Sequence
fusionado	O
a	O
exón	B-Sequence
22	O
se	O
indica	O
como	O
un	O
cuadro	O
rayado	O
que	O
incluye	O
el	O
TTD	O
(	O
R722W	O
)	O
mutación	B-Sequence
indicado	O
por	O
una	O
flecha	O
vertical	O
.	O

Pollo	B-Taxon
beta	B-Protein
-	I-Protein
globina	I-Protein
exones	B-Sequence
2	O
y	O
3	O
incluyendo	O
el	O
3	B-Sequence
'	I-Sequence
UTR	I-Sequence
se	O
indican	O
como	O
recuadros	O
negros	O
con	O
los	O
correspondientes	O
números	O
romanos	O
seguidos	O
del	O
beta	B-Protein
-	I-Protein
globina	I-Protein
señal	B-Sequence
de	I-Sequence
poliadenilación	I-Sequence
(	O
PoliA	B-Sequence
*	I-Sequence
)	O
.	O

Para	O
el	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelos	B-Sequence
,	O
las	O
flechas	O
verticales	O
indican	O
XPCS	O
(	O
codificación	O
G602D	O
)	O
y	O
XP	O
(	O
codificación	O
R683W	O
)	O
mutaciones	B-Sequence
en	O
exones	B-Sequence
19	O
y	O
22	O
,	O
respectivamente	O
.	O

El	O
único	O
3	O
'	O
Investigacion	B-Sequence
ubicado	O
fuera	O
de	O
la	O
orientación	O
construir	B-Sequence
está	O
marcado	O
por	O
una	O
línea	O
negra	O
gruesa	O
.	O

Sitios	B-Sequence
de	I-Sequence
restricción	I-Sequence
:	O
B	O
,	O
BamHI	O
;	O
C	O
,	O
ClaI	O
;	O
E	O
,	O
EcoRI	O
;	O
H	B-Protein
,	O
HindIII	B-Protein
;	O
Hp	O
,	O
HpaI	O
;	O
Sf	O
,	O
SfiI	O
.	O

(	O
B	O
)	O
Análisis	O
de	O
transferencia	O
Southern	O
de	O
EcoRI	O
-	O
digerido	O
ADN	B-Sequence
genómico	I-Sequence
desde	O
peso	B-Sequence
,	O
XPD	B-Protein
+	O
XPCS	O
/	O
peso	B-Sequence
,	O
y	O
XPD	B-Protein
+	O
XP	O
/	O
peso	B-Sequence
embrionario	O
recombinante	O
célula	B-Cell
madre	I-Cell
clones	O
hibridados	O
con	O
el	O
3	O
'	O
Investigacion	B-Sequence
representada	O
en	O
(	O
A	O
)	O
.	O

los	O
wt	B-Sequence
alelo	I-Sequence
da	O
un	O
6	O
.	O
5	O
-	O
kilobase	O
(	O
kb	O
)	O
fragmento	B-Sequence
,	O
mientras	O
que	O
ambos	O
apuntaron	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelos	B-Sequence
dar	O
un	O
5	O
.	O
1	O
kb	O
fragmento	B-Sequence
.	O

(	O
C	O
)	O
Genotipado	O
de	O
peso	B-Sequence
y	O
dirigido	O
alelos	B-Sequence
por	O
PCR	O
utilizando	O
cebadores	B-Sequence
F2	O
,	O
R1	O
y	O
mR	O
como	O
se	O
indica	O
en	O
(	O
A	O
)	O
produce	O
fragmentos	B-Sequence
de	O
399	O
pb	B-Sequence
y	O
468	O
pb	B-Sequence
,	O
respectivamente	O
.	O

(	O
D	O
)	O
Detección	O
por	O
RT	O
-	O
PCR	O
de	O
ARNm	B-Chemical
expresión	O
que	O
se	O
origina	O
en	O
el	O
objetivo	O
+	O
XP	O
y	O
+	O
XPCS	O
alelos	B-Sequence
en	O
embrionario	O
célula	B-Cell
madre	I-Cell
clones	O
usando	O
cebadores	B-Sequence
F1	O
(	O
hibridación	O
fuera	O
de	O
la	O
orientación	O
construir	B-Sequence
)	O
y	O
mR	O
como	O
se	O
indica	O
en	O
(	O
A	O
)	O
da	O
como	O
resultado	O
un	O
1	O
,	O
416	O
-	O
fragmento	B-Sequence
pb	I-Sequence
.	O

(	O
E	O
)	O
Análisis	O
de	O
transferencia	O
Northern	O
del	O
total	O
ARN	B-Sequence
aislado	O
de	O
testículos	O
de	O
homocigotos	O
peso	B-Sequence
y	O
XpdTTD/TTD	O
,	O
heterocigotos	O
XPD	B-Protein
+	O
XPCS	O
/	O
peso	B-Sequence
y	O
XpdTTD/	O
peso	B-Sequence
,	O
y	O
heterocigoto	O
compuesto	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
como	O
se	O
indica	O
.	O

Hibridación	O
con	O
un	O
1	O
.	O
4	O
kb	O
ratón	B-Protein
xpd	I-Protein
sonda	B-Sequence
de	I-Sequence
ADNc	I-Sequence
detecta	O
ARNm	B-Chemical
de	O
4	O
,	O
3	O
.	O
3	O
y	O
2	O
.	O
7kb	O
de	O
peso	B-Sequence
,	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelos	B-Sequence
,	O
respectivamente	O
.	O

Un	O
bromuro	B-Chemical
de	I-Chemical
etidio	I-Chemical
(	O
EtBr	B-Chemical
)	O
-	O
gel	O
teñido	O
que	O
muestra	O
la	O
cantidad	O
de	O
total	O
ARN	B-Sequence
cargado	O
se	O
muestra	O
a	O
continuación	O
.	O

tabla	O
1	O

Frecuencia	O
de	O
XPD	B-Protein
+	O
XP	O
/	O
+	O
XP	O
,	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O

Nulo	O
alelo	B-Sequence
Puede	O
aliviar	O
el	O
retraso	O
en	O
el	O
desarrollo	O
,	O
la	O
piel	O
y	O
las	O
características	O
del	O
cabello	O
de	O
TTD	O

``	O
Para	O
probar	O
el	O
potencial	O
de	O
un	O
homocigoto	O
letal	O
``	O
''	O
null	O
''	O
''	O
''	O
alelo	B-Sequence
sin	O
embargo	O
contribuir	O
a	O
orgánico	B-Taxon
fenotipo	O
,	O
combinamos	O
un	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelo	B-Sequence
con	O
un	O
XpdTTD	O
viable	O
alelo	B-Sequence
cruzando	O
el	O
correspondiente	O
heterocigoto	O
animales	B-Taxon
.	O

Similar	O
al	O
TTD	O
hemicigoto	O
ratones	B-Taxon
llevando	O
uno	O
verdadero	O
XPD	B-Protein
knockear	O
alelo	B-Sequence
(	O
XpdTTD	O
/	O
KO	O
)	O
,	O
heterocigoto	O
compuesto	O
XpdTTD	O
/	O
+	O
XPCS	O
ratones	B-Taxon
nacieron	O
en	O
las	O
frecuencias	O
mendelianas	O
esperadas	O
.	O

expresión	O
de	O
la	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelo	B-Sequence
también	O
se	O
redujo	O
en	O
los	O
testículos	O
de	O
heterocigotos	O
compuestos	O
animales	B-Taxon
,	O
mientras	O
que	O
la	O
expresión	O
del	O
XpdTTD	O
alelo	B-Sequence
se	O
incrementó	O
en	O
relación	O
con	O
peso	B-Sequence
por	O
~	O
5	O
veces	O
(	O
Figura	O
1E	O
)	O
.	O

Por	O
falta	O
de	O
disponibilidad	O
anticuerpos	B-GENE
y	O
la	O
incapacidad	O
de	O
distinguir	O
entre	O
varios	O
formas	B-Sequence
mutantes	I-Sequence
de	O
XPD	B-Protein
diferenciándose	O
solo	O
por	O
un	O
solo	O
aminoácidos	B-Chemical
sustituciones	B-Sequence
,	O
no	O
pudimos	O
determinar	O
la	O
cantidad	O
relativa	O
de	O
XPD	B-Protein
proteína	B-Chemical
de	O
los	O
diferentes	O
alelos	B-Sequence
.	O

A	O
pesar	O
de	O
los	O
niveles	O
reducidos	O
de	O
ARNm	B-Chemical
expresión	O
,	O
el	O
homocigoto	O
letal	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelo	B-Sequence
mejoró	O
múltiples	O
XpdTTD	O
-	O
síntomas	O
de	O
enfermedad	O
asociados	O
en	O
compuesto	O
heterocigoto	O
XpdTTD	O
/	O
+	O
XPCS	O
animales	B-Taxon
incluyendo	O
el	O
característico	O
cabello	O
quebradizo	O
y	O
rasgos	O
cutáneos	O
totalmente	O
penetrantes	O
en	O
TTD	O
homo	O
y	O
hemicigótico	O
ratones	B-Taxon
(	O
Figura	O
2A-2C	O
)	O
.	O

En	O
marcado	O
contraste	O
con	O
XpdTTD/TTD	O
(	O
y	O
XpdTTD/KO	O
)	O
ratones	B-Taxon
que	O
presentan	O
pérdida	O
completa	O
del	O
cabello	O
en	O
el	O
primer	O
ciclo	O
capilar	O
y	O
pérdida	O
parcial	O
del	O
cabello	O
en	O
ciclos	O
posteriores	O
a	O
lo	O
largo	O
de	O
su	O
vida	O
[	O
21	O
]	O
,	O
compuesto	O
heterocigoto	O
XpdTTD	O
/	O
+	O
XPCS	O
ratones	B-Taxon
mostraron	O
algo	O
de	O
pérdida	O
de	O
cabello	O
solo	O
durante	O
el	O
primer	O
ciclo	O
capilar	O
y	O
solo	O
localmente	O
en	O
la	O
parte	O
posterior	O
(	O
Figura	O
2A	O
)	O
.	O

Exploración	O
electrón	B-Chemical
El	O
análisis	O
microscópico	O
del	O
cabello	O
XpdTTD/+XPCS	O
reveló	O
una	O
apariencia	O
casi	O
normal	O
,	O
con	O
características	O
similares	O
a	O
TTD	O
,	O
tales	O
como	O
cabellos	O
rotos	O
que	O
se	O
encuentran	O
solo	O
con	O
muy	O
baja	O
frecuencia	O
(	O
datos	O
no	O
publicados	O
)	O
.	O

Aminoácidos	B-Chemical
análisis	O
confirmó	O
que	O
cisteína	B-Chemical
niveles	O
en	O
el	O
cabello	O
de	O
la	O
XpdTTD	O
/	O
+	O
XPCS	O
ratones	B-Taxon
fueron	O
significativamente	O
más	O
altos	O
que	O
en	O
XpdTTD	O
/	O
TTD	O
animales	B-Taxon
,	O
pero	O
se	O
mantuvo	O
por	O
debajo	O
del	O
peso	B-Sequence
nivel	O
(	O
Figura	O
2C	O
)	O
.	O

Los	O
hemicigotos	O
TTD	O
(	O
XpdTTD/KO	O
)	O
no	O
muestran	O
diferencias	O
significativas	O
en	O
las	O
características	O
cutáneas	O
y	O
la	O
longevidad	O
en	O
relación	O
con	O
los	O
homocigotos	O
XpdTTD/TTD	O
ratones	B-Taxon
[	O
21	O
]	O
.	O

Figura	O
2	O

Rescate	O
parcial	O
de	O
fenotipos	O
TTD	O
cutáneos	O
,	O
sanguíneos	O
y	O
de	O
desarrollo	O
en	O
compuestos	O
heterocigotos	O
XpdTTD	O
/	O
+	O
XPCS	O
Ratones	B-Taxon

A	O
)	O
Fotografías	O
de	O
XpdTTD	O
/	O
TTD	O
homocigoto	O
de	O
5	O
meses	O
de	O
edad	O
,	O
XpdTTD	O
/	O
+	O
XPCS	O
heterocigoto	O
compuesto	O
y	O
peso	B-Sequence
ratones	B-Taxon
.	O

Recuadros	O
:	O
imágenes	O
de	O
pérdida	O
de	O
cabello	O
de	O
primera	O
ronda	O
.	O

(	O
B	O
)	O
Análisis	O
histológico	O
de	O
la	O
piel	O
de	O
XpdTTD	O
/	O
TTD	O
,	O
XpdTTD	O
/	O
+	O
XPCS	O
y	O
peso	B-Sequence
ratones	B-Taxon
.	O

En	O
la	O
epidermis	O
de	O
XpdTTD	O
/	O
+	O
XPCS	O
y	O
peso	B-Sequence
ratones	B-Taxon
.	O

Ampliación	O
400x	O
.	O

(	O
C	O
)	O
cisteína	B-Chemical
contenido	O
de	O
pelo	O
de	O
peso	B-Sequence
,	O
XpdTTD	O
/	O
TTD	O
y	O
XpdTTD	O
/	O
+	O
XPCS	O
ratones	B-Taxon
.	O

El	O
valor	O
p	O
indica	O
diferencias	O
significativas	O
entre	O
mutantes	B-Sequence
y	O
peso	B-Sequence
,	O
así	O
como	O
entre	O
XpdTTD/TTD	O
y	O
XpdTTD/+XPCS	O
ratones	B-Taxon
.	O

Las	O
barras	O
de	O
error	O
indican	O
el	O
error	O
estándar	O
de	O
la	O
media	O
(	O
SEM	O
)	O
.	O

(	O
D	O
)	O
Valores	O
de	O
hematocrito	O
de	O
sangre	O
de	O
XpdTTD	O
/	O
TTD	O
y	O
XpdTTD	O
/	O
+	O
XPCS	O
ratones	B-Taxon
.	O

Los	O
valores	O
de	O
p	O
indican	O
la	O
importancia	O
de	O
la	O
diferencia	O
relativa	O
a	O
peso	B-Sequence
.	O

Las	O
barras	O
de	O
error	O
indican	O
SEM	O
.	O

E	O
)	O
Pesos	O
corporales	O
de	O
XpdTTD	O
/	O
TTD	O
y	O
XpdTTD	O
/	O
+	O
XPCS	O
en	O
desarrollo	O
ratones	B-Taxon
después	O
del	O
destete	O
representado	O
como	O
un	O
porcentaje	O
del	O
peso	O
de	O
la	O
edad	O
-	O
control	O
emparejado	O
peso	B-Sequence
y	O
compañeros	O
de	O
camada	O
heterocigotos	O
(	O
hz	O
)	O
(	O
fijado	O
en	O
100	O
%	O
)	O
.	O

Las	O
barras	O
de	O
error	O
indican	O
SEM	O
.	O

Otras	O
características	O
prominentes	O
de	O
TTD	O
en	O
la	O
epidermis	O
,	O
incluida	O
la	O
acantosis	O
(	O
engrosamiento	O
de	O
la	O
capa	O
de	O
la	O
nucleado	B-GENE
células	B-Cell
)	O
,	O
hiperqueratosis	O
(	O
engrosamiento	O
prominente	O
de	O
la	O
capa	O
córnea	O
)	O
,	O
hiperplasia	O
pronunciada	O
de	O
la	O
capa	O
granular	O
y	O
de	O
las	O
glándulas	O
sebáceas	O
(	O
causando	O
una	O
apariencia	O
grasosa	O
del	O
cabello	O
)	O
,	O
estuvieron	O
ausentes	O
en	O
la	O
piel	O
de	O
XpdTTD	O
/	O
+	O
XPCS	O
ratones	B-Taxon
,	O
según	O
lo	O
establecido	O
por	O
examen	O
microscópico	O
ciego	O
de	O
secciones	O
de	O
piel	O
(	O
Figura	O
2B	O
)	O
.	O

Además	O
,	O
la	O
anemia	O
y	O
el	O
retraso	O
en	O
el	O
desarrollo	O
están	O
presentes	O
en	O
pacientes	O
con	O
TTD	O
[	O
24	O
]	O
y	O
en	O
XpdTTD	O
/	O
TTD	O
ratones	B-Taxon
[	O
15	O
]	O
ambos	O
fueron	O
rescatados	O
parcialmente	O
en	O
heterocigotos	O
compuestos	O
XpdTTD	O
/	O
+	O
XPCS	O
ratones	B-Taxon
(	O
Figura	O
2D	O
y	O
2E	O
)	O
.	O

Rescate	O
de	O
características	O
de	O
Progeroid	O
en	O
TTD	O
Ratones	B-Taxon
por	O
homocigoto	O
letal	O
XPD	B-Protein
Alelos	B-Sequence

Debido	O
a	O
que	O
los	O
pacientes	O
con	O
TTD	O
,	O
XPCS	O
y	O
CS	O
(	O
pero	O
no	O
XP	O
)	O
y	O
los	O
correspondientes	O
ratón	B-Taxon
modelos	O
comparten	O
síntomas	O
progeroides	O
acelerados	O
similares	O
[	O
12	O
,	O
13	O
,	O
15	O
,	O
23	O
]	O
,	O
luego	O
abordamos	O
los	O
parámetros	O
relacionados	O
con	O
el	O
envejecimiento	O
en	O
heterocigotos	O
compuestos	O
ratones	B-Taxon
(	O
Figura	O
3	O
)	O
.	O

Mientras	O
que	O
XpdTTD	O
/	O
TTD	O
animales	B-Taxon
mostrar	O
hueso	O
reducido	O
mineral	B-Chemical
densidad	O
como	O
una	O
indicación	O
del	O
inicio	O
temprano	O
de	O
la	O
osteoporosis	O
antes	O
de	O
~	O
14	O
meses	O
de	O
edad	O
[	O
15	O
]	O
,	O
vértebras	O
de	O
la	O
cola	O
del	O
compuesto	O
heterocigoto	O
XpdTTD	O
/	O
+	O
XPCS	O
ratones	B-Taxon
eran	O
comparables	O
a	O
peso	B-Sequence
incluso	O
a	O
los	O
20	O
meses	O
de	O
edad	O
(	O
Figura	O
3B	O
y	O
3C	O
)	O
.	O

Además	O
,	O
mientras	O
que	O
XpdTTD/TTD	O
ratones	B-Taxon
desarrolló	O
cifosis	O
antes	O
que	O
peso	B-Sequence
animales	B-Taxon
(	O
inicio	O
~	O
3	O
meses	O
versus	O
12	O
-	O
20	O
meses	O
)	O
,	O
heterocigoto	O
compuesto	O
XpdTTD	O
/	O
+	O
XPCS	O
ratones	B-Taxon
no	O
lo	O
hizo	O
(	O
Figura	O
3B	O
)	O
.	O

Las	O
curvas	O
de	O
apariencia	O
general	O
y	O
peso	O
corporal	O
revelaron	O
que	O
la	O
caquexia	O
prematura	O
relacionada	O
con	O
la	O
edad	O
asociada	O
con	O
la	O
TTD	O
y	O
la	O
falta	O
de	O
condición	O
física	O
general	O
se	O
rescataron	O
por	O
completo	O
en	O
el	O
heterocigoto	O
compuesto	O
XpdTTD	O
/	O
+	O
XPCS	O
ratones	B-Taxon
(	O
Figura	O
3A	O
y	O
3D	O
)	O
.	O

Finalmente	O
,	O
la	O
vida	O
útil	O
de	O
los	O
heterocigotos	O
compuestos	O
se	O
extendió	O
en	O
relación	O
con	O
XpdTTD	O
/	O
TTD	O
ratones	B-Taxon
(	O
Tabla	O
2	O
)	O
.	O

figura	O
3	O

Rescate	O
de	O
TTD	O
-	O
Características	O
progeroides	O
segmentarias	O
asociadas	O
en	O
heterocigotos	O
compuestos	O
XPD	B-Protein
TTD	O
/	O
+	O
XPCS	O
Ratones	B-Taxon

(	O
A	O
)	O
Fotografías	O
de	O
20	O
meses	O
de	O
edad	O
peso	B-Sequence
,	O
compuesto	O
heterocigoto	O
XpdTTD	O
/	O
+	O
XPCS	O
,	O
y	O
homocigoto	O
XpdTTD	O
/	O
TTD	O
ratones	B-Taxon
.	O

Tenga	O
en	O
cuenta	O
la	O
caquexia	O
extrema	O
(	O
falta	O
de	O
grasa	O
subcutánea	O
)	O
en	O
el	O
XpdTTD/TTD	O
ratón	B-Taxon
y	O
la	O
ausencia	O
de	O
este	O
fenotipo	O
en	O
peso	B-Sequence
y	O
XpdTTD	O
/	O
+	O
XPCS	O
ratones	B-Taxon
.	O

(	O
B	O
)	O
Radiografías	O
de	O
un	O
varón	O
de	O
20	O
meses	O
peso	B-Sequence
,	O
XpdTTD	O
/	O
+	O
XPCS	O
y	O
XpdTTD	O
/	O
TTD	O
ratones	B-Taxon
.	O

Envejecimiento	O
XpdTTD	O
/	O
TTD	O
ratones	B-Taxon
desarrollar	O
cifosis	O
(	O
curvatura	O
de	O
la	O
columna	O
vertebral	O
)	O
y	O
reducción	O
del	O
hueso	O
mineral	B-Chemical
densidad	O
como	O
se	O
muestra	O
en	O
el	O
segmento	O
6-8	O
de	O
las	O
vértebras	O
de	O
la	O
cola	O
contadas	O
desde	O
la	O
pelvis	O
(	O
ver	O
primer	O
plano	O
a	O
la	O
derecha	O
)	O
.	O

Tenga	O
en	O
cuenta	O
la	O
ausencia	O
de	O
estas	O
características	O
en	O
el	O
XpdTTD	O
/	O
+	O
XPCS	O
ratón	B-Taxon
.	O

(	O
C	O
)	O
Cuantificación	O
del	O
hueso	O
relativo	O
mineral	B-Chemical
densidad	O
de	O
las	O
vértebras	O
de	O
la	O
cola	O
desde	O
los	O
20	O
meses	O
de	O
edad	O
del	O
macho	O
peso	B-Sequence
(	O
n	O
=	O
3	O
)	O
,	O
XpdTTD	O
/	O
+	O
XPCS	O
(	O
n	O
=	O
4	O
)	O
y	O
XpdTTD	O
/	O
TTD	O
(	O
n	O
=	O
3	O
)	O
ratones	B-Taxon
.	O

Los	O
valores	O
de	O
p	O
indican	O
la	O
importancia	O
de	O
la	O
diferencia	O
relativa	O
a	O
XpdTTD/TTD	O
.	O

Las	O
barras	O
de	O
error	O
indican	O
SEM	O
.	O

(	O
D	O
)	O
Curvas	O
de	O
peso	O
corporal	O
en	O
función	O
del	O
tiempo	O
.	O

Tenga	O
en	O
cuenta	O
que	O
la	O
caquexia	O
dependiente	O
de	O
la	O
edad	O
observada	O
en	O
XpdTTD	O
/	O
TTD	O
ratones	B-Taxon
fue	O
rescatado	O
tanto	O
en	O
macho	O
como	O
en	O
hembra	O
XpdTTD/+XPCS	O
ratones	B-Taxon
.	O

Diferencias	O
significativas	O
entre	O
peso	B-Sequence
y	O
XpdTTD/TTD	O
pero	O
no	O
entre	O
peso	B-Sequence
y	O
XpdTTD	O
/	O
+	O
XPCS	O
ratones	B-Taxon
se	O
observaron	O
a	O
los	O
9	O
y	O
18	O
meses	O
de	O
edad	O
como	O
se	O
indica	O
con	O
asteriscos	O
.	O

Las	O
barras	O
de	O
error	O
indican	O
SEM	O
.	O

Tabla	O
2	O

pleiotrópico	O
XPD	B-Protein
Efectos	O
bialélicos	O
en	O
Ratones	B-Taxon
y	O
Células	B-Cell

Para	O
determinar	O
si	O
el	O
homocigoto	O
letal	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelo	B-Sequence
fue	O
único	O
en	O
su	O
capacidad	O
para	O
mejorar	O
los	O
síntomas	O
asociados	O
con	O
el	O
XpdTTD	O
alelo	B-Sequence
,	O
generamos	O
compuesto	O
heterocigoto	O
XpdTTD	O
/	O
+	O
XP	O
ratones	B-Taxon
cruzando	O
el	O
correspondiente	O
heterocigoto	O
animales	B-Taxon
.	O

Similar	O
a	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelo	B-Sequence
,	O
el	O
homocigoto	O
letal	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelo	B-Sequence
Síntomas	O
cutáneos	O
rescatados	O
,	O
incluida	O
la	O
pérdida	O
de	O
cabello	O
(	O
excepto	O
localmente	O
durante	O
la	O
primera	O
ronda	O
;	O
datos	O
no	O
publicados	O
)	O
,	O
reducción	O
cisteína	B-Chemical
contenido	O
(	O
cisteína	B-Chemical
índice	O
9	O
.	O
3	O
+/-	O
0	O
.	O
9	O
desviación	O
estándar	O
[	O
87	O
%	O
de	O
peso	B-Sequence
]	O
,	O
pags	O
=	O
0	O
.	O
01	O
versus	O
TTD	O
)	O
,	O
caquexia	O
prematura	O
asociada	O
con	O
el	O
envejecimiento	O
(	O
hombres	O
y	O
mujeres	O
tenían	O
36	O
.	O
1	O
+/-	O
6	O
.	O
4	O
g	O
[	O
93	O
%	O
de	O
peso	B-Sequence
]	O
y	O
39	O
.	O
2	O
+/-	O
3	O
.	O
2	O
g	O
[	O
116	O
%	O
de	O
peso	B-Sequence
]	O
,	O
respectivamente	O
)	O
y	O
reducción	O
de	O
la	O
esperanza	O
de	O
vida	O
(	O
Tabla	O
2	O
)	O
.	O

Tomados	O
en	O
conjunto	O
,	O
estos	O
datos	O
indican	O
que	O
dos	O
independientes	O
alelos	B-Sequence
,	O
que	O
por	O
sí	O
solos	O
no	O
pueden	O
respaldar	O
la	O
viabilidad	O
(	O
Tabla	O
1	O
)	O
,	O
sin	O
embargo	O
,	O
pudieron	O
mejorar	O
los	O
fenotipos	O
asociados	O
a	O
TTD	O
in	O
vivo	O
(	O
Tabla	O
2	O
)	O
.	O

Molecular	B-Chemical
Mecanismos	O
de	O
los	O
efectos	O
bialélicos	O

A	O
continuación	O
,	O
recurrimos	O
a	O
la	O
tecnología	O
basada	O
en	O
UV	O
celular	B-Cell
ensayos	O
,	O
incluidos	O
los	O
no	O
programados	O
ADN	B-Sequence
síntesis	O
después	O
de	O
la	O
irradiación	O
UV	O
(	O
UV	O
-	O
UDS	O
)	O
,	O
recuperación	O
de	O
ARN	B-Sequence
síntesis	O
después	O
de	O
la	O
irradiación	O
UV	O
(	O
UV-RRS	O
)	O
,	O
y	O
supervivencia	O
UV	O
,	O
que	O
informan	O
sobre	O
las	O
subvías	O
NER	O
(	O
global	O
genoma	B-Sequence
NER	O
y	O
NER	O
acoplado	O
a	O
la	O
transcripción	O
)	O
y	O
NER	O
total	O
,	O
respectivamente	O
.	O

En	O
ninguno	O
de	O
estos	O
ensayos	O
mejoró	O
la	O
respuesta	O
a	O
UV	O
en	O
heterocigotos	O
compuestos	O
en	O
relación	O
con	O
homocigotos	O
TTD	O
(	O
Figura	O
4A-4C	O
)	O
.	O

Sin	O
embargo	O
,	O
a	O
diferencia	O
de	O
los	O
fenotipos	O
TTD	O
in	O
vivo	O
descritos	O
anteriormente	O
,	O
en	O
los	O
que	O
XpdTTD/TTD	O
y	O
XpdTTD/KO	O
animales	B-Taxon
eran	O
indistinguibles	O
,	O
los	O
efectos	O
de	O
la	O
dosis	O
de	O
XpdTTD	O
se	O
observaron	O
en	O
la	O
supervivencia	O
UV	O
,	O
UV-UDS	O
y	O
UV-RRS	O
,	O
lo	O
que	O
indica	O
que	O
celular	B-Cell
parámetros	O
medidos	O
en	O
fibroblastos	B-Cell
aquí	O
no	O
siempre	O
se	O
correlacionan	O
con	O
el	O
fenotipo	O
al	O
nivel	O
del	O
intacto	O
organismo	B-Taxon
.	O

XpdTTD	O
/	O
KO	O
hemicigoto	O
células	B-Cell
por	O
lo	O
tanto	O
,	O
se	O
usaron	O
como	O
la	O
línea	O
de	O
base	O
sobre	O
la	O
cual	O
comparar	O
la	O
actividad	O
de	O
heterocigotos	O
compuestos	O
células	B-Cell
.	O

Relativo	O
a	O
XpdTTD	O
/	O
KO	O
hemicigoto	O
células	B-Cell
,	O
la	O
supervivencia	O
UV	O
fue	O
mejorada	O
por	O
el	O
homocigoto	O
letal	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelo	B-Sequence
en	O
XpdTTD	O
/	O
+	O
XPCS	O
compuesto	O
heterocigoto	O
células	B-Cell
y	O
en	O
menor	O
medida	O
por	O
la	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelo	B-Sequence
(	O
Figura	O
4A	O
)	O
.	O

Debido	O
a	O
embrionario	O
y	O
celular	B-Cell
letalidad	O
,	O
no	O
pudimos	O
probar	O
la	O
supervivencia	O
UV	O
asociada	O
exclusivamente	O
con	O
la	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelos	B-Sequence
.	O

Sin	O
embargo	O
,	O
XPDXP	O
homocigoto	O
(	O
XPDR683W	O
)	O
y	O
XPDXPCS	O
hemicigoto	O
(	O
XPDG602D	O
)	O
humano	B-Taxon
células	B-Cell
se	O
sabe	O
que	O
son	O
muy	O
sensibles	O
a	O
los	O
rayos	O
UV	O
[	O
19	O
,	O
25	O
]	O
,	O
al	O
igual	O
que	O
células	B-Cell
de	O
un	O
homocigoto	O
viable	O
XpdXPCS	O
/	O
XPCS	O
(	O
XPDG602D	O
/	O
G602D	O
)	O
ratón	B-Taxon
modelo	O
(	O
Figura	O
4A	O
,	O
línea	O
punteada	O
)	O
[	O
23	O
]	O
.	O

Por	O
lo	O
tanto	O
,	O
la	O
supervivencia	O
de	O
XpdTTD/+XPCS	O
(	O
y	O
XpdTTD/+XP	O
)	O
células	B-Cell
probablemente	O
representa	O
un	O
nivel	O
de	O
resistencia	O
UV	O
que	O
ni	O
alelo	B-Sequence
mutante	I-Sequence
puede	O
impartir	O
por	O
sí	O
solo	O
(	O
Tabla	O
2	O
)	O
.	O

Efectos	O
significativos	O
de	O
la	O
heterocigosidad	O
compuesta	O
en	O
las	O
subvías	O
NER	O
en	O
relación	O
con	O
XpdTTD/KO	O
células	B-Cell
se	O
observaron	O
en	O
XpdTTD	O
/	O
+	O
XP	O
células	B-Cell
pero	O
sólo	O
para	O
la	O
actividad	O
UV-UDS	O
.	O

Finalmente	O
,	O
ninguno	O
de	O
los	O
mutante	B-Sequence
TFIIH	B-GENE
combinaciones	O
(	O
llevar	O
alteraciones	B-Sequence
asociado	O
con	O
TTD	O
[	O
XPDR722W	O
]	O
,	O
XPCS	O
[	O
XPDG602D	O
]	O
o	O
XP	O
[	O
XPDR683W	O
]	O
)	O
mostró	O
sinergismo	O
en	O
una	O
reacción	O
NER	O
in	O
vitro	O
reconstituida	O
con	O
diferentes	O
mutante	B-Sequence
complejos	B-GENE
TFIIH	I-GENE
(	O
Figura	O
4D	O
)	O
.	O

Tomados	O
en	O
conjunto	O
,	O
estos	O
datos	O
son	O
consistentes	O
con	O
la	O
complementación	O
interalélica	O
de	O
la	O
sensibilidad	O
UV	O
en	O
células	B-Cell
pero	O
subrayan	O
la	O
falta	O
de	O
correlación	O
entre	O
las	O
características	O
de	O
reparación	O
relacionadas	O
con	O
UV	O
y	O
los	O
fenotipos	O
progeroides	O
TTD	O
en	O
animal	B-Taxon
modelos	O

Figura	O
4	O

TFIIH	B-GENE
Funciones	O
y	O
Mecanismos	O
de	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O

(	O
A	O
)	O
Celular	B-Cell
supervivencia	O
después	O
de	O
la	O
radiación	O
ultravioleta	O
.	O

Rescate	O
de	O
supervivencia	O
hemicigoto	O
XpdTTD	O
/	O
KO	O
por	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelos	B-Sequence
se	O
ilustra	O
con	O
flechas	O
marcadas	O
A	O
y	O
B	O
,	O
respectivamente	O
.	O

Supervivencia	O
UV	O
de	O
homocigotos	O
XpdXPCS	O
/	O
XPCS	O
células	B-Cell
(	O
asterisco	O
)	O
del	O
viable	O
normalmente	O
expresado	O
alelo	B-Sequence
(	O
XpdXPCS	O
)	O
se	O
representa	O
con	O
una	O
línea	O
de	O
puntos	O
.	O

Las	O
curvas	O
de	O
supervivencia	O
representan	O
un	O
promedio	O
de	O
cuatro	O
experimentos	O
independientes	O
;	O
1	O
-	O
2	O
célula	B-Cell
líneas	O
por	O
genotipo	B-Sequence
se	O
incluyeron	O
en	O
cada	O
experimento	O
.	O

Las	O
barras	O
de	O
error	O
indican	O
SEM	O
entre	O
experimentos	O
.	O

(	O
B	O
)	O
UV-UDS	O
,	O
una	O
medida	O
de	O
la	O
genoma	B-Sequence
reparar	O

Número	O
de	O
experimentos	O
:	O
n	O
=	O
15	O
(	O
XpdTTD	O
/	O
TTD	O
)	O
,	O
n	O
=	O
6	O
(	O
XpdTTD	O
/	O
KO	O
)	O
,	O
n	O
=	O
4	O
(	O
XpdTTD	O
/	O
+	O
XPCS	O
)	O
,	O
n	O
=	O
2	O
(	O
XpdTTD	O
/	O
+	O
XP	O
)	O
;	O
1	O
-	O
2	O
célula	B-Cell
líneas	O
por	O
genotipo	B-Sequence
se	O
incluyeron	O
en	O
cada	O
experimento	O
.	O

El	O
asterisco	O
indica	O
una	O
diferencia	O
significativa	O
con	O
XpdTTD/TTD	O
;	O
los	O
cruces	O
indican	O
diferencias	O
significativas	O
con	O
XpdTTD/KO	O
.	O

(	O
C	O
)	O
UV-RRS	O
,	O
una	O
medida	O
de	O
reparación	O
acoplada	O
a	O
la	O
transcripción	O
de	O
lesiones	O
inducidas	O
por	O
UV	O
.	O

Número	O
de	O
experimentos	O
:	O
n	O
=	O
7	O
(	O
XpdTTD	O
/	O
TTD	O
)	O
,	O
n	O
=	O
2	O
(	O
XpdTTD	O
/	O
KO	O
)	O
,	O
n	O
=	O
4	O
(	O
XpdTTD	O
/	O
+	O
XPCS	O
)	O
,	O
n	O
=	O
2	O
(	O
XpdTTD	O
/	O
+	O
XP	O
)	O
;	O
1	O
-	O
2	O
célula	B-Cell
líneas	O
por	O
genotipo	B-Sequence
se	O
incluyeron	O
en	O
cada	O
experimento	O
.	O

(	O
D	O
)	O
Incisión	O
/	O
excisión	B-Sequence
actividad	O
de	O
combinaciones	O
de	O
alterado	B-Sequence
complejos	B-GENE
TFIIH	I-GENE
en	O
una	O
reacción	O
NER	O
reconstituida	O
.	O

Cantidades	O
iguales	O
de	O
poblaciones	O
simples	O
o	O
mixtas	O
de	O
recombinantes	O
TFIIH	B-GENE
(	O
que	O
contiene	O
XPD	B-Protein
,	O
XPB	B-Protein
,	O
p62	B-Protein
,	O
p52	B-Protein
,	O
Su	B-Sequence
-	O
p44	B-Protein
,	O
Bandera	O
-	O
p34	B-Protein
,	O
cdk7	B-Protein
,	O
ciclina	B-Protein
H	I-Protein
,	O
Mat1	B-Protein
,	O
y	O
p8	B-Protein
)	O
se	O
mezclaron	O
con	O
recombinantes	O
XPG	B-Protein
,	O
XPF	B-Protein
/	O
ERCC1	B-Protein
,	O
XPC	B-Protein
/	O
hHR23B	B-Protein
,	O
RPA	O
y	O
un	O
radiomarcado	B-Chemical
sintético	B-Sequence
sustrato	O
NER	O
.	O

los	O
excisión	B-Sequence
productos	O
(	O
26	O
-	O
34	O
nucleótidos	B-Chemical
de	O
longitud	O
)	O
se	O
visualizaron	O
en	O
nucleótido	B-Chemical
resolución	O
en	O
un	O
gel	O
de	O
poliacrilamida	O
desnaturalizante	O
como	O
se	O
indica	O
.	O

Tenga	O
en	O
cuenta	O
la	O
actividad	O
débil	O
correspondiente	O
a	O
cada	O
uno	O
y	O
combinado	O
complejo	B-GENE
TFIIH	I-GENE
(	O
carriles	O
3	O
-	O
8	O
)	O
en	O
relación	O
con	O
el	O
peso	B-Sequence
(	O
carril	O
1	O
)	O
y	O
controles	O
negativos	O
(	O
carril	O
2	O
)	O
.	O

(	O
mi	O
)	O
XPD	B-Protein
reducción	O
dependiente	O
de	O
la	O
dosis	O
de	O
TFIIH	B-GENE
en	O
homocigotos	O
XpdTTD/TTD	O
,	O
hemicigotos	O
XpdTTD/KO	O
,	O
y	O
compuestos	O
heterocigotos	O
XpdTTD/+XPCS	O
y	O
XpdTTD/+XP	O
células	B-Cell
por	O
inmunofluorescencia	O
comparativa	O
de	O
los	O
subunidad	B-Protein
p62	I-Protein
de	I-Protein
TFIIH	I-Protein
.	O

Los	O
números	O
romanos	O
representan	O
diferentes	O
portaobjetos	O
microscópicos	O
y	O
los	O
números	O
arábigos	O
diferentes	O
célula	B-Cell
líneas	O
rotuladas	O
de	O
la	O
siguiente	O
manera	O
:	O
(	O
I	O
)	O
peso	B-Sequence
células	B-Cell
(	O
1	O
)	O
etiquetado	O
con	O
perlas	O
de	O
2	O
mu	O
m	O
,	O
XpdTTD	O
/	O
TTD	O
células	B-Cell
(	O
2	O
)	O
con	O
0	O
.	O
79	O
-	O
perlas	O
mu	O
m	O
,	O
y	O
XpdTTD	O
/	O
KO	O
células	B-Cell
(	O
3	O
)	O
sin	O
cuentas	O
;	O
(	O
II	O
)	O
peso	B-Sequence
células	B-Cell
1	O
)	O
etiquetado	O
con	O
0	O
.	O
79	O
-	O
cuentas	O
mu	O
m	O
y	O
XpdTTD	O
/	O
+	O
XPCS	O
células	B-Cell
(	O
4	O
)	O
sin	O
cuentas	O
;	O
y	O
(	O
III	O
)	O
peso	B-Sequence
células	B-Cell
(	O
1	O
)	O
etiquetado	O
con	O
0	O
.	O
79	O
-	O
mu	O
m	O
perlas	O
y	O
XpdTTD	O
/	O
+	O
XP	O
células	B-Cell
(	O
5	O
)	O
sin	O
cuentas	O
.	O

(	O
F	O
)	O
Cuantificación	O
de	O
la	O
señal	O
inmunofluorescente	O
de	O
al	O
menos	O
50	O
núcleos	B-GENE
por	O
célula	B-Cell
línea	O
y	O
2	O
-	O
6	O
experimentos	O
por	O
genotipo	B-Sequence
.	O

Barras	O
que	O
representan	O
células	B-Cell
analizados	O
en	O
el	O
mismo	O
portaobjetos	O
microscópico	O
se	O
representan	O
uno	O
al	O
lado	O
del	O
otro	O
,	O
con	O
peso	B-Sequence
fijado	O
al	O
100	O
%	O
.	O

El	O
valor	O
p	O
indica	O
la	O
mínima	O
diferencia	O
significativa	O
entre	O
peso	B-Sequence
y	O
lo	O
indicado	O
célula	B-Cell
líneas	O
analizadas	O
en	O
el	O
mismo	O
portaobjetos	O
microscópico	O
dentro	O
de	O
un	O
experimento	O
.	O

A	O
continuación	O
preguntamos	O
si	O
el	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelos	B-Sequence
,	O
a	O
pesar	O
de	O
la	O
disminución	O
ARNm	B-Chemical
niveles	O
,	O
mejoró	O
los	O
síntomas	O
de	O
TTD	O
al	O
aumentar	O
la	O
TFIIH	B-GENE
niveles	O
en	O
heterocigotos	O
compuestos	O
XpdTTD	O
/	O
+	O
XPCS	O
y	O
XpdTTD	O
/	O
+	O
XP	O
células	B-Cell
.	O

Previamente	O
,	O
usando	O
inmunohistoquímica	O
comparativa	O
,	O
nosotros	O
y	O
otros	O
hemos	O
demostrado	O
una	O
reducción	O
de	O
hasta	O
el	O
70	O
%	O
de	O
TFIIH	B-GENE
niveles	O
en	O
primaria	O
fibroblastos	B-Cell
de	O
pacientes	O
con	O
TTD	O
en	O
comparación	O
con	O
peso	B-Sequence
controles	O
debido	O
a	O
la	O
reducción	O
de	O
la	O
estabilidad	O
[	O
16	O
,	O
17	O
]	O
.	O

pesar	O
de	O
la	O
sobreexpresión	O
de	O
ARNm	B-Chemical
de	O
la	O
XpdTTD	O
alelo	B-Sequence
relativo	O
a	O
la	O
wt	B-Sequence
alelo	I-Sequence
(	O
Figura	O
1E	O
)	O
,	O
TFIIH	B-GENE
proteína	B-Chemical
los	O
niveles	O
se	O
redujeron	O
en	O
un	O
50	O
%	O
en	O
primaria	O
ratón	B-Taxon
XpdTTD	O
/	O
TTD	O
fibroblastos	B-Cell
(	O
Figura	O
4E	O
y	O
4F	O
)	O
,	O
imitando	O
así	O
la	O
situación	O
en	O
humano	B-Taxon
pacientes	O
con	O
DTT	O
.	O

De	O
acuerdo	O
con	O
el	O
gene	B-Sequence
dosificación	O
,	O
una	O
reducción	O
adicional	O
de	O
hasta	O
el	O
70	O
%	O
de	O
la	O
peso	B-Sequence
nivel	O
se	O
observó	O
en	O
hemicigotos	O
XpdTTD	O
/	O
KO	O
células	B-Cell
.	O

En	O
consonancia	O
con	O
la	O
baja	O
ARNm	B-Chemical
niveles	O
de	O
expresión	O
,	O
ni	O
el	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelo	B-Sequence
fue	O
capaz	O
de	O
restaurar	O
TFIIH	B-GENE
abundancia	O
a	O
peso	B-Sequence
niveles	O
en	O
heterocigoto	O
compuesto	O
XpdTTD	O
células	B-Cell
(	O
Figura	O
4E	O
y	O
4F	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
la	O
supervivencia	O
UV	O
mejorada	O
observada	O
en	O
heterocigotos	O
compuestos	O
células	B-Cell
(	O
Figura	O
4A	O
)	O
y	O
probablemente	O
el	O
rescate	O
de	O
los	O
síntomas	O
progeroides	O
TTD	O
(	O
Figura	O
3	O
)	O
no	O
se	O
debió	O
a	O
la	O
normalización	O
de	O
TFIIH	B-GENE
niveles	O
,	O
lo	O
que	O
sugiere	O
un	O
efecto	O
cualitativo	O
más	O
que	O
cuantitativo	O
en	O
estos	O
fenotipos	O
in	O
vivo	O
.	O

Por	O
el	O
contrario	O
,	O
el	O
nivel	O
de	O
XPCS	O
ARNm	B-Chemical
expresión	O
afectó	O
la	O
capacidad	O
de	O
la	O
codificación	O
proteína	B-Chemical
(	O
XPDG602D	O
)	O
para	O
restaurar	O
el	O
fenotipo	O
del	O
cabello	O
TTD	O
a	O
la	O
normalidad	O
.	O

En	O
particular	O
,	O
XpdTTD	O
/	O
+	O
XPCS	O
animales	B-Taxon
tenía	O
un	O
fenotipo	O
de	O
cabello	O
TTD	O
parcial	O
,	O
que	O
se	O
correlaciona	O
con	O
niveles	O
bajos	O
de	O
XPD	B-Protein
+	O
expresión	O
XPCS	O
,	O
mientras	O
que	O
XpdTTD	O
/	O
XPCS	O
animales	B-Taxon
tenido	O
peso	B-Sequence
cabello	O
,	O
en	O
correlación	O
con	O
los	O
niveles	O
de	O
expresión	O
normales	O
del	O
XpdXPCS	O
viable	O
alelo	B-Sequence
(	O
Tabla	O
2	O
y	O
datos	O
no	O
publicados	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
el	O
rango	O
de	O
niveles	O
de	O
expresión	O
de	O
estos	O
dos	O
alelos	B-Sequence
mutantes	I-Sequence
afectó	O
su	O
capacidad	O
de	O
complementar	O
algunos	O
fenotipos	O
(	O
pelo	O
)	O
.	O

Una	O
visión	O
general	O
de	O
las	O
relaciones	O
funcionales	O
entre	O
XPD	B-Protein
alelos	B-Sequence
,	O
fenotipos	O
,	O
y	O
el	O
supuesto	O
subyacente	O
TFIIH	B-GENE
función	O
en	O
ratones	B-Taxon
y	O
células	B-Cell
se	O
presenta	O
en	O
la	O
Tabla	O
2	O
.	O

Discusión	O

Disección	O
de	O
los	O
efectos	O
bialélicos	O
de	O
otros	O
determinantes	O
del	O
fenotipo	O

Aunque	O
las	O
consecuencias	O
fenotípicas	O
,	O
denominadas	O
aquí	O
efectos	O
bialélicos	O
,	O
resultan	O
de	O
dos	O
alelos	B-Sequence
mutantes	I-Sequence
En	O
pacientes	O
heterocigotos	O
compuestos	O
han	O
sido	O
postulados	O
,	O
tales	O
efectos	O
históricamente	O
han	O
sido	O
difíciles	O
de	O
distinguir	O
de	O
la	O
influencia	O
del	O
medio	O
ambiente	O
y	O
genético	B-Sequence
antecedentes	O
.	O

usamos	O
un	O
genéticamente	B-Sequence
definido	O
mamífero	B-Taxon
sistema	O
modelo	O
bajo	O
condiciones	O
ambientales	O
controladas	O
para	O
revelar	O
efectos	O
fenotípicos	O
atribuibles	O
específicamente	O
a	O
combinaciones	O
de	O
diferencialmente	O
mutado	B-Sequence
XPD	B-Protein
alelos	B-Sequence
.	O

Los	O
efectos	O
bialélicos	O
observados	O
fueron	O
de	O
tres	O
tipos	O
generales	O
.	O

En	O
el	O
primero	O
,	O
el	O
alelo	B-Sequence
asociado	O
en	O
un	O
estado	O
homocigoto	O
con	O
un	O
fenotipo	O
más	O
cercano	O
a	O
peso	B-Sequence
determinó	O
singularmente	O
el	O
resultado	O
fenotípico	O
,	O
fenómeno	O
ampliamente	O
conocido	O
en	O
humano	B-Taxon
enfermedad	O
recesiva	O
.	O

porque	O
estos	O
XPD	B-Protein
alelos	B-Sequence
funcionado	O
en	O
o	O
cerca	O
peso	B-Sequence
``	O
niveles	O
con	O
respecto	O
a	O
una	O
función	O
particular	O
,	O
llamamos	O
a	O
estos	O
efectos	O
``	O
''	O
dominantes	O
''	O
''	O
.	O
''	O

Tal	O
alelos	B-Sequence
``	O
También	O
puede	O
denominarse	O
``	O
''	O
separación	O
de	O
funciones	O
''	O
''	O
.	O
''	O
alelos	B-Sequence
,	O
porque	O
permiten	O
la	O
disección	O
de	O
los	O
roles	O
de	O
los	O
multifuncionales	O
proteinas	B-Chemical
en	O
fenotipos	O
específicos	O
.	O

En	O
segundo	O
lugar	O
,	O
destacando	O
la	O
relevancia	O
potencial	O
de	O
los	O
hallazgos	O
actuales	O
para	O
todos	O
los	O
diploides	O
.	O
organismos	B-Taxon
incluso	O
humanos	B-Taxon
fue	O
la	O
observación	O
de	O
que	O
en	O
un	O
heterocigoto	O
compuesto	O
animal	B-Taxon
,	O
los	O
XPD	B-Protein
alelo	B-Sequence
relación	O
podría	O
pasar	O
de	O
dominante	O
|	O
arecesivo	O
a	O
Arecesivo	O
|	O
dominante	O
con	O
respecto	O
a	O
diferentes	O
fenotipos	O
de	O
una	O
manera	O
dependiente	O
del	O
tiempo	O
y	O
específica	O
del	O
tejido	O
(	O
ver	O
a	O
continuación	O
y	O
la	O
Tabla	O
2	O
)	O
.	O

En	O
el	O
tercer	O
tipo	O
de	O
efecto	O
bialélico	O
,	O
conocido	O
como	O
complementación	O
interalélica	O
,	O
dos	O
alelos	B-Sequence
mutantes	I-Sequence
produjo	O
un	O
fenotipo	O
más	O
cercano	O
a	O
peso	B-Sequence
de	O
lo	O
que	O
cualquiera	O
podría	O
hacerlo	O
solo	O
en	O
un	O
estado	O
homo	O
-	O
o	O
hemicigoto	O
.	O

Como	O
se	O
resume	O
en	O
la	O
Tabla	O
2	O
,	O
se	O
observaron	O
ejemplos	O
de	O
todos	O
los	O
tipos	O
de	O
efectos	O
bialélicos	O
en	O
una	O
variedad	O
de	O
XPD	B-Protein
-	O
fenotipos	O
asociados	O
,	O
que	O
van	O
desde	O
cabello	O
quebradizo	O
hasta	O
progeria	O
segmentaria	O
.	O

TFIIH	B-GENE
en	O
Transcripción	O
y	O
Reparación	O
:	O
Mecanismos	O
de	O
XPD	B-Protein
Pleiotropía	O
de	O
la	O
enfermedad	O

Observamos	O
diferencias	O
en	O
la	O
capacidad	O
de	O
XpdTTD	O
frente	O
a	O
homocigotos	O
letales	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelos	B-Sequence
para	O
funcionar	O
en	O
dos	O
fenotipos	O
relacionados	O
con	O
la	O
transcripción	O
separados	O
en	O
el	O
organismo	B-Taxon
tanto	O
por	O
el	O
tiempo	O
como	O
por	O
el	O
espacio	O
:	O
letalidad	O
embrionaria	O
y	O
diferenciación	O
terminal	O
de	O
enucleación	B-Cell
de	I-Cell
células	I-Cell
sanguíneas	I-Cell
y	I-Cell
de	I-Cell
piel	I-Cell
.	O

La	O
letalidad	O
homocigota	O
en	O
estadio	O
de	O
preblastocisto	O
compartida	O
por	O
XpdKO	O
,	O
XPD	B-Protein
+	O
XPCS	O
,	O
y	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelos	B-Sequence
lo	O
más	O
probable	O
es	O
que	O
refleje	O
un	O
defecto	O
en	O
la	O
transcripción	O
basal	O
que	O
es	O
incompatible	O
con	O
la	O
vida	O
.	O

En	O
XpdTTD/+XPCS	O
y	O
XpdTTD/+XP	O
compuesto	O
heterocigoto	O
ratones	B-Taxon
,	O
la	O
letalidad	O
embrionaria	O
fue	O
totalmente	O
rescatada	O
por	O
el	O
XpdTTD	O
alelo	B-Sequence
.	O

Porque	O
la	O
letalidad	O
embrionaria	O
también	O
se	O
rescató	O
por	O
completo	O
en	O
XpdTTD	O
/	O
KO	O
hemicigotos	O
ratones	B-Taxon
,	O
el	O
XpdTTD	O
alelo	B-Sequence
puede	O
ser	O
considerado	O
como	O
peso	B-Sequence
y	O
por	O
lo	O
tanto	O
dominante	O
a	O
cada	O
uno	O
de	O
los	O
letales	O
homocigotos	O
alelos	B-Sequence
(	O
XpdKO	O
,	O
XPD	B-Protein
+	O
XPCS	O
,	O
y	O
XPD	B-Protein
+	O
XP	O
)	O
con	O
respecto	O
a	O
este	O
fenotipo	O
particular	O
(	O
Tabla	O
2	O
)	O
.	O

Por	O
otro	O
lado	O
,	O
se	O
cree	O
que	O
las	O
características	O
cutáneas	O
y	O
anémicas	O
específicas	O
de	O
TTD	O
son	O
el	O
resultado	O
de	O
un	O
tipo	O
específico	O
de	O
insuficiencia	O
transcripcional	O
causada	O
por	O
el	O
agotamiento	O
de	O
TFIIH	B-GENE
durante	O
la	O
diferenciación	O
terminal	O
de	O
la	O
piel	O
,	O
tallo	O
del	O
cabello	O
y	O
células	B-Cell
de	I-Cell
sangre	I-Cell
[	O
16	O
,	O
24	O
]	O
.	O

En	O
heterocigotos	O
compuestos	O
ratones	B-Taxon
,	O
ambos	O
homocigotos	O
letales	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelos	B-Sequence
pudieron	O
aliviar	O
XpdTTD	O
:	O
características	O
cutáneas	O
y	O
anémicas	O
específicas	O
y	O
,	O
por	O
lo	O
tanto	O
,	O
pueden	O
definirse	O
como	O
dominantes	O
sobre	O
XpdTTD	O
alelo	B-Sequence
con	O
respecto	O
a	O
estos	O
fenotipos	O
.	O

Concluimos	O
que	O
los	O
defectos	O
que	O
conducen	O
a	O
la	O
letalidad	O
embrionaria	O
y	O
la	O
diferenciación	O
terminal	O
aberrante	O
de	O
la	O
piel	O
,	O
el	O
cabello	O
y	O
la	O
sangre	O
representan	O
dos	O
deficiencias	O
transcripcionales	O
cualitativa	O
y/o	O
cuantitativamente	O
diferentes	O
.	O

Durante	O
el	O
desarrollo	O
embrionario	O
temprano	O
,	O
XpdTTD	O
es	O
dominante	O
sobre	O
el	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelos	B-Sequence
,	O
mientras	O
que	O
más	O
adelante	O
en	O
la	O
ontogénesis	O
de	O
la	O
piel	O
,	O
el	O
tallo	O
del	O
cabello	O
y	O
células	B-Cell
de	I-Cell
sangre	I-Cell
,	O
la	O
situación	O
se	O
invierte	O
.	O

En	O
su	O
papel	O
en	O
la	O
reparación	O
de	O
fotolesiones	O
UV	O
,	O
el	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelo	B-Sequence
impartió	O
un	O
claro	O
beneficio	O
de	O
supervivencia	O
UV	O
sobre	O
un	O
solo	O
XpdTTD	O
alelo	B-Sequence
o	O
dos	O
XpdXPCS	O
alelos	B-Sequence
independiente	O
de	O
los	O
niveles	O
de	O
expresión	O
,	O
lo	O
cual	O
es	O
consistente	O
con	O
la	O
complementación	O
interalélica	O
.	O

Sin	O
embargo	O
,	O
la	O
observación	O
de	O
que	O
ningún	O
otro	O
celular	B-Cell
o	O
se	O
mejoraron	O
los	O
parámetros	O
bioquímicos	O
relacionados	O
con	O
UV	O
en	O
XpdTTD/+	O
XPCS	O
argumenta	O
en	O
contra	O
de	O
la	O
complementación	O
de	O
esta	O
actividad	O
de	O
reparación	O
en	O
el	O
rescate	O
de	O
los	O
síntomas	O
progeroides	O
TTD	O
in	O
vivo	O
.	O

Complementación	O
interalélica	O
y	O
XPD	B-Protein
Función	O

¿Qué	O
nos	O
dice	O
la	O
complementación	O
interalélica	O
sobre	O
el	O
mecanismo	O
de	O
XPD	B-Protein
función	O
?	O

La	O
complementación	O
interalélica	O
se	O
observa	O
con	O
mayor	O
frecuencia	O
en	O
multimeric	O
proteinas	B-Chemical
con	O
múltiples	O
funciones	O
dominios	B-Sequence
.	O

Desafortunadamente	O
,	O
la	O
relación	O
estructura-función	O
entre	O
las	O
enfermedades	O
que	O
causan	O
mutaciones	B-Sequence
y	O
XPD	B-Protein
funcional	O
dominios	B-Sequence
,	O
incluyendo	O
información	O
estructural	O
detallada	O
sobre	O
XPD	B-Protein
o	O
incluso	O
su	O
estequiometría	O
dentro	O
TFIIH	B-GENE
,	O
permanece	O
desconocido	O
.	O

Sin	O
embargo	O
,	O
en	O
base	O
a	O
la	O
capacidad	O
de	O
célula	B-Cell
extractos	O
que	O
son	O
defectuosos	O
en	O
dos	O
diferentes	O
TFIIH	B-GENE
componentes	O
(	O
XPD	B-Protein
y	O
XPB	B-Protein
)	O
para	O
complementar	O
la	O
actividad	O
NER	O
in	O
vitro	O
[	O
26	O
]	O
,	O
es	O
probable	O
que	O
TFIIH	B-GENE
(	O
o	O
sus	O
componentes	O
)	O
pueden	O
multimerizarse	O
o	O
intercambiarse	O
al	O
menos	O
durante	O
la	O
reacción	O
NER	O
.	O

Es	O
más	O
,	O
XPD	B-Protein
``	O
se	O
sabe	O
que	O
es	O
una	O
subunidad	O
``	O
''	O
flojamente	O
unida	O
''	O
''	O
de	O
''	O
TFIIH	B-GENE
[	O
27	O
]	O
.	O

Prevemos	O
así	O
la	O
molecular	B-Chemical
mecanismo	O
de	O
complementación	O
interalélica	O
para	O
involucrar	O
el	O
intercambio	O
de	O
XPD	B-Protein
moléculas	B-Chemical
dentro	O
de	O
complejo	B-GENE
TFIIH	I-GENE
o	O
facturación	O
de	O
complejos	B-GENE
TFIIH	I-GENE
que	O
contiene	O
diferentes	O
XPD	B-Protein
moléculas	B-Chemical
en	O
el	O
sitio	B-Sequence
de	O
ADN	B-Sequence
daños	O
durante	O
el	O
curso	O
del	O
global	O
genoma	B-Sequence
así	O
como	O
la	O
transcripción	O
-	O
reparación	O
acoplada	O
de	O
UV	O
-	O
inducida	O
o	O
endógena	O
ADN	B-Sequence
daño	O
.	O

Un	O
paradigma	O
bialélico	O
para	O
XPD	B-Protein
Trastornos	O

Hace	O
poco	O
,	O
proteinas	B-Chemical
procedente	O
de	O
presunto	O
nulo	O
alelos	B-Sequence
se	O
caracterizaron	O
bioquímicamente	O
como	O
inactivos	O
en	O
la	O
transcripción	O
basal	O
[	O
27	O
]	O
,	O
proporcionando	O
una	O
explicación	O
de	O
por	O
qué	O
estos	O
alelos	B-Sequence
no	O
pudo	O
rescatar	O
la	O
letalidad	O
en	O
haploide	O
S	B-Taxon
.	I-Taxon
bomba	I-Taxon
con	O
un	O
nulo	O
mutación	B-Sequence
en	O
el	O
XPD	B-Protein
homólogo	B-Sequence
rad15	B-Protein
[	O
19	O
]	O
.	O

Nuestros	O
datos	O
sugieren	O
que	O
ciertos	O
supuestos	O
nulos	O
alelos	B-Sequence
,	O
aunque	O
incapaces	O
por	O
sí	O
solos	O
de	O
respaldar	O
la	O
transcripción	O
basal	O
,	O
de	O
hecho	O
pueden	O
tener	O
un	O
impacto	O
sustancial	O
en	O
el	O
resultado	O
de	O
la	O
enfermedad	O
en	O
heterocigotos	O
compuestos	O
humanos	B-Taxon
,	O
como	O
lo	O
hacen	O
en	O
ratón	B-Taxon
modelos	O

La	O
evidencia	O
clínica	O
que	O
respalda	O
esta	O
hipótesis	O
proviene	O
de	O
una	O
serie	O
de	O
pacientes	O
del	O
grupo	O
D	O
de	O
complementación	O
XP	O
que	O
no	O
encajan	O
en	O
el	O
marco	O
del	O
paradigma	O
monoalélico	O
actual	O
de	O
XPD	B-Protein
trastornos	O
(	O
Figura	O
5	O
)	O
.	O

En	O
contraste	O
con	O
dos	O
pacientes	O
XPDXPCS	O
hemicigóticos	O
que	O
portan	O
la	O
codificación	O
XPDG47R	O
o	O
XPDR666W	O
alelos	B-Sequence
que	O
murieron	O
de	O
la	O
enfermedad	O
antes	O
de	O
los	O
2	O
años	O
de	O
edad	O
,	O
dos	O
pacientes	O
XPDXPCS	O
heterocigotos	O
compuestos	O
que	O
portaban	O
la	O
misma	O
codificación	O
XPDG47R	O
-	O
o	O
XPDR666W	O
-	O
alelos	B-Sequence
además	O
del	O
supuesto	O
nulo	O
XPDL461V+del716-730	O
,	O
ambos	O
tenían	O
síntomas	O
de	O
enfermedad	O
considerablemente	O
más	O
leves	O
y	O
sobrevivieron	O
más	O
de	O
diez	O
veces	O
más	O
(	O
A.	O
Lehmann	O
,	O
comunicación	O
personal	O
)	O
(	O
Figura	O
5	O
)	O
.	O

La	O
heterocigosidad	O
compuesta	O
también	O
se	O
asocia	O
con	O
el	O
síndrome	O
de	O
combinación	O
de	O
XP	O
y	O
TTD	O
(	O
XPTTD	O
)	O
informado	O
recientemente	O
[	O
8	O
]	O
.	O

Similar	O
al	O
XpdTTD/+XPCS	O
y	O
XpdTTD/+XP	O
ratones	B-Taxon
descrito	O
aquí	O
,	O
los	O
dos	O
pacientes	O
con	O
XPTTD	O
descritos	O
hasta	O
ahora	O
tenían	O
vello	O
intermedio	O
cisteína	B-Chemical
valores	O
.	O

``	O
Además	O
,	O
el	O
paciente	O
XPTTD	O
XP38BR	O
portaba	O
un	O
TTD	O
``	O
''	O
causal	O
``	O
''	O
''	O
mutación	B-Sequence
en	O
uno	O
alelo	B-Sequence
y	O
una	O
novela	O
mutación	B-Sequence
puntual	I-Sequence
codificando	O
XPDL485P	O
en	O
el	O
otro	O
.	O

Aunque	O
el	O
XPDL485P	O
-	O
codificación	O
alelo	B-Sequence
no	O
logra	O
complementar	O
la	O
viabilidad	O
en	O
el	O
haploide	O
S	B-Protein
.	I-Protein
bomba	I-Protein
rad15	I-Protein
supresión	B-Sequence
tensión	O
y	O
es	O
por	O
lo	O
tanto	O
interpretable	O
como	O
un	O
nulo	O
alelo	B-Sequence
[	O
8	O
]	O
,	O
no	O
obstante	O
sugerimos	O
que	O
el	O
fenotipo	O
XPTTD	O
combinado	O
en	O
este	O
paciente	O
involucra	O
contribuciones	O
fenotípicas	O
de	O
ambos	O
alelos	B-Sequence
.	O

Tomados	O
en	O
conjunto	O
,	O
estos	O
datos	O
sugieren	O
un	O
cambio	O
a	O
un	O
paradigma	O
bialélico	O
para	O
pacientes	O
heterocigotos	O
compuestos	O
en	O
el	O
grupo	O
D	O
de	O
complementación	O
XP	O
.	O

Figura	O
5	O

Relaciones	O
genotipo	O
-	O
fenotipo	O
en	O
XPD	B-Protein
Trastornos	O

De	O
acuerdo	O
con	O
la	O
hipótesis	O
monoalélica	O
actual	O
,	O
el	O
fenotipo	O
está	O
determinado	O
únicamente	O
por	O
el	O
factor	O
causal	O
.	O
alelo	B-Sequence
producto	O

Si	O
un	O
segundo	O
,	O
diferente	O
alelo	B-Sequence
está	O
presente	O
,	O
se	O
considera	O
un	O
nulo	O
funcional	O
.	O

Hay	O
una	O
falta	O
de	O
correlación	O
entre	O
la	O
sitio	B-Sequence
de	O
El	O
XPD	B-Protein
mutación	B-Sequence
y	O
el	O
desorden	O
resultante	O
.	O

Proponemos	O
una	O
hipótesis	O
bialélica	O
para	O
heterocigotos	O
compuestos	O
en	O
la	O
que	O
ambos	O
alelos	B-Sequence
puede	O
contribuir	O
al	O
fenotipo	O
.	O

Ejemplos	O
de	O
pacientes	O
heterocigotos	O
compuestos	O
en	O
los	O
que	O
un	O
segundo	O
supuesto	O
nulo	O
alelo	B-Sequence
es	O
probable	O
que	O
contribuya	O
al	O
resultado	O
de	O
la	O
enfermedad	O
se	O
proporcionan	O
anteriormente	O
en	O
comparación	O
con	O
los	O
correspondientes	O
pacientes	O
homo	O
-	O
o	O
hemicigotos	O
con	O
la	O
misma	O
causa	O
alelo	B-Sequence
.	O

Números	O
en	O
el	O
esquema	O
de	O
la	O
proteína	B-Chemical
indicar	O
la	O
helicasa	O
dominios	B-Sequence
.	O

Potencial	O
de	O
Combinado	O
Recesivo	O
Alelos	B-Sequence
para	O
afectar	O
la	O
diversidad	O
fenotípica	O
en	O
Mamíferos	B-Taxon

En	O
humanos	B-Taxon
se	O
desconoce	O
la	O
relevancia	O
clínica	O
de	O
los	O
efectos	O
bialélicos	O
como	O
la	O
complementación	O
interalélica	O
.	O

Aunque	O
la	O
complementación	O
interalélica	O
entre	O
dos	O
endógenos	O
alelos	B-Sequence
mutantes	I-Sequence
ha	O
sido	O
descrito	O
en	O
células	B-Cell
de	O
un	O
paciente	O
heterocigoto	O
compuesto	O
con	O
acidemia	O
metilmalónica	O
,	O
no	O
se	O
observaron	O
efectos	O
observables	O
en	O
el	O
resultado	O
de	O
la	O
enfermedad	O
en	O
el	O
paciente	O
[	O
28	O
]	O
.	O

Por	O
lo	O
tanto	O
,	O
hasta	O
donde	O
sabemos	O
,	O
la	O
mejora	O
de	O
las	O
características	O
progeroides	O
observada	O
aquí	O
es	O
la	O
primera	O
demostración	O
in	O
vivo	O
en	O
heterocigotos	O
compuestos	O
.	O
animales	B-Taxon
de	O
complementación	O
interalélica	O
relevante	O
para	O
un	O
humano	B-Taxon
enfermedad	O
.	O

Teniendo	O
en	O
cuenta	O
que	O
el	O
~	O
1	O
,	O
200	O
alelos	B-Sequence
que	O
se	O
sabe	O
que	O
existe	O
para	O
el	O
CTRF	B-Protein
gene	B-Sequence
implicado	O
en	O
el	O
común	O
autosómico	B-GENE
trastorno	O
recesivo	O
fibrosis	O
quística	O
solo	O
[	O
29	O
]	O
teóricamente	O
puede	O
dar	O
lugar	O
a	O
~	O
700.000	O
diferentes	O
alelo	B-Sequence
combinaciones	O
,	O
el	O
número	O
potencial	O
de	O
alelo	B-Sequence
combinaciones	O
de	O
diferentes	O
recesivos	O
mutaciones	B-Sequence
y	O
genoma	B-Sequence
de	I-Sequence
polimorfismos	I-Sequence
de	I-Sequence
un	I-Sequence
solo	I-Sequence
nucleótido	I-Sequence
#	O
¿NOMBRE	O
?	O

Sugerimos	O
los	O
efectos	O
bialélicos	O
como	O
una	O
variable	O
previamente	O
subestimada	O
pero	O
importante	O
al	O
considerar	O
genotipo	B-Sequence
#	O
¿NOMBRE	O
?	O
autosómico	B-GENE
enfermedad	O
recesiva	O
a	O
la	O
diversidad	O
fenotípica	O
normal	O
en	O
mamíferos	B-Taxon
.	O

La	O
extensión	O
del	O
concepto	O
anterior	O
implica	O
que	O
recesivo	O
mutaciones	B-Sequence
puede	O
entrar	O
en	O
la	O
selección	O
evolutiva	O
en	O
la	O
F1	O
siempre	O
que	O
el	O
segundo	O
alelo	B-Sequence
lleva	O
un	O
recesivo	O
diferente	O
modificación	B-Sequence
.	O

Finalmente	O
,	O
nuestros	O
datos	O
resaltan	O
el	O
potencial	O
de	O
la	O
clínicamente	O
relevante	O
alelos	B-Sequence
previamente	O
designado	O
como	O
nulo	O
,	O
con	O
poca	O
o	O
ninguna	O
expresión	O
o	O
actividad	O
detectable	O
,	O
para	O
contribuir	O
sin	O
embargo	O
al	O
fenotipo	O
.	O

Materiales	O
y	O
métodos	O

Derivación	O
y	O
análisis	O
de	O
mutante	B-Sequence
ratones	B-Taxon
.	O

Generación	O
de	O
XpdTTD	O
(	O
XPDR722W	O
)	O
y	O
XpdTTD	O
/	O
KO	O
ratones	B-Taxon
ha	O
sido	O
descrito	O
previamente	O
[	O
21	O
,	O
22	O
]	O
.	O

Una	O
descripción	O
detallada	O
de	O
la	O
generación	O
de	O
segmentación	O
.	O
construcciones	B-Sequence
por	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
XPD	B-Protein
#	O
¿NOMBRE	O
?	O
alelos	B-Sequence
que	O
lleva	O
mutaciones	B-Sequence
codificando	O
el	O
G602D	O
y	O
el	O
R683W	O
alteraciones	B-Sequence
se	O
proporcionará	O
a	O
petición	O
.	O

quimérico	O
ratones	B-Taxon
y	O
ratón	B-Taxon
embrionario	O
fibroblastos	B-Cell
se	O
generaron	O
de	O
acuerdo	O
con	O
los	O
procedimientos	O
estándar	O
.	O

La	O
tinción	O
con	O
hematoxilina	O
y	O
eosina	O
se	O
realizó	O
de	O
acuerdo	O
con	O
los	O
procedimientos	O
estándar	O
.	O

Aminoácidos	B-Chemical
el	O
análisis	O
se	O
realizó	O
como	O
se	O
describe	O
en	O
[	O
21	O
]	O
.	O

Los	O
valores	O
sanguíneos	O
se	O
analizaron	O
utilizando	O
Animal	B-Taxon
Blood	O
Counter	O
Vet	O
(	O
ABX	O
Diagnostix	O
,	O
Montpellier	O
,	O
Francia	O
)	O
.	O

Se	O
tomaron	O
radiografías	O
y	O
el	O
hueso	O
relativo	O
mineral	B-Chemical
la	O
densidad	O
se	O
calculó	O
como	O
se	O
describe	O
en	O
[	O
15	O
]	O
.	O

Ratones	B-Taxon
utilizados	O
en	O
este	O
estudio	O
estaban	O
en	O
un	O
fondo	O
mixto	O
129Ola/C57BL6	O
a	O
menos	O
que	O
se	O
indique	O
lo	O
contrario	O
.	O

Todos	O
los	O
experimentos	O
que	O
implican	O
ratones	B-Taxon
fueron	O
juzgados	O
y	O
aprobados	O
por	O
el	O
comité	O
nacional	O
de	O
genético	B-Sequence
identificacion	O
de	O
organismos	B-Taxon
y	O
el	O
animal	B-Taxon
comité	O
de	O
ética	O
,	O
y	O
se	O
realizaron	O
de	O
acuerdo	O
con	O
las	O
normas	O
nacionales	O
e	O
internacionales	O
.	O

Sensibilidad	O
UV	O
,	O
UV-UDS	O
,	O
UV-RRS	O
y	O
TFIIH	B-GENE
incisión	O
/	O
excisión	B-Sequence
actividad	O
.	O

Los	O
ensayos	O
de	O
supervivencia	O
UV	O
,	O
UV-UDS	O
y	O
UV-RRS	O
se	O
realizaron	O
como	O
se	O
describió	O
anteriormente	O
[	O
21	O
,	O
30	O
]	O
.	O

Para	O
UV-RRS	O
,	O
los	O
valores	O
promedio	O
del	O
experimento	O
representativo	O
que	O
contiene	O
dos	O
peso	B-Sequence
,	O
tres	O
XpdTTD	O
/	O
TTD	O
,	O
dos	O
XpdTTD	O
/	O
XPCS	O
y	O
uno	O
XpdTTD	O
/	O
XP	O
célula	B-Cell
se	O
presenta	O
la	O
línea	O
.	O

El	O
valor	O
de	O
~	O
48	O
%	O
UV	O
-	O
UDS	O
presentado	O
en	O
este	O
estudio	O
para	O
XpdTTD	O
/	O
TTD	O
células	B-Cell
difiere	O
de	O
nuestros	O
datos	O
previamente	O
publicados	O
de	O
25	O
%	O
UV	O
-	O
UDS	O
[	O
21	O
]	O
,	O
posiblemente	O
debido	O
a	O
la	O
alta	O
variabilidad	O
intrínseca	O
al	O
ensayo	O
o	O
variaciones	O
de	O
rutina	O
en	O
el	O
célula	B-Cell
condiciones	O
de	O
cultivo	O
.	O

Para	O
la	O
incisión	O
/	O
excisión	B-Sequence
ensayo	O
de	O
actividad	O
,	O
recombinante	O
TFIIH	B-GENE
fue	O
preparado	O
y	O
analizado	O
como	O
se	O
describe	O
anteriormente	O
[	O
27	O
]	O
.	O

Inmunofluorescencia	O
comparativa	O
.	O

Marcaje	O
con	O
perlas	O
de	O
látex	O
y	O
análisis	O
de	O
inmunofluorescencia	O
comparativo	O
del	O
subunidad	B-Protein
p62	I-Protein
del	I-Protein
TFIIH	I-Protein
se	O
realizó	O
como	O
se	O
describió	O
anteriormente	O
[	O
16	O
,	O
17	O
]	O
utilizando	O
primaria	O
ratón	B-Taxon
embrionario	O
fibroblastos	B-Cell
en	O
los	O
pasajes	O
2	O
-	O
5	O
.	O

Dos	O
o	O
más	O
célula	B-Cell
líneas	O
por	O
genotipo	B-Sequence
(	O
excepto	O
para	O
el	O
XpdTTD	O
/	O
+	O
XP	O
células	B-Cell
,	O
en	O
el	O
que	O
sólo	O
uno	O
célula	B-Cell
se	O
usó	O
la	O
línea	O
en	O
experimentos	O
repetidos	O
)	O
y	O
los	O
experimentos	O
se	O
repitieron	O
de	O
2	O
a	O
6	O
veces	O
por	O
genotipo	B-Sequence
.	O

Agradecimientos	O

Estamos	O
muy	O
agradecidos	O
a	O
Steven	O
Bergink	O
,	O
Koos	O
Jaspers	O
y	O
Bjorn	O
Schumacher	O
por	O
los	O
debates	O
reflexivos	O
y	O
la	O
lectura	O
crítica	O
del	O
manuscrito	O
ya	O
Ruud	O
Koppenol	O
y	O
Tom	O
de	O
Vries	O
por	O
la	O
fotografía	O
.	O

Contribuciones	O
de	O
autor	O
.	O

JOA	O
,	O
JJ	O
,	O
JHJH	O
,	O
GTJvdH	O
y	O
JRM	O
concibieron	O
y	O
diseñaron	O
los	O
experimentos	O
.	O

JOA	O
,	O
JJ	O
,	O
JdW	O
,	O
FC	O
,	O
DH	O
,	O
MvdV	O
,	O
WT	O
,	O
JH	O
,	O
WJvL	O
y	O
JRM	O
realizaron	O
los	O
experimentos	O
.	O

JOA	O
,	O
JJ	O
,	O
JdW	O
,	O
FC	O
,	O
DH	O
,	O
MvdV	O
,	O
JH	O
,	O
HBT	O
,	O
WJvL	O
,	O
JME	O
,	O
JHJH	O
y	O
JRM	O
analizaron	O
los	O
datos	O
.	O

JdB	O
y	O
GTJvdH	O
contribuyeron	O
reactivos	B-Chemical
/	O
materiales	O
/	O
herramientas	O
de	O
análisis	O
.	O

JOA	O
,	O
JHJH	O
y	O
JRM	O
escribieron	O
el	O
documento	O
.	O

Financiamiento	O

Esta	O
investigación	O
fue	O
apoyada	O
por	O
la	O
Organización	O
Holandesa	O
para	O
la	O
Investigación	O
Científica	O
(	O
NWO	O
)	O
a	O
través	O
de	O
la	O
fundación	O
del	O
Instituto	O
de	O
Investigación	O
de	O
Enfermedades	O
de	O
los	O
Ancianos	O
,	O
así	O
como	O
subvenciones	O
de	O
los	O
Institutos	O
Nacionales	O
de	O
Salud	O
(	O
1PO1	O
AG17242	O
-	O
02	O
)	O
,	O
Instituto	O
Nacional	O
de	O
Ciencias	O
de	O
la	O
Salud	O
Ambiental	O
(	O
1UO1	O
ES011044	O
)	O
,	O
Comisión	O
Europea	O
(	O
QRTL	O
-	O
1999	O
-	O
02002	O
)	O
y	O
Sociedad	O
Holandesa	O
del	O
Cáncer	O
(	O
EUR	O
99	O
-	O
2004	O
)	O
.	O

JRM	O
fue	O
miembro	O
del	O
Fondo	O
de	O
Investigación	O
del	O
Cáncer	O
Damon	O
Runyon	O
(	O
DRG	O
1677	O
)	O
.	O

abreviaturas	O

pb	B-Sequence
-	O
Base	B-Sequence
par	I-Sequence

CS	O
-	O
Síndrome	O
de	O
Cockayne	O

E	O
[	O
número	O
]	O
-	O
día	O
embrionario	O
[	O
número	O
]	O

kb	O
-	O
kilobase	O

NER	O
-	O
nucleótido	B-Chemical
excisión	B-Sequence
reparar	O

SEM	O
-	O
error	O
estándar	O
de	O
la	O
media	O

TFIIH	B-GENE
-	O
transcripción	B-GENE
basal	I-GENE
/	I-GENE
factor	I-GENE
de	I-GENE
reparación	I-GENE
de	I-GENE
ADN	I-GENE
IIH	I-GENE

TTD	O
-	O
tricotiodistrofia	O

UV	O
-	O
RRS	O
-	O
recuperación	O
de	O
ARN	B-Sequence
síntesis	O
después	O
de	O
la	O
radiación	O
ultravioleta	O

UV	O
-	O
UDS	O
-	O
no	O
programado	O
ADN	B-Sequence
síntesis	O
después	O
de	O
la	O
radiación	O
ultravioleta	O

peso	B-Sequence
-	O
tipo	B-Sequence
salvaje	I-Sequence

XP	O
-	O
xeroderma	O
pigmentoso	O

XPCS	O
-	O
xeroderma	O
pigmentoso	O
combinado	O
con	O
síndrome	O
de	O
Cockayne	O

XPTTD	O
-	O
combinación	O
de	O
xeroderma	O
pigmentoso	O
y	O
tricotiodistrofia	O

notas	O
al	O
pie	O

Conflicto	O
de	O
intereses	O
.	O

Los	O
autores	O
han	O
declarado	O
que	O
no	O
existen	O
intereses	O
contrapuestos	O
.	O

moneda	O
a	O
Dirección	O
actual	O
:	O
Instituto	O
de	O
Biotecnología	O
,	O
Universidad	O
de	O
Helsinki	O
,	O
Helsinki	O
,	O
Finlandia	O

moneda	O
b	O
Dirección	O
actual	O
:	O
Departamento	O
de	O
Molecular	B-Chemical
y	O
Célula	B-Cell
Biología	O
,	O
Universidad	O
de	O
California	O
Berkeley	O
,	O
Berkeley	O
,	O
California	O
,	O
Estados	O
Unidos	O
de	O
América	O

moneda	O
c	O
Dirección	O
actual	O
:	O
Instituto	O
de	O
Tecnología	O
Biomédica	O
,	O
Universidad	O
de	O
Twente	O
,	O
Bilthoven	O
,	O
Países	O
Bajos	O

Genético	B-Sequence
fondo	O
determina	O
la	O
respuesta	O
a	O
la	O
hemostasia	O
y	O
la	O
trombosis	O

Resumen	O

Antecedentes	O

La	O
trombosis	O
es	O
la	O
consecuencia	O
fatal	O
e	O
incapacitante	O
de	O
las	O
enfermedades	O
cardiovasculares	O
,	O
la	O
principal	O
causa	O
de	O
mortalidad	O
y	O
morbilidad	O
en	O
los	O
países	O
occidentales	O
.	O

dos	O
endogámicos	O
ratón	B-Taxon
Las	O
cepas	O
C57BL/6J	O
y	O
A/J	O
tienen	O
marcadas	O
diferencias	O
en	O
la	O
susceptibilidad	O
a	O
la	O
obesidad	O
,	O
la	O
aterosclerosis	O
y	O
la	O
remodelación	O
de	O
los	O
vasos	O
.	O

Sin	O
embargo	O
,	O
no	O
está	O
claro	O
cómo	O
estos	O
diversos	O
genético	B-Sequence
los	O
antecedentes	O
influyen	O
en	O
las	O
vías	O
que	O
se	O
sabe	O
que	O
regulan	O
la	O
trombosis	O
y	O
la	O
hemostasia	O
.	O

El	O
objetivo	O
de	O
este	O
estudio	O
fue	O
evaluar	O
la	O
trombosis	O
y	O
la	O
hemostasia	O
en	O
estas	O
dos	O
cepas	O
endogámicas	O
y	O
determinar	O
la	O
respuesta	O
fenotípica	O
de	O
A/J	O
cromosomas	B-GENE
en	O
el	O
fondo	O
C57BL/6J	O
.	O

Métodos	O

A/J	O
y	O
C57Bl/6J	O
ratones	B-Taxon
fueron	O
evaluados	O
por	O
diferencias	O
en	O
trombosis	O
y	O
hemostasia	O
.	O

Se	O
indujo	O
un	O
trombo	O
en	O
la	O
arteria	O
carótida	O
mediante	O
la	O
aplicación	O
de	O
la	O
carótida	O
expuesta	O
a	O
cloruro	B-Chemical
férrico	I-Chemical
y	O
se	O
midió	O
el	O
flujo	O
sanguíneo	O
hasta	O
que	O
el	O
vaso	O
se	O
ocluyó	O
.	O

Los	O
tiempos	O
de	O
sangrado	O
y	O
resangrado	O
,	O
como	O
marcadores	O
indirectos	O
de	O
trombosis	O
y	O
hemostasia	O
,	O
se	O
determinaron	O
después	O
de	O
cortar	O
la	O
cola	O
y	O
colocarlos	O
en	O
solución	O
salina	O
tibia	O
.	O

Veinte	O
uno	O
cromosoma	B-GENE
sustitución	B-Sequence
cepas	O
,	O
A	O
/	O
J	O
cromosomas	B-GENE
en	O
un	O
fondo	O
C57BL/6J	O
,	O
fueron	O
examinados	O
para	O
la	O
respuesta	O
al	O
ensayo	O
de	O
sangrado	O
de	O
la	O
cola	O
.	O

Resultados	O

El	O
tiempo	O
de	O
oclusión	O
del	O
trombo	O
se	O
redujo	O
notablemente	O
en	O
el	O
A	O
/	O
J	O
ratones	B-Taxon
en	O
comparación	O
con	O
C57BL	O
/	O
6J	O
ratones	B-Taxon
.	O

El	O
tiempo	O
de	O
sangrado	O
de	O
la	O
cola	O
fue	O
similar	O
en	O
las	O
dos	O
cepas	O
,	O
pero	O
el	O
tiempo	O
de	O
resangrado	O
aumentó	O
notablemente	O
en	O
A/J	O
.	O
ratones	B-Taxon
en	O
comparación	O
con	O
C57BL	O
/	O
6J	O
ratones	B-Taxon
.	O

Los	O
tiempos	O
de	O
coagulación	O
y	O
la	O
morfología	O
de	O
la	O
cola	O
fueron	O
similares	O
,	O
pero	O
la	O
cola	O
colágeno	B-GENE
el	O
contenido	O
fue	O
mayor	O
en	O
A/J	O
que	O
en	O
C57BL/6J	O
ratones	B-Taxon
.	O

Tres	O
cromosoma	B-GENE
sustitución	B-Sequence
Las	O
cepas	O
,	O
B6	O
-	O
Chr5A	O
/	O
J	O
,	O
B6	O
-	O
Chr11A	O
/	O
J	O
y	O
B6	O
-	O
Chr17A	O
/	O
J	O
,	O
se	O
identificaron	O
con	O
un	O
mayor	O
tiempo	O
de	O
resangrado	O
,	O
un	O
fenotipo	O
similar	O
a	O
A	O
/	O
J	O
ratones	B-Taxon
.	O

Ratones	B-Taxon
heterosómico	O
para	O
cromosomas	B-GENE
5	O
o	O
17	O
tuvieron	O
tiempos	O
de	O
resangrado	O
similares	O
a	O
C57BL/6J	O
ratones	B-Taxon
,	O
pero	O
cuando	O
estos	O
dos	O
cromosoma	B-GENE
sustitución	B-Sequence
se	O
cruzaron	O
las	O
cepas	O
B6-Chr5A/J	O
y	O
B6-Chr17A/J	O
,	O
se	O
restableció	O
el	O
fenotipo	O
A/J	O
en	O
esta	O
progenie	O
doblemente	O
heterosómica	O
.	O

Conclusión	O

Estos	O
resultados	O
indican	O
que	O
la	O
susceptibilidad	O
a	O
la	O
trombosis	O
arterial	O
y	O
la	O
hemostasia	O
es	O
notablemente	O
diferente	O
en	O
C57BL/	O
y	O
A/J	O
ratones	B-Taxon
.	O

Tres	O
A/J	O
cromosoma	B-GENE
sustitución	B-Sequence
se	O
identificaron	O
cepas	O
que	O
expresaron	O
un	O
fenotipo	O
similar	O
a	O
A	O
/	O
J	O
para	O
resangrado	O
,	O
el	O
fondo	O
C57Bl	O
/	O
6J	O
podría	O
modificar	O
el	O
fenotipo	O
A	O
/	O
J	O
,	O
y	O
la	O
combinación	O
de	O
dos	O
A	O
/	O
J	O
QTL	B-Sequence
podría	O
restaurar	O
el	O
fenotipo	O
.	O

los	O
diversos	O
genético	B-Sequence
antecedentes	O
y	O
diferencias	O
en	O
la	O
respuesta	O
a	O
la	O
trombosis	O
inducida	O
por	O
lesiones	O
vasculares	O
y	O
el	O
ensayo	O
de	O
sangrado	O
de	O
la	O
cola	O
,	O
sugieren	O
el	O
potencial	O
para	O
identificar	O
nuevos	O
genético	B-Sequence
determinantes	O
del	O
riesgo	O
trombótico	O
.	O

Antecedentes	O

La	O
historia	O
familiar	O
[	O
1	O
]	O
es	O
el	O
factor	O
de	O
riesgo	O
más	O
importante	O
para	O
las	O
enfermedades	O
cardiovasculares	O
(	O
ECV	O
)	O
.	O

Mientras	O
que	O
un	O
número	O
de	O
mutaciones	B-Sequence
geneticas	I-Sequence
han	O
sido	O
identificados	O
,	O
éstos	O
representan	O
sólo	O
un	O
pequeño	O
porcentaje	O
de	O
las	O
enfermedades	O
cardiovasculares	O
en	O
humano	B-Taxon
poblaciones	O

La	O
formación	O
de	O
trombos	O
en	O
placas	O
ateroscleróticas	O
fisuradas	O
es	O
el	O
evento	O
precipitante	O
en	O
la	O
transición	O
de	O
una	O
enfermedad	O
aterosclerótica	O
estable	O
o	O
subclínica	O
y	O
conduce	O
a	O
infarto	O
agudo	O
de	O
miocardio	O
,	O
accidente	O
cerebrovascular	O
isquémico	O
u	O
oclusión	O
arterial	O
periférica	O
.	O

La	O
trombosis	O
arterial	O
y	O
venosa	O
son	O
respuestas	O
complejas	O
y	O
están	O
influenciadas	O
por	O
múltiples	O
genético	B-Sequence
factores	O
ambientales	O
[	O
2	O
-	O
5	O
]	O
.	O

polimorfismos	B-Sequence
y	O
mutaciones	B-Sequence
en	O
factores	O
de	O
coagulación	O
,	O
factores	O
fibrinolíticos	O
,	O
plaqueta	B-Cell
receptores	O
de	O
superficie	O
,	O
metilentetrahidrofalato	B-Protein
reductasa	I-Protein
,	O
óxido	B-Protein
nítrico	I-Protein
sintasa	I-Protein
endotelial	I-Protein
,	O
y	O
antioxidante	B-Chemical
enzimas	B-Sequence
han	O
sido	O
implicados	O
como	O
genético	B-Sequence
determinantes	O
de	O
la	O
susceptibilidad	O
a	O
la	O
trombosis	O
[	O
6	O
,	O
7	O
]	O
.	O

Se	O
han	O
hecho	O
grandes	O
avances	O
en	O
el	O
diagnóstico	O
y	O
tratamiento	O
de	O
la	O
trombosis	O
en	O
la	O
última	O
década	O
.	O

Sin	O
embargo	O
,	O
las	O
estrategias	O
para	O
prevenir	O
la	O
trombosis	O
se	O
han	O
quedado	O
muy	O
rezagadas	O
debido	O
,	O
en	O
parte	O
,	O
a	O
la	O
contribución	O
de	O
múltiples	O
,	O
aún	O
no	O
definidos	O
,	O
genético	B-Sequence
Factores	O
que	O
conducen	O
al	O
riesgo	O
trombótico	O
.	O

Además	O
,	O
no	O
está	O
claro	O
cómo	O
genético	B-Sequence
fondo	O
influye	O
en	O
la	O
función	O
de	O
moléculas	B-Chemical
y	O
vías	O
que	O
se	O
sabe	O
que	O
regulan	O
la	O
formación	O
y	O
lisis	O
de	O
trombos	O
y	O
,	O
por	O
lo	O
tanto	O
,	O
contribuyen	O
al	O
riesgo	O
de	O
enfermedad	O
trombótica	O
.	O

Muchos	O
de	O
los	O
endogámicos	O
disponibles	O
ratón	B-Taxon
las	O
cepas	O
,	O
como	O
C57BL/6J	O
(	O
B6	O
)	O
y	O
A/J	O
,	O
se	O
han	O
clasificado	O
como	O
resistentes	O
o	O
susceptibles	O
a	O
determinadas	O
enfermedades	O
complejas	O
(	O
Cuadro	O
1	O
)	O
.	O

Estas	O
dos	O
cepas	O
tienen	O
respuestas	O
diversas	O
a	O
la	O
obesidad	O
inducida	O
por	O
la	O
dieta	O
[	O
8	O
]	O
(	O
susceptible	O
a	O
B6	O
;	O
resistente	O
a	O
A	O
/	O
J	O
)	O
,	O
aterosclerosis	O
inducida	O
por	O
la	O
dieta	O
(	O
susceptible	O
a	O
B6	O
;	O
resistente	O
a	O
A	O
/	O
J	O
)	O
[	O
9	O
]	O
,	O
hiperplasia	O
neointimal	O
inducida	O
por	O
ligadura	O
arterial	O
(	O
resistente	O
a	O
B6	O
;	O
resistente	O
a	O
A	O
/	O
J	O
)	O
,	O
y	O
remodelación	O
de	O
vasos	O
inducida	O
por	O
ligadura	O
(	O
resistente	O
a	O
B6	O
;	O
susceptible	O
a	O
A	O
/	O
J	O
)	O
[	O
10	O
]	O
.	O

Estas	O
condiciones	O
predisponen	O
a	O
la	O
trombosis	O
per	O
se	O
,	O
pero	O
estas	O
ratones	B-Taxon
no	O
han	O
sido	O
evaluados	O
sistemáticamente	O
para	O
la	O
trombosis	O
.	O

La	O
formación	O
y	O
lisis	O
del	O
coágulo	O
,	O
que	O
finalmente	O
determina	O
la	O
trombosis	O
,	O
requiere	O
plaqueta	B-Cell
agregación	O
,	O
coagulación	O
y	O
funciones	O
fibrinolíticas	O
.	O

Pueden	O
ocurrir	O
interacciones	O
entre	O
estas	O
vías	O
y	O
factores	O
adicionales	O
pueden	O
modular	O
estos	O
procesos	O
.	O

La	O
identificación	O
de	O
nuevos	O
moduladores	O
y	O
factores	O
de	O
estas	O
vías	O
se	O
puede	O
identificar	O
asociando	O
el	O
fenotipo	O
con	O
un	O
ubicación	B-Sequence
(	I-Sequence
s	I-Sequence
)	I-Sequence
en	I-Sequence
un	I-Sequence
cromosoma	I-Sequence
específico	I-Sequence
,	O
a	O
locus	B-Sequence
de	I-Sequence
rasgo	I-Sequence
cuantitativo	I-Sequence
(	O
QTL	B-Sequence
)	O
.	O

tabla	O
1	O

Identificacion	O
de	O
ratones	B-Taxon
susceptible	O
o	O
resistente	O
a	O
la	O
obesidad	O
,	O
aterosclerosis	O
y	O
lesiones	O
vasculares	O

R	O
:	O
resistente	O
;	O
S	O
:	O
susceptible	O
.	O

Referencia	O
proporcionada	O
por	O
número	O
entre	O
paréntesis	O
.	O

Lepob	O
,	O
por	B-Protein
favor	I-Protein
-	O
/	O
-	O
,	O
y	O
PAI-F1	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
estaban	O
en	O
un	O
fondo	O
B6	O
.	O

un	O
panel	O
de	O
cromosoma	B-GENE
sustitución	B-Sequence
``	O
(	O
CSS	O
)	O
se	O
generó	O
[	O
11	O
]	O
mediante	O
un	O
programa	O
de	O
mejoramiento	O
``	O
''	O
asistido	O
por	O
marcadores	O
``	O
''	O
en	O
el	O
que	O
la	O
progenie	O
de	O
un	O
cruce	O
B6	O
x	O
A	O
/	O
J	O
se	O
retrocruzó	O
sucesivamente	O
con	O
el	O
B6	O
''	O
ratones	B-Taxon
.	O

Genético	B-Sequence
Se	O
usaron	O
marcadores	O
para	O
identificar	O
la	O
homocigosidad	O
en	O
el	O
fondo	O
(	O
B6	O
)	O
y	O
el	O
individuo	O
A	O
/	O
J	O
cromosoma	B-GENE
.	O

Estas	O
cepas	O
tienen	O
una	O
cromosoma	B-GENE
de	O
A	O
/	O
J	O
ratones	B-Taxon
en	O
un	O
fondo	O
B6	O
.	O

Esto	O
permite	O
la	O
identificación	O
de	O
un	O
rasgo	O
en	O
uno	O
o	O
más	O
CSS	O
e	O
implica	O
que	O
al	O
menos	O
uno	O
QTL	B-Sequence
reside	O
en	O
este	O
cromosoma	B-GENE
.	O

El	O
uso	O
de	O
este	O
panel	O
requiere	O
menos	O
ratones	B-Taxon
para	O
determinar	O
el	O
QTL	B-Sequence
que	O
hace	O
un	O
genoma	B-Sequence
#	O
¿NOMBRE	O
?	O

Otra	O
ventaja	O
es	O
la	O
capacidad	O
de	O
detección	O
de	O
QTL	B-Sequence
en	O
presencia	O
de	O
otros	O
QTL	B-Sequence
.	O

Además	O
,	O
las	O
pantallas	O
iniciales	O
con	O
el	O
CSS	O
simplifican	O
el	O
mapeo	O
fino	O
de	O
QTL	B-Sequence
.	O

Varios	O
estudios	O
de	O
este	O
panel	O
CSS	O
,	O
B6	O
Chr1	O
-	O
19	O
,	O
X	O
,	O
YA	O
/	O
J	O
,	O
han	O
sido	O
reportados	O
para	O
comportamiento	O
[	O
12	O
]	O
,	O
aumento	O
de	O
peso	O
[	O
13	O
]	O
,	O
esteroles	B-Chemical
[	O
13	O
]	O
,	O
y	O
plasma	O
aminoácidos	B-Chemical
niveles	O
[	O
13	O
,	O
14	O
]	O
,	O
y	O
han	O
identificado	O
muchos	O
más	O
QTL	B-Sequence
que	O
los	O
estudios	O
de	O
los	O
mismos	O
rasgos	O
usando	O
un	O
genoma	B-Sequence
#	O
¿NOMBRE	O
?	O

El	O
propósito	O
de	O
este	O
estudio	O
fue	O
evaluar	O
las	O
dos	O
cepas	O
endogámicas	O
de	O
ratones	B-Taxon
para	O
el	O
riesgo	O
protrombótico	O
,	O
utilizando	O
un	O
cloruro	B-Chemical
férrico	I-Chemical
modelo	O
de	O
lesión	O
vascular	O
,	O
ensayo	O
de	O
sangrado	O
de	O
cola	O
y	O
medidas	O
de	O
coagulación	O
y	O
fibrinólisis	O
.	O

Los	O
resultados	O
de	O
este	O
estudio	O
indican	O
que	O
las	O
dos	O
cepas	O
endogámicas	O
,	O
B6	O
y	O
A	O
/	O
J	O
ratones	B-Taxon
,	O
tienen	O
diversos	O
fenotipos	O
protrombóticos	O
,	O
no	O
relacionados	O
con	O
la	O
coagulación	O
o	O
plaqueta	B-Cell
agregación	O
.	O

Además	O
,	O
en	O
el	O
CSS	O
,	O
la	O
expresión	O
de	O
los	O
fenotipos	O
A	O
/	O
J	O
,	O
tiempo	O
de	O
resangrado	O
y	O
oclusión	O
arterial	O
,	O
se	O
modificó	O
en	O
el	O
fondo	O
B6	O
y	O
sugirió	O
que	O
ocurrieron	O
interacciones	O
entre	O
los	O
A	O
/	O
J	O
QTL	B-Sequence
.	O

Por	O
lo	O
tanto	O
,	O
debería	O
ser	O
posible	O
identificar	O
genético	B-Sequence
determinantes	O
de	O
la	O
susceptibilidad	O
a	O
la	O
hemostasia	O
patológica	O
y	O
la	O
trombosis	O
.	O

Métodos	O

Ratones	B-Taxon

Las	O
cepas	O
endogámicas	O
,	O
B6	O
(	O
#	O
000664	O
)	O
,	O
Lepob	O
(	O
#	O
000632	O
)	O
,	O
A	O
/	O
J	O
(	O
#	O
000646	O
)	O
y	O
gene	B-Sequence
#	O
¿NOMBRE	O
?	O
inhibidor	B-Protein
del	I-Protein
activador	I-Protein
del	I-Protein
plasminógeno	I-Protein
(	I-Protein
Plg	I-Protein
)	I-Protein
deficiente	O
ratones	B-Taxon
(	O
PAI	B-Protein
-	I-Protein
1	I-Protein
-	O
/	O
-	O
)	O
(	O
#	O
002507	O
)	O
[	O
15	O
]	O
ratones	B-Taxon
en	O
un	O
fondo	O
B6	O
se	O
obtuvieron	O
de	O
Jackson	O
Laboratory	O
(	O
Bar	O
Harbor	O
,	O
Maine	O
)	O
a	O
las	O
6	O
semanas	O
de	O
edad	O
.	O

los	O
por	B-Protein
favor	I-Protein
-	O
/	O
-	O
ratones	B-Taxon
se	O
generaron	O
como	O
se	O
describió	O
anteriormente	O
[	O
16	O
]	O
y	O
se	O
mantuvieron	O
en	O
el	O
fondo	O
B6	O
,	O
generado	O
cruzando	O
ratones	B-Taxon
del	O
fondo	O
mixto	O
original	O
(	O
B6	O
:	O
129	O
)	O
durante	O
ocho	O
generaciones	O
con	O
B6	O
ratones	B-Taxon
.	O

los	O
por	B-Protein
favor	I-Protein
-	O
/	O
-	O
ratones	B-Taxon
no	O
se	O
reproducen	O
bien	O
y	O
por	B-Protein
favor	I-Protein
Se	O
utilizaron	O
parejas	O
heterocigóticas	O
para	O
la	O
reproducción	O
.	O

Genotipos	B-Sequence
(	O
por	B-Protein
favor	I-Protein
+	B-Sequence
/	O
+	B-Sequence
,	O
por	B-Protein
favor	I-Protein
+	B-Sequence
/	O
-	O
,	O
por	B-Protein
favor	I-Protein
-	O
/	O
-	O
)	O
de	O
las	O
crías	O
se	O
determinaron	O
mediante	O
un	O
ensayo	O
de	O
PCR	O
a	O
las	O
3	O
o	O
4	O
semanas	O
de	O
edad	O
mediante	O
un	O
punzón	O
en	O
la	O
oreja	O
[	O
17	O
]	O
.	O

Parejas	O
reproductoras	O
del	O
CSS	O
ratones	B-Taxon
fueron	O
transferidos	O
del	O
Dr	O
.	O
Laboratorio	O
de	O
Nadeau	O
.	O

Todos	O
ratones	B-Taxon
fueron	O
alojados	O
y	O
criados	O
en	O
la	O
Unidad	O
de	O
Recursos	O
Biológicos	O
de	O
la	O
Fundación	O
de	O
la	O
Clínica	O
Cleveland	O
(	O
CCF	O
)	O
.	O

Ratones	B-Taxon
fueron	O
alojados	O
en	O
jaulas	O
aisladoras	O
esterilizadas	O
,	O
mantenidas	O
en	O
un	O
ciclo	O
de	O
14	O
horas	O
de	O
luz	O
/	O
10	O
horas	O
de	O
oscuridad	O
,	O
y	O
se	O
les	O
proporcionó	O
esterilizados	O
comida	B-Chemical
y	O
agua	B-Chemical
ad	O
libitum	O
.	O

Ratones	B-Taxon
fueron	O
alimentados	O
con	O
una	O
dieta	O
estándar	O
de	O
laboratorio	O
esterilizable	O
en	O
autoclave	O
que	O
constaba	O
de	O
:	O
23	O
%	O
proteína	B-Chemical
,	O
4	O
.	O
5	O
%	O
de	O
grasa	O
,	O
6	O
%	O
de	O
fibra	O
,	O
(	O
Purina	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
,	O
y	O
probado	O
entre	O
las	O
7	O
y	O
las	O
9	O
semanas	O
de	O
edad	O
.	O

Todos	O
animal	B-Taxon
experimentos	O
se	O
realizaron	O
de	O
acuerdo	O
con	O
un	O
protocolo	O
aprobado	O
por	O
la	O
Institucional	O
Animal	B-Taxon
Comité	O
Asesor	O
de	O
Atención	O
e	O
Investigación	O
del	O
CCF	O
.	O

lesión	O
vascular	O

Para	O
inducir	O
la	O
formación	O
de	O
trombosis	O
en	O
la	O
arteria	O
carótida	O
,	O
un	O
cloruro	B-Chemical
férrico	I-Chemical
(	O
FeCl3	B-Chemical
)	O
se	O
empleó	O
el	O
modelo	O
de	O
lesión	O
del	O
vaso	O
[	O
18	O
,	O
19	O
]	O
.	O

Ratones	B-Taxon
fueron	O
anestesiados	O
con	O
ketamina/xilazina	O
(	O
80	O
mg/kg	O
,	O
5	O
mg/kg	O
)	O
,	O
se	O
realizó	O
una	O
incisión	O
cervical	O
en	O
la	O
línea	O
media	O
y	O
se	O
aisló	O
la	O
arteria	O
carótida	O
común	O
izquierda	O
mediante	O
disección	O
roma	O
.	O

La	O
sonda	O
de	O
flujo	O
(	O
Transonic	O
Systems	O
,	O
modelo	O
0	O
.	O
5PSB	O
)	O
se	O
colocó	O
debajo	O
de	O
la	O
arteria	O
y	O
cuando	O
se	O
alcanzó	O
una	O
línea	O
de	O
base	O
estable	O
,	O
se	O
colocó	O
un	O
0	O
.	O
Tira	O
de	O
5	O
x	O
2	O
mm	O
de	O
papel	O
filtro	O
saturado	O
con	O
10	O
%	O
FeCl3	B-Chemical
La	O
solución	O
se	O
aplicó	O
a	O
la	O
superficie	O
de	O
la	O
arteria	O
carótida	O
durante	O
3	O
min	O
.	O

El	O
tiempo	O
de	O
oclusión	O
se	O
determinó	O
a	O
partir	O
de	O
la	O
adición	O
del	O
FeCl3	B-Chemical
solución	O
a	O
la	O
oclusión	O
de	O
la	O
arteria	O
(	O
flujo	O
sanguíneo	O
mínimo	O
)	O
.	O

La	O
sonda	O
de	O
flujo	O
estuvo	O
en	O
su	O
lugar	O
desde	O
el	O
establecimiento	O
de	O
la	O
línea	O
de	O
base	O
hasta	O
varios	O
minutos	O
después	O
de	O
que	O
se	O
alcanzó	O
la	O
oclusión	O
estable	O
o	O
se	O
detuvo	O
a	O
los	O
30	O
minutos	O
si	O
no	O
se	O
había	O
ocluido	O
.	O

El	O
flujo	O
sanguíneo	O
se	O
registró	O
cada	O
10	O
segundos	O
(	O
Transonic	O
Systems	O
,	O
modelo	O
TS420	O
)	O
.	O

No	O
hubo	O
diferencia	O
en	O
el	O
peso	O
corporal	O
entre	O
los	O
ratones	B-Taxon
que	O
se	O
probaron	O
en	O
el	O
modelo	O
de	O
lesión	O
vascular	O
.	O

Ensayo	O
de	O
sangrado	O
y	O
resangrado	O

Para	O
el	O
ensayo	O
de	O
sangrado	O
de	O
la	O
cola	O
,	O
ratones	B-Taxon
fueron	O
anestesiados	O
con	O
ketamina/xilazina	O
(	O
80	O
mg/kg	O
,	O
5	O
mg/kg	O
)	O
,	O
la	O
cola	O
precalentada	O
durante	O
5	O
min	O
en	O
10	O
mL	O
de	O
solución	O
salina	O
a	O
37	O
grados	O
C	O
en	O
un	O
agua	B-Chemical
bañera	O
.	O

La	O
cola	O
se	O
levantó	O
de	O
la	O
solución	O
salina	O
y	O
se	O
amputó	O
un	O
segmento	O
de	O
cola	O
de	O
5	O
mm	O
y	O
se	O
devolvió	O
inmediatamente	O
a	O
la	O
solución	O
salina	O
.	O

El	O
tiempo	O
de	O
sangrado	O
se	O
midió	O
como	O
el	O
tiempo	O
entre	O
el	O
comienzo	O
del	O
sangrado	O
y	O
el	O
cese	O
del	O
sangrado	O
.	O

Con	O
la	O
cola	O
permaneciendo	O
en	O
la	O
misma	O
solución	O
salina	O
,	O
se	O
midió	O
el	O
tiempo	O
de	O
resangrado	O
desde	O
el	O
tiempo	O
entre	O
el	O
cese	O
del	O
sangrado	O
y	O
el	O
comienzo	O
del	O
segundo	O
sangrado	O
.	O

coagulación	O
,	O
por	B-Protein
favor	I-Protein
,	O
alfa	B-Protein
2	I-Protein
-	I-Protein
antiplasmina	I-Protein
,	O
fibrinógeno	B-GENE
,	O
fibrinolítico	O
y	O
PAI	B-Protein
-	I-Protein
1	I-Protein
ensayos	O

Ratones	B-Taxon
fueron	O
anestesiados	O
con	O
isoflurano	O
(	O
Abbott	O
)	O
,	O
se	O
les	O
extrajo	O
sangre	O
del	O
seno	O
orbital	O
en	O
tubos	O
capilares	O
sin	O
recubrimiento	O
,	O
y	O
se	O
colocó	O
inmediatamente	O
una	O
gota	O
de	O
sangre	O
en	O
un	O
reactivo	B-Chemical
tira	O
(	O
Simbióticos	O
)	O
para	O
protrombina	B-Protein
(	O
PT	O
)	O
o	O
tiempo	O
de	O
tromboplastina	O
parcial	O
activada	O
(	O
aPTT	O
)	O
e	O
insertado	O
en	O
el	O
analizador	O
de	O
coagulación	O
precalibrado	O
(	O
SCA2000	O
,	O
Synbiotics	O
)	O
.	O

PAI	B-Protein
-	I-Protein
1	I-Protein
la	O
actividad	O
se	O
determinó	O
de	O
acuerdo	O
con	O
el	O
método	O
de	O
Chandler	O
et	O
al	O
[	O
20	O
]	O
.	O

PAI	B-Protein
-	I-Protein
1	I-Protein
concentración	O
de	O
antígeno	O
se	O
determinó	O
por	O
ELISA	O
[	O
21	O
]	O
usando	O
oveja	B-Taxon
#	O
¿NOMBRE	O
?	O
ratón	B-Protein
PAI	I-Protein
-	I-Protein
1	I-Protein
(	O
American	O
Diagnostica	O
)	O
como	O
la	O
captura	O
anticuerpo	B-GENE
y	O
ratón	B-Protein
PAI	I-Protein
-	I-Protein
1	I-Protein
(	O
American	O
Diagnostica	O
)	O
como	O
estándar	O
(	O
0-3,5	O
ng/ml	O
)	O
.	O

por	B-Protein
favor	I-Protein
se	O
determinó	O
con	O
un	O
ensayo	O
cromogénico	O
[	O
22	O
]	O
y	O
la	O
actividad	O
fibrinolítica	O
determinada	O
por	O
la	O
degradación	O
de	O
la	O
fibrina	O
[	O
23	O
]	O
.	O

Para	O
los	O
controles	O
negativos	O
en	O
estos	O
ensayos	O
,	O
plasma	O
de	O
PAI	B-Protein
-	I-Protein
1	I-Protein
o	O
por	B-Protein
favor	I-Protein
deficiente	O
ratones	B-Taxon
se	O
utilizó	O
.	O

Funcionalmente	O
activo	O
ratón	B-Protein
alfa	I-Protein
2	I-Protein
-	I-Protein
antiplasmina	I-Protein
se	O
determinó	O
con	O
un	O
plasmina	B-Protein
ensayo	O
de	O
captura	O
y	O
detección	O
con	O
un	O
ratón	B-Taxon
anticuerpo	B-GENE
(	O
Molecular	B-Chemical
Innovaciones	O
,	O
Southfield	O
,	O
MI	O
)	O
,	O
y	O
fibrinógeno	B-GENE
con	O
un	O
ensayo	O
ELISA	O
con	O
anticuerpos	B-GENE
que	O
reconocen	O
ratón	B-Taxon
fibrinógeno	B-GENE
(	O
Hyphen	O
BioMed	O
,	O
Francia	O
)	O
.	O

Análisis	O
histoquímico	O
e	O
inmunohistoquímico	O

Las	O
colas	O
congeladas	O
o	O
las	O
carótidas	O
lesionadas	O
en	O
OCT	O
se	O
seccionaron	O
a	O
5	O
µm	O
de	O
espesor	O
y	O
se	O
tiñeron	O
con	O
tricrómico	O
de	O
Masson	O
(	O
HT	O
15	O
,	O
Sigma	O
Diagnostics	O
)	O
.	O

Para	O
el	O
análisis	O
cuantitativo	O
de	O
colágeno	B-GENE
En	O
las	O
secciones	O
de	O
la	O
cola	O
,	O
se	O
midieron	O
cuatro	O
secciones	O
de	O
2-3	O
sitios	O
usando	O
análisis	O
de	O
imágenes	O
asistido	O
por	O
computadora	O
(	O
Image-Pro	O
Plus	O
,	O
Cybernetics	O
)	O
.	O

Para	O
la	O
determinación	O
del	O
área	O
de	O
la	O
luz	O
carotídea	O
lesionada	O
,	O
se	O
analizaron	O
y	O
promediaron	O
para	O
cada	O
sección	O
3	O
o	O
4	O
secciones	O
de	O
diferentes	O
sitios	O
con	O
una	O
separación	O
aproximada	O
de	O
100	O
µm	O
.	O
ratón	B-Taxon
.	O

Estadísticas	O

Los	O
datos	O
se	O
presentan	O
como	O
media	O
+/-	O
SEM	O
.	O

El	O
análisis	O
estadístico	O
para	O
comparaciones	O
entre	O
A/J	O
y	O
B6	O
ratones	B-Taxon
y	O
entre	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
peso	B-Sequence
)	O
y	O
por	B-Protein
favor	I-Protein
-	O
/	O
-	O
compañeros	O
de	O
camada	O
se	O
comparó	O
con	O
una	O
prueba	O
t	O
de	O
dos	O
colas	O
.	O

Diferencias	O
entre	O
B6	O
,	O
Lepob	O
,	O
PAI	B-Protein
-	I-Protein
1	I-Protein
-	O
/	O
-	O
ratones	B-Taxon
se	O
determinaron	O
mediante	O
un	O
ANOVA	O
unidireccional	O
y	O
un	O
post-test	O
de	O
Newman-Keuls	O
.	O

Un	O
valor	O
de	O
P	O
<	O
0	O
.	O
05	O
fue	O
considerado	O
significativo	O
.	O

El	O
análisis	O
estadístico	O
para	O
comparaciones	O
entre	O
B6	O
ratones	B-Taxon
y	O
CSS	O
se	O
determinaron	O
con	O
pruebas	O
t	O
de	O
dos	O
colas	O
y	O
el	O
nivel	O
de	O
los	O
valores	O
P	O
significativos	O
(	O
consulte	O
las	O
leyendas	O
de	O
las	O
figuras	O
)	O
se	O
determinaron	O
con	O
una	O
corrección	O
de	O
Bonferroni	O
para	O
tener	O
en	O
cuenta	O
las	O
pruebas	O
de	O
hipótesis	O
múltiples	O
[	O
13	O
]	O
.	O

Resultados	O

Marcadas	O
diferencias	O
en	O
la	O
formación	O
de	O
trombos	O
arteriales	O
en	O
B6	O
y	O
A/J	O
ratones	B-Taxon

los	O
FeCl3	B-Chemical
modelo	O
de	O
lesión	O
de	O
la	O
arteria	O
cartoide	O
[	O
24	O
]	O
,	O
un	O
modelo	O
de	O
trombosis	O
arterial	O
bien	O
caracterizado	O
,	O
se	O
utilizó	O
para	O
inducir	O
un	O
trombo	O
oclusivo	O
en	O
el	O
B6	O
y	O
A	O
/	O
J	O
ratón	B-Taxon
cepas	O
bajo	O
investigación	O
.	O

Se	O
encontró	O
una	O
marcada	O
diferencia	O
en	O
el	O
tiempo	O
de	O
oclusión	O
del	O
trombo	O
arterial	O
entre	O
el	O
B6	O
y	O
el	O
A/J	O
ratones	B-Taxon
(	O
Figura	O
1A	O
)	O
.	O

El	O
tiempo	O
de	O
oclusión	O
en	O
el	O
A/J	O
ratones	B-Taxon
era	O
2	O
-	O
veces	O
menos	O
que	O
para	O
el	O
B6	O
ratones	B-Taxon
.	O

Una	O
dosis	O
del	O
5	O
%	O
de	O
FeCl3	B-Chemical
fue	O
probado	O
en	O
el	O
A	O
/	O
J	O
y	O
B6	O
ratones	B-Taxon
y	O
el	O
tiempo	O
de	O
oclusión	O
fue	O
menor	O
en	O
el	O
A/J	O
que	O
en	O
el	O
B6	O
ratones	B-Taxon
,	O
los	O
mismos	O
resultados	O
que	O
con	O
la	O
dosis	O
del	O
10	O
%	O
.	O

El	O
tiempo	O
de	O
oclusión	O
(	O
min	O
para	O
B6	O
(	O
15	O
+/-	O
3	O
,	O
n	O
=	O
3	O
)	O
y	O
A	O
/	O
J	O
(	O
8	O
+/-	O
1	O
,	O
n	O
=	O
3	O
)	O
al	O
5	O
%	O
fue	O
mayor	O
que	O
al	O
10	O
%	O
para	O
B6	O
(	O
10	O
+/-	O
1	O
,	O
n	O
=	O
17	O
y	O
A	O
/	O
J	O
(	O
5	O
+/-	O
2	O
,	O
n	O
=	O
14	O
)	O
.	O

Las	O
curvas	O
del	O
flujo	O
sanguíneo	O
después	O
FeCl3	B-Chemical
aplicación	O
indicó	O
un	O
patrón	O
con	O
una	O
disminución	O
gradual	O
antes	O
de	O
la	O
oclusión	O
para	O
el	O
B6	O
ratones	B-Taxon
(	O
Figura	O
1B	O
)	O
,	O
pero	O
para	O
el	O
A/J	O
ratones	B-Taxon
el	O
flujo	O
sanguíneo	O
disminuyó	O
abruptamente	O
a	O
cero	O
(	O
Figura	O
1C	O
)	O
,	O
demostrando	O
una	O
marcada	O
diferencia	O
con	O
la	O
cepa	O
B6	O
.	O

Los	O
tiempos	O
medios	O
de	O
oclusión	O
fueron	O
significativamente	O
diferentes	O
entre	O
las	O
dos	O
cepas	O
(	O
Figura	O
1A	O
)	O
.	O

El	O
tamaño	O
de	O
las	O
carótidas	O
en	O
las	O
dos	O
cepas	O
fue	O
notablemente	O
diferente	O
.	O

El	O
área	O
(	O
mm2	O
)	O
de	O
la	O
luz	O
(	O
0	O
.	O
066	O
+/-	O
0	O
.	O
007	O
,	O
n	O
=	O
6	O
)	O
fue	O
significativamente	O
menor	O
en	O
el	O
A	O
/	O
J	O
ratones	B-Taxon
que	O
para	O
B6	O
ratones	B-Taxon
0	O
.	O
128	O
+/-	O
0	O
.	O
007	O
,	O
n	O
=	O
6	O
)	O
.	O

Sin	O
embargo	O
,	O
la	O
relación	O
entre	O
el	O
trombo	O
y	O
la	O
luz	O
fue	O
similar	O
para	O
A	O
/	O
J	O
(	O
0,63	O
+/-	O
0,03	O
)	O
en	O
comparación	O
con	O
B6	O
ratones	B-Taxon
(	O
0	O
.	O
67	O
+/-	O
0	O
.	O
09	O
)	O
.	O

Las	O
tasas	O
de	O
tensión	O
pura	O
calculadas	O
[	O
25	O
]	O
fueron	O
un	O
14	O
%	O
menores	O
en	O
el	O
A	O
/	O
J	O
ratones	B-Taxon
en	O
comparación	O
con	O
B6	O
ratones	B-Taxon
.	O

Figura	O
1	O

Tiempo	O
de	O
oclusión	O
arterial	O
en	O
B6	O
y	O
A/J	O
ratones	B-Taxon
.	O

Los	O
paneles	O
A	O
y	O
B	O
son	O
curvas	O
de	O
oclusión	O
representativas	O
de	O
cada	O
genotipo	B-Sequence
.	O

Las	O
flechas	O
rojas	O
indican	O
la	O
duración	O
de	O
cloruro	B-Chemical
férrico	I-Chemical
Aplicación	O
a	O
la	O
carótida	O
.	O

Panel	O
A	O
:	O
B6	O
ratones	B-Taxon
,	O
Panel	O
B	O
:	O
A	O
/	O
J	O
ratones	B-Taxon
.	O

Panel	O
C	O
:	O
tiempo	O
de	O
oclusión	O
arterial	O
,	O
media	O
+/-	O
SEM	O
de	O
14	O
-	O
17	O
ratones	B-Taxon
por	O
genotipo	B-Sequence
.	O

El	O
símbolo	O
indica	O
una	O
diferencia	O
significativa	O
(	O
*	O
*	O
P	O
<	O
0	O
.	O
01	O
)	O
entre	O
B6	O
ratones	B-Taxon
determinado	O
con	O
una	O
prueba	O
.	O

Marcadas	O
diferencias	O
en	O
el	O
tiempo	O
de	O
resangrado	O
en	O
B6	O
y	O
A/J	O
ratones	B-Taxon

El	O
tiempo	O
de	O
sangrado	O
,	O
un	O
indicador	O
de	O
la	O
actividad	O
hemostática	O
,	O
se	O
determinó	O
después	O
de	O
precalentar	O
la	O
cola	O
,	O
cortar	O
un	O
segmento	O
de	O
5	O
mm	O
,	O
colocar	O
la	O
cola	O
en	O
solución	O
salina	O
tibia	O
y	O
medir	O
el	O
tiempo	O
que	O
tardaba	O
en	O
detenerse	O
el	O
sangrado	O
.	O

Encontramos	O
que	O
este	O
procedimiento	O
era	O
consistente	O
y	O
reproducible	O
en	O
diferentes	O
ratón	B-Taxon
cepas	O
y	O
no	O
era	O
dependiente	O
del	O
género	O
.	O

El	O
tiempo	O
de	O
sangrado	O
no	O
fue	O
diferente	O
en	O
A/J	O
ratones	B-Taxon
en	O
comparación	O
con	O
B6	O
ratones	B-Taxon
(	O
Figura	O
2A	O
)	O
.	O

Para	O
determinar	O
si	O
se	O
alteraron	O
rutas	O
específicas	O
en	O
las	O
cepas	O
B6	O
y	O
A	O
/	O
J	O
,	O
ratones	B-Taxon
con	O
alteraciones	O
conocidas	O
de	O
la	O
hemostasia	O
,	O
Lepob	O
ratones	B-Taxon
,	O
o	O
trombosis	O
,	O
por	B-Protein
favor	I-Protein
-	O
/	O
-	O
y	O
PAI	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
,	O
también	O
fueron	O
probados	O
.	O

el	O
lepob	O
ratones	B-Taxon
han	O
deteriorado	O
plaqueta	B-Cell
agregación	O
[	O
26	O
]	O
y	O
fueron	O
evaluados	O
como	O
referencia	O
para	O
plaqueta	B-Cell
función	O

en	O
el	O
lepob	O
ratones	B-Taxon
(	O
Figura	O
2A	O
)	O
hubo	O
un	O
aumento	O
de	O
casi	O
10	O
veces	O
en	O
el	O
tiempo	O
de	O
sangrado	O
en	O
comparación	O
con	O
B6	O
ratones	B-Taxon
.	O

El	O
tiempo	O
de	O
sangrado	O
también	O
aumentó	O
significativamente	O
(	O
P	O
=	O
0,0001	O
)	O
en	O
un	O
66	O
%	O
en	O
el	O
por	B-Protein
favor	I-Protein
-	O
/	O
-	O
ratones	B-Taxon
comparado	O
con	O
peso	B-Sequence
ratones	B-Taxon
compañeros	O
de	O
camada	O

El	O
tiempo	O
de	O
sangrado	O
no	O
fue	O
diferente	O
en	O
PAI	B-Protein
-	I-Protein
1	I-Protein
-	O
/	O
-	O
ratones	B-Taxon
en	O
comparación	O
con	O
B6	O
ratones	B-Taxon
.	O

En	O
contraste	O
con	O
el	O
Lepob	O
ratones	B-Taxon
con	O
un	O
plaqueta	B-Cell
defecto	O
y	O
aumento	O
de	O
10	O
veces	O
en	O
el	O
tiempo	O
de	O
sangría	O
,	O
no	O
hubo	O
diferencia	O
en	O
el	O
tiempo	O
de	O
sangría	O
entre	O
B6	O
y	O
A	O
/	O
J	O
ratones	B-Taxon
y	O
sugirió	O
plaqueta	B-Cell
la	O
agregación	O
no	O
se	O
altera	O
en	O
estas	O
dos	O
cepas	O
.	O

Figura	O
2	O

Tiempo	O
de	O
sangrado	O
y	O
resangrado	O
en	O
B6	O
,	O
A	O
/	O
J	O
,	O
Lepob	O
,	O
por	B-Protein
favor	I-Protein
-	O
/	O
-	O
y	O
PAI	B-Protein
-	I-Protein
1	I-Protein
-	O
/	O
-	O
ratones	B-Taxon
.	O

Panel	O
A	O
,	O
B	O
:	O
Tiempo	O
de	O
sangrado	O
(	O
segundos	O
)	O
y	O
Panel	O
C	O
,	O
D	O
:	O
Tiempo	O
de	O
resangrado	O
(	O
segundos	O
)	O
.	O

Para	O
determinar	O
diferencias	O
estadísticas	O
,	O
valores	O
de	O
B6	O
y	O
A	O
/	O
J	O
y	O
de	O
peso	B-Sequence
y	O
por	B-Protein
favor	I-Protein
-	O
/	O
-	O
compañeros	O
de	O
camada	O
se	O
compararon	O
con	O
at	O
-	O
test	O
,	O
y	O
los	O
valores	O
de	O
B6	O
,	O
PAI	B-Protein
-	I-Protein
1	I-Protein
-/-	O
y	O
Lepob	O
se	O
compararon	O
mediante	O
un	O
ANOVA	O
unidireccional	O
y	O
una	O
prueba	O
posterior	O
de	O
Newman-Keuls	O
.	O

Los	O
símbolos	O
indican	O
una	O
diferencia	O
significativa	O
(	O
*	O
P	O
<	O
0	O
.	O
05	O
,	O
*	O
*	O
P	O
<	O
0	O
.	O
01	O
,	O
*	O
*	O
*	O
P	O
<	O
0	O
.	O
001	O
)	O
entre	O
B6	O
o	O
peso	B-Sequence
ratones	B-Taxon
.	O

Los	O
valores	O
son	O
la	O
media	O
+/-	O
SEM	O
de	O
10	O
-	O
34	O
ratones	B-Taxon
por	O
genotipo	B-Sequence
.	O

El	O
tiempo	O
de	O
resangrado	O
,	O
un	O
indicador	O
de	O
la	O
estabilidad	O
del	O
trombo	O
,	O
se	O
midió	O
como	O
el	O
tiempo	O
entre	O
el	O
cese	O
del	O
sangrado	O
y	O
el	O
comienzo	O
del	O
segundo	O
sangrado	O
(	O
Figura	O
2B	O
)	O
.	O

Los	O
tiempos	O
de	O
resangrado	O
fueron	O
significativamente	O
mayores	O
en	O
A	O
/	O
J	O
(	O
2,6	O
veces	O
,	O
P	O
<	O
0,001	O
)	O
ratones	B-Taxon
que	O
el	O
B6	O
ratones	B-Taxon
.	O

Por	O
el	O
contrario	O
,	O
el	O
tiempo	O
de	O
resangrado	O
fue	O
de	O
casi	O
8	O
.	O
5	O
-	O
doblar	O
menos	O
en	O
el	O
Lepob	O
ratones	B-Taxon
que	O
el	O
B6	O
ratones	B-Taxon
.	O

Para	O
determinar	O
cómo	O
las	O
alteraciones	O
en	O
el	O
sistema	O
fibrinolítico	O
pueden	O
afectar	O
el	O
tiempo	O
de	O
resangrado	O
,	O
por	B-Protein
favor	I-Protein
-	O
/	O
-	O
y	O
PAI	B-Protein
-	I-Protein
1	I-Protein
-	O
/	O
-	O
ratones	B-Taxon
también	O
fueron	O
probados	O
(	O
Figura	O
2B	O
)	O
.	O

El	O
tiempo	O
de	O
resangrado	O
no	O
fue	O
diferente	O
en	O
por	B-Protein
favor	I-Protein
-	O
/	O
-	O
ratones	B-Taxon
comparado	O
con	O
peso	B-Sequence
compañeros	O
de	O
camada	O
,	O
pero	O
PAI	B-Protein
-	I-Protein
1	I-Protein
-	O
/	O
-	O
ratones	B-Taxon
tuvieron	O
un	O
tiempo	O
de	O
resangrado	O
significativamente	O
reducido	O
(	O
P	O
<	O
0,05	O
)	O
,	O
que	O
fue	O
de	O
1	O
.	O
8	O
-	O
pliegue	O
más	O
bajo	O
que	O
para	O
el	O
B6	O
ratones	B-Taxon
.	O

Aunque	O
un	O
por	B-Protein
favor	I-Protein
deficiencia	O
no	O
dio	O
como	O
resultado	O
un	O
tiempo	O
de	O
resangrado	O
prolongado	O
como	O
se	O
anticipó	O
,	O
un	O
PAI	B-Protein
-	I-Protein
1	I-Protein
deficiencia	O
resultó	O
en	O
un	O
tiempo	O
más	O
corto	O
.	O

El	O
tiempo	O
de	O
resangrado	O
marcadamente	O
aumentado	O
en	O
la	O
A/J	O
puede	O
sugerir	O
diferencias	O
en	O
la	O
regulación	O
de	O
la	O
por	B-Protein
favor	I-Protein
la	O
red	O
.	O

No	O
hay	O
diferencia	O
en	O
la	O
coagulación	O
sanguínea	O
entre	O
B6	O
y	O
A/J	O
ratones	B-Taxon

Para	O
determinar	O
si	O
las	O
diferencias	O
en	O
la	O
coagulación	O
eran	O
factores	O
que	O
contribuyeron	O
a	O
los	O
resultados	O
de	O
sangrado	O
y	O
resangrado	O
,	O
protrombina	B-Protein
Se	O
midieron	O
el	O
tiempo	O
(	O
PT	O
)	O
y	O
el	O
tiempo	O
de	O
tromboplastina	O
parcial	O
activada	O
(	O
TTPa	O
)	O
.	O

El	O
PT	O
es	O
una	O
medida	O
de	O
la	O
vía	O
de	O
coagulación	O
extrínseca	O
(	O
activación	O
de	O
Factor	B-Protein
VIII	I-Protein
por	O
factor	B-Protein
tisular	I-Protein
)	O
mientras	O
que	O
aPTT	O
es	O
una	O
medida	O
de	O
la	O
vía	O
intrínseca	O
(	O
activación	O
de	O
Factores	B-Protein
XII	I-Protein
,	I-Protein
XI	I-Protein
,	I-Protein
IX	I-Protein
y	I-Protein
VIII	I-Protein
)	O
.	O

Los	O
productos	O
de	O
ambas	O
vías	O
activan	O
Factor	B-Protein
X	I-Protein
que	O
inicia	O
la	O
vía	O
común	O
que	O
conduce	O
a	O
la	O
generación	O
de	O
trombina	O
y	O
la	O
formación	O
de	O
coágulos	O
de	O
fibrina	O
.	O

PT	O
y	O
aPTT	O
se	O
midieron	O
en	O
B6	O
y	O
A/J	O
ratones	B-Taxon
y	O
los	O
valores	O
no	O
fueron	O
diferentes	O
entre	O
los	O
dos	O
ratón	B-Taxon
cepas	O
(	O
Tabla	O
2	O
)	O
.	O

Estos	O
resultados	O
sugieren	O
que	O
la	O
vía	O
de	O
la	O
coagulación	O
no	O
es	O
diferente	O
en	O
las	O
dos	O
cepas	O
endogámicas	O
.	O

Tabla	O
2	O

Coagulación	O
y	O
plasminógeno	B-Protein
Parámetros	O
del	O
sistema	O
en	O
B6	O
y	O
A/J	O
consanguíneos	O
ratón	B-Taxon
son	O

Los	O
valores	O
son	O
la	O
media	O
+/-	O
SEM	O
.	O

*	O
PAG	O
<	O
0	O
.	O
05	O
,	O
*	O
*	O
PAG	O
<	O
0	O
.	O
01	O
.	O

norte	O
=	O
5	O
-	O
8	O
.	O

por	B-Protein
favor	I-Protein
y	O
PAI	B-Protein
-	I-Protein
1	I-Protein
mayor	O
en	O
A/J	O
que	O
en	O
B6	O
ratones	B-Taxon

por	B-Protein
favor	I-Protein
la	O
concentración	O
fue	O
34	O
%	O
mayor	O
en	O
el	O
A/J	O
ratones	B-Taxon
que	O
en	O
B6	O
ratones	B-Taxon
.	O

Además	O
,	O
la	O
actividad	O
fibrinolítica	O
,	O
PAI	B-Protein
-	I-Protein
1	I-Protein
actividad	O
,	O
y	O
alfa	B-Protein
2	I-Protein
-	I-Protein
antiplasmina	I-Protein
también	O
se	O
incrementaron	O
en	O
el	O
A/J	O
ratones	B-Taxon
en	O
comparación	O
con	O
el	O
B6	O
ratones	B-Taxon
(	O
Tabla	O
2	O
)	O
.	O

Las	O
consecuencias	O
funcionales	O
de	O
estas	O
diferencias	O
no	O
están	O
claras	O
,	O
ya	O
que	O
fibrinógeno	B-GENE
también	O
es	O
mayor	O
en	O
la	O
A/J	O
ratones	B-Taxon
.	O

Para	O
determinar	O
si	O
hubo	O
proteína	B-Chemical
cambios	O
en	O
la	O
estructura	O
de	O
por	B-Protein
favor	I-Protein
de	O
la	O
A/J	O
ratones	B-Taxon
plasma	O
de	O
la	O
B6	O
y	O
la	O
A/J	O
ratones	B-Taxon
fueron	O
sometidos	O
a	O
electroforesis	O
en	O
condiciones	O
reducidas	O
,	O
no	O
reducidas	O
y	O
no	O
desnaturalizantes	O
.	O

No	O
hay	O
diferencia	O
en	O
la	O
migración	O
para	O
inmunoteñidos	O
por	B-Protein
favor	I-Protein
en	O
estas	O
condiciones	O
se	O
observó	O
(	O
datos	O
no	O
mostrados	O
)	O
.	O

La	O
densidad	O
del	O
Western	O
blot	O
de	O
SDS	B-Chemical
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
se	O
comparó	O
y	O
la	O
densidad	O
de	O
las	O
bandas	O
fue	O
56	O
%	O
mayor	O
en	O
el	O
A/J	O
que	O
en	O
el	O
B6	O
ratones	B-Taxon
(	O
seis	O
individuales	O
ratones	B-Taxon
fueron	O
probados	O
en	O
al	O
menos	O
dos	O
ocasiones	O
)	O
a	O
partir	O
de	O
la	O
misma	O
cantidad	O
de	O
plasma	O
(	O
Fig	O
.	O
1B	O
)	O
.	O

Así	O
,	O
la	O
concentración	O
de	O
por	B-Protein
favor	I-Protein
en	O
plasma	O
de	O
la	O
A/J	O
ratones	B-Taxon
fue	O
mayor	O
que	O
el	O
plasma	O
de	O
la	O
B6	O
ratones	B-Taxon
según	O
lo	O
determinado	O
por	O
dos	O
métodos	O
y	O
no	O
se	O
observó	O
ninguna	O
diferencia	O
en	O
la	O
migración	O
después	O
de	O
la	O
electroforesis	O
,	O
lo	O
que	O
sugiere	O
que	O
no	O
hay	O
cambios	O
marcados	O
en	O
la	O
estructura	O
de	O
por	B-Protein
favor	I-Protein
en	O
los	O
dos	O
ratón	B-Taxon
cepas	O

Morfología	O
de	O
la	O
cola	O
en	O
B6	O
y	O
A/J	O

las	O
colas	O
de	O
los	O
ratones	B-Taxon
fueron	O
examinados	O
en	O
busca	O
de	O
diferencias	O
que	O
pudieran	O
explicar	O
las	O
variaciones	O
en	O
los	O
valores	O
de	O
sangrado	O
y	O
resangrado	O
.	O

Secciones	O
de	O
la	O
cola	O
del	O
B6	O
y	O
A/J	O
ratones	B-Taxon
se	O
tiñeron	O
con	O
hematoxilina	O
/	O
eosina	O
o	O
tricrómico	O
de	O
Masson	O
y	O
en	O
la	O
Figura	O
3	O
se	O
muestran	O
secciones	O
representativas	O
.	O

No	O
se	O
observaron	O
diferencias	O
cualitativas	O
obvias	O
en	O
los	O
folículos	O
pilosos	O
,	O
las	O
glándulas	O
sebáceas	O
o	O
el	O
centro	O
del	O
hueso/cartílago	O
en	O
las	O
secciones	O
teñidas	O
con	O
hematoxilina/eosina	O
(	O
Figura	O
3A	O
)	O
.	O

Las	O
secciones	O
de	O
las	O
colas	O
se	O
tiñeron	O
con	O
el	O
tricrómico	O
de	O
Masson	O
(	O
Figura	O
3B	O
)	O
que	O
detecta	O
colágeno	B-GENE
,	O
el	O
mayor	O
plaqueta	B-Cell
sustrato	O
adhesivo	O
para	O
el	O
inicio	O
de	O
la	O
formación	O
de	O
trombos	O
.	O

Colágeno	B-GENE
se	O
cuantificó	O
el	O
contenido	O
(	O
%	O
del	O
área	O
de	O
la	O
cola	O
)	O
(	O
Figura	O
3C	O
)	O
de	O
3-4	O
secciones	O
de	O
2-3	O
áreas/ratón	O
.	O

La	O
cantidad	O
de	O
colágeno	B-GENE
fue	O
mayor	O
en	O
el	O
A/J	O
que	O
en	O
el	O
B6	O
ratones	B-Taxon
(	O
PAG	O
<	O
0	O
.	O
05	O
)	O
.	O

Colágeno	B-GENE
en	O
vasos	O
en	O
tejido	O
adiposo	O
en	O
la	O
A/J	O
ratones	B-Taxon
también	O
se	O
incrementa	O
en	O
comparación	O
con	O
el	O
B6	O
ratones	B-Taxon
(	O
datos	O
no	O
mostrados	O
)	O
.	O

figura	O
3	O

Morfología	O
de	O
la	O
cola	O
y	O
colágeno	B-GENE
.	O

Se	O
extirparon	O
las	O
colas	O
,	O
se	O
incluyeron	O
en	O
OCT	O
,	O
se	O
seccionaron	O
y	O
se	O
tiñeron	O
con	O
hematoxilina/eosina	O
o	O
tricrómico	O
de	O
Masson	O
.	O

Panel	O
A	O
:	O
secciones	O
representativas	O
teñidas	O
con	O
hematoxilina	O
y	O
eosina	O
de	O
B6	O
y	O
A/J	O
ratones	B-Taxon
.	O

Panel	O
B	O
:	O
Secciones	O
representativas	O
teñidas	O
con	O
Tricrómico	O
de	O
Masson	O
de	O
B6	O
y	O
A/J	O
ratones	B-Taxon
.	O

El	O
color	O
azul	O
identifica	O
el	O
colágeno	B-GENE
.	O

Panel	O
C	O
:	O
El	O
porcentaje	O
de	O
la	O
colágeno	B-GENE
El	O
área	O
(	O
excluyendo	O
el	O
hueso/cartílago	O
central	O
)	O
del	O
área	O
total	O
de	O
la	O
cola	O
de	O
cada	O
sección	O
se	O
determinó	O
en	O
3	O
o	O
4	O
secciones	O
en	O
2	O
o	O
3	O
sitios	O
para	O
cada	O
cola	O
y	O
se	O
promedió	O
para	O
cada	O
sección	O
.	O
ratón	B-Taxon
.	O

Los	O
valores	O
son	O
la	O
media	O
+/-	O
SEM	O
de	O
4	O
-	O
8	O
ratones	B-Taxon
por	O
genotipo	B-Sequence
.	O

El	O
símbolo	O
indica	O
una	O
diferencia	O
significativa	O
(	O
*	O
P	O
<	O
0	O
.	O
05	O
)	O
entre	O
B6	O
ratones	B-Taxon
determinado	O
por	O
la	O
prueba	O
t	O
.	O

El	O
ensayo	O
de	O
sangrado	O
de	O
la	O
cola	O
identifica	O
tres	O
cromosomas	B-GENE
con	O
QTL	B-Sequence
para	O
volver	O
a	O
sangrar	O
en	O
CSS	O

Utilizando	O
el	O
ensayo	O
de	O
sangrado/resangrado	O
de	O
la	O
cola	O
como	O
marcador	O
sustituto	O
de	O
la	O
hemostasia	O
y	O
la	O
trombosis	O
,	O
se	O
examinaron	O
los	O
CSS	O
.	O

Los	O
tiempos	O
de	O
sangrado	O
(	O
Figura	O
4A	O
)	O
para	O
el	O
B6	O
y	O
el	O
A/J	O
ratones	B-Taxon
no	O
fueron	O
diferentes	O
,	O
pero	O
seis	O
de	O
las	O
cepas	O
,	O
B6	O
-	O
Chr5	O
,	O
6	O
,	O
8	O
,	O
14	O
,	O
15	O
y	O
YA	O
/	O
J	O
,	O
tuvieron	O
tiempos	O
de	O
sangrado	O
más	O
bajos	O
(	O
P	O
<	O
0,002	O
)	O
(	O
49-79	O
segundos	O
)	O
en	O
comparación	O
con	O
el	O
valor	O
de	O
la	O
B6	O
ratones	B-Taxon
(	O
121	O
seg	O
)	O
.	O

El	O
tiempo	O
de	O
resangrado	O
(	O
Figura	O
4B	O
)	O
,	O
determinado	O
como	O
el	O
tiempo	O
entre	O
el	O
cese	O
del	O
sangrado	O
y	O
el	O
inicio	O
del	O
segundo	O
sangrado	O
,	O
se	O
incrementó	O
notablemente	O
en	O
el	O
A/J	O
.	O
ratones	B-Taxon
en	O
comparación	O
con	O
el	O
B6	O
ratones	B-Taxon
y	O
dos	O
cepas	O
,	O
B6	O
-	O
Chr11A	O
/	O
J	O
(	O
CSS	O
-	O
11	O
)	O
y	O
B6	O
-	O
Chr17A	O
/	O
J	O
(	O
CSS	O
-	O
17	O
)	O
,	O
tuvieron	O
tiempos	O
de	O
resangrado	O
significativamente	O
(	O
P	O
<	O
0,002	O
)	O
más	O
largos	O
en	O
comparación	O
con	O
la	O
B6	O
ratones	B-Taxon
que	O
eran	O
similares	O
a	O
los	O
valores	O
de	O
la	O
A	O
/	O
J	O
ratones	B-Taxon
.	O

Otra	O
cepa	O
,	O
B6	O
-	O
Chr5A	O
/	O
J	O
(	O
CSS	O
-	O
5	O
)	O
,	O
se	O
acercó	O
a	O
la	O
significación	O
en	O
P	O
<	O
0	O
.	O
008	O
.	O

El	O
tiempo	O
de	O
resangrado	O
se	O
detuvo	O
a	O
los	O
600	O
segundos	O
y	O
el	O
porcentaje	O
de	O
ratones	B-Taxon
con	O
este	O
valor	O
determinado	O
para	O
las	O
tres	O
cepas	O
:	O
CSS-5-60	O
%	O
,	O
CSS-11-60	O
%	O
y	O
CSS-A17-46	O
%	O
.	O

El	O
porcentaje	O
de	O
B6	O
ratones	B-Taxon
con	O
un	O
tiempo	O
de	O
resangrado	O
de	O
600	O
seg	O
fue	O
de	O
7	O
%	O
y	O
para	O
el	O
A/J	O
ratones	B-Taxon
el	O
porcentaje	O
fue	O
del	O
85	O
%	O
.	O

Figura	O
4	O

Tiempo	O
de	O
sangrado	O
y	O
resangrado	O
en	O
el	O
SCS	O
.	O

Panel	O
A	O
:	O
Tiempo	O
de	O
sangrado	O
(	O
segundos	O
)	O
.	O

Panel	O
B	O
:	O
Tiempo	O
de	O
resangrado	O
(	O
segundos	O
)	O
.	O

Las	O
barras	O
son	O
la	O
media	O
+/-	O
SEM	O
de	O
7	O
-	O
28	O
ratones	B-Taxon
.	O

Diferencias	O
estadísticas	O
entre	O
B6	O
ratones	B-Taxon
y	O
CSS	O
se	O
determinaron	O
con	O
at	O
-	O
test	O
,	O
y	O
se	O
hizo	O
una	O
corrección	O
de	O
Bonferroni	O
para	O
determinar	O
el	O
valor	O
de	O
significación	O
(	O
P	O
<	O
0,002	O
)	O
.	O

Los	O
símbolos	O
indican	O
una	O
diferencia	O
significativa	O
entre	O
los	O
valores	O
de	O
B6	O
.	O

*	O
PAG	O
<	O
0	O
.	O
002	O
.	O

El	O
tiempo	O
de	O
resangrado	O
en	O
las	O
cepas	O
parentales	O
y	O
CSS	O
se	O
compararon	O
con	O
los	O
valores	O
de	O
la	O
progenie	O
de	O
ratones	B-Taxon
que	O
se	O
cruzaron	O
con	O
B6	O
ratones	B-Taxon
para	O
producir	O
heterosomía	O
ratones	B-Taxon
para	O
las	O
cepas	O
CSS-5	O
,	O
(	O
B6xCSS-5	O
)	O
F1	O
y	O
CSS-17	O
(	O
B6xCSS-17	O
)	O
F1	O
(	O
Figura	O
5	O
)	O
.	O

Los	O
valores	O
de	O
sangrado	O
para	O
CSS	O
-	O
5F1	O
y	O
CSS	O
-	O
17F1	O
ratones	B-Taxon
eran	O
similares	O
al	O
B6	O
en	O
lugar	O
del	O
A	O
/	O
J	O
ratones	B-Taxon
,	O
lo	O
que	O
sugiere	O
que	O
el	O
rasgo	O
A	O
/	O
J	O
es	O
recesivo	O
.	O

El	O
sangrado	O
y	O
el	O
resangrado	O
en	O
la	O
progenie	O
del	O
cruce	O
,	O
B6-Chr5A/J	O
x	O
B6-Chr17A/J	O
(	O
CSS-5	O
x	O
CSS-17	O
)	O
resultó	O
en	O
la	O
recuperación	O
del	O
fenotipo	O
A/J	O
en	O
la	O
progenie	O
de	O
estas	O
cepas	O
heterosómicas	O
dobles	O
.	O

Así	O
,	O
a	O
pesar	O
de	O
la	O
heterosómica	O
cromosomas	B-GENE
de	O
5	O
y	O
17	O
en	O
la	O
progenie	O
de	O
CSS-5	O
x	O
CSS-17	O
,	O
el	O
fenotipo	O
ahora	O
era	O
similar	O
a	O
A/J	O
.	O

Esto	O
sugirió	O
que	O
los	O
rasgos	O
en	O
el	O
A	O
/	O
J	O
cromosomas	B-GENE
estaban	O
interactuando	O
para	O
producir	O
el	O
fenotipo	O
.	O

Figura	O
5	O

Tiempo	O
de	O
sangrado	O
y	O
resangrado	O
en	O
los	O
retrocruzamientos	O
CSS	O
.	O

Panel	O
A	O
:	O
Tiempo	O
de	O
sangrado	O
(	O
segundos	O
)	O
y	O
Panel	O
B	O
:	O
Tiempo	O
de	O
resangrado	O
(	O
segundos	O
)	O
se	O
probaron	O
en	O
heterosomía	O
ratones	B-Taxon
,	O
(	O
B6xCSS	O
-	O
5	O
)	O
F1	O
(	O
5F1	O
)	O
y	O
(	O
B6xCSS	O
-	O
17	O
)	O
F1	O
(	O
17F1	O
)	O
y	O
doblemente	O
heterosómico	O
ratones	B-Taxon
por	O
cromosomas	B-GENE
5	O
y	O
17	O
(	O
5x17	O
)	O
.	O

Las	O
barras	O
son	O
la	O
media	O
+/-	O
SEM	O
de	O
5	O
-	O
28	O
ratones	B-Taxon
.	O

Diferencias	O
estadísticas	O
entre	O
B6	O
ratones	B-Taxon
y	O
el	O
CSS	O
se	O
determinaron	O
con	O
at-test	O
,	O
y	O
se	O
hizo	O
una	O
corrección	O
de	O
Bonferroni	O
para	O
determinar	O
el	O
valor	O
de	O
significación	O
(	O
P	O
<	O
0,01	O
)	O
.	O

Los	O
símbolos	O
indican	O
una	O
diferencia	O
significativa	O
entre	O
los	O
valores	O
de	O
B6	O
.	O

*	O
PAG	O
<	O
0	O
.	O
01	O
.	O

Interacciones	O
de	O
CSS	O
para	O
PAI	B-Protein
-	I-Protein
1	I-Protein
antígeno	O
y	O
actividad	O

Componentes	O
de	O
la	O
por	B-Protein
favor	I-Protein
el	O
sistema	O
reside	O
en	O
cromosomas	B-GENE
CSS-5	O
(	O
PAI	B-Protein
-	I-Protein
1	I-Protein
)	O
,	O
CSS	O
-	O
11	O
(	O
alfa	B-Protein
2	I-Protein
-	I-Protein
antiplasmina	I-Protein
)	O
,	O
y	O
CSS-17	O
(	O
por	B-Protein
favor	I-Protein
)	O
.	O

Como	O
se	O
informa	O
en	O
la	O
Tabla	O
2	O
,	O
el	O
A	O
/	O
J	O
ratones	B-Taxon
había	O
aumentado	O
por	B-Protein
favor	I-Protein
antígeno	O
,	O
actividad	O
fibrinolítica	O
,	O
alfa	B-Protein
2	I-Protein
-	I-Protein
antiplasmina	I-Protein
,	O
PAI	B-Protein
-	I-Protein
1	I-Protein
actividad	O
y	O
fibrinógeno	B-GENE
en	O
comparación	O
con	O
B6	O
ratones	B-Taxon
.	O

En	O
CSS-17	O
ratones	B-Taxon
,	O
los	O
por	B-Protein
favor	I-Protein
el	O
antígeno	O
también	O
aumentó	O
significativamente	O
(	O
P	O
=	O
0,015	O
)	O
(	O
152	O
+/-	O
6	O
,	O
n	O
=	O
12	O
)	O
en	O
comparación	O
con	O
el	O
B6	O
ratones	B-Taxon
,	O
pero	O
para	O
CSS	O
-	O
5	O
y	O
CSS	O
-	O
5	O
x	O
17	O
,	O
el	O
por	B-Protein
favor	I-Protein
el	O
antígeno	O
fue	O
similar	O
a	O
los	O
valores	O
para	O
el	O
B6	O
ratones	B-Taxon
.	O

La	O
actividad	O
fibrinolítica	O
no	O
fue	O
diferente	O
en	O
las	O
cepas	O
CSS	O
-	O
5	O
o	O
CSS	O
-	O
17	O
en	O
comparación	O
con	O
la	O
B6	O
ratones	B-Taxon
.	O

alfa	B-Protein
2	I-Protein
-	I-Protein
antiplasmina	I-Protein
se	O
redujo	O
significativamente	O
(	O
P	O
=	O
<	O
0,01	O
)	O
en	O
CSS	O
-	O
5	O
ratones	B-Taxon
(	O
142	O
+/-	O
4	O
mu	O
g	O
/	O
mL	O
,	O
n	O
=	O
5	O
)	O
,	O
significativamente	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
mayor	O
en	O
CSS	O
-	O
11	O
(	O
201	O
+/-	O
6	O
,	O
n	O
=	O
8	O
)	O
,	O
pero	O
no	O
diferente	O
en	O
CSS	O
-	O
17	O
o	O
CSS-5	O
x	O
17	O
ratones	B-Taxon
en	O
comparación	O
con	O
el	O
B6	O
ratones	B-Taxon
.	O

PAI	B-Protein
-	I-Protein
1	I-Protein
el	O
antígeno	O
y	O
la	O
actividad	O
se	O
determinaron	O
en	O
el	O
CSS	O
con	O
tiempos	O
de	O
resangrado	O
aumentados	O
,	O
CSS-5	O
,	O
CSS-11	O
y	O
CSS-17	O
(	O
Figura	O
6	O
)	O
,	O
el	O
heterosómico	O
,	O
CSS-5F1	O
,	O
CSS-17F1	O
y	O
el	O
doble	O
heterosómico	O
,	O
CSS-5	O
x	O
17	O
.	O

CSS-5	O
,	O
CSS-17	O
,	O
CSS-5F1	O
y	O
CSS-17F1	O
generalmente	O
habían	O
reducido	O
PAI	B-Protein
-	I-Protein
1	I-Protein
antígeno	O
en	O
comparación	O
con	O
B6	O
ratones	B-Taxon
.	O

el	O
reducido	O
PAI	B-Protein
-	I-Protein
1	I-Protein
el	O
antígeno	O
fue	O
un	O
rasgo	O
dominante	O
debido	O
a	O
que	O
los	O
valores	O
fueron	O
similares	O
en	O
los	O
CSS-5	O
y	O
CSS-17	O
homosómicos	O
y	O
heterosómicos	O
.	O

Las	O
cepas	O
heterosómicas	O
dobles	O
CSS-5	O
x	O
CSS-17	O
tenían	O
valores	O
similares	O
a	O
las	O
cepas	O
parentales	O
B6	O
y	O
A/J	O
.	O

PAI	B-Protein
-	I-Protein
1	I-Protein
la	O
actividad	O
se	O
redujo	O
significativamente	O
en	O
CSS	O
-	O
5	O
y	O
CSS	O
-	O
17F1	O
ratones	B-Taxon
,	O
pero	O
de	O
nuevo	O
en	O
el	O
CSS	O
-	O
5	O
x	O
CSS	O
-	O
17	O
tensa	O
el	O
valor	O
para	O
PAI	B-Protein
-	I-Protein
1	I-Protein
la	O
actividad	O
se	O
restauró	O
al	O
valor	O
de	O
las	O
cepas	O
parentales	O
B6	O
y	O
A/J	O
.	O

los	O
PAI	B-Protein
-	I-Protein
1	I-Protein
antígeno	O
(	O
5	O
.	O
4	O
ng	O
/	O
mL	O
+/-	O
0	O
.	O
5	O
,	O
n	O
=	O
7	O
)	O
y	O
actividad	O
(	O
170	O
U	O
/	O
mL	O
+/-	O
20	O
,	O
n	O
=	O
6	O
)	O
en	O
el	O
CSS	O
-	O
11	O
ratones	B-Taxon
no	O
fue	O
diferente	O
que	O
para	O
B6	O
ratones	B-Taxon
.	O

Figura	O
6	O

PAI	B-Protein
-	I-Protein
1	I-Protein
en	O
los	O
retrocruzamientos	O
CSS	O
.	O

Panel	O
A	O
:	O
Plasma	O
PAI	B-Protein
-	I-Protein
1	I-Protein
antígeno	O
(	O
ng	O
/	O
ml	O
)	O
y	O
Panel	O
B	O
:	O
Plasma	O
PAI	B-Protein
-	I-Protein
1	I-Protein
actividad	O
(	O
U	O
/	O
mL	O
)	O
fueron	O
probados	O
en	O
heterosomía	O
ratones	B-Taxon
,	O
(	O
B6xCSS	O
-	O
5	O
)	O
F1	O
(	O
5F1	O
)	O
y	O
(	O
B6xCSS	O
-	O
17	O
)	O
F1	O
(	O
17F1	O
)	O
y	O
doblemente	O
heterosómico	O
ratones	B-Taxon
por	O
cromosomas	B-GENE
5	O
y	O
17	O
(	O
5x17	O
)	O
.	O

Las	O
barras	O
son	O
la	O
media	O
+/-	O
SEM	O
de	O
5	O
-	O
18	O
ratones	B-Taxon
.	O

Diferencias	O
estadísticas	O
entre	O
B6	O
ratones	B-Taxon
y	O
CSS	O
se	O
determinaron	O
con	O
at	O
-	O
test	O
,	O
y	O
se	O
hizo	O
una	O
corrección	O
de	O
Bonferroni	O
para	O
determinar	O
el	O
valor	O
de	O
significación	O
(	O
P	O
<	O
0,01	O
)	O
.	O

Los	O
símbolos	O
indican	O
una	O
diferencia	O
significativa	O
entre	O
los	O
valores	O
de	O
B6	O
.	O

*	O
PAG	O
<	O
0	O
.	O
01	O
.	O

Interacciones	O
de	O
CSS	O
para	O
la	O
formación	O
de	O
trombos	O
arteriales	O

El	O
ensayo	O
de	O
sangrado	O
de	O
la	O
cola	O
fue	O
rápido	O
y	O
facilitó	O
la	O
detección	O
de	O
las	O
21	O
cepas	O
de	O
CSS	O
y	O
,	O
posteriormente	O
,	O
las	O
cepas	O
identificadas	O
se	O
analizaron	O
para	O
determinar	O
la	O
oclusión	O
arterial	O
después	O
de	O
la	O
FeCl3	B-Chemical
lesión	O
(	O
Figura	O
7	O
)	O
.	O

El	O
CSS	O
-	O
5	O
y	O
el	O
CSS	O
-	O
17	O
tuvieron	O
tiempos	O
de	O
oclusión	O
similares	O
al	O
B6	O
ratones	B-Taxon
,	O
pero	O
la	O
progenie	O
doblemente	O
heterosómica	O
CSS	O
-	O
5	O
x	O
CSS	O
-	O
17	O
tuvo	O
tiempos	O
de	O
oclusión	O
más	O
altos	O
que	O
el	O
B6	O
ratones	B-Taxon
o	O
las	O
cepas	O
heterosómicas	O
CSS-5F1	O
y	O
CSS-17F1	O
o	O
A/J	O
.	O

En	O
CSS	O
heterosómico	O
doble	O
-	O
5	O
x	O
CSS	O
-	O
17	O
ratones	B-Taxon
,	O
solo	O
uno	O
o	O
tres	O
ratones	B-Taxon
probado	O
había	O
ocluido	O
por	O
30	O
min	O
;	O
los	O
otros	O
dos	O
ratones	B-Taxon
no	O
ocluyó	O
a	O
los	O
30	O
min	O
.	O

Si	O
bien	O
solo	O
una	O
pequeña	O
cantidad	O
de	O
CSS	O
ratones	B-Taxon
han	O
sido	O
probados	O
para	O
la	O
oclusión	O
arterial	O
,	O
los	O
resultados	O
sugieren	O
que	O
la	O
interacción	O
de	O
la	O
genes	B-Sequence
en	O
cromosoma	B-GENE
5	O
y	O
17	O
también	O
determina	O
el	O
tiempo	O
de	O
oclusión	O
arterial	O
.	O

Figura	O
7	O

Tiempo	O
de	O
oclusión	O
arterial	O
en	O
los	O
retrocruzamientos	O
CSS	O
.	O

El	O
tiempo	O
de	O
oclusión	O
se	O
determinó	O
en	O
condiciones	O
heterosómicas	O
.	O
ratones	B-Taxon
,	O
(	O
B6xCSS	O
-	O
5	O
)	O
F1	O
(	O
5F1	O
)	O
y	O
(	O
B6xCSS	O
-	O
17	O
)	O
F1	O
(	O
17F1	O
)	O
,	O
y	O
doblemente	O
heterosómico	O
ratones	B-Taxon
por	O
cromosomas	B-GENE
5	O
y	O
17	O
(	O
5x17	O
)	O
.	O

Las	O
barras	O
son	O
la	O
media	O
+/-	O
SEM	O
de	O
5	O
-	O
18	O
ratones	B-Taxon
.	O

Diferencias	O
estadísticas	O
entre	O
B6	O
ratones	B-Taxon
CSS	O
se	O
determinaron	O
con	O
at	O
-	O
test	O
,	O
y	O
se	O
hizo	O
una	O
corrección	O
de	O
Bonferroni	O
para	O
determinar	O
el	O
valor	O
de	O
significación	O
(	O
P	O
<	O
0,02	O
)	O
.	O

Los	O
símbolos	O
indican	O
una	O
diferencia	O
significativa	O
entre	O
los	O
valores	O
de	O
B6	O
.	O

*	O
PAG	O
<	O
0	O
.	O
0001	O
.	O

Discusión	O

En	O
este	O
estudio	O
,	O
se	O
evaluó	O
sistemáticamente	O
el	O
riesgo	O
trombótico	O
en	O
dos	O
cepas	O
endogámicas	O
de	O
ratones	B-Taxon
que	O
tienen	O
marcadas	O
diferencias	O
en	O
la	O
susceptibilidad	O
a	O
la	O
obesidad	O
inducida	O
por	O
la	O
dieta	O
,	O
la	O
aterosclerosis	O
inducida	O
por	O
la	O
dieta	O
y	O
la	O
hiperplasia	O
neointimal	O
inducida	O
por	O
la	O
ligadura	O
y	O
la	O
remodelación	O
de	O
los	O
vasos	O
.	O

El	O
tiempo	O
de	O
oclusión	O
arterial	O
,	O
el	O
sangrado	O
de	O
la	O
cola	O
y	O
el	O
tiempo	O
de	O
resangrado	O
se	O
evaluaron	O
como	O
predictores	O
potenciales	O
de	O
la	O
respuesta	O
trombótica	O
.	O

Las	O
evaluaciones	O
de	O
las	O
dos	O
cepas	O
endogámicas	O
se	O
compararon	O
con	O
los	O
valores	O
de	O
gene	B-Sequence
dirigido	O
ratones	B-Taxon
de	O
El	O
por	B-Protein
favor	I-Protein
red	O
con	O
respuestas	O
fibrinolíticas	O
alteradas	O
,	O
así	O
como	O
en	O
leptina	B-Protein
deficiente	O
ratones	B-Taxon
con	O
un	O
reducido	O
plaqueta	B-Cell
función	O

Se	O
encontraron	O
marcadas	O
diferencias	O
en	O
la	O
respuesta	O
trombótica	O
entre	O
las	O
dos	O
cepas	O
endogámicas	O
,	O
B6	O
y	O
A/J	O
,	O
y	O
las	O
diferencias	O
observadas	O
no	O
se	O
correlacionaron	O
con	O
cambios	O
en	O
la	O
coagulación	O
o	O
plaqueta	B-Cell
función	O

La	O
revisión	O
del	O
CSS	O
identificó	O
tres	O
cromosomas	B-GENE
que	O
albergaba	O
genes	B-Sequence
lo	O
que	O
contribuyó	O
al	O
fenotipo	O
A/J	O
de	O
mayor	O
tiempo	O
de	O
resangrado	O
.	O

Ratones	B-Taxon
homosómico	O
para	O
estos	O
cromosomas	B-GENE
o	O
doblemente	O
heterosómico	O
para	O
dos	O
de	O
los	O
cromosomas	B-GENE
,	O
5	O
y	O
17	O
,	O
para	O
expresar	O
el	O
fenotipo	O
A	O
/	O
J	O
,	O
tiempo	O
de	O
resangrado	O
elevado	O
.	O

PAI	B-Protein
-	I-Protein
1	I-Protein
el	O
antígeno	O
y	O
la	O
actividad	O
disminuyeron	O
tanto	O
en	O
CSS	O
-	O
5	O
como	O
en	O
CSS	O
-	O
17	O
y	O
en	O
el	O
heterosómico	O
ratones	B-Taxon
,	O
CSS	O
-	O
5F1	O
y	O
CSS	O
-	O
17F1	O
,	O
pero	O
no	O
en	O
la	O
cepa	O
CSS	O
-	O
11	O
.	O

Los	O
valores	O
fueron	O
restaurados	O
en	O
el	O
doblemente	O
heterosómico	O
para	O
dos	O
de	O
cromosomas	B-GENE
,	O
5	O
y	O
17	O
.	O

El	O
tiempo	O
de	O
oclusión	O
arterial	O
fue	O
similar	O
al	O
de	O
B6	O
en	O
las	O
cepas	O
homocigóticas	O
CSS-5	O
y	O
CSS-17	O
,	O
pero	O
aumentó	O
en	O
las	O
cepas	O
doblemente	O
heterosómicas	O
para	O
dos	O
de	O
ellas	O
.	O
cromosomas	B-GENE
,	O
5	O
y	O
17	O
.	O

los	O
FeCl3	B-Chemical
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
ahora	O
es	O
ampliamente	O
utilizado	O
para	O
evaluar	O
genético	B-Sequence
e	O
intervenciones	O
farmacológicas	O
[	O
24	O
]	O
.	O

Las	O
dos	O
cepas	O
endogámicas	O
tenían	O
marcadas	O
diferencias	O
en	O
el	O
tiempo	O
de	O
oclusión	O
de	O
la	O
arteria	O
carótida	O
después	O
FeCl3	B-Chemical
lesión	O
.	O

Después	O
FeCl3	B-Chemical
tratamiento	O
,	O
la	O
formación	O
de	O
trombos	O
y	O
la	O
oclusión	O
se	O
acortó	O
notablemente	O
en	O
el	O
A	O
/	O
J	O
ratones	B-Taxon
en	O
comparación	O
con	O
el	O
B6	O
ratones	B-Taxon
.	O

Estos	O
resultados	O
no	O
han	O
sido	O
informados	O
previamente	O
.	O

Un	O
estudio	O
reciente	O
[	O
25	O
]	O
de	O
puro	O
estrés	O
en	O
ratas	B-Taxon
,	O
encontró	O
que	O
la	O
magnitud	O
de	O
los	O
cambios	O
en	O
el	O
estrés	O
puro	O
con	O
el	O
aumento	O
del	O
flujo	O
sanguíneo	O
varió	O
con	O
las	O
diferentes	O
cepas	O
.	O

Sería	O
necesaria	O
una	O
mayor	O
investigación	O
,	O
más	O
allá	O
del	O
alcance	O
de	O
este	O
estudio	O
,	O
para	O
determinar	O
la	O
contribución	O
de	O
las	O
diferencias	O
de	O
tamaño	O
y	O
la	O
tensión	O
pura	O
de	O
las	O
carótidas	O
a	O
las	O
tasas	O
de	O
oclusión	O
arterial	O
en	O
las	O
arterias	O
B6	O
y	O
A	O
/	O
J	O
ratones	B-Taxon
.	O

En	O
estudios	O
preliminares	O
,	O
hemos	O
notado	O
diferencias	O
en	O
la	O
composición	O
del	O
trombo	O
en	O
B6	O
y	O
A/J	O
ratones	B-Taxon
.	O

El	O
patrón	O
de	O
cese	O
del	O
flujo	O
sanguíneo	O
para	O
las	O
dos	O
cepas	O
endogámicas	O
fue	O
diferente	O
al	O
de	O
Lepob	O
.	O
ratones	B-Taxon
[	O
26	O
]	O
con	O
discapacidad	O
plaqueta	B-Cell
la	O
función	O
y	O
el	O
tiempo	O
de	O
coagulación	O
fue	O
similar	O
en	O
las	O
dos	O
cepas	O
.	O

En	O
el	O
ratones	B-Taxon
con	O
deficiencias	O
de	O
la	O
por	B-Protein
favor	I-Protein
red	O
[	O
27	O
]	O
,	O
el	O
tiempo	O
de	O
formación	O
de	O
trombos	O
se	O
redujo	O
en	O
la	O
por	B-Protein
favor	I-Protein
-	O
/	O
-	O
ratones	B-Taxon
,	O
pero	O
aumentó	O
en	O
el	O
PAI	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
,	O
lo	O
que	O
sugiere	O
que	O
las	O
alteraciones	O
en	O
plasmina	B-Protein
actividad	O
que	O
afecta	O
la	O
tasa	O
de	O
lisis	O
del	O
coágulo	O
,	O
puede	O
modular	O
los	O
eventos	O
que	O
conducen	O
a	O
la	O
formación	O
de	O
trombos	O
oclusivos	O
.	O

El	O
ensayo	O
de	O
sangrado	O
de	O
la	O
cola	O
se	O
ha	O
utilizado	O
ampliamente	O
en	O
ratones	B-Taxon
evaluar	O
el	O
impacto	O
de	O
las	O
deficiencias	O
y	O
la	O
sobreexpresión	O
de	O
plaqueta	B-Cell
y	O
coagulación	O
proteinas	B-Chemical
en	O
ratones	B-Taxon
.	O

Sweeny	O
et	O
al	O
[	O
28	O
]	O
examinaron	O
25	O
cepas	O
de	O
ratones	B-Taxon
y	O
solo	O
encontre	O
el	O
RIIS/J	O
ratones	B-Taxon
haber	O
aumentado	O
el	O
tiempo	O
de	O
sangrado	O
debido	O
a	O
la	O
reducción	O
antígeno	B-Protein
de	I-Protein
von	I-Protein
Willebrand	I-Protein
.	O

Broze	O
et	O
al	O
[	O
29	O
]	O
evaluaron	O
ratones	B-Taxon
con	O
deleciones	B-Sequence
de	I-Sequence
genes	I-Sequence
de	O
la	O
vía	O
de	O
la	O
coagulación	O
y	O
encontró	O
que	O
aunque	O
el	O
tiempo	O
de	O
sangrado	O
no	O
se	O
incrementó	O
,	O
el	O
resangrado	O
persistió	O
a	O
pesar	O
del	O
electrocauterio	O
de	O
la	O
cola	O
en	O
FVIII	B-Protein
y	O
REPARAR	B-Protein
deficiente	O
ratones	B-Taxon
.	O

Esta	O
observación	O
planteó	O
la	O
posibilidad	O
de	O
que	O
el	O
tiempo	O
de	O
resangrado	O
pueda	O
ser	O
un	O
indicador	O
sensible	O
de	O
genético	B-Sequence
Influencias	O
en	O
la	O
formación	O
y	O
estabilidad	O
del	O
trombo	O
.	O

Ratones	B-Taxon
que	O
son	O
deficientes	O
en	O
los	O
factores	O
necesarios	O
para	O
el	O
normal	O
plaqueta	B-Cell
función	O
,	O
plaqueta	B-Cell
glicoproteína	O
Ib	O
[	O
30	O
]	O
,	O
y	O
proteasa	B-Protein
-	I-Protein
receptor	I-Protein
activado	I-Protein
-	I-Protein
4	I-Protein
,	O
[	O
31	O
]	O
han	O
aumentado	O
el	O
tiempo	O
de	O
sangrado	O
de	O
la	O
cola	O
.	O

los	O
leptina	B-Protein
deficiencia	O
con	O
reducción	O
plaqueta	B-Cell
agregación	O
muestra	O
claramente	O
un	O
marcado	O
aumento	O
en	O
el	O
tiempo	O
de	O
sangrado	O
y	O
el	O
aumento	O
del	O
tiempo	O
de	O
sangrado	O
en	O
por	B-Protein
favor	I-Protein
-	O
/	O
-	O
y	O
UPA	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
sugiere	O
que	O
por	B-Protein
favor	I-Protein
y	O
UPA	B-Protein
puede	O
ejercer	O
una	O
influencia	O
sobre	O
plaqueta	B-Cell
respuesta	O
para	O
promover	O
la	O
formación	O
normal	O
de	O
trombos	O
.	O

En	O
general	O
,	O
el	O
marcado	O
aumento	O
en	O
los	O
tiempos	O
de	O
resangrado	O
observado	O
en	O
ciertos	O
ratón	B-Taxon
cepas	O
sugiere	O
genético	B-Sequence
otros	O
factores	O
además	O
de	O
la	O
coagulación	O
pueden	O
desempeñar	O
un	O
papel	O
en	O
la	O
estabilidad	O
de	O
un	O
trombo	O
.	O

En	O
el	O
ensayo	O
de	O
sangrado	O
de	O
cola	O
,	O
A	O
/	O
J	O
ratones	B-Taxon
no	O
tuvo	O
cambios	O
en	O
el	O
tiempo	O
de	O
sangrado	O
,	O
pero	O
el	O
tiempo	O
de	O
resangrado	O
fue	O
mayor	O
en	O
comparación	O
con	O
B6	O
ratones	B-Taxon
.	O

En	O
nuestro	O
estudio	O
,	O
por	B-Protein
favor	I-Protein
-	O
/	O
-	O
ratones	B-Taxon
había	O
aumentado	O
el	O
tiempo	O
de	O
sangrado	O
,	O
PAI	B-Protein
-	I-Protein
1	I-Protein
-	O
/	O
-	O
había	O
disminuido	O
el	O
tiempo	O
de	O
resangrado	O
y	O
UPA	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
tuvo	O
un	O
aumento	O
del	O
tiempo	O
de	O
sangrado	O
similar	O
al	O
por	B-Protein
favor	I-Protein
-	O
/	O
-	O
ratones	B-Taxon
(	O
J.	O
Hoover-Plough	O
,	O
A.	O
Shchurin	O
y	O
E.	O
Hart	O
,	O
resultados	O
no	O
publicados	O
)	O
.	O

No	O
se	O
han	O
informado	O
aumentos	O
en	O
el	O
tiempo	O
de	O
sangrado	O
o	O
resangrado	O
en	O
ninguno	O
de	O
los	O
por	B-Protein
favor	I-Protein
red	O
dirigida	O
ratones	B-Taxon
.	O

Matsuno	O
et	O
al	O
[	O
32	O
]	O
no	O
informaron	O
diferencias	O
en	O
el	O
tiempo	O
de	O
sangrado	O
para	O
tPA	B-Protein
-	O
/	O
-	O
,	O
UPA	B-Protein
-	O
/	O
-	O
,	O
PAI	B-Protein
-	I-Protein
1	I-Protein
-	O
/	O
-	O
ratones	B-Taxon
comparado	O
con	O
peso	B-Sequence
ratones	B-Taxon
,	O
y	O
el	O
ensayo	O
fue	O
similar	O
,	O
pero	O
el	O
segmento	O
del	O
clip	O
de	O
la	O
cola	O
fue	O
considerablemente	O
más	O
corto	O
y	O
los	O
tiempos	O
de	O
sangrado	O
se	O
redujeron	O
en	O
comparación	O
con	O
los	O
tiempos	O
informados	O
en	O
nuestro	O
estudio	O
.	O

El	O
tiempo	O
de	O
sangrado	O
no	O
se	O
ha	O
informado	O
previamente	O
para	O
por	B-Protein
favor	I-Protein
-	O
/	O
-	O
ratones	B-Taxon
.	O

Hemos	O
encontrado	O
valores	O
similares	O
para	O
por	B-Protein
favor	I-Protein
-	O
/	O
-	O
ratones	B-Taxon
en	O
un	O
fondo	O
50	O
%	O
B6	O
:	O
50	O
%	O
129	O
(	O
J.	O
Hoover	O
-	O
Plough	O
,	O
A.	O
Shchurin	O
y	O
E.	O
Hart	O
,	O
resultados	O
no	O
publicados	O
)	O
.	O

Los	O
resultados	O
de	O
este	O
estudio	O
sugieren	O
que	O
no	O
sólo	O
es	O
el	O
tiempo	O
de	O
sangrado	O
genéticamente	B-Sequence
determinado	O
por	O
el	O
fondo	O
,	O
pero	O
también	O
que	O
el	O
tiempo	O
de	O
resangrado	O
de	O
la	O
cola	O
es	O
genéticamente	B-Sequence
determinado	O

Si	O
bien	O
es	O
posible	O
que	O
la	O
presión	O
arterial	O
sea	O
más	O
alta	O
en	O
ratones	B-Taxon
con	O
un	O
tiempo	O
elevado	O
de	O
sangrado	O
de	O
la	O
cola	O
,	O
varios	O
estudios	O
sugieren	O
que	O
este	O
no	O
es	O
el	O
caso	O
.	O

Estudios	O
de	O
A/J	O
[	O
33	O
-	O
36	O
]	O
ratones	B-Taxon
han	O
informado	O
disminución	O
de	O
la	O
presión	O
arterial	O
o	O
ninguna	O
diferencia	O
en	O
comparación	O
con	O
la	O
B6	O
ratones	B-Taxon
.	O

La	O
presión	O
arterial	O
se	O
midió	O
en	O
el	O
por	B-Protein
favor	I-Protein
-	O
/	O
-	O
ratones	B-Taxon
(	O
D.	O
Hellard	O
,	O
J.	O
Hoover-Plough	O
y	O
E.	O
Plough	O
,	O
resultados	O
no	O
publicados	O
)	O
,	O
y	O
estos	O
ratones	B-Taxon
han	O
reducido	O
la	O
presión	O
arterial	O
en	O
comparación	O
con	O
peso	B-Sequence
compañeros	O
de	O
camada	O
,	O
y	O
UPA	B-Protein
-	O
/	O
-	O
[	O
37	O
]	O
y	O
Lepob	O
[	O
38	O
,	O
39	O
]	O
ratones	B-Taxon
también	O
tienen	O
presión	O
arterial	O
reducida	O
,	O
pero	O
no	O
hay	O
correspondencia	O
entre	O
la	O
presión	O
arterial	O
y	O
los	O
tiempos	O
de	O
sangrado	O
o	O
resangrado	O
de	O
la	O
cola	O
.	O

El	O
análisis	O
morfométrico	O
de	O
la	O
cola	O
indicó	O
una	O
diferencia	O
en	O
la	O
colágeno	B-GENE
contenido	O
de	O
la	O
cola	O
en	O
el	O
A/J	O
ratones	B-Taxon
.	O

Diferencias	O
en	O
la	O
estructura	O
y/o	O
metabolismo	O
de	O
colágeno	B-GENE
o	O
la	B-GENE
matriz	I-GENE
extracelular	I-GENE
proteinas	B-Chemical
puede	O
contribuir	O
al	O
aumento	O
del	O
resangrado	O
y	O
a	O
la	O
reducción	O
del	O
tiempo	O
de	O
oclusión	O
en	O
el	O
A/J	O
ratones	B-Taxon
y	O
justifican	O
una	O
mayor	O
investigación	O
.	O

los	O
genes	B-Sequence
por	O
por	B-Protein
favor	I-Protein
,	O
PAI	B-Protein
-	I-Protein
1	I-Protein
,	O
y	O
alfa	B-Protein
2	I-Protein
-	I-Protein
antiplasmina	I-Protein
residir	O
en	O
los	O
tres	O
cromosomas	B-GENE
identificado	O
para	O
QTL	B-Sequence
para	O
el	O
tiempo	O
de	O
resangrado	O
y	O
puede	O
o	O
no	O
ser	O
coincidente	O
con	O
los	O
fenotipos	O
observados	O
que	O
se	O
encuentran	O
en	O
el	O
A	O
/	O
J	O
ratones	B-Taxon
y	O
CSS	O
.	O

No	O
es	O
probable	O
que	O
simplemente	O
la	O
concentración	O
de	O
estos	O
componentes	O
explique	O
el	O
aumento	O
del	O
tiempo	O
de	O
resangrado	O
y	O
la	O
reducción	O
del	O
tiempo	O
de	O
oclusión	O
arterial	O
en	O
la	O
A/J	O
.	O
ratones	B-Taxon
.	O

En	O
comparación	O
con	O
el	O
B6	O
ratones	B-Taxon
,	O
el	O
A/J	O
ratones	B-Taxon
y	O
las	O
tres	O
cepas	O
con	O
tiempo	O
de	O
resangrado	O
elevado	O
tenían	O
variable	O
por	B-Protein
favor	I-Protein
,	O
PAI	B-Protein
-	I-Protein
1	I-Protein
,	O
y	O
alfa	B-Protein
2	I-Protein
-	I-Protein
antiplasmina	I-Protein
.	O

Dos	O
formas	B-Sequence
alélicas	I-Sequence
de	O
El	O
ratón	B-Protein
por	I-Protein
favor	I-Protein
gene	B-Sequence
han	O
sido	O
reportados	O
para	O
B6	O
y	O
A	O
/	O
J	O
ratones	B-Taxon
[	O
40	O
]	O
.	O

por	B-Protein
favor	I-Protein
la	O
concentración	O
se	O
incrementó	O
en	O
A	O
/	O
J	O
ratones	B-Taxon
en	O
comparación	O
con	O
B6	O
ratones	B-Taxon
.	O

Aunque	O
no	O
detectamos	O
diferencias	O
en	O
por	B-Protein
favor	I-Protein
estructura	O
,	O
esto	O
no	O
excluiría	O
posibles	O
diferencias	O
funcionales	O
.	O

Una	O
cepa	O
congénica	O
(	O
específica	O
para	O
un	O
homosómico	O
región	B-Sequence
de	O
A/J	O
y	O
el	O
resto	O
cr	B-GENE
y	O
el	O
fondo	O
es	O
de	O
B6	O
ratones	B-Taxon
)	O
de	O
A/J	O
cromosoma	B-GENE
17	O
que	O
incluye	O
el	O
por	B-Protein
favor	I-Protein
gene	B-Sequence
se	O
probó	O
en	O
el	O
ensayo	O
de	O
sangrado	O
.	O

Los	O
valores	O
de	O
sangrado	O
y	O
resangrado	O
en	O
esta	O
cepa	O
congénica	O
fueron	O
similares	O
a	O
los	O
valores	O
de	O
B6	O
ratones	B-Taxon
,	O
indicando	O
que	O
el	O
QTL	B-Sequence
no	O
es	O
por	B-Protein
favor	I-Protein
.	O

Hay	O
genes	B-Sequence
para	O
otras	O
proteasas	O
y	O
matriz	O
proteinas	B-Chemical
que	O
residen	O
en	O
cromosoma	B-GENE
17	O
además	O
de	O
desconocido	O
genes	B-Sequence
.	O

secuencia	B-Sequence
de	I-Sequence
pares	I-Sequence
de	I-Sequence
bases	I-Sequence
de	I-Sequence
ADN	I-Sequence
datos	O
para	O
el	O
PAI	B-Protein
-	I-Protein
1	I-Protein
gene	B-Sequence
o	O
la	O
alfa	B-Protein
2	I-Protein
-	I-Protein
antiplasmina	I-Protein
gene	B-Sequence
en	O
B6	O
y	O
A/J	O
ratones	B-Taxon
no	O
han	O
informado	O
diferencias	O
[	O
51	O
]	O
,	O
pero	O
genes	B-Sequence
aguas	O
arriba	O
de	O
la	O
región	B-Sequence
de	I-Sequence
codificación	I-Sequence
puede	O
ser	O
importante	O

Nuestros	O
resultados	O
sugieren	O
que	O
nuevos	O
o	O
desconocidos	O
genes	B-Sequence
puede	O
interactuar	O
con	O
el	O
por	B-Protein
favor	I-Protein
componentes	O
del	O
sistema	O
para	O
modificar	O
su	O
función	O
.	O

En	O
resumen	O
,	O
este	O
estudio	O
informa	O
marcadas	O
diferencias	O
en	O
dos	O
cepas	O
endogámicas	O
de	O
ratones	B-Taxon
,	O
B6	O
y	O
A	O
/	O
J	O
,	O
en	O
la	O
formación	O
de	O
trombosis	O
arterial	O
en	O
un	O
FeCl3	B-Chemical
modelo	O
de	O
lesión	O
vascular	O
,	O
tiempo	O
de	O
resangrado	O
en	O
un	O
ensayo	O
de	O
sangrado	O
de	O
cola	O
,	O
plasminógeno	B-Protein
función	O
,	O
y	O
tejido	O
y	O
vaso	O
colágeno	B-GENE
deposición	O

Tres	O
cromosomas	B-GENE
de	O
A	O
/	O
J	O
ratones	B-Taxon
se	O
identificaron	O
que	O
tenían	O
QTL	B-Sequence
para	O
el	O
tiempo	O
de	O
resangrado	O
.	O

los	O
genes	B-Sequence
puede	O
interactuar	O
con	O
los	O
componentes	O
del	O
por	B-Protein
favor	I-Protein
red	O
y	O
modular	O
el	O
tiempo	O
de	O
oclusión	O
arterial	O
.	O

Conclusión	O

Las	O
marcadas	O
diferencias	O
independientes	O
demostradas	O
en	O
el	O
B6	O
y	O
A/J	O
ratones	B-Taxon
puede	O
ser	O
explotado	O
para	O
identificar	O
genético	B-Sequence
determinantes	O
de	O
la	O
trombosis	O
y	O
la	O
hemostasia	O
.	O

Nuestros	O
resultados	O
de	O
la	O
evaluación	O
CSS	O
sugieren	O
que	O
nuevos	O
o	O
desconocidos	O
genes	B-Sequence
se	O
puede	O
utilizar	O
para	O
identificar	O
la	O
genes	B-Sequence
responsable	O
de	O
los	O
rasgos	O
relacionados	O
con	O
la	O
trombosis	O
arterial	O
,	O
sangrado	O
de	O
cola/resangrado	O
y	O
vaso	O
la	B-GENE
matriz	I-GENE
extracelular	I-GENE
.	O

La	O
identificación	O
de	O
las	O
diferencias	O
en	O
las	O
cepas	O
parentales	O
,	O
como	O
las	O
descritas	O
en	O
este	O
estudio	O
,	O
y	O
la	O
detección	O
del	O
CSS	O
es	O
un	O
primer	O
paso	O
en	O
el	O
descubrimiento	O
de	O
nuevos	O
genético	B-Sequence
determinantes	O
del	O
riesgo	O
trombótico	O
.	O

abreviaturas	O

B6	O
=	O
C57BL	O
/	O
6J	O

CSS	O
=	O
cromosoma	B-GENE
sustitución	B-Sequence
son	O

CSS	O
-	O
#	O
=	O
B6	O
-	O
cr	B-Sequence
#	O
A	O
/	O
J	O

CSS	O
-	O
#	O
F1	O
=	O
(	O
B6	O
x	O
CSS	O
-	O
#	O
)	O
F1	O

peso	B-Sequence
=	O
tipo	B-Sequence
salvaje	I-Sequence

-	O
/	O
-	O
=	O
deficiente	O

por	B-Protein
favor	I-Protein
=	O
plasminógeno	B-Protein

PAI	B-Protein
-	I-Protein
1	I-Protein
=	O
inhibidor	B-Protein
del	I-Protein
activador	I-Protein
del	I-Protein
plasminógeno	I-Protein
-	I-Protein
1	I-Protein

tPA	B-Protein
=	O
activador	B-Protein
tisular	I-Protein
del	I-Protein
plasminógeno	I-Protein

UPA	B-Protein
=	O
activador	B-Protein
de	I-Protein
plasminógeno	I-Protein
de	I-Protein
uroquinasa	I-Protein

SEM	O
=	O
error	O
estándar	O
de	O
la	O
media	O

QTL	B-Sequence
=	O
locus	B-Sequence
de	I-Sequence
rasgo	I-Sequence
cuantitativo	I-Sequence

Conflicto	O
de	O
intereses	O

El	O
autor	O
(	O
s	O
)	O
declara	O
que	O
no	O
tienen	O
intereses	O
en	O
competencia	O
.	O

Contribuciones	O
de	O
los	O
autores	O

JHP	O
concibió	O
y	O
diseñó	O
el	O
estudio	O
,	O
coordinó	O
los	O
experimentos	O
y	O
redactó	O
el	O
manuscrito	O
.	O

AS	O
desarrolló	O
y	O
realizó	O
el	O
ensayo	O
de	O
sangrado	O
de	O
la	O
cola	O
y	O
participó	O
en	O
la	O
redacción	O
del	O
manuscrito	O
.	O

EH	O
llevó	O
a	O
cabo	O
el	O
modelo	O
de	O
lesión	O
vascular	O
y	O
los	O
análisis	O
y	O
el	O
ensayo	O
de	O
sangrado	O
de	O
la	O
cola	O
,	O
participó	O
en	O
la	O
cola	O
colágeno	B-GENE
análisis	O
y	O
coordinación	O
de	O
los	O
ratón	B-Taxon
cría	O

JS	O
participó	O
en	O
el	O
análisis	O
de	O
los	O
resultados	O
del	O
modelo	O
de	O
lesión	O
vascular	O
y	O
colágeno	B-GENE
analiza	O

JHN	O
y	O
AHE	O
proporcionaron	O
las	O
parejas	O
reproductoras	O
CSS	O
,	O
JHN	O
participó	O
en	O
las	O
discusiones	O
de	O
los	O
resultados	O
y	O
JBS	O
y	O
JHN	O
desarrollaron	O
el	O
CSS	O
.	O

Todos	O
los	O
autores	O
han	O
leído	O
y	O
aprobado	O
el	O
manuscrito	O
final	O
.	O

Historial	O
previo	O
a	O
la	O
publicación	O

Se	O
puede	O
acceder	O
al	O
historial	O
previo	O
a	O
la	O
publicación	O
de	O
este	O
artículo	O
aquí	O
:	O

Agradecimientos	O

Los	O
autores	O
agradecen	O
al	O
Dr.	O
UN	O
.	O

Vasanji	O
,	O
Shiyang	O
Wang	O
y	O
Jenna	O
Saraniti	O
por	O
su	O
ayuda	O
con	O
los	O
análisis	O
de	O
imágenes	O
,	O
David	O
Hellard	O
por	O
realizar	O
las	O
mediciones	O
de	O
la	O
presión	O
arterial	O
,	O
Dr.	O
Y	O
.	O
Shchurina	O
para	O
el	O
plasminógeno	B-Protein
análisis	O
,	O
los	O
Dres	O
.	O

Lindsey	O
Burrage	O
y	O
Jonathan	O
Smith	O
por	O
sus	O
útiles	O
debates	O
y	O
Robin	O
Lewis	O
por	O
su	O
asistencia	O
en	O
la	O
preparación	O
del	O
manuscrito	O
.	O

Este	O
estudio	O
fue	O
apoyado	O
por	O
subvenciones	O
de	O
NIH	O
,	O
HL17964	O
,	O
HL65204	O
,	O
HL078701	O
(	O
JHP	O
)	O
,	O
T32	O
HL07914	O
(	O
AS	O
)	O
y	O
RR12305	O
(	O
JHN	O
)	O
.	O

CAF	B-GENE
-	I-GENE
1	I-GENE
es	O
esencial	O
para	O
heterocromatina	B-GENE
Organización	O
en	O
embriones	O
pluripotentes	O
Células	B-Cell

Resumen	O

Durante	O
mamífero	B-Taxon
desarrollo	O
,	O
cromatina	B-GENE
la	O
dinámica	O
y	O
el	O
marcado	O
epigenético	O
son	O
importantes	O
para	O
genoma	B-Sequence
reprogramación	O

Datos	O
recientes	O
sugieren	O
un	O
papel	O
importante	O
para	O
el	O
cromatina	B-GENE
maquinaria	O
de	O
montaje	O
en	O
este	O
proceso	O
.	O

Para	O
analizar	O
el	O
papel	O
de	O
factor	B-GENE
de	I-GENE
ensamblaje	I-GENE
de	I-GENE
cromatina	I-GENE
1	I-GENE
(	O
CAF	B-GENE
-	I-GENE
1	I-GENE
)	O
durante	O
el	O
desarrollo	O
previo	O
a	O
la	O
implantación	O
,	O
generamos	O
un	O
ratón	B-Taxon
línea	O
que	O
lleva	O
un	O
objetivo	O
mutación	B-Sequence
en	O
el	O
gene	B-Sequence
codificando	O
su	O
subunidad	O
grande	O
,	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
.	O

Pérdida	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
en	O
homocigoto	O
mutantes	B-Sequence
lleva	O
a	O
una	O
detención	O
del	O
desarrollo	O
a	O
los	O
16	O
-	O
célula	B-Cell
escenario	O
.	O

Ausencia	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
en	O
estos	O
embriones	O
resulta	O
en	O
severas	O
alteraciones	O
en	O
la	O
nuclear	B-GENE
organización	O
de	O
constitutivos	O
heterocromatina	B-GENE
.	O

Brindamos	O
evidencia	O
de	O
que	O
en	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
,	O
dominios	B-GENE
de	I-GENE
heterocromatina	I-GENE
están	O
ampliamente	O
reorganizados	O
entre	O
los	O
dos	O
-	O
célula	B-Cell
y	O
estadios	O
de	O
blastocisto	O
.	O

En	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
mutante	B-Sequence
-16	O
célula	B-Cell
embriones	O
en	O
etapa	O
,	O
la	O
organización	O
alterada	O
de	O
heterocromatina	B-GENE
presenta	O
similitudes	O
con	O
la	O
estructura	O
de	O
heterocromatina	B-GENE
en	O
dos	O
-	O
a	O
cuatro	O
-	O
célula	B-Cell
escenario	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
,	O
lo	O
que	O
sugiere	O
que	O
CAF	B-GENE
-	I-GENE
1	I-GENE
se	O
requiere	O
para	O
la	O
maduración	O
de	O
heterocromatina	B-GENE
durante	O
el	O
desarrollo	O
preimplantacional	O
.	O

en	O
embrionario	O
Células	B-Cell
madre	I-Cell
,	O
agotamiento	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
utilizando	O
ARN	B-Sequence
la	O
interferencia	O
da	O
como	O
resultado	O
la	O
mala	O
localización	O
,	O
la	O
pérdida	O
de	O
agrupamiento	O
y	O
la	O
descondensación	O
de	O
dominios	B-GENE
de	I-GENE
heterocromatina	I-GENE
pericéntricos	I-GENE
.	O

Además	O
,	O
la	O
pérdida	O
de	O
CAF	B-GENE
-	I-GENE
1	I-GENE
en	O
estos	O
células	B-Cell
resulta	O
en	O
la	O
alteración	O
de	O
la	O
epigenética	O
histona	B-Chemical
marcas	O
de	O
metilación	O
a	O
nivel	O
de	O
heterocromatina	B-GENE
pericéntrica	I-GENE
.	O

Estas	O
alteraciones	O
de	O
heterocromatina	B-GENE
no	O
se	O
encuentran	O
en	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
ratón	B-Taxon
embrionario	O
fibroblastos	B-Cell
,	O
que	O
son	O
células	B-Cell
que	O
ya	O
están	O
comprometidos	O
con	O
el	O
linaje	O
,	O
lo	O
que	O
sugiere	O
que	O
CAF	B-GENE
-	I-GENE
1	I-GENE
se	O
requiere	O
específicamente	O
para	O
heterocromatina	B-GENE
organización	O
en	O
embriones	O
pluripotentes	O
células	B-Cell
.	O

Nuestros	O
hallazgos	O
subrayan	O
el	O
papel	O
de	O
la	O
cromatina	B-GENE
maquinaria	O
de	O
montaje	O
en	O
el	O
control	O
de	O
la	O
organización	O
espacial	O
y	O
el	O
marcado	O
epigenético	O
de	O
la	O
genoma	B-Sequence
en	O
embriones	O
tempranos	O
y	O
embrionarios	O
Células	B-Cell
madre	I-Cell
.	O

Sinopsis	O

cromatina	B-GENE
es	O
el	O
apoyo	O
de	O
nuestro	O
genético	B-Sequence
información	O
.	O

Se	O
compone	O
de	O
numerosas	O
unidades	O
repetidas	O
llamadas	O
nucleosomas	B-GENE
en	O
el	O
cual	O
ADN	B-Sequence
envuelve	O
un	O
núcleo	O
de	O
proteínas	B-Chemical
histonas	I-Chemical
.	O

Modificaciones	O
en	O
la	O
composición	O
y	O
propiedades	O
bioquímicas	O
de	O
nucleosomas	B-GENE
desempeñar	O
un	O
papel	O
importante	O
en	O
la	O
regulación	O
de	O
genoma	B-Sequence
función	O

``	O
Tales	O
modificaciones	O
se	O
denominan	O
``	O
''	O
epigenéticas	O
''	O
''	O
cuando	O
se	O
heredan	O
a	O
través	O
de	O
''	O
célula	B-Cell
divisiones	O
y	O
conferir	O
nueva	O
información	O
a	O
cromatina	B-GENE
,	O
además	O
de	O
genético	B-Sequence
información	O
proporcionada	O
por	O
ADN	B-Sequence
.	O

Generalmente	O
se	O
cree	O
que	O
durante	O
genoma	B-Sequence
replicación	O
,	O
lo	O
básico	O
cromatina	B-GENE
``	O
la	O
maquinaria	O
de	O
montaje	O
acumula	O
``	O
''	O
ingenuidad	O
''	O
''	O
''	O
nucleosomas	B-GENE
y	O
,	O
en	O
un	O
paso	O
posterior	O
,	O
nucleosomas	B-GENE
son	O
selectivamente	O
modificado	B-Sequence
por	O
una	O
serie	O
de	O
enzimas	B-Sequence
adquirir	O
información	O
epigenética	O
.	O

Aquí	O
,	O
los	O
autores	O
estudiaron	O
el	O
papel	O
de	O
un	O
cromatina	B-GENE
factor	O
de	O
montaje	O
(	O
CAF	B-GENE
-	I-GENE
1	I-GENE
)	O
en	O
ratón	B-Taxon
embrionario	O
Células	B-Cell
madre	I-Cell
y	O
embriones	O
tempranos	O
.	O

Sorprendentemente	O
,	O
muestran	O
que	O
CAF	B-GENE
-	I-GENE
1	I-GENE
Confiere	O
información	O
epigenética	O
a	O
determinados	O
regiones	B-Sequence
genómicas	I-Sequence
.	O

Además	O
,	O
este	O
estudio	O
reveló	O
que	O
CAF	B-GENE
-	I-GENE
1	I-GENE
es	O
necesario	O
para	O
la	O
correcta	O
organización	O
espacial	O
de	O
cromosomas	B-GENE
en	I-GENE
el	I-GENE
nucleo	I-GENE
.	O

Este	O
nuevo	O
conocimiento	O
puede	O
contribuir	O
a	O
una	O
mejor	O
comprensión	O
del	O
papel	O
de	O
cromatina	B-GENE
en	O
el	O
mantenimiento	O
del	O
embrión	O
célula	B-Cell
madre	I-Cell
identidad	O
y	O
plasticidad	O
.	O

Introducción	O

Durante	O
ratón	B-Taxon
desarrollo	O
previo	O
a	O
la	O
implantación	O
,	O
el	O
genoma	B-Sequence
sufre	O
una	O
serie	O
de	O
importantes	O
cambios	O
epigenéticos	O
necesarios	O
para	O
el	O
desarrollo	O
embrionario	O
.	O
gene	B-Sequence
expresión	O
,	O
el	O
mantenimiento	O
de	O
la	O
totipotencia	O
y	O
los	O
primeros	O
eventos	O
de	O
diferenciación	O
[	O
1	O
,	O
2	O
]	O
.	O

Si	O
bien	O
muchos	O
estudios	O
han	O
establecido	O
la	O
importancia	O
de	O
ADN	B-Sequence
metilación	O
en	O
la	O
reprogramación	O
epigenética	O
,	O
los	O
datos	O
recientes	O
apuntan	O
a	O
un	O
papel	O
crucial	O
de	O
cromatina	B-GENE
en	O
este	O
proceso	O
[	O
3	O
-	O
5	O
]	O
.	O

Sin	O
embargo	O
,	O
sabemos	O
muy	O
poco	O
sobre	O
el	O
papel	O
de	O
histona	B-Chemical
enzimas	B-Sequence
modificadoras	I-Sequence
,	O
cromatina	B-GENE
factores	O
de	O
remodelación	O
y	O
histona	B-Chemical
chaperonas	O
durante	O
el	O
desarrollo	O
previo	O
a	O
la	O
implantación	O
,	O
o	O
en	O
Células	B-Cell
madre	I-Cell
derivados	O
de	O
embriones	O
tempranos	O
[	O
6	O
]	O
.	O

Un	O
subconjunto	O
de	O
identificados	O
histona	B-Chemical
acompañantes	O
y	O
complejos	B-GENE
remodeladores	I-GENE
de	I-GENE
cromatina	I-GENE
puede	O
colaborar	O
para	O
promover	O
nucleosoma	B-GENE
ensamblaje	O
in	O
vitro	O
y	O
,	O
por	O
lo	O
tanto	O
,	O
se	O
encuentran	O
en	O
una	O
posición	O
estratégica	O
para	O
controlar	O
cromatina	B-GENE
montaje	O
y	O
maduración	O
durante	O
el	O
desarrollo	O
[	O
7	O
,	O
8	O
]	O
.	O

Entre	O
histona	B-Chemical
acompañantes	O
,	O
factor	B-GENE
de	I-GENE
ensamblaje	I-GENE
de	I-GENE
cromatina	I-GENE
1	I-GENE
(	O
CAF	B-GENE
-	I-GENE
1	I-GENE
)	O
es	O
una	O
subunidad	O
de	O
tres	O
(	O
p150	B-Protein
,	O
p60	B-Protein
,	O
y	O
p48	B-Protein
)	O
complejo	B-GENE
que	O
promueve	O
histona	B-Chemical
Deposición	O
de	O
H3	O
y	O
H4	O
en	O
recién	O
sintetizados	O
ADN	B-Sequence
durante	O
la	O
replicación	O
o	O
ADN	B-Sequence
reparación	O
[	O
9	O
,	O
10	O
]	O
.	O

Específicamente	O
,	O
CAF	B-GENE
-	I-GENE
1	I-GENE
deposita	O
el	O
histona	B-Chemical
H3	O
variante	B-Sequence
H3	O
.	O
1	O
en	O
cromatina	B-GENE
,	O
en	O
una	O
vía	O
acoplada	O
a	O
ADN	B-Sequence
síntesis	O
,	O
mientras	O
que	O
una	O
segunda	O
histona	B-Chemical
acompañante	O
,	O
HIRA	B-Protein
,	O
participa	O
en	O
la	O
deposición	O
del	O
H3	O
.	O
3	O
variante	B-Sequence
en	O
un	O
ADN	B-Sequence
vía	O
independiente	O
de	O
síntesis	O
[	O
11	O
,	O
12	O
]	O
.	O

Además	O
de	O
este	O
específico	O
cromatina	B-GENE
actividad	O
de	O
montaje	O
,	O
CAF	B-GENE
-	I-GENE
1	I-GENE
interactúa	O
con	O
varios	O
proteinas	B-Chemical
presentar	O
en	O
heterocromatina	B-GENE
,	O
incluyendo	O
heterocromatina	B-GENE
proteína	B-Chemical
1	O
(	O
HP1	O
)	O
y	O
MBD1	B-Protein
,	O
a	O
metilo	B-Chemical
#	O
¿NOMBRE	O
?	O
dominio	B-Sequence
proteína	B-Chemical
que	O
recluta	O
histona	B-Chemical
desacetilasa	O
y	O
represiva	O
histona	B-Chemical
actividades	O
de	O
metiltransferasa	O
[	O
13	O
-	O
15	O
]	O
.	O

Es	O
más	O
,	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
se	O
requiere	O
para	O
garantizar	O
una	O
replicación	O
:	O
grupo	O
específico	O
de	O
HP1	O
moléculas	B-Chemical
en	O
sitios	B-Sequence
de	I-Sequence
replicación	I-Sequence
en	O
heterocromatina	B-GENE
pericéntrica	I-GENE
durante	O
la	O
fase	O
S	O
media	O
-	O
tardía	O
[	O
16	O
]	O
.	O

Tomados	O
en	O
conjunto	O
,	O
estos	O
datos	O
sugieren	O
roles	O
para	O
CAF	B-GENE
-	I-GENE
1	I-GENE
en	O
la	O
formación	O
de	O
heterocromatina	B-GENE
y	O
en	O
la	O
heredabilidad	O
de	O
los	O
rasgos	O
epigenéticos	O
.	O

Si	O
bien	O
la	O
función	O
de	O
este	O
conservado	B-Sequence
evolutivamente	I-Sequence
histona	B-Chemical
chaperona	O
ha	O
sido	O
estudiada	O
bioquímicamente	O
extensamente	O
,	O
todavía	O
carecemos	O
de	O
información	O
sobre	O
su	O
importancia	O
durante	O
el	O
desarrollo	O
temprano	O
en	O
mamíferos	B-Taxon
y	O
en	O
pluripotentes	O
células	B-Cell
como	O
embrionario	O
células	B-Cell
madre	I-Cell
(	I-Cell
ES	I-Cell
)	I-Cell
.	O

Aquí	O
hemos	O
analizado	O
la	O
importancia	O
de	O
CAF	B-GENE
-	I-GENE
1	I-GENE
durante	O
temprano	O
ratón	B-Taxon
desarrollo	O
por	O
genético	B-Sequence
ablación	O
y	O
en	O
ES	O
células	B-Cell
por	O
agotamiento	O
usando	O
ARN	B-Sequence
interferencia	O
(	O
ARNi	O
)	O
.	O

Mostramos	O
que	O
CAF	B-GENE
-	I-GENE
1	I-GENE
es	O
esencial	O
para	O
la	O
viabilidad	O
en	O
los	O
primeros	O
ratón	B-Taxon
embriones	O
y	O
ES	O
células	B-Cell
.	O

Brindamos	O
evidencia	O
de	O
que	O
CAF	B-GENE
-	I-GENE
1	I-GENE
se	O
requiere	O
para	O
la	O
organización	O
espacial	O
y	O
el	O
marcado	O
epigenético	O
de	O
dominios	B-GENE
de	I-GENE
heterocromatina	I-GENE
en	O
embriones	O
pluripotentes	O
células	B-Cell
.	O

Resultados	O

Nosotros	O
usamos	O
gene	B-Sequence
orientación	O
en	O
ES	O
células	B-Cell
para	O
eliminar	B-Sequence
exón	I-Sequence
3	O
en	O
el	O
Chaf1a	B-Protein
gene	B-Sequence
,	O
que	O
codifica	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
(	O
Figura	O
1A	O
)	O
.	O

Chaf1a	B-Protein
+	B-Sequence
/	O
-	O
ratones	B-Taxon
nacieron	O
con	O
una	O
frecuencia	O
mendeliana	O
,	O
eran	O
de	O
tamaño	O
y	O
peso	O
normales	O
,	O
no	O
mostraban	O
anormalidades	O
obvias	O
y	O
eran	O
fértiles	O
.	O

Cruce	O
heterocigoto	O
ratones	B-Taxon
no	O
logró	O
generar	O
un	O
recién	O
nacido	O
viable	O
Chaf1a	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
.	O

Además	O
,	O
ningún	O
homocigoto	O
Chaf1a	B-Protein
-/-	O
se	O
detectaron	O
embriones	O
en	O
cualquiera	O
de	O
las	O
etapas	O
posteriores	O
a	O
la	O
implantación	O
.	O

Sin	O
embargo	O
,	O
pudimos	O
detectar	O
Chaf1a	B-Protein
-/-	O
embriones	O
en	O
el	O
día	O
embrionario	O
4	O
(	O
E4	O
)	O
utilizando	O
una	O
estrategia	O
de	O
PCR	O
(	O
Figura	O
1B	O
)	O
.	O

Representan	O
sólo	O
el	O
10	O
%	O
de	O
los	O
embriones	O
E4	O
obtenidos	O
de	O
Chaf1a	B-Protein
+	B-Sequence
/	O
-	O
ratones	B-Taxon
se	O
entrecruza	O
,	O
lo	O
que	O
sugiere	O
que	O
más	O
de	O
la	O
mitad	O
de	O
los	O
homocigotos	O
mutante	B-Sequence
los	O
embriones	O
habían	O
degenerado	O
antes	O
de	O
esta	O
etapa	O
.	O

Es	O
más	O
,	O
mutante	B-Sequence
embriones	O
contenían	O
sólo	O
ocho	O
a	O
16	O
células	B-Cell
en	O
la	O
etapa	O
E4	O
,	O
en	O
lugar	O
de	O
32	O
células	B-Cell
observado	O
por	O
tipo	B-Sequence
salvaje	I-Sequence
o	O
blastocistos	O
heterocigóticos	O
(	O
Figura	O
1C	O
y	O
1D	O
)	O
.	O

Un	O
análisis	O
posterior	O
por	O
microscopía	O
óptica	O
usando	O
inmunofluorescencia	O
(	O
IF	O
)	O
nos	O
permitió	O
comparar	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O

Una	O
pérdida	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
la	O
tinción	O
no	O
se	O
pudo	O
detectar	O
antes	O
de	O
las	O
ocho	O
-	O
célula	B-Cell
etapa	O
(	O
datos	O
no	O
publicados	O
)	O
que	O
sugiere	O
que	O
la	O
madre	O
contribuyó	O
proteína	B-Chemical
está	O
presente	O
en	O
el	O
embrión	O
hasta	O
los	O
cuatro	O
-	O
célula	B-Cell
escenario	O
.	O

Así	O
,	O
el	O
agotamiento	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
proteína	B-Chemical
a	O
partir	O
de	O
esta	O
etapa	O
permite	O
un	O
máximo	O
de	O
dos	O
adicionales	O
célula	B-Cell
divisiones	O
antes	O
de	O
la	O
detención	O
del	O
desarrollo	O
.	O

Sorprendentemente	O
,	O
encontramos	O
que	O
el	O
nuclear	B-GENE
organización	O
de	O
heterocromatina	B-GENE
apareció	O
anormal	O
en	O
el	O
núcleos	B-GENE
de	O
Chaf1a	B-Protein
-	O
/	O
-	O
embriones	O
.	O

heterocromatina	B-GENE
pericéntrica	I-GENE
,	O
el	O
principal	O
componente	O
de	O
la	O
constitución	O
heterocromatina	B-GENE
se	O
puede	O
visualizar	O
fácilmente	O
en	O
interfase	O
núcleos	B-GENE
por	O
el	O
fluorocromo	O
DAPI	O
y	O
por	O
inmunotinción	O
con	O
HP1	B-Protein
alfa	I-Protein
[	O
16	O
,	O
17	O
-	O
19	O
]	O
.	O

En	O
tipo	B-Sequence
salvaje	I-Sequence
blastocistos	O
y	O
en	O
ratón	B-Taxon
somático	O
células	B-Cell
,	O
dominios	B-GENE
de	I-GENE
heterocromatina	I-GENE
pericéntricos	I-GENE
agruparse	O
y	O
formar	O
un	O
orden	O
superior	O
estructuras	B-GENE
de	I-GENE
cromatina	I-GENE
llamado	O
cromocentros	B-GENE
[	O
20	O
]	O
,	O
que	O
se	O
visualizan	O
como	O
focos	O
densos	O
en	O
DAPI	O
(	O
Figura	O
1C	O
)	O
.	O

Estas	O
estructuras	O
no	O
se	O
detectaron	O
en	O
Chaf1a	B-Protein
-	O
/	O
-	O
embriones	O
(	O
Figura	O
1D	O
)	O
.	O

Ya	O
que	O
cromatina	B-GENE
arquitectura	O
y	O
estructuras	O
de	O
orden	O
superior	O
son	O
importantes	O
para	O
genoma	B-Sequence
función	O
[	O
21	O
]	O
,	O
decidimos	O
caracterizar	O
este	O
fenotipo	O
con	O
más	O
detalle	O
.	O

Para	O
ello	O
,	O
examinamos	O
el	O
estado	O
de	O
heterocromatina	B-GENE
organización	O
entre	O
los	O
dos	O
-	O
célula	B-Cell
y	O
estadios	O
de	O
blastocisto	O
.	O

En	O
dos	O
-	O
célula	B-Cell
escenario	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
,	O
la	O
tinción	O
DAPI	O
es	O
difusa	O
y	O
fibrilar	O
,	O
con	O
regiones	O
de	O
mayor	O
densidad	O
alrededor	O
del	O
cuerpos	B-GENE
precursores	I-GENE
nucleolares	I-GENE
(	O
Figura	O
1E	O
)	O
.	O

Dominios	B-GENE
de	I-GENE
heterocromatina	I-GENE
se	O
ensamblan	O
progresivamente	O
en	O
DAPI	O
-	O
focos	O
densos	O
entre	O
los	O
cuatro	O
-	O
célula	B-Cell
y	O
32	O
-	O
célula	B-Cell
estadios	O
de	O
blastocisto	O
(	O
Figura	O
1F	O
)	O
.	O

Localización	O
de	O
HP1	B-Protein
alfa	I-Protein
confirmó	O
que	O
las	O
estructuras	O
visualizadas	O
por	O
tinción	O
DAPI	O
corresponden	O
a	O
constitutivas	O
heterocromatina	B-GENE
(	O
Figura	O
1E	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
la	O
nuclear	B-GENE
organización	O
de	O
heterocromatina	B-GENE
se	O
modifica	O
dramáticamente	O
durante	O
el	O
desarrollo	O
previo	O
a	O
la	O
implantación	O
,	O
entre	O
los	O
dos	O
-	O
célula	B-Cell
y	O
estadios	O
de	O
blastocisto	O
.	O

En	O
Chaf1a	B-Protein
-	O
/	O
-	O
Embriones	O
E4	O
,	O
que	O
se	O
detienen	O
entre	O
los	O
ocho	O
-	O
y	O
16	O
-	O
célula	B-Cell
etapa	O
,	O
los	O
focos	O
densos	O
en	O
DAPI	O
eran	O
apenas	O
detectables	O
(	O
Figura	O
1D	O
)	O
.	O

En	O
cambio	O
,	O
la	O
tinción	O
DAPI	O
fue	O
difusa	O
dentro	O
del	O
núcleo	B-GENE
,	O
con	O
regiones	O
de	O
mayor	O
densidad	O
alrededor	O
del	O
nucleolos	B-GENE
y	O
en	O
la	O
periferia	O
del	O
núcleos	B-GENE
(	O
Figura	O
1D	O
)	O
.	O

Localización	O
de	O
HP1	B-Protein
alfa	I-Protein
mostró	O
un	O
patrón	O
difuso	O
similar	O
al	O
DAPI	O
,	O
con	O
algo	O
de	O
enriquecimiento	O
en	O
el	O
nuclear	B-GENE
periferia	O
y	O
alrededor	O
del	O
nucleolos	B-GENE
(	O
Figura	O
1D	O
)	O
.	O

Esta	O
organización	O
anormal	O
de	O
heterocromatina	B-GENE
en	O
Chaf1a	B-Protein
-	O
/	O
-	O
embriones	O
es	O
una	O
reminiscencia	O
de	O
la	O
heterocromatina	B-GENE
organización	O
encontrada	O
en	O
dos	O
-	O
a	O
cuatro	O
-	O
célula	B-Cell
escenario	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O
(	O
comparar	O
la	O
Figura	O
1D	O
y	O
1F	O
)	O
.	O

Estos	O
datos	O
evidencian	O
un	O
papel	O
clave	O
para	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
durante	O
el	O
desarrollo	O
previo	O
a	O
la	O
implantación	O
,	O
y	O
revelan	O
que	O
este	O
proteína	B-Chemical
se	O
requiere	O
para	O
la	O
correcta	O
organización	O
3	O
-	O
D	O
de	O
heterocromatina	B-GENE
dentro	I-GENE
de	I-GENE
los	I-GENE
núcleos	I-GENE
de	I-GENE
células	I-GENE
embrionarias	I-GENE
.	O

A	O
continuación	O
,	O
nos	O
preguntamos	O
si	O
un	O
requisito	O
similar	O
para	O
CAF	B-GENE
-	I-GENE
1	I-GENE
también	O
se	O
pudo	O
observar	O
en	O
ES	O
células	B-Cell
que	O
se	O
derivan	O
del	O
interior	O
del	O
blastocisto	O
célula	B-Cell
masa	O
.	O

Dada	O
la	O
detención	O
temprana	O
del	O
desarrollo	O
observada	O
en	O
Chaf1a	B-Protein
-	O
/	O
-	O
embriones	O
,	O
tales	O
células	B-Cell
no	O
podía	O
derivarse	O
directamente	O
de	O
embriones	O
nulos	O
,	O
por	O
lo	O
que	O
utilizamos	O
una	O
estrategia	O
de	O
ARNi	O
(	O
Figura	O
2A	O
)	O
.	O

p150CAF	B-Protein
-	I-Protein
1	I-Protein
caída	O
en	O
ES	O
células	B-Cell
se	O
cuantificó	O
mediante	O
análisis	O
de	O
transferencia	O
Western	O
e	O
IF	O
.	O

(	O
Figura	O
S1	O
)	O
.	O

p150CAF	B-Protein
-	I-Protein
1	I-Protein
ARNi	O
-	O
ES	O
empobrecido	O
células	B-Cell
muestra	O
un	O
fenotipo	O
muy	O
similar	O
al	O
células	B-Cell
de	O
Chaf1a	B-Protein
-	O
/	O
-	O
E4	O
ratones	B-Taxon
.	O

Se	O
perdieron	O
los	O
focos	O
densos	O
en	O
DAPI	O
y	O
se	O
observaron	O
HP1	B-Protein
alfa	I-Protein
y	O
tinción	O
DAPI	O
alrededor	O
del	O
nucleolos	B-GENE
y	O
en	O
la	O
periferia	O
del	O
núcleo	B-GENE
(	O
Figura	O
2B	O
)	O
.	O

Este	O
resultado	O
indica	O
que	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
es	O
esencial	O
para	O
nuclear	B-GENE
organización	O
de	O
heterocromatina	B-GENE
en	O
ES	O
células	B-Cell
de	O
manera	O
similar	O
a	O
los	O
embriones	O
de	O
preimplantación	O
temprana	O
.	O

Sorprendentemente	O
,	O
no	O
observamos	O
esta	O
severa	O
alteración	O
en	O
heterocromatina	B-GENE
organización	O
en	O
primaria	O
ratón	B-Taxon
embrionario	O
fibroblastos	B-Cell
(	O
MEF	O
)	O
siguientes	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
agotamiento	O
por	O
ARNi	O
.	O

p150CAF	B-Protein
-	I-Protein
1	I-Protein
El	O
agotamiento	O
en	O
MEF	O
resultó	O
en	O
una	O
fuerte	O
inhibición	O
de	O
célula	B-Cell
proliferación	O
(	O
datos	O
no	O
publicados	O
)	O
,	O
pero	O
no	O
alteró	O
el	O
agrupamiento	O
de	O
dominios	B-GENE
de	I-GENE
heterocromatina	I-GENE
(	O
Figuras	O
2C	O
y	O
S2	O
)	O
.	O

Similar	O
,	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
agotamiento	O
en	O
3T3	O
células	B-Cell
no	O
afectó	O
heterocromatina	B-GENE
organización	O
[	O
16	O
]	O
.	O

Estas	O
observaciones	O
revelan	O
una	O
función	O
específica	O
para	O
CAF	B-GENE
-	I-GENE
1	I-GENE
en	O
el	O
embrión	O
temprano	O
y	O
ES	O
células	B-Cell
.	O

También	O
nos	O
preguntamos	O
si	O
la	O
pérdida	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
en	O
ES	O
células	B-Cell
afecta	O
específicamente	O
a	O
la	O
subcompartimento	B-GENE
nuclear	I-GENE
de	I-GENE
heterocromatina	I-GENE
,	O
o	O
si	O
podría	O
resultar	O
en	O
una	O
pérdida	O
más	O
global	O
de	O
nuclear	B-GENE
organización	O
y	O
arquitectura	O
.	O

Utilizamos	O
un	O
específico	O
anticuerpo	B-GENE
en	O
contra	O
de	O
leucemia	B-Protein
promielocítica	I-Protein
(	O
LMP	B-Protein
)	O
proteína	B-Chemical
para	O
estudiar	O
el	O
destino	O
de	O
los	O
cuerpos	B-GENE
nucleares	I-GENE
PML	I-GENE
,	O
que	O
están	O
bien	O
caracterizados	O
estructuras	B-GENE
subnucleares	I-GENE
[	O
22	O
]	O
.	O

No	O
pudimos	O
detectar	O
ninguna	O
diferencia	O
significativa	O
en	O
la	O
distribución	O
y	O
el	O
aspecto	O
de	O
cuerpos	B-GENE
nucleares	I-GENE
PML	I-GENE
entre	O
controlar	O
y	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
(	O
Figura	O
2D	O
)	O
.	O

Estos	O
datos	O
muestran	O
que	O
nuclear	B-GENE
la	O
arquitectura	O
no	O
se	O
altera	O
globalmente	O
siguiendo	O
CAF	B-GENE
-	I-GENE
1	I-GENE
pérdida	O
de	O
función	O
.	O

Además	O
,	O
el	O
análisis	O
de	O
Western	O
blot	O
reveló	O
que	O
CAF	B-GENE
-	I-GENE
1	I-GENE
el	O
agotamiento	O
no	O
resultó	O
en	O
niveles	O
alterados	O
de	O
cromatina	B-GENE
arquitectónico	O
proteinas	B-Chemical
tal	O
como	O
histona	B-Chemical
H3	O
y	O
HP1	B-Protein
alfa	I-Protein
(	O
Figura	O
S1	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
CAF	B-GENE
-	I-GENE
1	I-GENE
se	O
requiere	O
específicamente	O
en	O
embriones	O
tempranos	O
y	O
en	O
ES	O
células	B-Cell
para	O
la	O
correcta	O
organización	O
de	O
la	O
compartimento	B-GENE
subnuclear	I-GENE
de	I-GENE
heterocromatina	I-GENE
.	O

Estudios	O
previos	O
realizados	O
en	O
mamífero	B-Taxon
célula	B-Cell
Las	O
líneas	O
mostraron	O
que	O
CAF	B-GENE
-	I-GENE
1	I-GENE
se	O
requiere	O
actividad	O
para	O
la	O
progresión	O
de	O
la	O
fase	O
S	O
[	O
16	O
,	O
23	O
,	O
24	O
]	O
.	O

Mostramos	O
aquí	O
que	O
3	O
días	O
después	O
de	O
la	O
transfección	O
del	O
ARNi	O
vector	B-Sequence
,	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
(	O
identificado	O
por	O
una	O
ausencia	O
total	O
de	O
CAF	B-GENE
-	I-GENE
1	I-GENE
IF	O
señal	O
)	O
aparecen	O
aún	O
activos	O
para	O
la	O
replicación	O
,	O
como	O
lo	O
revela	O
incorporación	B-Sequence
de	O
El	O
análogo	B-Chemical
de	I-Chemical
timidina	I-Chemical
bromodesoxiuridina	O
(	O
BrdU	O
)	O
(	O
Figura	O
3A	O
)	O
,	O
la	O
PCNA	B-Protein
(	O
antígeno	B-Protein
nuclear	I-Protein
de	I-Protein
células	I-Protein
en	I-Protein
proliferación	I-Protein
)	O
patrón	O
(	O
Figura	O
3B	O
)	O
y	O
análisis	O
de	O
citometría	O
de	O
flujo	O
(	O
Figura	O
3C	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
en	O
estos	O
células	B-Cell
,	O
ADN	B-Sequence
la	O
replicación	O
persiste	O
a	O
pesar	O
de	O
los	O
cambios	O
drásticos	O
en	O
heterocromatina	B-GENE
organización	O

Sin	O
embargo	O
,	O
24	O
h	O
después	O
,	O
ES	O
células	B-Cell
dejar	O
de	O
proliferar	O
y	O
morir	O
,	O
revelando	O
que	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
se	O
requiere	O
para	O
un	O
esencial	O
celular	B-Cell
proceso	O
,	O
como	O
en	O
los	O
embriones	O
.	O

En	O
conjunto	O
,	O
nuestros	O
datos	O
demuestran	O
que	O
la	O
pérdida	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
función	O
en	O
ES	O
células	B-Cell
y	O
embriones	O
tempranos	O
altera	O
primero	O
la	O
organización	O
de	O
heterocromatina	B-GENE
en	I-GENE
el	I-GENE
núcleo	I-GENE
y	O
,	O
en	O
un	O
paso	O
posterior	O
,	O
célula	B-Cell
ciclo	O
y	O
viabilidad	O
.	O

Para	O
caracterizar	O
mejor	O
los	O
defectos	O
de	O
heterocromatina	B-GENE
organización	O
,	O
realizamos	O
dos	O
colores	O
ADN	B-Sequence
experimentos	O
de	O
hibridación	O
in	O
situ	O
con	O
fluorescencia	O
(	O
FISH	O
)	O
para	O
revelar	O
la	O
distribución	O
espacial	O
de	O
regiones	B-GENE
cromosómicas	I-GENE
pericéntricas	I-GENE
y	I-GENE
céntricas	I-GENE
,	O
En	O
cual	O
ratón	B-Taxon
se	O
componen	O
principalmente	O
de	O
grandes	O
bloques	O
de	O
mayor	O
y	O
menor	O
repeticiones	B-Sequence
de	I-Sequence
satélite	I-Sequence
,	O
respectivamente	O
[	O
20	O
]	O
.	O

Dominios	B-GENE
pericéntricos	I-GENE
de	I-GENE
diferentes	I-GENE
cromosomas	I-GENE
forman	O
grupos	O
,	O
que	O
son	O
revelados	O
por	O
FISH	O
como	O
manchas	O
grandes	O
que	O
coinciden	O
con	O
focos	O
densos	O
en	O
DAPI	O
en	O
la	O
interfase	O
núcleo	B-GENE
(	O
Figura	O
4A	O
)	O
.	O

En	O
la	O
periferia	O
de	O
cada	O
dominio	B-GENE
pericéntrico	I-GENE
,	O
céntrico	O
regiones	B-Sequence
forman	O
entidades	O
individuales	O
(	O
Figura	O
4A	O
)	O
.	O

En	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
ARNi	O
-	O
agotado	O
células	B-Cell
,	O
observamos	O
una	O
interrupción	O
de	O
heterocromatina	B-GENE
pericéntrica	I-GENE
grupos	O
que	O
coincide	O
con	O
la	O
desaparición	O
de	O
focos	O
densos	O
en	O
DAPI	O
(	O
Figura	O
4B	O
)	O
.	O

Individual	O
dominios	B-GENE
pericéntricos	I-GENE
de	I-GENE
cromosomas	I-GENE
individuales	I-GENE
ahora	O
se	O
encuentran	O
aislados	O
o	O
agregados	O
en	O
un	O
patrón	O
menos	O
denso	O
que	O
los	O
grupos	O
regulares	O
observados	O
en	O
el	O
control	O
células	B-Cell
(	O
Figura	O
4B	O
)	O
.	O

Estos	O
agregados	O
,	O
que	O
a	O
menudo	O
se	O
encuentran	O
en	O
la	O
nuclear	B-GENE
periferia	O
,	O
también	O
se	O
revelan	O
mediante	O
la	O
tinción	O
DAPI	O
como	O
una	O
firma	O
típica	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
pérdida	O
de	O
función	O
.	O

Cuantificación	O
de	O
la	O
fluorescencia	O
a	O
lo	O
largo	O
de	O
una	O
línea	O
trazada	O
aleatoriamente	O
a	O
lo	O
largo	O
de	O
la	O
núcleo	B-GENE
reveló	O
una	O
menor	O
intensidad	O
de	O
fluorescencia	O
y	O
una	O
distribución	O
más	O
amplia	O
de	O
DAPI	O
y	O
principales	O
satélite	B-Sequence
señales	O
de	O
hibridación	O
en	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
(	O
Figura	O
4C	O
y	O
4D	O
)	O
,	O
indicando	O
descondensación	O
de	O
dominios	B-GENE
de	I-GENE
heterocromatina	I-GENE
pericéntricos	I-GENE
.	O

En	O
cambio	O
,	O
céntrico	O
dominios	B-Sequence
mostró	O
una	O
intensidad	O
y	O
forma	O
similar	O
al	O
control	O
células	B-Cell
,	O
sugiriendo	O
que	O
no	O
se	O
ven	O
afectados	O
por	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
agotamiento	O
(	O
Figura	O
4C	O
y	O
4D	O
)	O
.	O

En	O
conclusión	O
,	O
estos	O
resultados	O
muestran	O
que	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
se	O
requiere	O
para	O
la	O
adecuada	O
condensación	O
y	O
agrupamiento	O
de	O
dominios	B-GENE
de	I-GENE
heterocromatina	I-GENE
pericéntricos	I-GENE
.	O

Dado	O
el	O
papel	O
conocido	O
de	O
CAF	B-GENE
-	I-GENE
1	I-GENE
en	O
la	O
deposición	O
de	O
histona	B-Chemical
H3	O
.	O
1	O
y	O
H4	O
asociados	O
con	O
ADN	B-Sequence
síntesis	O
[	O
11	O
,	O
12	O
]	O
,	O
nos	O
preguntamos	O
si	O
este	O
defecto	O
en	O
el	O
orden	O
superior	O
cromatina	B-GENE
organización	O
podría	O
reflejar	O
una	O
aberrante	O
nucleosomal	B-GENE
organización	O

Utilizando	O
ADNasa	B-Protein
I	I-Protein
ensayos	O
de	O
nucleasa	O
microcócica	O
(	O
MNasa	O
)	O
,	O
no	O
pudimos	O
observar	O
ninguna	O
diferencia	O
significativa	O
entre	O
el	O
control	O
y	O
el	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
a	O
nivel	O
de	O
volumen	O
genoma	B-Sequence
cromatina	B-GENE
o	O
en	O
pericéntrico	B-GENE
repite	B-Sequence
(	O
Figura	O
5	O
)	O
.	O

En	O
una	O
segunda	O
serie	O
de	O
experimentos	O
,	O
comparamos	O
la	O
asociación	O
de	O
histona	B-Chemical
H3	O
con	O
cromatina	B-GENE
en	I-GENE
núcleos	I-GENE
aislado	O
de	O
células	B-Cell
transfectado	O
con	O
control	O
y	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
ARNi	O
Vectores	B-Sequence
de	I-Sequence
plásmido	I-Sequence
.	O

Núcleos	B-GENE
se	O
incubaron	O
en	O
tampones	O
con	O
diferentes	O
sal	B-Chemical
concentraciones	O
que	O
van	O
desde	O
100	O
mM	O
NaCl	B-Chemical
a	O
1M	O
NaCl	B-Chemical
.	O

En	O
todas	O
las	O
condiciones	O
,	O
la	O
cantidad	O
de	O
histona	B-Chemical
H3	O
restante	O
asociado	O
con	O
cromatina	B-GENE
era	O
indistinguible	O
en	O
control	O
y	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
(	O
datos	O
no	O
publicados	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
la	O
pérdida	O
de	O
agrupamiento	O
y	O
descondensación	O
de	O
heterocromatina	B-GENE
pericéntrica	I-GENE
es	O
improbable	O
que	O
sea	O
la	O
consecuencia	O
de	O
defectos	O
severos	O
en	O
nucleosomal	B-GENE
organización	O

Nuestros	O
hallazgos	O
mostraron	O
que	O
la	O
nuclear	B-GENE
localización	O
de	O
HP1	B-Protein
alfa	I-Protein
está	O
severamente	O
alterado	O
en	O
Chaf1a	B-Protein
-	O
/	O
-	O
embriones	O
y	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
.	O

Por	O
lo	O
tanto	O
,	O
examinamos	O
el	O
estado	O
de	O
otras	O
marcas	O
epigenéticas	O
que	O
previamente	O
se	O
mostró	O
que	O
caracterizan	O
heterocromatina	B-GENE
pericéntrica	I-GENE
.	O

Primero	O
probamos	O
ADN	B-Sequence
Metilación	O
de	O
CpG	O
[	O
25	O
]	O
en	O
las	O
principales	O
repeticiones	B-Sequence
de	I-Sequence
satélite	I-Sequence
no	O
encontró	O
diferencias	O
significativas	O
entre	O
el	O
control	O
y	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
(	O
Figura	O
6	O
)	O
.	O

Como	O
el	O
LTM7	O
ES	O
célula	B-Cell
la	O
línea	O
que	O
usamos	O
en	O
nuestros	O
experimentos	O
de	O
ARNi	O
es	O
una	O
hembra	O
(	O
XX	O
)	O
célula	B-Cell
línea	O
,	O
ADN	B-Sequence
la	O
metilación	O
se	O
reduce	O
globalmente	O
en	O
estos	O
células	B-Cell
[	O
26	O
]	O
.	O

Para	O
descartar	O
la	O
posibilidad	O
de	O
que	O
la	O
hipometilación	O
de	O
pericéntrico	B-GENE
repite	B-Sequence
podría	O
contribuir	O
a	O
la	O
desestabilización	O
de	O
dominios	B-GENE
de	I-GENE
heterocromatina	I-GENE
en	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
,	O
probamos	O
nuestro	O
ARNi	O
vector	B-Sequence
de	I-Sequence
plásmido	I-Sequence
en	O
un	O
XY	O
ES	O
célula	B-Cell
línea	O
,	O
y	O
confirmó	O
que	O
la	O
pérdida	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
conduce	O
a	O
la	O
interrupción	O
de	O
heterocromatina	B-GENE
organización	O
independientemente	O
del	O
grado	O
de	O
ADN	B-Sequence
metilación	O
en	O
pericéntrico	B-GENE
repite	B-Sequence
(	O
datos	O
no	O
publicados	O
)	O
.	O

A	O
continuación	O
,	O
analizamos	O
histona	B-Chemical
modificaciones	B-Sequence
[	O
27	O
]	O
en	O
cromatina	B-GENE
experimentos	O
de	O
inmunoprecipitación	O
(	O
ChIP	O
)	O
usando	O
nativos	O
cromatina	B-GENE
[	O
28	O
]	O
.	O

Encontramos	O
eso	O
ADN	B-GENE
pericéntrico	I-GENE
fue	O
inmunoprecipitado	O
con	O
una	O
eficiencia	O
2	O
veces	O
menor	O
con	O
H4K20me3	O
[	O
29	O
,	O
30	O
]	O
anticuerpos	B-GENE
siguiente	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
agotamiento	O
(	O
Figura	O
7A	O
y	O
7B	O
)	O
.	O

Inmunoprecipitación	O
de	O
menores	O
repeticiones	B-Sequence
de	I-Sequence
satélite	I-Sequence
en	O
el	O
mismo	O
experimento	O
fue	O
menos	O
afectado	O
(	O
Figura	O
7B	O
)	O
,	O
mostrando	O
que	O
la	O
pérdida	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
La	O
función	O
afecta	O
principalmente	O
a	O
H4K20me3	O
en	O
heterocromatina	B-GENE
pericéntrica	I-GENE
.	O

Además	O
,	O
no	O
se	O
detectó	O
ninguna	O
diferencia	O
significativa	O
en	O
la	O
eficiencia	O
de	O
inmunoprecipitación	O
en	O
partículas	O
A	O
intracisternales	O
(	O
IAP	O
)	O
elementos	B-Sequence
(	O
Figura	O
7B	O
)	O
,	O
que	O
no	O
son	O
centroméricos	O
elementos	B-Sequence
de	I-Sequence
ADN	I-Sequence
repetidos	I-Sequence
también	O
enriquecido	O
en	O
H4K20me3	O
[	O
31	O
]	O
.	O

Este	O
resultado	O
muestra	O
que	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
contribuye	O
a	O
los	O
niveles	O
normales	O
de	O
H4K20me3	O
en	O
heterocromatina	B-GENE
pericéntrica	I-GENE
,	O
pero	O
no	O
necesariamente	O
en	O
otros	O
lugares	B-Sequence
.	O

La	O
marca	O
H3K9me3	O
[	O
32	O
]	O
también	O
se	O
redujo	O
significativamente	O
en	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
,	O
aunque	O
en	O
menor	O
medida	O
que	O
H4K20me3	O
(	O
Figura	O
7A	O
y	O
7B	O
)	O
.	O

En	O
tipo	B-Sequence
salvaje	I-Sequence
células	B-Cell
,	O
la	O
mayoría	O
de	O
las	O
señales	O
H4K20me3	O
y	O
H3K9me3	O
están	O
presentes	O
en	O
el	O
nivel	O
de	O
dominios	O
densos	O
en	O
DAPI	O
cuando	O
se	O
visualizan	O
mediante	O
IF	O
[	O
29	O
]	O
(	O
Figuras	O
7C	O
y	O
7D	O
)	O
.	O

H3K9me3	O
fue	O
severamente	O
perturbado	O
en	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
,	O
mostrando	O
un	O
patrón	O
difuso	O
similar	O
a	O
HP1	B-Protein
alfa	I-Protein
(	O
Figura	O
7C	O
)	O
.	O

El	O
patrón	O
H4K20me3	O
se	O
alteró	O
aún	O
más	O
severamente	O
,	O
mostrando	O
una	O
pérdida	O
de	O
los	O
puntos	O
típicos	O
revelados	O
en	O
el	O
control	O
células	B-Cell
y	O
una	O
reducción	O
en	O
la	O
intensidad	O
de	O
la	O
señal	O
(	O
Figura	O
7D	O
)	O
.	O

De	O
acuerdo	O
con	O
nuestros	O
experimentos	O
de	O
ChIP	O
,	O
H4K20me3	O
residual	O
epitopos	B-Sequence
fueron	O
detectados	O
al	O
nivel	O
del	O
material	O
denso	O
en	O
DAPI	O
reubicado	O
.	O

En	O
conjunto	O
,	O
nuestros	O
resultados	O
muestran	O
que	O
el	O
agotamiento	O
de	O
CAF	B-GENE
-	I-GENE
1	I-GENE
en	O
ES	O
células	B-Cell
conduce	O
a	O
una	O
interrupción	O
simultánea	O
de	O
heterocromatina	B-GENE
Organización	O
tridimensional	O
y	O
alteración	O
del	O
marcaje	O
epigenético	O
.	O

Discusión	O

Aquí	O
,	O
proporcionamos	O
evidencia	O
de	O
que	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
tiene	O
una	O
función	O
crucial	O
durante	O
ratón	B-Taxon
embriogénesis	O
temprana	O
y	O
en	O
ES	O
células	B-Cell
.	O

Estudios	O
previos	O
demostraron	O
que	O
CAF	B-GENE
-	I-GENE
1	I-GENE
es	O
esencial	O
para	O
la	O
progresión	O
de	O
ADN	B-Sequence
replicación	O
en	O
vertebrados	B-Taxon
.	O

En	O
Xenopus	B-Taxon
laevis	I-Taxon
,	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
se	O
requiere	O
la	O
función	O
para	O
el	O
rápido	O
célula	B-Cell
divisiones	O
que	O
ocurren	O
durante	O
el	O
desarrollo	O
temprano	O
[	O
33	O
]	O
.	O

Similar	O
,	O
CAF	B-GENE
-	I-GENE
1	I-GENE
es	O
esencial	O
en	O
mamífero	B-Taxon
célula	B-Cell
Líneas	O
para	O
la	O
progresión	O
de	O
ADN	B-Sequence
replicación	O
[	O
16	O
,	O
23	O
,	O
24	O
,	O
34	O
]	O
.	O

Nuestros	O
hallazgos	O
revelan	O
un	O
papel	O
para	O
CAF	B-GENE
-	I-GENE
1	I-GENE
en	O
el	O
nuclear	B-GENE
organización	O
de	O
dominios	B-GENE
de	I-GENE
heterocromatina	I-GENE
durante	O
el	O
desarrollo	O
temprano	O
y	O
en	O
ES	O
células	B-Cell
.	O

Mostramos	O
que	O
en	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
,	O
tiempo	O
ADN	B-Sequence
replicación	O
inicialmente	O
persiste	O
sin	O
perturbaciones	O
significativas	O
en	O
nucleosomal	B-GENE
organización	O
,	O
severa	O
heterocromatina	B-GENE
se	O
pueden	O
observar	O
defectos	O
de	O
organización	O
.	O

Pérdida	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
no	O
afectó	O
cuerpos	B-GENE
de	I-GENE
LMP	I-GENE
en	O
ES	O
célula	B-Cell
núcleos	B-GENE
,	O
mostrando	O
que	O
nuclear	B-GENE
la	O
arquitectura	O
no	O
se	O
altera	O
generalmente	O
.	O

Por	O
último	O
,	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
el	O
agotamiento	O
da	O
como	O
resultado	O
la	O
detención	O
de	O
ES	O
célula	B-Cell
división	O
y	O
célula	B-Cell
muerte	O
.	O

Dados	O
los	O
principales	O
defectos	O
observados	O
en	O
heterocromatina	B-GENE
organización	O
,	O
es	O
tentador	O
especular	O
que	O
estos	O
defectos	O
causan	O
la	O
detención	O
del	O
desarrollo	O
en	O
los	O
embriones	O
y	O
la	O
muerte	O
en	O
ES	O
células	B-Cell
.	O

El	O
rol	O
de	O
CAF	B-GENE
-	I-GENE
1	I-GENE
en	O
el	O
nuclear	B-GENE
organización	O
de	O
heterocromatina	B-GENE
incluye	O
la	O
localización	O
espacial	O
,	O
la	O
condensación	O
y	O
el	O
agrupamiento	O
de	O
dominios	B-GENE
pericéntricos	I-GENE
.	O

Esta	O
importante	O
función	O
de	O
CAF	B-GENE
-	I-GENE
1	I-GENE
no	O
se	O
reveló	O
en	O
los	O
MEF	O
primarios	O
,	O
3T3	O
células	B-Cell
,	O
o	O
humano	B-Taxon
célula	B-Cell
líneas	O
,	O
lo	O
que	O
sugiere	O
que	O
es	O
específico	O
de	O
embriones	O
pluripotentes	O
células	B-Cell
.	O

Alternativamente	O
,	O
embriones	O
tempranos	O
y	O
ES	O
células	B-Cell
,	O
cuyo	O
genoma	B-Sequence
es	O
más	O
plástico	O
que	O
somático	O
células	B-Cell
,	O
podría	O
representar	O
un	O
contexto	O
particularmente	O
sensible	O
en	O
el	O
que	O
la	O
importancia	O
de	O
CAF	B-GENE
-	I-GENE
1	I-GENE
en	O
heterocromatina	B-GENE
se	O
exacerba	O
la	O
organización	O
.	O

En	O
ES	O
células	B-Cell
,	O
importante	O
arquitectura	O
cromatina	B-GENE
proteinas	B-Chemical
son	O
hiperdinámicos	O
y	O
se	O
unen	O
relativamente	O
débilmente	O
a	O
cromatina	B-GENE
[	O
35	O
]	O
.	O

En	O
esto	O
celular	B-Cell
contexto	O
,	O
nuestros	O
hallazgos	O
muestran	O
que	O
heterocromatina	B-GENE
nuclear	I-GENE
la	O
arquitectura	O
se	O
basa	O
en	O
CAF	B-GENE
-	I-GENE
1	I-GENE
función	O

En	O
cambio	O
,	O
en	O
los	O
indiferenciados	O
células	B-Cell
que	O
ya	O
están	O
comprometidos	O
con	O
el	O
linaje	O
(	O
como	O
los	O
MEF	O
)	O
genoma	B-Sequence
la	O
arquitectura	O
podría	O
ser	O
más	O
estable	O
que	O
en	O
ES	O
células	B-Cell
y	O
por	O
lo	O
tanto	O
no	O
puede	O
ser	O
interrumpido	O
por	O
CAF	B-GENE
-	I-GENE
1	I-GENE
agotamiento	O

Esta	O
importante	O
función	O
de	O
CAF	B-GENE
-	I-GENE
1	I-GENE
en	O
embriones	O
pluripotentes	O
células	B-Cell
podría	O
ser	O
parcialmente	O
conservado	B-Sequence
durante	O
la	O
evolución	O
.	O

De	O
hecho	O
,	O
en	O
Arabidopsis	B-Taxon
thaliana	I-Taxon
en	O
el	O
cual	O
CAF	B-GENE
-	I-GENE
1	I-GENE
no	O
es	O
esencial	O
para	O
la	O
viabilidad	O
[	O
36	O
]	O
,	O
la	O
pérdida	O
de	O
CAF	B-GENE
-	I-GENE
1	I-GENE
se	O
asocia	O
con	O
una	O
leve	O
alteración	O
en	O
cromocentro	B-GENE
tamaño	O
[	O
37	O
]	O
.	O

Este	O
fenotipo	O
recuerda	O
de	O
algún	O
modo	O
a	O
la	O
pérdida	O
de	O
CAF	B-GENE
-	I-GENE
1	I-GENE
#	O
¿NOMBRE	O
?	O
heterocromatina	B-GENE
organización	O
a	O
principios	O
ratón	B-Taxon
embriones	O

En	O
ratón	B-Taxon
ES	O
células	B-Cell
,	O
mostramos	O
que	O
CAF	B-GENE
-	I-GENE
1	I-GENE
también	O
se	O
requiere	O
para	O
niveles	O
regulares	O
de	O
H4K20me3	O
en	O
pericéntrico	B-GENE
repite	B-Sequence
,	O
pero	O
no	O
en	O
IAP	O
elementos	B-Sequence
,	O
que	O
son	O
secuencias	B-Sequence
repetidas	I-Sequence
repartidos	O
por	O
todo	O
el	O
ratón	B-Taxon
genoma	B-Sequence
.	O

Estos	O
datos	O
sugieren	O
que	O
la	O
adecuada	O
nuclear	B-GENE
organización	O
y	O
marcaje	O
epigenético	O
de	O
heterocromatina	B-GENE
pericéntrica	I-GENE
están	O
acoplados	O
en	O
ES	O
células	B-Cell
.	O

Alternativamente	O
,	O
la	O
organización	O
tridimensional	O
de	O
heterocromatina	B-GENE
y	O
el	O
marcado	O
epigenético	O
podría	O
representar	O
dos	O
funciones	O
independientes	O
de	O
CAF	B-GENE
-	I-GENE
1	I-GENE
.	O

El	O
requerimiento	O
variable	O
de	O
CAF	B-GENE
-	I-GENE
1	I-GENE
a	O
través	O
de	O
las	O
especies	O
podría	O
reflejar	O
la	O
adquisición	O
de	O
nuevas	O
propiedades	O
que	O
afectan	O
la	O
función	O
de	O
histona	B-Chemical
H3	O
variantes	B-Sequence
durante	O
la	O
evolución	O
de	O
eucariotas	B-Taxon
.	O

CAF	B-GENE
-	I-GENE
1	I-GENE
es	O
esencial	O
en	O
mamíferos	B-Taxon
pero	O
prescindible	O
en	O
Saccharomyces	B-Taxon
cerevisiae	I-Taxon
[	O
38	O
]	O
.	O

Curiosamente	O
,	O
el	O
levadura	B-Taxon
en	I-Taxon
ciernes	I-Taxon
genoma	B-Sequence
no	O
contiene	O
regiones	B-GENE
de	I-GENE
heterocromatina	I-GENE
equivalentes	O
a	O
los	O
de	O
mayor	O
eucariotas	B-Taxon
,	O
y	O
varias	O
señas	O
de	O
identidad	O
caracteristicas	B-Sequence
de	O
heterocromatina	B-GENE
tales	O
como	O
di	O
y	O
trimetilación	O
en	O
H3K9	O
,	O
H3K27	O
y	O
H4K20	O
no	O
se	O
observan	O
en	O
el	O
silencioso	O
cromatina	B-GENE
de	O
S	B-Taxon
.	I-Taxon
cerevisias	I-Taxon
.	O

En	O
mamíferos	B-Taxon
,	O
la	O
dimetilación	O
de	O
H3K9	O
se	O
asocia	O
predominantemente	O
con	O
H3	O
.	O
1	O
,	O
pero	O
no	O
con	O
H3	O
.	O
3	O
,	O
que	O
lleva	O
modificaciones	B-Sequence
típicamente	O
encontrado	O
en	O
transcrito	O
regiones	B-GENE
de	I-GENE
cromatina	I-GENE
[	O
39	O
]	O
.	O

Fuera	O
del	O
centromérico	O
H3	O
variante	B-Sequence
,	O
S	B-Taxon
.	I-Taxon
cerevisias	I-Taxon
posee	O
sólo	O
H3	O
.	O
3	O
,	O
que	O
se	O
expresa	O
e	O
incorpora	O
en	O
cromatina	B-GENE
en	O
una	O
replicación	O
-	O
manera	O
independiente	O
en	O
mayor	O
eucariotas	B-Taxon
[	O
12	O
]	O
.	O

Estos	O
datos	O
sugieren	O
un	O
papel	O
específico	O
para	O
H3	O
.	O
1	O
en	O
regiones	B-GENE
de	I-GENE
heterocromatina	I-GENE
.	O

Mostramos	O
aquí	O
que	O
CAF	B-GENE
-	I-GENE
1	I-GENE
,	O
que	O
es	O
un	O
H3	O
.	O
1	O
replicación	O
-	O
carga	O
dependiente	O
complejo	B-GENE
[	O
11	O
]	O
,	O
se	O
requiere	O
específicamente	O
para	O
la	O
nuclear	B-GENE
organización	O
de	O
heterocromatina	B-GENE
pericéntrica	I-GENE
en	O
embriones	O
y	O
ES	O
células	B-Cell
.	O

Una	O
posibilidad	O
sería	O
un	O
escenario	O
en	O
el	O
que	O
la	O
incorporación	O
de	O
H3	O
.	O
1	O
en	O
cromatina	B-GENE
se	O
requiere	O
para	O
el	O
correcto	O
nuclear	B-GENE
organización	O
de	O
constitutivos	O
heterocromatina	B-GENE
en	O
un	O
contexto	O
embrionario	O
.	O

Si	O
bien	O
esto	O
tiene	O
que	O
abordarse	O
experimentalmente	O
,	O
vale	O
la	O
pena	O
mencionar	O
un	O
posible	O
mecanismo	O
alternativo	O
que	O
podría	O
explicar	O
la	O
interrupción	O
de	O
dominios	B-GENE
de	I-GENE
heterocromatina	I-GENE
en	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
embriones	O
nulos	O
y	O
ES	O
células	B-Cell
.	O

CAF	B-GENE
-	I-GENE
1	I-GENE
podría	O
ser	O
necesario	O
para	O
la	O
carga	O
,	O
en	O
heterocromatina	B-GENE
,	O
de	O
un	O
socio	O
interactivo	O
necesario	O
para	O
la	O
agrupación	O
de	O
dominios	B-GENE
pericéntricos	I-GENE
.	O

Después	O
de	O
una	O
o	O
dos	O
rondas	O
de	O
ADN	B-Sequence
replicación	O
en	O
ausencia	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
,	O
heterocromatina	B-GENE
se	O
vería	O
privado	O
de	O
esto	O
molécula	B-Chemical
,	O
lo	O
que	O
provocaría	O
la	O
interrupción	O
de	O
su	O
organización	O
3	O
-	O
D	O
.	O

Un	O
candidato	O
potencial	O
es	O
el	O
HP1	B-Protein
proteína	B-Chemical
,	O
que	O
interactúa	O
con	O
CAF	B-GENE
-	I-GENE
1	I-GENE
[	O
13	O
,	O
16	O
]	O
.	O

De	O
acuerdo	O
con	O
un	O
informe	O
reciente	O
[	O
40	O
]	O
,	O
nuestro	O
análisis	O
de	O
heterocromatina	B-GENE
en	O
embriones	O
preimplantacionales	O
ha	O
revelado	O
cambios	O
drásticos	O
en	O
nuclear	B-GENE
organización	O
entre	O
los	O
dos	O
-	O
célula	B-Cell
y	O
estadios	O
de	O
blastocisto	O
.	O

Experimentos	O
de	O
clonación	O
en	O
ratón	B-Taxon
reveló	O
que	O
el	O
nuclear	B-GENE
organización	O
de	O
heterocromatina	B-GENE
en	I-GENE
núcleos	I-GENE
de	I-GENE
células	I-GENE
ES	I-GENE
se	O
revirtió	O
rápidamente	O
en	O
el	O
-	O
célula	B-Cell
etapa	O
-	O
forma	O
específica	O
después	O
nuclear	B-GENE
transferencia	O
[	O
40	O
]	O
.	O

Por	O
lo	O
tanto	O
,	O
la	O
remodelación	O
de	O
heterocromatina	B-GENE
Paralelos	O
de	O
organización	O
3	O
-	O
D	O
nuclear	B-GENE
reprogramación	O
hacia	O
un	O
estado	O
embrionario	O
temprano	O
en	O
embriones	O
clonados	O
.	O

Esta	O
drástica	O
reorganización	O
de	O
heterocromatina	B-GENE
organización	O
es	O
similar	O
a	O
la	O
observada	O
en	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
,	O
y	O
en	O
desarrollo	O
detenido	O
16	O
-	O
célula	B-Cell
escenario	O
Chaf1a	B-Protein
-	O
/	O
-	O
embriones	O
.	O

Estos	O
datos	O
muestran	O
que	O
CAF	B-GENE
-	I-GENE
1	I-GENE
está	O
involucrado	O
en	O
la	O
creación	O
adecuada	O
heterocromatina	B-GENE
arquitectura	O
durante	O
la	O
primera	O
célula	B-Cell
divisiones	O
de	O
la	O
vida	O
embrionaria	O
.	O

Dada	O
la	O
importancia	O
de	O
nuclear	B-GENE
organización	O
en	O
el	O
control	O
de	O
gene	B-Sequence
expresión	O
[	O
21	O
,	O
41	O
]	O
,	O
este	O
hallazgo	O
sugiere	O
que	O
CAF	B-GENE
-	I-GENE
1	I-GENE
contribuye	O
a	O
los	O
programas	O
coordinados	O
de	O
gene	B-Sequence
expresión	O
durante	O
la	O
embriogénesis	O
temprana	O
.	O

Nuestros	O
hallazgos	O
abren	O
nuevas	O
perspectivas	O
en	O
la	O
comprensión	O
de	O
cromatina	B-GENE
dinámica	O
durante	O
el	O
desarrollo	O
temprano	O
y	O
en	O
embriones	O
pluripotentes	O
células	B-Cell
.	O

Si	O
bien	O
la	O
mayoría	O
de	O
los	O
estudios	O
se	O
centraron	O
en	O
el	O
papel	O
de	O
ADN	B-Sequence
metilación	O
y	O
histona	B-Chemical
enzimas	B-Sequence
modificadoras	I-Sequence
[	O
3	O
]	O
,	O
nuestros	O
datos	O
apuntan	O
a	O
la	O
importancia	O
de	O
la	O
cromatina	B-GENE
maquinaria	O
de	O
montaje	O
.	O

Mostramos	O
que	O
además	O
de	O
ensamblar	O
nucleosomas	B-GENE
,	O
CAF	B-GENE
-	I-GENE
1	I-GENE
proporciona	O
información	O
espacial	O
y	O
epigenética	O
a	O
dominios	B-GENE
de	I-GENE
heterocromatina	I-GENE
en	O
embriones	O
tempranos	O
y	O
ES	O
células	B-Cell
.	O

Materiales	O
y	O
métodos	O

Generación	O
de	O
Chaf1a	B-Protein
mutante	B-Sequence
ratones	B-Taxon
y	O
embriones	O
.	O

Usando	O
PCR	O
,	O
amplificamos	O
dos	O
fragmentos	B-Sequence
genómicos	I-Sequence
(	O
alrededor	O
de	O
3	O
kb	O
cada	O
uno	O
)	O
flanqueando	O
Chaf1a	B-Protein
exón	B-Sequence
3	O
.	O

Estas	O
fragmentos	B-Sequence
de	I-Sequence
ADN	I-Sequence
fueron	O
ensamblados	O
por	O
clonación	O
convencional	O
con	O
la	O
neomicina	O
y	O
DT	B-Protein
(	O
toxina	B-Protein
diftérica	I-Protein
)	O
casetes	B-Sequence
,	O
como	O
se	O
describe	O
en	O
la	O
Figura	O
1A	O
.	O

los	O
construir	B-Sequence
fue	O
transfectado	O
en	O
ES	O
células	B-Cell
por	O
electroporación	O
.	O

Identificamos	O
ES	O
recombinantes	O
células	B-Cell
llevando	O
el	O
mutante	B-Sequence
Chaf1atm1Ger	O
(	O
abreviado	O
Chaf1a	B-Protein
-	O
en	O
el	O
manuscrito	O
)	O
alelo	B-Sequence
por	O
Southern	O
blot	O
(	O
Figura	O
1A	O
)	O
.	O

nosotros	O
derivamos	O
Chaf1a	B-Protein
+	B-Sequence
/	O
-	O
ratones	B-Taxon
inyectando	O
ES	O
recombinado	O
células	B-Cell
en	O
blastocistos	O
C57BL/6N	O
.	O

Embriones	O
E4	O
obtenidos	O
del	O
cruce	O
de	O
Chaf1a	B-Protein
+	B-Sequence
/	O
-	O
ratones	B-Taxon
fueron	O
genotipados	O
por	O
amplificación	O
por	O
PCR	O
anidada	O
.	O

Los	O
embriones	O
se	O
recolectaron	O
en	O
una	O
mezcla	O
de	O
reacción	O
de	O
PCR	O
que	O
contenía	O
cebadores	B-Sequence
de	I-Sequence
oligonucleótidos	I-Sequence
1	O
,	O
2	O
y	O
3	O
(	O
Figura	O
1A	O
)	O
que	O
amplifican	O
la	O
tipo	B-Sequence
salvaje	I-Sequence
y	O
alelos	B-Sequence
mutantes	I-Sequence
.	O

Después	O
de	O
30	O
ciclos	O
de	O
amplificación	O
,	O
se	O
usó	O
1	O
µl	O
de	O
cada	O
reacción	O
de	O
PCR	O
en	O
una	O
segunda	O
ronda	O
de	O
amplificación	O
de	O
PCR	O
con	O
un	O
nuevo	O
conjunto	O
de	O
cebadores	B-Sequence
de	I-Sequence
oligonucleótidos	I-Sequence
.	O

Después	O
de	O
30	O
ciclos	O
de	O
amplificación	O
,	O
las	O
reacciones	O
de	O
PCR	O
se	O
llevaron	O
a	O
cabo	O
en	O
un	O
agarosa	B-Chemical
gel	O
,	O
que	O
reveló	O
la	O
presencia	O
del	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
150	O
pb	B-Sequence
)	O
y	O
recombinante	O
(	O
200	O
pb	B-Sequence
)	O
alelos	B-Sequence
.	O

P150CAF-1	B-Protein
agotamiento	O
por	O
ARNi	O
.	O

el	O
ARNi	O
vector	B-Sequence
de	I-Sequence
plásmido	I-Sequence
que	O
utilizamos	O
en	O
este	O
estudio	O
contiene	O
el	O
ratón	B-Taxon
H1	O
promotor	B-Sequence
y	O
un	O
puromicina	B-Chemical
selección	O
gene	B-Sequence
(	O
SB	O
y	O
MG	O
,	O
datos	O
no	O
publicados	O
)	O
.	O

Caracterizamos	O
en	O
detalle	O
las	O
propiedades	O
de	O
este	O
nuevo	O
vector	B-Sequence
usando	O
un	O
objetivo	O
GFP	O
gene	B-Sequence
y	O
FACS	O
:	O
extinción	O
del	O
objetivo	O
genes	B-Sequence
en	O
ES	O
células	B-Cell
es	O
altamente	O
eficiente	O
en	O
el	O
70	O
%	O
de	O
los	O
células	B-Cell
,	O
de	O
eficiencia	O
intermedia	O
en	O
15	O
%	O
,	O
e	O
ineficiente	O
en	O
el	O
15	O
%	O
restante	O
de	O
células	B-Cell
análisis	O

los	O
secuencia	B-Sequence
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
siARN	B-Sequence
(	O
ARN	B-Sequence
de	I-Sequence
interferencia	I-Sequence
corto	I-Sequence
)	O
dúplex	O
[	O
16	O
]	O
fue	O
clonado	O
en	O
este	O
plásmido	B-Sequence
.	O

El	O
control	O
vector	B-Sequence
expresó	O
un	O
siARN	B-Sequence
que	O
se	O
dirige	O
a	O
GFP	O
ARN	B-Sequence
degradación	O

ES	O
células	B-Cell
fueron	O
transfectados	O
por	O
electroporación	O
con	O
el	O
Vector	B-Sequence
de	I-Sequence
plásmido	I-Sequence
de	I-Sequence
ARN	I-Sequence
,	O
se	O
sembró	O
en	O
portaobjetos	O
recubiertos	O
de	O
gelatina	O
y	O
se	O
cultivó	O
durante	O
24	O
h	O
en	O
ausencia	O
de	O
selección	O
.	O

puromicina	B-Chemical
(	O
2	O
µ	O
g	O
/	O
ml	O
)	O
al	O
medio	O
de	O
cultivo	O
y	O
se	O
células	B-Cell
se	O
cultivaron	O
durante	O
un	O
período	O
adicional	O
de	O
48	O
h	O
.	O

Utilizando	O
el	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
ARNi	O
vector	B-Sequence
,	O
SI	O
la	O
cuantificación	O
microscópica	O
revela	O
una	O
completa	O
CAF	B-GENE
-	I-GENE
1	I-GENE
agotamiento	O
en	O
la	O
mayoría	O
células	B-Cell
(	O
Figura	O
S1B	O
)	O
.	O

El	O
análisis	O
de	O
transferencia	O
Western	O
(	O
Figura	O
S1A	O
)	O
revela	O
residuos	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
expresión	O
,	O
como	O
se	O
esperaba	O
del	O
15	O
%	O
de	O
células	B-Cell
que	O
no	O
inhiben	O
el	O
objetivo	O
gene	B-Sequence
.	O

Los	O
MEF	O
(	O
paso	O
3	O
,	O
confluencia	O
del	O
90	O
%	O
)	O
se	O
transfectaron	O
durante	O
4	O
h	O
con	O
el	O
ARNi	O
vector	B-Sequence
de	I-Sequence
plásmido	I-Sequence
utilizando	O
Lipofectamine	O
2000	O
(	O
Invitrogene	O
,	O
Carlsbad	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
según	O
las	O
condiciones	O
del	O
fabricante	O
.	O

Células	B-Cell
se	O
tripsinizaron	O
,	O
se	O
sembraron	O
en	O
placas	O
a	O
una	O
dilución	O
de	O
1	O
/	O
3	O
y	O
se	O
cultivaron	O
durante	O
48	O
h	O
en	O
presencia	O
de	O
puromicina	B-Chemical
.	O

Célula	B-Cell
líneas	O
.	O

EN	O
-	O
1	O
ES	O
células	B-Cell
[	O
42	O
]	O
(	O
obsequio	O
de	O
M.	O
Vernet	O
)	O
sirvieron	O
para	O
gene	B-Sequence
apuntando	O

LTM7	O
ES	O
células	B-Cell
se	O
utilizaron	O
en	O
todos	O
los	O
experimentos	O
de	O
ARNi	O
.	O

Derivamos	O
esto	O
célula	B-Cell
línea	O
de	O
(	O
C57BL/6	O
x	O
129	O
)	O
hembras	O
F1	O
cruzadas	O
con	O
machos	O
C3H/HeJ	O
.	O

LTM7	O
son	O
XX	O
ES	O
células	B-Cell
,	O
competente	O
para	O
la	O
transmisión	O
de	O
línea	O
germinal	O
.	O

MEFs	O
primarios	O
se	O
derivaron	O
de	O
embriones	O
E13	O
como	O
se	O
describe	O
en	O
[	O
43	O
]	O
.	O

Inmunofluorescencia	O
.	O

Células	B-Cell
se	O
fijaron	O
durante	O
20	O
min	O
en	O
PBS	O
con	O
4	O
%	O
de	O
paraformaldehído	O
,	O
y	O
se	O
realizó	O
la	O
inmunodetección	O
como	O
se	O
describió	O
anteriormente	O
[	O
44	O
]	O
.	O

Se	O
recolectaron	O
embriones	O
E4	O
y	O
se	O
trataron	O
con	O
tyrode	O
ácido	B-Chemical
para	O
eliminar	O
la	O
zona	O
pelúcida	O
,	O
depositada	O
en	O
portaobjetos	O
de	O
microscopio	O
y	O
procesada	O
para	O
inmunotinción	O
como	O
se	O
describe	O
para	O
ES	O
células	B-Cell
.	O

anticuerpos	B-GENE
anti	O
-	O
HP1	B-Protein
alfa	I-Protein
(	O
2HP1H5	O
,	O
Euromedex	O
,	O
Francia	O
)	O
,	O
anti-H4K20me3	O
(	O
Abcam	O
,	O
Cambridge	O
,	O
Reino	O
Unido	O
)	O
,	O
anti-BrdU	O
(	O
DakoCytomation	O
,	O
Glostrup	O
,	O
Dinamarca	O
)	O
,	O
anti-	O
PCNA	B-Protein
(	O
DakoCytomation	O
)	O
,	O
y	O
anti	O
-	O
LMP	B-Protein
(	O
Upstate	O
Biotechnology	O
,	O
Lake	O
Placid	O
,	O
Nueva	O
York	O
,	O
Estados	O
Unidos	O
)	O
se	O
utilizaron	O
todos	O
a	O
una	O
dilución	O
de	O
1/1000	O
.	O

anticuerpos	B-GENE
anti	O
-	O
ratón	B-Protein
p150CAF1	I-Protein
[	O
16	O
]	O
y	O
anti	O
-	O
H3K9me3	O
(	O
Upstate	O
Biotechnology	O
)	O
se	O
usaron	O
en	O
1	O
/	O
250	O
y	O
1	O
/	O
500	O
,	O
respectivamente	O
.	O

Todo	O
secundario	O
anticuerpos	B-GENE
fueron	O
comprados	O
de	O
Molecular	B-Chemical
Sondas	O
(	O
Sunnyvale	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
.	O

Análisis	O
de	O
Western	O
Blot	O
.	O

Células	B-Cell
se	O
lisaron	O
en	O
tampón	O
Laemli	O
y	O
se	O
corrieron	O
en	O
un	O
4	O
%	O
-	O
12	O
%	O
SDS	B-Chemical
Gel	O
degradado	O
PÁGINA	O
.	O

Nosotros	O
usamos	O
anticuerpos	B-GENE
en	O
contra	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
(	O
[	O
16	O
]	O
;	O
dilución	O
1	O
/	O
500	O
)	O
,	O
HP1	B-Protein
alfa	I-Protein
(	O
2G9	O
,	O
Euromedex	O
;	O
1	O
/	O
500	O
)	O
,	O
Histona	B-Chemical
H3	O
(	O
Abcam	O
;	O
1	O
/	O
500	O
)	O
,	O
H3K9me3	O
(	O
Upstate	O
;	O
1	O
/	O
500	O
)	O
y	O
beta	B-Protein
-	I-Protein
actina	I-Protein
(	O
Norte	O
del	O
estado	O
;	O
1	O
/	O
40	O
000	O
)	O
.	O

ADN	B-Sequence
PEZ	O
.	O

Sondas	B-Sequence
se	O
describieron	O
previamente	O
[	O
20	O
]	O
.	O

biotina	B-Chemical
-	O
dieciséis	O
-	O
dUTP	B-Chemical
o	O
Digoxigenina	B-Chemical
-	O
11	O
-	O
dUTP	B-Chemical
(	O
Roche	O
,	O
Basilea	O
,	O
Suiza	O
)	O
etiquetado	O
sondas	B-Sequence
fueron	O
generados	O
por	O
nick	O
traducción	O
(	O
Roche	O
)	O
y	O
FISH	O
realizado	O
como	O
se	O
describe	O
[	O
20	O
]	O
.	O

La	O
adquisición	O
de	O
imágenes	O
se	O
realizó	O
con	O
el	O
microscopio	O
Deltavision	O
RT	O
(	O
objetivo	O
100x	O
,	O
1,4	O
NA	O
)	O
,	O
las	O
imágenes	O
se	O
desconvolucionaron	O
y	O
los	O
perfiles	O
de	O
fluorescencia	O
se	O
midieron	O
a	O
lo	O
largo	O
de	O
una	O
línea	O
arbitraria	O
utilizando	O
SoftWorx	O
.	O

Núcleos	B-GENE
preparación	O
,	O
digestión	O
con	O
nucleasas	O
y	O
análisis	O
bioquímico	O
de	O
cromatina	B-GENE
.	O

ES	O
células	B-Cell
se	O
incubaron	O
en	O
hielo	O
durante	O
10	O
min	O
en	O
tampón	O
1	O
(	O
15	O
mM	O
tris	B-Chemical
-	O
HCl	B-Chemical
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
0	O
.	O
3M	O
sacarosa	B-Chemical
,	O
60	O
mm	O
KCl	B-Chemical
,	O
15	O
mm	O
NaCl	B-Chemical
,	O
5	O
mm	O
MgCl2	B-Chemical
,	O
0	O
.	O
1	O
mm	O
EGTA	B-Chemical
)	O
con	O
0	O
.	O
15	O
%	O
IGEPAL	O
(	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
Missouri	O
,	O
Estados	O
Unidos	O
)	O
.	O

Núcleos	B-GENE
fueron	O
purificados	O
por	O
centrifugación	O
(	O
10	O
000	O
xg	O
durante	O
30	O
min	O
,	O
a	O
4	O
grados	O
C	O
)	O
en	O
sacarosa	B-Chemical
cojines	O
(	O
tampón	O
1	O
con	O
sacarosa	O
1,2	O
M	O
)	O
y	O
resuspendido	O
en	O
tampón	O
de	O
nucleasa	O
(	O
tampón	O
50	O
mM	O
tris	B-Chemical
-	O
HCl	B-Chemical
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
20	O
mM	O
NaCl	B-Chemical
,	O
0	O
.	O
32M	O
sacarosa	B-Chemical
,	O
4	O
mm	O
MgCl2	B-Chemical
,	O
1	O
mm	O
CaCl2	B-Chemical
)	O
.	O

Sobre	O
2	O
.	O
106	O
núcleos	B-GENE
se	O
incubaron	O
con	O
cantidades	O
crecientes	O
de	O
MNase	O
(	O
0	O
,	O
04	O
-	O
1	O
,	O
6	O
unidades	O
)	O
o	O
ADNasa	B-Protein
I	I-Protein
(	O
0	O
.	O
25	O
-	O
16	O
unidades	O
)	O
.	O

El	O
tiempo	O
de	O
digestión	O
a	O
37	O
grados	O
C	O
fue	O
de	O
10	O
min	O
para	O
MNase	O
y	O
2	O
min	O
para	O
ADNasa	B-Protein
I	I-Protein
.	O

Las	O
digestiones	O
se	O
detuvieron	O
agregando	O
SDS	B-Chemical
al	O
1	O
%	O
y	O
EDTA	B-Chemical
a	O
50	O
mM	O
.	O

ADN	B-Sequence
fueron	O
preparados	O
por	O
digestión	O
con	O
proteinasa	O
K	O
seguido	O
de	O
fenol	B-Chemical
-	O
cloroformo	B-Chemical
extracción	O
y	O
isopropanol	B-Chemical
precipitación	O

Para	O
probar	O
la	O
asociación	O
de	O
histona	B-Chemical
H3	O
con	O
cromatina	B-GENE
en	O
control	O
y	O
p150	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
,	O
aislado	O
núcleos	B-GENE
se	O
incubaron	O
en	O
hielo	O
durante	O
30	O
min	O
en	O
tampón	O
2	O
(	O
50	O
mM	O
Hepes	B-Chemical
[	O
pH7	O
.	O
9	O
]	O
,	O
20	O
%	O
Glicerol	B-Chemical
,	O
3	O
mm	O
MgCl2	B-Chemical
,	O
0	O
.	O
1	O
%	O
IGEPAL	O
,	O
0	O
.	O
5	O
mm	O
TDT	B-Chemical
,	O
0	O
.	O
5	O
mm	O
PMSF	B-Chemical
)	O
complementado	O
con	O
0	O
.	O
1	O
millón	O
,	O
0	O
.	O
3	O
millones	O
,	O
0	O
.	O
45	O
millones	O
,	O
0	O
.	O
7	O
millones	O
o	O
1	O
millón	O
NaCl	B-Chemical
.	O

Después	O
de	O
la	O
centrifugación	O
a	O
15	O
000	O
g	O
,	O
los	O
sedimentos	O
y	O
los	O
sobrenadantes	O
se	O
analizaron	O
mediante	O
Western	O
blot	O
utilizando	O
un	O
histona	B-Chemical
H3	O
anticuerpo	B-GENE
(	O
Abcam	O
)	O
.	O

Chip	O
.	O

Preparamos	O
nativo	O
cromatina	B-GENE
fragmentos	B-Sequence
de	O
dos	O
a	O
seis	O
nucleosomas	B-GENE
de	O
longitud	O
como	O
se	O
describe	O
[	O
28	O
]	O
.	O

5	O
tazas	O
de	O
cromatina	B-GENE
se	O
incubaron	O
durante	O
la	O
noche	O
con	O
10	O
mu	O
l	O
de	O
comercial	O
anticuerpos	B-GENE
.	O

Después	O
de	O
la	O
incubación	O
con	O
proteína	B-Chemical
-	O
Sefarosa	O
G	O
y	O
tres	O
lavados	O
,	O
inmunoprecipitado	O
ADN	B-Sequence
fue	O
purificado	O
,	O
dimensionado	O
en	O
un	O
agarosa	B-Chemical
gel	O
,	O
y	O
analizado	O
por	O
Southern	O
blot	O
.	O

Las	O
señales	O
de	O
hibridación	O
se	O
cuantificaron	O
usando	O
un	O
Instant	O
Imager	O
(	O
PerkinElmer	O
,	O
Wellesley	O
,	O
California	O
,	O
Estados	O
Unidos	O
)	O
.	O

anticuerpos	B-GENE
específicos	O
para	O
H4K20me3	O
se	O
adquirieron	O
de	O
Abcam	O
.	O

anticuerpos	B-GENE
para	O
H3K9me3	O
se	O
compraron	O
tanto	O
de	O
Abcam	O
como	O
de	O
Upstate	O
Biotechnology	O
y	O
dieron	O
resultados	O
similares	O
.	O

Para	O
el	O
análisis	O
de	O
transferencia	O
de	O
Southern	O
,	O
usamos	O
un	O
240	O
-	O
pb	B-Sequence
EcoRI	O
/	O
BamHI	O
fragmento	B-Sequence
de	O
pSAT	O
(	O
principal	O
sonda	B-Sequence
satelital	I-Sequence
)	O
[	O
45	O
-	O
47	O
]	O
y	O
un	O
360	O
-	O
pb	B-Sequence
EcoRI	O
/	O
HindIII	O
fragmento	B-Sequence
de	O
R198	O
,	O
correspondiente	O
a	O
tres	O
ejemplares	O
de	O
120	O
-	O
pb	B-Sequence
menor	O
repetición	B-Sequence
de	I-Sequence
satélite	I-Sequence
[	O
49	O
]	O
.	O

Sondas	B-Sequence
utilizados	O
en	O
los	O
experimentos	O
FISH	O
se	O
describen	O
en	O
[	O
46	O
-	O
48	O
]	O
.	O

los	O
Investigacion	B-Sequence
para	O
PAI	O
elementos	B-Sequence
fue	O
descrito	O
en	O
[	O
50	O
]	O
.	O

información	O
de	O
soporte	O

Figura	O
S1	O

Análisis	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
Agotamiento	O
por	O
RNAi	O
con	O
Western	O
Blot	O
e	O
IF	O

(	O
A	O
)	O
Análisis	O
de	O
transferencia	O
Western	O
de	O
ES	O
células	B-Cell
transfectado	O
con	O
control	O
(	O
cont	O
)	O
o	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
(	O
p150	B-Protein
)	O
ARNi	O
Vectores	B-Sequence
de	I-Sequence
plásmido	I-Sequence
.	O

beta	B-Protein
-	I-Protein
actina	I-Protein
se	O
utilizó	O
como	O
control	O
de	O
carga	O
.	O

Cantidad	O
de	O
células	B-Cell
se	O
indica	O
el	O
uso	O
en	O
cada	O
carril	O
.	O

p150CAF	B-Protein
-	I-Protein
1	I-Protein
la	O
caída	O
no	O
afecta	O
significativamente	O
HP1	B-Protein
alfa	I-Protein
,	O
histona	B-Chemical
Niveles	O
H3	O
o	O
H3K9me3	O
.	O

(	O
B	O
)	O
Análisis	O
IF	O
.	O

ES	O
células	B-Cell
transfectado	O
con	O
control	O
(	O
cont	O
)	O
o	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
(	O
p150	B-Protein
)	O
vector	B-Sequence
siARN	I-Sequence
fueron	O
inmunoteñidos	O
con	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
anticuerpo	B-GENE
(	O
verde	O
)	O
y	O
DAPI	O
(	O
azul	O
)	O
.	O

Barra	O
de	O
escala	O
=	O
5	O
mu	O
m	O
.	O

La	O
fluorescencia	O
se	O
cuantificó	O
a	O
lo	O
largo	O
de	O
una	O
línea	O
trazada	O
a	O
través	O
de	O
la	O
núcleo	B-GENE
y	O
los	O
datos	O
fueron	O
graficados	O
,	O
revelando	O
eficiente	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
agotamiento	O
por	O
ARNi	O
.	O

La	O
aparente	O
diferencia	O
en	O
la	O
eficiencia	O
de	O
CAF	B-GENE
-	I-GENE
1	I-GENE
caída	O
revelada	O
por	O
Western	O
blot	O
y	O
IF	O
probablemente	O
refleja	O
la	O
observación	O
de	O
que	O
el	O
ARNi	O
vector	B-Sequence
de	I-Sequence
plásmido	I-Sequence
utilizado	O
en	O
este	O
estudio	O
es	O
eficiente	O
en	O
el	O
85	O
%	O
de	O
los	O
SE	O
transfectados	O
célula	B-Cell
población	O
,	O
mientras	O
que	O
el	O
15	O
%	O
de	O
células	B-Cell
mostrar	O
ninguna	O
inhibición	O
del	O
objetivo	O
gene	B-Sequence
(	O
ver	O
Materiales	O
y	O
Métodos	O
)	O
.	O

(	O
1	O
.	O
3	O
MB	O
TIF	O
)	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Figura	O
S2	O

CAF	B-GENE
-	I-GENE
1	I-GENE
#	O
¿NOMBRE	O
?	O
fibroblastos	B-Cell
Activo	O
para	O
ADN	B-Sequence
La	O
replicación	O
no	O
muestra	O
una	O
alteración	O
heterocromatina	B-GENE
nuclear	I-GENE
Arquitectura	O

Inmunodetección	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
(	O
verde	O
)	O
y	O
BrdU	O
(	O
rojo	O
)	O
en	O
MEF	O
transfectados	O
con	O
control	O
(	O
cont	O
)	O
o	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
ARNi	O
vectores	B-Sequence
.	O

Los	O
MEF	O
se	O
marcaron	O
con	O
impulsos	O
durante	O
1	O
h	O
con	O
BrdU	O
antes	O
de	O
la	O
fijación	O
y	O
el	O
análisis	O
IF	O
.	O

los	O
p150	B-Protein
#	O
¿NOMBRE	O
?	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
y	O
fluorescencia	O
BrdU	O
.	O

La	O
tinción	O
DAPI	O
se	O
muestra	O
en	O
el	O
panel	O
de	O
la	O
derecha	O
.	O

los	O
CAF	B-GENE
citoplasmático	I-GENE
-	I-GENE
1	I-GENE
El	O
patrón	O
IF	O
no	O
es	O
específico	O
.	O

(	O
343	O
KB	O
TIF	O
)	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Agradecimientos	O

Agradecemos	O
a	O
E	O
.	O

Heard	O
y	O
S	O
.	O

Khochbin	O
por	O
la	O
lectura	O
crítica	O
y	O
las	O
sugerencias	O
;	O
S	O
.	O

Jounier	O
y	O
H	O
.	O

humbertclaude	O
para	O
célula	B-Cell
cultura	O
;	O
j	O

Mitja	O
,	O
S	O
.	O

Thessier	O
y	O
J	O
.	O

C	O
.	O

Robillard	O
para	O
animal	B-Taxon
cuidado	O
m	O

Vernet	O
para	O
AT-1	O
células	B-Cell
;	O
k	O

nacerdina	O
para	O
el	O
LMP	B-Protein
anticuerpo	B-GENE
;	O
n	O

Gilbert	O
y	O
T	O
.	O

Mejor	O
para	O
sondas	B-Sequence
;	O
g	O

Hamard	O
por	O
su	O
asesoramiento	O
sobre	O
la	O
inyección	O
de	O
blastocisto	O
;	O
PAGS	O
.	O

Le	O
Baccon	O
por	O
su	O
ayuda	O
en	O
el	O
análisis	O
de	O
imágenes	O
;	O
y	O
C	O
.	O

Mann	O
,	O
A	O
.	O

Sentenac	O
y	O
E	O
.	O

Moustacchi	O
por	O
su	O
apoyo	O
.	O

abreviaturas	O

BrdU	O
-	O
bromodesoxiuridina	O

CAF	B-GENE
-	I-GENE
1	I-GENE
-	O
factor	B-GENE
de	I-GENE
ensamblaje	I-GENE
de	I-GENE
cromatina	I-GENE
1	I-GENE

CHIP	O
-	O
cromatina	B-GENE
inmunoprecipitación	O

E4	O
-	O
día	O
embrionario	O
4	O

ES	O
-	O
tallo	O
embrionario	O

FISH	O
-	O
hibridación	O
fluorescente	O
in	O
situ	O

IAP	O
-	O
partícula	O
A	O
intracisternal	O

SI	O
-	O
inmunofluorescencia	O

MEF-	O
ratón	B-Taxon
embrionario	O
fibroblasto	B-Cell

PCNA	B-Protein
-	O
antígeno	B-Protein
nuclear	I-Protein
de	I-Protein
células	I-Protein
en	I-Protein
proliferación	I-Protein

LMP	B-Protein
-	O
leucemia	B-Protein
promielocítica	I-Protein

ARNi	O
-	O
ARN	B-Sequence
interferencia	O

siARN	B-Sequence
-	O
ARN	B-Sequence
de	I-Sequence
interferencia	I-Sequence
corto	I-Sequence

Figuras	O
y	O
Tablas	O

Figura	O
1	O

Pérdida	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
La	O
función	O
conduce	O
a	O
la	O
detención	O
temprana	O
del	O
desarrollo	O
y	O
la	O
alteración	O
de	O
heterocromatina	B-GENE
Organización	O

(	O
A	O
)	O
Generación	O
de	O
Chaf1a	B-Protein
+	B-Sequence
/	O
-	O
ratones	B-Taxon
por	O
recombinación	O
homóloga	O
en	O
ES	O
células	B-Cell
.	O

(	O
Arriba	O
)	O
Esquema	O
de	O
la	O
p150CAF1	B-Protein
proteína	B-Chemical
indicando	O
la	O
interacción	O
dominios	B-Sequence
(	O
Identificación	O
)	O
para	O
HP1	B-Protein
y	O
p60CAF	B-Protein
-	I-Protein
1	I-Protein
,	O
y	O
el	O
ácido	B-Chemical
dominio	B-Sequence
(	O
AD	O
)	O
.	O

(	O
Medio	O
)	O
Estructura	O
de	O
la	O
murino	B-Taxon
Chaf1a	B-Protein
gene	B-Sequence
.	O

Los	O
bloques	O
y	O
las	O
líneas	O
representan	O
exones	B-Sequence
y	O
intrones	B-Sequence
,	O
respectivamente	O
.	O

Una	O
estrella	O
indica	O
la	O
sitio	B-Sequence
de	I-Sequence
inicio	I-Sequence
de	I-Sequence
traducción	I-Sequence
.	O

A	O
continuación	O
se	O
muestra	O
el	O
Chaf1a	B-Protein
apuntando	O
vector	B-Sequence
,	O
que	O
incluye	O
regiones	B-Sequence
de	I-Sequence
homología	I-Sequence
de	I-Sequence
ADN	I-Sequence
genómico	I-Sequence
(	O
5	O
HR	O
y	O
3	O
HR	O
)	O
,	O
el	O
toxina	B-Protein
diftérica	I-Protein
(	O
DT	B-Protein
)	O
,	O
y	O
neomicina	B-Chemical
selección	O
genes	B-Sequence
.	O

Recombinado	O
(	O
Rec	O
)	O
ES	O
células	B-Cell
y	O
ratones	B-Taxon
fueron	O
identificados	O
por	O
Southern	O
blot	O
utilizando	O
ScaI	O
(	O
S	O
)	O
y	O
el	O
indicado	O
Investigacion	B-Sequence
.	O

(	O
B	O
)	O
Estrategia	O
de	O
mejoramiento	O
utilizada	O
para	O
la	O
producción	O
de	O
E4	O
Chaf1a	B-Protein
-	O
/	O
-	O
embriones	O
.	O

El	O
genotipado	O
se	O
realizó	O
por	O
PCR	O
utilizando	O
los	O
tres	O
cebadores	B-Sequence
de	I-Sequence
oligonucleótidos	I-Sequence
indicado	O
en	O
(	O
A	O
)	O
(	O
1	O
,	O
2	O
y	O
3	O
)	O
.	O

Se	O
muestra	O
un	O
ejemplo	O
del	O
resultado	O
de	O
un	O
experimento	O
de	O
genotipado	O
.	O

(	O
C	O
)	O
Inmunodetección	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
(	O
verde	O
)	O
y	O
HP1	B-Protein
alfa	I-Protein
(	O
rojo	O
)	O
en	O
embriones	O
E4	O
derivados	O
de	O
Chaf1a	B-Protein
+	B-Sequence
/	O
-	O
entrecruzamientos	O
.	O

Porque	O
Chaf1a	B-Protein
+	B-Sequence
/	O
+	B-Sequence
y	O
Chaf1a	B-Protein
+	B-Sequence
#	O
¿NOMBRE	O
?	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
,	O
ambos	O
están	O
designados	O
como	O
tipo	B-Sequence
salvaje	I-Sequence
.	O

p150CAF	B-Protein
-	I-Protein
1	I-Protein
expresión	O
,	O
que	O
indica	O
la	O
fase	O
S	O
en	O
curso	O
,	O
se	O
puede	O
detectar	O
en	O
la	O
mayoría	O
células	B-Cell
dentro	O
de	O
tipo	B-Sequence
salvaje	I-Sequence
blastocisto	O
(	O
panel	O
superior	O
)	O
.	O

El	O
panel	O
inferior	O
muestra	O
un	O
12	O
-	O
célula	B-Cell
embrión	O
etiquetado	O
negativamente	O
para	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
.	O

Sólo	O
se	O
puede	O
observar	O
un	O
marcado	O
de	O
fondo	O
no	O
específico	O
.	O

En	O
cada	O
panel	O
,	O
la	O
imagen	O
de	O
la	O
derecha	O
muestra	O
la	O
fusión	O
entre	O
el	O
HP1	B-Protein
alfa	I-Protein
fluorescencia	O
y	O
DAPI	O
-	O
teñido	O
ADN	B-Sequence
en	O
azul	O
.	O

El	O
color	O
rosa	O
indica	O
la	O
asociación	O
de	O
HP1	B-Protein
con	O
material	O
denso	O
en	O
DAPI	O
.	O

La	O
parte	O
inferior	O
de	O
cada	O
panel	O
muestra	O
la	O
ampliación	O
de	O
un	O
núcleo	B-GENE
seleccionado	O
del	O
embrión	O
anterior	O
(	O
cuadrado	O
blanco	O
)	O
.	O

La	O
punta	O
de	O
flecha	O
indica	O
el	O
típico	O
focos	B-GENE
de	I-GENE
heterocromatina	I-GENE
revelado	O
por	O
DAPI	O
y	O
HP1	B-Protein
alfa	I-Protein
tinción	O
en	O
tipo	B-Sequence
salvaje	I-Sequence
embriones	O

Estos	O
focos	O
no	O
son	O
visibles	O
en	O
Chaf1a	B-Protein
-	O
/	O
-	O
embriones	O
.	O

DAPI	O
y	O
HP1	B-Protein
alfa	I-Protein
las	O
tinciones	O
son	O
difusas	O
dentro	O
de	O
la	O
núcleo	B-GENE
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
-	O
embriones	O
empobrecidos	O
,	O
con	O
enriquecimiento	O
en	O
el	O
nuclear	B-GENE
periferia	O
,	O
revelando	O
anormal	O
heterocromatina	B-GENE
organización	O

Las	O
barras	O
de	O
escala	O
representan	O
10	O
mu	O
m	O
.	O

(	O
mi	O
)	O
Tipo	B-Sequence
salvaje	I-Sequence
embriones	O
aislados	O
en	O
el	O
día	O
embrionario	O
2	O
(	O
E2	O
,	O
dos	O
células	B-Cell
)	O
,	O
E2	O
.	O
5	O
(	O
cuatro	O
células	B-Cell
)	O
,	O
E3	O
(	O
ocho	O
células	B-Cell
)	O
,	O
E3	O
.	O
5	O
(	O
16	O
células	B-Cell
)	O
,	O
y	O
E4	O
(	O
32	O
células	B-Cell
)	O
son	O
exhibidos	O
.	O

heterocromatina	B-GENE
fue	O
monitoreado	O
por	O
tinción	O
DAPI	O
(	O
panel	O
superior	O
)	O
y	O
HP1	B-Protein
inmunomarcaje	O
(	O
en	O
rojo	O
,	O
panel	O
inferior	O
)	O
.	O

(	O
F	O
)	O
Ampliación	O
de	O
un	O
núcleo	B-GENE
(	O
teñido	O
con	O
DAPI	O
)	O
representativo	O
de	O
cada	O
etapa	O
.	O

El	O
panel	O
de	O
la	O
derecha	O
muestra	O
el	O
núcleo	B-GENE
de	O
un	O
ES	O
célula	B-Cell
.	O

La	O
barra	O
de	O
escala	O
representa	O
10	O
mu	O
m	O
.	O

Figura	O
2	O

Agotamiento	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
en	O
ES	O
Células	B-Cell
Resulta	O
en	O
una	O
Alteración	O
Severa	O
de	O
heterocromatina	B-GENE
Organización	O

(	O
A	O
)	O
Estrategia	O
utilizada	O
para	O
agotar	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
por	O
ARNi	O
en	O
ES	O
células	B-Cell
.	O

los	O
siARN	B-Sequence
expresión	O
vector	B-Sequence
incluye	O
un	O
puromicina	B-Chemical
selección	O
casete	B-Sequence
(	O
Puro	O
)	O
,	O
el	O
ratón	B-Taxon
H1	O
promotor	B-Sequence
,	O
y	O
el	O
siARN	B-Sequence
codificación	O
secuencia	B-Sequence
.	O

ES	O
células	B-Cell
se	O
mantuvieron	O
bajo	O
puromicina	B-Chemical
selección	O
durante	O
las	O
48	O
h	O
siguientes	O
a	O
la	O
transfección	O
.	O

(	O
B	O
)	O
Anormal	O
heterocromatina	B-GENE
organización	O
en	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
.	O

Inmunodetección	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
(	O
verde	O
)	O
y	O
HP1	B-Protein
alfa	I-Protein
(	O
rojo	O
)	O
en	O
ES	O
células	B-Cell
transfectado	O
con	O
control	O
(	O
cont	O
)	O
y	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
siARN	B-Sequence
.	O

siARN	B-Sequence
resultados	O
de	O
expresión	O
eficientes	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
agotamiento	O

La	O
imagen	O
de	O
la	O
derecha	O
muestra	O
la	O
fusión	O
entre	O
HP1	B-Protein
alfa	I-Protein
fluorescencia	O
y	O
DAPI	O
-	O
teñido	O
ADN	B-Sequence
en	O
azul	O
.	O

Barra	O
de	O
escala	O
=	O
10	O
mu	O
m	O
.	O

(	O
C	O
)	O
heterocromatina	B-GENE
la	O
organización	O
no	O
se	O
altera	O
en	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O

Inmunodetección	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
(	O
verde	O
)	O
y	O
HP1	B-Protein
alfa	I-Protein
(	O
rojo	O
)	O
en	O
MEF	O
transfectados	O
con	O
control	O
(	O
cont	O
)	O
o	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
siARN	B-Sequence
.	O

La	O
imagen	O
de	O
la	O
derecha	O
muestra	O
la	O
fusión	O
entre	O
HP1	B-Protein
alfa	I-Protein
fluorescencia	O
y	O
DAPI	O
-	O
teñido	O
ADN	B-Sequence
en	O
azul	O
.	O

(	O
D	O
)	O
cuerpos	B-GENE
de	I-GENE
LMP	I-GENE
no	O
se	O
alteran	O
en	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
.	O

Inmunodetección	O
de	O
LMP	B-Protein
(	O
rojo	O
)	O
en	O
ES	O
células	B-Cell
transfectado	O
con	O
control	O
(	O
cont	O
)	O
o	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
siARN	B-Sequence
.	O

La	O
imagen	O
de	O
la	O
derecha	O
muestra	O
la	O
fusión	O
entre	O
LMP	B-Protein
fluorescencia	O
y	O
DAPI	O
-	O
teñido	O
ADN	B-Sequence
en	O
azul	O
.	O

figura	O
3	O

p150CAF	B-Protein
-	I-Protein
1	I-Protein
Agotamiento	O
y	O
pérdida	O
de	O
heterocromatina	B-GENE
La	O
organización	O
es	O
compatible	O
con	O
Active	O
ADN	B-Sequence
Replicación	O
en	O
ES	O
Células	B-Cell

(	O
A	O
)	O
ES	O
células	B-Cell
fueron	O
transfectados	O
con	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
o	O
controlar	O
vectores	B-Sequence
siARN	I-Sequence
.	O

Después	O
de	O
3	O
d	O
bajo	O
puromicina	B-Chemical
selección	O
,	O
células	B-Cell
fueron	O
marcados	O
por	O
pulsos	O
durante	O
10	O
min	O
con	O
BrdU	O
e	O
inmediatamente	O
analizados	O
por	O
IF	O
.	O

Sin	O
diferencia	O
significativa	O
en	O
BrdU	O
incorporación	B-Sequence
podría	O
detectarse	O
entre	O
control	O
y	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
.	O

La	O
imagen	O
de	O
la	O
derecha	O
muestra	O
la	O
fusión	O
entre	O
el	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
y	O
fluorescencia	O
BrdU	O
.	O

Barra	O
de	O
escala	O
=	O
10	O
mu	O
m	O
.	O

(	O
B	O
)	O
Inmunodetección	O
de	O
PCNA	B-Protein
(	O
rojo	O
)	O
no	O
reveló	O
diferencias	O
significativas	O
en	O
la	O
formación	O
de	O
focos	O
de	O
replicación	O
entre	O
el	O
control	O
y	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
.	O

Inmunodetección	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
se	O
muestra	O
en	O
verde	O
y	O
la	O
fusión	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
y	O
PCNA	B-Protein
aparece	O
en	O
amarillo	O
.	O

(	O
C	O
)	O
El	O
análisis	O
de	O
citometría	O
de	O
flujo	O
mostró	O
un	O
resultado	O
similar	O
célula	B-Cell
#	O
¿NOMBRE	O
?	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
.	O

Los	O
resultados	O
se	O
presentan	O
como	O
el	O
porcentaje	O
de	O
células	B-Cell
en	O
cada	O
fase	O
de	O
la	O
célula	B-Cell
ciclo	O
(	O
G1	O
,	O
S	O
,	O
G2	O
/	O
M	O
)	O
,	O
según	O
lo	O
definido	O
por	O
BrdU	O
incorporación	B-Sequence
y	O
ADN	B-Sequence
contenido	O
.	O

Los	O
datos	O
presentados	O
son	O
la	O
media	O
de	O
tres	O
experimentos	O
independientes	O
;	O
las	O
barras	O
de	O
error	O
indican	O
la	O
desviación	O
estándar	O
.	O

Todos	O
los	O
experimentos	O
se	O
realizaron	O
3	O
días	O
después	O
de	O
la	O
transfección	O
del	O
vectores	B-Sequence
siARN	I-Sequence
.	O

Figura	O
4	O

Agotamiento	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
Conduce	O
a	O
la	O
pérdida	O
de	O
agrupamiento	O
,	O
localización	O
alterada	O
y	O
descondensación	O
de	O
Dominios	B-GENE
de	I-GENE
heterocromatina	I-GENE
pericéntricos	I-GENE

Distribución	O
de	O
dominios	B-GENE
pericéntricos	I-GENE
(	I-GENE
rojo	I-GENE
)	I-GENE
y	I-GENE
céntricos	I-GENE
(	I-GENE
verde	I-GENE
)	I-GENE
se	O
analizó	O
en	O
la	O
interfase	O
núcleos	B-GENE
de	O
ratón	B-Taxon
ES	O
células	B-Cell
por	O
ADN	B-Sequence
PESCADO	O
,	O
usando	O
mayor	O
satélite	B-Sequence
(	I-Sequence
pSAT	I-Sequence
)	I-Sequence
[	I-Sequence
47	I-Sequence
]	I-Sequence
y	I-Sequence
satélite	I-Sequence
menor	I-Sequence
(	I-Sequence
pMR150	I-Sequence
)	I-Sequence
[	I-Sequence
48	I-Sequence
]	I-Sequence
sondas	I-Sequence
de	I-Sequence
ADN	I-Sequence
,	O
respectivamente	O
.	O

(	O
A	O
)	O
En	O
ES	O
células	B-Cell
expresando	O
control	O
(	O
continuación	O
)	O
siARN	B-Sequence
,	O
regiones	B-GENE
pericéntricas	I-GENE
de	I-GENE
varios	I-GENE
cromosomas	I-GENE
asociar	O
en	O
racimos	O
(	O
rojo	O
)	O
.	O

Estas	O
cromocentros	B-GENE
forma	O
focos	O
como	O
lo	O
revela	O
la	O
tinción	O
DAPI	O
(	O
imagen	O
de	O
la	O
izquierda	O
)	O
,	O
mientras	O
que	O
la	O
céntrica	O
regiones	B-Sequence
(	O
verde	O
)	O
siguen	O
siendo	O
entidades	O
independientes	O
en	O
la	O
periferia	O
de	O
estos	O
dominios	B-Sequence
.	O

La	O
imagen	O
de	O
la	O
derecha	O
muestra	O
la	O
fusión	O
entre	O
el	O
pericéntrico	B-GENE
y	O
señales	O
FISH	O
céntricas	O
.	O

(	O
B	O
)	O
La	O
organización	O
de	O
dominios	B-GENE
pericéntricos	I-GENE
fue	O
alterado	O
en	O
células	B-Cell
expresando	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
siARN	B-Sequence
.	O

En	O
lugar	O
de	O
formar	O
bien	O
-	O
definido	O
cromocentros	B-GENE
,	O
dominios	B-GENE
pericéntricos	I-GENE
fueron	O
encontrados	O
aislados	O
o	O
asociados	O
en	O
agregados	O
heterogéneos	O
de	O
varios	O
tamaños	O
,	O
a	O
menudo	O
en	O
la	O
nuclear	B-GENE
periferia	O

Barra	O
de	O
escala	O
=	O
10	O
mu	O
m	O
.	O

(	O
C	O
)	O
ES	O
de	O
control	O
células	B-Cell
.	O

La	O
fluorescencia	O
se	O
cuantificó	O
a	O
lo	O
largo	O
de	O
una	O
línea	O
dibujada	O
aleatoriamente	O
a	O
lo	O
largo	O
de	O
la	O
núcleo	B-GENE
en	O
la	O
imagen	O
fusionada	O
y	O
los	O
datos	O
fueron	O
trazados	O
.	O

Se	O
pueden	O
distinguir	O
picos	O
claros	O
correspondientes	O
a	O
cromocentros	B-GENE
(	O
rojo	O
)	O
y	O
el	O
menor	O
condensado	O
satélites	B-Sequence
(	O
verde	O
)	O
.	O

(	O
D	O
)	O
ES	O
células	B-Cell
expresando	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
siARN	B-Sequence
.	O

p150CAF	B-Protein
-	I-Protein
1	I-Protein
el	O
agotamiento	O
condujo	O
a	O
una	O
menor	O
intensidad	O
de	O
fluorescencia	O
y	O
una	O
distribución	O
más	O
amplia	O
de	O
señales	O
correspondientes	O
a	O
DAPI	O
(	O
azul	O
)	O
y	O
mayor	O
satélite	B-Sequence
hibridación	O
(	O
rojo	O
,	O
parcela	O
)	O
mientras	O
que	O
la	O
organización	O
del	O
menor	O
satélites	B-Sequence
permaneció	O
inafectado	O
.	O

Los	O
recuadros	O
en	O
las	O
imágenes	O
de	O
la	O
derecha	O
muestran	O
un	O
típico	O
cromocentro	B-GENE
en	O
control	O
células	B-Cell
(	O
C	O
)	O
y	O
un	O
interrumpido	O
cromocentro	B-GENE
en	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
(	O
D	O
)	O
.	O

Figura	O
5	O

Nucleosomal	B-GENE
La	O
organización	O
no	O
se	O
altera	O
en	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
Células	B-Cell

Los	O
núcleos	O
se	O
prepararon	O
a	O
partir	O
de	O
ES	O
células	B-Cell
transfectado	O
con	O
control	O
o	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
vector	B-Sequence
siARN	I-Sequence
.	O

Núcleos	B-GENE
fueron	O
digeridos	O
con	O
cantidades	O
crecientes	O
de	O
ADNasa	B-Protein
I	I-Protein
o	O
MNasa	O
.	O

(	O
A	O
)	O
Después	O
de	O
la	O
digestión	O
con	O
las	O
nucleasas	O
indicadas	O
,	O
total	O
ADN	B-Sequence
fue	O
preparado	O
y	O
corrido	O
hacia	O
un	O
agarosa	B-Chemical
gel	O
que	O
se	O
tiñó	O
con	O
bromuro	B-Chemical
de	I-Chemical
etidio	I-Chemical
revelar	O
volumen	O
ADN	B-Sequence
genómico	I-Sequence
.	O

(	O
B	O
)	O
El	O
ADN	B-Sequence
fue	O
borrado	O
en	O
un	O
nylon	B-Chemical
membrana	O
,	O
que	O
luego	O
se	O
hibridó	O
con	O
el	O
alfa-	O
32P	B-Chemical
#	O
¿NOMBRE	O
?	O
sonda	B-Sequence
de	I-Sequence
repetición	I-Sequence
de	I-Sequence
satélite	I-Sequence
[	O
47	O
]	O
.	O

Figura	O
6	O

ADN	B-Sequence
Metilación	O
de	O
CpG	O
en	O
heterocromatina	B-GENE
pericéntrica	I-GENE
No	O
es	O
alterado	B-Sequence
en	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
Células	B-Cell

Total	O
ADN	B-Sequence
fue	O
aislado	O
de	O
células	B-Cell
transfectado	O
con	O
un	O
control	O
o	O
el	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
vector	B-Sequence
siARN	I-Sequence
y	O
digerido	O
con	O
MaeII	O
,	O
cuyo	O
secuencia	B-Sequence
de	I-Sequence
reconocimiento	I-Sequence
está	O
presente	O
en	O
mayor	O
repeticiones	B-Sequence
de	I-Sequence
satélite	I-Sequence
.	O

Digesto	O
ADN	B-Sequence
fue	O
atropellado	O
en	O
un	O
agarosa	B-Chemical
gel	O
y	O
analizado	O
por	O
transferencia	O
de	O
Southern	O
utilizando	O
el	O
pSAT	O
mayor	O
sonda	B-Sequence
satelital	I-Sequence
[	O
47	O
]	O
.	O

Figura	O
7	O

Alteración	O
del	O
Marcaje	O
Epigenético	O
en	O
heterocromatina	B-GENE
pericéntrica	I-GENE
en	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
Células	B-Cell

(	O
A	O
)	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
el	O
agotamiento	O
conduce	O
a	O
la	O
reducción	O
de	O
H4K20me3	O
y	O
H3K9me3	O
en	O
heterocromatina	B-GENE
pericéntrica	I-GENE
.	O

Enriquecimiento	O
de	O
histona	B-Chemical
marcas	O
en	O
mayor	O
repeticiones	B-Sequence
de	I-Sequence
satélite	I-Sequence
fue	O
determinado	O
por	O
ChIP	O
del	O
control	O
(	O
cont	O
)	O
y	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
(	O
p150	B-Protein
)	O
siARN	B-Sequence
#	O
¿NOMBRE	O
?	O
células	B-Cell
.	O

ADN	B-Sequence
preparado	O
a	O
partir	O
de	O
la	O
entrada	O
y	O
la	O
anticuerpo	B-GENE
#	O
¿NOMBRE	O
?	O
fracción	B-GENE
fueron	O
corridos	O
hacia	O
un	O
agarosa	B-Chemical
gel	O
y	O
analizado	O
por	O
Southern	O
blot	O
con	O
el	O
pSAT	O
major	O
sonda	B-Sequence
de	I-Sequence
repetición	I-Sequence
de	I-Sequence
satélite	I-Sequence
[	O
47	O
]	O
.	O

(	O
B	O
)	O
Las	O
señales	O
de	O
hibridación	O
se	O
cuantificaron	O
usando	O
un	O
Instant	O
Imager	O
.	O

Después	O
de	O
la	O
autorradiografía	O
,	O
la	O
membrana	O
fue	O
despojada	O
y	O
rehibridada	O
con	O
una	O
pequeña	O
sonda	B-Sequence
satelital	I-Sequence
[	O
49	O
]	O
.	O

Después	O
de	O
la	O
cuantificación	O
,	O
la	O
membrana	O
fue	O
despojada	O
y	O
rehibridada	O
con	O
un	O
IAP	O
sonda	B-Sequence
LTR	I-Sequence
[	O
50	O
]	O
.	O

Los	O
resultados	O
se	O
presentan	O
como	O
la	O
cantidad	O
de	O
ADN	B-Sequence
inmunoprecipitado	O
de	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
dividido	O
por	O
el	O
ADN	B-Sequence
obtenido	O
del	O
control	O
células	B-Cell
.	O

La	O
figura	O
muestra	O
el	O
valor	O
medio	O
y	O
la	O
desviación	O
estándar	O
de	O
tres	O
experimentos	O
ChIP	O
independientes	O
.	O

(	O
C	O
y	O
D	O
)	O
Los	O
patrones	O
de	O
fluorescencia	O
H3K9me3	O
y	O
H4K20me3	O
están	O
severamente	O
alterados	O
en	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
.	O

Inmunodetección	O
de	O
H3K9me3	O
(	O
C	O
,	O
verde	O
)	O
,	O
H4K20me3	O
(	O
D	O
,	O
verde	O
)	O
y	O
HP1	B-Protein
alfa	I-Protein
(	O
rojo	O
)	O
en	O
control	O
y	O
p150CAF	B-Protein
-	I-Protein
1	I-Protein
siARN	B-Sequence
#	O
¿NOMBRE	O
?	O
células	B-Cell
.	O

Fusión	O
de	O
HP1	B-Protein
alfa	I-Protein
con	O
H3K9me3	O
(	O
C	O
)	O
y	O
H4K20me3	O
(	O
D	O
)	O
se	O
muestra	O
en	O
amarillo	O
.	O

Las	O
barras	O
de	O
escala	O
representan	O
10	O
mu	O
m	O
.	O

notas	O
al	O
pie	O

moneda	O
Dirección	O
actual	O
:	O
Unit	O
e	O
de	O
G	O
ene	O
tique	O
Fonctionnelle	O
de	O
la	O
Souris	O
,	O
Centre	O
National	O
de	O
la	O
Recherche	O
Scientifique	O
URA	O
2578	O
,	O
Institut	O
Pasteur	O
,	O
París	O
,	O
Francia	O

Conflicto	O
de	O
intereses	O
.	O

Los	O
autores	O
han	O
declarado	O
que	O
no	O
existen	O
intereses	O
contrapuestos	O
.	O

Una	O
versión	O
anterior	O
de	O
este	O
artículo	O
apareció	O
como	O
Publicación	O
anticipada	O
en	O
línea	O
el	O
11	O
de	O
septiembre	O
de	O
2006	O
(	O
doi	O
:	O
10	O
.	O
1371/journal	O
.	O
pgen	O
.	O
0020181.	O
eor	O
)	O
.	O

Contribuciones	O
de	O
autor	O
.	O

MH	O
,	O
SB	O
,	O
AVP	O
,	O
JPQ	O
,	O
GA	O
y	O
MG	O
concibieron	O
y	O
diseñaron	O
los	O
experimentos	O
.	O

MH	O
,	O
SB	O
,	O
AVP	O
y	O
PH	O
realizaron	O
los	O
experimentos	O
.	O

MH	O
,	O
SB	O
,	O
AVP	O
y	O
JPQ	O
analizaron	O
los	O
datos	O
.	O

MG	O
escribió	O
el	O
artículo	O
.	O

Financiamiento	O

Este	O
estudio	O
fue	O
financiado	O
por	O
subvenciones	O
de	O
la	O
Association	O
Pour	O
la	O
Recherche	O
Sur	O
le	O
Cancer	O
y	O
la	O
Fondation	O
Pour	O
la	O
Recherche	O
Medicale	O
a	O
MG	O
,	O
y	O
subvenciones	O
de	O
un	O
Programa	O
Colaborativo	O
del	O
Instituto	O
Curie/Commissariat	O
al'Energie	O
Atomique	O
a	O
MG	O
y	O
GA	O
.	O

El	O
equipo	O
de	O
GA	O
está	O
etiquetado	O
por	O
la	O
Ligue	O
Contre	O
le	O
Cancer	O
y	O
forma	O
parte	O
de	O
Epigenome	O
Network	O
.	O

AVP	O
ha	O
sido	O
apoyado	O
por	O
el	O
Instituto	O
Curie	O
y	O
la	O
Fondation	O
Franco	O
Norv	O
e	O
gienne	O
;	O
MH	O
por	O
la	O
CEA	O
,	O
el	O
Instituto	O
Curie	O
y	O
el	O
Canceropole	O
IdF	O
.	O

Rb	B-Protein
#	O
¿NOMBRE	O
?	O
neuronal	B-Cell
Diferenciación	O
a	O
través	O
de	O
Célula	B-Cell
#	O
¿NOMBRE	O
?	O

Resumen	O

Hace	O
tiempo	O
que	O
se	O
sabe	O
que	O
la	O
pérdida	O
de	O
la	O
proteína	B-Protein
de	I-Protein
retinoblastoma	I-Protein
(	O
Rb	B-Protein
)	O
perturba	O
la	O
diferenciación	O
neural	O
,	O
pero	O
el	O
mecanismo	O
subyacente	O
nunca	O
ha	O
sido	O
resuelto	O
.	O

Rb	B-Protein
la	O
ausencia	O
perjudica	O
célula	B-Cell
salida	O
del	O
ciclo	O
y	O
desencadena	O
la	O
muerte	O
de	O
algunos	O
neuronas	B-Cell
,	O
por	O
lo	O
que	O
los	O
defectos	O
de	O
diferenciación	O
bien	O
pueden	O
ser	O
indirectos	O
.	O

De	O
hecho	O
,	O
mostramos	O
que	O
las	O
anomalías	O
tanto	O
en	O
la	O
diferenciación	O
como	O
en	O
las	O
respuestas	O
electrofisiológicas	O
provocadas	O
por	O
la	O
luz	O
en	O
Rb	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
se	O
rescatan	O
cuando	O
la	O
división	O
ectópica	O
y	O
la	O
apoptosis	O
son	O
bloqueadas	O
específicamente	O
por	O
borrando	B-Sequence
factor	B-Protein
de	I-Protein
transcripción	I-Protein
E2f	I-Protein
(	I-Protein
E2f	I-Protein
)	I-Protein
1	I-Protein
.	O

Sin	O
embargo	O
,	O
integral	O
célula	B-Cell
#	O
¿NOMBRE	O
?	O
célula	B-Cell
#	O
¿NOMBRE	O
?	O
células	B-Cell
amacrinas	I-Cell
(	O
SAC	O
)	O
,	O
colinérgico	B-Chemical
interneuronas	B-Cell
crítico	O
en	O
la	O
selectividad	O
de	O
la	O
dirección	O
y	O
las	O
explosiones	O
rítmicas	O
importantes	O
para	O
el	O
desarrollo	O
.	O

típicamente	O
,	O
Rb	B-Protein
se	O
cree	O
que	O
bloquea	O
la	O
división	O
al	O
reprimir	O
E2fs	O
,	O
pero	O
promueve	O
la	O
diferenciación	O
al	O
potenciar	O
factores	O
específicos	O
de	O
tejido	O
.	O

Sorprendentemente	O
,	O
sin	O
embargo	O
,	O
Rb	B-Protein
promueve	O
la	O
diferenciación	O
SAC	O
mediante	O
la	O
inhibición	O
E2f3	B-Protein
actividad	O
.	O

Dos	O
E2f3	B-Protein
isoformas	B-Sequence
existen	O
,	O
y	O
encontramos	O
ambos	O
en	O
la	O
retina	O
en	O
desarrollo	O
,	O
aunque	O
curiosamente	O
muestran	O
una	O
distribución	O
subcelular	O
distinta	O
.	O

Se	O
cree	O
que	O
E2f3b	O
media	O
Rb	B-Protein
función	O
en	O
reposo	O
células	B-Cell
.	O

Sin	O
embargo	O
,	O
en	O
lo	O
que	O
es	O
,	O
hasta	O
donde	O
sabemos	O
,	O
el	O
primer	O
trabajo	O
para	O
diseccionar	O
E2f	O
isoforma	B-Sequence
función	O
in	O
vivo	O
demostramos	O
que	O
Rb	B-Protein
promueve	O
la	O
diferenciación	O
SAC	O
a	O
través	O
de	O
E2f3a	O
.	O

Estos	O
datos	O
revelan	O
un	O
mecanismo	O
a	O
través	O
del	O
cual	O
Rb	B-Protein
regula	O
directamente	O
la	O
diferenciación	O
neuronal	O
e	O
,	O
inesperadamente	O
,	O
implica	O
la	O
inhibición	O
de	O
E2f3a	O
,	O
no	O
la	O
potenciación	O
de	O
factores	O
específicos	O
de	O
tejido	O
.	O

Resumen	O
del	O
autor	O

los	O
proteína	B-Protein
de	I-Protein
retinoblastoma	I-Protein
(	O
Rb	B-Protein
)	O
,	O
un	O
importante	O
supresor	O
de	O
tumores	O
,	O
bloquea	O
la	O
división	O
y	O
la	O
muerte	O
al	O
inhibir	O
la	O
familia	O
de	O
factores	O
de	O
transcripción	O
E2f	O
.	O

A	O
diferencia	O
de	O
,	O
Rb	B-Protein
se	O
cree	O
que	O
promueve	O
la	O
diferenciación	O
al	O
potenciar	O
los	O
factores	O
de	O
transcripción	O
específicos	O
de	O
tejido	O
,	O
aunque	O
los	O
defectos	O
de	O
diferenciación	O
en	O
Rb	B-Protein
nulo	O
células	B-Cell
podría	O
ser	O
una	O
consecuencia	O
indirecta	O
de	O
la	O
división	O
y	O
muerte	O
impulsada	O
por	O
E2f	O
.	O

Aquí	O
,	O
resolvemos	O
diferentes	O
mecanismos	O
por	O
los	O
cuales	O
Rb	B-Protein
controla	O
la	O
división	O
,	O
muerte	O
y	O
diferenciación	O
en	O
la	O
retina	O
.	O

eliminando	O
E2f1	B-Protein
rescata	O
la	O
división	O
aberrante	O
de	O
diferenciar	O
Rb	B-Protein
#	O
¿NOMBRE	O
?	O
neuronas	B-Cell
,	O
así	O
como	O
la	O
muerte	O
en	O
células	B-Cell
propenso	O
a	O
la	O
apoptosis	O
,	O
y	O
restaura	O
tanto	O
la	O
diferenciación	O
normal	O
como	O
la	O
función	O
de	O
los	O
principales	O
célula	B-Cell
tipos	O
,	O
como	O
los	O
fotorreceptores	O
.	O

Sin	O
embargo	O
,	O
Rb	B-Protein
#	O
¿NOMBRE	O
?	O
neuronas	B-Cell
amacrinas	I-Cell
diferenciarse	O
anormalmente	O
incluso	O
cuando	O
E2f1	B-Protein
se	O
elimina	O
,	O
proporcionando	O
un	O
ejemplo	O
inequívoco	O
de	O
un	O
papel	O
directo	O
para	O
Rb	B-Protein
en	O
neuronales	B-Cell
diferenciación	O

En	O
lugar	O
de	O
potenciar	O
un	O
célula	B-Cell
-	O
factor	O
específico	O
,	O
Rb	B-Protein
promueve	O
el	O
estallido	O
estelar	O
célula	B-Cell
diferenciación	O
mediante	O
la	O
inhibición	O
de	O
otro	O
E2f	O
,	O
E2f3a	O
.	O

Esta	O
célula	B-Cell
#	O
¿NOMBRE	O
?	O
Rb	B-Protein
-	O
vía	O
E2f	O
,	O
y	O
sugiere	O
que	O
deberíamos	O
reevaluar	O
su	O
papel	O
en	O
la	O
diferenciación	O
de	O
otros	O
célula	B-Cell
tipos	O

Introducción	O

La	O
simplicidad	O
de	O
la	O
retina	O
la	O
convierte	O
en	O
un	O
tejido	O
ideal	O
para	O
estudiar	O
la	O
neurogénesis	O
.	O

Su	O
desarrollo	O
procede	O
a	O
través	O
de	O
tres	O
pasos	O
superpuestos	O
que	O
comienzan	O
con	O
el	O
progenitor	O
retiniano	O
.	O
célula	B-Cell
(	O
RPC	O
)	O
proliferación	O
,	O
seguida	O
por	O
el	O
nacimiento	O
de	O
la	O
transición	O
retiniana	O
post-mitótica	O
células	B-Cell
(	O
RTC	O
,	O
también	O
denominados	O
precursores	O
)	O
,	O
y	O
finaliza	O
con	O
la	O
diferenciación	O
terminal	O
de	O
siete	O
principales	O
célula	B-Cell
tipos	O
(	O
Figura	O
1A	O
)	O
[	O
1	O
]	O
.	O

Los	O
RPC	O
son	O
multipotentes	O
y	O
salen	O
del	O
célula	B-Cell
ciclo	O
para	O
generar	O
diferentes	O
RTC	O
en	O
períodos	O
de	O
tiempo	O
específicos	O
en	O
desarrollo	O
[	O
1	O
]	O
.	O

``	O
Este	O
proceso	O
de	O
``	O
''	O
nacimiento	O
''	O
''	O
de	O
RTC	O
requiere	O
un	O
acoplamiento	O
de	O
diferenciación	O
y	O
''	O
célula	B-Cell
salida	O
del	O
ciclo	O
.	O

Una	O
vez	O
nacidos	O
,	O
los	O
RTC	O
post-mitóticos	O
migran	O
y	O
forman	O
diferentes	O
capas	O
retinianas	O
.	O

Varillas	B-Cell
y	O
conos	B-Cell
conforman	O
la	O
capa	O
nuclear	O
externa	O
(	O
ONL	O
)	O
;	O
células	B-Cell
horizontales	I-Cell
,	I-Cell
bipolares	I-Cell
y	I-Cell
amacrinas	I-Cell
,	O
así	O
como	O
también	O
Célula	B-Cell
de	I-Cell
glía	I-Cell
de	I-Cell
Müller	I-Cell
cuerpos	O
,	O
residen	O
en	O
la	O
capa	O
nuclear	O
interna	O
(	O
INL	O
)	O
;	O
y	O
células	B-Cell
ganglionares	I-Cell
y	I-Cell
amacrinas	I-Cell
desplazadas	I-Cell
formar	O
el	O
célula	B-Cell
ganglionar	I-Cell
capa	O
(	O
GCL	O
)	O
(	O
Figura	O
1A	O
)	O
.	O

La	O
capa	O
plexiforme	O
externa	O
(	O
OPL	O
)	O
y	O
la	O
capa	O
plexiforme	O
interna	O
(	O
IPL	O
)	O
albergan	O
conexiones	B-GENE
sinápticas	I-GENE
separando	O
ONL/INL	O
e	O
INL/GCL	O
,	O
respectivamente	O
.	O

Figura	O
1	O

E2f1	B-Protein
,	O
pero	O
no	O
E2f2	B-Protein
o	O
E2f3	B-Protein
,	O
Pérdida	O
Rescates	O
División	O
ectópica	O
y	O
Célula	B-Cell
muerte	O
en	O
el	O
Rb	B-Protein
Retina	O
noqueada	O

(	O
A	O
)	O
Desarrollo	O
de	O
la	O
retina	O
.	O

En	O
E11	O
,	O
la	O
retina	O
es	O
un	O
NBL	O
de	O
RPC	O
en	O
división	O
(	O
círculo	O
blanco	O
,	O
verde	O
núcleos	B-GENE
)	O
.	O

RPC	O
cuerpos	B-GENE
celulares	I-GENE
oscilar	O
a	O
lo	O
largo	O
procesos	B-GENE
a	O
medida	O
que	O
avanzan	O
a	O
través	O
de	O
la	O
célula	B-Cell
ciclo	O

En	O
P0	O
,	O
el	O
NBL	O
contiene	O
RPC	O
y	O
RTC	O
posmitóticos	O
(	O
círculos	O
de	O
colores	O
,	O
círculos	O
rojos	O
)	O
.	O
núcleos	B-GENE
)	O
y	O
está	O
separado	O
de	O
la	O
GCL	O
por	O
la	O
IPL	O
.	O

Para	O
P8	O
no	O
hay	O
RPC	O
,	O
menos	O
RTC	O
,	O
una	O
OPL	O
y	O
más	O
diferenciado	O
varillas	B-Cell
(	O
r	B-Cell
)	O
y	O
conos	B-Cell
(	O
C	B-Cell
)	O
en	O
la	O
ONL	O
;	O
células	B-Cell
horizontales	I-Cell
(	I-Cell
h	I-Cell
)	I-Cell
,	I-Cell
bipolares	I-Cell
(	I-Cell
b	I-Cell
)	I-Cell
,	I-Cell
de	I-Cell
M	I-Cell
u	I-Cell
ller	I-Cell
(	I-Cell
m	I-Cell
)	I-Cell
y	I-Cell
amacrinas	I-Cell
(	I-Cell
a	I-Cell
)	I-Cell
en	O
el	O
INL	O
;	O
y	O
ganglio	B-Cell
(	I-Cell
g	I-Cell
)	I-Cell
y	I-Cell
células	I-Cell
amacrinas	I-Cell
desplazadas	I-Cell
en	O
la	O
GCL	O
.	O

El	O
desarrollo	O
se	O
completa	O
en	O
~	O
P18	O
.	O

(	O
B	O
)	O
Rb	B-Protein
se	O
cree	O
que	O
regula	O
célula	B-Cell
ciclo	O
y	O
apoptosis	O
mediante	O
la	O
represión	O
de	O
E2fs	O
,	O
pero	O
para	O
promover	O
la	O
diferenciación	O
mediante	O
la	O
potenciación	O
de	O
factores	O
de	O
transcripción	O
específicos	O
de	O
tejido	O
.	O

Sin	O
embargo	O
,	O
Rb	B-Protein
la	O
pérdida	O
también	O
podría	O
perturbar	O
la	O
diferenciación	O
a	O
través	O
de	O
los	O
efectos	O
indirectos	O
de	O
la	O
división	O
anormal	O
o	O
la	O
muerte	O
y	O
/	O
o	O
mediante	O
la	O
regulación	O
directa	O
de	O
la	O
diferenciación	O
genes	B-Sequence
por	O
E2fs	O
.	O

(	O
C	O
y	O
D	O
)	O
Cortes	O
retinianos	O
horizontales	O
de	O
los	O
indicados	O
genotipos	B-Sequence
y	O
las	O
edades	O
estaban	O
manchadas	O
por	O
núcleos	B-GENE
(	O
DAPI	O
,	O
azul	O
)	O
,	O
y	O
(	O
C	O
)	O
fase	O
S	O
(	O
anti-BrdU	O
,	O
rojo	O
)	O
o	O
(	O
D	O
)	O
apoptosis	O
(	O
TUNEL	O
,	O
rojo	O
)	O
.	O

Las	O
barras	O
de	O
escala	O
son	O
de	O
50	O
mu	O
m	O
.	O

(	O
E	O
-	O
G	O
)	O
Cuantificación	O
de	O
(	O
E	O
)	O
todas	O
las	O
BrdU	O
+	O
células	B-Cell
,	O
(	O
F	O
)	O
BrdU	O
ectópico	O
+	O
células	B-Cell
en	O
GCL	O
en	O
P0	O
,	O
y	O
(	O
G	O
)	O
total	O
TUNEL	O
+	O
células	B-Cell
.	O

(	O
H	O
)	O
RT	O
en	O
tiempo	O
real	O
-	O
Análisis	O
PCR	O
de	O
E2fs	O
y	O
objetivo	O
E2f	O
genes	B-Sequence
en	O
retinas	O
P8	O
de	O
las	O
indicadas	O
genotipos	B-Sequence
.	O

Las	O
barras	O
de	O
error	O
representan	O
SD	O
de	O
mediciones	O
de	O
tres	O
animales	B-Taxon
,	O
y	O
los	O
asteriscos	O
indican	O
una	O
diferencia	O
significativa	O
entre	O
los	O
peso	B-Sequence
e	O
indicado	O
genotipos	B-Sequence
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
;	O
p	O
<	O
0	O
.	O
01	O
;	O
ANOVA	O
y	O
prueba	O
Tukey	O
HSD	O
para	O
[	O
E	O
-	O
G	O
]	O
y	O
prueba	O
de	O
Fisher	O
para	O
[	O
H	O
]	O
)	O
.	O

los	O
proteína	B-Protein
de	I-Protein
retinoblastoma	I-Protein
(	O
Rb	B-Protein
)	O
es	O
fundamental	O
para	O
célula	B-Cell
salida	O
del	O
ciclo	O
durante	O
la	O
transición	O
retiniana	O
célula	B-Cell
nacimiento	O
.	O

Rb	B-Protein
knockout	O
(	O
KO	O
)	O
RTC	O
continúan	O
proliferando	O
de	O
manera	O
inapropiada	O
y	O
algunos	O
(	O
Células	B-Cell
bastoncillos	I-Cell
,	I-Cell
ganglionares	I-Cell
y	I-Cell
bipolares	I-Cell
)	O
mueren	O
por	O
apoptosis	O
[	O
2	O
,	O
3	O
]	O
.	O

Rb	B-Protein
controla	O
el	O
célula	B-Cell
ciclo	O
al	O
unirse	O
e	O
inhibir	O
los	O
factores	O
de	O
transcripción	O
E2f	O
(	O
E2fs	O
)	O
(	O
Figura	O
1B	O
)	O
,	O
definidos	O
primero	O
como	O
factores	O
de	O
transcripción	O
que	O
se	O
unen	O
adenoviral	B-Taxon
E2	O
elementos	B-Sequence
regulatorios	I-Sequence
y	O
posteriormente	O
demostrado	O
ser	O
crítico	O
célula	B-Cell
reguladores	O
de	O
ciclo	O
[	O
4	O
,	O
5	O
]	O
.	O

E2fs	O
se	O
une	O
a	O
ADN	B-Sequence
como	O
heterodímeros	O
con	O
proteinas	B-Chemical
de	O
la	O
familia	O
Tfdp	O
relacionada	O
.	O

E2f1	B-Protein
,	O
E2f2	B-Protein
``	O
,	O
y	O
E2f3a	O
están	O
``	O
''	O
activando	O
E2fs	O
''	O
''	O
que	O
se	O
requieren	O
para	O
''	O
fibroblasto	B-Cell
división	O

Son	O
potentes	O
activadores	O
transcripcionales	O
que	O
pueden	O
impulsar	O
G0	O
fibroblastos	B-Cell
en	O
el	O
ciclo	O
,	O
y	O
se	O
inhiben	O
cuando	O
se	O
unen	O
a	O
Rb	B-Protein
[	O
4	O
,	O
5	O
]	O
.	O

División	O
ectópica	O
en	O
Rb	B-Protein
Los	O
embriones	O
KO	O
se	O
pueden	O
rescatar	O
en	O
diversos	O
grados	O
en	O
diferentes	O
tejidos	O
eliminando	O
E2f1	B-Protein
,	O
E2f2	B-Protein
,	O
o	O
E2f3	B-Protein
[	O
6	O
-	O
9	O
]	O
,	O
pero	O
qué	O
miembro	O
(	O
s	O
)	O
impulsan	O
la	O
división	O
en	O
Rb	B-Protein
KO	O
RTC	O
es	O
desconocido	O
.	O

Otros	O
miembros	O
de	O
la	O
familia	O
,	O
como	O
E2f4	B-Protein
y	O
E2f5	B-Protein
``	O
,	O
se	O
conocen	O
como	O
``	O
''	O
E2fs	O
represivas	O
''	O
''	O
porque	O
son	O
activadores	O
débiles	O
y	O
parecen	O
estar	O
principalmente	O
involucrados	O
en	O
''	O
gene	B-Sequence
silenciamiento	O
en	O
reposo	O
o	O
diferenciado	O
células	B-Cell
.	O

La	O
activación	O
de	O
E2fs	O
también	O
puede	O
promover	O
la	O
apoptosis	O
en	O
el	O
Rb	B-Protein
Retina	O
KO	O
(	O
Figura	O
1B	O
)	O
.	O

Originalmente	O
,	O
E2f1	B-Protein
fue	O
considerado	O
el	O
principal	O
miembro	O
pro-apoptótico	O
de	O
la	O
familia	O
[	O
10	O
]	O
.	O

Sin	O
embargo	O
,	O
este	O
punto	O
de	O
vista	O
fue	O
reevaluado	O
cuando	O
se	O
demostró	O
que	O
E2f1	B-Protein
o	O
E2f3	B-Protein
supresión	B-Sequence
rescata	O
la	O
apoptosis	O
en	O
el	O
sistema	O
nervioso	O
central	O
(	O
SNC	O
)	O
en	O
desarrollo	O
de	O
Rb	B-Protein
Embriones	O
KO	O
[	O
6	O
,	O
11	O
]	O
.	O

Posteriormente	O
,	O
se	O
demostró	O
que	O
la	O
apoptosis	O
del	O
SNC	O
es	O
un	O
resultado	O
indirecto	O
de	O
defectos	O
placentarios	O
y	O
probable	O
hipoxia	O
[	O
12-14	O
]	O
.	O

Por	O
supuesto	O
,	O
E2f3	B-Protein
#	O
¿NOMBRE	O
?	O
fibroblastos	B-Cell
recientemente	O
se	O
ha	O
demostrado	O
que	O
requiere	O
E2f1	B-Protein
[	O
15	O
]	O
.	O

Por	O
lo	O
tanto	O
,	O
es	O
controvertido	O
si	O
E2f3	B-Protein
se	O
requiere	O
para	O
la	O
apoptosis	O
de	O
cualquier	O
Rb	B-Protein
KO	O
célula	B-Cell
escribe	O
.	O

Determinar	O
qué	O
E2fs	O
activadores	O
promueven	O
la	O
muerte	O
en	O
distintos	O
Rb	B-Protein
Los	O
tejidos	O
KO	O
requieren	O
modelos	O
condicionales	O
en	O
lugar	O
de	O
líneas	O
germinales	O
de	O
Rb	B-Protein
supresión	B-Sequence
para	O
evitar	O
efectos	O
secundarios	O
secundarios	O
(	O
como	O
la	O
hipoxia	O
)	O
.	O

La	O
diversidad	O
familiar	O
E2f	O
se	O
amplía	O
con	O
E2f3	B-Protein
isoformas	B-Sequence
.	O

Alternativa	O
promotores	B-Sequence
generar	O
dos	O
formularios	B-Sequence
(	O
a	O
y	O
b	O
)	O
que	O
son	O
idénticos	O
excepto	O
por	O
distintos	O
primero	O
exones	B-Sequence
[	O
dieciséis	O
]	O
.	O

E2f3a	O
es	O
un	O
activador	O
fuerte	O
y	O
,	O
al	O
igual	O
que	O
otros	O
E2fs	O
activadores	O
,	O
su	O
expresión	O
se	O
induce	O
cuando	O
está	O
en	O
reposo	O
.	O
células	B-Cell
son	O
estimulados	O
a	O
dividirse	O
[	O
16	O
]	O
.	O

E2f3b	O
,	O
como	O
el	O
represivo	O
E2fs	O
,	O
está	O
presente	O
tanto	O
en	O
el	O
estado	O
de	O
reposo	O
como	O
en	O
el	O
de	O
división	O
.	O
células	B-Cell
,	O
y	O
en	O
reposo	O
fibroblastos	B-Cell
se	O
asocia	O
principalmente	O
con	O
Rb	B-Protein
,	O
sugiriendo	O
que	O
media	O
la	O
represión	O
[	O
16	O
-	O
18	O
]	O
.	O

De	O
hecho	O
,	O
silenciar	O
a	O
los	O
cdkn2d	B-Protein
(	O
p19Arf	B-Protein
)	O
lugar	B-Sequence
en	O
átono	O
células	B-Cell
se	O
basa	O
en	O
E2f3b	O
[	O
19	O
]	O
.	O

También	O
pueden	O
existir	O
otros	O
E2fs	O
en	O
isoformas	B-Sequence
desde	O
al	O
menos	O
dos	O
ARNm	B-Chemical
especies	B-Sequence
han	O
sido	O
detectados	O
por	O
E2f1	B-Protein
y	O
E2f2	B-Protein
[	O
dieciséis	O
]	O
.	O

Los	O
roles	O
de	O
E2f	O
isoformas	B-Sequence
in	O
vivo	O
son	O
desconocidos	O
.	O

E2fs	O
también	O
están	O
regulados	O
por	O
localización	O
subcelular	O
.	O

Aunque	O
esta	O
característica	O
ha	O
sido	O
mejor	O
caracterizada	O
para	O
E2fs	O
represiva	O
[	O
20-22	O
]	O
,	O
también	O
afecta	O
la	O
activación	O
de	O
E2fs	O
[	O
23-25	O
]	O
.	O

La	O
distribución	O
de	O
E2f	O
isoformas	B-Sequence
nunca	O
ha	O
sido	O
evaluado	O
.	O

Se	O
sabe	O
desde	O
hace	O
muchos	O
años	O
que	O
Rb	B-Protein
la	O
pérdida	O
perturba	O
neuronales	B-Cell
diferenciación	O
[	O
26	O
-	O
29	O
]	O
.	O

Sin	O
embargo	O
,	O
el	O
trabajo	O
previo	O
no	O
pudo	O
excluir	O
la	O
posibilidad	O
de	O
que	O
los	O
defectos	O
de	O
diferenciación	O
sean	O
simplemente	O
una	O
consecuencia	O
indirecta	O
de	O
la	O
división	O
anormal	O
y	O
la	O
muerte	O
.	O

Si	O
Rb	B-Protein
regula	O
la	O
diferenciación	O
directamente	O
,	O
no	O
está	O
claro	O
si	O
lo	O
hace	O
en	O
todos	O
o	O
en	O
un	O
subconjunto	O
de	O
neuronas	B-Cell
.	O

Además	O
,	O
el	O
mecanismo	O
nunca	O
ha	O
sido	O
resuelto	O
.	O

En	O
otra	O
célula	B-Cell
tipos	O
donde	O
Rb	B-Protein
puede	O
promover	O
la	O
diferenciación	O
directamente	O
,	O
como	O
el	O
músculo	O
y	O
el	O
hueso	O
,	O
parece	O
hacerlo	O
a	O
través	O
de	O
medios	O
independientes	O
de	O
E2f	O
al	O
potenciar	O
los	O
factores	O
de	O
transcripción	O
específicos	O
del	O
tejido	O
(	O
Figura	O
1B	O
)	O
[	O
30-33	O
]	O
.	O

En	O
la	O
retina	O
,	O
otros	O
han	O
notado	O
formas	O
anormales	O
Rb	B-Protein
KO	O
varillas	B-Cell
y	O
han	O
sugerido	O
Rb	B-Protein
puede	O
promover	O
directamente	O
su	O
morfogénesis	O
mediante	O
la	O
activación	O
de	O
factores	O
específicos	O
de	O
la	O
retina	O
[	O
29	O
]	O
.	O

Sin	O
embargo	O
,	O
los	O
defectos	O
de	O
diferenciación	O
en	O
cualquier	O
Rb	B-Protein
KO	O
neurona	B-Cell
podría	O
ser	O
un	O
efecto	O
indirecto	O
de	O
la	O
división	O
ectópica	O
y/o	O
apoptosis	O
(	O
Figura	O
1B	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
es	O
fundamental	O
estudiar	O
la	O
diferenciación	O
de	O
Rb	B-Protein
KO	O
células	B-Cell
en	O
ausencia	O
de	O
proliferación	O
ectópica	O
y	O
muerte	O
.	O

Aquí	O
establecemos	O
que	O
Rb	B-Protein
suprime	O
la	O
división	O
RTC	O
y	O
la	O
muerte	O
al	O
inhibir	O
E2f1	B-Protein
,	O
no	O
E2f2	B-Protein
o	O
E2f3	B-Protein
.	O

Cuando	O
se	O
rescataron	O
estos	O
defectos	O
,	O
la	O
mayoría	O
de	O
los	O
defectos	O
retinianos	O
neuronas	B-Cell
,	O
incluyendo	O
varillas	B-Cell
sobrevivió	O
,	O
se	O
diferenció	O
y	O
funcionó	O
normalmente	O
.	O

Por	O
lo	O
tanto	O
,	O
inesperadamente	O
,	O
los	O
factores	O
de	O
diferenciación	O
específicos	O
de	O
la	O
retina	O
funcionan	O
independientemente	O
de	O
Rb	B-Protein
.	O

Sin	O
embargo	O
,	O
una	O
evaluación	O
exhaustiva	O
de	O
la	O
Rb	B-Protein
/	O
E2f1	B-Protein
retina	O
rescatada	O
doble	O
-	O
nula	O
reveló	O
un	O
defecto	O
de	O
diferenciación	O
en	O
colinérgico	B-Chemical
estallido	O
estelar	O
células	B-Cell
amacrinas	I-Cell
(	O
SAC	O
)	O
.	O

Avances	O
recientes	O
han	O
revelado	O
que	O
estos	O
interneuronas	B-Cell
son	O
fundamentales	O
para	O
la	O
selectividad	O
de	O
la	O
dirección	O
y	O
los	O
estallidos	O
rítmicos	O
importantes	O
para	O
el	O
desarrollo	O
[	O
34	O
-	O
36	O
]	O
.	O

Sin	O
embargo	O
,	O
su	O
diferenciación	O
es	O
poco	O
conocida	O
.	O

Contrariamente	O
a	O
la	O
opinión	O
predominante	O
de	O
que	O
Rb	B-Protein
promueve	O
la	O
diferenciación	O
a	O
través	O
de	O
factores	O
de	O
transcripción	O
específicos	O
de	O
tejido	O
independientes	O
de	O
E2f	O
,	O
mostramos	O
que	O
Rb	B-Protein
facilita	O
el	O
desarrollo	O
del	O
SAC	O
a	O
través	O
de	O
E2f3	B-Protein
.	O

Defectos	O
en	O
Rb	B-Protein
SAC	O
nulos	O
correlacionados	O
con	O
específicos	O
E2f3	B-Protein
expresión	O
en	O
estos	O
células	B-Cell
,	O
y	O
E2f3	B-Protein
la	O
expresión	O
estaba	O
ausente	O
en	O
neuronas	B-Cell
que	O
diferenciaba	O
sin	O
Rb	B-Protein
.	O

E2f3	B-Protein
también	O
está	O
presente	O
en	O
un	O
subconjunto	O
específico	O
de	O
otros	O
neuronas	B-Cell
del	I-Cell
SNC	I-Cell
,	O
lo	O
que	O
implica	O
que	O
esto	O
puede	O
ser	O
un	O
mecanismo	O
general	O
por	O
el	O
cual	O
Rb	B-Protein
Facilita	O
la	O
neurogénesis	O
.	O

Para	O
definir	O
el	O
mecanismo	O
con	O
más	O
detalle	O
,	O
determinamos	O
qué	O
E2f3	B-Protein
isoforma	B-Sequence
Rb	B-Protein
objetivos	O
para	O
controlar	O
la	O
diferenciación	O
SAC	O
.	O

E2f3b	O
media	O
Rb	B-Protein
función	O
en	O
reposo	O
fibroblastos	B-Cell
[	O
19	O
]	O
,	O
sin	O
embargo	O
,	O
hasta	O
donde	O
sabemos	O
,	O
ningún	O
estudio	O
previo	O
ha	O
analizado	O
las	O
funciones	O
de	O
E2f3a	O
o	O
E2f3b	O
in	O
vivo	O
.	O

Usando	O
un	O
isoforma	B-Sequence
#	O
¿NOMBRE	O
?	O
ratón	B-Taxon
mostramos	O
que	O
Rb	B-Protein
impulsa	O
la	O
diferenciación	O
SAC	O
a	O
través	O
de	O
E2f3a	O
.	O

Así	O
,	O
independiente	O
de	O
E2f1	B-Protein
-	O
efectos	O
mediados	O
sobre	O
la	O
división	O
y	O
la	O
muerte	O
,	O
Rb	B-Protein
regula	O
neuronales	B-Cell
diferenciación	O
,	O
pero	O
sólo	O
en	O
aspectos	O
específicos	O
.	O
neuronas	B-Cell
e	O
,	O
inesperadamente	O
,	O
a	O
través	O
de	O
E2f3a	O
,	O
factores	O
de	O
diferenciación	O
no	O
específicos	O
de	O
tejido	O
.	O

Resultados	O

Rb	B-Protein
Regula	O
la	O
División	O
y	O
la	O
Muerte	O
a	O
través	O
de	O
E2f1	B-Protein

Usamos	O
el	O
alfa	O
-	O
Cre	O
transgén	B-Sequence
para	O
eliminar	B-Sequence
floxed	I-Sequence
Rb	B-Protein
exón	B-Sequence
19	O
en	O
día	O
embrionario	O
(	O
E	O
)	O
10	O
en	O
retina	O
periférica	O
[	O
2	O
]	O
.	O

RbloxP	O
/	O
loxP	B-Sequence
;	O
Alfa	O
-	O
Cre	O
ratones	B-Taxon
fueron	O
criados	O
con	O
cepas	O
que	O
carecían	O
E2f1	B-Protein
o	O
E2f2	B-Protein
en	O
la	O
línea	O
germinal	O
,	O
o	O
una	O
cepa	O
portadora	O
de	O
flojo	B-Sequence
E2f3	B-Protein
alelo	B-Sequence
[	O
5	O
]	O
.	O

RbloxP	O
/	O
loxP	B-Sequence
;	O
E2f1	B-Protein
+	B-Sequence
/	O
-	O
y	O
RbloxP	O
/	O
loxP	B-Sequence
;	O
E2f1	B-Protein
+	B-Sequence
/	O
-	O
;	O
Alfa	O
-	O
Cre	O
ratones	B-Taxon
fueron	O
criados	O
para	O
producir	O
RbloxP	O
/	O
loxP	B-Sequence
;	O
E2f1	B-Protein
-	O
/	O
-	O
;	O
Alfa	O
-	O
Cre	O
ratones	B-Taxon
a	O
una	O
frecuencia	O
de	O
1/8	O
y	O
los	O
controles	O
de	O
camada	O
a	O
la	O
misma	O
o	O
mayor	O
(	O
1/4	O
)	O
frecuencia	O
.	O

Por	O
simplicidad	O
nos	O
referiremos	O
al	O
RbloxP/	O
loxP	B-Sequence
;	O
E2f1	B-Protein
-	O
/	O
-	O
;	O
alfa	O
-	O
Cre	O
retina	O
periférica	O
como	O
el	O
Rb	B-Protein
/	O
E2f1	B-Protein
Retina	O
de	O
doble	O
knockout	O
(	O
DKO	O
)	O
.	O

Se	O
emplearon	O
estrategias	O
similares	O
en	O
el	O
caso	O
de	O
E2f2	B-Protein
o	O
E2f3	B-Protein
.	O

Cre	O
-	O
mediado	O
excisión	B-Sequence
de	O
Rb	B-Protein
y	O
E2f3	B-Protein
alelos	B-Sequence
en	O
la	O
retina	O
fue	O
confirmado	O
por	O
PCR	O
como	O
se	O
describe	O
anteriormente	O
[	O
2	O
,	O
5	O
]	O
.	O

Para	O
medir	O
ectópico	O
célula	B-Cell
división	O
,	O
ratones	B-Taxon
fueron	O
marcados	O
con	O
pulsos	O
con	O
bromodesoxiuridina	O
(	O
BrdU	O
)	O
2	O
h	O
antes	O
del	O
sacrificio	O
y	O
la	O
retina	O
periférica	O
analizada	O
para	O
BrdU	O
incorporación	B-Sequence
por	O
inmunofluorescencia	O
.	O

Como	O
se	O
informó	O
antes	O
[	O
2	O
,	O
3	O
]	O
,	O
Rb	B-Protein
Las	O
retinas	O
KO	O
exhibieron	O
ectópicos	O
tanto	O
espaciales	O
como	O
temporales	O
.	O
ADN	B-Sequence
síntesis	O
(	O
Figuras	O
1C	O
y	O
S1A	O
)	O
.	O

Esto	O
se	O
detecta	O
fácilmente	O
en	O
E14	O
,	O
E16	O
y	O
el	O
día	O
postnatal	O
(	O
P	O
)	O
0	O
en	O
la	O
retina	O
interna	O
donde	O
BrdU	O
+	O
anormal	O
ganglio	B-Cell
y	O
amacrino	B-Cell
Los	O
RTC	O
están	O
ubicados	O
,	O
o	O
en	O
la	O
región	O
más	O
externa	O
de	O
la	O
retina	O
P0	O
,	O
donde	O
BrdU	O
+	O
fotorreceptor	B-Cell
Los	O
RTC	O
residen	O
(	O
Figuras	O
S1A	O
y	O
S2	O
,	O
flechas	O
)	O
[	O
2	O
]	O
.	O

División	O
RTC	O
ectópica	O
en	O
Rb	B-Protein
KO	O
retinas	O
es	O
aún	O
más	O
evidente	O
en	O
P8	O
o	O
P18	O
,	O
cuando	O
la	O
división	O
se	O
completa	O
en	O
tipo	B-Sequence
salvaje	I-Sequence
(	O
peso	B-Sequence
)	O
retina	O
(	O
Figuras	O
1C	O
y	O
S1A	O
)	O
.	O

Sorprendentemente	O
,	O
la	O
fase	O
S	O
posicionada	O
ectópicamente	O
células	B-Cell
en	O
E14	O
,	O
E16	O
y	O
P0	O
y	O
todas	O
las	O
divisiones	O
anormales	O
en	O
P8	O
y	O
P18	O
fueron	O
completamente	O
suprimidas	O
en	O
el	O
Rb	B-Protein
/	O
E2f1	B-Protein
Retina	O
DKO	O
(	O
Figuras	O
1C	O
,	O
1E	O
,	O
1F	O
,	O
S1A	O
y	O
S2	O
)	O
.	O

A	O
diferencia	O
de	O
,	O
supresión	B-Sequence
de	O
E2f2	B-Protein
o	O
E2f3	B-Protein
no	O
tuvo	O
ningún	O
efecto	O
en	O
ninguna	O
etapa	O
del	O
desarrollo	O
.	O

Análisis	O
de	O
mitosis	O
células	B-Cell
con	O
anti	O
-	O
fosfohistona	O
3	O
(	O
PH3	O
)	O
-	O
específico	O
anticuerpos	B-GENE
confirmó	O
que	O
la	O
pérdida	O
de	O
E2f1	B-Protein
,	O
pero	O
no	O
E2f2	B-Protein
o	O
E2f3	B-Protein
,	O
división	O
ectópica	O
suprimida	O
(	O
Figura	O
S3	O
)	O
.	O

Borrando	B-Sequence
una	O
E2f1	B-Protein
alelo	B-Sequence
fase	O
S	O
ectópica	O
parcialmente	O
suprimida	O
y	O
mitosis	O
en	O
Rb	B-Protein
KO	O
RTC	O
(	O
Figuras	O
1C	O
,	O
1E	O
,	O
1F	O
,	O
S1A	O
,	O
S2	O
y	O
S3	O
)	O
,	O
lo	O
que	O
sugiere	O
que	O
E2f1	B-Protein
impulsa	O
la	O
división	O
ectópica	O
en	O
Rb	B-Protein
KO	O
RTC	O
de	O
forma	O
dependiente	O
de	O
la	O
dosis	O
.	O

Estos	O
datos	O
contrastan	O
con	O
hallazgos	O
previos	O
en	O
el	O
cristalino	O
y	O
SNC	O
de	O
Rb	B-Protein
Embriones	O
KO	O
,	O
donde	O
supresión	B-Sequence
de	O
cualquier	O
activación	O
de	O
E2f	O
suprime	O
la	O
división	O
ectópica	O
hasta	O
cierto	O
punto	O
[	O
6-9	O
]	O
.	O

Pérdida	O
de	O
Rb	B-Protein
en	O
la	O
retina	O
resulta	O
en	O
una	O
considerable	O
apoptosis	O
de	O
RTC	O
,	O
eliminando	O
la	O
mayoría	O
células	B-Cell
bipolares	I-Cell
y	I-Cell
ganglionares	I-Cell
así	O
como	O
muchos	O
varillas	B-Cell
(	O
Figura	O
2A	O
-	O
2D	O
)	O
[	O
2	O
,	O
3	O
]	O
.	O

La	O
pérdida	O
de	O
Rb	B-Protein
KO	O
varillas	B-Cell
es	O
evidente	O
desde	O
el	O
ONL	O
más	O
delgado	O
,	O
y	O
la	O
muerte	O
de	O
estos	O
células	B-Cell
así	O
como	O
también	O
neuronas	B-Cell
bipolares	I-Cell
y	I-Cell
ganglionares	I-Cell
se	O
puede	O
detectar	O
directamente	O
por	O
marcaje	O
doble	O
para	O
apoptosis	O
y	O
célula	B-Cell
-	O
marcadores	O
específicos	O
de	O
tipo	O
[	O
2	O
]	O
(	O
M	O
.	O
P	O
.	O
y	O
R	O
.	O
B	O
.	O
,	O
datos	O
no	O
publicados	O
)	O
.	O

Pérdida	O
de	O
periférico	O
Rb	B-Protein
KO	O
celulas	B-Cell
ganglionares	I-Cell
también	O
es	O
evidente	O
por	O
el	O
adelgazamiento	O
del	O
nervio	O
óptico	O
(	O
D.C.	O
y	O
R.B.	O
,	O
datos	O
no	O
publicados	O
)	O
.	O

Borrando	B-Sequence
E2f1	B-Protein
,	O
pero	O
no	O
E2f2	B-Protein
o	O
E2f3	B-Protein
,	O
bloqueó	O
este	O
ectópico	O
célula	B-Cell
muerte	O
de	O
forma	O
dependiente	O
de	O
la	O
dosis	O
(	O
Figuras	O
1D	O
,	O
1G	O
y	O
S1B	O
)	O
.	O

Figura	O
2	O

E2f1	B-Protein
Supresión	B-Sequence
Rescates	O
Células	B-Cell
ganglionares	I-Cell
,	I-Cell
bastones	I-Cell
y	I-Cell
bipolares	I-Cell
en	I-Cell
la	I-Cell
retina	I-Cell
Rb	I-Cell
KO	I-Cell

(	O
A	O
)	O
Secciones	O
horizontales	O
de	O
retina	O
de	O
ratones	B-Taxon
de	O
las	O
edades	O
indicadas	O
y	O
genotipos	B-Sequence
fueron	O
manchados	O
por	O
núcleos	B-GENE
(	O
DAPI	O
,	O
azul	O
)	O
y	O
marcadores	O
que	O
detectan	O
celulas	B-Cell
ganglionares	I-Cell
(	O
pou4f2	B-Protein
,	O
rojo	O
)	O
,	O
varillas	B-Cell
y	O
conos	B-Cell
(	O
Hundimiento	B-Protein
[	O
detención	B-Protein
de	I-Protein
varilla	I-Protein
]	O
,	O
verde	O
)	O
,	O
y	O
Células	B-Cell
bipolares	I-Cell
de	I-Cell
varilla	I-Cell
(	O
Prkca	B-Protein
,	O
verde	O
y	O
cabina5	B-Protein
,	O
rojo	O
)	O
.	O

Las	O
barras	O
de	O
escala	O
son	O
de	O
50	O
mu	O
m	O
.	O

(	O
B	O
)	O
Cuantificación	O
de	O
pou4f2	B-Protein
+	O
celulas	B-Cell
ganglionares	I-Cell
.	O

(	O
C	O
)	O
Cuantificación	O
de	O
Prkca	B-Protein
#	O
¿NOMBRE	O
?	O
cabina5	B-Protein
+	O
células	B-Cell
bipolares	I-Cell
.	O

(	O
D	O
)	O
Espesor	O
de	O
la	O
ONL	O
,	O
que	O
representa	O
el	O
número	O
de	O
varillas	B-Cell
.	O

Las	O
barras	O
de	O
error	O
representan	O
SD	O
de	O
mediciones	O
de	O
tres	O
animales	B-Taxon
,	O
y	O
los	O
asteriscos	O
indican	O
una	O
diferencia	O
significativa	O
entre	O
las	O
retinas	O
de	O
peso	B-Sequence
y	O
lo	O
indicado	O
genotipos	B-Sequence
,	O
a	O
menos	O
que	O
se	O
indique	O
lo	O
contrario	O
mediante	O
líneas	O
de	O
conexión	O
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
;	O
p	O
<	O
0	O
.	O
01	O
;	O
ANOVA	O
y	O
prueba	O
Tukey	O
HSD	O
)	O
.	O

(	O
E	O
y	O
F	O
)	O
Los	O
ERG	O
se	O
registraron	O
a	O
partir	O
de	O
los	O
indicados	O
genotipos	B-Sequence
bajo	O
condiciones	O
adaptadas	O
a	O
la	O
oscuridad	O
(	O
escotópicas	O
)	O
,	O
y	O
se	O
determinaron	O
las	O
series	O
de	O
intensidad	O
(	O
E	O
)	O
y	O
las	O
amplitudes	O
de	O
onda	O
b	O
(	O
F	O
)	O
en	O
función	O
del	O
logaritmo	O
de	O
la	O
intensidad	O
del	O
destello	O
.	O

(	O
F	O
)	O
Ilustra	O
además	O
que	O
la	O
influencia	O
relativa	O
de	O
la	O
mutaciones	B-Sequence
sobre	O
el	O
fotorreceptores	B-Cell
(	O
indicado	O
por	O
la	O
amplitud	O
de	O
la	O
onda	O
a	O
saturada	O
,	O
gráfico	O
de	O
la	O
derecha	O
)	O
no	O
fue	O
sustancialmente	O
diferente	O
de	O
su	O
efecto	O
sobre	O
la	O
respuesta	O
de	O
la	O
onda	O
b	O
(	O
dominada	O
por	O
la	O
bipolares	B-Cell
,	O
gráfico	O
de	O
la	O
izquierda	O
)	O
a	O
la	O
misma	O
intensidad	O
de	O
10	O
cd	O
.	O
s/m2	O
.	O

para	O
investigar	O
el	O
molecular	B-Chemical
mecanismo	O
que	O
subyace	O
al	O
papel	O
único	O
de	O
E2f1	B-Protein
,	O
evaluamos	O
la	O
expresión	O
de	O
conocido	B-Sequence
Objetivos	O
E2f	O
,	O
así	O
como	O
otros	O
genes	B-Sequence
que	O
regulan	O
la	O
célula	B-Cell
ciclo	O
y	O
apoptosis	O
.	O

Numerosos	O
positivos	O
y	O
negativos	O
.	O
célula	B-Cell
Los	O
reguladores	O
del	O
ciclo	O
y	O
apoptóticos	O
estaban	O
regulados	O
al	O
alza	O
en	O
el	O
Rb	B-Protein
Retina	O
KO	O
(	O
Figura	O
1H	O
)	O
.	O

Entre	O
la	O
familia	O
E2f	O
,	O
E2f1	B-Protein
,	O
E2f2	B-Protein
,	O
E2f3a	O
,	O
y	O
E2f7	B-Protein
fueron	O
inducidos	O
siguiendo	O
Rb	B-Protein
pérdida	O
,	O
pero	O
E2f3b	O
,	O
E2f4	B-Protein
,	O
y	O
E2f5	B-Protein
no	O
se	O
vieron	O
afectados	O
.	O

De	O
acuerdo	O
con	O
BrdU	O
y	O
terminal	O
dUTP	B-Chemical
análisis	O
de	O
etiquetado	O
de	O
nick-end	O
(	O
TUNEL	O
)	O
,	O
E2f1	B-Protein
supresión	B-Sequence
invirtió	O
específicamente	O
todos	O
estos	O
molecular	B-Chemical
defectos	O
,	O
pero	O
E2f3	B-Protein
supresión	B-Sequence
no	O
tuvo	O
ningún	O
efecto	O
(	O
Figura	O
1H	O
)	O
.	O

Diferenciación	O
normal	O
en	O
el	O
Rb	B-Protein
/	O
E2f1	B-Protein
Retina	O
DKO	O

Porque	O
E2f1	B-Protein
supresión	B-Sequence
bloquea	O
la	O
división	O
anormal	O
y	O
la	O
muerte	O
en	O
el	O
Rb	B-Protein
KO	O
retina	O
,	O
la	O
Rb	B-Protein
/	O
E2f1	B-Protein
DKO	O
retina	O
brindó	O
una	O
oportunidad	O
única	O
para	O
evaluar	O
si	O
Rb	B-Protein
controla	O
la	O
diferenciación	O
independientemente	O
de	O
célula	B-Cell
efectos	O
del	O
ciclo	O
.	O

los	O
Rb	B-Protein
/	O
E2f1	B-Protein
DKO	O
retina	O
tenía	O
muchos	O
Hundimiento	B-Protein
+	O
(	O
S	B-Protein
-	I-Protein
antígeno	I-Protein
/	O
detención	B-Protein
de	I-Protein
varilla	I-Protein
)	O
fotorreceptores	B-Cell
,	O
pou4f2	B-Protein
+	O
(	O
Brn3b	B-Protein
)	O
celulas	B-Cell
ganglionares	I-Cell
,	O
y	O
numerosos	O
Prkca	B-Protein
+	O
/	O
cabina5	B-Protein
+	O
neuronas	B-Cell
bipolares	I-Cell
(	O
Figura	O
2A-2D	O
)	O
.	O

Por	O
el	O
contrario	O
,	O
no	O
hubo	O
tal	O
rescate	O
de	O
célula	B-Cell
escribe	O
en	O
Rb	B-Protein
/	O
E2f2	B-Protein
o	O
Rb	B-Protein
/	O
E2f3	B-Protein
Retinas	O
DKO	O
(	O
Figura	O
S4	O
)	O
.	O

Análisis	O
con	O
general	O
neuronales	B-Cell
marcadores	O
Mtap2	B-Protein
(	O
MAP2	B-Protein
)	O
y	O
Snap25	B-Protein
,	O
así	O
como	O
otros	O
marcadores	O
expresados	O
en	O
células	B-Cell
bipolares	I-Cell
(	O
Chx10	B-Protein
,	O
Rcvrn	B-Protein
,	O
vsx1	B-Protein
,	O
Tacr3	B-Protein
,	O
y	O
atp2b1	B-Protein
)	O
y	O
fotorreceptores	B-Cell
de	I-Cell
varilla	I-Cell
(	O
Rho	B-Protein
y	O
Rcvrn	B-Protein
)	O
confirmó	O
el	O
rescate	O
del	O
Rb	B-Protein
/	O
E2f1	B-Protein
DKO	O
retina	O
(	O
Tabla	O
S1	O
)	O
.	O

Es	O
más	O
,	O
neuronas	B-Cell
exhibió	O
la	O
misma	O
morfología	O
compleja	O
que	O
en	O
peso	B-Sequence
retina	O

Célula	B-Cell
bipolar	I-Cell
los	O
cuerpos	O
estaban	O
ubicados	O
en	O
el	O
INL	O
y	O
tenían	O
ascendente	O
y	O
descendente	O
procesos	B-GENE
terminando	O
en	O
OPL	O
e	O
IPL	O
,	O
respectivamente	O
(	O
Figura	O
2A	O
)	O
.	O

Además	O
,	O
el	O
Rb	B-Protein
/	O
E2f1	B-Protein
La	O
retina	O
DKO	O
tenía	O
una	O
ONL	O
de	O
apariencia	O
saludable	O
que	O
consistía	O
en	O
morfológicamente	O
normal	O
varillas	B-Cell
con	O
descender	O
procesos	B-GENE
terminando	O
en	O
la	O
OPL	O
y	O
ascendiendo	O
procesos	B-GENE
que	O
terminó	O
en	O
segmentos	B-GENE
interior	I-GENE
y	I-GENE
exterior	I-GENE
(	O
Figura	O
2A	O
)	O
.	O

Se	O
sugirió	O
que	O
Rb	B-Protein
podría	O
regular	O
fotorreceptor	B-Cell
diferenciación	O
,	O
posiblemente	O
a	O
través	O
de	O
vara	B-Cell
-	O
factores	O
de	O
transcripción	O
específicos	O
(	O
Figura	O
1B	O
)	O
[	O
29	O
]	O
.	O

Sin	O
embargo	O
,	O
si	O
Rb	B-Protein
regula	O
fotorreceptor	B-Cell
diferenciación	O
,	O
lo	O
hace	O
inhibiendo	O
E2f1	B-Protein
,	O
no	O
potenciando	O
vara	B-Cell
factores	O
de	O
diferenciación	O
,	O
como	O
Otx2	B-Protein
,	O
crx	B-Protein
,	O
o	O
NRL	B-Protein
.	O

Es	O
imposible	O
saber	O
si	O
E2f1	B-Protein
perturba	O
la	O
diferenciación	O
directamente	O
,	O
al	O
afectar	O
la	O
expresión	O
de	O
genes	B-Sequence
que	O
modulan	O
la	O
maduración	O
,	O
y/o	O
indirectamente	O
a	O
través	O
de	O
sus	O
efectos	O
sobre	O
la	O
proliferación	O
y	O
supervivencia	O
(	O
Figura	O
1B	O
)	O
.	O

Al	O
igual	O
que	O
con	O
la	O
división	O
ectópica	O
y	O
la	O
apoptosis	O
(	O
Figura	O
1C	O
y	O
1D	O
)	O
,	O
el	O
rescate	O
de	O
Rb	B-Protein
KO	O
Células	B-Cell
bipolares	I-Cell
,	I-Cell
ganglionares	I-Cell
y	I-Cell
bastoncillos	I-Cell
de	I-Cell
la	I-Cell
retina	I-Cell
era	O
dependiente	O
de	O
E2f1	B-Protein
dosis	O
(	O
Figura	O
2A-2D	O
)	O
.	O

Aparte	O
de	O
su	O
papel	O
en	O
la	O
conducción	O
de	O
la	O
división	O
ectópica	O
de	O
Rb	B-Protein
KO	O
RTC	O
,	O
E2f1	B-Protein
también	O
promueve	O
la	O
división	O
normal	O
de	O
RPC	O
ya	O
que	O
en	O
su	O
ausencia	O
la	O
proliferación	O
de	O
RPC	O
cae	O
~	O
2	O
veces	O
(	O
D.C.	O
y	O
R.B.	O
,	O
datos	O
no	O
publicados	O
)	O
.	O

Esta	O
modesta	O
reducción	O
de	O
los	O
números	O
de	O
RPC	O
en	O
ausencia	O
de	O
E2f1	B-Protein
explica	O
la	O
ligera	O
reducción	O
en	O
el	O
número	O
de	O
celulas	B-Cell
ganglionares	I-Cell
en	O
P0	O
,	O
en	O
el	O
número	O
de	O
células	B-Cell
bipolares	I-Cell
en	O
P18	O
o	O
P30	O
,	O
y	O
en	O
el	O
espesor	O
de	O
la	O
ONL	O
en	O
P18	O
o	O
P30	O
en	O
el	O
E2f1	B-Protein
KO	O
y	O
Rb	B-Protein
/	O
E2f1	B-Protein
Retina	O
DKO	O
(	O
Figura	O
2B-2D	O
)	O
.	O

La	O
morfología	O
de	O
E2f1	B-Protein
KO	O
neuronas	B-Cell
era	O
peso	B-Sequence
(	O
Figura	O
2A	O
)	O
.	O

A	O
pesar	O
de	O
una	O
ligera	O
caída	O
en	O
el	O
valor	O
absoluto	O
célula	B-Cell
números	O
,	O
la	O
proporción	O
de	O
Rb	B-Protein
/	O
E2f1	B-Protein
DKO	O
y	O
E2f1	B-Protein
KO	O
células	B-Cell
bipolares	I-Cell
era	O
lo	O
mismo	O
que	O
peso	B-Sequence
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Ligeramente	O
reducido	O
célula	B-Cell
los	O
números	O
no	O
se	O
debieron	O
a	O
la	O
muerte	O
residual	O
de	O
RTC	O
ya	O
que	O
no	O
hemos	O
observado	O
apoptosis	O
ectópica	O
en	O
ninguna	O
etapa	O
embrionaria	O
o	O
posnatal	O
en	O
el	O
desarrollo	O
Rb	B-Protein
/	O
E2f1	B-Protein
Retina	O
DKO	O
(	O
Figuras	O
1D	O
,	O
1G	O
y	O
S2	O
)	O
.	O

Es	O
más	O
,	O
borrando	B-Sequence
Ccnd1	B-Protein
,	O
que	O
actúa	O
aguas	O
arriba	O
de	O
Rb	B-Protein
proteinas	B-Chemical
,	O
también	O
reduce	O
el	O
número	O
de	O
RPC	O
,	O
pero	O
no	O
suprime	O
ningún	O
defecto	O
en	O
el	O
Rb	B-Protein
KO	O
retina	O
(	O
D	O
.	O
C	O
.	O
y	O
R	O
.	O
B	O
.	O
,	O
datos	O
no	O
publicados	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
la	O
división	O
de	O
RPC	O
ligeramente	O
reducida	O
y	O
el	O
rescate	O
dramático	O
de	O
defectos	O
severos	O
en	O
Rb	B-Protein
Los	O
KO	O
RTC	O
son	O
efectos	O
distintos	O
derivados	O
de	O
la	O
supresión	B-Sequence
de	O
E2f1	B-Protein
.	O

Función	O
normal	O
de	O
la	O
Rb	B-Protein
/	O
E2f1	B-Protein
Retina	O
DKO	O

el	O
descubrimiento	O
que	O
E2f1	B-Protein
la	O
pérdida	O
rescata	O
incluso	O
la	O
morfología	O
de	O
Rb	B-Protein
KO	O
neuronas	B-Cell
es	O
sorprendente	O
porque	O
Rb	B-Protein
se	O
cree	O
que	O
regula	O
la	O
diferenciación	O
principalmente	O
a	O
través	O
de	O
vías	O
independientes	O
de	O
E2f	O
[	O
30-33	O
]	O
.	O

Sin	O
embargo	O
,	O
la	O
morfología	O
normal	O
puede	O
no	O
equivaler	O
a	O
una	O
diferenciación	O
completamente	O
normal	O
.	O

Por	O
lo	O
tanto	O
,	O
comparamos	O
los	O
electrorretinogramas	O
(	O
ERG	O
)	O
de	O
adultos	O
peso	B-Sequence
(	O
alfa	O
-	O
Cre	O
)	O
,	O
E2f1	B-Protein
-	O
/	O
-	O
,	O
alfa	O
-	O
Cre	O
;	O
RbloxP	O
/	O
loxP	B-Sequence
y	O
alfa-Cre	O
;	O
RbloxP	O
/	O
loxP	B-Sequence
;	O
E2f1	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
.	O

Los	O
ERG	O
evalúan	O
funcionalmente	O
la	O
señalización	O
visual	O
en	O
el	O
mamífero	B-Taxon
retina	O
de	O
fotorreceptores	B-Cell
para	O
células	B-Cell
amacrinas	I-Cell
(	O
pero	O
normalmente	O
no	O
células	B-Cell
ganglionares	I-Cell
)	O
,	O
y	O
están	O
dominados	O
por	O
Células	B-Cell
bipolares	I-Cell
de	I-Cell
conos	I-Cell
y	I-Cell
bastones	I-Cell
.	I-Cell
.	O

Por	O
lo	O
general	O
,	O
una	O
señal	O
ERG	O
comienza	O
con	O
una	O
desviación	O
negativa	O
iniciada	O
por	O
el	O
fotorreceptores	B-Cell
(	O
la	O
onda	O
a	O
)	O
,	O
que	O
termina	O
con	O
una	O
gran	O
desviación	O
positiva	O
debido	O
a	O
la	O
activación	O
de	O
EN	B-Cell
células	I-Cell
bipolares	I-Cell
(	O
la	O
onda	O
b	O
)	O
.	O

Las	O
respuestas	O
a	O
la	O
luz	O
tenue	O
en	O
condiciones	O
adaptadas	O
a	O
la	O
oscuridad	O
(	O
escotópicas	O
)	O
evalúan	O
específicamente	O
la	O
vara	B-Cell
sistema	O
,	O
y	O
eran	O
defectuosos	O
en	O
el	O
Rb	B-Protein
Retina	O
KO	O
(	O
Figura	O
2E	O
)	O
.	O

La	O
reducción	O
sustancial	O
de	O
las	O
ondas	O
a	O
y	O
b	O
es	O
consistente	O
con	O
varilla	B-Cell
y	I-Cell
celda	I-Cell
bipolar	I-Cell
apoptosis	O
[	O
2	O
]	O
.	O

La	O
sensibilidad	O
de	O
la	O
respuesta	O
residual	O
apareció	O
sin	O
cambios	O
,	O
lo	O
que	O
sugiere	O
que	O
surgió	O
de	O
las	O
porciones	O
Cre-negativas	O
de	O
la	O
retina	O
.	O

Las	O
respuestas	O
fueron	O
casi	O
las	O
mismas	O
en	O
el	O
peso	B-Sequence
y	O
E2f1	B-Protein
retina	O
KO	O
,	O
y	O
,	O
lo	O
más	O
importante	O
,	O
también	O
la	O
Rb	B-Protein
/	O
E2f1	B-Protein
La	O
mediana	O
de	O
respuesta	O
de	O
DKO	O
estaba	O
en	O
el	O
extremo	O
inferior	O
del	O
rango	O
normal	O
para	O
la	O
mayoría	O
de	O
las	O
intensidades	O
(	O
Figura	O
2F	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
E2f1	B-Protein
supresión	B-Sequence
rescató	O
casi	O
por	O
completo	O
el	O
vara	B-Cell
sistema	O
en	O
el	O
Rb	B-Protein
KO	O
retina	O
.	O

Grabaciones	O
adaptadas	O
a	O
la	O
luz	O
(	O
fotópicas	O
)	O
para	O
evaluar	O
específicamente	O
la	O
cono	B-Cell
sistema	O
arrojó	O
resultados	O
comparables	O
.	O

Conos	B-Cell
representan	O
sólo	O
el	O
3	O
%	O
de	O
fotorreceptores	B-Cell
y	O
,	O
a	O
diferencia	O
de	O
varillas	B-Cell
,	O
desarrollarse	O
sin	O
Rb	B-Protein
,	O
pero	O
requieren	O
varillas	B-Cell
para	O
la	O
supervivencia	O
,	O
y	O
en	O
el	O
Rb	B-Protein
retina	O
KO	O
,	O
tienen	O
una	O
morfología	O
anormal	O
y	O
su	O
sináptico	B-GENE
objetivos	O
,	O
células	B-Cell
bipolares	I-Cell
,	O
están	O
muy	O
agotados	O
[	O
2	O
]	O
.	O

La	O
respuesta	O
fotópica	O
,	O
producto	O
de	O
cono	B-Cell
y	O
principalmente	O
bipolar	B-Cell
actividad	O
,	O
se	O
redujo	O
mucho	O
por	O
Rb	B-Protein
pérdida	O
,	O
pero	O
fue	O
rescatado	O
considerablemente	O
en	O
el	O
Rb	B-Protein
/	O
E2f1	B-Protein
Retina	O
DKO	O
(	O
Figura	O
S5	O
)	O
.	O

Una	O
vez	O
más	O
,	O
la	O
amplitud	O
mediana	O
estaba	O
en	O
el	O
extremo	O
inferior	O
de	O
la	O
E2f1	B-Protein
Rango	O
de	O
KO	O
.	O

La	O
respuesta	O
fotópica	O
en	O
E2f1	B-Protein
KO	O
ratones	B-Taxon
se	O
redujo	O
ligeramente	O
en	O
relación	O
con	O
peso	B-Sequence
(	O
Figura	O
S5B	O
)	O
,	O
posiblemente	O
porque	O
E2f1	B-Protein
se	O
requiere	O
para	O
la	O
expansión	O
máxima	O
de	O
los	O
RPC	O
embrionarios	O
,	O
y	O
el	O
E2f1	B-Protein
KO	O
retina	O
tiene	O
,	O
como	O
se	O
señaló	O
anteriormente	O
,	O
un	O
poco	O
menos	O
células	B-Cell
que	O
la	O
peso	B-Sequence
retina	O
,	O
aunque	O
célula	B-Cell
las	O
proporciones	O
de	O
tipo	O
no	O
se	O
ven	O
afectadas	O
(	O
D.C.	O
y	O
R.B.	O
,	O
datos	O
no	O
publicados	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
las	O
respuestas	O
fotópicas	O
marginalmente	O
subnormales	O
en	O
el	O
Rb	B-Protein
/	O
E2f1	B-Protein
La	O
retina	O
DKO	O
se	O
puede	O
atribuir	O
tanto	O
a	O
una	O
reducción	O
de	O
cono	B-Cell
números	O
en	O
E2f1	B-Protein
KO	O
ratones	B-Taxon
``	O
solo	O
,	O
y	O
una	O
ligera	O
reducción	O
``	O
''	O
genuina	O
''	O
''	O
en	O
''	O
cono	B-Cell
función	O
atribuible	O
a	O
Rb	B-Protein
pérdida	O
en	O
relación	O
con	O
peso	B-Sequence
.	O

Este	O
leve	O
efecto	O
puede	O
relacionarse	O
con	O
un	O
verdadero	O
defecto	O
de	O
diferenciación	O
en	O
un	O
subconjunto	O
de	O
células	B-Cell
amacrinas	I-Cell
se	O
discute	O
más	O
adelante	O
.	O

Esta	O
discusión	O
no	O
debe	O
oscurecer	O
el	O
principal	O
resultado	O
que	O
E2f1	B-Protein
supresión	B-Sequence
recupera	O
la	O
mayor	O
parte	O
de	O
la	O
respuesta	O
ERG	O
.	O

Por	O
lo	O
tanto	O
,	O
E2f1	B-Protein
supresión	B-Sequence
no	O
solo	O
rescata	O
la	O
morfología	O
sino	O
también	O
ambas	O
vara	B-Cell
y	O
cono	B-Cell
función	O
del	O
sistema	O
en	O
el	O
Rb	B-Protein
KO	O
retina	O
.	O

Diferenciación	O
SAC	O
anormal	O
independiente	O
de	O
Célula	B-Cell
Defectos	O
de	O
ciclo	O
y	O
supervivencia	O

Los	O
ERG	O
evalúan	O
principalmente	O
fotorreceptor	B-Cell
y	O
célula	B-Cell
bipolar	I-Cell
función	O
,	O
pero	O
puede	O
pasar	O
por	O
alto	O
los	O
defectos	O
de	O
diferenciación	O
en	O
otros	O
células	B-Cell
.	O

Para	O
probar	O
diferencias	O
sutiles	O
,	O
teñimos	O
el	O
Rb	B-Protein
/	O
E2f1	B-Protein
Retina	O
DKO	O
con	O
43	O
marcadores	O
(	O
Tabla	O
S1	O
)	O
.	O

Treinta	O
y	O
dos	O
proteinas	B-Chemical
mostró	O
patrones	O
idénticos	O
en	O
peso	B-Sequence
,	O
E2f1	B-Protein
KO	O
,	O
y	O
Rb	B-Protein
/	O
E2f1	B-Protein
DKO	O
retina	O
(	O
Tabla	O
S1	O
)	O
.	O

Los	O
otros	O
11	O
marcadores	O
revelaron	O
una	O
célula	B-Cell
Defecto	O
de	O
diferenciación	O
independiente	O
del	O
ciclo	O
y	O
de	O
la	O
apoptosis	O
en	O
SAC	O
.	O

primero	O
estudiamos	O
Calb2	B-Protein
(	O
calretinina	B-Protein
)	O
,	O
que	O
marca	O
un	O
subconjunto	O
de	O
células	B-Cell
amacrinas	I-Cell
y	I-Cell
ganglionares	I-Cell
cuerpos	O
,	O
así	O
como	O
tres	O
pistas	O
correspondientes	O
a	O
sus	O
procesos	B-GENE
en	O
la	O
IPL	O
(	O
Figura	O
3A	O
)	O
.	O

Normal	O
Calb2	B-Protein
Se	O
observó	O
tinción	O
en	O
el	O
E2f1	B-Protein
KO	O
IPL	O
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Sin	O
embargo	O
,	O
solo	O
uno	O
Calb2	B-Protein
#	O
¿NOMBRE	O
?	O
Rb	B-Protein
KO	O
IPL	O
,	O
y	O
este	O
defecto	O
no	O
fue	O
rescatado	O
en	O
el	O
Rb	B-Protein
/	O
E2f1	B-Protein
Retina	O
DKO	O
(	O
Figura	O
3A	O
)	O
.	O

nosotros	O
cuantificamos	O
Calb2	B-Protein
+	O
cuerpos	B-GENE
celulares	I-GENE
en	O
el	O
Rb	B-Protein
KO	O
INL	O
(	O
correspondiente	O
a	O
célula	B-Cell
amacrina	I-Cell
solo	O
tinción	O
)	O
y	O
observó	O
una	O
reducción	O
desde	O
P8	O
en	O
adelante	O
(	O
Figuras	O
3C	O
y	O
S6	O
)	O
.	O

figura	O
3	O

Defectos	O
de	O
diferenciación	O
en	O
Rb	B-Protein
KO	O
SAC	O

(	O
A	O
)	O
P18	O
secciones	O
horizontales	O
de	O
peso	B-Sequence
,	O
Rb	B-Protein
KO	O
,	O
y	O
Rb	B-Protein
/	O
E2f1	B-Protein
La	O
retina	O
DKO	O
se	O
tiñó	O
para	O
núcleos	B-GENE
(	O
DAPI	O
,	O
azul	O
)	O
,	O
Calb2	B-Protein
(	O
verde	O
)	O
,	O
y	O
Slc18a3	B-Protein
(	O
rojo	O
)	O
.	O

(	O
B	O
)	O
Imágenes	O
confocales	O
de	O
secciones	O
horizontales	O
P30	O
de	O
peso	B-Sequence
y	O
Rb	B-Protein
Las	O
retinas	O
KO	O
se	O
tiñeron	O
para	O
núcleos	B-GENE
(	O
DAPI	O
,	O
azul	O
)	O
,	O
Chat	B-Protein
y	O
Slc18a3	B-Protein
(	O
ambos	O
rojos	O
)	O
,	O
y	O
camk2a	B-Protein
(	O
verde	O
)	O
.	O

En	O
el	O
Rb	B-Protein
Sección	O
KO	O
,	O
la	O
mancha	O
roja	O
es	O
Chat	B-Protein
sólo	O
como	O
Slc18a3	B-Protein
falta	O
(	O
ver	O
[	O
A	O
]	O
)	O
.	O

(	O
C	O
)	O
Cuantificación	O
de	O
densidad	O
Calb2	B-Protein
+	O
cuerpos	B-GENE
celulares	I-GENE
en	O
el	O
INL	O
,	O
total	O
Slc18a3	B-Protein
+	O
cuerpos	B-GENE
celulares	I-GENE
,	O
y	O
camk2a	B-Protein
+	O
cuerpos	B-GENE
celulares	I-GENE
en	O
el	O
INL	O
.	O

Las	O
barras	O
de	O
error	O
representan	O
SD	O
de	O
mediciones	O
de	O
tres	O
animales	B-Taxon
,	O
y	O
los	O
asteriscos	O
indican	O
diferencias	O
significativas	O
entre	O
las	O
retinas	O
de	O
peso	B-Sequence
y	O
lo	O
indicado	O
genotipos	B-Sequence
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
;	O
p	O
<	O
0	O
.	O
01	O
;	O
ANOVA	O
y	O
prueba	O
Tukey	O
HSD	O
)	O
.	O

Las	O
barras	O
de	O
escala	O
son	O
50	O
mu	O
m	O
en	O
(	O
A	O
)	O
y	O
20	O
mu	O
m	O
en	O
(	O
B	O
)	O
.	O

De	O
los	O
tres	O
Calb2	B-Protein
+	O
pistas	O
en	O
la	O
IPL	O
,	O
las	O
dos	O
pistas	O
exteriores	O
son	O
de	O
SAC	O
,	O
llamadas	O
así	O
por	O
su	O
extensa	O
dendrítica	B-GENE
-	I-GENE
árbol	I-GENE
-	O
como	O
morfología	O
[	O
37	O
]	O
.	O

Los	O
SAC	O
son	O
colinérgico	B-Chemical
,	O
representa	O
~	O
5	O
.	O
2	O
%	O
de	O
neuronas	B-Cell
amacrinas	I-Cell
38	O
]	O
,	O
y	O
son	O
fundamentales	O
tanto	O
para	O
la	O
selectividad	O
de	O
dirección	O
[	O
34	O
,	O
35	O
]	O
como	O
para	O
la	O
actividad	O
rítmica	O
espontánea	O
que	O
se	O
produce	O
durante	O
el	O
desarrollo	O
normal	O
de	O
la	O
retina	O
[	O
36	O
]	O
.	O

SAC	O
en	O
el	O
INL	O
sinapsis	B-GENE
en	O
la	O
capa	O
OFF	O
de	O
la	O
IPL	O
que	O
responde	O
a	O
la	O
disminución	O
de	O
la	O
luz	O
,	O
mientras	O
que	O
los	O
SAC	O
desplazados	O
en	O
la	O
GCL	O
tienen	O
procesos	B-GENE
que	O
hacen	O
sinapsis	O
en	O
la	O
capa	O
ON	O
cercana	O
de	O
la	O
IPL	O
que	O
responde	O
al	O
aumento	O
de	O
la	O
luz	O
(	O
revisado	O
en	O
[	O
39	O
]	O
)	O
.	O

SAC	O
maduro	O
procesos	B-GENE
mancha	O
específicamente	O
para	O
Slc18a3	B-Protein
(	O
transportador	B-Protein
vesicular	I-Protein
de	I-Protein
acetilcolina	I-Protein
,	O
VAChT	B-Protein
)	O
[	O
37	O
]	O
y	O
,	O
significativamente	O
,	O
este	O
marcador	O
estaba	O
ausente	O
en	O
la	O
periferia	O
Rb	B-Protein
KO	O
o	O
Rb	B-Protein
/	O
E2f1	B-Protein
Retina	O
DKO	O
P18	O
(	O
Figuras	O
3A	O
y	O
S7B	O
)	O
.	O

Chat	B-Protein
,	O
expresada	O
de	O
la	O
misma	O
lugar	B-Sequence
,	O
también	O
es	O
específico	O
de	O
SAC	O
,	O
pero	O
marca	O
ambos	O
cuerpos	B-GENE
celulares	I-GENE
y	O
procesos	B-GENE
de	O
SAC	O
maduros	O
[	O
37	O
]	O
.	O

Chat	B-Protein
se	O
vio	O
en	O
menos	O
células	B-Cell
en	O
la	O
madurez	O
Rb	B-Protein
KO	O
retina	O
,	O
y	O
estuvo	O
presente	O
en	O
el	O
soma	B-GENE
pero	O
ausente	O
de	O
procesos	B-GENE
(	O
Figura	O
3B	O
)	O
.	O

Obtuvimos	O
resultados	O
similares	O
para	O
Sv2c	B-Protein
,	O
a	O
vesícula	B-GENE
sináptica	I-GENE
proteína	B-Chemical
encontrado	O
en	O
SAC	O
[	O
40	O
]	O
;	O
Kcnc1b	B-Protein
y	O
Kcnc2	B-Protein
,	O
potasio	B-Chemical
canales	O
expresados	O
en	O
SAC	O
soma	B-GENE
y	O
dendritas	B-GENE
así	O
como	O
un	O
número	O
muy	O
reducido	O
de	O
celulas	B-Cell
ganglionares	I-Cell
[	O
41	O
]	O
;	O
ácido	B-Chemical
gamma-aminobutírico	I-Chemical
(	O
GABA	B-Chemical
)	O
,	O
un	O
inhibidor	O
neurotransmisor	B-Chemical
presentes	O
en	O
aproximadamente	O
la	O
mitad	O
de	O
células	B-Cell
amacrinas	I-Cell
incluidos	O
los	O
SAC	O
,	O
así	O
como	O
neuronas	B-Cell
horizontales	I-Cell
y	I-Cell
algunas	I-Cell
bipolares	I-Cell
[	O
37	O
]	O
;	O
y	O
Calb1	B-Protein
(	O
calbindin	B-Protein
)	O
,	O
que	O
se	O
expresa	O
en	O
muchos	O
células	B-Cell
amacrinas	I-Cell
y	O
etiquetas	O
SAC	O
proceso	B-GENE
débilmente	O
(	O
Figura	O
S7A	O
y	O
S7B	O
;	O
Tabla	O
S1	O
;	O
y	O
datos	O
no	O
mostrados	O
)	O
.	O

Finalmente	O
,	O
también	O
examinamos	O
el	O
efecto	O
de	O
Rb	B-Protein
supresión	B-Sequence
en	O
la	O
diferenciación	O
SAC	O
usando	O
un	O
Chx10	B-Protein
#	O
¿NOMBRE	O
?	O
transgén	B-Sequence
que	O
se	O
expresa	O
en	O
un	O
patrón	O
de	O
mosaico	O
a	O
través	O
de	O
la	O
retina	O
,	O
generando	O
parches	O
de	O
Cre-expresando	O
células	B-Cell
[	O
42	O
]	O
.	O

De	O
acuerdo	O
con	O
el	O
mosaico	O
.	O
supresión	B-Sequence
patrón	O
,	O
observamos	O
marcadamente	O
reducido	O
Chat	B-Protein
/	O
Slc18a3	B-Protein
tinción	O
en	O
la	O
IPL	O
de	O
Chx10	B-Protein
-	O
Cre	O
;	O
RbloxP	O
/	O
loxP	B-Sequence
retina	O
en	O
comparación	O
con	O
peso	B-Sequence
(	O
Figura	O
S7C	O
)	O
.	O

Juntos	O
,	O
estos	O
resultados	O
sugieren	O
un	O
papel	O
para	O
Rb	B-Protein
en	O
la	O
diferenciación	O
SAC	O
.	O

Los	O
hallazgos	O
anteriores	O
podrían	O
indicar	O
un	O
defecto	O
en	O
la	O
especificación	O
de	O
SAC	O
,	O
la	O
supervivencia	O
de	O
SAC	O
o	O
los	O
niveles	O
y/o	O
el	O
transporte	O
de	O
los	O
marcadores	O
descritos	O
anteriormente	O
.	O

camk2a	B-Protein
marca	O
tanto	O
SAC	O
como	O
celulas	B-Cell
ganglionares	I-Cell
[	O
37	O
]	O
,	O
sino	O
porque	O
celulas	B-Cell
ganglionares	I-Cell
se	O
eliminan	O
en	O
el	O
Rb	B-Protein
KO	O
retina	O
,	O
camk2a	B-Protein
es	O
un	O
marcador	O
SAC	O
específico	O
en	O
este	O
contexto	O
.	O

Es	O
importante	O
destacar	O
que	O
camk2a	B-Protein
#	O
¿NOMBRE	O
?	O
dendritas	B-GENE
estuvieron	O
presentes	O
en	O
ambos	O
peso	B-Sequence
y	O
Rb	B-Protein
KO	O
retina	O
(	O
Figura	O
3B	O
)	O
,	O
y	O
el	O
número	O
de	O
camk2a	B-Protein
+	O
soma	B-GENE
fue	O
similar	O
en	O
peso	B-Sequence
y	O
Rb	B-Protein
KO	O
retina	O
en	O
P30	O
y	O
más	O
allá	O
,	O
aunque	O
menos	O
células	B-Cell
manchado	O
en	O
Rb	B-Protein
Retina	O
KO	O
en	O
P18	O
,	O
lo	O
que	O
sugiere	O
un	O
retraso	O
en	O
su	O
aparición	O
(	O
Figuras	O
3C	O
y	O
S6B	O
)	O
.	O

Por	O
lo	O
tanto	O
,	O
Rb	B-Protein
no	O
se	O
requiere	O
para	O
la	O
supervivencia	O
de	O
SAC	O
o	O
para	O
proceso	B-GENE
consecuencia	O
,	O
sino	O
que	O
parece	O
regular	O
la	O
expresión	O
y	O
/	O
o	O
estabilidad	O
de	O
Calb2	B-Protein
,	O
Calb1	B-Protein
,	O
Chat	B-Protein
,	O
Slc18a3	B-Protein
,	O
Sv2c	B-Protein
,	O
Kcnc1b	B-Protein
,	O
Kcnc2	B-Protein
,	O
y	O
GABA	B-Chemical
en	O
SAC	O
,	O
pero	O
sale	O
camk2a	B-Protein
expresión	O
prácticamente	O
intacta	O
.	O

La	O
presencia	O
de	O
Chat	B-Protein
en	O
algunos	O
cuerpos	B-GENE
celulares	I-GENE
pero	O
nunca	O
en	O
procesos	B-GENE
(	O
Figura	O
3B	O
)	O
también	O
sugiere	O
un	O
defecto	O
de	O
transporte	O
.	O

El	O
patrón	O
de	O
desarrollo	O
de	O
Slc18a3	B-Protein
expresión	O
también	O
apoyó	O
esta	O
noción	O
.	O

en	O
maduro	O
peso	B-Sequence
SAC	O
Slc18a3	B-Protein
solo	O
esta	O
en	O
procesos	B-GENE
,	O
pero	O
en	O
los	O
SAC	O
posnatales	O
tempranos	O
,	O
se	O
encuentra	O
en	O
el	O
cuerpo	B-GENE
de	I-GENE
la	I-GENE
célula	I-GENE
,	O
y	O
avanza	O
hacia	O
los	O
emergentes	O
procesos	B-GENE
en	O
aproximadamente	O
P4-P6	O
.	O

Como	O
se	O
señaló	O
anteriormente	O
,	O
Slc18a3	B-Protein
estuvo	O
ausente	O
en	O
P18	O
en	O
el	O
Rb	B-Protein
retina	O
KO	O
(	O
Figura	O
3A	O
)	O
;	O
en	O
P4	O
o	O
P5	O
estaba	O
en	O
cuerpos	B-GENE
celulares	I-GENE
,	O
aunque	O
rara	O
vez	O
estuvo	O
presente	O
en	O
Rb	B-Protein
KO	O
procesos	B-GENE
(	O
Figuras	O
4A	O
y	O
S6	O
)	O
.	O

Slc18a3	B-Protein
se	O
volvió	O
virtualmente	O
indetectable	O
en	O
Rb	B-Protein
KO	O
SAC	O
por	O
P8	O
(	O
Figuras	O
3C	O
y	O
S6C	O
)	O
.	O

Estos	O
datos	O
sugieren	O
que	O
Rb	B-Protein
afecta	O
tanto	O
la	O
síntesis/estabilidad	O
como	O
el	O
transporte	O
de	O
los	O
marcadores	O
SAC	O
.	O

Figura	O
4	O

E2f3	B-Protein
Pérdida	O
Rescates	O
Diferenciación	O
de	O
Rb	B-Protein
KO	O
SAC	O

(	O
A	O
)	O
Secciones	O
retinales	O
horizontales	O
de	O
las	O
edades	O
indicadas	O
y	O
genotipos	B-Sequence
fueron	O
manchados	O
por	O
núcleos	B-GENE
(	O
DAPI	O
,	O
azul	O
)	O
,	O
marcador	O
de	O
mitosis	O
PH3	O
(	O
verde	O
)	O
y	O
Slc18a3	B-Protein
(	O
rojo	O
)	O
,	O
que	O
marca	O
SAC	O
soma	B-GENE
en	O
etapas	O
tempranas	O
y	O
procesos	B-GENE
de	O
~	O
P5	O
en	O
adelante	O
.	O

Las	O
flechas	O
muestran	O
PH3	O
+	O
mitótico	O
núcleos	B-GENE
en	O
Rb	B-Protein
ko	O
,	O
Rb	B-Protein
/	O
E2f2	B-Protein
DKO	O
,	O
y	O
Rb	B-Protein
/	O
E2f3	B-Protein
Retinas	O
DKO	O
.	O

E2f1	B-Protein
pérdida	O
rescata	O
la	O
mitosis	O
ectópica	O
y	O
célula	B-Cell
defectos	O
de	O
muerte	O
,	O
pero	O
no	O
el	O
defecto	O
SAC	O
.	O

E2f2	B-Protein
la	O
pérdida	O
no	O
tiene	O
ningún	O
efecto	O
.	O

E2f3	B-Protein
pérdida	O
no	O
rescata	O
la	O
mitosis	O
ectópica	O
y	O
célula	B-Cell
defectos	O
de	O
pérdida	O
,	O
pero	O
rescata	O
el	O
defecto	O
SAC	O
.	O

inactivando	O
E2f1	B-Protein
y	O
E2f3	B-Protein
juntos	O
rescata	O
la	O
mitosis	O
ectópica	O
,	O
célula	B-Cell
muerte	O
y	O
defectos	O
del	O
SAC	O
.	O

(	O
B	O
)	O
La	O
fracción	O
de	O
camk2a	B-Protein
+	O
células	B-Cell
que	O
son	O
Chat	B-Protein
#	O
¿NOMBRE	O
?	O
Slc18a3	B-Protein
#	O
¿NOMBRE	O
?	O

C	O
)	O
Las	O
secciones	O
horizontales	O
de	O
la	O
retina	O
P5	O
se	O
tiñeron	O
para	O
núcleos	B-GENE
(	O
DAPI	O
,	O
azul	O
)	O
,	O
Slc18a3	B-Protein
(	O
verde	O
)	O
,	O
y	O
isl1	B-Protein
(	O
rojo	O
)	O
.	O

Las	O
flechas	O
muestran	O
doble	O
etiqueta	O
isl1	B-Protein
+	O
/	O
Slc18a3	B-Protein
+	O
células	B-Cell
en	O
el	O
INL	O
interior	O
.	O

(	O
D	O
)	O
Secciones	O
horizontales	O
de	O
la	O
retina	O
P0	O
del	O
indicado	O
genotipos	B-Sequence
fueron	O
manchados	O
por	O
núcleos	B-GENE
(	O
DAPI	O
,	O
azul	O
)	O
,	O
célula	B-Cell
marcador	O
de	O
división	O
mki67	B-Protein
(	O
verde	O
)	O
,	O
y	O
isl1	B-Protein
(	O
rojo	O
)	O
.	O

Las	O
flechas	O
muestran	O
los	O
SAC	O
divisorios	O
con	O
doble	O
etiqueta	O
.	O

(	O
E	O
)	O
La	O
fracción	O
de	O
isl1	B-Protein
+	O
células	B-Cell
en	O
el	O
NBL	O
interno	O
(	O
INBL	O
)	O
de	O
las	O
retinas	O
P0	O
que	O
se	O
están	O
dividiendo	O
(	O
mki67	B-Protein
+	O
)	O
.	O

Las	O
barras	O
de	O
error	O
representan	O
SD	O
de	O
mediciones	O
de	O
tres	O
animales	B-Taxon
,	O
y	O
los	O
asteriscos	O
indican	O
diferencias	O
significativas	O
entre	O
las	O
retinas	O
de	O
peso	B-Sequence
y	O
lo	O
indicado	O
genotipos	B-Sequence
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
;	O
p	O
<	O
0	O
.	O
01	O
;	O
ANOVA	O
y	O
prueba	O
Tukey	O
HSD	O
)	O
.	O

Las	O
barras	O
de	O
escala	O
en	O
(	O
A	O
)	O
,	O
(	O
C	O
)	O
y	O
(	O
D	O
)	O
son	O
50	O
mu	O
m	O
.	O

Rb	B-Protein
Regula	O
la	O
Diferenciación	O
SAC	O
a	O
través	O
de	O
E2f3	B-Protein

Rb	B-Protein
se	O
une	O
a	O
más	O
de	O
100	O
proteinas	B-Chemical
[	O
43	O
]	O
y	O
en	O
algunos	O
no	O
-	O
células	B-Cell
neuronales	I-Cell
,	O
como	O
el	O
músculo	O
esquelético	O
,	O
adipocitos	B-Cell
y	O
hueso	O
Rb	B-Protein
se	O
cree	O
que	O
se	O
une	O
y	O
potencia	O
los	O
factores	O
de	O
transcripción	O
específicos	O
de	O
tejido	O
que	O
promueven	O
la	O
diferenciación	O
[	O
31	O
-	O
33	O
]	O
.	O

Así	O
,	O
esperábamos	O
que	O
Rb	B-Protein
podría	O
interactuar	O
con	O
factores	O
específicos	O
de	O
la	O
retina	O
para	O
facilitar	O
la	O
diferenciación	O
del	O
SAC	O
.	O

Un	O
papel	O
directo	O
de	O
E2f	O
en	O
la	O
mediación	O
Rb	B-Protein
-	O
Defectos	O
de	O
diferenciación	O
dependiente	O
(	O
independientes	O
de	O
célula	B-Cell
ciclo	O
o	O
defectos	O
de	O
muerte	O
)	O
no	O
ha	O
sido	O
descrito	O
hasta	O
donde	O
sabemos	O
,	O
pero	O
debido	O
a	O
que	O
E2f	O
puede	O
regular	O
alguna	O
diferenciación	O
genes	B-Sequence
[	O
44	O
-	O
48	O
]	O
,	O
primero	O
probamos	O
si	O
E2f2	B-Protein
o	O
E2f3	B-Protein
podría	O
perturbar	O
Rb	B-Protein
Maduración	O
KO	O
SAC	O
.	O

En	O
múltiples	O
momentos	O
,	O
E2f1	B-Protein
supresión	B-Sequence
mitosis	O
ectópica	O
suprimida	O
(	O
PH3	O
+	O
células	B-Cell
)	O
,	O
pero	O
no	O
revirtió	O
el	O
defecto	O
SAC	O
,	O
y	O
E2f2	B-Protein
supresión	B-Sequence
no	O
tuvo	O
efecto	O
sobre	O
ninguno	O
de	O
los	O
dos	O
defectos	O
(	O
Figura	O
4A	O
)	O
.	O

Sorprendentemente	O
,	O
aunque	O
E2f3	B-Protein
supresión	B-Sequence
no	O
revirtió	O
la	O
mitosis	O
ectópica	O
,	O
rescató	O
Calb2	B-Protein
,	O
Slc18a3	B-Protein
,	O
Chat	B-Protein
,	O
GABA	B-Chemical
,	O
Kcnc1b	B-Protein
,	O
Kcnc2	B-Protein
,	O
y	O
Sv2c	B-Protein
tinción	O
en	O
múltiples	O
momentos	O
(	O
Figura	O
4A	O
y	O
datos	O
no	O
mostrados	O
)	O
.	O

Rb	B-Protein
/	O
E2f3	B-Protein
Las	O
pistas	O
de	O
DKO	O
SAC	O
estaban	O
un	O
poco	O
más	O
desordenadas	O
que	O
en	O
peso	B-Sequence
retina	O
,	O
muy	O
probablemente	O
debido	O
a	O
la	O
ausencia	O
de	O
sináptico	B-GENE
compañero	O
células	B-Cell
,	O
que	O
son	O
asesinados	O
por	O
E2f1	B-Protein
.	O

En	O
efecto	O
,	O
este	O
pequeño	O
defecto	O
fue	O
rescatado	O
en	O
el	O
Rb	B-Protein
/	O
E2f1	B-Protein
/	O
E2f3	B-Protein
retina	O
triple	O
knockout	O
,	O
donde	O
célula	B-Cell
bipolar	I-Cell
y	I-Cell
ganglionar	I-Cell
se	O
rescató	O
la	O
muerte	O
y	O
se	O
restableció	O
la	O
diferenciación	O
del	O
SAC	O
(	O
Figura	O
4A	O
)	O
.	O

E2f3	B-Protein
supresión	B-Sequence
solo	O
no	O
afectó	O
la	O
diferenciación	O
SAC	O
(	O
Figura	O
4A	O
)	O
;	O
así	O
se	O
desata	O
E2f3	B-Protein
actividad	O
que	O
es	O
perjudicial	O
,	O
y	O
el	O
papel	O
crítico	O
para	O
Rb	B-Protein
es	O
inhibir	O
E2f3	B-Protein
.	O

Cuantificamos	O
la	O
fracción	O
de	O
camk2a	B-Protein
#	O
¿NOMBRE	O
?	O
genotipos	B-Sequence
y	O
encontró	O
que	O
el	O
60	O
%	O
de	O
peso	B-Sequence
P30	O
camk2a	B-Protein
+	O
células	B-Cell
expresado	O
Chat	B-Protein
y	O
Slc18a3	B-Protein
,	O
que	O
se	O
redujo	O
a	O
sólo	O
5	O
.	O
6	O
%	O
en	O
el	O
Rb	B-Protein
KO	O
retina	O
,	O
y	O
se	O
mantuvo	O
bajo	O
en	O
3	O
.	O
7	O
%	O
en	O
el	O
Rb	B-Protein
/	O
E2f1	B-Protein
DKO	O
retina	O
,	O
pero	O
aumentó	O
al	O
91	O
%	O
en	O
el	O
Rb	B-Protein
/	O
E2f3	B-Protein
Retina	O
DKO	O
(	O
Figura	O
4B	O
)	O
.	O

Esta	O
última	O
fracción	O
es	O
superior	O
a	O
peso	B-Sequence
porque	O
celulas	B-Cell
ganglionares	I-Cell
,	O
que	O
normalmente	O
constituyen	O
~	O
40	O
%	O
de	O
camk2a	B-Protein
+	O
células	B-Cell
,	O
mueren	O
por	O
apoptosis	O
.	O

Para	O
cuantificar	O
el	O
efecto	O
de	O
diferentes	O
E2fs	O
en	O
la	O
división	O
ectópica	O
específicamente	O
en	O
SAC	O
,	O
explotamos	O
isl1	B-Protein
(	O
islote1	B-Protein
)	O
.	O

Este	O
marcador	O
se	O
expresa	O
tanto	O
en	O
SAC	O
como	O
en	O
celulas	B-Cell
ganglionares	I-Cell
,	O
por	O
lo	O
tanto	O
isl1	B-Protein
+	O
células	B-Cell
en	O
el	O
INL	O
son	O
exclusivamente	O
SACs	O
[	O
49	O
]	O
.	O

Encontramos	O
que	O
98	O
.	O
2	O
%	O
+/-	O
1	O
.	O
8	O
%	O
de	O
isl1	B-Protein
+	O
células	B-Cell
en	O
el	O
interior	O
de	O
formación	O
INL	O
en	O
P5	O
también	O
fueron	O
Slc18a3	B-Protein
+	O
,	O
confirmando	O
que	O
isl1	B-Protein
es	O
un	O
excelente	O
marcador	O
SAC	O
(	O
Figura	O
4C	O
)	O
.	O

Es	O
más	O
,	O
isl1	B-Protein
,	O
a	O
diferencia	O
de	O
Slc18a3	B-Protein
,	O
es	O
nuclear	B-GENE
,	O
que	O
facilita	O
la	O
puntuación	O
de	O
isl1	B-Protein
+	O
/	O
mki67	B-Protein
+	O
células	B-Cell
.	O

También	O
se	O
expresa	O
antes	O
que	O
Slc18a3	B-Protein
lo	O
que	O
permite	O
el	O
análisis	O
de	O
SAC	O
poco	O
después	O
de	O
su	O
nacimiento	O
en	O
~	O
E15	O
;	O
por	O
lo	O
tanto	O
,	O
podríamos	O
estudiar	O
la	O
retina	O
en	O
P0	O
,	O
un	O
momento	O
en	O
que	O
la	O
división	O
ectópica	O
es	O
alta	O
en	O
la	O
retina	O
interna	O
y	O
antes	O
de	O
Rb	B-Protein
#	O
¿NOMBRE	O
?	O
célula	B-Cell
salida	O
de	O
ciclo	O
asociada	O
a	O
diferenciación	O
terminal	O
[	O
2	O
]	O
.	O

En	O
P0	O
,	O
sin	O
peso	B-Sequence
isl1	B-Protein
+	O
células	B-Cell
en	O
la	O
capa	O
neuroblástica	O
interna	O
(	O
NBL	O
)	O
(	O
que	O
es	O
el	O
futuro	O
INL	O
)	O
se	O
estaban	O
dividiendo	O
,	O
pero	O
57	O
+/-	O
14	O
isl1	B-Protein
+	O
/	O
mki67	B-Protein
+	O
células	B-Cell
fueron	O
detectados	O
en	O
el	O
Rb	B-Protein
KO	O
interno	O
NBL	O
(	O
Figura	O
4D	O
)	O
.	O

De	O
hecho	O
,	O
alrededor	O
de	O
un	O
tercio	O
de	O
todos	O
isl1	B-Protein
+	O
células	B-Cell
en	O
todo	O
el	O
NBL	O
interior	O
se	O
dividían	O
en	O
el	O
Rb	B-Protein
retina	O
KO	O
,	O
o	O
~	O
50	O
%	O
en	O
la	O
periferia	O
donde	O
se	O
expresa	O
Cre	O
(	O
Figura	O
4E	O
y	O
datos	O
no	O
mostrados	O
)	O
.	O

Este	O
defecto	O
fue	O
suprimido	O
en	O
el	O
Rb	B-Protein
/	O
E2f1	B-Protein
DKO	O
retina	O
,	O
donde	O
detectamos	O
solo	O
1	O
+/-	O
1	O
dividiendo	O
SAC	O
,	O
pero	O
no	O
el	O
Rb	B-Protein
/	O
E2f3	B-Protein
Retina	O
DKO	O
,	O
donde	O
había	O
53	O
+/-	O
8	O
SAC	O
en	O
división	O
(	O
Figura	O
4D	O
y	O
4E	O
)	O
.	O

Observamos	O
efectos	O
similares	O
en	O
P0	O
con	O
Calb2	B-Protein
,	O
que	O
marca	O
los	O
SAC	O
recién	O
nacidos	O
y	O
otros	O
células	B-Cell
amacrinas	I-Cell
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Así	O
,	O
en	O
Rb	B-Protein
KO	O
SAC	O
,	O
E2f1	B-Protein
supresión	B-Sequence
suprime	O
la	O
división	O
ectópica	O
pero	O
no	O
la	O
diferenciación	O
aberrante	O
,	O
mientras	O
que	O
E2f3	B-Protein
supresión	B-Sequence
suprime	O
la	O
diferenciación	O
aberrante	O
pero	O
no	O
la	O
división	O
ectópica	O
.	O

Expresión	O
específica	O
de	O
E2f3	B-Protein
en	O
SAC	O
y	O
otros	O
subconjuntos	O
de	O
Neuronas	B-Cell
del	I-Cell
SNC	I-Cell

El	O
efecto	O
único	O
de	O
E2f3	B-Protein
en	O
la	O
interrupción	O
de	O
la	O
diferenciación	O
de	O
los	O
SAC	O
,	O
pero	O
no	O
de	O
otros	O
retinales	O
neuronas	B-Cell
puede	O
ser	O
debido	O
a	O
célula	B-Cell
#	O
¿NOMBRE	O
?	O
célula	B-Cell
#	O
¿NOMBRE	O
?	O
E2f3	B-Protein
.	O

Determinar	O
entre	O
estas	O
dos	O
posibilidades	O
no	O
es	O
fácil	O
,	O
ya	O
que	O
la	O
inmunotinción	O
de	O
E2f	O
en	O
ratón	B-Taxon
tejidos	O
es	O
problemático	O
.	O

No	O
solucionamos	O
este	O
problema	O
por	O
E2f1	B-Protein
o	O
E2f2	B-Protein
,	O
pero	O
usó	O
un	O
protocolo	O
modificado	O
[	O
50	O
]	O
para	O
rastrear	O
con	O
éxito	O
E2f3	B-Protein
expresión	O
(	O
Figura	O
5	O
)	O
.	O

En	O
P0	O
,	O
E2f3	B-Protein
se	O
detectó	O
en	O
RPC	O
,	O
consistente	O
con	O
un	O
supuesto	O
papel	O
en	O
la	O
proliferación	O
normal	O
(	O
Figura	O
5A	O
)	O
.	O

La	O
señal	O
era	O
específica	O
ya	O
que	O
estaba	O
ausente	O
en	O
el	O
E2f3	B-Protein
Retina	O
periférica	O
KO	O
(	O
Figura	O
5A	O
)	O
.	O

A	O
medida	O
que	O
la	O
retina	O
se	O
diferenciaba	O
y	O
la	O
división	O
RPC	O
disminuía	O
,	O
el	O
número	O
de	O
E2f3	B-Protein
+	O
células	B-Cell
también	O
se	O
redujo	O
,	O
y	O
en	O
P8	O
,	O
cuando	O
la	O
división	O
prácticamente	O
ha	O
terminado	O
,	O
sólo	O
un	O
subconjunto	O
de	O
post-mitótico	O
células	B-Cell
en	O
la	O
retina	O
interna	O
expresado	O
E2f3	B-Protein
(	O
Figura	O
5A	O
)	O
.	O

por	O
P18	O
,	O
E2f3	B-Protein
también	O
se	O
detectó	O
en	O
dos	O
pistas	O
en	O
la	O
IPL	O
(	O
Figura	O
5A	O
y	O
5B	O
)	O
,	O
que	O
recuerda	O
a	O
los	O
marcadores	O
SAC	O
como	O
Chat	B-Protein
y	O
Slc18a3	B-Protein
(	O
c	O
.	O
f	O
.	O
Figuras	O
3	O
y	O
4	O
)	O
.	O

Esta	O
citoplasmático	B-GENE
E2f3	B-Protein
la	O
tinción	O
también	O
fue	O
específica	O
,	O
ya	O
que	O
estuvo	O
ausente	O
en	O
el	O
E2f3	B-Protein
KO	O
retina	O
periférica	O
de	O
alfa-Cre	O
;	O
E2f3loxP	O
/	O
loxP	B-Sequence
ratones	B-Taxon
(	O
Figura	O
5A	O
)	O
.	O

De	O
hecho	O
,	O
el	O
doble	O
etiquetado	O
con	O
E2f3	B-Protein
(	O
rojo	O
y	O
Chat	B-Protein
más	O
Slc18a3	B-Protein
(	O
verde	O
)	O
confirmó	O
que	O
E2f3	B-Protein
está	O
presente	O
en	O
ambos	O
SAC	O
soma	B-GENE
y	O
dendritas	B-GENE
(	O
Figura	O
5B	O
)	O
.	O

Rb	B-Protein
proteína	B-Chemical
también	O
se	O
detectó	O
en	O
la	O
retina	O
interna	O
(	O
Figura	O
5A	O
)	O
,	O
y	O
mostró	O
una	O
distribución	O
similar	O
a	O
la	O
de	O
E2f3	B-Protein
en	O
SACs	O
(	O
Figura	O
5B	O
)	O
,	O
y	O
también	O
estuvo	O
presente	O
en	O
maduros	O
celulas	B-Cell
ganglionares	I-Cell
y	O
Células	B-Cell
de	I-Cell
M	I-Cell
u	I-Cell
ller	I-Cell
como	O
se	O
informó	O
[	O
51	O
]	O
.	O

Rb	B-Protein
tinción	O
en	O
SAC	O
procesos	B-GENE
era	O
específico	O
ya	O
que	O
estaba	O
ausente	O
en	O
la	O
retina	O
periférica	O
de	O
alfa	O
Cre	O
;	O
RbloxP	O
/	O
loxP	B-Sequence
ratones	B-Taxon
(	O
Figura	O
5A	O
)	O
.	O

Estos	O
datos	O
sugieren	O
que	O
Rb	B-Protein
y	O
E2f3	B-Protein
colocalizar	O
en	O
SACs	O
y	O
que	O
E2f3	B-Protein
desencadena	O
defectos	O
en	O
la	O
diferenciación	O
SAC	O
porque	O
se	O
expresa	O
específicamente	O
en	O
estos	O
retinales	O
neuronas	B-Cell
.	O

Figura	O
5	O

E2f3	B-Protein
y	O
Rb	B-Protein
Expresión	O
en	O
SAC	O

(	O
A	O
)	O
Paneles	O
izquierdos	O
:	O
secciones	O
retinianas	O
horizontales	O
P0	O
,	O
P8	O
y	O
P18	O
del	O
indicado	O
genotipos	B-Sequence
fueron	O
manchados	O
por	O
E2f3	B-Protein
(	O
rojo	O
)	O
y	O
DAPI	O
(	O
azul	O
)	O
.	O

La	O
flecha	O
indica	O
la	O
unión	O
entre	O
el	O
E2f3	B-Protein
periférico	O
nulo	O
y	O
peso	B-Sequence
retina	O
P0	O
central	O
.	O

Nótese	O
la	O
ausencia	O
de	O
E2f3	B-Protein
proteína	B-Chemical
en	O
el	O
periférico	O
E2f3	B-Protein
KO	O
RPC	O
en	O
P0	O
y	O
en	O
la	O
retina	O
interna	O
periférica	O
neuronas	B-Cell
en	O
P18	O
.	O

Panel	O
extremo	O
derecho	O
:	O
P18	O
secciones	O
retinales	O
del	O
indicado	O
genotipos	B-Sequence
fueron	O
manchados	O
por	O
Rb	B-Protein
(	O
rojo	O
)	O
y	O
DAPI	O
(	O
azul	O
)	O
.	O

Nótese	O
la	O
ausencia	O
de	O
Rb	B-Protein
proteína	B-Chemical
en	O
el	O
periférico	O
Rb	B-Protein
retina	O
interna	O
KO	O
neuronas	B-Cell
.	O

(	O
B	O
)	O
peso	B-Sequence
Las	O
secciones	O
de	O
retina	O
P18	O
se	O
tiñeron	O
para	O
núcleos	B-GENE
(	O
DAPI	O
,	O
azul	O
)	O
,	O
E2f3	B-Protein
(	O
rojo	O
)	O
o	O
Rb	B-Protein
(	O
rojo	O
y	O
Chat	B-Protein
más	O
Slc18a3	B-Protein
(	O
verde	O
)	O
.	O

Las	O
flechas	O
indican	O
doble	O
etiquetado	O
soma	B-GENE
.	O

Tenga	O
en	O
cuenta	O
que	O
la	O
IPL	O
procesos	B-GENE
también	O
tienen	O
doble	O
etiqueta	O
.	O

Las	O
barras	O
de	O
escala	O
son	O
de	O
50	O
mu	O
m	O
.	O

También	O
encontramos	O
que	O
E2f3	B-Protein
está	O
presente	O
en	O
un	O
subconjunto	O
específico	O
de	O
adultos	O
neuronas	B-Cell
en	O
varias	O
regiones	O
del	O
cerebro	O
(	O
datos	O
no	O
mostrados	O
)	O
.	O

Por	O
ejemplo	O
,	O
en	O
la	O
amígdala	O
P20	O
,	O
E2f3	B-Protein
colocalizado	O
con	O
el	O
general	O
neuronales	B-Cell
marcadores	O
Mtap2	B-Protein
y	O
mecp2	B-Protein
[	O
52	O
]	O
,	O
pero	O
no	O
con	O
Calb2	B-Protein
,	O
que	O
marca	O
un	O
subconjunto	O
de	O
neuronas	B-Cell
,	O
o	O
con	O
el	O
glial	B-Cell
marcador	O
Gfap	B-Protein
(	O
datos	O
no	O
mostrados	O
)	O
.	O

A	O
diferencia	O
de	O
los	O
sacos	O
retinianos	O
,	O
E2f3	B-Protein
no	O
se	O
coexpresó	O
en	O
Chat	B-Protein
#	O
¿NOMBRE	O
?	O
Slc18a3	B-Protein
+	O
neuronas	B-Cell
colinérgicas	I-Cell
ubicado	O
en	O
varias	O
regiones	O
del	O
cerebro	O
y	O
la	O
médula	O
espinal	O
(	O
datos	O
no	O
mostrados	O
)	O
.	O

De	O
acuerdo	O
,	O
no	O
pudimos	O
detectar	O
defectos	O
en	O
neuronas	B-Cell
colinérgicas	I-Cell
Rb	I-Cell
KO	I-Cell
en	O
el	O
prosencéfalo	O
en	O
desarrollo	O
,	O
pero	O
otros	O
Rb	B-Protein
KO	O
neuronas	B-Cell
en	O
esta	O
región	O
mostró	O
defectos	O
de	O
diferenciación	O
que	O
fueron	O
rescatados	O
por	O
borrando	B-Sequence
E2f3	B-Protein
[	O
53	O
]	O
.	O

Juntos	O
,	O
estos	O
resultados	O
sugieren	O
que	O
el	O
mecanismo	O
común	O
por	O
el	O
cual	O
Rb	B-Protein
promueve	O
la	O
diferenciación	O
neural	O
es	O
a	O
través	O
de	O
E2f3	B-Protein
inhibición	O

Localización	O
distinta	O
de	O
E2f3	B-Protein
isoformas	B-Sequence

Como	O
se	O
señaló	O
anteriormente	O
,	O
E2f3	B-Protein
y	O
Rb	B-Protein
la	O
tinción	O
en	O
SAC	O
fue	O
tanto	O
nuclear	B-GENE
y	O
citoplasmático	B-GENE
(	O
Figura	O
5A	O
y	O
5B	O
)	O
.	O

los	O
anticuerpo	B-GENE
que	O
trabajó	O
en	O
inmunotinción	O
reconoce	O
un	O
C	B-Sequence
-	I-Sequence
región	I-Sequence
terminal	I-Sequence
y	O
por	O
lo	O
tanto	O
,	O
no	O
distingue	O
a	O
/	O
b	O
isoformas	B-Sequence
.	O

Hasta	O
donde	O
sabemos	O
,	O
la	O
ubicación	O
subcelular	O
de	O
E2f3	B-Protein
isoformas	B-Sequence
no	O
se	O
ha	O
determinado	O
en	O
ningún	O
célula	B-Cell
escribe	O
.	O

Para	O
verificar	O
las	O
ubicaciones	O
duales	O
de	O
E2f3	B-Protein
y	O
para	O
determinar	O
cuales	O
isoformas	B-Sequence
estaban	O
presentes	O
en	O
la	O
retina	O
,	O
analizamos	O
nuclear	B-GENE
y	O
fracciones	B-GENE
citoplasmáticas	I-GENE
por	O
Western	O
blot	O
en	O
diferentes	O
momentos	O
del	O
desarrollo	O
.	O

Análisis	O
con	O
la	O
sartén	O
-	O
E2f3	B-Protein
anticuerpo	B-GENE
(	O
sc	O
-	O
878	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
detectó	O
un	O
E2f3a	O
de	O
55	O
-	O
kD	O
especies	B-Sequence
y	O
un	O
40	O
-	O
kD	O
E2f3b	O
polipéptido	B-Sequence
(	O
Figura	O
6	O
)	O
.	O

Para	O
confirmar	O
que	O
la	O
parte	O
superior	O
especies	B-Sequence
en	O
nuestros	O
lisados	O
retinianos	O
fue	O
E2f3a	O
,	O
explotamos	O
la	O
novela	O
ratones	B-Taxon
esa	O
falta	O
E2f3	B-Protein
exón	B-Sequence
1a	O
y	O
por	O
lo	O
tanto	O
expresan	O
E2f3b	O
exclusivamente	O
(	O
R	O
.	O
O	O
.	O
y	O
G	O
.	O
L	O
.	O
,	O
datos	O
no	O
publicados	O
)	O
.	O

La	O
estrategia	O
de	O
genotipado	O
se	O
analiza	O
en	O
detalle	O
más	O
adelante	O
y	O
se	O
describe	O
en	O
la	O
Figura	O
7A	O
.	O

El	O
análisis	O
occidental	O
confirmó	O
que	O
la	O
banda	O
superior	O
estaba	O
ausente	O
en	O
E2f3a	O
-	O
/	O
-	O
ratones	B-Taxon
(	O
Figuras	O
6	O
y	O
S8	O
)	O
.	O

En	O
consonancia	O
con	O
la	O
caída	O
E2f3	B-Protein
#	O
¿NOMBRE	O
?	O
células	B-Cell
durante	O
peso	B-Sequence
maduración	O
retinal	O
(	O
Figura	O
5A	O
)	O
,	O
la	O
cantidad	O
total	O
de	O
E2f3a	O
fue	O
menor	O
en	O
P18	O
en	O
comparación	O
con	O
P0	O
(	O
Figura	O
6	O
)	O
.	O

E2f3b	O
estuvo	O
presente	O
en	O
cantidades	O
similares	O
en	O
ambos	O
momentos	O
.	O

En	O
P0	O
y	O
P18	O
,	O
E2f3a	O
estuvo	O
presente	O
en	O
ambos	O
nuclear	B-GENE
y	O
fracciones	B-GENE
citoplasmáticas	I-GENE
,	O
pero	O
en	O
marcado	O
contraste	O
,	O
E2f3b	O
fue	O
exclusivamente	O
nuclear	B-GENE
en	O
ambos	O
momentos	O
(	O
Figura	O
6	O
)	O
.	O

Se	O
detectaron	O
dos	O
bandas	O
E2f3a	O
que	O
migran	O
de	O
cerca	O
,	O
más	O
claramente	O
evidentes	O
en	O
P18	O
,	O
de	O
las	O
cuales	O
la	O
que	O
migra	O
más	O
rápido	O
especies	B-Sequence
era	O
dominante	O
en	O
nuclear	B-GENE
y	O
el	O
mas	O
lento	O
especies	B-Sequence
era	O
dominante	O
en	O
citoplasma	B-GENE
(	O
Figura	O
6	O
)	O
.	O

La	O
identidad	O
de	O
ambos	O
como	O
E2f3a	O
especies	B-Sequence
fue	O
confirmado	O
por	O
su	O
ausencia	O
en	O
la	O
retina	O
P18	O
E2f3a	O
KO	O
(	O
Figura	O
S8	O
)	O
.	O

Análisis	O
de	O
pou4f2	B-Protein
,	O
a	O
nuclear	B-GENE
factor	O
de	O
transcripción	O
expresado	O
en	O
celulas	B-Cell
ganglionares	I-Cell
,	O
mostró	O
que	O
nuclear	B-GENE
proteinas	B-Chemical
no	O
había	O
contaminado	O
el	O
fracción	B-GENE
citoplasmática	I-GENE
y	O
análisis	O
de	O
Slc18a3	B-Protein
,	O
a	O
citoplasmático	B-GENE
marcador	O
SAC	O
,	O
confirmó	O
que	O
tampoco	O
había	O
ocurrido	O
lo	O
contrario	O
(	O
Figura	O
6	O
)	O
.	O

Estos	O
datos	O
muestran	O
,	O
hasta	O
donde	O
sabemos	O
por	O
primera	O
vez	O
,	O
que	O
E2f3a	O
y	O
E2f3b	O
exhiben	O
patrones	O
distintos	O
de	O
distribución	O
subcelular	O
,	O
y	O
plantean	O
la	O
posibilidad	O
de	O
que	O
la	O
localización	O
de	O
E2f3a	O
pueda	O
estar	O
regulada	O
por	O
factores	O
post	O
-	O
traduccionales	O
aún	O
desconocidos	O
.	O
modificaciones	B-Sequence
.	O

Figura	O
6	O

Distribución	O
subcelular	O
de	O
E2f3	B-Protein
isoformas	B-Sequence
y	O
otra	O
Célula	B-Cell
Ciclo	O
Proteínas	B-Chemical
en	O
la	O
retina	O
en	O
desarrollo	O

nucleares	O
y	O
citoplasmático	B-GENE
extractos	O
de	O
un	O
número	O
equivalente	O
de	O
retinal	O
células	B-Cell
desde	O
ratones	B-Taxon
de	O
lo	O
indicado	O
genotipos	B-Sequence
y	O
las	O
edades	O
fueron	O
analizadas	O
por	O
Western	O
Blot	O
para	O
detectar	O
el	O
indicado	O
proteinas	B-Chemical
.	O

Lisado	O
de	O
E2f3a	O
-	O
/	O
-	O
ratones	B-Taxon
se	O
usó	O
como	O
control	O
para	O
confirmar	O
la	O
ubicación	O
de	O
E2f3a	O
proteína	B-Chemical
.	O

C	B-GENE
,	O
citoplasmático	B-GENE
extractos	O
;	O
norte	B-GENE
,	O
nuclear	B-GENE
extractos	O

Figura	O
7	O

El	O
E2f3a	O
isoforma	B-Sequence
Impulsa	O
el	O
defecto	O
de	O
diferenciación	O
en	O
Rb	B-Protein
KO	O
SAC	O

(	O
A	O
)	O
Diagramas	O
esquemáticos	O
de	O
los	O
ratón	B-Taxon
peso	B-Sequence
,	O
E2f3a	O
-	O
/	O
-	O
,	O
y	O
el	O
Cre	O
-	O
recombinado	O
flojo	B-Sequence
E2f3	B-Protein
lugares	B-Sequence
(	O
indicado	O
aquí	O
como	O
E2f3	B-Protein
-	O
/	O
-	O
por	O
simplicidad	O
)	O
.	O

E2f3a	O
-	O
/	O
-	O
ratones	B-Taxon
falta	O
la	O
mayor	O
parte	O
de	O
E2f3	B-Protein
exón	B-Sequence
1a	O
y	O
parte	O
de	O
intrón	B-Sequence
1a	O
(	O
recuadro	O
de	O
puntos	O
rojos	O
)	O
.	O

Las	O
flechas	O
indican	O
PCR	O
cebadores	B-Sequence
.	O

Genotipado	O
de	O
un	O
E2f3a	O
+	B-Sequence
/	O
-	O
ratón	B-Taxon
se	O
muestra	O
a	O
la	O
derecha	O
.	O

(	O
B	O
)	O
RT	O
-	O
Detección	O
por	O
PCR	O
de	O
E2f3a	O
y	O
E2f3b	O
ARNm	B-Chemical
en	O
la	O
retina	O
.	O

los	O
secuencias	B-Sequence
de	O
cebadores	B-Sequence
son	O
1aF	O
(	O
5'-GCCTCTACACCACGCCACAAG-3	O
'	O
)	O
,	O
1bF	O
(	O
5'-CGGAAATGCCCTTACAGC-3	O
'	O
)	O
y	O
4R	O
(	O
5'-CTCAGTCACTTCTTTGACAG-3	O
'	O
)	O
.	O

peso	B-Sequence
la	O
retina	O
expresa	O
tanto	O
E2f3a	O
como	O
E2f3b	O
ARNm	B-Chemical
.	O

Como	O
era	O
de	O
esperar	O
,	O
E2f3a	O
-	O
/	O
-	O
retina	O
carece	O
de	O
E2f3a	O
ARNm	B-Chemical
y	O
todavía	O
expresa	O
E2f3b	O
ARNm	B-Chemical
.	O

E2f3	B-Protein
-	O
/	O
-	O
la	O
retina	O
carece	O
de	O
longitud	O
completa	O
E2f3a	O
y	O
E2f3b	O
ARNm	B-Chemical
,	O
y	O
en	O
su	O
lugar	O
expresa	O
un	O
truncado	O
ARNm	B-Chemical
carente	O
exón	B-Sequence
3	O
.	O

(	O
C	O
)	O
Análisis	O
de	O
RT	O
-	O
PCR	O
en	O
tiempo	O
real	O
de	O
E2f	O
genes	B-Sequence
en	O
retinas	O
P8	O
de	O
las	O
indicadas	O
genotipos	B-Sequence
.	O

Las	O
barras	O
de	O
error	O
representan	O
SD	O
de	O
mediciones	O
de	O
tres	O
animales	B-Taxon
,	O
y	O
los	O
asteriscos	O
indican	O
una	O
diferencia	O
significativa	O
entre	O
peso	B-Sequence
y	O
lo	O
indicado	O
genotipos	B-Sequence
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
;	O
p	O
<	O
0	O
.	O
01	O
;	O
ANOVA	O
y	O
prueba	O
Tukey	O
HSD	O
)	O
.	O

(	O
D	O
)	O
Rescate	O
de	O
Rb	B-Protein
KO	O
SAC	O
por	O
E2f3a	O
supresión	B-Sequence
.	O

Secciones	O
retinianas	O
horizontales	O
del	O
indicado	O
genotipos	B-Sequence
y	O
las	O
edades	O
estaban	O
manchadas	O
por	O
núcleos	B-GENE
(	O
DAPI	O
,	O
azul	O
)	O
,	O
fase	O
M	O
(	O
PH3	O
,	O
verde	O
)	O
y	O
el	O
marcador	O
SAC	O
Slc18a3	B-Protein
(	O
rojo	O
)	O
.	O

E2f3a	O
supresión	B-Sequence
no	O
suprime	O
la	O
división	O
ectópica	O
,	O
pero	O
rescata	O
el	O
defecto	O
SAC	O
.	O

Las	O
barras	O
de	O
escala	O
son	O
de	O
50	O
mu	O
m	O
.	O

M	O
,	O
molecular	B-Chemical
marcador	O
de	O
tamaño	O

También	O
examinamos	O
la	O
distribución	O
de	O
otros	O
célula	B-Cell
reguladores	O
del	O
ciclo	O
durante	O
el	O
desarrollo	O
de	O
la	O
retina	O
.	O

como	O
E2f3a	O
,	O
Rb	B-Protein
estuvo	O
presente	O
en	O
los	O
dos	O
peso	B-Sequence
citoplasma	B-GENE
y	O
núcleo	B-GENE
en	O
P0	O
,	O
pero	O
en	O
P18	O
,	O
cuando	O
los	O
niveles	O
de	O
Rb	B-Protein
había	O
aumentado	O
,	O
era	O
principalmente	O
nuclear	B-GENE
(	O
Figura	O
6	O
)	O
.	O

un	O
muy	O
débil	O
citoplasmático	B-GENE
Rb	B-Protein
señal	O
fue	O
evidente	O
en	O
P18	O
,	O
lo	O
cual	O
es	O
consistente	O
con	O
Rb	B-Protein
tinción	O
de	O
SAC	O
procesos	B-GENE
(	O
Figura	O
5B	O
)	O
,	O
y	O
con	O
la	O
proporción	O
muy	O
pequeña	O
de	O
SAC	O
en	O
la	O
retina	O
[	O
38	O
]	O
.	O

E2f1	B-Protein
También	O
se	O
detectó	O
en	O
ambos	O
nuclear	B-GENE
y	O
fracciones	B-GENE
citoplasmáticas	I-GENE
,	O
aunque	O
a	O
diferencia	O
de	O
E2f3a	O
fue	O
predominantemente	O
nuclear	B-GENE
tanto	O
en	O
P0	O
como	O
en	O
P18	O
(	O
Figura	O
6	O
)	O
.	O

El	O
compañero	O
de	O
dimerización	O
E2f	O
,	O
Tfdp1	B-Protein
,	O
que	O
carece	O
de	O
nuclear	B-GENE
localización	O
señal	B-Sequence
[	O
54	O
]	O
,	O
fue	O
principalmente	O
citoplasmático	B-GENE
tanto	O
en	O
P0	O
como	O
en	O
P18	O
,	O
y	O
el	O
Cdk	O
inhibidores	B-Chemical
cdkn1a	B-Protein
y	O
Cdkn1b	B-Protein
mostró	O
un	O
patrón	O
similar	O
de	O
distribución	O
(	O
Figura	O
6	O
)	O
.	O

Así	O
,	O
entre	O
los	O
célula	B-Cell
reguladores	O
de	O
ciclo	O
que	O
examinamos	O
,	O
la	O
mayoría	O
mostró	O
una	O
distribución	O
bivalente	O
,	O
y	O
E2f3b	O
fue	O
inusual	O
en	O
su	O
única	O
nuclear	B-GENE
compartimentación	O
.	O

Rb	B-Protein
Regula	O
la	O
Diferenciación	O
SAC	O
a	O
través	O
de	O
E2f3a	O

Para	O
probar	O
cual	O
E2f3	B-Protein
isoforma	B-Sequence
es	O
responsable	O
de	O
aberrante	O
Rb	B-Protein
Diferenciación	O
KO	O
SAC	O
explotamos	O
E2f3a	O
-	O
/	O
-	O
ratones	B-Taxon
(	O
Figura	O
7A	O
)	O
.	O

La	O
estrategia	O
de	O
genotipado	O
descrita	O
en	O
la	O
Figura	O
7A	O
se	O
usó	O
para	O
distinguir	O
el	O
E2f3a	O
,	O
peso	B-Sequence
nulo	O
alelos	B-Sequence
.	O

La	O
PCR	O
con	O
transcriptasa	O
inversa	O
(	O
RT	O
-	O
PCR	O
)	O
confirmó	O
la	O
presencia	O
de	O
E2f3a	O
y	O
E2f3b	O
especies	B-Sequence
de	I-Sequence
ARN	I-Sequence
en	O
desarrollo	O
peso	B-Sequence
retina	O
,	O
y	O
la	O
ausencia	O
específica	O
de	O
E2f3a	O
ARN	B-Sequence
en	O
la	O
E2f3a-/-retina	O
(	O
Figura	O
7B	O
)	O
.	O

E2f3a	O
proteína	B-Chemical
estaba	O
ausente	O
en	O
el	O
lisado	O
de	O
retina	O
E2f3a-/-	O
(	O
Figuras	O
6	O
y	O
S8	O
)	O
.	O

Es	O
importante	O
destacar	O
que	O
los	O
niveles	O
de	O
E2f3b	O
mensaje	B-Sequence
eran	O
similares	O
en	O
el	O
Rb	B-Protein
KO	O
y	O
Rb	B-Protein
/	O
E2f3a	O
DKO	O
retina	O
,	O
descartando	O
la	O
posibilidad	O
de	O
que	O
cualquier	O
efecto	O
de	O
E2f3a	O
supresión	B-Sequence
podríamos	O
observar	O
que	O
se	O
debieron	O
a	O
la	O
regulación	O
a	O
la	O
baja	O
de	O
E2f3b	O
(	O
Figura	O
7C	O
)	O
.	O

Además	O
,	O
los	O
niveles	O
de	O
otros	O
E2fs	O
eran	O
los	O
mismos	O
en	O
el	O
Rb	B-Protein
ko	O
,	O
Rb	B-Protein
/	O
E2f3	B-Protein
DKO	O
,	O
y	O
Rb	B-Protein
/	O
E2f3a	O
DKO	O
retina	O
,	O
descartando	O
cualquier	O
efecto	O
de	O
regulación	O
cruzada	O
(	O
Figura	O
7C	O
)	O
[	O
55	O
]	O
.	O

E2f3a	O
puede	O
desencadenar	O
célula	B-Cell
inducción	O
del	O
ciclo	O
,	O
pero	O
debido	O
a	O
que	O
los	O
defectos	O
SAC	O
no	O
están	O
vinculados	O
a	O
célula	B-Cell
perturbación	O
del	O
ciclo	O
(	O
Figuras	O
3A	O
y	O
4	O
)	O
,	O
y	O
en	O
vista	O
de	O
la	O
asociación	O
predominante	O
entre	O
E2f3b	O
y	O
Rb	B-Protein
en	O
reposo	O
células	B-Cell
[	O
16	O
,	O
19	O
]	O
,	O
sospechamos	O
que	O
E2f3b	O
puede	O
perturbar	O
la	O
diferenciación	O
en	O
Rb	B-Protein
KO	O
SAC	O
.	O

Sin	O
embargo	O
,	O
inesperadamente	O
,	O
E2f3a	O
supresión	B-Sequence
suprimió	O
el	O
Rb	B-Protein
Defecto	O
KO	O
SAC	O
(	O
Figura	O
7D	O
)	O
.	O

Así	O
,	O
aparte	O
de	O
su	O
papel	O
en	O
célula	B-Cell
control	O
de	O
ciclo	O
,	O
Rb	B-Protein
la	O
regulación	O
de	O
E2f3a	O
es	O
fundamental	O
para	O
garantizar	O
una	O
adecuada	O
neuronales	B-Cell
diferenciación	O

Discusión	O

Rb	B-Protein
Controles	O
retina	O
Célula	B-Cell
División	O
y	O
Muerte	O
a	O
través	O
de	O
E2f1	B-Protein

El	O
trabajo	O
a	O
principios	O
de	O
la	O
década	O
de	O
1990	O
mostró	O
que	O
Rb	B-Protein
la	O
pérdida	O
desencadena	O
defectos	O
en	O
célula	B-Cell
neuronal	I-Cell
salida	O
del	O
ciclo	O
,	O
supervivencia	O
y	O
diferenciación	O
[	O
26-28	O
]	O
.	O

Gran	O
parte	O
de	O
la	O
muerte	O
es	O
una	O
consecuencia	O
indirecta	O
de	O
la	O
probable	O
hipoxia	O
relacionada	O
con	O
defectos	O
de	O
la	O
placenta	O
[	O
12	O
-	O
14	O
]	O
.	O

Sin	O
embargo	O
,	O
los	O
estudios	O
quiméricos	O
y	O
de	O
KO	O
dirigidos	O
revelan	O
que	O
Rb	B-Protein
promueve	O
de	O
forma	O
autónoma	O
célula	B-Cell
salida	O
de	O
ciclo	O
en	O
recien	O
nacido	O
neuronas	B-Cell
,	O
y	O
se	O
requiere	O
para	O
la	O
supervivencia	O
de	O
un	O
subconjunto	O
de	O
neuronas	B-Cell
,	O
particularmente	O
en	O
la	O
retina	O
[	O
2	O
,	O
3	O
,	O
13	O
,	O
14	O
,	O
56	O
-	O
59	O
]	O
.	O

Sin	O
embargo	O
,	O
si	O
Rb	B-Protein
también	O
regula	O
la	O
diferenciación	O
queda	O
oscurecida	O
por	O
los	O
efectos	O
potencialmente	O
indirectos	O
de	O
la	O
división	O
ectópica	O
y	O
la	O
muerte	O
.	O

Además	O
,	O
un	O
mecanismo	O
a	O
través	O
del	O
cual	O
Rb	B-Protein
puede	O
regular	O
neuronales	B-Cell
la	O
maduración	O
no	O
ha	O
sido	O
dilucidada	O
.	O

Aquí	O
,	O
borrando	B-Sequence
E2f1	B-Protein
rescató	O
específicamente	O
la	O
división	O
ectópica	O
y	O
la	O
muerte	O
en	O
el	O
Rb	B-Protein
KO	O
retina	O
.	O

Importante	O
,	O
mayor	O
Rb	B-Protein
/	O
E2f1	B-Protein
DKO	O
neuronas	B-Cell
diferenciados	O
normalmente	O
,	O
y	O
los	O
ERG	O
revelaron	O
el	O
rescate	O
de	O
vara	B-Cell
#	O
¿NOMBRE	O
?	O
cono	B-Cell
-	O
función	O
mediada	O
,	O
lo	O
que	O
implica	O
un	O
flujo	O
de	O
señal	O
regular	O
desde	O
fotorreceptores	B-Cell
para	O
células	B-Cell
bipolares	I-Cell
y	I-Cell
amacrinas	I-Cell
.	O

División	O
y	O
muerte	O
genes	B-Sequence
fueron	O
inducidos	O
en	O
Rb	B-Protein
KO	O
células	B-Cell
,	O
y	O
borrando	B-Sequence
E2f1	B-Protein
,	O
pero	O
no	O
E2f2	B-Protein
o	O
E2f3	B-Protein
,	O
invirtió	O
estos	O
molecular	B-Chemical
eventos	O
.	O

E2f1	B-Protein
también	O
puede	O
regular	O
los	O
objetivos	O
de	O
diferenciación	O
,	O
pero	O
si	O
esto	O
contribuye	O
a	O
defectos	O
en	O
la	O
retina	O
célula	B-Cell
la	O
maduración	O
es	O
imposible	O
de	O
separar	O
de	O
las	O
consecuencias	O
potencialmente	O
indirectas	O
de	O
la	O
división	O
desregulada	O
y	O
la	O
muerte	O
.	O

En	O
cualquier	O
caso	O
,	O
está	O
claro	O
que	O
en	O
la	O
mayoría	O
de	O
retina	O
células	B-Cell
,	O
incluyendo	O
fotorreceptores	B-Cell
[	O
29	O
]	O
,	O
los	O
factores	O
de	O
transcripción	O
que	O
promueven	O
la	O
función	O
de	O
diferenciación	O
independientemente	O
de	O
Rb	B-Protein
.	O

También	O
hemos	O
encontrado	O
que	O
E2f1	B-Protein
supresión	B-Sequence
rescata	O
célula	B-Cell
-	O
división	O
ectópica	O
autónoma	O
,	O
muerte	O
y	O
defectos	O
de	O
diferenciación	O
en	O
casos	O
esporádicos	O
Rb	B-Protein
Clones	O
KO	O
generados	O
usando	O
un	O
Cre	O
retrovirus	B-Taxon
vector	B-Sequence
(	O
M	O
.	O
P	O
.	O
y	O
R	O
.	O
B	O
.	O
,	O
datos	O
no	O
publicados	O
)	O
.	O

Estos	O
datos	O
son	O
consistentes	O
con	O
la	O
observación	O
de	O
que	O
E2f1	B-Protein
sobreexpresión	O
en	O
recién	O
nacido	O
fotorreceptores	B-Cell
impulsa	O
la	O
división	O
ectópica	O
y	O
la	O
apoptosis	O
[	O
60	O
]	O
,	O
y	O
se	O
suma	O
a	O
la	O
creciente	O
evidencia	O
que	O
indica	O
que	O
E2f1	B-Protein
es	O
el	O
miembro	O
principal	O
,	O
y	O
quizás	O
el	O
único	O
,	O
de	O
los	O
tres	O
E2f	O
activadores	O
requeridos	O
para	O
inducir	O
la	O
apoptosis	O
en	O
Rb	B-Protein
KO	O
células	B-Cell
[	O
10	O
,	O
15	O
]	O
.	O

Así	O
,	O
desregulado	O
E2f1	B-Protein
actividad	O
en	O
la	O
retina	O
,	O
ya	O
sea	O
como	O
resultado	O
de	O
la	O
inactivación	O
de	O
Rb	B-Protein
o	O
por	O
sobreexpresión	O
,	O
promueve	O
célula	B-Cell
división	O
y	O
desencadena	O
la	O
apoptosis	O
en	O
RTC	O
susceptibles	O
.	O

E2f1	B-Protein
,	O
en	O
lugar	O
de	O
otros	O
E2fs	O
,	O
puede	O
ser	O
un	O
objetivo	O
potencial	O
para	O
nuevas	O
terapias	O
para	O
prevenir	O
el	O
retinoblastoma	O
en	O
RB1	B-Protein
+	B-Sequence
/	O
-	O
humanos	B-Taxon
.	O

Nuestros	O
estudios	O
ERG	O
revelaron	O
el	O
rescate	O
de	O
la	O
Rb	B-Protein
KO	O
vara	B-Cell
-	O
bipolar	B-Cell
sistema	O
,	O
y	O
restauración	O
casi	O
completa	O
del	O
cono	B-Cell
-	O
bipolar	B-Cell
seguimiento	O
del	O
sistema	O
E2f1	B-Protein
supresión	B-Sequence
.	O

Hubo	O
una	O
respuesta	O
ligeramente	O
inferior	O
en	O
el	O
Rb	B-Protein
/	O
E2f1	B-Protein
Retina	O
DKO	O
en	O
relación	O
con	O
la	O
E2f1	B-Protein
Retina	O
de	O
control	O
KO	O
.	O

Esta	O
diferencia	O
podría	O
reflejar	O
un	O
papel	O
para	O
Rb	B-Protein
en	O
desarrollo	O
de	O
conos	B-Cell
,	O
células	B-Cell
bipolares	I-Cell
,	O
u	O
otro	O
células	B-Cell
que	O
pueden	O
contribuir	O
al	O
ERG	O
fotópico	O
,	O
incluidos	O
los	O
SAC	O
potenciales	O
,	O
que	O
tienen	O
un	O
defecto	O
grave	O
en	O
el	O
Rb	B-Protein
/	O
E2f1	B-Protein
DKO	O
retina	O
.	O

Rb	B-Protein
Controla	O
la	O
Diferenciación	O
SAC	O
a	O
través	O
de	O
E2f3a	O

El	O
análisis	O
exhaustivo	O
de	O
marcadores	O
reveló	O
que	O
,	O
en	O
marcado	O
contraste	O
con	O
otras	O
retinas	O
neuronas	B-Cell
,	O
E2f1	B-Protein
supresión	B-Sequence
no	O
suprimió	O
defectos	O
en	O
Rb	B-Protein
KO	O
colinérgico	B-Chemical
SAC	O
.	O

En	O
cambio	O
,	O
observamos	O
E2f1	B-Protein
#	O
¿NOMBRE	O
?	O
proteinas	B-Chemical
.	O

Estos	O
datos	O
amplían	O
la	O
comprensión	O
del	O
desarrollo	O
de	O
estos	O
importantes	O
interneuronas	B-Cell
,	O
pero	O
más	O
críticamente	O
,	O
proporciona	O
a	O
nuestro	O
conocimiento	O
la	O
primera	O
evidencia	O
inequívoca	O
de	O
que	O
Rb	B-Protein
regula	O
la	O
neurogénesis	O
más	O
allá	O
de	O
la	O
mitosis	O
terminal	O
.	O

Rb	B-Protein
une	O
más	O
de	O
100	O
factores	O
[	O
43	O
]	O
,	O
y	O
en	O
varios	O
no	O
-	O
células	B-Cell
neuronales	I-Cell
,	O
como	O
el	O
músculo	O
esquelético	O
,	O
adipocitos	B-Cell
,	O
y	O
hueso	O
,	O
se	O
une	O
y	O
potencia	O
los	O
factores	O
de	O
transcripción	O
específicos	O
de	O
tejido	O
que	O
promueven	O
la	O
diferenciación	O
[	O
31	O
-	O
33	O
]	O
.	O

La	O
idea	O
que	O
Rb	B-Protein
Promueve	O
la	O
diferenciación	O
muscular	O
al	O
potenciar	O
miod1	B-Protein
la	O
actividad	O
fue	O
cuestionada	O
[	O
61	O
]	O
,	O
y	O
se	O
propusieron	O
otros	O
mecanismos	O
[	O
62	O
,	O
63	O
]	O
,	O
pero	O
sin	O
involucrar	O
la	O
represión	O
E2f	O
.	O

Sorprendentemente	O
,	O
sin	O
embargo	O
,	O
descubrimos	O
que	O
Rb	B-Protein
promueve	O
la	O
diferenciación	O
de	O
SAC	O
a	O
través	O
de	O
E2f3	B-Protein
(	O
Figura	O
8	O
)	O
.	O

Figura	O
8	O

Rb	B-Protein
Regula	O
Procesos	O
Distintos	O
a	O
través	O
de	O
E2f1	B-Protein
y	O
E2f3a	O

El	O
texto	O
rojo	O
y	O
las	O
flechas	O
indican	O
Rb	B-Protein
-	O
eventos	O
dependientes	O
.	O

El	O
texto	O
negro	O
y	O
las	O
flechas	O
indican	O
eventos	O
para	O
los	O
cuales	O
no	O
hay	O
evidencia	O
directa	O
de	O
Rb	B-Protein
intervención	O
.	O

Rb	B-Protein
no	O
parece	O
moderar	O
la	O
expansión	O
de	O
RPC	O
y	O
no	O
es	O
necesario	O
para	O
la	O
diferenciación	O
de	O
RPC	O
en	O
RTC	O
,	O
pero	O
es	O
esencial	O
para	O
unir	O
el	O
nacimiento	O
de	O
RTC	O
con	O
la	O
mitosis	O
terminal	O
,	O
bloqueándolos	O
así	O
fuera	O
del	O
ciclo	O
.	O

Rb	B-Protein
realiza	O
esta	O
función	O
al	O
inhibir	O
E2f1	B-Protein
.	O

Rb	B-Protein
también	O
se	O
requiere	O
para	O
la	O
diferenciación	O
de	O
SAC	O
,	O
y	O
en	O
este	O
caso	O
,	O
actúa	O
inhibiendo	O
E2f3a	O
.	O

No	O
hay	O
evidencia	O
directa	O
de	O
que	O
Rb	B-Protein
se	O
requiere	O
para	O
la	O
diferenciación	O
terminal	O
de	O
otros	O
célula	B-Cell
tipos	O

Códigos	O
de	O
colores	O
y	O
abreviaturas	O
como	O
en	O
la	O
Figura	O
1A	O
.	O

Rb	B-Protein
regulación	O
de	O
la	O
diferenciación	O
SAC	O
a	O
través	O
de	O
E2f3	B-Protein
era	O
independiente	O
de	O
su	O
papel	O
en	O
el	O
control	O
de	O
la	O
división	O
o	O
la	O
muerte	O
:	O
E2f3	B-Protein
supresión	B-Sequence
rescatados	O
Rb	B-Protein
KO	O
SAC	O
defectos	O
pero	O
no	O
suprimió	O
la	O
proliferación	O
aberrante	O
o	O
la	O
muerte	O
,	O
mientras	O
que	O
E2f1	B-Protein
supresión	B-Sequence
revirtió	O
la	O
proliferación	O
anormal	O
y	O
la	O
muerte	O
,	O
pero	O
no	O
rescató	O
la	O
diferenciación	O
del	O
SAC	O
.	O

El	O
doble	O
etiquetado	O
confirmó	O
que	O
E2f1	B-Protein
pero	O
no	O
E2f3	B-Protein
supresión	B-Sequence
invertido	O
Rb	B-Protein
División	O
KO	O
SAC	O
.	O

Es	O
más	O
,	O
borrando	B-Sequence
E2f1	B-Protein
,	O
pero	O
no	O
E2f3	B-Protein
,	O
expresión	O
desregulada	O
inversa	O
de	O
célula	B-Cell
ciclo	O
y	O
apoptosis	O
genes	B-Sequence
en	O
el	O
Rb	B-Protein
KO	O
retina	O
.	O

E2f3	B-Protein
se	O
expresa	O
en	O
un	O
subconjunto	O
de	O
neuronas	B-Cell
del	I-Cell
SNC	I-Cell
(	O
este	O
trabajo	O
)	O
y	O
unidades	O
específicas	O
célula	B-Cell
#	O
¿NOMBRE	O
?	O
Rb	B-Protein
cerebro	O
anterior	O
KO	O
neuronas	B-Cell
[	O
53	O
]	O
.	O

Por	O
lo	O
tanto	O
,	O
E2f3	B-Protein
la	O
inhibición	O
es	O
el	O
primero	O
,	O
y	O
puede	O
ser	O
el	O
único	O
,	O
mecanismo	O
por	O
el	O
cual	O
Rb	B-Protein
participa	O
directamente	O
en	O
neuronales	B-Cell
diferenciación	O

Para	O
profundizar	O
en	O
el	O
mecanismo	O
de	O
acción	O
de	O
Rb	B-Protein
en	O
SAC	O
determinamos	O
el	O
E2f3	B-Protein
isoforma	B-Sequence
apunta	O
a	O
promover	O
la	O
diferenciación	O
.	O

E2f3b	O
era	O
el	O
principal	O
candidato	O
,	O
ya	O
que	O
Rb	B-Protein
y	O
E2f3b	O
colaboran	O
para	O
reprimir	O
objetivos	O
en	O
reposo	O
células	B-Cell
in	O
vitro	O
[	O
19	O
]	O
.	O

Sin	O
embargo	O
,	O
en	O
el	O
primer	O
trabajo	O
que	O
conocemos	O
para	O
examinar	O
la	O
función	O
de	O
cualquier	O
E2f	O
proteína	B-Chemical
isoforma	B-Sequence
in	O
vivo	O
,	O
hicimos	O
la	O
sorprendente	O
observación	O
de	O
que	O
Rb	B-Protein
regula	O
la	O
diferenciación	O
SAC	O
a	O
través	O
de	O
E2f3a	O
(	O
Figura	O
8	O
)	O
.	O

Formalmente	O
,	O
no	O
podemos	O
excluir	O
la	O
posibilidad	O
de	O
que	O
borrando	B-Sequence
E2f3b	O
también	O
podría	O
rescatar	O
la	O
diferenciación	O
SAC	O
,	O
pero	O
la	O
prueba	O
definitiva	O
requerirá	O
un	O
análisis	O
de	O
E2f3b	O
nulo	O
ratones	B-Taxon
.	O

No	O
obstante	O
,	O
nuestros	O
datos	O
prueban	O
que	O
Rb	B-Protein
definitivamente	O
regula	O
la	O
diferenciación	O
SAC	O
a	O
través	O
de	O
la	O
activación	O
E2f3	B-Protein
isoforma	B-Sequence
.	O

Localización	O
distinta	O
de	O
E2f3a	O
y	O
E2f3b	O

La	O
ubicación	O
subcelular	O
de	O
E2f	O
isoformas	B-Sequence
hasta	O
donde	O
sabemos	O
,	O
no	O
se	O
ha	O
abordado	O
antes	O
.	O

E2f3a	O
y	O
E2f3b	O
comparten	O
110	O
C-terminal	B-Sequence
aminoácidos	B-Chemical
que	O
codifican	O
el	O
NLS	O
,	O
ADN	B-Sequence
-	O
encuadernación	O
,	O
casilla	O
marcada	O
,	O
transactivación	O
,	O
y	O
Rb	B-Protein
-	O
dominios	B-Sequence
vinculantes	I-Sequence
[	O
16	O
]	O
,	O
pero	O
exhiben	O
una	O
distribución	O
subcelular	O
diferente	O
en	O
el	O
desarrollo	O
de	O
la	O
retina	O
células	B-Cell
.	O

E2f3a	O
es	O
ambos	O
nuclear	B-GENE
y	O
citoplasmático	B-GENE
,	O
pero	O
E2f3b	O
siempre	O
es	O
nuclear	B-GENE
.	O

El	O
exclusivo	O
121	O
-	O
y	O
seis	O
-	O
residuo	B-Sequence
N	I-Sequence
-	I-Sequence
terminales	I-Sequence
de	O
E2f3a	O
y	O
E2f3b	O
,	O
respectivamente	O
,	O
probablemente	O
medien	O
esta	O
diferencia	O
.	O

Esta	O
región	B-Sequence
en	O
E2f1	B-Protein
,	O
E2f2	B-Protein
,	O
y	O
E2f3a	O
se	O
une	O
ccna2	B-Protein
,	O
estableciendo	O
un	O
bucle	O
regulador	O
negativo	O
que	O
desactiva	O
E2fs	O
a	O
mediados	O
de	O
la	O
fase	O
S	O
tardía	O
[	O
64	O
,	O
65	O
]	O
.	O

Sin	O
embargo	O
,	O
incluso	O
E2f3b	O
,	O
que	O
carece	O
de	O
este	O
dominio	B-Sequence
,	O
vincula	O
y	O
está	O
regulado	O
por	O
ccna2	B-Protein
[	O
18	O
]	O
,	O
por	O
lo	O
que	O
el	O
dominio	B-Sequence
diferencia	O
puede	O
no	O
explicar	O
las	O
distribuciones	O
únicas	O
que	O
observamos	O
.	O

Rb	B-Protein
familia	O
y	O
tfdp	O
proteinas	B-Chemical
también	O
puede	O
determinar	O
la	O
localización	O
de	O
E2f	O
[	O
20	O
-	O
22	O
]	O
,	O
y	O
encontramos	O
que	O
una	O
parte	O
de	O
ambos	O
Rb	B-Protein
y	O
Tfdp1	B-Protein
proteinas	B-Chemical
están	O
citoplasmático	B-GENE
en	O
la	O
retina	O
células	B-Cell
.	O

De	O
hecho	O
,	O
la	O
inmunotinción	O
reveló	O
que	O
Rb	B-Protein
y	O
E2f3	B-Protein
colocalizar	O
a	O
SAC	O
procesos	B-GENE
.	O

los	O
nuclear	B-GENE
La	O
localización	O
de	O
E2f3b	O
contrasta	O
con	O
la	O
de	O
otros	O
E2fs	O
represivos	O
en	O
diferenciar	O
el	O
músculo	O
,	O
donde	O
E2f5	B-Protein
cambia	O
de	O
la	O
núcleo	B-GENE
para	O
citoplasma	B-GENE
,	O
tiempo	O
E2f4	B-Protein
permanece	O
en	O
ambos	O
compartimentos	O
[	O
23	O
]	O
.	O

La	O
distinta	O
compartimentación	O
de	O
E2f3a	O
y	O
E2f3b	O
en	O
la	O
retina	O
sugiere	O
actividades	O
temporal	O
y	O
funcionalmente	O
distintas	O
.	O

Rb	B-Protein
la	O
distribución	O
coincide	O
con	O
la	O
de	O
E2f3a	O
,	O
en	O
consonancia	O
con	O
su	O
papel	O
crítico	O
en	O
el	O
apoyo	O
a	O
la	O
diferenciación	O
de	O
SAC	O
a	O
través	O
de	O
E2f3a	O
.	O

División	O
y	O
diferenciación	O
ectópica	O

Rb	B-Protein
es	O
fundamental	O
para	O
garantizar	O
que	O
muchos	O
tipos	O
de	O
diferenciación	O
terminal	O
células	B-Cell
dejar	O
el	O
célula	B-Cell
ciclo	O
(	O
p	O
.	O
ej	O
.	O
,	O
neuronas	B-Cell
,	O
epitelios	O
del	O
intestino	O
y	O
de	O
la	O
piel	O
,	O
músculos	O
y	O
fibras	O
del	O
cristalino	O
)	O
(	O
revisado	O
en	O
[	O
66	O
]	O
)	O
.	O

Los	O
primeros	O
estudios	O
de	O
sobreexpresión	O
in	O
vitro	O
sugirieron	O
Rb	B-Protein
podría	O
atenuar	O
la	O
expansión	O
del	O
ciclismo	O
células	B-Cell
pero	O
los	O
estudios	O
de	O
KO	O
in	O
vivo	O
indican	O
que	O
su	O
papel	O
principal	O
es	O
bloquear	O
la	O
división	O
en	O
la	O
diferenciación	O
terminal	O
células	B-Cell
.	O

En	O
su	O
ausencia	O
,	O
muchos	O
(	O
pero	O
claramente	O
no	O
todos	O
)	O
los	O
aspectos	O
de	O
la	O
diferenciación	O
continúan	O
relativamente	O
imperturbables	O
.	O

En	O
la	O
retina	O
,	O
transición	O
diferenciadora	O
células	B-Cell
nacen	O
en	O
ausencia	O
de	O
Rb	B-Protein
,	O
migre	O
a	O
la	O
capa	O
correcta	O
y	O
exprese	O
los	O
marcadores	O
apropiados	O
(	O
[	O
2	O
]	O
y	O
este	O
trabajo	O
)	O
.	O

en	O
el	O
cerebro	O
,	O
Rb	B-Protein
KO	O
neuronas	B-Cell
migran	O
fuera	O
de	O
la	O
zona	O
ventricular	O
y	O
se	O
encienden	O
Tubb3	B-Protein
(	O
beta	B-Protein
III	I-Protein
-	I-Protein
tubulina	I-Protein
)	O
,	O
pero	O
continúa	O
incorporar	B-Sequence
BrdU	O
[	O
13	O
]	O
,	O
y	O
en	O
el	O
epitelio	O
intestinal	O
,	O
diferenciado	O
enterocitos	B-Cell
migran	O
hacia	O
las	O
vellosidades	O
y	O
activan	O
la	O
expresión	O
de	O
serotonina	B-Chemical
,	O
sin	O
embargo	O
,	O
continúa	O
incorporar	B-Sequence
BrdU	O
[	O
67	O
]	O
.	O

En	O
el	O
caso	O
de	O
los	O
SAC	O
,	O
los	O
defectos	O
de	O
diferenciación	O
que	O
observamos	O
(	O
p	O
.	O
ej	O
.	O
,	O
pérdida	O
de	O
Slc18a3	B-Protein
y	O
Chat	B-Protein
)	O
no	O
se	O
debieron	O
a	O
una	O
división	O
aberrante	O
,	O
pero	O
es	O
posible	O
que	O
haya	O
otros	O
problemas	O
con	O
estos	O
células	B-Cell
que	O
son	O
causados	O
por	O
la	O
división	O
ectópica	O
.	O

Sin	O
embargo	O
,	O
es	O
claro	O
que	O
muchos	O
aspectos	O
de	O
la	O
diferenciación	O
en	O
múltiples	O
célula	B-Cell
Los	O
tipos	O
son	O
compatibles	O
con	O
la	O
división	O
ectópica	O
.	O

Sin	O
embargo	O
,	O
la	O
división	O
de	O
diferenciación	O
terminal	O
células	B-Cell
es	O
peligroso	O
,	O
ya	O
que	O
puede	O
facilitar	O
la	O
transformación	O
,	O
como	O
es	O
el	O
caso	O
del	O
retinoblastoma	O
(	O
revisado	O
en	O
[	O
66	O
]	O
)	O
.	O

¿Cómo	O
perturba	O
E2f3a	O
la	O
diferenciación	O
SAC	O
?	O

E2f3a	O
podría	O
interrumpir	O
la	O
diferenciación	O
de	O
SAC	O
a	O
través	O
de	O
su	O
bien	O
conocido	O
papel	O
como	O
activador	O
transcripcional	O
,	O
o	O
en	O
vista	O
del	O
descubrimiento	O
de	O
que	O
es	O
parcialmente	O
citoplasmático	B-GENE
,	O
E2f3a	O
puede	O
afectar	O
procesos	O
distintos	O
de	O
gene	B-Sequence
reglamento	O

Ambos	O
escenarios	O
son	O
factibles	O
ya	O
que	O
E2fs	O
regula	O
la	O
diferenciación	O
.	O
genes	B-Sequence
[	O
44	O
-	O
48	O
]	O
,	O
y	O
célula	B-Cell
reguladores	O
de	O
ciclo	O
,	O
tales	O
como	O
Cdkn1b	B-Protein
,	O
tener	O
citoplasmático	B-GENE
actividades	O
que	O
influyen	O
en	O
la	O
diferenciación	O
[	O
68	O
,	O
69	O
]	O
.	O

Muchos	O
factores	O
de	O
transcripción	O
se	O
desplazan	O
entre	O
núcleo	B-GENE
y	O
citoplasma	B-GENE
durante	O
la	O
neurogénesis	O
(	O
p	O
.	O
ej	O
.	O
,	O
[	O
70	O
]	O
y	O
sus	O
referencias	O
)	O
.	O

Puede	O
ser	O
difícil	O
identificar	O
E2f3a	O
-	O
objetivo	O
específico	O
genes	B-Sequence
o	O
citoplasmático	B-GENE
proteinas	B-Chemical
en	O
SAC	O
ya	O
que	O
estos	O
neuronas	B-Cell
son	O
una	O
pequeña	O
proporción	O
(	O
<	O
1	O
%	O
)	O
del	O
total	O
de	O
la	O
retina	O
y	O
sólo	O
~	O
5	O
.	O
2	O
%	O
de	O
neuronas	B-Cell
amacrinas	I-Cell
[	O
38	O
]	O
.	O

¿E2fs	O
media	O
todo	O
?	O
Rb	B-Protein
funciones	O
?	O

Otros	O
han	O
sugerido	O
que	O
Rb	B-Protein
promueve	O
la	O
diferenciación	O
en	O
no	O
-	O
células	B-Cell
neuronales	I-Cell
a	O
través	O
de	O
medios	O
independientes	O
de	O
E2f	O
[	O
31	O
-	O
33	O
]	O
.	O

Sin	O
embargo	O
,	O
estos	O
estudios	O
no	O
evaluaron	O
si	O
estos	O
célula	B-Cell
los	O
tipos	O
se	O
diferencian	O
normalmente	O
si	O
Rb	B-Protein
es	O
eliminado	B-Sequence
junto	O
con	O
uno	O
o	O
más	O
miembros	O
de	O
la	O
familia	O
E2f	O
.	O

Un	O
estudio	O
informó	O
que	O
Rb	B-Protein
mutantes	B-Sequence
que	O
no	O
se	O
unen	O
a	O
E2f	O
todavía	O
inducen	O
la	O
diferenciación	O
[	O
30	O
]	O
.	O

Sin	O
embargo	O
,	O
los	O
ensayos	O
de	O
unión	O
se	O
realizaron	O
en	O
solución	O
y	O
hemos	O
encontrado	O
que	O
varios	O
de	O
estos	O
mutantes	B-Sequence
enlazar	O
E2f	O
,	O
aunque	O
débilmente	O
,	O
en	O
cromatina	B-GENE
(	O
T	O
.	O
Yu	O
y	O
R	O
.	O
B	O
.	O
,	O
datos	O
no	O
publicados	O
)	O
.	O

Es	O
posible	O
que	O
Rb	B-Protein
-	O
la	O
potenciación	O
mediada	O
por	O
factores	O
de	O
transcripción	O
específicos	O
de	O
tejido	O
puede	O
ser	O
,	O
al	O
menos	O
en	O
algunos	O
casos	O
,	O
una	O
actividad	O
redundante	O
,	O
y	O
que	O
el	O
único	O
factor	O
crítico	O
Rb	B-Protein
función	O
es	O
inhibir	O
E2f	O
.	O

Nuestro	O
estudio	O
es	O
el	O
primero	O
,	O
según	O
nuestro	O
conocimiento	O
,	O
en	O
evaluar	O
exhaustivamente	O
si	O
Rb	B-Protein
KO	O
células	B-Cell
puede	O
diferenciar	O
en	O
ausencia	O
de	O
diferentes	O
E2fs	O
.	O

la	O
luz	O
de	O
nuestros	O
hallazgos	O
,	O
será	O
importante	O
reevaluar	O
los	O
defectos	O
de	O
diferenciación	O
en	O
otros	O
Rb	B-Protein
Tejidos	O
KO	O
en	O
ausencia	O
de	O
miembros	O
de	O
la	O
familia	O
E2f	O
activadores	O
individuales	O
y	O
combinados	O
.	O

Materiales	O
y	O
métodos	O

Ratón	B-Taxon
cepas	O
y	O
genotipado	O
.	O

Ratones	B-Taxon
fueron	O
tratados	O
de	O
acuerdo	O
con	O
las	O
directrices	O
institucionales	O
y	O
nacionales	O
.	O

Alfa	O
-	O
Cre	O
ratones	B-Taxon
(	O
P.	O
Gruss	O
)	O
,	O
Chx10	B-Protein
#	O
¿NOMBRE	O
?	O
ratones	B-Taxon
(	O
C	O
.	O
Cepko	O
)	O
,	O
RbloxP	O
/	O
loxP	B-Sequence
ratones	B-Taxon
(	O
A.	O
Berns	O
)	O
,	O
E2f1	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
,	O
E2f2	B-Protein
-	O
/	O
-	O
ratones	B-Taxon
,	O
E2f3loxP	O
/	O
loxP	B-Sequence
ratones	B-Taxon
,	O
y	O
E2f3a	O
-	O
/	O
-	O
ratones	B-Taxon
se	O
mantuvieron	O
en	O
un	O
fondo	O
mixto	O
(	O
NMRI	O
x	O
C57/Bl	O
x	O
FVB/N	O
x	O
129sv	O
)	O
.	O

Una	O
descripción	O
detallada	O
de	O
E2f3a	O
-	O
/	O
-	O
ratones	B-Taxon
se	O
publicará	O
en	O
otro	O
lugar	O
.	O

Ratones	B-Taxon
de	O
diferente	O
genotipos	B-Sequence
se	O
compararon	O
dentro	O
de	O
la	O
misma	O
camada	O
y	O
en	O
un	O
mínimo	O
de	O
tres	O
camadas	O
.	O

No	O
hemos	O
notado	O
ninguna	O
diferencia	O
fenotípica	O
en	O
camadas	O
separadas	O
.	O

El	O
genotipado	O
se	O
realizó	O
como	O
antes	O
[	O
2	O
,	O
5	O
]	O
,	O
y	O
el	O
cebadores	B-Sequence
utilizado	O
para	O
el	O
genotipado	O
E2f3a	O
-	O
/	O
-	O
ratones	B-Taxon
fueron	O
E2f3a	O
KL	O
(	O
5'-CTCCAGACCCCCGATTATTT-3	O
'	O
)	O
,	O
E2f3a	O
KR1	O
(	O
5'-TCCAGTGCACTACTCCCTCC-3	O
'	O
)	O
y	O
E2f3a	O
KM	O
(	O
5'-GCTAGCAGTGCCCTTTTGTC-3	O
'	O
)	O
.	O

Histología	O
,	O
inmunofluorescencia	O
y	O
mediciones	O
.	O

Los	O
globos	O
oculares	O
se	O
fijaron	O
en	O
paraformaldehído	O
al	O
4	O
%	O
durante	O
1	O
h	O
a	O
4	O
°C	O
,	O
se	O
incluyeron	O
en	O
OCT	O
(	O
TissueTek	O
4583	O
,	O
Sakura	O
,	O
http	O
:	O
//www.sakuraeu.com	O
)	O
,	O
se	O
congelaron	O
en	O
hielo	O
seco	O
y	O
se	O
cortaron	O
en	O
secciones	O
de	O
12	O
µm	O
en	O
Superfrost	O
.	O
más	O
diapositivas	O
(	O
VWR	O
,	O
http	O
:	O
//www.vwr.com	O
)	O
.	O

Para	O
el	O
análisis	O
de	O
la	O
fase	O
S	O
,	O
se	O
inyectó	O
intraperitonealmente	O
BrdU	O
(	O
100	O
µg/g	O
de	O
peso	O
corporal	O
)	O
2	O
h	O
antes	O
del	O
sacrificio	O
.	O

BrdU	O
+	O
células	B-Cell
fueron	O
detectados	O
usando	O
un	O
biotina	B-Chemical
#	O
¿NOMBRE	O
?	O
oveja	B-Taxon
policlonal	O
anticuerpo	B-GENE
(	O
1:500	O
,	O
Servicios	O
de	O
Biotecnología	O
de	O
Maine	O
,	O
http	O
:	O
//www.mainebiotechnology.com	O
)	O
.	O

Todos	O
los	O
demás	O
anticuerpos	B-GENE
se	O
describen	O
en	O
la	O
Tabla	O
S1	O
.	O

Para	O
E2f3	B-Protein
,	O
mki67	B-Protein
,	O
y	O
Rb	B-Protein
tinción	O
,	O
la	O
recuperación	O
del	O
antígeno	O
se	O
realizó	O
mediante	O
secciones	O
en	O
ebullición	O
en	O
ácido	B-Chemical
cítrico	I-Chemical
solución	O
durante	O
15	O
min	O
según	O
Ino	O
[	O
50	O
]	O
,	O
excepto	O
en	O
cortes	O
congelados	O
.	O

TUNEL	O
se	O
realizó	O
como	O
se	O
describe	O
[	O
13	O
]	O
.	O

Brevemente	O
,	O
las	O
secciones	O
se	O
incubaron	O
durante	O
1	O
hora	O
a	O
37	O
grados	O
C	O
con	O
75	O
m	O
l	O
de	O
solución	O
de	O
mezcla	O
que	O
constaba	O
de	O
0	O
.	O
5	O
mu	O
l	O
de	O
desoxinucleótido	B-Protein
transferasa	I-Protein
terminal	I-Protein
,	O
1	O
mu	O
l	O
de	O
biotina	B-Chemical
-	O
dieciséis	O
-	O
dUTP	B-Chemical
,	O
7	O
.	O
5	O
mu	O
l	O
de	O
CoCl2	B-Chemical
,	O
15	O
mu	O
l	O
de	O
5	O
x	O
desoxinucleótido	B-Protein
transferasa	I-Protein
terminal	I-Protein
tampón	O
y	O
51	O
mu	O
l	O
de	O
agua	O
destilada	O
agua	B-Chemical
.	O

Después	O
de	O
tres	O
lavados	O
en	O
tampón	O
4	O
x	O
SSC	O
,	O
las	O
secciones	O
se	O
incubaron	O
con	O
Alexa	O
488	O
o	O
Alexa	O
568	O
-	O
estreptavidina	O
(	O
1	O
:	O
1	O
000	O
;	O
Molecular	B-Chemical
Sondas	O
,	O
http	O
:	O
//sondas	O
.	O
invitrogeno	O
com	O
)	O
durante	O
1	O
h	O
a	O
temperatura	O
ambiente	O
.	O

Primario	O
anticuerpos	B-GENE
o	O
etiquetado	O
células	B-Cell
se	O
visualizaron	O
utilizando	O
Burro	B-Taxon
anti	O
-	O
ratón	B-Taxon
Alexa	O
488	O
o	O
Alexa	O
568	O
,	O
Burro	B-Taxon
anti	O
-	O
Conejo	B-Taxon
Alexa	O
488	O
o	O
Alexa	O
568	O
,	O
Burro	B-Taxon
anti	O
-	O
cabra	B-Taxon
Alexa	O
488	O
o	O
Alexa	O
568	O
y	O
estreptavidina	O
Alexa	O
488	O
o	O
Alexa	O
568	O
(	O
1	O
:	O
1	O
000	O
;	O
Molecular	B-Chemical
sondas	O
)	O
.	O

Núcleos	B-GENE
fueron	O
contra	O
-	O
teñidas	O
con	O
4	O
,	O
6	O
-	O
diamidino	O
-	O
2	O
-	O
fenindol	B-Chemical
(	O
DAPI	O
;	O
Sigma	O
,	O
http	O
:	O
//www.sigmaaldrich.com	O
)	O
.	O

Etiquetado	O
células	B-Cell
se	O
visualizaron	O
utilizando	O
un	O
microscopio	O
Zeiss	O
(	O
http	O
:	O
//www.zeiss.com	O
)	O
Axioplan-2	O
con	O
objetivos	O
Plan	O
Neofluar	O
e	O
imágenes	O
capturadas	O
con	O
una	O
cámara	O
Zeiss	O
AxionCam	O
.	O

Para	O
las	O
muestras	O
doblemente	O
marcadas	O
,	O
las	O
imágenes	O
confocales	O
se	O
obtuvieron	O
con	O
un	O
Zeiss	O
LSM	O
5	O
.	O
0	O
microscopio	O
de	O
barrido	O
láser	O
.	O

La	O
retina	O
se	O
separó	O
en	O
tres	O
compartimentos	O
dividiendo	O
el	O
borde	O
ventricular	O
de	O
la	O
retina	O
en	O
partes	O
iguales	O
y	O
extendiendo	O
una	O
línea	O
hasta	O
el	O
borde	O
vítreo	O
[	O
2	O
]	O
.	O

El	O
contenedor	O
1	O
contiene	O
solo	O
células	B-Cell
que	O
expresó	O
Cre	O
como	O
progenitores	O
;	O
bin	O
3	O
está	O
en	O
la	O
retina	O
central	O
y	O
contiene	O
células	B-Cell
derivado	O
de	O
progenitores	O
que	O
no	O
expresaron	O
Cre	O
.	O

Para	O
célula	B-Cell
Para	O
los	O
recuentos	O
o	O
la	O
medición	O
del	O
espesor	O
,	O
utilizamos	O
una	O
región	O
de	O
0	O
a	O
100	O
mu	O
m	O
periférica	O
al	O
límite	O
que	O
separa	O
los	O
recipientes	O
1	O
y	O
2	O
.	O

Las	O
mediciones	O
se	O
realizaron	O
en	O
un	O
microscopio	O
Axioplan-2	O
utilizando	O
el	O
software	O
Axiovison	O
.	O

Cuantificación	O
de	O
fase	O
S	O
,	O
fase	O
M	O
y	O
células	B-Cell
apoptóticas	I-Cell
se	O
realizó	O
en	O
cortes	O
horizontales	O
que	O
incluían	O
el	O
nervio	O
óptico	O
.	O

Cuantificación	O
de	O
diferenciados	O
célula	B-Cell
tipos	O
se	O
realizó	O
utilizando	O
secciones	O
horizontales	O
a	O
distancias	O
iguales	O
del	O
nervio	O
óptico	O
.	O

Se	O
contaron	O
un	O
mínimo	O
de	O
tres	O
secciones	O
por	O
ojo	O
y	O
tres	O
ojos	O
de	O
diferentes	O
camadas	O
.	O

ARN	B-Sequence
extracción	O
,	O
transcripción	O
inversa	O
y	O
PCR	O
.	O

Total	O
ARN	B-Sequence
se	O
aisló	O
de	O
la	O
retina	O
periférica	O
diseccionada	O
utilizando	O
TRIzol	O
reactivo	B-Chemical
(	O
Invitrogen	O
,	O
http	O
:	O
//	O
www	O
.	O
invitrogen	O
.	O
com	O
)	O
seguida	O
de	O
digestión	O
con	O
ADNasa	O
libre	O
de	O
RNasa	O
(	O
ADN	B-Sequence
-	O
gratis	O
,	O
Ambion	O
,	O
http	O
:	O
//	O
www	O
.	O
ambición	O
com	O
)	O
para	O
eliminar	O
ADN	B-Sequence
contaminación	O

Primero	O
-	O
cadena	B-Sequence
de	I-Sequence
ADNc	I-Sequence
fue	O
sintetizado	O
desde	O
0	O
.	O
2	O
-	O
0	O
.	O
5	O
tazas	O
de	O
total	O
ARN	B-Sequence
usando	O
el	O
SuperScript	O
II	O
primero	O
-	O
hebra	B-Sequence
sistema	O
de	O
síntesis	O
(	O
Invitrogen	O
)	O
.	O

PCR	O
cebadores	B-Sequence
se	O
enumeran	O
en	O
la	O
Tabla	O
S2	O
.	O

La	O
PCR	O
cuantitativa	O
en	O
tiempo	O
real	O
se	O
realizó	O
utilizando	O
un	O
PRISM	O
7900HT	O
de	O
Applied	O
Biosystems	O
(	O
http	O
:	O
//appliedbiosystems.com	O
)	O
.	O

Las	O
pruebas	O
se	O
realizaron	O
por	O
duplicado	O
en	O
tres	O
muestras	O
biológicas	O
separadas	O
con	O
SYBR	O
Green	O
PCR	O
Master	O
Mix	O
(	O
Applied	O
Biosystems	O
)	O
exactamente	O
como	O
se	O
describió	O
anteriormente	O
[	O
71	O
]	O
.	O

Brevemente	O
,	O
se	O
prepararon	O
stocks	O
maestros	O
de	O
manera	O
que	O
cada	O
10	O
?	O
l	O
de	O
reacción	O
contuviera	O
5	O
?	O
l	O
de	O
SYBR	O
Green	O
PCR	O
Master	O
Mix	O
,	O
0	O
.	O
1	O
mu	O
l	O
de	O
cada	O
uno	O
cebador	B-Sequence
directo	I-Sequence
e	I-Sequence
inverso	I-Sequence
existencias	O
50	O
mu	O
M	O
)	O
,	O
0	O
.	O
8	O
mu	O
l	O
de	O
azul	O
H2O	B-Chemical
(	O
0	O
.	O
73	O
%	O
Azul	O
Comida	B-Chemical
Color	O
;	O
McCormick	O
,	O
http	O
:	O
//www	O
.	O
mccormick	O
com	O
)	O
,	O
2	O
mu	O
l	O
de	O
agua	O
diluida	O
ADNc	B-Sequence
plantilla	O
y	O
2	O
mu	O
l	O
de	O
amarillo	O
H2O	B-Chemical
(	O
0	O
.	O
73	O
%	O
Amarillo	O
Comida	B-Chemical
Color	O
)	O
.	O

La	O
PCR	O
consistió	O
en	O
40	O
ciclos	O
de	O
desnaturalización	O
a	O
95	O
°C	O
durante	O
15	O
sy	O
hibridación	O
y	O
extensión	O
a	O
55	O
°C	O
durante	O
30	O
s	O
.	O

Un	O
ciclo	O
adicional	O
(	O
95	O
grados	O
C	O
,	O
15	O
s	O
,	O
60	O
grados	O
C	O
)	O
generó	O
una	O
curva	O
de	O
disociación	O
para	O
confirmar	O
una	O
sola	O
producto	B-Sequence
.	O

Se	O
determinó	O
la	O
cantidad	O
de	O
ciclos	O
requerida	O
para	O
alcanzar	O
un	O
umbral	O
en	O
el	O
rango	O
lineal	O
y	O
se	O
comparó	O
con	O
una	O
curva	O
estándar	O
para	O
cada	O
cebador	B-Sequence
conjunto	O
generado	O
por	O
cinco	O
diluciones	O
triples	O
de	O
ADN	B-Sequence
genómico	I-Sequence
o	O
ADNc	B-Sequence
muestras	O
de	O
concentración	O
conocida	O
.	O

Valores	O
obtenidos	O
para	O
la	O
prueba	O
ARN	B-Sequence
se	O
normalizaron	O
a	O
Hprt1	B-Protein
ARNm	B-Chemical
niveles	O

manchas	O
occidentales	O
.	O

Ratón	B-Taxon
las	O
retinas	O
se	O
homogeneizaron	O
pasándolas	O
a	O
través	O
de	O
un	O
BD	O
9	O
de	O
calibre	O
30	O
http	O
:	O
//www	O
.	O
bd	O
com	O
)	O
aguja	O
5	O
-	O
10	O
veces	O
en	O
1	O
x	O
solución	O
de	O
PBS	O
.	O

Nuclear	B-GENE
y	O
citoplasmático	B-GENE
proteinas	B-Chemical
fueron	O
extraídos	O
usando	O
el	O
NE	O
-	O
PER	O
Nuclear	B-GENE
y	O
citoplasmático	B-GENE
Kit	O
de	O
extracción	O
(	O
Producto	O
n.º	O
78833	O
,	O
Pierce	O
Biotechnology	O
,	O
http	O
:	O
//www.piercenet.com	O
)	O
.	O

Proteínas	B-Chemical
estaban	O
separados	O
por	O
un	O
10	O
%	O
SDS	B-Chemical
#	O
¿NOMBRE	O
?	O

Después	O
de	O
bloquear	O
durante	O
la	O
noche	O
a	O
4	O
grados	O
C	O
en	O
leche	O
descremada	O
al	O
5	O
%	O
,	O
las	O
membranas	O
se	O
incubaron	O
en	O
el	O
primario	O
anticuerpo	B-GENE
durante	O
2	O
horas	O
a	O
temperatura	O
ambiente	O
.	O

Después	O
de	O
tres	O
lavados	O
de	O
10	O
min	O
en	O
TPBS	O
(	O
100	O
mM	O
Na2HPO4	B-Chemical
,	O
100	O
mm	O
NaH2PO4	B-Chemical
,	O
0	O
.	O
5	O
norte	O
NaCl	B-Chemical
,	O
0	O
.	O
1	O
%	O
Tween	O
-	O
20	O
)	O
,	O
las	O
membranas	O
se	O
incubaron	O
durante	O
30	O
min	O
a	O
temperatura	O
ambiente	O
en	O
el	O
secundario	O
Rábano	B-Taxon
picante	I-Taxon
peroxidasa	O
-	O
conjugada	O
anticuerpo	B-GENE
(	O
Laboratorios	O
Jackson	O
ImmunoResearch	O
,	O
http	O
:	O
//www.jacksonimmuno.com	O
)	O
.	O

Las	O
transferencias	O
se	O
desarrollaron	O
usando	O
el	O
sistema	O
de	O
detección	O
quimioluminiscente	O
ECL-Plus	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
,	O
http	O
:	O
//www.pharmacia.ca	O
)	O
,	O
de	O
acuerdo	O
con	O
las	O
instrucciones	O
del	O
fabricante	O
.	O

La	O
siguiente	O
primaria	O
anticuerpos	B-GENE
fueron	O
usados	O
:	O
E2f	B-Protein
-	I-Protein
1	I-Protein
(	O
SC-193	O
)	O
,	O
E2f	B-Protein
-	I-Protein
3	I-Protein
(	O
SC-878	O
)	O
,	O
cdkn1a	B-Protein
(	O
p21	B-Protein
,	O
SC	O
-	O
471	O
)	O
,	O
Cdkn1b	B-Protein
(	O
p27	B-Protein
,	O
SC-528	O
)	O
,	O
pou4f2	B-Protein
(	O
Brn3b	B-Protein
,	O
SC	O
-	O
6062	O
)	O
,	O
y	O
Tfdp1	B-Protein
(	O
Dp1	B-Protein
,	O
SC	O
-	O
610	O
)	O
de	O
Santa	O
Cruz	O
Biotechnology	O
(	O
http	O
:	O
//	O
www	O
.	O
scbt	O
.	O
com	O
)	O
,	O
pRB	O
(	O
554136	O
)	O
de	O
BD	O
Science	O
-	O
Pharmingen	O
(	O
http	O
:	O
//	O
www	O
.	O
bdbiosciences	O
.	O
com	O
)	O
y	O
Slc18a3	B-Protein
(	O
VAChT	B-Protein
,	O
G448A	O
)	O
de	O
Promega	O
(	O
http	O
:	O
//	O
www	O
.promega	O
.com	O
)	O
.	O

Electrorretinografía	O
.	O

Los	O
ERG	O
se	O
registraron	O
desde	O
la	O
oscuridad	O
-	O
adaptados	O
ratones	B-Taxon
como	O
se	O
describe	O
[	O
72	O
]	O
.	O

Brevemente	O
,	O
ratones	B-Taxon
se	O
adaptaron	O
a	O
la	O
oscuridad	O
durante	O
la	O
noche	O
y	O
se	O
anestesiaron	O
mediante	O
inyección	O
subcutánea	O
de	O
ketamina	O
(	O
66,7	O
mg/kg	O
de	O
peso	O
corporal	O
)	O
y	O
xilazina	O
(	O
11,7	O
mg/kg	O
de	O
peso	O
corporal	O
)	O
.	O

Se	O
dilataron	O
las	O
pupilas	O
y	O
se	O
obtuvieron	O
registros	O
ERG	O
de	O
un	O
solo	O
destello	O
en	O
condiciones	O
adaptadas	O
a	O
la	O
oscuridad	O
(	O
escotópicas	O
)	O
y	O
adaptadas	O
a	O
la	O
luz	O
(	O
fotópicas	O
)	O
.	O

La	O
adaptación	O
a	O
la	O
luz	O
se	O
logró	O
con	O
una	O
iluminación	O
de	O
fondo	O
de	O
30	O
candelas	O
(	O
cd	O
)	O
por	O
metro	O
cuadrado	O
comenzando	O
10	O
minutos	O
antes	O
de	O
la	O
grabación	O
.	O

La	O
estimulación	O
de	O
un	O
solo	O
flash	O
blanco	O
osciló	O
entre	O
10-4	O
y	O
25	O
cd	O
.	O
s	O
/	O
m2	O
,	O
dividido	O
en	O
diez	O
pasos	O
de	O
0	O
.	O
5	O
y	O
1	O
cd	O
de	O
registro	O
.	O
s/m2	O
.	O

Se	O
promediaron	O
diez	O
respuestas	O
con	O
un	O
intervalo	O
entre	O
estímulos	O
de	O
5	O
s	O
(	O
para	O
10-4	O
,	O
10-3	O
,	O
10-2	O
,	O
3	O
x	O
10-2	O
,	O
10-1	O
y	O
3	O
x	O
10-1	O
cd	O
.	O
s/m2	O
)	O
o	O
17	O
s	O
(	O
para	O
1	O
,	O
3	O
,	O
10	O
y	O
25	O
cd	O
.	O
s	O
/	O
m2	O
)	O
.	O

Las	O
frecuencias	O
de	O
corte	O
del	O
filtro	O
de	O
paso	O
de	O
banda	O
eran	O
0	O
.	O
1	O
y	O
3	O
000	O
Hz	O
.	O

Estadísticas	O
.	O

Diferente	O
genotipos	B-Sequence
se	O
evaluaron	O
mediante	O
el	O
análisis	O
de	O
varianza	O
(	O
ANOVA	O
)	O
seguido	O
de	O
la	O
prueba	O
de	O
diferencia	O
honestamente	O
significativa	O
(	O
HSD	O
)	O
de	O
Tukey	O
o	O
la	O
prueba	O
de	O
Fisher	O
(	O
programa	O
XLSTAT	O
,	O
http	O
:	O
//www.xlstat.com	O
)	O
.	O

información	O
de	O
soporte	O

Figura	O
S1	O

Borrando	B-Sequence
E2f1	B-Protein
,	O
pero	O
no	O
E2f2	B-Protein
o	O
E2f3	B-Protein
,	O
Rescata	O
División	O
Ectópica	O
y	O
Célula	B-Cell
Muerte	O
en	O
P0	O
y	O
P18	O
Rb	B-Protein
Retina	O
noqueada	O

Secciones	O
horizontales	O
de	O
lo	O
indicado	O
genotipos	B-Sequence
y	O
las	O
edades	O
estaban	O
manchadas	O
por	O
núcleos	B-GENE
(	O
DAPI	O
,	O
azul	O
)	O
,	O
y	O
(	O
A	O
)	O
fase	O
S	O
(	O
anti-BrdU	O
,	O
rojo	O
)	O
o	O
(	O
B	O
)	O
apoptosis	O
(	O
TUNEL	O
,	O
rojo	O
)	O
.	O

En	O
Rb	B-Protein
-	O
/	O
-	O
retinas	O
,	O
BrdU	O
+	O
células	B-Cell
extender	O
más	O
allá	O
de	O
los	O
límites	O
normales	O
en	O
P0	O
(	O
flechas	O
)	O
,	O
y	O
ectópico	O
ADN	B-Sequence
la	O
síntesis	O
continúa	O
en	O
múltiples	O
capas	O
en	O
etapas	O
posteriores	O
.	O

La	O
barra	O
de	O
escala	O
es	O
de	O
50	O
mu	O
m	O
.	O

La	O
NBL	O
es	O
donde	O
se	O
ubican	O
los	O
RPC	O
divisorios	O
.	O

(	O
PDF	O
de	O
815	O
KB	O
)	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Figura	O
S2	O

Borrando	B-Sequence
E2f1	B-Protein
Rescata	O
la	O
división	O
ectópica	O
y	O
la	O
apoptosis	O
en	O
el	O
embrión	O
Rb	B-Protein
Retina	O
noqueada	O

Secciones	O
horizontales	O
de	O
lo	O
indicado	O
genotipos	B-Sequence
y	O
las	O
edades	O
(	O
E14	O
y	O
E16	O
,	O
el	O
período	O
durante	O
el	O
cual	O
nacen	O
los	O
SAC	O
)	O
se	O
tiñeron	O
para	O
núcleos	B-GENE
(	O
DAPI	O
,	O
azul	O
)	O
y	O
fase	O
S	O
(	O
dos	O
paneles	O
superiores	O
,	O
anti	O
-	O
BrdU	O
,	O
rojo	O
)	O
o	O
apoptosis	O
(	O
dos	O
paneles	O
inferiores	O
,	O
TUNEL	O
,	O
rojo	O
)	O
.	O

En	O
Rb	B-Protein
-	O
/	O
-	O
retinas	O
,	O
BrdU	O
+	O
y	O
TUNEL	O
+	O
células	B-Cell
se	O
puede	O
ver	O
en	O
la	O
retina	O
interna	O
(	O
flechas	O
)	O
.	O

Inactivación	O
de	O
E2f1	B-Protein
rescatado	O
estos	O
defectos	O
.	O

La	O
barra	O
de	O
escala	O
es	O
de	O
50	O
mu	O
m	O
.	O

La	O
NBL	O
es	O
donde	O
se	O
ubican	O
los	O
RPC	O
divisorios	O
.	O

(	O
PDF	O
de	O
754	O
KB	O
)	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Figura	O
S3	O

Borrando	B-Sequence
E2f1	B-Protein
,	O
pero	O
no	O
E2f2	B-Protein
o	O
E2f3	B-Protein
,	O
Rescata	O
Mitosis	O
Ectópica	O
en	O
el	O
Rb	B-Protein
Retina	O
noqueada	O

(	O
A	O
)	O
Secciones	O
retinales	O
horizontales	O
del	O
indicado	O
genotipos	B-Sequence
y	O
las	O
edades	O
estaban	O
manchadas	O
por	O
núcleos	B-GENE
(	O
DAPI	O
,	O
azul	O
)	O
y	O
fase	O
M	O
(	O
anti-PH3	O
,	O
rojo	O
)	O
.	O

La	O
barra	O
de	O
escala	O
es	O
de	O
50	O
mu	O
m	O
.	O

(	O
B	O
)	O
Cuantificación	O
de	O
todos	O
los	O
PH3	O
+	O
células	B-Cell
.	O

(	O
C	O
)	O
Cuantificación	O
de	O
PH3+	O
ectópico	O
células	B-Cell
.	O

Las	O
barras	O
de	O
error	O
representan	O
la	O
desviación	O
estándar	O
(	O
SD	O
)	O
y	O
los	O
asteriscos	O
indican	O
una	O
diferencia	O
significativa	O
entre	O
la	O
retina	O
de	O
peso	B-Sequence
e	O
indicado	O
genotipos	B-Sequence
(	O
*	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
01	O
;	O
ANOVA	O
y	O
prueba	O
Tukey	O
HSD	O
)	O
.	O

(	O
PDF	O
de	O
628	O
KB	O
)	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Figura	O
S4	O

Borrando	B-Sequence
E2f2	B-Protein
o	O
E2f3	B-Protein
no	O
rescata	O
Célula	B-Cell
ganglionar	I-Cell
,	I-Cell
bastón	I-Cell
o	I-Cell
bipolar	I-Cell
muerte	O
en	O
el	O
Rb	B-Protein
Retina	O
noqueada	O

(	O
A	O
)	O
Secciones	O
horizontales	O
de	O
retina	O
de	O
ratones	B-Taxon
de	O
las	O
edades	O
indicadas	O
y	O
genotipos	B-Sequence
fueron	O
manchados	O
por	O
núcleos	B-GENE
(	O
DAPI	O
,	O
azul	O
)	O
y	O
marcadores	O
que	O
detectan	O
celulas	B-Cell
ganglionares	I-Cell
(	O
pou4f2	B-Protein
,	O
rojo	O
)	O
,	O
varillas	B-Cell
y	O
conos	B-Cell
(	O
Hundimiento	B-Protein
[	O
detención	B-Protein
de	I-Protein
varilla	I-Protein
]	O
,	O
verde	O
)	O
,	O
y	O
Células	B-Cell
bipolares	I-Cell
de	I-Cell
varilla	I-Cell
(	O
Prkca	B-Protein
,	O
verde	O
)	O
.	O

La	O
barra	O
de	O
escala	O
es	O
de	O
50	O
mu	O
m	O
.	O

(	O
B	O
)	O
Cuantificación	O
del	O
total	O
células	B-Cell
ganglionares	I-Cell
(	I-Cell
Pou4f2	I-Cell
+	I-Cell
)	I-Cell
.	O

(	O
C	O
)	O
Cuantificación	O
del	O
total	O
Células	B-Cell
bastones	I-Cell
bipolares	I-Cell
(	I-Cell
Prkca	I-Cell
+	I-Cell
)	I-Cell
.	O

(	O
D	O
)	O
Espesor	O
de	O
la	O
ONL	O
,	O
que	O
representa	O
el	O
número	O
de	O
varillas	B-Cell
.	O

Las	O
barras	O
de	O
error	O
representan	O
SD	O
y	O
los	O
asteriscos	O
indican	O
una	O
diferencia	O
significativa	O
entre	O
la	O
retina	O
de	O
peso	B-Sequence
e	O
indicado	O
genotipos	B-Sequence
(	O
*	O
*	O
,	O
p	O
<	O
0	O
.	O
01	O
;	O
ANOVA	O
y	O
prueba	O
Tukey	O
HSD	O
)	O
.	O

(	O
PDF	O
de	O
488	O
KB	O
)	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Figura	O
S5	O

E2f1	B-Protein
Supresión	B-Sequence
Rescata	O
alfa-Cre	O
;	O
Función	O
retinal	O
RbloxP	O
/	O
loxP	O

Los	O
ERG	O
se	O
registraron	O
desde	O
el	O
indicado	O
genotipos	B-Sequence
en	O
condiciones	O
adaptadas	O
a	O
la	O
luz	O
(	O
fotópicas	O
)	O
.	O

(	O
A	O
)	O
Serie	O
de	O
intensidad	O
.	O

(	O
B	O
)	O
Las	O
amplitudes	O
de	O
onda	O
b	O
en	O
función	O
del	O
logaritmo	O
de	O
la	O
intensidad	O
del	O
destello	O
.	O

(	O
PDF	O
de	O
383	O
KB	O
)	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Figura	O
S6	O

Defectos	O
de	O
diferenciación	O
en	O
Rb	B-Protein
KO	O
SAC	O

Secciones	O
retinales	O
horizontales	O
de	O
indicado	O
genotipos	B-Sequence
y	O
las	O
edades	O
estaban	O
manchadas	O
por	O
núcleos	B-GENE
(	O
DAPI	O
,	O
azul	O
)	O
y	O
Calb2	B-Protein
(	O
[	O
A	O
]	O
,	O
rojo	O
;	O
solo	O
densamente	O
teñido	O
células	B-Cell
se	O
contaron	O
para	O
la	O
Figura	O
3C	O
)	O
,	O
camk2a	B-Protein
(	O
[	O
B	O
]	O
,	O
verde	O
)	O
,	O
y	O
Slc18a3	B-Protein
(	O
[	O
C	O
]	O
,	O
rojo	O
)	O
.	O

Las	O
barras	O
de	O
escala	O
son	O
de	O
50	O
mu	O
m	O
.	O

(	O
PDF	O
de	O
564	O
KB	O
)	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Figura	O
S7	O

Neurotransmisor	B-Chemical
GABA	I-Chemical
en	O
el	O
Rb	B-Protein
Retina	O
KO	O
y	O
SAC	O
anormales	O
en	O
Chx10	B-Protein
-	O
Cre	O
;	O
RbloxP	O
/	O
loxP	B-Sequence
Retina	O

Secciones	O
horizontales	O
de	O
lo	O
indicado	O
genotipos	B-Sequence
y	O
las	O
edades	O
de	O
la	O
retina	O
se	O
tiñeron	O
para	O
núcleos	B-GENE
(	O
DAPI	O
,	O
azul	O
)	O
,	O
y	O
(	O
A	O
y	O
B	O
)	O
GABA	B-Chemical
(	O
rojo	O
y	O
Slc18a3	B-Protein
(	O
verde	O
)	O
o	O
(	O
C	O
)	O
Chat	B-Protein
y	O
Slc18a3	B-Protein
(	O
rojo	O
)	O
.	O

(	O
A	O
)	O
En	O
P18	O
peso	B-Sequence
retina	O
,	O
GABA	B-Chemical
etiquetó	O
cuatro	O
pistas	O
IPL	O
,	O
de	O
las	O
cuales	O
las	O
dos	O
pistas	O
internas	O
co-teñidas	O
con	O
Slc18a3	B-Protein
.	O

Estas	O
últimas	O
huellas	O
desaparecieron	O
en	O
el	O
Rb	B-Protein
KO	O
retina	O
,	O
y	O
fueron	O
rescatados	O
por	O
E2f3	B-Protein
KO	O
pero	O
no	O
E2f1	B-Protein
KO	O

(	O
B	O
)	O
En	O
el	O
límite	O
de	O
la	O
peso	B-Sequence
(	O
centro	O
)	O
y	O
Rb	B-Protein
Área	O
KO	O
(	O
retina	O
periférica	O
)	O
el	O
interior	O
GABA	B-Chemical
+	O
Las	O
huellas	O
de	O
SAC	O
se	O
pueden	O
ver	O
desapareciendo	O
hacia	O
la	O
periferia	O
(	O
izquierda	O
)	O
.	O

(	O
C	O
)	O
Slc18a3	B-Protein
tinción	O
en	O
la	O
IPL	O
de	O
Chx10	B-Protein
-	O
Cre	O
;	O
RbloxP	O
/	O
loxP	B-Sequence
retina	O
es	O
consistente	O
con	O
el	O
patrón	O
de	O
mosaico	O
de	O
Rb	B-Protein
inactivación	O

Las	O
barras	O
de	O
escala	O
son	O
de	O
50	O
mu	O
m	O
.	O

(	O
PDF	O
de	O
633	O
KB	O
)	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Figura	O
S8	O

Distribución	O
subcelular	O
de	O
E2f3a	O
isoforma	B-Sequence
en	O
la	O
retina	O
en	O
desarrollo	O

Nuclear	B-GENE
y	O
citoplasmático	B-GENE
extractos	O
de	O
un	O
número	O
equivalente	O
de	O
retinal	O
células	B-Cell
desde	O
ratones	B-Taxon
de	O
lo	O
indicado	O
genotipos	B-Sequence
y	O
las	O
edades	O
se	O
analizaron	O
mediante	O
transferencia	O
Western	O
para	O
detectar	O
el	O
E2f3a	O
proteína	B-Chemical
.	O

Lisados	O
de	O
E2f3a	O
-	O
/	O
-	O
ratones	B-Taxon
de	O
edades	O
emparejadas	O
se	O
utilizaron	O
como	O
control	O
para	O
confirmar	O
la	O
ubicación	O
de	O
E2f3a	O
proteína	B-Chemical
.	O

C	B-GENE
,	O
citoplasmático	B-GENE
extractos	O
;	O
norte	B-GENE
,	O
nuclear	B-GENE
extractos	O

(	O
PDF	O
de	O
115	O
KB	O
)	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Tabla	O
S1	O

Lista	O
de	O
anticuerpos	B-GENE
y	O
patrones	O
de	O
marcadores	O
en	O
Rb	B-Protein
/	O
E2f1	B-Protein
DKO	O
SAC	O

(	O
97	O
KB	O
DOC	O
)	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Tabla	O
S2	O

RT	O
en	O
tiempo	O
real	O
-	O
PCR	O
imprimaciones	B-Sequence

(	O
49	O
KB	O
DOCUMENTO	O
)	O

Haga	O
clic	O
aquí	O
para	O
obtener	O
un	O
archivo	O
de	O
datos	O
adicional	O
.	O

Números	O
de	O
acceso	O

Los	O
números	O
de	O
acceso	O
de	O
GenBank	O
(	O
http	O
:	O
//	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
genbank	O
)	O
para	O
los	O
principales	O
genes	B-Sequence
y	O
gene	B-Sequence
Los	O
productos	O
discutidos	O
en	O
este	O
documento	O
son	O
camk2a	B-Protein
(	O
NM_009792	O
)	O
,	O
Chat	B-Protein
(	O
NM_009891	O
)	O
,	O
E2f1	B-Protein
(	O
NM_007891	O
)	O
,	O
E2f2	B-Protein
(	O
NM_177733	O
)	O
,	O
E2f3	B-Protein
(	O
NM_010093	O
)	O
,	O
Rb	B-Protein
(	O
NM_009029	O
)	O
,	O
y	O
Slc18a3	B-Protein
(	O
NM_021712	O
)	O
.	O

Agradecimientos	O

Agradecemos	O
a	O
K	O
.	O

McClellan	O
y	O
R	O
.	O

Slack	O
por	O
compartir	O
datos	O
no	O
publicados	O
,	O
L	O
.	O

Galli	O
-	O
Resta	O
por	O
sugerir	O
isl1	B-Protein
(	O
islote1	B-Protein
)	O
como	O
marcador	O
temprano	O
de	O
SAC	O
,	O
J	O
.	O

Eubanks	O
por	O
su	O
asesoramiento	O
sobre	O
inmunotinción	O
,	O
A	O
.	O

Berns	O
,	O
C	O
.	O

Cepko	O
y	O
P	O
.	O

Gruss	O
por	O
ratones	B-Taxon
,	O
y	O
T	O
.	O

Edlund	O
,	O
F	O
.	O

Haeseleer	O
,	O
R	O
.	O

Janz	O
,	O
S	O
.	O

Sugita	O
,	O
P	O
.	O

UN	O
.	O

Hargrave	O
,	O
C	O
.	O

m	O

Artesanía	O
,	O
X	O
.	O

Zhu	O
,	O
R	O
.	O

McInnes	O
,	O
R	O
.	O

l	O

Chow	O
y	O
J	O
.	O

saari	O
para	O
anticuerpos	B-GENE
.	O

abreviaturas	O

ANOVA	O
-	O
análisis	O
de	O
varianza	O

BrdU	O
-	O
bromodesoxiuridina	O

cd	O
-	O
candela	O

SNC	O
-	O
sistema	O
nervioso	O
central	O

DAPI	O
-	O
4	O
,	O
6	O
-	O
diamidino	O
-	O
2	O
-	O
fenindol	B-Chemical

DKO	O
-	O
doble	O
nocaut	O

E	O
[	O
número	O
]	O
-	O
día	O
embrionario	O
[	O
número	O
]	O

E2f	O
-	O
factor	O
de	O
transcripción	O
E2f	O

ERG	O
-	O
electrorretinograma	O

HSD	O
-	O
diferencia	O
honestamente	O
significativa	O

GABA	B-Chemical
-	O
ácido	B-Chemical
gamma-aminobutírico	I-Chemical

GCL-	O
célula	B-Cell
ganglionar	I-Cell
capa	O

INL	O
-	O
capa	O
nuclear	O
interna	O

IPL	O
-	O
capa	O
plexiforme	O
interna	O

KO	O
-	O
nocaut	O

NBL	O
-	O
capa	O
neuroblástica	O

ONL	O
-	O
capa	O
nuclear	O
externa	O

OPL	O
-	O
capa	O
plexiforme	O
externa	O

P	O
[	O
número	O
]	O
-	O
día	O
postnatal	O
[	O
número	O
]	O

PH3	O
-	O
fosfohistona	O
3	O

Rb	B-Protein
-	O
proteína	B-Protein
de	I-Protein
retinoblastoma	I-Protein

RPC	O
-	O
progenitor	O
retinal	O
célula	B-Cell

RTC	O
-	O
transición	O
retiniana	O
célula	B-Cell

RT	O
-	O
PCR	O
-	O
PCR	O
de	O
transcriptasa	O
inversa	O

SAC	O
-	O
estallido	O
estelar	O
célula	B-Cell
amacrina	I-Cell

SD	O
-	O
desviación	O
estándar	O

TUNEL	O
-	O
terminal	O
dUTP	B-Chemical
mella	O
-	O
etiqueta	O
final	O

peso	B-Sequence
-	O
tipo	B-Sequence
salvaje	I-Sequence

notas	O
al	O
pie	O

Contribuciones	O
de	O
autor	O
.	O

DC	O
y	O
RB	O
concibieron	O
y	O
diseñaron	O
los	O
experimentos	O
.	O

DC	O
realizó	O
la	O
mayoría	O
de	O
los	O
experimentos	O
.	O

RO	O
,	O
PW	O
y	O
GL	O
proporcionaron	O
la	O
E2f3	B-Protein
flojo	B-Sequence
y	O
E2f3a	O
KO	O
ratones	B-Taxon
.	O

DC	O
y	O
RB	O
analizaron	O
los	O
datos	O
.	O

MP	O
,	O
NT	O
y	O
MWS	O
realizaron	O
el	O
análisis	O
ERG	O
.	O

DC	O
y	O
RB	O
escribieron	O
el	O
artículo	O
.	O

Financiamiento	O

``	O
Este	O
trabajo	O
fue	O
apoyado	O
por	O
becas	O
del	O
Instituto	O
Canadiense	O
para	O
la	O
Investigación	O
en	O
Salud	O
y	O
la	O
Fundación	O
Fighting	O
Blindness	O
Canada	O
a	O
RB	O
,	O
y	O
por	O
el	O
Consejo	O
Alemán	O
de	O
Investigación	O
(	O
DFG	O
Se837/4-1	O
y	O
5-1	O
)	O
y	O
la	O
Unión	O
Europea	O
(	O
IP	O
``	O
''	O
EVI-GenoRet	O
''	O
''	O
LSHG-CT-512036	O
)	O
a	O
MWS	O
.	O
''	O

Conflicto	O
de	O
intereses	O
.	O

Los	O
autores	O
han	O
declarado	O
que	O
no	O
existen	O
intereses	O
contrapuestos	O
.	O

